PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Muhi, S; Stinear, TP				Muhi, Stephen; Stinear, Timothy P.			Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis	VACCINE			English	Review						Buruli ulcer; Mycobacterium ulcerans; BCG; Vaccine; Mycolactone	MYCOBACTERIUM-ULCERANS; IMMUNE-RESPONSE; RISK-FACTORS; REDUCTIVE EVOLUTION; PROTECTIVE EFFICACY; CONTROLLED-TRIAL; MACROLIDE TOXIN; DNA VACCINE; DISEASE; INFECTION	Buruli ulcer, caused by Mycobacterium ulcerans, is a neglected tropical disease endemic to over 30 countries, with increasing incidence in temperate, coastal Victoria, Australia. Strategies to control transmission are urgently required. This study systematically reviews the literature to identify and describe candidate prophylactic Buruli ulcer vaccines. This review highlights that Mycobacterium bovis Bacillus Calmette-Guerin (BCG) vaccine is the only vaccine studied in randomised controlled trials and confirms its importance as a benchmark for comparison against putative vaccines in pre-clinical studies. Nevertheless, BCG alone is unable to offer long-term protection in humans. A number of experimental vaccines that exceed the protection provided by BCG in mice have emerged, particularly those utilising recombinant BCG expressing immunogenic M. ulcerans proteins. Although progress is promising, there remain key questions about the optimal approach to characterising the immunological correlates of protection in humans and strategies to investigate the safety and efficacy of such vaccines in humans. (c) 2021 Elsevier Ltd. All rights reserved.	[Muhi, Stephen] Royal Melbourne Hosp, Victorian Infect Dis Serv, Melbourne, Vic, Australia; [Muhi, Stephen; Stinear, Timothy P.] Univ Melbourne, Peter Doherty Inst, Dept Microbiol & Immunol, Melbourne, Vic, Australia		Stinear, TP (通讯作者)，Univ Melbourne, Peter Doherty Inst, Dept Microbiol & Immunol, Melbourne, Vic, Australia.	tstinear@ummelb.edu.au		Stinear, Timothy/0000-0003-0150-123X	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council (NHMRC) of Australia [GNT1194325, GNT1191368]	SM is supported by a Postgraduate Scholarship from the National Health and Medical Research Council of Australia (GNT1191368) . TPS is supported by an Investigator Award from the National Health and Medical Research Council of Australia (GNT1194325) .	Adusumilli S, 2005, CELL MICROBIOL, V7, P1295, DOI 10.1111/j.1462-5822.2005.00557.x; Agbenorku Pius, 2012, Plast Surg Int, V2012, P752749, DOI 10.1155/2012/752749; Aiga H, 2004, AM J TROP MED HYG, V71, P387, DOI 10.4269/ajtmh.2004.71.387; ALSOP DG, 1972, AUST NZ J SURG, V41, P317, DOI 10.1111/j.1445-2197.1969.tb06535.x; AMOFAH GK, 1993, T ROY SOC TROP MED H, V87, P644, DOI 10.1016/0035-9203(93)90272-R; [Anonymous], 1969, LANCET, V1, P111; [Anonymous], 1970, Br Med J, V2, P390; Baron L, 2016, J EXP MED, V213, P2885, DOI 10.1084/jem.20160662; Bieri R, 2017, ACS CHEM BIOL, V12, P1297, DOI 10.1021/acschembio.7b00053; Bieri R, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004450; Bolz M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004431; Bolz M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004011; Carson C, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002668; CLANCEY J., 1962, ANN SOC BELGE MED TROP, V42, P585; Connor DH, 1965, INT J LEPROSY, V33, P698; Converse PJ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000985; Coutanceau E, 2006, MICROBES INFECT, V8, P2075, DOI 10.1016/j.micinf.2006.03.009; Cowan R, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003503; Dangy JP, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004808; Debacker M, 2006, EMERG INFECT DIS, V12, P1325, DOI 10.3201/eid1209.050598; Demangel C, 2009, NAT REV MICROBIOL, V7, P50, DOI 10.1038/nrmicro2077; Doig KD, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-258; Dreyer A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003477; Einarsdottir T, 2011, HUM VACCINES, V7, P1198, DOI 10.4161/hv.7.11.17751; FENNER F, 1957, AM REV TUBERC PULM, V76, P76; Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6; Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133; Fraga AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033406; Gao LY, 2003, INFECT IMMUN, V71, P922, DOI 10.1128/IAI.71.2.922-929.2003; George KM, 2000, INFECT IMMUN, V68, P877, DOI 10.1128/IAI.68.2.877-883.2000; Gooding TM, 2001, INFECT IMMUN, V69, P1704, DOI 10.1128/IAI.69.3.1704-1707.2001; Gowthaman U, 2012, TRENDS MOL MED, V18, P607, DOI 10.1016/j.molmed.2012.07.008; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hall BS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004061; Hart B. E., 2016, Trials in Vaccinology, V5, P88, DOI 10.1016/j.trivac.2016.04.001; Hart BE, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005229; Hart BE, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004046; Henry R, 2020, EMERG INFECT DIS, V26, P504, DOI 10.3201/eid2603.ET2603; Hesseling AC, 2007, VACCINE, V25, P14, DOI 10.1016/j.vaccine.2006.07.020; Hong H, 2008, NAT PROD REP, V25, P447, DOI 10.1039/b803101k; Horwitz MA, 2009, VACCINE, V27, P441, DOI 10.1016/j.vaccine.2008.10.058; Huygen Kris, 2003, Expert Rev Vaccines, V2, P561, DOI 10.1586/14760584.2.4.561; Huygen K, 2009, MED MICROBIOL IMMUN, V198, P69, DOI 10.1007/s00430-009-0109-6; Jamrozik E, 2021, VACCINE, V39, P633, DOI 10.1016/j.vaccine.2020.10.075; Kaser M, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-177; Nguyen LC, 2021, CLIN INFECT DIS, V72, P710, DOI 10.1093/cid/ciaa935; Loftus MJ, 2018, EMERG INFECT DIS, V24, P1988, DOI 10.3201/eid2411.171593; Loftus MJ, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006323; MACCALLUM P, 1948, J PATHOL BACTERIOL, V60, P93, DOI 10.1002/path.1700600111; Mangas KM, 2020, PEERJ, V8, DOI 10.7717/peerj.9659; Mangas KM, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00753-19; McKenna M, 2016, J CELL SCI, V129, P1404, DOI 10.1242/jcs.182352; Molyneux DH, 2017, LANCET, V389, P312, DOI 10.1016/S0140-6736(16)30171-4; Nackers F, 2006, AM J TROP MED HYG, V75, P768, DOI 10.4269/ajtmh.2006.75.768; Nain Z, 2020, MOL IMMUNOL, V120, P146, DOI 10.1016/j.molimm.2020.02.009; Noeske J, 2004, AM J TROP MED HYG, V70, P520, DOI 10.4269/ajtmh.2004.70.520; Noll KE, 2019, CELL HOST MICROBE, V25, P484, DOI 10.1016/j.chom.2019.03.009; O'Brien DP, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007178; O'Brien DP, 2018, MED J AUSTRALIA, V208, P287, DOI 10.5694/mja17.00879; O'Brien DP, 2017, INTERN MED J, V47, P1011, DOI 10.1111/imj.13511; O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y; Ogbechi J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0427-y; Oliveira MS, 2005, INFECT IMMUN, V73, P6299, DOI 10.1128/IAI.73.10.6299-6310.2005; Pahlevan AA, 1999, J IMMUNOL, V163, P3928; Phillips R, 2009, J INFECT DIS, V200, P1675, DOI 10.1086/646615; Phillips RO, 2020, LANCET, V395, P1259, DOI 10.1016/S0140-6736(20)30047-7; Phillips RO, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003457; Portaels F, 2004, INFECT IMMUN, V72, P62, DOI 10.1128/IAI.72.1.62-65.2004; Portaels F, 2002, CLIN DIAGN LAB IMMUN, V9, P1389, DOI 10.1128/CDLI.9.6.1389-1391.2002; Porter JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070520; Qi WH, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000580; RADFORD AJ, 1975, AUST NZ J MED, V5, P162, DOI 10.1111/j.1445-5994.1975.tb03649.x; Raghunathan PL, 2005, CLIN INFECT DIS, V40, P1445, DOI 10.1086/429623; Roestenberg M, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00297; Roltgen K, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01018; Ross BC, 1997, J CLIN MICROBIOL, V35, P1696, DOI 10.1128/JCM.35.7.1696-1700.1997; Rosseels V, 2006, INFECT IMMUN, V74, P202, DOI 10.1128/IAI.74.1.202-212.2006; Roupie V, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002604; Ruf MT, 2017, VIRULENCE, V8, P1918, DOI 10.1080/21505594.2017.1370530; Ruf MT, 2012, ANTIMICROB AGENTS CH, V56, P687, DOI 10.1128/AAC.05543-11; Sarfo FS, 2009, CLIN VACCINE IMMUNOL, V16, P61, DOI 10.1128/CVI.00235-08; Setia MS, 2006, LANCET INFECT DIS, V6, P162, DOI 10.1016/S1473-3099(06)70412-1; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; SMITH PG, 1976, T ROY SOC TROP MED H, V70, P449, DOI 10.1016/0035-9203(76)90128-0; Stinear T, 1999, J CLIN MICROBIOL, V37, P1018, DOI 10.1128/JCM.37.4.1018-1023.1999; Stinear TP, 2007, GENOME RES, V17, P192, DOI 10.1101/gr.5942807; Stinear TP, 2004, P NATL ACAD SCI USA, V101, P1345, DOI 10.1073/pnas.0305877101; Stinear TP, 2005, J BACTERIOL, V187, P1668, DOI 10.1128/JB.187.5.1668-1676.2005; Tanghe A, 2001, INFECT IMMUN, V69, P5403, DOI 10.1128/IAI.69.9.5403-5411.2001; Tanghe A, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000199; Tanghe A, 2007, INFECT IMMUN, V75, P2642, DOI 10.1128/IAI.01622-06; Torrado E, 2007, INFECT IMMUN, V75, P977, DOI 10.1128/IAI.00889-06; Torrado E, 2010, J IMMUNOL, V184, P947, DOI 10.4049/jimmunol.0902717; Trubiano JA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002463; Wallace JR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005553; Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9; Watanabe M, 2015, VACCINE, V33, P2232, DOI 10.1016/j.vaccine.2015.03.046; Yip MJ, 2007, J BACTERIOL, V189, P2021, DOI 10.1128/JB.01442-06; Zimmermann P, 2018, J INFECT DIS, V218, P679, DOI 10.1093/infdis/jiy207	99	2	2	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 8	2021	39	50					7238	7252		10.1016/j.vaccine.2021.05.092		DEC 2021	15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK8NB	34119347				2022-04-29	WOS:000727714000004
J	Silver, MC; Neumann, PJ; Ma, SY; Kim, DD; Cohen, JT; Nyaku, M; Roberts, C; Sinha, A; Ollendorf, DA				Silver, Madison C.; Neumann, Peter J.; Ma, Siyu; Kim, David D.; Cohen, Joshua T.; Nyaku, Mawuli; Roberts, Craig; Sinha, Anushua; Ollendorf, Daniel A.			Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines	VACCINE			English	Review						Vaccine; Economic evaluation; Cost-effectiveness; Perspective; Costing	MIDDLE-INCOME COUNTRIES; COST-EFFECTIVENESS; CONJUGATE VACCINE; IMMUNIZATION; INVESTMENT	Background: The health and economic benefits of immunization may extend beyond the elements traditionally included in cost-effectiveness analyses (CEAs). This review investigated how broader impacts are considered in economic evaluations of vaccines and whether their inclusion would substantially change CEA findings. Methods: We reviewed CEAs of vaccines associated with the largest global health burden, published from 2014 to 2019 using the Tufts CEA Registry and Tufts Global Health CEA Registry. We supplemented this with a systematic review of published and grey literature. We conducted descriptive analyses to examine the frequency of inclusion of specific social factors and study characteristics associated with their inclusion. We also conducted a case study of the human papilloma virus (HPV) vaccine to illustrate the potential change in CEA findings from selected social impacts. Results: We identified 475 relevant health economic assessments. Overall, 40% of studies included at least one category of social impact. The most commonly included non-healthcare cost among cost-perQALY studies was productivity (25%), while cost-per-DALY studies reported transportation costs most frequently (24%). Few studies examined the impact of vaccination on other sectors such as education and housing (<3%). Middle-income and North American settings were positively associated with social impact inclusion, while sub-Saharan African location was negatively associated. In the HPV case study, the addition of nonhealth costs improved cost-effectiveness by up to 90% or made the vaccine cost saving, depending on geographic setting. The cost-saving scenario saved up to $30,000 in costs per case of cervical cancer averted. Conclusions: A minority of vaccine CEAs include social impacts, particularly for nonhealth sectors. The omission of these impacts may result in a systematic undervaluation of vaccines from a societal perspective. Further efforts are required to document the full benefits of vaccination for policymaker consideration. CO 2021 Elsevier Ltd. All rights reserved.	[Silver, Madison C.; Neumann, Peter J.; Ma, Siyu; Kim, David D.; Cohen, Joshua T.; Ollendorf, Daniel A.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, 800 Washington St,Box 063, Boston, MA 02111 USA; [Nyaku, Mawuli; Roberts, Craig; Sinha, Anushua] Merck & Co Inc, Kenilworth, NJ USA		Silver, MC (通讯作者)，Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, 800 Washington St,Box 063, Boston, MA 02111 USA.	Msilver@hsph.harvard.edu		Ollendorf, Daniel/0000-0001-6016-8129; Silver, Madison/0000-0002-0344-2002			Alsan M, 2006, WORLD DEV, V34, P613, DOI 10.1016/j.worlddev.2005.09.006; Amiri A., 2013, IMPACT MATERNAL CHIL; [Anonymous], 2020, IMM AG 2030 GLOB STR; [Anonymous], Grey Matters: a practical tool for searching health-related grey literature; [Anonymous], 2019, UN DAT NAT IMM TECHN; Bill WT., 2014, FDN METHODS EC EVALU; Bloom DE, 2018, BROAD SOCIOECONOMIC; Board of the Governors of the Federal Reserve System, 2020, FOREIGN EXCHANGE RAT; Chambers JD, 2015, EXPERT REV PHARM OUT, V15, P399, DOI 10.1586/14737167.2015.1001371; Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Deogaonkar R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-878; Fink G, 2018, PRIORITIZING DEV COS, P266; Griffiths UK, 2013, J PEDIATR-US, V163, pS50, DOI 10.1016/j.jpeds.2013.03.031; Minh HV, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2297-x; Jit M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0446-9; Jit M, 2014, LANCET GLOB HEALTH, V2, pE406, DOI 10.1016/S2214-109X(14)70237-2; Kim DD, 2020, PHARMACOECONOMICS, V38, P1135, DOI 10.1007/s40273-020-00942-2; Kim SY, 2007, B WORLD HEALTH ORGAN, V85, P833, DOI 10.2471/BLT.06.038893; Liu WS, 2017, LEARN PUBL, V30, P115, DOI 10.1002/leap.1089; Mahumud RA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223658; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Mandrik O, 2020, VALUE HEALTH, V24, P463, DOI 10.1016/j.jval.2021.01.002; Mauskopf J, 2018, VALUE HEALTH, V21, P1133, DOI 10.1016/j.jval.2018.08.005; Neumann PJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168512; Neumann PJ, 2015, VALUE HEALTH, V18, P271, DOI 10.1016/j.jval.2014.12.002; Neumann PG., 2017, COST EFFECTIVENESS H, V2nd; Ozawa S, 2012, VACCINE, V31, P96, DOI 10.1016/j.vaccine.2012.10.103; Paternina-Caicedo A, 2015, PEDIATR INFECT DIS J, V34, pE176, DOI 10.1097/INF.0000000000000727; Sibak M, 2015, VACCINE, V33, pA182, DOI 10.1016/j.vaccine.2014.12.044; Sim SY, 2020, HEALTH AFFAIR, V39, P1343, DOI 10.1377/hlthaff.2020.00103; Standaert Baudouin, 2017, J Mark Access Health Policy, V5, P1335163, DOI 10.1080/20016689.2017.1335163; Standaert Baudouin, 2017, J Mark Access Health Policy, V5, P1336044, DOI 10.1080/20016689.2017.1336044; US Bureau of Labor Statistics, 2020, CONS PRIC IND; van der Putten IM, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6267343; Wolfson LJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220921; World Bank Country and Lending Groups, 2020, WORLD BANK; World Health Organization, 2019, WHO GUID STAND EC EV	38	1	1	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 5	2021	39	46					6727	6734		10.1016/j.vaccine.2021.09.070		NOV 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	YJ0BG	34656380				2022-04-29	WOS:000744203800003
J	Lee, SI; Jeong, CG; Mattoo, SU; Nazki, S; Aganja, RP; Kim, SC; Khatun, A; Oh, Y; Noh, SH; Lee, SM; Kim, WI				Lee, Sim-In; Jeong, Chang-Gi; Mattoo, Sameer ul Salam; Nazki, Salik; Aganja, Ram Prasad; Kim, Seung-Chai; Khatun, Amina; Oh, Yeonsu; Noh, Sang-Hyun; Lee, Sang-Myeong; Kim, Won-Il			Protective immunity induced by concurrent intradermal injection of porcine circovirus type 2 and Mycoplasma hyopneumoniae inactivated vaccines in pigs	VACCINE			English	Article						Porcine circovirus type 2; Mycoplasma hyopneumoniae; Intradermal vaccine; T-cell immune response	RESPIRATORY SYNDROME VIRUS; MULTISYSTEMIC WASTING SYNDROME; WHOLE-BLOOD; VACCINATION; DISEASE; TRANSMISSION; PCV2; INFECTION; EFFICACY; CELLS	Vaccines against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mhp) are routinely used by intramuscular injection. However, since intramuscular vaccination causes stress and increases the risk of cross-contamination among pigs, research on intradermal vaccination is currently being actively conducted. This study was designed to evaluate the efficacy of intradermally administered inactivated vaccines against PCV2 and Mhp in pigs. Three-week-old specific pathogen-free pigs were divided into three groups (5 pigs per group). Pigs in the two groups were intradermally vaccinated with the PCV2 or Mhp vaccine using a needle-free injector. Pigs in the third group were kept as nonvaccinated controls. At 21 days post-vaccination, pigs in one of these vaccinated groups and the nonvaccinated group were intranasally challenged with PCV2b and Mhp, while the other vaccinated group pigs were maintained as vaccine controls. Vaccine efficacy was evaluated by observing weight gain, pathogen load, pathological changes, and humoral or cellular immune responses. As a result, vaccinated pigs revealed significantly higher body weight gain, with lower clinical scores. Vaccinated pigs also showed higher antibody responses but lower PCV2b or Mhp loads in sera, nasal swabs, or lungs than nonvaccinated pigs. Intriguingly, vaccinated pigs upregulated cytotoxic T cells (CTLs), helper T type 1 cells (Th1 cells), and helper T type 17 cells (Th17 cells) after immunization and showed significantly higher levels of CTLs, Th1 and Th17 cells at 14 days post-challenge than nonvaccinated and challenged pigs. This study demonstrated that protective immune responses against PCV2 and Mhp could be efficiently induced in pigs using a relatively small volume of intradermal vaccines, probably due to effective antigen delivery to antigen-presenting cells in the dermis. CO 2021 Published by Elsevier Ltd.	[Lee, Sim-In; Jeong, Chang-Gi; Nazki, Salik; Kim, Seung-Chai; Khatun, Amina; Kim, Won-Il] Jeonbuk Natl Univ, Coll Vet Med, 79 Gobong Ro, Iksan, Jeonbuk, South Korea; [Mattoo, Sameer ul Salam; Aganja, Ram Prasad; Lee, Sang-Myeong] Jeonbuk Natl Univ, Div Biotechnol, Iksan, South Korea; [Nazki, Salik] Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England; [Khatun, Amina] Sher e Bangla Agr Univ, Fac Anim Sci & Vet Med, Dept Pathol, Dhaka 1207, Bangladesh; [Oh, Yeonsu] Kangwon Natl Univ, Dept Vet Pathol, Coll Vet Med, Chunchon 24341, South Korea; [Oh, Yeonsu] Kangwon Natl Univ, Inst Vet Sci, Chunchon 24341, South Korea; [Noh, Sang-Hyun] MSD Anim Hlth Korea Ltd, Seoul 04637, South Korea		Kim, WI (通讯作者)，Jeonbuk Natl Univ, Coll Vet Med, 79 Gobong Ro, Iksan, Jeonbuk, South Korea.; Lee, SM (通讯作者)，Jeonbuk Natl Univ, Div Biotechnol, Coll Environm & Biosource Sci, 79 Gobong Ro, Iksan, Jeonbuk, South Korea.	lunark321@gmail.com; jcg0102@gmail.com; drsameerulsalam@gmail.com; saliknazki@gmail.com; rpaganja@gmail.com; leesor2@jbnu.ac.kr; amina.vet.sau.bd@gmail.com; yeonoh@kangwon.ac.kr; livensh@gmail.com; leesangm@jbnu.ac.kr; kwi0621@jbnu.ac.kr	Khatun, Amina/U-7070-2017	Khatun, Amina/0000-0002-8384-1854; Nazki, Salik/0000-0002-2837-3365; Kim, Seung-Chai/0000-0002-1152-2248	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the Technology Development Program for Bioindustry [318038-2]; Technology Commercialization Program of the Ministry of Agriculture, Food and Rural Affairs in the Republic of Korea [821070-03]	This work was supported by Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the Technology Development Program for Bioindustry (318038-2) and the Technology Commercialization Program (821070-03) of the Ministry of Agriculture, Food and Rural Affairs in the Republic of Korea.	Afghah Z, 2017, VET MICROBIOL, V206, P21, DOI 10.1016/j.vetmic.2016.10.002; Alarcon P, 2013, PREV VET MED, V110, P88, DOI 10.1016/j.prevetmed.2013.02.010; Baker SR, 2012, J SWINE HEALTH PROD, V20, P123; Beffort L, 2017, VET REC, V181, DOI 10.1136/vr.104466; Carasova P, 2007, RES VET SCI, V83, P274, DOI 10.1016/j.rvsc.2006.11.013; Chae C, 2004, VET J, V168, P41, DOI 10.1016/j.tvjl.2003.09.018; Chae C, 2016, VET J, V212, P1, DOI 10.1016/j.tvjl.2015.10.030; Chae C, 2012, VET J, V194, P151, DOI 10.1016/j.tvjl.2012.06.031; Chen JW, 2010, J IMMUNOL METHODS, V357, P33, DOI 10.1016/j.jim.2010.03.006; Duffy D, 2014, IMMUNITY, V40, P436, DOI 10.1016/j.immuni.2014.03.002; Fano E, 2005, CAN J VET RES, V69, P223; Fano E, 2007, CAN J VET RES, V71, P195; Fort M, 2009, VACCINE, V27, P4031, DOI 10.1016/j.vaccine.2009.04.028; Garcia-Morante B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175034; Garcillan B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00020; Ge XN, 2012, VIRUS RES, V164, P100, DOI 10.1016/j.virusres.2011.10.005; Glajcar A, 2019, VIRCHOWS ARCH, V475, P13, DOI 10.1007/s00428-019-02568-y; Hansen MS, 2010, J COMP PATHOL, V143, P120, DOI 10.1016/j.jcpa.2010.01.012; Hubert A, 2018, HUM VACC IMMUNOTHER, V14, P1432, DOI 10.1080/21645515.2018.1434384; Jones HP, 2003, FRONT BIOSCI-LANDMRK, V8, pD930, DOI 10.2741/1098; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Karlsson Fridrik, 2015, Curr Protoc Cytom, V71, DOI 10.1002/0471142956.cy0635s71; Karuppannan AK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050099; Kim C, 2017, CLIN EXP IMMUNOL, V187, P71, DOI 10.1111/cei.12829; Kim D, 2011, VACCINE, V29, P3206, DOI 10.1016/j.vaccine.2011.02.034; Kurmann J, 2011, CLIN VACCINE IMMUNOL, V18, P1644, DOI 10.1128/CVI.05183-11; Leggat Peter A, 2009, J Occup Med Toxicol, V4, P25, DOI 10.1186/1745-6673-4-25; Lopez-Lorenzo G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51473-6; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Ma L, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3753081; Maes D, 2008, VET MICROBIOL, V126, P297, DOI 10.1016/j.vetmic.2007.09.008; Maes D, 2018, TRANSBOUND EMERG DIS, V65, P110, DOI 10.1111/tbed.12677; Marois C, 2010, J APPL MICROBIOL, V108, P1523, DOI 10.1111/j.1365-2672.2009.04556.x; Martelli P, 2014, VET MICROBIOL, V168, P357, DOI 10.1016/j.vetmic.2013.11.025; Meerts Peter, 2006, BMC Vet Res, V2, P6, DOI 10.1186/1746-6148-2-6; Michiels A, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1195-0; Ndure J, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00477; Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201; Odeh AN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155648; Oh T, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2091-6; Olvera A, 2004, J VIROL METHODS, V117, P75, DOI 10.1016/j.jviromet.2003.12.007; Opriessnig T., 2011, Animal Health Research Reviews, V12, P133, DOI 10.1017/S1466252311000120; Opriessnig T, 2017, VACCINE, V35, P248, DOI 10.1016/j.vaccine.2016.11.085; Opriessnig T, 2012, VIRUS RES, V164, P20, DOI 10.1016/j.virusres.2011.09.014; Opriessnig T, 2010, VET MICROBIOL, V142, P177, DOI 10.1016/j.vetmic.2009.09.056; Otake S, 2002, VET REC, V150, P114; Park C, 2016, VACCINE, V34, P270, DOI 10.1016/j.vaccine.2015.11.034; Park KH, 2019, VET MICROBIOL, V231, P87, DOI 10.1016/j.vetmic.2019.03.002; Pogranichnyy RM, 2000, VIRAL IMMUNOL, V13, P143, DOI 10.1089/vim.2000.13.143; Polo J, 2013, J ANIM SCI, V91, P2192, DOI 10.2527/jas.2012-5705; Poveda JB, 1998, METH MOL B, V104, P105; Rabenau HF, 2007, MED MICROBIOL IMMUN, V196, P151, DOI 10.1007/s00430-007-0037-2; Rakibuzzaman AGM, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030506; Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118; Rose N, 2012, VIRUS RES, V164, P78, DOI 10.1016/j.virusres.2011.12.002; Saade G, 2020, VET RES, V51, DOI 10.1186/s13567-020-00807-8; Seo HW, 2014, CAN J VET RES, V78, P233; Seo HW, 2014, VACCINE, V32, P2480, DOI 10.1016/j.vaccine.2014.02.088; Sibila M, 2012, J COMP PATHOL, V147, P285, DOI 10.1016/j.jcpa.2012.01.003; Silva-Campa E, 2012, VIROLOGY, V430, P73, DOI 10.1016/j.virol.2012.04.009; Sno M., 2016, Trials in Vaccinology, V5, P24, DOI 10.1016/j.trivac.2016.01.002; Tang CL, 2019, PARASITOL RES, V118, P559, DOI 10.1007/s00436-018-6186-y; Tassis PD, 2012, VET REC, V170, P261, DOI 10.1136/vr.100239; Teunissen MBM, 2012, CURR TOP MICROBIOL, V351, P25, DOI 10.1007/82_2011_169; Trible BR, 2012, VACCINE, V30, P4079, DOI 10.1016/j.vaccine.2012.04.022; Yang LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037513; Yang X, 2020, BIOL MODULATION TREG; Zhai SL, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-88	68	0	0	5	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6691	6699		10.1016/j.vaccine.2021.07.043		OCT 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34538524				2022-04-29	WOS:000708078600016
J	Hofmeister, MG; Weng, MK; Thoroughman, D; Thomasson, ED; McBee, S; Foster, MA; Collins, J; Burkholder, C; Augustine, RJ; Spradling, PR				Hofmeister, Megan G.; Weng, Mark K.; Thoroughman, Douglas; Thomasson, Erica D.; McBee, Shannon; Foster, Monique A.; Collins, Jim; Burkholder, Cole; Augustine, Ryan J.; Spradling, Philip R.			Prevalence of indications for adult hepatitis A vaccination among hepatitis A outbreak-associated cases, Three US States, 2016-2019	VACCINE			English	Article						Hepatitis A; Hepatitis A vaccines; Postexposure prophylaxis; Disease outbreaks; United States	IMMUNIZATION	Background: Safe and effective hepatitis A vaccines have been recommended in the United States for at risk adults since 1996; however, adult vaccination coverage is low. Methods: Among a random sample of adult outbreak-associated hepatitis A cases from three states that were heavily affected by person-to-person hepatitis A outbreaks, we assessed the presence of documented Advisory Committee on Immunization Practices (ACIP) indications for hepatitis A vaccination, hepatitis A vaccination status, and whether cases that were epidemiologically linked to an outbreak associated hepatitis A case had received postexposure prophylaxis (PEP). Results: Overall, 74.1% of cases had a documented ACIP indication for hepatitis A vaccination. Fewer than 20% of epidemiologically linked cases received PEP. Conclusions: Efforts are needed to increase provider awareness of and adherence to ACIP childhood and adult hepatitis A vaccination and PEP recommendations in order to stop the current person-to-person hepatitis A outbreaks and prevent similar outbreaks in the future. Published by Elsevier Ltd.	[Hofmeister, Megan G.; Weng, Mark K.; Foster, Monique A.; Augustine, Ryan J.; Spradling, Philip R.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA; [Thoroughman, Douglas] Kentucky Dept Publ Hlth, Frankfort, KY USA; [Thoroughman, Douglas; Thomasson, Erica D.] Ctr Dis Control & Prevent, Div State & Local Readiness, Career Epidemiol Field Officer Program, Atlanta, GA 30333 USA; [Thomasson, Erica D.; McBee, Shannon] West Virginia Dept Hlth & Human Resources, Bur Publ Hlth, Charleston, WV USA; [Collins, Jim; Burkholder, Cole] Michigan Dept Hlth & Human Serv, Div Communicable Dis, Lansing, MI USA		Hofmeister, MG (通讯作者)，Ctr Dis Control & Prevent, 1600 Clifton Rd,US12-3, Atlanta, GA 30333 USA.	lxn7@cdc.gov		Thoroughman, Doug/0000-0003-1150-1268; Weng, Mark/0000-0002-7902-2602			Centers for Disease Control and Prevention, 2020, WIDESPR PERS TO PERS; Centers for Disease Control and Prevention, 2020, OUTBR SPEC CONS HEP; Centers for Disease Control and Prevention, 2019, VACCINATION COVERAGE; Fiore Anthony E., 2006, Morbidity and Mortality Weekly Report, V55, P1; Hill HA, 2020, MMWR-MORBID MORTAL W, V69, P1505, DOI 10.15585/mmwr.mm6942a1; Hofmeister MG, 2021, J INFECT DIS, V223, P426, DOI 10.1093/infdis/jiaa636; Immunization Action Coalition, 2019, HEP A VACC MAND CHIL; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; Nelson NP, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6905a1; Philadelphia Department of Public Health Division of Disease Control, 2020, HEP OUTBR RESP UPD R; Snyder MR, 2019, AM J PUBLIC HEALTH, V109, pS297, DOI 10.2105/AJPH.2019.305139; The County of San Diego, 2018, HEP OUTBR ACT REP; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; Yin SM, 2020, CLIN INFECT DIS, V71, pE571, DOI 10.1093/cid/ciaa298	14	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 22	2021	39	44					6460	6463		10.1016/j.vaccine.2021.09.051		OCT 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WX9RH	34598818				2022-04-29	WOS:000718925300003
J	Sahraian, MA; Ghadiri, F; Azimi, A; Moghadasi, AN				Sahraian, Mohammad Ali; Ghadiri, Fereshteh; Azimi, Amirreza; Moghadasi, Abdorreza Naser			Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV	VACCINE			English	Article						Multiple sclerosis; Covid-19; Sinopharm vaccine; Adverse event		MS patients were one of the first populations vaccinated in Iran. To date, the most used vaccine brand on Iranian MS patients is Sinopharm COVID-19 vaccine. Here is the first study on the adverse events after the first dose of Sinopharm vaccine on 583 Iranian MS patients. A Google form link was sent to MS patients through social networks, between May 1, 2021 and May 22, 2021. No serious adverse event was reported. At least one complaint (mostly transient) was reported by 350 (60%) of vaccine recipients. Constitutional symptoms (malaise, fatigue, fever, shivering, & generalized body pain) (51%) and headache (9%) were the most reported complaints. We found a relation between gender and prior infection with COVID-19 and reported symptoms (p value less than 0.05). Only five recipients (0.9%) reported MS relapse after vaccination. MS worsening was a minor incident related to fever. (c) 2021 Elsevier Ltd. All rights reserved.	[Sahraian, Mohammad Ali; Ghadiri, Fereshteh; Azimi, Amirreza; Moghadasi, Abdorreza Naser] Univ Tehran Med Sci, Neurosci Inst, Multiple Sclerosis Res Ctr, Tehran, Iran		Moghadasi, AN (通讯作者)，Univ Tehran Med Sci, Sina MS Res Ctr, Sina Hosp, Hasan Abad Sq, Tehran, Iran.	abdorrezamoghadasi@gmail.com					Achiron A, 2021, MULT SCLER J, V27, P864, DOI 10.1177/13524585211003476; Almasi-Hashiani A, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01747-8; DiPiazza AT, 2021, BIOCHEM BIOPH RES CO, V538, P211, DOI 10.1016/j.bbrc.2020.10.060; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073; Grebenciucova E, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0800-8; Hejazizadeh N, 2020, IRAN J NURSING, V33, P1; Jayadevan R, 2021, SURVEY SYMPTOMS FOLL; Kelly H, 2021, J NEUROIMMUNOL, V356, DOI 10.1016/j.jneuroim.2021.577599; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Ruggieri Anna, 2016, Ann Ist Super Sanita, V52, P198, DOI 10.4415/ANN_16_02_11; Saeed BQ, 2021, INT J INFECT DIS, V111, P219, DOI 10.1016/j.ijid.2021.08.013; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Yang TT, 2017, J NEUROL SCI, V380, P256, DOI 10.1016/j.jns.2017.07.042	14	3	3	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 15	2021	39	43					6347	6350		10.1016/j.vaccine.2021.09.030		OCT 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS5LV	34579974	Bronze, Green Published			2022-04-29	WOS:000715223200003
J	Suliman, DM; Nawaz, FA; Mohanan, P; Modber, MAKA; Musa, MK; Musa, MB; El Chbib, D; Elhadi, YAM; Essar, MY; Isa, MA; Lucero-Prisno, DE; Moonesar, IA				Suliman, Duaa Mohamed; Nawaz, Faisal A.; Mohanan, Parvathy; Modber, Mohamed Abdul Kareem Adam; Musa, Muhammad Kabir; Musa, Mohamed Babiker; El Chbib, Diala; Elhadi, Yasir Ahmed Mohammed; Essar, Mohammad Yasir; Isa, Mashkur Abdulhamid; Lucero-Prisno, Don Eliseo, III; Moonesar, Immanuel Azaad			UAE efforts in promoting COVID-19 vaccination and building vaccine confidence Comment	VACCINE			English	Editorial Material						UAE; Vaccination program; COVID-19 Vaccine; Vaccine Hesitancy; COVID-19 response		The United Arab Emirates (UAE) is leading globally in many indicators for tackling the COVID-19 pandemic. This ranges from taking adequate preventive measures to the free vaccination drive and viable public health strategy. As of 18 August 2021, the UAE has significantly reduced the number of cases and successfully administered 17,454,250 doses. Furthermore, efforts and plans are underway to provide the third dose to high-risk people three months after completing the second dose and six months later to others. The UAE is considered one of the leaders globally for vaccinating "medically eligible" residents against COVID-19, with over 70% of the population currently fully vaccinated in the drive towards achieving herd immunity. The UAE's vaccination program is on track, covering a significant part of the population. The massive efforts of the National Vaccination Program's roll-out made by the UAE government and the various health authorities and stakeholders were vital for the general public's active participation in its success. (C) 2021 Elsevier Ltd. All rights reserved.	[Suliman, Duaa Mohamed; Moonesar, Immanuel Azaad] Mohammed Bin Rashid Sch Govt, Dept Acad Affairs Hlth Policy, Dubai, U Arab Emirates; [Nawaz, Faisal A.] Mohammed Bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates; [Mohanan, Parvathy] Med Univ Sofia, Fac Med, Sofia, Bulgaria; [Modber, Mohamed Abdul Kareem Adam] Univ Khartoum, Fac Nursing Sci, Khartoum, Sudan; [Musa, Muhammad Kabir] Ahmadu Bello Univ, Fac Pharmaceut Sci, Zaria, Nigeria; [Musa, Mohamed Babiker] Omdurman Islamic Univ, Fac Pharm, Khartoum, Sudan; [El Chbib, Diala] Lebanese Univ, Fac Med Sci, Beirut, Lebanon; [Elhadi, Yasir Ahmed Mohammed] Alexandria Univ, High Inst Publ Hlth, Dept Hlth Adm & Behav Sci, Alexandria, Egypt; [Essar, Mohammad Yasir] Kabul Univ Med Sci, Kabul, Afghanistan; [Isa, Mashkur Abdulhamid] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Lucero-Prisno, Don Eliseo, III] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London, England; [Lucero-Prisno, Don Eliseo, III] Univ Philippines, Open Univ, Los Banos, Laguna, Philippines		Moonesar, IA (通讯作者)，Mohammed Bin Rashid Sch Govt, Dept Acad Affairs Hlth Policy, Dubai, U Arab Emirates.	immanuel.moonesar@mbrsg.ac.ae	Elhadi, Yasir/AAH-8884-2021; Essar, Mohammad Yasir/AGD-2397-2022	Elhadi, Yasir/0000-0003-3649-0374; Lucero-Prisno, Don Eliseo III/0000-0002-2179-6365; El Chbib, Diala/0000-0003-2773-754X; Nawaz, Faisal/0000-0002-0701-7628; Mohanan, Parvathy/0000-0002-2380-7048	Mohammed Bin Rashid School of Government, Dubai, UAE; Alliance for Health Policy and Systems Research at the World Health Organization as part of the Knowledge to Policy (K2P) Center Mentor-ship Program [BIRD Project]	The author (s) disclosed receipt of the following financial sup-port for the research, authorship, and/or publication of this article: The authors would like to acknowledge Mohammed Bin Rashid School of Government, Dubai, UAE and the Alliance for Health Policy and Systems Research at the World Health Organization for support as part of the Knowledge to Policy (K2P) Center Mentor-ship Program [BIRD Project] .	Abu Dhabi Media Office, 2021, MALAFFI SUPPORTS ROL; Alsuwaidi AR, 2021, NAT IMMUNOL, V22, P1066, DOI 10.1038/s41590-021-01000-5; Alsuwaidi AR, 2020, HUM VACC IMMUNOTHER, V16, P3163, DOI 10.1080/21645515.2020.1753439; [Anonymous], 2021, GULFNEWS; [Anonymous], 2021, NATL NEWS; [Anonymous], 2021, UAE HANDLING COVID 1; [Anonymous], 2020, GULF TODAY; [Anonymous], 2021, GLOBALTIMES; [Anonymous], 2021, WALL STR J; [Anonymous], 2021, ARABIAN BUSINESS; [Anonymous], 2021, GULFNEWS; CNBC, 2021, UAE FLOATS MOV RESTR; CNBC Health and Science, 2020, DUB IS OFF PFIZ VACC; El Sharif A, UAE 1 COUNTRY ARAB W; GlobalMediaInsights, 2021, UAE POPULATION STAT; Godchaux-Berezhnova I, 2021, USING GLOBAL PRACTIC; Gulf Business, 2021, SEHA OPENS NEW COVID; Koornneef E, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2597-1; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; MOHAP, 2021, GET COVID 19 VACC EX; MOHAP,, 2021, COVID 19 VACC MIN HL; Muqattash R, 2020, DATA BRIEF, V33, DOI 10.1016/j.dib.2020.106446; National Emergency Crisis and Disaster Management Authority, 2020, VACCINE; NCEMA, 2021, HOM UAE COR COVID 19; ORF, UAES VACCINE DRIVE T; SSHAP, RAP REV VACC HES BUI; TAG 911, 2021, COVID 19 UPDATES UAE; UAE Government, 2021, VACC COVID 19 UAE OF; UAE Government, 2021, DISTR COVID 19 VACC; UAE Health, 2021, UAE ANN SCI RES PART; UAE Health, 2021, ASTRAZENECA COVID 19; WEQAYA, 2021, UAE RES PROM TOGETHE; WHO, VACC IMM; World Health Organization, 2020, GLOBAL TUBERCULOSIS	34	3	3	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 15	2021	39	43					6341	6345		10.1016/j.vaccine.2021.09.015		OCT 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS5LV	34561138	Green Published, Bronze			2022-04-29	WOS:000715223200001
J	Wiley, KE; Levy, D; Shapiro, GK; Dube, E; SteelFisher, GK; Sevdalis, N; Ganter-Restrepo, F; Menning, L; Leask, J				Wiley, K. E.; Levy, D.; Shapiro, G. K.; Dube, E.; SteelFisher, G. K.; Sevdalis, N.; Ganter-Restrepo, F.; Menning, L.; Leask, J.			A user-centered approach to developing a new tool measuring the behavioural and social drivers of vaccination	VACCINE			English	Article						Childhood vaccination; Survey; Qualitative interview; Social research; User-centered design	DESIGN THINKING; HESITANCY; VACCINES	Background: Children around the world remain under-vaccinated for many reasons. To develop effective vaccine delivery programmes and monitor intervention impact, vaccine programme implementers need to understand reasons for under-vaccination within their local context. The World Health Organization (WHO) Working Group on the Behavioural and Social Drivers of Vaccination (BeSD) is developing stan-dardised tools for assessing childhood vaccine acceptance and uptake that can be used across regions and countries. The tools will include: (1) a validated survey; (2) qualitative interview guides; and (3) cor-responding user guidance. We report a user-centred needs assessment of key end-users of the BeSD tools. Methods: Twenty qualitative interviews (Apr-Aug 2019) with purposively sampled vaccine programme managers, partners and stakeholders from UNICEF and WHO country and regional offices. The interviews assessed current systems, practices and challenges in data utilisation and reflections on how the BeSD tools might be optimised. Framework analysis was used to code the interviews. Results: Regarding current practices, participants described a variety of settings, data systems, and fre-quencies of vaccination attitude measurement. They reported that the majority of data used is quantita-tive, and there is appetite for increased use of qualitative data. Capacity for conducting studies on social/ behavioural drivers of vaccination was high in some jurisdictions and needed in others. Issues include barriers to collecting such data and variability in sources. Reflecting on the tools, participants described the need to explore the attitudes and practices of healthcare workers in addition to parents and care-givers. Participants were supportive of the proposed mixed-methods structure of the tools and training in their usage, and highlighted the need for balance between tool standardisation and flexibility to adapt locally. Conclusions: A user-centred approach in developing the BeSD tools has given valuable direction to their design, bringing the use of behavioural and social data to the heart of programme planning. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Wiley, K. E.] Univ Sydney, Fac Med & Hlth, Sch Publ Hlth, Room 127,Edward Ford Bldg A27, Sydney, NSW, Australia; [Levy, D.; Leask, J.] Univ Sydney, Fac Med & Hlth, Susan Wakil Sch Nursing & Midwifery, Sydney, NSW, Australia; [Shapiro, G. K.] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Support Care, Toronto, ON, Canada; [Dube, E.] Univ Laval, Fac Social Sci, Dept Anthropol, Quebec City, PQ, Canada; [SteelFisher, G. K.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Sevdalis, N.] Kings Coll London, Hlth Serv & Populat Res Dept, Ctr Implementat Sci, London, England; [Ganter-Restrepo, F.; Menning, L.] WHO Headquarters Dept Immunizat Vaccines & Biol, Geneva, Switzerland		Wiley, KE (通讯作者)，Univ Sydney, Fac Med & Hlth, Sch Publ Hlth, Room 127,Edward Ford Bldg A27, Sydney, NSW, Australia.	Kerrie.Wiley@sydney.edu.au	Sevdalis, Nick/O-1419-2017	Sevdalis, Nick/0000-0001-7560-8924; Shapiro, Gilla/0000-0002-2214-8263; Wiley, Kerrie/0000-0001-9699-7754; Ganter Restrepo, Francine/0000-0002-2147-6249	World Health OrganizationWorld Health Organization; Expanded Programme for Immunization Geneva, Switzerland; Global Alliance for Vaccines and Immunizations (GAVI)	This study was sponsored by the World Health Organization, Expanded Programme for Immunization Geneva, Switzerland and funded by The Global Alliance for Vaccines and Immunizations (GAVI).	Atkinson R., 2001, SOC RES UPDATE, V33, P1; Dube E, 2018, EXPERT REV VACCINES, V17, P989, DOI 10.1080/14760584.2018.1541406; Dube E, 2018, VACCINE, V36, P1509, DOI 10.1016/j.vaccine.2017.12.012; Eines TF, 2018, J NURS MANAGE, V26, P425, DOI 10.1111/jonm.12559; Experts SAGo, 2014, REP SAGE WORK GROUP; Fabri M, 2016, J ASSIST TECHNOL, V10, P102, DOI 10.1108/JAT-02-2016-0008; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Katsulis Z, 2016, APPL ERGON, V56, P117, DOI 10.1016/j.apergo.2016.03.011; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Munoz DC, 2015, INT J PUBLIC HEALTH, V60, P767, DOI 10.1007/s00038-015-0715-6; Nielsen J., 2012, MANY TEST USERS USAB; Organization WH, 2019, WHO UNICEF JOINT REP; World Health Organization, IMPR VACC DEM ADDR H	15	0	0	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6283	6290		10.1016/j.vaccine.2021.09.007		SEP 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34538695	hybrid			2022-04-29	WOS:000705822100017
J	Rizk, JG; Barr, CE; Rizk, Y; Lewin, JC				Rizk, John G.; Barr, Charles E.; Rizk, Youssef; Lewin, John C.			The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action	VACCINE			English	Editorial Material									[Rizk, John G.] Arizona State Univ, Edson Coll, Phoenix, AZ 85004 USA; [Barr, Charles E.] Pivotal Strateg Consulting LLC, Danville, CA USA; [Barr, Charles E.] Diya Hlth, Oakland, CA USA; [Rizk, Youssef] Lebanese Amer Univ, Med Ctr, St Johns Hosp, Dept Internal Med,Div Family Med, Lebanon, NH USA; [Lewin, John C.] Natl Coalit Hlth Care, Washington, DC USA		Rizk, JG (通讯作者)，Arizona State Univ, Edson Coll, Phoenix, AZ 85004 USA.	john.rizk@lau.edu		Rizk, John/0000-0002-5216-8695			Abu Mouch S, 2021, VACCINE, V39, P3790, DOI 10.1016/j.vaccine.2021.05.087; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Karron RA, 2021, JAMA-J AM MED ASSOC, V325, P2445, DOI 10.1001/jama.2021.7637; Ledford H, 2021, NATURE, V592, P495, DOI 10.1038/d41586-021-00998-w; Lee GM, 2020, JAMA-J AM MED ASSOC, V324, P1937, DOI 10.1001/jama.2020.19692; MacNeil JR, 2021, MMWR-MORBID MORTAL W, V70, P651, DOI 10.15585/mmwr.mm7017e4; Rizk JG, 2021, JAMA CARDIOL, V6, P1451, DOI 10.1001/jamacardio.2021.3444; Rizk JG, 2021, DRUG DISCOV TODAY, V26, P593, DOI 10.1016/j.drudis.2020.11.025; Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; See I, 2021, JAMA-J AM MED ASSOC, V325, P2448, DOI 10.1001/jama.2021.7517; VAERS, INF HEALTHC PROV	12	2	2	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6017	6018		10.1016/j.vaccine.2021.08.006		SEP 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34400020	Green Published, Bronze			2022-04-29	WOS:000701799200002
J	Xu, XL; Rodgers, MD; Guo, WH				Xu, Xinglu; Rodgers, Mark D.; Guo, Weihong (Grace)			A hub-and-spoke design for ultra-cold COVID-19 vaccine distribution	VACCINE			English	Article						Vaccine distribution; Network design; Resource allocation; COVID-19 pandemic	MODEL	An orderly and effective vaccination campaign is essential in combating the global COVID-19 pandemic. As one of the pioneers, the U.S. Center for Disease Control proposes a phased plan to promote the vaccination process. This plan starts with vaccinating the high-priority population in Phase 1, then turns to the remainder of the public in Phase 2, and ends with a scale-back network in Phase 3. The phased plan not only provides a sense of hope to impacted communities that this global pandemic can be defeated, but can serve as a template for other countries. To enhance this plan, this paper develops a generalizable framework for designing a hub-and-spoke vaccination dispensing network to achieve the goals in the Phase 2, which aims to expand the vaccination coverage for the general public. We introduce a new coverage index to measure the priority of different potential dispensing sites based on geo-data and develop an optimization model for network design. The hub-and-spoke network enhances the accessibility of the vaccines to various communities and helps to overcome the challenges related to ultra-cold storage facility shortage. A case study of Middlesex County in New Jersey is presented to demonstrate the application of the framework and provide insights for the Phase 2. Results from the baseline scenario show that increasing the driving time limit from 10 min to 25 min can improve the total coverage index from 40.8 to 55.9. Additionally, we explore how the changes of parameters impact the network design and discuss potential solutions for some special cases. When we allow 4 outreach nodes per hub, all potential 45 outreach points can be covered in the vaccination network within a 20-minute drive, and the total coverage index reaches its maximum value of 58.3. (c) 2021 Elsevier Ltd. All rights reserved.	[Xu, Xinglu; Guo, Weihong (Grace)] Rutgers State Univ, Dept Ind & Syst Engn, Piscataway, NJ 08854 USA; [Rodgers, Mark D.] Rutgers State Univ, Dept Supply Chain Management, Piscataway, NJ 07102 USA; [Xu, Xinglu] Dalian Univ Technol, State Key Lab Coastal & Offshore Engn, 2 Linggong Rd, Dalian 116023, Liaoning, Peoples R China		Guo, WH (通讯作者)，Rutgers State Univ, Dept Ind & Syst Engn, Piscataway, NJ 08854 USA.	wg152@soe.rutgers.edu		Guo, Weihong/0000-0001-8433-6326			Aruffo E, 2021, COMMUNITY STRUCTURED; Azadi Z, 2020, ANN OPER RES, V292, P215, DOI 10.1007/s10479-019-03164-8; Bar Gai DH, 2018, VACCINE, V36, P3505, DOI 10.1016/j.vaccine.2018.04.072; Centers for Disease Control and Prevention (CDC), 2020, COVID 19 VACC PROGR; Chen SI, 2014, IIE TRANS, V46, P853, DOI 10.1080/0740817X.2013.813094; Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312; Cotfas LA, 2021, IEEE ACCESS, V9, P33203, DOI 10.1109/ACCESS.2021.3059821; Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053; De Boeck K, 2020, OMEGA-INT J MANAGE S, V97, DOI 10.1016/j.omega.2019.08.004; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Ducharme J, WHY YOU MAY NOT BE A; Elrod JK, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2341-x; Esri, **NON-TRADITIONAL**; Farahani RZ, 2013, COMPUT IND ENG, V64, P1096, DOI 10.1016/j.cie.2013.01.012; FHWA, 2017, NAT HOUS TRAV SURV; Goldhill O., 2020, QUARTZ; Greasley A, 2012, J MANUF TECHNOL MANA, V23, P794, DOI 10.1108/17410381211253344; Han YJ, 2011, IEEE T AUTOM SCI ENG, V8, P683, DOI 10.1109/TASE.2011.2159838; Howard J, 2020, THE CNN; Johnson-Bolden N, 2020, OCCUP HEALTH SAF; Larson RC, 2012, VALUE HEALTH, V15, P158, DOI 10.1016/j.jval.2011.07.014; Lee BY, 2016, VACCINE, V34, P4998, DOI 10.1016/j.vaccine.2016.08.036; Lim J, 2016, OPER RES HEALTH CARE, V9, P40, DOI 10.1016/j.orhc.2016.02.003; Lin Q, 2020, EUR J OPER RES, V283, P182, DOI 10.1016/j.ejor.2019.11.005; Liu YZ, 2020, J MED ETHICS, V46, P499, DOI 10.1136/medethics-2020-106516; Malande OO, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212270; MCRRC, 2019, MIDDL COUNT IS PLAC; Mills MC, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100674; Mofrad M, 2018, OPER RES HEALTH CARE, V19, P66, DOI 10.1016/j.orhc.2018.03.003; NJDOH, 2020, COVID 19 VACC PLAN; Norman BA, 2013, VACCINE, V31, P5232, DOI 10.1016/j.vaccine.2013.08.079; Pladson K., 2021, DTSCH WELLE; Proano RA, 2012, OMEGA-INT J MANAGE S, V40, P53, DOI 10.1016/j.omega.2011.03.006; Rabta B, 2018, INT J DISAST RISK RE, V28, P107, DOI 10.1016/j.ijdrr.2018.02.020; Risanger S, 2021, HEALTH CARE MANAG SC, V24, P330, DOI 10.1007/s10729-020-09538-w; Roy S, 2021, IEEE ACCESS, V9, P15110, DOI 10.1109/ACCESS.2021.3053268; Schoch-Spana M, 2021, VACCINE, V39, P6004, DOI 10.1016/j.vaccine.2020.10.059; Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923; USCB, QUICKFACTS MIDDL COU; World Health Organization (WHO), 2020, YEAR PREC WHOS COVID	40	0	0	2	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6127	6136		10.1016/j.vaccine.2021.08.069		SEP 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34509324	Bronze, Green Published			2022-04-29	WOS:000701799200017
J	Lee, T; Gutierrez, RL; Maciel, M; Poole, S; Testa, KJ; Trop, S; Duplessis, C; Lane, A; Riddle, MS; Hamer, M; Alcala, A; Prouty, M; Maier, N; Erdem, R; Bourgeois, AL; Porter, CK				Lee, Tida; Gutierrez, Ramiro L.; Maciel, Milton; Poole, Steven; Testa, Kayla J.; Trop, Stefanie; Duplessis, Christopher; Lane, Alison; Riddle, Mark S.; Hamer, Melinda; Alcala, Ashley; Prouty, Michael; Maier, Nicole; Erdem, Rahsan; Bourgeois, A. Louis; Porter, Chad K.			Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli	VACCINE			English	Article						Enterotoxigenic Escherichia coli; Double mutant heat-labile enterotoxin; ETEC; dmLT; Vaccine; Intramuscular; CS6; CssBA	COLONIZATION FACTOR; MILK IMMUNOGLOBULIN; TRAVELERS DIARRHEA; ORAL CHALLENGE; PREVALENCE; EPIDEMIOLOGY; PROTECTION; ETIOLOGY; RISK	Introduction: Enterotoxigenic Escherichia coli (ETEC) is a common cause of infectious diarrhoea and a leading cause of morbidity and mortality in children living in resource-limited settings. It is also the leading cause of travellers' diarrhoea among civilian and military travellers. Its dual importance in global public health and travel medicine highlights the need for an effective vaccine. ETEC express colonization factors (CFs) that mediate adherence to the small intestine. An epidemiologically prevalent CF is coli surface antigen 6 (CS6). We assessed the safety and immunogenicity of a CS6-targeted candidate vaccine, CssBA, co-administered intramuscularly with the double-mutant heat-labile enterotoxin, dmLT [LT (R192G/L211A)]. Methods: This was an open-label trial. Fifty subjects received three intramuscular injections (Days 1, 22 and 43) of CssBA alone (5 1.1g), dmLT alone (0.1 1.1g) or CssBA (5, 15, 45 1.1g) + dmLT (0.1 and 0.5 1.1g). Subjects were actively monitored for adverse events for 28 days following the third vaccination. Antibody responses (IgG and IgA) were characterized in the serum and from lymphocyte supernatants (ALS) to CS6 and the native ETEC heat labile enterotoxin, LT. Results: Across all dose cohorts, the vaccine was safe and well-tolerated with no vaccine-related severe or serious adverse events. Among vaccine-related adverse events, a majority (98%) were mild with 79% being short-lived vaccine site reactions. Robust antibody responses were induced in a dose-dependent manner with a clear dmLT adjuvant effect. Response rates in subjects receiving 45 1.1g CssBA and 0.5 1.1g dmLT ranged from 50 to 100% across assays. Conclusion: This is the first study to demonstrate the safety and immunogenicity of CssBA and/or dmLT administered intramuscularly. Co-administration of the two components induced robust immune responses to CS6 and LT, paving the way for future studies to evaluate the efficacy of this vaccine target and development of a multivalent, subunit ETEC vaccine. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).	[Lee, Tida; Gutierrez, Ramiro L.; Maciel, Milton; Poole, Steven; Testa, Kayla J.; Trop, Stefanie; Duplessis, Christopher; Alcala, Ashley; Prouty, Michael; Porter, Chad K.] Naval Med Res Ctr, Enter Dis Dept, San Diego, CA 20014 USA; [Maciel, Milton; Poole, Steven; Testa, Kayla J.; Trop, Stefanie; Alcala, Ashley] Henry M Jackson Fdn, Bethesda, MD USA; [Hamer, Melinda] Walter Reed Army Inst Res, Silver Spring, MD USA; [Lane, Alison; Riddle, Mark S.; Hamer, Melinda] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Maier, Nicole; Erdem, Rahsan; Bourgeois, A. Louis] PATH, Seattle, WA USA; [Lee, Tida] Naval Med Ctr, Portsmouth, VA USA; [Maciel, Milton; Poole, Steven] NIAID, Div Aids, Bethesda, MD 20892 USA; [Trop, Stefanie] Beckman Coulter Life Sci Inc, Indianapolis, IN USA; [Lane, Alison] Naval Med Ctr, San Diego, CA USA; [Riddle, Mark S.] Univ Nevada, Reno, NV 89557 USA; [Hamer, Melinda] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Prouty, Michael] Naval Med Res Unit 6, Lima, Peru		Porter, CK (通讯作者)，Naval Med Res Ctr, Enter Dis Dept, San Diego, CA 20014 USA.	chad.k.porter2.civ@mail.mil		Erdem, Rahsan/0000-0002-4397-2606; Trop, Stefanie/0000-0003-0094-248X	PATH under a Cooperative Research and Development Agreement [NMR 9589]; Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1112376]	This study was funded by PATH under a Cooperative Research and Development Agreement (NMR 9589) . This work was sup-ported, in part, by the Bill & Melinda Gates Foundation (OPP1112376) . Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. The authors are in debt to Amanda Vazquez and Susan Cicatelli for their efforts in coordinating the conduct of the trial and to Aaron Kim, Zuzana Villar and Elizabeth Ward for their efforts to process blood samples and to perform the immunologic assays reported here. We would also like to thank the study volunteers without whom this trial would not have been possible.	Bernstein DI, 2019, VACCINE, V37, P602, DOI 10.1016/j.vaccine.2018.12.011; BLACK RE, 1984, PEDIATRICS, V73, P799; Bloom DE, 2000, SCIENCE, V287, P1207, DOI 10.1126/science.287.5456.1207; Boston Consulting Group, 2018, VACC TACKL DRUG RES; Centers for Disease Control and Prevention, 2019, ANTIBIOTIC RESISTANC; Clarkson KA, 2021, EBIOMEDICINE, V66, DOI 10.1016/j.ebiom.2021.103308; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; CRAVIOTO A, 1988, EPIDEMIOL INFECT, V101, P123, DOI 10.1017/S0950268800029289; El-Kamary SS, 2013, CLIN VACCINE IMMUNOL, V20, P1764, DOI 10.1128/CVI.00464-13; Freedman DJ, 1998, J INFECT DIS, V177, P662, DOI 10.1086/514227; Ghosal A, 2009, INFECT IMMUN; Guerrant DI, 1999, AM J TROP MED HYG, V61, P707, DOI 10.4269/ajtmh.1999.61.707; Hosangadi D, 2019, VACCINE, V37, P7372, DOI 10.1016/j.vaccine.2017.09.083; Isidean SD, 2011, VACCINE, V29, P6167, DOI 10.1016/j.vaccine.2011.06.084; Jansson L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004487; Jiang ZD, 2002, J INFECT DIS, V185, P497, DOI 10.1086/338834; Laird RM, 2018, VACCINE, V36, P6695, DOI 10.1016/j.vaccine.2018.09.052; LEVINE MM, 1979, INFECT IMMUN, V23, P729, DOI 10.1128/IAI.23.3.729-736.1979; LOPEZVIDA Y, 1990, J INFECT DIS, V162, P442, DOI 10.1093/infdis/162.2.442; Maciel M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224073; Maciel M, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00460-19; Olson S, 2019, TROP DIS TRAVEL MED, V5, DOI 10.1186/s40794-018-0077-1; Poole ST, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00788-18; Porter CK, 2017, MIL MED, V182, P4, DOI 10.7205/MILMED-D-17-00064; Porter CK, 2010, DIAGN MICR INFEC DIS, V66, P241, DOI 10.1016/j.diagmicrobio.2009.10.002; Qadri F, 2005, EMERG INFECT DIS, V11, P1104, DOI 10.3201/eid1107.041266; Qadri F, 2000, J CLIN MICROBIOL, V38, P27; Qadri F, 2005, CLIN MICROBIOL REV, V18, P465, DOI 10.1128/CMR.18.3.465-483.2005; Ramakrishnan A, 2021, VACCINE, V39, P487, DOI 10.1016/j.vaccine.2020.12.034; Riddle MS, 2020, VACCINE, V38, P7040, DOI 10.1016/j.vaccine.2020.09.025; Rollenhagen JE, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00634-18; Roy SP, 2012, MOL MICROBIOL, V86, P1100, DOI 10.1111/mmi.12044; Shah N, 2009, AM J TROP MED HYG, V80, P609, DOI 10.4269/ajtmh.2009.80.609; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]; TACKET CO, 1988, NEW ENGL J MED, V318, P1240, DOI 10.1056/NEJM198805123181904; Tobias J, 2008, VACCINE, V26, P5373, DOI 10.1016/j.vaccine.2008.07.091; Tribble DR, 2017, MIL MED, V182, P17, DOI 10.7205/MILMED-D-17-00068; Vidal RM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007037; von Mentzer A, 2014, NAT GENET, V46, P1321, DOI 10.1038/ng.3145; Walker R, 2017, VACCINE, V35, P6790, DOI 10.1016/j.vaccine.2017.06.076; Walker RI, 2015, VACCINE, V33, P946, DOI 10.1016/j.vaccine.2014.11.048; Wenneras C, 2004, J HEALTH POPUL NUTR, V22, P370; World Health Organization, 2020, DRAFT WHO PREF PROD; World Health Organization, 2021, LEV VACC RED ANT US; Zhang WP, 2012, EXPERT REV VACCINES, V11, P677, DOI [10.1586/erv.12.37, 10.1586/ERV.12.37]	45	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5548	5556		10.1016/j.vaccine.2021.08.032		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34419306	Green Published, hybrid			2022-04-29	WOS:000704399700014
J	Chua, HY; Kwan, MYW; Chan, ELY; Wong, JSC; Peiris, JSM; Cowling, BJ; Chiu, SS				Chua, Huiying; Kwan, Mike Y. W.; Chan, Eunice L. Y.; Wong, Joshua S. C.; Peiris, J. S. Malik; Cowling, Benjamin J.; Chiu, Susan S.			Influenza vaccine effectiveness against influenza-associated hospitalization in children in Hong Kong, 2010-2020	VACCINE			English	Article						Influenza; Vaccine effectiveness; Public Health	BURDEN; INFECTIONS; VIRUS	Background: Influenza virus infections can cause hospitalizations in children, and annual vaccination of children can provide protection against influenza. Methods: We analyzed a test-negative design study with data spanning from 2010/11 through 2019/20 to evaluate influenza vaccine effectiveness (VE) against influenza hospitalization in children by age group, influenza type/subtype and time period within each season. We enrolled children admitted to hospital with acute febrile respiratory illnesses. Nasopharyngeal aspirates were tested by culture and/or RTPCR to determine influenza status, and vaccination status was obtained by interviewing parents or legal guardians and was verified where possible. VE was estimated by conditional logistic regression model adjusting for sex, age and age-squared, matching on week. Results: Influenza seasons in Hong Kong are prolonged with influenza-associated hospitalizations occurring in almost every month of the year during the study period. Influenza vaccination was effective in preventing influenza-associated hospitalizations in children of all ages. Influenza VE was higher in younger children than in older children, and higher against hospitalization due to influenza A(H1N1) pdm09 than A(H3N2) and B. Conclusions: The childhood influenza vaccination program in Hong Kong has prevented influenza associated hospitalizations particularly in younger children. Our findings support the use of influenza vaccines in children as an effective approach to influenza control and prevention. (c) 2021 Elsevier Ltd. All rights reserved.	[Chua, Huiying; Peiris, J. S. Malik; Cowling, Benjamin J.] Univ Hong Kong, Li Ka Shing Fac Med, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Sch Publ Hlth, Hong Kong, Peoples R China; [Kwan, Mike Y. W.; Wong, Joshua S. C.] Princess Margaret Hosp, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China; [Chan, Eunice L. Y.; Chiu, Susan S.] Univ Hong Kong, Dept Paediat & Adolescent Med, Queen Mary Hosp, Hong Kong, Peoples R China; [Chan, Eunice L. Y.; Chiu, Susan S.] Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Peoples R China		Cowling, BJ (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Pokfulam, 7 Sassoon Rd, Hong Kong, Peoples R China.	bcowling@hku.hk		Kwan, Mike Yat Wah/0000-0002-1476-9625; Wong, Joshua Sung Chih/0000-0003-4815-5821	Health and Medical Research Fund; Food and Health Bureau, The Government of the Hong Kong Special Administrative Region [INFHKU-3]	This research was supported by the Health and Medical Research Fund, the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region (grant no. INFHKU-3).	Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527; Centre for Health Protection, FLU EXPR 2020 FLU EXPR 2020; Centre for Health Protection, INFL VACC PROGR 2005 INFL VACC PROGR 2005; Centre for Health Protection, 2019 20 SEAS INFL VA 2019 20 SEAS INFL VA; Chiu SS, 2002, NEW ENGL J MED, V347, P2097, DOI 10.1056/NEJMoa020546; Chiu SS, 2019, EURO SURVEILL, V24; Chiu SS, 2016, VACCINE, V34, P2164, DOI 10.1016/j.vaccine.2016.03.032; Chiu SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092914; Chiu SS, 2009, CLIN INFECT DIS, V49, P1016, DOI 10.1086/605570; Chon I, 2019, VACCINE-X, V1, DOI 10.1016/j.jvacx.2019.100011; CLOVER RD, 1991, J INFECT DIS, V163, P300, DOI 10.1093/infdis/163.2.300; Cobey S, 2018, CLIN INFECT DIS, V67, P327, DOI 10.1093/cid/ciy097; Cobey S, 2017, CURR OPIN VIROL, V22, P105, DOI 10.1016/j.coviro.2016.12.004; Cowling BJ, 2017, CLIN INFECT DIS, V65, P300, DOI 10.1093/cid/cix312; Cowling BJ, 2014, VACCINE, V32, P5278, DOI 10.1016/j.vaccine.2014.07.084; Feng S, 2018, LANCET RESP MED, V6, P925, DOI 10.1016/S2213-2600(18)30419-3; Flannery B, 2020, J INFECT DIS, V221, P8, DOI 10.1093/infdis/jiz543; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; GRUBER WC, 1990, AM J DIS CHILD, V144, P595, DOI 10.1001/archpedi.1990.02150290089035; Jackson ML, 2018, VACCINE, V36, P751, DOI 10.1016/j.vaccine.2017.12.022; Kalligeros M, 2020, VACCINE, V38, P2893, DOI 10.1016/j.vaccine.2020.02.049; Kawakami C, 2019, EURO SURVEILL, V24; Lee J, REAL TIME TRACKING I; Leung VK, 2016, EURO SURVEILL, V21; Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1; Neuzil Kathleen M, 2002, Semin Pediatr Infect Dis, V13, P174, DOI 10.1053/spid.2002.125860; Neuzil KM, 2001, PEDIATR INFECT DIS J, V20, P733, DOI 10.1097/00006454-200108000-00004; Ng S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059077; Ng S, 2012, PEDIATR INFECT DIS J, V31, P964, DOI 10.1097/INF.0b013e318263280e; Okoli GN, 2021, EXPERT REV VACCINES, V20, P585, DOI 10.1080/14760584.2021.1899821; Potter BI, 2019, VIRUS EVOL, V5, DOI 10.1093/ve/vez046; Powell LN, 2019, J PEDIAT INFECT DIS; Sugaya N, 2018, VACCINE, V36, P1063, DOI 10.1016/j.vaccine.2018.01.024; Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064; Wu P, 2012, J INFECT DIS, V206, P1862, DOI 10.1093/infdis/jis628; Yin JK, 2017, CLIN INFECT DIS, V65, P719, DOI 10.1093/cid/cix420	36	0	0	2	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4842	4848		10.1016/j.vaccine.2021.07.014		JUL 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34301433				2022-04-29	WOS:000679483400015
J	Arakaki, L; Tollefson, D; Kharono, B; Drain, PK				Arakaki, Lola; Tollefson, Deanna; Kharono, Brenda; Drain, Paul K.			Prevalence of rotavirus among older children and adults with diarrhea: A systematic review and meta-analysis	VACCINE			English	Review						Rotavirus; Enteric disease; Diarrhea; Elderly; Adults; Adolescents	GROUP-A ROTAVIRUS; ACUTE GASTROENTERITIS; VACCINE INTRODUCTION; GENETIC-CHARACTERIZATION; MOLECULAR EPIDEMIOLOGY; HOSPITALIZED CHILDREN; INFECTION; ETIOLOGY; SURVEILLANCE; DISEASE	Background: Older children and adults are susceptible to rotavirus, but the extent to which rotavirus affects this population is not fully understood, hindering accuracy of global rotavirus estimations. Objective: To determine what proportion of diarrhea cases are due to rotavirus among persons > 5 years old and to estimate this proportion by age strata. Methods: We conducted a systematic review and meta-analysis using the PRISMA guidelines. We included studies that reported on conditional rotavirus prevalence (i.e., percent of diarrhea due to rota virus) in persons >= 5 years old who were symptomatic with diarrhea/gastroenteritis and had laboratory confirmation for rotavirus infection. Studies on nosocomial infections and outbreak investigations were excluded. We collected age group-specific conditional rotavirus prevalence and other variables, such as study geography, study setting, and study type. We calculated pooled conditional rotavirus prevalence, corresponding 95% confidence intervals (95% CI), heterogeneity (I-2) estimates, and prediction intervals (PI). Results: Sixty-six studies from 32 countries met the inclusion criteria. Conditional rotavirus prevalence ranged from 0% to 30% across the studies. The total pooled prevalence of rotavirus among persons > 5 years old with diarrhea was 7.6% (95% CI: 6.2-9.2%, I-2 = 99.6%, PI: 0-24%). The pooled prevalence of rotavirus among older children and adolescents was 8.7% (95% CI: 6.2-11.7%, I-2 = 96%, PI:0-27%), among younger adults was 5.4% (95% CI: 1.4-11.8%, I-2 = 96%, PI:0-31%), and among older adults was 4.7% (95% CI: 2.8-7.0%, I-2 = 96%, PI:0-16%). Pooled conditional rotavirus prevalences did not differ by other variables. Conclusion: In this systematic review and meta-analysis of rotavirus among persons >= 5 years old with diarrhea, we found relatively low pooled conditional rotavirus prevalence compared to what is typically reported for children < 5 years; however, results should be interpreted with caution as the wide prediction intervals suggest large heterogeneity. (C) 2021 Elsevier Ltd. All rights reserved.	[Arakaki, Lola; Tollefson, Deanna; Kharono, Brenda; Drain, Paul K.] Univ Washington, Strateg Anal Res & Training START Ctr, 3980 15th Ave NE, Seattle, WA 98195 USA; [Arakaki, Lola] Univ Washington, Dept Epidemiol, 3980 15th Ave NE, Seattle, WA 98195 USA; [Tollefson, Deanna; Kharono, Brenda; Drain, Paul K.] Univ Washington, Dept Global Hlth, 3980 15th Ave NE, Seattle, WA 98195 USA; [Drain, Paul K.] Univ Washington, Dept Med, 1959 NE Pacific St, Seattle, WA 98195 USA		Tollefson, D (通讯作者)，Univ Washington, Strateg Anal Res & Training START Ctr, 3980 15th Ave NE, Seattle, WA 98195 USA.	lsa2118@uw.edu; dtollef@uw.edu; kharonob88@yahoo.co.uk; pkdrain@uw.edu		Drain, Paul/0000-0002-9569-4097; Tollefson, Deanna/0000-0002-6901-1854	Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR	This work was completed by the Strategic, Analysis, Research, and Training Program (START) at the University of Washington. START is a collaborative effort with, and is funded by, the Bill & Melinda Gates Foundation. The funder commissioned the study but did not have exclusive control of the design, data collection and analysis, decision to pursue publication, conclusions, or preparation of the manuscript.	Aliabadi N, 2019, LANCET GLOB HEALTH, V7, pE893, DOI 10.1016/s2214-109x(19)30207-4; Amarilla A, 2007, MED SCI MONITOR, V13, pCR333; Anderson EJ, 2004, LANCET INFECT DIS, V4, P91, DOI 10.1016/S1473-3099(04)00928-4; Anderson EJ, 2012, J INFECTION, V64, P89, DOI 10.1016/j.jinf.2011.09.003; Andersson M, 2017, J CLIN VIROL, V96, P1, DOI 10.1016/j.jcv.2017.09.005; [Anonymous], 2013, Wkly Epidemiol Rec, V88, P49; Atchison CJ, 2016, J INFECT DIS, V213, P243, DOI 10.1093/infdis/jiv398; Baker JM, 2019, CLIN INFECT DIS, V68, P976, DOI 10.1093/cid/ciy580; Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117; Banyai K., 2004, Acta Microbiologica et Immunologica Hungarica, V51, P431, DOI 10.1556/AMicr.51.2004.4.3; Barnes GL, 1998, J CLIN MICROBIOL, V36, P133, DOI 10.1128/JCM.36.1.133-138.1998; BINGNAN F, 1991, Journal of Clinical Microbiology, V29, P1359; Bittencourt  J A, 2000, Braz J Infect Dis, V4, P279; Borenstein M., 2009, INTRO META ANAL; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Breiman RF, 2014, PEDIATR INFECT DIS J, V33, pS54, DOI 10.1097/INF.0000000000000094; Bresee JS, 2012, J INFECT DIS, V205, P1374, DOI 10.1093/infdis/jis206; Carvalho-Costa FA, 2011, PEDIATR INFECT DIS J, V30, pS35, DOI 10.1097/INF.0b013e3181fefd5f; Cheun HI, 2010, KOREAN J PARASITOL, V48, P113, DOI 10.3347/kjp.2010.48.2.113; Chowdhury F, 2005, Trop Gastroenterol, V26, P80; Das SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070402; de Wit MAS, 2001, AM J EPIDEMIOL, V154, P666, DOI 10.1093/aje/154.7.666; de Wit MAS, 2001, CLIN INFECT DIS, V33, P280, DOI 10.1086/321875; Elhag WI, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-209; Hasing ME, 2009, J MED VIROL, V81, P2109, DOI 10.1002/jmv.21632; Faruque ASG, 2004, SCAND J INFECT DIS, V36, P204, DOI 10.1080/00365540410019219; Fernandez J, 2011, AGING CLIN EXP RES, V23, P145, DOI 10.3275/7040; Fletcher S, 2015, WEST PAC SURVEILL RE, V6, P7, DOI [10.5365/wpsar.2015.6.2.006, 10.5365/WPSAR.2015.6.2.006]; GERMANI Y, 1994, J CLIN MICROBIOL, V32, P1532, DOI 10.1128/JCM.32.6.1532-1536.1994; Gong XH, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019699; Gower CM, 2022, CLIN INFECT DIS, V74, P437, DOI 10.1093/cid/ciab460; Grassi T, 2008, TURKISH J PEDIATR, V50, P132; Grytdal SP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148395; Hacimustafaoglu M, 2011, TURKISH J PEDIATR, V53, P604; Hemming-Harlo M, 2017, J PEDIATR INFECT DIS, V6, P317, DOI 10.1093/jpids/piw061; Hilmarsdottir I, 2012, EUR J CLIN MICROBIOL, V31, P1501, DOI 10.1007/s10096-011-1470-0; Huhulescu S, 2009, INFECTION, V37, P103, DOI 10.1007/s15010-008-8106-z; Degiuseppe JI, 2017, J MED VIROL, V89, P423, DOI 10.1002/jmv.24650; IntHout J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010247; Isabel S, 2018, VACCINE, V36, P2033, DOI 10.1016/j.vaccine.2018.02.064; Jain S, 2016, INFECT GENET EVOL, V46, P65, DOI 10.1016/j.meegid.2016.10.021; Jain Swapnil, 2016, VirusDisease, V27, P77, DOI 10.1007/s13337-016-0303-2; Jansen A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-143; Jia L, 2016, J INFECT DEV COUNTR, V10, P1200, DOI 10.3855/jidc.6831; Johns Hopkins Bloomberg School of Public Health, VIEW HUB VIEW HUB; Kim HS, 2016, ANN CLIN LAB SCI, V46, P282; Kittigul L, 2014, SE ASIAN J TROP MED, V45, P816; Konca C, 2014, J PEDIATR INFECT, V8, P7, DOI 10.5152/ced.2014.1549; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Lahon A, 2013, EPIDEMIOL INFECT, V141, P969, DOI 10.1017/S0950268812001537; Lopman B, 2019, LANCET INFECT DIS, V19, P128, DOI 10.1016/S1473-3099(18)30798-9; Luchs A, 2014, BRAZ J INFECT DIS, V18, P53, DOI 10.1016/j.bjid.2013.05.010; da Silva MFM, 2017, J MED VIROL, V89, P64, DOI 10.1002/jmv.24605; Mladenova Z, 2010, EUR J CLIN MICROBIOL, V29, P555, DOI 10.1007/s10096-010-0895-1; Nair GB, 2010, GUT PATHOG, V2, DOI 10.1186/1757-4749-2-4; Nakajima H, 2001, LANCET, V357, P1950, DOI 10.1016/S0140-6736(00)05086-8; Nakamura N, 2016, J MED VIROL, V88, P1180, DOI 10.1002/jmv.24445; Nayak MK, 2018, ARCH VIROL, V163, P745, DOI 10.1007/s00705-017-3670-0; Nilsson M, 2000, J INFECT DIS, V182, P678, DOI 10.1086/315772; Podkolzin AT, 2009, J INFECT DIS, V200, pS228, DOI 10.1086/605054; Rohatgi A., 2011, WEBPLOTDIGITIZER; Schwarzer G, 2019, RES SYNTH METHODS, V10, P476, DOI 10.1002/jrsm.1348; Sethi D, 2001, EPIDEMIOL INFECT, V126, P63, DOI 10.1017/S0950268801005088; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; Shen Z, 2013, ARCH VIROL, V158, P1671, DOI 10.1007/s00705-013-1663-1; Steenland MW, 2013, AM J TROP MED HYG, V89, P641, DOI 10.4269/ajtmh.13-0307; Stroni GP, 2014, BALK MED J, V31, P196, DOI 10.5152/balkanmedj.2014.13142; Szucs G, 1999, ACTA PAEDIATR, V88, P61, DOI 10.1111/j.1651-2227.1999.tb14328.x; Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013; Tatte VS, 2014, VACCINE, V32, pA68, DOI 10.1016/j.vaccine.2014.03.009; Tatte VS, 2010, J MED VIROL, V82, P519, DOI 10.1002/jmv.21708; Thongprachum A, 2015, J MED VIROL, V87, P1141, DOI 10.1002/jmv.24155; Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1; Troeger C, 2018, JAMA PEDIATR, V172, P958, DOI 10.1001/jamapediatrics.2018.1960; Uchida R, 2006, J CLIN MICROBIOL, V44, P3499, DOI 10.1128/JCM.01089-06; Unal N, 2016, ACTA MEDICA MEDITERR, V32, P81; Wang YH, 2007, ARCH VIROL, V152, P669, DOI 10.1007/s00705-006-0904-y; Wang Y, 2017, INFECT GENET EVOL, V47, P143, DOI 10.1016/j.meegid.2016.11.018; Wang YH, 2011, ARCH VIROL, V156, P2221, DOI 10.1007/s00705-011-1122-9; Wang YH, 2009, J MED VIROL, V81, P382, DOI 10.1002/jmv.21387; Zhang SX, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0141-1; Zhang SX, 2017, J MED VIROL, V89, P71, DOI 10.1002/jmv.24606; Zhang ZK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173881; Zhirakovskaia E, 2016, INFECT GENET EVOL, V39, P1, DOI 10.1016/j.meegid.2016.01.001; Zhu M, 2013, EPIDEMIOL INFECT, V141, P540, DOI 10.1017/S0950268812000970	85	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4577	4590		10.1016/j.vaccine.2021.06.073		JUL 2021	14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	34244008				2022-04-29	WOS:000681356500003
J	Mwaba, J; Chisenga, CC; Xiao, SM; Ng'ombe, H; Banda, E; Shea, P; Mabula-Bwalya, C; Mwila-Kazimbaya, K; Laban, NM; Alabi, P; Chirwa-Chobe, M; Simuyandi, M; Harris, J; Iyer, AS; Bosomprah, S; Scalzo, P; Murt, KN; Ram, M; Kwenda, G; Ali, M; Sack, DA; Chilengi, R; Debes, AK				Mwaba, John; Chisenga, Caroline Cleopatra; Xiao, Shaoming; Ng'ombe, Harriet; Banda, Elena; Shea, Patrick; Mabula-Bwalya, Chileshe; Mwila-Kazimbaya, Katayi; Laban, Natasha Makabilo; Alabi, Peter; Chirwa-Chobe, Masuzyo; Simuyandi, Michelo; Harris, Jason; Iyer, Anita S.; Bosomprah, Samuel; Scalzo, Paul; Murt, Kelsey N.; Ram, Malathi; Kwenda, Geoffrey; Ali, Mohammad; Sack, David A.; Chilengi, Roma; Debes, Amanda K.			Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia	VACCINE			English	Article						Cholera; Oral Cholera Vaccine; Dose interval; Immunogenicity; Zambia	ANTIBODY-SECRETING CELL; WHOLE-CELL; IMMUNE-RESPONSES; FIELD-TRIAL; BANGLADESH; BIVALENT; PROTECTION; CHILDREN; TITER	Two-dose killed oral cholera vaccines (OCV) are currently being used widely to control cholera. The stan-dard dose-interval for OCV is 2 weeks; however, during emergency use of the vaccine, it may be more appropriate to use the available doses to quickly give a single dose to more people and give a delayed second dose when more vaccine becomes available. This study is an open label, randomized, phase 2 clinical trial of the vibriocidal response induced by OCV, comparing the responses when the second dose was given either 2 weeks (standard dose interval) or 6 months (extended dose interval) after the first dose. Vaccine was administered to healthy participants > 1 year of age living in the Lukanga Swamps area of Zambia. Three age cohorts (<5 years, 5-14 years, and > 15 years) were randomized to the either dose-interval. The primary outcome was the vibriocidal GMT 14 days after the second dose. 156 of 172 subjects enrolled in the study were included in this analysis. The Inaba vibriocidal titers were not significantly different 14 days post dose two for a standard dose-interval GMT: 45.6 (32- 64.9), as compared to the GMT 47.6 (32.6-69.3), for the extended dose-interval, (p = 0.87). However, the Ogawa vibriocidal GMTs were significantly higher 14 days post dose two for the extended-dose inter-val at 87.6 (58.9-130.4) compared to the standard dose-interval group at 49.7 (34.1-72.3), p = 0.04. Vibriocidal seroconversion rates (a > 4-fold rise in vibriocidal titer) were not significantly different between dose-interval groups. This study demonstrated that vibriocidal titers 14 days after a second dose when given at an extended\ dose interval were similar to the standard dose-interval. The findings suggest that a flexible dosing schedule may be considered when epidemiologically appropriate. The trial was registered at Clinical Trials.gov (NCT03373669). (c) 2021 Published by Elsevier Ltd.	[Mwaba, John; Chisenga, Caroline Cleopatra; Ng'ombe, Harriet; Banda, Elena; Mabula-Bwalya, Chileshe; Mwila-Kazimbaya, Katayi; Laban, Natasha Makabilo; Alabi, Peter; Chirwa-Chobe, Masuzyo; Simuyandi, Michelo; Bosomprah, Samuel; Chilengi, Roma] Ctr Infect Dis Res Zambia, Res Dept, Lusaka, Zambia; [Xiao, Shaoming; Shea, Patrick; Scalzo, Paul; Murt, Kelsey N.; Ram, Malathi; Ali, Mohammad; Sack, David A.; Debes, Amanda K.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St,E5036, Baltimore, MD 21205 USA; [Mwaba, John; Ng'ombe, Harriet; Mwila-Kazimbaya, Katayi; Kwenda, Geoffrey] Univ Zambia, Sch Hlth Sci, Dept Biomed Sci, Lusaka, Zambia; [Harris, Jason; Iyer, Anita S.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA USA; [Harris, Jason] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Laban, Natasha Makabilo] London Sch Hyg & Trop Med, London, England		Debes, AK (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St,E5036, Baltimore, MD 21205 USA.	adebes1@jhu.edu	Simuyandi, Michelo/I-5598-2018	Simuyandi, Michelo/0000-0002-7348-2835; Mabula-Bwalya, Chileshe/0000-0002-6329-5534; Ibukunoluwa Alabi, Peter/0000-0002-1436-5911	Bill AMP; Melinda Gates FoundationCGIAR [OPP1148763]; National institute of Allergy and Infectious DiseaseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [5R01AI123422]	The study was funded by the Bill & Melinda Gates Foundation (OPP1148763), which provided financial support through the John Hopkins University Delivery of Oral Cholera Vaccine Effectively (DOVE) project and from a grant from the National institute of Allergy and Infectious Disease (5R01AI123422). The funding agencies had no role in collecting, analyzing, or interpreting the results.	Akhtar M, 2017, VACCINE, V35, P321, DOI 10.1016/j.vaccine.2016.11.055; Akter A, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007634; Ali M, 2005, LANCET, V366, P44, DOI 10.1016/S0140-6736(05)66550-6; Ali M, 2019, INT HEALTH, V11, P229, DOI 10.1093/inthealth/ihy085; Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P477; [Anonymous], 2011, VACCINE, V29, P8285; Azman AS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001867; Azman AS, 2020, LANCET MICROBE, V1, pE336, DOI 10.1016/S2666-5247(20)30141-5; Baik YO, 2015, VACCINE, V33, P6360, DOI 10.1016/j.vaccine.2015.08.075; Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1; Bi QF, 2017, LANCET INFECT DIS, V17, P1080, DOI [10.1016/s1473-3099(17)30359-6, 10.1016/S1473-3099(17)30359-6]; Central_Statistical_Office, 2013, CENTR PROV; Charles RC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002828; Chowdhury F, 2020, VACCINE, V38, P1753, DOI 10.1016/j.vaccine.2019.12.034; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1991, J INFECT DIS, V163, P1235, DOI 10.1093/infdis/163.6.1235; Desai SN, 2015, AM J TROP MED HYG, V93, P527, DOI 10.4269/ajtmh.14-0683; Donken R, 2015, VACCINE, V33, P1426, DOI 10.1016/j.vaccine.2015.01.072; Falkard B, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007057; Franke MF, 2018, LANCET GLOB HEALTH, V6, pE1028, DOI 10.1016/S2214-109X(18)30284-5; HORNICK RB, 1971, B NEW YORK ACAD MED, V47, P1181; Iyer AS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006196; Iyer AS, 2016, SCI REP-UK, V6, DOI 10.1038/srep35742; Kanungo S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003574; Kanungo S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096499; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; Kauffman RC, 2016, MBIO, V7, DOI [10.1128/mBio.02021-16, 10.1128/mbio.02021-16]; Khan MI., VACCINE, V39, P4516; Legros D., 2018, J INFECT DIS; Mohan VR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218033; MOSLEY WH, 1968, B WORLD HEALTH ORGAN, V38, P777; MOSLEY WH, 1968, B WORLD HEALTH ORGAN, V38, P335; Qadri F, 2018, LANCET INFECT DIS, V18, P666, DOI 10.1016/S1473-3099(18)30108-7; Qadri F, 2013, VACCINE, V31, P452, DOI 10.1016/j.vaccine.2012.11.012; Rahman A, 2013, CLIN VACCINE IMMUNOL, V20, P1592, DOI 10.1128/CVI.00347-13; Ritter AS, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz057; Sack DA, 2019, LANCET INFECT DIS, V19, P122, DOI 10.1016/S1473-3099(18)30662-5; Sinyange N, 2018, MMWR-MORBID MORTAL W, V67, P556, DOI 10.15585/mmwr.mm6719a5; von Seidlein L, 2013, J INFECT DIS, V208, pS8, DOI 10.1093/infdis/jit194	40	2	2	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4516	4523		10.1016/j.vaccine.2021.06.034		JUL 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34217572				2022-04-29	WOS:000672160300019
J	Myles, IA; Vinciguerra, JS; Premus, RT				Myles, Ian A.; Vinciguerra, Joshua S.; Premus, Robert T.			Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site	VACCINE			English	Article						COVID-19; Pfizer; Mass Vaccination; SARS-CoV-2	ANAPHYLAXIS	Healthcare providers can play a key role in reaching the target for vaccine uptake through educating the public on the risk may be of severe allergic reactions to COVID-19 vaccines. Thus, it is important to resolve reports in the literature which present conflicting data on vaccine safety. We performed a prospective study of Pfizer-BioNTech vaccinations administered at the Albany Community Vaccination Center. All potential vaccinees to the site were screened for allergic history prior to triage by a board-certified allergist. In the first 14 days of operation, our site vaccinated 14,655 individuals, 3.9% of which had a personal history of anaphylaxis. While some vaccine recipients had non-allergic complications, none of the visitors suffered any objective, immediate allergic symptoms. Our findings indicate that specialist-confirmed rates of immediate allergic reaction to mRNA SARS-CoV-2 vaccination are far lower than self-reported rates defined by subjective, unconfirmed symptoms. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).	[Myles, Ian A.] NIAID, US Publ Hlth Serv, US Dept HHS, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Vinciguerra, Joshua S.] New York State Dept Hlth, Albany, NY USA; [Premus, Robert T.] Fed Emergency Management Assoc, Washington, DC USA		Myles, IA (通讯作者)，NIAID, US Publ Hlth Serv, US Dept HHS, 9000 Rockville Pike, Bethesda, MD 20892 USA.	myles@niaid.nih.gov		Myles, Ian/0000-0001-9316-3703	Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Department of Health and Human Services, New York State Department of Health; Department of Homeland SecurityUnited States Department of Homeland Security (DHS)	This program was made possible through funding of the Department of Health and Human Services, New York State Department of Health, and the Department of Homeland Security. This work was further supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH).	Blumenthal KG, JAMA-J AM MED ASSOC, V2021; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lee S, 2017, J ALLERGY CLIN IMMUN, V139, P182, DOI 10.1016/j.jaci.2016.04.029; Luskin KT, J ALLERGY CLIN IMMUN, V2021; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Shimabukuro TT, 2021, JAMA-J AM MED ASSOC, V325, P1101, DOI 10.1001/jama.2021.1967; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P461, DOI 10.1016/j.jaci.2013.08.016	8	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4404	4406		10.1016/j.vaccine.2021.06.061		JUL 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34217573	Green Published, hybrid			2022-04-29	WOS:000672160300003
J	Smith, LE; Hodson, A; Rubin, GJ				Smith, Louise E.; Hodson, Ava; Rubin, G. James			Parental attitudes towards mandatory vaccination; a systematic review	VACCINE			English	Review						Exemptions; Child vaccination; Vaccine refusal; Vaccine hesitancy; Uptake; Policy	NO JAB; IMMUNIZATIONS; GOVERNMENT; CHILDREN; POLICIES; BELIEFS; REFUSAL; HEALTH; PLAY; PAY	Uptake of childhood vaccines is decreasing. While mandatory vaccination schemes can increase vaccine uptake rates, they can also cause backlash among some parents. We conducted a systematic review investigating parental beliefs about vaccine mandates and factors associated with support for mandatory vaccination schemes. We searched Embase, Ovid MEDLINE, Global Health, APA PsycINFO and Web of Science from inception to 17th September 2020. Seventeen studies (five qualitative, twelve quantitative) were eligible for inclusion. We synthesised results of qualitative and quantitative studies separately. As quantitative studies were heterogeneous in the mandatory vaccination schemes and associated factors investigated, there was no scope to conduct a meta-analysis. Instead, data were narratively synthesised, considering risk of bias ratings. Qualitative data were synthesised using meta-ethnography, synthesising themes reported across studies included. Quantitative studies reported that support for mandatory vac-cination schemes was reasonably high (73% to 88%). However, due to heterogeneity, there was little evi-dence for any factors being consistently associated with support for mandatory vaccination. Qualitative studies gave an insight into how parents perceive mandatory vaccination. Studies found that parents per-ceived mandatory vaccination schemes as an infringement of their rights, and particularly disliked schemes offering financial incentives for vaccination. Nevertheless, some parents felt that schemes lim-iting access to schooling of unvaccinated children gave them "peace of mind." Results should be taken with caution due to the purposive use of non-representative samples. Before deciding to mandate vacci-nation, it is important to understand the impact it could have on parental beliefs and attitudes about vaccination. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Smith, Louise E.; Rubin, G. James] Kings Coll London, Dept Psychol Med, London, England; [Smith, Louise E.; Hodson, Ava; Rubin, G. James] NIHR Hlth Protect Res Unit Emergency Preparedness, London, England; [Hodson, Ava] Kings Coll London, Dept War Studies, London, England		Smith, LE (通讯作者)，Kings Coll London, Weston Educ Ctr, Dept Psychol Med, Cutcombe Rd, London SE5 9RJ, England.	louise.e.smith@kcl.ac.uk			National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response	This study was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emergency Preparedness and Response, a partnership between Public Health England, King's College London and the University of East Anglia. The views expressed are those of the authors and not necessarily those of the NIHR, Public Health England or the Department of Health and Social Care. The funding source had no involvement in the study.	Adams, 2017, MDM POLICY PRACT, V2; Adams J, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19940; Aharon AA, 2017, PATIENT EDUC COUNS, V100, P768, DOI 10.1016/j.pec.2016.11.016; [Anonymous], 2019, LANCET CHILD ADOLESC, V3, P281, DOI 10.1016/S2352-4642(19)30092-6; ANONYMOUS, 2019, LANCET, V393, P960; [Anonymous], 2021, BBC NEWS; Armiento R, 2020, VACCINE, V38, P5231, DOI 10.1016/j.vaccine.2020.05.094; Atkins S, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-21; Betsch C, 2016, EUR J PUBLIC HEALTH, V26, P378, DOI 10.1093/eurpub/ckv154; Calo WA, 2020, HUM VACC IMMUNOTHER, V16, P128, DOI 10.1080/21645515.2019.1646580; Centers for Disease Control and Prevention, 2020, REQ VACC CHILD CAR S; European Medicines Agency, 2021, 1 COVID 19 VACC APPR; Gardner B, 2010, ARCH DIS CHILD, V95, P658, DOI 10.1136/adc.2009.169813; Gravagna K, 2020, VACCINE, V38, P7865, DOI 10.1016/j.vaccine.2020.09.063; Grossman Z, 2019, PEDIATR INFECT DIS J, V38, pE75, DOI 10.1097/INF.0000000000002147; Gualano MR, 2019, HUM VACC IMMUNOTHER, V15, P918, DOI 10.1080/21645515.2018.1564437; Helps C, 2018, J PUBLIC HEALTH POL, V39, P156, DOI 10.1057/s41271-017-0116-6; Jain V, 2020, SHOULD COVID 19 VACC; Kalucka SK, 2016, FAM MED PRIM CARE RE, V18, P425, DOI 10.5114/fmpcr.2016.63695; Kennedy AM, 2005, J SCHOOL HEALTH, V75, P276, DOI 10.1111/j.1746-1561.2005.00037.x; Kennedy AM, 2005, PUBLIC HEALTH REP, V120, P252, DOI 10.1177/003335490512000306; Krasnicka J, 2020, BMC PEDIATR, V20, DOI 10.1186/s12887-020-02235-1; Krasnicka J, 2018, HUM VACC IMMUNOTHER, V14, P2884, DOI 10.1080/21645515.2018.1496766; Krok-Schoen JL, 2018, J RURAL HEALTH, V34, P283, DOI 10.1111/jrh.12285; Larson Heidi J, 2018, Lancet, V391, P527, DOI 10.1016/S0140-6736(18)30193-4; Lee C, 2016, J INFECTION, V72, P659, DOI 10.1016/j.jinf.2016.04.002; Lee C, 2016, VACCINE, V34, P3972, DOI 10.1016/j.vaccine.2016.06.048; MacDonald NE, 2018, VACCINE, V36, P5811, DOI 10.1016/j.vaccine.2018.08.042; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n723; Makaric ZL, 2018, VACCINE, V36, P7530, DOI 10.1016/j.vaccine.2018.10.055; McDonald P, 2019, VACCINE, V37, P742, DOI 10.1016/j.vaccine.2018.12.018; McNaughton RJ, 2016, VACCINE, V34, P2259, DOI 10.1016/j.vaccine.2016.03.009; Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873; Noblit GW, 1988, META ETHNOGRAPHY SYN; Omer SB, 2019, NATURE, V571, P469, DOI 10.1038/d41586-019-02232-0; Paxton GA, 2016, MED J AUSTRALIA, V205, P296, DOI 10.5694/mja16.00351; Peijin LS, 2016, 201646 ESPN; Hong QN, 2019, J CLIN EPIDEMIOL, V111, P49, DOI 10.1016/j.jclinepi.2019.03.008; Roush SW, 2007, JAMA-J AM MED ASSOC, V298, P2155, DOI 10.1001/jama.298.18.2155; Salmon DA, 2015, LANCET INFECT DIS, V15, P872, DOI 10.1016/S1473-3099(15)00156-5; Screening and Immunisations Team COVER Team, 2019, CHILDH VACC COV STAT; Shucksmith, 2016, PLOS ONE, V11; Sibley CG, 2020, ECLINICALMEDICINE, P23; Tabacchi G, 2016, HUM VACC IMMUNOTHER, V12, P1909, DOI 10.1080/21645515.2016.1151990; Tarrant M, 2008, J PAEDIATR CHILD H, V44, P541, DOI 10.1111/j.1440-1754.2008.01334.x; Trent MJ, 2019, VACCINE, V37, P5250, DOI 10.1016/j.vaccine.2019.07.066; Troupe D., 2017, Californian Journal of Health Promotion, V15, P46; Walkinshaw E, 2011, CAN MED ASSOC J, V183, pE1165, DOI 10.1503/cmaj.109-3992; Wang E, 2014, AM J PUBLIC HEALTH, V104, pE62, DOI 10.2105/AJPH.2014.302190; World Health Organization, 2020, TABL 1 SUMM WHO POS; World Health Organization, 2021, COR COVID 19	51	4	4	2	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4046	4053		10.1016/j.vaccine.2021.06.018		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TI1ID	34140173	Green Submitted			2022-04-29	WOS:000672535200008
J	Bifulco, M; Pisanti, S; Fusco, I				Bifulco, Maurizio; Pisanti, Simona; Fusco, Idamaria			Lessons from the 1656 Neapolitan Plague: Something to learn for the current coronavirus Pandemic?	VACCINE			English	Editorial Material						History of vaccine; Plague; Epidemy; Prevention; Coronavirus; Covid-19		In the spring of 1656, an epidemic of bubonic plague suddenly fell on Naples, the capital of the Kingdom of the Two Sicilies. The epidemic had put a strain on the government authorities, forcing them to take sometimes drastic measures but, in most cases, scarcely decisive. The current health emergency caused by Covid-19 disease has many similarities with the epidemics of the past. Here we report the parallelism among plague and Covid-19 in several respects. Taking as a paradigm the plague epidemic of Naples of 1656, we can easily understand how history, showing us how past epidemics were managed and overcome, even with the intrinsic differences due to the limits of time and scientific progress, can still give us a useful lesson to face the present. (C) 2021 Published by Elsevier Ltd.	[Bifulco, Maurizio] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy; [Pisanti, Simona] Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, Salerno, Italy; [Fusco, Idamaria] CNR ISEM Inst Hist Mediterranean Europe, Cagliari, Italy		Bifulco, M (通讯作者)，Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy.	maubiful@unina.it					Alfani G, 2013, EUR REV ECON HIST, V17, P408, DOI 10.1093/ereh/het013; Arrizabalaga J, 2018, HIST MED CONTEXT, P62; Carlucci L, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.559288; Cipolla CM, 1985, CONTRO NEMICO INVISI; Cohn Jr. S. K., 2010, CULTURES PLAGUE MED; Cohn Samuel K Jr, 2008, Med Hist Suppl, P74; De Renzi S, 1968, NAPOLI NELLANNO 1656; Elliott CP, 2016, PAST PRESENT, P3, DOI 10.1093/pastj/gtv058; Fosi I, 2006, ROMA MODERNA CONT, VXIV, P1; Fusco I., 2017, ANN DEMOGRAPHIE HIST, V134, P95; Fusco I., 2009, POPOLAZIONE STORIA, V1, P115; Fusco I, 2004, FORZE PRINCIPE RECUR, P137; Fusco I, 2020, MED HIST S1, V4, P21; Fusco I, 2007, DEMOGRAFIA FISCALITA; Fusco I, 2017, GRANDE EPIDEMIA POTE; Green A, 2020, LANCET, V395, P682, DOI 10.1016/S0140-6736(20)30382-2; Green MH, 2015, MEDIEVAL GLOBE, V1, P27; Latiosi A, 1656, BREVE DISCORSO PESTE; Manconi F, 1994, GRANDE PESTE BAROCCA; Mordechai L, 2019, PAST PRESENT, P3, DOI 10.1093/pastj/gtz009; Quadri SA, 2020, INT J INFECT DIS, V96, P219, DOI 10.1016/j.ijid.2020.05.007; Scasciamacchia S, 2012, EMERG INFECT DIS, V18, P186, DOI 10.3201/eid1801.110597; Seguy I, 2017, ANN DEMOGRAPHIE HIST, V2, P15; Steensma DP, 2020, MAYO CLIN PROC, V95, pE7, DOI 10.1016/j.mayocp.2019.11.006; White LA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231256	25	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 16	2021	39	27					3641	3643		10.1016/j.vaccine.2021.05.046		JUN 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SO5NX	34052067	Bronze, Green Published			2022-04-29	WOS:000659020000014
J	Laurenz, M; von Eiff, C; Borchert, K; Jacob, C; Seidel, K; Schley, K				Laurenz, Maren; von Eiff, Christof; Borchert, Kathrin; Jacob, Christian; Seidel, Karolin; Schley, Katharina			Vaccination rates and adherence in pneumococcal conjugate vaccination in mature born infants before and after vaccination schedule change-A claims database analysis	VACCINE			English	Article						Vaccination rates; Pneumococcal conjugate vaccine; Hexavalent vaccination; Mature newborns; Claims data analysis		Background: In August 2015, the German Standing Committee on Vaccination (STIKO) changed the pneu-mococcal conjugate vaccination (PCV) schedule for mature infants from a 3+1 scheme to a 2+1 scheme. It was expected that a reduction of doses would be associated with a higher acceptance of the vaccination. Aim of this study was to assess vaccination rates and adherence for PCV after the change of recommen-dation based on real-world data. Methods: A retrospective claims data analysis using the InGef Research Database was conducted. The study population consisted of all mature infants born in 2013 (last birth cohort completely under 3+1 rec-ommendation) or 2016 (first birth cohort completely under 2+1 recommendation) with an individual follow-up of 24 months. Hexavalent combination vaccination (HEXA) with a consistent 3+1 recommen-dation was analyzed as reference. Results: After follow-up of 24 months, 90.9% (91.2%) of the 2016 (2013) cohort received at least one dose of PCV. At the same age, 67.7% of the 2013 cohort received a booster dose according to the 3+1 schedule and 75.6% of the 2016 cohort received a booster dose presumably either according to the 2+1 (71.7%) or 3 +1 (3.9%) schedule. Of those receiving the booster dose, only 46.3% (2016) and 45.1% (2013) received the booster dose on time as recommended. The HEXA vaccination rate increased from 88.9% (2013) to 91.6% (2016) with a full series completion in 69.1% (2013) vs 72.9% (2016). The proportion of infants receiving the booster vaccination on time rose to 50.0% in 2016 (47.8% in 2013). Conclusions: Although the rate for the PCV booster dose slightly increased, nearly a quarter of the infants born in 2016 did not receive a booster dose at all. Furthermore, vaccinations were still frequently delayed, and the rate of unvaccinated infants remained constant. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Laurenz, Maren; von Eiff, Christof] Pfizer Pharma GmbH, Linkstr 10, D-10785 Berlin, Germany; [Borchert, Kathrin; Jacob, Christian; Seidel, Karolin] Xcenda GmbH, Lange Laube 31, D-30159 Hannover, Germany; [Schley, Katharina] Pfizer Deutschland GmbH, Linkstr 10, D-10785 Berlin, Germany		Laurenz, M (通讯作者)，Pfizer Pharma GmbH, Linkstr 10, D-10785 Berlin, Germany.	Maren.Laurenz@pfizer.com; Christof.vonEiff@pfizer.com; Kathrin.Borchert@xcenda.de; Christian.Jacob@xcenda.de; Karolin.Seidel@xcenda.de; Katharina.Schley@pfizer.com		Schley, Katharina/0000-0002-0975-4154; Seidel, Karolin/0000-0002-2682-5620			Andersohn F, 2016, PHARMACOEPIDEM DR S, V25, P106, DOI 10.1002/pds.3895; AQUA-Institut fur angewandte Qualitatsforderung und Forschung im Gesundheitswesen GmbH, 2014, BUND ERF 2013 16 1 G; Bayerisches Landesamt fur Gesundheit und Lebensmittelsicherheit (LGL), 2019, BAYER IMPFW; Boey L, 2020, HUM VACC IMMUNOTHER, V16, P2136, DOI 10.1080/21645515.2020.1763739; Bundesministerium fur Gesundheit, 2019, KENNZ GES KRANK 2007; Bundesministerium fur Gesundheit, 2021, GES DIG; Bundeszentrale fur gesundheitliche Aufklarung (BZgA), 2020, UNT U1 U9 WAS WIRD G; Bundeszentrale fur gesundheitliche Aufklarung (BZgA), 2020, DEUTSCHL SUCHT IMPF; Centers for Disease Control and Prevention (CDC), 2019, IMM INF SYST; DOnofrio A, 2013, MODELING INTERPLAY H, DOI [10.1007/978-1-4614-5474-8, DOI 10.1007/978-1-4614-5474-8]; ECDC, 2017, IMM INF SYST EU EEA; Gemeinsamer Bundesausschuss, 2016, RICHTL GEM BUND FRUH; https://www. rki.de/DE/Content/Infekt/EpidBull/Archiv/2020/32_33/Tabelle.html? nn=2371176, 2020, EP B IMPF KIND DEUTS, DOI [10.25646/7027, DOI 10.25646/7027]; IQTIG-Institut fur Qualitatssicherung und Transparenz im Gesundheitswesen, 2017, BUND ERF 2016 GEB; Naing L, 2006, ARCH OROFAC SCI, V1, P9; Nogal A, 2019, TRANSDISCIPLINARY IN, V3, P115, DOI [10.11116/TDI2019.3.5, DOI 10.11116/TDI2019.3.5]; Robert Koch-Institu, 2010, EP B IMPF SCHUL 2008; Robert Koch-Institut, 2015, 362015 R KOCH I; Robert Koch-Institut, 2020, EP B ERH IMPF KIND J; Robert Koch-Institut, 2006, EP B EMPF STAND IMPF; Robert Koch-Institut, 2016, EP B MITT STAND IMPF; Robert Koch-Institut, 2006, EP B PNEUM IMPF 7 VA; Statistisches Bundesamt DESTATIS, 2019, ERG BEV GRUNDL ZENS; Wichmann O, 2007, PEDIATR INFECT DIS J, V26, P782, DOI 10.1097/INF.0b013e318060aca1; World Health Organization, 2012, 142012 WHO	25	2	2	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 2	2021	39	24					3287	3295		10.1016/j.vaccine.2021.04.029		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SM1SV	33962835	hybrid			2022-04-29	WOS:000657392500007
J	Ikilezi, G; Bachmeier, SD; Cogswell, IE; Maddison, ER; Stutzman, HN; Tsakalos, G; Brenzel, L; Dieleman, JL; Micah, AE				Ikilezi, Gloria; Bachmeier, Steven D.; Cogswell, Ian E.; Maddison, Emilie R.; Stutzman, Hayley N.; Tsakalos, Golsum; Brenzel, Logan; Dieleman, Joseph L.; Micah, Angela E.			Tracking government spending on immunization: The joint reporting forms, national health accounts, comprehensive multi-year plans and co-financing data	VACCINE			English	Article						Immunization spending; Government spending; Joint Reporting Form; National Health Accounts		Background: Coverage rates for immunization have dropped in lower income countries during the COVID-19 pandemic, raising concerns regarding potential outbreaks and premature death. In order to re-invigorate immunization service delivery, sufficient financing must be made available from all sources, and particularly from government resources. This study utilizes the most recent data available to provide an updated comparison of available data sources on government spending on immunization. Methods: We examined data from WHO/UNICEF's Joint Reporting Form (JRF), country Comprehensive Multi-Year Plan (cMYP), country co-financing data for Gavi, and WHO National Health Accounts (NHA) on government spending on immunization for consistency by comparing routine and vaccine spending where both values were reported. We also examined spending trends across time, quantified underreporting and utilized concordance analyses to assess the magnitude of difference between the data sources. Results: Routine immunization spending reported through the cMYP was nearly double that reported through the JRF (rho = 0.64, 95% 0.53 to 0.77) and almost four times higher than that reported through the NHA on average (rho = 3.71, 95% 1.00 to 13.87). Routine immunization spending from the JRF was comparable to spending reported in the NHA (rho = 1.30, 95% 0.97 to 1.75) and vaccine spending from the JRF was comparable to that from the cMYP data (rho = 0.97, 95% 0.84 to 1.12). Vaccine spending from both the JRF and cMYP was higher than Gavi co-financing by a at least two (rho = 2.66, 95% 2.45 to 2.89) and (rho = 2.66, 95% 2.15 to 3.30), respectively. Implications: Overall, our comparative analysis provides a degree of confidence in the validity of existing reporting mechanisms for immunization spending while highlighting areas for potential improvements. Users of these data sources should factor these into consideration when utilizing the data. Additionally, partners should work with governments to encourage more reliable, comprehensive, and accurate reporting of vaccine and immunization spending. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Ikilezi, Gloria; Cogswell, Ian E.; Maddison, Emilie R.; Stutzman, Hayley N.; Tsakalos, Golsum] Gates Ventures, Kirkland, WA USA; [Ikilezi, Gloria; Bachmeier, Steven D.; Dieleman, Joseph L.; Micah, Angela E.] Inst Hlth Metr & Evaluat, 3980 15th Ave NE, Seattle, WA 98195 USA; [Brenzel, Logan] Bill & Melinda Gates Fdn, Seattle, WA USA		Micah, AE (通讯作者)，Inst Hlth Metr & Evaluat, 3980 15th Ave NE, Seattle, WA 98195 USA.	Gloria.Ikilezi@gatesventures.com; sbachmei@uw.edu; icogswel@uw.edu; ermadd@uw.edu; hstutzma@uw.edu; hashimig@uw.edu; Logan.Brenzel@gatesfoundation.org; dieleman@uw.edu; amicah@uw.edu					Abou Nader A, 2015, HEALTH POLICY PLANN, V30, P281, DOI 10.1093/heapol/czu002; [Anonymous], 2017, ANAL IMMUNIZATION FI; [Anonymous], 2017, GLOBAL VACCINE ACTIO; [Anonymous], GAVIS COFINANCING PO; [Anonymous], GLOBAL HLTH EXPENDIT; [Anonymous], 2011, WHOUNICEF GUIDANCE N; [Anonymous], 2015, GUIDANCE NOTE STRENG; Giavarina D, 2015, BIOCHEM MEDICA, V25, P141, DOI 10.11613/BM.2015.015; Leach-Kemon K, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-421; Wang HD, 2020, LANCET, V396, P1160, DOI 10.1016/S0140-6736(20)30977-6; WHO, IMM FIN IND; WHO, WHO UNICEF GUID DEV; WHO, GLOB VACC ACT PLAN 2; WHO, HLTH ACCOUNTS; WHO, IMM PLANN FIN; World Health Organization, WHO UNICEF JOINT REP; World Health Organization, IMMUNIZATION VACCINE; World Health Organization, IMM AG 2030 GLOB STR	18	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3410	3418		10.1016/j.vaccine.2021.04.047		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	34020816	hybrid, Green Published			2022-04-29	WOS:000657001300017
J	Welsh, KJ; Baumblatt, J; Chege, W; Goud, R; Nair, N				Welsh, Kerry J.; Baumblatt, Jane; Chege, Wambui; Goud, Ravi; Nair, Narayan			Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)	VACCINE			English	Article						Thrombocytopenia; Immune thrombocytopenia; mRNA COVID-19 vaccines; VAERS	PURPURA	Background: The objective of this study is to assess cases of thrombocytopenia, including immune thrombocytopenia (ITP), reported to the Vaccine Adverse Event Reporting System (VAERS) following vaccination with mRNA COVID-19 vaccines. Methods: This case-series study analyzed VAERS reports of thrombocytopenia after vaccination with Pfizer-BioNTech COVID-19 Vaccine or Moderna COVID-19 Vaccine. Results: Fifteen cases of thrombocytopenia were identified among 18,841,309 doses of Pfizer-BioNTech COVID-19 Vaccine and 13 cases among 16,260,102 doses of Moderna COVID-19 Vaccine. The reporting rate of thrombocytopenia was 0.80 per million doses for both vaccines. Based on an annual incidence rate of 3.3 ITP cases per 100,000 adults, the observed number of all thrombocytopenia cases, which includes ITP, following administration of mRNA COVID-19 vaccines is not greater than the number of ITP cases expected. Conclusions: The number of thrombocytopenia cases reported to VAERS does not suggest a safety concern attributable to mRNA COVID-19 vaccines at this time. Published by Elsevier Ltd.	[Welsh, Kerry J.; Baumblatt, Jane; Chege, Wambui; Goud, Ravi; Nair, Narayan] US FDA, Div Epidemiol, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave,Bld 71, Silver Spring, MD 20993 USA		Nair, N (通讯作者)，US FDA, Div Epidemiol, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave,Bld 71, Silver Spring, MD 20993 USA.	Narayan.Nair@fda.hhs.gov					Anderson S., 2020, CBER PLANS MONITORIN; Bhattacharjee Sukrita, 2020, SN Compr Clin Med, V2, P2048, DOI 10.1007/s42399-020-00521-8; CDC, 2021, COVID DAT TRACK COVI; Cecinati V, 2013, HUM VACC IMMUNOTHER, V9, P1158, DOI 10.4161/hv.23601; Dooling K, 2021, MMWR-MORBID MORTAL W, V69, P1657, DOI 10.15585/mmwr.mm695152e2; DuMouchel W, 1999, AM STAT, V53, P177, DOI 10.2307/2686093; European Medicines Agency, 2021, ASTRAZENECAS COVID 1; FDA, 2020, FACT SHEET HEALTHC P; Lambert MP, 2017, BLOOD, V129, P2829, DOI 10.1182/blood-2017-03-754119; Marks P., 2021, JOINT CDC FDA STATEM; Miller E, 2001, ARCH DIS CHILD, V84, P227, DOI 10.1136/adc.84.3.227; Moderna, 2020, MRNA 1272 SPONS BRIE; Pfizer BioNTech, 2020, VACC REL BIOL PROD A VACC REL BIOL PROD A; Shimabukuro T., 2021, COVID 19 VACCINE SAF; Swinkels M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00880; Szarfman A, 2002, DRUG SAFETY, V25, P381, DOI 10.2165/00002018-200225060-00001; Terrell DR, 2010, AM J HEMATOL, V85, P174, DOI 10.1002/ajh.21616; Wise RP, 2007, VACCINE, V25, P5717, DOI 10.1016/j.vaccine.2007.02.067; Emily JW, 2011, VACCINE, V29, P1319, DOI 10.1016/j.vaccine.2010.11.051	19	43	44	12	26	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3329	3332		10.1016/j.vaccine.2021.04.054		JUN 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	34006408	Bronze, Green Published	Y	N	2022-04-29	WOS:000657001300006
J	Silva, AJD; Jesus, ALS; Leal, LRS; Silva, GAS; Melo, CML; Freitas, AC				Silva, Anna Jessica D.; Jesus, Andre Luiz S.; Leal, Ligia Rosa S.; Silva, Guilherme Antonio S.; Melo, Cristiane Moutinho L.; Freitas, Antonio C.			Pichia pastoris displaying ZIKV protein epitopes from the Envelope and NS1 induce in vitro immune activation	VACCINE			English	Article						Yeast surface display; Epitopes; ZIKV; Whole-cell vaccines	T-CELLS; VIRUS; VACCINES; PREDICTION; PROMOTES; IL-10	The severe consequences of ZIKV infection and its emergence and re-emergence in several countries have boosted vaccines' development. Yeasts such as Pichia pastoris has been widely employed as antigen carriers for immunization against infectious agents. Components of the yeast cell wall have immunostimulatory properties, and recombinant antigens can be anchored to the cell surface to enhance the presentation to the immune system. Here we aimed at producing and anchoring ZIKV proteins in the P. pastoris surface as a vaccine approach. Expression cassettes were designed with epitopes of the Envelope and NS1 proteins. Immunofluorescence microscopy confirmed the anchoring of recombinant proteins. Yeasts' ability to stimulate immune cells was evaluated in vitro by incubation with lymphocytes and monocytes isolated from mouse spleen. P. pastoris expressing EnvNS1 epitopes promoted increased levels of IL-6, IL-10, and TNF-alpha cytokines and an increase in the number of CD4+, CD8+, and CD16+ lymphocytes, similarly to ZIKV. This profile is indicative of the activation of immunological cells and suggests an immunogenic potential of the proposed yeast vaccines against ZIKV, reinforcing the possibility of P. pastoris as adjuvant and carrier of antigens. (C) 2021 Elsevier Ltd. All rights reserved.	[Silva, Anna Jessica D.; Jesus, Andre Luiz S.; Leal, Ligia Rosa S.; Freitas, Antonio C.] Univ Fed Pernambuco, Dept Genet, Lab Estudos Mol & Terapia Expt, Recife, PE, Brazil; [Silva, Guilherme Antonio S.; Melo, Cristiane Moutinho L.] Univ Fed Pernambuco, Dept Antibiot, Lab Anal Imunol & Antitumorais, Recife, PE, Brazil		Freitas, AC (通讯作者)，Univ Fed Pernambuco, Dept Genet, Av Prof Moraes Rego 1235,Cidade Univ, Recife, PE, Brazil.	acf_ufpe@yahoo.com.br	de Melo, Cristiane Moutinho Lagos/AAU-4226-2020; de Souza Silva, Guilherme Antonio/ABD-7367-2020	de Melo, Cristiane Moutinho Lagos/0000-0002-8831-0163; de Souza Silva, Guilherme Antonio/0000-0003-4364-6648; Jesus, Andre Luiz/0000-0003-2335-5712	Brazilian Agency FACEPE [APQ-0110-2.02/16]	This work was supported by Brazilian Agency FACEPE (Edital 04/2016 -PPE: Virus Zika, APQ-0110-2.02/16).	Ardiani A, 2010, FEMS YEAST RES, V10, P1060, DOI 10.1111/j.1567-1364.2010.00665.x; Badawi MM, 2016, AM J BIOMED RES, V4, P46; Barrett ADT, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0061-9; Bazan SB, 2011, VACCINE, V29, P8165, DOI 10.1016/j.vaccine.2011.07.141; Bilusic M, 2014, CANCER IMMUNOL IMMUN, V63, P225, DOI 10.1007/s00262-013-1505-8; Brault AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15039-8; Chen MY, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00646-x; Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039; Cohn A, 2018, J IMMUNOTHER, V41, P141, DOI 10.1097/CJI.0000000000000219; Couto-Lima D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05186-3; da Cruz IJ, 2019, INT J BIOL MACROMOL, V123, P1331, DOI 10.1016/j.ijbiomac.2018.09.120; Dar H, 2016, ASIAN PAC J TROP MED, V9, P822, DOI 10.1016/j.apjtm.2016.07.004; de Almeida JRM, 2005, YEAST, V22, P725, DOI 10.1002/yea.1243; Dikhit MR, 2016, INFECT GENET EVOL, V45, P187, DOI 10.1016/j.meegid.2016.08.037; Glasner A, 2017, J VIROL, V91, DOI [10.1128/JVI.00785-17, 10.1128/jvi.00785-17]; Goo L, 2018, VIROLOGY, V515, P191, DOI 10.1016/j.virol.2017.12.032; Heinz FX, 2012, VACCINE, V30, P4301, DOI 10.1016/j.vaccine.2011.09.114; Hessert M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007237; Higuera A, 2019, ACTA TROP, V190, P99, DOI 10.1016/j.actatropica.2018.11.010; Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]; Jacob D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086658; Kam YW, 2017, J INFECT DIS, V216, P172, DOI 10.1093/infdis/jix261; Kim H, 2014, FEMS YEAST RES; Kong WL, 2018, MICROB PATHOGENESIS, V114, P476, DOI 10.1016/j.micpath.2017.12.031; Kumar R, 2019, FEMS YEAST RES, V19, DOI 10.1093/femsyr/foz007; Laidlaw BJ, 2015, NAT IMMUNOL, V16, P871, DOI 10.1038/ni.3224; Lei H, 2020, MICROB CELL FACT, V19, DOI 10.1186/s12934-020-01316-1; Lei H, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4131324; Lima NS, 2017, TRENDS IMMUNOL, V38, P594, DOI 10.1016/j.it.2017.05.004; Liu M, 2011, VACCINE, V29, P1745, DOI 10.1016/j.vaccine.2010.12.119; Liu XL, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0072-6; Lum FM, 2018, J INFECT DIS, V218, P814, DOI 10.1093/infdis/jiy225; Maucourant C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020131; Mirza MU, 2016, SCI REP-UK, V6, DOI 10.1038/srep37313; Moyer TJ, 2016, J CLIN INVEST, V126, P799, DOI 10.1172/JCI81083; Ngono AE, 2018, ANNU REV IMMUNOL, V36, P279, DOI 10.1146/annurev-immunol-042617-053142; Nizzoli G, 2016, EUR J IMMUNOL, V46, P1622, DOI 10.1002/eji.201546136; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pena LJ, 2018, J GEN VIROL, V99, P1529, DOI 10.1099/jgv.0.001153; Poland GA, 2019, MAYO CLIN PROC, V94, P2572, DOI 10.1016/j.mayocp.2019.05.016; Quintana-Domeque C, 2018, ECON HUM BIOL, V30, P14, DOI 10.1016/j.ehb.2018.04.003; Schubert B, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0263-6; Shibasaki S, 2009, ANAL SCI, V25, P41, DOI 10.2116/analsci.25.41; Simonin Y, 2016, EBIOMEDICINE, V12, P161, DOI 10.1016/j.ebiom.2016.09.020; Tappe D, 2016, MED MICROBIOL IMMUN, V205, P269, DOI 10.1007/s00430-015-0445-7; Vetvicka V, 2011, WORLD J CLIN ONCOL, V2, P115, DOI 10.5306/wjco.v2.i2.115; Wasilenko JL, 2010, BIOTECHNOL PROGR, V26, P542, DOI 10.1002/btpr.343; Xv Z, 2019, VIRAL IMMUNOL, V32, P308, DOI 10.1089/vim.2019.0055; Zhang W, 2019, ANTIVIR RES, V170, DOI 10.1016/j.antiviral.2019.104578	49	0	0	4	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2545	2554		10.1016/j.vaccine.2021.03.065		APR 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33814233				2022-04-29	WOS:000642189300011
J	Robinson, E; Jones, A; Lesser, I; Daly, M				Robinson, Eric; Jones, Andrew; Lesser, India; Daly, Michael			International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples	VACCINE			English	Review						COVID-19; Coronavirus; Vaccine; Intentions; Acceptance; Attitudes	ACCEPTABILITY; ADULTS	Background: Widespread uptake of COVID-19 vaccines will be essential to controlling the COVID-19 pandemic. Vaccines have been developed in unprecedented time and quantifying levels of hesitancy towards vaccination among the general population is of importance. Methods: Systematic review and meta-analysis of studies using large nationally representative samples (n >= 1000) to examine the percentage of the population intending to vaccinate, unsure, or intending to refuse a COVID-19 vaccine when available. Generic inverse meta-analysis and meta-regression were used to pool estimates and examine time trends. PubMed, Scopus and pre-printer servers were searched from January-November 2020. Registered on PROSPERO (CRD42020223132). Findings: Twenty-eight nationally representative samples (n = 58,656) from 13 countries indicate that as the pandemic has progressed, the percentage of people intending to vaccinate decreased and the percentage of people intending to refuse vaccination increased. Pooled data from surveys conducted during June-October suggest that 60% (95% CI: 49% to 69%) intend to vaccinate and 20% (95% CI: 13% to 29%) intend to refuse vaccination, although intentions vary substantially between samples and countries (I-2 > 90%). Being female, younger, of lower income or education level and belonging to an ethnic minority group were consistently associated with being less likely to intend to vaccinate. Findings were consistent across higher vs. lower quality studies. Interpretation: Intentions to be vaccinated when a COVID-19 vaccine becomes available have been declining across countries and there is an urgent need to address social inequalities in vaccine hesitancy and promote widespread uptake of vaccines as they become available. (C) 2021 Elsevier Ltd. All rights reserved.	[Robinson, Eric; Jones, Andrew; Lesser, India] Univ Liverpool, Dept Psychol, Eleanor Rathbone Bldg, Liverpool L69 7ZA, Merseyside, England; [Daly, Michael] Maynooth Univ, Dept Psychol, Maynooth, Kildare, Ireland		Robinson, E (通讯作者)，Univ Liverpool, Dept Psychol, Eleanor Rathbone Bldg, Liverpool L69 7ZA, Merseyside, England.	eric.robinson@liv.ac.uk		, India/0000-0003-2867-2928; Daly, Michael/0000-0003-1557-8326	European Research CouncilEuropean Research Council (ERC)European Commission	ER's time was part-funded by the European Research Council and their support is gratefully acknowledged.	American Association for Public Opinion Research, 2020, MARG SAMPL ERR CRED; Applewhite A, 2020, J PRIM CARE COMMUNIT, V11, DOI 10.1177/2150132720958532; Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Chan Denise P C, 2015, Prev Med Rep, V2, P803, DOI 10.1016/j.pmedr.2015.09.002; Daly Michael, 2020, medRxiv, DOI 10.1101/2020.11.27.20239970; Fancourt D, 2020, LANCET, V396, P464, DOI 10.1016/S0140-6736(20)31690-1; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Galarce EM, 2011, VACCINE, V29, P5284, DOI 10.1016/j.vaccine.2011.05.014; Gallup, 1997, POLLS AR COND; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Haby MM, 2016, HEALTH RES POLICY SY, V14, DOI 10.1186/s12961-016-0155-7; Hacquin A, PSYARXIV; Iboi EA, 2020, INFECT DIS MODEL, V5, P510, DOI 10.1016/j.idm.2020.07.006; Kirby T, 2020, LANCET RESP MED, V8, P547, DOI 10.1016/S2213-2600(20)30228-9; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lesser I., 2019, JCOVIRO; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Malhotra N, 2007, POLIT ANAL, V15, P286, DOI 10.1093/pan/mpm003; Maringe C, 2020, LANCET ONCOL, V21, P1023, DOI 10.1016/S1470-2045(20)30388-0; Morgan R, 2019, CURR OPIN VIROL, V35, P35, DOI 10.1016/j.coviro.2019.02.009; Myers LB, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-15; Paul E., 2020, ANTIVACCINE ATTITUDE, DOI [10.1101/2020.10.21.20216218, DOI 10.1101/2020.10.21.20216218]; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Tricco A.C., 2017, RAPID REV STRENGTHEN; Varker T, 2015, J EVAL CLIN PRACT, V21, P1199, DOI 10.1111/jep.12405; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; WHO, 2020, WHO COVID 19 WEEKL O; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Yeager DS, 2011, PUBLIC OPIN QUART, V75, P709, DOI 10.1093/poq/nfr020	33	93	94	16	27	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2024	2034		10.1016/j.vaccine.2021.02.005		APR 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RJ9QH	33722411	Bronze, Green Submitted, Green Published	Y	N	2022-04-29	WOS:000637937500003
J	Quan, DH; Counoupas, C; Nagalingam, G; Pinto, R; Petrovsky, N; Britton, WJ; Triccas, JA				Quan, Diana H.; Counoupas, Claudio; Nagalingam, Gayathri; Pinto, Rachel; Petrovsky, Nikolai; Britton, Warwick J.; Triccas, James A.			Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity	VACCINE			English	Article						Tuberculosis; Protective vaccine; Adjuvant; Advax; Reactogenicity		The development of safe and effective adjuvants is a critical goal of vaccine development programs. In this report, we defined the immunostimulatory profile and protective effect against aerosol Mycobacterium tuberculosis infection of vaccine formulations incorporating the semi-crystalline adjuvant delta-inulin (Advax). Advax formulated with CpG oligonucleotide and the QS-21 saponin (Advax(CpQS)) was the most effective combination, demonstrated by the capacity of CysVac2/Advax(CpQS) to significantly reduce the bacterial burden in the lungs of M. tuberculosis-infected mice. CysVac2/Advax(CpQS) protection was associated with rapid influx of neutrophils, macrophages and monocytes to the site of vaccination and the induction of antigen-specific IFN-gamma(+)/IL-2(+)/TNF+ polyfunctional CD4(+) T cells in the lung. When compared to the highly potent adjuvant combination of monophosphoryl lipid A and dimethyldioctadecylammonium bromide (MPL/DDA), Advax(CpQS) imparted a similar level of protective efficacy yet without the profound stimulation of inflammatory cytokines and vaccination site ulceration observed with MPL/DDA. Addition of DDA to CysVac2/Advax(CpQS) further improved the protective effect of the vaccine, which correlated with increased polyfunctional CD4(+) T cells in the lung but with no increase in vaccine reactogenicity. The data demonstrate that Advax formulations can decouple protective tuberculosis immunity from reactogenicity, making them ideal candidates for human application. (C) 2021 Elsevier Ltd. All rights reserved.	[Quan, Diana H.; Counoupas, Claudio; Nagalingam, Gayathri; Pinto, Rachel; Britton, Warwick J.; Triccas, James A.] Univ Sydney, Fac Med & Hlth, Sch Med Sci, Sydney, NSW 2006, Australia; [Quan, Diana H.; Counoupas, Claudio; Nagalingam, Gayathri; Pinto, Rachel; Triccas, James A.] Univ Sydney, Centenary Inst, TB Res Program, Sydney, NSW 2006, Australia; [Petrovsky, Nikolai] Flinders Univ S Australia, Dept Endocrinol, Adelaide, SA, Australia; [Petrovsky, Nikolai] Vaxine Pty Ltd, Adelaide, SA 5042, Australia; [Britton, Warwick J.] Royal Prince Alfred Hosp, Dept Clin Immunol, Camperdown, NSW 2050, Australia; [Triccas, James A.] Univ Sydney, Charles Perkins Ctr, Sydney, NSW 2006, Australia; [Triccas, James A.] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW 2006, Australia		Triccas, JA (通讯作者)，Univ Sydney, Fac Med & Hlth, Sch Med Sci, Sydney, NSW 2006, Australia.	jamie.triccas@sydney.edu.au	Petrovsky, Nikolai/P-1912-2017	Petrovsky, Nikolai/0000-0002-1580-5245	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [APP1102597]; NHMRC Centre of Research Excellence in Tuberculosis ControlNational Health and Medical Research Council (NHMRC) of Australia [APP1153493]; European H2020 grant [TBVAC2020 15 643381]; NSW Government; NHMRC Centre of Research Excellence in Tuberculosis ControlNational Health and Medical Research Council (NHMRC) of Australia; National Institute of Allergy and Infectious Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [HHSN272201800044C, HHSN272201400053C, HHS-N272200800039C, U01-AI061142]; Australian Postgraduate AwardAustralian Government	This work was supported by a National Health and Medical Research Council (NHMRC) Project Grant (APP1102597), the NHMRC Centre of Research Excellence in Tuberculosis Control (APP1153493). We acknowledge the support of the European H2020 grant TBVAC2020 15 643381. The NSW Government provided support through its infrastructure grant to the Centenary Institute. D.Q. was supported by postgraduate scholarship funding from the NHMRC Centre of Research Excellence in Tuberculosis Control and an Australian Postgraduate Award. Development of Advax adjuvants was supported by funding from National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Contracts, HHSN272201800044C, HHSN272201400053C, HHS-N272200800039C and U01-AI061142.	Amjad W, 2021, DIGEST DIS SCI, V66, P2101, DOI 10.1007/s10620-020-06437-6; ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994; Andersen P, 2007, TRENDS MICROBIOL, V15, P7, DOI 10.1016/j.tim.2006.11.008; Bosio CM, 1998, INFECT IMMUN, V66, P5048, DOI 10.1128/IAI.66.10.5048-5051.1998; Braian C, 2013, J INNATE IMMUN, V5, P591, DOI 10.1159/000348676; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Counoupas C, 2020, 202002 BIORXIV; Counoupas C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09119-y; Counoupas C, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.12; Cui WG, 2014, J IMMUNOL, V192, P4221, DOI 10.4049/jimmunol.1302569; Davis ID, 2004, P NATL ACAD SCI USA, V101, P10697, DOI 10.1073/pnas.0403572101; Ellis RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046094; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Florido M, 2015, EUR J IMMUNOL, V45, P780, DOI 10.1002/eji.201444954; Gordon D, 2014, VACCINE, V32, P6469, DOI 10.1016/j.vaccine.2014.09.034; Gordon DL, 2012, VACCINE, V30, P5407, DOI 10.1016/j.vaccine.2012.06.009; Hopkins RJ, 2013, VACCINE, V31, P3051, DOI 10.1016/j.vaccine.2013.04.063; Kisich KO, 2002, INFECT IMMUN, V70, P4591, DOI 10.1128/IAI.70.8.4591-4599.2002; Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005; Korsholm KS, 2010, IMMUNOLOGY, V129, P75, DOI 10.1111/j.1365-2567.2009.03164.x; La Rosa C, 2012, J INFECT DIS, V205, P1294, DOI 10.1093/infdis/jis107; Lacaille-Dubois MA, 2019, PHYTOMEDICINE, V60, DOI 10.1016/j.phymed.2019.152905; Li JL, 2012, NAT PROTOC, V7, P221, DOI 10.1038/nprot.2011.438; Lindenstrom T, 2013, J IMMUNOL, V190, P6311, DOI 10.4049/jimmunol.1300248; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Mitchell TC, 2017, CURR OPIN IMMUNOL, V47, P17, DOI 10.1016/j.coi.2017.06.009; Palm NW, 2009, IMMUNOL REV, V227, P221, DOI 10.1111/j.1600-065X.2008.00731.x; Pearse MJ, 2004, VACCINE, V22, P2391, DOI 10.1016/j.vaccine.2003.12.031; Petroski N, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P199, DOI 10.1016/B978-0-12-804019-5.00010-4; Petrovsky N, 2015, VACCINE, V33, P5920, DOI 10.1016/j.vaccine.2015.09.030; Pinto R, 2013, J INFECT DIS, V207, P778, DOI 10.1093/infdis/jis751; Ragupathi G, 2011, EXPERT REV VACCINES, V10, P463, DOI [10.1586/ERV.11.18, 10.1586/erv.11.18]; Ramos-Kichik V, 2009, TUBERCULOSIS, V89, P29, DOI 10.1016/j.tube.2008.09.009; Rubin-Bejerano I, 2007, CELL HOST MICROBE, V2, P55, DOI 10.1016/j.chom.2007.06.002; SANCHEZ A, 1973, AM J CLIN NUTR, V26, P1180, DOI 10.1093/ajcn/26.11.1180; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Selders GS, 2017, REGEN BIOMATER, V4, P55, DOI 10.1093/rb/rbw041; Tait DR, 2019, NEW ENGL J MED, V381, P2429, DOI 10.1056/NEJMoa1909953; Vasan S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008617; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; WHO, 2001, GLOBAL TUBERCULOSIS; World Health Organization, 2020, GLOBAL TUBERCULOSIS	42	0	0	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 1	2021	39	14					1990	1996		10.1016/j.vaccine.2021.02.041		MAR 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RC7NX	33714652	Green Submitted			2022-04-29	WOS:000632984100016
J	Sell, TK; Gastfriend, D; Watson, M; Watson, C; Richardson, L; Cicero, A; Inglesby, T; Connell, N				Sell, Tara Kirk; Gastfriend, Daniel; Watson, Matthew; Watson, Crystal; Richardson, Lauren; Cicero, Anita; Inglesby, Tom; Connell, Nancy			Building the global vaccine manufacturing capacity needed to respond to pandemics Comment	VACCINE			English	Editorial Material									[Sell, Tara Kirk; Gastfriend, Daniel; Watson, Matthew; Watson, Crystal; Richardson, Lauren; Cicero, Anita; Inglesby, Tom; Connell, Nancy] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Ctr Hlth Secur, Baltimore, MD 21205 USA		Connell, N (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Ctr Hlth Secur, Baltimore, MD 21205 USA.		Connell, Nancy/AFN-1305-2022		Open Philanthropy Project	Parts of this study were supported by the Open Philanthropy Project.	FDA, EM US AUTH; Frederiksen LSF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01817; Hanney SR, 2020, HEALTH RES POLICY SY, V18, DOI 10.1186/s12961-020-00571-3; Hernandez R., 2015, BIOPHARM INT, V28; Kiss AA, 2015, J CHEM TECHNOL BIOT, V90, P349, DOI 10.1002/jctb.4584; Matheny J, 2007, BIOSECUR BIOTERROR, V5, P228, DOI 10.1089/bsp.2007.0030; McLean KA, 2016, VACCINE, V34, P5410, DOI 10.1016/j.vaccine.2016.08.019; Smith LM, 2009, BIOSECUR BIOTERROR, V7, P259, DOI 10.1089/bsp.2009.0921; WHO, GLOB ACT PLAN INFL V	9	4	4	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 19	2021	39	12					1667	1669		10.1016/j.vaccine.2021.02.017		MAR 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QX3ZD	33640143	Green Published, Bronze			2022-04-29	WOS:000629283700001
J	Net, P; Colrat, F; Costa, MN; Bianic, F; Thommes, E; Alvarez, FP				Net, Pierre; Colrat, Florian; Costa, Mafalda Nascimento; Bianic, Florence; Thommes, Edward; Alvarez, Fabian P.			Estimating public health and economic benefits along 10 years of Fluzone (R) High Dose in the United States	VACCINE			English	Article						Influenza; Elderly; Vaccination; Cardio-respiratory outcomes; Economic burden	INACTIVATED INFLUENZA VACCINE; COST-EFFECTIVENESS; SEASONAL INFLUENZA; OLDER; HOSPITALIZATIONS; ADULTS; US; PREVENTION; EFFICACY; IMPACT	Objective: The objective of this study was to estimate the public health and economic benefits (from a Medicare perspective) of Fluzone High-Dose (R) in the US elderly population, since its introduction in 2010. Methods: A budget impact model was developed using a decision tree framework and applied over 9 influenza seasons (2010/11 to 2018/19). The decision tree model was designed to capture influenza cases, hospitalizations possibly related to influenza or laboratory confirmed influenza, and influenza-related deaths. The analysis included influenza vaccines recommended by ACIP since 2010: SD TIV (trivalent), SD QIV (quadrivalent), HD TIV, aTIV (adjuvanted), ccQIV (cell-cultured). Two strategies were compared to evaluate the impact of HD TIV: a 'with HD TIV' strategy representative of the US vaccine landscape, and a `without HD TIV' where the absence of HD TIV was modelled. Clinical and economic inputs were based on public US data from the CDC and national databases, while data on vaccine effectiveness were extracted from published literature and clinical trials. The impact of HD TIV was further explored in five scenario analyses and deterministic sensitivity analyses (DSA). Results: Over 10 years, it is estimated that HD TIV resulted in an averted 1,333,479 influenza cases, 769,476 medical visits, 40,004 ED presentations, 520,342 cardiorespiratory hospitalizations and 73,689 deaths and generated an absolute $4.6 billion in savings, translating into a return on investment of 214.4%. Hospitalizations costs represented 98.4% and 98.3% of the management costs in the `with HD TIV' strategy and `without HD TIV' strategy respectively. Hospitalizations and HD TIV relative vaccine efficacy vs SD TIV as a major cost driver were further confirmed in scenario analysis and DSA. HD TIV remained cost saving under all the scenarios. Conclusion: The model showed that HD TIV higher efficacy translated into increased averted health and economic outcomes. HD TIV represented a cost saving intervention from a payer perspective since its introduction.(C) 2021 The Authors. Published by Elsevier Ltd.	[Net, Pierre; Bianic, Florence] Syneos Hlth, Montrouge, France; [Colrat, Florian; Alvarez, Fabian P.] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France; [Costa, Mafalda Nascimento] Syneos Hlth, London, England; [Thommes, Edward] Sanofi Pasteur, Swiftwater, PA USA		Alvarez, FP (通讯作者)，Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France.	pierre.net@syneoshealth.com; mafalda.costa@syneoshealth.com; florence.bianic@syneoshealth.com; edward.thommes@sanofi.com; fabian.alvarez@sanofipasteur.com		Alvarez, Fabian P./0000-0003-3085-6275	Sanofi Pasteur	This publication was produced with support from Sanofi Pasteur. Manuscripts were accepted after rigorous peer review process that was managed by an expert Guest Editor independently appointed by the Editor-in-Chief.	[Anonymous], 2019, US FLU SEAS PREL BUR; Becker DL, 2016, HUM VACC IMMUNOTHER, V12, P3036, DOI 10.1080/21645515.2016.1215395; Beyer WEP, 2013, VACCINE, V31, P6030, DOI 10.1016/j.vaccine.2013.09.063; CDC, 2019, MORBIDITY MORTALITY; CDC, 2019, CDC SEAS FLU VACC EF; CDC, 2018, 2010 11 2017 18 INFL; CDC, 2019, WEEKL US INFL SURV R; CDC, 2019, FLU PEOPL ASTHM; CDC, 2019, DIS BURD INFL; CDC, NAT POP PROJ 2014 20; CDC, 2019, PEOPL 65 YEARS OLD I; Centers for Disease Control and Prevention (CDC), 2019, NATL VITAL STAT SYST; Centers for Medicare & Medicaid Services, 2018, SEASONAL INFLUENZA V; Chit A, 2015, LANCET INFECT DIS, V15, P1459, DOI 10.1016/S1473-3099(15)00249-2; Chit A, 2015, VACCINE, V33, P734, DOI 10.1016/j.vaccine.2014.10.079; Clements KM, 2014, HUM VACC IMMUNOTHER, V10, P1171, DOI 10.4161/hv.28221; DiazGranados CA, 2015, VACCINE, V33, P4988, DOI 10.1016/j.vaccine.2015.07.006; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1; Healthcare Cost and Utilization Project, HCUPNET; Kochanek K, 2015, NATL VITAL STAT REP, V63; Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090; Lee JKH, 2018, EXPERT REV VACCINES, V17, P435, DOI 10.1080/14760584.2018.1471989; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Mullooly JP, 2007, VACCINE, V25, P846, DOI 10.1016/j.vaccine.2006.09.041; Murphy S, 2015, NATL VITAL STAT REP, V63; Murphy Sherry L, 2013, Natl Vital Stat Rep, V61, P1; National Advisory Committee on Immunization (NACI), 2018, LIT REV UPD EFF EFF; Putri WCWS, 2018, VACCINE, V36, P3960, DOI 10.1016/j.vaccine.2018.05.057; Raviotta JM, 2016, J AM GERIATR SOC, V64, P2126, DOI 10.1111/jgs.14323; Reed C, 2014, MMWR-MORBID MORTAL W, V63, P1151; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Shireman TI, 2019, J AM MED DIR ASSOC, V20, P874, DOI 10.1016/j.jamda.2018.12.003; Stewart RJ, 2018, CLIN INFECT DIS, V66, P1035, DOI 10.1093/cid/cix922; Sullivan SD, 2014, VALUE HEALTH, V17, P5, DOI 10.1016/j.jval.2013.08.2291; The Agency for Healthcare Research and Quality (AHRQ), US APPR PRIC IND AN; The Medicare Payment Advisory Commission (Medpac), 2019, JUNE 2019 REP C MED; United States Census Bureau, 2009, NAT POP PROJ CONST N; US Census Bureau, 2012, NAT POP PROJ DAT MID; US Centers for Disease Control and Prevention (CDC), 2018, KEY FACTS INFL FLU; van Aalst R, 2020, VACCINE, V38, P372, DOI 10.1016/j.vaccine.2019.09.105; van Aalst R, 2019, VACCINE, V37, P4499, DOI 10.1016/j.vaccine.2019.06.066; Warren-Gash C, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01794-2017; Weinberger B, 2008, CLIN INFECT DIS, V46, P1078, DOI 10.1086/529197; Wells C, 2019, HIGH DOSE INFLUENZA; Wolters Kluwer, MEDI SPAN PRIC RX; World Health Organisation, 2018, FACT SHEETS INFL; Xu J, 2017, NATL VITAL STAT REP, V66; Xu Jiaquan, 2016, Natl Vital Stat Rep, V64, P1; Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211	50	1	2	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 15	2021	39			1			A56	A69		10.1016/j.vaccine.2021.01.016		MAR 2021	14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QV2JM	33509695	hybrid			2022-04-29	WOS:000627802900008
J	Constantinou, CA; Ziogas, DC; Venetsanopoulou, A; Gamaletsou, MN; Koutsogeorgopoulou, L; Barbouni, A; Tzioufas, AG; Sipsas, NV				Constantinou, Costas A.; Ziogas, Dimitrios C.; Venetsanopoulou, Aliki; Gamaletsou, Maria N.; Koutsogeorgopoulou, Loukia; Barbouni, Anastasia; Tzioufas, Athanasios G.; Sipsas, Nikolaos, V			A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness	VACCINE			English	Article						Pneumococcal vaccination; Autoimmune rheumatic diseases; Vaccination uptake		Introduction: Patients with autoimmune rheumatic diseases (ARDs) are at increased risk for pneumococcal infections and should be vaccinated against Streptococcus pneumoniae. Data on the rates of pneumococcal vaccination among patients with ARDs in Southern Europe are scarce. Here, we estimate the pneumococcal vaccination rate in patients living in Greece with ARDs, explore the patients' awareness regarding vaccination, and try to recognize factors that influence the vaccine uptake. Methods: Between October 2015 and September 2016, a structured questionnaire was provided to all consecutive patients with ARDs attending one outpatient clinic of our department. The survey included parameters concerning patients' demographics, underlying ARD and immunosuppressive medications, other comorbidities, vaccine type, knowledge about infection risk and necessity of vaccination. Univariate and multivariate analyses were performed to study any association of these factors with the vaccination uptake. Results: Overall, 395 patients with ARDs (30.13% aged >65 years and 78.99% female) participated in our survey. The most frequent ARD was rheumatoid arthritis (43.04%); 40.51% of patients were receiving biologic agents and 44.56% steroids. Pneumococcal vaccination rate was 49.37%, while 45.06% of patients have been vaccinated during the last five years and only 8.21% of them had a second pneumococcal vaccine, as per national guidelines. The decision of vaccination was significantly influenced by the patient's age (>65 years) (p < 0.001) and the complete awareness of reasons for being vaccinated (p < 0.001), but not by presence of comorbidities, the type of ARD or administration of a biologic agent. The main reason for no vaccination was that it was not suggested by the caring physician (82.50%). Conclusions: In our cohort of patients with ARDs the pneumococcal vaccination was suboptimal. Better understanding of the significance of vaccination by the patient and suggestion for vaccination by the caring physician will improve vaccination uptake and optimize the clinical benefits among patients with ARDs. (C) 2021 Elsevier Ltd. All rights reserved.	[Constantinou, Costas A.; Venetsanopoulou, Aliki; Gamaletsou, Maria N.; Koutsogeorgopoulou, Loukia; Tzioufas, Athanasios G.; Sipsas, Nikolaos, V] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Pathophysiol, Sch Med, Athens, Greece; [Ziogas, Dimitrios C.] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Internal Med 1, Sch Med, Athens, Greece; [Barbouni, Anastasia] Univ West Attica, Natl Sch Publ Hlth, Athens, Greece		Ziogas, DC (通讯作者)，Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Internal Med 1, Sch Med, Athens, Greece.	ziogasdc@gmail.com					Anagnostopoulos I, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-98; Andrianakos A, 2003, J RHEUMATOL, V30, P1589; Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637; Costello R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153848; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524; Fessler BJ, 2002, BEST PRACT RES CL RH, V16, P281, DOI 10.1053/berh.2001.0226; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Giese C, 2016, VACCINE, V34, P3657, DOI 10.1016/j.vaccine.2016.05.028; Haroon M, 2011, JOINT BONE SPINE, V78, P374, DOI 10.1016/j.jbspin.2010.10.012; Hmamouchi I, 2015, VACCINE, V33, P1446, DOI 10.1016/j.vaccine.2015.01.065; Jimenez-Garcia R, 2014, VACCINE, V32, P4386, DOI 10.1016/j.vaccine.2014.06.074; Kim DK, 2018, ANN INTERN MED, V168, P210, DOI 10.7326/M17-3439; Koetz K, 2000, P NATL ACAD SCI USA, V97, P9203, DOI 10.1073/pnas.97.16.9203; Krasselt M, 2017, RHEUMATOL INT, V37, P229, DOI 10.1007/s00296-016-3608-y; Moraes-Fontes MF, 2016, INT J RHEUMATOL, V2016, DOI 10.1155/2016/2845617; Nguyen MTT, 2017, SCAND J RHEUMATOL, V46, P446, DOI 10.1080/03009742.2016.1242774; Papadopoulou D, 2015, BEST PRACT RES CL RH, V29, P306, DOI 10.1016/j.berh.2015.02.001; Papadopoulou D, 2014, RHEUMATOL INT, V34, P151, DOI 10.1007/s00296-013-2907-9; Sardu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032487; Seoane-Mato D, 2017, REUMATOL CLIN; Shea KM, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu024; Smitten AL, 2008, J RHEUMATOL, V35, P387; Starkebaum G, 2002, SEMIN HEMATOL, V39, P121, DOI 10.1053/shem.2002.31918; Subesinghe S, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1187-4; Tektonidou MG, 2015, ARTHRIT CARE RES, V67, P1078, DOI 10.1002/acr.22575; Thomas E, 2003, J RHEUMATOL, V30, P958; Vinogradova Y, 2009, BRIT J GEN PRACT, V59, P742, DOI 10.3399/bjgp09X472629; Wagner UG, 1998, P NATL ACAD SCI USA, V95, P14447, DOI 10.1073/pnas.95.24.14447; Wotton CJ, 2012, J EPIDEMIOL COMMUN H, V66, P1177, DOI 10.1136/jech-2011-200168	29	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 12	2021	39	11					1593	1597		10.1016/j.vaccine.2021.02.009		FEB 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QP4DD	33610375				2022-04-29	WOS:000623785800007
J	Okoli, GN; Racovitan, F; Abdulwahid, T; Righolt, CH; Mahmud, SM				Okoli, G. N.; Racovitan, F.; Abdulwahid, T.; Righolt, C. H.; Mahmud, S. M.			Variable seasonal influenza vaccine effectiveness across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains: A systematic review and meta-analysis of the evidence from test-negative design studies after the 2009/10 influenza pandemic	VACCINE			English	Review						Seasonal influenza; Vaccine effectiveness; Test-negative design; Systematic review; Meta-analysis	LABORATORY-CONFIRMED INFLUENZA; UNITED-KINGDOM; PRIMARY-CARE; SOUTH-AFRICA; PREDOMINANT CIRCULATION; HEALTH-CARE; SPAIN; TRIVALENT; CHILDREN; PROTECTION	Background: We examined the influence of some factors on seasonal influenza vaccine effectiveness (VE) from test-negative design (TND) studies. Methods: We systematically searched for full-text publications of VE against laboratory-confirmed influenza from TND studies in outpatient settings after the 2009/10 influenza pandemic. Two reviewers independently selected and extracted data from the included studies. We calculated pooled adjusted VE across geographical regions, age groups and levels of vaccine antigenic similarity with circulating virus strains, using an inverse variance, random-effects model. Results: We included 76 full-text articles from 11,931 citations. VE estimates against A(H1N1)pdm09, A (H3N2), influenza B, and all influenza were homogenous and point pooled VE higher in the Southern hemisphere compared with the Northern hemisphere. The difference in pooled VE between the Southern and Northern hemispheres was statistically significant for A(H3N2), influenza B, and all influenza. A consistent pattern was observed in pooled VE across both hemispheres and continents, with the highest point pooled VE being against A(H1N1)pdm09, followed by influenza B, and lowest against A (H3N2). A nearly consistent pattern was observed in pooled VE across age groups in the Northern hemisphere, with pooled VE mostly decreasing with age. Point pooled VE against A(H3N2), influenza B, and all influenza were statistically significantly higher when vaccine was antigenically similar to circulating virus strains compared with when antigenically dissimilar. Similar pattern was observed in the Northern hemisphere, but there was a lack of data from the Southern hemisphere. Conclusion: Consistent patterns appear to exist in seasonal influenza VE across regions, age groups, and levels of vaccine antigenic similarity with circulating virus strains, with best vaccine performance against A(H1N1)pdm09 and worst against A(H3N2). The evidence highlights the need to consider geographical location, age, and vaccine antigenic similarity with circulating virus strains when designing and evaluating influenza VE studies. (C) 2021 Elsevier Ltd. All rights reserved.	[Okoli, G. N.; Mahmud, S. M.] Univ Manitoba, Coll Pharm, Rady Fac Hlth Sci, Winnipeg, MB, Canada; [Okoli, G. N.; Abdulwahid, T.] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, George & Fay Yee Ctr Healthcare Innovat, Winnipeg, MB, Canada; [Okoli, G. N.; Racovitan, F.; Righolt, C. H.; Mahmud, S. M.] Univ Manitoba, Vaccine & Drug Evaluat Ctr, 339-750 McDermot Ave, Winnipeg, MB R3E 0T5, Canada; [Righolt, C. H.; Mahmud, S. M.] Univ Manitoba, Rady Fac Hlth Sci, Community Hlth Sci, Winnipeg, MB, Canada		Mahmud, SM (通讯作者)，Univ Manitoba, Vaccine & Drug Evaluat Ctr, 339-750 McDermot Ave, Winnipeg, MB R3E 0T5, Canada.	Salah.Mahmud@umanitoba.ca			Canada Research Chairs ProgramCanada Research Chairs; Manitoba Training Program Fellowship Award; Centre on Aging Betty Havens Memorial Graduate Fellowship Award; Evelyn Shapiro Award	No funding was attained for this study. S. M. Mahmud is supported, in part, by funding from the Canada Research Chairs Program. G. N. Okoli is a recipient of the Manitoba Training Program Fellowship Award, the Centre on Aging Betty Havens Memorial Graduate Fellowship Award, and the Evelyn Shapiro Award, all for health services research.	Allen JD, 2018, HUM VACC IMMUNOTHER, V14, P1840, DOI 10.1080/21645515.2018.1462639; Andrews N, 2014, EUROSURVEILLANCE, V19, P5, DOI 10.2807/1560-7917.ES2014.19.27.20851; Barr IG, 2010, VACCINE, V28, P1156, DOI 10.1016/j.vaccine.2009.11.043; Bateman AC, 2013, J INFECT DIS, V207, P1262, DOI 10.1093/infdis/jit020; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Boni MF, 2008, VACCINE, V26, pC8, DOI 10.1016/j.vaccine.2008.04.011; Carville KS, 2015, VACCINE, V33, P341, DOI 10.1016/j.vaccine.2014.11.019; Castilla J, 2013, EUROSURVEILLANCE, V18, P17; Castilla J, 2020, VACCINE, V38, P1925, DOI 10.1016/j.vaccine.2020.01.028; Castilla J, 2016, VACCINE, V34, P1350, DOI 10.1016/j.vaccine.2016.01.054; Castilla J, 2013, CLIN INFECT DIS, V57, P167, DOI 10.1093/cid/cit194; Chan YWD, 2019, HUM VACC IMMUNOTHER, V15, P97, DOI 10.1080/21645515.2018.1514222; Chon I, 2019, VACCINE-X, V1, DOI 10.1016/j.jvacx.2019.100011; Cowling BJ, 2016, VACCINE, V34, P61, DOI 10.1016/j.vaccine.2015.11.016; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Darvishian M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169528; Darvishian M, 2014, LANCET INFECT DIS, V14, P1228, DOI 10.1016/S1473-3099(14)70960-0; Englund H, 2013, EPIDEMIOL INFECT, V141, P1807, DOI 10.1017/S0950268812002282; Feng S, 2016, VACCINE, V34, P1672, DOI 10.1016/j.vaccine.2016.02.039; Fielding JE, 2012, EUROSURVEILLANCE, V17, P8; Fielding JE, 2016, VACCINE, V34, P4905, DOI 10.1016/j.vaccine.2016.08.067; Filipovic SK, 2015, EPIDEMIOL INFECT, V143, P2596, DOI 10.1017/S0950268814003677; Flannery B, 2020, J INFECT DIS, V221, P8, DOI 10.1093/infdis/jiz543; Flannery B, 2019, CLIN INFECT DIS, V68, P1798, DOI 10.1093/cid/ciy775; Flannery B, 2016, J INFECT DIS, V214, P1010, DOI 10.1093/infdis/jiw181; Gaglani M, 2016, J INFECT DIS, V213, P1546, DOI 10.1093/infdis/jiv577; Gherasim A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179160; Gherasim A, 2016, VACCINE, V34, P2371, DOI 10.1016/j.vaccine.2016.03.035; Hekimoglu CH, 2018, BALK MED J, V35, P77, DOI 10.4274/balkanmedj.2017.0487; Helmeke C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122910; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Huizenga HM, 2011, BRIT J MATH STAT PSY, V64, P1, DOI 10.1348/000711010X522687; Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]; Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053; Jimenez-Jorge S, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.28.21187; Jimenez-Jorge S, 2012, VACCINE, V30, P3595, DOI 10.1016/j.vaccine.2012.03.048; Jimenez-Jorge S, 2015, VACCINE, V33, P3276, DOI 10.1016/j.vaccine.2015.03.051; Jimenez-Jorge S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-441; Kelly HA, 2016, MED J AUSTRALIA, V204, DOI 10.5694/mja15.01017; Kelly HA, 2013, INFLUENZA OTHER RESP, V7, P729, DOI 10.1111/irv.12018; Levy A, 2014, VACCINE, V32, P6312, DOI 10.1016/j.vaccine.2014.08.066; Lewnard JA, 2018, AM J EPIDEMIOL, V187, P2686, DOI 10.1093/aje/kwy163; Lo YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058222; Lorenzo MMG, 2013, CHEST, V143, P502, DOI 10.1378/chest.12-1711; Ma CN, 2017, HUM VACC IMMUNOTHER, V13, P2379, DOI [10.1080/21645515.2017.1359364, 10.1080/21645515.2017.1353845]; Martinez-Baz I, 2019, J INFECT DIS, V220, P1136, DOI 10.1093/infdis/jiz266; Martinez-Baz I, 2015, HUM VACC IMMUNOTHER, V11, P1626, DOI 10.1080/21645515.2015.1038002; Martinez-Baz I, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-191; McAnerney JM, 2017, INFLUENZA OTHER RESP, V11, P177, DOI 10.1111/irv.12436; McAnerney JM, 2015, INFLUENZA OTHER RESP, V9, P143, DOI 10.1111/irv.12305; McGowan J, 2016, J CLIN EPIDEMIOL, V75, P40, DOI 10.1016/j.jclinepi.2016.01.021; McHugh ML, 2013, BIOCHEM MEDICA, V23, P143, DOI 10.11613/BM.2013.018; McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647; McLean HQ, 2014, CLIN INFECT DIS, V59, P1375, DOI 10.1093/cid/ciu680; Mohl A, 2018, EPIDEMIOL INFECT, V146, P78, DOI 10.1017/S0950268817002709; Nunes B, 2014, VACCINE, V32, P4443, DOI 10.1016/j.vaccine.2014.06.053; Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736; Olsen SJ, 2020, MMWR-MORBID MORTAL W, V69, P1305, DOI 10.15585/mmwr.mm6937a6; Pebody R, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES.2015.20.36.30013; PEBODY R, 2016, EUROSURVEILLANCE, V21; Pebody RG, 2013, EPIDEMIOL INFECT, V141, P620, DOI 10.1017/S0950268812001148; Pebody RG, 2013, EUROSURVEILLANCE, V18, P25; Pebody R, 2019, EUROSURVEILLANCE, V24, P23, DOI 10.2807/1560-7917.ES.2019.24.31.1800488; Pebody R, 2017, EUROSURVEILLANCE, V22, P10, DOI 10.2807/1560-7917.ES.2017.22.44.17-00306; Pebody RG, 2020, VACCINE, V38, P489, DOI 10.1016/j.vaccine.2019.10.071; Pierse N, 2016, VACCINE, V34, P503, DOI 10.1016/j.vaccine.2015.11.073; Pitigoi D, 2015, REV ROMANA MED LAB, V23, P9, DOI 10.1515/rrlm-2015-0007; Pitigoi D, 2012, REV ROMANA MED LAB, V20, P127; Powell L, 2019, J INVEST MED, V67, P598, DOI 10.1136/jim-2018-000974.623; Redlberger-Fritz M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149916; Regan AK, 2019, VACCINE, V37, P2634, DOI 10.1016/j.vaccine.2019.02.027; Regan AK, 2019, VACCINE, V37, P755, DOI 10.1016/j.vaccine.2018.12.006; Rizzo C, 2016, VACCINE, V34, P3102, DOI 10.1016/j.vaccine.2016.04.072; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010; Savulescu C, 2014, VACCINE, V32, P4404, DOI 10.1016/j.vaccine.2014.06.063; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; Skowronski DM, 2019, EUROSURVEILLANCE, V24, P39, DOI 10.2807/1560-7917.ES.2019.24.46.1900585; Skowronski DM, 2017, J INFECT DIS, V216, P1487, DOI 10.1093/infdis/jix526; Skowronski DM, 2016, CLIN INFECT DIS, V63, P21, DOI 10.1093/cid/ciw176; Skowronski DM, 2015, J INFECT DIS, V212, P726, DOI 10.1093/infdis/jiv177; Skowronski DM, 2014, J INFECT DIS, V210, P126, DOI 10.1093/infdis/jiu048; Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153; Skowronski DM, 2012, CLIN INFECT DIS, V55, P332, DOI 10.1093/cid/cis431; Stein Y, 2018, CLIN INFECT DIS, V66, P1383, DOI 10.1093/cid/cix1013; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Sullivan SG, 2013, EUROSURVEILLANCE, V18, P5, DOI 10.2807/1560-7917.ES2013.18.41.20605; Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064; Sullivan SG, 2014, J MED VIROL, V86, P1017, DOI 10.1002/jmv.23847; Sullivan SG, 2013, CLIN INFECT DIS, V57, P474, DOI 10.1093/cid/cit255; Suzuki M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088813; Tewawong N, 2015, PLOS ONE, V10; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Treanor JJ, 2012, CLIN INFECT DIS, V55, P951, DOI 10.1093/cid/cis574; van Doorn E, 2017, VACCINE, V35, P2831, DOI 10.1016/j.vaccine.2017.04.012; Vilcu AM, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.09.003; Wang Y, 2016, VACCINE, V34, P2460, DOI 10.1016/j.vaccine.2016.03.056; Wu SS, 2018, VACCINE, V36, P5774, DOI 10.1016/j.vaccine.2018.07.077; Yang P, 2014, VACCINE, V32, P5285, DOI 10.1016/j.vaccine.2014.07.083; Yaron-Yakoby H, 2018, EUROSURVEILLANCE, V23, P27, DOI 10.2807/1560-7917.ES.2018.23.7.17-00026; Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635	101	5	6	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1225	1240		10.1016/j.vaccine.2021.01.032		FEB 2021	16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33494964				2022-04-29	WOS:000618493500011
J	Wilson, SE; Bunko, A; Johnson, S; Murray, J; Wang, Y; Deeks, SL; Crowcroft, NS; Friedman, L; Loh, LC; MacLeod, M; Taylor, C; Li, Y				Wilson, Sarah E.; Bunko, Andrean; Johnson, Steven; Murray, Jillian; Wang, Yue; Deeks, Shelley L.; Crowcroft, Natasha S.; Friedman, Lindsay; Loh, Lawrence C.; MacLeod, Melissa; Taylor, Christina; Li, Ye			The geographic distribution of un-immunized children in Ontario, Canada: Hotspot detection using Bayesian spatial analysis	VACCINE			English	Article						Bayesian analysis; Spatial analysis; Geographic clustering; Un-immunized; Student immunizations; Non-medical immunization exemptions		Background: In Ontario, Canada, little is currently known about the extent to which un-immunized children may cluster geographically. Our objectives were to: describe the geographic distribution of fully un-immunized children; identify geographic clusters (hotspots) of un-immunized children; and to characterize the contribution of spatial effects and covariates on hotspots, where found. Methods: Our analytic cohort consisted of Ontario students aged 7-17 years in the 2016-2017 school year. We defined students as un-immunized if they had zero doses of any vaccine and a non-medical exemption recorded in Ontario's registry. We calculated unadjusted proportions of un-immunized students by Census Subdivision (CSD) and then used a sequential approach to identify hotspots starting first with hotspot identification at the CSD level and then probed identified hotspots further by Dissemination Area (DA) and including covariates. Hotspots were identified using the Besag-York-Mollie Bayesian spatial model and were defined as areas with >95% probability of having two times the proportion of un-immunized students, relative to the province overall. Results: We identified 15,208 (0.94%) un-immunized children within our cohort consisting of more than 1.61 million students. Unadjusted proportions of un-immunized students varied greatly by geography, ranging from 0% to 21.5% by CSD. We identified 16 hotspot CSDs which clustered in five distinct areas, all of which were located in southern Ontario. The contribution of covariates and spatial effects on the risk of having un-immunized students varied greatly across hotspot areas. Conclusions: Although the provincial proportion (0.94%) of un-immunized students is small, geographical clustering of such students is evident in Ontario and in some areas presents an important risk for future outbreaks. Further qualitative work within these hotspot areas would be a helpful next step to better characterize the factors associated with vaccine refusal in these communities. Crown Copyright (C) 2020 Published by Elsevier Ltd.	[Wilson, Sarah E.; Bunko, Andrean; Johnson, Steven; Murray, Jillian; Deeks, Shelley L.; Crowcroft, Natasha S.; Friedman, Lindsay; Li, Ye] Publ Hlth Ontario, 480 Univ Ave,Suite 1701, Toronto, ON M5G 1M1, Canada; [Wilson, Sarah E.; Wang, Yue; Deeks, Shelley L.; Crowcroft, Natasha S.; Loh, Lawrence C.; Li, Ye] Univ Toronto, Dalla Lana Sch Publ Hlth, 155 Coll St, Toronto, ON M5T 3M7, Canada; [Wilson, Sarah E.; Crowcroft, Natasha S.] ICES, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Crowcroft, Natasha S.] Univ Toronto, Dept Lab Med & Pathobiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada; [Loh, Lawrence C.] Peel Publ Hlth, 7120 Hurontario St, Mississauga, ON L5W 1N4, Canada; [MacLeod, Melissa] Southwestern Publ Hlth, 410 Buller St, Woodstock, ON N4S 6G9, Canada; [Taylor, Christina] Huron Perth Publ Hlth, 77722B London Rd RR 5, Clinton, ON N0M 1L0, Canada		Wilson, SE (通讯作者)，Publ Hlth Ontario, 661 Univ Ave,Suite 1701, Toronto, ON M5G 1M1, Canada.	sarah.wilson@oahpp.ca		Crowcroft, Natasha/0000-0002-6761-8783; Wilson, Sarah/0000-0002-8239-0094	Public Health Ontario	This project was funded by Public Health Ontario.	Aloe C, 2017, P NATL ACAD SCI USA, V114, P7101, DOI 10.1073/pnas.1700240114; Atwell JE, 2013, PEDIATRICS, V132, P624, DOI 10.1542/peds.2013-0878; BESAG J, 1991, ANN I STAT MATH, V43, P1, DOI 10.1007/BF00116466; Birnbaum MS, 2013, VACCINE, V31, P750, DOI 10.1016/j.vaccine.2012.11.092; Brennan JM, 2017, AM J PUBLIC HEALTH, V107, P108, DOI 10.2105/AJPH.2016.303498; Bryden GM, 2019, VACCINE, V37, P4525, DOI 10.1016/j.vaccine.2019.06.060; Cadena J, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/s12911-018-0706-7; Carrel M, 2015, PEDIATRICS, V136, P80, DOI 10.1542/peds.2015-0831; City of Toronto, 2019, IMMUNIZATION COVERAG; Deeks S. L., 2014, Canada Communicable Disease Report, V40, P42; Delamater PL, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5368-y; Eccles KM, 2015, CAN J PUBLIC HEALTH, V106, pE355, DOI 10.17269/cjph.106.4981; Foty RG, 2010, VACCINE, V28, P6518, DOI 10.1016/j.vaccine.2010.06.097; Government of Ontario, 1990, IMM SCH PUP ACT RSO; Government of Ontario, 2019, ONT; Hahne S, 2009, PEDIATR INFECT DIS J, V28, P795, DOI 10.1097/INF.0b013e3181a3e2d5; Holowaty EJ, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-21; Lieu TA, 2015, PEDIATRICS, V135, P280, DOI 10.1542/peds.2014-2715; Ministry of Health and Long-Term Care, 2019, ONT CENTR FORMS REP; Olsen SF, 1996, BRIT MED J, V313, P863; Omer SB, 2008, AM J EPIDEMIOL, V168, P1389, DOI 10.1093/aje/kwn263; Ontario Agency for Health Protection and Promotion (Public Health Ontario), 2019, IMM COV REP SCH PUP; Quach S, 2012, CAN MED ASSOC J, V184, P1673, DOI 10.1503/cmaj.111628; Rezaeian M, 2007, J EPIDEMIOL COMMUN H, V61, P98, DOI 10.1136/jech.2005.043117; Richards JL, 2013, VACCINE, V31, P3009, DOI 10.1016/j.vaccine.2013.04.053; Riesen M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021006; Statistics Canada, 2019, DICT CENS POP 2016 D; Statistics Canada, 2016, POST CODEOM CONV FIL; Statistics Canada, 2018, CENS 2011 CENS QUEST; Statistics Canada, 2019, CENS PROF 2016 CENS; Sullivan AB, 2011, ANN EPIDEMIOL, V21, P245, DOI 10.1016/j.annepidem.2010.11.015; Tavia Grant, 2019, GLOBE MAIL; TOBLER WR, 1970, ECON GEOGR, V46, P234, DOI 10.2307/143141; Wang E, 2014, AM J PUBLIC HEALTH, V104, pE62, DOI 10.2105/AJPH.2014.302190; Wilson SE, 2019, VACCINE, V37, P3123, DOI 10.1016/j.vaccine.2019.04.033; Wilson Sarah E, 2015, CMAJ Open, V3, pE317, DOI 10.9778/cmajo.20140088; Yang YT, 2016, AM J PUBLIC HEALTH, V106, P172, DOI 10.2105/AJPH.2015.302926	37	3	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1349	1357		10.1016/j.vaccine.2020.11.017		FEB 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QH8AG	33518467	hybrid			2022-04-29	WOS:000618493500026
J	Archundia, IG; de la Rosa, G; Olvera, F; Calderon, A; Benard-Valle, M; Alagon, A; Corzo, G				Archundia, Irving G.; de la Rosa, Guillermo; Olvera, Felipe; Calderon, Arlene; Benard-Valle, Melisa; Alagon, Alejandro; Corzo, Gerardo			Assessment of neutralization of Micrurus venoms with a blend of anti-Micrurus tener and anti-ScNtx antibodies	VACCINE			English	Article						Antivenoms; Coral snakes; Elapid snakes; Micrurus venoms; Phospholipase A(2); Short-chain alpha-neurotoxin; Snake antivenoms; Snakebites	AMERICAN CORAL SNAKE; ALPHA-NEUROTOXIN; TOXICITY; CARDIOTOXIN; EXPRESSION; ANTIVENOMS; ELAPIDAE; COLOMBIA; CLONING; TOXINS	Background: Micrurus venoms contain two main groups of toxic protein components: short-chain alpha-neurotoxins (SNtx) and phospholipases type A(2) (PLA(2)). In North America, generally, the Micrurus venoms have low abundance of SNtx compared to that of PLA(2)s; however, both are highly toxic to mammals, and consequently both can play a major role in the envenomation processes. Concerning the commercial horse-derived antivenoms against Micrurus from the North America region, they contain a relatively large amount of antibodies against PLA(2)s, and a low content of antibodies against short chain alpha-neurotoxins. This is mainly due to the lower relative abundance of SNtxs, and also to its poor immunogenicity due to their size and nature. Hence, Micrurus antivenoms made in North America usually present low neutralizing capacity towards Micrurus venoms whose lethality depend largely on short chain alpha-neurotoxins, such as South American Micrurus species. Methods: Horses were hyperimmunized with either the venom of M. tener (PLA(2)-predominant) or a recombinant short-chain consensus alpha-neurotoxin (ScNtx). Then, the combination of the two monospecific horse antibodies (anti-M. tener and anti-ScNtx) was used to test their efficacy against eleven Micrurus venoms. Results: The blend of anti-M. tener and anti-ScNtx antibodies had a better capacity to neutralize the lethality of diverse species from North, Central and South American Micrurus venoms. The antibodies combination neutralized both the ScNtx and ten out of eleven Micrurus venom tested, and particularly, it neutralized the venoms of M. distans and M. laticollaris that were neither neutralized by monospecific anti-M. tener nor anti-ScNtx. Conclusions: These results provide a proof-of-principle for using recombinant immunogens to enrich poor or even non-neutralizing antisera against elapid venoms containing short chain alpha-neurotoxins to develop antivenoms with higher effectiveness and broader neutralizing capacity. (C) 2020 Elsevier Ltd. All rights reserved.	[Archundia, Irving G.; Olvera, Felipe; Calderon, Arlene; Benard-Valle, Melisa; Alagon, Alejandro; Corzo, Gerardo] UNAM, Dept Med Mol & Bioproc, Inst Biotecnol, Av Univ 2001, Cuernavaca 62210, Morelos, Mexico; [de la Rosa, Guillermo] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada		de la Rosa, G; Corzo, G (通讯作者)，UNAM, Inst Biotecnol, Av Univ 2001, Cuernavaca 62210, Morelos, Mexico.	g.delarosa@utoronto.ca; corzo@ibt.unam.mx	de la Rosa, Guillermo/H-1243-2018; Corzo, Gerardo/B-3778-2014	de la Rosa, Guillermo/0000-0001-7157-1319; Corzo, Gerardo/0000-0002-9513-1622	Direccion General de Asuntos del Personal Academico (DGAPA-UNAM)Universidad Nacional Autonoma de Mexico [IN203118, IN207218, 303045, CONACyT-EPE-CGIFPN -1, 740739, 769050]	This work received funding from the Direccion General de Asuntos del Personal Academico (DGAPA-UNAM) grant number IN203118 awarded to GC and IN207218 awarded to AA; and to CONACyT-FORDECYT grant No. 303045 "Venenos y Antivenenos"awarded to consortium Alagon-Becerril-Corzo-Possani. GR was supported by CONACyT-EPE-CGIFPN -1 and -2 No. 740739 and 769050.	[Anonymous], 1981, WHO Offset Publ, P1; Benard-Valle M, 2020, J PROTEOMICS, V225, DOI 10.1016/j.jprot.2020.103863; Benard-Valle M, 2014, TOXICON, V77, P6, DOI 10.1016/j.toxicon.2013.10.005; Bolanos R., 1978, Bulletin of the Pan American Health Organization, V12, P23; BOUGIS PE, 1987, TOXICON, V25, P427, DOI 10.1016/0041-0101(87)90076-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carbajal-Saucedo A, 2013, TOXICON, V66, P64, DOI 10.1016/j.toxicon.2013.02.006; Castillo-Beltran MC, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007250; CHAN TK, 1975, TOXICON, V13, P61, DOI 10.1016/0041-0101(75)90159-2; Chippaux JP, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0127-6; Chippaux JP, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005662; Chippaux Jean-Philippe, 2010, Biologie Aujourd hui, V204, P87, DOI 10.1051/jbio/2009043; CHIPPAUX JP, 1991, TOXICON, V29, P1279, DOI 10.1016/0041-0101(91)90116-9; Corzo G, 2002, J BIOL CHEM, V277, P23627, DOI 10.1074/jbc.M200511200; de Castro KLP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02422; de la Rosa G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11639-2; de la Rosa G, 2018, TOXICON, V155, P32, DOI 10.1016/j.toxicon.2018.10.001; de la Rosa G, 2017, PEPTIDES, V88, P80, DOI 10.1016/j.peptides.2016.12.006; de Roodt AR, 2004, J TOXICOL-CLIN TOXIC, V42, P171, DOI 10.1081/CLT-120030943; Fernandez J, 2011, J PROTEOME RES, V10, P1816, DOI 10.1021/pr101091a; Guerrero-Garzon JF, 2018, BIOCHIMIE, V147, P114, DOI 10.1016/j.biochi.2018.01.006; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROVICI P, 1984, ARCH BIOCHEM BIOPHYS, V229, P270, DOI 10.1016/0003-9861(84)90153-X; Lomonte B, 2016, TOXICON, V122, P7, DOI 10.1016/j.toxicon.2016.09.008; Longbottom J, 2018, LANCET, V392, P673, DOI 10.1016/S0140-6736(18)31224-8; Olamendi-Portugal T, 2008, PROTEOMICS, V8, P1919, DOI 10.1002/pmic.200700668; Rabosky ARD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11484; Ramos HR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004484; Rey-Suarez P, 2016, J PROTEOMICS, V136, P262, DOI 10.1016/j.jprot.2016.02.006; Rey-Suarez P, 2012, TOXICON, V60, P851, DOI 10.1016/j.toxicon.2012.05.023; Rey-Suarez P, 2011, J PROTEOMICS, V75, P655, DOI 10.1016/j.jprot.2011.09.003; Rigoni M, 2008, J BIOL CHEM, V283, P34013, DOI 10.1074/jbc.M803243200; ROJAS G, 1994, TOXICON, V32, P351, DOI 10.1016/0041-0101(94)90087-6; Roman-Dominguez Luis, 2019, Toxicon X, V4, P100013, DOI 10.1016/j.toxcx.2019.100013; Sanchez EE, 2008, TOXICON, V51, P297, DOI 10.1016/j.toxicon.2007.10.004; Sanz L, 2019, J PROTEOMICS, V200, P90, DOI 10.1016/j.jprot.2019.03.014; Sriprapat S, 2003, TOXICON, V41, P57, DOI 10.1016/S0041-0101(02)00209-X; TAN NH, 1990, TOXICON, V28, P1193, DOI 10.1016/0041-0101(90)90119-R; Vergara I, 2014, J PROTEOMICS, V105, P295, DOI 10.1016/j.jprot.2014.02.027	40	2	2	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					1000	1006		10.1016/j.vaccine.2020.12.052		JAN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7FB	33423840				2022-04-29	WOS:000610835100019
J	Chaudhury, S; MacGill, RS; Early, AM; Bolton, JS; King, CR; Locke, E; Pierson, T; Wirth, DF; Neafsey, DE; Bergmann-Leitner, ES				Chaudhury, Sidhartha; MacGill, Randall S.; Early, Angela M.; Bolton, Jessica S.; King, C. Richter; Locke, Emily; Pierson, Tony; Wirth, Dyann F.; Neafsey, Daniel E.; Bergmann-Leitner, Elke S.			Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine	VACCINE			English	Article						Serology; Circumsporozoite protein; Polymorphism; Vaccine; Protection; Malaria	PLASMODIUM-FALCIPARUM; CELL EPITOPES; DIVERSITY	The circumsporozoite protein (CSP) is the main surface antigen of malaria sporozoites, a prime vaccine target, and is known to have polymorphisms in the C-terminal region. Vaccines using a single allele may have lower efficacy against genotypic variants. Recent studies have found evidence suggesting the efficacy of the CSP-based RTS,S malaria vaccine may be limited against P. falciparum CSP alleles that diverge from the 3D7 vaccine allele, particularly in this polymorphic C-terminal region. In order to assess the breadth of the RTS,S-induced antibody responses against CSP C-terminal antigenic variants, we used a novel multiplex assay to measure reactivity of serum samples from a recent RTS,S study against C-terminal peptides from 3D7 and seven additional CSP alleles that broadly represent the genetic diversity found in circulating P. falciparum field isolates. We found that responses to the variants showed, on average, a similar to 30-fold reduction in reactivity relative to the vaccine-matched 3D7 allele. The extent of this reduction, ranging from 21 to 69-fold, correlated with the number of polymorphisms between the variants and 3D7. We calculated antibody breadth of each sample as the median relative reactivity to the seven CSP variants compared to 3D7. Surprisingly, protection from 3D7 challenge in the RTS,S study was associated with higher C-terminal antibody breadth. These findings suggest CSP C-terminal-specific avidity or fine-specificity may play a role in RTS,S-mediated protection and that breadth of C-terminal CSP-specific antibody responses may be a marker of protection. Published by Elsevier Ltd.	[Chaudhury, Sidhartha] WRAIR, Ctr Enabling Capabil, Silver Spring, MD 20910 USA; [MacGill, Randall S.; King, C. Richter; Locke, Emily] PATHs Malaria Vaccine Initiat, Washington, DC 20001 USA; [Early, Angela M.; Wirth, Dyann F.; Neafsey, Daniel E.] MIT, Broad Inst, Cambridge, MA 02142 USA; [Early, Angela M.; Wirth, Dyann F.; Neafsey, Daniel E.] Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02142 USA; [Bolton, Jessica S.; Pierson, Tony; Bergmann-Leitner, Elke S.] WRAIR, Malaria Biol Branch, Immunol Core, Silver Spring, MD 20910 USA		Bergmann-Leitner, ES (通讯作者)，WRAIR, Malaria Biol Branch, Immunol Core, Silver Spring, MD 20910 USA.	elke.s.bergmann-leitner.civ@mail.mil	Bergmann-Leitner, Elke S./B-3548-2011	Bergmann-Leitner, Elke S./0000-0002-8571-8956; MacGill, Randall/0000-0002-4566-1481	PATH's Malaria Vaccine Initiative	This study was funded by PATH's Malaria Vaccine Initiative.	Bailey JA, 2012, J INFECT DIS, V206, P580, DOI 10.1093/infdis/jis329; Bergmann-Leitner ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071610; Bergmann-Leitner ES, 2005, INT IMMUNOL, V17, P245, DOI 10.1093/intimm/dxh205; Birkett A, 2002, INFECT IMMUN, V70, P6860, DOI 10.1128/IAI.70.12.6860-6870.2002; Bolton JS, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-03225-5; Calle JM, 1950, J IMMUNOL, V1992, P2695; Chaudhury S, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1348-9; Cohen J, 2010, HUM VACCINES, V6, P90, DOI 10.4161/hv.6.1.9677; Coppi A, 2011, J EXP MED, V208, P341, DOI 10.1084/jem.20101488; Dobano C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10195-z; Doud MB, 2012, P NATL ACAD SCI USA, V109, P7817, DOI 10.1073/pnas.1205737109; GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199; Herrera R, 2015, INFECT IMMUN, V83, P3771, DOI 10.1128/IAI.02676-14; Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120; Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829; Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2; Laurens MB, 2020, HUM VACC IMMUNOTHER, V16, P480, DOI 10.1080/21645515.2019.1669415; Murugan R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8029; Nardin EH, 1950, J IMMUNOL, V2001, P481; Neafsey DE, 2015, NEW ENGL J MED, V373, P2025, DOI 10.1056/NEJMoa1505819; Oyen D, 2017, P NATL ACAD SCI USA, V114, pE10438, DOI 10.1073/pnas.1715812114; Pholcharee T, 2019, J MOL BIOL; PRINGLE JC, 2018, SCI REP, V8, P1; Rich SM, 2000, PARASITOL TODAY, V16, P390, DOI 10.1016/S0169-4758(00)01741-5; Scally SW, 2018, J EXP MED, V215, P63, DOI 10.1084/jem.20170869; SHI YP, 1993, INFECT IMMUN, V61, P2425, DOI 10.1128/IAI.61.6.2425-2433.1993; Stewart VA, 2006, VACCINE, V24, P6483, DOI 10.1016/j.vaccine.2006.06.033; Suscovich TJ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb4757; Ubillos I, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1186-4; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006	30	4	4	2	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					968	975		10.1016/j.vaccine.2020.12.055		JAN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7FB	33431225	Green Submitted, hybrid			2022-04-29	WOS:000610835100015
J	Fielding, J; Sullivan, SG; Beard, F; Macartney, K; Williams, J; Dawson, A; Gilbert, GL; Massey, P; Crooks, K; Moss, R; McCaw, JM; McVernon, J				Fielding, J.; Sullivan, S. G.; Beard, F.; Macartney, K.; Williams, J.; Dawson, A.; Gilbert, G. L.; Massey, P.; Crooks, K.; Moss, R.; McCaw, J. M.; McVernon, J.			Constructing an ethical framework for priority allocation of pandemic vaccines	VACCINE			English	Article						Pandemic vaccine; Vaccine allocation; Vaccine ethics; Priority populations	PUBLIC-HEALTH; INFLUENZA	Background: Allocation of scarce resources during a pandemic extends to the allocation of vaccines when they eventually become available. We describe a framework for priority vaccine allocation that employed a cross-disciplinary approach, guided by ethical considerations and informed by local risk assessment. Methods: Published and grey literature was reviewed, and augmented by consultation with key informants, to collate past experience, existing guidelines and emerging strategies for pandemic vaccine deployment. Identified ethical issues and decision-making processes were also included. Concurrently, simulation modelling studies estimated the likely impacts of alternative vaccine allocation approaches. Assembled evidence was presented to a workshop of national experts in pandemic preparedness, vaccine strategy, implementation and ethics. All of this evidence was then used to generate a proposed ethical framework for vaccine priorities best suited to the Australian context. Findings: Published and emerging guidance for priority pandemic vaccine distribution differed widely with respect to strategic objectives, specification of target groups, and explicit discussion of ethical considerations and decision-making processes. Flexibility in response was universally emphasised, informed by real-time assessment of the pandemic impact level, and identification of disproportionately affected groups. Model outputs aided identification of vaccine approaches most likely to achieve overarching goals in pandemics of varying transmissibility and severity. Pandemic response aims deemed most relevant for an Australian framework were: creating and maintaining trust, promoting equity, and reducing harmful outcomes. Interpretation: Defining clear and ethically-defendable objectives for pandemic response in context aids development of flexible and adaptive decision support frameworks and facilitates clear communication and engagement activities. (C) 2020 Elsevier Ltd. All rights reserved.	[Fielding, J.; McCaw, J. M.; McVernon, J.] Univ Melbourne, Victorian Infect Dis Lab, Epidemiol Unit, Melbourne, Vic, Australia; [Fielding, J.; McCaw, J. M.; McVernon, J.] Royal Melbourne Hosp, Peter Doherty Inst Infect & Immun Melbourne, Melbourne, Vic, Australia; [Sullivan, S. G.] Royal Melbourne Hosp, WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia; [Sullivan, S. G.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Doherty Dept, Melbourne, Vic, Australia; [Beard, F.; Macartney, K.] Sydney Childrens Hosp Network, Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia; [Beard, F.] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia; [Macartney, K.] Univ Sydney, Discipline Child & Adolescent Hlth, Sydney, NSW, Australia; [Williams, J.; Dawson, A.; Gilbert, G. L.] Univ Sydney, Sch Publ Hlth, Sydney Hlth Eth, Sydney, NSW, Australia; [Dawson, A.; Gilbert, G. L.] Univ Sydney, Marie Bashir Inst Emerging Infect & Biosecur, Sydney, NSW, Australia; [Massey, P.; Crooks, K.] Populat Hlth, Hunter New England Local Hlth Dist, Wallsend, NSW, Australia; [Massey, P.] James Cook Univ, Coll Med & Dent, Townsville, Qld, Australia; [Crooks, K.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia; [Moss, R.; McCaw, J. M.; McVernon, J.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Modelling & Simulat Unit, Melbourne, Vic, Australia; [McCaw, J. M.] Univ Melbourne, Sch Math & Stat, Melbourne, Vic, Australia		McVernon, J (通讯作者)，Univ Melbourne, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Lab, Epidemiol Unit, 792 Elizabeth St, Melbourne, Vic 3000, Australia.; McVernon, J (通讯作者)，Royal Melbourne Hosp, 792 Elizabeth St, Melbourne, Vic 3000, Australia.	j.mcvernon@unimelb.edu.au		Massey, Peter/0000-0001-7194-1914; Fielding, James/0000-0003-2995-9576; sullivan, sheena/0000-0002-0856-0294	Australian Government Department of Health, Office of Health Protection; Australian Government National Health and Medical Research CouncilNational Health and Medical Research Council (NHMRC) of Australia	Australian Government Department of Health, Office of Health Protection; Australian Government National Health and Medical Research Council	Akst J., 2020, SCIENTIST; Altmann DM, 2020, LANCET; [Anonymous], 2011, REV AUSTR HLTH SECT; [Anonymous], GUID ALL TARG PAND I; Bambery B, 2018, PUBLIC HEALTH ETH-UK, V11, P221, DOI 10.1093/phe/phx021; Black AJ, 2017, EPIDEMICS-NETH, V19, P61, DOI 10.1016/j.epidem.2017.01.004; Buccieri K, 2013, PUBLIC HEALTH ETH-UK, V6, P185, DOI 10.1093/phe/pht005; Emanuel EJ, 2006, SCIENCE, V312, P854, DOI 10.1126/science.1125347; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Federal Office of Public Health, SWISS INFL PAND PLAN; Fernandes N., 2020, WP1240E IESE BUS SCH, DOI 10.2139/ssrn.3557504; Flint SM, 2010, MED J AUSTRALIA, V192, P617, DOI 10.5694/j.1326-5377.2010.tb03654.x; Gostin LO, 2006, JAMA-J AM MED ASSOC, V295, P554, DOI 10.1001/jama.295.5.554; Government of Canada, 2017, CAN PAND INFL PREP P; Grill K, 2017, HEALTH CARE ANAL, V25, P291, DOI 10.1007/s10728-015-0299-6; Hanquet G, 2011, VACCINE, V29, P370, DOI 10.1016/j.vaccine.2010.10.079; Hashim Ahmed, 2012, J Infect Public Health, V5, P286, DOI 10.1016/j.jiph.2012.04.001; Kass NE, 2008, BIOSECUR BIOTERROR, V6, P227, DOI 10.1089/bsp.2008.0020; Larson HJ, 2020, NATURE, V580, P306, DOI 10.1038/d41586-020-00920-w; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4552; McDougall R, 2015, BIOETHICS, V29, P523, DOI 10.1111/bioe.12149; Ministry of Health, 2017, NZ INFL PAND PLAN FR; Moss R., 2020, MODELLING IMPACT COV; Moss R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1866-7; Poland GA, 2010, VACCINE, V28, pD3, DOI 10.1016/j.vaccine.2010.08.024; Racine T., 2012, 2009 INFLUENZA H1N1; Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141; Secretariat general de la defense et de la securite nationale, 2011, NAT INFL PAND PREV R; Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182; Stern E, 2010, ASSESSMENT REPORT EU; Straetemans M, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-236; Tillett RL, 2020, LANCET INFECT DIS; Upshur R, 2005, STAND GUARD THEE ETH; Van Elslande J, 2020, CLIN INFECT DIS; Williams JH, 2020, BMC MED ETHICS, V21, DOI 10.1186/s12910-020-00477-3; World Health Organization, 2020, COR DIS COVID 19 TEC; World Health Organization, 2020, Q SIM DIFF COVID 19; World Health Organization, 2020, WHO COVID 19 EXPL GE; Zhang SX, 2020, UNPRECEDENTED DISRUP	40	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 29	2021	39	5					797	804		10.1016/j.vaccine.2020.12.053		JAN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PV7RR	33408013	Bronze, Green Published			2022-04-29	WOS:000610181400006
J	Toll, M; Li, A				Toll, Mathew; Li, Ang			Vaccine sentiments and under-vaccination: Attitudes and behaviour around Measles, Mumps, and Rubella vaccine (MMR) in an Australian cohort	VACCINE			English	Article						Vaccine hesitancy; Vaccine refusal; Under-vaccination; Vaccine attitudes; Immunisation policy	IMMUNIZATION; COUNTRIES	Objective: The study aimed to examine the consistency in factors associated with attitudes towards vaccination and MMR vaccination status. Methods: Using the nationally representative Longitudinal Study of Australian Children matched with the Australian Childhood Immunisation Register, 4,779 children were included from 2004-2005 to 2010-11. Different MMR vaccine dosages and general attitude towards vaccination were modelled individually with multinomial logit regressions, controlling for demographic, socioeconomic, and health related factors of the children and their primary carers. Results: The group with non-vaccination and negative attitudes was characterised by more siblings and older parents the group with under-vaccination but positive attitudes was characterised by younger parental age; and the group with under-vaccination and neutral attitudes was characterised by less socio-economically advantaged areas. The presence of parental medical condition(s), being private or public renters, and higher parental education were associated with under-vaccination but not with attitudes towards vaccination, whilst parental religion was associated with attitudes towards vaccination but not reflected in the vaccine uptake. Conclusions: Vaccine attitudes were largely consistent with MRR vaccine outcomes. However, there was variation in the associations of factors with vaccine attitudes and uptake. The results have implications for different policy designs that target subgroups with consistent or inconsistent vaccination attitudes and behaviour. Parents with intentional and unintentional under-vaccination are of policy concern and require different policy solutions. (C) 2020 Elsevier Ltd. All rights reserved.	[Toll, Mathew] Univ Sydney, Fac Arts & Social Sci, Sch Social & Polit Sci, Dept Sociol & Social Policy, Camperdown, NSW, Australia; [Toll, Mathew] Univ Sydney, Fac Arts & Social Sci, LCT Ctr Knowledge Bldg, Camperdown, NSW, Australia; [Li, Ang] Univ Sydney, Fac Med & Hlth, Camperdown, NSW, Australia; [Li, Ang] Sydney Local Hlth Dist, Sydney Hlth Econ, Camperdown, NSW, Australia		Toll, M (通讯作者)，Univ Sydney, Fac Arts & Social Sci A02, Sch Social & Polit Sci, Dept Sociol & Social Policy, Camperdown, NSW 2006, Australia.	Mathew.toll@sydney.edu.au		Li, Ang/0000-0002-6269-6432; Toll, Mathew/0000-0002-9075-5081			[Anonymous], 2019, 6401 0 CONS PRIC IND; Attwell K, 2019, MILBANK Q, V97, P978, DOI 10.1111/1468-0009.12417; Beard FH, 2017, MED J AUSTRALIA, V206, P381, DOI 10.5694/mja16.00944; Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Brown KF, 2010, VACCINE, V28, P4235, DOI 10.1016/j.vaccine.2010.04.052; Department of Health, 2020, CHILDH IMM COV; Falagas ME, 2008, CURR MED RES OPIN, V24, P1719, DOI 10.1185/03007990802085692; Haynes K, 2004, AUST NZ J PUBL HEAL, V28, P72, DOI 10.1111/j.1467-842X.2004.tb00636.x; Homel J, 2018, CHILD CARE HLTH DEV, V44, P583, DOI 10.1111/cch.12560; Homel J, 2016, MEDICINE; Image T., 2019, LANCET; Johnstone, 2005, 1 LSAC AUSTR I GAM S; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Leask J, 2017, J PAEDIATR CHILD H, V53, P439, DOI 10.1111/jpc.13472; Li A, 2021, PREV MED, V145, DOI 10.1016/j.ypmed.2020.106406; Lim C, 2019, VACCINE-X, V1, DOI 10.1016/j.jvacx.2019.100010; Marin M, 2018, MMWR-MORBID MORTAL W, V67, P33, DOI 10.15585/mmwr.mm6701a7; Navin MC, 2020, PREV MED REP, V17, DOI 10.1016/j.pmedr.2020.101049; Pearce A, 2008, BMJ-BRIT MED J, V336, P754, DOI 10.1136/bmj.39489.590671.25; Pearce A, 2015, VACCINE, V33, P3377, DOI 10.1016/j.vaccine.2015.04.089; Reich JA, 2016, SEX RES SOC POLICY, V13, P341, DOI 10.1007/s13178-016-0227-z; Saint-Victor DS, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0148; Smith DT, 2020, POLITICS-OXFORD, V40, P189, DOI 10.1177/0263395719859457; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016; Tickner S, 2006, VACCINE, V24, P7030, DOI 10.1016/j.vaccine.2006.06.060; World Health Organization, 2019, 10 THREATS GLOB HLTH; World Health Organization, 2014, REP SAGE WORK GROUP	30	1	1	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					751	759		10.1016/j.vaccine.2020.11.021		JAN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PR1FI	33218781				2022-04-29	WOS:000606987100019
J	Dulin, N; Spanier, A; Merino, K; Hutter, JN; Waterman, PE; Lee, C; Hamer, MJ				Dulin, Nicholas; Spanier, Adam; Merino, Kristen; Hutter, Jack N.; Waterman, Paige E.; Lee, Christine; Hamer, Melinda J.			Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials	VACCINE			English	Review						Marburg virus; Systematic review; Ebola virus	HEMORRHAGIC-FEVER; IMMUNE-RESPONSE; EBOLA; VECTORS; IMMUNOGENICITY; OUTBREAK; MACAQUES; EFFICACY; SAFETY	Background: Recent deadly outbreaks of Marburg virus underscore the need for an effective vaccine. A summary of the latest research is needed for this WHO priority pathogen. This systematic review aimed to determine progress towards a vaccine for Marburg virus. Methods: Article search criteria were developed to query PubMed for peer-reviewed articles from 1990 through 2019 on Marburg virus vaccine clinical trials in humans and pre-clinical studies in non-human primates (NHP). Abstracts were reviewed by two authors. Relevant articles were reviewed in full. Discrepancies were resolved by a third author. Data abstracted included year, author, title, vaccine construct, number of subjects, efficacy, and demographics. Assessment for risk of bias was performed using the Syrcle tool for animal studies, and the Cochrane Collaboration risk of bias tool for human studies. Results: 101 articles were identified; 27 were related to Marburg vaccines. After full text review, 21 articles were selected. 215 human subjects were in three phase 1 clinical trials, and 203 NHP in 18 studies. Vaccine constructs were DNA plasmids, recombinant vesicular stomatitis virus (VSV) vectors, adenovirus vectors, virus-like particles (VLP), among others. Two human phase 1 studies of DNA vaccines had 4 adverse effects requiring vaccine discontinuation among 128 participants and 31-80% immunogenicity. In NHP challenge studies, 100% survival was seen in 6 VSV vectored vaccines, 2 DNA vaccines, 2 VLP vaccines, and in 1 adenoviral vectored vaccine. Conclusion: In human trials, two Marburg DNA vaccines provided either low immunogenicity or a failure to elicit durable immunity. A variety of NHP candidate Marburg vaccines demonstrated favorable survival and immunogenicity parameters, to include VSV, VLP, and adenoviral vectored vaccines. Elevated binding antibodies appeared to be consistently associated with protection across the NHP challenge studies. Further human trials are needed to advance vaccines to limit the spread of this highly lethal virus. Published by Elsevier Ltd.	[Dulin, Nicholas; Spanier, Adam; Waterman, Paige E.; Hamer, Melinda J.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Merino, Kristen; Hutter, Jack N.; Waterman, Paige E.; Lee, Christine; Hamer, Melinda J.] Walter Reed Army Inst Res, Silver Spring, MD USA; [Hamer, Melinda J.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA		Hamer, MJ (通讯作者)，Walter Reed Army Inst Res, Clin Trials Ctr, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	Melinda.j.hamer.mil@mail.mil		Hamer, Melinda/0000-0002-6736-1738			Adjemian J, 2011, J INFECT DIS, V204, pS796, DOI 10.1093/infdis/jir312; Baden LR, 2015, J INFECT DIS, V211, P518, DOI 10.1093/infdis/jiu485; Bausch DG, 2006, NEW ENGL J MED, V355, P909, DOI 10.1056/NEJMoa051465; Callendret B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192312; Centers for Disease Control and Prevention, SEL AG LIST; Daddario-DiCaprio KM, 2006, LANCET, V367, P1399, DOI 10.1016/S0140-6736(06)68546-2; Dye JM, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8040094; Fitchett JRA, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.020703; Gai WW, 2017, J MED VIROL, V89, P2069, DOI 10.1002/jmv.24832; Geisbert TW, 2010, J VIROL, V84, P10386, DOI 10.1128/JVI.00594-10; Geisbert TW, 2010, EMERG INFECT DIS, V16, P1119, DOI 10.3201/eid1607.100159; Geisbert TW, 2009, J VIROL, V83, P7296, DOI 10.1128/JVI.00561-09; Geisbert TW, 2008, VACCINE, V26, P6894, DOI 10.1016/j.vaccine.2008.09.082; Grant-Klein RJ, 2015, HUM VACC IMMUNOTHER, V11, P1991, DOI 10.1080/21645515.2015.1039757; Hevey M, 1998, VIROLOGY, V251, P28, DOI 10.1006/viro.1998.9367; Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43; Ignatyev GM, 1996, J BIOTECHNOL, V44, P111, DOI 10.1016/0168-1656(95)00104-2; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Kibuuka H, 2015, LANCET, V385, P1545, DOI 10.1016/S0140-6736(14)62385-0; Kuhn JH, 2013, ARCH VIROL, V158, P301, DOI 10.1007/s00705-012-1454-0; Ledgerwood JE, 2017, NEW ENGL J MED, V376, P928, DOI [10.1056/NEJMoa1410863, 10.1056/nejmoa1410863]; Lefebvre A, 2014, MED MALADIES INFECT, V44, P412, DOI 10.1016/j.medmal.2014.08.005; Marzi A, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03071; Marzi A, 2016, J INFECT DIS, V214, pS360, DOI 10.1093/infdis/jiw218; Mehand MS, 2018, ANTIVIR RES, V159, P63, DOI 10.1016/j.antiviral.2018.09.009; Milligan ID, 2016, JAMA-J AM MED ASSOC, V315, P1610, DOI 10.1001/jama.2016.4218; Mire CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094355; Mire CE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002600; Mire CE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001567; National Institutes of Health National Institute of Allergy and Infectious Diseases website, NIAID EM INF DIS PAT; Pavot V, 2017, METHODS MOL BIOL, V1581, P97, DOI 10.1007/978-1-4939-6869-5_6; Pigott DM, 2015, T ROY SOC TROP MED H, V109, P366, DOI 10.1093/trstmh/trv024; Pigott DM, 2014, ELIFE, V3, DOI [10.7554/eLife.04395, 10.7554/eLife.02851]; Radosevic K, 2010, CLIN VACCINE IMMUNOL, V17, P1687, DOI 10.1128/CVI.00311-10; Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216; Reynolds P, 2017, VIRUS GENES, V53, P501, DOI 10.1007/s11262-017-1455-x; Sabin Institute, SAB VACC I REC 20 5; Sarwar UN, 2015, J INFECT DIS, V211, P549, DOI 10.1093/infdis/jiu511; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; Swenson DL, 2008, CLIN VACCINE IMMUNOL, V15, P460, DOI 10.1128/CVI.00431-07; Swenson DL, 2016, VIRUSES, V8, P94, DOI [10.3390/v8040094., DOI 10.3390/V8040094]; Themis Company Briefing Document, 2019, VACCINES RELATED BIO; Towner JS, 2006, J VIROL, V80, P6497, DOI 10.1128/JVI.00069-06; Volz A, 2017, ADV VIRUS RES, V97, P187, DOI 10.1016/bs.aivir.2016.07.001; Woolsey C, 2018, J INFECT DIS, V218, pS582, DOI 10.1093/infdis/jiy293	45	5	5	1	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					202	208		10.1016/j.vaccine.2020.11.042			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33309082				2022-04-29	WOS:000604750300009
J	Garrison-Desany, H; Ochieng, BO; Odiere, MR; Kuo, H; Gibson, DG; Were, J; Kagucia, EW; Pasetti, MF; Kim, H; Reymann, M; O'Brien, K; Hayford, K				Garrison-Desany, Henri; Ochieng, Benard Omondi; Odiere, Maurice R.; Kuo, Helen; Gibson, Dustin G.; Were, Joyce; Kagucia, E. Wangeci; Pasetti, Marcela F.; Kim, Hani; Reymann, Mardi; O'Brien, Katherine; Hayford, Kyla			Adjustments for oral fluid quality and collection methods improve prediction of circulating tetanus antitoxin: Approaches for correcting antibody concentrations detected in a non-invasive specimen	VACCINE			English	Article						Tetanus toxoid; Serological surveillance; Serological survey; Oral fluid; Serum; Total IgG	RUBELLA-SPECIFIC IGG; HEPATITIS-B; MEASLES; SERUM; SURVEILLANCE; DIAGNOSIS; SAMPLES; SEROEPIDEMIOLOGY; ELIMINATION; VALIDATION	Objectives: To examine whether anti-tetanus toxoid (anti-TT) immunoglobulin G (IgG) levels measured in oral fluid and adjusted for collection difficulties and specimen quality are associated with total IgG and anti-TTIgG in oral fluid and assess if statistical adjustment for them improves prediction of anti-TT IgG in serum. Methods: 267 children, ages 12 to 15 months, enrolled in the M-SIMU randomized controlled trial participated in this nested cross-sectional analysis. Venous blood and oral fluid (OF) specimens were collected, and OF collection difficulties such as crying or gagging were recorded. OF volume was documented and total IgG was measured in OF specimens and anti-TT IgG was measured in OF and serum by enzyme immunoassay (EIA). Collection difficulties, volume and sociodemographic characteristics were assessed in relation to total IgG and anti-TT IgG in OF via multivariate regression. These models were extended to evaluate the association between anti-TT IgG in OF and in serum. A prediction model was developed to adjust anti-TT IgG in OF estimates as proxy for serum. Results: Blood in the specimen, sores in the mouth and crying were positively associated with total IgG concentration while high oral fluid volume and sucking on the swab were inversely associated. None were significant predictors of anti-TT IgG in OF after adjusting for total IgG (geometric mean [GM] ratio: 1.99; 95% confidence interval: 1.78-2.24) and vaccination history (GM ratio: 2.44; 95% CI: 1.98-3.01). When predicting anti-TT IgG levels in serum with OF, total IgG modified the effect of anti-TT IgG in OF. Conclusions: Anti-TT IgG in OF is a good proxy for levels in serum, after controlling for total IgG in the specimen and other variables. Post hoc adjustments for OF volume and total IgG concentration are an important consideration when conducting serosurveys with oral fluid. (C) 2020 The Authors. Published by Elsevier Ltd.	[Garrison-Desany, Henri; Kuo, Helen; Kagucia, E. Wangeci; O'Brien, Katherine; Hayford, Kyla] Int Vaccine Access Ctr, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Ochieng, Benard Omondi; Odiere, Maurice R.; Were, Joyce] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Kisumu, Kenya; [Gibson, Dustin G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Pasetti, Marcela F.; Reymann, Mardi] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA; [Kim, Hani] Bill & Melinda Gates Fdn, Global Hlth, Seattle, WA USA		Hayford, K (通讯作者)，Int Vaccine Access Ctr, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.	kylahayford@jhu.edu	Ochieng, Benard Omondi/AAD-7307-2019	Garrison-Desany, Henri/0000-0003-4164-7065; Hayford, Kyla/0000-0002-9872-2313; Gibson, Dustin/0000-0002-9073-3376	Bill and Melinda Gates FoundationBill & Melinda Gates Foundation	The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Dr. Hani Kim was employed by Johns Hopkins University at the time of her involvement with the study during study set-up and data collection. Since her involvement, she has transitioned to a role at the Bill and Melinda Gates Foundation. All authors report no conflict of interest.].	[Anonymous], 2017, STAT STAT SOFTW REL; Augustine SAJ, 2016, JOVE-J VIS EXP, DOI 10.3791/54415; Ben Salah A, 2003, J VIROL METHODS, V114, P151, DOI 10.1016/j.jviromet.2003.09.008; BENARYEH H, 1985, ARCH ORAL BIOL, V30, P97, DOI 10.1016/0003-9969(85)90032-9; BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015; Buchinsky FJ, 2006, J CLIN VIROL, V35, P450, DOI 10.1016/j.jcv.2005.09.014; Chapey E, 2015, CLIN VACCINE IMMUNOL, V22, P398, DOI 10.1128/CVI.00552-14; Cutts FT, 2016, TROP MED INT HEALTH, V21, P1086, DOI 10.1111/tmi.12737; De Cock L, 2004, J VIROL METHODS, V122, P179, DOI 10.1016/j.jviromet.2004.09.001; Drammeh BS, 2008, CLIN CHEM, V54, P1883, DOI 10.1373/clinchem.2008.108761; Estevez PT, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-104; Facente SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008217; FURNIVAL GM, 1974, TECHNOMETRICS, V16, P499, DOI 10.2307/1267601; Garcia-Calleja JM, 2004, SEX TRANSM INFECT, V80, DOI 10.1136/sti.2004.010298; Gibson DG, 2017, LANCET GLOB HEALTH, V5, pE428, DOI 10.1016/s2214-109x(17)30072-4; Granger DA, 2007, PHYSIOL BEHAV, V92, P583, DOI 10.1016/j.physbeh.2007.05.004; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hayford KT, 2013, J VIROL METHODS, V193, P512, DOI 10.1016/j.jviromet.2013.07.014; HOLMBERG K, 1971, Journal of Periodontal Research, V6, P1, DOI 10.1111/j.1600-0765.1971.tb00581.x; Jenkins MM, 2009, AM J MED GENET A, V149A, P2378, DOI 10.1002/ajmg.a.33043; Kenya National Bureau of Statistics Kenya Ministry of Health National AIDS Control Council Kenya Medical Research Institute National Council for Population and Development The DHS Progrma ICF Internatinoal, 2014, NAT AIDS CONTR COUNC; Kristiansen M, 1997, APMIS, V105, P843, DOI 10.1111/j.1699-0463.1997.tb05093.x; Manikkavasagan G, 2010, EMERG INFECT DIS, V16, P1532, DOI 10.3201/eid1610.100560; Mooney K, 2015, INT J PHARM PRACT, V23, P429, DOI 10.1111/ijpp.12195; Morris M, 2002, J IMMUNOL METHODS, V266, P111, DOI 10.1016/S0022-1759(02)00114-X; Nigatu W., 2003, Ethiopian Journal of Health Development, V17, P149; Nokes DJ, 2001, B WORLD HEALTH ORGAN, V79, P588; Nokes DJ, 1998, T ROY SOC TROP MED H, V92, P679, DOI 10.1016/S0035-9203(98)90811-2; Onis M. de, 2006, Acta Paediatrica, V95, P76; PARRY JV, 1989, J MED VIROL, V28, P255, DOI 10.1002/jmv.1890280410; Parry JV, 1991, REV MED VIROL, V1, P73; Ramsay ME, 2003, J INFECT DIS, V187, pS198, DOI 10.1086/368024; Riis JL, 2017, PEPTIDES, V91, P58, DOI 10.1016/j.peptides.2017.03.006; Salvaterra E, 2014, PATHOBIOLOGY, V81, P304, DOI 10.1159/000362091; Scobie HM, 2017, AM J TROP MED HYG, V96, P415, DOI 10.4269/ajtmh.16-0452; Scobie HM, 2016, CLIN VACCINE IMMUNOL, V23, P546, DOI 10.1128/CVI.00052-16; Simon JK, 2011, CLIN VACCINE IMMUNOL, V18, P355, DOI 10.1128/CVI.00354-10; SQUIER C A, 1991, Critical Reviews in Oral Biology and Medicine, V2, P13; Tapia MD, 2006, PEDIATR INFECT DIS J, V25, P819, DOI 10.1097/01.inf.0000232629.72160.bb; TEW JG, 1985, INFECT IMMUN, V49, P487, DOI 10.1128/IAI.49.3.487-493.1985; van Eijsden M, 2005, CLIN CHEM, V51, P230; Vyse AJ, 2001, PUBLIC HEALTH, V115, P201, DOI 10.1016/S0033-3506(01)00444-9; Warrener L, 2011, B WORLD HEALTH ORGAN, V89, P675, DOI 10.2471/BLT.11.088427; Wilson SE, 2012, CAN MED ASSOC J, V184, pE70, DOI 10.1503/cmaj.110506; World Health Organization Department of Immunization V and B, 2007, IMMUNOLOGICAL BASIS	45	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					423	430		10.1016/j.vaccine.2020.11.027			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33257104	Green Published, hybrid			2022-04-29	WOS:000604750300033
J	Ghaswalla, PK; Bengtson, LGS; Marshall, GS; Buikema, AR; Bancroft, T; Schladweiler, KM; Koep, E; Novy, P; Hogea, CS				Ghaswalla, Parinaz K.; Bengtson, Lindsay G. S.; Marshall, Gary S.; Buikema, Ami R.; Bancroft, Tim; Schladweiler, Krista M.; Koep, Eleena; Novy, Patricia; Hogea, Cosmina S.			Meningococcal vaccination in patients with newly diagnosed asplenia in the United States	VACCINE			English	Article						Meningococcal vaccines; Asplenia; Meningococcus serogroups A, C, W, and Y; Meningococcus serogroup B	IMMUNOCOMPROMISING CONDITIONS RECOMMENDATIONS; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; ADVISORY-COMMITTEE; CONJUGATE VACCINE; SPLENECTOMY; COVERAGE; PROPHYLAXIS; ADULTS; BIAS	Background: Patients with asplenia are recommended to receive meningococcal ACWY (MenACWY) and B (MenB) vaccines in the United States (US). Objectives: To examine uptake and time to receipt of meningococcal vaccines in newly diagnosed asplenia patients, and identify factors associated with vaccination. Methods: For this retrospective database analysis, patients were identified from 1/1/2010 (MenACWY) or 1/1/2015 (MenB) through 3/31/2018 from an administrative claims database including commercially insured US patients with >= 1 inpatient or >= 2 outpatient claims with evidence of a new asplenia diagnosis (sickle cell disease was excluded); continuous enrollment for >= 12 months before and >= 6 months after the index date; and age >= 2 (MenACWY) or >= 10 (MenB) years. Co-primary outcomes were uptake and time to receipt of >= 1 dose, separately for MenACWY and MenB, by Kaplan-Meier analysis. Cox proportional hazards regression models were used to identify characteristics associated with vaccination. Results: Among 2,273 and 741 patients eligible for the MenACWY and MenB analyses, respectively, 28.1% and 9.7% received MenACWY and MenB in the first 3 years after a new asplenia diagnosis. Patients were more likely to receive meningococcal vaccines if they had received pneumococcal vaccines (MenACWY: hazard ratio [HR] 26.02; 95% confidence interval [CI] 21.01-32.22; MenB: HR 3.89; 95% CI 2.07-7.29) or attended >= 1 well-care visit (MenACWY: HR 6.63; 95% CI 4.84-9.09; MenB: HR 11.17; 95% CI 3.02-41.26). Conclusions: Meningococcal vaccination rates among newly diagnosed asplenia patients were low, high-lighting the need to educate providers about the recommendations for high-risk conditions and ensure healthcare access for vulnerable patients. (C) 2020 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.	[Ghaswalla, Parinaz K.; Novy, Patricia; Hogea, Cosmina S.] GSK, Vaccines, 5 Crescent Dr, Philadelphia, PA 19112 USA; [Bengtson, Lindsay G. S.; Buikema, Ami R.; Bancroft, Tim; Schladweiler, Krista M.] Optum, 11000 Optum Circle, Eden Prairie, MN 55344 USA; [Marshall, Gary S.] Norton Childrens, 571 S Floyd St,Suite 321, Louisville, KY 40202 USA; [Marshall, Gary S.] Univ Louisville, Sch Med, 571 S Floyd St,Suite 321, Louisville, KY 40202 USA; [Koep, Eleena] UnitedHlth Grp, 12700 Whitewater Dr, Minnetonka, MN 55343 USA		Ghaswalla, PK (通讯作者)，GSK, Vaccines, 5 Crescent Dr, Philadelphia, PA 19112 USA.	parinaz.k.ghaswalla@gsk.com; lindsay.bengtson@optum.com; gary.marshall@louisville.edu; ami.buikema@optum.com; thimothy.bancrift@optum.com; krista.schladweiler@optum.com; eleena.koep@uhg.com; patricia.l.novy@gsk.com; cosmina.s.hogea@gsk.com		Schladweiler, Krista/0000-0002-3558-0565; Bancroft, Tim/0000-0002-4998-582X; Novy, Patricia/0000-0003-0655-4672	GSKGlaxoSmithKline	This work was supported by GSK (Study identifier: HO-1819581). GSK was involved in all stages of study conduct, including analysis of the data. GSK also covered all costs associated with the development and publication of this manuscript.	Bengtson L, 2019, OPEN FORUM INFECT DI, V6, pS959; Bennett NM, 2013, MMWR-MORBID MORTAL W, V62, P521; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Boam T, 2017, J INFECT PUBLIC HEAL, V10, P803, DOI 10.1016/j.jiph.2017.01.006; Bonanni P, 2017, HUM VACC IMMUNOTHER, V13, P359, DOI 10.1080/21645515.2017.1264797; Bruni L, 2006, EPIDEMIOL INFECT, V134, P837, DOI 10.1017/S0950268805005704; Centers for Disease Control and Prevention (CDC), 2019, MENINGOCOCCAL DISEAS; Centers for Disease Control and Prevention (CDC), 2020, RECOMMENDED ADULT IM; Coignard-Biehler Helene, 2011, J Infect Public Health, V4, P187, DOI 10.1016/j.jiph.2011.06.004; Di Sabatino A, 2017, INTERN EMERG MED, V12, P1139, DOI 10.1007/s11739-017-1730-9; GREENLAND S, 1977, AM J EPIDEMIOL, V106, P184, DOI 10.1093/oxfordjournals.aje.a112451; Hasse B, 2005, SWISS MED WKLY, V135, P291; Healthcare Cost and Utilization Project (HCUP), CLINICAL CLASSIFICAT; Hernandez MC, 2019, SURGERY, V166, P556, DOI 10.1016/j.surg.2019.04.046; Hernandez-Garcia I, 2019, REV ESP SALUD PUBLIC, V93; Kempe A, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0344; Kirkineska L, 2014, HIPPOKRATIA, V18, P7; Lammers AJJ, 2010, EUR J CLIN MICROBIOL, V29, P399, DOI 10.1007/s10096-009-0870-x; Lanes S, 2015, EMERG THEMES EPIDEMI, V12, DOI 10.1186/s12982-015-0027-6; Mbaeyi SA, 2020, MMWR RECOMM REP, V69, DOI 10.15585/mmwr.rr6909a1; Mitchell AP, 2017, AM J MED, V130, P856, DOI 10.1016/j.amjmed.2017.01.024; National Committee for Quality Assurance (NCQA), HEDIS QUALITY MEASUR; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Ramachandra J, 2003, ANN ROY COLL SURG, V85, P252, DOI 10.1308/003588403766274962; Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI [10.1093/cid/cit816, 10.1093/cid/cit684]; Shatz DV, 2002, J TRAUMA, V53, P950, DOI 10.1097/00005373-200211000-00023; Taniguchi LU, 2014, SURG INFECT, V15, P686, DOI 10.1089/sur.2013.051; United States Department of Labor, CPI FOR ALL URBAN CO; US Preventive Services Task Force, 2013, SICKLE CELL DISEASE; Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2; Wang B, 2019, VACCINE, V37, P2768, DOI 10.1016/j.vaccine.2019.04.020	31	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					272	281		10.1016/j.vaccine.2020.11.068			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33309081	hybrid			2022-04-29	WOS:000604750300016
J	Lau, CL; Mayfield, HJ; Sinclair, JE; Brown, SJ; Waller, M; Enjeti, AK; Baird, A; Short, KR; Mengersen, K; Litt, J				Lau, Colleen L.; Mayfield, Helen J.; Sinclair, Jane E.; Brown, Samuel J.; Waller, Michael; Enjeti, Anoop K.; Baird, Andrew; Short, Kirsty R.; Mengersen, Kerrie; Litt, John			Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework	VACCINE			English	Article						SARS-CoV-2; Vaccination; Adverse events; Thrombosis; thrombocytopenia syndrome; Bayesian networks; Model		Thrombosis and Thrombocytopenia Syndrome (TTS) has been associated with the AstraZencea (AZ) COVID-19 vaccine (Vaxzevria). Australia has reported low TTS incidence of 3/100,000 after the first dose, with case fatality rate (CFR) of 5-6%. Risk-benefit analysis of vaccination has been challenging because of rapidly evolving data, changing levels of transmission, and variation in rates of TTS, COVID19, and CFR between age groups. We aim to optimise risk-benefit analysis by developing a model that enables inputs to be updated rapidly as evidence evolves. A Bayesian network was used to integrate local and international data, government reports, published literature and expert opinion. The model estimates probabilities of outcomes under different scenarios of age, sex, low/medium/high transmission (0.05%/0.45%/5.76% of population infected over 6 months), SARS-CoV-2 variant, vaccine doses, and vaccine effectiveness. We used the model to compare estimated deaths from AZ vaccine-associated TTS with i) COVID-19 deaths prevented under different scenarios, and ii) deaths from COVID-19 related atypical severe blood clots (cerebral venous sinus thrombosis & portal vein thrombosis). For a million people aged 1 death from TTS, 25 deaths prevented under low transmission, and 3000 deaths prevented under high transmission. Risks versus benefits varied significantly between age groups and transmission levels. Under high transmission, deaths prevented by AZ vaccine far exceed deaths from TTS (by 8 to > 4500 times depending on age). Probability of dying from COVID-related atypical severe blood clots was 58-126 times higher (depending on age and sex) than dying from TTS. To our knowledge, this is the first example of the use of Bayesian networks for risk-benefit analysis for a COVID-19 vaccine. The model can be rapidly updated to incorporate new data, adapted for other countries, extended to other outcomes (e.g., severe disease), or used for other vaccines. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Lau, Colleen L.; Mayfield, Helen J.; Waller, Michael] Univ Queensland, Fac Med, Sch Publ Hlth, 288 Herston Rd, Brisbane, Qld 4006, Australia; [Sinclair, Jane E.; Brown, Samuel J.; Short, Kirsty R.] Univ Queensland, Fac Sci, Sch Chem & Mol Biosci, Brisbane, Qld, Australia; [Enjeti, Anoop K.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia; [Enjeti, Anoop K.] Calvary Mater Newcastle Hosp, Waratah, NSW, Australia; [Enjeti, Anoop K.] John Hunter Hosp, NSW Hlth Pathol, New Lambton Hts, NSW, Australia; [Baird, Andrew] St Kilda Med Grp, St Kilda, Vic, Australia; [Mengersen, Kerrie] Queensland Univ Technol, Fac Sci, Sch Math Sci, Brisbane, Qld, Australia; [Litt, John] Flinders Univ S Australia, Coll Med & Publ Hlth, Discipline Gen Practice, Adelaide, SA, Australia; [Litt, John] Sci Advisory Comm, Immunisat Coalit, Melbourne, Vic, Australia		Lau, CL (通讯作者)，Univ Queensland, Fac Med, Sch Publ Hlth, 288 Herston Rd, Brisbane, Qld 4006, Australia.	colleen.lau@uq.edu.au	; Lau, Colleen/F-5974-2012	Enjeti, Anoop/0000-0001-8069-090X; Litt, John/0000-0002-3103-0064; Brown, Samuel/0000-0002-7542-8664; Sinclair, Jane/0000-0002-9178-3869; Mayfield, Helen/0000-0003-3462-4324; Lau, Colleen/0000-0001-8288-4169	Immunisation Coalition; AstraZenecaAstraZeneca; PfizerPfizer; Australian National Health and Medical Research Council (NHMRC) FellowshipNational Health and Medical Research Council (NHMRC) of Australia [APP1193826]	This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The CoRiCal project was supported by the Immunisation Coalition through educational grants received from pharmaceutical compa-nies that manufacture vaccines. However, the CoRiCal project did not receive any direct funding from AstraZeneca, Pfizer, or any other companies that produce COVID-19 vaccines. All co-authors of this paper provided in-kind contribution of their time and exper-tise to develop the CoRiCal interactive tool, and the research and modelling that underpin the risk calculations provided by the tool. CLL was supported by an Australian National Health and Medical Research Council (NHMRC) Fellowship (APP1193826) .	Ageno W, 2017, THROMB HAEMOSTASIS, V117, P794, DOI 10.1160/TH16-10-0781; [Anonymous], 2021, VACCINE EFFECTIVENES, P2021; [Anonymous], 2021, AUSTR GOV DEP HLTH A; [Anonymous], 2021, AUSTR BUR STAT DAT D; [Anonymous], 2021, NSW GOVT NSW COVID 1; [Anonymous], 2021, NORWEGIAN I PUBLIC H; Australian Government Department of Health, 2021, NAT NOT DIS SURV SYS; Australian Government Department of Health, 2021, COR COVID 19 CAS NUM; Australian Government Department of Health, 2021, COVID 19 VACC WEEKL; Australian Government Department of Health, 2021, COVID 19 VACC WEIGH; Biddle Nicholas, 2021, VACCINE WILLINGNESS; Burn Edward., BACKGROUND RATES 5 T, V2021; Bussel James B., INGRID PABINGER FASC, P2021; Butcher Rachel, 2020, EXTENDING RANGE SYMP, P2020, DOI 10.22.20217554; Chen Vivien, MED J AUSTRALIA, P2021; Clift AK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3731; Doherty Institute, 2021, DOH MOD REP REV 10 A; Edoardo Bertone, 2020, SYSTEMS-BASEL, V8; Fenton Norman, 2012, RISK ASSESSMENT DECI, V1, P524; Fenton Norman E., 2021, BAYESIAN NETWORK MOD; Franklin Michael, 2021, ALBERTA DOCTORS FIND; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; ISARIC4C (Coronavirus Clinical Characterisation Consortium), ISARIC4C 2021; Johns Hopkins, COVID 19 RISK TOOLS; Kristoffersen ES, 2020, STROKE, V51, P3023, DOI 10.1161/STROKEAHA.120.030800; Lai K, 2020, ABS200811040; Lifespan; Warren Alpert Medical School of Brown University, 2021, MYCOVIDRISK; MacIntyre CR, 2021, VACCINE, V39, P4784, DOI 10.1016/j.vaccine.2021.07.013; Mayfield Helen J, DESIGNING EVIDENCE B, V2021, DOI 10.28.21265588; McLachlan Scott., 2020, FUNDAMENTAL LIMITATI; Medicines & Healthcare products Regulatory Agency, COR VACC WEEKL SUMM, V2021; National Institute on Ageing, 2021, MY COVID 19 VIS RISK; Prodhan Georgina, 2020, EXTENDING RANGE COVI, P2020, DOI 10.20.20215814; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shimabukuro Tom, THROMB THROMB SYNDR; Sogaard KK, 2016, THROMB RES, V141, P1, DOI 10.1016/j.thromres.2016.02.024; Taquet M, 2021, ECLINICALMEDICINE, V39, DOI 10.1016/j.eclinm.2021.101061; The microCOVID Project, 2021, MICROCOVID PROJ; Tran VT, 2021, BMC MED INFORM DECIS, V21, DOI 10.1186/s12911-021-01594-8; University of Oxford, OXF VACC REACH ON BI; Vitale Vincenzina, SPAT STAT-NETH, V2021; VITT Communication Committee, 2021, THANZ MULT VITT GUID; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wu Y, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001357; Zhai Xueting, INFORM COMMUNICATION	46	2	2	7	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7429	7440		10.1016/j.vaccine.2021.10.079		DEC 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	34810000	Green Published, Green Submitted, hybrid			2022-04-29	WOS:000731300100012
J	Thuluva, S; Matur, R; Kishore, TSA; Reddy, GVS				Thuluva, Subhash; Matur, Ramesh; Kishore, T. S. A.; Reddy, G. V. Subba			A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEV (TM)) in 1-15 years-old healthy hepatitis A vaccine-naive children	VACCINE			English	Article						Children; Adolescents; Healive (R); Hepatitis A vaccine; India; Vaccine trial	INDIA	The Biological E inactivated hepatitis A (HAPIBEV (TM)) vaccine was developed by importing the Healive (R) vaccine bulk from China and fill-finish it in India. Healive (R) vaccine is approved in China for both children and adults. This study assessed the safety and immunogenicity of HAPIBEVTM vaccine as compared to the Havrix 720 (R) vaccine of GlaxoSmithKline (GSK) pharmaceuticals when administered intramuscularly (IM) 6 months apart in 1-15 years old hepatitis A virus (HAV) vaccine naive children in India. This Phase 3, single blind, parallel, randomized, active-controlled, two-arm study was conducted at 8 centers in India in healthy HAV vaccine-naive children. Subjects were stratified into 2 age subsets (1-7 and 8-15 years) and randomly assigned to either BE-HAPIBEVTM or GSK's Havrix (R) vaccine and administered 2 IM injections 6 months apart. The immunogenicity evaluations included: (1) proportion of subjects who achieved the following at Day 210 from baseline: (a) seroconversion (>20 mIU/mL) with anti-HAV immunoglobulin G (IgG) antibodies, (b) >= 4-fold increase in anti-HAV IgG antibodies, and (c) >= 2-fold increase in anti-HAV IgG antibodies concentration who were already seroconverted at baseline and (2) geometric mean concentrations (GMC) of anti-HAV IgG antibodies at baseline and Day 210. Safety was evaluated throughout the study. A total of 467 (89.8%) subjects completed the study. The non-inferiority criterion was met by HAPIBEV (TM) vaccine as seroconversion rates in both vaccine groups were 100%. Overall, other immunogenicity eval-uations were either similar in both vaccine groups or higher in the HAPIBEV (TM) group compared with the Havrix (R) group. The safety profile was also comparable between HAPIBEV (TM) and Havrix (R) groups. The most common adverse event (AE) was injection site pain, and the majority of AEs were mild in severity. The HAPIBEV (TM) vaccine demonstrated an immunological and safety profile on par with Havrix (R) in 1-15 years old healthy HAV vaccine-naive Indian children. (C) 2021 Elsevier Ltd. All rights reserved.	[Thuluva, Subhash; Matur, Ramesh; Kishore, T. S. A.; Reddy, G. V. Subba] Biol E Ltd, 18-1&3, Hyderabad 500020, Telangana, India		Thuluva, S (通讯作者)，Biol E Ltd, 18-1&3, Hyderabad 500020, Telangana, India.	subhash.thuluva@biologicale.com		Thuluva, Subhash/0000-0002-9099-420X	Biological E Limited, Azamabad, Hyderabad, Telangana, INDIA	The study was funded by Biological E Limited, 18/1&3, Azamabad, Hyderabad -500 020, Telangana, INDIA.	Abarca K, 2008, INT J INFECT DIS, V12, P270, DOI 10.1016/j.ijid.2007.08.006; Agrawal A, 2019, INFECT DIS THER, V8, P483, DOI 10.1007/s40121-019-00270-9; [Anonymous], 2012, Wkly Epidemiol Rec, V87; [Anonymous], 2000, Wkly Epidemiol Rec, V75, P38; [Anonymous], 2021, GLOBAL VIRAL HEPATIT; Brundage SC, 2006, AM FAM PHYSICIAN, V73, P2162; Franco E, 2012, WORLD J HEPATOL, V4, P68, DOI 10.4254/wjh.v4.i3.68; Hussain Z, 2006, J GASTROEN HEPATOL, V21, P689, DOI 10.1111/j.1440-1746.2006.04232.x; Jacobsen KH, 2009, GLOBAL PREVALENCE HE; Jeong SH, 2010, INTERVIROLOGY, V53, P15, DOI 10.1159/000252779; Lee SD, 2000, J GASTROEN HEPATOL, V15, pG94, DOI 10.1046/j.1440-1746.2000.02239.x; Matheny SC, 2012, AM FAM PHYSICIAN, V86, P1027; Mathur P, 2008, INDIAN J MED RES, V128, P699; Murhekar MV, 2018, AM J TROP MED HYG, V99, P1058, DOI 10.4269/ajtmh.18-0232; Ott JJ, 2012, VACCINE, V31, P3, DOI 10.1016/j.vaccine.2012.04.104; Rakesh PS, 2014, J GLOB INFECT DIS, V6, P59, DOI 10.4103/0974-777X.132040; Satsangi Sandeep, 2016, Med J Armed Forces India, V72, P204, DOI 10.1016/j.mjafi.2016.06.011; Sood V, 2019, INDIAN PEDIATR, V56, P741, DOI 10.1007/s13312-019-1640-1; Verma R, 2012, HUM VACC IMMUNOTHER, V8, P1132, DOI 10.4161/hv.20475; Wang YJ, 2020, HUM VACC IMMUNOTHER, V16, P2559, DOI 10.1080/21645515.2020.1715687; Wasley A, 2006, EPIDEMIOL REV, V28, P101, DOI 10.1093/epirev/mxj012; WHO, 2017, GLOB HEP REP 2017; Wu JY, 2012, HUM VACC IMMUNOTHER, V8, P1836, DOI 10.4161/hv.21909; Yu CK, 2016, HUM VACC IMMUNOTHER, V12, P2595, DOI 10.1080/21645515.2016.1197450	24	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 3	2021	39	49					7166	7174		10.1016/j.vaccine.2021.10.018		NOV 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ2JG	34763950				2022-04-29	WOS:000726620400011
J	Momoh, J; Oteri, AJ; Mogekwu, F; Onwu, N; Dieng, B; Bawa, S; Braka, F; Nsubuga, P; Shuaib, F				Momoh, Jenny; Oteri, Avuwa Joseph; Mogekwu, Fred; Onwu, Nneka; Dieng, Boubacar; Bawa, Samuel; Braka, Fiona; Nsubuga, Peter; Shuaib, Faisal			Ensuring accountability in implementation of supplementary immunisation activities: A case study of the 2017/2018 measles vaccination campaign in Nigeria	VACCINE			English	Article						Measles; Immunisation; Accountability; Vaccination; Nigeria; Campaign		Introduction: Globally, there is a growing concern with accountability and health systems. This has been attributed majorly to discontent with health system performance. Within the Nigerian health system, weak accountability has been consistently singled out as a key challenge underpinning the poor performance of the immunisation programme. In preparation for the 2017/2018 Measles Vaccination Campaign in Nigeria, the National Measles Technical Coordinating Committee (NMTCC) was inaugurated with one of its key mandates being to ensure accountability in the conduct of the 2017/2018 MVC. This paper aims to share the innovative measures applied in the 2017/2018 Measles MVC to improve accountability and to highlight the contribution of the accountability framework to improving measles vaccination coverage. Methods: We identified gaps in accountability from the post-campaign coverage reports and reviews of previous campaigns. We adapted an accountability framework developed by the Nigeria National Routine Immunization Strategic Plan (2013-2015),- which cuts across all levels. Selected indicators were used to monitor the implementation of the framework. Administrative actions such as sanctions and rewards were taken as necessary. Findings: We found that the implementation of the accountability framework was highly instrumental in achieving a high level of coordination among all stakeholders and to improving efficient utilization of resources. We also found that the implementation of the accountability framework in the 2017/2018 MVC contributed to the improved performance of states in terms of measles vaccination coverage compared to the 2015/2016 campaign. Conclusion: We have demonstrated that the implementation of the accountability framework in the 2017/2018 MVC led to a considerable reduction in the misuse and abuse of resources and also contributed to remarkable improvement in the measles vaccination coverages across states compared to the 2015/2016 MVC. (C) 2021 World Health Organization. Published by Elsevier Ltd.	[Oteri, Avuwa Joseph; Mogekwu, Fred; Onwu, Nneka; Shuaib, Faisal] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria; [Momoh, Jenny] Natl Measles Tech Coordinating Comm, Abuja, Nigeria; [Dieng, Boubacar] Gavi Vaccine Alliance, Versoix, Switzerland; [Bawa, Samuel; Braka, Fiona] WHO, Country Off, Abuja, Nigeria; [Nsubuga, Peter] Global Publ Hlth Solut, Atlanta, GA USA		Oteri, AJ (通讯作者)，Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria.	joseph.oteri@nphcda.gov.ng			World Health Organization Country Office in Nigeria	This supplement was sponsored by the World Health Organization Country Office in Nigeria. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors.	Berlan D, 2012, HEALTH POLICY PLANN, V27, P271, DOI 10.1093/heapol/czr036; Brinkerhoff DW, 2014, HEALTH POLICY PLANN, V29, P685, DOI 10.1093/heapol/czs132; Brinkerhoff DW, 2003, ACCOUNTABILITY HLTH, P1; Cleary SM, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-320; Erchick DJ, 2017, INT J HEALTH POLICY, V6, P403, DOI 10.15171/ijhpm.2016.150; FMoH and WHO, 2013, NAT WORKSH STRENTH R; Freedman LP, 2013, REPROD HEALTH MATTER, V21, P103, DOI 10.1016/S0968-8080(13)42744-1; IOM, 2010, PUBL HLTH ROL MEAS A; Joshi A., 2012, SSRN; MNP, 2018, NEW ER HEALTHC ACC S; Molyneux S, 2012, HEALTH POLICY PLANN, V27, P541, DOI 10.1093/heapol/czr083; National Bureau of Statistics, NAT PRIM HLTH CAR DE; National Population Commission (NPC) [Nigeria], 2013, NIG DEM HLTH SURV 20; National Primary Health Care Development Agency & Partners, 2016, MEASL VACC COV SURV; NMTCC, 2017, NIG NAT PLAN MEASL F; NPHCDA, 2012, NIG NAT ROUT IMM STR; ODonnell G, 1999, SELF RESTRAINING STA, P395; Onwujekwe OE, TROPICAL MED INT; Pierre L., 2012, ROUTINE IMMUNIZATION; Tegegne SG, 2016, J INFECT DIS, V213, pS96, DOI 10.1093/infdis/jiv492; Uzochukwu B, 2015, IMPLEMENTING BASIC H; WHO and NPHCDA, DAT QUAL SELF ASS DQ; Wonodi BC, 2012, LANDSCAPE ANAL ROUTI, V30, P2008	23	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 17	2021	39			3			C12	C20		10.1016/j.vaccine.2021.02.068		NOV 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WZ1KH	33714654	hybrid			2022-04-29	WOS:000719731500003
J	Buus, M; da Silva, I; Nielsen, S; Thysen, SM; Fisker, AB				Buus, M.; da Silva, I.; Nielsen, S.; Thysen, S. M.; Fisker, A. B.			Coverage and factors associated with receiving campaign polio vaccines in an urban population in Guinea-Bissau	VACCINE			English	Article						Oral polio vaccine; Supplementary immunization activities; Immunization coverage	SUPPLEMENTARY IMMUNIZATION ACTIVITIES; ROUTINE IMMUNIZATION; MEASLES-VACCINE; EQUITY; IMPACT	Background: Polio eradication campaigns are intended to complement routine immunization. Studies addressing factors associated with campaign coverage are warranted to identify children missed by campaigns. Methods: Bandim Health Project runs demographic surveillance with registration of routine immunization and campaign participation data in urban Guinea-Bissau. We assessed coverage and factors associated with receiving campaign polio vaccines in children aged 0-35 months in two polio eradication campaigns conducted in 2017 and 2018 using univariate and multivariate regression models. Results: Campaign coverage reached 84% in 2017 and 88% in 2018. We found lower coverage among children of young and not formally educated mothers in univariate analyses; Children <9 months and Fula children had lower campaign coverage in both univariate and multivariate analyses. Conclusions: To increase campaign coverage in urban Guinea-Bissau attention may be directed at informing young mothers, mothers of young children, mothers without formal education, and the Fula ethnic group about campaigns. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Buus, M.; Nielsen, S.; Thysen, S. M.; Fisker, A. B.] Univ Southern Denmark, Odense Univ Hosp, Dept Clin Res, OPEN,Bandim Hlth Project, Studiestraede 6, DK-1455 Copenhagen, Denmark; [Buus, M.; da Silva, I.; Nielsen, S.; Thysen, S. M.; Fisker, A. B.] INDEPTH Network, Bandim Hlth Project, Bissau, Guinea Bissau; [Buus, M.] Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark		Fisker, AB (通讯作者)，Univ Southern Denmark, Odense Univ Hosp, Dept Clin Res, OPEN,Bandim Hlth Project, Studiestraede 6, DK-1455 Copenhagen, Denmark.	afisker@health.sdu.dk	; Fisker, Ane/E-9283-2019	Thysen, Sanne Marie/0000-0003-4541-3901; Nielsen, Sebastian/0000-0003-3384-7489; Fisker, Ane/0000-0002-8521-0992	Aase og Ejnar Danielsens Fond [1010-0526]; Else og Mogens Wedell-Wedellsborgs Fond [20-18-2]; Fonden til Laegevidenskabens Fremme [18-L-0078]; Jyske Bank Almennyttige Fond; Aarhus Universitets ForskningsFond [28604]; Sapere Aude Research Leader grant from Independent Research Fund Denmark [9060-00018B]; Lundbeck FoundationLundbeckfonden [R313-2019-635]	This work was supported by Aase og Ejnar Danielsens Fond [1010-0526], Else og Mogens Wedell-Wedellsborgs Fond [20-18-2], Fonden til Laegevidenskabens Fremme [18-L-0078], Jyske Bank Almennyttige Fond and Aarhus Universitets ForskningsFond [28604]. ABFs research is supported through a Sapere Aude Research Leader grant from Independent Research Fund Denmark [9060-00018B] and an Ascending Investigator grant from Lundbeck Foundation [R313-2019-635]. The funding agencies had no role in the study design, data collection, data analysis and interpretation of data, the writing of the article or the decision of submission for publication.	Crocker-Buque T, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4473-7; Ezeanolue EHK, 2017, BEST PRACTICES GUIDA; Fisker AB, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000448; GPEI-Global Polio Eradication Initiative, 2020, POLIO NOW; Helleringer S, 2014, J INFECT DIS, V210, pS531, DOI 10.1093/infdis/jiu278; Helleringer S, 2012, B WORLD HEALTH ORGAN, V90, P495, DOI 10.2471/BLT.11.092494; Mekonnen ZA, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08935-8; Minetti A, 2014, AM J EPIDEMIOL, V179, P245, DOI 10.1093/aje/kwt236; Mogensen SW, 2017, EBIOMEDICINE, V17, P192, DOI 10.1016/j.ebiom.2017.01.041; Mutua MK, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-6; Portnoy A, 2020, VALUE HEALTH, V23, P891, DOI 10.1016/j.jval.2020.03.012; Portnoy A, 2018, VACCINE, V36, P170, DOI 10.1016/j.vaccine.2017.10.080; Schoeps A, 2013, VACCINE, V32, P96, DOI 10.1016/j.vaccine.2013.10.063; Sutter R.W., 2018, VACCINES, P866, DOI DOI 10.1016/B978-0-323-35761-6.00048-1; UNICEF/Gavi, 2018, URBAN IMMUNIZATION T; Vijayaraghavan M, 2007, HEALTH POLICY, V83, P27, DOI 10.1016/j.healthpol.2006.11.008; WHO, 2017, RECOMMENDED ROUTINE; WHO, 2020, POLIO IMMUNIZATION C; World Health Organization Global Polio Eradication Initiative, 2019, WHOPOLIO1904; World Health Organization. Regional Office for Africa, 2017, REACHING EVERY DISTR	20	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 5	2021	39	46					6720	6726		10.1016/j.vaccine.2021.08.090		NOV 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YJ0BG	34654578	hybrid			2022-04-29	WOS:000744203800002
J	Van Dongen, JAP; Rouers, EDM; Bonten, MJM; Bruijning-Verhagen, PCJ				van Dongen, Josephine A. P.; Rouers, Elsbeth D. M.; Bonten, Marc J. M.; Bruijning-Verhagen, Patricia C. J.		RIVAR Study Team	Evaluation of non-specific effects of human rotavirus vaccination in medical risk infants	VACCINE			English	Article						Non-specific effects; Vaccination; Rotavirus	NEONATAL BCG VACCINATION; ORAL POLIO VACCINE; ALLERGIC DISEASE; MORTALITY; BIRTH; PROTECTION; BISSAU; ATOPY	Background: The WHO recommends research into non-specific effects of vaccination. For rotavirus vaccines, these have not yet been well established. We studied non-specific effects up to 18 months of age using data from a quasi-experimental before-after study comparing cohorts of rotavirus vaccinated and unvaccinated infants with medical risk conditions. Methods: Infants were enrolled at six weeks of age before and after a stepped-wedge implementation of a hospital-based risk-group rotavirus vaccination program. Other infant vaccinations were administered according to the Dutch National Immunization Program and similar in both cohorts. Non-specific effect outcomes were prospectively collected using monthly questionnaires and included acute hospitalization (excluding for acute gastroenteritis), monthly incidence of acute respiratory illness and eczema. We used time-to-event analysis and negative binomial regression to assess the effect of at least one dose of rotavirus vaccination for each of these outcomes. Findings The analysis included 496 rotavirus unvaccinated and 719 vaccinated medical risk infants. In total, 1067 (88%) were premature, 373 (31%) small for gestational age and 201 (17%) had a congenital pathology. The adjusted hazard ratio for first acute hospitalization was 0.91 (95 %CI 0.76;1.16) for rotavirus vaccinated versus unvaccinated infants. Adjusted incidence rate ratio for acute respiratory illness was 1.05 (95 %CI 0.96;1.15) and for eczema 0.89 (95 %CI 0.69;1.15). Conclusion: The results suggest no, or minimal non-specific effects from rotavirus vaccination on acute hospitalization, acute respiratory illness or eczema in medical risk infants. Trial registration: as NTR5361 in the Dutch trial registry, www.trialregister.nl. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://	[van Dongen, Josephine A. P.; Bonten, Marc J. M.; Bruijning-Verhagen, Patricia C. J.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Rouers, Elsbeth D. M.; Bruijning-Verhagen, Patricia C. J.] Natl Inst Publ Hlth & Environm, Ctr Epidemiol & Surveillance Infect Dis, Bilthoven, Netherlands; [Bonten, Marc J. M.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands		Van Dongen, JAP (通讯作者)，Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	jdongen3@umcutrecht.nl			GSK Biologicals SAUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [203108]; Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [836021024]; Healthcare Insurers Innovation Foundation; UMC Utrecht	Formatting of funding sources UMC Utrecht, GSK Biologicals SA (studyID 203108) , the Nether-lands Organisation for Health Research and Development (grant-number 836021024) , Healthcare Insurers Innovation Foundation.	Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009; Aaby P, 2014, NAT IMMUNOL, V15, P895, DOI 10.1038/ni.2961; Aaby P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6495; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P301; Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004; Biering-Sorensen S, 2018, J INFECT DIS, V217, P759, DOI 10.1093/infdis/jix612; Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525; Clinicaltrials.gov, BCG COVID TRIALS 202; de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002; Freyne B, 2018, J INFECT DIS, V217, P1798, DOI 10.1093/infdis/jiy069; Freyne B, 2014, ARCH DIS CHILD, V99, P182, DOI 10.1136/archdischild-2013-305655; Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170; Hopkin JM, 1996, THORAX, V51, P1995, DOI [10.1136/thx.51.suppl_3.a1, DOI 10.1136/THX.51.SUPPL_3.A1]; Jensen KJ, 2015, J INFECT DIS, V211, P956, DOI 10.1093/infdis/jiu508; Kandasamy R, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5225; Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Koekenbier E, ESCMID C, V2021; Lund N, 2015, CLIN INFECT DIS, V61, P1504, DOI 10.1093/cid/civ617; Lund N, 2012, VACCINE, V30, P6694, DOI 10.1016/j.vaccine.2012.08.055; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Pollard AJ, 2017, ARCH DIS CHILD, V102, P1077, DOI 10.1136/archdischild-2015-310282; Prentice S, 2021, LANCET INFECT DIS, V21, P993, DOI 10.1016/S1473-3099(20)30653-8; Rogers MAM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44193-4; Steenhuis TJ, 2008, CLIN EXP ALLERGY, V38, P79, DOI 10.1111/j.1365-2222.2007.02859.x; Steiner L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224766; Stensballe LG, 2019, J PEDIAT INF DIS SOC, V8, P213, DOI 10.1093/jpids/piy029; van Dongen JAP, ESPID C 2021 UNPUB; van Dongen JAP, 2021, PEDIATR INFECT DIS J, V40, P300, DOI 10.1097/INF.0000000000003002; Wilson Sarah E, 2015, BMC Res Notes, V8, P439, DOI 10.1186/s13104-015-1412-5	33	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6151	6156		10.1016/j.vaccine.2021.08.067		SEP 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34507856	hybrid			2022-04-29	WOS:000701799200020
J	Trogstad, L; Robertson, AH; Mjaaland, S; Magnus, P				Trogstad, Lill; Robertson, Anna Hayman; Mjaaland, Siri; Magnus, Per			Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study	VACCINE			English	Article						Bleedings; Vaccines; Cohort study; Adverse events	SEX	Objective: To compare prevalence of skin, nose and gingival bleedings after receipt of adeno-vectored or mRNA-vaccines against COVID-19. The hypothesis is that milder symptoms indicating altered thrombocyte function may affect a larger proportion of vaccinated individuals than the recently reported severe cases with thrombosis and thrombocytopenia. Methods: Using an ongoing large, population-based cohort study, more than 80 000 cohort participants were asked through electronic questionnaires about COVID-19 vaccination and potential side effects during weeks 11-13, 2021. The response rate was 58% (81267/138924). Among the vaccinated, 83% were female, 85% health care workers and 80% were aged 40-55 years. The prevalence of self-reported episodes of skin, nose and gingival bleedings were compared after mRNA and adenovirus-vectored vaccination. Estimates were adjusted for age, sex, occupation, previous COVID-19 infection and chronic disease. Results: Four of the 3416 subjects (0.2%) who were vaccinated with a single dose of mRNA vaccine reported skin bleeding as a side effect, as opposed to 163 of 5132 subjects (3.2%) vaccinated with a single dose of the adenovirus-vectored vaccine, OR (odds ratio) = 16.0 (95% confidence interval (CI) 7.5-34.1). Corresponding ORs for nose and gingival bleeding were 8.0 (4.0-15.8) and 9.3 (4.3-20.0), respectively. Conclusions: These findings could potentially indicate that the adenovirus-vectored vaccine may lead to mild bleeding episodes in a larger proportion of vaccinated individuals, and not only in rare cases with documented thrombosis and thrombocytopenia. Studies are needed to understand the possible mechanisms behind these observations, and to establish or refute whether they share similarities with the severe thromboembolic bleeding complications. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Trogstad, Lill; Robertson, Anna Hayman; Mjaaland, Siri] Norwegian Inst Publ Hlth, Div Infect Control & Environm Hlth, POB 222, N-0213 Oslo, Norway; [Magnus, Per] Norwegian Inst Publ Hlth, Ctr Fertil & Hlth, POB 222, N-0213 Oslo, Norway		Trogstad, L (通讯作者)，Norwegian Inst Publ Hlth, Div Infect Control & Environm Hlth, POB 222, N-0213 Oslo, Norway.	lill.trogstad@fhi.no		Trogstad, Lill/0000-0002-9557-5725; Mjaaland, Siri/0000-0002-3870-5861			Blauenfeldt RA, 2021, J THROMB HAEMOST, V19, P1771, DOI 10.1111/jth.15347; Fink AL, 2015, PHYSIOLOGY, V30, P408, DOI 10.1152/physiol.00035.2015; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Jin SW, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009420; Magnus P, 2016, INT J EPIDEMIOL, V45, P382, DOI 10.1093/ije/dyw029; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Trogstad L, 2012, EUROSURVEILLANCE, V17, P11	8	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5854	5857		10.1016/j.vaccine.2021.08.055		SEP 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34479760	Green Published, Green Submitted, hybrid			2022-04-29	WOS:000697501500019
J	Driscoll, AJ; Ortiz, JR; Hartert, TV; Riddell, CA				Driscoll, Amanda J.; Ortiz, Justin R.; Hartert, Tina, V; Riddell, Corinne A.			Recalibrating public health expectations of respiratory syncytial virus lower respiratory tract illness prevention on chronic respiratory disease	VACCINE			English	Letter									[Driscoll, Amanda J.; Ortiz, Justin R.] Univ Maryland, Sch Med, 685 W Baltimore St, Baltimore, MD 21201 USA; [Hartert, Tina, V] Vanderbilt Univ, Med Ctr, 2525 West End Ave, Nashville, TN 37232 USA; [Riddell, Corinne A.] Univ Calif Berkeley, 2121 Berkeley Way West, Berkeley, CA 94720 USA		Ortiz, JR (通讯作者)，Univ Maryland, Sch Med, 685 W Baltimore St, Baltimore, MD 21201 USA.	jortiz@som.umaryland.ed		Hartert, Tina/0000-0001-7470-1166; Driscoll, Amanda/0000-0003-1385-960X; Ortiz, Justin/0000-0002-3138-5965			Brunwasser SM, 2020, LANCET RESP MED, V8, P795, DOI 10.1016/S2213-2600(20)30109-0; Driscoll AJ, 2020, VACCINE, V38, P2435, DOI 10.1016/j.vaccine.2020.01.020; Griffin MP, 2020, NEW ENGL J MED, V383, P415, DOI 10.1056/NEJMoa1913556; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; Riddell CA, 2018, VACCINE, V36, P8100, DOI 10.1016/j.vaccine.2018.10.041	5	0	0	4	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 31	2021	39	37					5257	5258		10.1016/j.vaccine.2021.07.074		AUG 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UC7ZI	34366146				2022-04-29	WOS:000686741800005
J	Sundaram, M; Nasreen, S; Calzavara, A; He, SY; Chung, H; Bronskill, SE; Buchan, SA; Tadrous, M; Tanuseputro, P; Wilson, K; Wilson, S; Kwong, JC				Sundaram, Maria; Nasreen, Sharifa; Calzavara, Andrew; He, Siyi; Chung, Hannah; Bronskill, Susan E.; Buchan, Sarah A.; Tadrous, Mina; Tanuseputro, Peter; Wilson, Kumanan; Wilson, Sarah; Kwong, Jeffrey C.		Canadian Immunization Res	Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments	VACCINE			English	Article						Long-term care; Mortality; Hospitalization; Baseline rates; COVID-19 vaccine safety	TERM-CARE RESIDENTS	Background: Nursing home (NH) residents are prioritized for COVID-19 vaccination. We report monthly mortality, hospitalizations, and emergency department (ED) visit incidence rates (IRs) during 2010-2020 to provide context for COVID-19 vaccine safety assessments. Methods: We observed outcomes among all NH residents in Ontario using administrative databases. IRs were calculated by month, sex, and age group. Comparisons between months were assessed using one-samplet-tests; comparisons by age and sex were assessed using chi-squared tests. Results: From 2010 to 2019, there were 83,453 (SD: 652.4) NH residents per month, with an average of 2.3 (SD: 0.28) deaths, 3.1 (SD: 0.16) hospitalizations, and 3.6 (SD: 0.17) ED visits per 100 residents per month. From March to December 2020, mortality IRs were increased, but hospitalization and ED visit IRs were reduced (p < 0.05). Conclusion: We identified consistent monthly mortality, hospitalization, and ED visit IRs during 2010- 2019. Marked differences in these rates were observed during 2020, coinciding with the COVID-19 pandemic. (c) 2021 Elsevier Ltd. All rights reserved.	[Sundaram, Maria; Nasreen, Sharifa; Calzavara, Andrew; He, Siyi; Chung, Hannah; Bronskill, Susan E.; Buchan, Sarah A.; Tadrous, Mina; Tanuseputro, Peter; Wilson, Sarah; Kwong, Jeffrey C.] ICES, G1 06,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada; [Sundaram, Maria; Nasreen, Sharifa; Bronskill, Susan E.; Buchan, Sarah A.; Wilson, Sarah; Kwong, Jeffrey C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Bronskill, Susan E.; Tadrous, Mina] Womens Coll Res Inst, Toronto, ON, Canada; [Buchan, Sarah A.; Wilson, Sarah; Kwong, Jeffrey C.] Publ Hlth Ontario, Toronto, ON, Canada; [Tanuseputro, Peter; Wilson, Kumanan] Univ Ottawa, Dept Med, Ottawa, ON, Canada; Bruyere Res Inst, Ottawa, ON, Canada; Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Kwong, Jeffrey C.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Kwong, Jeffrey C.] Univ Hlth Network, Toronto, ON, Canada; Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada		Kwong, JC (通讯作者)，ICES, G1 06,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	jeff.kwong@utoronto.ca		Nasreen, Sharifa/0000-0002-9793-113X; Sundaram, Maria/0000-0001-8056-3302; Tanuseputro, Peter/0000-0002-4409-0795			[Anonymous], 2020, TABLE 17 10 0005 01; [Anonymous], 2021, COVID 19 LONG TERM C; [Anonymous], 2020, COVID 19 CAN TIM; [Anonymous], 2020, COVID 19 MOD UPD COV; [Anonymous], 2020, WHO SAGE ROADM PRIOR; [Anonymous], 2021, LONG TERM CAR OV INF; [Anonymous], 2020, COVID 19 PROV TEST G; Branswell H., 2020, STATNEWS; Brown KA, 2020, TEMPORAL VARIATIONS; GACVS, 2021, COVID 19 VACC SAF SU; Gruneir Andrea, 2016, Healthc Policy, V12, P76; Gruneir A, 2010, J AM GERIATR SOC, V58, P510, DOI 10.1111/j.1532-5415.2010.02736.x; Information C.I.f.H, 2020, PAND EXP LONG TERM C; Law B., 2020, D2 3 PRIORITY LIST A; Ontario A, 2021, CASE NUMBERS SPREAD; Sepulveda ER, 2020, J AM MED DIR ASSOC, V21, P1572, DOI 10.1016/j.jamda.2020.08.039; Stall NM, 2020, CAN MED ASSOC J, V192, pE946, DOI 10.1503/cmaj.201197; Sundaram ME, 2021, CAN MED ASSOC J, V193, pE723, DOI 10.1503/cmaj.202608; Tanuseputro P, 2015, J AM MED DIR ASSOC, V16, P874, DOI 10.1016/j.jamda.2015.06.004	19	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 31	2021	39	37					5265	5270		10.1016/j.vaccine.2021.07.060		AUG 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UC7ZI	34373124	Bronze, Green Published, Green Submitted			2022-04-29	WOS:000686741800007
J	Jackson, B; Harvey, Y; Perez-Martin, E; Wilsden, G; Juleff, N; Charleston, B; Seago, J				Jackson, Ben; Harvey, Yongjie; Perez-Martin, Eva; Wilsden, Ginette; Juleff, Nicholas; Charleston, Bryan; Seago, Julian			The selection of naturally stable candidate foot-and-mouth disease virus vaccine strains for East Africa	VACCINE			English	Article						Foot-and-mouth disease; FMD vaccine; Foot-and-mouth disease virus; Strain stability; Virus neutralisation test	CELL-CULTURE; CAPSID PROTEINS; SEROTYPE	Foot-and-mouth disease (FMD) is a global burden on the livestock industry. The causative agent, FMD virus (FMDV), is highly infectious and exists in seven distinct serotypes. Vaccination remains the most effective control strategy in endemic regions and current FMD vaccines are made from inactivated preparations of whole virus. The inherent instability of FMDV and the emergence of new strains presents challenges to efficacious vaccine development. Currently, vaccines available in East Africa are comprised of relatively historic strains with unreported stabilities. As an initial step to produce an improved multivalent FMD vaccine we have identified naturally stable East African FMDV strains for each of the A, O, SAT1 and SAT2 serotypes and investigated their potential for protecting ruminants against strains that have recently circulated in East Africa. Interestingly, high diversity in stability between and within serotypes was observed, and in comparison to non-African A serotype viruses reported to date, the East African strains tested in this study are less stable. Candidate vaccine strains were adapted to propagation in BHK-21 cells with minimal capsid changes and used to generate vaccinate sera that effectively neutralised a panel of FMDV strains selected to improve FMD vaccines used in East Africa. This work highlights the importance of combining tools to predict and assess FMDV vaccine stability, with cell culture adaptation and serological tests in the development of FMD vaccines. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Jackson, Ben; Harvey, Yongjie; Perez-Martin, Eva; Wilsden, Ginette; Charleston, Bryan; Seago, Julian] Pirbright Inst, Woking GU24 0NF, Surrey, England; [Juleff, Nicholas] Bill & Melinda Gates Fdn, 500 5th Ave N, Seattle, WA 98109 USA		Seago, J (通讯作者)，Pirbright Inst, Woking GU24 0NF, Surrey, England.	julian.seago@pirbright.ac.uk	Perez-MArtin, Eva/AFP-6433-2022	Perez-Martin, Eva/0000-0002-4355-4367	Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1131495, OPP1154700]; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BBS/E/I/00007039]	This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [OPP1131495 and OPP1154700] . Under the grant conditions of the Foundation, a Creative Commons Attri-bution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. This work was also supported by a BBSRC grant (BBS/E/I/00007039) . We thank members of WRLFMD, Donald King, Nick J Knowles, Valerie Mioulet, for providing strain information, and Tim Doel and Claudia Doel for helpful discussion.	Balinda SN, 2010, INFECT GENET EVOL, V10, P1058, DOI 10.1016/j.meegid.2010.06.017; Barnett PV, 2003, VACCINE, V21, P3240, DOI 10.1016/S0264-410X(03)00219-6; Brehm KE, 2009, J CLIN MICROBIOL, V47, P3156, DOI 10.1128/JCM.00510-09; BROWN F, 1963, NATURE, V199, P1168, DOI 10.1038/1991168a0; DIEZ J, 1990, J VIROL, V64, P5519; Dill V, 2020, VIRUS GENES, V56, P1, DOI 10.1007/s11262-019-01714-7; DOEL TR, 1981, ARCH VIROL, V70, P21, DOI 10.1007/BF01320790; GOLDING SM, 1976, RES VET SCI, V20, P142, DOI 10.1016/S0034-5288(18)33445-3; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Kotecha A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31856-x; Kotecha A, 2016, J GEN VIROL, V97, P1557, DOI 10.1099/jgv.0.000462; Kotecha A, 2015, NAT STRUCT MOL BIOL, V22, P788, DOI 10.1038/nsmb.3096; Lloyd-Jones K, 2017, VACCINE, V35, P6842, DOI 10.1016/j.vaccine.2017.10.040; Maree FF, 2010, VIRUS RES, V153, P82, DOI 10.1016/j.virusres.2010.07.010; Mohapatra JK, 2015, J GEN VIROL, V96, P553, DOI 10.1099/vir.0.071597-0; OIE, 2012, FOOT AND MOUTH DIS M; RWEYEMAMU MM, 1984, J BIOL STAND, V12, P323, DOI 10.1016/S0092-1157(84)80013-X; Scott KA, 2017, J VIROL, V91, DOI [10.1128/jvi.02312-16, 10.1128/JVI.02312-16]; Willems T, 2020, J VIROL METHODS, V276, DOI 10.1016/j.jviromet.2019.113786; Zhao QZ, 2003, J VIROL, V77, P3269, DOI 10.1128/JVI.77.5.3269-3280.2003	21	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					5015	5024		10.1016/j.vaccine.2021.07.001		AUG 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TX3GY	34303562	hybrid, Green Published			2022-04-29	WOS:000682979100015
J	HogenEsch, E; De Mucio, B; Haddad, LB; Vilajeliu, A; Ropero, AM; Yildirim, I; Omer, SB				HogenEsch, Elena; De Mucio, Bremen; Haddad, Lisa B.; Vilajeliu, Alba; Ropero, Alba Maria; Yildirim, Inci; Omer, Saad B.			Differences in maternal group B Streptococcus screening rates in Latin American countries	VACCINE			English	Article						Streptococcus agalactiae; Pregnancy; Latin America; Health disparities	PREGNANT-WOMEN; DISEASE WORLDWIDE; COST-EFFECTIVENESS; COLONIZATION; PREVENTION; IMMUNIZATION; STILLBIRTHS; PREVALENCE; VACCINE; HEALTH	Objective: To determine rates and results of maternal Group B streptococcus (GBS) screening during pregnancy and identify sociodemographic characteristics associated with GBS screening in Latin American countries. Background: GBS is a primary cause of morbidity and mortality in neonates and is prevented by screening pregnant women for GBS before delivery and intrapartum antibiotic treatment. Yet, data regarding national GBS screening practices and the epidemiology of maternal GBS colonization in Latin America are limited. Methods: We conducted a retrospective observational study using de-identified records of pregnant women in six Latin American countries from a regional database. 460,328 collected from January 1, 2009 through December 31, 2012 met study criteria and were included. Maternal screening rates for GBS were determined, association of demographic variables (ethnicity, age, education level, and civil status) with maternal GBS screening was determined using logistic regression, odds ratios were calculated comparing incidence of adverse neonatal outcomes (sepsis, pneumonia, and meningitis) between countries with high and low rates of GBS screening, maternal GBS colonization prevalence was determined by year and association of demographic variables with maternal GBS colonization was determined using logistic regression. Results: Maternal GBS screening was less than 15% in each country, except Uruguay which screened greater than 65% of women. The final regression model examining maternal screening rates and demographic variables included the covariates ethnicity, maternal age group, education level and civil status. Countries with lower rates of maternal GBS screening had increased odds of neonatal sepsis [OR 23.3; 95% CI (15.2-35.9)] and pneumonia [OR 19.9; 95% CI (12.1-32.6)]. In Uruguay, GBS prevalence over the study period was 18.5%. Black women, older women and women without a primary education had higher rates of GBS colonization (21.3%, 20.4% and 21.9% respectively). Conclusions: Our study highlights the need for national policy and investments to increase maternal GBS screening and better understand the prevalence of maternal GBS colonization in Latin America. Further research on the burden of neonatal GBS disease within Latin America is needed to inform the introduction of a maternal GBS vaccine, when available. (C) 2020 The Authors. Published by Elsevier Ltd.	[HogenEsch, Elena] Emory Univ, Sch Med, 201 Dowman Dr, Atlanta, GA 30322 USA; [De Mucio, Bremen] Latin Amer Ctr Perinatol Panamer Hlth Org, Ave Brasil 2697,1er Piso, Montevideo 11600, Uruguay; [Haddad, Lisa B.] Emory Univ, Sch Med, Dept Obstet & Gynecol, Atlanta, GA USA; [Vilajeliu, Alba; Ropero, Alba Maria] Pan Amer Hlth Org PAHO WHO Reg Off Amer, Comprehens Family Immunizat Unit, Family Hlth Promot & Life Course Dept, 525 23rd St NW, Washington, DC 20037 USA; [Yildirim, Inci] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Sch Med,Div Pediat Infect Dis, 2015 Uppergate Dr, Atlanta, GA 30322 USA; [Omer, Saad B.] Yale Sch Publ Hlth, Yale Inst Global Hlth, Dept Med, Sect Infect Dis,Yale Sch Med,Dept Epidemiol Micro, 333 Cedar St, New Haven, CT 06510 USA		HogenEsch, E (通讯作者)，Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA.	elena.hogenesch@northwestern.edu; demuciob@paho.org; lisa.haddad@emory.edu; vilajelmar@paho.org; roperoal@paho.org; inci.yildirim@emory.edu; saad.omer@yale.edu		De Mucio, Bremen/0000-0003-0662-9742; Haddad, Lisa/0000-0002-7631-6760	Georgia Clinical and Translational Science Alliance [TL1 TR002382]	This work was supported by the Georgia Clinical and Translational Science Alliance [TL1 TR002382].	Agency CI, WORLD FACTBOOK; [Anonymous], 2020, OBSTET GYNECOL, V135, pE51, DOI [10.1097/AOG.0000000000003668, 10.1097/AOG.0000000000003335]; [Anonymous], WHO PREFERRED PRODUC; Bank TW, WORLD BANK UR; Berardi A, 2006, ACTA OBSTET GYN SCAN, V85, P1012, DOI 10.1080/00016340500408424; Botelho ACN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196925; Bryant AS, 2011, MATERN CHILD HLTH J, V15, P1160, DOI 10.1007/s10995-010-0682-8; CLAP/WR, 2010, PER INF SYST SIP PER; Colbourn T, 2007, EARLY HUM DEV, V83, P149, DOI 10.1016/j.earlhumdev.2007.01.004; Corp, 2017, SPSS STAT MAC; Fielding JE., 2016, ADDRESSING SOCIAL DE; Fiscella K, 2016, ANNU REV PUBL HEALTH, V37, P375, DOI 10.1146/annurev-publhealth-032315-021439; Friedrich F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228022; Giorgakoudi K, 2018, VACCINE, V36, P7033, DOI 10.1016/j.vaccine.2018.09.058; Heath PT, 2016, VACCINE, V34, P2876, DOI 10.1016/j.vaccine.2015.12.072; Kim SY, 2017, VACCINE, V35, P6238, DOI 10.1016/j.vaccine.2017.08.085; Kobayashi M, 2019, VACCINE, V37, P7307, DOI 10.1016/j.vaccine.2016.12.029; Kwatra G, 2016, LANCET INFECT DIS, V16, P1076, DOI 10.1016/S1473-3099(16)30055-X; Latin American Center for Perinatology PAHO, LAT ADV SIP REG; Lawn JE, 2017, CLIN INFECT DIS, V65, pS89, DOI 10.1093/cid/cix653; Le Doare K, 2017, CLIN INFECT DIS, V65, pS143, DOI 10.1093/cid/cix654; Le Doare K, 2013, VACCINE, V31, pD7, DOI 10.1016/j.vaccine.2013.01.009; Mitra AK, 2010, INT J ENV RES PUB HE, V7, P2238, DOI 10.3390/ijerph7052238; Organization WH, 2017, GROUP B STREPT VACC; Pan American Health Organization/World Health Organization EaIfAiHDHA Metrics and Evidence Unit, 2018, HLTH SIT AM COR IND; Quiroga M, 2008, BRAZ J MICROBIOL, V39, P245, DOI 10.1590/S1517-83822008000200009; Rao GG, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014634; Ropero Alvarez AM, 2017, PAN AM J PUBLC HLTH, V41; Ropero-Alvarez AM, 2016, HUM VACC IMMUNOTHER, V12, P2206, DOI 10.1080/21645515.2016.1157240; Russell LB, 2017, VACCINE, V35, P6905, DOI 10.1016/j.vaccine.2017.07.108; Russell NJ, 2017, CLIN INFECT DIS, V65, pS100, DOI 10.1093/cid/cix658; Schrag SJ, 2002, NEW ENGL J MED, V347, P233, DOI 10.1056/NEJMoa020205; Schrag SJ, 2013, VACCINE, V31, pD20, DOI 10.1016/j.vaccine.2012.11.056; Seale AC, 2017, CLIN INFECT DIS, V65, pS200, DOI 10.1093/cid/cix664; UNICEF W, 2019, GLOB DEL CAR COV TRE; Vekemans J, 2019, VACCINE, V37, P7391, DOI 10.1016/j.vaccine.2017.09.087; Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1; Vizzotti C, 2015, VACCINE, V33, P6413, DOI 10.1016/j.vaccine.2015.07.109; WHO, 2016, WORLD HLTH STAT 2016	39	3	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39			2			B3	B11		10.1016/j.vaccine.2020.10.082		JUL 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UD6SH	33308886	hybrid			2022-04-29	WOS:000687335900002
J	Earle, KA; Ambrosino, DM; Fiore-Gartland, A; Goldblatt, D; Gilbert, PB; Siber, GR; Dull, P; Plotkin, SA				Earle, Kristen A.; Ambrosino, Donna M.; Fiore-Gartland, Andrew; Goldblatt, David; Gilbert, Peter B.; Siber, George R.; Dull, Peter; Plotkin, Stanley A.			Evidence for antibody as a protective correlate for COVID-19 vaccines	VACCINE			English	Article						COVID-19; SARS-CoV-2; Vaccine; Correlate of protection		A correlate of protection (CoP) is urgently needed to expedite development of additional COVID-19 vaccines to meet unprecedented global demand. To assess whether antibody titers may reasonably predict efficacy and serve as the basis of a CoP, we evaluated the relationship between efficacy and in vitro neutralizing and binding antibodies of 7 vaccines for which sufficient data have been generated. Once calibrated to titers of human convalescent sera reported in each study, a robust correlation was seen between neutralizing titer and efficacy (rho = 0.79) and binding antibody titer and efficacy (rho = 0.93), despite geographically diverse study populations subject to different forces of infection and circulating variants, and use of different endpoints, assays, convalescent sera panels and manufacturing platforms. Together with evidence from natural history studies and animal models, these results support the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines. (C) 2021 The Authors. Published by Elsevier Ltd.	[Earle, Kristen A.; Dull, Peter] Bill & Melinda Gates Fdn, Vaccine Dev & Surveillance, 500 5th Ave N, Seattle, WA 98109 USA; [Fiore-Gartland, Andrew; Gilbert, Peter B.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1100 Fairview Ave N, Seattle, WA 98109 USA; [Goldblatt, David] UCL, Great Ormond St Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England; [Plotkin, Stanley A.] Univ Penn, Dept Pediat, Perelman Sch Med, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA		Dull, P (通讯作者)，Bill & Melinda Gates Fdn, Vaccine Dev & Surveillance, 500 5th Ave N, Seattle, WA 98109 USA.	Peter.Dull@gatesfoundation.org	Goldblatt, David/C-5972-2008	Goldblatt, David/0000-0002-0769-5242			Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Chen XM, 2021, VIROLOGY, V559, P1, DOI 10.1016/j.virol.2021.03.009; Gabriel EE, 2019, STAT MED, V38, P1135, DOI 10.1002/sim.7996; Hansen CB, 2021, J IMMUNOL, V206, P109, DOI 10.4049/jimmunol.2000898; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Janssen Biotech Inc, FDA BRIEF DOC JANSS FDA BRIEF DOC JANSS; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Novavax, 2021, ANN UK S AFR TRIAL R ANN UK S AFR TRIAL R; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Qin L, 2007, J INFECT DIS, V196, P1304, DOI 10.1086/522428; Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037	16	123	123	8	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4423	4428		10.1016/j.vaccine.2021.05.063		JUL 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO		hybrid, Green Published, Green Submitted	Y	N	2022-04-29	WOS:000672160300008
J	Feng, YL; Yao, T; Chang, Y; Gao, LY; Shao, ZH; Dong, S; Wu, YT; Shi, XH; Shi, J; Feng, D; Cheng, YP; Pan, MH; Li, CX; Wang, J; Lan, GH; Lu, HY; Wang, PY; Xiang, SM; Nong, LH; Wang, FZ; Liang, XF; Wang, SP				Feng, Yongliang; Yao, Tian; Chang, Yue; Gao, Linying; Shao, Zhihong; Dong, Shuang; Wu, Yuanting; Shi, Xiaohong; Shi, Jing; Feng, Dan; Cheng, Yanpeng; Pan, Minghu; Li, Chunxia; Wang, Jun; Lan, Guanghua; Lu, Hongyan; Wang, Peiyu; Xiang, Shaomi; Nong, Lihua; Wang, Fuzhen; Liang, Xiaofeng; Wang, Suping			Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial	VACCINE			English	Article						Hepatitis B vaccine; Adults infected with HIV; Randomised controlled trial; Immunogenicity; Long-term durability	IMMUNE-RESPONSE; SEROLOGIC RESPONSE; HIV; RISK	Objectives: To explore the immunogenicity and persistence of the 60 mg hepatitis B vaccine in adults infected with human immunodeficiency virus (HIV). Methods: We conducted a randomised controlled trial for adults infected with HIV. A total of 182 patients were randomly allocated to receive 20 mg (IM20 group) or 60 mg (IM60 group) of recombinant hepatitis B vaccine at months 0, 1, and 6 to assess the immunogenicity and were followed-up from month 7 to 42 to assess long-term immunogenicity. Results: Our data showed that the response rate and geometric mean concentration (GMC) of antibodies to hepatitis B surface antigen (anti-HBs) in the IM60 group at month 7 were higher than those in the IM20 group (P > 0.05). The GMC of anti-HBs among the two groups decreased rapidly during the follow-up period (P > 0.05). Survival analysis showed that 25% of patients with anti-HBs > 10 mIU/mL were 20 months in the IM60 group and 9.3 months in the IM20 group. Conclusion: The three-dose 60 mg hepatitis B vaccine showed partially better immunogenicity and persistence than the three-dose 20 mg vaccine. Trial Registration: The trial was registered on clinicaltrials.gov, NCT03316807. (c) 2021 Elsevier Ltd. All rights reserved.	[Feng, Yongliang; Yao, Tian; Chang, Yue; Gao, Linying; Shao, Zhihong; Dong, Shuang; Wu, Yuanting; Shi, Xiaohong; Shi, Jing; Feng, Dan; Cheng, Yanpeng; Pan, Minghu; Li, Chunxia; Wang, Jun; Wang, Suping] Shanxi Med Univ, Sch Publ Hlth, Taiyuan 030001, Shanxi, Peoples R China; [Feng, Yongliang; Yao, Tian; Chang, Yue; Gao, Linying; Dong, Shuang; Wu, Yuanting; Shi, Xiaohong; Shi, Jing; Wang, Suping] Shanxi Med Univ, Ctr Clin Epidemiol & Evidence Based Med, Taiyuan 030001, Shanxi, Peoples R China; [Lan, Guanghua; Lu, Hongyan] Guangxi Ctr Dis Control & Prevent, Nanning 530028, Guangxi, Peoples R China; [Wang, Peiyu; Xiang, Shaomi; Nong, Lihua] Ningming Ctr Dis Control & Prevent, Ningming 532500, Guangxi, Peoples R China; [Wang, Fuzhen] Chinese Ctr Dis Control & Prevent, Beijing 100021, Peoples R China; [Liang, Xiaofeng] Chinese Prevent Med Assoc, Beijing 100021, Peoples R China		Wang, SP (通讯作者)，Shanxi Med Univ, Sch Publ Hlth, Taiyuan 030001, Shanxi, Peoples R China.; Wang, SP (通讯作者)，Shanxi Med Univ, Ctr Clin Epidemiol & Evidence Based Med, Taiyuan 030001, Shanxi, Peoples R China.; Liang, XF (通讯作者)，Chinese Prevent Med Assoc, Beijing 100021, Peoples R China.	liangxf@cpma.org.cn; supingwang@sxmu.edu.cn			National Science and Technology Major Project of the Ministry of Science and Technology of China [2018ZX10721202, 2012ZX10002001]	The study was supported by the National Science and Technology Major Project of the Ministry of Science and Technology of China (2018ZX10721202, 2012ZX10002001).	[Anonymous], 2018, LANCET GASTROENTEROL, V3, P383, DOI [DOI 10.1016/S2468-1253(18)30056-6, 10.1016/S2468-1253(18)30056-6]; Bureau of Disease Control and Prevention, EP SIT STAT REP INF; Burki T, 2018, LANCET INFECT DIS, V18, P1311, DOI 10.1016/S1473-3099(18)30680-7; Case KK, 2019, AIDS, V33, pS197, DOI 10.1097/QAD.0000000000002440; Chaiklang K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080409; Chaiwarith R, 2019, AIDS RES THER, V16, DOI 10.1186/s12981-019-0249-8; Chinese Society of Infectious Diseases Chinese Medical Association, 2019, Zhonghua Gan Zang Bing Za Zhi, V27, P938, DOI 10.3760/cma.j.issn.1007-3418.2019.12.007; Cruciani M, 2009, VACCINE, V27, P17, DOI 10.1016/j.vaccine.2008.10.040; Dan F., 2018, PREVALENCE RELATED F; Flynn PM, 2011, JAIDS-J ACQ IMM DEF, V56, P325, DOI 10.1097/QAI.0b013e318203e9f2; Fonseca MO, 2005, VACCINE, V23, P2902, DOI 10.1016/j.vaccine.2004.11.057; Gara N, 2015, CLIN INFECT DIS, V60, P505, DOI 10.1093/cid/ciu867; HADLER SC, 1991, J INFECT DIS, V163, P454, DOI 10.1093/infdis/163.3.454; Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1; Kerneis S, 2014, CLIN INFECT DIS, V58, P1130, DOI 10.1093/cid/cit937; Kim HN, 2008, INT J STD AIDS, V19, P600, DOI 10.1258/ijsa.2007.007197; Laksananun N, 2019, AIDS RES THER, V16, DOI 10.1186/s12981-019-0225-3; Launay O, 2016, JAMA INTERN MED, V176, P603, DOI 10.1001/jamainternmed.2016.0741; Launay O, 2011, JAMA-J AM MED ASSOC, V305, P1432, DOI 10.1001/jama.2011.351; Lee JH, 2020, VACCINE, V38, P3995, DOI 10.1016/j.vaccine.2020.04.022; Leuridan E, 2011, CLIN INFECT DIS, V53, P68, DOI 10.1093/cid/cir270; Ni JD, 2013, INT J STD AIDS, V24, P117, DOI 10.1177/0956462412472309; Overton ET, 2005, CLIN INFECT DIS, V41, P1045, DOI 10.1086/433180; Potsch DV, 2012, VACCINE, V30, P5973, DOI 10.1016/j.vaccine.2012.07.028; Qiao YC, 2019, INT J INFECT DIS, V81, P215, DOI 10.1016/j.ijid.2019.02.016; Rey D, 2015, LANCET INFECT DIS, V15, P1283, DOI 10.1016/S1473-3099(15)00220-0; Salmon-Ceron D, 2005, J HEPATOL, V42, P799, DOI 10.1016/j.jhep.2005.01.022; Tedaldi Ellen M, 2004, Clin Infect Dis, V38, P1478, DOI 10.1086/420740; Thio CL, 2002, LANCET, V360, P1921, DOI 10.1016/S0140-6736(02)11913-1; Wilson CM, 2001, J ADOLESCENT HEALTH, V29, P123, DOI 10.1016/S1054-139X(01)00278-6	30	1	2	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 16	2021	39	27					3582	3589		10.1016/j.vaccine.2021.05.044		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SO5NX	34052065				2022-04-29	WOS:000659020000006
J	Glenn, BA; Nonzee, NJ; Tieu, L; Pedone, B; Cowgill, BO; Bastani, R				Glenn, Beth A.; Nonzee, Narissa J.; Tieu, Lina; Pedone, Bettina; Cowgill, Burt O.; Bastani, Roshan			Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood	VACCINE			English	Article						Human papillomavirus; HPV vaccine; Vaccination; College health; health behavior; Sexual health	FEMALE COLLEGE-STUDENTS; DECISION-MAKING; YOUNG-WOMEN; EMERGING ADULTHOOD; UNITED-STATES; KNOWLEDGE; BARRIERS; ATTITUDES; RATES; FACILITATORS	Purpose: Young adulthood is characterized by changes in health care decision-making, insurance coverage, and sexual risk. Although the human papillomavirus (HPV) vaccine is now approved for adults up to age 45, and catch-up vaccination is currently recommended up through age 26, vaccination rates remain low in young adults. This study explored perspectives on HPV vaccination among young adults receiving care at the student health center of a large public university. Methods: We conducted semi-structured interviews (n = 27) and four focus groups with female and male undergraduate and graduate students (n = 18) and semi-structured interviews with health care providers (n = 6). Interviews and focus groups explored perceived risk of HPV infection, benefits of the HPV vaccine, and motivations for and barriers to HPV vaccination. Results: Many young adults cited their parents' views and recommendations from medical providers as influential on their decision-making process. Students perceived that cervical cancer prevention was a main benefit of the HPV vaccine and sexual activity was a risk factor for HPV infection. Students often lacked knowledge about the vaccine's benefits for males and expressed some concerns about the safety and side effects of a vaccine perceived as new. Logistical barriers to vaccination included uncertainty over vaccination status and insurance coverage for the vaccine, and concerns about balancing the vaccine schedule with school obligations. Providers' vaccine recommendations were impacted by health system factors, including clinical infrastructure, processes for recommending and documenting vaccination, and office visit priorities. Suggested vaccination promotion strategies included improving the timing and messaging of outreach efforts on campus and bolstering clinical infrastructure. Conclusions: Although college may be an opportune time to reach young adults for HPV vaccination, obstacles including navigating parental influence and independent decision-making, lack of awareness of vaccination status, and numerous logistical and system-level barriers may impede vaccination during this time. (c) 2021 Elsevier Ltd. All rights reserved.	[Glenn, Beth A.; Nonzee, Narissa J.; Tieu, Lina; Cowgill, Burt O.; Bastani, Roshan] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, 650 Charles Young Dr South,A2-125 CHS, Los Angeles, CA 90095 USA; [Glenn, Beth A.; Nonzee, Narissa J.; Tieu, Lina; Cowgill, Burt O.; Bastani, Roshan] Univ Calif Los Angeles, UCLA Ctr Canc Prevent & Control Res, UCLA Kaiser Permanente Ctr Hlth Equ, Fielding Sch Publ Hlth, 650 Charles Young Dr South,A2-125 CHS, Los Angeles, CA 90095 USA; [Glenn, Beth A.; Nonzee, Narissa J.; Tieu, Lina; Cowgill, Burt O.; Bastani, Roshan] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, 650 Charles Young Dr South,A2-125 CHS, Los Angeles, CA 90095 USA; [Pedone, Bettina] Univ Calif Los Angeles, UCLA Arthur Ashe Student Hlth & Wellness Ctr, 221 Westwood Plaza, Los Angeles, CA 90095 USA		Glenn, BA (通讯作者)，Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, 650 Charles Young Dr South,A2-125 CHS, Los Angeles, CA 90095 USA.; Glenn, BA (通讯作者)，Univ Calif Los Angeles, UCLA Ctr Canc Prevent & Control Res, UCLA Kaiser Permanente Ctr Hlth Equ, Fielding Sch Publ Hlth, 650 Charles Young Dr South,A2-125 CHS, Los Angeles, CA 90095 USA.; Glenn, BA (通讯作者)，Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, 650 Charles Young Dr South,A2-125 CHS, Los Angeles, CA 90095 USA.	bglenn@ucla.edu; nnonzee@ucla.edu; linatieu@ucla.edu; bpedone@ashe.ucla.edu; bcowgill@ucla.edu; bastani@ucla.edu			UCLA Healthy Campus Initiative; NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA01604244S2]; NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1 TR001883, TL1 TR000121]; Agency for Healthcare Research and Quality (AHRQ)United States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32 HS000046]	This work was supported by the UCLA Healthy Campus Initiative. Beth Glenn also received support through NCI P30 CA01604244S2. Narissa Nonzee was supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI TL1 TR000121 and TL1 TR001883 and Agency for Healthcare Research and Quality (AHRQ) T32 HS000046. Lina Tieu was also supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI TL1 TR001883.	Afonso NM, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3969-x; Allen JD, 2009, J ADOLESCENT HEALTH, V45, P535, DOI 10.1016/j.jadohealth.2009.05.014; Allen JD, 2009, PREV MED, V48, P420, DOI 10.1016/j.ypmed.2008.12.005; American College Health Association, 2018, NAT COLL HLTH ASS RE; [Anonymous], 2013, INC COST SEX TRANSM; Barnard M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182266; Bastani R, 2011, CANCER EPIDEM BIOMAR, V20, P1463, DOI 10.1158/1055-9965.EPI-11-0267; Black, 2020, HUMAN PAPILLOMAVIRUS; Blodt S, 2012, EUR J PUBLIC HEALTH, V22, P808, DOI 10.1093/eurpub/ckr188; Caleb S, 2022, J AM COLL HEALTH, V70, P428, DOI 10.1080/07448481.2020.1752698; Centers for Disease Control and Prevention, 2018, VACCINATION COVERAGE; Chuang E, 2017, VACCINE, V35, P4540, DOI 10.1016/j.vaccine.2017.07.028; Daley EM, 2010, J WOMENS HEALTH, V19, P1885, DOI 10.1089/jwh.2009.1861; Elwyn G, 2012, J GEN INTERN MED, V27, P1361, DOI 10.1007/s11606-012-2077-6; Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700; Gilmore K, 2019, J AM PSYCHOANAL ASS, V67, P625, DOI 10.1177/0003065119868680; Glenn BA, 2015, VACCINE, V33, P289, DOI 10.1016/j.vaccine.2014.11.032; Henrikson Nora B, 2016, Prev Med Rep, V4, P94, DOI 10.1016/j.pmedr.2016.05.002; Hochberg Z, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00918; Hopfer S, 2011, QUAL HEALTH RES, V21, P262, DOI 10.1177/1049732310383868; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Jones G, 2016, J AM COLL HEALTH, V64, P545, DOI 10.1080/07448481.2016.1192542; Jones M, 2008, J AM COLL HEALTH, V57, P23, DOI 10.3200/JACH.57.1.23-32; Joseph NP, 2014, J PEDIATR ADOL GYNEC, V27, P83, DOI 10.1016/j.jpag.2013.08.011; Kahn JA, 2008, OBSTET GYNECOL, V111, P1103, DOI 10.1097/AOG.0b013e31817051fa; Katz ML, 2012, J AM COLL HEALTH, V60, P449, DOI 10.1080/07448481.2012.673523; Kellogg C, 2019, HUM VACC IMMUNOTHER, V15, P1760, DOI 10.1080/21645515.2019.1627819; Krieger JL, 2011, HUM COMMUN RES, V37, P107, DOI 10.1111/j.1468-2958.2010.01395.x; Lee HY, 2018, J COMMUN HEALTH, V43, P459, DOI 10.1007/s10900-018-0482-4; Licht AS, 2010, SEX TRANSM INFECT, V86, P74, DOI 10.1136/sti.2009.037705; Lindley LL, 2013, J AM COLL HEALTH, V61, P18, DOI 10.1080/07448481.2012.750607; Lyons HA, 2014, SOCIOL PERSPECT, V57, P79, DOI 10.1177/0731121413517557; Manhart LE, 2011, VACCINE, V29, P5238, DOI 10.1016/j.vaccine.2011.05.024; Marchand E, 2012, J COMMUN HEALTH, V37, P1136, DOI 10.1007/s10900-012-9572-x; Massey PM, 2020, VACCINE; Mehta P, 2013, INT Q COMMUNITY HEAL, V33, P175, DOI 10.2190/IQ.33.2.f; Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI [10.15585/mmwr.mm6832a3, 10.1111/ajt.15633]; Mortensen GL, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-68; National Cancer Institute, 2015, HPV CANC; Patel DA, 2012, J AM COLL HEALTH, V60, P151, DOI 10.1080/07448481.2011.580028; Pierre-Victor D, 2018, HEALTH EQUITY, V2, P90, DOI 10.1089/heq.2017.0028; Pitts MJ, 2017, HEALTH COMMUN, V32, P995, DOI 10.1080/10410236.2016.1196421; Ragan KR, 2018, VACCINE, V36, P331, DOI 10.1016/j.vaccine.2017.07.041; Rambout L, 2014, PREV MED, V58, P22, DOI 10.1016/j.ypmed.2013.10.009; Ratanasiripong NT, 2012, J AM COLL HEALTH, V60, P461, DOI 10.1080/07448481.2012.684365; Ratanasiripong NT, 2015, PUBLIC HEALTH NURS, V32, P645, DOI 10.1111/phn.12198; Satterwhite CL, 2013, SEX TRANSM DIS, V40, P187, DOI 10.1097/OLQ.0b013e318286bb53; Schmotzer GL, 2013, J COMMUN HEALTH, V38, P1106, DOI 10.1007/s10900-013-9720-y; Schwartz SJ, 2019, PREV SCI, V20, P305, DOI 10.1007/s11121-019-0975-0; Stephens Dionne P, 2016, Hisp Health Care Int, V14, P184; Stephens Dionne P, 2014, Womens Reprod Health (Phila), V1, P120; Stratil JM, 2020, COST EFFECT RESOUR A, V18, DOI 10.1186/s12962-020-0203-6; Thompson EL, 2016, PREV MED, V86, P92, DOI 10.1016/j.ypmed.2016.02.003; Unger Z, 2015, WOMEN HEALTH ISS, V25, P458, DOI 10.1016/j.whi.2015.06.003; Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2; Warner EL, 2017, JMIR CANCER, V3, DOI 10.2196/cancer.7345; Wood D., 2018, HDB LIFE COURSE HLTH, P123, DOI DOI 10.1007/978-3-319-47143-3_7	57	1	1	3	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3435	3444		10.1016/j.vaccine.2021.04.019		JUN 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SL6BM	33992435				2022-04-29	WOS:000657001300020
J	Gulla, K; Cibelli, N; Cooper, JW; Fuller, HC; Schneiderman, Z; Witter, S; Zhang, YQ; Changela, A; Geng, H; Hatcher, C; Narpala, S; Tsybovsky, Y; Zhang, BS; McDermott, AB; Kwong, PD; Gowetski, DB				Gulla, Krishana; Cibelli, Nicole; Cooper, Jonathan W.; Fuller, Haley C.; Schneiderman, Zachary; Witter, Sara; Zhang, Yaqiu; Changela, Anita; Geng, Hui; Hatcher, Christian; Narpala, Sandeep; Tsybovsky, Yaroslav; Zhang, Baoshan; McDermott, Adrian B.; Kwong, Peter D.; Gowetski, Daniel B.		VRC Production Program	A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation	VACCINE			English	Article						GMP manufacturing; DS-SOSIP; Envelope trimer; Glycoprotein; HIV-1 vaccine; Non-affinity chromatography; Prefusion-closed conformation	CRYO-EM STRUCTURE; ANTIBODY 2G12; FUSION PEPTIDE; GP140 TRIMERS; NEUTRALIZATION; GLYCOPROTEIN; EPITOPE; SOSIP.664; DESIGN; GP120	Metastable glycosylated immunogens present challenges for GMP manufacturing. The HIV-1 envelope (Env) glycoprotein trimer is covered by N-linked glycan comprising half its mass and requires both trimer assembly and subunit cleavage to fold into a prefusion-closed conformation. This conformation, the vaccine-desired antigenic state, is both metastable to structural rearrangement and labile to subunit dissociation. Prior reported GMP manufacturing for a soluble trimer stabilized in a near-native state by disulfide (SOS) and Ile-to-Pro (IP) mutations has employed affinity methods based on antibody 2G12, which recognizes only similar to 30% of circulating HIV strains. Here, we develop a scalable manufacturing process based on commercially available, non-affinity resins, and we apply the process to current GMP (cGMP) production of trimers from clades A and C, which have been found to boost cross-clade neutralizing responses in vaccine-test species. The clade A trimer, which we named "BG505 DS-SOSIP.664", contained an engineered disulfide (201C-433C; DS) within gp120, which further stabilized this trimer in a prefusion-closed conformation resistant to CD4-induced triggering. BG505 DS-SOSIP.664 was expressed in a CHO-DG44 stable cell line and purified with initial and final tangential flow filtration steps, three commercially available resin-based chromatography steps, and two orthogonal viral clearance steps. The non-affinity purification enabled efficient scale-up, with a 250 L-scale cGMP run yielding 9.6 g of purified BG505 DS-SOSIP.664. Antigenic analysis indicated retention of a prefusion-closed conformation, including recognition by apex-directed and fusion peptide-directed antibodies. The developed manufacturing process was suitable for 50 L-scale production of a second prefusion-stabilized Env trimer vaccine candidate, ConC-FP8v2 RnS-3mut-2G-SOSIP.664, yielding 7.8 g of this consensus clade C trimer. The successful process development and purification scale-up of HIV-1 Env trimers from different clades by using commercially available materials provide experimental demonstration for cGMP manufacturing of trimeric HIV-Env vaccine immunogens, in an antigenically desired conformation, without the use of costly affinity resins. Published by Elsevier Ltd.	[Gulla, Krishana; Cibelli, Nicole; Cooper, Jonathan W.; Fuller, Haley C.; Schneiderman, Zachary; Witter, Sara; Zhang, Yaqiu; Changela, Anita; Geng, Hui; Hatcher, Christian; Narpala, Sandeep; Zhang, Baoshan; McDermott, Adrian B.; Kwong, Peter D.; Gowetski, Daniel B.; VRC Production Program] NIH, Vaccine Res Ctr, NIAID, Bldg 10, Bethesda, MD 20892 USA; [Tsybovsky, Yaroslav] Leidos Biomed Res Inc, Electron Microscopy Lab, Canc Res Technol Program, Frederick Natl Lab Canc Res, Frederick, MD USA		Kwong, PD; Gowetski, DB (通讯作者)，NIH, Vaccine Res Ctr, NIAID, Bldg 10, Bethesda, MD 20892 USA.	pdkwong@nih.gov; daniel.gowetski@nih.gov		Cibelli, Nicole/0000-0001-6125-9065; McDermott, Adrian/0000-0003-0616-9117	Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Frederick National Laboratory for Cancer Research, NIH [HHSN261200800001E]	We thank Prasanthi Bandi, Nga Tran, Lena Wang, YooJung Yang, and members of the downstream process development team at the Vaccine Production Program Laboratory for their assistance with the ConCFP8v2 RnS3mut2GSOSIP.664 program. We thank Jonathan Stuckey for assistance with figures, Shuishu Wang for assistance with manuscript preparation, and members of the Structural Biology Section for discussions and comments. Support for this work was provided by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health. This work was also supported in part with federal funds from the Frederick National Laboratory for Cancer Research, NIH, under Contract HHSN261200800001E.	AlSalmi W, 2015, J BIOL CHEM, V290, P19780, DOI 10.1074/jbc.M115.656611; Bale S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01116; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Chen PF, 2021, J BIOTECHNOL, V325, P269, DOI 10.1016/j.jbiotec.2020.10.014; Cheng C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215163; Chuang GY, 2020, J VIROL, V94, DOI 10.1128/JVI.00074-20; Chuang GY, 2017, J VIROL, V91, DOI 10.1128/JVI.02268-16; Cupo A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215106; Darling AJ, 2000, METH BIOTEC, V9, P195; de Taeye SW, 2015, CELL, V163, P1702, DOI 10.1016/j.cell.2015.11.056; Dey AK, 2018, BIOTECHNOL BIOENG, V115, P885, DOI 10.1002/bit.26498; Do Kwon Y, 2015, NAT STRUCT MOL BIOL, V22, P522, DOI 10.1038/nsmb.3051; Doria-Rose NA, 2016, J VIROL, V90, P76, DOI 10.1128/JVI.01791-15; Dubrovskaya V, 2019, IMMUNITY, V51, P915, DOI 10.1016/j.immuni.2019.10.008; Georgiev IS, 2015, J VIROL, V89, P5318, DOI 10.1128/JVI.03451-14; Guenaga J, 2017, IMMUNITY, V46, P792, DOI 10.1016/j.immuni.2017.04.014; Guenaga J, 2016, J VIROL, V90, P2806, DOI 10.1128/JVI.02652-15; Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601; Joyce MG, 2017, CELL REP, V21, P2992, DOI 10.1016/j.celrep.2017.11.016; Julien JP, 2015, P NATL ACAD SCI USA, V112, P11947, DOI 10.1073/pnas.1507793112; Kong L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12040; Kong R, 2019, CELL, V178, P567, DOI 10.1016/j.cell.2019.06.030; Kong R, 2016, SCIENCE, V352, P828, DOI 10.1126/science.aae0474; Kulp DW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01549-6; Kwong PD, 2018, IMMUNITY, V48, P855, DOI 10.1016/j.immuni.2018.04.029; Lee JH, 2016, SCIENCE, V351, P1043, DOI 10.1126/science.aad2450; Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159; Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MYERS G, 1992, AIDS RES HUM RETROV, V8, P1459, DOI 10.1089/aid.1992.8.1459; Ou L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59711-y; Ozorowski G, 2017, NATURE, V547, P360, DOI 10.1038/nature23010; Pugach P, 2015, J VIROL, V89, P3380, DOI 10.1128/JVI.03473-14; Rutten L, 2018, CELL REP, V23, P584, DOI 10.1016/j.celrep.2018.03.061; Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Sharma SK, 2015, CELL REP, V11, P539, DOI 10.1016/j.celrep.2015.03.047; Sliepen K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10262-5; Steichen JM, 2016, IMMUNITY, V45, P483, DOI 10.1016/j.immuni.2016.08.016; Stewart-Jones GBE, 2016, CELL, V165, P813, DOI 10.1016/j.cell.2016.04.010; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Verkerke HP, 2016, J VIROL, V90, P9471, DOI 10.1128/JVI.01351-16; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Ward AB, 2017, IMMUNOL REV, V275, P21, DOI 10.1111/imr.12507; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Xu K, 2018, NAT MED, V24, P857, DOI 10.1038/s41591-018-0042-6; Zhang P, 2018, CELL HOST MICROBE, V23, P832, DOI 10.1016/j.chom.2018.05.002	51	3	3	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3379	3387		10.1016/j.vaccine.2021.04.063		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	34020817				2022-04-29	WOS:000657001300013
J	Pu, J; Yu, Q; Yin, ZF; Zhang, Y; Li, XQ; Yin, QZ; Chen, HB; Long, RX; Zhao, ZM; Mou, TW; Zhao, H; Feng, SY; Xie, ZP; Wang, LC; He, ZL; Liao, Y; Fan, ST; Jiang, RJ; Wang, JF; Zhang, LL; Li, J; Zheng, HW; Cui, PF; Jiang, GR; Guo, L; Xu, MJ; Yang, HJ; Lu, S; Wang, XY; Gao, Y; Xu, XL; Cai, LR; Zhou, J; Yu, L; Chen, Z; Hong, C; Du, D; Zhao, HL; Li, Y; Ma, KL; Ma, YF; Liu, DL; Yao, SB; Li, CG; Che, YC; Liu, LD; Li, QH				Pu, Jing; Yu, Qin; Yin, Zhifang; Zhang, Ying; Li, Xueqi; Yin, Qiongzhou; Chen, Hongbo; Long, Runxiang; Zhao, Zhimei; Mou, Tangwei; Zhao, Heng; Feng, Shiyin; Xie, Zhongping; Wang, Lichun; He, Zhanlong; Liao, Yun; Fan, Shengtao; Jiang, Ruiju; Wang, Jianfeng; Zhang, Lingli; Li, Jing; Zheng, Huiwen; Cui, Pingfang; Jiang, Guorun; Guo, Lei; Xu, Mingjue; Yang, Huijuan; Lu, Shan; Wang, Xuanyi; Gao, Yang; Xu, Xingli; Cai, Linrui; Zhou, Jian; Yu, Li; Chen, Zhuo; Hong, Chao; Du, Dan; Zhao, Hongling; Li, Yan; Ma, Kaili; Ma, Yunfei; Liu, Donglan; Yao, Shibao; Li, Changgui; Che, Yanchun; Liu, Longding; Li, Qihan			The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18?59 years: A phase I randomized, double-blinded, controlled trial	VACCINE			English	Article						SARS-CoV-2; Inactivated vaccine; Phase I	COVID-19	Background: This study examined the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine. Method: In a phase I randomized, double-blinded, placebo-controlled trial involving 192 healthy adults 18-59 years old, two injections of three doses (50 EU, 100 EU, 150 EU) of an inactivated SARS-CoV-2 vaccine or placebo were administered intramuscularly at a 2-or 4-week interval. The safety and immunogenicity of the vaccine were evaluated. Results: Vaccination was completed in 191 subjects. Forty-four adverse reactions occurred within 28 days, most commonly mild pain and redness at the injection site or slight fatigue. At days 14 and 28, the seroconversion rates were 87.5% and 79.2% (50 EU), 100% and 95.8% (100 EU), and 95.8% and 87.5% (150 EU), respectively, with geometric mean titers (GMTs) of 18.1 and 10.6, 54.5 and 15.4, and 37.1 and 18.5, respectively, for the schedules with 2-week and 4-week intervals. Seroconversion was associated with synchronous upregulation of antibodies against the S protein, N protein and virion and a cytotoxic T lymphocyte (CTL) response. No cytokines and immune cells related to immunopathology were observed. Transcriptome analysis revealed the genetic diversity of immune responses induced by the vaccine. Interpretation: In a population aged 18-59 years in this trial, this inactivated SARS-CoV-2 vaccine was safe and immunogenic. Trial registration: CTR20200943 and NCT04412538. (c) 2021 Elsevier Ltd. All rights reserved.	[Pu, Jing; Zhang, Ying; Li, Xueqi; Yin, Qiongzhou; Chen, Hongbo; Long, Runxiang; Zhao, Zhimei; Mou, Tangwei; Zhao, Heng; Xie, Zhongping; Wang, Lichun; He, Zhanlong; Liao, Yun; Fan, Shengtao; Jiang, Ruiju; Li, Jing; Zheng, Huiwen; Cui, Pingfang; Jiang, Guorun; Guo, Lei; Xu, Mingjue; Yang, Huijuan; Gao, Yang; Xu, Xingli; Zhou, Jian; Yu, Li; Hong, Chao; Zhao, Hongling; Li, Yan; Ma, Kaili; Ma, Yunfei; Liu, Donglan; Yao, Shibao; Che, Yanchun; Liu, Longding; Li, Qihan] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China; [Yu, Qin; Feng, Shiyin; Zhang, Lingli; Cai, Linrui; Chen, Zhuo; Du, Dan] Sichuan Univ, Natl Drug Clin Trial Inst, West China Hosp 2, Chengdu 610041, Peoples R China; [Yin, Zhifang; Wang, Jianfeng; Li, Changgui] Natl Inst Food & Drug Control, Beijing 100050, Peoples R China; [Lu, Shan] Univ Massachusetts, Dept Med, Med Sch, Worcester, MA 01655 USA; [Wang, Xuanyi] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Shanghai 200032, Peoples R China		Li, CG; Che, YC; Liu, LD; Li, QH (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, 935 Jiaoling Rd, Kunming 650118, Yunnan, Peoples R China.	changguili@aliyum.com; cheyanchun@imbcams.com.cn; liuld@imbccams.com.cn; liqihan@imbccams.com.cn		Ma, Kaili/0000-0002-5242-3000; Guo, Lei/0000-0003-1733-1802	National Key R&D Program of China [2020YFC0849700]; Program of the Chinese Academy of Medicine Science [2020HY320001]; Major Science and Technology Special Projects of Yunnan Province [202003AC100009]	We appreciate the contributions of all investigators at West China Second Hospital of Sichuan University who worked on the trial. This work was supported by the National Key R&D Program of China (2020YFC0849700), the Program of the Chinese Academy of Medicine Science (2020HY320001) and the Major Science and Technology Special Projects of Yunnan Province (202003AC100009).	Alm E, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003416; Chen FF, 2020, J CRIT CARE, V60, P32, DOI 10.1016/j.jcrc.2020.07.003; Chen H, 2020, VALID PROTECTIVE IMM; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Johns_Hopkins_University, 2020, COVID 19 DASHB CTR S; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; N.L, 2021, QUICK GUID COVID 19; Ogawa J, 2020, D614G MUTATION SARS, V21, P214932; Cruz MP, 2021, REV CLIN ESP, V221, P55, DOI [10.1016/j.rce.2020.03.001, 10.1016/j.rceng.2020.03.001]; Rehman SU, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030240; Tezer H, 2020, TURK J MED SCI, V50, P592, DOI 10.3906/sag-2004-174; Wang FZ, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.924700; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Zhang XL, 2018, VACCINE, V36, P2394, DOI 10.1016/j.vaccine.2018.03.056; Zheng HW, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008949; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	19	18	19	9	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 12	2021	39	20					2746	2754		10.1016/j.vaccine.2021.04.006		APR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RU8YE	33875266	Green Published, Bronze			2022-04-29	WOS:000645426400003
J	Azzi, L; Focosi, D; Dentali, F; Baj, A; Maggi, F				Azzi, Lorenzo; Focosi, Daniele; Dentali, Francesco; Baj, Andreina; Maggi, Fabrizio			Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naive BNT162b2 vaccine recipients	VACCINE			English	Editorial Material						BNT162b2; mRNA-1273; COVID-19; SARS-CoV-2			[Azzi, Lorenzo] ASST Sette Laghi, Unit Oral Med & Pathol, Varese, Italy; [Azzi, Lorenzo; Dentali, Francesco; Baj, Andreina; Maggi, Fabrizio] Univ Insubria, Dept Med & Surg, Varese, Italy; [Focosi, Daniele] Pisa Univ Hosp, North Western Tuscany Blood Bank, Pisa, Italy; [Dentali, Francesco] ASST Sette Laghi, Dept Med, Varese, Italy; [Baj, Andreina; Maggi, Fabrizio] ASST Sette Laghi, Microbiol Lab, Varese, Italy		Baj, A (通讯作者)，Univ Insubria, Dept Med & Surg, Varese, Italy.; Baj, A (通讯作者)，ASST Sette Laghi, Microbiol Lab, Varese, Italy.	andreina.baj@uninsubria.it	Focosi, Daniele/K-6609-2016; Maggi, Fabrizio/L-2974-2013; Baj, Andreina/C-8047-2013; Maggi, Fabrizio/AAU-5965-2021	Focosi, Daniele/0000-0001-8811-195X; Maggi, Fabrizio/0000-0001-7489-5271; Baj, Andreina/0000-0003-0088-2712; Maggi, Fabrizio/0000-0001-7489-5271			Ayoub HH, 2021, EPIDEMIOLOGICAL IMPA; Bonelli F, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01224-20; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; WHO, 2020, SAGE ROADM PRIOR US; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195	5	4	4	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2489	2490		10.1016/j.vaccine.2021.03.086		APR 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33824042	Green Published, Bronze			2022-04-29	WOS:000642189300002
J	Mphahlele, MJ; Groome, MJ; Page, NA; Bhagwandin, N; Mwenda, JM; Steele, AD				Mphahlele, M. Jeffrey; Groome, Michelle J.; Page, Nicola A.; Bhagwandin, Niresh; Mwenda, Jason M.; Steele, A. Duncan			A decade of rotavirus vaccination in Africa - Saving lives and changing the face of diarrhoeal diseases: Report of the 12th African Rotavirus Symposium	VACCINE			English	Article						12th African Rotavirus Symposium; Rotavirus; Rotavirus strains; Rotavirus vaccines; Africa	SYSTEMATIC ANALYSIS; COST-EFFECTIVENESS; DOUBLE-BLIND; IMMUNOGENICITY; MORTALITY; CHILDREN; SAFETY; GASTROENTERITIS; COUNTRIES; DS-1-LIKE	The African Rotavirus Network organised the 12th African Rotavirus Symposium (ARS) from 30 July to 1 August 2019 in Johannesburg, South Africa. The symposium theme "A decade of rotavirus vaccination in Africa - Saving lives and changing the face of diarrhoeal diseases", included sessions aimed at sharing ideas and expertise on prevention and control of diarrhoeal disease in Africa. Inter alia, the delegates reviewed global and regional epidemiological trends on rotavirus diarrhoea, progress and experiences on rotavirus vaccine introduction, including vaccine safety monitoring and impact in Africa, scientific advances in developing newer rotavirus vaccines, surveillance and research on other diarrhoeal pathogens, and providing an enabling environment for networking. Importantly, the 12th ARS served to commemorate the 20th anniversary of the African Rotavirus Network (AfrRN) coinciding with the 50th anniversary of the South African Medical Research Council. Four oral, live-attenuated rotavirus vaccines are currently prequalified by the WHO (Rotarix, RotaTeq, Rotavac and RotaSiil). African countries utilising rotavirus vaccines in routine national immunisation programmes are realising their effectiveness and impact on diarrhoeal disease morbidity. An similar to 40% reduction in hospitalisations of <5-year-olds with acute gastroenteritis following rotavirus vaccine introduction, was reported between 2006 and 2018 in 92,000 children from the WHO-coordinated African Rotavirus Surveillance Network (AfrRSN) comprising 33 Member States. This was corroborated by a metaanalysis of published data, sourced from January 2000 to August 2018 that reported substantial reductions in rotavirus hospitalisations in countries using rotavirus vaccines. However, it was highlighted that the transition of some countries from Gavi-eligibility and vaccine supply shortfalls present significant challenges to achieving the full impact of rotavirus immunization in Africa. The wide diversity of rotavirus genotypes continues in Africa, with variation observed both geographically and temporally. There is currently no evidence to suggest that the emergence of rotavirus strains not included in the current vaccines do escape vaccine-induced immunity.	[Mphahlele, M. Jeffrey] South African Med Res Council, 1 Soutpansberg Rd, ZA-0001 Pretoria, South Africa; [Mphahlele, M. Jeffrey; Steele, A. Duncan] Sefako Makgatho Hlth Sci Univ, Dept Virol, Diarrhoea Pathogens Res Unit, ZA-0204 Pretoria, South Africa; [Groome, Michelle J.] Univ Witwatersrand, Fac Hlth Sci, Wits Vaccines & Infect Dis Analyt Res Unit, South African Med Res Council, Johannesburg, South Africa; [Page, Nicola A.] Natl Inst Communicable Dis, Ctr Enter Dis, ZA-2131 Johannesburg, South Africa; [Bhagwandin, Niresh] South African Med Res Council, Francie van Zijl Dr, ZA-7505 Cape Town, South Africa; [Mwenda, Jason M.] WHO, Reg Off Africa, Brazzaville, Rep Congo; [Steele, A. Duncan] Bill & Melinda Gates Fdn, Enter & Diarrhoeal Dis Programme, Global Hlth, Seattle, WA USA		Mphahlele, MJ (通讯作者)，South African Med Res Council, 1 Soutpansberg Rd, ZA-0001 Pretoria, South Africa.	jeffrey.mphahlele@mrc.ac.za		Steele, Andrew Duncan/0000-0002-4946-037X	SAMRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR; US CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; Bharat Biotech International Ltd (Hyderabad, India); GSK Biologicals (Rixensart, Belgium)GlaxoSmithKline; Serum Institute of India (Pune, India); Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1202256]; PATH [GAT.2111-01665413-GRT]; SAMRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [PC96160]; GSKGlaxoSmithKline; Bharat Biotech; Serum Institute of India; WHO AFROWorld Health Organization; PATH	The authors are grateful to presenters and delegates of the 12th African Rotavirus Symposium. The symposium was supported by the following organisations: SAMRC, WHO AFRO, Bill & Melinda Gates Foundation, PATH and the US CDC. Special thanks to the International Scientific Advisory Committee, Local Organising Committee and the SAMRC secretariat (Mrs Mandy Salomo, Ms Arlene Smith and Kefiloe Masemola). We acknowledge financial support from Bharat Biotech International Ltd (Hyderabad, India), GSK Biologicals (Rixensart, Belgium) and Serum Institute of India (Pune, India).; The symposium was funded by grants from the following organizations: Bill & Melinda Gates Foundation (Grant number OPP1202256) PATH (grant number GAT.2111-01665413-GRT) SAMRC (grant number PC96160) And unrestricted grants from GSK, Bharat Biotech, and Serum Institute of India.	Aliabadi N, 2019, LANCET GLOB HEALTH, V7, pE893, DOI 10.1016/s2214-109x(19)30207-4; [Anonymous], 2013, Wkly Epidemiol Rec, V88, P49; Armah GE, 2013, J INFECT DIS, V208, P423, DOI 10.1093/infdis/jit174; Bines JE, 2015, LANCET INFECT DIS, V15, P1389, DOI 10.1016/S1473-3099(15)00227-3; Clark A, 2019, LANCET GLOB HEALTH, V7, pE1541, DOI 10.1016/S2214-109X(19)30412-7; Cowley D, 2016, J GEN VIROL, V97, P403, DOI 10.1099/jgv.0.000352; Gikonyo JN, 2020, INT J INFECT DIS, V100, P434, DOI 10.1016/j.ijid.2020.09.005; Groome MJ, 2020, LANCET INFECT DIS, V20, P851, DOI 10.1016/S1473-3099(20)30001-3; Groome MJ, 2020, CLIN INFECT DIS, V70, P1606, DOI 10.1093/cid/ciz431; Isanaka S, 2017, NEW ENGL J MED, V376, P1121, DOI [10.1056/nejmoa1609462, 10.1056/NEJMoa1609462]; Jere KC, 2019, EMERG INFECT DIS, V25, P1734, DOI 10.3201/eid2509.190258; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Maringa WM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9080663; Mwangi PN, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050391; Mwenda JM, 2019, VACCINE, V37, P2975, DOI 10.1016/j.vaccine.2019.03.047; Mwenda Jason M, 2018, Vaccine, V36, P7119, DOI 10.1016/j.vaccine.2018.06.026; Operario DJ, 2017, J INFECT DIS, V216, P220, DOI 10.1093/infdis/jix294; Page N A, 2018, Vaccine, V36, P7231, DOI 10.1016/j.vaccine.2017.10.062; Pecenka C, 2020, VACCINE, V38, P1277, DOI 10.1016/j.vaccine.2019.12.014; Pecenka C, 2018, VACCINE, V36, P7472, DOI 10.1016/j.vaccine.2018.10.068; Seheri L M, 2018, Vaccine, V36, P7222, DOI 10.1016/j.vaccine.2017.11.068; Shah MP, 2017, EXPERT REV VACCINES, V16, P987, DOI 10.1080/14760584.2017.1371595; Tate JE, 2018, NEW ENGL J MED, V379, P1288, DOI 10.1056/NEJMc1807645; Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013; Troeger C, 2018, JAMA PEDIATR, V172, P958, DOI 10.1001/jamapediatrics.2018.1960; Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1; Yen C, 2016, HUM VAC IMMUNOTHERAP, P1	28	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 22	2021	39	17					2319	2324		10.1016/j.vaccine.2021.03.014		APR 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RL7KL	33775436				2022-04-29	WOS:000639147100001
J	Cambou, MC; Copeland, TP; Nielsen-Saines, K; Macinko, J				Cambou, Mary Catherine; Copeland, Timothy P.; Nielsen-Saines, Karin; Macinko, James			Insurance status predicts self-reported influenza vaccine coverage among pregnant women in the United States: A cross-sectional analysis of the National Health Interview Study Data from 2012 to 2018	VACCINE			English	Article						Maternal vaccination; Influenza vaccine; Influenza vaccine coverage; Pregnant women; Determinants		While the influenza vaccine is recommended for all pregnant women, influenza vaccine coverage among this high-risk population remains inadequate. Factors associated with vaccine coverage among pregnant women, including insurance status, are poorly understood. In a cross-sectional study of the National Health Interview Survey (NHIS) data from 2012 to 2018, we evaluated predictors of self-reported influenza vaccine coverage in pregnant women. Among 1,942 pregnant women surveyed, 39% reported receiving the influenza vaccine in accordance with national recommendations. Influenza vaccine coverage increased by 8 percentage points from 2012 to 2018. Only 15% of uninsured pregnant women received the influenza vaccine, compared to 41% of those with insurance (design-corrected F-test, p-value < 0.001). In the multivariate Poisson regression analysis, significant predictors of influenza vaccine coverage were health insurance (prevalence ratio [PR] 1.90, 95% confidence interval [CI] 1.23-2.93), ratio of household income to federal poverty level (FPL) threshold greater than 400% (PR 1.54, 95% CI 1.20-1.96), graduate school education (PR 1.52, 95% CI 1.04-2.23), and the 2015-2018 survey year period (PR 1.27, 95% CI 1.08-1.49). While previous literature focuses heavily on demographics, our research underscores the need to further explore modifiable factors that impact vaccine uptake during pregnancy, particularly the interplay between health insurance and access to care. (C) 2021 Elsevier Ltd. All rights reserved.	[Cambou, Mary Catherine] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, 10833 Le Conte Ave,CHS 37-121, Los Angeles, CA 90095 USA; [Cambou, Mary Catherine; Copeland, Timothy P.; Macinko, James] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, 650 Charles E Young Dr,CHS 31-235B, Los Angeles, CA 90095 USA; [Nielsen-Saines, Karin] Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Infect Dis, 10833 Le Conte Ave,12-441 MDCC, Los Angeles, CA 90095 USA		Cambou, MC (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, 10833 Le Conte Ave,CHS 37-121, Los Angeles, CA 90095 USA.	mcambou@mednet.ucla.edu		Macinko, James/0000-0001-8055-5441; Copeland, Timothy/0000-0002-3813-3576	UCLA Postdoctoral Fellowship Training Program in Global HIV Prevention Research [T32MH080634]	Mary Catherine Cambou was supported by the UCLA Postdoctoral Fellowship Training Program in Global HIV Prevention Research (Currier and Gorbach, PIs); T32MH080634.	Ahluwalia IB, 2010, OBSTET GYNECOL, V116, P949, DOI 10.1097/AOG.0b013e3181f1039f; [Anonymous], 2017, PREGNANT WOMEN FLU V; Aris E, 2020, VACCINE, V38, P2984, DOI 10.1016/j.vaccine.2020.02.057; Bagley N, 2014, J HEALTH POLIT POLIC, V39, P441, DOI 10.1215/03616878-2416325; Barber A, 2017, MMWR-MORBID MORTAL W, V66, P56, DOI 10.15585/mmwr.mm6602a4; Blewett JARD Lynn A., 2019, IPUMS HLTH SURVEYS N, V6.4; Burris HH, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.01.004; Centers for Disease Control and Prevention (CDC), 2013, MMWR Morb Mortal Wkly Rep, V62, P854; Chamberlain AT, 2015, VACCINE, V33, P3571, DOI 10.1016/j.vaccine.2015.05.048; Curtin Sally C, 2013, Natl Vital Stat Rep, V62, P1; D'Angelo DV, 2015, MMWR-MORBID MORTAL W, V64, P1; Daw JR, 2017, HEALTH AFFAIR, V36, P598, DOI 10.1377/hlthaff.2016.1241; Doraivelu K, 2019, VACCINE, V37, P6054, DOI 10.1016/j.vaccine.2019.08.044; Ghaswalla P, 2019, AM J PREV MED, V57, pE87, DOI 10.1016/j.amepre.2019.04.013; Gorman JR, 2012, VACCINE, V31, P213, DOI 10.1016/j.vaccine.2012.10.064; Greene SK, 2009, AM J PREV MED, V37, P552, DOI 10.1016/j.amepre.2009.08.022; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Groom HC, 2016, AM J PREV MED, V50, P480, DOI 10.1016/j.amepre.2015.08.017; Haberg SE, 2013, NEW ENGL J MED, V368, P333, DOI 10.1056/NEJMoa1207210; Henninger Michelle, 2013, Perm J, V17, P31, DOI 10.7812/TPP/12-115; Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3; Koepke R, 2017, VACCINE, V35, P2298, DOI 10.1016/j.vaccine.2017.03.024; Kriss JL, 2019, MATERN CHILD HLTH J, V23, P201, DOI 10.1007/s10995-018-2633-8; Lindley MC, 2019, MMWR-MORBID MORTAL W, V68, P885, DOI 10.15585/mmwr.mm6840e1; Lu PJ, 2015, AM J PREV MED, V48, P647, DOI 10.1016/j.amepre.2014.12.008; Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480; Mertz D, 2017, VACCINE, V35, P521, DOI 10.1016/j.vaccine.2016.12.012; Mosby LG, 2011, AM J OBSTET GYNECOL, V205, P10, DOI 10.1016/j.ajog.2010.12.033; National Center for Health Statistics, 2019, NATL HLTH INTERVIEW; Office of Disease Prevention and Health Promotion, INCREASE PERCENTAGE; Razzaghi H, 2020, MMWR-MORBID MORTAL W, V69, P1391, DOI 10.15585/mmwr.mm6939a2; Rolnick SJ, 2013, VACCINE, V31, P3928, DOI 10.1016/j.vaccine.2013.06.041; Seiler N, 2014, PUBLIC HEALTH REP, V129, P526, DOI 10.1177/003335491412900611; Strassberg ER, 2018, VACCINE, V36, P4548, DOI 10.1016/j.vaccine.2018.05.121; Thompson MG, 2019, CLIN INFECT DIS, V68, P1444, DOI 10.1093/cid/ciy737	35	2	2	3	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2068	2073		10.1016/j.vaccine.2021.03.026		APR 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RJ9QH	33744045	Green Accepted			2022-04-29	WOS:000637937500008
J	Hamidi, A; Hoeksema, F; Velthof, P; Lemckert, A; Gillissen, G; Luitjens, A; Bines, JE; Pullagurla, SR; Kumar, P; Volkin, DB; Joshi, SB; Havenga, M; Bakker, WAM; Yallop, C				Hamidi, Ahd; Hoeksema, Femke; Velthof, Pim; Lemckert, Angelique; Gillissen, Gert; Luitjens, Alfred; Bines, Julie E.; Pullagurla, Swathi R.; Kumar, Prashant; Volkin, David B.; Joshi, Sangeeta B.; Havenga, Menzo; Bakker, Wilfried A. M.; Yallop, Christopher			Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine	VACCINE			English	Article						Oral rotavirus vaccine; Fixed bed bioreactor; Manufacturing process; Cost-of-goods modelling; Stable liquid formulation	LENTIVIRAL VECTOR; BED BIOREACTOR; DOUBLE-BLIND; RV3-BB; IMMUNOGENICITY; PURIFICATION; SAFETY; TRIAL	Despite solid evidence of the success of rotavirus vaccines in saving children from fatal gastroenteritis, more than 82 million infants worldwide still lack access to a rotavirus vaccine. The main barriers to global rotavirus vaccine coverage include cost, manufacturing capacity and suboptimal efficacy in low- and lower-middle income countries. One vaccine candidate with the potential to address the latter is based on the novel, naturally attenuated RV3 strain of rotavirus, RV3-BB vaccine administered in a birth dose strategy had a vaccine efficacy against severe rotavirus gastroenteritis of 94% at 12 months of age in infants in Indonesia. To further develop this vaccine candidate, a well-documented and low-cost manufacturing process is required. A target fully loaded cost of goods (COGs) of <=$3.50 per course of three doses was set based on predicted market requirements. COGs modelling was leveraged to develop a process using Vero cells in cell factories reaching high titers, reducing or replacing expensive reagents and shortening process time to maximise output. Stable candidate liquid formulations were developed allowing two-year storage at 2-8 degrees C. In addition, the formulation potentially renders needless the pretreatment of vaccinees with antacid to ensure adequate gastric acid neutralization for routine oral vaccination. As a result, the formulation allows small volume dosing and reduction of supply chain costs. A dose ranging study is currently underway in Malawi that will inform the final clinical dose required. At a clinical dose of <= 6.3 log(10) FFU, the COGs target of <=$3.50 per three dose course was met. At a clinical dose of 6.5 log(10) FFU, the final manufacturing process resulted in a COGs that is substantially lower than the current average market price, 2.44 USD per dose. The manufacturing and formulation processes were transferred to BioFarma in Indonesia to enable future RV3-BB vaccine production. (C) 2021 Batavia Biosciences BV. Published by Elsevier Ltd.	[Hamidi, Ahd; Hoeksema, Femke; Velthof, Pim; Lemckert, Angelique; Gillissen, Gert; Luitjens, Alfred; Havenga, Menzo; Bakker, Wilfried A. M.; Yallop, Christopher] Batavia Biosci BV, Zernikedreef 16, NL-2333 CL Leiden, Netherlands; [Bines, Julie E.] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Paediat,Dept Gastroenterol & Clin Nutr, Parkville, Vic 3052, Australia; [Pullagurla, Swathi R.; Kumar, Prashant; Volkin, David B.; Joshi, Sangeeta B.] Univ Kansas, Vaccine Analyt & Formulat Ctr, Dept Pharmaceut Chem, Lawrence, KS 66047 USA		Yallop, C (通讯作者)，Batavia Biosci BV, Zernikedreef 16, NL-2333 CL Leiden, Netherlands.	c.yallop@bataviabiosciences.com	Joshi, Sudhanshu/L-2284-2019	Joshi, Sudhanshu/0000-0003-4748-5001; Bines, Julie/0000-0002-5452-6601	Bill and Melinda Gates FoundationBill & Melinda Gates Foundation [OPP1148427]	This work was funded by the Bill and Melinda Gates Foundation (grant number: OPP1148427).	[Anonymous], 2013, VACCINE, V31, P6170, DOI 10.1016/j.vaccine.2013.05.037; [Anonymous], 2019, SUPP ROT VACC PROF S; [Anonymous], 2007, WHO TRS; [Anonymous], 2020, VACC DET PROD PROF; [Anonymous], 2018, ROTATEQ PRODUCT INSE; [Anonymous], 2005, ICH Q2 ANAL VALIDAT; [Anonymous], 2016, PROD EC VACC; [Anonymous], 2019, SUMMARY WHO POSITION; Aunins JG., 2009, ENCY IND BIOTECHNOLO, P1; Aunins JG, 2011, CHEM ENG PROG, V107, P37; Barrett PN, 2009, EXPERT REV VACCINES, V8, P607, DOI [10.1586/erv.09.19, 10.1586/ERV.09.19]; Bhandari N, 2009, J INFECT DIS, V200, P421, DOI 10.1086/600104; Bines JE, 2018, NEW ENGL J MED, V378, P719, DOI 10.1056/NEJMoa1706804; Bines JE, 2015, LANCET INFECT DIS, V15, P1389, DOI 10.1016/S1473-3099(15)00227-3; Boniface K, 2020, J INFECT DIS, V221, P1070, DOI 10.1093/infdis/jiz333; Burke RM, 2019, CURR OPIN INFECT DIS, V32, P435, DOI 10.1097/QCO.0000000000000572; Chandola TR, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00302; Clark A, 2019, LANCET GLOB HEALTH, V7, pE1541, DOI 10.1016/S2214-109X(19)30412-7; Clark A, 2019, LANCET INFECT DIS, V19, P717, DOI 10.1016/S1473-3099(19)30126-4; Clark A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183392; Cowley D, 2019, VACCINE, V37, P7233, DOI 10.1016/j.vaccine.2019.09.071; Cowley D, 2018, VACCINE, V36, P5872, DOI 10.1016/j.vaccine.2018.08.027; Danchin M, 2013, VACCINE, V31, P2610, DOI 10.1016/j.vaccine.2013.04.008; Egan W, 2009, BIOLOGICALS, V37, P379, DOI 10.1016/j.biologicals.2009.08.012; Ella R, 2018, HUM VACC IMMUNOTHER, V14, P1791, DOI 10.1080/21645515.2018.1450709; Farkas K., 2013, FOOD ENVIRON VIROL; Jiang BM, 2019, VACCINE, V37, P3040, DOI 10.1016/j.vaccine.2019.04.023; Kirkwood CD, 2019, VACCINE, V37, P7328, DOI 10.1016/j.vaccine.2017.03.076; Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014; Kumar P., 2020, J PHARM SCI-US; Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007; Leinonen HM, 2019, MOL THER-METH CLIN D, V15, P63, DOI 10.1016/j.omtm.2019.08.006; Lesch HP, 2015, HUM GENE THER, V26, P560, DOI 10.1089/hum.2015.081; Lopez AL, 2019, HUM VACC IMMUNOTHER, V15, P1260, DOI 10.1080/21645515.2018.1551673; Mansoor OD, 2013, B WORLD HEALTH ORGAN, V91, P75, DOI 10.2471/BLT.12.110700; Pecenka C, 2020, VACCINE, V38, P1277, DOI 10.1016/j.vaccine.2019.12.014; Peixoto C, 2007, J BIOTECHNOL, V127, P452, DOI 10.1016/j.jbiotec.2006.08.002; Pullagurla SR., 2020, MODELING LONG UNPUB; Rajendran R, 2014, AMB EXPRESS, V4, DOI 10.1186/s13568-014-0025-z; Sharma S., 2020, VIRUSES-BASEL, V12; Shukla RS, 2020, FORMULATION DE UNPUB; Steele AD, 2019, HUM VACC IMMUNOTHER, V15, P1215, DOI 10.1080/21645515.2018.1553593; Tapia F, 2016, APPL MICROBIOL BIOT, V100, P2121, DOI 10.1007/s00253-015-7267-9; UNICEF Supplies and Logistics-Rotavirus Vaccines (RV), 2020, ROT VACC SUPPL DEM U; Valkama AJ, 2018, GENE THER, V25, P39, DOI 10.1038/gt.2017.91; Vernay O, 2019, J VIROL METHODS, V268, P9, DOI 10.1016/j.jviromet.2019.01.001; Vicente T, 2008, J MEMBRANE SCI, V311, P270, DOI 10.1016/j.memsci.2007.12.021; WHO-Market Information for Access to Vaccines, 2020, MARK INF ACC VACC ML; Yang Xing, 2012, Chinese Journal of Biologicals, V25, P754	49	2	2	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2048	2059		10.1016/j.vaccine.2021.03.033		APR 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QH	33744044	Green Published, hybrid			2022-04-29	WOS:000637937500006
J	Molodecky, NA; Usman, A; Javaid, A; Wahdan, A; Parker, EPK; Ahmed, JA; Shah, N; Agbor, J; Mahamud, A; Safdar, RM				Molodecky, Natalia A.; Usman, Asma; Javaid, Asif; Wahdan, Ashraf; Parker, Edward P. K.; Ahmed, Jamal A.; Shah, Nadeem; Agbor, John; Mahamud, Abdirahman; Safdar, Rana M.			Quantifying movement patterns and vaccination status of high risk mobile populations in Pakistan and Afghanistan to inform poliovirus risk and vaccination strategy	VACCINE			English	Article						Movement patterns; Mobile populations; Poliovirus risk; Vaccination; Pakistan and Afghanistan		Background: Stopping serotype 1 wild poliovirus transmission in Pakistan and Afghanistan requires ensuring all children <5 years of age are repeatedly vaccinated, including the large proportion living in mobile groups. Vaccinating children living in high-risk mobile populations (HRMPs) remains a priority for the polio programme. Methods: In 2017-2018, group-level censuses were conducted in 43 districts of Pakistan, gathering information for all HRMP children <5 years of age residing in settlements. Demographic and mobility information was collected, including HRMP type, ethnicity, language, mode of transportation and movement patterns. Vaccination status was recorded for the most recent polio campaign. Proportion of HRMP children by demographic factors and mode of transportation was determined and the magnitude of movement was quantified based on the origin, previous and next locations. Magnitude of cross-border movement with Afghanistan was evaluated, as was primary crossing point. Vaccination status was evaluated for each district by demographic and mode of transportation information. Results: In total, 188,130 HRMP children <5 years of age were assessed. The predominant HRMP type, ethnic group, language and mode of transport was Afghan refugees (27%), Pashtun (69%), Pashto (69%) and bus (52%). Overall, 84% of children originated outside of their current district, including 29% from Afghanistan. Previous and next locations, were reported outside of current location by 34% and 77% of children. Afghanistan was previous and next location for 5% and 11% of children, with 5.5% and 3% of children crossing the Afghanistan border in the past 6-months and next 3-months. Primary crossing route was Torkham (79%). Overall vaccination coverage was 98% (IQR: 96%-99%) and consistently >90% across HRMP type, ethnic group, language and mobility means. Conclusion: Large numbers of HRMPs were found across Pakistan, with substantial links throughout the country and with Afghanistan. While vaccination coverage of HRMPs was high, ensuring these populations are consistently vaccinated remains a priority. (C) 2021 Published by Elsevier Ltd.	[Molodecky, Natalia A.; Usman, Asma; Javaid, Asif; Wahdan, Ashraf; Ahmed, Jamal A.; Mahamud, Abdirahman] WHO, Islamabad, Pakistan; [Molodecky, Natalia A.; Usman, Asma; Javaid, Asif; Wahdan, Ashraf; Ahmed, Jamal A.; Shah, Nadeem; Agbor, John; Mahamud, Abdirahman; Safdar, Rana M.] Natl Emergency Operat Ctr Polio Eradicat, Islamabad, Pakistan; [Molodecky, Natalia A.] Imperial Coll London, Dept Infect Dis Epidemiol, London, England; [Wahdan, Ashraf] EMRO, WHO, Amman, Jordan; [Parker, Edward P. K.] London Sch Hyg & Trop Med, Vaccine Ctr, Fac Infect & Trop Dis, London, England; [Safdar, Rana M.] Minist Natl Hlth Serv Regulat & Coordinat, Islamabad, Pakistan; [Ahmed, Jamal A.; Mahamud, Abdirahman] WHO, Geneva, Switzerland; [Agbor, John] UNICEF, Islamabad, Pakistan		Molodecky, NA (通讯作者)，Natl Emergency Operat Ctr NEOC Polio Eradicat NIH, Islamabad, Pakistan.	n.molodecky@imperial.ac.uk					Angez M, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-51; European Asylum Support Office (EASO), 2020, PAK SIT AFGH REF; GPEI, PAK NAT EM ACT PLAN; GPEI, 2020, DAT MON WILD POL; GPEI, MICROPLANN PUZZL PLA; GPEI, CALL ACT SUPP COVID; GPEI, POL ER ENDG STRAT PL; GPEI, BEST PRACT MICR POL; GPEI, POL ENDG STRAT 2019; Hussain I, 2017, PEDIATR INFECT DIS J, V36, pE230, DOI 10.1097/INF.0000000000001622; Khowaja AR, 2012, B WORLD HEALTH ORGAN, V90, P822, DOI 10.2471/BLT.12.106260; Meo Anusha Sultan, 2020, J Diabetes Sci Technol, V14, P793, DOI 10.1177/1932296820931942; Molodecky NA, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002323; Owais A, 2013, VACCINE, V31, P3313, DOI 10.1016/j.vaccine.2013.05.015; Parker EPK, 2018, FUTURE MICROBIOL, V13, P97, DOI 10.2217/fmb-2017-0128; R Core Team, 2020, R LANGUAGE ENV STAT; Sheikh SS, 2014, PAKISTAN OMAN MED J, V29, P190; Shoaib M, 2020, SOC WORK PUBLIC HLTH, V35, P557, DOI 10.1080/19371918.2020.1806172; Sreevatsava M, 2020, VACCINE, V38, P4399, DOI 10.1016/j.vaccine.2020.04.068; Wesolowski A, 2015, P NATL ACAD SCI USA, V112, P11887, DOI 10.1073/pnas.1504964112	20	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2124	2132		10.1016/j.vaccine.2021.03.001		APR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QH	33736917	Green Submitted			2022-04-29	WOS:000637937500016
J	Rosa, SS; Prazeres, DMF; Azevedo, AM; Marques, MPC				Rosa, Sara Sousa; Prazeres, Duarte M. F.; Azevedo, Ana M.; Marques, Marco P. C.			mRNA vaccines manufacturing: Challenges and bottlenecks	VACCINE			English	Review						Vaccination; mRNA vaccines; mRNA manufacturing; mRNA applications	DENDRITIC CELLS; IN-VITRO; VACCINATION TRIAL; DIRECT-INJECTION; PURIFICATION; DELIVERY; EXPRESSION; INFLUENZA; IMMUNOGENICITY; LYMPHOCYTES	Vaccines are one of the most important tools in public health and play an important role in infectious diseases control. Owing to its precision, safe profile and flexible manufacturing, mRNA vaccines are reaching the stoplight as a new alternative to conventional vaccines. In fact, mRNA vaccines were the technology of choice for many companies to combat the Covid-19 pandemic, and it was the first technology to be approved in both United States and in Europe Union as a prophylactic treatment. Additionally, mRNA vaccines are being studied in the clinic to treat a number of diseases including cancer, HIV, influenza and even genetic disorders. The increased demand for mRNA vaccines requires a technology platform and cost-effective manufacturing process with a well-defined product characterisation. Large scale production of mRNA vaccines consists in a 1 or 2-step in vitro reaction followed by a purification platform with multiple steps that can include Dnase digestion, precipitation, chromatography or tangential flow filtration. In this review we describe the current state-of-art of mRNA vaccines, focusing on the challenges and bottlenecks of manufacturing that need to be addressed to turn this new vaccination technology into an effective, fast and cost-effective response to emerging health crises. (C) 2021 Elsevier Ltd. All rights reserved.	[Rosa, Sara Sousa; Prazeres, Duarte M. F.; Azevedo, Ana M.] Univ Lisbon, iBB Inst Bioengn & Biosci, Inst Super Tecn, Dept Bioengn, Av Rovisco Pais, P-1049001 Lisbon, Portugal; [Marques, Marco P. C.] UCL, Dept Biochem Engn, Bernard Katz Bldg,Gordon St, London WC1H 0AH, England		Azevedo, AM (通讯作者)，Univ Lisbon, iBB Inst Bioengn & Biosci, Inst Super Tecn, Dept Bioengn, Av Rovisco Pais, P-1049001 Lisbon, Portugal.; Marques, MPC (通讯作者)，UCL, Dept Biochem Engn, Bernard Katz Bldg,Gordon St, London WC1H 0AH, England.	a.azevedo@tecnico.ulisboa.pt; marco.marques@ucl.ac.uk	Prazeres, Duarte Miguel F/E-2526-2011; Azevedo, Ana Margarida/A-2985-2011; Rosa, Sara/AAE-1647-2022	Prazeres, Duarte Miguel F/0000-0002-6928-692X; Azevedo, Ana Margarida/0000-0001-5659-466X; Rosa, Sara/0000-0003-4415-1364	Fundacao para a Ciencia e a Tecnologia (FCT)Portuguese Foundation for Science and TechnologyEuropean Commission [SFRH/BD/148437/2019]; iBB-Institute for Bioengineering and Biosciences [UIDB/04565/2020]; Future Biomanufacturing Research Hub [EP/S01778X/1]; Engineering and Physical Sciences Research Council (EPSRC)UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC); Biotechnology and Biological Sciences Research Council (BBSRC), UK Research and InnovationUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)	The authors gratefully acknowledge the Fundacao para a Ciencia e a Tecnologia (FCT), for funding Sara Sousa Rosa's [SFRH/BD/148437/2019] PhD studentships and the iBB-Institute for Bioengineering and Biosciences [grant UIDB/04565/2020], and the support by the Future Biomanufacturing Research Hub [grant EP/S01778X/1], funded by the Engineering and Physical Sciences Research Council (EPSRC) and Biotechnology and Biological Sciences Research Council (BBSRC) as part of UK Research and Innovation.	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Akash MSH, 2020, ESSENTIALS OF PHARMACEUTICAL ANALYSIS, P167, DOI 10.1007/978-981-15-1547-7_13; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Allard SD, 2012, CLIN IMMUNOL, V142, P252, DOI 10.1016/j.clim.2011.10.010; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; [Anonymous], 2020, CELL, V183, P552, DOI 10.1016/j.cell.2020.09.039; Armbruster N, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040132; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Baiersdorfer M, 2019, MOL THER-NUCL ACIDS, V15, P26, DOI 10.1016/j.omtn.2019.02.018; Bancel, 2016, Patent No. [2014/152030A1, 2014152030]; Baronti L, 2018, ANAL BIOANAL CHEM, V410, P3239, DOI 10.1007/s00216-018-0943-8; Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170; Beissert T, 2020, MOL THER, V28, P119, DOI 10.1016/j.ymthe.2019.09.009; Bell GD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201464; Blakney AK, 2020, BIOMACROMOLECULES, V21, P2482, DOI 10.1021/acs.biomac.0c00445; Bloom DE, 2018, P NATL ACAD SCI USA, V115, P12868, DOI 10.1073/pnas.1717157115; Bloom DE, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaj2345; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Buonaguro L, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-LB-094; Burris HA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2523; Cafri G, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2643; Chakraborty T, 2016, PCT/US, Patent No. [2014/026835 US20160024547A1, 2014152027]; ClinicalTrials.gov, 2003, IMM TREAT PAT MET BR; CONRY RM, 1995, CANCER RES, V55, P1397; Coolen AL, 2019, BIOMATERIALS, V195, P23, DOI 10.1016/j.biomaterials.2018.12.019; Diken M, 2011, GENE THER, V18, P702, DOI 10.1038/gt.2011.17; Dimov N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11533-1; Drury G, 2019, VACCINE, V37, P2415, DOI 10.1016/j.vaccine.2019.01.050; Easton LE, 2010, RNA, V16, P647, DOI 10.1261/rna.1862210; Fisher AC, 2019, TRENDS BIOTECHNOL, V37, P253, DOI 10.1016/j.tibtech.2018.08.008; Fuchs AL, 2016, RNA, V22, P1454, DOI 10.1261/rna.056614.116; Funkner A., 2018, Patent No. [WO/ 2018/096179A1, 2018096179]; Gan LM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08852-4; Gandhi RT, 2016, JAIDS-J ACQ IMM DEF, V71, P246, DOI 10.1097/QAI.0000000000000852; Geall AJ, 2013, SEMIN IMMUNOL, V25, P152, DOI 10.1016/j.smim.2013.05.001; Gruber P, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700030; Halan V, 2019, CURR PROTEIN PEPT SC, V20, P4, DOI 10.2174/1389203718666171020103559; Heartlein M, 2014, Patent No. [WO/2014/152966A1, 2014152966]; Hoerr I, 2000, EUR J IMMUNOL, V30, P1; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Hung CF, 2018, HUM GENE THER, V29, P614, DOI 10.1089/hum.2017.080; Issa W.J., 2016, Patent No. [US/2016/0024141 A1, 20160024141]; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jenner E, 1798, SAMPSON LOW; JOHANNING FW, 1995, NUCLEIC ACIDS RES, V23, P1495, DOI 10.1093/nar/23.9.1495; Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181; Kapoor Y, 2021, J PHARM INNOV, V16, P2, DOI 10.1007/s12247-019-09426-z; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kennedy J, 2020, PEDIATR DRUGS, V22, P105, DOI 10.1007/s40272-020-00385-4; Ketterer T, 2018, Patent No. [2016/062152, 2016062152]; Kim I, 2007, RNA, V13, P289, DOI 10.1261/rna.342607; Kis Z, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010003; Kis Z, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201800376; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kreiter S, 2010, CANCER RES, V70, P9031, DOI 10.1158/0008-5472.CAN-10-0699; Kubler H, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0068-y; Kwon H, 2018, BIOMATERIALS, V156, P172, DOI 10.1016/j.biomaterials.2017.11.034; Kyte JA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1232237; Leal L, 2018, AIDS, V32, P2533, DOI [10.1097/QAD.0000000000002026, 10.1097/qad.0000000000002026]; Li M, 2016, J CONTROL RELEASE, V228, P9, DOI 10.1016/j.jconrel.2016.02.043; Lichtenegger FS, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1117; Linares-Fernandez S, 2020, TRENDS MOL MED, V26, P311, DOI 10.1016/j.molmed.2019.10.002; Lou B, 2019, BIOCONJUGATE CHEM, V30, P461, DOI 10.1021/acs.bioconjchem.8b00524; Lukavsky PJ, 2004, RNA, V10, P889, DOI 10.1261/rna.5264804; Lundstrom K, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040039; Mao HH, 2020, ADV BIOCHEM ENG BIOT, V171, P155, DOI 10.1007/10_2019_107; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Matsui A, 2015, SCI REP-UK, V5, DOI 10.1038/srep15810; McKenna SA, 2007, NAT PROTOC, V2, P3270, DOI 10.1038/nprot.2007.480; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Oyston P, 2012, J MED MICROBIOL, V61, P889, DOI 10.1099/jmm.0.039180-0; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pascolo, 2015, Patent No. [2015/000959, 2015000959]; Pascolo S, 2004, EXPERT OPIN BIOL TH, V4, P1285, DOI 10.1517/14712598.4.8.1285; Pascolo S., 2017, J MULTIDISCIPLINARY, V4, P6937; Pascolo S, 2015, EXPERT REV VACCINES, V14, P153, DOI 10.1586/14760584.2015.1000871; Pasteur L, 1885, CR HEBD ACAD SCI, V101, P765; Patel MR, 2020, J CLIN ONCOL, V38; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111; Plotkin SA, 2011, NAT REV MICROBIOL, V9, P889, DOI 10.1038/nrmicro2668; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard C, 2013, TRENDS MOL MED, V19, P705, DOI 10.1016/j.molmed.2013.09.002; Poveda C, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040131; Probst J, 2007, GENE THER, V14, P1175, DOI 10.1038/sj.gt.3302964; Qiu P, 1996, GENE THER, V3, P262; Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269; Schmid A, 2017, METHODS MOL BIOL, V1499, P237, DOI 10.1007/978-1-4939-6481-9_15; Sebastian M, 2019, CANCER IMMUNOL IMMUN, V68, P799, DOI 10.1007/s00262-019-02315-x; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Steinle H, 2017, STEM CELLS, V35, P68, DOI 10.1002/stem.2402; Sullenger BA, 2016, SCIENCE, V352, P1417, DOI 10.1126/science.aad8709; Sun ND, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35570-6; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Tusup M, 2019, CHIMIA, V73, P391, DOI 10.2533/chimia.2019.391; Udhayakumar VK, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601412; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Walther J, 2015, J BIOTECHNOL, V213, P3, DOI 10.1016/j.jbiotec.2015.05.010; Weide B, 2008, J IMMUNOTHER, V31, P180, DOI 10.1097/CJI.0b013e31815ce501; Weide B, 2009, J IMMUNOTHER, V32, P498, DOI 10.1097/CJI.0b013e3181a00068; Weissman Drew, 2013, Methods Mol Biol, V969, P43, DOI 10.1007/978-1-62703-260-5_3; Weng YH, 2020, BIOTECHNOL ADV, V40, DOI 10.1016/j.biotechadv.2020.107534; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wochner A, 2017, Patent No. [US 2017/0114378 A1, 20170114378]; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; World Health Organization, CALL PUBL CONS EV QU; Xiao L, 2019, MOL THER, V27, P1114, DOI 10.1016/j.ymthe.2019.03.011; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; Zeng Chunxi, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_217; Zhao MN, 2016, DRUG DELIV, V23, P2596, DOI 10.3109/10717544.2015.1038856	119	27	27	84	147	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 15	2021	39	16					2190	2200		10.1016/j.vaccine.2021.03.038		APR 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QI	33771389	Green Published, Bronze, Green Submitted			2022-04-29	WOS:000637937900003
J	Diaco, M; Chang, LJ; Seet, B; Robertson, CA; Chit, A; Mercer, M; Greenberg, DP; Hollingsworth, R; Samson, SI				Diaco, Mia; Chang, Lee-Jah; Seet, Bruce; Robertson, Corey A.; Chit, Ayman; Mercer, Monica; Greenberg, David P.; Hollingsworth, Rosalind; Samson, Sandrine I.			Introductory paper: High-dose influenza vaccine Preface	VACCINE			English	Editorial Material							RANDOMIZED CONTROLLED-TRIALS; AGED 65 YEARS; SEASONAL INFLUENZA; COST-EFFECTIVENESS; OLDER-ADULTS; STANDARD; IMMUNOGENICITY; EFFICACY; HOSPITALIZATION; EPIDEMIOLOGY	Seasonal influenza has a significant impact on global public health each year, especially in older adults 65 years of age and above. This paper presents the evolution of high-dose influenza vaccine and the quantity as well as quality of evidence on this vaccine. Its introduces other peer-reviewed manuscripts included in this supplement covering the benefits high-dose influenza vaccine over ten consecutive influenza seasons. The development of the high-dose influenza vaccine represents an important step in the evolution of influenza vaccines, offering an advancement in prevention of influenza and a step in encouraging healthy aging in older adults. A video summary of the article can be accessed via the Supplementary data link at the end of this article. (C) 2020 The Authors. Published by Elsevier Ltd.	[Diaco, Mia; Chang, Lee-Jah; Robertson, Corey A.; Chit, Ayman; Mercer, Monica; Hollingsworth, Rosalind] Sanofi Pasteur, Swiftwater, PA USA; [Seet, Bruce] Sanofi Pasteur, Toronto, ON, Canada; [Greenberg, David P.; Samson, Sandrine I.] Sanofi Pasteur, Campus Sanofi Lyon, Lyon, France		Samson, SI (通讯作者)，Sanofi Pasteur, Campus Sanofi Lyon, Lyon, France.	mia.diaco@sanofi.com; lee-jah.chang@sanofi.com; bruce.seet@sanofi.com; corey.robertson@sanofi.com; ayman.chit@sanofi.com; monica.mercer@sanofi.com; david.greenberg@sanofi.com; ros.hollingsworth@sanofi.com; sandrine.samson@sanofi.com		samson, sandrine/0000-0001-8365-5093	Sanofi Pasteur	This publication was produced with support from Sanofi Pasteur. Manuscripts were accepted after rigorous peer review process that was managed by an expert Guest Editor independently appointed by the Editor-in-Chief.	Andrew MK, 2021, VACCINE, V39, pA36, DOI 10.1016/j.vaccine.2020.09.011; Andrew MK, 2017, J INFECT DIS, V216, P405, DOI 10.1093/infdis/jix282; Barberis I, 2016, J Prev Med Hyg, V57, pE115; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bruxvoort KJ, 2019, VACCINE, V37, P5807, DOI 10.1016/j.vaccine.2019.08.024; Caldera F, 2021, VACCINE, V39, pA15, DOI 10.1016/j.vaccine.2020.11.037; CDC. Centers for Disease Control (CDC), FREQUENTLY ASKED QUE; CDC. Centers for Disease Control (CDC), INFLUENZA VACCINES U; Chang LJ, 2019, VACCINE, V37, P5825, DOI 10.1016/j.vaccine.2019.08.016; Chit A, 2015, LANCET INFECT DIS, V15, P1459, DOI 10.1016/S1473-3099(15)00249-2; Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010; Cobey S, 2018, CLIN INFECT DIS, V67, P327, DOI 10.1093/cid/ciy097; Colrat F, 2021, VACCINE, V39, pA42, DOI 10.1016/j.vaccine.2020.12.036; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Dao CN, 2010, J INFECT DIS, V202, P881, DOI 10.1086/655904; DeMarcus L, 2019, VACCINE, V37, P4015, DOI 10.1016/j.vaccine.2019.06.004; DiazGranados CA, 2015, VACCINE, V33, P4565, DOI 10.1016/j.vaccine.2015.07.003; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; DiazGranados CA, 2013, VACCINE, V31, P861, DOI 10.1016/j.vaccine.2012.12.013; Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790; FDA. US Food and Drug Administration (FDA), 2019, SUBMITTING DOCUMENTS; Flannery B, 2019, J INFECT DIS, V220, P1237, DOI 10.1093/infdis/jiy717; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Gozalo PL, 2012, J AM GERIATR SOC, V60, P1260, DOI 10.1111/j.1532-5415.2012.04048.x; Gravenstein S, 2018, HUM VACC IMMUNOTHER, V14, P736, DOI 10.1080/21645515.2017.1398872; Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7; Guthrie B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6341; Hannoun C, 2013, EXPERT REV VACCINES, V12, P1085, DOI 10.1586/14760584.2013.824709; Hariton E, 2018, BJOG-INT J OBSTET GY, V125, P1716, DOI 10.1111/1471-0528.15199; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; Izurieta HS, 2015, LANCET INFECT DIS, V15, P293, DOI 10.1016/S1473-3099(14)71087-4; Izurieta HS, 2020, J INFECT DIS; Kaka AS, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx001; Lee, 2021, VACCINE, V39, pA24, DOI [10.1016/j.vaccine.2020.09.004, DOI 10.1016/J.VACCINE.2020.09.004]; Lu Y, 2019, J INFECT DIS, V220, P1511, DOI 10.1093/infdis/jiz360; Macias AE, 2021, VACCINE, V39, pA6, DOI 10.1016/j.vaccine.2020.09.048; NACI, LIT REV UPDATE EFFIC; Net P, 2021, VACCINE, V39, pA56, DOI 10.1016/j.vaccine.2021.01.016; Ng TWY, 2019, J INFECT DIS, V219, P1525, DOI 10.1093/infdis/jiy720; Perez-Vilar S, 2019, VACCINE, V37, P3856, DOI 10.1016/j.vaccine.2019.05.041; Raviotta JM, 2016, J AM GERIATR SOC, V64, P2126, DOI 10.1111/jgs.14323; Richardson DM, 2015, CLIN INFECT DIS, V61, P171, DOI 10.1093/cid/civ261; Robison SG, 2018, VACCINE, V36, P6683, DOI 10.1016/j.vaccine.2018.09.050; Schanzer DL, 2008, VACCINE, V26, P4697, DOI 10.1016/j.vaccine.2008.06.087; Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641; Shireman TI, 2019, J AM MED DIR ASSOC, V20, P874, DOI 10.1016/j.jamda.2018.12.003; Sibbald B, 1998, BRIT MED J, V316, P201; Smetana J, 2018, HUM VACC IMMUNOTHER, V14, P540, DOI 10.1080/21645515.2017.1343226; Thompson WW, 2006, J INFECT DIS, V194, pS82, DOI 10.1086/507558; van Aalst R, 2021, VACCINE, V39, pA51, DOI 10.1016/j.vaccine.2020.05.080; van Aalst R, 2020, VACCINE, V38, P372, DOI 10.1016/j.vaccine.2019.09.105; Weir JP, 2016, INFLUENZA OTHER RESP, V10, P354, DOI 10.1111/irv.12383; WHO, WHO INFLUENZA BURDEN; Yinong YX, 2019, VACCINE, V37, P1484, DOI 10.1016/j.vaccine.2019.01.063; Young-Xu YN, 2018, J INFECT DIS, V217, P1718, DOI 10.1093/infdis/jiy088	56	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 15	2021	39			1			A1	A5		10.1016/j.vaccine.2020.09.005		MAR 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QV2JM	33549389	hybrid			2022-04-29	WOS:000627802900001
J	Hoydahl, LS; Frigstad, T; Rasmussen, IB; Oynebraten, I; Schjetne, KW; Andersen, JT; Michaelsen, TE; Lunde, E; Bogen, B; Sandlie, I				Hoydahl, Lene S.; Frigstad, Terje; Rasmussen, Ingunn B.; Oynebraten, Inger; Schjetne, Karoline W.; Andersen, Jan Terje; Michaelsen, Terje E.; Lunde, Elin; Bogen, Bjarne; Sandlie, Inger			Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses	VACCINE			English	Article						Antibody engineering; Antigen presentation; Subunit vaccine; Cross-presentation; APC targeting; T-cell activation		Targeted delivery of antigen to antigen-presenting cells (APCs) enhances antigen presentation and thus, is a potent strategy for making more efficacious vaccines. This can be achieved by use of antibodies with specificity for endocytic surface molecules expressed on the APC. We aimed to compare two different antibody-antigen fusion modes in their ability to induce T-cell responses; first, exchange of immunoglobulin (Ig) constant domain loops with a T-cell epitope (Troybody), and second, fusion of T-cell epitope or whole antigen to the antibody C-terminus. Although both strategies are well-established, they have not previously been compared using the same system. We found that both antibody-antigen fusion modes led to presentation of the T-cell epitope. The strength of the T-cell responses varied, however, with the most efficient Troybody inducing CD4 T-cell proliferation and cytokine secretion at 10-100-fold lower concentration than the antibodies carrying antigen fused to the C-terminus, both in vitro and after intravenous injection in mice. Furthermore, we exchanged this loop with an MHCI-restricted T-cell epitope, and the resulting antibody enabled efficient cross-presentation to CD8 T cells in vivo. Targeting of antigen to APCs by use of such antibody-antigen fusions is thus an attractive vaccination strategy for increased activation of both CD4 and CD8 peptide-specific T cells. (C) 2021 The Authors. Published by Elsevier Ltd.	[Hoydahl, Lene S.; Frigstad, Terje; Rasmussen, Ingunn B.; Oynebraten, Inger; Schjetne, Karoline W.; Andersen, Jan Terje; Bogen, Bjarne; Sandlie, Inger] Univ Oslo, Ctr Immune Regulat, N-0372 Oslo, Norway; [Hoydahl, Lene S.; Frigstad, Terje; Rasmussen, Ingunn B.; Oynebraten, Inger; Schjetne, Karoline W.; Andersen, Jan Terje; Bogen, Bjarne; Sandlie, Inger] Univ Oslo, Dept Immunol, N-0372 Oslo, Norway; [Hoydahl, Lene S.; Frigstad, Terje; Rasmussen, Ingunn B.; Oynebraten, Inger; Schjetne, Karoline W.; Andersen, Jan Terje; Bogen, Bjarne; Sandlie, Inger] Oslo Univ Hosp, N-0372 Oslo, Norway; [Hoydahl, Lene S.; Frigstad, Terje; Rasmussen, Ingunn B.; Andersen, Jan Terje; Lunde, Elin; Sandlie, Inger] Univ Oslo, Ctr Immune Regulat, N-0316 Oslo, Norway; [Hoydahl, Lene S.; Frigstad, Terje; Rasmussen, Ingunn B.; Andersen, Jan Terje; Lunde, Elin; Sandlie, Inger] Univ Oslo, Dept Biosci, N-0316 Oslo, Norway; [Andersen, Jan Terje] Univ Oslo, Inst Clin Med, Dept Pharmacol, N-0318 Oslo, Norway; [Andersen, Jan Terje] Oslo Univ Hosp, N-0318 Oslo, Norway; [Michaelsen, Terje E.] Norwegian Inst Publ Hlth, Dept Infect Immunol, N-0403 Oslo, Norway; [Michaelsen, Terje E.] Univ Oslo, Sch Pharm, N-0316 Oslo, Norway; [Oynebraten, Inger] Oslo Univ Hosp, Dept Pathol, N-0372 Oslo, Norway; [Oynebraten, Inger] Univ Oslo, N-0372 Oslo, Norway; [Frigstad, Terje] Nextera, N-0349 Oslo, Norway; [Schjetne, Karoline W.] Vaccibody AS, N-0349 Oslo, Norway		Hoydahl, LS (通讯作者)，Univ Oslo, Ctr Immune Regulat, N-0372 Oslo, Norway.; Hoydahl, LS (通讯作者)，Univ Oslo, Dept Immunol, N-0372 Oslo, Norway.; Hoydahl, LS (通讯作者)，Oslo Univ Hosp, N-0372 Oslo, Norway.	l.s.hoydahl@medisin.uio.no	Høydahl, Lene/AAN-6511-2021; Øynebråten, Inger/W-3369-2019	Øynebråten, Inger/0000-0001-8914-5676; Andersen, Jan Terje/0000-0003-1710-1628	Research Council of Norway through its Centers of Excellence funding scheme [179573/V40]	This work was supported by the Research Council of Norway through its Centers of Excellence funding scheme, under project number 179573/V40. We are grateful to Sivaganesh Sathiaruby for technical assistance.	Adler LN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00319; Andersen JT, 2008, FEBS J, V275, P4097, DOI 10.1111/j.1742-4658.2008.06551.x; Andersen JT, 2012, J BIOL CHEM, V287, P22927, DOI 10.1074/jbc.M112.355131; Andersen TK, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0101-0; BAIER G, 1995, J VIROL, V69, P2357, DOI 10.1128/JVI.69.4.2357-2365.1995; Berntzen G, 2005, J IMMUNOL METHODS, V298, P93, DOI 10.1016/j.jim.2005.01.002; BEVAN MJ, 1976, J IMMUNOL, V117, P2233; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Biragyn A, 1999, NAT BIOTECHNOL, V17, P253, DOI 10.1038/6995; Biragyn A, 2001, J IMMUNOL, V167, P6644, DOI 10.4049/jimmunol.167.11.6644; BOGEN B, 1989, EMBO J, V8, P1947, DOI 10.1002/j.1460-2075.1989.tb03599.x; BOGEN B, 1992, EUR J IMMUNOL, V22, P703, DOI 10.1002/eji.1830220313; BOGEN B, 1986, EUR J IMMUNOL, V16, P1373, DOI 10.1002/eji.1830161110; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971; Chatterjee B, 2012, BLOOD, V120, P2011, DOI 10.1182/blood-2012-01-402370; Cruz FM, 2017, ANNU REV IMMUNOL, V35, P149, DOI 10.1146/annurev-immunol-041015-055254; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P9266, DOI 10.1021/bi980270i; Dekkers G, 2017, MABS-AUSTIN, V9, P767, DOI 10.1080/19420862.2017.1323159; EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78; EISEN HN, 1968, BIOCHEMISTRY-US, V7, P4126, DOI 10.1021/bi00851a048; Feige MJ, 2004, J MOL BIOL, V344, P107, DOI 10.1016/j.jmb.2004.09.033; Flobakk M, 2008, J IMMUNOL, V181, P7062, DOI 10.4049/jimmunol.181.10.7062; Fossum E, 2015, EUR J IMMUNOL, V45, P624, DOI 10.1002/eji.201445080; Guermonprez P, 2002, EUR J IMMUNOL, V32, P3071, DOI 10.1002/1521-4141(200211)32:11<3071::AID-IMMU3071>3.0.CO;2-A; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hos BJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00884; Kim JK, 1999, EUR J IMMUNOL, V29, P2819, DOI 10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6; LESK AM, 1988, NATURE, V335, P188, DOI 10.1038/335188a0; Lunde E, 1999, NAT BIOTECHNOL, V17, P670, DOI 10.1038/10883; Lunde E, 1997, MOL IMMUNOL, V34, P1167, DOI 10.1016/S0161-5890(97)00143-0; Lunde E, 2002, J IMMUNOL, V168, P2154, DOI 10.4049/jimmunol.168.5.2154; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Mi WT, 2008, J IMMUNOL, V181, P7550, DOI 10.4049/jimmunol.181.11.7550; Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; Norderhaug L, 1997, J IMMUNOL METHODS, V204, P77, DOI 10.1016/S0022-1759(97)00034-3; Oynebraten I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104814; Qiao SW, 2008, P NATL ACAD SCI USA, V105, P9337, DOI 10.1073/pnas.0801717105; Radoshevich L, 2018, NAT REV MICROBIOL, V16, P32, DOI 10.1038/nrmicro.2017.126; Rasmussen IB, 2012, PROTEIN ENG DES SEL, V25, P89, DOI 10.1093/protein/gzr063; Rock KL, 2016, TRENDS IMMUNOL, V37, P724, DOI 10.1016/j.it.2016.08.010; Roopenian DC, 2003, J IMMUNOL, V170, P3528, DOI 10.4049/jimmunol.170.7.3528; Roos AK, 2006, MOL THER, V13, P320, DOI 10.1016/j.ymthe.2005.08.005; Roos AK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007226; Rothlisberger D, 2005, J MOL BIOL, V347, P773, DOI 10.1016/j.jmb.2005.01.053; Ruffini PA, 2010, VACCINE, V29, P191, DOI 10.1016/j.vaccine.2010.10.057; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Schjetne KW, 2007, J IMMUNOL, V178, P4169, DOI 10.4049/jimmunol.178.7.4169; Schjetne KW, 2002, INT IMMUNOL, V14, P1423, DOI 10.1093/intimm/dxf110; Schuurhuis DH, 2000, J EXP MED, V192, P145, DOI 10.1084/jem.192.1.145; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Stapleton NM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1608; Todorova B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04547-2; Trumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005; Tunheim G, 2008, INT IMMUNOL, V20, P295, DOI 10.1093/intimm/dxm141; Ward ES, 2003, INT IMMUNOL, V15, P187, DOI 10.1093/intimm/dxg018	60	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 12	2021	39	11					1583	1592		10.1016/j.vaccine.2021.02.012		FEB 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QP4DD	33612340	Green Published, hybrid			2022-04-29	WOS:000623785800006
J	van den Boogaard, J; de Gier, B; Lima, PDB; Desai, S; de Melker, HE; Hahne, SJM; Veldhuijzen, IK				van den Boogaard, Jossy; de Gier, Brechje; Lima, Priscila de Oliveira Bressane; Desai, Shalini; de Melker, Hester E.; Hahne, Susan J. M.; Veldhuijzen, Irene K.			Immunogenicity, duration of protection, effectiveness and safety of rubella containing vaccines: A systematic literature review and meta-analysis	VACCINE			English	Review						Rubella; Rubella containing vaccine; Immunogenicity; Duration of protection; Effectiveness; Safety; Review; Meta-analysis; Congenital rubella syndrome	YELLOW-FEVER VACCINE; SYRINGE JET INJECTOR; MUMPS-RUBELLA; MMR VACCINE; VARICELLA VACCINE; ADVERSE EVENTS; COMBINED MEASLES; IMMUNE-RESPONSE; ANTIBODY PERSISTENCE; CONJUGATE VACCINE	Background: Rubella containing vaccines (RCV) prevent rubella virus infection and subsequent congenital rubella syndrome (CRS). To update the evidence on immunogenicity, duration of protection, effectiveness and safety of RCV, we conducted a systematic literature review. Methods: We searched EMBASE and SCOPUS, using keywords for rubella vaccine in combination with immunogenicity (seroconversion and seropositivity), duration of protection, efficacy/effectiveness, and safety. Original research papers involving at least one dose of RCV (at any age), published between 11-2010 and 17-5-2019 were included. Where appropriate, meta-analyses were performed. Quality of included studies was assessed using GRADE methodology. Results: We included 36 papers (32 randomized controlled trials (RCTs) and 4 observational studies) on immunogenicity (RA27/3 strain) in children and adolescent girls, 14 papers (5 RCTs and 9 observational studies) on duration of protection, one paper on vaccine effectiveness (VE) (BRDII strain), and 74 studies on safety, including three on safety in pregnancy. Meta-analysis of immunogenicity data showed 99% seroconversion (95% CI: 98-99%) after a single dose of RCV in children, independent of co-administration with other vaccines. Seroconversion after RCV1 below 9 months of age (BRDII strain, at 8 months) was 93% (95% CI: 92-95%). For duration of protection, the included studies showed a seropositivity of 88%-100% measured 1-20 years after one or two RCV doses. The single study on VE of BRDII strain, reported 100% VE after one and two doses. Among 34,332 individuals participating in the RCTs, 140 severe adverse events (SAEs) were reported as possibly related to RCV. Among the case reports on SAEs, the association with RCV was confirmed in one report (on fulminant encephalitis). Among 3,000 pregnant women who were inadvertently vaccinated, no SAEs were reported. Conclusions: One and two doses of RCV are highly immunogenic for a long period of time, effective in preventing rubella and CRS, and safe. (C) 2021 Elsevier Ltd. All rights reserved.	[van den Boogaard, Jossy; de Gier, Brechje; Lima, Priscila de Oliveira Bressane; de Melker, Hester E.; Hahne, Susan J. M.; Veldhuijzen, Irene K.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control Cib, Bilthoven, Netherlands; [van den Boogaard, Jossy] European Ctr Dis Prevent & Control ECDC, European Programme Intervent Epidemiol Training E, Stockholm, Sweden; [Desai, Shalini] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland		van den Boogaard, J (通讯作者)，RIVM, Antonie Van Leeuwenhoeklaan 9, NL-3720 BA Bilthoven, Netherlands.	jossy.van.den.boogaard@rivm.nl		Veldhuijzen, Irene/0000-0002-3132-4070	WHOWorld Health Organization [2019/908284]	This study was funded by the WHO (WHO registration 2019/908284).	Abedi GR, 2012, VACCINE, V30, P7052, DOI 10.1016/j.vaccine.2012.09.053; Abu-Elyazeed R, 2018, HUM VACC IMMUNOTHER, V14, P2624, DOI 10.1080/21645515.2018.1489186; Ankrah DNA, 2018, HUM VACC IMMUNOTHER, V14, P172, DOI 10.1080/21645515.2017.1384105; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205; [Anonymous], 2011, Wkly Epidemiol Rec, V86, P301; Bavdekar A, 2018, VACCINE, V36, P1220, DOI 10.1016/j.vaccine.2018.01.006; BEASLEY RP, 1969, AM J DIS CHILD, V118, P301, DOI 10.1001/archpedi.1969.02100040303027; Bennani BN, 2011, ANN DERMATOL VENER, V138, P753, DOI 10.1016/j.annder.2011.01.049; Berry AA, 2017, HUM VACC IMMUNOTHER, V13, P1516, DOI 10.1080/21645515.2017.1309486; Binamer Y, 2015, ANN SAUDI MED, V35, P254, DOI 10.5144/0256-4947.2015.254; Blatter MM, 2012, PEDIATR INFECT DIS J, V31, pE133, DOI 10.1097/INF.0b013e318259fc8a; Bryant KA, 2012, HUM VACC IMMUNOTHER, V8, P1036, DOI 10.4161/hv.20357; Carmona A, 2010, PEDIATR INFECT DIS J, V29, P269, DOI 10.1097/INF.0b013e3181c15977; Castillo-Solorzano C, 2011, J INFECT DIS, V204, pS713, DOI 10.1093/infdis/jir489; Cheng DR, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-105; Chiu NC, 2018, HUM VACC IMMUNOTHER, V14, P1075, DOI 10.1080/21645515.2018.1425659; Clarke E, 2016, LANCET GLOB HEALTH, V4, pE534, DOI 10.1016/S2214-109X(16)30075-4; Crevat D, 2015, PEDIATR INFECT DIS J, V34, P884, DOI 10.1097/INF.0000000000000752; Cunha MPL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/853083; Das Pradip Kumar, 2013, J Indian Med Assoc, V111, P232; de Valk H., 1998, RESEAU NATL SANTE PU, P1; Deichmann KA, 2015, VACCINE, V33, P2379, DOI 10.1016/j.vaccine.2015.02.070; Di Pietrantonj C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004407.pub4; Ortega JLD, 2017, VACCINE, V35, P3116, DOI 10.1016/j.vaccine.2017.04.027; Diaz-Ortega JL, 2014, VACCINE, V32, P3680, DOI 10.1016/j.vaccine.2014.04.031; dos Santos EM, 2019, MEM I OSWALDO CRUZ, V114, DOI 10.1590/0074-02760180517; dos Santos EM, 2014, MEM I OSWALDO CRUZ, V109, P335, DOI 10.1590/0074-0276130351; Durando P, 2016, VACCINE, V34, P4278, DOI 10.1016/j.vaccine.2016.07.009; Ergenoglu AM, 2012, TURKISH J PEDIATR, V54, P230; Ferrera G, 2012, HUM VACC IMMUNOTHER, V8, P355; Ferrini W, 2013, PEDIATRICS, V132, pE1035, DOI 10.1542/peds.2012-2930; Finale E, 2017, ANN I SUPER SANITA, V53, P152, DOI 10.4415/ANN_17_02_12; FURUKAWA T, 1970, J AMER MED ASSOC, V213, P987; Gal O, 2016, REV ROMANA MED LAB, V24, P337, DOI 10.1515/rrlm-2016-0028; Gil-Bistes D, 2012, J DERMATOL, V39, P492, DOI 10.1111/j.1346-8138.2011.01380.x; Gomber S, 2011, INDIAN J MED RES, V134, P302; Goncalves G, 2016, EPIDEMIOL INFECT, V144, P3139, DOI 10.1017/S0950268816001655; Grant GB, 2017, MMWR-MORBID MORTAL W, V66, P1256, DOI 10.15585/mmwr.mm6645a4; Gunatheesan S, 2012, AUSTRALAS J DERMATOL, V53, pE76, DOI 10.1111/j.1440-0960.2011.00781.x; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.03.017, 10.1016/j.jclinepi.2011.06.004]; Hahne S, 2009, PEDIATR INFECT DIS J, V28, P795, DOI 10.1097/INF.0b013e3181a3e2d5; He HG, 2014, VACCINE, V32, P4001, DOI 10.1016/j.vaccine.2014.04.044; Huang LM, 2014, VACCINE, V32, P5363, DOI 10.1016/j.vaccine.2014.02.085; Huang LM, 2013, HUM VACC IMMUNOTHER, V9, P1308, DOI 10.4161/hv.24035; Kemmeren JM, 2011, EUR J PEDIATR, V170, P339, DOI 10.1007/s00431-010-1294-4; Khetsuriani N, 2010, VACCINE, V28, P6455, DOI 10.1016/j.vaccine.2010.07.043; Klein NP, 2012, PEDIATRICS, V129, P809, DOI 10.1542/peds.2011-3198; Knuf M, 2012, EUR J PEDIATR, V171, P463, DOI 10.1007/s00431-011-1569-4; Knuf M, 2010, EUR J PEDIATR, V169, P925, DOI 10.1007/s00431-010-1142-6; Kontio M, 2016, J INFECT DIS, V213, P2005, DOI 10.1093/infdis/jiw058; Kontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568; Kuniyoshi K, 2017, JAMA OPHTHALMOL, V135, P478, DOI 10.1001/jamaophthalmol.2017.0380; Lalwani S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007202; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lee H, 2011, PEDIATR INT, V53, P374, DOI 10.1111/j.1442-200X.2010.03244.x; Leonardi M, 2011, PEDIATRICS, V128, pE1387, DOI 10.1542/peds.2010-2132; Li Y, 2019, LANCET INFECT DIS, V19, P402, DOI 10.1016/S1473-3099(18)30650-9; Linder N, 2011, J TROP PEDIATRICS, V57, P299, DOI 10.1093/tropej/fmp104; Lochlainn LMN, 2019, LANCET INFECT DIS, V19, P1235, DOI 10.1016/S1473-3099(19)30395-0; Lopes SRC, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15061149; Diaz-Ortega JL, 2010, VACCINE, V28, P7228, DOI 10.1016/j.vaccine.2010.08.055; Lum LCS, 2010, VACCINE, V28, P1566, DOI 10.1016/j.vaccine.2009.11.054; Mangtani P, 2020, VACCINE, V38, P963, DOI 10.1016/j.vaccine.2019.11.070; Manzotti F, 2010, ITAL J PEDIATR, V36, DOI 10.1186/1824-7288-36-59; Marlow R, 2018, VACCINE, V36, P2300, DOI 10.1016/j.vaccine.2018.03.021; Marshall GS, 2016, HUM VACC IMMUNOTHER, V12, P2188, DOI 10.1080/21645515.2016.1165374; Martins RD, 2015, CONTEMP CLIN TRIALS, V41, P1, DOI 10.1016/j.cct.2014.11.014; McLean HQ, 2018, VACCINE, V36, P5732, DOI 10.1016/j.vaccine.2018.08.010; Meng FY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172108; Mentzer D, 2013, BUNDESGESUNDHEITSBLA, V56, P1253, DOI 10.1007/s00103-013-1792-4; MMR-161 Study Group, 2018, Vaccine, V36, P5781, DOI 10.1016/j.vaccine.2018.07.076; Mufson MA, 2015, J PEDIAT INF DIS SOC, V4, P339, DOI 10.1093/jpids/piu081; Silva JRN, 2011, VACCINE, V29, P6327, DOI 10.1016/j.vaccine.2011.05.019; Nessa A, 2016, BANGLADESH MED RES C, V42, P84, DOI DOI 10.3329/BMRCB.V42I2.32052; Okafuji T, 2016, JPN J INFECT DIS, V69, P221, DOI 10.7883/yoken.JJID.2015.162; Okazaki N, 2011, VACCINE, V29, P4878, DOI 10.1016/j.vaccine.2011.04.036; Owatanapanich S, 2014, SE ASIAN J TROP MED, V45, P1053; Paulke-Korinek M, 2011, VACCINE, V29, P5130, DOI 10.1016/j.vaccine.2011.05.046; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Perez-Vilar S, 2013, AN PEDIATR, V78, P297, DOI 10.1016/j.anpedi.2012.07.013; Pina LM, 2012, PEDIATR INFECT DIS J, V31, P1173, DOI 10.1097/INF.0b013e318268dfe4; Povey M, 2019, LANCET INFECT DIS, V19, P287, DOI 10.1016/S1473-3099(18)30716-3; Reef SE, 2018, RUBELLA VACCINES; Reisinger KS, 2018, VACCINE; Rinderknecht S, 2011, PEDIATR INFECT DIS J, V30, pE179, DOI 10.1097/INF.0b013e31822256a5; Ruger G, 2012, PEDIATR INFECT DIS J, V31, P1166, DOI 10.1097/INF.0b013e318267fd8b; Rumke HC, 2011, VACCINE, V29, P3842, DOI 10.1016/j.vaccine.2011.02.067; Sanz PG, 2012, RHEUMATOL INT, V32, P4061, DOI 10.1007/s00296-011-2130-5; Seagle EE, 2018, VACCINE, V36, P818, DOI 10.1016/j.vaccine.2017.12.075; Sharma Hitt, 2010, Indian J Community Med, V35, P134, DOI 10.4103/0970-0218.62575; Sharma HJ, 2011, J INFECT DEV COUNTR, V5, P874, DOI 10.3855/jidc.1847; Shoho Y, 2018, TOHOKU J EXP MED, V246, P73, DOI 10.1620/tjem.246.73; Shuper A, 2011, SCAND J INFECT DIS, V43, P75, DOI 10.3109/00365548.2010.513067; Sood A, 2017, HUM VACC IMMUNOTHER, V13, P1523, DOI 10.1080/21645515.2017.1302629; Gualberto FAS, 2013, J CLIN VIROL, V58, P737, DOI 10.1016/j.jcv.2013.10.016; Steward MW, 1997, OVERVIEW MEASUREMENT; Sukumaran L, 2015, CLIN INFECT DIS, V60, pE58, DOI 10.1093/cid/civ061; The MMR-162 study group, 2018, HUMAN VACCINES IMMUN; van der Maas NAT, 2016, J INFECT DIS, V213, P1466, DOI 10.1093/infdis/jiv756; Verma A, 2017, TURK J GASTROENTEROL, V28, P144, DOI 10.5152/tjg.2016.0559; Vesikari L, 2012, VACCINE, V30, P3082, DOI 10.1016/j.vaccine.2012.02.062; Vesikari T, 2011, VACCINE, V29, P4274, DOI 10.1016/j.vaccine.2011.03.043; Vesikari T, 2010, PEDIATR INFECT DIS J, V29, pE47, DOI 10.1097/INF.0b013e3181dffabf; WHO, 2015, MEASL RUB SURV DAT 2; WHO, 2020, WKLY EPIDEMIOL REC, V95, P301; WHO, 2018, MAN LAB BAS SURV MEA; Wiedmann RT, 2015, VACCINE, V33, P2132, DOI 10.1016/j.vaccine.2015.03.017; Woo EJ, 2016, PEDIATR INFECT DIS J, V35, pE253, DOI 10.1097/INF.0000000000001201; Xu H, 2013, VACCINE, V32, P85, DOI 10.1016/j.vaccine.2013.10.070; Yetman RJ, 2013, HUM VACC IMMUNOTHER, V9, P1691, DOI 10.4161/hv.24873; Yu AM, 2018, PEDIATR DERMATOL, V35, pE262, DOI 10.1111/pde.13532; Yurdakok K, 2012, J VACC VACCINAT, V3	112	2	2	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					889	900		10.1016/j.vaccine.2020.12.079		JAN 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7FB	33454135				2022-04-29	WOS:000610835100007
J	Huang, ZH; He, JF; Su, JL; Ou, ZQ; Liu, GX; Fu, R; Shou, Q; Zheng, MH; Group, T; Luxembourg, A; Liao, XY; Zhang, JK				Huang, Zhuhang; He, Jianfeng; Su, Jiali; Ou, Zhiqiang; Liu, Guixiu; Fu, Rong; Shou, Qiong; Zheng, Minghuan; Group, Thomas; Luxembourg, Alain; Liao, Xueyan; Zhang, Jikai			Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study	VACCINE			English	Article						China; Prophylaxis; Immunobridging; Immunogenicity; Quadrivalent human papillomavirus vaccine; Safety	HPV VACCINE; BURDEN; ADOLESCENTS; INFECTION; TYPE-16; IMPACT; TRIAL; MALES	Background: The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was approved for use in Chinese women aged 20-45 years in 2017. This Phase 3, open-label study (NCT03493542) aimed to assess immunogenicity and safety of the qHPV vaccine in Chinese girls aged 9-19 years versus Chinese young women aged 20-26 years; we report results from Day 1 through Month 7. The study will continue through Month 60 to assess antibody persistence in Chinese girls aged 9-19 years. Methods: Participants aged 9-26 years received three doses of the qHPV vaccine (Day 1, Month 2, Month 6). Geometric mean titers (GMTs) and seroconversion percentages for anti-HPV6/11/16/18 antibodies were determined by competitive Luminex immunoassay (cLIA) in serum samples obtained on Day 1 and at Month 7. Injection-site adverse events (AEs) and systemic AEs within 30 days post-vaccination, and serious AEs (SAEs) occurring at any time during the study, were recorded. Results: In total, 766 participants (383 aged 9-19 years; 383 aged 20-26 years) were enrolled and received >= 1 vaccine dose. All participants in the per-protocol immunogenicity population of both age groups seroconverted to each of the vaccine HPV types at Month 7. Anti-HPV6/11/16/18 antibody GMTs at Month 7 in participants aged 9-19 years were non-inferior to those in participants aged 20-26 years. Injection-site AEs and systemic AEs were reported by 36.6% and 49.3% of 9-19-year-olds, and 40.7% and 54.8% of 20-26-year-olds, respectively. There were no vaccine-related SAEs. No participants discontinued the vaccine due to an AE and no deaths were reported. Conclusion: Antibody responses induced by the 3-dose qHPV vaccination regimen in Chinese girls aged 9-19 years were non-inferior to those in Chinese young women aged 20-26 years. The vaccine was generally well tolerated in the study population. (C) 2020 The Authors. Published by Elsevier Ltd.	[Huang, Zhuhang; Su, Jiali; Ou, Zhiqiang; Zhang, Jikai] Guangdong Prov Inst Biol Prod & Mat Med, 200 Xipengling Rd, Guangzhou 510440, Guangdong, Peoples R China; [He, Jianfeng] Guangdong Prov Ctr Dis Control & Prevent, 160 Qunxian Rd, Guangzhou 511430, Guangdong, Peoples R China; [Liu, Guixiu; Fu, Rong; Shou, Qiong; Zheng, Minghuan; Liao, Xueyan] MSD R&D China Co Ltd, 21 Rong Da Rd, Beijing 100012, Peoples R China; [Group, Thomas; Luxembourg, Alain] Merck & Co Inc, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA		Zhang, JK (通讯作者)，Guangdong Prov Inst Biol Prod & Mat Med, 200 Xipengling Rd, Guangzhou 510440, Guangdong, Peoples R China.	gui.xiu.liu@merck.com; rong.fu1@merck.com; qiong.shou@merck.com; ming.huan.zheng@merck.com; thomas_group@merck.com; alain_luxembourg@merck.com; xue.yan.liao@merck.com; 56061237@qq.com			Merck Sharp Dohme Corp.Merck & Company	Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.	[Anonymous], 2017, Wkly Epidemiol Rec, V92, P241; Block SL, 2006, PEDIATRICS, V118, P2135, DOI 10.1542/peds.2006-0461; Block SL, 2010, PEDIATR INFECT DIS J, V29, P95, DOI 10.1097/INF.0b013e3181b77906; Chen W, 2019, VACCINE, V37, P889, DOI 10.1016/j.vaccine.2018.12.030; de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7; Dobson SRM, 2013, JAMA-J AM MED ASSOC, V309, P1793, DOI 10.1001/jama.2013.1625; Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3; Ferris DG, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-3947; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354; Giuliano AR, 2007, J INFECT DIS, V196, P1153, DOI 10.1086/521679; Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537; Huang T, 2018, VACCINE, V36, P1368, DOI 10.1016/j.vaccine.2018.02.006; Lacey CJN, 2006, VACCINE, V24, P35, DOI 10.1016/j.vaccine.2006.06.015; Li RC, 2012, VACCINE, V30, P4284, DOI 10.1016/j.vaccine.2012.02.079; Luxembourg A, 2017, EXPERT REV VACCINES, V16, P1119, DOI 10.1080/14760584.2017.1383158; Markowitz LE, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1968; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7; Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971; Roberts C, 2014, HUM VACC IMMUNOTHER, V10, P2168, DOI 10.4161/hv.29205; Serrano B, 2018, BEST PRACT RES CL OB, V47, P14, DOI 10.1016/j.bpobgyn.2017.08.006; Vichnin M, 2015, PEDIATR INFECT DIS J, V34, P983, DOI 10.1097/INF.0000000000000793; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; Wei LH, 2019, VACCINE, V37, P3617, DOI 10.1016/j.vaccine.2018.08.009; World Health Organization (WHO), 2017, M GLOB ADV COMM VACC; Yujie X., 2020, CHINA APPROVES PRODU	27	0	3	4	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					760	766		10.1016/j.vaccine.2020.11.008		JAN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PR1FI	33239228				2022-04-29	WOS:000606987100020
J	Maykin, MM; Heuser, C; Feltovich, H				Maykin, Melanie M.; Heuser, Cara; Feltovich, Helen		Soc Maternal-Fetal Med Hlth Policy	Pregnant people deserve the protection offered by SARS-CoV-2 vaccines Comment	VACCINE			English	Editorial Material						SARS-CoV-2; COVID-19; Vaccination; Research and development; Maternal immunization; Pregnancy; Lactation; Fetal; Neonatal; High-risk patients			[Maykin, Melanie M.] Univ Hawaii, John A Burns Sch Med, Dept Obstet Gynecol & Womens Hlth, Div Maternal Fetal Med, Honolulu, HI 96822 USA; [Heuser, Cara; Feltovich, Helen] Intermt Healthcare, Dept Obstet & Gynecol, Div Maternal Fetal Med, Salt Lake City, UT USA; [Heuser, Cara; Feltovich, Helen] Univ Utah, Salt Lake City, UT USA		Feltovich, H (通讯作者)，Intermt Healthcare, Dept Obstet & Gynecol, Div Maternal Fetal Med, Provo, UT 84604 USA.						[Anonymous], 2020, REV OP WARP SPEED RE; Bureau USC, 2018, FULL TIM YEAR ROUND; Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3; Estes ML, 2016, SCIENCE, V353, P772, DOI 10.1126/science.aag3194; Faden RR, 2019, VACCINE; Pettirosso E, 2020, AUST NZ J OBSTET GYN, V60, P640, DOI 10.1111/ajo.13204; Prochaska E, 2020, AM J REPROD IMMUNOL, V84, DOI 10.1111/aji.13306; Richtmann R., 2020, CASE REP WOMENS HLTH, V27, DOI [10.1016/j.crwh.2020.e00243, DOI 10.1016/J.CRWH.2020.E00243]; Schwartz DA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020194; Smith DD, 2020, AM J PERINAT, V37, P792, DOI 10.1055/s-0040-1712103; Trippella G, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060485	11	11	11	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					171	172		10.1016/j.vaccine.2020.12.007			2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33308888	Bronze, Green Published			2022-04-29	WOS:000604750300003
J	Juliao, P; Abadia, I; Welby, S; Wery, S; Wong, DN; De Leon, T; DeAntonio, R; Naranjo, L; Guignard, A; Marano, C				Juliao, Patricia; Abadia, Ivonne; Welby, Sarah; Wery, Stephanie; Wong, Digna; De Leon, Tirza; DeAntonio, Rodrigo; Naranjo, Laura; Guignard, Adrienne; Marano, Cinzia			Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama	VACCINE			English	Article						Antibody persistence; Havrix; Hepatitis A; Panama; Seroprevalence; Vaccination	DOSE IMMUNIZATION STRATEGY; LONG-TERM PERSISTENCE; FOLLOW-UP; IMMUNE MEMORY; MENDOZA PROVINCE; ARGENTINA; AGE; IMPACT; IMMUNOGENICITY; SEROPREVALENCE	Background: Hepatitis A virus (HAV) remains a global public health concern, which is potentially growing in Latin America, due to an expected shift from high to intermediate endemicity levels. The use of HAV vaccines in pediatric national immunization programs (NIPs), either as a 2-dose or a 1-dose schedule, has been explored in Latin American countries; however, evidence demonstrating long-term protection in this population is limited in the region. We evaluated long-term antibody persistence following a 1-dose partial series and the recommended 2-dose schedule used in Panama's pediatric NIP. Methods: Two independent cross-sectional serological surveys were conducted at year 8 (Y8) and Y10 following vaccination under the NIP with 1 or 2 doses of an inactivated HAV vaccine (Havrix, GSK). Seropositivity (anti-HAV antibody concentration >= 15 mIU/mL) rates and antibody geometric mean concentrations (GMCs) were assessed at each serosurvey. Non-inferiority of 1 dose versus 2 doses was also explored. Results: This study (NCT02712359) included 600 and 599 children at Y8 and Y10 post-vaccination, respectively. Seropositivity rates were 74.3% (95% confidence interval [CI]: 69.0; 79.2) and 97.7% (95% CI: 95.3; 99.1) at Y8 and 71.9% (95% CI: 66.4; 76.9) and 96.3% (95% CI: 93.5; 98.2) at Y10, in the 1-dose and 2-dose groups, respectively. Antibody GMCs were lower in the 1-dose versus the 2-dose group in both surveys. Non-inferiority was not demonstrated since the lower limit of the 2-sided 95% CI for the between-group difference in seropositivity rates (1-dose minus 2-dose) was < -10%. Conclusion: Anti-HAV antibody persistence was observed in lower percentages of children receiving 1 dose versus 2 doses of Havrix, at 8 and 10 years post-vaccination in Panama. Further investigations are needed to confirm antibody persistence and conclude on the protection afforded beyond 10 years in the pediatric population in Latin America. (C) 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.	[Juliao, Patricia; Naranjo, Laura] GSK, Panama City, Panama; [Abadia, Ivonne; Wong, Digna] Inst Invest Cient, Panama City, Panama; [Abadia, Ivonne; Wong, Digna] Serv Alta Tecnol Panama, Panama City, Panama; [Welby, Sarah; Wery, Stephanie; Guignard, Adrienne] GSK, Wavre, Belgium; [De Leon, Tirza] Unidad Materno Infantil Jose Domingo Obaldia, Chiriqui, Panama; [DeAntonio, Rodrigo] Cevaxin, Panama City, Panama; [Marano, Cinzia] GSK, Torrile, Italy		Juliao, P (通讯作者)，City Knowledge, Bldg 230,4th Floor,POB 08-19-08530, Panama City, Panama.	patricia.d.juliao@gsk.com; josivo@usa.net; sarah.x.welby@gsk.com; stephanie.x.wery@gsk.com; dwong@indivasta.org.pa; tirzarelis@cwpanama.net; rodrigo.deantonio@cevaxin.com; laura.t.naranjo@gsk.com; adrienne.x.guignard@gsk.com; cinzia.x.marano@gsk.com	DeAntonio, Rodrigo/AAM-2032-2021	DeAntonio, Rodrigo/0000-0003-2586-4115	GlaxoSmithKline Biologicals SAGlaxoSmithKline	GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.	Allen CJ, 2000, MED J AUSTRALIA, V172, P325; Andre Francis, 2002, Expert Rev Vaccines, V1, P9, DOI 10.1586/14760584.1.1.9; [Anonymous], 2012, Wkly Epidemiol Rec, V87; Bian GL, 2010, VACCINE, V28, P4798, DOI 10.1016/j.vaccine.2010.04.096; Cervio G, 2011, HEPATIC MED-EVID RES, V3, P99, DOI 10.2147/HMER.S22309; Chen Y, 2018, VACCINE, V36, P114, DOI 10.1016/j.vaccine.2017.11.036; Curran D, 2016, HUM VACC IMMUNOTHER, V12, P2765, DOI 10.1080/21645515.2016.1203495; Dagan R, 2016, PEDIATR INFECT DIS J, V35, pE220, DOI 10.1097/INF.0000000000001176; de Brito WI, 2018, BRAZ J INFECT DIS, V22, P166, DOI 10.1016/j.bjid.2018.04.001; de Suman O, 2003, REV HOSP NINO, V19, P23; Decker M, 2018, PLOTKINS VACCINES, P198; Souto FJD, 2019, VACCINE, V37, P771, DOI 10.1016/j.vaccine.2018.12.054; Espul C, 2015, J VIRAL HEPATITIS, V22, P453, DOI 10.1111/jvh.12317; Espul C, 2017, HUM VACC IMMUNOTHER, V13, P2707, DOI 10.1080/21645515.2017.1358326; Espul C, 2012, HEPATIC MED-EVID RES, V4, P53, DOI 10.2147/HMER.S33847; Estripeaut D, 2015, VACCINE, V33, P3200, DOI 10.1016/j.vaccine.2015.04.100; Franco E, 2012, WORLD J HEPATOL, V4, P68, DOI 10.4254/wjh.v4.i3.68; Hens N, 2014, VACCINE, V32, P1507, DOI 10.1016/j.vaccine.2013.10.088; Hung HMJ, 2009, BIOMETRICAL J, V51, P324, DOI 10.1002/bimj.200800219; Iwarson S, 2004, J TRAVEL MED, V11, P120, DOI 10.2310/7060.2004.17079; Jacobsen KH, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031716; Jacobsen KH, 2010, VACCINE, V28, P6653, DOI 10.1016/j.vaccine.2010.08.037; KOFF RS, 1992, VACCINE, V10, pS15, DOI 10.1016/0264-410X(92)90533-P; Lim J, 2014, YONSEI MED J, V55, P126, DOI 10.3349/ymj.2014.55.1.126; Lopez EL, 2010, PEDIATR INFECT DIS J, V29, P568, DOI 10.1097/INF.0b013e3181d57a85; Maiwald H, 1997, VACCINE, V15, P346, DOI 10.1016/S0264-410X(97)00211-9; Mayorga O, 2016, J INFECT DIS, V214, P1498, DOI 10.1093/infdis/jiw411; Ministerio de Salud, CAL VAC; Ministerio de Salud y Proteccion Social, LIN ESTR INTR VAC HE; National Institute for Biological Standards and Control, INT STAND; Ott JJ, 2013, INT J INFECT DIS, V17, pE939, DOI 10.1016/j.ijid.2013.04.012; Ott JJ, 2012, VACCINE, V31, P3, DOI 10.1016/j.vaccine.2012.04.104; Roels T H, 1998, WMJ, V97, P32; Spradling PR, 2016, HEPATOLOGY, V63, P703, DOI 10.1002/hep.28375; Stuurman AL, 2017, HUM VACC IMMUNOTHER, V13, P724, DOI 10.1080/21645515.2016.1242539; Tanaka J, 2000, VACCINE, V18, pS57, DOI 10.1016/S0264-410X(99)00466-1; Theeten H, 2015, VACCINE, V33, P5723, DOI 10.1016/j.vaccine.2015.07.008; Uruena A, 2016, PEDIATR INFECT DIS J, V35, P1339, DOI 10.1097/INF.0000000000001322; Vacchino MN, 2008, J VIRAL HEPATITIS, V15, P47, DOI 10.1111/j.1365-2893.2008.01029.x; Van Damme Pierre, 2004, Expert Rev Vaccines, V3, P249, DOI 10.1586/14760584.3.3.249; Van Damme Pierre, 2007, Travel Med Infect Dis, V5, P79, DOI 10.1016/j.tmaid.2006.04.004; Van Effelterre T, 2017, HUM VACC IMMUNOTHER, V13, P1942, DOI 10.1080/21645515.2017.1323158; Van Herck K, 2005, EXPERT REV VACCINES, V4, P459, DOI 10.1586/14760584.4.4.459; Van Herck K, 2011, J MED VIROL, V83, P1885, DOI 10.1002/jmv.22200; Vizzotti C, 2015, J PEDIAT INF DIS SOC, V4, pE62, DOI 10.1093/jpids/piu068; Vizzotti C, 2015, VACCINE, V33, pA227, DOI 10.1016/j.vaccine.2014.12.077; Vizzotti C, 2014, PEDIATR INFECT DIS J, V33, P84, DOI 10.1097/INF.0000000000000042; WHO, HEP FACT SHEET; World Health Organization, VACC PREV DIS SURV S; World Health Organization, 2019, WHO VACC PREV DIS MO; World Health Organization (WHO), 2019, IMMUNOLOGICAL BASIS; Yanez LA, 2014, J CLIN VIROL, V59, P38, DOI 10.1016/j.jcv.2013.11.005	52	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2021	39	1					26	34		10.1016/j.vaccine.2020.11.030			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PI2XL	33239226	hybrid			2022-04-29	WOS:000600959400005
J	Robertson, JS; Loizides, U; Adisa, A; Manjavacas, ALD; Rodilla, V; Strnadova, C; Weisser, K; Balocco, R				Robertson, James S.; Loizides, Ursula; Adisa, Akinola; de la Rica Manjavacas, Ana Lopez; Rodilla, Vicente; Strnadova, Colette; Weisser, Karin; Balocco, Raffaella			International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety	VACCINE			English	Review						International Nonproprietary Names; Novel vaccine substances; Pharmacovigilance; Patient safety; COVID-19; SARS-CoV-2; mRNA vaccines; Viral vector vaccines	HUMAN-PAPILLOMAVIRUS; STRATEGIES	International Nonproprietary Names (INN) are assigned by the World Health Organization (WHO) to pharmaceutical substances to ensure global recognition by a unique name. INN facilitate safe prescribing through naming consistency, efficient communication and exchange of information, transnational access and pharmacovigilance of medicinal products. Traditional vaccines such as inactivated or live-attenuated vaccines have not been assigned INN and provision of a general name falls within the scope of the WHO Expert Committee on Biological Standardization (ECBS). However, novel vaccines that contain welldefined active ingredients such as nucleic acids or recombinant proteins fulfil the criteria to be assigned INN. In the current environment where multiple SARS-CoV-2 vaccines are being developed to combat the COVID-19 pandemic and with virus variants emerging, assigning INN to well-defined vaccine substances will strengthen pharmacovigilance and ultimately enhance the safety of vaccine recipients. This article examines the background to INN for vaccines and explains the applicability and value of assigning INN to novel well-defined vaccines. CO 2021 World Health Organization. Published by Elsevier Ltd.	[Loizides, Ursula; Balocco, Raffaella] WHO, INN HPS MHP, INN Programme & Classificat Med Prod, CH-1211 Geneva, Switzerland; [Adisa, Akinola] Dept Hlth, Therapeut Goods Adm, Woden, ACT 2606, Australia; [de la Rica Manjavacas, Ana Lopez] Agencia Espanola Medicamentos & Prod Sanitarios, Madrid 28022, Spain; [Rodilla, Vicente] Univ CEU Cardenal Herrera, Valencia 46113, Spain; [Strnadova, Colette] Hlth Prod & Food Branch, Hlth Canada, Ottawa, ON K1A 0K9, Canada; [Weisser, Karin] Paul Ehrlich Inst, Div Safety Med Prod & Med Devices, Fed Inst Vaccines & Biomed, Paul Ehrlich Str 7, D-63225 Langen, Germany		Balocco, R (通讯作者)，WHO, Int Nonproprietary Names Programme INN, INN HPS MHP, Geneva, Switzerland.; Balocco, R (通讯作者)，WHO, Classificat Med Prod, INN HPS MHP, Geneva, Switzerland.	baloccor@who.int					Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; [Anonymous], 2020, WHO DRUG INF, V34, P641; [Anonymous], 2019, INT NONPROPRIETARY N; [Anonymous], Vaccine Knowledge Project-Types of vaccine; [Anonymous], 2021, WHO DRUG INF, V35, P578; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Cheng LQ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030391; Clark TG, 2005, DEV BIOLOGICALS, V121, P153; COCKBURN WC, 1992, BIOLOGICALS, V20, P1; Cox MMJ, 2009, BIOLOGICALS, V37, P182, DOI 10.1016/j.biologicals.2009.02.014; Cutts FT, 2007, B WORLD HEALTH ORGAN, V85, P719, DOI 10.2471/BLT.06.038414; Einstein MH, 2007, GYNECOL ONCOL, V106, P453, DOI 10.1016/j.ygyno.2007.04.038; Fomsgaard A, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020258; HILLEMAN MR, 1987, INFECTION, V15, P3, DOI 10.1007/BF01646107; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Loizides U, 2021, LANCET, V397, P577, DOI 10.1016/S0140-6736(21)00099-4; McShane H, 2002, CURR OPIN MOL THER, V4, P23; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Parmiani G, 2014, HUM VACC IMMUNOTHER, V10, P3175, DOI 10.4161/hv.29418; Przedpelski A, 2020, MBIO, V11, DOI 10.1128/mBio.01668-20; Rappuoli R, 2019, P NATL ACAD SCI USA, V116, P14, DOI 10.1073/pnas.1819612116; Robertson JS, 2019, BIOLOGICALS, V60, P15, DOI 10.1016/j.biologicals.2019.05.006; Shah RR, 2017, METHODS MOL BIOL, V1494, P1, DOI 10.1007/978-1-4939-6445-1_1; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Vander Stichele RH, 2021, VACCINE, V39, P176, DOI 10.1016/j.vaccine.2020.11.055; Young LS, 2006, J PATHOL, V208, P299, DOI 10.1002/path.1896	27	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					21	27		10.1016/j.vaccine.2021.11.054		DEC 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FV	34844820	Green Submitted, Green Published, hybrid			2022-04-29	WOS:000731299800007
J	Hasso-Agopsowicz, M; Lopman, BA; Lanata, CF; McQuade, ETR; Kang, G; Prudden, HJ; Khalil, I; Platts-Mills, JA; Kotloff, K; Jit, M; Riddle, MS; Pavlinac, PB; Luz, PM; Pitzer, VE; Breiman, RF; Giersing, BK				Hasso-Agopsowicz, Mateusz; Lopman, Benjamin A.; Lanata, Claudio F.; McQuade, Elizabeth T. Rogawski; Kang, Gagandeep; Prudden, Holly J.; Khalil, Ibrahim; Platts-Mills, James A.; Kotloff, Karen; Jit, Mark; Riddle, Mark S.; Pavlinac, Patricia B.; Luz, Paula M.; Pitzer, Virginia E.; Breiman, Robert F.; Giersing, Birgitte K.			World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens	VACCINE			English	Article						Enteric infections; Vaccine; Morbidity; ETEC; Shigella; Norovirus; Campylobacter	CHILDREN YOUNGER; DIARRHEA; INFECTION; MORTALITY	Background: Diarrhoeal infections are one of the leading causes of child's mortality and morbidity. Vaccines against Shigella, enterotoxigenic E. coli (ETEC), norovirus and invasive non-typhoidal Salmonella are in clinical development, however, their full value in terms of short and long-term health and socio-economic burden needs to be evaluated and communicated, to rationalise investment in vac-cine development, and deployment. While estimates of mortality of enteric infections exist, the long-term morbidity estimates are scarce and have not been systematically collected. Methods: The World Health Organization (WHO) has convened a Burden of Enteric Diseases Morbidity Working Group (BoED MWG) who identified key workstreams needed to characterise the morbidity bur -den of enteric infections. The group also identified four criteria for the prioritisation of pathogens of which impact on long-term morbidity needs to be assessed. Results: The BoED MWG suggested to identify and analyse the individual level data from historical data-sets to estimate the impact of enteric infections and confounders on long-term morbidity, including growth faltering and cognitive impairment in children (workstream 1); to conduct a systematic review of evidence on the association of aetiology specific diarrhoea with short-and long-term impact on growth, including stunting, and possibly cognitive impairment in children, while accounting for potential confounders (workstream 2); and to conduct a systematic review of evidence on the association of aeti-ology specific diarrhoea with short-and long-term impact on health outcomes in adults. The experts pri-oritised four pathogens for this work: Campylobacter jejuni, ETEC (LT or ST), norovirus (G1 or G2), and Shigella (dysenteriae, flexneri, sonnei). Conclusions: The proposed work will contribute to improving the understanding of the impact of enteric pathogens on long-term morbidity. The timing of this work is critical as all four pathogens have vaccine candidates in the clinical pipeline and decisions about investments in development, manufacturing or vaccine procurement and use are expected to be made soon. Published by Elsevier Ltd.	[Hasso-Agopsowicz, Mateusz; Giersing, Birgitte K.] WHO, Geneva, Switzerland; [Lopman, Benjamin A.; McQuade, Elizabeth T. Rogawski; Breiman, Robert F.] Emory Univ, Atlanta, GA 30322 USA; [Lanata, Claudio F.] Nutr Res Inst, Lima, Peru; [Kang, Gagandeep] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; [Khalil, Ibrahim; Pavlinac, Patricia B.] Univ Washington, Seattle, WA 98195 USA; [Platts-Mills, James A.] Univ Virginia, Charlottesville, VA USA; [Kotloff, Karen] Univ Maryland, College Pk, MD 20742 USA; [Jit, Mark] London Sch Hyg & Trop Med, London, England; [Riddle, Mark S.] Univ Nevada, Reno, NV 89557 USA; [Luz, Paula M.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil; [Pitzer, Virginia E.] Yale Univ, New Haven, CT 06520 USA		Hasso-Agopsowicz, M (通讯作者)，WHO, Immunizat Vaccines & Biol, Geneva, Switzerland.	hassoagopsowiczm@who.int		Hasso-Agopsowicz, Mateusz/0000-0003-4137-4685			Butkeviciute E, 2021, VACCINE, V39, P4391, DOI 10.1016/j.vaccine.2021.05.086; Davids BJ, 2019, INFECT IMMUN, V87, DOI [10.1128/IAI.00219-19, 10.1128/iai.00219-19]; Donnenberg MS, 2013, TRENDS MICROBIOL, V21, P317, DOI 10.1016/j.tim.2013.05.003; Guerrant RL, 2013, NAT REV GASTRO HEPAT, V10, P220, DOI 10.1038/nrgastro.2012.239; Hutubessy RCW, 2021, FULL VALUE VACCINE A; IHME, 2020, GLOBAL BURDEN DIS; Jenikova G, 2011, VACCINE, V29, P9529, DOI 10.1016/j.vaccine.2011.09.126; Khalil I, 2021, VACCINE, V39, P4266, DOI 10.1016/j.vaccine.2021.04.018; Khalil IA, 2018, LANCET GLOB HEALTH, V6, pE758, DOI 10.1016/S2214-109X(18)30283-3; Lamberti LM, 2016, PEDIATR INFECT DIS J, V35, P992, DOI 10.1097/INF.0000000000001232; Lee P, 2011, VACCINATION GIARDIA, P333, DOI [10.1007/978-3-7091-0198-8_21, DOI 10.1007/978-3-7091-0198-8_21]; Mead JR, 2010, FUTURE MICROBIOL, V5, P335, DOI 10.2217/FMB.09.115; Acosta AM, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000370; Platts-Mills JA, 2017, AM J CLIN NUTR, V105, P1132, DOI 10.3945/ajcn.116.138800; Rogawski ET, 2018, LANCET GLOB HEALTH, V6, pE1319, DOI [10.1016/s2214-109x(18)30351-6, 10.1016/S2214-109X(18)30351-6]; Rojas-Lopez M, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00440; Schnee AE, 2018, AM J EPIDEMIOL, V187, P2210, DOI 10.1093/aje/kwy106; Troeger C, 2018, LANCET GLOB HEALTH, V6, pE255, DOI 10.1016/S2214-109X(18)30045-7; World Health Organization (WHO), 2021, WHO PREF PROD CHAR V; World Health Organization (WHO), 2020, WHO PREF PROD CHAR V	20	1	1	5	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 20	2021	39	52					7521	7525		10.1016/j.vaccine.2021.11.033		DEC 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1EI	34838322	hybrid, Green Accepted			2022-04-29	WOS:000731295900001
J	Wu, K; Choi, A; Koch, M; Elbashir, S; Ma, LZ; Lee, D; Woods, A; Henry, C; Palandjian, C; Hill, A; Jani, H; Quinones, J; Nunna, N; O'Connell, S; McDermott, AB; Falcone, S; Narayanan, E; Colpitts, T; Bennett, H; Corbett, KS; Seder, R; Graham, BS; Stewart-Jones, GBE; Carfi, A; Edwards, DK				Wu, Kai; Choi, Angela; Koch, Matthew; Elbashir, Sayda; Ma, LingZhi; Lee, Diana; Woods, Angela; Henry, Carole; Palandjian, Charis; Hill, Anna; Jani, Hardik; Quinones, Julian; Nunna, Naveen; O'Connell, Sarah; McDermott, Adrian B.; Falcone, Samantha; Narayanan, Elisabeth; Colpitts, Tonya; Bennett, Hamilton; Corbett, Kizzmekia S.; Seder, Robert; Graham, Barney S.; Stewart-Jones, Guillaume B. E.; Carfi, Andrea; Edwards, Darin K.			Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice	VACCINE			English	Article						COVID-19; SARS-CoV-2 variants of concern; mRNA-1273; Primary series; Booster dose; Neutralization	IMMUNOGENICITY; INFLUENZA; SPIKE	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased susceptibility to neutralization by vaccine-induced immunity, most notably B.1.351 (Beta), although the overall impact on vaccine efficacy remains to be determined. Here, we present the initial evaluation in mice of 2 updated mRNA vaccines designed to target SARS-CoV-2 variants: (1) monovalent mRNA-1273.351 encodes for the spike protein found in B.1.351 and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice; mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with mRNA-1273. The results demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against B.1.351, while mRNA-1273.211 was effective at providing broad cross-variant neutralization. A third (booster) dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. Both mRNA-1273.351 and mRNA-1273.211 are being evaluated in pre-clinical challenge and clinical studies. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Wu, Kai; Choi, Angela; Koch, Matthew; Elbashir, Sayda; Ma, LingZhi; Lee, Diana; Woods, Angela; Henry, Carole; Palandjian, Charis; Hill, Anna; Jani, Hardik; Quinones, Julian; Nunna, Naveen; Falcone, Samantha; Narayanan, Elisabeth; Colpitts, Tonya; Bennett, Hamilton; Stewart-Jones, Guillaume B. E.; Carfi, Andrea; Edwards, Darin K.] Moderna Inc, 200 Technol Sq, Cambridge, MA 02139 USA; [O'Connell, Sarah; McDermott, Adrian B.; Corbett, Kizzmekia S.; Seder, Robert; Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, 10 Ctr Dr, Bethesda, MD 20814 USA		Edwards, DK (通讯作者)，Moderna Inc, 200 Technol Sq, Cambridge, MA 02139 USA.	kai.wu@modernatx.com; darin.edwards@modernatx.com	Jani, Hardik/AFJ-5680-2022	McDermott, Adrian/0000-0003-0616-9117	Moderna, Inc.	This research was funded by Moderna, Inc.	Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Choi A, 2021, NAT MED, V27, P2025, DOI 10.1038/s41591-021-01527-y; Choi A, 2021, J VIROL, V95, DOI 10.1128/JVI.01313-21; Corbett KS, 2021, NAT IMMUNOL, V22, P1306, DOI 10.1038/s41590-021-01021-0; Deng XD, 2021, CELL, V184, P3426, DOI 10.1016/j.cell.2021.04.025; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; FDA, 2021, COVID 19 VACC; Francica JR, 2017, BLOOD ADV, V1, P2329, DOI 10.1182/bloodadvances.2017011411; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Greaney AJ, 2021, CELL HOST MICROBE, V29, P463, DOI 10.1016/j.chom.2021.02.003; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; John S, 2018, VACCINE, V36, P1689, DOI 10.1016/j.vaccine.2018.01.029; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kustin T, 2021, NAT MED, V27, P1379, DOI 10.1038/s41591-021-01413-7; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI 10.1038/s41564-020-0688-y; McCallum M, 2021, CELL, V184, P2332, DOI [10.1016/j.cell.2021.03.028, 10.1101/2021.01.14.426475]; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; Tada T, 2021, MBIO, V12, DOI 10.1128/mBio.00696-21; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Volz E, 2021, CELL, V184, P64, DOI 10.1016/j.cell.2020.11.020; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1126/science.abb2507, 10.1101/2020.02.11.944462]; Wu K, 2021, NEW ENGL J MED, V384, P1468, DOI 10.1056/NEJMc2102179; Yurkovetskiy L, 2020, CELL, V183, P739, DOI 10.1016/j.cell.2020.09.032; Zhou H, 2021, MBIO, V12, DOI [10.1128/mBio.01386-21, 10.1101/2021.03.24.436620]; Zhou P, 2020, NATURE, V588, pE6, DOI [10.1038/s41586-020-2012-7, 10.1038/s41586-020-2951-z]	44	29	29	5	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7394	7400		10.1016/j.vaccine.2021.11.001		DEC 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	33880468	hybrid, Green Submitted, Green Published			2022-04-29	WOS:000731300100008
J	Hecht, J; Suliman, S; Wegiel, B				Hecht, Jonathan; Suliman, Sara; Wegiel, Barbara			Bacillus Calmette-Guerin (BCG) vaccination to treat endometriosis	VACCINE			English	Article						BCG; Endometriosis; Immune niche	MIGRATION-INHIBITORY FACTOR; NATURAL-KILLER-CELLS; HORMONE AGONIST; DISEASE STAGE; MACROPHAGE; PERITONEAL; GROWTH; ACTIVATION; EXPRESSION; ADHESION	Bacille Calmette-Guerin (BCG), a vaccine intended to protect against tuberculosis disease, can elicit protection against heterologous infections, and even specific types of cancer. In this mini-review, we will address the possible use of BCG as a therapeutic for endometriosis, a syndrome of chronic pelvic pain due to ectopic growth of endometrial-type tissue outside of the uterine lining. These implanted tissues cycle synchronously with menses in pre-menopausal women, generating cellular debris inciting chronic inflammation and tissue scarring leading to pelvic pain and infertility. Further, these lesions may evolve into ovarian clear cell carcinoma. We hypothesize that implantation, survival and transformation of these implants is enabled by a form of immune suppression within the peritoneum, which may be overcome by BCG vaccination. (c) 2021 Elsevier Ltd. All rights reserved.	[Hecht, Jonathan] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02214 USA; [Suliman, Sara] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, Boston, MA 02115 USA; [Wegiel, Barbara] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, Div Surg Oncol, Boston, MA 02214 USA		Hecht, J (通讯作者)，Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02214 USA.; Wegiel, B (通讯作者)，Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, Div Surg Oncol, Boston, MA 02214 USA.	jhecht@bidmc.harvard.edu; bwegiel@bidmc.harvard.edu					Akoum A, 2006, FERTIL STERIL, V85, P1379, DOI 10.1016/j.fertnstert.2005.10.073; [Anonymous], 1992, World Health Organ Tech Rep Ser, V820, P1; Antsiferova YS, 2005, FERTIL STERIL, V84, P1705, DOI 10.1016/j.fertnstert.2005.05.066; Barbieri RL, 1997, AM J MANAG C, V3, P285; Barcz E, 2012, FERTIL STERIL, V97, P1380, DOI 10.1016/j.fertnstert.2012.03.057; BAST RC, 1974, NEW ENGL J MED, V290, P1458, DOI 10.1056/NEJM197406272902605; Blok BA, 2020, CLIN INFECT DIS, V70, P455, DOI 10.1093/cid/ciz246; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Brandau S, 2001, EUR UROL, V39, P518, DOI 10.1159/000052497; Canesin G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00066; Capobianco A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00009; Choi HJ, 2017, BMB REP, V50, P429, DOI 10.5483/BMBRep.2017.50.8.097; Christ AP, 2010, AM J RESP CELL MOL, V43, P243, DOI 10.1165/rcmb.2009-0040OC; Dou QC, 1997, MOL HUM REPROD, V3, P383, DOI 10.1093/molehr/3.5.383; Duan J, 2018, REPROD BIOMED ONLINE, V37, P254, DOI 10.1016/j.rbmo.2018.05.017; Falconer H, 2006, HUM REPROD, V21, P1856, DOI 10.1093/humrep/del044; Faustman DL, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.2941; Fazleabas AT, 2015, CONTRACEPTION, V92, P116, DOI 10.1016/j.contraception.2015.06.006; Giamarellos-Bourboulis EJ, 2020, CELL, V183, P315, DOI 10.1016/j.cell.2020.08.051; Glitz C, 2009, BRAZ J MED BIOL RES, V42, P1039, DOI 10.1590/S0100-879X2009001100007; Gul A, 2001, EUR J OBSTET GYN R B, V98, P209, DOI 10.1016/S0301-2115(01)00307-4; Hirsch M, 2016, AM J OBSTET GYNECOL, V214, P452, DOI 10.1016/j.ajog.2015.12.039; Hudson QJ, 2020, REPROD SCI, V27, P1920, DOI 10.1007/s43032-020-00211-9; Itil IM, 2006, AUST NZ J OBSTET GYN, V46, P38, DOI 10.1111/j.1479-828X.2006.00512.x; Itoh H, 2011, CYTOTECHNOLOGY, V63, P133, DOI 10.1007/s10616-010-9321-x; Izumi G, 2018, J OBSTET GYNAECOL RE, V44, P191, DOI 10.1111/jog.13559; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Klein BY, 2020, VACCINE, V38, P6427, DOI 10.1016/j.vaccine.2020.07.066; Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Lalor MK, 2010, VACCINE, V28, P1635, DOI 10.1016/j.vaccine.2009.11.004; Lardone RD, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00965; Lin W, 2010, J OBSTET GYNAECOL RE, V36, P344, DOI 10.1111/j.1447-0756.2009.01123.x; Liu QH, 2015, MOL CELLS, V38, P886, DOI 10.14348/molcells.2015.0125; Mahdian S, 2015, FERTIL STERIL, V103, P153, DOI 10.1016/j.fertnstert.2014.09.031; Matalliotakis M, 2018, INT J MOL MED, V41, P1469, DOI 10.3892/ijmm.2018.3368; Monsanto SP, 2016, FERTIL STERIL, V105, P968, DOI 10.1016/j.fertnstert.2015.11.047; Montenegro ML, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0105-0; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Muzii L, 2019, MINERVA GINECOL, V71, P54, DOI 10.23736/S0026-4784.18.04320-4; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Patel BG, 2018, BEST PRACT RES CL OB, V50, P50, DOI 10.1016/j.bpobgyn.2018.01.006; Podgaec S, 2007, HUM REPROD, V22, P1373, DOI 10.1093/humrep/del516; Prentice S, 2021, LANCET INFECT DIS, V21, P993, DOI 10.1016/S1473-3099(20)30653-8; Rakhila H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110434; Ristori G, 1999, NEUROLOGY, V53, P1588, DOI 10.1212/WNL.53.7.1588; SALVIN SB, 1973, INFECT IMMUN, V7, P68, DOI 10.1128/IAI.7.1.68-75.1973; Suliman S, 2016, J IMMUNOL, V197, P1100, DOI 10.4049/jimmunol.1501996; Takaesu Y, 2016, J OBSTET GYNAECOL RE, V42, P1152, DOI 10.1111/jog.13023; Thiruchelvam U, 2015, AM J REPROD IMMUNOL, V74, P291, DOI 10.1111/aji.12408; Van Ginderachter JA, 2006, IMMUNOBIOLOGY, V211, P487, DOI 10.1016/j.imbio.2006.06.002; van Puffelen JH, 2020, NAT REV UROL, V17, P513, DOI 10.1038/s41585-020-0346-4; Wang Y, 2014, INT J CLIN EXP PATHO, V7, P194; Wu MH, 2010, EXP BIOL MED, V235, P668, DOI 10.1258/ebm.2010.009321; Yang HL, 2017, REPRODUCTION, V154, P815, DOI 10.1530/REP-17-0342; Yao YS, 2018, CELL, V175, P1634, DOI 10.1016/j.cell.2018.09.042; Zhang Q, 2016, MOL CELL ENDOCRINOL, V428, P1, DOI 10.1016/j.mce.2016.03.015	58	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 8	2021	39	50					7353	7356		10.1016/j.vaccine.2021.07.020		DEC 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK8NB	34301432				2022-04-29	WOS:000727714000016
J	Pepin, J; Labbe, AC; Carignan, A; Parent, ME; Yu, J; Grenier, C; Beauchemin, S; De Wals, P; Valiquette, L; Rousseau, MC				Pepin, Jacques; Labbe, Annie-Claude; Carignan, Alex; Parent, Marie-Elise; Yu, Jennifer; Grenier, Cynthia; Beauchemin, Stephanie; De Wals, Philippe; Valiquette, Louis; Rousseau, Marie-Claude			Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada	VACCINE			English	Article						BCG; SARS-CoV-2; COVID-19; Vaccine effectiveness	CALMETTE-GUERIN VACCINATION; DURATION; PATTERNS	Background: Early in the coronavirus disease 2019 (COVID-19) pandemic, before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines became available, it was hypothesized that BCG (Bacillus Calmette-Guerin), which stimulates innate immunity, could provide protection against SARS-CoV-2. Numerous ecological studies, plagued by methodological deficiencies, revealed a country-level association between BCG use and lower COVID-19 incidence and mortality. We aimed to determine whether BCG administered in early life decreased the risk of SARS-CoV-2 infection in adulthood and the severity of COVID-19. Methods: This case-control study was conducted in Quebec, Canada. Cases were patients with a positive SARS-CoV-2 nucleic acid amplification test performed at two hospitals between March-October 2020. Controls were identified among patients with non-COVID-19 samples processed by the same microbiology laboratories during the same period. Enrolment was limited to individuals born in Quebec between 1956 and 1976, whose vaccine status was accessible in a computerized registry of 4.2 million BCG vaccinations. Results: We recruited 920 cases and 2123 controls. Fifty-four percent of cases (n = 424) and 53% of controls (n = 1127) had received BCG during childhood (OR: 1.03; 95% CI: 0.89-1.21), while 12% of cases (n = 114) and 11% of controls (n = 235) had received two or more BCG doses (OR: 1.14; 95% CI: 0.88- 1.46). After adjusting for age, sex, material deprivation, recruiting hospital and occupation there was no evidence of protection conferred by BCG against SARS-CoV-2 (AOR: 1.01; 95% CI: 0.84-1.21). Among cases, 77 (8.4%) needed hospitalization and 18 (2.0%) died. The vaccinated were as likely as the unvaccinated to require hospitalization (AOR: 1.01, 95% CI: 0.62-1.67) or to die (AOR: 0.85, 95% CI: 0.32-2.39). Conclusions: BCG does not provide long-term protection against symptomatic COVID-19 or severe forms of the disease. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Pepin, Jacques; Carignan, Alex; Grenier, Cynthia; Valiquette, Louis] Univ Sherbrooke, Dept Microbiol & Infect Dis, 3001,12ieme Ave Nord, Sherbrooke, PQ J1H 5N4, Canada; [Labbe, Annie-Claude; Beauchemin, Stephanie] Hop Maison Neuve Rosemont, CIUSSS Est de Ile de Montreal, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada; [Labbe, Annie-Claude] Univ Montreal, Dept Microbiol Infect Dis & Immunol, Pavillon Roger Gaudry,2900 Blvd Edouard Montpetit, Montreal, PQ H3T 1J4, Canada; [Parent, Marie-Elise; Yu, Jennifer; Rousseau, Marie-Claude] Inst Natl Rech Sci, Ctr Armand Frappier Sante Biotechnol, 531 Boul Prairies, Laval, PQ H7V 1B7, Canada; [De Wals, Philippe] Univ Laval, Dept Social & Prevent Med, 2725 Ch St Foy, Quebec City, PQ G1V 4G5, Canada		Rousseau, MC (通讯作者)，Inst Natl Rech Sci, Ctr Armand Frappier Sante Biotechnol, 531 Boul Prairies, Laval, PQ H7V 1B7, Canada.	marie-claude.rousseau@inrs.ca		Valiquette, Louis/0000-0002-8300-8416; Labbe, Annie-Claude/0000-0001-8936-3307; Beauchemin, Stephanie/0000-0002-3524-1774; Yu, Jennifer/0000-0002-6024-1282	Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke through Fondation du Centre Hospitalier Universitaire de Sherbrooke; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Quebec Ministry of Education, Leisure and Sports [12532]	This work was supported by the Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke through a special COVID19 emergency funding provided by the Fondation du Centre Hospitalier Universitaire de Sherbrooke. Funding for computerization of the BCG vaccination registry was provided by a grant from the Canada Foundation for Innovation and the Quebec Ministry of Education, Leisure and Sports [grant number 12532, to M.C.R.]. The funder had no role in study design, in collection, analysis and interpretation of data, in the writing of the report nor in the decision to submit.	Abdallah Abdallah M, 2017, Adv Exp Med Biol, V1019, P155, DOI 10.1007/978-3-319-64371-7_8; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Abubakar I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17370; Andrejko KL, 2021, CLIN INFECT DIS, DOI 10.1093/cid/ciab640; [Anonymous], 2018, R LANGUAGE ENV STAT; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Berg MK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1463; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Boger B, 2021, AM J INFECT CONTROL, V49, P21, DOI 10.1016/j.ajic.2020.07.011; Butt AA, ANN INTERN MED; Calmette A., 1933, ANN I PASTEUR PARIS, V50, P433; Carignan A, 2020, CAN MED ASSOC J, V192, pE702, DOI 10.1503/cmaj.200869; de Chaisemartin C, 2021, CLIN INFECT DIS, V72, pE501, DOI 10.1093/cid/ciaa1223; De Serres G, 2013, Euro Surveill, V18; De Serres G, 2021, ENQUETE EPIDEMIOLOGI; De Wals P, 2020, CAN J PUBLIC HEALTH, V111, P939, DOI 10.17269/s41997-020-00439-7; Dolgikh S, 2020, FURTHER EVIDENCE POS, DOI [10.1101/2020.04.07.20056994v2, DOI 10.1101/2020.04.07.20056994V2]; Enamorado T, 2019, AM POLIT SCI REV, V113, P353, DOI 10.1017/S0003055418000783; Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117; Frappier A, 1992, REVE LUTTE ONE DREAM; George B, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa399; Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189; Institut National de Sante Publique du Quebec, IND DEF MAT SOC; Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053; de Castro MJ, 2015, CLIN INFECT DIS, V60, P1611, DOI 10.1093/cid/civ144; Joy M, 2021, CLIN EPIDEMIOL GLOB, V9, P202, DOI 10.1016/j.cegh.2020.08.015; Kane PB, 2020, J GEN INTERN MED, V35, P3753, DOI 10.1007/s11606-020-06244-9; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Kissling E, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.29.2100670; Levi M, 2021, J INFECTION, V82, pE41, DOI 10.1016/j.jinf.2020.11.022; Malik YS, 2020, HUM VACC IMMUNOTHER, V16, P2954, DOI 10.1080/21645515.2020.1818522; Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020; Mostafa HH, 2020, J CLIN VIROL, V130, DOI 10.1016/j.jcv.2020.104578; Muthumbi E, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0041-2; Naeslund C.., VACCINATION PREVENTI; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Nguipdop-Djomo P, 2016, LANCET INFECT DIS, V16, P219, DOI 10.1016/S1473-3099(15)00400-4; Piche V, 2003, DEMOGRAPHIE QUEBECOI, P225; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ponte C, 2018, HUM VACC IMMUNOTHER, V14, P28, DOI 10.1080/21645515.2017.1382788; Rieckmann A, 2017, INT J EPIDEMIOL, V46, P695, DOI 10.1093/ije/dyw120; Rivas MN, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145157; Roth A, 2006, EXPERT REV VACCINES, V5, P277, DOI 10.1586/14760584.5.2.277; Rousseau MC, 2017, VACCINE, V35, P4777, DOI 10.1016/j.vaccine.2017.06.064; Rousseau MC, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-2; Skowronski DM, 2022, CLIN INFECT DIS, V74, P1158, DOI 10.1093/cid/ciab616; Sohrabi Y, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1228; Urashima M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155589; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Woloshin S, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2015897; World Health Organization, REP BCG VACC US PROT; Yamazaki-Nakashimada MA, 2020, HUM VACC IMMUNOTHER, V16, P1841, DOI 10.1080/21645515.2019.1706930; Zimmermann P, 2018, EXPERT REV VACCINES, V17, P547, DOI 10.1080/14760584.2018.1483727	54	5	5	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 8	2021	39	50					7300	7307		10.1016/j.vaccine.2021.08.019		DEC 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK8NB	34493410	Green Published, hybrid			2022-04-29	WOS:000727714000010
J	Mvundura, M; Frivold, C; Osborne, AJ; Soni, P; Robertson, J; Kumar, S; Anena, J; Gueye, A; Menozzi-Arnaud, M; Giersing, B; Kahn, AL; Scarna, T; Kristensen, D				Mvundura, Mercy; Frivold, Collrane; Osborne, Anna Janik; Soni, Priyanka; Robertson, Joanie; Kumar, Sandeep; Anena, Jacqueline; Gueye, Abdoulaye; Menozzi-Arnaud, Marion; Giersing, Birgitte; Kahn, Anna-Lea; Scarna, Tiziana; Kristensen, Debra			Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations	VACCINE			English	Article						Vaccine product innovation; Immunization; Vaccine; Low-and middle-income countries; Prioritization; Delivery technologies; Product development; Coverage and equity	DELIVERY	As part of the Vaccine Innovation Prioritisation Strategy (VIPS), three immunization-stakeholder consultations were conducted between September 2018 and February 2020 to ensure that countries' needs drove the prioritization of vaccine product innovations. All consultations targeted respondents with immunization program experience. They included: (1) an online survey to identify immunization implementation barriers and desired vaccine attributes in three use settings, (2) an online survey to identify and evaluate the most important immunization challenges for ten exemplar vaccines, and (3) in-depth interviews to better understand the perceived programmatic benefits and challenges that could be addressed by nine innovations and to rank the innovations that could best address current challenges. The first consultation included responses from 442 participants in 61 countries, representing 89% of the 496 respondents who correctly completed at least one section of the online survey. For facility-based settings, missed opportunities for vaccination due to reluctance to open multidose vaccine vials was the barrier most frequently selected by respondents. In community-based (outreach) and campaign settings, limited access to immunization services due to geographic barriers was most frequently selected. Multidose presentations with preservative or single-dose presentations were most frequently selected as desired vaccine attributes for facility-based settings while improved thermostability was most frequently selected for outreach and campaign settings. The second online survey was completed by 220 respondents in 54 countries. For the exemplar vaccines, vaccine ineffectiveness or wastage due to heat or freeze exposure and missed opportunities due to multidose vial presentations were identified as the greatest vaccine-specific challenges. In-depth interviews with 84 respondents in six countries ranked microarray patches, dual-chamber delivery devices, and heat-stable/controlled temperature chain qualified liquid vaccines as the three innovations that could have the greatest impact in helping address current immunization program challenges. These findings informed the VIPS prioritization and provided broader application to designing immunization interventions to better meet country needs. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Mvundura, Mercy; Frivold, Collrane; Robertson, Joanie; Kristensen, Debra] PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA; [Osborne, Anna Janik; Soni, Priyanka; Menozzi-Arnaud, Marion; Scarna, Tiziana] Vaccine Alliance, Gavi, Global Hlth Campus,Chemin Pommier 40, CH-1218 Geneva, Switzerland; [Kumar, Sandeep] PATH, 15th Floor,Dr Gopal Das Bhawan,28 Barakhamba Rd,C, New Delhi 110001, India; [Anena, Jacqueline] PATH, POB 7404, Kampala, Uganda; [Gueye, Abdoulaye] PATH, Fann Residence, Rue St John Perse Angle F, Dakar, Senegal; [Giersing, Birgitte; Kahn, Anna-Lea] WHO, Vaccine Prod & Delivery Res Immunisat Vaccines &, CH-1211 Geneva 27, Switzerland		Mvundura, M (通讯作者)，PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.	mmvundura@path.org; cfrivold@path.org; aosborne@gavi.org; jrobertson@path.org; sdkumar@path.org; janena@path.org; agueye@path.org; mmenozziarnaud@gavi.org; giersingb@who.int; kahna@who.int; tscarna@gavi.org; dkristensen@path.org		Mvundura, Mercy/0000-0002-7711-9558			Gavi the Vaccine Alliance., SUPPL PROC STRAT 201; Gavi the Vaccine Alliance., VACC INN PRIOR STRAT; Giersing B., STRATEGIES VAC UNPUB; Giersing BK, 2017, VACCINE, V35, P6793, DOI 10.1016/j.vaccine.2017.04.063; Kristensen D., GLOBAL COLLABO UNPUB; Kristensen DD, 2016, VACCINE, V34, P6236, DOI 10.1016/j.vaccine.2016.10.057; MacDonald N, 2020, VACCINE, V38, P5364, DOI 10.1016/j.vaccine.2020.05.003; Papania M.J., 2018, PLOTKINS VACCINES, pe17, DOI DOI 10.1016/B978-0-323-35761-6.00068-7; Vaccine Innovation Prioritisation Strategy (VIPS), 2020, VIPS PRIOR PROC METH; World Health Organization, 2020, PROGR CHALL ACH UN I; Zehrung D, 2017, VACCINE, V35, P2265, DOI 10.1016/j.vaccine.2016.11.095	11	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 3	2021	39	49					7195	7207		10.1016/j.vaccine.2021.08.024		NOV 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ2JG	34412922	hybrid, Green Published			2022-04-29	WOS:000726620400015
J	Srivastava, V; Ratna, M; Ray, A; Shukla, S; Shrivastava, V; Kothari, N; Gupta, A; Kukreja, M; Jandu, HS				Srivastava, Varun; Ratna, Manish; Ray, Arindam; Shukla, Santosh; Shrivastava, Vipin; Kothari, Nitin; Gupta, Amandeep; Kukreja, Meenal; Jandu, Harkabir Singh			Strengthening the immunization supply chain: A time-to-supply based approach to cold chain network optimization & extension in Madhya Pradesh	VACCINE			English	Article						Vaccine supply chain optimization; Cold chain network extension; Immunization supply chain strengthening; Health facility location allocation; Time-to-supply	VACCINE; TEMPERATURES; MODELS; SYSTEM	Expansion of immunization coverage is dependent in part on delivering potent vaccines in an equitable and timely manner to immunization outreach session sites from Cold Chain Points (CCPs). When duration of travel between the last CCP and the session site (Time-to-Supply) is too long, three consequences may arise: decreased potency due to exposure to heat and freezing, beneficiary dropouts due to delayed ses-sion starts, and, increased operational costs for the Health Facility (HF) conducting the outreach sessions. Guided by the Government of India's recommendation on cold chain point expansion to ensure that all session sites are within a maximum of 60 min from the last CCP, CHAI and the State Routine Immunization Cell in the state of Madhya Pradesh collaborated to pilot a novel approach to cold chain network optimization and expansion in eight districts of Madhya Pradesh. Opportunities for realignment of remote sub-health centers (SHCs) and corresponding session sites to alternative existing CCPs or to HFs which could be converted to new CCPs were identified, and proposed using a greedy adding algorithm-based optimization which relied on health facility level geo-location data. Health facility geo-coordinates were collected through tele-calling and site visits, and a Microsoft Excel based optimization tool was developed. This exercise led to an estimated reduction in the number of remote SHCs falling beyond the permis-sible travel time from CCPs by 56.89 percent (132 remote sites), from 232 to 100. The 132 resolved sites include 73 sites realigned to existing CCPs, and 59 sites to be attached to 22 newly proposed CCPs. Both the network optimization approach and the institutional capacity built during this project will continue to be useful to India's immunization program. The approach is replicable and may be leveraged by devel-oping countries facing similar challenges due to geographical, institutional, and financial constraints. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Srivastava, Varun; Ratna, Manish; Kothari, Nitin; Gupta, Amandeep; Kukreja, Meenal; Jandu, Harkabir Singh] Clinton Hlth Access Initiat, 40,Okhla Phase 3, Delhi 110020, India; [Ray, Arindam] Bill & Melinda Gates Fdn, 5th Floor,Olof Palme Marg, New Delhi 110067, India; [Shukla, Santosh; Shrivastava, Vipin] Govt Madhya Pradesh, Directorate Hlth Serv, Link Rd 3, Bhopal 462003, India		Srivastava, V (通讯作者)，Clinton Hlth Access Initiat, 40,Okhla Phase 3, Delhi 110020, India.	vsrivastava@clintonhealthaccess.org; mratna@clintonhealthaccess.org; arindam.ray@gatesfoundation.org; shukla.1956@mp.gov.in; vipincoldchain@yahoo.com; nkothari@clintonhealthaccess.org; amandeep.gupta@clintonhealthaccess.org; mkukreja@clintonhealthaccess.org; hjandu@clintonhealthaccess.org	Ray, Arindam/AAN-1525-2020	Ray, Arindam/0000-0002-5955-0352; Srivastava, Varun/0000-0001-5648-4030; Ratna, Manish/0000-0003-0486-3201	Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPPID: INV-010007]	We would like to thank the Government of India and the Government of Madhya Pradesh for their continued support through the entire research. This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation [OPPID: INV-010007] . Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.	Ahmadi-Javid A, 2017, COMPUT OPER RES, V79, P223, DOI 10.1016/j.cor.2016.05.018; Amarilies Harummi Sekar, 2020, IOP Conference Series: Materials Science and Engineering, V847, DOI 10.1088/1757-899X/847/1/012007; [Anonymous], 2008, TRAIN MIDL MAN MLM M; Ashok A, 2017, VACCINE, V35, P2217, DOI 10.1016/j.vaccine.2016.08.045; Assi TM, 2013, VACCINE, V31, P2828, DOI 10.1016/j.vaccine.2013.04.011; Bar Gai DH, 2018, VACCINE, V36, P3505, DOI 10.1016/j.vaccine.2018.04.072; Bollapragada R, 2005, OPER RES LETT, V33, P134, DOI 10.1016/j.orl.2004.05.007; Chatterjee S, 2018, VACCINE, V36, P3836, DOI 10.1016/j.vaccine.2018.05.006; Chen DX, 2009, HUM VACCINES, V5, P26, DOI 10.4161/hv.5.1.6494; Chopra S, 2003, TRANSPORT RES E-LOG, V39, P123, DOI 10.1016/S1366-5545(02)00044-3; Duijzer LE, 2018, EUR J OPER RES, V268, P174, DOI 10.1016/j.ejor.2018.01.015; Gu TT, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0898-6; Haidari LA, 2017, VACCINE, V35, P199, DOI 10.1016/j.vaccine.2016.11.025; Haidari LA, 2013, J PUBLIC HEALTH MAN, V19, pS65, DOI 10.1097/PHH.0b013e31828a83fe; Hanson CM, 2017, VACCINE, V35, P2127, DOI 10.1016/j.vaccine.2016.09.070; Humphreys G, 2011, B WORLD HEALTH ORGAN, V89, P324, DOI 10.2471/BLT.11.030511; Kaufmann JR, 2011, HEALTH AFFAIR, V30, P1113, DOI 10.1377/hlthaff.2011.0368; Klerk WJ, 2021, RELIAB ENG SYST SAFE, V207, DOI 10.1016/j.ress.2020.107344; Lemmens S, 2016, CHEM ENG RES DES, V109, P366, DOI 10.1016/j.cherd.2016.02.015; Li XP, 2011, MATH METHOD OPER RES, V74, P281, DOI 10.1007/s00186-011-0363-4; Lim J, 2016, OPER RES HEALTH CARE, V9, P40, DOI 10.1016/j.orhc.2016.02.003; Lloyd J, 2017, VACCINE, V35, P2115, DOI 10.1016/j.vaccine.2016.11.097; Milstien JB, 2006, TEMPERATURE SENSITIV; Ministry of Health & Family Welfare Government of India, 2018, RUR HLTH STAT 2017 2; Ministry of Health & Family Welfare Government of India., 2016, HDB VACC COLD CHAIN; Ministry of Health & Family Welfare. Government of India, 2018, IMM HDB HLTH WORK; Ministry of Health & Family Welfare Government of India., 2019, UN IMM PROGR COMPR M; Ministry of Health & Family Welfare Government of India, 2017, IMM HDB MED OFF; Ministry of Women & Child Development Government of India, 2018, OP GUID CONV ACT PLA; Murhekar MV, 2013, B WORLD HEALTH ORGAN, V91, P906, DOI 10.2471/BLT.13.119974; National Institute of Health and Family Welfare, 2011, REV ACT PLAN PREP IM; Nelson C, 2007, VACCINE, V25, P433, DOI 10.1016/j.vaccine.2006.08.017; Panigrahi SK, 2015, VACCINE, V33, P943, DOI 10.1016/j.vaccine.2015.01.021; Phillips DE, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2626-0; Privor-Dumm LA, 2021, VACCINE, V39, P5240, DOI 10.1016/j.vaccine.2020.06.082; Prosser W, 2017, VACCINE, V35, P2162, DOI 10.1016/j.vaccine.2016.09.073; Rahman SU, 1999, J OPER RES SOC, V50, P892, DOI 10.1057/palgrave.jors.2600795; Samant Y, 2007, Rural Remote Health, V7, P617; Sarley D, 2017, VACCINE, V35, P2167, DOI 10.1016/j.vaccine.2016.11.068; Shariff SSR, 2012, COMPUT IND ENG, V62, P1000, DOI 10.1016/j.cie.2011.12.026; World Health Organization, 2021, COVID 19 VACC SUPPL; World Health Organization, 2015, US PASS CONT COOL PA; World Health Organization, 2015, IMM PRACT PRACT GUID; World Health Organization (WHO), 2013, GLOB VACC ACT PLAN 2	44	1	1	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6660	6670		10.1016/j.vaccine.2021.09.062		OCT 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34629207	Green Published, hybrid			2022-04-29	WOS:000708078600013
J	Romano, CJ; Hall, C; Khodr, ZG; Bukowinski, AT; Gumbs, GR; Conlin, AMS				Romano, Celeste J.; Hall, Clinton; Khodr, Zeina G.; Bukowinski, Anna T.; Gumbs, Gia R.; Conlin, Ava Marie S.			History of pandemic H1N1-containing influenza vaccination and risk for spontaneous abortion and birth defects	VACCINE			English	Article						Influenza vaccine; Spontaneous abortion; Birth defects; Military personnel; Pregnancy	SEASONAL INFLUENZA; PRETERM DELIVERY; PREGNANCY; SAFETY; ASSOCIATION; H1N1PDM09; VACCINES; RECEIPT; COHORT; VIRUS	Background: One recent study suggested an association between receipt of pandemic H1N1 (pH1N1)containing vaccines in consecutive influenza seasons and spontaneous abortion, but corroborating scientific evidence is limited. In the present study, we leveraged a population of vaccine-compliant pregnant military women to examine history of pH1N1-containing influenza vaccination and adverse pregnancy outcomes. Because seasonal influenza vaccination is compulsory for military service, safety concerns regarding repeat vaccination are particularly relevant in this population. Methods: Pregnancies and live births from Department of Defense Birth and Infant Health Research program data were linked with military personnel immunization records to identify women vaccinated with a pH1N1-containing vaccine in pregnancy prior to 21 6/7 weeks' gestation, October 2009-April 2015. Cox and modified Poisson regression models estimated associations between vaccination with pH1N1-versus non-pH1N1-containing influenza vaccine in the season prior to the index pregnancy, and spontaneous abortion and birth defects, respectively. Cox models were calculated for two periods of follow-up: through (1) 21 6/7 weeks' gestation and (2) 28 days postvaccination. Results: Of 26,264 pregnancies, 21,736 (82.8%) were among women who received a dose of pH1N1containing vaccine in the prior influenza season and 4,528 (17.2%) were among women who received non-pH1N1-containing vaccine in the prior influenza season. Among 23,121 infants, 19,365 (83.8%) and 3,756 (16.2%) had mothers exposed and unexposed to pH1N1-containing vaccine in the prior influenza season, respectively. The adjusted hazard ratio (aHR) for spontaneous abortion approximated 1.0 across the complete follow-up period (95% confidence interval [CI]: 0.89-1.13) and was slightly elevated when censored at 28 days postvaccination, though the CI was imprecise (aHR: 1.19; 95% CI: 0.97-1.46). No associations with birth defects were observed. Conclusion: This work lends additional safety evidence and support for vaccination against pH1N1 in pregnancy, regardless of the vaccine received in the prior influenza season. (c) 2021 Elsevier Ltd. All rights reserved.	[Romano, Celeste J.; Hall, Clinton; Khodr, Zeina G.; Bukowinski, Anna T.; Gumbs, Gia R.; Conlin, Ava Marie S.] Naval Hlth Res Ctr, Deployment Hlth Res Dept, 140 Sylvester Rd, San Diego, CA 92106 USA; [Romano, Celeste J.; Hall, Clinton; Khodr, Zeina G.; Bukowinski, Anna T.; Gumbs, Gia R.] Leidos Inc, 140 Sylvester Rd, San Diego, CA 92106 USA		Romano, CJ (通讯作者)，Naval Hlth Res Ctr, Deployment Hlth Res Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.	celeste.j.romano.ctr@mail.mil			Defense Health Agency Immu-nization Healthcare Division [N1222]; U.S. Navy Bureau of Medicine and Surgery [60504]	This work was supported by the Defense Health Agency Immu-nization Healthcare Division and the U.S. Navy Bureau of Medicine and Surgery under work unit nos. N1222 and 60504, respectively.	Barrett John P, 2012, J Registry Manag, V39, P69; Belongia EA, 2017, EXPERT REV VACCINES, V16, P723, DOI 10.1080/14760584.2017.1334554; Bukowinski Anna T, 2017, MSMR, V24, P39; Chambers CD, 2017, VACCINE, V35, P5323, DOI 10.1016/j.vaccine.2017.08.038; Chambers CD, 2016, VACCINE, V34, P4443, DOI 10.1016/j.vaccine.2016.06.054; Chambers CD, 2013, VACCINE, V31, P5026, DOI 10.1016/j.vaccine.2013.08.097; Conlin AMS, 2018, VACCINE, V36, P2855, DOI 10.1016/j.vaccine.2018.03.061; Conlin AMS, 2013, OBSTET GYNECOL, V121, P511, DOI 10.1097/AOG.0b013e318280d64e; Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x; Cuningham W, 2019, INFLUENZA OTHER RESP, V13, P438, DOI 10.1111/irv.12649; Dawood FS, 2021, LANCET INFECT DIS, V21, P97, DOI 10.1016/S1473-3099(20)30592-2; Donahue JG, 2019, VACCINE, V37, P6673, DOI 10.1016/j.vaccine.2019.09.035; Donahue JG, 2017, VACCINE, V35, P5314, DOI 10.1016/j.vaccine.2017.06.069; Eick-Cost AA, 2009, SURVEILLANCE SNAPSHO; Foppa IM, 2019, VACCINE-X, V1, DOI 10.1016/j.jvacx.2019.100008; Global Advisory Committee on Vaccine Safety, 2014, SAF IMM PREGN REV EV; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Gunnes N, 2020, EUR J EPIDEMIOL, V35, P371, DOI 10.1007/s10654-020-00600-z; Haberg SE, 2013, NEW ENGL J MED, V368, P333, DOI 10.1056/NEJMoa1207210; Hall C, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa138; Headquarters Departments of the Army Navy Air Force and Coast Guard, 2013, AR40562BUMEDINEST623; Heikkinen T, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.07.007; Hernan MA, 2010, EPIDEMIOLOGY, V21, P13, DOI 10.1097/EDE.0b013e3181c1ea43; Kim SS, 2020, CLIN INFECT DIS; Office of the Under Secretary of Defense for Personnel and Readiness, 2019, DOD IMM PROGR DOD IN; Oppermann M, 2012, VACCINE, V30, P4445, DOI 10.1016/j.vaccine.2012.04.081; Pasternak B, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2794; Regan AK, 2018, VACCINE, V36, P2227, DOI 10.1016/j.vaccine.2017.12.033; Sammon CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051734; Vazquez-Benitez G, 2016, AM J EPIDEMIOL, V184, P176, DOI 10.1093/aje/kww043; Xu RH, 2012, PHARMACOEPIDEM DR S, V21, P844, DOI 10.1002/pds.3301; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	32	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 22	2021	39	44					6553	6562		10.1016/j.vaccine.2021.09.003		OCT 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WX9RH	34598819				2022-04-29	WOS:000718925300015
J	Bhat, S; Caldera, F; Farraye, AF				Bhat, Shubha; Caldera, Freddy; Farraye, A. Francis			Standardizing shared vaccination responsibilities among specialists to improve vaccination rates of immunosuppressed patients	VACCINE			English	Editorial Material									[Bhat, Shubha] Inst Digest Dis, Dept Pharm, Cleveland, OH USA; [Bhat, Shubha] Inst Digest Dis, Dept Gastroenterol, Cleveland, OH USA; [Caldera, Freddy] Univ Wisconsin Madison, Div Gastroenterol & Hepatol, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Farraye, A. Francis] Mayo Clin, Div Gastroenterol & Hepatol, Ctr Inflammatory Bowel Dis, Jacksonville, FL USA		Bhat, S (通讯作者)，Cleveland Clin, Clin Pharm Specialist Gastroenterol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	bhats@ccf.org; fcaldera@medicine.wisc.edu; farraye.francis@mayo.edu					Bhat Shubha, 2021, Gastroenterology, DOI 10.1053/j.gastro.2021.01.026; Centers for Disease Control and Prevention, 2021, MRNA COVID 19 VACC; Dalal RS, 2021, CLIN GASTROENTEROL H, V19, P1730, DOI 10.1016/j.cgh.2021.02.004; Doornekamp L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030480; Harpaz R, 2016, JAMA-J AM MED ASSOC, V316, P2547, DOI 10.1001/jama.2016.16477; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Paulsen MR, 2021, J PHARM PRACT, V34, P943, DOI 10.1177/0897190020958261; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; The NPD Group Inc, 2019, 31 PERC US HOUS LACK; WHO, 2012, WORLD MALARIA REPORT 2012, P1	10	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6015	6016		10.1016/j.vaccine.2021.08.073		SEP 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34493411	Green Published, Bronze			2022-04-29	WOS:000701799200001
J	Bozorgi, A; Fahimnia, B				Bozorgi, Ali; Fahimnia, Behnam			Transforming the vaccine supply chain in Australia: Opportunities and challenges	VACCINE			English	Article							MICRONEEDLE-PATCH; COLD CHAIN; INVENTORY MODEL; ACCEPTABILITY; DELIVERY; IMPACT; DRUG	Background: Analyzing potential benefits of thermostable vaccines delivered through Micro Array Patch (MAP) has received great attention in low and middle-income countries. The experience may or may not be the same in developed countries where the infrastructure is more developed. It is anticipated that transforming the vaccine supply chain from syringe-and-needle to thermostable MAP-delivered vaccines will result in reduced supply chain costs - including manufacturing/supply, logistics/distribution, and administration costs - as well as reduced wastes and improved safety. This paper provides an end-to-end supply chain analysis comparing the key aspects (cost, safety and environmental aspects) of the conventional syringe-and-needle vaccine supply chain with those of the MAP vaccine supply chain for influenza vaccine delivery in Australia. Directions for future research in this area will be provided. Objective: To determine the potential supply chain impacts of replacing syringe-and-needle flu vaccine with MAP-enabled thermostable flu vaccine in Australia. Methods: We analyze the current flu vaccine supply chain in Australia to identify practical limitations and opportunities for improvement. Data/information is collected through interviewing the key stakeholders across vaccine supply chain including vaccine manufacturers, logistics providers, clinics, hospitals, and pharmacies. Findings: A detailed practice-informed analysis is completed on the key operations of the flu vaccine sup-ply chain. Barriers and limitations of the conventional flu vaccine are discussed, along with potential improvements that can be achieved through the implementation of MAP-enabled flu vaccine delivery. We discuss how technology-driven innovations can help advance vaccine supply chains, improve vaccine visibility, reduce wastes, and enable informed decision-making. Conclusion: We find that the benefits of moving from syringe-and-needle vaccines to thermostable MAP-delivered vaccines are beyond transportation and storage cost saving. Potential benefits through cost saving, waste reduction, and service level improvement are discussed along with various safety and wellbeing consequences followed by directions for future research in this area. (C) 2021 Elsevier Ltd. All rights reserved.	[Bozorgi, Ali; Fahimnia, Behnam] Univ Sydney Business Sch, Inst Transport & Logist Studies, Sydney, NSW, Australia		Fahimnia, B (通讯作者)，Univ Sydney Business Sch, Inst Transport & Logist Studies, Sydney, NSW, Australia.	ali.hajiaghabozorgi@sydney.edu.au; ben.fahimnia@sydney.edu.au		Bozorgi, Ali/0000-0003-1044-496X	Australian Government's Department of Industry, Innovation and Science (Innovative Manufacturing CRC Ltd.); Vaxxas Pty Ltd [IMCRC/VAX/14112018]	This study was co-funded by the Australian Government's Department of Industry, Innovation and Science (Innovative Man-ufacturing CRC Ltd.) and Vaxxas Pty Ltd (IMCRC/VAX/14112018) . We are grateful to the management and employees of our industry partner, Vaxxas (a venture capital funded technology start-up company based in Brisbane, Australia) , who actively participated in all stages of this research. We are extremely thankful to Dr Yan Dan Goh (a general practitioner from MediCentral, Australia) as well as Dr Cristyn Davies and Dr Rachel Skinner (Faculty of Med-icine and Health at The University of Sydney) for their invaluable feedback and constructive comments during this research. Finally, we acknowledge the following organizations for supplying the key information and important supply chain insights that were needed for our analysis and investigation: NSW Health, Seqirus Australia (vaccine supplier) , Department of Health Systems and Populations at the Macquarie University, Toll Group, Royal Prince Alfred Hospi-tal (Sydney) , Medicentral Medical Centre, St. Vincent's Hospital (Sydney and Melbourne) , The Royal Melbourne Hospital, MedicalHQ Group (Adelaide) , Priceline Pharmacies (Sydney, Melbourne, Adelaide) , MediCentral Pharmacy (Sydney) , Slade Pharmacy (Mel-bourne) , Chemist Warehouse (Sydney, Melbourne) , and Chemmart (Brisbane) .	A. G. D. of Health, OUTC 1 POP HLTH; [Anonymous], SBS NEWS; [Anonymous], WHO | Recommended composition of influenza virus vaccines for use in the 2019 southern hemisphere influenza season; Assi TM, 2012, VACCINE, V30, P4517, DOI 10.1016/j.vaccine.2012.04.041; Bar Gai DH, 2018, VACCINE, V36, P3505, DOI 10.1016/j.vaccine.2018.04.072; Barbosa-Povoa AP, 2014, FRONT ENERGY RES, DOI 10.3389/fenrg.2014.00023; Behzadi Golnar, 2013, International Journal of Logistics Economics and Globalisation, V5, P167, DOI 10.1504/IJLEG.2013.058821; Bonney M, 2011, INT J PROD ECON, V133, P43, DOI 10.1016/j.ijpe.2009.10.033; Bozorgi A, 2016, INT J PROD ECON, V176, P123, DOI 10.1016/j.ijpe.2016.03.011; Bozorgi A, 2014, INT J PROD ECON, V155, P114, DOI 10.1016/j.ijpe.2014.01.006; Caffarel-Salvador E, 2015, INT J PHARMACEUT, V489, P158, DOI 10.1016/j.ijpharm.2015.04.076; De Boeck K, 2020, OMEGA-INT J MANAGE S, V97, DOI 10.1016/j.omega.2019.08.004; Dieckmann E, 2019, FOOD PACKAGING SHELF, V21, DOI 10.1016/j.fpsl.2019.100360; Duijzer LE, 2018, EUR J OPER RES, V268, P174, DOI 10.1016/j.ejor.2018.01.015; Fahimnia Behnam, 2019, Decision Sciences, V50, P1127, DOI 10.1111/deci.12369; Ream PSF, 2016, ARCH ENVIRON OCCUP H, V71, P59, DOI 10.1080/19338244.2014.927347; Ghodrat M, 2017, MINERAL MET MAT SER, P131, DOI 10.1007/978-3-319-52192-3_14; Guthridge SL, 1996, AUST NZ J PUBL HEAL, V20, P657, DOI 10.1111/j.1467-842X.1996.tb01084.x; Hoschler K, 2017, LANCET, V390, P627, DOI 10.1016/S0140-6736(17)31364-8; Jabbarzadeh A, 2016, TRANSPORT RES B-METH, V94, P121, DOI 10.1016/j.trb.2016.09.004; Jeong HR, 2017, J DRUG TARGET, V25, P29, DOI 10.1080/1061186X.2016.1200589; Kartoglu U, 2010, VACCINE, V28, P4065, DOI 10.1016/j.vaccine.2010.03.076; Kettwich SC, 2007, J PEDIATR ONCOL NURS, V24, P20, DOI 10.1177/1043454206296023; Kim YC, 2012, ADV DRUG DELIVER REV, V64, P1547, DOI 10.1016/j.addr.2012.04.005; Kolli CS, 2015, THER DELIV, V6, P1081, DOI 10.4155/tde.15.67; Kolluru C, 2019, DRUG DELIV TRANSL RE, V9, P192, DOI 10.1007/s13346-018-00608-9; Lee BY, 2017, VACCINE, V35, P3135, DOI 10.1016/j.vaccine.2017.03.081; Lee BY, 2015, VACCINE, V33, P4727, DOI 10.1016/j.vaccine.2015.02.076; Lee BY, 2012, VACCINE, V30, P5637, DOI 10.1016/j.vaccine.2012.06.087; Lee HL, 1997, MANAGE SCI, V43, P546, DOI 10.1287/mnsc.43.4.546; Leone M, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040211; Marshall S, 2017, VACCINE, V35, P4896, DOI 10.1016/j.vaccine.2017.07.083; Marshall S, 2016, VACCINE, V34, P723, DOI 10.1016/j.vaccine.2015.12.002; Masjuki HH, 2001, ENERGY, V26, P723, DOI 10.1016/S0360-5442(01)00028-7; McKenny L., 2015, SYDNEY MORNING HERAL; Mistilis MJ, 2015, J PHARM SCI-US, V104, P740, DOI 10.1002/jps.24283; Murphy CL, 2014, COLLEGIAN, V21, P295, DOI 10.1016/j.colegn.2013.06.003; Nakandala D, 2017, INT J PROD RES, V55, P5341, DOI 10.1080/00207543.2017.1312587; Newman LP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193263; Page SL, 2008, AUST FAM PHYSICIAN, V37, P892; Prausnitz MR, 2017, ANNU REV CHEM BIOMOL, V8, P177, DOI 10.1146/annurev-chembioeng-060816-101514; Raju G., 2016, PERSPECT SCI, V8, P683; Reimer RF, 1998, AUST NZ J PUBL HEAL, V22, P274, DOI 10.1111/j.1467-842X.1998.tb01189.x; Siegert MW, 2019, INT J LIFE CYCLE ASS, V24, P1040, DOI 10.1007/s11367-018-1549-2; Sivamani RK, 2005, SKIN RES TECHNOL, V11, P152, DOI 10.1111/j.1600-0846.2005.00107.x; Stellingwerf HM, 2018, TRANSPORT RES D-TR E, V58, P80, DOI 10.1016/j.trd.2017.11.008; Tesfahun E, 2014, WASTE MANAGE RES, V32, P215, DOI 10.1177/0734242X14521683; Thornton J, 2018, TRANSPORT RES REC, V2672, P122, DOI 10.1177/0361198118773194; Trent R, 1998, INT J PURCH MATER MA, V34, P2, DOI [10.1111/j.1745-493X.1998.tb00296.x, DOI 10.1111/J.1745-493X.1998.TB00296.X]; Wise J, 2017, BMJ-BRIT MED J, V357, pJ3120, DOI [10.1136/bmj.j3120, DOI 10.1136/BMJ.J3120, 10.1136/BMJ.J3120]	50	2	2	5	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6157	6165		10.1016/j.vaccine.2021.08.033		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UY8XC	34489129				2022-04-29	WOS:000701799200021
J	Paradowska-Stankiewicz, I; Rumik, A; Bogusz, J; Zbrzezniak, J; Rastawicki, W; Smietanska, K; Vargas-Zambrano, JC; Macina, D				Paradowska-Stankiewicz, Iwona; Rumik, Agnieszka; Bogusz, Joanna; Zbrzezniak, Jakub; Rastawicki, Waldemar; Smietanska, Karolina; Vargas-Zambrano, Juan C.; Macina, Denis			Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents	VACCINE			English	Article						Pertussis; Vaccines; Seroprevalence; Waning	REDUCED RISK; IMMUNITY; RECIPIENTS; DURABILITY; EXEMPTIONS; CALIFORNIA; DISEASE	Background: In the context of reported resurgence of pertussis in the last decade, researchers hypothesized that acellular (aP) pertussis vaccines elicit a shorter-lived protection compared to whole-cell (wP) pertussis vaccines. However, in the studies seeking to demonstrate this hypothesis, exposure to each vaccine type was not concurrent, and contradictory epidemiologic modeling questioned its validity. The context of pertussis vaccination history in Poland, with both vaccine types used concurrently in comparable proportions, provided an opportunity to investigate this hypothesis. We sought to compare waning of protection by primary series vaccine type by measuring anti-pertussis toxin antibody concentrations as proxy for recent infection. Materials and methods: Serological samples from 2,745 children and adolescents aged >5 years and <16 years and with completed 5-dose pertussis vaccination series were tested by ELISA for pertussis toxin (PT) antibodies. Participants were stratified by type of priming vaccine (wP or aP). Vaccination timeliness and priming-specific trends in anti-PT antibody levels by time since last vaccine dose were analyzed. Results: A total of 1,161 (42.5%) children received wP vaccines, and 1,314 (48.1%) received aP vaccines for their primary series and toddler booster. Overall, 53.57% of the subjects received doses 2-4 in a timely manner, while only 41.52% received all 5 doses at the recommended intervals. Using GMCs or seropositivity measures, both priming groups showed a re-increase in anti-PT antibody levels signing infection in recent years from 8 years after the school-entry booster onward. Comparisons did not show any significant differences between the two groups in the timing or intensity of this re-increase. Conclusion: Our results clearly confirm that vaccine-elicited immunity against pertussis wanes among adolescents even after a complete infant, toddler and school-entry vaccination series. The timing and intensity of the waning of protection appear similar with whole-cell as with acellular pertussis vaccines. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Paradowska-Stankiewicz, Iwona; Rumik, Agnieszka; Bogusz, Joanna; Zbrzezniak, Jakub; Rastawicki, Waldemar; Smietanska, Karolina] Natl Inst Publ Hlth, Natl Inst Hyg, Natl Res Inst, Ul Chocimska 24, PL-00791 Warsaw, Poland; [Vargas-Zambrano, Juan C.; Macina, Denis] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France		Paradowska-Stankiewicz, I (通讯作者)，Natl Inst Publ Hlth, Natl Inst Hyg, Natl Res Inst, Ul Chocimska 24, PL-00791 Warsaw, Poland.	istankiewicz@pzh.gov.pl; juan.vargas@sanofi.com; denis.macina@sanofi.com		Rastawicki, Waldemar/0000-0002-3301-8632	Sanofi Pasteur; National Institute of Public Health National Institute of Hygiene - National Research Institute of Poland	This study was funded by Sanofi Pasteur under a collaborative agreement with the National Institute of Public Health National Institute of Hygiene - National Research Institute of Poland.	Andre P, 2013, CLIN INFECT DIS, V57, P1658, DOI 10.1093/cid/cit552; Atwell JE, 2013, PEDIATRICS, V132, P624, DOI 10.1542/peds.2013-0878; Barkoff AM, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv050; Campbell P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035874; Carlson J., 2018, PERTUSSIS SURVEILLAN; Centers for Disease Control and Prevention (CDC), 2020, 2019 PROV PERT SURV; de Celles MD, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaj1748; de Celles MD, 2014, P NATL ACAD SCI USA, V111, pE716, DOI 10.1073/pnas.1323795111; Glanz JM, 2013, JAMA PEDIATR, V167, P1060, DOI 10.1001/jamapediatrics.2013.2353; Guiso N, 2012, CLIN INFECT DIS, V55, P1433, DOI 10.1093/cid/cis671; Heininger U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155949; Hewlett EL, 2005, NEW ENGL J MED, V352, P1215, DOI 10.1056/NEJMcp041025; Holubova J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040695; Imdad A, 2013, PEDIATRICS, V132, P37, DOI 10.1542/peds.2012-3449; Jogi P, 2014, VACCINE, V32, P5311, DOI 10.1016/j.vaccine.2014.07.066; Kaczmarek MC, 2013, MED J AUSTRALIA, V198, P624, DOI 10.5694/mja13.10044; Kiraly N, 2013, CLIN INFECT DIS, V57, P770, DOI 10.1093/cid/cit351; Klein NP, 2013, PEDIATRICS, V131, pE1716, DOI 10.1542/peds.2012-3836; Klein NP, 2012, NEW ENGL J MED, V367, P1012, DOI 10.1056/NEJMoa1200850; Liko J, 2013, NEW ENGL J MED, V368, P581, DOI 10.1056/NEJMc1212006; Magpantay FMG, 2016, PARASITOLOGY, V143, P835, DOI 10.1017/S0031182015000979; Martin SW, 2015, CLIN INFECT DIS, V60, P223, DOI 10.1093/cid/ciu788; Misegades LK, 2012, CLIN INFECT DIS, V55, P1432, DOI 10.1093/cid/cis669; Mooi FR, 2014, EPIDEMIOL INFECT, V142, P685, DOI 10.1017/S0950268813000071; Octavia S, 2012, J INFECT DIS, V205, P1220, DOI 10.1093/infdis/jis178; Public Health England, HLTH PROTECTION REPO; Quinn HE, 2014, PEDIATRICS, V133, pE513, DOI 10.1542/peds.2013-3181; Rodgers L, 2013, CLIN INFECT DIS, V56, P322, DOI 10.1093/cid/cis888; Sheridan SL, 2012, CLIN INFECT DIS, V55, P1434, DOI 10.1093/cid/cis672; Sheridan SL, 2012, JAMA-J AM MED ASSOC, V308, P454, DOI 10.1001/jama.2012.6364; Stefanoff P, 2014, EPIDEMIOL INFECT, V142, P714, DOI 10.1017/S0950268813001684; Tarr GAM, 2013, AM J EPIDEMIOL, V178, P309, DOI 10.1093/aje/kws465; Tartof SY, 2013, PEDIATRICS, V131, pE1047, DOI 10.1542/peds.2012-1928; Warfel JM, 2014, P NATL ACAD SCI USA, V111, P787, DOI 10.1073/pnas.1314688110; Winter K, 2018, PEDIATR INFECT DIS J, V37, P324, DOI 10.1097/INF.0000000000001761; Witt MA, 2013, CLIN INFECT DIS, V56, P1248, DOI 10.1093/cid/cit046; Zielinski A, 2004, SCAND J INFECT DIS, V36, P114, DOI 10.1080/00365540310018897	37	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6067	6073		10.1016/j.vaccine.2021.08.105		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34511302	hybrid			2022-04-29	WOS:000701799200009
J	Azam, JM; Saitta, B; Bonner, K; Ferrari, MJ; Pulliam, JRC				Azam, James M.; Saitta, Barbara; Bonner, Kimberly; Ferrari, Matthew J.; Pulliam, Juliet R. C.			Modelling the relative benefits of using the measles vaccine outside cold chain for outbreak response	VACCINE			English	Article						Measles; Outbreak response; Vaccine cold chain; Extended controlled temperature conditions; Outside cold chain	HEPATITIS-B-VACCINE; MASS VACCINATION; TEMPERATURE; MENINGITIS; STABILITY; TIME; PREDICTION; CAMPAIGN; ESSENCE	Introduction: Rapid outbreak response vaccination is a strategy for measles control and elimination. Measles vaccines must be stored and transported within a specified temperature range, but this can pre-sent significant challenges when targeting remote populations. Measles vaccine licensure for delivery outside cold chain (OCC) could provide more vaccine transport/storage space without ice packs, and a solution to shorten response times. However, due to vaccine safety and wastage considerations, the OCC strategy will require other operational changes, potentially including the use of 1-dose (monodose) instead of 10-dose vials, requiring larger transport/storage equipment currently achieved with 10-dose vials. These trade-offs require quantitative comparisons of vaccine delivery options to evaluate their rel-ative benefits. Methods: We developed a modelling framework combining elements of the vaccine supply chain -cold chain, vial, team, and transport equipment types -with a measles transmission dynamics model to com-pare vaccine delivery options. We compared 10 strategies resulting from combinations of the vaccine supply elements and grouped into three main classes: OCC, partial cold chain (PCC), and full cold chain (FCC). For each strategy, we explored a campaign with 20 teams sequentially targeting 5 locations with 100,000 individuals each. We characterised the time needed to freeze ice packs and complete the cam-paign (campaign duration), vaccination coverage, and cases averted, assuming a fixed pre-deployment delay before campaign commencement. We performed sensitivity analyses of the pre-deployment delay, population sizes, and two team allocation schemes. Results: The OCC, PCC, and FCC strategies achieve campaign durations of 50, 51, and 52 days, respectively. Nine of the ten strategies can achieve a vaccination coverage of 80%, and OCC averts the most cases. Discussion: The OCC strategy, therefore, presents improved operational and epidemiological outcomes relative to current practice and the other options considered. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Azam, James M.; Pulliam, Juliet R. C.] Stellenbosch Univ, DSI NRF Ctr Excellence Epidemiol Modelling & Anal, Stellenbosch, South Africa; [Saitta, Barbara] Med Sans Frontieres, Access Campaign, New York, NY USA; [Bonner, Kimberly] Univ Minnesota Twin Cities, Minneapolis, MN USA; [Ferrari, Matthew J.] Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA		Azam, JM (通讯作者)，SACEMA, 19 Jonkershoek Rd, ZA-7600 Stellenbosch, South Africa.	jamesazam@sun.ac.za	Pulliam, Juliet/A-6516-2008	Pulliam, Juliet/0000-0003-3314-8223; Azam, JAMES MBA/0000-0001-5782-7330	Department of Science and Innovation; National Research Foundation	This work is based on the research supported by the Department of Science and Innovation and the National Research Foundation. Any opinion, finding, and conclusion or recommendation expressed in this material is that of the authors and the NRF does not accept any liability in this regard.	[Anonymous], 2017, IEEE T POWER SYSTEMS, V38, P444; Bjornstad ON., 2018, EPIDEMICS MODELS DAT, DOI [10.1007/978-3-319-97487-3, DOI 10.1007/978-3-319-97487-3]; Blake A, 2019, DEMOCRATIC REPUBLIC, P1; Clenet D, 2018, EUR J PHARM BIOPHARM, V125, P76, DOI 10.1016/j.ejpb.2018.01.005; Comes T, 2018, J HUMANIT LOGIST SUP, V8, P49, DOI 10.1108/JHLSCM-03-2017-0006; Dadari IK, 2021, J GLOB HEALTH, V11, DOI 10.7189/jogh.11.04004; Danet C, 2013, MEDICINS SANS FRONTI; Duijzer LE, 2018, EUR J OPER RES, V271, P606, DOI 10.1016/j.ejor.2018.05.054; Ferrari MJ, 2008, NATURE, V451, P679, DOI 10.1038/nature06509; Ferrari MJ, 2014, INT HEALTH, V6, P282, DOI 10.1093/inthealth/ihu062; Gerard SP, 2014, PUBLIC HEALTH ACTION, V4, P6, DOI 10.5588/pha.13.0099; Grais RF, 2008, J R SOC INTERFACE, V5, P67, DOI 10.1098/rsif.2007.1038; Grais RF, 2006, EPIDEMIOL INFECT, V134, P845, DOI 10.1017/S0950268805005716; Guichard S, 2010, VACCINE, V28, P858, DOI 10.1016/j.vaccine.2009.08.035; Juan-Giner A, 2020, VACCINE, V38, P2473, DOI 10.1016/j.vaccine.2020.02.005; Kolwaite AR, 2016, VACCINE, V34, P3324, DOI 10.1016/j.vaccine.2016.03.080; Lee BY, 2010, VACCINE, V28, P5292, DOI 10.1016/j.vaccine.2010.05.048; Li SL, 2019, P ROY SOC B-BIOL SCI, V286, DOI 10.1098/rspb.2019.0774; Lydon P, 2014, B WORLD HEALTH ORGAN, V92, P86, DOI 10.2471/BLT.13.123471; Patel MK, 2018, LANCET GLOB HEALTH, V6, pE596, DOI 10.1016/S2214-109X(18)30233-X; Roberts L, 2020, NATURE, V580, P446, DOI 10.1038/d41586-020-01011-6; Roduit B, 2019, MOLECULES, V24, DOI 10.3390/molecules24122217; Roduit B, 2014, THERMOCHIM ACTA, V579, P31, DOI 10.1016/j.tca.2014.01.005; Shea K, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001970; Trentini F, 2017, LANCET INFECT DIS, V17, P1089, DOI 10.1016/S1473-3099(17)30421-8; WHO, 2015, GUID STAB EV VACC US, P2268; Winter AK, 2018, REVEALING MEASLES OU, DOI [10.1093/aje/kwy114/5033615, DOI 10.1093/AJE/KWY114/5033615]; World Health Organization Controlled Temperature Chain Working Group, 2017, WHOIVB1720; World Hlth Org, 2019, VACCINE, V37, P219, DOI 10.1016/j.vaccine.2017.07.066; Zipursky S, 2014, VACCINE, V32, P1431, DOI 10.1016/j.vaccine.2014.01.038	30	1	1	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5845	5853		10.1016/j.vaccine.2021.08.053		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34481696	Green Submitted, hybrid			2022-04-29	WOS:000697501500018
J	Li, L; Honda-Okubo, Y; Huang, Y; Jang, H; Carlock, MA; Baldwin, J; Piplani, S; Bebin-Blackwell, AG; Forgacs, D; Sakamoto, K; Stella, A; Turville, S; Chataway, T; Colella, A; Triccas, J; Ross, TM; Petrovsky, N				Li, Lei; Honda-Okubo, Yoshikazu; Huang, Ying; Jang, Hyesun; Carlock, Michael A.; Baldwin, Jeremy; Piplani, Sakshi; Bebin-Blackwell, Anne G.; Forgacs, David; Sakamoto, Kaori; Stella, Alberto; Turville, Stuart; Chataway, Tim; Colella, Alex; Triccas, Jamie; Ross, Ted M.; Petrovsky, Nikolai			Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection	VACCINE			English	Article							DELTA INULIN; INFLUENZA VACCINE; IMMUNOGENICITY; EFFICACY; VECTORS; SAFETY; TRIAL	The development of a safe and effective vaccine is a key requirement to overcoming the COVID-19 pandemic. Recombinant proteins represent the most reliable and safe vaccine approach but generally require a suitable adjuvant for robust and durable immunity. We used the SARS-CoV-2 genomic sequence and in silico structural modelling to design a recombinant spike protein vaccine (Covax-19 (TM)). A synthetic gene encoding the spike extracellular domain (ECD) was inserted into a baculovirus backbone to express the protein in insect cell cultures. The spike ECD was formulated with Advax-SM adjuvant and first tested for immunogenicity in C57BL/6 and BALB/c mice. Covax-19 vaccine induced high spike protein binding antibody levels that neutralised the original lineage B.1.319 virus from which the vaccine spike protein was derived, as well as the variant B.1.1.7 lineage virus. Covax-19 vaccine also induced a high frequency of spike-specific CD4 + and CD8 + memory T-cells with a dominant Thl phenotype associated with the ability to kill spike-labelled target cells in vivo. Ferrets immunised with Covax-19 vaccine intramuscularly twice 2 weeks apart made spike receptor binding domain (RBD) IgG and were protected against an intranasal challenge with SARS-CoV-2 virus given two weeks after the last immunisation. Notably, ferrets that received the two higher doses of Covax-19 vaccine had no detectable virus in their lungs or in nasal washes at day 3 post-challenge, suggesting that in addition to lung protection, Covax-19 vaccine may have the potential to reduce virus transmission. This data supports advancement of Covax-19 vaccine into human clinical trials. (C) 2021 Elsevier Ltd. All rights reserved.	[Li, Lei; Honda-Okubo, Yoshikazu; Baldwin, Jeremy; Piplani, Sakshi; Petrovsky, Nikolai] Vaxine Pty Ltd, Bedford Pk, Adelaide, SA 5042, Australia; [Li, Lei; Honda-Okubo, Yoshikazu; Piplani, Sakshi; Chataway, Tim; Colella, Alex; Petrovsky, Nikolai] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA 5042, Australia; [Huang, Ying; Jang, Hyesun; Carlock, Michael A.; Bebin-Blackwell, Anne G.; Forgacs, David; Ross, Ted M.] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA; [Ross, Ted M.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Sakamoto, Kaori] Univ Georgia, Dept Pathol, Athens, GA 30602 USA; [Stella, Alberto; Turville, Stuart] Westmead Hosp, Ctr Virus Res, Westmead Millennium Inst, Sydney, NSW 2145, Australia; [Stella, Alberto; Turville, Stuart] Univ Sydney, Sydney, NSW 2145, Australia; [Triccas, Jamie] Univ Sydney, Sch Med Sci, Sydney, NSW 2006, Australia; [Triccas, Jamie] Univ Sydney, Marie Bashir Inst, Sydney, NSW 2006, Australia		Petrovsky, N (通讯作者)，Vaxine Pty Ltd, Bedford Pk, Adelaide, SA 5042, Australia.	nikolai.petrovsky@flinders.edu.au	Honda-Okubo, Yoshikazu/AAM-5898-2021	Honda-Okubo, Yoshikazu/0000-0002-2872-8621; Forgacs, David/0000-0002-3553-3320; Sakamoto, Kaori/0000-0003-0592-6403; Chataway, Tim/0000-0003-0254-8099			Adney DR, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030212; Aggarwal A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002762; Appay V, 2008, NAT MED, V14, P623, DOI 10.1038/nm.f.1774; Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4; Coish JM, 2020, MICROBES INFECT, V22, P405, DOI 10.1016/j.micinf.2020.06.006; Dyer O, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3985; Fedson DS, 2006, HUM VACCINES, V2, P38, DOI 10.4161/hv.2.1.2554; Gordon D, 2014, VACCINE, V32, P6469, DOI 10.1016/j.vaccine.2014.09.034; Gordon DL, 2016, VACCINE, V34, P3780, DOI 10.1016/j.vaccine.2016.05.071; Gordon DL, 2012, VACCINE, V30, P5407, DOI 10.1016/j.vaccine.2012.06.009; Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088; Gupta T, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106717; Ho NI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02874; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Honda-Okubo Y, 2015, VACCINE, V33, P4892, DOI 10.1016/j.vaccine.2015.07.051; Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023; Kost TA, 2005, NAT BIOTECHNOL, V23, P567, DOI 10.1038/nbt1095; Kostoff RN, 2020, INT J MOL MED, V46, P1599, DOI 10.3892/ijmm.2020.4733; Kupferschmidt K, 2021, SCIENCE, V371, P9, DOI 10.1126/science.371.6524.9; Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1789, DOI 10.1002/jmv.25900; Layton RC, 2011, VACCINE, V29, P6242, DOI 10.1016/j.vaccine.2011.06.078; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Lei XB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17665-9; Leitner WW, 1999, VACCINE, V18, P765, DOI 10.1016/S0264-410X(99)00271-6; Lokugamage KG, 2020, J VIROL, V94, DOI [10.1128/JVI.01410-20, 10.1101/2020.03.07.982264]; Looi MK, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4113; Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210; Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036; Piplani S., 2020, ARXIV200506199; Qi XX, 2020, CHEM COMMUN, V56, P8683, DOI 10.1039/d0cc03263h; Rollier CS, 2011, CURR OPIN IMMUNOL, V23, P377, DOI 10.1016/j.coi.2011.03.006; Saif LJ, 2020, NAT BIOTECHNOL, V38, P1242, DOI 10.1038/s41587-020-0732-8; Salazar E, 2020, J CLIN INVEST, V130, P6728, DOI 10.1172/JCI141206; Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Toscano MG, 2004, GENE THER, V11, P956, DOI 10.1038/sj.gt.3302259; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Watterson D., 2020, RES SQ PREPR, Vv1, DOI [10.21203/rs.3.rs-68892/v1, DOI 10.21203/RS.3.RS-68892/V1]; Weinberger B, 2018, CURR OPIN PHARMACOL, V41, P34, DOI 10.1016/j.coph.2018.03.014; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803; Yan YM, 2020, NAT PROTOC, V15, P1829, DOI 10.1038/s41596-020-0312-x; Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228; Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3; Zhi Y, 2005, VIROLOGY, V335, P34, DOI 10.1016/j.virol.2005.01.050	53	7	7	9	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5940	5953		10.1016/j.vaccine.2021.07.087		SEP 2021	14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34420786	Bronze, Green Published, Green Submitted			2022-04-29	WOS:000697501500029
J	Schoch-Spana, M; Brunson, EK; Long, R; Ruth, A; Ravi, SJ; Trotochaud, M; Borio, L; Brewer, J; Buccina, J; Connell, N; Hall, LL; Kass, N; Kirkland, A; Koonin, L; Larson, H; Lu, BF; Omer, SB; Orenstein, WA; Poland, GA; Privor-Dumm, L; Quinn, SC; Salmon, D; White, A				Schoch-Spana, Monica; Brunson, Emily K.; Long, Rex; Ruth, Alexandra; Ravi, Sanjana J.; Trotochaud, Marc; Borio, Luciana; Brewer, Janesse; Buccina, Joseph; Connell, Nancy; Hall, Laura Lee; Kass, Nancy; Kirkland, Anna; Koonin, Lisa; Larson, Heidi; Lu, Brooke Fisher; Omer, Saad B.; Orenstein, Walter A.; Poland, Gregory A.; Privor-Dumm, Lois; Quinn, Sandra Crouse; Salmon, Daniel; White, Alexandre			The public's role in COVID-19 vaccination: Human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States	VACCINE			English	Article						COVID-19; SARS-CoV-2; Vaccine uptake; Vaccine confidence; Community engagement; Epidemic management; response	COMMUNITY ENGAGEMENT; HEALTH-CARE; HESITANCY; PERSPECTIVE; DISPARITIES; SAFETY; EBOLA; BIAS	Given the social and economic upheavals caused by the COVID-19 pandemic, political leaders, health offi-cials, and members of the public are eager for solutions. One of the most promising, if they can be suc-cessfully developed, is vaccines. While the technological development of such countermeasures is currently underway, a key social gap remains. Past experience in routine and crisis contexts demonstrates that uptake of vaccines is more complicated than simply making the technology available. Vaccine uptake, and especially the widespread acceptance of vaccines, is a social endeavor that requires consid-eration of human factors. To provide a starting place for this critical component of a future COVID-19 vac-cination campaign in the United States, the 23-person Working Group on Readying Populations for COVID-19 Vaccines was formed. One outcome of this group is a synthesis of the major challenges and opportu-nities associated with a future COVID-19 vaccination campaign and empirically-informed recommenda-tions to advance public understanding of, access to, and acceptance of vaccines that protect against SARS-CoV-2. While not inclusive of all possible steps than could or should be done to facilitate COVID-19 vac-cination, the working group believes that the recommendations provided are essential for a successful vaccination program. (c) 2020 Elsevier Ltd. All rights reserved.	[Schoch-Spana, Monica; Ravi, Sanjana J.; Trotochaud, Marc; Connell, Nancy] Johns Hopkins Ctr Hlth Secur, Baltimore, MD 21202 USA; [Brunson, Emily K.; Long, Rex] Texas State Univ, Dept Anthropol, San Marcos, TX USA; [Schoch-Spana, Monica; Ruth, Alexandra; Ravi, Sanjana J.; Trotochaud, Marc; Brewer, Janesse; Connell, Nancy; Kass, Nancy; Salmon, Daniel] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Borio, Luciana; Buccina, Joseph] In Q Tel, Arlington, VA USA; [Hall, Laura Lee] Ctr Sustainable Hlth Care Qual & Equ, Washington, DC USA; [Ruth, Alexandra; Kass, Nancy] Johns Hopkins Berman Inst Bioeth, Baltimore, MD USA; [Kirkland, Anna] Univ Michigan, Dept Womens & Gender Studies, Ann Arbor, MI 48109 USA; [Koonin, Lisa] Hlth Preparedness Partners, Atlanta, GA USA; [Larson, Heidi] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Lu, Brooke Fisher] Univ Maryland, Dept Commun, College Pk, MD 20742 USA; [Omer, Saad B.] Yale Inst Global Hlth, New Haven, CT USA; [Omer, Saad B.] Yale Sch Med, New Haven, CT USA; [Omer, Saad B.] Yale Sch Publ Hlth, New Haven, CT USA; [Orenstein, Walter A.] Emory Vaccine Ctr, Atlanta, GA USA; [Orenstein, Walter A.] Emory Sch Med, Atlanta, GA USA; [Orenstein, Walter A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Poland, Gregory A.] Mayo Clin, Mayo Clin Vaccine Res Grp, Rochester, MN USA; [Privor-Dumm, Lois] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Baltimore, MD USA; [Quinn, Sandra Crouse] Univ Maryland, Sch Publ Hlth, College Pk, MD 20742 USA; [Salmon, Daniel] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD USA; [White, Alexandre] Johns Hopkins Sch Med, Dept Hist Med, Baltimore, MD USA; [White, Alexandre] Johns Hopkins Univ, Ctr Med Humanities & Social Med, Baltimore, MD USA		Schoch-Spana, M (通讯作者)，Johns Hopkins Ctr Hlth Secur, Baltimore, MD 21202 USA.; Schoch-Spana, M (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.	mschoch1@jhu.edu	Connell, Nancy/AFN-1305-2022; Kirkland, Anna/AAG-8289-2019	Kirkland, Anna/0000-0001-5711-4074; Ruth, Alexandra/0000-0002-5521-8803; Brunson, Emily/0000-0001-6321-1882; White, Alexandre/0000-0002-5296-6072; Privor-Dumm, Lois/0000-0001-9807-2544	National Science FoundationNational Science Foundation (NSF); CONVERGE facility at the Natu-ral Hazards Center at the University of Colorado Boulder [1841338]	This COVID-19 Working Group effort was supported by the National Science Foundation-funded Social Science Extreme Events Research (SSEER) Network and the CONVERGE facility at the Natu-ral Hazards Center at the University of Colorado Boulder (NSF Award #1841338) . Any opinions, findings, and conclusions or rec-ommendations expressed in this material are those of the authors and do not necessarily reflect the views of the NSF, SSEER, or CONVERGE.	Abramowitz SA, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003706; Agiesta J., 2020, CNN, V11; Allam H., 2020, NPR; Altman M, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.180128; [Anonymous], 2020, HUMAN GENOME PROJECT; Ball P, 2020, NATURE, V581, P371, DOI 10.1038/d41586-020-01452-z; Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4; Bloom BR, 2014, PUBLIC TRUST VACCINE; Bogel-Burroughs N., 2020, NEW YORK TIMES; Bollyky TJ, 2020, JAMA-J AM MED ASSOC, V323, P2462, DOI 10.1001/jama.2020.6641; Bridges K., 2020, HUMAN RIGHTS MAGAZIN; Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567; Brunson EK, 2013, PEDIATRICS, V131, pE1397, DOI 10.1542/peds.2012-2452; Bulatao R.A., 2004, UNDERSTANDING RACIAL; Center for Multicultural Health, 2020, EV ASS H1N1 OUTR AFR; Centers for Disease Control and Prevention, 2020, COR DIS 2019 CAS US, P2020; Centers for Disease Control and Prevention, GAT HLTH COMM; Centers for Disease Control and Prevention, 2020, NAT STAT LEV PLAC FL; Chou WYS, 2018, JAMA-J AM MED ASSOC, V320, P2417, DOI 10.1001/jama.2018.16865; College of Physicians of Philadelphia, 2018, VACC DEV TEST REG; Colwell RR, 2019, SCI CRISIS BEST PRAC; Community Preventive Services Task Force, 2016, INCRE APPR VACC HOM; CONVERGE, 2020, COVID 19 WORK GROUPS; CONVERGE, 2020, CONVERGE TRAIN MOD; Corum J., 2020, NEW YORK TIMES, V5; D'Heilly S, 2002, AM J INFECT CONTROL, V30, P261, DOI 10.1067/mic.2002.121554; D'Heilly SJ, 2006, VACCINE, V24, P4024, DOI 10.1016/j.vaccine.2005.09.061; Department of Health and Human Services, 2020, NIH DIR EM TRANSF RE; Doyle AA, 2020, EVIDENCE TRADEOFFSST, DOI [10.2139/ssrn.3578841, DOI 10.2139/SSRN.3578841]; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; European External Action Service Strategic Communications and Information Analysis Division, 2020, EEAS SPEC REP UPD SH; Frenkel S., 2020, NEW YORK TIMES; Goldstein AC., WASH POST; Hall WJ, 2015, AM J PUBLIC HEALTH, V105, pE60, DOI 10.2105/AJPH.2015.302903; Hart PS, 2012, COMMUN RES, V39, P701, DOI 10.1177/0093650211416646; Henninger Michelle L, 2017, Perm J, V21, P16, DOI 10.7812/TPP/16-191; Hoffman KM, 2016, P NATL ACAD SCI USA, V113, P4296, DOI 10.1073/pnas.1516047113; Institute of Medicine (US), 2010, 2009 H1N1 INFL VACC; Jamison P., 2020, WASH POST; Johns Hopkins Center for Health Security, 2019, PREP HIGH IMP RESP P; Knowles, 2020, WASH POST; Koonin LM, 2011, DISASTER MED PUBLIC, V5, P253, DOI 10.1001/dmp.2011.83; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Law T., 2020, TIME; Liamputtong P., 2011, FOCUS GROUP METHODOL; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; MADDEN TJ, 1992, PERS SOC PSYCHOL B, V18, P3, DOI 10.1177/0146167292181001; Maqbool A., 2020, BBC NEWS 0427; Marston C, 2016, B WORLD HEALTH ORGAN, V94, P376, DOI 10.2471/BLT.15.168492; McEwen JE, 2014, ANNU REV GENOM HUM G, V15, P481, DOI 10.1146/annurev-genom-090413-025327; Moon S, 2015, LANCET, V386, P2204, DOI 10.1016/S0140-6736(15)00946-0; Murphy FG, 2013, COMMUNITY ENGAGEMENT; National Aeronautics and Space Administration, 2019, HUM FACT NASA; National Vaccine Advisory Committee (NVAC), 2012, H1N1 VACC SAF RISK A; Navathe A. S., 2020, NEW YORK TIMES; Oshinsky DM., 2005, POLIO AM STORY; Pew Research Center, 2020, WID DECL SHAR WHO SA; Plough A, 2011, J PUBLIC HEALTH MAN, V17, P20, DOI 10.1097/PHH.0b013e3181ff2ad7; Poland CM, 2015, VACCINE, V33, P277, DOI 10.1016/j.vaccine.2014.11.022; Poland CM, 2011, VACCINE, V29, P6145, DOI 10.1016/j.vaccine.2011.07.131; Poland GA, 2019, JAMA-J AM MED ASSOC, V322, P209, DOI 10.1001/jama.2019.7445; Ponizovskiy V, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00934; Quinn SC, 2011, AM J PUBLIC HEALTH, V101, P285, DOI 10.2105/AJPH.2009.188029; Rosenstock I.M., 1990, HLTH BEHAV HLTH ED T, P39; Scharff DP, 2010, J HEALTH CARE POOR U, V21, P879, DOI 10.1353/hpu.0.0323; Schoch-Spana MBE., 2020, PUBLICS ROLE COVID 1; Schoch-Spana M, 2007, BIOSECUR BIOTERROR, V5, P8, DOI 10.1089/bsp.2006.0036; Schoch-Spana M, 2010, BIOSECUR BIOTERROR, V8, P243, DOI 10.1089/bsp.2010.0021; Seeber L, 2015, CURR DRUG SAF, V10, P31, DOI 10.2174/157488631001150407105400; Smout EM, 2016, INT J INFECT DIS, V45, P191, DOI 10.1016/j.ijid.2016.02.444; SteelFisher GK, 2010, NEW ENGL J MED, V362, DOI 10.1056/NEJMp1005102; Sullivan Gail M, 2011, J Grad Med Educ, V3, P449, DOI 10.4300/JGME-D-11-00221.1; U.S. Department of Health and Human Services (HHS), 2020, FACT SHEET EXPL OP W; U.S. Department of Health and Human Services Press Office, 2020, TRUMP ADM ANN FRAM L; United Nations, 2016, PROT HUM FUT HLTH CR PROT HUM FUT HLTH CR; United Nations, 2020, PRESS FREED CRIT COU; Vraga EK, 2020, POLIT COMMUN, V37, P136, DOI 10.1080/10584609.2020.1716500; Washington HA., 2006, MED APARTHEID DARK H; Westrick SC, 2018, VACCINE, V36, P5657, DOI 10.1016/j.vaccine.2018.07.027; World Health Organization, 2015, REP EB INT ASS PAN; World Health Organization, 2005, IMPL INT HLTH REG RE; World Health Organization (WHO), 2020, 206 WHO, V2019, P2633	82	56	56	8	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					6004	6012		10.1016/j.vaccine.2020.10.059		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	US5XJ	33160755	Bronze, Green Published	Y	N	2022-04-29	WOS:000697501500035
J	Eldridge, HJ; Egan, AM; Matassov, D; Hamm, S; Hermida, L; Chen, T; Tremblay, M; Sciotto-Brown, S; Xu, R; Dimitrov, A; Smith, RE; Gurwith, M; Chen, TR				Eldridge, H. John; Egan, A. Michael; Matassov, Demetrius; Hamm, Stefan; Hermida, Luz; Chen, Tracy; Tremblay, Marc; Sciotto-Brown, Susan; Xu, Rong; Dimitrov, Antony; Smith, R. Emily; Gurwith, Marc; Chen, T. Robert		Benefit Risk Assessment VAccines	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses	VACCINE			English	Review						Vaccine; Protein; Safety; Benefit; Risk; Nipah; Hendra	BANGLADESH; INFECTION; EPIDEMIOLOGY; ENCEPHALITIS; OUTBREAKS; PROTEIN; HORSES; GENE	Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum phosphate. This vaccine is currently under clinical evaluation in a Phase 1 study. The Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template may also help contribute to improved public acceptance and communication of licensed protein vaccines. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Eldridge, H. John; Egan, A. Michael; Matassov, Demetrius; Hamm, Stefan; Hermida, Luz; Chen, Tracy; Tremblay, Marc; Sciotto-Brown, Susan] Auro Vaccines LLC, Pearl River, NY USA; [Xu, Rong] Sabin Vaccine Inst, Washington, DC USA; [Dimitrov, Antony] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Smith, R. Emily; Gurwith, Marc; Chen, T. Robert] Brighton Collaborat, Decatur, GA 30030 USA		Smith, RE (通讯作者)，Brighton Collaborat, Decatur, GA 30030 USA.	brightoncollaborationv3swg@gmail.com			CEPI	Auro Vaccines would like to acknowledge CEPI for the generous and steadfast funding of this vaccine program. We would also like to thank the additional BRAVATO members and participants for their support and helpful comments.	Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; [Anonymous], 1999, JAMA, V281, P1787; Arankalle VA, 2011, EMERG INFECT DIS, V17, P907, DOI 10.3201/eid1705.100968; Arunkumar G, 2018, J INFECT DIS; Bill RM, 2015, J PHARM PHARMACOL, V67, P319, DOI 10.1111/jphp.12353; Chadha MS, 2006, EMERG INFECT DIS, V12, P235, DOI 10.3201/eid1202.051247; Chakraborty A, 2016, EPIDEMIOL INFECT, V144, P371, DOI 10.1017/S0950268815001314; Chambers Adam C, 2018, Curr Protoc Protein Sci, V91, DOI 10.1002/cpps.47; Ching PKG, 2015, EMERG INFECT DIS, V21, P328, DOI 10.3201/eid2102.141433; Cox MMJ, 2008, INFLUENZA OTHER RESP, V2, P211, DOI 10.1111/j.1750-2659.2008.00053.x; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Harcourt BH, 2005, EMERG INFECT DIS, V11, P1594, DOI 10.3201/eid1110.050513; Lo MK, 2012, EMERG INFECT DIS, V18, P248, DOI 10.3201/eid1802.111492; Luby SP, 2009, CLIN INFECT DIS, V49, P1743, DOI 10.1086/647951; Maltz Fraidy, 2019, P T, V44, P406; MURRAY K, 1995, SCIENCE, V268, P94, DOI 10.1126/science.7701348; OSullivan JD, 1997, LANCET, V349, P93, DOI 10.1016/S0140-6736(96)06162-4; Pitisuttithum P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027837; Singh RK, 2019, VET QUART, V39, P26, DOI 10.1080/01652176.2019.1580827; Wang LF, 1998, J VIROL, V72, P1482, DOI 10.1128/JVI.72.2.1482-1490.1998; Wang M, 2016, BIOENGINEERED, V7, P155, DOI 10.1080/21655979.2016.1191707; Weatherman S, 2018, CURR OPIN VIROL, V28, P7, DOI 10.1016/j.coviro.2017.09.004; Yu M, 1998, VIROLOGY, V251, P227, DOI 10.1006/viro.1998.9302; Yu M, 1998, J GEN VIROL, V79, P1775, DOI 10.1099/0022-1317-79-7-1775; Yuen KY, ELSEVIER ONE HLTH, V12	26	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 7	2021	39	38					5436	5441		10.1016/j.vaccine.2021.07.030		AUG 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UG5UY	34373117	hybrid			2022-04-29	WOS:000689318300014
J	Klein, NP; Peyrani, P; Yacisin, K; Caldwell, N; Xu, X; Scully, IL; Scott, DA; Jansen, KU; Gruber, WC; Watson, W				Klein, Nicola P.; Peyrani, Paula; Yacisin, Kari; Caldwell, Nicole; Xu, Xia; Scully, Ingrid L.; Scott, Daniel A.; Jansen, Kathrin U.; Gruber, William C.; Watson, Wendy			A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age	VACCINE			English	Article						Clinical trial; Lot consistency; Immunogenicity and safety; Streptococcus pneumoniae; 20-valent pneumococcal conjugate vaccine	INITIAL VACCINATION; DISEASE; PREVENTION; SEROTYPES; RESPONSES; BURDEN	Introduction: Introduction of pneumococcal conjugate vaccines (PCVs), including the 13-valent PCV (PCV13), has considerably reduced pneumococcal disease burden. However, additional serotypes not in PCV13 continue to present a substantial disease burden. The 20-valent PCV (PCV20) was developed to expand protection against pneumococcal disease beyond PCV13. As part of the phase 3 clinical development program, the current study assessed consistency of immune responses across 3 lots of PCV20 and described the safety profile of PCV20. Methods: This phase 3, randomized, multicenter, double-blind study of pneumococcal vaccine-naive adults 18-49 years of age randomized 1710 participants in a 2:2:2:1 ratio to receive 1 of 3 lots of PCV20 or PCV13. Immunogenicity was assessed through serotype-specific opsonophagocytic activity (OPA) titers before and approximately 1 month (28-42 days) after vaccination. Reported local reactions within 10 days, systemic events within 7 days, adverse events (AEs) within 30 days, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination were evaluated. Results: Equivalence in immune responses (OPA geometric mean titers) for all 20 vaccine serotypes was demonstrated across the 3 PCV20 lots. Robust responses, assessed by OPA geometric mean fold rises, percentage of participants achieving >4-fold rises, and percentage of participants with OPA titers >lower limit of quantitation, were observed after PCV20. Reported rates of local reactions, systemic events, and AEs were similar between the pooled PCV20 lots and PCV13; most events were mild or moderate. Reported rates of SAEs and NDCMCs were low and similar between the PCV20 and PCV13 groups. Conclusions: Three different lots of PCV20 demonstrated robust and consistent immunogenicity. The safety and tolerability of PCV20 was acceptable and similar to that of PCV13. (Clinicaltrials.gov: NCT03828617). (c) 2021 Elsevier Ltd. All rights reserved.	[Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA 94612 USA; [Peyrani, Paula] Pfizer Inc, Vaccine Med Dev & Sci Clin Affairs, Collegeville, PA 19426 USA; [Yacisin, Kari; Caldwell, Nicole; Xu, Xia; Scott, Daniel A.; Watson, Wendy] Pfizer Inc, Vaccine Res & Dev, 500 Arcola Rd, Collegeville, PA 19426 USA; [Scully, Ingrid L.; Jansen, Kathrin U.; Gruber, William C.] Pfizer Inc, Vaccine Res & Dev, Pearl River, NY 10965 USA		Yacisin, K (通讯作者)，Pfizer Inc, Vaccine Res & Dev, 500 Arcola Rd, Collegeville, PA 19426 USA.	Nicola.Klein@kp.org; Paula.Peyrani@pfizer.com; Kari.Yacisin@pfizer.com; Nicole.Caldwell@pfizer.com; Xia.Xu3@pfizer.com; Ingrid.Scully@pfizer.com; Dan.Scott@pfizer.com; Kathrin.Jansen@pfizer.com; bill.gruber@pfizer.com; wendy.watson2@pfizer.com		Scott, Daniel/0000-0002-4916-145X	Pfizer Inc.Pfizer	This study was sponsored by Pfizer Inc.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P129; Balsells E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177113; Blasi F, 2012, CLIN MICROBIOL INFEC, V18, P7, DOI 10.1111/j.1469-0691.2012.03937.x; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Centers for Disease Control and Prevention, 2017, PNEUM DIS SURV REP; Clutterbuck EA, 2012, J INFECT DIS, V205, P1408, DOI 10.1093/infdis/jis212; Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056; Cui YDA, 2017, HUM VACC IMMUNOTHER, V13, P1229, DOI 10.1080/21645515.2016.1277300; de Miguel S, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1483, DOI 10.1093/cid/ciaa1483]; Drijkoningen JJC, 2014, CLIN MICROBIOL INFEC, V20, P45, DOI 10.1111/1469-0691.12461; Essink B, 2020, IDWEEK; Frasch CE, 2009, VACCINE, V27, P6468, DOI 10.1016/j.vaccine.2009.06.013; Frenck RW, 2016, VACCINE, V34, P3454, DOI 10.1016/j.vaccine.2016.04.093; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; Harboe ZB, 2014, CLIN INFECT DIS, V59, P1066, DOI 10.1093/cid/ciu524; Hausdorff WP, 2016, HUM VACC IMMUNOTHER, V12, P358, DOI 10.1080/21645515.2015.1118593; Hurley D, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa45, DOI 10.1093/CID/CIAA45]; Isturiz RE, 2019, VACCINE, V37, P3352, DOI 10.1016/j.vaccine.2019.04.087; Isturiz RE, 2016, EXPERT REV VACCINES, V15, P279, DOI 10.1586/14760584.2016.1132171; Jackson LA, 2013, VACCINE, V31, P3594, DOI 10.1016/j.vaccine.2013.04.084; McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312; Metcalf BJ, 2016, CLIN MICROBIOL INFEC, V22, DOI [10.1016/j.cmi.2016.08.001, 10.1016/j.cmi.2015.08.027]; Miller E, 2011, VACCINE, V29, P9127, DOI 10.1016/j.vaccine.2011.09.112; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Perdrizet J, 2020, INT S PNEUM PNEUM DI; Pfizer Inc. U.S. FDA Approves PREVNAR 20TM, PFIZ PNEUM 20 VAL CO; Pilishvili T, 2020, IDWEEK 2020 OCT 21 V; Pilishvili T, 2015, VACCINE, V33, pD60, DOI 10.1016/j.vaccine.2015.05.102; Scully IL, 2019, OPEN FORUM INFECT DI, V6, DOI [10.1093/ofid/ofz360.1201.S484-S, DOI 10.1093/OFID/OFZ360.1201.S484-S]; Steens A, 2013, VACCINE, V31, P6232, DOI 10.1016/j.vaccine.2013.10.032; Thompson A, 2019, VACCINE, V37, P6201, DOI 10.1016/j.vaccine.2019.08.048; Tomczyk S, 2016, CLIN INFECT DIS, V62, P1119, DOI 10.1093/cid/ciw067; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; US Department of Health and Human Services, 1997, GUID IND EV COMB VAC; van der Linden M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220453; van der Linden M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131494; Wantuch PL, 2019, HUM VACC IMMUNOTHER, V15, P874, DOI 10.1080/21645515.2018.1564444; Yahiaoui RY, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3341-0	38	6	7	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 7	2021	39	38					5428	5435		10.1016/j.vaccine.2021.07.004		AUG 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UG5UY	34315611	Bronze			2022-04-29	WOS:000689318300013
J	Vink, M; Upadhaya, N; Amin, HA; Liwal, MG; Siddiqui, AM; Naseem, M; Syawash, A; van der Loeff, MS				Vink, Martijn; Upadhaya, Nawaraj; Amin, Hazrat Amin; Liwal, Mohammad Gul; Siddiqui, Abdul Majeed; Naseem, Mohammad; Syawash, Aziza; van der Loeff, Maarten Schim			Does support to Private Health Practitioners increase childhood vaccination coverage? Findings from a comparative study in Afghanistan	VACCINE			English	Article						Private Health Practitioners; Public-private partnership; Uruzgan; Afghanistan; Childhood vaccinations; Polio; Measles	MIDDLE-INCOME COUNTRIES; MEASLES VACCINATION; IMMUNIZATION; ATTAINMENT; IMPACT	Introduction: In Afghanistan coverage of childhood vaccinations is very low, especially in remote and insecure areas with a weak public health structure. Private health providers (PHPs) in these areas play an important role in health care provision, some of whom have received (para)medical training. In 2009 HealthNet TPO initiated a Public-Private Partnership program in Uruzgan province, training and equipping 34 PHPs in remote and conflict-affected locations to provide quality childhood vaccination services. We aimed to assess the impact of this program on child vaccination coverage. Methods: A cross-sectional household survey was performed in three districts of Uruzgan Province from January through April 2013. A stratified cluster sampling approach was used to select villages; in each of the villages 15 households were randomly selected. Vaccination information, based on vaccination cards and mother's recall, was obtained about all children aged 12-23 months in these households. Results: In total 113 children from 8 PHP villages and 286 children from 18 non-PHP villages were included. A clustered analysis showed that coverage of polio-3, diphtheria-tetanus-pertussis (DTP)-3 and of measles-1 were significantly higher in PHP villages (73.5%, 66.4% and 69.9% respectively) than in non-PHP villages (36.0%, 5.2% and 26.2% respectively; P < 0.0001 for all comparisons). The proportion of children being fully vaccinated (excluding BCG) was 54.9% in the PHP villages and 4.9% in the non-PHP villages (P < 0.0001). Vaccinated children in non-PHP villages were mainly vaccinated during mass vaccination campaigns (92.5%), while in PHP villages this was done by PHPs (47.2%) or a combination of PHPs and mass vaccination campaigns (39.2%). Conclusion: Our study shows that PHPs in remote and conflict affected locations in Afghanistan can play an important role to increase childhood vaccination coverage. Expanding this program to comparable provinces in Afghanistan and to other countries struggling with insecurity and weak public health systems may save much childhood morbidity and mortality. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Vink, Martijn; Upadhaya, Nawaraj; Syawash, Aziza] Hlth Net TPO, Czaar Peterstr 159, NL-1018 PJ Amsterdam, Netherlands; [Amin, Hazrat Amin; Liwal, Mohammad Gul; Siddiqui, Abdul Majeed; Naseem, Mohammad] HealthNet TPO, House 144,Main St 5,Dist 3, Dehnow Dehbori, Kabul, Afghanistan; [Vink, Martijn; van der Loeff, Maarten Schim] Univ Amsterdam, Med Ctr, Locat Acad Med Ctr AMC, Med Microbiol Dept,Expt Parasitol L1 116, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [van der Loeff, Maarten Schim] Publ Hlth Serv Amsterdam GGD, Nieuwe Achtergracht 100, NL-1018 WT Amsterdam, Netherlands		Vink, M (通讯作者)，Univ Amsterdam, Locat Acad Med Ctr AMC, Med Microbiol Dept, Med Ctr AUMC,Expt Parasitol L1 116, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.m.vink@amsterdamumc.nl; navarajtpo@gmail.com; drhazratamin@healthnettpoaf.org; drmohammad-gulliwal@gmail.com; majeed@healthnettpoaf.org; naseem@healthmettpoaf.org; asyawash@yahoo.com; mschinvdloeff@ggd.amsterdam.ni			Dutch Ministry of Foreign Affairs; GAVI, the Vaccine Alliance	This PPP evaluation study was implemented as part of the Dutch Consortium of Uruzgan (DCU) program, funded by the Dutch Ministry of Foreign Affairs and GAVI, the Vaccine Alliance.	Agampodi S B, 2007, Indian J Med Sci, V61, P192; Anekwe TD, 2015, VACCINE, V33, P5020, DOI 10.1016/j.vaccine.2015.04.072; Canning D, 2011, SOC SCI MED, V72, P1429, DOI 10.1016/j.socscimed.2011.02.043; Carthaigh NN, 2015, INT HEALTH, V7, P169, DOI 10.1093/inthealth/ihu086; Central Statistics Organization IRoA, 2013, HLTH DEV; Central Statistics Organization IRoA, 2013, SETTL POP UR PROV CI SETTL POP UR PROV CI; Central Statistics Organization IRoA, 2018, AFGH LIV COND SURV 2 AFGH LIV COND SURV 2; Das JK, 2020, CONFL HEALTH, V14, DOI 10.1186/s13031-020-00271-3; Driessen J, 2015, SOC SCI MED, V139, P115, DOI 10.1016/j.socscimed.2015.06.018; GRM International IRoA, 2006, REG RUR EC REG STRAT REG RUR EC REG STRAT; KIT Royal Tropical Institute NSIA, 2019, AFGH HLTH SURV 2018; Knoema, 2020, AFGH MEASL REP CAS K AFGH MEASL REP CAS K; Levin A, 2019, VACCINE, V37, P3568, DOI 10.1016/j.vaccine.2019.05.023; Levin A, 2011, HEALTH POLICY PLANN, V26, pi4, DOI 10.1093/heapol/czr037; Mirzazada S, 2020, CONFL HEALTH, V14, DOI 10.1186/s13031-020-00285-x; Mitrovich R, 2017, LIT REV IMMUNIZATION; Mugali RR, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4193-z; Nandi A, 2020, HUM VACC IMMUNOTHER, V16, P1900, DOI 10.1080/21645515.2019.1708669; Nandi A, 2019, ANN NY ACAD SCI, V1449, P70, DOI 10.1111/nyas.14127; Ozawa S, 2017, B WORLD HEALTH ORGAN, V95, P629, DOI 10.2471/BLT.16.178475; Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086; Sami S, 2020, CONFL HEALTH, V14, DOI 10.1186/s13031-020-00272-2; Sarveswaran G, 2019, J TROP PEDIATRICS, V65, P427, DOI 10.1093/tropej/fmy071; Sato Ryoko, 2019, Confl Health, V13, P49, DOI 10.1186/s13031-019-0235-8; Topuzoglu A, 2005, PUBLIC HEALTH, V119, P862, DOI 10.1016/j.puhe.2005.01.015; Uddin MJ, 2010, HEALTH POLICY PLANN, V25, P50, DOI 10.1093/heapol/czp041; United Nations International Children's Fund (UNICEF), 2021, STATE WORLDS CHILDRE; USAID, 2009, AFGH PRIV SECT HLTH AFGH PRIV SECT HLTH; World Health Organization, 2020, 10 FACTS IMMUNIZATIO; World Health Organization, 2018, VACCINATION COVERAGE; World Health Organization, 2018, GUID IMM PROGR MAN W GUID IMM PROGR MAN W	31	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					5007	5014		10.1016/j.vaccine.2021.07.018		AUG 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TX3GY	34325933	hybrid			2022-04-29	WOS:000682979100014
J	Gosset, A; Diallo, MY; Betsem, E; Schaeffer, L; Meda, N; Vray, M; Sombie, R; Shimakawa, Y; Boyer, S				Gosset, Andrea; Diallo, Mamadou Yaya; Betsem, Edouard; Schaeffer, Laura; Meda, Nicolas; Vray, Muriel; Sombie, Roger; Shimakawa, Yusuke; Boyer, Sylvie			Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NeoVac Study)	VACCINE			English	Article						Hepatitis B vaccine; Birth dose; Mother-to-child transmission; Cost-effectiveness; Burkina Faso; Africa	HEPATOCELLULAR-CARCINOMA; VIRUS INFECTION; TRANSMISSION; BARRIERS; RISK; HBV; AGE	Background: The World Health Organization (WHO) recommends a first hepatitis B vaccine dose within 24 h of birth (HepB-BD) to prevent mother-to-child transmission. Evidence for this strategy's economic value in Africa is limited. We assessed the costs and cost-effectiveness of adding HepB-BD to the current three-dose pentavalent schedule (HepB3) in the Dafra district of the Hauts-Bassins Region in Burkina Faso. Methods: Using a decision tree combined with a Markov model, we estimated the expected number of life-years (LY) and disability-adjusted life-years (DALYs) saved, incremental costs, and incremental cost-effectiveness ratios (ICER) of HepB-BD + HepB3 versus HepB3 alone in Dafra's 2017 birth cohort (n = 11,462). Institutional delivery rates, vaccine coverage, and vaccination costs from a health system perspective were estimated from field-collected data. We estimated the effectiveness of HepB-BD, age specific transition probabilities, and horizontal transmission risks using data from previous African studies. Costs and health outcomes were discounted at an annual rate of 3%. We conducted one-way and probabilistic sensitivity analyses to assess uncertainty. Results: In the base-case analysis without discounting, HepB-BD + HepB3 yielded a net cost saving of US $18,979 and saved 163 DALYs compared with HepB3 alone. With discounting, HepB-BD + HepB3 compared with HepB3 resulted in an incremental cost of US$554 and 31 DALYs averted, translating into an ICER of US$18/DALY averted. In one-way sensitivity analyses, HepB-BD + HepB3 remained cost-effective (at the cost-effectiveness threshold of US$671 i.e. the Burkina Faso per-capita gross domestic product) for all parameter changes. However, results were very sensitive to variations in HepB-BD unit cost per vaccinated neonate and perinatal transmission risk in mothers carrying the hepatitis B e antigen. The probabilities of HepBBD + HepB3 being cost-effective were 71.7% and 86.7%, at the cost-effectiveness thresholds of US$335 and US$671, respectively. Conclusion: Introducing HepB-BD in Burkina Faso is likely to be cost-effective. CO 2021 Elsevier Ltd. All rights reserved.	[Gosset, Andrea; Diallo, Mamadou Yaya; Boyer, Sylvie] Aix Marseille Univ, INSERM, IRD, SESSTIM Sci Econ & Soci Sante & Traitement lInfor, Marseille, France; [Betsem, Edouard] Lab Mixte Int Vaccinol LAMIVAC, Bobo Dioulasso, Burkina Faso; [Betsem, Edouard; Schaeffer, Laura; Vray, Muriel; Shimakawa, Yusuke] Agence Med Prevent AMP, Bobo Dioulasso, Burkina Faso; [Meda, Nicolas] Inst Pasteur, Unite Epidemiol Malad Emergentes, Paris, France; [Meda, Nicolas] Ctr Muraz, Bobo Dioulasso, Burkina Faso; [Sombie, Roger] Ctr Hosp Univ Yalgado Ouedraogo, Dept Hepatogastroenterol, Ouagadougou, Burkina Faso		Shimakawa, Y (通讯作者)，Inst Pasteur, 25-28 Rue Docteur Roux, F-75724 Paris 15, France.; Boyer, S (通讯作者)，Aix Marseille Univ, INSERM, IRD, SESSTIM Fac Med, 27 Bd Jean Moulin, F-0005 Marseille, France.	yusuke.shimakawa@gmail.com; sylvie.boy-er@inserm.fr		Schaeffer, Laura/0000-0002-5850-3415; Gosset, Andrea/0000-0003-0743-2458	Total FoundationTotal SA	This work was funded by the Total Foundation.	Attema AE, 2018, PHARMACOECONOMICS, V36, P745, DOI 10.1007/s40273-018-0672-z; Attia K, 2008, WORLD J GASTROENTERO, V14, P286, DOI 10.3748/wjg.14.286; Bassoum O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020301; Brenzel L., 2013, COMMON APPROACH COST; Chen HL, 2004, HEPATOLOGY, V39, P58, DOI 10.1002/hep.20006; Dao B, 2001, Rev Med Brux, V22, P83; Edmunds WJ, 1996, EPIDEMIOL INFECT, V117, P313, DOI 10.1017/S0950268800001497; EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197, DOI 10.1098/rspb.1993.0102; Ekra D, 2008, VACCINE, V26, P2753, DOI 10.1016/j.vaccine.2008.03.018; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Ferlay J., 2013, GLOBOCAN 2012 V10 CA; Geneva: World Health Organization, 2019, WHO GUID STAND EC EV; Giles-Vemick T, 2016, AM J TROP MED HYG, V95, P1368, DOI 10.4269/ajtmh.16-0398; Global Burden of Disease Collaborative Network, 2017, GLOBAL BURDEN DIS ST; Goldstein ST, 2005, INT J EPIDEMIOL, V34, P1329, DOI 10.1093/ije/dyi206; Hagan JE, 2019, AM J TROP MED HYG, V101, P891, DOI 10.4269/ajtmh.18-0926; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Ilboudo D, 2002, Med Trop (Mars), V62, P99; Institute for Health Metrics and Evaluation (IHME), 2016, EP VIS INC DEC CIRRH; Keane E, 2016, ALIMENT PHARM THER, V44, P1005, DOI 10.1111/apt.13795; Kim BK, 2011, ANTIVIR THER, V16, P1169, DOI 10.3851/IMP1982; Klingler C, 2012, VACCINE, V31, P252, DOI 10.1016/j.vaccine.2012.08.007; Lingani M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5432-7; Lothgren M, 2000, HEALTH ECON, V9, P623, DOI 10.1002/1099-1050(200010)9:7<623::AID-HEC539>3.0.CO;2-V; Machaira M, 2015, J ANTIMICROB CHEMOTH, V70, P396, DOI 10.1093/jac/dku404; MCMAHON BJ, 1992, AM J MED, V92, P254, DOI 10.1016/0002-9343(92)90073-K; Mendy M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058029; Ministere de la sante du Burkina Faso, 2017, PLAN ACT SAN DAFR; Miyahara R, 2016, VACCINE, V34, P3335, DOI 10.1016/j.vaccine.2016.05.017; Nayagam S, 2016, LANCET INFECT DIS, V16, P1399, DOI 10.1016/S1473-3099(16)30204-3; Njouom, 2018, EFFICACITE VACCINATI; Peng CY, 2012, J HEPATOL, V57, P442, DOI 10.1016/j.jhep.2012.02.033; Peto TJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-7; Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; Reardon JM, 2019, CONFL HEALTH, V13, DOI 10.1186/s13031-019-0188-y; Sachs Jeffrey, 2001, MACROECONOMICS HLTH; Scott N, 2018, LANCET GLOB HEALTH, V6, pE659, DOI 10.1016/S2214-109X(18)30219-5; Shimakawa Y, 2016, GUT, V65, P2007, DOI 10.1136/gutjnl-2015-309892; Shimakawa Y, 2015, LIVER INT, V35, P2318, DOI 10.1111/liv.12814; Shimakawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069430; Sosler S, UPDATE GAVIS SUPPORT; Tall H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060583; Umoh NJ, 2011, LIVER INT, V31, P215, DOI 10.1111/j.1478-3231.2010.02418.x; UNICEF, GLOB DEL CAR COV TRE; UNICEF Supply Division, 2017, SUPPL LOG; WHO, LIFE TABLES; WHO, WHO VACC PREV DIS MO; Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017; Wordsworth S, 2011, APPL METHODS COSTEFF; World Bank, 2017, GDP CAP CURR US; World Health Organization, 2012, World Health Organ Tech Rep Ser, P1; World Health Organization, WHO UNICEF EST HEPB; World Health Organization, 2002, GUID EST COSTS INTR; World Health Organization Global Hepatitis Programme, 2015, GUIDELINES PREVENTIO; Yang JD, 2017, LANCET GASTROENTEROL, V2, P103, DOI 10.1016/S2468-1253(16)30161-3	55	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4659	4670		10.1016/j.vaccine.2021.06.059		JUL 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	34238606				2022-04-29	WOS:000681356500011
J	Plutzer, E; Warner, SB				Plutzer, Eric; Warner, Seth B.			A potential new front in health communication to encourage vaccination: Health education teachers	VACCINE			English	Article						Vaccine hesitancy; Health communication; Health education	INTERVENTION; KNOWLEDGE; HPV	Objective: To assess the potential for a new channel for effective vaccine health communication in the United States: the nation's health education teachers. Methods: Content analysis of current curricular standards governing health education in the fifty states and the District of Columbia, and a 2019 nationally representative survey of middle and high school health education teachers in the United States. Results: Only 12 states require any discussion of vaccines or immunization, and none provide detailed guidance to teachers on critical knowledge that might help young adults make wise immunization decisions. Only 42% of teachers discuss benefits of vaccination and immunization in their classes. In contrast to the teaching of evolution and climate change, only a small minority (2.4%) are classified as vaccine skeptics. Conclusions: Public school health education classes are an under-utilized health communication channel with the unrealized potential to convey medically accurate information to millions of young Americans. Low levels of vaccine skepticism among teachers suggest that this channel can be effectively utilized to improve vaccination uptake and thereby improve collective health outcomes. (c) 2021 Elsevier Ltd. All rights reserved.	[Plutzer, Eric; Warner, Seth B.] Penn State Univ, University Pk, PA 16802 USA		Plutzer, E (通讯作者)，Penn State Univ, University Pk, PA 16802 USA.	plutzer@psu.edu; sbw59@psu.edu		Warner, Seth/0000-0001-6856-0184; Plutzer, Eric/0000-0002-5456-7227			AAPOR, 2016, STAND DEF FIN DISP C, V9th; Alan Guttmacher Institute, 2018, HIV SEX ED STAT POL HIV SEX ED STAT POL; Antolik EM, 2019, THESIS INDIANA U PEN THESIS INDIANA U PEN; Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Berkman M, 2010, EVOLUTION CREATIONIS; Berkman MB, 2011, SCIENCE, V331, P404, DOI 10.1126/science.1198902; Billington JK, 2016, AM J PUBLIC HEALTH, V106, P269, DOI 10.2105/AJPH.2015.302967; Centers for Disease Control, 2010, CUM BIRTH RAT LIV BI CUM BIRTH RAT LIV BI; Centers for Disease Control, 2017, HLTH US TABL 66 HLTH US TABL 66; Dechene A, 2010, PERS SOC PSYCHOL REV, V14, P238, DOI 10.1177/1088868309352251; Fahlman MM, 2008, J SCHOOL HEALTH, V78, P216, DOI 10.1111/j.1746-1561.2008.00289.x; Flay Brian R, 2009, Tob Induc Dis, V5, P6, DOI 10.1186/1617-9625-5-6; Flora JA, 1997, ANN EPIDEMIOL, V7, pS104, DOI 10.1016/S1047-2797(97)80013-0; Foshee VA, 2004, AM J PUBLIC HEALTH, V94, P619, DOI 10.2105/AJPH.94.4.619; Gargano LM, 2013, HUM VACC IMMUNOTHER, V9, P2627, DOI 10.4161/hv.25823; Goldstein ND, 2019, AM J PUBLIC HEALTH, V109, P102, DOI 10.2105/AJPH.2018.304765; Grossman PL, 1995, EDUC RESEARCHER, V24, P5, DOI DOI 10.3102/0013189X024008005; Jones M, 2014, AM J PUBLIC HEALTH, V104, pE3, DOI 10.2105/AJPH.2014.302065; Kestenbaum LA, 2015, PEDIATR ANN, V44, pE71, DOI 10.3928/00904481-20150410-07; Laughlin N., 2021, MORNING CONSULT; Lipsky Michael, 1983, STREET LEVEL BUREAUC; McCright AM, 2011, SOCIOL QUART, V52, P155, DOI 10.1111/j.1533-8525.2011.01198.x; Merzouk MD, 2011, J PEDIATR ADOL GYNEC, V24, P278, DOI 10.1016/j.jpag.2011.03.010; Moss JL, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1414; National Center for Education Statistics, 2017, ENR PUBL EL SEC SCH ENR PUBL EL SEC SCH; National Center for Education Statistics, 2018, PUBL EL SCH GRAD SPA PUBL EL SCH GRAD SPA; National Center for Education Statistics, 2019, PUBL SEC SCH GRAD SP PUBL SEC SCH GRAD SP; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Pacheco J, 2014, J HEALTH POLIT POLIC, V39, P565, DOI 10.1215/03616878-2682612; Perkins RB, 2015, VACCINE, V33, P1223, DOI 10.1016/j.vaccine.2014.11.021; Plutzer E., 2020, EVOL EDUC OUTREACH, V13, P1, DOI DOI 10.1186/s12052-020-00126-8; Plutzer E., HARVARD DATAVERSE, V2021, DOI [10.7910/DVN/T262TM, DOI 10.7910/DVN/T262TM]; Plutzer E, 2016, SCIENCE, V351, P664, DOI 10.1126/science.aab3907; Schoeppe J, 2017, HEALTH PROMOT PRACT, V18, P654, DOI 10.1177/1524839917697303; Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923; Valliant R, 2018, SURVEY WEIGHTS STEP; Valliant R, 2013, PRACTICAL TOOLS DESI, P321; Walling EB, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3863	38	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4671	4677		10.1016/j.vaccine.2021.06.050		JUL 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TU9NN	34215451				2022-04-29	WOS:000681356500012
J	Lipsitch, M; Kahn, R				Lipsitch, Marc; Kahn, Rebecca			Interpreting vaccine efficacy trial results for infection and transmission	VACCINE			English	Article						COVID-19; SARS-CoV-2; Trials; Vaccine efficacy	COVID-19 VACCINE	Randomized controlled trials (RCTs) have shown high efficacy of multiple vaccines against SARS-CoV-2 disease (COVID-19), and recent studies have shown the vaccines are also effective against infection. Evidence for the effect of each of these vaccines on ability to transmit the virus is also beginning to emerge. We describe an approach to estimate these vaccines' effects on viral positivity, a prevalence mea-sure which under the reasonable assumption that vaccinated individuals who become infected are no more infectious than unvaccinated individuals forms a lower bound on efficacy against transmission. Specifically, we recommend separate analysis of positive tests triggered by symptoms (usually the pri-mary RCT outcome) and cross-sectional prevalence of positive tests obtained regardless of symptoms. The odds ratio of carriage for vaccine vs. placebo provides an unbiased estimate of vaccine effectiveness against viral positivity, under certain assumptions, and we show through simulations that likely depar -tures from these assumptions will only modestly bias this estimate. Applying this approach to published data from the RCT of the Moderna vaccine, we estimate that one dose of vaccine reduces the potential for transmission by at least 61%, possibly considerably more. We describe how these approaches can be translated into observational studies of vaccine effectiveness. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Lipsitch, Marc; Kahn, Rebecca] Harvard TH Chan Sch Publ Hlth, Ctr Communicable Dis Dynam, Dept Epidemiol, Boston, MA USA; [Lipsitch, Marc] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA		Lipsitch, M (通讯作者)，677 Huntington Ave,Suite 506, Boston, MA 02115 USA.	mlipsitch@hsph.harvard.edu			Morris-Singer by National Cancer Institute of the US National Institutes of Health [U01CA261277]; UK Department of Health and Social Care using UK Aid	This work was supported by the MorrisSinger fund by National Cancer Institute of the US National Institutes of Health Seronet cooperative agreement U01CA261277 and by the UK Department of Health and Social Care using UK Aid funding managed by the NIHR.The content is solely the responsibility of the authors and does not necessarily represent the official views of any government agency.	Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309; Biotech J. Inc, 2021, VACC REL BIOL PROD A; Borremans B, 2020, ELIFE, V9, DOI 10.7554/eLife.60122; Bubar Kate M, 2021, medRxiv, DOI [10.1101/2020.09.08.20190629, 10.1126/science.abe6959]; Buitrago-Garcia D., 2020, ASYMPTOMATIC SARS CO, DOI [10.1101/2020.04.25.20079103, DOI 10.1101/2020.04.25.20079103]; CDC, YOUV BEEN FULL VACC; Cevik M, 2021, LANCET MICROBE, V2, pE13, DOI 10.1016/S2666-5247(20)30172-5; Cohen, EFFECTIVENESS 1 DOSE, V2021; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Halloran ME, 1996, AM J EPIDEMIOL, V144, P83, DOI 10.1093/oxfordjournals.aje.a008858; Halloran ME, 1997, AM J EPIDEMIOL, V146, P789; Halloran ME, 2010, DESIGN ANAL VACCINE, V18; Harris R, NATL PUBLIC RADIO, P2021; Hernan MA, 2016, J CLIN EPIDEMIOL, V79, P70, DOI 10.1016/j.jclinepi.2016.04.014; Hernan MA, 2010, EPIDEMIOLOGY, V21, P13, DOI 10.1097/EDE.0b013e3181c1ea43; Kahn R, 2019, AM J EPIDEMIOL, V188, P467, DOI 10.1093/aje/kwy239; Larremore DB, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd5393; Lewnard JA, 2018, AM J EPIDEMIOL, V187, P2686, DOI 10.1093/aje/kwy163; Lipsitch, 2020, LEVERAGING PATHOGEN; Lipsitch, 2021050321256556 MED, V2021; Lipsitch M, 2019, Epidemiol Infect, V147, pe306, DOI 10.1017/S0950268819001961; Lipsitch M, 2020, SCIENCE, V370, P763, DOI 10.1126/science.abe5938; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n296; Matrajt Laura, 2020, medRxiv, DOI 10.1101/2020.08.14.20175257; McAloon C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039652; O'Hagan JJ, 2012, AIDS, V26, P123, DOI 10.1097/QAD.0b013e32834e1ce7; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Regev-Yochay, 2021, DECREASED INFECTIVIT, DOI [10.2139/ssrn.3815668, DOI 10.2139/SSRN.3815668]; Richterman A, 2022, OPEN FORUM INFECT DI, V9, DOI 10.1093/ofid/ofab259; Rinta-Kokko H, 2009, VACCINE, V27, P3831, DOI 10.1016/j.vaccine.2009.04.009; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1	37	0	0	11	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4082	4088		10.1016/j.vaccine.2021.06.011		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID		hybrid, Green Submitted, Green Published			2022-04-29	WOS:000672535200012
J	Reneer, ZB; Abreu, RB; Jamal, US; Corn, MR; Paugh, JL; Ross, TM				Reneer, Z. Beau; Abreu, Rodrigo B.; Jamal, Ummar S.; Corn, Matthew R.; Paugh, Jordan L.; Ross, Ted M.			Seasonal influenza vaccination does not effectively expand H2 cross-reactive antibodies in humans	VACCINE			English	Article						Pandemic; Immunization; Influenza		Influenza viruses cause millions of infections and hundreds of thousands of deaths every year. Influenza virus vaccinations are produced every year and contain H1N1 and H3N2 influenza A viruses and either one or two influenza B viruses. In this study, we examined the effects of seasonal influenza vaccinations in people on both circulating serum antibody titers and memory B-cell activation to H2Nx influenza viruses. In addition to evaluating the human cohort as a whole, participants were also divided into three separate groups based upon their likelihood of being either exposed to or imprinted with H2N2 influenza viruses in the 1950s and 1960s. While participants born after H2N2 influenza viruses left the human population had lower HAI, ELISA and neutralizing antibody titers to these viruses, a select number of cross reactive antibodies to some of the H2 HA proteins were boosted after seasonal influenza vaccination. However, these results varied and were not consistent by age group or specific H2 HA protein. Overall, seasonal influenza vaccination did not significantly expand cross-reactive antibodies to H2 HA antigens. (c) 2021 Elsevier Ltd. All rights reserved.	[Reneer, Z. Beau; Abreu, Rodrigo B.; Jamal, Ummar S.; Corn, Matthew R.; Paugh, Jordan L.; Ross, Ted M.] Univ Georgia, Ctr Vaccines & Immunol, CVI Room 1504,501 DW Brooks Dr, Athens, GA 30602 USA; [Reneer, Z. Beau; Ross, Ted M.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA		Ross, TM (通讯作者)，Univ Georgia, Ctr Vaccines & Immunol, CVI Room 1504,501 DW Brooks Dr, Athens, GA 30602 USA.	tedross@uga.edu		Ross, Ted/0000-0003-1947-7469; Corn, Matthew/0000-0001-5025-6301			Abreu RB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00902; Babu TM, 2018, J INFECT DIS, V218, P1054, DOI 10.1093/infdis/jiy291; Francis T., 1960, P AM PHILOS SOC, V104, P7; Gostic KM, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008109; Gostic KM, 2016, SCIENCE, V354, P722, DOI 10.1126/science.aag1322; Green TD, 2003, J VIROL, V77, P2046, DOI 10.1128/JVI.77.3.2046-2055.2003; Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167; Knipe DH Peter, 2013, FIELDS VIROL; Lindstrom SE, 2004, VIROLOGY, V328, P101, DOI 10.1016/j.virol.2004.06.009; Meade P, 2020, MBIO, V11, DOI 10.1128/mBio.03243-19; Reneer ZB, 2019, BIOCHEM SOC T, V47, P251, DOI 10.1042/BST20180602; Reneer ZB, 2020, J VIROL; WHO, 2011, MAN LAB DIAGN VIR SU; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	14	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4173	4183		10.1016/j.vaccine.2021.05.064		JUN 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34127298				2022-04-29	WOS:000672535200023
J	Vanderslott, S; Marks, T				Vanderslott, Samantha; Marks, Tatjana			Charting mandatory childhood vaccination policies worldwide	VACCINE			English	Review						Mandatory childhood vaccines; International; Vaccination policy; Mandates; Regional and country comparison	MEASLES OUTBREAK; SAUDI-ARABIA; IMMUNIZATION; INDONESIA; HESITANCY; IMMUNITY; COVERAGE; PARENTS	Mandatory childhood vaccination is becoming an increasingly important policy intervention for governments trying to address low vaccination rates. Mandates require vaccination for a certain purpose, most commonly related to school entry for children. However, the discussion surrounding the extent and impact of mandatory vaccination programmes for babies and children have largely been limited to high-income countries. While many recent publications discuss the issue, they have not been inclusive of low-and middle-income countries. This paper thus presents a comprehensive and updatable database of mandatory childhood vaccination policies worldwide, covering 149 countries. The list indicates whether a country has a mandatory vaccination policy and the strictness of the mandate on a scale ranging across three levels of mandatory, mandatory for school entry or recommended. It draws on extensive desk-based research analysing a variety of sources, supplemented by consultations with experts from various health authorities. The paper provides an overview of the state of mandatory childhood vaccination across different World Health Organization (WHO) regions and with country case studies, setting out the general trends and issues, and engages with a discussion about why, how, and where mandatory vaccination is put in place. Our findings show in-country variation in vaccination policy and a variation between vaccination in policy compared to in practice. We observe, particularly for high-income countries, that the occurrence of recent outbreaks is a major factor for the introduction of mandatory vaccination. Also, many low-and middle-income countries have resorted to mandatory vaccination policies because of a lack of other policy options yet still have lower than targeted vaccination rates due to problems with vaccine supply, delivery, and access. Offering comparisons between countries will provide a useful tool for government decision-makers considering the merits of mandatory vaccination. Crown Copyright (c) 2021 Published by Elsevier Ltd. All rights reserved.	[Vanderslott, Samantha; Marks, Tatjana] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford Vaccine Grp, Old Rd, Oxford OX3 7LE, England; [Vanderslott, Samantha; Marks, Tatjana] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford Martin Sch, Old Rd, Oxford OX3 7LE, England		Vanderslott, S (通讯作者)，Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford Vaccine Grp, Old Rd, Oxford OX3 7LE, England.	samantha.vanderslott@paediatrics.ox.ac.uk		Marks, Tatjana/0000-0002-1426-1581; Vanderslott, Samantha/0000-0001-8685-7758	National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); New Venture Fund	SV receives funding from the National Institute for Health Research (NIHR) and the New Venture Fund.	Ahmed A, 2018, J INFECT PUBLIC HEAL, V11, P153, DOI 10.1016/j.jiph.2017.09.007; Andrus, 2018, VACCINOLOGY LATIN AM; [Anonymous], 1998, PUBLIC HLTH SCH CHIL; [Anonymous], 1990, IMMUNIZATION SCH PUP; [Anonymous], 2021, QGIS GEOGR INF SYST; [Anonymous], 2019, GUARDIAN; Attwell K, 2019, MILBANK Q, V97, P978, DOI 10.1111/1468-0009.12417; Attwell K, 2019, VACCINE, V37, P2843, DOI 10.1016/j.vaccine.2019.03.065; Attwell K, 2018, VACCINE, V36, P7377, DOI 10.1016/j.vaccine.2018.10.019; Bauomy Jasmin, 2020, EURONEWS; Bazylevych M, 2011, MED ANTHROPOL Q, V25, P436, DOI 10.1111/j.1548-1387.2011.01179.x; Beard FH, 2017, MED J AUSTRALIA, V206, P381, DOI 10.5694/mja16.00944; Bedford J, 2017, J HEALTH COMMUN, V22, P81, DOI 10.1080/10810730.2016.1253122; Blume S, 2006, SOC SCI MED, V62, P628, DOI 10.1016/j.socscimed.2005.06.020; Blume Stuart, 2017, IMMUNIZATION VACCINE; Colgrove J, 2007, PUBLIC HEALTH REP, V122, P248, DOI 10.1177/003335490712200215; D'Ancona F, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.22.1800238; Day A, 2013, HLTH HIST, V15, P53; Delamater PL, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-3301; Drew L, 2019, NATURE, V575, pS58, DOI 10.1038/d41586-019-03642-w; ECDC, VACC PREV DIS PROGR; Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007; Giri Bhakta R, 2011, Indian J Community Med, V36, P109, DOI 10.4103/0970-0218.84128; Govindarajan, 2017, SCROLL; Gravagna K, 2020, VACCINE, V38, P7865, DOI 10.1016/j.vaccine.2020.09.063; Hanaoka M, 2022, J PUBLIC HEALTH-HEID, V30, P823, DOI 10.1007/s10389-020-01352-6; Haverkate M, 2012, EUROSURVEILLANCE, V17, P12; Hodge James G, 2001, KY Law J, V90, P831; Jadidi Rahmatollah, 2015, Int J Biomed Sci, V11, P93; Jahan S, 2008, J PUBLIC HEALTH-UK, V30, P384, DOI 10.1093/pubmed/fdn070; Jin-Kyung L., 2012, KOREAN NATL IMMUNIZA; Kazungu Jacob S, 2017, Wellcome Open Res, V2, P12, DOI 10.12688/wellcomeopenres.10690.1; Khalil MKM, 2005, ANN SAUDI MED, V25, P324, DOI 10.5144/0256-4947.2005.324; Kmeid M, 2019, INT HEALTH, V11, P568, DOI 10.1093/inthealth/ihz023; Kraut AM, 2017, B HIST MED, V91, P814, DOI 10.1353/bhm.2017.0093; Lewis-Bell KN, 2017, REV PANAM SALUD PUBL, V41, DOI [10.26633/rpsp.2017.127, 10.26633/RPSP.2017.127]; MacDonald N, 2020, EUR J PUBLIC HEALTH, V30, pV177; MacDonald NE, 2018, VACCINE, V36, P5811, DOI 10.1016/j.vaccine.2018.08.042; Mahery P, 2019, S AFR J BIOETH LAW, V12, P76, DOI 10.7196/SAJBL.2019.v12i2.678; Malone KM., 2003, LAW PUBLIC HLTH PRAC, V338, P339, DOI DOI 10.1093/ACPROF:OSO/9780195301489.003.0014; Marefiaw TA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218470; Mohanty S, 2019, AM J PUBLIC HEALTH, V109, P96, DOI 10.2105/AJPH.2018.304768; Moszynski P, 2007, BRIT MED J, V334, P1292, DOI 10.1136/bmj.39248.481701.DB; Omer SB, 2019, NATURE, V571, P469, DOI 10.1038/d41586-019-02232-0; Onyemelukwe, 2016, OXF U COMMONW LAW J, V16, P100, DOI [10.1080/14729342.2016.1244450, DOI 10.1080/14729342.2016.1244450]; PAHO, 2015, 31 CAR EPI M GEORG G; Paul KT, 2019, J PUBLIC HEALTH POL, V40, P166, DOI 10.1057/s41271-019-00163-8; Pejin LS, 2016, TIGHTENING MEASURES; Pronyk P, 2019, LANCET PLANET HEALTH, V3, pE114, DOI 10.1016/S2542-5196(18)30287-0; QGIS.org, 2021, QGIS GEOGR INF SYST; Remes P, 2012, VACCINE, V30, P5363, DOI 10.1016/j.vaccine.2012.06.025; Rezza G, 2019, PATHOG GLOB HEALTH, V113, P291, DOI 10.1080/20477724.2019.1705021; Sabin Vaccine Institute, 2019, DEC SUST IMM FIN; Sabin Vaccine Institute, 2018, LEG LANDSC REV LEG A; Satherley, 2019, NEWSHUB; Scroll, 2018, KERALA GOVT MAKES VA; Senate of Pakistan, 2019, ISL COMP VACC PROP H; Signorelli C, 2018, LANCET INFECT DIS, V18, P26, DOI 10.1016/S1473-3099(17)30696-5; Stein-Zamir C, 2017, HUM VACC IMMUNOTHER, V13, P2102, DOI 10.1080/21645515.2017.1341028; The New Humanitarian, 2013, BUILD HLTH SYST SCRA; Trent MJ, 2019, VACCINE, V37, P5250, DOI 10.1016/j.vaccine.2019.07.066; Trumbo SP, 2019, VACCINE, V37, P4840, DOI 10.1016/j.vaccine.2018.10.069; Trumbo SP, 2013, J PUBLIC HEALTH POL, V34, P82, DOI 10.1057/jphp.2012.66; UNICEF, 2016, GUYAN SIT AN CHILDR; Varghese, 2016, GULF TIMES; Vora, 2017, SCROLL; WHO, INT TRAV HLTH COUNT; Whyte C., 2019, NEW SCI; Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430; World Health Organization, 2017, JOINT EXT EV IHR COR; Yufika A, 2020, VACCINE, V38, P2592, DOI 10.1016/j.vaccine.2020.01.072	71	1	1	4	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4054	4062		10.1016/j.vaccine.2021.04.065		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TI1ID	34119351				2022-04-29	WOS:000672535200009
J	Chua, JV; Davis, C; Husson, JS; Nelson, A; Prado, I; Flinko, R; Lam, KWJ; Mutumbi, L; Mayer, BT; Dong, D; Fulp, W; Mahoney, C; Gerber, M; Gottardo, R; Gilliam, BL; Greene, K; Gao, HM; Yates, N; Ferrari, G; Tomaras, G; Montefiori, D; Schwartz, JA; Fouts, T; DeVico, AL; Lewis, GK; Gallo, RC; Sajadi, MM				Chua, Joel V.; Davis, Charles; Husson, Jennifer S.; Nelson, Amy; Prado, Ilia; Flinko, Robin; Lam, Ka Wing J.; Mutumbi, Lydiah; Mayer, Bryan T.; Dong, Dan; Fulp, William; Mahoney, Celia; Gerber, Monica; Gottardo, Raphael; Gilliam, Bruce L.; Greene, Kelli; Gao, Hongmei; Yates, Nicole; Ferrari, Guido; Tomaras, Georgia; Montefiori, David; Schwartz, Jennifer A.; Fouts, Timothy; DeVico, Anthony L.; Lewis, George K.; Gallo, Robert C.; Sajadi, Mohammad M.			Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial	VACCINE			English	Article						HIV; Vaccine; Chimeric subunit vaccine; Full-length single chain (FLSC); CD4i	CELLULAR CYTOTOXICITY ADCC; MEDIATED EFFECTOR FUNCTION; PROTECTIVE EFFICACY; ENVELOPE GLYCOPROTEIN; NONNEUTRALIZING ANTIBODIES; ANTIGENIC PROPERTIES; SIV CHALLENGES; DOUBLE-BLIND; B-CELL; BINDING	A major challenge for HIV vaccine development is to raise anti-envelope antibodies capable of recognizing and neutralizing diverse strains of HIV-1. Accordingly, a full length single chain (FLSC) of gp120-CD4 chimeric vaccine construct was designed to present a highly conserved CD4-induced (CD4i) HIV-1 envelope structure that elicits cross-reactive anti-envelope humoral responses and protective immunity in animal models of HIV infection. IHV01 is the FLSC formulated in aluminum phosphate adjuvant. We enrolled 65 healthy adult volunteers in this first-in-human phase 1a randomized, double-blind, placebo controlled study with three dose-escalating cohorts (75 mg, 150 mg, and 300 mg doses). Intramuscular injections were given on weeks 0, 4, 8, and 24. Participants were followed for an additional 24 weeks after the last immunization. The overall incidence of adverse events (AEs) was not significantly different between vaccinees and controls. The majority (89%) of vaccine-related AE were mild. The most common vaccine-related adverse event was injection site pain. There were no vaccine-related serious AE, discontinuation due to AE, intercurrent HIV infection, or significant decreases in CD4 count. By the final vaccination, all vaccine recipients developed antibodies against IHV01 and demonstrated anti-CD4i epitope antibodies. The elicited antibodies reacted with CD4 non-liganded Env antigens from diverse HIV-1 strains. Antibody-dependent cell-mediated cytotoxicity against heterologous infected cells or gp120 bound to CD4+ cells was evident in all cohorts as were anti-gp120 T-cell responses. IHV01 vaccine was safe, well tolerated, and immunogenic at all doses tested. The vaccine raised broadly reactive humoral responses against conserved CD4i epitopes on gp120 that mediates antiviral functions. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Chua, Joel V.; Davis, Charles; Husson, Jennifer S.; Nelson, Amy; Lam, Ka Wing J.; Mutumbi, Lydiah; Gilliam, Bruce L.; Sajadi, Mohammad M.] Univ Maryland, Sch Med, Div Clin Care & Res, Inst Human Virol, Baltimore, MD 21201 USA; [Prado, Ilia; Flinko, Robin; DeVico, Anthony L.; Lewis, George K.] Univ Maryland, Sch Med, Div Vaccine Res, Inst Human Virol, Baltimore, MD 21201 USA; [Mayer, Bryan T.; Dong, Dan; Fulp, William; Mahoney, Celia; Gerber, Monica; Gottardo, Raphael] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA; [Gottardo, Raphael] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA; [Greene, Kelli; Gao, Hongmei; Yates, Nicole; Ferrari, Guido; Tomaras, Georgia; Montefiori, David] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA; [Schwartz, Jennifer A.; Sajadi, Mohammad M.] Intralytix, Columbia, MD USA; [Fouts, Timothy] Adv BioSci Labs, Rockville, MD USA; [DeVico, Anthony L.; Lewis, George K.; Gallo, Robert C.] Global Virus Network, Baltimore, MD USA; [Gallo, Robert C.] Univ Maryland, Sch Med, Div Basic Sci, Inst Human Virol, Baltimore, MD 21201 USA		Sajadi, MM (通讯作者)，Inst Human Virol, 725 West Lombard St, Baltimore, MD 21201 USA.	msajadi@ihv.umaryland.edu	Fulp, William/AAD-2369-2022	Chua, Joel/0000-0002-7579-4672; Gerber, Monica/0000-0001-9878-9166; , Mohammad/0000-0001-7798-3605; Mayer, Bryan/0000-0003-2258-5276	 [to RCG]	This study was supported by the [Grant number #to RCG]. Statistical analysis support was supported by the grant ().	Acharya P, 2014, J VIROL, V88, P12895, DOI 10.1128/JVI.02194-14; Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886; Barouch DH, 2013, CELL, V155, P531, DOI 10.1016/j.cell.2013.09.061; Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bournazos S, 2014, CELL, V158, P1243, DOI 10.1016/j.cell.2014.08.023; Bryan J., 2019, J OPEN SOURCE SOFTWA, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/joss.01686]; Calhoun P., 2019, EXACT UNCONDITIONAL; Copenhaver M.D., 1988, J STAT COMPUT SIM, P1, DOI [10.1080/00949658808811082, DOI 10.1080/00949658808811082]; DeCamp AC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185959; Decker JM, 2005, J EXP MED, V201, P1407, DOI 10.1084/jem.20042510; DeVico A, 2007, P NATL ACAD SCI USA, V104, P17477, DOI 10.1073/pnas.0707399104; DeVico AL, 2007, CURR HIV RES, V5, P561, DOI 10.2174/157016207782418560; Ferrari G, 2011, J VIROL, V85, P7029, DOI 10.1128/JVI.00171-11; Finnegan CM, 2002, J VIROL, V76, P12123, DOI 10.1128/JVI.76.23.12123-12134.2002; Finnegan CM, 2001, J VIROL, V75, P11096, DOI 10.1128/JVI.75.22.11096-11105.2001; Florese RH, 2009, J IMMUNOL, V182, P3718, DOI 10.4049/jimmunol.0803115; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Fouts TR, 2015, P NATL ACAD SCI USA, V112, pE992, DOI 10.1073/pnas.1423669112; Fouts TR, 2000, J VIROL, V74, P11427, DOI 10.1128/JVI.74.24.11427-11436.2000; Gnanakaran S, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000955; Gohain N, 2015, J VIROL, V89, P8840, DOI 10.1128/JVI.01232-15; Gomez-Roman VR, 2005, J IMMUNOL, V174, P2185, DOI 10.4049/jimmunol.174.4.2185; Gordon SN, 2016, J IMMUNOL, V197, P2726, DOI 10.4049/jimmunol.1600674; Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6; Guan YJ, 2013, P NATL ACAD SCI USA, V110, pE69, DOI 10.1073/pnas.1217609110; Guan YJ, 2009, P NATL ACAD SCI USA, V106, P3952, DOI 10.1073/pnas.0813392106; Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Hidajat R, 2009, J VIROL, V83, P791, DOI 10.1128/JVI.01672-08; Horwitz JA, 2017, CELL, V170, P637, DOI 10.1016/j.cell.2017.06.048; Huang CC, 2004, P NATL ACAD SCI USA, V101, P2706, DOI 10.1073/pnas.0308527100; Huang YD, 2009, STAT BIOPHARM RES, V1, P81, DOI 10.1198/sbr.2009.0008; Kramski M, 2013, CURR HIV RES, V11, P388, DOI 10.2174/15701; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lewis GK, 2017, IMMUNOL REV, V275, P271, DOI 10.1111/imr.12510; Lewis GK, 2015, VIRUSES-BASEL, V7, P5115, DOI 10.3390/v7092856; Lewis GK, 2014, CURR OPIN HIV AIDS, V9, P263, DOI 10.1097/COH.0000000000000055; Lewis GK, 2013, CURR HIV RES, V11, P354, DOI 10.2174/1570162X113116660060; Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159; Mengistu M, 2017, P NATL ACAD SCI USA, V114, pE9893, DOI 10.1073/pnas.1705074114; Mengistu M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004772; Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26; Orlandi C, 2016, J IMMUNOL METHODS, V433, P51, DOI 10.1016/j.jim.2016.03.002; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; Pollara J, 2018, CYTOM PART A, V93A, P436, DOI 10.1002/cyto.a.23348; Pollara J, 2014, J VIROL, V88, P7715, DOI 10.1128/JVI.00156-14; Pollara J, 2013, CURR HIV RES, V11, P378, DOI 10.2174/1570162X113116660059; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Sajadi MM, 2012, J VIROL, V86, P5014, DOI 10.1128/JVI.06547-11; Sajadi MM, 2018, CELL, V173, P1783, DOI 10.1016/j.cell.2018.03.061; Schmaljohn AL, 2013, CURR HIV RES, V11, P345, DOI 10.2174/1570162X113116660057; Schwartz JA, 2016, CLIN VACCINE IMMUNOL, V23, P618, DOI 10.1128/CVI.00115-16; Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09; Stafford KA, 2020, JAIDS-J ACQ IMM DEF, V84, P37, DOI 10.1097/QAI.0000000000002306; Su B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02968; Sui Y, 2019, J CLIN INVEST, V129, P1314, DOI 10.1172/JCI122110; Sun Y, 2011, J VIROL, V85, P6906, DOI 10.1128/JVI.00326-11; Thomas MA, 2014, VIROLOGY, V471, P81, DOI 10.1016/j.virol.2014.10.001; Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Tran EEH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002797; Xiao P, 2010, J VIROL, V84, P7161, DOI 10.1128/JVI.00410-10; Yates NL, 2018, J VIROL, V92, DOI 10.1128/JVI.01843-17	65	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3879	3891		10.1016/j.vaccine.2021.05.090		JUN 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34099328	hybrid, Green Published			2022-04-29	WOS:000663773600014
J	Stuurman, AL; Biccler, J; Carmona, A; Descamps, A; Diez-Domingo, J; Quiles, CM; Nohynek, H; Rizzo, C; Riera-Montes, M				Stuurman, Anke L.; Biccler, Jorne; Carmona, Antonio; Descamps, Alexandre; Diez-Domingo, Javier; Quiles, Cintia Munoz; Nohynek, Hanna; Rizzo, Caterina; Riera-Montes, Margarita		DRIVE Public Partners	Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform	VACCINE			English	Article						Vaccine effectiveness; Influenza; Test-negative design; Public-private partnership; Europe	SENSITIVITY	DRIVE (Development of Robust and Innovative Vaccine Effectiveness) is an IMI funded public-private platform that aims to annually estimate brand-specific influenza vaccine effectiveness (IVE), for public health and regulatory purposes. IVE analyses and reporting are conducted by public partners in the consortium. In 2019/20, four primary care-based test-negative design (TND) studies (Austria, England, Italy (n = 2)), eight hospital-based TND studies (Finland, France, Italy, Romania, Spain (n = 4)), and one populationbased cohort study (Finland) were conducted. The COVID-19 pandemic affected influenza surveillance in all participating study sites, therefore the study period was truncated on February 29, 2020. Agestratified (6 m-17y, 18-64y, >= 65y), confounder-adjusted, site-specific adjusted IVE estimates were calculated and pooled through meta-analysis. Parsimonious confounder-adjustment was performed, adjusting the estimates for age, sex and calendar time. TND studies included 3531 cases (351 vaccinated) and 5546 controls (1415 vaccinated) of all ages. IVE estimates were available for 8/11 brands marketed in Europe in 2019. Most children and adults < 64y were captured in primary care setting and the most frequently observed vaccine brand was Vaxigrip Tetra. The estimate against any influenza for Vaxigrip Tetra in primary care setting was 61% (95%CI 38-77) in children and 32% (95%CI -13-59) in adults up to 64y. Most adults >= 65y were captured in hospital setting and the most frequently observed brand was Fluad, with an estimate of 52% (95%CI 27-68). The population-based cohort covered 511,854 person-years and two vaccine brands. In children aged 2-6y, the IVE against any influenza was 68% (95%CI 58-75) for Fluenz Tetra and 71% (56-80) for Vaxigrip Tetra. In adults >= 65y, IVE against any influenza was 29% (20-36) for Vaxigrip Tetra. DRIVE is a growing platform. Public health institutes with surveillance data and hospitals in countries with high influenza vaccine coverage are encouraged to join DRIVE. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Stuurman, Anke L.; Biccler, Jorne; Riera-Montes, Margarita] P95 Pharmacovigilance & Epidemiol, Leuven, Belgium; [Carmona, Antonio; Diez-Domingo, Javier; Quiles, Cintia Munoz] FISABIO Publ Hlth, Valencia, Spain; [Descamps, Alexandre] Inst Natl Sante & Rech Med INSERM, Paris, France; [Nohynek, Hanna] Finnish Inst Hlth & Welf, Helsinki, Finland; [Rizzo, Caterina] Bambino Gesu Pediat Hosp, Rome, Italy		Stuurman, AL (通讯作者)，P95 Pharmacovigilance & Epidemiol, Leuven, Belgium.	anke.stuurman@p-95.com; jorne.biccler@p-95.com; antonio.carmona@fisabio.es; alexandre.descamps@aphp.fr; Javier.Diez@fisabio.es; munoz_cin@gva.es; Hanna.Nohynek@thl.fi; caterina1.rizzo@opbg.net; margarita.riera@p-95.com	Draganescu, Anca Cristina/AAH-6671-2021; Riera, Margarita/B-1039-2013; Sandulescu, Oana/M-6242-2017	Riera, Margarita/0000-0002-7632-3944; Sandulescu, Oana/0000-0002-2586-4070; chironna, maria/0000-0002-1043-1256; Auvinen, Raija/0000-0003-1300-1048; Descamps, Alexandre/0000-0003-2437-7876; Andres Verges, Cristina/0000-0002-3200-0895; Stuurman, Anke/0000-0002-4157-1315; Diez-Domingo, Javier/0000-0003-1008-3922; Martin-Quiros, Alejandro/0000-0003-4630-7668; MENA PINILLA, GUILLERMO/0000-0003-0147-6302; Carmona Serrano, Antonio/0000-0002-1366-1671; Loconsole, Daniela/0000-0003-2057-9745	Innovative Medicines Initiative 2 Joint Undertaking from the European Union's Horizon 2020 research and innovation programme [777363]; EFPIA; Austria MUV by Biomedica; Austria MUV by SanofiPasteur; Austria MUV by Valneva; Finland HUS by the Finnish Institute for Health and Welfare; Finland HUS by the HUS; Finland THL by the Finnish Institute for Health and Welfare; Italy BIVE by the IRCCS, Bambino GesU Children's Hospital; Italy ISS by the Italian Medicines Agency; Romania NIID by the National Institute for Infectious Diseases "Prof.Dr. Matei Bals", Romania; Romania NIID by the Foundation for Influenza Epidemiology, France (GIHSN grant) - Sanofi Pasteur [2019/20]; France I-REIVAC network by INSERM; France I-REIVAC network by Foundation for Influenza Epidemiology, France (GIHSN); Spain FISABIO by FISABIOPublic Health; Spain FISABIO by CIBER-ESP (ISCIII); Spain FISABIO by Sanofi Pasteur; Spain VHUH by VHUH; Spain Germans Trias i Pujol University Hospital by Germans Trias I Pujol University Hospital; Spain Germans Trias i Pujol University Hospital by Germans Trias I Pujol Research Institute (IGTP)	The DRIVE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 777363) ; this Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. The following sites were cofunded: Austria MUV by Biomedica, SanofiPasteur and Valneva; Finland HUS by the Finnish Institute for Health and Welfare and HUS; Finland THL by the Finnish Institute for Health and Welfare; Italy BIVE by the IRCCS, Bambino GesU Children's Hospital; Italy ISS by the Italian Medicines Agency; Romania NIID by the National Institute for Infectious Diseases "Prof.Dr. Matei Bals", Romania, and by the Foundation for Influenza Epidemiology, France (GIHSN grant 2019/20) this Foundation is partly supported by Sanofi Pasteur; France I-REIVAC network by INSERM and by the Foundation for Influenza Epidemiology, France (GIHSN) ; Spain FISABIO by FISABIOPublic Health, CIBER-ESP (ISCIII) and Sanofi Pasteur; Spain VHUH by VHUH; Spain Germans Trias i Pujol University Hospital by Germans Trias I Pujol University Hospital and Germans Trias I Pujol Research Institute (IGTP) .	[Anonymous], FLU NEWS EUROPE; Baum U, EMERG THEMES EPIDEMI, V2021, P18; Baum U., 2018, D7 4 SETTING BRAND S; Bollaerts K., 2018, D7 2 CORE PROTOCOL T; Committee for Medicinal Products for Human Use, 2016, EMACHMPVWP4572592014; DRIVE consortium, GOVERNANCE; DRIVE consortium, 2020, BRAND SPEC INFL VACC; DRIVE consortium, DRIVE DEV ROB INN VA; DRIVE consortium, PART DRIVE; Jackson ML, 2015, VACCINE, V33, P1313, DOI 10.1016/j.vaccine.2015.01.069; Jokinen J., 2018, SCAND J PUBLIC HEALT; Lane CR, 2016, VACCINE, V34, P1070, DOI 10.1016/j.vaccine.2016.01.002; Lipsitch M, 2016, INT J EPIDEMIOL, V45, P2060, DOI 10.1093/ije/dyw124; Loc J., 2020, CLIN INFECT DIS; Mira-Iglesias A, 2018, EUROSURVEILLANCE, V23, P7, DOI 10.2807/1560-7917.ES.2018.23.8.17-00318; Nelson JC., 2017, VACCINE; NHS England, IMPL JOINT COMM VACC; Olsen SJ, 2020, MMWR-MORBID MORTAL W, V69, P1305, DOI 10.15585/mmwr.mm6937a6; Poole C, 2020, INT J EPIDEMIOL, V49, P1497, DOI 10.1093/ije/dyaa097; Public Health England, SURVEILLANCE INFLUEN; Puig-Barbera J, 2015, Euro Surveill, V20; Rizzo C, D7 6 BRAND SPECIFIC; Rose A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.10.2000153; Stuurman AL, 2020, VACCINE, V38, P6455, DOI 10.1016/j.vaccine.2020.07.063; Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064; Turunen T., 2018, D7 1 CORE PROTOCOL T; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Westreich D, 2016, AM J EPIDEMIOL, V184, P354, DOI 10.1093/aje/kww063; World Health Organization, REC COMP INFL VIR VA	29	1	1	2	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3964	3973		10.1016/j.vaccine.2021.05.059		JUN 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34092427	hybrid			2022-04-29	WOS:000663773600023
J	Youssef, Y; Chmaisse, A; Boutros, C; Chamseddine, S; Fayad, D; Zaraket, H; Dbaibo, G				Youssef, Yolla; Chmaisse, Ahmad; Boutros, Celina; Chamseddine, Sarah; Fayad, Danielle; Zaraket, Hassan; Dbaibo, Ghassan			The burden of Respiratory Syncytial Virus (RSV) infection in the Middle East and North Africa (MENA) region across age groups: A systematic review	VACCINE			English	Review						Respiratory Syncytial Virus; Review; Epidemiology; Diagnosis; Complications; Mortalities; MENA region	YOUNG-CHILDREN; CLINICAL CHARACTERISTICS; HOSPITALIZED INFANTS; VIRAL-INFECTIONS; TRACT INFECTIONS; MYCOPLASMA-PNEUMONIAE; HONG-KONG; EPIDEMIOLOGY; SEASONALITY; INFLUENZA	Respiratory Syncytial Virus (RSV) is a common respiratory virus that generally causes a mild illness in children and adults or severe symptoms with complications in infants and the elderly, particularly in the presence of underlying comorbidities. While epidemiological data about this virus are available globally, data from the Middle East and North Africa (MENA) region are still scarce. For this reason, we conducted a systematic review to determine the burden of RSV disease in the MENA region by searching the available literature up until September 2018. A total of 1242 studies were retrieved of which 90 were included in the review. Most of the included studies were conducted in subjects aged 0-18 years with the majority being in children below 3 years of age, while only 2 studies included exclusively adults above 18 years of age. RSV infection rates varied greatly between different studies on hospitalized subjects and ranged between 4% and 82%, while the range was smaller in studies on outpatient subjects (between 6% and 36%). When calculating the RSV infection rates in the hospitalized subjects with different inclusion criteria, we found that it was 19%, 70%, and 33% among subjects admitted with Acute Respiratory Infections (ARIs), Acute Lower Respiratory Infections (ALRIs), and bronchiolitis, respectively. RSV infections were most common during the winter season. With regards to complications, intensive care unit admissions ranged between 1% and 15%, while the need for mechanical ventilation ranged between 1% and 10%. The overall RSV related mortality rate across all age groups in studies included in our review was 1.9%. This review identifies several limitations in the existing data and under-representation of the adult population. Future studies should be providing more evidence on the RSV burden in adults and children with comorbidities in order to better assess the potential impact of future preventive strategies in the MENA region. (c) 2021 Elsevier Ltd. All rights reserved.	[Youssef, Yolla; Chmaisse, Ahmad; Boutros, Celina; Chamseddine, Sarah; Fayad, Danielle; Zaraket, Hassan; Dbaibo, Ghassan] Amer Univ Beirut, Ctr Infect Dis Res, Beirut, Lebanon; [Youssef, Yolla; Dbaibo, Ghassan] Amer Univ Beirut, Med Ctr, Dept Pediat & Adolescent Med, Div Pediat Infect Dis, Beirut, Lebanon; [Zaraket, Hassan] Amer Univ Beirut, Dept Expt Pathol Immunol & Microbiol, Beirut, Lebanon		Dbaibo, G (通讯作者)，Amer Univ Beirut, Med Ctr, Ctr Infect Dis Res, Div Pediat Infect Dis,Dept Pediat & Adolescent Me, Beirut, Lebanon.; Zaraket, H (通讯作者)，Amer Univ Beirut, Ctr Infect Dis Res, Dept Expt Pathol Immunol & Microbiol, Beirut, Lebanon.	hz34@aub.edu.lb; H.gdbaibo@aub.edu.lb		Chmaisse, Ahmad/0000-0002-9523-5341			Aamir UB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074018; Abdelmogheth Anas-Alwogud A, 2014, Sultan Qaboos Univ Med J, V14, pe546; Abdulhaq AA, 2017, ADV VIROL, V2017, DOI 10.1155/2017/4247853; Abushahin A, 2018, INT J GEN MED, V11, P41, DOI 10.2147/IJGM.S156078; Akhter J., 2009, Saudi Pharmaceutical Journal, V17, P177; Al Kharosi Z, 2017, RESPIROLOGY, V22, P208; Al Rashed A, 1998, ANN TROP MED PARASIT, V92, P595, DOI 10.1080/00034989859294; Al Shibli A, 2016, PAEDIATR INT CHILD H, V36, P175, DOI 10.1080/20469047.2016.1162390; Al-Muhsen S. Z., 2010, Current Pediatric Research, V14, P75; Albargish K A, 1999, East Mediterr Health J, V5, P941; Ali A, 2017, J MED VIROL, V89, P1151, DOI 10.1002/jmv.24768; Arjeyni Y, 2017, ARCH IRAN MED, V20, P368, DOI 0172006/AIM.009; Assaf-Casals A., 2015, British Journal of Medicine and Medical Research, V6, P77, DOI 10.9734/BJMMR/2015/12608; August A, 2017, VACCINE, V35, P3749, DOI 10.1016/j.vaccine.2017.05.045; Bashir U, 2017, ARCH VIROL, V162, P763, DOI 10.1007/s00705-016-3146-7; Bashir U, 2017, INFECT GENET EVOL, V47, P125, DOI 10.1016/j.meegid.2016.11.024; Behrendt CE, 1998, EUR J PEDIATR, V157, P215, DOI 10.1007/s004310050798; Bont L, 2016, INFECT DIS THER, V5, P271, DOI 10.1007/s40121-016-0123-0; Bukhari EE, 2013, SAUDI MED J, V34, P1151; Byington CL, 2015, PEDIATRICS, V135, pE24, DOI 10.1542/peds.2014-2151; Caini S, 2018, INFLUENZA OTHER RESP, V12, P344, DOI 10.1111/irv.12544; Chan PKS, 1999, EPIDEMIOL INFECT, V123, P257, DOI 10.1017/S0950268899002824; Domachowske JB, 2018, PEDIATR INFECT DIS J, V37, P886, DOI [10.1097/INF.0000000000001916, 10.1097/inf.0000000000001916]; El Kholy AA, 2013, PEDIATR INT, V55, P283, DOI 10.1111/ped.12051; Enan KA, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-312; Falsey AR, 2007, SEMIN RESP CRIT CARE, V28, P171, DOI 10.1055/s-2007-976489; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Falsey AR, 2003, J CLIN MICROBIOL, V41, P4160, DOI 10.1128/JCM.41.9.4160-4165.2003; FALSEY AR, 1995, J AM GERIATR SOC, V43, P30, DOI 10.1111/j.1532-5415.1995.tb06238.x; Falsey AR, 2000, CLIN MICROBIOL REV, V13, P371, DOI 10.1128/CMR.13.3.371-384.2000; Farid E, 2006, J BAHRAIN MED SOC MA, V18, P169; Fattouh AM, 2011, ITAL J PEDIATR, V37, DOI 10.1186/1824-7288-37-14; Fisman D, 2012, CLIN MICROBIOL INFEC, V18, P946, DOI 10.1111/j.1469-0691.2012.03968.x; Fleming DM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1218-z; Fodha I, 2004, ANN TROP PAEDIATR, V24, P219, DOI 10.1179/027249304225018966; FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956; Griffin MP, 2020, NEW ENGL J MED, V383, P415, DOI 10.1056/NEJMoa1913556; Griffin MP, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01714-16, 10.1128/aac.01714-16]; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Hassan Mona A, 2008, Egypt J Immunol, V15, P153; Hendaus MA, 2018, PEDIATRICS, V141, DOI 10.1542/peds.141.1_MeetingAbstract.436; HIJAZI Z, 1995, PEDIATR INFECT DIS J, V14, P322, DOI 10.1097/00006454-199504000-00016; Hijazi Z, 1996, J TROP PEDIATRICS, V42, P276, DOI 10.1093/tropej/42.5.276; Horton KC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180954; Htar MTT, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000400; Janahi I, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2225-z; Jroundi I, 2016, EPIDEMIOL INFECT, V144, P516, DOI 10.1017/S095026881500151X; Jroundi I, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-015-0076-x; Justice, 2020, STATPEARLS; Keyvani H, 2017, J MED MICROBIOL, V66, P1602, DOI 10.1099/jmm.0.000628; Khamis FA, 2012, J MED VIROL, V84, P1323, DOI 10.1002/jmv.23330; Khuri-Bulos N, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021898; Khuri-Bulos N, 2010, SCAND J INFECT DIS, V42, P368, DOI 10.3109/00365540903496544; Langley GF, 2011, PEDIATR INFECT DIS J, V30, P510, DOI 10.1097/INF.0b013e3182184ae7; Lapena S, 2005, EUR J EPIDEMIOL, V20, P271, DOI 10.1007/s10654-004-4539-6; Lee N, 2013, CLIN INFECT DIS, V57, P1069, DOI 10.1093/cid/cit471; Loubet P, 2017, CLIN MICROBIOL INFEC, V23, P253, DOI 10.1016/j.cmi.2016.11.014; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; Mazur NI, 2018, LANCET INFECT DIS, V18, pE295, DOI 10.1016/S1473-3099(18)30292-5; Meqdam MMM, 1998, J TROP PEDIATRICS, V44, P92, DOI 10.1093/tropej/44.2.92; Munoz FM, 2019, J INFECT DIS, V220, P1802, DOI 10.1093/infdis/jiz390; NADIA M, 2013, J EGYPT PUBLIC HEAL, V0088, P00052; Naghipour M, 2007, J TROP PEDIATRICS, V53, P179, DOI 10.1093/tropej/fml089; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Obando-Pacheco P, 2018, J INFECT DIS, V217, P1356, DOI 10.1093/infdis/jiy056; Ohm-Smith MJ, 2004, J CLIN MICROBIOL, V42, P2996, DOI 10.1128/JCM.42.7.2996-2999.2004; Olchanski N, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy031; Pangesti KNA, 2018, REV MED VIROL, V28, DOI DOI 10.1002/rmv.1968; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Pourakbari B, 2014, TURKISH J PEDIATR, V56, P354; Rahbarimanesh Ali Akbar, 2018, Maedica (Bucur), V13, P17; Rose EB, 2018, MMWR-MORBID MORTAL W, V67, P71, DOI 10.15585/mmwr.mm6702a4; Saha SK, 2018, LANCET, V392, P145, DOI 10.1016/S0140-6736(18)31127-9; Shatizadeh Somayeh, 2014, Med J Islam Repub Iran, V28, P102; Shi T, 2020, J INFECT DIS, V222, pS577, DOI 10.1093/infdis/jiz059; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; SPENCE L, 1968, AM J EPIDEMIOL, V88, P257, DOI 10.1093/oxfordjournals.aje.a120884; Sruamsiri R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011491; Staat MA, 2013, PEDIATR INFECT DIS J, V32, P911, DOI 10.1097/INF.0b013e31828df3e3; Stein RT, 2017, PEDIATR PULM, V52, P556, DOI 10.1002/ppul.23570; Stensballe LG, 2003, PEDIATR INFECT DIS J, V22, pS21, DOI 10.1097/00006454-200302001-00004; SUNG RYT, 1987, J INFECT DIS, V156, P527, DOI 10.1093/infdis/156.3.527; Tang AM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12137-1; Van de Steen O, 2016, INFECT DIS THER, V5, P125, DOI 10.1007/s40121-016-0109-y; von Elm E, 2007, LANCET, V370, P1453, DOI [10.2471/BLT.07.045120, 10.1016/j.jclinepi.2007.11.008, 10.1371/journal.pmed.0040296]; Wahab AA, 2001, J TROP PEDIATRICS, V47, P363, DOI 10.1093/tropej/47.6.363; Walsh Edward E., 2012, Infectious Disorders - Drug Targets, V12, P98; Welliver RC, 2007, PEDIATR INFECT DIS J, V26, pS29, DOI 10.1097/INF.0b013e318157da59; WHO W.H.O, MIDDL E N AFR REG CO; Yassine HM, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050713; Yusuf S, 2007, EPIDEMIOL INFECT, V135, P1077, DOI 10.1017/S095026880600776X; Zhao M, 2017, J VIROL, V91, DOI 10.1128/JVI.00176-17; Zhu Q, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj1928	94	0	0	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3803	3813		10.1016/j.vaccine.2021.05.076		JUN 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34099329				2022-04-29	WOS:000663773600006
J	Gubernot, D; Jazwa, A; Niu, ME; Baumblatt, J; Gee, J; Moro, P; Duffy, J; Harrington, T; McNeil, MM; Broder, K; Su, J; Kamidani, S; Olson, CK; Panagiotakopoulos, L; Shimabukuro, T; Forshee, R; Anderson, S; Bennett, S				Gubernot, Diane; Jazwa, Amelia; Niu, Manette; Baumblatt, Jane; Gee, Julianne; Moro, Pedro; Duffy, Jonathan; Harrington, Theresa; McNeil, Michael M.; Broder, Karen; Su, John; Kamidani, Satoshi; Olson, Christine K.; Panagiotakopoulos, Lakshmi; Shimabukuro, Tom; Forshee, Richard; Anderson, Steven; Bennett, Sarah			US Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines	VACCINE			English	Review						Background rates; Incidence rates; Vaccine safety; Adverse events; COVID-19; Surveillance	GUILLAIN-BARRE-SYNDROME; ACUTE DISSEMINATED ENCEPHALOMYELITIS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; H1N1 INFLUENZA VACCINATION; UNITED-STATES; OLMSTED COUNTY; MULTIPLE-SCLEROSIS; SMALLPOX VACCINATION; UNPROVOKED SEIZURES; KAWASAKI-DISEASE	The Coronavirus Disease 2019 (COVID-19) pandemic has had a devastating impact on global health, and has resulted in an unprecedented, international collaborative effort to develop vaccines to control the outbreak, protect human lives, and avoid further social and economic disruption. Mass vaccination campaigns are underway in multiple countries and are expected worldwide once more vaccine becomes available. Some early candidate vaccines use novel platforms, such as mRNA encapsulated in lipid nanoparticles, and relatively new platforms, such as replication-deficient viral vectors. While these new vaccine platforms hold promise, limited safety data in humans are available. Serious health outcomes linked to vaccinations are rare, and some outcomes may occur incidentally in the vaccinated population. Knowledge of background incidence rates of these medical conditions is a critical component of vaccine safety monitoring to aid in the assessment of adverse events temporally associated with vaccination and to put these events into context with what would be expected due to chance alone. A list of 22 potential adverse events of special interest (AESI), including neurologic, autoimmune, and cardiovascular disorders, was compiled by subject matter experts at the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention. The most recently available U.S. background rates for these medical conditions, overall and by age, sex, and race/ethnicity (when available), were sourced from reported statistics (data published by medical panels/ associations or federal government reports), and literature reviews in PubMed. This review provides estimates of background incidence rates for medical conditions that may be monitored or studied as AESI during safety surveillance and research for COVID19 vaccines and other new vaccines. Published by Elsevier Ltd.	[Gubernot, Diane; Niu, Manette; Baumblatt, Jane; Forshee, Richard; Anderson, Steven] US FDA, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA; [Jazwa, Amelia; Gee, Julianne; Moro, Pedro; Duffy, Jonathan; Harrington, Theresa; McNeil, Michael M.; Broder, Karen; Su, John; Kamidani, Satoshi; Olson, Christine K.; Panagiotakopoulos, Lakshmi; Shimabukuro, Tom; Bennett, Sarah] Ctr Dis Control & Prevent, CDC 2019 COVID 19 Response Team, 1600 Clifton Rd, Atlanta, GA 30329 USA; [Kamidani, Satoshi] Emory Univ, Sch Med, Dept Pediat, 2015 Uppergate Dr NE,Room 534, Atlanta, GA 30322 USA		Gubernot, D (通讯作者)，US FDA, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.	Diane.Gubernot@fda.hhs.gov; wev7@cdc.gov; Manette.Niu@fda.hhs.gov; Jane.Baumblatt@fda.hhs.gov; dzg2@cdc.gov; psm9@cdc.gov; lzd5@cdc.gov; tsh3@cdc.gov; mmm2@cdc.gov; krb2@cdc.gov; ezu2@cdc.gov; oyi0@cdc.gov; cco7@cdc.gov; xfq3@cdc.gov; ayv6@cdc.gov; Richard.Forshee@fda.hhs.gov; Steven.Anderson@fda.hhs.gov; iyk3@cdc.gov		Jazwa, Amelia/0000-0003-0097-2670			Abrams JY, 2015, VACCINE, V33, P382, DOI 10.1016/j.vaccine.2014.10.044; Agrawal N, 2009, STROKE, V40, P3415, DOI 10.1161/STROKEAHA.109.564633; Alshekhlee A, 2008, NEUROLOGY, V70, P1608, DOI 10.1212/01.wnl.0000310983.38724.d4; Amer Soc Reprod Med, 2012, FERTIL STERIL, V98, P1103, DOI 10.1016/j.fertnstert.2012.06.048; American College of Obstetricians and Gynecologists' Committee on Practice BulletinsGynecology, 2018, Obstet Gynecol, V132, pe197, DOI 10.1097/AOG.0000000000002899; Annegers JF, 1999, EPILEPSIA, V40, P502, DOI 10.1111/j.1528-1157.1999.tb00748.x; Arness MK, 2004, AM J EPIDEMIOL, V160, P642, DOI 10.1093/aje/kwh269; Avalos LA, 2012, BIRTH DEFECTS RES A, V94, P417, DOI 10.1002/bdra.23014; Baradhi, 2020, MYOPERICARDITIS; Baxter R, 2013, CLIN INFECT DIS, V57, P197, DOI 10.1093/cid/cit222; Beckman MG, 2010, AM J PREV MED, V38, pS495, DOI 10.1016/j.amepre.2009.12.017; Benn EKT, 2008, EPILEPSIA, V49, P1431, DOI 10.1111/j.1528-1167.2008.01564.x; Bhatt P, 2019, J PEDIATR-US, V206, P26, DOI 10.1016/j.jpeds.2018.10.044; Black S, 1997, PEDIATR INFECT DIS J, V16, P500, DOI 10.1097/00006454-199705000-00009; Black S, 2009, LANCET, V374, P2115, DOI 10.1016/S0140-6736(09)61877-8; Broers MC, 2019, NEUROEPIDEMIOLOGY, V52, P161, DOI 10.1159/000494291; Centers for Disease Control and Prevention, 2020, HLTH DEP REP CAS MUL; Centers for Disease Control and Prevention, 2009, GEN QUEST ANSW GUILL; Centers for Disease Control and Prevention, 2018, LCWK2 DEATHS PERC TO; Centers for Disease Control and Prevention, 2018, NATL VITAL STAT SYST; Centers for Disease Control and Prevention, 2020, KAW DIS; Chang A, 2019, PEDIATR INFECT DIS J, V38, P582, DOI 10.1097/INF.0000000000002239; Dekker CL, VACCINE, V2021; Donahue JG, 2009, PEDIATRICS, V123, pE228, DOI 10.1542/peds.2008-2384; Dubey D, 2018, ANN NEUROL, V83, P166, DOI 10.1002/ana.25131; Duffy J, 2014, NEUROLOGY, V83, P1823, DOI 10.1212/WNL.0000000000000987; Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756; Filosto M, 2021, J NEUROL NEUROSUR PS, V92, P751, DOI 10.1136/jnnp-2020-324837; Floh A, 2017, CIRCULATION, V136; France EK, 2008, PEDIATRICS, V121, pE687, DOI 10.1542/peds.2007-1578; Fullerton HJ, 2003, NEUROLOGY, V61, P189, DOI 10.1212/01.WNL.0000078894.79866.95; Fuzak JK, 2013, PEDIATR EMERG CARE, V29, P131, DOI 10.1097/PEC.0b013e31828058cd; George BP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104169; Ghimire LV, 2019, CARDIOL YOUNG, V29, P828, DOI 10.1017/S1047951119000982; Glanz J, 2008, PEDIATRICS, V121, pE506, DOI 10.1542/peds.2007-1129; Goncalves LF, 2020, REV ASSOC MED BRAS, V66, P136, DOI [10.1590/1806-9282.66.S2.136, 10.1590/1806-9282.66.s2.136]; Greene SK, 2012, AM J EPIDEMIOL, V175, P1100, DOI 10.1093/aje/kws195; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; Harduar-Morano L, 2011, J ALLERGY CLIN IMMUN, V128, P594, DOI 10.1016/j.jaci.2011.04.049; Hassan MB, 2020, AM J OPHTHALMOL, V220, P110, DOI 10.1016/j.ajo.2020.07.014; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Holman Robert C, 2010, Hawaii Med J, V69, P194; Holman RC, 2010, PEDIATR INFECT DIS J, V29, P483, DOI 10.1097/INF.0b013e3181cf8705; Hoyert Donna L, 2020, Natl Vital Stat Rep, V69, P1; Hua W, 2009, PEDIATR INFECT DIS J, V28, P943, DOI 10.1097/INF.0b013e3181a66471; Huang W, 2014, AM J MED, V127, P829, DOI 10.1016/j.amjmed.2014.03.041; Jackson LA, 2002, AM J EPIDEMIOL, V156, P634, DOI 10.1093/aje/kwf073; JEFFERY DR, 1993, ARCH NEUROL-CHICAGO, V50, P532, DOI 10.1001/archneur.1993.00540050074019; Klaric JS, 2019, MIL MED, V184, P126, DOI 10.1093/milmed/usy343; Klein NP, 2015, PEDIATRICS, V135, pE321, DOI 10.1542/peds.2014-1822; Klein NP, 2010, VACCINE, V28, P1062, DOI 10.1016/j.vaccine.2009.10.115; Koton S, 2020, JAMA NEUROL, V77, P109, DOI 10.1001/jamaneurol.2019.3258; Koton S, 2014, JAMA-J AM MED ASSOC, V312, P259, DOI 10.1001/jama.2014.7692; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kumar N, 2016, CARDIOLOGY, V135, P27, DOI 10.1159/000445206; Kuntz J, 2018, VACCINE, V36, P1524, DOI 10.1016/j.vaccine.2018.02.030; Lambert PH, 2020, VACCINE, V38, P4783, DOI 10.1016/j.vaccine.2020.05.064; Lang K, 2012, DEMOGRAPHY, V49, P989, DOI 10.1007/s13524-012-0113-0; Langer-Gould A, 2011, NEUROLOGY, V77, P1143, DOI 10.1212/WNL.0b013e31822facdd; Langer-Gould A, 2013, NEUROLOGY, V80, P1734, DOI 10.1212/WNL.0b013e3182918cc2; Laughlin RS, 2009, NEUROLOGY, V73, P39, DOI 10.1212/WNL.0b013e3181aaea47; Leake JAD, 2004, PEDIATR INFECT DIS J, V23, P756, DOI 10.1097/01.inf.0000133048.75452.dd; Lee GM, 2020, JAMA-J AM MED ASSOC, V324, P1937, DOI 10.1001/jama.2020.19692; Lee S, 2017, J ALLERGY CLIN IMMUN, V139, P182, DOI 10.1016/j.jaci.2016.04.029; Lin AH, 2013, MIL MED, V178, P18, DOI 10.7205/MILMED-D-12-00226; Ma L, 2014, J ALLERGY CLIN IMMUN, V133, P1075, DOI 10.1016/j.jaci.2013.10.029; MacDorman Marian F, 2015, Natl Vital Stat Rep, V64, P1; Madsen TE, 2017, NEUROLOGY, V89, P990, DOI 10.1212/WNL.0000000000004325; Maglione Margaret A, 2014, Evid Rep Technol Assess (Full Rep), P1, DOI 10.23970/AHRQEPCERTA215; Mayr WT, 2003, NEUROLOGY, V61, P1373, DOI 10.1212/01.WNL.0000094316.90240.EB; McCarthy NL, 2013, AM J PREV MED, V45, P91, DOI 10.1016/j.amepre.2013.02.020; McNeil MM, 2016, J ALLERGY CLIN IMMUN, V137, P868, DOI 10.1016/j.jaci.2015.07.048; Mody P, 2018, EUR HEART J-QUAL CAR, V4, P98, DOI 10.1093/ehjqcco/qcx040; Morgan J, 2008, CLIN INFECT DIS, V46, pS242, DOI 10.1086/524747; Morgenstern LB, 2013, ANN NEUROL, V74, P778, DOI 10.1002/ana.23972; Moro PL, 2015, CLIN INFECT DIS, V61, P980, DOI 10.1093/cid/civ423; Myers TR, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz071; NICOLOSI A, 1986, J INFECT DIS, V154, P399, DOI 10.1093/infdis/154.3.399; O'Leary ST, 2012, PEDIATRICS, V129, P248, DOI 10.1542/peds.2011-1111; Oberle D, 2016, PEDIATR INFECT DIS J, V35, P535, DOI 10.1097/INF.0000000000001073; Pahud BA, 2012, VACCINE, V30, P247, DOI 10.1016/j.vaccine.2011.10.104; Panagiotakopoulos L, 2020, OBSTET GYNECOL, V136, P1086, DOI 10.1097/AOG.0000000000004166; Pellegrino P, 2015, EPIDEMIOLOGY, V26, pE12, DOI 10.1097/EDE.0000000000000210; Polakowski LL, 2013, AM J EPIDEMIOL, V178, P962, DOI 10.1093/aje/kwt051; Prothro C., 2010, Morbidity and Mortality Weekly Report, V59, P657; Querol L, 2021, J NEUROL, V268, P3706, DOI 10.1007/s00415-020-09998-8; RODRIGUEZ M, 1995, NEUROLOGY, V45, P244, DOI 10.1212/WNL.45.2.244; Rossen LM, 2018, PAEDIATR PERINAT EP, V32, P19, DOI 10.1111/ppe.12417; Salinas JL, 2017, J NEUROL SCI, V377, P102, DOI 10.1016/j.jns.2017.04.006; Sechi E, 2019, NEUROLOGY, V93, pE414, DOI 10.1212/WNL.0000000000007828; Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710; Shaw J, 2020, PLATELETS, V31, P307, DOI 10.1080/09537104.2019.1635687; Shui IM, 2012, NEUROEPIDEMIOLOGY, V39, P109, DOI 10.1159/000339248; Silber MH, 2002, SLEEP, V25, P197, DOI 10.1093/sleep/25.2.197; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Stein PD, 2004, AM J CARDIOL, V93, P1194, DOI 10.1016/j.amjcard.2004.01.061; Su J, 2021, MMWR-MORBID MORTAL W; Tong X, 2016, INT J STROKE, V11, P874, DOI 10.1177/1747493016654490; Tseng HF, 2010, JAMA-J AM MED ASSOC, V303, P1699, DOI 10.1001/jama.2010.529; U.S. Food and Drug Administration, 2021, COVID 19 VACC; VAERS, 2020, VACC ADV EV REP SYST; Vellozzi C, 2014, AM J PUBLIC HEALTH, V104, P696, DOI 10.2105/AJPH.2013.301651; Ventura Stephanie J, 2012, Natl Vital Stat Rep, V60, P1; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Vora NM, 2014, NEUROLOGY, V82, P443, DOI 10.1212/WNL.0000000000000086; Watts RG, 2004, CLIN PEDIATR, V43, P691, DOI 10.1177/000992280404300802; Weycker D, 2020, J MED ECON, V23, P184, DOI 10.1080/13696998.2019.1669329; White H, 2005, CIRCULATION, V111, P1327, DOI 10.1161/01.CIR.0000157736.19739.D0; WHO, 2020, CLIN MAN SEV AC RESP; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Williams Valerie F, 2017, MSMR, V24, P2; Wise ME, 2012, AM J EPIDEMIOL, V175, P1110, DOI 10.1093/aje/kws196; World Health Organization, 2020, WHO DIR GEN STAT IHR; Zahuranec DB, 2014, NEUROLOGY, V82, P2180, DOI 10.1212/WNL.0000000000000519; Zhang Y, 2008, CIRCULATION, V118, P1577, DOI 10.1161/CIRCULATIONAHA.108.772285	115	12	12	10	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 23	2021	39	28					3666	3677		10.1016/j.vaccine.2021.05.016		JUN 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SS0GD	34088506	Bronze, Green Published			2022-04-29	WOS:000661420000005
J	Liles, E; Irving, SA; Dandamudi, P; Belongia, EA; Daley, MF; DeStefano, F; Jackson, LA; Jacobsen, SJ; Kharbanda, E; Klein, NP; Weintraub, E; Naleway, AL				Liles, Elizabeth; Irving, Stephanie A.; Dandamudi, Padma; Belongia, Edward A.; Daley, Matthew F.; DeStefano, Frank; Jackson, Lisa A.; Jacobsen, Steven J.; Kharbanda, Elyse; Klein, Nicola P.; Weintraub, Eric; Naleway, Allison L.			Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination	VACCINE			English	Article						Inflammatory bowel disease; Pediatric; Incidence; Rotavirus vaccine	POPULATION-BASED COHORT; CROHNS-DISEASE; ULCERATIVE-COLITIS; NORTHERN CALIFORNIA; CHILDREN; RISK; GASTROENTERITIS; PREVALENCE; PARENTS; SEARCH	Background: Recent studies have reported an increase in Inflammatory bowel disease (IBD) incidence in young children, highlighting the need to better understand risk factors for the development of IBD. Licensed for use in infants in 2006, the oral, live-attenuated rotavirus vaccine has biologic plausibility for instigating inflammation of the gut mucosa as a pathway to immune dysregulation. Methods: Over a ten-year period, we evaluated incidence of IBD within a cohort of children under the age of ten, enrolled in seven integrated healthcare delivery systems. We conducted a nested case-control study to evaluate the association between rotavirus vaccination and IBD using conditional logistic regression. Cases were confirmed via medical record review and matched to non-IBD controls on date of birth, sex, and study site. Results: Among 2.4 million children under the age of 10 years, 333 cases of IBD were identified with onset between 2007 and 2016. The crude incidence of IBD increased slightly over the study period (p-value for trend = 0.046). Of the 333 cases, 227 (68%) were born prior to 2007. Forty-two cases born in 2007 or later, with continuous enrollment since birth were included in the case-control study and matched to 210 controls. The adjusted odds ratio for any rotavirus vaccination in IBD cases, compared to matched controls, was 0.72 (95% confidence interval 0.19-2.65). Conclusions: Data from this large pediatric cohort demonstrate a small overall increase in IBD incidence in young children over a ten-year period. The data suggest that rotavirus vaccination is not associated with development of IBD. (c) 2021 Elsevier Ltd. All rights reserved.	[Liles, Elizabeth; Irving, Stephanie A.; Dandamudi, Padma; Naleway, Allison L.] Kaiser Permanente Ctr Hlth Res, 3800 North Interstate Ave, Portland, OR 97227 USA; [Belongia, Edward A.] Marshfield Clin Res Inst, 1000 North Oak Ave,ML2, Marshfield, WI 54449 USA; [Daley, Matthew F.] Kaiser Permanente Colorado Inst Hlth Res, 2550 South Parker Rd,Suite 200, Aurora, CO 80014 USA; [DeStefano, Frank; Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd NE,MS V18-4, Atlanta, GA 30333 USA; [Jackson, Lisa A.] Kaiser Permanente Washington Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA; [Jacobsen, Steven J.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 South Los Robles Ave, Pasadena, CA 91101 USA; [Kharbanda, Elyse] HealthPartners Inst Educ & Res, 8170 33rd Ave South,MS 23301A, Bloomington, MN 55425 USA; [Klein, Nicola P.] Kaiser Permanente Div Res, Vaccine Study Ctr, 1 Kaiser Plaza,16th Floor, Oakland, CA 94612 USA		Liles, E (通讯作者)，3800 North Interstate Ave, Portland, OR 97227 USA.	Beth.G.Liles@kpchr.org; Stephanie.A.lrving@kpchr.org; Padmavati.D.Dandamudi@kpchr.org; Belongia.Edward@marshfieldclinic.org; Matthew.F.Daley@kp.org; fxd1@cdc.gov; Lisa.A.Jackson@kp.org; Elyse.O.Kharbanda@healthpartners.com; Nicola.Klein@kp.org; eiw8@cdc.gov; Allison.Naleway@kpchr.org		Belongia, Edward/0000-0001-7478-0415; Irving, Stephanie/0000-0001-7437-6797	U.S. Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [200-2012-53584-0006]	The authors wish to acknowledge the contributions of Ning Smith (Kaiser Permanente Center for Health Research) ; Umesh Parashar (Centers for Disease Control and Prevention) ; Kate Burniece (Kaiser Permanente Colorado) ; Stacy Harsh and Mara Kalter (Kaiser Permanente Center for Health Research) ; and Bernie Dizon, Anna Lawless, Gina Lee, Kerresa Morrissette, Claire Park, Jose Pio, and Denison Ryan (Kaiser Permanente Southern California) . This work was supported by the U.S. Centers for Disease Control and Prevention (Task Order 200-2012-53584-0006) . The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.	Abramson O, 2010, J PEDIATR-US, V157, P233, DOI 10.1016/j.jpeds.2010.02.024; Alberto L, 2006, GASTROENTEROLOGY, V130, P1588, DOI 10.1053/j.gastro.2006.02.004; [Anonymous], 2007, J PEDIATR GASTR NUTR, V44, P653; Aujnarain Amiirah, 2013, Curr Gastroenterol Rep, V15, P326, DOI 10.1007/s11894-013-0326-4; Baggs J, 2011, PEDIATRICS, V127, pS45, DOI 10.1542/peds.2010-1722H; Baron S, 2005, GUT, V54, P357, DOI 10.1136/gut.2004.054353; Bayless TM, 1996, GASTROENTEROLOGY, V111, P573, DOI 10.1053/gast.1996.v111.pm8780559; Benchimol EI, 2009, GUT, V58, P1490, DOI 10.1136/gut.2009.188383; Benchimol EI, 2017, AM J GASTROENTEROL, V112, P1412, DOI 10.1038/ajg.2017.208; Benchimol EI, 2014, GASTROENTEROLOGY, V147, P803, DOI 10.1053/j.gastro.2014.06.023; Benchimol EI, 2011, INFLAMM BOWEL DIS, V17, P423, DOI 10.1002/ibd.21349; Boyle J, 2020, VACCINE, V38, P2416, DOI 10.1016/j.vaccine.2020.01.032; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Castro M, 2008, INFLAMM BOWEL DIS, V14, P1246, DOI 10.1002/ibd.20470; Dempsey AF, 2011, PEDIATRICS, V128, P848, DOI 10.1542/peds.2011-0400; Ghione S, 2018, AM J GASTROENTEROL, V113, P265, DOI 10.1038/ajg.2017.228; Glanz Jason M, 2016, Vaccine, V34 Suppl 1, pA1, DOI 10.1016/j.vaccine.2015.10.082; Glanz JM, 2013, JAMA PEDIATR, V167, P274, DOI 10.1001/jamapediatrics.2013.502; GREENBERG HB, 1979, GASTROENTEROLOGY, V76, P349; Grimaldi-Bensouda L, 2014, J INTERN MED, V275, P398, DOI 10.1111/joim.12155; Herrinton LJ, 2008, AM J GASTROENTEROL, V103, P1998, DOI 10.1111/j.1572-0241.2008.01960.x; Heyman MB, 2005, J PEDIATR-US, V146, P35, DOI 10.1016/j.jpeds.2004.08.043; Jakobsen C, 2011, INFLAMM BOWEL DIS, V17, P2541, DOI 10.1002/ibd.21654; Kappelman MD, 2013, DIGEST DIS SCI, V58, P519, DOI 10.1007/s10620-012-2371-5; Lehtinen P, 2011, INFLAMM BOWEL DIS, V17, P1778, DOI 10.1002/ibd.21550; Levine A, 2011, INFLAMM BOWEL DIS, V17, P1314, DOI 10.1002/ibd.21493; Malaty HM, 2010, J PEDIATR GASTR NUTR, V50, P27, DOI 10.1097/MPG.0b013e3181b99baa; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; Parashar Umesh D., 2006, Morbidity and Mortality Weekly Report, V55, P1; Porter CK, 2008, GASTROENTEROLOGY, V135, P781, DOI 10.1053/j.gastro.2008.05.081; Rogler G, 2016, DIGEST DIS, V34, P48, DOI 10.1159/000447283; SYPRIMEKORA J, 2018, WORLD J GASTROENTERO, V0024, P02741; Ungaro R, 2014, AM J GASTROENTEROL, V109, P1728, DOI 10.1038/ajg.2014.246; WHORWELL PJ, 1978, LANCET, V2, P697	34	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 16	2021	39	27					3614	3620		10.1016/j.vaccine.2021.05.032		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SO5NX	34052066	Green Accepted			2022-04-29	WOS:000659020000010
J	Chung, JR; Flannery, B; Kim, SS; Gaglani, M; Raiyani, C; Belongia, EA; McLean, HQ; Nowalk, MP; Zimmerman, RK; Jackson, ML; Jackson, LA; Martin, ET; Monto, AS; Patel, M				Chung, Jessie R.; Flannery, Brendan; Kim, Sara S.; Gaglani, Manjusha; Raiyani, Chandni; Belongia, Edward A.; McLean, Huong Q.; Nowalk, Mary Patricia; Zimmerman, Richard K.; Jackson, Michael L.; Jackson, Lisa A.; Martin, Emily T.; Monto, Arnold S.; Patel, Manish			Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States	VACCINE			English	Article							VIRUS; PROTECTION	Introduction: Mid-season influenza vaccine effectiveness (VE) estimates are a useful tool to help guide annual influenza vaccine strain selection, vaccine policy, and public health messaging. We propose using a sample size-driven approach with data-driven inputs for publication of mid-season influenza VE. Methods: We used pooled inputs for VE by (sub)type and average vaccine coverage by age groups using data from eight seasons of the US Influenza VE Network to calculate sample sizes needed to estimate mid-season VE. Results: We estimate that 135 influenza-positive cases would be needed to detect an overall VE of 40% with 55% vaccine coverage among test-negative controls. Larger sample sizes would be required to produce reliable estimates specifically against influenza A/H3N2 and for older age groups. Conclusion: Using an existing network, most of the recent influenza seasons in the US would facilitate valid mid-season VE estimates using the proposed sample sizes for broad age groupings. Published by Elsevier Ltd.	[Chung, Jessie R.; Flannery, Brendan; Kim, Sara S.; Patel, Manish] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop 24-7, Atlanta, GA 30329 USA; [Gaglani, Manjusha] Texas A&M Univ, Coll Med, Temple, TX 76508 USA; [Gaglani, Manjusha; Raiyani, Chandni] Baylor Scott & White Hlth, Temple, TX USA; [Belongia, Edward A.; McLean, Huong Q.] Marshfield Clin Res Inst, Marshfield, WI USA; [Nowalk, Mary Patricia; Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Jackson, Michael L.; Jackson, Lisa A.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA; [Martin, Emily T.; Monto, Arnold S.] Univ Michigan, Ann Arbor, MI 48109 USA		Chung, JR; Flannery, B (通讯作者)，Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop 24-7, Atlanta, GA 30329 USA.	jchung@cdc.gov; bif4@cdc.gov; omy1@cdc.gov; manjusha.gaglani@bswhealth.org; chandni.raiyani@bswhealth.org; belongia.edward@mcrf.mfldclin.edu; mclean.huong@marshfieldresearch.org; tnowalk@pitt.edu; zimmrk@upmc.edu; michael.l.jackson@kp.org; michael.l.jackson@kp.org; etmartin@umich.edu; asmonto@umich.edu; aul3@cdc.gov	Raiyani, Chandni/ABG-4297-2020; Nowalk, Mary Patricia/ACU-4712-2022	Raiyani, Chandni/0000-0002-5448-9548; Chung, Jessie/0000-0001-5205-966X	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01IP001034U01IP001039]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1TR001857]	This study was supported by the Centers for Disease Control and Prevention [cooperative agreements U01IP001034U01IP001039]. At Pittsburgh, the project was also supported by the National Institutes of Health through grant UL1TR001857.	[Anonymous], 2007, ACCESSED NOVEMBER 6; Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2; Flannery B, 2020, J INFECT DIS, V221, P8, DOI 10.1093/infdis/jiz543; Flannery B, 2019, CLIN INFECT DIS, V68, P1798, DOI 10.1093/cid/ciy775; Flannery B, 2018, MMWR-MORBID MORTAL W, V67, P180, DOI 10.15585/mmwr.mm6706a2; Flannery B, 2017, MMWR-MORBID MORTAL W, V66, P167, DOI 10.15585/mmwr.mm6606a3; Flannery B, 2015, MMWR-MORBID MORTAL W, V64, P10; Flannery B, 2014, MMWR-MORBID MORTAL W, V63, P137; FLEISS JL, 1980, BIOMETRICS, V36, P343, DOI 10.2307/2529990; Gaglani M, 2016, J INFECT DIS, V213, P1546, DOI 10.1093/infdis/jiv577; Jackson L, 2013, MMWR-MORBID MORTAL W, V62, P119; Jackson L, 2013, MMWR-MORBID MORTAL W, V62, P32; Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]; Leung VK, 2016, EUROSURVEILLANCE, V21, P35, DOI 10.2807/1560-7917.ES.2016.21.16.30202; McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647; Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; World Health Organization, DESCR PROC SEAS H5N1; Wu MJ, 2021, VACCINE, V39, P1788, DOI 10.1016/j.vaccine.2021.01.065; Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635	22	0	0	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3324	3328		10.1016/j.vaccine.2021.05.004		JUN 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	33994240				2022-04-29	WOS:000657001300005
J	Millar, EV; Bennett, JW; Barin, B; Carey, PM; Law, NN; English, CE; Schwartz, MM; Cochrane, T; Ellis, MW; Tribble, DR; Cooke, MT; Hennessey, JP				Millar, Eugene V.; Bennett, Jason W.; Barin, Burc; Carey, Patrick M.; Law, Natasha N.; English, Caroline E.; Schwartz, Michael M.; Cochrane, Terrence; Ellis, Michael W.; Tribble, David R.; Cooke, M. Timothy; Hennessey, John P.			Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: A phase 2 vaccine trial among US Army Infantry trainees	VACCINE			English	Article						Staphylococcus aureus; MRSA; Vaccine; Colonization; Military trainees	NASAL COLONIZATION; CLUMPING FACTOR; SKIN; CANDIDA; INFECTION; RALS3P-N; IMMUNITY; ALS1P; MRSA	Background: Military trainees are at increased risk for Staphylococcus aureus colonization and infection. Disease prevention strategies are needed, but a S. aureus vaccine does not currently exist. Methods: We enrolled US Army Infantry trainees (Fort Benning, GA) in a phase 2, randomized, doubleblind, placebo-controlled trial of NDV-3A, a vaccine containing a recombinant adhesin/invasion protein of Candida albicans that has structural similarity to the S. aureus protein clumping factor A. Study participants received one intramuscular dose of NDV-3A or placebo (adjuvant alone) within 72 h of arrival on base. Longitudinal nasal and oral (throat) swabs were collected throughout the 14-week Infantry training cycle. Safety, immunogenicity, and efficacy of NDV-3A against S. aureus nasal / oral acquisition were the endpoints. Results: The NDV-3A candidate had minimal reactogenicity and elicited robust antigen-specific B-and T cell responses. During the 56-day post-vaccination period, there was no difference in the incidence of S. aureus nasal acquisition between those who were randomized to receive NDV-3A vs. placebo (25.6% vs. 29.1%; vaccine efficacy [VE]: 12.1%; p = 0.31). In time-to-event analysis, there was no difference between study groups with respect to the S. aureus colonization-free interval (VE: 13%; p = 0.29). Similarly, the efficacy of NDV-3A against S. aureus oral acquisition was poor (VE: 2.4%; p = 0.52). Conclusions: A single dose of NDV-3A did not prevent nasal nor oral acquisition of S. aureus in a population of military trainees at high risk for colonization. (c) 2021 Elsevier Ltd. All rights reserved.	[Millar, Eugene V.; Law, Natasha N.; English, Caroline E.; Tribble, David R.] Uniformed Serv Univ Hlth Sci Bethesda, Dept Prevent Med & Biostat, Infect Dis Clin Res Program, Bethesda, MD USA; [Millar, Eugene V.; Law, Natasha N.; English, Caroline E.] Henry M Jackson Fdn, Adv Mil Med Inc, Bethesda, MD USA; [Bennett, Jason W.] Walter Reed Army Inst Res, Silver Spring, MD USA; [Barin, Burc] Emmes Co, Rockville, MD USA; [Carey, Patrick M.; Law, Natasha N.] Benning Martin Army Community Hosp, Ft Benning, GA USA; [Schwartz, Michael M.; Cochrane, Terrence; Cooke, M. Timothy; Hennessey, John P.] NovaDigm Therapeut Inc, Grand Forks, ND USA; [Ellis, Michael W.] Univ Toledo, Med Ctr, Toledo, OH USA		Millar, EV (通讯作者)，Uniformed Serv Univ Hlth Sci Bethesda, Dept Prevent Med & Biostat, Infect Dis Clin Res Program, Bethesda, MD USA.	emillar@idcrp.org			Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; US Army Medical Materiel Development Activity (USAMMDA) [PMB.16.232/16-0725-ISA]; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [Y1-Al-5072]; Defense Health Program, U.S. Department of DefenseUnited States Department of Defense [HU0001190002]	This work (IDCRP-104) was conducted by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed Services University of the Health Sciences (USU) through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. This project was supported by an award from the US Army Medical Materiel Development Activity (USAMMDA; award PMB.16.232/16-0725-ISA to JWB). This project was supported with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-Al-5072 and from the Defense Health Program, U.S. Department of Defense, under award HU0001190002. Funders were not involved in the design or execution of the study; the collection, analysis, or interpretation of data; the writing of the manuscript; or the decision to submit the article for publication.	Broker BM, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5010031; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Edwards JE, 2018, CLIN INFECT DIS, V66, P1928, DOI 10.1093/cid/ciy185; Ellis MW, 2014, INFECT CONT HOSP EP, V35, P1251, DOI 10.1086/678060; Ellis MW, 2014, CLIN INFECT DIS, V58, P1540, DOI 10.1093/cid/ciu166; Fowler VG, 2014, CLIN MICROBIOL INFEC, V20, P66, DOI 10.1111/1469-0691.12570; Fritz SA, 2013, CLIN INFECT DIS, V56, P1554, DOI 10.1093/cid/cit123; Geoghegan JA, 2010, J BIOL CHEM, V285, P6208, DOI 10.1074/jbc.M109.062208; Ibrahim AS, 2006, INFECT IMMUN, V74, P3039, DOI 10.1128/IAI.74.5.3039-3041.2006; Ibrahim AS, 2013, VACCINE, V31, P5549, DOI 10.1016/j.vaccine.2013.09.016; Josefsson E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002206; Kolata JB, 2015, J INFECT DIS, V212, P830, DOI 10.1093/infdis/jiv128; Li X, 2016, MBIO, V7, DOI 10.1128/mBio.02232-15; Lin L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000703; Lin L, 2009, FEMS IMMUNOL MED MIC, V55, P293, DOI 10.1111/j.1574-695X.2008.00531.x; Luna BM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217439; Luo G, 2012, 18 C INT SOC HUM AN; Marshall HS, 2019, J INFECTION, V79, P582, DOI 10.1016/j.jinf.2019.09.018; Millar EV, 2019, INFECTION, V47, P729, DOI 10.1007/s15010-019-01282-w; Millar EV, 2017, CLIN INFECT DIS, V65, P461, DOI 10.1093/cid/cix327; Millar EV, 2015, ANTIMICROB AGENTS CH, V59, P943, DOI 10.1128/AAC.03993-14; Minegishi Y, 2009, J EXP MED, V206, P1291, DOI 10.1084/jem.20082767; OBrien L, 2002, MOL MICROBIOL, V44, P1033, DOI 10.1046/j.1365-2958.2002.02935.x; Phan QT, 2007, PLOS BIOL, V5, P543, DOI 10.1371/journal.pbio.0050064; Schaffer AC, 2006, INFECT IMMUN, V74, P2145, DOI 10.1128/IAI.74.4.2145-2153.2006; Schmidt CS, 2012, VACCINE, V30, P7594, DOI 10.1016/j.vaccine.2012.10.038; Schroder JM, 2010, CURR OPIN INFECT DIS, V23, P106, DOI 10.1097/QCO.0b013e328335b004; Sheppard DC, 2004, J BIOL CHEM, V279, P30480, DOI 10.1074/jbc.M401929200; Spellberg BJ, 2006, J INFECT DIS, V194, P256, DOI 10.1086/504691; Spellberg BJ, 2005, INFECT IMMUN, V73, P6191, DOI 10.1128/IAI.73.9.6191-6193.2005; Stranger-Jones YK, 2006, P NATL ACAD SCI USA, V103, P16942, DOI 10.1073/pnas.0606863103; Yeaman MR, 2014, P NATL ACAD SCI USA, V111, pE5555, DOI 10.1073/pnas.1415610111; Yeaman MR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00463	33	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 27	2021	39	23					3179	3188		10.1016/j.vaccine.2021.04.031		MAY 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SF2TJ	33962841				2022-04-29	WOS:000652613400009
J	Ostolin, TLVD; Gusmao, MR; Mathias, FAS; Cardoso, JMD; Roatt, BM; Aguiar-Soares, RDD; Ruiz, JC; Resende, DD; de Brito, RCF; Reis, AB				Valentim Di Paschoale Ostolin, Thais Lopes; Gusmao, Miria Rodrigues; Siqueira Mathias, Fernando Augusto; de Oliveira Cardoso, Jamille Mirelle; Roatt, Bruno Mendes; de Oliveira Aguiar-Soares, Rodrigo Dian; Ruiz, Jeronimo Conceicao; Resende, Daniela de Melo; Fortes de Brito, Rory Cristiane; Reis, Alexandre Barbosa			A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice	VACCINE			English	Article						Leishmania infantum; Visceral leishmaniasis; Chimera; Multi-epitope vaccine; Immune response; BALB/c	IL-10; QS-21; GENOME; DOGS	In Brazil, canine visceral leishmaniasis is an important public health problem due to its alarming growth. The high prevalence of infected dogs reinforces the need for a vaccine for use in prophylactic vaccination campaigns. In the present study, we evaluate the immunogenicity and protection of the best dose of Chimera A selected through the screening of cytokines production important in disease. BALB/c mice were vaccinated subcutaneously with three doses and challenged intravenously with 1 x 10(7) L. infantum promastigotes. Spleen samples were collected to assess the intracellular cytokine profile production, T cell proliferation and parasite load. At first, three different doses of Chimera A (5 mu g, 10 mu g and 20 mu g) were evaluated through the production of IFN-gamma and IL-10 cytokines. Since the dose of 20 mu g showed the best results, it was chosen to continue the study. Secondarily, Chimera A at dose of 20 mu g was formulated with Saponin plus Monophosphoryl lipid A. Vaccination with Chimera A alone and formulated with SM adjuvant system was able to increase the percentage of the proliferation of specific T lymphocytes and stimulated a Th1 response with increased levels of IFN-gamma, TNF-alpha and IL-2, and decreased of IL-4 and IL-10. The vaccine efficacy through real-time PCR demonstrated a reduction in the splenic parasite load in animals that received Chimera A formulated with the SM adjuvant system (92%). Additionally, we observed increased levels of nitric oxide in stimulated-culture supernatants. The Chimera A formulated with the SM adjuvant system was potentially immunogenic, being able to induce immunoprotective mechanisms and reduce parasite load. Therefore, the use of T-cell multi-epitope vaccine is promising against visceral leishmaniasis. (C) 2021 Elsevier Ltd. All rights reserved.	[Valentim Di Paschoale Ostolin, Thais Lopes; Gusmao, Miria Rodrigues; Siqueira Mathias, Fernando Augusto; de Oliveira Cardoso, Jamille Mirelle; Roatt, Bruno Mendes; de Oliveira Aguiar-Soares, Rodrigo Dian; Fortes de Brito, Rory Cristiane; Reis, Alexandre Barbosa] Univ Fed Ouro Preto, Lab Imunopatol, Nucleo Pesquisas Ciencias Biol NUPEB, Ouro Preto, MG, Brazil; [Siqueira Mathias, Fernando Augusto; Ruiz, Jeronimo Conceicao; Resende, Daniela de Melo] Fiocruz Minas, Inst Rene Rachou, Grp Informat Biossistemas & Genom, Belo Horizonte, MG, Brazil; [Roatt, Bruno Mendes; Reis, Alexandre Barbosa] Inst Nacl Ciencia & Tecnol Doencas Trop INCT DT, Salvador, BA, Brazil		Reis, AB (通讯作者)，Univ Fed Ouro Preto, Lab Imunopatol, Nucleo Pesquisas Ciencias Biol NUPEB, Ouro Preto, MG, Brazil.	alexreis@ufop.edu.br	Reis, Alexandre/AAV-8516-2021; De Brito, Rory Cristiane Fortes/N-3147-2018	Reis, Alexandre/0000-0001-8123-4164; De Brito, Rory Cristiane Fortes/0000-0002-7591-5331	Brazilian agency CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [560943/2010-5, 27/2013, 301526/2015-0, 486618/2013-7, 310104/2018-1, 435224/2018-2]; Brazilian agency FAPEMIGFundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) [APQ 03505-13, PRONEX APQ-01373-14, APQ-01661-13, PPM-00710-15, APQ-02638-17, APQ-02556-18, APQ-00931-18]; Brazilian agency CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]; Universidade Federal de Ouro Preto [082017080]; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	The autors acknowledge the Brazilian agencies CNPq (MCTI/CNPq/CT-BIOTEC-GENOPROT no 560943/2010-5, MCTI/CNPq/CTBIOTEC no 27/2013, 301526/2015-0, 486618/2013-7, 310104/2018-1 and 435224/2018-2), FAPEMIG (APQ 03505-13 Programa de Pesquisa para o SUS -PPSUS MS/CNPq/FAPEMIG/SES, PRONEX APQ-01373-14, APQ-01661-13, PPM-00710-15, APQ-02638-17, APQ-02556-18 and APQ-00931-18), CAPES (this study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Finance Code 001), and Universidade Federal de Ouro Preto for financial support (grant number 082017080). T.L.V.D.P.O. are grateful for CAPES fellowships, A.B.R. and B.M.R. are also grateful to CNPq for fellowships.	Alves-Silva MV, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00100; Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886; [Anonymous], LEISHM PAHO WHO; Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Bahrami AA, 2019, INT REV IMMUNOL, V38, P307, DOI 10.1080/08830185.2019.1657426; Bambini S, 2009, DRUG DISCOV TODAY, V14, P252, DOI 10.1016/j.drudis.2008.12.007; Brusic V, 2005, EXPERT REV VACCINES, V4, P407, DOI 10.1586/14760584.4.3.407; Carcelen J, 2009, VACCINE, V27, P5964, DOI 10.1016/j.vaccine.2009.07.069; Coura-Vital W, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003374; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; De Brito RCF, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020252; De Groot AS, 2004, METHODS, V34, P425, DOI 10.1016/j.ymeth.2004.06.004; Dias DS, 2018, TRANSL RES, V200, P18, DOI 10.1016/j.trsl.2018.05.001; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474; Dikhit MR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01763; Duarte MC, 2016, REV SOC BRAS MED TRO, V49, P398, DOI 10.1590/0037-8682-0120-2016; De Brito RCF, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040162; Gannavaram S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00241; Golec M, 2015, PATHOL BIOL, V63, P130, DOI 10.1016/j.patbio.2015.03.002; Gradoni L, 2015, VET PARASITOL, V208, P94, DOI 10.1016/j.vetpar.2015.01.003; He YQ, 2010, J BIOMED BIOTECHNOL, P1, DOI [10.1155/2010/218590, 10.1155/2010/297505]; Jawed JJ, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109098; Kane MM, 2001, J IMMUNOL, V166, P1141, DOI 10.4049/jimmunol.166.2.1141; Kaye PM, 2004, IMMUNOL REV, V201, P239, DOI 10.1111/j.0105-2896.2004.00188.x; Lage DP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020289; Liu G, 2002, VACCINE, V20, P2808, DOI 10.1016/S0264-410X(02)00209-8; Loeuillet C, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1413-9; Martins VT, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12359; Marty-Roix R, 2016, J BIOL CHEM, V291, P1123, DOI 10.1074/jbc.M115.683011; Mesquita I, 2018, CYTOKINE, V112, P16, DOI 10.1016/j.cyto.2018.07.001; Moreira ND, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047907; Moreno J, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00168; Nagill R, 2015, ASIAN PAC J TROP MED, V8, P511, DOI 10.1016/j.apjtm.2015.06.008; Nakayama T, 2016, VACCINE, V34, P5815, DOI 10.1016/j.vaccine.2016.08.051; Costa CHN, 2011, REV SOC BRAS MED TRO, V44, P232, DOI 10.1590/S0037-86822011005000014; Newman MJ, 1997, VACCINE, V15, P1001, DOI 10.1016/S0264-410X(96)00293-9; Nieto A, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-39; Owusu-Agyei S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007302; Palatnik-de-Sousa CB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00813; Rappuoli R, 2001, VACCINE, V19, P2688, DOI 10.1016/S0264-410X(00)00554-5; Reis AB, 2006, VET IMMUNOL IMMUNOP, V112, P102, DOI 10.1016/j.vetimm.2006.02.001; Reis AB, 2010, TRENDS PARASITOL, V26, P341, DOI 10.1016/j.pt.2010.04.005; Roberts MTM, 2005, INFECT IMMUN, V73, P7620, DOI 10.1128/IAI.73.11.7620-7628.2005; Sachdeva R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007880; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Reis LES, 2013, VET PARASITOL, V197, P498, DOI 10.1016/j.vetpar.2013.07.006; Srivastava S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1553-y; Tritto E, 2009, VACCINE, V27, P3331, DOI 10.1016/j.vaccine.2009.01.084; Vakili B, 2018, INT J BIOL MACROMOL, V120, P1127, DOI 10.1016/j.ijbiomac.2018.08.125; Vijayamahantesh, 2017, MICROBES INFECT, V19, P358, DOI 10.1016/j.micinf.2017.03.002; Vitoriano-Souza J, 2019, VACCINE, V37, P7269, DOI 10.1016/j.vaccine.2019.09.067; Vitoriano-Souza J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040745; WHO, 2019, INT NEGL TROP DIS GL	54	1	1	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 12	2021	39	20					2755	2763		10.1016/j.vaccine.2021.04.004		APR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RU8YE	33875268				2022-04-29	WOS:000645426400004
J	Choi, SK; Baik, YO; Kim, CW; Kim, SK; Oh, IN; Yoon, H; Yu, DJ; Lee, C				Choi, Seuk Keun; Baik, Yeong Ok; Kim, Chan Wha; Kim, Soo Kyung; Oh, Il Nam; Yoon, Hyeseon; Yu, Dajung; Lee, Chankyu			An open-label, comparative, single dose, clinical Phase I study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults	VACCINE			English	Article						Typhoid; Conjugate vaccine; Safety; Immunogenicity; Vi-CRM197; Typbar-TCV (R)	EFFICACY; CRM197; TY21A; FEVER	An injectable typhoid conjugate vaccine (TCV) provides longer-lasting protection, requires fewer doses, and is suitable for children aged >2 years. In addition, TCV is preferred at most ages owing to its improved immunological properties as it overcomes the limitation of Vi polysaccharide vaccines. Here, we assessed the safety, tolerability, and immunogenicity of a TCV, Vi-CRM197, termed EuTCV, in an open-label clinical phase I study in healthy Filipino adults. This study was conducted in 75 healthy adults aged 18-45 years who were randomized in a 1:1:1 ratio based on the vaccines administered: EuTCV (Test), Typbar-TCV(R) (WHO prequalified vaccine) and Typhim Vi(R) (Vi polysaccharide vaccine). The study vaccines were administered at a dose of 25 mu g of Vi-CRM197 conjugate by intramuscular injection as a single dose to each of the 25 participants/group, and their immunogenicity and overall safety were assessed for 42 days post-vaccination. All study participants (n = 25/group) completed the trial without dropouts. There were no deaths, SAEs, or events leading to premature withdrawal from the study. Anti-Vi IgG antibody titer (geometric mean titer) of EuTCV group on day 42 was 65.325 [95% CI (36.860, 115.771)], which was significantly higher than that of the WHO prequalified TCV [24.795, 95% CI (16.164, 38.033) p = 0.0055] and the Vi polysaccharide vaccine [7.998, 95% CI (3.800, 16.835) p < 0.0001]. Moreover, the seroconversion rate of EuTCV and Typbar-TCV(R) was 100%, but that of Typhim Vi(R) was only 84%. The IgG1-3 subclass titers and serum bactericidal assay results in the EuTCV group showed higher and better bactericidal capacity than the other groups. EuTCV was well tolerated and exhibited an acceptable safety profile in the study population. The Vi-CRM197 conjugate dose of 25 mu g may be considered effective in terms of efficacy and safety. (C) 2021 Published by Elsevier Ltd.	[Choi, Seuk Keun; Baik, Yeong Ok; Kim, Soo Kyung; Oh, Il Nam; Yoon, Hyeseon; Yu, Dajung; Lee, Chankyu] EuBiol Co Ltd, R&D Ctr, Chunchon, South Korea; [Choi, Seuk Keun; Kim, Chan Wha] Korea Univ, Dept Biotechnol, Seoul, South Korea		Lee, C (通讯作者)，125 Wonmudong Gil, Chuncheon Si 24410, Gangwon Do, South Korea.	cklee@eubiologics.com		OH, ILNAM/0000-0001-8741-9960			Broker M, 2016, HUM VACC IMMUNOTHER, V12, P664, DOI 10.1080/21645515.2015.1086048; Canh DG, 2004, INFECT IMMUN, V72, P6586, DOI 10.1128/IAI.72.11.6586-6588.2004; Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346; Gruber WC, 2012, ANN NY ACAD SCI, V1263, P15, DOI 10.1111/j.1749-6632.2012.06673.x; Guzman CA, 2006, VACCINE, V24, P3804, DOI 10.1016/j.vaccine.2005.07.111; IVANOFF B, 1994, B WORLD HEALTH ORGAN, V72, P957; Jang MS, 2016, MICROB PATHOGENESIS, V97, P19, DOI 10.1016/j.micpath.2016.05.013; Klugman KP, 1996, VACCINE, V14, P435, DOI 10.1016/0264-410X(95)00186-5; LEVINE MM, 1987, LANCET, V1, P1049; Levine MM, 1999, VACCINE, V17, pS22, DOI 10.1016/S0264-410X(99)00231-5; Milligan R, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001261.pub4; Mitra M, 2016, HUM VACC IMMUNOTHER, V12, P939, DOI 10.1080/21645515.2015.1117715; MURPHY JR, 1991, INFECT IMMUN, V59, P4291, DOI 10.1128/IAI.59.11.4291-4293.1991; Park C, 2017, HUM VACC IMMUNOTHER, V13, P1169, DOI 10.1080/21645515.2016.1261772; Parry CM, 2002, NEW ENGL J MED, V347, P1770, DOI 10.1056/NEJMra020201; Rijpkema S, GENEVA 17 20 OCTOBER; Rijpkema S, 2018, BIOLOGICALS, V56, P29, DOI 10.1016/j.biologicals.2018.09.001; Sinha A, 1999, LANCET, V354, P734, DOI 10.1016/S0140-6736(98)09001-1; Stamboulian D, 2010, INT J INFECT DIS, V14, pE868, DOI 10.1016/j.ijid.2010.03.017; Szu SC, 2013, VACCINE, V31, P1970, DOI 10.1016/j.vaccine.2013.02.006; vanPierre Damme, 2011, PLOS ONE, V6, DOI [10.1016/journal.pone.0025398, DOI 10.1016/JOURNAL.PONE.0025398]; World Hlth Org, 2019, VACCINE, V37, P214, DOI 10.1016/j.vaccine.2018.04.022	22	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 6	2021	39	19					2620	2627		10.1016/j.vaccine.2021.03.089		APR 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RU2SP	33849723				2022-04-29	WOS:000645000500004
J	Carr, DJJ; Berube, AN; Filiberti, A; Gmyrek, GB				Carr, Daniel J. J.; Berube, Amanda N.; Filiberti, Adrian; Gmyrek, Grzegorz B.			Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0 Delta NLS vaccine against ocular HSV-1 challenge	VACCINE			English	Article						Herpes simplex virus type 1; Cornea; Vaccine; Neovascularization; Neonatal Fc receptor	SEROPOSITIVE ASYMPTOMATIC INDIVIDUALS; CD8(+) T-CELLS; PROTECTIVE IMMUNITY; STROMAL KERATITIS; TRANSGENIC MICE; I INTERFERON; MOUSE MODEL; IGG; EXPRESSION; INFECTION	The neonatal Fc receptor (FcRn) is constitutively expressed in the cornea and is up-regulated in response to herpes simplex virus type 1 (HSV-1). Previously, we found targeting cornea FcRn expression by small interfering RNA-mediated knockdown reduced the local efficacy of HSV-1 0 Delta NLS vaccinated C57BL/6 mice against ocular challenge with HSV-1. The current study was undertaken to evaluate the HSV-1 0 Delta NLS vaccine efficacy in FcRn deficient (FcRn KO) mice challenged with HSV-1. Whereas there was little neutralizing antibody detected in the serum of HSV-1 0 Delta NLS vaccinated FcRn KO mice, these mice exhibited the same degree of protection against ocular challenge with HSV-1 as wild type (WT) C57BL/6 mice as measured by cumulative survival, infectious virus shed or retained in tissue, and corneal pathology including opacity and neovascularization. Mock-vaccinated FcRn KO mice were found to be more sensitive to ocular HSV-1 infection compared to mock-vaccinated (WT) mice in terms of cumulative survival and virus shedding. In addition, the FcRn KO mice generated significantly fewer effector (CD3(+)CD44(+)CD62L(-)) and central (CD3(+)CD44(+)CD62L(+)) memory CD8(+) T cells compared to the WT mice 7 days post infection. Collectively, mock-vaccinated FcRn KO mice are susceptible to ocular HSV-1 infection but HSV-1 0 Delta NLS vaccinated FcRn KO mice are resistant suggesting that in addition to the FcRn, other pathways are involved in mediating the protective effect of the HSV-1 0 Delta NLS vaccine against subsequent HSV-1 challenge. (C) 2021 Elsevier Ltd. All rights reserved.	[Carr, Daniel J. J.; Berube, Amanda N.; Filiberti, Adrian; Gmyrek, Grzegorz B.] Univ Oklahoma, Dept Ophthalmol, Hlth Sci Ctr, 608 Stanton L Young Blvd,DMEI 415A, Oklahoma City, OK 73104 USA; [Carr, Daniel J. J.] Univ Oklahoma, Dept Microbiol & Immunol, Hlth Sci Ctr, Oklahoma City, OK 73104 USA		Carr, DJJ (通讯作者)，Univ Oklahoma, Dept Ophthalmol, Hlth Sci Ctr, 608 Stanton L Young Blvd,DMEI 415A, Oklahoma City, OK 73104 USA.	dan-carr@ouhsc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AI053108]; NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30 EY021725]; Research to Prevent BlindnessResearch to Prevent Blindness (RPB)	This work was supported by NIH R01 AI053108, NEI core grant P30 EY021725, and an unrestricted grant from Research to Prevent Blindness. We thank the staff of the Dean McGee Eye Institute animal facility for their efforts in maintaining and monitoring our mice.	Bai Y, 2011, P NATL ACAD SCI USA, V108, P18406, DOI 10.1073/pnas.1115348108; Baker K, 2011, P NATL ACAD SCI USA, V108, P9927, DOI 10.1073/pnas.1019037108; Bournazos S, 2017, IMMUNITY, V47, P224, DOI 10.1016/j.immuni.2017.07.009; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; Bryant-Hudson K, 2013, PROG RETIN EYE RES, V36, P281, DOI 10.1016/j.preteyeres.2013.06.003; Carr Daniel J J, 2020, Immunohorizons, V4, P608, DOI 10.4049/immunohorizons.2000060; Chentoufi AA, 2010, J IMMUNOL, V184, P2561, DOI 10.4049/jimmunol.0902322; Chucair-Elliott AJ, 2017, J LEUKOCYTE BIOL, V101, P1253, DOI 10.1189/jlb.4A1116-459R; Chucair-Elliott AJ, 2016, AM J PATHOL, V186, P2665, DOI 10.1016/j.ajpath.2016.06.007; Chucair-Elliott AJ, 2015, INVEST OPHTH VIS SCI, V56, P1097, DOI 10.1167/iovs.14-15596; Conrady CD, 2013, J IMMUNOL, V190, P2807, DOI 10.4049/jimmunol.1203265; Davido DJ, 2018, J VIROL, V92, DOI 10.1128/JVI.01036-18; Dervillez X, 2013, J IMMUNOL, V191, P5124, DOI 10.4049/jimmunol.1301415; Farooq AV, 2012, SURV OPHTHALMOL, V57, P448, DOI 10.1016/j.survophthal.2012.01.005; Filiberti A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.24; Garg R, 2014, J GEN VIROL, V95, P301, DOI 10.1099/vir.0.058461-0; Gimenez F, 2013, PROG RETIN EYE RES, V33, P1, DOI 10.1016/j.preteyeres.2012.07.002; Gmyrek GB, 2020, J VIROL, V94, DOI 10.1128/JVI.01000-20; Gurung HR, 2018, MUCOSAL IMMUNOL, V11, P172, DOI 10.1038/mi.2017.26; Gurung HR, 2017, IMMUNOL CELL BIOL, V95, P87, DOI 10.1038/icb.2016.80; Halford WP, 1997, VIROLOGY, V238, P53, DOI 10.1006/viro.1997.8806; Horton RE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00200; Hu K, 2011, VACCINE, V29, P1455, DOI 10.1016/j.vaccine.2010.12.031; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kacskovics I, 2011, MABS-AUSTIN, V3, P431, DOI 10.4161/mabs.3.5.17023; Kim H, 2008, INVEST OPHTH VIS SCI, V49, P2025, DOI 10.1167/iovs.07-0871; Koujah L, 2019, CELL MOL LIFE SCI, V76, P405, DOI 10.1007/s00018-018-2938-1; Kroll CM, 2014, J NEUROIMMUNOL, V276, P219, DOI 10.1016/j.jneuroim.2014.08.005; Leach JL, 1996, J IMMUNOL, V157, P3317; Li FJ, 2014, CURR TOP MICROBIOL, V382, P29, DOI 10.1007/978-3-319-07911-0_2; Li ZL, 2011, P NATL ACAD SCI USA, V108, P4388, DOI 10.1073/pnas.1012861108; Martin WL, 1999, BIOCHEMISTRY-US, V38, P12639, DOI 10.1021/bi9913505; Menendez CM, 2016, J IMMUNOL, V197, P1262, DOI 10.4049/jimmunol.1600207; METCALF JF, 1987, CURR EYE RES, V6, P167, DOI 10.3109/02713688709020085; Montgomery ML, 2019, J VIROL, V93, DOI 10.1128/JVI.00314-19; Naidu SK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228252; Petkova SB, 2006, INT IMMUNOL, V18, P1759, DOI 10.1093/intimm/dxl110; Prabhat P, 2007, P NATL ACAD SCI USA, V104, P5889, DOI 10.1073/pnas.0700337104; Ramsey NLM, 2020, J VIROL, V94, DOI 10.1128/JVI.00335-20; Rao P, 2019, EXP EYE RES, V184, P101, DOI 10.1016/j.exer.2019.04.022; Rowe AM, 2013, PROG RETIN EYE RES, V32, P88, DOI 10.1016/j.preteyeres.2012.08.002; Royer DJ, 2016, MUCOSAL IMMUNOL, V9, P1065, DOI 10.1038/mi.2015.124; Royer DJ, 2019, MUCOSAL IMMUNOL, V12, P827, DOI 10.1038/s41385-019-0131-y; Royer DJ, 2017, J IMMUNOL, V199, P1898, DOI 10.4049/jimmunol.1700316; Royer DJ, 2017, J VIROL, V91, DOI 10.1128/JVI.02342-16; Royer DJ, 2016, J VIROL, V90, P5514, DOI 10.1128/JVI.00517-16; Royer DJ, 2015, EXPERT REV OPHTHALMO, V10, P113, DOI 10.1586/17469899.2015.1004315; Simister NE, 1996, EUR J IMMUNOL, V26, P1527, DOI 10.1002/eji.1830260718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400; Srivastava R, 2017, J VIROL, V91, DOI 10.1128/JVI.01793-16; Srivastava R, 2015, J IMMUNOL, V194, P2232, DOI 10.4049/jimmunol.1402606; St Leger AJ, 2011, J IMMUNOL, V186, P3927, DOI 10.4049/jimmunol.1003735; Tan TC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00703; Watkinson RE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005253; Wilhelmus KR, 2020, OPHTHALMOLOGY, V127, pS5, DOI 10.1016/j.ophtha.2020.01.037; Wuest TR, 2010, J EXP MED, V207, P101, DOI 10.1084/jem.20091385; Xu XL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008703; Yoshida M, 2004, IMMUNITY, V20, P769, DOI 10.1016/j.immuni.2004.05.007	60	3	3	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2526	2536		10.1016/j.vaccine.2021.03.075		APR 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33814229				2022-04-29	WOS:000642189300009
J	Dong, TQ; Wakefield, J				Dong, Tracy Qi; Wakefield, Jon			Modeling and presentation of vaccination coverage estimates using data from household surveys	VACCINE			English	Article						Vaccination coverage; High-resolution maps; Uncertainty; Bayesian model-based geostatistics; Small area estimation; Survey sampling	AFRICA; MORTALITY	It is becoming increasingly popular to produce high-resolution maps of vaccination coverage by fitting Bayesian geostatistical models to data from household surveys. Usually, the surveys adopt a stratified cluster sampling design. We discuss a number of crucial choices with respect to two key aspects of the map production process: the acknowledgement of the survey design in modeling, and the appropriate presentation of estimates and their uncertainties. Specifically, we consider the importance of accounting for urban/rural stratification and cluster-level non-spatial excess variation in survey outcomes, when fitting geostatistical models. We also discuss the trade-off between the geographical scale and precision of model-based estimates, and demonstrate visualization methods for mapping and ranking that emphasize the probabilistic interpretation of results. A novel approach to coverage map presentation is proposed to allow comparison and control of the overall map uncertainty. We use measles vaccination coverage in Nigeria as a motivating example and illustrate the different issues using data from the 2018 Nigeria Demographic and Health Survey. (C) 2021 Elsevier Ltd. All rights reserved.	[Dong, Tracy Qi; Wakefield, Jon] Univ Washington, Dept Biostat, Hlth Sci Bldg,NE Pacific St, Seattle, WA 98195 USA; [Wakefield, Jon] Univ Washington, Dept Stat, Padelford Hall,NE Stevens Way, Seattle, WA 98195 USA		Dong, TQ (通讯作者)，Univ Washington, Dept Biostat, Hlth Sci Bldg,NE Pacific St, Seattle, WA 98195 USA.	qd8@uw.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AI029168, U54-GM111274]	TQD was supported by NIH Grant U54-GM111274 and JW was supported by NIH Grant R01-AI029168.	andWAKEFIELD J, 2020, J SURV STAT METHODOL; Bosco C, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2016.0825; Burgert-Brucker, 2015, DHS SPATIAL ANAL REP; Chiles J.-P., 2009, GEOSTATISTICS MODELI, V497; Diggle P. J., 2019, MODEL BASED GEOSTATI; Gething PW, 2016, NEW ENGL J MED, V375, P2435, DOI 10.1056/NEJMoa1606701; Golding N, 2017, LANCET, V390, P2171, DOI 10.1016/S0140-6736(17)31758-0; Graetz N, 2018, NATURE, V555, P48, DOI 10.1038/nature25761; ICF, 2020, DHS PROGR GPS DAT CO; ICF, 2020, DEM HLTH SURV DHS PR; Lindgren F, 2011, J R STAT SOC B, V73, P423, DOI 10.1111/j.1467-9868.2011.00777.x; Mosser JF, 2019, LANCET, V393, P1843, DOI 10.1016/S0140-6736(19)30226-0; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; NPC and ICF, 2019, NIG DEM HLTH SURV 20; Osgood-Zimmerman A, 2018, NATURE, V555, P41, DOI 10.1038/nature25760; Rue H, 2009, J R STAT SOC B, V71, P319, DOI 10.1111/j.1467-9868.2008.00700.x; Sbarra AN, 2021, NATURE, V589, P415, DOI 10.1038/s41586-020-03043-4; Steele JE, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2016.0690; Takahashi S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15585; UNICEF, 2020, UNICEF MULT IND CLUS; United Nations, 2015, TRANSF OUR WORLD 203; Utazi CE, 2019, STAT METHODS MED RES, V28, P3226, DOI 10.1177/0962280218797362; Utazi CE, 2021, STAT MED, V40, P2197, DOI 10.1002/sim.8897; Utazi CE, 2020, VACCINE, V38, P3062, DOI 10.1016/j.vaccine.2020.02.070; Utazi CE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09611-1; Utazi CE, 2018, VACCINE, V36, P1583, DOI 10.1016/j.vaccine.2018.02.020; Wakefield J, 2013, SPRINGER SER STAT, P1, DOI 10.1007/978-1-4419-0925-1; Watanabe S, 2010, J MACH LEARN RES, V11, P3571; Wilson K, 2020, BIOSTATISTICS, V21, pE17, DOI 10.1093/biostatistics/kxy041; WorldPop, 2019, NIG TOT NUMB PEOPL P; WorldPop, 2020, WORLDPOP PROJ; WorldPop. Nigeria 100m Age structures, 2014, ALPH VERS 2014 EST N, DOI [10.5258/SOTON/WP0019, DOI 10.5258/SOTON/WP0019]	32	2	2	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2584	2594		10.1016/j.vaccine.2021.03.007		APR 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33824039	Green Submitted			2022-04-29	WOS:000642189300016
J	Zhang, Y; Li, DD; Zhao, H; Wang, LC; Liao, Y; Li, XQ; Mou, TW; Li, QH				Zhang, Ying; Li, Dandan; Zhao, Heng; Wang, Lichun; Liao, Yun; Li, Xueqi; Mou, Tangwei; Li, Qihan			The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response	VACCINE			English	Editorial Material							SARS-COV; VIRUS; PROTEIN		[Zhang, Ying; Li, Dandan; Zhao, Heng; Wang, Lichun; Liao, Yun; Li, Xueqi; Mou, Tangwei; Li, Qihan] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China		Li, QH (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, 935 Jiaoling Rd, Kunming 650118, Yunnan, Peoples R China.	liqihan@imbcams.com.cn		Li, Dandan/0000-0002-3527-3522	National Key R&D Program of China [2020YFC0849700, 2020YFC0860600]; Program of Chinese Academy of Medicine Science [2020HY320001]; Major Science and Technology Special Projects of Yunnan Province [202003AC100003, 202003AC100009]	This work was supported by the National Key R&D Program of China (2020YFC0849700 and 2020YFC0860600) , the Program of Chinese Academy of Medicine Science (2020HY320001) and the Major Science and Technology Special Projects of Yunnan Province (202003AC100003 and 202003AC100009) .	Collisson EW, 2000, DEV COMP IMMUNOL, V24, P187, DOI 10.1016/S0145-305X(99)00072-5; Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19; Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gupta P, 2019, INDIAN J MED MICROBI, V37, P459, DOI 10.4103/ijmm.IJMM_20_54; Ignjatovic J, 2005, ARCH VIROL, V150, P1813, DOI 10.1007/s00705-005-0541-x; Johns_Hopkins_University, 2020, COVID 19 DASHB CENT; Kang SS, 2020, ACTA PHARM SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009; LECOMTE J, 1987, ARCH VIROL, V97, P123, DOI 10.1007/BF01310740; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Liao Y, 2020, J MED VIROL, V92, P2830, DOI 10.1002/jmv.26200; NAKANAGA K, 1986, J VIROL, V59, P168, DOI 10.1128/JVI.59.1.168-171.1986; Pu J, 2020, MEDRXIV, V2020; Rego GNA, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030474; Subbarao K, 2020, CELL HOST MICROBE, V27, P692, DOI 10.1016/j.chom.2020.04.019; Supekar VM, 2004, P NATL ACAD SCI USA, V101, P17958, DOI 10.1073/pnas.0406128102; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337; Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	21	1	1	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2500	2503		10.1016/j.vaccine.2021.03.067		APR 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33814228	Bronze, Green Published			2022-04-29	WOS:000642189300005
J	Guidry, JPD; Perrin, PB; Laestadius, LI; Vraga, EK; Miller, CA; Fuemmeler, BF; Burton, CW; Ryan, M; Carlyle, KE				Guidry, Jeanine P. D.; Perrin, Paul B.; Laestadius, Linnea, I; Vraga, Emily K.; Miller, Carrie A.; Fuemmeler, Bernard F.; Burton, Candace W.; Ryan, Mark; Carlyle, Kellie E.			US public support for COVID-19 vaccine donation to low- and middle- income countries during the COVID-19 pandemic	VACCINE			English	Article						COVID-19; COVID-19 vaccine; Distribution		As COVID-19 vaccines become available to the public, there will be a massive worldwide distribution effort. Vaccine distribution has historically been unequal primarily due to the inability of nations with developing economies to purchase enough vaccine to fully vaccinate their populations. Inequitable access to COVID-19 vaccines will not just cause humanitarian suffering, it will likely also be associated with increased economic suffering worldwide. This study focuses on the U.S. population and its beliefs about future COVID-19 vaccine donation by the U.S. to low- and middle-income countries. This study carried out a survey among 788 U.S. adults. Variables include demographics, COVID-19 vaccine priority status, COVID-19 vaccine donation beliefs, and Social Dominance Orientation. Analyses showed that older respondents were both less likely to endorse higher levels of COVID-19 vaccine donations and were more likely to want to wait until all in the U.S. who want the vaccine have received it; those who identified as Democrats were more likely to endorse higher levels of future COVID19 vaccine donation than Republicans; and those scoring higher on SDO were both less likely to endorse higher levels of COVID-19 vaccine donations as well as more likely to want to wait until all in the U.S. who want the vaccine have received it. Policymakers, as well as healthcare providers and public health communication professionals, should give consideration to those messages most likely to engender support for global prevention efforts with each audience segment. (C) 2021 Elsevier Ltd. All rights reserved.	[Guidry, Jeanine P. D.] Virginia Commonwealth Univ, Robertson Sch Media & Culture, 901 W Main St,Rm 2216, Richmond, VA 23284 USA; [Perrin, Paul B.] Virginia Commonwealth Univ, Dept Psychol, 1806 W Franklin St, Richmond, VA 23284 USA; [Laestadius, Linnea, I] Univ Wisconsin, Joseph J Zilber Sch Publ Hlth, 1240 N 10th St, Milwaukee, WI 53205 USA; [Vraga, Emily K.] Univ Minnesota, Hubbard Sch Journalism & Mass Commun, 338 Murphy Hall,206 Church St SE, Minneapolis, MN 55455 USA; [Miller, Carrie A.; Fuemmeler, Bernard F.; Ryan, Mark; Carlyle, Kellie E.] Virginia Commonwealth Univ, Sch Med, 1201 E Marshall St, Richmond, VA 23298 USA; [Burton, Candace W.] Univ Calif Irvine, Sue & Bill Gross Sch Nursing, Irvine, CA 92697 USA		Guidry, JPD (通讯作者)，Virginia Commonwealth Univ, Robertson Sch Media & Culture, 901 W Main St,Rm 2216, Richmond, VA 23284 USA.	guidryjd@vcu.edu	Laestadius, Linnea/AAC-1911-2019	Laestadius, Linnea/0000-0003-3272-9317; Vraga, Emily/0000-0002-3016-3869; Guidry, Jeanine/0000-0002-6903-7464			Amiot CE, 2003, PERS SOC PSYCHOL B, V29, P597, DOI 10.1177/0146167203029005005; Bloom BR, 2020, NEW ENGL J MED, V383, P2202, DOI 10.1056/NEJMp2025331; Branswell H, 2020, MODERNAS COVID 19 VA; Centers for Disease Control and Prevention, 2020, CDC IS MAK COVID 19; Clemans-Cope L, 2007, PUBLIC HEALTH REP, V122, P206, DOI 10.1177/003335490712200210; Collins S, 2020, US HLTH INSURANCE CO; Corum J., 2020, CORONAVIRUS VACCINE; da Costa VG, 2020, J INFECT PUBLIC HEAL, V13, P1797, DOI 10.1016/j.jiph.2020.09.023; Fays C, 2020, GLOBAL EC COST COVID; Freeman D, 2009, PERS SOC PSYCHOL B, V35, P72, DOI 10.1177/0146167208325415; GAVI-The Vaccine Alliance, 2020, DOES COVID 19 COMP P; Gollust SE, 2009, AM J PUBLIC HEALTH, V99, P2160, DOI 10.2105/AJPH.2009.161414; Guimond S, 2003, J PERS SOC PSYCHOL, V84, P697, DOI 10.1037/0022-3514.84.4.697; Kelly ML, 2020, PFIZER CEO NEXT STEP; Kumar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033025; Liu YZ, 2020, J MED ETHICS, V46, P499, DOI 10.1136/medethics-2020-106516; Maugh TH, 2009, US WILL DONATE 10 SW; National Institutes of Health, 2020, NIH MOD INV COVID 19; Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003; PRATTO F, 1994, J PERS SOC PSYCHOL, V67, P741, DOI 10.1037/0022-3514.67.4.741; Pratto F, 2000, J CROSS CULT PSYCHOL, V31, P369, DOI 10.1177/0022022100031003005; Rebmann T, 2012, EXPERT REV VACCINES, V11, P1009, DOI [10.1586/ERV.12.63, 10.1586/erv.12.63]; Sharun K, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa184; Southwell BG, 2020, HEALTH COMMUN, V35, P1707, DOI 10.1080/10410236.2020.1837462; Southwell BG, 2011, HEALTH COMMUN, V26, P583, DOI 10.1080/10410236.2011.575453; U.S. Food Drug Administration, 2020, PFIZ BIONTECH COVID; World Health Organization, 2020, REP WHO PAND INFL A; Xu AJ, 2020, ORGAN BEHAV HUM DEC, V161, P65, DOI 10.1016/j.obhdp.2020.01.007; Yamada T, 2009, NEW ENGL J MED, V361, P1129, DOI 10.1056/NEJMp0906972	29	5	5	12	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 22	2021	39	17					2452	2457		10.1016/j.vaccine.2021.03.027		APR 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RL7KL	33745729	Green Published, Bronze			2022-04-29	WOS:000639147100018
J	Yamawaki, RA; Rubio, MD; Alves, LBR; de Almeida, AM; Ferreira, TS; Berchieri, A; Penha, RAC				Yamawaki, Roberto Alexandre; Rubio, Marcela da Silva; Rodrigues Alves, Lucas Bocchini; de Almeida, Adriana Maria; Ferreira, Taisa Santiago; Berchieri Junior, Angelo; Casarin Penha Filho, Rafael Antonio			Evaluation of transfer of maternal immunity to the offspring of broiler breeders vaccinated with a candidate recombinant vaccine against Salmonella Enteritidis	VACCINE			English	Article						Poultry; Humoral immunity; Intestinal morphology; Progeny; Salmonella Enteritidis; Recombinant vaccine		Salmonella Enteritidis (SE) is a major cause of foodborne diseases in humans being frequently related to the consumption of poultry products. Therefore, guaranteeing early immunity to chicks is an important tool to prevent the colonization and infection by this pathogen. The present study evaluated the effectiveness of a candidate recombinant vaccine against SE. Thirty female and five male broiler breeders that were ten weeks-old were divided into 3 groups: unvaccinated (UV), vaccinated with recombinant vaccine candidate (VAC) and vaccinated with commercial bacterin (BAC). Samples of serum and embryonated egg were collected at seven and twelve weeks after the booster dose to quantify the transfer rate of IgY to egg yolks and offspring. Subsequently, forty day-old offspring were divided into two groups (UV and VAC) and challenged on the following day with 107 CFU/chick of SE. Samples of serum, intestine, liver, and cecal content were harvested. Throughout the experiment period, significantly higher levels of IgY were observed in the egg yolk and also in the serum of broiler breeders and offspring of the VAC group in comparison to the UV group. In addition, increased transfer rates of IgY were observed in the VAC group when compared to the BAC group. Furthermore, higher villus-crypt ratios were found out in duodenum, jejunum and ileum at four days post-infection in the offspring from the VAC group. A high challenge dose of SE (107 CFU per chick) was used and despite the stronger humoral immune response provoked by the candidate vaccine, there were no statistical differences in the recovery of viable SE cells from the offspring cecal contents. Therefore, the effect of vaccination to improve intestinal quality may affect the development of the chickens and consequently increase the resistance to lower SE challenge doses. (C) 2021 Elsevier Ltd. All rights reserved.	[Yamawaki, Roberto Alexandre; Rubio, Marcela da Silva; Rodrigues Alves, Lucas Bocchini; de Almeida, Adriana Maria; Ferreira, Taisa Santiago; Berchieri Junior, Angelo; Casarin Penha Filho, Rafael Antonio] Sao Paulo State Univ UNESP, Sch Agr & Vet Sci, BR-14884900 Jaboticabal, SP, Brazil		Penha, RAC (通讯作者)，Sao Paulo State Univ UNESP, Sch Agr & Vet Sci, BR-14884900 Jaboticabal, SP, Brazil.; Penha, RAC (通讯作者)，Sao Paulo State Univ FCAV Unesp, Sch Agr & Vet Sci, Dept Vet Pathol, Via Acesso Prof Paulo Donato Castellane S-N, BR-14884900 Jaboticabal, SP, Brazil.	adrianaalmeida@fcav.unesp.br; berchier@fcav.unesp.br; rafaelpenha@safesaudeanimal.com	Berchieri Junior, Angelo/ABA-2618-2021	Berchieri Junior, Angelo/0000-0003-2522-6500			Agrawal R, 2016, VET WORLD, V9, P425, DOI 10.14202/vetworld.2016.425-431; Al-Natour MQ, 2004, AVIAN DIS, V48, P177, DOI 10.1637/5319; Armwood BT, 2019, AVIAN DIS, V63, P289, DOI 10.1637/11970-091218-Reg.1; Asheg AA, 2003, FOLIA MICROBIOL, V48, P277, DOI 10.1007/BF02930969; Atterbury RJ, 2009, VET REC, V165, P493, DOI 10.1136/vr.165.17.493; Babu U, 2003, VET IMMUNOL IMMUNOP, V91, P39, DOI 10.1016/S0165-2427(02)00265-9; Biloni A, 2013, POULTRY SCI, V92, P2337, DOI 10.3382/ps.2013-03279; Penha RAC, 2012, VACCINE, V30, P7637, DOI 10.1016/j.vaccine.2012.10.020; Penha RAC, 2010, VACCINE, V28, P2853, DOI 10.1016/j.vaccine.2010.01.058; Eeckhaut V, 2018, VET MICROBIOL, V218, P7, DOI 10.1016/j.vetmic.2018.03.022; Hamal KR, 2006, POULTRY SCI, V85, P1364, DOI 10.1093/ps/85.8.1364; Holt PS, 1996, FOOD MICROBIOL, V13, P417, DOI 10.1006/fmic.1996.0048; Holt PS, 1999, POULTRY SCI, V78, P1510, DOI 10.1093/ps/78.11.1510; Huberman YD, 2019, POULTRY SCI, V98, P2422, DOI 10.3382/ps/pez003; Inoue AY, 2008, AVIAN DIS, V52, P567, DOI 10.1637/8096-082707-Reg.1; Ishida Yuuichi, 2018, Food Saf (Tokyo), V6, P151, DOI 10.14252/foodsafetyfscj.2018003; Jazi V, 2018, POULTRY SCI, V97, P2034, DOI 10.3382/ps/pey035; Kirk MD, 2015, PLOS MED, V12, DOI [10.1371/journal.pmed.1001940, 10.1371/journal.pmed.1001921]; Kowalczyk J, 2019, POULTRY SCI, V98, P3150, DOI 10.3382/ps/pez126; Laudadio V, 2012, POULTRY SCI, V91, P265, DOI 10.3382/ps.2011-01675; Markovic R, 2009, ARCH MED VET, V41, P163, DOI 10.4067/S0301-732X2009000200010; Methner U, 1997, BERL MUNCH TIERARZTL, V110, P373; O'Brien SJ, 2013, CLIN INFECT DIS, V56, P705, DOI 10.1093/cid/cis967; Ozdogan M, 2012, J ANIM PHYSIOL AN N, V96, P95, DOI 10.1111/j.1439-0396.2010.01126.x; Rajan K, 2017, CRIT REV MICROBIOL, V43, P370, DOI 10.1080/1040841X.2016.1223600; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd ed; Tran TQL, 2010, CAN J VET RES, V74, P185; Ulmer-Franco AM, 2012, AVIAN BIOL RES, V5, P81, DOI 10.3184/175815512X13350053184471; Upadhyaya I, 2013, INT J MOL SCI, V14, P10608, DOI 10.3390/ijms140510608; Van Immerseel F, 2002, VACCINE, V20, P3034, DOI 10.1016/S0264-410X(02)00227-X; Villagran-de la Mora Z, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9100777; Woodward MJ, 2002, AVIAN PATHOL, V31, P383, DOI 10.1080/03079450220141660; Zar J.H., 1999, BIOSTATISTICAL ANAL; Zhang S, 2019, POULTRY SCI, V98, P6349, DOI 10.3382/ps/pez457	34	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 22	2021	39	17					2408	2415		10.1016/j.vaccine.2021.03.050		APR 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RL7KL	33781602				2022-04-29	WOS:000639147100013
J	Ayasse, M; Ahmed, A; McCullum, C; Espinosa, ML; Paller, AS; Silverberg, JI				Ayasse, Marissa; Ahmed, Adnan; McCullum, Catherine; Espinosa, Maria L.; Paller, Amy S.; Silverberg, Jonathan, I			Vaccines do not cause atopic dermatitis: A systematic review and meta-analysis	VACCINE			English	Review						Atopic dermatitis; Vaccine; Immunity		Background: Previous studies found conflicting results about the association of vaccinations and likelihood of atopic dermatitis (AD). Objectives: To determine whether vaccinations increase the likelihood of AD. Methods: A systematic review was performed of all published studies in MEDLINE, EMBASE, LILACS, Scopus, and Web of Science databases. At least 2 reviewers conducted title/abstract, full-text review, and data extraction. Quality of evidence was assessed using the Newcastle-Ottawa Scale (NOS). Results: Forty-four studies met inclusion criteria; 37 had sufficient data for meta-analysis. There were no associations any vaccine regimen (random-effects logistic regression: odds ratio [95% confidence interval]: 0.961 [0.822-1.124]; n = 21 studies) BCG (0.927 [0.701-1.226]; n = 8), pertussis (0.790 [0.416-1.499]; n = 4), single (1.031 [0.920-1.155]; n = 17) or multiple vaccines (0.902 [0.608-1.338]; n = 7) with likelihood of AD. This remained true in studies with high-quality (NOS >= 7) (OR [95% CI]: 0.941 [0.793-1.117]; n = 13 studies) or low-quality (NOS < 7) (OR [95% CI]: 1.058 [0.669-1.674]; n = 8 studies). Limitations: No randomized controlled trials. Conclusions: No vaccine regimen was consistently associated with developing AD. (C) 2021 Elsevier Ltd. All rights reserved.	[Ayasse, Marissa; McCullum, Catherine; Silverberg, Jonathan, I] George Washington Univ, Dept Dermatol, Sch Med & Hlth Sci, 2150 Penn Ave NW,Suite 2B-425, Washington, DC 20037 USA; [Ahmed, Adnan; Espinosa, Maria L.; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA		Silverberg, JI (通讯作者)，George Washington Univ, Dept Dermatol, Sch Med & Hlth Sci, 2150 Penn Ave NW,Suite 2B-425, Washington, DC 20037 USA.	jonathanISilverberg@Gmail.com	silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805			Ahmadiafshar Akefeh, 2005, Iran J Allergy Asthma Immunol, V4, P185; Anderson HR, 2001, AM J PUBLIC HEALTH, V91, P1126, DOI 10.2105/AJPH.91.7.1126; Annus T, 2004, ALLERGY, V59, P1068, DOI 10.1111/j.1398-9995.2004.00557.x; Bernsen RMD, 2006, VACCINE, V24, P2035, DOI 10.1016/j.vaccine.2005.10.056; Bernsen RMD, 2003, EUR RESPIR J, V22, P962, DOI 10.1183/09031936.03.00039803; Bernsen RMD, 2006, PEDIATR PULM, V41, P463, DOI 10.1002/ppul.20397; Dulny G, 2015, IRAN J ALLERGY ASTHM, V14, P402; Eifan AO, 2009, PEDIAT ALLERG IMM-UK, V20, P545, DOI 10.1111/j.1399-3038.2008.00846.x; Enriquez R, 2005, J ALLERGY CLIN IMMUN, V115, P737, DOI 10.1016/j.jaci.2004.12.1128; Flohr C, 2012, PEDIAT ALLERG IMM-UK, V23, P324, DOI 10.1111/j.1399-3038.2011.01248.x; Garcia-Marcosa L, 2005, INT ARCH ALLERGY IMM, V137, P303, DOI 10.1159/000086461; Gruber C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e36; Gruber C, 2002, PEDIAT ALLERG IMM-UK, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Gruber C, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e282; Gruber C, 2008, ALLERGY, V63, P1464, DOI 10.1111/j.1398-9995.2008.01696.x; Kemp T, 1997, EPIDEMIOLOGY, V8, P678, DOI 10.1097/00001648-199710000-00011; Kiraly N, 2016, ALLERGY, V71, P541, DOI 10.1111/all.12830; Kiraly N, 2013, ALLERGY, V68, P1168, DOI 10.1111/all.12216; Koppen S, 2004, VACCINE, V22, P3375, DOI 10.1016/j.vaccine.2004.02.033; Kummeling I, 2007, PEDIATRICS, V119, pE367, DOI 10.1542/peds.2006-1479; Laubereau B, 2002, EUR J MED RES, V7, P387; Linehan MF, 2014, J ALLERGY CLIN IMMUN, V133, P688, DOI 10.1016/j.jaci.2013.08.007; Ludman S, 2014, CURR ALLERGY CLIN IM, V27, P108; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Martignon G, 2005, PEDIAT ALLERG IMM-UK, V16, P193, DOI 10.1111/j.1399-3038.2005.00254.x; Matheson MC, 2010, PEDIAT ALLERG IMM-UK, V21, P301, DOI 10.1111/j.1399-3038.2009.00950.x; McKeever TM, 2004, AM J PUBLIC HEALTH, V94, P985, DOI 10.2105/AJPH.94.6.985; Miyake Y, 2008, CLIN EXP ALLERGY, V38, P486, DOI 10.1111/j.1365-2222.2007.02869.x; Mohrenschlager M, 2007, PEDIAT ALLERG IMM-UK, V18, P5, DOI 10.1111/j.1399-3038.2006.00485.x; Mrozek-Budzyn D, 2018, POSTEP DERM ALERGOL, V35, P381, DOI 10.5114/ada.2018.77668; Nagel G, 2012, PEDIAT ALLERG IMM-UK, V23, P737, DOI 10.1111/pai.12007; Nakajima K, 2007, THORAX, V62, P270, DOI 10.1136/thx.2006.062547; Nilsson L, 2003, ARCH PEDIAT ADOL MED, V157, P1184, DOI 10.1001/archpedi.157.12.1184; Okada H, 2010, CLIN EXP IMMUNOL, V160, P1, DOI 10.1111/j.1365-2249.2010.04139.x; Olesen AB, 2003, ACTA DERM-VENEREOL, V83, P445, DOI 10.1080/00015550310014997; Patel AR, 2013, PRIM CARE RESP J, V22, P278, DOI 10.4104/pcrj.2013.00039; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Rosenlund H, 2009, PEDIATRICS, V123, P771, DOI 10.1542/peds.2008-0013; Rottem Menachem, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P223, DOI 10.1097/01.moo.0000122312.13359.eb; Schlaud M, 2017, VACCINE, V35, P5156, DOI 10.1016/j.vaccine.2017.07.111; Schmitz R, 2011, DTSCH ARZTEBL INT, V108, P99, DOI 10.3238/arztebl.2011.0099; Silverberg JI, 2010, J ALLERGY CLIN IMMUN, V126, P300, DOI 10.1016/j.jaci.2010.05.041; Singh M, 2013, AM J RHINOL ALLERGY, V27, pE107, DOI 10.2500/ajra.2013.27.3940; Steenhuis TJ, 2008, CLIN EXP ALLERGY, V38, P79, DOI 10.1111/j.1365-2222.2007.02859.x; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Thostesen LM, 2017, PEDIAT ALLERG IMM-UK, V28, P588, DOI 10.1111/pai.12748; Timmermann CAG, 2015, PEDIAT ALLERG IMM-UK, V26, P742, DOI 10.1111/pai.12391; Venter C, 2016, J ALLERGY CLIN IMMUN, V137, pAB60, DOI 10.1016/j.jaci.2015.12.200; Wang IJ, 2012, J FORMOS MED ASSOC, V111, P711, DOI 10.1016/j.jfma.2011.09.022; Yoneyama H, 2000, Arerugi, V49, P585	51	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 26	2021	39	13					1805	1811		10.1016/j.vaccine.2021.02.036		MAR 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QY9YH	33648762				2022-04-29	WOS:000630391900003
J	Wendland, EM; Kops, NL; Bessel, M; Comerlato, J; Maranhao, AGK; Souza, FMA; Villa, LL; Pereira, GFM				Wendland, Eliana M.; Kops, Natalia Luiza; Bessel, Marina; Comerlato, Juliana; Kalume Maranhao, Ana Goretti; Alves Souza, Flavia Moreno; Villa, Luisa Lina; Mendes Pereira, Gerson Fernando			Effectiveness of a universal vaccination program with an HPV quadrivalent vaccine in young Brazilian women	VACCINE			English	Article						HPV; Human papillomavirus vaccine; Prophylactic vaccine effectiveness; Public health units	HUMAN-PAPILLOMAVIRUS; INFECTION; EFFICACY	We examined human papillomavirus (HPV) vaccine effectiveness in a nationwide sample of women aged 16 to 25 years who utilized the public health system in Brazil. This was a cross-sectional, multicentric survey conducted between September 2016 and November 2017 (POP-Brazil Study). A total of 5,945 young adult women were recruited from 119 public primary care units from all 27 federative units of Brazil by trained health professionals. The participants participated in a face-to-face interview and provided biological samples for genital HPV analysis. HPV genotyping was performed using a Linear Array HPV genotyping test in a central laboratory. Sampling weights were applied to the data. Overall, 11.92% (95% CI 10.65, 13.20) of the participants reported having been vaccinated. The frequency of vaccination was highest in 16- to 17-year-old women, with a decreasing vaccination rate with increasing age, and vaccinated women were more likely to belong to the high socioeconomic status group. The use of a quadrivalent vaccine decreased the HPV types 6, 11, 16, and 18 by 56.78%, from 15.64% in unvaccinated women to 6.76% in vaccinated women (P < 0.01), even after adjustment for age. Those who received the vaccine had lower HPV 16 (2.34% in vaccinated vs 8.91% in unvaccinated, P < 0.01) and 6 rates (2.06% vs 5.77%, P < 0.01). Additionally, a higher rate of high-risk HPV types other than HPV 16 and 18 (40.47% in vaccinated vs 32.63% in unvaccinated, P < 0.01) was observed. In conclusion, the results of this study support the effectiveness of HPV vaccination in Brazil. Continuous surveillance must be assured to monitor the HPV infection rate in the vaccination era. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Wendland, Eliana M.; Kops, Natalia Luiza; Bessel, Marina; Comerlato, Juliana] Hosp Moinhos Vento, Porto Alegre, RS, Brazil; [Wendland, Eliana M.; Comerlato, Juliana] Fed Univ Hlth Sci Porto Alegre, Dept Publ Hlth, Porto Alegre, RS, Brazil; [Kalume Maranhao, Ana Goretti] Minist Hlth, Natl Immunizat Program, Brasilia, DF, Brazil; [Alves Souza, Flavia Moreno; Mendes Pereira, Gerson Fernando] Dept Chron Condit & Sexually Transmitted Infect, Brasilia, DF, Brazil; [Villa, Luisa Lina] Univ Sao Paulo, Dept Radiol & Oncol, Fac Med, Sao Paulo, Brazil; [Villa, Luisa Lina] Inst Canc Estado Sao Paulo ICESP, Sao Paulo, Brazil		Wendland, EM (通讯作者)，Rua Ramiro Barcelos 910, BR-90035004 Porto Alegre, RS, Brazil.	elianawend@gmail.com	VILLA, LUISA/AAH-4761-2019	VILLA, LUISA/0000-0003-4074-2335	Hospital Moinhos de Vento through the Program for Supporting the Institutional Development of the Public Health System (PROADI-SUS); Ministry of Health of Brazil	This work was supported by the Hospital Moinhos de Vento through the Program for Supporting the Institutional Development of the Public Health System (PROADI-SUS), supported by the Ministry of Health of Brazil.	ABEP. Associacao Brasileira de Empresas de Pesquisa, CRIT BRAS 2018; Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cavararo R, 2010, CENSO DEMOGRAFICO 20, P203; Cohen PA, 2019, LANCET, V393, P169, DOI 10.1016/S0140-6736(18)32470-X; de Sanjose S, 2019, SUMMARY REPORT; Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3; Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055; Gupta G, 2017, HUM VACC IMMUNOTHER, V13, P1421, DOI 10.1080/21645515.2017.1289301; Huh WK, 2017, LANCET, V390, P2143, DOI 10.1016/S0140-6736(17)31821-4; Jin Jill, 2018, JAMA, V319, P1058, DOI 10.1001/jama.2018.0687; Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044; Malagon T, 2012, LANCET INFECT DIS, V12, P781, DOI 10.1016/S1473-3099(12)70187-1; Markowitz LE, 2020, J INFECT DIS, V221, P910, DOI 10.1093/infdis/jiz555; McClung NM, 2019, CANCER EPIDEM BIOMAR, V28, P602, DOI 10.1158/1055-9965.EPI-18-0885; Mesher D, 2016, EMERG INFECT DIS, V22, P1732, DOI 10.3201/eid2210.160675; Ministerio da Saude, 2018, INF TECN AMPL OF VAC, P39; National Health and Nutrition Examination Survey, NAT HLTH NUTR EX SUR, DOI 11-2012/HPVSWR_G.htm; Onyekwuluje JM, 2012, CLIN LAB, V58, P61; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Pedroza C, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0217-0; Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108; Spencer JC, 2019, PREV MED, V123, P197, DOI 10.1016/j.ypmed.2019.03.037; Stevens MP, 2008, J CLIN MICROBIOL, V46, P3813, DOI 10.1128/JCM.01169-08; Wendland EM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61582-2; Wendland EM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021170; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	29	1	1	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 26	2021	39	13					1840	1845		10.1016/j.vaccine.2021.02.040		MAR 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QY9YH	33674171	hybrid			2022-04-29	WOS:000630391900008
J	Tzanakaki, G; Xirogianni, A; Tsitsika, A; Clark, SA; Kesanopoulos, K; Bratcher, HB; Papandreou, A; Rodrigues, CMC; Maiden, MCJ; Borrow, R; Tsolia, M				Tzanakaki, G.; Xirogianni, A.; Tsitsika, A.; Clark, S. A.; Kesanopoulos, K.; Bratcher, H. B.; Papandreou, A.; Rodrigues, C. M. C.; Maiden, M. C. J.; Borrow, R.; Tsolia, M.			Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017)	VACCINE			English	Article						N. meningitidis; MenB-fHbp; gMATS; MEASURE assay; IMD; MenDeVAR index; Vaccines	NEISSERIA-MENINGITIDIS; NEW-ZEALAND; ADOLESCENTS; DIVERSITY; IDENTIFICATION; VACCINATION; ANTIBODY; ASSAY	Invasive meningococcal disease (IMD) is associated with high case fatality rates and long-term sequelae among survivors. Meningococci belonging to six serogroups (A, B, C, W, X, and Y) cause nearly all IMD worldwide, with serogroup B meningococci (MenB) the predominant cause in many European countries, including Greece (similar to 80% of all IMD). In the absence of protein-conjugate polysaccharide MenB vaccines, two protein-based vaccines are available to prevent MenB IMD in Greece: 4CMenB (Bexsero (TM), GlaxoSmithKline), available since 2014; and MenB-FHbp, (Trumenba (TM), Pfizer), since 2018. This study investigated the potential coverage of MenB vaccines in Greece using 107 MenB specimens, collected from 2010 to 2017 (66 IMD isolates and 41 clinical samples identified solely by non-culture PCR), alongside 6 MenB isolates from a carriage study conducted during 2017-2018. All isolates were characterized by multilocus sequence typing (MLST), PorA, and FetA antigen typing. Whole Genome Sequencing (WGS) was performed on 66 isolates to define the sequences of vaccine components factor H-binding protein (fHbp), Neisserial Heparin Binding Antigen (NHBA), and Neisseria adhesin A (NadA). The expression of fHbp was investigated with flow cytometric meningococcal antigen surface expression (MEASURE) assay. The fHbp gene was present in-frame in all isolates tested by WGS and in 41 MenB clinical samples. All three variant families of fHbp peptides were present, with subfamily B peptides (variant 1) occurring in 69.2% and subfamily A in 30.8% of the samples respectively. Sixty three of 66 (95.5%) MenB isolates expressed sufficient fHbp to be susceptible to bactericidal killing by MenB-fHbp induced antibodies, highlighting its potential to protect against most IMD in Greece. (C) 2021 Elsevier Ltd. All rights reserved.	[Tzanakaki, G.; Xirogianni, A.; Kesanopoulos, K.; Papandreou, A.] Univ West Attica, Sch Publ Hlth, Dept Publ Hlth Policy, Natl Meningitis Reference Lab NMRL, Athens, Greece; [Tsitsika, A.; Tsolia, M.] Natl Kapodistrian Univ, Med Sch, Dept Paediat 2, Athens, Greece; [Clark, S. A.; Borrow, R.] Publ Hlth England, Meningococcal Reference Unit, Manchester Royal Infirm, Manchester, Lancs, England; [Bratcher, H. B.; Rodrigues, C. M. C.; Maiden, M. C. J.] Univ Oxford, Dept Zool, Peter Medawar Bldg Pathogen Res, South Pk Rd, Oxford, England		Tzanakaki, G (通讯作者)，Univ West Attica, Sch Publ Hlth, Dept Publ Hlth Policy, Natl Meningitis Reference Lab, 196 Alexandras Ave, Athens, Greece.	gtzanakaki@uniwa.gr	Maiden, Martin C J/C-5055-2014; Tzanakaki, Georgina/AAZ-6598-2021	Maiden, Martin C J/0000-0001-6321-5138; Rodrigues, Charlene/0000-0003-0942-3707	Pfizer SAPfizer [IIR_WI220747]	Funding for this study was provided by Pfizer SA (IIR_WI220747) (excluding MenDeVar index and gMATS). The authors are solely responsible for the content and interpretation.	Acheson P, 2012, ARCH DIS CHILD, V97, P248, DOI 10.1136/archdischild-2011-301074; Bambini S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065043; Bettinger JA, 2020, VACCINE, V38, P2026, DOI 10.1016/j.vaccine.2019.12.051; BORROW R, 2006, INT M REP EM U ATT G, V24, P5093, DOI DOI 10.1016/J.VACCINE.2006.03.091; Bratcher HB, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1138; Brehony C, 2016, VACCINE, V34, P4690, DOI 10.1016/j.vaccine.2016.08.015; Chatt C, 2014, EUROSURVEILLANCE, V19, P25, DOI 10.2807/1560-7917.ES2014.19.44.20949; Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6; Clark SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089921; Drakopoulou Z, 2008, FEMS IMMUNOL MED MIC, V53, P178, DOI 10.1111/j.1574-695X.2008.00406.x; Esposito S, 2013, EUR J CLIN MICROBIOL, V32, P1129, DOI 10.1007/s10096-013-1856-2; European Centre for Disease Prevention and Control, SURVEILLANCE ATLAS I; FINNE J, 1983, LANCET, V2, P355; FINNE J, 1987, J IMMUNOL, V138, P4402; Fletcher LD, 2004, INFECT IMMUN, V72, P2088, DOI 10.1128/IAI.72.4.2088-2100.2004; Guiddir T, 2018, CLIN INFECT DIS, V67, P1220, DOI 10.1093/cid/ciy257; Harrison OB, 2013, EMERG INFECT DIS, V19, P566, DOI 10.3201/eid1904.111799; Holst J, 2014, VACCINE, V32, P2722, DOI 10.1016/j.vaccine.2014.02.068; Hong E, 2012, VACCINE, V31, P183, DOI 10.1016/j.vaccine.2012.10.072; Jeppesen CA, 2015, J INFECTION, V71, P43, DOI 10.1016/j.jinf.2015.02.006; Jolley Keith A, 2018, Wellcome Open Res, V3, P124, DOI 10.12688/wellcomeopenres.14826.1; Jolley KA, 2012, MICROBIOL-SGM, V158, P1005, DOI 10.1099/mic.0.055459-0; Jolley KA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-595; Kremastinou J, 2003, FEMS IMMUNOL MED MIC, V39, P23, DOI 10.1016/S0928-8244(03)00174-3; Lemee L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107240; Lucidarme J, 2009, J CLIN MICROBIOL, V47, P3577, DOI 10.1128/JCM.00936-09; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Marshall HS, 2020, NEW ENGL J MED, V382, P318, DOI 10.1056/NEJMoa1900236; Masignani V, 2003, J EXP MED, V197, P789, DOI 10.1084/jem.20021911; McMillan M, 2021, CLIN INFECT DIS, V73, pE99, DOI 10.1093/cid/ciaa610; McNeil LK, 2018, MBIO, V9, DOI 10.1128/mBio.00036-18; Muzzi A, 2019, VACCINE, V37, P991, DOI 10.1016/j.vaccine.2018.12.061; Oster P, 2005, VACCINE, V23, P2191, DOI 10.1016/j.vaccine.2005.01.063; Rodrigues CMC, 2021, JMC, V59, DOI [10.1128/ JCM.02161-20, DOI 10.1128/JCM.02161-20]; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Russell JE, 2004, EMERG INFECT DIS, V10, P674, DOI 10.3201/eid1004.030247; Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2; Stewart A, 2013, PERSPECT PUBLIC HEAL, V133, P104, DOI 10.1177/1757913912439928; Thabuis A, 2018, EUROSURVEILLANCE, V23, P17, DOI 10.2807/1560-7917.ES.2018.23.28.1700590; Thompson EAL, 2003, MICROBIOL-SGM, V149, P1849, DOI 10.1099/mic.0.26131-0; Tzanakaki G, 2006, CLIN MICROBIOL INFEC, V12, P1024, DOI 10.1111/j.1469-0691.2006.01521.x; Tzanakaki G, 2005, CLIN MICROBIOL INFEC, V11, P386, DOI 10.1111/j.1469-0691.2005.01109.x; Tzanakaki G, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-111; Vetter V, 2016, EXPERT REV VACCINES, V15, P641, DOI 10.1586/14760584.2016.1130628; Vogel U, 2013, LANCET INFECT DIS, V13, P416, DOI 10.1016/S1473-3099(13)70006-9; WAS RI, 2016, VACCINE, V34, P510, DOI DOI 10.1016/J.VACCINE.2015.11.070; Wedege E, 2007, CLIN VACCINE IMMUNOL, V14, P830, DOI 10.1128/CVI.00039-07; Zlotnick GW, 2015, HUM VACC IMMUNOTHER, V11, P5, DOI 10.4161/hv.34293	48	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 12	2021	39	11					1621	1630		10.1016/j.vaccine.2021.01.073		FEB 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QP4DD	33597116				2022-04-29	WOS:000623785800010
J	Xu, WH; Yang, M				Xu, Wanhong; Yang, Ming			Genetic variation and evolution of foot-and-mouth disease virus serotype A in relation to vaccine matching	VACCINE			English	Article						Foot-and-mouth disease virus serotype A; Antigenic site; Antigenic variation; Sequence and phylogenetic analysis; Virus evolution	NEUTRALIZING ANTIGENIC SITES; MIDDLE-EAST; MOLECULAR EPIDEMIOLOGY; DATAMONKEY; EFFICIENT; SELECTION; VARIANTS; AFRICA	Foot-and-mouth disease (FMD) is a severe, highly contagious viral disease that affects a wide variety of domestic and wild cloven-hoofed animals. FMD vaccines can play a vital role in disease control and are very widely used globally each year. However, due to the diversity of FMDV, the choice of FMD vaccine is still a huge challenge. In this study, 45 FMDV/A isolates were phylogenetically categorized into three topotypes: ASIA (n = 31), AFRICA (n = 10), and EURO-SA (n = 4). Three sera collected from vaccinated cattle with FMDV A22/IRQ/24/64, AfiRN/05, and A/ARG/01 were used to evaluate their antigenic relationship (r 1 ) with the field isolates. The IRQ.124/64 serum demonstrated a 39% (17/44) match (r(1) >= 0.3) to the field isolates, whereas IRN/05 serum and ARG/Olserum showed an 18% (8/44) and a 2% (1/44) match (r(1) >= 0.3) to the field isolates, respectively. The A22/IRQ/24/64 matched with isolates mainly from topotype ASIA, with limited cross-topotype match with isolates from topotypes AFRICA and EURO-SA. However, the A/IRN/05 did not show a cross-topotype match with topotype AFRICA isolates and A/ARG/01 failed to match any isolates from topotypes ASIA and AFRICA. After analyzing the amino acid variation of the known antigenic sites of 45 strains of FMDV/A, it was found that together antigenic sites 1 and 3 contributed about 71% of the amino acid changes to the vaccine evaluated. Based on the capsid sequences, the FMDV/A evolved unequally among topotypes. The topotypes of ASIA and AFRICA evolves faster than that of EURO-SA. The FMDV/A continues to show a high level of genetic diversity driven by a high substitution rate, purifying selection, and positive selection concentrated on antigenic sites or near antigenic sites. The current research shows the challenges of the FMDV/A vaccine selection and emphasizes the importance of continuous monitoring of antigenic evolution for the selection of effective vaccines. (C) 2021 Published by Elsevier Ltd.	[Xu, Wanhong; Yang, Ming] Natl Ctr Foreign Anim Dis, 1015 Arlington St, Winnipeg, MB R3E 3M4, Canada		Yang, M (通讯作者)，Natl Ctr Foreign Anim Dis, 1015 Arlington St, Winnipeg, MB R3E 3M4, Canada.	Ming.Yang@canada.ca			Canadian Food Inspection Agency	The authors gratefully thank the FAO/OIE World Reference Laboratory for FMD and Pirbright Institute, Pirbright, UK for providing FMDV isolates and vaccine antisera. Funding: this work was supported by the Canadian Food Inspection Agency.	BACHRACH HL, 1968, ANNU REV MICROBIOL, V22, P201, DOI 10.1146/annurev.mi.22.100168.001221; Bari FD, 2014, VACCINE, V32, P5794, DOI 10.1016/j.vaccine.2014.08.033; BAXT B, 1989, J VIROL, V63, P2143, DOI 10.1128/JVI.63.5.2143-2151.1989; BOLWELL C, 1989, J GEN VIROL, V70, P45, DOI 10.1099/0022-1317-70-1-45; Bouckaert R, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006650; Carrillo C, 2005, J VIROL, V79, P6487, DOI 10.1128/JVI.79.10.6487-6504.2005; CROWTHER JR, 1993, J GEN VIROL, V74, P1547, DOI 10.1099/0022-1317-74-8-1547; Das B, 2016, INFECT GENET EVOL, V41, P36, DOI 10.1016/j.meegid.2016.03.024; Datamonkey, COLLECTION STATE ART; Di Nardo A, 2011, REV SCI TECH OIE, V30, P63; Dill V, 2017, J VIROL METHODS, V246, P58, DOI 10.1016/j.jviromet.2017.04.007; Fig Tree, MOL EVALUTION PHYLOG; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Jackson T, 2003, VIRUS RES, V91, P33, DOI 10.1016/S0168-1702(02)00258-7; Jamal SM, 2011, J GEN VIROL, V92, P2849, DOI 10.1099/vir.0.035626-0; Kahn S, 2002, CAN VET J, V43, P349; Klein J, 2009, INFECT GENET EVOL, V9, P153, DOI 10.1016/j.meegid.2008.11.005; Knowles NJ, 2016, TRANSBOUND EMERG DIS, V63, pE431, DOI 10.1111/tbed.12299; Knowles NJ, 2003, VIRUS RES, V91, P65, DOI 10.1016/S0168-1702(02)00260-5; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msv279, 10.1093/molbev/msw054]; LEA S, 1994, STRUCTURE, V2, P123, DOI 10.1016/S0969-2126(00)00014-9; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; Ludi AB, 2014, J GEN VIROL, V95, P384, DOI 10.1099/vir.0.057521-0; Mahapatra M, 2011, VET MICROBIOL, V149, P242, DOI 10.1016/j.vetmic.2010.11.003; Mahapatra M, 2016, VACCINE, V34, P3199, DOI 10.1016/j.vaccine.2016.02.057; Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003; MARTINEZ HM, 1983, NUCLEIC ACIDS RES, V11, P4629, DOI 10.1093/nar/11.13.4629; MARTINEZ MA, 1992, J VIROL, V66, P3557; Mattion N, 2009, VACCINE, V27, P741, DOI 10.1016/j.vaccine.2008.11.026; Mioulet V, 2018, SCI REP-UK, V8, P1; Murrell B, 2013, MOL BIOL EVOL, V30, P1196, DOI 10.1093/molbev/mst030; Murrell B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002764; OIE/FAO Reference Laboratory Network for Foot-and-Mouth Disease website, FMDV PROT STRAINS; Parida S, 2009, EXPERT REV VACCINES, V8, P347, DOI 10.1586/14760584.8.3.347; Paton DJ, 2005, REV SCI TECH OIE, V24, P981, DOI 10.20506/rst.24.3.1632; Pereira H G, 1976, Dev Biol Stand, V35, P167; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pond SLK, 2020, MOL BIOL EVOL, V37, P295, DOI 10.1093/molbev/msz197; Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105; Pond SLK, 2005, BIOINFORMATICS, V21, P2531, DOI 10.1093/bioinformatics/bti320; Porphyre T, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00047; Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032; Reeve R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159360; Reeve R, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001027; Reference Laboratory Report, ANN REP OIE FAO REF; RWEYEMAMU MM, 1978, J HYG-CAMBRIDGE, V81, P107, DOI 10.1017/S002217240005381X; RWEYEMAMU MM, 1982, VET REC, V111, P163, DOI 10.1136/vr.111.8.163; SAIZ JC, 1991, J VIROL, V65, P2518, DOI 10.1128/JVI.65.5.2518-2524.1991; SAMUEL AR, 1990, VACCINE, V8, P390, DOI 10.1016/0264-410X(90)90100-Z; Sutmoller P, 2003, VIRUS RES, V91, P101, DOI 10.1016/S0168-1702(02)00262-9; THOMAS AAM, 1988, J VIROL, V62, P2782, DOI 10.1128/JVI.62.8.2782-2789.1988; THOMAS AAM, 1988, ARCH VIROL, V99, P237, DOI 10.1007/BF01311072; Tully DC, 2008, VIROLOGY, V382, P250, DOI 10.1016/j.virol.2008.09.011; Upadhyaya S, 2014, VACCINE, V32, P631, DOI 10.1016/j.vaccine.2013.08.102; Waters R, 2018, VACCINE, V36, P1901, DOI 10.1016/j.vaccine.2018.02.016; Weaver S, 2018, MOL BIOL EVOL, V35, P773, DOI 10.1093/molbev/msx335; Wekesa SN, 2014, INFECT GENET EVOL, V21, P408, DOI 10.1016/j.meegid.2013.12.006; Xu WH, 2018, VACCINE, V36, P3802, DOI 10.1016/j.vaccine.2018.05.045; Yang M, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0650-z; Yang M, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-136; Yoon SH, 2011, MOL CELLS, V31, P413, DOI 10.1007/s10059-011-0249-6	62	0	0	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 1	2021	39	9					1420	1427		10.1016/j.vaccine.2021.01.042		FEB 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8CD	33526282				2022-04-29	WOS:000618498600008
J	McFadden, K; Seale, H				McFadden, Kathleen; Seale, Holly			A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults	VACCINE			English	Review						Hospital; Immunization; Pharmacy; Nurses; Influenza; Standing operating procedures	STANDING-ORDERS; INCREASE INFLUENZA; PNEUMOCOCCAL VACCINATION; QUALITY IMPROVEMENT; DECISION-MAKING; CLINICAL-TRIAL; OLDER-ADULTS; RATES; CARE; IMMUNIZATION	Background: Despite positive steps towards transforming immunisation understanding and practice to better incorporate adults, coverage, especially those at higher risk, is not where it should be. One way to increase uptake is to take advantage of environments outside of primary care which present easy opportunities for vaccination. This study provides a narrative review of hospital-based strategies in acute care settings aimed at improving influenza vaccination rates for adult inpatients. Methods: A search was conducted using Scopus, Embase and PubMed databases for articles reporting on hospital-based interventions aimed at improving influenza vaccination for adults. Studies published in English were included and descriptively analysed. Results: A total of 31 articles were included. Tested interventions included 7 standing order protocols (SOP); 4 reminders; 4 assessment/administration programs; 1 patient education program; 1 organisational-based program; 7 multi-component strategies and 8 studies comparing SOPs with other strategies. One article was included in both SOPs and reminders categories. Studies were published between 1983 and 2017 and conducted in the USA, Canada, or Australia. 18 studies reported statistical significance. Individually, each type of intervention showed success. SOPs were significantly more effective than other individual interventions, but multi-component interventions (which included an SOP) were more effective than SOPs alone. Three articles reported no significant increase in uptake attributed mainly to patient refusals, even with a strategy involving patient education. Only three studies tested provider-level strategies including hospital campaigns, hospital reward programs and interdepartmental competitions, and showed success. Conclusions: Hospital-based interventions are an effective means of improving opportunistic inpatient vaccination. Suggestions for future research include organisational or system-based interventions; qualitative review of barriers and enablers to inpatient vaccination programs; and re-examination of outpatient settings for vaccine delivery. Most studies were not randomised or controlled; therefore, we also recommend additional RCT studies to confirm existing findings on individual strategies. (C) 2020 Elsevier Ltd. All rights reserved.	[McFadden, Kathleen; Seale, Holly] Univ New South Wales, Sch Populat Hlth, Sydney, NSW, Australia		Seale, H (通讯作者)，Univ New South Wales, Sch Populat Hlth, Samuels Ave, Kensington, NSW 2033, Australia.	h.seale@unsw.edu.au		Seale, Holly/0000-0002-1877-5395; McFadden, Kathleen/0000-0003-1546-8901			AIHW (Australian Institute of Health and Welfare), 2018, AUSTR HLTH; Australian Government Department of Health, 2013, IMM AUSTR PROGR NAT; Bakare M, 2007, SOUTH MED J, V100, P140, DOI 10.1097/01.smj.0000254189.87955.68; Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728; Betsch C., 2015, SCOTTISH INDEX MULTI, V2, P61, DOI 10.1177/2372732215600716; Bloom HG, 1999, J AM GERIATR SOC, V47, P106, DOI 10.1111/j.1532-5415.1999.tb01910.x; BLOOM HG, 1988, J AM GERIATR SOC, V36, P897, DOI 10.1111/j.1532-5415.1988.tb05782.x; Bourdet SV, 2003, AM J HEALTH-SYST PH, V60, P1767, DOI 10.1093/ajhp/60.17.1767; Cohen ES, 2015, BMJ QUAL SAF, V24, P221, DOI 10.1136/bmjqs-2014-003556; Corscadden L, 2017, AUST J PRIM HEALTH, V23, P223, DOI [10.1071/PY16093, 10.1071/py16093]; Cotugno S, 2017, AM J HEALTH-SYST PH, V74, pS90, DOI 10.2146/ajhp160755; CROUSE BJ, 1994, J FAM PRACTICE, V38, P258; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; Dexter PR, 2004, JAMA-J AM MED ASSOC, V292, P2366, DOI 10.1001/jama.292.19.2366; Donato AA, 2007, INFECT CONT HOSP EP, V28, P219, DOI 10.1086/511797; Dube E, 2014, AM J INFECT CONTROL, V42, pE55, DOI 10.1016/j.ajic.2014.01.006; Ellerbeck EF, 2003, J RURAL HEALTH, V19, P433, DOI 10.1111/j.1748-0361.2003.tb00579.x; FEDSON DS, 1983, AM J PUBLIC HEALTH, V73, P442, DOI 10.2105/AJPH.73.4.442; Ferguson-Myrthil N, 2009, HOSP PHARM, V44, P874; Gerard MN, 2008, J AM MED INFORM ASSN, V15, P776, DOI 10.1197/jamia.M2698; Ginson S.H., 2000, CAN J HOSP PHARM, P270; Goebel LJ, 2005, J AM GERIATR SOC, V53, P1008, DOI 10.1111/j.1532-5415.2005.53320.x; Heidenreich PA, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000950; Hill John D, 2017, Hosp Pharm, V52, P617, DOI 10.1177/0018578717722788; Hinshaw D, 2011, AM J INFECT CONTROL, V39, P342, DOI 10.1016/j.ajic.2010.12.006; Holt TA, 2012, J GEN INTERN MED, V27, P974, DOI 10.1007/s11606-012-2025-5; Honeycutt AA, 2007, VACCINE, V25, P1484, DOI 10.1016/j.vaccine.2006.10.029; Kim S, 2014, PREV MED, V67, P119, DOI 10.1016/j.ypmed.2014.07.015; Kreager A M, 2001, Lippincotts Case Manag, V6, P138, DOI 10.1097/00129234-200107000-00002; Kreager AM, 2001, LIPPINCOTTS CASE MAN, V6, P43; Lawson F, 2000, J GERONTOL A-BIOL, V55, pM522, DOI 10.1093/gerona/55.9.M522; Ma V, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4742-5; MacIntyre CR, 2003, GERONTOLOGY, V49, P33, DOI 10.1159/000066500; MARGOLIS KL, 1988, ARCH INTERN MED, V148, P2205, DOI 10.1001/archinte.148.10.2205; McIntyre A, 2014, CAN J AGING, V33, P92, DOI 10.1017/S0714980813000640; Mihalek Alexandra J, 2019, Hosp Pediatr, V9, P550, DOI 10.1542/hpeds.2019-0026; Neudorf C, 2003, CAN J PUBLIC HEALTH, V94, P338, DOI 10.1007/BF03403556; Nichol KL, 1998, AM J MED, V105, P385, DOI 10.1016/S0002-9343(98)00293-9; NICHOL KL, 1991, AM J MED, V91, P584, DOI 10.1016/0002-9343(91)90210-O; Norman DA, 2019, VACCINE, V37, P2244, DOI 10.1016/j.vaccine.2019.02.077; Ompad DC, 2006, EPIDEMIOL REV, V28, P54, DOI 10.1093/epirev/mxj004; Ovbiagele B, 2009, J STROKE CEREBROVASC, V18, P38, DOI 10.1016/j.jstrokecerebrovasdis.2008.08.002; Parry MF, 2004, INFECT CONT HOSP EP, V25, P929, DOI 10.1086/502322; Peterson S, 2015, AM J MED QUAL, V30, P323, DOI 10.1177/1062860614532682; PHCAG. (Primary Health Care Advisory Group), 2015, BETT OUTC PEOPL CHRO; Rees S, 2011, J NURS CARE QUAL, V26, P358, DOI 10.1097/NCQ.0b013e31821fb6bb; Ridda I, 2008, VACCINE, V26, P5633, DOI 10.1016/j.vaccine.2008.07.070; RUSHTON TC, 1994, VACCINE, V12, P1173, DOI 10.1016/0264-410X(94)90239-9; Sorensen K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80; Thiese MS, 2014, BIOCHEM MEDICA, V24, P199, DOI 10.11613/BM.2014.022; Trick WE, 2009, INFECT CONT HOSP EP, V30, P86, DOI 10.1086/593121; Wheelock A, 2013, EXPERT REV VACCINES, V12, P893, DOI 10.1586/14760584.2013.814841; WHO (World Health Organization), 2018, INFL SEAS; Winston CA, 2006, AM J MED QUAL, V21, P125, DOI 10.1177/1062860605284361	54	4	4	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					658	666		10.1016/j.vaccine.2020.12.042		JAN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PR1FI	33357955				2022-04-29	WOS:000606987100008
J	Gordeychuk, I; Kyuregyan, K; Kondrashova, A; Bayurova, E; Gulyaev, S; Gulyaeva, T; Potemkin, I; Karlsen, A; Isaeva, O; Belyakova, A; Lyashenko, A; Sorokin, A; Chumakov, A; Morozov, I; Isaguliants, M; Ishmukhametov, A; Mikhailov, M				Gordeychuk, Ilya; Kyuregyan, Karen; Kondrashova, Alla; Bayurova, Ekaterina; Gulyaev, Stanislav; Gulyaeva, Tatiana; Potemkin, Ilya; Karlsen, Anastasia; Isaeva, Olga; Belyakova, Alla; Lyashenko, Anna; Sorokin, Alexey; Chumakov, Alexey; Morozov, Igor; Isaguliants, Maria; Ishmukhametov, Aydar; Mikhailov, Mikhail			Immunization with recombinant ORF2 p551 protein protects common marmosets (Callithrix jacchus) against homologous and heterologous hepatitis E virus challenge	VACCINE			English	Article						Hepatitis E virus; Recombinant protein vaccine; Capsid protein; Bacterial expression system; Viral challenge; Nonhuman primates	MONOCLONAL-ANTIBODIES; LIFE-CYCLE; NON-A; CELLS; ANTIGENICITY; IMMUNOGENICITY; IDENTIFICATION; PARAMETERS; ADAPTATION; EXPRESSION	Background: Hepatitis E virus (HEV) is a major causative agent of acute hepatitis worldwide, prompting continuous HEV vaccine efforts. Vaccine development is hampered by the lack of convenient animal models susceptible to infection with different HEV genotypes. We produced recombinant open reading frame 2 protein (pORF2; p551) of HEV genotype (GT) 3 and assessed its immunogenicity and protectivity against HEV challenge in common marmosets (Callithrix jacchus, CM). Methods: p551 with consensus sequence corresponding to amino acid residues 110-660 of HEV GT3 pORF2 was expressed in E. coli and purified by affinity chromatography. CMs were immunized intramuscularly with 20 lg of p551 VLPs with alum adjuvant (n = 4) or adjuvant alone (n = 2) at weeks 0, 3, 7 and 19. At week 27, p551-immunized and control animals were challenged with HEV GT1 or GT3 and thereafter longitudinally screened for markers of liver function, anti-HEV IgG and HEV RNA in feces and sera. Results: Purified p551 formed VLPs with particle size of 27.71 +/- 2.42 nm. Two immunizations with p551 induced anti-HEV IgG mean titer of 1:1810. Immunized CMs challenged with homologous and heterologous HEV genotype did not develop HEV infection during the follow-up. Control CMs infected with both HEV GT1 and GT3 demonstrated signs of HEV infection with virus shedding and elevation of the levels of liver enzymes. High levels of anti-HEV IgG persisted in vaccinated CMs and control CMs that resolved HEV infection, for up to two years post challenge. Conclusions: CMs are shown to be a convenient laboratory animal model susceptible to infection with HEV GT1 and GT3. Immunization with HEV GT3 ORF2/p551 triggers potent anti-HEV antibody response protecting CMs from homologous and heterologous HEV challenge. This advances p551 in VLPs as a prototype vaccine against HEV. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Gordeychuk, Ilya; Kyuregyan, Karen; Kondrashova, Alla; Bayurova, Ekaterina; Gulyaev, Stanislav; Gulyaeva, Tatiana; Potemkin, Ilya; Karlsen, Anastasia; Belyakova, Alla; Lyashenko, Anna; Sorokin, Alexey; Chumakov, Alexey; Morozov, Igor; Isaguliants, Maria; Ishmukhametov, Aydar] Russian Acad Sci, Chumakov Fed Sci Ctr Res & Dev Immune & Biol Prod, Moscow 108819, Russia; [Gordeychuk, Ilya; Kondrashova, Alla; Chumakov, Alexey; Ishmukhametov, Aydar] Sechenov First Moscow State Med Univ, Inst Translat Med & Biotechnol, Moscow 127994, Russia; [Kyuregyan, Karen; Potemkin, Ilya; Karlsen, Anastasia; Isaeva, Olga; Mikhailov, Mikhail] II Mechnikov Res Inst Vaccines & Sera, Moscow 105064, Russia; [Kyuregyan, Karen; Potemkin, Ilya; Karlsen, Anastasia; Isaeva, Olga; Mikhailov, Mikhail] Russian Med Acad Continuous Profess Educ, Moscow 125993, Russia; [Karlsen, Anastasia; Isaguliants, Maria] NF Gamaleya Fed Res Ctr Epidemiol & Microbiol, Moscow 123098, Russia; [Isaguliants, Maria] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden		Gordeychuk, I (通讯作者)，Village Inst Poliomyelitis, Settlement Moskovskiy, Premises 8,Bldg 1, Moscow 108819, Russia.	gordeychuk_iv@chumakovs.su; karen-kyuregyan@yandex.ru; bayurova_eo@chumakovs.su; gulyaev_sa@chumakovs.su; gulyaeva_tv@chumakovs.su; axi0ma@mail.ru; isaeva.06@mail.ru; belyakova_av@chumakovs.su; annalyashen@yandex.ru; Maria.Issagouliantis@ki.se; ishmukhametov@chumakovs.su; michmich2@yandex.ru	Kyuregyan, Karen/D-6300-2014; Gordeychuk, Ilya/AAD-6017-2022; Bayurova, Ekaterina/S-8583-2019; Gordeychuk, Ilya V/D-6515-2014; Gulyaev, Stanislav/AAD-2538-2022; Kondrashova, Alla/AAD-1911-2022	Kyuregyan, Karen/0000-0002-3599-117X; Gordeychuk, Ilya/0000-0002-4551-7535; Bayurova, Ekaterina/0000-0002-6160-2203; Gordeychuk, Ilya V/0000-0002-4551-7535; Kondrashova, Alla/0000-0003-3993-6909			Abbott DH, 2003, COMPARATIVE MED, V53, P339; Antunes SG, 1998, P NATL ACAD SCI USA, V95, P11745, DOI 10.1073/pnas.95.20.11745; Aravalli RN, 2020, GENES-BASEL, V11, DOI 10.3390/genes11070729; BALAYAN MS, 1983, INTERVIROLOGY, V20, P23, DOI 10.1159/000149370; Brok HPM, 2001, CYTOMETRY, V45, P294, DOI 10.1002/1097-0320(20011201)45:4<294::AID-CYTO10002>3.0.CO;2-C; Cao YF, 2017, VACCINE, V35, P5073, DOI 10.1016/j.vaccine.2017.05.072; Cao YF, 2018, HUM VACC IMMUNOTHER, V14, P2254, DOI 10.1080/21645515.2018.1469591; Carson M, 2007, ACTA CRYSTALLOGR D, V63, P295, DOI 10.1107/S0907444906052024; Chandra V, 2008, J VIROL, V82, P7100, DOI 10.1128/JVI.00403-08; Corneillie L, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060564; Dalton HR, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a032144; Diarrassouba A, 2016, Klin Lab Diagn, V61, P299, DOI 10.18821/0869-2084-2016-5-299-303; Glynou K, 2003, PROTEIN EXPRES PURIF, V27, P384, DOI 10.1016/S1046-5928(02)00614-9; Gordeychuk IV, 2018, ACTA NATURAE, V10, P63, DOI 10.32607/20758251-2018-10-4-63-69; Gulyaev S. A., 2017, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P35; Guu TSY, 2009, P NATL ACAD SCI USA, V106, P12992, DOI 10.1073/pnas.0904848106; Innis BL, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a032573; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jagessar SA, 2013, EXP ANIM TOKYO, V62, P159, DOI 10.1538/expanim.62.159; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; Jothikumar N, 2006, J VIROL METHODS, V131, P65, DOI 10.1016/j.jviromet.2005.07.004; Khuroo MS, 2016, WORLD J GASTROENTERO, V22, P7030, DOI 10.3748/wjg.v22.i31.7030; Kirkwood CD, 2020, EXPERT REV VACCINES, V19, P1129, DOI 10.1080/14760584.2020.1874930; Kmush BL, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz144; Kramer JA, 2015, VET PATHOL, V52, P404, DOI 10.1177/0300985814537839; Kuehnel F, 2012, J MED PRIMATOL, V41, P241, DOI 10.1111/j.1600-0684.2012.00550.x; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msv279, 10.1093/molbev/msw054]; Kyuregyan K K, 2019, Vopr Virusol, V64, P274, DOI 10.36233/0507-4088-2019-64-6-274-280; Kyuregyan KK, 2016, B EXP BIOL MED+, V160, P368, DOI 10.1007/s10517-016-3173-0; Lanford RE, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a031815; Lei QS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26975-4; Li SW, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000537; Li SW, 2005, VACCINE, V23, P2893, DOI 10.1016/j.vaccine.2004.11.064; Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997; Li YK, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010109; Liang JH, 2010, INT J MOL SCI, V11, P2962, DOI 10.3390/ijms11082962; Mansuy JM, 2016, HEPATOLOGY, V63, P1145, DOI 10.1002/hep.28436; Mazalovska M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080826; Meng JH, 2001, VIROLOGY, V288, P203, DOI 10.1006/viro.2001.1093; Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860; Mikhaylov MI., 2009, MEDITSINSKAYA VIRUSO, V26, P239; Milich DR, 1997, P NATL ACAD SCI USA, V94, P14648, DOI 10.1073/pnas.94.26.14648; Montpellier C, 2018, GASTROENTEROLOGY, V154, P211, DOI 10.1053/j.gastro.2017.09.020; Nair VP, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005521; Nan YC, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01419; Neumann B, 2016, J MED PRIMATOL, V45, P139, DOI 10.1111/jmp.12216; Orsi A, 2011, REGUL TOXICOL PHARM, V59, P19, DOI 10.1016/j.yrtph.2010.12.003; Pallerla SR, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9100856; Primadharsini PP, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050909; Purdy MA, 2017, J GEN VIROL, V98, P2645, DOI 10.1099/jgv.0.000940; Rein DB, 2012, HEPATOLOGY, V55, P988, DOI 10.1002/hep.25505; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Shiota T, 2013, J VIROL, V87, P6031, DOI 10.1128/JVI.00444-13; Shrestha MP, 2007, NEW ENGL J MED, V356, P895, DOI 10.1056/NEJMoa061847; Shukla P, 2012, J VIROL, V86, P5697, DOI 10.1128/JVI.00146-12; Smith DB, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031880; Smith DB, 2016, J GEN VIROL, V97, P537, DOI 10.1099/jgv.0.000393; Takahashi M, 2010, J CLIN MICROBIOL, V48, P1112, DOI 10.1128/JCM.02002-09; Todt D, 2020, P NATL ACAD SCI USA, V117, P1731, DOI 10.1073/pnas.1912307117; Wang B, 2021, COMPUT STRUCT BIOTEC, V19, P1907, DOI 10.1016/j.csbj.2021.03.038; Wang L, 2016, ADV EXP MED BIOL, V948, P161, DOI 10.1007/978-94-024-0942-0_9; Wang S, 2013, VIRUS RES, V176, P101, DOI 10.1016/j.virusres.2013.05.013; Wang XJ, 2015, J VIROL, V89, P5491, DOI 10.1128/JVI.00107-15; Webb GW, 2020, CLIN MICROBIOL INFEC, V26, P828, DOI 10.1016/j.cmi.2020.03.039; Wen JY, 2016, ANTIVIR RES, V128, P36, DOI 10.1016/j.antiviral.2016.02.002; Wu T, 2007, MOL IMMUNOL, V44, P3261, DOI 10.1016/j.molimm.2007.01.002; Yamashita T, 2009, P NATL ACAD SCI USA, V106, P12986, DOI 10.1073/pnas.0903699106; Yang YL, 2021, WORLD J GASTROENTERO, V27, P2458, DOI 10.3748/wjg.v27.i20.2458; Yin X, 2018, P NATL ACAD SCI USA, V115, P4773, DOI 10.1073/pnas.1721345115; Yu XY, 2019, VACCINE, V37, P4581, DOI 10.1016/j.vaccine.2019.04.006; Zhang J, 2005, VACCINE, V23, P2881, DOI 10.1016/j.vaccine.2004.11.065; Zhang J, 2015, NEW ENGL J MED, V372, P1478, DOI 10.1056/NEJMx150008; Zhang J, 2009, VACCINE, V27, P1869, DOI 10.1016/j.vaccine.2008.12.061; Zhang JZ, 2001, J MED VIROL, V64, P125, DOI 10.1002/jmv.1027; Zhao Q, 2015, VET MICROBIOL, V180, P10, DOI 10.1016/j.vetmic.2015.08.016; Zheng MH, 2018, VACCINE, V36, P2104, DOI 10.1016/j.vaccine.2018.03.005; Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6	78	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					89	99		10.1016/j.vaccine.2021.11.042		DEC 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FV	34836660	hybrid			2022-04-29	WOS:000731299800015
J	Aw, R; Ashik, MR; Islam, AAZM; Khan, I; Mainuddin, M; Islam, MA; Ahasan, MM; Polizzi, KM				Aw, Rochelle; Ashik, Muktadir R.; Islam, Ariful A. Z. M.; Khan, Imran; Mainuddin, Mohammad; Islam, Md Ashraful; Ahasan, Mohammad M.; Polizzi, Karen M.			Production and purification of an active CRM197 in Pichia pastoris and its immunological characterization using a Vi-typhoid antigen vaccine	VACCINE			English	Article						CRM197; Pichia pastoris; Komagataella phaffii; Typhoid conjugated vaccine; Vi-CRM197; Diphtheria toxoid mutant	T-CELL IMMUNOTOXIN; DIPHTHERIA-TOXIN; CONJUGATE VACCINES; PROTEIN EXPRESSION; MUTANT; SECRETION; VI-CRM197	CRM197 is a commonly used glycoconjugate carrier that improves the immunogenicity of vaccines, particularly in infants. Despite the advantages of this diphtheria toxoid mutant, low yields, production in inclusion bodies, and the requirement for specific growth conditions have limited the breadth of successful recombinant protein expression platforms available for its expression. We evaluated Pichia pastoris as a production host, using the methanol inducible AOX1 promoter and a modified a-mating factor signal peptide for secretion into the supernatant. Final purified yields >100 mg L-1 culture were achieved when produced in a bioreactor, which is equivalent to the productivity obtained from bioprocesses using the native Corynebacterium diphtheriae host. Recombinant CRM197 was purified to >95% homogeneity and showed the expected endonuclease activity. Furthermore, mice immunized with a Salmonella enterica serovar Typhi capsular Vi antigen conjugated to our recombinant CRM197 showed greater than 5-fold increase in immune response. Overall, the results demonstrate that Pichia pastoris is a suitable expression host for the production of high quality CRM197 for vaccine applications. (c) 2021 Elsevier Ltd. All rights reserved.	[Aw, Rochelle; Polizzi, Karen M.] Imperial Coll London, Dept Chem Engn, London SW7 2AZ, England; [Aw, Rochelle; Polizzi, Karen M.] Imperial Coll London, Imperial Coll Ctr Synthet Biol, London SW7 2AZ, England; [Ashik, Muktadir R.; Islam, Ariful A. Z. M.; Khan, Imran; Mainuddin, Mohammad; Islam, Md Ashraful; Ahasan, Mohammad M.] Incepta Vaccine Ltd, Dhaka 1341, Bangladesh		Polizzi, KM (通讯作者)，Imperial Coll London, Dept Chem Engn, London SW7 2AZ, England.	k.polizzi@imperial.ac.uk		Aw, Rochelle/0000-0002-8480-9813; Polizzi, Karen/0000-0001-5435-2667	Department of Health and Social Care using UK Aid; Engineering and Physical Sciences Research Council (EPSRC)UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/R013764/1]	This research is funded by the Department of Health and Social Care using UK Aid funding and is managed by the Engineering and Physical Sciences Research Council (EPSRC, grant number: EP/R013764/1) . The views expressed in this publication are those of the author (s) and not necessarily those of the Department of Health and Social Care.	Ahmad M, 2014, APPL MICROBIOL BIOT, V98, P5301, DOI 10.1007/s00253-014-5732-5; An SJ, 2011, VACCINE, V29, P7618, DOI 10.1016/j.vaccine.2011.08.019; Aw R, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-016-0432-8; Aw R, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-128; Bhutta ZA, 2014, LANCET INFECT DIS, V14, P119, DOI 10.1016/S1473-3099(13)70241-X; Broker M, 2011, BIOLOGICALS, V39, P195, DOI 10.1016/j.biologicals.2011.05.004; Cabral KMS, 2003, PROTEIN EXPRES PURIF, V31, P115, DOI 10.1016/S1046-5928(03)00136-0; Deng Q, 2008, ANNU REV MICROBIOL, V62, P271, DOI 10.1146/annurev.micro.62.081307.162848; Fiorino F, 2012, VACCINE, V30, P6111, DOI 10.1016/j.vaccine.2012.05.081; Goffin P, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700168; Hickey JM, 2018, J PHARM SCI-US, V107, P1806, DOI 10.1016/j.xphs.2018.03.002; Hohenblum H, 2004, BIOTECHNOL BIOENG, V85, P367, DOI 10.1002/bit.10904; Jahic M, 2003, MICROB CELL FACT, V2, DOI 10.1186/1475-2859-2-6; Kimura Y, 2007, J BIOCHEM, V142, P105, DOI 10.1093/jb/mvm115; Kothari S, 2013, VACCINE, V31, P4714, DOI 10.1016/j.vaccine.2013.08.037; Lesinski GB, 2001, J MICROBIOL METH, V47, P135, DOI 10.1016/S0167-7012(01)00290-1; Lin-Cereghino GP, 2013, GENE, V519, P311, DOI 10.1016/j.gene.2013.01.062; Lin-Cereghino J, 2005, BIOTECHNIQUES, V38, P44, DOI 10.2144/05381BM04; Liu YY, 2003, PROTEIN EXPRES PURIF, V30, P262, DOI 10.1016/S1046-5928(03)00129-3; Matthews CB, 2018, BIOTECHNOL BIOENG, V115, P103, DOI 10.1002/bit.26440; Micoli F, 2011, VACCINE, V29, P712, DOI 10.1016/j.vaccine.2010.11.022; Micoli F, 2020, P NATL ACAD SCI USA, V117, P24443, DOI 10.1073/pnas.2005857117; Mishra RPN, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180238; Moginger U, 2016, SCI REP-UK, V6, DOI 10.1038/srep20488; MURAKAMI S, 1982, MOL CELL BIOL, V2, P588, DOI 10.1128/MCB.2.5.588; Park AR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201060; Peraino JS, 2013, J IMMUNOL METHODS, V398, P33, DOI 10.1016/j.jim.2013.09.006; RAPPUOLI R, 1983, APPL ENVIRON MICROB, V46, P560, DOI 10.1128/AEM.46.3.560-564.1983; Retallack DM CL, High level expression of recombinant toxin proteins patent, Patent No. [US 896636 B22014, 89663622014]; Shinefield HR, 2010, VACCINE, V28, P4335, DOI 10.1016/j.vaccine.2010.04.072; Stefan A, 2011, J BIOTECHNOL, V156, P245, DOI 10.1016/j.jbiotec.2011.08.024; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; Uthailak N, 2017, MOL BIOTECHNOL, V59, P117, DOI 10.1007/s12033-017-0001-3; van Damme P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025398; Wang Y, 2009, PROCESS BIOCHEM, V44, P949, DOI 10.1016/j.procbio.2009.04.019; Wang ZH, 2017, J IMMUNOL METHODS, V448, P51, DOI 10.1016/j.jim.2017.05.008; Wildt S, 2005, NAT REV MICROBIOL, V3, P119, DOI 10.1038/nrmicro1087; Woo JH, 2006, J BIOTECHNOL, V121, P75, DOI 10.1016/j.jbiotec.2005.07.004; Woo JH, 2004, APPL ENVIRON MICROB, V70, P3370, DOI 10.1128/AEM.70.6.3370-3376.2004; Woo JH, 2002, PROTEIN EXPRES PURIF, V25, P270, DOI 10.1016/S1046-5928(02)00009-8; Zhou J, 1999, J Tongji Med Univ, V19, P253	41	0	0	9	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7379	7386		10.1016/j.vaccine.2021.10.083		DEC 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	34774362				2022-04-29	WOS:000731300100006
J	Laurenz, M; von Eiff, C; Borchert, K; Jacob, C; Seidel, K; Schley, K				Laurenz, Maren; von Eiff, Christof; Borchert, Kathrin; Jacob, Christian; Seidel, Karolin; Schley, Katharina			Vaccination rates and adherence in premature infants before and after pneumococcal conjugate vaccine schedule change for term infants-A claims database analysis in Germany	VACCINE			English	Article						Vaccination rates; Pneumococcal conjugate vaccine; Hexavalent vaccination; Premature newborns; Claims data analysis	PRETERM; BIRTH; IMMUNIZATION	Background: In 2015, the German Standing Committee on Vaccination (STIKO) changed the pneumococ-cal conjugate vaccination (PCV) schedule for mature infants from a 3+1 scheme (2, 3, 4, and 11-14 months of age) to a 2+1 scheme (2, 4, and 11-14 months of age). For premature infants, the 3+1 scheme remained. The aim of this study was to assess vaccination rates, completeness, and timeliness for PCV in premature infants before and after the modified recommendation. Methods: A retrospective claims data analysis using the "Institut fur angewandte Gesundheitsforschung Berlin" Research Database was conducted. Premature infants born in 2013 and 2016 with an individual follow-up of 24 months were included. Hexavalent combination (HEXA) vaccination with a consistent 3 +1 recommendation for mature and premature infants was analyzed as reference vaccination. Results: After 24 months, the PCV rate for at least one dose remained stable in premature newborns of 2016 compared to 2013, while the HEXA vaccination rate increased slightly. However, a significant decrease of a completed PCV schedule (4 doses) in premature infants was noted, whereas the complete-ness of HEXA vaccination did not change. The timeliness of PCV in premature newborns increased for the first and the booster PCV, while the timeliness of HEXA immunization did not change from 2013 to 2016. Conclusion: Although STIKO still recommends a 3+1 PCV schedule for premature infants in Germany, pre-mature infants were vaccinated according to the changed recommendations for mature born infants. A substantial share of premature infants remained unvaccinated, and their vaccinations were often delayed. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Laurenz, Maren; von Eiff, Christof] Pfizer Pharma GmbH, Linkstr 10, D-10785 Berlin, Germany; [Borchert, Kathrin; Jacob, Christian; Seidel, Karolin] Xcenda GmbH, Lange Laube 31, D-30159 Hannover, Germany; [Schley, Katharina] Pfizer Deutschland GmbH, Linkstr 10, D-10785 Berlin, Germany		Laurenz, M (通讯作者)，Pfizer Pharma GmbH, Linkstr 10, D-10785 Berlin, Germany.	Maren.Laurenz@pfizer.com; Christof.vonEiff@pfizer.com; Kathrin.Borchert@xcenda.de; christian.jacob@xcenda.de; Karolin.Seidel@xcenda.de; Katharina.Schley@pfizer.com			Pfizer Pharma GmbH, Germany	This study was funded by Pfizer Pharma GmbH, Germany.	AQUA-Institut fur angewandte Qualitatsforderung und Forschung im Gesundheitswesen GmbH, 2014, BUND ZUM ERF 2013 16; Berger R, 2019, DTSCH ARZTEBL INT, V116, P858, DOI 10.3238/arztebl.2019.0858; Bundeszentrale fur gesundheitliche Aufklarung (BZgA), PNEUM IMPF IMPF KIND; Deutsche Akademie fur Kinder- und Jugendmedizin e.V, 2013, UB ATM BEI EH FRUHG; European Medicines Agency (EMA), 2016, EPAR SUMM PUBL HEX; Gagneur A, 2015, HUM VACC IMMUNOTHER, V11, P2556, DOI 10.1080/21645515.2015.1074358; IQTIG-Institut fur Qualitatssicherung und Transparenz im Gesundheitswesen, 2017, BUND ZUM ERF 2016 GE; Kent A, 2019, CLIN INFECT DIS, V69, P84, DOI 10.1093/cid/ciy842; Langkamp DL, 2001, ARCH PEDIAT ADOL MED, V155, P167, DOI 10.1001/archpedi.155.2.167; Laurenz M, 2021, VACCINE, V39, P3287, DOI 10.1016/j.vaccine.2021.04.029; Martinon-Torres F, 2015, PEDIATRICS, V135, pE876, DOI 10.1542/peds.2014-2941; Miller JE, 2016, LANCET INFECT DIS, V16, P952, DOI 10.1016/S1473-3099(16)00150-X; Naing L, 2006, ARCH OROFAC SCI, V1, P9; Pinquier D, 2009, ARCH PEDIATRIE, V16, P1533, DOI 10.1016/j.arcped.2009.09.009; Robert Koch Institut Robert Koch Institut, 2020, EPIDEMIOLOGISCHES B; Robert Koch-Institut, 2016, 342016 STIKO; Robert Koch-Institut, 2020, 262020 RKI; Robert Koch-Institut, 2015, WISS BEGR AND PNEUM; Robert Koch-Institut, 32332020 RKI; Robert Koch-Institut, 2001, 282001 STIKO; Robert Koch-Institut, 2020, KV IMPFS AUSW ABR KA; Robert Koch-Institut, 2006, 312006 RKI; Ruckinger S, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-12; Statistisches Bundesamt DESTATIS, DIAGN KRANK AB 2000; Statistisches Bundesamt DESTATIS, 12612 0001 LEBENDGEB; Tozzi AE, 2014, VACCINE, V32, P793, DOI 10.1016/j.vaccine.2013.12.044; van der Linden M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220453	27	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7387	7393		10.1016/j.vaccine.2021.11.002		DEC 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	34852945	hybrid			2022-04-29	WOS:000731300100007
J	Voss, G; Jacquet, JM; Tornieporth, N; Kampmann, B; Karron, R; Sobanjo-ter Meulen, A; Chen, R; Gruber, M; Lurie, N; Weller, C; Cramer, JP; Saville, M; Darko, M				Voss, Gerald; Jacquet, Jeanne-Marie; Tornieporth, Nadia; Kampmann, Beate; Karron, Ruth; Sobanjo-ter Meulen, Ajoke; Chen, Robert; Gruber, Marion; Lurie, Nicole; Weller, Charlie; Cramer, Jakob P.; Saville, Melanie; Darko, Mimi			Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020	VACCINE			English	Article						Maternal immunization; Emerging infectious diseases; Vaccines; Pregnancy; Lassa virus fever	SAFETY; IMMUNIZATION; COUNTRIES	Infectious diseases may cause serious morbidity and mortality in pregnant women, their foetuses, and infants; the risk associated with any newly emerging infectious disease (EID) is likely unknown at the time of its emergence. While the ongoing SARS-CoV-2 pandemic shows that the development of vaccines against new pathogens can be considerably accelerated, the immunization of pregnant women generally lags behind the general population. Guided by the priority pathogen list for WHO's R&D Blueprint for Action to Prevent Epidemics, this workshop sought to define the evidence needed for use of vaccines against EIDs in pregnant and lactating women, using Lassa fever as a model. Close to 60 maternal immunization (MI) and vaccine safety experts, regulators, vaccine developers, Lassa fever experts, and investigators from Lassa-affected countries examined the critical steps for vaccine development and immunization decisions for pregnant and lactating women. This paper reports on key themes and recommendations from the workshop. Current practice still assumes the exclusion of pregnant women from early vaccine trials. A shift in paradigm is needed to progress towards initial inclusion of pregnant women in Phase 2 and 3 trials. Several practical avenues were delineated. Participants agreed that vaccine platforms should be assessed early for their suitability for maternal immunization. It was noted that, in some cases, nonclinical data derived from assessing a given platform using other antigens may be adequate evidence to proceed to a first clinical evaluation and that concurrence from regulators may be sought with supporting rationale. For clinical trials, essential prerequisites such as documenting the disease burden in pregnant women, study site infrastructure, capabilities, and staff experience were noted. Early and sustained communication with the local community was considered paramount in any program for the conduct of MI trials and planned vaccine introduction.	[Voss, Gerald; Jacquet, Jeanne-Marie; Lurie, Nicole; Saville, Melanie] Coalit Epidem Preparedness & Innovat, London, England; [Tornieporth, Nadia; Cramer, Jakob P.] Univ Appl Sci & Arts, Hannover, Germany; [Kampmann, Beate] London Sch Hyg & Trop Med, Vaccine Ctr, Fac Infect Dis, London, England; [Karron, Ruth] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD USA; [Sobanjo-ter Meulen, Ajoke] Bill & Melinda Gates Fdn, Seattle, WA USA; [Chen, Robert] Task Force Global Hlth, Brighton Collaborat, Decatur, GA USA; [Gruber, Marion] US FDA, Off Vaccines Res & Review, Ctr Biol Evaluat & Res, Silver Spring, MD USA; [Weller, Charlie] Wellcome Trust Res Labs, Vaccines Programme, London, England; [Darko, Mimi] Food & Drugs Author, Cantonments, Accra, Ghana		Voss, G (通讯作者)，Coalit Epidem Preparedness & Innovat, London, England.	Gerald.voss@cepi.net			Coalition for Epidemic Pre-paredness (CEPI)	The workshop was funded by the Coalition for Epidemic Pre-paredness (CEPI) .	Ali M, 2017, LANCET INFECT DIS, V17, P538, DOI [10.1016/S1473-3099(16)30523-0, 10.1016/s1473-3099(16)30523-0]; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P53; [Anonymous], 2015, Wkly Epidemiol Rec, V90, P433; Blencowe H, 2010, INT J EPIDEMIOL, V39, P102, DOI 10.1093/ije/dyq027; Brighton Collaboration, BEN RISK ASS VACC TE; Campbell H, 2018, J MED MICROBIOL, V67, P1426, DOI 10.1099/jmm.0.000829; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P386; do Amaral WN, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040511; European Medicines Agency, 2020, ICH S5 R3 GUID REPR; Global Alliance to Prevent Prematurity and Stillbirth, 2017, MAT IMM SAF MON LOW; Graham AL, 2019, CURR TROP MED REP, V6, P205, DOI 10.1007/s40475-019-00190-1; International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 2020, ICH HARMONISED GUIDE; Jackson LA, 2011, J INFECT DIS, V204, P854, DOI 10.1093/infdis/jir440; Khan AI, 2017, HUM VACC IMMUNOTHER, V13, P2245, DOI [10.1080/21645515.2017.1343773, 10.1080/21645515.2017.1356525]; Kochhar S, 2019, VACCINE, V37, P2967, DOI 10.1016/j.vaccine.2019.03.074; Kochhar S, 2017, VACCINE, V35, P6469, DOI 10.1016/j.vaccine.2017.09.033; Krubiner CB, 2021, VACCINE, V39, P85, DOI 10.1016/j.vaccine.2019.01.011; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; Marchant A, 2017, LANCET INFECT DIS, V17, pE197, DOI 10.1016/S1473-3099(17)30229-3; Modi N, 2021, AM J OBSTET GYNECOL, V224, P423, DOI 10.1016/j.ajog.2021.01.006; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Moro PL, 2016, VACCINE, V34, P5991, DOI 10.1016/j.vaccine.2016.08.026; Munoz FM, 2019, J INFECT DIS, V220, P1802, DOI 10.1093/infdis/jiz390; Nigeria Centre for Disease Control, UPD LASS FEV OUTBR N; Okogbenin S, 2019, EMERG INFECT DIS, V25, P1494, DOI 10.3201/eid2508.181299; Perinatal Society of Australia and New Zealand, INTERDISCIPLINARY MA; Restivo V, 2018, HUM VACC IMMUNOTHER, V14, P724, DOI 10.1080/21645515.2017.1321722; Salami K, 2020, VACCINE, V38, P4135, DOI 10.1016/j.vaccine.2020.01.017; Stuurman AL, 2018, VACCINE, V36, P6736, DOI 10.1016/j.vaccine.2018.09.033; US Food and Drug Administration, 2017, DRAFT GUID DET TOX R; WHO Global Advisory Committee on Vaccine Safety, 2014, SAF IMM PREGN REV EV; World Health Organisation, 2012, WKLY EPIDEMIOL REC, V87, P461; World Health Organization, 2005, World Health Organ Tech Rep Ser, V927, P1; World Health Organization, YELLOW FEVER; World Health Organization, 2018, WHO RES DEV BLUEPR A; World Health Organization, 2014, WKLY EPIDEMIOL REC, V89, P329	36	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7357	7362		10.1016/j.vaccine.2021.10.048		DEC 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	34799142	Bronze, Green Published			2022-04-29	WOS:000731300100001
J	von Reyn, CF				von Reyn, C. Fordham			BCG versus rBCG: What is the way forward?	VACCINE			English	Editorial Material							TUBERCULOSIS; VACCINE; PROTECTION		[von Reyn, C. Fordham] Geisel Sch Med, Hanover, NH 03755 USA		von Reyn, CF (通讯作者)，Geisel Sch Med, Hanover, NH 03755 USA.						Aronson NE, 2004, JAMA-J AM MED ASSOC, V291, P2086, DOI 10.1001/jama.291.17.2086; CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362; Hatherill M, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03154; Knight GM, 2014, P NATL ACAD SCI USA, V111, P15520, DOI 10.1073/pnas.1404386111; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]; Nguipdop-Djomo P, 2016, LANCET INFECT DIS, V16, P219, DOI 10.1016/S1473-3099(15)00400-4; Singh AK, 2021, VACCINE, V39, P7321, DOI 10.1016/j.vaccine.2021.09.040; von Reyn CF, 2017, J ROY SOC MED, V110, P428, DOI 10.1177/0141076817732965; von Reyn CF, 2014, CLIN INFECT DIS, V59, P608, DOI 10.1093/cid/ciu331	10	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 8	2021	39	50					7319	7320		10.1016/j.vaccine.2021.10.052		DEC 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK8NB	34865823	Bronze			2022-04-29	WOS:000727714000012
J	Abu-Raya, B; Maertens, K; Munoz, FM; Zimmermann, P; Curtis, N; Halperin, SA; Rots, N; Barug, D; Holder, B; Rice, TF; Kampmann, B; Leuridan, E; Sadarangani, M				Abu-Raya, Bahaa; Maertens, Kirsten; Munoz, Flor M.; Zimmermann, Petra; Curtis, Nigel; Halperin, Scott A.; Rots, Nynke; Barug, Daan; Holder, Beth; Rice, Thomas F.; Kampmann, Beate; Leuridan, Elke; Sadarangani, Manish			Factors affecting antibody responses to immunizations in infants born to women immunized against pertussis in pregnancy and unimmunized women: Individual-Participant Data Meta-analysis	VACCINE			English	Article						Modification; Pertussis toxin; Filamentous haemagglutinin; Pertactin; Tetanus-toxoid; Diphtheria-toxoid	INFLUENZAE TYPE-B; ACELLULAR PERTUSSIS; TDAP IMMUNIZATION; FOLLOW-UP; MATERNAL ANTIBODIES; COMBINED DIPHTHERIA; TETANUS-DIPHTHERIA; VACCINE RESPONSES; INACTIVATED POLIO; CONJUGATE VACCINE	Background: Exploring factors that affect immune responses to immunizations in infants born to women immunized with tetanus-diphtheria-acellular-pertussis (Tdap) in pregnancy compared with unimmunized women is important in designing immunization programs. Methods: Individual-participant data meta-analysis of 8 studies reporting post-immunization immunoglobulin G (IgG) levels to vaccine antigens in infants born to either women immunized with Tdap in pregnancy or unimmunized women, using mixed-effects models. Results: In infants of Tdap-immunized women, two-fold higher levels of anti-pertussis toxin (PT) and antidiphtheria-toxoid (DT) IgG pre-primary immunization were associated with 9% and 10% lower postprimary immunization levels, (geometric mean ratio [GMR], PT: 0.91; 95% CI, 0.88-0.95,n = 494, DT: 0.9; 0.87-0.93,n = 519). Timing of immunization in pregnancy did not affect post-primary immunization anti-Bordetella pertussis, anti-tetanus-toxoid (TT) and anti-DT IgG levels. Spacing of infant immunization did not affect post-primary immunization anti-B. pertussis and anti-DT levels. In infants of Tdap-immunized women, two-fold higher levels of anti-PT and anti-filamentous haemagglutinin (FHA) IgG pre-primary immunization were associated with lower post-booster immunization levels, (GMR, PT: 0.91; 0.85-0.97,n = 224, FHA: 0.92; 0.85-0.99,n = 232). Timing of immunization in pregnancy did not affect post-booster immunization anti-Bordetella pertussis, anti-tetanus-toxoid (TT) and anti-DT IgG levels. Spacing of infant immunization did not affect post-booster immunization anti-PT, anti-pertactin (PRN), anti-TT and anti-DT IgG levels. In infants of unimmunized women, two-fold higher IgG levels of some vaccine antigens pre-primary immunization were associated with 8-17% lower post-primary immunization levels (GMR, PT 0.92, 95% CI:0.88-0.97, n = 373; FHA:0.88, 95% CI:0.85-0.92,n = 378; PRN:0.84, 95% CI:0.81-0.88, n = 367; TT:0.88, 95% CI:0.83-0.93, n = 241; DT: 0.83, 95% CI:0.79-0.87,n = 278). Two-fold higher levels of anti-FHA IgG pre-primary immunization were associated with 8% lower post-booster immunization levels (GMR, 0.92; 95% CI: 0.86-0.99,n = 138). Discussion: Increased IgG levels pre-primary immunization is associated with reduced post-primary and post-booster immunization levels for some antigens in infants of women immunized or unimmunized in pregnancy, but their clinical significance is uncertain. (c) 2021 Elsevier Ltd. All rights reserved.	[Abu-Raya, Bahaa; Sadarangani, Manish] Univ British Columbia, BC Childrens Hosp, Vaccine Evaluat Ctr, Res Inst, 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada; [Abu-Raya, Bahaa; Sadarangani, Manish] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada; [Maertens, Kirsten; Leuridan, Elke] Univ Antwerp, Ctr Evaluat Vaccinat, Vaccine & Infect Dis Inst, Antwerp, Belgium; [Munoz, Flor M.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Munoz, Flor M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Zimmermann, Petra; Curtis, Nigel] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Zimmermann, Petra; Curtis, Nigel] Royal Childrens Hosp Melbourne, Murdoch Childrens Res Inst, Infect Dis Res Grp, Parkville, Vic, Australia; [Zimmermann, Petra] Univ Fribourg, Fribourg Hosp HFR, Dept Pediat, Fribourg, Switzerland; [Zimmermann, Petra] Univ Fribourg, Fac Sci & Med, Fribourg, Switzerland; [Halperin, Scott A.] Dalhousie Univ, Canadian Ctr Vaccinol, Dept Pediat, Izaak Walton Killam Hlth Ctr, Halifax, NS, Canada; [Halperin, Scott A.] Dalhousie Univ, Canadian Ctr Vaccinol, Dept Microbiol & Immunol, Izaak Walton Killam Hlth Ctr, Halifax, NS, Canada; [Halperin, Scott A.] Nova Scotia Hlth Author, Halifax, NS, Canada; [Rots, Nynke; Barug, Daan] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Bilthoven, Netherlands; [Holder, Beth] Imperial Coll, Inst Reprod & Dev Biol, Dept Metab Digest & Reprod, London, England; [Holder, Beth; Rice, Thomas F.] Imperial Coll, Dept Med, Div Infect Dis, Sect Paediat, London, England; [Kampmann, Beate] Gambia London Sch Hyg & Trop Med, Med Res Council Unit, Vaccines & Immun Theme, Fajara, Gambia; [Kampmann, Beate] London Sch Hyg & Trop Med, Vaccine Ctr, Fac Infect & Trop Dis, London, England; [Maertens, Kirsten] Ctr Evaluat Vaccinat, Univ Pl 1, B-2610 Antwerp, Belgium		Abu-Raya, B (通讯作者)，Univ British Columbia, BC Childrens Hosp, Vaccine Evaluat Ctr, Res Inst, 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada.	baburaya@bcchr.ubc.ca; kristen.maertens@uantwerpen.be	Zimmermann, Petra/I-4670-2019; Sadarangani, Manish/V-5609-2019; Curtis, Nigel/B-3491-2012	Zimmermann, Petra/0000-0002-2388-4318; Sadarangani, Manish/0000-0002-9985-6452; Maertens, Kirsten/0000-0002-2880-441X; Curtis, Nigel/0000-0003-3446-4594; Rice, Thomas/0000-0001-6975-5530			Abu Raya B, 2014, VACCINE, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038; Abu-Raya B, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.689394; Abu-Raya B, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-3579; Abu-Raya B, 2020, J PEDIAT INF DIS SOC, V9, P118, DOI 10.1093/jpids/piy128; AGNESE PAD, 1950, AM J PUBLIC HEALTH, V40, P674, DOI 10.2105/AJPH.40.6.674; Amenaca F, 2005, PEDIATRICS, V116, P1292, DOI 10.1542/peds.2004-2336; Amirthalingam G, 2016, CLIN INFECT DIS, V63, pS236, DOI 10.1093/cid/ciw559; Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3; Barug D, 2020, VACCINE, V38, P4632, DOI 10.1016/j.vaccine.2020.04.001; Barug D, 2019, LANCET INFECT DIS, V19, P392, DOI 10.1016/S1473-3099(18)30717-5; Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091; BOOY R, 1992, LANCET, V339, P507, DOI 10.1016/0140-6736(92)90336-2; European Centre for Disease Prevention and Control, 2020, PERT ECDC ANN EP REP; Hoang HTT, 2016, VACCINE, V34, P151, DOI 10.1016/j.vaccine.2015.10.098; Halperin SA, 2018, CLIN INFECT DIS, V67, P1063, DOI 10.1093/cid/ciy244; HALSEY N, 1985, B WORLD HEALTH ORGAN, V63, P1151; Hammitt LL, 2007, VACCINE, V25, P6958, DOI 10.1016/j.vaccine.2007.06.059; Healy CM, 2018, JAMA-J AM MED ASSOC, V320, P1464, DOI 10.1001/jama.2018.14298; Kim D, 2011, BLOOD, V117, P6143, DOI 10.1182/blood-2010-11-320317; Kitchin NRE, 2007, ARCH DIS CHILD, V92, P11, DOI 10.1136/adc.2005.076109; Maertens K, 2017, PEDIATR INFECT DIS J, V10; Maertens K, 2017, PEDIATR INFECT DIS J, V36, P1186, DOI 10.1097/INF.0000000000001601; Maertens K, 2016, CLIN INFECT DIS, V63, pS197, DOI 10.1093/cid/ciw551; Maertens K, 2016, VACCINE, V34, P3613, DOI 10.1016/j.vaccine.2016.04.066; Maertens K, 2016, VACCINE, V34, P142, DOI 10.1016/j.vaccine.2015.10.100; Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633; Naidu MA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.03.002; Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446; Omenaca F, 2007, PEDIATRICS, V119, pE179, DOI 10.1542/peds.2005-2907; Orije MRP, 2020, VACCINE, V38, P20, DOI 10.1016/j.vaccine.2019.10.025; Orije MR, 2019, INT NEON MAT IMM S V; Perrett KP, 2020, VACCINE, V38, P2105, DOI 10.1016/j.vaccine.2019.10.104; Rice TF, 2019, CLIN EXP IMMUNOL, V197, P1, DOI 10.1111/cei.13275; Schloesser RL, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.5.e60; Siegrist C. A., VACCINES TXB; Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508; Simondon F, 1999, EUR J CLIN MICROBIOL, V18, P23, DOI 10.1007/s100960050221; Tejedor JC, 2007, PEDIATR INFECT DIS J, V26, P1, DOI 10.1097/01.inf.0000247070.60063.09; Vono M, 2019, CELL REP, V28, P1773, DOI 10.1016/j.celrep.2019.07.047; Voysey M, 2017, JAMA PEDIATR, V171, P637, DOI 10.1001/jamapediatrics.2017.0638; Wanlapakorn N, 2020, CLIN INFECT DIS, V71, P72, DOI 10.1093/cid/ciz778; Winter K, 2017, CLIN INFECT DIS, V64, P3, DOI 10.1093/cid/ciw634; Zimmermann P, 2019, ECLINICALMEDICINE, V13, P21, DOI 10.1016/j.eclinm.2019.06.010; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	44	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 22	2021	39	44					6545	6552		10.1016/j.vaccine.2021.09.022		OCT 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WX9RH	34598822				2022-04-29	WOS:000718925300014
J	Singh, AK; Phatak, SR; Singh, R; Bhattacharjee, K; Singh, NK; Gupta, A; Sharma, A				Singh, Awadhesh Kumar; Phatak, Sanjeev Ratnakar; Singh, Ritu; Bhattacharjee, Kingshuk; Singh, Nagendra Kumar; Gupta, Arvind; Sharma, Arvind			Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield (TM)(R)) and BBV-152 (Covaxin (TM)(R)) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study	VACCINE			English	Article						SARS-CoV-2; Vaccines; Immunogenicity; Anti-spike antibody; Comorbidities		Background: We assessed the humoral immune response of both ChAdOx1-nCOV (Covishield (TM)) and BBV-152 (Covaxin (TM)) vaccines in Indian health care workers (HCW). Methods: A Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study was conducted that measured SARS-CoV-2 anti-spike binding antibody quantitatively, 21 days or more after the first and second dose of two vaccines in both severe acute respiratory syndrome (SARS-CoV-2) naive and recovered HCW. Primary aim was to analyze antibody response (seropositivity rate, Geometric Mean Titre [GMT] and 95% Confidence Interval [CI]) following each dose of both vaccines and its correlation to age, sex, blood group, body mass index (BMI) and comorbidities. Here we report the results of anti-spike antibody response after first and two completed doses. Results: Among the 515 HCW (305 Male, 210 Female) who took two doses of both vaccines, 95.0% showed seropositivity to anti-spike antibody. However, both seropositivity rate and GMT (95% CI) of anti-spike antibody was significantly higher in Covishield vs. Covaxin recipients (98.1 vs. 80.0%; 129.3 vs. 48.3 AU/mL; both p < 0.001). This difference persisted in 457 SARS-CoV-2 naive and propensity matched (age, sex and BMI) analysis of 116 participants. Age > 60-years, males, people with any comorbidities, and history of hypertension (HTN) had a significantly less anti-spike antibody GMT compared to age <= 60 years, females, no comorbidities and no HTN respectively, after the completion of two doses of either vaccine. Gender, presence of comorbidities, and vaccine type were independent predictors of antibody seropositivity rate and anti-spike antibody titre levels in multiple logistic and log transformed linear regression analysis. Both vaccine recipients had similar solicited mild to moderate adverse events and none had severe or unsolicited side effects. Conclusions: Both vaccines elicited good immune response after two doses, although seropositivity rates and GMT of anti-spike antibody titre was significantly higher in Covishield compared to Covaxin recipients. (C) 2021 Elsevier Ltd. All rights reserved.	[Singh, Awadhesh Kumar; Singh, Ritu] GD Hosp & Diabet Inst, Kolkata 700013, W Bengal, India; [Phatak, Sanjeev Ratnakar] Vijayratna Diabet Ctr, Ahmadabad, Gujarat, India; [Singh, Nagendra Kumar] Diabet & Heart Res Ctr, Dhanbad, Jharkhand, India; [Gupta, Arvind] Rajasthan Hosp, Dept Diabet Obes & Metab Disorders, Jaipur, Rajasthan, India; [Sharma, Arvind] Mahatma Gandhi Med Coll & Hosp, Dept Community Med, Jaipur, Rajasthan, India		Singh, AK (通讯作者)，GD Hosp & Diabet Inst, Kolkata 700013, W Bengal, India.	drawadheshkumarsingh@gmail.com					Achiron A, 2021, THER ADV NEUROL DISO, V14, DOI 10.1177/17562864211012835; Chan LL, 2021, CLIN J AM SOC NEPHRO, V16, P1258, DOI 10.2215/CJN.04080321; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Goel Rishi R, 2021, medRxiv, DOI 10.1101/2021.03.03.21252872; Grupper A, 2021, CLIN J AM SOC NEPHRO, V16, P1037, DOI 10.2215/CJN.03500321; Khoury DS, 2021, WHAT LEVEL NEUTRALIS, DOI [10.1101/2021.03.09.21252641, DOI 10.1101/2021.03.09.21252641]; Marchi S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253977; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Shenoy P, IMMUNOGENICITY CHADO, DOI [10.1101/2021.06.06.21258417, DOI 10.1101/2021.06.06.21258417]; Simon B, MEDRXIV, DOI [10.1101/2021.03.26.21254259, DOI 10.1101/2021.03.26.21254259]; Singh AK, ANTIBODY RESPONSE 1, DOI [10.1101/2021.04.07.21255078, DOI 10.1101/2021.04.07.21255078]; von Elm E, 2007, PREV MED, V45, P247, DOI [10.1016/j.ypmed.2007.08.012, 10.1016/S0140-6736(07)61602-X]; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Ward H, REACT 2 ROUND 5 INCR, DOI [10.1101/ 2021.02.26.21252512, DOI 10.1101/2021.02.26.21252512;THIS]	17	3	3	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 22	2021	39	44					6492	6509		10.1016/j.vaccine.2021.09.055		OCT 2021	18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WX9RH		Green Published, Bronze			2022-04-29	WOS:000718925300008
J	Yamazaki, Y; Ikeda, M; Imada, T; Furuno, K; Mizukami, T; de Solom, R; Shoji, Y; Oe, M; Aizawa, M; Giardina, PC; Schmoele-Thoma, B; Scott, DA				Yamazaki, Yoshitaka; Ikeda, Masanori; Imada, Takayuki; Furuno, Kenji; Mizukami, Tomoyuki; de Solom, Richard; Shoji, Yasuko; Oe, Motoki; Aizawa, Masakazu; Giardina, Peter C.; Schmoele-Thoma, Beate; Scott, Daniel A.			A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines	VACCINE			English	Article						Pneumococcal vaccine; Japan; Immunogenicity; Safety; Immunocompetent; Immunocompromised	IMMUNOCOMPROMISING CONDITIONS RECOMMENDATIONS; STREPTOCOCCUS-PNEUMONIAE SEROTYPES; POST-HOC ANALYSIS; POLYSACCHARIDE VACCINE; ADVISORY-COMMITTEE; CHILDREN; ADULTS; RECIPIENTS; EFFICACY; PCV13	Background: This open-label, single-arm, phase 3 study evaluated safety and immunogenicity of the 13valent pneumococcal conjugate vaccine (PCV13) in pneumococcal vaccine-naive Japanese individuals aged 6-64 years at increased risk of pneumococcal disease (PD). Methods: Participants received 1 PCV13 dose. Reactogenicity events were recorded for 7 days (individuals aged 6-to 17-year-old) or 14 days (individuals aged 18 to 64 years old) postvaccination. Adverse events (AEs) were collected for 1 month postvaccination. Opsonophagocytic activity (OPA) and anticapsular immunoglobulin G (IgG) geometric mean concentrations (GMCs) were measured for vaccine serotypes before and 1 month postvaccination. Post hoc analyses compared immunogenicity in participants categorized as at-risk (immunocompetent but having chronic medical conditions associated with increased PD risk) or high-risk (immunocompromised due to diseases/conditions and/or medications). Results: 206 participants aged 6-to 17-year-old (n = 53) and 18 to 64 years old (n = 153) completed the study. Reactogenicity events were generally mild to moderate in severity. AEs were reported in 16% (33/206) of participants; 1.0% (2/206) were severe. Six AEs were vaccine-related; most were associated with local reactions. No serious AEs occurred. Circulating antibody levels for all 13 serotypes increased postvaccination. OPA geometric mean fold rises (GMFRs) from prevaccination to 1 month postvaccination were 5.5-61.7; lower limits of the 2-sided, 95% CI were > 1 for all serotypes. IgG GMFRs were consistent with OPA analyses. In post hoc analyses, 55.8% (115/206) and 44.2% (91/206) of participants were categorized as at risk and at high risk of PD, respectively; OPA GMFRs from prevaccination to 1 month post vaccination were 3.9-635.1, with lower limits of the 2-sided 95% CIs > 1 for all 13 serotypes across these risk groups; IgG GMFRs were consistent with OPA analyses. Conclusions: PCV13 was well tolerated and immunogenic in Japanese individuals aged 6-64 years considered at increased risk of PD. Results were broadly comparable with past PCV13 studies in other Japanese and non-Japanese populations. Registration number: NCT03571607; JapicCTI-184024. (c) 2021 Elsevier Ltd. All rights reserved.	[Yamazaki, Yoshitaka] Nagano Prefectural Shinshu Med Ctr, Pulm & Infect Dis, Nagano, Japan; [Ikeda, Masanori] Fukuyama City Hosp, Dept Pediat, Hiroshima, Japan; [Imada, Takayuki] Nippon Kokan Fukuyama Hosp, Hlth Management, Hiroshima, Japan; [Furuno, Kenji] Fukuoka Childrens Hosp, Gen Pediat & Interdisciplinary Med, Fukuoka, Japan; [Mizukami, Tomoyuki] Natl Hosp Org, Kumamoto Med Ctr, Pediat, Kumamoto, Japan; [de Solom, Richard] Pfizer Australia, Vaccine Clin Res & Dev Australia, Sydney, NSW, Australia; [Shoji, Yasuko; Oe, Motoki; Aizawa, Masakazu] Pfizer R&D Japan GK, Vaccine Res & Dev, Tokyo, Japan; [Giardina, Peter C.] Pfizer Inc, Vaccine Clin Res & Dev, Pearl River, NY USA; [Schmoele-Thoma, Beate] Pfizer Pharma GmbH, Vaccine Clin Res & Dev, Berlin, Germany; [Scott, Daniel A.] Pfizer Inc, Vaccine Clin Res & Dev, Collegeville, PA USA		de Solom, R (通讯作者)，Pfizer Australia, Level 15-18,151 Clarence St, Sydney, NSW 2000, Australia.	yoshitakayamazaki@hotmail.com; mikeda@okayama-u.ac.jp; tamikoru_imadafa@kki.biglobe.ne.jp; furuno.k@fcho.jp; mizukami.tomoyuki.tg@mail.hosp.go.jp; richard.desolom@pfizer.com; yasuko.shoji@pfizer.com; motoki.oe@pfizer.com; masakazu.aizawa@pfizer.com; peter.giardina@pfizer.com; Beate.Schmoele-Thoma@Pfizer.com; dan.scott@pfizer.com		Mizukami, Tomoyuki/0000-0002-2508-2810; Furuno, Kenji/0000-0003-3991-8348	Pfizer Inc.Pfizer	This study was sponsored by Pfizer Inc. Pfizer was responsible for the design and conduct of the study; was involved with collection, management, analysis, and interpretation of the data and preparation and review of the manuscript; and Pfizer employees are co-authors. Pfizer did not have the right to veto or suppress publication.	Akata K, 2017, J INFECT CHEMOTHER, V23, P301, DOI 10.1016/j.jiac.2017.01.008; [Anonymous], 2019, Weekly Epidemiological Record, V94, P85; [Anonymous], 2008, Wkly Epidemiol Rec, V83, P373; Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB; Bennett NM, 2013, MMWR-MORBID MORTAL W, V62, P521; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Bhorat AE, 2015, AIDS, V29, P1345, DOI 10.1097/QAD.0000000000000689; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056; Cordonnier C, 2015, CLIN INFECT DIS, V61, P313, DOI 10.1093/cid/civ287; De Montalembert M, 2015, PEDIATR BLOOD CANCER, V62, P1427, DOI 10.1002/pbc.25502; Director-General for Statistics Information Policy and Policy Evaluation Ministry of Health Labour and Welfare, 2018, VIT STAT JAP 2018; ECDC Vaccine Scheduler, 2020, VACC SCHED ALL COUNT; Frenck R, 2014, PEDIATR INFECT DIS J, V33, P183, DOI 10.1097/INF.0000000000000056; Fukusumi M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2113-y; Glesby MJ, 2015, J INFECT DIS, V212, P18, DOI 10.1093/infdis/jiu631; Htar MTT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177985; Huijts SM, 2017, VACCINE, V35, P4444, DOI 10.1016/j.vaccine.2017.01.071; Hung TY, 2017, CANCER-AM CANCER SOC, V123, P4215, DOI 10.1002/cncr.30764; Imai K, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018553; Izumi Y, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-016-1207-7; Jackson LA, 2013, VACCINE, V31, P3585, DOI 10.1016/j.vaccine.2013.05.010; Kumar D, 2008, BONE MARROW TRANSPL, V41, P743, DOI 10.1038/sj.bmt.1705964; Melegaro A, 2004, EPIDEMIOL INFECT, V132, P433, DOI 10.1017/S0950268804001980; Moberley SA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub2; Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3; Morimoto K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122247; Nace DA, 2017, J AM MED DIR ASSOC, V18, P99, DOI 10.1016/j.jamda.2016.11.010; Nakano S, 2020, VACCINE, V38, P1818, DOI 10.1016/j.vaccine.2019.12.022; National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases Control Division Ministry of Health Labour and Welfare, 2018, PNEUM INF 2017; Pavliakova D, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00128-18; PMDA, 2020, NEW DRUGS APPR FY 20; Shiramoto M, 2015, HUM VACC IMMUNOTHER, V11, P2198, DOI 10.1080/21645515.2015.1030550; Suaya JA, 2018, VACCINE, V36, P1477, DOI 10.1016/j.vaccine.2018.01.049; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Ubukata K, 2018, EMERG INFECT DIS, V24, P2010, DOI 10.3201/eid2411.180326; Walters JAE, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001390.pub4	37	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 15	2021	39	43					6414	6421		10.1016/j.vaccine.2021.08.106		OCT 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS5LV	34563397				2022-04-29	WOS:000715223200013
J	Chard, AN; Martinez, M; Matanock, A; Kassem, AM				Chard, Anna N.; Martinez, Maureen; Matanock, Almea; Kassem, Ahmed M.			Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020	VACCINE			English	Article						Poliovirus; Vaccine; Oral poliovirus vaccine; Vaccine effectiveness; Afghanistan	POLIOMYELITIS ERADICATION; PARALYTIC POLIOMYELITIS; IMMUNIZATION; WORLDWIDE; IMMUNOGENICITY; MONOVALENT; COUNTRIES; OUTBREAKS; EFFICACY; IMMUNITY	Background: Afghanistan is one of two countries with endemic wild poliovirus type 1 (WPV1). The oral poliovirus vaccine (OPV) is the predominant vaccine used for polio eradication. Although OPV has been administered in routine childhood immunization and during frequent supplementary immunization activities, WPV1 continues to circulate in Afghanistan and case incidence has been increasing since 2017. We estimated the effectiveness of OPV in Afghanistan during 2010-2020. Methods: We conducted a matched case-control analysis using acute flaccid paralysis (AFP) surveillance data from 29,370 children < 15 years with AFP onset between January 1, 2010 and December 31, 2020. We matched children with confirmed WPV1 (cases) with children with non-polio AFP (controls) by age at onset of paralysis (+/-3 months), date of onset of paralysis (+/-3 months), and province of residence, and compared their reported OPV vaccination history to estimate the effectiveness of OPV in preventing paralysis by WPV1 using conditional logistic regression. To account for changes in OPV formulations provided over the analysis period, we stratified the analysis based on dates of the global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) in April 2016. Results: Between January 1, 2010 and December 31, 2020, there were 329 WPV1 cases in Afghanistan. The per-dose estimated effectiveness of OPV against WPV1 was 19% (95% CI: 15%-22%) and of > 7 doses was 94% (95% CI: 90%-97%). Before the global switch from tOPV to bOPV, the per-dose estimated effectiveness of OPV was 14% (95% CI: 11%-18%) and of > 7 doses was 92% (95% CI: 85%-96%). After the switch, the per-dose estimated effectiveness of OPV against WPV1 was 32% (24%-39%) and of > 7 doses was 96% (95% CI: 90%-99%). Discussion: OPV is highly effective in preventing paralysis by WPV1; these results indicate that continued WPV1 transmission in Afghanistan is due to failure to vaccinate, not failure of the vaccine. Although difficult to implement in parts of country, improving the administration of OPV in routine immunization and supplementary immunization activities will be critical for achieving polio eradication in Afghanistan. Published by Elsevier Ltd.	[Chard, Anna N.; Martinez, Maureen; Matanock, Almea; Kassem, Ahmed M.] Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd, Atlanta, GA 30333 USA; [Chard, Anna N.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd, Atlanta, GA 30333 USA		Chard, AN (通讯作者)，Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd, Atlanta, GA 30333 USA.	mmn9@cdc.gov		Kassem, Ahmed/0000-0003-4053-7841			Alleman MM, 2020, MMWR-MORBID MORTAL W, V69, P489, DOI 10.15585/mmwr.mm6916a1; Church JA, 2019, LANCET INFECT DIS, V19, P203, DOI 10.1016/S1473-3099(18)30602-9; Global Polio Eradication Initiative, 2020, M REPORT 22 25 JUN 2; Global Polio Eradication Initiative, 2019, AFGH POL ER IN ANN R; Grassly NC, 2007, LANCET, V369, P1356, DOI 10.1016/S0140-6736(07)60531-5; Grassly NC, 2014, J INFECT DIS, V210, pS439, DOI 10.1093/infdis/jit601; Grassly NC, 2009, J INFECT DIS, V200, P794, DOI 10.1086/605330; Hampton LM, 2016, MMWR-MORBID MORTAL W, V65, P934, DOI 10.15585/mmwr.mm6535a3; Jafari H, 2014, SCIENCE, V345, P922, DOI 10.1126/science.1255006; Jenkins HE, 2008, NEW ENGL J MED, V359, P1666, DOI 10.1056/NEJMoa0803259; John J, 2014, LANCET, V384, P1505, DOI 10.1016/S0140-6736(14)60934-X; Jorba J, 2019, MMWR-MORBID MORTAL W, V68, P1024, DOI 10.15585/mmwr.mm6845a4; KRUGMAN S, 1961, AM J DIS CHILD, V101, P23, DOI 10.1001/archpedi.1961.04020020025005; Kuehn B, 2019, JAMA-J AM MED ASSOC, V322, P2276, DOI 10.1001/jama.2019.20068; Leke RGF, 2020, LANCET GLOB HEALTH, V8, pE1345, DOI [10.1016/S2214-109X(20)30382-X, 10.1016/52214-109X(20)30382-X]; Mahamud A, 2014, J INFECT DIS, V210, pS187, DOI 10.1093/infdis/jiu261; Martinez M, 2020, MMWR-MORBID MORTAL W, V69, P1464, DOI 10.15585/mmwr.mm6940a3; Martinez M, 2019, MMWR-MORBID MORTAL W, V68, P729, DOI 10.15585/mmwr.mm6833a4; MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615, DOI 10.1093/oxfordjournals.aje.a115009; O'Reilly KM, 2012, LANCET, V380, P491, DOI 10.1016/S0140-6736(12)60648-5; Offit P., 2018, PLOTKINS VACCINES; Parker EPK, 2014, J INFECT DIS, V210, P853, DOI 10.1093/infdis/jiu182; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; ROBERTSON H. E., 1962, CANADIAN JOUR PUBL HEALTH, V53, P179; StataCorp, 2019, STATA STAT SOFTWARE; Stepner M., 2017, CALIPMATCH STATA MOD; Tangermann RH, 2000, B WORLD HEALTH ORGAN, V78, P330; United Nations Development Programme, 2020, HUM DEV REP 2020 NEX; Verani JR, 2017, VACCINE, V35, P3295, DOI 10.1016/j.vaccine.2017.04.037; WHO, 2020, IMMUNIZATION VACCINE; World Health Organization, SURV STAND VACC PREV, Vsecond; World Health Organization, GRAD SCI EV TABL 1 E; World Hlth Org, 2017, VACCINE, V35, P1197, DOI 10.1016/j.vaccine.2016.11.017	33	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6250	6255		10.1016/j.vaccine.2021.09.020		SEP 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34538696				2022-04-29	WOS:000705822100012
J	Braeye, T; Cornelissen, L; Catteau, L; Haarhuis, F; Proesmans, K; De Ridder, K; Djiena, A; Mahieu, R; De Leeuw, F; Dreuw, A; Hammami, N; Quoilin, S; Van Oyen, H; Wyndham-Thomas, C; Van Cauteren, D				Braeye, Toon; Cornelissen, Laura; Catteau, Lucy; Haarhuis, Freek; Proesmans, Kristiaan; De Ridder, Karin; Djiena, Achille; Mahieu, Romain; De Leeuw, Frances; Dreuw, Alex; Hammami, Naima; Quoilin, Sophie; Van Oyen, Herman; Wyndham-Thomas, Chloe; Van Cauteren, Dieter			Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021	VACCINE			English	Article								In Belgium, high-risk contacts of an infected person were offered PCR-testing irrespective of their vacci-nation status. We estimated vaccine effectiveness (VE) against infection and onwards transmission, con-trolling for previous infections, household-exposure and temporal trends. We included 301,741 tests from 25 January to 24 June 2021. Full-schedule vaccination was associated with significant protection against infection. In addition, mRNA-vaccines reduced onward transmission: VE-estimates increased to >90% when index and contact were fully vaccinated. The small number of viral-vector vaccines included limited interpretability. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Braeye, Toon; Cornelissen, Laura; Catteau, Lucy; Haarhuis, Freek; Proesmans, Kristiaan; De Ridder, Karin; Quoilin, Sophie; Van Oyen, Herman; Wyndham-Thomas, Chloe; Van Cauteren, Dieter] Sciensano, Dept Epidemiol & Publ Hlth, Brussels, Belgium; [Djiena, Achille] Agence Vie Qualite, Charleroi, Belgium; [Mahieu, Romain; De Leeuw, Frances] Common Community Commiss Brussels, Brussels, Belgium; [Dreuw, Alex] Minist German Speaking Community, Eupen, Belgium; [Hammami, Naima] Agcy Care & Hlth Infect Prevent & Control, Flemish Community, Ghent, Belgium		Braeye, T (通讯作者)，Sciensano, Dept Epidemiol & Publ Hlth, Brussels, Belgium.			Cornelissen, Laura/0000-0002-4550-9439; Mahieu, Romain/0000-0001-6789-684X			Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bjork J, 2021, EFFECTIVENESS BNT162; Chia PY, 2021, VIROLOGICAL SEROLOGI, DOI [10.1101/2021.07.28.21261295v1, DOI 10.1101/2021.07.28.21261295V1]; de Valpine P, 2017, J COMPUT GRAPH STAT, V26, P403, DOI 10.1080/10618600.2016.1172487; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Harris RJ, NEW ENGL J MED, V2021; Ledford H, 2021, NATURE, V594, P164, DOI 10.1038/d41586-021-01505-x; Moustsen-Helms IR, 2021, VACCINE EFFECTIVENES; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sciensano, COVID 19 FAQ; Sciensano, COVID 19 PROC; Shah Anoop V, 2021, EFFECT VACCINATION T, DOI [10.1101/2021.03.11.21253275, DOI 10.1101/2021.03.11.21253275]; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1	15	3	3	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5456	5460		10.1016/j.vaccine.2021.08.060		SEP 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34454789	Green Published, hybrid			2022-04-29	WOS:000704399700002
J	Leidner, AJ; Tang, ZL; Guo, A; Anderson, TC; Tsai, YP				Leidner, Andrew J.; Tang, Zhaoli; Guo, Angela; Anderson, Tara C.; Tsai, Yuping			Insurance reimbursements for recombinant zoster vaccine in the private sector	VACCINE			English	Article						Shingles; Herpes zoster; Recombinant zoster vaccine; Reimbursement; Private insurance	HERPES-ZOSTER; UNITED-STATES; RECOMMENDATIONS; EFFICACY; ADULTS	A two-dose series of the recombinant zoster vaccine (RZV, Shingrix) was licensed by the Food and Drug Administration in 2017 and recommended by the Advisory Committee on Immunization Practices in 2018 for adults in the United States age 50 years and older. Despite the health benefits of shingles vaccination, coverage has remained low, with financial barriers among healthcare providers identified as one potential factor. This study estimates the reimbursement levels for RZV among a large sample of privately insured individuals in the US from the 2018 IBM (R) MarketScan (R) Commercial Claims and Encounters database. Of 198,534 claims for an RZV dose, the mean reimbursement was $149. Most claims (83%) exceeded $140, which was the private sector vaccine price reported on the CDC vaccine price list in April 2018. These results can be useful for providers considering procuring RZV and for state immunization programs considering ways to improve vaccination coverage. Published by Elsevier Ltd.	[Leidner, Andrew J.; Anderson, Tara C.; Tsai, Yuping] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA; [Tang, Zhaoli] CDC, Contractor Natl Ctr Immunizat & Resp Dis, Berry Technol Solut, Atlanta, GA 30333 USA; [Guo, Angela] CDC, Contractor Natl Ctr Immunizat & Resp Dis, Strateg Innovat Solut, Atlanta, GA 30333 USA		Leidner, AJ (通讯作者)，Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,NE,MS A-19, Atlanta, GA 30329 USA.	aleidner@cdc.gov		Leidner, Andrew/0000-0001-8869-5561			[Anonymous], 2019, GUID HLTH EC STUD PR; Black LI, 2020, NCHS DATA BRIEF; Centers for Disease Control Prevention, ADULTVAXVIEW; Centers for Disease Control & Prevention, WHAT EV SHOULD KNOW; Curran D, 2018, VACCINE, V36, P5037, DOI 10.1016/j.vaccine.2018.07.005; Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5; Guo A, 2019, VACCINE, V37, P5509, DOI 10.1016/j.vaccine.2019.08.002; Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1; Hurley LP, 2014, ANN INTERN MED, V160, P161, DOI 10.7326/M13-2332; Insinga RP, 2005, J GEN INTERN MED, V20, P748, DOI 10.1111/j.1525-1497.2005.0150.x; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Leidner AJ, 2017, CTR DIS CONTROL PREV; Lindley MC, 2018, VACCINE, V36, P1093, DOI 10.1016/j.vaccine.2018.01.015; Lu PJ, 2020, AM J PREV MED, V59, P21, DOI 10.1016/j.amepre.2020.01.017; Lutz CS, 2018, AM J PREV MED, V55, P308, DOI 10.1016/j.amepre.2018.05.011; Neumann P. J., 2016, Cost-effectiveness in health and medicine; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Pike J, 2019, VACCINE, V37, P7, DOI 10.1016/j.vaccine.2018.11.055; Prosser LA, 2019, ANN INTERN MED, V170, P380, DOI 10.7326/M18-2347; Schmader KE, 2012, CLIN INFECT DIS, V55, P1320, DOI 10.1093/cid/cis638; Shen A, 2019, VACCINE, V37, P792, DOI 10.1016/j.vaccine.2018.12.045; Tak CR, 2020, HUM VACC IMMUNOTHER, V16, P70, DOI 10.1080/21645515.2019.1637218; Tsai YP, 2019, AM J PREV MED, V57, P180, DOI 10.1016/j.amepre.2019.03.011; Woolhandler S, 2003, NEW ENGL J MED, V349, P768, DOI 10.1056/NEJMsa022033; Yarnoff B, 2019, VACCINE, V37, P6180, DOI 10.1016/j.vaccine.2019.08.056; Yarnoff B, 2019, MED CARE, V57, P410, DOI 10.1097/MLR.0000000000001117	26	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5091	5094		10.1016/j.vaccine.2021.07.050		AUG 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34348844				2022-04-29	WOS:000684878300005
J	Fluckiger, AC; Ontsouka, B; Bozic, J; Diress, A; Ahmed, T; Berthoud, T; Tran, A; Duque, D; Liao, MM; McCluskie, M; Diaz-Mitoma, F; Anderson, DE; Soare, C				Fluckiger, Anne-Catherine; Ontsouka, Barthelemy; Bozic, Jasminka; Diress, Abebaw; Ahmed, Tanvir; Berthoud, Tamara; Tran, Anh; Duque, Diane; Liao, Mingmin; McCluskie, Michael; Diaz-Mitoma, Francisco; Anderson, David E.; Soare, Catalina			An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity	VACCINE			English	Article						SARS-COV-2; Vaccine; Virus-like-particles; Immunogenicity; Neutralizing antibodies	IMMUNIZATION; VECTORS	We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified pre fusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Fluckiger, Anne-Catherine] Bionaria, 11Bis Rue Garenne, F-69290 St Genis Les Olleires, France; [Ontsouka, Barthelemy; Bozic, Jasminka; Diress, Abebaw; Ahmed, Tanvir; Berthoud, Tamara; Soare, Catalina] VBI Vaccines, 201-310 Hunt Club Rd, Ottawa, ON K1V 1C1, Canada; [Diaz-Mitoma, Francisco; Anderson, David E.] VBI Vaccines, 222 Third St, Cambridge, MA USA; [Tran, Anh; Duque, Diane; McCluskie, Michael] Natl Res Council Canada, Dept Human Hlth Therapeut, 100 Sussex Dr, Ottawa, ON K1A0R6, Canada; [Liao, Mingmin] Univ Saskatchewan, Vaccine & Infect Dis Org Int Vaccine Ctr, 120 Vet Rd, Saskatoon, SK S7N 5E3, Canada		Fluckiger, AC (通讯作者)，Bionaria, 11Bis Rue Garenne, F-69290 St Genis Les Olleires, France.	afluckiger@vbivaccines.com		Diaz-Mitoma, Francisco/0000-0003-0292-4859	Government of Canada Innovation, Science and Industry (ISED) through the Strategic Innovation Fund (SIF)	VBI2902a study was supported by Government of Canada Innovation, Science and Industry (ISED) funding through the Strategic Innovation Fund (SIF) .	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], CORONAVIRUS DIS 2019; [Anonymous], CORONAVIRUS DIS COVI; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bos R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00243-x; Cai Yongfei, 2020, bioRxiv, DOI 10.1101/2020.05.16.099317; Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596; Chan JFW, 2020, CLIN INFECT DIS, V71, P2428, DOI 10.1093/cid/ciaa325; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1101/2020.06.11.145920, 10.1038/s41586-020-2622-0]; Cote J, 1998, BIOTECHNOL BIOENG, V59, P567, DOI 10.1002/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.0.CO;2-8; Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742; Cubas R, 2009, J IMMUNOTHER, V32, P118, DOI 10.1097/CJI.0b013e31818f13c4; Eichinger KM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01673; Garrone P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002330; Keating GM, 2003, DRUGS, V63, P1021, DOI 10.2165/00003495-200363100-00006; Kirchmeier M, 2014, CLIN VACCINE IMMUNOL, V21, P174, DOI 10.1128/CVI.00662-13; Kittel M, 2021, INT J INFECT DIS, V103, P590, DOI 10.1016/j.ijid.2020.12.003; Kuo TY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77077-z; Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301; McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7; Negre D, 2000, GENE THER, V7, P1613, DOI 10.1038/sj.gt.3301292; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Peeples L, 2020, P NATL ACAD SCI USA, V117, P8218, DOI 10.1073/pnas.2005456117; Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Roncati L, 2020, ANN HEMATOL, V99, P1419, DOI 10.1007/s00277-020-04066-7; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Sun ZY, 2021, ENGINEERING-PRC, V7, P1441, DOI 10.1016/j.eng.2020.07.014; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1126/science.abb2507, 10.1101/2020.02.11.944462]; Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337	39	3	3	2	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					4988	5001		10.1016/j.vaccine.2021.07.034		AUG 2021	14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TX3GY	34304928	hybrid, Green Published			2022-04-29	WOS:000682979100012
J	Weiss, D; Sandhu, H; Fleming, M; Lee, CW				Weiss, Debora; Sandhu, Hardeep; Fleming, Monica; Lee, Chung-won			Improving supervision practices in resource-limited settings: Opportunities to sustain short-term gains from external technical support	VACCINE			English	Editorial Material						Global health; Immunization workforce development; Project sustainability; Supportive supervision			[Weiss, Debora; Sandhu, Hardeep; Fleming, Monica; Lee, Chung-won] Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Strateg Informat & Workforce Dev Branch, Atlanta, GA USA		Weiss, D (通讯作者)，Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.	woy2@cdc.gov					Avortri GS, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001151; Bura V, 2019, ENHANCING IMMUNIZATI; Clements C John, 2011, Vaccine, V29, P8477, DOI 10.1016/j.vaccine.2011.08.048; Deloitte Touche Tohmatsu Ltd, 2017, GAVI TCA EV BAS ASS GAVI TCA EV BAS ASS; Kok MC, 2018, HEALTH POLICY PLANN, V33, P988, DOI 10.1093/heapol/czy082; Marquez L, 2002, MAXIMISING ACCESS QU, P1; The Vaccine Alliance (Gavi), 2020, EV IND COUNTR HLTH S EV IND COUNTR HLTH S; Vasan A, 2016, HLTH POLICY PLAN, P1; Ward K, 2019, VACCINE, V37, P2821, DOI 10.1016/j.vaccine.2019.04.015; World Health Organization (WHO), 2013, GLOB VACC ACT PLAN 2	10	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4772	4774		10.1016/j.vaccine.2021.06.064		JUL 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34275673				2022-04-29	WOS:000679483400004
J	Sarhan, AT; Bahey-El-Din, M; Zaghloul, TI				Sarhan, Amal Tarek; Bahey-El-Din, Mohammed; Zaghloul, Taha Ibrahim			Recombinant Ax21 protein is a promising subunit vaccine candidate against Stenotrophomonas maltophilia in a murine infection model	VACCINE			English	Article						Stenotrophomonas maltophilia; Vaccine; Ax21 family protein; Outer membrane protein; BCG	OUTER-MEMBRANE PROTEINS; IMMUNITY	Stenotrophomonas maltophilia is an emerging pathogen that can cause several disease manifestations such as bacteremia, meningitis, respiratory tract infections and others. More seriously, this pathogen has a highly evolving antibiotic resistance profile. Antibiotic misuse is further aggravating the situation by inducing the development of multi- and even pan-resistance. Thus, employing diverse strategies to overcome this increasing antibiotic resistance is of paramount importance. In general, vaccination is one of these strategies that prevents the onset of infection, provides long term protection against infection, and most importantly diminishes the antibiotic consumption, thus, resulting in controlling resistance. Unfortunately, vaccine research concerning S. maltophilia is very scarce in the literature. Ax21 protein is an outer membrane protein implicated in several virulence mechanisms of S. maltophilia such as quorum sensing, biofilm formation, and antibiotic resistance. Our computational analysis of Ax21 revealed its potential immunogenicity. In the current study, Ax21 protein of S. maltophilia was cloned and heterologously expressed in Escherichia coli. Mice were immunized with the purified recombinant antigen using Bacillus Calmette-Guerin (BCG) and incomplete Freund's adjuvant (IFA) as immune-adjuvants. Enzyme-linked immunosorbent assay (ELISA) revealed significant antigen-specific IgG1, IgG2a and total IgG levels in immunized mice which reflected successful immune stimulation. Immunized mice that were challenged with S. maltophilia showed a substantial reduction in bacterial bioburden in lungs, liver, kidneys, and heart. In addition, liver histological examination demonstrated a remarkable decrease in pathological signs such as necrosis, vacuolation, bile duct fibrosis and necrosis, infiltration of inflammatory cells, and hemorrhage. Whole cell ELISA and opsonophagocytic assay confirmed the ability of serum antibodies from immunized mice to bind and facilitate phagocytosis of S. maltophilia, respectively. To our knowledge, this is the first report to demonstrate the vaccine protective efficacy of Ax21 outer membrane protein against S. maltophilia infection. (C) 2021 Elsevier Ltd. All rights reserved.	[Sarhan, Amal Tarek; Zaghloul, Taha Ibrahim] Alexandria Univ, Inst Grad Studies & Res IGSR, Dept Biotechnol, Alexandria 21526, Egypt; [Bahey-El-Din, Mohammed] Alexandria Univ, Fac Pharm, Dept Microbiol & Immunol, Alexandria 21521, Egypt		Bahey-El-Din, M (通讯作者)，Alexandria Univ, Fac Pharm, Dept Microbiol & Immunol, Alexandria 21521, Egypt.	m.bahey-el-din@alexu.edu.eg		Sarhan, Amal/0000-0002-2444-0946			Abdel-Fattah M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213880; Adegoke AA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02276; An SQ, 2018, ARCH MICROBIOL, V200, P183, DOI 10.1007/s00203-017-1433-7; Bahey-El-Din M, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2020.151415; Bao HY, 2020, INFECTION, V48, P205, DOI 10.1007/s15010-019-01369-4; BOTTONE EJ, 1986, J CLIN MICROBIOL, V24, P995, DOI 10.1128/JCM.24.6.995-997.1986; Boyaka PN, 2019, HOST DEFENSES MUCOSA, P285, DOI [10.1016/B978-0-7234-3691-1.00040-4, DOI 10.1016/B978-0-7234-3691-1.00040-4]; Carty SA, 2018, HEMATOLOGY BASIC PRI, VSeventh, P221, DOI 10.1016/B978-0-323-35762-3.00021-4; Chen YY, 2015, J MICROBIOL, V53, P535, DOI 10.1007/s12275-015-5202-5; Chen ZA, 2013, INT IMMUNOPHARMACOL, V16, P376, DOI 10.1016/j.intimp.2013.02.017; Cruz-Cordova A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00050; de Boer YS, 2015, HISTOPATHOLOGY, V66, P351, DOI 10.1111/his.12558; Delany I, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012476; Devos S, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00298; du Sert NP, 2020, BRIT J PHARMACOL, V177, P3617, DOI [10.1111/bph.15193, 10.1371/journal.pbio.3000410, 10.1177/0271678X20943823, 10.1113/JP280389, 10.1113/EP088870, 10.1371/journal.pbio.3000411]; Du ZJ, 2011, AFR J BIOTECHNOL, V10, P1953; Elhosary MA, 2019, MICROB PATHOGENESIS, V131, P181, DOI 10.1016/j.micpath.2019.04.014; Elkhoumesy TR, 2017, EC MICROBIOLOGY, V6, P97; Elsner HA, 1997, ANN HEMATOL, V74, P155; Falagas ME, 2009, EUR J CLIN MICROBIOL, V28, P719, DOI 10.1007/s10096-009-0709-5; Feldkamp Carolyn S., 1996, P5, DOI 10.1016/B978-012214730-2/50003-0; Ferrer-Navarro M, 2016, J PROTEOMICS, V142, P122, DOI 10.1016/j.jprot.2016.05.001; Ferrer-Navarro M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067207; Freyne B, 2015, T ROY SOC TROP MED H, V109, P46, DOI 10.1093/trstmh/tru196; Gajdacs M, 2019, HEALTH SERV RES MANA, V6, DOI 10.1177/2333392819870774; Golde WT, 2005, LAB ANIMAL, V34, P39, DOI 10.1038/laban1005-39; Gutierrez C, 2016, RESPIR MED CASE REP, V19, P12, DOI 10.1016/j.rmcr.2016.06.003; Hamid N, 2008, CLIN VACCINE IMMUNOL, V15, P1461, DOI 10.1128/CVI.00093-08; Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06; Jalan R, 2014, J HEPATOL, V60, P1310, DOI 10.1016/j.jhep.2014.01.024; Li Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214596; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mishra RPN, 2012, CURR OPIN MICROBIOL, V15, P596, DOI 10.1016/j.mib.2012.08.002; Mohan T, 2013, INDIAN J MED RES, V138, P779; Molloy K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00198; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Park HJ, 2014, J MICROBIOL, V52, P1030, DOI 10.1007/s12275-014-4442-0; Petri A, 2003, SURG TODAY, V33, P224, DOI 10.1007/s005950300050; Petridou E, 2010, J VET DIAGN INVEST, V22, P772, DOI 10.1177/104063871002200522; Platsouka E, 2002, SCAND J INFECT DIS, V34, P391, DOI 10.1080/00365540110080520; Rahman MS, 2019, ARTIF INTELL MED, V94, P28, DOI 10.1016/j.artmed.2018.12.010; Ramos CAF, 2015, TOXICOL REP, V2, P482, DOI 10.1016/j.toxrep.2015.01.001; Rasooli I, 2020, INT J PEPT RES THER, V26, P2653, DOI 10.1007/s10989-020-10056-0; Ronald PC, 2011, DISCOV MED, V12, P461; Su F, 2016, HUM VACC IMMUNOTHER, V12, P1070, DOI 10.1080/21645515.2015.1114195; Tagliabue A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01068; Talwani R, 2011, CLIN LIVER DIS, V15, P111, DOI 10.1016/j.cld.2010.09.002; Toleman MA, 2007, EMERG INFECT DIS, V13, P559, DOI 10.3201/eid1304.061378; Trifonova A, 2019, INFECT DIS-NOR, V51, P168, DOI 10.1080/23744235.2018.1531145; Wang XL, 2016, FISH SHELLFISH IMMUN, V57, P318, DOI 10.1016/j.fsi.2016.08.054; Yousief SW, 2020, MICROBES INFECT, V22, P127, DOI 10.1016/j.micinf.2019.09.002	52	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4471	4480		10.1016/j.vaccine.2021.06.051		JUL 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34187706				2022-04-29	WOS:000672160300014
J	Davies, C; Stoney, T; Hutton, H; Parrella, A; Kang, M; Macartney, K; Leask, J; McCaffery, K; Zimet, G; Brotherton, JML; Marshall, HS; Skinner, SR				Davies, Cristyn; Stoney, Tanya; Hutton, Heidi; Parrella, Adriana; Kang, Melissa; Macartney, Kristine; Leask, Julie; McCaffery, Kirsten; Zimet, Gregory; Brotherton, Julia M. L.; Marshall, Helen S.; Skinner, S. Rachel		HPV Edu Study Grp	School-based HPV vaccination positively impacts parents' attitudes toward adolescent vaccination	VACCINE			English	Article						HPV; HPV vaccine; Adolescent; Parent; Decision-making; Attitudes; Knowledge; School-based vaccination; Implementation	HUMAN-PAPILLOMAVIRUS VACCINATION; DECISION-MAKING; HEALTH; IMMUNIZATION; DELIVERY; COVERAGE; SCALE; FOCUS	Introduction: This qualitative study aimed to explore parental attitudes, knowledge and decision-making about HPV vaccination for adolescents in the context of a gender-neutral school-based Australian National Immunisation Program (NIP). Methods: Semi-structured interviews with parents of adolescents eligible for HPV vaccination were undertaken as part of an evaluation of a cluster-randomised controlled trial of a complex intervention in 40 schools (2013-2015). In this qualitative study, we purposively recruited a nested sample of parents from 11 schools across two Australian jurisdictions. Interviews explored parent knowledge and understanding of the HPV vaccine program; HPV vaccination decision-making; their adolescent's knowledge about HPV vaccination; and their adolescent's understanding about HPV vaccination, sexual awareness and behaviour. Transcripts were analysed using inductive and deductive thematic analysis. Results: Parents' of 22 adolescents had positive attitudes towards the program; the school-based delivery platform was the key driver shaping acceptance of and decision-making about HPV vaccination. They had difficulty recalling, or did not read, HPV vaccination information sent home. Some adolescents were involved in discussions about vaccination, with parents' responsible for ultimate vaccine decision making. All parents supported in-school education for adolescents about HPV and HPV vaccination. Parents' knowledge about HPV vaccination was limited to cervical cancer and was largely absent regarding vaccination in males. Conclusions: Parents' positive attitudes towards the NIP and inclusion of the HPV vaccine is central to their vaccine decision-making and acceptance. More intensive communication strategies including school education opportunities are required to improve parents' knowledge of HPV-related disease and to promote vaccine decision-making with adolescents. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Davies, Cristyn; Macartney, Kristine; Skinner, S. Rachel] Univ Sydney, Fac Med & Hlth, Special Child & Adolescent Hlth, Locked Bag 4001, Westmead, NSW 2145, Australia; [Stoney, Tanya; Hutton, Heidi] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Parrella, Adriana; Marshall, Helen S.] Univ Adelaide, Womens & Childrens Hlth Network, Adelaide, SA, Australia; [Parrella, Adriana; Marshall, Helen S.] Univ Adelaide, Sch Med, Adelaide, SA, Australia; [Parrella, Adriana; Marshall, Helen S.] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia; [Parrella, Adriana] South Australian Hlth & Med Res Inst SAHMRI, Adelaide, SA, Australia; [Kang, Melissa] Univ Technol Sydney, Fac Hlth, Sch Publ Hlth, Sydney, NSW, Australia; [Macartney, Kristine] Natl Ctr Immunisat Res & Surveillance, Sydney, NSW, Australia; [Leask, Julie] Univ Sydney, Fac Med & Hlth, Susan Wakil Sch Nursing & Midwifery, Sydney, NSW, Australia; [McCaffery, Kirsten] Univ Sydney, Fac Med & Hlth, Sydney Sch Publ Hlth, Sydney Hlth Literacy Lab, Sydney, NSW, Australia; [Zimet, Gregory] Indiana Univ, Dept Pediat, Indianapolis, IN 46204 USA; [Brotherton, Julia M. L.] VCS Fdn, VCS Populat Hlth, Melbourne, Vic, Australia; [Brotherton, Julia M. L.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia		Davies, C (通讯作者)，Univ Sydney, Fac Med & Hlth, Special Child & Adolescent Hlth, Locked Bag 4001, Westmead, NSW 2145, Australia.	Cristyn.Davies@sydney.edu.au		Parrella, Adriana/0000-0002-8232-9103; Leask, Julie/0000-0001-5095-1443	Australian National Health and Medical Research CouncilNational Health and Medical Research Council (NHMRC) of Australia [1026765]; NHMRC Practitioner FellowshipNational Health and Medical Research Council (NHMRC) of Australia [APP1155066]; GSK Australia [4806]; Seqirus (BioCSL)	This work was supported by the Australian National Health and Medical Research Council [grant application number 1026765]; Helen Marshall was supported by a NHMRC Practitioner Fellowship [APP1155066]. GSK Australia [4806] provided an investigator initiated educational grant for the development of HPV educational materials, which were used in this study. The study was also supported by an investigator-initiated research grant from Seqirus (BioCSL).	Arie S, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6765; Australian Government Department of Health, 2020, HIST HUM PAP HPV IMM; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Brotherton J, 2020, PAPILLOMAVIRUS RES, V9, DOI 10.1016/j.pvr.2019.100192; Brotherton JML, 2019, MED J AUSTRALIA, V211, P31, DOI 10.5694/mja2.50221; Brotherton JML, 2018, BEST PRACT RES CL OB, V47, P42, DOI 10.1016/j.bpobgyn.2017.08.010; Burgess T, 2016, J PUBLIC HEALTH-UK, V38, pE430, DOI 10.1093/pubmed/fdv190; Burns S, 2021, SEX EDUC-SEX SOC LEA, V21, P253, DOI 10.1080/14681811.2020.1788527; Chantler T, 2019, VACCINE, V37, P5218, DOI 10.1016/j.vaccine.2019.07.061; Chesson HW, 2014, SEX TRANSM DIS, V41, P660, DOI 10.1097/OLQ.0000000000000193; Coles VAH, 2015, INT J STD AIDS, V26, P777, DOI 10.1177/0956462414554629; Cooper SC, 2016, HEALTH EDUC J, V75, P610, DOI 10.1177/0017896915608884; Cummings M, 2012, AUST FAM PHYSICIAN, V41, P339; Davies C, 2017, SEX EDUC-SEX SOC LEA, V17, P256, DOI 10.1080/14681811.2017.1300770; Davies C, 2014, FEM MEDIA STUD, V14, P711, DOI 10.1080/14680777.2013.830632; Feldstein LR, 2020, VACCINE, V38, P680, DOI 10.1016/j.vaccine.2019.10.054; Fenton ATHR, 2020, J ADOLESCENT HEALTH, V66, P447, DOI 10.1016/j.jadohealth.2019.10.020; Gilkey MB, 2014, VACCINE, V32, P6259, DOI 10.1016/j.vaccine.2014.09.007; Gorjana R, 2017, PREV MED, V95, P26, DOI 10.1016/j.ypmed.2016.11.019; Kang M, JAMA NETW OPEN; Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154; Lee Lai-Yang, 2017, F1000Res, V6, P866, DOI 10.12688/f1000research.10691.1; Lorch, IN PRESS; Marshall HS, 2013, VACCINE, V31, P3059, DOI 10.1016/j.vaccine.2013.04.064; NCIRS, 2021, IMP EV AUSTR NAT HUM; Netfa F, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5020058; Newman PA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019206; O'Neill J, 2019, VACCINE, V37, P272, DOI 10.1016/j.vaccine.2018.11.034; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Paul P, 2014, VACCINE, V32, P320, DOI 10.1016/j.vaccine.2013.11.070; Perez S, 2017, VACCINE, V35, P4713, DOI 10.1016/j.vaccine.2017.07.043; Perez S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3828-9; Perman S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4168-0; Phillips A, 2018, DRUG SAFETY, V41, P329, DOI 10.1007/s40264-017-0625-z; Richard L, 2011, ANNU REV PUBL HEALTH, V32, P307, DOI 10.1146/annurev-publhealth-031210-101141; Robbins SCC, 2010, HEALTH PSYCHOL, V29, P618, DOI 10.1037/a0021449; Selvey LA, 2020, VACCINE, V38, P2971, DOI 10.1016/j.vaccine.2020.02.047; Shapiro GK, 2018, PREV MED, V116, P203, DOI 10.1016/j.ypmed.2018.09.017; Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043; Sisnowski J, VACCINE; Skinner, MED TODAY, V22, P65; Skinner SR, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2168-5; Skinner SR, 2010, J ADOLESCENT HEALTH, V47, P215, DOI 10.1016/j.jadohealth.2010.07.002; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Vasileiou K, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0594-7; Waller J, 2020, VACCINE, V38, P1040, DOI 10.1016/j.vaccine.2019.11.046; Ward K, 2013, COMMUN DIS INTELL, V37, pE156; Whop LJ, 2021, PREV MED, V144, DOI 10.1016/j.ypmed.2020.106314	49	2	2	6	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4190	4198		10.1016/j.vaccine.2021.05.051		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TI1ID	34127299	hybrid, Green Published			2022-04-29	WOS:000672535200025
J	McGuinness, D; Kaufhold, RM; McHugh, PM; Winters, MA; Smith, WJ; Giovarelli, C; He, J; Zhang, YH; Musey, L; Skinner, JM				McGuinness, Debra; Kaufhold, Robin M.; McHugh, Patrick M.; Winters, Michael A.; Smith, William J.; Giovarelli, Cecilia; He, Jian; Zhang, Yuhua; Musey, Luwy; Skinner, Julie M.			Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice	VACCINE			English	Article						Pneumococcal vaccine; Immunogenicity; Monkey model	STREPTOCOCCUS-PNEUMONIAE; CROSS-REACTIVITY; CAPSULAR POLYSACCHARIDE; ANTIBODIES; DISEASE; IMMUNITY; SERUM; IMMUNIZATION; RESPONSES; CHILDREN	Invasive pneumococcal disease (IPD) is responsible for serious illnesses such as bacteremia, sepsis, meningitis, and pneumonia in young children, older adults, and persons with immunocompromising con-ditions and often leads to death. Although the most recent pneumococcal conjugate vaccines (PCVs) have been designed to target serotypes identified as the primary causative agents of IPD, the epidemiological landscape continues to change stressing the need to develop new PCVs. We have developed an investi-gational 24-valent PCV (PCV24) including serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F all conjugated to CRM197 and evaluated this vaccine in adult monkeys. PCV24 was shown to be immunogenic and induced functional antibody for all vaccine serotypes. Of the serotypes common to PCV13 and V114 (PCV15), PCV24 had a similar immunogenic response with the exceptions of 23F which had higher IgG GMCs for PCV13 and V114, and 7F which had higher GMCs for PCV13. Functional antibody responses were similar for the serotypes in common between PCV24, PCV13 and V114 vaccines, with the exception of serotype 7F which was greater for PCV13. Overall, this study shows that PCV24 provided similar immunogenicity as the lower valent vac-cines in adult monkeys with no apparent serotype interference. In addition, PCV24 also provided protec-tion against pneumococcal infection in a mouse challenge model. (c) 2021 Elsevier Ltd. All rights reserved.	[McGuinness, Debra; Kaufhold, Robin M.; Skinner, Julie M.] Merck & Co Inc, Dept Infect Dis Vaccines, West Point, PA 19486 USA; [McHugh, Patrick M.; Winters, Michael A.; Smith, William J.; Giovarelli, Cecilia; He, Jian] Merck & Co Inc, Dept Vaccine Proc Res, West Point, PA USA; [McHugh, Patrick M.; Winters, Michael A.; Smith, William J.; Giovarelli, Cecilia; He, Jian] Merck & Co Inc, Dept Dev, West Point, PA USA; [Zhang, Yuhua] Merck & Co Inc, Dept Nonclin Stat, West Point, PA USA; [Musey, Luwy] Merck & Co Inc, Dept Clin Res, West Point, PA USA		McGuinness, D (通讯作者)，Merck & Co Inc, Dept Infect Dis Vaccines, West Point, PA 19486 USA.	debra.mcguinness@merck.com		Zhang, yuhua/0000-0003-2285-2645; Kaufhold, Robin/0000-0001-9048-6208	Merck, Sharp and Dohme Corp.; Merck & Co., Inc., Kenilworth, NJ,USA	Funding for this research was provided by Merck, Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ,USA.	Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Bratcher PE, 2010, J CLIN MICROBIOL, V48, P3044, DOI 10.1128/JCM.00839-10; Bridy-Pappas AE, 2005, PHARMACOTHERAPY, V25, P1193, DOI 10.1592/phco.2005.25.9.1193; Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06; Calix JJ, 2012, J BIOL CHEM, V287, P27885, DOI 10.1074/jbc.M112.380451; Caro-Aguilar I, 2017, VACCINE, V35, P865, DOI 10.1016/j.vaccine.2016.12.055; Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056; Cui YDA, 2017, HUM VACC IMMUNOTHER, V13, P1229, DOI 10.1080/21645515.2016.1277300; Ermlich SJ, 2018, VACCINE, V36, P6875, DOI 10.1016/j.vaccine.2018.03.012; Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517; Goldblatt D, 2011, CLIN VACCINE IMMUNOL, V18, P1728, DOI 10.1128/CVI.05252-11; Golden AR, 2016, VACCINE, V34, P2527, DOI 10.1016/j.vaccine.2016.03.058; Greenberg D, 2018, VACCINE, V36, P6883, DOI 10.1016/j.vaccine.2018.02.113; Heilmann C, 1990, APMIS Suppl, V15, P1; Hurley D., 2020, CLIN INFECT DIS; Jakobsen H, 2003, INFECT IMMUN, V71, P2956, DOI 10.1128/IAI.71.5.2956-2959.2003; LeBlanc JJ, 2019, VACCINE, V37, P5466, DOI 10.1016/j.vaccine.2019.05.003; Licciardi PV, 2010, VACCINE, V28, P3793, DOI 10.1016/j.vaccine.2010.03.033; Marchese RD, 2009, CLIN VACCINE IMMUNOL, V16, P387, DOI 10.1128/CVI.00415-08; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; McCool TL, 1999, INFECT IMMUN, V67, P4862, DOI 10.1128/IAI.67.9.4862-4869.1999; Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Nolan K, 2020, BIOANALYSIS; Park S, 2011, INFECT IMMUN, V79, P314, DOI 10.1128/IAI.00768-10; Peterson JT, 2019, HUM VACC IMMUNOTHER, V15, P540, DOI 10.1080/21645515.2018.1532250; Philipp MT, 2012, J MED PRIMATOL, V41, P60, DOI 10.1111/j.1600-0684.2011.00512.x; Pilishvili T, 2015, AM J PREV MED, V49, pS383, DOI 10.1016/j.amepre.2015.09.008; Rajam G, 2007, CLIN VACCINE IMMUNOL, V14, P1223, DOI 10.1128/CVI.00184-07; Savulescu C, 2017, LANCET RESP MED, V5, P648, DOI [10.1016/S2213-2600(17)30110-8, 10.1016/s2213-2600(17)30110-8]; Simell B, 2012, CLIN VACCINE IMMUNOL, V19, P1618, DOI 10.1128/CVI.00248-12; Skinner JM, 2011, VACCINE, V29, P8870, DOI 10.1016/j.vaccine.2011.09.078; Song JY, 2013, J KOREAN MED SCI, V28, P4, DOI 10.3346/jkms.2013.28.1.4; Sun Y, 2001, INFECT IMMUN, V69, P336, DOI 10.1128/IAI.69.1.336-344.2001; Thompson A, 2019, VACCINE, V37, P6201, DOI 10.1016/j.vaccine.2019.08.048; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; van der Linden M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131494; van Westen E, 2013, VACCINE, V31, P5834, DOI 10.1016/j.vaccine.2013.09.073; Xie JF, 2020, PEDIATR INFECT DIS J, V39, P70, DOI 10.1097/INF.0000000000002522; Yeh SH, 2010, PEDIATRICS, V126, pE493, DOI 10.1542/peds.2009-3027; Zivich PN, 2018, PNEUMONIA, V10, DOI 10.1186/s41479-018-0055-4	41	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4231	4237		10.1016/j.vaccine.2021.04.067		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34074546				2022-04-29	WOS:000672535200030
J	Kaur, R; Pham, M; Pichichero, M				Kaur, Ravinder; Pham, Minh; Pichichero, Michael			Serum antibody levels to pneumococcal polysaccharides 22F, 33F, 19A and 6A that correlate with protection from colonization and acute otitis media in children	VACCINE			English	Article						Streptococcus pneumoniae; Serotypes 22F, 33F, 19A and 6A; Correlates of protection; Acute otitis media; Colonization	STREPTOCOCCUS-PNEUMONIAE VACCINE; CONJUGATE VACCINE; NASOPHARYNGEAL CARRIAGE; UNITED-STATES; IMPACT; SEROTYPES; DISEASE; IMMUNOGENICITY; ERA; TOLERABILITY	Background: Serotypes 22F and 33F have been added to a new pneumococcal-conjugate vaccine (PCV-15) because of their prevalence in causing invasive pneumococcal diseases (IPD). Method: We measured anti-polysaccharide 22F, 33F, 19A and 6A antibodies in children before and after pneumococcal colonization and acute otitis media (AOM) episodes caused by these specific-serotypes. A two-step method for construction of correlate of protection (COP) models included using a generalized estimating equation for the relationship between antibody level, age and colonization history followed by logistic-regression modelling that included colonization or AOM episodes as independent variables, and age adjusted antibody level as the predictor. Results: A vaccine-induced serum antibody level of 0.45 mu g/ml for 22F, 0.51 mu g/ml for 6A and 4.1 mu g/ml for 19A correlated with prevention of pneumococcal colonization by respective serotypes (insufficient number of cases for 33F to find COP against colonization). Antibody levels of 0.25 mu g/ml for 22F, 33F and 6A and 2 mu g/ml for 19A correlated with prevention of AOM by the respective serotypes. Conclusions: A COP threshold of anti-22F, 33F, 19A and 6A serum antibodies for NP colonization and AOM in young children can be derived using GEE and logistic regression modelling. (C) 2021 Elsevier Ltd. All rights reserved.	[Kaur, Ravinder; Pichichero, Michael] Rochester Gen Hosp, Ctr Infect Dis & Immunol, Res Inst, 1425 Portland Ave, Rochester, NY 14621 USA; [Pham, Minh] Rochester Inst Technol, Coll Sci, Sch Math Sci, Rochester, NY 14623 USA		Kaur, R (通讯作者)，Rochester Gen Hosp, Ctr Infect Dis & Immunol, Res Inst, 1425 Portland Ave, Rochester, NY 14621 USA.	Ravinder.kaur@rochesterregional.org			Merck through an Investigator Initiated grant	This study was funded by Merck through an Investigator Initiated grant to RK.	Almudevar A., 2018, LANCET CHILD ADOLESC; Almudevar A, 2017, HUM VACC IMMUNOTHER, V13, P2316, DOI [10.1080/21645515.2017.1359364, 10.1080/21645515.2017.1329064]; Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; Auranen K, 2013, VACCINE, V32, P153, DOI 10.1016/j.vaccine.2013.08.061; Balmer P, 2007, J CLIN PATHOL, V60, P345, DOI 10.1136/jcp.2006.041210; Casey JR, 2013, PEDIATR INFECT DIS J, V32, P805, DOI 10.1097/INF.0b013e31828d9acc; Cohen R, 2012, PEDIATR INFECT DIS J, V31, P297, DOI 10.1097/INF.0b013e318247ef84; Dagan R, 2005, J INFECT DIS, V192, P367, DOI 10.1086/431679; Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005; Ermlich SJ, 2018, VACCINE, V36, P6875, DOI 10.1016/j.vaccine.2018.03.012; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Fleming-Dutra KE, 2014, PEDIATR INFECT DIS J, V33, pS152, DOI 10.1097/INF.0000000000000083; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; Ghaffar F, 2004, CLIN INFECT DIS, V39, P930, DOI 10.1086/423379; Goldblatt D, 2015, CLIN VACCINE IMMUNOL, V22, P1154, DOI 10.1128/CVI.00437-15; Goldblatt D, 2013, VACCINE, V32, P146, DOI 10.1016/j.vaccine.2013.06.040; Golden AR, 2016, VACCINE, V34, P2527, DOI 10.1016/j.vaccine.2016.03.058; Henckaerts I, 2006, CLIN VACCINE IMMUNOL, V13, P356, DOI 10.1128/CVI.13.3.356-360.2006; Hicks LA, 2007, J INFECT DIS, V196, P1346, DOI 10.1086/521626; Hotomi M, 2016, FOLIA MICROBIOL, V61, P375, DOI 10.1007/s12223-016-0445-z; Huang SS, 2005, PEDIATRICS, V116, pE408, DOI 10.1542/peds.2004-2338; Jokinen JT, 2004, J INFECT DIS, V190, P545, DOI 10.1086/422531; Kaplan SL, 2013, PEDIATR INFECT DIS J, V32, P203, DOI 10.1097/INF.0b013e318275614b; Kaplan SL, 2004, PEDIATRICS, V113, P443, DOI 10.1542/peds.113.3.443; Kaur R, 2020, VACCINE, V38, P4423, DOI 10.1016/j.vaccine.2020.04.063; Kaur R, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0181; Kaur R, 2016, PEDIATR INFECT DIS J, V35, P901, DOI 10.1097/INF.0000000000001206; Kayhty H, 2009, IMMUNOLOGICAL BASIS; Loughlin AM, 2014, PEDIATR INFECT DIS J, V33, P504, DOI 10.1097/INF.0000000000000279; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; McFetridge R, 2015, VACCINE, V33, P2793, DOI 10.1016/j.vaccine.2015.04.025; Mitchell AM, 2010, CLIN MICROBIOL INFEC, V16, P411, DOI 10.1111/j.1469-0691.2010.03183.x; Myint TTH, 2013, ADV THER, V30, P127, DOI 10.1007/s12325-013-0007-6; O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833; Ojal J, 2017, VACCINE, V35, P4652, DOI 10.1016/j.vaccine.2017.05.088; Pichichero M, 2018, LANCET CHILD ADOLESC, V2, P561, DOI 10.1016/S2352-4642(18)30168-8; Pichichero ME, 2012, HUM VACC IMMUNOTHER, V8, P799, DOI 10.4161/hv.19820; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Principi N, 2015, HUM VACC IMMUNOTHER, V11, P1494, DOI 10.1080/21645515.2015.1033600; Principi N, 2012, FUTURE MICROBIOL, V7, P457, DOI [10.2217/fmb.12.23, 10.2217/FMB.12.23]; Shakl JR, 2013, TRENDS MICROBIOL, V21, P129, DOI 10.1016/j.tim.2012.11.005; Sobanjo-ter Meulen A, 2015, PEDIATR INFECT DIS J, V34, P186, DOI 10.1097/INF.0000000000000516; Sorensen RU, 1998, J ALLERGY CLIN IMMUN, V102, P215, DOI 10.1016/S0091-6749(98)70089-2; Tan TQ, 2012, CLIN MICROBIOL REV, V25, P409, DOI 10.1128/CMR.00018-12; Usuf E, 2018, CLIN MICROBIOL INFEC, V24, P389, DOI 10.1016/j.cmi.2017.07.018; van Hoek AJ, 2014, VACCINE, V32, P4349, DOI 10.1016/j.vaccine.2014.03.017; Voysey M, 2018, CLIN INFECT DIS, V66, P913, DOI 10.1093/cid/cix895; WHO, TRAIN MAN ENZ LINK I; Xu Q, 2015, MUCOSAL IMMUNOL, V8, P1110, DOI 10.1038/mi.2015.1; Yildirim I, 2010, VACCINE, V29, P283, DOI 10.1016/j.vaccine.2010.10.032	50	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3900	3906		10.1016/j.vaccine.2021.05.089		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34116872				2022-04-29	WOS:000663773600016
J	Munoz, FM; Cramer, JP; Dekker, CL; Dudley, MZ; Graham, BS; Gurwith, M; Law, B; Perlman, S; Polack, FP; Spergel, JM; Van Braeckel, E; Ward, BJ; Didierlaurent, AM; Lambert, PH				Munoz, Flor M.; Cramer, Jakob P.; Dekker, Cornelia L.; Dudley, Matthew Z.; Graham, Barney S.; Gurwith, Marc; Law, Barbara; Perlman, Stanley; Polack, Fernando P.; Spergel, Jonathan M.; Van Braeckel, Eva; Ward, Brian J.; Didierlaurent, Arnaud M.; Lambert, Paul Henri		Brighton Collaboration Vaccine	Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data	VACCINE			English	Review						Adverse event; Immunization; Guidelines; Case definition; Vaccine; Enhanced disease; Respiratory; Systemic disease	RESPIRATORY SYNCYTIAL VIRUS; MULTIPLE ORGAN DYSFUNCTION; INTERNATIONAL CONSENSUS DEFINITIONS; FAILURE ASSESSMENT SCORE; SEVERE DENGUE DISEASE; SYNDROME CORONAVIRUS; MEASLES-VIRUS; IMMUNE-RESPONSES; INFLAMMATORY CYTOKINES; EMERGENCY-DEPARTMENT	This is a Brighton Collaboration Case Definition of the term "Vaccine Associated Enhanced Disease" to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Munoz, Flor M.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Munoz, Flor M.] Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA; [Munoz, Flor M.] Baylor Coll Med, Dept Microbiol, Houston, TX 77030 USA; [Cramer, Jakob P.] CEPI, Coalit Epidem Preparedness Innovat, London, England; [Dekker, Cornelia L.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Dudley, Matthew Z.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD USA; [Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Gurwith, Marc] Safety Platform Emergency Vaccines, Los Altos Hills, CA USA; [Law, Barbara] Safety Platform Emergency Vaccines, Manta, Ecuador; [Perlman, Stanley] Univ Iowa, Dept Pediat, Dept Microbiol & Immunol, Iowa City, IA 52242 USA; [Polack, Fernando P.] Fdn Infant, Buenos Aires, DF, Argentina; [Spergel, Jonathan M.] Univ Penn, Dept Pediat, Perelman Sch Med, Div Allergy & Immunol,Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Van Braeckel, Eva] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [Van Braeckel, Eva] Univ Ghent, Dept Internal Med & Paediat, Ghent, Belgium; [Ward, Brian J.] McGill Univ, Res Inst, Hlth Ctr, Montreal, PQ, Canada; [Didierlaurent, Arnaud M.; Lambert, Paul Henri] Univ Geneva, Ctr Vaccinol, Geneva, Switzerland		Munoz, FM (通讯作者)，Inst Baylor Coll Med, Houston, TX 77030 USA.	florm@bcm.edu		Spergel, Jonathan/0000-0002-4658-5353; Dudley, Matthew/0000-0003-1201-4066; Munoz, Flor/0000-0002-0457-7689	Coalition for Epidemic Preparedness Innovations (CEPI)	We acknowledge the financial support provided by the Coalition for Epidemic Preparedness Innovations (CEPI) for our work under a service order entitled Safety Platform for Emergency vACcines (SPEAC) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA.	Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15; Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688; Agulnik A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00354; Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642; [Anonymous], 1968, Br Med J, V2, P449; Baay M, 2020, BIOLOGICALS, V66, P35, DOI 10.1016/j.biologicals.2020.06.005; Beltramo F, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.09.31; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Boukhvalova MS, 2006, VACCINE, V24, P5027, DOI 10.1016/j.vaccine.2006.03.064; Britto C, 2018, EXPERT OPIN BIOL TH, V18, P1171, DOI 10.1080/14712598.2018.1526277; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Cameron MJ, 2007, J VIROL, V81, P8692, DOI 10.1128/JVI.00527-07; Castilow EM, 2008, J IMMUNOL, V181, P6692, DOI 10.4049/jimmunol.181.10.6692; Castilow EM, 2008, J IMMUNOL, V180, P2376, DOI 10.4049/jimmunol.180.4.2376; Centers for Disease Control and Prevention, 2020, MULT INFL SYNDR CHIL; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Chapman SM, 2017, ARCH DIS CHILD, V102, P487, DOI 10.1136/archdischild-2016-311088; Chapman SM, 2016, RESUSCITATION, V109, P87, DOI 10.1016/j.resuscitation.2016.07.230; Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005; CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957; CONNORS M, 1992, J VIROL, V66, P7444, DOI 10.1128/JVI.66.12.7444-7451.1992; CONNORS M, 1994, J VIROL, V68, P5321, DOI 10.1128/JVI.68.8.5321-5325.1994; Dakhama A, 2005, J IMMUNOL, V175, P1876, DOI 10.4049/jimmunol.175.3.1876; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525; Dewi W, 2019, Ann Burns Fire Disasters, V32, P135; Duerr A, 2012, J INFECT DIS, V206, P258, DOI 10.1093/infdis/jis342; El-Mashad GM, 2020, AN PEDIATR, V92, P277, DOI 10.1016/j.anpedi.2019.05.018; Erlenhoefer C, 2001, J VIROL, V75, P4499, DOI 10.1128/JVI.75.10.4499-4505.2001; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Flipse J, 2013, TRAFFIC, V14, P25, DOI 10.1111/tra.12012; Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894; FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956; Gan ES, 2017, EXPERT REV ANTI-INFE, V15, P111, DOI 10.1080/14787210.2017.1254550; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Graciano AL, 2005, CRIT CARE MED, V33, P1484, DOI 10.1097/01.CCM.0000170943.23633.47; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; GRAHAM BS, 1993, J IMMUNOL, V151, P2032; Griffin DE, 2008, FRONT BIOSCI-LANDMRK, V13, P1352, DOI 10.2741/2767; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201; Halstead SB, 2016, VACCINE, V34, P1643, DOI 10.1016/j.vaccine.2016.02.004; Heininger U, 2012, VACCINE, V30, P1265, DOI 10.1016/j.vaccine.2011.12.048; Heinz FX, 2017, MICROBIOL MOL BIOL R, V81, DOI [10.1128/MMBR.00055-16, 10.1128/mmbr.00055-16]; Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255; Hussell T, 1997, EUR J IMMUNOL, V27, P3341, DOI 10.1002/eji.1830271233; Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC; John DV, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0191-6; Jones AE, 2009, CRIT CARE MED, V37, P1649, DOI 10.1097/CCM.0b013e31819def97; Jorquera PA, 2016, EXPERT REV VACCINES, V15, P173, DOI 10.1586/14760584.2016.1115353; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; Katz SL, 2009, CURR TOP MICROBIOL, V329, P3; KATZ SL, 1960, NEW ENGL J MED, V263, P180, DOI 10.1056/NEJM196007282630408; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Killikelly AM, 2016, SCI REP-UK, V6, DOI 10.1038/srep34108; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Knudson CJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004757; KRAUSE PJ, 1978, J PEDIATR-US, V93, P565, DOI 10.1016/S0022-3476(78)80889-0; Lambert PH, 2020, VACCINE, V38, P4783, DOI 10.1016/j.vaccine.2020.05.064; Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0; Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166; Leteurtre S, 1999, MED DECIS MAKING, V19, P399, DOI 10.1177/0272989X9901900408; Leteurtre S, 2013, CRIT CARE MED, V41, P1761, DOI 10.1097/CCM.0b013e31828a2bbd; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Loebbermann J, 2013, P NATL ACAD SCI USA, V110, P2987, DOI 10.1073/pnas.1217580110; Lu Yanhui, 2019, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V44, P996, DOI 10.11817/j.issn.1672-7347.2019.180372; Mahmudpour M, 2020, CYTOKINE, V133, DOI 10.1016/j.cyto.2020.155151; Martines RB, 2020, EMERG INFECT DIS, V26, P2005, DOI 10.3201/eid2609.202095; Matics TJ, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2017.2352; McElroy T, 2019, BMC EMERG MED, V19, DOI 10.1186/s12873-019-0287-5; Moghaddam A, 2006, NAT MED, V12, P905, DOI 10.1038/nm1456; Monaghan Alan, 2005, Paediatr Nurs, V17, P32; Moss WJ, 2001, VIRAL IMMUNOL, V14, P297, DOI 10.1089/08828240152716556; O'Hagan DT, 2017, CURR OPIN IMMUNOL, V47, P93, DOI 10.1016/j.coi.2017.07.010; Openshaw PJM, 2005, CLIN MICROBIOL REV, V18, P541, DOI 10.1128/CMR.18.3.541-555.2005; Parshuram CS, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0712-3; Parshuram CS, 2011, CRIT CARE, V15, DOI 10.1186/cc10337; Polack FP, 2000, NAT MED, V6, P776, DOI 10.1038/77506; Polack FP, 1999, NAT MED, V5, P629, DOI 10.1038/9473; Polack FP, 2003, NAT MED, V9, P1209, DOI 10.1038/nm918; Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; Priyamvada L, 2017, J INFECT DIS, V216, pS906, DOI 10.1093/infdis/jix513; Rajao DS, 2014, CURR TOP MICROBIOL, V385, P307, DOI 10.1007/82_2014_391; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rechtien A, 2017, CELL REP, V20, P2251, DOI 10.1016/j.celrep.2017.08.023; Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]; ROD T, 1970, Scandinavian Journal of Infectious Diseases, V2, P161, DOI 10.3109/inf.1970.2.issue-3.02; Royal College of Paediatrics and Child Health, 2020, GUID PAED MULT INFL; Rubin GD, 2020, RADIOLOGY, V296, P172, DOI 10.1148/radiol.2020201365; Schlapbach LJ, 2018, INTENS CARE MED, V44, P179, DOI 10.1007/s00134-017-5021-8; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Sheahan T, 2011, J VIROL, V85, P217, DOI 10.1128/JVI.01805-10; Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Singh J, 2015, J PHARMACOL PHARMACO, V6, P185, DOI 10.4103/0976-500X.162004; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Srikiatkhachorn A, 1997, J EXP MED, V186, P421, DOI 10.1084/jem.186.3.421; Srikiatkhachorn A, 2016, EXPERT REV VACCINES, V15, P455, DOI 10.1586/14760584.2016.1116949; Stokes KL, 2013, J VIROL, V87, P10070, DOI 10.1128/JVI.01347-13; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; The Council for International Organizations of Medical Sciences, 2020, CIOMS FORM; Theron M, 2005, CYTOKINE, V32, P30, DOI 10.1016/j.cyto.2005.07.007; Thompson BT, 2017, NEW ENGL J MED, V377, P562, DOI [10.1056/NEJMra1608077, 10.1056/NEJMc1711824]; Thompson EA, 2017, CURR OPIN IMMUNOL, V47, P1, DOI 10.1016/j.coi.2017.06.006; Typpo KV, 2009, PEDIATR CRIT CARE ME, V10, P562, DOI 10.1097/PCC.0b013e3181a64be1; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Vittucci AC, 2018, MINERVA PEDIATR, V70, P566, DOI 10.23736/S0026-4946.18.05305-7; Walsh KB, 2014, J VIROL, V88, P6281, DOI 10.1128/JVI.00464-14; Wan SW, 2013, J FORMOS MED ASSOC, V112, P3, DOI 10.1016/j.jfma.2012.11.006; Watson RS, 2017, PEDIATR CRIT CARE ME, V18, pS4, DOI 10.1097/PCC.0000000000001047; Wilder-Smith A, 2019, LANCET, V393, P350, DOI 10.1016/S0140-6736(18)32560-1; WILKINSON JD, 1986, CRIT CARE MED, V14, P271, DOI 10.1097/00003246-198604000-00002; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337; YOUNG LW, 1970, AMER J ROENTGENOL RA, V110, P439, DOI 10.2214/ajr.110.3.439; Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012; Zhang R, 2020, EUR RADIOL, V30, P4417, DOI 10.1007/s00330-020-06854-1; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zielecki F, 2013, J VIROL, V87, P5300, DOI 10.1128/JVI.03496-12	128	16	16	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 21	2021	39	22					3053	3066		10.1016/j.vaccine.2021.01.055		MAY 2021	14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SE0YP	33637387	Green Published, hybrid			2022-04-29	WOS:000651801800016
J	Kwon, JH; Criado, MF; Killmaster, L; Ali, MZ; Giasuddin, M; Samad, MA; Karim, MR; Brum, E; Hasan, MZ; Lee, DH; Spackman, E; Swayne, DE				Kwon, Jung-Hoon; Criado, Miria Ferreira; Killmaster, Lindsay; Ali, Md Zulfekar; Giasuddin, Mohammad; Samad, Mohammed A.; Karim, Md Rezaul; Brum, Eric; Hasan, Md Zakiul; Lee, Dong-Hun; Spackman, Erica; Swayne, David E.			Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh	VACCINE			English	Article						Antigenicity; Bangladesh; Highly pathogenic avian influenza; Vaccine	A(H5N1) VIRUSES; GENETIC EVOLUTION; H5N1 VIRUSES; WILD BIRDS; PROTECTION; POULTRY; HEMAGGLUTININ; QUANTITATION; VACCINATION; INFECTION	H5N1 highly pathogenic avian influenza viruses (HPAIVs) have caused outbreaks in poultry in Bangladesh since 2007. While clade 2.2.2 and 2.3.4.2 HPAIVs have not been detected since 2012, clade 2.3.2.1a viruses have caused continuous outbreaks since 2012 despite the use of vaccines. In this study, we evaluated the efficacy of two H5 vaccines licensed in Bangladesh, RE-6 inactivated vaccine, and a recombinant her-pesvirus of turkeys vaccine with an H5 insert (rHVT-H5), for protection against recent field viruses in chickens. We selected three viruses for efficacy tests (A/chicken/Bangladesh/NRL-AI-3237/2017, A/cro w/Bangladesh/NRL-AI-8471/2017 and A/chicken/Bangladesh/NRL-AI-8323/2017) from 36 H5 viruses iso-lated from Bangladesh between 2016 and 2018 by comparing the amino acid sequences at five antigenic sites (A-E) and analyzing hemagglutination inhibition (HI) titers with reference antisera. The RE-6 and rHVT-H5 vaccines both conferred 80?100% clinical protection (i.e. reduced morbidity and mortality) against the three challenge viruses with no significant differences in protection. In addition, both vaccines significantly decreased viral shedding from infected chickens as compared to challenge control chickens. Based on these metrics, the current licensed H5 vaccines protected chickens against the recent field viruses. However, the A/crow/Bangladesh/NRL-AI-8471/2017 virus exhibited antigenic divergence including: several unique amino acid changes in antigenic epitope sites A and B and was a serological out -lier in cross HI tests as visualized on the antigenic map. The continuing emergence of such antigenic vari-ants which could alter the dominant antigenicity of field viruses should be continuously monitored and vaccines should be updated if field efficacy declines. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).	[Kwon, Jung-Hoon; Criado, Miria Ferreira; Killmaster, Lindsay; Spackman, Erica; Swayne, David E.] ARS, USDA, US Natl Poultry Res Ctr, 934 Coll Stn Rd, Athens, GA 30605 USA; [Kwon, Jung-Hoon] Kyungpook Natl Univ, Coll Vet Med, Daegu 41566, South Korea; [Ali, Md Zulfekar; Giasuddin, Mohammad; Samad, Mohammed A.; Karim, Md Rezaul] Bangladesh Livestock Res Inst, Anim Hlth Res Div, Natl Reference Lab Avian Influenza, Dhaka 1341, Bangladesh; [Brum, Eric; Hasan, Md Zakiul] Food & Agr Org United Nations FAO, Emergency Ctr Transboundary Anim Dis ECTAD, Dhaka 1341, Bangladesh; [Lee, Dong-Hun] Univ Connecticut, Dept Pathobiol & Vet Sci, Storrs, CT 06269 USA; [Criado, Miria Ferreira] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA		Swayne, DE (通讯作者)，ARS, USDA, US Natl Poultry Res Ctr, 934 Coll Stn Rd, Athens, GA 30605 USA.	David.Swayne@USDA.GOV	Ali, Zulfekar/I-5799-2015	Ali, Zulfekar/0000-0002-3971-8699; Kwon, jung-hoon/0000-0002-6737-2242; Brum, Eric/0000-0002-0244-7178	Agricultural Research Service project [6040-32000-066-00D]; USAID Emerging Pandemic Threats programUnited States Agency for International Development (USAID); Emergency Centre for Transboundary Animal Diseases (ECTAD) Food and Agricultural Organization of the United Nations (FAO); APHIS/ARS interagency agreementUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [60-6040-6-005]	This research component conducted at U.S. National Poultry Research Center was supported by Agricultural Research Service project 6040-32000-066-00D and the APHIS/ARS interagency agreement 60-6040-6-005. The authors thank the USAID Emerging Pandemic Threats program and the Emergency Centre for Transboundary Animal Diseases (ECTAD) Food and Agricultural Organization of the United Nations (FAO) for financial and technical support to the National Reference Laboratory for Avian Influenza in avian influenza surveillance of poultry, and to the Ecohealth Alliance PREDICT II project for support of avian influenza surveillance of crows. The Department of Livestock Service is thanked for providing clinical samples.	Ansari WK, 2016, VET MICROBIOL, V193, P49, DOI 10.1016/j.vetmic.2016.07.025; Barman S, 2019, EMERG MICROBES INFEC, V8, P650, DOI 10.1080/22221751.2019.1605845; Barman S, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.60; Bertran K, 2017, VACCINE, V35, P6336, DOI 10.1016/j.vaccine.2017.05.051; Bi YH, 2016, CELL HOST MICROBE, V20, P810, DOI 10.1016/j.chom.2016.10.022; Nguyen DT, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0100-7; Doud MB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03665-3; Escorcia M, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-15; Fadel HM, 2017, VET WORLD, V10, P695, DOI 10.14202/vetworld.2017.695-701; Gambotto A, 2008, LANCET, V371, P1464, DOI 10.1016/S0140-6736(08)60627-3; Gerloff NA, 2014, VIROLOGY, V450, P297, DOI 10.1016/j.virol.2013.12.023; Gilbert M, 2010, ECOHEALTH, V7, P448, DOI 10.1007/s10393-010-0672-8; Gu M, 2013, EMERG INFECT DIS, V19, P2021, DOI 10.3201/eid1912.130340; Hill EM, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006439; Islam A, 2006, J VIROL METHODS, V132, P127, DOI 10.1016/j.jviromet.2005.10.009; Islam MR, 2012, TRANSBOUND EMERG DIS, V59, P460, DOI 10.1111/j.1865-1682.2011.01297.x; Kapczynski DR, 2015, VACCINE, V33, P1197, DOI 10.1016/j.vaccine.2014.12.028; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Khan SU, 2014, ARCH VIROL, V159, P509, DOI 10.1007/s00705-013-1842-0; Kilany W, 2014, AVIAN PATHOL, V43, P514, DOI 10.1080/03079457.2014.966302; Koel BF, 2014, MBIO, V5, DOI 10.1128/mBio.01070-14; Kreijtz JHCM, 2008, J VIROL, V82, P5161, DOI 10.1128/JVI.02694-07; Kwon JH, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa046; Lee CW, 2004, J VIROL METHODS, V119, P151, DOI 10.1016/j.jviromet.2004.03.014; Lee DH, 2020, CSH PERSPECT MED; Lee DH, 2015, J VIROL, V89, P6521, DOI 10.1128/JVI.00728-15; Lycett SJ, 2016, SCIENCE, V354, P213, DOI 10.1126/science.aaf8852; Marinova-Petkova A, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.11; Monne I, 2013, EMERG INFECT DIS, V19, P1630, DOI 10.3201/eid1910.130534; Palya V, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3143189; Parvin R, 2018, EPIDEMIOL INFECT, V146, P1259, DOI [10.1017/S0950268818001292, 10.1017/s0950268818001292]; Pedersen Janice C., 2008, V436, P53, DOI 10.1007/978-1-59745-279-3_8; Peng YS, 2017, SCI REP-UK, V7, DOI 10.1038/srep43566; Poen MJ, 2019, VIRUS EVOL, V5, DOI 10.1093/ve/vez004; Rahman M, 2020, INFLUENZA OTHER RESP, V14, P349, DOI 10.1111/irv.12716; Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211; Sonnberg S, 2013, VIRUS RES, V178, P63, DOI 10.1016/j.virusres.2013.05.009; Spackman E, 2020, METHODS MOL BIOL, V2123, P149, DOI 10.1007/978-1-0716-0346-8_12; Spackman E, 2014, INFLUENZA OTHER RESP, V8, P654, DOI 10.1111/irv.12290; Spackman Erica, 2008, V436, P27, DOI 10.1007/978-1-59745-279-3_5; Sutton TC, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090461; Swayne D.E, 2016, ANIMAL INFLUENZA; Swayne DE, 2014, ECOHEALTH, V11, P94, DOI 10.1007/s10393-013-0861-3; Swayne DE, 2012, AVIAN DIS, V56, P818, DOI 10.1637/10183-041012-Review.1; Swayne DE, 2020, DIS POULTRY, V14th; Tanimura N, 2006, VET PATHOL, V43, P500, DOI 10.1354/vp.43-4-500; Yang GY, 2019, VIROLOGY, V534, P36, DOI 10.1016/j.virol.2019.05.011; Yang H, 2016, J VIROL, V90, P5770, DOI 10.1128/JVI.00180-16; Youk S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222457; Zeng XY, 2016, AVIAN DIS, V60, P253, DOI 10.1637/11179-052015-ResNoteR; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	51	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 18	2021	39	21					2824	2832		10.1016/j.vaccine.2021.04.022		MAY 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RX4UJ	33910774	hybrid			2022-04-29	WOS:000647220100003
J	Bannister, S; Sudbury, E; Villanueva, P; Perrett, K; Curtis, N				Bannister, Samantha; Sudbury, Eva; Villanueva, Paola; Perrett, Kirsten; Curtis, Nigel			The safety of BCG revaccination: A systematic review	VACCINE			English	Review						Bacillus Calmette-Gu?rin; Safety; Adverse events; Off-target effects; Tuberculosis	BACILLUS-CALMETTE-GUERIN; SCHOOL-AGED CHILDREN; TUBERCULOUS MENINGITIS; ADVERSE-REACTIONS; RANDOMIZED-TRIAL; VACCINATION; PREVENTION; BIRTH; 1ST; LEPROSY	Introduction: Revaccination with Bacillus Calmette-Gu?rin (BCG) vaccine is not generally recommended due to a lack of proven efficacy of repeat doses for protection against tuberculosis. However, there is a growing interest in the use of BCG vaccine for its ?off-target? effects which might involve revaccination. We did a systematic review of the safety of BCG revaccination. Methods: MEDLINE (1946 to March 2020) and the BCG World Atlas (updated 2017) were searched, limiting to studies of BCG administration by the intradermal or percutaneous route. Adverse events as well as patient and vaccine characteristics were reviewed. Results: The search identified 388 articles, of which 24 met the inclusion criteria. These reported 22 studies comprising eight randomised trials, four case-control studies, four observational studies and six case series or reports. Overall, there was evidence for a small increase in the rate of mild local and systemic reactions. No serious adverse events were reported in immunocompetent individuals. Conclusions: Evidence to date suggests that revaccination with BCG vaccine carries minimal risk. Future studies of BCG vaccine for novel applications should report adverse event data stratified by prior BCG vaccination status. ? 2020 Published by Elsevier Ltd.	[Bannister, Samantha; Sudbury, Eva; Villanueva, Paola; Perrett, Kirsten; Curtis, Nigel] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Bannister, Samantha; Sudbury, Eva; Villanueva, Paola; Curtis, Nigel] Murdoch Childrens Res Inst, Infect Dis Res Grp, Parkville, Vic, Australia; [Bannister, Samantha; Sudbury, Eva; Villanueva, Paola; Curtis, Nigel] Royal Childrens Hosp Melbourne, Infect Dis Unit, Parkville, Vic, Australia; [Perrett, Kirsten] Murdoch Childrens Res Inst, Populat Allergy Grp, Parkville, Vic, Australia; [Perrett, Kirsten] Royal Childrens Hosp Melbourne, Dept Allergy & Immunol, Parkville, Vic, Australia		Curtis, N (通讯作者)，Univ Melbourne, Dept Paediat, Royal Childrens Hosp Melbourne, 50 Flemington Rd, Parkville, Vic 3052, Australia.	nigel.curtis@rch.org.au	Perrett, Kirsten/P-8813-2019	Perrett, Kirsten/0000-0002-5683-996X; Bannister, Samantha/0000-0001-7507-3704	Australian Government Research Training Program (RTP) ScholarshipAustralian GovernmentDepartment of Industry, Innovation and Science; Clifford Family PhD Scholarship by the University of Melbourne	Dr Bannister is supported by an Australian Government Research Training Program (RTP) Scholarship and a Clifford Family PhD Scholarship administered by the University of Melbourne.	Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240; [Anonymous], 2018, Wkly Epidemiol Rec, V93, P73; [Anonymous], 1995, B WORLD HEALTH ORGAN, P805; [Anonymous], 2017, SAGE EVIDENCE RECOMM; [Anonymous], 2017, THE BCG WORLD ATLAS; Aydinlioglu H, 1993, Paediatr Perinat Epidemiol, V7, P334, DOI 10.1111/j.1365-3016.1993.tb00408.x; Barreto ML, 2011, VACCINE, V29, P4875, DOI 10.1016/j.vaccine.2011.05.023; Biering-Sorensen S, 2012, PEDIATR INFECT DIS J, V31, P306, DOI 10.1097/INF.0b013e3182458289; Bothamley GH, 2003, BMJ-BRIT MED J, V327, P243, DOI 10.1136/bmj.327.7409.243; Choi IS, 2003, ALLERGY, V58, P1114, DOI 10.1034/j.1398-9995.2003.00246.x; Choi IS, 2002, ANN ALLERG ASTHMA IM, V88, P584, DOI 10.1016/S1081-1206(10)61890-X; Cuchet E, 2004, ANN DERMATOL VENER, V131, P1077, DOI 10.1016/S0151-9638(04)93844-6; Cunha AJLA, 2002, INT J TUBERC LUNG D, V6, P1110; Cunha SS, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000167; Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4; Dourado I, 2003, INT J TUBERC LUNG D, V7, P399; du Preez K, 2019, LANCET GLOB HEALTH, V7, pE28, DOI 10.1016/S2214-109X(18)30474-1; El Ouazzani H, 2007, ANN DERMATOL VENER, V134, P129, DOI 10.1016/S0151-9638(07)91603-8; Faustman DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041756; Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6; Fjallbrant H, 2007, SCAND J INFECT DIS, V39, P792, DOI 10.1080/00365540701367777; Gyldenlove M, 2012, HUM VACC IMMUNOTHER, V8, P423, DOI 10.4161/hv.19067; Hatherill M, 2014, VACCINE, V32, P3982, DOI 10.1016/j.vaccine.2014.04.084; Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170; Leung CC, 2001, INT J TUBERC LUNG D, V5, P717; Lotte A, 1984, Adv Tuberc Res, V21, P107; Nabeshima Shigeki, 2005, Journal of Infection and Chemotherapy, V11, P18, DOI 10.1007/s10156-004-0357-8; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]; NYBOE J, 1969, B WORLD HEALTH ORGAN, V41, P63; Pollard AJ, 2017, ARCH DIS CHILD; PONNIGHAUS JM, 1993, LEPROSY REV, V64, P338; Rakshit S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130540; Ristori G, 2014, NEUROLOGY, V82, P41, DOI 10.1212/01.wnl.0000438216.93319.ab; Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0; Roth AE, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c671; SIMILA S, 1988, TUBERCLE, V69, P67, DOI 10.1016/0041-3879(88)90043-8; Stewart JH, 2011, EXPERT REV ANTICANC, V11, P1671, DOI [10.1586/era.11.163, 10.1586/ERA.11.163]; Tala-Heikkila MM, 1998, AM J RESP CRIT CARE, V157, P1324, DOI 10.1164/ajrccm.157.4.9706037; Talbot EA, 1997, CLIN INFECT DIS, V24, P1139, DOI 10.1086/513642; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Turnbull FM, 2002, CLIN INFECT DIS, V34, P447, DOI 10.1086/338462; von Reyn CF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175215; Whelan KT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005934; Williams SK, 2010, EXPERT OPIN PHARMACO, V11, P947, DOI 10.1517/14656561003657145; Yamanaka K, 2000, Nagoya J Med Sci, V63, P123; Zimmermann P, 2018, J INFECT DIS, V218, P679, DOI 10.1093/infdis/jiy207	46	6	7	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 12	2021	39	20					2736	2745		10.1016/j.vaccine.2020.08.016		APR 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RU8YE	33810902				2022-04-29	WOS:000645426400002
J	Amin-Chowdhury, Z; Groves, N; Sheppard, CL; Litt, D; Fry, NK; Andrews, N; Ladhani, SN				Amin-Chowdhury, Zahin; Groves, Natalie; Sheppard, Carmen L.; Litt, David; Fry, Norman K.; Andrews, Nick; Ladhani, Shamez N.			Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes	VACCINE			English	Article						Pneumococcal disease; Conjugate vaccines; Whole genome sequencing		Background: A 15-valent pneumococcal conjugate vaccine (PCV15) aims to protect against serotype 22F and 33F in addition to the serotypes within the 13-valent PCV (PCV13) which was introduced to the UK childhood immunisation programme in April 2010. Little is known about the specific epidemiology, clinical features or outcomes of invasive pneumococcal disease (IPD) due to these two serotypes. Methods: Public Health England (PHE) conducts enhanced IPD surveillance in England. Hospital laboratories routinely submit invasive pneumococcal isolates to PHE for serotyping and enhanced clinical information is collected through questionnaires sent to general practitioners. IPD due to serotypes 22F and 33F diagnosed during 2014/15-2018/19 were compared with IPD due to PCV13 serotypes and remaining serotypes. Results: In total, 25,415 isolates (93.4%) were serotyped and questionnaires were completed for 22,097 (86.9%) cases. Serotype 22F was responsible for 1,788 (7.0%) and serotype 33F for 893 (3.5%) cases compared to 19.9% (n = 5,047) for PCV13 and 69.6% (n = 17,687) for the remaining serotypes. IPD incidence increased for both serotypes since 2005/06, especially in older adults, but plateaued after PCV13 introduction. Comorbidity prevalence was 68.7% (n = 1,037) for serotype 22F and 67.2% (n = 505) for serotype 33F, with invasive pneumonia being the most common clinical presentation 1,067/1,482; 72.0%, and 514/755; 68.1%, respectively. There were 3,617 deaths within 30 days of disease onset, including 236 (CFR, 15.4%) among 22F, 128 (CFR, 16.5%) among 33F and 21.3% (925/4,350) among PCV13-type IPD cases. When compared with PCV13-type IPD, serotype 22F (aOR 0.58, 95%CI 0.49-0.68, p < 0.001) and 33F (aOR 0.73, 95%CI 0.59-0.91, p = 0.004) were independently associated with lower odds of death. The major circulating sequence types (STs) in 22F (ST 433, ST698) and 33F (ST717, ST100, ST673) were not associated with an increased risk of death compared to the other STs. Conclusions: Serotype 22F and 33F-type IPD are associated with a lower risk of death compared to PCV13-type, with those presenting with septicaemia more likely to have a fatal outcome compared to pneumonia. PCV15 has the potential to prevent up to an additional 10% of IPD cases in England. (C) 2021 Elsevier Ltd. All rights reserved.	[Amin-Chowdhury, Zahin; Fry, Norman K.; Andrews, Nick; Ladhani, Shamez N.] Publ Hlth England, Immunisat & Countermeasures Div, 61 Colindale Ave, London NW9 5EQ, England; [Groves, Natalie; Sheppard, Carmen L.; Litt, David; Fry, Norman K.] Publ Hlth England, Resp & Vaccine Preventable Bacterial Reference Un, London, England; [Andrews, Nick] Publ Hlth England, Stat Modelling & Econ Dept, 61 Colindale Ave, London NW9 5EQ, England; [Ladhani, Shamez N.] St Georges Univ London, Paediat Infect Dis Res Grp, Cranmer Terrace, London SW17 0RE, England		Amin-Chowdhury, Z; Ladhani, SN (通讯作者)，Publ Hlth England, Immunisat & Countermeasures Div, 61 Colindale Ave, London NW9 5EQ, England.	zahin.amin@phe.gov.uk; shamez.ladhani@phe.gov.uk		Groves, Natalie/0000-0002-3832-3484			Amin-Chowdhury Z, 2020, CLIN INFECT DIS, V71, pE235, DOI 10.1093/cid/ciaa043; Andrews N, 2019, VACCINE, V37, P4491, DOI 10.1016/j.vaccine.2019.06.071; Balsells E, 2018, J INFECTION, V77, P368, DOI 10.1016/j.jinf.2018.06.004; Balsells E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177113; BURMAN LA, 1985, REV INFECT DIS, V7, P133; Converso TR, 2020, EXPERT REV VACCINES, V19, P57, DOI 10.1080/14760584.2020.1711055; Daniels Calvin C, 2016, J Pediatr Pharmacol Ther, V21, P27, DOI 10.5863/1551-6776-21.1.27; Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005; Deng XD, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02099; Desai Shalini, 2016, CMAJ Open, V4, pE545; Fleming-Dutra KE, 2014, PEDIATR INFECT DIS J, V33, pS152, DOI 10.1097/INF.0000000000000083; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; Golden AR, 2016, VACCINE, V34, P2527, DOI 10.1016/j.vaccine.2016.03.058; Golden AR, 2015, J ANTIMICROB CHEMOTH, V70, P1960, DOI 10.1093/jac/dkv061; Gonzalez BE, 2006, PEDIATR INFECT DIS J, V25, P301, DOI 10.1097/01.inf.0000207484.52850.38; Greenberg D, 2018, VACCINE, V36, P6883, DOI 10.1016/j.vaccine.2018.02.113; Jacobs MR, 2008, CLIN INFECT DIS, V47, P1388, DOI 10.1086/592972; Kapatai G, 2016, PEERJ, V4, DOI 10.7717/peerj.2477; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Levy C, 2019, J PEDIATR-US, V213, P252, DOI 10.1016/j.jpeds.2019.07.057; Lochen A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75691-5; Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1; Pichon B, 2013, J CLIN MICROBIOL, V51, P820, DOI 10.1128/JCM.01917-12; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Public Health England, 2013, PNEUM GREEN BOOK; Rupp R, 2019, HUM VACC IMMUNOTHER, V15, P549, DOI 10.1080/21645515.2019.1568159; Savulescu C, 2017, LANCET RESP MED, V5, P648, DOI [10.1016/S2213-2600(17)30110-8, 10.1016/s2213-2600(17)30110-8]; Sempere J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00309; Sheppard CL, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090687; Sheppard CL, 2017, PEERJ, V5, DOI 10.7717/peerj.3571; Southern J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195799; Thompson A, 2019, VACCINE, V37, P6201, DOI 10.1016/j.vaccine.2019.08.048; van Hoek AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039150; Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7; Wijayasri S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226353	36	3	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 1	2021	39	14					1997	2004		10.1016/j.vaccine.2021.02.026		MAR 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RC7NX	33715901				2022-04-29	WOS:000632984100017
J	Khanna, M; Rady, H; Dai, GX; Ramsay, AJ				Khanna, Mayank; Rady, Hamada; Dai, Guixiang; Ramsay, Alistair J.			Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates	VACCINE			English	Article						Neonates; TB vaccination; BCG; recombinant MVA; Pulmonary immunity; Protection	T-CELL RESPONSES; VACCINE; IMMUNOGENICITY; PREVENTION; EFFICACY; INNATE; METAANALYSIS; ADENOVIRUS; INFECTION; MACAQUES	Bacille-Calmette-Guerin (BCG) has variable efficacy as an adult tuberculosis (TB) vaccine but can reduce the incidence and severity of TB infection in humans. We have engineered modified vaccinia Ankara (MVA) strain vaccine constructs to express the secreted mycobacterial proteins Ag85A and ESAT-6 (MVA-AE) and evaluated their immunogenicity and protective efficacy as mucosal booster vaccines for BCG given subcutaneously in early life. Intranasal delivery of MVA-AE to young adult mice induced CD4(+) and CD8(+) T cell responses to both Ag85A and ESAT-6 in lung mucosae. These responses were markedly enhanced in mice that had been primed neonatally with BCG prior to intranasal MVA-AE immunization (BCG/MVA-AE), as evidenced by numbers of pulmonary Ag85A, ESAT-6, and PPD-specific CD4(+) and CD8(+) T cells and by their capacity to secrete multiple antimicrobial factors, including IFNc, IL-2 and IL-17. Moreover, MVA-AE boosting generated multifunctional lung CD4(+) T cells responding to ESAT-6, which were not, as expected, detected in control mice given BCG, and elevated Ag85A-specific circulating antibody responses. After aerosol challenge with M. tuberculosis H37Rv (Mtb), the BCG/MVA-AE group had significantly reduced mycobacterial burden in the lungs, compared with either BCG primed mice boosted with control MVA or mice given only BCG. These data indicate that intranasal delivery of MVA-AE can boost BCG-induced Th1 and Th17-based immunity locally in the lungs and improve the protective efficacy of neonatally-administered BCG against M. tuberculosis infection. (C) 2021 Elsevier Ltd. All rights reserved.	[Khanna, Mayank; Rady, Hamada; Dai, Guixiang; Ramsay, Alistair J.] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA; [Khanna, Mayank; Rady, Hamada; Dai, Guixiang] Louisiana Vaccine Ctr, New Orleans, LA 70112 USA		Ramsay, AJ (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA.	aramsa@lsuhsc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AI058810, 5PO1 HL076100]; Louisiana Vaccine Center - Louisiana Board of Regents [PKSFI-PRS-02]	This work was supported by NIH grants R01 AI058810 (AJR) and 5PO1 HL076100 (AJR), and by the Louisiana Vaccine Center funded by the Louisiana Board of Regents (PKSFI-PRS-02).	Auten MW, 2012, VACCINE, V30, P2768, DOI 10.1016/j.vaccine.2012.02.020; Brandt L, 1996, J IMMUNOL, V157, P3527; Brook B, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax4517; CHEN NX, 1995, TRANSPLANTATION, V59, P933, DOI 10.1097/00007890-199504150-00002; Choi HG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020300; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Counoupas C, 2019, EXPERT REV VACCINES, V18, P353, DOI 10.1080/14760584.2019.1585246; D'Souza S, 2003, INFECT IMMUN, V71, P483, DOI 10.1128/IAI.71.1.483-493.2003; Dadaglio G, 2002, J IMMUNOL, V168, P2219, DOI 10.4049/jimmunol.168.5.2219; Dai GX, 2016, VACCINE, V34, P6267, DOI 10.1016/j.vaccine.2016.10.065; Dakic A, 2004, J IMMUNOL, V172, P1018, DOI 10.4049/jimmunol.172.2.1018; Dalmia N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136635; Dalmia N, 2012, EXPERT REV VACCINES, V11, P1221, DOI [10.1586/erv.12.94, 10.1586/ERV.12.94]; Darrah PA, 2020, NATURE, V577, P95, DOI 10.1038/s41586-019-1817-8; Darrah PA, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0113-9; Goodridge HS, 2016, NAT REV IMMUNOL, V16, P392, DOI 10.1038/nri.2016.43; Goonetilleke NP, 2003, J IMMUNOL, V171, P1602, DOI 10.4049/jimmunol.171.3.1602; Gopal R, 2012, EUR J IMMUNOL, V42, P364, DOI 10.1002/eji.201141569; Hansen SG, 2018, NAT MED, V24, P130, DOI 10.1038/nm.4473; Hussey GD, 2002, IMMUNOLOGY, V105, P314, DOI 10.1046/j.1365-2567.2002.01366.x; Joosten SA, 2018, J CLIN INVEST, V128, P1837, DOI 10.1172/JCI97508; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628; Lund N, 2015, CLIN INFECT DIS, V61, P1504, DOI 10.1093/cid/civ617; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Mateen FJ, 2013, VACCINE, V31, P2517, DOI 10.1016/j.vaccine.2012.06.020; McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]; Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006; Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282; Ota MOC, 2004, VACCINE, V22, P511, DOI 10.1016/j.vaccine.2003.07.020; Pathan AA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001052; Radosevic K, 2007, INFECT IMMUN, V75, P4105, DOI 10.1128/IAI.00004-07; Rady HF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148701; Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0; Satti I, 2014, LANCET INFECT DIS, V14, P939, DOI 10.1016/S1473-3099(14)70845-X; Scriba TJ, 2011, J INFECT DIS, V203, P1832, DOI 10.1093/infdis/jir195; Stylianou E, 2015, VACCINE, V33, P6800, DOI 10.1016/j.vaccine.2015.10.017; Tameris M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087340; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4; Thomas ZRM, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002790; Thysen SM, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035595; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Umemura M, 2007, J IMMUNOL, V178, P3786, DOI 10.4049/jimmunol.178.6.3786; Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1; Williams A, 2005, INFECT IMMUN, V73, P3814, DOI 10.1128/IAI.73.6.3814-3816.2005; Wood N, 2018, JAMA PEDIATR, V172, P1045, DOI 10.1001/jamapediatrics.2018.2349; World Health Organization, 2020, GLOBAL TUBERCULOSIS; Wozniak TM, 2010, INFECT IMMUN, V78, P4187, DOI 10.1128/IAI.01392-09; Wyatt Linda S, 2017, Curr Protoc Protein Sci, V89, DOI 10.1002/cpps.33	50	0	0	4	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 19	2021	39	12					1780	1787		10.1016/j.vaccine.2021.01.071		MAR 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QX3ZD	33632562	Green Accepted			2022-04-29	WOS:000629283700016
J	Marin-Lopez, A; Wang, YC; Jiang, JJ; Ledizet, M; Fikrig, E				Marin-Lopez, Alejandro; Wang, Yuchen; Jiang, Junjun; Ledizet, Michel; Fikrig, Erol			AgBR1 and NeSt1 antisera protect mice from Aedes aegypti-borne Zika infection	VACCINE			English	Article						ZIKV; Vaccine; Aedes aegypti; Salivary protein		Zika virus (ZIKV) is primarily spread by Aedes. aegypti mosquitoes. Infection with ZIKV can result in diverse clinical symptoms in humans, ranging from mild to severe. Previously, we demonstrated that passive immunization against A. aegypti AgBR1 or NeSt1 antiserum, two mosquito saliva proteins that are transmitted with the virus, conferred partial protection against ZIKV in mice. Each individual antiserum altered the early host response in the skin and reduced viremia. Here, we show that passive immunization with a combination of AgBR1- and NeSt1-specific antibodies enhanced survival and reduced the viral burden in blood, thereby protecting mice from mosquito-borne ZIKV infection. This finding suggests that targeting a combination of mosquito saliva proteins, with AgBR1 and NeSt1 as model antigens, may be used as a vaccine strategy to help prevent mosquito-borne ZIKV infection. (C) 2021 Elsevier Ltd. All rights reserved.	[Marin-Lopez, Alejandro; Wang, Yuchen; Jiang, Junjun; Fikrig, Erol] Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis, New Haven, CT 06510 USA; [Wang, Yuchen] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Hubei, Peoples R China; [Jiang, Junjun] Guangxi Med Univ, Sch Publ Hlth, Nanning 530021, Guangxi, Peoples R China; [Ledizet, Michel] L2 Diagnost LLC, New Haven, CT USA; [Fikrig, Erol] Howard Hughes Med Inst, Chevy Chase, MD USA		Marin-Lopez, A; Wang, YC (通讯作者)，Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis, New Haven, CT 06510 USA.	alejandro.marinlopez@yale.edu; wangyuchener@whu.edu.cn; junjun.jiang@yale.edu; mledizet@L2dx.com; erol.fikrig@yale.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI089992, AI127865, AI152904]; China Scholarship CouncilChina Scholarship Council [201806270109]; Guangxi Bagui Scholar; Howard Hughes Medical InstituteHoward Hughes Medical Institute	This work was supported by NIH grant AI089992, AI127865 and AI152904. Y.W. is supported by China Scholarship Council (No.201806270109). J.J. is supported by Guangxi Bagui Scholar. E. F. is an investigator supported by the Howard Hughes Medical Institute.	Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI [10.1371/journal.pntd.0004750, 10.1371/journal.pntd.0004682]; Anguita J, 2002, IMMUNITY, V16, P849, DOI 10.1016/S1074-7613(02)00325-4; Collin N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000441; Colpitts TM, 2012, CLIN MICROBIOL REV, V25, P635, DOI 10.1128/CMR.00045-12; Conway MJ, 2014, J VIROL, V88, P164, DOI 10.1128/JVI.02235-13; Dai JF, 2009, CELL HOST MICROBE, V6, P482, DOI 10.1016/j.chom.2009.10.006; DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4; Donovan MJ, 2007, INFECT IMMUN, V75, P2523, DOI 10.1128/IAI.01928-06; Dragovic SM, 2018, CELL HOST MICROBE, V23, P523, DOI 10.1016/j.chom.2018.03.008; Gomes R, 2008, P NATL ACAD SCI USA, V105, P7845, DOI 10.1073/pnas.0712153105; Grard G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002681; Hastings AK, 2019, J VIROL, V93, DOI 10.1128/JVI.00395-19; Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442; Huang YJS, 2014, VIRUSES-BASEL, V6, P4703, DOI 10.3390/v6114703; Jiang J, 2020, VACCINES BASEL, V8; Jin L, 2018, NAT IMMUNOL, V19, P342, DOI 10.1038/s41590-018-0063-9; Kraemer MUG, 2015, SCI DATA, V2, DOI 10.1038/sdata.2015.35; Manning JE, 2018, J INFECT DIS, V218, P7, DOI 10.1093/infdis/jiy179; MARCHETTE NJ, 1969, AM J TROP MED HYG, V18, P411, DOI 10.4269/ajtmh.1969.18.411; Nuttall PA, 2000, J MOL MICROB BIOTECH, V2, P381; Olds CL, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1774-0; Oliveira F, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3043; Pingen M, 2016, IMMUNITY, V44, P1455, DOI 10.1016/j.immuni.2016.06.002; Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338; Schneider BS, 2008, T ROY SOC TROP MED H, V102, P400, DOI 10.1016/j.trstmh.2008.01.024; Schneider BS, 2006, VIRAL IMMUNOL, V19, P74, DOI 10.1089/vim.2006.19.74; Sun P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14115-z; Uraki R, 2019, NAT MICROBIOL; Uraki R, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0120-x; Uraki R, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006350; Yu X, 2019, TRENDS PARASITOL	31	0	0	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 19	2021	39	12					1675	1679		10.1016/j.vaccine.2021.01.072		MAR 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QX3ZD	33622591	Green Accepted			2022-04-29	WOS:000629283700003
J	Bonanni, P; Angelillo, IF; Villani, A; Biasci, P; Scotti, S; Russo, R; Maio, T; Rosati, GV; Barretta, M; Bozzola, E; Castiglia, P; Chiamenti, G; Conforti, G; Conversano, M; Ferro, A; Francia, F; Macri, PG; Azzari, C				Bonanni, P.; Angelillo, I. F.; Villani, A.; Biasci, P.; Scotti, S.; Russo, R.; Maio, T.; Rosati, G. Vitali; Barretta, M.; Bozzola, E.; Castiglia, P.; Chiamenti, G.; Conforti, G.; Conversano, M.; Ferro, A.; Francia, F.; Macri, P. G.; Azzari, C.			Maintain and increase vaccination coverage in children, adolescents, adults and elderly people: Let's avoid adding epidemics to the pandemic: Appeal from the Board of the Vaccination Calendar for Life in Italy: Maintain and increase coverage also by re-organizing vaccination services and reassuring the population	VACCINE			English	Editorial Material						Vaccination; Coverage; COVID-19; Organization; Children; Adolescent; Adult immunization	IMMUNIZATION	The Board of the Vaccination Calendar for Life (Bonanni et al., 2014, 2017) [1,2]), a coalition of four major scientific and professional societies of public health physicians, pediatricians and general practitioners in Italy, made an appeal to health authorities in order to sustain vaccination in COVID-19 times. The five pillars to maintain and increase vaccination coverage at all ages are described as follows: 1) Guarantee paediatric vaccination coverage to all newborns and paediatric boosters and adolescent immunizations, not interrupting active calls and scheduled sessions. 2) Re-organise the way paediatric and adolescent vaccinations are offered. 3) Set-up recovery programs for vaccinations not carried out after the start of the COVID-19 emergency. 4) Provide the preparation of tenders for the supply of flu vaccines with suitable quantities to increase coverage in all Regions and Autonomous Provinces with extreme urgency. 5) Prepare plans to increase coverage for influenza, pneumococcal, tetanus diphtheria and shingles. The Board of the Calendar for Life appeals to the National and Local Health Authorities for a strong and coordinated commitment in favor of the widest offer and acceptance of vaccinations, whose vital importance for collective health is now even more evident to all, in order to avoid that delays in the necessary initiatives should add damage from other epidemics to those suffered by our population due to the COVID-19 pandemic. (C) 2020 Elsevier Ltd. All rights reserved.	[Bonanni, P.; Angelillo, I. F.; Castiglia, P.; Conversano, M.; Ferro, A.; Francia, F.] Italian Soc Hyg Prevent Med & Publ Hlth SItI, Turin, Italy; [Villani, A.; Russo, R.; Bozzola, E.; Azzari, C.] Italian Soc Paediat SIP, Cosenza, Italy; [Scotti, S.; Maio, T.] Italian Federat Gen Practitioners FIMMG, Rome, Italy; [Biasci, P.; Rosati, G. Vitali; Barretta, M.; Chiamenti, G.; Conforti, G.] Italian Federat Primary Care Paeditaricians FIMP, Bari, Italy; [Macri, P. G.] MeLCo Med Legale Contemporanea, Rome, Italy		Bonanni, P (通讯作者)，Univ Florence, Dept Hlth Sci, Viale GB Morgagni 48, Florence, Italy.	paolo.bonanni@unifi.it	Angelillo, Italo Francesco/AAK-1301-2021	Angelillo, Italo Francesco/0000-0003-1213-6602; bozzola, elena/0000-0001-5947-2414; Bonanni, Paolo/0000-0003-2875-3744			Abbas K, 2020, LANCET GLOB HEALTH, V8, pE1264, DOI [10.1016/S2214-109X(20)30308-9, 10.1016/52214-109X(20)30308-9]; Bechini A, 2020, J Prev Med Hyg, V61, pE125, DOI 10.15167/2421-4248/jpmh2020.61.2.1626; Bonanni P, 2018, EXPERT REV VACCINES, V17, P103, DOI 10.1080/14760584.2018.1419069; Bonanni P, 2017, HUM VACC IMMUNOTHER, V13, P2531, DOI 10.1080/21645515.2017.1366394; Bonanni Paolo, 2014, Epidemiol Prev, V38, P131; Bramer CA, 2020, MMWR-MORBID MORTAL W, V69, P630, DOI 10.15585/mmwr.mm6920e1; Dinleyici EC, 2021, HUM VACC IMMUNOTHER, V17, P400, DOI 10.1080/21645515.2020.1804776; Matrajt Laura, 2020, medRxiv, DOI 10.1101/2020.08.14.20175257; World Health Organization, 2020, REG OFF EUR GUID ROU	9	10	10	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1187	1189		10.1016/j.vaccine.2020.10.024		FEB 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33309482	Green Published, Bronze			2022-04-29	WOS:000618493500006
J	Nunes, AA; De Abreu, ADL; Cintra, O; Cintra, MACT; Coelho, EB; De Barros, ENC				Nunes, Altacilio Aparecido; Lopes De Abreu, Ariane De Jesus; Cintra, Otavio; Cintra, Monica A. C. T.; Coelho, Eduardo Barbosa; Castro De Barros, Eliana Nogueira			Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination	VACCINE			English	Article						Meningococcus; Meningococcal disease; Meningitis; Neisseria meningitidis; Vaccine; Epidemiology; Brazil; Meningococcemia	C CONJUGATE VACCINATION; NEISSERIA-MENINGITIDIS; SAO-PAULO; ADOLESCENTS; PREVALENCE; CARRIAGE; CHILDREN; SALVADOR; PROGRAM	Background: Meningococcal disease (MD) presents a substantial public health problem in Brazil. Meningococcal C conjugate (MenC) vaccination was introduced into the routine infant immunization program in 2010, followed by adolescent vaccination in 2017. We evaluated changes in national and regional MD incidence and mortality between 2005 and 2018, serogroup distribution and vaccine coverage. Methods: Data were obtained from national surveillance systems from 2005 to 2018. Age-stratified incidence and mortality rates were calculated and a descriptive time-series analysis was performed comparing rates in the pre-(2005-2009) and post-vaccination (2011-2018) periods; MDdue to specific meningococcal serogroups were analyzed in the pre-(2007-2009) and post-vaccination (2011-2018) periods. Results: From 2005 to 2018, 31,108 MD cases were reported with 6496 deaths; 35% of cases and deaths occurred in children < 5 years. Incidence and mortality rates declined steadily since 2012 in all agestrata, with significantly lower incidence and mortality in the post-vaccine introduction period in children aged < 1-year, 1-4 years, 5-9 years and 10-14 years. A significant decline in MenC disease in children < 5 years was observed following MenC vaccine introduction; infants < 1 year, from 3.30/100,000 (2007-2009) to 1.08/100,000 (2011-2018) and from 1.44/100,000 to 0.42/100,000 in 1-4 year-olds for these periods. Reductions in MenB disease was also observed. MenW remains an important cause ofMD with 748 cases reported across 2005-2018. While initial infant vaccination coverage was high (>95% nationwide), this has since declined (to 83% in 2018); adolescent uptake was < 20% in 2017/18). Regional variations in outcomes and vaccine coverage were observed. Conclusion: A substantial decline in incidence and mortality rates due toMDwas seen following MenC vaccine introduction in Brazil, especially among children < 5 years chiefly driven by reductions in MenC serogroup. While these benefits are considerable, the prevalence of MD due to other serogroups such as MenW and MenB remains a concern. A video summary linked to this article can be found on Figshare: https://doi.org/10.6084/m9.figshare.13379612.v1 (C) 2020 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the CC BY license	[Nunes, Altacilio Aparecido; Cintra, Monica A. C. T.; Coelho, Eduardo Barbosa] Univ Sao Paulo, Ribeirao Preto Med Sch, Ribeirao Preto, SP, Brazil; [Lopes De Abreu, Ariane De Jesus] Inst Nacl Cardiol, Rio De Janeiro, RJ, Brazil; [Cintra, Otavio] GSK, Wavre, Belgium; [Castro De Barros, Eliana Nogueira] GSK, Rio De Janeiro, RJ, Brazil		Cintra, O (通讯作者)，GSK, Wavre, Belgium.	oacintra@uol.com.br	; Coelho, Eduardo Barbosa/G-3463-2012	Abreu, Ariane/0000-0002-5599-0991; Coelho, Eduardo Barbosa/0000-0003-3491-3396	GlaxoSmithKline Biologicals SAGlaxoSmithKline [HO-16-18041]	GlaxoSmithKline Biologicals SA funded this study (GSK Study identifier: HO-16-18041) and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also covered all costs associated with the development and publication of this manuscript.	Andrade AL, 2017, VACCINE, V35, P2025, DOI 10.1016/j.vaccine.2017.03.010; Azevedo AC, 2020, INFECT GENET EVOL, V78, DOI 10.1016/j.meegid.2019.104079; Barroso DE, 2013, EMERG INFECT DIS, V19, P1847, DOI [10.3201/eid1911.130610, 10.3201/13-0610]; Batista RS, 2017, ASIAN PAC J TROP MED, V10, P1019, DOI 10.1016/j.apjtm.2017.10.004; Bettinger JA, 2009, PEDIATR INFECT DIS J, V28, P220, DOI 10.1097/INF.0b013e31819040e7; Bierrenbach AL, 2018, HUM VACC IMMUNOTHER, V14, P1138, DOI 10.1080/21645515.2017.1391431; Booy R, 2019, HUM VACC IMMUNOTHER, V15, P470, DOI 10.1080/21645515.2018.1532248; Borrow R, 2017, EXPERT REV VACCINES, V16, P313, DOI 10.1080/14760584.2017.1258308; Borrow R, 2013, VACCINE, V31, P4477, DOI 10.1016/j.vaccine.2013.07.083; Brasil Ministerio da Saude Secretaria de Vigilancia em Saude, 2018, INF TECN AMPL OF VAC; Brazil. DATASUS, INF SAUD TABN; Campbell H, 2009, VACCINE, V27, pB20, DOI 10.1016/j.vaccine.2009.04.067; Cardoso CW, 2012, VACCINE, V30, P5541, DOI 10.1016/j.vaccine.2012.06.044; Cohn AC, 2010, CLIN INFECT DIS, V50, P184, DOI 10.1086/649209; Cordeiro SM, 2018, MICROBES INFECT, V20, P19, DOI 10.1016/j.micinf.2017.09.010; Crum-Cianflone N, 2016, INFECT DIS THER, V5, P89, DOI 10.1007/s40121-016-0107-0; de Moraes C, 2017, MEM I OSWALDO CRUZ, V112, P237, DOI 10.1590/0074-02760160173; de Moraes JC, 2015, PEDIATR INFECT DIS J, V34, P1197, DOI 10.1097/INF.0000000000000853; Chicuto LAD, 2020, HUM VACC IMMUNOTHER, V16, P1945, DOI 10.1080/21645515.2019.1700710; do Macedo LE, 2018, HUM VACC IMMUNOTHER, V14, P1131, DOI 10.1080/21645515.2017.1415682; Estado de Santa Catarina, 2021, B EP 01 2019 VIG DOE, V39, P605; Feijo RB, 2020, BRAZ J INFECT DIS, V24, P349, DOI 10.1016/j.bjid.2020.06.007; Gabutti G, 2015, J Prev Med Hyg, V56, pE116; Gentile A., 2018, REV HOSP NINOS B AIR, V60, P42; Gorla MC, 2020, ACCESS MICROBIOL, V2; Harrison Lee H, 2011, Vaccine, V29, P3363, DOI 10.1016/j.vaccine.2011.02.058; IBGE, BRAZ DEM CENS BRAZ P; Krone M, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.14.1800245; Ladhani SN, 2012, VACCINE, V30, P3710, DOI 10.1016/j.vaccine.2012.03.011; Lahra MM, 2017, COMMUN DIS INTELL, V41, pE369; MacNeil JR, 2015, PEDIATRICS, V135, pE305, DOI 10.1542/peds.2014-2035; Emmerick ICM, 2014, EPIDEMIOL SERV SAUDE, V23, P215, DOI 10.5123/S1679-49742014000200003; Ministerio da Saude (BR), GUIA VIGILANCIA EPID; Ministerio da Saude Brasil, 2020, VAC MEN ACWY CONJ AD; Ministerio da Saude Brasil, NOT INF MUD CAL NAC; Ministerio da Saude Brasil. Departamento de Vigilancia Epidemiologica Coordenacao Geral do Programa Nacional de Imunizacoes, 2010, INTR VAC C CONJ CAL; Organizacao Mundial da Saude-OMS, 2009, CID 10 CLASSIFICACAO; Pace D, 2012, VACCINE, V30, pB3, DOI 10.1016/j.vaccine.2011.12.062; Parikh SR, 2020, J INFECTION, V81, P483, DOI 10.1016/j.jinf.2020.05.079; Pelton SI, 2016, J ADOLESCENT HEALTH, V59, pS3, DOI 10.1016/j.jadohealth.2016.04.012; Nunes AMPB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166475; Azevedo LCP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064524; Presa JV, 2019, INT J INFECT DIS, V80, P137, DOI 10.1016/j.ijid.2019.01.009; Ribeiro IG, 2019, EPIDEMIOL SERV SAUDE, V28, DOI [10.5123/S1679-49742019000300009, 10.5123/s1679-49742019000300009]; Ruttimann RW, 2014, PEDIATR INFECT DIS J, V33, P284, DOI 10.1097/INF.0000000000000228; Sadarangani M, 2014, CLIN INFECT DIS, V59, P1208, DOI 10.1093/cid/ciu597; Safadi MAP, 2017, REV PANAM SALUD PUBL, V41, DOI 10.26633/RPSP.2017.118; Safadi MAP, 2015, VACCINE, V33, P6529, DOI 10.1016/j.vaccine.2015.10.055; Safadi Marco Aurelio P, 2014, J Pediatric Infect Dis Soc, V3, P91, DOI 10.1093/jpids/piu027; de Lemos APS, 2007, J CLIN MICROBIOL, V45, P1266, DOI 10.1128/JCM.02510-06; Tauil MD, 2014, BRAZ J INFECT DIS, V18, P379, DOI 10.1016/j.bjid.2013.11.012; Vetter V, 2016, EXPERT REV VACCINES, V15, P641, DOI 10.1586/14760584.2016.1130628; Villena R, 2019, VACCINE, V37, P6915, DOI 10.1016/j.vaccine.2019.09.050; Weckx LY, 2017, BRAZ J INFECT DIS, V21, P587, DOI 10.1016/j.bjid.2017.06.005; Weidlich L, 2008, J INFECTION, V57, P324, DOI 10.1016/j.jinf.2008.07.014; Whittaker R, 2017, VACCINE, V35, P2034, DOI 10.1016/j.vaccine.2017.03.007	56	6	6	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 15	2021	39	3					605	616		10.1016/j.vaccine.2020.11.067			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VN	33358262	hybrid			2022-04-29	WOS:000604750400021
J	Eze, P; Aniebo, CL; Agu, UJ; Agu, SA; Acharya, Y				Eze, Paul; Aniebo, Chioma Lynda; Agu, Ujunwa Justina; Agu, Sergius Alex; Acharya, Yubraj			Validity of maternal recall for estimating childhood vaccination coverage-Evidence from Nigeria	VACCINE			English	Article						Childhood immunization; Parental recall; Recall bias; Vaccination cards; Nigeria	CARDS	Background: Vaccination coverage surveys in low-and middle-income countries typically estimate vaccination coverage using data from vaccination cards, parental recall, or a combination of the two. However, these surveys are often complicated by the pervasive absence of vaccination cards, forcing researchers to rely on parental recall. We assessed the validity of mothers' recall against home-based vaccination cards using data from a community-based household survey in Nigeria. Methods: A cross-sectional survey of 1,254 mothers of children aged 12-23 months was performed in Enugu State, Nigeria in July 2020. Data on vaccination status for BCG, OPV, DPT, Measles, Yellow fever, and Vitamin A supplement were collected using two data sources: home-based vaccination cards and mothers' recall. We evaluated the level of agreement between the two data sources; estimated the sensitivity and specificity of mothers' recalls; and computed multivariable regression models to identify socio-demographic factors associated with mothers' recall bias. Results: Out of 1,254 mothers interviewed, 578 (46.1%) mothers with vaccination cards were included in this analysis. Vaccination coverage levels were generally similar across data sources, though recall-based data generally underestimated the coverage. The level of agreement between the two data sources was high (>91.0% for all vaccine types) with recall bias due to under-reporting generally higher than recall bias due to over-reporting. The sensitivity of parental recalls was high for all vaccine types, while the specificity was low across vaccine types. Across all vaccines, mothers recall bias was significantly associated with the rural residence and not receiving postnatal care. Conclusion: In the absence of vaccination cards, mothers' recall of their children' vaccination status for BCG, OPV, DPT, Measles, Yellow fever and Vitamin A is a valid instrument for estimating childhood vaccination coverage in this setting in Nigeria. However, additional research is needed to confirm these findings at higher sub-national and national levels. (c) 2021 Elsevier Ltd. All rights reserved.	[Eze, Paul; Acharya, Yubraj] Penn State Univ, Dept Hlth Policy & Adm, University Pk, PA 16802 USA; [Aniebo, Chioma Lynda; Agu, Ujunwa Justina] Enugu State Univ Teaching Hosp, Dept Paediat, Parklane, Enugu, Nigeria; [Agu, Sergius Alex] Univ Nigeria Teaching Hosp, Dept Paediat, Ituku Ozalla, Enugu, Nigeria		Eze, P (通讯作者)，Penn State Univ, Dept Hlth Policy & Adm, University Pk, PA 16802 USA.	peze@psu.edu; yua36@psu.edu					Anichukwu OI, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026324; Binyaruka P, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3270-z; BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V; Chard AN, 2020, MMWR-MORBID MORTAL W, V69, P1706, DOI 10.15585/mmwr.mm6945a7; Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053; Cutts FT, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001404; Dansereau E, 2020, GATES OPEN RES, P1; Eze P, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-047445; Eze P, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09958-x; George K, 1990, Indian J Pediatr, V57, P588, DOI 10.1007/BF02726779; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Hu Y, 2019, VALIDITY MATERNAL RE; Kabore L, 2020, VACCINE, V38, P2808, DOI 10.1016/j.vaccine.2020.02.023; Kiely M, 2020, VACCINE, V38, P1202, DOI 10.1016/j.vaccine.2019.11.014; Liu G, 2016, ACCURACY PARENT REPO, V4, P7; Luman ET, 2009, VACCINE, V27, P2534, DOI 10.1016/j.vaccine.2008.10.002; MACLURE M, 1987, AM J EPIDEMIOL, V126, P161, DOI 10.1093/aje/126.2.161; Mansour Z, 2019, VACCINE, V37, P4177, DOI 10.1016/j.vaccine.2019.05.032; Miles M, 2013, VACCINE, V31, P1560, DOI 10.1016/j.vaccine.2012.10.089; Murhekar MV, 2017, INDIAN J MED RES, V145, P377, DOI 10.4103/ijmr.IJMR_1666_15; National Population Commission National Bureau of Statistics, 2016, NAT STAT LOC GOV POP; National Population Commission (NPC) [Nigeria] and ICF, 2019, NIGERIA DEMOGRAPHIC; National Primary Healthcare Development Agency (NPHCDA), 2018, NAT IMM SCHED NIG; Odusanya OO, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-381; Oku A, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4020-6; Orenstein WA, 2017, P NATL ACAD SCI USA, V114, P4031, DOI 10.1073/pnas.1704507114; Piot P, 2019, NATURE, V575, P119, DOI 10.1038/s41586-019-1656-7; Porth JM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020048; Remy Vanessa, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27041; Selimuzzaman A, 2008, TAJ J TEACH ASS, V21, P40; Seror V, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08792-5; Viera AJ, 2005, FAM MED, V37, P360; von Elm E, 2007, EPIDEMIOLOGY, V18, P800, DOI 10.1097/EDE.0b013e3181577654; Wagner AL, 2019, HUM VACC IMMUNOTHER, V15, P2844, DOI 10.1080/21645515.2019.1625647; WHO, 2019, IMM AG 2030 GLOB STR; Wilson R, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6655-y; World Health Organization, 2018, WHO VACC COV CLUST; World Health Organization, 2020, FACT SHEETS	38	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					28	36		10.1016/j.vaccine.2021.11.060		DEC 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FV	34863616				2022-04-29	WOS:000731299800008
J	Soma, S; Lewinsohn, DA; Lewinsohn, DM				Soma, Shogo; Lewinsohn, Deborah A.; Lewinsohn, David M.			Donor Unrestricted T Cells: Linking innate and adaptive immunity	VACCINE			English	Article						BCG; Donor Unrestricted T cell; MR1; CD1; Gamma Delta; HLA-E	MYCOBACTERIUM-TUBERCULOSIS INFECTION; HLA-E; ANTIGEN; VACCINE; MR1; EXPRESSION; SUBSET; HETEROGENEITY; POLYMORPHISM; ACTIVATION	Donor Unrestricted T Cells (DURTs) are characterized by their use of antigen presentation molecules that are often invariant. As these cells recognize diverse mycobacterial antigens, often found in BCG, these cells have the potential to either serve as targets for vaccination, or as a means to enable the induction of traditional T and B cell immunity. Here, we will review specific DURT family members, and their relationship to BCG. (c) 2021 Published by Elsevier Ltd.	[Soma, Shogo] Oregon Hlth & Sci Univ, Dept Med, Pulm & Crit Care Med, Portland, OR 97239 USA; [Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Infect Dis, Portland, OR 97239 USA; [Lewinsohn, David M.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA		Lewinsohn, DM (通讯作者)，Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA.	lewinsod@ohsu.edu		Soma, Shogo/0000-0002-7990-8403	NIH NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI134790, AI129980]; Bill & Melinda Gates Founda-tionBill & Melinda Gates FoundationCGIAR [INV-01899]; NIH NIAIDBAA-NIAID-NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI201700104]; VA Merit ReviewUS Department of Veterans Affairs [2I01BX000533]	For Dr. Soma: NIH NIAID AI134790 For Dr. Deborah Lewinsohn: NIH NIAID AI129980 For Dr. David Lewinsohn: VA Merit Review 2I01BX000533; NIH NIAID AI134790; NIH NIAID AI129980; NIH NIAIDBAA-NIAID-NIH AI201700104; Bill & Melinda Gates Founda-tion INV-01899.T	Adams EJ, 2014, CURR OPIN IMMUNOL, V26, P1, DOI 10.1016/j.coi.2013.09.005; [Anonymous], 2020, GLOBAL TUBERCULOSIS; Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369; Chua WJ, 2012, INFECT IMMUN, V80, P3256, DOI 10.1128/IAI.00279-12; Darrah PA, 2020, NATURE, V577, P95, DOI 10.1038/s41586-019-1817-8; Dascher CC, 2003, INT IMMUNOL, V15, P915, DOI 10.1093/intimm/dxg091; De Libero G, 2014, FRONT IMMUNOL, V5, DOI [10.3389/fimmu.2014.00219, 10.3389/fimmu.2014.00679]; De P, 2018, J BIOL CHEM, V293, P9706, DOI 10.1074/jbc.RA118.002582; Dijkman K, 2019, NAT MED, V25, P255, DOI 10.1038/s41591-018-0319-9; Downey AM, 2019, FEBS LETT, V593, P1627, DOI 10.1002/1873-3468.13488; Gherardin NA, 2018, IMMUNOL CELL BIOL, V96, P507, DOI 10.1111/imcb.12021; Gherardin NA, 2016, IMMUNITY, V44, P32, DOI 10.1016/j.immuni.2015.12.005; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Gold MC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000407; Gong JH, 1998, J CLIN INVEST, V101, P383, DOI 10.1172/JCI318; Grotzke JE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000374; Gutierrez-Arcelus M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08604-4; Harriff MJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao2556; Heinzel AS, 2002, J EXP MED, V196, P1473, DOI 10.1084/jem.20020609; Hinks TSC, 2016, AM J RESP CRIT CARE, V194, P1208, DOI 10.1164/rccm.201601-0002OC; Hoft DF, 2018, MUCOSAL IMMUNOL, V11, P486, DOI 10.1038/mi.2017.67; Hoft DF, 1998, J IMMUNOL, V161, P1045; Howson LJ, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc9492; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; Joosten SA, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/2695396; Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605; Kwon YS, 2015, TUBERCULOSIS, V95, P267, DOI 10.1016/j.tube.2015.03.004; Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890; Lepore M, 2017, ELIFE, V6, DOI 10.7554/eLife.24476; Lewinsohn DM, 2006, J IMMUNOL, V177, P437, DOI 10.4049/jimmunol.177.1.437; Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862; Lopez K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00199; McMurtrey C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188288; Montamat-Sicotte DJ, 2011, J CLIN INVEST, V121, P2493, DOI 10.1172/JCI46216; MORITA M, 1995, J MED CHEM, V38, P2176, DOI 10.1021/jm00012a018; Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]; Ogg G, 2019, CURR OPIN IMMUNOL, V59, P121, DOI 10.1016/j.coi.2019.07.006; Olieslagers TI, 2017, HLA, V89, P143, DOI 10.1111/tan.12965; Pincikova T, 2018, CHEST, V153, pE93, DOI 10.1016/j.chest.2018.01.020; Pinheiro MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050923; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; Qaqish A, 2017, J IMMUNOL, V198, P4753, DOI 10.4049/jimmunol.1602019; Rahimpour A, 2015, J EXP MED, V212, P1095, DOI 10.1084/jem.20142110; Rakshit S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130540; Ravens S, 2020, P NATL ACAD SCI USA, V117, P18649, DOI 10.1073/pnas.1922588117; Reantragoon R, 2013, J EXP MED, V210, P2305, DOI 10.1084/jem.20130958; Rigau M, 2020, SCIENCE, V367, P642, DOI 10.1126/science.aay5516; Ruibal P, 2021, IMMUNOL REV, V301, P30, DOI 10.1111/imr.12948; Sakai S, 2021, MUCOSAL IMMUNOL, V14, P199, DOI 10.1038/s41385-020-0332-4; Sakala IG, 2015, J IMMUNOL, V195, P587, DOI 10.4049/jimmunol.1402545; Sandstrom A, 2014, IMMUNITY, V40, P490, DOI 10.1016/j.immuni.2014.03.003; Seshadri C, 2017, GENES IMMUN, V18, P8, DOI 10.1038/gene.2016.41; Sharma PK, 2015, IMMUNOLOGY, V145, P443, DOI 10.1111/imm.12461; Spencer CT, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003119; Suliman S, 2020, J INFECT DIS, V222, P995, DOI 10.1093/infdis/jiaa173; Suliman S, 2019, J IMMUNOL, V203, P2917, DOI 10.4049/jimmunol.1900674; Tilloy F, 1999, J EXP MED, V189, P1907, DOI 10.1084/jem.189.12.1907; van Meijgaarden KE, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004671; Van Rhijn I, 2015, J IMMUNOL, V195, P1927, DOI 10.4049/jimmunol.1500943; Van Rhijn I, 2014, J IMMUNOL, V192, P4054, DOI 10.4049/jimmunol.1400158; Van Rhijn I, 2013, NAT IMMUNOL, V14, P706, DOI 10.1038/ni.2630; Venkataswamy MM, 2009, J IMMUNOL, V183, P1644, DOI 10.4049/jimmunol.0900858; Vermijlen D, 2018, SEMIN CELL DEV BIOL, V84, P75, DOI 10.1016/j.semcdb.2017.10.009; Vorkas CK, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00524-20; Watanabe Y, 2006, VACCINE, V24, P5700, DOI 10.1016/j.vaccine.2006.04.049; Wong EB, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0442-2; Xia M, 2016, INFECT IMMUN, V84, P2449, DOI 10.1128/IAI.01322-15; Yu HF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70615-9; Zhao J, 2015, ELIFE, P4; Zheng J, 2013, CELL MOL IMMUNOL, V10, P50, DOI 10.1038/cmi.2012.43	70	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 8	2021	39	50					7295	7299		10.1016/j.vaccine.2021.10.044		DEC 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK8NB	34740474	Bronze			2022-04-29	WOS:000727714000009
J	Cuevas-Juarez, E; Pando-Robles, V; Palomares, LA				Cuevas-Juarez, Esmeralda; Pando-Robles, Victoria; Palomares, Laura A.			Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives	VACCINE			English	Review						Flavivirus vaccines; Virus-like particles; Single-round infectious particles; Vaccine design; Vaccine production	JAPANESE ENCEPHALITIS-VIRUS; TICK-BORNE ENCEPHALITIS; T-CELL RESPONSES; ANTIBODY-DEPENDENT ENHANCEMENT; NUCLEOCAPSID-LIKE PARTICLES; YELLOW-FEVER VACCINE; DENGUE VIRUS; ZIKA VIRUS; WEST-NILE; ENVELOPE GLYCOPROTEIN	The genus flavivirus of the Flaviridae family includes several human pathogens, like dengue, Zika, Japanese encephalitis, and yellow fever virus. These viruses continue to be a significant threat to human health. Vaccination remains the most useful approach to reduce the impact of flavivirus fever. However, currently available vaccines can induce severe side effects or have low effectiveness. An alternative is the use of recombinant vaccines, of which virus-like particles (VLP) and single-round infectious particles (SRIP) are of especial interest. VLP consist of the virus structural proteins produced in a heterologous sys-tem that self-assemble in a structure almost identical to the native virus. They are highly immunogenic and have been effective vaccines for other viruses for over 30 years. SRIP are promising vaccine candi-dates, as they induce both cellular and humoral responses, as viral proteins are expressed. Here, the state of the art to produce both types of particles and their use as vaccines against flaviviruses are discussed. We summarize the different approaches used for the design and production of flavivirus VLP and SRIP, the evidence for their safety and efficacy, and the main challenges for their use as commercial vaccines. (c) 2021 Elsevier Ltd. All rights reserved.	[Cuevas-Juarez, Esmeralda; Palomares, Laura A.] Univ Nacl Autonoma Mexico, Dept Med Mol & Bioproc, Inst Biotecnol, Ave Univ 2001, Cuernavaca 62210, Morelos, Mexico; [Pando-Robles, Victoria] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Ave Univ 655, Cuernavaca 62100, Morelos, Mexico		Palomares, LA (通讯作者)，Univ Nacl Autonoma Mexico, Dept Med Mol & Bioproc, Inst Biotecnol, Ave Univ 2001, Cuernavaca 62210, Morelos, Mexico.	esmeralda.cuevas@ibt.unam.mx; victoria.pando@insp.mx; laura.palomares@ibt.unam.mx		PANDO-ROBLES, VICTORIA/0000-0002-9633-5627	UNAM-PAPIITPrograma de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico [IT-200521, IV-200820]; CONACyT scholarshipConsejo Nacional de Ciencia y Tecnologia (CONACyT)	This work was supported by UNAM-PAPIIT IT-200521 and IV-200820. ECJ is a graduate student in the Programa de Doctorado en Ciencias Bioquimicas and received a CONACyT scholarship.	Araujo SC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030492; Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365; de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2; Batchelor Patricia, 2015, Trop Dis Travel Med Vaccines, V1, P11, DOI 10.1186/s40794-015-0013-6; Bogovic P, 2015, WORLD J CLIN CASES, V3, P430, DOI 10.12998/wjcc.v3.i5.430; Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608; Breugelmans JG, 2013, VACCINE, V31, P1819, DOI 10.1016/j.vaccine.2013.01.054; Burchard GD, 2009, J TRAVEL MED, V16, P204, DOI 10.1111/j.1708-8305.2009.00330.x; Chang DC, 2008, NAT BIOTECHNOL, V26, P571, DOI 10.1038/nbt1400; Chang GJJ, 2003, VIROLOGY, V306, P170, DOI 10.1016/S0042-6822(02)00028-4; Charoensri N, 2014, J VIROL METHODS, V205, P116, DOI 10.1016/j.jviromet.2014.04.019; Co MDT, 2002, VIROLOGY, V293, P151, DOI 10.1006/viro.2001.1255; Collins ND, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0566-9; Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296; Daep CA, 2014, J NEUROVIROL, V20, P539, DOI 10.1007/s13365-014-0285-z; Dai SY, 2018, VIROL SIN, V33, P213, DOI 10.1007/s12250-018-0030-5; Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515; Fan YC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25596-1; Ferlenghi I, 2001, MOL CELL, V7, P593, DOI 10.1016/S1097-2765(01)00206-4; Fowler AM, 2018, CELL HOST MICROBE, V24, P743, DOI 10.1016/j.chom.2018.09.015; Gambino F, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109107; Garg H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61103-1; Garg H, 2019, VACCINE, V37, P7123, DOI 10.1016/j.vaccine.2019.09.093; Garg H, 2017, J VIROL, V91, DOI 10.1128/JVI.00834-17; Geerling E, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030477; Gehrke R, 2003, J VIROL, V77, P8924, DOI 10.1128/JVI.77.16.8924-8933.2003; George J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10901-1; Gil L, 2016, J IMMUNOL, V197, P3597, DOI 10.4049/jimmunol.1600927; Gil L, 2009, INT IMMUNOL, V21, P1175, DOI 10.1093/intimm/dxp082; Grubor-Bauk B, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2388; Guy B, 2011, VACCINE, V29, P7229, DOI 10.1016/j.vaccine.2011.06.094; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; Halstead SB, 2017, LANCET INFECT DIS, V17, pE378, DOI 10.1016/S1473-3099(17)30362-6; HEINZ FX, 1994, VIROLOGY, V198, P109, DOI 10.1006/viro.1994.1013; Hsieh SC, 2008, VIROLOGY, V374, P338, DOI 10.1016/j.virol.2007.12.041; Huang YT, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0181-8; Huang Y, 2012, J VIROL METHODS, V179, P217, DOI 10.1016/j.jviromet.2011.11.002; Hutter J, 2013, J IMMUNOL, V190, P220, DOI 10.4049/jimmunol.1201060; Ishikawa T, 2008, VACCINE, V26, P2772, DOI 10.1016/j.vaccine.2008.03.010; Kaiser JA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090823; Katzelnick LC, 2020, SCIENCE, V369, P1123, DOI 10.1126/science.abb6143; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Khetarpal N, 2017, AM J TROP MED HYG, V96, P126, DOI 10.4269/ajtmh.16-0503; Konishi E, 2002, VACCINE, V20, P1058, DOI 10.1016/S0264-410X(01)00446-7; KONISHI E, 1992, VIROLOGY, V188, P714, DOI 10.1016/0042-6822(92)90526-U; Konishi E, 2001, J VIROL, V75, P2204, DOI 10.1128/JVI.75.5.2204-2212.2001; Kubinski M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030451; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Kuwahara M, 2010, CLIN VACCINE IMMUNOL, V17, P1560, DOI 10.1128/CVI.00087-10; Liu WQ, 2010, VIRUS GENES, V40, P53, DOI 10.1007/s11262-009-0418-2; Liu Y., 2014, SCI WORLD J, P1, DOI 10.1186/s12866-014-0233-3; Lu CY, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040076; Mani S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064595; Martins RDM, 2014, VACCINE, V32, P6676, DOI 10.1016/j.vaccine.2014.05.003; Mason PW, 2006, VIROLOGY, V351, P432, DOI 10.1016/j.virol.2006.04.003; Matsuda M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34865-y; Matsuda S, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00286; McMahon AW, 2007, VACCINE, V25, P1727, DOI 10.1016/j.vaccine.2006.11.027; Merino-Ramos T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108056; Metz SW, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0970-2; Zurbia-Flores GM, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1895644; Neddermeyer AH, 2018, CURR THER RES CLIN E, V88, P8, DOI 10.1016/j.curtheres.2017.10.003; Nerome K, 2018, J GEN VIROL, V99, P897, DOI 10.1099/jgv.0.001081; NIH, CLINICALTRIALS GOV; Ohtaki N, 2010, VACCINE, V28, P6588, DOI 10.1016/j.vaccine.2010.07.055; Pierson TC, 2020, NAT MICROBIOL, V5, P796, DOI 10.1038/s41564-020-0714-0; Plevka P, 2011, EMBO REP, V12, P602, DOI 10.1038/embor.2011.75; Poddar A, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896-016-0280-y; Qiao M, 2004, J INFECT DIS, V190, P2104, DOI 10.1086/425933; Queiroz Sabrina Ribeiro de Almeida, 2018, Rev. Soc. Bras. Med. Trop., V51, P66, DOI 10.1590/0037-8682-0220-2017; Rajpoot RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26904-5; Rebollo B, 2018, DIAGN MICR INFEC DIS, V91, P233, DOI 10.1016/j.diagmicrobio.2018.02.003; Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12; Rumyantsev AA, 2013, P NATL ACAD SCI USA, V110, P13103, DOI 10.1073/pnas.1306245110; Rumyantsev AA, 2011, VACCINE, V29, P5184, DOI 10.1016/j.vaccine.2011.05.032; Salvo MA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006210; Shan C, 2018, J VIROL, V92, DOI 10.1128/JVI.01002-18; Shen W, 2018, EPITOPE RESURFACING, P1; Shukla R, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02644; Shustov AV, 2007, J VIROL, V81, P11737, DOI 10.1128/JVI.01112-07; Shustov AV, 2010, VIROLOGY, V400, P8, DOI 10.1016/j.virol.2009.12.015; Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316; Smit JM, 2011, VIRUSES-BASEL, V3, P160, DOI 10.3390/v3020160; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Suphatrakul A, 2015, VACCINE, V33, P5613, DOI 10.1016/j.vaccine.2015.08.090; Suzuki R, 2014, J GEN VIROL, V95, P60, DOI 10.1099/vir.0.058008-0; Suzuki R, 2009, J VIROL, V83, P1870, DOI 10.1128/JVI.01891-08; Takahashi H, 2009, MICROBES INFECT, V11, P1019, DOI 10.1016/j.micinf.2009.07.009; Tang YX, 2012, CHINESE MED J-PEKING, V125, P1986, DOI 10.3760/cma.j.issn.0366-6999.2012.11.027; Thomas RE, 2016, DRUG DES DEV THER, V10, P3345, DOI 10.2147/DDDT.S99600; Tripathi L, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01005; Turtle L, 2016, J EXP MED, V213, P1331, DOI 10.1084/jem.20151517; Ulbert S, 2019, HUM VACC IMMUNOTHER, V15, P2337, DOI 10.1080/21645515.2019.1621149; Urakami A, 2017, J VIROL, V91, DOI [10.1128/JVI.01181-17, 10.1128/jvi.01181-17]; Vannice KS, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00338-z; Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14; Widman DG, 2008, VACCINE, V26, P2762, DOI 10.1016/j.vaccine.2008.03.009; Xie XP, 2018, CELL HOST MICROBE, V24, P487, DOI 10.1016/j.chom.2018.09.008; Yamaji H, 2013, BIOENGINEERED, V4, P438, DOI 10.4161/bioe.24514; Yamaji H, 2013, APPL MICROBIOL BIOT, V97, P1071, DOI 10.1007/s00253-012-4371-y; Yamaji H, 2012, J BIOSCI BIOENG, V114, P657, DOI 10.1016/j.jbiosc.2012.06.012; Yamanaka A, 2017, J VIROL METHODS, V243, P164, DOI 10.1016/j.jviromet.2017.02.011; Yamanaka A, 2014, VACCINE, V32, P4289, DOI 10.1016/j.vaccine.2014.06.017; Yoshii K, 2005, VACCINE, V23, P3946, DOI 10.1016/j.vaccine.2005.03.004; Yoshii K, 2008, J GEN VIROL, V89, P200, DOI 10.1099/vir.0.82824-0; Yun Seok-Min, 2014, Osong Public Health Res Perspect, V5, P274, DOI 10.1016/j.phrp.2014.08.005; Zai J, 2013, ACTA VIROL, V57, P27, DOI 10.4149/av_2013_01_27; Zhang FQ, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-17; Zhang S, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-333; Zhang Y, 2003, EMBO J, V22, P2604, DOI 10.1093/emboj/cdg270	110	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 26	2021	39	48					6990	7000		10.1016/j.vaccine.2021.10.049		NOV 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XB3QQ	34753613				2022-04-29	WOS:000721246800006
J	Dar, SA; Kole, S; Shin, SM; Jeong, HJ; Jung, SJ				Dar, Showkat Ahmad; Kole, Sajal; Shin, Su-Mi; Jeong, Hyeon-Jong; Jung, Sung-Ju			Comparative study on antigen persistence and immunoprotective efficacy of intramuscular and intraperitoneal injections of squalene - aluminium hydroxide (Sq plus Al) adjuvanted viral hemorrhagic septicaemia virus vaccine in olive flounder (Paralichthys olivaceus)	VACCINE			English	Article						Squalene; Adjuvant; Viral hemorrhagic septicemia virus; Intramuscular injection; Olive flounder	SALMO-SALAR L.; ATLANTIC SALMON; LONG-TERM; INACTIVATED VACCINE; ANTIBODY-RESPONSE; RAINBOW-TROUT; PROTECTION; SAFETY; RHABDOVIRUSES; DISEASE	The profitability of the olive flounder (Paralichthys olivaceus) aquaculture industry in Korea depends on high production and maintenance of flesh quality, as consumers prefer to eat raw flounders from aquaria and relish the raw muscles as 'sashimi'. For sustaining high production, easy-to-deliver and efficient vaccination strategies against serious pathogens, such as viral hemorrhagic septicemia virus (VHSV), is very important as it cause considerable losses to the industry. Whereas, a safe and non-invasive vaccine formulation that is free from unacceptable side-effects and does not devalue the fish is needed to maintain flesh quality. We previously developed a squalene-aluminium hydroxide (Sq + Al) adjuvanted VHSV vaccine that conferred moderate to high protection in flounder, without causing any side effects when administered through the intraperitoneal (IP) injection route. However, farmers often demand intramuscular (IM) injection vaccines as they are relatively easy to administer in small fishes. Therefore, we administered the developed vaccine via IP and IM routes and investigated the safety and persistency of the vaccine at the injection site. In addition, we conducted a comparative analysis of vaccine efficacy and serum antibody response. The clinical and histological observation of the IM and IP groups showed that our vaccine remained persistence at the injection sites for 10-17 weeks post vaccination (wpv), without causing any adverse effects to the fish. The relative percentage of survival were 100% and 71.4% for the IP group and 88.9% and 92.3% for the IM group at 3 and 17 wpv, respectively. Thus, considering the persistency period (24 wpv) and both short and long-term efficacy of our vaccine, the present study offers an option to flounder farmers in selecting either IM or IP delivery strategy according to their cultured fish size and harvesting schedule - IM vaccination for small-sized fish and IP vaccination for table-sized fish. (c) 2021 Elsevier Ltd. All rights reserved.	[Dar, Showkat Ahmad; Kole, Sajal; Shin, Su-Mi; Jeong, Hyeon-Jong; Jung, Sung-Ju] Chonnam Natl Univ, Dept Aqualife Med, Chungnam, South Korea		Jung, SJ (通讯作者)，Chonnam Natl Univ, Dept Aqualife Med, Chungnam, South Korea.	sungju@chonnam.ac.kr			National Research Foundation of Korea (NRF) - government of Korea [NRF-2019H1D3A1A01071161]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the government of Korea (grant no. NRF-2019H1D3A1A01071161).	Akamatsu MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233632; Amend DF., 1981, FISH BIOLOGICS SEROD, V49, P447; Aunsmo A, 2008, J FISH DIS, V31, P515, DOI 10.1111/j.1365-2761.2007.00899.x; Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Bjorge MH, 2011, APPL ANIM BEHAV SCI, V133, P127, DOI 10.1016/j.applanim.2011.04.018; Bowden TJ, 2003, FISH SHELLFISH IMMUN, V14, P363, DOI 10.1006/fsim.2002.0439; Chalmers L, 2020, FISH SHELLFISH IMMUN, V97, P624, DOI 10.1016/j.fsi.2019.12.070; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; Embregts CWE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01340; Erkinharju T, 2017, J FISH DIS, V40, P1805, DOI 10.1111/jfd.12649; Erkinharju T, 2019, J FISH DIS, V42, P1731, DOI 10.1111/jfd.13101; Fraser TWK, 2014, AQUACULTURE, V433, P481, DOI 10.1016/j.aquaculture.2014.07.009; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Gravningen K, 2008, FISH SHELLFISH IMMUN, V24, P523, DOI 10.1016/j.fsi.2007.10.014; Gudmundsdottir BK, 2007, VACCINE, V25, P5512, DOI 10.1016/j.vaccine.2007.02.009; Hesser EF., 1960, PROG FISH CULT, V22, P104; Hoare R, 2019, FISH SHELLFISH IMMUN, V85, P44, DOI 10.1016/j.fsi.2017.10.005; Hwang JY, 2020, FISH SHELLFISH IMMUN, V102, P20, DOI 10.1016/j.fsi.2020.04.004; Jaafar RM, 2015, FISH SHELLFISH IMMUN, V47, P797, DOI 10.1016/j.fsi.2015.10.023; Karlsen M, 2012, VACCINE, V30, P5688, DOI 10.1016/j.vaccine.2012.05.069; Kim EH, 2020, ELIFE, V9, DOI 10.7554/eLife.52687; Kole S, 2019, FISH SHELLFISH IMMUN, V91, P136, DOI 10.1016/j.fsi.2019.05.017; Kole S, 2019, VACCINE, V37, P973, DOI 10.1016/j.vaccine.2018.12.063; Koppang EO, 2005, J FISH DIS, V28, P13, DOI 10.1111/j.1365-2761.2004.00583.x; Koppang EO, 2008, J IMMUNOL, V181, P4807, DOI 10.4049/jimmunol.181.7.4807; Larsen HAS, 2012, FISH SHELLFISH IMMUN, V33, P277, DOI 10.1016/j.fsi.2012.05.012; Lorenzen N, 1999, FISH SHELLFISH IMMUN, V9, P345, DOI 10.1006/fsim.1999.0194; Miller TA, 1998, DIS AQUAT ORGAN, V34, P13, DOI 10.3354/dao034013; Mutoloki S, 2006, VACCINE, V24, P578, DOI 10.1016/j.vaccine.2005.08.070; Mutoloki S, 2004, FISH SHELLFISH IMMUN, V16, P633, DOI 10.1016/j.fsi.2003.10.002; Mutoloki S, 2008, FISH SHELLFISH IMMUN, V24, P386, DOI 10.1016/j.fsi.2007.08.009; Mutoloki S, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-336; O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061; Plant KP, 2011, DEV COMP IMMUNOL, V35, P1256, DOI 10.1016/j.dci.2011.03.007; Rahman MH, 2000, FISH PATHOL, V35, P199, DOI 10.3147/jsfp.35.199; Ramirez-Paredes JG, 2019, J FISH DIS, V42, P1191, DOI 10.1111/jfd.13041; Schetters STT, 2020, FASEB J, V34, P12406, DOI 10.1096/fj.202000848R; Tafalla C, 2013, FISH SHELLFISH IMMUN, V35, P1740, DOI 10.1016/j.fsi.2013.02.029; Treasurer J, 2008, AQUACULTURE, V275, P51, DOI 10.1016/j.aquaculture.2008.01.006; Villumsen KR, 2015, FISH SHELLFISH IMMUN, V42, P193, DOI 10.1016/j.fsi.2014.09.024; Vinay TN, 2013, VACCINE, V31, P4603, DOI 10.1016/j.vaccine.2013.07.036; Xu WT, 2019, FISH SHELLFISH IMMUN, V84, P56, DOI 10.1016/j.fsi.2018.09.024; Zhang JQ, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1719-2	44	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6866	6875		10.1016/j.vaccine.2021.10.026		NOV 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34696933				2022-04-29	WOS:000719580000008
J	Draper, M; Stergiopoulos, S				Draper, Marina; Stergiopoulos, Stella			Shingles vaccination uptake in Massachusetts adults aged 50 years and older	VACCINE			English	Article						Herpes zoster vaccination; Shingles; Consumer perceptions; Vaccine acceptance; Vaccination decision-making; Vaccine hesitancy	HERPES-ZOSTER VACCINATION; UNITED-STATES; COST-EFFECTIVENESS; SUBUNIT VACCINE; COVERAGE; DESIGN; QUALITY; TRUST; US	Background: Shingles (herpes zoster), a medical condition caused by reactivation of latent varicella zoster virus and characterized by painful rash, will affect almost one third of Americans during their lifetime. A licensed vaccine (zoster vaccine live [ZVL]) was recommended for individuals > 60 years old in 2008 to reduce shingles incidence. The Healthy People (HP) 2020 target for shingles vaccination in > 60 year-olds was 30%; in 2014, it stood at 31.8% and in 2017 at 34.9%. While the national coverage target is met, vari-ability remains across age, gender and ethnicity. Understanding factors influencing patient acceptance of the shingles vaccination is needed to help guide program activities and improve vaccination coverage in the adult population. Purpose: To understand Massachusetts consumers' knowledge, attitudes, behaviors, and barriers to obtaining a shingles vaccination. Methods: We performed a telephone survey using a stratified sample of Massachusetts residents > 50 years-old who i) responded to the 2012 Massachusetts Behavioral Risk Factor Surveillance System (n = 10,822), ii) agreed to a follow-up survey (n = 6,873), and iii) reported awareness of the shingles vacci-nation (n = 1,000; n = 529 vaccinated respondents (VR) and n = 471 non-vaccinated respondents (NVR)). Multivariable logistic regression identified factors independently associated with receiving shingles vaccina-tion. Results: Across both groups, most respondents (n = 989, 99%) were aware of shingles, perceived shingles as painful, and knew of others who had had shingles. Multivariable logistic regression indicated an association between shingles vaccination and physician recommendation, influenza vaccination, and perception of shin-gles risk. Conclusions: More than half of the sub-sample reported not knowing about shingles vaccine, therefore, opportunities to increase awareness should be prioritized. Since provider recommendation and flu vaccina-tion receipt had the greatest odds of increasing shingles vaccination, standard practice should include adding shingles to flu vaccine recommendations for age-eligible patients. (c) 2021 Elsevier Ltd. All rights reserved.	[Draper, Marina] Northeastern Univ, Sch Publ Policy & Urban Affairs, Grad Law & Publ Policy PhD Program, 360 Huntington Ave, Boston, MA 02115 USA; [Stergiopoulos, Stella] Tufts Univ, Sch Med, 136 Harrison Ave, Boston, MA 02111 USA		Draper, M (通讯作者)，9 Cherry St, Danvers, MA 01923 USA.	draper.mar@northeastern.edu			Massachusetts Department of Public Health (DPH) Immunization Program, a subcomponent of the main Federal Immunization Grant [5H23IP122540-10]; Northeastern University (Boston, MA)	Massachusetts Department of Public Health (DPH) Immunization ProgramMassachusetts Department of Public Health (DPH) Immunization Program Special thanks to Dr. Gary Euler (deceased) from the National Center for Immunization and Respiratory Diseases (NCIRD), U.S. Centers for Control and Prevention (CDC) (Atlanta, GA). Dr. Euler helped to conceptualize this research and added immeasurable perspective to this project. In addition, thanks to Megan Lindley (CDC) for her ongoing support with the development of the survey, technical help, writing and editing assistance, and critical review of this article. Thank you also to key stakeholders at CDC who were involved with developing the shingles survey: Dr. Jim Singleton and Dr. Raphael Harpaz. The survey research was made possible by a grant (5H23IP122540-10) from the Massachusetts Department of Public Health (DPH) Immunization Program, a subcomponent of the main Federal Immunization Grant. Additional funding was received from Northeastern University (Boston, MA) to conduct focus groups at area senior centers.	[Anonymous], 2012, PUBLIC HEALTH REP, V127, P1; Betts RE, 2007, J AM ACAD DERMATOL, V57, pS143, DOI 10.1016/j.jaad.2007.09.017; CDC, 2016, OV SER STAND AD IMM; CDC, 2008, MMWR EARLY RELEASE, V57, P1; CDC, 2021, BRFSS ASTHM CALL BAC; CDC, 2018, AD VACC PRIC LIST; CDC, 2021, SEL ART REL BRFSS OT; Centers for Disease Control and Prevention, NAT AD IMM PLAN NAIP; Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P1528; Department of Health and Human Services. National Cancer Institute, 2005, THEORY GLANCE GUIDE, V2nd; Department of Health and Human Services Secretary's Advisory Committee on National Health Promotion and Disease Prevention Objectives for 2030 (Committee), 2018, 4 DEP HLTH HUM SERV; Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5; Fendrick AM, 2010, HEALTH AFFAIR, V29, P2017, DOI 10.1377/hlthaff.2010.0878; Fleming DM, 2004, EPIDEMIOL INFECT, V132, P1, DOI 10.1017/S0950268803001523; GAO, 2011, GAO1261; Guffey T, 2012, SAGE OPEN, V2, DOI 10.1177/2158244012466092; Hales CM, 2014, MMWR-MORBID MORTAL W, V63; Hall MA, 2002, HEALTH SERV RES, V37, P1419, DOI 10.1111/1475-6773.01070; Hurley LP, 2010, ANN INTERN MED, V152, P555, DOI 10.7326/0003-4819-152-9-201005040-00005; Kautter J, 2007, HEALTH CARE FINANC R, V29, P15; Krueger R.A., 2000, FOCUS GROUPS PRACTIC, V3rd; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Lavange LM, 2010, ANN EPIDEMIOL, V20, P642, DOI 10.1016/j.annepidem.2010.05.006; Le P, 2018, JAMA INTERN MED, V178, P248, DOI 10.1001/jamainternmed.2017.7431; Lu PJ, 2017, AM J PREV MED, V52, P362, DOI 10.1016/j.amepre.2016.08.031; Lu PJ, 2011, AM J PREV MED, V40, pE1, DOI 10.1016/j.amepre.2010.10.012; Lua PJ, 2009, VACCINE, V27, P882, DOI 10.1016/j.vaccine.2008.11.077; MacDougall DM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009062; Marrufo G., 2011, ESTIMATING EFFECTS D; Mbah MLN, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002469; MDPH, 2010, HLTH MASS; MDPH, PROF HLTH MASS AD 20; Mortensen GL, 2011, DAN MED BULL, V58; Onwuegbuzie AJ, 2007, QUAL REP, V12, P281; Opstelten W, 2009, VACCINE, V27, P192, DOI 10.1016/j.vaccine.2008.10.047; Osborn R, 2016, HEALTH AFFAIR, V35, P2327, DOI 10.1377/hlthaff.2016.1088; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Paek E, 2010, GERONTOLOGY, V56, P20, DOI 10.1159/000240046; PCORI, 2012, DRAFT NAT PRIOR RES; Pew Research Center, 2014, OLDER ADULTS TECHNOL; Le P, 2015, ANN INTERN MED, V163, P489, DOI 10.7326/M15-0093; Rothberg MB, 2007, CLIN INFECT DIS, V44, P1280, DOI 10.1086/514342; Schiller JS, 2008, VACCINATION COVERAGE; Tashakkori A., 2003, HDB MIXED METHODS SO; Thom DH, 2004, HEALTH AFFAIR, V23, P124, DOI 10.1377/hlthaff.23.4.124; Vaccination Coverage among Adults in the United States, 2017, NAT HLTH INT SURV; Williams WW, 2015, MMWR-MORBID MORTAL W, V64, P95; Williams WW, 2013, MMWR-MORBID MORTAL W, V62, P66; Williams Walter W., 2012, Morbidity and Mortality Weekly Report, V61, P66	49	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 5	2021	39	46					6781	6786		10.1016/j.vaccine.2021.09.032		NOV 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	YJ0BG	34625290				2022-04-29	WOS:000744203800008
J	Friedensohn, L; Zur, M; Timofeyev, M; Burshtein, S; Ben Michael, Y; Fink, N; Glassberg, E				Friedensohn, Limor; Zur, Meital; Timofeyev, Maxim; Burshtein, Saar; Ben Michael, Yossi; Fink, Noam; Glassberg, Elon			Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults	VACCINE			English	Article						COVID 19; BNT162b2; mRNA vaccine; Seroconversion; SARS-CoV-2	IMMUNITY; DELIVERY; ANTIGEN	Route of vaccine administration plays a role in extent and quality of immunogenicity. 790 military personnel accidentally received the first of two doses of Pfizer/BioNTech mRNA anti Covid-19 vaccine using a needle intended for subcutaneous administration. A serological blood test (on day 21, prior to the second intramuscular dose) was performed, analyzing whether immunological response was elicited. 98.2% demonstrated seroconversion. IgG titers were negatively correlated with age and did not correlate with BMI. Our results could help reassure providers confronted with a similar mistake and may even imply a possibly new and effective administration route. (C) 2021 Elsevier Ltd. All rights reserved.	[Friedensohn, Limor; Zur, Meital; Timofeyev, Maxim; Burshtein, Saar; Ben Michael, Yossi; Fink, Noam; Glassberg, Elon] Israeli Def Forces, Med Corps, 1 Dolizky St, IL-6436601 Tel Aviv, Israel; [Friedensohn, Limor] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Glassberg, Elon] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel; [Glassberg, Elon] Univ Hlth Sci, Uniformed Serv, Bethesda, MD USA		Friedensohn, L (通讯作者)，Israeli Def Forces, Med Corps, 1 Dolizky St, IL-6436601 Tel Aviv, Israel.	Limor.fri@gmail.com		Timofeyev, Maxim/0000-0002-3678-9133			Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; [Anonymous], 2020, PUBL ASS REP AUTH TE; Belyakov IM, 2009, J IMMUNOL, V183, P6883, DOI 10.4049/jimmunol.0901466; Mishra H, 2010, J PHARM PHARM SCI, V13, P495, DOI 10.18433/J3XK53; Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Takasuka N, 2004, INT IMMUNOL, V16, P1423, DOI 10.1093/intimm/dxh143	8	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6210	6212		10.1016/j.vaccine.2021.07.096		SEP 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34531083	Bronze, Green Published			2022-04-29	WOS:000705822100007
J	Prelog, M; Almanzar, G; Stern, R; Robrade, K; Holzer, MT; Winzig, C; Kleines, M; Stiasny, K; Meyer, T; Speth, F; Haas, JP				Prelog, M.; Almanzar, G.; Stern, R.; Robrade, K.; Holzer, M. T.; Winzig, C.; Kleines, M.; Stiasny, K.; Meyer, T.; Speth, F.; Haas, J. P.			Humoral and cellular immune response to tick-borne-encephalitis (TBE) vaccination depends on booster doses in patients with Juvenile Idiopathic Arthritis (JIA)	VACCINE			English	Article						TBEV vaccination; Cell mediated immunity; IgG avidity; JIA	RHEUMATOID-ARTHRITIS; INFLUENZA VACCINATION; ANTIBODY-RESPONSES; PEDIATRIC-PATIENTS; METHOTREXATE; AVIDITY; TNF; RECOMMENDATIONS; VACCINES; TETANUS	Juvenile Idiopathic Arthritis (JIA) patients living in areas with high prevalence of tick-borne-encephalitisvirus-(TBEV)-infection are recommended for administration of inactivated TBE-vaccination. However, there are serious concerns regarding protective vaccine-induced immune responses against TBEV in immunocompromised patients. The present study aimed to analyze the humoral and cellular immune response to TBE-vaccination in previously TBE-vaccinated JIA patients compared to healthy controls (HC) including investigation of IgGanti-TBEV avidity, neutralization capacity, cellular reactivity by IFNgamma-ELISPOT and cytokine secretion assays. Similar IgG-anti-TBEV antibody concentrations, neutralization titers and cellular reactivity were found between JIA and HC. The number and the early timing of booster vaccinations after primary vaccination had the most prominent effect on neutralizing antibodies in JIA and on IgG-anti-TBEV concentrations in both JIA and HC. Administration of booster vaccinations made it more likely for JIA patients to have IgGanti-TBEV concentrations >165 VIEU/ml and avidities >60%. TNF-alpha inhibitors had a positive and MTX administration a negative effect on humoral immune responses. In conclusion, irrespective of having JIA or not, vaccinated children showed similar humoral and cellular immunity against TBEV several years after primary TBE-vaccination. However, in JIA, booster vaccinations mounted a significantly higher humoral immune response than in JIA without boosters. Our results highlight the need for timely administration of boosters particularly in JIA. Although immunosuppressive treatment at vaccinations in diagnosed JIA had a negative effect mainly on TBEV-specific cellular immunity, most JIA patients mounted a favorable humoral immune response which was maintained over time. Thus, successful TBE-vaccination seems highly feasible in JIA patients with immunosuppressive regimens. CO 2021 Published by Elsevier Ltd.	[Prelog, M.; Almanzar, G.; Stern, R.; Robrade, K.; Holzer, M. T.; Winzig, C.] Univ Hosp Wuerzburg, Dept Pediat, Josef Schneider Str 2, D-97080 Wurzburg, Germany; [Kleines, M.] RWFH Aachen, Dept Med Microbiol, Pauwelsstr 30, D-52074 Aachen, Germany; [Stiasny, K.] Med Univ Vienna, Dept Virol, Kinderspitalgasse 15, A-1090 Vienna, Austria; [Meyer, T.] Univ Hosp Wuerzburg, Dept Surg, Pediat Surg Unit, Josef Schneider Str 2, D-97080 Wurzburg, Germany; [Speth, F.; Haas, J. P.] German Ctr Pediat & Adolescent Rheumatol, Gehfeldstr 24, D-82467 Garmisch Partenkirchen, Germany		Prelog, M (通讯作者)，Univ Hosp Wuerzburg, Dept Pediat, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	prelog_m@ukw.de	Kleines, Michael/C-8801-2009	Kleines, Michael/0000-0003-4866-6007	Baxter; PfizerPfizer	This investigated initiated study was partly funded by a competitive research grant of Baxter and Pfizer.	Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Amicizia D, 2013, HUM VACC IMMUNOTHER, V9, P1163, DOI 10.4161/hv.23802; [Anonymous], [No title captured], DOI 10.1371/journal.pone.0034145.s002; Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; Askling HH, 2015, VACCINE, V33, P4962, DOI 10.1016/j.vaccine.2015.07.030; Bouche FB, 2002, VIRAL IMMUNOL, V15, P451, DOI 10.1089/088282402760312331; Dengler TJ, 1999, VACCINE, V17, P867, DOI 10.1016/S0264-410X(98)00272-2; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; Elkayam O, 2004, SEMIN ARTHRITIS RHEU, V33, P283, DOI 10.1053/j.semarthrit.2003.10.003; Fomin I, 2006, ANN RHEUM DIS, V65, P191, DOI 10.1136/ard.2005.036434; Garner-Spitzer E, 2013, J IMMUNOL, V191, P2426, DOI 10.4049/jimmunol.1300293; Gassmann C, 1997, J MED VIROL, V51, P242, DOI 10.1002/(SICI)1096-9071(199703)51:3&lt;242::AID-JMV17&gt;3.0.CO;2-M; Gelinck LBS, 2008, VACCINE, V26, P3528, DOI 10.1016/j.vaccine.2008.04.028; Gelinck LBS, 2008, ANN RHEUM DIS, V67, P713, DOI 10.1136/ard.2007.077552; Goldblatt D, 1998, J INFECT DIS, V177, P1112, DOI 10.1086/517407; Goodnow CC, 2010, NAT IMMUNOL, V11, P681, DOI 10.1038/ni.1900; Haglund M, 2003, VACCINE, V21, pS11, DOI 10.1016/S0264-410X(02)00811-3; Hainz U, 2005, VACCINE, V23, P3232, DOI 10.1016/j.vaccine.2005.01.085; Heijstek MW, 2011, AUTOIMMUN REV, V11, P112, DOI 10.1016/j.autrev.2011.08.010; Heijstek MW, 2011, ANN RHEUM DIS, V70, P1704, DOI 10.1136/ard.2011.150193; Hertzell KB, 2016, VACCINE, V34, P650, DOI 10.1016/j.vaccine.2015.12.029; Hofer M, 2002, BEST PRACT RES CL RH, V16, P379, DOI 10.1053/berh.2002.0235; Holzmann H, 1996, J MED VIROL, V48, P102, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;102::AID-JMV16&gt;3.0.CO;2-I; Jilkova E, 2009, EXPERT OPIN BIOL TH, V9, P797, DOI 10.1517/14712590903066711; Kapetanovic MC, 2007, RHEUMATOLOGY, V46, P608, DOI 10.1093/rheumatology/kel366; Kapetanovic MC, 2006, RHEUMATOLOGY, V45, P106, DOI 10.1093/rheumatology/kei193; Kapetanovic MC, 2011, ARTHRITIS RHEUM-US, V63, P3723, DOI 10.1002/art.30580; Kiessig ST, 1993, KLIN LAB, V39, P877; Kollaritsch H, 2012, EXPERT REV VACCINES, V11, P1103, DOI [10.1586/ERV.12.86, 10.1586/erv.12.86]; Lindblom P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100860; Paulke-Korinek M, 2009, VACCINE, V27, P7027, DOI 10.1016/j.vaccine.2009.09.068; Pichichero ME, 1999, J INFECT DIS, V180, P1390, DOI 10.1086/314989; Prelog M, 2008, VACCINE, V26, P595, DOI 10.1016/j.vaccine.2007.11.074; Prelog M, 2013, VACCINE, V31, P2420, DOI 10.1016/j.vaccine.2013.03.058; Rendi-Wagner P, 2007, VACCINE, V25, P5097, DOI 10.1016/j.vaccine.2007.01.116; Ridings J, 1997, CLIN EXP IMMUNOL, V108, P366, DOI 10.1046/j.1365-2249.1997.3631264.x; Sengler C, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen-2015-000074; Stiasny K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034145; Stiasny K, 2009, VACCINE, V27, P7021, DOI 10.1016/j.vaccine.2009.09.069; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; Weinberger B, 2010, VACCINE, V28, P3511, DOI 10.1016/j.vaccine.2010.03.024; Zavadska D, 2013, HUM VACC IMMUNOTHER, V9, P362, DOI 10.4161/hv.22766; Zlamy M, 2010, VACCINE, V28, P8053, DOI 10.1016/j.vaccine.2010.10.002	43	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5918	5927		10.1016/j.vaccine.2021.08.029		SEP 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34462165				2022-04-29	WOS:000697501500026
J	Wang, RJ; Chen, K; Wang, YT; Liu, C; Wu, ZY; Wang, DM; Qu, CF				Wang, Ruijun; Chen, Kun; Wang, Yuting; Liu, Chang; Wu, Zhiyuan; Wang, Dongmei; Qu, Chunfeng			Booster immunization improves the generation of T follicular helper (Tfh) cells specific to hepatitis B surface antigen (HBsAg) after prenatal HBsAg exposure	VACCINE			English	Article						T follicular helper cells; Antibodies against hepatitis B surface antigens; Prenatal exposure; Interleukin 21; Vaccine booster	ADOLESCENT BOOSTER; VIRUS; TIME; PERSISTENCE; EXPRESSION; INFECTION; RESPONSES	Breakthrough infections of hepatitis B virus (HBV) after neonatal vaccination occurred in some adolescents and young adults who were born to mothers with hepatitis B surface antigen (HBsAg). We aimed to determine the impacts of prenatal HBsAg exposure on the generation of T follicular helper (Tfh) cells and antibodies (anti-HBs) specific to HBsAg. To mimic human prenatal HBsAg exposure, we mated female Alb1-HBV (HBV-M) mice with male C57BL/6J mice. Of their first filial generation (F1), HBV-M/F1' expressed HBsAg in liver tissues and blood, and HBV-M/F1- mice exposed HBsAg in amniotic fluid. At their four weeks old, each HBV-M/F1 mouse was immunized with hepatitis B vaccine containing 5 lg HBsAg subcutaneously. Both HBV-M/F1- and HBV-M/F1' mice had reduced generation of HBsAg-specific CD4'CXCR5'PD1' Tfh cells and CD138'IgD- plasma cells in comparison with C57BL/6J mice. Results of coculturing the Tfh cells with B cells that were isolated from different strains of mice indicated that CD4' T cell activation in response to HBsAg was critical for anti-HBs generation after prenatal HBsAg exposure. When interleukin (IL) 21 was supplemented, the generation of HBsAg-specific Tfh and plasma cells in HBV-M/F1- mice was improved, while supplementation showed little effect in HBV-M/F1' mice. In HBV-M/F1- mice, HBV vaccine booster improved the generation of Tfh cells and plasma cells, and enhanced anti-HBs production. Conclusion: Impaired generation of HBsAg-specific Tfh cells and plasma cells after prenatal HBsAg exposure can be improved by HBV vaccine booster, most likely increasing IL-21 production. (C) 2021 Elsevier Ltd. All rights reserved.	Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Immunol, Beijing 100021, Peoples R China		Qu, CF (通讯作者)，Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, 17 Panjiayuan South Lane, Beijing 100021, Peoples R China.	quchf@cicams.ac.cn		Wang, Ruijun/0000-0001-8778-8328	Key Research Projects for Precision Medicine [2017YFC0908103]; National Natural Science Foundation FundNational Natural Science Foundation of China (NSFC) [81972628, 81571620]; Innovation Fund for Medical Sciences of Chinese Academy of Medical Sciences (CIFMS) [2019-I2M-2-004]	This work was supported by Key Research Projects for Precision Medicine (2017YFC0908103) , National Natural Science Foundation Fund (81972628, 81571620) , and Innovation Fund for Medical Sciences of Chinese Academy of Medical Sciences (CIFMS, 2019-I2M-2-004, Cohort study of the esophageal cancer and liver cancer) .	[Anonymous], 2017, Wkly Epidemiol Rec, V92, P369; Carmody E, 2017, INT J INFECT DIS, V60, P88, DOI 10.1016/j.ijid.2017.04.019; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; Dilworth MR, 2013, PLACENTA, V34, pS34, DOI 10.1016/j.placenta.2012.10.011; Fazilleau N, 2009, NAT IMMUNOL, V10, P375, DOI 10.1038/ni.1704; Gao SX, 2020, J MED MICROBIOL, V69, P591, DOI 10.1099/jmm.0.001152; Hong M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7588; Kondo K, 2019, INT IMMUNOL, V31, P119, DOI 10.1093/intimm/dxy081; Li Y, 2020, EMERG MICROBES INFEC, V9, P1881, DOI 10.1080/22221751.2020.1808533; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martinez V, 2005, J INFECT DIS, V191, P2053, DOI 10.1086/430320; MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425; Nian YQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.661580; Poovorawan Y, 2011, J VIRAL HEPATITIS, V18, P369, DOI 10.1111/j.1365-2893.2010.01312.x; Qu C, 2017, HEPATOMA RES, V3, P228, DOI 10.20517/2394-5079.2017.41; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Shekhar S, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/7906724; Song WZ, 2019, IMMUNOL REV, V288, P85, DOI 10.1111/imr.12740; The Jackson laboratoty, 2021, C57BL6J TG ALB1 HBV; Tian YJ, 2016, IMMUNITY, V44, P1204, DOI 10.1016/j.immuni.2016.04.008; Wang F, 2018, INT J INFECT DIS, V77, P90, DOI 10.1016/j.ijid.2018.09.026; Wang FS, 2014, HEPATOLOGY, V60, P2099, DOI 10.1002/hep.27406; Wang RJ, 2021, HEPATOL INT, V15, P328, DOI 10.1007/s12072-021-10156-z; Wang XW, 2018, GASTROENTEROLOGY, V154, P2222, DOI 10.1053/j.gastro.2018.03.021; Wang Y, 2014, INT J INFECT DIS, V29, P31, DOI 10.1016/j.ijid.2014.07.015; Wang YT, 2017, VACCINE, V35, P1064, DOI 10.1016/j.vaccine.2016.12.062; Weinstein JS, 2018, J EXP MED, V215, P337, DOI 10.1084/jem.20170457; Weinstein JS, 2016, NAT IMMUNOL, V17, P1197, DOI 10.1038/ni.3554; WONG VCW, 1980, BRIT J OBSTET GYNAEC, V87, P958, DOI 10.1111/j.1471-0528.1980.tb04458.x; Yang YT, 2019, VACCINE, V37, P458, DOI 10.1016/j.vaccine.2018.11.067	31	1	1	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5571	5579		10.1016/j.vaccine.2021.08.020		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34412920				2022-04-29	WOS:000704399700017
J	Kontopoulou, K; Ainatzoglou, A; Nakas, CT; Ifantidou, A; Goudi, G; Antoniadou, E; Adamopoulos, V; Papadopoulos, N; Papazisis, G				Kontopoulou, Konstantina; Ainatzoglou, Alexandra; Nakas, Christos T.; Ifantidou, Athina; Goudi, Georgia; Antoniadou, Eleni; Adamopoulos, Vasilios; Papadopoulos, Nikitas; Papazisis, Georgios			Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive	VACCINE			English	Article						BNT162b2 mRNA vaccine; Immunogenicity; Seropositive; Greece		This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20-67. After the first dose, titers varied upon age and history of infection, being lower in the 50+ age group and significantly higher among the seropositive. After the second dose, immunogenicity was significantly boosted in the age 50+ and SARS-CoV-2-naive individuals, indicating the effectuality of its timely administration, yet questioning its value among the seropositive. (c) 2021 Elsevier Ltd. All rights reserved.	[Kontopoulou, Konstantina; Ifantidou, Athina; Adamopoulos, Vasilios; Papadopoulos, Nikitas] G Gennimatas Gen Hosp, Dept Microbiol, Thessaloniki, Greece; [Ainatzoglou, Alexandra; Papazisis, Georgios] Aristotle Univ Thessaloniki, Sch Med, Dept Clin Pharmacol, Thessaloniki, Greece; [Nakas, Christos T.] Univ Thessaly, Lab Biometry, Magnisia, Greece; [Nakas, Christos T.] Univ Bern, Univ Hosp Bern, Inselspital, Univ Inst Clin Chem, Bern, Switzerland; [Goudi, Georgia] G Gennimatas Gen Hosp, Dept Cardiol, Thessaloniki, Greece; [Antoniadou, Eleni] G Gennimatas Gen Hosp, Intens Care Unit, Thessaloniki, Greece; [Papazisis, Georgios] Aristotle Univ Thessaloniki, Sch Med, Special Unit Biomed Res & Educ, Clin Trials Unit, Thessaloniki, Greece		Papazisis, G (通讯作者)，Aristotle Univ Thessaloniki, Sch Med, Dept Clin Pharmacol, Thessaloniki, Greece.; Papazisis, G (通讯作者)，Aristotle Univ Thessaloniki, Sch Med, Special Unit Biomed Res & Educ, Clin Trials Unit, Thessaloniki, Greece.	papazisg@auth.gr	; Nakas, Christos/F-3052-2011	Gkounti, Georgia/0000-0002-6944-6188; Nakas, Christos/0000-0003-4155-722X; Papazisis, Georgios/0000-0003-1641-9095			Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Gobbi F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030422; Kontopoulou Konstantina, 2021, J Med Microbiol, V70, DOI 10.1099/jmm.0.001387; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Robertson JFR, 2021, LANCET, V397, P879, DOI 10.1016/S0140-6736(21)00455-4; Samanovic Marie I, 2021, medRxiv, DOI 10.1101/2021.02.07.21251311; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]	9	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5078	5081		10.1016/j.vaccine.2021.07.065		AUG 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34344551	Bronze, Green Published			2022-04-29	WOS:000684878300002
J	Guilfoyle, K; Major, D; Skeldon, S; James, H; Tingstedt, JL; Polacek, C; Lassauniere, R; Engelhardt, OG; Fomsgaard, A				Guilfoyle, Kate; Major, Diane; Skeldon, Sarah; James, Heather; Tingstedt, Jeanette L.; Polacek, Charlotta; Lassauniere, Ria; Engelhardt, Othmar G.; Fomsgaard, Anders			Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model	VACCINE			English	Article						DNA vaccine; Influenza; Ferret; Broad protection; Pandemic	IMMUNE-RESPONSES; VIRUS; PIGS; HEMAGGLUTININ; ANTIBODIES; INFECTION; SAFETY; H1N1	This study describes the protective efficacy of a novel influenza plasmid DNA vaccine in the ferret challenge model. The rationally designed polyvalent influenza DNA vaccine encodes haemagglutinin and neuraminidase proteins derived from less glycosylated pandemic H1N1 (2009) and H3N2 (1968) virus strains as well as the nucleoprotein (NP) and matrix proteins (M1 and M2) from a different pandemic H1N1 (1918) strain. Needle-free intradermal immunisation with the influenza DNA vaccine protected ferrets against homologous challenge with an H1N1pdm09 virus strain, demonstrated by restriction of viral replication to the upper respiratory tract and reduced duration of viral shedding post-challenge. Breadth of protection was demonstrated in two heterologous efficacy experiments in which animals immunised with the influenza DNA vaccine were protected against challenge with a highly pathogenic avian influenza H5N1 virus strain with reproducible survival and clinical outcomes. Crown Copyright (c) 2020 Published by Elsevier Ltd.	[Guilfoyle, Kate; Major, Diane; Skeldon, Sarah; James, Heather; Engelhardt, Othmar G.] Natl Inst Biol Stand & Control NIBSC, Blanche Lane, Potters Bar EN6 3QG, Herts, England; [Tingstedt, Jeanette L.; Polacek, Charlotta; Lassauniere, Ria; Fomsgaard, Anders] Statens Serum Inst, Dept Virus & Microbiol Special Diagnost, Virus Res & Dev Lab, Artillerivej 5, DK-2300 Copenhagen S, Denmark; [Fomsgaard, Anders] Univ Southern Denmark, Clin Inst, Infect Dis Res Unit, Sdr Blvd 29, DK-5000 Odense C, Denmark; [Guilfoyle, Kate] Viroclin Xplore, Nistelrooise Baan 3, NL-35374 Schaijk, Netherlands		Engelhardt, OG (通讯作者)，Natl Inst Biol Stand & Control NIBSC, Blanche Lane, Potters Bar EN6 3QG, Herts, England.	othmar.engelhardt@nibsc.org		Tingstedt, Jeanette Linnea/0000-0001-6005-0518; Fomsgaard, Anders/0000-0003-4304-0603	European UnionEuropean Commission [602012]	This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 602012 UNISEC consortium.	Belser JA, 2011, DIS MODEL MECH, V4, P575, DOI 10.1242/dmm.007823; Borggren M, 2016, VACCINE, V34, P3634, DOI 10.1016/j.vaccine.2016.05.030; Borggren M, 2015, HUM VACC IMMUNOTHER, V11, P1983, DOI 10.1080/21645515.2015.1011987; Bragstad K, 2013, VACCINE, V31, P2281, DOI 10.1016/j.vaccine.2013.02.061; Bragstad K, 2011, INFLUENZA OTHER RESP, V5, P13, DOI 10.1111/j.1750-2659.2010.00177.x; Bruder D, 2006, VIRAL IMMUNOL, V19, P147, DOI 10.1089/vim.2006.19.147; Busquets N, 2010, VET RES, V41, DOI 10.1051/vetres/2010046; Carragher DM, 2008, J IMMUNOL, V181, P4168, DOI 10.4049/jimmunol.181.6.4168; Couzens L, 2014, J VIROL METHODS, V210, P7, DOI 10.1016/j.jviromet.2014.09.003; Donnelly JJ, 1997, VACCINE, V15, P865, DOI 10.1016/S0264-410X(96)00268-X; Drape RJ, 2006, VACCINE, V24, P4475, DOI 10.1016/j.vaccine.2005.08.012; Eisfeld AJ, 2014, NAT PROTOC, V9, P2663, DOI 10.1038/nprot.2014.180; Enkirch T, 2015, VIROLOGY, V479, P259, DOI 10.1016/j.virol.2015.03.017; Ferrari L, 2011, RES VET SCI, V90, P64, DOI 10.1016/j.rvsc.2010.04.026; Fujimoto Y, 2016, J GEN VIROL, V97, P2104, DOI 10.1099/jgv.0.000518; Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7; Gorres JP, 2011, CLIN VACCINE IMMUNOL, V18, P1987, DOI 10.1128/CVI.05171-11; Heinen PP, 2002, J GEN VIROL, V83, P1851, DOI 10.1099/0022-1317-83-8-1851; Holzer B, 2018, J IMMUNOL, V200, P4068, DOI 10.4049/jimmunol.1800142; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jegaskanda S, 2013, J VIROL, V87, P5512, DOI 10.1128/JVI.03030-12; Jones S, 2009, VACCINE, V27, P2506, DOI 10.1016/j.vaccine.2009.02.061; Karlsson I, 2018, VET IMMUNOL IMMUNOP, V195, P25, DOI 10.1016/j.vetimm.2017.11.007; Karlsson I, 2017, HUM VACC IMMUNOTHER, V13, P1823, DOI 10.1080/21645515.2017.1321183; Koday MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189780; Krammer F, 2018, MBIO, V9, DOI 10.1128/mBio.02332-17; Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432; Lalor PA, 2008, J INFECT DIS, V197, P1643, DOI 10.1086/588431; Lambert LC, 2010, NEW ENGL J MED, V363, P2036, DOI 10.1056/NEJMra1002842; LaMere MW, 2011, J IMMUNOL, V186, P4331, DOI 10.4049/jimmunol.1003057; Li L, 2016, EXPERT REV VACCINES, V15, P313, DOI 10.1586/14760584.2016.1124762; Liu MA, 2011, IMMUNOL REV, V239, P62, DOI 10.1111/j.1600-065X.2010.00980.x; Ljungberg K, 2002, VACCINE, V20, P2045, DOI 10.1016/S0264-410X(02)00049-X; Luke JM, 2014, METHODS MOL BIOL, V1143, P91, DOI 10.1007/978-1-4939-0410-5_6; Maher JA, 2004, LAB ANIMAL, V33, P50, DOI 10.1038/laban1004-50; Matsuoka Yumiko, 2009, Curr Protoc Microbiol, VChapter 15, DOI [10.1002/9780471729259.mc15g03s13, 10.1002/9780471729259.mc15g02s13]; Nelson J, 2013, HUM VACC IMMUNOTHER, V9, P2211, DOI 10.4161/hv.25048; Ng S, 2019, NAT MED, V25, P962, DOI 10.1038/s41591-019-0463-x; Pica N, 2013, ANNU REV MED, V64, P189, DOI [10.1146/annurev-med-120611-145115, 10.1146/annure]; Potter CW, 2001, J APPL MICROBIOL, V91, P572, DOI 10.1046/j.1365-2672.2001.01492.x; Rosa D. S., 2015, Journal of Vaccines and Vaccination, V6, P283; Russell RJ, 2008, P NATL ACAD SCI USA, V105, P17736, DOI 10.1073/pnas.0807142105; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; Vergara-Alert J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040524; Viegas EO, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206838; WHO, 2011, MAN LAB DIAGN VIR SU, P153; WHO, PAND H1N1 2009 UPD 6; Williams JA, 2014, CURR GENE THER, V14, P170, DOI 10.2174/156652321403140819122538; Williams JA, 2013, VACCINES, V1, P225, DOI 10.3390/vaccines1030225	50	4	4	5	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4903	4913		10.1016/j.vaccine.2020.09.062		JUL 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	33036805	Bronze			2022-04-29	WOS:000679483400022
J	O'Dell, FJ; Williams, AN; Poland, A				O'Dell, F. J.; Williams, A. N.; Poland, A.			The contributions of William Money MRCS to smallpox vaccination and control - A little-known story	VACCINE			English	Editorial Material						History; Smallpox; Smallpox vaccine; Vaccination; History of medicine		This history of vaccinology article outlines the work of William Money (1790-1843), who conducted a study related to smallpox disease, immunity, and vaccination. His hitherto unpublished study demon-strated that smallpox could be contracted more than once; notably, results from his studies showed that vaccination was not dangerous. He was also the author of a celebrated Vade Mecum in human anatomy. Here, we outline the work he conducted in England: from serving as the house surgeon at Northampton Infirmary to his post as a surgeon at the Royal Metropolitan Hospital in London. (C) 2021 Elsevier Ltd. All rights reserved.	[O'Dell, F. J.] Northampton Gen Hosp, Archivist Arch & Museum Serv, Northampton, England; [Williams, A. N.] Northampton Gen Hosp, Virtual Acad Unit, Arch, Northampton, England; [Poland, A.] Mayo Clin, Vaccine Res Grp, Rochester, MN USA; [Poland, A.] Mayo Clin, Div Gen Internal Med, Rochester, MN USA		O'Dell, FJ (通讯作者)，Northampton Gen Hosp, Archivist Arch & Museum Serv, Northampton, England.						[Anonymous], 1827, MEDICOCHIRURGICAL T MEDICOCHIRURGICAL T, V13; [Anonymous], 1843, GENTLEMANS MAGAZINE, VXX, P668; [Anonymous], 1821, MEDICOCHIRURGICAL T MEDICOCHIRURGICAL T, V11; [Anonymous], 1832, MEDICOCHIRURGICAL T MEDICOCHIRURGICAL T, V17; [Anonymous], 1839, MEDICOCHIURGICAL T MEDICOCHIURGICAL T, V22; [Anonymous], 1840, MEDICOCHIRURGICAL T MEDICOCHIRURGICAL T, V23; [Anonymous], 1838, MEDICOCHIRURGICAL T MEDICOCHIRURGICAL T, V21; [Anonymous], 1837, MEDICOCHIRURGICAL T MEDICOCHIRURGICAL T, V19; [Anonymous], 1819, MEDICOCHIRURGICAL T MEDICOCHIRURGICAL T, V10; [Anonymous], 1818, MEDICOCHIRURGICAL T MEDICOCHIRURGICAL T, V9; Bell W., 1806, COMMUNICATION 0118 COMMUNICATION 0118; DUDGEON JA, 1963, BRIT MED J, P1367; Fenner F, SMALLPOX ITS ERADICA; Harday G, HIST GEN INFIR UNPUB HIST GEN INFIR UNPUB; Kwik G., 2003, SCI AM; Mockett J., 1836, MOCKETTS J COLLECTIO; Money W, MANUSCRIPT STA UNPUB MANUSCRIPT STA UNPUB; Riedel Stefan, 2005, Proc (Bayl Univ Med Cent), V18, P21; Waddy FF, 1974, HIST NORTHAMPTON GEN	19	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4914	4919		10.1016/j.vaccine.2021.06.082		JUL 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34272094				2022-04-29	WOS:000679483400023
J	Velandia-Gonzalez, M; Vilajeliu, A; Contreras, M; Trumbo, SP; Pacis, C; Ropero, AM; Ruiz-Matus, C				Velandia-Gonzalez, Martha; Vilajeliu, Alba; Contreras, Marcela; Trumbo, Silas P.; Pacis, Carilu; Ropero, Alba Maria; Ruiz-Matus, Cuauhtemoc			Monitoring progress of maternal and neonatal immunization in Latin America and the Caribbean	VACCINE			English	Article						Maternal and neonatal immunization; Immunization coverage levels; Data quality; Vaccination of pregnant women; Vaccination of newborns		Introduction: The Americas committed to strengthening maternal and neonatal immunization (MNI) through the Pan American Health Organization (PAHO) Regional Immunization Action Plan (RIAP) 2016-20. We describe the progress toward RIAP MNI-related targets and those related to improvement of data quality and information systems; analyze national MNI policies and vaccination coverages; and identify enablers and challenges of monitoring and reporting MNI vaccination coverage in Latin America and the Caribbean (LAC). Methodology: Descriptive study of national MNI policies, vaccination coverage, and information systems. Sources of information included PAHO-World Health Organization (WHO) / UNICEF Joint Reporting Forms on immunization (JRF) 2013-2019, and other reports. Results: LAC has met two of three RIAP targets related to MNI (countries with universal hepatitis B birth dose introduction and elimination of maternal and neonatal tetanus) and is on track to meet the other (countries with vaccination of pregnant women). As of 2018, of the 49 countries and territories in LAC, 32 vaccinate pregnant women against influenza and 29 provide tetanus-containing vaccine. Twenty-five countries offer universal hepatitis B birth dose vaccine and 31 offer BCG vaccine. In 2018, regional influenza vaccine coverage among pregnant woman was 75%. Regional coverages for BCG and hepatitis B birth dose (<24 h) vaccines were 93% and 79%, respectively. Countries have exceeded RIAP targets related to the quality of vaccination coverage data and the establishment of electronic immunization registries (EIRs). Challenges in monitoring MNI coverage include estimation of denominators and difficulties disaggregating data by group (e.g., pregnant women versus other groups). Conclusion: Despite progress in improving MNI in LAC, countries must further strengthen immunization monitoring systems and data quality to better report vaccination coverage among pregnant women and newborns. EIR and MNI information systems must be integrated, such that countries can use accurate data to design more timely and effective vaccination strategies. (C) 2020 The Authors. Published by Elsevier Ltd.	[Velandia-Gonzalez, Martha; Vilajeliu, Alba; Contreras, Marcela; Pacis, Carilu; Ropero, Alba Maria; Ruiz-Matus, Cuauhtemoc] Pan Amer Hlth Org, Comprehens Family Immunizat Unit, Washington, DC USA; [Trumbo, Silas P.] Vanderbilt Univ, Med Ctr, Nashville, TN USA		Velandia-Gonzalez, M (通讯作者)，525 23rd St NW, Washington, DC 20037 USA.	velandiam@paho.org		Velandia-Gonzalez, Martha/0000-0002-7636-3604			54th Directing Council Pan American Health Organization., 2015, 67 SESS REG COMM WHO; 57th Directing Council Pan American Health Organization., 2019, 71 SESS REG COMM WHO; Alvarez AMR, 2017, REV PANAM SALUD PUBL, V41, DOI 10.26633/RPSP.2017.159; Alvarez AMR, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4227-6; [Anonymous], 2018, Wkly Epidemiol Rec, V93, P73; [Anonymous], TRIANGULATION IMPROV; Borda-Olivas Alfredo, 2018, Rev. perú. med. exp. salud publica, V35, P465, DOI 10.17843/rpmesp.2018.353.3619; Cabezas-Sánchez César, 2014, Rev. perú. med. exp. salud publica, V31, P204; Danovaro-Holliday MC, 2014, REV PANAM SALUD PUBL, V35, P453; Castillo-Solorzano C, 2011, J INFECT DIS, V204, pS571, DOI 10.1093/infdis/jir472; Cesare N, 2020, INT J INFECT DIS, V98, P275, DOI 10.1016/j.ijid.2020.06.092; Garib Z, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4721836; Krishnaswamy S, 2019, HUM VACC IMMUNOTHER, V15, P942, DOI 10.1080/21645515.2018.1564433; Marshall H, 2016, HUM VACC IMMUNOTHER, V12, P848, DOI 10.1080/21645515.2015.1127485; Pan American Health Organization, REP TECHN ADV GROUP; Pan American Health Organization, 2019, 25 M TECHN ADV GROUP; Pan American Health Organization, 2019, COR IND 2019 HLTH TR; Pan American Health Organization, 2015, BAS IND 2015 HLTH SI; Pan American Health Organization, 2020, IMM LIF COURS PRIM C; Pan American Health Organization, 2016, COR IND 2016 HLTH SI; Pan American Health Organization, 2020, 359 PAN AM HLTH ROG; Pan American Health Organization, 2020, VACC NEWB CONT COVID; Pan American Health Organization, PAHO SUPP COUNTR FAC; Pan American Health Organization, 2017, MAT NEON IMM FIELD G; Pan American Health Organization, 2019, IMM AM 2019 SUMM; Pan American Health Organization, 2018, COR IND 2018 HLTH SI; Pan American Health Organization, 2020, COVID 19 SUMM STAT N; Pan American Health Organization, 2019, IMM NEWSL, VXLI, P4; Pan American Health Organization, PAHO WHO UNICEF JOIN; Pan American Health Organization, 2015, REG IMM ACT PLAN AM; Pan American Health Organization, 2018, IMM NEWSL, VXXXX, P5; Ropero-Alvarez AM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-361; Ropero-Alvarez AM., HUM VACC IMMUNOTHER; World Health Organization, 2018, WORK TOG INT RES GUI; World Health Organization, 2019, REP SAGE WORK GROUP; World Health Organization, 2017, WKLY EPIDEMIOL REC, V2017, P369, DOI [10.1016/j.vaccine.2017.07.046, DOI 10.1016/J.VACCINE.2017.07.046]; World Health Organization, IMM AG 2030 GLOB STR	37	3	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39			2			B55	B63		10.1016/j.vaccine.2020.12.043		JUL 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UD6SH	33715899	hybrid			2022-04-29	WOS:000687335900008
J	Kobayashi, M; Abdul-Karim, A; Milucky, JL; Zakariah, A; Leidner, AJ; Asiedu-Bekoe, F; Opare, D; Eleeza, JB; Ofosu, W; Walker, C; Whitney, CG; Lessa, FC				Kobayashi, Miwako; Abdul-Karim, Abass; Milucky, Jennifer L.; Zakariah, Adam; Leidner, Andrew J.; Asiedu-Bekoe, Franklin; Opare, David; Eleeza, John B.; Ofosu, Winfred; Walker, Chastity; Whitney, Cynthia G.; Lessa, Fernanda C.			Estimating the economic burden of pneumococcal meningitis and pneumonia in northern Ghana in the African meningitis belt post-PCV13 introduction	VACCINE			English	Article						13-valent pneumococcal conjugate vaccine; African meningitis belt; Economic burden of pneumococcal disease	BACTERIAL-MENINGITIS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; MENINGOCOCCAL SEROGROUP; BURKINA-FASO; DISEASE; COUNTRIES; OUTBREAK; CHILDREN; SEQUELAE	Background: Ghana introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine infant immunization program in 2012, using a three-dose primary series without a booster. Despite 5 years), $911 (5-14 years), and $784 ( 5 years), $3,247 (5-14 years), and $2,883 ( 15 years). Most (78.0-93.4%) of the total societal cost was due to indirect costs related to deaths from PCV13-type diseases. Conclusions: The estimated economic burden of PCV13-type disease in northern Ghana remains substantial, especially in older children and adults who were expected to have benefited from indirect effects from infant immunization. Additional interventions such as changes in the infant immunization schedule, reactive vaccination, or catch-up PCV13 vaccination may be needed to control remaining vaccine type disease. Published by Elsevier Ltd.	[Kobayashi, Miwako; Milucky, Jennifer L.; Lessa, Fernanda C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA USA; [Abdul-Karim, Abass] Zonal Publ Hlth Lab, Tamale, Ghana; [Zakariah, Adam] Ghana Hlth Serv, Bulisa, Ghana; [Leidner, Andrew J.] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA; [Asiedu-Bekoe, Franklin; Opare, David] Ghana Hlth Serv, Accra, Ghana; [Eleeza, John B.] Ghana Hlth Serv, Tamale, Ghana; [Ofosu, Winfred] Ghana Hlth Serv, Bolgatanga, Ghana; [Walker, Chastity] Ctr Global Hlth, Div Global Hlth Protect, Accra, Ghana; [Whitney, Cynthia G.] Emory Univ, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA USA		Kobayashi, M (通讯作者)，1600 Clifton Rd NE MS H24-6, Atlanta, GA 30329 USA.	mkobayashi@cdc.gov		Walker, Chastity/0000-0001-7126-2452; Leidner, Andrew/0000-0001-8869-5561	Gavi, the Vaccine Alliance, through the CDC Foundation [97117]	This work was supported by Gavi, the Vaccine Alliance, through the CDC Foundation (under memorandum of understanding #97117) . Results from the Probabilistic Sensitivity Analysis are presented as a frequency histogram. The figure shows the full range of totalcost estimates when parameter values were varied across 10,000 simulation iterations. The density or height of the histogram bars correspond to total cost estimates that occurred more frequently across the 10,000 simulation iterations. The dashed line represents the base case scenario.	Abdulai AG, 2018, POLITICS POLICY, V46, P233, DOI 10.1111/polp.12250; Aku FY, 2017, MMWR-MORBID MORTAL W, V66, P806, DOI 10.15585/mmwr.mm6630a2; Akweongo P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079880; [Anonymous], 2019, Weekly Epidemiological Record, V94, P85; Aston SJ, 2019, AM J RESP CRIT CARE, V200, P359, DOI 10.1164/rccm.201807-1333OC; Ayieko Philip, 2009, Cost Eff Resour Alloc, V7, P3, DOI 10.1186/1478-7547-7-3; Bigogo GM, 2019, CLIN INFECT DIS, V69, P2177, DOI 10.1093/cid/ciz139; Boisier P, 2007, VACCINE, V25, pA24, DOI 10.1016/j.vaccine.2007.04.036; Bozio CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203205; Bwaka A, 2019, J INFECT DIS, V220, pS140, DOI 10.1093/infdis/jiz336; Chandran A, 2011, PEDIATR INFECT DIS J, V30, P3, DOI 10.1097/INF.0b013e3181ef25f7; Chola Lumbwe, 2009, Cost Eff Resour Alloc, V7, P16, DOI 10.1186/1478-7547-7-16; Coldiron ME, 2021, IN PRESS; Colombini A, 2011, VACCINE, V29, P5474, DOI 10.1016/j.vaccine.2011.05.058; Cooper LV, 2019, VACCINE, V37, P5657, DOI 10.1016/j.vaccine.2017.12.069; Edmond K, 2010, LANCET INFECT DIS, V10, P317, DOI 10.1016/S1473-3099(10)70048-7; Fernandez K, 2019, J INFECT DIS, V220, pS225, DOI 10.1093/infdis/jiz355; Ferrer BE, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1906-9; Fleming-Dutra KE, 2014, PEDIATR INFECT DIS J, V33, pS152, DOI 10.1097/INF.0000000000000083; Gervaix A, EXPERT REV VACCINES, V2021, P1; Gessner BD, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-22; Ghana Statistical Service, 2009, GHAN CHILD VERB AUT; Ghana Statistical Service (GSS) Ghana Health Service (GHS) ICF International, 2015, GHAN DEM HLTH SURV 2; Ghana TFHaSAotPotRo, 1998, CHILDR ACT; Hamaluba M, 2015, LANCET INFECT DIS, V15, P405, DOI 10.1016/S1473-3099(15)70007-1; Ho YC, 2015, HUM VACC IMMUNOTHER, V11, P1081, DOI 10.1080/21645515.2015.1023969; Huang SS, 2011, VACCINE, V29, P3398, DOI 10.1016/j.vaccine.2011.02.088; Klugman KP, 2014, LANCET GLOB HEALTH, V2, pE365, DOI 10.1016/S2214-109X(14)70241-4; Kwambana-Adams BA, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1914-3; Leimkugel J, 2005, J INFECT DIS, V192, P192, DOI 10.1086/431151; Letsa T, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5529-z; Molesworth AM, 2002, T ROY SOC TROP MED H, V96, P242, DOI 10.1016/S0035-9203(02)90089-1; Mueller JE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052464; O'Brien KL, 2019, LANCET, V394, P757, DOI 10.1016/S0140-6736(19)30721-4; Le P, 2014, TROP MED INT HEALTH, V19, P1321, DOI 10.1111/tmi.12370; Pike J, 2018, APPL HEALTH ECON HEA, V16, P765, DOI 10.1007/s40258-018-0416-4; Scott JAG, 2007, VACCINE, V25, P2398, DOI 10.1016/j.vaccine.2006.09.008; Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0; Sinha A, 2012, PAEDIATR INT CHILD H, V32, P65, DOI 10.1179/2046905512Y.0000000010; Soeters HM, 2020, VACCINE, V38, P5726, DOI 10.1016/j.vaccine.2020.06.002; Soeters HM, 2019, J INFECT DIS, V220, pS165, DOI 10.1093/infdis/jiz358; Soeters HM, 2019, J INFECT DIS, V220, pS253, DOI 10.1093/infdis/jiz301; Swartz MN, 2004, NEW ENGL J MED, V351, P1826, DOI 10.1056/NEJMp048246; Tam PYI, 2017, VACCINE, V35, P1817, DOI 10.1016/j.vaccine.2017.02.045; The National Health Insurance Authority, NATL HLTH INSURANCE; The World Bank, OFF EXCH RAT LCU PER; The World Bank, CURR HLTH EXP PER CA; Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1; UNICEF, 2020, PROD MEN VACC SUPPL; Usuf E, 2016, COST EFFECT RESOUR A, V14, DOI 10.1186/s12962-016-0053-4; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Whitney CG, 2018, CLIN INFECT DIS, V67, P375, DOI 10.1093/cid/ciy135; WHO and UNICEF, 2019, GHAN WHO UNICEF EST; Wolfson LJ, 2008, B WORLD HEALTH ORGAN, V86, P27, DOI 10.2471/BLT.07.045096; World Bank, LIF EXP BIRTH TOT YE; World Health Organization,, 2016, WHO MAN EST EC BURD; Zhang SS, 2016, J GLOB HEALTH, V6, DOI 10.7189/jogh.06.010408	57	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4685	4699		10.1016/j.vaccine.2021.06.043		JUL 2021	15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	34218962				2022-04-29	WOS:000681356500014
J	Brown, CC; Young, SG; Pro, GC				Brown, Clare C.; Young, Sean G.; Pro, George C.			COVID-19 vaccination rates vary by community vulnerability: A county-level analysis	VACCINE			English	Article						Vaccination; Vulnerability; COVID-19; SARS-CoV-2; Equity		We used the COVID-19 Community Vulnerability Index and 7 theme scores to assess associations between vulnerability and county-level COVID-19 vaccination (n = 2415 counties) through May 25th, 2021. When comparing vaccination rates among quintiles of CCVI scores, Theme 3 (housing type, transportation, household composition, and disability) was associated with the largest disparity, with the least vulnerable counties (Q1) having 33% higher rates of vaccination among individuals aged 18+ (53.5% vs 40.2%) compared to counties with the highest vulnerability (Q5). Using generalized linear models with binomial distributions and log links, we found that a 10-point increase in the CCVI index, socioeconomic vulnerability, housing type and composition, and epidemiological factors were associated with at least a 1.0 percentage point decline in county-level vaccination. The association between community vulnerability and lower vaccination rates suggests the need for continued efforts for equitable COVID-19 vaccination across marginalized communities. (c) 2021 Elsevier Ltd. All rights reserved.	[Brown, Clare C.] Univ Arkansas Med Sci, Dept Hlth Policy & Management, Fay W Boozman Coll Publ Hlth, 4301 West Markham Slot 820, Little Rock, AR 72205 USA; [Young, Sean G.] Univ Arkansas Med Sci, Dept Environm & Occupat Hlth, Fay W Boozman Coll Publ Hlth, 4301 West Markham Slot 820, Little Rock, AR 72205 USA; [Pro, George C.] Univ Arkansas Med Sci, Dept Hlth Behav & Hlth Educ, Fay W Boozman Coll Publ Hlth, 4301 West Markham Slot 820, Little Rock, AR 72205 USA		Brown, CC (通讯作者)，Univ Arkansas Med Sci, Dept Hlth Policy & Management, Fay W Boozman Coll Publ Hlth, 4301 West Markham Slot 820, Little Rock, AR 72205 USA.	cbrown3@uams.edu; SGYoung@uams.edu; GCPro@uams.edu	Young, Sean G/H-6469-2014	Young, Sean G/0000-0002-0054-0627			Arling Greg, 2021, Online J Public Health Inform, V13, pe5, DOI 10.5210/ojphi.v13i1.11621; Hughes MM, 2021, MMWR-MORBID MORTAL W, V70, P431, DOI 10.15585/mmwr.mm7012e1; Ivory D., NEW YORK TIMES; Karmakar M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.36462; Mackey K, 2021, ANN INTERN MED, V174, P362, DOI 10.7326/M20-6306; Murthy BP, 2021, MMWR-MORBID MORTAL W, V70, P759, DOI 10.15585/mmwr.mm7020e3; Painter EM, DEMOGRAPHIC CHARACTE; Patel JA, 2020, PUBLIC HEALTH, V183, P110, DOI 10.1016/j.puhe.2020.05.006; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Selden TM, 2020, HEALTH AFFAIR, V39, P1624, DOI 10.1377/hlthaff.2020.00897; Singu S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00406; Surgo Ventures, COVID 19 COMM VULN I; Thakur N, 2020, AM J RESP CRIT CARE, V202, P943, DOI 10.1164/rccm.202005-1523PP	13	4	4	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 13	2021	39	31					4245	4249		10.1016/j.vaccine.2021.06.038		JUL 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TG0WP	34167838	Bronze, Green Published			2022-04-29	WOS:000671133900003
J	Adams, AL; Eberle, K; Colon, JR; Courville, E; Xin, H				Adams, Abby L.; Eberle, Karen; Colon, Jonothan Rosario; Courville, Evan; Xin, Hong			Synthetic conjugate peptide Fba-Met6 (MP12) induces complement-mediated resistance against disseminated Candida albicans	VACCINE			English	Article						Vaccine; Peptide; Fungal; Humoral; Complement; Candidiasis	BINDS HUMAN PLASMINOGEN; MONOCLONAL-ANTIBODY; VACCINE; IDENTIFICATION; ANTIGENS	The fungal genus Candida includes common commensals of the human mucosal membranes, and the most prevalently isolated species, C. albicans, poses a threat of candidemia and disseminated infection associated with an unacceptably high mortality rate and an immense $4 billion burden (US) yearly. Nevertheless, the demand for a vaccine remains wholly unfulfilled and increasingly pressing. We developed a double-peptide construct that is feasible for use in humans with the intention of preventing morbid infection by targeting epitopes derived from fructose bisphosphate aldolase (Fba) and methionine synthase (Met6) which are expressed on the C. albicans cell surface. To test the applicability of the design, we vaccinated mice via the intramuscular (IM) route with the conjugate denoted Fba-Met6 MP12 and showed that the vaccine enhanced survival against a lethal challenge. Because overall endpoint IgG1 and IgG2a antibody titers were robust and these mouse subclasses are associated with protective functionality, we investigated the potential of Fba and Met6 specific antibodies to facilitate the well-defined anti-Candida response by complement, which opsonizes fungi for degradation by primary effectors. Notably, reductions in the fungal burdens and enhanced survival were both abrogated in MP12vaccinated mice that were pre-challenge dosed with cobra venom factor (CVF), a complement depleting factor. Altogether, we demonstrated that complement is relevant to MP12-based protection against disseminated C. albicans, delineating that a novel, multivalent targeted vaccine against proteins on the surface of C. albicans can enhance the natural response to infection. (c) 2021 Elsevier Ltd. All rights reserved.	[Adams, Abby L.; Eberle, Karen; Colon, Jonothan Rosario; Courville, Evan; Xin, Hong] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, 1901 Perdido St, New Orleans, LA 70112 USA		Xin, H (通讯作者)，Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, 1901 Perdido St, New Orleans, LA 70112 USA.	HXin@lsuhsc.edu		Rosario-Colon, Jonothan/0000-0003-4676-2898	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R414AI124900-01]; Department of Defense CDMRP AwardUnited States Department of Defense [PR171482]; Louisiana State University Health Sciences Center (LSUHSC)	This work was supported by the National Institutes of Health grant R414AI124900-01 and the Department of Defense CDMRP Award PR171482. The author thanks Louisiana State University Health Sciences Center (LSUHSC) for the support of our research.	Blumberg EA, 1996, CLIN INFECT DIS, V22, P462, DOI 10.1093/clinids/22.3.462; Capodagli GC, 2014, BIOCHEMISTRY-US, V53, P7604, DOI 10.1021/bi501141t; CASSONE A, 1987, CRIT REV MICROBIOL, V15, P87, DOI 10.3109/10408418709104451; Cassone A, 2013, NAT REV MICROBIOL, V11, P884, DOI 10.1038/nrmicro3156; Chen K, 2016, CELL HOST MICROBE, V20, P596, DOI 10.1016/j.chom.2016.10.003; Clancy CJ, 2008, J CLIN MICROBIOL, V46, P1647, DOI 10.1128/JCM.02018-07; Conti Heather R, 2014, Curr Protoc Immunol, V105, DOI 10.1002/0471142735.im1906s105; Crowe JD, 2003, MOL MICROBIOL, V47, P1637, DOI 10.1046/j.1365-2958.2003.03390.x; Cutler JE, 2016, LA patent, Patent No. [US9416173B2, 9416173]; Deenick EK, 2005, EUR J IMMUNOL, V35, P2949, DOI 10.1002/eji.200425719; Diebel LN, 1999, J TRAUMA, V47, P1045, DOI 10.1097/00005373-199912000-00009; Freire-Beneitez V, 2016, SCI REP-UK, V6, DOI 10.1038/srep22989; Gudlaugsson O, 2003, CLIN INFECT DIS, V37, P1172, DOI 10.1086/378745; Han YM, 2001, J IMMUNOL, V167, P1550, DOI 10.4049/jimmunol.167.3.1550; Hernandez-Chavez MJ, 2017, J FUNGI, V3, DOI 10.3390/jof3040051; Hinkula J, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030064; Johnson A, 2003, NAT REV MICROBIOL, V1, P106, DOI 10.1038/nrmicro752; LEATHERBARROW RJ, 1984, MOL IMMUNOL, V21, P321, DOI 10.1016/0161-5890(84)90103-2; Li FQ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-253; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Liedke SC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12540-y; Lin L, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000703; Marin E, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01343; MUKHERJEE J, 1995, J EXP MED, V181, P405, DOI 10.1084/jem.181.1.405; Mullick A, 2004, INFECT IMMUN, V72, P5868, DOI 10.1128/IAI.72.10.5868-5876.2004; Nishimura, 2018, J THROMBOSIS HAEMOTO, V16, P987; PEREIRA HA, 1984, CLIN EXP IMMUNOL, V57, P307; Pitarch A, 2004, PROTEOMICS, V4, P3084, DOI 10.1002/pmic.200400903; Rady HF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148701; Sadler K, 1999, VACCINE, V18, P416, DOI 10.1016/S0264-410X(99)00255-8; Saint-Macary ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0111108; Shams F, 2016, MICROBIOLOGYOPEN, V5, P340, DOI 10.1002/mbo3.331; Smahel M, 2014, GENE THER, V21, P225, DOI 10.1038/gt.2013.81; Turner JS, 2018, CELL REP, V25, P1395, DOI 10.1016/j.celrep.2018.10.042; Wang XJ, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0095-0; Wegmann F, 2015, CLIN VACCINE IMMUNOL, V22, P1004, DOI 10.1128/CVI.00736-14; Wells J, 2006, INFECT IMMUN, V74, P390, DOI 10.1128/IAI.74.1.390-393.2006; Xiao H, 2007, AM J PATHOL, V170, P52, DOI 10.2353/ajpath.2007.060573; Xin H., 2014, Journal of Vaccines and Vaccination, V5, P241; Xin H, 2019, MED MYCOL, V57, P745, DOI 10.1093/mmy/myy122; Xin H, 2016, VACCINE, V34, P245, DOI 10.1016/j.vaccine.2015.11.035; Xin H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035106; Xin H, 2011, CLIN VACCINE IMMUNOL, V18, P1656, DOI 10.1128/CVI.05215-11; Yano A, 2005, VACCINE, V23, P2322, DOI 10.1016/j.vaccine.2005.01.031; Yano A, 2013, VACCINE, V31, P1510, DOI 10.1016/j.vaccine.2012.12.083	45	1	1	2	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4099	4107		10.1016/j.vaccine.2021.06.001		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34127293				2022-04-29	WOS:000672535200014
J	Thomas, D; Motomoke, E; Crawford, J; Defawe, O; Makaya, A; Ngwato, JW; Bompongo, J; Monzembela, J; Ailstock, G; Bancroft, E; Magadzire, B; Baabo, D; Watson, N				Thomas, Dorothy; Motomoke, Eomba; Crawford, Jessica; Defawe, Olivier; Makaya, Archimede; Ngwato, Jean Willy; Bompongo, Joel; Monzembela, Jose; Ailstock, Gabriella; Bancroft, Emily; Magadzire, Bvudzai; Baabo, Dominique; Watson, Noel			Optimized supply chain model reduces health system costs in DRC & nbsp;	VACCINE			English	Article						Vaccine supply chain; EPI; Activity based costing; Costs; Democratic Republic of the Congo	VACCINE; CHALLENGES; DELIVERY; CHILDREN; NEED	Objective: In 2017, an optimized immunization supply chain (iSC) model was implemented in Equateur Province, Democratic Republic of the Congo. The optimized model aimed to address iSC challenges and featured direct deliveries to service delivery points (SDPs), longer replenishment intervals and increased cold chain capacity. This assessment examines iSC costs before and 5 months after implementing the optimized model. Materials & Methods: We used a nonexperimental pre-post study design to compare iSC costs before and after implementation. We applied an activity-based costing approach with a comparison arm to assess procurement, management, storage and transportation costs for three iSC tiers: Province (n = 1); Zone (n = 4) and SDP (n = 15). We included data from 3 treatment Zones and 11 treatment SDPs; 1 control Zone and 4 control SDPs. We used sample and population data to estimate iSC costs for the entirety of Equateur Province. Results: In the period immediately before implementing the optimized model, estimated annual iSC costs were $974,237. Following implementation, estimated annual iSC costs were $642,627-a 34% ($331,610) reduction. This change in costs was influenced by a 43% ($180,313) reduction in SDP costs, a 67% ($198,092) reduction in Zonal costs and an 18% ($46,795) increase in Provincial costs. After implementing the optimized model, average iSC costs for treatment Zones was $6,895 (SD: $6,072); for the control Zone was $21,738; for treatment SDPs was $989 (SD: $969); and for control SDPs was $1,356 (SD: $1,062). Conclusions: We observed an absolute reduction in iSC costs in treatment Zones while control Zone post implementation iSC costs remained the same or increased. The greatest cost reductions were for storage and transport at Zones and SDPs. Although cost implications of this model must continue to be evaluated over time, these findings are promising and will inform decisions around project expansion. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Thomas, Dorothy; Crawford, Jessica; Defawe, Olivier; Ailstock, Gabriella; Bancroft, Emily; Magadzire, Bvudzai] VillageReach, 2900 Eastlake Ave East,Suite 230, Seattle, WA 98102 USA; [Motomoke, Eomba] VillageReach, 8b Mongala, Kinshasa, DEM REP CONGO; [Makaya, Archimede] VillageReach, Av Mundji, Mbandaka, Equateur, DEM REP CONGO; [Bompongo, Joel] John Snow Inc, Res & Training Inst, 32 Ave Justice, Kinshasa, DEM REP CONGO; [Ngwato, Jean Willy; Monzembela, Jose] Equateur Prov Hlth Dept, Av Mundji, Mbandaka, Equateur, DEM REP CONGO; [Baabo, Dominique] Projet Dev Sect Sante, Av Huileries, Kinshasa, DEM REP CONGO; [Watson, Noel] OPS MEND LLC, 43 Riverside Ave, Medford, MA 02155 USA		Crawford, J (通讯作者)，VillageReach, 2900 Eastlake Ave East,Suite 230, Seattle, WA 98102 USA.	jessica.crawford@villagereach.org		Ailstock, gabriella/0000-0002-1234-5319; Thomas, Dorothy/0000-0001-5510-5940	Government of the Democratic Republic of the Congo through Ministry of Health; World BankThe World Bank India; Government of the Democratic Republic of the Congo through Cellule d'Appui et de Gestion Financiere; Global Fund to Fight AIDS, Tuberculosis and Malaria; Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1195513]	This project is funded by the Government of the Democratic Republic of the Congo through two agencies of the Ministry of Health: the Projet de Developpement du Systeme de Sante (with funding from the World Bank) and the Cellule d'Appui et de Gestion Financiere (with funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria). Funding is also provided from the Bill & Melinda Gates Foundation [OPP1195513]. The views, conclusions and recommendations expressed herein are solely those of the authors and do not necessarily reflect the official policy or position of the Bill & Melinda Gates Foundation.	Aina M, 2017, VACCINE, V35, P2175, DOI 10.1016/j.vaccine.2016.11.100; Andrus JK, 2011, HEALTH AFFAIR, V30, P1104, DOI 10.1377/hlthaff.2011.0361; Assi TM, 2013, VACCINE, V31, P2828, DOI 10.1016/j.vaccine.2013.04.011; Brown ST, 2014, VACCINE, V32, P4097, DOI 10.1016/j.vaccine.2014.04.090; Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004; Kaufmann JR, 2011, HEALTH AFFAIR, V30, P1113, DOI 10.1377/hlthaff.2011.0368; Lee BY, 2016, VACCINE, V34, P4998, DOI 10.1016/j.vaccine.2016.08.036; McCord J, 2013, 4 USAID 4 USAID; Ministere du Plan et Suivi de la Mise en oeuvre de la Revolution de la Modernite (MPSMRM) Ministere de la Sante Publique (MSP) and ICF International, ENQ DEM SAN REP DEM ENQ DEM SAN REP DEM; Mvundura M, 2014, VACCINE, V32, P834, DOI 10.1016/j.vaccine.2013.12.029; Mwencha M, 2017, GLOB HEALTH-SCI PRAC, V5, P399, DOI 10.9745/GHSP-D-16-00395; Numbi FKM, 2017, VACCINE, V35, P2105, DOI 10.1016/j.vaccine.2016.11.096; Prosser W, 2016, SYSTEM DESIGN APPROA; Prosser W, 2017, VACCINE, V35, P2162, DOI 10.1016/j.vaccine.2016.09.073; Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096; Sarac A, 2010, INT J PROD ECON, V128, P77, DOI 10.1016/j.ijpe.2010.07.039; Sarley D., 2010, 4 USAID 4 USAID; Shittu E, 2016, HEALTH AFFAIR, V35, P293, DOI 10.1377/hlthaff.2015.1328; Songane M, 2018, INT J HEALTH ECON MA, V18, P197, DOI 10.1007/s10754-017-9229-5; Tien M., 2013, 4 USAID 4 USAID; United Nations Population Division, WORLD POPULATION PRO; VillageReach, EXPL NEW DISTR MOD V EXPL NEW DISTR MOD V; Vledder M., 2010, ENHANCING PUBLIC SUP ENHANCING PUBLIC SUP; Vledder M, 2019, HEALTH SYST REFORM; WHO Immunization Practices Advisory Committee, 2014, IMM SUPPL CHAIN LOG IMM SUPPL CHAIN LOG; World Health Organization, WHOIVB0814 WHOIVB0814; World Health Organization, WHOIVB1811 WHOIVB1811; Yadav P, 2015, HEALTH SYST REFORM, V1, P142, DOI 10.4161/23288604.2014.968005; Zaffran M, 2013, VACCINE, V31, pB73, DOI 10.1016/j.vaccine.2012.11.036	29	0	0	2	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4166	4172		10.1016/j.vaccine.2021.05.083		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34127290	hybrid, Green Published			2022-04-29	WOS:000672535200022
J	Uwins, C; Cyriac, S; Bhandoria, G				Uwins, Christina; Cyriac, Sunu; Bhandoria, Geetu			HPV vaccine: Expanding indications and global disparity	VACCINE			English	Editorial Material							HUMAN-PAPILLOMAVIRUS VACCINATION; PREVENTION; CANCER; DNA		[Uwins, Christina] Royal Surrey NHS Fdn Trust, Acad Dept Gynaecol Oncol, Robot Gynaecol Oncol, Guildford, Surrey, England; [Cyriac, Sunu] Amala Inst Med Sci, Dept Med Oncol & Haematol, Malignant Haematol & BMT, Trichur, Kerala, India; [Bhandoria, Geetu] Command Hosp, Dept Obstet & Gynecol, Gynecol Oncol & Obstet, Kolkata, W Bengal, India		Bhandoria, G (通讯作者)，Command Hosp, Dept Obstet & Gynecol, Kolkata 700027, W Bengal, India.	bhandoriageetu@gmail.com	Bhandoria, Geetu/V-9237-2019	Bhandoria, Geetu/0000-0002-6865-7856; Uwins, Christina/0000-0002-3439-2183			Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7; Datta S, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4108-y; Fox-Lewis A, 2020, OCCUP ENVIRON MED, V77, P809, DOI 10.1136/oemed-2019-106333; Gillison ML, 2015, J CLIN ONCOL, V33, P3235, DOI 10.1200/JCO.2015.61.6995; Goon Peter KC, 2018, ADIS J FIGURE, DOI [10.6084/m9.figshare.6194924.v1, DOI 10.6084/M9.FIGSHARE.6194924.V1]; HALLMO P, 1991, EUR ARCH OTO-RHINO-L, V248, P425, DOI 10.1007/BF01463570; Harrison R, 2020, OBSTET GYNECOL, V136, P663, DOI 10.1097/AOG.0000000000004021; Herrero R, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0068329, DOI 10.1371/J0URNAL.P0NE.0068329]; Hirth JM, 2017, VACCINE, V35, P3446, DOI 10.1016/j.vaccine.2017.05.025; Rioux M, 2013, J OTOLARYNGOL-HEAD N, V42, DOI 10.1186/1916-0216-42-54; Sankaranarayanan R, 2019, LANCET ONCOL, V20, pE637, DOI 10.1016/S1470-2045(19)30531-5; Timbang MR, 2019, HUM VACC IMMUNOTHER, V15, P1920, DOI 10.1080/21645515.2019.1600985; WHO World Health Organization, WHO IMM COUNTR PROF; Zhou QF, 2019, CANCER MANAG RES, V11, P3643, DOI 10.2147/CMAR.S201975	14	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3787	3789		10.1016/j.vaccine.2021.05.082		JUN 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34092426				2022-04-29	WOS:000663773600002
J	Blanchard-Rohner, G; Enriquez, N; Lemaitre, B; Cadau, G; Giostra, E; Hadaya, K; Meyer, P; Gasche-Soccal, PM; Berney, T; van Delden, C; Siegrist, CA				Blanchard-Rohner, G.; Enriquez, N.; Lemaitre, B.; Cadau, G.; Giostra, E.; Hadaya, K.; Meyer, P.; Gasche-Soccal, P. M.; Berney, T.; van Delden, C.; Siegrist, C-A			Pneumococcal immunity and PCV13 vaccine response in SOT-candidates and recipients	VACCINE			English	Article						Vaccine; Solid organ Transplantation	CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; IMMUNOGENICITY; ANTIBODIES; DISEASE	Background: Solid organ transplantation (SOT) candidates and recipients are highly vulnerable to invasive pneumococcal diseases (IPD). Data on which to base optimal immunization recommendations for this population is scant. The national distribution of IPD serotypes led the Swiss Health Authorities to recommend in 2014 one dose of pneumococcal-13-valent-conjugate-vaccine (PCV13), without any subsequent dose of the 23-valent-polysaccharide-pneumococcal-vaccine (PPV23). Methods: This is a retrospective analysis of pneumococcal immunity using a multiplex binding assay, to assess seroprotection rates against a selection of seven PCV13-and seven PPV23-serotypes in SOT candidates and recipients evaluated and/or transplanted in 2014/2015 in the University Hospitals of Geneva. Seroprotection was defined as serotype-specific antibody concentration greater than 0.5 mg/l and overall seroprotection when this was achieved for > 6/7 serotypes. Results: Pre-vaccination and at time of transplant sera were available for 35/43 (81%), and 43/43 (100%) SOT-candidates respectively. At listing, 17/35 (49%) SOT-candidates were seroprotected against PCV13 and 21/35 (60%) against PPV23 serotypes. Following one systematic dose of PCV13 at listing, 35/43 (81%) SOT-recipients were seroprotected at day of transplant against PCV13-serotypes and 34/43 (79%) against PPV23 serotypes, compared to 21/41 (51%) and 28/41 (68%) respectively in the controls transplanted in 2013, before the systematic PCV13-vaccination. Conclusions: The systematic vaccination with PCV13 of all SOT candidates without additional PPV23 is a good strategy as it confers seroprotection against a wide range of pneumococcal serotypes. Indeed, one of five PCV13-vaccinated SOT-candidates was nevertheless not seroprotected at time of transplant, reflecting their partial immune competence, and indicating the need for additional dose of pneumococcal vaccines before transplant. (c) 2021 Elsevier Ltd. All rights reserved.	[Blanchard-Rohner, G.; Enriquez, N.; Siegrist, C-A] Ctr Vaccinol & Neonatal Immunol, Med Fac, Dept Pediat & Pathol Immunol, Geneva, Switzerland; [Blanchard-Rohner, G.; Enriquez, N.; Siegrist, C-A] Univ Hosp Geneva, Geneva, Switzerland; [Blanchard-Rohner, G.; Siegrist, C-A] Univ Hosp Geneva, Dept Woman Child & Adolescent Med, Unit Immunol & Vaccinol, Geneva, Switzerland; [Blanchard-Rohner, G.; Enriquez, N.; Giostra, E.; Hadaya, K.; Meyer, P.; Gasche-Soccal, P. M.; Berney, T.; van Delden, C.; Siegrist, C-A] Fac Med, Geneva, Switzerland; [Enriquez, N.; van Delden, C.] Univ Hosp Geneva, Transplant Infect Dis Unit, Geneva, Switzerland; [Lemaitre, B.; Cadau, G.] Univ Hosp Geneva, Lab Vaccinol, Geneva, Switzerland; [Giostra, E.] Univ Hosp Geneva, Dept Gastroenterol, Geneva, Switzerland; [Giostra, E.] Univ Hosp Geneva, Dept Hepatol, Geneva, Switzerland; [Hadaya, K.] Univ Hosp Geneva, Div Nephrol, Geneva, Switzerland; [Meyer, P.] Univ Hosp Geneva, Div Cardiol, Geneva, Switzerland; [Gasche-Soccal, P. M.] Univ Hosp Geneva, Div Pneumol, Geneva, Switzerland; [Berney, T.] Univ Hosp Geneva, Div Transplantat, Geneva, Switzerland		Blanchard-Rohner, G (通讯作者)，Univ Geneva, Unit Immunol & Vaccinol, Dept Pediat Gynecol & Obstet, Div Gen Pediat,Geneva Univ Hosp, Geneva, Switzerland.	Geraldine.blanchardrohner@hcuge.ch					Bjarnarson SP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072588; Blanchard-Rohner G, 2019, AM J TRANSPLANT, V19, P512, DOI 10.1111/ajt.15097; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Broeders EN, 2013, CLIN NEPHROL, V79, P313, DOI 10.5414/CN107779; CDC, PNEUMOCOCCAL VACCINA; (CFV) OfdlspOeCfplv, 2014, THE B, V8; Chesi C, 2009, TRANSPL INFECT DIS, V11, P507, DOI 10.1111/j.1399-3062.2009.00436.x; Clutterbuck EA, 2012, J INFECT DIS, V205, P1408, DOI 10.1093/infdis/jis212; Collaboration EBPI Zurich ceOfdlsp, 2019, ENQUETE COUVERTURE V; Crum-Cianflone NF, 2010, J INFECT DIS, V202, P1114, DOI 10.1086/656147; Daly TM, 2015, CLIN VACCINE IMMUNOL, V22, P148, DOI 10.1128/CVI.00735-14; Dendle C, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12866; Eriksson M, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13343; Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928; Gasink LB, 2006, CHEST, V130, P218, DOI 10.1378/chest.130.1.218; Goldblatt D, 2011, CLIN VACCINE IMMUNOL, V18, P1744, DOI 10.1128/CVI.05158-11; Goldblatt D, 2009, CLIN INFECT DIS, V49, P1318, DOI 10.1086/606046; Hammitt LL, 2006, J INFECT DIS, V193, P1487, DOI 10.1086/503805; Institute for Infectious Diseases S, 2019, ANN REP NAT CTR INV; Johnson SE, 1999, J INFECT DIS, V180, P133, DOI 10.1086/314845; Kamboj KK, 2003, J INFECT DIS, V187, P1629, DOI 10.1086/374785; Kumar D, 2007, AM J TRANSPLANT, V7, P1209, DOI 10.1111/j.1600-6143.2006.01705.x; Kumar D, 2003, J INFECT DIS, V187, P1639, DOI 10.1086/374784; Lazarus R, 2011, CLIN INFECT DIS, V52, P736, DOI 10.1093/cid/cir003; Lee LH, 2003, VACCINE, V21, P2190, DOI 10.1016/S0264-410X(03)00025-2; Lochen A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75691-5; Marchese RD, 2009, CLIN VACCINE IMMUNOL, V16, P387, DOI 10.1128/CVI.00415-08; McCashland TM, 2000, J INFECT DIS, V181, P757, DOI 10.1086/315245; Nagel J, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0636-z; Oesterreich S, 2020, VACCINE, V38, P3339, DOI 10.1016/j.vaccine.2020.02.088; Office federal de la sante publique UddSpDMt, 2014, MALADIES PNEUMOCOQUE; OFSP, 2021, CHIFFR MAL INF; OFSP, 2014, B OFSP; Papadatou I, 2016, CLIN VACCINE IMMUNOL, V23, P388, DOI 10.1128/CVI.00721-15; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Prevention CCfDCa, 2017, 2017 CHILDH PNEUM CO; Rheumatology BSaHCobotFACoIaebtSSfAaIatSSf, 2013, BACKGR DOC IMM MED I; Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119; Tobudic S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046133; Tuerlinckx D, 2007, CLIN EXP IMMUNOL, V149, P295, DOI 10.1111/j.1365-2249.2007.03409.x; van Kessel DA, 2017, TRANSPL IMMUNOL, V40, P31, DOI 10.1016/j.trim.2016.11.001; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Zielen S, 2000, INFECT IMMUN, V68, P1435, DOI 10.1128/IAI.68.3.1435-1440.2000	43	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 11	2021	39	26					3459	3466		10.1016/j.vaccine.2021.05.030		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SN6KQ	34023135				2022-04-29	WOS:000658397000002
J	Longchamps, C; Ducarroz, S; Crouzet, L; Vignier, N; Pourtau, L; Allaire, C; Colleville, AC; El Aarbaoui, T; Melchior, M				Longchamps, C.; Ducarroz, S.; Crouzet, L.; Vignier, N.; Pourtau, L.; Allaire, C.; Colleville, A. C.; Aarbaoui, T. El; Melchior, M.		ECHO Study Grp	COVID-19 vaccine hesitancy among persons living in homeless shelters in France	VACCINE			English	Article							MIGRANTS	COVID-19 vaccine hesitancy is frequent and can constitute a barrier to the dissemination of vaccines once they are available. Unequal access to vaccines may also contribute to socioeconomic inequalities with regard to COVID-19. We studied vaccine hesitancy among persons living in homeless shelters in France between May and June 2020 (n = 235). Overall, 40.9% of study participants reported vaccine hesitancy, which is comparable to general population trends in France. In multivariate regression models, factors associated with vaccine hesitancy are: being a woman (OR = 2.55; 95% CI 1.40-4.74), living with a partner (OR = 2.48, 95% CI 1.17-5.41), no legal residence in France (OR = 0.51, 95% CI 0.27-0.92), and health literacy (OR = 0.38, 95% CI 0.21, 0.68). Our results suggest that trends in vaccine hesitancy and associated factors are similar among homeless persons as in the general population. Dissemination of information on vaccine risks and benefits needs to be adapted to persons who experience severe disadvantage. (C) 2021 Elsevier Ltd. All rights reserved.	[Longchamps, C.; Vignier, N.; Aarbaoui, T. El; Melchior, M.] Sorbonne Univ, INSERM, Inst Pierre Louis Epidemiol & Sante Publ, IPLESP,Equipe Rech Epidemiol Sociale, F-75012 Paris, France; [Ducarroz, S.; Crouzet, L.] Univ Claude Bernard Lyon 1, HeSPeR, Hlth Serv & Performance Res Lab, EA 7425, F-F6900 Lyon, France; [Vignier, N.; Melchior, M.] CNRS, French Collaborat Inst Migrat, F-93300 Aubervilliers, France; [Vignier, N.] Ctr Hosp Cayenne, INSERM, CIC 1424, Cayenne, France; [Vignier, N.] Ctr Hosp Cayenne, Corevih Guyane, Cayenne, France; [Pourtau, L.] Univ Paul Valery Montpellier 3, Lab Etud & Rech Sociol & Ethnol Montpellier, EA 4584, F-34080 Montpellier, France; [Allaire, C.; Colleville, A. C.] French Natl Publ Hlth Agcy, Sante Publ France, F-94415 St Maurice, France		Longchamps, C (通讯作者)，Sorbonne Univ, INSERM, Inst Pierre Louis Epidemiol & Sante Publ, IPLESP,Equipe Rech Epidemiol Sociale, F-75012 Paris, France.		Vignier, Nicolas/AAH-8382-2021; Ducarroz, Simon/ABW-4392-2022	Vignier, Nicolas/0000-0002-9410-9327; 	French Collaborative Institute on Migration, France's Public Health Agency; French National Research AgencyFrench National Research Agency (ANR) [Flash COVID-19]	The funders of our study are: The French Collaborative Institute on Migration, France's Public Health Agency, and the French National Research Agency (Flash COVID-19).	Baggett TP, 2020, JAMA-J AM MED ASSOC, V323, P2191, DOI 10.1001/jama.2020.6887; Burger AE, 2021, VACCINE, V39, P943, DOI 10.1016/j.vaccine.2020.12.069; Calixte R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17186856; Clark E, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008484; Costantini L, 2021, J AFFECT DISORDERS, V279, P473, DOI 10.1016/j.jad.2020.09.131; Cour des Comptes, 2017, HEBERGEMENT PERSONNE; Debussche X, 2018, SAGE OPEN MED, V6, DOI 10.1177/2050312118801250; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Drefahl S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18926-3; Haute Autorite de Sante, 2020, STRAT VACC SARS COV; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Priebe S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-187; Ralli M, 2020, EUR REV MED PHARMACO, V24, P9765, DOI [10.26355/eurrev_202009_23071, 10.26355/eurrev_202009_3071]; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Wilson L, 2018, VACCINE, V36, P1055, DOI 10.1016/j.vaccine.2018.01.025; World Health Organization, 2014, SAGE WORK GROUP DEAL	16	6	6	3	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3315	3318		10.1016/j.vaccine.2021.05.012		JUN 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	34011464	Green Published, Green Submitted, Bronze			2022-04-29	WOS:000657001300003
J	Polkowska, A; Rinta-Kokko, H; Toropainen, M; Palmu, AA; Nuorti, JP				Polkowska, Aleksandra; Rinta-Kokko, Hanna; Toropainen, Maija; Palmu, Arto A.; Nuorti, J. Pekka			Long-term population effects of infant 10-valent pneumococcal conjugate vaccination on pneumococcal meningitis in Finland	VACCINE			English	Article						Pneumococcal meningitis; PCV10; Serotype replacement; Streptococcus pneumoniae	PNEUMONIAE SEROTYPE 19A; STREPTOCOCCUS-PNEUMONIAE; BACTERIAL-MENINGITIS; IMPACT; DISEASE; CHILDREN; VACCINES; EPIDEMIOLOGY; ENGLAND; ADULTS	Background: No previous studies have reported long-term follow-up of ten-valent pneumococcal conju-gate vaccine (PCV10) program impact on pneumococcal meningitis (PM). We assessed the effects of infant PCV10 program on PM incidence, mortality and serotype distribution in children and adults during 7 years after introduction. Methods: We conducted a population-based observational study. A case of PM was defined as isolation of Streptococcus pneumoniae from cerebrospinal fluid or, a patient with S. pneumoniae isolated from blood and an ICD-10 hospital discharge diagnosis of bacterial meningitis within 30 days before or after positive culture date. We compared age-and serotype-specific incidence and associated 30-day mortality rates in 2011 & ndash;2017 (PCV10 period) with those in 2004 & ndash;2010 (pre-PCV10 baseline) by using Poisson regression models. Absolute rate differences and 95% confidence intervals (CIs) were calculated from the parameter estimates by using delta method. Results: During the PCV10 period, the overall incidence of PCV10 serotype meningitis decreased by 68% (95%CI 57%-77%), and the overall PM incidence by 27% (95%CI: 12%-39%). In age groups 0 & ndash;4, 50 & ndash;64, and > 18 years, the overall PM incidence was reduced by 64%, 34% and 19%, respectively. In adults > 65 years of age, a 69% reduction in PCV10 serotypes was offset by 157% (56%-342%) increase in non-PCV10 serotypes. The overall PM-related mortality rate decreased by 42% (95%CI 4%-65%). Overall case fatality proportion (CFP) was 16% in pre-PCV10 period and 12% in PCV10 period (p = 0.41); among persons 50 & ndash;64 years the CFP decreased from 25% to 10% (p = 0.04). Conclusions: We observed substantial impact and herd protection for vaccine-serotype PM and associ-ated mortality after infant PCV10 introduction. However, in older adults > 65 years of age, PM burden remains unchanged due to serotype replacement. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Polkowska, Aleksandra; Toropainen, Maija; Nuorti, J. Pekka] Tampere Univ, Fac Social Sci, Hlth Sci Unit, Arvo Ylpon Katu 34, Tampere 33520, Finland; [Rinta-Kokko, Hanna; Palmu, Arto A.] Finnish Inst Hlth & Welf THL, Dept Publ Hlth Solut, Publ Hlth Evaluat & Project Unit, Mannerheimintie 166, Helsinki, Finland; [Nuorti, J. Pekka] Finnish Inst Hlth & Welf THL, Dept Hlth Secur, Infect Dis & Vaccinat Unit, Mannerheimintie 166, Helsinki, Finland		Nuorti, JP (通讯作者)，Tampere Univ, Fac Social Sci, Hlth Sci Unit, Arvo Ylpon Katu 34, Tampere 33520, Finland.	aleksandra.polkowska@tuni.fi; hanna.rinta-kokko@thl.fi; maija.toropainen@thl.fi; arto.palmu@thl.fi; pekka.nuorti@tuni.fi					Alari A, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0755-7; Azevedo J, 2016, J MED MICROBIOL, V65, P1164, DOI 10.1099/jmm.0.000346; Ben-Shimol S, 2016, VACCINE, V34, P4543, DOI 10.1016/j.vaccine.2016.07.038; Bijlsma MW, 2016, LANCET INFECT DIS, V16, P339, DOI 10.1016/S1473-3099(15)00430-2; Brandileone MCC, 2018, VACCINE, V36, P2559, DOI 10.1016/j.vaccine.2018.04.010; Brouwer MC, 2010, NEUROLOGY, V75, P1533, DOI 10.1212/WNL.0b013e3181f96297; Brouwer MC, 2010, CLIN MICROBIOL REV, V23, P467, DOI 10.1128/CMR.00070-09; Casado-Flores J, 2008, PEDIATR INFECT DIS J, V27, P1020, DOI 10.1097/INF.0b013e31817bd2dc; Castelblanco RL, 2014, LANCET INFECT DIS, V14, P813, DOI 10.1016/S1473-3099(14)70805-9; De Wals P, 2018, VACCINE, V36, P5495, DOI 10.1016/j.vaccine.2018.07.069; Edmond K, 2010, LANCET INFECT DIS, V10, P317, DOI 10.1016/S1473-3099(10)70048-7; Forstner C, 2020, VACCINE, V38, P1129, DOI 10.1016/j.vaccine.2019.11.026; Grando IM, 2015, CAD SAUDE PUBLICA, V31, P276, DOI 10.1590/0102-311X00169913; Hanquet G, 2019, THORAX, V74, P473, DOI 10.1136/thoraxjnl-2018-211767; Harboe ZB, 2014, CLIN INFECT DIS, V59, P1066, DOI 10.1093/cid/ciu524; Hirose TE, 2015, J PEDIAT-BRAZIL, V91, P130, DOI 10.1016/j.jped.2014.07.002; Hsu HE, 2009, NEW ENGL J MED, V360, P244, DOI 10.1056/NEJMoa0800836; Htar MTT, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1147-x; Htar MTT, 2013, ADV THER, V30, P748, DOI 10.1007/s12325-013-0051-2; Imohl M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0787-1; Isturiz R, 2017, EXPERT REV VACCINES, V16, P1007, DOI 10.1080/14760584.2017.1362339; Jacobs DM, 2017, VACCINE, V35, P6160, DOI 10.1016/j.vaccine.2017.09.050; Jit M, 2010, J INFECTION, V61, P114, DOI 10.1016/j.jinf.2010.04.008; Jokinen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120290; Klemets P, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-96; McIntyre PB, 2012, LANCET, V380, P1703, DOI 10.1016/S0140-6736(12)61187-8; Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1; Mook-Kanamori BB, 2011, CLIN MICROBIOL REV, V24, P557, DOI 10.1128/CMR.00008-11; Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Mrkvan T, 2018, EXPERT REV VACCINES, V17, P797, DOI 10.1080/14760584.2018.1516551; Naucler P, 2017, CLIN INFECT DIS, V65, P1780, DOI 10.1093/cid/cix685; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Olarte L, 2015, CLIN INFECT DIS, V61, P767, DOI 10.1093/cid/civ368; Oligbu G, 2019, EMERG INFECT DIS, V25, P1708, DOI 10.3201/eid2509.180747; Palmu AA, 2013, LANCET, V381, P214, DOI 10.1016/S0140-6736(12)61854-6; Pichon B, 2013, J CLIN MICROBIOL, V51, P820, DOI 10.1128/JCM.01917-12; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Pircon JY, 2018, VACCINE, V36, P6933, DOI 10.1016/j.vaccine.2018.10.003; Polkowska Aleksandra, 2017, BMJ Open, V7, pe015080, DOI 10.1136/bmjopen-2016-015080; Regev-Yochay G, 2018, EMERG INFECT DIS, V24, P1275, DOI 10.3201/eid2407.170721; Rinta-Kokko H, 2018, VACCINE, V36, P1934, DOI 10.1016/j.vaccine.2018.03.001; Rodenburg GD, 2010, EMERG INFECT DIS, V16, P816, DOI 10.3201/eid1605.091223; Ruiz-Contreras J, 2017, VACCINE, V35, P4646, DOI 10.1016/j.vaccine.2017.06.070; Siira L, 2012, J CLIN MICROBIOL, V50, P2727, DOI 10.1128/JCM.00689-12; van der Linden M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131494; van Hoek AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039150; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Weinberger R, 2016, VACCINE, V34, P2062, DOI 10.1016/j.vaccine.2016.02.043	49	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 27	2021	39	23					3216	3224		10.1016/j.vaccine.2021.02.030		MAY 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SF2TJ	33934915	hybrid			2022-04-29	WOS:000652613400013
J	Yoshimura, M; Shinmura, Y; Shishido, T; Takagi, S; Kameyama, K; Sonoda, K; Yoksan, S; Kimachi, K				Yoshimura, Masaya; Shinmura, Yasuhiko; Shishido, Tatsuya; Takagi, Shota; Kameyama, Kazuhisa; Sonoda, Kengo; Yoksan, Sutee; Kimachi, Kazuhiko			Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys	VACCINE			English	Article						Dengue vaccine; KD-382; Immunogenicity; Protective efficacy; Persistence; Baseline serostatus	VIRUS-INFECTION; THAILAND	An effective dengue vaccine should induce a long-lasting immune response against all four serotypes simultaneously with a minimum number of immunizations. Our live attenuated tetravalent dengue vaccine candidate, KD-382, was developed using a classical host range mutation strategy (no addition of artificial genetic modification). In our previous study, cynomolgus monkeys immunized with a single dose of KD-382 seroconverted to all four serotypes. However, it is important to determine if neutralizing antibodies (NAbs) induced by KD-382 can work as a long-lasting immune response to prevent dengue. In this study, a single dose of KD-382 induced a strong NAb response against all four serotypes in cynomolgus monkeys. We also confirmed that NAb titers against all four serotypes persist for at least five years, indicating its high potential as a dengue vaccine candidate. Next, we evaluated the effect of pre-existing dengue immunity on NAb responses induced by KD-382. We administered KD-382 to cynomolgus monkeys pre-administered one of the monovalent parental wild-type strains 60 days before vaccination. Regardless of the pre-immunized serotype, all the monkeys showed sufficient tetravalent NAb responses, which lasted for over two years. All the KD-382 vaccinated monkeys were then challenged with different parental wild-type viruses than that used for pre-administration; viral RNA in the serum was less than the lower limit of quantification, indicating complete protection against secondary heterologous dengue infection without any harmful disease enhancement. Consequently, KD-382 successfully induced a longlasting and protective tetravalent NAb response in monkeys, suggesting that KD-382 is a promising vaccine candidate usable for both dengue seronegative and seropositive individuals. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Yoshimura, Masaya; Shinmura, Yasuhiko; Shishido, Tatsuya; Takagi, Shota; Kameyama, Kazuhisa; Sonoda, Kengo; Kimachi, Kazuhiko] KM Biol Co Ltd, Kita Ku, 1-6-1 Okubo, Kumamoto, Kumamoto 8608568, Japan; [Yoksan, Sutee] Mahidol Univ, Inst Mol Biosci, Ctr Vaccine Dev, 25-25 Phuttamonthon 4 Rd, Salaya 73170, Nakhon Pathom, Thailand		Kimachi, K (通讯作者)，KM Biol Co Ltd, Kita Ku, 1-6-1 Okubo, Kumamoto, Kumamoto 8608568, Japan.	yoshimura-ma@kmbiologics.com; shinmura-ya@kmbiologics.com; kimachi@kmbiologics.com		Yoshimura, Masaya/0000-0002-4593-4902			[Anonymous], 2019, VACCINE, V37, P4848, DOI 10.1016/j.vaccine.2018.09.063; [Anonymous], 2016, Wkly Epidemiol Rec, V91, P349; [Anonymous], 2006, GUIDELINES PROPER CO; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Biswal S, 2019, NEW ENGL J MED, V381, P2009, DOI 10.1056/NEJMoa1903869; Burattini MN, 2016, CLINICS, V71, P455, DOI 10.6061/clinics/2016(08)08; Yam-Puc JC, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00218; Gibbons RV, 2007, AM J TROP MED HYG, V77, P910, DOI 10.4269/ajtmh.2007.77.910; Guy B, 2016, NAT REV MICROBIOL, V14, P45, DOI 10.1038/nrmicro.2015.2; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0; Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0; Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005; Kirkpatrick BD, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1517; KONTNY U, 1988, J VIROL, V62, P3928, DOI 10.1128/JVI.62.11.3928-3933.1988; Lopez-Medina Eduardo, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa761; Moodie Z, 2018, J INFECT DIS, V217, P742, DOI 10.1093/infdis/jix609; Tran NH, 2019, HUM VACC IMMUNOTHER, V15, P2315, DOI 10.1080/21645515.2019.1578595; NIMMANNITYA S, 1969, AM J TROP MED HYG, V18, P954, DOI 10.4269/ajtmh.1969.18.954; Nisalak A, 2016, AM J TROP MED HYG, V94, P1342, DOI 10.4269/ajtmh.15-0337; Osorio JE, 2011, VACCINE, V29, P7251, DOI 10.1016/j.vaccine.2011.07.020; SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Suppiah J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006817; Utama IMS, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007785; Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112; World Health Organization, 2018, BACKGR PAP DENG VACC, V10, P1; Yoshimura M, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04506; Zellweger RM, 2014, J IMMUNOL, V193, P4117, DOI 10.4049/jimmunol.1401597	30	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 27	2021	39	23					3169	3178		10.1016/j.vaccine.2021.04.030		MAY 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SF2TJ	33941407	hybrid			2022-04-29	WOS:000652613400008
J	Dion, SB; Major, M; Grajales, AG; Nepal, RM; Cane, A; Gessner, B; Vojicic, J; Suaya, JA				Dion, Stephane B.; Major, Maria; Grajales, Ana Gabriela; Nepal, Rajeev M.; Cane, Alejandro; Gessner, Bradford; Vojicic, Jelena; Suaya, Jose A.			Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines	VACCINE			English	Article						Canada; Invasive pneumococcal disease; Pneumococcal conjugate vaccine; Serotype distribution; Serotype prevalence	STREPTOCOCCUS-PNEUMONIAE; 13-VALENT; COLONIZATION; CHILDREN; ENGLAND; BURDEN; ADULTS; USA	Background: In 2010-2011, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced the 7-or 10-valent vaccine (PCV7 and PCV10, respectively) in pediatric immunization programs across Canada. For adults aged > 65 years, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been publicly funded for several decades; PCV13 funding was not recommended in this population, partly due to expected ongoing vaccine-serotype disease decline stemming from herd effects of the pediatric program. Higher-valent PCVs (ie, 15-and 20-valent PCVs [PCV15 and PCV20, respectively]) currently in development may become available in Canada in the coming years. Methods: Using the National Microbiology Laboratory surveillance reports, annual case counts and sero-type distribution of invasive pneumococcal disease (IPD) from 2010 to 2017 in Canada were examined to assess the impact of existing programs on PCV13-serotype IPD and determine the proportion of IPD that can potentially be prevented by current and forthcoming higher-valent PCVs. Results: The percentages of PCV13-serotype IPD decreased from 55% [1492/2708] in 2010 to 30% [902/3006] in 2017 in all age groups combined, including a decline from 67% [221/331] to 18% [40/219] in children aged < 5 years and from 50% [487/967] to 23% [287/1238] in adults aged >= 65 years. Overall, IPD cases declined mainly before 2014 and have plateaued since then. In 2017, PCV15-and PCV20-serotypes (inclusive of PCV13 serotypes) accounted for 42% and 58% of IPD cases, respectively, in all ages. Conclusions: In Canada, publicly funded pediatric PCV13 use was associated with large declines in IPD due to vaccine serotypes. Substantial residual PCV13-serotype IPD proportions observed among all ages imply limits to indirect protection afforded by the pediatric PCV13 program at the current uptake level and suggest the adult PPSV23 program alone is insufficient. Higher-valent PCVs have the potential to address a substantial proportion of remaining IPD cases among all age groups. (c) 2021 Elsevier Ltd. All rights reserved.	[Dion, Stephane B.; Major, Maria; Grajales, Ana Gabriela; Nepal, Rajeev M.; Vojicic, Jelena] Pfizer Canada ULC, 17300 Trans Canada Highway, Kirkland, PQ H9J 2M5, Canada; [Cane, Alejandro; Gessner, Bradford] Pfizer Inc, Collegeville, PA USA; [Suaya, Jose A.] Pfizer Inc, New York, NY USA		Vojicic, J (通讯作者)，Pfizer Canada ULC, 17300 Trans Canada Highway, Kirkland, PQ H9J 2M5, Canada.	Stephane.Dion@pfizer.com; Maria.Major@pfizer.com; AnaGabriela.Grajales@pfizer.com; Rajeev.Nepal@pfizer.com; Alejandro.Cane@pfizer.com; Bradford.Gessner@pfizer.com; Jelena.vojicic@pfizer.com; Jose.A.Suaya@pfizer.com		Major, Maria/0000-0003-3719-7225	Pfizer Inc. - Pfizer Inc.Pfizer	This work was sponsored by Pfizer Inc. Editorial/medical writing support was provided by Srividya Ramachandran, PhD, of ICON plc (North Wales, PA, USA) and was funded by Pfizer Inc.	Adebanjo TA, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0836; Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; Andrews NJ, 2012, VACCINE, V30, P6802, DOI 10.1016/j.vaccine.2012.09.019; Arguedas A, 2020, EXPERT REV VACCINES, V19, P353, DOI 10.1080/14760584.2020.1750378; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Centers for Disease Control and Prevention, 2020, RECOMMENDED CHILD AD; Chalmers JD, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0242-0; Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428; Demczuk WHB, 2018, VACCINE, V36, P4701, DOI 10.1016/j.vaccine.2018.06.018; Demczuk WHB, 2013, CAN J MICROBIOL, V59, P778, DOI 10.1139/cjm-2013-0614; Djennad A, 2018, ECLINICALMEDICINE, V6, P42, DOI 10.1016/j.eclinm.2018.12.007; Fleming-Dutra KE, 2014, PEDIATR INFECT DIS J, V33, pS152, DOI 10.1097/INF.0000000000000083; Gessner BD, 2019, VACCINE, V37, P5777, DOI 10.1016/j.vaccine.2018.05.097; Government of Canada, 2019, CANADAS PROVINCIAL T; Government of Canada, INVASIVE PNEUMOCOCCA; Government of Canada, CANADIAN IMMUNIZATIO; Hanquet G, 2019, THORAX, V74, P473, DOI 10.1136/thoraxjnl-2018-211767; Health and Social Services of Quebec, 2018, PRINCIPAL MODIFICATI; Isturiz R, 2017, EXPERT REV VACCINES, V16, P1007, DOI 10.1080/14760584.2017.1362339; Joint Committee on Vaccination and Immunisation, 2015, INTERIM JCVI STATEME; Kolditz M, 2019, CLIN INFECT DIS, V68, P2117, DOI 10.1093/cid/ciy993; Krone CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119875; LeBlanc J, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2019-000550; Mahmud SM, 2017, HUM VACC IMMUNOTHER, V13, P1884, DOI 10.1080/21645515.2017.1320006; McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312; Moore MR, 2016, LANCET RESP MED, V4, P399, DOI 10.1016/S2213-2600(16)00052-7; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; National Advisory Committee on Immunization (NACI), 2016, UPDATE USE 13 VALENT; National Advisory Committee on Immunizations (NACI), 2018, UPDATE USE PNEUMOCOC; National Laboratory Surveillance of Invasive Streptococcal Disease in Canada, 2017, ANN SUMMARY 2017; O'Donnell S, 2017, VACCINE, V35, P5924, DOI 10.1016/j.vaccine.2017.08.072; Ontario Agency for Health Protection and Promotion (Public Health Ontario), 2019, IMMUNIZATION COVERAG; Petit Genevieve, 2003, Can J Infect Dis, V14, P215; Pilishvili T., 2018, IMPACT PCV13 INVASIV; Public Health Agency Canada, 2016, VACCINE UPTAKE CANAD; Public Health Agency Canada, CANADIAN NOTIFIABLE; Rudnick W, 2013, VACCINE, V31, P5863, DOI 10.1016/j.vaccine.2013.09.049; Sings HL, 2019, CLIN INFECT DIS, V68, P2135, DOI 10.1093/cid/ciy920; Spiller M, 2019, ADVISORY COMMITTEE I; Stacey HL, 2019, HUM VACC IMMUNOTHER, V15, P530, DOI 10.1080/21645515.2018.1532249; Stoecker C, 2016, J GEN INTERN MED, V31, P901, DOI 10.1007/s11606-016-3651-0; The Public Health Agency of Canada, 2010, UPDATE USE CONJUGATE; The Public Health Agency of Canada, 2002, STATEMENT RECOMMENDE; The Public Health Agency of Canada, 2010, UPDATE PEDIAT INVASI; Thompson A, 2019, VACCINE, V37, P6201, DOI 10.1016/j.vaccine.2019.08.048; Trzcinski K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060520; van der Linden M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220453; Wijayasri S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226353; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-01968-5]; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	50	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 21	2021	39	22					3007	3017		10.1016/j.vaccine.2021.02.069		MAY 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SE0YP	33824041				2022-04-29	WOS:000651801800010
J	Kochhar, S; Dube, E; Graham, J; Jee, Y; Memish, ZA; Menning, L; Nohynek, H; Salmon, D; Top, KA; MacDonald, NE				Kochhar, Sonali; Dube, Eve; Graham, Janice; Jee, Youngmee; Memish, Ziad A.; Menning, Lisa; Nohynek, Hanna; Salmon, Daniel; Top, Karina A.; MacDonald, Noni E.			COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER)	VACCINE			English	Editorial Material						COVID-19; Vaccine; Safety; Hesitancy; Healthcare; Workers; Providers; Vaccine recipients; Answers; Communication	SUPPORT		[Kochhar, Sonali] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Kochhar, Sonali] Global Healthcare Consulting, Delhi, India; [Dube, Eve] Quebec Natl Inst Publ Hlth, Quebec City, PQ, Canada; [Dube, Eve] Laval Univ, Quebec City, PQ, Canada; [Graham, Janice] Dalhousie Univ, Halifax, NS, Canada; [Jee, Youngmee] Seoul Natl Univ, GSPA, Seoul, South Korea; [Jee, Youngmee] Korea Fdn, Special Representat Hlth Diplomacy, Seogwipo Si, South Korea; [Memish, Ziad A.] Minist Hlth, King Saud Med City, Res & Innovat Ctr, Riyadh, Saudi Arabia; [Menning, Lisa] WHO HQ Dept Immunizat Vaccines & Biol, Geneva, Switzerland; [Nohynek, Hanna] Finnish Inst Hlth & Welf THL, Helsinki, Finland; [Salmon, Daniel] Johns Hopkins Univ, Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21218 USA; [Top, Karina A.] Dalhousie Univ, Pediat & Community Hlth & Epidemiol, Halifax, NS, Canada; [MacDonald, Noni E.] Dalhousie Univ, IWK Hlth Ctr, Paediat, Halifax, NS, Canada		Kochhar, S (通讯作者)，Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.; Kochhar, S (通讯作者)，Global Healthcare Consulting, Delhi, India.	sonalikochhar@yahoo.co.in	Kochhar, Sonali/H-4036-2012; Jee, Youngmee/AGW-0164-2022; Memish, Ziad Ahmed/AEJ-9424-2022	Kochhar, Sonali/0000-0002-1150-5691; Jee, Youngmee/0000-0001-5369-6628; Memish, Ziad Ahmed/0000-0002-5099-0714; Graham, Janice/0000-0002-6326-8122; Top, Karina/0000-0002-9981-368X			Bloom BR, 2020, NEW ENGL J MED, V383, P2202, DOI 10.1056/NEJMp2025331; Kochhar S, 2020, VACCINE, V38, P6194, DOI 10.1016/j.vaccine.2020.07.013; MacDonald NE, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100402; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Tomes N, 2020, CAN MED ASSOC J, V192, pE1211, DOI 10.1503/cmaj.201905; van der Linden SL, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2541-4; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Vivion M, 2020, PUBLIC HEALTH, V178, P112, DOI 10.1016/j.puhe.2019.09.007	8	0	0	4	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2504	2505		10.1016/j.vaccine.2021.03.060		APR 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33836897	Green Published, Bronze			2022-04-29	WOS:000642189300006
J	Steimle, LN; Havumaki, J; Eisenberg, MC; Eisenberg, JNS; Prosser, LA; Pike, J; Ortega-Sanchez, IR; Mattison, CP; Hall, AJ; Steele, MK; Lopman, BA; Hutton, DW				Steimle, Lauren N.; Havumaki, Joshua; Eisenberg, Marisa C.; Eisenberg, Joseph N. S.; Prosser, Lisa A.; Pike, Jamison; Ortega-Sanchez, Ismael R.; Mattison, Claire P.; Hall, Aron J.; Steele, Molly K.; Lopman, Benjamin A.; Hutton, David W.			Cost-effectiveness of pediatric norovirus vaccination in daycare settings	VACCINE			English	Article						Norovirus; Vaccination; Cost-effectiveness		Objective: Noroviruses are the leading cause of acute gastroenteritis in the United States and outbreaks frequently occur in daycare settings. Results of norovirus vaccine trials have been promising, however there are open questions as to whether vaccination of daycare children would be cost-effective. We investigated the incremental cost-effectiveness of a hypothetical norovirus vaccination for children in daycare settings compared to no vaccination. Methods: We conducted a model-based cost-effectiveness analysis using a disease transmission model of children attending daycare. Vaccination with a 90% coverage rate in addition to the observed standard of care (exclusion of symptomatic children from daycare) was compared to the observed standard of care. The main outcomes measures were infections and deaths averted, quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER). Cost-effectiveness was analyzed from a societal perspective, including medical costs to children as well as productivity losses of parents, over a two-year time horizon. Data sources included outbreak surveillance data and published literature. Results: A 50% efficacious norovirus vaccine averts 571.83 norovirus cases and 0.003 norovirus-related deaths per 10,000 children compared to the observed standard of care. A $200 norovirus vaccine that is 50% efficacious has a net cost increase of $178.10 per child and 0.025 more QALYs, resulting in an ICER of $7,028/QALY. Based on the probabilistic sensitivity analysis, we estimated that a $200 vaccination with 50% efficacy was 94.0% likely to be cost-effective at a willingness-to-pay of $100,000/QALY threshold and 95.3% likely at a $150,000/QALY threshold. Conclusion: Due to the large disease burden associated with norovirus, it is likely that vaccinating children in daycares could be cost-effective, even with modest vaccine efficacy and a high per-child cost of vaccination. Norovirus vaccination of children in daycare has a cost-effectiveness ratio similar to other commonly recommended childhood vaccines. (C) 2021 The Authors. Published by Elsevier Ltd.	[Steimle, Lauren N.] Georgia Inst Technol, H Milton Stewart Sch Ind & Syst Engn, Atlanta, GA 30332 USA; [Havumaki, Joshua] Yale Univ, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA; [Eisenberg, Marisa C.; Eisenberg, Joseph N. S.] Univ Michigan, Dept Epidemiol, Sch Publ Hlth, Ann Arbor, MI 48109 USA; [Eisenberg, Marisa C.] Univ Michigan, Dept Math, Ann Arbor, MI 48109 USA; [Eisenberg, Marisa C.] Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA; [Prosser, Lisa A.; Hutton, David W.] Univ Michigan, Dept Hlth Management & Policy, Sch Publ Hlth, Ann Arbor, MI 48109 USA; [Prosser, Lisa A.] Univ Michigan, Susan B Meister Child Hlth Evaluat & Res Ctr, Dept Pediat, Med Sch, Ann Arbor, MI 48109 USA; [Pike, Jamison; Ortega-Sanchez, Ismael R.; Mattison, Claire P.; Hall, Aron J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; [Mattison, Claire P.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA; [Steele, Molly K.] Emory Univ, Dept Environm Hlth, Atlanta, GA 30322 USA; [Lopman, Benjamin A.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA		Steimle, LN (通讯作者)，755 Ferst Dr NW, Atlanta, GA 30332 USA.	steimle@gatech.edu		Mattison, Claire/0000-0001-8558-8779; Steele, Molly/0000-0001-7601-0924	University of MichiganUniversity of Michigan System [U01IP000965]; Centers for Diseases Control and Prevention [U01IP000965]	This study was funded by the Joint Initiative in Vaccine Economics, Phase 5, a cooperative agreement between the University of Michigan and the Centers for Diseases Control and Prevention (U01IP000965).	American Academy of Pediatrics, 2006, RED BOOK REP COMM IN; Annunziata K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050553; [Anonymous], 2019, ENROLLMENT 3 4 5 YEA; Atmar RL, 2008, EMERG INFECT DIS, V14, P1553, DOI 10.3201/eid1410.080117; Atmar RL, 2011, NEW ENGL J MED, V365, P2178, DOI 10.1056/NEJMoa1101245; Bartsch SM, 2012, VACCINE, V30, P7097, DOI 10.1016/j.vaccine.2012.09.040; Bartsch SM., 2020, J INFECT DIS; Bernstein DI, 2015, J INFECT DIS, V211, P870, DOI 10.1093/infdis/jiu497; Bouzon-Alejandro M, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-81; Centers for Medicare Medicaid Services, PHYS FEE SCHED LOOK; Centers for Medicare & Medicaid Services, ADD ADD B UPD; Fallahi S, 2011, J FOOD PROTECT, V74, P1847, DOI 10.4315/0362-028X.JFP-11-081; Gastanaduy PA, 2013, J INFECT DIS, V207, P1058, DOI 10.1093/infdis/jis942; Gaythorpe KAM, 2018, EPIDEMIOL INFECT, V146, P147, DOI 10.1017/S0950268817002692; Grosse SD, 2019, J MED ECON, V22, P501, DOI 10.1080/13696998.2018.1542520; Grytdal SP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148395; Gualano MR, 2018, J INFECT PUBLIC HEAL, V11, P867, DOI 10.1016/j.jiph.2018.07.008; Hall AJ, 2013, EMERG INFECT DIS, V19, P1198, DOI 10.3201/eid1908.130465; Hall AJ, 2011, EMERG INFECT DIS, V17, P1381, DOI 10.3201/eid1708.101533; Havumaki J, 2021, EPIDEMIOLOGY, V32, P351, DOI 10.1097/EDE.0000000000001322; Lee RM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-446; Lopman BA, 2011, CLIN INFECT DIS, V52, P466, DOI 10.1093/cid/ciq163; Lu PJ, 2013, MMWR SURVEILL SUMM, V62, P1; Martin Alan, 2008, J Med Econ, V11, P471, DOI 10.3111/13696990802321047; Milbrath MO, 2013, EPIDEMIOL INFECT, V141, P1572, DOI 10.1017/S0950268813000496; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; Neumann PJ, 2016, COST EFFECTIVENESS H; Phillips G, 2010, AM J EPIDEMIOL, V171, P1014, DOI 10.1093/aje/kwq021; Prosser LA, 2019, ANN INTERN MED, V170, P380, DOI 10.7326/M18-2347; Ramani S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005334; Ramani S, 2014, CURR OPIN GASTROEN, V30, P25, DOI 10.1097/MOG.0000000000000022; Rockx B, 2002, CLIN INFECT DIS, V35, P246, DOI 10.1086/341408; Steele MK, 2016, EPIDEMICS-NETH, V17, P42, DOI 10.1016/j.epidem.2016.10.006; Teunis PFM, 2015, EPIDEMIOL INFECT, V143, P1710, DOI 10.1017/S095026881400274X; U.S. Bureau of Economic Analysis, CROSS DOM PROD IMPL; Venuto MM., 2018, ESTIMATE EC BURDEN N; Widdowson MA, 2007, PEDIATRICS, V119, P684, DOI 10.1542/peds.2006-2876	37	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2133	2145		10.1016/j.vaccine.2021.02.066		APR 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QH	33741192	hybrid, Green Accepted			2022-04-29	WOS:000637937500017
J	Ebama, MS; Chu, SY; Azziz-Baumgartner, E; Lafond, KE; McCarron, M; Hadler, SC; Porter, RM; McKinlay, M; Bresee, J				Ebama, Malembe S.; Chu, Susan Y.; Azziz-Baumgartner, Eduardo; Lafond, Kathryn E.; McCarron, Margaret; Hadler, Stephen C.; Porter, Rachael M.; McKinlay, Mark; Bresee, Joseph			Ancillary benefits of seasonal influenza vaccination in middle-income countries	VACCINE			English	Article						Influenza vaccine; Vaccine introduction; Immunization program; Health system; Middle-income countries	HEALTH SYSTEMS; GLOBAL BURDEN; IMMUNIZATION; IMPACT; VACCINES; INTRODUCTIONS	While seasonal influenza vaccines (SIV) remain the best method to prevent influenza-associated illnesses, implementing SIV programs may benefit countries beyond disease reduction, strengthening health systems and national immunization programs, or conversely, introduce new challenges. Few studies have examined perceived impacts of SIV introduction beyond disease reduction on health systems; understanding such impacts will be particularly salient in the context of COVID-19 vaccine introduction. We collected qualitative data from key informants-Partnership for Influenza Vaccine Introduction (PIVI) contacts in six middle-income PIVI vaccine recipient countries-to understand perceptions of ancillary benefits and challenges from SIV implementation. Respondents reported benefits associated with SIV introduction, including improved attitudes to SIV among risk groups (characterized by increased demand) and perceptions that SIV introduction improved relationships with other ministries and collaboration with mass media. Challenges included sustaining investment in SIV programs, as vaccine supply did not always meet coverage goals, and managing SIV campaigns. (C) 2021 Elsevier Ltd. All rights reserved.	[Ebama, Malembe S.; Hadler, Stephen C.; McKinlay, Mark; Bresee, Joseph] Task Force Global Hlth, Ctr Vaccine Equ, 325 Swanton Way, Decatur, GA 30030 USA; [Chu, Susan Y.] Ctr Global Hlth, Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA; [Azziz-Baumgartner, Eduardo; Lafond, Kathryn E.; McCarron, Margaret; Porter, Rachael M.; Bresee, Joseph] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA		Ebama, MS (通讯作者)，Task Force Global Hlth, Ctr Vaccine Equ, 325 Swanton Way, Decatur, GA 30030 USA.	mebama@taskforce.org		McCarron, Margaret/0000-0002-5826-1014	U.S. Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	This work was supported by funding from the U.S. Centers for Disease Control and Prevention.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Bhan MK, 2019, LANCET GLOB HEALTH, V7, pE827, DOI 10.1016/S2214-109X(19)30195-0; Bresee JS, 2019, VACCINE, V37, P5089, DOI 10.1016/j.vaccine.2019.06.049; Burchett HED, 2014, VACCINE, V32, P6505, DOI 10.1016/j.vaccine.2014.09.031; Fischer WA, 2014, GLOB HEART, V9, P325, DOI 10.1016/j.gheart.2014.08.004; Hyde TB, 2012, VACCINE, V30, P6347, DOI 10.1016/j.vaccine.2012.08.029; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Kostova D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066312; Largeron Nathalie, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27043; Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9; Ortiz JR, 2019, EXPERT REV VACCINES, V18, P711, DOI 10.1080/14760584.2019.1635462; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Preaud E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-813; Principi N, 2018, HUM VACC IMMUNOTHER, V14, P684, DOI 10.1080/21645515.2017.1405188; Shearer JC, 2012, VACCINE, V30, P7582, DOI 10.1016/j.vaccine.2012.10.036; The World Bank, WORLD BANK COUNTR LE; Torres-Rueda S, 2015, AFR HEALTH SCI, V15, P868, DOI 10.4314/ahs.v15i3.22; UN, 2019, WORLD POPULATION PRO; Wang SA, 2013, VACCINE, V31, pB122, DOI 10.1016/j.vaccine.2012.10.116; World Health Organization, 2020, IMM SYST IND COUNTR	20	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 1	2021	39	14					1892	1896		10.1016/j.vaccine.2021.02.048		MAR 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RC7NX	33714656				2022-04-29	WOS:000632984100004
J	Piras-Douce, F; Raynal, F; Raquin, A; Girerd-Chambaz, Y; Gautheron, S; Sanchez, MEN; Vangelisti, M; Mantel, N				Piras-Douce, Fabienne; Raynal, Franck; Raquin, Alix; Girerd-Chambaz, Yves; Gautheron, Sylviane; Sanchez, Martha Erika Navarro; Vangelisti, Manuel; Mantel, Nathalie			Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models	VACCINE			English	Article						Yellow Fever vaccine; Neurovirulence; Neurotropism; Viscerotropism; Immunogenicity; Protection; Vero cells; Serum-free; Stamaril; YF-VAX		Yellow fever (YF) remains a threat to human health in tropical regions of Africa and South America. Live-attenuated YF-17D vaccines have proven to be safe and effective in protecting travellers and populations in endemic regions against YF, despite very rare severe reactions following vaccination - YF vaccine-associated viscerotropic disease (YEL-AVD) and neurological disease (YEL-AND). We describe the generation and selection of a live-attenuated YF-17D vaccine candidate and present its preclinical profile. Initially, 24 YF-17D vaccine candidate sub-strains from the Stamaril (R) and YF-VAX (R) lineage were created through transfection of viral genomic RNA into Vero cells cultured in serum-free media to produce seed lots. The clone with the 'optimal' preclinical profile, i.e. the lowest neurovirulence, neurotropism and viscerotropism, and immunogenicity at least comparable with Stamaril and YF-VAX in relevant animal models, was selected as the vaccine candidate and taken forward for assessment at various production stages. The 'optimal' vaccine candidate was obtained from the YF-VAX lineage (hence named vYF-247) and had five nucleotide differences relative to its parent, with only two changes that resulted in amino acid changes at position 480 of the envelope protein (E) (valine to leucine), and position 65 of the nonstructural protein 2A (NS2A) (methionine to valine). vYF-247 was less neurovirulent in mice than Stamaril and YF-VAX irrespective of production stage. Its attenuation profile in terms of neurotropism and viscerotropism was similar to YF-VAX in A129 mice, a 'worst case' animal model lacking type-I IFN receptors required to initiate viral clearance. Thus, vYF-247 would not be expected to have higher rates of YEL-AVD or YEL-AND than Stamaril and YF-VAX. In hamsters, vYF-247 was immunogenic and protected against high viremia and death induced by a lethal challenge with the hamster-adapted Jimenez P10 YF virus strain. Our data suggests that vYF-247 would provide robust protection against YF disease in humans, similar to currently marketed YF vaccines. (C) 2021 The Authors. Published by Elsevier Ltd.	[Piras-Douce, Fabienne; Raynal, Franck; Raquin, Alix; Girerd-Chambaz, Yves; Gautheron, Sylviane; Mantel, Nathalie] Sanofi Pasteur, Res & External Innovat, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France; [Sanchez, Martha Erika Navarro] Sanofi Pasteur, Analyt Sci, Marcy Letoile, France; [Vangelisti, Manuel] Sanofi Pasteur, Marcy Letoile, France		Mantel, N (通讯作者)，Sanofi Pasteur, Res & External Innovat, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France.	fabienne.piras-douce@sanofi.com; franck.raynal@sanofi.com; alix.raquin@sanofi.com; yves.girerd-chambaz@sanofi.com; Sylviane.gautheron@sanofi.com; erika.navarrosanchez@sanofi.com; manuel.vangelisti@sanofi.com; nathalie.mantel@sanofi.com		GAUTHERON, Sylviane/0000-0002-3562-7829; MANTEL, Nathalie/0000-0001-8984-3183	Sanofi Pasteur - Bill and Melinda Gates Foundation [OPP1127586]	Funding was provided by Sanofi Pasteur. The study was also partially funded by Bill and Melinda Gates Foundation grant number OPP1127586.	[Anonymous], 2013, Wkly Epidemiol Rec, V88, P269; Barban V, 2007, VACCINE, V25, P2941, DOI 10.1016/j.vaccine.2006.06.082; Barrett PN, 2009, EXPERT REV VACCINES, V8, P607, DOI [10.1586/erv.09.19, 10.1586/ERV.09.19]; Beck AS, 2015, EXPERT REV VACCINES, V14, P1479, DOI 10.1586/14760584.2015.1083430; Blake LE, 2014, MBIO, V5, DOI 10.1128/mBio.01253-14; Clenet D, 2019, EUR J PHARM BIOPHARM, V142, P334, DOI 10.1016/j.ejpb.2019.07.008; Cottin P, 2013, EXPERT REV VACCINES, V12, P1351, DOI 10.1586/14760584.2013.836320; Erickson AK, 2015, J GEN VIROL, V96, P1328, DOI 10.1099/vir.0.000075; Freire MS, 2005, VACCINE, V23, P2501, DOI 10.1016/j.vaccine.2004.10.035; Guirakhoo F, 1999, VIROLOGY, V257, P363, DOI 10.1006/viro.1999.9695; Guy B, 2010, HUM VACCINES, V6, P696, DOI 10.4161.hv.6.9.12739; HAHN CS, 1987, P NATL ACAD SCI USA, V84, P2019, DOI 10.1073/pnas.84.7.2019; Hu AYC, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014578, 10.1371/journal.pone.0029229]; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Johansson MA, 2014, T ROY SOC TROP MED H, V108, P482, DOI 10.1093/trstmh/tru092; Julander JG, 2016, CURR OPIN VIROL, V18, P64, DOI 10.1016/j.coviro.2016.03.010; Julander JG, 2011, VACCINE, V29, P6008, DOI 10.1016/j.vaccine.2011.06.034; Lindsey NP, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw045; Meier KC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000614; Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030; Monath TP, 2011, NEW ENGL J MED, V364, P1326, DOI 10.1056/NEJMoa1009303; Monath TP, 2010, VACCINE, V28, P3827, DOI 10.1016/j.vaccine.2010.03.023; Murray J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188333; SAGE Working Group, 2013, BACKGROUND PAPER YEL; Silva ML, 2010, CLIN VACCINE IMMUNOL, V17, P118, DOI 10.1128/CVI.00369-09; Souza YRM, 2019, MEM I OSWALDO CRUZ, V114; Tesh RB, 2001, J INFECT DIS, V183, P1431, DOI 10.1086/320199; Tomashek KM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040179; UNICEF, 2016, YELL FEV VACC CURR S; World Health Organization, 2019, YELLOW FEVER; World Health Organization, 1998, REQUIRMENTS YELLOW F; Wu RH, 2017, J VIROL, V91, DOI [10.1128/JVI.01836-16, 10.1128/jvi.01836-16]	32	2	2	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 26	2021	39	13					1846	1856		10.1016/j.vaccine.2021.02.033		MAR 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QY9YH	33685778	hybrid, Green Published			2022-04-29	WOS:000630391900009
J	Bauer, BU; Knittler, MR; Prufer, TL; Wolf, A; Matthiesen, S; Runge, M; Ganter, M				Bauer, Benjamin U.; Knittler, Michael R.; Pruefer, T. Louise; Wolf, Annika; Matthiesen, Svea; Runge, Martin; Ganter, Martin			Humoral immune response to Q fever vaccination of three sheep flocks naturally pre-infected with Coxiella burnetii	VACCINE			English	Article						Coxiella burnetii; Sheep; Humoral immune response; Vaccine; Phase-specific antibodies; Zoonosis	SEROLOGICAL CROSS-REACTIONS; REAL-TIME PCR; PHASE-I; ENVIRONMENTAL CONTAMINATION; GOATS; LIPOPOLYSACCHARIDE; MANAGEMENT; DIAGNOSIS; DYNAMICS; OUTBREAK	Q fever is a zoonotic disease caused by the bacterium Coxiella burnetii; Coxiella-infected ruminants are the main reservoir shedding the pathogen during abortion or parturition through birth products. Germany has a long history of small-scale Q fever epidemics in the human population mostly associated with lambing sheep. Therefore, fast and efficient control measures are essentially required to prevent transmission from infected sheep flocks to humans. In our present study, three sheep flocks were vaccinated with an inactivated C. burnetii phase I vaccine after a field infection with C burnetii was diagnosed. Serum samples and vaginal swabs were collected at different time points to evaluate the extent of the outbreak and the consequences of the vaccination. The serum samples were examined by phase-specific IgG phase I and phase II ELISAs and a commercial ELISA, simultaneously detecting both phase variations. Moreover, vaginal swabs were analysed by qPCR. The fourth flock with no Q fever history and non-vaccinated animals were used as a control group to evaluate the phase-specific ELISAs. The inactivated C burnetii phase I vaccine induced an IgG phase II response and boosted the humoral immune reaction against natural preinfections. Furthermore, the longevity of vaccine-induced antibodies seems to depend on previous infections. Around 16 months after primary vaccination, mainly IgG phase I antibodies were detectable. Vaccination did not prevent shedding at the next lambing season. Most interestingly, the phase-specific ELISAs revealed more C. burnetii positive animals than the blended ELISA-Assay. Taken together, phase-specific ELISAs are suitable tools to provide insights into natural- or vaccine-induced humoral immune responses to C. burnetii in sheep. (C) 2021 Elsevier Ltd. All rights reserved.	[Bauer, Benjamin U.; Wolf, Annika; Ganter, Martin] Univ Vet Med Hannover, Clin Swine & Small Ruminants, Forens Med & Ambulatory Serv, Bischofsholer Damm 15, D-30173 Hannover, Germany; [Knittler, Michael R.; Matthiesen, Svea] Friedrich Loeffler Inst, Inst Immunol, D-17493 Greifswald, Isle Of Riems, Germany; [Pruefer, T. Louise; Runge, Martin] Lower Saxony State Off Consumer Protect & Food Sa, Food & Vet Inst Braunschweig Hannover, D-30173 Hannover, Germany		Bauer, BU (通讯作者)，Univ Vet Med Hannover, Clin Swine & Small Ruminants, Forens Med & Ambulatory Serv, Bischofsholer Damm 15, D-30173 Hannover, Germany.	benjamin.bauer@tiho-hannover.de		Matthiesen, Svea/0000-0002-8020-8666	Federal Ministry of Education of Research (BMBF)Federal Ministry of Education & Research (BMBF) [01KI1726B, 01KI1726C]	This work was funded by the Federal Ministry of Education of Research (BMBF) under grant number 01KI1726B and 01KI1726C as part of the Zoonotic Infectious Diseases Research Network.	Achard D., 2017, PRINCIPLES PRACTICE, P367; Alvarez-Alonso R, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00352; AMANO KI, 1984, J BACTERIOL, V160, P994, DOI 10.1128/JB.160.3.994-1002.1984; Anderson A, 2013, MMWR RECOMM REP, V62, P1; Andoh M, 2007, INFECT IMMUN, V75, P3245, DOI 10.1128/IAI.01767-06; Arricau-Bouvery N, 2005, VACCINE, V23, P4392, DOI 10.1016/j.vaccine.2005.04.010; Astobiza I, 2011, RES VET SCI, V91, pE58, DOI 10.1016/j.rvsc.2010.11.014; Astobiza I, 2011, APPL ENVIRON MICROB, V77, P7405, DOI 10.1128/AEM.05530-11; Avbersek J, 2019, TURK J VET ANIM SCI, V43, P264, DOI 10.3906/vet-1806-31; Bauer B, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9080652; Bottcher J, 2011, VET MICROBIOL, V151, P291, DOI 10.1016/j.vetmic.2011.03.007; Botner A, 2010, EFSA J, V8, DOI 10.2903/j.efsa.2010.1595; BROOKS DL, 1986, AM J VET RES, V47, P1235; Denison AM, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-91; Eibach R, 2013, BERL MUNCH TIERARZTL, V126, P3, DOI 10.2376/0005-9366-126-3; Fischer S, 2016, GESUNDHEITSWESEN, V78, DOI 10.1055/s-0036-1578893; Frangoulidis D, 2014, INT J MED MICROBIOL, V304, P868, DOI 10.1016/j.ijmm.2014.06.011; Gilsdorf A, 2008, EPIDEMIOL INFECT, V136, P1084, DOI 10.1017/S0950268807009533; HACKSTADT T, 1985, INFECT IMMUN, V48, P359, DOI 10.1128/IAI.48.2.359-365.1985; HACKSTADT T, 1988, INFECT IMMUN, V56, P802, DOI 10.1128/IAI.56.4.802-807.1988; Hatchette T, 2003, VECTOR-BORNE ZOONOT, V3, P11, DOI 10.1089/153036603765627415; Hilbert Angela, 2012, BMC Res Notes, V5, P152, DOI 10.1186/1756-0500-5-152; Hilke J, 2019, VACCINE, V37, P5844, DOI 10.1016/j.vaccine.2019.08.011; Horigan MW, 2011, J VET DIAGN INVEST, V23, P924, DOI 10.1177/1040638711416971; Joulie A, 2017, APPL ENVIRON MICROB, V83, DOI 10.1128/AEM.00222-17; Joulie A, 2015, APPL ENVIRON MICROB, V81, P7253, DOI 10.1128/AEM.02180-15; Klee SR, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-2; Kuley R, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2143-7; LaScola B, 1996, J CLIN MICROBIOL, V34, P2270, DOI 10.1128/JCM.34.9.2270-2274.1996; Lukacova M, 1999, FOLIA MICROBIOL, V44, P579, DOI 10.1007/BF02816263; Musso D, 1997, CLIN DIAGN LAB IMMUN, V4, P208, DOI 10.1128/CDLI.4.2.208-212.1997; Porten K, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-147; Roest HIJ, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-67; Schoffelen T, 2013, J INFECTION, V67, P565, DOI 10.1016/j.jinf.2013.08.008; Shannon JG, 2005, P NATL ACAD SCI USA, V102, P8722, DOI 10.1073/pnas.0501863102; Sidi-Boumedine K, 2011, GENE, V34, P176; Sting R, 2013, VET MICROBIOL, V167, P600, DOI 10.1016/j.vetmic.2013.09.015; STOKER MGP, 1956, CAN J MICROBIOL, V2, P310, DOI 10.1139/m56-036; Van den Brom R, 2015, VET MICROBIOL, V181, P119, DOI 10.1016/j.vetmic.2015.07.011; Wegdam-Blans MCA, 2012, J INFECTION, V64, P247, DOI 10.1016/j.jinf.2011.12.014; Wolf A, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000679; Zhang GQ, 2007, J IMMUNOL, V179, P8372, DOI 10.4049/jimmunol.179.12.8372; Zhang Guoquan, 2004, Expert Rev Vaccines, V3, P577, DOI 10.1586/14760584.3.5.577; Zhang GQ, 2013, INFECT IMMUN, V81, P2112, DOI 10.1128/IAI.00297-13; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	45	2	2	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 5	2021	39	10					1499	1507		10.1016/j.vaccine.2021.01.062		FEB 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QM3RT	33558108				2022-04-29	WOS:000621700000007
J	Wilck, MB; Xu, ZJ; Stek, JE; Goveia, MG; Lee, AW				Wilck, Marissa B.; Xu, Z. Jin; Stek, Jon E.; Goveia, Michelle G.; Lee, Andrew W.			Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS (TM))	VACCINE			English	Article						Safety; Immunogenicity; DTaP-IPV-Hib-HepB Vaccine; Integrated analyses; Haemophilus influenzae type B; PRP; Hexavalent		Background: DTaP-IPV-Hib-HepB is a fully-liquid, hexavalent combination vaccine (Vaxelis (TM)) approved for vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). Hib capsular polysaccharide, polyribosylribitol phosphate (PRP), is conjugated to Neisseria meningitidis outer membrane protein complex (OMPC). Safety and immunogenicity of DTaP-IPV-Hib-HepB were evaluated in 6 Phase III clinical studies including > 5,200 children. Studies included vaccination schedules in the United States (2, 4, 6 months of age) and Europe (2, 3, 4, 12 months of age and 2,4,11-12 months of age). Methods: Data pertaining to anti-PRP responses of DTaP-IPV-Hib-Hep B compared to control vaccines from 5 Phase III studies are summarized. Results: Post-infant series, the percentage of participants that achieved protective antibody thresholds for PRP (anti-PRP titer >= 0.15 mu g/mL and > 1.0 mu g/mL, respectively) were higher in DTaP-IPV-Hib-HepB recipients compared to recipients who received control vaccines. A high level of protective responses (96.6% at >= 0.15 mu g/mL [95% CI:94.8, 97.9%]; 72.9% at >= 1.0 mu g/mL [95% CI:69.2,76.4%]) were seen post-dose 2 of the 2 + 1 vaccination schedule and met superiority criteria over comparator, p-value < 0.001. In the same schedule, prior to administration of the toddler dose (in the second year of life), anti-PRP titers were higher in DTaP-IPV-Hib-HepB recipients (91.4% at >= 0.15 mu g/mL; 46.8% at >= 1.0 mu g/mL) as compared to recipients who received control vaccines (63.4% at >= 0.15 mu g/mL; 17.1% at >= 1.0 mu g/mL). One-month post-toddler dose, high levels of anti-PRP titers were achieved in both DTaP-IPV-Hib-HepB recipients (99.8% at >= 0.15 mu g/mL; 96.6% at >= 1.0 mu g/mL) and recipients who received control vaccines (99.5% at >= 0.15 mu g/mL; 94.9% at >= 1.0 mu g/mL). Conclusions: These results support that DTaP-IPV-Hib-HepB induces a robust and sustained early Hib response. During the high-risk period for Hib disease after the infant vaccine and prior to the toddler dose; >90% of recipients maintained superior protective anti-PRP levels compared to control. (C) 2021 Published by Elsevier Ltd.	[Wilck, Marissa B.; Xu, Z. Jin; Stek, Jon E.; Goveia, Michelle G.; Lee, Andrew W.] Merck & Co Inc, 2000 Galloping Hill Rd,UG1CD-44, Kenilworth, NJ 07033 USA		Wilck, MB (通讯作者)，Merck & Co Inc, 2000 Galloping Hill Rd,UG1CD-44, Kenilworth, NJ 07033 USA.	marissa.wilck@merck.com; jin_xu@merck.com; jon_stek@merck.com; michelle_goveia@merck.com; andrew_wen-tseng_lee@merck.com			Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA	Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (sponsor). Although the sponsor formally reviewed a penultimate draft, the opinions expressed are those of the authors and may not necessarily reflect those of the sponsor. All co-authors approved the final version of the manuscript. The authors would like to acknowledge Karyn Davis, employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, for her assistance with the journal submission process.	[Anonymous], RotaTeq [package insert]; [Anonymous], Vaxelis [package insert]; [Anonymous], Infanrix hexa [package insert]; [Anonymous], Prevnar 13 [package insert]; [Anonymous], Pentacel [package insert]; Bielicki JA, 2013, VACCINE, V31, P5375, DOI 10.1016/j.vaccine.2013.09.025; Block SL, 2017, PEDIATR INFECT DIS J, V36, P202, DOI 10.1097/INF.0000000000001405; Briere E, AGE HIB DIS IMPLICAT; Capeding MRZ, 1996, AM J TROP MED HYG, V55, P516, DOI 10.4269/ajtmh.1996.55.516; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Dagan R, 2010, VACCINE, V28, P5513, DOI 10.1016/j.vaccine.2010.06.026; Decker MD, 2001, PEDIATR INFECT DIS J, V20, pS10, DOI 10.1097/00006454-200111001-00002; Decker MD, 1998, PEDIATR INFECT DIS J, V17, pS113, DOI 10.1097/00006454-199809001-00004; DECKER MD, 1993, J PEDIATR-US, V122, P410, DOI 10.1016/S0022-3476(05)83428-6; Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447; Glanz JM, 2013, JAMA PEDIATR, V167, P1060, DOI 10.1001/jamapediatrics.2013.2353; Goldfarb Neil I, 2005, Manag Care, V14, P3; GRANOFF DM, 1992, J PEDIATR-US, V121, P187, DOI 10.1016/S0022-3476(05)81186-2; HALL CB, 1993, PEDIATRICS, V92, P480; Halperin SA, 2014, PEDIATR INFECT DIS J, V33, P73, DOI 10.1097/01.inf.0000437806.76221.20; Hammitt LL, 2016, LANCET GLOB HEALTH, V4, pE185, DOI 10.1016/S2214-109X(15)00316-2; Happe LE, 2007, AM J MANAG CARE, V13, P506; Kalies H, 2006, PEDIATR INFECT DIS J, V25, P507, DOI 10.1097/01.inf.0000222413.47344.23; Koslap-Petraco MB, 2008, J PEDIATR HEALTH CAR, V22, P300, DOI 10.1016/j.pedhc.2007.09.004; Lernout T, 2014, VACCINE, V32, P284, DOI 10.1016/j.vaccine.2013.10.084; Mangtani P, 2010, VACCINE, V28, P1677, DOI 10.1016/j.vaccine.2009.12.011; Marshall GS, 2007, PEDIATR INFECT DIS J, V26, P496, DOI 10.1097/INF.0b013e31805d7f17; Marshall GS, 2015, PEDIATRICS, V136, pE323, DOI 10.1542/peds.2014-4102; Miller E, 2003, P 21 ANN M EUR SOC P; MURPHY TV, 1993, JAMA-J AM MED ASSOC, V269, P246, DOI 10.1001/jama.269.2.246; Oliver JL, 2020, VACCINE, V38, P5718, DOI 10.1016/j.vaccine.2020.06.015; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P136, DOI 10.15585/mmwr.mm6905a5; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; Park YJ, 2013, JPN J INFECT DIS, V66, P6, DOI 10.7883/yoken.66.6; Pellissier JM, 2000, AM J MANAG CARE, V6, P1038; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SIBER GR, 1990, NEW ENGL J MED, V323, P1387, DOI 10.1056/NEJM199011153232005; Siedler A, 2002, PEDIATR INFECT DIS J, V21, P826, DOI 10.1097/00006454-200209000-00008; Silfverdal SA, 2016, VACCINE, V34, P3810, DOI 10.1016/j.vaccine.2016.05.054; Southern J, 2006, VACCINE, V24, P215, DOI 10.1016/j.vaccine.2005.07.060; Tapiero B, 2013, PEDIATR INFECT DIS J, V32, P54, DOI 10.1097/INF.0b013e3182717edf; Tsang RSW, 2014, EPIDEMIOL INFECT, V142, P1344, DOI 10.1017/S0950268814000405; VELLA PP, 1990, PEDIATRICS, V85, P668; Vesikari T, 2017, PEDIATR INFECT DIS J, V36, P209, DOI 10.1097/INF.0000000000001406; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; WARD JI, 1988, J CLIN MICROBIOL, V26, P72, DOI 10.1128/JCM.26.1.72-78.1988; WARD JI, 1981, LANCET, V1, P1281; WEINBERG GA, 1988, J PEDIATR-US, V113, P621, DOI 10.1016/S0022-3476(88)80369-X; World Health Organization, 2013, IMMUNIZATION VACCINE; World Health Organization, 2013, WKLY EPIDEMIOL REC, V88, P413; Xu J, 2019, PEDIATR INFECT DIS J, V38, P439, DOI [10.1097/INF.0000000000002257, 10.1097/inf.0000000000002257]	52	0	1	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 1	2021	39	9					1428	1434		10.1016/j.vaccine.2021.01.046		FEB 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8CD	33541794				2022-04-29	WOS:000618498600009
J	Jonsson, G; Hansson, C; Mellhammar, L; Gullstrand, B; Bengtsson, AA; Sahl, C; Skattum, L				Jonsson, Goran; Hansson, Christina; Mellhammar, Lisa; Gullstrand, Birgitta; Bengtsson, Anders A.; Sahl, Cecilia; Skattum, Lillemor			Increased serum bactericidal activity of autologous serum in C2 deficiency after vaccination against Haemophilus influenzae type b, and further support for an MBL-dependent C2 bypass mechanism	VACCINE			English	Article						C2 deficiency; Haemophilus influenzae type b vaccination; Serum bactericidal activity; Mannose-binding lectin; C2 bypass		Deficiencies of C2 and other components of the classical pathway of complement are associated with increased risk of infections with encapsulated bacteria, such as Haemophilus (H.) influenzae. Defense against H. influenzae is dependent on specific antibodies and complement, which mediate serum bactericidal activity (SBA) and opsonization. Due to lack of normal classical and lectin complement pathway function in C2 deficiency (C2D), SBA would have to depend either on the alternative pathway or on C2 bypass mechanisms. Here we studied SBA against H. influenzae type b (Hib) before and after vaccination in a group of C2-deficient persons, as the bactericidal capacity of antibodies in autologous complement in relation to vaccination has not been investigated at group level in C2D. Sera from 22 persons with C2D and 26 healthy controls were available. Out of these, 18 persons with C2D and all controls had been vaccinated with Act-HIB (R). SBA against Hib bacteria was analyzed with autologous serum as the only complement source. Antibodies to Hib capsular polysaccharide had been analyzed previously. Concentrations of mannose-binding lectin (MBL) and other complement components were measured in serum. SBA of both C2-deficient persons and controls was significantly more efficient after vaccination (p = 0.002 and p < 0.0001, respectively). After vaccination, all but two C2-deficient sera and one control serum showed sufficient SBA (<50% surviving bacteria). Before vaccination, SBA of C2-deficient sera was negatively correlated to serum concentrations of MBL (lower proportion of surviving bacteria with higher MBL concentration; r = -0.55, p = 0.008). After vaccination, SBA of C2-deficient sera was negatively correlated to serum concentrations of IgG Hib antibodies (r = -0.56, p = 0.01). In conclusion, SBA against Hib in autologous serum is increased after vaccination in persons with C2D. In unvaccinated C2-deficient persons SBA was correlated to MBL concentration, providing further support for an MBL-dependent C2 bypass mechanism operating in C2D. (C) 2021 The Authors. Published by Elsevier Ltd.	[Jonsson, Goran; Mellhammar, Lisa] Lund Univ, Dept Clin Sci Lund, Sect Infect Med, Lund, Sweden; [Jonsson, Goran; Mellhammar, Lisa] Skane Univ Hosp, Lund, Sweden; [Hansson, Christina; Skattum, Lillemor] Clin Immunol & Transfus Med, Lund, Region Skane, Sweden; [Hansson, Christina; Sahl, Cecilia; Skattum, Lillemor] Lund Univ, Dept Lab Med, Sect Microbiol Immunol & Glycobiol, Lund, Sweden; [Gullstrand, Birgitta; Bengtsson, Anders A.] Lund Univ, Dept Clin Sci Lund, Sect Rheumatol, Lund, Sweden		Skattum, L (通讯作者)，Clin Immunol & Transfus Med, Lund, Region Skane, Sweden.; Skattum, L (通讯作者)，Lund Univ, Dept Lab Med, Sect Microbiol Immunol & Glycobiol, Lund, Sweden.	Goran.jonsson@med.lu.se; Christina.l.hansson@skane.se; lisa.mellhammar@med.lu.se; birgitta.gullstrand@med.lu.se; anders.bengtsson@med.lu.se; cecilia.sahl@med.lu.se; lillemor_melander.skattum@med.lu.se	Sahl, Cecilia/M-2035-2016	Sahl, Cecilia/0000-0003-0469-8832	Swedish Society of Medicine, Region Skane; Medical Faculty of Lund University	The study was supported by the Swedish Society of Medicine, Region Skane and the Medical Faculty of Lund University.	Alper CA, 2003, J CLIN IMMUNOL, V23, P297, DOI 10.1023/A:1024540917593; Brodszki N, 2015, VACCINE, V33, P1839, DOI 10.1016/j.vaccine.2015.02.025; da Costa MG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02664; Goldblatt D, 1998, J INFECT DIS, V177, P1112, DOI 10.1086/517407; JARVIS GA, 1991, J IMMUNOL, V147, P1962; JOHNSON CA, 1992, J BIOL CHEM, V267, P9347; Jonsson G, 2005, MEDICINE, V84, P23, DOI 10.1097/01.md.0000152371.22747.1e; Jonsson G, 2006, J IMMUNOL, V177, P722, DOI 10.4049/jimmunol.177.1.722; Jonsson G, 2012, CLIN IMMUNOL, V144, P214, DOI 10.1016/j.clim.2012.06.008; McGrath FDG, 2006, J IMMUNOL, V176, P2950, DOI 10.4049/jimmunol.176.5.2950; Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000; Ram S, 2010, CLIN MICROBIOL REV, V23, P740, DOI 10.1128/CMR.00048-09; SCHREIBER JR, 1986, J INFECT DIS, V153, P8, DOI 10.1093/infdis/153.1.8; Selander B, 2006, J CLIN INVEST, V116, P1425, DOI 10.1172/JCI25982; Selander B, 2000, J CLIN IMMUNOL, V20, P138, DOI 10.1023/A:1006638631581; Shang Shi-qiang, 2005, J Zhejiang Univ Sci B, V6, P53, DOI 10.1631/jzus.2005.B0053; SJOHOLM AG, 1979, INT ARCH ALLER A IMM, V58, P274, DOI 10.1159/000232203; Sjoholm AG, 2001, METH MOLEC MED, V67, P529, DOI 10.1385/1-59259-149-3:529; Skattum L, 2008, CLIN IMMUNOL, V129, P123, DOI 10.1016/j.clim.2008.06.010; Skattum L, 2011, MOL IMMUNOL, V48, P1643, DOI 10.1016/j.molimm.2011.05.001; STEUER KLK, 1989, J IMMUNOL, V143, P2256; TRUEDSSON L, 1993, J IMMUNOL, V151, P5856; Yaseen S, 2017, FASEB J, V31, P2210, DOI 10.1096/fj.201601306R	23	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1297	1302		10.1016/j.vaccine.2021.01.007		FEB 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33509693	hybrid			2022-04-29	WOS:000618493500019
J	Castano-Zubieta, MR; Rossetti, CA; Garcia-Gonzalez, DG; Maurizio, E; Hensel, ME; Rice-Ficht, AC; Ficht, TA; Arenas-Gamboa, AM				Castano-Zubieta, M. Raquel; Rossetti, Carlos A.; Garcia-Gonzalez, Daniel G.; Maurizio, Estefania; Hensel, Martha E.; Rice-Ficht, Allison C.; Ficht, Thomas A.; Arenas-Gamboa, Angela M.			Evaluation of the safety profile of the vaccine candidate Brucella melitensis 16M Delta vjbR strain in goats	VACCINE			English	Article						Brucella; Brucellosis; Vaccine; Microencapsulation; Goats	ABORTUS; IMMUNIZATION; PROTECTION; INFECTION; MUTANT; CATTLE; SHEEP; EWES; MICE	Small ruminant brucellosis is caused by the Gram negative cocci-bacillus Brucella (B.) melitensis, the most virulent Brucella species for humans. In goats and sheep, middle to late-term gestation abortion, stillbirths and the delivery of weak infected offspring are the characteristic clinical signs of the disease. Vaccination with the currently available Rev. 1 vaccine is the best option to prevent and control the disease, although it is far from ideal. In this study, we investigate the safety of the B. melitensis 16M Delta vjbR strain during a 15-month period beginning at vaccination of young goats, impregnation, delivery and lactation. Forty, 4 to 6 months old, healthy female crossbreed goats were randomly divided into four groups (n = 10) and immunized subcutaneously with a single vaccine dose containing 1x10(9) CFU of B. melitensis 16M Delta vjbR delivered in alginate microcapsules or non-encapsulated. Controls received empty capsules or the commercially available Rev.1 vaccine. Seven months post-vaccination, when animals were sexually mature, all goats were naturally bred using brucellosis-free males, and allowed to carry pregnancies to term. Blood samples to assess the humoral immune response were collected throughout the study. At two months post-delivery, all dams and their offspring were euthanized and a necropsy was performed to collect samples for bacteriology and histology. Interestingly, none of the animals that received the vaccine candidate regardless of the formulation exhibited any clinical signs associated with vaccination nor shed the vaccine strain through saliva, vagina or the milk. Gross and histopathologic changes in all nannies and offspring were unremarkable with no evidence of tissue colonization or vertical transmission to fetuses. Altogether, these data demonstrate that vaccination with the mutant strain 16M Delta vjbR is safe for use in the non-pregnant primary host. (C) 2020 Elsevier Ltd. All rights reserved.	[Castano-Zubieta, M. Raquel; Rossetti, Carlos A.; Maurizio, Estefania] CICVyA INTA Inst Nacl Tecnol Agr, Inst Patobiol, Nicolas Repetto & Los Reseros S-N,B1686, Hurlingham, Bs As, Argentina; [Garcia-Gonzalez, Daniel G.; Hensel, Martha E.; Ficht, Thomas A.; Arenas-Gamboa, Angela M.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA; [Maurizio, Estefania] Consejo Nacl Invest Cient & Tecn, Godoy Cruz 2290,C1425, Caba, Argentina; [Rice-Ficht, Allison C.] Texas A&M Univ, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77843 USA		Arenas-Gamboa, AM (通讯作者)，Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA.	aarenas@cvm.tamu.edu			National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01TW009981]; International Research Scientist Development Award [IRSDA/K01]; Instituto Nacional de Tecnologia Agropecuaria (INTA) [PNSA 1115052]; NIH Institutional Training Grant T32 fellowshipUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5OD11083-7]; CONICET (Argentina)Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	This study was supported by the National Institute of Health (NIH) Grant #K01TW009981 International Research Scientist Development Award (IRSDA/K01) and Instituto Nacional de Tecnologia Agropecuaria (INTA), Grant PNSA 1115052. Student stipend support provided by the NIH Institutional Training Grant T32 fellowship (5OD11083-7) (MH) and by CONICET (Argentina) (EM).	Abraham S M, 1996, Pharm Dev Technol, V1, P63, DOI 10.3109/10837459609031419; Adetunji SA, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007112; ALEXANDER B, 1981, VET REC, V108, P500, DOI 10.1136/vr.108.23.500; Alton G. G., 1990, Animal brucellosis., P383; ALTON GG, 1987, TROP ANIM HEALTH PRO, V19, P65, DOI 10.1007/BF02297320; Arenas-Gamboa AM, 2012, CLIN VACCINE IMMUNOL, V19, P249, DOI 10.1128/CVI.05321-11; Arenas-Gamboa AM, 2009, INFECT IMMUN, V77, P877, DOI 10.1128/IAI.01017-08; Arenas-Gamboa AM, 2008, INFECT IMMUN, V76, P2448, DOI 10.1128/IAI.00767-07; Blasco J M, 2010, Prilozi, V31, P145; CHERWONOGRODZKY JW, 1988, J CLIN MICROBIOL, V26, P1120, DOI 10.1128/JCM.26.6.1120-1123.1988; DEBAGUES MPJ, 1989, ANN RECH VET, V20, P205; Aparicio ED, 2013, REV SCI TECH OIE, V32, P53; Dorneles EMS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136696; ELBERG SS, 1957, J BACTERIOL, V73, P211, DOI 10.1128/JB.73.2.211-217.1957; Goenka R, 2011, J INFECT DIS, V203, P1136, DOI 10.1093/infdis/jiq171; Hensel ME, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212457; Lantier F., 1985, Brucella melitensis. CEC seminar, Brussels, November 1984, P247; Li ZQ, 2018, MICROB PATHOGENESIS, V124, P250, DOI 10.1016/j.micpath.2018.08.052; Martirosyan A, 2011, IMMUNOL REV, V240, P211, DOI 10.1111/j.1600-065X.2010.00982.x; MICUSAN VV, 1977, IMMUNOLOGY, V32, P373; Ponsart C, 2019, VET RES, V50, DOI 10.1186/s13567-019-0717-0; Pourjafar M., 2012, Online Journal of Veterinary Research, V16, P195; Rossetti CA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005692; Weeks JN, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-167; Zriba S, 2019, VACCINE X, V3, DOI [10.1016/j.jvacx.2019.100041100041., DOI 10.1016/J.JVACX.2019.100041100041]; ZUNDEL E, 1992, ANN RECH VET, V23, P177	26	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 15	2021	39	3					617	625		10.1016/j.vaccine.2020.11.033			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VN	33328142	Green Accepted			2022-04-29	WOS:000604750400022
J	Poland, GA				Poland, Gregory A.			Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy	VACCINE			English	Editorial Material									[Poland, Gregory A.] Mayo Clin, Mayo Vaccine Res Grp, Rochester, MN USA		Poland, GA (通讯作者)，Mayo Clin, 601 C Guggenheim,200 First St SW, Rochester, MN 55905 USA.	Poland.gregory@mayo.edu						0	21	21	6	22	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 15	2021	39	3					457	459		10.1016/j.vaccine.2020.12.017			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VN	33339671	Bronze, Green Published			2022-04-29	WOS:000604750400001
J	Lentzen, MP; Huebenthal, V; Kaiser, R; Kreppel, M; Zoeller, JE; Zirk, M				Lentzen, Max-Philipp; Huebenthal, Viola; Kaiser, Rolf; Kreppel, Matthias; Zoeller, Joachim E.; Zirk, Matthias			A retrospective analysis of social media posts pertaining to COVID-19 vaccination side effects	VACCINE			English	Article						COVID-19; Vaccination; Adverse effects; Social media; Misinformation	INSTAGRAM	Objectives: With an uprising influence of social media platforms like Twitter and Instagram a multitude of worldwide accessible information is available. Since the beginning of COVID-19 pandemic the exchange of medical information about several topics related to this infectious disease and its vaccination has increased rapidly. The purpose of this investigation was to assess the content associated with COVID-19 vaccination and its side effects and evaluate its educational quality. Methods: We conducted this retrospective study to investigate 600 Twitter and Instagram posts by #covidvaccinesideeffects due to number of 'likes', comments, type of post, language, its purpose and source. In addition, posts were evaluated due to educational quality by three examiners of different edu-cational levels. Results: The majority of posts showed 0 to 50 "likes" and 0 to 5 comments in English language. A com-parison between Twitter and Instagram by the influence of application showed significant differences in number of posts and "likes" or comments (p < 0.05). The major post type were texts for Twitter (251; 83.7%) and videos for Instagram (104; 34.7%). While a majority of posts by #covidvaccinesideeffects report about the occurrence of side effects, the majority of them were mild and general COVID-19 vacci-nation feedback during the first 4 months was positive. But, only 3 to 7% were rated by "excellent" edu-cational and validatable content. Interrater reliability between all three examiners presented a high concordance with 89% (p = 0.001). Conclusions: This study presents an analysis of quantity and quality of social media content according to COVID-19 vaccinations and its side effects. It supports the deduction that most of the content on Twitter and Instagram is shared by patients and unclear sources and thus is limited informative. Nevertheless, influence of social media on medical information especially during COVID-19 pandemic is increasing and practitioners have to face its effect on their patients. (c) 2021 Elsevier Ltd. All rights reserved.	[Lentzen, Max-Philipp; Huebenthal, Viola; Kreppel, Matthias; Zoeller, Joachim E.; Zirk, Matthias] Univ Cologne, Univ Hosp Cologne, Dept Oral & Craniomaxillofacial & Plast Surg, Cologne, Germany; [Lentzen, Max-Philipp; Huebenthal, Viola; Kaiser, Rolf; Kreppel, Matthias; Zoeller, Joachim E.; Zirk, Matthias] Univ Cologne, Fac Med, Cologne, Germany; [Kaiser, Rolf] Univ Cologne, Univ Hosp Cologne, Dept Virol, Cologne, Germany		Lentzen, MP (通讯作者)，Univ Cologne, Univ Hosp Cologne, Dept Oral & Craniomaxillofacial & Plast Surg, Cologne, Germany.; Lentzen, MP (通讯作者)，Univ Cologne, Fac Med, Cologne, Germany.			Lentzen, Max-Philipp/0000-0003-2041-5687			Abdulla ZA, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10070788; Ahmed N, 2018, VACCINE, V36, P7556, DOI 10.1016/j.vaccine.2018.10.049; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Garcia JB, 2021, REV ESP CARDIOL, V74, P812, DOI [10.1016/j.rec.2021.04.005, 10.1016/j.recesp.2021.03.009]; Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463; Buyuk SK, 2019, HEALTH PROMOT PERSPE, V9, P319, DOI 10.15171/hpp.2019.44; Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y; Chae S, 2021, J MED INTERNET RES, V23, DOI 10.2196/29155; Cho MJ, 2019, PLAST RECONSTR SURG, V143, P1533, DOI 10.1097/PRS.0000000000005533; Cinelli M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73510-5; COVID-19 vaccines, 2006, DRUGS LACT DAT LACTM; Dabbagh A, 2020, J CLIN ANESTH, V65, DOI 10.1016/j.jclinane.2020.109887; Dagotto G, 2020, CELL HOST MICROBE, V28, P364, DOI 10.1016/j.chom.2020.08.002; Dara Sanjeeta, 2021, Cureus, V13, pe18400, DOI 10.7759/cureus.18400; Dorfman RG, 2018, AESTHET SURG J, V38, P332, DOI [10.1093/asj/sjx120, 10.1093/asj/sjx210]; Guess AM, 2020, VACCINE, V38, P7799, DOI 10.1016/j.vaccine.2020.10.018; Guntuku SC, 2021, VACCINE, V39, P4034, DOI 10.1016/j.vaccine.2021.06.014; Harrison AG, 2020, TRENDS IMMUNOL, V41, P1100, DOI 10.1016/j.it.2020.10.004; Hegarty E, 2017, J ORTHOD, V44, P90, DOI 10.1080/14653125.2017.1319010; Hyland P, PLOS ONE, V2021, DOI [10.1371/journal.pone.0258871-0258871, DOI 10.1371/JOURNAL.PONE.0258871-0258871]; Kang GJ, 2017, VACCINE, V35, P3621, DOI 10.1016/j.vaccine.2017.05.052; Katz M, JMIR MED EDUC, V7, DOI [10.2196/25892-25892, DOI 10.2196/25892-25892]; Kim Y, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207550; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; Larsen MK, 2016, J CRANIOFAC SURG, V27, P350, DOI 10.1097/SCS.0000000000002384; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Modanloo S, 2019, VACCINE, V37, P7493, DOI 10.1016/j.vaccine.2019.09.075; Mullens CL, 2020, PLAST RECONSTR SURG, V146, P413, DOI 10.1097/PRS.0000000000007001; Ortiz-Sanchez E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155394; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rogliani P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030227; Sorice SC, 2017, PLAST RECONSTR SURG, V140, P1047, DOI 10.1097/PRS.0000000000003769; Timberlake AT, 2018, PLAST RECONSTR SURG, V142, P1094, DOI 10.1097/PRS.0000000000004811; Topol EJ, 2021, CELL, V184, P1401, DOI 10.1016/j.cell.2020.12.039; Wissinger CL, 2019, TEACH LEARN MED, V31, P335, DOI 10.1080/10401334.2018.1528155; Wolf ME, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081599; Wong WW, 2011, AESTHET SURG J, V31, P972, DOI 10.1177/1090820X11423764; Yan ZP, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14050406; Zhou P, 2020, NATURE, V588, pE6, DOI [10.1038/s41586-020-2012-7, 10.1038/s41586-020-2951-z]	39	3	3	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					43	51		10.1016/j.vaccine.2021.11.052		DEC 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FV	34857421	Green Published, Bronze			2022-04-29	WOS:000731299800010
J	Olivieri, MAC; Moyano, RD; Mon, ML; Gravisaco, MJ; Pinedo, MFA; Delgado, FO; Pando, RH; Alonso, MN; Cuerda, MX; Santangelo, MD; Romano, MI				Colombatti Olivieri, Maria Alejandra; Damian Moyano, Roberto; Laura Mon, Maria; Jose Gravisaco, Maria; Alvarado Pinedo, Maria Fiorella; Oscar Delgado, Fernando; Hernandez Pando, Rogelio; Natalia Alonso, Maria; Ximena Cuerda, Maria; de la Paz Santangelo, Maria; Isabel Romano, Maria			Evaluation of a virulent strain of Mycobacterium avium subsp. Paratuberculosis used as a heat-killed vaccine	VACCINE			English	Article						Vaccine; Immune response; Mycobacterium avium subsp.; paratuberculosis; Silirum	IMMUNE-RESPONSES; SSP PARATUBERCULOSIS; T-CELLS; GAMMA-INTERFERON; FIELD-STRAIN; DAIRY-CATTLE; TUBERCULOSIS; INFECTION; CALVES; DISEASE	Bovine paratuberculosis is one of the most important chronic infectious diseases in livestock. This disease is difficult to control because of its inefficient management (test and cull strategy and inadequate biosecurity). Thus, the development of an effective vaccine is essential. In this study, we evaluated a local virulent strain (6611) of Mycobacterium avium subsp. paratuberculosis as an inactivated vaccine in comparison with the Silirum vaccine in mouse model and cattle. Regarding the mice model, only the groups vaccinated with 6611 showed lower colony forming unit (CFU) counts with a lower lesion score in the liver in comparison to the control group at 6 and 12 weeks post-challenge (wpc). The immune response was predominantly humoral (IgG1), although both vaccinated groups presented a cellular response with IFNc production as well, but the 6611 group had also significant production of IL-2, IL-6, IL-17a, TNF, and IL-10. In cattle, the 6611 vaccinated group was the only one that maintained significant antibody values at the end of the trial, with significant production of IgG2 and IFNc. No PPDb reactor was detected in the vaccinated animals, according to the intradermal caudal fold tuberculin test. Our results indicate that the 6611 local strain protected mice from challenge with a virulent strain, by inducing a humoral and cellular immune response. In the bovine, the natural host, the evaluated vaccine also induced humoral and cellular immune responses, with higher levels of CD4 + CD25+ and CD8 + CD25+ T cells populations than the commercial vaccine. Despite the encouraging results obtained in this study, an experimental challenge trial in cattle is mandatory to evaluate the efficacy of our candidate vaccine in the main host. (C) 2021 Elsevier Ltd. All rights reserved.	[Colombatti Olivieri, Maria Alejandra; Damian Moyano, Roberto; Laura Mon, Maria; Jose Gravisaco, Maria; Natalia Alonso, Maria; Ximena Cuerda, Maria; de la Paz Santangelo, Maria; Isabel Romano, Maria] INTA CONICET, Inst Agrobiotecnol & Biol Mol IABIMO, RA-1686 Buenos Aires, DF, Argentina; [Alvarado Pinedo, Maria Fiorella] Univ La Plata, Fac Ciencias Vet, Ctr Diagnost & Invest Vet CEDIVE, RA-7130 Buenos Aires, DF, Argentina; [Oscar Delgado, Fernando] INTA CONICET, Inst Patobiol Vet IPVET, RA-1686 Buenos Aires, DF, Argentina; [Hernandez Pando, Rogelio] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Patol, Secc Patol Expt, Mexico City, DF, Mexico		Olivieri, MAC (通讯作者)，Hurlingham PO 1686, Buenos Aires, DF, Argentina.	colombatti.alejandra@inta.gob.ar			National Agency for Science and Technology Promotion, Argentina Grants FONARSEC FS Agrobiotechnology; INTA [PNBIO 1131032]	The present study was supported by the National Agency for Science and Technology Promotion, Argentina Grants FONARSEC FS Agrobiotechnology. INTA Grant PNBIO 1131032.	[Anonymous], 2018, BOVINE TUBERCULOSIS, V8th; Bastida Felix, 2011, J Immune Based Ther Vaccines, V9, P8, DOI 10.1186/1476-8518-9-8; Blumerman SL, 2007, EUR J IMMUNOL, V37, P1204, DOI 10.1002/eji.200636216; Brown CC, 2007, PATHOLOGY DOMESTIC A, P222; Chaubey KK, 2016, VET QUART, V36, P203, DOI 10.1080/01652176.2016.1196508; Coad M, 2013, VET REC, V172, DOI 10.1136/vr.101201; Olivieri MAC, 2018, RES VET SCI, V121, P4, DOI 10.1016/j.rvsc.2018.09.009; Coussens PM, 2012, COMP IMMUNOL MICROB, V35, P233, DOI 10.1016/j.cimid.2012.01.004; de Silva K, 2018, VET IMMUNOL IMMUNOP, V195, P56, DOI 10.1016/j.vetimm.2017.11.008; de Silva K, 2013, PREV VET MED, V112, P203, DOI 10.1016/j.prevetmed.2013.08.006; Espinosa J, 2021, TRANSBOUND EMERG DIS, V68, P692, DOI 10.1111/tbed.13732; Feng HB, 2017, MOLECULES, V22, DOI 10.3390/molecules22010106; Fernandez B, 2019, VET IMMUNOL IMMUNOP, V213, DOI 10.1016/j.vetimm.2019.109886; Garrido JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080985; Gideon HP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004603; Groenendaal H, 2015, J DAIRY SCI, V98, P6070, DOI 10.3168/jds.2014-8914; Gupta SK, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79407-7; Gupta S, 2019, VET QUART, V39, P143, DOI 10.1080/01652176.2019.1667042; Jungersen G, 2002, CLIN DIAGN LAB IMMUN, V9, P453, DOI 10.1128/CDLI.9.2.453-460.2002; Kalis CHJ, 2001, AM J VET RES, V62, P270, DOI 10.2460/ajvr.2001.62.270; Kathaperumal K, 2008, VACCINE, V26, P1652, DOI 10.1016/j.vaccine.2008.01.015; Knust B, 2013, JAVMA-J AM VET MED A, V242, P663, DOI 10.2460/javma.242.5.663; Kozakiewicz L, 2013, ADV EXP MED BIOL, V783, P225, DOI 10.1007/978-1-4614-6111-1_12; Krueger LA, 2016, J DAIRY SCI, V99, P9040, DOI 10.3168/jds.2016-11144; Mon ML, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/140829; Mortier RAR, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-94; Olsen I, 2005, INFECT IMMUN, V73, P5628, DOI 10.1128/IAI.73.9.5628-5635.2005; Patton EA, 2011, VET CLIN N AM-FOOD A, V27, P573, DOI 10.1016/j.cvfa.2011.07.004; Pitt JM, 2012, J IMMUNOL, V189, P4079, DOI 10.4049/jimmunol.1201061; Platt R, 2010, VET IMMUNOL IMMUNOP, V136, P122, DOI 10.1016/j.vetimm.2010.02.003; Plattner BL, 2013, VET PATHOL, V50, P630, DOI 10.1177/0300985812463404; Pooley HB, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1972-z; Pooran A, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.02242-2018; Ramos-Espinosa O, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw075; Ren Z, 2008, J GASTROEN HEPATOL, V23, P310, DOI 10.1111/j.1440-1746.2007.04865.x; Risalde MA, 2020, COMP IMMUNOL MICROB, V68, DOI 10.1016/j.cimid.2019.101388; Robinson MW, 2011, INFECT IMMUN, V79, P2089, DOI 10.1128/IAI.00779-10; Rook GAW, 2004, TRENDS IMMUNOL, V25, P483, DOI 10.1016/j.it.2004.06.005; Rosseels V, 2008, EXPERT REV VACCINES, V7, P817, DOI 10.1586/14760584.7.6.817; Roussey JA, 2016, VET IMMUNOL IMMUNOP, V181, P42, DOI 10.1016/j.vetimm.2016.03.008; Roussey Jonathan A, 2014, Front Vet Sci, V1, P20, DOI 10.3389/fvets.2014.00020; Roy A, 2018, PREV VET MED, V156, P68, DOI 10.1016/j.prevetmed.2018.05.010; Seder RA, 2000, NATURE, V406, P793, DOI 10.1038/35021239; Serbina NV, 2001, INFECT IMMUN, V69, P4320, DOI 10.1128/IAI.69.7.4320-4328.2001; Serrano M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169735; Singh SV, 2007, VACCINE, V25, P7102, DOI 10.1016/j.vaccine.2007.07.054; Stabel JR, 2011, CLIN VACCINE IMMUNOL, V18, P2079, DOI 10.1128/CVI.05421-11; Stringer LA, 2013, VET REC, V173, P551, DOI 10.1136/vr.101799; Subharat S, 2012, VET IMMUNOL IMMUNOP, V149, P225, DOI 10.1016/j.vetimm.2012.07.005; Sweeney RW, 2009, AM J VET RES, V70, P493, DOI 10.2460/ajvr.70.4.493; Thukral Akanksha, 2020, NPJ Vaccines, V5, P15, DOI 10.1038/s41541-020-0164-y; Uzonna JE, 2003, VACCINE, V21, P3101, DOI 10.1016/S0264-410X(03)00261-5; Waters WR, 2003, INFECT IMMUN, V71, P5130, DOI 10.1128/IAI.71.9.5130-5138.2003; Windsor PA, 2014, AUST VET J, V92, P263, DOI 10.1111/avj.12194; Wong EA, 2020, J IMMUNOL, V204, P644, DOI 10.4049/jimmunol.1901211	55	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7401	7412		10.1016/j.vaccine.2021.10.084		DEC 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	34774361				2022-04-29	WOS:000731300100009
J	Ortega-Sanchez, IR; Mott, JA; Kittikraisak, W; Khanthamaly, V; McCarron, M; Keokhonenang, S; Ounaphom, P; Pathammavong, C; Phounphenghack, K; Sayamoungkhoun, P; Chanthavilay, P; Bresee, J; Tengbriacheu, C				Ortega-Sanchez, Ismael R.; Mott, Joshua A.; Kittikraisak, Wanitchaya; Khanthamaly, Viengphone; McCarron, Margaret; Keokhonenang, Soukphadeth; Ounaphom, Phonepaseuth; Pathammavong, Chansay; Phounphenghack, Kongxay; Sayamoungkhoun, Panome; Chanthavilay, Phetsavanh; Bresee, Joseph; Tengbriacheu, Chankham			Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >=60 years of age in Lao People's Democratic Republic	VACCINE			English	Article						Influenza; Vaccination; Risk group; Cost-effectiveness; Pregnancy; Healthcare worker; Adults >=60 years; Lao PDR	MIDDLE-INCOME COUNTRIES; PANDEMIC INFLUENZA; MEDICAL COSTS; IMPACT; INFECTIONS; THAILAND; VACCINES; CHILDREN; DISEASE	Background: Pregnant women, healthcare workers (HW), and adults >= 60 years have shown an increased vulnerability to seasonal influenza virus infections and/or complications. In 2012, the Lao People's Democratic Republic (Lao PDR) initiated a national influenza vaccination program for these target groups. A cost-effectiveness evaluation of this program was undertaken to inform program sustainability. Methods: We designed a decision-analytical model and collected influenza-related medical resource utilization and cost data, including indirect costs. Model inputs were obtained from medical record abstraction, interviews of patients and staff at hospitals in the national influenza sentinel surveillance system and/or from literature reviews. We compared the annual disease and economic impact of influenza illnesses in each of the target groups in Lao PDR under scenarios of no vaccination and vaccination, and then estimated the cost-effectiveness of the vaccination program. We performed sensitivity analyses to identify influential variables. Results: Overall, the vaccination of pregnant women, HWs, and adults >= 60 years could annually save 11,474 doctor visits, 1,961 days of hospitalizations, 43,027 days of work, and 1,416 life-years due to laboratory-confirmed influenza illness. After comparing the total vaccination program costs of 23.4 billion Kip, to the 18.4 billion Kip saved through vaccination, we estimated the vaccination program to incur a net cost of five billion Kip (599,391 USD) annually. The incremental cost per life-year saved (ICER) was 44 million Kip (5,295 USD) and 6.9 million Kip (825 USD) for pregnant women and adults >= 60 years, respectively. However, vaccinating HWs provided societal cost-savings, returning 2.88 Kip for every single Kip invested. Influenza vaccine effectiveness, attack rate and illness duration were the most influential variables to the model. Conclusion: Providing influenza vaccination to HWs in Lao PDR is cost-saving while vaccinating pregnant women and adults >= 60 is cost-effective and highly cost-effective, respectively, per WHO standards. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).	[Ortega-Sanchez, Ismael R.] US Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; [Mott, Joshua A.; Kittikraisak, Wanitchaya] US Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Nonthaburi, Thailand; [Khanthamaly, Viengphone] US Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Viangchan, Laos; [McCarron, Margaret] US Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; [Keokhonenang, Soukphadeth; Pathammavong, Chansay; Phounphenghack, Kongxay; Sayamoungkhoun, Panome; Tengbriacheu, Chankham] Minist Hlth, Maternal & Child Hlth Ctr, Viangchan, Laos; [Ounaphom, Phonepaseuth] Minist Hlth, Dept Hyg & Hlth Promot, Viangchan, Laos; [Bresee, Joseph] US Ctr Dis Control & Prevent, Task Force Global Hlth & Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; [Chanthavilay, Phetsavanh] Univ Hlth Sci, Minist Hlth, Viangchan, Laos		Mott, JA (通讯作者)，Minist Publ Hlth, Cdc Reg Influenza Program, DDC 7 Bldg,5th Floor,Soi 4,Tivanon Rd, Nonthaburi 11000, Thailand.	jmott@cdc.gov					Akin L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157657; Benowitz I, 2010, CLIN INFECT DIS, V51, P1355, DOI 10.1086/657309; Chan YWD, 2019, HUM VACC IMMUNOTHER, V15, P97, DOI 10.1080/21645515.2018.1514222; Chiu SS, 2018, J INFECT DIS, V217, P1365, DOI 10.1093/infdis/jiy027; Cowling BJ, 2020, CLIN INFECT DIS, V71, P1741, DOI 10.1093/cid/ciz1058; Dawood FS, 2021, LANCET INFECT DIS, V21, P97, DOI 10.1016/S1473-3099(20)30592-2; de Boer PT, 2017, EXPERT REV PHARM OUT, V17, P249, DOI 10.1080/14737167.2017.1343145; Drummond MF., 2005, METHODS EC EVALUATIO; Edoka I, 2021, VACCINE, V39, P412, DOI 10.1016/j.vaccine.2020.11.028; Fairbrother G, 2010, VACCINE, V28, P4913, DOI 10.1016/j.vaccine.2010.05.036; Feng S, 2018, LANCET RESP MED, V6, P925, DOI 10.1016/S2213-2600(18)30419-3; Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816; Haddix AC, 2003, PREVENTION EFFECTIVE; Hanshaoworakul W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006051; Hasan R, 2014, PEDIATR INFECT DIS J, V33, pE45, DOI 10.1097/INF.0000000000000062; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jamotte A, 2017, HUM VACC IMMUNOTHER, V13, P877, DOI 10.1080/21645515.2016.1256928; Khamphaphongphane B, 2021, WEST PAC SURVEILL RE, V12, DOI 10.5365/wpsar.2020.11.2.001; Khamphaphongphane B, 2013, INFLUENZA OTHER RESP, V7, P304, DOI 10.1111/j.1750-2659.2012.00394.x; Kittikraisak W, 2016, INFLUENZA OTHER RESP, V10, P211, DOI 10.1111/irv.12361; Kittikraisak W, 2015, INFLUENZA OTHER RESP, V9, P85, DOI 10.1111/irv.12302; Kraigsley AM, 2021, VACCINE, V39, P3419, DOI 10.1016/j.vaccine.2021.04.043; Kuster SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026239; Levy JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134318; Marseille E, 2015, B WORLD HEALTH ORGAN, V93, P118, DOI 10.2471/BLT.14.138206; Meeyai A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001829; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Moro PL, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.050; Neumann P. J., 2016, Cost-effectiveness in health and medicine; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Ng YX, 2019, VACCINE, V37, P3925, DOI 10.1016/j.vaccine.2019.03.054; Ortega-Sanchez IR, 2012, VACCINE, V30, P4175, DOI 10.1016/j.vaccine.2012.04.057; Ott JJ, 2013, HUM VACC IMMUNOTHER, V9, P1500, DOI 10.4161/hv.24704; Peasah SK, 2013, VACCINE, V31, P5339, DOI 10.1016/j.vaccine.2013.09.013; Portnoy A, 2020, PHARMACOECONOMICS, V38, P995, DOI 10.1007/s40273-020-00930-6; Prasad N, 2019, J INFECT DIS, V219, P1893, DOI 10.1093/infdis/jiz035; Prasert K, 2019, VACCINE, V37, P783, DOI 10.1016/j.vaccine.2018.12.047; Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195; Skowronski DM, 2016, CLIN INFECT DIS, V63, P1265, DOI 10.1093/cid/ciw544; Suphanchaimat R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17041247; Ting EEK, 2017, VACCINE, V35, P1828, DOI 10.1016/j.vaccine.2017.02.044; Vellozzi C, 2009, VACCINE, V27, P2114, DOI 10.1016/j.vaccine.2009.01.125; Xeuatvongsa A, 2019, VACCINE, V37, P3002, DOI 10.1016/j.vaccine.2019.04.047	43	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 20	2021	39	52					7633	7645		10.1016/j.vaccine.2021.11.011		DEC 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1EI	34802790	hybrid			2022-04-29	WOS:000731295900015
J	Sugishita, Y; Sugawara, T				Sugishita, Yoshiyuki; Sugawara, Tamie			Effectiveness and cost-effectiveness of influenza vaccination for elderly people	VACCINE			English	Review							TEST-NEGATIVE DESIGN; SEASONAL INFLUENZA; ANTIBODY-RESPONSE; IMMUNE-RESPONSE; ADULTS; VACCINES; PROGRAM; QUADRIVALENT; POPULATION; EFFICACY	For elderly people who have low incidence of influenza, calculation of credible vaccine effectiveness (VE) sometimes becomes difficult. Currently, VE for elderly people is insufficient to ascertain the precise efficacy specifically. Cost-effectiveness of influenza vaccination of elderly people is discussed widely in terms of topics and areas. This report describes research results demonstrating influenza vaccination effectiveness among elderly people based on recent findings. Newly available influenza vaccination for elderly people appears to be cost-effective compared with that of trivalent inactiveted influenza vaccine. Overall, for all influenza virus types, it remains unclear whether influenza vaccination shows high VE. A decreasing effect of repeated vaccination was confirmed partially by test negative design and a serological study of cohorts. However, some studies have found no such decreasing effect. Measurement of VE and subsequent analysis of the cost-effectiveness of influenza vaccination for elderly people requires long-term monitoring using serological studies and test negative design. (C) 2021 Elsevier Ltd. All rights reserved.	[Sugishita, Yoshiyuki; Sugawara, Tamie] Natl Inst Infect Dis, Tokyo, Japan		Sugishita, Y (通讯作者)，Natl Inst Infect Dis, Shinjuku Ku, 1-23-1 Toyama, Tokyo, Japan.	yoshiyuk@gmail.com					Allsup S, 2004, VACCINE, V23, P639, DOI 10.1016/j.vaccine.2004.07.008; [Anonymous], 1998, Morbidity and Mortality Weekly Report, V47, P1; Bella A, 2019, EXPERT REV VACCINES, V18, P671, DOI 10.1080/14760584.2019.1627206; Brydak LB, 2004, VIRAL IMMUNOL, V17, P609, DOI 10.1089/vim.2004.17.609; Brydak LB, 2003, J CLIN IMMUNOL, V23, P214, DOI 10.1023/A:1023314029788; Brydak L, 2012, CLIN DRUG INVEST, V32, P73, DOI 10.2165/11594030-000000000-00000; Capri S, 2018, HUM VACC IMMUNOTHER, V14, P1331, DOI 10.1080/21645515.2018.1438792; Centers for Disease Control and Prevention, BACKGR EP 2021 22 AC; Centers for Disease Control and Prevention, SEAS FLU VACC; Centers for Disease Control and Prevention, ADM PNEUM VACC; Centers for Disease Control and Prevention, CDC SEAS FLU VACC EF; Chen Qiong, 2020, Aging Med (Milton), V3, P1, DOI 10.1002/agm2.12102; Chit A, 2015, LANCET INFECT DIS, V15, P1459, DOI 10.1016/S1473-3099(15)00249-2; Chit A, 2015, VACCINE, V33, P734, DOI 10.1016/j.vaccine.2014.10.079; Darvishian M, 2017, LANCET RESP MED, V5, P200, DOI 10.1016/S2213-2600(17)30043-7; Devlin N, 2004, HEALTH ECON, V13, P437, DOI 10.1002/hec.864; Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816; Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003; Gardner EM, 2001, VACCINE, V19, P4610, DOI 10.1016/S0264-410X(01)00246-8; Gherasim A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179160; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001; Hamborsky J, 2015, EPIDEMIOLOGY PREVENT, V13th, P187; Hay AJ, 2001, PHILOS T R SOC B, V356, P1861, DOI 10.1098/rstb.2001.0999; Iorio AM, 2007, GERONTOLOGY, V53, P411, DOI 10.1159/000110579; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jiang MH, 2020, VACCINE, V38, P1057, DOI 10.1016/j.vaccine.2019.11.045; Keitel WA, 1997, VACCINE, V15, P1114, DOI 10.1016/S0264-410X(97)00003-0; Kitamura S, 2020, AM J INFECT CONTROL, V48, P1422, DOI 10.1016/j.ajic.2020.05.011; Lee BY, 2009, VACCINE, V27, P7110, DOI 10.1016/j.vaccine.2009.09.056; Leung MK, 2016, VACCINE, V34, P2469, DOI 10.1016/j.vaccine.2016.04.008; Maciosek MV, 2006, AM J PREV MED, V31, P72, DOI 10.1016/j.amepre.2006.03.008; Martinez-Baz I, 2017, J INFECT DIS, V215, P847, DOI 10.1093/infdis/jix055; McPake B, 2020, HLTH EC INT PERSPECT, DOI [10.4324/9781315169729, DOI 10.4324/9781315169729]; Meier G, 2015, J MED ECON, V18, P746, DOI 10.3111/13696998.2015.1044456; Newall AT, 2014, VACCINE, V32, P1323, DOI 10.1016/j.vaccine.2014.01.017; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ohkusa Y, 2006, PUBLIC POL REV, V2, P45; Ortqvist A, 2018, VACCINE, V36, P5556, DOI 10.1016/j.vaccine.2018.07.052; Patel MS, 2006, PREV MED, V42, P240, DOI 10.1016/j.ypmed.2005.12.004; Praditsuwan Rungnirand, 2005, Journal of the Medical Association of Thailand, V88, P256; Raviotta JM, 2016, J AM GERIATR SOC, V64, P2126, DOI 10.1111/jgs.14323; Reichert TA, 2001, NEW ENGL J MED, V344, P889, DOI 10.1056/NEJM200103223441204; Remarque EJ, 1998, J MED VIROL, V55, P82, DOI 10.1002/(SICI)1096-9071(199805)55:1&lt;82::AID-JMV13&gt;3.0.CO;2-1; Rondy M, 2017, EUROSURVEILLANCE, V22, P6, DOI [10.2807/1560-7917.ES.2017.22.30.30580, 10.2807/1560-7917.es.2017.22.30.30580]; Rondy M, 2017, VACCINE, V35, P4298, DOI 10.1016/j.vaccine.2017.06.088; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Seki Y, 2018, J INFECT CHEMOTHER, V24, P873, DOI 10.1016/j.jiac.2018.07.013; Skowronski DM, 2008, J INFECT DIS, V197, P490, DOI 10.1086/524146; Song JY, 2020, VACCINE, V38, P318, DOI 10.1016/j.vaccine.2019.10.012; Song JY, 2010, VACCINE, V28, P3929, DOI 10.1016/j.vaccine.2010.03.067; Stratton KR, 2000, VACCINES 21 CENTURY, DOI [10.17226/5501, DOI 10.17226/5501]; Sugishita Y, 2020, VACCINE, V38, P3759, DOI 10.1016/j.vaccine.2020.03.025; TERZIN AL, 1979, J HYG-CAMBRIDGE, V82, P225, DOI 10.1017/S0022172400025638; Thorrington D, 2019, VACCINE, V37, P2051, DOI 10.1016/j.vaccine.2019.03.002; Van Bellinghen LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098437; Weaver M, 2001, ARCH INTERN MED, V161, P111, DOI 10.1001/archinte.161.1.111; WHO, INFL SEAS; Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017; You JHS, 2009, J EPIDEMIOL COMMUN H, V63, P906, DOI 10.1136/jech.2008.081885; You JHS, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0618-9; Yun JW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209643; Zhang DT, 2019, VACCINE, V37, P1853, DOI 10.1016/j.vaccine.2019.02.013	63	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 20	2021	39	52					7531	7540		10.1016/j.vaccine.2021.09.054		DEC 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XQ1EI	34857422				2022-04-29	WOS:000731295900003
J	Thompson, MG; Soto, G; Peretz, A; Newes-Adeyi, G; Yoo, YM; Hirsch, A; Katz, MA; Tinoco, Y; Avni, YS; Ticona, E; Malosh, R; Martin, E; Matos, E; Reynolds, S; Wesley, M; Ferdinands, J; Cheung, A; Levine, M; Bravo, E; Arriola, CS; Castillo, ME; Castro, JC; Dawood, F; Greenberg, D; Quijandria, JMN; Azziz-Baumgartner, E; Monto, A; Balicer, RD				Thompson, Mark G.; Soto, Giselle; Peretz, Alon; Newes-Adeyi, Gabriella; Yoo, Young M.; Hirsch, Avital; Katz, Mark A.; Tinoco, Yeny; Avni, Yonat Shemer; Ticona, Eduardo; Malosh, Ryan; Martin, Emily; Matos, Eduardo; Reynolds, Sue; Wesley, Meredith; Ferdinands, Jill; Cheung, Angela; Levine, Min; Bravo, Eduar; Arriola, Carmen Sofia; Castillo, Maria Ester; Castro, Juan Carlos; Dawood, Fatimah; Greenberg, David; Quijandria, Joan Manuel Neyra; Azziz-Baumgartner, Eduardo; Monto, Arnold; Balicer, Ran D.			Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019	VACCINE			English	Article						Healthcare; Influenza; Vaccine effectiveness	TEST-NEGATIVE DESIGN; ANTIBODY-RESPONSE; UNITED-STATES; VIRUS; ILLNESS; WORKERS; SEASON; METAANALYSIS; PROTECTION; COMMUNITY	Background: There are limited data on influenza vaccine effectiveness (IVE) in preventing laboratory confirmed influenza illness among healthcare personnel (HCP). Methods: HCP with direct patient contact working full-time in hospitals were followed during three influenza seasons in Israel (2016-2017 to 2018-2019) and Peru (2016 to 2018). Trivalent influenza vaccines were available at all sites, except during 2018-2019 when Israel used quadrivalent vaccines; vaccination was documented by electronic medical records, vaccine registries, and/or self-report (for vaccinations outside the hospital). Twice-weekly active surveillance identified acute respiratory symptoms or febrile illness (ARFI); self-collected respiratory specimens were tested by real-time reverse transcription polymerase chain reaction (PCR) assay. IVE was 100 x 1-hazard ratio (adjusted for sex, age, occupation, and hospital). Results: Among 5,489 HCP who contributed 10,041 person-seasons, influenza vaccination coverage was 47% in Israel and 32% in Peru. Of 3,056 ARFIs in Israel and 3,538 in Peru, A or B influenza virus infections were identified in 205 (7%) in Israel and 87 (2.5%) in Peru. IVE against all viruses across seasons was 1% (95% confidence interval [CI] =-30%, 25%) in Israel and 12% (95% CI =-61%, 52%) in Peru. Conclusion: Estimates of IVE were null using person-time models during six study seasons in Israel and Peru. (c) 2021 Published by Elsevier Ltd.	[Thompson, Mark G.; Reynolds, Sue; Ferdinands, Jill; Levine, Min; Arriola, Carmen Sofia; Dawood, Fatimah; Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent CDC, Atlanta, GA USA; [Soto, Giselle; Tinoco, Yeny; Quijandria, Joan Manuel Neyra] US Naval Med Res Unit 6, Bellavista, Peru; [Peretz, Alon; Hirsch, Avital; Katz, Mark A.; Balicer, Ran D.] Clalit Res Inst, Tel Aviv, Israel; [Peretz, Alon] Rabin Med Ctr, Petah Tiqwa, Israel; [Newes-Adeyi, Gabriella; Wesley, Meredith; Cheung, Angela] ABT Associates Inc, Atlanta, GA USA; [Yoo, Young M.] Battelle Mem Inst, Atlanta, GA USA; [Avni, Yonat Shemer; Greenberg, David] Ben Gurion Univ Negev, Soroka Univ, Med Ctr, Beer Sheva, Israel; [Ticona, Eduardo] Dos Mayo Hosp, Lima, Peru; [Malosh, Ryan; Martin, Emily; Monto, Arnold] Univ Michigan, Detroit, MI USA; [Matos, Eduardo] Hosp Loayza, Lima, Peru; [Bravo, Eduar] Hosp Nacl Cayetano Heredia, Lima, Peru; [Castillo, Maria Ester] Inst Salud Nino, Lima, Peru; [Castro, Juan Carlos] Hosp Carrion, Lima, Peru		Thompson, MG (通讯作者)，Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd,MS A-247, Atlanta, GA 30329 USA.	isq8@cdc.gov		Tinoco, Yeny/0000-0003-3181-2178; Newes-Adeyi, Gabriella/0000-0002-4411-0370; Katz, Mark/0000-0002-5532-7276	US CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [HHSD2002013M53890B, NMR-9619/CDC13FED1310208/NM R9864/CDC16FED1612328];  [200-2014-F-60406]	Role of the Funding Source US CDC funded these efforts through contract HHSD2002013M53890B (Achieving Public Health Impact through Research; task 200-2014-F-60406: "The Epidemiology and Prevention of Influenza Virus Infections in Low-and Middle-Income Countries") to Abt Associates. US CDC also funded the Inter-Agency Agreement (Number NMR-9619/CDC13FED1310208/NM R9864/CDC16FED1612328) to Naval Medical Research Unit 6 (NAMRU6) .	Al Qahtani AA, 2021, HUM VACC IMMUNOTHER, V17, P119, DOI 10.1080/21645515.2020.1764827; Amorim LDAF, 2015, INT J EPIDEMIOL, V44, P324, DOI 10.1093/ije/dyu222; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P117; Belongia EA, 2017, EXPERT REV VACCINES, V16, P723, DOI 10.1080/14760584.2017.1334554; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Benet T, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-30; Bridges CB, 2003, CLIN INFECT DIS, V37, P1094, DOI 10.1086/378292; Cherian T, 2019, VACCINE, V37, P6255, DOI 10.1016/j.vaccine.2019.07.079; Colucci Maria Eugenia, 2019, Acta Biomed, V90, P21, DOI 10.23750/abm.v90i9-S.8699; Cowling BJ, 2020, CLIN INFECT DIS, V71, P1704, DOI 10.1093/cid/ciz1034; Dawood FS, IMMUNOGENICITY TRIAL; De Serres G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0163586; Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2; Durand CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071079; Flannery B, 2018, J INFECT DIS, V218, P189, DOI 10.1093/infdis/jix634; Foppa IM, 2013, VACCINE, V31, P3104, DOI 10.1016/j.vaccine.2013.04.026; Gaglani M, 2014, J INFECT DIS, V209, P1705, DOI 10.1093/infdis/jit825; Glatman-Freedman A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010078; Glatman-Freedman A, 2017, J CLIN VIROL, V93, P71, DOI 10.1016/j.jcv.2017.05.020; Henkle E, 2014, INFECT CONT HOSP EP, V35, P538, DOI 10.1086/675832; Huang KYA, 2017, SCI REP-UK, V7, DOI 10.1038/srep40027; Imai C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198685; Kissling E, 2019, EUROSURVEILLANCE, V24, P31, DOI 10.2807/1560-7917.ES.2019.24.48.1900604; Kuster SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026239; Laguio-Vila MR, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofu115; Leung VKY, 2017, VACCINE, V35, P2558, DOI 10.1016/j.vaccine.2017.03.063; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Marshall Stephen W, 2007, Epidemiol Perspect Innov, V4, P4, DOI 10.1186/1742-5573-4-4; McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647; Naleway AL, 2019, JMIR RES PROTOC, V8, DOI 10.2196/11333; Ng ANM, 2011, J HOSP INFECT, V79, P279, DOI 10.1016/j.jhin.2011.08.004; Ng TWY, 2019, J INFECT DIS, V219, P1525, DOI 10.1093/infdis/jiy720; Ohmit SE, 2015, J INFECT DIS, V211, P1519, DOI 10.1093/infdis/jiu650; Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736; Ohmit SE, 2013, CLIN INFECT DIS, V56, P1363, DOI 10.1093/cid/cit060; Panatto D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010119; Pebody R, 2017, EUROSURVEILLANCE, V22; Rondy M, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.9.18-00086; Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010; Seaman CP, 2019, J CLIN VIROL, V118, P28, DOI 10.1016/j.jcv.2019.07.010; Shefer Abigail, 2011, Morbidity and Mortality Weekly Report, V60, P1; Spencer S, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00027-19; Stein Y, 2018, CLIN INFECT DIS, V66, P1383, DOI 10.1093/cid/cix1013; Sullivan SG, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.43.17-00707; Sullivan SG, 2014, EXPERT REV VACCINES, V13, P1571, DOI 10.1586/14760584.2014.966695; Thompson M, 2020, IMMUNOGENICITY TRIAL; Thompson MG, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2280-0; Thompson MG, 2016, VACCINE, V34, P3443, DOI 10.1016/j.vaccine.2016.04.085; Thompson MG, 2016, VACCINE, V34, P981, DOI 10.1016/j.vaccine.2015.10.119; Tinoco YO, 2017, CLIN INFECT DIS, V65, P1532, DOI 10.1093/cid/cix565; Tokars JI, 2018, CLIN INFECT DIS, V66, P1511, DOI 10.1093/cid/cix1060; Vanhems P, 2016, HUM VACC IMMUNOTHER, V12, P485, DOI 10.1080/21645515.2015.1079677; Volling C, 2019, CLIN MICROBIOL INFEC, V25, P217, DOI 10.1016/j.cmi.2018.05.002; Wesley MG, 2020, INFLUENZA OTHER RESP, V14, P391, DOI 10.1111/irv.12737; Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908; Wu SS, 2018, VACCINE, V36, P5774, DOI 10.1016/j.vaccine.2018.07.077; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	59	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6956	6967		10.1016/j.vaccine.2021.07.077		NOV 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34509322				2022-04-29	WOS:000719580000019
J	Corcoran, KE; Scheitle, CP; DiGregorio, BD				Corcoran, Katie E.; Scheitle, Christopher P.; DiGregorio, Bernard D.			Christian nationalism and COVID-19 vaccine hesitancy and uptake	VACCINE			English	Article						Christian nationalism; COVID-19; Vaccine hesitancy; Religion	AMERICANS; ATTITUDES; IDENTITY; RELIGION; ACCEPTANCE; BOUNDARIES; KNOWLEDGE; BLACK; BLUE	Understanding COVID-19 vaccine hesitancy and uptake is vital for informing public health interventions. Prior U.S. research has found that religious conservatism is positively associated with anti-vaccine attitudes. One of the strongest predictors of anti-vaccine attitudes in the U.S. is Christian nationalism-a U.S. cultural ideology that wants civic life to be permeated by their particular form of nationalist Christianity. However, there are no studies examining the relationship between Christian nationalism and COVID-19 vaccine hesitancy and uptake. Using a new nationally representative sample of U.S. adults, we find that Christian nationalism is one of the strongest predictors of COVID-19 vaccine hesitancy and is negatively associated with having received or planning to receive a COVID-19 vaccine. Since Christian nationalists make up approximately 20 percent of the population, these findings could have important implications for achieving herd immunity. (c) 2021 Elsevier Ltd. All rights reserved.	[Corcoran, Katie E.; Scheitle, Christopher P.; DiGregorio, Bernard D.] West Virginia Univ, Dept Sociol & Anthropol, POB 6326, Morgantown, WV 26506 USA		Corcoran, KE (通讯作者)，West Virginia Univ, Dept Sociol & Anthropol, POB 6326, Morgantown, WV 26506 USA.	kecorcoran@mail.wvu.edu; cpscheitle@mail.wvu.edu; bdigrego@mix.wvu.edu		Corcoran, Katie/0000-0002-7948-5877	Science and Religion: Identity and Belief Formation grant initiative spearheaded by the Religion and Public Life Program at Rice University; University of California-San DiegoUniversity of California System; Templeton Religion Trust via The Issachar Fund	This research was supported by a grant from the Science and Religion: Identity and Belief Formation grant initiative spearheadedby the Religion and Public Life Program at Rice University and the University of California-San Diego and provided by the Templeton Religion Trust via The Issachar Fund. The funding source had no involvement in the study design, data collection, analysis and interpretation of data, in writing the manuscript, or in the decision to submit the article for publication.	Baker JO, 2020, SOCIOL FORUM, V35, P587, DOI 10.1111/socf.12619; Baker JO, 2009, J SCI STUD RELIG, V48, P719, DOI 10.1111/j.1468-5906.2009.01475.x; Baum MA, 2011, J HEALTH POLIT POLIC, V36, P1021, DOI 10.1215/03616878-1460569; Baumgaertner B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191728; Brewer NT, 2011, SEX TRANSM DIS, V38, P197, DOI 10.1097/OLQ.0b013e3181f12dbf; Buckman C, 2020, SOC SCI MED, V260, DOI 10.1016/j.socscimed.2020.113187; Bunch L, 2021, HEC FORUM, V33, P143, DOI 10.1007/s10730-021-09440-0; Callaghan Timothy, 2020, CORRELATES DISPARITI; Constantine NA, 2007, J ADOLESCENT HEALTH, V40, P108, DOI 10.1016/j.jadohealth.2006.10.007; Corbie-Smith G., 2021, JAMA HLTH FORUM, V2, pe210434, DOI [10.1001/jamahealthforum.2021.0434, DOI 10.1001/JAMAHEALTHFORUM.2021.0434]; Courtot, 2021, CONFRONTING COVID 19; Cowan S., 2021, SOCIUS, V7, P1, DOI [10.1177/23780231211023657, DOI 10.1177/23780231211023657]; Dahab R, 2019, ETHNIC RACIAL STUD, V42, P1727, DOI 10.1080/01419870.2018.1506142; Davis J, 2018, J SCI STUD RELIG, V57, P300, DOI 10.1111/jssr.12510; Davis JT, 2019, ETHNIC RACIAL STUD, V42, P2123, DOI 10.1080/01419870.2018.1527939; Dembosky, 2021, STOP BLAMING TUSKEGE; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Gadarian SK, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249596; Galbraith KV, 2016, SOC SCI MED, V159, P116, DOI 10.1016/j.socscimed.2016.04.028; Gerend MA, 2011, WOMEN HEALTH, V51, P25, DOI 10.1080/03630242.2011.540744; Hamel Liz, KFF COVID 19 VACCINE; Hornsey MJ, 2020, SOC SCI MED, V255, DOI 10.1016/j.socscimed.2020.113019; Hubbard K, 2021, US NEWS; Jochman JC, 2018, SOCIOL QUART, V59, P584, DOI 10.1080/00380253.2018.1481726; Katz ML, 2009, VACCINE, V27, P3945, DOI 10.1016/j.vaccine.2009.04.040; Khubchandani Jagdish, 2021, Brain Behav Immun Health, V15, P100277, DOI 10.1016/j.bbih.2021.100277; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; McDaniel EL, 2011, AM POLIT RES, V39, P205, DOI 10.1177/1532673X10371300; Menard S, 2011, SOC FORCES, V89, P1409, DOI 10.1093/sf/89.4.1409; Mesch GS, 2015, HEALTH PROMOT INT, V30, P213, DOI 10.1093/heapro/dau094; Motta M, 2021, AM POLIT RES, V49, P428, DOI 10.1177/1532673X211022639; Nguyen Long H, 2021, medRxiv, DOI 10.1101/2021.02.25.21252402; NORC, 2021, PAN DES AMERISPEAK; Olagoke AA, 2021, J RELIG HEALTH, V60, P65, DOI 10.1007/s10943-020-01090-9; Perry SL, 2020, J SCI STUD RELIG, V59, P405, DOI 10.1111/jssr.12677; Perry SL, 2019, SOCIOL RELIG, V80, P277, DOI 10.1093/socrel/sry046; Perry SL, 2019, SOCIOL RACE ETHNIC, V5, P130, DOI 10.1177/2332649218790983; Perry Samuel L., SOCIOL RELIG, DOI [10.1093/socrel/sraa047, DOI 10.1093/SOCREL/SRAA047]; Perry SamuelL., 2020, SOC PROBL; Perry SL, PUBLIC UNDERSTAND SC, V2021; Piltch-Loeb R, MEDRXIV 2021, DOI [10.1101/2021.08.05.21261675, DOI 10.1101/2021.08.05.21261675]; Roser Max, 2021, CUMULATIVE CONFIRMED; Schnabel Landon., 2018, SOCIUS SOCIOLOGICAL, V4, P1, DOI DOI 10.1177/2378023118790189; Scott EM, 2021, VACCINE, V39, P1058, DOI 10.1016/j.vaccine.2021.01.022; Sherkat DE, 2018, SOC SCI QUART, V99, P1791, DOI 10.1111/ssqu.12535; Turner Akiva., 2017, PAEDIAT HLTH, V5, P1, DOI [10.7243/2052-935X-5-1, DOI 10.7243/2052-935X-5-1]; Washington HA., 2006, MED APARTHEID DARK H; Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598; Wellman James K., 2008, EVANGELICAL VS LIBER; Wellman JK, 2007, SOCIOL RELIG, V68, P383, DOI 10.1093/socrel/68.4.383; Whitehead A. L., 2020, SOCIUS, V6, DOI [10.1177/2378023120977727, DOI 10.1177/2378023120977727]; Whitehead AL, 2018, SOCIOL RELIG, V79, P147, DOI 10.1093/socrel/srx070; Whitehead AL, 2015, SOCIOL PERSPECT, V58, P422, DOI 10.1177/0731121415577724; Whitehead Andrew L, 2020, TAKING AM BACK GOD C; Young JL, 2021, AM J BIOETHICS, V21, P100, DOI 10.1080/15265161.2020.1870767	56	6	6	22	22	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6614	6621		10.1016/j.vaccine.2021.09.074		OCT 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WI0SZ	34629205	Bronze, Green Published			2022-04-29	WOS:000708078600007
J	Yacoub, MR; Cucca, V; Asperti, C; Ramirez, GA; Della-Torre, E; Moro, M; Zandalasini, C; Di Napoli, D; Ambrosio, A; Signorelli, C; Colombo, S; Beretta, L; Ciceri, F; Zangrillo, A; Dagna, L				Yacoub, Mona-Rita; Cucca, Valentina; Asperti, Chiara; Ramirez, Giuseppe A.; Della-Torre, Emanuel; Moro, Matteo; Zandalasini, Camilla; Di Napoli, Davide; Ambrosio, Alberto; Signorelli, Carlo; Colombo, Sergio; Beretta, Luigi; Ciceri, Fabio; Zangrillo, Alberto; Dagna, Lorenzo			Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine	VACCINE			English	Article						Anaphylaxis; COVID vaccine; Drug allergy; Mast cell disorders; Safety; Tryptase	COVID-19; MASTOCYTOSIS	Among 6146 hospital employees, 118 subjects with severe allergic background were identified through a screening questionnaire and stratified into 3 groups (Low-risk (LR), Intermediate (IR) and High-risk (HR) group), based on their allergic anamnesis. Data reports on hypersensitivity reactions (HypR) have been collected in both allergic and non-allergic subjects. Seventeen patients (14%) in the allergic population had a HypR after the first, the second or both doses. Skin manifestations were the most frequent ones. Allergic events were more frequent in HR (35%) than IR (10%; p = 0.005) or LR (0%; p = 0.074) subjects. No patient had anaphylaxis. All patients completed the vaccination schedule. 13 HypR occurred in patients without severe allergic background (13/6028, 0,2%) including one (1/6148, 0.016% of total population) WAO grade-4 anaphylaxis. Our data suggest that BNT162b2 mRNA Covid-19 vaccine is relatively safe also in patients with severe allergic background; however, some precautions are required for high-risk patients. (c) 2021 Elsevier Ltd. All rights reserved.	[Yacoub, Mona-Rita; Cucca, Valentina; Ramirez, Giuseppe A.; Della-Torre, Emanuel; Dagna, Lorenzo] IRCCS Osped San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis, Milan, Italy; [Yacoub, Mona-Rita; Asperti, Chiara; Ramirez, Giuseppe A.; Della-Torre, Emanuel; Colombo, Sergio; Beretta, Luigi; Ciceri, Fabio; Zangrillo, Alberto; Dagna, Lorenzo] Univ Vita Salute San Raffaele, Milan, Italy; [Moro, Matteo; Zandalasini, Camilla; Di Napoli, Davide; Ambrosio, Alberto] IRCCS Osped San Raffaele, Med Affairs Dept, Milan, Italy; [Signorelli, Carlo] Univ Vita Salute San Raffaele, Sch Hyg & Publ Hlth, Milan, Italy; [Colombo, Sergio; Beretta, Luigi; Zangrillo, Alberto] IRCCS Osped San Raffaele, Anaesthesiol & Intens Care Unit, Milan, Italy; [Ciceri, Fabio] IRCCS Osped San Raffaele, Haematol & Bone Matt Ow Transplantat Unit, Milan, Italy		Yacoub, MR (通讯作者)，IRCCS Osped San Raffaele, Immunol Rheumatol Allergy & Rare Dis Unit, Via Olgettina 60, I-20132 Milan, Italy.; Yacoub, MR (通讯作者)，Univ Vita Salute San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.	yacoub.monarita@hsr.it	Yacoub, Mona Rita/AAP-6227-2020; Della Torre, Emanuel/AAB-5024-2022; Ramirez, Giuseppe Alvise/K-4923-2018; Signorelli, Carlo/AAC-7630-2022	Yacoub, Mona Rita/0000-0003-2417-0410; Ramirez, Giuseppe Alvise/0000-0002-2889-366X; ZANGRILLO, Alberto/0000-0002-7687-7648			Agenzia Italiana del Farmaco (Italian Medicine Agency), 2021, DOMANDE RISPOSTE VAC; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Caminati M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080853; Cardona V, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100472; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; European Centre for Disease Prevention and Control, 2021, COVID 19 VACC TRACK; European Medicines Agency, 2021, EUDR VIG EUR DAT SUS; Health UDo Services H, 2020, COMMON TERMINOLOGY C; Larson KF, 2021, CIRCULATION, V144, P506, DOI 10.1161/CIRCULATIONAHA.121.055913; Moghimi SM, 2021, MOL THER, V29, P898, DOI 10.1016/j.ymthe.2021.01.030; Nilsson L, 2017, PEDIAT ALLERG IMM-UK, V28, P628, DOI 10.1111/pai.12762; Nittner-Marszalska M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060553; Paoletti G, 2021, WORLD ALLERGY ORGAN, V14, DOI 10.1016/j.waojou.2021.100541; Rama TA, 2021, J ALLERGY CLIN IMMUN, V147, P877, DOI 10.1016/j.jaci.2021.01.004; Ramirez GA, ANN RHEUM DIS, V2021; Ramirez GA, 2021, CLIN IMMUNOL, V231, DOI 10.1016/j.clim.2021.108845; Rojas-Perez-Ezquerra P, 2021, J INVEST ALLERG CLIN, V31, P180, DOI 10.18176/jiaci.0683; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Stone CA, 2019, BRIT J CLIN PHARMACO, V85, P2694, DOI 10.1111/bcp.14112; Su JR, 2019, J ALLERGY CLIN IMMUN, V143, P1465, DOI 10.1016/j.jaci.2018.12.1003; Tan Chin Kimg, 2021, J Hepatol, V75, P1250, DOI 10.1016/j.jhep.2021.06.009; Turner PJ, 2021, VACCINE HESITANCY DR; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893; Vormehr M, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1758004; Wenande E, 2016, CLIN EXP ALLERGY, V46, P907, DOI 10.1111/cea.12760	26	2	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 22	2021	39	44					6464	6469		10.1016/j.vaccine.2021.09.048		OCT 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WX9RH	34598820				2022-04-29	WOS:000718925300004
J	Abayneh, T; Getachew, B; Gelaye, E; Traxler, R; Vieira, AR				Abayneh, T.; Getachew, B.; Gelaye, E.; Traxler, R.; Vieira, A. R.			Viability evaluation of freeze dried and suspension anthrax spore vaccine formulations stored at different temperatures	VACCINE			English	Article						Anthrax; Freeze dried vaccine; Viability evaluation		Anthrax is endemic in Ethiopia with sporadic outbreaks despite the regular vaccination of domestic livestock. This has raised concerns on the effectiveness of the vaccination strategy which may be associated with breaches in the vaccine cold chain maintenance. This study was aimed at demonstrating the tolerance of anthrax vaccine to cold chain breaches through evaluation of viable spore counts expressed as colony forming units per mL (CFU/mL) of freeze-dried and suspension anthrax vaccines stored at 5 degrees C, 20 degrees C and 37 degrees C for up to 6 months. Both vaccine formulations maintained above the recommended minimum required titre (2 x 10(6) culturable spores per dose for cattle, buffaloes and horses, and not <1 x 10(6) for sheep and goats) for up to 6 months at 5 degrees C storage. In storage at 20 degrees C, the viability of freeze-dried anthrax vaccine maintained the minimum required titre up to 6 months while up to 90 days in case of the suspension formulation. Both types of vaccine formulations maintained the minimum titre per dose for up to 30 days at 37 degrees C storage. Generally, both vaccine formulations showed similar trends in titre fall in all of the three storage temperatures (5 degrees C, 20 degrees C and 37 degrees C) as observed in the almost linearly overlapping 95% confidence intervals (CI) up to day 90 at 5 degrees C and 20 degrees C storages while up to day 30 at 37 degrees C storage. However, a significant (P < 0.05) drop in titre was observed after day 90 for storages at 5 degrees C and 20 degrees C, and after day 30 for 37 degrees C storage as observed in the non overlapping 95% CI from the average titres of previous time points. This study showed that if temperature excursion occurs above the recommended temperature range (4-8 degrees C) during storage or transport, the vaccine should remain effective and can still be used in vaccination programs. (C) 2021 The Authors. Published by Elsevier Ltd.	[Abayneh, T.; Getachew, B.; Gelaye, E.] Natl Vet Inst, POB 19, Bishoftu, Ethiopia; [Traxler, R.; Vieira, A. R.] Ctr Dis Control & Prevent, Atlanta, GA USA		Abayneh, T (通讯作者)，Natl Vet Inst, POB 19, Bishoftu, Ethiopia.	takeletefera99@gmail.com			American Society for Microbiology by the Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [6 NU2GGH001807-03-05 11]	This publication was supported by Cooperative Agreement 6 NU2GGH001807-03-05 11 awarded to the American Society for Microbiology by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Department of Health and Human Services.	Bahiru G, 2016, ETHIOPIAN VET J, V20, P75; Dutta T K, 2011, J Assoc Physicians India, V59, P573; Habing WH., VETERINARY; Jula G. M., 2007, Archives of Razi Institute, V62, P145; Miller J. H., 1972, EXPT MOL GENETICS, P31; Misra RP, 1991, 87 FAO, P3; MOA-MOH, 2015, ZOON DIS PRIOR INTER, P29; OIE Manual of standards for diagnostic tests and vaccines, 2004, ANTHRAX, V4th, P283; OIE Terrestrial Manual, 2018, ANTHRAX; Romha G, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05544-z; STERNE MAX, 1939, ONDERSTEPOORT JOUR VET SCI AND ANIMAL INDUST, V12, P9; STERNE MAX, 1939, ONDERSTEPOORT JOUR VET SCI AND ANIMAL INDUST, V13, P307; Sutton S., 2012, JGXP, V26, P74; USDA, 2015, STAND OP PROC BACT P; Verma A, 2018, VACCINE, V36, P6379, DOI 10.1016/j.vaccine.2018.09.012; WHO, 2006, GUID STAB EV VACC	16	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6245	6249		10.1016/j.vaccine.2021.09.023		SEP 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34538525	hybrid			2022-04-29	WOS:000705822100011
J	Benjamin-Chung, J; Arnold, BF; Mishra, K; Kennedy, CJ; Nguyen, A; Pokpongkiat, NN; Djajadi, S; Seth, A; Klein, NP; Hubbard, AE; Reingold, A; Colford, JM				Benjamin-Chung, Jade; Arnold, Benjamin F.; Mishra, Kunal; Kennedy, Chris J.; Nguyen, Anna; Pokpongkiat, Nolan N.; Djajadi, Stephanie; Seth, Anmol; Klein, Nicola P.; Hubbard, Alan E.; Reingold, Arthur; Colford Jr, John M.			City-wide school-located influenza vaccination: A retrospective cohort study	VACCINE			English	Article						Influenza; Influenza vaccination; School-located influenza vaccination	UNITED-STATES; VACCINES RECOMMENDATIONS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; SEASONAL INFLUENZA; NEGATIVE CONTROLS; AGE-CHILDREN; IMPACT; PREVENTION; ENGLAND	Background: We measured the effectiveness of a city-wide school-located influenza vaccination (SLIV) program implemented in over 102 elementary schools in Oakland, California. Methods: We conducted a retrospective cohort study among Kaiser Permanente Northern California (KPNC) members of all ages residing in either the intervention or a multivariate-matched comparison site from September 2011 -August 2017. Outcomes included medically attended acute respiratory illness (MAARI), influenza hospitalization, and Oseltamivir prescriptions. We estimated difference-in-differences (DIDs) in 2014-15, 2015-16, and 2016-17 using generalized linear models and adjusted for race, ethnicity, age, sex, health plan, and language. Results: Pre-intervention member characteristics were similar between sites. The proportion of KPNC members vaccinated for influenza by KPNC or the SLIV program was 8-11% higher in the intervention site than the comparison site during the intervention period. Among school-aged children, SLIV was associ-ated with lower Oseltamivir prescriptions per 1,000 (DIDs:-3.5 (95% CI-5.5,-1.5) in 2015-16;-4.0 (95% CI-6.5,-1.6) in 2016-17) but not with other outcomes. SLIV was associated with lower MAARI per 1,000 in adults 65 + years (2014-15:-13.2, 95% CI -23.2,-3.2; 2015-16:-21.5, 95% CI-31.1,-11.9; 2016-17:-13.0, 95% CI -23.2,-2.9). There were few significant associations with other outcomes among adults. Conclusions: A city-wide SLIV intervention was associated with higher influenza vaccination coverage, lower Oseltamivir prescriptions in school-aged children, and lower MAARI among people over 65 years, suggesting possible indirect effects of SLIV among older adults. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Benjamin-Chung, Jade] Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA; [Benjamin-Chung, Jade; Mishra, Kunal; Kennedy, Chris J.; Nguyen, Anna; Pokpongkiat, Nolan N.; Djajadi, Stephanie; Seth, Anmol; Hubbard, Alan E.; Reingold, Arthur; Colford Jr, John M.] Univ Calif Berkeley, Div Epidemiol & Biostat, Berkeley, CA 94720 USA; [Arnold, Benjamin F.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; [Arnold, Benjamin F.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA; [Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA		Benjamin-Chung, J (通讯作者)，Stanford Univ, 259 Campus Dr,HRP Redwood Bldg,T152A, Stanford, CA 94305 USA.	jadebc@stanford.edu		Nguyen, Anna/0000-0002-2211-9040; Kennedy, Chris/0000-0001-7444-2766; Pokpongkiat, Nolan/0000-0002-9901-671X; Mishra, Kunal/0000-0001-6672-7913; Arnold, Benjamin/0000-0001-6105-7295; Seth, Anmol/0000-0003-1170-8250	Flu Lab [20142281]	This work was supported by a grant from the Flu Lab (https://theflulab.org/) to the University of California, Berkeley (Grant number: 20142281; PI: AR).	Ainslie KEC, 2019, EXPERT REV VACCINES, V18, P615, DOI 10.1080/14760584.2019.1622419; Arnold BF, 2016, EPIDEMIOLOGY, V27, P637, DOI 10.1097/EDE.0000000000000504; Benjamin-Chung J, 2021, AM J PUBLIC HEALTH, V111, P1078, DOI 10.2105/AJPH.2021.306177; Benjamin-Chung J, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003238; Benjamin-Chung J, 2018, INT J EPIDEMIOL, V47, P332, DOI 10.1093/ije/dyx201; Centers for Disease Control, 2019, SEASONAL INFLUENZA V; Centers for Disease Control and Prevention, 2020, BURD INFL; Davis MM, 2008, PEDIATRICS, V122, pE260, DOI 10.1542/peds.2007-2963; Diamond A, 2013, REV ECON STAT, V95, P932, DOI 10.1162/REST_a_00318; Freedman DA, 2006, AM STAT, V60, P299, DOI 10.1198/000313006X152207; Gaglani MJ, 2014, CLIN INFECT DIS, V59, P333, DOI 10.1093/cid/ciu344; Glezen WP, 2010, J INFECT DIS, V202, P1626, DOI 10.1086/657089; Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1; Grohskopf LA, 2015, AM J TRANSPLANT, V15, P2767, DOI 10.1111/ajt.13505; Grohskopf LA, 2014, MMWR-MORBID MORTAL W, V63, P691; Hull HF, 2010, PROCEDIA VACCINOL, V2, P92, DOI 10.1016/j.provac.2010.03.017; Humiston SG, 2014, AM J PREV MED, V46, P1, DOI 10.1016/j.amepre.2013.08.021; Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]; King JC, 2006, NEW ENGL J MED, V355, P2523, DOI 10.1056/NEJMoa055414; Kjos SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072243; Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb; Longini IM, 2012, PEDIATRICS, V129, pS63, DOI 10.1542/peds.2011-0737D; McBean M, 2011, PROCEDIA VACCINOL, V4, DOI 10.1016/j.provac.2011.07.009; Pannaraj PS, 2014, CLIN INFECT DIS, V59, P325, DOI 10.1093/cid/ciu340; Pebody RG, 2015, EUROSURVEILLANCE, V20, P37, DOI 10.2807/1560-7917.ES.2015.20.39.30029; Pebody RG, 2014, EUROSURVEILLANCE, V19, P5, DOI 10.2807/1560-7917.ES2014.19.22.20823; Pebody RG, 2018, EUROSURVEILLANCE, V23, P35, DOI 10.2807/1560.7917.ES.2o18.23.25.1700496; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Petersen ML, 2012, STAT METHODS MED RES, V21, P31, DOI 10.1177/0962280210386207; Piedra PA, 2005, VACCINE, V23, P1540, DOI 10.1016/j.vaccine.2004.09.025; Piedra PA, 2007, PEDIATRICS, V120, pE553, DOI 10.1542/peds.2006-2836; Szilagyi PG, 2019, J SCHOOL HEALTH, V89, P1004, DOI 10.1111/josh.12840; Szilagyi PG, 2018, VACCINE, V36, P2861, DOI 10.1016/j.vaccine.2018.03.047; Szilagyi PG, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1746; Tran CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114479; Wing C, 2018, ANNU REV PUBL HEALTH, V39, P453, DOI 10.1146/annurev-publhealth-040617-013507; Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635	37	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6302	6307		10.1016/j.vaccine.2021.08.099		SEP 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WE7SY	34535312	Green Accepted, Green Submitted, hybrid			2022-04-29	WOS:000705822100020
J	Maltezou, HC; Effraimidou, E; Cassimos, DC; Medic, S; Topalidou, M; Konstantinidis, T; Theodoridou, M; Rodolakis, A				Maltezou, Helena C.; Effraimidou, Evgnosia; Cassimos, Dimitrios C.; Medic, Snezana; Topalidou, Maria; Konstantinidis, Theocharis; Theodoridou, Maria; Rodolakis, Alexandros			Vaccination programs for pregnant women in Europe, 2021	VACCINE			English	Article						Vaccination; Immunization; Program; Pregnant woman; Pregnancy; Europe	INFANTS; PERTUSSIS; INFLUENZA	Vaccination during pregnancy is increasingly adopted worldwide in order to protect the mother and her offspring. We studied the current vaccination programs specifically for pregnant women in 42 European countries. Vaccination programs for pregnant women are in place in 37 countries, as follows: influenza (36 countries), pertussis (28), hepatitis B (12), tetanus (10), pneumococcal disease (10), meningococcal disease (10), rabies (8), tick-borne encephalitis (6), hepatitis A (5), poliomyelitis (4), diphtheria (3), Haemophilus influenzae (2), and human papilloma virus (1). Recommendations for vaccination against influenza and pertussis concern almost exclusively pregnant women regardless of high-risk conditions, however differences between vaccination recommendations are noted in terms of timing. Vaccinations against hepatitis B, hepatitis A, pneumococcal disease, meningococcal disease, poliomyelitis, H. influenzae, rabies, and tick-born encephalitis mainly concern pregnant women at high-risk for exposure or serious illness and post-exposure vaccinations. Overall, five European countries have no vaccination recommendations specifically for pregnant women. In conclusion, there are significant differences in vaccination programs for pregnant women in Europe. Vaccination programs for pregnant women should expand in order to protect maternal and infant health. A consensus-based vaccination program is needed. (c) 2021 Elsevier Ltd. All rights reserved.	[Maltezou, Helena C.] Natl Publ Hlth Org, Directorate Res Studies & Documentat, 3-5 Agrafon St, Athens 15123, Greece; [Effraimidou, Evgnosia; Cassimos, Dimitrios C.] Democritus Univ Thrace, Pediat Dept, Alexandroupolis, Greece; [Medic, Snezana] Univ Novi Sad, Fac Med, Dept Epidemiol, Novi Sad, Serbia; [Medic, Snezana] Inst Publ Hlth Vojvodina, Ctr Dis Control & Prevent, Novi Sad, Serbia; [Topalidou, Maria] Komotini Gen Hosp, Pediat Clin, Komotini, Greece; [Konstantinidis, Theocharis] Univ Gen Hosp Alexandroupolis, Blood Transfuss Ctr, Alexandroupolis, Greece; [Theodoridou, Maria] Univ Athens, Dept Pediat 1, Athens, Greece; [Rodolakis, Alexandros] Univ Athens, Alexandra Gen Hosp, Dept Obstet & Gynecol 1, Athens, Greece		Maltezou, HC (通讯作者)，Natl Publ Hlth Org, Directorate Res Studies & Documentat, 3-5 Agrafon St, Athens 15123, Greece.	helen-maltezou@ath.forthnet.gr		Maltezou, Helena/0000-0003-0264-3547; Konstantinidis, Theocharis/0000-0003-4296-3414; N.Medic, Sneza/0000-0002-5778-9861			Cassimos DC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010034; Cho Geum Joon, 2013, Obstet Gynecol Sci, V56, P368, DOI 10.5468/ogs.2013.56.6.368; European Center for Disease Prevention and Control, 2021, VACC SCHED; European Commission, 2021, STAT PLAY IMPL COUNC; Goodnight William H, 2005, Crit Care Med, V33, pS390, DOI 10.1097/01.CCM.0000182483.24836.66; Kandeil W, 2020, EXPERT REV VACCINES, V19, P621, DOI 10.1080/14760584.2020.1791092; Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052; Kochhar S, 2019, VACCINE, V37, P3267, DOI 10.1016/j.vaccine.2019.04.075; Lindley MC, 2019, MMWR-MORBID MORTAL W, V68, P885, DOI 10.15585/mmwr.mm6840e1; Maertens K, 2014, VACCINE, V32, P1786, DOI 10.1016/j.vaccine.2014.01.083; Maltezou HC, 2021, HUM VACC IMMUNOTHER, V17, P2723, DOI 10.1080/21645515.2021.1889934; Maltezou HC, 2020, VACCINE, V38, P4625, DOI 10.1016/j.vaccine.2020.04.060; Maltezou HC, 2019, VACCINE, V37, P7576, DOI 10.1016/j.vaccine.2019.09.061; Oliveira D, 2020, J CLIN VIROL, V133, DOI 10.1016/j.jcv.2020.104680; Omer SB, 2018, PEDIATR INFECT DIS J, V37, P436, DOI [10.1097/INF.0000000000001914, 10.1097/inf.0000000000001914]; Regan AK, 2021, EXPERT REV VACCINES, V20, P649, DOI 10.1080/14760584.2021.1915138; WHO, 2020, VACC PREV DIS MON SY; Wiley KE, 2013, VACCINE, V31, P618, DOI 10.1016/j.vaccine.2012.11.052; World Health Organization, 2021, VACC US; World Health Organization, 2018, WKLY EPIDEMIOL REC, DOI DOI 10.1371/jour	20	3	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6137	6143		10.1016/j.vaccine.2021.08.074		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34462162				2022-04-29	WOS:000701799200018
J	Pallikkuth, S; Williams, E; Pahwa, R; Hoffer, M; Pahwa, S				Pallikkuth, Suresh; Williams, Erin; Pahwa, Rajendra; Hoffer, Michael; Pahwa, Savita			Association of Flu specific and SARS-CoV-2 specific CD4 T cell responses in SARS-CoV-2 infected asymptomatic heath care workers	VACCINE			English	Article						Flu and COVID; COVID19; SARS-CoV-2 and Influenza; COVID and T cell immunity; COVID and immune response; SARS-CoV-2 antigen specific immunity	BCG VACCINATION; VIRUS	Influenza vaccination is widely advocated to avoid infection with influenza virus, a serious respiratory pathogen, and this was greatly emphasized during the raging COVID-19 epidemic. We conducted a study for baseline Flu specific immunity in a group of health care workers with documented past SARs-CoV-2 infection (designated COVID+) with mild or no symptoms and compared them with a control group that had not been infected with SARS CoV-2 (COVID-). Concurrently, we examined flu and SARS-CoV-2 specific T cell responses using the AIM (activation induced molecules) assay by flow cytometry. All COVID+ and 40% COVID-participants exhibited AIM responses to SARS-CoV-2 peptides, but only COVID+ were positive for SARs-CoV-2 antibody. Influenza HIN1 antigen specific CD4 T cells were found in 92% COVID+ and 76% COVID-participants and exhibited a strong direct correlation with SARS-CoV-2 specific CD4 T cells. This observation suggests that influenza specific T cell immunity may impact immune responses to SARS-CoV-2. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Pallikkuth, Suresh; Pahwa, Rajendra; Pahwa, Savita] Univ Miami, Dept Microbiol & Immunol, Miller Sch Med, Miami, FL 33136 USA; [Williams, Erin; Hoffer, Michael] Univ Miami, Dept Otolaryngol, Miller Sch Med, Miami, FL 33136 USA		Pahwa, S (通讯作者)，Univ Miami, Microbiol & Immunol Pediat & Med, Miller Sch Med, 1580 NW 10th Ave,BCRI 712, Miami, FL 33136 USA.	spahwa@med.miami.edu		Hoffer, Michael/0000-0002-5574-4387	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI108472, AG068110, P30AI073961]	This work was supported by National Institutes of Health Grant: R01AI108472 (to S.P.) and AG068110 (to SP and S Pallikkuth) and P30AI073961 (to S.P) .	Anbarasu A, 2020, HUM VACC IMMUNOTHER, V16, P2217, DOI 10.1080/21645515.2020.1773141; Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Ashford JW, 2021, AM J MED, V134, P153, DOI 10.1016/j.amjmed.2020.10.003; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4; da Silva Antunes R, J INFECT DIS, V2021; Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117; George VK, 2015, J INFECT DIS, V211, P1959, DOI 10.1093/infdis/jiu840; Gold JE, 2020, MBIO, P11; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; L'Huillier AG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67172-6; Lipsitch M, 2020, NAT REV IMMUNOL, V20, P709, DOI 10.1038/s41577-020-00460-4; Madan M, 2020, PUBLIC HEALTH, V185, P91, DOI 10.1016/j.puhe.2020.05.042; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Pallikkuth S, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000257; Sette A, 2020, NAT REV IMMUNOL, V20, P457, DOI 10.1038/s41577-020-0389-z; Shuwa HA, 2021, MED-CAMBRIDGE, V2, P720, DOI 10.1016/j.medj.2021.03.013; Tapia-Calle G, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040181; Urashima M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155589; Walk J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08659-3; Zeng QH, 2008, P NATL ACAD SCI USA, V105, P9065, DOI 10.1073/pnas.0800502105; Zheng J, 2018, CURR OPIN VIROL, V28, P43, DOI 10.1016/j.coviro.2017.11.002	25	3	3	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6019	6024		10.1016/j.vaccine.2021.08.092		SEP 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34531078	Green Published, hybrid			2022-04-29	WOS:000701799200003
J	Golden, AR; Adam, HJ; Baxter, M; Martin, I; Demczuk, W; Mulvey, MR; Karlowsky, JA; Zhanel, GG				Golden, Alyssa R.; Adam, Heather J.; Baxter, Melanie; Martin, Irene; Demczuk, Walter; Mulvey, Michael R.; Karlowsky, James A.; Zhanel, George G.		Canadian Antimicrobial Resistance	Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007-2018	VACCINE			English	Article						Streptococcus pneumoniae; Canada; Invasive; Noninvasive; Antimicrobial resistance; PCV-13	PNEUMOCOCCAL CONJUGATE VACCINE; ANTIMICROBIAL RESISTANCE; EPIDEMIOLOGY	The population of pneumococci circulating in Canada is constantly shifting under the pressures of antimicrobial and conjugate vaccine use. A new 15-valent pneumococcal conjugate vaccine (PCV), containing PCV-13 serotypes plus additional serotypes 22F and 33F, is currently undergoing clinical trials. The purpose of this study was to utilize whole genome sequencing to characterize invasive and respiratory Streptococcus pneumoniae isolates collected from Canadian hospitals pre-(2007-2011) and post-PCV13 implementation (2012-2018) in Canada, particularly serotypes 22F and 33F. Isolates were obtained from the CANWARD 2007 to 2018 study. Overall, 597 S. pneumoniae isolates were sequenced using the Illumina MiSeq platform: 180 (101 respiratory, 79 blood) isolates of serotype 22F, 74 (41 respiratory, 33 blood) isolates of serotype 33F and 343 isolates randomly selected to broadly encompass pneumococci in Canada. Genomes were clustered using PopPUNK v2.0.2 and assigned to a Global Pneumococcal Sequencing Cluster (GPSC) and MLST sequence type (ST), and visualized using Cytoscape v3.8.0. Acquired resistance genes were identified using ResFinder 2.1, and genes with chromosomal mutations conferring resistance were extracted and compared to standard reference genome R6. PopPUNK clustering suggests that a clone of S. pneumoniae serotype 22F/ST433/GPSC19 demonstrating mefA-mediated macrolide resistance is emerging in Canada post-PCV-13 introduction, collected from both invasive and respiratory sources. Similarly, there is evidence to support a post-PCV-13 shift towards macrolideand trimethoprim/sulfamethoxazole-resistant serotype 33F/ST100/GPSC3, including a cluster associated with invasive isolates. While some lineages containing vaccine serotypes were predominantly identified pre-PCV-13 implementation (serotype 5/GPSC8, serotype 7F/GPSC15), others (serotype 19A/GPSC1 and 4, serotype 3/GPSC12) continue to maintain a significant presence over time despite inclusion in PCV-13. Further genomic surveillance is necessary to determine additional trends over time in these upcoming vaccine serotypes, as well as the overall pneumococcal population in Canada. (c) 2021 Elsevier Ltd. All rights reserved.	[Golden, Alyssa R.; Adam, Heather J.; Baxter, Melanie; Mulvey, Michael R.; Karlowsky, James A.; Zhanel, George G.] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Med Microbiol & Infect Dis, Room 543-745 Bannatyne Ave, Winnipeg, MB R3E 0J9, Canada; [Adam, Heather J.; Karlowsky, James A.] Diagnost Serv Shared Hlth Manitoba, Dept Clin Microbiol, Hlth Sci Ctr, MS673-820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada; [Martin, Irene; Demczuk, Walter; Mulvey, Michael R.] Publ Hlth Agcy Canada, Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada		Golden, AR (通讯作者)，Univ Manitoba, Dept Med Microbiol, MS673-820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	alyssa.golden@umanitoba.ca	Demczuk, Walter/K-5994-2016	Demczuk, Walter/0000-0003-3723-9843	University of Manitoba; Diagnostic Services - Shared Health Manitoba; National Microbiology Laboratory; MerckMerck & Company	This study was supported in part by the University of Manitoba, Diagnostic Services - Shared Health Manitoba, the National Microbiology Laboratory and by a research grant from the Investigator Initiated Studies Program of Merck. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck or its affiliates or related companies.	Adam HJ, 2018, J ANTIMICROB CHEMOTH, V73, P12, DOI 10.1093/jac/dky158; AUSTRIAN R, 1976, MT SINAI J MED, V43, P699; Azarian T, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007438; Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021; Bettinger JA, 2010, VACCINE, V28, P2130, DOI 10.1016/j.vaccine.2009.12.026; Brandileone MCC, 2021, VACCINE, V39, P3207, DOI 10.1016/j.vaccine.2021.02.063; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Clinical and Laboratory Standards Institute, 2018, M07 CLSI, V11th; CLSI, PERFORMANCE STANDARD, V31st; Cock PJA, 2013, PEERJ, V1, DOI 10.7717/peerj.167; Demczuk WHB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178040; Demczuk WHB, 2013, CAN J MICROBIOL, V59, P778, DOI 10.1139/cjm-2013-0614; Ermlich SJ, 2018, VACCINE, V36, P6875, DOI 10.1016/j.vaccine.2018.03.012; Gladstone RA, 2019, EBIOMEDICINE, V43, P338, DOI 10.1016/j.ebiom.2019.04.021; Golden AR, 2021, DIAGN MICR INFEC DIS, V101, DOI 10.1016/j.diagmicrobio.2021.115447; Golden AR, 2019, J ANTIMICROB CHEMOTH, V74, P39, DOI 10.1093/jac/dkz286; Golden AR, 2018, J ANTIMICROB CHEMOTH, V73, P20, DOI 10.1093/jac/dky157; Golden AR, 2016, VACCINE, V34, P2527, DOI 10.1016/j.vaccine.2016.03.058; Greenberg D, 2018, VACCINE, V36, P6883, DOI 10.1016/j.vaccine.2018.02.113; Hurley D, 2020, CLIN INFECT DIS, DOI DOI 10.1093/CID/CIAA1045; Kawaguchiya M, 2020, J INFECT PUBLIC HEAL, V13, P1094, DOI 10.1016/j.jiph.2020.04.012; Lees JA, 2019, GENOME RES, V29, P304, DOI 10.1101/gr.241455.118; Lo SW, 2019, LANCET INFECT DIS, V19, P759, DOI 10.1016/S1473-3099(19)30297-X; McGee L, 2001, J CLIN MICROBIOL, V39, P2565, DOI 10.1128/JCM.39.7.2565-2571.2001; Metcalf BJ, 2016, CLIN MICROBIOL INFEC, V22, DOI [10.1016/j.cmi.2016.08.001, 10.1016/j.cmi.2015.08.027]; National Advisory Committee on Immunization (NACI), 2018, UPD US PNEUM VACC AD; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Public Health Agency of Canada (PHAC), 2019, NAT LAB SURV INV STR; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sheppard CL, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090687; Siira L, 2020, VACCINE, V38, P5454, DOI 10.1016/j.vaccine.2020.06.040; Suaya JA, 2020, J INFECTION, V81, P557, DOI 10.1016/j.jinf.2020.07.035; Wood DE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r46; Zankari E, 2012, J ANTIMICROB CHEMOTH, V67, P2640, DOI 10.1093/jac/dks261; Zhanel GG, 2019, J ANTIMICROB CHEMOTH, V74, P5, DOI 10.1093/jac/dkz283	35	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5474	5483		10.1016/j.vaccine.2021.08.061		SEP 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34454785				2022-04-29	WOS:000704399700004
J	Kanji, JN; Bailey, A; Fenton, J; Ling, SH; Rivera, R; Plitt, S; Sligl, WI; Taylor, S; Turnbull, L; Tipples, G; Charlton, CL				Kanji, Jamil N.; Bailey, Ashley; Fenton, Jayne; Ling, Sean H.; Rivera, Rafael; Plitt, Sabrina; Sligl, Wendy, I; Taylor, Sean; Turnbull, LeeAnn; Tipples, Graham; Charlton, Carmen L.			Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests	VACCINE			English	Article						mRNA-1273; BNTb162b2; mRNA vaccine; SARS-CoV-2; titer; neutralizing antibodies; commercial assays; clinical laboratories	INFECTION	Background: With rapid approval of SARS-CoV-2 vaccines, the ability of clinical laboratories to detect vaccine-induced antibodies with available high-throughput commercial assays is unknown. We aimed to determine if commercial serology assays can detect vaccine-induced antibodies (VIAs) and understand the vaccination response. Methods: This cohort study recruited healthcare workers and residents of long-term care facilities (re-ceiving the BNT162b2 and mRNA-1273 products, respectively) who underwent serum collection pre -vaccination (BNT162b2 group), 2-weeks post vaccination (both groups), and pre-2nd dose (both groups). Sera were tested for the presence of SARS-CoV-2 IgG using four commercial assays (Abbott SARS-CoV-2 IgG, Abbott SARS-CoV-2 IgG II Quant, DiaSorin Trimeric S IgG, and GenScript cPASS) to detect VIAs. Secondary outcomes included description of post-vaccination antibody response and correlation with neutralizing titers. Results: 225 participants (177 receiving BNT162b2 and 48 receiving mRNA-1273) were included (median age 41 years; 66-78% female). Nucleocapsid IgG was found in 4.1% and 21.9% of the BNT162b2 (baseline) and mRNA-1273 (2-weeks post first dose). All anti-spike assays detected antibodies post-vaccination, with an average increase of 87.2% (range 73.8-94.3%; BNT162b2), and 25.2% (range 23.8-26.7%; mRNA-1273) between the first and last sampling time points (all p < 0.05). Neutralizing antibodies were detected at all post-vaccine timepoints for both vaccine arms, with increasing titers over time (all p < 0.05). Conclusions: Anti-spike vaccine-induced SARS-CoV-2 IgG are detectable by commercially available high-throughput assays and increases over time. Prior to second dose of vaccination, neutralizing antibodies are detectable in 73-89% of individuals, suggesting most individuals would have some degree of protec-tion from subsequent infection. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Kanji, Jamil N.; Sligl, Wendy, I] Univ Alberta, Dept Med, Div Infect Dis, 8440 112 St NW, Edmonton, AB T6G 2B7, Canada; [Kanji, Jamil N.; Bailey, Ashley; Fenton, Jayne; Ling, Sean H.; Turnbull, LeeAnn; Tipples, Graham; Charlton, Carmen L.] Univ Alberta Hosp, Publ Hlth Lab, Alberta Precis Labs, 8440 112 St NW, Edmonton, AB T6G 2B7, Canada; [Kanji, Jamil N.; Charlton, Carmen L.] Univ Alberta Hosp, Fac Med & Dent, Dept Lab Med & Pathol, 8440 112 St NW, Edmonton, AB T6G 2B7, Canada; [Rivera, Rafael; Plitt, Sabrina] Univ Alberta, Sch Publ Hlth, 3-003 Edmonton Clin Hlth Acad,11405-87 Ave NW, Edmonton, AB T6G 1C9, Canada; [Plitt, Sabrina] Publ Hlth Agcy Canada, Ctr Communicable Dis & Infect Control, Ottawa, ON K1A 0K9, Canada; [Sligl, Wendy, I] Univ Alberta, Dept Crit Care Med, 8440-112 St NW, Edmonton, AB T6G 2B7, Canada; [Taylor, Sean] GenScript USA Inc, 860 Centennial Ave, Piscataway, NJ 08854 USA; [Tipples, Graham; Charlton, Carmen L.] Univ Alberta, Ctr Pharm & Hlth Res, Li Ka Shing Inst Virol, 6-010 Katz Grp, Edmonton, AB T6G 2E1, Canada; [Tipples, Graham] Univ Alberta, Fac Med & Dent, Dept Med Microbiol & Immunol, 8440-112 St NW, Edmonton, AB T6G 2B7, Canada; [Kanji, Jamil N.] Foothills Med Ctr, Alberta Precis Lab, Publ Hlth Lab, 3030 Hosp Dr NW, Calgary, AB T2N 4W4, Canada; [Kanji, Jamil N.] Univ Calgary, Div Infect Dis, Dept Med, 3030 Hosp Dr NW, Calgary, AB T2N 4W4, Canada; [Kanji, Jamil N.] Univ Calgary, Dept Pathol & Lab Med, Cumming Sch Med, 3030 Hosp Dr NW, Calgary, AB T2N 4W4, Canada		Kanji, JN (通讯作者)，Foothills Med Ctr, Alberta Precis Lab, Publ Hlth Lab, 3030 Hosp Dr NW, Calgary, AB T2N 4W4, Canada.	jamil.kanji@ahs.ca		Rivera, Rafael/0000-0003-0718-2882; Taylor, Sean/0000-0003-3411-0673; Kanji, Jamil/0000-0002-1043-6807; Ling, Sean/0000-0002-5768-500X			Abbott, SARS COV 2 IMM; Addetia A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02107-20; Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; Andrew MK, 2020, LANCET, V396, P1942, DOI 10.1016/S0140-6736(20)32481-8; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; British Broadcasting Corporation (BBC), COV FRANC SAYS JUST; Bruni M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103188; Centers for Disease Control and Prevention, VACC REC GUID ADV CO; Centers for Disease Control and Prevention, CHICK VAR INT LAB TE; DiaSorin, LIAIS R SARS COV 2 T; Garcia-Beltran WF, 2021, CELL, V184, P476, DOI 10.1016/j.cell.2020.12.015; GenScript, SARS COV 2 SURR VIR; Government of Alberta, COVID 19 VACC DISTR; Government of Canada, NATL ADVISORY COMMIT; Greub G, 2001, MED MICROBIOL IMMUN, V189, P165, DOI 10.1007/s430-001-8024-0; Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011; Mai HK, 2021, EMERG INFECT DIS, V27, P663, DOI 10.3201/eid2702.204226; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kempster SL, 2020, LANCET INFECT DIS, V20, pE17, DOI 10.1016/S1473-3099(19)30274-9; Krammer F., 2021, ROBUST SPIKE ANTIBOD, DOI [10.1101/2021.01.29.21250653, DOI 10.1101/2021.01.29.21250653]; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Montecino-Rodriguez E, 2013, J CLIN INVEST, V123, P958, DOI 10.1172/JCI64096; Muecksch F, 2021, J INFECT DIS, V223, P389, DOI 10.1093/infdis/jiaa659; Perera RAPM, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02504-20; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Roche, ROCH PARTN MOD INCL; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Rostami A, 2021, CLIN MICROBIOL INFEC, V27, P331, DOI 10.1016/j.cmi.2020.10.020; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Soundararajan, 2021, FDA AUTHORIZED COVID, DOI [10.1101/2021.02.15.21251623, DOI 10.1101/2021.02.15.21251623]; Spradling PR, 2013, CLIN VACCINE IMMUNOL, V20, P559, DOI 10.1128/CVI.00694-12; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Taylor SC, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02438-20; Van Caeseele P, 2020, CAN MED ASSOC J, V192, pE973, DOI 10.1503/cmaj.201588; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284	45	3	3	3	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5563	5570		10.1016/j.vaccine.2021.08.022		SEP 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34454782	Green Submitted, hybrid, Green Published			2022-04-29	WOS:000704399700016
J	Burke, PF; Masters, D; Massey, G				Burke, Paul F.; Masters, Daniel; Massey, Graham			Enablers and barriers to COVID-19 vaccine uptake: An international study of perceptions and intentions	VACCINE			English	Article						COVID-19; Vaccination hesitancy; Health beliefs model; Conspiracy beliefs; Immunization; Structural equation model	HEALTH BELIEF MODEL; HESITANCY; DETERMINANTS; PREFERENCES; BEHAVIOR	The development of COVID-19 vaccines is occurring at unprecedented speeds, but require high coverage rates to be successful. This research examines individuals' psychological beliefs that may act as enablers and barriers to vaccination intentions. Using the health beliefs model as a guide to our conceptual framework, we explore factors influencing vaccine hesitancy and health beliefs regarding risks and severity of the disease, along with individual variables such as income, age, religion, altruism, and collectivism. A questionnaire using newly created measures for various antecedents provided 4303 usable responses from Australia, Canada, England, New Zealand, and the United States. A factor analytic and structural equation model indicates that trust in vaccine approval, the perceived effectiveness of the vaccine for protecting others, and conspiracy beliefs are the most significant drivers of intentions to vaccinate. Older people, those seeking employment, and those who have received a recent influenza vaccine are more likely to be vaccinated against COVID-19. The findings have implications for improving communication strategies targeting individuals about the merits of vaccination, particularly focusing on younger individuals and expanded message framing to include altruistic considerations, and to improve government transparency regarding the effectiveness and side effects of vaccines. CO 2021 Published by Elsevier Ltd.	[Burke, Paul F.; Massey, Graham] Univ Technol Sydney, Fac Business, Sydney, NSW, Australia; [Masters, Daniel] Univ Technol Sydney, Ctr Business Intelligence & Data Analyt BIDA, Sydney, NSW, Australia; [Masters, Daniel; Massey, Graham] Univ Technol Sydney, UTS Business, POB 123, Broadway, NSW 2007, Australia		Burke, PF (通讯作者)，Univ Technol Sydney, UTS Business, POB 123, Broadway, NSW 2007, Australia.	paul.burke@uts.edu.au; Daniel.Masters@student.edu.au; graham.massey@uts.edu.au	Burke, Paul/I-3106-2013	Burke, Paul/0000-0003-0978-0237			Adams A, 2014, NEPHROL NURS J, V41, P393; Alexandrova R, 2021, BIOTECHNOL BIOTEC EQ, V35, P74, DOI 10.1080/13102818.2020.1847683; Barton BL, 2020, HEALTH PROMOT INT; Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004; Bertin P, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.565128; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Burke PF, 2013, J PROD INNOVAT MANAG, V30, P1227, DOI 10.1111/jpim.12056; Coe Antoinette B, 2012, Innov Pharm, V3, P1; Corace K, 2013, AM J INFECT CONTROL, V41, P679, DOI 10.1016/j.ajic.2013.01.014; Downs JS, 2008, VACCINE, V26, P1595, DOI 10.1016/j.vaccine.2008.01.011; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Dubova A, 2015, VACCINE, V33, P2530, DOI 10.1016/j.vaccine.2015.03.048; Fishbein M., 1975, BELIEF ATTITUDE INTE; FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Gellin BG, 2000, PEDIATRICS, V106, P1097, DOI 10.1542/peds.106.5.1097; Gerend MA, 2012, ANN BEHAV MED, V44, P171, DOI 10.1007/s12160-012-9366-5; Glanz JM, 2011, VACCINE, V29, P994, DOI 10.1016/j.vaccine.2010.11.085; GODIN G, 1992, BRIT J ADDICT, V87, P1335; Grabenstein JD, 2013, VACCINE, V31, P2011, DOI 10.1016/j.vaccine.2013.02.026; Guo N, 2017, VACCINE, V35, P2848, DOI 10.1016/j.vaccine.2017.04.006; HERSHEY JC, 1994, ORGAN BEHAV HUM DEC, V59, P177, DOI 10.1006/obhd.1994.1055; Hochbaum G. M., 1958, PUBLIC PARTICIPATION; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Irwin Mitchell, 2021, LEXOLOGY; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Jolley D, EFFECTS ANTIVACCINE; Kochhar S, 2020, VACCINE, V38, P6194, DOI 10.1016/j.vaccine.2020.07.013; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Liao QY, 2020, VACCINE, V38, P4557, DOI 10.1016/j.vaccine.2020.05.012; Paulussen TGW, 2006, VACCINE, V24, P644, DOI 10.1016/j.vaccine.2005.08.053; Philip RK, 2016, PEDIATR INFECT DIS J, V35, P1343, DOI 10.1097/INF.0000000000001321; Poland GA, 2011, NEW ENGL J MED, V364, P97, DOI 10.1056/NEJMp1010594; Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009; Santos AJ, 2017, EPIDEMIOL INFECT, V145, P1786, DOI 10.1017/S0950268817000814; SCHLEGEL RP, 1992, J APPL SOC PSYCHOL, V22, P358, DOI 10.1111/j.1559-1816.1992.tb01545.x; Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043; Shapiro GK, 2016, PAPILLOMAVIRUS RES, V2, P167, DOI 10.1016/j.pvr.2016.09.001; Siegrist M, 2003, RISK ANAL, V23, P705, DOI 10.1111/1539-6924.00349; Smith PJ, 2010, PUBLIC HEALTH REP, V125, P534, DOI 10.1177/003335491012500408; SPENCE M, 1974, J ECON THEORY, V7, P296, DOI 10.1016/0022-0531(74)90098-2; Sun XD, 2020, VACCINE, V38, P1520, DOI 10.1016/j.vaccine.2019.11.062; Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065; van der Weerd W, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-575; Verelst F, 2019, VACCINE, V37, P2079, DOI 10.1016/j.vaccine.2019.02.056; Vetter P, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1470; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, 2014, REP SAG WORK GROUP V; Wu AMS, 2020, J INFECT PUBLIC HEAL, V13, P970, DOI 10.1016/j.jiph.2020.04.009	50	15	15	16	22	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5116	5128		10.1016/j.vaccine.2021.07.056		AUG 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UA0TP	34340856	Bronze, Green Published			2022-04-29	WOS:000684878300008
J	Sun, J; Zheng, ZH; Li, M; Liu, ZH; Su, X; Jin, X				Sun, Jin; Zheng, Zhihang; Li, Min; Liu, Zhihua; Su, Xiao; Jin, Xia			Development of a novel ZIKV vaccine comprised of immunodominant CD4+and CD8+T cell epitopes identified through comprehensive epitope mapping in Zika virus infected mice	VACCINE			English	Article						Zika virus; CD4+T cell; CD8+T cell; Epitopes; Vaccine	CD8(+) T-CELL; DENGUE VIRUS; ENHANCEMENT; PROTECTION; CONTRIBUTE	Zika virus (ZIKV) caused over two million human infections in more than 80 countries around 2015- 2016. Current vaccines under development are mostly focused on inducing antibodies that despite cap-able of inhibiting the virus, may have the potential to trigger antibody dependent enhancement (ADE). T cell vaccines that do not induce antibodies targeting viral surface will unlikely cause ADE, but be capable of potentiating the effectiveness of an antibody-inducing vaccine. To develop such a protective T cell vac-cine, we first examined the repertoire of antigen-specific T cells in immunocompetent mice that have been transiently infected by ZIKV. Through epitope mapping using 427 overlapping peptides spanning the entire length of ZIKV polyprotein, we discovered 27 immunodominant epitopes scattered throughout the virus on C, E, NS1-NS5 proteins. Among them, 8 were confirmed as CD4+ T cell epitopes, and 16 as CD8+ T cell epitopes, while 3 for both T cell subsets. From these 27 newly identified epitopes, the top 10 epitopes were selected to formulate three T cell vaccines comprised of either CD4+ T cell epitopes, or CD8+ T cell epitopes, or a mixture of both. Immunization with these T cell epitopes induced T cell-mediated cytotoxicity and cytokine production, and conferred varying degrees of protection against ZIKV challenge. Moreover, these new T cell vaccines also improved the protective efficacy of a neutraliz-ing antibody-inducing recombinant E80 protein vaccine. Together, our results provided additional evi-dence in support of the protective role of ZIKV-specific CD4+ and CD8+ T cells, and laid foundation for future development of T cell vaccines for ZIKV. (c) 2021 Elsevier Ltd. All rights reserved.	[Sun, Jin] Univ Chinese Acad Sci, Chinese Acad Sci, Inst Pasteur Shanghai, CAS Key Lab Mol Virol & Immunol,Ctr Microbes Dev, Shanghai 200031, Peoples R China; [Zheng, Zhihang; Li, Min; Liu, Zhihua; Jin, Xia] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 201058, Peoples R China; [Su, Xiao] Univ Chinese Acad Sci, Chinese Acad Sci, Inst Pasteur Shanghai, CAS Key Lab Mol Virol & Immunol, Shanghai 200031, Peoples R China		Jin, X (通讯作者)，Fudan Univ, Vaccine & Immunol Res Ctr, Shanghai, Peoples R China.; Jin, X (通讯作者)，Fudan Univ, Translat Med Res Inst Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China.	jinxia@shphc.org.cn			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31870916, 31670941]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [19ZR1462900]	This work was supported in part by the National Science Foundation of China (grant No. 31870916 and No. 31670941) to XJ; and Science and Technology Commission of Shanghai Municipality (grant No. 19ZR1462900) to JS.	Anthony DD, 2003, METHODS, V29, P260, DOI 10.1016/S1046-2023(02)00348-1; Bailey MJ, 2019, MBIO, V10, DOI [10.1128/mBio.02861-18, 10.1128/mbio.02861-18]; Brien JD, 2008, J IMMUNOL, V181, P8568, DOI 10.4049/jimmunol.181.12.8568; Bullard BL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35755-z; Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515; Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058; Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181; DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4; Gagnon SJ, 1996, J VIROL, V70, P141, DOI 10.1128/JVI.70.1.141-147.1996; Gambino F, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109107; Grifoni A, 2018, J IMMUNOL, V201, P3487, DOI 10.4049/jimmunol.1801090; Grubor-Bauk B, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2388; Hassan AO, 2019, CELL REP, V28, P2634, DOI 10.1016/j.celrep.2019.08.005; Hassert M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01678; Hessert M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007237; Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]; IHR Emergency Committee, 2016, WHO STAT 2 M IHR EM WHO STAT 2 M IHR EM; Jurado KA, 2018, NAT MICROBIOL, V3, P141, DOI 10.1038/s41564-017-0060-z; Koblischke M., 2018, FRONT IMMUNOL, V9, DOI [10.3389/ fimmu.2018.0119610.3389/ fimmu.2018.01196.s001, DOI 10.3389/FIMMU.2018.0119610.3389/FIMMU.2018.01196.S001]; KURANE I, 1989, J EXP MED, V170, P763, DOI 10.1084/jem.170.3.763; Li M, 2017, SCI CHINA LIFE SCI, V60, P1396, DOI 10.1007/s11427-017-9192-0; Liang HB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11754-0; Liang HB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194860; Lim MQ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02225; Lindenbarch B.D., 2007, FIELDS VIROLOGY, V5th, P1101; Lucas CGO, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05519-4; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Musso D, 2018, LANCET INFECT DIS, V18, pE172, DOI 10.1016/S1473-3099(17)30446-2; Nazerai L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01977; Ngono AE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb2154; Ngono AE, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007474; Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010; Regla-Nava JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05458-0; Reynolds CJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18781-1; Richner JM, 2017, CELL, V169, P176, DOI 10.1016/j.cell.2017.03.016; Rodenhuis-Zybert IA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000718; Slon-Campos JL, 2019, NAT IMMUNOL, V20, P1291, DOI 10.1038/s41590-019-0477-z; Tian Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00531; Weaver Scott C, 2016, Antiviral Res, V130, P69, DOI 10.1016/j.antiviral.2016.03.010; Wen JS, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107566; Wen J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01669-z; Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36; Wirawan M, 2019, STRUCTURE, V27, P253, DOI 10.1016/j.str.2018.10.009; Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709; Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974; Zhan Y, 2019, VACCINE, V37, P2122, DOI 10.1016/j.vaccine.2019.02.063	46	0	0	8	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5173	5186		10.1016/j.vaccine.2021.07.036		AUG 2021	14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34353682				2022-04-29	WOS:000684878300014
J	Guktur, RE; Nep, EI; Asala, O; Olorunfemi, PO; Ngwuluka, NC; Ochekpe, NA; Sagay, AS				Guktur, R. E.; Nep, E., I; Asala, O.; Olorunfemi, P. O.; Ngwuluka, N. C.; Ochekpe, N. A.; Sagay, A. S.			Carboxymethylated and acetylated xerogel derivatives of Plectranthus esculentus starch protect Newcastle disease vaccines against cold chain failure	VACCINE			English	Article						Acetylation; xerogel; Antibody; Carboxymethylation; Freeze-dried; Stabilizer; Starch; Vaccine; Newcastle disease; Cold chain failure	FORMULATION; CHALLENGES; STABILIZER; IGG	Developing vaccine stabilizers from local natural sources is desirable especially if the stabilizer would enhance the ability of the antigen to withstand frequent failures in cold chains. The study was undertaken to formulate immunogenic live Newcastle Disease (ND) LaSota vaccines stabilized with modified native starches for use at cold and ambient temperatures and to assess the immunogenicity of the starch stabilized vaccines in vaccinated chickens. Native starch extracted from the tubers of Plectranthus esculentus (Family, Lamiaceae) was modified by carboxymethylation and acetylation/xerogel formation and used as vaccine stabilizers of ND LaSota virus with/without buffers/bulking excipients. Cold Chain Failure (CCF) was simulated by storing the vaccines at 5 +/- 2 degrees C for one month then at 37 +/- 1 degrees C for 96 h. The stability of the samples were evaluated in comparison with peptone stabilized ND vaccines using pH, residual moisture, XRD, reconstitution time, mean embryo infective dose (EID50) and haemagglutination (HA) tests. Haemagglutination inhibition was used to evaluate the efficacy of the vaccines in conferring positive serum antibody titers (>= 2(3) log(2)) in vaccine-naive 2-week old broilers that were orally administered a single dose of the vaccines kept at 37 +/- 1 degrees C for 96 h and bled weekly over four weeks. Temperature, pH, moisture content and amorphousness impacted vaccine stability. Peptone stabilized vaccines were significantly less stable and most affected by temperature changes with 1.2log(10)EID50 loss while buffered/bulked trehalose, carboxymethylated and acetylated/xerogelized starch stabilized vaccines were most stable (0.2-0.5log(10)EID(50) loss in titer) after 96 h in CCF. Buffered trehalose stabilized vaccine (TVB) had lower HA titres than peptone and starch stabilized vaccines containing D-mannitol and Na2HPO4. Antibody titres of vaccinated broilers were between 3.3 +/- 1.398 and 8.35 +/- 2.678. All the vaccines were immunogenic (HI >= 2(3)) and developed HI titres (>= 2(4)) considered to be protective. Carboxymethylated and acetylated/xerogel derivatives of P. esculentus starch have a great potential as vaccine stabilizers especially in areas prone to CCF. (C) 2021 The Authors. Published by Elsevier Ltd.	[Guktur, R. E.; Olorunfemi, P. O.] Univ Jos, Fac Pharmaceut Sci, Dept Pharmaceut Microbiol & Biotechnol, PMB 2084, Jos, Nigeria; [Nep, E., I; Ngwuluka, N. C.] Univ Jos, Fac Pharmaceut Sci, Dept Pharmaceut, PMB 2084, Jos, Nigeria; [Guktur, R. E.; Asala, O.] Natl Vet Res Inst, Viral Vaccines Prod Div, PMB 01, Vom, Nigeria; [Ochekpe, N. A.] Univ Jos, Fac Pharmaceut Sci, Dept Pharmaceut Chem, PMB 2084, Jos, Nigeria; [Sagay, A. S.] Univ Jos, Coll Hlth Sci, Dept Obstet & Gynaecol, Jos Univ Teaching Hosp, Jos, Nigeria		Ochekpe, NA (通讯作者)，Univ Jos, Fac Pharmaceut Sci, Dept Pharmaceut Chem, PMB 2084, Jos, Nigeria.	nelson.ochekpe@biodrudel.com			Support of Training and Mentoring In Nigeria For Academics (STAMINA) University of Jos [5D43TW010130-04]	The authors acknowledge the Support of Training and Mentoring In Nigeria For Academics (STAMINA) University of Jos for sponsoring this study -grant number 5D43TW010130-04; National Veterinary Research Institute (NVRI), Vom, for affording us the use of its facilities to carry out the research; Dr. G.D Bwala for technical assistance.	Abdi RD, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0785-6; Amorij JP, 2008, PHARM RES-DORDR, V25, P1256, DOI 10.1007/s11095-008-9559-6; Bedu-Addo KF, 2004, LYOPHILIZATION PHARM; Bello MB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020270; Cardoso FMC, 2017, ACTA VIROL, V61, P231, DOI 10.4149/av_2017_301; Cattoli G, 2010, VET MICROBIOL, V142, P168, DOI 10.1016/j.vetmic.2009.09.063; Chen DX, 2009, EXPERT REV VACCINES, V8, P547, DOI [10.1586/erv.09.20, 10.1586/ERV.09.20]; Cleland JL, 2001, J PHARM SCI, V90, P310, DOI 10.1002/1520-6017(200103)90:3<310::AID-JPS6>3.3.CO;2-I; Dimitrov KM, 2017, VET MICROBIOL, V206, P126, DOI 10.1016/j.vetmic.2016.12.019; Duralliu A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12040303; Eleazu OC, 2014, ACTA SCI POLON-TECHN, V13, P249, DOI 10.17306/J.AFS.2014.3.3; Flood A, 2016, DEV FREEZE DRIED HEA, P1, DOI [10.17605/OSF.IO/CFK8Z, DOI 10.17605/OSF.IO/CFK8Z]; Guktur R. E., 2013, World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS), V2, P4168; Heljo VP, 2013, EUR J PHARM BIOPHARM, V85, P752, DOI 10.1016/j.ejpb.2013.03.033; Kang MS, 2010, POULTRY SCI, V89, P1167, DOI 10.3382/ps.2009-00620; Kanojia G, 2017, HUM VACC IMMUNOTHER, V13, P2364, DOI [10.1080/21645515.2017.1359363, 10.1080/21645515.2017.1356952]; Kemas CU, 2017, INT J BIOL MACROMOL, V98, P94, DOI 10.1016/j.ijbiomac.2017.01.101; Kemas U. C., 2013, World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS), V2, P906; Kemas UC, 2020, BRIT J PHARMACOL, V4, DOI [10.5920/bjpharm.684, DOI 10.5920/BJPHARM.684]; Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007; Lemon S M, 1994, Int J Technol Assess Health Care, V10, P177; Li S, 2014, BIOPHYS J, V106, P1447, DOI 10.1016/j.bpj.2014.02.018; Liu T, 2019, VET MICROBIOL, V228, P53, DOI 10.1016/j.vetmic.2018.11.013; Mebrahtu K, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1355-x; Miller PJ, 2019, MANUAL DIAGNOSTIC TE, V2019th, P964; Milstien JB, 2006, VACCINES BIOL, P1; Mirmoghtadaie L, 2009, FOOD CHEM, V116, P709, DOI 10.1016/j.foodchem.2009.03.019; Nep EI, 2016, FOOD HYDROCOLLOID, V60, P265, DOI 10.1016/j.foodhyd.2016.02.037; Nirmala L, 2011, INDIAN J SCI TECHNOL, V4, P404; Nssien M, 2002, AFRICAN J BIOMED RES, V5, P87; Ochekpe NA, 2013, J PHARMTECH RES AM J, V3; Ohtake S, 2011, ADV DRUG DELIVER REV, V63, P1053, DOI 10.1016/j.addr.2011.06.011; Ojewola G. S., 2006, Journal of Animal and Veterinary Advances, V5, P472; Okwor EC, 2009, INT J POULT SCI, V8, P999, DOI [10.3923/ijps.2009.999.1002, DOI 10.3923/IJPS.2009.999.1002]; Olayinka FS, 2015, J FOOD SCI TECH MYS, V52, P8364, DOI 10.1007/s13197-015-1891-3; Pastorino B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118963; Qiao Z, 2017, Patent No. [US 9,839,613 B2, 9839613]; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rezatofighi SE, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.9016; Shuaib M, 2006, BROILERS, V5, P411; Spychaj T, 2013, POLIMERY-W, V58, P503, DOI 10.14314/polimery.2013.503; Tian W, 2018, Oral Vaccine Fast-dissolving Dosage Form Using Starch, Patent No. [US 9,956,169 B2, 9956169]; Welch CN, 2019, ARCH VIROL, V164, P2031, DOI 10.1007/s00705-019-04288-9; Young M, 2002, LAB MANUAL; Yousif E. I., 2012, Annals of Agricultural Science (Cairo), V57, P87, DOI 10.1016/j.aoas.2012.03.008; Yuan H, 2020, APPL MICROBIOL BIOT, V104, P1683, DOI 10.1007/s00253-019-10280-9; Zhao K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053314; Zoth SC, 2008, BRAZ J MED BIOL RES, V41, P318, DOI 10.1590/S0100-879X2008000400010	48	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4871	4884		10.1016/j.vaccine.2021.06.062		JUL 2021	14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34253418	hybrid			2022-04-29	WOS:000679483400019
J	Mugo, N; Eckert, LO; Odero, L; Gakuo, S; Ngure, K; Celum, C; Baeten, JM; Barnabas, RV; Wald, A				Mugo, Nelly; Eckert, Linda O.; Odero, Lydia; Gakuo, Stephen; Ngure, Kenneth; Celum, Connie; Baeten, Jared M.; Barnabas, Ruanne V.; Wald, Anna			Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa	VACCINE			English	Article						HIV infected; Adolescents; HPV vaccine; Africa	CERVICAL INTRAEPITHELIAL NEOPLASIA; DOUBLE-BLIND; PARTICLE VACCINE; YOUNG-WOMEN; IMMUNOGENICITY; EFFICACY; SAFETY; VIRUS; CHILDREN; IMPACT	Objectives: HIV infected children remain at increased risk of HPV associated malignancies as they initiate sexual activity. Though they mount a vigorous immune response to the quadrivalent human papillomavirus (QHPV-6, -11, -16, and -18; Gardasil (R)) vaccine, durability of the immune response is uncertain. We assessed antibody responses to HPV 6, -11, -16 and -18 for up to 48 months following administration of quadrivalent human papillomavirus vaccine in HIV-infected girls and boys ages 9-14 years in Kenya. Design: Of 178 girls and boys who had previously received three doses of the quadrivalent HPV vaccine, 176 enrolled into extended follow up for 4 years. HPV antibodies to -6, -11, -16 and -18 were measured at 24, 36 and 48 months after the first vaccine dose using the total immunoglobulin G immunoassay (IgG LIA). We evaluated the magnitude and trend in HPV vaccine response and the effect of plasma HIV-1 RNA on HPV vaccine response from month 24 to month 48 of follow up. Results: At re-enrollment, 24 months after initial vaccination, median age of participants was 14 years (range 11-17); 167 (95%) were receiving antiretroviral therapy and 110 (66%) had plasma HIV RNA < 40 copies/mL. The rate of HPV seropositivity at 48 months was 83% for HPV-6; 80% for HPV-11; 90% for HPV-16; and 77% for HPV-18. There was a plateau in mean log10 HPV-specific antibody titer between month 24 and 48. The mean log10 HPV-type specific antibody titer for children with undetectable HIV viral load (<40) at the time of vaccination consistently remained higher for the 48 months of follow up compared to children with detectable viral load. Conclusion: Children with HIV infection may retain long term antibody response following HPV immunization. Further work to define whether HIV-infected children are protected from HPV acquisition with low levels of HPV antibodies is needed. (C) 2020 Published by Elsevier Ltd.	[Mugo, Nelly] Kenya Govt Med Res Ctr, Ctr Clin Res, Nairobi, Kenya; [Mugo, Nelly; Eckert, Linda O.; Ngure, Kenneth; Celum, Connie; Baeten, Jared M.; Barnabas, Ruanne V.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Mugo, Nelly; Odero, Lydia; Gakuo, Stephen] Partners Hlth Res & Dev, Thika, Kenya; [Eckert, Linda O.] Univ Washington, Dept Obstet & Gynaecol, Seattle, WA 98195 USA; [Ngure, Kenneth] Jomo Kenyatta Univ Agr & Technol, Dept Community Hlth, Juja, Kenya; [Celum, Connie; Baeten, Jared M.; Barnabas, Ruanne V.; Wald, Anna] Univ Washington, Dept Med, Seattle, WA USA; [Celum, Connie; Baeten, Jared M.; Barnabas, Ruanne V.; Wald, Anna] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Wald, Anna] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Wald, Anna] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA		Mugo, N (通讯作者)，Kenya Med Res Inst KEMRI, Ctr Clin Res CCR, Nairobi, Kenya.; Mugo, N (通讯作者)，Univ Washington, Dept Global Hlth, Int Clin Res Ctr, Box 359927,325 Ninth Ave, Seattle, WA 98104 USA.	rwamba@uw.edu		Eckert, Linda/0000-0002-1357-8405	Investigator-Initiated Studies Program of Merck Sharp Dohme Corp; MISP [IISP 51802]	This study was supported in part by a research grant from Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp and received by Nelly Mugo (MISP) IISP 51802. The opinions expressed in this paper are those of the authors and do not neces-sarily represent those of Merck Sharp & Dohme Corp.	Apter D, 2015, CLIN VACCINE IMMUNOL, V22, P361, DOI 10.1128/CVI.00591-14; Arbyn M, 2018, EXPERT REV VACCINES, V17, P1085, DOI 10.1080/14760584.2018.1548282; Bagheri-Jamebozorgi M, 2014, HUM VACC IMMUNOTHER, V10, P3731, DOI 10.4161/hv.34393; Brown DR, 2011, HUM VACCINES, V7, P230, DOI 10.4161/hv.7.2.13948; Cameron RL, 2017, J EPIDEMIOL COMMUN H, V71, P954, DOI 10.1136/jech-2017-209113; De Vuyst H, 2012, BRIT J CANCER, V107, P1624, DOI 10.1038/bjc.2012.441; Denny LA, 2012, VACCINE, V30, pF168, DOI 10.1016/j.vaccine.2012.06.045; Dias D, 2005, CLIN DIAGN LAB IMMUN, V12, P959, DOI 10.1128/CDLI.12.8.959-969.2005; Drolet M, 2019, LANCET; Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031; Goodman T., UPDATE HPV VACCINE I; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Huh WK, 2017, LANCET, V390, P2143, DOI 10.1016/S0140-6736(17)31821-4; Joura EA, 2008, VACCINE, V26, P6844, DOI 10.1016/j.vaccine.2008.09.073; Kahn JA, 2013, CLIN INFECT DIS, V57, P735, DOI 10.1093/cid/cit319; Kelly H, 2018, LANCET HIV, V5, pE45, DOI 10.1016/S2352-3018(17)30149-2; Kojic EM, 2014, CLIN INFECT DIS, V59, P127, DOI 10.1093/cid/ciu238; Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253; Kuhs KAL, 2014, J INFECT DIS, V210, P1890, DOI 10.1093/infdis/jiu357; Lehtinen M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-015867; Levin MJ, 2017, VACCINE, V35, P1712, DOI 10.1016/j.vaccine.2017.02.021; Levin MJ, 2010, JAIDS-J ACQ IMM DEF, V55, P197, DOI 10.1097/QAI.0b013e3181de8d26; Pacheco-Dominguez RL, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819001341; Ll V., 2006, BRIT J CANCER; Longet S, 2011, J VIROL, V85, P13253, DOI 10.1128/JVI.06093-11; Machalek DA, 2018, J INFECT DIS, V217, P1590, DOI 10.1093/infdis/jiy075; Massad LS, 2014, AIDS, V28, P2601, DOI 10.1097/QAD.0000000000000455; Massad LS, 2009, CANCER-AM CANCER SOC, V115, P524, DOI 10.1002/cncr.24067; Merck & Co, 2009, GARDASIL PROD INF GARDASIL PROD INF; Moscicki AB, 2019, CLIN INFECT DIS; Mugo NR, 2018, VACCINE, V36, P7025, DOI 10.1016/j.vaccine.2018.09.059; Munoz N, 2010, JNCI-J NATL CANCER I, V102, P325, DOI 10.1093/jnci/djp534; Olsson SE, 2007, VACCINE, V25, P4931, DOI 10.1016/j.vaccine.2007.03.049; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Rowhani-Rahbar A, 2007, J INFECT DIS, V196, P887, DOI 10.1086/520883; Stanley M, 2006, VACCINE, V24, P106, DOI 10.1016/j.vaccine.2006.05.110; Stanley M, 2010, GYNECOL ONCOL, V117, pS5, DOI [10.1016/j.ygyno.2010.01.024, 10.1016/j.ygyno.2010.04.002]; Villa L, 2007, LANCET, V369, P1861, DOI 10.1016/S0140-6736(07)60852-6; West DJ, 1996, VACCINE, V14, P1019, DOI 10.1016/0264-410X(96)00062-X	39	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4751	4758		10.1016/j.vaccine.2020.12.020		JUL 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	33485644				2022-04-29	WOS:000681356500021
J	Ferrari, D; Di Resta, C; Tomaiuolo, R; Sabetta, E; Pontillo, M; Motta, A; Locatelli, M				Ferrari, Davide; Di Resta, Chiara; Tomaiuolo, Rossella; Sabetta, Eleonora; Pontillo, Marina; Motta, Andrea; Locatelli, Massimo			Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects	VACCINE			English	Article						COVID-19; Serological test; mRNA vaccine; Roche Anti-SARS-CoV-2-S; Immune response; Vaccination		Background: The first COVID-19 vaccines are being distributed to the general population. However, the shortage of doses is slowing down the goal of reaching herd immunity. The aim of the study was to verify whether previously SARS-CoV-2 infected subjects, a considerable portion of the population, should receive the same vaccination treatment of seronegative individuals. Methods: Health-professionals either recovered from COVID-19 or never infected by SARS-CoV-2 were serologically tested at different time-points right before, and several days after, vaccination. Results: Previously infected individuals showed humoral immune responses, 21 days after the first dose, that was approximately 10-folds higher than the seronegative group 21 days after the second dose. Seropositivity persists for at least 11 months. Conclusion: During a shortage of COVID-19 vaccine doses, previously SARS-CoV-2 infected individuals should be dispensed from the vaccination campaign. When dose availability returns to normality, injection of a single dose for seropositive individuals should be considered. (c) 2021 Elsevier Ltd. All rights reserved.	[Ferrari, Davide] Univ Parma, SCVSA Dept, I-43121 Parma, Italy; [Di Resta, Chiara; Sabetta, Eleonora; Pontillo, Marina; Motta, Andrea; Locatelli, Massimo] IRCCS Osped San Raffaele, I-20158 Milan, Italy; [Tomaiuolo, Rossella] Univ Vita Salute San Raffaele, Milan 20158, Italy		Ferrari, D (通讯作者)，Univ Parma, SCVSA Dept, I-43121 Parma, Italy.	davide.ferrari@unipr.it		Tomaiuolo, Rossella/0000-0002-2828-782X; ferrari, davide/0000-0001-7084-6800	Ministry of Health of Italy, "Bando Ricerca COVID-19" [COVID-2020-12371619]; COVIDIAGNOSTIX - Health Technology Assessment in Covid serological diagnostics	This project was supported by Ministry of Health of Italy, "Bando Ricerca COVID-19"; project number: COVID-2020-12371619; project title: COVIDIAGNOSTIX - Health Technology Assessment in Covid serological diagnostics.	Amoako A, NEW ENGL J MED, V2021, DOI [10.1101/2021.01.29.21250653, DOI 10.1101/2021.01.29.21250653]; Bradley Todd, 2021, medRxiv, DOI 10.1101/2021.02.03.21251078; Ferrari D, 2020, CLIN CHEM LAB MED, V58, P1095, DOI 10.1515/cclm-2020-0398; Ferrari Davide, 2020, Acta Biomed, V91, P47, DOI 10.23750/abm.v91i1.9195; Ferrari D, 2018, FORENSIC SCI INT, V282, P127, DOI 10.1016/j.forsciint.2017.11.005; Iavarone C, 2017, EXPERT REV VACCINES, V16, P871, DOI 10.1080/14760584.2017.1355245; Kittel M, 2021, INT J INFECT DIS, V103, P590, DOI 10.1016/j.ijid.2020.12.003; L'Huillier AG, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.01.005; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Perkmann T, 2020, CLIN CHEM, V66, P1405, DOI 10.1093/clinchem/hvaa198; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1126/science.abb2507, 10.1101/2020.02.11.944462]	15	6	6	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 13	2021	39	31					4256	4260		10.1016/j.vaccine.2021.06.020		JUL 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TG0WP	34147292	Bronze, Green Published			2022-04-29	WOS:000671133900005
J	Oostdijk, C; Van Zoonen, K; Ruijs, WLM; Mollema, L				Oostdijk, C.; Van Zoonen, K.; Ruijs, W. L. M.; Mollema, L.			Household decision-making for the MenACWY vaccination: How parents and adolescents deal with an adolescent vaccination decision	VACCINE			English	Article						Vaccinations; Decision-making; Parents; Adolescents; MenACWY vaccination; Meningococcal disease	W MENINGOCOCCAL DISEASE; SELF-CONSENT; HESITANCY; ATTITUDES; VACCINES; INCREASE; BELIEFS; AGE	Objective: Between 2015 and 2018 The Netherlands experienced increases of invasive meningococcal disease (IMD) serogroup W (MenW), from 0.02 cases/100,000 people between 2010 and 2014 up to 0.5 cases/100,000 in 2017. Therefore in 2018 the MenACWY vaccination was introduced in the National Immunisation Programme (NIP) and a catch-up campaign was initiated among adolescents. This study aimed to gain insight into the decision-making process within households regarding the MenACWY vaccination. The focus was on the differences in the decision-making process of parents and adolescents and of those that had accepted the MenACWY vaccination and those that had not, in order to assess how these types of decisions are made within households. Method: We conducted a total of 38 semi-structured interviews in 20 households (7 not vaccinated) with 20 parents and 18 adolescents (18 dyads) across The Netherlands concerning their decision-making process. Interview guides were constructed based on the Precaution Adaption Process (PAP) model. We performed thematic analysis using qualitative data analysis software (MAXQDA). Results: Parents are the main actors in the household decision-making process regarding the MenACWY vaccination. Parents start their decision-making process before adolescents are even aware of the issue. Households in the study took different approaches in involving the adolescent in the decision-making, resulting in three styles of household decision-making: parents decide without the adolescent, parents involve the adolescent, or parents leave it up to the adolescent to decide. Conclusion: Parents influence adolescent reasoning, engagement and involvement during the MenACWY vaccination decision-making. And this is the case both among those that have accepted and rejected the MenACWY vaccination. Adolescent engagement with the MenACWY vaccination decision-making is either short-lived or non-existent. However, the moment offers opportunities to engage adolescents on vaccinations and decision-making, with parents as key figures to promote this. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Oostdijk, C.; Van Zoonen, K.; Ruijs, W. L. M.; Mollema, L.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, POB 13720, NL-3720 BA Bilthoven, Netherlands		Oostdijk, C (通讯作者)，Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, POB 13720, NL-3720 BA Bilthoven, Netherlands.	christiaan.oostdijk@rivm.nl			ZonMwNetherlands Organization for Health Research and Development; Infectious Disease Control programme [522006001]	This work was supported by ZonMw and funded through their Infectious Disease Control programme 2014 - 2017 [project number 522006001, 2019 - 2020] .	Agrawal S, 2018, J MED ETHICS, V44, P531, DOI 10.1136/medethics-2017-104694; Alexander AB, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-192; Audrey S, 2020, VACCINE, V38, P7472, DOI 10.1016/j.vaccine.2020.09.074; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brown KF, 2010, VACCINE, V28, P4235, DOI 10.1016/j.vaccine.2010.04.052; Campbell H, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.28.21188; Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6; Clarke V., QUALITATIVE PSYCHOL, P222; de Vries M, 2020, EMERG INFECT DIS, V26, P1420, DOI 10.3201/eid2607.191812; Dempsey AF, 2006, PEDIATRICS, V117, P1486, DOI 10.1542/peds.2005-1381; Doyle TJ, 2010, EMERG INFECT DIS, V16, P113, DOI 10.3201/eid1601.091026; Dube E, 2015, CAN J INFECT DIS MED, V26, P163, DOI 10.1155/2015/732464; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Efron AM, 2009, J CLIN MICROBIOL, V47, P1979, DOI 10.1128/JCM.02390-08; Fisher H, 2019, VACCINE, V37, P417, DOI 10.1016/j.vaccine.2018.12.007; Ford CA, 2014, J ADOLESCENT HEALTH, V54, P183, DOI 10.1016/j.jadohealth.2013.07.028; Gamble HL, 2010, J PEDIATR PSYCHOL, V35, P704, DOI 10.1093/jpepsy/jsp108; Gaschignard J, 2013, PEDIATR INFECT DIS J, V32, P798, DOI 10.1097/INF.0b013e31828e9e91; GILOVICH T., 2002, HEURISTICS BIASES PS; Gowda C, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-509; Herman R, 2019, HUM VACC IMMUNOTHER, V15, P1752, DOI 10.1080/21645515.2019.1571891; Jackson C, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012851; Kegler, 2002, EMERGING THEORIES HL, P16; Knol MJ, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.16.18-00158; Ladhani SN, 2015, CLIN INFECT DIS, V60, P578, DOI 10.1093/cid/ciu881; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; McRee AL, 2012, SEX TRANSM DIS, V39, P394, DOI 10.1097/OLQ.0b013e318248aaa0; Mills E, 2005, J CLIN EPIDEMIOL, V58, P1081, DOI 10.1016/j.jclinepi.2005.09.002; Mustapha MM, 2016, VACCINE, V34, P1515, DOI 10.1016/j.vaccine.2016.02.014; RIVM, 2019, VACC JAARV RIJKSV NE VACC JAARV RIJKSV NE; RIVM, STAND ZAK MEN SER W STAND ZAK MEN SER W; Romijnders KAGJ, 2019, VACCINE, V37, P5637, DOI 10.1016/j.vaccine.2019.07.060; Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215; Sturm LA, 2005, J DEV BEHAV PEDIATR, V26, P441, DOI 10.1097/00004703-200512000-00009; Timmermans DRM, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-45; Timmermans DRM, 2005, VACCINE, V23, P3329, DOI 10.1016/j.vaccine.2005.01.075; Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048; van Keulen HM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-111; WEINSTEIN ND, 1988, HEALTH PSYCHOL, V7, P355, DOI 10.1037/0278-6133.7.4.355; World Health Organisation, 2014, CONS REG CONS VACC C; Zhou HJ, 2013, EMERG INFECT DIS, V19, P1496, DOI 10.3201/eid1909.130160	41	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 13	2021	39	31					4283	4290		10.1016/j.vaccine.2021.06.036		JUL 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TG0WP	34172331	hybrid			2022-04-29	WOS:000671133900009
J	Piche-Renaud, PP; Ji, CE; Farrar, DS; Friedman, JN; Science, M; Kitai, I; Burey, S; Feldman, M; Morris, SK				Piche-Renaud, Pierre-Philippe; Ji, Catherine; Farrar, Daniel S.; Friedman, Jeremy N.; Science, Michelle; Kitai, Ian; Burey, Sharon; Feldman, Mark; Morris, Shaun K.			Impact of the COVID-19 pandemic on the provision of routine childhood immunizations in Ontario, Canada	VACCINE			English	Article						Immunization coverage; COVID-19; Health systems; Cross-sectional survey; Pediatrics; Primary care and family medicine	HEALTH; CARE; CHILDREN; MEASLES	Background: The COVID-19 pandemic has a worldwide impact on all health services, including childhood immunizations. In Canada, there is limited data to quantify and characterize this issue. Methods: We conducted a descriptive, cross-sectional study by distributing online surveys to physicians across Ontario. The survey included three sections: provider characteristics, impact of COVID-19 on professional practice, and impact of COVID-19 on routine childhood immunization services. Multivariable logistic regression identified factors associated with modification of immunization services. Results: A total of 475 respondents answered the survey from May 27th to July 3rd 2020, including 189 family physicians and 286 pediatricians. The median proportion of in-person visits reported by physicians before the pandemic was 99% and dropped to 18% during the first wave of the pandemic in Ontario. In total, 175 (44.6%) of the 392 respondents who usually provide vaccination to children acknowledged a negative impact caused by the pandemic on their immunization services, ranging from temporary closure of their practice (n = 18; 4.6%) to postponement of vaccines in certain age groups (n = 103; 26.3%). Pediatricians were more likely to experience a negative impact on their immunization services compared to family physicians (adjusted odds ratio [aOR] = 2.64, 95% CI: 1.48-4.68), as well as early career physicians compared to their more senior colleagues (aOR = 2.69, 95% CI: 1.30-5.56), whereas physicians from suburban settings were less impacted than physicians from urban settings (aOR = 0.62, 95% CI: 0.39-0.99). Some of the proposed solutions to decreased immunization services included assistance in accessing personal protective equipment, dedicated centers or practices for vaccination, universal centralized electronic immunization records and education campaigns for parents. Conclusions: COVID-19 has caused substantial modifications to pediatric immunization services across Ontario. Strategies to mitigate barriers to immunizations during the pandemic need to be implemented in order to avoid immunity gaps that could lead to an eventual increase in vaccine preventable diseases. (c) 2021 Elsevier Ltd. All rights reserved.	[Piche-Renaud, Pierre-Philippe; Science, Michelle; Kitai, Ian; Morris, Shaun K.] Hosp Sick Children, Div Infect Dis, Toronto, ON, Canada; [Ji, Catherine] Univ Hlth Network, Toronto Western Family Hlth Team, Toronto, ON, Canada; [Ji, Catherine] Univ Toronto, Dept Family & Community Med, Fac Med, Toronto, ON, Canada; [Farrar, Daniel S.; Morris, Shaun K.] Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON, Canada; [Friedman, Jeremy N.; Feldman, Mark] Hosp Sick Children, Div Pediat Med, Toronto, ON, Canada; [Science, Michelle; Kitai, Ian; Feldman, Mark; Morris, Shaun K.] Univ Toronto, Dept Pediat, Fac Med, Toronto, ON, Canada; [Burey, Sharon] Pediatricians Alliance Ontario, Toronto, ON, Canada; [Burey, Sharon] Western Univ, Dept Paediat, Schulich Sch Med & Dent, London, ON, Canada; [Morris, Shaun K.] Dalla Lana Sch Publ Hlth, Div Clin Publ Hlth, Toronto, ON, Canada; [Morris, Shaun K.] Dalla Lana Sch Publ Hlth, Ctr Vaccine Preventable Dis, Toronto, ON, Canada		Morris, SK (通讯作者)，Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	Shaun.morris@sickkids.ca		Ji, Catherine/0000-0001-7544-6005	Creative Professional Activity grant from the Department of Paediatrics at The Hospital for Sick Children, Toronto	This study was supported by a Creative Professional Activity grant from the Department of Paediatrics at The Hospital for Sick Children, Toronto.	[Anonymous], GLOBAL NEWS; Canadian Pediatric Society, STICK IMM SCHED COVI; Chanchlani N, 2020, CAN MED ASSOC J, V192, pE921, DOI 10.1503/cmaj.201008; Cote RC., LANCET REG HLTH W PA, V2021; Coughlan C, 2020, POSTGRAD MED J; DeSilva MB, 2020, MMWR-MORBID MORTAL W, DOI [10.15585/mmwr. mm6919e2external, DOI 10.15585/MMWR.MM6919E2EXTERNAL]; Driedger H., CONTINUITY ROUTINE I, V2021; Glazier RH, 2021, CAN MED ASSOC J, V193, pE200, DOI 10.1503/cmaj.202303; Guttmann A, 2006, PEDIATRICS, V117, P595, DOI 10.1542/peds.2004-2784; Hoffman J, VACCINE RATES DROP D; Jiang L, 2020, LANCET INFECT DIS; Kitano T, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246326; Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5; Li HM, 2020, J PEDIATR-US, V224, P146, DOI 10.1016/j.jpeds.2020.05.013; Medecins Sans Frontieres, MEASL IS STEAD SIL K; Ontario College of Pharmacists, ADM INJ; Paules CI, 2019, NEW ENGL J MED, V380, P2185, DOI 10.1056/NEJMp1905099; Peci H., 2021, IMPACT COVID 19 PAND; Poudel A, MEASLES OUTBREAKS RE; Public Health Agency of Canada (PHAC), INT GUID CONT IMM PR; Public Health Agency of Canada (PHAC), FLU INFL FLUWATCH SU; Public Health Ontario, IMM COV REP SCH PUP; Public Health Ontario, MONTHL INF DIS SURV; Singer E, 2013, ANN AM ACAD POLIT SS, V645, P112, DOI 10.1177/0002716212458082; Suk JE, 2016, EMERG INFECT DIS, V22, P1106, DOI 10.3201/eid2206.151652; Wesseh C S, 2017, Public Health Action, V7, pS82, DOI 10.5588/pha.16.0104; WHO, 2020, GUIDING PRINCIPLES I; Wilson SE, 2016, CAN J PUBLIC HEALTH, V107, pE575, DOI [10.17269/cjph.107.5679, 10.17269/CJPH.107.5679]; World Health Organization, SPEC FEAT IMM COVID; Zureik, 2020, USAGE MEDICAMENTS VI	30	5	5	3	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 13	2021	39	31					4373	4382		10.1016/j.vaccine.2021.05.094		JUL 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TG0WP	34108076	Green Submitted, Bronze			2022-04-29	WOS:000671133900020
J	Jensen, A; Simoes, EAF; Christiansen, CB; Stensballe, LG				Jensen, Andreas; Simoes, Eric A. F.; Christiansen, Claus Bohn; Stensballe, Lone Graff			Respiratory syncytial virus and influenza hospitalizations in Danish children 2010-2016	VACCINE			English	Article						Respiratory syncytial virus; Vaccine; Influenza; Child; Infant	RISK-FACTORS; YOUNG-CHILDREN; INFECTIONS; BURDEN; COHORT; COMPLICATIONS; DISEASE; VACCINE; CARE	Objective: To pave the way for universal or risk factor-based vaccination strategies, the present study aimed to describe the epidemiology and compare risk factors for hospitalization associated with respiratory syncytial virus (RSV) and influenza virus infections in Danish children. Methods: National register-based cohort study among 403,422 Danish children born 2010-2016. Results: Prior asthma hospitalization, number of children in the household, chronic disease and maternal history of asthma hospitalization were the most important risk factors for both RSV and influenza hospitalization. The incidence of influenza increased at school start. Conclusions: Our findings enable targeted vaccination programs for high-risk children with asthma-like disease, chronic disease, siblings in the household, or maternal history of asthma hospitalization. (c) 2021 Elsevier Ltd. All rights reserved.	[Jensen, Andreas; Stensballe, Lone Graff] Copenhagen Univ Hosp, Rigshosp, Dept Paediat & Adolescent Med, Copenhagen, Denmark; [Simoes, Eric A. F.] Univ Colorado, Dept Pediat, Sch Med, Sect Infect Dis, Aurora, CO USA; [Simoes, Eric A. F.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Simoes, Eric A. F.] Colorado Sch Publ Hlth, Ctr Global Hlth, Aurora, CO USA; [Christiansen, Claus Bohn] Copenhagen Univ Hosp, Rigshosp, Dept Clin Microbiol, Copenhagen, Denmark; [Christiansen, Claus Bohn] Labmed Skane, Dept Clin Microbiol, Lund, Sweden		Jensen, A (通讯作者)，Copenhagen Univ Hosp, Rigshosp, Dept Paediat & Adolescent Med, Copenhagen, Denmark.	andreas.jensen.01@regionh.dk			Dagmar Marshall Foundation, Denmark	The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Andreas Jensen, Claus Bohn Christiansen and Lone Graff Stensballe have no conflicts of interest to disclose. Eric A. F. Simoes reports grants, personal fees and non-financial support from Astra Zeneca Inc, Merck & Co., Regeneron Inc, Pfizer Inc, and Roche Inc, personal fees, non-financial support and other from Abbvie Inc, personal fees from Alere Inc, and Cidara Inc, other from GSK Inc, grants from Johnson and Johnson, grants and non-financial support from Novavax Inc, outside the submitted work. The study was funded by The Dagmar Marshall Foundation, Denmark.	[Anonymous], 2018, PFIZER BEGINS PHASE; [Anonymous], 2019, 5 RESVINET C 12 14 N; [Anonymous], 2019, CASE MED RES; [Anonymous], 2012, PUBLIC HLTH GUIDANCE; Bliddal M, 2018, EUR J EPIDEMIOL, V33, P27, DOI 10.1007/s10654-018-0356-1; Buchbinder SP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179597; Cai W, 2020, INFLUENZA OTHER RESP, V14, P658, DOI 10.1111/irv.12729; CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957; Cicirello H., 2020, CLIN INFECT DIS; Coleman BL, 2018, INFLUENZA OTHER RESP, V12, P22, DOI 10.1111/irv.12504; Danish Health Authority, 2019, VACC RISK GROUPS; Enserink M, 2020, SCIENCE, V368, P1169, DOI 10.1126/science.368.6496.1169; Flannery B, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4244; Flu Vaccination Coverage, 2020, FLU VACCINATION COVE; FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956; Gill PJ, 2015, LANCET RESP MED, V3, P139, DOI 10.1016/S2213-2600(14)70252-8; Griffin MP, 2020, NEW ENGL J MED, V383, P415, DOI 10.1056/NEJMoa1913556; Haerskjold A, 2016, PEDIATR INFECT DIS J, V35, P61, DOI 10.1097/INF.0000000000000924; Hardelid P, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00489-2017; Homaira N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011398; Jensen A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226045; Jules A, 2015, PEDIATRICS, V135, pE66, DOI 10.1542/peds.2014-1168; Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Kristensen K, 2012, CLIN INFECT DIS, V54, P810, DOI 10.1093/cid/cir928; Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977; Lee JJ, 2018, EPIDEMIOL INFECT, V146, P817, DOI 10.1017/S0950268818000353; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1; Parrish CR, 2015, J VIROL, V89, P2990, DOI 10.1128/JVI.03146-14; Pedersen CB, 2006, DAN MED BULL, V53, P441; Resch B, 2020, PEDIATR INFECT DIS J, V39, P12, DOI 10.1097/INF.0000000000002494; Resch B, 2011, PEDIATR INFECT DIS J, V30, P797, DOI 10.1097/INF.0b013e318215cf3e; Sasbon JS, 2011, PEDIATR CRIT CARE ME, V12, pE136, DOI 10.1097/PCC.0b013e3181e28862; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Schmidt-Ott Ruprecht, 2020, Hum Vaccin Immunother, V16, P836, DOI 10.1080/21645515.2019.1682843; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Shi T, 2015, J GLOB HEALTH, V5, P203, DOI 10.7189/jogh.05.020416; Simon AE, 2016, ACAD PEDIATR, V16, P68, DOI 10.1016/j.acap.2015.10.006; Tang AM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12137-1; Thygesen LC, 2011, SCAND J PUBLIC HEALT, V39, P12, DOI 10.1177/1403494811399956; Vesikari T, 2018, LANCET RESP MED, V6, P345, DOI [10.1016/S2213-2600(18)30108-5, 10.1016/s2213-2600(18)30108-5]; Wang X, 2020, LANCET GLOB HEALTH, V8, pE497, DOI 10.1016/S2214-109X(19)30545-5	47	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4126	4134		10.1016/j.vaccine.2021.05.097		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34116876				2022-04-29	WOS:000672535200017
J	Diaz-Mitoma, F; Popovic, V; Spaans, JN				Diaz-Mitoma, Francisco; Popovic, Vlad; Spaans, Johanna N.			Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac (R), compared with Engerix-B (R) in healthy Asian adults: A phase 3 randomized clinical trial	VACCINE			English	Article						3-antigen; hepatitis B virus; Safety; Seroprotection rate; Vaccine	HBV COAT PROTEIN; PRE-S COMPONENTS; VIRAL-HEPATITIS; PREVALENCE	Background: Sci-B-Vac (R), a 3-antigen hepatitis B vaccine (3A-HBV), contains all three recombinant hepatitis B virus (HBV) envelope proteins (S, pre-S1, and pre-S2). In 2005, 3A-HBV manufacturing transferred facilities (A to B), where it continues to be manufactured. Methods: This phase 3, single-blind, randomized study, conducted at one site in Vietnam, compared efficacy and safety among two 3A-HBV lots, lot A and lot B, and a single-antigen hepatitis B vaccine (1A-HBV), Engerix-B(R). Primary objective was to demonstrate equivalence at day 210 of two 3A-HBV lots in seroprotection rate (SPR; defined as percentage of participants achieving hepatitis B surface antigen antibody [anti-HBs] titers >= 10 mIU/mL). Secondary objectives were assessing immunogenicity at days 180, 210, and 360, and safety of 3A-HBV. Results: 3A-HBV SPR equivalence was demonstrated at day 210 (lot A: 97.3% [95% CI: 92.4%, 99.4%] vs. lot B: 100.0% [97.0%, 100.0%]). Compared to 1A-HBV, lot B SPR was higher at day 180 (98.3% vs. 81.2%; difference: 17.1% [9.7%, 24.6%]) and non-inferior at day 210 (100% vs. 98.3%; difference: 1.7% [-0.6%, 4.1%]). 3A-HBV lot B showed the same SPR after 2 doses (98.3%) as 1A-HBV after 3 doses (98.3%). Adverse events (AEs) were comparable with both 3A-HBV lots (lot A: 68.7% vs. lot B: 54.2%), but higher than 1A-HBV (35.3%). Vaccination-related AEs included transient injection site pain (38.9%), myalgia (9.3%), and fatigue (7.5%). Eight serious AEs were reported (lot A: 3/134 [2.2%]; lot B: 1/134 [0.8%]; 1A-HBV: 4/133 [2.3%]). One serious AE, syncope, was noted as probably related to study vaccine, lot B. Conclusions: The two 3A-HBV lots had equivalent immunogenicity, but lot B elicited faster onset of seroprotection and higher anti-HBs titers than both lot A and 1A-HBV in an Asian population. This supports 3A-HBV lot B as an effective choice for HBV vaccination, with a favorable safety profile. (C) 2021 The Authors. Published by Elsevier Ltd.	[Diaz-Mitoma, Francisco; Popovic, Vlad; Spaans, Johanna N.] VBI Vaccines Inc, Cambridge, MA USA		Diaz-Mitoma, F (通讯作者)，VBI Vaccines Inc, 310 Hunt Club Rd, Ottawa, ON K1V 1C1, Canada.	fdiazmitoma@vbivaccines.com		Diaz-Mitoma, Francisco/0000-0003-0292-4859	VBI Vaccines Inc.	This work was supported by VBI Vaccines Inc. Data collection and analysis were conducted by SciGen, prior to the acquisition of Sci-B-Vac by VBI Vaccines Inc. The authors, who are employees of VBI Vaccines, Inc., were responsible for data interpretation and the decision to submit the article for publication.	Ashtari S, 2015, WORLD J HEPATOL, V7, P1708, DOI 10.4254/wjh.v7.i12.1708; Cassidy A, 2011, EXPERT REV VACCINES, V10, P1709, DOI [10.1586/erv.11.151, 10.1586/ERV.11.151]; Chu D, 2013, GUT LIVER, V7, P450, DOI 10.5009/gnl.2013.7.4.450; de Martel C, 2015, HEPATOLOGY, V62, P1190, DOI 10.1002/hep.27969; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Esaulenko EV, 2021, CLIN INFECT DIS, V73, pE3333, DOI 10.1093/cid/ciaa1649; Finn A, 2020, DIGITAL EUROPEAN ASS; GlaxoSmithKline Biologicals, 2020, ENGERIX B PACKAGE IN; Hatzakis A, 2011, J VIRAL HEPATITIS, V18, P1, DOI 10.1111/j.1365-2893.2011.01499.x; Hope VD, 2014, EPIDEMIOL INFECT, V142, P270, DOI 10.1017/S0950268813000940; Hsu CE, 2007, J NATL MED ASSOC, V99, P900; Hung IFN, 2021, CLIN INFECT DIS, V73, pE304, DOI 10.1093/cid/ciaa804; Hyun Kim Bo, 2018, Clin Liver Dis (Hoboken), V12, P1, DOI 10.1002/cld.732; JR MSC, 2015, WORLD J GASTROENTERO, V21, P11924, DOI DOI 10.3748/WJG.V21.I42.11924; Kohler M, 2000, INFUS THER TRANSFUS, V27, P174, DOI 10.1159/000025276; Kowdley KV, 2012, HEPATOLOGY, V56, P422, DOI 10.1002/hep.24804; Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001; Lee AW, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029616; Lin SY, 2007, HEPATOLOGY, V46, P1034, DOI 10.1002/hep.21784; MacLachlan JH, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021410; Mitchell T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027717; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Poliquin G, AM ASS STUDY LIVER D; Roberts H, 2016, HEPATOLOGY, V63, P388, DOI 10.1002/hep.28109; Stanaway JD, 2016, LANCET, V388, P1081, DOI 10.1016/S0140-6736(16)30579-7; Vedio AB, 2013, J INFECT PUBLIC HEAL, V6, P448, DOI 10.1016/j.jiph.2013.05.004; World Health Organization, 2012, World Health Organ Tech Rep Ser, P1; World Health Organization, 2020, HEP B; YAP I, 1992, VACCINE, V10, P439, DOI 10.1016/0264-410X(92)90391-V; YAP I, 1995, J GASTROEN HEPATOL, V10, P51, DOI 10.1111/j.1440-1746.1995.tb01047.x	30	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3892	3899		10.1016/j.vaccine.2021.05.067		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34116873	hybrid			2022-04-29	WOS:000663773600015
J	Luk, TT; Zhao, SZ; Wu, YD; Wong, JYH; Wang, MP; Lam, TH				Luk, Tzu Tsun; Zhao, Shengzhi; Wu, Yongda; Wong, Janet Yuen-ha; Wang, Man Ping; Lam, Tai Hing			Prevalence and determinants of SARS-CoV-2 vaccine hesitancy in Hong Kong: A population-based survey	VACCINE			English	Article						Coronavirus; COVID-19; Vaccine hesitancy; Vaccine acceptance; Chinese	COVID-19; INFLUENZA	Background: Although vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the most desired solution to end the coronavirus disease (COVID-19) pandemic, there are growing concerns that vaccine hesitancy would undermine its potential. We examined the intention to receive vaccination against SARS-CoV-2 and the associated factors in a representative sample of Chinese adults in Hong Kong. Methods: We did a dual-frame (landline and mobile) cross-sectional survey of a random sample of 1501 Hong Kong residents aged 18 years or older (53.6% females) in April 2020. We collected data on the intention to receive SARS-CoV-2 vaccine when it becomes available (yes/no/undecided), knowledge and perceptions of COVID-19, smoking, alcohol drinking, and sociodemographic factors. Prevalence estimates were weighted by the sex, age, and education of the general population of Hong Kong. Results: Overall, 45.3% (95% CI: 42.3-48.4%) of the participants had intentions to vaccinate against SARSCoV-2 when it becomes available, 29.2% (26.5-32.1%) were undecided, and 25.5% (22.9-28.2%) had no intention. The most common reason for vaccine hesitancy (undecided or no intention) was safety concerns (56.5%). Multivariable partial proportional odds model showed higher vaccine hesitancy in males, younger adults, those with no chronic disease, current smokers, and non-alcohol drinkers. After adjusting for sociodemographic and other factors, inadequate knowledge of SARS-CoV-2 transmission (adjusted ORs ranged from 1.27 to 2.63; P < 0.05) and lower perceived danger of COVID-19 (adjusted ORs ranged from 1.62 to 2.47; P < 0.001) were significantly associated with vaccine hesitancy. Conclusions: In a representative sample of Chinese adults in Hong Kong, only 45.3% of the participants intended to vaccinate against SARS-CoV-2 when available. Vaccine hesitancy was associated with inadequate knowledge about SARS-CoV-2 transmission and lower perceived danger of COVID-19, which needed to be addressed to improve vaccination uptake. (c) 2021 Elsevier Ltd. All rights reserved.	[Luk, Tzu Tsun; Zhao, Shengzhi; Wu, Yongda; Wong, Janet Yuen-ha; Wang, Man Ping] Univ Hong Kong, Sch Nursing, 4-F,William MW Mong Block,21 Sassoon Rd, Hong Kong, Peoples R China; [Lam, Tai Hing] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Peoples R China		Wang, MP (通讯作者)，Univ Hong Kong, Sch Nursing, 4-F,William MW Mong Block,21 Sassoon Rd, Hong Kong, Peoples R China.	luktt@connect.hku.hk; lubeczz@connect.hku.hk; yongdang@connect.hku.hk; janetyh@hku.hk; mpwang@hku.hk; hrmrlth@hku.hk	Luk, Tzu Tsun/A-2667-2017	Luk, Tzu Tsun/0000-0002-7056-1976			Adam DC, 2020, NAT MED, V26, P1714, DOI 10.1038/s41591-020-1092-0; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Census and Statistics Department, 2017, 2016 POP BY CENS MAI; Census and Statistics Department, 2020, 69 CENS STAT DEP; Chor JSY, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3391; Chu DK., 2020, LANCET, V395, P1973, DOI DOI 10.1016/S0140-6736(20)31142-9; Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Havers FP, 2020, JAMA INTERN MED, V180, P1576, DOI 10.1001/jamainternmed.2020.4130; Ho, 2020, TOB CONTROL, DOI [10.1136/tobaccocontrol-2020-055960, DOI 10.1136/tobaccocontrol-2020-055960]; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Lau JTF, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4164; Leng AL, 2021, VACCINE, V39, P247, DOI 10.1016/j.vaccine.2020.12.009; Leung GM, 2004, ANN INTERN MED, V141, P662, DOI 10.7326/0003-4819-141-9-200411020-00006; Liao QY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017713; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Morley J, TRENDS REGIONAL VARI, V2021; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0; Thorpe S, 2016, MATERN CHILD HLTH J, V20, P172, DOI 10.1007/s10995-015-1817-8; Williams R, 2006, STATA J, V6, P58, DOI 10.1177/1536867X0600600104; World Health Organization, RISK COMM COMM ENG A; World Health Organization, SMOK COVID 19 SCI BR; World Health Organization (WHO), MOD TRANSM VIR CAUS; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xu X, 2020, NAT MED, V26, P1193, DOI 10.1038/s41591-020-0949-6	32	13	13	6	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 16	2021	39	27					3602	3607		10.1016/j.vaccine.2021.05.036		JUN 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SO5NX	34034950	Bronze, Green Published			2022-04-29	WOS:000659020000008
J	Powell, H; Liu, H; Pekosz, A				Powell, Harrison; Liu, Hsuan; Pekosz, Andrew			Changes in sialic acid binding associated with egg adaptation decrease live attenuated influenza virus replication in human nasal epithelial cell cultures	VACCINE			English	Article						Influenza; Nasal epithelial cells; LAIV; Vaccines; Egg adaption	RECEPTOR-BINDING; A VIRUS; VACCINE; SPECIFICITY; H3N2; H1; STRAIN; HEMAGGLUTININS; RECOGNITION; INFECTION	Live Attenuated Influenza Virus (LAIV) is administered to and replicates in the sinonasal epithelium. Candidate LAIV vaccine strains are selected based on their ability to replicate to a high titer in embryonated hen's eggs, a process that can lead to mutations which alter the receptor binding and antigenic structure of the hemagglutinin (HA) protein. In the 2012-2013 northern hemisphere vaccine, the H3N2 HA vaccine strain contained three amino acid changes - H156Q, G186V and S219Y - which altered HA antigenic structure and thus presumably decreased vaccine efficacy. To determine if these mutations also altered LAIV replication, reabcombinant viruses were created that encoded the wild-type (WT) parental HA of A/Victoria/361/2011 (WT HA LAIV), the egg adapted HA (EA HA LAIV) from the A/Victoria/361/2011 vaccine strain and an HA protein with additional amino acid changes to promote alpha 2,3 sialic acid binding (2,3 EA HA LAIV). The WT HA LAIV bound alpha 2,6 sialic compared to the EA HA LAIV and 2,3 EA HA LAIV which both demonstrated an increased preference for alpha 2,3 sialic acid. On MDCKs, the WT HA and EA HA LAIVs showed similar replication at 32 degrees C but at 37 degrees C the EA HA LAIV replicated to lower infectious virus titers. The 2,3 EA HA LAIV replicated poorly at both temperatures. This replication phenotype was similar on human nasal epithelial cell (hNEC) cultures, however the WT HA LAIV induced the highest amount of IFN-lambda and infected more nasal epithelial cells compared to the other viruses. Together, these data indicate that egg adaption mutations in the HA protein that confer preferential alpha 2,3 sialic acid binding may adversely affect LAIV replication and contribute to reduced vaccine efficacy. (C) 2021 Elsevier Ltd. All rights reserved.	[Powell, Harrison; Liu, Hsuan; Pekosz, Andrew] Johns Hopkins Univ, W Harry Feinstone Dept Mol Microbiol & Immunol, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA		Pekosz, A (通讯作者)，Johns Hopkins Univ, W Harry Feinstone Dept Mol Microbiol & Immunol, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA.	apekosz1@jhu.edu			Centers of Excellence in Influenza Research and Surveillance [HHS N2772201400007C, T32 AI007417]	We would like to thank the members of the Pekosz laboratory, the Sabra Klein laboratory, and the Kimberly Davis laboratory for data discussion and feedback. We thank Katherine Fenstermacher, Nick Wohlgemuth and Laura Canaday for their feedback and assistance with this project. The work was supported by Centers of Excellence in Influenza Research and Surveillance HHS N2772201400007C (AP) and T32 AI007417 (HP).	AstraZeneca, 2017, UPD LIV ATT INFL VAC; Bradley KC, 2011, J VIROL, V85, P12387, DOI 10.1128/JVI.05570-11; Byrd-Leotis L, 2019, J VIROL, V93, DOI 10.1128/JVI.01178-19; Byrd-Leotis L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071541; CDC, ACIP VOT US LAIV 201; CDC, DIS BURD INFL 2020; Chan MCW, 2018, EMERG INFECT DIS, V24, P1825, DOI 10.3201/eid2410.180652; Charles DD, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00165; Cobey S, 2018, CLIN INFECT DIS, V67, P327, DOI 10.1093/cid/ciy097; COX NJ, 1988, VIROLOGY, V167, P554, DOI 10.1016/0042-6822(88)90118-3; de Courcey F, 2012, AM J PHYSIOL-CELL PH, V303, pC1173, DOI 10.1152/ajpcell.00384.2011; Fischer WA, 2015, VACCINE, V33, P4495, DOI 10.1016/j.vaccine.2015.07.023; Fischer WA, 2014, VACCINE, V32, P1761, DOI 10.1016/j.vaccine.2013.12.069; Fodor E, 1999, J VIROL, V73, P9679, DOI 10.1128/JVI.73.11.9679-9682.1999; Forero A, 2017, VACCINE, V35, P6112, DOI 10.1016/j.vaccine.2017.09.058; Gambaryan AS, 1999, VIROLOGY, V258, P232, DOI 10.1006/viro.1999.9732; Gambaryan AS, 1997, VIROLOGY, V232, P345, DOI 10.1006/viro.1997.8572; Glycomics CfF, 2020, MAMM PRINT ARR VERS; Gould PS, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100269; Guo Yongqing, 2004, Lin Chuang Er Bi Yan Hou Ke Za Zhi, V18, P88; Hawksworth A, 2020, VACCINE, V38, P4209, DOI 10.1016/j.vaccine.2020.04.004; Ibricevic A, 2006, J VIROL, V80, P7469, DOI 10.1128/JVI.02677-05; Imai M, 2012, CURR OPIN VIROL, V2, P160, DOI 10.1016/j.coviro.2012.03.003; Jaspers I, 2013, J VIS EXP, V80; Karakus U, 2020, J VIROL, V94, DOI 10.1128/JVI.01357-19; Kiseleva I. V., 2007, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P40; Kiss G, 2014, MICROSC MICROANAL, V20, P164, DOI 10.1017/S1431927613013937; Kumari K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-42; Kumlin U, 2008, INFLUENZA OTHER RESP, V2, P147, DOI 10.1111/j.1750-2659.2008.00051.x; Lanthier PA, 2011, VACCINE, V29, P7849, DOI 10.1016/j.vaccine.2011.07.093; Laporte M, 2020, J VIROL, V94, DOI 10.1128/JVI.01430-19; Lindemann J, 2002, CLIN OTOLARYNGOL, V27, P135, DOI 10.1046/j.1365-2273.2002.00544.x; Matrosovich M, 2000, J VIROL, V74, P8502, DOI 10.1128/JVI.74.18.8502-8512.2000; Matrosovich MN, 1997, VIROLOGY, V233, P224, DOI 10.1006/viro.1997.8580; MATROSOVICH MN, 1993, VIROLOGY, V196, P111, DOI 10.1006/viro.1993.1459; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; McQuillan AM, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00088; Mochalova L, 2003, VIROLOGY, V313, P473, DOI 10.1016/S0042-6822(03)00377-5; Nelson SW, 2019, INFLUENZA OTHER RESP, V13, P593, DOI 10.1111/irv.12671; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; Nicholls JM, 2008, TRENDS MICROBIOL, V16, P149, DOI 10.1016/j.tim.2008.01.008; Nobusawa E, 2000, VIROLOGY, V278, P587, DOI 10.1006/viro.2000.0679; Nogales A, 2018, VIRUSES-BASEL, V10; Park DY, 2016, ALLERGY ASTHMA IMMUN, V8, P69, DOI 10.4168/aair.2016.8.1.69; Parker L, 2019, VACCINE, V37, P4543, DOI 10.1016/j.vaccine.2019.06.016; Parker L, 2016, J GEN VIROL, V97, P1333, DOI 10.1099/jgv.0.000457; Pekosz A, 2009, VIROLOGY, V386, P61, DOI 10.1016/j.virol.2009.01.005; Ramanathan M, 2007, OTOLARYNG HEAD NECK, V136, P348, DOI 10.1016/j.otohns.2006.11.011; Rodriguez L, 2019, VIRUSES-BASEL, V11; Sassaki GL, 2013, BIOCHEMISTRY-US, V52, P7217, DOI 10.1021/bi400677n; Schagen J, 2018, LAB INVEST, V98, P1478, DOI 10.1038/s41374-018-0100-1; Shcherbik S, 2019, VACCINE-X, V2, DOI 10.1016/j.jvacx.2019.100031; Shcherbik S, 2016, J VIROL METHODS, V227, P33, DOI 10.1016/j.jviromet.2015.10.009; Sheldon EA, 2013, INFLUENZA OTHER RESP, V7, P1142, DOI 10.1111/irv.12027; Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153; Stevens J, 2010, J VIROL, V84, P8287, DOI 10.1128/JVI.00058-10; Takemae N, 2010, J GEN VIROL, V91, P938, DOI 10.1099/vir.0.016691-0; Toback SL, 2012, EXPERT REV VACCINES, V11, P1293, DOI [10.1586/erv.12.108, 10.1586/ERV.12.108]; WHO, 2013, REC COMP INFL VIR VA; Wohigemuth N, 2017, VACCINE, V35, P6691, DOI 10.1016/j.vaccine.2017.10.018; Wohlgemuth N, 2018, J VIROL, V92, DOI 10.1128/JVI.01425-18; Zeneca A, 2020, FLUMIST QUADRIVALENT	64	0	0	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 2	2021	39	24					3225	3235		10.1016/j.vaccine.2021.04.057		JUN 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SM1SV	33985852				2022-04-29	WOS:000657392500001
J	Chan, YW; Wong, ML; Kwok, FY; Au, AKW; Leung, ECM; Chuang, SK				Chan, Yung-wai; Wong, Miu-ling; Kwok, Fong-yuen; Au, Albert Ka-Wing; Leung, Emily Chi-mei; Chuang, Shuk-kwan			The effect of seasonal influenza vaccine on medically-attended influenza and non-influenza respiratory viruses infections at primary care level, Hong Kong SAR, 2017/18 to 2019/20	VACCINE			English	Article						Influenza; Influenza vaccine; Vaccine effectiveness; Respiratory viruses		Effectiveness of seasonal influenza vaccine (SIV) varies with the degree of matching with the vaccine and circulating viruses. We continued our SIV effectiveness against medically-attended influenza-like illness (ILI) under the Department of Health Hong Kong's sentinel private medical practitioners (PMP) network, using the test-negative case-control design, for the 2018/19 and 2019/20 season. In addition, we studied the potential interference between SIV and ILI caused by non-influenza respiratory viruses (NIRV) based on data collated from 2017/18 to 2019/20 seasons. 3404 patients were analysed. Across the 2017/18 to 2019/20 seasons, the vaccine effectiveness (VE) of SIV was 44% (95% CI 30-56%) against pan-negative controls, 57% (95%CI 42-68%) against NIRV controls and 50% (95%CI 38-59%) against both. SIV was moderately effective against medically-attended ILI caused by influenza A/B in both 2018/19 and 2019/20 winter seasons (53.2% (95%CI 36.7-65.5%) and 41.8% (95%CI 6.3-64.1%), respectively). The VE against the main circulating subtype, influenza A(H1), was higher for the 2018/19 season (57.2% (95%CI 39.8- 69.9%), compared to 34.6% (95%CI-9.6-61.4%) in the 2019/20 season). When compared to pan negative controls, those with single NIRV infections were similarly likely to have received SIV (OR 1.05 (95%CI 0.72-1.54) within the influenza season; OR 0.97 (95%CI 0.73-1.29) when including non-influenza seasons). Analyses by type of virus showed no increased risk of SIV identified among those with single infections of EV/RV, HMPV and parainfluenza but a 2-fold increased risk was shown for those with single infections of adenovirus and parainfluenza virus (adenovirus: OR 2.54 (95%CI 1.24-5.14) within influenza season and OR 1.78 (95%CI 1.01-3.09) for the whole period; parainfluenza virus: OR 2.01 (95%CI 1.22- 3.29) within influenza season and OR 1.89 (95%CI 1.29-2.76) for the whole period). SIV programme and surveillance of influenza and NIRV, including SARS-CoV-2, should continue during the COVID-19 pandemic. (c) 2021 Published by Elsevier Ltd.	[Chan, Yung-wai; Wong, Miu-ling; Kwok, Fong-yuen; Au, Albert Ka-Wing; Leung, Emily Chi-mei; Chuang, Shuk-kwan] Ctr Hlth Protect, Communicable Dis Branch, Dept Hlth, Hong Kong, Peoples R China		Chan, YW (通讯作者)，Ctr Hlth Protect, Communicable Dis Branch, Dept Hlth, Hong Kong, Peoples R China.	chanyungwai@gmail.com	CHAN, YUNG WAI/AAS-9746-2021	CHAN, YUNG WAI/0000-0001-9238-7051			Amato M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030535; Centre for Health Protection, VACCI SCHEM; Chan KH, 2020, BMJ-BRIT MED J, P369; Chan YWD, 2019, HUM VACC IMMUNOTHER, V15, P97, DOI 10.1080/21645515.2018.1514222; Chan YWD, 2020, WELLCOME OPEN RES, V5, P91, DOI DOI 10.12688/WELLCOMEOPENRES.15896.1; Chiu SS, 2020, VACCINE, V38, P8078, DOI 10.1016/j.vaccine.2020.10.081; Chiu SS, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.5.1900056; Cowling BJ, 2012, CLIN INFECT DIS, V54, P1778, DOI 10.1093/cid/cis307; De Wals P, 2020, TITLE COULD SEASONAL, DOI [10.1101/2020.09.02.20186734, DOI 10.1101/2020.09.02.20186734]; Demicheli V, 2018, COCHRANE DB SYST REV, V2018; Demicheli V, 2018, COCHRANE DATABASE SY, V2018; Di Bari M, 2020, VACCINES-BASEL, V8, P1; Fink G., 2020, INACTIVATED TRIVALEN, DOI 10.1136/bmjebm-2020-111549; Huang AT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18450-4; Imada EL, 2020, PREPR SERV HEAL SCI; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; Marin-Hernandez D, 2021, J MED VIROL, V93, P64, DOI 10.1002/jmv.26120; Ragni P, 2020, VACCINES-BASEL, V8, P1; RStudio Team, 2016, RSTUDIO INT DEV R; Skowronski DM, 2020, CLIN INFECT DIS, V71, P2285, DOI 10.1093/cid/ciaa626; Wolff GG, 2020, VACCINE, V38, P350, DOI 10.1016/j.vaccine.2019.10.005	21	0	0	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3372	3378		10.1016/j.vaccine.2021.04.059		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	34016472				2022-04-29	WOS:000657001300012
J	Hogan, AB; Winskill, P; Watson, OJ; Walker, PGT; Whittaker, C; Baguelin, M; Brazeau, NF; Charles, GD; Gaythorpe, KAM; Hamlet, A; Knock, E; Laydon, DJ; Lees, JA; Lochen, A; Verity, R; Whittles, LK; Muhib, F; Hauck, K; Ferguson, NM; Ghani, AC				Hogan, Alexandra B.; Winskill, Peter; Watson, Oliver J.; Walker, Patrick G. T.; Whittaker, Charles; Baguelin, Marc; Brazeau, Nicholas F.; Charles, Giovanni D.; Gaythorpe, Katy A. M.; Hamlet, Arran; Knock, Edward; Laydon, Daniel J.; Lees, John A.; Lochen, Alessandra; Verity, Robert; Whittles, Lilith K.; Muhib, Farzana; Hauck, Katharina; Ferguson, Neil M.; Ghani, Azra C.			Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis	VACCINE			English	Article						SARS-CoV-2; Mathematical model; COVID-19; Vaccination model; Optimisation	INFLUENZA VACCINATION; COVID-19 VACCINE; POPULATION	The worldwide endeavour to develop safe and effective COVID-19 vaccines has been extraordinary, and vaccination is now underway in many countries. However, the doses available in 2021 are likely to be limited. We extend a mathematical model of SARS-CoV-2 transmission across different country settings to evaluate the public health impact of potential vaccines using WHO-developed target product profiles. We identify optimal vaccine allocation strategies within-and between-countries to maximise averted deaths under constraints on dose supply. We find that the health impact of SARS-CoV-2 vaccination depends on the cumulative population-level infection incidence when vaccination begins, the duration of natural immunity, the trajectory of the epidemic prior to vaccination, and the level of healthcare available to effectively treat those with disease. Within a country we find that for a limited supply (doses for < 20% of the population) the optimal strategy is to target the elderly. However, with a larger supply, if vaccination can occur while other interventions are maintained, the optimal strategy switches to targeting key transmitters to indirectly protect the vulnerable. As supply increases, vaccines that reduce or block infection have a greater impact than those that prevent disease alone due to the indirect protection provided to high-risk groups. Given a 2 billion global dose supply in 2021, we find that a strategy in which doses are allocated to countries proportional to population size is close to optimal in averting deaths and aligns with the ethical principles agreed in pandemic preparedness planning. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Hogan, Alexandra B.; Winskill, Peter; Watson, Oliver J.; Walker, Patrick G. T.; Whittaker, Charles; Baguelin, Marc; Brazeau, Nicholas F.; Charles, Giovanni D.; Gaythorpe, Katy A. M.; Hamlet, Arran; Knock, Edward; Laydon, Daniel J.; Lees, John A.; Lochen, Alessandra; Verity, Robert; Whittles, Lilith K.; Hauck, Katharina; Ferguson, Neil M.; Ghani, Azra C.] Imperial Coll London, MRC Ctr Global Infect Dis Anal, Sch Publ Hlth, St Marys Campus,Norfolk Pl, London W2 1PG, England; [Hogan, Alexandra B.; Winskill, Peter; Watson, Oliver J.; Walker, Patrick G. T.; Whittaker, Charles; Baguelin, Marc; Brazeau, Nicholas F.; Charles, Giovanni D.; Gaythorpe, Katy A. M.; Hamlet, Arran; Knock, Edward; Laydon, Daniel J.; Lees, John A.; Lochen, Alessandra; Verity, Robert; Whittles, Lilith K.; Hauck, Katharina; Ferguson, Neil M.; Ghani, Azra C.] Imperial Coll London, Abdul Latif Jameel Inst Dis & Emergency Analyt, Sch Publ Hlth, St Marys Campus,Norfolk Pl, London W2 1PG, England; [Muhib, Farzana] PATH, 455 Massachusetts Ave NW,Suite 1000, Washington, DC 20001 USA; [Baguelin, Marc] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England		Hogan, AB (通讯作者)，Imperial Coll London, MRC Ctr Global Infect Dis Anal, Sch Publ Hlth, St Marys Campus,Norfolk Pl, London W2 1PG, England.; Hogan, AB (通讯作者)，Imperial Coll London, Abdul Latif Jameel Inst Dis & Emergency Analyt, Sch Publ Hlth, St Marys Campus,Norfolk Pl, London W2 1PG, England.	a.hogan@imperial.ac.uk; p.winskill@imperial.ac.uk; o.watson15@imperial.ac.uk; patrick.walker06@im-perial.ac.uk; charles.whittaker16@imperial.ac.uk; m.baguelin@imperial.ac.uk; n.brazeau@imperial.ac.uk; gc1610@imperial.ac.uk; k.gaythorpe@imperial.ac.uk; arran.hamlet14@imperial.ac.uk; e.knock@imperial.ac.uk; d.laydon@imperial.ac.uk; j.lees@imperial.ac.uk; a.lochen17@imperial.ac.uk; r.verity@imperial.ac.uk; l.whit-tles@imperial.ac.uk; fmuhib@path.org; k.hauck@imperial.ac.uk; neil.ferguson@imperial.ac.uk; a.ghani@imperial.ac.uk		Gaythorpe, Katy/0000-0003-3734-9081; Whittaker, Charlie/0000-0002-5003-2575; Lees, John/0000-0001-5360-1254; Hauck, Katharina/0000-0003-3138-4169	Imperial College LondonGeneral Electric; Wellcome TrustWellcome Trust; UK Foreign, Common-wealth & Development Office (FCDO) [221350/Z/20/Z]; Medical Research Council (MRC) Doctoral Training Programme studentshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Bill and Melinda Gates FoundationBill & Melinda Gates Foundation; UK MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/R015600/1]; UK FCDO [MR/R015600/1]; European UnionEuropean Commission; NIHR HPRU in Modelling and Health Economics [NIHR200908]; Vaccine Efficacy Evaluation for Priority Emerging Diseases (VEEPED) from the National Institute for Health Research [NIHR: PR-OD-1017-20002]; Community Jameel	PW and ABH acknowledge fellowship funding from Imperial College London. PGTW, OJW, ACG and NMF acknowledge grant funding from The Wellcome Trust and the UK Foreign, Common-wealth & Development Office (FCDO) (reference 221350/Z/20/Z). CW acknowledges support through a Medical Research Council (MRC) Doctoral Training Programme studentship. NB, GC and ACG acknowledge support from the Bill and Melinda Gates Foundation. All authors acknowledge funding support for the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK MRC and the UK FCDO, under the MRC/FCDO Concordat agreement, also part of the EDCTP2 programme supported by the European Union. NMF and KH acknowledge funding by Community Jameel. NMF acknowledges support from the NIHR HPRU in Modelling and Health Economics, a partnership between PHE, Imperial College London and LSHTM (grant code NIHR200908). DJL and NMF acknowledge funding from Vaccine Efficacy Evaluation for Priority Emerging Diseases (VEEPED) grant (reference NIHR: PR-OD-1017-20002) from the National Institute for Health Research. ACG, ABH, MB, and PW received personal fees from the World Health Organization in relation to developing the online interface (approximately GBP 1,000 per individual), and the WHO provided input into the design of and data underpinning the online interface. The funders had no other role in study design, conduct, or interpretation of results. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Disclaimer: The views expressed are those of the authors and not necessarily those of the United Kingdom (UK) Department of Health and Social Care, the National Health Service, the National Institute for Health Research (NIHR), or Public Health England (PHE).	Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; Arinaminpathy N, 2017, AM J EPIDEMIOL, V186, P92, DOI 10.1093/aje/kwx037; Babus A, 2020, OPTIMAL ALLOCATION C, DOI [10.1101/2020.07.22.20160143, DOI 10.1101/2020.07.22.20160143]; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; BBC, 2020, BBC; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bradley AJ, 1999, BBA-BIOMEMBRANES, V1418, P19, DOI 10.1016/S0005-2736(99)00013-9; Brazeau NF, 2020, REPORT 34 COVID 19 I, DOI [10.25561/83545, DOI 10.25561/83545]; Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810; Bubar KM, 2021, SCIENCE, V371, P916, DOI 10.1126/science.abe6959; Chen X, 2021, SCIENCE, DOI [10.1101/2020.08.23.20179820, DOI 10.1126/science.abe6959]; Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Craven J, 2021, REGUL AFF PROF SOC; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Davies NG, 2020, MEDRXIV, DOI [10.1101/2020.12.24.20248822, DOI 10.1101/2021.02.01.21250959, 10.1126/science.abg3055]; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Emanuel EJ, 2020, SCIENCE, V369, P1309, DOI 10.1126/science.abe2803; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Gavi. Gavi, 2020, 92 LOWAND MIDDLE INC; GAVI GAVI, ENS GLOB EQ ACC COVI; Hall M., 2020, ISARIC COVID 19 CLIN, DOI [10.1101/2020.07.17.20155218, DOI 10.1101/2020.07.17.20155218]; Hall V., 2020, DO ANTIBODY POSITIVE, DOI [10.1101/2021.01.13.21249642, DOI 10.1101/2021.01.13.21249642]; Hall VJ., 2021, SSRN ELECT J, DOI [10.2139/ssrn.3790399, DOI 10.2139/SSRN.3790399]; Hansen CH, 2021, LANCET, V6736, P1; Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008; Institute of Global Health Innovation. Institute of Global Health Innovation, 2020, YOUGOV COVID 19 GLOB; Intensive Care National Audit & Research Centre, 2020, ICNARC REPORT COVID; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jentsch PC, 2021, LANCET INFECT DIS, V21, P1097, DOI 10.1016/S1473-3099(21)00057-8; Jones NK, 2021, ELIFE, V10, DOI 10.7554/eLife.68808; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Mahase E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2815; Matrajt L, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf1374; Ministerio de Ciencia e Innovaciaon Gobierno de Espana Ministerio de Sanidad Gobierno de Espana Consejo Interterritorial Instituto de Salud Carlos III, 2020, ESTUDIO NACL SERO EP; MRC Centre for Global Infectious Disease Analysis Imperial College London. MRC Centre for Global Infectious Disease Analysis Imperial College London, 2021, FUT SCEN HEALTHC BUR; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Persad G, 2009, LANCET, V373, P423, DOI 10.1016/S0140-6736(09)60137-9; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Public Health England. Public Health England, 2021, PHE MONITORING EARLY; Russell FM, 2021, HUM VACC IMMUNOTHER, V17, P1317, DOI 10.1080/21645515.2020.1827882; Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517; Schumacher D., 2020, OMPR MODEL SOLVE MIX; Stone J., 2020, INDEPENDENT; To Kelvin Kai-Wang, 2021, Clin Infect Dis, V73, pe2946, DOI 10.1093/cid/ciaa1275; United Nations United Nations, 2020, UN WORLD POPULATION; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walker PGT, 2020, SCIENCE, V369, P413, DOI 10.1126/science.abc0035; WHO, 2021, NATL HLTH WORKFORCE; World Bank, 2020, DATABANK WORLD DEV I; World Health Organization, 2019, COR DIS COVID 19 OUT, P1; World Health Organization, 2020, 172 COUNTRIES MULTIP; World Health Organization, 2020, WHO TARGET PRODUCT P; World Health Organization (WHO) WHO, 2020, ETHICS COVID 19 RESO; Worldometer, COR UPD; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	61	11	11	8	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 21	2021	39	22					2995	3006		10.1016/j.vaccine.2021.04.002			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SE0YP	33933313	Green Submitted, hybrid, Green Published			2022-04-29	WOS:000651801800009
J	Ito, S; Nakamura, J; Fukuta, M; Ura, T; Teshigawara, T; Fukushima, J; Mizuki, N; Okuda, K; Shimada, M				Ito, Saori; Nakamura, Jutaro; Fukuta, Michiko; Ura, Takehiro; Teshigawara, Takeshi; Fukushima, Jun; Mizuki, Nobuhisa; Okuda, Kenji; Shimada, Masaru			Prophylactic and therapeutic vaccine against Pseudomonas aeruginosa keratitis using bacterial membrane vesicles	VACCINE			English	Article						Vaccine; Pseudomonas aeruginosa keratitis; membrane vesicles (MVs); Mouse model	PASSIVE IMMUNOTHERAPY; PROTEOMIC ANALYSIS; PROTECTION; IMMUNIZATION; MICE; INFECTIONS; ADENOVIRUS; VIRULENCE; PROTEASES; IMPACT	Purpose: Pseudomonas aeruginosa (P. aeruginosa) infection is one of the major causes of keratitis. However, effective prophylactic and therapeutic vaccines against P. aeruginosa keratitis have yet to be developed. In this study, we explored the use of P. aeruginosa membrane vesicles (MVs) as a prophylactic vaccine as well as the use of immune sera derived from P. aeruginosa MV-immunized animals as a treat-ment for P. aeruginosa corneal infections in C57BL/6 mice. Methods: C57BL/6 mice were intramuscularly immunized with P. aeruginosa MVs; the mouse corneas were then scarified and topically infected with several P. aeruginosa strains, followed by determination of corneal clinical score and corneal bacterial load. Next, immune sera derived from P. aeruginosa MV-immunized ICR mice were administered intraperitoneally to na & iuml;ve C57BL/6 mice, followed by topical P. aeruginosa challenge. Finally, the immune sera were also used as a topical treatment in the mice with established P. aeruginosa corneal infections. Results: P. aeruginosa-specific IgG and IgA antibodies induced by intramuscular immunization were detected not only in the sera but also in the eye-wash solution. Both active and passive immunization significantly inhibited P. aeruginosa corneal infection. Finally, topical treatment with immune sera in the mice with established P. aeruginosa corneal infections notably decreased the corneal clinical score and corneal bacterial load. Conclusions: P. aeruginosa keratitis can be attenuated by vaccination of P. aeruginosa MVs and topical application of P. aeruginosa MV-specific immune sera. (c) 2021 Elsevier Ltd. All rights reserved.	[Ito, Saori; Nakamura, Jutaro; Fukuta, Michiko; Ura, Takehiro; Mizuki, Nobuhisa] Yokohama City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Yokohama, Kanagawa 2360004, Japan; [Teshigawara, Takeshi] Yokosuka Chuoh Eye Clin, Dept Ophthalmol, Yokosuka, Kanagawa 2380008, Japan; [Fukushima, Jun] Akita Prefectural Univ, Dept Microbiol, Akita 0100195, Japan; [Okuda, Kenji; Shimada, Masaru] Yokohama City Univ, Grad Sch Med, Dept Mol Biodef Res, Yokohama, Kanagawa 2360004, Japan; [Okuda, Kenji] Okuda Vaccine Res Inst, Yokohama, Kanagawa 2350045, Japan; [Okuda, Kenji] Yokohama City Univ, Yokohama, Kanagawa 2360004, Japan		Shimada, M (通讯作者)，Yokohama City Univ, Grad Sch Med, Dept Mol Biodef Res, Yokohama, Kanagawa 2360004, Japan.	mshimada@yokohama-cu.ac.jp		Shimada, Masaru/0000-0002-5271-4238; Nakamrua, Jutaro/0000-0002-5565-5050; Teshigawara, Takeshi/0000-0001-8264-101X	Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [26462531, 17K11288, 20K09603]	This work was partially supported by a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No.26462531, No.17K11288 and 20K09603).	Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Balczon R, 2019, FASEB J, V33, P10300, DOI 10.1096/fj.201900322R; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; Brown L, 2015, NAT REV MICROBIOL, V13, P620, DOI 10.1038/nrmicro3480; Chatzinikolaou I, 2000, ARCH INTERN MED, V160, P501, DOI 10.1001/archinte.160.4.501; Choi DS, 2011, PROTEOMICS, V11, P3424, DOI 10.1002/pmic.201000212; Choo JD, 2009, OPTOMETRY VISION SCI, V86, P93, DOI 10.1097/OPX.0b013e318194e973; Cohen J., 1988, STAT POWER ANAL BEHA; Costa I, 2014, MBIO, V5, DOI 10.1128/mBio.01625-14; Avila-Calderon ED, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/352493; Dannelly HK, 2001, ARCH MICROBIOL, V177, P47, DOI 10.1007/s00203-001-0360-8; DAVIS SD, 1975, ANTIMICROB AGENTS CH, V8, P350, DOI 10.1128/AAC.8.3.350; Domingues S, 2017, CURR OPIN MICROBIOL, V38, P16, DOI 10.1016/j.mib.2017.03.012; Ekanayaka SA, 2016, INVEST OPHTH VIS SCI, V57, P5799, DOI 10.1167/iovs.16-20103; Ellen AF, 2009, EXTREMOPHILES, V13, P67, DOI 10.1007/s00792-008-0199-x; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; GERKE JR, 1977, INVEST OPHTH VIS SCI, V16, P76; Hazlett LD, 2000, INVEST OPHTH VIS SCI, V41, P805; Hertle R, 2001, INFECT IMMUN, V69, P6962, DOI 10.1128/IAI.69.11.6962-6969.2001; HESSBURG PC, 1962, AM J OPHTHALMOL, V53, P359, DOI 10.1016/0002-9394(62)91187-X; HIRAO Y, 1978, JPN J EXP MED, V48, P41; Hobden JA, 2002, DNA CELL BIOL, V21, P391, DOI 10.1089/10445490260099674; Hosking J, 2007, CLIN VACCINE IMMUNOL, V14, P1393, DOI 10.1128/CVI.00167-07; Hue B, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/794935; Jain R, 2014, CORNEA, V33, P22, DOI 10.1097/ICO.0000000000000011; Kao DJ, 2009, CHEM BIOL DRUG DES, V74, P33, DOI 10.1111/j.1747-0285.2009.00825.x; Keenan JI, 1998, FEMS MICROBIOL LETT, V161, P21, DOI 10.1111/j.1574-6968.1998.tb12924.x; Keiser PB, 2011, VACCINE, V29, P1413, DOI 10.1016/j.vaccine.2010.12.039; Koeberling O, 2014, VACCINE, V32, P2688, DOI 10.1016/j.vaccine.2014.03.068; Konda N, 2014, OPTOMETRY VISION SCI, V91, P47, DOI 10.1097/OPX.0000000000000082; Kovacs-Simon A, 2011, INFECT IMMUN, V79, P548, DOI 10.1128/IAI.00682-10; KREGER AS, 1986, INVEST OPHTH VIS SCI, V27, P932; Lister PD, 2009, CLIN MICROBIOL REV, V22, P582, DOI 10.1128/CMR.00040-09; Maisonneuve C, 2014, P NATL ACAD SCI USA, V111, P12294, DOI 10.1073/pnas.1400478111; Masinick SA, 1997, INVEST OPHTH VIS SCI, V38, P910; Matsumoto T, 1999, J MED MICROBIOL, V48, P765, DOI 10.1099/00222615-48-8-765; MOON MM, 1988, INVEST OPHTH VIS SCI, V29, P1277; Muralinath M, 2011, INFECT IMMUN, V79, P887, DOI 10.1128/IAI.00950-10; Norina TJ, 2008, SINGAP MED J, V49, P67; PENN W P, 1963, Antimicrob Agents Chemother (Bethesda), V161, P411; Petousis-Harris H, 2018, HUM VACC IMMUNOTHER, V14, P1058, DOI 10.1080/21645515.2017.1381810; Pierson T, 2011, J PROTEOME RES, V10, P954, DOI 10.1021/pr1009756; Prados-Rosales R, 2011, J CLIN INVEST, V121, P1471, DOI 10.1172/JCI44261; Preston MJ, 1997, INFECT IMMUN, V65, P3086, DOI 10.1128/IAI.65.8.3086-3090.1997; Roberts R, 2008, VACCINE, V26, P4639, DOI 10.1016/j.vaccine.2008.07.004; Robertson DM, 2011, INVEST OPHTH VIS SCI, V52, P2844, DOI 10.1167/iovs.10-6469; Rodrigues FMP, 2020, JAMA-J AM MED ASSOC, V324, P2187, DOI 10.1001/jama.2020.20449; Saha S, 2007, J IMMUNOL, V179, P1147, DOI 10.4049/jimmunol.179.2.1147; Saha S, 2006, VACCINE, V24, P6240, DOI 10.1016/j.vaccine.2006.05.077; Samadi PM, 2019, IRAN J BASIC MED SCI, V22, P58, DOI 10.22038/ijbms.2018.31499.7643; Sardinas G, 2006, VACCINE, V24, P206, DOI 10.1016/j.vaccine.2005.07.064; Sheth H B, 1995, Biomed Pept Proteins Nucleic Acids, V1, P141; Siegman-Igra Y, 1998, Int J Infect Dis, V2, P211, DOI 10.1016/S1201-9712(98)90055-8; TANAKA E, 1991, J BACTERIOL, V173, P6153, DOI 10.1128/jb.173.19.6153-6158.1991; van der Ley P, 2001, INFECT IMMUN, V69, P5981, DOI 10.1128/IAI.69.10.5981-5990.2001; van der Pol L, 2015, BIOTECHNOL J, V10, P1689, DOI 10.1002/biot.201400395; Wang HB, 2010, GENE THER, V17, P4, DOI 10.1038/gt.2009.122; Worgall S, 2005, J CLIN INVEST, V115, P1281, DOI 10.1172/JCI200523135; Wu YT, 2015, OPTOMETRY VISION SCI, V92, P659, DOI 10.1097/OPX.0000000000000597; Zaidi TS, 2006, INFECT IMMUN, V74, P975, DOI 10.1128/IAI.74.2.975-983.2006; Zepp F, 2010, VACCINE, V28, pC14, DOI 10.1016/j.vaccine.2010.07.020; Zhao KL, 2013, INFECT IMMUN, V81, P4509, DOI 10.1128/IAI.01008-13	62	1	1	3	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 27	2021	39	23					3152	3160		10.1016/j.vaccine.2021.04.035		MAY 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SF2TJ	33934918				2022-04-29	WOS:000652613400006
J	Kimura, S; Maeda, K; Nagashima, R; Miura, K; Arakawa, M; Ebina, H; Tanaka, N; Morita, E				Kimura, Sakika; Maeda, Koki; Nagashima, Ryuichi; Miura, Koya; Arakawa, Masashi; Ebina, Hirotaka; Tanaka, Nobuyuki; Morita, Eiji			Efficient immunogenic peptide antigen delivery to dendritic cells using an ESCRT-mediated extracellular vesicle formation method	VACCINE			English	Article						Vaccine development; Extracellular vesicle designing; Cytotoxic T lymphocyte activation; Cell-mediated immunity; Endosomal sorting complexes required for; transport (ESCRT)	PROTEINS; EXOSOMES; BINDING	In the activation of cell-mediated adaptive immune responses that play major roles in the elimination of virus-infected or tumor cells, it is important that dendritic cells present antigen peptides on major histocompatibility complex (MHC) class I molecules and activate pathogen-specific cytotoxic T lymphocytes (CTL). As exogenous peptide antigens are generally presented on MHC class II but not class I, the development of a method for exogenous antigen delivery that facilitates MHC class I presentation is necessary for a potentially effective vaccine that is expected to provoke cell-mediated adaptive immune responses. Here, we developed extracellular vesicles that incorporate antigenic proteins by utilizing endosomal sorting complexes required for transport (ESCRT)-mediated vesicle formation pathway. Furthermore, we proved that these vesicles could deliver their contents to the cytoplasm of dendritic cells and activate antigen-specific CTLs. These technologies could be applied to the development of novel CTL-inducing peptide vaccines. (c) 2021 Elsevier Ltd. All rights reserved.	[Kimura, Sakika; Maeda, Koki; Miura, Koya; Arakawa, Masashi; Morita, Eiji] Hirosaki Univ, Fac Agr & Life Sci, Dept Biochem & Mol Biol, 3 Bunkyo Cho, Hirosaki, Aomori 0368561, Japan; [Nagashima, Ryuichi; Tanaka, Nobuyuki] Miyagi Canc Ctr Res Inst, Div Canc Biol & Therapeut, Natori, Miyagi, Japan; [Ebina, Hirotaka] Osaka Univ, Inst Open & Transdisciplinary Res Initiat, BIKEN Innovat Vaccine Res Alliance Labs, Virus Vaccine Grp, Osaka, Japan; [Ebina, Hirotaka] Osaka Univ, Res Inst Microbial Dis, BIKEN Innovat Vaccine Res Alliance Labs, Virus Vaccine Grp, Suita, Osaka, Japan; [Ebina, Hirotaka] Osaka Univ, Res Fdn Microbial Dis, Suita, Osaka, Japan; [Tanaka, Nobuyuki] Tohoku Univ, Dept Canc Biol & Therapeut, Grad Sch Med, Sendai, Miyagi, Japan		Morita, E (通讯作者)，Hirosaki Univ, Fac Agr & Life Sci, Dept Biochem & Mol Biol, 3 Bunkyo Cho, Hirosaki, Aomori 0368561, Japan.	moritae@hirosaki-u.ac.jp			Japan Society for the Promotion of Science (JSPS) KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23790503, 26460555, 16H01188, 17H06413, 20K21874]; AMED Grant for Research on Emerging and Re-emerging Infectious Diseases [20333747, 19fk0108168h0001, 20he0622012h0001]; JST CREST, JapanCore Research for Evolutional Science and Technology (CREST) [JPMJCR17H4]; Takeda Medical Research Foundation, Japan	This research was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Numbers 23790503, 26460555, 16H01188, 17H06413, and 20K21874) and AMED Grant for Research on Emerging and Re-emerging Infectious Diseases (Grant Number 20333747, 19fk0108168h0001, 20he0622012h0001). This work was also supported by JST CREST, Grant Number JPMJCR17H4, Japan, and the Takeda Medical Research Foundation, Japan.	BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.iy.12.040194.003511; de Vries E, 2020, TRENDS MICROBIOL, V28, P57, DOI 10.1016/j.tim.2019.08.010; Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002; Elsharkasy OM, 2020, ADV DRUG DELIVER REV, V159, P332, DOI 10.1016/j.addr.2020.04.004; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/NMETH.1318, 10.1038/nmeth.1318]; Hayashi N, 2010, P JPN ACAD B-PHYS, V86, P494, DOI 10.2183/pjab.86.494; Huang L, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807189; Hung ME, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.31027; Ishida K, 2019, J VIROL, V93, DOI 10.1128/JVI.00612-19; Kooijmans SAA, 2013, J CONTROL RELEASE, V172, P229, DOI 10.1016/j.jconrel.2013.08.014; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; Malonis RJ, 2020, CHEM REV, V120, P3210, DOI 10.1021/acs.chemrev.9b00472; Mentkowski KI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46407-1; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Puertollano R, 2005, J BIOL CHEM, V280, P9258, DOI 10.1074/jbc.M412481200; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Roche S, 2008, CELL MOL LIFE SCI, V65, P1716, DOI 10.1007/s00018-008-7534-3; Schoneberg J, 2017, NAT REV MOL CELL BIO, V18, P5, DOI 10.1038/nrm.2016.121; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; Votteler J, 2013, CELL HOST MICROBE, V14, P232, DOI 10.1016/j.chom.2013.08.012; Votteler J, 2016, NATURE, V540, P292, DOI 10.1038/nature20607; Yim N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12277	24	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 21	2021	39	22					2976	2982		10.1016/j.vaccine.2021.04.021		MAY 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SE0YP	33926749				2022-04-29	WOS:000651801800006
J	Wang, JH; Lyu, Y; Zhang, HJ; Jing, RZ; Lai, XZ; Feng, HYF; Knoll, MD; Fang, H				Wang, Jiahao; Lyu, Yun; Zhang, Haijun; Jing, Rize; Lai, Xiaozhen; Feng, Huangyufei; Knoll, Maria Deloria; Fang, Hai			Willingness to pay and financing preferences for COVID-19 vaccination in China	VACCINE			English	Article						SARS-CoV-2; COVID-19; Vaccine; Willingness to pay; Financing	INFLUENZA; VACCINES; COVERAGE; DEMAND	Background: The COVID-19 pandemic has caused significant diseases and economic burdens in the world. Vaccines are often considered as a cost-effective way to prevent and control infectious diseases, and the research and development of COVID-19 vaccines have been progressing unprecedently. It is needed to understand individuals' willingness to pay (WTP) among general population, which provides information about social demand, access and financing for future COVID-19 vaccination. Objective: To investigate individuals' WTP and financing mechanism preference for COVID-19 vaccination during the pandemic period in China. Methods: During March 1-18, 2020, we conducted a network stratified random sampling survey with 2058 respondents in China. The survey questionnaires included out-of-pocket WTP, financing mechanism preference as well as basic characteristics of the respondents; risk perception and impact of the COVID-19 pandemic; attitude for future COVID-19 vaccination. Multivariable Tobit regression was used to determine impact factors for respondents' out-of-pocket WTP. Results: The individuals' mean WTP for full COVID-19 vaccination was CNY 254 (USD 36.8) with median of CNY 100 (USD 14.5). Most respondents believed that governments (90.9%) and health insurance (78.0%) needed to pay for some or full portions of COVID-19 vaccination, although 84.3% stated that individuals needed to pay. Annual family income, employee size in the workplace, and whether considering the COVID-19 pandemic in China in a declining trend affected respondents' WTP significantly. Conclusion: The findings demonstrated the individuals' WTP for COVID-19 vaccination in China and their preferences for financing sources from individuals, governments and health insurance. And to suggest an effective and optimal financing strategy, the public health perspective with equal access to COVID-19 vaccination should be prioritized to ensure a high vaccination rate. (C) 2021 Published by Elsevier Ltd.	[Wang, Jiahao; Lyu, Yun; Zhang, Haijun; Jing, Rize; Lai, Xiaozhen; Feng, Huangyufei] Peking Univ, Sch Publ Hlth, Beijing 100083, Peoples R China; [Wang, Jiahao; Lyu, Yun; Zhang, Haijun; Jing, Rize; Lai, Xiaozhen; Feng, Huangyufei; Fang, Hai] Peking Univ, China Ctr Hlth Dev Studies, Beijing 100083, Peoples R China; [Knoll, Maria Deloria] Johns Hopkins Univ, Int Vaccine Access Ctr, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Fang, Hai] Peking Univ Hlth Sci Ctr Chinese Ctr Dis Control, Beijing 100083, Peoples R China; [Fang, Hai] Natl Hlth Commiss Peoples Republ China, Key Lab Reprod Hlth, Beijing 100083, Peoples R China		Fang, H (通讯作者)，Peking Univ, China Ctr Hlth Dev Studies, Beijing 100083, Peoples R China.	jiahaowang@pku.edu.cn; yun.lyu@bjmu.edu.cn; haijunzhang@pku.edu.cn; rzjing2015@hsc.pku.edu.cn; laixiaozhen@pku.edu.cn; yffenghuang@pku.edu.cn; mknoll2@jhu.edu; hfang@hsc.pku.edu.cn	Wang, Jiahao/ABA-3280-2021	Wang, Jiahao/0000-0001-7575-6580; Deloria Knoll, Maria/0000-0001-9041-2671; Jing, Rize/0000-0002-1469-909X	Peking University (PKU); Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities	This research was supported by the Special Research Fund of Peking University (PKU) for the Prevention and Control of COVID-19 and the Fundamental Research Funds for the Central Universities.	[Anonymous], COVID 19 COUNTRIES A; [Anonymous], COVID 19 VACCINES ET; [Anonymous], CHINAS BASIC MED; [Anonymous], ANHUI STARTS ITS EME; [Anonymous], OPINION COVID 19 VAC; [Anonymous], PRESS C JOINT PREV C; [Anonymous], 2020, PRESS C JOINT PREV C; [Anonymous], NOTICE GEN OFFICE ST; [Anonymous], WHO CORONAVIRUS DIS; [Anonymous], 140 ROUT PRESS C PRE; [Anonymous], GOVT PAY 200 YUAN DO; [Anonymous], DOES COVID 19 COMPAR; [Anonymous], ENSURING COVID 19 VA, DOI [10.1377/hblog20200327.868172/full/, DOI 10.1377/HBLOG20200327.868172/FULL]; [Anonymous], CAPITA DISPOSABLE IN; [Anonymous], PPP conversion factor, GDP (LCU per international $)-Iran, Islamic Rep; [Anonymous], Draft landscape of COVID-19 candidate vaccines; Asgary A, 2012, SCAND J PUBLIC HEALT, V40, P412, DOI 10.1177/1403494812453884; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575; Enami T., 2010, JMAJ - Japan Medical Association Journal, V53, P111; European Commission, CORONAVIRUS VACCINES; Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802; Frew EJ, 2004, HEALTH POLICY, V68, P289, DOI 10.1016/j.healthpol.2003.10.003; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Guo N, 2017, VACCINE, V35, P2848, DOI 10.1016/j.vaccine.2017.04.006; Harapan H, 2017, HUM VACC IMMUNOTHER, V13, P786, DOI 10.1080/21645515.2016.1259045; Hinman AR, 2004, CLIN INFECT DIS, V38, P1445, DOI 10.1086/420748; Hou ZY, 2014, VACCINE, V32, P4471, DOI 10.1016/j.vaccine.2014.06.047; Immunization Financing A Resource Guide For Advocates, POLICYMAKERS PROGRAM; Irwin KL, 2017, VACCINE, V35, P6915, DOI 10.1016/j.vaccine.2017.06.026; Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Lv M, 2016, VACCINE, V34, P2135, DOI 10.1016/j.vaccine.2016.02.032; MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9; Meng, 2014, CHINESE HLTH EC, V033, P86; Nationwide, HLTH INSURANCE PAID; Painter JE, 2018, HUM VACC IMMUNOTHER, V14, P1665, DOI 10.1080/21645515.2018.1423928; Pereira CCA, 2011, VACCINE, V29, P1443, DOI 10.1016/j.vaccine.2010.12.027; Q&A, WORLD BANKS COVID 19; Rosenstock I.M., 1990, HLTH BEHAV HLTH ED T, P39; RUSSELL S, 1995, HEALTH POLICY PLANN, V10, P94, DOI 10.1093/heapol/10.1.94; Saif L. J., 2020, EUR MED J, V1, DOI [10.33590/emj/ 200324., DOI 10.33590/EMJ/200324]; Sarasty O, 2020, VACCINE, V38, P8090, DOI 10.1016/j.vaccine.2020.11.013; Tian HY, 2020, SCIENCE, V368, P638, DOI 10.1126/science.abb6105; Ughasoro MD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003838; Wang Q, 2018, VACCINE, V36, P7262, DOI 10.1016/j.vaccine.2018.10.045; WHO, 2020, WHO DIRECTOR GEN OPE; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, 2014, PRINCIPLES CONSIDERA; Wu SQ, 2013, BMC PUBLIC HEALTH, V13, DOI [10.1186/1471-2458-13-320, 10.1186/1471-2458-13-636]; Yu WZ, 2018, VACCINE, V36, P3041, DOI 10.1016/j.vaccine.2018.04.008; Zheng YM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3422-0	53	10	10	8	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 1	2021	39	14					1968	1976		10.1016/j.vaccine.2021.02.060		MAR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RC7NX	33714653	Bronze, Green Published			2022-04-29	WOS:000632984100013
J	Zhang, ZJZ; Pan, JB; Chen, M; Zhang, TG; Li, J; Lu, L				Zhang, Zhujiazi; Pan, Jingbin; Chen, Meng; Zhang, Tiegang; Li, Juan; Lu, Li			Seroepidemiology of pertussis in China: A population-based, cross-sectional study	VACCINE			English	Article						Pertussis; Anti-PT IgG; Seroepidemiology; Immunisation		Background: Despite high pertussis vaccination coverage and significant decrease of pertussis since the adoption of the Expanded Programme on Immunization (1978), increased pertussis incidence has been reported in China from 2013 to 2017. This study aimed at evaluating the immune response to pertussis among vaccinated children and beyond in China. Methods: The study recruited 2 144 healthy subjects. Serum IgG antibodies against pertussis toxin (anti-PT IgG) were measured by ELISA. Anti-PT IgG concentration (GMC), seropositivity rate (GMC >= 40 IU/ml), and recent infection rate (GMC > 100 IU/ml) were calculated. Participants <= 2 years-old were further stratified by vaccination schedule intervals and participants <= 6 years-old by vaccine used (Domestic DTaP or DTaP-IPV//PRP similar to T (Pentaxim, SP)). Results: Among 0-6-year-olds, the anti-PT IgG GMC was 5.99 IU/ml (95%CI 5.39-6.67). The GMC increased in accordance with the primary vaccination series (4-6 months) and the toddler booster (18-23 months), and continuously declined thereafter to its nadir at 6 years-old [3.72 IU/ml (95%CI 2.91-4.77)]. GMCs were markedly higher in those vaccinated with DTaP-IPV/PRP similar to T compared to DTaP. In individuals > 6 years-old, the GMC was 5.67 IU/ml (95%CI 5.36-6.00), the seropositivity rate was 6.7% (95%CI 5.5-7.9) and the recent infection rate was 1.2% (95%CI 0.7-1.7). The seropositivity rates increased from 6 years-old and peaked at 9 years-old (10.3% [95%CI 0.7-19.8]). Conclusions: Vaccination against pertussis increases anti-PT IgG, but wanes over time. The sero-estimated infection rates increase from school age and peak at about 9 years-old. These results support the addition of a booster of pertussis vaccine at preschool age. (C) 2021 Elsevier Ltd. All rights reserved.	[Zhang, Zhujiazi; Pan, Jingbin; Chen, Meng; Zhang, Tiegang; Li, Juan; Lu, Li] Beijing Ctr Dis Prevent & Control, Beijing Res Ctr Prevent Med, Dept Immunizat & Prevent, He Ping Li Zhong Jie 16, Beijing 100013, Peoples R China		Lu, L (通讯作者)，Beijing Ctr Dis Prevent & Control, Beijing Res Ctr Prevent Med, Dept Immunizat & Prevent, He Ping Li Zhong Jie 16, Beijing 100013, Peoples R China.	lulibj@sina.com					Abu Sin M, 2009, PEDIATR INFECT DIS J, V28, P242, DOI 10.1097/INF.0b013e31818a5d69; Ausiello CM, 2000, J INFECT DIS, V181, P1989, DOI 10.1086/315509; Barkoff AM, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv050; Campins-Marti M, 2001, VACCINE, V20, P641, DOI 10.1016/S0264-410X(01)00393-0; Cattaneo LA, 1996, J INFECT DIS, V173, P1256, DOI 10.1093/infdis/173.5.1256; de Celles MD, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaj1748; de Greeff SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014183; de Melker HE, 2000, J CLIN MICROBIOL, V38, P800, DOI 10.1128/JCM.38.2.800-806.2000; de Melker HE, 2006, J INFECTION, V53, P106, DOI 10.1016/j.jinf.2005.10.020; Drakes-Jamtberg K, 2019, 21 YEAR REPORT; Edwards KM, 2014, EXPERT REV VACCINES, V13, P1183, DOI 10.1586/14760584.2014.946015; Haller S, 2015, PEDIATR INFECT DIS J, V34, P513, DOI 10.1097/INF.0000000000000654; Hendrikx LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027681; Hethcote HW, 1999, MATH BIOSCI, V158, P47, DOI 10.1016/S0025-5564(99)00004-8; Huang H, 2015, EPIDEMIOL INFECT, V143, P1950, DOI 10.1017/S095026881400260X; Huang HT, 2018, VACCINE, V36, P7950, DOI 10.1016/j.vaccine.2018.11.009; Hviid A, 2006, VACCINE, V24, P1401, DOI 10.1016/j.vaccine.2005.09.019; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; Jogi P, 2014, VACCINE, V32, P5311, DOI 10.1016/j.vaccine.2014.07.066; KIMURA A, 1990, INFECT IMMUN, V58, P7, DOI 10.1128/IAI.58.1.7-16.1990; Li XM, 2015, HUM VACC IMMUNOTHER, V11, P2434, DOI 10.1080/21645515.2015.1062954; Liang XF., 2007, NATL IMMUNIZATION PR, V13, P245, DOI DOI 10.3969/J.ISSN.1006-916X.2007.03.015; Liu XG, 2018, PEDIATR INFECT DIS J, V37, pE145, DOI [10.1097/INF.0000000000001814, 10.1097/inf.0000000000001814]; Ma J, 2012, CHIN J VACC IMMUNIZ, V18, P207, DOI SUN:ZGJM.0.2012-03-006.; Minh NNT, 1999, PEDIATR INFECT DIS J, V18, P366, DOI 10.1097/00006454-199904000-00012; National Medical Products Administration, 2017, INV UNQ PROD DPAT VA; Ning G, 2018, ZHONGGUO YI MIAO HE, V24, P264; RAMSAY MEB, 1993, EPIDEMIOL INFECT, V111, P41, DOI 10.1017/S095026880005665X; Rendi-Wagner P, 2010, VACCINE, V28, P3285, DOI 10.1016/j.vaccine.2010.02.104; ROBERTS M, 1993, VACCINE, V11, P866, DOI 10.1016/0264-410X(93)90363-3; Sisi R, 2014, J CLIN PEDIAT, V32, P271; THOMAS MG, 1989, J INFECT DIS, V159, P211, DOI 10.1093/infdis/159.2.211; Vidor E, 2008, HUM VACCINES, V4, P328, DOI 10.4161/hv.4.5.6008; Wang LC, 2012, VACCINE, V30, P7174, DOI 10.1016/j.vaccine.2012.10.009; WHO, VACC PREV DIS MON SY; WHO Publication, 2011, VACCINE, V29, P2355, DOI 10.1016/j.vaccine.2010.11.059; Xu YH, 2015, HUM VACC IMMUNOTHER, V11, P421, DOI 10.4161/21645515.2014.988549; Xu YH, 2014, HUM VACC IMMUNOTHER, V10, P192, DOI 10.4161/hv.26335; YAO Kai-Hu, 2018, CHINESE J CONT PEDIA, V1, DOI [10.7499/j.issn.1008-8830.2018.01.001, DOI 10.7499/J.ISSN.1008-8830.2018.01.001]; Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0; Zhang Q, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-138; Zhang Q, 2011, J INFECTION, V63, P441, DOI 10.1016/j.jinf.2011.07.018; Zhu FC, 2011, HUM VACCINES, V7, P272, DOI 10.4161/hv.7.2.13861	43	1	1	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 19	2021	39	12					1687	1692		10.1016/j.vaccine.2021.02.032		MAR 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QX3ZD	33642160				2022-04-29	WOS:000629283700005
J	Amani, A; Tatang, CA; Bayiha, CN; Woung, M; Bama, SN; Nangmo, A; Mbang, MA; Douba, EE				Amani, Adidja; Tatang, Collins A.; Bayiha, Christian N.; Woung, Marcel; Bama, Solange Ngo; Nangmo, Armanda; Mbang, Marie A.; Douba, Emmanuel Epee			A reactive vaccination campaign with single dose oral cholera vaccine (OCV) during a cholera outbreak in Cameroon	VACCINE			English	Article						Cholera outbreak; Oral cholera vaccine; Reactive mass vaccination campaign; Single dose; Epidemic curve; Health district		Background: Cameroon chose Oral Cholera Vaccine (OCV) mass vaccination campaign in addition to other interventions to respond to outbreaks since 2015. There is still a persistent controversy on the effectiveness of reactive OCV mass vaccination campaign. Objective: This article aimed to share evidence-based observations on the effect of a reactive single-dose OCV mass vaccination campaign on cholera cases in Cameroon. Methods: Health area centered risk analysis was used to identify nine high risk health areas among four health districts in the North Region as hotspots. About 537,274 people at risk of cholera transmission one year of age and above including pregnant women were eligible to receive OCV. A total of 537,279 doses of OCV was deployed for vaccination from August 1-5, 2019 through door-to-door strategy for urban health districts, and fixed/ temporary fixed posts strategies for rural health districts. Results: The overall vaccination coverage was 99.9%. Vaccine wastage rate was less than 0.5% (0.0011%). Independent monitoring showed vaccination coverage at 97.2%. The 2019 epidemic curve went down after OCV intervention on the contrary to that in the year 2018 at the same period. After OCV intervention, cholera cases dropped from about 10.5 to 9.3 cases per week at the regional level while at the district level, they dropped from 5.3 to 2.1, 2.2 to 1.7, 0.6 to 0 and 1.7 to 1.5 cases per week respectively for Garoua, Garoua II, Tchollire and Pitoa. Though not statistically significant (p = 1.4, alpha = 0.05), cases per 1000 population seemed to remain unchanged among OCV zones (0.32/1000) and non-OCV zones (0.31/1000) in 2018 while they increased from 0.37 (OCV zones) to 0.53 (non-OCV zones) cases per 1000 population in 2019. Conclusion: There might have been a general trend in the reduction of the number of new cases after a reactive single-dose OCV campaign. (C) 2021 Elsevier Ltd. All rights reserved.	[Amani, Adidja; Tatang, Collins A.; Bama, Solange Ngo; Mbang, Marie A.] Minist Publ Hlth, Sub Directorate Vaccinat, Yaounde, Cameroon; [Bayiha, Christian N.] Minist Publ Hlth, Immunizat Serv Delivery Unit, EPI Cent Tech Grp, Yaounde, Cameroon; [Woung, Marcel; Douba, Emmanuel Epee] Country Off, WHO Hlth Emergency Program, Yaounde, Cameroon; [Nangmo, Armanda] Evodoula Dist Hosp, Evodoula, Cameroon		Tatang, CA (通讯作者)，Minist Publ Hlth, Sub Directorate Vaccinat, Yaounde, Cameroon.	sousdirectionvaccination@gmail.com					Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832; [Anonymous], 2011, WHA64 15; Ateudjieu J, 2017, ORAL CHOLERA VACCINE; Azman AS, 2016, LANCET GLOB HLTH; Bhattacharya SK, 2013, LANCET INFECT DIS; DeRoeck D, MANUAL ORAL CHOLERA; Djoufack V., 2011, ETUDE MULTIECHELLES; Ferreras E, 2018, NEW ENGL J MED; Institut National de la Statistique du Cameroun, 2015, ENQ GRAPP IND MULT M; Lopez AL, 2018, CLIN INFECT DIS; MINSANTE, PLAN NAT REP EP CHOL; MINSANTE, PLAN NAT CONT; MINSANTE WHO, 2018, HLTH POP DEN CAM; WHO, 2018, ANA RISQ CHOL CAM	14	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1290	1296		10.1016/j.vaccine.2021.01.017		FEB 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33494966				2022-04-29	WOS:000618493500018
J	Atsmon, J; Machluf, N; Yayon-Gur, V; Sabbah, C; Spaans, JN; Yassin-Rajkumar, B; Anderson, DE; Popovic, V; Diaz-Mitoma, F				Atsmon, Jacob; Machluf, Nathalie; Yayon-Gur, Vered; Sabbah, Cyril; Spaans, Johanna N.; Yassin-Rajkumar, Bebi; Anderson, David E.; Popovic, Vlad; Diaz-Mitoma, Francisco			Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study	VACCINE			English	Article						Hepatitis B; Vaccination; Immunogenicity; Seroprotection; Tri-antigenic		Background: Sci-B-Vac (R) is a tri-antigenic recombinant Hepatitis B vaccine (TAV) containing the small (s), medium (pre-S2) and large (pre-S1) hepatitis B surface (HBs) antigens. To comply with vaccine licensure, a new reference standard batch was qualified by characterizing the seroprotection rate (SPR) for anti-HBs titers >= 10 mIU/mL, following vaccination. Methods: Ninety-one healthy adults aged 20-40 years were enrolled in an open label, single-arm phase IV study receiving three IM doses of 10 mu g TAV at 0, 1 and 6 months. Immunogenicity was evaluated monthly and at 7, 9 and 12 months. The primary endpoint to qualify the reference standard was an SPR >= 95% by month 7. Secondary endpoints were proportion of high responders (anti-HBs titers >= 100 mIU/mL) and geometric mean concentrations (GMC) of HBs antibodies each month. Participants were followed for safety to month 12. Results: The primary endpoint was met 2 months after the second dose at month 3 [SPR 98.8%; 95% CI: 93.7%, 99.7%]. Proportion of high responders at months 3 and 7 were 81.4% and 97.6%, respectively. GMC at months 3 and 7 were 413.6 mIU/mL and 6799.9 mIU/mL, respectively. TAV was safe and well-tolerated. Conclusions: The new reference standard batch of TAV was qualified successfully, demonstrating efficacy, a favorable safety profile and a rapid onset of seroprotection, including after two vaccine doses. (C) 2020 The Authors. Published by Elsevier Ltd.	[Atsmon, Jacob] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; [Machluf, Nathalie; Yayon-Gur, Vered; Sabbah, Cyril] SciVac Ltd, IL-7610303 Rehovot, Israel; [Spaans, Johanna N.; Yassin-Rajkumar, Bebi; Anderson, David E.; Popovic, Vlad; Diaz-Mitoma, Francisco] VBI Vaccines Inc, Cambridge, MA USA		Diaz-Mitoma, F (通讯作者)，VBI Vaccines Inc, 310 Hunt Club Rd, Ottawa, ON K1V 1C1, Canada.	fdiazmitoma@vbivaccines.com		Diaz-Mitoma, Francisco/0000-0003-0292-4859	VBI Vaccines Inc.	The study was funded by VBI Vaccines Inc., the manufacturer of Sci-B-Vac (R).	FDA, 2007, GUID IND TOX GRAD SC; Guan R., 1993, P INT S VIR HEP LIV, P86; Hellstrom UB, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-7; Hourvitz A, 1996, J VIRAL HEPATITIS, V3, P37, DOI 10.1111/j.1365-2893.1996.tb00079.x; Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038; Kent SBH., 1990, ANTIGENIC STRUCTURE; Nelson JC, 2009, AM J PUBLIC HEALTH, V99, pS389, DOI 10.2105/AJPH.2008.151332; Pyrsopoulos N T, 2001, Curr Gastroenterol Rep, V3, P71, DOI 10.1007/s11894-001-0044-1; Raz R, 2001, ISRAEL MED ASSOC J, V3, P328; Raz R, 1996, VACCINE, V14, P207, DOI 10.1016/0264-410X(95)00185-4; Sarkar N, 2015, INT J MOL SCI, V16, P17746, DOI 10.3390/ijms160817746; Schumann A, 2007, J VIRAL HEPATITIS, V14, P592, DOI 10.1111/j.1365-2893.2007.00848.x; Shapira MY, 2001, J HEPATOL, V34, P123, DOI 10.1016/S0168-8278(00)00082-9; SHOUVAL D, 1994, VACCINE, V12, P1453, DOI 10.1016/0264-410X(94)90155-4; Shouval D., 1993, VIRAL HEPATITIS LIVE, P543; Shouval D, 2015, MED MICROBIOL IMMUN, V204, P57, DOI 10.1007/s00430-014-0374-x; Tohme RA, 2011, VACCINE, V29, P9316, DOI 10.1016/j.vaccine.2011.10.011; Van Den Ende C, 2017, EXPERT REV VACCINES, V16, P811, DOI 10.1080/14760584.2017.1338568; Van Der Meeren O, 2015, HUM VACC IMMUNOTHER, V11, P1726, DOI 10.1080/21645515.2015.1039758; Vesikari T., LANCET INFECT DIS; Wilson JN, 2007, VACCINE, V25, P3705, DOI 10.1016/j.vaccine.2007.01.012; Yang SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27251; YAP I, 1992, VACCINE, V10, P439, DOI 10.1016/0264-410X(92)90391-V; YAP I, 1995, J GASTROEN HEPATOL, V10, P51, DOI 10.1111/j.1440-1746.1995.tb01047.x; Yerushalmi B, 1997, PEDIATR INFECT DIS J, V16, P587, DOI 10.1097/00006454-199706000-00009	25	4	4	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1328	1332		10.1016/j.vaccine.2020.12.050		FEB 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33451780	hybrid			2022-04-29	WOS:000618493500023
J	Bonanni, P; Villani, A; Scotti, S; Biasci, P; Russo, R; Maio, T; Rosati, GV; Moscadelli, A; Conforti, G; Azzari, C; Ferro, A; Francia, F; Chiamenti, G; Barretta, M; Castiglia, P; Macri, P; Conversano, M; Bozzola, E; Angelillo, IF				Bonanni, P.; Villani, A.; Scotti, S.; Biasci, P.; Russo, R.; Maio, T.; Rosati, G. Vitali; Moscadelli, A.; Conforti, G.; Azzari, C.; Ferro, A.; Francia, F.; Chiamenti, G.; Barretta, M.; Castiglia, P.; Macri, P.; Conversano, M.; Bozzola, E.; Angelillo, I. F.			The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: A continuing example of impact on public health policies	VACCINE			English	Editorial Material						Lifetime immunization schedule; Vaccination strategies; Public health		The Vaccination Calendar for Life is an alliance of scientific and professional societies of public health physicians, paediatricians and general practitioners in Italy which provides a periodical update on the ideal, scientifically driven vaccination calendar throughout lifetime. Since 2012, the Lifetime Immunization Schedule has represented a benchmark for Regional and National Authorities to set up the updated list of vaccines provided actively and free of charge to infants, children, adolescents, adults and the elderly by inclusion in the Triennial National Vaccination Plan (TNVP), and in the Essential Levels of Care (LEA). The impact of the different editions of the Lifetime Immunization Schedule on the TNVP was deep, representing the inspiring source for the present vaccination policy. The 2019 edition called for more attention to pregnant women immunization; risk groups vaccination; uniform high coverage with the MMRV vaccine; extension of Meningococcal B vaccination also at adolescent age; use of quadrivalent conjugate meningococcal vaccine also at 1 year of life; progressive decrease of the age of free-of-charge offer of influenza to >= 60 and then to >= 50 year-old population; implementation of flu immunization ages 6 months-6 years; HPV vaccination also offered to 25-year old women at the time of the first screening (gender neutral immunization already offered); sequential PCV13-PPV23 pneumococcal vaccination in 65 year-old subjects; increased coverage with rotavirus vaccine in infants and zoster vaccine in the elderly. (C) 2021 Published by Elsevier Ltd.	[Bonanni, P.; Moscadelli, A.; Ferro, A.; Francia, F.; Castiglia, P.; Conversano, M.; Angelillo, I. F.] Italian Soc Hyg Prevent Med & Publ Hlth SItI, Turin, Italy; [Villani, A.; Russo, R.; Azzari, C.; Bozzola, E.] Italian Soc Paediat SIP, Cosenza, Italy; [Scotti, S.; Maio, T.] Italian Federat Gen Practitioners FIMMG, Rome, Italy; [Biasci, P.; Rosati, G. Vitali; Conforti, G.; Chiamenti, G.; Barretta, M.] Italian Federat Primary Care Paeditaricians FIMP, Bari, Italy; [Macri, P.] MeLCo Med Legale Contemporanea, Rome, Italy		Bonanni, P (通讯作者)，Italian Soc Hyg Prevent Med & Publ Hlth SItI, Turin, Italy.	paolo.bonanni@unifi.it	Angelillo, Italo Francesco/AAK-1301-2021	Angelillo, Italo Francesco/0000-0003-1213-6602			Bonanni P, 2018, HUM VACC IMMUNOTHER, V14, P699, DOI 10.1080/21645515.2017.1388480; Bonanni P, 2017, HUM VACC IMMUNOTHER, V13, P2531, DOI 10.1080/21645515.2017.1366394; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Costantino C, 2018, HUM VACC IMMUNOTHER, V14, P2297, DOI 10.1080/21645515.2018.1471306; Drolet M, 2015, LANCET INFECT DIS, V15, P565, DOI 10.1016/S1473-3099(14)71073-4; Gabutti G, 2015, NEUROL SCI, V36, P1667, DOI 10.1007/s10072-015-2230-1; Ghelardi A, 2018, GYNECOL ONCOL, V151, P229, DOI 10.1016/j.ygyno.2018.08.033; Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480; Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633; Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3	10	5	5	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1183	1186		10.1016/j.vaccine.2021.01.019		FEB 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33589048				2022-04-29	WOS:000618493500005
J	Elsenpeter, HMS				Elsenpeter, Hannah M. S.			How COVID exposed the hypocrisy within me	VACCINE			English	Editorial Material									[Elsenpeter, Hannah M. S.] Duluth Family Med Clin, Duluth, MN 55805 USA		Elsenpeter, HMS (通讯作者)，Duluth Family Med Clin, Duluth, MN 55805 USA.	salkx008@umn.edu						0	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1178	1179		10.1016/j.vaccine.2021.01.030		FEB 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33487465				2022-04-29	WOS:000618493500003
J	Akmatov, MK; Holstiege, J; Steffen, A; Batzing, J				Akmatov, Manas K.; Holstiege, Jakob; Steffen, Annika; Baetzing, Joerg			Utilization of influenza vaccination among chronically ill individuals in Germany: A nationwide claims-based analysis	VACCINE			English	Article						Asthma; Chronic diseases; Germany; HIV; Immunodeficiency; Influenza; Multiple sclerosis; Vaccination uptake	HEALTH-CARE; ADULTS; OUTPATIENT; INSURANCE; COVERAGE; IMMUNIZATION; MORBIDITY; COUNTRIES; INTERVIEW; MEASLES	Background: Individuals with chronic diseases have a higher risk of serious complications or even death in case of influenza infection. The European Union (EU) set a goal to reach a vaccination coverage of 75% in seniors and chronically ill individuals. The aim of this study was to assess influenza vaccination uptake among individuals with a wide spectrum of chronic diseases and examine its regional variations and temporal trends over a period of the last ten years. Methods: We used nationwide SHI-physician outpatient claims data from the years 2009 to 2018 covering 87% of the total German population to assess influenza vaccination uptake among individuals over 1 year of age with at least one of the following chronic diseases: pulmonary, cardiovascular, liver, kidney, metabolic, neurological and musculoskeletal diseases, as well as immune deficiency disorders, including HIV infection. Results: Influenza vaccination coverage varied across patient populations between 19% (multiple sclerosis) and 44% (chronic kidney disease) in the influenza season 2017/18. Vaccination coverage was slightly higher among females than males, except for HIV/AIDS patients. Among HIV-patients vaccination coverage was higher by 7 percent points among males (43%) than females (37%). The coverage was higher nearly for all patient groups in the eastern than western federal states. Over the observation period vaccination uptake showed decreasing trends in most of the target groups. Among patients with HIV/AIDS and immune deficiency disorders a stagnating trend was observed. Conclusions: Vaccination uptake among chronically ill individuals is suboptimal and far from the EU-defined target of 75%. There were substantial variations in coverage by disease groups, individual factors and regions. The disease-specific evaluation of the current study allows identification of populations at higher risk with considerable vaccination gaps. Further efforts are needed to improve vaccination uptake in these vulnerable population groups. (C) 2021 Elsevier Ltd. All rights reserved.	[Akmatov, Manas K.; Holstiege, Jakob; Steffen, Annika; Baetzing, Joerg] Cent Res Inst Ambulatory Hlth Care Fed Republ Ger, Berlin, Germany		Akmatov, MK (通讯作者)，Cent Res Inst Ambulatory Hlth Care Germany, Dept Epidemiol & Hlth Care Atlas, Salzufer 8, D-10587 Berlin, Germany.	makmatov@zi.de					Ahmed F, 2004, AM J MANAG CARE, V10, P698; Akmatov MK, 2020, B WORLD HEALTH ORGAN, V98, P40, DOI 10.2471/BLT.19.229773; Ali I, 2020, HUM VACC IMMUNOTHER, V16, P2594, DOI 10.1080/21645515.2020.1787065; an der Heiden M, 2019, EPID B, V46, P483; Baker AM, 1998, J GEN INTERN MED, V13, P469, DOI 10.1046/j.1525-1497.1998.00136.x; Batzing-Feigenbaum J, 2019, SEASONAL INFLUENZA V; Batzing-Feigenbaum J, 2017, VACCINATION SEASONAL; Beck A, 1997, J AM GERIATR SOC, V45, P543, DOI 10.1111/j.1532-5415.1997.tb03085.x; Bodeker B, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1970-4; Bodeker B, 2015, BUNDESGESUNDHEITSBLA, V58, P174, DOI 10.1007/s00103-014-2097-y; Braeye T, 2020, VACCINE, V38, P3243, DOI 10.1016/j.vaccine.2020.02.082; Chambers C V, 1991, J Am Board Fam Pract, V4, P19; DIMDI, 2019, INT STAT CLASS DIS R; European Union, 2009, COUNC REC 22 DEC 200; Federal Joint Committee, 2008, GUID ACC 116B SGB SP; Feng ZJ, 2020, CHINA CDC WEEKLY, V2, P113, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003; Friberg IO, 2016, SCAND J PUBLIC HEALT, V44, P264, DOI 10.1177/1403494815618843; Fullard ME, 2018, PARKINSONISM RELAT D, V48, P45, DOI 10.1016/j.parkreldis.2017.12.012; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Gray CL, 2018, ENVIRON RES, V166, P529, DOI 10.1016/j.envres.2018.06.020; Herrett E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016604; Huber J, 2012, GESUNDHEITSWESEN, V74, P627, DOI 10.1055/s-0031-1301268; Huber J, 2010, BUNDESGESUNDHEITSBLA, V53, P925, DOI 10.1007/s00103-010-1119-7; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Kurch-Bek D, 2019, BUNDESGESUNDHEITSBLA, V62, P84, DOI 10.1007/s00103-018-2854-4; Laurence A, 2020, J BIOMED OPT, V25, DOI 10.1117/1.JBO.25.11.116003; Markun S, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01873-2017; Mereckiene J., 2018, OVERVIEW VACCINE REC; Moran WP, 1996, AM J MED, V101, P612, DOI 10.1016/S0002-9343(96)00327-0; Murdaca G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020204; Murdaca G, 2014, AUTOIMMUN REV, V13, P75, DOI 10.1016/j.autrev.2013.07.007; National Association of Statutory Health Insurance Physicians (KBV), 2005, QUAL ASS TREATM CAR; Plass D, 2014, EPIDEMIOL INFECT, V142, P2024, DOI 10.1017/S0950268813003312; Poethko-Muller C, 2013, BUNDESGESUNDHEITSBLA, V56, P845, DOI 10.1007/s00103-013-1693-6; Poethko-Muller C, 2019, BUNDESGESUNDHEITSBLA, V62, P410, DOI 10.1007/s00103-019-02901-5; Rattay P, 2013, BUNDESGESUNDHEITSBLA, V56, P832, DOI 10.1007/s00103-013-1665-x; Robert Koch Institute, 2018, REP EP INFL GERM SEA; Robert Koch Institute, 2019, REC STAND VACC COMM; Robert Koch Institute, 2013, REP EP INFL GERM SEA; Sanftenberg L, 2019, DTSCH ARZTEBL INT, V116, P645, DOI 10.3238/arztebl.2019.0645; Scholz S, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7458-x; Schubert I, 2010, GESUNDHEITSWESEN, V72, P316, DOI 10.1055/s-0030-1249688	42	4	4	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					952	960		10.1016/j.vaccine.2020.12.081		JAN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7FB	33451775				2022-04-29	WOS:000610835100013
J	Arcon, N; Picchio, MS; Fenoy, IM; Moretta, RE; Soto, AS; Sibilia, MDP; Sanchez, VR; Prato, CA; Tribulatti, MV; Goldman, A; Martin, V				Arcon, Nadia; Picchio, Mariano S.; Fenoy, Ignacio M.; Moretta, Rosalia E.; Soto, Ariadna S.; Perrone Sibilia, Matias D.; Sanchez, Vanesa R.; Prato, Cecilia A.; Virginia Tribulatti, Maria; Goldman, Alejandra; Martin, Valentina			Synergistic effect of GRA7 and profilin proteins in vaccination against chronic Toxoplasma gondii infection	VACCINE			English	Article						Toxoplasma gondii; GRA7; Profilin; BMDCs activation; Vaccine	PROTECTIVE IMMUNITY; HOST; RECOGNITION; ACTIVATION; RESISTANCE; TGPI-1; CELLS; ROP2	Toxoplasmosis is a zoonotic disease with worldwide prevalence in humans and warm-blooded animal populations. In livestock Toxoplasma gondii is the causal agent of significant economic losses since it can cause abortions in goats and sheep. It is estimated that one third of the world population is infected. Although there are effective therapies for acute infection, these are sometimes poorly tolerated, teratogenic, and have a long administration time. Considering the deficiencies that exist related to the prevention and treatment of toxoplasmosis, the development of a safe and effective vaccine would be extremely valuable in fighting against this infection. In the present work, we characterize for the first time the adjuvant and immunogenic potential of a recombinant profilin protein (rTgPF), in a vaccine formulation alone or in combination with the well-known GRA7 antigen candidate in a murine toxoplasmosis model. Since TgPF acts as a ligand for TLR11 and 12 inducing innate immune responses that promote type 1 adaptive responses, we first study the capacity of the mix rGRA7 + rTgPF to initiate an immune response by evaluating dendritic cell activation. Both rTgPF and rGRA7 induces activation of mouse BMDCs more efficiently than the single proteins, evidenced by increased expression of CD80 and CD86 co-stimulatory proteins and secretion of IL-6, IL-10 and IL-12 cytokines after in vitro stimulation. The sum of the effects of rGRA7 and rTgPF on BMDCs maturation led us to assay them in a vaccination protocol. BALB/c mice vaccinated with this mix elicited a Th1-biased immunity via the induction of lymphocyte proliferation, activation of CD4*T cells and increased IFN-gamma production that resulted in enhanced protection against chronic Toxoplama gondii infection. Profilin per se induce only cellular immunity but augments the effect of rGRA7 immune responses when used together, thus allowing us to postulate rTgPF as a potential adjuvant in a protein vaccine. (C) 2020 Elsevier Ltd. All rights reserved.	[Arcon, Nadia; Picchio, Mariano S.; Fenoy, Ignacio M.; Moretta, Rosalia E.; Soto, Ariadna S.; Perrone Sibilia, Matias D.; Sanchez, Vanesa R.; Goldman, Alejandra; Martin, Valentina] Univ Nacl San Martin UNSAM, Escuela Ciencia & Tecnol, CESyMA, Lab Inmunol Vacunas & Alergia, Buenos Aires, DF, Argentina; [Prato, Cecilia A.; Virginia Tribulatti, Maria] Univ Nacl San Martin UNSAM, Inst Invest Biotecnol, Lab Inmunol Mol, Buenos Aires, DF, Argentina; [Arcon, Nadia; Picchio, Mariano S.; Fenoy, Ignacio M.; Moretta, Rosalia E.; Soto, Ariadna S.; Perrone Sibilia, Matias D.; Sanchez, Vanesa R.; Prato, Cecilia A.; Virginia Tribulatti, Maria; Goldman, Alejandra; Martin, Valentina] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina		Martin, V (通讯作者)，Univ Nacl San Martin UNSAM, Escuela Ciencia & Tecnol, CESyMA, Lab Inmunol Vacunas & Alergia, Buenos Aires, DF, Argentina.	vmartin@unsam.edu.ar		SANCHEZ, VANESA/0000-0002-6684-7947	Agencia Nacional de Promocion Cientifica y Tecnologica (ANP-CyT, Argentina)ANPCyT [PICT-2014-1377, PICT-20150592, PICT-2018-02424, PICT-201-0582, PICT-START UP-20184686]	We especially thank Tech. Irina Garcia Suarez and Tech. Maria Laura Furlan for their excellent technical assistance. This work was supported by research grants from the Agencia Nacional de Promocion Cientifica y Tecnologica (PICT-2014-1377, PICT-20150592, PICT-2018-02424, PICT-201-0582, PICT-START UP-20184686, ANP-CyT, Argentina), (http://www.agencia.mincyt.gob.ar/).	Besteiro S, 2011, CELL MICROBIOL, V13, P797, DOI 10.1111/j.1462-5822.2011.01597.x; BUXTON D, 1991, VET REC, V129, P89, DOI 10.1136/vr.129.5.89; Criscuolo E, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/8303648; Dunay IR, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00057-17; Dupont CD, 2012, SEMIN IMMUNOPATHOL, V34, P793, DOI 10.1007/s00281-012-0339-3; Gao Q, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3022-z; Hedhli D, 2016, MED MICROBIOL IMMUN, V205, P345, DOI 10.1007/s00430-016-0452-3; Hedhli D, 2009, VACCINE, V27, P2274, DOI 10.1016/j.vaccine.2009.01.100; Ihara F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01709; Jebbari H, 1998, PARASITE IMMUNOL, V20, P231, DOI 10.1046/j.1365-3024.1998.00152.x; Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346; Khan IA, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00136; Khan IA, 2019, CURR CLIN MICROBIOL, V6, P44, DOI 10.1007/s40588-019-0114-5; Koblansky AA, 2013, IMMUNITY, V38, P119, DOI 10.1016/j.immuni.2012.09.016; Koh HJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006126; Krishnaswamy JK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02169; Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10; Lim SSY, 2014, KOREAN J PARASITOL, V52, P581, DOI 10.3347/kjp.2014.52.6.581; Mercier C, 2015, TRENDS PARASITOL, V31, P604, DOI 10.1016/j.pt.2015.02.002; Mohan T, 2013, INDIAN J MED RES, V138, P779; Neal LM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004203; Nempont C, 2008, J IMMUNOL, V181, P2036, DOI 10.4049/jimmunol.181.3.2036; Nigro M, 2003, DIAGN MICR INFEC DIS, V47, P609, DOI 10.1016/S0732-8893(03)00156-1; Nish SA, 2014, ELIFE, V3, DOI 10.7554/eLife.01949; Pappas G, 2009, INT J PARASITOL, V39, P1385, DOI 10.1016/j.ijpara.2009.04.003; Picchio MS, 2018, EXP PARASITOL, V185, P62, DOI 10.1016/j.exppara.2018.01.006; Pittman KJ, 2015, MICROBIOL MOL BIOL R, V79, P387, DOI 10.1128/MMBR.00027-15; Plattner F, 2008, CELL HOST MICROBE, V3, P77, DOI 10.1016/j.chom.2008.01.001; Prato CA, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101278; Pyo KH, 2016, ONCOTARGET, V7, P74107, DOI 10.18632/oncotarget.12316; Rezaei F, 2019, J MICROBIOL METH, V165, DOI 10.1016/j.mimet.2019.105696; Rezaei F, 2019, MICROB PATHOGENESIS, V126, P172, DOI 10.1016/j.micpath.2018.11.003; Sanchez VR, 2015, ACTA TROP, V150, P159, DOI 10.1016/j.actatropica.2015.07.013; Sanchez VR, 2011, EXP PARASITOL, V128, P448, DOI 10.1016/j.exppara.2011.04.004; Sinai AP, 2016, CURR CLIN MICROBIOL, V3, P175, DOI 10.1007/s40588-016-0045-3; Singh Sarman, 2016, Trop Parasitol, V6, P113; Suzuki Y, 1997, INFECT IMMUN, V65, P2339, DOI 10.1128/IAI.65.6.2339-2345.1997; Tanaka S, 2014, VACCINE, V32, P1781, DOI 10.1016/j.vaccine.2014.01.095; Wang JL, 2019, TRENDS PARASITOL, V35, P239, DOI 10.1016/j.pt.2019.01.005; Wang JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00730; Wang ZD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00389; Weeratunga P, 2017, J MICROBIOL, V55, P909, DOI 10.1007/s12275-017-7392-5; Yang CS, 2016, INFECT IMMUN, V84, P339, DOI 10.1128/IAI.00734-15; Yang WB, 2017, ACTA TROP, V176, P427, DOI 10.1016/j.actatropica.2017.09.007; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Yarovinsky F, 2008, J IMMUNOL, V181, P8478, DOI 10.4049/jimmunol.181.12.8478; Zhang NZ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01505	47	1	1	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					933	942		10.1016/j.vaccine.2020.12.072		JAN 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7FB	33451777				2022-04-29	WOS:000610835100011
J	Leader, AE; Burke-Garcia, A; Massey, PM; Roark, JB				Leader, Amy E.; Burke-Garcia, Amelia; Massey, Philip M.; Roark, Jill B.			Understanding the messages and motivation of vaccine hesitant or refusing social media influencers	VACCINE			English	Article						Social media; Online influencers; Vaccination; Vaccine hesitancy; Health communication; Information dissemination	HERD-IMMUNITY; HPV; COMMUNICATION; KNOWLEDGE; TRUST; US	Background: While anti-vaccine messages on social media have been studied for content, reach, and effectiveness, less is known about those who create and promote the messages. Online influencers, or 'everyday people who are influential within their online social networks', are viewed as trusted voices who are often making similar life decisions as their followers. Therefore, their experiences with and perspectives on health issues can be persuasive. Methods: We collaborated with a formal network of online influencers to interview, using a semistructured interview guide, vaccine hesitant influencer mothers about their views on vaccination; their process for developing health-related social media content; their motivation to promote anti-vaccine messages; and their opinions on current vaccination messaging. Prescreening ensured a diverse sample by race/ethnicity, age, education, number of children, and geographic residence. Interviews occurred by telephone, were audio recorded, and transcribed. Themes were generated independently by two coders using a deductive coding approach. Results: We interviewed 15 online influencer mothers from across the U.S. (average age 39 years old; all married; 13 Caucasian, 1 African American, 1 Hispanic). In some capacity, 5 of the 15 wrote about vaccination on their blog. Those who chose not to post anti-vaccine content did so for fear of alienating followers or having their platform be the site of combative discourse among readers. When researching their social media posts, the influencers did not trust mainstream sources of health information and relied on alternative sources and search engines. Implications: This exploratory study interviewed influential mothers who have the ability to spread anti-vaccine messages on social media. While most do not contribute to the anti-vaccine sentiment, understanding the motivation and practices of those that do assists the public health community in better understanding the online vaccination communication environment, leading to more effective messages to counterbalance anti-vaccine content on social media. (C) 2020 Elsevier Ltd. All rights reserved.	[Leader, Amy E.] Thomas Jefferson Univ, Div Populat Sci, Med Oncol, 834 Chestnut St,Suite 314, Philadelphia, PA 19107 USA; [Burke-Garcia, Amelia] Univ Chicago, NORC, 4350 East West Highway,8th Floor, Bethesda, MD 20814 USA; [Massey, Philip M.] Drexel Dornsife Sch Publ Hlth, Dept Community Hlth & Prevent, 3215 Market St, Philadelphia, PA 19104 USA; [Roark, Jill B.] 109 Casa Bay Pl, St Augustine, FL 32080 USA		Leader, AE (通讯作者)，Thomas Jefferson Univ, Dept Med Oncol, 834 Chestnut St,Suite 314, Philadelphia, PA 19107 USA.	amy.leader@jefferson.edu		Massey, Philip/0000-0002-5855-3404; Leader, Amy/0000-0002-9514-3631; Massey, Philip/0000-0002-0577-8618			Blankenship Elizabeth B, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-138; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567; Burke-Garcia A., 2017, THESIS; Burke-Garcia A., 2019, INFLUENCING HLTH COM; Burke-Garcia A, 2017, P 50 HAW INT C SYST; Burke-Garcia A, 2018, JMIR RES PROTOC, V7, DOI 10.2196/resprot.7764; Camporesi S, 2017, J BIOETHIC INQ, V14, P23, DOI 10.1007/s11673-016-9767-4; Casalo LV, 2020, J BUS RES, V117, P510, DOI 10.1016/j.jbusres.2018.07.005; CDC, 2019, MEASL CAS OUTBR; Chen T, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8221; Duplaga M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176360; Dyda A, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09327-8; Elkin LE, 2020, VACCINE, V38, P2771, DOI 10.1016/j.vaccine.2020.02.041; Fraser MR, 2019, J PUBLIC HEALTH MAN, V25, P511, DOI 10.1097/PHH.0000000000001065; Gruzd A., 2017, P 8 INT C SOC MED SO, P17; Haase N, 2020, PSYCHOL HEALTH, V35, P346, DOI 10.1080/08870446.2019.1630561; HealthyPeople 2020, 2020, HEALTHYPEOPLE 2020; Hoffman BL, 2019, VACCINE, V37, P2216, DOI 10.1016/j.vaccine.2019.03.003; Influencer Marketing Hub, 2020, STAT INFL MARK 2020; Isaac BM, 2017, MMWR-MORBID MORTAL W, V66, P60, DOI 10.15585/mmwr.mm6602a5; Kang GJ, 2017, VACCINE, V35, P3621, DOI 10.1016/j.vaccine.2017.05.052; Kearney MD, 2019, HEALTH EDUC BEHAV, V46, P37, DOI 10.1177/1090198119859412; Leask J, 2006, VACCINE, V24, P7238, DOI 10.1016/j.vaccine.2006.05.010; Lee C, 2016, VACCINE, V34, P3972, DOI 10.1016/j.vaccine.2016.06.048; Marlow LAV, 2007, HUM VACCINES, V3, P171, DOI 10.4161/hv.3.5.4310; Miller CL, 2020, WOMEN HEALTH, V60, P763, DOI 10.1080/03630242.2020.1713966; Mirreh M., 2017, INSIDE PERFORMANCE M; Mischlinger J, 2020, CLIN INFECT DIS, V70, P1258, DOI 10.1093/cid/ciz586; Newman PA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019206; Ortiz RR, 2019, HUM VACC IMMUNOTHER, V15, P1465, DOI 10.1080/21645515.2019.1581543; Ortiz-Sanchez E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155394; Pew Research Center, 2019, SOC MED FACT SHEET; Pew Research Center, INT HLTH CAR SOC MED; Ruiz JB, 2014, VACCINE, V32, P5776, DOI 10.1016/j.vaccine.2014.08.042; Sobo EJ, 2016, SOC SCI MED, V165, P187, DOI 10.1016/j.socscimed.2016.06.015; Statista.com, 2020, GLOB DIG POP APR 202; Uzunoglu E, 2014, INT J INFORM MANAGE, V34, P592, DOI 10.1016/j.ijinfomgt.2014.04.007; Wang YX, 2019, SOC SCI MED, V240, DOI 10.1016/j.socscimed.2019.112552; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Wright K, 2019, J MED INTERNET RES, V21, DOI 10.2196/12441	41	6	6	5	27	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					350	356		10.1016/j.vaccine.2020.11.058			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PN8VM	33280856	Green Accepted			2022-04-29	WOS:000604750300025
J	Bellizzi, S; Aidyralieva, C; Al-Shaikh, A; Muthu, N; Al-Sadder, A; Al-Raiby, J				Bellizzi, Saverio; Aidyralieva, Chinara; Al-Shaikh, Ala'a; Muthu, Nazeema; Al-Sadder, Anwar; Al-Raiby, Jamela			Inclusiveness of prisons in COVID-19 vaccination deployment: Evidence from Jordan	VACCINE			English	Editorial Material							NEED		[Bellizzi, Saverio; Aidyralieva, Chinara; Al-Shaikh, Ala'a; Muthu, Nazeema; Al-Sadder, Anwar; Al-Raiby, Jamela] Jordan WHO Country Off, Amman, Jordan		Bellizzi, S (通讯作者)，Jordan WHO Country Off, Amman, Jordan.	bellizzis@who.int		Al-Shaikh, Ala'a/0000-0002-3844-7292			Braithwaite I, 2021, LANCET RESP MED, V9, P569, DOI 10.1016/S2213-2600(21)00137-5; Irshaidat S, 2021, INFECT CONT HOSP EP, DOI 10.1017/ice.2021.277; Neufeld M, 2021, LANCET REG HEALTH-EU, V4, DOI 10.1016/j.lanepe.2021.100088; Saloner B, 2020, JAMA-J AM MED ASSOC, V324, P602, DOI 10.1001/jama.2020.12528; UNHCR, 2021, REF REC COVID 19 VAC; UNICEF, 2020, GEOGR MULT VULN AN J; UNRWA, WE WORK; Vest N, 2021, J URBAN HEALTH, V98, P53, DOI 10.1007/s11524-020-00504-z; Ward JA, 2021, AM J PREV MED, V60, P840, DOI 10.1016/j.amepre.2021.01.018	9	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					1	2		10.1016/j.vaccine.2021.11.022		DEC 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FV	34823909	Green Published, Bronze			2022-04-29	WOS:000731299800001
J	Chen, TE; Dai, MH; Xia, SL				Chen, Tianen; Dai, Minhao; Xia, Shilin			Perceived facilitators and barriers to intentions of receiving the COVID-19 vaccines among elderly Chinese adults	VACCINE			English	Article						COVID-19 vaccination; Elderly Chinese adults; Vaccination decision-making process; Integrative model of behavioral prediction		Elderly adults hold different beliefs regarding vaccination and are at higher risks for COVID-19 related illnesses and deaths. The current study aims to explore elderly (aged 65 or above) Chinese adults' intentions to get vaccinated against COVID-19 and the facilitators and barriers to vaccination intentions. We conducted in-depth interviews with 35 elderly adults in China through the lens of the integrative model of behavioral prediction. The results identified a number of facilitators, including convenience (both individual and collective), psychological and physiological wellbeing, collective wellbeing, supportive normative referents, and trust in the government, and some barriers, including vaccine ineffectiveness, side effects, safety, unsupportive normative referents, and the accessibility, affordability, and availability of COVID-19 vaccines. In addition, the results revealed participants' decision-making process: collective wellbeing and trust in the government overrode perceived barriers and perceived individual-level risks, which eventually overwhelmingly led to a high level of intentions to get vaccinated. Practical implications related to vaccine promotion and trust in the government were discussed. (c) 2021 Elsevier Ltd. All rights reserved.	[Chen, Tianen] Cornell Univ, Coll Agr & Life Sci, Dept Commun, Ithaca, NY 14850 USA; [Dai, Minhao] Kennesaw State Univ, Radow Coll Humanities & Social Sci, Sch Commun & Media, Kennesaw, GA 30144 USA; [Xia, Shilin] Univ Maryland, Dept Commun, College Pk, MD 20740 USA		Dai, MH (通讯作者)，Kennesaw State Univ, Radow Coll Humanities & Social Sci, Sch Commun & Media, Kennesaw, GA 30144 USA.	tc447@cornell.edu; mdai@kennesaw.edu; sphxia37@umd.edu		Dai, Minhao/0000-0003-4030-3965			[Anonymous], 2021, XINMIN EVENING 0317; [Anonymous], 2014, THE PEOPLES DAILY; [Anonymous], 2021, THE PEOPLES DAILY; Bernard H.R., 2017, RES METHODS ANTHR QU, V6th ed; Blind P.K., 2007, 7 GLOBAL FORUM REINV, P26; Bozym M., 2021, FACTORS INFLUENCING, DOI [10.1101/2021.03.21.21254047, DOI 10.1101/2021.03.21.21254047]; Centers for Disease Control and Prevention, COVID 19 VACC US; Centers for Disease Control and Prevention (2021b), COVID 19 GUID OLD AD; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Fishbein M, 2000, AIDS CARE, V12, P273, DOI 10.1080/09540120050042918; Gramacho WG, 2021, VACCINE, V39, P2608, DOI 10.1016/j.vaccine.2021.03.080; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; HILL RJ, 1977, CONTEMP SOCIOL, V6, P244, DOI 10.2307/2065853; Karic T, 2021, PERS INDIV DIFFER, V175, DOI 10.1016/j.paid.2021.110697; Kreps SE, 2021, VACCINE, V39, P3250, DOI 10.1016/j.vaccine.2021.04.044; Latkin C, 2021, VACCINE, V39, P2237, DOI 10.1016/j.vaccine.2021.02.058; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Luk TT, 2021, VACCINE, V39, P3602, DOI 10.1016/j.vaccine.2021.05.036; Luo Y, 2015, SOC SCI MED, V127, P134, DOI 10.1016/j.socscimed.2014.09.039; Mallapaty S, 2021, NATURE, V593, P178, DOI 10.1038/d41586-021-01146-0; Matsui D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-149; Mo PKH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020129; Moxham-Hall V, 2020, PUBLIC OPINION TRUST; Mueller AL, 2020, AGING-US, V12, P9959, DOI 10.18632/aging.103344; Nagata JM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-388; National Health Commission of the People's Republic of China, 2021, JUNE 25S UPD COVID 1; OECD, 2013, GOV GLANC, P19, DOI DOI 10.1787/GOV_GLANCE-2013-6-EN; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Starks H, 2007, QUAL HEALTH RES, V17, P1372, DOI 10.1177/1049732307307031; Steele LG, 2013, SOC INDIC RES, V114, P441, DOI 10.1007/s11205-012-0154-1; The State Council of the People's Republic of China, 2021, GUID COVID 19 VACC, VFirst; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; WHO, 2021, NOV COR 2019 NCOV SI; Wong TKY, 2011, INT POLIT SCI REV, V32, P263, DOI 10.1177/0192512110378657; World Health Organization, DRAFT LANDSC TRACK C; World Health Organization, 2020, LIST WHOS RESP COVID; Wu JB, 2020, CHINA INFORM, V34, P109, DOI 10.1177/0920203X19852917; Yzer M., 2012, HLTH COMMUNICATION M, P21	44	0	0	5	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					100	106		10.1016/j.vaccine.2021.11.039		DEC 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XQ1FV	34839994	Green Published, Bronze			2022-04-29	WOS:000731299800016
J	Jin, P; Sun, F; Liu, Q; Wang, QY; Zhang, YX; Liu, XH				Jin, Peng; Sun, Fei; Liu, Qin; Wang, Qiyao; Zhang, Yuanxing; Liu, Xiaohong			An oral vaccine based on chitosan/aluminum adjuvant induces both local and systemic immune responses in turbot (Scophthalmus maximus)	VACCINE			English	Article						Alum adjuvant; Chitosan nanoparticles; Oral vaccine; Vibrio anguillarum	CHITOSAN; ACTIVATION	Oral vaccination is the most convenient method for disease protection in aquaculture due to possibility of adding vaccines as part of fish diet. However, low protective efficiency is the major problem of oral vaccination owing to some reasons, especially for antigens degradation. In this study, we developed an oral inactivated vaccine based on a chitosan/aluminum adjuvant system, and investigated immune response induced by the vaccine. As a result, Th1 and Th2 cells mediated immune responses were observed after the vaccination according to the upregulation of IL-6, IL-12, IFNc and IgM genes expression that were deemed as the driver cytokines for triggering the responses. Moreover, ratio of IgT'/IgM' B cells was elevated in intestine after vaccination, while IgM antibodies were also observed in the sera of vaccinated fish, suggested that both local and systemic immune responses were induced by the inactivated vaccine. Totally, this oral vaccine can be used for V. anguillarum protection and this chitosan/aluminum system is an efficient candidate adjuvant for developing more vaccines in the future. (c) 2021 Elsevier Ltd. All rights reserved.	[Jin, Peng; Sun, Fei; Liu, Qin; Wang, Qiyao; Liu, Xiaohong] East China Univ Sci & Technol, State Key Lab Bioreactor Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China; [Zhang, Yuanxing] Southern Marine Sci & Engn Guangdong Lab Zhuhai, Zhuhai 519000, Peoples R China; [Liu, Qin; Wang, Qiyao; Zhang, Yuanxing; Liu, Xiaohong] Shanghai Engn Res Ctr Maricultured Anim Vaccines, Shanghai 200237, Peoples R China		Liu, XH (通讯作者)，East China Univ Sci & Technol, State Key Lab Bioreactor Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.	liuxiaohong@ecust.edu.cn			National Key Research and Development Program of China [2018YFC0311303]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32025038]; Fundamented Research Funds for Central Universities [222201211729]	This work was financially supported by grants from National Key Research and Development Program of China (2018YFC0311303 to XL) , the National Natural Science Foundation of China (32025038 to QL) , and the Fundamented Research Funds for Central Universities (222201211729) .	AbdelAllah NH, 2020, INT J BIOL MACROMOL, V152, P904, DOI 10.1016/j.ijbiomac.2020.02.287; Benne N, 2016, J CONTROL RELEASE, V234, P124, DOI 10.1016/j.jconrel.2016.05.033; Carroll EC, 2016, IMMUNITY, V44, P597, DOI 10.1016/j.immuni.2016.02.004; Halimi M, 2019, FISH SHELLFISH IMMUN, V90, P431, DOI 10.1016/j.fsi.2019.05.020; Koppolu B, 2013, BIOMATERIALS, V34, P2359, DOI 10.1016/j.biomaterials.2012.11.066; Kumar A, 2016, INT J BIOL MACROMOL, V91, P615, DOI 10.1016/j.ijbiomac.2016.05.054; Lebre F, 2018, INT J PHARMACEUT, V552, P7, DOI 10.1016/j.ijpharm.2018.09.044; Lebre F, 2017, INT J PHARMACEUT, V527, P103, DOI 10.1016/j.ijpharm.2017.05.028; Li XY, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-89; Mutoloki S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00519; Sui ZW, 2010, VACCINE, V28, P7690, DOI 10.1016/j.vaccine.2010.09.019; Villiers C, 2009, MOL CELL PROTEOMICS, V8, P1252, DOI 10.1074/mcp.M800589-MCP200; Wang YQ, 2014, ADV HEALTHC MATER, V3, P670, DOI 10.1002/adhm.201300335; Wu YB, 2020, POLYMERS-BASEL, V12, DOI 10.3390/polym12051177; Xia YF, 2015, VACCINE, V33, P5997, DOI 10.1016/j.vaccine.2015.07.101; Xu HY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.562795; Xu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10728; Xu Z, 2013, P NATL ACAD SCI USA, V110, P13097, DOI 10.1073/pnas.1304319110; Zhang JC, 2019, FISH SHELLFISH IMMUN, V89, P52, DOI 10.1016/j.fsi.2019.03.040; Zhang YA, 2010, NAT IMMUNOL, V11, P827, DOI 10.1038/ni.1913; Zhu WT, 2019, FISH SHELLFISH IMMUN, V87, P379, DOI 10.1016/j.fsi.2019.01.033	21	1	1	11	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7477	7484		10.1016/j.vaccine.2021.10.063		DEC 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	34844823				2022-04-29	WOS:000731300100018
J	Vasudevan, L; Ostermann, J; Wang, YF; Harrison, SE; Yelverton, V; Mcdonald, JA; Fish, LJ; Williams, C; Walter, EB				Vasudevan, Lavanya; Ostermann, Jan; Wang, Yunfei; Harrison, Sayward E.; Yelverton, Valerie; Mcdonald, Jodi-Ann; Fish, Laura J.; Williams, Charnetta; Walter, Emmanuel B.			Predictors of HPV vaccination in the southern US: A survey of caregivers from 13 states	VACCINE			English	Article						Human Papillomavirus; Immunization; Adolescents; Southern United States; Provider recommendation	HUMAN-PAPILLOMAVIRUS VACCINATION; AGED 13-17 YEARS; UNITED-STATES; ADOLESCENTS; COVERAGE; RECOMMENDATION; PARENTS	Background and objectives: Despite a high burden of human papillomavirus (HPV)-attributable cancers, the southern US lags other regions in HPV vaccination coverage. This study sought to characterize and contextualize predictors of HPV vaccination in the southern US. Methods: From December 2019 - January 2020, parents of adolescents (ages 9-17 years) living in thirteen southern US states were recruited from a nationally-representative online survey panel and completed a cross-sectional survey. The primary study outcome was initiation of HPV vaccination. Results: Of 1105 parents who responded to the survey, most were >35 years of age and of female gender. HPV vaccination initiation was reported only among 37.3% of adolescents and was highest at age 12. Cumulative HPV vaccination coverage was highest at age 15 (60%) but lower than coverage for tetanus-diphtheria-acellular pertussis (Tdap, 79.3%) and Meningococcal vaccines (MenACWY, 67.3%). Provider recommendation was strongly associated with higher odds of HPV vaccination (aOR: 49.9, 95 %CI: 23.1-107.5). In alternative predictive models, home/online (vs. public) schooling and parents' working status were associated with lower odds of vaccination; health care visits in the past 12 months and shorter travel times to adolescents' usual health care provider were associated with greater odds of vaccination. Conclusions: Our findings suggest missed opportunities for HPV vaccination in the southern US and support strengthening provider recommendation for on-time initiation of HPV vaccination among adolescents. Other strategies to increase HPV vaccinations may include encouraging co-administration with other adolescent vaccines, increasing vaccine access, and promoting vaccinations for home/onlineschool students. (c) 2021 Elsevier Ltd. All rights reserved.	[Vasudevan, Lavanya; Fish, Laura J.] Duke Univ, Sch Med, Dept Family Med & Community Hlth, 2200 W Main St,Suite 600, Durham, NC 27705 USA; [Vasudevan, Lavanya; Ostermann, Jan; Walter, Emmanuel B.] Duke Global Hlth Inst, 310 Trent Dr, Durham, NC 27710 USA; [Ostermann, Jan; Yelverton, Valerie] Univ South Carolina, Dept Hlth Serv Policy & Management, 915 Greene St, Columbia, SC 29208 USA; [Ostermann, Jan; Harrison, Sayward E.] Univ South Carolina, South Carolina Smart State Ctr Healthcare Qual, 915 Greene St, Columbia, SC 29208 USA; [Wang, Yunfei; Mcdonald, Jodi-Ann; Walter, Emmanuel B.] Duke Human Vaccine Inst, Duke Vaccine & Trials Unit, 2608 Erwin Rd,Suite 210, Durham, NC 27705 USA; [Harrison, Sayward E.] Univ South Carolina, Barnwell Coll, Dept Psychol, 1512 Pendleton St,Suite 220, Columbia, SC 29208 USA; [Fish, Laura J.] Duke Canc Inst, 2424 Erwin Rd,Suite 602, Durham, NC 27710 USA; [Williams, Charnetta] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, 1600 Clifton Rd, Atlanta, GA 30329 USA; [Walter, Emmanuel B.] Duke Univ, Sch Med, Dept Pediat, DUMC, Box 3675, Durham, NC 27710 USA		Vasudevan, L (通讯作者)，2200 W Main St,Suite 600, Durham, NC 27710 USA.	lavanya.vasudevan@duke.edu			Centers for Dis-ease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01IP001095];  [1KL2TR002554]	Dr. Walter is an investigator for Pfizer vaccine studies, an unfunded co-investigator for a Moderna vaccine study, and a mem-ber of an advisory board for Vaxcyte. All other authors have no con-flicts of interests to declare. The authors thank KnowledgePanel (R) members for participating in the survey and the IPSOS team (Sergei Rodkin, Yifei Liu, An Liu) for supporting survey implementation. The authors thank Dr. Megan Lindley (Centers for Disease Control and Prevention) for reviewing the manuscript and providing constructive comments. The authors also thank Christopher Todd (Duke Human Vaccine Institute) for survey programming and administrative support. The research presented in this manuscript was supported by a cooperative agreement (U01IP001095) with the Centers for Dis-ease Control and Prevention. Dr. Vasudevan receives funding from the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number 1KL2TR002554. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Role of Funder/Sponsor The Centers for Disease Control and Prevention provided input on the study design, interpretation of data, manuscript prepara-tion, and the decision to submit the manuscript for publication but was not directly involved in data collection and analysis.	Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764; Centers for Disease Control and Prevention, 2019, VACC BOYS GIRLS; Centers for Disease Control and Prevention, 2019, HPV ASS CANC STAT; Centers for Disease Control and Prevention, 2019, EST 92 CANC CAUS HPV; Centers for Disease Control and Prevention, 2019, CANC ASS HUM PAP HPV; Conrey R, 2020, VACCINE, V38, P4119, DOI 10.1016/j.vaccine.2020.03.059; Dempsey AF, 2011, PEDIATRICS, V128, P848, DOI 10.1542/peds.2011-0400; Dorell CG, 2011, PUBLIC HEALTH REP, V126, P60, DOI 10.1177/00333549111260S208; Elam-Evans LD, 2020, MMWR-MORBID MORTAL W, V69, P1109, DOI 10.15585/mmwr.mm6933a1; Gilkey MB, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2018-2500; Gilkey MB, 2016, VACCINE, V34, P1187, DOI 10.1016/j.vaccine.2016.01.023; Hennebery RB, 2020, J COMMUN HEALTH, V45, P775, DOI 10.1007/s10900-020-00793-0; IPSOS, IPSOS KNOWLEDGEPANEL; Jagsi R, 2020, JAMA-J AM MED ASSOC, V324, P270, DOI 10.1001/jama.2020.9442; Katz IT, 2010, SEX HEALTH, V7, P279, DOI 10.1071/SH09130; Kaul S, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100189; Khan N, 2020, J AM DENT ASSOC, V151, P51, DOI 10.1016/j.adaj.2019.08.022; Kyanko KA, 2020, J GEN INTERN MED, V35, P1940, DOI 10.1007/s11606-019-05590-7; Landis K, 2018, VACCINE, V36, P3498, DOI 10.1016/j.vaccine.2018.04.075; Litton AG, 2011, J PEDIATR ADOL GYNEC, V24, P166, DOI 10.1016/j.jpag.2011.01.004; Mohammed KA, 2016, J ADOLESCENT HEALTH, V59, P592, DOI 10.1016/j.jadohealth.2016.06.005; National HPV Vaccination Roundtable, 2019, SCH ENTR REQ HPV VAC; Office of the Assistant Secretary for Health, SERVICES DOHAH; Palmer J, 2015, J VAC, P2015, DOI DOI 10.1155/2015/869468; Paskett ED, 2016, CANCER EPIDEM BIOMAR, V25, P593, DOI 10.1158/1055-9965.EPI-15-1243; Probst JC, 2018, J RURAL HEALTH, V34, pS3, DOI 10.1111/jrh.12222; Rand CM, 2018, ACAD PEDIATR, V18, pS72, DOI 10.1016/j.acap.2018.01.002; Rodriguez SA, 2020, PREV MED, V131, DOI 10.1016/j.ypmed.2019.105968; Rolnick SJ, 2013, VACCINE, V31, P3928, DOI 10.1016/j.vaccine.2013.06.041; Samsky MD, 2020, JAMA CARDIOL, V5, P292, DOI 10.1001/jamacardio.2019.4987; Schoenborn NL, 2019, JAMA INTERN MED, V179, P1642, DOI 10.1001/jamainternmed.2019.3806; Szilagyi PG, 2020, VACCINE, V38, P6027, DOI 10.1016/j.vaccine.2020.06.074; The Community Guide, 2014, VACC PROGR HLTH CAR; von Elm E, 2007, PREV MED, V45, P247, DOI [10.1016/j.ypmed.2007.08.012, 10.1016/S0140-6736(07)61602-X]; Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2; Yoo W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172548	36	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7485	7493		10.1016/j.vaccine.2021.10.036		DEC 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XQ1FY	34742592				2022-04-29	WOS:000731300100019
J	Huang, JJ; Bai, YJ; Ding, HY; Wang, BY; Ngai, CH; Kwok, KO; Wong, ELY; Wong, MCS; Yeoh, EK				Huang, Junjie; Bai, Yijun; Ding, Hanyue; Wang, Boyuan; Ngai, Chun Ho; Kwok, Kin-on; Wong, Eliza L. Y.; Wong, Martin C. S.; Yeoh, Eng-Kiong			Acceptance of pneumococcal vaccination in older adults: A general population-based survey	VACCINE			English	Article						Pneumococcal infection; Vaccine; Acceptance	HEALTH BELIEF MODEL; INFLUENZA VACCINATION; ELDERLY-PEOPLE; DETERMINANTS	Background: Pneumococcal infection is a leading cause of disability and death globally. The Hong Kong Government has launched two programmes for pneumococcal vaccination -The Vaccination Subsidy Scheme (VSS) and the Government Vaccination Programme (GVP). This study aimed to examine the enabling factors, obstacles and perception of pneumococcal vaccination, and their association with its uptake in a general Chinese population. Methods: We performed a population-based, telephone survey in the general public aged 65 or above via simple random sampling. A validated survey based on the Health Belief Model (HBM) was used. Their socio-demographic information; history of previous participation in the GVP or VSS; and self-perceived health status were captured. Binary logistic regression models were constructed to examine the factors independently associated with vaccination. Results: A total of 1,000 respondents were enrolled in the study, with 402 (40.2%) respondents having intention to join the GVP/VSS in 12 months. Respondents with long-term medical consultant and medication (adjusted odds ratios [aOR] = 1.541, 95% confidence interval (CI): 1.008-2.356, p = 0.046); high levels of perceived susceptibility of infections (aOR = 3.624, 95 %CI: 2.318-5.665, p < 0.001); high levels of perceived benefits of vaccine (aOR = 1.699, 95 %CI: 1.153-2.504, p < 0.001); recommendations from government (aOR = 8.025, 95 %CI: 4.771-13.497, p < 0.001) or physicians (aOR = 7.399, 95 %CI: 3.472-15.764, p = 0.008); and high levels of self-efficacy (aOR = 3.045, 95 %CI: 1.458-6.362, p = 0.003) were more likely to have intention to participate in the vaccination programme. Conclusions: The acceptance rate of pneumococcal vaccination programme remained suboptimal in the population. The government and physicians should be involved in the promotion of pneumococcal vaccination and GVP/VSS by increasing perceived benefits and self-efficacy, and reducing barriers towards vaccination among the target population. More studies are required to confirm our findings in other settings. (c) 2021 Elsevier Ltd. All rights reserved.	[Huang, Junjie; Bai, Yijun; Ding, Hanyue; Wang, Boyuan; Ngai, Chun Ho; Kwok, Kin-on; Wong, Eliza L. Y.; Wong, Martin C. S.; Yeoh, Eng-Kiong] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Fac Med, Hong Kong, Peoples R China; [Wong, Martin C. S.] Chinese Acad Med Sci & Peking Union Med Coll, Sch Publ Hlth, Beijing, Peoples R China; [Wong, Martin C. S.] Peking Univ, Sch Publ Hlth, Dept Global Hlth, Beijing, Peoples R China		Wong, MCS; Yeoh, EK (通讯作者)，Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Fac Med, Sch Publ Hlth,Prince Wales Hosp, 4-F, Hong Kong, Peoples R China.	wong_martin@cuhk.edu.hk; yeoh_ek@cuhk.edu.hk	Kwok, Kin On/A-5074-2018	Kwok, Kin On/0000-0002-2804-5433; NGAI, CHUN HO/0000-0002-1851-5374	Health and Medical Research Fund, Food and Health Bureau, Hong Kong Special Administrative Region Government (CID-CUHK-Small project)	This project was funded by Health and Medical Research Fund, Food and Health Bureau, Hong Kong Special Administrative Region Government (CID-CUHK-Small project).	Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826; Centers for Disease Control and Prevention, PNEUMOCOCCAL VACCINA; Dominguez A, 2005, CLIN INFECT DIS, V40, P1250, DOI 10.1086/429236; Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368; Fall E, 2018, PSYCHOL HEALTH, V33, P746, DOI 10.1080/08870446.2017.1401623; Fogelberg S, 2018, PHARMACOEPIDEM DR S, V27, P1159, DOI 10.1002/pds.4653; Guclu OA, 2019, VACCINE, V37, P6617, DOI 10.1016/j.vaccine.2019.09.049; Higuchi M, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0841-3; Hong Kong Information Services Department, 2015, PNEUMOCOCCAL VACCINA; Huang JJ, 2021, EUR J CANCER CARE, V30, DOI 10.1111/ecc.13369; Ijaz K, 2020, INT J HUM-COMPUT INT, V36, P1195, DOI 10.1080/10447318.2020.1726107; Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678; Jain A, 2017, VACCINE, V35, P2315, DOI 10.1016/j.vaccine.2017.03.013; Jones CL, 2015, HEALTH COMMUN, V30, P566, DOI 10.1080/10410236.2013.873363; Kan T, 2018, PUBLIC HEALTH, V156, P67, DOI 10.1016/j.puhe.2017.12.007; Klett-Tammen CJ, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2784-8; Koivula I, 1997, AM J MED, V103, P281, DOI 10.1016/S0002-9343(97)00149-6; Lamontagne F, 2008, CAN MED ASSOC J, V179, P773, DOI 10.1503/cmaj.070221; Lau JTF, 2006, VACCINE, V24, P5526, DOI 10.1016/j.vaccine.2006.04.014; Oishi Kazunori, 2015, Nihon Naika Gakkai Zasshi, V104, P2301; Peterson Robert A, 1981, NA ADV CONSUMER RES, V08, P287; Pleis JR, 2007, P 2006 JOINT STAT M, P3540; Public Health England, 2015, PNEUM POL VACC PPV C; Sakamoto A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6080-7; Shapiro ED, 2012, JAMA-J AM MED ASSOC, V307, P847, DOI 10.1001/jama.2012.194; Turrell G, 2000, J EPIDEMIOL COMMUN H, V54, P207, DOI 10.1136/jech.54.3.207; Vila-Corcoles A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-222; Wang ZX, 2021, HUM VACC IMMUNOTHER, V17, P1455, DOI 10.1080/21645515.2020.1814653; Wang ZX, 2021, HUM VACC IMMUNOTHER, V17, P527, DOI 10.1080/21645515.2020.1776545; Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1	30	1	1	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6883	6893		10.1016/j.vaccine.2021.10.024		NOV 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WY9EK	34711437				2022-04-29	WOS:000719580000010
J	Jeon, S; Kelly, M; Yun, J; Lee, B; Park, M; Whang, Y; Lee, C; Halvorsen, YD; Verma, S; Charles, RC; Harris, JB; Calderwood, SB; Leung, DT; Bhuiyan, TR; Qadri, F; Kamruzzaman, M; Cho, S; Vann, WF; Xu, P; Kovac, P; Ganapathy, R; Lynch, J; Ryan, ET				Jeon, Suhi; Kelly, Meagan; Yun, Jeesun; Lee, Byungman; Park, Minchul; Whang, Yoonhee; Lee, Chankyu; Halvorsen, Yuan-Di; Verma, Smriti; Charles, Richelle C.; Harris, Jason B.; Calderwood, Stephen B.; Leung, Daniel T.; Bhuiyan, Taufiqur R.; Qadri, Firdausi; Kamruzzaman, Mohammad; Cho, Somyoung; Vann, Willie F.; Xu, Peng; Kovac, Pavol; Ganapathy, Ravi; Lynch, Julia; Ryan, Edward T.			Scalable production and immunogenicity of a cholera conjugate vaccine	VACCINE			English	Article						Cholera conjugate vaccine; Vibrio cholerae; O-specific polysaccharide; OSP; rTTHc	INFLUENZAE TYPE-B; MUCOSAL IMMUNE-RESPONSES; CONTROLLED FIELD TRIAL; RURAL EAST PAKISTAN; GROUP-C CONJUGATE; EL-TOR VACCINES; POLYSACCHARIDE VACCINES; PARENTERAL CHOLERA; ANTIBODY-RESPONSE; TRANSCUTANEOUS IMMUNIZATION	There is a need to develop cholera vaccines that are protective in young children under 5 years of age, which induce long-term immunity, and which can be incorporated into the Expanded Programme of Immunization (EPI) in cholera-endemic countries. The degree of protection afforded by currently available oral cholera vaccines (OCV) to young children is significantly lower than that induced by vaccination of older vaccine recipients. Immune responses that protect against cholera target the O-specific polysaccharide (OSP) of Vibrio cholerae, and young children have poor immunological responses to bacterial polysaccharides, which are T cell independent antigens. To overcome this, we have developed a cholera conjugate vaccine (CCV) containing the OSP of V. cholerae O1, the main cause of endemic and epidemic cholera. Here, we describe production of CCV through a scalable manufacturing process and preclinical evaluation of immunogenicity in the presence and absence of aluminum phosphate (alum) as an adjuvant. The vaccine displays V. cholerae O1 Inaba OSP in sun-burst display via single point attachment of core oligosaccharide to a recombinant tetanus toxoid heavy chain fragment (rTTHc). Two different pilot-scale production batches of non-GMP CCV were manufactured and characterized in terms of physico-chemical properties and immunogenicity. In preclinical testing, the vaccine induced OSP-and lipopolysaccharide (LPS)-specific IgG and IgM responses, vibriocidal responses, memory B cell responses, and protection in a V. cholerae O1 challenge model. The addition of alum to the administered vaccine increased OSP-specific immune responses. These results support evaluation of CCV in humans. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Jeon, Suhi; Yun, Jeesun; Lee, Byungman; Park, Minchul; Whang, Yoonhee; Lee, Chankyu] Eubiologics Ltd, Seoul, South Korea; [Kelly, Meagan; Halvorsen, Yuan-Di; Verma, Smriti; Charles, Richelle C.; Harris, Jason B.; Calderwood, Stephen B.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA; [Charles, Richelle C.; Calderwood, Stephen B.; Ryan, Edward T.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Harris, Jason B.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Harris, Jason B.] MassGen Hosp Children, Div Global Hlth, Boston, MA USA; [Leung, Daniel T.] Univ Utah, Sch Med, Div Infect Dis, Salt Lake City, UT USA; [Bhuiyan, Taufiqur R.; Qadri, Firdausi; Kamruzzaman, Mohammad] Icddr B, Dhaka, Bangladesh; [Cho, Somyoung; Ganapathy, Ravi; Lynch, Julia] Int Vaccine Inst, Seoul, South Korea; [Vann, Willie F.] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA; [Xu, Peng; Kovac, Pavol] NIDDK, LBC, NIH, Bethesda, MD 20892 USA; [Ryan, Edward T.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA		Ryan, ET (通讯作者)，Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA.	etryan@mgh.harvard.edu	Verma, Smriti/J-9950-2019; Qadri, Firdausi/AAF-4583-2019	Verma, Smriti/0000-0002-3760-8090; 	RIGHT Fund, Seoul, South Korea [RF-2018-V01]; Wellcome TrustWellcome TrustEuropean Commission [221595/Z/20/Z]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI106878, AI137164]; Fogarty International Center, Training Grant in Vaccine Development and Public Health [TW005572]; Emerging Global Fellowship Award [TW010362]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	This research was supported through programs funded by the RIGHT Fund ID: RF-2018-V01 (Research in Global Health Technologies), Seoul, South Korea, the Wellcome Trust reference No: 221595/Z/20/Z, and the National Institutes of Health, including the National Institute of Allergy and Infectious Diseases (AI106878 [ETR and FQ], and AI137164 [RCC, JBH]), the Fogarty International Center, Training Grant in Vaccine Development and Public Health (TW005572 [MK, TRB]), and Emerging Global Fellowship Award TW010362 [TRB], and the Intramural Research Program of the NIH and NIDDK (PX and PK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like to thank Drs. Robert Hall, Christian Gonzalez, and Daniel Stoughton, U.S. National Institutes of Health, USA and the Pre-clinical Vaccine and Product Development Services for critical efforts, guidance, and input.	Abu Sayeed M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003881; Aktar A, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006399; Alam MM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002683; ALBERT MJ, 1994, J INFECT DIS, V169, P230, DOI 10.1093/infdis/169.1.230; Alberti KP, 2008, T ROY SOC TROP MED H, V102, P251, DOI 10.1016/j.trstmh.2007.10.015; Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832; Ali M, 2012, B WORLD HEALTH ORGAN, V90, P209, DOI 10.2471/BLT.11.093427; [Anonymous], 1968, Bull World Health Organ, V38, P917; AZURIN JC, 1967, B WORLD HEALTH ORGAN, V37, P703; BARBOUR ML, 1993, PEDIATR INFECT DIS J, V12, P478, DOI 10.1097/00006454-199306000-00005; Barnes GK, 2016, SCAND J IMMUNOL, V84, P118, DOI 10.1111/sji.12451; BENENSON AS, 1968, B WORLD HEALTH ORGAN, V38, P359; BENENSON AS, 1968, B WORLD HEALTH ORGAN, V38, P347; Bi QF, 2017, LANCET INFECT DIS, V17, P1080, DOI [10.1016/s1473-3099(17)30359-6, 10.1016/S1473-3099(17)30359-6]; Bishop AL, 2010, INFECT IMMUN, V78, P4402, DOI 10.1128/IAI.00398-10; Bongat AFG, 2010, GLYCOCONJUGATE J, V27, P69, DOI 10.1007/s10719-009-9259-4; Borrow R, 1999, EPIDEMIOL INFECT, V123, P201, DOI 10.1017/S0950268899002915; Charles RC, 2020, MBIO, V11, DOI 10.1128/mBio.02847-20; Clark SA, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111675; CLEMENTS ML, 1982, J INFECT DIS, V145, P465, DOI 10.1093/infdis/145.4.465; Clutterbuck EA, 2012, J INFECT DIS, V205, P1408, DOI 10.1093/infdis/jis212; Cross DL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.574057; DASGUPTA A, 1967, B WORLD HEALTH ORGAN, V37, P371; Daugla DM, 2014, LANCET, V383, P40, DOI 10.1016/S0140-6736(13)61612-8; GANGAROSA EJ, 1967, LANCET, V1, P646; GANGULY R, 1975, B WORLD HEALTH ORGAN, V52, P323; Gavi-the Vaccine Alliance, 2018, CHOL SUPPL PROC ROAD, P4; GILMOUR C B, 1952, Bull World Health Organ, V7, P343; Global Task Force on Cholera Control GTFCC, 2019, CHOL VACC RES PRIOR, P3; Global Task Force on Cholera Control GTFCC, 2021, CHOL ROADM RES AG 20, P16; HAHNZORIC M, 1989, SCAND J INFECT DIS, V21, P421, DOI 10.3109/00365548909167447; Harris JB, 2012, LANCET, V379, P2466, DOI 10.1016/S0140-6736(12)60436-X; Harris JB, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000221; HISATSUNE K, 1993, BIOCHEM BIOPH RES CO, V190, P302, DOI 10.1006/bbrc.1993.1046; Islam K, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006376; Johnson RA, 2012, CLIN VACCINE IMMUNOL, V19, P1712, DOI 10.1128/CVI.00321-12; Kanungo S, 2009, VACCINE, V27, P6887, DOI 10.1016/j.vaccine.2009.09.008; Kauffman RC, 2021, MBIO, V12, DOI 10.1128/mBio.03679-20; Klugman K P, 2001, Lancet Infect Dis, V1, P85, DOI 10.1016/S1473-3099(01)00063-9; Kossaczka Z, 1999, INFECT IMMUN, V67, P5806, DOI 10.1128/IAI.67.11.5806-5810.1999; Legros D, 2018, J INFECT DIS, V218, pS137, DOI 10.1093/infdis/jiy486; Leung DT, 2012, CLIN VACCINE IMMUNOL, V19, P690, DOI 10.1128/CVI.05615-11; MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685; Maertens K, 2017, PEDIATR INFECT DIS J, V36, P1186, DOI 10.1097/INF.0000000000001601; MASCARTLEMONE F, 1988, SCAND J IMMUNOL, V28, P443, DOI 10.1111/j.1365-3083.1988.tb01474.x; MOSLEY WH, 1969, B WORLD HEALTH ORGAN, V40, P177; MOSLEY WH, 1968, B WORLD HEALTH ORGAN, V38, P335; Mosley WH, 1970, J INFECT DIS, V121, P1; MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2; Nurkka A, 2000, VACCINE, V19, P547, DOI 10.1016/S0264-410X(00)00180-8; Ochiai RL, 2014, CLIN VACCINE IMMUNOL, V21, P661, DOI 10.1128/CVI.00791-13; Ou L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59711-y; Safadi MAP, 2014, EMERG INFECT DIS, V20, P806, DOI 10.3201/eid2005.130948; Pezzoli L, 2020, VACCINE, V38, pA132, DOI 10.1016/j.vaccine.2019.08.086; Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494; Qadri F, 1997, INFECT IMMUN, V65, P3571, DOI 10.1128/IAI.65.9.3571-3576.1997; Rollenhagen JE, 2009, VACCINE, V27, P4917, DOI 10.1016/j.vaccine.2009.06.040; Saha A, 2011, VACCINE, V29, P8285, DOI 10.1016/j.vaccine.2011.08.108; Sinclair D, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008603.pub2; SIRISINHA S, 1970, Infection and Immunity, V2, P29; Slifka MK, 1996, J IMMUNOL METHODS, V199, P37, DOI 10.1016/S0022-1759(96)00146-9; Sur D, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001289; SVENNERHOLM AM, 1977, SCAND J IMMUNOL, V6, P1345; TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P593, DOI 10.1097/00006454-199307000-00010; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; Tarique AA, 2012, CLIN VACCINE IMMUNOL, V19, P594, DOI 10.1128/CVI.05689-11; Truck J, 2017, PEDIATR INFECT DIS J, V36, pE130, DOI 10.1097/INF.0000000000001497; van Ravenhorst MB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191261; Vianzon V, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00188-17; Thiem VD, 2011, CLIN VACCINE IMMUNOL, V18, P730, DOI 10.1128/CVI.00532-10; WALDOR MK, 1994, P NATL ACAD SCI USA, V91, P11388, DOI 10.1073/pnas.91.24.11388; Wang Z, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00626-16; Xu P, 2011, BIOCONJUGATE CHEM, V22, P2179, DOI 10.1021/bc2001984; Zhang Q, 2000, INFECT IMMUN, V68, P2692, DOI 10.1128/IAI.68.5.2692-2697.2000; Zhang Q, 2001, INFECT IMMUN, V69, P4337, DOI 10.1128/IAI.69.7.4337-4341.2001	75	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6936	6946		10.1016/j.vaccine.2021.10.005		NOV 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34716040	Green Published, hybrid			2022-04-29	WOS:000719580000017
J	Shubitz, LF; Robb, EJ; Powell, DA; Bowen, RA; Bosco-Lauth, A; Hartwig, A; Porter, SM; Trinh, H; Moale, H; Bielefeldt-Ohmann, H; Hoskinson, J; Orbach, MJ; Frelinger, JA; Galgiani, JN				Shubitz, Lisa F.; Robb, Edward J.; Powell, Daniel A.; Bowen, Richard A.; Bosco-Lauth, Angela; Hartwig, Airn; Porter, Stephanie M.; Trinh, Hien; Moale, Hilary; Bielefeldt-Ohmann, Helle; Hoskinson, James; Orbach, Marc J.; Frelinger, Jeffrey A.; Galgiani, John N.			Delta cps1 vaccine protects dogs against experimentally induced coccidioidomycosis	VACCINE			English	Article						Coccidioidomycosis; Vaccine; Dogs; Avirulent; Fungal	EPIDEMIOLOGY; INFECTION	Coccidioidomycosis is a significant health problem of dogs and humans in endemic regions, especially California and Arizona in the U.S. Both species would greatly benefit from a vaccine to prevent this disease. A live avirulent vaccine candidate, Dcps1, was tested for tolerability and efficacy to prevent pul-monary coccidioidomycosis in a canine challenge model. Vaccine injection-site reactions were transient and there were no systemic effects observed. Six of seven vaccine sites tested and all draining lymph nodes were sterile post-vaccination. Following infection with Coccidioides posadasii, strain Silveira, arthroconidia into the lungs, dogs given primary and booster vaccinations had significantly reduced lung fungal burdens (P = 0.0003) and composite disease scores (P = 0.0002) compared to unvaccinated dogs. Dogs vaccinated once had fungal burdens intermediate between those given two doses or none, but dis-ease scores were not significantly different from unvaccinated (P = 0.675). Dcps1 was well-tolerated in the dogs and it afforded a high level of protection when given as prime and boost. These results drive the Dcps1 vaccine toward a licensed veterinary vaccine and support continued development of this vaccine to prevent coccidioidomycosis in humans. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Shubitz, Lisa F.; Powell, Daniel A.; Trinh, Hien; Moale, Hilary; Orbach, Marc J.; Frelinger, Jeffrey A.; Galgiani, John N.] Univ Arizona, Valley Fever Ctr Excellence, 1656 E Mabel St,POB 245215, Tucson, AZ 85724 USA; [Robb, Edward J.] Aniv Lifesci LLC, 3250 Airflite Way STE 400, Long Beach, CA 90807 USA; [Powell, Daniel A.] Univ Arizona, Dept Immunobiol, 1656 E Mabel St,POB 245221, Tucson, AZ 85724 USA; [Bowen, Richard A.; Bosco-Lauth, Angela; Hartwig, Airn; Porter, Stephanie M.] Colorado State Univ, Coll Vet Med & Biomed Sci, 1601 Campus Delivery, Ft Collins, CO 80523 USA; [Bielefeldt-Ohmann, Helle] Univ Queensland, Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Hoskinson, James] DACVR, Hoskinson, 5001 Foothills Dr, Berthoud, CO 80513 USA; [Orbach, Marc J.] Univ Arizona, Sch Plant Sci, 1140 E South Campus Dr,POB 210036 303 Forbes Bldg, Tucson, AZ 85721 USA; [Galgiani, John N.] Univ Arizona, Dept Med, 1501 N Campbell Ave POB 245035, Tucson, AZ 85724 USA		Shubitz, LF (通讯作者)，Univ Arizona, Valley Fever Ctr Excellence, 1656 E Mabel St,POB 245215, Tucson, AZ 85724 USA.	Lfshubit@email.arizona.edu		Porter, Stephanie/0000-0001-6664-6451; Powell, Daniel/0000-0003-0503-3330	National Institutes of Allergy and Infectious DiseaseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [RO1-AI-132140]; Anivive Lifesciences, LLC, Long Beach, CA	This work was funded by the National Institutes of Allergy and Infectious Disease [grant number RO1-AI-132140] and Anivive Lifesciences, LLC, Long Beach, CA.	Abuodeh RO, 2000, J INFECT DIS, V181, P2106, DOI 10.1086/315525; Allio T, 2016, THER INNOV REGUL SCI, V50, P660, DOI 10.1177/2168479016641717; Ampel NM, 2002, CLIN DIAGN LAB IMMUN, V9, P1039, DOI 10.1128/CDLI.9.5.1039-1043.2002; Benedict K, 2019, MMWR SURVEILL SUMM, V68, P1, DOI 10.15585/mmwr.ss6807a1; Davidson AP, 2019, MED MYCOL, V57, pS67, DOI 10.1093/mmy/myy113; DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P559; Fierer J, 2006, J INFECT DIS, V193, P1323, DOI 10.1086/502972; Freedman M, 2017, 7 INT COCC S; Galgiani JN, 2016, CLIN INFECT DIS, V63, pE112, DOI 10.1093/cid/ciw360; Galgiani JN, 2020, CLIN INFECT DIS, V70, P2008, DOI 10.1093/cid/ciz933; Gorris ME, 2018, GEOHEALTH, V2, P6, DOI 10.1002/2017GH000095; Graupmann-Kuzma A, 2008, J AM ANIM HOSP ASSOC, V44, P226, DOI 10.5326/0440226; Hector RF, 2005, CLIN TECH SMALL AN P, V20, P240, DOI 10.1053/j.ctsap.2005.07.005; Hogrefe WR, 2005, BIOMARKERS, V10, pS50, DOI 10.1080/13547500500216629; Holbrook ED, 2019, MED MYCOL, V57, P800, DOI 10.1093/mmy/myy157; HUPPERT M, 1972, ANTIMICROB AGENTS CH, V1, P367, DOI 10.1128/AAC.1.5.367; Johnson LR, 2003, J AM VET MED ASSOC, V222, P461, DOI 10.2460/javma.2003.222.461; Jones JM, 2018, MED MYCOL, V56, P172, DOI 10.1093/mmy/myx041; Kent Hill HK., 2020, COST VALLEY FEVER AR, P1; Kirkland TN, 2016, J FUNGI, V2, DOI 10.3390/jof2040034; Litvintseva AP, 2015, CLIN INFECT DIS, V60, pE1, DOI 10.1093/cid/ciu681; Mafi N, 2020, MED MYCOL, V58, P626, DOI 10.1093/mmy/myz099; McCotter OZ, 2019, MED MYCOL, V57, pS30, DOI 10.1093/mmy/myy095; Narra HP, 2016, INFECT IMMUN, V84, P3007, DOI 10.1128/IAI.00633-16; NATHANSON N, 1979, AM J EPIDEMIOL, V110, P672, DOI 10.1093/oxfordjournals.aje.a112848; Nguyen C, 2013, CLIN MICROBIOL REV, V26, P505, DOI 10.1128/CMR.00005-13; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; PAPPAGIANIS D, 1993, AM REV RESPIR DIS, V148, P656, DOI 10.1164/ajrccm/148.3.656; Shubitz LF, 2005, JAVMA-J AM VET MED A, V226, P1846, DOI 10.2460/javma.2005.226.1846; Shubitz LE, 2007, ANN NY ACAD SCI, V1111, P395, DOI 10.1196/annals.1406.007; Shubitz LF, 2021, J INFECT DIS, V223, P166, DOI 10.1093/infdis/jiaa419; Shubitz LF, 2018, VACCINE, V36, P3375, DOI 10.1016/j.vaccine.2018.04.026; Soffler C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043207; Weaver E, 2020, SPAT SPATIO-TEMPORAL, V32, DOI 10.1016/j.sste.2019.100317; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; Wilson L, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16071113	36	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6894	6901		10.1016/j.vaccine.2021.10.029		NOV 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34696935	hybrid			2022-04-29	WOS:000719580000011
J	Zhu, WB; Liu, ZH; Zheng, XL; Li, J; Lu, KJ; Jiang, X; Zhang, XJ; Ren, FF; Zhang, XM; Xu, JW; Wu, ZX; Sun, M; Dong, SZ				Zhu, Wenbing; Liu, Zhuohang; Zheng, Xuelin; Li, Jun; Lu, Kongjie; Jiang, Xi; Zhang, Xuejian; Ren, Fangfang; Zhang, Xuemei; Xu, Jingwen; Wu, Zhongxiang; Sun, Ming; Dong, Shaozhong			A broad and potent IgM antibody against tetra-EV-As induced by EVA71 and CVA16 co-immunization	VACCINE			English	Article						Enterovirus A; IgM antibody; Potent; Broad; Co-immunization	ENTEROVIRUS 71 VACCINE; MOUTH-DISEASE; HAND; FOOT; COXSACKIEVIRUS; INFECTION; CHINA; MODEL; IMMUNOGENICITY; IDENTIFICATION	Objective: To determine the potent and broad neutralizing monoclonal antibody (mAb) against entero-virus A (EV-A) in vitro and in vivo induced by enterovirus A71(EVA71) and coxsackievirus 16 (CVA16) co-immunization. Methods: The mAb was Generated by co-immunization with EVA71 and CVA16 through hybridomas technology. The characteristics and neutralizing ability of mAb were analysed in vitro and in mice. Results: We screened three mAb, the IgM antibody M20 and IgG antibody B1 and C31. All three antibod-ies showed cross-reactivity against tetra-EV-As. However, M20 showed potent and broad neutralizing ability against tetra-EV-As than B1 and C31. Meanwhile, M20 provided cross-antiviral efficacy in tetra -EV-As orally infected mice. Moreover, M20 binds to a conserved neutralizing epitope within the GH loop of tetra-EV-As VP1. Conclusions: M20 and its property exhibited potent and broad antiviral activity against tetra-EV-As, and that is expected to be a potential preventive and therapeutic candidate against EV-As. (c) 2021 Elsevier Ltd. All rights reserved.	[Zhu, Wenbing; Liu, Zhuohang; Zheng, Xuelin; Li, Jun; Lu, Kongjie; Jiang, Xi; Zhang, Xuejian; Ren, Fangfang; Zhang, Xuemei; Xu, Jingwen; Wu, Zhongxiang; Sun, Ming; Dong, Shaozhong] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China		Dong, SZ (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.	dsz@imbcams.com.cn		Zhu, Wenbing/0000-0001-9210-1439			Chai N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14234; Chapman AP, 2002, ADV DRUG DELIVER REV, V54, P531, DOI 10.1016/S0169-409X(02)00026-1; Chen YC, 2004, J GEN VIROL, V85, P69, DOI 10.1099/vir.0.19423-0; Dang MH, 2014, PROTEIN CELL, V5, P692, DOI 10.1007/s13238-014-0087-3; Deng YQ, 2015, APPL MICROBIOL BIOT, V99, P7663, DOI 10.1007/s00253-015-6652-8; Dong CH, 2010, HUM VACCINES, V6, P1028, DOI 10.4161/hv.6.12.12982; Du RX, 2019, HUM VACC IMMUNOTHER, V15, P2343, DOI 10.1080/21645515.2019.1565266; Fujii K, 2018, J VIROL, V92, DOI 10.1128/JVI.00682-18; Gong S, 2018, AIDS, V32, pF5, DOI [10.1097/QAD.0000000000001857, 10.1097/qad.0000000000001857]; Gronwall C, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00066; Guang D, 2007, VIRUS RES, V125, P61, DOI 10.1016/j.virusres.2006.12.005; He SZ, 2018, VIROLOGY, V518, P328, DOI 10.1016/j.virol.2018.03.012; Ku ZQ, 2021, NATURE, V595, P718, DOI 10.1038/s41586-021-03673-2; Ku ZQ, 2015, J VIROL, V89, P12084, DOI 10.1128/JVI.02189-15; Lam S, 2015, MABS-AUSTIN, V7, P1178, DOI 10.1080/19420862.2015.1083664; Lee H, 2013, J VIROL, V87, P11363, DOI 10.1128/JVI.01926-13; Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224; Li XL, 2009, BIOCHEM BIOPH RES CO, V390, P1126, DOI 10.1016/j.bbrc.2009.09.103; Lim XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029751; Lin YW, 2009, J VIROL, V83, P6477, DOI 10.1128/JVI.00434-09; Liu CC, 2014, VACCINE, V32, P6177, DOI 10.1016/j.vaccine.2014.08.064; Liu CC, 2011, VACCINE, V29, P4362, DOI 10.1016/j.vaccine.2011.04.010; Liu QW, 2015, MICROBES INFECT, V17, P155, DOI 10.1016/j.micinf.2014.11.004; Liu QW, 2014, ANTIVIR RES, V105, P26, DOI 10.1016/j.antiviral.2014.02.015; Lizasoain A, 2020, INT J INFECT DIS, V94, P1, DOI 10.1016/j.ijid.2020.02.012; Mao LX, 2010, J CLIN VIROL, V49, P100, DOI 10.1016/j.jcv.2010.07.009; Mirand A, 2012, CLIN MICROBIOL INFEC, V18, pE110, DOI 10.1111/j.1469-0691.2012.03789.x; REED L. J., 1938, AMER JOUR HYG, V27, P493; Schweizer D, 2014, EUR J PHARM BIOPHARM, V88, P291, DOI 10.1016/j.ejpb.2014.08.001; Shang LQ, 2013, ANTIVIR RES, V97, P183, DOI 10.1016/j.antiviral.2012.12.005; Shen CG, 2019, THERANOSTICS, V9, P210, DOI 10.7150/thno.28434; Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8; Tchoudakova A, 2009, MABS, V1, P163, DOI 10.4161/mabs.1.2.7945; Thiberville SD, 2013, ANTIVIR RES, V99, P345, DOI 10.1016/j.antiviral.2013.06.009; Wu CY, 2020, ANTIVIR RES, V175, DOI 10.1016/j.antiviral.2020.104716; Xing WJ, 2014, LANCET INFECT DIS, V14, P308, DOI 10.1016/S1473-3099(13)70342-6; Xu LF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00477-9; Yang LS, 2016, ANTIVIR RES, V134, P50, DOI 10.1016/j.antiviral.2016.08.025; Zhang ZJ, 2017, J VIROL, V91, DOI 10.1128/JVI.02450-16; Zhou B, 2019, ANTIVIR RES, V161, P28, DOI 10.1016/j.antiviral.2018.11.001; Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1; Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923	42	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 22	2021	39	44					6510	6519		10.1016/j.vaccine.2021.09.056		OCT 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WX9RH	34600750				2022-04-29	WOS:000718925300009
J	Muller, F; Chandra, S; Wright, V; Rashid, M; Redditt, V				Mueller, Frank; Chandra, Shivani; Wright, Vanessa; Rashid, Meb; Redditt, Vanessa			Concordance of self-reported varicella history and serology among adolescent and adult refugee patients at a primary care clinic in Toronto, Canada	VACCINE			English	Article						Varicella; Vaccination; Immunization; Refugees; Immigrants; Migrants; Vaccine-preventable disease (VPD)	ZOSTER-VIRUS; RISK-FACTORS; VACCINATION; SUSCEPTIBILITY; SEROPREVALENCE; CHICKENPOX; MIGRANTS; IMMUNITY; RUBELLA; MEASLES	Background: Previous studies have found higher rates of varicella susceptibility among migrants from tropical regions. This study seeks to estimate the prevalence of varicella susceptibility in a cohort of newly arrived refugees and refugee claimants at a primary care clinic in Toronto and to compare patients' self-reported history of varicella infection with serologic test results. Methods: We conducted a retrospective chart review of 1888 refugee patients aged 13 years and older rostered at a specialized primary care clinic in Toronto from December 2011 to October 2017. Basic sociodemographic variables, self-reported varicella history, and varicella serologic results were exam-ined. Results: Based on serologic testing, 8.5% of individuals were varicella non-immune, with highest rates of varicella susceptibility among adolescents aged 13-19 years (13.5%). All adults over age 60 were varicella immune on serology (n = 56). A positive self-reported history of varicella infection was strongly predic-tive of varicella immunity on serology (PPV 96.8%; 95% CI: 95.2-97.9). A self-reported history of no prior varicella infection did not correlate reliably with serologic test results (NPV 15.8%; 95% CI: 13.3-18.0). A substantial proportion of patients (34.1%) were unsure of their varicella history. Conclusion: Identification and immunization of varicella susceptible refugee newcomers remains a health care priority. Self-reported history of varicella infection had mixed reliability as a predictor of varicella immunity. (c) 2021 Elsevier Ltd. All rights reserved.	[Mueller, Frank; Chandra, Shivani; Wright, Vanessa; Rashid, Meb; Redditt, Vanessa] Womens Coll Hosp, Crossrds Clin, 76 Grenville St, Toronto, ON M5S 1B2, Canada; [Mueller, Frank] Georg August Univ, Dept Gen Practice, Univ Med Ctr Gottingen, Humboldtallee 38, D-37073 Gottingen, Germany; [Chandra, Shivani; Redditt, Vanessa] Womens Coll Hosp, Inst Hlth Syst Solut & Virtual Care, 76 Grenville St, Toronto, ON M5S 1B2, Canada; [Rashid, Meb; Redditt, Vanessa] Univ Toronto, Dept Family & Community Med, 500 Univ Ave, Toronto, ON M5G 1V7, Canada		Redditt, V (通讯作者)，Womens Coll Hosp, 76 Grenville St, Toronto, ON M5S 1B2, Canada.	Frank.Mueller@med.uni-goettingen.de; Shivani.Chandra@wchospital.ca; Vanessa.Wright@wchospital.ca; Meb.Rashid@wchospital.ca; Vanessa.Redditt@wchospital.ca		Wright, Vanessa/0000-0002-5840-0694; Muller, Frank/0000-0002-9496-9423	German Academic Exchange ServiceDeutscher Akademischer Austausch Dienst (DAAD)	FM received a scholarship by the German Academic Exchange Service. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn KH, 2016, J OBSTET GYNAECOL, V36, P563, DOI 10.3109/01443615.2015.1127905; [Anonymous], 2018, ATL SUST DEV GOALS 2; Cadieux G, 2017, J IMMIGR MINOR HEALT, V19, P6, DOI 10.1007/s10903-015-0313-y; Canada Open Government Portal, 2020, CAN ADM PERM RES COU; Christiansen D, 2004, VACCINE, V22, P4233, DOI 10.1016/j.vaccine.2004.04.024; Cohen JI, 2014, CLIN VACCINE IMMUNOL, V21, P1288, DOI 10.1128/CVI.00250-14; Duncan JR, 2017, VACCINE, V35, P2351, DOI 10.1016/j.vaccine.2017.03.054; Freidl GS, 2018, VACCINE, V36, P1664, DOI 10.1016/j.vaccine.2018.01.079; Gershon AA, 2017, J INFECTION, V74, pS27, DOI 10.1016/S0163-4453(17)30188-3; Gershon AA, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.16; Greenaway C, 2014, EPIDEMIOL INFECT, V142, P1695, DOI 10.1017/S0950268813002768; Greenaway C, 2021, LANCET INFECT DIS, V21, P116, DOI 10.1016/S1473-3099(20)30277-2; Gushulak BD, 2011, CAN MED ASSOC J, V183, pE952, DOI 10.1503/cmaj.090287; Hsan K, 2019, TRAVEL MED INFECT DI, V31, DOI 10.1016/j.tmaid.2019.101465; Jablonka A, 2017, INFECT DIS THER, V6, P487, DOI 10.1007/s40121-017-0169-7; Law B, 1999, PEDIATRICS, V104, P1, DOI 10.1542/peds.104.1.1; Lesens O, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw042; Leung J, 2018, HUM VACC IMMUNOTHER, V14, P2460, DOI 10.1080/21645515.2018.1480283; Leung J, 2015, HUM VACC IMMUNOTHER, V11, P662, DOI 10.1080/21645515.2015.1008880; Leung J, 2015, J IMMIGR MINOR HEALT, V17, P310, DOI 10.1007/s10903-013-9946-x; Merrett P, 2007, CLIN INFECT DIS, V44, P1040, DOI 10.1086/512673; Mipatrini D, 2017, PATHOG GLOB HEALTH, V111, P59, DOI 10.1080/20477724.2017.1281374; Oztas D, 2020, CENT EUR J PUBL HEAL, V28, P130, DOI 10.21101/cejph.a5543; Pottie K, 2011, CAN MED ASSOC J, V183, pE824, DOI 10.1503/cmaj.090313; Public Health Agency of Canada, 2021, VAR CHICK VACC CAN I; Public Health Agency of Canada, CAN IMM GUID; Public Health Ontario, 2019, LAB SERV VAR SER TES; Public Health Ontario, 2020, MEASL MUMPS RUB MMR; Redditt VJ, 2015, CAN FAM PHYSICIAN, V61, pE303; Sharrar RG, 2000, VACCINE, V19, P916, DOI 10.1016/S0264-410X(00)00297-8; Staehelin C, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/taz035; Toikkanen SE, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13070650; United Nations High Commissioner for Refugees, 2020, GLOB TRENDS FORC DIS; Vairo F, 2017, EUROSURVEILLANCE, V22, P8, DOI 10.2807/1560-7917.ES.2017.22.46.17-00020; World Health Organization, 2019, WHO VACC PREV DIS MO; Wutzler P, 2017, EXPERT REV VACCINES, V16, P833, DOI 10.1080/14760584.2017.1343669; Zafack JG, 2019, PEDIATR INFECT DIS J, V38, P377, DOI 10.1097/INF.0000000000002162	37	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 15	2021	39	43					6391	6397		10.1016/j.vaccine.2021.09.027		OCT 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS5LV	34563396				2022-04-29	WOS:000715223200010
J	Sisnowski, J; Vujovich-Dunn, C; Gidding, H; Brotherton, J; Wand, H; Lorch, R; Veitch, M; Sheppeard, V; Effler, P; Skinner, SR; Venn, A; Davies, C; Hocking, J; Whop, L; Leask, J; Canfell, K; Sanci, L; Smith, M; Kang, M; Temple-Smith, M; Kidd, M; Burns, S; Selvey, L; Meijer, D; Ennis, S; Thomson, C; Lane, N; Kaldor, J; Guy, R				Sisnowski, J.; Vujovich-Dunn, C.; Gidding, H.; Brotherton, J.; Wand, H.; Lorch, R.; Veitch, M.; Sheppeard, V; Effler, P.; Skinner, S. R.; Venn, A.; Davies, C.; Hocking, J.; Whop, L.; Leask, J.; Canfell, K.; Sanci, L.; Smith, M.; Kang, M.; Temple-Smith, M.; Kidd, M.; Burns, S.; Selvey, L.; Meijer, D.; Ennis, S.; Thomson, C.; Lane, N.; Kaldor, J.; Guy, R.			Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states	VACCINE			English	Article						Primary prevention; Cervical cancer; Immunisation programs	HUMAN-PAPILLOMAVIRUS VACCINATION; GENITAL WARTS; INEQUALITIES; PREVALENCE; DAUGHTERS	Background: Schools are the primary setting for the delivery of adolescent HPV vaccination in Australia. Although this strategy has achieved generally high vaccination coverage, gaps persist for reasons that are mostly unknown. This study sought to identify school-level correlates of low vaccination course initiation and completion in New South Wales, Tasmania, and Western Australia to inform initiatives to increase uptake. Methods: Initiation was defined as the number of first doses given in a school in 2016 divided by vaccine eligible student enrolments. Completion was the number of third doses given in a school in 2015-2016 divided by the number of first doses. Low initiation and completion were defined as coverage < 25th percentile of all reporting schools. We investigated correlations between covariates using Spearman's rank correlation coefficients. Due to multicollinearity, we used univariable logistic regression to investigate associations between school characteristics and low coverage. Results: Median initiation was 84.7% (IQR: 75.0%-90.4%) across 1,286 schools and median completion was 93.8% (IQR: 86.0%-97.3%) across 1,295 schools. There were strong correlations between a number of school characteristics, particularly higher Indigenous student enrolments and lower attendance, increasing remoteness, higher postcode socioeconomic disadvantage, and smaller school size. Characteristics most strongly associated with low initiation in univariate analyses were small school size, location in Tasmania, and schools catering for special educational needs. Low completion was most strongly associated with schools in Tasmania and Western Australia, remote location, small size, high proportion of Indigenous student enrolments, and low attendance rates. Conclusion: This study provides indicative evidence that characteristics of schools and school populations are associated with the likelihood of low initiation and completion of the HPV vaccination course. The findings will guide further research and help target initiatives to improve vaccination uptake in schools with profiles associated with lower coverage. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Sisnowski, J.; Vujovich-Dunn, C.; Wand, H.; Lorch, R.; Kaldor, J.; Guy, R.] Univ New South Wales, Fac Med, Kirby Inst, Wallace Wurth Bldg,High St, Kensington, NSW, Australia; [Sisnowski, J.; Whop, L.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia; [Gidding, H.] Univ New South Wales, Sch Publ Hlth & Community Med, Kensington, NSW, Australia; [Gidding, H.; Leask, J.] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia; [Brotherton, J.] VCS Fdn, Populat Hlth, East Melbourne, Vic, Australia; [Brotherton, J.; Hocking, J.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Carlton, Vic, Australia; [Veitch, M.; Lane, N.] Tasmanian Govt, Dept Hlth & Human Serv, Hobart, Tas, Australia; [Sheppeard, V] Hlth Protect NSW, Communicable Dis Branch, St Leonards, NSW, Australia; [Sheppeard, V; Smith, M.] Univ Sydney, Sydney Sch Publ Hlth, Camperdown, NSW, Australia; [Effler, P.; Thomson, C.] Communicable Dis Control Directorate, Dept Hlth, East Perth, WA, Australia; [Skinner, S. R.; Davies, C.] Childrens Hosp Westmead, Sydney Childrens Hosp Network, Westmead, NSW, Australia; [Skinner, S. R.; Davies, C.] Univ Sydney, Fac Med & Hlth, Specialty Child & Adolescent Hlth, Camperdown, NSW, Australia; [Venn, A.] Univ Tasmania, Menzies Inst Med Res, Tasmanian, Australia; [Whop, L.] Charles Darwin Univ, Menzies Sch Hlth Res, Cairns, Qld, Australia; [Leask, J.] Univ Sydney, Fac Med & Hlth, Sydney Nursing Sch, Camperdown, NSW, Australia; [Canfell, K.; Smith, M.] Canc Council, Canc Res Div, Woolloomooloo, NSW, Australia; [Sanci, L.; Temple-Smith, M.] Univ Melbourne, Med Dent & Hlth Sci, Carlton, Vic, Australia; [Kang, M.] Univ Sydney, Westmead Clin Sch, Sydney, NSW, Australia; [Kidd, M.] Flinders Univ S Australia, Southgate Inst Hlth Soc & Equ, Bedford Pk, SA, Australia; [Burns, S.] Curtin Univ, Sch Populat Hlth, Perth, WA, Australia; [Selvey, L.] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia; [Meijer, D.; Ennis, S.] Hlth Protect NSW, Immunisat Unit, St Leonards, NSW, Australia; [Gidding, H.] Univ Sydney, Northern Clin Sch, St Leonards, NSW, Australia		Vujovich-Dunn, C (通讯作者)，UNSW, Kirby Inst Level 6,Wallace Wurth Bldg,High St, Sydney, NSW 2052, Australia.	jsisnowski@larby.unsw.edu.au; Jovich-dunn@kirby.unsw.edu.au; heather.gidding@sydney.edu.ah; jbrother@vcs.org.au; hwand@kirby.unsw.edu.au; rlorch@kirby.unsw.edu.au; mark.veitch@health.tas.gov.au; Sheppeard@health.nsw.gov.au; Paul.Effler@health.wa.gov.au; rachel.skinner@sydney.edu.au; alison.venn@utas.edu.au; cristyn.davies@sydney.edu.au; j.hocking@uniinelb.edu.au; lisa.whop@anu.edu.au; julie.leask@sydney.edu.au; karen.canfell@nswcc.org.au; l.sanci@unimelb.edu.au; Megan.Smith@nswcc.org.au; Melissa.Kang@uts.edu.au; m.temple-smith@unimelb.edu.au; michael.kidd@flinders.edu.au; S.Burns@curtin.edu.au; l.selvey@uq.edu.au; Dennis.Meijer@health.nsw.gov.au; Ennis@healthmsw.gov.au; Chloe.Thomson@health.wa.gov.au; nikki.lane@health.tas.gov.au; Jkaldor@kirby.unsw.edu.au; rguy@kirby.unsw.edu.au	Selvey, Linda/B-8473-2017	Selvey, Linda/0000-0001-8493-0974	HPV Partnership Project (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [APP1132344]; Australian Government Research Training Program Scholarship - NHMRC Early Career Fellowship [1142035]; NHRMC Cancer Institute NSW [APP1159491]	The study was conducted as part of the HPV Partnership Project (NHMRC grant number APP1132344) , which was formed between researchers, the National HPV Vaccination Program Register, and the health departments of three states, New South Wales, Tasma-nia, and Western Australia to understand why gaps persist in the HPV vaccination school based program. Dr Sisnowski was funded by an Australian Government Research Training Program Scholar-ship, Dr Whop was funded by the NHMRC Early Career Fellowship (#1142035) , and Dr Smith was funded by NHRMC grant (APP1159491) Cancer Institute NSW.	Ali H, 2017, MED J AUSTRALIA, V206, P204, DOI 10.5694/mja16.00597; Ali H, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2032; Ali H, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-140; Association of Independent Schools of NSW, SCH FIND; Association of Independent Schools of Western Australia, SEARCH SCH; Australian Bureau of Statistics, 2018, 2033 0 55 001 CENS P; Australian Government Department of Prime Minister and Cabinet, CLOS GAP REP 2019; Australian Government Department of Prime Minister and Cabinet, CLOS GAP ED SCH ATT; Australian Institute of Health and Welfare, 2017, AUSTR CANC INC MORT; Australian Institute of Health and Welfare, 2018, WEB UPD HPV IMM RAT; Australian Institute of Health and Welfare, 2017, CANC IN AUSTR; Barbaro B, 2014, AUST NZ J PUBL HEAL, V38, P419, DOI 10.1111/1753-6405.12218; Bernat DH, 2013, J ADOLESCENT HEALTH, V53, P630, DOI 10.1016/j.jadohealth.2013.07.035; Blasnik M., 2010, STAT SOFTWARE COMPON; Bodson J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183725; Canfell K, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100170; Constantine NA, 2007, J ADOLESCENT HEALTH, V40, P108, DOI 10.1016/j.jadohealth.2006.10.007; Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3; Drolet M, 2016, VACCINE, V34, P1874, DOI 10.1016/j.vaccine.2016.02.069; Dunne EF IC, 2015, CONTROL COMMUNICABLE; Fisher H, 2014, J PUBLIC HEALTH-UK, V36, P36, DOI 10.1093/pubmed/fdt042; Gertig DM, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-227; Hughes A, 2014, EUROSURVEILLANCE, V19, P12, DOI 10.2807/1560-7917.ES2014.19.2.20677; Independent Schools Tasmania, SCHOOLS; Lew JB, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-446; Machalek DA, 2018, J INFECT DIS, V217, P1590, DOI 10.1093/infdis/jiy075; Mak DB, 2013, J PAEDIATR CHILD H, V49, P895, DOI 10.1111/jpc.12030; Malagon T, 2015, CANCER EPIDEM BIOMAR, V24, P276, DOI 10.1158/1055-9965.EPI-14-1052; Marlow LAV, 2009, VACCINE, V27, P2483, DOI 10.1016/j.vaccine.2009.02.057; National HPV Vaccination Program Register, 2017, NAT AUSTR HPV 3 DOS; National HPV Vaccination Program Register, NAT AUSTR HPV 3 DOS; O'Neill J, 2019, VACCINE, V37, P272, DOI 10.1016/j.vaccine.2018.11.034; Pirotta M, 2010, SEX TRANSM INFECT, V86, P181, DOI 10.1136/sti.2009.040188; Preaud Emmanuelle, 2013, J Med Econ, V16, P763, DOI 10.3111/13696998.2013.793691; Roberts SA, 2011, EPIDEMIOL INFECT, V139, P400, DOI 10.1017/S095026881000066X; Rowe M, 2017, MARSHALL J MED, V3, DOI [10.18590/issn.2379-953610.18590/issn.2379-9536/, DOI 10.18590/ISSN.2379-953610.18590/ISSN.2379-9536]; Shelton RC, 2013, J RELIG HEALTH, V52, P1120, DOI 10.1007/s10943-011-9553-x; Sinka K, 2014, J EPIDEMIOL COMMUN H, V68, P57, DOI 10.1136/jech-2013-202620; Smith MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101048; Spencer AM, 2014, J EPIDEMIOL COMMUN H, V68, P571, DOI 10.1136/jech-2013-202629; SYRJANEN K, 1990, SEX TRANSM DIS, V17, P15, DOI 10.1097/00007435-199017010-00004; Tabrizi SN, 2014, J CLIN VIROL, V60, P250, DOI 10.1016/j.jcv.2014.04.013; Tiley K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029087; Watson M, 2014, AUST NZ J PUBL HEAL, V38, DOI 10.1111/1753-6405.12149; Wilson AR, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0323-5	45	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6117	6126		10.1016/j.vaccine.2021.08.076		SEP 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UY8XC	34493408	hybrid			2022-04-29	WOS:000701799200016
J	Jiang, YF; Li, XB; Yu, LX; Tong, W; Chen, PF; Wang, SY; Zhao, K; Tan, XM; Gao, F; Yu, H; Li, GX; Li, LW; Zhang, YJ; van den Born, E; Zhou, YJ; Tong, GZ				Jiang, Yifeng; Li, Xianbin; Yu, Lingxue; Tong, Wu; Chen, Pengfei; Wang, Shuaiyong; Zhao, Kuan; Tan, Xiangmei; Gao, Fei; Yu, Hai; Li, Guoxin; Li, Liwei; Zhang, Yujiao; van den Born, Erwin; Zhou, Yanjun; Tong, Guangzhi			Immune efficacy of a candidate porcine reproductive and respiratory syndrome vaccine rHN-NP49 administered by a Needle-free intradermal delivery system in comparison with intramuscular injection	VACCINE			English	Article						PRRS; Needle-free; Intradermal delivery; Immune efficiency	SYNDROME VIRUS; DNA VACCINE; SWINE; CELLS; PIGS; PERFORMANCE; CHALLENGE; RESPONSES; VIRULENT; NSP2	Porcine reproductive and respiratory syndrome (PRRS) is one of the major drivers of economic loss in the swine industry worldwide. In commercial pig production, vaccination is the first option in an attempt to control infectious diseases. Pigs are therefore often immunized with different vaccines, and almost all of them are delivered via the intramuscular (IM) route. However, the IM injection may result in physical damage, stress reactions, and is labor demanding. An alternative route is urgently needed to reduce the disadvantages of conventional vaccination. In this study, a needle-free intradermal (ID) delivery system was evaluated for delivering a live PRRS vaccine as compared with the traditional needle-syringe method. Fifty-two 4-week-old piglets were divided into six groups: piglets in groups A-C were immunized using ID delivery system with 10(4), 10(5) and 10(6) TCID50 of PRRS candidate vaccine strain rHNNP49, respectively; piglets in group D were immunized IM with 10(5) TCID50 of rHN-NP49; and group E and F were used as challenge and control groups, respectively. At 28 days post vaccination, piglets in group A to E were challenged with a lethal dose of highly-pathogenic PRRSV. Similar results were found in viremia and antibody response among the ID and IM groups during the immunization stage. After challenge, similar results were found in average body weight gain, viral shedding, serum viral load, and clinical score among the immunization groups, with a higher protection ratio in the ID group compared with IM group with the same immunization dose. These results demonstrated that the ID delivery system could provide similar or even better protection compared with IM route, and could be an effective route for PRRS vaccination. (C) 2021 Elsevier Ltd. All rights reserved.	[Jiang, Yifeng; Li, Xianbin; Yu, Lingxue; Tong, Wu; Chen, Pengfei; Wang, Shuaiyong; Zhao, Kuan; Tan, Xiangmei; Gao, Fei; Yu, Hai; Li, Guoxin; Li, Liwei; Zhang, Yujiao; Zhou, Yanjun; Tong, Guangzhi] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Dept Swine Infect Dis, Shanghai 200241, Peoples R China; [van den Born, Erwin] MSD Anim Hlth, POB 31, NL-5830 AA Boxmeer, Netherlands; [Tong, Guangzhi] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China		Zhou, YJ; Tong, GZ (通讯作者)，Chinese Acad Agr Sci, Shanghai Vet Res Inst, 518 Ziyue Rd, Shanghai 200241, Peoples R China.	yjzhou@shvri.ac.cn; gztong@shvri.ac.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32072875, 31670158]; earmarked fund for Modern Agro-Industry Technology Research System of China [CARS-35]	The authors declare that they have no known competing finan-cial interests or personal relationships that could have appeared to influence the work reported in this paper. We thank Andrew G. Harrison in the Department of Immunol-ogy at UConn Health for helpful discussions and proofreading. This work was supported by the National Natural Science Foundation of China (32072875, 31670158) and the earmarked fund for Modern Agro-Industry Technology Research System of China (CARS-35) .	Abadie V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008159; BENFIELD DA, 1992, J VET DIAGN INVEST, V4, P127, DOI 10.1177/104063879200400202; Borggren M, 2016, VACCINE, V34, P3634, DOI 10.1016/j.vaccine.2016.05.030; Borggren M, 2015, HUM VACC IMMUNOTHER, V11, P1983, DOI 10.1080/21645515.2015.1011987; Chase CCI, 2008, J SWINE HEALTH PROD, V16, P254; Eble PL, 2009, VACCINE, V27, P1272, DOI 10.1016/j.vaccine.2008.12.011; Han W, 2009, VIRUS GENES, V38, P276, DOI 10.1007/s11262-008-0322-1; Hickling JK, 2011, B WORLD HEALTH ORGAN, V89, P221, DOI 10.2471/BLT.10.079426; Houser TA, 2004, MEAT SCI, V68, P329, DOI 10.1016/j.meatsci.2004.03.016; Khoa LD, 2019, ANDROLOGY-US, V7, P69, DOI 10.1111/andr.12557; Kimman TG, 2009, VACCINE, V27, P3704, DOI 10.1016/j.vaccine.2009.04.022; Ko EY, 2018, KOREAN J FOOD SCI AN, V38, P1155, DOI 10.5851/kosfa.2018.e46; Kouiavskaia D, 2015, J INFECT DIS, V211, P1447, DOI 10.1093/infdis/jiu624; Laurent PE, 2007, VACCINE, V25, P8833, DOI 10.1016/j.vaccine.2007.10.020; Leng X, 2012, CLIN VACCINE IMMUNOL, V19, P1199, DOI 10.1128/CVI.05646-11; Li JZ, 2017, ARCH VIROL, V162, P235, DOI 10.1007/s00705-016-3099-x; Liu JK, 2013, ARCH VIROL, V158, P1811, DOI 10.1007/s00705-013-1669-8; McAllister L, 2014, LANCET, V384, P674, DOI 10.1016/S0140-6736(14)60524-9; Miller MA, 1999, B WORLD HEALTH ORGAN, V77, P808; Mittelholzer C, 2000, VET MICROBIOL, V74, P293, DOI 10.1016/S0378-1135(00)00195-4; Nfon CK, 2008, VET IMMUNOL IMMUNOP, V126, P236, DOI 10.1016/j.vetimm.2008.07.012; Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201; Pandya M, 2012, VACCINE, V30, P3106, DOI 10.1016/j.vaccine.2012.02.049; Pielenhofer J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00266; Romani N, 2010, IMMUNOL CELL BIOL, V88, P424, DOI 10.1038/icb.2010.39; Sarno MJ, 2000, PEDIATR INFECT DIS J, V19, P839, DOI 10.1097/00006454-200009000-00006; Sun Y, 2013, VACCINE, V31, P538, DOI 10.1016/j.vaccine.2012.11.013; Temple D, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10101898; Temple D, 2017, PORCINE HEALTH MANAG, V3, DOI 10.1186/s40813-017-0056-3; Tian ZJ, 2009, VET MICROBIOL, V138, P34, DOI 10.1016/j.vetmic.2009.03.003; Tong GZ, 2007, EMERG INFECT DIS, V13, P1434, DOI 10.3201/eid1309.070399; TONG Y, 1999, CHIN J PREV VET MED, V21, P406; Wang G, 2016, DEV COMP IMMUNOL, V62, P1, DOI 10.1016/j.dci.2016.04.019; Wei TianChao, 2008, Zhongguo Yufang Shouyi Xuebao / Chinese Journal of Preventive Veterinary Medicine, V30, P944; WENSVOORT G, 1992, VET MICROBIOL, V33, P185, DOI 10.1016/0378-1135(92)90046-V; Xing Y, 2019, EXPERT OPIN DRUG DEL, V16, P995, DOI 10.1080/17425247.2019.1649251; Xu YZ, 2012, VET MICROBIOL, V159, P1, DOI 10.1016/j.vetmic.2012.03.015; Yu ZQ, 2017, VET MICROBIOL, V208, P97, DOI 10.1016/j.vetmic.2017.07.019; Zempsky WT, 2016, CLIN J PAIN, V32, P211, DOI 10.1097/AJP.0000000000000257; Zuckermann FA, 2007, VET MICROBIOL, V123, P69, DOI 10.1016/j.vetmic.2007.02.009	40	0	0	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5557	5562		10.1016/j.vaccine.2021.08.023		SEP 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34412921				2022-04-29	WOS:000704399700015
J	Jung, Y; Min, JY; Kim, HJ; Min, KB				Jung, Yoojoong; Min, Jin-Young; Kim, Hye-Jin; Min, Kyoug-Bok			Disparities in infant mortality from all-infectious, vaccine-preventable, and non-vaccine preventable diseases in relation to parental education	VACCINE			English	Article						Vaccine; Education level; Infant mortality; Infectious diseases; Vaccine-preventable; Non-vaccine-preventable	UNITED-STATES; HOSPITALIZATIONS; VACCINATIONS	Background: The burden of infectious diseases in infants is substantial. Parental education has been considered as a critical factor for predicting infant mortality. However, even though some studies have been done about relationship between infectious disease and parent's education level, no researches have been conducted specifically about vaccine-preventable and non-vaccine-preventable disease mortality by parent's educational level. Purpose: This study aimed to compare infant mortality rates from all-infectious diseases, vaccine preventable and non-vaccine-preventable diseases by mother's and father's education levels. Methods: We used 2017 US Linked Birth and Infant Death Data from National Center for Health Statistics, which included 3,153,574 live births and 13,870 deaths. To identify the association between each mother's and father's education level and all-infectious disease, vaccine-preventable disease, and non-vaccine-preventable disease infant mortality, logistic regression analyses were conducted by using educational level 1 as the reference. All-infectious diseases, vaccine-preventable and non-vaccine-preventable diseases were identified by vaccination recommendation of 2017 CDC guideline. Education levels were classified into four groups: level 1, through 12th grade with no diploma; Level 2, high school graduate or GED completed; Level 3, some college credit but no degree or associate degree; and Level 4, bachelor's degree, master's degree, doctorate or professional degree. Results: Higher parents' education level was appreciably associated with lower infant mortality from all cause, all-infectious diseases, vaccine-preventable diseases, and non-vaccine-preventable diseases. Moreover, each mother's and father's education level was correlated to infant mortality due to vaccine-preventable diseases on the whole education level, while all-infectious disease and non vaccine-preventable disease mortality is related with parent's education level only if their education level is fairly high. In other words, the adjusted odds for vaccine-preventable disease mortality were significantly lower than that for all-infectious and non-vaccine-preventable disease mortality at education level 2 and 3 and still smaller at education level 4. Conclusion: These finding implies that each mother's and father's higher education level was associated with lower infant mortality rate from all-infectious diseases, vaccine-preventable diseases, and non vaccine-preventable diseases. Furthermore, each level of mother's and father's education was more likely to be related to infant mortality by vaccine-preventable diseases than that of infant mortality by all infectious diseases, and non-vaccine-preventable diseases. (c) 2021 Elsevier Ltd. All rights reserved.	[Jung, Yoojoong] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; [Min, Jin-Young] Vet Med Res Inst, Vet Hlth Serv Med Ctr, Seoul, South Korea; [Kim, Hye-Jin; Min, Kyoug-Bok] Seoul Natl Univ, Inst Hlth Policy & Management, Med Res Ctr, Seoul, South Korea; [Min, Kyoug-Bok] Seoul Natl Univ, Coll Med, Dept Prevent Med, 103 Daehak Ro, Seoul 110799, South Korea		Min, KB (通讯作者)，Seoul Natl Univ, Coll Med, Dept Prevent Med, 103 Daehak Ro, Seoul 110799, South Korea.	minkb@snu.ac.kr			Basic Science Research Pro-gram through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and TechnologyNational Research Foundation of Korea [2019R1A2C1004966]; Education and Research Encouragement Fund of Seoul National University Hospital	This research was supported by the Basic Science Research Pro-gram through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (grant number, 2019R1A2C1004966) . This work was supported by the Education and Research Encouragement Fund of Seoul National University Hospital.	Amrhein V, 2019, NATURE, V567, P305, DOI 10.1038/d41586-019-00857-9; Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; Centers for Disease Control and Prevention,, US GUID 2018 PER 201; Centers for Disease Control and Prevention, 2017, REC IMM SCHED CHILDR; Centers for Disease Control and Prevention, EPIDEMIOLOGY PREVENT; Falagas ME, 2008, CURR MED RES OPIN, V24, P1719, DOI 10.1185/03007990802085692; Foutz J, 2017, UNINSURED PRIMER KEY; Glynn S. J., 2016, BREADWINNING MOTHERS; Grant CC, 2010, BRIT J GEN PRACT, V60, DOI 10.3399/bjgp10X483535; Green T, 2019, DEMOGR RES, V41, P713, DOI 10.4054/DemRes.2019.41.25; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Luman ET, 2005, JAMA-J AM MED ASSOC, V293, P1204, DOI 10.1001/jama.293.10.1204; Lutz, 2010, VIENNA YEARB POPUL R, V8, P175, DOI DOI 10.1553/populationyearbook2010s175; McGovern ME, 2015, AM J EPIDEMIOL, V182, P791, DOI 10.1093/aje/kwv125; Ostapchuk M, 2004, AM FAM PHYSICIAN, V70, P899; Ozer M, 2018, HEALTH ECON, V27, P1218, DOI 10.1002/hec.3770; Plotkin S, 2017, PLOTKINS VACCINES; Rammohan A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-336; Russell PJ, 2020, BIOL DYNAMIC SCI, V5th; Saez-Llorens X, 2003, LANCET, V361, P2139, DOI 10.1016/S0140-6736(03)13693-8; Sierra G, 2016, POP ASS AM 2016 ANN; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; Simpson G, 1997, Vital Health Stat 10, P1; Tamborini CR, 2015, DEMOGRAPHY, V52, P1383, DOI 10.1007/s13524-015-0407-0; Wamani H, 2004, INT J EQUITY HEALTH, V3, P1, DOI [10.1186/1475-9276-3-9, DOI 10.1186/1475-9276-3-9]; Wei FF, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-18; WHO, WHO VACC PREV DIS MO; Williams SE, 2014, HUM VACC IMMUNOTHER, V10, P2584, DOI 10.4161/hv.28596; Yorita KL, 2008, PEDIATRICS, V121, P244, DOI 10.1542/peds.2007-1392	30	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5658	5665		10.1016/j.vaccine.2021.08.009		SEP 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34420790				2022-04-29	WOS:000704399700027
J	Litwin, C; Smith, L; Donken, R; Krajden, M; van Niekerk, D; Naus, M; Cook, D; Albert, A; Ogilvie, G				Litwin, Charles; Smith, Laurie; Donken, Robine; Krajden, Mel; van Niekerk, Dirk; Naus, Monika; Cook, Darrel; Albert, Arianne; Ogilvie, Gina			High-risk HPV prevalence among women undergoing cervical cancer screening: Findings a decade after HPV vaccine implementation in British Columbia, Canada	VACCINE			English	Article						Human papillomavirus vaccine; HPV prevalence; HPV vaccine evaluation; Canada; Population-based evaluation; Cervical cancer screening	POPULATION-BASED EVALUATION; HUMAN-PAPILLOMAVIRUS; CLINICAL-TRIALS; PROGRAMS; IMPACT	Background: British Columbia (BC) introduced a publicly funded, school-based human papillomavirus (HPV) immunization program in 2008 with the quadrivalent vaccine. In 2010/2011, a baseline evaluation of HPV prevalence was conducted among women undergoing cervical cancer screening. After 10 years of publicly funded HPV vaccination, HPV-type prevalence was re-evaluated. Methods: From August 2017 to March 2018, 1107 physicians were invited to return cytobrushes used during routine Pap screening to the Cervical Cancer Screening Laboratory for HPV testing. Only age or year of birth was collected. Specimens were screened for high-risk HPV (hrHPV) and positive samples were genotyped. HPV type prevalence was compared for females 15-22 yrs (those eligible for the school-based vaccination) and 23+ yrs (ineligible for school-based vaccination) for the 2010/2011 and the 2017/2018 data. Results: There were 3309 valid samples received for testing; of these, 3107 were included in the analysis. The overall hrHPV prevalence was 12.2% (95% CI 11.3-13.3) in 2010/11, and 12.0% (95% CI 10.9-13.2) in 2017/18. For the 15-22 age group, the prevalence for any hrHPV was 26.8% (95% CI 23.1-30.8) in 2010/11 and 25.4% (95% CI 15.3-37.9) in 2017/18. For those aged 15-22, HPV16 prevalence in 2010/11 was 8.8% (95% CI 6.5-11.5) and in 2017/18 was 6.3% (95% CI 1.8-15.5), with corresponding figures for HPV18 3.7% (95% CI 2.3-5.7) and 0% (95% CI 0.0-5.7), respectively. For all hrHPV types, there were no statistically sig-nificant differences between the 2010/11 and 2017/18 periods. Conclusions: This study illustrates the prevalence of hrHPV in BC over time in women undergoing cervical cancer screening, where an indication of a decline in HPV16/18 is seen in vaccine eligible women. (c) 2021 Elsevier Ltd. All rights reserved.	[Litwin, Charles; Donken, Robine; Krajden, Mel; van Niekerk, Dirk; Naus, Monika; Ogilvie, Gina] Univ British Columbia, Fac Med, Vancouver, BC, Canada; [Litwin, Charles; Smith, Laurie; Donken, Robine; Albert, Arianne; Ogilvie, Gina] BC Womens Hosp & Hlth Serv, Womens Hlth Res Inst, Vancouver, BC, Canada; [Smith, Laurie; van Niekerk, Dirk] BC Canc, Vancouver, BC, Canada; [Donken, Robine] BC Childrens Hosp Res Inst, Vaccine Evaluat Ctr, Vancouver, BC, Canada; [Krajden, Mel; Naus, Monika; Cook, Darrel] BC Ctr Dis Control, Vancouver, BC, Canada; [Donken, Robine] Vrije Univ, Amsterdam UMC, Epidemiol & Data Sci, Amsterdam, Netherlands		Litwin, C (通讯作者)，BC Womens Hosp & Hlth Ctr, Womens Hlth Res Inst, 4500 Oak St, Vancouver, BC V6H 3N1, Canada.	charles.litwin@alumni.ubc.ca		Litwin, Charles/0000-0003-1890-0499; Albert, Arianne/0000-0002-3050-0888; Smith, Laurie/0000-0002-9463-1713	Canadian Health Research Institute, Foundation Scheme FundingCanadian Institutes of Health Research (CIHR) [FDN: 143339]; Canadian Immunization Research Network; Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research	Funding was received from the Canadian Health Research Institute, Foundation Scheme Funding (FDN: 143339). RD has received salary funding from the Canadian Immunization Research Network and the Michael Smith Foundation for Health Research.	[Anonymous], 2018, R LANGUAGE ENV STAT; BC Cancer Agency, BRIT COL AD NEW CERV BRIT COL AD NEW CERV; BC Cancer Screening, 2020, SCREEN PERF REP 2013 SCREEN PERF REP 2013; BC Centre for Disease Control, 2019, IMM UPT GRAD 6 STUD IMM UPT GRAD 6 STUD; Bird Y, 2017, INT J PREVENTIVE MED, V8, DOI 10.4103/ijpvm.IJPVM_49_17; Donken R, 2021, INT J CANCER, V149, P191, DOI 10.1002/ijc.33513; Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3; Drolet M, 2015, LANCET INFECT DIS, V15, P565, DOI 10.1016/S1473-3099(14)71073-4; Hariri S, 2015, CANCER EPIDEM BIOMAR, V24, P393, DOI 10.1158/1055-9965.EPI-14-0649; Lehtinen M, 2013, NAT REV CLIN ONCOL, V10, P400, DOI 10.1038/nrclinonc.2013.84; Lenselink CH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003743; Lu BB, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-13; Lukac CD, 2020, SEX TRANSM DIS, V47, P691, DOI 10.1097/OLQ.0000000000001235; Markowitz LE, 2019, VACCINE, V37, P3918, DOI 10.1016/j.vaccine.2019.04.099; Mesher D, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009915; Moore RA, 2009, CANCER CAUSE CONTROL, V20, P1387, DOI 10.1007/s10552-009-9365-4; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Ogilvie GS, 2013, VACCINE, V31, P1129, DOI 10.1016/j.vaccine.2012.09.085; Ogilvie G, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000270; Ogilvie GS, 2015, INT J CANCER, V137, P1931, DOI 10.1002/ijc.29508; Racey CS, 2020, J INFECT DIS, V221, P81, DOI 10.1093/infdis/jiz422; Sankaranarayanan R, 2016, INDIAN J MED RES, V144, P169, DOI 10.4103/0971-5916.195023; Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108; Soederlund-Strand A, 2014, CANCER EPIDEM BIOMAR, V23, P2757, DOI 10.1158/1055-9965.EPI-14-0687; Steben M, 2018, J OBSTET GYNAECOL CA, V40, P1635, DOI 10.1016/j.jogc.2018.05.024; Stevenson M., 2013, EPIR R PACKAGE ANAL, P9; Tabrizi SN, 2014, LANCET INFECT DIS, V14, P958, DOI 10.1016/S1473-3099(14)70841-2; Tranberg M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2039-0; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F	29	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5198	5204		10.1016/j.vaccine.2021.07.009		AUG 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34344555				2022-04-29	WOS:000684878300016
J	Clarke, M; Goodchild, LM; Evans, S; Giles, LC; Sullivan, SG; Barr, IG; Lambert, S; Marshall, H				Clarke, Michelle; Goodchild, Louise M.; Evans, Sue; Giles, Lynne C.; Sullivan, Sheena G.; Barr, Ian G.; Lambert, Stephen; Marshall, Helen			Body mass index and vaccine responses following influenza vaccination during pregnancy	VACCINE			English	Article						Influenza; Obesity; Vaccine; Immunogenicity; Vaccination	OBESITY; RISK	Background and Aims: Influenza vaccination is recommended by the World Health Organisation for pregnant women, offering the dual benefit of protecting pregnant women and their newborn infants against influenza infection. Various factors can influence vaccine immunogenicity, with obesity being one factor implicated in varied responses. This study aimed to investigate the impact of body mass index (BMI) on vaccine responses following influenza vaccination during pregnancy. Methods: Pregnant women attending the Women's and Children's Hospital in South Australia during 2014-2016 were invited to participate. Participant's clinical and demographic factors were recorded prior to administration of licensed seasonal influenza vaccination. Blood samples were collected before and one month post-vaccination to measure antibody responses by haemagglutination inhibition (HI) assay. Seroprotection was defined as a post-vaccination HI titre >= 1:40. Regression models assessed associations with failure to achieve seroprotective antibodies to H1, H3, and B influenza strains. Results: A total of 96 women were enrolled in the study at a median gestation of 22 weeks with a BMI range of 18-49 kg/m(2). Paired sera samples were available for 90/96 (94%). Most pregnant women (72/90, 80%) demonstrated seroprotective antibody titres to all three influenza vaccine antigens (A(H1N1)pdm09, A (H3N2), B/Yamagata) following vaccination. Compared with women with BMI < 30 kg/m(2), those with high BMI were less likely to fail to achieve seroprotective antibodies, however this was not statistically significant (RR 0.42, 95% CI 0.11-1.68; p = 0.22). A greater proportion of women vaccinated during their second (47/53, 93%) or third trimester (18/25, 72%) demonstrated seroprotection to all three vaccine antigens following vaccination compared with women vaccinated during their first trimester (7/12, 58%). Conclusion: High BMI did not impair seroprotection levels following influenza vaccination in pregnant women. Gestation at vaccination may be an important consideration for optimising vaccine protection for pregnant women and their newborns. Further assessment of first trimester influenza vaccine responses is warranted. (C) 2021 Elsevier Ltd. All rights reserved.	[Clarke, Michelle; Goodchild, Louise M.; Evans, Sue; Marshall, Helen] Womens & Childrens Hlth Network, Adelaide, SA, Australia; [Clarke, Michelle; Marshall, Helen] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia; [Clarke, Michelle; Giles, Lynne C.; Marshall, Helen] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia; [Giles, Lynne C.] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia; [Sullivan, Sheena G.; Barr, Ian G.] Royal Melbourne Hosp, WHO Collaborating Ctr Reference & Res Influenza, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Sullivan, Sheena G.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Infect Dis, Melbourne, Vic, Australia; [Sullivan, Sheena G.] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA; [Barr, Ian G.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Lambert, Stephen] Univ Queensland, Child Hlth Res Ctr, South Brisbane, Qld, Australia		Marshall, H (通讯作者)，Womens & Childrens Hosp, Vaccinol & Immunol Res Trials Unit, Adelaide, SA 5006, Australia.	michelle.clarke@adelaide.edu.au; louise.goodchild@adelaide.edu.au; sue.evans@adelaide.edu.au; lynne.giles@adelaide.edu.au; sheena.sullivan@influenzacentre.org; ian.barr@influenzacentre.org; sblambert@uq.edu.au; helen.marshall@adelaide.edu.au	; Lambert, Stephen/B-8348-2008	sullivan, sheena/0000-0002-0856-0294; Lambert, Stephen/0000-0002-2709-193X	Women's and Children's Hospital Foundation	This work was funded by a Women's and Children's Hospital Foundation project grant.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Australian Institute of Health and Welfare, 2020, AUSTR MOTH BAB 2018; Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB; Castrucci MR, 2018, HUM VACC IMMUNOTHER, V14, P637, DOI 10.1080/21645515.2017.1338547; Christian LM, 2014, VACCINE, V32, P2958, DOI 10.1016/j.vaccine.2014.03.075; Cuningham W, 2019, INFLUENZA OTHER RESP, V13, P438, DOI 10.1111/irv.12649; Eliakim A, 2006, AUTOIMMUNITY, V39, P137, DOI 10.1080/08916930600597326; European Medicines Agency, 2016, EMACHMPVWP4572592014 EMACHMPVWP4572592014; Fezeu L, 2011, OBES REV, V12, P653, DOI 10.1111/j.1467-789X.2011.00864.x; Gandhi M, 2015, J REPROD IMMUNOL, V112, P34, DOI 10.1016/j.jri.2015.06.003; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Kaminski DA, 2010, TRENDS IMMUNOL, V31, P384, DOI 10.1016/j.it.2010.08.001; Karisson EA, 2010, J IMMUNOL, V184, P3127, DOI 10.4049/jimmunol.0903220; Kay AW, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00289; Lin Kuo-Cherng, 1999, Kaohsiung Journal of Medical Sciences, V15, P640; Marzullo P, 2014, ENDOCRINE, V45, P392, DOI 10.1007/s12020-013-0006-z; McLarnon A, 2012, NAT REV ENDOCRINOL, V8, P3; Mertz D, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4318-3; Ng M, 2014, LANCET, V384, P746; Park HL, 2014, HUM VACC IMMUNOTHER, V10, P1181, DOI 10.4161/hv.28332; Pedersen AF, 2009, BRAIN BEHAV IMMUN, V23, P427, DOI 10.1016/j.bbi.2009.01.004; de Heredia FP, 2012, P NUTR SOC, V71, P332, DOI 10.1017/S0029665112000092; Pheiffer C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031326; Procaccini C, 2012, MOL ASPECTS MED, V33, P35, DOI 10.1016/j.mam.2011.10.012; Quach THT, 2020, MATERN CHILD HLTH J, V24, P229, DOI 10.1007/s10995-019-02844-y; Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2017, MAN OB PREGN; Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208; Sperling RS, 2012, OBSTET GYNECOL, V119, P631, DOI 10.1097/AOG.0b013e318244ed20; Sweet MA, 2015, INFECT CONT HOSP EP, V36, P249, DOI 10.1017/ice.2014.59; Tagliabue C, 2016, EUR J CLIN MICROBIOL, V35, P325, DOI 10.1007/s10096-015-2558-8; Talbot HK, 2012, VACCINE, V30, P3937, DOI 10.1016/j.vaccine.2012.03.071; Trombetta CM, 2016, EXPERT REV VACCINES, V15, P967, DOI 10.1586/14760584.2016.1164046; Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053; Walker JL, 2020, J INFECT DIS, V221, P16, DOI 10.1093/infdis/jiz310; WHO, 2012, WEEKLY EPIDEMIOLOGIC; WHO Global Influenza Surveillance Network, 2019, MAN LAB DIAGN VIR SU MAN LAB DIAGN VIR SU; Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630	38	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4864	4870		10.1016/j.vaccine.2021.06.065		JUL 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34266699				2022-04-29	WOS:000679483400018
J	Mateo-Urdiales, A; Del Manso, M; Andrianou, X; Spuri, M; D'Ancona, F; Filia, A; Rota, MC; Petrone, D; Vescio, MF; Riccardo, F; Bella, A; Pezzotti, P; Fabiani, M				Mateo-Urdiales, Alberto; Del Manso, Martina; Andrianou, Xanthi; Spuri, Matteo; D'Ancona, Fortunato; Filia, Antonietta; Rota, Maria Cristina; Petrone, Daniele; Vescio, Maria Fenicia; Riccardo, Flavia; Bella, Antonino; Pezzotti, Patrizio; Fabiani, Massimo			Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021	VACCINE			English	Article						COVID-19; Vaccines; Healthcare workers; Pandemic		In Italy, the COVID-19 vaccination campaign started in December 2020 with the vaccination of healthcare workers (HCW). To analyse the real-life impact that vaccination is having on this population group, we measured the association between week of diagnosis and HCW status using log-binomial regression. By the week 22-28 March, we observed a 74% reduction (PPR 0.26; 95% CI 0.22-0.29) in the proportion of cases reported as HCW and 81% reduction in the proportion of symptomatic cases reported as HCW, compared with the week with the lowest proportion of cases among HCWs prior to the vaccination campaign (31 August-7 September). The reduction, both in relative and absolute terms, of COVID-19 cases in HCWs that started around 30 days after the start of the vaccination campaign suggest that COVID-19 vaccines are being effective in preventing infection in this group. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Mateo-Urdiales, Alberto; Del Manso, Martina; Andrianou, Xanthi; Spuri, Matteo; D'Ancona, Fortunato; Filia, Antonietta; Rota, Maria Cristina; Petrone, Daniele; Vescio, Maria Fenicia; Riccardo, Flavia; Bella, Antonino; Pezzotti, Patrizio; Fabiani, Massimo] Ist Super Sanita, Dept Infect Dis, Rome, Italy; [Mateo-Urdiales, Alberto; Del Manso, Martina] European Ctr Dis Prevent & Control ECDC, European Programme Intervent Epidemiol Training E, Stockholm, Sweden; [Andrianou, Xanthi] Cyprus Univ Technol, Cyprus Int Inst Environm & Publ Hlth, Limassol, Cyprus; [Spuri, Matteo; Petrone, Daniele] Univ Roma La Sapienza, Dept Stat, Rome, Italy		Pezzotti, P (通讯作者)，Dipartimento Malattie Infett, Viale Regina Elena 299, I-00161 Rome, Italy.	Patrizio.pezzotti@iss.it	Vescio, Fenicia/N-5776-2017	Vescio, Fenicia/0000-0002-3285-919X; Andrianou, Xanthi D./0000-0002-2906-5743			[Anonymous], 2021, OPEN DATA CONSEGNA S; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; CZARSKA-THORLEY D., COVID 19 VACCINE MOD; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Daniel W, 2021, NEW ENGL J MED, V384, P1962, DOI 10.1056/NEJMc2102153; EpiCentro, COVID 19 INT SURV DA COVID 19 INT SURV DA; Hall VJ, 2021, 3790399 SSRN 3790399 SSRN; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; Ministero della Salute, PIAN STRAT NAZ VACC PIAN STRAT NAZ VACC; PHE, PHE MON EARL IMP EFF PHE MON EARL IMP EFF; PINHO A.C., EMA RECOMMENDS COVID; PINHO AC., 2020, EMA RECOMMENDS 1 COV; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rossman H, PATTERNS COVID 19 PA PATTERNS COVID 19 PA, V2021; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201	15	7	7	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4788	4792		10.1016/j.vaccine.2021.07.003		JUL 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34253419	Green Published, hybrid			2022-04-29	WOS:000679483400009
J	Hoehl, S; Ciesek, S; Graf, J; Wicker, S				Hoehl, Sebastian; Ciesek, Sandra; Graf, Juergen; Wicker, Sabine			A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated	VACCINE			English	Editorial Material									[Hoehl, Sebastian; Ciesek, Sandra; Graf, Juergen; Wicker, Sabine] Goethe Univ Frankfurt, Occupat Hlth Serv, Univ Hosp Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany		Wicker, S (通讯作者)，Goethe Univ Frankfurt, Occupat Hlth Serv, Univ Hosp Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	sabine.wicker@kgu.de		Hoehl, Sebastian/0000-0002-5100-9385			Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Richterman A, 2020, JAMA-J AM MED ASSOC, V324, P2155, DOI 10.1001/jama.2020.21399; WHO, EFF VIR VAR COVID 19; Wolf RC, 2020, NEUROPSYCHOBIOLOGY, V79, P335, DOI 10.1159/000505601; World Health Organization, WHO SAGE VAL FRAM AL	5	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4025	4026		10.1016/j.vaccine.2021.06.012		JUN 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34127291	Green Published, Bronze			2022-04-29	WOS:000672535200002
J	Noguera, M; Vela, A; Kraft, C; Chevalier, M; Goutebroze, S; de Paz, X; Kunze, M; Rathkjen, P; Schacht, E; Garcia-Morante, B				Noguera, Marta; Vela, Antonio; Kraft, Christian; Chevalier, Mathieu; Goutebroze, Sylvain; de Paz, Xavier; Kunze, Marius; Rathkjen, Poul; Schacht, Erik; Garcia-Morante, Beatriz			Effects of three commercial vaccines against porcine parvovirus 1 in pregnant gilts	VACCINE			English	Article						Porcine parvovirus 1; Vaccination; Subunit vaccine; Bivalent vaccine; Octavalent vaccine; Gilts	RESPIRATORY SYNDROME VIRUS; EXPERIMENTAL-INFECTION; CAPSID PROTEIN; PROTECTION; EVOLUTION; SEQUENCES; IMMUNITY; IMMUNOGENICITY; VACCINATION; PREVENTION	Porcine parvovirosis is a common and important cause of reproductive failure in naIve dams. Even though vaccination is generally effective at preventing disease occurrence, the homology between the vaccine and challenge strains has been recently suggested to play a role in protection. Therefore, the purpose of this study was to evaluate and compare the efficacy of three currently available commercial vaccines against porcine parvovirus genotype 1 (PPV1) in an experimental model using pregnant gilts. Seventy-seven PPV1-negative gilts were included in the trial and randomly allocated to four groups. In group 1, gilts received two doses, three weeks apart, of a PPV1 subunit vaccine (ReproCyc(R) ParvoFLEX). Following the same scheme, gilts from group 2 received two doses of a PPV1 bivalent vaccine (ERYSENG(R) PARVO). In group 3, gilts received two doses, four weeks apart, of a PPV1 octavalent vaccine (Porcilis(R) Ery + Parvo + Lepto). Lastly, gilts from group 4 were left untreated and were used as challenge controls. All gilts were artificially inseminated three weeks after completion of vaccination. Pregnant animals were subsequently challenged around 40 days of gestation with a heterologous PPV1 strain. Foetuses were harvested at around day 90 of gestation and evaluated for their macroscopic appearance (i.e., normal, mummified, or autolytic). Along the study, safety parameters after vaccination, antibody responses against PPV1 and viremia in gilts were also measured. All the foetuses in the challenge control group were mummified, which validated the challenge model, whereas the three evaluated vaccines protected the progeny against PPV1 by preventing the appearance of clinical manifestations associated to parvovirosis. Remarkably, the PPV1 subunit vaccine induced an earlier seroconversion of gilts and was the only vaccine that could prevent viremia after challenge. This vaccine also achieved the largest average litter size accompanied with a high average proportion of clinically healthy foetuses. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Noguera, Marta; Kraft, Christian] Boehringer Ingelheim Vet Res Ctr GmbH & Co KG, Bemeroder Str 31, D-30559 Hannover, Germany; [Vela, Antonio] ThinkinPig, Avda Gomez Laguna 41, Zaragoza 50009, Spain; [Chevalier, Mathieu; Goutebroze, Sylvain] Boehringer Ingelheim Sante Anim, Parc Ind Plaine Ain 805,Allee Cypres, F-01150 St Vulbas, France; [de Paz, Xavier; Kunze, Marius; Rathkjen, Poul; Schacht, Erik] Boehringer Ingelheim Vetmed GmbH, Binger Str 173, D-55216 Ingelheim, Germany; [Garcia-Morante, Beatriz] Centcinc, C Montserrat Casanovas 105, Barcelona 08032, Spain		Noguera, M (通讯作者)，Boehringer Ingelheim Vet Res Ctr GmbH & Co KG, Bemeroder Str 31, D-30559 Hannover, Germany.	marta.noguera@boehringer-ingelheim.com; avela@thinkinpig.com; christian.kraft@boehringer-ingelheim.com; mathieu.chevalier@boehringer-ingelheim.com; sylvain.goutebroze@boehringer-ingelheim.com; xavier.de_paz_solanes@boehringer-ingelheim.com; marius.kunze@boehringer-ingelheim.com; poul.rathkjen@boehringer-ingelheim.com; erik.schacht@boehringer-ingelheim.com; bea.garciamorante@gmail.com	Morante, Beatriz Garcia/AAV-4930-2020	Morante, Beatriz Garcia/0000-0002-5610-9932; Kraft, Christian/0000-0002-6483-4296	Boehringer Ingelheim Animal Health, Inc.Boehringer Ingelheim	Boehringer Ingelheim Animal Health, Inc. sponsored financially the experimental study reported in this publication.	Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bower B, 2001, ALLEN LEMAN SWINE C, P105; Cadar D, 2011, ARCH VIROL, V156, P2233, DOI 10.1007/s00705-011-1125-6; CARTWRIGHT SF, 1967, VET REC, V81, P196; Dias AS, 2013, RES VET SCI, V94, P341, DOI 10.1016/j.rvsc.2012.09.009; Foerster T, 2016, J GEN VIROL, V97, P1408, DOI 10.1099/jgv.0.000446; Garcia-Morante B, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080789; Garcia-Morante B, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02394-4; Garcia-Morante B, 2019, PORCINE HEALTH MANAG, V5, DOI 10.1186/s40813-019-0138-5; Garcia-Morante B, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02593; Gardner IA, 1996, J AM VET MED ASSOC, V208, P863; Guo CH, 2014, ARCH VIROL, V159, P963, DOI 10.1007/s00705-013-1907-0; Hao XF, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-320; JOHNSON RH, 1969, VET REC, V85, P446, DOI 10.1136/vr.85.16.446; Jozwik A, 2009, J GEN VIROL, V90, P2437, DOI 10.1099/vir.0.012054-0; Kiss I, 2020, VET MED-RES REP, V11, P17, DOI 10.2147/VMRR.S236912; MENGELING WL, 1979, AM J VET RES, V40, P204; PARKE CR, 1993, AUST VET J, V70, P177, DOI 10.1111/j.1751-0813.1993.tb06124.x; PAUL PS, 1980, AM J VET RES, V41, P1368; PAUL PS, 1980, AM J VET RES, V41, P2007; Rymerson RT, 2003, MOL BREEDING, V11, P267, DOI 10.1023/A:1023426906756; Sanchez-Matamoros A, 2019, PORCINE HEALTH MANAG, V5, DOI 10.1186/s40813-019-0118-9; Shangjin C, 2009, VIRUS RES, V140, P209, DOI 10.1016/j.virusres.2008.11.003; Soares RM, 2003, J GEN VIROL, V84, P1505, DOI 10.1099/vir.0.19011-0; Spickler AR, 2003, J VET INTERN MED, V17, P273, DOI 10.1892/0891-6640(2003)017&lt;0273:AIVVMO&gt;2.3.CO;2; Streck AF, 2011, BERL MUNCH TIERARZTL, V124, P242, DOI 10.2376/0005-9366-124-242; Streck AF, 2020, CURR ISSUES MOL BIOL, V37, P33, DOI 10.21775/cimb.037.033; Streck AF, 2015, INFECT GENET EVOL, V36, P300, DOI 10.1016/j.meegid.2015.10.007; Streck AF, 2013, J GEN VIROL, V94, P2050, DOI 10.1099/vir.0.052555-0; Streck AF, 2011, J GEN VIROL, V92, P2628, DOI 10.1099/vir.0.033662-0; Truyen U., 2019, DIS SWINE, P611; van den Born E, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-2272-3; Wang JC, 2020, APPL MICROBIOL BIOT, V104, P3847, DOI 10.1007/s00253-020-10483-5; Williams SI, 2008, CAN VET J, V49, P269; Zeeuw EJL, 2007, J GEN VIROL, V88, P420, DOI 10.1099/vir.0.82302-0; Zimmermann P, 2006, J GEN VIROL, V87, P295, DOI 10.1099/vir.0.81086-0	37	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3997	4005		10.1016/j.vaccine.2021.05.042		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34099327	hybrid			2022-04-29	WOS:000663773600027
J	Sun, YW; Jackson, K; Dalmon, CA; Shapiro, BL; Nie, SX; Wong, C; Arnold, BF; Porco, TC; Acharya, NR				Sun, Yuwei; Jackson, Kaitlyn; Dalmon, Cyril A.; Shapiro, Brett L.; Nie, Sixiang; Wong, Carmen; Arnold, Benjamin F.; Porco, Travis C.; Acharya, Nisha R.			Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study	VACCINE			English	Article						Herpes zoster; Herpes zoster ophthalmicus; Recombinant zoster vaccine; Shingrix vaccine; Vaccine effectiveness; Real-world evidence; Infectious disease; Epidemiology; Hawaii	SUBUNIT VACCINE; EFFICACY; ADULTS	Background: The incidence of herpes zoster (HZ) has been on the rise for decades in the United States. Clinical trials for the recombinant zoster vaccine (RZV) demonstrated vaccine efficacy of over 90% in preventing herpes zoster. However, there is limited information on its effectiveness outside of a clinical trial setting, as well as its effectiveness against herpes zoster ophthalmicus (HZO). Methods: A de-identified electronic health records database from Kaiser Permanente Hawaii (KPH) was used to conduct this retrospective cohort study to assess the effectiveness of the recombinant zoster vaccine against HZ and HZO in immunocompetent, vaccine age-eligible individuals without a prior history of HZ, who were continuously enrolled in KPH for >365 days prior to becoming age-eligible for RZV between January 1, 2018, through December 31, 2019. Results: A total of 78 356 adults were included in this study, with 11 864 (15.1%) adults receiving two valid doses of the recombinant zoster vaccine. The incidence rate of HZ was 325.6 (95% CI: 217.7 to 464.4) cases per 100 000 person-years in vaccinated persons compared to 1063.3 cases per 100 000 person-years (95% CI: 1006.0 to 1122.8) in the unvaccinated group. The incidence rate of HZO was 11.9 (95% CI: 0.7 to 52.3) cases per 100 000 person-years in the vaccinated group compared to 72.1 (95% CI: 58.0 to 88.3) in the unvaccinated group. RZV was 83.5% (95% CI: 74.9% to 89.2%) effective against HZ and 93.3% (95% CI: 48.7% to 99.1%) effective against HZO. Conclusions: RZV has demonstrated high effectiveness against both HZ and HZO outside of a clinical trial setting in the United States. Vaccine coverage is low, emphasizing the need for public health efforts to increase vaccination to reduce morbidity from HZ and HZO. (c) 2021 Elsevier Ltd. All rights reserved.	[Sun, Yuwei; Jackson, Kaitlyn; Arnold, Benjamin F.; Porco, Travis C.; Acharya, Nisha R.] Univ Calif San Francisco, FI Proctor Fdn, 490 Illinois St,2nd Floor, San Francisco, CA 94158 USA; [Dalmon, Cyril A.; Shapiro, Brett L.] Hawaii Permanente Med Grp, Wailuku, HI USA; [Nie, Sixiang; Wong, Carmen] Kaiser Permanente Hawaii, Ctr Integrated Hlth Care Res, Wailuku, HI USA; [Arnold, Benjamin F.; Porco, Travis C.; Acharya, Nisha R.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA; [Porco, Travis C.; Acharya, Nisha R.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA		Acharya, NR (通讯作者)，Univ Calif San Francisco, FI Proctor Fdn, 490 Illinois St,2nd Floor, San Francisco, CA 94158 USA.	Nisha.Acharya@ucsf.edu		Arnold, Benjamin/0000-0001-6105-7295; Jackson, Kaitlyn/0000-0002-5154-1494; Shapiro, Brett/0000-0002-9722-6561	National Eye Institute and Office of Research on Women's Health at the National Institutes of Health [R01 EY028739]; Research to Prevent Blindness FoundationResearch to Prevent Blindness (RPB); National Eye Institute at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY06190]; That Man May See Foundation	This work was supported by the National Eye Institute and Office of Research on Women's Health at the National Institutes of Health [grant number R01 EY028739 to N.R.A.] . The Department of Ophthalmology at the University of California, San Francisco is supported by an unrestricted grant from the Research to Prevent Blindness Foundation; a core grant from the National Eye Institute at the National Institutes of Health [grant number EY06190] ; and the That Man May See Foundation.	Austin PC, 2016, STAT MED, V35, P5642, DOI 10.1002/sim.7084; Baxter R, 2018, AM J EPIDEMIOL, V187, P161, DOI 10.1093/aje/kwx245; Baylor, 2006, APPR LETT ZOST; Borkar DS, 2013, OPHTHALMOLOGY, V120, P451, DOI 10.1016/j.ophtha.2012.09.007; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5; Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674; Haneuse S, 2019, JAMA-J AM MED ASSOC, V321, P602, DOI 10.1001/jama.2018.21554; Harpaz R, 2019, CLIN INFECT DIS, V69, P341, DOI 10.1093/cid/ciy953; Harvey M, 2020, PAIN, V161, P361, DOI 10.1097/j.pain.0000000000001718; Izurieta HS, 2021, CLIN INFECT DIS; Kim JH, 2021, HUM VACC IMMUNOTHER, V17, P2050, DOI 10.1080/21645515.2020.1859321; Kong CL, 2020, OPHTHALMOLOGY, V127, P324, DOI 10.1016/j.ophtha.2019.10.001; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Mathur MB, 2018, EPIDEMIOLOGY, V29, pE45, DOI 10.1097/EDE.0000000000000864; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Sun YW, 2021, CLIN INFECT DIS, V73, P949, DOI 10.1093/cid/ciab121; Thompson RR, 2021, CLIN INFECT DIS, V73, pE3210, DOI 10.1093/cid/ciaa1185; Tseng HF, 2011, JAMA-J AM MED ASSOC, V305, P160, DOI 10.1001/jama.2010.1983; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Willer DO, 2019, VACCINE, V37, P6262, DOI 10.1016/j.vaccine.2019.09.028; Wolfson LJ, 2020, CLIN INFECT DIS, V70, P995, DOI 10.1093/cid/ciz305; Yih WK, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-68	24	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3974	3982		10.1016/j.vaccine.2021.05.056		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34116874				2022-04-29	WOS:000663773600024
J	Tang, XY; Yan, XX; Wei, X; Qin, QL; Lin, YD; Geater, A; Deng, QY; Zhong, G; Li, Q				Tang, Xian-Yan; Yan, Xing-Xing; Wei, Xue; Qin, Qing-Lian; Lin, Yue-Dong; Geater, Alan; Deng, Qiu-Yun; Zhong, Ge; Li, Qiao			Timeliness, completeness, and timeliness-and-completeness of serial routine vaccinations among rural children in Southwest China: A multi-stage stratified cluster sampling survey	VACCINE			English	Article						Timeliness; Completeness; Routine vaccines; Serial vaccinations; Rural China; Children	TIMELY MEASLES VACCINATION; AGE 24 MONTHS; UNITED-STATES; NATIONAL CAUSES; IMMUNIZATION; COVERAGE; MORTALITY; DISEASE; BORN	Introduction: Vaccination coverage is widely used as metric of vaccination programme performance. However, VPDs outbreaks were reported in areas with high vaccination coverage. Timeliness and completeness have been considered more important assessment indicators of routine vaccination than overall vaccination coverage, but little is known in rural China. This study aimed to assess the timeliness and completeness of serial routine vaccinations among children in rural Southwest China. Methods: A multi-stage stratified cluster survey was conducted among 1062 children aged 18-48 months in rural Guangxi. Vaccination status was obtained from child's vaccination certificate. We calculated timely vaccination coverage, complete vaccination coverage, timely-and-complete vaccination coverage and 95% CI for routine vaccination through weighted estimation analysis. Weighted Kaplan-Meier analyses were applied to estimate the median delay periods for each dose of serial routine vaccines, including one-dose BCG, three-dose HepB, three-dose OPV, four-dose DTP, two-dose MCV, two-dose JEV and two dose MPV-A. Complete coverage, and timely-and-complete coverage for combined 5-vaccine series were calculated. Results: For each dose of routine vaccines, overall vaccination coverages were over 90%, but timely vaccination coverage ranged from the lowest of 44.4% for JEV1 to the highest of 92.5% for MPV-A1. For multi dose routine vaccines, complete vaccination coverages varied from the lowest of 92.9% for MCV to the highest of 100% for HepB, and timely-and-complete vaccination coverages were lower than 80%, ranging from the lowest of 30% for JEV to the highest of 77.2% for MPV-A. For combined 5-vaccine series, complete coverage was 77%, while timely-and-complete coverage was 12.1%. MPV-A1 had the longest median delay of 176 days, but BCG and HepB1 had the shortest of 1 day. Conclusions: The overall coverages of serial routine vaccinations were high, but the timeliness and completeness were poor. Relevant agencies of vaccination service should address timeliness-and completeness into the assessment indicators of routine vaccination service quality. (c) 2021 Elsevier Ltd. All rights reserved.	[Tang, Xian-Yan; Yan, Xing-Xing; Qin, Qing-Lian; Lin, Yue-Dong; Li, Qiao] Guangxi Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 22nd Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China; [Wei, Xue] Nanning Ctr Hlth Informat, Nanning, Guangxi Zhuang, Peoples R China; [Geater, Alan] Prince Songkla Univ, Fac Med, Epidemiol Unit, Hat Yai, Thailand; [Deng, Qiu-Yun; Zhong, Ge] Guangxi Ctr Dis Control & Prevent, Inst Vaccinat, Nanning, Guangxi Zhuang, Thailand		Tang, XY; Li, Q (通讯作者)，Guangxi Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 22nd Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.	tangxianyan0746@163.com; 382099225@qq.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81,502,890, 81960615]; China Medical Board [14-202, 19-307]; Guangxi Medical University Training Program for Distinguished Young Scholars	This study was funded by the National Natural Science Foundation of China(Grant No. 81,502,890 and 81960615), the China Medical Board(Grant No. 14-202 and 19-307), and the Guangxi Medical University Training Program for Distinguished Young Scholars (2017) awarded to Guo-Dong Lu. The sponsors had no role in study design, data collection, data analysis, or manuscript writing.	Adetifa IMO, 2018, VACCINE, V36, P7965, DOI 10.1016/j.vaccine.2018.11.005; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Cao L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206566; Choudhary TS, 2019, VACCINE, V37, P2331, DOI 10.1016/j.vaccine.2019.03.039; Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2; Clouston S, 2014, VACCINE, V32, P3533, DOI 10.1016/j.vaccine.2014.04.030; Cutts FT, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001404; Gan M., 2015, J APPL PREVENTION ME, V21, P15; Hao LX, 2019, INT J EPIDEMIOL, V48, P1240, DOI 10.1093/ije/dyz058; Hao LX, 2016, VACCINE, V34, P6545, DOI 10.1016/j.vaccine.2016.02.005; Hill HA, 2019, MMWR-MORBID MORTAL W, V68, P913, DOI 10.15585/mmwr.mm6841e2; Hinman AR, 2015, AM J PREV MED, V49, pS399, DOI 10.1016/j.amepre.2015.04.018; Hu Y, 2018, HUM VACC IMMUNOTHER, V14, P2876, DOI 10.1080/21645515.2018.1504523; Hu Y, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070758; Hu Y, 2014, HUM VACC IMMUNOTHER, V10, P1408, DOI 10.4161/hv.28054; HUANG Y, 2019, PROGR MICROBIOLOGY I, V47, P49; Huang Y, 2018, LANCET GLOB HEALTH, V6, pE39, DOI [10.1016/s2214-109x(17)30445-x, 10.1016/S2214-109X(17)30445-X]; Kurosky SK, 2016, VACCINE, V34, P387, DOI 10.1016/j.vaccine.2015.11.011; Liang XF, 2013, VACCINE, V31, pJ8, DOI 10.1016/j.vaccine.2012.12.019; Liu J, 2019, B WORLD HEALTH ORGAN, V97, P230, DOI [10.2471/BLT.18.219469, 10.2471/blt.18.219469]; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; Liu XL, 2020, HUM VACC IMMUNOTHER, V16, P1574, DOI 10.1080/21645515.2019.1688034; Lu M, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-017-0261-y; Lv M, 2016, VACCINE, V34, P2135, DOI 10.1016/j.vaccine.2016.02.032; Ma C, 2019, MMWR-MORBID MORTAL W, V68, P1112, DOI 10.15585/mmwr.mm6848a2; Marinovic AB, 2015, EMERG INFECT DIS, V21, P209, DOI 10.3201/eid2102.130504; Meng QH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31283-y; Ni ZL, 2017, EPIDEMIOL INFECT, V145, P1763, DOI 10.1017/S0950268817000589; Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Robinson CL, 2018, MMWR-MORBID MORTAL W, V67, P156, DOI 10.15585/mmwr.mm6705e2; Schneider R, 2020, VACCINE, V38, P1551, DOI 10.1016/j.vaccine.2019.11.057; Shrivastwa N, 2016, PEDIATR INFECT DIS J, V35, P955, DOI 10.1097/INF.0000000000001223; Pham TT, 2018, VACCINE, V36, P5760, DOI 10.1016/j.vaccine.2018.08.002; Tang XY, 2017, J EPIDEMIOL, V27, P317, DOI 10.1016/j.je.2016.08.006; Tang XY, 2016, TROP MED INT HEALTH, V21, P886, DOI 10.1111/tmi.12719; Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016; Tippins A, 2017, VACCINE, V35, P6404, DOI 10.1016/j.vaccine.2017.10.001; Wagner AL, 2018, AM J PREV MED, V54, P96, DOI 10.1016/j.amepre.2017.09.014; Wagner AL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-888; Wang HL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218782; Yu GQ, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3240-4; Yu WZ, 2018, VACCINE, V36, P8131, DOI 10.1016/j.vaccine.2018.10.005; Zheng Zhi-Gang, 2010, Zhongguo Yi Miao He Mian Yi, V16, P65	45	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 2	2021	39	24					3236	3249		10.1016/j.vaccine.2021.04.048		JUN 2021	14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SM1SV	33966907				2022-04-29	WOS:000657392500002
J	Machado, AA; Edwards, SA; Mueller, M; Saini, V				Machado, Amanda Alberga; Edwards, Sarah A.; Mueller, Melissa; Saini, Vineet			Effective interventions to increase routine childhood immunization coverage in low socioeconomic status communities in developed countries: A systematic review and critical appraisal of peer-reviewed literature	VACCINE			English	Review						Health equity; Immunization; Vaccine hesitancy; Precision public health; Deprivation; Access	IMPROVE IMMUNIZATION; VACCINATION STATUS; CHILDREN; PROGRAM; RATES; IMPACT; AGE; INFANTS; WOMEN; RISK	Objectives: Childhood immunization coverage rates are known to be disproportionate according to population's socioeconomic status (SES). This systematic review examined and appraised quality of interventions deemed effective to increase routine childhood immunization uptake in low SES populations in developed countries. Methods: A literature search was conducted using Medline, Embase, CINAHL, EBMR, PsycInfo, PubMed, and Health STAR. We systematically searched and critically appraised articles published between January 1990 and December 2019 using the Effective Public Health Practice Project Quality Assessment tool. This systematic review provides a synthesis of the available evidence for childhood immunization interventions deemed effective for low SES parents or families of children < 5 years of age. Synthesis: The search yielded 3317 records, of which 2975 studies met the inclusion criteria. From the 100 relevant studies, a total of 40 were included. The majority of effective and strongly rated studies synthesized consisted of multi-component interventions. Such interventions addressed access, community based mobilization, outreach, appointment reminders, education, clinical tracking and incentives, and were language and health literacy appropriate to support low SES parents. Improving access to low SES parents was deemed effective in the vast majority of strongly rated studies. Incorrect contact information of low SES parents due to increased social mobility (i.e. household moves) rendered reminders ineffective, and therefore, updating contact information should be pursued proactively by front-line healthcare providers. In addition, plain language communication with low SES parents regarding immunization was deemed effective in improving immunization uptake. Conclusion: Comprehensive multi-component interventions including improved access, appointment reminders, education and precision health communication are effective for addressing health inequities in immunization coverage amongst marginalized populations. Most low SES parents still believe that the benefits of immunization outweigh the risks. (c) 2021 Elsevier Ltd. All rights reserved.	[Machado, Amanda Alberga; Edwards, Sarah A.; Mueller, Melissa; Saini, Vineet] Alberta Hlth Serv, Res & Innovat, Prov Populat & Publ Hlth, 10201 Southport Rd SW, Calgary, AB T2W 3N2, Canada; [Edwards, Sarah A.; Saini, Vineet] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Edwards, Sarah A.; Saini, Vineet] Univ Calgary, Cumming Sch Med, OBrien Inst Publ Hlth, Calgary, AB, Canada		Saini, V (通讯作者)，10201 Southport Rd SW, Calgary, AB T2W 3N2, Canada.	vineet.saini@ahs.ca					ABRAMSON JS, 1995, J PEDIATR-US, V126, P583, DOI 10.1016/S0022-3476(95)70354-3; Adedokun ST, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4137-7; Adorador A, 2011, J AM ACAD NURSE PRAC, V23, P501, DOI 10.1111/j.1745-7599.2011.00632.x; Alemi F, 1996, MED CARE, V34, pOS45; Armijo-Olivo S, 2012, J EVAL CLIN PRACT, V18, P12, DOI 10.1111/j.1365-2753.2010.01516.x; Barnes K, 1999, ARCH PEDIAT ADOL MED, V153, P518; Bell CA, 2015, VACCINE, V33, P4572, DOI 10.1016/j.vaccine.2015.07.004; Beverley PCL, 2002, BRIT MED BULL, V62, P15, DOI 10.1093/bmb/62.1.15; BIRKHEAD GS, 1995, JAMA-J AM MED ASSOC, V274, P312, DOI 10.1001/jama.274.4.312; Bocquier A, 2017, EXPERT REV VACCINES, V16, P1107, DOI 10.1080/14760584.2017.1381020; Boslaugh SE., 2013, HLTH CARE SYSTEMS WO; Browngoehl K, 1997, PEDIATRICS, V99, pE41, DOI 10.1542/peds.99.1.e4; Busby & Chesterley, 2015, COMMENTARY NO 412 SH; CAMPBELL JR, 1994, CLIN PEDIATR, V33, P268, DOI 10.1177/000992289403300503; Carpiano RM, 2019, PREV MED, V123, P278, DOI 10.1016/j.ypmed.2019.03.033; Cockman P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5703; Dombkowski KJ, 2004, PUBLIC HEALTH REP, V119, P144, DOI 10.1177/003335490411900207; Dube E, 2016, CAN MED ASSOC J, V188, pE17, DOI 10.1503/cmaj.150707; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Dummer TJB, 2012, CAN J PUBLIC HEALTH, V103, pE363, DOI 10.1007/BF03404442; Else-Quest NM, 2016, PSYCHOL WOMEN QUART, V40, P319, DOI 10.1177/0361684316647953; Fairbrother G, 1997, ARCH PEDIAT ADOL MED, V151, P1229, DOI 10.1001/archpedi.1997.02170490055010; Findley Sally, 2004, Ethn Dis, V14, pS134; Findley SE, 2003, AM J PUBLIC HEALTH, V93, P1041, DOI 10.2105/AJPH.93.7.1041; Fleiss J., 1986, RELIABILITY MEASUREM; Fu LY, 2012, PEDIATRICS, V129, pE496, DOI 10.1542/peds.2010-3610; Glatman-Freedman Aharona, 2012, Hum Vaccin Immunother, V8, P293, DOI 10.4161/hv.19003; Hambidge SJ, 2009, PEDIATRICS, V124, P455, DOI 10.1542/peds.2008-0446; Harper PG, 1997, ARCH PEDIAT ADOL MED, V151, P1220, DOI 10.1001/archpedi.1997.02170490046008; Hellerstedt WL, 1999, AM J PREV MED, V16, P50, DOI 10.1016/S0749-3797(98)00144-5; Hicks P, 2007, J AM BOARD FAM MED, V20, P581, DOI 10.3122/jabfm.2007.06.060071; Hoekstra EJ, 1998, JAMA-J AM MED ASSOC, V280, P1143, DOI 10.1001/jama.280.13.1143; Hofstetter AM, 2015, VACCINE, V33, P5741, DOI 10.1016/j.vaccine.2015.09.042; Hutchins SS, 1999, J PUBLIC HEALTH POL, V20, P408, DOI 10.2307/3343128; Irigoyen MM, 2006, AMBUL PEDIATR, V6, P100, DOI 10.1016/j.ambp.2005.10.006; Jackson C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4178-y; Joyce T, 2005, PEDIATRICS, V115, pE526, DOI 10.1542/peds.2004-1533; Kerpelman LC, 2000, JAMA-J AM MED ASSOC, V284, P53, DOI 10.1001/jama.284.1.53; Larson Heidi J, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4; LeBaron CW, 1998, ARCH PEDIAT ADOL MED, V152, P327; Lemstra M, 2011, PAED CHILD HEALT-CAN, V16, pE1, DOI 10.1093/pch/16.1.e1; Lernout T, 2014, VACCINE, V32, P284, DOI 10.1016/j.vaccine.2013.10.084; Mayer JP, 1999, J COMMUN HEALTH, V24, P13, DOI 10.1023/A:1018761114561; Mendel-Van Alstyne JA, 2018, VACCINE, V36, P6464, DOI 10.1016/j.vaccine.2017.09.007; Minkovitz C, 1999, ARCH PEDIAT ADOL MED, V153, P1242, DOI 10.1001/archpedi.153.12.1242; Miraglia del Giudice M, 2018, EUR J PEDIATR, P243; Murphy AW, 1996, IRISH MED J, V89, P220; Newton P, 2017, CHILD CARE HLTH DEV, V43, P504, DOI 10.1111/cch.12453; Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313; OEFFINGER KC, 1992, J FAM PRACTICE, V35, P288; Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3; Peretti-watel P, 2019, SOCIOL HLTH ILLNESS, P1; READING R, 1994, BRIT MED J, V308, P1142, DOI 10.1136/bmj.308.6937.1142; Rodewald LE, 1997, ARCH PEDIAT ADOL MED, V151, P798, DOI 10.1001/archpedi.1997.02170450048007; Rodewald LE, 1999, PEDIATRICS, V103, P31, DOI 10.1542/peds.103.1.31; ROSENBERG Z, 1995, AM J PREV MED, V11, P14, DOI 10.1016/S0749-3797(18)30401-X; Saini V, 2017, CAN J PUBLIC HEALTH, V108, pE124, DOI [10.17269/cjph.108.5885, 10.17269/CJPH.108.5885]; Sege R, 2015, PEDIATRICS, V136, P97, DOI 10.1542/peds.2014-2955; Shefer A, 1999, EPIDEMIOL REV, V21, P96, DOI 10.1093/oxfordjournals.epirev.a017992; Shefer AM, 2001, AM J PREV MED, V20, P47, DOI 10.1016/S0749-3797(01)00279-3; Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187; STEHRGREEN PA, 1993, PUBLIC HEALTH REP, V108, P426; Szilagyi PG, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e58; Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016; Taylor JA, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.3.e1; Thomas TN, 2014, AM J PREV MED, V47, P624, DOI 10.1016/j.amepre.2014.06.017; United Nations, 2019, WORLD EC SITUATION P; Walsh B, 2016, HEALTH AFFAIR, V35, P356, DOI [10.1377/hlthaff.2015.10, 10.1377/hlthaff.2015.1019]; Waterman SH, 1996, AM J PREV MED, V12, P8, DOI 10.1016/S0749-3797(18)30252-6; Wood D, 1998, JAMA-J AM MED ASSOC, V279, P29, DOI 10.1001/jama.279.1.29	70	2	2	2	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 21	2021	39	22					2938	2964		10.1016/j.vaccine.2021.03.088		MAY 2021	27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SE0YP	33933317				2022-04-29	WOS:000651801800004
J	Verboom, DM; Varkila, MRJ; Morrow, B; Davies, T; de Palacios, PI; Poolman, J; Hermans, PWM; Dudley, EG; Roberts, E; Cremer, OL; Bonten, MJM				Verboom, D. M.; Varkila, M. R. J.; Morrow, B.; Davies, T.; de Palacios, P. Ibarra; Poolman, J.; Hermans, P. W. M.; Dudley, E. G.; Roberts, E.; Cremer, O. L.; Bonten, M. J. M.			O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands	VACCINE			English	Article						Vaccine; Escherichia coli; ExPEC; ICU; Bloodstream infections		Objectives: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease. Methods: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing. Results: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates sero-grouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37). Conclusions: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Verboom, D. M.; Varkila, M. R. J.; Hermans, P. W. M.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Verboom, D. M.; Varkila, M. R. J.; Cremer, O. L.] Univ Med Ctr Utrecht, Dept Intens Care, Utrecht, Netherlands; [Morrow, B.; Davies, T.] Janssen Res & Dev LLC, Raritan, NJ USA; [de Palacios, P. Ibarra] Janssen Vaccines, Bern, Switzerland; [Poolman, J.; Hermans, P. W. M.] Janssen Vaccines & Prevent BV, Leiden, Netherlands; [Dudley, E. G.; Roberts, E.] Penn State Univ, Dept Food Sci, E Coli Reference Ctr, University Pk, PA 16802 USA; [Bonten, M. J. M.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands		Verboom, DM (通讯作者)，Room F06-149,POB 85500, NL-3508 GA Utrecht, Netherlands.	d.m.verboom@asz.nl			Innovative Medicine Initiative (IMI); European UnionEuropean Commission; EFPIA companies [115 620]	D. Verboom and M. Bonten were funded by the Innovative Medicine Initiative (IMI), European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution (COMBACTE-CARE, grant agreement 115 620).	Ananias M, 2008, BRAZ J MED BIOL RES, V41, P877, DOI 10.1590/S0100-879X2008001000008; Ciesielczuk H, 2016, EUR J CLIN MICROBIOL, V35, P1661, DOI 10.1007/s10096-016-2707-8; DebRoy C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147434; European Centre for Disease Prevention and Control, 2016, SURV ANT RES EUR ANN; Flores-Mireles AL, 2015, NAT REV MICROBIOL, V13, P269, DOI 10.1038/nrmicro3432; Frenck RW, 2019, LANCET INFECT DIS, V19, P631, DOI 10.1016/S1473-3099(18)30803-X; Gagliotti C, 2011, EURO SURVEILL B EUR, VMar 16; Geurtsen JWE, 2019, 2011 20ECCMID; Huttner A, 2017, LANCET INFECT DIS, V17, P528, DOI [10.1016/s1473-3099(17)30108-1, 10.1016/S1473-3099(17)30108-1]; Joensen KG, 2015, J CLIN MICROBIOL, V53, P2410, DOI 10.1128/JCM.00008-15; Klouwenberg PMCK, 2013, CRIT CARE MED, V41, P2373, DOI 10.1097/CCM.0b013e3182923712; Laupland KB, 2008, CLIN MICROBIOL INFEC, V14, P1041, DOI 10.1111/j.1469-0691.2008.02089.x; ORSKOV I, 1977, BACTERIOL REV, V41, P667, DOI 10.1128/MMBR.41.3.667-710.1977; ORSKOV I, 1985, J HYG-CAMBRIDGE, V95, P551, DOI 10.1017/S0022172400060678; Poolman JT, 2018, EXPERT REV VACCINES, V17, P607, DOI 10.1080/14760584.2018.1488590; Seemann T, ABRICATE; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; UK Department of Health and Social Care, 2019, TACKLING ANTIMICROBI; van der Steen M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138088; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Webber C, 2017, VACCINE, V35, P1266, DOI 10.1016/j.vaccine.2017.01.032	21	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 19	2021	39	12					1670	1674		10.1016/j.vaccine.2021.02.031		MAR 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QX3ZD	33642161	hybrid			2022-04-29	WOS:000629283700002
J	Juste, RA; Geijo, MV; Elguezabal, N; Sevilla, IA; Alonso-Hearn, M; Garrido, JM				Juste, R. A.; Geijo, M., V; Elguezabal, N.; Sevilla, I. A.; Alonso-Hearn, M.; Garrido, J. M.			Paratuberculosis vaccination specific and non-specific effects on cattle lifespan	VACCINE			English	Article						Paratuberculosis; Vaccine; Non-specific effects; Trained immunity; Cattle; Overall mortality; Killed vaccines; Mycobacteria	TRAINED IMMUNITY; TUBERCULIN REACTION; JOHNES-DISEASE; BCG; MORTALITY; VACCINES; PROTECTION; REDUCTION; INFECTION; MEASLES	Records of cattle vaccination against paratuberculosis (PTB) have been analyzed to determine whether or not non-specific effect (NSE) on overall mortality similar to that observed in BCG vaccinated humans occurs in animals. The results of a previously reported slaughterhouse study on PTB prevalence were used as a reference on the age incidence of advanced patent (clinical) epidemio-pathogenic forms. In the proper vaccine study, cows in 30 cattle farms in the Basque Country, Spain were followed-up for between 1 and 13 years. Vaccinated groups were composed by 1008 (592 right-censored) animals younger than 3 months treated as calves and by 3761 (3160 right-censored) vaccinated at any older age. Controls were 339 (157 right-censored) and 4592 (2213 right-censored) age matched animals, respectively. Individual last year presence in the annual testing was considered age at culling or death. A survival analysis was carried out according age at vaccination of vaccinated versus non-vaccinated animals. PTB age incidence in the slaughterhouse study was subtracted from the difference between vaccinated and non-vaccinated animals at the same age in order to estimate PTB-specific and non-specific effects. The maximum difference was observed at the 2-3 years interval with a 33.9% mortality reduction in the calf vaccinated group. This corresponded also with the maximum NSE that was 24.5% for a PTB incidence of 9.5%. Overall, vaccination afforded to calves a 26.5% yearly mortality protection, split between 11.1% PTB-specific and 15.4% NSE. These results support a NSE on total mortality associated with PTB vaccination that appeared to persist for up to 6-7 years. This confirms for the first time in an animal field study the innate immune system memory predicted by the recently proposed trained immunity theory. Contrasting the literature, no deleterious effects of killed vaccines on females were observed. Mortality reduction would offset vaccination costs and could improve livestock systems efficiency and potentially reduce antibiotic use. (C) 2021 The Authors. Published by Elsevier Ltd.	[Juste, R. A.; Geijo, M., V; Elguezabal, N.; Sevilla, I. A.; Alonso-Hearn, M.; Garrido, J. M.] NEIKER, Dept Anim Hlth, Basque Inst Agr Res & Dev, Basque Res & Technol Alliance BRTA, Parque Tecnol Bizkaia,p-812, E-48160 Derio, Spain; [Juste, R. A.] SERIDA, Agrifood Reg Res & Dev Serv, Asturias 33300, Spain		Juste, RA (通讯作者)，NEIKER, Basque Inst Agr Res & Dev, Derio 48160, Spain.	rjuste@neiker.eus	Geijo, Maria V./ABC-5808-2021; Elguezabal, Natalia/ABF-8199-2021; Sevilla, Iker A./O-6060-2014	Geijo, Maria V./0000-0002-3120-1038; Sevilla, Iker A./0000-0003-3968-3390; Elguezabal, Natalia/0000-0002-8765-5477	Spanish central government; Basque government research project VACPARACZV [INIA RTA2005-00147]; Direccion de Agricultura	The authors want to thank Carlos Boix, Jose M. Plazaola (GFADFG), Inaki Arrazola (BFA-DFB), Koldo Perez (AFA-DFA), Pilar Santamaria (EJ-GV) and Lucio Carbajo (Ministry of Agriculture) for administrative support towards the implementation of paratuberculosis cattle vaccination field trial in the Basque Country promoted by CZ Veterinaria and authorized by the Spanish Agency for Drugs and Sanitary products (AEMPS) with code 11/012/ECV. We also thank the owners that provided animals, records and labor for this study successful follow-up. We are also indebted to practitioners in the three Basque territories for their continued and essential collaboration. Funding was provided by Spanish central government and Basque government research project VACPARACZV (INIA RTA2005-00147) and by the Direccion de Agricultura. The authors thank Jordi Casal for useful comments on the manuscript. We also thank the reviewers that did a thorough job and required answers and changes that have substantially improved this paper.	Aaby P, 2019, CLIN MICROBIOL INFEC, V25, P1459, DOI 10.1016/j.cmi.2019.08.011; AABY P, 1981, LANCET, V2, P93; AABY P, 1989, B WORLD HEALTH ORGAN, V67, P443; Aaby P, 2020, VACCINE, V38, P10, DOI 10.1016/j.vaccine.2019.10.034; Aaby P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013335; Aaby P, 2016, T ROY SOC TROP MED H, V110, P570, DOI 10.1093/trstmh/trw073; Agmon-Levin N, 2012, LUPUS, V21, P118, DOI 10.1177/0961203311429316; Alonso-Hearn M, 2012, J DAIRY SCI, V95, P618, DOI 10.3168/jds.2009-2860; Alonso-Hearn M, 2009, FOODBORNE PATHOG DIS, V6, P513, DOI 10.1089/fpd.2008.0226; Andersen A, 2017, VACCINE, V35, P7018, DOI 10.1016/j.vaccine.2017.10.047; Asin J, 2018, IMMUNOL RES, V66, P777, DOI 10.1007/s12026-018-9059-7; Balseiro A, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00041; Balseiro A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180546; Bastida Felix, 2011, J Immune Based Ther Vaccines, V9, P8, DOI 10.1186/1476-8518-9-8; Bates A, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2014-6; Beltran-Beck B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098048; Benn CS, 2016, EBIOMEDICINE, V10, P312, DOI 10.1016/j.ebiom.2016.07.016; Berendsen MLT, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001862; Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525; Brook B, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax4517; Buddle BM, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00259; BUERGELT CD, 1978, J AM VET MED ASSOC, V173, P478; Burden P, 2021, PREV VET MED, V186, DOI 10.1016/j.prevetmed.2020.105210; Butkeviciute E, 2018, FUTURE MICROBIOL, V13, P1193, DOI 10.2217/fmb-2018-0026; Byrne KA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01099; CHIODINI RJ, 1984, CORNELL VET, V74, P218; Cho J, 2012, J DAIRY SCI, V95, P1855, DOI 10.3168/jds.2011-4787; Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806; Cuezva-Samaniego J, 1966, ERRADICACION TUBERCU; Diez-Delgado I, 2019, COMP IMMUNOL MICROB, V66, DOI 10.1016/j.cimid.2019.101329; Diez-Delgado I, 2018, PREV VET MED, V155, P11, DOI 10.1016/j.prevetmed.2018.04.002; Donzelli A, 2018, HUM VACC IMMUNOTHER, V14, P2904, DOI 10.1080/21645515.2018.1502520; Escobar Luis E, 2020, medRxiv, DOI [10.1073/pnas.2008410117, 10.1101/2020.05.05.20091975]; Fisker AB, 2014, VACCINE, V32, P598, DOI 10.1016/j.vaccine.2013.11.074; Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6; Garrido JM, 2010, VET MICROBIOL, V144, P240, DOI 10.1016/j.vetmic.2009.12.041; Ghosh TK, 2012, J ANIM PHYSIOL AN N, V96, P275, DOI 10.1111/j.1439-0396.2011.01155.x; Gyssens IC, 2019, CLIN MICROBIOL INFEC, V25, P1457, DOI 10.1016/j.cmi.2019.05.024; Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170; Imada J., 2020, Paratuberculosis: organism, disease, control, P1, DOI 10.1079/9781789243413.0001; Jones GJ, 2016, VET IMMUNOL IMMUNOP, V182, P85, DOI 10.1016/j.vetimm.2016.10.010; JUSTE RA, 1993, PREV VET MED, V15, P101, DOI 10.1016/0167-5877(93)90106-4; Juste RA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165607; Juste Ramon A, 2009, BMC Res Notes, V2, P233, DOI 10.1186/1756-0500-2-233; Kandasamy R, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5225; Kleinnijenhuis J, 2015, T ROY SOC TROP MED H, V109, P29, DOI 10.1093/trstmh/tru168; Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628; Kowalewicz-Kulbat M, 2017, EXPERT REV VACCINES, V16, P699, DOI 10.1080/14760584.2017.1333906; Kristensen I, PAPERS ROUTINE VACCI; Kuhtreiber WM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0062-8; Lopez V, 2016, VET IMMUNOL IMMUNOP, V172, P21, DOI 10.1016/j.vetimm.2016.03.003; Lujan L, 2013, IMMUNOL RES, V56, P317, DOI 10.1007/s12026-013-8404-0; McAloon CG, 2019, VET J, V246, P59, DOI 10.1016/j.tvjl.2019.01.010; Molina E, 2018, 14 INT C PAR RIV MAY, P105; Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020; Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042; Netea MG, 2014, SEMIN IMMUNOL, V26, P512, DOI 10.1016/j.smim.2014.09.006; Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006; de Val BP, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-191; Rossi G, 2017, J DAIRY SCI, V100, P7446, DOI 10.3168/jds.2017-12721; Serrano M, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00175; Shann F, 2013, CLIN THER, V35, P109, DOI 10.1016/j.clinthera.2013.01.007; Shoenfeld Y, 2011, J AUTOIMMUN, V36, P4, DOI 10.1016/j.jaut.2010.07.003; Tarancon R, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008404; Thomas J, 2017, VET MICROBIOL, V208, P195, DOI 10.1016/j.vetmic.2017.08.007; Timmermann CAG, 2015, TROP MED INT HEALTH, V20, P1733, DOI 10.1111/tmi.12614; Tiwari A, 2006, CAN VET J, V47, P874; Vazquez P, 2012, SPAN J AGRIC RES, V10, P662, DOI 10.5424/sjar/2012103-2728; Vazquez P, 2014, SPAN J AGRIC RES, V12, P1049, DOI 10.5424/sjar/2014124-5978; Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053; Welaga P, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023752; Whittington R, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1943-4; Windsor PA, 2015, VET MICROBIOL, V181, P161, DOI 10.1016/j.vetmic.2015.07.019	73	3	3	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 12	2021	39	11					1631	1641		10.1016/j.vaccine.2021.01.058		FEB 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QP4DD	33597115	hybrid			2022-04-29	WOS:000623785800011
J	Gaspar, EB; De Gaspari, E				Gaspar, Emanuelle Baldo; De Gaspari, Elizabeth			Avidity assay to test functionality of anti-SARS-Cov-2 antibodies	VACCINE			English	Editorial Material							IGG ANTIBODIES; CORONAVIRUS; INFECTION; MATURATION; DIAGNOSIS		[Gaspar, Emanuelle Baldo] Embrapa Pecuaria Sul, Bage, RS, Brazil; [De Gaspari, Elizabeth] Adolfo Lutz Inst, Dept Imunol, Sao Paulo, SP, Brazil; [De Gaspari, Elizabeth] Univ Sao Paulo, Inst Ciencias Biomed, Programa Posgrad Interunidades Biotecnol, Sao Paulo, SP, Brazil		De Gaspari, E (通讯作者)，Adolfo Lutz Inst, Div Immunol, Dr Arnaldo Av 355,11 Floor,Room 1116, BR-01246902 Sao Paulo, SP, Brazil.	elizabeth.gaspari@ial.sp.gov.br		De Gaspari, Elizabeth/0000-0001-8332-2248	FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [12/15568-0, 13/11147-2, 14/11172-0, 14/07182-0, 18/04202-0]	The research was supported with grants by FAPESP (no.12/15568-0,13/11147-2,14/11172-0,14/07182-0,18/04202-0). Also, we would like to thank the NL-Diagnostica for donation of the kit cPassTM SARS-CoV-2 Neutralization, and Mabtech for kit donation.	Anfasa F, 2019, J CLIN VIROL, V117, P68, DOI 10.1016/j.jcv.2019.06.001; Bauer G, 2021, J MED VIROL, V93, P311, DOI 10.1002/jmv.26262; Brady AM, 2017, J IMMUNOL METHODS, V447, P31, DOI 10.1016/j.jim.2017.04.004; Chan KH, 2007, CLIN VACCINE IMMUNOL, V14, P1433, DOI 10.1128/CVI.00056-07; Chan PKS, 2005, J INFECT DIS, V192, P166, DOI 10.1086/430615; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; de Lima GT, 2020, PATHOG DIS, V78, DOI 10.1093/femspd/ftaa028; Demey B, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.033; Gaspar EB, 2013, HUM VACC IMMUNOTHER, V9, P572, DOI 10.4161/hv.23237; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Granoff DM, 1998, CLIN DIAGN LAB IMMUN, V5, P479, DOI 10.1128/CDLI.5.4.479-485.1998; Gutierrez J, 1996, MICROBIOS, V87, P113; HEDMAN K, 1989, J INFECT DIS, V159, P736, DOI 10.1093/infdis/159.4.736; HEDMAN K, 1988, J CLIN IMMUNOL, V8, P214, DOI 10.1007/BF00917569; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Leung GM, 2006, EPIDEMIOL INFECT, V134, P211, DOI 10.1017/S0950268805004826; Liu TC, 2020, NAT BIOMED ENG, V4, P1188, DOI 10.1038/s41551-020-00642-4; Ma CQ, 2014, VACCINE, V32, P6170, DOI 10.1016/j.vaccine.2014.08.086; Murchu EO, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2162; Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259; Sheridan C, 2020, NAT BIOTECHNOL, V38, P515, DOI 10.1038/d41587-020-00010-2; Soler M, 2020, ACS SENSORS, V5, P2663, DOI 10.1021/acssensors.0c01180; Thomas HIJ, 1996, CLIN EXP IMMUNOL, V103, P185, DOI 10.1046/j.1365-2249.1996.951642.x; Vermont C, 2002, FEMS IMMUNOL MED MIC, V34, P89, DOI 10.1016/S0928-8244(02)00342-5; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Walker SN, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01533-20; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	27	8	8	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 5	2021	39	10					1473	1475		10.1016/j.vaccine.2021.02.003		FEB 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QM3RT	33581919	Bronze, Green Published			2022-04-29	WOS:000621700000001
J	Hutton, DW; McCullough, JS; Prosser, L; Ye, W; Herman, WH; Zhang, P; Pilishvili, T; Pike, J				Hutton, David W.; McCullough, Jeffrey S.; Prosser, Lisa; Ye, Wen; Herman, William H.; Zhang, Ping; Pilishvili, Tamara; Pike, Jamison			Costs implications of pneumococcal vaccination of adults aged 30-60 with a recent diagnosis of diabetes	VACCINE			English	Article								Objective: The 23-valent pneumococcal polysaccharide vaccine is routinely recommended for adults with diabetes, but little is known about adherence to this recommendation and how vaccination of these adults affects costs related to pneumococcal disease. Research design and methods: We used data from a commercial insurance claims dataset to examine a cohort of non-elderly adults with a new diagnosis of diabetes and adults with no diagnosis of diabetes from 2005 to 2014. We examined rates of pneumococcal polysaccharide vaccination and the relationship between vaccination and pneumococcal disease costs, comparing results for persons with a diagnosis of diabetes and those with no diagnosis of diabetes. Results: Overall rates of pneumococcal polysaccharide vaccination among adults 30-60 years old were <1%/year. Rates of pneumococcal polysaccharide vaccination were higher for adults with diabetes. Pneumococcal polysaccharide vaccination rates more than doubled from 2.9% per year in 2005 to 6.0% per year in 2014 for adults vaccinated during the same year as their diabetes diagnosis. Using a two-part differences-in-differences model on a propensity-score matched dataset, pneumococcal polysaccharide vaccination may reduce average annual per-person pneumococcal disease costs by $90.54 [95% CI: $183.59, -$2.49, (p = 0.056)] in persons with diabetes from two years before to two years after vaccination. Conclusions: Non-elderly adults with diabetes have low but rising rates of pneumococcal polysaccharide vaccination. Pneumococcal polysaccharide vaccination has a modest impact reducing overall costs of pneumococcal disease in this population. (C) 2020 Elsevier Ltd. All rights reserved.	[Hutton, David W.; McCullough, Jeffrey S.; Prosser, Lisa] Univ Michigan, Dept Hlth Management & Policy, 1415 Washington Hts,Room M3515, Ann Arbor, MI 48109 USA; [Prosser, Lisa] Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; [Ye, Wen] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Herman, William H.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Herman, William H.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; [Zhang, Ping; Pilishvili, Tamara; Pike, Jamison] Ctr Dis Control & Prevent, Atlanta, GA USA		Hutton, DW (通讯作者)，Univ Michigan, Dept Hlth Management & Policy, 1415 Washington Hts,Room M3515, Ann Arbor, MI 48109 USA.	dwhutton@umich.edu			University of MichiganUniversity of Michigan System [U01IP000965]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01IP000965]	This study was funded by the Joint Initiative for Vaccine Economics, Phase 5, a cooperative agreement between the University of Michigan and the Centers for Disease Control and Prevention (U01IP000965). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. There are no relevant conflicts of interest to disclose.	[Anonymous], 2000, MMWR Recomm Rep, V49, P1; Belotti F, 2015, STATA J, V15, P3, DOI 10.1177/1536867X1501500102; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Black CL, 2013, MMWR-MORBID MORTAL W, V62, P733; Brundage JF, 2006, LANCET INFECT DIS, V6, P303, DOI 10.1016/S1473-3099(06)70466-2; Centers for Disease Control and Prevention, 2018, PNEUM DIS; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen JL, 2014, ADV THER, V31, P392, DOI 10.1007/s12325-014-0115-y; Cho BH, 2013, VACCINE, V31, P6011, DOI 10.1016/j.vaccine.2013.10.024; Deb P, 2018, ANNU REV PUBL HEALTH, V39, P489, DOI 10.1146/annurev-publhealth-040617-013517; Hill HA, 2018, MMWR-MORBID MORTAL W, V67, P1123, DOI 10.15585/mmwr.mm6740a4; Huss A, 2009, CAN MED ASSOC J, V180, P48, DOI 10.1503/cmaj.080734; Jackson LA, 2008, CLIN INFECT DIS, V47, P1328, DOI 10.1086/592691; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Smith KJ, 2013, VACCINE, V31, P3950, DOI 10.1016/j.vaccine.2013.06.037; Smith KJ, 2012, JAMA-J AM MED ASSOC, V307, P804, DOI 10.1001/jama.2012.169; Smith SA, 2000, DIABETES CARE, V23, P95, DOI 10.2337/diacare.23.1.95; Stoecker C, 2016, J GEN INTERN MED, V31, P901, DOI 10.1007/s11606-016-3651-0; Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1	21	0	0	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1333	1338		10.1016/j.vaccine.2020.11.060		FEB 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33494965	Green Accepted			2022-04-29	WOS:000618493500024
J	Ruiz, JB; Bell, RA				Ruiz, Jeanette B.; Bell, Robert A.			Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey	VACCINE			English	Article						COVID-19; Coronavirus; Vaccine; Conspiracy beliefs; Media; Social media		Background: Public polling indicates that vaccine uptake will be suboptimal when COVID-19 vaccines become available. Formative research seeking an understanding of weak vaccination intentions is urgently needed. Methods: Nationwide online survey of 804 U.S. English-speaking adults. Compensated participants were recruited from the U.S. through an internet survey panel of 2.5 million residents developed by a commercial survey firm. Recruitment was based on quota sampling to produce a U.S. Census-matched sample representative of the nation with regard to region of residence, sex, and age. Results: COVID-19 vaccination intentions were weak, with 14.8% of respondents being unlikely to get vaccinated and another 23.0% unsure. Intent to vaccinate was highest for men, older people, individuals who identified as white and non-Hispanic, the affluent and college-educated, Democrats, those who were married or partnered, people with pre-existing medical conditions, and those vaccinated against influenza during the 2019-2020 flu season. In a multiple linear regression, significant predictors of vaccination intent were general vaccine knowledge (beta = 0.311, p < .001), rejection of vaccine conspiracies (beta = -0.117, p = .003), perceived severity of COVID-19 (beta = 0.273, p < .001), influenza vaccine uptake (beta = 0.178, p < .001), having >= 5 pre-existing conditions (beta = 0.098, p = .003), being male (beta = 0.119, p < .001), household income of >= $120,000 (beta = 0.110, p = .004), identifying as a Democrat (beta = 0.075, p < .029), and not relying upon social media for virus information (beta = -0.090, p (002). Intent to vaccinate was lower for Fox News (57.3%) than CNN/MSNBC viewers (76.4%) (chi(2)(1) = 12.68, p < .001). Political party differences in threat appraisals and vaccine conspiracy beliefs are described. Conclusions: Demographic characteristics, vaccine knowledge, perceived vulnerability to COVID-19, risk factors for COVID-19, and politics likely contribute to vaccination hesitancy. Published by Elsevier Ltd.	[Ruiz, Jeanette B.; Bell, Robert A.] Univ Calif Davis, Dept Commun, One Shields Ave, Davis, CA 95616 USA		Ruiz, JB (通讯作者)，Univ Calif Davis, One Shields Ave,Kerr Hall 364, Davis, CA 95620 USA.	jbruiz@ucdavis.edu; rabell@ucdavis.edu					Achenbach J., WASH POST; Ball P, 2020, NATURE, V581, P371, DOI 10.1038/d41586-020-01452-z; BECKER MH, 1974, HEALTH EDUC QUART, V2, P409, DOI 10.1177/109019817400200407; Centers for Disease and Prevention, 2019, FLU VACCINATION COVE; Champion V.L., 2008, HLTH BEHAV HLTH ED T, V5th, P45; Featherstone JD, 2019, VACCINE, V37, P2993, DOI 10.1016/j.vaccine.2019.04.063; Frakt A., 2020, NEW YORK TIMES; Funk C., FACT TANK NEWS NUMBE; Godoy M, 2020, CORONAVIRUS CRISIS; Gramlich J., 2020, FACTTANK NEWS NUMBER; Grieco E., 2020, AMERICANSMAIN SOURCE; Haseltine WA., 2020, SCI AM; Havranek EP, 2015, CIRCULATION, V132, P873, DOI 10.1161/CIR.0000000000000228; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Jurkowitz M, 2020, AMERICANS ARE FOLLOW; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Logan J, 2018, VACCINE, V36, P4118, DOI 10.1016/j.vaccine.2018.05.037; National Institutes of Health, 2020, CORONAVIRUS DIS 2019; Neergaard L, 2020, AP NORC POLL HALF AM; Osborne H., 2020, NEWSWEEK; Piltch-Loeb R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010076; Poland GA, 2020, VACCINE, V38, P4219, DOI 10.1016/j.vaccine.2020.04.073; Rabin RC, NEW YORK TIMES; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Shapiro GK, 2016, PAPILLOMAVIRUS RES, V2, P167, DOI 10.1016/j.pvr.2016.09.001; Spink A, 2001, LIBR INFORM SCI RES, V23, P45, DOI 10.1016/S0740-8188(00)00067-0; Stein Richard A, 2017, Germs, V7, P168, DOI 10.18683/germs.2017.1122; van Green T., 2020, 5 FACTS PARTISAN REA; Witte K., 2001, EFFECTIVE HLTH RISK; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Zingg A, 2012, VACCINE, V30, P3771, DOI 10.1016/j.vaccine.2012.03.014	32	145	145	17	35	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 12	2021	39	7					1080	1086		10.1016/j.vaccine.2021.01.010		FEB 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QC9HH	33461833	Bronze, Green Submitted, Green Published	Y	N	2022-04-29	WOS:000615141100012
J	Ghiga, I; Richardson, S; Alvarez, AMR; Kato, M; Naidoo, D; Otsu, S; Nguyen, PT; Nguyen, PN; Nguyen, T				Ghiga, Ioana; Richardson, Sol; Alvarez, Alba Maria Ropero; Kato, Masaya; Naidoo, Dhamari; Otsu, Satoko; Phuc Thi Nguyen; Phuong Nam Nguyen; Tim Nguyen			PIPDeploy: Development and implementation of a gamified table top simulation exercise to strengthen national pandemic vaccine preparedness and readiness	VACCINE			English	Article						Influenza; Vaccine response; Pandemic preparedness; Gamification; Simulation exercise	INFLUENZA VACCINATION; DESIGN; NEED; GAMIFICATION; AMERICA; MODELS	Successful emergency vaccination campaigns rely on effective deployment and vaccination plans. This applies to localised outbreaks as well as for pandemics. In the wake of the 2009 H1N1 influenza pandemic, analysis of the global Vaccine Deployment Initiative, through which the World Health Organization (WHO) donated pandemic influenza vaccines to countries in need, revealed that an absence of vaccine deployment plans in many countries significantly hindered vaccine deployment. Through the Pandemic Influenza Preparedness Framework adopted by the World Health Assembly in 2011, WHO is engaging in several capacity building activities to improve pandemic influenza preparedness and response and make provisions for access to vaccines and sharing of other benefits. The Framework calls for the development and exercise of operational plans for deployment of influenza vaccines to enhance pandemic preparedness. To this end, WHO has supported the development of PIPDeploy, an interactive, in-person table top simulation exercise to facilitate learning for emergency preparedness. It employs various game design elements including a game board, time pressure, leaderboards and teams to enhance participants' motivation. PIPDeploy formed part of five WHO Pandemic Influenza Vaccine Deployment Workshops attended by national-level managers responsible for pandemic influenza vaccine response predominantly in non-producing countries. The purpose of this study was to describe the features and application of PIPDeploy, and present findings of the evaluation of participants' experiences during the simulation involving a "hot wash" discussion and collection of quantitative data. The simulation's instructional approach was widely accepted by participants, who reported that the format was novel and engaging. They reflected on its utility for identifying gaps in their own vaccine deployment plans and regulatory frameworks for importation of vaccine products. All participants found the simulation relevant to their professional objectives. A range of other potential applications were suggested, including PIPDeploy's adaptation to sub-national contexts and to other epidemic diseases. (C) 2020 Published by Elsevier Ltd.	[Ghiga, Ioana; Tim Nguyen] WHO, WHO Hlth Emergencies Programme, Global Infect Hazard Preparedness Dept, Geneva, Switzerland; [Richardson, Sol] Kings Coll London, Inst Psychiat Psychol & Neurosci, 16 Crespigny Park, London SE5 8AF, England; [Alvarez, Alba Maria Ropero] WHO, Reg Off Amer, Washington, DC USA; [Kato, Masaya; Phuong Nam Nguyen] WHO, Reg Off Western Pacific, Manila, Philippines; [Naidoo, Dhamari] WHO, Country Off Nigeria, Abuja, Nigeria; [Otsu, Satoko; Phuc Thi Nguyen] WHO, Country Off Viet Nam, Hanoi, Vietnam		Ghiga, I (通讯作者)，WHO, 20 Ave Appia, CH-1211 Geneva, Switzerland.	ghigai@who.int		Richardson, Sol/0000-0003-0863-1061	World Health OrganizationWorld Health Organization	This study was funded by the World Health Organization.	Alvarez Alba Maria Ropero, 2005, ADV IMPL INT HLTH RE; Annetta LA, 2010, REV GEN PSYCHOL, V14, P105, DOI 10.1037/a0018985; [Anonymous], 2014, RED CROSS RED CRESCE, V3; BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497; Deterding S., 2011, P 15 INT ACAD MINDTR, P9, DOI 10.1145/2181037.2181040; Fan VY, 2018, B WORLD HEALTH ORGAN, V96, P129, DOI 10.2471/BLT.17.199588; Federal Emergency Management Agency, 2008, HSEEP GLOSS; Flatla D.R., 2011, P 24 ANN ACM S US IN, P403, DOI [DOI 10.1145/2047196.2047248, 10.1145/2047196.2047248.]; GaneshAID, 2019, PIPDEPLOY GAM TEST D; Girard MP, 2010, VACCINE, V28, P4895, DOI [10.1016/j.vaccine.2010.05.031, 10.1016/j.vaccine.2010.07.034]; Gustafson K. L., 2002, TRENDS ISSUES INSTRU; Kanat IE, 2013, 2013 IEEE INTERNATIONAL CONFERENCE ON INTELLIGENCE AND SECURITY INFORMATICS: BIG DATA, EMERGENT THREATS, AND DECISION-MAKING IN SECURITY INFORMATICS, P134, DOI 10.1109/ISI.2013.6578802; Kerfoot BP, 2010, AM J PREV MED, V39, P472, DOI 10.1016/j.amepre.2010.07.016; Khalil MK, 2016, ADV PHYSIOL EDUC, V40, P147, DOI 10.1152/advan.00138.2015; Lopez X, P 8 EUR C GAM BAS LE, P110; Majuri J, 2018, P 2 INT GAMIFIN C GA, P11, DOI [10.1016/j.chb.2015.08.048, DOI 10.1016/J.CHB.2015.08.048]; *NATL ALL PUB CHAR, 2016, CLOS LOOK CHART SCH, P1, DOI DOI 10.17226/21891; Ogershok PR, 2004, MED TEACH, V26, P514, DOI 10.1080/01421590410001711553; Ping Z, 2008, COMMUN ACM, V51, P145, DOI 10.1145/1400214.1400244; Porter RM, 2020, VACCINE, V38, P1152, DOI 10.1016/j.vaccine.2019.11.025; Reeves B., 2009, TOTAL ENGAGEMENT USI; Ropero-Alvarez AM, 2016, HUM VACC IMMUNOTHER, V12, P2206, DOI 10.1080/21645515.2016.1157240; Ropero-Alvarez AM, 2012, VACCINE, V30, P916, DOI 10.1016/j.vaccine.2011.11.092; Ryan R.M., 2002, HDB SELF DETERMINATI, P3; Sailer M, 2017, COMPUT HUM BEHAV, V69, P371, DOI 10.1016/j.chb.2016.12.033; Seaborn K, 2015, INT J HUM-COMPUT ST, V74, P14, DOI 10.1016/j.ijhcs.2014.09.006; Seventieth World Health Assembly, 2017, REV PAND INFL PREP F; Sixty-fourth World Health Assembly, 2011, WHA645 WHO; Takayama, 2013, 1 INT C GAM DES RES, P75, DOI [10.1145/2583008.2583018., DOI 10.1145/2583008.2583018]; Thomas, 1998, ACM SIGCHI B, V19, P21; US Department of Homeland Security, 2007, HSEEP, V1, P6; Van den Broeck A, 2010, J OCCUP ORGAN PSYCH, V83, P981, DOI 10.1348/096317909X481382; van Rijswijk J, 2016, COCHRANE DB SYST REV, V6, DOI [10.1002/14651858.CD012209, DOI 10.1002/14651858.CD012209]; WHITE RW, 1959, PSYCHOL REV, V66, P297, DOI 10.1037/h0040934; World Government Summit, 2016, GAM FUT ED; World Health Organization, 2020, WHO CONC FAIR ACC EQ; World Health Organization, 2012, GAP GUID DEV IMPL NA; World Health Organization, 2019, M REP PAND INFL DEPL; World Health Organization, 2019, REP PAND INFL VACC D; World Health Organization, 2011, MAIN OP LESS LEARNT; World Health Organization, 2011, PAND INFL PREP FRAM; World Health Organization, 2017, WHO SIM EX MAN PRACT; World Health Organization, 2011, WHA6410 WHO; World Health Organization, 2019, REP WHO PAND VACC DE; World Health Organization, 2019, PAND INFL PREP WHO M; World Health Organization Regional Office for the Western Pacific, 2019, M REP WORKSH NAT PAN; Wouters P, 2008, REV EDUC RES, V78, P645, DOI 10.3102/0034654308320320; Zhang WQ, 2017, VACCINE, V35, P851, DOI 10.1016/j.vaccine.2016.12.056; Zicherman, 2011, LONG ENGAGEMENT SHOT; Zimmerman G, 2004, RULES PLAY GAME DESI, P80	50	1	2	2	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					364	371		10.1016/j.vaccine.2020.11.047			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PN8VM	33293160	Green Published, hybrid			2022-04-29	WOS:000604750300027
J	Gold, MS; Lincoln, G; Bednarz, J; Braunack-Mayer, A; Stocks, N				Gold, M. S.; Lincoln, G.; Bednarz, J.; Braunack-Mayer, A.; Stocks, N.			Consumer acceptability and validity of m-Health for the detection of adverse events following immunization - The Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) randomised control trial	VACCINE			English	Article						Adverse events following immunisation; Active vaccine safety surveillance; Pharmacovigilance; m-Health	INFLUENZA VACCINE SAFETY; ACTIVE SURVEILLANCE; FEASIBILITY	Introduction: Monitoring for adverse events following immunisation (AEFI) is critical for vaccine pharma-covigilance. Given the global and expanding availability of mobile phones their utility for consumer-based vaccine safety surveillance is of interest but little is known about consumer acceptability. This study nested within the Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) randomised control trial sought to evaluate the acceptability of SMS for AEFI surveillance. Methods: The primary STARSS study was a multi-centre RCT evaluating the efficacy of repeated SMS prompts for AEFI surveillance with participants being adult vaccinees or parents of children receiving any vaccine. This nested study enrolled primary RCT participants who completed a detailed computer assisted telephone interview to determine their attitudes towards SMS-based surveillance and ascertain their knowledge and attitudes toward vaccine safety, efficacy, data privacy and use of electronic health records. Attitudes to surveillance and related behaviour were used as measures of acceptability. Results: 20% (1200/6555) of the participants were enrolled and 1139 completed the full-length question-naire. 96% indicated that SMS-based surveillance after immunisation to check the safety of the vaccine "should be done" but 62% of all respondents said it should be done but consent should be sought first. Neither vaccine safety attitudes nor attitudes toward privacy were associated with opposition to SMS-based surveillance. In terms of SMS related behaviour demographic rather than attitudinal factors were associated with non-compliance. Conclusion: Overall, the attitude towards SMS-based surveillance was very favourable. Experiencing the SMS surveillance has the effect of reducing opposition to an SMS surveillance system, and at the same time increasing the likelihood of a preference for prior consent. Detection of a vaccine safety signal could be impeded in particular demographic groups who are non-compliant and we should undertake further research to understand why these groups are non-compliant and how this can be improved. Crown Copyright (C) 2020 Published by Elsevier Ltd. All rights reserved.	[Gold, M. S.] Univ Adelaide, Adelaide Med Sch, Discipline Paediat, Adelaide, SA, Australia; [Lincoln, G.] South Australian Hlth & Med Res Inst, Australia & New Zealand Dialysis & Transplant Reg, Adelaide, SA, Australia; [Bednarz, J.] Univ Adelaide, Sch Publ Hlth, Adelaide Hlth Technol Assessment, Adelaide, SA, Australia; [Braunack-Mayer, A.] Univ Wollongong, Fac Arts Sch Hlth & Soc, Social Sci & Humanities, Wollongong, NSW, Australia; [Stocks, N.] Univ Adelaide, Adelaide Med Sch, Discipline Gen Practice, Adelaide, SA, Australia		Gold, MS (通讯作者)，Womens & Childrens Hosp, 75 King William Rd, Adelaide, SA 5006, Australia.	michael.gold@adelaide.edu.au	Braunack-Mayer, Annette/AAE-7796-2019	Braunack-Mayer, Annette/0000-0003-4427-0224	NHMRCNational Health and Medical Research Council (NHMRC) of Australia [GNT1067703]	NHMRC GNT1067703 Partnership Project.	[Anonymous], 2000, MMWR-MORBID MORTAL W, V50, P1; Armstrong PK, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000016; Baron S, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2477; Berry JG, 2013, CLIN TRIALS, V10, P483, DOI 10.1177/1740774513480568; Berry JG, 2012, VACCINE, V30, P4167, DOI 10.1016/j.vaccine.2012.04.056; Blyth CC, 2011, VACCINE, V29, P5107, DOI 10.1016/j.vaccine.2011.05.054; Cajita MI, 2018, CIN-COMPUT INFORM NU, V36, P376, DOI 10.1097/CIN.0000000000000442; Cashman P, 2019, VACCINE, V37, P2427, DOI 10.1016/j.vaccine.2019.02.082; Diese M, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5186-2; Fagerland MW, 2008, STAT MED, V27, P4238, DOI 10.1002/sim.3202; Hosmer D.W., 2013, APPL LOGISTIC REGRES, V3rd ed.; Iwaya LH, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/11642; Kazi Abdul Momin, 2017, JMIR Public Health Surveill, V3, pe5, DOI 10.2196/publichealth.5386; Lei JY, 2018, VACCINE, V36, P1577, DOI 10.1016/j.vaccine.2018.02.012; Mackenzie IS, 2012, BRIT J CLIN PHARMACO, V73, P801, DOI 10.1111/j.1365-2125.2011.04142.x; Munnoch SA, 2019, J MED INTERNET RES, V21, DOI 10.2196/14791; Pillsbury A, 2015, EUROSURVEILLANCE, V20, P6, DOI 10.2807/1560-7917.ES.2015.20.43.30050; Pillsbury A, 2017, VACCINE, V35, P7101, DOI 10.1016/j.vaccine.2017.10.091; Pillsbury AJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.4079; Pillsbury AJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023263; Regan AK, 2015, VACCINE, V33, P3689, DOI [10.1016/j.vaccine.2015.06.022, 10]; research2guidance, 2013, GLOBAL MOBILE HLTH M; Rhoads SJ, 2017, TELEMED E-HEALTH, V23, P833, DOI 10.1089/tmj.2016.0272; Silva BMC, 2015, J BIOMED INFORM, V56, P265, DOI 10.1016/j.jbi.2015.06.003; Stuurman AL, 2017, EXPERT REV VACCINES, V16, P187, DOI 10.1080/14760584.2017.1264272; Tozzi AE, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00036; Tsafack M, 2015, PAN AFR MED J, V22, DOI 10.11604/pamj.2015.22.351.8368; Vrijhoef HJM, 2009, J TELEMED TELECARE, V15, P362, DOI 10.1258/jtt.2009.090405; Wilson K, 2016, HUM VACC IMMUNOTHER, V12, P1738, DOI 10.1080/21645515.2016.1152434; World Health Organisation, GLOB VACC SAF BLUEPR	30	0	0	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					237	246		10.1016/j.vaccine.2020.12.011			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33309486				2022-04-29	WOS:000604750300012
J	Dinc, HO; Saltoglu, N; Can, G; Balkan, II; Budak, B; Ozbey, D; Caglar, B; Karaali, R; Mete, B; Tok, YT; Ersoy, Y; Kuskucu, MA; Midilli, K; Ergin, S; Kocazeybek, BS				Dinc, Harika Oyku; Saltoglu, Nese; Can, Gunay; Balkan, Ilker Inanc; Budak, Beyhan; Ozbey, Dogukan; Caglar, Bilge; Karaali, Ridvan; Mete, Bilgul; Tok, Yesim Tuyji; Ersoy, Yagmur; Kuskucu, Mert Ahmet; Midilli, Kenan; Ergin, Sevgi; Kocazeybek, Bekir Sami			Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection	VACCINE			English	Article						COVID-19; CoronaVac; Chemiluminescent microparticle immunoassay; Healthcare workers the anti-spike/RBD antibody	CORONAVIRUS; PROTEINS	Background and Objectives: Healthcare workers (HCWs) were among the first groups to be vaccinated in Turkey. The data to be obtained by the vaccination of HCWs would guide wide spread vaccination programs. Materials and Methods: The study included 330 HCWs working at Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Hospital and vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses (28 days apart). Anti-Spike/RBD IgG levels were measured 14 days after the first dose and 28 days after the second dose. Chemiluminescent microparticle immunoassay (CMIA) (ARCHITECT IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test (PRNT), was used. Results: Of the participants, 211 (63.9%) were female, 119 (36.1%) were male, and mean age was 39.6 +/- 7. 7 years. In those without prior COVID-19 history; (n = 255) antibody positivity was detected as 48.2% (95% CI: 42.1-54.3) 14 days after the first dose of vaccine, and 99.2% (95% CI: 98.1-100) at day 28 after the second dose. Antibody titers were significantly lower in patients with hypertension (p = 0.011). In those with prior history of COVID-19 (n = 75); both the antibody positivity rates after the first vaccine (48.2% vs 100%, p = 0.000) and the anti-spike/RBD antibody levels after the second vaccine (with a >= 1050 AU/mL titer equivalent to PRNT 1/80 dilution) was significant than infection-naive group (25.9% vs. 54.7%, p = 0.000). Antibody positivity after two doses of vaccination for all study group was 99.4% (95% CI: 98.6-100). Conclusions: Two doses CoronaVac produce effective humoral immunity in HCWs. Antibody response is significantly higher in those with prior history of COVID-19 than infection-naive group. Given no significant benefit of the second dose, a single shot of vaccination may be sufficient for those with prior history of COVID-19. Monitoring humoral and cellular immune responses, considering new variants, is required to validate this approach. (C) 2021 Elsevier Ltd. All rights reserved.	[Dinc, Harika Oyku] Bezmialem Vakif Univ Istanbul, Fac Pharm, Dept Pharmaceut Microbiol, Istanbul, Turkey; [Dinc, Harika Oyku; Ozbey, Dogukan; Tok, Yesim Tuyji; Ersoy, Yagmur; Kuskucu, Mert Ahmet; Midilli, Kenan; Ergin, Sevgi; Kocazeybek, Bekir Sami] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Med Microbiol, TR-34098 Istanbul, Turkey; [Saltoglu, Nese; Balkan, Ilker Inanc; Budak, Beyhan; Caglar, Bilge; Karaali, Ridvan; Mete, Bilgul] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Infect Dis & Clin Microbiol, TR-34098 Istanbul, Turkey; [Can, Gunay] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Publ Hlth, TR-34098 Istanbul, Turkey		Saltoglu, N (通讯作者)，Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Infect Dis & Clin Microbiol, TR-34098 Istanbul, Turkey.	saltoglu@iuc.edu.tr	KARAALİ, Rıdvan/AAQ-1018-2020; Dinc, Harika Oyku/AAG-1168-2020	KARAALİ, Rıdvan/0000-0003-2440-7529; Dinc, Harika Oyku/0000-0003-3628-7392; Caglar, Bilge/0000-0002-2718-4044	IU- Cerrahpasa Scientific Research Projects Unit [35691]	This work was supported by IU- Cerrahpasa Scientific Research Projects Unit (Project ID: 35691).	Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Aran D., 2021, ESTIMATING REAL WORL, DOI [10.1101/2021.02.05.21251139, DOI 10.1101/2021.02.05.21251139]; Bhimraj A., INFECT DIS SOC AM GU; CDC, COVID 19 VACC REQ AS; Dinc HO, 2021, MIKROBIYOL BUL, V55, P207, DOI 10.5578/mb.20219907; FDA, CONV PLASM; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Hall VJ, 2021, LANCET, V397, P1459, DOI 10.1016/S0140-6736(21)00675-9; Hitchings MDT., 2021, LANCET REG HLTH AM, V1, DOI [10.1101/2021.04.07.21255081, DOI 10.1101/2021.04.07.21255081]; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; Liu L, 2020, MICROBES INFECT, V22, P206, DOI 10.1016/j.micinf.2020.05.008; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Republic of Turkey, MIN HLTH COVID 19 IN; Tan YJ, 2004, CLIN DIAGN LAB IMMUN, V11, P362, DOI 10.1128/CDLI.11.2.362-371.2004; Walker PGT, 2020, SCIENCE, V369, P413, DOI 10.1126/science.abc0035; WHO, EV ASS SIN CORONAVAC; WHO, STRAT ADV GROUP EXP; WHO, 2020, WHOBS20202403; Wu HS, 2004, J BIOMED SCI, V11, P117, DOI [10.1159/000075294, 10.1007/BF02256554]; Zhang H, SINGLE CELL SEQUENCI, DOI [10.2139/ssrn.3774153, DOI 10.2139/SSRN.3774153]; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	21	2	2	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					52	58		10.1016/j.vaccine.2021.11.051		DEC 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FV	34839992	Bronze, Green Published			2022-04-29	WOS:000731299800011
J	Alleva, DG; Delpero, AR; Scully, MM; Murikipudi, S; Ragupathy, R; Greaves, EK; Sathiyaseelan, T; Haworth, JR; Shah, NJ; Rao, V; Nagre, S; Lancaster, TM; Webb, SS; Jasa, AI; Ronca, SE; Green, FM; Elyard, HA; Yee, J; Klein, J; Karnes, L; Sollie, F; Zion, TC				Alleva, David G.; Delpero, Andrea R.; Scully, Melanie M.; Murikipudi, Sylaja; Ragupathy, Ramya; Greaves, Emma K.; Sathiyaseelan, Thillainaygam; Haworth, Jeffrey R.; Shah, Nishit J.; Rao, Vidhya; Nagre, Shashikant; Lancaster, Thomas M.; Webb, Sarah S.; Jasa, Allison, I; Ronca, Shannon E.; Green, Freedom M.; Elyard, Hanne Andersen; Yee, JoAnn; Klein, Jeffrey; Karnes, Larry; Sollie, Frans; Zion, Todd C.			Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452	VACCINE			English	Article						Infectious disease; Coronavirus; Prophylaxis; Pandemic; COVID-19; Fc-fusion	MONTANIDE ISA 720; SARS-COV-2; IMMUNOGENICITY; BNT162B2; ISA-720; SAFETY; TRIAL; SARS	AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (Fc gamma R) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide (TM) ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These pre-clinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. (C) 2021 The Authors. Published by Elsevier Ltd.	[Alleva, David G.; Delpero, Andrea R.; Scully, Melanie M.; Murikipudi, Sylaja; Ragupathy, Ramya; Greaves, Emma K.; Sathiyaseelan, Thillainaygam; Haworth, Jeffrey R.; Shah, Nishit J.; Rao, Vidhya; Nagre, Shashikant; Lancaster, Thomas M.; Zion, Todd C.] Akston Biosci Corp, 100 Cummings Ctr,Suite 454C, Beverly, MA 01915 USA; [Webb, Sarah S.; Jasa, Allison, I] Biomere Biomed Res Models, 57 Union St, Worcester, MA 01608 USA; [Ronca, Shannon E.; Green, Freedom M.] Baylor Coll Med, Feigin ABSL 3 Facil, 1102 Bates Ave,300-15, Houston, TX 77030 USA; [Elyard, Hanne Andersen] BIOQUAL Inc, 9600 Med Ctr Dr,Suite 101, Rockville, MD 20850 USA; [Yee, JoAnn] Univ Calif Davis, CA Natl Primate Res Ctr, Primate Assay Lab, Davis, CA 95616 USA; [Klein, Jeffrey; Karnes, Larry] Sinclair Res Ctr, 562 State Rd DD, Auxvasse, MO 65231 USA; [Sollie, Frans] Pharmaceut Res Associates Grp BV, Amerikaweg 18, NL-9407 TK Assen, Netherlands		Zion, TC (通讯作者)，Akston Biosci Corp, 100 Cummings Ctr,Suite 454C, Beverly, MA 01915 USA.	todd.zion@akstonbio.com		Zion, Todd/0000-0002-9757-0020; Haworth, Jeffrey/0000-0002-2880-0363			Ascarateil S., 2015, J IMMUNOTHER CANCER, V3, pP428, DOI [10.1186/2051-1426-3-S2-P428, DOI 10.1186/2051-1426-3-S2-P428]; Aucouturier Jerome, 2002, Expert Rev Vaccines, V1, P111, DOI 10.1586/14760584.1.1.111; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bos R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00243-x; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6; Di Caro A, 2021, CLIN MICROBIOL INFEC, V27, P823, DOI 10.1016/j.cmi.2021.03.011; Ewer K, 2017, HUM VACC IMMUNOTHER, V13, P3020, DOI 10.1080/21645515.2017.1383575; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Greaney AJ., 2020, 425021 BIORXIV, DOI [10.1101/2020.12.31.425021, DOI 10.1101/2020.12.31.425021, 12.31.425021]; Greaney AJ, 2021, CELL HOST MICROBE, V29, P463, DOI 10.1016/j.chom.2021.02.003; Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516; Heaton PM, 2020, NEW ENGL J MED, V383, P1986, DOI 10.1056/NEJMe2025111; Herrera S, 2011, AM J TROP MED HYG, V84, P12, DOI 10.4269/ajtmh.2011.09-0516; Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027; Karnik M, 2021, MOL NEUROBIOL, DOI 10.1007/s12035-021-02399-6; Ko EJ, 2018, HUM VACC IMMUNOTHER, V14, P3041, DOI 10.1080/21645515.2018.1495301; Kounis NG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030221; Lawrence GW, 1997, VACCINE, V15, P176, DOI 10.1016/S0264-410X(96)00150-8; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI 10.1038/s41564-020-0688-y; Li YZ, 2021, EMERG MICROBES INFEC, V10, P342, DOI 10.1080/22221751.2021.1887767; Loureiro S, 2012, INNOVATION VACCINOLO, P45, DOI [10.1007/978-94-007-4543-8_3, DOI 10.1007/978-94-007-4543-8_3]; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Miles AP, 2005, VACCINE, V23, P2530, DOI 10.1016/j.vaccine.2004.08.049; Oliveira GA, 2005, INFECT IMMUN, V73, P3587, DOI 10.1128/IAI.73.6.3587-3597.2005; Organization WH, 2021, WHO GUID DOC, V2021; Park JG, 2021, J VIROL METHODS, V287, DOI 10.1016/j.jviromet.2020.113995; Park KS, 2021, ADV DRUG DELIVER REV, V169, P137, DOI 10.1016/j.addr.2020.12.008; Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772; Qiu Q, 2008, VACCINE, V26, P5527, DOI 10.1016/j.vaccine.2008.07.034; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Sarkar J, 2020, VET RES COMMUN, V44, P101, DOI 10.1007/s11259-020-09778-9; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; University J.H, COVID 19 DASHB CTR S; Verbeke R, 2021, J CONTROL RELEASE, V333, P511, DOI 10.1016/j.jconrel.2021.03.043; Wall EC, 2021, LANCET, V397, P2331, DOI 10.1016/S0140-6736(21)01290-3; Weaver, 2020, SARS COV 2 INFECT IN; Weiss S, 2020, J INFECT DIS, V222, P1629, DOI [10.1101/2020.04.14.20059501, 10.1093/infdis/jiaa531]; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xie Xuping, 2021, bioRxiv, DOI 10.1101/2021.01.07.425740; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yee JL, 2020, J MED PRIMATOL, V49, P322, DOI 10.1111/jmp.12483; Zhang NR, 2016, CELL MOL IMMUNOL, V13, P180, DOI 10.1038/cmi.2015.03; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	45	2	2	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6601	6613		10.1016/j.vaccine.2021.09.077		OCT 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34642088	hybrid, Green Published			2022-04-29	WOS:000708078600006
J	Bryden, GM; Rockloff, M; Browne, M; Unsworth, C				Bryden, Gabrielle M.; Rockloff, Matthew; Browne, Matthew; Unsworth, Carolyn			Effect of contamination and purity priming on attitudes to vaccination and other health interventions: A randomised controlled experiment	VACCINE			English	Article						Health psychology; Priming experiment; Vaccine hesitancy; Health attitudes; Disgust sensitivity; Contamination fear	COMPLEMENTARY; MEDICINE; BELIEFS; DISGUST	The objective of this experiment is to assess whether priming for contamination and purity causes a change in attitudes to health interventions, including vaccination, and complementary and alternative medicines (CAMs). An online priming experiment was conducted with four between-subject experimen-tal conditions including photos of: 1) biological contamination, 2) chemical contamination, 3) pure envi-ronments, such as pristine landscapes, and 4) hazard signs/icons indicating physical threats. Two control conditions included photos of neutral scenes and neutral icons, whereby experimental groups were com-pared against the related control groups (photograph for conditions 1-3 and neutral icons for condition 4). Subjects were randomly assigned to one of the six conditions, and after exposure to the images they were asked to rate 10 conventional and alternative health interventions for effectiveness and safety, as well being assessed for disgust sensitivity using the reduced-item DPSS-R [10]. A total of 642 adults com-pleted the experiment. Exposure to primes did not cause a differential change in ratings of health inter-ventions. Nevertheless, higher levels of sensitivity to disgust were associated with lower ratings of the effectiveness of MMR vaccination, tetanus injection, antibiotics, and surgery; and higher levels of sensi-tivity to disgust were associated with higher ratings of effectiveness of vitamins/minerals. In conclusion, this online experiment did not find an experimental effect of priming for contamination and purity on subjects' ratings of the safety and effectiveness of conventional and alternative health interventions. This indicates that attitudes to these health interventions are not influenced by a temporary increase in the salience of feelings of contamination or purity. However, individual differences in disgust sensitiv -ity are related to their attitudes to vaccination and CAM interventions. (c) 2021 Elsevier Ltd. All rights reserved.	[Bryden, Gabrielle M.; Rockloff, Matthew; Browne, Matthew] Cent Queensland Univ, Sch Human Hlth & Social Sci, Univ Dr, Branyan, Qld 4670, Australia; [Unsworth, Carolyn] Federat Univ Australia, Sch Hlth, Gippsland Campus,Northways Rd, Churchill, Vic 3842, Australia		Browne, M (通讯作者)，Cent Queensland Univ, Sch Human Hlth & Social Sci, Univ Dr, Branyan, Qld 4670, Australia.	m.browne@cqu.edu.au		Bryden, Gabrielle/0000-0003-4162-9414; Unsworth, Carolyn/0000-0001-6430-2823; Rockloff, Matthew/0000-0002-0080-2690	Commonwealth Government Australian Postgraduate Award (APA) Scholarship	Funding source A Commonwealth Government Australian Postgraduate Award (APA) Scholarship supported this research.	Attwell K, 2018, SOC SCI MED, V196, P106, DOI 10.1016/j.socscimed.2017.11.022; Benjamini Y, 2000, J EDUC BEHAV STAT, V25, P60, DOI 10.3102/10769986025001060; Bihari T, 2006, ALTERN COMPLEMENT TH, V12, P233, DOI 10.1089/act.2006.12.233; Bishop FL, 2007, J HEALTH PSYCHOL, V12, P851, DOI 10.1177/1359105307082447; Braun MH, 2016, INT J FOOD SCI TECH, V1, P29, DOI 10.1386/ijfd.1.1.29_1; Browne M, 2018, HUM VACC IMMUNOTHER, V14, P2540, DOI 10.1080/21645515.2018.1480244; Browne M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132562; Bryden GM, 2018, VACCINE, V36, P1227, DOI 10.1016/j.vaccine.2017.12.068; Clifford S, 2016, POLIT BEHAV, V38, P155, DOI 10.1007/s11109-015-9310-z; Fergus TA, 2009, J ANXIETY DISORD, V23, P703, DOI 10.1016/j.janxdis.2009.02.009; Flynn T, 2015, RES J I PUBLIC RELAT, V2, P1; Gullion JS, 2008, PUBLIC HEALTH NURS, V25, P401, DOI 10.1111/j.1525-1446.2008.00724.x; Hornsey MJ, 2020, SOC SCI MED, V255, DOI 10.1016/j.socscimed.2020.113019; Kurdi B, 2017, BEHAV RES METHODS, V49, P457, DOI 10.3758/s13428-016-0715-3; Luo JY, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00573; Luz PM, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819000517; Majid U, 2020, QUAL HEALTH RES, V30, P1762, DOI 10.1177/1049732320933863; Marchewka A, 2014, BEHAV RES METHODS, V46, P596, DOI 10.3758/s13428-013-0379-1; Moran M. B., 2016, Journal of Communication in Healthcare, V9, P151, DOI 10.1080/17538068.2016.1235531; Navin M, 2013, DISGUST CONTAMINATIO; Nissen N, 2015, ANTHROPOL MED, V22, P162, DOI 10.1080/13648470.2015.1043789; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Rhodehamel EJ., 1992, HACCP PRINCIPLES APP, P8, DOI [10.1007/978-1-4684-8818-0_3, DOI 10.1007/978-1-4684-8818-0_3]; Roulin N, 2015, IND ORGAN PSYCHOL-US, V8, P190, DOI 10.1017/iop.2015.24; Scheres J, 2019, ZESZYTY NAUKOWE OCHR, V17, P2, DOI [10.4467/20842627oz.19.001.11297, DOI 10.4467/20842627OZ.19.001.11297]; Schulz KF, 2010, BMC MED, V8, DOI [10.1136/bmj.c332, 10.1186/1741-7015-8-18]; Smeets MAM, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00096; Sobo EJ, 2015, MED ANTHROPOL Q, V29, P381, DOI 10.1111/maq.12214; Tomljenovic H, 2020, PSYCHOL HEALTH, V35, P538, DOI 10.1080/08870446.2019.1673894; Toronchuk JA, 2007, COGNITION EMOTION, V21, P1799, DOI 10.1080/02699930701298515	30	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6653	6659		10.1016/j.vaccine.2021.09.063		OCT 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WI0SZ	34635374				2022-04-29	WOS:000708078600012
J	Hart, P; Farrar, J				Hart, Peter; Farrar, Jeremy			The influenza vaccines roadmap - A better future through improved influenza vaccines	VACCINE			English	Editorial Material							SEASONAL INFLUENZA; INFECTIONS; BURDEN		[Hart, Peter; Farrar, Jeremy] Wellcome Trust Res Labs, 215 Euston Rd, London NW1 2BE, England		Hart, P (通讯作者)，Wellcome Trust Res Labs, 215 Euston Rd, London NW1 2BE, England.	p.hart@wellcome.org					Baselga-Moreno V, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6713-5; Buckley BS, 2019, CLIN MICROBIOL INFEC, V25, P1213, DOI 10.1016/j.cmi.2019.06.030; Chung H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1943; de Francisco N, 2015, VACCINE, V33, P6537, DOI 10.1016/j.vaccine.2015.10.066; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Head MG, 2020, LANCET GLOB HEALTH, V8, pE1295, DOI 10.1016/S2214-109X(20)30357-0; Head MG, 2016, EBIOMEDICINE, V3, P180, DOI 10.1016/j.ebiom.2015.12.016; Hungerford D, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2034; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9; Sparrow E, 2021, VACCINE, V39, P512, DOI 10.1016/j.vaccine.2020.12.018; Troeger CE, 2019, LANCET RESP MED, V7, P69, DOI [10.1016/S2213-2600(18)30496-X, 10.1016/s2213-2600(18)30496-x]	12	0	0	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6570	6572		10.1016/j.vaccine.2021.09.071		OCT 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34635377	Green Published, Bronze			2022-04-29	WOS:000708078600002
J	Lewis, G; Lazzaro, T; Crawford, NW				Lewis, G.; Lazzaro, T.; Crawford, N. W.			Recurrent lipoatrophy following multiple vaccinations: A case study	VACCINE			English	Editorial Material									[Lewis, G.; Lazzaro, T.; Crawford, N. W.] Murdoch Childrens Res Inst, SAEFVIC, Parkville, Vic, Australia; [Lazzaro, T.; Crawford, N. W.] Univ Melbourne, Parkville, Vic, Australia; [Lewis, G.; Lazzaro, T.; Crawford, N. W.] Royal Childrens Hosp, Parkville, Vic, Australia		Lewis, G (通讯作者)，Murdoch Childrens Res Inst, SAEFVIC, Parkville, Vic, Australia.; Lewis, G (通讯作者)，Royal Childrens Hosp, Parkville, Vic, Australia.	georgina.lewis@mcri.edu.au					Ojaimi S, 2009, VACCINE, V27, P4876, DOI 10.1016/j.vaccine.2009.06.026; Schnyder JL, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101868	2	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 22	2021	39	44					6563	6564		10.1016/j.vaccine.2021.09.046		OCT 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WX9RH	34602300				2022-04-29	WOS:000718925300016
J	Choudhary, P; Fourie, KR; Ng, S; Hamonic, G; Berube, N; Popowych, Y; Wilson, HL				Choudhary, P.; Fourie, K. R.; Ng, S.; Hamonic, G.; Berube, N.; Popowych, Y.; Wilson, H. L.			Intrauterine immunizations trigger antigen-specific mucosal and systemic immunity in pigs and passive protection in suckling piglets	VACCINE			English	Article						Pig; Uterus; Vaccine; Passive protection; Infectious disease; Priming; Porcine epidemic diarrhea virus; Lawsonia intracellularis	CELLS; INSEMINATION; SPERMATOZOA; ANTIBODIES; DELIVERY; VACCINES; UTERINE; UTERUS; MICE; CD4	We assessed whether vaccines administered to the uterus at breeding can lead to sufficient colostral antibodies to protect suckling piglets against Porcine Endemic Diarrhea Virus (PEDV). An antigen from Lawsonia intracellularis, a disease that impacts weanling intestinal health, was also included because we have extensive knowledge on the pig immune response to this antigen. Gilts were mock-bred at 2nd estrus with killed sperm including an intrauterine (i.u.) vaccine comprised of recombinant (r) PEDV Spike protein (rPEDVS1) and L. intracellularis flagellin (rFliC) formulated with poly I:C, host defense peptide, and polyphosphazene (TriAdj). Gilts returned to estrus within 3 weeks and they were inseminated with killed sperm (3rd estrus) or live sperm (4th estrus) with rPEDVS1-TriAdj vaccine. They also received an i.m. injection of rFliC-TriAdj at 3rd and 4th estrus to establish whether i.u. vaccination primes systemic immunity without inducing mucosal tolerance. Control gilts were administered semen alone at 2nd estrus which allowed us to compare litter weights and sizes to industry standards. Colostrum from gilts challenged with low dose PEDV plus alum was used as positive reference samples for neutralizing antibodies and passive protection. Thirteen weeks later, the i.u.-vaccinated gilts showed significant PEDVS1-specific serum, colostral, and uterine antibody titers and colostral PEDVS1-neutralizing antibodies but poor cell-mediated immunity. Piglets born to i.u. vaccinated gilts received partial passive protection from PEDV infection 3 days after birth but eventually succumbed to the disease. Immunization by the i.u./i.m. route triggered significant anti-FliC cell-mediated immunity and colostral FliC antibodies that remained high in weaned piglet serum. This trial and a repeat trial wherein gilts were immunized at 1st estrus without semen and at 2nd estrus with live semen showed that intrauterine immunization did not impact fertility, number of live births or piglet growth kinetics. Further optimization is needed to promote robust passive protection in suckling offspring. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Choudhary, P.; Fourie, K. R.; Ng, S.; Hamonic, G.; Berube, N.; Popowych, Y.; Wilson, H. L.] Univ Saskatchewan, Vaccine & Infect Dis Org VIDO, 120 Vet Rd, Saskatoon, SK S7N 5E3, Canada; [Fourie, K. R.; Wilson, H. L.] Univ Saskatchewan, Dept Vet Microbiol, Western Coll Vet Med, Saskatoon, SK S7N 5B4, Canada; [Hamonic, G.] Univ Saskatchewan, Dept Large Anim Clin Sci, Western Coll Vet Med, Saskatoon, SK S7N 5B4, Canada		Wilson, HL (通讯作者)，Univ Saskatchewan, VIDO, 120 Vet Rd, Saskatoon, SK S7N 5E3, Canada.	heather.wilson@usask.ca			Alberta Agriculture and Forestry; Saskatchewan Ministry of Agriculture; Canada-Saskatchewan Growing Forward 2 Bilateral Agreement Agriculture Development Fund grant; Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	Financial support was provided by the Alberta Agriculture and Forestry and Saskatchewan Ministry of Agriculture and the Canada-Saskatchewan Growing Forward 2 Bilateral Agreement Agriculture Development Fund grant to HLW with co-investigator JA Pasternak. Funding was also provided by a Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant to HLW. rPEDVS1 antigen was made and purified by Will Deck and Robert Brownlie at VIDO. We gratefully acknowledge the skilled animal husbandry and handling at Prairie Swine Centre, Inc. by Raelene Petracek, Josi Panisson and Tatjana Ometlic and at VIDO, including Colette Wheler, Stew Walker and Jan Erickson. PC is a post-doctoral fellow at VIDO, Saskatoon, SK, Canada. We are grateful to Shirley Hauta for processing postmortem samples for the PEDV trial and assistance from Donna Dent for assistance with antibody ELISAs. This manuscript is published with permission by the Director of VIDO as journal series #923.	BISCHOF RJ, 1994, J REPROD IMMUNOL, V26, P131, DOI 10.1016/0165-0378(94)90036-1; Czerkinsky C, 1999, IMMUNOL REV, V170, P197, DOI 10.1111/j.1600-065X.1999.tb01339.x; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Fourie KR, 2021, VET IMMUNOL IMMUNOP, V237, DOI 10.1016/j.vetimm.2021.110256; Gerdts V, 2006, VET RES, V37, P487, DOI 10.1051/vetres:2006012; Hafer A. L., 1996, Swine Health and Production, V4, P128; Hamonic G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01015; Kaeoket K, 2003, J VET MED A, V50, P169, DOI 10.1046/j.1439-0442.2003.00532.x; Kaser T, 2017, VACCINE, V35, P91, DOI 10.1016/j.vaccine.2016.11.050; Katila T, 2012, REPROD DOMEST ANIM, V47, P31, DOI 10.1111/j.1439-0531.2012.02120.x; Kemp B, 2005, THERIOGENOLOGY, V63, P643, DOI 10.1016/j.theriogenology.2004.09.038; Knox RV, 2016, THERIOGENOLOGY, V85, P83, DOI 10.1016/j.theriogenology.2015.07.009; Koketsu Y, 2017, PORCINE HEALTH MANAG, V3, DOI 10.1186/s40813-016-0049-7; Kowalczyk DW, 2001, VACCINE, V19, P3583, DOI 10.1016/S0264-410X(01)00070-6; Makadiya N, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0512-8; McCluskie MJ, 2002, FEMS IMMUNOL MED MIC, V32, P179, DOI 10.1016/S0928-8244(01)00305-4; Obradovic M, 2019, VET MICROBIOL, V235, P270, DOI 10.1016/j.vetmic.2019.07.014; Pasternak JA, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.12855; Pasternak JA, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12732; Peiponen KS, 2018, ACTA VET SCAND, V60, DOI 10.1186/s13028-018-0374-8; Polewicz M, 2011, VACCINE, V29, P7718, DOI 10.1016/j.vaccine.2011.07.135; Pozzi PS, 2012, ISR J VET MED, V67, P24; Rozeboom KJ, 1999, J ANIM SCI, V77, P2201; Salogni C, 2016, J VET DIAGN INVEST, V28, P550, DOI 10.1177/1040638716656024; Serenius T, 2006, J ANIM SCI, V84, P2590, DOI 10.2527/jas.2005-499; Srivastava A, 2015, APMIS, V123, P275, DOI 10.1111/apm.12351; Taylor U, 2009, ANIM REPROD SCI, V115, P279, DOI 10.1016/j.anireprosci.2008.11.019; Wang XW, 2020, VET MICROBIOL, V240, DOI 10.1016/j.vetmic.2019.108511; WIRA CR, 1989, IMMUNOLOGY, V68, P24; Woodrow KA, 2012, ANNU REV BIOMED ENG, V14, P17, DOI 10.1146/annurev-bioeng-071811-150054	30	0	0	3	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6322	6332		10.1016/j.vaccine.2021.08.080		SEP 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34535320	hybrid			2022-04-29	WOS:000705822100023
J	Kotler, L; Greenberg, D; Givon-Lavi, N; van der Beek, BA; Dagan, R; Ben-Shimol, S				Kotler, Leore; Greenberg, David; Givon-Lavi, Noga; van der Beek, Bart Adriaan; Dagan, Ron; Ben-Shimol, Shalom			Decline in pneumococcal nasopharyngeal carriage in children 6-23 months with respiratory illnesses following pneumococcal conjugate vaccine implementation	VACCINE			English	Article						Streptococcus pneumoniae; Pneumococcal conjugated vaccine (PCV); Nasopharyngeal carriage; Colonization; Children	SEROTYPE REPLACEMENT; STREPTOCOCCUS-PNEUMONIAE; INVASIVE DISEASE; IMPACT; PCV7	Background: Following pneumococcal conjugate vaccines (PCVs) implementation, worldwide, pneumococcal carriage rates remained stable, indicating full replacement of vaccine-serotypes (VT) with non VT. However, data are scarce regarding PCV impact on pneumococcal carriage rates in healthy vs. sick children. We assessed pneumococcal carriage rates dynamics in healthy and sick children 6-23 months, following PCV introduction. Methods: This is a prospective, population-based surveillance conducted during the years 2009-2017, in southern Israel. Three groups were defined as follows: Children without respiratory infection signs (the healthy/non-respiratory group); Children who had a chest radiography at the hospital (the Hosp-CXR group); and children with community-acquired alveolar pneumonia (CAAP). Rate ratios (RRs; 95% CI) were calculated, comparing between late-13-valent PCV (PCV13) period (2016-2017) and early-PCV period (2009-2010). Rate ratios were adjusted for antibiotic administration, seasonality and ethnicity, and separate calculations were performed for 6-11 and 12-23 month old children. Results: Overall, 51% of 8627 nasopharyngeal cultures were positive. In 2009-2010 (early-PCV period), the overall carriage rate was 55%; serotypes included in the PCV13 carriage rates were 28%, 31% and 38% in the healthy/non-respiratory, Hosp-CXR, and CAAP groups, respectively. Overall carriage rates in healthy/non-respiratory episodes were stable (-54%) when comparing between 2016 and 17 and 2009-10 (RR = 0.98; 0.84-1.15). In contrast, rates significantly declined for Hosp-CXR (RR = 0.78; 0.63-0.98) and CAAP (RR = 0.65; 0.47-0.89). These trends were driven by 80% VT reductions, coupled with non-VT increase. Conclusions: Following 7-valent PCV/ PCV13 introduction, pneumococcal carriage rates declined in respiratory diseases, but not in healthy children and children without respiratory infections. These trends suggest that a reduction in pneumococcal carriage rates during respiratory infections indicates a decline in respiratory infections caused by VT, while carriage rates in non-respiratory cases reflect non-VT predominance, that have low disease potential for respiratory disease. (c) 2021 Elsevier Ltd. All rights reserved.	[Kotler, Leore; Greenberg, David; Givon-Lavi, Noga; van der Beek, Bart Adriaan; Dagan, Ron; Ben-Shimol, Shalom] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel; [Kotler, Leore; Greenberg, David; Givon-Lavi, Noga; Ben-Shimol, Shalom] Soroka Univ Med Ctr, Pediat Infect Dis Unit, IL-84101 Beer Sheva, Israel		Ben-Shimol, S (通讯作者)，Soroka Univ Med Ctr, Pediat Infect Dis Unit, IL-84101 Beer Sheva, Israel.	shalomb2@clalit.org	van der Beek, Bart Adriaan/AAA-6486-2021; Ben-Shimol, Shalom/G-3368-2015	Ben-Shimol, Shalom/0000-0002-7690-0991; Dagan, Ron/0000-0002-8888-1046			Ben-Shimol S, 2012, VACCINE, V30, P6600, DOI 10.1016/j.vaccine.2012.08.012; Ben-Shimol S, 2021, EMERG INFECT DIS, V27, P150, DOI 10.3201/eid2701.201178; Ben-Shimol S, 2016, HUM VACC IMMUNOTHER, V12, P268, DOI 10.1080/21645515.2015.1095414; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Cohen R, 2012, PEDIATR INFECT DIS J, V31, P297, DOI 10.1097/INF.0b013e318247ef84; Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005; Desai AP, 2015, PEDIATR INFECT DIS J, V34, P1168, DOI 10.1097/INF.0000000000000849; Faingelernt Y, 2020, J INFECT DIS, V221, P812, DOI 10.1093/infdis/jiz513; Gladstone RA, 2015, VACCINE, V33, P2015, DOI 10.1016/j.vaccine.2015.03.012; Greenberg D, 2015, VACCINE, V33, P4623, DOI 10.1016/j.vaccine.2015.06.062; Greenberg D, 2011, PEDIATR INFECT DIS J, V30, P227, DOI 10.1097/INF.0b013e3181f87802; Hanage WP, 2010, EPIDEMICS-NETH, V2, P80, DOI 10.1016/j.epidem.2010.03.005; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Olarte L, 2017, CLIN INFECT DIS, V64, P1699, DOI 10.1093/cid/cix115; Ouldali N, 2019, JAMA PEDIATR, V173, P362, DOI 10.1001/jamapediatrics.2018.5273; Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/ERV.12.53, 10.1586/erv.12.53]; Varon E, 2015, VACCINE, V33, P6178, DOI 10.1016/j.vaccine.2015.10.015; Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8	18	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5757	5761		10.1016/j.vaccine.2021.08.082		SEP 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34481698				2022-04-29	WOS:000697501500007
J	Decker, MD; Garman, PM; Hughes, H; Yacovone, MA; Collins, LC; Fegley, CD; Lin, G; DiPietro, G; Gordon, DM				Decker, Michael D.; Garman, Patrick M.; Hughes, Hayley; Yacovone, Margaret A.; Collins, Limone C.; Fegley, Christopher D.; Lin, Grace; DiPietro, Gina; Gordon, Daniel M.			Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members	VACCINE			English	Article						Myopericarditis; Myocarditis; Pericarditis; Smallpox vaccine; Cardiovascular adverse event; Neurological adverse event	YOUNG SWEDISH ORIENTEERS; UNEXPECTED CARDIAC DEATHS; MYOCARDITIS; MYOPERICARDITIS; PERICARDITIS; INFECTION; EVENTS	Objectives: To evaluate the rates of myopericarditis (primary objective) and rates of cardiovascular and neurological adverse events (secondary objectives) in temporal association with ACAM2000 (R) smallpox vaccine. Methods: Observational cohort study conducted through monthly surveillance from 2009 to 2017 of electronic medical records of military service members (SM) for pre-specified cardiac and neurological International Classification of Diseases (ICD) codes reported in the 30 days following smallpox vaccination. ICD codes potentially predictive of myopericarditis and codes for encephalitis, Guillain-Barre syndrome, and sudden death were classified into Group 1. All other cardiovascular and neurological ICD codes were classified into Group 2. Medical records containing Group 1 codes were individually reviewed to confirm coding accuracy and to seek additional data in support of myopericarditis adjudication, which was performed by an independent clinical panel. Chart reviews were not performed for Group 2 codes, which were reported in aggregate only. Results: 897,227 SM who received ACAM2000 smallpox vaccine and 450,000 SM who received Dryvax smallpox vaccine were included in the surveillance population. The rate of adjudicated myopericarditis among ACAM2000 smallpox vaccine recipients was 20.06/100,000 and was significantly higher for males (21.8/100,000) than females (8.5/100,000) and for those < 40 years of age (21.1/100,000) than for those 40 years or older (6.3/100,000). Overall rates for any cardiovascular event (Group 1 plus Group 2) were 113.5/100,000 for ACAM2000 vaccine and 439.3/100,000 for Dryvax vaccine; rate ratio, 0.26 (95% CI, 0.24-0.28). The rates of subjects with one or more defined neurological events were 2.12/100,000 and 1.11/100,000 for ACAM2000 and Dryvax vaccines respectively; rate ratio, 1.91 (95% CI, 0.71-5.10). Conclusions: Electronic records surveillance of the entire vaccinated SM population over a ten-year period found rates of myopericarditis, of defined neurological events, and of overall cardiac events that were consistent with those of prior passive surveillance studies involving Dryvax or ACAM2000 smallpox vaccines. (C) 2021 Elsevier Ltd. All rights reserved.	[Decker, Michael D.; Gordon, Daniel M.] Sanofi Pasteur Inc, Swiftwater, PA USA; [Decker, Michael D.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA; [Garman, Patrick M.; Hughes, Hayley; Yacovone, Margaret A.] Off Army Surg Gen, Mil Vaccine Agcy, Falls Church, VA USA; [Yacovone, Margaret A.; Collins, Limone C.] Def Hlth Agcy, Immunizat Healthcare Branch, Falls Church, VA USA; [Fegley, Christopher D.] United Biosource Corp, Blue Bell, PA USA; [Lin, Grace; DiPietro, Gina] Gaithersburg Inc, Emergent BioSolut, Gaithersburg, MD 20877 USA; [Garman, Patrick M.] Pfizer Inc, US Med Affairs, New York, NY USA; [Hughes, Hayley] Maryland Air Natl Guard, Baltimore, MD USA; [Yacovone, Margaret A.] NIAID, Rockville, MD USA; [Fegley, Christopher D.] PRA Hlth Sci, Blue Bell, PA USA; [Gordon, Daniel M.] DMGordon Consulting LLC, Edmond, OK USA		Decker, MD (通讯作者)，POB 425, Baxter, TN 38544 USA.	ms005@mdd1.org; patrick.garman@pfizer.com; hayley.hughes.drph@gmail.com; margaret.yacovone@nih.gov; dmgordon13@outlook.com		Decker, Michael/0000-0003-1008-7472; Gordon, Daniel/0000-0003-1062-5701			ACAM2000TM, LIV VACC SMALLP VACC; Alibek K, 2004, INT J INFECT DIS, V8, pS3, DOI 10.1016/j.ijid.2004.09.004; ANDERSON T, 1951, LANCET, V260, P1248; Casey CG, 2005, JAMA-J AM MED ASSOC, V294, P2734, DOI 10.1001/jama.294.21.2734; Department of Defense, SMALLP VACC SCREEN F; Department of Defense, MEDC PART ACAM2000 S; Department of Defense, UPD CLIN POL DEP DEF; Department of Defense, SMALLP VACC ADM COMP; Department of Defense Defense Health Agency Immunization Healthcare Branch, CLIN GUID POST SMALL; Department of Defense Military Health System, SMALLP ACAM2000; Dryvax, SMALLPOX VACCINE DRI; Engler RJM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118283; Faix DJ, 2020, VACCINE, V38, P7323, DOI 10.1016/j.vaccine.2020.09.037; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; Friman G, 1997, SCAND J INFECT DIS, P41; Fulginiti VA, 2003, CLIN INFECT DIS, V37, P241, DOI 10.1086/375824; Grosenbach DW, 2018, NEW ENGL J MED, V379, P44, DOI [10.1056/nejmoa1705688, 10.1056/NEJMoa1705688]; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; KARJALAINEN J, 1983, ACTA MED SCAND, V213, P65; Koplow DA., 2003, SMALLPOX FIGHT ERADI; Kuntz J, 2018, VACCINE, V36, P1524, DOI 10.1016/j.vaccine.2018.02.030; Lane HC, 2001, NAT MED, V7, P1271, DOI 10.1038/nm1201-1271; Larsson E, 1999, APMIS, V107, P325, DOI 10.1111/j.1699-0463.1999.tb01561.x; LeardMann CA, 2007, HUM VACCINES, V3, P245, DOI 10.4161/hv.4589; Lin AH, 2013, MIL MED, V178, P18, DOI 10.7205/MILMED-D-12-00226; MACADAM DB, 1962, BRIT MED J, P1099; Marshall M, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-052478; MCCAFFREY FM, 1991, AM J DIS CHILD, V145, P177, DOI 10.1001/archpedi.1991.02160020069020; McNeil MM, 2014, VACCINE, V32, P4758, DOI 10.1016/j.vaccine.2014.06.034; Ornato Joseph P, 2007, J Am Coll Cardiol, V49, P1389, DOI 10.1016/j.jacc.2007.01.020; Poland GA, 2005, VACCINE, V23, P2078, DOI 10.1016/j.vaccine.2005.01.012; Smith P, 2012, CRIT CARE MED, V40, pU345; Volkmann A, 2021, VACCINE, V39, P3067, DOI 10.1016/j.vaccine.2020.08.050; Wesslen L, 1996, EUR HEART J, V17, P902; Wesslen L, 2001, SCAND J INFECT DIS, V33, P429, DOI 10.1080/00365540152029891; WOODRUFF JF, 1980, AM J PATHOL, V101, P425; World Health Organization, 1980, GLOB ERAD SMALLP FIN	38	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5541	5547		10.1016/j.vaccine.2021.08.041		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34454787				2022-04-29	WOS:000704399700013
J	Janssen, RS; Bruxvoort, K; Jacobsen, SJ; Slezak, J; David, C; Hyer, R; Poland, GA				Janssen, Robert S.; Bruxvoort, Katia; Jacobsen, Steven J.; Slezak, Jeff; David, Coline; Hyer, Randall; Poland, Gregory A.			Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination	VACCINE			English	Article						Hepatitis B; Seroprotection; Vaccine; Vaccine Effectiveness; Value	ADVISORY-COMMITTEE; UNITED-STATES; RECOMMENDATIONS; IMMUNOGENICITY; SAFETY; EFFICACY	Background: In the absence of field efficacy studies, estimating the real-world effectiveness of vaccines may consider immunogenicity from randomized controlled clinical trials and real-world adherence. Combining seroprotection rates (SPRs) with regimen completion rates gives an estimate of an effective vaccine protection rate (eVPR), which can be leveraged to evaluate real-world cost-effectiveness by linking it with vaccine costs to estimate the cost-per-protected patient (CPP). Methods: This study evaluated eVPR and CPP as estimates of vaccine clinical-and cost-effectiveness of two-dose (HepB-CpG) and three-dose (HepB-Alum) hepatitis B virus (HBV) vaccines in the general adult population and a subpopulation with diabetes mellitus. eVPR was calculated from head-to-head SPR data from phase 3 clinical trials directly comparing HepB-CpG and HepB-Alum vaccine regimens and real world head-to-head adherence data. CPP was calculated as the average cost of each regimen divided by eVPR. Results: Higher eVPR in the adult population was achieved with HepB-CpG (68.0%) versus HepB-Alum (41.6%), reflecting the combination of higher SPR and vaccine regimen completion. The CPP for HepBCpG ($331.31) was $45.67 (95% CI: $36.66, $55.19) less than HepB-Alum ($377.09). Greater savings were observed among persons with diabetes, with CPP $149.60 (95% CI: $80.29, $195.63) lower with HepB-CpG ($367.57) than HepB-Alum ($517.37). Conclusions: Metrics estimating vaccine real-world effectiveness and value may guide informed decisions in vaccine selection. For example, using eVPR and CPP, HepB-CpG represents a more effective, value advantaged approach than HepB-Alum toward reducing HBV infection. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Janssen, Robert S.] Dynavax Technol, Clin Dev, 2100 Powell St, Emeryville, CA 94608 USA; [Bruxvoort, Katia; Jacobsen, Steven J.; Slezak, Jeff] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles Ave, Pasadena, CA 91101 USA; [David, Coline] Dynavax Technol, Market Access & Policy, 2100 Powell St, Emeryville, CA 94608 USA; [Hyer, Randall] Dynavax Technol, Med Affairs, 2100 Powell St, Emeryville, CA 94608 USA; [Poland, Gregory A.] Mayo Clin, Mayo Vaccine Res Grp, 200 1st St SW, Rochester, MN 55905 USA; [Hyer, Randall] Moderna, 200 Technol Sq, Cambridge, MA 02139 USA		Janssen, RS (通讯作者)，2100 Powell St,Suite 900, Emeryville, CA 94608 USA.	rjanssen@dynavax.com		Bruxvoort, Katia/0000-0001-8277-2431	Dynavax Technologies Corporation, Emeryville, California	This work was supported by Dynavax Technologies Corporation, Emeryville, California. Employees of Dynavax, who are authors of this manuscript, were involved in study design; the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the article for publication.	ACIP, 2018, EV REC FRAM; Bridges CB, 2019, VACCINE, V37, P5111, DOI 10.1016/j.vaccine.2019.05.089; Bruxvoort K, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.27577; Bruxvoort K, 2018, AM J EPIDEMIOL, V187, P1856, DOI 10.1093/aje/kwy076; Centers for Disease Control and Prevention, VIR HEP SURV REP 201; Douvin C, 1997, DIABETES CARE, V20, P148, DOI 10.2337/diacare.20.2.148; Fonkwo PN, 2008, EMBO REP, V9, pS13, DOI 10.1038/embor.2008.110; Gessner BD, 2017, VACCINE, V35, P6255, DOI 10.1016/j.vaccine.2017.09.048; Grassly NC, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0138; Halperin SA, 2012, VACCINE, V30, P2556, DOI 10.1016/j.vaccine.2012.01.087; Hargreaves AL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0783; Heyward WL, 2013, VACCINE, V31, P5300, DOI 10.1016/j.vaccine.2013.05.068; Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038; Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P814; Kuan RK, 2013, VACCINE, V31, P4024, DOI 10.1016/j.vaccine.2013.05.014; La Fauci V, 2016, PUBLIC HEALTH, V139, P198, DOI 10.1016/j.puhe.2016.08.007; Lee G, 2018, MMWR-MORBID MORTAL W, V67, P1271, DOI 10.15585/mmwr.mm6745a4; Lu PJ, 2011, VACCINE, V29, P7049, DOI 10.1016/j.vaccine.2011.07.030; Matthews I, 2018, HUM VACC IMMUNOTHER, V14, P1957, DOI 10.1080/21645515.2018.1467200; Mihigo R, 2019, VACCINE, V37, P2838, DOI 10.1016/j.vaccine.2019.03.077; Moreno-Fernandez J, 2020, PRIM CARE DIABETES, V14, P343, DOI 10.1016/j.pcd.2019.09.004; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Nelson JC, 2009, AM J PUBLIC HEALTH, V99, pS389, DOI 10.2105/AJPH.2008.151332; Nguyen MH, 2019, J HEPATOL, V70, P24, DOI 10.1016/j.jhep.2018.09.021; Novitas Solutions, CENTR FLU BILL 2020; Rosenthal EM, 2020, VACCINE, V38, P8206, DOI 10.1016/j.vaccine.2020.10.067; Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2; Schillie S, 2018, MMWR-MORBID MORTAL W, V67, P455, DOI 10.15585/mmwr.mm6715a5; Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1; Shefer Abigail, 2011, Morbidity and Mortality Weekly Report, V60, P1; Shim E, 2012, VACCINE, V30, P6700, DOI 10.1016/j.vaccine.2012.08.045; Standaert Baudouin, 2020, J Mark Access Health Policy, V8, P1719588, DOI 10.1080/20016689.2020.1719588; Teisberg E, 2020, ACAD MED, V95, P682, DOI 10.1097/ACM.0000000000003122; Trantham L, 2018, VACCINE, V36, P5333, DOI 10.1016/j.vaccine.2018.05.111; Weinberg GA, 2010, J INFECT DIS, V201, P1607, DOI 10.1086/652404; WHO, GUIDELINES PREVENTIO; WHO, 2020, WHO UNICEF WARN DECL; Wilder-Smith A, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0911-8; Wong RJ, 2021, HEPATOLOGY, V74, P607, DOI 10.1002/hep.31782; World Health Organization, 2016, GUID CLIN EV VACC RE	40	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5666	5672		10.1016/j.vaccine.2021.07.100		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34404556	hybrid			2022-04-29	WOS:000704399700028
J	Ysebaert, C; Castado, C; Mortier, MC; Rioux, S; Feron, C; Di Paolo, E; Weynants, V; Blais, N; Devos, N; Hermand, P				Ysebaert, Carine; Castado, Cindy; Mortier, Marie-Cecile; Rioux, Stephane; Feron, Christiane; Di Paolo, Emmanuel; Weynants, Vincent; Blais, Normand; Devos, Nathalie; Hermand, Philippe			UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen	VACCINE			English	Article						AERIS; COPD; Cross-reactivity; Moraxella catarrhalis; UspA2; Vaccine	NONTYPABLE HAEMOPHILUS-INFLUENZAE; OUTER-MEMBRANE PROTEINS; BRANHAMELLA-CATARRHALIS; BINDING-PROTEIN; SURFACE; EXACERBATIONS; DISEASE; ADULTS; A1	Moraxella catarrhalis (Mcat) is a key pathogen associated with exacerbations of chronic obstructive pulmonary disease (COPD) in adults and playing a significant role in otitis media in children. A vaccine would help to reduce the morbidity and mortality associated with these diseases. UspA2 is an Mcat surface antigen considered earlier as vaccine candidate before the interest in this molecule vanished due to sequence variability. However, the observation that some conserved domains are the target of bactericidal antibodies prompted us to reconsider UspA2 as a potential vaccine antigen. We first determined its prevalence among the COPD patients from the AERIS study, as the prevalence of UspA2 in a COPD-restricted population had yet to be documented. The gene was found in all Mcat isolates either as UspA2 or UspA2H variant. The percentage of UspA2H variant was higher than in any report so far, reaching 51%. A potential link between the role of UspA2H in biofilm formation and this high prevalence is discussed. To study further UspA2 as a vaccine antigen, recombinant UspA2 molecules were designed and used in animal models and bactericidal assays. We showed that UspA2 is immunogenic and that UspA2 immunization clears Mcat pulmonary challenge in a mouse model. In a serum bactericidal assay, anti-UspA2 antibodies generated in mice, guinea pigs or rabbits were able to kill Mcat strains of various origins, including a subset of isolates from the AERIS study, cross-reacting with UspA2H and even UspA1, a closely related Mcat surface protein. In conclusion, UspA2 is a cross-reactive Mcat antigen presenting the characteristics of a vaccine candidate. (c) 2021 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Ysebaert, Carine; Castado, Cindy; Mortier, Marie-Cecile; Rioux, Stephane; Feron, Christiane; Di Paolo, Emmanuel; Weynants, Vincent; Blais, Normand; Devos, Nathalie; Hermand, Philippe] GSK, Rue Inst 89, B-1330 Rixensart, Belgium		Hermand, P (通讯作者)，GSK, Rue Inst 89, B-1330 Rixensart, Belgium.	philippe.hermand@gsk.com		Weynants, Vincent/0000-0002-6163-4838; Castado, Cindy/0000-0002-4306-9441	GlaxoSmithKline Biologicals SAGlaxoSmithKline	This work was sponsored and financially supported by GlaxoSmithKline Biologicals SA, which was involved in all stages of the study conduct and analysis.This work was sponsored and financially supported by GlaxoSmithKline Biologicals SA, which was involved in all stages of the study conduct and analysis.	Aebi C, 1997, INFECT IMMUN, V65, P4367, DOI 10.1128/IAI.65.11.4367-4377.1997; Aebi C, 1998, INFECT IMMUN, V66, P3113, DOI 10.1128/IAI.66.7.3113-3119.1998; AKKOYUNLU M, 1991, INFECT IMMUN, V59, P1231, DOI 10.1128/IAI.59.4.1231-1238.1991; Blais N, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00022-19; Bootsma HJ, 2000, J INFECT DIS, V181, P1376, DOI 10.1086/315374; Brooks MJ, 2008, INFECT IMMUN, V76, P5330, DOI 10.1128/IAI.00573-08; Chen DX, 1996, INFECT IMMUN, V64, P1900, DOI 10.1128/IAI.64.6.1900-1905.1996; Chen DX, 1999, INFECT IMMUN, V67, P1310, DOI 10.1128/IAI.67.3.1310-1316.1999; CHRISTENSEN JJ, 1994, FEMS MICROBIOL LETT, V119, P155; Cope LD, 1999, J BACTERIOL, V181, P4026, DOI 10.1128/JB.181.13.4026-4034.1999; HELMINEN ME, 1994, J INFECT DIS, V170, P867, DOI 10.1093/infdis/170.4.867; Hill DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045452; Hoiczyk E, 2000, EMBO J, V19, P5989, DOI 10.1093/emboj/19.22.5989; HOL C, 1995, FEMS IMMUNOL MED MIC, V11, P207; Koo H, 2017, NAT REV MICROBIOL, V15, P740, DOI 10.1038/nrmicro.2017.99; Lafontaine ER, 2000, J BACTERIOL, V182, P1364, DOI 10.1128/JB.182.5.1364-1373.2000; Mason KW, 2004, VACCINE, V22, P3449, DOI 10.1016/j.vaccine.2004.02.027; Mawas F, 2007, VACCINE, V25, P4801, DOI 10.1016/j.vaccine.2007.04.026; McMichael JC, 1998, INFECT IMMUN, V66, P4374; Meier PS, 2002, VACCINE, V20, P1754, DOI 10.1016/S0264-410X(02)00030-0; Murphy TF, 2005, AM J RESP CRIT CARE, V172, P195, DOI 10.1164/rccm.200412-1747OC; Ngo CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150949; Nordstrom T, 2005, J IMMUNOL, V175, P3628, DOI 10.4049/jimmunol.175.6.3628; Nordstrom T, 2004, J IMMUNOL, V173, P4598, DOI 10.4049/jimmunol.173.7.4598; Pearson MM, 2007, INFECT IMMUN, V75, P4316, DOI 10.1128/IAI.01347-06; Pearson MM, 2006, INFECT IMMUN, V74, P1588, DOI 10.1128/IAI.74.3.1588-1596.2006; Perez AC, 2019, VACCINE, V37, P5551, DOI 10.1016/j.vaccine.2016.12.066; Perez AC, 2017, HUM VACC IMMUNOTHER, V13, P2322, DOI [10.1080/21645515.2017.1374522, 10.1080/21645515.2017.1356951]; Ren DB, 2016, EXPERT OPIN THER TAR, V20, P19, DOI 10.1517/14728222.2015.1081686; Romling U, 2012, J INTERN MED, V272, P541, DOI 10.1111/joim.12004; Singh B, 2016, MBIO, V7, DOI 10.1128/mBio.00066-16; Singh B, 2015, INFECT IMMUN, V83, P3458, DOI 10.1128/IAI.00310-15; Singh B, 2010, MOL MICROBIOL, V75, P1426, DOI 10.1111/j.1365-2958.2010.07066.x; Su YC, 2013, MICROBES INFECT, V15, P375, DOI 10.1016/j.micinf.2013.02.004; Tan TT, 2006, J INFECT DIS, V194, P493, DOI 10.1086/505581; Verhaegh SJC, 2008, MICROBIOL-SGM, V154, P1178, DOI 10.1099/mic.0.2007/015057-0; Wilkinson TMA, 2017, THORAX, V72, P919, DOI 10.1136/thoraxjnl-2016-209023	37	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5641	5649		10.1016/j.vaccine.2021.08.002		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34446318	hybrid			2022-04-29	WOS:000704399700025
J	Kristinsdottir, I; Haraldsson, A; Love, A; Asgeirsdottir, TL; Thors, V				Kristinsdottir, Iris; Haraldsson, Asgeir; Love, Arthur; Asgeirsdottir, Tinna Laufey; Thors, Valtyr			Burden of rotavirus disease in young children in Iceland - Time to vaccinate?	VACCINE			English	Article						Gastroenteritis; Rotavirus; Vaccination; Cost-effectiveness	ACUTE GASTROENTERITIS; IMPACT; TRANSMISSION; INFECTION; PATHOGENS; EFFICACY; SEIZURES; SAFETY; ERA	Background: Acute gastroenteritis poses a significant burden on young children, families, health care facilities and societies. Rotavirus is the most common pathogen, but rotavirus infections are vaccine preventable. Information on the epidemiology of gastroenteritis in Icelandic children has until now not been available and rotavirus vaccination is currently not offered to Icelandic infants. The objective of this study was to assess the burden of rotavirus acute gastroenteritis in young children in Iceland and determine the potential benefit of adding rotavirus vaccine to the Icelandic childhood immunization schedule. Methods: For a two-year period, children < 6 years old attending a children's emergency department for acute gastroenteritis were recruited at the Children's Hospital in Reykjavik, Iceland. Demographic information and Vesikari scores were registered. Stool samples were analyzed for pathogens. Duration of symptoms, treatment given, and secondary household infections were among the collected information. Annual cost of the infections in young children was estimated based on health care expenditures and lost days of parental work. Results: 325 children were included in the study, 75% of which were < 24 months old. A pathogen was identified in 80% of cases, of which rotavirus was identified in 54%. Rotavirus caused a more severe disease than other pathogens, more often leading to fluid treatment in the emergency department and admissions. Median duration of rotavirus-illness was six days and caused a median of four days lost from work by parents. The estimated annual cost of rotavirus acute gastroenteritis was (sic)2.9 million. Conclusions: Rotavirus causes significant disease burden in young children. Although rarely life-threatening in high income countries, the costs for society are substantial. The inclusion of rotavirus vaccine in the national immunization schedule will reduce the disease burden and would be cost-saving in Iceland. (C) 2021 Published by Elsevier Ltd.	[Kristinsdottir, Iris; Haraldsson, Asgeir; Love, Arthur; Thors, Valtyr] Univ Iceland, Fac Med, Reykjavik, Iceland; [Kristinsdottir, Iris; Haraldsson, Asgeir; Thors, Valtyr] Landspitali Univ Hosp, Childrens Hosp Iceland, IS-101 Reykjavik, Iceland; [Love, Arthur] Landspitali Univ Hosp, Div Virol, Dept Clin Microbiol, Reykjavik, Iceland; [Asgeirsdottir, Tinna Laufey] Univ Iceland, Fac Econ, Reykjavik, Iceland		Thors, V (通讯作者)，Landspitali Univ Hosp, Childrens Hosp Iceland, IS-101 Reykjavik, Iceland.	valtyr@landspitali.is		Thors, Valtyr/0000-0002-0976-9604; Kristinsdottir, Iris/0000-0002-8869-9332			Adlhoch C, 2013, PEDIATR INFECT DIS J, V32, pE82, DOI 10.1097/INF.0b013e3182720b71; [Anonymous], LAUN EFTIR LAUNTHORN; [Anonymous], OFFICIAL EXCHANGE RA; [Anonymous], Vaccines Licensed for Use in the United States; [Anonymous], 2021, PREQ VACC; [Anonymous], LIFANDI ANDVANA FAED; Atchison CJ, 2016, J INFECT DIS, V213, P243, DOI 10.1093/infdis/jiv398; Bloom-Feshbach K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054445; Brisson M, 2010, PEDIATR INFECT DIS J, V29, P73, DOI 10.1097/INF.0b013e3181b41506; Bruun T, 2016, PEDIATR INFECT DIS J, V35, P396, DOI 10.1097/INF.0000000000001055; Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186; Dennehy PH, 2000, PEDIATR INFECT DIS J, V19, pS103, DOI 10.1097/00006454-200010001-00003; Domingo JD, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-58; Diez-Domingo J, 2011, EUR J PEDIATR, V170, P213, DOI 10.1007/s00431-010-1289-1; Edwards CH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183306; Forster J, 2009, PEDIATRICS, V123, pe393, DOI 10.1542/peds.2008-2088; Giaquinto C, 2007, J INFECT DIS, V195, pS36, DOI 10.1086/516716; Gibory M, 2017, J CLIN VIROL, V97, P50, DOI 10.1016/j.jcv.2017.10.017; Hallowell BD, 2019, MMWR-MORBID MORTAL W, V68, P539, DOI 10.15585/mmwr.mm6824a2; Heggie R, 2019, HUM VACC IMMUNOTHER, V15, P1265, DOI 10.1080/21645515.2018.1543522; Hemming-Harlo M, 2016, PEDIATR INFECT DIS J, V35, P1304, DOI 10.1097/INF.0000000000001305; Karafillakis E, 2015, VACCINE, V33, P2097, DOI 10.1016/j.vaccine.2015.03.016; Koch J, 2011, PEDIATR INFECT DIS J, V30, P112, DOI 10.1097/INF.0b013e3181f1eb21; Leino T, 2017, VACCINE, V35, P5611, DOI 10.1016/j.vaccine.2017.08.052; Marlow R, 2015, VACCINE, V33, P5212, DOI 10.1016/j.vaccine.2015.07.012; Marquis A, 2020, PEDIATR INFECT DIS J; Oskarsson Y, 2015, VACCINE, V33, P7211, DOI 10.1016/j.vaccine.2015.10.125; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; Payne DC, 2014, CLIN INFECT DIS, V58, P173, DOI 10.1093/cid/cit671; Poelaert D, 2018, VACCINE, V36, P2243, DOI 10.1016/j.vaccine.2018.02.080; Quee FA, 2020, LANCET INFECT DIS, V20, P598, DOI 10.1016/S1473-3099(20)30058-X; Reyes JF, 2017, VACCINE, V35, P345, DOI 10.1016/j.vaccine.2016.11.056; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046; Sabbe M, 2016, EUROSURVEILLANCE, V21, P19, DOI 10.2807/1560-7917.ES.2016.21.27.30273; Samdal K, 2009, NIPH SYSTEMATIC REV; Sheridan SL, 2016, J PEDIAT INF DIS SOC, V5, P206, DOI 10.1093/jpids/piu097; Shin M, 2016, PEDIATR INFECT DIS J, V35, pE97, DOI 10.1097/INF.0000000000001026; Soares-Weiser K, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008521.pub4; Tate JE, 2009, PEDIATRICS, V124, P465, DOI 10.1542/peds.2008-3528; Troeger C, 2018, JAMA PEDIATR, V172, P958, DOI 10.1001/jamapediatrics.2018.1960; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; Verberk JDM, 2018, PEDIATR INFECT DIS J, V37, pE248, DOI 10.1097/INF.0000000000001880; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664; Waters V, 2000, PEDIATR INFECT DIS J, V19, P843, DOI 10.1097/00006454-200009000-00007; Wolffs PFG, 2011, J CLIN MICROBIOL, V49, P1926, DOI 10.1128/JCM.01925-10; World Health Organization, 2009, WKLY EPIDEMIOL REC, V84, P232	47	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 7	2021	39	38					5422	5427		10.1016/j.vaccine.2021.07.053		AUG 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UG5UY	34384634	Green Submitted			2022-04-29	WOS:000689318300012
J	Mahajan, A; Kaur, J; Sidana, C; Shivam, S; Singh, H				Mahajan, Akshay; Kaur, Jasmine; Sidana, Chirag; Shivam, Shashwat; Singh, Harpreet			Geo-prioritization framework for COVID-19 vaccine allocation in India	VACCINE			English	Editorial Material						COVID-19 vaccine; Vaccine delivery; Geo-prioritization framework; Healthcare workers		Up until now, countries have adopted a 'isolate-test-treat-trace' strategy to contain the COVID-19 pandemic. The next critical intervention in the fight against COVID-19 will be effective delivery of safe and efficacious vaccines. Various countries such as the USA, the UK, Canada, Israel, etc., have started administering vaccines to priority population groups. India is gearing up its critical components of the vaccine delivery system to effectively deliver vaccines across the country and has prioritized certain population groups to whom the vaccine will be administered. Considering India's ambitious target to vaccinate close to 300 million people in the first phase of the vaccination drive with limited initial supply (which will be ramped up gradually), it is critical for stakeholders at all the levels - national, state and district - to understand the estimated need for vaccines across geographies based on the vulnerable population and disease epidemiology with the objective of preventing maximum number of future infections from the disease. This paper aims to describe a comprehensive geo-prioritization framework based on existing prevalence of COVID-19, high-risk co-morbidities, and demographic analysis to identify states/districts that could be most in need of the COVID-19 vaccines. (C) 2021 Published by Elsevier Ltd.	[Mahajan, Akshay; Sidana, Chirag; Shivam, Shashwat] William J Clinton Fdn, New Delhi, India; [Kaur, Jasmine; Singh, Harpreet] Indian Council Med Res, New Delhi, India		Singh, H (通讯作者)，Indian Council Med Res, Div Biomed Informat, New Delhi 110029, India.	amahajan@clintonhealthaccess.org; jasmine.kaur.7393@gmail.com; chirag.sid@gmail.com; sshivam@clintonhealthaccess.org; hsingh@bmi.icmr.org.in			Indian Council of Medical Research, New DelhiIndian Council of Medical Research (ICMR)	This study has been funded by Indian Council of Medical Research, New Delhi.	Acharya R, 2020, LANCET GLOB HEALTH, V8, pE1142, DOI 10.1016/S2214-109X(20)30300-4; Andrews M., INDIAN J MED RES, V0; [Anonymous], STATE POPULATION DAT; [Anonymous], WHO Director-General's opening remarks at the media briefing on COVID-19: 11 March 2020; [Anonymous], COVID-19 Vaccines Operational Guidelines; Kaunain SM, 2021, INDIAN EXPRESS 0103; Schmidt H, 2021, NAT MED, V27, P1298, DOI 10.1038/s41591-021-01379-6; Schmidt H, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3795; Shahidi Tauseef., 2020, LIVEMINT 1207	9	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 31	2021	39	37					5254	5256		10.1016/j.vaccine.2021.07.084		AUG 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UC7ZI	34364717	Bronze, Green Published			2022-04-29	WOS:000686741800004
J	Inserra, F; Tajer, C; Antonietti, L; Mariani, J; Ferder, L; Manucha, W				Inserra, Felipe; Tajer, Carlos; Antonietti, Laura; Mariani, Javier; Ferder, Leon; Manucha, Walter			Vitamin D supplementation: An alternative to enhance the effectiveness of vaccines against SARS-CoV-2?	VACCINE			English	Letter						vitamin D; immune response; SARS-CoV-2 vaccines			[Inserra, Felipe; Ferder, Leon] Maimonides Univ, Buenos Aires, DF, Argentina; [Tajer, Carlos; Antonietti, Laura; Mariani, Javier] Univ Nacl Arturo Jauretche, Hosp Alta Complejidad Red El Cruce Nestor Kirchne, Buenos Aires, DF, Argentina; [Manucha, Walter] Univ Nacl Cuyo, Consejo Nacl Invest Cient & Tecn, Inst Med & Biol Expt Cuyo IMBECU, Mendoza, Argentina		Manucha, W (通讯作者)，Consejo Nacl Invest Cient & Tecn, Consejo Nacl Invest Cient & Tecn, Inst Med & Biol Expt Cuyo IMBECU, Mendoza, Argentina.	wmanucha@mendoza-conicet.gob.ar		Manucha, Walter/0000-0002-2279-7626; Tajer, Carlos/0000-0002-6787-6651			[Anonymous], NUTR METAB CARDIOVAS, V31, P36; Bakdash G, 2014, VACCINE, V32, P6294, DOI 10.1016/j.vaccine.2014.08.075; Bui L., SAGE OPEN MED, V9; Ducharme FM., PREVENTION COVID 19; Ferder M, 2013, AM J PHYSIOL-CELL PH, V304, pC1027, DOI 10.1152/ajpcell.00403.2011; Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988; Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008; Lee MD, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040409; Lei WT, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111175; Lemire J, 2000, Z RHEUMATOL, V59, P24; Mariani J, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05073-3; Mariani J, 2021, HEALTH SECUR, V19, P302, DOI 10.1089/hs.2020.0137; Petrelli F, 2021, J STEROID BIOCHEM, V211, DOI 10.1016/j.jsbmb.2021.105883; Ricci A, 2021, RESP RES, V22, DOI 10.1186/s12931-021-01666-3; Rutigliano I, 2021, NUTRITION, V84, DOI 10.1016/j.nut.2020.111101; Schwalfenberg GK, 2011, MOL NUTR FOOD RES, V55, P96, DOI 10.1002/mnfr.201000174	16	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					4930	4931		10.1016/j.vaccine.2021.07.031		AUG 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TX3GY	34303561	Bronze, Green Published			2022-04-29	WOS:000682979100004
J	Mathivathanan, K				Mathivathanan, Kanagavalli			Will COVID-19 vaccine equity be possible in India?	VACCINE			English	Letter						COVID-19; COVID-19 vaccine; Vaccine hesitancy; Vaccine equity; Covishield; Covaxin; India			[Mathivathanan, Kanagavalli] Maharshi Menhi Homoeopath Med Coll & Hosp, Dept Obstet, Katihar 854105, Bihar, India		Mathivathanan, K (通讯作者)，Maharshi Menhi Homoeopath Med Coll & Hosp, Dept Obstet, Katihar 854105, Bihar, India.	vallimathi17@gmail.com		Mathivathanan, Kanagavalli/0000-0001-6575-1233			[Anonymous], 2021, BUSINESS TODAY; [Anonymous], 2021, RIGHT EQ ACC COVID 1 RIGHT EQ ACC COVID 1; [Anonymous], 2021, CTR REV PROGR VACC S CTR REV PROGR VACC S; Baylis F, 2021, NATURE, V591, P529, DOI 10.1038/d41586-021-00757-x; Changoiwala P., 2021, NATL GEOGR; Praveen SV, 2021, DIABETES METAB SYND, V15, P595, DOI 10.1016/j.dsx.2021.02.031; Ramakumar R., 2021, THEWIRE THEWIRE; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Tyagi Kanika, 2021, Diabetes Metab Syndr, V15, P1007, DOI 10.1016/j.dsx.2021.05.001	9	0	0	4	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					4928	4929		10.1016/j.vaccine.2021.07.049		AUG 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TX3GY	34330556	Bronze, Green Published			2022-04-29	WOS:000682979100003
J	Gooch, KE; Smith, TRF; Salguero, FJ; Fotheringham, SA; Watson, RJ; Dennis, MJ; Handley, A; Humphries, HE; Longet, S; Tipton, T; Sarfas, C; Sibley, L; Slack, GS; Rayner, E; Ryan, KA; Schultheis, K; Ramos, SJ; White, A; Charlton, S; Sharpe, SA; Gleeson, F; Humeau, LM; Hall, Y; Broderick, KE; Carroll, MW				Gooch, Karen E.; Smith, Trevor R. F.; Salguero, Francisco J.; Fotheringham, Susan A.; Watson, Robert J.; Dennis, Mike J.; Handley, Alastair; Humphries, Holly E.; Longet, Stephanie; Tipton, Tom; Sarfas, Charlotte; Sibley, Laura; Slack, Gillian S.; Rayner, Emma; Ryan, Kathryn A.; Schultheis, Katherine; Ramos, Stephanie J.; White, Andrew; Charlton, Sue; Sharpe, Sally A.; Gleeson, Fergus; Humeau, Laurent M.; Hall, Yper; Broderick, Kate E.; Carroll, Miles W.			One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model	VACCINE			English	Article						COVID-19; DNA vaccine; Nonhuman Primate Virus Challenge; SARS-CoV-2	TRANSFECTION; SURFACE; MICE; COV	Safe and effective vaccines will provide essential medical countermeasures to tackle the COVID-19 pandemic. Here, we assessed the safety, immunogenicity and efficacy of the intradermal delivery of INO4800, a synthetic DNA vaccine candidate encoding the SARS-CoV-2 spike protein in the rhesus macaque model. Single and 2 dose vaccination regimens were evaluated. Vaccination induced both binding and neutralizing antibodies, along with IFN-gamma-producing T cells against SARS-CoV-2. Upon administration of a high viral dose (5 x 10(6) pfu) via the intranasal and intratracheal routes we observed significantly reduced virus load in the lung and throat, in the vaccinated animals compared to controls. 2 doses of INO-4800 was associated with more robust vaccine-induced immune responses and improved viral protection. Importantly, histopathological examination of lung tissue provided no indication of vaccineenhanced disease following SARS-CoV-2 challenge in INO-4800 immunized animals. This vaccine candidate is currently under clinical evaluation as a 2 dose regimen. Crown Copyright (C) 2021 Published by Elsevier Ltd.	[Gooch, Karen E.; Salguero, Francisco J.; Fotheringham, Susan A.; Watson, Robert J.; Dennis, Mike J.; Handley, Alastair; Humphries, Holly E.; Longet, Stephanie; Tipton, Tom; Sarfas, Charlotte; Sibley, Laura; Slack, Gillian S.; Rayner, Emma; Ryan, Kathryn A.; White, Andrew; Charlton, Sue; Sharpe, Sally A.; Hall, Yper; Carroll, Miles W.] Publ Hlth England PHE, Salisbury SP4 0JG, Wilts, England; [Smith, Trevor R. F.; Schultheis, Katherine; Ramos, Stephanie J.; Humeau, Laurent M.; Broderick, Kate E.] Inovio Pharmaceut, Plymouth Meeting, PA 19462 USA; [Gleeson, Fergus] Univ Oxford, Dept Oncol, Oxford, England; [Carroll, Miles W.] Univ Oxford, Wellcome Ctr Human Genet, Nuffield Dept Med, Oxford OX3 7BN, England		Carroll, MW (通讯作者)，Publ Hlth England PHE, Salisbury SP4 0JG, Wilts, England.; Broderick, KE (通讯作者)，Inovio Pharmaceut Inc, 10480 Wateridge Circle, San Diego, CA 92121 USA.			Watson, Robert/0000-0003-3146-3457; White, Andrew/0000-0001-9481-0079; Longet, Stephanie/0000-0001-5026-431X; Ryan, Kathryn Ann/0000-0001-8608-1144; Slack, Gillian S/0000-0002-4361-7516	Coalition for Epidemic Preparedness Innovations (CEPI); David Weiner laboratory at the Wistar Institute [INO-4800]	The studies described in this manuscript were funded by a grant from the Coalition for Epidemic Preparedness Innovations (CEPI). The authors would like to thank Amy Shurtleff for her expert advice throughout this study. We would also like to thank the David Weiner laboratory at the Wistar Institute for their valuable support of the INO-4800 vaccine program.	Alwis R.d., 2020, 280446 BIORXIV, DOI [10.1101/2020.09.03.280446, DOI 10.1101/2020.09.03.280446]; Amante DH, 2015, HUM GENE THER METHOD, V26, P134, DOI 10.1089/hgtb.2015.020; Amante DH, 2014, HUM GENE THER METHOD, V25, P315, DOI 10.1089/hgtb.2014.061; Andrade V.M., INO 4800 DNA VACCINE, V2021; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bewley K.R., 2020, IMMUNOLOGICAL PATHOL; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Diehl MC, 2013, HUM VACC IMMUNOTHER, V9, P2246, DOI 10.4161/hv.24702; Gabor, 2020, PHASE 1 ASSESSMENT S, DOI [10.1101/2020.11.09.20228551, DOI 10.1101/2020.11.09.20228551]; Garcia-Beltran WF, 2021, CELL, V184, P2523, DOI 10.1016/j.cell.2021.04.006; Gary EN, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102699; Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200; Lewandowski K, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00963-19; Mammen M.P., SAFETY IMMUNOGENICIT, V2021; Mohammadi Abbas, 2020, medRxiv, DOI 10.1101/2020.05.14.20102038; Moore JP, 2021, JAMA-J AM MED ASSOC, V325, P821, DOI 10.1001/jama.2021.1114; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Patel A, 2020, INTRADERMAL DELIVERE, DOI [10.1101/2020.07.28.225649., DOI 10.1101/2020.07.28.225649]; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rauch S., 2020, MRNA VACCINE CVNCOV, DOI [10.1101/2020.12.23.424138, DOI 10.1101/2020.12.23.424138]; Reed C.C., 2021, DESIGN IMMUNOGENICIT; De Rosa SC, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137079; Salguero FJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21389-9; Saunders, NATURE, V2021; Sibley Laura S, 2012, Cells, V1, P5, DOI 10.3390/cells1010005; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Tebas P, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100689; Tebas P, 2019, J INFECT DIS, V220, P400, DOI 10.1093/infdis/jiz132; Vogel A.B., 2020, BIORXIV, V370, P1022, DOI 10.1101/2020.09.08.280818; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wolf RC, 2020, NEUROPSYCHOBIOLOGY, V79, P335, DOI 10.1159/000505601; World Health O., 51 WHO; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu K., PRELIMINARY ANAL SAF, V2021; Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	43	7	7	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4885	4894		10.1016/j.vaccine.2021.06.057		JUL 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34253420	Green Published, Green Submitted, hybrid			2022-04-29	WOS:000679483400020
J	Sandmann, F; Jit, M; Andrews, N; Buckley, HL; Campbell, H; Ribeiro, S; Sile, B; Stowe, J; Tessier, E; Ramsay, M; Amirthalingam, G; Choi, YH				Sandmann, Frank; Jit, Mark; Andrews, Nick; Buckley, Hannah L.; Campbell, Helen; Ribeiro, Sonia; Sile, Bersabeh; Stowe, Julia; Tessier, Elise; Ramsay, Mary; Amirthalingam, Gayatri; Choi, Yoon H.			Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis	VACCINE			English	Article						Pertussis; Resurgence; Maternal vaccination; Mathematical model; Economic evaluation; Public health	QUALITY-OF-LIFE; VACCINATION; DECISIONS	Introduction: An unexpected resurgence of pertussis cases and infant deaths was observed in some countries that had switched to acellular pertussis vaccines in the primary immunisation schedule. In response to the outbreaks, maternal pertussis vaccination programmes in pregnant women have been adopted worldwide, including the USA in 2011 and the UK in 2012. Following the success of the programme in England, we evaluated the health and economic impact of stopping versus continuing the maternal pertussis immunisation to inform public health policy making. Methods: We used a mathematical model to estimate the number of infant hospitalisations and deaths related to pertussis in England over 2019-2038. Losses in quality-adjusted life years, QALYs, were considered for infants (aged 0-2 months) who survived or died from pertussis, bereaved parents (of infants who died from pertussis), and women with pertussis (aged 20-44 years). Direct medical costs to the National Health Service included infant hospitalisations, maternal vaccinations, and disease in women. Costs and QALYs were discounted at 3.5%. Changes in the incremental cost-effectiveness ratio, ICER, were explored in sensitivity analyses. Results: The model supports continuing the maternal pertussis immunisation programme as a costeffective intervention at an ICER of 14,500 pound/QALY (2.5% and 97.5%-quantile: 7,300 pound/QALY to 32,400 pound/ QALY). Stopping versus continuing the maternal programme results in an estimated mean of 972 (range 582 to 1489) versus 308 (184 to 471) infant hospitalisations annually. Results were most sensitive to the number of hospitalisations and deaths when stopping the maternal programme. At a cost-effectiveness threshold of 30,000 pound/QALY, the probability of the maternal programme being cost-effective was 96.2%. Conclusion: Our findings support continuing the maternal pertussis vaccination programme as otherwise higher levels of disease activity and infant mortality are expected to return. These results have led policy makers to decide to continue the maternal programme in the UK routine immunisation schedule. (c) 2021 Published by Elsevier Ltd.	[Sandmann, Frank; Jit, Mark; Andrews, Nick; Choi, Yoon H.] Publ Hlth England PHE, Natl Infect Serv NIS, Stat Modelling & Econ Dept, 61 Colindale Ave, London NW9 5EQ, England; [Sandmann, Frank; Jit, Mark] London Sch Hyg & Trop Med LSHTM, Dept Infect Dis Epidemiol, London, England; [Jit, Mark] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Peoples R China; [Buckley, Hannah L.] Univ Leeds, Sch Med, PICANet, Leeds, W Yorkshire, England; [Campbell, Helen; Ribeiro, Sonia; Sile, Bersabeh; Stowe, Julia; Tessier, Elise; Ramsay, Mary; Amirthalingam, Gayatri] Publ Hlth England PHE, Natl Infect Serv NIS, Immunisat & Countermeasures Dept, London, England		Sandmann, F (通讯作者)，Publ Hlth England PHE, Natl Infect Serv NIS, Stat Modelling & Econ Dept, 61 Colindale Ave, London NW9 5EQ, England.			Campbell, Helen/0000-0001-9840-8917; Sile, Bersabeh/0000-0003-2890-862X; Stowe, Julia/0000-0002-3999-6461; Tessier, Elise/0000-0002-2712-7971; Sandmann, Frank/0000-0001-5641-1931	Public Health England (PHE) [NIHR200908, HPRU2012-10096, NIHR200929]; National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation at the London School of Hygiene and Tropical Medicine; NIHR HPRU in Modelling and Health Economics; Imperial College LondonGeneral Electric [NIHR200908]; LSHTM [NIHR200908]	Funding sources This work was supported by Public Health England (PHE) , which is an executive agency of the Department of Health (DH) . The authors had sole responsibility for the study design, data collection, data analysis, data interpretation, and writing of the report. MJ was supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with PHE (Grant Reference Code HPRU2012-10096; NIHR200929) . FGS and MJ were also supported by the NIHR HPRU in Modelling and Health Economics, a partnership between PHE, Imperial College London and LSHTM (grant code NIHR200908) . The views expressed are those of the authors and not necessarily those of the National Health Service (NHS) , the NIHR, the DH, or PHE.	Amirthalingam G, 2016, CLIN INFECT DIS, V63, pS236, DOI 10.1093/cid/ciw559; Andrews N, 2020, CLIN INFECT DIS; [Anonymous], 2014, Wkly Epidemiol Rec, V89, P337; Atkins KE, 2016, AM J EPIDEMIOL, V183, P1159, DOI 10.1093/aje/kwv347; Barton GR, 2008, VALUE HEALTH, V11, P886, DOI 10.1111/j.1524-4733.2008.00358.x; Brisson M, 2010, PEDIATR INFECT DIS J, V29, P73, DOI 10.1097/INF.0b013e3181b41506; Byrne L, 2018, EPIDEMIOL INFECT, V146, P197, DOI 10.1017/S0950268817002497; Campbell H, 2013, EURO SURVEILL, V18; Campbell H, 2018, J MED MICROBIOL, V67, P1426, DOI 10.1099/jmm.0.000829; Campbell H, 2012, EMERG INFECT DIS, V18, P38, DOI 10.3201/eid1801.110784; Choi YH, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0665-8; Drummond MF., 2015, METHODS EC EVALUATIO, P353; Fernandes EG, 2019, HUM VACC IMMUNOTHER, V15, P14, DOI 10.1080/21645515.2018.1509646; Gkentzi D, 2017, ARCH DIS CHILD-FETAL, V102, pF456, DOI 10.1136/archdischild-2016-312341; Gopal DP, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l401; Guimaraes LM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1222-3; Hill L, 2018, J PRIM HEALTH CARE, V10, P62, DOI 10.1071/HC17040; Joint Committee on Vaccination and Immunisation (JCVI), 2019, M HELD 05 JUN 2019 S; Joint Committee on Vaccination and Immunisation (JCVI), 2013, COD PRACT JUN 2013; Klok Rogier M, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P599, DOI 10.1586/14737167.4.6.599; Lapidot Rotem, 2016, Trop Dis Travel Med Vaccines, V2, P26, DOI 10.1186/s40794-016-0043-8; Locht C, 2018, VACCINE, V36, P5460, DOI 10.1016/j.vaccine.2017.11.055; NICE, 2013, GUID METH TECHN APPR; O'Brien BJ, 2002, HEALTH ECON, V11, P175, DOI 10.1002/hec.655; Office for National Statistics (ONS), 2018, EST POP UK ENGL WAL; Song J, 2010, FAM RELAT, V59, P269, DOI 10.1111/j.1741-3729.2010.00601.x; Surridge J, 2007, ARCH DIS CHILD, V92, P970, DOI 10.1136/adc.2006.114082; van Hoek AJ, 2016, J INFECTION, V73, P28, DOI 10.1016/j.jinf.2016.04.012; van Hoek AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111807; Ward JI, 2005, NEW ENGL J MED, V353, P1555, DOI 10.1056/NEJMoa050824	30	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4500	4509		10.1016/j.vaccine.2021.06.042		JUL 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34183204	Green Accepted, Green Published, hybrid			2022-04-29	WOS:000672160300017
J	Fogel, B; Schaefer, EW; Hicks, SD				Fogel, Benjamin; Schaefer, Eric W.; Hicks, Steven D.			Early influenza vaccination rates decline in children during the COVID-19 pandemic	VACCINE			English	Article							HEALTH-CARE; HESITANCY; VACCINES	Background: This investigation sought to determine whether early season rates of pediatric influenza vaccination changed in a season when there was a concurrent COVID-19 pandemic. Methods: This study used cohort and cross sectional data from an academic primary care division in Southcentral Pennsylvania that serves approximately 17,500 patients across 4 practice sites. Early season (prior to November 1) vaccination rates in 2018, 2019 and 2020 were recorded for children, age 6 months to 17 years. To explore the impact of COVID-19 on vaccination, we fit a model with a logit link (estimated via generalized estimating equations to account for clustering by patient over time) on calendar year, adjusted for race, ethnicity, age, and insurance type. We examined interaction effects of demographic covariates with calendar year. Results: Early vaccination rates were lower in 2020 (29.7%) compared with 2018 and 2019 (34.2% and 33.3%). After adjusting for covariates and accounting for clustering over time, the odds of early vaccination in 2020 were 19% lower compared to 2018 (OR 0.81, 95% CI: 0.78-0.85). In 2020, children with private insurance were more likely to receive early vaccination than in 2018 (OR 1.51, 95% CI: 1.04-1.15), whereas children with public insurance were less likely to receive early vaccination in 2020 than in 2018 (OR 0.62, 95% CI: 1.38-1.65). Conclusions: Early influenza vaccination rates declined in a year with a concurrent COVID-19 pandemic. Modeling that accounts for individual trends and demographic variables identified specific populations with lower odds of early vaccination in 2020. Additional research is needed to investigate whether the COVID-19 pandemic impacted parental intent to obtain the influenza vaccine, or introduced barriers to healthcare access. (C) 2021 Elsevier Ltd. All rights reserved.	[Fogel, Benjamin; Hicks, Steven D.] Penn State Coll Med, Dept Pediat, Hershey, PA 17033 USA; [Schaefer, Eric W.] Penn State Coll Med, Dept Publ Hlth Sci, 500 Univ Dr, Hershey, PA 17033 USA		Fogel, B (通讯作者)，Penn State Coll Med, Dept Pediat, Hershey, PA 17033 USA.	bfogel@pennstatehealth.psu.edu; ESchaefer@phs.psu.edu; shicks1@pennstatehealth.psu.edu					Atherly A, 2020, JMIR PUBLIC HLTH SUR, V6, P388, DOI 10.2196/21607; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041; Flood EM, 2010, CLIN THER, V32, P1448, DOI 10.1016/j.clinthera.2010.06.020; Flores G, 2010, PEDIATRICS, V125, pE979, DOI 10.1542/peds.2010-0188; Flu Vaccination Coverage, US 2015 16 INFL SEAS US 2015 16 INFL SEAS; Fogel B, 2017, VACCINE, V35, P5278, DOI 10.1016/j.vaccine.2017.07.067; Fogel BN, 2020, CLIN PEDIATR, V59, P352, DOI 10.1177/0009922819901002; Grech Victor, 2020, Early Hum Dev, P105213, DOI 10.1016/j.earlhumdev.2020.105213; Grech V, 2020, EARLY HUM DEV, V148, DOI 10.1016/j.earlhumdev.2020.105116; Grohskopf LA, 2020, JAMA-J AM MED ASSOC, V324, P1029, DOI 10.1001/jama.2020.15845; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Jones N, 2020, NATURE, V588, P388, DOI 10.1038/d41586-020-03519-3; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Nelson R, 2020, LANCET INFECT DIS, V20, P546, DOI 10.1016/S1473-3099(20)30304-2; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nowalk MP, 2007, J NATL MED ASSOC, V99, P636; Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017; O'Leary ST, 2021, JAMA PEDIATR, V175, P305, DOI 10.1001/jamapediatrics.2020.4733; O'Reilly FW, 2005, OCCUP MED-OXFORD, V55, P474, DOI 10.1093/occmed/kqi099; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Poehling KA, 2010, PEDIATRICS, V126, P665, DOI 10.1542/peds.2009-2620; Quick Facts, US CENS BUR 2019 US CENS BUR 2019; Robbins SCC, 2011, J PAEDIATR CHILD H, V47, P419, DOI 10.1111/j.1440-1754.2010.01993.x; Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Zhao J., 2020, INTERACTIONS SARS CO, DOI [10.1101/2020.09.18.20189647, DOI 10.1101/2020.09.18.20189647]	28	0	0	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 13	2021	39	31					4291	4295		10.1016/j.vaccine.2021.06.041		JUL 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TG0WP	34172330	Bronze			2022-04-29	WOS:000671133900010
J	Karafillakis, E; Francis, MR; Paterson, P; Larson, HJ				Karafillakis, E.; Francis, M. R.; Paterson, P.; Larson, H. J.			Trust, emotions and risks: Pregnant women's perceptions, confidence and decision-making practices around maternal vaccination in France	VACCINE			English	Article						Maternal vaccination; Vaccine confidence; Trust; Decision-making; Emotions; Risk perception; France	INFLUENZA VACCINATION; HESITANCY	Maternal vaccination is an important strategy to reduce maternal and newborn mortality and morbidity. Yet, vaccination uptake is suboptimal in many countries, including France. This mixed-method study aimed to identify factors influencing maternal vaccination, exploring pregnant women's perceptions, confidence, and decision-making processes in France. Maternal vaccination uptake was positively associated with awareness of maternal vaccines, confidence in vaccine effectiveness and receiving a recommendation from a healthcare professional. A trusting relationship with healthcare professionals was observed as crucial for women during pregnancy. Even if women considered themselves as sole decision-makers, healthcare professionals' role in decision-making was viewed as substantial. Pregnancy can be a complex time for assessing risks, which was evident in the strong emotional reactions to maternal vaccination and anxieties about safety. As new maternal vaccines are developed, it is crucial to consider women's values, risk perceptions and emotions in the development of strategies to support acceptance of maternal vaccination. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Karafillakis, E.; Francis, M. R.; Paterson, P.; Larson, H. J.] London Sch Hyg & Topical Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Vaccine Confidence Project, London, England		Karafillakis, E (通讯作者)，London Sch Hyg & Topical Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Vaccine Confidence Project, London, England.	emilie.karafillakis@lshtm.ac.uk	; Larson, Heidi J./N-1018-2017	Karafillakis, Emilie/0000-0001-8648-906X; Larson, Heidi J./0000-0002-8477-7583	GlaxoSmithKline(GSK)GlaxoSmithKline	This work was supported by GlaxoSmithKline(GSK). The funder reviewed the study protocol but had no role in data collection, analysis, interpretation, or writing of this manuscript.	Baron J, 2004, ORGAN BEHAV HUM DEC, V94, P74, DOI 10.1016/j.obhdp.2004.03.003; Bartolo S, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2628-5; Bergin N, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050847; Blondel B, 2012, VACCINE, V30, P5661, DOI 10.1016/j.vaccine.2012.06.077; Chapman GB, 2006, HEALTH PSYCHOL, V25, P82, DOI 10.1037/0278-6133.25.1.82; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Descamps A, 2020, HUM VACC IMMUNOTHER, V16, P1093, DOI 10.1080/21645515.2019.1688035; Dugas M, 2012, SOC SCI MED, V74, P1968, DOI 10.1016/j.socscimed.2012.01.041; Frew PM, 2014, HUM VACC IMMUNOTHER, V10, P2576, DOI 10.4161/hv.32248; Gaudelus J, 2016, MED MALADIES INFECT, V46, P424, DOI 10.1016/j.medmal.2016.07.004; Hosmer DW, 2013, WILEY SER PROBAB ST, P153; Kilich E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234827; Larson H. J, 2020, STUCK VACCINE RUMORS; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Loubet P, 2016, VACCINE, V34, P2390, DOI 10.1016/j.vaccine.2016.03.034; Lyerly AD, 2007, OBSTET GYNECOL, V109, P979, DOI 10.1097/01.AOG.0000258285.43499.4b; Mak TK, 2008, LANCET INFECT DIS, V8, P44, DOI 10.1016/S1473-3099(07)70311-0; Mundry R, 2009, AM NAT, V173, P119, DOI 10.1086/593303; Munoz FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00436; O'Brien D, 2017, MIDWIFERY, V46, P1, DOI 10.1016/j.midw.2017.01.002; Offeddu V, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7172-8; Privileggio L, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-246; Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068; Raude J, 2016, EXPERT REV VACCINES, V15, P937, DOI 10.1080/14760584.2016.1184092; Rawal H, 2018, STATE VACCINE CONFID; Reich JA., 2017, STUD LAW POLIT SOC, V73; Sante Publique France, 2020, REC VACC SPEC PERS E; Takayama M, 2012, PREV MED, V54, P358, DOI 10.1016/j.ypmed.2012.03.008; Vaux S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-30; Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018; Wetterberg A., 2004, BERKELEY J SOCIOL, P26	31	2	2	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4117	4125		10.1016/j.vaccine.2021.05.096		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TI1ID	34099326	hybrid, Green Published			2022-04-29	WOS:000672535200016
J	Ito, N; Okamoto, T; Sasaki, M; Miyamoto, S; Takahashi, T; Izumi, F; Inukai, M; Jarusombuti, S; Okada, K; Nakagawa, K; Fujii, Y; Nishiyama, S; Masatani, T; Sawa, H; Sugiyama, M				Ito, Naoto; Okamoto, Takuya; Sasaki, Michihito; Miyamoto, Shoya; Takahashi, Tatsuki; Izumi, Fumiki; Inukai, Maho; Jarusombuti, Supasiri; Okada, Kazuma; Nakagawa, Kento; Fujii, Yuji; Nishiyama, Shoko; Masatani, Tatsunori; Sawa, Hirofumi; Sugiyama, Makoto			Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein	VACCINE			English	Article						Rabies; Attenuated live vaccine; Reverse genetics; Glycoprotein; Leucine	VULPES-VULPES; VIRUS; PATHOGENICITY; VIRULENCE; MUTATIONS; GENERATION; ERA	To improve the safety of genetically modified live rabies vaccine strains, most studies have utilized an attenuating Arg-to-Glu mutation at position 333 in the glycoprotein (G333), which is responsible for attenuation of the live vaccine strain SAG2. The Glu residue requires two nucleotide substitutions to revert to pathogenic Arg, thus significantly lowering the probability of pathogenic reversion caused by the Glu-to-Arg mutation at G333. However, only one nucleotide substitution is sufficient to convert the Glu residue to another pathogenic residue, Lys, and thereby to cause pathogenic reversion. This indicates a potential safety problem of SAG2 and the live vaccine candidates attenuated by Glu at G333. In this study, aiming to solve this problem, we examined the utility of a Leu residue, which requires two nucleotide substitutions to be both Arg and Lys, as an attenuating mutation at G333. Using a reverse genetics system of the live vaccine strain ERA, we generated ERA-G333Leu by introducing an Arg-toLeu mutation at G333. Similar to ERA-G333Glu, which is attenuated by an Arg-to-Glu mutation at G333, ERA-G333Leu did not cause obvious clinical signs in 6-week-old mice after intracerebral inoculation. Importantly, after 10 passages in suckling mouse brains, ERA-G333Glu acquired a pathogenic Lys or Arg at G333 and a high level of lethality in mice, whereas ERA-G333Leu retained the attenuating Leu at G333 and only showed a modest level of virulence probably caused by a mutation at G194. In addition, ERA-G333Leu and ERA-G333Glu induced neutralizing antibody response and protective immunity in mice with similar efficiencies. The results demonstrate that, compared to ERA-G333Glu, ERA-G333Leu is more stably attenuated, also indicating the high utility of a Leu residue as an attenuating mutation at G333 in the development of live rabies vaccine strains with a high level of safety. (c) 2021 Elsevier Ltd. All rights reserved.	[Ito, Naoto; Okamoto, Takuya; Miyamoto, Shoya; Izumi, Fumiki; Inukai, Maho; Jarusombuti, Supasiri; Okada, Kazuma; Nishiyama, Shoko; Masatani, Tatsunori; Sugiyama, Makoto] Gifu Univ, Lab Zoonot Dis, Fac Appl Biol Sci, 1-1 Yanagido, Gifu 5011193, Japan; [Ito, Naoto; Takahashi, Tatsuki; Nakagawa, Kento] Gifu Univ, United Grad Sch Vet Sci, Gifu, Japan; [Ito, Naoto; Fujii, Yuji; Nishiyama, Shoko; Masatani, Tatsunori] Gifu Univ, Joint Grad Sch Vet Sci, Gifu, Japan; [Sasaki, Michihito; Sawa, Hirofumi] Hokkaido Univ, Div Mol Pathobiol, Res Ctr Zoonosis Control, Sapporo, Hokkaido, Japan; [Jarusombuti, Supasiri] Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi, Japan		Ito, N (通讯作者)，Gifu Univ, Lab Zoonot Dis, Fac Appl Biol Sci, 1-1 Yanagido, Gifu 5011193, Japan.	naotoito@gifu-u.ac.jp	Sawa, Hirofumi/AAW-8816-2021; Sasaki, Michihito/AAY-1900-2021; Sawa, Hirofumi/F-6954-2012	Sasaki, Michihito/0000-0003-1607-2175; Sawa, Hirofumi/0000-0003-2569-2755; Jarusombuti, Supasiri/0000-0001-9737-3337; Fujii, Yuji/0000-0003-4613-7232	Japan Society for the Promotion of Science, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [15K07720]; Ministry of Education, Culture, Sports, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	This study was partially supported by GrantsinAid for Scientific Research from Japan Society for the Promotion of Science, Japan (No. 15K07720) and also a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan for Joint Research Program of the Research Center for Zoonosis Control, Hokkaido University.	BINGHAM J, 1992, VET REC, V131, P55, DOI 10.1136/vr.131.3.55; CLARK HF, 1978, SCIENCE, V199, P1072, DOI 10.1126/science.628831; Cliquet F, 2004, DEV BIOLOGICALS, V119, P185; Debbie JG., 1979, J AM VET MED ASS; DIETZSCHOLD B, 1983, P NATL ACAD SCI-BIOL, V80, P70, DOI 10.1073/pnas.80.1.70; Dietzschold ML, 2004, VACCINE, V23, P518, DOI 10.1016/j.vaccine.2004.06.031; Esh JB., 1982, J AM VET MED ASS; Faber M, 2005, J VIROL, V79, P14141, DOI 10.1128/JVI.79.22.14141-14148.2005; Faber M, 2002, J VIROL, V76, P3374, DOI 10.1128/JVI.76.7.3374-3381.2002; Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709; Hostnik P, 2014, J WILDLIFE DIS, V50, P397, DOI 10.7589/2013-07-183; LAFAY F, 1994, VACCINE, V12, P317, DOI 10.1016/0264-410X(94)90095-7; Mahl P, 2014, VET RES, V45, DOI 10.1186/s13567-014-0077-8; McGettigan JP, 2003, J VIROL, V77, P237, DOI 10.1128/JVI.77.1.237-244.2003; Morimoto K, 2001, VACCINE, V19, P3543, DOI 10.1016/S0264-410X(01)00064-0; Muller T, 2009, ARCH VIROL, V154, P1081, DOI 10.1007/s00705-009-0408-7; Muller TF, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003953; Nakagawa K, 2017, VACCINE, V35, P5622, DOI 10.1016/j.vaccine.2017.08.050; Nakagawa K, 2012, VACCINE, V30, P3610, DOI 10.1016/j.vaccine.2012.03.044; Okolo MIO., 1989, MICROBIOS; SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x; SEIF I, 1985, J VIROL, V53, P926, DOI 10.1128/JVI.53.3.926-934.1985; Shuai L, 2015, ANTIVIR RES, V121, P9, DOI 10.1016/j.antiviral.2015.06.011; Tao LH, 2010, J VIROL, V84, P8926, DOI 10.1128/JVI.00787-10; TUFFEREAU C, 1989, VIROLOGY, V172, P206, DOI 10.1016/0042-6822(89)90122-0; Vuta V, 2016, VACCINE, V34, P5021, DOI 10.1016/j.vaccine.2016.08.013; Wallace RM, 2021, EMERG INFECT DIS, V26, pE1, DOI 10.3201/eid2612.201266; WANDELER AI, 1982, COMP IMMUNOL MICROB, V5, P173, DOI 10.1016/0147-9571(82)90032-7; WHO, 2013, WHO TECH REP SER, V982, P1; World Health Organization, 2018, WHO TECH REP SER; World Organization for Animal Health (OIE), 2019, MAN DIAGNOSTIC TESTS, V2019, P578; Yang DK, 2014, CLIN EXP VACCINE RES, V3, P176, DOI 10.7774/cevr.2014.3.2.176; Zhu SM, 2015, J NEUROVIROL, V21, P335, DOI 10.1007/s13365-015-0350-2	33	0	0	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 23	2021	39	28					3777	3784		10.1016/j.vaccine.2021.05.002		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SS0GD	34092430				2022-04-29	WOS:000661420000015
J	Jayaraman, Y; Veeraraghavan, B; Kumar, CPG; Sukumar, B; Rajkumar, P; Kangusamy, B; Verghese, VP; Varghese, R; Jayaraman, R; Kapoor, AN; Gupta, N; Kanagasabai, K; David, JK; Rajaraman, J; Sockalingam, G; Khera, A; Haldar, P; Aggarwal, MK; Pillai, RK; Manchanda, V; Theodore, RBJ; Rajahamsan, J; Mohan, G; Jayalekshmi, V; Nedunchelian, K; Devasena, N; Sridharan, S; Selvi, R; Ravinder, T; Babu, RN; Mathevan, G; Sugumari, C; Rao, PS; Kini, PG; Dwibedi, B; Kanga, A; Grover, N; Narayanan, H; Mehendale, SM				Jayaraman, Yuvaraj; Veeraraghavan, Balaji; Kumar, C. P. Girish; Sukumar, Bharathy; Rajkumar, Prabu; Kangusamy, Boopathi; Verghese, Valsan Philip; Varghese, Rosemol; Jayaraman, Ranjith; Kapoor, Ambujam Nair; Gupta, Nivedita; Kanagasabai, K.; David, Joseph K.; Rajaraman, Jayasri; Sockalingam, Gowtham; Khera, Ajay; Haldar, Pradeep; Aggarwal, M. K.; Pillai, Rajamohanan K.; Manchanda, Vikas; Theodore, Ramani Bai Joseph; Rajahamsan, Jyothi; Mohan, Girija; Jayalekshmi, V.; Nedunchelian, Krishnamoorthy; Devasena, N.; Sridharan, Sujatha; Selvi, R.; Ravinder, T.; Babu, R. Narayana; Mathevan, G.; Sugumari, C.; Rao, P. Sugandhi; Kini, Pushpa G.; Dwibedi, Bhagirathi; Kanga, Anil; Grover, Neelam; Narayanan, Harish; Mehendale, Sanjay M.			Hospital-based sentinel surveillance for bacterial meningitis in under-five children prior to the introduction of the PCV13 in India	VACCINE			English	Article						Bacterial meningitis; Children; Hib; Meningococcal; Pneumococcal; Serotype; Antimicrobial resistance; PCV; Surveillance	INFLUENZAE TYPE-B; RESISTANT STREPTOCOCCUS-PNEUMONIAE; INVASIVE PNEUMOCOCCAL INFECTIONS; CONJUGATE VACCINES; DISEASE; EPIDEMIOLOGY; YOUNGER; BURDEN	Introduction: A hospital-based sentinel surveillance network for bacterial meningitis was established in India to estimate the burden of bacterial meningitis, and the proportion of major vaccine-preventable causative organisms. This report summarises the findings of the surveillance conducted between March 2012, and September 2016 in eleven hospitals. Methods: We enrolled eligible children with bacterial meningitis in the age group of one to 59 months. CSF samples were collected and processed for biochemistry, culture, latex agglutination, and real-time PCR. Pneumococcal isolates were serotyped and tested for antimicrobial susceptibility. Results: Among 12 941 enrolled suspected meningitis cases, 586 (4.5%) were laboratory confirmed. S. pneumoniae (74.2%) was the most commonly detected pathogen, followed by H. influenzae (22.2%), and N. meningitidis (3.6%). Overall 58.1% of confirmed bacterial meningitis cases were children aged between one, and 11 months. H. influenzae meningitis cases had a high (12.3%) case fatality rate. The serotypes covered in PCV13 caused 72% pneumococcal infections, and the most common serotypes were 14 (18.3%), 6B (12.7%) and 19F (9.9%). Non-susceptibility to penicillin was 57%. Forty-five (43.7%) isolates exhibited multidrug resistance, of which 37 were PCV13 serotype isolates. Conclusions: The results are representative of the burden of bacterial meningitis among under-five children in India. The findings were useful in rolling out PCV in the National Immunization Program. The nonsusceptibility to penicillin and multidrug resistance was an important observation. Timely expansion of PCV across India will significantly reduce the burden of antimicrobial resistance. Continued surveillance is needed to understand the trend after PCV expansion in India.	[Jayaraman, Yuvaraj; Kumar, C. P. Girish; Sukumar, Bharathy; Rajkumar, Prabu; Kangusamy, Boopathi; Kanagasabai, K.; David, Joseph K.; Rajaraman, Jayasri; Sockalingam, Gowtham; Narayanan, Harish; Mehendale, Sanjay M.] ICMR Natl Inst Epidemiol, 2 Main Rd, Chennai, Tamil Nadu, India; [Veeraraghavan, Balaji; Verghese, Valsan Philip; Varghese, Rosemol; Jayaraman, Ranjith] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; [Kapoor, Ambujam Nair; Gupta, Nivedita; Mehendale, Sanjay M.] Indian Council Med Res, New Delhi, India; [Khera, Ajay; Haldar, Pradeep; Aggarwal, M. K.] Govt India, Minist Hlth & Family Welf, New Delhi, India; [Pillai, Rajamohanan K.; Theodore, Ramani Bai Joseph; Rajahamsan, Jyothi] Govt Med Coll, Thiruvananthapuram, Kerala, India; [Manchanda, Vikas] Chacha Nehru Bal Chikitsalaya Hosp, New Delhi, India; [Mohan, Girija; Jayalekshmi, V.] Govt TD Med Coll, Allepey, Kerala, India; [Nedunchelian, Krishnamoorthy; Devasena, N.] Inst Child Hlth & Hosp Children, Chennai, Tamil Nadu, India; [Sridharan, Sujatha; Selvi, R.] Govt Stanley Med Coll, Chennai, Tamil Nadu, India; [Ravinder, T.; Babu, R. Narayana] Govt Kilpauk Med Coll, Chennai, Tamil Nadu, India; [Mathevan, G.; Sugumari, C.] Govt Madurai Med Coll, Madurai, Tamil Nadu, India; [Rao, P. Sugandhi; Kini, Pushpa G.] Kasturba Med Coll & Hosp, Manipal, Karnataka, India; [Dwibedi, Bhagirathi] MICMR Reg Med Res Ctr, Bhubaneswar, Odisha, India; [Kanga, Anil; Grover, Neelam] Indira Gandhi Inst Med Sci, Shimla, India		Jayaraman, Y (通讯作者)，ICMR Natl Inst Epidemiol, 2 Main Rd, Chennai, Tamil Nadu, India.	j_yuvan@yahoo.com	Kumar, CP Girish/J-1278-2017	Kumar, CP Girish/0000-0002-5464-1028	Ministry of Health and Family Welfare, Government of India [G.27017/02/2011-CC]	This study was supported by a grant from Ministry of Health and Family Welfare, Government of India [Grant No: G.27017/02/2011-CC&V].	[Anonymous], 2011, LAB METHODS DIAGNOSI, V2nd; [Anonymous], 2014, PNEUMONIA, V3, P222, DOI [10.1007/BF03399445, DOI 10.1007/BF03399445]; Balaji V, 2015, INDIAN J MED RES, V142, P286, DOI 10.4103/0971-5916.166588; Ceyhan M, 2014, HUM VACC IMMUNOTHER, V10, P2706, DOI 10.4161/hv.29678; Chinchankar Nandita, 2002, Indian Pediatr, V39, P914; Dash N, 2008, J INFECT DEV COUNTR, V2, P112, DOI 10.3855/T2.2.112; Dutta AK, 2020, INFECT DIS THER, V9, P537, DOI 10.1007/s40121-020-00323-4; Fitzwater SP, 2019, VACCINE, V37, P1608, DOI 10.1016/j.vaccine.2019.01.080; Goetghebuer T, 2000, TROP MED INT HEALTH, V5, P207, DOI 10.1046/j.1365-3156.2000.00535.x; Hajjeh R, 2013, J PEDIATR-US, V163, pS1, DOI 10.1016/j.jpeds.2013.03.022; Jafri RZ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-17; Jayaraman Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197198; Kaplan SL, 2002, PEDIATR INFECT DIS J, V21, P141, DOI 10.1097/00006454-200202000-00011; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; Lalitha MK, 2002, LANCET, V359, P445, DOI 10.1016/S0140-6736(02)07578-5; Lucas MJ, 2016, J INFECTION, V73, P18, DOI 10.1016/j.jinf.2016.04.009; Mani R, 2007, Indian J Med Microbiol, V25, P108; Manoharan A, 2017, LANCET INFECT DIS, V17, P305, DOI [10.1016/S1473-3099(16)30466-2, 10.1016/s1473-3099(16)30466-2]; Minz S, 2008, INDIAN J MED RES, V128, P57; Molander V, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-532; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Oligbu G, 2019, EMERG INFECT DIS, V25, P1708, DOI 10.3201/eid2509.180747; Oordt-Speets AM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198772; Ramachandran P, 2013, INDIAN J MED RES, V137, P712; Sinclair D, 2010, TROP MED INT HEALTH, V15, P1421, DOI 10.1111/j.1365-3156.2010.02660.x; Theodoridou MN, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-101; Thomas K, 1999, LANCET, V353, P1216, DOI 10.1016/S0140-6736(98)07228-6; Tsai CJ, 2008, CLIN INFECT DIS, V46, P1664, DOI 10.1086/587897; Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368; Vandana G, 2016, PEDIAT INFECT DIS, V8, P47, DOI 10.1016/j.pid.2016.06.004; Verghese VP, 2017, INDIAN J MED MICROBI, V35, P228, DOI 10.4103/ijmm.IJMM_17_124; Wahl B, 2019, LANCET GLOB HEALTH, V7, pE735, DOI 10.1016/S2214-109X(19)30081-6; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; World Health Organisation, DEF MEN 2030 BAS SIT; Zunt JR, 2018, LANCET NEUROL, V17, P1061, DOI 10.1016/S1474-4422(18)30387-9	35	1	1	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 23	2021	39	28					3737	3744		10.1016/j.vaccine.2021.05.041		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SS0GD	34074545	hybrid			2022-04-29	WOS:000661420000011
J	Fukuda, M; Nakamura, J; Ito, S; Kawazoe, K; Miyanaga, Y; Teshigawara, T; Okuda, K; Mizuki, N; Shimada, M				Fukuda, Michiko; Nakamura, Jutaro; Ito, Saori; Kawazoe, Kenji; Miyanaga, Yoshitaka; Teshigawara, Takeshi; Okuda, Kenji; Mizuki, Nobuhisa; Shimada, Masaru			Vaccination inhibits the human adenoviral transduction in a mouse keratoconjunctivitis model	VACCINE			English	Article						Conjunctivitis; Adenovirus; Vector; Mouse; Vaccine	EPIDEMIC KERATOCONJUNCTIVITIS; CORNEAL TRANSPLANTATION; TOPICAL TREATMENT; TYPE-5 INFECTION; POVIDONE-IODINE; IN-VIVO; VECTORS; DEXAMETHASONE; KERATITIS; TROPISM	Adenovirus infections are a major cause of epidemic keratoconjunctivitis (EKC), which can lead to corneal subepithelial infiltrates and multifocal corneal opacity. In the current study, we investigated the use of an E1/E3-deleted adenovirus serotype 5 (Ad5) vector as a vaccine administered intramuscularly (IM) or intranasally (IN) against subsequent challenges with a luciferase-expressing Ad5 (Ad5-Luci) vector via eyedrop. We evaluated the adaptive immune response to Ad5 vector vaccination and confirmed a robust polyfunctional CD8 T cell response in splenic cells. Neutralizing Ad5 antibodies were also measured in the sera of vaccinated mice as well as Ad5 antibody in the eye wash solutions. Upon challenge with Ad5-Luci vector 8 weeks post the primary immunization, transduction was significantly reduced by > 70% in the vaccinated mice, which was slightly better in IM-vs. that in IN-vaccinated animals. Resistance to subse-quent challenge was observed 10 months post primary IM vaccination, with sustained reduction up to 60% in the Ad5-Luci vector transduction. Passive immunization of naive mice with antisera from IM to vaccinated mice subsequently challenged with the Ad5-Luci vector resulted in approximately 40% loss in transduction efficiency. Furthermore, the mice that received IM immunization with or without CD8 T cell depletion showed > 40% and 70% reductions, respectively, in Ad8 genomic copies after Ad8 topical challenge. We conclude that Ad-vector vaccination successfully induced an adaptive immune response that prevented subsequent Ad transduction in the cornea and conjunctiva-associated tissues in a mouse model of adenovirus keratoconjunctivitis, and that both cellular and humoral immunity play an impor-tant role in preventing Ad transduction. (c) 2021 Elsevier Ltd. All rights reserved.	[Fukuda, Michiko; Nakamura, Jutaro; Ito, Saori; Mizuki, Nobuhisa] Yokohama City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Yokohama, Kanagawa 2360004, Japan; [Kawazoe, Kenji] Kawazoe Eye Clin, Fukuoka 8110120, Japan; [Miyanaga, Yoshitaka] Nishikasai Inoue Eye Hosp, Tokyo 1340088, Japan; [Teshigawara, Takeshi] Yokosuka Chuoh Eye Clin, Dept Ophthalmol, Yokosuka, Kanagawa 2380008, Japan; [Okuda, Kenji; Shimada, Masaru] Yokohama City Univ, Grad Sch Med, Dept Mol Biodef Res, Yokohama, Kanagawa 2360004, Japan; [Okuda, Kenji] Okuda Vaccine Res Inst, Yokohama, Kanagawa 2350045, Japan; [Okuda, Kenji] Yokohama City Univ, Yokohama, Kanagawa 2360004, Japan		Shimada, M (通讯作者)，Yokohama City Univ, Dept Mol Biodef Res, Grad Sch Med, Kanazawa Ku, 3-9 Fukuura, Kanazawa, Ishikawa 2360004, Japan.	mshimada@yokohama-cu.ac.jp		Nakamrua, Jutaro/0000-0002-5565-5050; Shimada, Masaru/0000-0002-5271-4238	Ministry of Education, Culture, Sports, Science, and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [26462531, 17K11288]; Japan Society for the Promotion of Science (JSPS)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [24112]	This work was partially supported by a grantinaid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (#26462531 and #17K11288) . JN was supported by the Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellowship for Research Abroad (KaitokuNIH, #24112) . The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Ms. Asako Morita, Ms. Mari Tomizawa, and Ms. Yuka Takeuchi for their technical assistance.	Adhikary AK, 2014, J CLIN VIROL, V61, P477, DOI 10.1016/j.jcv.2014.10.015; Adlhoch C, 2010, EURO SURVEILL, V15; Agarwal P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169532; Buckwalter SP, 2012, J CLIN MICROBIOL, V50, P766, DOI 10.1128/JCM.05629-11; Chigbu DI, 2018, INFECT DRUG RESIST, V11, P981, DOI 10.2147/IDR.S162669; Chintakuntlawar AV, 2007, INVEST OPHTH VIS SCI, V48, P781, DOI 10.1167/iovs.06-1036; Chintakuntlawar AV, 2009, J INTERF CYTOK RES, V29, P657, DOI 10.1089/jir.2009.0006; Clement C, 2011, INVEST OPHTH VIS SCI, V52, P339, DOI 10.1167/iovs.10-5944; De Hauwere B, 1995, Bull Soc Belge Ophtalmol, V259, P33; Einfeld DA, 2001, J VIROL, V75, P11284, DOI 10.1128/JVI.75.23.11284-11291.2001; FORD E, 1987, EPIDEMIOL REV, V9, P244, DOI 10.1093/oxfordjournals.epirev.a036304; Ghebremedhin B, 2014, EUR J MICROBIOL IMMU, V4, P26, DOI 10.1556/EuJMI.4.2014.1.2; Gonzalez G, 2019, J CLIN VIROL, V112, P1, DOI 10.1016/j.jcv.2019.01.004; GORDON YJ, 1992, INVEST OPHTH VIS SCI, V33, P574; GORDON YJ, 1993, OPHTHALMOLOGY, V100, P1835; Gottsch J D, 1999, Ophthalmic Epidemiol, V6, P29; Grivennikov SI, 2005, IMMUNITY, V22, P93, DOI 10.1016/j.immuni.2004.11.016; HALL JM, 1989, INVEST OPHTH VIS SCI, V30, P138; Hillenkamp J, 2002, OPHTHALMOLOGY, V109, P845, DOI 10.1016/S0161-6420(02)00992-2; Hogan MJ, 2018, AM J OPHTHALMOL, V190, pXXIX, DOI 10.1016/j.ajo.2018.03.041; Huang J, 2014, CLIN OPHTHALMOL, V8, P315, DOI 10.2147/OPTH.S55284; HUTTER H, 1990, KLIN MONATSBL AUGENH, V197, P214, DOI 10.1055/s-2008-1046272; JAWETZ E, 1955, SCIENCE, V122, P1190, DOI 10.1126/science.122.3181.1190-a; Jhanji V, 2015, SURV OPHTHALMOL, V60, P435, DOI 10.1016/j.survophthal.2015.04.001; Jogler C, 2006, J VIROL, V80, P3549, DOI 10.1128/JVI.80.7.3549-3558.2006; JONES BR, 1958, P ROY SOC MED, V51, P917, DOI 10.1177/003591575805101105; Kaneko H, 2019, JPN J INFECT DIS, V72, P353, DOI 10.7883/yoken.JJID.2019.064; Kovalyuk N, 2017, ACTA OPHTHALMOL, V95, pe686, DOI 10.1111/aos.13416; Levinger E, 2010, CORNEA, V29, P638, DOI 10.1097/ICO.0b013e3181c33034; Li D, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4232-8; Lynch JP, 2011, SEMIN RESP CRIT CARE, V32, P494, DOI 10.1055/s-0031-1283287; McKelvey T, 2004, GENE THER, V11, P791, DOI 10.1038/sj.gt.3302232; Meyer-Rusenberg B, 2011, DTSCH ARZTEBL INT, V108, P475, DOI 10.3238/arztebl.2011.0475; Mizuguchi H, 2002, GENE, V285, P69, DOI 10.1016/S0378-1119(02)00410-9; Pacesa M, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0822-5; Ramke M, 2016, EXP EYE RES, V147, P144, DOI 10.1016/j.exer.2016.05.016; Romanowski EG, 1996, ARCH OPHTHALMOL-CHIC, V114, P581, DOI 10.1001/archopht.1996.01100130573014; ROSSA V, 1991, KLIN MONATSBL AUGENH, V199, P192, DOI 10.1055/s-2008-1046070; Sambursky Robert P, 2007, Optometry, V78, P236, DOI 10.1016/j.optm.2006.11.012; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; Shoji M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030302; Singh G, 2015, VIROLOGY, V485, P452, DOI 10.1016/j.virol.2015.08.018; Small JC, 2014, J LEUKOCYTE BIOL, V96, P821, DOI 10.1189/jlb.1A0813-451RR; TROUSDALE MD, 1994, CORNEA, V13, P435, DOI 10.1097/00003226-199409000-00011; TSAI JC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1167, DOI 10.1001/archopht.1992.01080200147043; Walsh MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005635; Wang HB, 2010, GENE THER, V17, P4, DOI 10.1038/gt.2009.122; WARD JB, 1993, CORNEA, V12, P216, DOI 10.1097/00003226-199305000-00006; WARING GO, 1976, AM J OPHTHALMOL, V82, P781, DOI 10.1016/0002-9394(76)90017-9; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Xin KQ, 2007, VACCINE, V25, P3809, DOI 10.1016/j.vaccine.2007.01.117; Xin KQ, 2005, GENE THER, V12, P1769, DOI 10.1038/sj.gt.3302590; Xu LM, 2004, J IMMUNOL, V173, P721, DOI 10.4049/jimmunol.173.2.721; Zhang EP, 1996, GRAEF ARCH CLIN EXP, V234, P714, DOI 10.1007/BF00292359; Zhang EP, 2005, GRAEF ARCH CLIN EXP, V243, P72, DOI 10.1007/s00417-004-0952-5; Zhang L, 2016, EPIDEMIOL INFECT, V144, P1661, DOI 10.1017/S0950268815003246; Zhou DM, 2013, MOL THER, V21, P696, DOI 10.1038/mt.2012.248; Zhou XH, 2017, IMMUNOL CELL BIOL, V95, P108, DOI 10.1038/icb.2016.73	58	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 11	2021	39	26					3498	3508		10.1016/j.vaccine.2021.05.010		JUN 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SN6KQ	34016474				2022-04-29	WOS:000658397000008
J	Huang, JM; Wang, SY; Lai, MR; Tseng, YK; Chi, YH; Huang, LM				Huang, Jen-Min; Wang, Shih-Yun; Lai, Mei-Ru; Tseng, Yu-Kai; Chi, Ya-Hui; Huang, Li-Min			Development of a respiratory syncytial virus vaccine using human hepatitis B core-based virus-like particles to induce mucosal immunity	VACCINE			English	Article						RSV; Mucosal immunity; Virus-like particle; HBc antigen; Adjuvant	FUSION GLYCOPROTEIN; NANOPARTICLE VACCINE; ANTIBODY-RESPONSES; DISEASE SEVERITY; STRUCTURAL BASIS; YOUNG-CHILDREN; INFECTION; PROTEIN; NEUTRALIZATION; REINFECTION	Background: Respiratory syncytial virus (RSV) is an important viral pathogen responsible for severe infection of the lower respiratory tract in children under the age of 5 years. No vaccines against RSV are currently in clinical use. Vaccine-associated enhanced respiratory disease (ERD) caused by excess Th2 type responses was observed in a clinical trial of formalin-inactivated RSV (FI-RSV) in antigen-na & iuml;ve infants. Thus, inducing a balanced immune response is a crucial issue in the development of an RSV vaccine. Methods: In this study, we constructed, expressed, and purified a recombinant RSV vaccine candidate (i.e., HR & Oslash;24) containing the two heptad repeat regions and the antigenic sites & Oslash;, II, and IV of the RSV F protein. The RSV vaccine candidate was intranasally administrated to BALB/c and C57BL/6 mice in combination with virus-like particles (VLPs) derived from the core protein of the hepatitis B virus (HBc). Mucosal immunity to HR & Oslash;24 was then assessed. Results: Intranasal administration of HBc VLPs in combination with HR & Oslash;24 induced serum IgGs against HR & Oslash;24 as well as lung HR & Oslash;24-specific sIgAs in both C57BL/6 and BALB/c mouse models. The secretion of IFN-c from splenocyte re-stimulation and an elevated ratio of serum IgG2a to IgG1 indicated that the immune response induced by the HBc VLPs/HR & Oslash;24 mixture was Th1-biased. Weight loss of <5% and no to low eosinophil infiltration was observed in histological analysis of the lung following a challenge with the RSV A2 strain. These results suggest that the HBc VLPs/HR & Oslash;24 combination conferred substantial partial protection against RSV-induced illness in mice. Conclusions: Long-term immunity to RSV-induced illness was achieved via intranasal vaccination using a mixture of HBc VLPs and HR & Oslash;24 in mouse models.	[Huang, Jen-Min; Wang, Shih-Yun; Lai, Mei-Ru; Tseng, Yu-Kai; Huang, Li-Min] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Pediat, Coll Med, Taipei, Taiwan; [Chi, Ya-Hui] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan, Taiwan; [Huang, Li-Min] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan		Huang, LM (通讯作者)，Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Pediat, Coll Med, Taipei, Taiwan.; Chi, YH (通讯作者)，Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan, Taiwan.	ychi@nhri.edu.tw; lmhuang@ntu.edu.tw		Chi, Ya-Hui/0000-0002-9216-0938	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST 106-2321-B-002022, MOST 107-2321-B-002-011, MOST 108-2321-B-002-006]	The authors gratefully acknowledge the use of EM012300 equipment belonging to the Core Facility Center of National Cheng Kung University. The authors thank staffs at the Animal Center of NHRI for technical support. This work was supported by the Ministry of Science and Technology, Taiwan (MOST 106-2321-B-002022, MOST 107-2321-B-002-011, and MOST 108-2321-B-002-006).	ARBIZA J, 1992, J GEN VIROL, V73, P2225, DOI 10.1099/0022-1317-73-9-2225; Arcuri HA, 2008, PROTEIN EXPRES PURIF, V62, P146, DOI 10.1016/j.pep.2008.08.005; Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; BEELER JA, 1989, J VIROL, V63, P2941, DOI 10.1128/JVI.63.7.2941-2950.1989; Braun M, 2012, EUR J IMMUNOL, V42, P330, DOI 10.1002/eji.201142064; Broos K, 2008, CLIN VACCINE IMMUNOL, V15, P852, DOI 10.1128/CVI.00382-07; Capella C, 2017, J INFECT DIS, V216, P1398, DOI 10.1093/infdis/jix489; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chong CSW, 2005, J CONTROL RELEASE, V102, P85, DOI 10.1016/j.jconrel.2004.09.014; Corti D, 2013, NATURE, V501, P439, DOI 10.1038/nature12442; DeVincenzo JP, 2005, J INFECT DIS, V191, P1861, DOI 10.1086/430008; Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894; Geevarghese B, 2014, HUM VACC IMMUNOTHER, V10, P1047, DOI 10.4161/hv.27908; Gill N, 2010, NAT IMMUNOL, V11, P558, DOI 10.1038/ni0710-558; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Graham BS, 2017, CURR OPIN VIROL, V23, P107, DOI 10.1016/j.coviro.2017.03.012; Graham BS, 2015, CURR OPIN IMMUNOL, V35, P30, DOI 10.1016/j.coi.2015.04.005; Graham BS, 2011, IMMUNOL REV, V239, P149, DOI 10.1111/j.1600-065X.2010.00972.x; GRAHAM BS, 1988, J MED VIROL, V26, P153, DOI 10.1002/jmv.1890260207; Habibi MS, 2015, AM J RESP CRIT CARE, V191, P1040, DOI 10.1164/rccm.201412-2256OC; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; Hwang HS, 2014, ANTIVIR RES, V110, P115, DOI 10.1016/j.antiviral.2014.07.016; Joyce C, 2018, VACCINE, V36, P4265, DOI 10.1016/j.vaccine.2018.05.112; Kang SM, 2012, EXPERT REV VACCINES, V11, P995, DOI 10.1586/ERV.12.70; Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138; Khan IU, 2019, INT IMMUNOL, V31, P199, DOI 10.1093/intimm/dxy078; Ko SH, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02885; Leemans A, 2019, VIRUS RES, V266, P58, DOI 10.1016/j.virusres.2019.04.006; Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046; McLellan JS, 2013, CURR TOP MICROBIOL, V372, P83, DOI 10.1007/978-3-642-38919-1_4; McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283; McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914; MURPHY BR, 1988, J CLIN MICROBIOL, V26, P1595, DOI 10.1128/JCM.26.8.1595-1597.1988; Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9; Okamoto M, 2010, J MED VIROL, V82, P2092, DOI 10.1002/jmv.21920; Openshaw PJ, 2013, CURR TOP MICROBIOL, V372, P359, DOI 10.1007/978-3-642-38919-1_18; Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781; PRINCE GA, 1979, INFECT IMMUN, V26, P764, DOI 10.1128/IAI.26.2.764-766.1979; Quan FS, 2011, J INFECT DIS, V204, P987, DOI 10.1093/infdis/jir474; Rossey I, 2019, EXPERT REV VACCINES, V18, P1053, DOI 10.1080/14760584.2019.1675520; Ruckwardt TJ, 2016, CURR OPIN VIROL, V16, P151, DOI 10.1016/j.coviro.2016.01.003; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; Taylor G, 2017, VACCINE, V35, P469, DOI 10.1016/j.vaccine.2016.11.054; Tian DY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01858-w; Turner TL, 2014, CLINICOECONOMIC OUTC, V6, P217, DOI 10.2147/CEOR.S60710; Wright PF, 2002, J INFECT DIS, V185, P1011, DOI 10.1086/339822; Wu SJ, 2007, J GEN VIROL, V88, P2719, DOI 10.1099/vir.0.82753-0	47	0	0	2	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 2	2021	39	24					3259	3269		10.1016/j.vaccine.2021.04.038		JUN 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SM1SV	33972124				2022-04-29	WOS:000657392500004
J	Groeneweg, L; Loeffen, YGT; Versluys, AB; Wolfs, TFW				Groeneweg, Leonie; Loeffen, Yvette G. T.; Versluys, Anne Birgitta; Wolfs, Tom F. W.			Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients	VACCINE			English	Review						Measles; Vaccine; Haematopoietic stem cell transplantation; Solid organ transplantation; Safety; Efficacy	IMMUNIZATION; IMMUNITY; CHILDREN; VIRUS; ANTIBODIES; DISEASES; RUBELLA; MUMPS	Background and objective: Vaccination with the live attenuated measles vaccine is currently recommended two years after hematopoietic stem cell transplantation (HSCT) and generally contraindicated after solid organ transplantation (SOT) due to safety concerns. However, in the last few years new data on the administration of the measles vaccine to HSCT recipients less two years post-transplantation and to SOT recipients have become available. This new data may change current guidelines and practices. The objective of this review is to provide an overview of the current data on the safety and efficacy of early measles vaccination for HSCT- and SOT recipients. Method: PubMed and EMBASE were searched from the earliest date available through October 2019 to identify all research that reported on the safety and efficacy of measles vaccination after SOT or less than two years after HSCT. Results: A total of ten studies was included in this review. In the six studies that evaluated the efficacy of measles vaccination after SOT, seroconversion rates ranged from 41 to 100% after one dose and 73 to 100% after two doses. In the four studies that evaluated the efficacy of measles vaccination less than two years after HSCT, seroconversion rates ranged from 33 to 100% after one dose and 100% after two doses. In all studies, the administration of the measles vaccine after transplantation was considered to be safe. There were no cases of infection with the attenuated vaccine strain, and there were no adverse events related to the vaccination. Conclusion: Data on the administration of the measles vaccine after SOT and less than two years after HSCT is scarce. However, the current data available suggest that it is efficacious and well tolerable. Therefore, early measles vaccination could be considered in selected groups of SOT- and HSCT recipients during increased measles transmission or an outbreak setting. & nbsp;(c) 2021 Elsevier Ltd. All rights reserved.	[Groeneweg, Leonie] Univ Utrecht, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [Groeneweg, Leonie] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [Loeffen, Yvette G. T.; Wolfs, Tom F. W.] Wilhelmina Childrens Hosp, Dept Pediat Infect Dis & Immunol, Lundlaan 6, NL-3584 EA Utrecht, Netherlands; [Versluys, Anne Birgitta] Princess Maxima Ctr Pediat Oncol, Dept Blood & Marrow Transplantat, NL-3584 CS Utrecht, Netherlands		Wolfs, TFW (通讯作者)，Wilhelmina Childrens Hosp, Dept Pediat Infect Dis & Immunol, Lundlaan 6, NL-3584 EA Utrecht, Netherlands.	T.Wolfs@umcutrecht.nl					Chaves TDS, 2005, PEDIATR TRANSPLANT, V9, P192, DOI 10.1111/j.1399-3046.2005.00279.x; Chen X, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-29; Chong PP, 2017, CLIN THER, V39, P1581, DOI 10.1016/j.clinthera.2017.07.005; Cordonnier C, 2019, LANCET INFECT DIS, V19, pE200, DOI 10.1016/S1473-3099(18)30600-5; Croce E, 2017, VACCINE, V35, P1216, DOI 10.1016/j.vaccine.2017.01.048; Danziger-Isakov L, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13563; Garrido HMG, 2019, AM J HEMATOL, V94, pE270, DOI 10.1002/ajh.25590; Inaba H, 2012, BRIT J HAEMATOL, V156, P109, DOI 10.1111/j.1365-2141.2011.08913.x; Kano H, 2002, TRANSPLANTATION, V74, P543, DOI 10.1097/00007890-200208270-00020; Kawano Y, 2015, VACCINE, V33, P1440, DOI 10.1016/j.vaccine.2015.01.075; Khan S, 2006, PEDIATR TRANSPLANT, V10, P78, DOI 10.1111/j.1399-3046.2005.00403.x; Lee DG, 2013, INFECT CHEMOTHER, V45, P272, DOI 10.3947/ic.2013.45.3.272; Ljungman P, 2005, BONE MARROW TRANSPL, V35, P737, DOI 10.1038/sj.bmt.1704870; LJUNGMAN P, 1994, BLOOD, V84, P657; Ljungman P, 2009, BONE MARROW TRANSPL, V44, P521, DOI 10.1038/bmt.2009.263; Lobermann M, 2012, AUTOIMMUN REV, V11, P212, DOI 10.1016/j.autrev.2011.05.015; Machado CM, 2005, BONE MARROW TRANSPL, V35, P787, DOI 10.1038/sj.bmt.1704878; Moss WJ, 2017, LANCET, V390, P2490, DOI 10.1016/S0140-6736(17)31463-0; National Institutes of Health-National heart lung and blood institute, ASSESSMENT TOOL BEFO; Offit P., 2018, PLOTKINS VACCINES; Organization, 2013, WHOIVB1301; Patel M, 2019, MMWR-MORBID MORTAL W, V68, P402, DOI 10.15585/mmwr.mm6817e1; Patel SR, 2007, CLIN INFECT DIS, V44, P625, DOI 10.1086/511641; PAUKSEN K, 1992, BONE MARROW TRANSPL, V9, P427; Pergam Steven A, 2019, Biol Blood Marrow Transplant, V25, pe321, DOI 10.1016/j.bbmt.2019.07.034; Pittet LF, 2019, AM J TRANSPLANT, V19, P844, DOI 10.1111/ajt.15101; Plotkin SA, 2020, J INFECT DIS, V221, P1571, DOI 10.1093/infdis/jiz381; RAND EB, 1993, J PEDIATR-US, V123, P87, DOI 10.1016/S0022-3476(05)81545-8; Rocca S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004738; Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI [10.1093/cid/cit816, 10.1093/cid/cit684]; Shaw PJ, 2002, BLOOD, V99, P3486, DOI 10.1182/blood-2002-01-0212; Shinjoh M, 2015, VACCINE, V33, P701, DOI 10.1016/j.vaccine.2014.11.052; Suresh S, 2019, PEDIATR TRANSPLANT, V23, DOI 10.1111/petr.13571; Warmington L, 2005, PEDIATR TRANSPLANT, V9, P311, DOI 10.1111/j.1399-3046.2005.00313.x; World health organization, MEASLES EUROPEAN REG; ZAMORA I, 1994, PEDIATR NEPHROL, V8, P190, DOI 10.1007/BF00865476	36	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3338	3345		10.1016/j.vaccine.2021.04.049		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	33992440				2022-04-29	WOS:000657001300008
J	Park, MA; Jenkins, SM; Smith, CY; Pyle, RC; Sacco, KA; Ryu, E; Hagan, JB; Joshi, AY; Snyder, MR; Abraham, RS				Park, Miguel A.; Jenkins, Sarah M.; Smith, Carin Y.; Pyle, Regan C.; Sacco, Keith A.; Ryu, Euijung; Hagan, John B.; Joshi, Avni Y.; Snyder, Melissa R.; Abraham, Roshini S.			Pneumococcal serotype-specific cut-offs based on antibody responses to pneumococcal polysaccharide vaccination in healthy adults	VACCINE			English	Article						Pneumococcal; Serotype; Pneumococcal polysaccharide vaccine; Pneumovax (R); Pneumococcal conjugate vaccine; Prevnar (R); Antibody response; Humoral immunodeficiency; Primary immunodeficiency; Multiplex bead analysis	STREPTOCOCCUS-PNEUMONIAE VACCINE; RECURRENT INFECTIONS; PRACTICE PARAMETER; DISEASE; IMMUNOGLOBULIN; DIAGNOSIS; DEFICIENCY; MANAGEMENT; RISK	Antibody responses to pneumococcal polysaccharide vaccination are frequently used as a diagnostic tool for humoral immunodeficiencies, part of the larger collection of inborn errors of immunity. Currently, arbitrary criteria, such as a serotype specific titer of >/= 1.3 mu g/mL is most often used as a cut-off for interpretation of pneumococcal antibody responses. The magnitude of the antibody response to each of the 23 serotypes in Pneumovax (R), and serotype-specific cut-offs in healthy pneumococcal vaccine-naive adults has not been previously characterized. IgG antibody concentrations were measured prospectively for 23 pneumococcal serotypes pre and 4-6 weeks post-Pneumovax (R) vaccination in 100 healthy adults, using a multiplex bead-based assay. Antibodies to 19 of 23 serotypes were informative for distinguishing subjects who responded to vaccination, and the serotype threshold was determined to be 9 of 19 serotypes, which characterized an antibody response to pneumococcal vaccination. While this study may facilitate classification of IgG serotype-specific antibody responses post-pneumococcal vaccination in adult patients undergoing diagnostic immunological evaluation for antibody immunodeficiencies or other relevant contexts, additional studies in healthy children and S. pneumoniae protein-conjugate-vaccinated healthy adults will need to be undertaken in the future. (C) 2021 Elsevier Ltd. All rights reserved.	[Park, Miguel A.; Pyle, Regan C.; Hagan, John B.; Joshi, Avni Y.] Dept Med, Div Allerg Dis, Glenwood Springs, CO USA; [Jenkins, Sarah M.; Smith, Carin Y.; Ryu, Euijung] Dept Quantitat Hlth Sci, Div Clin Trials & Biostat, Glenwood Springs, CO USA; [Pyle, Regan C.] Allergy Asthma & Immunol Rockies PC, Glenwood Springs, CO USA; [Sacco, Keith A.] NIH, Allergy & Immunol Program, Bldg 10, Bethesda, MD 20892 USA; [Park, Miguel A.; Jenkins, Sarah M.; Smith, Carin Y.; Ryu, Euijung; Hagan, John B.; Joshi, Avni Y.] Mayo Clin, Rochester, MN USA; [Snyder, Melissa R.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Abraham, Roshini S.] Nationwide Childrens Hosp, Dept Pathol & Lab Med, 700 Childrens Dr, Columbus, OH 43205 USA		Abraham, RS (通讯作者)，Nationwide Childrens Hosp, Dept Pathol & Lab Med, 700 Childrens Dr, Columbus, OH 43205 USA.	Roshini.Abraham@nationwidechildrens.org		Smith, Carin/0000-0002-3610-6945; Sacco, Keith/0000-0001-8189-7769	Division of Allergic Diseases, Department of Medicine; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN	Division of Allergic Diseases, Department of Medicine, and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.	Ballow M, 2012, J ALLERGY CLIN IMMUN, V130, P283, DOI 10.1016/j.jaci.2012.04.028; Bewick T, 2012, THORAX, V67, P540, DOI 10.1136/thoraxjnl-2011-201092; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Bonilla FA, 2018, J ALLERGY CLIN IMMUN, V141, P474, DOI 10.1016/j.jaci.2017.12.980; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Brandao AP, 2004, VACCINE, V23, P762, DOI 10.1016/j.vaccine.2004.07.024; De Schutter I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089013; de Waroux OL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086136; Hajjar J, 2018, J ALLERGY CLIN IMMUN, V142, P1358, DOI 10.1016/j.jaci.2018.06.013; Harboe ZB, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000081; Hare ND, 2009, J ALLERGY CLIN IMMUN, V123, P195, DOI 10.1016/j.jaci.2008.09.021; Hicks LA, 2007, J INFECT DIS, V196, P1346, DOI 10.1086/521626; Jacob G., 2004, Journal of Allergy and Clinical Immunology, V113, pS288, DOI 10.1016/j.jaci.2004.01.514; Jansen AGSC, 2009, VACCINE, V27, P2394, DOI 10.1016/j.vaccine.2009.01.127; Jeurissen A, 2007, CLIN CHEM, V53, P505, DOI 10.1373/clinchem.2006.080051; Jolles S, 2017, CLIN EXP IMMUNOL, V188, P333, DOI 10.1111/cei.12915; Martinez JE, 2006, CLIN VACCINE IMMUNOL, V13, P459, DOI 10.1128/CVI.13.4.459-466.2006; McNulty CMG, 2019, J ALLER CL IMM-PRACT, V7, P1061, DOI 10.1016/j.jaip.2018.12.016; Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002; Paris K, 2007, ANN ALLERG ASTHMA IM, V99, P462, DOI 10.1016/S1081-1206(10)60572-8; Pitsiou GG, 2011, RESP MED, V105, P1776, DOI 10.1016/j.rmed.2011.07.008; PLIKAYTIS BD, 1994, J CLIN MICROBIOL, V32, P2441, DOI 10.1128/JCM.32.10.2441-2447.1994; Plikaytis BD, 2000, J CLIN MICROBIOL, V38, P2043; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Schaballie H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00546; Sjostrom K, 2006, CLIN INFECT DIS, V42, P451, DOI 10.1086/499242; Sleeman K, 2001, J INFECT DIS, V183, P239, DOI 10.1086/317924; Sorensen RU, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00986; Sorensen RU, 1998, PEDIATR INFECT DIS J, V17, P685, DOI 10.1097/00006454-199808000-00005; Sorensen RU, 1998, J ALLERGY CLIN IMMUN, V102, P215, DOI 10.1016/S0091-6749(98)70089-2; Tarrago D, 2007, CLIN MICROBIOL INFEC, V13, P369, DOI 10.1111/j.1469-0691.2006.01677.x; van Hoek AJ, 2012, J INFECTION, V65, P17, DOI 10.1016/j.jinf.2012.02.017; Weinberger DM, 2010, CLIN INFECT DIS, V51, P692, DOI 10.1086/655828	33	2	2	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 18	2021	39	21					2850	2856		10.1016/j.vaccine.2021.04.015		MAY 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RX4UJ	33896666				2022-04-29	WOS:000647220100006
J	Black, SB; Law, B; Chen, RT; Dekker, CL; Sturkenboom, M; Huang, WT; Gurwith, M; Poland, G				Black, Steven B.; Law, Barbara; Chen, Robert T.; Dekker, Cornelia L.; Sturkenboom, Miriam; Huang, Wan-Ting; Gurwith, Marc; Poland, Greg			The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety	VACCINE			English	Article						Vaccine safety; Background rates; COVID-19 vaccines	GUILLAIN-BARRE-SYNDROME; MULTIPLE-SCLEROSIS; FEATURES	Beginning in December of 2019, a novel coronavirus, SARS-CoV-2, emerged in China and is now a global pandemic with extensive morbidity and mortality. With the emergence of this threat, an unprecedented effort to develop vaccines against this virus began. As vaccines are now being introduced globally, we face the prospect of millions of people being vaccinated with multiple types of vaccines many of which use new vaccine platforms. Since medical events happen without vaccines, it will be important to know at what rate events occur in the background so that when adverse events are identified one has a frame of reference with which to compare the rates of these events so as to make an initial assessment as to whether there is a potential safety concern or not. Background rates vary over time, by geography, by sex, socioeconomic status and by age group. Here we describe two key steps for post-introduction safety evaluation of COVID-19 vaccines: Defining a dynamic list of Adverse Events of Special Interest (AESI) and establishing background rates for these AESI. We use multiple examples to illustrate use of rates and caveats for their use. In addition we discuss tools available from the Brighton Collaboration that facilitate case evaluation and understanding of AESI. (c) 2021 Elsevier Ltd. All rights reserved.	[Black, Steven B.; Law, Barbara; Chen, Robert T.; Dekker, Cornelia L.; Huang, Wan-Ting; Gurwith, Marc] Brighton Collaborat, Decatur, GA 30030 USA; [Sturkenboom, Miriam] Univ Utrecht, Utrecht, Netherlands; [Poland, Greg] Mayo Clin, Rochester, MI USA		Black, SB (通讯作者)，Brighton Collaborat, Decatur, GA 30030 USA.	stevblack@gmail.com		Huang, Wan-Ting/0000-0002-4344-9567			Alonso A, 2007, J NEUROL, V254, P1736, DOI 10.1007/s00415-007-0602-z; Annette Rid, 2020, JAMA; BEGHI E, 1985, ARCH NEUROL-CHICAGO, V42, P1053, DOI 10.1001/archneur.1985.04060100035016; Black S, 2009, LANCET, V374, P2115, DOI 10.1016/S0140-6736(09)61877-8; COVID CDC and Response Team, 2021, MMWR-MORBID MORTAL W, V70.2, P46; Dodd CN, BACKGROUND RATES ADV; Dudley MZ, 2020, LANCET INFECT DIS; Huang WC, 2015, NEUROEPIDEMIOLOGY, V44, P249, DOI 10.1159/000430917; JEFFERY DR, 1993, ARCH NEUROL-CHICAGO, V50, P532, DOI 10.1001/archneur.1993.00540050074019; KATUSIC SK, 1986, ANN NEUROL, V20, P622, DOI 10.1002/ana.410200511; Klein NP, 2010, VACCINE, V28, P1062, DOI 10.1016/j.vaccine.2009.10.115; Kuitunen I, 2020, PEDIATR INFECT DIS J, V39, pE423, DOI 10.1097/INF.0000000000002845; Lieu TA, 2007, MED CARE, V45, pS89, DOI 10.1097/MLR.0b013e3180616c0a; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Michelson KA, 2018, PEDIATR EMERG CARE, V16, P16; Nemet AY, 2015, J CLIN NEUROSCI, V22, P1949, DOI 10.1016/j.jocn.2015.04.030; Remschmidt C, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0882-3; Torjesen Ingrid, 2021, COVID 19 NORWAY INVE; Toru Takii, 2010, CIRC J; Whitaker HJ, 2009, STAT METHODS MED RES, V18, P7, DOI 10.1177/0962280208092342; Willame C, 2021, DRUG SAFETY, V44, P383, DOI 10.1007/s40264-020-01031-1; Yang MS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005750; Yeh RW, 2010, NEW ENGL J MED, V362, P2155, DOI 10.1056/NEJMoa0908610	23	12	12	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 6	2021	39	19					2712	2718		10.1016/j.vaccine.2021.03.016		APR 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RU2SP	33846042	Green Published, Bronze			2022-04-29	WOS:000645000500015
J	Allington, D; McAndrew, S; Moxham-Hall, VL; Duffy, B				Allington, Daniel; McAndrew, Siobhan; Moxham-Hall, Vivienne Louisa; Duffy, Bobby			Media usage predicts intention to be vaccinated against SARS-CoV-2 in the US and the UK	VACCINE			English	Article						Vaccine hesitancy; Media use; Voting history; Coronavirus; Covid-19	SOCIAL MEDIA; EXPOSURE; BELIEFS; INFORMATION; ACCEPTANCE; COVID-19; ONLINE; HEALTH	There is existing evidence of a relationship between media use and vaccine hesitancy. Four online questionnaires were completed by general population samples from the US and the UK in June 2020 (N = 1198, N = 3890, N = 1663, N = 2237). After controls, all four studies found a positive association between intention to be vaccinated and usage of broadcast and print media. The three studies which operationalised media usage in terms of frequency found no effect for social media. However, the study which operationalised media use in terms of informational reliance found a negative effect for social media. Youth, low household income, female gender, below degree-level of education, and membership of other than white ethnic groups were each also found to be associated with lower intentions to be vaccinated in at least two of the four studies. In all four studies, intention to be vaccinated was positively associated with having voted either for Hillary Clinton in the 2016 US presidential elections or for Labour Party candidates in the 2019 UK general election. Neither of the UK studies found an association with having voted for Conservative Party candidates, but both US studies found a negative association between intention to be vaccinated and having voted for Donald Trump. The consistent finding of greater intention to be vaccinated among users of legacy media but not among users of social media suggests that social media do not currently provide an adequate replacement for legacy media, at least in terms of public health communication. The finding of a negative association with social media in the study which measured informational reliance rather than frequency is consistent with the view that uncritical consumption of social media may be acting to promote vaccine hesitancy. (C) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Allington, Daniel] Kings Coll London, Dept Digital Humanities, London, England; [McAndrew, Siobhan] Univ Bristol, Sch Sociol Polit & Int Studies, Bristol, Avon, England; [Moxham-Hall, Vivienne Louisa; Duffy, Bobby] Kings Coll London, Policy Inst, London, England		Allington, D (通讯作者)，Kings Coll London, Dept Digital Humanities, London, England.	daniel.allington@kcl.ac.uk	Allington, Daniel/AAO-6928-2021	Allington, Daniel/0000-0002-5378-0552	Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/V015494/1]; King's College LondonGeneral Electric; Health Protection Research Unit for Emergency Preparedness and Response at the National Institute for Health Research	This work was supported by the Economic and Social Research Council, ES/V015494/1. Data for studies 1-3 were provided to the researchers free of charge by the Center for Countering Digital Hate. Data collection for study 4 was funded by King's College London and the Health Protection Research Unit for Emergency Preparedness and Response at the National Institute for Health Research.	Ahmed N, 2018, VACCINE, V36, P7556, DOI 10.1016/j.vaccine.2018.10.049; Allington D., 2021, PSYCHOL MED; Basch CH, 2017, CHILD CARE HLTH DEV, V43, P499, DOI 10.1111/cch.12442; BBC, 2020, COR US EC SEES SHARP; Bednarczyk RA, 2011, VACCINE, V29, P3138, DOI 10.1016/j.vaccine.2011.02.045; Biasio LR, 2020, ASSESSING COVID 19 V; Bou-Hamad I, 2020, COMMUN RES, V47, P55, DOI 10.1177/0093650216681896; Callaghan T, 2019, SOC SCI MED, V238, DOI 10.1016/j.socscimed.2019.112407; Carlson M, 2018, DIGIT JOURNAL, V6, P4, DOI 10.1080/21670811.2017.1298044; Catalan-Matamoros D, 2020, HUM VACC IMMUNOTHER, V16, P1055, DOI 10.1080/21645515.2019.1708163; Catalan-Matamoros D, 2019, REV LAT COMUN SOC, V74, P786, DOI 10.4185/RLCS-2019-1357; Catalan-Matamoros D, 2019, PERSPECT PUBLIC HEAL, V139, P34, DOI 10.1177/1757913918780142; Cates JR, 2009, J RURAL HEALTH, V25, P93, DOI 10.1111/j.1748-0361.2009.00204.x; Chong YY, 2020, INT J NURS STUD, V108, DOI 10.1016/j.ijnurstu.2020.103644; Cornwall W, 2020, SCIENCE, V369, P14, DOI 10.1126/science.369.6499.14; Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P1049, DOI [10.15585/mmwr.mm6932a1, 10.1101/2020.04.22.20076141v1]; Daley MF, 2018, AM J PREV MED, V55, P44, DOI 10.1016/j.amepre.2018.04.010; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Ditto, 2017, TRANSLATIONAL ISSUES, V3, P254, DOI [10.1037/tps0000121, DOI 10.1037/TPS0000121]; Dunn AG, 2017, VACCINE, V35, P3033, DOI 10.1016/j.vaccine.2017.04.060; Dunn AG, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4343; Fazekas KI, 2008, J WOMENS HLTH, V17; Featherstone JD, 2019, VACCINE, V37, P2993, DOI 10.1016/j.vaccine.2019.04.063; Feleszko W., 2020, SSRN SCHOLARLY PAPER; Forster AS, 2010, VACCINE, V28, P1673, DOI 10.1016/j.vaccine.2009.11.082; Fridman I, 2020, JMIR PUBLIC HLTH SUR, V6, P398, DOI 10.2196/22060; Garimella V.R.K., 2017, ICWSM 17; Garrett RK, 2016, J COMPUT-MEDIAT COMM, V21, P331, DOI 10.1111/jcc4.12164; Glanz JM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1117; Guidry JPD, 2015, VACCINE, V33, P5051, DOI 10.1016/j.vaccine.2015.08.064; Hitchens L, 2006, BROADCASTING PLURALI; Hornsey MJ, 2020, J EXP SOC PSYCHOL, V88, DOI 10.1016/j.jesp.2019.103947; Jeudin P, 2013, HUM VACC IMMUNOTHER, V9, P1413, DOI 10.4161/hv.24422; Jones-Jang SM, 2021, AM BEHAV SCI, V65, P371, DOI 10.1177/0002764219869406; Jylha KM, 2020, ANAL SOC ISS PUB POL, V20, P315, DOI 10.1111/asap.12203; Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112; Kennedy J, 2019, EUR J PUBLIC HEALTH, V29, P512, DOI 10.1093/eurpub/ckz004; Kim S, P INT AAAI C WEB SOC, V14, P949; Knuutila A., 2020, COMPROP DATA MEMO; Lewandowsky Stephan, 2020, J Cogn, V3, P9, DOI 10.5334/joc.99; Li HOY, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002604; Marchal N., 2020, SOCIAL MEDIA SOC, P1; Mason Lance E., 2018, J MEDIA LITERACY ED, V10, P1; Murphy J., 2020, PREPARING COVID 19 V; ONS, 2020, COR IMP OUTP UK EC; Perez S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3828-9; Pieraccini M, 2020, LEGAL PERSPECTIVES ON SUSTAINABILITY, P1, DOI 10.1016/S2215-0366(20)30308-4; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Reifler J., 2018, AVOIDING ECHOCHAMBER; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040; Stroud NJ, 2008, POLIT BEHAV, V30, P341, DOI 10.1007/s11109-007-9050-9; Tomljenovic H, 2020, PSYCHOL HEALTH, V35, P538, DOI 10.1080/08870446.2019.1673894; Vraga EK, 2018, INFORM COMMUN SOC, V21, P1337, DOI 10.1080/1369118X.2017.1313883; Wang YX, 2019, SOC SCI MED, V240, DOI 10.1016/j.socscimed.2019.112552; Warzel C, 2019, NEW YORK TIMES; Wicks RH, 2014, AM BEHAV SCI, V58, P1131, DOI 10.1177/0002764213506208; Yarchi M, 2021, POLIT COMMUN, V38, P98, DOI 10.1080/10584609.2020.1785067	60	8	8	16	26	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2595	2603		10.1016/j.vaccine.2021.02.054		APR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RQ1OX	33810905	Bronze			2022-04-29	WOS:000642189300017
J	Hasnan, S; Tan, NC				Hasnan, Syarafina; Tan, Ngiap Chuan			Multi-domain narrative review of vaccine hesitancy in childhood	VACCINE			English	Review						Vaccine hesitancy; Childhood vaccination; Domains; Child; Parent; Clinician; Healthcare system		Vaccine hesitancy, where individuals delay or refuse some or all vaccines, is a perennial problem. It undermines the success of the immunisation programmes and places the society, especially vulnerable populations such as children, at risk of contracting infectious diseases. The phenomenon has been extensively analysed based on four aspects - confidence, complacency, convenience and costs. We suggest the alternative use of a multi-dimensional framework adapted from the "Generalist Wheel of Knowledge, Understanding and Inquiry" that was developed by Prof Larry Green and Kurt Stange, to assess the multiple facilitators and barriers towards vaccine hesitancy in childhood vaccination. The framework identifies domains in the healthcare system namely the child and parent/family, the clinician, the healthcare system and policy, and the infectious disease and corresponding vaccine that influence vaccine hesitancy. This narrative review includes literature beyond those covered by the World health Organisation Global Vaccine Action Plan (WHO GVAP). It identifies emotional distress, past negative experience and misconceptions that contribute to vaccine hesitancy in children and family, while attitude and motivation underpin vaccine hesitancy in clinicians. The healthcare system contributes to vaccine hesitancy when enforcements, diligent monitoring and transparency are absent or lacking. Inefficient dissemination of information about the disease and its associated vaccine as well as inadequate surveillance of misinformation add to vaccine hesitancy. The inter-domain factors highlight the roles of relationship between the clinician, child and parent, information mastery of the clinician, prioritisation of resources and equity in combating vaccine hesitancy. Using this framework, we present evidence-based strategies which have been effective in mitigating vaccine hesitancy for each domain and their corresponding inter-domains. By providing new perspectives of a complex problem and its potential solutions, this narrative review aims to complement and support the WHO GVAP by developing a coordinated multi-domain strategy to mitigate vaccine hesitancy in childhood. (C) 2021 Published by Elsevier Ltd.	[Hasnan, Syarafina] Flinders Univ S Australia, Sturt Rd, Bedford Pk, SA 5042, Australia; [Tan, Ngiap Chuan] SingHlth Polyclin, 167 Jalan Bukit Merah,Connect One Tower 5,15-10, Singapore 160267, Singapore		Tan, NC (通讯作者)，SingHlth Polyclin, 167 Jalan Bukit Merah,Connect One Tower 5,15-10, Singapore 160267, Singapore.	hasn0009@flinders.edu.au; tan.ngiap.chuan@singhealth.com.sg					Ahmad J., 2019, REUTERS; Alshammari TM, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4054-9; Attwell K, 2015, VACCINE, V33, P6235, DOI 10.1016/j.vaccine.2015.09.092; Bach AT, 2015, INTEGR PHARM RES PRA, V4, P67, DOI 10.2147/IPRP.S63822; Baethge C, 2019, RES INTEGR PEER REV, V4, DOI 10.1186/s41073-019-0064-8; Barrows MA, 2015, J PEDIATR HEALTH CAR, V29, P385, DOI 10.1016/j.pedhc.2015.04.019; Baxter AL, 2017, VACCINE, V35, P4213, DOI 10.1016/j.vaccine.2017.06.029; Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728; Bhat-Schelbert K, 2012, VACCINE, V30, P2448, DOI 10.1016/j.vaccine.2012.01.049; Birmingham E, 2011, PREV MED, V52, P274, DOI 10.1016/j.ypmed.2011.01.008; Bone A, 2010, VACCINE, V28, P8157, DOI 10.1016/j.vaccine.2010.09.096; Boom JA, 2014, SPRBRIEF PUB HEALT, P19, DOI 10.1007/978-3-319-07563-1_5; Chow MYK, 2017, AUST FAM PHYSICIAN, V46, P145; Corben P, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5389-6; DeLong G, 2012, ACCOUNT RES, V19, P65, DOI 10.1080/08989621.2012.660073; Dodd D, 2003, AM J MANAG CARE, V9, pS6; Dolan SB, 2019, VACCINE, V37, P1859, DOI 10.1016/j.vaccine.2019.02.017; Drew L, 2019, NATURE, V575, pS58, DOI 10.1038/d41586-019-03642-w; Drezner K, 2015, J PUBLIC HEALTH MAN, V21, P263, DOI 10.1097/PHH.0000000000000197; Dube E, 2018, EXPERT REV VACCINES, V17, P989, DOI 10.1080/14760584.2018.1541406; Dube E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156118; Eddy M, 2019, NEW YORK TIMES; Eibl MM, 2015, IMMUNOTHERAPY-UK, V7, P1273, DOI 10.2217/IMT.15.74; Fairbrother G, 2001, AMBUL PEDIATR, V1, P206, DOI 10.1367/1539-4409(2001)001<0206:IOFIOD>2.0.CO;2; Fokoun C, 2018, HUM VACC IMMUNOTHER, V14, P1580, DOI 10.1080/21645515.2018.1458807; Freed GL, 2011, PEDIATRICS, V127, pS107, DOI 10.1542/peds.2010-1722P; Gold MS, 2020, VACCINE, V38, P3025, DOI 10.1016/j.vaccine.2020.02.046; Grabenstein JD, 2013, VACCINE, V31, P2011, DOI 10.1016/j.vaccine.2013.02.026; Grady C, 2004, NAT IMMUNOL, V5, P465, DOI 10.1038/ni0504-465; Gregoire MC, 2019, CAN MED ASSOC J, V191, pE676, DOI 10.1503/cmaj.109-5763; Groom H, 2015, J PUBLIC HEALTH MAN, V21, P227, DOI 10.1097/PHH.0000000000000069; Hansen ND, 2019, JMIR PUBLIC HLTH SUR, V5, P209, DOI 10.2196/publichealth.9544; Hull B. P, 2017, IMMUNISATION COVERAG; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Kelly Jacalyn, 2014, EJIFCC, V25, P227; Kempe A, 2011, AM J PREV MED, V40, P548, DOI 10.1016/j.amepre.2010.12.025; Koslap-Petraco M, 2019, J AM ASSOC NURSE PRA, V31, P624, DOI 10.1097/JXX.0000000000000342; Kreuter MW, 2012, FAM COMMUNITY HEALTH, V35, P15, DOI 10.1097/FCH.0b013e3182385d13; Kumar MM, 2019, CLIN PEDIATR, V58, P17, DOI 10.1177/0009922818805217; Ladhani S, 2011, VACCINE, V29, P9137, DOI 10.1016/j.vaccine.2011.09.107; MacDonald NE, 2018, HUM VACC IMMUNOTHER, V14, P218, DOI 10.1080/21645515.2017.1394533; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003; McSherry LA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208482; Meissner H. C, 2016, AAP NEWS; Moss JL, 2016, SOC SCI MED, V159, P100, DOI 10.1016/j.socscimed.2016.04.030; Ngui Emmanuel M, 2015, WMJ, V114, P10; Omer SB, 2019, NATURE, V571, P469, DOI 10.1038/d41586-019-02232-0; Orenstein WA, 2015, PUBLIC HEALTH REP, V130, P573; Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Payne DC, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-83; Polillio A M, 1997, Pediatr Nurs, V23, P46; Rao T S Sathyanarayana, 2011, Indian J Psychiatry, V53, P95, DOI 10.4103/0019-5545.82529; Riaz A, 2018, VACCINE, V36, P5288, DOI 10.1016/j.vaccine.2018.07.024; Rigby MJ, 2020, EUR J PUBLIC HEALTH, V30, P449, DOI 10.1093/eurpub/ckz199; Robbins SCC, 2010, SEX HEALTH, V7, P271, DOI 10.1071/SH09140; Roser M., 2019, VACCINATION; Ruffin MT, 2015, J AM BOARD FAM MED, V28, P324, DOI 10.3122/jabfm.2015.03.140082; Ruffin MT, 2019, FAM MED, V51, P786, DOI 10.22454/FamMed.2019.959213; Santhanes D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21912-x; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schoeppe J, 2017, HEALTH PROMOT PRACT, V18, P654, DOI 10.1177/1524839917697303; Schwartz Jason L, 2012, Virtual Mentor, V14, P50, DOI 10.1001/virtualmentor.2012.14.1.mhst1-1201; Shen SX, 2019, CAN FAM PHYSICIAN, V65, P175; Sherman SM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197648; Shibli R, 2019, VACCINE, V37, P524, DOI 10.1016/j.vaccine.2018.11.051; Singer A, 2010, NJ PCORE VFC C 9 10; Singh K, 2016, J POSTGRAD MED, V62, P4, DOI 10.4103/0022-3859.173187; Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187; Stange KC, 2001, FAM MED, V33, P286; Stevens Kristen E, 2016, Pediatr Nurs, V42, P267; Stinchfield PK, 2008, AM J MED, V121, pS11, DOI 10.1016/j.amjmed.2008.05.003; Taddio A, 2019, PAED CHILD HEALT-CAN, V24, pS3, DOI 10.1093/pch/pxz025; Taddio A, 2010, CAN MED ASSOC J, V182, pE843, DOI 10.1503/cmaj.101720; Taddio A, 2009, CLIN THER, V31, pS152, DOI 10.1016/j.clinthera.2009.07.022; Tsai Y, 2018, MED CARE, V56, P54, DOI 10.1097/MLR.0000000000000844; Tull K, 2019, 672 K4D HELPD I DEV; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Walkinshaw E, 2011, CAN MED ASSOC J, V183, pE1167, DOI 10.1503/cmaj.109-3993; Wallis J, 2019, CLIN EXP IMMUNOL, V196, P189, DOI 10.1111/cei.13287; Whewell T., 2019, BBC; WHO, 2016, VACCINE, V34, P3629, DOI 10.1016/j.vaccine.2015.11.005; Wilson K, 2017, HUM VACC IMMUNOTHER, V13, P1155, DOI 10.1080/21645515.2016.1271519; Yarnoff B, 2019, MED CARE, V57, P410, DOI 10.1097/MLR.0000000000001117; Zhang EJ, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025866	86	1	1	5	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 1	2021	39	14					1910	1920		10.1016/j.vaccine.2021.02.057		MAR 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RC7NX	33750590				2022-04-29	WOS:000632984100006
J	Das, SC; Price, JD; Gosling, K; MacLennan, N; Ataide, R; Seow, J; Irani, V; Atmosukarto, II; Anders, RF; Richards, JS; MacRaild, CA; Norton, RS				Das, Sreedam C.; Price, Jason D.; Gosling, Katharine; MacLennan, Nicola; Ataide, Ricardo; Seow, Jeffrey; Irani, Vashti; Atmosukarto, Ines I.; Anders, Robin F.; Richards, Jack S.; MacRaild, Christopher A.; Norton, Raymond S.			Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2	VACCINE			English	Article						Malaria; Merozoite surface protein 2; Liposome; Conserved epitope; Immune response; Complement fixation	PLASMODIUM-FALCIPARUM; IMMUNOGENICITY; SAFETY; ADULTS	Merozoite surface protein 2 (MSP2) is a highly abundant, GPI-anchored surface antigen on merozoites of the malaria parasite Plasmodium falciparum. It consists of highly conserved N- and C-terminal domains, and a central polymorphic region that allows all MSP2 alleles to be categorized into the 3D7 or FC27 family. Previously it has been shown that epitope accessibility differs between lipid-bound and lipid-free MSP2, suggesting that lipid interactions modulate the conformation and antigenicity in a way that may better mimic native MSP2 on the merozoite surface. Therefore, we have immunised mice with MSP2 engrafted onto liposomes using a C-terminal tether that mimics the native GPI anchor. To improve the immunogenicity of the formulated antigen, liposomes were supplemented with Pathogen Associated Molecular Pattern molecules, specifically agonists of the Toll-like receptor 4 (TLR4) or TLR2. Induced antibodies were directed mostly towards conserved epitopes, predominantly in the conserved C-terminal region of MSP2. We also found that immunisation with a combination of 3D7 and FC27 MSP2 enhanced antibody responses to conserved epitopes, and that the overall responses of mice immunised with MSP2-engrafted liposomes were comparable in magnitude to those of mice immunised with MSP2 formulated in Montanide ISA720. The antibodies elicited in mice by immunising with MSP2-engrafted liposomes recognised the native form of parasite MSP2 on western blots and were found to be cross-reactive with isolated 3D7 and FC27 merozoites when investigated by ELISA. The liposome-tethered MSP2 induced higher titres of complement-fixing antibodies to 3D7 and FC27 MSP2 than did MSP2 formulated in Montanide ISA720. Our results indicate that liposomal formulation represents a viable strategy for eliciting a strong immune response that favours conserved epitopes in MSP2 and thus a strain-transcendent immune response. (C) 2021 Elsevier Ltd. All rights reserved.	[Das, Sreedam C.; Seow, Jeffrey; MacRaild, Christopher A.; Norton, Raymond S.] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, Parkville, Vic 3052, Australia; [Price, Jason D.; Gosling, Katharine; MacLennan, Nicola; Atmosukarto, Ines I.] Lipotek Pty Ltd, Canberra, ACT 2601, Australia; [Ataide, Ricardo; Irani, Vashti; Richards, Jack S.] Burnet Inst, Ctr Biomed Res, Melbourne, Vic 3004, Australia; [Anders, Robin F.] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic 3086, Australia; [Norton, Raymond S.] Monash Univ, ARC Ctr Fragment Based Design, Parkville, Vic 3052, Australia		MacRaild, CA; Norton, RS (通讯作者)，Monash Inst Pharmaceut Sci, 381 Royal Parade, Parkville, Vic 3052, Australia.	chris.macraild@monash.edu; ray.norton@monash.edu	Ataide, Ricardo/B-7307-2017	Ataide, Ricardo/0000-0002-1014-0432; Norton, Raymond/0000-0001-8893-0584; Das, Sreedam/0000-0002-7587-0065; Richards, Jack/0000-0001-5786-6989; Seow, Jeffrey/0000-0003-0722-8561	Australian National Health and Medical Research Council (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [1042520, 1125788]; NHMRCNational Health and Medical Research Council (NHMRC) of Australia; Faculty of Pharmacy and Pharmaceutical Sciences; Monash Graduate Scholarships	This work was supported in part by Australian National Health and Medical Research Council (NHMRC) grants 1042520 and 1125788 to JSR, CAM and RSN. RSN acknowledges fellowship support from the NHMRC. SCD was supported by Faculty of Pharmacy and Pharmaceutical Sciences and Monash Graduate Scholarships.	Adda CG, 2012, INFECT IMMUN, V80, P4177, DOI 10.1128/IAI.00665-12; Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Anders RF, 2010, HUM VACCINES, V6, P39, DOI 10.4161/hv.6.1.10712; Bale S, 2017, J VIROL, V91, DOI 10.1128/JVI.00443-17; Bovier PA, 2008, EXPERT REV VACCINES, V7, P1141, DOI 10.1586/14760584.7.8.1141; Boyle MJ, 2015, IMMUNITY, V42, P580, DOI 10.1016/j.immuni.2015.02.012; Boyle MJ, 2013, INT J PARASITOL, V43, P1, DOI 10.1016/j.ijpara.2012.11.002; Butts C, 2005, J CLIN ONCOL, V23, P6674, DOI 10.1200/JCO.2005.13.011; Cabrera G, 2004, INFECT IMMUN, V72, P284, DOI 10.1128/IAI.72.1.284-294.2004; Das SC, 2017, FEBS J, V284, P2649, DOI 10.1111/febs.14135; DRUILHE P, 1987, INFECT IMMUN, V55, P888, DOI 10.1128/IAI.55.4.888-891.1987; Duah NO, 2010, PARASITE IMMUNOL, V32, P125, DOI 10.1111/j.1365-3024.2009.01165.x; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; Duncan CJA, 2012, HUM VACC IMMUNOTHER, V8, P706, DOI 10.4161/hv.19712; Dutta S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003840; Eacret JS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45440-4; Feng GQ, 2018, J INFECT DIS, V218, P35, DOI 10.1093/infdis/jiy170; FENTON B, 1991, MOL CELL BIOL, V11, P963, DOI 10.1128/MCB.11.2.963; FRIES LF, 1992, P NATL ACAD SCI USA, V89, P358, DOI 10.1073/pnas.89.1.358; Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342; Genton B, 2000, VACCINE, V18, P2504, DOI 10.1016/S0264-410X(00)00036-0; Genton B, 2003, VACCINE, V22, P30, DOI 10.1016/S0264-410X(03)00536-X; Huang WC, 2018, NAT NANOTECHNOL, V13, P1174, DOI 10.1038/s41565-018-0271-3; JONES GL, 1991, MOL BIOCHEM PARASIT, V48, P1, DOI 10.1016/0166-6851(91)90158-3; Kusi KA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-182; Kusi KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015391; LEATHERBARROW RJ, 1984, MOL IMMUNOL, V21, P321, DOI 10.1016/0161-5890(84)90103-2; Lilienthal GM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00958; MacRaild CA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119899; MacRaild CA, 2012, BBA-BIOMEMBRANES, V1818, P2572, DOI 10.1016/j.bbamem.2012.06.015; McCarthy JS, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0024413, 10.1371/journal.pone.0021914]; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Mischler R, 2002, VACCINE, V20, pB17, DOI 10.1016/S0264-410X(02)00512-1; Morales RAV, 2015, SCI REP-UK, V5, DOI 10.1038/srep10103; Osier FHA, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-108; Pejawar-Gaddy S, 2014, BIOCONJUGATE CHEM, V25, P1470, DOI 10.1021/bc5002246; Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030; Reiling L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08528-z; Schuerman L, 2019, LANCET, V394, P735, DOI 10.1016/S0140-6736(19)31567-3; Schwendener Reto A, 2014, Ther Adv Vaccines, V2, P159, DOI 10.1177/2051013614541440; Shao S, 2015, NAT CHEM, V7, P438, DOI [10.1038/NCHEM.2236, 10.1038/nchem.2236]; Smith MT, 2013, CURR OPIN BIOTECH, V24, P620, DOI 10.1016/j.copbio.2013.01.011; SMYTHE JA, 1991, P NATL ACAD SCI USA, V88, P1751, DOI 10.1073/pnas.88.5.1751; TAYLOR RR, 1995, INFECT IMMUN, V63, P4382, DOI 10.1128/IAI.63.11.4382-4388.1995; Taylor RR, 1998, AM J TROP MED HYG, V58, P406, DOI 10.4269/ajtmh.1998.58.406; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Tongren JE, 2005, INFECT IMMUN, V73, P8119, DOI 10.1128/IAI.73.12.8119-8129.2005; Uchida T, 2014, JPN J INFECT DIS, V67, P235, DOI 10.7883/yoken.67.235; van Broekhoven CL, 2004, CANCER RES, V64, P4357, DOI 10.1158/0008-5472.CAN-04-0138; van Dissel JT, 2014, VACCINE, V32, P7098, DOI 10.1016/j.vaccine.2014.10.036; Watson DS, 2011, CLIN VACCINE IMMUNOL, V18, P289, DOI 10.1128/CVI.00425-10; Zhang XC, 2008, J MOL BIOL, V379, P105, DOI 10.1016/j.jmb.2008.03.039	52	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 19	2021	39	12					1746	1757		10.1016/j.vaccine.2021.02.010		MAR 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QX3ZD	33618946				2022-04-29	WOS:000629283700012
J	Chang, LJ; Anderson, EJ; Jeanfreau, R; He, Y; Hicks, B; Shrestha, A; Pandey, A; Landolfi, V; DeBruijn, I				Chang, Lee-Jah; Anderson, Evan J.; Jeanfreau, Robert; He, Ying; Hicks, Bryony; Shrestha, Anju; Pandey, Aseem; Landolfi, Victoria; DeBruijn, Iris		QHD04 Study Grp	Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through < 18 years of age: A randomized controlled phase II dose-finding trial	VACCINE			English	Article						Influenza vaccination; High-dose; Pediatric; IIV4-HD; Safety; Immunogenicity		Quadrivalent high-dose inactivated influenza vaccine (Fluzone (R) High-Dose Quadrivalent, IIV4-HD) was licensed in the USA in 2019 for adults >= 65 years of age. This Phase II study examined safety and immunogenicity of 3 dose formulations of IIV4-HD in healthy children. In a randomized, modified double-blind, active-controlled trial in the USA and Canada, 661 children aged 6 months through < 18 years received 1 or 2 doses intramuscularly of standard-dose quadrivalent influenza vaccine (IIV4-SD; 15 mg HA/strain), IIV4-HD at 3 dose levels (30, 45, and 60 mu g HA/strain), or adjuvanted trivalent influenza vaccine (aIIV3, 7.5 mu g HA/strain). Rates of unsolicited AEs were similar irrespective of dose. No treatment-related serious adverse events or deaths were reported. Reactogenicity was slightly higher for IIV4-HD than IIV4-SD, although most solicited reactions were grade 1 or 2. Hemagglutination inhibition (HAI) and seroneutralization antibody titers were measured 28-35 days after each dose. Geometric mean HAI titers increased with increasing hemagglutinin dose, especially in children 6 months through < 3 years. For IIV4-HD 60 mu g, in participants 6 months through < 18 years of age, the geometric mean titer ratio (95% confidence interval) versus IIV4-SD was 1.35 (0.94, 1.94) for A/H1N1, 2.51 (1.77, 3.55) for A/H3N2, 1.60 (1.17, 2.18) for B/Victoria, and 1.51 (1.13, 2.03) for B/Yamagata. The GMT ratio (95% confidence interval) for IIV4-HD 60 mu g versus IIV4-SD was highest for participants 6 months through < 3 years of age: 4.24 (2.05, 8.76) for A/H1N1, 3.14 (1.53, 6.44) for A/H3N2, 2.04 (1.10, 3.77) for B/Victoria, and 1.92 (1.08, 3.41) for B/Yamagata; similarly, seroneutralization antibody GMT ratio was highest in these participants: 170 (84.6, 340) for A/H1N1, 7.13 (4.90, 10.4) for A/H3N2, 35.8 (22.1, 58.1) for B/Victoria, and 22.7 (14.7, 35.0) for B/Yamagata. This study showed that IIV4-HD (60 mg HA/strain) provides improved immunogenicity without affecting vaccine safety in children. (C) 2021 The Authors. Published by Elsevier Ltd.	[Chang, Lee-Jah; He, Ying; Hicks, Bryony; Pandey, Aseem; Landolfi, Victoria] Sanofi Pasteur, Res & Dev, Swiftwater, PA 18370 USA; [Anderson, Evan J.] Emory Univ, Ctr Childhood Infect & Vaccines CCIV Childrens He, Atlanta, GA USA; [Anderson, Evan J.] Emory Univ, Dept Pediat, Dept Med, Sch Med, Atlanta, GA USA; [Jeanfreau, Robert] MedPharm, Metairie, LA USA; [Shrestha, Anju] Sanofi Pasteur, Global Pharmacovigilance, Swiftwater, PA 18370 USA; [DeBruijn, Iris] Sanofi Pasteur, Res & Dev, Marcy Letoile, France; [He, Ying] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA		Chang, LJ (通讯作者)，Sanofi Pasteur, Global Clin Dev, 1 Discovery Dr, Swiftwater, PA 18370 USA.	lee-jah.chang@sanofi.com; evanderson@emory.edu; robertjeanfreau@medpharmics.com; ying.he@ot-suka-us.com; bryony.hicks@sanofi.com; anju.Shrestha@sanofi.com; aseem.Pandey@sanofi.com; victoria.landolfi@sanofi.com; iris.debruijn@sanofi.com			Sanofi Pasteur	This study was supported by Sanofi Pasteur.; Role of The Funding Source This work was supported by Sanofi Pasteur.	[Anonymous], 1995, ICH E2A CLIN SAF DAT; Chang LJ, 2019, VACCINE, V37, P5825, DOI 10.1016/j.vaccine.2019.08.016; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790; GiaQuinta S, 2015, PEDIATR TRANSPLANT, V19, P219, DOI 10.1111/petr.12419; Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7; Greenberg DP, 2013, VACCINE, V31, P770, DOI 10.1016/j.vaccine.2012.11.074; Hakim H, 2016, VACCINE, V34, P3141, DOI 10.1016/j.vaccine.2016.04.053; Halasa NB, 2015, J PEDIAT INF DIS SOC, V4, P214, DOI 10.1093/jpids/piu061; Jain VK, 2017, J PEDIATR INFECT DIS, V6, P9, DOI 10.1093/jpids/piw068; Lee JKH, 2018, EXPERT REV VACCINES, V17, P435, DOI 10.1080/14760584.2018.1471989; LEPOW ML, 1977, J INFECT DIS, V136, pS601, DOI 10.1093/infdis/136.Supplement_3.S601; McManus M, 2014, PEDIATR BLOOD CANCER, V61, P815, DOI 10.1002/pbc.24863; Moriarty LF, 2014, HUM VACC IMMUNOTHER, V10, P2721, DOI 10.4161/hv.29669; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Poehling KA, 2013, PEDIATRICS, V131, P207, DOI 10.1542/peds.2012-1255; Robertson CA, 2019, PEDIATR INFECT DIS J, V38, P323, DOI 10.1097/INF.0000000000002227; Robison SG, 2018, VACCINE, V36, P6683, DOI 10.1016/j.vaccine.2018.09.050; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Samson SI, 2019, EXPERT REV VACCINES, V18, P295, DOI 10.1080/14760584.2019.1575734; Sanchez L, 2020, HUM VACC IMMUNOTHER, V16, P858, DOI 10.1080/21645515.2019.1677437; Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641; Stephenson I, 2004, VIRUS RES, V103, P91, DOI 10.1016/j.virusres.2004.02.019; Vesikari T, 2018, LANCET RESP MED, V6, P345, DOI [10.1016/S2213-2600(18)30108-5, 10.1016/s2213-2600(18)30108-5]; Yinong YX, 2019, VACCINE, V37, P1484, DOI 10.1016/j.vaccine.2019.01.063; Young-Xu YN, 2018, J INFECT DIS, V217, P1718, DOI 10.1093/infdis/jiy088	27	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 12	2021	39	11					1572	1582		10.1016/j.vaccine.2021.02.014		FEB 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QP4DD	33610374	hybrid			2022-04-29	WOS:000623785800005
J	Palmu, AA; De Wals, P; Toropainen, M; Ladhani, SN; Deceuninck, G; Knol, MJ; Sanders, EAM; Miller, E				Palmu, Arto A.; De Wals, Philippe; Toropainen, Maija; Ladhani, Shamez N.; Deceuninck, Genevieve; Knol, Mirjam J.; Sanders, Elisabeth A. M.; Miller, Elizabeth			Similar impact and replacement disease after pneumococcal conjugate vaccine introduction in hospitalised children with invasive pneumococcal disease in Europe and North America	VACCINE			English	Article						Vaccination; Streptococcus pneumoniae; Conjugate vaccines; Surveillance; Bias		High incidence of childhood invasive pneumococcal disease (IPD) in the US declined steeply after 7-valent pneumococcal conjugate vaccine (PCV7) introduction, outweighing reductions observed elsewhere. We re-analysed aggregate published data and compared pre- and post-PCV IPD-incidence in different countries to explore PCV impact on hospitalised and outpatient IPD separately. The proportion of hospitalised IPD cases was consistently high (>80%) in England&Wales, Finland, the Netherlands, and Quebec/Canada, but only 32% in the US before PCV introduction, increasing to 69% during the PCV era. In the US, a higher reduction in outpatient IPD incidence (94% in 2015 versus 1998-99) was observed compared to hospitalised IPD (79%); a 51% reduction in the non-PCV13-type IPD incidence among outpatient cases was estimated compared to a >2-fold increase for hospitalised cases. After stratification by hospitalization status, PCV programmes resulted in similar impact and serotype replacement in hospitalised IPD in US when compared to other countries. Crown Copyright (C) 2021 Published by Elsevier Ltd. All rights reserved.	[Palmu, Arto A.] Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, Tampere, Finland; [De Wals, Philippe] Laval Univ, Dept Social & Prevent Med, Quebec City, PQ, Canada; [Toropainen, Maija] Finnish Inst Hlth & Welf, Dept Hlth Secur, Helsinki, Finland; [Ladhani, Shamez N.; Miller, Elizabeth] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London, England; [Ladhani, Shamez N.] St Georges Univ London, Paediat Infect Dis Res Grp, London, England; [Deceuninck, Genevieve] Quebec Univ Hosp Res Ctr, Quebec City, PQ, Canada; [Knol, Mirjam J.; Sanders, Elisabeth A. M.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands; [Sanders, Elisabeth A. M.] Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands		Palmu, AA (通讯作者)，THL, Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, Finn Medi 1,Biokatu 6, Tampere 33520, Finland.	arto.palmu@thl.fi			GlaxoSmithKlineGlaxoSmithKline; PfizerPfizer; Sanofi	AAP and MT report grants from GlaxoSmithKline, Pfizer, and Sanofi to the Finnish Institute for Health and Welfare for research projects in which they are investigators. PDW received research grants from GSK, Pfizer and Sanofi. SNL performs contract work on behalf of St. George's University of London for pharmaceutical companies, including vaccine manufacturers but does not receive any personal remuneration. EAMS reports grant from GlaxoSmithKline and Pfizer to the University Medical Center Utrecht for research projects in which she was an investigator. All other authors declare no competing interests.	Carstairs KL, 2007, ANN EMERG MED, V49, P772, DOI 10.1016/j.annemergmed.2006.10.026; De Wals P, 2018, VACCINE, V36, P421, DOI 10.1016/j.vaccine.2017.11.054; De Wals P, 2014, VACCINE, V32, P1501, DOI 10.1016/j.vaccine.2013.11.028; Hicks LA, 2007, J INFECT DIS, V196, P1346, DOI 10.1086/521626; Knol MJ, 2015, EMERG INFECT DIS, V21, P2040, DOI 10.3201/eid2111.140780; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Lewnard JA, 2019, LANCET INFECT DIS, V19, pE213, DOI 10.1016/S1473-3099(18)30660-1; Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1; Moore MR, 2016, LANCET RESP MED, V4, P399, DOI 10.1016/S2213-2600(16)00052-7; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Palmu AA, 2014, LANCET RESP MED, V2, P717, DOI 10.1016/S2213-2600(14)70139-0; Palmu AA, 2015, PEDIATRICS, V136, pE22, DOI 10.1542/peds.2015-0458; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Rinta-Kokko H, 2018, VACCINE, V36, P1934, DOI 10.1016/j.vaccine.2018.03.001; Rodenburg GD, 2010, EMERG INFECT DIS, V16, P816, DOI 10.3201/eid1605.091223; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Wilkinson M, 2009, ACAD EMERG MED, V16, P220, DOI 10.1111/j.1553-2712.2008.00328.x; Zeretzke CM, 2012, PEDIATR EMERG CARE, V28, P640, DOI 10.1097/PEC.0b013e31825cfd3e	18	3	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 12	2021	39	11					1551	1555		10.1016/j.vaccine.2021.01.070		FEB 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QP4DD	33610373	Green Accepted, hybrid			2022-04-29	WOS:000623785800002
J	Blunck, BN; Aideyan, L; Ye, XY; Avadhanula, V; Ferlic-Stark, L; Zechiedrich, L; Gilbert, BE; Piedra, PA				Blunck, Brittani N.; Aideyan, Letisha; Ye, Xunyan; Avadhanula, Vasanthi; Ferlic-Stark, Laura; Zechiedrich, Lynn; Gilbert, Brian E.; Piedra, Pedro A.			A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas	VACCINE			English	Article						Neutralizing antibody; Competitive antibody; Binding antibody; Original antigenic sin; Vaccine; Respiratory viruses	ORIGINAL ANTIGENIC SIN; HUMAN METAPNEUMOVIRUS; INFECTION; CHILDREN; VACCINE; RSV; HOSPITALIZATION; ANTIBODY; ILLNESS; YOUNG	Respiratory syncytial virus (RSV)-specific serum antibody has been correlated to protection of infection and reduction of severe disease, but reinfection is still frequent. In this study, we evaluated RSV-specific serum antibody activity following natural RSV re-infection to examine the longevity of the humoral immune response in adults. Nineteen healthy adult volunteers under sixty-five years of age were enrolled during the 2018-2019 RSV season in Houston, TX. Blood was collected at three study visits. The kinetics of RSV-neutralizing, RSV F site-specific competitive, and RSV-binding antibodies in serum samples were measured by microneutralization and enzyme-linked immunosorbent assays. Three distinct profiles of RSV-specific antibody kinetics were identified that were consistent with RSV infection status: uninfected, acutely infected, and recently infected. The uninfected group had stable antibody titers for the duration of the study period (185 days). The acutely infected group had lower antibody responses at the beginning of the study, supporting a correlate of infection, followed by a significant antibody response after infection that was maintained for at least 125 days. Unlike the acutely infected group, the recently infected group had a significant precipitous decrease in RSV antibody in only 60 days. This study is the first, to our knowledge, to describe this abrupt loss of RSV-specific antibody in detail. This rapid decline of antibody may present an obstacle for the development of vaccines with lasting protection against RSV, and perhaps other respiratory pathogens. Neutralizing antibody responses were greater to prototypic than contemporaneous RSV strains, regardless of infection status, indicating that original antigenic sin may impact the humoral immune response to new or emerging RSV strains. (C) 2021 Elsevier Ltd. All rights reserved.	[Blunck, Brittani N.; Aideyan, Letisha; Ye, Xunyan; Avadhanula, Vasanthi; Ferlic-Stark, Laura; Zechiedrich, Lynn; Gilbert, Brian E.; Piedra, Pedro A.] Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Zechiedrich, Lynn] Verna & Marrs McLean, Dept Biochem & Mol Biol, Houston, TX USA; [Zechiedrich, Lynn] Dept Pharmacol & Chem Biol, Houston, TX USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA		Piedra, PA (通讯作者)，Dept Mol Virol & Microbiol, Houston, TX 77030 USA.; Piedra, PA (通讯作者)，Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.	ppiedra@bcm.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01GM115501]	Funding was from discretionary funds from PAP and BEG, and NIH grant R01GM115501 to LZ.	Avadhanula V, 2015, J INFECT DIS, V211, P582, DOI 10.1093/infdis/jiu473; Branche AR, 2015, DRUG AGING, V32, P261, DOI 10.1007/s40266-015-0258-9; Chen YZ, 2020, CELL, V183, P1496, DOI 10.1016/j.cell.2020.10.051; Falsey AR, 2006, J MED VIROL, V78, P1493, DOI 10.1002/jmv.20724; Garcia DF, 2007, PEDIATR PULM, V42, P66, DOI 10.1002/ppul.20546; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Habibi MS, 2015, AM J RESP CRIT CARE, V191, P1040, DOI 10.1164/rccm.201412-2256OC; Hause AM, 2018, J INFECT DIS, V218, P528, DOI 10.1093/infdis/jiy167; Hause AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175792; Lee FEH, 2004, ANTIVIR RES, V63, P191, DOI 10.1016/j.antiviral.2004.04.005; Luchsinger V, 2012, CLIN INFECT DIS, V54, P905, DOI 10.1093/cid/cir955; Matias G, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4177-z; McLellan JS, 2013, CURR TOP MICROBIOL, V372, P83, DOI 10.1007/978-3-642-38919-1_4; Moreira LP, 2018, INFLUENZA OTHER RESP, V12, P326, DOI 10.1111/irv.12518; Piedra PA, 2003, VACCINE, V21, P2448, DOI 10.1016/S0264-410X(03)00098-7; Piedra PA, 2003, VACCINE, V21, P3479, DOI 10.1016/S0264-410X(03)00355-4; PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3; Piedra PA, 1996, PEDIATR INFECT DIS J, V15, P23, DOI 10.1097/00006454-199601000-00006; Piedra PA, 2016, METHODS MOL BIOL, V1442, P77, DOI 10.1007/978-1-4939-3687-8_7; Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014; Schickli JH, 2005, J VIROL, V79, P10678, DOI 10.1128/JVI.79.16.10678-10689.2005; Shi T, 2020, J INFECT DIS, V222, pS577, DOI 10.1093/infdis/jiz059; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Singh A, 2006, EPA600R06022, DOI [10.3389/ fimmu.2019.00706, DOI 10.3389/FIMMU.2019.00706]; Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P398, DOI 10.1016/j.jaci.2008.10.043; Tan L, 2013, J VIROL, V87, P8213, DOI 10.1128/JVI.03278-12; Tapia LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090786; Terrosi C, 2009, EPIDEMIOL INFECT, V137, P1684, DOI 10.1017/S0950268809002593; Trento A, 2003, J GEN VIROL, V84, P3115, DOI 10.1099/vir.0.19357-0; Vatti A, 2017, J AUTOIMMUN, V83, P12, DOI 10.1016/j.jaut.2017.04.008; Wyde PR, 2005, ANTIVIR RES, V66, P57, DOI 10.1016/j.antiviral.2004.12.009; Ye XY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00706; Ye XY, 2018, J INFECT DIS, V217, P1247, DOI 10.1093/infdis/jiy026; Zhang A, 2019, J IMMUNOL, V202, P335, DOI 10.4049/jimmunol.1801149; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	35	2	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1248	1256		10.1016/j.vaccine.2021.01.045		FEB 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33509697	Green Accepted			2022-04-29	WOS:000618493500013
J	Ly, TDA; Castaneda, S; Hoang, VT; Dao, TL; Gautret, P				Tran Duc Anh Ly; Castaneda, Sergei; Van Thuan Hoang; Thi Loi Dao; Gautret, Philippe			Vaccine-preventable diseases other than tuberculosis, and homelessness: A scoping review of the published literature, 1980 to 2020	VACCINE			English	Review						Homelessness; Outbreak; Vaccine-preventable diseases; Immunization; Vaccination recommendation	INJECTION-DRUG USERS; HEPATITIS-B-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INVASIVE PNEUMOCOCCAL DISEASE; RISK-FACTORS; CORYNEBACTERIUM-DIPHTHERIAE; VIRAL-HEPATITIS; SUBSTANCE USE; A SEROPREVALENCE; HEALTH-SERVICES	Background: Homelessness may result in the breakdown of regular health services, including routine vaccination programmes. A scoping review was conducted to describe vaccine-preventable diseases (VPD) other than tuberculosis in people experiencing homelessness (PEH). Methods: We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). We searched peer-reviewed literature published in English, French, Spanish or Portuguese reporting the outbreak of VPD or VPD prevalence in both infant and adult homeless populations published between 1980 and 2020, using PubMed/Medline, SciELO, Google Scholar, and Web of Science databases. Relevant information from the studies was charted in Microsoft Excel and results were summarised using a descriptive analytical method. Results: Eighty-one articles were included. A high prevalence of past hepatitis B virus (HBV) and hepatitis A virus (HAV) infections were observed through serosurveys, mostly in high income countries or high-middle income countries (USA, Canada, France, Iran or Brazil). Ten outbreaks of HAV infection were also reported, with lethality rates ranging from 0 to 4.8%. The studies identified numerous risk factors positively associated with HBV infection, including older age, homosexual or bisexual practice, injected drug use (IDU), and, with HAV infection including IDU, having sexual partner(s) with a history of unspecified hepatitis, insertive anal penetration, or originating from a country with a high prevalence of anti-HAV antibody. Eleven outbreaks of pneumococcal infection affecting PEH were reported in Canada and USA, with lethality rates from 0 to 15.6%. Six diphtheria outbreaks were reported. Vaccination status was rarely documented in these studies. Conclusions: The literature suggests that homeless populations generally experience a high VPD burden suggesting the need for a national vaccination programme and planning for delivering vaccines in this population. (C) 2021 Elsevier Ltd. All rights reserved.	[Tran Duc Anh Ly; Van Thuan Hoang; Thi Loi Dao; Gautret, Philippe] Aix Marseille Univ, AP HM, VITROME, SSA,IRD, Marseille, France; [Tran Duc Anh Ly; Castaneda, Sergei; Van Thuan Hoang; Thi Loi Dao; Gautret, Philippe] IHU Mediterranee Infect, Marseille, France; [Van Thuan Hoang] Thai Binh Univ Med & Pharm, Family Med Dept, Thai Binh, Vietnam; [Thi Loi Dao] Thai Binh Univ Med & Pharm, Pneumol Dept, Thai Binh, Vietnam		Gautret, P (通讯作者)，Inst Hosp Univ Med Terranee Infect, VITROME, 19-21 Blvd Jean Moulin, F-13385 Marseille 05, France.	philippe.gautret@club-internet.fr	Gautret, Philippe/AAY-5126-2021; , Van Thuan Hoang/ABD-2512-2021	Gautret, Philippe/0000-0002-1664-958X; HOANG, Van Thuan/0000-0003-1369-8615			Alderman EM, 1998, J ADOLESCENT HEALTH, V22, P389, DOI 10.1016/S1054-139X(97)00265-6; Aldridge RW, 2018, LANCET, V391, P241, DOI 10.1016/S0140-6736(17)31869-X; Altice FL, 2005, J URBAN HEALTH, V82, P151, DOI 10.1093/jurban/jti016; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; Anh TD, 2021, CLIN RES HEPATOL GAS, V45, DOI 10.1016/j.clinre.2020.11.003; Badiaga S, 2008, EMERG INFECT DIS, V14, P1353, DOI 10.3201/eid1409.080204; Badiaga S, 2009, EUR J PUBLIC HEALTH, V19, P157, DOI 10.1093/eurpub/ckn142; Bal B, 2010, SUBST USE MISUSE, V45, P1668, DOI 10.3109/10826081003674856; Borba RCN, 2015, AN ACAD BRAS CIENC, V87, P1311, DOI 10.1590/0001-3765201520140663; Boyce Daniel E C, 2009, Hawaii Med J, V68, P113; Brito Valquiria O. C., 2007, Rev. Saúde Pública, V41, P47; Brouqui P, 2006, ANN NY ACAD SCI, V1078, P223, DOI 10.1196/annals.1374.041; Cardona-Arias JA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238655; Centers for Disease control and Prevention, 2020, AD IMM SCHED; Cheung RC, 2002, J CLIN GASTROENTEROL, V34, P476, DOI 10.1097/00004836-200204000-00021; Craine N, 2010, J PUBLIC HEALTH-UK, V32, P328, DOI 10.1093/pubmed/fdp131; Dangel A, 2018, EMERG INFECT DIS, V24, P1239, DOI 10.3201/eid2407.172026; Doosti-Irani A, 2017, J RES HEALTH SCI, V17; Doshani M, 2019, MMWR-MORBID MORTAL W, V68, P153, DOI 10.15585/mmwr.mm6806a6; European Centre for Disease Prevention and Control, 2018, PUBL HLTH GUID HIV H; Fabianova K, 2008, EUROSURVEILLANCE, V13; Foroughi M, 2017, SEX TRANSM INFECT, V93, P421, DOI 10.1136/sextrans-2016-052557; Foster M, 2018, MMWR-MORBID MORTAL W, V67, P1208, DOI 10.15585/mmwr.mm6743a3; Funke G, 1999, EMERG INFECT DIS, V5, P477, DOI 10.3201/eid0503.990326; Fuster D, 2019, J COMMUN HEALTH, V44, P1044, DOI 10.1007/s10900-019-00679-w; Garfein RS, 2007, DRUG ALCOHOL DEPEN, V91, pS4, DOI 10.1016/j.drugalcdep.2007.05.007; Gelberg L, 2001, PUBLIC HEALTH, V115, P286, DOI 10.1016/S0033-3506(01)00461-9; Getahun H, 2015, EUR RESPIR J, V46, P1563, DOI 10.1183/13993003.01245-2015; Hamilton K, 2018, INT J TUBERC LUNG D, V22, P1135, DOI 10.5588/ijtld.17.0784; HARNISCH JP, 1989, ANN INTERN MED, V111, P71, DOI 10.7326/0003-4819-111-1-71; Harris HW, 2002, ARCH SURG-CHICAGO, V137, P1217, DOI 10.1001/archsurg.137.11.1217; Haussig JM, 2018, INT J INFECT DIS, V66, P5, DOI 10.1016/j.ijid.2017.10.008; Havelaar AH, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001923; Hennessey KA, 2009, PUBLIC HEALTH REP, V124, P813, DOI 10.1177/003335490912400608; Heuvelings CC, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019642; Hou JinLin, 2005, International Journal of Medical Sciences, V2, P50; Jahanbakhsh F, 2018, INT J HEALTH POLICY, V7, P225, DOI 10.15171/ijhpm.2017.74; James TL, 2009, J EMERG MED, V36, P412, DOI 10.1016/j.jemermed.2007.10.001; Klinkenberg WD, 2003, COMPR PSYCHIAT, V44, P293, DOI 10.1016/S0010-440X(03)00094-4; Kreshak AA, 2018, J EMERG MED, V55, P620, DOI 10.1016/j.jemermed.2018.07.031; Legoupil C, 2017, AIDS CARE, V29, P686, DOI 10.1080/09540121.2016.1231886; Leiva-Hidalgo Jorge, 2013, Rev. costarric. salud pública, V22, P113; Lemay JA, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz362; Lifson AR, 2001, J URBAN HEALTH, V78, P690, DOI 10.1093/jurban/78.4.690; Lopez-Zetina J, 2001, ADDICTION, V96, P589, DOI 10.1046/j.1360-0443.2001.9645897.x; Ly TDA, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2018.04.032; Lyons M, 2006, INCIDENCE BLOOD BORN, P16; Marrie TJ, 2017, CAN RESPIR J, V2017, DOI 10.1155/2017/2397429; McKee G, 2018, Can Commun Dis Rep, V44, P317, DOI 10.14745/ccdr.v44i12a02; MCMAHON BJ, 1990, AM J MED, V88, P460, DOI 10.1016/0002-9343(90)90423-B; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; Metcalf BJ, 2021, CLIN INFECT DIS, V72, pE948, DOI 10.1093/cid/ciaa1680; Ministere des Solidarites et de la Sante, 2020, CALENDRIER VACCINATI; Moquillaza-Risco Marlene, 2015, Rev. perú. med. exp. salud publica, V32, P693; Moses S, 2002, CAN J PUBLIC HEALTH, V93, P123, DOI 10.1007/BF03404552; Mosites E, 2019, EMERG INFECT DIS, V25, P1911, DOI 10.3201/eid2510.181408; Njord Levi, 2008, Int J Adolesc Med Health, V20, P367; Noell J, 2001, SEX TRANSM DIS, V28, P4, DOI 10.1097/00007435-200101000-00003; Noska AJ, 2017, CLIN INFECT DIS, V65, P252, DOI 10.1093/cid/cix295; Nyitray AG, 2018, J INFECT DIS, V217, P777, DOI 10.1093/infdis/jix617; O'Carroll A, 2008, EUR J PUBLIC HEALTH, V18, P448, DOI 10.1093/eurpub/ckn038; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ochnio JJ, 2001, CAN MED ASSOC J, V165, P293; Parriott A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5393-x; Patey O, 1997, J CLIN MICROBIOL, V35, P441, DOI 10.1128/JCM.35.2.441-445.1997; Peak CM, 2020, CLIN INFECT DIS, V71, P14, DOI 10.1093/cid/ciz788; Plevneshi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007255; PORTO SOB, 1994, J ADOLESCENT HEALTH, V15, P577, DOI 10.1016/1054-139X(94)90142-P; Poulos R, 2007, AUST NZ J PUBL HEAL, V31, P247, DOI 10.1111/j.1467-842X.2007.00056.x; Queiroz D A, 1995, Rev Soc Bras Med Trop, V28, P199; Carvalho PMRD, 2017, CAD SAUDE PUBLICA, V33, P1, DOI [10.1590/0102-311x00109216, 10.1590/0102-311X00109216]; ROBERTSON MJ, 1986, AM J PUBLIC HEALTH, V76, P561, DOI 10.2105/AJPH.76.5.561; Rodwell TC, 2010, EMERG INFECT DIS, V16, P1292, DOI 10.3201/eid1608.100196; Roy E, 2002, CAN J PUBLIC HEALTH, V93, P52, DOI 10.1007/BF03404418; Roy E, 1999, CAN MED ASSOC J, V161, P689; Sachdeva H, 2019, Can Commun Dis Rep, V45, P262, DOI 10.14745/ccdr.v45i10a03; Scheibe A, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05359-y; Schillberg E, 2014, CLIN INFECT DIS, V59, P651, DOI 10.1093/cid/ciu366; Shariatzadeh MR, 2005, MEDICINE, V84, P147, DOI 10.1097/01.md.0000164302.03972.d7; Steele Russell W, 2003, Semin Pediatr Infect Dis, V14, P38, DOI 10.1053/spid.2003.127216; Stein JA, 2012, HEALTH PSYCHOL, V31, P20, DOI 10.1037/a0023643; Syed NA, 2003, EUR J GASTROEN HEPAT, V15, P901, DOI 10.1097/00042737-200308000-00011; Tjon GMS, 2005, J MED VIROL, V77, P360, DOI 10.1002/jmv.20464; Ly TDA, 2021, J INFECTION, V82, P60, DOI 10.1016/j.jinf.2020.11.026; Tran DAL, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101768; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Tyrrell GJ, 2012, EMERG INFECT DIS, V18, P733, DOI 10.3201/eid1805.110235; Vahdani Parviz, 2006, Arch Iran Med, V9, P153; Vahdani P, 2009, ARCH IRAN MED, V12, P483; Vallejo F, 2008, EUR ADDICT RES, V14, P116, DOI 10.1159/000130415; Vanderkooi OG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028547; Volf V, 2008, EUR J PUBLIC HEALTH, V18, P44, DOI 10.1093/eurpub/ckm072; WANG EEL, 1991, PEDIATR INFECT DIS J, V10, P130, DOI 10.1097/00006454-199102000-00011; Wilson E, 2019, MMWR-MORBID MORTAL W, V68, P330, DOI 10.15585/mmwr.mm6814a4; World Health Organization, 2008, GLOB BRIEF VECT BORN; Xiaoli L, 2020, MICROB GENOMICS, V6, DOI 10.1099/mgen.0.000467; Zasada AA, 2013, EMERG INFECT DIS, V19, P1870, DOI 10.3201/eid1911.130297; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	98	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1205	1224		10.1016/j.vaccine.2021.01.035		FEB 2021	20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QH8AG	33509694				2022-04-29	WOS:000618493500010
J	Fatoba, AJ; Maharaj, L; Adeleke, VT; Okpeku, M; Adeniyi, AA; Adeleke, MA				Fatoba, Abiodun J.; Maharaj, Leah; Adeleke, Victoria T.; Okpeku, Moses; Adeniyi, Adebayo A.; Adeleke, Matthew A.			Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2)	VACCINE			English	Article						Multi-epitope; Immunoinformatics; Immune-response; SARS-CoV-2; Vaccine		At the beginning of the year 2020, the world was struck with a global pandemic virus referred to as SARS-CoV-2 (COVID-19) which has left hundreds of thousands of people dead. To control this virus, vaccine design becomes imperative. In this study, potential epitopes-based vaccine candidates were explored. Six hundred (600) genomes of SARS-CoV-2 were retrieved from the viPR database to generate CD8(+) T-cell, CD4+ T-cell and linear B-cell epitopes which were screened for antigenicity, immunogenicity and non-allergenicity. The results of this study provide 19 promising candidate CD8(+) T-cell epitopes that strongly overlap with 8 promising B-cells epitopes. Another 19 CD4(+) T-cell epitopes were also identified that can induce IFN-gamma and IL-4 cytokines. The most conserved MHC-I and MHC-II for both CD8(+ )and CD4(+) T-cell epitopes are HLA-A*02:06 and HLA-DRB1*01:01 respectively. These epitopes also bound to Tolllike receptor 3 (TLR3). The population coverage of the conserved Major Histocompatibility Complex Human Leukocyte Antigen (HLA) for both CD8(+) T-cell and CD4(+) T-cell ranged from 65.6% to 100%. The detailed analysis of the potential epitope-based vaccine and their mapping to the complete COVID-19 genome reveals that they are predominantly found in the location of the surface (S) and membrane (M) glycoproteins suggesting the potential involvement of these structural proteins in the immunogenic response and antigenicity of the virus. Since the majority of the potential epitopes are located on M protein, the design of multi-epitope vaccine with the structural protein is highly promising though the whole M protein could also serve as a viable epitope for the development of an attenuated vaccine. Our findings provide a baseline for the experimental design of a suitable vaccine against SARS-CoV-2. (C) 2021 Elsevier Ltd. All rights reserved.	[Fatoba, Abiodun J.; Maharaj, Leah; Okpeku, Moses; Adeleke, Matthew A.] Univ KwaZulu Natal, Sch Life Sci, Discipline Genet, P Bag X54001, ZA-4000 Durban, South Africa; [Adeleke, Victoria T.] Univ KwaZulu Natal, Discipline Chem Engn, Howard Campus, ZA-4041 Durban, South Africa; [Adeniyi, Adebayo A.] Univ Free State, Fac Nat & Agr Sci, Dept Chem, Bloemfontein, South Africa; [Adeniyi, Adebayo A.] Fed Univ, Dept Ind Chem, Oye Ekiti, Nigeria		Adeniyi, AA; Adeleke, MA (通讯作者)，Univ KwaZulu Natal, Sch Life Sci, Discipline Genet, P Bag X54001, ZA-4000 Durban, South Africa.	adeniyiaa@ufs.ac.za; adelekem@ukzn.ac.za	Adeleke, Victoria/AAM-9623-2021; Okpeku, Moses/T-8184-2019; Fatoba, Abiodun Joseph/AAW-6315-2021; Adeleke, Matthew/AAG-3151-2021; Adeniyi, Adebayo/C-8843-2014	Adeleke, Victoria/0000-0002-4495-0644; Okpeku, Moses/0000-0002-8337-6294; Fatoba, Abiodun Joseph/0000-0003-2055-7036; Adeleke, Matthew/0000-0002-3271-8442; Adeniyi, Adebayo/0000-0003-2421-1382	College of Agriculture, Engineering and Science, University of KwaZulu-Natal	The College postdoctoral fellowship awarded to the first author by the College of Agriculture, Engineering and Science, University of KwaZulu-Natal is gratefully appreciated. The authors also wish to acknowledge Centre for High Performance Computing, South Africa for the computer programs and facilities that were used in this project.	Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286; Adhikari UK, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6718083; Adhikari UK, 2017, INFECT GENET EVOL, V56, P75, DOI 10.1016/j.meegid.2017.10.022; Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254; Alam A, 2016, IMMUNOLOGY, V149, P386, DOI 10.1111/imm.12656; Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361; Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700; Chakraborty Sajib, 2010, In Silico Biology, V10, P235, DOI 10.3233/ISB-2010-0435; Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14; Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681; Dar AA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00366; Dash Raju, 2017, Adv Appl Bioinform Chem, V10, P11, DOI 10.2147/AABC.S115859; de Assis RR, 2021, NAT COMMUN, V12, DOI [10.1038/s41467-020-20095-2, 10.1101/2020.04.15.043364]; de Oliveira VL, 2011, ARCH VIROL, V156, P597, DOI 10.1007/s00705-010-0894-7; de Vries SJ, 2017, NUCLEIC ACIDS RES, V45, pW361, DOI 10.1093/nar/gkx335; Dhanda SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/263952; Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Enayatkhani M, 2021, J BIOMOL STRUCT DYN, V39, P2857, DOI [10.1080/07391102.2020.1756411, 10.1080/07391102.2020.1857843]; Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; He LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep12501; Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Igic R., 2020, SCR MED-BRNO, V51, P6, DOI [10.5937/scriptamed51-25852, DOI 10.5937/SCRIPTAMED51-25852]; Ilinskaya AN, 2016, TOXICOL APPL PHARM, V299, P70, DOI 10.1016/j.taap.2016.01.005; Iyer AS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0367; Jespersen MC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00298; Jin X, 2009, VACCINE, V27, P7080, DOI 10.1016/j.vaccine.2009.09.060; Joshi Amit, 2020, Inform Med Unlocked, V19, P100338, DOI 10.1016/j.imu.2020.100338; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Kori Priyanka, 2015, Journal of Pharmaceutical Investigation, V45, P579, DOI 10.1007/s40005-015-0205-0; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424; Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026; Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158; Mellet J, 2019, SAMJ S AFR MED J, V109, pS30, DOI 10.7196/SAMJ.2019.v109i8b.13825; Misra N, 2011, BIOINFORMATION, V6, P255, DOI 10.6026/97320630006255; Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238; Panagioti E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00276; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Saha CK, 2017, ASIAN PAC J TROP MED, V10, P601, DOI 10.1016/j.apjtm.2017.06.016; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Shah VK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01949; Shrock E, 2020, SCIENCE; Sun BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI 10.1080/22221751.2020.1762515; Tabiasco J, 2006, J IMMUNOL, V177, P8708, DOI 10.4049/jimmunol.177.12.8708; Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490; Thompson Julie D, 2002, Curr Protoc Bioinformatics, VChapter 2, DOI 10.1002/0471250953.bi0203s00; Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002; Tshabalala M, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/746151; van Dijk ADJ, 2006, BIOINFORMATICS, V22, P2340, DOI 10.1093/bioinformatics/btl395; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; Vara-pastrana E, 2020, IMMUNOINFORMATIC ANA, V2020; Vercammen E, 2008, CLIN MICROBIOL REV, V21, P13, DOI 10.1128/CMR.00022-07; Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; Wang JQ, 2003, CLIN CHEM, V49, P1989, DOI 10.1373/clinchem.2003.023184; Wang XY, 2016, EXP THER MED, V12, P2439, DOI 10.3892/etm.2016.3636; Yang JY, 2020, P NATL ACAD SCI USA, V117, P1496, DOI 10.1073/pnas.1914677117; Zaharieva N., 2017, J PROTEOM BIOINFORM, V10, P11, DOI [10.4172/jpb.1000454, DOI 10.4172/JPB.1000454]; Zobayer N, 2019, BIOINFORMATION, V15, P530, DOI 10.6026/97320630015530	71	13	13	4	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 12	2021	39	7					1111	1121		10.1016/j.vaccine.2021.01.003		FEB 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QC9HH	33478794	Green Published, Bronze			2022-04-29	WOS:000615141100016
J	Abdi, I; Gidding, H; Leong, RN; Moore, HC; Seale, H; Menzies, R				Abdi, Ikram; Gidding, Heather; Leong, Robert Neil; Moore, Hannah C.; Seale, Holly; Menzies, Robert			Vaccine coverage in children born to migrant mothers in Australia: A population-based cohort study	VACCINE			English	Article						Vaccine coverage; Linked data; Diphtheria-tetanus-pertussis; Timeliness; Migrants	IMMUNIZATION COVERAGE; NEW-ZEALAND; IMMIGRANT	Background: Overall, infant immunisation coverage is currently >90% in Australia, but there are pockets of under-immunised children including children from migrant backgrounds. This study aimed to examine whether on-time vaccination coverage of diphtheria-tetanus-pertussis dose 3 (DTP3) for children born in Australia differed by mother's region of birth and if so, what factors were associated with these differences. Methods: We conducted a population-based cohort study using linked data on perinatal, immunisation and birth records for 2 million children born in Western Australia and New South Wales between 1996 and 2012. We assessed on-time coverage of DTP3 (vaccination from 2 weeks prior to, and up until 30 days after, the due date) in children with mothers born overseas. Logistic regression models were developed to determine factors associated with on-time coverage for each maternal region of birth and all regions combined, adjusting for a range of demographic factors. Adjusted estimates of coverage were calculated for the different regions of birth. Results: On-time DTP3 coverage was 76.2% in children of Australian born mothers, lower in children of mothers from Oceania (66.7%) and North America (68%), and higher in children born to mothers from South-East Asia (79.9%) and Southern Asia (79.3%). While most variables were consistently associated with lower coverage in all regions of birth, higher socioeconomic status and jurisdiction of birth showed varied results. Adjusted estimates of DTP3 coverage increased in children born to mothers from Australia (78.3%), Oceania (70.5%), Northern Africa (81.5%) and the Middle East (79.6%). DTP3 coverage decreased in children born to mothers from Europe and former USSR (74.6%), North-east Asia (75.2%), Southern Asia (76.7%), North America (65.5) and South/Central America and the Caribbean (73.2%). Conclusions: On-time vaccination rates differed by mother's region of birth. More research is needed to determine the main reasons for these remaining differences to improve vaccine uptake and also help guide policy and practice. (C) 2021 Elsevier Ltd. All rights reserved.	[Abdi, Ikram; Gidding, Heather; Leong, Robert Neil; Seale, Holly] Univ New South Wales, Sch Populat Hlth, Sydney, NSW, Australia; [Gidding, Heather] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia; [Gidding, Heather] Northern Sydney Local Hlth Dist, Kolling Inst, Women & Babies Res, St Leonards, NSW, Australia; [Gidding, Heather] Univ Sydney, Northern Clin Sch, Sydney, NSW, Australia; [Moore, Hannah C.] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Telethon Kids Inst, Perth, WA, Australia; [Menzies, Robert] Univ New South Wales, Kirby Inst, Kensington, NSW, Australia; [Menzies, Robert] Sanofi Pasteur, Macquarie Pk, NSW, Australia		Abdi, I (通讯作者)，Univ New South Wales, Sch Publ Hlth & Community Med, Kensington, NSW 2052, Australia.	i.abdi@unsw.edu.au	Moore, Hannah/W-4727-2018	Moore, Hannah/0000-0001-6434-8290	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [APP1082342]; NHMRC FellowshipsNational Health and Medical Research Council (NHMRC) of Australia; Telethon Kids Institute Emerging Research Leader Fellowship	The data was supported by a National Health and Medical Research Council (NHMRC) project grant (APP1082342). HCM and HG are supported by NHMRC Fellowships. HCM is further supported by a Telethon Kids Institute Emerging Research Leader Fellowship.	Abdi I, 2020, VACCINE, V38, P6410, DOI 10.1016/j.vaccine.2020.07.071; Australia G.o.W, 2016, W AUSTR IMM STRAT 20; Charania NA, 2019, VACCINE, V37, P2661, DOI 10.1016/j.vaccine.2019.04.001; Charania NA, 2018, HUM VACC IMMUNOTHER, V14, P3026, DOI 10.1080/21645515.2018.1496769; Gidding HF, 2019, VACCINE; Gidding HF, 2017, INT J POPULAT DATA S, V2; Government A, 2020, NAT IMM PROGR; Government A, 2020, IMM COV RAT ALL CHIL; Government Q, 2019, ACC REM IND AUSTR; Guttmann A, 2008, AMBUL PEDIATR, V8, P205, DOI 10.1016/j.ambp.2008.01.010; Harmsen IA, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2572-x; Hull Brynley P, 2003, Commun Dis Intell Q Rep, V27, P357; Karki S, 2016, VACCINE, V34, P6388, DOI 10.1016/j.vaccine.2016.10.012; Kowal SP, 2015, CAN J PUBLIC HEALTH, V106, pE230, DOI 10.17269/cjph.106.4803; McDonald JT, 2004, SOC SCI MED, V59, P1613, DOI 10.1016/j.socscimed.2004.02.004; Mixer RE, 2007, J EPIDEMIOL COMMUN H, V61, P797, DOI 10.1136/jech.2005.045633; Moore HC, 2018, VACCINE, V36, P4062, DOI 10.1016/j.vaccine.2018.05.084; Moore HC, 2016, AUST NZ J PUBL HEAL, V40, P159, DOI 10.1111/1753-6405.12481; Najjar Z, 2014, WEST PAC SURVEILL RE, V5, DOI [10.5365/wpsar.2013.4.4.002, 10.5365/WPSAR.2013.4.4.002]; Pal M, 2014, J PRIM HEALTH CARE, V6, P304, DOI 10.1071/HC14304; Paterson J, 2006, VACCINE, V24, P4883, DOI 10.1016/j.vaccine.2006.02.050; Pillsbury A, 2014, COMMUN DIS INTELL, V38, pE179; Pink B., 2008, INTRO SOCIOECONOMIC; Riise OR, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0487-4; Statistics A.B.o, 2019, STAND AUSTR CLASS CO; Statistics A.B.o., 2020, MIGRATION; Statistics A.B.o., 2012, 34150 STAT ABO; Wolf E, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4544; Yilmaz G, 2006, CHILD CARE HLTH DEV, V32, P73, DOI 10.1111/j.1365-2214.2006.00570.x	29	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					984	993		10.1016/j.vaccine.2020.12.058		JAN 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PW7FB	33431224				2022-04-29	WOS:000610835100017
J	Santana, CP; Luhm, KR; Shimakura, SE				Santana, Clarice Paiva; Luhm, Karin Regina; Shimakura, Silvia Emiko			Impact of Tdap vaccine during pregnancy on the incidence of pertussis in children under one year in Brazil - A time series analysis	VACCINE			English	Article						Pertussis; Tdap vaccine; Vaccination in pregnancy		Pertussis is a globally distributed infectious disease that is a significant cause of morbidity and mortality, especially in infants who are too young to be immunized. This disease is common in childhood, and when it occurs during the first few months of life, it leads to hospitalization and, sometimes, death. Brazil has adopted the strategy of maternal immunization against pertussis in late 2014. This study aims to analyze public data on the disease to determine whether there was an impact on the disease burden following the introduction of the vaccine Tdap in pregnant women and its magnitude. We performed a time-series analysis of the incidence of pertussis between October 2010 and January 2019. We stratified the population of interest into three groups: infants aged less than two months old, infants aged two to six months, and infants aged six months to one year, according to Brazil's vaccination schedule. We found a protective effect of maternal vaccination in all age groups, more prominent on the first group. Before the intervention, infants under two months had a higher risk of getting pertussis in comparison with infants two to six months old (HR 1.15, CI 95%: 1.11-1.19). After the intervention, age under two months is a protective factor compared with two to six months (HR 0.90, CI 95%: 0.82-0.98). The pertussis incidence reduced in all age groups and all Brazil's Regions. (C) 2020 Elsevier Ltd. All rights reserved.	[Santana, Clarice Paiva; Luhm, Karin Regina] Univ Fed Parana UFPR, Postgrad Program Publ Hlth Curitiba, Rua Padre Camargo 280, BR-80060240 Curitiba, Parana, Brazil; [Shimakura, Silvia Emiko] Univ Fed Parana UFPR, Stat Dept, Ctr Politecn Sn, BR-81531990 Curitiba, Parana, Brazil		Santana, CP (通讯作者)，Univ Fed Parana UFPR, Postgrad Program Publ Hlth Curitiba, Rua Padre Camargo 280, BR-80060240 Curitiba, Parana, Brazil.	claricepaiva@hotmail.com		Shimakura, Silvia/0000-0002-5468-2516			Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3; [Anonymous], 2015, B EPIDEMIOL, V46, P1; Barug D, 2019, LANCET INFECT DIS, V19, P392, DOI 10.1016/S1473-3099(18)30717-5; Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091; Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; BRASIL, 2016, B EPIDEMIOLOGICO, V47, P1; Edwards KM, 2003, VACCINE, V21, P3483, DOI 10.1016/S0264-410X(03)00356-6; Fernandes EG, 2019, VACCINE, V37, P5481, DOI 10.1016/j.vaccine.2019.03.049; Forsyth K, 2015, PEDIATRICS, V135, pE1475, DOI 10.1542/peds.2014-3925; Guiso N, 2014, J INFECTION, V68, pS119, DOI 10.1016/j.jinf.2013.09.022; Hamborsky J., 2015, EPIDEMIOLOGY PREVENT, V13th ed, P261; Maertens K, 2016, VACCINE, V34, P142, DOI 10.1016/j.vaccine.2015.10.100; Ministerio da Saude, 2014, INF TECN IMPL VAC AD, V22; Nieves DJ, 2016, EMERGING INFECTIONS 10, P311, DOI 10.1128/microbiolspec.EI10-0008-2015; Rice TF, 2019, CLIN EXP IMMUNOL, V197, P1, DOI 10.1111/cei.13275; Uriarte PS, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01207; Santana CP, 2019, 39 C BRAS PED PORT A; Secretaria de Vigilancia em Saude, 2018, INF EP COQ; States M., 2015, WKLY EPIDEMIOL REC R, V90, P433; Tan TN, 2015, PEDIATR INFECT DIS J, V34, pE222, DOI 10.1097/INF.0000000000000795; UNDP; IPEA; FJP, 2016, DES HUM NAS MACR BRA; Vizzotti C, 2016, VACCINE, V34, P6223, DOI 10.1016/j.vaccine.2016.10.081	22	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					976	983		10.1016/j.vaccine.2020.12.056		JAN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7FB	33446384				2022-04-29	WOS:000610835100016
J	Fan, ST; Liao, Y; Jiang, GR; Wang, LC; Zhao, H; Yu, L; Xu, XL; Li, DD; Zhang, Y; Li, QH				Fan, Shengtao; Liao, Yun; Jiang, Guorun; Wang, Lichun; Zhao, Heng; Yu, Li; Xu, Xingli; Li, Dandan; Zhang, Ying; Li, Qihan			Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally	VACCINE			English	Article						HFMD; Enterovirus 71; Coxsackievirus A16; Bivalent vaccine	ANTIGEN-PRESENTING CELLS; MOUTH-DISEASE; PROTECTIVE IMMUNITY; LANGERHANS CELLS; DENDRITIC CELLS; CA16 INFECTION; T-CELLS; SAFETY; IMMUNOGENICITY; HAND	Human hand, foot, and mouth disease (HFMD), an important infectious disease in children, is caused mainly by enterovirus 71 (EV71) and coxsackievirus A16 (CA16). In this study, a bivalent inactivated EV71/CA16 vaccine is developed and evaluated in immunized BALB/c mice injected through the intradermal route. Q-RT-PCR detection of the mRNA of immune signal molecules in local epithelial tissues inoculated with the vaccine indicates activation of innate immunity, which includes upregulation of immune-related chemokines, interferons and CD molecules. Further, the finding that neutralizing antibodies and specific T cellular responses were elicited in adult mice after two immunizations with the vaccine at a 28-day interval, which endowed offspring mice to defend a viral challenge, suggests the successful induction of specific protective antiviral immunity. All these data suggest that immunization with this bivalent EV71/CA16 vaccine via the intradermal route elicits effective immunity against EV71 and CA16 infection. (C) 2020 Elsevier Ltd. All rights reserved.	[Fan, Shengtao; Liao, Yun; Jiang, Guorun; Wang, Lichun; Zhao, Heng; Yu, Li; Xu, Xingli; Li, Dandan; Zhang, Ying; Li, Qihan] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China		Li, QH (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China.	liqihan@imbcams.com.cn			Yunnan Fundamental Research Projects [202001AS070047, 2019FB101]; Yunnan Health Training Project for High Level Talents [H-2017035]; Yunnan Province technology innovation talent training object project [202005AD160006]; Major Science and Technology Special Projects of Yunnan Province [2017ZF020, 202002AA100009]; CAMS Initiative for Innovative Medicine [2016-I2M-1-019, 2020-I2M-2-014]; State Project for Essential Drug Research and Development [2017ZX093070132, 2016ZX09101120-2, 2018ZX09737011-002]; National Science and Technology Major Project [2018ZX10101001]; Yunnan Key Laboratory of Vaccine Research & Development in Severe Infectious Diseases	This study was supported by the Yunnan Fundamental Research Projects (grant No. 202001AS070047 and 2019FB101), Yunnan Health Training Project for High Level Talents (H-2017035) and Yunnan Province technology innovation talent training object project (202005AD160006). This study was funded by the Major Science and Technology Special Projects of Yunnan Province (2017ZF020, 202002AA100009), the CAMS Initiative for Innovative Medicine(2016-I2M-1-019, 2020-I2M-2-014), the State Project for Essential Drug Research and Development (2017ZX093070132 and 2016ZX09101120-2 and 2018ZX09737011-002), the National Science and Technology Major Project (2018ZX10101001), and funds from the Yunnan Key Laboratory of Vaccine Research & Development in Severe Infectious Diseases.	Aswathyraj S, 2016, MED MICROBIOL IMMUN, V205, P397, DOI 10.1007/s00430-016-0465-y; Bando JK, 2016, NAT IMMUNOL, V17, P783, DOI 10.1038/ni.3484; Cai YC, 2014, VACCINE, V32, P2406, DOI 10.1016/j.vaccine.2014.03.012; Chiu SS, 2007, PEDIATRICS, V119, P1076, DOI 10.1542/peds.2006-3176; Chiu SS, 2009, VACCINE, V27, P4834, DOI 10.1016/j.vaccine.2009.05.066; Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566; Fan ST, 2019, NPJ VACCINES, V4, DOI [10.1038/s41541-019-0141-5, 10.1038/s41541-019-0108-6]; Filippelli M, 2014, WORLD J GASTROENTERO, V20, P10383, DOI 10.3748/wjg.v20.i30.10383; Hervouet C, 2010, J IMMUNOL, V184, P4842, DOI 10.4049/jimmunol.0901695; Hu YJ, 2017, VIRUS RES, V228, P90, DOI 10.1016/j.virusres.2016.11.024; Huang J, 2018, EMERG INFECT DIS, V24; Hung IFN, 2012, VACCINE, V30, P6427, DOI 10.1016/j.vaccine.2012.08.014; Hung IFN, 2012, VACCINE, V30, P2707, DOI 10.1016/j.vaccine.2011.12.069; Kashem SW, 2017, ANNU REV IMMUNOL, V35, P469, DOI 10.1146/annurev-immunol-051116-052215; Kim BS, 2015, J INVEST DERMATOL, V135, P673, DOI 10.1038/jid.2014.401; Koh WM, 2016, PEDIATR INFECT DIS J, V35, pE285, DOI 10.1097/INF.0000000000001242; Ku ZQ, 2014, VACCINE, V32, P4296, DOI 10.1016/j.vaccine.2014.06.025; Laurent PE, 2010, VACCINE, V28, P5850, DOI 10.1016/j.vaccine.2010.06.062; Leroux-Roels I, 2008, VACCINE, V26, P6614, DOI 10.1016/j.vaccine.2008.09.078; Li J, 2017, LANCET INFECT DIS, V17, P1017, DOI 10.1016/S1473-3099(17)30471-1; Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224; Malissen B, 2014, NAT REV IMMUNOL, V14, P417, DOI 10.1038/nri3683; Mao Q, 2018, CHIN J VIRAL DIS, V8, P481; Nestle FO, 2009, NAT REV IMMUNOL, V9, P679, DOI 10.1038/nri2622; Otsuka M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01768; Song J, 2016, VIRUS RES, V214, P1, DOI 10.1016/j.virusres.2016.01.002; STREILEIN JW, 1984, IMMUNOBIOLOGY, V168, P285, DOI 10.1016/S0171-2985(84)80117-5; Sun SY, 2014, HUM VACC IMMUNOTHER, V10, P2885, DOI 10.4161/hv.29823; Tsang P, 2014, VACCINE, V32, P2507, DOI 10.1016/j.vaccine.2013.09.074; Van Damme P, 2009, VACCINE, V27, P454, DOI 10.1016/j.vaccine.2008.10.077; Wang JJ, 2017, VIROLOGY, V500, P198, DOI 10.1016/j.virol.2016.10.031; Wang JJ, 2014, VACCINE, V32, P4436, DOI 10.1016/j.vaccine.2014.06.062; Weizman OE, 2019, NAT IMMUNOL, V20, P1004, DOI 10.1038/s41590-019-0430-1; Yao C, 2015, J ALLERGY CLIN IMMUN, V136, P1387, DOI 10.1016/j.jaci.2015.04.001; Yu SB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203792; Zhang W, 2018, EMERG MICROBES INFEC, V7, DOI [10.1038/S41426-018-0094-1, 10.1038/s41426-018-0094-1]; Zhang Y, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-94; Zhang Y, 2015, VACCINE, V33, P6290, DOI 10.1016/j.vaccine.2015.09.047	38	0	2	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 15	2021	39	3					596	604		10.1016/j.vaccine.2020.11.070			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VN	33342637				2022-04-29	WOS:000604750400020
J	Marchal, C; Belhassen, M; Guiso, N; Jacoud, F; Van Ganse, E; Le Pannerer, M; Cohen, R; Verdier, R; Uhart, M				Marchal, Clarisse; Belhassen, Manon; Guiso, Nicole; Jacoud, Flore; Van Ganse, Eric; Le Pannerer, Marie; Cohen, Robert; Verdier, Regis; Uhart, Mathieu			Vaccination coverage rates for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data	VACCINE			English	Article						Vaccination coverage rates; Claims database; Booster vaccines; Diphtheria-tetanus-poliomyelitis and pertussis; National immunization program	UNITED-STATES; SURVEILLANCE; INFANTS	Background: Maintaining a high vaccination coverage rate (VCR) throughout the lifetime and complying with the National Immunization Program are essential to optimize the protection of the population. The study objectives were to evaluate the evolution of the VCRs and the compliance with the vaccination visits for the diphtheria, tetanus, poliomyelitis and pertussis boosters in France since the changes implemented in the 2013 National Immunization Program. Methods: Cumulative booster VCRs were estimated at all vaccination visits, from 2013 to 2017, among persons eligible for a booster vaccination from a 1/97th random sample of French claims data. Broader age groups around the recommended ages by the vaccination schedule (6, 11-13, 25, 45, 65, 75, 85, 95y) were used: all persons aged 5 to 8, 10 to 15, 21 to 29, 41 to 49, 61 to 69, 71 to 79, 81 to 89 and 91 to 99. Results: Over the study period, the diphtheria-tetanus-poliomyelitis booster VCRs increased, reaching in 2017: 73.3% at 8 years old, 75.6% at 15 years old, 46.6% at 29 years old, 38.4% at 49 years old, 36.3% at 69 years old, 30.8% at 79 years old, 22.1% at 89 years old and 11.0% at 99 years old. The pertussis VCRs were also increasing at all vaccination visits, in particular at the vaccination visits at 6 and 11-13 years old (from 16.4% to 63.8% and from 50.3% to 61.2%, respectively). Delayed vaccinations were observed at all vaccination visits. Conclusion: VCRs for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination increased from 2013 to 2017 while remaining suboptimal across all ages and lower in the adult populations. The analysis also shows that the introduction in 2013 of a pertussis vaccination at 6 years of age was relatively wellestablished in 2017 while other changes in recommendations were slowly or partially implemented. (C) 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.	[Marchal, Clarisse; Belhassen, Manon; Jacoud, Flore; Van Ganse, Eric] PELyon Pharmaco Epidemiol Lyon, Lyon, France; [Van Ganse, Eric] Croix Rousse Univ Hosp, Resp Med, Lyon, France; [Van Ganse, Eric] Univ Claude Bernard Lyon 1, HESPER 7425, Hlth Serv & Performance Res, Lyon, France; [Le Pannerer, Marie; Verdier, Regis; Uhart, Mathieu] Sanofi Pasteur, Lyon, France; [Cohen, Robert] Univ Paris Est, IMRB GRC GEMINI, Creteil, France; [Cohen, Robert] Ctr Hosp Intercommunal Creteil, Clin Res Ctr CRC, Creteil, France; [Cohen, Robert] GPIP, Pediat Infect Dis Grp, St Maur, France; [Cohen, Robert] ACTIV, Pediat Clin & Therapeut Assoc Val de Marne, St Maur des Fosses, France; [Cohen, Robert] Ctr Hosp Intercommunal Creteil, Serv Neonatol, Unite Court Sejour, Petits Nourrissons, Creteil, France		Marchal, C (通讯作者)，PELyon, 210 Ave Jean Jaures, F-69007 Lyon, France.	clarisse.marchal@pelyon.fr	Cohen, Robert/AAM-4426-2021	Cohen, Robert/0000-0001-6151-0686			Antona D., 2018, B EPIDEMIOL HEBD, V42, P828; Antona D, 2007, B EPIDEMIOL HEBD, V6, P45; Beaufils E, 2016, GYNECOL OBSTET FERTI, V44, P591, DOI 10.1016/j.gyobfe.2016.08.003; Celant N, 2014, ENQUETE SANTE PROTEC; Centers for Disease Control and Prevention, 2017, CHILDH DIPHTH TOX TE; Chardon O, 2014, ETUDES RESULTATS DRE; Cohen R, 2016, MED MALADIES INFECT, V46, P188, DOI 10.1016/j.medmal.2016.03.005; European Centre for Disease Prevention and Control (ECDC), VACC SCHED PERT REC; Guignon N, 2019, ETUDES RESULTATS DRE; Guignon N, 2017, ETUDES RESULTATS DRE; Guiso N, 2017, VACCINE, V35, P6083, DOI 10.1016/j.vaccine.2017.09.072; Guthmann JP, 2007, B EPIDEMIOL HEBD SAI, V51-52, P441; Haut Conseil de la Sante Publique, 2012, SIMPL CAL VACC; Haut Conseil de la Sante Publique, 2008, AV REL REC VACC CONQ; Haut Conseil de la Sante Publique, 2015, AV REL RUPT STOCKS T; Havers FP, 2020, MMWR-MORBID MORTAL W, V69, P77, DOI 10.15585/mmwr.mm6903a5; Hull B, 2019, COMMUN DIS INTELL, V43, DOI 10.33321/cdi.2019.43.47; Kurova N, 2018, VACCINE, V36, P7936, DOI 10.1016/j.vaccine.2018.11.007; Lernout T, 2014, VACCINE, V32, P284, DOI 10.1016/j.vaccine.2013.10.084; Levy-Bruhl D, ANAL ENQUETE SANTE P; Lu PJ, 2016, AM J PREV MED, V50, P616, DOI 10.1016/j.amepre.2015.09.033; Martin-Latry K, 2010, PHARMACOEPIDEM DR S, V19, P256, DOI 10.1002/pds.1912; Ministere des Affaires sociales et de la Sante, 2013, CAL VACC REC VACC 20; Sante Publique France, COUV VACC DONN DIPHT; Tubiana S, 2015, PEDIATR INFECT DIS J, V34, P814, DOI 10.1097/INF.0000000000000739; Tuppin P, 2017, REV EPIDEMIOL SANTE, V65, pS149, DOI 10.1016/j.respe.2017.05.004; Vaccination Info Service, 2019, VACC COURS VIE; Vaccination Info Service, 2019, MAL LEURS VACC; Vie Le Sage F, 2015, Arch Pediatr, V22, P37, DOI 10.1016/S0929-693X(15)30020-8; Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2	30	2	2	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 15	2021	39	3					505	511		10.1016/j.vaccine.2020.12.021			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VN	33357956	hybrid			2022-04-29	WOS:000604750400009
J	Hu, SY; Xu, XQ; Zhang, YY; Liu, YW; Yang, CX; Wang, YY; Wang, Y; Yu, YQ; Hong, Y; Zhang, XX; Bian, R; Cao, X; Xu, LL; Zhao, FH				Hu, Shangying; Xu, Xiaoqian; Zhang, Yanyang; Liu, Yawen; Yang, Chunxia; Wang, Yueyun; Wang, Yan; Yu, Yanqin; Hong, Ying; Zhang, Xingxing; Bian, Rui; Cao, Xian; Xu, Lili; Zhao, Fanghui			A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China	VACCINE			English	Article						Human papillomavirus; HPV vaccine; Survey; Knowledge; Willingness; Practice	HPV VACCINATION; AWARENESS; WOMEN; ACCEPTABILITY; PREVENTION; STUDENTS; BEHAVIOR; PARENTS; DISEASE; CANCER	Background: Human papillomavirus (HPV) vaccine has been increasingly discussed in mainland China since its first approval in 2016. To date, nearly all studies assessing HPV vaccine perceptions and attitudes were implemented during pre-licensure period. Therefore, the nationwide post-marketing survey was conducted to update knowledge, attitudes and practice on HPV vaccine among general population in mainland China. Methods: Participants aged 18-45 years living in mainland China were recruited in April 2019 by multi-stage non-randomized sampling. Sociodemographic factors, HPV and HPV vaccine related awareness, knowledge, attitudes, vaccine uptake and potential obstacles were assessed in questionnaires. Bivariate analysis and multivariate regression were used to identify disparity among subgroups with different sociodemographic characteristics. Results: 4,000 women (32.1 +/- 7.81y) and 1,000 men (31.8 +/- 7.96y) were included in final analysis. Less than one third of participants had heard of HPV (female: 31%; male: 22%) and HPV vaccine (female: 34%; male: 23%). Knowledge score was also unfavorable on HPV (female: 3 out of 13; male: 1.8 out of 13) and HPV vaccine (female: 3 out of 6; male: 2 out of 5). Only 3% females had been vaccinated three years after HPV licensure in China, although willingness to get vaccinated among those unvaccinated were high (mean willingness score +/- SD: female: 3.3 +/- 0.97; male: 3.0 +/- 0.98). Industry of employment and household income were the major factors related to awareness and knowledge of vaccine, whereas HPV and HPV vaccine awareness were key influential factors for willingness. The main obstacles of vaccination were safety concerns, lack of knowledge, and high price of HPV vaccines. Conclusions: Findings highlight a lack of vaccine awareness, knowledge, and poor uptake in mainland China and underscore the necessity of health education campaigns. The identified priority groups, contents to be delivered and practical obstacles could furthermore provide insight into health education to reduce disparities and accelerate HPV vaccine roll-out in China. (C) 2020 The Authors. Published by Elsevier Ltd.	[Hu, Shangying; Xu, Xiaoqian; Zhao, Fanghui] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Canc Epidemiol,Natl Canc Ctr, 17 South Panjiayuan Lane,POB 2258, Beijing 100021, Peoples R China; [Zhang, Yanyang] Henan Prov Ctr Dis Control & Prevent, Inst Expanded Program Immunizat, Zhengzhou, Peoples R China; [Liu, Yawen] Jilin Univ, Sch Publ Hlth, Dept Epidemiol & Stat, Changchun, Peoples R China; [Yang, Chunxia] Sichuan Univ, West China Univ Hosp 4, West China Sch Publ Hlth, Dept Epidemiol & Biostat, Chengdu, Peoples R China; [Wang, Yueyun] Southern Med Univ, Affiliated Shenzhen Matern & Child Healthcare Hos, Dept Healthcare, Shenzhen, Peoples R China; [Wang, Yan] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Canc Inst, Urumqi, Peoples R China; [Yu, Yanqin] Baotou Med Coll, Sch Publ Hlth, Baotou, Inner Mongolia, Peoples R China; [Hong, Ying] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Nanjing, Peoples R China; [Zhang, Xingxing; Bian, Rui; Cao, Xian; Xu, Lili] MSD China, MRL Global Med Affairs, Shanghai, Peoples R China		Zhao, FH (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Canc Epidemiol,Natl Canc Ctr, 17 South Panjiayuan Lane,POB 2258, Beijing 100021, Peoples R China.	zhaofangh@cicams.ac.cn	liu, yawen/J-2471-2014		MSD China	Funding for this research was provided by MSD China.	Abou El-Ola MJ, 2018, THER CLIN RISK MANAG, V14, DOI 10.2147/TCRM.S152737; Alhashimi E, 2018, WORLD J PHARM RES, V7, P62, DOI [10.17605/OSF.IO/VJ3RM., DOI 10.17605/OSF.IO/VJ3RM.]; [Anonymous], 2019, ACCESS HPV VACCINE E; BETTINGHAUS EP, 1986, PREV MED, V15, P475, DOI 10.1016/0091-7435(86)90025-3; Brisson M, 2019, LANCET ONCOL, V20, P319, DOI 10.1016/S1470-2045(19)30072-5; Cates JR, 2010, J ADOLESCENT HEALTH, V47, P305, DOI 10.1016/j.jadohealth.2010.04.003; Coleman MA, 2011, VACCINE, V29, P3945, DOI 10.1016/j.vaccine.2011.03.093; Cooper DL, 2018, AM J MENS HEALTH, V12, P1966, DOI 10.1177/1557988318803163; Cummings T, 2015, SEX TRANSM DIS, V42, P601, DOI 10.1097/OLQ.0000000000000358; Donders GGG, 2008, ARCH GYNECOL OBSTET, V277, P291, DOI 10.1007/s00404-007-0487-1; Herrero R, 2015, LANCET ONCOL, V16, pE206, DOI 10.1016/S1470-2045(14)70481-4; Hickler B, 2015, VACCINE, V33, P4155, DOI 10.1016/j.vaccine.2015.04.034; Li J, 2009, VACCINE, V27, P1210, DOI 10.1016/j.vaccine.2008.12.020; Marlow LAV, 2013, VACCINE, V31, P763, DOI 10.1016/j.vaccine.2012.11.083; McCormack PL, 2014, DRUGS, V74, P1253, DOI 10.1007/s40265-014-0255-z; Mohammed KA, 2018, PREV MED, V109, P39, DOI 10.1016/j.ypmed.2018.01.016; National Bureau of Statistics of China, 2016, NAT DAT; National Services Scotland Information Services Division, 2015, CANC CERV UT ICD 10; Ojinnaka Chinedum O, 2017, Prev Med Rep, V5, P257, DOI 10.1016/j.pmedr.2017.01.005; Palefsky JM, 1996, OBSTET GYN CLIN N AM, V23, P895, DOI 10.1016/S0889-8545(05)70281-3; Palefsky JM, 2010, J ADOLESCENT HEALTH, V46, pS12, DOI 10.1016/j.jadohealth.2010.01.010; Reiter PL, 2013, VACCINE, V31, P3121, DOI 10.1016/j.vaccine.2013.04.068; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405; Santhanes D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21912-x; Sauvageau C, 2016, HUM VACC IMMUNOTHER, V12, P1560, DOI 10.1080/21645515.2015.1112474; Serrano B, 2018, BEST PRACT RES CL OB, V47, P14, DOI 10.1016/j.bpobgyn.2017.08.006; Tadesse SK, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0231-0; The Lancet, 2018, Lancet, V392, P360, DOI 10.1016/S0140-6736(18)31695-7; Thompson EL, 2020, VACCINE, V38, P3143, DOI 10.1016/j.vaccine.2020.01.053; WHO, 2019, IMPR VACC DEM ADDR H; Working Group on Human Papillomavirus Immunization, 2018, STRAT ADV GROUP EXP; World Health Organization, 2020, VACC INTR SLID; World Health Organization. International Agency for Research on Cancer, 2018, GLOB CANC OBS; Xue L, 2018, HUM VACC IMMUNOTHER, V14, P404, DOI 10.1080/21645515.2017.1393132; Yujie X., 2020, CHINA APPROVES PRODU; Zhang Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-2045-8; Zhao FH, 2012, ASIAN PAC J CANCER P, V13, P2369, DOI 10.7314/APJCP.2012.13.5.2369; Zhao FH, 2019, LANCET, V393, P969, DOI 10.1016/S0140-6736(18)32849-6; Zhou M, 2019, HUM VACC IMMUNOTHER, V15, P1688, DOI 10.1080/21645515.2018.1547605; Zou HC, 2016, HUM VACC IMMUNOTHER, V12, P1551, DOI 10.1080/21645515.2015.1099771	40	11	12	6	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2021	39	1					35	44		10.1016/j.vaccine.2020.11.029			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PI2XL	33243631	hybrid			2022-04-29	WOS:000600959400006
J	Byrne, T; Patel, P; Shrotri, M; Beale, S; Michie, S; Butt, J; Hawkins, N; Hardelid, P; Rodger, A; Aryee, A; Braithwaite, I; Fong, WLE; Fragaszy, E; Geismar, C; Kovar, J; Navaratnam, AMD; Nguyen, V; Hayward, A; Aldridge, RW; Wijlaar, L; Nastouli, E; Spyer, M; Killingley, B; Cox, I; Lampos, V; McKendry, RA; Cheng, T; Liu, YZ; Johnson, AM; Gibbs, J; Gilson, R				Byrne, Thomas; Patel, Parth; Shrotri, Madhumita; Beale, Sarah; Michie, Susan; Butt, Jabeer; Hawkins, Nicky; Hardelid, Pia; Rodger, Alison; Aryee, Anna; Braithwaite, Isobel; Fong, Wing Lam Erica; Fragaszy, Ellen; Geismar, Cyril; Kovar, Jana; Navaratnam, Annalan M. D.; Nguyen, Vincent; Hayward, Andrew; Aldridge, Robert W.; Wijlaar, Linda; Nastouli, Eleni; Spyer, Moira; Killingley, Ben; Cox, Ingemar; Lampos, Vasileios; McKendry, Rachel A.; Cheng, Tao; Liu, Yunzhe; Johnson, Anne M.; Gibbs, Jo; Gilson, Richard			Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch)	VACCINE			English	Article						COVID-19; Vaccine; Intention; Public Health	MINORITY ETHNIC-GROUPS; UNDER-REPRESENTATION	Background: Vaccination intention is key to the success of any vaccination programme, alongside vaccine availability and access. Public intention to take a COVID-19 vaccine is high in England and Wales compared to other countries, but vaccination rate disparities between ethnic, social and age groups has led to concern. Methods: Online survey of prospective household community cohort study participants across England and Wales (Virus Watch). Vaccination intention was measured by individual participant responses to 'Would you accept a COVID-19 vaccine if offered?', collected in December 2020 and February 2021. Responses to a 13-item questionnaire collected in January 2021 were analysed using factor analysis to investigate psychological influences on vaccination intention. Results: Survey response rate was 56% (20,785/36,998) in December 2020 and 53% (20,590/38,727) in February 2021, with 14,880 adults reporting across both time points. In December 2020, 1,469 (10%) participants responded 'No' or 'Unsure'. Of these people, 1,266 (86%) changed their mind and responded 'Yes' or 'Already had a COVID-19 vaccine' by February 2021. Vaccination intention increased across all ethnic groups and levels of social deprivation. Age was most strongly associated with vaccination intention, with 16-24-year-olds more likely to respond "Unsure" or "No" versus "Yes" than 65-74-year-olds in December 2020 (OR: 4.63, 95 %CI: 3.42, 6.27 & OR 7.17 95 %CI: 4.26,12.07 respectively) and February 2021 (OR: 27.92 95 %CI: 13.79, 56.51 & OR 17.16 95 %CI: 4.12, 71.55). The association between ethnicity and vaccination intention weakened, but did not disappear, over time. Both vaccine-and illness-related psychological fac-tors were shown to influence vaccination intention. Conclusions: Four in five adults (86%) who were reluctant or intending to refuse a COVID-19 vaccine in December 2020 had changed their mind in February 2021 and planned to accept, or had already accepted, a vaccine. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Byrne, Thomas; Patel, Parth; Shrotri, Madhumita; Beale, Sarah; Aryee, Anna; Braithwaite, Isobel; Fong, Wing Lam Erica; Fragaszy, Ellen; Geismar, Cyril; Navaratnam, Annalan M. D.; Nguyen, Vincent; Aldridge, Robert W.] UCL, Inst Hlth Informat, Ctr Publ Hlth Data Sci, 222 Euston Rd, London NW1 2DA, England; [Beale, Sarah; Geismar, Cyril; Kovar, Jana; Navaratnam, Annalan M. D.; Nguyen, Vincent; Hayward, Andrew] UCL, Inst Epidemiol & Hlth Care, 1-19 Torrington Pl, London WC1E 7HB, England; [Michie, Susan] UCL, Ctr Behav Change, 1-19 Torrington Pl, London WC1E 7HB, England; [Butt, Jabeer] Race Equal Fdn, 27 Greenwood Pl, London NW5 1LB, England; [Hardelid, Pia; Wijlaar, Linda; Nastouli, Eleni; Spyer, Moira] UCL Great Ormond St Inst Child Hlth, Dept Populat Policy & Practice, 30 Guilford St, London WC1N 1EH, England; [Rodger, Alison; Johnson, Anne M.; Gibbs, Jo; Gilson, Richard] UCL, Inst Global Hlth, 30 Guilford St, London WC1N 1EH, England; [Rodger, Alison] Royal Free London NHS Fdn Trust, Pond St, London NW3 2QG, England; [Fragaszy, Ellen] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England; [Nastouli, Eleni; Spyer, Moira] Francis Crick Inst, 1 Midland Rd, London NW1 1AT, England; [Killingley, Ben] Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Hlth Protect & Influenza Res Grp, Nottingham, England; [Killingley, Ben] Univ Coll London Hosp, Euston Rd, London WC1H 8NJ, England; [Cox, Ingemar; Lampos, Vasileios] UCL, Dept Comp Sci, 17-19 Gordon St, London WC1H 0AH, England; [McKendry, Rachel A.] UCL, London Ctr Nanotechnol, London, England; [McKendry, Rachel A.] UCL, Div Med, London, England; [Cheng, Tao; Liu, Yunzhe] UCL, Dept Civil Environm & Geomat Engn, SpaceTimeLab, London, England		Aldridge, RW (通讯作者)，UCL, Inst Hlth Informat, Ctr Publ Hlth Data Sci, 222 Euston Rd, London NW1 2DA, England.	t.byrne@ucl.ac.uk; parth.patel@ucl.ac.uk; r.aldridge@ucl.ac.uk		Shrotri, Madhumita/0000-0001-9791-122X; Cheng, Tao/0000-0002-5503-9813; Patel, Parth/0000-0001-5207-2776; Aryee, Anna/0000-0001-9537-8011; Aldridge, Robert/0000-0003-0542-0816; Lampos, Vasileios/0000-0001-8555-2063; Fragaszy, Ellen/0000-0002-0178-6098; Geismar, Cyril/0000-0002-8486-5890; Byrne, Thomas/0000-0001-8667-0870	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_PC 19,070, MR/V028375/1]; Wellcome Trust through a Wellcome Clinical Research Career Development Fellowship [206602]	The research costs for the study have been supported by the MRC Grant Ref: MC_PC 19,070 awarded to UCL on 30 March 2020 and MRC Grant Ref: MR/V028375/1 awarded on 17 August 2020. The study also received $15,000 of Facebook advertising credit to support a pilot social media recruitment campaign on 18th August 2020. This study was supported by the Wellcome Trust through a Wellcome Clinical Research Career Development Fellowship to RA [206602]. The sponsors of the study had no role in conducting this analysis or drafting this manuscript.	[Anonymous], 2021, IMPERIAL NEWS; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Department of Health and Social Care, 2020, PRIOR GROUPS COR COV; Department of Transport, 2020, TRAV VEH AV INC ETHN; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gill PS, 2013, BRIT J GEN PRACT, V63, P342, DOI 10.3399/bjgp13X668456; GOV.UK, 2021, OFF UK COR DASHB; GOV.UK, 2021, UK COVID 19 VACC DEL; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Hayanga B, 2021, AGEING SOC, V41, P1521, DOI 10.1017/S0144686X19001624; Hayward A, 2020, RISK FACTORS SYMPTOM, DOI [10.1101/2020.12.15.20248254, DOI 10.1101/2020.12.15.20248254]; Ipsos Mori KnowledgePanel Poll, 2021, UPT COVID 19 VACC; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; MacKenna B., TRENDS REGIONAL VARI, DOI [10.1101/2021.01.25.21250356, DOI 10.1101/2021.01.25.21250356V3, DOI 10.1101/2021.01.25.21250356]; Martin, ASS DEMOGRAPHIC OCCU, DOI [10.1101/2021.02.11.21251548v2, DOI 10.1101/2021.02.11.21251548V2]; MHCLG, 2019, MHCLG OP DAT IND MUL; Office for National Statistics, 2021, COR VACC HES GREAT B; Office for National Statistics, COR VACC RAT PEOPL A; Patel P, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2282; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Race Equality Foundation, 2021, COV VACC PROGR NEED; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n513; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Royal Society & British Academy, COVID 19 VACC DEPL B; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Scientific Advisory Group for Emergencies (SAGE), 2020, FACTORS INFLUENCING; Smart A, 2017, ETHNIC HEALTH, V22, P65, DOI 10.1080/13557858.2016.1182126; Watkinson RE, 2021, LANCET PUBLIC HEALTH, V6, pE145, DOI 10.1016/S2468-2667(20)30287-5; Williams DR, 2019, ANNU REV PUBL HEALTH, V40, P105, DOI 10.1146/annurev-publhealth-040218-043750; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization, 2019, 10 HLTH ISS WHO WILL	32	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 26	2021	39	48					7108	7116		10.1016/j.vaccine.2021.09.066		NOV 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XB3QQ	34728095	Green Published, Green Accepted, hybrid, Green Submitted			2022-04-29	WOS:000721246800020
J	Chapin-Bardales, J; Myers, T; Gee, J; Shay, DK; Marquez, P; Baggs, J; Zhang, BC; Licata, C; Shimabukuro, TT				Chapin-Bardales, Johanna; Myers, Tanya; Gee, Julianne; Shay, David K.; Marquez, Paige; Baggs, James; Zhang, Bicheng; Licata, Charles; Shimabukuro, Tom T.			Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system	VACCINE			English	Article						COVID-19; COVID-19 vaccines; mRNA COVID-19 vaccines; Reactogenicity	PRACTICES INTERIM RECOMMENDATION; ADVISORY-COMMITTEE; UNITED-STATES; VACCINATION; MODERNA	Background: Post-authorization monitoring of mRNA-based COVID-19 vaccines is needed to better characterize their reactogenicity. We assessed reactions reported during the 2 weeks after receipt of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines. Methods: We monitored persons who enrolled in v-safe after vaccination health checker(SM), a U.S. smartphone-based vaccine monitoring system, after receiving BNT162b2 or mRNA-1273. V-safe participants received text message prompts to complete web-based surveys. We analyzed responses from persons who received BNT162b2 or mRNA-1273 from December 14, 2020 through March 14, 2021 and completed at least one survey by March 28, 2021. We measured the proportion of participants reporting local and systemic reactions solicited in surveys completed days 0 through 7 post-vaccination. For day 14 surveys, participants described new or worsening symptoms in a free-text response. We assessed the proportion of participants reporting new or worsening local and systemic reactions. Results: One-third of participants were aged <45 years, two-thirds were female, and approximately half received BNT162b2 vaccine. A total of 4,717,908 participants reported during the 7 days after dose 1 and 2,906,377 reported during the 7 days after dose 2. Most reported at least one injection-site reaction (68.5% after dose 1; 72.9% after dose 2) or at least one systemic reaction (50.6% after dose 1; 69.5% after dose 2). Reactogenicity was greater after dose 2 and among mRNA-1273 recipients, persons aged 45 years, and females. New or worsening local and systemic reactions were uncommon during week 2 after either dose; the most frequent were local reactions for dose 1 mRNA-1273 recipients (2.6%). These reactions were reported more often among females after dose 1 mRNA-1273 (3.6%). Conclusions: During post-authorization monitoring among 4 million vaccinees, local and systemic reactions were commonly reported following mRNA-based vaccines. Reactions were most common during the first week following dose 2 and among persons aged <45 years, females, and mRNA-1273 recipients. Published by Elsevier Ltd.	[Chapin-Bardales, Johanna; Myers, Tanya; Gee, Julianne; Shay, David K.; Marquez, Paige; Baggs, James; Zhang, Bicheng; Licata, Charles; Shimabukuro, Tom T.] Ctr Dis Control & Prevent, CDC COVID 19 Response Team, 1600 Clifton Rd NE, Atlanta, GA 30329 USA		Gee, J (通讯作者)，Ctr Dis Control & Prevent, COVID 19 Response Team, 1600 Clifton Rd NE,Mailstop V18-4, Atlanta, GA 30329 USA.	ecoevent416@cdc.gov		Myers, Tanya/0000-0003-3213-8402; Zhang, Bicheng/0000-0003-0856-2115			Ackerson B, 2021, VACCINE, V39, P926, DOI 10.1016/j.vaccine.2020.12.076; Advisory Council on Immunization Practices, 2021, LIVE M ARCH JAN 27; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2021, CDC COVID 19 DATA TR; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Blumenthal KG, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMc2104751; Blumenthal KG, 2021, NEW ENGL J MED, V384, P1273, DOI 10.1056/NEJMc2102131; Cassell DL, SAS GLOB FOR 2007; Centers for Disease Control and Prevention, 2021, POSS SID EFF GETT CO; Centers for Disease Control and Prevention, 2021, VACC DEM TRENDS; Centers for Disease Control and Prevention, 2021, V SAF ACT SURV COVID; Centers for Disease Control and Prevention, 2020, COVID 19 VACC ANSW P; Chapin-Bardales J, 2021, JAMA-J AM MED ASSOC, V325, P2201, DOI 10.1001/jama.2021.5374; Christie A, 2021, MMWR-MORBID MORTAL W, V70, P858, DOI 10.15585/mmwr.mm7023e2externalicon; El Yousfi M, 2005, MECH AGEING DEV, V126, P874, DOI 10.1016/j.mad.2005.03.008; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; McMahon DE, 2021, J AM ACAD DERMATOL, V85, P46, DOI 10.1016/j.jaad.2021.03.092; Oliver SE, 2021, MMWR-MORBID MORTAL W, V69, P1653, DOI 10.15585/mmwr.mm695152e1; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Samarakoon U, 2021, NEW ENGL J MED, V385, P662, DOI 10.1056/NEJMc2108620; Shimabukuro TT, 2021, JAMA-J AM MED ASSOC, V325, P1101, DOI 10.1001/jama.2021.1967; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Weise, 2021, USA TODAY; Wortham JM, 2020, MMWR-MORBID MORTAL W, V69, P923, DOI 10.15585/mmwr.mm6928e1	28	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 26	2021	39	48					7066	7073		10.1016/j.vaccine.2021.10.019		NOV 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XB3QQ	34763946	Bronze, Green Published			2022-04-29	WOS:000721246800015
J	Sanz-Rojo, S; Jimenez-Garcia, R; Lopez-de-Andres, A; de Miguel-Diez, J; Perez-Farinos, N; Zamorano-Leon, JJ				Sanz-Rojo, Sara; Jimenez-Garcia, Rodrigo; Lopez-de-Andres, Ana; de Miguel-Diez, Javier; Perez-Farinos, Napoleon; Zamorano-Leon, Jose J.			Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020	VACCINE			English	Article						Influenza; Vaccine; Uptake; Diabetes; Cancer; Health care workers; Cerebrovascular diseases; Cardiovascular diseases; Respiratory diseases	SEASONAL INFLUENZA; SELF-REPORT	Objective: Using the 2020 European Health Survey for Spain (EHSS2020), which ran from July 2019 to July 2020, we aimed to describe influenza vaccination uptake among the following target groups; individuals aged >65 years, health care workers (HCWs), and persons with high-risk chronic medical conditions. We analyzed changes in uptake since the previous Spanish National Health Interview Survey conducted in 2017 and identified variables associated with vaccine uptake. [Methods: We performed a cross-sectional study. The primary study variable was the self-reported uptake of influenza vaccine in the previous year. We analyzed sex, age, country of birth, and being an HCW. We identified participants with self-reported respiratory diseases, cardiovascular disease, diabetes, cancer, and cerebrovascular diseases. Multivariable logistic regression was applied to assess changes over time and to identify variables associated with vaccination in target groups.[ Results: Uptake was 19.2% in 22,072 participants aged >15 years. Uptake was 54.4% for those aged >65 years, 41.6% for those with a high-risk medical condition, and 26.53% among HCWs. Uptake by disease was 52.1% for cerebrovascular diseases, 51.3% for cardiovascular diseases, 48.3% for diabetes, 46.1% for cancer, and 36.2% for respiratory diseases. No significant improvement has been observed since 2017 in any target group, except for participants with cancer, whose uptake increased from 33.2% to 46.1%(p < 0.001). The variables that significantly increased the probability of reporting vaccine uptake were female sex, age >35 years, being born in Spain, self-reported respiratory or cardiovascular diseases, diabetes, cancer, and being a HCW. Conclusions: Influenza vaccination uptake among target groups in Spain is below desirable levels and has not improved significantly since 2017. Older age, female sex, and being born in Spain are positive predictors of vaccine uptake. The COVID-19 pandemic highlights the urgent need to implement new strategies to increase influenza vaccine uptake. (c) 2021 Elsevier Ltd. All rights reserved.	[Sanz-Rojo, Sara; Jimenez-Garcia, Rodrigo; Lopez-de-Andres, Ana; Zamorano-Leon, Jose J.] Univ Complutense, Fac Med, Dept Publ Hlth & Maternal & Child Hlth, Madrid, Spain; [de Miguel-Diez, Javier] Univ Complutense Madrid, Inst Invest Sanitaria Gregorio Maranon IiSGM, Hosp Gen Univ Gregorio Maranon, Resp Care Dept, Madrid, Spain; [Perez-Farinos, Napoleon] Univ Malaga, Fac Med, Publ Hlth & Psychiat Dept, Malaga, Spain		Jimenez-Garcia, R (通讯作者)，Univ Complutense Madrid, Dept Publ Hlth & Maternal & Child Hlth, Pza Ramon y Cajal S-N, Madrid 28040, Spain.	rodrijim@ucm.es	; Jimenez Garcia, Rodrigo/D-4953-2019	ZAMORANO LEON, JOSE JAVIER/0000-0003-0686-4208; de Miguel-Diez, Javier/0000-0003-4543-573X; Jimenez Garcia, Rodrigo/0000-0001-5906-9393	FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, Instituto deSalud Carlos III) - European Union through the Fondo Europeo de Desarrollo Regional (FEDER, "Una manera de hacer Europa") [PI20/00118]	This study forms part of research funded by the FIS (Fondo de Investigaciones Sanitarias-Health Research Fund, Instituto deSalud Carlos III) co-financed by the European Union through the Fondo Europeo de Desarrollo Regional (FEDER, "Una manera de hacer Europa") : grant no. PI20/00118.	Akmatov MK, 2021, VACCINE, V39, P952, DOI 10.1016/j.vaccine.2020.12.081; Astray-Mochales J, 2016, VACCINE, V34, P4898, DOI 10.1016/j.vaccine.2016.08.065; Bonet-Esteve A, 2021, BMC FAM PRACT, V22, DOI 10.1186/s12875-021-01434-8; Casalino E, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0193029, 10.1371/journa.pone.0193029]; CDC, FLU VACCINATION COVE; Centers for Disease Control and Prevention (CDC), INFL VACC COV HLTH C; Dios-Guerra C, 2017, VACCINE, V35, P7095, DOI 10.1016/j.vaccine.2017.10.086; Epicentro, 2019, SIST SORV PASS; European Centre for Disease Prevention and Control, EXP OP PRIOR RISK GR; European Centre for Disease Prevention and Control, 2018, SEASONAL INFLUENZA V; Godoy P, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0259-0; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Info BDCAP, NUM 4 FLU VACC COV R; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Kini A, 2022, VACCINE, V40, P1643, DOI 10.1016/j.vaccine.2021.04.013; Korn E.L., 1999, ANAL HLTH SURVEYS; Kwon Y, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040367; Loiacono MM, 2020, VACCINE-X, V4, DOI 10.1016/j.jvacx.2020.100054; Lu PJ, 2019, AM J PREV MED, V57, P458, DOI 10.1016/j.amepre.2019.04.007; Mangtani P, 2007, EPIDEMIOL INFECT, V135, P139, DOI 10.1017/S0950268806006479; Martinez-Huedo MA, 2020, HUM VACC IMMUNOTHER, V16, P95, DOI 10.1080/21645515.2019.1646577; Ministerio de Sanidad, NAT HLTH SURV 2017 M; Ministerio de Sanidad, VACCINATION COVERAGE; Ministerio de Sanidad, CARG ENF GRIP EST IM; Ministerio de Sanidad, EUR HLTH SURV SPAIN; Ministerio de Sanidad, REC VAC FRENT GRIP T; Montserrat-Capdevila J, 2015, GAC SANIT, V29, P383, DOI 10.1016/j.gaceta.2015.02.004; National Center for Immunization and Respiratory Diseases US Centers for Disease Control and Prevention, WEEKL CUM NUMB INFL; OECD, 2019, HLTH GLANC 2019, DOI [10.1787/88aec836-en, DOI 10.1787/88AEC836-EN]; Luceron CO, 2021, REV ESP SALUD PUBLIC, V95; Paget J, 2020, VACCINE, V38, P6485, DOI 10.1016/j.vaccine.2020.08.024; de la Cruz SP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020327; Public Health Agency of Canada, SEASONAL INFLUENZA V; Public Health England, SEASONAL INFLUENZA V; Rodriguez-Rieiro C, 2010, VACCINE, V28, P6203, DOI 10.1016/j.vaccine.2010.07.013; Rolfes MA, 2018, INFLUENZA OTHER RESP, V12, P132, DOI 10.1111/irv.12486; Rolnick SJ, 2013, VACCINE, V31, P3928, DOI 10.1016/j.vaccine.2013.06.041; Rosano A, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2549-9; Schumacher S, 2021, INFECTION, V49, P387, DOI 10.1007/s15010-020-01555-9; Torner N, 2016, ATEN PRIM, V48, P192, DOI 10.1016/j.aprim.2014.09.014; Trucchi C, 2021, HUM VACC IMMUNOTHER, V17, P1387, DOI 10.1080/21645515.2020.1810494; WHO, INFL SEAS; WHO Regional Office for Europe, METH ASS INFL VACC C; World Health Organization, WHO SAGE SEAS INFL V; Zimmerman RK, 2003, VACCINE, V21, P1486, DOI 10.1016/S0264-410X(02)00700-4; Zurcher K, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-041354	46	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 26	2021	39	48					7012	7020		10.1016/j.vaccine.2021.10.059		NOV 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XB3QQ	34742593				2022-04-29	WOS:000721246800008
J	Baptiste, AEJ; Masresha, B; Wagai, J; Luce, R; Oteri, J; Dieng, B; Bawa, S; Ikeonu, OC; Chukwuji, M; Braka, F; Sanders, EAM; Hahne, S; Hak, E				Baptiste, Anne Eudes Jean; Masresha, Balcha; Wagai, John; Luce, Richard; Oteri, Joseph; Dieng, Boubacar; Bawa, Samuel; Ikeonu, Obianuju Caroline; Chukwuji, Martin; Braka, Fiona; Sanders, E. A. M.; Hahne, Susan; Hak, Eelko			Trends in measles incidence and measles vaccination coverage in Nigeria, 2008-2018	VACCINE			English	Article						Measles; Coverage; Epidemiology; Nigeria		Introduction: All WHO regions have set measles elimination objective for 2020. To address the specific needs of achieving measles elimination, Nigeria is using a strategy focusing on improving vaccination coverage with the first routine dose of (monovalent) measles (MCV1) at 9 months, providing measles vaccine through supplemental immunization activities (children 9-59 months), and intensified measles case-based surveillance system. Methods: We reviewed measles immunization coverage from population-based surveys conducted in 2010, 2013 and 2017-18. Additionally, we analyzed measles case-based surveillance reports from 2008-2018 to determine annual, regional and age-specific incidence rates. Findings: Survey results indicated low MCV1 coverage (54.0% in 2018); with lower coverage in the North (mean 45.5%). Of the 153,097 confirmed cases reported over the studied period, 85.5% (130,871) were from the North. Moreover, 70.8% (108,310) of the confirmed cases were unvaccinated. Annual measles incidence varied from a high of 320.39 per 1,000,000 population in 2013 to a low of 9.80 per 1,000,000 in 2009. The incidence rate is higher among the 9-11 months (524.0 per million) and 12-59 months (376.0 per million). Between 2008 and 2018, the incidence rate had showed geographical variation, with higher incidence in the North (70.6 per million) compare to the South (17.8 per million). Conclusion: The aim of this study was to provide a descriptive analysis of measles vaccine coverage and incidence in Nigeria from 2008 to 2018 to assess country progress towards measles elimination. Although the total numbers of confirmed measles cases had decreased over the time period, measles routine coverage remains sub-optimal, and the incidence rates are critically high. The high burden of measles in the North highlight the need for region-specific interventions. The measles program relies heavily on polio resources. As the polio program winds down, strong commitments will be required to achieve elimination goals. (C) 2021 World Health Organization.Published by Elsevier Ltd.	[Baptiste, Anne Eudes Jean; Wagai, John; Bawa, Samuel; Ikeonu, Obianuju Caroline; Chukwuji, Martin; Braka, Fiona] WHO, Country Off, Abuja, Nigeria; [Masresha, Balcha] WHO, African Reg Off, Brazzaville, Rep Congo; [Luce, Richard] WHO, Intercountry Support Team West Africa, Ouagadougou, Burkina Faso; [Oteri, Joseph] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria; [Dieng, Boubacar] Global Alliance Vaccines & Immunizat, Abuja, Nigeria; [Sanders, E. A. M.; Hahne, Susan] Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands; [Hak, Eelko] Univ Groningen, Groningen Res Inst Pharm, Groningen, Netherlands		Baptiste, AEJ (通讯作者)，WHO, Country Off, Abuja, Nigeria.	jeana@who.int			World Health Organization Country Office in Nigeria	This supplement was sponsored by the World Health Organization Country Office in Nigeria. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors.	Aly HAA, 2015, WHO TECH REP SER, V994, P1; Carazo S, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4870-x; Federal Ministry of Health and WHO Nigeria, 2012, GUID MEASL SURV OUTB; Hayford K, 2019, VACCINE, V37, P2387, DOI 10.1016/j.vaccine.2019.02.037; Hutt U, 2000, PREDICTING PREVENTIN, P279; Liu FC, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1766-6; Masresha B, 2019, J IMMUNOL SCI, V2, P113; Masresha Balcha, 2018, J Immunol Sci, VSuppl, P135; National Bureau of Statistics of Nigeria-UNICEF, NIG MULT IND CLUST S; National Population Commission (NPC) [Nigeria] and ICF International, 2013, NIG DEM SURV, P538; PAHO, PAHO WHO MEASL ELIM; Peabody Taguiwalo, 2006, DIS CONTROL PRIORITI, V2nd 2nd; Phillips MA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.50; Postolovska I, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000466; Strebel PM, 2000, MEASLES; Sundaram Maria E, 2019, AM MED ASS, V321, P1156; Talley L, 2003, AM J TROP MED HYG, V68, P545, DOI 10.4269/ajtmh.2003.68.545; The World Bank, NIGERIA; Weldegebriel GG, 2011, J INFECT DIS, V204, pS226, DOI 10.1093/infdis/jir136; Winter AK, 2018, J INFECT DIS, V218, P355, DOI 10.1093/infdis/jiy137; World Health Organisation, 2016, PLANNING IMPLEMENTIN, P201; World Health Organization, 2017, MEASL VACC WHO POS P; World Health Organization, 2018, GLOB ACT PLAN PHYS A, DOI DOI 10.1016/J.JPOLMOD.2006.06.007; World Health Organization, 2010, WHO VACC PREV DIS MO; World Health Organization, 2018, 2018 ASS REP GLOB VA, P36	25	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 17	2021	39			3			C89	C95		10.1016/j.vaccine.2021.03.095		NOV 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WZ1KH	33875267	hybrid, Green Published			2022-04-29	WOS:000719731500013
J	de Haas, TDJ; Yeung, KHT; Hutubessy, R; van der Putten, IM; Nelson, EAS				de Haas, Thomas D. J.; Yeung, Karene Hoi Ting; Hutubessy, Raymond; van der Putten, Ingeborg Maria; Nelson, E. Anthony S.			Programme costs for introducing age/gestation-based universal influenza vaccine schedules for young children and pregnant women in Hong Kong	VACCINE			English	Article						Influenza; Immunisation; Economic evaluation; Young children; Pregnant women; High income countries	PREVALENCE	Background: Hong Kong experiences year-round influenza activity with winter and summer peaks. The government's Vaccination Subsidy Scheme (VSS) provides vaccine to high-risk groups prior to the larger winter peak. The VSS is predominantly administered through the private sector. This study aimed to cost the two theoretical routine influenza vaccination schedules using both northern and southern hemisphere vaccines, administered according to child's age and women's gestation, from a governmental perspective; and compare these costs to the costs of government's seasonal VSS assuming equivalent coverage estimates to determine the budget impacts of these influenza vaccination programmes in Hong Kong. Methods: We used the World Health Organization's Flutool Plus to estimate the incremental annual costs for immunising young children aged 6 months to 2 years and pregnant women with influenza vaccine during 2021, assuming the latter group accesses the public system for some antenatal care. Inputs were based on literature review, publicly available data and expert opinions. Sensitivity analyses were done with various coverage rates and vaccine costs. Results: The annual incremental cost (including vaccine price) to vaccinate young children with three doses of influenza vaccine during the first two years of life was estimated at USD 1,175,146 (per-dosecost of USD 10.55) at 75% coverage while that to vaccinate pregnant women with one dose at 60% coverage was estimated at USD 398,555 (per-dose-cost of USD 13.39). Across a range of sensitivity analyses we predict that routine year-round schedules could be cost-saving to the government compared to the VSS. Implementing routine immunisation to both risk groups equates to USD 1,573,701, i.e., 0.012% of Hong Kong's annual healthcare spending. Conclusion: Proposed year-round universal schedules providing influenza immunisation according to the child's age or the woman's gestation are predicted to be cost-saving compared to the current seasonally administered subsidised vaccine programme. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[de Haas, Thomas D. J.; van der Putten, Ingeborg Maria] Maastricht Univ, Dept Hlth Serv Res, Care & Publ Hlth Res Inst, CAPHRI, Maastricht, Netherlands; [Yeung, Karene Hoi Ting; Nelson, E. Anthony S.] Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China; [Hutubessy, Raymond] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland		Yeung, KHT (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, Shatin, 6-F,Lui Che Woo Clinical Sci Bldg, Hong Kong, Peoples R China.	t.dehaas@student.maastrichtuniversity.nl; karene@link.cuhk.edu.hk; hutubessyr@who.int; i.vanderputten@maastrichtuniversity.nl; tony-nelson@cuhk.edu.hk		van der Putten, Ingeborg M/0000-0002-7734-2856			Butalid RL., 2018, THESIS MAASTRICHT U; Census and Statistics Department HKSAR, 2020, TRENDS INFANT MORTAL; Census and Statistics Department HKSAR, HONG KONG POP PROJ 2; Centre for Disease Control and Prevention, 2020, CDC VACC PRIC LIST; Centre for Health Protection, REC SEAS INFL VACC 2; Centre for Health Protection, 2019, CONS REC PERT VACC P; Centre for Health Protection, 2019, DET VACC SUBS SCHEM; Centre for Health Protection, SEASONAL INFLUENZA V; Chan D, 2013, COMMUNICABLE DIS WAT, V10, P74; Chan D, 2017, COMMUNICABLE DIS WAT, V14, P23; Chan PKS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002024; Children's Vaccine Program at PATH, 2003, GUIDELINES IMPLEMENT; Dang TKNS, 2021, VACCINE, V39, P6754, DOI 10.1016/j.vaccine.2021.09.076; Department of Health, 2020, BUDG HEAD, P1; Drug Office, 2019, VACC SEAS INFL; Family Health Service, CHILD HLTH IMM; Hong Kong College of Obstetrics and Gynaecology, 2014, TERR WID AUD OBST GY; Hong Kong Monetary Authority, 2019, 2019 ANN REP, P54; Janagaraj PD., 2018, COMMUN DIS INTELL, V2019, P43; Lau JTF, 2010, VACCINE, V28, P5389, DOI 10.1016/j.vaccine.2010.05.071; Maertens K, 2020, EUR J PEDIATR, V179, P235, DOI 10.1007/s00431-019-03563-w; Nelson EAS, 2014, VACCINE, V32, P6692, DOI 10.1016/j.vaccine.2014.04.063; Pereira CC, 2010, EXPERT REV VACCINES, V9, P1343, DOI [10.1586/erv.10.129, 10.1586/ERV.10.129]; Tarrant M, 2013, MATERN CHILD HLTH J, V17, P23, DOI 10.1007/s10995-011-0943-1; The Government of Hong Kong Special Administrative Region, 2019 20 SEAS INFL VA; The Government of the Hong Kong Special Administrative Region, DH LAUNCH PERT VACC; WHO, 2020, BURD DIS; Wong MCS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003359; World Health Organization, REC COMP INFL VIR VA; World Health Organization, 2018, BEST PRACT MICR POL; World Health Organization, INFL EC FLUT PLUS SI; World Health Organization, 2020, FLUT PLUS WHO SEAS I; Yeung KHT, 2018, VACCINE, V36, P5524, DOI 10.1016/j.vaccine.2018.07.066; Yeung KHT, 2018, VACCINE, V36, P3477, DOI 10.1016/j.vaccine.2018.04.081; Yeung KHT., 2017, IDENTIFYING LOWERING; You JHS, 2015, HUM VACC IMMUNOTHER, V11, P564, DOI 10.1080/21645515.2015.1011016; Yuen CYS, 2013, VACCINE, V31, P5281, DOI 10.1016/j.vaccine.2013.08.063	37	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 5	2021	39	46					6762	6780		10.1016/j.vaccine.2021.10.009		NOV 2021	19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YJ0BG	34743828	hybrid			2022-04-29	WOS:000744203800007
J	Giese, H; Neth, H; Gaissmaier, W				Giese, Helge; Neth, Hansjoerg; Gaissmaier, Wolfgang			Determinants of information diffusion in online communication on vaccination: The benefits of visual displays	VACCINE			English	Article						Vaccination; Informed medical decisions; Icon arrays; Risk literacy; Echo chambers; Vaccine hesitancy	WEB 2.0; CHALLENGES; BIAS	Objective: Social media are an increasingly important source of information on the benefits and risks of vaccinations, but the high prevalence of misinformation provides challenges for informed vaccination decisions. It is therefore important to understand which messages are likely to diffuse online and why, and how relevant aspects-such as scientific facts on vaccination effectiveness-can be made more comprehensible and more likely to be shared. In two studies, we (i) explore which characteristics of messages on flu vaccination facilitate their diffusion in online communication, and (ii) whether visual displays (i.e., icon arrays) facilitate the comprehension and diffusion of scientific effectiveness information. Methods: In Study 1, 208 participants each rated a random sample of 15 out of 63 messages on comprehensibility, trustworthiness, persuasiveness, familiarity, informativeness, valence, and arousal, and then reported which information they would share with subsequent study participants. In Study 2 (N = 758), we employed the same rating procedure for a selected set of 9 messages and experimentally manipulated how scientific effectiveness information was displayed. Results: Study 1 illustrated that scientific effectiveness information was difficult to understand and thus did not diffuse well. Study 2 demonstrated that visual displays improved the understanding of this information, which could, in turn, increase its social impact. Conclusions: The comprehensibility of scientific information is an important prerequisite for its diffusion. Visual displays can facilitate informed vaccination decisions by rendering important information on vaccination effectiveness more transparent and increasing the willingness to share this information. (c) 2021 Elsevier Ltd. All rights reserved.	[Giese, Helge; Neth, Hansjoerg; Gaissmaier, Wolfgang] Univ Konstanz, Dept Psychol, POB 43, D-78457 Constance, Germany		Giese, H (通讯作者)，Univ Konstanz, Dept Psychol, POB 43, D-78457 Constance, Germany.	helge.giese@uni-konstanz.de		Giese, Helge/0000-0001-7609-0215; Neth, Hansjorg/0000-0001-5427-3141	German Research Foundation [DFG]German Research Foundation (DFG) [FOR 2374, 441541975, EXC 2117-422037984]	This work was supported by the German Research Foundation [DFG] under Grant FOR 2374 (DFG Research Unit) , the project Grant Number 441541975, and under Germany's Excellence Strategy-EXC 2117-422037984. We would like to thank Larissa Baer and Joachim Gassert for their support in rating the material.	Arkes HR, 2012, PSYCHOL SCI, V23, P547, DOI 10.1177/0956797612437428; Berger J, 2012, J MARKETING RES, V49, P192, DOI 10.1509/jmr.10.0353; Betsch C, 2013, HEALTH PSYCHOL, V32, P146, DOI 10.1037/a0027387; Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025; Betsch C, 2011, MED DECIS MAKING, V31, P742, DOI 10.1177/0272989X11400419; BRADLEY MM, 1994, J BEHAV THER EXP PSY, V25, P49, DOI 10.1016/0005-7916(94)90063-9; Brown KF, 2010, VACCINE, V28, P4181, DOI 10.1016/j.vaccine.2010.04.012; Claessen FMAP, 2016, PSYCHOSOMATICS, V57, P47, DOI 10.1016/j.psym.2015.09.005; Demicheli V, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub6; Demicheli V, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub5; Fagerlin A, 2005, MED DECIS MAKING, V25, P398, DOI 10.1177/0272989X05278931; Fagerlin A, 2011, JNCI-J NATL CANCER I, V103, P1436, DOI 10.1093/jnci/djr318; FESTINGER L, 1962, SCI AM, V207, P93, DOI 10.1038/scientificamerican1062-93; Funk C., 2019, TRUST MISTRUST AM VI; Gaissmaier W, 2012, HEALTH PSYCHOL, V31, P286, DOI 10.1037/a0024850; Garcia-Retamero R, 2010, SOC SCI MED, V70, P1019, DOI 10.1016/j.socscimed.2009.11.031; Giese H, 2020, VACCINE, V38, P2070, DOI 10.1016/j.vaccine.2019.11.038; Guadagno RE, 2013, COMPUT HUM BEHAV, V29, P2312, DOI 10.1016/j.chb.2013.04.016; Heath C, 2001, J PERS SOC PSYCHOL, V81, P1028, DOI 10.1037//0022-3514.81.6.1028; Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112; Miton H, 2015, TRENDS COGN SCI, V19, P633, DOI 10.1016/j.tics.2015.08.007; Neth H, 2018, RISKYR TOOLBOX RENDE; Neth H, 2021, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.567817; Okan Y, 2018, RISK ANAL, V38, P929, DOI 10.1111/risa.12895; Pornpitakpan C, 2004, J APPL SOC PSYCHOL, V34, P243, DOI 10.1111/j.1559-1816.2004.tb02547.x; Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040; Schwartz LM, 2007, MED DECIS MAKING, V27, P655, DOI 10.1177/0272989x07306786; Sheeran P, 2014, PSYCHOL BULL, V140, P511, DOI 10.1037/a0033065; Siegrist M, 2001, RISK ANAL, V21, P199, DOI 10.1111/0272-4332.211102; Stone ER, 2017, RISK ANAL, V37, P612, DOI 10.1111/risa.12660; Trevena LJ, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-S2-S7; Vosoughi S, 2018, SCIENCE, V359, P1146, DOI 10.1126/science.aap9559	32	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 15	2021	39	43					6407	6413		10.1016/j.vaccine.2021.09.016		OCT 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS5LV	34561137				2022-04-29	WOS:000715223200012
J	Schneider, JC; Chen, HC; Bautista, E; Retallack, D				Schneider, Jane C.; Chen, Hubert C.; Bautista, Edgar; Retallack, Diane			Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults	VACCINE			English	Article						Anthrax; rPA; MPLA; Post-exposure prophylaxis; Vaccine; Clinical trial	PROTECTIVE ANTIGEN; PROTEIN-PRODUCTION; DEAMIDATION; BIOTHRAX(R); STRAIN	Px563L is a next-generation anthrax vaccine candidate consisting of a protein subunit, mutant recombinant protective antigen SNKE167-DFF-315-E308D (mrPA), and liposome-embedded monophosphoryl lipid A (MPLA) adjuvant. Px563L has the potential to deliver an improved safety and immunogenicity profile relative to the currently licensed vaccine, which is produced from filtered B. anthracis culture supernatants. We conducted a Phase 1, double-blind, placebo-controlled, dose-escalation study in 54 healthy subjects to evaluate Px563L at 3 dose levels of mrPA (10, 50, and 80 mcg). For each dose level, 18 subjects were randomized in an 8:8:2 ratio to Px563L (mrPA with adjuvant), RPA563 (mrPA only) or placebo (saline). Each subject received an intramuscular (IM) injection on Day 0 and Day 28. Primary safety and immunogenicity analysis was conducted after all subjects completed the Day 70 visit, a duration deemed clinically relevant for post-exposure prophylaxis. Long-term safety was assessed through Day 393. Vaccinations with Px563L at all dose levels were well-tolerated. There were no serious adverse events or adverse events (AE) leading to early withdrawal. In all treatment groups, most AEs were due to injection site reactions, and all AEs at the 10 and 50 mcg dose levels were mild. For the primary immunogenicity endpoint (protective toxin neutralizing antibody 50% neutralization factor [TNA NF50]), titers started to increase significantly after the second administration of Px563L, from Day 35 through Day 70, with the geometric mean and lower bound of the 95% confidence interval exceeding 0.56, a threshold correlating with significant survival in animal models of anthrax exposure. In conclusion, Px563L, administered as two IM doses 28 days apart, was well-tolerated and elicited a protective antibody response starting at seven days after the second vaccination. These findings support the continued development of Px563L in a two-dose regimen for anthrax post-exposure prophylaxis. ClinicalTrials.gov identifier NCT02655549. (C) 2021 The Authors. Published by Elsevier Ltd.	[Schneider, Jane C.; Chen, Hubert C.] Pfenex Inc, 10790 Roselle St, San Diego, CA 92121 USA; [Bautista, Edgar] eBio Consulting, 10790 Roselle St, San Diego, CA 92121 USA; [Retallack, Diane] Ligand Pharmaceut, 10790 Roselle St, San Diego, CA 92121 USA		Schneider, JC (通讯作者)，Pfenex Inc, 10790 Roselle St, San Diego, CA 92121 USA.	carrieschneider2000@icloud.com; dretallack@-ligand.com		Schneider, Jane/0000-0001-5496-8699; Chen, Hubert/0000-0002-7599-7218			[Anonymous], 2015, BIOTHRAX ANTHRAX VAC; Bower WA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6804a1; Brown LD, 2001, STAT SCI, V16, P101, DOI 10.1214/ss/1009213286; D'Souza AJM, 2013, J PHARM SCI-US, V102, P454, DOI 10.1002/jps.23422; Hopkins RJ, 2016, VACCINE, V34, P2096, DOI 10.1016/j.vaccine.2016.03.006; Hopkins RJ, 2014, VACCINE, V32, P2217, DOI 10.1016/j.vaccine.2014.01.073; Ionin B, 2013, CLIN VACCINE IMMUNOL, V20, P1016, DOI 10.1128/CVI.00099-13; Joellenbeck L.M., 2002, ANTHRAX VACCINE IS I; Li H, 2008, J IMMUNOL METHODS, V333, P89, DOI 10.1016/j.jim.2008.01.007; Longstreth J, 2016, EXPERT REV VACCINES, V15, P1467, DOI 10.1080/14760584.2016.1254556; Omland KS, 2008, CLIN VACCINE IMMUNOL, V15, P946, DOI 10.1128/CVI.00003-08; Peachman KK, 2012, CLIN VACCINE IMMUNOL, V19, P11, DOI 10.1128/CVI.05376-11; Ramirez DM, 2002, J IND MICROBIOL BIOT, V28, P232, DOI 10.1038/sj/jim/700239; Rao M, 2011, VACCINE, V29, P873, DOI 10.1016/j.vaccine.2010.11.049; Reed MD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130952; Retallack DM, 2012, PROTEIN EXPRES PURIF, V81, P157, DOI 10.1016/j.pep.2011.09.010; Schneider JC, 2005, BIOTECHNOL PROGR, V21, P343, DOI 10.1021/bp049696g; Semenova VA, 2004, CLIN DIAGN LAB IMMUN, V11, P919, DOI 10.1128/CDLI.11.5.919-923.2004; Shepard CW, 2002, EMERG INFECT DIS, V8, P1124, DOI 10.3201/eid0810.020349; SINGH Y, 1989, J BIOL CHEM, V264, P19103; SINGH Y, 1994, J BIOL CHEM, V269, P29039; U.S. Food and Drug Administration, 2007, GUID IND TOX GRAD SC; Wagner L, 2012, CLIN VACCINE IMMUNOL, V19, P1465, DOI 10.1128/CVI.00174-12; Wolfe DN, 2020, VACCINE, V38, P7970, DOI 10.1016/j.vaccine.2020.10.053; Zomber G, 2005, J BIOL CHEM, V280, P39897, DOI 10.1074/jbc.M508569200	25	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6333	6339		10.1016/j.vaccine.2021.08.075		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34544599	hybrid			2022-04-29	WOS:000705822100024
J	Brosh-Nissimov, T; Sorek, N; Yeshayahu, M; Zherebovich, I; Elmaliach, M; Cahan, A; Amit, S; Rotlevi, E				Brosh-Nissimov, Tal; Sorek, Nadav; Yeshayahu, Michal; Zherebovich, Irena; Elmaliach, Maria; Cahan, Amos; Amit, Sharon; Rotlevi, Erela			Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19	VACCINE			English	Article						COVID-19 vaccine; BNT162b2; Pfizer; BioNTech; Bell's palsy; Facial palsy; Herpes virus; Herpes simplex virus; Varicella zoster virus; Epstein Barr virus; Cytomegalovirus; Human herpes virus 6; Human herpes virus 7; Reactivation; Oropharyngeal shedding	BELLS-PALSY	Introduction: Concerns were raised over an increase in Bell's palsy, herpes simplex and herpes zoster after BNT162b2 vaccination, all are manifestations of herpesviruses reactivation. As herpesviruses commonly reactivate in the oropharynx, we have hypothesized that oropharyngeal shedding of herpesviruses will increase after vaccination. Methods: Immune-competent Adults, excluding those using topical steroids or manifesting symptomatic herpesvirus infection, were sampled before BNT162b2 vaccination and one week after. Herpesviruses 1-7 shedding was tested with a multiplexed PCR. Results: In 103 paired samples the prevalence of herpesviruses was similar before and after vaccination: HSV1, 3.9% vs. 5.8% (p = 0.75); HSV2, 0% vs. 1% (p = not applicable, NA); VZV, 0% vs. 0% (p = NA); EBV, 14.6% vs. 17.5% (p = 0.63); CMV, 0% vs. 0% (p = NA); HHV6, 4.9% vs. 7.8% (p = 0.55); HHV7, 71.8% vs. 72.8% (p = 1); any herpesvirus, 73.8% vs. 74.8% (p = 1). Discussion: We did not find evidence for increased oropharyngeal reactivation of herpesviruses one week after BNT162b2. (c) 2021 Elsevier Ltd. All rights reserved.	[Brosh-Nissimov, Tal; Cahan, Amos] Samson Assuta Ashdod Univ Hosp, Infect Dis Unit, Ashdod, Israel; [Brosh-Nissimov, Tal; Yeshayahu, Michal; Rotlevi, Erela] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel; [Sorek, Nadav] Samson Assuta Ashdod Univ Hosp, Microbiol Lab, Ashdod, Israel; [Sorek, Nadav; Yeshayahu, Michal; Zherebovich, Irena; Elmaliach, Maria; Rotlevi, Erela] Maccabi Healthcare Serv, Tel Aviv, Israel; [Amit, Sharon] Sheba Med Ctr, Clin Microbiol, Ramat Gan, Israel		Brosh-Nissimov, T (通讯作者)，Samson Assuta Ashdod Univ Hosp, Infect Dis Unit, Ashdod, Israel.	talbros@assuta.co.il		Brosh-Nissimov, Tal/0000-0001-7154-2032			Baringer JR, 1996, ANN INTERN MED, V124, P63, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00010; Bostan E, 2021, J COSMET DERMATOL-US, V20, P1566, DOI 10.1111/jocd.14035; Colella G, 2021, J NEUROL, V268, P3589, DOI 10.1007/s00415-021-10462-4; DOUGLAS R G JR, 1970, Journal of Immunology, V104, P289; Eid E, 2021, J MED VIROL, V93, P5231, DOI 10.1002/jmv.27036; FDA, 2020, PFIZ BIONT COVID 19; Food and Drug Administration, 2020, VACC REL BIOL PROD A, P1; Furer V, 2021, RHEUMATOLOGY, V60, pSI90, DOI 10.1093/rheumatology/keab345; Israeli Ministry Of Health, 2021, ADV EV COVID 19 VACC; Ozonoff A, 2021, LANCET INFECT DIS, V21, P450, DOI 10.1016/S1473-3099(21)00076-1; Peitersen E, 2002, ACTA OTO-LARYNGOL, V122, P4, DOI 10.1080/000164802320401694; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Repajic Michael, 2021, Brain Behav Immun Health, V13, P100217, DOI 10.1016/j.bbih.2021.100217; Rodriguez-Jimenez Pedro, 2021, JAAD Case Rep, V12, P58, DOI 10.1016/j.jdcr.2021.04.014; Salo J., 2021, NEW YORK POST; Schirm J, 1997, APMIS, V105, P815, DOI 10.1111/j.1699-0463.1997.tb05089.x; Shemer A, 2021, ISR MED ASSOC J, V23, P143; Shin SY, 2012, ANN LAB MED, V32, P44, DOI 10.3343/alm.2012.32.1.44; Yap T, 2021, ORAL DIS, V27, P378, DOI 10.1111/odi.13523	19	6	6	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5729	5731		10.1016/j.vaccine.2021.08.088		SEP 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34481701	Green Published, Bronze			2022-04-29	WOS:000697501500002
J	Hayman, B; Dennehy, M				Hayman, Benoit; Dennehy, Maureen			Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization	VACCINE			English	Article						COVID-19 vaccines; Public health; Manufacturing capabilities; Technology platforms; Global supply		Members of the Developing Countries Vaccine Manufacturers' Network (DCVMN) have been actively engaged in the development of COVID-19 vaccine candidates. According to the WHO COVID-19 vaccine landscape updated on 29 December 2020, 18 member manufacturers had vaccines in preclinical or clin-ical trials, including three members with candidates in Phase III trials. Once successful candidates have been identified there will be a need for large scale vaccine manufacturing and supply, in which DCVMN member manufacturers can play a key role. In an internal survey in 2019, DCVMN members reported the capability to supply over 3.5 billion vaccine doses annually, and the provision of over 50 dis-tinct vaccines to 170 countries. To describe the capabilities of DCVMN member manufacturers more pre-cisely, a 121-question survey was circulated to 41 Network members. The survey assessed the manufacturers' capabilities in utilizing various technology platforms, cell cultures and filling technolo-gies, in addition to their capacities for manufacturing drug products. The survey also evaluated manufac-turers' preparedness to dedicate existing capacities to COVID-19 vaccine production. Results revealed that sampled manufacturers have strong capabilities for manufacturing vaccines based on recombinant technologies, particularly with mammalian cells, and microbial and yeast expression systems. Capabilities in utilizing cell cultures were distributed across multiple cell types, however manufacturing capacities with Vero and CHO cells were prominent. Formulating and filling findings illustrated further large-scale capabilities of Network members. Sampled manufacturers reported that over 50% of their capacity for vaccine manufacturing could be dedicated to COVID-19 vaccine production. (c) 2021 Elsevier Ltd. All rights reserved.	[Hayman, Benoit] DCVMN Int, Route Crassier 7, CH-1262 Nyon, Switzerland; [Dennehy, Maureen] Qual Assist, Cape Town, South Africa		Hayman, B (通讯作者)，DCVMN Int, Route Crassier 7, CH-1262 Nyon, Switzerland.	b.hayman@dcvmn.net		Hayman, Benoit/0000-0001-6137-4549			Afkhami S, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.30; [Anonymous], COVID 19 CORONA VIRU; [Anonymous], WHO Director-General's opening remarks at the media briefing on COVID-19: 11 March 2020; [Anonymous], 2019, REPORT DEV CO VACC, DOI [10.1016/j.vaccine.2020.05.062, DOI 10.1016/J.VACCINE.2020.05.062]; AstraZeneca, 2020, ASTRAZENECA TAKES NE; BBC News, 2020, NEWS ARTICLE; Berkley S., 2020, COVAX EXPLAINED; Byme B, 2015, CURR OPIN STRUC BIOL, V32, P9, DOI 10.1016/j.sbi.2015.01.005; CNBC, 2020, NEWS ARTICLE 29 OCT NEWS ARTICLE 29 OCT; European Centre for Disease Prevention and Control, TIMELINE ECDCS RESPO; Gavi the Vaccine Alliance, 2020, NEWS ARTICLE; Gomez P.L., 2018, PLOTKINS VACCINES, p51, DOI 10.1016/B978-0-323-35761-6.00005-5; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Hayman B, 2020, VACCINE-X, V5, DOI 10.1016/j.jvacx.2020.100066; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kovesdi I, 2010, VIRUSES-BASEL, V2, P1681, DOI 10.3390/v2081681; Meng W, 2020, DCVMN ANN GEN M VIRT; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Pagliusi S, 2020, VACCINE, V38, P5418, DOI 10.1016/j.vaccine.2020.06.022; Pollet J, 2021, ADV DRUG DELIVER REV, V170, P71, DOI 10.1016/j.addr.2021.01.001; Tabari P, 2020, IRAN J MED SCI, V45, P157, DOI [10.30476/ijms.2020.85810.1537, 10.30476/IJMS.2020.85810.1537]; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; U.S. Food and Drug Administration, 2020, FDA TAKES KEY ACTION; U.S. Food and Drug Administration, 2020, FDA TAKES ADDITIONAL; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; WHO, DRAFT LANDSCAPE COVI; World Health Organisation, 2020, 172 COUNTRIES MULTIP	27	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5153	5161		10.1016/j.vaccine.2021.07.044		AUG 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34362602	Green Published, Bronze			2022-04-29	WOS:000684878300012
J	Lim, H; In, HJ; Kim, YJ; Jang, S; Lee, HY; Kim, SH; Lee, SH; Park, JH; Yang, HJ; Yoo, JS; Lee, SW; Kim, MY; Chung, GT; Yeo, SG				Lim, Heeji; In, Hyun Ju; Kim, You-Jin; Jang, Sundong; Lee, Ha Yun; Kim, Su Hwan; Lee, Sun Hwa; Park, Jun Hyuk; Yang, Hyo Jin; Yoo, Jung-Sik; Lee, Sang-Won; Kim, Mi Young; Chung, Gyung Tae; Yeo, Sang Gu			Development of an attenuated smallpox vaccine candidate: The KVAC103 strain	VACCINE			English	Article						Smallpox; Vaccinia virus; Attenuated vaccine; KVAC103 strain	VIRUS; IMMUNOGENICITY; PROTECTION; MONKEYPOX; SOFTWARE; SAFETY; MVA	Smallpox, a disease caused by the variola virus, is one of the most dangerous diseases and had killed numerous people before it was eradicated in 1980. However, smallpox has emerged as the most threatening bio-terrorism agent; as the first-and second-generation smallpox vaccines have been controversial and have caused severe adverse reactions, new demands for safe smallpox vaccines have been raised and some attenuated smallpox vaccines have been developed. We have developed a cell culture-based highly attenuated third-generation smallpox vaccine candidate KVAC103 strain by 103 serial passages of the Lancy-Vaxina strain derived from the Lister in Vero cells. Several clones were selected, taking into consideration their shape, size, and growth rate in mammalian cells. The clones were then inoculated intracerebrally in suckling mice to test for neurovirulence by observing survival. Protective immune responses in adult mice were examined by measuring the levels of neutralization antibodies and IFN-c expression. Among several clones, clone 7 was considered the best alternative candidate because there was no mortality in suckling mice against a lethal challenge. In addition, enhanced neutralizing antibodies and T-cell mediated IFN-c production were observed in clone 7-immunized mice. Clone 7 was named "KVAC103" and was used for the skin toxicity test and full-genome analysis. KVAC103-inoculated rabbits showed reduced skin lesions compared to those inoculated with the Lister strain, Lancy-Vaxina. A whole genome analysis of KVAC103 revealed two major deleted regions that might contribute to the reduced virulence of KVAC103 compared to the Lister strain. Phylogenetic inference supported the close relationship with the Lister strain. Collectively, our data demonstrate that KVAC103 holds promise for use as a third generation smallpox vaccine strain due to its enhanced safety and efficacy. (C) 2021 The Authors. Published by Elsevier Ltd.	[Lim, Heeji; In, Hyun Ju; Kim, You-Jin; Lee, Ha Yun; Kim, Su Hwan; Kim, Mi Young; Chung, Gyung Tae] Natl Inst Hlth, Natl Inst Infect Dis, Ctr Vaccine Res, Cheongju 28159, Chungbuk, South Korea; [Jang, Sundong] Chungbuk Natl Univ, Coll Pharm, Cheongju 28160, Chungbuk, South Korea; [Lee, Sun Hwa] KU Med, Dept Lab Med, Seoul 02841, South Korea; [Park, Jun Hyuk] Chungcheongnam Do Inst Hlth & Environm Res, Dept Lab Med, Hongseong 32254, South Korea; [Yang, Hyo Jin; Lee, Sang-Won] Korea Dis Control & Prevent Agcy, Cheongju 28159, Chungbuk, South Korea; [Yoo, Jung-Sik] Natl Inst Hlth, Natl Inst Infect Dis, Ctr Infect Dis Res, Cheongju 28159, Chungbuk, South Korea; [Yeo, Sang Gu] Sejong Inst Hlth & Environm Res, Div Infect Dis, Sejong City 30015, South Korea		Yeo, SG (通讯作者)，Sejong Inst Hlth & Environm Res, Div Infect Dis, Sejong City 30015, South Korea.	sg10003@gmail.com			Research of Korea Centers for Disease Control and Prevention [4800-4845-300, 4800-4859-300];  [2012-NG48002-00];  [2020-NI-017-00]	This research was supported by a fund (4800-4845-300 and 4800-4859-300) from the Research of Korea Centers for Disease Control and Prevention and the Intramural research numbers are 2012-NG48002-00 and 2020-NI-017-00.	Arita I, 2005, LANCET INFECT DIS, V5, P647, DOI 10.1016/S1473-3099(05)70242-5; Artenstein AW, 2008, EXPERT REV VACCINES, V7, P1225, DOI 10.1586/14760584.7.8.1225; Artenstein AW, 2008, REV MED VIROL, V18, P217, DOI 10.1002/rmv.571; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Breman JG, 2002, NEW ENGL J MED, V346, P1300, DOI 10.1056/NEJMra020025; Brown J, 2017, BIOINFORMATICS, V33, P3137, DOI 10.1093/bioinformatics/btx373; Chin CS, 2013, NAT METHODS, V10, P563, DOI [10.1038/NMETH.2474, 10.1038/nmeth.2474]; Cruz AGB, 2017, J VIROL, V91, DOI 10.1128/JVI.00542-17; Di Giulio DB, 2004, LANCET INFECT DIS, V4, P15, DOI 10.1016/S1473-3099(03)00856-9; Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331; Elwood JM, 1989, J EPIDEMIOL COMMUNIT, V43, P92; Eto A, 2015, VACCINE, V33, P6106, DOI 10.1016/j.vaccine.2015.07.111; Ferrier-Rembert A, 2007, VACCINE, V25, P8290, DOI 10.1016/j.vaccine.2007.09.050; Gerlic M, 2013, P NATL ACAD SCI USA, V110, P7808, DOI 10.1073/pnas.1215995110; Gordon SN, 2011, J INFECT DIS, V203, P1043, DOI 10.1093/infdis/jiq162; Hashizume S., 1985, VACCINIA VIRUSES VEC, P88; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; Jacobs BL, 2009, ANTIVIR RES, V84, P1, DOI 10.1016/j.antiviral.2009.06.006; Kennedy RB, 2009, CURR OPIN IMMUNOL, V21, P314, DOI 10.1016/j.coi.2009.04.004; Kenner J, 2006, VACCINE, V24, P7009, DOI 10.1016/j.vaccine.2006.03.087; Langford M P, 1981, Methods Enzymol, V78, P339; Lee I, 2016, INT J SYST EVOL MICR, V66, P1100, DOI 10.1099/ijsem.0.000760; Lewis-Jones S, 2004, CURR OPIN INFECT DIS, V17, P81, DOI 10.1097/00001432-200404000-00003; Li ZQ, 2004, VACCINE, V22, P1486, DOI 10.1016/j.vaccine.2003.10.022; MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375; Meseda CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149364; Moussatche N, 2008, J INFECT DEV COUNTR, V2, P156, DOI 10.3855/jidc.258; Nalca A, 2010, DRUG DES DEV THER, V4, P71; Panchanathan V, 2010, IMMUNOL CELL BIOL, V88, P461, DOI 10.1038/icb.2009.110; Pauli, 2007, EUROSURVEILLANCE, V12; Perdiguero B, 2009, J INTERF CYTOK RES, V29, P581, DOI 10.1089/jir.2009.0073; Petersen BW, 2016, MMWR-MORBID MORTAL W, V65, P257, DOI 10.15585/mmwr.mm6510a2; Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299; Rice AD, 2011, J VIROL, V85, P550, DOI 10.1128/JVI.00254-10; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Ricordel M, 2017, MOL THER-ONCOLYTICS, V7, P1, DOI 10.1016/j.omto.2017.08.003; Sharon M, 2007, VACCINE, V25, P7743, DOI 10.1016/j.vaccine.2007.09.023; Singh RK, 2012, INDIAN J VIROL, V23, P1, DOI 10.1007/s13337-012-0068-1; Sklenovska N, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00241; TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B; Voigt EA, 2016, EXPERT REV VACCINES, V15, P1197, DOI 10.1080/14760584.2016.1175305; WHO, 2006, SMALLP BIOT WORLD HL; Wiser I, 2007, VACCINE, V25, P976, DOI 10.1016/j.vaccine.2006.09.046; Yadav S, 2010, ARCH VIROL, V155, P255, DOI 10.1007/s00705-009-0562-y; Zhai DY, 2010, J BIOL CHEM, V285, P5569, DOI 10.1074/jbc.M109.078113	46	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5214	5223		10.1016/j.vaccine.2021.06.060		AUG 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34334254	hybrid			2022-04-29	WOS:000684878300018
J	Redondo, E; Drago, G; Lopez-Belmonte, JL; Guillen, JM; Bricout, H; Alvarez, FP; Callejo, D; de Miguel, AG				Redondo, Esther; Drago, Georgina; Lopez-Belmonte, Juan Luis; Guillen, Jose Maria; Bricout, Helene; Alvarez, Fabian P.; Callejo, Daniel; de Miguel, Angel Gil			Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine	VACCINE			English	Article						Influenza; HD-QIV; Cost-effectiveness; Aged; Health services for the aged	ELDERLY ADULTS; EFFICACY; IMMUNOGENICITY; RESPONSES; SAFETY	Background: The normal ageing process is accompanied by immunosenescence and a progressive weakening of the immune system. High-dose inactivated influenza quadrivalent vaccine (HD-QIV) has shown greater immunogenicity, relative efficacy, and effectiveness than the standard-dose inactivated quadriva-lent vaccine (SD-QIV). The aim of the study was to assess the cost-utility of an HD-QIV strategy compared with an adjuvanted trivalent inactivated vaccine (aTIV) strategy in the population above 65 years of age in Spain. Methods: We evaluated the public health and economic benefits of alternatives by using a decision-tree model, which included influenza cases, visits to the general practitioner (GP), visits to the emergency department (ED), hospitalisations, and mortality related to influenza. We performed deterministic and probabilistic sensitivity analyses to account for both epidemiological and economical sources of uncertainty. Results: Our results show that switching from aTIV strategy to HD-QIV would prevent 36,476 cases of influenza, 5,143 visits to GP, 1,054 visits to the ED, 9,193 episodes of hospitalisation due to influenza or pneumonia, and 357 deaths due to influenza - increasing 3,514 life-years and 3,167 quality-adjusted life-years (QALYs). Healthcare costs increase by 678,874,301, leading to an incremental cost-effectiveness ratio (ICER) of 624,353/QALY. The sensitivity analysis indicates that the results are rather robust. Conclusion: Our analysis shows that HD-QIV in people over 65 years of age is an influenza-prevention strategy that is at least cost-effective, if not dominant, in Spain. It reduces cases of influenza, GP visits, hospitalisations, deaths, and associated healthcare costs. (C) 2021 The Authors. Published by Elsevier Ltd.	[Redondo, Esther] Ctr Salud Int Madrid Salud, Ayuntamiento Madrid, Madrid, Spain; [Drago, Georgina] Sanofi Pasteur, Barcelona, Spain; [Lopez-Belmonte, Juan Luis; Guillen, Jose Maria] Sanofi Pasteur, Madrid, Spain; [Bricout, Helene; Alvarez, Fabian P.] Sanofi Pasteur, Lyon, France; [Callejo, Daniel] IQVIA, Hlth Econ & Outcomes Res, Real World Evidence Solut, Barcelona, Spain; [de Miguel, Angel Gil] Univ Rey Juan Carlos, Dept Especialidades Med & Salud Publ, Madrid, Spain		Lopez-Belmonte, JL (通讯作者)，Sanofi Pasteur, Madrid, Spain.	JuanLuis.Lopez-Belmonte@sanofi.com		Alvarez, Fabian P./0000-0003-3085-6275	Sanofi Pasteur	This study was funded by Sanofi Pasteur.	[Anonymous], 2019, COB VAC TEMP 2018 20 COB VAC TEMP 2018 20; Sacristan JA, 2020, GAC SANIT, V34, P189, DOI 10.1016/j.gaceta.2019.06.007; Aspinall Richard, 2007, Immun Ageing, V4, P9, DOI 10.1186/1742-4933-4-9; Becker DL, 2016, HUM VACC IMMUNOTHER, V12, P3036, DOI 10.1080/21645515.2016.1215395; Center for Disease Control and Prevention, 2018, PEOPL HIGH RISK FLU; Chang LJ, 2019, VACCINE, V37, P5825, DOI 10.1016/j.vaccine.2019.08.016; Chit A, 2015, VACCINE, V33, P734, DOI 10.1016/j.vaccine.2014.10.079; College Ter Beoordeling Van Geneesmiddelen (CBG MEB), 2020, NLH4757001DC CBG MEB NLH4757001DC CBG MEB; Colrat F, VACCINE, V2021; Crepey P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233526; DiazGranados CA, 2015, VACCINE, V33; DiazGranados CA, 2015, VACCINE, V33, P4565, DOI 10.1016/j.vaccine.2015.07.003; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; DiazGranados CA, 2013, VACCINE, V31, P861, DOI 10.1016/j.vaccine.2012.12.013; DiazGranados CA, 2012, VACCINE, V31, P49, DOI 10.1016/j.vaccine.2012.10.084; Direccion General de Salud Publica Gobierno de Aragon, 2017, INF VIG TEMP GRIP INF VIG TEMP GRIP; Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011; European Centre for Disease Prevention and Control, 2020, SYST REV EFF EFF SAF; Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790; Gisbert R, 2007, BASE DATOS COSTES SA; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; Hollmann M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060477; Husereau D, 2013, COST EFFECTIVENESS R, P11; Instituto de Salud Carlos III, 2018, INF VIG GRIP ESP TEM INF VIG GRIP ESP TEM; Instituto Nacional de Estadistica, 2019, POBL FEN DEM NAC SER POBL FEN DEM NAC SER; Izurieta HS, 2020, J INFECT DIS, V222, P278, DOI 10.1093/infdis/jiaa080; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; Keitel WA, 2006, ARCH INTERN MED, V166, P1121, DOI 10.1001/archinte.166.10.1121; Lee JKH, 2018, EXPERT REV VACCINES, V17, P435, DOI 10.1080/14760584.2018.1471989; Leon-Gomez I, 2015, GAC SANIT, V29, P258, DOI 10.1016/j.gaceta.2015.01.011; López Bastida Julio, 2010, Gac Sanit, V24, P154; McConeghy KW, 2020, CLIN INFECT DIS; Mertz D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5061; Ministerio de Sanidad Consumo y Bienestar Social Subdireccion General de Informacion Sanitaria, 2018, REG ACT AT ESP RAE C REG ACT AT ESP RAE C; Ministerio de Sanidad Servicios Sociales e Igualdad Secretaria de Estado de Servicios Sociales e Igualdad, 2017, ESTR NAC PERS MAYOR ESTR NAC PERS MAYOR; National Advisory Committee on Immunization (NACI) An Advisory Committee Statement (ACS), 2018, LIT REV UPD EFF EFF LIT REV UPD EFF EFF; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Puig-Barbera J, 2013, VACCINE, V31, P3995, DOI 10.1016/j.vaccine.2013.05.070; Shireman TI, 2019, J AM MED DIR ASSOC, V20, P874, DOI 10.1016/j.jamda.2018.12.003; Shrestha S, 2015, SCI REP-UK, V5, DOI 10.1038/srep15314; Somes MP, 2018, VACCINE, V36, P3199, DOI 10.1016/j.vaccine.2018.04.063; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; van Aalst R, 2019, VACCINE, V37, P4499, DOI 10.1016/j.vaccine.2019.06.066; Warren-Gash C, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01794-2017; Weinberger B, 2008, CLIN INFECT DIS, V46, P1078, DOI 10.1086/529197; WHO, 2019, IMMUNIZATION VACCINE	46	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5138	5145		10.1016/j.vaccine.2021.07.048		AUG 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34344553	hybrid			2022-04-29	WOS:000684878300010
J	Kurokawa, N; Lavoie, PO; D'aoust, MA; Couture, MMJ; Dargis, M; Trepanier, S; Hoshino, S; Koike, T; Arai, M; Tsutsui, N				Kurokawa, Natsuki; Lavoie, Pierre-Olivier; D'aoust, Marc-Andre; Couture, Manon M-J; Dargis, Michele; Trepanier, Sonia; Hoshino, Shigeki; Koike, Tomohiro; Arai, Masaaki; Tsutsui, Naohisa			Development and characterization of a plant-derived rotavirus-like particle vaccine	VACCINE			English	Article						Rotavirus; Vaccine; Virus-like particle; Nicotiana benthamiana; Agrobacterium tumefaciens; Animal model	VIRUS-LIKE PARTICLES; HETEROTYPIC PROTECTION; IMMUNE-RESPONSES; CAPSID PROTEINS; EXPRESSION; IMMUNOGENICITY; INFECTION; EFFICACY; VECTOR; MICE	Background: Virus-like particles (VLPs) are unable to replicate in the recipient but stimulate the immune system through recognition of repetitive subunits. Parenterally delivered rotavirus-VLP (Ro-VLP) vaccine could have the potential to overcome the weaknesses of licensed oral live-attenuated rotavirus vaccines, namely, low efficacy in low-income and high mortality settings and a potential risk of intussusception. Methods: A monovalent Ro-VLP composed of viral protein (VP) 7, VP6 and VP2 of G1 genotype specificity was produced in Nicotiana benthamiana using Agrobacterium tumefaciens infiltration-based transient recombinant expression system. Plants expressing recombinant G1 Ro-VLP were harvested, then the resultant biomass was processed through a series of clarification and purification steps including standard extraction, filtration, ultrafiltration and chromatography. The purified G1 Ro-VLP was subsequently examined for its immunogenicity and toxicological profile using animal models. Results: G1 Ro-VLP had a purity of >= 90% and was structurally similar to triple-layered rotavirus particles as determined by cryogenic transmission electron microscopy. Two doses of aluminum hydroxide-adjuvanted G1 Ro-VLP (1 mu g, 5 mu g or 30 mu g), administered intramuscularly, elicited a robust homotypic neutralizing antibody response in rats. Also, rabbits administered G1 Ro-VLP (10 mu g or 30 mu g) four times intramuscularly with aluminum hydroxide adjuvant did not show any significant toxicity. Conclusions: Plant-derived Ro-VLP composed of VP7, VP6 and VP2 structural proteins would be a plausible alternative to live-attenuated oral rotavirus vaccines currently distributed worldwide. (C) 2021 Elsevier Ltd. All rights reserved.	[Kurokawa, Natsuki; Tsutsui, Naohisa] Mitsubishi Tanabe Pharma Corp, Chuo Ku, 17-10 Nihonbashi Koamicho, Tokyo 1038405, Japan; [Lavoie, Pierre-Olivier; D'aoust, Marc-Andre; Couture, Manon M-J; Dargis, Michele; Trepanier, Sonia] Medicago Inc, 1020 Route Eglise Off 600, Quebec City, PQ, Canada; [Hoshino, Shigeki; Arai, Masaaki] Mitsubishi Tanabe Pharma Corp, Aoba Ku, 1000 Kamoshida Cho, Yokohama, Kanagawa 2270033, Japan; [Koike, Tomohiro] Mitsubishi Tanabe Pharma Corp, Shonan Hlth Innovat Pk,2-26-1 Muraoka Higashi, Fujisawa, Kanagawa 2518555, Japan		Kurokawa, N (通讯作者)，Mitsubishi Tanabe Pharma Corp, Chuo Ku, 17-10 Nihonbashi Koamicho, Tokyo 1038405, Japan.	kurokawa.natsuki@me.mt-pharma.co.jp			Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan	This research was supported by Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan. We are grateful to the laboratory staff of Envigo CRS Limited., Suffolk, UK for conducting the toxicity study. We acknowledge the valuable advice of the staff (Bruce D Forrest, Jack D Love, Paula Keith and Gerald Kovacs) at Cognoscenti Bio-science LLC., New York, USA.	AU KS, 1989, J VIROL, V63, P4553, DOI 10.1128/JVI.63.11.4553-4562.1989; Ball JM, 2005, VIRAL IMMUNOL, V18, P27, DOI 10.1089/vim.2005.18.27; Bertolotti-Ciarlet A, 2003, VACCINE, V21, P3885, DOI 10.1016/S0264-410X(03)00308-6; BRUSSOW H, 1990, J VIROL, V64, P3635; Burke RM, 2019, CURR OPIN INFECT DIS, V32, P435, DOI 10.1097/QCO.0000000000000572; Changotra H, 2017, REV MED VIROL, V27, DOI 10.1002/rmv.1954; Ciarlet M, 1998, J VIROL, V72, P9233, DOI 10.1128/JVI.72.11.9233-9246.1998; Clark A, 2019, LANCET INFECT DIS, V19, P717, DOI 10.1016/S1473-3099(19)30126-4; Clarke E, 2015, MUCOSAL IMMUNOL, V8, P1, DOI 10.1038/mi.2014.114; Clements JD, 2016, CLIN VACCINE IMMUNOL, V23, P438, DOI 10.1128/CVI.00214-16; Conner ME, 1996, J INFECT DIS, V174, pS88, DOI 10.1093/infdis/174.Supplement_1.S88; Crawford SE, 1999, J VIROL, V73, P4813, DOI 10.1128/JVI.73.6.4813-4822.1999; CRAWFORD SE, 1994, J VIROL, V68, P5945, DOI 10.1128/JVI.68.9.5945-5952.1994; D'Aoust MA, 2010, PLANT BIOTECHNOL J, V8, P607, DOI 10.1111/j.1467-7652.2009.00496.x; Desselberger U, 2011, J INFECT DIS, V203, P188, DOI 10.1093/infdis/jiq031; DORMITZER PR, 1992, VIROLOGY, V187, P18; Doro R, 2014, INFECT GENET EVOL, V28, P446, DOI 10.1016/j.meegid.2014.08.017; Estes M, 2007, FIELDS VIROLOGY, V2, P1917, DOI DOI 10.1007/978-3-642-69159-1_3; ESTES MK, 1987, J VIROL, V61, P1488, DOI 10.1128/JVI.61.5.1488-1494.1987; Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010; Gomez E, 2009, HUM VACCINES, V5, P738, DOI 10.4161/hv.5.11.9879; Greco R, 2007, VACCINE, V25, P8228, DOI 10.1016/j.vaccine.2007.09.061; Huang Z, 2005, VACCINE, V23, P1851, DOI 10.1016/j.vaccine.2004.11.017; Jiang BM, 1999, VACCINE, V17, P1005, DOI 10.1016/S0264-410X(98)00317-X; Kurokawa N, SAFETY IMMUNOGENICIT; Laimbacher AS, 2012, MOL THER, V20, P1810, DOI 10.1038/mt.2012.108; Lavoie PO, 2016, Rotavirus-like particle production in plants, Patent No. [WO2016/ 115630, 2016115630]; Lee JM, 2011, BIOTECHNOL LETT, V33, P41, DOI 10.1007/s10529-010-0390-x; Li T, 2014, VACCINE, V32, P1921, DOI 10.1016/j.vaccine.2014.01.093; Lopez T, 2005, J VIROL, V79, P184, DOI 10.1128/JVI.79.1.184-192.2005; Madore HP, 1999, VACCINE, V17, P2461, DOI 10.1016/S0264-410X(98)00319-3; Matthijnssens J, 2008, ARCH VIROL, V153, P1621, DOI 10.1007/s00705-008-0155-1; MEYER JC, 1989, VIROLOGY, V171, P98, DOI 10.1016/0042-6822(89)90515-1; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Molinari P, 2008, J VIROL METHODS, V147, P364, DOI 10.1016/j.jviromet.2007.09.002; Palomares LA, 2009, BIOCHEM ENG J, V45, P158, DOI 10.1016/j.bej.2009.02.006; Pera FFPG, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0436-8; Pesavento JB, 2006, CURR TOP MICROBIOL, V309, P189; Pham T, 2017, SCI REP-UK, V7, DOI 10.1038/srep43487; Pillet S, 2015, VACCINE, V33, P6282, DOI 10.1016/j.vaccine.2015.09.065; Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008; Rodriguez-Limas WA, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-33; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Russell DW., 2001, MOL CLONING LAB MANU; Saldana S, 2006, VIRAL IMMUNOL, V19, P42, DOI 10.1089/vim.2006.19.42; Scotti N, 2013, EXPERT REV VACCINES, V12, P211, DOI [10.1586/erv.12.147, 10.1586/ERV.12.147]; Sheets RL, 2006, TOXICOL SCI, V91, P620, DOI 10.1093/toxsci/kfj170; SPEIJERS GJA, 1988, FUND APPL TOXICOL, V10, P425, DOI 10.1016/0272-0590(88)90288-6; Thuilliez C, 2009, EXP TOXICOL PATHOL, V61, P13, DOI 10.1016/j.etp.2008.07.003; Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1; Velasquez DE, 2018, EXPERT REV VACCINES, V17, P145, DOI 10.1080/14760584.2018.1418665; Verdier F, 2005, VACCINE, V23, P1359, DOI 10.1016/j.vaccine.2004.09.012; Weintraub ES, 2014, NEW ENGL J MED, V370, P513, DOI 10.1056/NEJMoa1311738; Xu RQ, 2008, PLANT METHODS, V4, DOI 10.1186/1746-4811-4-4	54	2	2	2	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					4979	4987		10.1016/j.vaccine.2021.07.039		AUG 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TX3GY	34325930				2022-04-29	WOS:000682979100011
J	Pasetti, MF; Healy, CM				Pasetti, Marcela F.; Healy, C. Mary			Maternal and neonatal immunization in the Americas: The benefits, the hurdles, and the way forward	VACCINE			English	Editorial Material									[Pasetti, Marcela F.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA; [Healy, C. Mary] Baylor Coll Med, Dept Pediat, Infect Dis Sect, Houston, TX 77030 USA		Pasetti, MF (通讯作者)，Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.	mpasetti@som.umaryland.edu					54th Directing Council Pan American Health Organization, 2015, 67 SESS REG COMM WHO; Alvarez AMR, 2021, VACCINE, V39, pB34, DOI 10.1016/j.vaccine.2020.07.051; Carcelen AC, 2021, VACCINE, V39, pB27, DOI 10.1016/j.vaccine.2020.10.031; Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; HogenEsch E, 2021, VACCINE, V39, pB3, DOI 10.1016/j.vaccine.2020.10.082; Kollmann TR, 2020, SCIENCE, V368, P612, DOI 10.1126/science.aaz9447; Saint-Gerons DM, 2021, VACCINE, V39, pB12, DOI 10.1016/j.vaccine.2020.07.048; Malik AF, 2021, VACCINE, V39, pB44, DOI 10.1016/j.vaccine.2020.09.009; Malik FA, 2021, VACCINE, V39, pB50, DOI 10.1016/j.vaccine.2020.09.014; Velandia-Gonzalez M, 2021, VACCINE, V39, pB55, DOI 10.1016/j.vaccine.2020.12.043; Wang EWQ, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab180; World Health Organization, 65 WORLD HLTH ASS 20, P20	13	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39			2			B1	B2		10.1016/j.vaccine.2021.06.009		JUL 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UD6SH	34130884	Green Published, hybrid			2022-04-29	WOS:000687335900001
J	Gentile, A; Pacchiotti, AC; Giglio, N; Nolte, MF; Talamona, N; Rogers, V; Berenstein, A; Castellano, VE				Gentile, Angela; Pacchiotti, Anabella Cecilia; Giglio, Norberto; Nolte, Maria Florencia; Talamona, Natalia; Rogers, Viviana; Berenstein, Ada; Castellano, Vanesa Edelvais			Vaccine hesitancy in Argentina: Validation of WHO scale for parents	VACCINE			English	Article						Vaccination; Vaccination Refusal; Vaccination Coverage; Immunization Programs	PROGRAMS; CHILDREN	Background: The WHO SAGE Working Group on Vaccine Hesitancy developed the Vaccine Hesitancy Scale (VHS) to identify and compare hesitancy in different global settings. The objectives of the study were to describe and analyze vaccine hesitancy and to validate the VHS in a group of parents in Buenos Aires city, Argentina. Methods: A cross-sectional survey was conducted in parents of 1-3 and 12-15 year-old children at three health centres in Buenos Aires City, between June 2018 and May 2019. Sociodemographic data were collected together with history of refusal and/or delay in children's vaccination (defined as hesitancy). The 10-item VHS using 5-point Likert-scale (higher scores indicating lower hesitancy) was administered and children's immunization record cards were verified. Link between hesitancy and socio-demographic variables, and hesitancy and vaccination status was analyzed for five specific vaccines. Cronbach's a was used to determine internal consistency reliability and factor analysis to confirm survey subdomains. Simple and multiple regression analysis was used to examine associations between VHS scores and hesitancy, and VHS scores and vaccination status. Results: Six hundred parents were surveyed and 469 immunization cards verified; 11.5% (n = 69) parents were hesitant. High maternal educational level showed significant association with hesitancy (OR 2.66 95% CI: 1.20-5.9) in the adjusted model. Hesitancy was significantly associated with incomplete MMR vaccination in children (OR 4.43 95% CI: 1.08-8.20) and HPV vaccination in adolescents (OR 3.75 95% CI: 1.54-9.12). Cronbach's a was 0.66 and factor analysis identified three underlying constructs: "Benefits", "Harms" and "Confidence in healthcare system". High scores in VHS were associated with lack of hesitancy (OR 1.2 95% CI: 1.13-1.27) and complete vaccination status (OR 1.07 95% CI: 1.02-1.12). Conclusions: Hesitancy was associated with high maternal educational level, and incomplete MMR and HPV immunization status in children and adolescents. VHS was a reliable and valid tool in this population. (C) 2021 Elsevier Ltd. All rights reserved.	[Gentile, Angela; Pacchiotti, Anabella Cecilia; Giglio, Norberto; Nolte, Maria Florencia; Talamona, Natalia; Castellano, Vanesa Edelvais] Hosp Ninos Dr Ricardo Gutierrez, Gallo 1330,C1425EFD, Buenos Aires, DF, Argentina; [Rogers, Viviana] Hosp Aleman, Pueyrredon 1640,C1118AAT, Buenos Aires, DF, Argentina; [Berenstein, Ada] Ctr Salud & Accion Comunitaria N, 15,Humberto 1 470,C1103ACJ, Buenos Aires, DF, Argentina		Pacchiotti, AC (通讯作者)，Hosp Ninos Dr Ricardo Gutierrez, Gallo 1330,C1425EFD, Buenos Aires, DF, Argentina.	hnrgvacunas@gmail.com			National Ministry of Health, Health Research Department	This work was supported by the National Ministry of Health, Health Research Department, through the grant SALUD INVESTIGA ``Dr. Abraam Sonis"awarded to Anabella C. Pacchiotti, MD.	Agence nationale de securite du medicament et des produits de sante, 2015, VACC ANT HPV RISQ MA VACC ANT HPV RISQ MA; [Anonymous], 2015, RESUMEN CONCLUSIONES; [Anonymous], LEY 27491 CONTROL EN; Baker JP, 2003, VACCINE, V21, P4003, DOI 10.1016/S0264-410X(03)00302-5; Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728; Brown AL, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311X00011618, 10.1590/0102-311x00011618]; Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038; Piqueras MC, 2019, GAC SANIT, V33, P53, DOI 10.1016/j.gaceta.2017.07.004; Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046; Dube E, 2016, PLOS CURR-TREE LIFE, V8, DOI [10.1371/currents.outbreaks.9-239605f4d320c6ad27ce2aea5aaad2, DOI 10.1371/CURRENTS.OUTBREAKS.9-239605F4D320C6AD27CE2AEA5AAAD2]; Gentile A, 2015, VACCINE, V33, P3913, DOI 10.1016/j.vaccine.2015.06.065; Gentile A, 2012, REV ARGENT SALUD PUB, V3, P30; Gentile AS, 2012, REV ARGENT SALUD PUB, V3, P30; Gilkey MB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159087; Gust DA, 2005, AM J PREV MED, V29, P105, DOI 10.1016/j.amepre.2005.04.010; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Luyten J, 2019, VACCINE, V37, P2494, DOI 10.1016/j.vaccine.2019.03.041; Luyten J, 2016, HEALTH AFFAIR, V35, P212, DOI 10.1377/hlthaff.2015.1088; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mendez-Castellano H, 1986, ARCH VENEZ PUER PEDI, V49, P93; Ministerio de salud Argentina, COB VAC JUR 2009 201 COB VAC JUR 2009 201; Ministerio de Salud Argentina, CAL NAC VAC 2017 CAL NAC VAC 2017; Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115; OPS Uruguay, 11 MIT VERD GRIP 11 MIT VERD GRIP; PAHO, CUAL SON 10 PRINC AM CUAL SON 10 PRINC AM; Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009; Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043; The World Bank, WORLD BANK COUNTR LE; US Centers for Disease Control and Prevention, 2015, 10 GREAT PUBL HLTH A 10 GREAT PUBL HLTH A; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0	31	2	2	5	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4611	4619		10.1016/j.vaccine.2021.06.080		JUL 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	34238609				2022-04-29	WOS:000681356500006
J	Ozawa, S; Yemeke, TT; Mitgang, E; Wedlock, PT; Higgins, C; Chen, HH; Pallas, SW; Abimbola, T; Wallace, A; Bartsch, SM; Lee, BCY				Ozawa, Sachiko; Yemeke, Tatenda T.; Mitgang, Elizabeth; Wedlock, Patrick T.; Higgins, Colleen; Chen, Hui -Han; Pallas, Sarah W.; Abimbola, Taiwo; Wallace, Aaron; Bartsch, Sarah M.; Lee, Bruce Y.			Systematic review of the costs for vaccinators to reach vaccination sites: Incremental costs of reaching hard-to-reach populations	VACCINE			English	Review						Costs; Vaccination; Immunization; Hard-to-reach; Vaccinator	INCREASE IMMUNIZATION RATES; HEPATITIS-B-VACCINE; ROUTINE IMMUNIZATION; EXPANDED PROGRAM; CENTRALIZED REMINDER/RECALL; CHILDHOOD IMMUNIZATIONS; INFLUENZA VACCINATION; CHOLERA-VACCINE; YOUNG-CHILDREN; COVERAGE	Introduction: Economic evidence on how much it may cost for vaccinators to reach populations is impor-tant to plan vaccination programs. Moreover, knowing the incremental costs to reach populations that have traditionally been undervaccinated, especially those hard-to-reach who are facing supply-side bar-riers to vaccination, is essential to expanding immunization coverage to these populations. Methods: We conducted a systematic review to identify estimates of costs associated with getting vacci-nators to all vaccination sites. We searched PubMed and the Immunization Delivery Cost Catalogue (IDCC) in 2019 for the following costs to vaccinators: (1) training costs; (2) labor costs, per diems, and incentives; (3) identification of vaccine beneficiary location; and (4) travel costs. We assessed if any of these costs were specific to populations that are hard-to-reach for vaccination, based on a framework for examining supply-side barriers to vaccination. Results: We found 19 studies describing average vaccinator training costs at $0.67/person vaccinated or targeted (SD $0.94) and $0.10/dose delivered (SD $0.07). The average cost for vaccinator labor and incen-tive costs across 29 studies was $2.15/dose (SD $2.08). We identified 13 studies describing intervention costs for a vaccinator to know the location of a beneficiary, with an average cost of $19.69/person (SD $26.65), and six studies describing vaccinator travel costs, with an average cost of $0.07/dose (SD $0.03). Only eight of these studies described hard-to-reach populations for vaccination; two studies examined incremental costs per dose to reach hard-to-reach populations, which were 1.3-2 times higher than the regular costs. The incremental cost to train vaccinators was $0.02/dose, and incremental labor costs for targeting hard-to-reach populations were $0.16-$1.17/dose. Conclusion: Additional comparative costing studies are needed to understand the potential differential costs for vaccinators reaching the vaccination sites that serve hard-to-reach populations. This will help immunization program planners and decision-makers better allocate resources to extend vaccination programs. (c) 2021 Elsevier Ltd. All rights reserved.	[Ozawa, Sachiko; Yemeke, Tatenda T.; Higgins, Colleen; Chen, Hui -Han] Univ N Carolina, Div Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Ozawa, Sachiko] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA; [Mitgang, Elizabeth; Wedlock, Patrick T.; Bartsch, Sarah M.; Lee, Bruce Y.] CUNY, Grad Sch Publ Hlth & Hlth Policy, Publ Hlth Informat Computat & Operat Res PHICOR, New York, NY 10021 USA; [Pallas, Sarah W.; Abimbola, Taiwo; Wallace, Aaron] US Ctr Dis Control & Prevent CDC, Global Immunizat Div, Atlanta, GA USA		Ozawa, S (通讯作者)，Univ N Carolina, Sch Pharm, Practice Adv & Clin Educ, UNC Eshelman, CB 7574,Beard Hall 115G, Chapel Hill, NC 27599 USA.	ozawa@unc.edu	Ozawa, Sachiko/D-4399-2014	Ozawa, Sachiko/0000-0001-7608-9038	Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [5 NU2GGH002000-02-00]; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Office of Behavioral and Social Sciences Research (OBSSR) [U01HD086861]; National Institute of General Medical Sciences (NIGMS) as part of the Models of Infectious Disease Agent Study (MIDAS) network [R01 GM127512]	Research reported in this publication was supported by the Centers for Disease Control and Prevention (CDC) via contract 5 NU2GGH002000-02-00, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Office of Behavioral and Social Sciences Research (OBSSR) via grant U01HD086861, and by National Institute of General Medical Sciences (NIGMS) as part of the Models of Infectious Disease Agent Study (MIDAS) network under grant R01 GM127512.	Adachi K, 2013, VACCINE, V31, P2317, DOI 10.1016/j.vaccine.2012.08.016; Akil L, 2016, INT J INFECT DIS, V49, P40, DOI 10.1016/j.ijid.2016.05.025; Al-lela OQB, 2012, VACCINE, V30, P3862, DOI 10.1016/j.vaccine.2012.04.014; Anderson Edwin L, 2014, Mo Med, V111, P344; Aylward B, 2011, VACCINE, V29, pD80, DOI 10.1016/j.vaccine.2011.10.005; Banerjee Abhijit Vinayak, 2010, BMJ, V340, pc2220, DOI 10.1136/bmj.c2220; Bawa S, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6194-y; Castaneda-Orjuela C, 2013, VACCINE, V31, pC72, DOI 10.1016/j.vaccine.2013.05.038; Cavailler P, 2006, VACCINE, V24, P4890, DOI 10.1016/j.vaccine.2005.10.006; Chandir S, 2017, VACCINE, V35, P5037, DOI 10.1016/j.vaccine.2017.07.026; Chatterjee S, 2016, INDIAN J MED RES, V143, P801, DOI 10.4103/0971-5916.192073; Cho BH, 2012, J SCH NURS, V28, P336, DOI 10.1177/1059840512457049; Colombini A, 2011, VACCINE, V29, P5474, DOI 10.1016/j.vaccine.2011.05.058; Cox SN, 2021, VACCINE, V39, P6796, DOI 10.1016/j.vaccine.2021.05.033; Dicko A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-573; Ebong Cliford E, 2011, Cost Eff Resour Alloc, V9, P9, DOI 10.1186/1478-7547-9-9; Fontanesi JM, 2002, HEALTH SERV RES, V37, P1291, DOI 10.1111/1475-6773.10772; Gandhi G, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-67; Gavi (the Vaccine Alliance), 2021, PHAS 5 2021 2025; Glazner JE, 2004, AMBUL PEDIATR, V4, P34, DOI 10.1367/1539-4409(2004)004<0034:UAIREO>2.0.CO;2; Glazner JE, 2001, PUBLIC HEALTH REP, V116, P219, DOI 10.1093/phr/116.3.219; Gracey M, 2009, LANCET, V374, P65, DOI 10.1016/S0140-6736(09)60914-4; Griffiths UK, 2005, HEALTH POLICY PLANN, V20, P50, DOI 10.1093/heapol/czi006; Griffiths UK, 2009, VACCINE, V27, P1426, DOI 10.1016/j.vaccine.2008.12.037; Griffiths UK, 2016, VACCINE, V34, P4213, DOI 10.1016/j.vaccine.2016.06.050; Hamid H, 2020, DRUGS THER PERSPECT, V36, P523, DOI 10.1007/s40267-020-00774-2; Haq Z, 2019, HEALTH RES POLICY SY, V17, DOI 10.1186/s12961-019-0452-z; Hayford K, 2014, VACCINE, V32, P2294, DOI 10.1016/j.vaccine.2014.02.075; Horne PR, 2000, AM J PREV MED, V19, P94, DOI 10.1016/S0749-3797(00)00182-3; Hui C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102065; Hussain SF, 2016, GLOBALIZATION HEALTH, V12, DOI 10.1186/s12992-016-0195-3; Hutubessy R, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-136; Immunization Costing Action Network (ICAN), 2019, IMM DEL COST CAT IDC IMM DEL COST CAT IDC; Jacobs B, 2012, REPROD HEALTH MATTER, V20, P112, DOI 10.1016/S0968-8080(12)40649-8; Janusz CB, 2015, VACCINE, V33, pA53, DOI 10.1016/j.vaccine.2015.01.016; Kaji A, 2016, J IMMIGR MINOR HEALT, V18, P1038, DOI 10.1007/s10903-015-0294-x; Kaucley L, 2015, COST EFFECT RESOUR A, V13, DOI 10.1186/s12962-015-0039-7; Kempe A, 2017, ACAD PEDIATR, V17, P330, DOI 10.1016/j.acap.2016.11.016; Kempe A, 2015, JAMA PEDIATR, V169, P365, DOI 10.1001/jamapediatrics.2014.3670; Kempe A, 2013, AM J PUBLIC HEALTH, V103, P1116, DOI 10.2105/AJPH.2012.301035; Khan IA, 2013, VACCINE, V31, P6058, DOI 10.1016/j.vaccine.2013.10.021; Le Gargasson JB, 2015, VACCINE, V33, pA40, DOI 10.1016/j.vaccine.2014.12.081; Levin CE, 2013, B WORLD HEALTH ORGAN, V91, P585, DOI 10.2471/BLT.12.113837; Levin CE, 2005, B WORLD HEALTH ORGAN, V83, P456; Lin CJ, 2012, JT COMM J QUAL PATIE, V38, P67, DOI 10.1016/S1553-7250(12)38009-4; Mantel C, 2020, BUNDESGESUNDHEITSBLA, V63, P25, DOI 10.1007/s00103-019-03066-x; Mascarenas A, 2005, PUBLIC HEALTH, V119, P542, DOI 10.1016/j.puhe.2004.08.020; McKenna VB, 2002, PUBLIC HEALTH REP, V117, P386, DOI 10.1016/S0033-3549(04)50176-0; Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097; Mokaya E, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.24.12631; Munk C, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4468-4; Mvundura M, 2015, VACCINE, V33, P2697, DOI 10.1016/j.vaccine.2015.03.084; Ngabo F, 2015, VACCINE, V33, P7357, DOI 10.1016/j.vaccine.2015.10.022; Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3; Ozawa S, 2019, VACCINE, V37, P5525, DOI 10.1016/j.vaccine.2019.06.081; Ozawa S, 2018, VACCINE, V36, P3641, DOI 10.1016/j.vaccine.2018.05.030; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Pegurri E, 2005, VACCINE, V23, P1624, DOI 10.1016/j.vaccine.2004.02.029; Portnoy A, 2020, PHARMACOECONOMICS, V38, P995, DOI 10.1007/s40273-020-00930-6; Portnoy A, 2015, VACCINE, V33, pA99, DOI 10.1016/j.vaccine.2014.12.037; Quentin W, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-137; Rask KJ, 2000, AM J PREV MED, V19, P99, DOI 10.1016/S0749-3797(00)00183-5; Rask KJ, 2000, AM J PREV MED, V18, P262, DOI 10.1016/S0749-3797(99)00156-7; Rask KJ, 2001, AM J PREV MED, V21, P267, DOI 10.1016/S0749-3797(01)00370-1; Robinson JS, 2001, B WORLD HEALTH ORGAN, V79, P150; Routh JA, 2017, AM J TROP MED HYG, V97, P37, DOI 10.4269/ajtmh.16-1023; Ruhago GM, 2015, COST EFFECT RESOUR A, V13, DOI 10.1186/s12962-015-0033-0; Ryman TK, 2012, J INFECT DIS, V205, pS65, DOI 10.1093/infdis/jir777; Sarker AR, 2015, VACCINE, V33, P4916, DOI 10.1016/j.vaccine.2015.07.042; Sartorius, 2016, S AFR MED J, V106; Schaetti C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001844; Schutte C, 2015, VACCINE, V33, pA47, DOI 10.1016/j.vaccine.2014.12.040; Silwal RC, 2006, PUBLIC HEALTH, V120, P805, DOI 10.1016/j.puhe.2006.05.019; Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001; Sume Gerald Etapelong, 2013, BMC Res Notes, V6, P100, DOI 10.1186/1756-0500-6-100; Szilagyi PG, 2011, ARCH PEDIAT ADOL MED, V165, P547, DOI 10.1001/archpediatrics.2011.73; Teng JE, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003050; Teshome S, 2018, HUM VACC IMMUNOTHER, V14, P2427, DOI 10.1080/21645515.2018.1460295; U.S. Bureau of Labor Statistics, 2017, CONS PRIC IND; Usuf E, 2014, VACCINE, V32, P1975, DOI 10.1016/j.vaccine.2014.01.045; Van Hoang M, 2008, B WORLD HEALTH ORGAN, V86, P429, DOI 10.2471/BLT.07.045161; Woodward A, 2014, HEALTH POLICY PLANN, V29, P818, DOI 10.1093/heapol/czt061; World Bank, 2018, WORLD DEV IND; World Bank, 2017, WORLD BANK COUNTR LE; World Health Organization, 2020, PROGR CHALL ACH UN I; World Health Organization, 2020, IMM AG 2030 GLOB STR; World Health Organization, 2020, IMM COV; Yin ZD, 2012, VACCINE, V30, P5569, DOI 10.1016/j.vaccine.2012.05.068; Yoo Byung-Kwang, 2009, Pediatrics, V124 Suppl 5, pS499, DOI 10.1542/peds.2009-1542I; Yu WZ, 2018, VACCINE, V36, P3041, DOI 10.1016/j.vaccine.2018.04.008	90	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4598	4610		10.1016/j.vaccine.2021.05.019		JUL 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TU9NN	34238610				2022-04-29	WOS:000681356500005
J	Patel, MK; Bergeri, I; Bresee, JS; Cowling, BJ; Crowcroft, NS; Fahmy, K; Hirve, S; Kang, G; Katz, MA; Lanata, CF; Jackson, ML; Joshi, S; Lipsitch, M; Mwenda, JM; Nogareda, F; Orenstein, WA; Ortiz, JR; Pebody, R; Schrag, SJ; Smith, PG; Srikantiah, P; Subissi, L; Valenciano, M; Vaughn, DW; Verani, JR; Wilder-Smith, A; Feikin, DR				Patel, Minal K.; Bergeri, Isabel; Bresee, Joseph S.; Cowling, Benjamin J.; Crowcroft, Natasha S.; Fahmy, Kamal; Hirve, Siddhivinayak; Kang, Gagandeep; Katz, Mark A.; Lanata, Claudio F.; Jackson, Maina L'Azou; Joshi, Sudhir; Lipsitch, Marc; Mwenda, Jason M.; Nogareda, Francisco; Orenstein, Walter A.; Ortiz, Justin R.; Pebody, Richard; Schrag, Stephanie J.; Smith, Peter G.; Srikantiah, Padmini; Subissi, Lorenzo; Valenciano, Marta; Vaughn, David W.; Verani, Jennifer R.; Wilder-Smith, Annelies; Feikin, Daniel R.			Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization	VACCINE			English	Article						COVID-19; Vaccination; Vaccine effectiveness		Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints, resulting in emergency use authorization/listing for several vaccines. However, given the short duration of follow-up during the clinical trials, strict eligibility criteria, emerging variants of concern, and the changing epidemiology of the pandemic, many questions still remain unanswered regarding vaccine performance. Post-introduction vaccine effectiveness evaluations can help us to understand the vaccine's effect on reducing infection and disease when used in real-world conditions. They can also address important questions that were either not studied or were incompletely studied in the trials and that will inform evolving vaccine policy, including assessment of the duration of effectiveness; effectiveness in key subpopulations, such as the very old or immunocompromised; against severe disease and death due to COVID-19; against emerging SARS-CoV-2 variants of concern; and with different vaccination schedules, such as number of doses and varying dosing intervals. WHO convened an expert panel to develop interim best practice guidance for COVID-19 vaccine effectiveness evaluations. We present a summary of the interim guidance, including discussion of different study designs, priority outcomes to evaluate, potential biases, existing surveillance platforms that can be used, and recommendations for reporting results.	[Patel, Minal K.; Bergeri, Isabel; Crowcroft, Natasha S.; Hirve, Siddhivinayak; Subissi, Lorenzo; Wilder-Smith, Annelies; Feikin, Daniel R.] WHO, 20 Ave Appia, CH-1211 Geneva, Switzerland; [Bresee, Joseph S.; Schrag, Stephanie J.; Verani, Jennifer R.] US Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA USA; [Cowling, Benjamin J.] Univ Hong Kong, Sch Publ Hlth, Pokfulam, Hong Kong, Peoples R China; [Fahmy, Kamal] WHO Reg Off Eastern Mediterranean, Monazamet El Seha El Alamia Str, Cairo 11371, Egypt; [Kang, Gagandeep] Christian Med Coll & Hosp, Ida Scudder Rd, Vellore 632004, Tamil Nadu, India; [Katz, Mark A.; Pebody, Richard] WHO Reg Off Europe, Marmorvej 51, DK-2100 Copenhagen, Denmark; [Lanata, Claudio F.] Inst Invest Nutr, Av Molina 1885, La Molina 15024, Peru; [Jackson, Maina L'Azou] Coalit Epidem Preparedness Innovat CEPI, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England; [Joshi, Sudhir] WHO Reg Off South East Asia, World Hlth House,Indraprastha Estate, New Delhi 110002, India; [Lipsitch, Marc] Harvard Univ, Ctr Communicable Dis Dynam, Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Mwenda, Jason M.] WHO Reg Off Africa, POB 06, Brazzaville, Rep Congo; [Nogareda, Francisco] Pan Amer Hlth Org, 525 23rd St NW, Washington, DC 20037 USA; [Orenstein, Walter A.] Emory Vaccine Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA; [Ortiz, Justin R.] Univ Maryland, Ctr Vaccine Dev & Global Hlth, Sch Med, 685 W Baltimore St,Room 480, Baltimore, MD 21201 USA; [Smith, Peter G.] London Sch Hyg & Trop Med, MRC Int Epidemiol & Stat Grp, Keppel St, London WC1E 7HT, England; [Srikantiah, Padmini; Vaughn, David W.] Bill & Melinda Gates Fdn, 500 5th Ave N, Seattle, WA 98109 USA; [Valenciano, Marta] Epiconcept, 25 Rue Titon, F-75011 Paris, France		Patel, MK (通讯作者)，WHO, Dept Immunizat Vaccines & Biol, 20 Ave Appia, CH-1211 Geneva, Switzerland.	patelm@who.int		Patel, Minal/0000-0002-8707-7531; Kang, Gagandeep/0000-0002-3656-564X; L'Azou Jackson, Maina/0000-0001-7753-0630; Ortiz, Justin/0000-0002-3138-5965; Smith, Peter/0000-0003-0080-7560	German Federal Ministry of Health (BMG) COVID-19 Research; National Cancer Institute of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA261277]	This work was supported by German Federal Ministry of Health (BMG) COVID-19 Research and development funding to WHO and by the National Cancer Institute of the National Institutes of Health under Award Number U01CA261277.	[Anonymous], WHO COR DIS COVID 19; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Basta NE, 2019, AM J EPIDEMIOL, V188, P987, DOI 10.1093/aje/kwz043; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Bernal JAL, 2019, CLIN INFECT DIS, V68, P1769, DOI 10.1093/cid/ciy906; Charlett A, LANCET, V2021; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; De Smedt T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199180; Fay M., VACCINE EFFICACY POI, DOI [10.1101/2021.02.04.21251133v1, DOI 10.1101/2021.02.04.21251133V1]; Garcia-Albeniz X, 2017, EUR J EPIDEMIOL, V32, P495, DOI 10.1007/s10654-017-0287-2; Griffith Gareth J, 2020, Nat Commun, V11, P5749, DOI 10.1038/s41467-020-19478-2; Immunizations V and Biologicals, 2008, GEN PROT MON IMP ROT; Jackson ML, 2015, VACCINE, V33, P1313, DOI 10.1016/j.vaccine.2015.01.069; Lewnard JA, 2018, AM J EPIDEMIOL, V187, P2686, DOI 10.1093/aje/kwy163; Lipsitch M, 2019, Epidemiol Infect, V147, pe306, DOI 10.1017/S0950268819001961; Lipsitch Marc, 2021, Vaccine, V39, P4082, DOI [10.1101/2021.02.25.21252415, 10.1016/j.vaccine.2021.06.011]; Lipsitch M, 2020, NAT MED, V26, P818, DOI 10.1038/s41591-020-0887-3; Lipsitch M, 2019, CLIN INFECT DIS, V68, P1631, DOI 10.1093/cid/ciy773; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; Our world in data, COR COVID 19 VACC; Ray GT, 2019, CLIN INFECT DIS, V68, P1623, DOI 10.1093/cid/ciy770; Schreiber L, DECREASED SARS COV 2, DOI [10.1101/2021.02.06.21251283v1.full.pdf, DOI 10.1101/2021.02.06.21251283V1.FULL.PDF]; Soundararajan, 2021, FDA AUTHORIZED COVID, DOI [10.1101/2021.02.15.21251623, DOI 10.1101/2021.02.15.21251623]; Sullivan SG, 2014, EXPERT REV VACCINES, V13, P1571, DOI 10.1586/14760584.2014.966695; The World Health Organization (WHO), WHO COVID 19 CAS DEF; VASILEIOU E, 2021, LANCET, DOI DOI 10.2139/SSRN.3789264; von Elm E, 2007, LANCET, V370, P1453, DOI [10.2471/BLT.07.045120, 10.1016/j.jclinepi.2007.11.008, 10.1371/journal.pmed.0040296]; WHO, 2020, DIAGN TEST SARS COV; WHO, WHO SURV CAS DEF ILI; World Health Organization, CLIN MAN COVID 19 IN; World Health Organization, 2017, EV INFL VACC EFF; World Health Organization, EV COVID 19 VACC EFF; World Health Organization, DRAFT LANDSC TRACK C; World Health Organization, 2021, SARS COV 2 GEN SEQ P	34	16	16	32	58	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4013	4024		10.1016/j.vaccine.2021.05.099		JUN 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34119350	Bronze, Green Published			2022-04-29	WOS:000672535200001
J	Aizawa, Y; Katsuta, T; Sakiyama, H; Tanaka-Taya, K; Moriuchi, H; Saitoh, A				Aizawa, Yuta; Katsuta, Tomohiro; Sakiyama, Hiroshi; Tanaka-Taya, Keiko; Moriuchi, Hiroyuki; Saitoh, Akihiko			Changes in childhood vaccination during the coronavirus disease 2019 pandemic in Japan	VACCINE			English	Article						Routine immunization; Vaccination; Infants; Children; COVID-19; Pandemic	MEASLES OUTBREAK; COVID-19; IMPACT; REGISTRY; CHILDREN	Background: The coronavirus disease 2019 (COVID-19) pandemic has greatly affected daily life. COVID-19 often causes asymptomatic or mild disease in children; however, delayed routine childhood immuniza-tion is a concern, as it could increase the risk of vaccine-preventable disease. No study has evaluated the status of childhood vaccinations in Japan during the COVID-19 pandemic. Methods: This retrospective observational study evaluated the number of vaccine doses administered to children in 4 Japanese cities (2 cities in the Tokyo metropolitan area and 2 cities far from Tokyo) during the period from 2016 to 2020. Vaccine doses administered between January and September 2020 during the COVID-19 pandemic were compared, by month, with those given during 2016-2019. Age-stratified demographic data were collected to determine whether factors other than change in the child population over time affected vaccination trends. Results: In all cities the decrease in vaccine doses administered was most apparent in March and April 2020, i.e., just before or coincident with the declaration of a nationwide COVID-19 emergency on April 7, 2020. The decrease started as early as February in the Tokyo metropolitan area. As child age increased, the decrease became more apparent. Before the lift of national emergency on May 25, catch-up of the vac-cination was observed in all age groups in all cities. Vaccine doses persistently increased in older age groups but not in infants. The overall vaccination trends did not differ significantly among the 4 cities. Conclusions: The COVID-19 pandemic significantly affected routine childhood immunization in Japan. Thus, a nationwide electronic surveillance system and announcements for guardians to encourage timely routine immunization are warranted. (c) 2021 Elsevier Ltd. All rights reserved.	[Aizawa, Yuta; Saitoh, Akihiko] Niigata Univ, Dept Pediat, Grad Sch Med & Dent Sci, Niigata, Japan; [Katsuta, Tomohiro] St Marianna Univ, Dept Pediat, Sch Med, Kawasaki, Kanagawa, Japan; [Sakiyama, Hiroshi] Sakiyama Childrens Clin, Dept Pediat, Tokyo, Japan; [Tanaka-Taya, Keiko] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan; [Moriuchi, Hiroyuki] Nagasaki Univ, Dept Pediat, Grad Sch Biomed Sci, Nagasaki, Japan; [Aizawa, Yuta] Med Assoc Niigata City, Comm Immunizat, Niigata, Japan; [Katsuta, Tomohiro; Tanaka-Taya, Keiko; Moriuchi, Hiroyuki; Saitoh, Akihiko] Japan Pediat Soc, Comm Immunizat & Infect Dis, Tokyo, Japan		Saitoh, A (通讯作者)，Niigata Univ, Dept Pediat, Grad Sch Med & Dent Sci, Chuo Ku, 1-757 Asahimachi Dori, Niigata 9518510, Japan.	asaitoh@med.niigata-u.ac.jp	Aizawa, Yuta/AAD-2310-2022		Committee on Immunization of the Medical Association of Niigata City; Medical Association of Kawasaki; Medical Association of Nagasaki; Medical Association of Fuchu	The authors are grateful to the health centers of Kawasaki City and Niigata City, the municipal office of Nagasaki City, and the Fuchu City Medical Association, which provided vaccination data. The authors are also grateful for the support of the Committee on Immunization of the Medical Association of Niigata City, the Medical Associations of Kawasaki, Nagasaki, and Fuchu, the member of the Committee on Immunization and Infectious Diseases of the Japan Pediatric Society.	Abrams EM, 2020, J PEDIATR-US, V222, P221, DOI 10.1016/j.jpeds.2020.04.049; Bell S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244049; BOUFFET E, 2020, PEDIATR BLOOD CANCER, V67, DOI DOI 10.1002/PBC.28327-28327; Bramer CA, 2020, MMWR-MORBID MORTAL W, V69, P630, DOI 10.15585/mmwr.mm6920e1; Brough HA, 2020, PEDIAT ALLERG IMM-UK, V31, P442, DOI 10.1111/pai.13262; Chandir S, 2020, VACCINE, V38, P7146, DOI 10.1016/j.vaccine.2020.08.019; Fuchu City Tokyo, 2021, POPULATION BASED RES; Gavish R, 2021, PEDIATR INFECT DIS J, V40, pE39, DOI 10.1097/INF.0000000000002963; Hargreaves AL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0783; Idogawa M, 2020, CLIN INFECT DIS, V71, P902, DOI 10.1093/cid/ciaa500; Isba R, 2020, ARCH DIS CHILD, V105, P704, DOI 10.1136/archdischild-2020-319385; Kadambari S, 2020, PEDIATR INFECT DIS J, V39, pE385, DOI 10.1097/INF.0000000000002870; Kakuya F, 2020, JPN J INFECT DIS, V73, P377, DOI 10.7883/yoken.JJID.2020.181; Kawasaki City Kanagawa Prefecture, POPULATION BASED NAT; Kemper, 2021, PEDIATRICS, P147, DOI [10.1542/peds.2020-035576-2020035576, DOI 10.1542/PEDS.2020-035576-2020035576]; Kobayashi A, 2020, VACCINE, V38, P4996, DOI 10.1016/j.vaccine.2020.05.067; Kuba Y, 2020, VACCINE, V38, P2361, DOI 10.1016/j.vaccine.2020.01.067; Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5; McDonald HI, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.19.2000848; Middeldorp M, 2021, VACCINE, V39, P1039, DOI 10.1016/j.vaccine.2020.12.080; Moore JP, 2021, JAMA-J AM MED ASSOC, V325, P821, DOI 10.1001/jama.2021.1114; Nagasaki City Nagasaki Prefecture, 2021, POP BAS NAT CENS; National Institute of Infectious Diseases Japan, 2021, INFECT AGENTS SURVEI; Niigata City Niigata Prefecture, 2021, POPULATION BASED RES; O'Leary ST, 2021, JAMA PEDIATR, V175, P305, DOI 10.1001/jamapediatrics.2020.4733; Place R, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.27948; Saitoh A, 2018, VACCINE, V36, P4582, DOI 10.1016/j.vaccine.2018.01.092; Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2; Saxena S, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2392; The Committee on Immunization and Infectious Diseases Japan Pediatric Society, 2020, Q A NOVEL CORONAVIRU; The Committee on Immunization and Infectious Diseases of Japan Pediatric Society, 2020, CHILDHOOD VACCINATIO; The Ministry of Health Labour and Welfare, 2020, 1 CONFIRMATION PATIE; World Health Organization, 2020, NOV COR CHIN; Zhong YJ, 2021, VACCINE, V39, P780, DOI 10.1016/j.vaccine.2020.12.054	34	4	4	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					4006	4012		10.1016/j.vaccine.2021.05.050		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34059371	Bronze, Green Published			2022-04-29	WOS:000663773600028
J	Bardenheier, BH; Gravenstein, S; Blackman, C; Gutman, R; Sarkar, IN; Feifer, RA; White, EM; McConeghy, K; Nanda, A; Mor, V				Bardenheier, Barbara H.; Gravenstein, Stefan; Blackman, Carolyn; Gutman, Roee; Sarkar, Indra Neil; Feifer, Richard A.; White, Elizabeth M.; McConeghy, Kevin; Nanda, Aman; Mor, Vincent			Adverse events following mRNA SARS-CoV-2 vaccination among US nursing home residents	VACCINE			English	Article						Skilled nursing facilities; SARS-CoV-2 mRNA vaccines; Vaccine safety monitoring	SAFETY	Background: The devastating impact of the SARS-CoV-2 pandemic prompted the development and emergency use authorization of two mRNA vaccines in early 2020. Vaccine trials excluded nursing home (NH) residents, limiting adverse event data that directly apply to this population. Methods: To prospectively monitor for potential adverse events associated with vaccination, we used Electronic Health Record (EHR) data from Genesis HealthCare, the largest NH provider in the United States. EHR data on vaccinations and pre-specified adverse events were updated daily and monitored for signal detection among residents of 147 facilities who received the first dose of vaccine between December 18, 2020 and January 3, 2021. For comparison, unvaccinated residents during the same time period were included from 137 facilities that started vaccinating at least 15 days after the vaccinating facilities. Results: As of January 3, 2021, 8553 NH residents had received one dose of SARS-CoV-2 vaccine and by February 20, 2021, 8371 residents had received their second dose of vaccine; 11,072 were included in the unvaccinated comparator group. No significant associations were noted for neurologic outcomes, anaphylaxis, or cardiac events. Conclusions: No major safety problems were detected following the first or second dose of the vaccine to prevent COVID-19 in the study cohort from December 18, 2020 through March 7, 2021. (c) 2021 Elsevier Ltd. All rights reserved.	[Bardenheier, Barbara H.; Gravenstein, Stefan; Gutman, Roee; Sarkar, Indra Neil; White, Elizabeth M.; McConeghy, Kevin; Mor, Vincent] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA; [Gravenstein, Stefan; Sarkar, Indra Neil; Nanda, Aman] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Gravenstein, Stefan; McConeghy, Kevin; Mor, Vincent] Providence Vet Adm Med Ctr, Ctr Innovat Long Term Serv & Supports, Providence, RI USA; [Blackman, Carolyn; Feifer, Richard A.] Genesis Healthcare, Kennett Sq, PA USA; [Sarkar, Indra Neil] Rhode Isl Qual Inst, Providence, RI USA		Bardenheier, BH (通讯作者)，Brown Univ, 121 S Main St,Box G-S121-6, Providence, RI 02912 USA.	barbara_bardenheier@brown.edu	Gutman, Roee/J-2355-2014	Gutman, Roee/0000-0001-7095-3016; Blackman, Carolyn/0000-0002-5975-9164; Gravenstein, Stefan/0000-0001-6000-6859; Bardenheier, Barbara/0000-0001-9911-235X; Nanda, Aman/0000-0002-3860-3267	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5U54AG06354602S5, 3P01AG02729611S1]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	This research was supported, in part, by a grant from the National Institute on Aging [5U54AG06354602S5] with supplemental funding from the Centers for Disease Control and Prevention under an interagency agreement, and another grant from the National Institute on Aging [3P01AG02729611S1] . All authors attest they meet the ICMJE criteria for authorship.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Brighton Collaboration, PRIORITY LIST ADVERS; Brown LD, 2001, STAT SCI, V16, P101, DOI 10.1214/ss/1009213286; Cattaneo MD, 2010, J ECONOMETRICS, V155, P138, DOI 10.1016/j.jeconom.2009.09.023; Centers for Disease Control and Prevention, COVID DATA TRACKER F; Centers for Disease Control and Prevention, RAPID CYCLE ANAL RCA; Dooling K, 2020, MMWR-MORBID MORTAL W, V69, P1857, DOI 10.15585/mmwr.mm6949e1; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; McNeil MM, 2014, VACCINE, V32, P5390, DOI 10.1016/j.vaccine.2014.07.073; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; ROYALL RM, 1986, INT STAT REV, V54, P221, DOI 10.2307/1403146; Shimabukuro T, 2021, JAMA-J AM MED ASSOC, V325, P780, DOI 10.1001/jama.2021.0600; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; The COVID Tracking Project, LONG TERM CARE COVID; Thomas KS, 2017, MED CARE, V55, pE68, DOI 10.1097/MLR.0000000000000334; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n149	18	7	7	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3844	3851		10.1016/j.vaccine.2021.05.088		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34092431	Bronze, Green Published			2022-04-29	WOS:000663773600010
J	Tufail, S; Shah, MA; Zafar, M; Asif, TA; Shehzad, A; Shah, MS; Habib, M; Saleemi, MK; Muddassar, M; Mirza, O; Iqbal, M; Rahman, M				Tufail, Soban; Shah, Majid Ali; Zafar, Maryam; Asif, Tayyab Ali; Shehzad, Aamir; Shah, Muhammad Salahuddin; Habib, Mudasser; Saleemi, Muhammad Kashif; Muddassar, Muhammad; Mirza, Osman; Iqbal, Mazhar; Rahman, Moazur			Identification of potent epitopes on hexon capsid protein and their evaluation as vaccine candidates against infections caused by members of Adenoviridae family	VACCINE			English	Article						Adenoviridae family; Hexon; Epitope; Virus-like particle; Vaccine; Hydropericardium syndrome	HYDROPERICARDIUM SYNDROME; PREDICTION; CHICKENS; FIBER-2; SERVER	Adenoviruses cause economically important diseases in vertebrates. Effective vaccines against adenoviral diseases are currently lacking. Here, we report a highly conserved epitopic region on hexon proteins of adenoviruses that generate a strong immune response when used as a virus-like-particle (VLP) vaccine, produced by inserting the epitopic region into the core protein of hepatitis B virus. For evaluation of its protective efficacy, the epitopic region from a representative adenovirus, fowl adenovirus serotype 4 (FAdV-4), was tested as a VLP vaccine which conferred 90% protection against challenge with a virulent FAdV-4 isolate in chickens. Importantly, such a high level of protection is not achieved when the epitopic region is employed as a part of a subunit vaccine. As the sequence and the structure of the epitopic region are highly conserved in hexon proteins of adenoviruses, the epitopic region could be employed as a promising VLP vaccine candidate against adenoviral diseases, in general. (c) 2021 Elsevier Ltd. All rights reserved.	[Tufail, Soban; Shah, Majid Ali; Zafar, Maryam; Asif, Tayyab Ali; Shehzad, Aamir; Iqbal, Mazhar; Rahman, Moazur] Natl Inst Biotechnol & Genet Engn NIBGE, Hlth Biotechnol Div, Drug Discovery & Struct Biol Grp, Faisalabad, Pakistan; [Tufail, Soban; Shah, Majid Ali; Zafar, Maryam; Asif, Tayyab Ali; Shehzad, Aamir; Iqbal, Mazhar; Rahman, Moazur] Pakistan Inst Engn & Appl Sci PIEAS, PO Nilore, Islamabad, Pakistan; [Shah, Muhammad Salahuddin; Habib, Mudasser] Nucl Inst Agr & Biol NIAB, Anim Sci Div, Vaccine Dev Grp, Faisalabad, Pakistan; [Saleemi, Muhammad Kashif] Univ Agr Faisalabad, Fac Vet Sci, Dept Pathol, Faisalabad 38040, Pakistan; [Muddassar, Muhammad] COMSATS Univ Islamabad, Dept Biosci, Pk Rd, Islamabad, Pakistan; [Mirza, Osman] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, Copenhagen, Denmark; [Rahman, Moazur] Univ Punjab, Sch Biol Sci, Lahore, Pakistan		Rahman, M (通讯作者)，Natl Inst Biotechnol & Genet Engn NIBGE, Hlth Biotechnol Div, Drug Discovery & Struct Biol Grp, Faisalabad, Pakistan.; Rahman, M (通讯作者)，Univ Punjab, Sch Biol Sci, Lahore, Pakistan.	moazur.rahman@fulbrightmail.org	Rahman, Moazur/C-5515-2019	Rahman, Moazur/0000-0003-2892-1250; Mirza, Osman Asghar/0000-0001-9435-0690	International Centre for Genetic Engineering and Biotechnology (ICGEB), Italy [CRP/PAK10-01]; Higher Education Commission (HEC) of PakistanHigher Education Commission of Pakistan; Synchrotron-light for Experimental Science and Applications in the Middle East (SESAME), Jordan (OPEN-SESAME Fellowship)	This work was supported by the International Centre for Genetic Engineering and Biotechnology (ICGEB), Italy (grant No. CRP/PAK10-01 awarded to Moazur Rahman), the Higher Education Commission (HEC) of Pakistan (through HEC-Indigenous PhD Fellowship and HEC-IRSIP Fellowship awarded to Soban Tufail), and the Synchrotron-light for Experimental Science and Applications in the Middle East (SESAME), Jordan (through OPEN-SESAME Fellowship awarded to Soban Tufail).	Aziz F, 2019, VIRUS RES, V273, DOI 10.1016/j.virusres.2019.197750; Chen Z, 2019, J VET MED SCI, V81, P245, DOI 10.1292/jvms.18-0168; CrawfordMiksza L, 1996, J VIROL, V70, P1836, DOI 10.1128/JVI.70.3.1836-1844.1996; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Harrach B, 2019, FEBS LETT, V593, P3660, DOI 10.1002/1873-3468.13687; Hu K, 2018, VACCINE, V36, P4287, DOI 10.1016/j.vaccine.2018.05.118; Malik IR, 2012, SCAND J INFECT DIS, V44, P55, DOI 10.3109/00365548.2011.608711; MURPHY BR, 1988, J CLIN MICROBIOL, V26, P1595, DOI 10.1128/JCM.26.8.1595-1597.1988; Niczyporuk JS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207668; Pan Q, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080216; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Roose K, 2013, EXPERT REV VACCINES, V12, P183, DOI [10.1586/ERV.12.150, 10.1586/erv.12.150]; Salahuddin M., 2006, International Journal of Biology and Biotechnology, V3, P599; Sanders B., 2014, VACCINE ANAL STRATEG, P45, DOI [10.1007/978-3- 662-45024-6_2, DOI 10.1007/978-3-662-45024-6_2]; Schachner A, 2014, VACCINE, V32, P1086, DOI 10.1016/j.vaccine.2013.12.056; Wang XL, 2018, VIRUS RES, V245, P1, DOI 10.1016/j.virusres.2017.12.003; Wilson I, 2002, THEORY PRACTICE HIST, P125; WOHLFART C, 1988, J VIROL, V62, P2321, DOI 10.1128/JVI.62.7.2321-2328.1988; Xue L, 2017, BIOCHEM ENG J, V117, P139, DOI 10.1016/j.bej.2016.10.009	20	0	0	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 16	2021	39	27					3560	3564		10.1016/j.vaccine.2021.05.023		JUN 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SO5NX	34030897				2022-04-29	WOS:000659020000004
J	Correia, R; Meneses, L; Richheimer, C; Alves, PM; Carrondo, MJT; Duarte, ARC; Paiva, A; Roldao, A				Correia, Ricardo; Meneses, Liane; Richheimer, Carolina; Alves, Paula M.; Carrondo, Manuel J. T.; Duarte, Ana Rita C.; Paiva, Alexandre; Roldao, Antonio			Improved storage of influenza HA-VLPs using a trehalose-glycerol natural deep eutectic solvent system	VACCINE			English	Article						Influenza HA-VLPs; Improved storage; Natural deep eutectic solvents; Trehalose; Glycerol	ECONOMIC-BENEFITS; VACCINE POWDER; FORMULATION; HEMAGGLUTININ; INJECTABILITY; TECHNOLOGY; WATER	Vaccines are typically stored under refrigerated conditions (2-8 degrees C) to limit potency and efficacy loss. Maintaining the cold chain is costly and prone to vaccine wastage due to unexpected changes in the stor-age conditions. The development of formulations conferring enhanced stability can extend vaccine shelf-life and facilitate storage under non-refrigerated conditions, thus simplifying the distribution process and reducing vaccine wastage. In this study, the suitability of a natural deep eutectic system (NADES) consist-ing of trehalose and glycerol (TGly) for storage of influenza hemagglutinin (HA)-displaying virus-like par-ticles (VLPs) was successfully demonstrated. TGly was efficient in maintaining the activity and physical integrity of HA-VLPs for up to 4 h at 50 degrees C (accelerated stability study), with half-life values = 20-34 h for the best TGly formulations. Importantly, improved storage is achieved at increasingly higher TGly con-centrations, hence confirming the importance of TGly content in its protective capacity. In addition, HA-VLPs were stable in TGly for over one month at room temperature (short-term stability study), with no impact on HA titer or particle size distribution. This work highlights the potential of NADES to improve stability of VLP-based vaccines, showing promising protective capacity under non-refrigerated conditions and short-term thermal stress, and thus having a notable impact on vaccine's cold chain. (c) 2021 Elsevier Ltd. All rights reserved.	[Correia, Ricardo; Richheimer, Carolina; Alves, Paula M.; Carrondo, Manuel J. T.; Roldao, Antonio] Inst Biol Expt & Tecnol, IBET, Apartado 12, P-2780901 Oeiras, Portugal; [Correia, Ricardo; Alves, Paula M.; Roldao, Antonio] Univ Nova Lisboa, Inst Tecnol Quim & Biol Antonio Xavier, ITQB NOVA, Av Republ, P-2780157 Oeiras, Portugal; [Meneses, Liane; Duarte, Ana Rita C.; Paiva, Alexandre] Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, LAQV REQUIMTE, P-2829516 Caparica, Portugal		Roldao, A (通讯作者)，Inst Biol Expt & Tecnol, IBET, Apartado 12, P-2780901 Oeiras, Portugal.	aroldao@ibet.pt	Correia, Ricardo/AAC-2584-2022; Paiva, Alexandre/K-8453-2012; Roldao, Antonio/J-2396-2013	Meneses, Liane/0000-0001-6478-245X; Paiva, Alexandre/0000-0003-0328-999X; Duarte, Ana/0000-0003-0800-0112; Roldao, Antonio/0000-0003-0414-4899; Carvalho Correia, Ricardo Jorge/0000-0002-9434-7974	EUEuropean Commission [602640]; European Union's Horizon 2020 (European Research Council) [ERC-2016-CoG 725034]; Portuguese "Fundacao para a Ciencia e a Tecnologia" (FCT)Portuguese Foundation for Science and Technology [IF/01704/2014, SFRH/BD/134107/2017, SFRH/BD/148510/2019, IF/01704/2014/CP1229/CT0001]; Associate Laboratory for Green Chemistry-LAQV - FCT/MCTES [UIDB/50006/2020]	This work was supported by the EU-funded project "EDUFLUVAC"(FP7-HEALTH-2013-INNOVATION-1, GA n. 602640) and the European Union's Horizon 2020 (European Research Council) under grant agreement No ERC-2016-CoG 725034. The work was also funded by the Portuguese "Fundacao para a Ciencia e a Tecnologia" (FCT) through the following initiatives: "Investigador FCT" Program (IF/01704/2014), Exploratory Research and Development Project (IF/01704/2014/CP1229/CT0001), and PhD fellowships (Ricardo Correia -SFRH/BD/134107/2017, Liane Meneses SFRH/BD/148510/2019). This work was supported by the Associate Laboratory for Green Chemistry-LAQV which is financed by national funds from FCT/MCTES (UIDB/50006/2020). The authors wish to thank: Marcos Sousa and Alexandre Murad for the support in HA-VLPs production, Sofia Carvalho and Mafalda Moleirinho for the support in HA-VLPs purification, Ana Sofia Moreira and Joana Oliveira for the support in nanoparticle analysis.	Amorij JP, 2007, VACCINE, V25, P6447, DOI 10.1016/j.vaccine.2007.06.054; Amorij JP, 2008, PHARM RES-DORDR, V25, P1256, DOI 10.1007/s11095-008-9559-6; Braun LJ, 2009, VACCINE, V27, P72, DOI 10.1016/j.vaccine.2008.10.027; Cardoso FMC, 2017, ACTA VIROL, V61, P231, DOI 10.4149/av_2017_301; Carvalho SB, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201800570; Carvalho SB, 2019, SEP PURIF TECHNOL, V218, P81, DOI 10.1016/j.seppur.2019.02.040; Carvalho SB, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700031; Castro VIB, 2018, CRYOBIOLOGY, V83, P15, DOI 10.1016/j.cryobiol.2018.06.010; Cilurzo F, 2011, AAPS PHARMSCITECH, V12, P604, DOI 10.1208/s12249-011-9625-y; Correia R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040589; Cox MMJ, 2009, BIOLOGICALS, V37, P182, DOI 10.1016/j.biologicals.2009.02.014; Craveiro R, 2019, ACS SUSTAIN CHEM ENG, V7, P19943, DOI 10.1021/acssuschemeng.9b05434; Dai YT, 2013, ANAL CHIM ACTA, V766, P61, DOI 10.1016/j.aca.2012.12.019; Dominguez de Maria, 2017, APPL GREEN SOLVENTS, P139, DOI DOI 10.1016/B978-0-12-805297-6.00006-1; Gerdil C, 2003, VACCINE, V21, P1776, DOI 10.1016/S0264-410X(03)00071-9; Girard MP, 2005, VACCINE, V23, P5708, DOI 10.1016/j.vaccine.2005.07.046; Hammond Oliver S, 2017, Angew Chem Int Ed Engl, V56, P9782, DOI 10.1002/anie.201702486; Holtz KM, 2014, BMC BIOTECHNOL, V14, DOI 10.1186/s12896-014-0111-y; ISLAMC M, 2020, MOLECULES, V25, P1619; Jonges M, 2010, J CLIN MICROBIOL, V48, P928, DOI 10.1128/JCM.02045-09; Kim YC, 2010, PROCEDIA VACCINOL, V2, P17, DOI 10.1016/j.provac.2010.03.004; Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007; Lee MS, 2018, J IND ENG CHEM, V65, P343, DOI 10.1016/j.jiec.2018.05.005; Loeffen WLA, 2011, VACCINE, V29, P1545, DOI 10.1016/j.vaccine.2010.12.096; Lydon P, 2014, B WORLD HEALTH ORGAN, V92, P86, DOI 10.2471/BLT.13.123471; McCraw DM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28700-7; Preaud E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-813; Saluja V, 2010, HUM VACCINES, V6, P854, DOI 104161/hv.6.11.12572; Savi LK, 2019, INT J FOOD SCI TECH, V54, P898, DOI 10.1111/ijfs.14013; SCHILD GC, 1975, B WORLD HEALTH ORGAN, V52, P223; Sequeira DP, 2018, VACCINE, V36, P3112, DOI 10.1016/j.vaccine.2017.02.043; Smith PJ, 2019, J PHYS CHEM B, V123, P5302, DOI 10.1021/acs.jpcb.8b12322; Vagenende V, 2009, BIOCHEMISTRY-US, V48, P11084, DOI 10.1021/bi900649t; Vermeij P, 2019, LIQUID VACCINES LIVE; White JA, 2016, VACCINE, V34, P3676, DOI 10.1016/j.vaccine.2016.04.074; WHO, 2017, 650 000 PEOPL RESP D; World Health Organization, 2005, MON VACC WAST COUNTR; Zhang QN, 2018, AAPS PHARMSCITECH, V19, P1520, DOI 10.1208/s12249-018-0963-x	38	0	0	4	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 2	2021	39	24					3279	3286		10.1016/j.vaccine.2021.04.033		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SM1SV	33966910				2022-04-29	WOS:000657392500006
J	Awad, AM; Ntoso, A; Connaire, JJ; Hernandez, GT; Dhillon, K; Rich, L; Henderson, H; Lynn, R; Hyer, RN; Xie, F; Erby, K; Janssen, RS				Awad, Ahmed M.; Ntoso, Adu; Connaire, Jeffrey J.; Hernandez, German T.; Dhillon, Kiranjit; Rich, Lisa; Henderson, Heather; Lynn, Robert; Hyer, Randall N.; Xie, Fang; Erby, Kimberly; Janssen, Robert S.		HBV-24 Study Grp	An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B (R)) in adults receiving hemodialysis	VACCINE			English	Article						Hepatitis B vaccine; Toll-like receptor 9; Hemodialysis	VIRUS INFECTION; PERSISTENCE; HBSAG-1018; DIALYSIS; EFFICACY	Background: Hemodialysis patients are at increased risk of hepatitis B virus (HBV) infection and are poorly responsive to HBV vaccines. Current vaccine recommendations for hemodialysis patients utilize more than twice the amount of hepatitis B surface antigen (HBsAg) used for healthy adults and achieve lower immune responses. Methods: An open-label, single-arm, multicenter trial was conducted among adults 18 years of age and older who were initiating or undergoing hemodialysis who had not previously received hepatitis B vaccine. Participants received four doses of HepB-CpG (HEPLISAV-B (R)) (20 mcg rHBsAg + 3000 mcg CpG 1018, a Toll-like receptor 9 agonist) administered at 0, 4, 8, and 16 weeks. Participants are being followed for 68 weeks. This paper reports the final immunogenicity analysis of the primary endpoint at study week 20 and an interim safety analysis. Results: We enrolled 119 participants receiving hemodialysis who were followed for a median of 47.4 weeks. Of the 119 participants, 75 were in the per-protocol population. At week 20, the seroprotection rate (% with antibodies to hepatitis B surface antigen [anti-HBs] >= 10 mIU/mL) was 89.3% and the percentage of participants with anti-HBs >= 100 mIU/mL was 81.3%. The anti-HBs geometric mean concentration was 1061.8 mIU/mL. HepB-CpG was well tolerated with no observed safety concerns. Conclusion: In patients receiving hemodialysis, HepB-CpG given as four doses was well tolerated and induced very high anti-HBs concentrations and seroprotection in a very high proportion of recipients. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Awad, Ahmed M.] Clin Res Consultants, 3930 Washington St, Kansas City, MO 64111 USA; [Ntoso, Adu] DaVita Franklin Dialysis, 150 South Independence Mall West, Philadelphia, PA 19106 USA; [Connaire, Jeffrey J.] DaVita Clin Res, 825 South 8th St,Suite 300, Minneapolis, MN USA; [Hernandez, German T.] El Paso Kidney Specialists, 1310 Murchison Dr,Suite 100, El Paso, TX 79902 USA; [Dhillon, Kiranjit] DaVita Clin Res Norfolk, 962 Norfolk Sq, Norfolk, VA 23502 USA; [Rich, Lisa] 2514 South 102nd St,Suite 120, Wauwatosa, WI 53227 USA; [Henderson, Heather] 18001 East 10 Mile Rd,Suite 3, Roseville, MI 48066 USA; [Lynn, Robert] Kidney Med Associates, 34 Marconi St,Suite 100, Bronx, NY 10461 USA; [Hyer, Randall N.; Xie, Fang; Erby, Kimberly; Janssen, Robert S.] Dynavax Technol Corp, 2100 Powell St,Suite 900, Emeryville, CA 94608 USA; [Hyer, Randall N.] Moderna, 200 Technol Sq, Cambridge, MA 02139 USA		Janssen, RS (通讯作者)，2100 Powell St,Suite 900, Emeryville, CA 94608 USA.	rjanssen@dynavax.com		Hernandez, German/0000-0001-5359-7769; Rich, Lisa/0000-0002-1948-1655	Dynavax Technologies Corporation	This study was funded by Dynavax Technologies Corporation.	[Anonymous], 2001, MMWR Recomm Rep, V50, P1; [Anonymous], 2017, WORLD MALARIA REPORT; BUTI M, 1992, AM J NEPHROL, V12, P144, DOI 10.1159/000168436; Charest AF, 2000, AM J KIDNEY DIS, V36, P976, DOI 10.1053/ajkd.2000.19099; Chaves SS, 2012, VACCINE, V30, P1644, DOI 10.1016/j.vaccine.2011.12.106; Floreani A, 2004, VACCINE, V22, P607, DOI 10.1016/j.vaccine.2003.09.001; FRASER GM, 1994, J HEPATOL, V21, P450; Girndt M, 2010, EUR NEPHROL, V4, P14; GlaxoSmithKline, 2020, ENGERIX B HEP B VACC; Heyward W, 2012, KIDN WEEK 2012 SAN D; Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038; Janssen RS, 2013, VACCINE, V31, P5306, DOI 10.1016/j.vaccine.2013.05.067; JILG W, 1984, LANCET, V2, P1174; JOHNSON DW, 1992, CLIN PHARMACOKINET, V22, P434, DOI 10.2165/00003088-199222060-00003; Keating GM, 2003, DRUGS, V63, P1021, DOI 10.2165/00003495-200363100-00006; Kramer A, 2018, CLIN KIDNEY J, V11, P108, DOI 10.1093/ckj/sfx149; Merck Sharp and Dohme Limited, 2019, HBVAXPRO 40 MCG SUMM; Miller ER, 1999, AM J KIDNEY DIS, V33, P356, DOI 10.1016/S0272-6386(99)70312-4; Mulley WR, 2017, NEPHROL DIAL TRANSPL, V32, P136, DOI 10.1093/ndt/gfv443; Navarro JF, 1996, AM J NEPHROL, V16, P95, DOI 10.1159/000168977; Ozer A, 2011, HEPAT MON, V11, P263; Previsani N, 2004, PERSP MED V, V10, P31; Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1; Sezer S, 2000, TRANSPLANT P, V32, P607, DOI 10.1016/S0041-1345(00)00914-3; Standing Committee on Vaccination at the Robert Koch Institute, 2012, EPIDEMIOL B, V30, P283; Tong NKC, 2005, KIDNEY INT, V68, P2298, DOI 10.1111/j.1523-1755.2005.00689.x; United States Renal Data System, 2020, 2019 USRDS ANN DAT R; Ye X, 2017, NEPHROL DIAL TRANSPL, V32, pIII698; Zitt E, 2017, VACCINE, V35, P814, DOI 10.1016/j.vaccine.2016.12.032	29	1	1	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3346	3352		10.1016/j.vaccine.2021.05.003		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	34001345	hybrid			2022-04-29	WOS:000657001300009
J	Pagliusi, S; Hayman, B; Jarrett, S				Pagliusi, Sonia; Hayman, Benoit; Jarrett, Stephen			Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report	VACCINE			English	Article								The Developing Countries Vaccine Manufacturers' Network held its 21st Annual General Meeting virtually in November 2020 given the COVID-19 pandemic. Vaccine manufacturing experts, leaders from local and global public health organizations and multilateral organizations, through diverse presentations, questions and answers, focused on the pandemic and the response of vaccine manufacturers where many are engaged in research and development and production agreements. The pandemic is expanding rapidly which makes the global availability and equitable access to safe and effective COVID-19 vaccines critical. Strategies put in place include the establishment of the Access to COVID-19 Tools Accelerator (ACT-A) within which the COVAX facility aims to distribute 2 billion COVID-19 vaccine doses by the end of 2021, with procurement mechanisms already being established. At the same time, regulatory authorities have emergency use authorizations aimed at the rapid approval of safe and effective vaccines, with a push for harmonization in regulatory approaches being advocated. The Meeting was also apprised of other innovations being developed for vaccines including multi-array patches for easier vaccine application, increased heat stability for mitigating cold chain and storage challenges, the barcoding of primary packaging for enhancing vaccine traceability, and gathering data for decision-making. Over time, these innovations will facilitate the widespread availability and equitable access of vaccines including those addressing epidemics and pandemics. In addition, a number of manufacturers described technologies they have for accelerating vaccine manufacturing and supply globally. Overall, there was agreement that manufacturers from developing countries play a critical role in the global research, development and supply of vaccines for a healthy future, with increasing collaboration and partnering between them a growing strength.	[Pagliusi, Sonia; Hayman, Benoit] DCVMN Int, Route Crassier 7, CH-1262 Eysins Nyon 1262, Switzerland; [Jarrett, Stephen] Gracious Int Inc, 28 Jiafeng Rd, Shanghai 200131, Peoples R China		Pagliusi, S (通讯作者)，DCVMN Int, Route Crassier 7, CH-1262 Eysins Nyon 1262, Switzerland.	s.pagliusi@dcvmn.net; b.hayman@dcvmn.net; swjarrett@graciousgroup.com		Hayman, Benoit/0000-0001-6137-4549	Engineering and Physical Sciences Research Council (EPSRC)UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/R013764/1]; Bill & Melinda Gates Foundation, United StatesCGIAR [OPP1204376]; Department of Health and Social Care; Bioengineering; Biozeen; Cytiva; GEA Group; Gihon; InDevR; Merck GroupMerck & Company; Univercells; ViroClinics; Rommelag; Syntegon; Temptime-Zebra Corporation; Tofflon	We thank all the DCVMN Members for inspiring presentations and productive discussions (cf. https://www.dcvmn.org/Members-list-412).We are grateful for the generous availability of all speakers who graciously made themselves available for the meeting and contributed to its success. Furthermore, we would like to extend our gratitude to all colleagues who directly or indirectly contributed to the knowledge shared in this report, particularly Ms. S. Villasenor for support throughout the meeting and Dr. M. Dennehy for serving as moderator. We thank corporate partners for supporting DCVMN with unrestricted educational grants: Bioengineering, Biozeen, Cytiva, GEA Group, Gihon, InDevR, Merck Group, Rommelag, Syntegon, Temptime-Zebra Corporation, Tofflon, Univercells and ViroClinics. Some reported activities are funded by the Department of Health and Social Care using UK Aid funding and is managed by the Engineering and Physical Sciences Research Council (EPSRC, grant number: EP/R013764/1, note: the views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care). This virtual meeting was partly supported by a grant from the Bill & Melinda Gates Foundation, United States, Grant no. OPP1204376.	Administration U.F.a.D., 2020, EMERGENCY USE AUTHOR; African Union Commission, PAN AFRICAN PARLIAME; Blankenship K., 2020, FIERCE PHARMA; CEPI, 2020, COVAX VACCINES PILLA; Chiu M., 2020, BAYLOR BIOLOGICAL LT; Coronavirus,, BHARAT BIOTECHS COVI; Fedosyuk S, 2019, VACCINE, V37, P6951, DOI 10.1016/j.vaccine.2019.04.056; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gross A, 2020, FINANCIAL TIMES, V23; Jarrett, 2020, VACCINE; Kis Z, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201800376; Kristensen DD, 2016, VACCINE, V34, P899, DOI 10.1016/j.vaccine.2016.01.001; Kupferschmidt K., 2020, SCI MAGAZINE; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; May B., 2020, BIOSPACE; McKay, Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice; Ndomondo-Sigonda M, 2011, CLIN PHARMACOL THER, V89, P176, DOI 10.1038/clpt.2010.299; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pagliusi S, 2020, VACCINE, V38, P5418, DOI 10.1016/j.vaccine.2020.06.022; Peyraud N, 2019, VACCINE, V37, P4427, DOI 10.1016/j.vaccine.2019.03.035; Toelzer C, 2020, SCIENCE, V370, P725, DOI 10.1126/science.abd3255; van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y; Von Hunolstein C., 2008, PHARMAEUROPA BIO, P7; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; WHO, CONSIDERATIONS EVALU; WHO, EMERGENCY USE LISTIN; WHO, MODEL PACKAGING COVI; WHO, 2002, GETTING STARTED VACC; WHO IHR, PROCEDURES PUBLIC HL; World Health organization, FREQUENTLY ASKED QUE; Xing D, 2014, EXPERT REV VACCINES, V13, P1175, DOI 10.1586/14760584.2014.939636; Yadaf, 2020, NATURE RESOUR; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	34	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2479	2488		10.1016/j.vaccine.2021.03.025		APR 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33838948	Green Published, Bronze			2022-04-29	WOS:000642189300001
J	Chen, DQ; Ye, ZJ; Pi, ZF; Mizukami, S; Aoyagi, K; Jiang, YW				Chen, Daqin; Ye, Zhaojia; Pi, Zhenfei; Mizukami, Satoshi; Aoyagi, Kiyoshi; Jiang, Yawen			Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China	VACCINE			English	Article						Cost-effectiveness; Markov model; Influenza; Pneumonia; Vaccine	SEASONAL INFLUENZA; POLYSACCHARIDE VACCINATION; ECONOMIC BURDEN; POPULATION; DISEASE; PEOPLE; OLDER; PNEUMONIA; MORTALITY; IMPACT	Objective: To assess the cost-effectiveness of dual influenza and pneumococcal vaccination for the elderly in Shenzhen, China. Methods: A Markov state-transition model with a weekly cycle was developed to compare the outcomes of dual influenza and pneumococcal vaccination for the prevention of influenza and pneumococcal infections compared with no vaccination among 70-74 years old people in Shenzhen over 5 years. The model allowed seasonal variation of influenza activity. We calculated the incremental cost-effectiveness ratio (ICER) with costs and quality-adjusted life years (QALYs) discounted at 5% annually from the societal perspective. The impact of parameter uncertainty on the results was examined using one-way and probabilistic sensitivity analyses (PSA). Results: In the base case, dual vaccination prevented 5042 influenza infections, 26 IPD cases, 3 disabilities, 34 deaths, and cost US$7.1 per person while resulting in a net gain of 0.0026 QALYs compared with no vaccination. Using once the Chinese gross domestic product per capita in 2019 (US$10,289) as the willingness-to-pay threshold, dual vaccination was cost-effective with an ICER of US$2699 per QALY gained. One-way sensitivity analyses showed that the ICER was relatively sensitive to changes in influenza attack rates and influenza vaccine effectiveness. Based on the results of PSA with 1000 Monte Carlo simulations, receiving both vaccines was cost-effective in 100% of the repetitions. Conclusion: The current study provides evidence that dual influenza and pneumococcal vaccination is a cost-effective disease prevention strategy for the elderly in Shenzhen, China. (C) 2021 Elsevier Ltd. All rights reserved.	[Chen, Daqin; Jiang, Yawen] Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen 518107, Guangdong, Peoples R China; [Ye, Zhaojia] Shenzhen Ctr Dis Control & Prevent, Shenzhen 518055, Guangdong, Peoples R China; [Pi, Zhenfei; Mizukami, Satoshi; Aoyagi, Kiyoshi] Nagasaki Univ, Dept Publ Hlth, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan		Jiang, YW (通讯作者)，Sun Yat Sen Univ, Room 215,Mingde Garden 6,132 East Outer Ring Rd, Guangzhou 510006, Guangdong, Peoples R China.	chendq26@mail2.sysu.edu.cn; yzj228@126.com; pizhnefei@126.com; s.mizukami@nagasaki-u.ac.jp; kiyoshi@nagasaki-u.ac.jp; jiangyw26@mail.sysu.edu.cn		Mizukami, Satoshi/0000-0002-9097-2115	Guangdong Provincial Funding Program of Basic and Applied Basic Research [2019A1515110397]	This work was supported by the Guangdong Provincial Funding Program of Basic and Applied Basic Research [grant numbers 2019A1515110397].	[Anonymous], US DOLLAR CHINESE YU; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; Bureau of Statistics of Shenzhen, AVERAGE ANN WAGE LEV; Cai Li, 2006, Kobe Journal of Medical Sciences, V52, P97; Darvishian M, 2017, LANCET RESP MED, V5, P200, DOI 10.1016/S2213-2600(17)30043-7; Dushoff J, 2004, P NATL ACAD SCI USA, V101, P16915, DOI 10.1073/pnas.0407293101; Edmunds WJ, 1999, STAT MED, V18, P3263, DOI 10.1002/(SICI)1097-0258(19991215)18:23&lt;3263::AID-SIM315&gt;3.0.CO;2-3; Fedson DS, 1997, VACCINE, V15, P1506, DOI 10.1016/S0264-410X(97)00091-1; Fielding JE, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-170; Gilchrist SAN, 2012, AM J PUBLIC HEALTH, V102, P596, DOI 10.2105/AJPH.2011.300512; Gray A, 2011, APPL METHODS COST EF; Honkanen PO, 1996, ARCH INTERN MED, V156, P205, DOI 10.1001/archinte.156.2.205; Horby PW, 2005, AUST NZ J PUBL HEAL, V29, P35, DOI 10.1111/j.1467-842X.2005.tb00745.x; Jiang MH, 2020, VACCINE, V38, P1057, DOI 10.1016/j.vaccine.2019.11.045; Jiang Y, 2020, DUAL INFLUENZA PNEUM, V9; Kraicer-Melamed H, 2016, VACCINE, V34, P1540, DOI 10.1016/j.vaccine.2016.02.024; Li L, 2019, LANCET PUBLIC HEALTH, V4, pE473, DOI 10.1016/S2468-2667(19)30163-X; Lin CJ, 2013, AM J MANAG CARE, V19, pE30; Liu G, 2019, CHINA GUIDELINES PHA; McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; National Health Commission of the People's Republic of China, 2019, 2019 CHINESE HLTH ST; National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), 2019, ZHONGHUA LIU XING, V40 40, P1333; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Qin Ying, 2012, Zhonghua Liu Xing Bing Xue Za Zhi, V33, P1101; Reber AJ, 2012, AGING DIS, V3, P68; Shami JJP, 2020, HUM VACC IMMUNOTHER, V16, P1937, DOI 10.1080/21645515.2019.1711300; Sisk JE, 2003, ANN INTERN MED, V138, P960, DOI 10.7326/0003-4819-138-12-200306170-00007; Smith KJ, 2008, VACCINE, V26, P1420, DOI 10.1016/j.vaccine.2008.01.007; Smith KJ, 2010, VACCINE, V28, P7620, DOI 10.1016/j.vaccine.2010.09.053; Somes MP, 2018, VACCINE, V36, P3199, DOI 10.1016/j.vaccine.2018.04.063; Sun S, 2011, QUAL LIFE RES, V20, P309, DOI 10.1007/s11136-010-9762-x; Walker DG, 2010, VACCINE, V28, P2356, DOI 10.1016/j.vaccine.2009.06.035; Weaver M, 2001, ARCH INTERN MED, V161, P111, DOI 10.1001/archinte.161.1.111; Weycker D, 2010, VACCINE, V28, P4955, DOI 10.1016/j.vaccine.2010.05.030; World Health Organization, LIFE TABLES COUNTRY; Wu David Bin-Chia, 2014, J Med Econ, V17, P312, DOI 10.3111/13696998.2014.898644; Xing NL, 2019, AM J INFECT CONTROL, V47, P1302, DOI 10.1016/j.ajic.2019.05.003; Yang J, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2801-2; Yang J, 2016, VACCINE, V34, P5724, DOI 10.1016/j.vaccine.2016.10.013; Yang J, 2015, INFECT DIS POVERTY, V4, DOI 10.1186/s40249-015-0077-6; Yaozh, INFORM DRUG WINNING; You JHS, 2009, J EPIDEMIOL COMMUN H, V63, P906, DOI 10.1136/jech.2008.081885; Zhang GuoHui, 2013, Chinese Journal of Biologicals, V26, P93; Zhang YY, 2016, HUM VACC IMMUNOTHER, V12, P3056, DOI 10.1080/21645515.2016.1221552; Zhou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073724; Zhu B, 2017, J PREV MED INF, V33, P75	47	1	4	2	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 15	2021	39	16					2244	2252		10.1016/j.vaccine.2021.03.041		APR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RJ9QI	33757667				2022-04-29	WOS:000637937900008
J	Nwogu, IB; Jones, M; Langley, T				Nwogu, Ifechukwu B.; Jones, Matthew; Langley, Tessa			Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review	VACCINE			English	Review						Meningococcal disease; Serogroup B; Vaccination; Cost-effectiveness	COST-EFFECTIVENESS; VACCINATION; DISEASE; IMPACT; MENINGITIS	Background: Meningococcal serogroup B (MenB) has emerged as the leading cause of invasive meningococcal disease (IMD) in several countries following the release of effective vaccines against serogroups A, C, W, and Y. In 2013, however, the first multicomponent MenB vaccine (Bexsero (R)) was licensed in Europe. Aim: To review the evidence on the cost-effectiveness of vaccination against MenB. Methods: Searches were performed in MEDLINE, EMBASE, Web of Science, NHS EED, Econlit, Tufts CEA registry, and HTA. Three reviewers independently screened and selected studies. Using a narrative synthesis, studies were categorized by vaccination strategies. The quality of included studies was assessed using the Comparative Health Economics Evaluation Reporting Standards (CHEERS) checklist. Results: 13 studies were included. Ten studies were conducted in the European region and three in the Americas. None of the vaccination strategies were considered cost-effective. Including herd effects improved value for money for MenB vaccines. Routine infant vaccination was the most effective short-term strategy, however, adolescent strategies offered the best value for money. Without herd immunity, routine infant vaccination had the lowest incremental cost-effectiveness ratio estimates. Conclusion: Routine MenB vaccination does not offer substantial value for money, mainly due to high vaccine costs and low disease incidence. (C) 2021 Elsevier Ltd. All rights reserved.Y	[Nwogu, Ifechukwu B.; Langley, Tessa] Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Nottingham, England; [Jones, Matthew] Univ Nottingham, Sch Med, Div Primary Care, Nottingham, England		Nwogu, IB (通讯作者)，Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham City Hosp, Clin Sci Bldg, Nottingham NG5 1PB, England.	inwogu@uw.edu		Nwogu, Ifechukwu/0000-0001-9845-9327; Langley, Tessa/0000-0001-9560-1148			Azzari C, 2014, VACCINE, V32, P1187, DOI 10.1016/j.vaccine.2013.09.055; Canadian Agency for Drugs and Technologies in Health Agence canadienne des medicaments et des technologies de la sante, 2009, DEV TESTING SEARCH F; Chit A, 2016, HUM VACC IMMUNOTHER, V12, P1257, DOI 10.1080/21645515.2015.1137405; Christensen H, 2017, VACCINE, V35, P208, DOI 10.1016/j.vaccine.2016.11.076; Christensen H, 2016, VACCINE, V34, P3412, DOI 10.1016/j.vaccine.2016.04.004; Christensen H, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5725; Christensen H, 2013, VACCINE, V31, P2638, DOI 10.1016/j.vaccine.2013.03.034; Di Nardo F, IG SANITA PUBBL, V73, P453; Drummond MF., 2005, METHODS EC EVALUATIO; Edmond K, 2010, LANCET INFECT DIS, V10, P317, DOI 10.1016/S1473-3099(10)70048-7; European Centre for Disease Prevention and Control, 2017, ANN EPIDEMIOLOGICAL; Gasparini R, 2016, HUM VACC IMMUNOTHER, V12, P2148, DOI 10.1080/21645515.2016.1160177; Ginsberg GM, 2016, INT J PUBLIC HEALTH, V61, P683, DOI 10.1007/s00038-016-0821-0; Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032; Hanquet G, QUADRIVALENT VACCINE; Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063; Harrison OB, 2011, MICROBIOL-SGM, V157, P2181, DOI 10.1099/mic.0.050518-0; Hill DJ, 2010, CLIN SCI, V118, P547, DOI 10.1042/CS20090513; Husereau D, 2013, EUR J HEAL EC; Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002; Izquierdo G, 2015, HUM VACC IMMUNOTHER, V11, P875, DOI 10.1080/21645515.2015.1010885; Kuhdari P, 2016, PATHOG GLOB HEALTH, V110, DOI 10.1080/20477724.2016.1195072; Ladhani SN, 2016, ARCH DIS CHILD, V101, P91, DOI 10.1136/archdischild-2015-308928; Leca M, 2015, PATHOL BIOL, V63, P144, DOI 10.1016/j.patbio.2015.04.003; Lecocq H, 2016, VACCINE, V34, P2240, DOI 10.1016/j.vaccine.2016.03.020; Leeds IL, 2019, AM J PREV MED, V56, P196, DOI 10.1016/j.amepre.2018.09.020; Liberati A., 2009, J CLIN EPIDEMIOL; MacNeil JR, 2015, MMWR-MORBID MORTAL W, V64, P1171, DOI 10.15585/mmwr.mm6441a3; Mameli C, 2015, FUTURE MICROBIOL, V10, P1579, DOI 10.2217/fmb.15.91; Nadel S, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00321; Naghavi M, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l94; Pitman R, 2012, MED DECIS MAKING, V32, P712, DOI 10.1177/0272989X12454578; Pouwels KB, 2013, HUM VACC IMMUNOTHER, V9, P1129, DOI 10.4161/hv.23888; Rappuoli R, 2013, LANCET, V382, P935, DOI 10.1016/S0140-6736(13)61925-X; Read RC, 2014, LANCET, V384, P2123, DOI 10.1016/S0140-6736(14)60842-4; Reese HE, 2019, J INFECT DIS, V220, pS263, DOI 10.1093/infdis/jiz251; Roderick M, 2014, J INFECTION, V68, pS76, DOI 10.1016/j.jinf.2013.09.026; Smit R, 2018, VALUE HEALTH, V21, pS238, DOI 10.1016/j.jval.2018.09.1421; Snape MD, 2013, CAN MED ASSOC J, V185, pE715, DOI 10.1503/cmaj.130257; Snape MD, 2013, PEDIATR INFECT DIS J, V32, P1116, DOI 10.1097/INF.0b013e31829cfff2; Thielen FW, 2016, EXPERT REV PHARM OUT, V16, P705, DOI 10.1080/14737167.2016.1246962; Tirani M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123383; Trotter CL, 2017, LANCET INFECT DIS, V17, P867, DOI [10.1016/s1473-3099(17)30301-8, 10.1016/S1473-3099(17)30301-8]; Tu HAT, 2014, VACCINE, V32, P5436, DOI 10.1016/j.vaccine.2014.07.096; van Mastrigt GAPG, 2016, EXPERT REV PHARM OUT, V16, P689, DOI 10.1080/14737167.2016.1246960; Wilczynski NL, 2004, CAN MED ASSOC J, V171, P1179, DOI 10.1503/cmaj.1040512; World Health Organization, MEN MEN	47	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 15	2021	39	16					2201	2213		10.1016/j.vaccine.2021.02.049		APR 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QI	33744052				2022-04-29	WOS:000637937900004
J	Yokomichi, H; Kojima, R; Horiuchi, S; Ooka, T; Akiyama, Y; Miyake, K; Mochizuki, M; Otawa, S; Shinohara, R; Yamagata, Z				Yokomichi, Hiroshi; Kojima, Reiji; Horiuchi, Sayaka; Ooka, Tadao; Akiyama, Yuka; Miyake, Kunio; Mochizuki, Mie; Otawa, Sanae; Shinohara, Ryoji; Yamagata, Zentaro		Japan Environm Childrens Study Grp	Effectiveness of influenza vaccination in infants and toddlers with and without prior infection history: The Japan Environment and Children's Study	VACCINE			English	Article						Influenza vaccine; Vaccine effectiveness; Influenza infection; Children; Japanese; Relative risk	TEST-NEGATIVE DESIGN; HERD-IMMUNITY; EFFICACY; VACCINES; ADULTS	We calculated the Poisson-regression-adjusted relative risk (RR) of new influenza infection by vaccination, prior infection, and vaccination after prior infection in a large Japanese birth cohort, using data from <= 89,253 children aged 6 months to 3 years. The effectiveness of risk reduction (1 - RR) by vaccination at ages 1.5-3 years was 21%-31%. The RR of new infection after prior infection vs. no prior infection was 2.58-19.3 at age 1-3 years. An analysis of the 1 - RR data stratified by having at least one senior sibling and/or attending nursery school revealed that vaccination reduced the RR by 22%-40%. The 1 - RR of new infection was 21% in 3-year-old children who were vaccinated after prior infection. All these findings are statistically significant. The results consistently indicate that, regardless of having at least one senior sibling, attending nursery school, and/or being previously infected with influenza, infants and toddlers will benefit from influenza vaccination. (C) 2021 The Authors. Published by Elsevier Ltd.	[Yokomichi, Hiroshi; Kojima, Reiji; Ooka, Tadao; Akiyama, Yuka; Miyake, Kunio; Yamagata, Zentaro] Univ Yamanashi, Dept Hlth Sci, Chuo Ku, 1110 Shimokato, Kofu, Yamanashi, Japan; [Horiuchi, Sayaka; Otawa, Sanae; Shinohara, Ryoji; Yamagata, Zentaro] Univ Yamanashi, Birth Cohort Ctr, Chuo Ku, 1110 Shimokato, Kofu, Yamanashi, Japan; [Mochizuki, Mie] Univ Yamanashi, Dept Paediat, Chuo Ku, 1110 Shimokato, Kofu, Yamanashi, Japan		Yokomichi, H (通讯作者)，Univ Yamanashi, Dept Hlth Sci, Chuo Ku, 1110 Shimokato, Kofu, Yamanashi, Japan.	hyokomichi@yamanashi.ac.jp; kojimar@yamanashi.ac.jp; sayakahoriuchi@gmail.com; tohoka@yamanashi.ac.jp; yukaa@yamanashi.ac.jp; kmiyake@yamanashi.ac.jp; mmie@sweet.ocn.ne.jp; osanae@yamanashi.ac.jp; rshinohara@yamanashi.ac.jp; zenymgt@yamanashi.ac.jp	Ooka, Tadao/AAR-1205-2021; Yokomichi, Hiroshi/B-2816-2013	Yokomichi, Hiroshi/0000-0001-7369-155X; Ooka, Tadao/0000-0002-1343-3986	Ministry of the Environment, JapanMinistry of the Environment, Japan	This study was funded by the Ministry of the Environment, Japan. The findings and conclusions of this article are solely the responsibility of the authors and do not represent the official views of the above government.	Belshe RB, 2010, VACCINE, V28, P2149, DOI 10.1016/j.vaccine.2009.11.068; Cobey S, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3730; Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003; Gupta V, 2006, VACCINE, V24, P3881, DOI 10.1016/j.vaccine.2006.01.010; Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053; Japan Pediatric Society, 2016, VACC SCHED REC JAP P; Kawamoto T, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-25; Keitel WA, 1997, VACCINE, V15, P1114, DOI 10.1016/S0264-410X(97)00003-0; Lee K, 2009, GLOB INST, P1; Lee VJ, 2018, INFLUENZA OTHER RESP, V12, P3, DOI 10.1111/irv.12533; Piedra PA, 2005, VACCINE, V23, P1540, DOI 10.1016/j.vaccine.2004.09.025; Plans-Rubio P, 2012, PREV MED, V55, P72, DOI 10.1016/j.ypmed.2012.02.015; Reichert TA, 2001, NEW ENGL J MED, V344, P889, DOI 10.1056/NEJM200103223441204; Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010; Shibata N, 2018, VACCINE, V36, P2809, DOI 10.1016/j.vaccine.2018.03.082; World Health Organization, EV INFL VACC EFF GUI; Yokomichi H, 2012, J VACCIN VACCIN, V3, DOI 0148.; Yokomichi H, 2020, INT J HEMATOL, V112, P105, DOI 10.1007/s12185-020-02866-1; Yokomichi H, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024687; Yokomichi H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088927	20	3	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 26	2021	39	13					1800	1804		10.1016/j.vaccine.2021.02.044		MAR 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QY9YH	33685777	hybrid			2022-04-29	WOS:000630391900002
J	Rane, MS; Page, LC; McVeigh, E; Miller, K; Baure, D; Halloran, ME; Duchin, JS				Rane, Madhura S.; Page, Libby C.; McVeigh, Emma; Miller, Kaetlin; Baure, David; Halloran, M. Elizabeth; Duchin, Jeffrey S.			Improving adolescent human papillomavirus (HPV) immunization uptake in school-based health centers through awareness campaigns	VACCINE			English	Article						Human papillomavirus; Human papillomavirus vaccine; School-based health centers; Adolescents; Immunization registry		Purpose: The aim of this study was to measure the effect of a multicomponent human papillomavirus (HPV) vaccine promotion campaign on adolescent HPV vaccine uptake at school-based health centers (SBHCs) in Seattle, WA. Methods: Youth-led HPV vaccine promotion campaigns were introduced in 2016 in 13 schools with SBHCs in Seattle. Five other schools with SBHCs served as controls. Vaccination records for students were obtained from the Washington Immunization Information System from September 2012 to August 2018. We compared increase in HPV vaccine uptake in SBHCs between 1) intervention and control schools, and 2) pre- and post-intervention periods in intervention schools using generalized estimating equations. Results: HPV vaccine uptake was high at baseline among students that use SBHCs for vaccines and has steadily increased between 2012 and 2018. Implementing the promotion campaign resulted in 14% higher (95% Confidence Interval (CI): 1%, 30%) HPV vaccine uptake in intervention SBHCs compared to control SBHCs, adjusting for time and confounders. Comparing pre-and post-intervention periods in intervention SBHCs, HPV vaccine uptake was 14% higher (95% CI: -4%, 35%) in the post-intervention period. SBHCs that received more active intervention activities saw 9% higher (95% CI: 1%, 21%) vaccine uptake compared to those that received passive intervention. Conclusion: The vaccination promotion program implemented in a school-based setting resulted in higher HPV vaccine uptake in the post-intervention period compared to pre-intervention period, but this increase was not statistically significant. Even so, schools that received more intervention activities for longer periods of time had higher HPV vaccine uptake. (C) 2021 Elsevier Ltd. All rights reserved.	[Rane, Madhura S.; Halloran, M. Elizabeth] Univ Washington, Dept Epidemiol, Box 357236,1959 NE Pacific St, Seattle, WA 98195 USA; [Page, Libby C.; McVeigh, Emma; Miller, Kaetlin; Baure, David; Duchin, Jeffrey S.] Publ Hlth Seattle & King Cty, Seattle, WA USA; [Halloran, M. Elizabeth] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Rane, Madhura S.; Halloran, M. Elizabeth] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Duchin, Jeffrey S.] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA; [Duchin, Jeffrey S.] Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA		Rane, MS (通讯作者)，Univ Washington, Dept Epidemiol, Box 357236,1959 NE Pacific St, Seattle, WA 98195 USA.	mrane@uw.edu			National Institute of Allergy and Infectious Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R37 AI032042]; Group Health Foundation; American Cancer Society, Inc.American Cancer Society	M.S.R and M.E.H are supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number [R37 AI032042]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The vaccine promotion project was supported by the Group Health Foundation and the American Cancer Society, Inc.	Ajzen I, 2002, J APPL SOC PSYCHOL, V32, P665, DOI 10.1111/j.1559-1816.2002.tb00236.x; Becker MH, 1974, HEALTH EDUC QUART, V2; Brabin L, 2008, BMJ-BRIT MED J, P1; Brotherton JML, 2013, MED J AUSTRALIA, V199, P614, DOI 10.5694/mja13.10272; Chao C, 2015, J ADOLESCENT HEALTH, V56, P85, DOI 10.1016/j.jadohealth.2014.08.014; Cox DS, 2010, HEALTH PSYCHOL, V29, P29, DOI 10.1037/a0016942; Desiante F, 2017, J PREVEN, V58, P18; French B, 2008, STAT MED, V27, P5005, DOI 10.1002/sim.3340; Fu LY, 2014, VACCINE, V32, P1901, DOI 10.1016/j.vaccine.2014.01.091; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354; Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537; Goggin P, 2018, HUM VACC IMMUNOTHER, V14, P118, DOI 10.1080/21645515.2017.1385688; Halekoh U, 2006, J STAT SOFTW, V15, P1, DOI 10.18637/jss.v015.i02; Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752; Jacob V, 2016, AM J PREV MED, V50, P797, DOI 10.1016/j.amepre.2015.11.003; Lim WT, 2014, COHORT STUDY, V14, P1; Luna J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083431; McClure CA, 2015, VACCINE, V33, P1786, DOI 10.1016/j.vaccine.2015.02.047; Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5; Middleman AB, 2016, HUM VACC IMMUNOTHER, V12, P2872, DOI 10.1080/21645515.2016.1208326; Muhamad NA, 2018, ACHIEVING HIGH UPTAK, P1; Munn MS, 2019, PUBLIC HEALTH REP, V134, P559, DOI 10.1177/0033354919867734; Nodulman JA, 2015, J SCHOOL HEALTH, V85, P289, DOI 10.1111/josh.12253; Office of Superintendent of Public Instruction, 2018, WASH SCH REP CARD; Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4; Perkins RB, 2015, VACCINE, V33, P1223, DOI 10.1016/j.vaccine.2014.11.021; Public Health Seattle King County, 2019, KING COUNTY SCH HLTH; Rickert VI, 2015, HUM VACC IMMUNOTHER, V11, P315, DOI 10.1080/21645515.2014.1004022; RStudio, 2015, RSTUDIO INT DEV ENV; SAS Institute Inc, 2013, SAS 94 STATEMENTS RE; Saville A, 2012, J ADOLESC HLTH, V51; U.S. Department of Health and Human Services, 2020, GUIDE COMMUNITY PREV; U.S. Department of Health and Human Services Healthy People, 2020, OFF DIS PREV HLTH PR; Vandelaer J, 2015, VACCINE, V33, P719, DOI 10.1016/j.vaccine.2014.11.037; Walker TY, 2018, MMWR-MORBID MORTAL W, V67, P909, DOI 10.15585/mmwr.mm6733a1; Walker TY, 2017, MMWR-MORBID MORTAL W, V66, P874, DOI 10.15585/mmwr.mm6633a2; Washington State Department of Health, 2015, WASHINGTON STATE DEP; Washington State Department of Health, CHILDH VACC PROGR; Wilson SE, 2013, VACCINE, V31, P757, DOI 10.1016/j.vaccine.2012.11.090	40	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 19	2021	39	12					1765	1772		10.1016/j.vaccine.2021.02.006		MAR 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QX3ZD	33640146	Green Accepted			2022-04-29	WOS:000629283700014
J	Wang, YN; Huang, CY; Tang, J; Liu, GF; Hu, MZ; Kang, XL; Zhang, J; Zhang, YZ; Pan, ZM; Jiao, XA; Geng, SZ				Wang, Yaonan; Huang, Cuiying; Tang, Juan; Liu, Guifeng; Hu, Maozhi; Kang, Xilong; Zhang, Jian; Zhang, Yunzeng; Pan, Zhiming; Jiao, Xin'an; Geng, Shizhong			Salmonella Pullorum spiC mutant is a desirable LASV candidate with proper virulence, high immune protection and easy-to-use oral administration	VACCINE			English	Article						Salmonella Pullorum; Live attenuated Salmonella vaccine; LASV-p; Safety; Immune protection; Cellular immunity		Live attenuated Salmonella vaccine (LASV) is considered to be an effective contributory measure during the control of Salmonella infection. A Salmonella Pullorum spiC mutant was evaluated comprehensively as a LASV candidate (LASV-p) for broilers in terms of safety and immunogenicity. LASV-p was adminstered to 3-day broilers by intramuscular injection. The LD50 increased 126 fold, and no tissue lesions were observed in the liver, spleen and cecum, in comparison with the control group inoculated with PBS and a passive group by wild-type Salmonella. Growth rates of all broilers were normal and not affected. LASV-p persisted in vivo until 21 days in liver, 28 days in spleen and 35 days in feces, and induced high levels of humoral IgG and mucosal IgA. Cellular immunity was also stimulated in the form of antigen-specific lymphocyte proliferation and higher counts of CD3(+)CD8(+) T cells and increased expression of mRNA of Th1 cytokines, IFN-gamma and IL-2, in the early stage, and Th2 cytokines, IL-4 and IL-10, in the later stages. LASV-p provided at least 90% immuneprotection against a wild-type Salmonella Pullorum and cross-protection in different degree against other Salmonella searovars. Oral vaccine could also offer high immune protection of 87.5%. These results indicated that LASV-p vaccine candidate had a high level of safety and immune protection and it might be developed as a novel easy-to-use oral vaccine to improve poultry health in the future. (C) 2021 Elsevier Ltd. All rights reserved.	Yangzhou Univ, Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China; Yangzhou Univ, Jiangsu Key Lab Zoonosis, Yangzhou 225009, Jiangsu, Peoples R China; Yangzhou Univ, Minist Agr China, Key Lab Prevent & Control Biol Hazard Factors Ani, Yangzhou 225009, Jiangsu, Peoples R China; Yangzhou Univ, Minist Educ, Joint Int Res Lab Agr & Agriprod Safety, Yangzhou 225009, Jiangsu, Peoples R China		Geng, SZ (通讯作者)，Yangzhou Univ, Coll Biosci & Biotechnol, Jiangsu Key Lab Zoonosis, 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China.	Jiao@yzu.edu.cn; gszhong@yzu.edu.cn			National Key Research and Development Program Special Project [2016YFD0501607]; Natural Science Foundation of Jiangsu Province of ChinaNatural Science Foundation of Jiangsu Province [BK20151306, BK20180911]; key Research and Development Program of Jiangsu [BE2018334]; Yangzhou University Science and Technology Innovation Team	This study was supported by the National Key Research and Development Program Special Project (2016YFD0501607), the Natural Science Foundation of Jiangsu Province of China (BK20151306, BK20180911), the key Research and Development Program of Jiangsu (BE2018334), and the Yangzhou University Science and Technology Innovation Team (2016).	Babu U, 2003, VET IMMUNOL IMMUNOP, V91, P39, DOI 10.1016/S0165-2427(02)00265-9; Barrow PA, 2012, AVIAN PATHOL, V41, P413, DOI 10.1080/03079457.2012.718071; Barrow PA, 2011, AVIAN PATHOL, V40, P1, DOI 10.1080/03079457.2010.542575; Penha RAC, 2012, VACCINE, V30, P7637, DOI 10.1016/j.vaccine.2012.10.020; Datey A, 2018, VACCINE, V36, P7715, DOI 10.1016/j.vaccine.2018.10.079; Desin TS, 2013, EXPERT REV VACCINES, V12, P87, DOI [10.1586/erv.12.138, 10.1586/ERV.12.138]; Freeman JA, 2002, J BACTERIOL, V184, P4971, DOI 10.1128/JB.184.18.4971-4980.2002; Frey J, 2007, VACCINE, V25, P5598, DOI 10.1016/j.vaccine.2006.11.058; Geng SZ, 2019, MICROB PATHOGENESIS, V129, P1, DOI 10.1016/j.micpath.2019.01.035; Geng SZ, 2016, CURR MICROBIOL, V72, P700, DOI 10.1007/s00284-016-1002-3; Geng SZ, 2014, VET MICROBIOL, V168, P388, DOI 10.1016/j.vetmic.2013.11.024; GILLES H-J, 1974, European Journal of Toxicology and Environmental Hygiene, V7, P77; Guo RX, 2019, VET MICROBIOL, V228, P165, DOI 10.1016/j.vetmic.2018.11.032; Guo RX, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00547; Guo RX, 2016, VET IMMUNOL IMMUNOP, V173, P27, DOI 10.1016/j.vetimm.2016.03.015; Haneda T, 2011, COMP IMMUNOL MICROB, V34, P399, DOI 10.1016/j.cimid.2011.07.001; Heithoff DM, 2015, VACCINE, V33, P100, DOI 10.1016/j.vaccine.2014.11.012; Johanns TM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001043; Li QC, 2013, INFECT IMMUN, V81, P3119, DOI 10.1128/IAI.00145-13; Liu HW, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-364; Mastroeni P, 2001, VET J, V161, P132, DOI 10.1053/tvjl.2000.0502; Nandre RM, 2015, CAN J VET RES, V79, P16; Nandre RM, 2014, VET IMMUNOL IMMUNOP, V162, P51, DOI 10.1016/j.vetimm.2014.08.014; Rana N, 2006, VET MICROBIOL, V115, P156, DOI 10.1016/j.vetmic.2006.01.011; The World Organisation for Animal Health (OIE), 2020, OIE LISTED DIS INFEC; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Uchiya K, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-179; Wang YN, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01784; Wigley P, 2001, INFECT IMMUN, V69, P7873, DOI 10.1128/IAI.69.12.7873-7879.2001; Wigley P, 2017, AVIAN PATHOL, V46, P119, DOI 10.1080/03079457.2016.1240866; Xu LJ, 2018, AVIAN PATHOL, V47, P238, DOI 10.1080/03079457.2017.1412084; Yin JL, 2015, CLIN VACCINE IMMUNOL, V22, P706, DOI 10.1128/CVI.00130-15; Yu XJ, 2002, CELL MICROBIOL, V4, P531, DOI 10.1046/j.1462-5822.2002.00211.x; Zhao XX, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0739-y; Zhu CH, 2015, J CLIN MICROBIOL, V53, P3881, DOI 10.1128/JCM.01976-15	35	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 1	2021	39	9					1383	1391		10.1016/j.vaccine.2021.01.059		FEB 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8CD	33551301				2022-04-29	WOS:000618498600004
J	Jas, D; Frances-Duvert, V; Brunet, S; Oberli, F; Guigal, PM; Poulet, H				Jas, Dominique; Frances-Duvert, Valerie; Brunet, Sylvie; Oberli, Frantz; Guigal, Pierre-Michel; Poulet, Herve			Evaluation of safety and immunogenicity of feline vaccines with reduced volume	VACCINE			English	Article						Feline vaccine; Reduced volume; Safety; Immunogenicity; Non-adjuvanted		A non adjuvanted vaccine against feline herpesvirus, feline calicivirus, feline panleucopenia and feline leukemia has been formulated in reduced volume (0.5 ml) with the same antigen content as the conventional 1 ml presentation. This paper reports studies evaluating the safety and the immunogenicity of this reduced volume vaccine in comparison with the conventional volume vaccine. The safety of both vaccines was evaluated in a small sized laboratory trial. It was further tested in a randomized controlled field trial on a total of 398 cats. Immediate and delayed local and systemic adverse events were monitored after vaccination. The immunogenicity of each vaccine was also checked by serological antibody responses against the vaccines antigens during the laboratory trial. These studies showed that the 0.5 ml vaccine was well tolerated in cats, inducing less local events, while keeping the same immunogenicity as the corresponding 1 ml vaccine. Reducing the volume of the vaccine is a way to improve the convenience of administration and to help following vaccination guidelines with the aim of reducing the incidence of adverse events following vaccination. (C) 2021 Elsevier Ltd. All rights reserved.	[Jas, Dominique; Frances-Duvert, Valerie; Brunet, Sylvie; Oberli, Frantz; Guigal, Pierre-Michel; Poulet, Herve] Boehringer Ingelheim Anim Hlth SCS France, R&D, 29 Ave Tony Garnier, F-69007 Lyon, France		Jas, D (通讯作者)，Boehringer Ingelheim Anim Hlth SCS France, R&D, 29 Ave Tony Garnier, F-69007 Lyon, France.	dominique.jas@boehringer-ingelheim.com					[Anonymous], 2011, GOOD VET PHARMACOVIG, V2; Cats CCM, 2015, VET SCI, V2, P111; Chanthavanich P, 2019, PEDIATR INFECT DIS J, V38, P757, DOI 10.1097/INF.0000000000002345; Dagan R, 1999, VACCINE, V17, P1919, DOI 10.1016/S0264-410X(98)00461-7; Day MJ, 2007, J SMALL ANIM PRACT, V48, P528, DOI 10.1111/j.1748-5827.2007.00462.x; Day MJ, 2007, VACCINE, V25, P4073, DOI 10.1016/j.vaccine.2007.02.049; Gaskell RM, 2002, VET REC, V150, P126; Graf R, 2018, J COMP PATHOL, V163, P1, DOI 10.1016/j.jcpa.2018.06.008; Graf R, 2015, J COMP PATHOL, V153, P266, DOI 10.1016/j.jcpa.2015.08.007; Guiot AL, 2008, VET REC, V162, P690, DOI 10.1136/vr.162.21.690; Hartmann K, 2015, J FELINE MED SURG, V17, P606, DOI 10.1177/1098612X15588451; Hendricks CG, 2014, J FELINE MED SURG, V16, P275, DOI 10.1177/1098612X13505579; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Horzinek MC, 2013, J FELINE MED SURG, V15, P530, DOI 10.1177/1098612X13489208; Jas D, 2009, VET J, V182, P86, DOI 10.1016/j.tvjl.2008.05.025; Jorgensen JT, 1996, ANN PHARMACOTHER, V30, P729, DOI 10.1177/106002809603000703; Macy D W, 1999, J Feline Med Surg, V1, P15, DOI 10.1016/S1098-612X(99)90005-0; Mostl K, 2015, J FELINE MED SURG, V17, P570, DOI 10.1177/1098612X15588448; Moore GE, 2007, JAVMA-J AM VET MED A, V231, P94, DOI 10.2460/javma.231.1.94; Nony P, 2001, VACCINE, V19, P3645, DOI 10.1016/S0264-410X(01)00098-6; Poulet H, 2007, J COMP PATHOL, V137, pS67, DOI 10.1016/j.jcpa.2007.04.020; Scherk MA, 2013, J FELINE MED SURG, V15, P785, DOI 10.1177/1098612X13500429; Shaw SC, 2009, JAVMA-J AM VET MED A, V234, P376, DOI 10.2460/javma.234.3.376; Srivastav A, 2012, JAVMA-J AM VET MED A, V241, P595, DOI 10.2460/javma.241.5.595; STARR RM, 1993, CORNELL VET, V83, P311; Wang W, 2015, INT J PHARMACEUT, V490, P308, DOI 10.1016/j.ijpharm.2015.05.069; Woodward KN, 2011, ISRN VET SCI, P1; Zijlstra Eric, 2018, J Diabetes Sci Technol, V12, P163, DOI 10.1177/1932296817735121	28	1	1	2	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 12	2021	39	7					1051	1057		10.1016/j.vaccine.2021.01.026		FEB 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QC9HH	33485645				2022-04-29	WOS:000615141100008
J	Rid, A; Shah, SK; Miller, FG; Danis, M; Nicolini, M; Ochoa, J; Taylor, HA; Wendler, DS; Grady, C				Rid, Annette; Shah, Seema K.; Miller, Franklin G.; Danis, Marion; Nicolini, Marie; Ochoa, Jorge; Taylor, Holly A.; Wendler, David S.; Grady, Christine			Ethical trade-offs in vaccine development and distribution-Response to Gurwitz	VACCINE			English	Letter									[Rid, Annette; Danis, Marion; Nicolini, Marie; Ochoa, Jorge; Taylor, Holly A.; Wendler, David S.; Grady, Christine] NIH, Dept Bioeth, Ctr Clin, Bldg 10-1C118, Bethesda, MD 20892 USA; [Shah, Seema K.] Northwestern Univ, Lurie Childrens Hosp, Dept Pediat, 225 E Chicago Ave, Chicago, IL 60611 USA; [Miller, Franklin G.] Weill Cornell Med Coll, 1300 York Ave, New York, NY 10065 USA		Grady, C (通讯作者)，NIH, Dept Bioeth, Ctr Clin, Bldg 10-1C118, Bethesda, MD 20892 USA.	mdanis@nih.gov; marie.nicolini@nih.gov; jorge.ochoa@nih.gov; holly.taylor2@nih.gov; dwendler@cc.nih.gov; cgrady@nih.gov			National Institutes of Health (NIH) Clinical Center, Department of BioethicsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This work was partially funded by the National Institutes of Health (NIH) Clinical Center, Department of Bioethics.	Bollyky TJ, 2020, TRAGEDY VACCINE NATL; Emanuel EJ, 2020, SCIENCE, V369, P1309, DOI 10.1126/science.abe2803; Grady C, 2020, VACCINE, V38, P6381, DOI 10.1016/j.vaccine.2020.08.017; Gurwitz D., ETHICAL TRADEOFFS SA; Liu YZ, 2020, J MED ETHICS, V46, P499, DOI 10.1136/medethics-2020-106516; World Health Organization, COVAX WORK GLOB EQ A; World Health Organization, 2020, WHO SAGE VAL FRAM AL	7	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 12	2021	39	7					1028	1029		10.1016/j.vaccine.2021.01.020		FEB 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QC9HH	33546811	Green Accepted			2022-04-29	WOS:000615141100003
J	Scheppler, L; De Clercq, N; McGoldrick, M; Dias, J				Scheppler, Lorenz; De Clercq, Norbert; McGoldrick, Mic; Dias, Jacqueline			Regulatory Harmonization and Streamlining of Clinical Trial Applications globally should lead to faster clinical development and earlier access to life-saving vaccines	VACCINE			English	Review						Clinical trial application; Regulatory convergence; Development; Streamline; Vaccine		Vaccines continue to play a central role in our ability to prevent disease, save lives, and improve health. The scientific community, including our own researchers, are driven by a shared purpose to improve vaccine technologies and bring the benefits of immunization to everyone, regardless of where they live - as soon as possible, especially when the medical need is considerable. Vaccine developers and manufacturers (sometimes referred to as "study sponsors" or "applicants") are exploring technological advancements to translate breakthrough discoveries into novel vaccines which have the potential to provide protection from life-threatening and debilitating infectious diseases. Developing new vaccines is a lengthy process regulated by guidance provided by independent organizations, National Regulatory Authorities (NRAs) and the World Health Organization. As most infectious diseases can span a considerable area of the world, clinical trials are often conducted across different countries and regions. Regulatory requirements for clinical trials (both Chemistry Manufacturing & Controls - CMC, nonclinical and clinical) vary significantly between the different countries and regions adding to the complexity of vaccine development and leading to significant delays in the development of novel vaccines and ultimately equitable access for populations to these innovations. Without progress in terms of regulatory convergence and harmonization the benefits from these scientific advancements will not be fully realized. There is an urgent need by global bodies such as WHO to partner with and the NRAs to establish and implement. 1. a common, global set of requirements for Clinical Trial Application (CTAs) per Phase of Development. 2. a parallel ethical committee and regulatory authority review rather than sequential reviews. 3. clear and transparent assessment timelines and commitment to these timelines. 4. a focus on reduced regulatory burden overall for NRAs, Ethics Committees (ECs) and vaccine developers. (C) 2020 The Authors. Published by Elsevier Ltd.	[Scheppler, Lorenz] Janssen Vaccines, Rehhagstr 79, Bern, Switzerland; [De Clercq, Norbert] GSK Vaccines, Ave Fleming, B-1300 Wavre, Belgium; [McGoldrick, Mic] Merck & Co Inc, Kenilworth, NJ USA; [Dias, Jacqueline] Pfizer NV SA, Blvd Plaine 17, B-1150 Brussels, Belgium		Scheppler, L (通讯作者)，Janssen Vaccines, Rehhagstr 79, Bern, Switzerland.	LScheppl@its.jnj.com					Bregu M, 2011, PHILOS T R SOC B, V366, P2841, DOI 10.1098/rstb.2011.0100; Buchy P, 2020, INT J INFECT DIS, V90, P188, DOI 10.1016/j.ijid.2019.10.005; International Council for Harmonization, 2020, MEMB OBS; Kauffmann F, 2019, VACCINE, V37, P6144, DOI 10.1016/j.vaccine.2019.08.018; Merck & Co. Inc, PNEUM 23; Plotkin SA, 2015, J INFECT DIS, V212, pS12, DOI 10.1093/infdis/jiu568; The History of Vaccines, 2018, VACC DEV TEST REG; UNAIDS, 2020, UNAIDS DAT REP 2020; WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1; World Health Organization, 2020, WHO IMM AG 2030; World Health Organization, 2019, WHO GLOB TUB REP 201	11	0	0	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 29	2021	39	5					790	796		10.1016/j.vaccine.2020.11.077		JAN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PV7RR	33422378	hybrid			2022-04-29	WOS:000610181400005
J	Rastegar, M; Tavana, M; Meraj, A; Mina, H				Rastegar, Mehdi; Tavana, Madjid; Meraj, Afshin; Mina, Hassan			An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic	VACCINE			English	Article						Vaccine supply chain; Healthcare equitability; Inventory-location problem; Mixed-integer linear programming; Influenza virus	SUPPLY CHAIN; UNITED-STATES; DESIGN; ISSUES	The addition of other respiratory illnesses such as flu could cripple the healthcare system during the coronavirus disease 2019 (COVID-19) pandemic. An annual seasonal influenza vaccine is the best way to help protect against flu. Fears of coronavirus have intensified the shortage of influenza shots in developing countries that hope to vaccinate many populations to reduce stress on their health services. We present an inventory-location mixed-integer linear programming model for equitable influenza vaccine distribution in developing countries during the pandemic. The proposed model utilizes an equitable objective function to distribute vaccines to critical healthcare providers and first responders, elderly, pregnant women, and those with underlying health conditions. We present a case study in a developing country to exhibit efficacy and demonstrate the optimization model's applicability. (C) 2020 Elsevier Ltd. All rights reserved.	[Rastegar, Mehdi; Mina, Hassan] Univ Tehran, Coll Engn, Sch Ind Engn, Tehran, Iran; [Tavana, Madjid] La Salle Univ, Business Syst & Analyt Dept, Distinguished Chair Business Analyt, Philadelphia, PA 19141 USA; [Tavana, Madjid] Univ Paderborn, Fac Business Adm & Econ, Business Informat Syst Dept, D-33098 Paderborn, Germany; [Meraj, Afshin] Univ Tehran, Dept Management, Tehran, Iran		Tavana, M (通讯作者)，La Salle Univ, Business Syst & Analyt Dept, Distinguished Chair Business Analyt, Philadelphia, PA 19141 USA.	mehdixastegar@ut.ac.ir; tavana@lasalle.edu; amearaj@ut.ac.ir; hassan.mina@ut.ac.ir		Tavana, Madjid/0000-0003-2017-1723	Czech Science FoundationGrant Agency of the Czech Republic [GACR19-13946S]	Dr. Madjid Tavana is grateful for the partial support he received from the Czech Science Foundation (GACR19-13946S) for this research.	Abrahams AS, 2012, DECIS SUPPORT SYST, V54, P215, DOI 10.1016/j.dss.2012.05.007; Cernuschi T, 2018, VACCINE, V36, P498, DOI 10.1016/j.vaccine.2017.12.010; Duijzer LE, 2018, EUR J OPER RES, V268, P174, DOI 10.1016/j.ejor.2018.01.015; Enayati S, 2020, EUR J OPER RES, V283, P714, DOI 10.1016/j.ejor.2019.11.025; Gooding E, 2019, VACCINE, V37, P5104, DOI 10.1016/j.vaccine.2019.06.006; Grech V, 2020, EARLY HUM DEV, V148, DOI 10.1016/j.earlhumdev.2020.105116; Hartmann K, 2020, VACCINE, V38, P5490, DOI 10.1016/j.vaccine.2020.06.016; Jacobson Sheldon H, 2006, Health Care Manag Sci, V9, P371, DOI 10.1007/s10729-006-0001-5; Jacobson SH, 2007, EXPERT REV VACCINES, V6, P981, DOI 10.1586/14760584.6.6.981; Jarrett S, 2020, VACCINE-X, V5, DOI 10.1016/j.jvacx.2020.100068; Lane KS, 2006, CLIN INFECT DIS, V42, pS125, DOI 10.1086/499591; Lin Q, 2020, EUR J OPER RES, V283, P182, DOI 10.1016/j.ejor.2019.11.005; Lydon P, 2015, VACCINE, V33, P3429, DOI 10.1016/j.vaccine.2015.03.042; Meshkini AH, 2012, DARU, V20, DOI 10.1186/2008-2231-20-19; Peter G, 2003, JAMA-J AM MED ASSOC, V290, P3122; Pishvaee MS, 2014, TRANSPORT RES E-LOG, V67, P14, DOI 10.1016/j.tre.2014.04.001; Privett N, 2014, OPER RES HEALTH CARE, V3, P226, DOI 10.1016/j.orhc.2014.09.002; Rodewald LE, 2006, CLIN INFECT DIS, V42, pS104, DOI 10.1086/499587; Saif A, 2016, EUR J OPER RES, V251, P274, DOI 10.1016/j.ejor.2015.10.056; Samii AB, 2012, EUR J OPER RES, V222, P495, DOI 10.1016/j.ejor.2012.05.003; Shrestha SS, 2010, VACCINE, V28, P6318, DOI 10.1016/j.vaccine.2010.06.095; Straetemans M, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-236; Uscher-Pines L, 2008, PUBLIC HEALTH, V122, P183, DOI 10.1016/j.puhe.2007.06.005; WHO (World Health Organization), 2018, INFL SEAS; Zandkarimkhani S, 2020, ANN OPER RES, V295, P425, DOI 10.1007/s10479-020-03677-7	25	16	16	11	28	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 15	2021	39	3					495	504		10.1016/j.vaccine.2020.12.022			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VN	33342632	Green Published, Bronze			2022-04-29	WOS:000604750400008
J	Sparrow, E; Wood, JG; Chadwick, C; Newall, AT; Torvaldsen, S; Moen, A; Torelli, G				Sparrow, Erin; Wood, James G.; Chadwick, Christopher; Newall, Anthony T.; Torvaldsen, Siranda; Moen, Ann; Torelli, Guido			Global production capacity of seasonal and pandemic influenza vaccines in 2019	VACCINE			English	Article						Vaccine; Influenza; Seasonal; Pandemic; Production; Capacity	TECHNOLOGY-TRANSFER; H5N1 VACCINES; IMMUNIZATION; CHALLENGES	Vaccines will be an important element in mitigating the impact of an influenza pandemic. While research towards developing universal influenza vaccines is ongoing, the current strategy for vaccine supply in a pandemic relies on seasonal influenza vaccine production to be switched over to pandemic vaccines. Understanding how much vaccine could be produced, in which regions of the world and in what timeframe is critical to informing influenza pandemic preparedness. Through the Global Action Plan for Influenza Vaccines, 2006-2016, WHO promoted an increase in vaccine production capacity and monitors the landscape through periodically surveying influenza vaccine manufacturers. This study compares global capacity for production of influenza vaccines in 2019 with estimates from previous surveys; provides an overview of countries with established production facilities; presents vaccine production by type and manufacturing process; and discusses limitations to these estimates. Results of the current survey show that estimated annual seasonal influenza vaccine production capacity changed little since 2015 increasing from 1.47 billion to 1.48 billion doses with potential maximum annual influenza pandemic vaccine production capacity increasing from 6.37 billion to 8.31 billion doses. However, this figure should be interpreted with caution as it presents a best-case scenario with several assumptions whichmayimpact supply. Further, pandemic vaccines would not be immediately available and could take four to six months for first supplies with several more months needed to reachmaximumcapacity. Amoderate-case scenario is also presented of 4.15 billion doses of pandemic vaccine in 12 months. It is important to note that two doses of pandemic vaccine are likely to be required to elicit an adequate immune response. Continued efforts are needed to ensure the sustainability of this production and to conduct research for vaccines that are faster to produce and more broadly protective taking into account lessons learned from COVID-19 vaccine development. (C) 2020 Published by Elsevier Ltd. This is an open access article under the CC BY IGO license.	[Sparrow, Erin; Chadwick, Christopher; Moen, Ann; Torelli, Guido] WHO, Geneva, Switzerland; [Sparrow, Erin; Wood, James G.; Newall, Anthony T.; Torvaldsen, Siranda] UNSW Sydney, Sch Publ Hlth & Community Med, Sydney, NSW, Australia; [Chadwick, Christopher] Univ Geneva, Fac Med, Inst Global Hlth, Geneva, Switzerland; [Torvaldsen, Siranda] Univ Sydney, Women & Babies Res, Northern Clin Sch, Sydney, NSW, Australia		Sparrow, E (通讯作者)，WHO, Geneva, Switzerland.	sparrowe@who.int		Torelli, Guido/0000-0003-3342-5331; Sparrow, Erin/0000-0003-3912-2550; Wood, James/0000-0002-0122-4482; Newall, Anthony/0000-0003-0836-1065	World Health OrganizationWorld Health Organization	This work was commissioned and supported by the World Health Organization.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; [Anonymous], 2017, WHO PREF CHAR NEXT G; [Anonymous], 2013, REC ASS QUAL SAF EFF; [Anonymous], 2017, PAND INFL RISK MAN W; [Anonymous], 2017, INFL VACC RESP START; [Anonymous], 2016, INFLUENZA VACCINE RE; [Anonymous], 2020, GUARDIAN; [Anonymous], 2020, DRAFT LANDSCAPE COVI; Australian Government, DEP HLTH CLIN UPD 20; Banzhoff A, 2008, INFLUENZA OTHER RESP, V2, P243, DOI 10.1111/j.1750-2659.2008.00059.x; Barberis I, 2016, J Prev Med Hyg, V57, pE115; Baxter R, 2011, VACCINE, V29, P2272, DOI 10.1016/j.vaccine.2011.01.039; Baz M, 2013, VIRUS RES, V178, P78, DOI 10.1016/j.virusres.2013.05.006; Buckland B, 2014, VACCINE, V32, P5496, DOI 10.1016/j.vaccine.2014.07.074; Chen LM, 2020, INFLUENZA OTHER RESP, V14, P215, DOI 10.1111/irv.12698; Engelhardt OG, 2018, VACCINE, V36, P4339, DOI 10.1016/j.vaccine.2018.05.076; Gostin LO, 2020, JAMA-J AM MED ASSOC, V324, P335, DOI 10.1001/jama.2020.10802; Grohmann G, 2016, VACCINE, V34, P5420, DOI 10.1016/j.vaccine.2016.07.047; Guan Y, 2010, PROTEIN CELL, V1, P9, DOI 10.1007/s13238-010-0008-z; Guo Q, 2016, CELL PHYSIOL BIOCHEM, V40, P921, DOI 10.1159/000453150; Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012; Jackson LA, 2015, JAMA-J AM MED ASSOC, V314, P237, DOI 10.1001/jama.2015.7916; Jivraj N, 2013, J ROY COLL PHYS EDIN, V43, P347, DOI 10.4997/JRCPE.2013.405; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Khamsi R, 2020, NATURE, V580, P578, DOI 10.1038/d41586-020-01063-8; Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254; Koutsakos M, 2019, J IMMUNOL, V202, P382, DOI 10.4049/jimmunol.1801070; Lane R, 2020, LANCET, V395, P1247, DOI 10.1016/S0140-6736(20)30796-0; McLean KA, 2016, VACCINE, V34, P5410, DOI 10.1016/j.vaccine.2016.08.019; Milian E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/504831; Minor PD, 2015, VACCINES-BASEL, V3, P90, DOI 10.3390/vaccines3010090; Ortiz JR, 2019, J INFECT DIS, V219, pS97, DOI 10.1093/infdis/jiz024; Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045; Ostrowsky J, 2020, CURR OPIN VIROL, V40, P28, DOI 10.1016/j.coviro.2020.02.003; Palache A, 2017, VACCINE, V35, P4681, DOI 10.1016/j.vaccine.2017.07.053; Palache ATT Vasiliev, 2020, INTERNAL MED REV; Partridge J, 2013, VACCINE, V31, P728, DOI 10.1016/j.vaccine.2012.10.111; Partridge J, 2010, VACCINE, V28, P4709, DOI 10.1016/j.vaccine.2010.04.083; Rockman S, 2010, HUM VACCINES, V6, P792, DOI 10.4161/hv.6.10.12915; Spreeuwenberg P, 2018, AM J EPIDEMIOL, V187, P2561, DOI 10.1093/aje/kwy191; Taubenberger JK, 2007, ANTIVIR THER, V12, P581; Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760; Zheng D, 2019, HUM VACC IMMUNOTHER, V15, P80, DOI 10.1080/21645515.2018.1515454; Ziegler T, 2018, INFLUENZA OTHER RESP, V12, P558, DOI 10.1111/irv.12570	44	17	17	4	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 15	2021	39	3					512	520		10.1016/j.vaccine.2020.12.018			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VN	33341308	Green Published, hybrid			2022-04-29	WOS:000604750400010
J	Haber, P; Tate, J; Marquez, PL; Moro, PL; Parashar, U				Haber, Penina; Tate, Jacqueline; Marquez, Paige L.; Moro, Pedro L.; Parashar, Umesh			Safety profile of rotavirus vaccines among individuals aged >= 8 months of age, United States, vaccine adverse event reporting system (VAERS), 2006-2019	VACCINE			English	Article						Vaccine safety; Post-licensure surveillance; Rotavirus vaccines; RotaTeq; Rotarix; Vaccine Adverse Event Reporting System	ADVISORY-COMMITTEE; INTUSSUSCEPTION; CHILDREN; INFANTS; RECOMMENDATIONS; GASTROENTERITIS; PREVENTION	Introduction: In 2006 and 2008, two live, oral rotavirus vaccines, RotaTeq (RV5) and Rotarix (RV1), were introduced into the routine immunization program in the United States. A previous rotavirus vaccine, RotaShield, was associated with an increased risk of intussusception, with data suggesting an age-dependent variation in risk. Advisory Committee on Immunization Practices (ACIP) currently recommends that RV5 or RV1 immunization be initiated by age 14 weeks and 6 days and completed by 8 months 0 days. Methods: We searched for U.S. VAERS reports of RV5, RV1, or unknown rotavirus vaccine brand among individuals aged >= 8 months. We analyzed reports by 2 age groups (individuals aged >= 8 months-<= 5 years and >= 6 years), vaccine brand name, adverse event (AE) reported, classification of seriousness (death, non-death serious, and non-serious) and mode of exposure (direct vs. indirect exposure). For serious reports we reviewed available medical records and assigned a primary diagnosis. Results: VAERS received a total of 344 U.S. reports following rotavirus vaccination among individuals >= 8 months of age, 32 (9.3%) were serious. In the younger age-group, 307 (99%) of 309 reports followed direct vaccination of the child. In contrast, in individuals aged >= 6 years, 21 (60%) of 35 reports were via potential indirect exposure to a vaccinated child. The frequently reported AEs in the younger age-group were inappropriate schedule of drug administration 104 (34%) and drug administered to patient of inappropriate age 45 (15%); in the older group these were accidental exposure 9 (26%) and eye irritation 7 (20%). No difference in the safety profile was observed between RV1 and RV5. Conclusions: We did not identify any unexpected AEs for RV vaccines among individuals aged >= 8 months. Health care providers should adhere to the ACIP recommended schedule and older individuals should apply necessary precautions to prevent potential secondary exposure from vaccinated children. Published by Elsevier Ltd.	[Haber, Penina; Marquez, Paige L.; Moro, Pedro L.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA; [Tate, Jacqueline; Parashar, Umesh] Ctr Dis Control & Prevent, Viral Gastroenteritis Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA		Haber, P (通讯作者)，Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.	phaber@cdc.gov					Boom JA, 2012, J INFECT DIS, V206, P1275, DOI 10.1093/infdis/jis490; Centers for Disease Control and Prevention, 1999, MMWR-MORBID MORTAL W, V48, P1007; Cortese Margaret M., 2009, Morbidity and Mortality Weekly Report, V58, P1; Ehresman K., 1999, Morbidity and Mortality Weekly Report, V48, P577; Food and Drug Administration, 2011, PROD APPR INF LIC AC; Haber P, 2015, VACCINE, V33, P4873, DOI 10.1016/j.vaccine.2015.07.054; Haber P, 2013, PEDIATRICS, V131, P1042, DOI 10.1542/peds.2012-2554; Halsey NA, 2012, VACCINE, V30, P5791, DOI 10.1016/j.vaccine.2012.04.005; JACQUELINE ET, 2008, PEDIATRICS, V121, pE1125; Lu HL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12458; McNeil MM, 2014, VACCINE, V32, P5390, DOI 10.1016/j.vaccine.2014.07.073; Moro P, 2017, DRUG SAFETY, V40, P145, DOI 10.1007/s40264-016-0482-1; Moro PL, 2019, EXPERT REV VACCINES, V18, P1091, DOI 10.1080/14760584.2019.1676154; Parashar Umesh D., 2006, Morbidity and Mortality Weekly Report, V55, P1; Patel Manish M, 2013, LIT REV PLOS ONE, V8; Payne DC, 2010, PEDIATRICS, V125, pE438, DOI 10.1542/peds.2009-1901; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; Simonsen L, 2005, J INFECT DIS, V192, pS36, DOI 10.1086/431512; Suspension of Rotavirus vaccine after reports of intussusception -United States, 2004, MMWR-MORBID MORTAL W, V53, P786; Tai JH, 2006, PEDIATRICS, V118, pE258, DOI 10.1542/peds.2005-2874; Zhou Weigong, 2003, MMWR Surveill Summ, V52, P1	21	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					746	750		10.1016/j.vaccine.2020.11.026		JAN 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PR1FI	33267969				2022-04-29	WOS:000606987100018
J	Pittet, LF; Tebruegge, M; Dutta, B; Donath, S; Messina, N; Casalaz, D; Hanekom, WA; Britton, WJ; Robins-Browne, R; Curtis, N; Ritz, N				Pittet, Laure F.; Tebruegge, Marc; Dutta, Binita; Donath, Susan; Messina, Nicole; Casalaz, Dan; Hanekom, Willem A.; Britton, Warwick J.; Robins-Browne, Roy; Curtis, Nigel; Ritz, Nicole		BCG Immune Response Study BIRS Grp	Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guerin (BCG) vaccine	VACCINE			English	Article						Randomised controlled trial; Mycobacterium bovis; Prevention; Buruli ulcer; Cross-protection; Mycolactone	BURULI ULCER; BOVIS BCG; RISK-FACTORS; INFECTION; OSTEOMYELITIS; DISEASE; TUBERCULOSIS; MYCOLACTONE; STRAIN	Background: Bacillus Calmette-Guerin (BCG) vaccine provides partial protection against Buruli ulcer caused by Mycobacterium ulcerans in epidemiological studies. This study aimed to quantify M. ulcerans-specific immune responses induced by BCG immunisation. Methods: Intracellular cytokine analysis of in-vitro experiments done 10 weeks after BCG immunisation in 130 Australian infants randomised to one of three BCG vaccine strains given either at birth (BCG-Denmark, BCG-Japan, or BCG-Russia) or at two months of age (BCG-Denmark). Results: Proportions of polyfunctional CD4(+) T-cells were higher in M. ulcerans-stimulated compared to unstimulated control samples. These proportions were not influenced by the vaccine strain or timing of the immunisation. The M. ulcerans-specific immune responses showed similar patterns to those observed in M. tuberculosis-stimulated samples, although they were of lower magnitude. Conclusions: Our data show that BCG immunisation induces M. ulcerans-specific immune responses in infants, likely explaining the cross-protective effect observed in epidemiological studies. (C) 2020 Published by Elsevier Ltd.	[Pittet, Laure F.; Messina, Nicole; Robins-Browne, Roy; Curtis, Nigel; Ritz, Nicole] Murdoch Childrens Res Inst, Infect Dis Grp, Parkville, Vic, Australia; [Pittet, Laure F.; Curtis, Nigel] Royal Childrens Hosp Melbourne, Infect Dis Unit, Parkville, Vic, Australia; [Tebruegge, Marc; Donath, Susan; Messina, Nicole; Curtis, Nigel; Ritz, Nicole] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Tebruegge, Marc] UCL, Great Ormond St Inst Child Hlth, London, England; [Tebruegge, Marc] Guys & St Thomas Natl Hlth Serv Fdn Trust, Dept Paediat Infect Dis & Immunol, Evelina London Childrens Hosp, London, England; [Dutta, Binita] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Louvain, Belgium; [Donath, Susan] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Parkville, Vic, Australia; [Casalaz, Dan] Mercy Hosp Women, Neonatal Intens Care Unit, Heidelberg, Vic, Australia; [Hanekom, Willem A.] Africa Hlth Res Inst, Durban, South Africa; [Britton, Warwick J.] Univ Sydney, Centenary Inst, Sydney, NSW, Australia; [Robins-Browne, Roy] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia; [Ritz, Nicole] Univ Basel, Infect Dis Unit, Childrens Hosp Basel, Basel, Switzerland; [Ritz, Nicole] Univ Basel, Migrant Hlth Serv, Childrens Hosp Basel, Basel, Switzerland; [Ritz, Nicole] Univ Basel, Dept Biomed, Mycobacterial Res Lab, Basel, Switzerland		Curtis, N (通讯作者)，Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Paediat, 50 Flemington Rd, Parkville, Vic 3052, Australia.	nigel.curtis@rch.org.au	Pittet, Laure F/AAH-4955-2021; Ritz, Nicole/G-2924-2015	Pittet, Laure F/0000-0002-2395-4574; Messina, Nicole/0000-0001-8404-4462; Ritz, Nicole/0000-0002-1498-1685; Robins-Browne, Roy/0000-0001-9179-7884; Britton, Warwick/0000-0001-6721-9646	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [P2GEP3_178155]	Dr Laure Pittet is supported by the Swiss National Science Foundation [Early Postdoc.Mobility grant number P2GEP3_178155].	Abdallah AM, 2015, SCI REP-UK, V5, DOI 10.1038/srep15443; Ahoua L, 2009, AFR J BIOTECHNOL, V8, P536; Angelidou A, 2020, VACCINE, V38, P2229, DOI 10.1016/j.vaccine.2019.11.060; [Anonymous], 2018, Wkly Epidemiol Rec, V93, P73; [Anonymous], 1969, LANCET, V1, P111; Baron L, 2016, J EXP MED, V213, P2885, DOI 10.1084/jem.20160662; Buultjens AH, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.02612-17; Converse PJ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000985; Darrah PA, 2020, NATURE, V577, P95, DOI 10.1038/s41586-019-1817-8; Debacker M, 2006, EMERG INFECT DIS, V12, P1325, DOI 10.3201/eid1209.050598; Dierig A, 2015, VACCINE, V33, P4994, DOI 10.1016/j.vaccine.2015.06.097; Favorov M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032567; Fritschi N, 2020, PAEDIATR RESPIR REV, V36, P57, DOI 10.1016/j.prrv.2020.08.004; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; Gooding TM, 2003, CLIN INFECT DIS, V36, P1076, DOI 10.1086/368315; Gooding TM, 2002, INFECT IMMUN, V70, P5562, DOI 10.1128/IAI.70.10.5562-5567.2002; Gooding TM, 2001, INFECT IMMUN, V69, P1704, DOI 10.1128/IAI.69.3.1704-1707.2001; Keller P, 2017, MYCOLACTONE PRODUCTI; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Marion E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033600; Nackers F, 2006, AM J TROP MED HYG, V75, P768, DOI 10.4269/ajtmh.2006.75.768; Nakanaga K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26425-1; Nausch N, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005415; Phillips R, 2009, J INFECT DIS, V200, P1675, DOI 10.1086/646615; Phillips RO, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003457; Pluschke G., 2019, BURULI ULCER MYCOBAC, V1 ed; Pollard AJ, 2017, ARCH DIS CHILD, V102, P1077, DOI 10.1136/archdischild-2015-310282; Pommelet V, 2014, CLIN INFECT DIS, V59, P1256, DOI 10.1093/cid/ciu584; Portaels F, 2004, INFECT IMMUN, V72, P62, DOI 10.1128/IAI.72.1.62-65.2004; Portaels F, 2002, CLIN DIAGN LAB IMMUN, V9, P1389, DOI 10.1128/CDLI.9.6.1389-1391.2002; Raghunathan PL, 2005, CLIN INFECT DIS, V40, P1445, DOI 10.1086/429623; Ritz N, 2008, FEMS MICROBIOL REV, V32, P821, DOI 10.1111/j.1574-6976.2008.00118.x; Ritz N, 2016, VACCINE, V34, P4132, DOI 10.1016/j.vaccine.2016.06.077; Ritz N, 2013, VACCINE, V31, P3098, DOI 10.1016/j.vaccine.2013.03.059; Ritz N, 2012, AM J RESP CRIT CARE, V185, P213, DOI 10.1164/rccm.201104-0714OC; Ritz N, 2009, TUBERCULOSIS, V89, P248, DOI 10.1016/j.tube.2009.03.002; Schipper HS, 2007, CLIN EXP IMMUNOL, V150, P451, DOI 10.1111/j.1365-2249.2007.03506.x; SMITH PG, 1976, T ROY SOC TROP MED H, V70, P449, DOI 10.1016/0035-9203(76)90128-0; Tanghe A, 2001, INFECT IMMUN, V69, P5403, DOI 10.1128/IAI.69.9.5403-5411.2001; Tanghe A, 2007, INFECT IMMUN, V75, P2642, DOI 10.1128/IAI.01622-06; Zakham F, 2011, CELL MOL BIOL, V57, P1462, DOI 10.1170/167; Zimmermann P, 2019, VACCINE, V37, P3735, DOI 10.1016/j.vaccine.2019.03.016; Zimmermann P, 2018, J INFECT DIS, V218, P679, DOI 10.1093/infdis/jiy207	43	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					652	657		10.1016/j.vaccine.2020.11.045		JAN 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PR1FI	33371993				2022-04-29	WOS:000606987100007
J	Preto, C; de Mello, AM; Maluf, EMCP; Krainski, ET; Graeff, G; de Sousa, GA; da Silva, LR; da Costa-Ribeiro, MCV; Buffon, MDM; Shimakura, SE; Raboni, SM; de Carvalho, DS; Luhm, KR				Preto, Clara; de Mello, Angela Maron; Cesario Pereira Maluf, Eliane Mara; Krainski, Elias Teixeira; Graeff, Gabriel; de Sousa, Gabriela Amanda; da Silva, Lineu Roberto; Vieira da Costa-Ribeiro, Magda Clara; Magalhaes Buffon, Marilene da Cruz; Shimakura, Silvia Emiko; Raboni, Sonia Mara; de Carvalho, Denise Siqueira; Luhm, Karin Regina			Vaccination coverage and adherence to a dengue vaccination program in the state of Parana, Brazil	VACCINE			English	Article						Dengue vaccines; Vaccination coverage; Immunization programs; Vaccination adherence; Vaccination compliance; Vaccination dropout rate	UNITED-STATES; ADOLESCENTS; ADULTS; DISPARITIES; BARRIERS; VACCINES; SAFETY	The success of vaccination programs depends on the level of acceptance of the vaccine to achieve high vaccine coverage rates (VCR). Vaccine hesitancy is a challenge, especially concerning new vaccines. Dengue vaccine, Dengvaxia (R), was licensed in Brazil in 2015 and implemented, in a pioneering publicly-funded initiative in the state of Parana, between 2016 and 2018. The vaccination program took place in five phases in the 30 municipalities most affected by dengue in the state, targeting individuals from nine to 44 years-old in two cities and from 15 to 27 years-old in the other 28 municipalities, totaling a target population of 500,000 individuals. A cross-sectional descriptive study was carried out to assess VCR and adherence to the dengue vaccine in this program. VCR, dropout ratio (DR), and compliance with the vaccination schedule (CVS) were analyzed by sex, age group, and municipality size. A total of 302,603 individuals (60.5%) received >= 1 dose, 44.2% received >= 2 doses, and 28.6% 3 doses. The DR was 52.8%. Among individuals who started vaccination, 40.6% achieved CVS. The highest VCR, highest CVS, and lowest DR occurred in the age group from 9 to 14 years old and from 28 to 44 years old and in smaller municipalities. A greater proportion of men started vaccination (male 64.0%; female 57.1%) however, the DR was higher in men (male 55.4%; female 49.9%), and a higher percentage of women completed the vaccination schedule according to the recommendations (CVS male 37.8%; female 43.6%). Differences were noted in the CVS according to the initial phase of the program (first phase 50.8%; second phase 18.8%). The heterogeneity in vaccine uptake and compliance according to sex, age, and municipality size suggests the need for differentiated strategies to address challenges with new and multiple-dose vaccines. (C) 2020 The Authors. Published by Elsevier Ltd.	[Preto, Clara; de Sousa, Gabriela Amanda; Vieira da Costa-Ribeiro, Magda Clara; Magalhaes Buffon, Marilene da Cruz; Shimakura, Silvia Emiko; de Carvalho, Denise Siqueira; Luhm, Karin Regina] Univ Fed Parana UFPR, Postgrad Program Publ Hlth Curitiba, Rua Padre Camargo 280, BR-80060240 Curitiba, Parana, Brazil; [de Mello, Angela Maron] Brazilian Publ Hlth Hlth Minist, Natl Audit Dept, Rua Candido Lopes 208, BR-80020060 Curitiba, Parana, Brazil; [Cesario Pereira Maluf, Eliane Mara; da Silva, Lineu Roberto; Raboni, Sonia Mara] Univ Fed Parana UFPR, Publ Hlth Dept, Rua Padre Camargo 280, BR-80060240 Curitiba, Parana, Brazil; [Krainski, Elias Teixeira] Univ Fed Parana UFPR, Stat Dept, Rua Padre Camargo 280, BR-80060240 Curitiba, Parana, Brazil; [Graeff, Gabriel] Fundacao Apoio Univ Fed Parana FUNPAR, Rua Joao Negrao 280, BR-80010200 Curitiba, Parana, Brazil		Preto, C (通讯作者)，Univ Fed Parana UFPR, Postgrad Program Publ Hlth Curitiba, Rua Padre Camargo 280, BR-80060240 Curitiba, Parana, Brazil.	clarampreto@hotmail.com	Krainski, Elias T/AGP-2119-2022	Krainski, Elias T/0000-0002-7063-2615; de Sousa, Gabriela Amanda/0000-0002-9466-3539; Preto, Clara/0000-0003-3929-1952; Shimakura, Silvia/0000-0002-5468-2516	Sanofi Pasteur	This investigator study received funding from Sanofi Pasteur which participated in the revision of the manuscript.	Araujo Valdelaine Etelvina Miranda de, 2017, Rev Bras Epidemiol, V20Suppl 01, P205, DOI 10.1590/1980-5497201700050017; Back Anne Tuiskunen, 2013, Infect Ecol Epidemiol, V3, DOI 10.3402/iee.v3i0.19839; Benoit CM, 2013, J TRAVEL MED, V20, P346, DOI 10.1111/jtm.12056; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760; BRASIL, 2009, BRAS LIVR RUB CAMP N; Brazilian Institute of Geography and Statistics-IBGE, 2016, NAT HOUS SAMPL SURV; Bridges CB, 2015, AM J PREV MED, V49, pS455, DOI 10.1016/j.amepre.2015.08.014; Craciun C, 2012, VACCINE, V30, P6789, DOI 10.1016/j.vaccine.2012.09.016; Cylus J, 2011, HEALTH AFFAIR, V30, P153, DOI 10.1377/hlthaff.2010.0216; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Friberg IO, 2016, SCAND J PUBLIC HEALT, V44, P264, DOI 10.1177/1403494815618843; Fry CA, 2016, PUBLIC HEALTH NURS, V33, P277, DOI 10.1111/phn.12257; Gallagher KE, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2845-z; Nunes PCG, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6641-4; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; Hadisoemarto PF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002427; Harapan H, 2017, HUM VACC IMMUNOTHER, V13, P786, DOI 10.1080/21645515.2016.1259045; Hughes MM, 2018, AM J PUBLIC HEALTH, V108, P517, DOI 10.2105/AJPH.2017.304257; Institute of Medicine and National Research Council, 2015, INVESTING HLTH WELL, DOI [10.17226/18869., DOI 10.17226/18869]; Instituto Brasileiro de Geografia e Estatistica, 2011, IND SOC MUN AN RES U; Jentes ES, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw062; Johnson DR, 2008, AM J MED, V121, pS28, DOI 10.1016/j.amjmed.2008.05.005; Johnson KD, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6693-5; Lau JS, 2014, J ADOLESCENT HEALTH, V54, P663, DOI 10.1016/j.jadohealth.2014.03.001; Lobao WM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206726; Loke AY, 2017, J PRIM CARE COMMUNIT, V8, P349, DOI 10.1177/2150131917742299; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Nanni A, 2017, VACCINE, V35, P6823, DOI 10.1016/j.vaccine.2017.10.023; Nelson JC, 2009, AM J PUBLIC HEALTH, V99, pS389, DOI 10.2105/AJPH.2008.151332; Olson D, 2018, PEDIATR INFECT DIS J, V37, P1184, DOI 10.1097/INF.0000000000002169; Pacheco FC, 2020, VACCINE, V38, P1881, DOI 10.1016/j.vaccine.2020.01.030; PAHO, 2019, EP UPD DENG; Rand CM, 2007, ARCH PEDIAT ADOL MED, V161, P252, DOI 10.1001/archpedi.161.3.252; Reyes MSGL, 2020, VACCINE, V38, P54, DOI 10.1016/j.vaccine.2019.10.001; Reynolds GL, 2016, PUBLIC HEALTH NURS, V33, P430, DOI 10.1111/phn.12254; Sakou II, 2011, EUR J PEDIATR, V170, P1419, DOI 10.1007/s00431-011-1456-z; Secretaria de Estado da Saude do Parana, 2017, MAN NORM PROC VAC DE; Sheikh S, 2018, VACCINE, V36, P4979, DOI 10.1016/j.vaccine.2018.06.044; Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265; Sociedade Brasileira de Imunizacoes, 2019, IM AD ID; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Thomas SJ, 2019, HUM VACC IMMUNOTHER, V15, P2295, DOI 10.1080/21645515.2019.1658503; Trantham L, 2018, VACCINE, V36, P5333, DOI 10.1016/j.vaccine.2018.05.111; Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2; Wang YY, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003320; Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1; World Health Organization, 2018, Weekly Epidemiological Record, V93, P457; World Health Organization, 2018, GUID IMM PROGR MAN; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	50	1	1	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					711	719		10.1016/j.vaccine.2020.12.030		JAN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PR1FI	33386178	hybrid			2022-04-29	WOS:000606987100014
J	Degeling, C; Williams, J; Carter, SM; Moss, R; Massey, P; Gilbert, GL; Shih, P; Braunack-Mayer, A; Crooks, K; Brown, D; McVernon, J				Degeling, C.; Williams, J.; Carter, S. M.; Moss, R.; Massey, P.; Gilbert, G. L.; Shih, P.; Braunack-Mayer, A.; Crooks, K.; Brown, D.; McVernon, J.			Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries	VACCINE			English	Article						Pandemic Influenza vaccination; Health policy; Public deliberation; Public health ethics	PUBLIC DELIBERATION; HEALTH-POLICY; PEOPLE; IMPACT	Background: Pandemic planning has historically been oriented to respond to an influenza virus, with vaccination strategy being a key focus. As the current COVID-19 pandemic plays out, the Australian government is closely monitoring progress towards development of SARS-CoV2 vaccines as a definitive intervention. However, as in any pandemic, initial supply will likely be exceeded by demand due to limited manufacturing output. Methods: We convened community juries in three Australian locations in 2019 to assess public acceptability and perceived legitimacy of influenza pandemic vaccination distribution strategies. Preparatory work included literature reviews on pandemic vaccine allocation strategies and on vaccine allocation ethics, and simulation modelling studies. We assumed vaccine would be provided to predefined priority groups. Jurors were then asked to recommend one of two strategies for distributing remaining early doses of vaccine: directly vaccinate people at higher risk of adverse outcomes from influenza; or indirectly protect the general population by vaccinating primary school students, who are most likely to spread infection. Results: Thirty-four participants of diverse backgrounds and ages were recruited through random digit dialling and topic-blinded social media advertising. Juries heard evidence and arguments supporting different vaccine distribution strategies, and questioned expert presenters. All three community juries supported prioritising school children for influenza vaccination (aiming for indirect protection), one by 10-2 majority and two by consensus. Justifications included that indirect protection benefits more people and is likely to be more publicly acceptable. Conclusions: In the context of an influenza pandemic, informed citizens were not opposed to prioritising groups at higher risks of adverse outcomes, but if resources and epidemiological conditions allow, achieving population benefits should be a strategic priority. These insights may inform future SARS-CoV-2 vaccination strategies. (C) 2020 Elsevier Ltd. All rights reserved.	[Degeling, C.; Carter, S. M.; Shih, P.; Braunack-Mayer, A.] Univ Wollongong, Australian Ctr Hlth Engagement Evidence & Values, Sch Hlth & Soc, Northfields Ave, Wollongong, NSW 2522, Australia; [Williams, J.; Gilbert, G. L.] Univ Sydney, Sch Publ Hlth, Sydney Hlth Eth, Sydney, NSW, Australia; [Moss, R.; Brown, D.; McVernon, J.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Modelling & Simulat Unit, Melbourne, Vic, Australia; [Massey, P.; Crooks, K.] Hunter New England Local Hlth Dist, Populat Hlth, Wallsend, NSW, Australia; [Massey, P.] James Cook Univ, Coll Med & Dent, Townsville, Qld, Australia; [Gilbert, G. L.] Univ Sydney, Marie Bashir Inst Emerging Infect, Sydney, NSW, Australia; [Crooks, K.] Charles Darwin Univ, Menzies Sch Hlth Res, Casuarina, Darwin, Australia; [Brown, D.; McVernon, J.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Victorian Infect Dis Lab Epidemiol Unit, Melbourne, Vic, Australia; [Brown, D.; McVernon, J.] Royal Melbourne Hosp, Melbourne, Vic, Australia		Degeling, C (通讯作者)，Univ Wollongong, Australian Ctr Hlth Engagement Evidence & Values, Sch Hlth & Soc, Northfields Ave, Wollongong, NSW 2522, Australia.	degeling@uow.edu.au	Degeling, Chris/ABE-2049-2020; Braunack-Mayer, Annette/AAE-7796-2019; Moss, Rob/R-4767-2018; Carter, Stacy/A-6544-2011	Degeling, Chris/0000-0003-4279-3443; Braunack-Mayer, Annette/0000-0003-4427-0224; Gilbert, Gwendolyn/0000-0001-7490-6727; Moss, Rob/0000-0002-4568-2012; Carter, Stacy/0000-0003-2617-8694; Massey, Peter/0000-0001-7194-1914	Australian Government Department of Health Office of Health Protection Approach to Market: Health [17-18/73536]; Australian Government National Health and Medical Research Council (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [GNT1116530, GNT1102962]; NHMRC Principal Research FellowshipNational Health and Medical Research Council (NHMRC) of Australia [GNT1117140]	This project was directly funded by the Australian Government Department of Health Office of Health Protection Approach to Market: Health/17-18/73536 Investigate and Model Initial Pandemic Influenza Vaccination Target Groups -extension to conduct Citizens' Juries.; The Australian Partnership for Preparedness Research on Infectious Disease Emergencies is a Centre of Research Excellence funded by the Australian Government National Health and Medical Research Council (NHMRC) GNT1116530. The Centre for Research Excellence in Emerging Infectious Disease (CREID) is funded by the Australian Government National Health and Medical Research Council (NHMRC) GNT1102962.; Jodie McVernon is supported by a NHMRC Principal Research Fellowship GNT1117140.	[Anonymous], 2020, LANCET, V395, P1089, DOI 10.1016/S0140-6736(20)30757-1; [Anonymous], 2019, COMM PERSP DISTR IN; Australian Government Department of Health, 2014, AUSTR HLTH MAN PLAN; Baum NM, 2009, AM J BIOETHICS, V9, P4, DOI 10.1080/15265160903197531; Black AJ, 2017, EPIDEMICS-NETH, V19, P61, DOI 10.1016/j.epidem.2017.01.004; Blacksher E, 2012, HASTINGS CENT REP, V42, P14, DOI 10.1002/hast.26; Braunack-Mayer AJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-501; Burgess MM, 2014, PUBLIC UNDERST SCI, V23, P48, DOI 10.1177/0963662512472160; Carter SM, 2020, J MED ETHICS, V46, P382, DOI 10.1136/medethics-2020-106185; Centers for Disease Control and Prevention (CDC), 2020, COVID 19 VACC PROGR; Degeling C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209798; Degeling C, 2018, HEALTH EXPECT, V21, P90, DOI 10.1111/hex.12589; Degeling C, 2017, SOC SCI MED, V179, P166, DOI 10.1016/j.socscimed.2017.03.003; Degeling C, 2015, SOC SCI MED, V131, P114, DOI 10.1016/j.socscimed.2015.03.009; Docter SP, 2011, J PUBLIC HEALTH POL, V32, P350, DOI 10.1057/jphp.2010.49; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Eubank S, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00726-x; Feminist SJ, 2016, EMPIRICAL BIOETHICS, P195; Fernandes N., 2020, WP1240E IESE BUS SCH, DOI 10.2139/ssrn.3557504; Fielding J, 2020, VACCINE; Flint SM, 2010, MED J AUSTRALIA, V192, P617, DOI 10.5694/j.1326-5377.2010.tb03654.x; Grill K, 2015, HLTH CARE ANAL, P1; Irwin A, 2013, SOC STUD SCI, V43, P118, DOI 10.1177/0306312712462461; Ives J, 2018, BMC MED ETHICS, V19, DOI 10.1186/s12910-018-0304-3; Karpowitz C., 2016, J PUBLIC DELIBERATIO, V12, P1, DOI DOI 10.16997/JDD.255; Karpowitz CF, 2014, DEMOCRACY CIVIC FORU; Marshall H, 2009, AM J PUBLIC HEALTH, V99, pS365, DOI 10.2105/AJPH.2008.153056; Pebody RG, 2018, EUROSURVEILLANCE, V23, P35, DOI 10.2807/1560.7917.ES.2o18.23.25.1700496; Rogers WA, 2009, HEALTH EXPECT, V12, P331, DOI 10.1111/j.1369-7625.2009.00562.x; Street J, 2014, SOC SCI MED, V109, P1, DOI 10.1016/j.socscimed.2014.03.005; Thomas James C, 2007, Am J Public Health, V97 Suppl 1, pS26, DOI 10.2105/AJPH.2006.093443; Thomas R, 2017, HEALTH EXPECT, V20, P626, DOI 10.1111/hex.12493; Vawter DE, 2011, J CLIN ETHIC, V22, P42; World Health Organization, 2020, 59 WHO; World Health Organization, 2020, ETH COVID 19 RES ALL; World Health Organization, 2009, PAND INFL PREP RESP; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7; Zhang JJ, 2020, SCIENCE, V368, P1481, DOI 10.1126/science.abb8001; Zhang SX, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112958	40	6	6	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					255	262		10.1016/j.vaccine.2020.12.010			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PN8VM	33317870	Bronze, Green Published			2022-04-29	WOS:000604750300014
J	Edoka, I; Kohli-Lynch, C; Fraser, H; Hofman, K; Tempia, S; McMorrow, M; Ramkrishna, W; Lambach, P; Hutubessy, R; Cohen, C				Edoka, Ijeoma; Kohli-Lynch, Ciaran; Fraser, Heather; Hofman, Karen; Tempia, Stefano; McMorrow, Meredith; Ramkrishna, Wayne; Lambach, Philipp; Hutubessy, Raymond; Cohen, Cheryl			A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme	VACCINE			English	Article						Cost-utility analysis; Seasonal influenza vaccine; South Africa; Cost Effectiveness Tool for Seasonal; Influenza Vaccination	EFFECTIVENESS THRESHOLDS; ECONOMIC-EVALUATION; PANDEMIC INFLUENZA; PREGNANT-WOMEN; HEALTH IMPACT; EFFICACY; BURDEN; MORTALITY; CHILDREN; VACCINES	Background: Seasonal influenza imposes a significant health and economic burden in South Africa, particularly in populations vulnerable to severe consequences of influenza. This study assesses the cost-effectiveness of South Africa's seasonal influenza vaccination strategy, which involves vaccinating vulnerable populations with trivalent inactivated influenza vaccine (TIV) during routine facility visits. Vulnerable populations included in our analysis are persons aged > 65 years; pregnant women; persons living with HIV/AIDS (PLWHA), persons of any age with underlying medical conditions (UMC) and children aged 6-59 months. Method: We employed the World Health Organisation's (WHO) Cost Effectiveness Tool for Seasonal Influenza Vaccination (CETSIV), a decision tree model, to evaluate the 2018 seasonal influenza vaccination campaign from a public healthcare provider and societal perspective. CETSIV was populated with existing country-specific demographic, epidemiologic and coverage data to estimate incremental cost-effectiveness ratios (ICERs) by comparing costs and benefits of the influenza vaccination programme to no vaccination. Results: The highest number of clinical events (influenza cases, outpatient visits, hospitalisation and deaths) were averted in PLWHA and persons with other UMCs. Using a cost-effectiveness threshold of US$ 3 400 per quality-adjusted life year (QALY), our findings suggest that the vaccination programme is cost-effective for all vulnerable populations except for children aged 6-59 months. ICERs ranged from -US$ 1 750 /QALY in PLWHA to -US$ 7 500/QALY in children. In probabilistic sensitivity analyses, the vaccination programme was cost-effective in pregnant women, PLWHA, persons with UMCs and persons aged >65 years in >80% of simulations. These findings were robust to changes in many model inputs but were most sensitive to uncertainty in estimates of influenza-associated illness burden. Conclusion: South Africa's seasonal influenza vaccination strategy of opportunistically targeting vulnerable populations during routine visits is cost-effective. A budget impact analysis will be useful for supporting future expansions of the programme. (C) 2020 Published by Elsevier Ltd.	[Edoka, Ijeoma; Kohli-Lynch, Ciaran; Fraser, Heather; Hofman, Karen] Univ Witwatersrand, Fac Hlth Sci, SAMRC Ctr Hlth Econ & Decis Sci PRICELESS SA, Sch Publ Hlth, 27 St Andrews Rd, Johannesburg, South Africa; [Tempia, Stefano; McMorrow, Meredith] Ctr Dis Control, Influenza Div, Atlanta, GA USA; [Tempia, Stefano; McMorrow, Meredith] Ctr Dis Control, Influenza Program, Pretoria, South Africa; [Tempia, Stefano; Cohen, Cheryl] Natl Inst Communicable Dis Natl Hlth Lab Serv, Ctr Resp Dis & Meningitis, Johannesburg, South Africa; [Tempia, Stefano] MassGenics, Duluth, GA USA; [Tempia, Stefano; Cohen, Cheryl] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa; [McMorrow, Meredith] US PHS, Rockville, MD USA; [Ramkrishna, Wayne] Natl Dept Hlth, Communicable Dis Cluster, Pretoria, South Africa; [Lambach, Philipp; Hutubessy, Raymond] WHO, Dept Immunizat Vaccines & Biol, Initiat Vaccine Res, Vaccines &, Geneva, Switzerland		Edoka, I (通讯作者)，Univ Witwatersrand, Fac Hlth Sci, SAMRC Ctr Hlth Econ & Decis Sci PRICELESS SA, Sch Publ Hlth, 27 St Andrews Rd, Johannesburg, South Africa.	Ijeoma.edoka@wits.ac.za		Cohen, Cheryl/0000-0003-0376-2302; McMorrow, Meredith/0000-0001-6363-4033; Fraser, Heather Lynne/0000-0002-7100-571X; Lambach, Philipp/0000-0003-0105-8899; Tempia, Stefano/0000-0003-4395-347X	WHO Department of Immunization, Vaccines and Biologicals; U.S. Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U50CK000431]; South African Medical Research CouncilSouth African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [23108]	The development and piloting of the Cost Effectiveness Tool for Seasonal Influenza Vaccination (CETSIV), was funded by a grant from the WHO Department of Immunization, Vaccines and Biologicals. This work was supported by the U.S. Centers for Disease Control and Prevention, under the terms of Cooperative Agreement Number U50CK000431. Edoka I, Kohli-Lynch C, Fraser H and Hofman K were also supported by the South African Medical Research Council (23108).	Abbott KC, 2011, AM J KIDNEY DIS, V57, P651, DOI 10.1053/j.ajkd.2011.02.380; Alshreef A, 2019, VALUE HEALTH REG ISS, V19, P65, DOI 10.1016/j.vhri.2019.03.001; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Barnes M, 2015, HEART, V101, P1738, DOI 10.1136/heartjnl-2015-307691; Beigi RH, 2009, CLIN INFECT DIS, V49, P1784, DOI 10.1086/649013; Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418; Biggerstaff M, 2019, VACCINE, V37, P6874, DOI 10.1016/j.vaccine.2019.09.059; Bitzan M, 2018, PEDIATR NEPHROL, V33, P2009, DOI 10.1007/s00467-017-3783-4; Blumberg L., 2017, INFLUENZA NICD RECOM; Claxton K, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19140; Cohen C, 2013, EMERG INFECT DIS, V19, P1766, DOI 10.3201/eid1911.130546; Cohen R, 2009, NY TIMES BK REV, P5; de Boer PT, 2018, VACCINE, V36, P997, DOI 10.1016/j.vaccine.2017.12.073; DEMICHELI V, 2018, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001269.PUB6; Demicheli V, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004876.pub4; Department of Health, 2013, GUID PHARM SUBM 2012; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Ebdrup Lotte, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2018-226108; Edney LC, 2018, PHARMACOECONOMICS, V36, P239, DOI 10.1007/s40273-017-0585-2; Edoka IP, 2020, HEALTH POLICY PLANN, V35, P546, DOI 10.1093/heapol/czz152; Fielding JE, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-170; Fischer WA, 2014, GLOB HEART, V9, P325, DOI 10.1016/j.gheart.2014.08.004; Fraser, COST SEASONAL UNPUB; Hollmann M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060477; Hughes RAC, 1997, LANCET, V349, P225; Hutubessy Raymond, 2003, Cost Eff Resour Alloc, V1, P8, DOI 10.1186/1478-7547-1-8; Igboh LS, 2021, INFLUENZA OTHER RESP, V15, P495, DOI 10.1111/irv.12818; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jefferson T, 2005, LANCET, V365, P773, DOI 10.1016/S0140-6736(05)17984-7; Jefferson T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004879.pub4; Jelsma Jennifer, 2003, Popul Health Metr, V1, P11, DOI 10.1186/1478-7954-1-11; Jit M, 2013, HUM VACC IMMUNOTHER, V9, P834, DOI 10.4161/hv.23637; Jit M, 2010, VACCINE, V29, P115, DOI 10.1016/j.vaccine.2010.08.078; Johnson LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001418; Lee BY, 2011, AM J KIDNEY DIS, V57, P724, DOI 10.1053/j.ajkd.2010.12.016; Leech AA, 2018, VALUE HEALTH, V21, P759, DOI 10.1016/j.jval.2017.12.016; Maciosek MV, 2006, AM J PREV MED, V31, P72, DOI 10.1016/j.amepre.2006.03.008; Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480; Marseille E, 2015, B WORLD HEALTH ORGAN, V93, P118, DOI 10.2471/BLT.14.138206; Massyn, DISTRICT HLTH BAROME; McMorrow, 2019, METAANALYSIS O UNPUB; McMorrow ML, 2019, VACCINE, V37, P25, DOI 10.1016/j.vaccine.2018.11.048; Michiels B, 2011, VACCINE, V29, P9159, DOI 10.1016/j.vaccine.2011.08.008; Myers ER, 2011, AM J OBSTET GYNECOL, V204, pS128, DOI 10.1016/j.ajog.2011.04.009; National Department of Health, 2018, INFL VACC POSTV EV 2; National Department of Health, 2018, UN PAT FEE SCHED; National Department of Health, 2017, NAT INFL POL STRAT P; National Department of Health, 2017, INFL VACC POSTV EV; Newall AT, 2014, PHARMACOECONOMICS, V32, P525, DOI 10.1007/s40273-014-0162-x; Newall AT, 2014, VACCINE, V32, P1323, DOI 10.1016/j.vaccine.2014.01.017; Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Nonaka K, 2019, JPN J INFECT DIS, V72, P347, DOI 10.7883/yoken.JJID.2018.494; Nosyk B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027059; Nunes MC, 2019, PLOS ONE, V13; Oakley JE, 2004, J R STAT SOC B, V66, P751, DOI 10.1111/j.1467-9868.2004.05304.x; Ochalek J, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000964; Onozuka D, 2018, INT J CARDIOL, V263, P158, DOI 10.1016/j.ijcard.2018.02.028; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Peasah SK, 2013, VACCINE, V31, P5339, DOI 10.1016/j.vaccine.2013.09.013; Reed C, 2012, VACCINE, V30, P1993, DOI 10.1016/j.vaccine.2011.12.098; Schwarze-Zander C, 2016, HIV AIDS REV, V15, P111, DOI 10.1016/j.hivar.2016.04.002; Sellers SA, 2017, INFLUENZA OTHER RESP, V11, P372, DOI 10.1111/irv.12470; Sinanovic E, 2009, VACCINE, V27, P6196, DOI 10.1016/j.vaccine.2009.08.004; Skedgel C, 2011, CAN J PUBLIC HEALTH, V102, P445, DOI 10.1007/BF03404197; South African Reserve Bank, 2018, SEL HIST RAT RAND PE; Statistics South Africa, 2017, MORT CAUS DEATH S AF; Tempia S, 2020, VACCINE, V38, P4288, DOI 10.1016/j.vaccine.2020.04.045; Tempia S, 2019, INFLUENZA OTHER RESP, V13, P484, DOI 10.1111/irv.12650; Tempia S, 2019, CLIN INFECT DIS, V69, P1036, DOI 10.1093/cid/ciy1017; Tempia S, 2018, INFLUENZA OTHER RESP, V12, P360, DOI 10.1111/irv.12529; Tempia S, 2015, CLIN INFECT DIS, V61, P1063, DOI 10.1093/cid/civ448; Tempia S, 2014, CLIN INFECT DIS, V58, P1241, DOI 10.1093/cid/ciu095; Teufel RJ, 2008, J HOSP MED, V3, P134, DOI 10.1002/jhm.286; Tignanelli CJ, 2018, AM J CRIT CARE, V27, P67, DOI 10.4037/ajcc2018901; Trogdon JG, 2010, AM J PREV MED, V39, P403, DOI 10.1016/j.amepre.2010.07.012; Vallejo-Torres L, 2018, HEALTH ECON, V27, P746, DOI 10.1002/hec.3633; Vamos EP, 2016, CAN MED ASSOC J, V188, pE342, DOI 10.1503/cmaj.151059; WHO, 2014, GLOB EP SURV STAND I; Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017; World Health Organization, 2019, INFL EC EC GUID; World Health Organization, 2017, GLOB HLTH OBS DAT RE; World Health Organization, 2012, INF SHEET OBS RAT VA; Yang KC, 2018, INT J INFECT DIS, V73, P102, DOI 10.1016/j.ijid.2018.05.024; Zhang SP, 2019, MICROB PATHOGENESIS, V137, DOI 10.1016/j.micpath.2019.103736	86	4	4	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					412	422		10.1016/j.vaccine.2020.11.028			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PN8VM	33272702	Green Accepted, hybrid			2022-04-29	WOS:000604750300032
J	Maiti, S; Howlader, DR; Halder, P; Bhaumik, U; Dutta, M; Dutta, S; Koley, H				Maiti, Suhrid; Howlader, Debaki Ranjan; Halder, Prolay; Bhaumik, Ushasi; Dutta, Moumita; Dutta, Shanta; Koley, Hemanta			Bivalent non-typhoidal Salmonella outer membrane vesicles immunized mice sera confer passive protection against gastroenteritis in a suckling mice model	VACCINE			English	Article						Invasive non-typhoidal Salmonella; Outer membrane vesicles; Vaccine; Suckling mice gastroenteritis model; Passive protective efficacy	ENTERICA SEROVAR TYPHIMURIUM; NECROSIS-FACTOR-ALPHA; SEROGROUP-B DISEASE; ANTIMICROBIAL RESISTANCE; VACCINE; ENTERITIDIS; ANTIBODIES; INDUCE; INFLAMMATION; CHEMOKINES	Invasive non-typhoidal Salmonella (iNTS) serovars, especially Salmonella Typhimurium (ST) and Salmonella Enteritidis (SE), cause gastroenteritis worldwide. Due to the emergence of multi-drug resistance in iNTS, a broad-spectrum vaccine is urgently needed for the prevention of iNTS infection. Currently, there is no effective licensed vaccine against iNTS available in the market. We have formulated an outer membrane vesicles (OMVs) based bivalent immunogen as a vaccine candidate to generate broad-spectrum protective immunity against both recently circulating prevalent ST and SE. We have isolated OMVs from ST and SE and formulated the immunogen by mixing both OMVs (1:1 ratio). Three doses of bivalent immunogen significantly induced humoral immune responses against lipopolysaccharides (LPSs) and outer membrane proteins (OMPs) as well as a cell-mediated immune response in adult mice. We also observed that proteins of OMVs act as an adjuvant for generation of high levels of anti-LPS antibodies through T cell activation. We then characterized the one-day old suckling mice model for both ST and SE mediated gastroenteritis and used the model for a passive protection study. In the passive protection study, we found the passive transfer of bivalent OMVs immunized sera significantly reduced ST and SE mediated colonization and gastroenteritis symptoms in the colon of suckling mice compared to non-immunized sera recipients. The overall study demonstrated that OMVs based bivalent vaccine could generate broad-spectrum immunity against prevalent iNTS mediated gastroenteritis. This study also established the suckling mice model as a suitable animal model for vaccine study against iNTS mediated gastroenteritis. (C) 2020 Elsevier Ltd. All rights reserved.	[Maiti, Suhrid; Howlader, Debaki Ranjan; Halder, Prolay; Bhaumik, Ushasi; Dutta, Shanta; Koley, Hemanta] ICMR Natl Inst Cholera & Enter Dis, Div Bacteriol, P-33 CIT Rd,Scheme XM, Kolkata 700010, India; [Dutta, Moumita] ICMR Natl Inst Cholera & Enter Dis, Div Electron Microscopy, P-33 CIT Rd,Scheme XM, Kolkata 700010, India		Koley, H (通讯作者)，ICMR Natl Inst Cholera & Enter Dis, Div Bacteriol, P-33 CIT Rd,Scheme XM, Kolkata 700010, India.	hemantakoley@hotmail.com		Koley, Hemanta/0000-0003-1222-5701	Indian Council of Medical ResearchIndian Council of Medical Research (ICMR) [5/3/8/61/ITR-F/2019-ITR]	We like to thank Professor Jeffrey H. Withey (Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, Michigan, USA) for his help in correcting the manuscript and Mr. Ananda Pal, for his technical and meaningful help in FACS analysis. We would also like to thank Mr. Subrata Singha and Mr. Keshab Paramanik for their help in animal keeping. This study was supported by Indian Council of Medical Research (File No: 5/3/8/61/ITR-F/2019-ITR dated 26.03.2019).	Baker K, 2009, SEMIN IMMUNOPATHOL, V31, P223, DOI 10.1007/s00281-009-0160-9; Barnes TC, 2011, INT J RHEUMATOL, V2011, DOI 10.1155/2011/721608; Barthel M, 2003, INFECT IMMUN, V71, P2839, DOI 10.1128/IAI.71.5.2839-2858.2003; Bishop AL, 2010, INFECT IMMUN, V78, P4402, DOI 10.1128/IAI.00398-10; BOYD JF, 1985, GUT, V26, P935, DOI 10.1136/gut.26.9.935; Broz P, 2012, GUT MICROBES, V3, P62, DOI 10.4161/gmic.19141; Ciacci-Woolwine F, 1998, INFECT IMMUN, V66, P1127, DOI 10.1128/IAI.66.3.1127-1134.1998; Crump JA, 2003, CLIN INFECT DIS, V37, P75, DOI 10.1086/375602; Cui W, 2010, BRAZ J MED BIOL RES, V43, P330, DOI [10.1590/S0100-879X2010007500020, 10.1590/S0100-879X2010000400002]; Davis MA, 1999, EMERG INFECT DIS, V5, P802, DOI 10.3201/eid0506.990610; DAY DW, 1978, HISTOPATHOLOGY, V2, P117, DOI 10.1111/j.1365-2559.1978.tb01700.x; Erben U, 2014, INT J CLIN EXP PATHO, V7, P4557; Fiorino F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00168; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; Geddes K, 2010, INFECT IMMUN, V78, P5107, DOI 10.1128/IAI.00759-10; Godinez I, 2009, INFECT IMMUN, V77, P387, DOI 10.1128/IAI.00933-08; Goh YS, 2011, IMMUNOLOGY, V133, P74, DOI 10.1111/j.1365-2567.2011.03411.x; Goh YS, 2015, INFECT IMMUN, V83, P3722, DOI 10.1128/IAI.00547-15; Haraga A, 2008, NAT REV MICROBIOL, V6, P53, DOI 10.1038/nrmicro1788; Havelaar AH, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001923; Ho DK, 2010, J IMMUNOL, V185, P1763, DOI 10.4049/jimmunol.1001244; Holst J, 2013, HUM VACC IMMUNOTHER, V9, P1241, DOI 10.4161/hv.24129; Howlader DR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203631; Hu RJ, 2020, MICROB CELL FACT, V19, DOI 10.1186/s12934-020-01372-7; Ingram JP, 2017, CYTOKINE, V98, P27, DOI 10.1016/j.cyto.2016.10.009; Kaparakis-Liaskos M., 2015, SCI REP, V15, P1, DOI DOI 10.1038/s41598-016-0001-8; Leitner DR, 2013, INFECT IMMUN, V81, P2379, DOI 10.1128/IAI.01382-12; Liu Q, 2017, J MICROBIOL BIOTECHN, V27, P1519, DOI 10.4014/jmb.1705.05028; Liu Q, 2016, INT J MED MICROBIOL, V306, P697, DOI 10.1016/j.ijmm.2016.08.004; Majowicz SE, 2010, CLIN INFECT DIS, V50, P882, DOI 10.1086/650733; Mantis NJ, 2010, IMMUNOL INVEST, V39, P383, DOI 10.3109/08820131003622635; MCGOVERN VJ, 1979, AM J SURG PATHOL, V3, P483, DOI 10.1097/00000478-197912000-00001; Micoli F, 2018, P NATL ACAD SCI USA, V115, P10428, DOI 10.1073/pnas.1807655115; Mitra M, 2016, HUM VACC IMMUNOTHER, V12, P939, DOI 10.1080/21645515.2015.1117715; Mitra S, 2013, VACCINE, V31, P3163, DOI 10.1016/j.vaccine.2013.05.001; Mitra S, 2012, FEMS IMMUNOL MED MIC, V66, P240, DOI 10.1111/j.1574-695X.2012.01004.x; Moor K, 2017, NATURE, V544, P498, DOI 10.1038/nature22058; Nadeau WJ, 2002, MICROBES INFECT, V4, P1379, DOI 10.1016/S1286-4579(02)00020-5; Oftung F, 2016, CLIN VACCINE IMMUNOL, V23, P353, DOI 10.1128/CVI.00666-15; Oster P, 2005, VACCINE, V23, P2191, DOI 10.1016/j.vaccine.2005.01.063; Raupach B, 2006, INFECT IMMUN, V74, P4922, DOI 10.1128/IAI.00417-06; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Rondini S, 2013, MICROB PATHOGENESIS, V63, P19, DOI 10.1016/j.micpath.2013.05.014; Sandbu S, 2007, CLIN VACCINE IMMUNOL, V14, P1062, DOI 10.1128/CVI.00094-07; SCHAGER AE, 2018, MBIO, V9, P1, DOI DOI 10.1128/MBIO.02379-015; Schild S, 2009, INFECT IMMUN, V77, P472, DOI 10.1128/IAI.01139-08; Schroeder HA, 2020, MUCOSAL IMMUNOL, V13, P814, DOI 10.1038/s41385-020-0267-9; Secundino I, 2006, IMMUNOLOGY, V117, P59, DOI 10.1111/j.1365-2567.2005.02263.x; Siegernund S, 2007, IMMUNOBIOLOGY, V212, P739, DOI 10.1016/j.imbio.2007.09.004; Sinha R, 2016, IMMUNOBIOLOGY, V221, P839, DOI 10.1016/j.imbio.2016.01.011; Sinha R, 2015, MICROBES INFECT, V17, P215, DOI 10.1016/j.micinf.2014.10.011; STOKES CR, 1975, NATURE, V255, P745, DOI 10.1038/255745a0; Suresh T, 2006, FOOD MICROBIOL, V23, P294, DOI 10.1016/j.fm.2005.04.001; Tennant SM, 2016, VACCINE, V34, P2907, DOI 10.1016/j.vaccine.2016.03.072; Tennant SM, 2015, INFECT IMMUN, V83, P4504, DOI 10.1128/IAI.00924-15; Tsolis RM, 1999, ADV EXP MED BIOL, V473, P261; Veldman, 2006, DRUG DISCOV TODAY TH, V3, P375, DOI DOI 10.1016/J.DDSTR.2006.08.004; Vieira SM, 2009, BRIT J PHARMACOL, V158, P779, DOI 10.1111/j.1476-5381.2009.00367.x; Wallis TS, 2000, MOL MICROBIOL, V36, P997, DOI 10.1046/j.1365-2958.2000.01892.x; WATSON DC, 1992, INFECT IMMUN, V60, P4679, DOI 10.1128/IAI.60.11.4679-4686.1992; Winter SE, 2010, CELL HOST MICROBE, V8, P36, DOI 10.1016/j.chom.2010.06.003; Zhang KY, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004385	62	1	1	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					380	393		10.1016/j.vaccine.2020.11.040			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33303233				2022-04-29	WOS:000604750300029
J	Ribera-Cano, A; Dupont, M; Houze-Cerfon, CH; Houze-Cerfon, V; Hart, A; Hertelendy, AJ; Ciottone, G; Bounes, V				Ribera-Cano, Anna; Dupont, Maud; Houze-Cerfon, Charles-Henri; Houze-Cerfon, Vanessa; Hart, Alexander; Hertelendy, Attila J.; Ciottone, Gregory; Bounes, Vincent			Evaluation of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination: A cross-sectional survey in France	VACCINE			English	Article						Mass vaccination; Mobile unit; COVID-19; Pandemic; Disaster Medicine		Aim of the study: In the context of the worldwide vaccination campaign against COVID-19, France has been deploying multiple sites for mass vaccination. This study aimed to assess the perceived usefulness of a prototype decontamination mobile unit (UMDEO) for COVID-19 vaccination among both the patient and healthcare providers perspectives. Methods: This was a descriptive cross-sectional study conducted in Toulouse over two days. UMDEO is a fully comprehensive, versatile solution that was deployed as a 5-row vaccination unit. A written ques-tionnaire was distributed from March 6th-7th, 2021 among all patients presenting for vaccination at the mobile center, as well as the team participating in the vaccination campaign. Results: Among the vaccinated patients (n = 1659), 1409 participants (84.9%) filled out the survey, as well as 68 out of 85 (80%) within the UMDEO team. The maximum patient rate was 98 people per hour. The majority of participants and caregivers (1307 [93.2%] and 67 [98.5%] respectively) agreed that the mobile unit increased access to vaccination. A total of 91.3% patients (n = 1281) and 95.6% caregivers (n = 65) believed that it would speed up the overall vaccination campaign. Conclusion: The majority of the vaccinated population and of the team participating in the survey were satisfied with the usefulness of UMDEO as a vaccination center. Toulouse is currently the only city to have used such a structure for vaccination, but it could be used as a basis for planning other mobile units to increase vaccination access. (c) 2021 Elsevier Ltd. All rights reserved.	[Ribera-Cano, Anna; Bounes, Vincent] Toulouse Univ Hosp, Disaster Med Unit, SAMU 31, F-31059 Toulouse, France; [Dupont, Maud; Houze-Cerfon, Charles-Henri; Houze-Cerfon, Vanessa] Toulouse UniversiCty Hosp, Emergency Dept, F-31059 Toulouse, France; [Houze-Cerfon, Charles-Henri] Univ Hosp Toulouse, Toulouse Inst Simulat Healthcare, Inst Toulousain Simulat Sante, ItSimS, Toulouse, France; [Hart, Alexander; Hertelendy, Attila J.; Ciottone, Gregory] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA		Houze-Cerfon, V (通讯作者)，Toulouse Univ Hosp, Emergency Dept, F-31059 Toulouse, France.	houze-cerfon.v@chu-toulouse.fr		CIOTTONE, MD, GREGORY R/0000-0002-3313-1379			Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], 2021, LES ECHOS; Asgary A, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040469; Bagcchi S, 2021, LANCET INFECT DIS, V21, P323, DOI 10.1016/S1473-3099(21)00081-5; Cavailler P, 2006, VACCINE, V24, P4890, DOI 10.1016/j.vaccine.2005.10.006; Chen SM, 2020, LANCET, V395, P1305, DOI 10.1016/S0140-6736(20)30744-3; Deceuninck G, 2019, VACCINE, V37, P4243, DOI 10.1016/j.vaccine.2019.06.021; Frederiksen LSF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01817; Goralnick E, 2021, NEW ENGL J MED, V384, pE67, DOI 10.1056/NEJMp2102535; Grabenstein JD, 2006, CURR TOP MICROBIOL, V304, P31; Heymann DL, 2006, CURR TOP MICROBIOL, V304, P1; Hosangadi D, 2020, HEALTH SECUR, V18, P473, DOI 10.1089/hs.2019.0146; Hosangadi D, 2020, VACCINE, V38, P4167, DOI 10.1016/j.vaccine.2020.04.037; Hudson Timothy L, 2003, Disaster Manag Response, V1, P110, DOI 10.1016/j.dmr.2003.10.001; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Mills MC, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100674; Pateron D, 2013, ANN FR MED URGENCE, V3, P69, DOI 10.1007/s13341-013-0294-1; Plotkin S. A., 2006, MASS VACCINATION GLO; Rahi M, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100501; Repplinger MD, 2017, WEST J EMERG MED, V18, P1068, DOI 10.5811/westjem.2017.7.33664; Ribordy P, 2012, PREHOSP DISASTER MED, V27, P425, DOI 10.1017/S1049023X12001033; Wiler JL, 2010, ANN EMERG MED, V55, P142, DOI 10.1016/j.annemergmed.2009.05.021	22	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7441	7445		10.1016/j.vaccine.2021.10.080		DEC 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	34782160	Green Published, Bronze			2022-04-29	WOS:000731300100013
J	Fan, ST; Li, DD; Zhao, H; Yu, L; Cui, PF; Wang, LC; Zhang, Y; Liao, Y; Xu, XL; Jiang, GR; Li, QH				Fan, Shengtao; Li, Dandan; Zhao, Heng; Yu, Li; Cui, Pingfang; Wang, Lichun; Zhang, Ying; Liao, Yun; Xu, Xingli; Jiang, Guorun; Li, Qihan			Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine	VACCINE			English	Article						SARS-CoV-2; Antibody; Antigen inoculation; Intradermal immunization	TUBERCULIN	In clinical trials, antibodies against SARS-CoV-2 were almost eliminated in participants six months after immunization with an inactivated SARS-CoV-2 vaccine. The short duration of antibody persistence is an urgent problem. In this study, the problem was solved by intradermal inoculation with trace antigen. Within 72 h after intradermal inoculation, slight inflammatory reactions, such as redness and swelling, were observed at the inoculation site of the participants. On the 7th, 60th and 180th days after inocula-tion, the antibodies of the participants were detected, and it was found that the neutralizing antibody and ELISA (IgGs) anti-S antibody levels rapidly increased and were maintained for 6 months. These results indicate that there was a SARS-CoV-2-specific immune response in the participants immunized with an inactivated SARS-CoV-2 vaccine, which could be quickly and massively activated by intradermal trace antigen inoculation to produce an effective clinically protective effect. (c) 2021 Elsevier Ltd. All rights reserved.	[Fan, Shengtao; Li, Dandan; Zhao, Heng; Yu, Li; Cui, Pingfang; Wang, Lichun; Zhang, Ying; Liao, Yun; Xu, Xingli; Jiang, Guorun; Li, Qihan] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China		Li, QH (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China.	liqihan@imbcams.com.cn			Yunnan Health Training Project for High Level Talents [H-2017035]; Yunnan Fundamental Research Projects [202001AS070047, 2019FB101]; Yunnan Province technology innovation talent training object project [202005AD160006]; Major Science and Technology Special Projects of Yunnan Province [202002AA100009]; Yunnan Key Laboratory of Vaccine Research & Development in Severe Infectious Diseases	This study was supported by the Yunnan Health Training Project for High Level Talents (H-2017035) . This study was supported by the Yunnan Fundamental Research Projects (grant No. 202001AS070047 and 2019FB101) and Yunnan Province technology innovation talent training object project (202005AD160006) . This study was funded by the Major Science and Technology Special Projects of Yunnan Province (202002AA100009) and funds from the Yunnan Key Laboratory of Vaccine Research & Development in Severe Infectious Diseases.	ASKENASE PW, 1976, J CLIN INVEST, V58, P1145, DOI 10.1172/JCI108567; Awadasseid A, 2021, INT J BIOL SCI, V17, P8, DOI 10.7150/ijbs.52569; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Castro-Rodriguez JA, 2007, T ROY SOC TROP MED H, V101, P493, DOI 10.1016/j.trstmh.2006.08.003; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; Commandeur S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099203; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kim E, 2021, EUR J IMMUNOL, V51, P1774, DOI 10.1002/eji.202149167; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Liao GY, 2016, J INFECT DIS, V214, P1728, DOI 10.1093/infdis/jiw433; Liao Y, 2021, EMERG MICROBES INFEC, V10, P1112, DOI 10.1080/22221751.2021.1937328; McNeil MM, 2018, J ALLERGY CLIN IMMUN, V141, P463, DOI 10.1016/j.jaci.2017.12.971; Pu J, 2021, VACCINE, V39, P2746, DOI 10.1016/j.vaccine.2021.04.006; Soysal A, 2005, LANCET, V366, P1443, DOI 10.1016/S0140-6736(05)67534-4; Thom ML, 2006, VET IMMUNOL IMMUNOP, V114, P25, DOI 10.1016/j.vetimm.2006.07.001; Ura T, 2021, VACCINE, V39, P197, DOI 10.1016/j.vaccine.2020.11.054; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923	19	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 26	2021	39	48					6980	6983		10.1016/j.vaccine.2021.10.043		NOV 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XB3QQ	34732278	Bronze, Green Published			2022-04-29	WOS:000721246800004
J	Ayaz, S; Dibben, O; Chapman, D				Ayaz, Sameer; Dibben, Oliver; Chapman, David			Presence of defective viral genes in H1N1 live attenuated influenza vaccine strains is not associated with reduced human cell fitness or vaccine effectiveness	VACCINE			English	Article						Influenza Virus; Live Attenuated Influenza Vaccine; Defective Viral Genomes; Vaccine Effectiveness; Defective Interfering Particles; Flumist; Fluenz	A VIRUS; RNA; REPLICATION; GENERATION; PARTICLES; TIME	In the 2013-2014 and 2015-2016 seasons, quadrivalent live attenuated influenza vaccine (LAIV) showed reduced pandemic 2009 H1N1 (A/H1N1pdm09) vaccine effectiveness (VE) in the U.S. Impaired fitness of A/H1N1pdm09 LAIV strains in primary human nasal epithelial cells (hNEC) was subsequently shown to be associated with reduced VE. As defective viral genes (DVG) have been detected in QLAIV, it was hypothesised that these might play a role in reduced A/H1N1pdm09 fitness. By applying RT-PCR based approaches, DVG for PB2, PB1 and PA segments were detected in all influenza A LAIV strains tested. Absolute quantification of PA vRNA as a biomarker, using a novel digital RT-PCR assay (RT-dPCR), showed that DVG were a minority population (between 10.2 and 27.8 % of PA vRNA) in LAIV, irrespective of subtype or VE. Importantly, no difference was observed between the fitter pre-2009 H1N1 A/New Caledonia/20/1999 (A/NC99) and less fit A/H1N1pdm09 A/Bolivia/509/2013 (A/BOL13), containing medians of 16.0 % and 10.2 % PA DVG, respectively. Manipulating propagation conditions and minimising A/ BOL13 PA DVG to 5.2 % failed to improve viral replication in hNEC, suggesting DVG were not limiting A/BOL13 fitness. Conversely, DVG were able to reduce A/NC99 replication in hNEC to A/BOL13-like levels, but only by enrichment of PA DVG to 66.5 % of vRNA. Notably, this required LAIV propagation under conditions markedly different to those used for vaccine production. We conclude from these data that abundance of DVG in QLAIV is not associated with variations in influenza A VE and that the reduced fitness of A/BOL13 previously described was not driven by the presence of DVG. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Ayaz, Sameer; Dibben, Oliver; Chapman, David] AstraZeneca, Biopharmaceut R&D, Liverpool, Merseyside, England		Ayaz, S (通讯作者)，AstraZeneca, Unit 6 Renaissance Way,Speke, Liverpool L24 9JW, Merseyside, England.	sameer.ayaz@astrazeneca.com					Alnaji FG, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008436; Basu AS, 2017, SLAS TECHNOL, V22, P369, DOI 10.1177/2472630317705680; Baum A, 2010, P NATL ACAD SCI USA, V107, P16303, DOI 10.1073/pnas.1005077107; Bosma TJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216944; Caspard H, 2016, VACCINE, V34, P5066, DOI 10.1016/j.vaccine.2016.08.079; Chan W, 2008, VIROLOGY, V380, P304, DOI 10.1016/j.virol.2008.07.027; Cheng X, 2012, VIROLOGY, V432, P91, DOI 10.1016/j.virol.2012.06.002; Dadonaite B, 2019, NAT MICROBIOL, V4, P1781, DOI 10.1038/s41564-019-0513-7; DAVIS AR, 1979, P NATL ACAD SCI USA, V76, P3092, DOI 10.1073/pnas.76.7.3092; DAVIS AR, 1980, P NATL ACAD SCI-BIOL, V77, P215, DOI 10.1073/pnas.77.1.215; DEBORDE DC, 1988, VIROLOGY, V163, P429, DOI 10.1016/0042-6822(88)90284-X; Dibben O, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00300-z; Diefenbacher M, 2018, CURR OPIN VIROL, V33, P42, DOI 10.1016/j.coviro.2018.07.002; Dimmock NJ, 2017, LANCET INFECT DIS, V17, P1234, DOI 10.1016/S1473-3099(17)30637-0; Dimmock NJ, 2014, J VIROL, V88, P5217, DOI 10.1128/JVI.03193-13; Dimmock NJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049394; Duhaut SD, 2003, J VIROL METHODS, V108, P75, DOI 10.1016/S0166-0934(02)00260-4; Fodor E, 2003, J VIROL, V77, P5017, DOI 10.1128/JVI.77.8.5017-5020.2003; Frensing T, 2014, APPL MICROBIOL BIOT, V98, P8999, DOI 10.1007/s00253-014-5933-y; Gaspard N, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx111; Gould PS, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100269; Hawksworth A, 2020, VACCINE, V38, P4209, DOI 10.1016/j.vaccine.2020.04.004; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Hoft DF, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00414-16, 10.1128/cvi.00414-16]; Hutchinson EC, 2010, J GEN VIROL, V91, P313, DOI 10.1099/vir.0.017608-0; Jin H, 2003, VIROLOGY, V306, P18, DOI 10.1016/S0042-6822(02)00035-1; Le Sage V, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107823; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MAASSAB HF, 1967, NATURE, V213, P612, DOI 10.1038/213612a0; Meng B, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0805-6; Miyamoto S., 2020, BIORXIV 2020 P 20200; Noda T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02517-w; Nogales A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010020; Parker L, 2019, VACCINE, V37, P4543, DOI 10.1016/j.vaccine.2019.06.016; Rhorer J, 2009, VACCINE, V27, P1101, DOI 10.1016/j.vaccine.2008.11.093; Russell AB, 2019, J VIROL, V93, DOI 10.1128/JVI.00500-19; Saira K, 2013, J VIROL, V87, P8064, DOI 10.1128/JVI.00240-13; Sun JY, 2020, PLOS PATHOG, V16, DOI [10.1371/journal.ppat.1008671, 10.1371/journal.ppat.1008671.r001, 10.1371/journal.ppat.1008671.r002, 10.1371/journal.ppat.1008671.r003]; te Velthuis AJW, 2018, NAT MICROBIOL, V3, P1234, DOI 10.1038/s41564-018-0240-5; Von Magnus P, 1947, ARK KEM MINERAL GEOL, V8; Wang J, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00766; WHO, 2018, WHO FACT SHEET INFL	42	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 5	2021	39	46					6735	6745		10.1016/j.vaccine.2021.10.011		NOV 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YJ0BG	34663504	hybrid			2022-04-29	WOS:000744203800004
J	Khaimova, R; Fischetti, B; Cope, R; Berkowitz, L; Bakshi, A				Khaimova, Rebecca; Fischetti, Briann; Cope, Rebecca; Berkowitz, Leonard; Bakshi, Anjali			Serological response with Heplisav-B (R) in prior Hepatitis B vaccine non-responders living with HIV	VACCINE			English	Article						HIV; Hepatitis B Virus; Vaccine; Non-responders; Immunity; Hepatitis B antibodies	INFECTED PATIENTS; VIRUS INFECTION; IMMUNOGENICITY; SAFETY	Background: As people living with HIV (PLWH) are at risk for contracting Hepatitis B Virus (HBV), they should be screened for HBV and vaccinated if not immune. Seroconversion rates in PLWH receiving traditional recombinant HBV vaccines (Engerix-B (R) and Recombivax-HB (R)) have historically been low with at most 70% achieving immunity. In 2017, a recombinant, adjuvanted HBV vaccine (Heplisav-B (R)) was approved for use in HIV-negative patients. Heplisav-B (R) has shown superior seroprotection in this population compared to Engerix-B (R) and Recombivax-HB (R), as well as interim analysis showing higher seropositivity rates in patients undergoing dialysis. However, its efficacy in PLWH is currently unknown. This study evaluates the rate of seroconversion following Heplisav-B (R) administration in PLWH with previous HBV vaccination failure. Methods: Retrospective, cross-sectional study at The Brooklyn Hospital Center's HIV primary care clinic in Brooklyn, NY. HIV-positive adults who received at least two doses of Heplisav-B (R) and had previously failed to seroconvert after vaccination with Engerix-B (R) or Recombivax-HB (R) were included. The primary outcome is the percentage of PLWH who became seropositive following Heplisav-B (R). Results: A total of 67 patients met the inclusion criteria. Twenty-five (37.3%) PLWH had failed at least 2 courses of recombinant vaccines. Fifty-eight (86.6%) PLWH became seropositive (Anti-HBs > 10 mIU/mL) at least two months after completing Heplisav-B (R). For the 9 (13.4%) patients that did not develop immunity, 3 (33%) had a detectable HIV RNA and 3 (33%) had a CD4 count < 200 cells/uL(3). Conclusions: Heplisav-B (R) was highly effective in achieving immunity to HBV in PLWH who failed non-adjuvanted recombinant vaccines. (C) 2021 Elsevier Ltd. All rights reserved.	[Khaimova, Rebecca; Fischetti, Briann; Cope, Rebecca] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Pharm Practice, 1 Univ Plaza, Brooklyn, NY 11201 USA; [Fischetti, Briann; Cope, Rebecca; Berkowitz, Leonard; Bakshi, Anjali] Brooklyn Hosp Ctr, Div Infect Dis, 121 Dekalb Ave, Brooklyn, NY 11201 USA		Khaimova, R (通讯作者)，1 Univ Plaza, Brooklyn, NY 11201 USA.	Rkhaimova@gmail.com; briann.fischetti@liu.edu; Rebecca.cope@liu.edu; lberkowitz@tbh.org; Abakshi@tbh.org		Fischetti, Briann/0000-0003-3758-0590; Cope, Rebecca/0000-0001-9962-0995			Adapted from the National Institute of Allergy and Infectious Diseases, 2018, UND VACC WORK; [Anonymous], Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluation Heplisav-B in Patients Undergoing Hemodialysis; [Anonymous], 2014, REC HB PACK INS; [Anonymous], 2017, WHO GUID HEP B C TES; [Anonymous], 2017, HEPL B PACK INS; [Anonymous], HIV and Chronic Kidney Disease: What You Need to Know; [Anonymous], CpG 1018, Dynavax's proprietary toll-like receptor 9 (TLR9) agonist adjuvant; [Anonymous], Dynavax Announces Heplisav-B Post-Marking Requirement Interim Report Completed; [Anonymous], PREVENTION HEPATITIS; [Anonymous], 2016, ENG B PACK INS; Ballocca F, 2017, TRENDS CARDIOVAS MED, V27, P558, DOI 10.1016/j.tcm.2017.06.005; BRUGUERA M, 1992, J CLIN GASTROENTEROL, V14, P27, DOI 10.1097/00004836-199201000-00007; CDC, 2018, VIR HEP SURV US; Chaiklang K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080409; Dynavax Technologies Corporation, 2017, M VACC REL BIOL PROD; Halperin SA, 2012, VACCINE, V30, P2556, DOI 10.1016/j.vaccine.2012.01.087; Heyward WL, 2013, VACCINE, V31, P5300, DOI 10.1016/j.vaccine.2013.05.068; Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038; Kourtis AP, 2012, NEW ENGL J MED, V366, P1749, DOI 10.1056/NEJMp1201796; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; LeFevre ML, 2014, ANN INTERN MED, V161, P58, DOI 10.7326/M14-1018; Lo Re V, 2008, J CLIN VIROL, V43, P32, DOI 10.1016/j.jcv.2008.03.030; Mast Eric E., 2006, Morbidity and Mortality Weekly Report, V55, P1; National Institute of Allergy and Infectious Diseases, B ENH HBV VACC PERS; Palacios R, 2008, HIV CLIN TRIALS, V9, P337, DOI 10.1310/hct0905-337; Panel on Opportunistic Infections in HIV-infected Adults and Adolescents, GUIDELINES PREVENTIO; Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X; Thio CL, 2009, HEPATOLOGY, V49, pS138, DOI 10.1002/hep.22883	28	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 22	2021	39	44					6529	6534		10.1016/j.vaccine.2021.09.050		OCT 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WX9RH	34600748				2022-04-29	WOS:000718925300011
J	Park, SJ; Kang, YM; Cho, HK; Kim, DY; Kim, S; Bae, Y; Kim, J; Kim, G; Lee, YJ; Kang, HM				Park, Seo-jeong; Kang, Yong-Myung; Cho, Hyun-Kyu; Kim, Do-Young; Kim, Sungyeop; Bae, Youchan; Kim, Jongho; Kim, Gyeongyeob; Lee, Youn-Jeong; Kang, Hyun-Mi			Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice	VACCINE			English	Article						Y280 lineage; Y439 lineage; Vaccine; Immunogenicity; Protective efficacy; Mice	AVIAN INFLUENZA; NEUTRALIZING ANTIBODY; A-VIRUS; H5N1; ASSAYS; CHICKENS; IMMUNITY	Since June 2020, the Y280 lineage H9N2 virus, which is distinct from the previously endemic Y439 lineage, has been circulating in poultry in Korea. In this study, we developed two whole inactivated vaccines, rgHS314 and vac564, against the Y280 and Y439 lineages, respectively, and evaluated their immunogenicity and protective efficacy against homologous or heterologous viral challenge in mice. Serum neutralizing antibody titers in the rgHS314-vaccinated group were higher (68 +/- 8.4 10log(2)) than in the vac564-vaccinated group (18 +/- 8.4 10log(2)). In homologous challenge, rgHS314 conferred 100% protection, with no severe clinical signs, no body weight loss, and no viral replication in any tissues tested except the nasal turbinate. Viral replication in the lungs at 1, 3, 5, and 7 days post-infection (dpi) was significantly lower than in the sham group (p < 0.01). By contrast, all mice in the sham group were dead by 8 dpi with severe clinical signs and weight loss. Likewise, vac564 conferred 100% protection with no weight loss and with significantly lower viral replication in the lung than in the sham group at 3 dpi (p < 0.01). However, both vaccines showed partial protection in heterologous challenge. Our results suggest that both the rgHS314 and vac564 vaccines could be candidate vaccines for further evaluation in humans. (C) 2021 Elsevier Ltd. All rights reserved.	[Park, Seo-jeong; Kang, Yong-Myung; Cho, Hyun-Kyu; Kim, Do-Young; Kim, Sungyeop; Bae, Youchan; Kim, Jongho; Kim, Gyeongyeob; Lee, Youn-Jeong; Kang, Hyun-Mi] Anim & Plant Quarantine Agcy, Gimcheon, South Korea		Kang, HM (通讯作者)，Anim & Plant Quarantine Agcy, Avian Influenza Res & Diagnost Div, 177 Hyeoksin 8-Ro, Gimcheon Si 39660, Gyeongsangbuk D, South Korea.	greenkang@korea.kr		Kim, Gyeongyeob/0000-0002-7972-1446; Park, Seo-jeong/0000-0002-3411-3498	Animal and Plant Quarantine Agency of the Republic of Korea [B-1543418-2020-22-01]	This research was supported by a grant (B-1543418-2020-22-01) from the Animal and Plant Quarantine Agency of the Republic of Korea.	Adlhoch C, AVIAN INFLUENZA OVER; Adlhoch C, 2021, EFSA J, V19, DOI 10.2903/j.efsa.2021.6497; APH, 2021, H7N9 SIT UPD; Choi JG, 2008, J VET SCI, V9, P67, DOI 10.4142/jvs.2008.9.1.67; Fellahi S, 2021, AVIAN DIS, V65, P46, DOI 10.1637/aviandiseases-D-20-00067; Han DP, 2016, INFLUENZA OTHER RESP, V10, P57, DOI 10.1111/irv.12334; Kaufmann L, 2017, JOVE-J VIS EXP, DOI 10.3791/55833; Kim HM, 2020, VACCINE, V38, P6080, DOI 10.1016/j.vaccine.2020.07.033; Lee DH, 2016, VIROLOGY, V488, P225, DOI 10.1016/j.virol.2015.11.023; Lee DH, 2011, VACCINE, V29, P4003, DOI 10.1016/j.vaccine.2011.03.067; Lin YP, 2000, P NATL ACAD SCI USA, V97, P9654, DOI 10.1073/pnas.160270697; Liu LT, 2019, VIROLOGY, V529, P7, DOI 10.1016/j.virol.2019.01.004; Louisirirotchanakul S, 2007, J CLIN MICROBIOL, V45, P2284, DOI 10.1128/JCM.00921-07; Mo IP, 2003, AVIAN DIS, V47, P182; NCIRD, 2017, INFL TYP VIR; Nogales A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010020; OIE, 2004, MANUAL DIAGNOSTIC TE, V5th; Pawar SD, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-251; Peacock TP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070620; Philippon DAM, 2020, J INFECT DIS, V222, P528, DOI 10.1093/infdis/jiaa105; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Song CL, 2020, POULTRY SCI, V99, P4334, DOI 10.1016/j.psj.2020.06.012; Song MS, 2013, J GEN VIROL, V94, P1230, DOI 10.1099/vir.0.051284-0; Song WJ, 2020, ZOONOSES PUBLIC HLTH, V67, P203, DOI 10.1111/zph.12685; Stephenson I, 2007, VACCINE, V25, P4056, DOI 10.1016/j.vaccine.2007.02.039; Swayne D. E., 2016, Animal influenza, P378; Swayne DE, 2009, COMP IMMUNOL MICROB, V32, P351, DOI 10.1016/j.cimid.2008.01.006; Swayne DE, 2006, ANN NY ACAD SCI, V1081, P174, DOI 10.1196/annals.1373.021; Talat S, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10101875; Tian GB, 2005, VIROLOGY, V341, P153, DOI 10.1016/j.virol.2005.07.011; Trombetta C M, 2018, J Prev Med Hyg, V59, pE1, DOI 10.15167/2421-4248/jpmh2018.59.1.870; Truelove S, 2016, INFLUENZA OTHER RESP, V10, P518, DOI 10.1111/irv.12408; Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12; Wood JM, 2012, VACCINE, V30, P210, DOI 10.1016/j.vaccine.2011.11.019; World Health Organization, 2020, CUM NUMB CONF HUM CA; World Health Organization, 2016, INFL HUM AN INT SUMM; Youk SS, 2020, EMERG MICROBES INFEC, V9, P616, DOI 10.1080/22221751.2020.1738903; Zhu HP, 2011, VACCINE, V29, P5421, DOI 10.1016/j.vaccine.2011.05.067	39	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6213	6220		10.1016/j.vaccine.2021.09.028		SEP 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34556363				2022-04-29	WOS:000705822100008
J	Malo, JA; Ware, RS; Lambert, SB				Malo, Jonathan A.; Ware, Robert S.; Lambert, Stephen B.			Estimating the risk of recurrent invasive pneumococcal disease in Australia, 1991-2016	VACCINE			English	Article						Invasive pneumococcal disease; Recurrence risk; Surveillance; Vaccines; Policy	CONJUGATE VACCINE; CHILDREN; BACTEREMIA; IMMUNODEFICIENCY; POPULATION; INFECTIONS; NATIONWIDE; ENGLAND	Background: Individuals who experience an initial episode of invasive pneumococcal disease (IPD) are at increased risk of recurrent episodes. However, the magnitude of risk has not been well-quantified in the pneumococcal conjugate vaccine era. Individuals with a previous episode of IPD are not commonly identified as a high-risk group in vaccination guidelines. Methods: Australian residents with at least one case of IPD between 1991 and 2016 were identified using routine public health surveillance data which included identified IPD risk factors. Incidence of recurrent IPD was calculated from 2001 onwards (after IPD became nationally notifiable) using time-to-event analyses with individuals contributing person-time at risk of recurrence if they survived greater than 14 days after initial episode onset. Results: From 1991 to 2016 there were 28,809 IPD episodes in 28,218 individuals. A total of 512 (1.8%) persons experienced 591 recurrent episodes. From 2001 to 2016 the incidence of recurrent IPD was 216.2 per 100,000 person-years, 27 times greater than the population rate of primary IPD during this period (8.0 per 100,000 population per year). Between 2011 and 2016, more than one-quarter of individuals experiencing recurrence had no IPD risk factors identified at first episode. Conclusions: There is substantially increased risk of recurrent IPD after an initial episode. At least one quarter of those with recurrent episodes have no identified risk factors at the initial episode. Given the potential preventability of future episodes, those with a previous IPD episode should be identified as a high-risk group and receive pneumococcal vaccination. Crown Copyright (c) 2021 Published by Elsevier Ltd. All rights reserved.	[Malo, Jonathan A.] Univ Queensland, Sch Populat Hlth, Herston, Qld, Australia; [Ware, Robert S.] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia; [Lambert, Stephen B.] Univ Queensland, Ctr Childrens Hlth Res, South Brisbane, Qld, Australia; [Lambert, Stephen B.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia		Lambert, SB (通讯作者)，Univ Queensland, Ctr Childrens Hlth Res, South Brisbane, Qld, Australia.	j.malo@uq.edu.au; sblambert@uq.edu.au	Lambert, Stephen/B-8348-2008; Ware, Robert/B-2024-2014	Lambert, Stephen/0000-0002-2709-193X; Ware, Robert/0000-0002-6129-6736			Australian Government Department of Health, PNEUM DIS INV CAS DE; Australian Technical Advisory Group on Immunisation (ATAGI), AUSTR IMM HDB RISK C; Backhaus E, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1648-2; Butters C, 2019, JAMA PEDIATR, V173, P1084, DOI 10.1001/jamapediatrics.2019.3203; Centers for Disease Control and Prevention, PNEUM VACC REC; Centers for Disease Control and Prevention, 2016, ABCS REP STREPT PNEU; Coccia MR, 1998, CLIN INFECT DIS, V26, P982, DOI 10.1086/513924; Einarsdottir HM, 2005, CLIN MICROBIOL INFEC, V11, P744, DOI 10.1111/j.1469-0691.2005.01221.x; Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368; Font B, 2001, EUR J CLIN MICROBIOL, V20, P636; Gaschignard J, 2014, CLIN INFECT DIS, V59, P244, DOI 10.1093/cid/ciu274; Government of Canada, PNEUM VACC CAN IMM G; Hull B, 2019, COMMUN DIS INTELL, V43, DOI 10.33321/cdi.2019.43.47; Hull B, 2009, COMMUN DIS INTELL, V33, P170; Ingels H, 2015, PEDIATR INFECT DIS J, V34, P644, DOI 10.1097/INF.0000000000000701; Ingels H, 2014, SCAND J INFECT DIS, V46, P265, DOI 10.3109/00365548.2013.877156; Jayasinghe S, 2017, CLIN INFECT DIS, V64, P175, DOI 10.1093/cid/ciw720; King MD, 2003, CLIN INFECT DIS, V37, P1029, DOI 10.1086/377736; Ladhani SN, 2013, EMERG INFECT DIS, V19, P61, DOI 10.3201/eid1901.120741; LEE W, 1994, PEDIATR INFECT DIS J, V13, P231, DOI 10.1097/00006454-199403000-00014; Malo JA, 2017, THESIS AUSTR NATL U; Mason EO, 2007, PEDIATR INFECT DIS J, V26, P480, DOI 10.1097/INF.0b013e31805ce277; McEllistrem MC, 2002, J INFECT DIS, V185, P1364, DOI 10.1086/339882; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Mufson MA, 2012, AM J MED SCI, V343, P303, DOI 10.1097/MAJ.0b013e31822d9860; National Centre for Immunisation Research and Surveillance, SIGN EV PNEUM VACC P; Orlicek SL, 1997, J PEDIATR-US, V130, P284, DOI 10.1016/S0022-3476(97)70356-1; Pedersen RH, 2011, HIV MED, V12, P323, DOI 10.1111/j.1468-1293.2010.00892.x; Public Health England, IMMUNISATION INFECT; Rock C, 2013, EUR J CLIN MICROBIOL, V32, P1135, DOI 10.1007/s10096-013-1859-z; RodriguezCreixems M, 1996, ARCH INTERN MED, V156, P1429, DOI 10.1001/archinte.156.13.1429; Sanz JC, 2014, INFECTION, V42, P475, DOI 10.1007/s15010-013-0571-3; Takashima M, 2019, VACCINE, V37, P1638, DOI 10.1016/j.vaccine.2019.01.085; Turett GS, 2001, ARCH INTERN MED, V161, P2141, DOI 10.1001/archinte.161.17.2141; van Aalst M, 2018, TRAVEL MED INFECT DI, V24, P89, DOI 10.1016/j.tmaid.2018.05.016; Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7	36	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5748	5756		10.1016/j.vaccine.2021.08.095		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34483025				2022-04-29	WOS:000697501500006
J	Zaman, K; Kovacs, SD; Vanderende, K; Aziz, A; Yunus, M; Khan, S; Snider, CJ; An, Q; Estivariz, CF; Oberste, MS; Pallansch, MA; Anand, A				Zaman, Khalequ; Kovacs, Stephanie D.; Vanderende, Kristin; Aziz, Asma; Yunus, Mohammed; Khan, Sara; Snider, Cynthia J.; An, Qian; Estivariz, Concepcion F.; Oberste, M. Steven; Pallansch, Mark A.; Anand, Abhijeet			Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial	VACCINE			English	Article						Poliovirus; Inactivated poliovirus vaccine; Immunization schedule	POLIOMYELITIS; COVERAGE	Background: After global oral poliovirus vaccine (OPV) cessation, the Strategic Advisory Group of Experts on Immunization (SAGE) currently recommends a two-dose schedule of inactivated poliovirus vaccine (IPV) beginning >14-weeks of age to achieve at least 90% immune response. We aimed to compare the immunogenicity of three different two-dose IPV schedules started before or at 14-weeks of age. Methods: We conducted a randomized, controlled, open-label, inequality trial at two sites in Dhaka, Bangladesh. Healthy infants at 6-weeks of age were randomized into one of five arms to receive two dose IPV schedules at different ages with and without OPV. The three IPV-only arms are presented: Arm C received IPV at 14-weeks and 9-months; Arm D received IPV at 6-weeks and 9-months; and Arm E received IPV at 6 and 14-weeks. The primary outcome was immune response defined as seroconversion from seronegative (<1:8) to seropositive (>1:8) after vaccination, or a four-fold rise in antibody titers and median reciprocal antibody titers to all three poliovirus types measured at 10-months of age. Findings: Of the 987 children randomized to Arms C, D, and E, 936 were included in the intention-to-treat analysis. At 10-months, participants in Arm C (IPV at 14-weeks and 9-months) had >99% cumulative immune response to all three poliovirus types which was significantly higher than the 77-81% observed in Arm E (IPV at 6 and 14-weeks). Participants in Arm D (IPV at 6-weeks and 9-months) had cumulative immune responses of 98-99% which was significantly higher than that of Arm E (p value < 0.0001) but not different from Arm C. Interpretation: Results support current SAGE recommendations for IPV following OPV cessation and provide evidence that the schedule of two full IPV doses could begin as early as 6-weeks. (c) 2021 Published by Elsevier Ltd.	[Zaman, Khalequ; Aziz, Asma; Yunus, Mohammed] Int Ctr Diarrhea Dis Bangladesh Icddr B, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh; [Kovacs, Stephanie D.; Vanderende, Kristin; Khan, Sara; Snider, Cynthia J.; An, Qian; Estivariz, Concepcion F.; Oberste, M. Steven; Pallansch, Mark A.; Anand, Abhijeet] Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA		Kovacs, SD (通讯作者)，Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.	uxv4@cdc.gov	AZIZ, ASMA/AAN-5947-2020	AZIZ, ASMA/0000-0003-0203-5744	Global Immunization Division of the CDC	The study was funded by the Global Immunization Division of the CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. icddr,b acknowledges with gratitude the commitment of CDC to its research efforts. icddr,b is also grateful to the Govern-ments of Bangladesh, Canada, Sweden, and the UK for providing core and unrestricted support. We thank the study staff at the Mir- pur and Mohakhali sites in Dhaka, Bangladesh; Will Weldon and the Population Immunity Laboratory Team for processing and test-ing the samples at the Polio and Picornavirus Laboratory Branch in the CDC; Warda Haque and Mahmuda Khatun for preparing the samples at icddr,b; Kathleen Wannemuehler for design and statis-tical support during protocol development; and all parents and infants who participated in this study. We would like to thank Sanofi Pasteur for donation of study vaccine.	Adams A, 2015, SCIENCE, V350, P609, DOI 10.1126/science.aad7294; Anand A, 2015, VACCINE, V33, P6816, DOI 10.1016/j.vaccine.2015.09.039; Anand A, 2014, J INFECT DIS, V210, pS465, DOI 10.1093/infdis/jiu343; [Anonymous], 2013, WEEKLY EPIDEMIOLOGIC, V89, P20; [Anonymous], 2017, WEEKLY EPIDEMIOLOGIC, V92, P301; Asturias EJ, 2016, LANCET, V388, P158, DOI 10.1016/S0140-6736(16)00703-0; Bandyopadhyay AS, 2021, LANCET INFECT DIS, V21, P559, DOI 10.1016/S1473-3099(20)30555-7; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P222; de Onis Mercedes, 2004, Food Nutr Bull, V25, pS27; Galindo M, 2007, NEW ENGL J MED, V356, P1536, DOI 10.1056/NEJMoa054960; Global Polio Eradication Initiative, 2015, BACKGR TECHN RAT INT; Global Polio Erradication Iniative, 2019, 20 M GLOB COMM CERT; Hampton LM, 2016, MMWR-MORBID MORTAL W, V65, P934, DOI 10.15585/mmwr.mm6535a3; Kew O, 2002, SCIENCE, V296, P356, DOI 10.1126/science.1068284; Mohammed AJ, 2010, NEW ENGL J MED, V362, P2351, DOI 10.1056/NEJMoa0909383; Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Resik S, 2013, NEW ENGL J MED, V368, P416, DOI 10.1056/NEJMoa1202541; Snider CJ, 2019, LANCET, V393, P2624, DOI 10.1016/S0140-6736(19)30503-3; Weldon WC, 2016, METHODS MOL BIOL, V1387, P145, DOI 10.1007/978-1-4939-3292-4_8	20	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5814	5821		10.1016/j.vaccine.2021.08.065		SEP 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34481702				2022-04-29	WOS:000697501500014
J	Liu, SR; Liu, JL				Liu, Siru; Liu, Jialin			Public attitudes toward COVID-19 vaccines on English-language Twitter: A sentiment analysis	VACCINE			English	Article							SOCIAL MEDIA	Objective: To identify themes and temporal trends in the sentiment of COVID-19 vaccine-related tweets and to explore variations in sentiment at world national and United States state levels. Methods: We collected English-language tweets related to COVID-19 vaccines posted between November 1, 2020, and January 31, 2021. We applied the Valence Aware Dictionary and sEntiment Reasoner tool to calculate the compound score to determine whether the sentiment mentioned in each tweet was positive (compound >= 0.05), neutral (-0.05 < compound < 0.05), or negative (compound <= -0.05). We applied the latent Dirichlet allocation analysis to extract main topics for tweets with positive and negative sentiment. Then we performed a temporal analysis to identify time trends and a geographic analysis to explore sentiment differences in tweets posted in different locations. Results: Out of a total of 2,678,372 COVID-19 vaccine-related tweets, tweets with positive, neutral, and negative sentiments were 42.8%, 26.9%, and 30.3%, respectively. We identified five themes for positive sentiment tweets (trial results, administration, life, information, and efficacy) and five themes for negative sentiment tweets (trial results, conspiracy, trust, effectiveness, and administration). On November 9, 2020, the sentiment score increased significantly (score = 0.234, p = 0.001), then slowly decreased to a neutral sentiment in late December and was maintained until the end of January. At the country level, tweets posted in Brazil had the lowest sentiment score of -0.002, while tweets posted in the United Arab Emirates had the highest sentiment score of 0.162. The overall average sentiment score for the United States was 0.089, with Washington, DC having the highest sentiment score of 0.144 and Wyoming having the lowest sentiment score of 0.036. Conclusions: Public sentiment on COVID-19 vaccines varied significantly over time and geography. Sentiment analysis can provide timely insights into public sentiment toward the COVID-19 vaccine and guide public health policymakers in designing locally tailored vaccine education programs. (C) 2021 Elsevier Ltd. All rights reserved.	[Liu, Siru] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN USA; [Liu, Jialin] Sichuan Univ, West China Hosp, Dept Med Informat, Chengdu, Peoples R China; [Liu, Jialin] Sichuan Univ, West China Hosp, Dept Otolaryngol, Chengdu, Peoples R China		Liu, JL (通讯作者)，Sichuan Univ, West China Hosp, Dept Med Informat, Chengdu, Peoples R China.; Liu, JL (通讯作者)，Sichuan Univ, West China Hosp, Dept Otolaryngol, Chengdu, Peoples R China.	siru.liu@vumc.org; dljl8@163.com		Liu, Siru/0000-0002-5003-5354			Agarwal A., 2011, P WORKSH LANG SOC ME, P30; Allen C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157734; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Chou WYS, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1249; Deiner MS, 2019, HEALTH INFORM J, V25, P1116, DOI 10.1177/1460458217740723; Du JC, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.22025; Dubey AD., PUBLIC SENTIMENT ANA, DOI [10.2139/ssrn.3772401, DOI 10.2139/SSRN.3772401]; Grajales FJ, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.2912; Hawn C, 2009, HEALTH AFFAIR, V28, P361, DOI 10.1377/hlthaff.28.2.361; Karafillakis E, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/17149; Killick R, 2012, J AM STAT ASSOC, V107, P1590, DOI 10.1080/01621459.2012.737745; Li Irene, 2020, Artificial Intelligence XXXVII. 40th SGAI International Conference on Artificial Intelligence, AI 2020. Proceedings. Lecture Notes in Artificial Intelligence, Subseries of Lecture Notes in Computer Science (LNCS 12498), P358, DOI 10.1007/978-3-030-63799-6_27; Limb M, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n76; Liu JL, 2020, J MED VIROL, V92, P1484, DOI 10.1002/jmv.25965; Liu JL, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13364; Liu S., 2020, 2020 IEEE INT C MULT, P1, DOI [10.1109/ ICHI48887.2020.9374346, DOI 10.1109/ICHI48887.2020.9374346]; Liu SR, 2021, J MED INTERNET RES, V23, DOI 10.2196/30251; Liu SR, 2021, J MED INTERNET RES, V23, DOI 10.2196/28118; Liu SR, 2021, BMC MED INFORM DECIS, V21, DOI 10.1186/s12911-021-01465-2; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3891; Martin S, 2020, VACCINE, V38, P6627, DOI 10.1016/j.vaccine.2020.07.072; Muller M., 2020, ARXIV200507503; Raghupathi V, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103464; Rosen B, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00440-6; Sinnenberg L, 2017, AM J PUBLIC HEALTH, V107, pE1, DOI 10.2105/AJPH.2016.303512; Ueta CB, 2011, ENDOCRINOLOGY, V152, P3571, DOI 10.1210/en.2011-1066; Valdez D, 2020, J MED INTERNET RES, V22, DOI 10.2196/21418; Wanjoya A., 2015, AM J TH APPL STAT, V4, P581, DOI [10.11648/j.ajtas.20150406.30, DOI 10.11648/J.AJTAS.20150406.30]; WHO, 2020, CLIN MAN SEV AC RESP; Wojcik S., 2019, SIZING TWITTER USERS	30	4	4	12	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5499	5505		10.1016/j.vaccine.2021.08.058		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WC6XU	34452774	Bronze, Green Published			2022-04-29	WOS:000704399700007
J	Britton, KJ; Pickering, JL; Pomat, WS; de Gier, C; Nation, ML; Pell, CL; Granland, CM; Solomon, V; Ford, RL; Greenhill, A; Hinds, J; Moore, HC; Richmond, PC; Blyth, CC; Lehmann, D; Satzke, C; Kirkham, LAS				Britton, Kathryn J.; Pickering, Janessa L.; Pomat, William S.; de Gier, Camilla; Nation, Monica L.; Pell, Casey L.; Granland, Caitlyn M.; Solomon, Vela; Ford, Rebecca L.; Greenhill, Andrew; Hinds, Jason; Moore, Hannah C.; Richmond, Peter C.; Blyth, Christopher C.; Lehmann, Deborah; Satzke, Catherine; Kirkham, Lea-Ann S.		10v13vPCV trial team	Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants	VACCINE			English	Article						Streptococcus pneumoniae; Serotype; Microarray; Pneumococcal conjugate vaccine; Carriage; Papua New Guinea	STREPTOCOCCUS-PNEUMONIAE; CHILDREN; SEROTYPE; COLONIZATION	Background: Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity. This study investigated PCV13 impact on serotype-specific pneumococcal carriage prevalence, density, and serotype diversity in PNG infants, who have some of the highest reported rates of pneumococcal carriage and disease in the world. Methods: Nasopharyngeal swabs were collected at 1, 4 and 9 months of age from PCV13-vaccinated infants (n = 57) and age-/season-matched, unvaccinated infants (at approximately 1 month, n = 53; 4 months, n = 57; 9 months, n = 52). Serotype-specific pneumococcal carriage density and antimicrobial resistance genes were identified by qPCR and microarray. Results: Pneumococci were present in 89% of swabs, with 60 different serotypes and four non-encapsulated variants detected. Multiple serotype carriage was common (47% of swabs). Vaccine type carriage prevalence was similar between PCV13-vaccinated and unvaccinated infants at 4 and 9 months of age. The prevalence of non-vaccine type carriage was also similar between cohorts, with non-vaccine types present in three-quarters of samples (from both vaccinated and unvaccinated infants) by 4 months of age. The median pneumococcal carriage density was high and similar at each age group (similar to 7.0 log(10)-in genome equivalents/mL). PCV13 had no effect on overall pneumococcal carriage density, vaccine type density, non-vaccine type density, or the prevalence of antimicrobial resistance genes. Conclusion: PNG infants experience dense and diverse pneumococcal colonisation with concurrent serotypes from 1 month of age. PCV13 had no impact on pneumococcal carriage density, even for vaccine serotypes. The low prevalence of vaccine serotypes, high pneumococcal carriage density and abundance of non-vaccine serotypes likely contribute to the lack of PCV13 impact on carriage in PNG infants. Indirect effects of the infant PCV programs are likely to be limited in PNG. Alternative vaccines with broader coverage should be considered. (C) 2021 The Authors. Published by Elsevier Ltd.	[Britton, Kathryn J.; Pickering, Janessa L.; Pomat, William S.; de Gier, Camilla; Granland, Caitlyn M.; Moore, Hannah C.; Richmond, Peter C.; Blyth, Christopher C.; Lehmann, Deborah; Kirkham, Lea-Ann S.] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Telethon Kids Inst, Perth, WA, Australia; [Britton, Kathryn J.; de Gier, Camilla; Richmond, Peter C.; Blyth, Christopher C.] Univ Western Australia, Sch Med, Div Paediat, Perth, WA, Australia; [Pomat, William S.; Solomon, Vela; Ford, Rebecca L.] Papua New Guinea Inst Med Res, Goroka, Papua N Guinea; [Nation, Monica L.; Pell, Casey L.; Satzke, Catherine] Murdoch Childrens Res Inst, Translat Microbiol Grp, Melbourne, Vic, Australia; [Greenhill, Andrew] Federat Univ, Sch Hlth & Life Sci, Ballarat, Vic, Australia; [Hinds, Jason] St Georges Univ London, Inst Infect & Immun, London, England; [Blyth, Christopher C.] Perth Childrens Hosp, Dept Paediat Infect Dis, Perth, WA, Australia; [Blyth, Christopher C.] QEII Med Ctr, Dept Microbiol, PathWest Lab Med WA, Perth, WA, Australia; [Satzke, Catherine] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Satzke, Catherine] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Kirkham, Lea-Ann S.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA, Australia		Kirkham, LAS (通讯作者)，Perth Childrens Hosp, Wesfarmers Ctr Vaccine & Infect Dis, Telethon Kids Inst, 15 Hosp Ave, Nedlands, WA 6009, Australia.	kate.britton@telethonkids.org.au; janessa.pikering@telethonkids.org.au; william.pomat@pngimr.org.pg; camilladegier@gmail.com; monica.nation@mcri.edu.au; casey.pell@mcri.edu.au; caitlyn.granland@telethonkids.org.au; veladurimao@gmail.com; rebecca.ford@pngimr.org.pg; andrew.greenhill@federation.edu.au; j.hinds@sghms.ac.uk; hannahmoore@telethonkids.org.au; peter.richmond@uwa.edu.au; christopher.blyth@uwa.edu.au; deborah.lehmann@telethonkids.org.au; catherine.satzke@mcri.edu.au; lea-ann.kirkham@telethonkids.org.au	Pickering, Janessa/L-2231-2019; Richmond, Peter C/G-3379-2012; Moore, Hannah/W-4727-2018	Pickering, Janessa/0000-0002-6441-2456; Richmond, Peter C/0000-0001-7562-7228; Blyth, Christopher Charles/0000-0003-2017-0683; Pell, Casey/0000-0003-3883-2163; Nation, Monica/0000-0002-3027-6919; Moore, Hannah/0000-0001-6434-8290; Britton, Kathryn Jane/0000-0002-8764-8293; Granland, Caitlyn/0000-0003-4044-6261	Robert Austrian Research Award in Pneumococcal Vaccinology - Pfizer; Australian Government Research Training Program Scholarship at The University of Western AustraliaAustralian Government; Wesfarmers Centre of Vaccines and Infectious Diseases at the Telethon Kids Institute; NHMRCNational Health and Medical Research Council (NHMRC) of Australia [1173163]	This study was funded by a Robert Austrian Research Award in Pneumococcal Vaccinology, supported by Pfizer, that was awarded to Dr Lea-Ann Kirkham at the 11th International Symposium in Pneumococci and Pneumococcal Disease (ISPPD-11) in 2018. Ms Kathryn Britton is supported by an Australian Government Research Training Program Scholarship at The University of Western Australia and a PhD top-up scholarship from the Wesfarmers Centre of Vaccines and Infectious Diseases at the Telethon Kids Institute. A/Prof Chris Blyth is supported by NHMRC investigator grant #1173163.	Aho Celestine, 2016, Vaccine Rep, V6, P36, DOI 10.1016/j.vacrep.2016.08.002; Baggett HC, 2017, CLIN INFECT DIS, V64, pS317, DOI 10.1093/cid/cix100; Balsells E, 2018, J INFECTION, V77, P368, DOI 10.1016/j.jinf.2018.06.004; Blyth CC, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0029-y; Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06; Cohen Robert, 2017, Expert Rev Vaccines, V16, P625, DOI 10.1080/14760584.2017.1320221; Dhoubhadel BG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110777; Dunne E. M., 2015, New Microbes and New Infections, V7, P86, DOI 10.1016/j.nmni.2015.06.008; Dunne EM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224392; Dunne EM, 2018, LANCET GLOB HEALTH, V6, pE1375, DOI 10.1016/S2214-109X(18)30383-8; Fan RR, 2016, EMERG INFECT DIS, V22, P1996, DOI 10.3201/eid2211.160902; Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517; Ford RL, 2018, 11 INT S PNEUM PNEUM; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; Hanke CR, 2016, PEDIATR INFECT DIS J, V35, P432, DOI 10.1097/INF.0000000000001030; Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688; Howard LM, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx161; Lehmann D, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0044-z; Manna S, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.06.031; Murad C, 2019, INT J INFECT DIS, V86, P73, DOI 10.1016/j.ijid.2019.06.024; National Statistical Office (Papua New Guinea) ICF, 2019, PAP NEW GUIN DEM HLT; Olwagen CP, 2017, MSPHERE, V2, DOI [10.1128/msphere.00404-17, 10.1128/mSphere.00404-17]; PNG Department of Health, 2016, STAND TREATM COMM IL, V10th; PNG National Department of Health Paediatric Society of Papua New Guinea, 2019, ANN REP CHILD MORB M; Salter SJ, 2012, MICROBIOL-SGM, V158, P1560, DOI 10.1099/mic.0.056580-0; Satzke C, 2019, VACCINE, V37, P296, DOI 10.1016/j.vaccine.2018.10.077; Satzke C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001903; Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062; Tigoi CC, 2012, CLIN INFECT DIS, V55, P180, DOI 10.1093/cid/cis371; Turner P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038271; van Selm S, 2003, INFECT IMMUN, V71, P6192, DOI 10.1128/IAI.71.11.6192-6198.2003; von Mollendorf C, 2019, VACCINE, V37, P4068, DOI 10.1016/j.vaccine.2019.05.078	32	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 7	2021	39	38					5401	5409		10.1016/j.vaccine.2021.07.085		AUG 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UG5UY	34384633	Green Accepted, hybrid, Green Published			2022-04-29	WOS:000689318300010
J	Johm, P; Nkoum, N; Ceesay, A; Mbaye, E; Larson, H; Kampmann, B				Johm, Penda; Nkoum, Nicole; Ceesay, Amie; Mbaye, El Hadji; Larson, Heidi; Kampmann, Beate			Factors influencing acceptance of vaccination during pregnancy in The Gambia and Senegal (vol 39, pg 3926, 2021)	VACCINE			English	Correction									[Johm, Penda; Ceesay, Amie; Kampmann, Beate] London Sch Hyg & Trop Med, Med Res Council Unit Gambia, Vaccines & Immun Theme, Fajara, Gambia; [Nkoum, Nicole; Mbaye, El Hadji] IRESSEF, Inst Hlth Res Epidemiol Surveillance & Training, Social Sci & Hlth Div, Diamniadio, Senegal; [Larson, Heidi] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Vaccine Confidence Project, London, England; [Johm, Penda; Kampmann, Beate] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, Vaccine Ctr, London, England		Kampmann, B (通讯作者)，London Sch Hyg & Trop Med, MRCG LSHTM, Vaccines & Immun Theme, Med Res Council,Unit Gambia, Fajara, Gambia.	bkampmann@mrc.gm	Larson, Heidi J./N-1018-2017	Larson, Heidi J./0000-0002-8477-7583			Johm P, 2021, VACCINE, V39, P3926, DOI 10.1016/j.vaccine.2021.05.068	1	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 31	2021	39	37					5331	5332		10.1016/j.vaccine.2021.07.086		AUG 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UC7ZI	34366144	hybrid			2022-04-29	WOS:000686741800016
J	Corcoran, M; Mereckiene, J; Cotter, S; Murchan, S; Lo, SW; McGee, L; Breiman, RF; Cunney, R; Humphreys, H; Bentley, SD; Gladstone, RA				Corcoran, M.; Mereckiene, J.; Cotter, S.; Murchan, S.; Lo, S. W.; McGee, L.; Breiman, R. F.; Cunney, R.; Humphreys, H.; Bentley, S. D.; Gladstone, R. A.			Using genomics to examine the persistence of Streptococcus pneumoniae serotype 19A in Ireland and the emergence of a sub-clade associated with vaccine failures	VACCINE			English	Article						Streptococcus pneumoniae (S; pneumoniae); Invasive Pneumococcal Disease (IPD); Whole Genome Sequencing (WGS); Vaccine failure; breakthrough cases; Serotype 19A; 13-valent Pneumococcal Conjugate Vaccine (PCV13)	INVASIVE PNEUMOCOCCAL DISEASE; CONJUGATE VACCINE; GENETIC-STRUCTURE; EPIDEMIOLOGY; CHILDREN; ENGLAND; WALES; CLONES; ADULTS; ST320	Background: Streptococcus pneumoniae serotype 19A remains a significant cause of invasive pneumococcal disease (IPD) in Ireland despite the successful introduction of a 13-valent pneumococcal conjugate vaccine (PCV13) in 2010 which reduced the overall incidence of IPD in children. Methods: Invasive Streptococcus pneumoniae serotype 19A isolates from the Irish reference laboratory between 2007-08 and 2017-18 were analysed using whole genome sequencing (WGS) to investigate the persistence of this vaccine-preventable serotype. We compared the entire national 19A collection to other international collections using a standardised nomenclature of Global Pneumococcal Sequencing Clusters (GPSC). Results: Expansion of GPSCs and clonal complexes (CCs) may have been associated with vaccine introduction and antimicrobial prescribing policies. A sub-clade of GPSC1-CC320 (n = 25) unique to Ireland, included five of the ten vaccine failures/breakthrough cases identified (p = 0.0086). This sub-clade was not observed in a global GPSC1-CC320 collection. All isolates within the sub-clade (n = 25) contained a galE gene variant rarely observed in a global pneumococcal collection (n = 37/13454, p < 0.001) nor within GPSC1-CC320 (n = 19/227) (p < 0.001). The sub-clade was estimated to have emerged at the start of the PCV-vaccine era (ancestral origin 2000, range 1995-2004) and expanded in Ireland, with most isolated after PCV13 introduction (n = 24/25). Conclusions: The identification of a sub-clade/variant of serotype 19A highlights the benefit of using WGS to analyse genotypes associated with persistence of a preventable serotype of S. pneumoniae. Particularly as this sub-clade identified was more likely to be associated with IPD in vaccinated children than other 19A genotypes. It is possible that changes to the galE gene, which is involved in capsule production but outside of the capsular polysaccharide biosynthesis locus, may affect bacterial persistence within the population. Discrete changes associated with vaccine-serotype persistence should be further investigated and may inform vaccine strategies. (c) 2021 Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/).	[Corcoran, M.; Cunney, R.] Childrens Hlth Ireland Temple St, Irish Meningitis & Sepsis Reference Lab, Dublin D01 YC67, Ireland; [Corcoran, M.; Cunney, R.; Humphreys, H.] Royal Coll Sugeons Ireland, Dept Clin Microbiol, Dublin, Ireland; [Mereckiene, J.; Cotter, S.; Murchan, S.] Hlth Protect Surveillance Ctr, Dublin, Ireland; [Lo, S. W.; Bentley, S. D.; Gladstone, R. A.] Wellcome Sanger Inst, Parasites & Microbes, Hinxton, England; [McGee, L.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Breiman, R. F.] Emory Univ, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA; [Cunney, R.] Childrens Hlth Ireland Temple St, Dept Microbiol, Dublin, Ireland; [Humphreys, H.] Beaumont Hosp, Dept Microbiol, Dublin, Ireland; [Gladstone, R. A.] Univ Oslo, Inst Basic Med Sci, Dept Biostat, N-0317 Oslo, Norway		Corcoran, M (通讯作者)，Childrens Hlth Ireland Temple St, Irish Meningitis & Sepsis Reference Lab, Dublin D01 YC67, Ireland.	mary.corcoran@cuh.ie	Gladstone, Rebecca A/J-8821-2017	Gladstone, Rebecca A/0000-0002-7993-3051; Corcoran, Mary/0000-0002-6669-9083	PfizerPfizer [W1243730]; Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1034556]; Wellcome Sanger Institute [098051, 206194]; US Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This study was funded by an Investigator Initiated Research grant from Pfizer (W1243730). Sequencing was performed in the Wellcome Sanger Institute as part of the Global Pneumococcal Sequencing Consortium project which was supported by the Bill & Melinda Gates Foundation (OPP1034556), the Wellcome Sanger Institute (grants 098051 and 206194), and the US Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This project was reviewed by Pfizer prior to submission. Pfizer did not have a role in data collection, study design, writing the manuscript or decision to submit it for publication.	Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; [Anonymous], STREPTOCOCCUS PNEUMO; Argimon S, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000093; Assefa S, 2009, BIOINFORMATICS, V25, P1968, DOI 10.1093/bioinformatics/btp347; Azarian T, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007438; Beall BW, 2011, J INFECT DIS, V203, P1360, DOI 10.1093/infdis/jir052; Brueggemann AB, 2007, PLOS PATHOG, V3, P1628, DOI 10.1371/journal.ppat.0030168; Brynildsrud O, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1108-8; Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553; Chen LL, 2018, BIOCHEMISTRY-MOSCOW+, V83, P37, DOI 10.1134/S0006297918010054; COFFEY TJ, 1991, MOL MICROBIOL, V5, P2255, DOI 10.1111/j.1365-2958.1991.tb02155.x; Corcoran M, 2017, EPIDEMIOL INFECT, V145, P2390, DOI 10.1017/S0950268817001194; Corcoran M, 2020, PEDIATR INFECT DIS J, V39, P339, DOI 10.1097/INF.0000000000002549; Croucher NJ, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005095; Croucher NJ, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1196; Croucher NJ, 2013, NAT GENET, V45, P656, DOI 10.1038/ng.2625; Desmet S, 2021, LANCET INFECT DIS, V21, P127, DOI 10.1016/S1473-3099(20)30173-0; Didelot X, 2018, NUCLEIC ACIDS RES, V46, DOI 10.1093/nar/gky783; ECDC, 2020, CONS ANT SYST US ATC; Enright MC, 1998, MICROBIOL-UK, V144, P3049, DOI 10.1099/00221287-144-11-3049; Epping L, 2018, MICROB GENOMICS, V4, DOI 10.1099/mgen.0.000186; Gladstone RA, 2020, MICROB GENOMICS, V6, DOI 10.1099/mgen.0.000357; Gladstone RA, 2019, EBIOMEDICINE, V43, P338, DOI 10.1016/j.ebiom.2019.04.021; Gladstone RA, 2017, MICROB GENOMICS, V3, DOI 10.1099/mgen.0.000119; Groves Sheppard, 2019, GENES-BASEL, V10; Hadfield J, 2018, BIOINFORMATICS, V34, P292, DOI 10.1093/bioinformatics/btx610; Hanage WP, 2011, VACCINE, V29, P8877, DOI 10.1016/j.vaccine.2011.09.075; Hanquet G, 2019, THORAX, V74, P473, DOI 10.1136/thoraxjnl-2018-211767; Ho TD, 2007, INFECT IMMUN, V75, P1661, DOI 10.1128/IAI.01342-06; Horacio AN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153602; Hsieh YC, 2013, J INFECT DIS, V208, P203, DOI 10.1093/infdis/jit145; Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348; Jolley Keith A, 2018, Wellcome Open Res, V3, P124, DOI 10.12688/wellcomeopenres.14826.1; Kandasamy R, 2020, J INFECT DIS, V221, P1361, DOI 10.1093/infdis/jiz178; Kapatai G, 2016, PEERJ, V4, DOI 10.7717/peerj.2477; Kaplan SL, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0567; Kim SH, 2020, VACCINE, V38, P6065, DOI 10.1016/j.vaccine.2019.09.065; Koutouzis EI, 2018, VACCINE, V36, P5245, DOI 10.1016/j.vaccine.2018.07.055; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Lees JA, 2019, GENOME RES, V29, P304, DOI 10.1101/gr.241455.118; Levy C, 2020, CLIN INFECT DIS, V70, P446, DOI 10.1093/cid/ciz221; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li Y, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4017-7; Li Y, 2016, MBIO, V7, DOI 10.1128/mBio.00756-16; Maguire F, 2018, Ir Med J, V111, P835; McGee L, 2001, J CLIN MICROBIOL, V39, P2565, DOI 10.1128/JCM.39.7.2565-2571.2001; Metcalf BJ, 2016, CLIN MICROBIOL INFEC, V22, DOI [10.1016/j.cmi.2016.08.001, 10.1016/j.cmi.2015.08.027]; Mitchell PK, 2019, MICROB GENOMICS, V5, DOI 10.1099/mgen.0.000252; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Mott MP, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S0950268819000013, 10.1017/s0950268819000013]; Oligbu G, 2017, CLIN INFECT DIS, V65, P1191, DOI 10.1093/cid/cix418; Page AJ, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000056; Page AJ, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000083; Page AJ, 2015, BIOINFORMATICS, V31, P3691, DOI 10.1093/bioinformatics/btv421; Pai R, 2005, J INFECT DIS, V192, P1988, DOI 10.1086/498043; Pillai DR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-642; Plummer M., 2006, R NEWS, V6, P7, DOI DOI 10.1159/000323281; Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490; Protasova IN, 2017, MICROBIOL IMMUNOL, V61, P359, DOI 10.1111/1348-0421.12503; Rockett RJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35270-1; Seemann T, GITHUB SHOVILL; Shin J, 2011, J ANTIMICROB CHEMOTH, V66, P1001, DOI 10.1093/jac/dkr048; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; van der Linden M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161257; van der Linden M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-70; van Gils EJM, 2010, JAMA-J AM MED ASSOC, V304, P1099, DOI 10.1001/jama.2010.1290; Varghese J, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2019.09.008; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7; Wood DE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r46; Wyllie AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep34888; Yildirim M, 2020, VACCINE, V38, P1671, DOI 10.1016/j.vaccine.2019.12.060	72	3	3	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					5064	5073		10.1016/j.vaccine.2021.06.017		AUG 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TX3GY	34301430	Green Published, hybrid			2022-04-29	WOS:000682979100020
J	Mogaji, E				Mogaji, Emmanuel			Marketing the COVID-19 vaccine and the implications for public health	VACCINE			English	Editorial Material						Marketing; COVID-19; Vaccine; COVID-19; Vaccine; Coronavirus; Public Health; Health Communication		COVID-19 vaccines are new brands of consumer health technology being introduced to the market. Considering consumer behaviour approaches in this time of crisis, the risk of vaccine hesitancy, the call for more transparency and effective messaging to gain trust, and equitable distribution of this vaccine, this is unexplored theoretical terrain. This commentary takes a multidisciplinary approach to understand and theoretically explore the marketing, distribution, and acceptance of the COVID-19 vaccine. The paper integrates marketing principles, including advertisement and branding of consumer health technology with supply chain management, public affairs, and public health. A theoretical framework was presented to illustrate this relationship and key areas of concerns. The practical implications relevant to equity, ethics, education, employment, and the economic impact was presented. (C) 2021 Elsevier Ltd. All rights reserved.	[Mogaji, Emmanuel] Univ Greenwich, Dept Mkt Events & Tourism, London, England		Mogaji, E (通讯作者)，Univ Greenwich, Dept Mkt Events & Tourism, London, England.	E.O.Mogaji@greenwich.ac.uk	Mogaji, Emmanuel/B-8900-2014	Mogaji, Emmanuel/0000-0003-0544-4842			Bianchi DW, 2021, JAMA-J AM MED ASSOC, V325, P1041, DOI 10.1001/jama.2021.1865; Chen LH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa085; Chen TE, 2021, HEALTH COMMUN, DOI 10.1080/10410236.2021.1876814; Hassan S, 2015, PROCD SOC BEHV, V172, P262, DOI 10.1016/j.sbspro.2015.01.363; Kuter BJ, 2021, VACCINE; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4042; McNeil MM, 2018, J ALLERGY CLIN IMMUN, V141, P463, DOI 10.1016/j.jaci.2017.12.971; Mogaji E, 2021, J PUBLIC AFF, V21, DOI 10.1002/pa.2546; Nkengasong J, 2020, COVID 19 VACC HOW TO COVID 19 VACC HOW TO; Su Z, 2020, BRAIN BEHAV IMMUNITY; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414	11	2	2	12	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4766	4768		10.1016/j.vaccine.2021.07.015		JUL 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TS2JX	34281742	Green Published, Bronze			2022-04-29	WOS:000679483400002
J	Rustandi, RR; Loughney, JW; Shang, L; Wang, SY; Pauley, CJ; Christanti, S; Kristopeit, A; Culp, TD				Rustandi, Richard R.; Loughney, John W.; Shang, Liang; Wang, Shiyi; Pauley, Cindy J.; Christanti, Sianny; Kristopeit, Adam; Culp, Timothy D.			Characterization of gH/gL/pUL128-131 pentameric complex, gH/gL/gO trimeric complex, gB and gM/gN glycoproteins in a human cytomegalovirus using automated capillary western blots	VACCINE			English	Article						Capillary western blot; CMV vaccine; pUL128-131 pentameric complex; gB; gH; gL; gO Trimeric complex	NEUTRALIZING ANTIBODY-RESPONSE; GENE ENCODES; VACCINE; INFECTION; ENVELOPE; CELLS; FIBROBLASTS; PREVENTION; PROTEINS; STRAINS	Human cytomegalovirus (HCMV) is currently a major cause of congenital disease in newborns and organ failure in transplant recipients. Despite decades of efforts, an effective vaccine against HCMV has yet to be developed. However, the discovery of pentameric gH complex on viral surface which contains potent neutralizing epitopes may help enable development of an effective vaccine. In our company ongoing Phase II clinical trial of whole-live virus HCMV vaccine (V160), the pentameric gH complex has been restored on the surface of live attenuated AD169 virus strain. The reconstructed HCMV virus contains a variety of surface glycoproteins including pentameric gH/gL/gUL128-131 complex, trimeric gH/gL/gO complex, gB glycoprotein, and gM/gN heterodimer complex. To further characterize this virus and enable the monitoring of multiple viral antigens during vaccine process development an effective and efficient analytical strategy was required to detect and quantify several viral surface proteins. In this paper, we present an innovative approach based on capillary western blot technology that allows fast and accurate quantitation of pentameric gH/gL/gUL128-131 complex, trimeric gH/gL/gO complex, and gB glycoprotein. This method is suitable for analyzing target proteins in multiple sample types including supernatants from infected cell culture, purification intermediates, concentration bulk, and the final vaccine product. In addition, the capillary western blot-based technology identified a previously unknown biochemical profile present in some HCMV viruses: triplet gH peaks of viral surface proteins in non-reducing environ-ment, which could potentially present a new strategy for specificity and identity testing. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Rustandi, Richard R.; Loughney, John W.; Shang, Liang; Wang, Shiyi; Pauley, Cindy J.; Christanti, Sianny; Kristopeit, Adam; Culp, Timothy D.] Vaccine Analyt Res Dev, Kenilworth, NJ USA; [Rustandi, Richard R.; Loughney, John W.; Shang, Liang; Wang, Shiyi; Pauley, Cindy J.; Christanti, Sianny; Kristopeit, Adam; Culp, Timothy D.] Vaccine Proc Dev Merck & Co Inc, Kenilworth, NJ USA		Rustandi, RR (通讯作者)，770 Sumneytown Pike POB 4, West Point, PA 19486 USA.	richard_rustandi@merck.com					Adler SP, 2019, J INFECT DIS, V220, P411, DOI 10.1093/infdis/jiz141; Arvin AM, 2004, CLIN INFECT DIS, V39, P233, DOI 10.1086/421999; Baldick CJ, 1996, J VIROL, V70, P6097, DOI 10.1128/JVI.70.9.6097-6105.1996; Calo S, 2016, J VIROL, V90, P4926, DOI 10.1128/JVI.02517-15; Chandramouli S, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan1457; Ciferri C, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005230; Ciferri C, 2015, P NATL ACAD SCI USA, V112, P1767, DOI 10.1073/pnas.1424818112; Fouts AE, 2012, J VIROL, V86, P7444, DOI 10.1128/JVI.00467-12; Freed DC, 2013, P NATL ACAD SCI USA, V110, pE4997, DOI 10.1073/pnas.1316517110; Fu TM, 2014, VACCINE, V32, P2525, DOI 10.1016/j.vaccine.2014.03.057; Fu TM, 2012, VACCINE, V30, P7469, DOI 10.1016/j.vaccine.2012.10.053; Gerna G, 2008, J GEN VIROL, V89, P853, DOI 10.1099/vir.0.83523-0; Griffiths PD, 2011, LANCET, V377, P1256, DOI 10.1016/S0140-6736(11)60136-0; Ha S, 2017, J VIROL, V91, DOI 10.1128/JVI.02033-16; Huber MT, 1999, J VIROL, V73, P3886, DOI 10.1128/JVI.73.5.3886-3892.1999; Huber MT, 1998, J VIROL, V72, P8191, DOI 10.1128/JVI.72.10.8191-8197.1998; IRMIERE A, 1983, VIROLOGY, V130, P118, DOI 10.1016/0042-6822(83)90122-8; Krzyzaniak M, 2007, J VIROL, V81, P10316, DOI 10.1128/JVI.00375-07; Li FS, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0038-0; Li G, 2015, P NATL ACAD SCI USA, V112, P4471, DOI 10.1073/pnas.1419875112; Li L, 1997, J VIROL, V71, P3090, DOI 10.1128/JVI.71.4.3090-3097.1997; Liu J, 2018, J VIROL, V92, DOI 10.1128/JVI.01336-18; Loughney JW, 2015, J BIOL CHEM, V290, P15985, DOI 10.1074/jbc.M115.652230; Luisi K, 2017, CURR OPIN VIROL, V23, P23, DOI 10.1016/j.coviro.2017.02.003; Mach M, 2005, J VIROL, V79, P2160, DOI 10.1128/JVI.79.4.2160-2170.2005; Mach M, 2007, J VIROL, V81, P5212, DOI 10.1128/JVI.01463-06; Minsker K, 2020, VACCINE, V38, P7166, DOI 10.1016/j.vaccine.2020.08.001; Pass RF, 2009, NEW ENGL J MED, V360, P1191, DOI 10.1056/NEJMoa0804749; Rustandi RR, 2016, METHODS MOL BIOL, V1466, P197, DOI 10.1007/978-1-4939-4014-1_16; Rustandi RR, 2012, ELECTROPHORESIS, V33, P2790, DOI 10.1002/elps.201200095; Shen SY, 2007, VACCINE, V25, P3319, DOI 10.1016/j.vaccine.2007.01.011; Shimamura M, 2006, J VIROL, V80, P4591, DOI 10.1128/JVI.80.9.4591-4600.2006; Stratton D, 2000, VACCINES 21 CENTURY, DOI [10.17226/5501rus, DOI 10.17226/5501RUS]; Vanarsdall AL, 2019, P NATL ACAD SCI USA, V116, P3728, DOI 10.1073/pnas.1814835116; Vlasak J, 2016, VACCINE, V34, P2321, DOI 10.1016/j.vaccine.2016.03.067; Wang D, 2005, P NATL ACAD SCI USA, V102, P18153, DOI 10.1073/pnas.0509201102; Wang D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9387; Wang D, 2011, VACCINE, V29, P9075, DOI 10.1016/j.vaccine.2011.09.056; Wille PT, 2010, J VIROL, V84, P2585, DOI 10.1128/JVI.02249-09; Zhou MM, 2013, J VIROL, V87, P9680, DOI 10.1128/JVI.01167-13	40	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4705	4715		10.1016/j.vaccine.2021.06.033		JUL 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	34229890	hybrid			2022-04-29	WOS:000681356500016
J	Burnett, E; Juin, S; Esona, MD; Desormeaux, AM; Aliabadi, N; Pierre, M; Andre-Alboth, J; Leshem, E; Etheart, MD; Patel, R; Dely, P; Fitter, D; Jean-Denis, G; Kalou, M; Katz, MA; Bowen, MD; Grant-Greene, Y; Boncy, J; Parashar, UD; Joseph, GA; Tate, JE				Burnett, Eleanor; Juin, Stanley; Esona, Mathew D.; Desormeaux, Anne Marie; Aliabadi, Negar; Pierre, Manise; Andre-Alboth, Jocelyn; Leshem, Eyal; Etheart, Melissa D.; Patel, Roopal; Dely, Patrick; Fitter, David; Jean-Denis, Gladzdin; Kalou, Mireille; Katz, Mark A.; Bowen, Michael D.; Grant-Greene, Yoran; Boncy, Jacques; Parashar, Umesh D.; Joseph, Gerard A.; Tate, Jacqueline E.			Effectiveness of monovalent rotavirus vaccine against hospitalizations due to all rotavirus and equine-like G3P[8] genotypes in Haiti 2014-2019	VACCINE			English	Article							LATIN-AMERICAN; EFFICACY; GASTROENTERITIS; SAFETY	Background: Rotavirus vaccines are effective in preventing severe rotavirus. Haiti introduced 2-dose monovalent (G1P[8]) rotavirus vaccine recommended for infants at 6 and 10 weeks of age in 2014. We calculated the effectiveness of rotavirus vaccine against hospitalization for acute gastroenteritis in Haiti. Methods: We enrolled children 6-59 months old admitted May 2014-September 2019 for acute watery diarrhea at any sentinel surveillance hospital. Stool was tested for rotavirus using enzyme immunoassay (EIA) and genotyped with multiplex one-step RT-PCR assay and Sanger sequencing for stratification by genotype. We used a case-negative design where cases were children positive for rotavirus and controls were negative for rotavirus. Only children eligible for vaccination were included and a child was consid-ered vaccinated if vaccine was given >= 14 days before enrollment. We used unconditional logistic regres-sion to calculate odds ratios and calculated 2-dose and 1-dose vaccine effectiveness (VE) as (1 -odds ratio) * 100. Results: We included 129 (19%) positive cases and 543 (81%) negative controls. Among cases, 77 (60%) were positive for equine-like G3P[8]. Two doses of rotavirus vaccine were 66% (95% CI: 44, 80) effective against hospitalizations due to any strain of rotavirus and 64% (95% CI: 33, 81) effective against hospital-izations due to the equine-like G3P[8] genotype. Conclusions: These findings are comparable to other countries in the Americas region. To the best of our knowledge, this is the first VE estimate both against the equine-like G3P[8] genotype and from a Caribbean country. Overall, these results support rotavirus vaccine use and demonstrate the importance of complete vaccination. Published by Elsevier Ltd.	[Burnett, Eleanor; Esona, Mathew D.; Aliabadi, Negar; Leshem, Eyal; Bowen, Michael D.; Parashar, Umesh D.; Tate, Jacqueline E.] NCIRD, Div Viral Dis, CDC, Atlanta, GA 30301 USA; [Juin, Stanley; Desormeaux, Anne Marie; Pierre, Manise; Etheart, Melissa D.; Patel, Roopal; Fitter, David; Kalou, Mireille; Katz, Mark A.; Grant-Greene, Yoran] CDC Country Off, Port Au Prince, Haiti; [Andre-Alboth, Jocelyn; Boncy, Jacques; Joseph, Gerard A.] Minist Publ Hlth & Populat, Lab Natl Sante Publ, Port Au Prince, Haiti; [Dely, Patrick] Minist Publ Hlth & Populat, Directorate Epidemiol, Lab & Res DELR, Port Au Prince, Haiti; [Jean-Denis, Gladzdin] Pan Amer Hlth Org, Port Au Prince, Haiti; [Leshem, Eyal] Sheba Med Ctr, Tel Aviv, Israel; [Leshem, Eyal] Tel Aviv Univ, Tel Aviv, Israel		Burnett, E (通讯作者)，NCIRD, Div Viral Dis, CDC, Atlanta, GA 30301 USA.; Joseph, GA (通讯作者)，Minist Publ Hlth & Populat, Lab Natl Sante Publ, Port Au Prince, Haiti.	wwg7@cdc.gov			Vaccine Alliance targeted country funds	Funding source Gavi, the Vaccine Alliance targeted country funds	[Anonymous], 2009, Wkly Epidemiol Rec, V84, P533; [Anonymous], 2020, HAITI WHO UNICEF COV; Bowen MD, 2021, DIVERSITY ROTAVIRUS; Burnett E, 2020, LANCET GLOB HEALTH, V8, pE1195, DOI 10.1016/S2214-109X(20)30262-X; Cayemittes M, 2013, HAITI ENQUETE MORTAL; Cayemittes M, 2007, HAITI ENQUETE MORTAL; Chavers T, 2018, EXPERT REV VACCINES, V17, P1037, DOI 10.1080/14760584.2018.1541409; Cowley D, 2016, J GEN VIROL, V97, P403, DOI 10.1099/jgv.0.000352; de Oliveira LH, 2015, VACCINE, V33, pA248, DOI 10.1016/j.vaccine.2014.11.060; Institut haitien de l'enfance-IHE/Haiti ICF, 2018, HAIT ENQ MORT MORB U HAIT ENQ MORT MORB U; Juin Eyal, 2021, AM J HYGIENE TROPICA; Juin S, 2017, AM J TROP MED HYG, V97, P12, DOI 10.4269/ajtmh.16-0948; Katz EM, 2019, VIROLOGY, V534, P114, DOI 10.1016/j.virol.2019.06.007; Leshem E, 2014, LANCET INFECT DIS, V14, P847, DOI 10.1016/S1473-3099(14)70832-1; Linhares AC, 2008, LANCET, V371, P1181, DOI 10.1016/S0140-6736(08)60524-3; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; Steenland MW, 2013, AM J TROP MED HYG, V89, P641, DOI 10.4269/ajtmh.13-0307; Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013; Velasquez DE, 2018, EXPERT REV VACCINES, V17, P145, DOI 10.1080/14760584.2018.1418665; Vesikari T, 2004, PEDIATR INFECT DIS J, V23, P937, DOI 10.1097/01.inf.0000141722.10130.50	20	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4458	4462		10.1016/j.vaccine.2021.06.055		JUL 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34187708	Green Accepted			2022-04-29	WOS:000672160300012
J	Scheiblhofer, S; Drothler, S; Braun, W; Braun, R; Boesch, M; Weiss, R				Scheiblhofer, Sandra; Drothler, Stephan; Braun, Werner; Braun, Reinhard; Boesch, Maximilian; Weiss, Richard			Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding	VACCINE			English	Article						Epicutaneous immunization; Laser; Skin micropores; SARS-CoV-2; Spike protein	INTRADERMAL DELIVERY; VACCINATION; CELLS; ABLATION	The skin represents an attractive target tissue for vaccination against respiratory viruses such as SARS-CoV-2. Laser-facilitated epicutaneous immunization (EPI) has been established as a novel technology to overcome the skin barrier, which combines efficient delivery via micropores with an inherent adjuvant effect due to the release of danger-associated molecular patterns. Here we delivered the S1 subunit of the Spike protein of SARS-CoV-2 to the skin of BALB/c mice via laser-generated micropores with or without CpG-ODN1826 or the B subunit of heat-labile enterotoxin of E.coli (LT-B). EPI induced serum IgG titers of 1:3200 that could be boosted 5 to 10-fold by co-administration of LT-B and CpG, respectively. Sera were able to inhibit binding of the spike protein to its receptor ACE2. Our data indicate that delivery of recom-binant spike protein via the skin may represent an alternative route for vaccines against Covid-19. (c) 2021 Elsevier Ltd. All rights reserved.	[Scheiblhofer, Sandra; Drothler, Stephan; Weiss, Richard] Univ Salzburg, Dept Biosci, Hellbrunnerstr 34, A-5020 Salzburg, Austria; [Braun, Werner; Braun, Reinhard; Boesch, Maximilian] Pantec Biosolut AG, Ruggell, Liechtenstein		Weiss, R (通讯作者)，Univ Salzburg, Dept Biosci, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	Richard.Weiss@sbg.ac.at	Boesch, Maximilian/AAT-1210-2021; Weiss, Richard/N-7279-2013	Boesch, Maximilian/0000-0002-0994-9883; Scheiblhofer, Sandra/0000-0003-2867-9054; Drothler, Stephan/0000-0001-8187-5180; Weiss, Richard/0000-0003-3185-7253	Pantec Biosolutions	The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RB is head of business development, WB is sales director, and MB is medical scientific director of Pantec Biosolutions. RW reports having received grant money from Pantec Biosolutions. SS and SD declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.	Abe KT, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142362; ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0; Canete PF, 2020, CELL, V183, P13, DOI 10.1016/j.cell.2020.09.013; Chatzis O, 2020, CLIN MICROBIOL INFEC; Czerkinsky C, 2010, MUCOSAL IMMUNOL, V3, P545, DOI 10.1038/mi.2010.55; Ellebedy A, 2020, RES SQ; Heine SJ, 2014, J IMMUNOL, V192, P1630, DOI 10.4049/jimmunol.1302743; Holland D, 2008, J INFECT DIS, V198, P650, DOI 10.1086/590434; Isho B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe5511; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Karlsson AC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe8063; Korotchenko E, 2021, ALLERGY, V76, P210, DOI 10.1111/all.14481; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Scheiblhofer S, 2017, VACCINE, V35, P1802, DOI 10.1016/j.vaccine.2016.11.105; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Terhorst D, 2015, J IMMUNOL, V194, P5895, DOI 10.4049/jimmunol.1500564; Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002; Van Damme P, 2009, VACCINE, V27, P454, DOI 10.1016/j.vaccine.2008.10.077; Wan JK, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107918; Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15; Weiss R, 2012, J CONTROL RELEASE, V162, P391, DOI 10.1016/j.jconrel.2012.06.031; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1126/science.abb2507, 10.1101/2020.02.11.944462]; Yu J, 2011, J CONTROL RELEASE, V156, P53, DOI 10.1016/j.jconrel.2011.07.024	23	0	0	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4399	4403		10.1016/j.vaccine.2021.06.068		JUL 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34226102	Bronze, Green Published			2022-04-29	WOS:000672160300002
J	Chen, YY; Wang, Y; Robertson, ID; Hu, CM; Chen, HC; Guo, AZ				Chen, Yingyu; Wang, Yu; Robertson, Ian D.; Hu, Changmin; Chen, Huanchun; Guo, Aizhen			Key issues affecting the current status of infectious diseases in Chinese cattle farms and their control through vaccination	VACCINE			English	Article						Cattle; Infectious diseases; Vaccination; Questionnaire; Focus group meeting; China	BRUCELLOSIS	Infectious diseases can have a major impact on the profitability of the cattle industry. To determine the occurrence of bovine infectious diseases in China and the adoption of vaccination to control them, a national-wide questionnaire and focus group meeting were performed. The questionnaire was administered to 189 farmers including 93 dairy farmers, 80 beef cattle farmers and 16 yak farmers. Since it is compulsory to vaccinate cattle against foot and mouth disease, the coverage of vaccination to this disease was the highest (100% of dairy and yak farms and 92.5% of beef farms). However, the implementation of vaccination against other diseases was vastly different between cattle types with less than 50% of farms adopting vaccination (except brucellosis vaccine in yak farms). In a focus group meeting of 36 cattle experts on the key issues affecting the frequency of infectious diseases in cattle and the vaccination practices adopted on Chinese cattle farms, the lack of effective vaccines against single or multiple pathogens, a lack of tools for the early and correct diagnosis of disease, difficulties in licensing novel vaccines and diagnostic agents, low efficiency in disseminating knowledge on diseases and control products to producers were identified as key issues. In conclusion, except for FMD, the control of most infectious diseases of cattle in China requires improving. Development of improved control measures and diagnostic tests along with the development and implementation of educational material for producers on cattle diseases should be given priority. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Chen, Yingyu; Wang, Yu; Hu, Changmin; Chen, Huanchun; Guo, Aizhen] Huazhong Agr Univ, State Key Lab Agr Microbiol, 1 Sizhishan Rd, Wuhan 430070, Hubei, Peoples R China; [Chen, Yingyu; Wang, Yu; Robertson, Ian D.; Hu, Changmin; Chen, Huanchun; Guo, Aizhen] Huazhong Agr Univ, Coll Vet Med, Wuhan 430070, Hubei, Peoples R China; [Chen, Yingyu; Wang, Yu; Robertson, Ian D.; Hu, Changmin; Chen, Huanchun; Guo, Aizhen] Huazhong Agr Univ, Key Lab Prevent Vet Med Hubei Prov, Hubei Int Sci & Technol Cooperat Base Vet Epidemi, Wuhan 430070, Hubei, Peoples R China; [Robertson, Ian D.] Murdoch Univ, Sch Vet Med, 90 South St, Murdoch, WA 6150, Australia		Guo, AZ (通讯作者)，Huazhong Agr Univ, State Key Lab Agr Microbiol, 1 Sizhishan Rd, Wuhan 430070, Hubei, Peoples R China.; Robertson, ID (通讯作者)，Murdoch Univ, Sch Vet Med, 90 South St, Murdoch, WA 6150, Australia.	I.Robertson@murdoch.edu.au; aizhen@mail.hzau.edu.cn	Wang, Yu/AAE-7736-2022	Robertson, Ian/0000-0002-4255-4752; Wang, Yu/0000-0002-6296-6965	Key Research and Development Program of Hubei Province [2020BBA055]; China Agriculture Research System of MOF and MARA [CARS-37]	This work was funded by the Key Research and Development Program of Hubei Province (2020BBA055) and the China Agriculture Research System of MOF and MARA (CARS-37).	Chen WJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004637; Chen XL, 2018, ACTA TROP, V187, P37, DOI 10.1016/j.actatropica.2018.07.024; Council GOotS, 2012, NAT PLAN MED AND LON; Cui Q., 2020, MICROB PATHOGENESIS; Deng ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121718; Ding Y, 2013, VIROL J, V10, DOI [10.1186/1743-422X-10-17, 10.1186/1743-422X-10-78]; Hou PL, 2019, TROP ANIM HEALTH PRO, V51, P791, DOI 10.1007/s11250-018-1751-z; Huang D., PLOS NEGLECT TROP D; Lee F, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050412; Li Y, 2020, TRANSBOUND EMERG DIS, V67, P1315, DOI 10.1111/tbed.13472; Li Z, 2015, VET MICROBIOL, V176, P155, DOI 10.1016/j.vetmic.2014.12.008; Made R., 1996, EPIDEMIOLOGICAL STUD; Molla W, 2017, PREV VET MED, V147, P34, DOI 10.1016/j.prevetmed.2017.08.019; Mostaan Saied, 2020, Avicenna Journal of Medical Biotechnology, V12, P140; Qi JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038239; Ran XH, 2019, ACTA TROP, V189, P117, DOI 10.1016/j.actatropica.2018.10.002; Richeson JT, 2019, VET CLIN N AM-FOOD A, V35, P575, DOI 10.1016/j.cvfa.2019.07.003; Robertson ID, 2020, ENGINEERING-PRC, V6, P20, DOI 10.1016/j.eng.2019.10.004; Roth F, 2003, B WORLD HEALTH ORGAN, V81, P867; Sergeant ESG, EPITOOLS EPIDEMIOLOG; Shi Baosuyalatu Y., 2020, CHINA ANIMAL HLTH IN, V37, P1, DOI [10.3969/j.issn.1005-944X.2020.01.001, DOI 10.3969/J.ISSN.1005-944X.2020.01.001]; van Straten M, 2016, VACCINE, V34, P5837, DOI 10.1016/j.vaccine.2016.10.011; Wang Y, 2020, PREV VET MED, V182, DOI 10.1016/j.prevetmed.2020.105086; Xin JQ, 2012, VET J, V191, P166, DOI 10.1016/j.tvjl.2011.02.011; Zeng JY, 2017, TROP ANIM HEALTH PRO, V49, P1339, DOI 10.1007/s11250-017-1331-7; Zhu Z, 2018, TRANSBOUND EMERG DIS, V65, P2027, DOI 10.1111/tbed.12895	26	0	0	2	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4184	4189		10.1016/j.vaccine.2021.05.078		JUN 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34127292	hybrid, Green Published			2022-04-29	WOS:000672535200024
J	Andayi, F; Emukule, GO; Osoro, E; Ndegwa, LK; Otiato, F; Muturi, P; Azziz-Baumgartner, E; Kalani, R; Anyango, E; Muthoka, PM; Ebama, MS; Bresee, J; Chaves, SS				Andayi, Fred; Emukule, Gideon O.; Osoro, Eric; Ndegwa, Linus K.; Otiato, Fredrick; Muturi, Peter; Azziz-Baumgartner, Eduardo; Kalani, Rosalia; Anyango, Edwina; Muthoka, Philip M.; Ebama, Malembe S.; Bresee, Joseph; Chaves, Sandra S.			Knowledge and attitude of Kenyan healthcare workers towards pandemic influenza disease and vaccination: 9 years after the last influenza pandemicY	VACCINE			English	Article						Pandemic influenza; Influenza vaccination; Preparedness; Healthcare workers; Kenya; KAP		Background: Healthcare workers (HCWs) are at high risk of exposure and transmission of infectious respiratory pathogens like influenza. Despite the potential benefits, safety and efficacy of influenza vaccination, vaccines are still underutilized in Africa, including among HCWs. Method: From May-June 2018, we conducted a cross-sectional, self-administered, written survey among HCWs from seven counties in Kenya and assessed their knowledge attitudes and perceptions towards pandemic influenza disease and vaccination. Using regression models, we assessed factors that were associated with the HCW's knowledge of pandemic influenza and vaccination. Results: A total of 2,035 HCWs, representing 49% of the targeted respondents from 35 health facilities, completed the question. Sixty eight percent of the HCWs had ever heard of pandemic influenza, and 80.0% of these were willing to receive pandemic influenza vaccine if it was available. On average, Kenyan HCWs correctly answered 55.0% (95% CI 54.0-55.9) of the questions about pandemic influenza and vaccination. Physicians (65.6%, 95% CI 62.5-68.7) and pharmacists (61.7%, 95% CI 57.9-65.5) scored higher compared to nurses (53.1%, 95% CI 51.7-54.5). HCWs with 5 or more years of work experience (55.8, 95% CI 54.5-57.0) had marginally higher knowledge scores compared to those with less experience (53.9%, 95% CI 52.5-55.3). Most participants who were willing to receive pandemic influenza vaccine did so to protect their relatives (88.7%) or patients (85.9%). Conclusion: Our findings suggest moderate knowledge of pandemic influenza and vaccination by HCWs in Kenya, which varied by cadre and years of work experience. These findings highlight the need for continued in-service health education to increase the HCW's awareness and knowledge of pandemic influenza to increase acceptance of influenza vaccination in the case of a pandemic. Published by Elsevier Ltd.	[Andayi, Fred; Emukule, Gideon O.; Ndegwa, Linus K.; Chaves, Sandra S.] Ctr Dis Control & Prevent Kenya, Influenza Program, Nairobi, Kenya; [Osoro, Eric] Washington State Univ Global Hlth Kenya, Nairobi, Kenya; [Otiato, Fredrick] Kenya Govt Med Res Ctr, Nairobi, Kenya; [Muturi, Peter] IHRC, Influenza Program, Nairobi, Kenya; [Azziz-Baumgartner, Eduardo; Bresee, Joseph; Chaves, Sandra S.] Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA; [Kalani, Rosalia; Muthoka, Philip M.] Kenya Minist Hlth, Dis Surveillance & Response Unit, Nairobi, Kenya; [Anyango, Edwina] Kenya Minist Hlth, Natl Vaccines & Immunizat Program, Nairobi, Kenya; [Ebama, Malembe S.; Bresee, Joseph] Task Force Global Hlth, Ctr Vaccine Equ, Decatur, GA USA		Emukule, GO (通讯作者)，KEMRI Headquarters, Mbagathi Rd,Off Mbagathi Way,POB 606, Nairobi 00621, Kenya.	uyr9@cdc.gov		Ndegwa, linus/0000-0002-3609-7962; ANDAYI, PhD, MPH, DVM, CIC, Fred/0000-0003-0768-9894; Osoro, Eric/0000-0001-5133-4279	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; Task Force for Global Health, Inc.	This study was supported by the Centers for Disease Control and Prevention, The Task Force for Global Health, Inc.	Albano L, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-208; Andayi F, 2019, TROP MED INFECT DIS, V4, DOI 10.3390/tropicalmed4020091; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Chor JSY, 2011, VACCINE, V29, P7364, DOI 10.1016/j.vaccine.2011.07.079; Dawa JA, 2018, INFLUENZA OTHER RESP, V12, P30, DOI 10.1111/irv.12488; Dawood FS, 2012, Lancet, V3099, P1; Emukule GO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138708; Emukule GO, 2017, PLOS ONE, V12, P2007; Hakim H, 2011, VACCINE, V29, P5963, DOI 10.1016/j.vaccine.2011.06.041; Ip DKM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1316-y; Jenkin DC, 2019, VACCINE-X, V2, DOI 10.1016/j.jvacx.2019.100036; Kaboli F, 2010, INFECT CONT HOSP EP, V31, P1017, DOI 10.1086/655465; Lansbury LE, 2017, VACCINE, V35, P1996, DOI 10.1016/j.vaccine.2017.02.059; McMorrow ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138272; Mytton OT, 2013, OCCUP MED-OXFORD, V63, P189, DOI 10.1093/occmed/kqt002; Njuguna H, 2013, VACCINE, V31, P4662, DOI 10.1016/j.vaccine.2013.07.005; Oria PA, 2011, VACCINE, V29, P3617, DOI 10.1016/j.vaccine.2011.01.063; Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018; Presanis AM, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5408; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Simpson CR, 2012, PRIM CARE RESP J, V21, P246, DOI 10.4104/pcrj.2012.00081; Simpson CR, 2012, LANCET INFECT DIS, V12, P696, DOI 10.1016/S1473-3099(12)70133-0; Viboud C, 2010, PLOS CURR-TREE LIFE, V2; Yap J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-442; Zaffina S, 2019, EXPERT REV VACCINES, V18, P411, DOI 10.1080/14760584.2019.1586541	25	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3991	3996		10.1016/j.vaccine.2021.05.057		JUN 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34108077	hybrid			2022-04-29	WOS:000663773600026
J	Vaillant, L; Oster, P; McMillan, B; Velin, D				Vaillant, Laurie; Oster, Paul; McMillan, Brynn; Velin, Dominique			Gastric eosinophils are detrimental for Helicobacter pylori vaccine efficacy	VACCINE			English	Article						Helicobacter pylori; Vaccine; Eosinophils; Th2 response	VACCINE-INDUCED REDUCTION; PYLORI INFECTION; EPITHELIAL-CELLS; MSIGLEC-F; T-CELLS; PROTECTION; MICE; IMMUNIZATION; EXPRESSION; INDUCTION	Helicobacter pylori (Hp) colonizes the human gastric mucosa with a high worldwide prevalence. Currently, Hp can be eradicated by the use of antibiotics. Due to the increase of antibiotic resistance, new therapeutic strategies need to be devised: one such approach being prophylactic vaccination. Pre-clinical and clinical data showed that a urease-based vaccine is efficient in decreasing Hp infection through the mobilization of T helper (Th)-dependent immune effectors, including eosinophils. Preliminary data have shown that upon vaccination and subsequent Hp infection, eosinophils accumulate in the gastric mucosa, suggesting a possible implication of this granulocyte subset in the vaccine-induced reduction of Hp infection. In our study, we confirm that activated eosinophils, expressing CD63, CD40, MHCII and PD-L1 at their cell surface, infiltrate the gastric mucosa during vaccine-induced reduction of Hp infection. Strikingly, we provide evidence that bone marrow derived eosinophils efficiently kill Hp in vitro, suggesting that eosinophils may participate to the vaccine-induced reduction of Hp infection. However, conversely to our expectations, the absence of eosinophils does not decrease the efficacy of this Hp vaccine in vivo. Indeed, vaccinated mice that have been genetically ablated of the eosinophil lineage or that have received anti-Sialic acid-binding immunoglobulin-like lectin F eosinophil-depleting antibodies, display a lower Hp colonization when compared to their eosinophil sufficient counterparts. Although the vaccine induces similar urease-specific humoral and Th responses in both eosinophil sufficient and deficient mice, a decreased production of anti-inflammatory cytokines, such as IL-10, TGFb, and calgranulin B, was specifically observed in eosinophil depleted mice. Taken together, our results suggest that gastric eosinophils maintain an anti-inflammatory environment, thus sustaining chronic Hp infection. Because eosinophils are one of the main immune effectors mobilized by Th2 responses, our study strongly suggests that the formulation of an Hp vaccine needs to include an adjuvant that preferentially primes Hp-specific Th1/Th17 responses. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Vaillant, Laurie; Oster, Paul; McMillan, Brynn; Velin, Dominique] Univ Lausanne, CHU Vaudois, Serv Gastroenterol & Hepatol, Lausanne, Switzerland		Velin, D (通讯作者)，Univ Lausanne, CHU Vaudois, Serv Gastroenterol & Hepatol, Lausanne, Switzerland.	Dominique.Velin@chuv.ch		VELIN, Dominique/0000-0001-6033-5871	Swiss National FoundationSwiss National Science Foundation (SNSF) [310030-173197]	This work was funded by Swiss National Foundation grant 310030-173197 (to D. Velin) .	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P1205, DOI 10.1016/j.jaci.2010.10.031; Aizawa H, 2003, GENOMICS, V82, P521, DOI 10.1016/S0888-7543(03)00171-X; Akhiani AA, 2004, J IMMUNOL, V173, P3348, DOI 10.4049/jimmunol.173.5.3348; Arnold IC, 2018, J EXP MED, V215, P2055, DOI 10.1084/jem.20172049; Begue RE, 2010, FEMS IMMUNOL MED MIC, V60, P142, DOI 10.1111/j.1574-695X.2010.00726.x; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; Bosnjak B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00840; Bureau F, 2002, J ALLERGY CLIN IMMUN, V110, P443, DOI 10.1067/mai.2002.126781; Chan YR, 2009, J IMMUNOL, V182, P4947, DOI 10.4049/jimmunol.0803282; Chu VT, 2014, IMMUNITY, V40, P582, DOI 10.1016/j.immuni.2014.02.014; Clements JD, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00215-18; Cover TL, 2009, GASTROENTEROLOGY, V136, P1863, DOI 10.1053/j.gastro.2009.01.073; CZINN SJ, 1993, VACCINE, V11, P637, DOI 10.1016/0264-410X(93)90309-L; Davoine F, 2004, INT ARCH ALLERGY IMM, V134, P165, DOI 10.1159/000078650; Delyria ES, 2009, GASTROENTEROLOGY, V136, P247, DOI 10.1053/j.gastro.2008.09.017; Di Sabatino A, 2018, J ALLER CL IMM-PRACT, V6, P1056, DOI 10.1016/j.jaip.2017.10.017; Dougan M, 2019, IMMUNITY, V50, P796, DOI 10.1016/j.immuni.2019.03.022; Ermak TH, 1998, J EXP MED, V188, P2277, DOI 10.1084/jem.188.12.2277; Fallone CA, 2016, GASTROENTEROLOGY, V151, P51, DOI 10.1053/j.gastro.2016.04.006; Johansson MW, 2014, CLIN EXP ALLERGY, V44, P482, DOI 10.1111/cea.12292; Kita H, 2013, INT ARCH ALLERGY IMM, V161, P3, DOI 10.1159/000350662; Korsholm KS, 2010, IMMUNOLOGY, V129, P75, DOI 10.1111/j.1365-2567.2009.03164.x; Lee JJ, 2010, CLIN EXP ALLERGY, V40, P563, DOI 10.1111/j.1365-2222.2010.03484.x; Lehours P., 2019, Helicobacter, V24, DOI 10.1111/hel.12644-12644; Li NAS, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00077; Lin A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01781; Linch SN, 2009, INFECT IMMUN, V77, P4976, DOI 10.1128/IAI.00306-09; Lingblom C, 2017, J IMMUNOL, V198, P4672, DOI 10.4049/jimmunol.1601005; Liu W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01115; Long H, 2016, TRANSFUS MED HEMOTH, V43, P96, DOI 10.1159/000445215; Mahmudi-Azer S, 2002, BLOOD, V99, P4039, DOI 10.1182/blood.V99.11.4039; Masterson JC, 2015, GUT, V64, P1236, DOI 10.1136/gutjnl-2014-306998; MCGOVERN TW, 1991, DIGEST DIS SCI, V36, P435, DOI 10.1007/BF01298871; Miquel-Clopes A, 2019, CLIN EXP IMMUNOL, V196, P205, DOI 10.1111/cei.13285; Moyat M, 2017, MUCOSAL IMMUNOL, V10, P271, DOI 10.1038/mi.2016.38; Moyat M, 2015, INFECT IMMUN, V83, P4217, DOI 10.1128/IAI.01026-15; Norton EB, 2011, CLIN VACCINE IMMUNOL, V18, P546, DOI 10.1128/CVI.00538-10; Oertli M, 2012, J CLIN INVEST, V122, P1082, DOI 10.1172/JCI61029; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Perl L, 2012, ANN ALLERG ASTHMA IM, V108, P34, DOI 10.1016/j.anai.2011.10.012; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Prevete N, 2013, INT J IMMUNOPATH PH, V26, P647, DOI 10.1177/039463201302600308; Qi HB, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01219-2; Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296; Riley JL, 2009, IMMUNOL REV, V229, P114, DOI 10.1111/j.1600-065X.2009.00767.x; Solnick JV, 2000, INFECT IMMUN, V68, P2560, DOI 10.1128/IAI.68.5.2560-2565.2000; Stenfeldt AL, 2004, IMMUNOLOGY, V112, P605, DOI 10.1111/j.1365-2567.2004.01906.x; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Sugawara R, 2016, J EXP MED, V213, P555, DOI 10.1084/jem.20141388; Taylor JM, 2008, MICROB PATHOGENESIS, V44, P20, DOI 10.1016/j.micpath.2007.06.006; Velin D, 2005, GASTROENTEROLOGY, V129, P142, DOI 10.1053/j.gastro.2005.04.010; Velin D, 2016, HELICOBACTER, V21, P26, DOI 10.1111/hel.12336; Velin D, 2009, GASTROENTEROLOGY, V136, P2237, DOI 10.1053/j.gastro.2009.02.077; Verdu EF, 1996, DIGESTION, V57, P180, DOI 10.1159/000201334; Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298; Weltzin R, 1997, VACCINE, V15, P370, DOI 10.1016/S0264-410X(97)00203-X; Wu MS, 2007, J INFECT DIS, V196, P1386, DOI 10.1086/522520; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Zeng M, 2015, LANCET, V386, P1457, DOI 10.1016/S0140-6736(15)60310-5; Zhang JQQ, 2004, EUR J IMMUNOL, V34, P1175, DOI 10.1002/eji.200324723	60	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 16	2021	39	27					3590	3601		10.1016/j.vaccine.2021.05.034		JUN 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SO5NX	34049736	hybrid			2022-04-29	WOS:000659020000007
J	Liu, YB; Xiong, Y; Liang, YQ; Deng, XY; Hu, Y; Hu, R; Chen, Q; Tang, FY; Wang, ZG; Sun, X; Guo, HX; Zhang, L; Zhu, FC				Liu, Yuanbao; Xiong, Yan; Liang, Yaqiong; Deng, Xiuying; Hu, Ying; Hu, Ran; Chen, Qiang; Tang, Fenyang; Wang, Zhiguo; Sun, Xiang; Guo, Hongxiong; Zhang, Lei; Zhu, Feng-Cai			Waning immunity and potential asymptomatic infection in 3-7 years old children who received one dose of measles-mumps-rubella vaccine: A 4-year prospective study	VACCINE			English	Article						Mumps; Waning immunity; Measles-mumps-rubella vaccine; Prevention	OUTBREAK; PERSISTENCE; ANTIBODIES; CHINA; PROVINCE	Background: Mumps outbreaks in adolescents who received two doses of measles-mumps-rubella vaccine (MMR) during childhood have been reported worldwide. In China, one dose of MMR administered in children aged among 18-24 months has a limited effect on the mumps epidemic. There are limited prospective studies evaluating the mumps immunity profile of children aged 3-7 years who received one dose of MMR. This study aimed to describe mumps immunity profile over a span of 4-years in kindergarten and primary school children. Methods: An observational, prospective study on one-dose MMR in children aged 3-7 years who underwent blood sample collection in 2015, 2016, and 2018 was conducted from 2015 to 2018. The seropositivity and geometric mean concentration of mumps IgG antibodies over time were analyzed. Results: A total of 3346 eligible children aged 3-7 years who underwent three rounds of blood sample collection were included. The overall seropositivity (79.6%) in 2015 was significantly higher than those recorded in 2016 (73.1%) and 2018 (71.4%). Approximately 11.6-15.9% of the participants were seropositive for mumps in 2015, and converted to negative in 2016. Meanwhile, 11.1-14.6% of the participants were seropositive for mumps in 2016, and the results converted to negative in 2018. Over 6.1-7.4% of the participants had asymptomatic infection from 2015 to 2016, while 9.0-9.9% of the participants were infected without clinical symptoms from 2016 to 2018. Conclusions: Kindergarten and primary school children who only received one dose of MMR were at higher risk of developing mumps. Waning immunity, seronegative conversion, and asymptomatic infection coexist in children who received one dose MMR. Determining the optimal age for administering the second dose of MMR in children should be prioritized to improve the control and prevention of mumps in China. (c) 2021 Elsevier Ltd. All rights reserved.	[Liu, Yuanbao; Zhu, Feng-Cai] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol, Nanjing 211166, Peoples R China; [Liu, Yuanbao; Deng, Xiuying; Hu, Ying; Hu, Ran; Chen, Qiang; Tang, Fenyang; Wang, Zhiguo; Sun, Xiang; Guo, Hongxiong; Zhang, Lei; Zhu, Feng-Cai] Jiangsu Prov Ctr Dis Control & Prevent, Dept Expanded Programme Immunizat, Nanjing 210009, Peoples R China; [Xiong, Yan] Qinhuai Dist Ctr Dis Control & Prevent, Nanjing 210029, Peoples R China; [Liang, Yaqiong] Nanjing Ctr Dis Control & Prevent, Dept Expanded Programme Immunizat, Nanjing 210009, Peoples R China		Zhu, FC (通讯作者)，Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol, 101 Longmian Ave, Nanjing 210029, Peoples R China.	jszfc@vip.sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82073623, 81502860]; Jiangsu Provincial Medical Youth Talent Project [QNRC2016547]; Medical and Scientific Research Project of Jiangsu Provincial Health and Family Planning Commission [H2017016]	This work was supported by the National Natural Science Foundation of China (grant number 82073623, 81502860) , and the Jiangsu Provincial Medical Youth Talent Project (grant number QNRC2016547) , and the Medical and Scientific Research Project of Jiangsu Provincial Health and Family Planning Commission (grant number H2017016) .	Almansour I, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01999; ANDERSON RM, 1985, NATURE, V318, P323, DOI 10.1038/318323a0; Barskey AE, 2012, NEW ENGL J MED, V367, P1704, DOI 10.1056/NEJMoa1202865; Bodewes R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233143; Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309; Carryn S, 2019, VACCINE, V37, P5323, DOI 10.1016/j.vaccine.2019.07.049; Clemmons NS, 2019, CLIN INFECT DIS, V68, P1684, DOI 10.1093/cid/ciy779; Cohen C, 2007, EMERG INFECT DIS, V13, P12; Cortese MM, 2011, J INFECT DIS, V204, P1413, DOI 10.1093/infdis/jir526; Cui AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169561; Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993; Dayan GH, 2008, NEW ENGL J MED, V358, P1580, DOI 10.1056/NEJMoa0706589; De Serres G, 2012, CLIN INFECT DIS, V55, P394, DOI 10.1093/cid/cis439; Dittrich S, 2011, VACCINE, V29, P9271, DOI 10.1016/j.vaccine.2011.09.072; ENNIS FA, 1969, J INFECT DIS, V119, P654, DOI 10.1093/infdis/119.6.654; Grennan Dara, 2019, JAMA, V322, P1022, DOI 10.1001/jama.2019.10982; Hassan T R, FRONT IMMUNOL, V11, P2020; Kaaijk P, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa505; Kaaijk P, 2020, J INFECT DIS, V221, P902, DOI 10.1093/infdis/jiz188; LeBaron CW, 2009, J INFECT DIS, V199, P552, DOI 10.1086/596207; Lewnard JA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5945; Li RZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46328; Liu YB, 2018, EXPERT REV VACCINES, V17, P445, DOI 10.1080/14760584.2018.1445529; Liu YB, 2015, SCI REP-UK, V5, DOI 10.1038/srep14660; Lochlainn LMN, 2019, LANCET INFECT DIS, V19, P1246, DOI 10.1016/S1473-3099(19)30396-2; Ma C, 2019, MMWR-MORBID MORTAL W, V68, P1112, DOI 10.15585/mmwr.mm6848a2; Ma R, 2018, VACCINE, V36, P2589, DOI 10.1016/j.vaccine.2018.03.074; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Qin W, 2019, HUM VACC IMMUNOTHER, V15, P2106, DOI 10.1080/21645515.2019.1581526; Ramanathan R, 2018, VACCINE, V36, P3721, DOI 10.1016/j.vaccine.2018.05.067; Rasheed MAU, 2019, P NATL ACAD SCI USA, V116, P19071, DOI 10.1073/pnas.1905570116; Schenk J, 2021, LANCET INFECT DIS, V21, P286, DOI 10.1016/S1473-3099(20)30442-4; Seagle EE, 2018, VACCINE, V36, P818, DOI 10.1016/j.vaccine.2017.12.075; Sun X, HUMAN VACCINES IMMUN, P1; Terada K, 2017, PEDIATR INT, V59, P885, DOI 10.1111/ped.13306; Vandermeulen C, 2009, J INFECT DIS, V199, P1457, DOI 10.1086/598482; Vygen S, 2016, EUROSURVEILLANCE, V21, P12, DOI 10.2807/1560-7917.ES.2016.21.10.30156; WAUGH CJ, 2020, SCI TRANSL MED, V0148, pE 131; WEIBEL RE, 1975, PEDIATRICS, V56, P380; Wohl S, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000611; Yang LJ, 2020, CURR OPIN VIROL, V40, P48, DOI 10.1016/j.coviro.2020.05.009	41	1	1	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 11	2021	39	26					3509	3515		10.1016/j.vaccine.2021.05.008		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SN6KQ	33994238				2022-04-29	WOS:000658397000009
J	Fairman, J; Agarwal, P; Barbanel, S; Behrens, C; Berges, A; Burky, J; Davey, P; Fernsten, P; Grainger, C; Guo, S; Iki, S; Iverson, M; Kane, M; Kapoor, N; Marcq, O; Migone, TS; Sauer, P; Wassil, J				Fairman, Jeff; Agarwal, Paresh; Barbanel, Sandrine; Behrens, Christopher; Berges, Aym; Burky, John; Davey, Peter; Fernsten, Phil; Grainger, Chris; Guo, Sherry; Iki, Sam; Iverson, Mark; Kane, Martin; Kapoor, Neeraj; Marcq, Olivier; Migone, Thi-Sau; Sauer, Paul; Wassil, James			Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)	VACCINE			English	Article						Pneumococcal conjugate vaccine; Immunogenicity; Streptococcus pneumoniae; Non-clinical; Serotypes	HUMAN CD4(+) CELLS; POLYSACCHARIDE VACCINE; DIPHTHERIA-TOXIN; ADULTS; SEROTYPES; SEQUENCE; EPITOPES; CHILDREN; DISEASE	Despite widespread utilization of pneumococcal conjugate vaccines (PCVs) and the resultant disease reduction, the development of PCVs containing additional serotypes remains a public health priority due to serotype replacement and the resultant shift to non-vaccine containing serotypes. However, incorporating additional serotypes to existing PCVs using conventional technologies has proven problematic. Immune responses to individual serotypes have consistently decreased as more polysaccharide-conjugates are added due to carrier suppression. Using our proprietary cell-free protein synthesis (CFPS) platform, we have successfully produced eCRM (R) based on the CRM197 sequence for use as an enhanced carrier protein to develop a 24-valent PCV. The eCRM carrier protein contains multiple nonnative amino acids (nnAAs) located outside of the primary T-cell epitope regions, thereby enabling site-specific covalent conjugation of the pneumococcal polysaccharides to the nnAAs to consistently expose the critical T-cell epitopes. eCRM also serves to reduce structural heterogeneity associated with classic reductive-amination conjugation while promoting formation of the conjugate matrix structures, the hallmark of PCVs. This process serves to increase the overall polysaccharide:protein ratio, enabling the inclusion of more serotypes while minimizing carrier-mediated immunological interference. The aim of this non-clinical study was to construct a 24-valent PCV and evaluate its immunogenicity. Using the XPressCF (R) CFPS platform, the eCRM carrier protein was separately conjugated through nnAAs to each of the 24 pneumococcal polysaccharides through click chemistry and mixed with aluminum phosphate to produce VAX-24, Vaxcyte's proprietary PCV preclinical candidate. VAX-24, Prevnar13 (R) and Pneumovax (R) 23 were administered to New Zealand White rabbits to compare the resulting opsonophagocytic activity (OPA) and anti-capsular IgG antibodies. VAX-24 showed conjugate-like immune responses to all 24 serotypes based on comparable OPA and IgG responses to Prevnar13 and higher responses than Pneumovax 23. This study demonstrates the utility of site-specific conjugation technology in a preclinical setting and the potential for a PCV with improved serotype coverage. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Fairman, Jeff; Agarwal, Paresh; Barbanel, Sandrine; Behrens, Christopher; Berges, Aym; Burky, John; Davey, Peter; Grainger, Chris; Guo, Sherry; Iki, Sam; Iverson, Mark; Kapoor, Neeraj; Marcq, Olivier; Migone, Thi-Sau; Sauer, Paul; Wassil, James] Vaxcyte Inc, 353 Hatch Dr, Foster City, CA 94404 USA; [Kane, Martin] Exponent, 149 Commonwealth Dr, Menlo Pk, CA 94025 USA; [Fernsten, Phil] VBT Labs, 1424 Gertrude Ave, Phoenixville, PA 19460 USA		Wassil, J (通讯作者)，353 Hatch Dr, Foster City, CA 94404 USA.	jim.wassil@vaxcyte.com		Fernsten, Philip/0000-0002-3084-5667; Behrens, Christopher/0000-0002-2286-6302; grainger, christopher/0000-0001-5297-5158; Agarwal, Paresh/0000-0003-3054-2794	Vaxcyte, Inc.	This work was sponsored by Vaxcyte, Inc. We thank Opal Daniels, Christine Burbank and Joe Harmuth at Covance Immunology Services, Denver, PA for coordinating the animal studies and performing the ELISA immunological testing and for Rob Burton for performing the OPA assay at the University of Alabama Birmingham.	Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; [Anonymous], 2010, BLASTN125324; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Dagan R, 2010, VACCINE, V28, P5513, DOI 10.1016/j.vaccine.2010.06.026; Demczuk WHB, 2013, CAN J MICROBIOL, V59, P778, DOI 10.1139/cjm-2013-0614; Diethelm-Okita BM, 2000, J INFECT DIS, V181, P1001, DOI 10.1086/315324; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; Fitzwater SP, 2012, PEDIATR INFECT DIS J, V31, P501, DOI 10.1097/INF.0b013e31824de9f6; GIANNINI G, 1984, NUCLEIC ACIDS RES, V12, P4063, DOI 10.1093/nar/12.10.4063; Grabenstein J. D., 2018, PLOTKINS VACCINES, V7th; Greenberg RN, 2014, VACCINE, V32, P2364, DOI 10.1016/j.vaccine.2014.02.002; Henriques-Normark B, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a010215; Hurley, 2019, 29 EUR C CLIN MICR I; Jackson LA, 2013, VACCINE, V31, P3594, DOI 10.1016/j.vaccine.2013.04.084; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Lee gm, 2019, PNEUMOCOCCAL WORKIN; Lee LH, 2003, VACCINE, V21, P2190, DOI 10.1016/S0264-410X(03)00025-2; Lo SW, 2019, LANCET INFECT DIS, V19, P759, DOI 10.1016/S1473-3099(19)30297-X; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Pichichero ME, 2013, HUM VACC IMMUNOTHER, V9, P2505, DOI 10.4161/hv.26109; Raju R, 1995, EUR J IMMUNOL, V25, P3207, DOI 10.1002/eji.1830251202; Richter SS, 2013, EMERG INFECT DIS, V19, P1074, DOI 10.3201/eid1907.121830; Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822; U.S. Food and Drug Administration, 2011, VACC REL BIOL PROD A; U.S. Food and Drug Administration, 2011, BLASTN124324262; Varghese J, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2019.09.008; World Health Organization, 2013, 60 WHO, P91; Yeh SH, 2010, PEDIATRICS, V126, pE493, DOI 10.1542/peds.2009-3027	30	5	5	3	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 27	2021	39	23					3197	3206		10.1016/j.vaccine.2021.03.070		MAY 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SF2TJ	33965258	hybrid			2022-04-29	WOS:000652613400011
J	Stabel, JR; Bannantine, JP				Stabel, J. R.; Bannantine, J. P.			Reduced tissue colonization of Mycobacterium avium subsp. paratuberculosis in neonatal calves vaccinated with a cocktail of recombinant proteins	VACCINE			English	Article						Mycobacterium avium subsp. paratuberculosis; Vaccine; Recombinant proteins; Immunity	CELLULAR IMMUNE-RESPONSES; PROTECTIVE EFFICACY; INFECTION; CANDIDATES; IMMUNOGENICITY; IMMUNIZATION; TUBERCULOSIS; EXPRESSION; CHALLENGE; ANTIGENS	An increasing prevalence of paratuberculosis supports the need for new efficacious vaccines as an essential management tool. Two separate studies were performed in neonatal calves to evaluate the effectiveness of pooled recombinant Mycobacterium avium subsp. paratuberculosis (MAP) proteins (MAP1087, MAP1204, MAP1272c, MAP2077c) as a potential vaccine. In the first study vaccinated calves were immunized with 400 mu g protein cocktail per dose, whereas the second study compared doses of 400 mu g and 800 mu g of protein cocktail, followed by challenge with live MAP for both vaccinated and nonvaccinated control calves 28 days post-vaccination. At the end of 12 months, tissue colonization with MAP was significantly reduced for the vaccinated calves compared to control animals. A higher dose of vaccine improved protection, with further reductions of MAP burden. Antigen-specific IFN-gamma responses and serum antibody responses were similar regardless of vaccination, indicating exposure to MAP invoked conventional host immune responses. Host immunity differed due to vaccination, resulting in increased percentages of CD4+ T cells and B cells after stimulation of PBMCs with antigen. Interestingly, gene expression in PBMCs was similar for both control and vaccinated calves except for significant increases in IFN-gamma, IL-12, and IL-17 expression observed in vaccinated calves. Vaccination with a cocktail of immunogenic recombinant MAP proteins was efficacious in reducing the level of infection and fecal shedding of neonatal calves and may be a potential tool for curtailing the spread of Johne's disease. Published by Elsevier Ltd.	[Stabel, J. R.; Bannantine, J. P.] USDA ARS, Natl Anim Dis Ctr, POB 70, Ames, IA 50010 USA		Stabel, JR (通讯作者)，USDA ARS, Natl Anim Dis Ctr, POB 70, Ames, IA 50010 USA.	judy.stabel@usda.gov		Bannantine, John/0000-0002-5692-7898	US Department of Agriculture, Agricultural Research Service Project (CRIS) [5030-32000221]	This work was supported by the US Department of Agriculture, Agricultural Research Service Project (CRIS#5030-32000221) . USDA is an equal opportunity employer.	Bannantine JP, 2008, PROTEOME SCI, V6, DOI 10.1186/1477-5956-6-5; Bannantine JP, 2012, CLIN VACCINE IMMUNOL, V19, P1083, DOI 10.1128/CVI.00195-12; Bannantine JP, 2004, J CLIN MICROBIOL, V42, P106, DOI 10.1128/JCM.42.1.106-114.2004; Bannantine JP, 2014, FRONT CELL INFECT MI, P4; Bull TJ, 2014, VET RES, V45, DOI 10.1186/s13567-014-0112-9; Carpenter SM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006704; Chandra S, 2012, VACCINE, V31, P242, DOI 10.1016/j.vaccine.2012.09.024; Collins MT, 2006, JAVMA-J AM VET MED A, V229, P1912, DOI 10.2460/javma.229.12.1912; Cooper AM, 2007, CURR OPIN IMMUNOL, V19, P441, DOI 10.1016/j.coi.2007.07.004; Faisal SM, 2013, CLIN VACCINE IMMUNOL, V20, P572, DOI 10.1128/CVI.00653-12; Ghosh P, 2015, VACCINE, V33, P7262, DOI 10.1016/j.vaccine.2015.10.116; Gopal R, 2012, EUR J IMMUNOL, V42, P364, DOI 10.1002/eji.201141569; Gupta S, 2019, VET QUART, V39, P143, DOI 10.1080/01652176.2019.1667042; Hines ME, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00026; Huntley JF, 2005, INFECT IMMUN, V73, P6877, DOI 10.1128/IAI.73.10.6877-6884.2005; Kathaperumal K, 2008, VACCINE, V26, P1652, DOI 10.1016/j.vaccine.2008.01.015; Kipnis A, 2005, INFECT IMMUN, V73, P7759, DOI 10.1128/IAI.73.11.7759-7764.2005; Koets A, 2006, VACCINE, V24, P2550, DOI 10.1016/j.vaccine.2005.12.019; Lamont EA, 2014, FRONT CELL INFECT MI, V4; Leite F, 2013, J VET DIAGN INVEST, V25, P27, DOI 10.1177/1040638712466395; Li LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184373; Lombard JE, 2013, PREV VET MED, V108, P234, DOI 10.1016/j.prevetmed.2012.08.006; Park HT, 2016, CLIN EXP VACCINE RES, V5, P108, DOI 10.7774/cevr.2016.5.2.108; Park KT, 2011, VACCINE, V29, P4709, DOI 10.1016/j.vaccine.2011.04.090; Patton EA, 2011, VET CLIN N AM-FOOD A, V27, P573, DOI 10.1016/j.cvfa.2011.07.004; Pitt JM, 2012, J IMMUNOL, V189, P4079, DOI 10.4049/jimmunol.1201061; Rigden RC, 2006, J MED MICROBIOL, V55, P1735, DOI 10.1099/jmm.0.46785-0; Romero-Adrian TB, 2015, WORLD J IMMUNOL, V5, P16, DOI [10.5411/wji.v5.i1.16., DOI 10.5411/wji.v5.i1.16, DOI 10.5411/WJI.V5.I1.16]; Roupie V, 2008, VACCINE, V26, P4783, DOI 10.1016/j.vaccine.2008.07.009; Settles EW, 2014, VACCINE, V32, P2062, DOI 10.1016/j.vaccine.2014.02.010; Shin SJ, 2005, INFECT IMMUN, V73, P5074, DOI 10.1128/IAI.73.8.5074-5085.2005; Shippy DC, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/cvi.00478-16, 10.1128/CVI.00478-16]; Souriau A, 2017, RES VET SCI, V115, P278, DOI 10.1016/j.rvsc.2017.05.025; Stabel JR, 2012, VACCINE, V31, P127, DOI 10.1016/j.vaccine.2012.10.090; Stabel JR, 2011, CLIN VACCINE IMMUNOL, V18, P2079, DOI 10.1128/CVI.05421-11; Stabel JR, 1997, J VET DIAGN INVEST, V9, P375, DOI 10.1177/104063879700900406; Stabel JR, 1996, J VET DIAGN INVEST, V8, P345, DOI 10.1177/104063879600800311; Sweeney RW, 2011, VET CLIN N AM-FOOD A, V27, P537, DOI 10.1016/j.cvfa.2011.07.001; Thukral A, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0164-y; Waters WR, 2016, CLIN VACCINE IMMUNOL, V23, P168, DOI 10.1128/CVI.00637-15; Waters WR, 2003, INFECT IMMUN, V71, P5130, DOI 10.1128/IAI.71.9.5130-5138.2003	41	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 27	2021	39	23					3131	3140		10.1016/j.vaccine.2021.04.051		MAY 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SF2TJ	33966908				2022-04-29	WOS:000652613400004
J	Kawamura, Y; Hattori, F; Higashimoto, Y; Kozawa, K; Yoshikawa, T				Kawamura, Yoshiki; Hattori, Fumihiko; Higashimoto, Yuki; Kozawa, Kei; Yoshikawa, Tetsushi			Evaluation of varicella vaccine effectiveness during outbreaks in schools or nurseries by cross-sectional study	VACCINE			English	Article						Varicella; Vaccine effectiveness; Outbreak; Elementary school; Nursery	BREAKTHROUGH VARICELLA; CHILDREN; IMMUNIZATION; SEVERITY; PROGRAM	Objective: The aim of this study was to elucidate vaccine effectiveness (VE) during varicella outbreaks in schools and nurseries in Japan. Methods: An outbreak was defined as emergence of three or more cases of varicella within 21 days at the same institute. Clinical information such as varicella vaccination status, and history of varicella was collected. If a child had varicella during the outbreak, information about absences, fever, and disease severity was collected. Results: From September 2018 to January 2020, four outbreaks were reported around our institute from three elementary schools and one nursery. A total of 676 children were analyzed in this study. Seventysix children (11.2%) were unvaccinated, 309 (45.7%) had received one dose of vaccine, and 291 (43.0%) had received two doses. Most children in Pre-K2 (1?2 years old) to Pre-K6 (5?6 years old), who were the targets of the national immunization schedule, received two doses. Meanwhile, most children older than third grade received single dose. Seventy-five children (11.1%) had varicella. Varicella prevalence from Pre-K5 to the third grade was greater than 10%. The adjusted VEs of single-and two-dose of varicella vaccine were 57.8% and 89.0%. The number of days absent was significantly longer in unvaccinated children than single-dose recipients (P = 0.0145). Unvaccinated children had significantly more severe skin eruptions than single-dose recipients (P = 0.0046) and two-dose recipients (P = 0.0258). Conclusions: Although VEs of single-dose varicella vaccination during outbreaks was not high, the VE of two-dose vaccination was similar to that in a previously reported case-control study. ? 2021 Elsevier Ltd. All rights reserved.	[Kawamura, Yoshiki; Kozawa, Kei; Yoshikawa, Tetsushi] Fujita Hlth Univ, Dept Pediat, Sch Med, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi 4701192, Japan; [Hattori, Fumihiko] Kariya Toyota Gen Hosp, Dept Pediat, Kariya, Aichi, Japan; [Higashimoto, Yuki] Fujita Hlth Univ, Fac Med Technol, Sch Med Sci, Toyoake, Aichi, Japan		Kawamura, Y (通讯作者)，Fujita Hlth Univ, Dept Pediat, Sch Med, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi 4701192, Japan.	yoshiki@fujita-hu.ac.jp		higashimoto, yuki/0000-0002-1794-9736			Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361, DOI 10.1128/CMR.9.3.361; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; Chaves SS, 2008, J INFECT DIS, V197, pS127, DOI 10.1086/522150; Chaves SS, 2007, NEW ENGL J MED, V356, P1121, DOI 10.1056/NEJMoa064040; Galil K, 2002, J INFECT DIS, V186, P102, DOI 10.1086/341089; Gould PL, 2009, PEDIATR INFECT DIS J, V28, P678, DOI 10.1097/INF.0b013e31819c1041; Hattori F, 2020, VACCINE, V38, P7331, DOI 10.1016/j.vaccine.2020.09.038; Hattori F, 2017, VACCINE, V35, P4936, DOI 10.1016/j.vaccine.2017.07.090; HUSE DM, 1994, J PEDIATR-US, V124, P869, DOI 10.1016/S0022-3476(05)83173-7; Leung J, 2017, EXPERT REV VACCINES, V16, P391, DOI 10.1080/14760584.2017.1294069; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; Mahamud A, 2012, VACCINE, V30, P6935, DOI 10.1016/j.vaccine.2012.07.076; Marin M, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3741; Miron D, 2005, PEDIATR INFECT DIS J, V24, P233, DOI 10.1097/01.inf.0000154323.20387.82; National Institute of Infectious Diseases J. Varicella (chickenpox), CASES REPORTED SENTI; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Ozaki T, 2013, J INFECT CHEMOTHER, V19, P188, DOI 10.1007/s10156-013-0577-x; Qin W, 2020, HUM VACC IMMUNOTHER, V16, P1851, DOI 10.1080/21645515.2019.1704574; Seward JF, 2004, JAMA-J AM MED ASSOC, V292, P704, DOI 10.1001/jama.292.6.704; Shapiro ED, 2011, J INFECT DIS, V203, P312, DOI 10.1093/infdis/jiq052; Suo LD, 2017, VACCINE, V35, P4368, DOI 10.1016/j.vaccine.2017.06.065; TAKAHASH.M, 1974, LANCET, V2, P1288, DOI 10.1016/S0140-6736(74)90144-5; Thomas CA, 2014, PEDIATR INFECT DIS J, V33, P1164, DOI 10.1097/INF.0000000000000444; Wharton M, 1996, INFECT DIS CLIN N AM, V10, P571, DOI 10.1016/S0891-5520(05)70313-5; Zhu S, 2018, AM J INFECT CONTROL, V46, pE1, DOI 10.1016/j.ajic.2017.07.029	25	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 18	2021	39	21					2901	2905		10.1016/j.vaccine.2021.04.009		MAY 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RX4UJ	33895017				2022-04-29	WOS:000647220100012
J	Menkir, TF; Jbaily, A; Verguet, S				Menkir, Tigist Ferede; Jbaily, Abdulrahman; Verguet, Stephane			Incorporating equity in infectious disease modeling: Case study of a distributional impact framework for measles transmission	VACCINE			English	Article						Dynamic transmission modeling; Measles; Vaccination; Equity; Socioeconomic status; Social contact matrices	COST-EFFECTIVENESS ANALYSIS; SPREAD	Introduction: Deterministic compartmental models of infectious diseases like measles typically reflect biological heterogeneities in the risk of infection and severity to characterize transmission dynamics. Given the known association of socioeconomic status and increased vulnerability to infection and mortality, it is also critical that such models further incorporate social heterogeneities. Methods: Here, we aimed to explore the influence of integrating income-associated differences in parameters of traditional dynamic transmission models. We developed a measles SIR model, in which the Susceptible, Infected and Recovered classes were stratified by income quintile, with income-specific transmission rates, disease-induced mortality rates, and vaccination coverage levels. We further provided a stylized illustration with secondary data from Ethiopia, where we examined various scenarios demonstrating differences in transmission patterns by income and in distributional vaccination coverage, and quantified impacts on disparities in measles mortality. Results: The income-stratified SIR model exhibited similar dynamics to that of the traditional SIR model, with amplified outbreak peaks and measles mortality among the poorest income group. All vaccination coverage strategies were found to substantially curb the overall number of measles deaths, yet most considerably for the poorest, with select strategies yielding clear reductions in measles mortality disparities. Discussion: The incorporation of income-specific differences can reveal distinct outbreak patterns across income groups and important differences in the subsequent effects of preventative interventions like vaccination. Our case study highlights the need to extend traditional modeling frameworks (e.g. SIR models) to be stratified by socioeconomic factors like income and to consider ensuing income-associated differences in disease-related morbidity and mortality. In so doing, we build on existing tools and characterize ongoing challenges in achieving health equity. ? 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Menkir, Tigist Ferede] Harvard Univ, Ctr Communicable Dis Dynam, Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Jbaily, Abdulrahman; Verguet, Stephane] Harvard Univ, Dept Global Hlth & Populat, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA		Verguet, S (通讯作者)，Harvard Univ, Dept Global Hlth & Populat, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.	verguet@hsph.harvard.edu			Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [INV-010-174]	We acknowledge funding from the Bill & Melinda Gates Foundation (INV-010-174), and we are grateful to Lelisa Fekadu for comments on an earlier version of the manuscript. We also would like to thank four anonymous reviewers for providing very valuable and constructive comments on the manuscript.	Akalu HB, 2015, J TROP DIS, V4, P2, DOI [10.4172/2329-891X.1000193, DOI 10.4172/2329-891X.1000193]; Central Statistical Agency The DHS Program-ICF, 2017, ETHIOPIA DEMOGRAPHIC; Chang AY, 2018, HEALTH AFFAIR, V37, P316, DOI 10.1377/hlthaff.2017.0861; Chowell G, 2016, PHYS LIFE REV, V18, P66, DOI 10.1016/j.plrev.2016.07.005; Cookson R, 2017, VALUE HEALTH, V20, P206, DOI 10.1016/j.jval.2016.11.027; DHS, GUIDE DHS STAT DHS 7; Drake TL, 2016, HEALTH ECON, V25, P124, DOI 10.1002/hec.3303; Ethiopian Public Health Institute Federal Ministry of Health The DHS Program-ICF, Mini Demographic and Health Survey 2019-Key Indicators; Figueroa-Munoz JI, 2008, TUBERCULOSIS CONTROL; Funk S, 2010, J R SOC INTERFACE, V7, P1247, DOI 10.1098/rsif.2010.0142; Gastanaduy PA, 2020, JAMA PEDIATR, V174, P56, DOI 10.1001/jamapediatrics.2019.4357; Hilton J, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2019.0317; Hoes J, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00209; IHME, ETHIOPIA; Jit M, 2011, PHARMACOECONOMICS, V29, P371, DOI 10.2165/11539960-000000000-00000; Jones J. H., 2007, NOTES R0; Kiti MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104786; Leo Y, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0598; Ma KC, 2021, MODELING IMPACT RACI, DOI [10.1101/2021.01.15.21249881v1, DOI 10.1101/2021.01.15.21249881V1]; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; O'Donnell O., ANAL HLTH EQUITY USI; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Portnoy A, 2019, LANCET GLOB HEALTH, V7, pE472, DOI 10.1016/S2214-109X(18)30537-0; Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697; Rohani P, 2007, MODELING INFECT DIS, V1st, P384; Sudfeld CR, 2010, INT J EPIDEMIOL, V39, P48, DOI 10.1093/ije/dyq021; Suen SC, 2017, J THEOR BIOL, V428, P1, DOI 10.1016/j.jtbi.2017.06.004; TB Modelling and Analysis Consortium Centre for the Mathematical Modelling of Infectious Diseases, EQUITY EC EVALUATION; Team R.C., 2021, LANG ENV STAT COMP; Verguet S, 2017, LANCET GLOB HEALTH, V5, pE1123, DOI 10.1016/S2214-109X(17)30341-8; Verguet S, 2016, PHARMACOECONOMICS, V34, P913, DOI 10.1007/s40273-016-0414-z; Verguet S, 2015, VACCINE, V33, P1291, DOI 10.1016/j.vaccine.2014.11.050; World Bank, 2020, ETHIOPIA OVERVIEW; World Health Organization, 2019, ETHIOPIA LAUNCHES ME; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	35	0	0	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 18	2021	39	21					2894	2900		10.1016/j.vaccine.2021.03.023		MAY 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RX4UJ	33863575	Green Published, hybrid			2022-04-29	WOS:000647220100011
J	Solans, L; Debrie, AS; Coutte, L; Locht, C				Solans, Luis; Debrie, Anne-Sophie; Coutte, Loic; Locht, Camille			Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative	VACCINE			English	Article						Pertussis; Live attenuated vaccine; Pertactin; Bordetella pertussis; Whooping cough	BORDETELLA-PERTUSSIS; MOLECULAR CHARACTERIZATION; CLINICAL-MANIFESTATIONS; CONTROLLED-TRIAL; STRAINS; CHILDREN; FITNESS	Pertussis, mainly caused by Bordetella pertussis, is a severe respiratory disease that can be fatal, especially in young infants. Vaccines, massively implemented since the middle of the last century, have substantially reduced the pertussis incidence, but have not been able to fully control the disease. One of the shortcomings of current pertussis vaccines is their inability to prevent infection by and transmission of B. pertussis, in contrast to immunity following natural infection. We have developed the live attenuated nasal vaccine BPZE1 and have shown that it prevents both disease and B. pertussis infection in preclinical models. This vaccine is now in clinical development. However, the initial clinical studies have suggested that vaccine take is hampered by pre-existing antibodies to pertactin. Here, we have constructed a pertactin-deficient BPZE1 derivative called BPZE1P in order to overcome this limitation. BPZE1P colonized the murine respiratory tract as efficiently as BPZE1 and induced antibodies at levels similar to those elicited by BPZE1. In the presence of pre-existing antibodies induced by acellular pertussis vaccination, BPZE1P colonized the mouse respiratory tract more efficiently than BPZE1. Both vaccines protected equally well the murine lungs and noses from challenge with laboratory and clinical strains of B. pertussis, including pertactin-deficient strains, against which current acellular pertussis vaccines are less efficient. BPZE1P may thus be an interesting alternative to BPZE1 to overcome vaccine take limitations due to preexisting antibodies to pertactin. (C) 2021 Elsevier Ltd. All rights reserved.	[Solans, Luis; Debrie, Anne-Sophie; Coutte, Loic; Locht, Camille] Univ Lille, U1019 UMR 8204, Inst Pasteur Lille, CHU Lille,CNRS,INSERM,CIIL Ctr Infect & Immun Lil, F-59000 Lille, France; [Solans, Luis] Exopol, Poligono Rio Gallego, San Mateo De Ga, Spain		Locht, C (通讯作者)，Inst Pasteur, Ctr Infect & Immun Lille, 1 Rue Prof Calmette, F-59019 Lille, France.	Camille.locht@pasteur-lille.fr	Coutte, Loic/G-4379-2012	Coutte, Loic/0000-0002-8626-8109	ILiAD Biotechnologies	We thank Guy Berbers, Rob Mariman and their colleagues from the rivm, Bilthoven, The Netherlands, for the generous gift of anti-Prn antibodies and B. pertussis clinical isolates together with information about the isolates and Scott Stibitz, FDA, Rockville, Md, USA, for pSS4940. This work was funded in part by ILiAD Biotechnologies.	Antoine R, 2005, J MOL BIOL, V351, P799, DOI 10.1016/j.jmb.2005.05.071; Barkoff AM, 2019, EUROSURVEILLANCE, V24, P39, DOI 10.2807/1560-7917.ES.2019.24.7.1700832; Barkoff AM, 2012, CLIN VACCINE IMMUNOL, V19, P1703, DOI 10.1128/CVI.00367-12; Bart MJ, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.01301-14; Bodilis H, 2013, EMERG INFECT DIS, V19, P471, DOI 10.3201/1903.121475; Bouchez V, 2009, VACCINE, V27, P6034, DOI 10.1016/j.vaccine.2009.07.074; Burns DL, 2014, J INFECT DIS, V209, pS32, DOI 10.1093/infdis/jit491; Carriquiriborde F, 2019, EMERG INFECT DIS, V25, P2048, DOI 10.3201/eid2511.190329; Clarke M, 2016, J INFECTION, V72, P171, DOI 10.1016/j.jinf.2015.11.004; Debrie AS, 2018, VACCINE, V36, P1345, DOI 10.1016/j.vaccine.2018.02.017; Feunou PF, 2014, VACCINE, V32, P4281, DOI 10.1016/j.vaccine.2014.06.019; Feunou PF, 2010, VACCINE, V28, P7047, DOI 10.1016/j.vaccine.2010.08.017; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Hegerle N, 2014, VACCINE, V32, P6597, DOI 10.1016/j.vaccine.2014.09.068; Hegerle N, 2012, CLIN MICROBIOL INFEC, V18, pE340, DOI 10.1111/j.1469-0691.2012.03925.x; IMAIZUMI A, 1983, INFECT IMMUN, V41, P1138, DOI 10.1128/IAI.41.3.1138-1143.1983; Jahnmatz M, 2020, LANCET INFECT DIS, V20, P1290, DOI 10.1016/S1473-3099(20)30274-7; Jayasundara D, 2020, EPIDEMICS-NETH, V31, DOI 10.1016/j.epidem.2020.100388; Lesne E, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02108; Lin A, 2020, J CLIN INVEST, V130, P2332, DOI 10.1172/JCI135020; Locht C, 2018, VACCINE, V36, P5460, DOI 10.1016/j.vaccine.2017.11.055; Locht C, 2017, J INFECT DIS, V216, P117, DOI 10.1093/infdis/jix254; Martin SW, 2015, CLIN INFECT DIS, V60, P223, DOI 10.1093/cid/ciu788; Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005; MENOZZI FD, 1994, INFECT IMMUN, V62, P769, DOI 10.1128/IAI.62.3.769-778.1994; Merkel TJ, 2020, CLIN INFECT DIS, V71, P412, DOI 10.1093/cid/ciz842; Mielcarek N, 2006, PLOS PATHOG, V2, P662, DOI 10.1371/journal.ppat.0020065; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Otsuka N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031985; Pawloski LC, 2014, CLIN VACCINE IMMUNOL, V21, P119, DOI 10.1128/CVI.00717-13; Safarchi A, 2015, VACCINE, V33, P6277, DOI 10.1016/j.vaccine.2015.09.064; Solans L, 2018, MUCOSAL IMMUNOL, V11, P1753, DOI 10.1038/s41385-018-0073-9; Stefanelli P, 2009, NEW MICROBIOL, V32, P159; STIBITZ S, 1994, METHOD ENZYMOL, V235, P458; Thorstensson R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083449; Tsang RSW, 2014, INT J INFECT DIS, V28, P65, DOI 10.1016/j.ijid.2014.08.002; Vodzak J, 2017, CLIN INFECT DIS, V64, P60, DOI 10.1093/cid/ciw632; Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0; Zeddeman A, 2014, EUROSURVEILLANCE, V19, P17, DOI 10.2807/1560-7917.ES2014.19.33.20881	40	3	3	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 18	2021	39	21					2843	2849		10.1016/j.vaccine.2021.04.014		MAY 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RX4UJ	33896662				2022-04-29	WOS:000647220100005
J	Lopes, KAD; Baptista, PN; Nascimento, RD; Pimentel, A; Ximenes, RAD				de Miranda Lopes, Katiuscia Araujo; Baptista, Paulo Neves; Nascimento, Renata de Medeiros; Pimentel, Analiria; de Alencar Ximenes, Ricardo Arraes			Clinical repercussions in pertussis infants post-Tdpa vaccination of pregnant woman: An immunization success?	VACCINE			English	Article						Pertussis; Infants; Maternal vaccine; Tdap	DISEASE; DIPHTHERIA; TETANUS	Introduction: In 2014, there was an epidemic of pertussis in Brazil that caused the death of 129 infants. To control the disease amongst infants under 6 months of age, and especially those under 2 months, the Brazilian Ministry of Health introduced Tdap immunization for all pregnant women. Methods: This study aimed to describe the morbidity and mortality variables of pertussis cases in 969 infants aged under 6 months, comparing the periods before and after the introduction of Tdap vaccine in pregnant women. Data was extracted from the Information System on Notifiable Diseases (SINAN) including every case of pertussis that occurred in the metropolitan region of Recife-Brazil in infants under 6 months from January 2009 to October 2018. In order to analyze the variables, patients were divided into two groups Pre-Tdap(2009-2014), and Post-Tdap (2016-2018). Results: There were no significant differences between the age groups and gender distribution in the period compared. In the Post- Tdap group compared with the Pre-Tdap group, the clinical presentation of pertussis in infants differed with more paroxysmal cough, and more vomiting, less apnea, and cyanosis. During this period, there were fewer complications and no deaths occurred. Conclusions: Maternal immunization with Tdap decreased disease severity, complication rates, and no deaths occurred in infants under 6 months of age diagnosed with pertussis. (C) 2021 Elsevier Ltd. All rights reserved.	[de Miranda Lopes, Katiuscia Araujo; Nascimento, Renata de Medeiros; de Alencar Ximenes, Ricardo Arraes] Univ Pernambuco, Rua Arnobio Marques 310, BR-50100130 Recife, PE, Brazil; [Baptista, Paulo Neves; Pimentel, Analiria] Univ Pernambuco, Univ Hosp Oswaldo Cruz, Recife, PE, Brazil		Lopes, KAD (通讯作者)，Univ Pernambuco, Rua Arnobio Marques 310, BR-50100130 Recife, PE, Brazil.	katiuscia.lopes@upe.br; raaximenes@uol.com.br		Araujo de Miranda Lopes, Katiuscia/0000-0002-0282-9184	Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]; Brazilian National Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [487030/2013-3 APQ]	This study was funded in part by the Coordination for the Improvement of Higher Education Personnel-Brazil (CAPES) under the financing code 001, and by the Brazilian National Council for Scientific and Technological Development (CNPq) under the universal edict 14/2013 track-C, process n. 487030/2013-3 APQ, and carried by the Health Secretariat in the State of Pernambuco and the Universidade de Pernambuco. Financial support did not participate in the study design, collection, analysis, and interpretation of data; in writing of the report; nor in the decision to submit the article for publication.	Acip P, 2008, MMWR RECOMMENDATION, V57; Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3; [Anonymous], 2018, B EPIDEMIOLOGICO COQ, V1; [Anonymous], 2017, GUIA VIGILANCIA SANI, V1; Berger JT, 2013, PEDIATR CRIT CARE ME, V14, P356, DOI 10.1097/PCC.0b013e31828a70fe; Bricks LF, 2013, J HEAL BIOL SCI, V1, P73; CDC, 2012, GUIDELINES VACCINATI; Coqueluche no Brasil, 2016, ANALISE SITUACAO EPI, V46; Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821; DataSUS, DADOS COBERTURA VACI; DataSUS, DADOS COQUELUCHE NO; Friedrich F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228022; Gabutti G, 2015, HUM VACCIN IMMUNOTHE, P5515; Gentile A, 2018, VACCINE, V36, P1375, DOI [10.1016/j.vaccine.2018.01.091, 10.1016/j.vaccine.2018.01.0]; Hartzell JD, 2014, CHEST, V146, P205, DOI 10.1378/chest.13-2942; Khodr ZG, 2017, VACCINE, V35, P5603, DOI 10.1016/j.vaccine.2017.08.041; Kilgore PE, 2016, CLIN MICROBIOL REV, V29, P449, DOI 10.1128/CMR.00083-15; Lapidot Rotem, 2016, Trop Dis Travel Med Vaccines, V2, P26, DOI 10.1186/s40794-016-0043-8; Liang JL, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6702a1; Saul N, 2018, VACCINE, V36, P1887, DOI 10.1016/j.vaccine.2018.02.047; Sedighi I, 2016, IRAN J PEDIATR, V26, DOI 10.5812/ijp.5514; Somerville RL, 2007, J PAEDIATR CHILD H, V43, P617, DOI 10.1111/j.1440-1754.2007.01154.x; Torres RSLA, 2015, J PEDIAT-BRAZIL, V91, P333, DOI [10.1016/j.jpedp.2015.04.006, 10.1016/j.jped.2014.09.004]	23	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2555	2560		10.1016/j.vaccine.2021.03.069		APR 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33814232				2022-04-29	WOS:000642189300012
J	Stalpers, CAL; Retmana, IA; Pennings, JLA; Vandebriel, RJ; Hendriksen, CFM; Akkermans, AM; Hoefnagel, MHN				Stalpers, Coen A. L.; Retmana, Irene A.; Pennings, Jeroen L. A.; Vandebriel, Rob J.; Hendriksen, Coenraad F. M.; Akkermans, Arnoud M.; Hoefnagel, Marcel H. N.			Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines	VACCINE			English	Article						Assay variability; In vivo potency test; Diphtheria; Tetanus; Pertussis; 3Rs	QUALITY-CONTROL; ANIMAL USE; REDUCTION; REPLACEMENT; REFINEMENT; PROGRESS; MOUSE; ASSAY	For batch release of legacy vaccines such as DTaP, in vivo potency release assays are required. We quantified the variability of in vivo potency release assays for four DTaP (Diphtheria, Tetanus, acellular Pertussis) products of different manufacturers. With their large CV (Coefficients of Variance) ranging from 16% to 132%, these in vivo assays are of limited value to ensure their potency is consistent and similar to the clinical batches used for the marketing authorisation. Our data show that, although individual potency test results show high variability, the DTaP batches are manufactured with great consistency, because repeated potency testing yields similar averages for the different batches. The economic impact of variability of in vivo tests is significant since it may result in the need for greater amount of antigen than may be required or for repeating a test. For monitoring the consistency of potency, in vitro assays are superior to in vivo assays. Animal-free potency determination is common practice for newly developed vaccines under modern GMP quality systems. However, replacement of in vivo potency tests for legacy vaccines like DTaP is challenging and would require a 'reverse characterisation' strategy in which the antigens are further characterised at the level of drug substance and drug product to identify critical quality attributes (CQA) that can be tested with in vitro assays. Based on these an updated set of release tests without animal tests can be proposed. Our data can serve as benchmark for the innovative methods. (C) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Stalpers, Coen A. L.; Retmana, Irene A.; Hoefnagel, Marcel H. N.] CBG MEB, Graadt van Roggenweg 500, NL-3531 AH Utrecht, Netherlands; [Stalpers, Coen A. L.; Pennings, Jeroen L. A.; Vandebriel, Rob J.; Akkermans, Arnoud M.] RIVM, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands; [Stalpers, Coen A. L.] Univ Utrecht, Dept Infect Dis & Immunol, Div Immunol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands; [Hendriksen, Coenraad F. M.] Intravacc, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands		Hoefnagel, MHN (通讯作者)，CBG MEB, Graadt van Roggenweg 500, NL-3531 AH Utrecht, Netherlands.	mh.hoefnagel@cbg-meb.nl		Pennings, Jeroen L.A./0000-0002-9188-6358	Innovative Medicines Initiative 2 Joint Undertaking [N-115924]; Dutch Ministry of Agriculture, Nature and Fishery; National Institute of Public Health & the Environment; VAC2VAC	We thank Shahjahan Shaid, Charline Hoebreck and Sylvie Uhlrich for critically reading the manuscript. The VAC2VAC project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement N-115924. This Joint Undertaking and innovation programme and EFPIA. The funding source was not involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.; JLAP and RJV were supported by VAC2VAC, the Dutch Ministry of Agriculture, Nature and Fishery, and the National Institute of Public Health & the Environment.	[Anonymous], 2020, EUROPEAN PHARM 10 1; [Anonymous], 2018, EUROPEAN PHARMACOPEI; Behr-Gross ME, 2003, PHARMEUROPA BIO, V2, P69; Behrensdorf-Nicol HA, 2013, VACCINE, V31, P6247, DOI 10.1016/j.vaccine.2013.10.028; BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204; Bruysters MWP, 2017, BIOLOGICALS, V48, P1, DOI 10.1016/j.biologicals.2017.06.006; Coombes L, 2012, BIOLOGICALS, V40, P466, DOI 10.1016/j.biologicals.2012.07.011; Coombes L, 2009, J IMMUNOL METHODS, V350, P142, DOI 10.1016/j.jim.2009.09.002; De Mattia Fabrizio, 2011, Biologicals, V39, P59, DOI 10.1016/j.biologicals.2010.12.001; Descamps J, 2011, PROCEDIA VACCINOL, V5, P184, DOI 10.1016/j.provac.2011.10.018; EU, 2010, OFFICIAL J EUROPEAN, pL276; Galazka AM, 1998, WHOGPV9807; Glenny AT, 1923, BRIT J EXP PATHOL, V4, P283; Goris N, 2007, VACCINE, V25, P3373, DOI 10.1016/j.vaccine.2006.12.049; Greene SA, 2019, MMWR-MORBID MORTAL W, V68, P458, DOI 10.15585/mmwr.mm6820a3; HENDRIKSEN CFM, 1994, BIOLOGICALS, V22, P257, DOI 10.1006/biol.1994.1037; Hendriksen CFM, 2009, EXPERT REV VACCINES, V8, P313, DOI 10.1586/14760584.8.3.313; Hinman AR, 2006, ANNU REV PUBL HEALTH, V27, P235, DOI 10.1146/annurev.publhealth.27.021405.102248; Kendrick P, 1936, AM J PUBLIC HEALTH N, V26, P8, DOI 10.2105/AJPH.26.1.8; Labadie A., 2008, PHARMEUROPA, V20, P655; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Metz B, 2002, VACCINE, V20, P2411, DOI 10.1016/S0264-410X(02)00192-5; Misquith A, 2014, COLLOID SURFACE B, V113, P312, DOI 10.1016/j.colsurfb.2013.09.006; Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086; Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003; Ramon G, 1924, ANN I PASTEUR, V38, P1; Ranheim T, 2015, VACCINE ANAL STRATEG, P521; Rosen O, 2016, TOXINS, V8, DOI 10.3390/toxins8100276; Russell WMS., 1959, PRINCIPLES HUMANE EX; Stickings P, 2011, PROCEDIA VACCINOL, V5, P200, DOI 10.1016/j.provac.2011.10.020; van der Ark A, 2000, BIOLOGICALS, V28, P105, DOI 10.1006/biol.2000.0247	31	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2506	2516		10.1016/j.vaccine.2021.03.078		APR 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RQ1OX	33824038	hybrid			2022-04-29	WOS:000642189300007
J	Angelis, A; Darrow, J				Angelis, Aris; Darrow, Jonathan			Safeguarding evidence-based decision making in the FDA for COVID-19 vaccines	VACCINE			English	Editorial Material									[Angelis, Aris] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England; [Angelis, Aris] London Sch Hyg & Trop Med, Dept Hlth Policy, London, England; [Angelis, Aris] London Sch Hyg & Trop Med, LSE Hlth, London, England; [Darrow, Jonathan] Harvard Med Sch, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, Dept Med,Brigham & Womens Hosp, Boston, MA 02115 USA; [Darrow, Jonathan] Bentley Univ, Dept Law & Taxat, Waltham, MA 02452 USA		Angelis, A (通讯作者)，London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England.	aris.angelis@lshtm.ac.uk			Arnold Ventures; Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited [NNF17SA0027784]	Thanks to Aaron S. Kesselheim, MD, JD, MPH, from the Program on Regulation, Therapeutics, and Law, Brigham and Women's Hospital, Harvard Medical School, for helpful feedback. Jonathan Darrow reports grants from Arnold Ventures during the conduct of the study. He is also funded by a Novo Nordisk Foundation grant for a scientifically independent Collaborative Research Programme (Grant No. NNF17SA0027784).	[Anonymous], 2020, DEV LICENSURE VACCIN; Avorn J, 2020, NEW ENGL J MED; Califf R, 2020, 7 FORMER FDA COMMISS; Califf RM, 2019, HEALTH AFFAIR, V38, P84, DOI 10.1377/hlthaff.2018.05185; Carpenter D, 2010, PRINC STUD AM POLIT, P1; Cavazzoni P, 2020, SENIOR FDA CAREER EX; Elbeshbishi S, 2020, US TODAY SUFFOLK POL US TODAY SUFFOLK POL; FDA, 2019, POSTMARKETING STUDIE; FDA, 2018, FOOD DRUG ADMINIST; FDA, 2020, EMERGENCY USE AUTHOR; Lynch HF, 2021, NAT MED, V27, P188, DOI 10.1038/s41591-020-01200-w; Gottlieb S., 2017, WHISTLEBLOWER PROTEC; Jamrozik E, 2020, LANCET INFECT DIS, V20, pE198, DOI 10.1016/S1473-3099(20)30438-2; Naci H, 2017, CHARACTERISTICS PREA; Naci H, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3869; Pease AM, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1680; Regulations ECoF, 2020, TITLE 42 PUBLIC HLTH; Sharfstein J, 2020, NATURE, V585, P161, DOI 10.1038/d41586-020-02542-8; Thomas K., 2020, 9 DRUG COMPANIES PLE; Troy D, 2019, HLTH AFFAIRS BLOG HL	20	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 22	2021	39	17					2328	2330		10.1016/j.vaccine.2021.03.053		APR 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RL7KL	33785254	Green Accepted, Green Published, Bronze			2022-04-29	WOS:000639147100003
J	Wan, C; Gao, C; Xie, Q; Wang, Y; Cheng, X; Fang, Y; Liu, ZY; Zhang, WJ; Zou, QM; Lu, GW; Gu, J				Wan, Chuang; Gao, Chen; Xie, Qin; Wang, Yin; Cheng, Xin; Fang, Yao; Liu, Zhiyong; Zhang, Weijun; Zou, Quanming; Lu, Guangwen; Gu, Jiang			Flagella hook protein FlgE is a novel vaccine candidate of Pseudomonas aeruginosa identified by a genomic approach	VACCINE			English	Article						Genomic library; Antigen screening; Pseudomonas aeruginosa; FlgE; Pneumonia		Infections due to Pseudomonas aeruginosa (PA) are becoming a serious threat to patients in intensive care units. A PA vaccine is a practical and economical solution to solve the problems caused by PA infection successfully. In recent years, several antigen candidates have been tested in animal and human clinical trials, but none of them has been approved to date. An alternative strategy for antigen screening and protective antigens is in urgent demand. In this study, we generated a genome-wide library of PA protein fragments tagged with maltose-binding protein (MBP). Using sera from patients who recovered after PA infection, we identified a novel protective antigen, FlgE, which is the structural component of the flagella hook. Vaccination with recombinant FlgE (reFlgE) induced a Th2-predominant immune response and reduced bacterial load and inflammation in PA-infected mice. Anti-reFlgE antibodies recognized native FlgE on the bacterial membrane in vitro and conferred protection in mice, which may be due to the mediation of opsonophagocytic killing and inhibition of bacterial motility. In addition, the combination of reFlgE with rePcrVNH, an engineered antigen we reported previously, provided elevated protection against PA infection. Our data demonstrate that FlgE is a promising vaccine candidate for PA and provide a new strategy for the efficient screening of antigens of other pathogens. (C) 2021 Elsevier Ltd. All rights reserved.	[Wan, Chuang; Gao, Chen; Wang, Yin; Cheng, Xin; Fang, Yao; Zhang, Weijun; Zou, Quanming; Gu, Jiang] Third Mil Med Univ, Coll Pharm, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Chongqing 400038, Peoples R China; [Xie, Qin; Liu, Zhiyong] Third Mil Med Univ, Southwest Hosp, Chongqing, Peoples R China; [Lu, Guangwen] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Lu, Guangwen] Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan, Peoples R China		Gu, J (通讯作者)，Third Mil Med Univ, Coll Pharm, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Chongqing 400038, Peoples R China.; Lu, GW (通讯作者)，Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.; Lu, GW (通讯作者)，Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan, Peoples R China.	lugw@scu.edu.cn; jianggu2012@163.com	Gu, Jiang/AAT-2432-2021	Gu, Jiang/0000-0001-8035-4551	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772155]; Natural Science Foundation of ChongqingNatural Science Foundation of Chongqing [CSTC2016JCYJA0080]	This research was supported by the National Natural Science Foundation of China (81772155) and Natural Science Foundation of Chongqing (CSTC2016JCYJA0080).	Adlbrecht C, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2792-z; Aronson NE, 2006, CLIN INFECT DIS, V43, P1045, DOI 10.1086/507539; Behrouz B, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/5689709; Bianconi I, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03021; Campodonico VL, 2010, INFECT IMMUN, V78, P746, DOI 10.1128/IAI.00806-09; Carratala J, 1998, ARCH INTERN MED, V158, P868, DOI 10.1001/archinte.158.8.868; Doring G, 2007, P NATL ACAD SCI USA, V104, P11020, DOI 10.1073/pnas.0702403104; DORING G, 1995, AM J RESP CRIT CARE, V151, P983; Folkesson A, 2012, NAT REV MICROBIOL, V10, P841, DOI 10.1038/nrmicro2907; Galvao CE, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1110-7; Gholami M, 2017, LETT APPL MICROBIOL, V65, P439, DOI 10.1111/lam.12796; Hou Q, 2015, EUR J GYNAECOL ONCOL, V36, P590, DOI 10.12892/ejgo2651.2015; Kapust RB, 1999, PROTEIN SCI, V8, P1668, DOI 10.1110/ps.8.8.1668; Lombardi C, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00573; Merakou C, 2018, SURG INFECT, V19, P757, DOI 10.1089/sur.2018.233; Minamino T, 2015, TRENDS MICROBIOL, V23, P267, DOI 10.1016/j.tim.2014.12.011; Mosquera-Rendon J, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2364-4; Munder A, 2005, MICROBES INFECT, V7, P600, DOI 10.1016/j.micinf.2004.12.021; Murray CK, 2011, J TRAUMA, V71, pS62, DOI 10.1097/TA.0b013e3182218c99; Ogunremi O, 2008, J PARASITOL, V94, P1402, DOI 10.1645/GE-1557.1; Petersen K, 2007, ANN SURG, V245, P803, DOI 10.1097/01.sla.0000251707.32332.c1; Pier GB, 2003, CARBOHYD RES, V338, P2549, DOI 10.1016/S0008-6215(03)00312-4; Raran-Kurussi S, 2015, PROTEIN EXPRES PURIF, V110, P159, DOI 10.1016/j.pep.2015.03.004; Raran-Kurussi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049589; Shen Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01619-1; Spangenberg C, 1996, FEBS LETT, V396, P213, DOI 10.1016/0014-5793(96)01099-X; Tanaka N, 2009, RNA, V15, P1865, DOI 10.1261/rna.1771509; Thirumala R, 2010, CRIT CARE CLIN, V26, P59, DOI 10.1016/j.ccc.2009.09.007; Wan C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00781; Waugh DS, 2016, PROTEIN SCI, V25, P559, DOI 10.1002/pro.2863; Weiner LM, 2016, INFECT CONT HOSP EP, V37, P1288, DOI 10.1017/ice.2016.174; Wieland K, 2018, AM J INFECT CONTROL, V46, P643, DOI 10.1016/j.ajic.2017.12.014; Wu WH, 2012, AM J RESP CRIT CARE, V186, P420, DOI 10.1164/rccm.201202-0182OC; Xu WT, 2020, BIOL PHARM BULL, V43, P1469, DOI 10.1248/bpb.b19-01052	34	2	2	3	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 22	2021	39	17					2386	2395		10.1016/j.vaccine.2021.03.051		APR 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RL7KL	33775439				2022-04-29	WOS:000639147100011
J	Deerin, JF; Clifton, R; Elmi, A; Lewis, PE; Kuo, I				Deerin, Jessica Fung; Clifton, Rebecca; Elmi, Angelo; Lewis, Paul E.; Kuo, Irene			Hepatitis B birth dose vaccination patterns in the military health System, 2014-2018	VACCINE			English	Article						Hepatitis B; Hepatitis B birth dose vaccine; Parental refusal; Vaccine hesitancy		Background: Since 2005, the universal hepatitis B (HepB) birth dose has been recommended for all medically stable infants weighing >= 2,000 g at birth. The timing of the birth dose provides a critical safeguard and prevents infection among infants born to HBsAg-positive mothers not identified prenatally. We assess infant HepB vaccination in the U.S. Department of Defense's Military Health System (MHS) to identify trends in vaccination coverage and sociodemographic factors associated with non-receipt of the birth dose, receiving the first HepB vaccine >3 days of life, and not receiving any HepB vaccine in the first 18 months of life utilizing parental refusal codes. To our knowledge, this is one of the first studies assessing trends in parental refusal of the HepB birth dose utilizing administrative claims parental refusal codes. Methods: We conducted a retrospective cohort analysis of MHS live births from January 1, 2014 through December 31, 2018 utilizing administrative claims data. Data were included from 44 hospitals in 24 unique states, territories, or countries. We analyzed diagnosis codes for vaccine refusal and vaccination and current procedural terminology (CPT) codes to identify vaccination patterns. Generalized linear mixed effects models with a logit link were used to assess factors associated with vaccination patterns. Results: HepB birth dose vaccination coverage increased from 79.6% in 2014 to 88.1% in 2018 (p<.0001). Refusal rates also increased from 3.7% in 2014 to 4.5% in 2018 (p<.0001). The percentage of patients with missing diagnosis codes for vaccine refusal or vaccination decreased from 16.7% in 2014 to 7.4% in 2018. Factors associated with non-receipt of the birth dose included earlier year of birth, white maternal race, higher maternal age, higher birth order, and longer infant length of stay in hospital. Conclusion: Vaccination coverage for HepB birth dose is high in the MHS and increased over time; concurrently, refusal rates also increased over time. Utilizing administrative claims data has the benefit of differentiating reasons for non-receipt of the birth dose over time. (C) 2021 Elsevier Ltd. All rights reserved.	[Deerin, Jessica Fung; Clifton, Rebecca; Kuo, Irene] George Washington Univ, Milken Inst Sch Publ Hlth, Dept Epidemiol, Washington, DC 20052 USA; [Elmi, Angelo] George Washington Univ, Milken Inst Sch Publ Hlth, Dept Biostat & Bioinformat, Washington, DC 20052 USA; [Lewis, Paul E.] Def Hlth Agcy, Armed Forces Hlth Surveillance Branch, Calverton, MD USA		Deerin, JF (通讯作者)，950 New Hampshire Ave NW, Washington, DC 20052 USA.	Jessicafdeerin@gwu.edu					Bradshaw Chanda, 2020, Hosp Pediatr, V10, P430, DOI 10.1542/hpeds.2019-0294; Chabra Shilpi, 2020, Hosp Pediatr, V10, pe18, DOI 10.1542/hpeds.2020-001255; Changoor NR, 2018, CANCER-AM CANCER SOC, V124, P3724, DOI 10.1002/cncr.31637; Daley MF, 2017, VACCINE, V35, P1873, DOI 10.1016/j.vaccine.2017.02.058; Dempsey AF, 2011, PEDIATRICS, V128, P848, DOI 10.1542/peds.2011-0400; Do WS, 2019, AM J SURG, V217, P843, DOI 10.1016/j.amjsurg.2019.02.021; Gilmartin CE, 2020, AUST NZ J OBSTET GYN, V60, P93, DOI 10.1111/ajo.13008; Glanz JM, 2013, JAMA PEDIATR, V167, P274, DOI 10.1001/jamapediatrics.2013.502; Hachem CY, 2008, ALIMENT PHARM THER, V28, P1078, DOI 10.1111/j.1365-2036.2008.03827.x; HHS, HLTH PEOPL 2020 OBJ; HHS, 2021, VIRAL HEPATITIS NATL; Hill HA, 2020, MMWR-MORBID MORTAL W, V69, P1505, DOI 10.15585/mmwr.mm6942a1; Hill HA, 2019, MMWR-MORBID MORTAL W, V68, P913, DOI 10.15585/mmwr.mm6841e2; Hill HA, 2018, MMWR-MORBID MORTAL W, V67, P1123, DOI 10.15585/mmwr.mm6740a4; Madlon-Kay DJ, 2011, J AM BOARD FAM MED, V24, P656, DOI 10.3122/jabfm.2011.06.110027; Madsen C, 2020, MIL MED; Massey J, 2018, PEDIATR INFECT DIS J; Mast Eric E., 2006, Morbidity and Mortality Weekly Report, V55, P1; Mbaeyi S, 2020, PEDIATR ANN, V49, pE523, DOI 10.3928/19382359-20201115-02; O'Leary ST, 2012, PEDIATR INFECT DIS J, V31, P1, DOI 10.1097/INF.0b013e3182345995; Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483; Oster NV, 2019, VACCINE, V37, P5738, DOI 10.1016/j.vaccine.2019.03.050; Robison SG, 2012, PEDIATRICS, V130, P32, DOI 10.1542/peds.2011-3154; Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1; Siddiqui M, 2013, HUM VACC IMMUNOTHER, V9, P2643, DOI 10.4161/hv.27243; Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215; Smith PJ, 2010, PUBLIC HEALTH REP, V125, P534, DOI 10.1177/003335491012500408; Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187; Wasley A, 2010, J INFECT DIS, V202, P192, DOI 10.1086/653622; Wightman A, 2011, PEDIATRICS, V128, P1094, DOI 10.1542/peds.2011-0666; Zhao Z, 2013, PREV MED, V57, P613, DOI 10.1016/j.ypmed.2013.08.012	31	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2094	2102		10.1016/j.vaccine.2021.03.010		APR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QH	33741189				2022-04-29	WOS:000637937500012
J	Klassen, AC; Milliron, BJ; Reynolds, L; Bakhtibekova, Z; Mamadraimov, S; Bahruddinov, M; Shokamolova, S; Shuster, M; Mukhtar, S; Gafurova, M; Iskandari, M; Majidian, R; Job-Johnson, B				Klassen, Ann Carroll; Milliron, Brandy-Joe; Reynolds, Leslie; Bakhtibekova, Zubayda; Mamadraimov, Suhaily; Bahruddinov, Mutribjon; Shokamolova, Sitora; Shuster, Michelle; Mukhtar, Sarah; Gafurova, Maftuna; Iskandari, Malika; Majidian, Rauf; Job-Johnson, Bridget			Formative research to address vaccine hesitancy in Tajikistan	VACCINE			English	Article						Vaccine hesitancy; Culture; Behavior change; Health communication; Child health; Central Asia		Introduction: Incomplete childhood vaccination is associated with caregiver vaccine hesitancy, conceptualized by "3 Cs": high complacency, low confidence, and low convenience. To expand on existing evidence drawn primarily from the Americas and Europe, and develop culturally appropriate interventions, this research explored drivers of vaccine hesitancy in the Central Asian country of Tajikistan. Methods: In twelve diverse districts, clinic-based immunization record abstraction identified purposive samples of children who were up-to-date (N = 300) or not (N = 300) on all first year vaccines. Using a modified case-control design, the structured face-to-face in-home survey of 600 caregivers compared knowledge, attitudes and practices regarding childhood vaccination by up-to-date status. Sociodemographic and psychological factors associated with hesitancy were identified, using a 22-item vaccine hesitancy scale, with subscales measuring complacency, confidence, and convenience. Overall contribution of vaccine hesitancy to up-to-date status was modeled, adjusting for other significant covariates. Results: Caregivers of not up-to-date children were more likely to report their child's health as poor, and report many logistical barriers to vaccination. Knowledge of vaccine-preventable illnesses was low, and complacency regarding vaccination was high among not up-to-date caregivers. In final multivariable models of predisposing, enabling and reinforcing influences on vaccination status, urban children, those with transportation and employed mothers were more likely to be up-to-date, while not up-to-date children included those born at home, seen as having fair or poor health, or reportedly told by clinicians to avoid immunization. Reinforcing factors included having a "vaccine passport", receiving useful information from medical providers, and believing that vaccine-preventable illnesses are serious and that most in their community are vaccinated. Additionally, vaccine hesitancy was negatively associated with up-todate status (odds ratio 0.15, 95% CI. 0.08, 0.26). Conclusions: Results confirm that in this traditional culture, there is a strong need for tailored communication campaigns to address vaccine hesitancy, while continuing to address systems-level barriers. (C) 2021 Elsevier Ltd. All rights reserved.	[Klassen, Ann Carroll; Reynolds, Leslie; Shuster, Michelle; Mukhtar, Sarah; Gafurova, Maftuna; Iskandari, Malika; Majidian, Rauf] Drexel Univ, Dept Community Hlth & Prevent, Dornsife Sch Publ Hlth, 3215 Market St,4th Floor, Philadelphia, PA 19104 USA; [Milliron, Brandy-Joe] Drexel Univ, Dept Nutr Sci, Coll Nursing & Hlth Profess, Philadelphia, PA 19101 USA; [Bakhtibekova, Zubayda; Mamadraimov, Suhaily; Bahruddinov, Mutribjon; Shokamolova, Sitora; Job-Johnson, Bridget] UNICEF Tajikistan, Dushanbe, Tajikistan		Klassen, AC (通讯作者)，Drexel Univ, Dept Community Hlth & Prevent, Dornsife Sch Publ Hlth, 3215 Market St,4th Floor, Philadelphia, PA 19104 USA.	ack57@drexel.edu			UNICEF Tajikistan; Drexel University	The authors acknowledge the contributions of the individuals and households who participated in the study, and generously provided their time and insights. We also thank the Tajikistan Ministry of Health and Social Protection, and its staff, for assisting in study design, data collection, and logistics. Funding for the research was provided by UNICEF Tajikistan, under a long-term agreement for services with Drexel University.	Akmatov MK, 2007, VACCINE, V25, P1756, DOI 10.1016/j.vaccine.2006.11.030; [Anonymous], 2017, TAJIKISTAN IMMUNIZAT; Bronfenbrenner U, 1992, 6 THEORIES CHILD DEV; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046; Dowding D, 2013, QUAL SOC WORK, V12, P541, DOI 10.1177/1473325013493540a; Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004; Green L, 2005, HLTH PROGRAM PLANNIN, V4th; Karam R, 2019, INTERPERSONAL COMMUN; Khodjamurodov G, 2016, HEALT SYST TRANSIT, V18, P1; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Matta P, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09526-3; Merritt MW, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000349; Rechel B, 2012, HEALTH POLICY PLANN, V27, P281, DOI 10.1093/heapol/czr040; Sallis JF, 2008, HLTH BEHAV HLTH ED, V4, P465, DOI DOI 10.7326/0003-4819-116-4-350_1; Statistical agency under the president of the Republic of Tajikistan Ministry of Health and social protection of population of the Republic of Tajikistan and ICF, 2018, TAJ DEM HLTH SURV 20; Wagner AL, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040155; Waisbord S, 2005, WHY INVEST COMMUNICA; WHO Country Office for Europe, 2019, MEASLES RUBELLA ELIM; World Bank, 2017, PROF POV PROSP TAJ; World Bank Group, 2018, TAJ SYST COUNTR DIAG	24	0	0	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 5	2021	39	10					1516	1527		10.1016/j.vaccine.2021.01.033		FEB 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QM3RT	33487469				2022-04-29	WOS:000621700000009
J	Singh, A				Singh, Ajit			Why not the 'marker' or DIVA vaccines for the control of emerging infectious diseases of humans?	VACCINE			English	Editorial Material									[Singh, Ajit] Lala Lajpat Rai Univ Vet & Anim Sci, Dept Vet Microbiol, Hisar 125004, Haryana, India		Singh, A (通讯作者)，Lala Lajpat Rai Univ Vet & Anim Sci, Dept Vet Microbiol, Hisar 125004, Haryana, India.	as.jakhar@luvas.edu.in		Singh, Ajit/0000-0003-0620-9879	Indian Council of Agricultural Research, New Delhi, IndiaIndian Council of Agricultural Research (ICAR)	The author is grateful to Indian Council of Agricultural Research, New Delhi, India for the grant of Emeritus Scientist scheme, and to LUVAS, Hisar, India for extending facilities of the work place.	James CM, 2007, VACCINE, V25, P5892, DOI 10.1016/j.vaccine.2007.05.023; Kennedy RB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01181; Moormann RJM, 2000, VET MICROBIOL, V73, P209, DOI 10.1016/S0378-1135(00)00146-2; O'Kennedy R., 2017, IMMUNOASSAYS DEV APP; Singh A. M., 2015, STEM CELL REP, V5, P1, DOI DOI 10.37591/RRJ0I]; Suarez DL, 2005, BIOLOGICALS, V33, P221, DOI 10.1016/j.biologicals.2005.08.003; van Oirschot JT, 1999, J BIOTECHNOL, V73, P195, DOI 10.1016/S0168-1656(99)00121-2; Vu HLX, 2013, VACCINE, V31, P4330, DOI 10.1016/j.vaccine.2013.07.020; Walsh EP, 2000, J GEN VIROL, V81, P709, DOI 10.1099/0022-1317-81-3-709; Xue QH, 2020, J VIROL, V94, DOI 10.1128/JVI.01573-19	10	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 5	2021	39	10					1476	1477		10.1016/j.vaccine.2021.01.069		FEB 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QM3RT	33573864				2022-04-29	WOS:000621700000002
J	Poland, EG; McGuire, DK; Ratishvili, T; Poland, GA				Poland, Eric G.; McGuire, Darren K.; Ratishvili, Tamar; Poland, Gregory A.			The economics of global COVID vaccine administration during a pandemic - Why continue skin alcohol preparation as a costly but ineffective practice?	VACCINE			English	Editorial Material							CONTROLLED-TRIAL; A INJECTION; HEALTH		[McGuire, Darren K.] Univ Texas SouthWestern Med Ctr, Dallas, TX USA; [McGuire, Darren K.] Parkland Hlth & Hosp Syst, Dallas, TX USA; [Ratishvili, Tamar; Poland, Gregory A.] Mayo Clin, Mayo Clin Vaccine Res Grp, Rochester, MN 55905 USA		Poland, GA (通讯作者)，Mayo Clin, Mayo Clin Vaccine Res Grp, Rochester, MN 55905 USA.	poland.gregory@mayo.edu	mcguire, darren keith/AAL-4172-2021				American Academyof Pediatrics, 2018, RED BOOK 2018 REP CO; Centers for Disease Control and Prevention, 2019, GEN BEST PRACTICE GU; Cochrane LJ, 2007, J CONTIN EDUC HEALTH, V27, P94, DOI 10.1002/chp.106; DANN TC, 1969, LANCET, V2, P96; Del Mar CB, 2001, MED J AUSTRALIA, V174, P306; Gittens Gemma, 2009, Nurs Stand, V23, P42; Global Mobility Management, 2018, SAL COMM JOBS GLOB; Gupta DM, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0555-2; Hutin Y, 2003, B WORLD HEALTH ORGAN, V81, P491; Ipp M, 2007, ARCH DIS CHILD, V92, P1105, DOI 10.1136/adc.2007.118695; KOIVISTO VA, 1978, LANCET, V1, P1072; LIAUW J, 1995, LANCET, V345, P1648, DOI 10.1016/S0140-6736(95)90156-6; MCCARTHY JA, 1993, DIABETES CARE, V16, P402, DOI 10.2337/diacare.16.1.402a; O'Neill J, 2013, AM J INFECT CONTROL, V41, P755, DOI 10.1016/j.ajic.2012.11.009; O'Neill J, 2012, OPHTHAL PLAST RECONS, V28, P307, DOI 10.1097/IOP.0b013e31825ca776; Organisation for Economic Cooperation and Development (OECD), 2017, REM NURS; Pennic F., 2020, TRAVEL NURSE PAY NEA; Pham T, 2009, OPHTHAL PLAST RECONS, V25, P178, DOI 10.1097/IOP.0b013e3181a145e5; Prasad V, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-1; Pratt RJ, 2005, BRIT J INFECT CONTRO, V6, P18; Public Health England, 2013, THE GREEN BOOK; Reiss I, 2000, LANCET, V356, P310, DOI 10.1016/S0140-6736(00)02509-5; SAUTTER RL, 1984, INFECT CONT HOSP EP, V5, P223, DOI 10.1017/S019594170006015X; Sutton CD, 1999, ANN ROY COLL SURG, V81, P183; U.S. Bureau of Labor Statistics, 2019, OCCUPATIONAL EMPLOYM; Ubel PA, 2015, HEALTH AFFAIR, V34, P239, DOI 10.1377/hlthaff.2014.0983; Wolicki J, 2020, CTR DIS CONTROL PREV; Wong H, 2019, HUM VACC IMMUNOTHER, V15, P995, DOI 10.1080/21645515.2018.1553474; Workman B, 1999, Nurs Stand, V13, P47; World Health Organization, 2010, WHO BEST PRACT INJ R; World Health Organization, 2003, GLOB ADV COMM VACC S; World Salaries.org, 2008, PROF NURS SAL INT CO	32	3	3	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1175	1177		10.1016/j.vaccine.2020.12.082		FEB 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33485647	Green Published			2022-04-29	WOS:000618493500002
J	Shimizu, T; Watanabe, Y; Ando, H; Ishima, Y; Ishida, T				Shimizu, Taro; Watanabe, Yuki; Ando, Hidenori; Ishima, Yu; Ishida, Tatsuhiro			Lymphoid follicle antigen (Ag) delivery and enhanced rodent humoral immune responses mediated by Ag-containing PEGylated liposomes	VACCINE			English	Article						PEGylated liposome; Humoral immune response; Lymphoid follicle; Marginal zone B cell; Spleen		Antigen (Ag) delivery to lymphoid follicles is important in achieving adaptive immunity. We recently developed a novel two-step Ag delivery system that efficiently induces cellular immune responses to Ags in mice by using priming intravenous (i.v.) injections of empty PEGylated liposomes (PEG-Lip) followed 3 days later by Ag-entrapped PEG-Lip (Ag-PEG-lip). In this study, we looked for humoral immune responses in rats and mice with IgG production specific to the encapsulated Ags. We observed that initial i.v. injections of empty PEG-Lip triggered accumulation of subsequent doses ovalbumin-PEG-Lip (OVA-PEG-lip) in splenic follicles and enhanced IgG production against OVA in both rats and mice. Anti-OVA IgG production was diminished by inhibition of splenic follicular accumulation of OVA-PEG-Lip by fin-golimod (FTY720), which inhibits lymphocyte egress from lymphoid tissues. This indicates that the follicular accumulation of Ags that we observed is an indispensable and unique step in the production of anti-OVA IgG. Interestingly, in BALB/c nude mice, which are T cell deficient, a high follicular accumulation of OVA-PEG-Lip was observed, but anti-OVA IgG production was not observed. This suggests that T cells are also indispensable for the induction of cellular immune responses by our two-step immunization procedure. Our unique Ag delivery platform, which efficiently delivers Ags to splenic follicles, may be a useful technique for the enhancement of cellular immunity, as well as humoral immunity. Further experimental evaluation should be undertaken in relevant animal models in order for efficacy, safety and immunological correlates to be determined. (C) 2021 Elsevier Ltd. All rights reserved.	[Shimizu, Taro; Watanabe, Yuki; Ando, Hidenori; Ishima, Yu; Ishida, Tatsuhiro] Tokushima Univ, Inst Biomed Sci, Dept Pharmacokinet & Biopharmaceut, 1-78-1 Sho Machi, Tokushima 7708505, Japan		Ishida, T (通讯作者)，Tokushima Univ, Inst Biomed Sci, Dept Pharmacokinet & Biopharmaceut, 1-78-1 Sho Machi, Tokushima 7708505, Japan.	ishida@tokushima-u.ac.jp	Shimizu, Taro/AAV-4027-2021	Shimizu, Taro/0000-0002-8326-2166	Nagai Foundation, TokyoNagai Foundation Tokyo; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Tokushima University;  [13J10060];  [15K18921]	This study was supported by the Nagai Foundation, Tokyo, the Japan Society for the Promotion of Science, a Grant-in-Aid for JSPS Fellows (13J10060), Young Scientists (15K18921) and a research program for the development of an intelligent Tokushima artificial exosome (iTEX) from Tokushima University.	Abu Lila AS, 2013, J CONTROL RELEASE, V172, P38, DOI 10.1016/j.jconrel.2013.07.026; Abu Lila AS, 2013, BIOL PHARM BULL, V36, P1842; Attanavanich K, 2004, J IMMUNOL, V172, P803, DOI 10.4049/jimmunol.172.2.803; Batista FD, 2009, NAT REV IMMUNOL, V9, P15, DOI 10.1038/nri2454; Bhowmick S, 2009, INFECT IMMUN, V77, P1514, DOI 10.1128/IAI.01739-07; Cinamon G, 2008, NAT IMMUNOL, V9, P54, DOI 10.1038/ni1542; Cyster JG, 2010, NAT IMMUNOL, V11, P989, DOI 10.1038/ni.1946; De Serrano LO, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0319-9; DENNERT G, 1972, NATURE-NEW BIOL, V238, P114, DOI 10.1038/newbio238114a0; Epstein JE, 2011, SCIENCE, V334, P475, DOI 10.1126/science.1211548; Ferguson AR, 2004, INT IMMUNOL, V16, P1411, DOI 10.1093/intimm/dxh142; Goenka R, 2014, J EXP MED, V211, P45, DOI 10.1084/jem.20130505; Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709; Hanke T, 1998, J GEN VIROL, V79, P83, DOI 10.1099/0022-1317-79-1-83; Hickling JK, 2011, B WORLD HEALTH ORGAN, V89, P221, DOI 10.2471/BLT.10.079426; Ishida T, 2007, J CONTROL RELEASE, V122, P349, DOI 10.1016/j.jconrel.2007.05.015; Link A, 2012, J IMMUNOL, V188, P3724, DOI 10.4049/jimmunol.1103312; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012; Nolte MA, 2003, J EXP MED, V198, P505, DOI 10.1084/jem.20021801; Pobre K, 2014, VACCINE, V32, P1423, DOI 10.1016/j.vaccine.2014.01.047; Roozendaal R, 2009, IMMUNITY, V30, P264, DOI 10.1016/j.immuni.2008.12.014; Rutemark C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041968; Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149-2918(02)80075-3; Schellekens H, 2003, NEPHROL DIAL TRANSPL, V18, P1257, DOI 10.1093/ndt/gfg164; Schwendener Reto A, 2014, Ther Adv Vaccines, V2, P159, DOI 10.1177/2051013614541440; Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800; Shimizu T, 2018, J IMMUNOL, V201, P2969, DOI 10.4049/jimmunol.1701351; Shimizu T, 2015, IMMUNOBIOLOGY, V220, P1151, DOI 10.1016/j.imbio.2015.06.005; Shimizu T, 2013, IMMUNOBIOLOGY, V218, P725, DOI 10.1016/j.imbio.2012.08.274; Sorman A, 2014, MOL IMMUNOL, V61, P79, DOI 10.1016/j.molimm.2014.06.010; Sultan H, 2019, CANCER IMMUNOL IMMUN, V68, P455, DOI 10.1007/s00262-018-02294-5; Van Mulder TJS, 2019, VACCINE, V37, P581, DOI 10.1016/j.vaccine.2018.12.016; Vora KA, 2005, J LEUKOCYTE BIOL, V78, P471, DOI 10.1189/jlb.0904487; Vyas JM, 2008, NAT REV IMMUNOL, V8, P607, DOI 10.1038/nri2368; Wang XM, 2011, J EXP MED, V208, P2497, DOI 10.1084/jem.20111449; Wang XY, 2007, J CONTROL RELEASE, V119, P236, DOI 10.1016/j.jconrel.2007.02.010; Watson DS, 2012, VACCINE, V30, P2256, DOI 10.1016/j.vaccine.2012.01.070; Zhang L, 2015, EXPERT REV VACCINES, V14, P1509, DOI 10.1586/14760584.2015.1081067; Zhang L, 2014, J IMMUNOL, V193, P1681, DOI 10.4049/jimmunol.1400331	40	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 12	2021	39	7					1131	1139		10.1016/j.vaccine.2021.01.008		FEB 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QC9HH	33478792				2022-04-29	WOS:000615141100018
J	Berman, L; Riedel, M				Berman, Len; Riedel, Michael			Coping with COVID	VACCINE			English	Editorial Material									[Berman, Len; Riedel, Michael] 710 WOR, New York, NY 10013 USA		Berman, L (通讯作者)，710 WOR, New York, NY 10013 USA.	Len@wor710.com						0	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 29	2021	39	5					777	778		10.1016/j.vaccine.2020.11.039		JAN 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PV7RR	33422380				2022-04-29	WOS:000610181400001
J	Damjanovska, S; Smith, C; Sayin, I; Burant, CJ; Gravenstein, S; Canaday, DH				Damjanovska, Sofi; Smith, Carson; Sayin, Ismail; Burant, Christopher J.; Gravenstein, Stefan; Canaday, David H.			Adjuvant effect of type I interferon induced by many but not all commercial influenza vaccines	VACCINE			English	Article						Human; Immunity; Influenza; Vaccine; IFN-alpha; Plasmacytoid dendritic cells	SEASONAL INFLUENZA; ALPHA; IMMUNOGENICITY; INDUCTION; EFFICACY; ADULTS; VIRUS; IFN	Background: Seasonal influenza vaccines approved and offered in the United States have varying reported degrees of effectiveness year over year and between manufacturers. Influenza vaccines produced from live virus may include single stranded RNA (ssRNA) that is a potent activator of the innate Toll-like receptor 7 (TLR-7) ligand. Plasmacytoid dendritic cells (pDC) can be activated by ssRNA to produce type I interferons such as IFN-alpha, which has been shown to have an adjuvant-like effect. Objective: Our aim was to determine if IFN-alpha induction in peripheral blood mononuclear cells (PBMCs) exposed to eight different commercial influenza vaccines is a pDC-dependent process mediated through TLR-7 signaling. Results: We demonstrate the ability of multiple vaccines to induce IFN-alpha in a TLR-7-dependent fashion. A number of vaccines however lacked IFN-alpha induction. The significance of these differences between vaccines is unclear, since all the approved vaccine formulations offer some degree of protection. Published by Elsevier Ltd.	[Damjanovska, Sofi; Sayin, Ismail; Canaday, David H.] Case Western Reserve Univ, Cleveland VA Med Ctr, Dept Med, 10900 Euclid Ave, Cleveland, OH 44106 USA; [Smith, Carson] Case Western Reserve Univ, Dept Pathol, 10900 Euclid Ave, Cleveland, OH 44106 USA; [Burant, Christopher J.] Case Western Reserve Univ, Cleveland VA Med Ctr, Sch Nursing, 10900 Euclid Ave, Cleveland, OH 44106 USA; [Gravenstein, Stefan] Brown Univ, Providence VA Med Ctr, Providence, RI 02912 USA		Canaday, DH (通讯作者)，Case Western Reserve Univ, Cleveland VA Med Ctr, Div Infect Dis, Cleveland, OH 44106 USA.	Dxc44@case.edu		Damjanovska, Sofi/0000-0001-6036-9190	VA Geriatric Research, Education and Clinical Center (GRECC); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI108972, AI129709]	This work was supported by VA Geriatric Research, Education and Clinical Center (GRECC) and NIH AI108972 and AI129709.	ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; Canaday DH, 2010, J CLIN IMMUNOL, V30, P373, DOI 10.1007/s10875-010-9374-9; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; Dunkle LM, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3021; Dunkle LM, 2017, NEW ENGL J MED, V376, P2427, DOI [10.1056/NEJMoa1608862, 10.1056/nejmoa1608862]; Fitzgerald-Bocarsly P, 2008, CYTOKINE GROWTH F R, V19, P3, DOI 10.1016/j.cytogfr.2007.10.006; Frey S, 2003, VACCINE, V21, P4234, DOI 10.1016/S0264-410X(03)00456-0; GOLDWATER PN, 1994, VACCINE, V12, P410, DOI 10.1016/0264-410X(94)90116-3; Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; Jewell NA, 2007, J VIROL, V81, P9790, DOI 10.1128/JVI.00530-07; Ng TWY, 2019, J INFECT DIS, V219, P1525, DOI 10.1093/infdis/jiy720; O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/ERV.12.140, 10.1586/erv.12.140]; Proietti E, 2002, J IMMUNOL, V169, P375, DOI 10.4049/jimmunol.169.1.375; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; Rizza P, 2010, AUTOIMMUNITY, V43, P204, DOI 10.3109/08916930903510880; Santini SM, 2002, J INTERF CYTOK RES, V22, P1071, DOI 10.1089/10799900260442494; Tovey MG, 2006, VACCINE, V24, pS46, DOI 10.1016/j.vaccine.2005.01.117; Tsai TF, 2013, INFECT CHEMOTHER, V45, P159, DOI 10.3947/ic.2013.45.2.159; van Aalst R, 2020, VACCINE, V38, P372, DOI 10.1016/j.vaccine.2019.09.105; Vono M, 2013, P NATL ACAD SCI USA, V110, P21095, DOI 10.1073/pnas.1319784110	23	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 29	2021	39	5					786	789		10.1016/j.vaccine.2020.12.051		JAN 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PV7RR	33390292	Green Accepted			2022-04-29	WOS:000610181400004
J	Guy, B				Guy, Bruno			Combine two different dengue vaccines could efficiently target dengue-naive subjects. Comment to Macias A, Ruiz-Palacios G, Ramos-Castaneda J. Combine dengue vaccines to optimize effectiveness. Vaccine. 2020 Jun 26;38(31): 4801-4804	VACCINE			English	Letter							SAFETY					bruno.guy69@orange.fr					Biswal S, 2020, LANCET, V395, P1423, DOI 10.1016/S0140-6736(20)30414-1; Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019; Guy B, 2009, AM J TROP MED HYG, V80, P302, DOI 10.4269/ajtmh.2009.80.302; Qiao M, 2011, AM J TROP MED HYG, V85, P724, DOI 10.4269/ajtmh.2011.10-0436; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820	5	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 29	2021	39	5					779	779		10.1016/j.vaccine.2020.08.075		JAN 2021	1	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PV7RR	32928589				2022-04-29	WOS:000610181400002
J	Jiang, XW; Shang, XP; Lin, JF; Zhao, YR; Wang, W; Qiu, YW				Jiang, Xuewen; Shang, Xiaopeng; Lin, Junfen; Zhao, Yanrong; Wang, Wei; Qiu, Yinwei			Impacts of free vaccination policy and associated factors on influenza vaccination behavior of the elderly in China: A quasi-experimental study	VACCINE			English	Article						Seasonal influenza; Influenza vaccine; Vaccination coverage; Vaccination behavior; Free vaccination policy; Quasi-experimental study	COVERAGE; METAANALYSIS; SEASONALITY; ADULTS	Background: Chinese elders are under high threats of seasonal influenza, while showing low influenza vaccination coverage comparing with other countries. The study explored the impacts of free vaccination policy and associated factors on influenza vaccination behavior of the elderly in Zhejiang Province, China, offering a guidance of interventions for protecting elders from seasonal influenza. Methods: 1210 elders >= 60 years were conveniently recruited between July and September of 2019. 607 of them were sampled from 6 counties with free vaccination policy, while the other 603 elderly people were sampled from another 6 comparable counties without the policy. A self-reported questionnaire, involving socio-democratic information, physical status and behavior, influenza knowledge, vaccination awareness, relatives of healthcare workers, and vaccination behavior, was completed by elders under supports of research assistants. Chi-square tests and logistic regression analyses were performed to explore the impacts of research factors. Results: A total of 464 (38.3%, 95%CI: 36.9-39.7%) elders claimed that they got vaccinated, and the vaccination coverages of elders in the counties with and without free vaccination policy were 68.4% (95% CI: 64.7-72.1%) and 8.1% (95%CI: 5.9-10.3%), respectively. Protective and risk factors of vaccination behavior were identified, including free vaccination policy (ORstop = 27.29, 95%CI: 18.69-39.82), positive vaccination awareness (ORstep = 7.93, 95%CI: 5.50-11.43), catching cold frequently (ORstep = 2.00, 95%CI: 1.32-3.05), and having relatives of healthcare workers (ORstep = 0.56, 95%CI: 0.34-0.93). Age, education level, monthly income, family structure, physical status, and influenza knowledge were significantly associated with vaccination behavior. Having relatives of healthcare workers may indirectly affect vaccination behavior through vaccination awareness. Conclusions: Free vaccination policy plays the most fundamental role of improving vaccination coverage among studied factors. To protect elders from seasonal influenza, effective measurements, such as issuing free vaccination policy, enriching influenza knowledge, and guiding positive vaccination awareness for both elders and healthcare professionals are recommended to be included into influenza immunization strategies. (C) 2020 The Authors. Published by Elsevier Ltd.	[Jiang, Xuewen; Shang, Xiaopeng; Lin, Junfen; Zhao, Yanrong; Wang, Wei; Qiu, Yinwei] Zhejiang Prov Ctr Dis Control & Prevent, 3399 Binsheng Rd, Hangzhou, Zhejiang, Peoples R China		Qiu, YW (通讯作者)，Zhejiang Prov Ctr Dis Control & Prevent, 3399 Binsheng Rd, Hangzhou, Zhejiang, Peoples R China.	ywqiu@cdc.zj.cn		Jiang, Xuewen/0000-0003-4900-9500			Baumgartner EA, 2012, J INFECT DIS, V206, P838, DOI 10.1093/infdis/jis467; Bloom-Feshbach K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054445; Centers for Disease Control and Prevention, 2020, MUCH INFL VACC IS PR; Centers for Disease Control and Prevention, 2018, WHAT AR BEN FLU VACC; Centers for Disease Control and Prevention, 2019, FLU VACC COV US 2018; Centers for Disease Control and Prevention, 2019, HIST REF SEAS INFL V; Chinese Center for Disease Control and Prevention, 2020, TECH GUID INFL VACC; Endrich MM, 2009, VACCINE, V27, P4018, DOI 10.1016/j.vaccine.2009.04.029; Fang R, 2013, CHIN GEN PRACTICE, V17, P1403, DOI [10.3969/j.issn.1007-9572.2014.12.019., DOI 10.3969/J.ISSN.1007-9572.2014.12.019]; GAP Advisory Group, 2017, 10 YEARS GLOB ACT PL; Giese C, 2016, VACCINE, V34, P3657, DOI 10.1016/j.vaccine.2016.05.028; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Health Commission of People's Republic of China, 2019, PLAN INFL PREV CONTR; Health Commission of People's Republic of China, 2020, NAT REP NOT INF DIS; Karki S, 2016, VACCINE, V34, P6388, DOI 10.1016/j.vaccine.2016.10.012; Kwon DS, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012618; Landi F, 2005, VACCINE, V23, P3896, DOI 10.1016/j.vaccine.2005.03.008; Lipsitch M, 2009, P NATL ACAD SCI USA, V106, P3645, DOI 10.1073/pnas.0900933106; Leyva-Moral JM, 2007, ENFERM CLIN, V17, P239; National Institutes for Food and Drug Control, 2019, PUBL DISTR INF BIOL; Reed C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118369; Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010; Scuffham PA, 2002, VACCINE, V20, P2562, DOI 10.1016/S0264-410X(02)00154-8; Shahrabani S, 2006, ISR MED ASSOC J, V8, P630; Smetana J, 2018, HUM VACC IMMUNOTHER, V14, P540, DOI 10.1080/21645515.2017.1343226; Smith PJ, 2016, VACCINE, V34, P1604, DOI 10.1016/j.vaccine.2016.01.061; Somes MP, 2018, VACCINE, V36, P3199, DOI 10.1016/j.vaccine.2018.04.063; Song X, 2016, ZHONG GUO YI MIAO HE, V22, P94; Thompson WW, 2009, INFLUENZA OTHER RESP, V3, P37, DOI 10.1111/j.1750-2659.2009.00073.x; Viboud C, 2006, PLOS MED, V3, P468, DOI 10.1371/journal.pmed.0030089; WHO (World Health Organization), 2018, INFL SEAS; Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1; World Health Organization (WHO), 2019, GLOB INFL STRAT 2019; Yang J, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01545-6; Zhang X, 2011, ZHEJIANG PREVENTIVE, V23, P31, DOI DOI 10.19485/J.CNKI.ISSN1007-0931.2011.09.010; [朱小凤 Zhu Xiaofeng], 2013, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V13, P543	36	2	2	7	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 29	2021	39	5					846	852		10.1016/j.vaccine.2020.12.040		JAN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PV7RR	33390294	hybrid			2022-04-29	WOS:000610181400012
J	Ramakrishnan, A; Joseph, SS; Reynolds, ND; Poncet, D; Maciel, M; Nunez, G; Espinoza, N; Nieto, M; Castillo, R; Royal, JM; Poole, S; McVeigh, A; Rollenhagen, JE; Heinrichs, J; Prouty, MG; Simons, MP; Renauld-Mongenie, G; Savarino, SJ				Ramakrishnan, A.; Joseph, S. S.; Reynolds, N. D.; Poncet, D.; Maciel, M.; Nunez, G.; Espinoza, N.; Nieto, M.; Castillo, R.; Royal, J. M.; Poole, S.; McVeigh, A.; Rollenhagen, J. E.; Heinrichs, J.; Prouty, M. G.; Simons, M. P.; Renauld-Mongenie, G.; Savarino, S. J.			Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6+ETEC challenge model	VACCINE			English	Article						Enterotoxigenic Escherichia coli; ETEC; CS6; Vaccine; Nonhuman primates; Intradermal	ENTEROTOXIGENIC ESCHERICHIA-COLI; HEAT-LABILE ENTEROTOXIN; SAFETY; EPIDEMIOLOGY; ADULTS; CS6	Colonization factors or Coli surface antigens (CFs or CS) are important virulence factors of Enterotoxigenic E. coli (ETEC) that mediate intestinal colonization and accordingly are targets of vaccine development efforts. CS6 is a highly prevalent CF associated with symptomatic ETEC infection both in endemic populations and amongst travelers. In this study, we used an Aotus nancymaae non-human primate ETEC challenge model with a CS6 + ETEC strain, B7A, to test the immunogenicity and protective efficacy (PE) of a recombinant CS6-based subunit vaccine. Specifically, we determined the ability of dscCssBA, the donor strand complemented recombinant stabilized fusion of the two subunits of the CS6 fimbriae, CssA and CssB, to elicit protection against CS6 + ETEC mediated diarrhea when given intradermally (ID) with the genetically attenuated double mutant heat-labile enterotoxin LT(R192G/L211A) (dmLT). ID vaccination with dscCssBA + dmLT induced strong serum antibody responses against CS6 and LT. Importantly, vaccination with dscCssBA + dmLT resulted in no observed diarrheal disease (PE = 100%, p = 0.03) following B7A challenge as compared to PBS immunized animals, with an attack rate of 62.5%. These data demonstrate the potential role that CS6 may play in ETEC infection and that recombinant dscCssBA antigen can provide protection against challenge with the homologous CS6 + ETEC strain, B7A, in the Aotus nancymaae diarrheal challenge model. Combined, these data indicate that CS6, and more specifically, a recombinant engineered derivative should be considered for further clinical development. (C) 2020 Published by Elsevier Ltd.	[Ramakrishnan, A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA; [Joseph, S. S.; Maciel, M.; Poole, S.; McVeigh, A.; Rollenhagen, J. E.] Henry M Jackson Fdn Adv Mil Med, 6720 Rockledge Dr, Bethesda, MD 20817 USA; [Reynolds, N. D.; Nunez, G.; Espinoza, N.; Nieto, M.; Castillo, R.; Simons, M. P.] Naval Med Res Unit 6, Dept Bacteriol, Venezuela Ave Block 36, Bellavista, Callao, Peru; [Poncet, D.; Renauld-Mongenie, G.] Sanofi Pasteur, Res & External Innovat, 1541 Av Marcel Merieux, F-69280 Marcy Letoile, France; [Royal, J. M.] Naval Med Res Unit 6, Dept Vet Serv, Venezuela Ave Block 36, Bellavista, Callao, Peru; [Heinrichs, J.; Savarino, S. J.] Sanofi Pasteur, Swiftwater, PA USA; [Prouty, M. G.; Savarino, S. J.] Naval Med Res Ctr, Enter Dis Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Ramakrishnan, A.] SQZ Biotechnol, 200 Arsenal Yards Blvd, Watertown, MA USA; [Joseph, S. S.] Amer Soc Radiat Oncol, 251 18th St South,8th Floor, Arlington, VA USA; [Reynolds, N. D.] US Naval Res Lab, 4555 Overlook Ave, Washington, DC USA		Prouty, MG (通讯作者)，Naval Med Res Ctr, Enter Dis Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	michael.g.prouty2.mil@mail.mil		Maciel, Milton/0000-0003-4877-9458	U.S. Army Military Infectious Diseases Research Program Work Unit Number U.S. Navy [WUN A1009]; Henry M. Jackson foundation for the Advancement of Military Medicine; Sanofi Pasteur [NCRADA-NMR-09-3183]	The authors wish to thank the Walter Reed Army Institute of Research for the provision of recombinant CS6. We thank Elise De Castro and Xavier Louis for their excellent technical assistance in the development of an LT seroneutralization assay and the CS6 Flow Cytometry assay, respectively. This research was supported by U.S. Army Military Infectious Diseases Research Program Work Unit Number U.S. Navy WUN A1009, Henry M. Jackson foundation for the Advancement of Military Medicine, and Sanofi Pasteur (NCRADA-NMR-09-3183). The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of the Navy, Department of Defense, nor the U.S. Government. S.J.S. N.D. R., J.M.R., M.P.S. and M.G.P. served as military service members over the course of this work, which was prepared as part of their official duties. Title 17 USC. 105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties. D.P., J.H. and G.R-M. are employees of Sanofi Pasteur. S.J.S. was an employee of the U.S. Navy and served as the Principal Investigator for NMRC and USUHS at the time of the study and is now an employee of Sanofi Pasteur. He was inventor on an issued patent held by the US Navy for adhesins as immunogens against enterotoxigenic Escherichia coli, and in the past received royalty through a licensing agreement between the U.S. Navy and Sanofi Pasteur. All other authors declare that there are no financial, institutional, or other relationship that might lead to bias or a conflict of interest.	Ambriz-Avina V, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/461941; Bouckenooghe AR, 2002, J TRAVEL MED, V9, P137, DOI 10.2310/7060.2002.23206; Cheng E, 1999, VACCINE, V18, P38, DOI 10.1016/S0264-410X(99)00168-1; Coster TS, 2007, INFECT IMMUN, V75, P252, DOI 10.1128/IAI.01131-06; Guerena-Burgueno F, 2002, INFECT IMMUN, V70, P1874, DOI 10.1128/IAI.70.4.1874-1880.2002; Halvorson HA, 2006, AM J GASTROENTEROL, V101, P1894, DOI 10.1111/j.1572-0241.2006.00654.x; Isidean SD, 2011, VACCINE, V29, P6167, DOI 10.1016/j.vaccine.2011.06.084; Katz DE, 2003, VACCINE, V21, P341, DOI 10.1016/S0264-410X(02)00613-8; Khalil IA, 2018, LANCET INFECT DIS, V18, P1229, DOI [10.1016/S1473-3099(18)30475-4, 10.1016/s1473-3099(18)30475-4]; Lapa JA, 2008, CLIN VACCINE IMMUNOL, V15, P1222, DOI 10.1128/CVI.00491-07; Liang H, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0116-6; Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069; Moor K, 2016, NAT PROTOC, V11, P1531, DOI 10.1038/nprot.2016.091; Nair P, 2014, J TRAVEL MED, V21, P153, DOI 10.1111/jtm.12114; Norton EB, 2011, CLIN VACCINE IMMUNOL, V18, P546, DOI 10.1128/CVI.00538-10; Poole ST, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00788-18; Porter CK, 2011, VACCINE, V29, P5869, DOI 10.1016/j.vaccine.2011.05.021; Porter CK, 2010, DIAGN MICR INFEC DIS, V66, P241, DOI 10.1016/j.diagmicrobio.2009.10.002; Qadri F, 2000, J CLIN MICROBIOL, V38, P27; Qadri F, 2005, CLIN MICROBIOL REV, V18, P465, DOI 10.1128/CMR.18.3.465-483.2005; Rollenhagen JE, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00634-18; Sincock SA, 2016, VACCINE, V34, P284, DOI 10.1016/j.vaccine.2015.11.017; Svennerholm AM, 2008, EXPERT REV VACCINES, V7, P795, DOI 10.1586/14760584.7.6.795; Tobias J, 2011, VACCINE, V29, P8863, DOI 10.1016/j.vaccine.2011.09.096	24	2	2	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 15	2021	39	3					487	494		10.1016/j.vaccine.2020.12.034			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VN	33357957				2022-04-29	WOS:000604750400007
J	Cox, AD; Lee, RK; Ulanova, M; Bruce, MG; Tsang, RSW				Cox, A. D.; Lee, R. Kuo; Ulanova, M.; Bruce, M. G.; Tsang, R. S. W.			Proceedings of a workshop to discuss the epidemiology of invasive Haemophilus influenzae disease with emphasis on serotype a and b in the Americas, 2019	VACCINE			English	Article						Haemophilus influenzae; epidemiology; Hia vaccine; PAHO	CONJUGATE VACCINES; CHILDREN; ALASKA; REPLACEMENT; MENINGITIS; NORTH	On March 9, 2019, a one-day workshop titled "The current epidemiology of invasive Haemophilus influenzae disease in the Americas", jointly organized by the Public Health Agency of Canada (PHAC), the Canadian Institute of Health Research (CIHR), and the National Research Council Canada (NRC), brought together experts in the epidemiology and surveillance of invasive Haemophilus influenzae (Hi) disease from the Pan American Health Organization (PAHO) and its five regional reference laboratories in South America, USA, and Canada in Ottawa, Ontario, Canada. This workshop built upon recommendations of previous related workshops and incorporated updated data.	[Cox, A. D.; Lee, R. Kuo] CNR, Ottawa, ON, Canada; [Ulanova, M.] Lakehead Univ, Northern Ontario Sch Med, Thunder Bay, ON, Canada; [Bruce, M. G.] US Ctr Dis Control & Prevent CDC, Artic Invest Program, Div Preparedness & Emerging Infect, Anchorage, AK USA; [Tsang, R. S. W.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada		Tsang, RSW (通讯作者)，Natl Microbiol Lab, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada.	Raymond.tsang@canada.ca					Adam HJ, 2010, VACCINE, V28, P4073, DOI 10.1016/j.vaccine.2010.03.075; Barbour ML, 1996, EMERG INFECT DIS, V2, P176, DOI 10.3201/eid0203.960303; BIJLMER HA, 1991, VACCINE, V9, pS5, DOI 10.1016/0264-410X(91)90172-3; Boisvert AA, 2015, CAN J INFECT DIS MED, V26, P291, DOI 10.1155/2015/613820; Bozio CH, 2021, CLIN INFECT DIS, V73, pE3670, DOI 10.1093/cid/ciaa990; Bruce MG, 2013, EMERG INFECT DIS, V19, P932, DOI 10.3201/eid1906.121805; Bruce Michael G, 2008, Emerg Infect Dis, V14, P48, DOI 10.3201/eid1401.070822; BULKOW LR, 1993, PEDIATR INFECT DIS J, V12, P484, DOI 10.1097/00006454-199306000-00006; Cox A D, 2017, Can Commun Dis Rep, V43, P89; Cox AD, 2017, VACCINE, V35, P6129, DOI 10.1016/j.vaccine.2017.09.055; Desai S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142179; Kimberlin DW, 2018, RED BOOK 2018; Li Y A, 2016, Can Commun Dis Rep, V42, P74; LOSONSKY GA, 1984, PEDIATR INFECT DIS J, V3, P539, DOI 10.1097/00006454-198411000-00012; McConnell A, 2007, PEDIATR INFECT DIS J, V26, P1025, DOI 10.1097/INF.0b013e31812f4f5b; Nolen LD, 2021, CLIN INFECT DIS, V73, pE280, DOI 10.1093/cid/ciaa750; Oh SY, 2008, J INFECT DIS, V197, P1275, DOI 10.1086/586716; Pan American Health Organization, 2015, INF REG SIREVA 2 201; Pickering LK, 2012, RED BOOK 2012 REPORT, P345; Plumb ID, 2018, PEDIATR INFECT DIS J, V37, P298, DOI 10.1097/INF.0000000000001764; Public Health Agency of Canada, 2020, NOT DIS ONL; Ribeiro GS, 2003, J INFECT DIS, V187, P109, DOI 10.1086/345863; Soeters HM, 2021, CLIN INFECT DIS, V73, pE371, DOI 10.1093/cid/ciaa875; Soeters HM, 2018, CLIN INFECT DIS, V67, P881, DOI 10.1093/cid/ciy187; State of Alaska Epidemiology Bulletin, 2018, UPD INV HAEM INFL TY; Tan B, 2016, HOTMOBILE'17: PROCEEDINGS OF THE 18TH INTERNATIONAL WORKSHOP ON MOBILE COMPUTING SYSTEMS AND APPLICATIONS, P1, DOI 10.1145/3032970.3032973; Tsang RSW, 2016, INT J CIRCUMPOL HEAL, V75, DOI 10.3402/ijch.v75.29798; Ulanova M, 2012, VACCINE, V30, P6960, DOI 10.1016/j.vaccine.2012.09.063; WARD JI, 1981, LANCET, V1, P1281; Whittaker R, 2017, EMERG INFECT DIS, V23, P396, DOI 10.3201/eid2303.161552; Wilkinson TMA, 2019, VACCINE, V37, P6102, DOI 10.1016/j.vaccine.2019.07.100	31	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					627	632		10.1016/j.vaccine.2020.12.015		JAN 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PR1FI	33358264				2022-04-29	WOS:000606987100001
J	Gold, MS; Lincoln, G; Cashman, P; Braunack-Mayer, A; Stocks, N				Gold, M. S.; Lincoln, G.; Cashman, P.; Braunack-Mayer, A.; Stocks, N.			Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial	VACCINE			English	Article						Adverse events following immunisation; Vaccine safety surveillance; Pharmacovigilance; m-Health	INFLUENZA VACCINE SAFETY; ACTIVE SURVEILLANCE; DRUG EVENTS; FEASIBILITY; H1N1	Introduction: Passive surveillance is recommended globally for the detection of adverse events following immunisation (AEFI) but this has significant challenges. Use of Mobile health for vaccine safety surveillance enables a consumer-centred approach to reporting. The Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) a randomised control trial (RCT) sought to evaluate the efficacy and acceptability of SMS for AEFI surveillance. Methods: Multi-centre RCT, participants were adult vaccinees or parents of children receiving any vaccine at a trial site. At enrolment randomisation occurred to one of two SMS groups or a control group. Prompts on days 2, 7 and 14 post-immunisation, were sent to the SMS group, to ascertain if a medical event following immunisation (MEFI) had occurred. No SMS's were sent to the control participants. Those in the SMS who notified an MEFI were pre-randomised to complete a computer assisted telephone interview or a web based report to determine if an AEFI had occurred whilst an AEFI in the controls was determined by a search for passive reports. The primary outcome was the AEFI detection rate in the SMS group compared to controls. Results: We enrolled 6,338 participants, who were equally distributed across groups and who received 11,675 vaccines. The SMS group (4,225) received 12,675 surveillance prompts with 9.8% being noncompliant and not responding. In those that responded 90% indicated that no MEFI had been experienced and 184 had a verified AEFI. 6 control subjects had a reported AEFI. The AEFI detection rate was 13 fold greater in the SMS group when compared with controls (4.3 vs 0.3%). Conclusion: We have demonstrated that the STARSS methodology improves AEFI detection. Our findings should inform the wider use of SMS-based surveillance which is particularly relevant since establishing robust and novel pharmacovigilance systems is critical to monitoring novel vaccines which includes potential COVID vaccines. Crown Copyright (C) 2020 Published by Elsevier Ltd. All rights reserved.	[Gold, M. S.] Univ Adelaide, Sch Med, Discipline Paediat, Adelaide, SA, Australia; [Lincoln, G.] South Australian Med Hlth Res Inst, Adelaide, SA, Australia; [Cashman, P.] Hunter New England, Populat Hlth, Forster, NSW, Australia; [Braunack-Mayer, A.] Univ Wollongong, Fac Arts Social Sci & Humanities, Sch Hlth & Soc, Wollongong, NSW, Australia; [Stocks, N.] Univ Adelaide, Adelaide Med Sch, Discipline Gen Practice, Adelaide, SA, Australia		Gold, MS (通讯作者)，Univ Adelaide, Sch Med, Discipline Paediat, Adelaide, SA, Australia.; Gold, MS (通讯作者)，Womens & Childrens Hosp, 75 King William Rd, Adelaide, SA 5006, Australia.	michael.gold@adelaide.edu.au	Braunack-Mayer, Annette/AAE-7796-2019	Braunack-Mayer, Annette/0000-0003-4427-0224	Australian National Health and Medical Research Council (ANHMRC)National Health and Medical Research Council (NHMRC) of Australia [GNT1067703]	Australian National Health and Medical Research Council (ANHMRC) GNT1067703 Partnership Project	Armstrong PK, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000016; Baron S, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2477; Blyth CC, 2011, VACCINE, V29, P5107, DOI 10.1016/j.vaccine.2011.05.054; Cashman P, 2019, VACCINE, V37, P2427, DOI 10.1016/j.vaccine.2019.02.082; Cashman P, 2014, VACCINE, V32, P5503, DOI 10.1016/j.vaccine.2014.07.061; Choe YJ, 2011, JPN J INFECT DIS, V64, P297; Clothier HJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224702; Clothier HJ, 2014, HUM VACC IMMUNOTHER, V10, P3726, DOI 10.4161/hv.34369; Dey A, 2019, COMMUN DIS INTELL, V43, DOI 10.33321/cdi.2019.43.29; Figueiras A, 1999, MED CARE, V37, P809, DOI 10.1097/00005650-199908000-00010; Fleiss JL, 2003, STAT METHODS RATES P, V3rd; Gidudu JF, 2020, VACCINE, V38, P1009, DOI 10.1016/j.vaccine.2019.11.050; Hatz C, 2011, VACCINE, V29, P5000, DOI 10.1016/j.vaccine.2011.04.099; Heininger U, 2017, VACCINE, V35, P3917, DOI 10.1016/j.vaccine.2017.06.033; Jacoby P, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-031851; Mackenzie IS, 2012, BRIT J CLIN PHARMACO, V73, P801, DOI 10.1111/j.1365-2125.2011.04142.x; Munnoch SA, 2019, J MED INTERNET RES, V21, DOI 10.2196/14791; Newes-Adeyi G, 2012, VACCINE, V30, P1050, DOI 10.1016/j.vaccine.2011.12.041; Parrella A, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-313; Pillsbury A, 2015, EUROSURVEILLANCE, V20, P6, DOI 10.2807/1560-7917.ES.2015.20.43.30050; Pillsbury A, 2017, VACCINE, V35, P7101, DOI 10.1016/j.vaccine.2017.10.091; Pillsbury AJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.4079; Pillsbury AJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023263; Regan AK, 2015, VACCINE, V33, P3689, DOI [10.1016/j.vaccine.2015.06.022, 10]; Ross Jamie, 2016, Implement Sci, V11, P146; Shameer A., WHO GLOBAL VACCINE S; Stuurman AL, 2017, EXPERT REV VACCINES, V16, P187, DOI 10.1080/14760584.2017.1264272; Tozzi AE, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00036; Tsafack M, 2015, PAN AFR MED J, V22, DOI 10.11604/pamj.2015.22.351.8368; Varallo FR, 2014, REV ESC ENFERM USP, V48, P739, DOI 10.1590/S0080-623420140000400023; Vrijhoef HJM, 2009, J TELEMED TELECARE, V15, P362, DOI 10.1258/jtt.2009.090405; Wilson K, 2016, HUM VACC IMMUNOTHER, V12, P1738, DOI 10.1080/21645515.2016.1152434	32	0	0	2	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					332	342		10.1016/j.vaccine.2020.11.056			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33279317				2022-04-29	WOS:000604750300023
J	Majed, L; Bresse, X; El Mouaddin, N; Schmidt, A; Daniels, VJ; Pavelyev, A; Levy-Bachelot, L; Elbasha, E				Majed, Laureen; Bresse, Xavier; El Mouaddin, Nadia; Schmidt, Aurelie; Daniels, Vincent J.; Pavelyev, Andrew; Levy-Bachelot, Laurie; Elbasha, Elamin			Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France	VACCINE			English	Article						Cost-effectiveness; France; HPV; Cervical cancer; Gender-neutral vaccination; 9-Valent vaccine	HUMAN-PAPILLOMAVIRUS VACCINE; INTRAEPITHELIAL NEOPLASIA; UNIVERSAL VACCINATION; PARTICLE VACCINE; INFECTION; LESIONS; EFFICACY; DISEASE; WOMEN; WARTS	Objectives: In France, 9-valent HPV vaccination is recommended routinely for 11-14-years-old girls and as catch-up for 15-19-years-old girls. Recently, recommendation for gender-neutral vaccination (GNV) has been approved. The objectives of the study were to assess the public health impact and cost-effectiveness of a 9-valent GNV compared with girls-only vaccination program (GOV). Methods: A published HPV disease transmission dynamic model accounting for herd protection effects with a 100-year time horizon was adapted and calibrated to French data. Epidemiological and economic outcomes included disease cases averted and quality-adjusted life years (QALY). Costs and incremental cost-effectiveness ratio (ICER) were measured in 2018 Euros ((sic)). A coverage rate of 26.2% among girls and boys was assumed for the GNV program based on the current female coverage rate in France. The base case included genital warts, cervical, vulvar, vaginal, and anal cancers. Scenario analyses included all HPV-related diseases and considered higher vaccination coverage rate (60%). Deterministic sensitivity analyses on key inputs were performed. Results: Over 100 years, GNV resulted in an additional reduction of 9,519 and 3,037 cervical cancer cases and deaths; 6,901 and 1,166 additional anal cancer cases and deaths; and a reduction of additional 1,284,077 genital warts compared with current GOV and an ICER of 24,763(sic)/QALY. When including all HPV-related diseases, the ICER was 15,184(sic)/QALY. At a higher coverage rate (60%), GNV would prevent 17,430 and 4,334 additional anogenital cancer cases and deaths and over two million genital warts compared with GOV with an ICER of 40,401(sic)/QALY. Results were sensitive to a higher discount rate (6% versus 4%) and a shorter duration of protection (20 years versus lifetime). Conclusions: In France, GNV has a significant impact in terms of public health benefits and may be considered cost-effective compared with GOV at low and high coverage rates. (C) 2020 Elsevier Ltd. All rights reserved.	[Majed, Laureen; Levy-Bachelot, Laurie] MSD France, Market Access, Puteaux La Defense, France; [Bresse, Xavier] MSD Vaccins, Market Access, Lyon, France; [El Mouaddin, Nadia] Icon Plc, Nanterre, France; [Schmidt, Aurelie] Icon Plc, Lyon, France; [Daniels, Vincent J.; Elbasha, Elamin] Merck & Co Inc, EDS Ctr Observat & Real World Evidence CORE, Kenilworth, NJ USA; [Pavelyev, Andrew] HCL Amer Inc, Sunnyvale, CA USA		Majed, L (通讯作者)，MSD France, Market Access Unit, 10-12 Cours Michelet, F-92800 Puteaux La Defense, France.	laureenmajed@free.fr		Daniels, Vincent/0000-0002-3226-7231; Elbasha, Elamin/0000-0002-9993-8036	MSD France	This study was supported by MSD France.	Abramowitz L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202564; [Anonymous], 2012, PLAN CANC 2014 2019; [Anonymous], 2015, INTR HPV VACC EUR UN; Bank W., 2019, GDP CAPITA PPP FRANC; Bergeron C, 2008, INT J TECHNOL ASSESS, V24, P10, DOI 10.1017/S0266462307080026; Boiron L, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1483-5; Borges P, 2014, INTEGRATED WATER RESOURCE MANAGEMENT IN BRAZIL, P9; Bresse X, 2013, HUM VACC IMMUNOTHER, V9, P823, DOI 10.4161/hv.22994; Brisson M., 2014, ADV COMM IMM PRACT A; Cancer Research UK, 2014, CERV CANC SURV STAT; Centers for Disease Control and Prevention, 2018, MAN CANC AR LINK HPV; CepiDC, 2015, EFF DEC CID CIM 21 A; CepiDC, 2016, INT DONN CAUS DEC 20; CepiDC, 2015, EFF DEC COD CIM 52 A; CepiDC, 2015, EFF DEC COD CIM 51 A; Chesson H., 2015, ADVISORY COMMITTEE I; CNOGF, 2007, COND GEN; Dasbach EJ, 2008, BJOG-INT J OBSTET GY, V115, P947, DOI 10.1111/j.1471-0528.2008.01743.x; Dasbach Erik J, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P491, DOI 10.1586/14737167.8.5.491; Demarteau N, 2011, INT J PUBLIC HEALTH, V56, P153, DOI 10.1007/s00038-010-0216-6; Department of Health and Social Care, 2018, EQ AN HUM PAP HPV VA; Donnees Papillomavirus humains (HPV), COUV VACC VACC HPV C; Elbasha E.H., 2010, INTEGRATED EC EVALUA; Elbasha EH, 2007, EMERG INFECT DIS, V13, P28, DOI 10.3201/eid1301.060438; Elbasha EH, 2010, VACCINE, V28, P6858, DOI 10.1016/j.vaccine.2010.08.030; European Medicine Agency, 2016, CERV EPAR SUMM PUBL; European Medicine Agency-Committee for Medicinal Products for Human Use, 2010, GARD HUM PAP VACC TY; European Medicines Agency, 2016, GARD 9 SUMM PROD CHA; European Medicines Agency, 2016, GARD 9 EPAR SUMM PUB; Favato G, 2012, MED CARE, V50, P1076, DOI 10.1097/MLR.0b013e318269e06d; French National Authority for Health (HAS), 2011, METH CHOIC EC EV HAS; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354; Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537; Gov.uk, 2018, HPV VACC GIV BOYS EN; Haeussler K, 2015, VALUE HLTH; Hartwig S, 2017, INFECT AGENTS CANCER, V12, DOI 10.1186/s13027-017-0129-6; Hartwig S, 2015, PAPILLOMAVIRUS RES, V1, P90, DOI 10.1016/j.pvr.2015.06.003; Hartwig S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-30; Haute autorite de sante, 2019, HAUTE AUTORITE SANTE; Health Information and Quality Authority, 2018, HLTH TECHN ASS EXT N; INCA, 2016, CANC FRANC; INCa, 2017, CANC FRANC; Institut national du cancer, 2018, DEP CANC COL UT; INVS, 2018, HUM PAP HPV VACC COV; (INVS), 2018, FNIFHS HUM PAP HPV V; Jehannin-Ligier K, 2017, PROJECTION INCIDENCE; Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044; Joura EA, 2007, LANCET, V369, P1693, DOI 10.1016/S0140-6736(07)60777-6; (KCE) B.K.H.C., 2018, COST EFF AN HPV VACC; Largeron N, 2017, EXPERT REV PHARM OUT, V17, P85, DOI 10.1080/14737167.2016.1208087; Lerner D, 2010, J OCCUP ENVIRON MED, V52, P926, DOI 10.1097/JOM.0b013e3181f12fb0; Mennini FS, 2017, COST EFFECT RESOUR A, V15, DOI 10.1186/s12962-017-0073-8; Ministere des Solidarites et de la Sante, 2018, CAL VACC REC VACC; Monsonego J, 2007, GYNECOL OBSTET FERTI, V35, P107, DOI 10.1016/j.gyobfe.2006.12.010; Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971; Public Senat, 2018, PUBLIC SENAT; Riethmuller D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1779-1; Shield KD, 2018, EUR J EPIDEMIOL, V33, P263, DOI 10.1007/s10654-017-0334-z; SNFCP, 2013, COND AN; Szende A, 2014, SELF REPORTED POPULA; Taira AV, 2004, EMERG INFECT DIS, V10, P1915, DOI 10.3201/eid1011.040222; Van Effelterre Thierry, 2014, Hum Vaccin Immunother, V10, P1794, DOI 10.4161/hv.28834; Villa L, 2007, LANCET, V369, P1861, DOI 10.1016/S0140-6736(07)60852-6; WHO, 2016, HUMAN PAPILLOMAVIRUS; WHO, 2004, CHOOS INT AR COST EF	66	5	5	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					438	446		10.1016/j.vaccine.2020.10.089			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33261895				2022-04-29	WOS:000604750300035
J	Peckeu, L; van der Ende, A; de Melker, HE; Sanders, EAM; Knol, MJ				Peckeu, L.; van der Ende, A.; de Melker, H. E.; Sanders, E. A. M.; Knol, M. J.			Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands	VACCINE			English	Article							SEROTYPE 19A; 13-VALENT	Background: In 2011, the 7-valent pneumococcal conjugate vaccine ( PCV7) was replaced by the 10-valent vaccine (PCV10) in the Netherlands. We report on impact and effectiveness against invasive pneumococcal disease (IPD) in children aged under 5 years by switching from PCV7 to PCV10. Method: We included IPD cases between 2004 and 2019 in children aged < 5 years reported via the national surveillance system. To assess the impact of the PCV10 vaccination program we compared IPD incidence 6-8 years after PCV10 introduction (2017-2019) to the two years just before the switch to PCV10 (2009-2011). We estimated vaccine effectiveness (VE) using the indirect cohort method, comparing vaccination status (at least two vaccine doses) in IPD-cases caused by PCV10 serotypes (cases) to non-PCV10 IPD cases (controls), in children eligible for PCV10. Results: The overall incidence decreased from 8.7 (n = 162) in 2009-2011 to 7.3 per 100.000 (n = 127) in 2017-2019 (Incidence rate ratio (IRR) 0.83, 95%CI: 0.66; 1.05). IPD caused by the additional serotypes included in PCV10 declined by 93% (IRR 0.07, 95%CI: 0.02; 0.23). Incidence of non-PCV10 IPD showed a non-significant increase (IRR 1.25, 95%CI: 0.96; 1.63). Among 231 IPD-cases eligible for PCV10, the overall VE was 91% (95%CI: 67; 97) and did not differ by sex or age at diagnosis. Effectiveness against non-PCV10 serotype 19A IPD was non-significant with an estimate of 28% (95%CI:-179; 81). Conclusion: PCV10 is highly effective in protecting against IPD in Dutch children under 5 years with limited serotype replacement after switching from PCV7 to PCV10. We found no evidence for significant cross-protection of PCV10 against 19A serotype IPD. (C) 2020 The Authors. Published by Elsevier Ltd.	[Peckeu, L.] European Ctr Dis Prevent & Control ECDC, European Programme Intervent Epidemiol Training E, Stockholm, Sweden; [Peckeu, L.; de Melker, H. E.; Sanders, E. A. M.; Knol, M. J.] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands; [van der Ende, A.] Univ Amsterdam, Amsterdam UMC, Med Microbiol & Infect Prevent, Amsterdam, Netherlands; [van der Ende, A.] Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands		Knol, MJ (通讯作者)，Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.	mirjam.knol@rivm.nl		Peckeu-Abboud, Laurene/0000-0002-1774-0975; van der Ende, Arie/0000-0003-1298-3086	Dutch Ministry of Health, Wellfare and Sports; European Centre for Disease Prevention and Control (SpIDnet project)	This work was supported by the Dutch Ministry of Health, Wellfare and Sports and by the European Centre for Disease Prevention and Control (SpIDnet project).	Andrews N, 2019, VACCINE, V37, P4491, DOI 10.1016/j.vaccine.2019.06.071; Andrews N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028435; Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; [Anonymous], 2019, Weekly Epidemiological Record, V94, P85; [Anonymous], 2007, Wkly Epidemiol Rec, V82, P93; Bentley SD, 2006, PLOS GENET, V2, P262, DOI 10.1371/journal.pgen.0020031; Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428; Deceuninck G, EFFECTIVENESS PNEUMO; Deceuninck G, 2015, VACCINE, V33, P2684, DOI 10.1016/j.vaccine.2015.04.005; Desmet S, 2020, LANCET INFECT DIS; Desmet SVJ, 2018, LANCET INFECT DIS; Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8; European Centre for Disease Prevention and Control (ECDC), 2018, ANT RES SURV EUR 201; Feigin V.L., 2017, LANCET NEUROL, V2015, P877; Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; Hicks LA, 2007, J INFECT DIS, V196, P1346, DOI 10.1086/521626; Izurieta P, 2018, LANCET INFECT DIS, V18, P831, DOI 10.1016/S1473-3099(18)30410-9; Jakobsen H, 2003, INFECT IMMUN, V71, P2956, DOI 10.1128/IAI.71.5.2956-2959.2003; Jokinen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120290; Knol MJ, 2015, EMERG INFECT DIS, V21, P2040, DOI 10.3201/eid2111.140780; Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5; Monge S, 2018, LANCET INFECT DIS, V18, P749, DOI 10.1016/S1473-3099(18)30166-X; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; National Institute for Public Health and the Environment (RIVM), NAT IMM PROGR NETH S; Naucler P, 2017, CLIN INFECT DIS, V65, P1780, DOI 10.1093/cid/cix685; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Rinta-Kokko H, 2020, VACCINE, V38, P1559, DOI 10.1016/j.vaccine.2019.11.049; Rinta-Kokko H, 2018, VACCINE, V36, P1934, DOI 10.1016/j.vaccine.2018.03.001; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; Sings HL, 2019, CLIN INFECT DIS, V68, P2135, DOI 10.1093/cid/ciy920; van Deursen AMM, 2012, EMERG INFECT DIS, V18, P1729, DOI 10.3201/eid1811.120329; van Gils EJM, 2010, JAMA-J AM MED ASSOC, V304, P1099, DOI 10.1001/jama.2010.1290; Vestjens SMT, 2019, VACCINE, V37, P6558, DOI 10.1016/j.vaccine.2019.08.025	34	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					431	437		10.1016/j.vaccine.2020.11.018			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33243632	hybrid			2022-04-29	WOS:000604750300034
J	Soreca, V				Soreca, Vincent			Locked Down	VACCINE			English	Editorial Material												vincentjs2021@gmail.com						0	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					167	168		10.1016/j.vaccine.2020.11.063			2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33308890				2022-04-29	WOS:000604750300001
J	Nieuwenhuizen, NE; Zyla, J; Zedler, U; Bandermann, S; Abu Abed, U; Brinkmann, V; Kaufmann, SHE				Nieuwenhuizen, Natalie E.; Zyla, Joanna; Zedler, Ulrike; Bandermann, Silke; Abu Abed, Ulrike; Brinkmann, Volker; Kaufmann, Stefan H. E.			Weaker protection against tuberculosis in BCG-vaccinated male 129 S2 mice compared to females	VACCINE			English	Article						BCG; Tuberculosis; Vaccination; Sex differences; T cells	SEX-DIFFERENCES; CHILDHOOD SURVIVAL; RESISTANCE; SUSCEPTIBILITY; INFECTION; RESPONSES; BIAS	BCG - the only available vaccine against tuberculosis (TB) - was first given to babies 100 years ago in 1921. While it is effective against TB meningitis and disseminated TB, its efficacy against pulmonary TB is variable, notably in adults and adolescents. TB remains one of the world's leading health problems, with a higher prevalence among men. Male sex is associated with increased susceptibility to Mycobacterium tuberculosis in mice, but sex-specific responses to BCG vaccination have not been examined. In this study we vaccinated TB-susceptible 129 S2 mice with BCG and challenged with low-dose M. tuberculosis H37Rv by aerosol infection. BCG was protective against TB in both sexes, as unvaccinated mice lost weight more rapidly than vaccinated ones and suffered from worse lung pathology. However, female mice were better protected than males, showing lower lung bacterial burdens and less weight loss. Overall, vaccinated female mice had increased numbers of T cells and less myeloid cells in the lungs compared to vaccinated males. Principal component analysis of measured features revealed that mice grouped according to timepoint, sex and vaccination status. The features that had the biggest impact on grouping overall included numbers of CD8 T cells, CD8 central memory T cells and CD4 T effector cells, with neutrophil and CD11b(+)GR-1 cell numbers having a big impact at day 29. Hierarchical clustering confirmed that the main difference in global immune response was due to mouse sex, with only a few misgrouped mice. In conclusion, we found sex-specific differences in response to M. tuberculosis H37Rv -challenge in BCG-vaccinated 129 S2 mice. This highlights the need to include both male and female mice in preclinical testing of vaccine candidates. (C) 2021 The Authors. Published by Elsevier Ltd.	[Nieuwenhuizen, Natalie E.; Zedler, Ulrike; Bandermann, Silke; Kaufmann, Stefan H. E.] Max Planck Inst Infect Biol, Dept Immunol, Charitepl 1, D-10117 Berlin, Germany; [Nieuwenhuizen, Natalie E.] Julius Maximilians Univ Wurzburg, Inst Hyg & Microbiol, Josef Schneider Str 2, D-97080 Wurzburg, Germany; [Zyla, Joanna] Silesian Tech Univ, Dept Data Sci & Engn, Akad 16, PL-44100 Gliwice, Poland; [Abu Abed, Ulrike; Brinkmann, Volker] Max Planck Inst Infect Biol, Microscopy Core Facil, Charitepl 1, D-10117 Berlin, Germany; [Kaufmann, Stefan H. E.] Max Planck Inst Biophys Chem, D-1137077 Gottingen, Germany; [Kaufmann, Stefan H. E.] Texas A&M Univ, Hagler Inst Adv Study, College Stn, TX USA		Nieuwenhuizen, NE (通讯作者)，Julius Maximilians Univ Wurzburg, Inst Hyg & Microbiol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	natalie.nieuwenhuizen@uni-wuerzburg.de	Kaufmann, Stefan HE/I-5454-2014	Kaufmann, Stefan HE/0000-0001-9866-8268; Zyla, Joanna/0000-0002-2895-7969	Max Planck SocietyMax Planck SocietyFoundation CELLEX; Ger-man Federal Ministry of Education and Research (Bundesminis-terium fur Bildung und Forschung [BMBF])Federal Ministry of Education & Research (BMBF) [03ZZ0806A, 03ZZ0827B]; Silesian University of Technology	This study was funded by the Max Planck Society and the Ger-man Federal Ministry of Education and Research (Bundesminis-terium fur Bildung und Forschung [BMBF] ) "inVAC" (grant no. 03ZZ0806A) and DIAT ( (grant no. 03ZZ0827B) to S.H.E.K. and N.E. N., and the Silesian University of Technology grant for Support and Development of Research Potential to J.Z.	Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae; Anderson KG, 2014, NAT PROTOC, V9, P209, DOI 10.1038/nprot.2014.005; Arnold AP, 2017, P NATL ACAD SCI USA, V114, P3787, DOI 10.1073/pnas.1702161114; Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Biering-Sorensen S, 2018, J INFECT DIS, V217, P759, DOI 10.1093/infdis/jix612; Billahalli T, PLOS ONE, V16, DOI [10.1371/journal.pone.0247745.eCollection, DOI 10.1371/JOURNAL.PONE.0247745.ECOLLECTION]; BROWN IN, 1987, IMMUNOLOGY, V62, P587; Calmette A, 1931, Proc R Soc Med, V24, P1481; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Dibbern J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11438-z; Domaszewska T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11812-x; Dorhoi A, 2014, EUR J IMMUNOL, V44, P2380, DOI 10.1002/eji.201344219; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Gengenbacher M, 2017, CURR OPIN IMMUNOL, V47, P8, DOI 10.1016/j.coi.2017.06.007; Hertz D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61503-3; Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96; Horton KC, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002119, 10.1371/journal.pmed.1002152]; Bini EI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093831; Kang PS, 1982, KOREAN J PREV MED, V15, P33; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Koeken VACM, 2020, J CLIN INVEST, V130, P5591, DOI 10.1172/JCI133935; Krementsov DN, 2017, P NATL ACAD SCI USA, V114, P3491, DOI 10.1073/pnas.1620889114; Lange C. A. P., 2021, LANCET INFECT DIS; Lidster K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51674-z; Maertzdorf J, 2012, P NATL ACAD SCI USA, V109, P7853, DOI 10.1073/pnas.1121072109; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Medina E, 1998, IMMUNOLOGY, V93, P270, DOI 10.1046/j.1365-2567.1998.00419.x; Miller LR, 2017, FASEB J, V31, P29, DOI 10.1096/fj.201600781R; Naranbhai V, 2014, J INFECT DIS, V209, P500, DOI 10.1093/infdis/jit494; Neyrolles O, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000199; Nhamoyebonde S, 2014, J INFECT DIS, V209, pS100, DOI 10.1093/infdis/jiu147; Ogongo P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00992; Osborn JF, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007633; Prabowo SA, 2019, TUBERCULOSIS, V119, DOI 10.1016/j.tube.2019.101876; Roden AC, 2004, J IMMUNOL, V173, P6098, DOI 10.4049/jimmunol.173.10.6098; Roth A, 2005, INT J EPIDEMIOL, V34, P540, DOI 10.1093/ije/dyh392; Roy A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4643; Scotland RS, 2011, BLOOD, V118, P5918, DOI 10.1182/blood-2011-03-340281; Smith CM, 2016, MBIO, V7, DOI [10.1128/mBio.01516-16, 10.1128/mbio.01516-16]; Srivastava S, 2014, IMMUNOL REV, V262, P179, DOI 10.1111/imr.12217; STEIN SC, 1953, AM REV TUBERC PULM, V68, P695; Takamura S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00733; Topham DJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00515; Tsuyuguchi K, 2001, CLIN EXP IMMUNOL, V123, P428, DOI 10.1046/j.1365-2249.2001.01474.x; Wald C, 2010, SCIENCE, V327, P1571, DOI 10.1126/science.327.5973.1571; World Health Organisation, 2020, WHO GLOBAL TUBERCULO; YAMAMOTO Y, 1991, INFECT IMMUN, V59, P4089, DOI 10.1128/IAI.59.11.4089-4096.1991; Zelmer Andrea, 2018, F1000Res, V7, P296, DOI 10.12688/f1000research.14239.2	50	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 8	2021	39	50					7253	7264		10.1016/j.vaccine.2021.09.039		DEC 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK8NB	34602301	hybrid			2022-04-29	WOS:000727714000005
J	Dankwa, EA; Donnelly, CA; Brouwer, AF; Zhao, R; Montgomery, MP; Weng, MK; Martin, NK				Dankwa, Emmanuelle A.; Donnelly, Christl A.; Brouwer, Andrew F.; Zhao, Rui; Montgomery, Martha P.; Weng, Mark K.; Martin, Natasha K.			Estimating vaccination threshold and impact in the 2017-2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United states	VACCINE			English	Article						Hepatitis A; Critical vaccination coverage; Persons who experience homelessness or who use drugs; Herd immunity; Dynamic modeling	EPIDEMIOLOGY; IMMUNIZATION; PARAMETER; COVERAGE; MICHIGAN; PEOPLE; MODELS	Background: Between September 2017 and June 2019, an outbreak of hepatitis A virus (HAV) occurred in Louisville, Kentucky, resulting in 501 cases and 6 deaths, predominantly among persons who experience homelessness or who use drugs (PEH/PWUD). The critical vaccination threshold (Vc) required to achieve herd immunity in this population is unknown. We investigated Vc and vaccination impact using epidemic modeling. Methods: To determine which population subgroups had high infection risks, we employed a technique based on comparing the proportion of cases arising before and after the epidemic peak, across subgroups. We also developed a dynamic deterministic model of HAV transmission among PEH/PWUD to estimate the basic reproduction number (R0), herd immunity threshold, Vc and the effect of timing of the vaccination intervention on epidemic and economic outcomes. Results: Of the 501 confirmed or probable cases, 385 (76.8%) were among PEH/PWUD. Among PEH/PWUD and within the general population, homelessness was a significant risk factor for infection in the initial stages of the outbreak (odds ratios for homeless versus not homeless: 2.62; 95% confidence interval (CI): 1.62-4.25 for PEH/PWUD and 2.39; 95% CI: 1.51-3.78 for all detected cases). Our estimate for R0 ranges between 2.85 and 3.54, corresponding to an estimate of 69% (95% CI: 65-72) for herd immunity threshold and 76% (95% CI: 72%-80%) for Vc, assuming a vaccine with 90% efficacy. The observed vaccination program was estimated to have averted 30 hospitalizations (95% CI: 19-43), associated with over US $490 000 (95% CI: $310 000-700 000) in hospitalization cost. Greater impact was observed with earlier and faster vaccination implementation. Conclusions: Vaccination coverage of at least 77% is likely required to prevent outbreaks of HAV among PEH/PWUD in Louisville, assuming a 90% vaccine efficacy. Proactive hepatitis A vaccination programs among PEH/PWUD will maximize health and economic benefits of these programs and reduce the likelihood of another outbreak. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Dankwa, Emmanuelle A.; Donnelly, Christl A.] Univ Oxford, Dept Stat, 24-29 St Giles, Oxford OX1 3LB, England; [Donnelly, Christl A.] Imperial Coll London, MRC Ctr Global Infect Dis Anal, St Marys Campus,Norfolk Pl, London W2 1PG, England; [Brouwer, Andrew F.] Univ Michigan, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA; [Zhao, Rui] Louisville Metro Dept Publ Hlth & Wellness, 400 E Gray St, Louisville, KY 40202 USA; [Montgomery, Martha P.; Weng, Mark K.] US Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,Mailstop US12-3, Atlanta, GA 30329 USA; [Martin, Natasha K.] Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, 9500 Gilman Dr, San Diego, CA 92093 USA; [Martin, Natasha K.] Univ Bristol, Populat Hlth Sci, Queens Rd, Bristol BS8 1QU, Avon, England		Dankwa, EA (通讯作者)，Univ Oxford, Dept Stat, 24-29 St Giles, Oxford OX1 3LB, England.	dankwa@stats.ox.ac.uk		Dankwa, Emmanuelle A./0000-0002-3084-5915; Brouwer, Andrew/0000-0002-3779-5287; Weng, Mark/0000-0002-7902-2602	US Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention [NU38PS004650]; National Institutes of Health NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01AI147490]; San Diego Center for AIDS Research (SD CFAR); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AI036214, U01GM110712]; NIH: NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); NIH: NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI); NIH: NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NIH: NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); NIH: NIDCRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR); NIH: NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); NIH: NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS); NIH: NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); NIH: NIMHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH: FICUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC); NIH: OARUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); NIHRNational Institute for Health Research (NIHR) [PR-OD-1017-20007, NIHR20090]; National Science FoundationNational Science Foundation (NSF) [DMS1853032]	This work was supported by the US Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (Epidemiologic and Economic Modeling Agreement number NU38PS004650). NKM was additionally supported by the National Institutes of Health NIAID and NIDA (grant number R01AI147490), and the San Diego Center for AIDS Research (SD CFAR), an NIH-funded program (P30 AI036214), which is supported by the following NIH Institutes and Centers: NIAID, NCI, NHLBI, NIA, NICHD, NIDA, NIDCR, NIDDK, NIGMS, NIMH, NIMHD, FIC, and OAR. CAD was supported by the MRC (Centre funding) and NIHR (funded by Vaccine Efficacy Evaluation for Priority Emerging Diseases: PR-OD-1017-20007 and HPRU in Emerging and Zoonotic Infections: NIHR20090). AFB was supported by the National Science Foundation (grant DMS1853032) and the National Institutes of Health (grant U01GM110712).	Brouwer AF, 2020, EPIDEMIOLOGY, V31, P628, DOI 10.1097/EDE.0000000000001218; Buchino S, 2019, SOLVING STREET HOMEL; Centers for Disease Control and Prevention, WIDSPR OUTBR HEP US; Centers for Disease Control and Prevention National Notifiable Diseases Surveillance System, HEP AC 2012 CAS DEF; Chodick G, 2008, J VIRAL HEPATITIS, V15, P62, DOI 10.1111/j.1365-2893.2008.01032.x; Coalition for the Homeless, 2017 HOM CENS 2017; COBELLI C, 1980, AM J PHYSIOL, V239, pR7, DOI 10.1152/ajpregu.1980.239.1.R7; Collier MG, 2015, VACCINE, V33, P2808, DOI 10.1016/j.vaccine.2015.04.019; Demicheli V, 2003, VACCINE, V21, P2242, DOI 10.1016/S0264-410X(03)00135-X; Dietz K., 1975, EPIDEMIOLOGY, V104, P104; Elam-Evans LD, 2020, MMWR-MORBID MORTAL W, V69, P1109, DOI 10.15585/mmwr.mm6933a1; Fares Auda, 2015, J Family Med Prim Care, V4, P96, DOI 10.4103/2249-4863.152263; Fazel S, 2014, LANCET, V384, P1529, DOI 10.1016/S0140-6736(14)61132-6; Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007; Fiore Anthony E., 2006, Morbidity and Mortality Weekly Report, V55, P1; Foster M, 2018, MMWR-MORBID MORTAL W, V67, P1208, DOI 10.15585/mmwr.mm6743a3; GLIKSON M, 1992, MEDICINE, V71, P14, DOI 10.1097/00005792-199201000-00002; Heffernan JM, 2005, J R SOC INTERFACE, V2, P281, DOI 10.1098/rsif.2005.0042; Hennessey KA, 2009, PUBLIC HEALTH REP, V124, P813, DOI 10.1177/003335490912400608; Hofmeister MG, 2020, EMERG INFECT DIS, V26, P1040, DOI 10.3201/eid2605.191224; Hong H, 2019, BIOINFORMATICS, V35, P2873, DOI 10.1093/bioinformatics/bty1069; Institute of Medicine (US) Committee on Health Care for Homeless People, 1988, HOM HLTH HUM NEEDS; Kentucky Department for Public Health, 2019, AC HEP OUTBR WEEKL R; Koekpe R, 2019, PUBLIC HEALTH REP, V134, P641; Lemon SM, 2018, J HEPATOL, V68, P167, DOI 10.1016/j.jhep.2017.08.034; Lloyd-Smith JO, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000180; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; McMahon BJ, 1996, ARCH PEDIAT ADOL MED, V150, P733, DOI 10.1001/archpedi.1996.02170320079014; Meshkat N, 2009, MATH BIOSCI, V222, P61, DOI 10.1016/j.mbs.2009.08.010; Nelson NP, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6905a1; R Core Team, R LANG ENV STAT COMP; Raue A, 2009, BIOINFORMATICS, V25, P1923, DOI 10.1093/bioinformatics/btp358; Saltelli A, 2007, GLOBAL SENSITIVITY A; SCHIFF ER, 1992, VACCINE, V10, pS18, DOI 10.1016/0264-410X(92)90534-Q; Sedgwick P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1407; Sobol I.M, 1993, MATH MODEL COMPUT EX, DOI DOI 10.18287/0134-2452-2015-39-4-459-461; U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration, 2017 2018 NAT SURV D; U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, 2017, KEY SUBSTANCE USE ME; United States Census Bureau, POP DIV SUBC POP EST; Van Effelterre TP, 2006, CLIN INFECT DIS, V43, P158, DOI 10.1086/505115; Walker ER, 2017, DRUG ALCOHOL DEPEN, V171, P31, DOI 10.1016/j.drugalcdep.2016.11.026; Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1; Wodi AP, 2021, EPIDEMIOLOGY PREVENT, V14th; Wooten Darcy A, 2019, Top Antivir Med, V26, P117; Worby CJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13182; World Health Organization, HEP FACT SHEET 2020; World Health Organization, IMMUNIZATION VACCINE; Zhang XS, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S0950268819001109, 10.1017/s0950268819001109]; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	49	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 3	2021	39	49					7182	7190		10.1016/j.vaccine.2021.10.001		NOV 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ2JG	34686394	hybrid			2022-04-29	WOS:000726620400013
J	Loeb, M; Russell, ML; Kelly-Stradiotto, C; Fuller, N; Fonseca, K; Earn, DJD; Chokani, K; Babiuk, L; Neupane, B; Singh, P; Pullenayegum, E				Loeb, Mark; Russell, Margaret L.; Kelly-Stradiotto, Caralyn; Fuller, Nola; Fonseca, Kevin; Earn, David J. D.; Chokani, Khami; Babiuk, Lorne; Neupane, Binod; Singh, Pardeep; Pullenayegum, Eleanor			Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial	VACCINE			English	Article						Influenza; Vaccine; MF59; Hutterite; Randomized trial; Adjuvant; Herd immunity	INFECTION-RATES; SCHOOLCHILDREN; HOSPITALIZATIONS; TECUMSEH; FAMILIES; ILLNESS; INFANTS; DISEASE; SAFETY	ABSTR A C T Background: Children play an important role in the transmission of influenza. The best choice of vaccine to achieve both direct and indirect protection is uncertain. The objective of the study was to test whether vaccinating children with MF59 adjuvanted trivalent influenza vaccine (aTIV) can reduce influenza in children and their extended households compared to inactivated quadrivalent vaccine (QIV). Methods: We conducted a cluster randomized trial in 42 Hutterite colonies in Alberta and Saskatchewan. Colonies were randomized such that children were assigned in a blinded manner to receive aTIV (0.25 ml of pediatric aTIV for ages 6 months to < 36 months or 0.5 ml for ages > 36 months to 6 years) or 0.5 ml of QIV. Participants included 424 children aged 6 months to 6 years who received the study vaccine and 1246 family cluster members who did not receive the study vaccine. The primary outcome was confirmed influenza A and B infection using a real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay. An intent to treat analysis was used. Data were collected from January 2017 to June 2019. Results: The mean percentage of children who received study vaccine was 62% for aTIV colonies and 74% for QIV colonies. There were 66 (3.4%) with RT-PCR confirmed influenza A and Bin the aTIV colonies (chil-dren and family clusters) versus 93 (4.4%) in the QIV colonies, hazard ratio (HR) 0.78 (95 %CI 0.36-1.71). Of these, 48 (2.5%) in the aTIV colonies and 76 (3.6%) in the QIV colonies had influenza A, HR 0.69, (95 %CI 0.29-1.66) while 18 (0.9%) and 17 (0.8%) in the aTIV versus QIV colonies respectively had influenza B, HR 1.22, (95 %CI 0.20-7.41). In children who received study vaccine, there were 5 Influenza A infections in the aTIV colonies (1.1%) compared to 30 (5.8%) in the QIV colonies, relative efficacy of 80%, HR 0.20, (95 %CI 0.06-0.66). Adverse events were significantly more common among children who received aTIV. No serious vaccine adverse events were reported. Conclusion: Vaccinating children with aTIV compared to QIV resulted in similar community RT-PCR con-firmed influenza illness and led to significant protection against influenza A in children. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Loeb, Mark; Kelly-Stradiotto, Caralyn; Fuller, Nola; Earn, David J. D.; Singh, Pardeep] McMaster Univ, 1280 Main St West, Hamilton, ON L8S 4K1, Canada; [Russell, Margaret L.] Univ Calgary, Calgary, AB, Canada; [Fonseca, Kevin] Alberta Prov Lab, Calgary, AB, Canada; [Chokani, Khami] Prince Albert Parkland Hlth Reg, Prince Albert, SK, Canada; [Babiuk, Lorne] Univ Alberta, Edmonton, AB, Canada; [Pullenayegum, Eleanor] Hosp Sick Children, Toronto, ON, Canada		Loeb, M (通讯作者)，McMaster Univ, 1280 Main St West, Hamilton, ON L8S 4K1, Canada.	loebm@mcmaster.ca			Seqirus	Funding for the study was provided by Seqirus which played no role in the design of the study, in data analysis, or in the preparation of the manuscript.	Diallo A, 2018, VACCINE, V36, P6424, DOI 10.1016/j.vaccine.2018.08.032; FOX JP, 1982, AM J EPIDEMIOL, V116, P212, DOI 10.1093/oxfordjournals.aje.a113407; FOY HM, 1976, J INFECT DIS, V134, P362, DOI 10.1093/infdis/134.4.362; GLEZEN WP, 1991, AM J EPIDEMIOL, V133, P296, DOI 10.1093/oxfordjournals.aje.a115874; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Langley JM, 2004, CAN MED ASSOC J, V171, P1213, DOI 10.1503/cmaj.1031737; Loeb M, 2016, ANN INTERN MED, V165, P617, DOI 10.7326/M16-0513; Loeb M, 2010, JAMA-J AM MED ASSOC, V303, P943, DOI 10.1001/jama.2010.250; Long CE, 1997, ARCH FAM MED, V6, P459, DOI 10.1001/archfami.6.5.459; Mertz D, 2016, EUROSURVEILLANCE, V21, P15, DOI 10.2807/1560-7917.ES.2016.21.42.30378; Miglioretti DL, 2007, AM J EPIDEMIOL, V165, P453, DOI 10.1093/aje/kwk020; MONTO AS, 1970, J INFECT DIS, V122, P16, DOI 10.1093/infdis/122.1-2.16; MONTO AS, 1985, AM J EPIDEMIOL, V121, P811, DOI 10.1093/oxfordjournals.aje.a114052; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Neuzil KM, 2002, ARCH PEDIAT ADOL MED, V156, P986, DOI 10.1001/archpedi.156.10.986; Nolan T, 2014, VACCINE, V32, P6146, DOI 10.1016/j.vaccine.2014.08.068; Reichert TA, 2001, NEW ENGL J MED, V344, P889, DOI 10.1056/NEJM200103223441204; Solares AR, 2014, J INFECT DEV COUNTR, V8, P1160, DOI 10.3855/jidc.4594; Stassijns J, 2016, VACCINE, V34, P714, DOI 10.1016/j.vaccine.2015.12.024; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Vesikari T, 2015, HUM VACC IMMUNOTHER, V11, P2102, DOI 10.1080/21645515.2015.1044167; Vesikari T, 2011, NEW ENGL J MED, V365, P1406, DOI 10.1056/NEJMoa1010331	22	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6843	6851		10.1016/j.vaccine.2021.10.035		NOV 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34702621	hybrid			2022-04-29	WOS:000719580000005
J	Nowalk, MP; D'Agostino, HEA; Zimmerman, RK; Saul, SG; Susick, M; Raviotta, JM; Sax, TM; Balasubramani, GK				Nowalk, Mary Patricia; D'Agostino, Helen Eleni Aslanidou; Zimmerman, Richard K.; Saul, Sean G.; Susick, Michael; Raviotta, Jonathan M.; Sax, Theresa M.; Balasubramani, G. K.			Agreement among sources of adult influenza vaccination in the age of immunization information systems	VACCINE			English	Article						Adult influenza vaccination; Immunization information systems; Vaccination status; Vaccine registries; Electronic medical records	SELF-REPORT; DATA COMPLETENESS; VALIDATION; PROGRESS; REGISTRY; STATES	Introduction: Many vaccination studies rely on self-reported vaccination status, with its inherent biases. Accuracy of influenza vaccination self-report has been evaluated periodically, typically using the medical record as the gold standard. The burgeoning of electronic medical records (EMRs) and immunization information systems (IISs) and the rise of adult vaccine administration in community pharmacies suggest the need for a reevaluation of self-reported vaccination status. Methods: Vaccination data from self-report, the state IIS, the health system EMR and other sources were compared for participants in outpatient and inpatient influenza vaccine effectiveness studies for four seasons (2016-2017 to 2019-2020). Agreement among the sources was calculated along with sensitivity and specificity. Tests for trend assessed changes in completeness of the Pennsylvania -Statewide IIS (PA-SIIS) data over time. Results: With self-report as the gold standard, agreement with the local EMR, PA-SIIS, and all sources was 62%, 77% and 85%, respectively. Sensitivity of the EMR was 42% (95% CI = 41, 43) and specificity was 91% (90, 92). With PA-SIIS-as the gold standard, agreement with the local EMR and all sources was 77% and 78%, respectively. Sensitivity of all sources combined was 96% (95, 97) and specificity was (63% (62, 64). Capture of influenza vaccinations in the IIS has not consistently improved over time, with a significant increase among children (P = 0.001), no change among working-age adults and a decrease among older adults (P = 0.004). However, PA-SIIS provided the largest percentage of verified vaccines (69.3%) compared with EMR (43.3%) and other sources (12.4%). Conclusion: Both self-report and PA-SIIS are good estimates of actual vaccine uptake. When high accuracy data are required, such as for vaccine effectiveness studies, triangulation using multiple sources should be conducted. (c) 2021 Elsevier Ltd. All rights reserved.	[Nowalk, Mary Patricia; Zimmerman, Richard K.; Saul, Sean G.; Susick, Michael; Raviotta, Jonathan M.] Univ Pittsburgh, Sch Med, Dept Family Med, Suite 520 Schenley Pl,4420 Bayard St, Pittsburgh, PA 15260 USA; [D'Agostino, Helen Eleni Aslanidou; Sax, Theresa M.; Balasubramani, G. K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Suite 600 Schenley Pl,4420 Bayard St, Pittsburgh, PA 15260 USA		Nowalk, MP (通讯作者)，Univ Pittsburgh, Sch Med, Dept Family Med, Suite 520 Schenley Pl,4420 Bayard St, Pittsburgh, PA 15260 USA.	tnowalk@pitt.edu	Nowalk, Mary Patricia/ACU-4712-2022		Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [5U01IP001035]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1TR001857]	This work was supported by the Centers for Disease Control and Prevention (CDC) [5U01IP001035] and by National Institutes of Health (NIH) [UL1TR001857]. This work represents the views of the authors and not the CDC or NIH. It is subject to CDC's public access policy.	Agresti A, 1992, STAT SCI, V7, P131, DOI [10.1214/ss/1177011454, DOI 10.1214/SS/1177011454]; [Anonymous], **NON-TRADITIONAL**; [Anonymous], 2009, HLTH INFORM TECHNOLO; Boyd TD, 2002, AM J PREV MED, V22, P184, DOI 10.1016/S0749-3797(01)00427-5; Cardemil C, 2013, MMWR-MORBID MORTAL W, V62, P1005; Curran EA, 2013, HUM VACC IMMUNOTHER, V9, P1346, DOI 10.4161/hv.24033; Ferdinands JM, 2019, J INFECT DIS, V220, P1265, DOI 10.1093/infdis/jiy723; Greene SK, 2009, AM J PREV MED, V37, P552, DOI 10.1016/j.amepre.2009.08.022; Hadler JL, 2012, J INFECT DIS, V206, P49, DOI 10.1093/infdis/jis306; Hendrickson BK, 2015, J PUBLIC HEALTH MAN, V21, P288, DOI 10.1097/PHH.0000000000000045; Jackson ML, 2014, ACAD PEDIATR, V14, P71, DOI 10.1016/j.acap.2013.10.002; Jimenez-Garcia R, 2014, VACCINE, V32, P4386, DOI 10.1016/j.vaccine.2014.06.074; Kolasa MS, 2006, AMBUL PEDIATR, V6, P21, DOI 10.1016/j.ambp.2005.08.006; Mac Donald R, 1999, AM J PREV MED, V16, P173, DOI 10.1016/S0749-3797(98)00159-7; Mangtani P, 2007, EPIDEMIOL INFECT, V135, P139, DOI 10.1017/S0950268806006479; Martin DW, 2015, J PUBLIC HEALTH MAN, V21, P296, DOI 10.1097/PHH.0000000000000040; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Murthy N, 2017, MMWR-MORBID MORTAL W, V66, P1178, DOI 10.15585/mmwr.mm6643a4; Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736; Rolnick SJ, 2013, VACCINE, V31, P3928, DOI 10.1016/j.vaccine.2013.06.041; Zimmerman RK, 2003, VACCINE, V21, P1486, DOI 10.1016/S0264-410X(02)00700-4	21	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6829	6836		10.1016/j.vaccine.2021.10.041		NOV 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34716041				2022-04-29	WOS:000719580000003
J	Fu, LY; Torres, R; Caleb, S; Cheng, YI; Gennaro, E; Thoburn, E; McLaughlin, J; Alexander-Parrish, R; Wang, JC				Fu, Linda Y.; Torres, Rachel; Caleb, Susan; Cheng, Yao, I; Gennaro, Erica; Thoburn, Elizabeth; McLaughlin, John; Alexander-Parrish, Ronika; Wang, Jichuan			Vaccination coverage among young homeless children compared to US national immunization survey data	VACCINE			English	Article						Public assistance; Social welfare; Child health; Homeless children; Poverty; Immunization	NEW-YORK-CITY; UNITED-STATES; HEALTH-STATUS; FAMILIES; INFANTS; CARE	Introduction: Comprehensive vaccination coverage among homeless children in the United States (US) is largely unknown although a few studies suggest low coverage with single vaccinations. This study compared vaccination coverage with a combined 7-vaccines series among homeless children in the District of Columbia (DC) to coverage among other US children. Materials and methods: A cross-sectional survey of homeless children in DC was conducted from 2018 to 2019. Recruitment occurred at housing shelters, social services centers, and a diaper dispensary, and through limited chain referral. English-speaking parents of a child aged 19 to 35 months who spent the majority of the last 30 nights homeless were recruited. Participants consented for their child's healthcare providers to submit vaccination records. The vaccination coverage estimate of this sample was compared with estimates of three populations in the 2018 National Immunization Survey (NIS): children in DC (NIS DC), children in the US (NIS US), and children in the US below the federal poverty level (NIS poor). Results: Most of the 135 children had experienced at least two lifetime episodes (63.7%) and 12 months (57%) of homelessness. The estimated percent up to date was 52.6% (95% CI: 43.8%, 61.3%). This estimate was 20.4 (95% CI: 11.9, 28.8, p < .0001), 20 (95% CI: 11.5, 28.4, p < .0001), and 11.5 (95% CI: 3.1, 20, p < .01) percentage points lower than estimates for the NIS DC, NIS US and NIS poor populations, respectively. After adjusting for child's age and race/ethnicity, vaccination coverage of the NIS DC sample was below that of NIS US (p < .01) and NIS poor samples (p < .05). Conclusion: Children experiencing homelessness may be at risk of under-vaccination, even when compared to a general population of children in poverty. Awareness of this heightened risk may allow for more precise targeting of vaccination delivery support specifically to children experiencing homelessness. (c) 2021 Elsevier Ltd. All rights reserved.	[Fu, Linda Y.; Gennaro, Erica] Childrens Natl Hosp, Goldberg Ctr Community Pediat Hlth, 111 Michigan Ave,NW, Washington, DC 20010 USA; [Fu, Linda Y.; Torres, Rachel; Caleb, Susan; Cheng, Yao, I; Wang, Jichuan] Childrens Natl Hosp, Ctr Translat Sci, 111 Michigan Ave,NW, Washington, DC 20010 USA; [Thoburn, Elizabeth; McLaughlin, John; Alexander-Parrish, Ronika] Pfizer Inc, 500 Arcola Rd, Collegeville, PA 19426 USA		Fu, LY (通讯作者)，NIH, Environm Influences Child Hlth Outcomes ECHO, Off Director, Three White Flint North,11601 Landsdown St, North Bethesda, MD 20852 USA.	linda.fu@nih.gov		Fu, Linda/0000-0002-5649-5167			Bates AS, 1998, PEDIATRICS, V101, P591, DOI 10.1542/peds.101.4.591; Briggs MA, 2013, PEDIATRICS, V131, P1206, DOI 10.1542/peds.2013-0645; Buckner JC, 2008, AM BEHAV SCI, V51, P721, DOI 10.1177/0002764207311984; Centers for Disease Control and Prevention, CHILDVAXVIEW; Child Trends, CHILDR YOUTH EXP HOM; Clark RE, 2019, HEALTH AFFAIR, V38, P721, DOI 10.1377/hlthaff.2019.00090; Clark SJ, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-33; FIERMAN AH, 1993, CLIN PEDIATR, V32, P151, DOI 10.1177/000992289303200305; Gennaro E, J PEDIAT, V2021; Hennessey KA, 2009, PUBLIC HEALTH REP, V124, P813, DOI 10.1177/003335490912400608; Henry M, 2021, 2020 ANN HOM ASS REP; Hill HA, 2018, MMWR-MORBID MORTAL W, V67, P1123, DOI 10.15585/mmwr.mm6740a4; Hinman AR, 2004, CLIN INFECT DIS, V38, P1445, DOI 10.1086/420748; Homeless Services Planning and Coordinating Committee, 2021, HOM METR WASH RES AN; Kerker BD, 2011, AM J PUBLIC HEALTH, V101, P546, DOI 10.2105/AJPH.2010.193102; Krishnarajah G, 2018, HUM VACC IMMUNOTHER, V14, P2932, DOI 10.1080/21645515.2018.1502526; Kroger AT, GEN BEST PRACTICE GU; Mansor-Lefebvre S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082854; MILLER DS, 1988, PEDIATRICS, V81, P668; Moffa M, 2019, INT J HYG ENVIR HEAL, V222, P335, DOI 10.1016/j.ijheh.2018.12.004; Mosenifar Zab, 2007, Proc Am Thorac Soc, V4, P185, DOI 10.1513/pats.200701-009GC; NORC at the University of Chicago, 2020, NAT IMM SURV CHILD U; Paskett Electra D, 2003, Clin Adv Hematol Oncol, V1, P607; Robinson CL, 2020, MMWR-MORBID MORTAL W, V69, P130, DOI 10.15585/mmwr.mm6905a3; Schwarz K, 2005, J PEDIATR GASTR NUTR, V41, P225, DOI 10.1097/01.mpg.0000172886.77795.d4; Shefer A, 2004, J HEALTH CARE POOR U, V15, P127, DOI 10.1353/hpu.2004.0013; Shinn M, 2013, AM J PUBLIC HEALTH, V103, pS324, DOI 10.2105/AJPH.2013.301468; Smith PJ, 2009, ARCH PEDIAT ADOL MED, V163, P462, DOI 10.1001/archpediatrics.2009.25; Walker Allison T, 2014, MMWR Suppl, V63, P7; WOOD DL, 1990, PEDIATRICS, V86, P858	30	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6637	6643		10.1016/j.vaccine.2021.09.073		OCT 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WI0SZ	34629209				2022-04-29	WOS:000708078600010
J	Colton, H; Greenfield, DM; Snowden, JA; Miller, PDE; Morley, NJ; Wright, J; Darton, TC; Evans, CM; de Silva, TI				Colton, Hayley; Greenfield, Diana M.; Snowden, John A.; Miller, Paul D. E.; Morley, Nicholas J.; Wright, Josh; Darton, Thomas C.; Evans, Cariad M.; de Silva, Thushan, I			Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant	VACCINE			English	Article						HSCT; Autologous; Haematopoetic stem cell transplant; Immunosuppressed; Immunity; Correlates of Protection; Routine vaccination programme; Infection; Diphtheria; Measles; Pneumococcal; Varicella; VZV; Tetanus; Haemophilus; Hib; Mumps; Rubella; MMR; Vaccination; UK	UK; ADULT	Current international guidelines recommend routinely vaccinating haematopoetic stem cell transplant (HSCT) recipients. Despite significant infection-related mortality following autologous HSCT, routine vaccination programmes (RVP) completion is poor. For recovered HSCT recipients, it is uncertain whether catch-up vaccination remains worthwhile years later. To determine potential susceptibility to vaccine preventable infections, we measured antibody titres in 56 patients, a median of 7 years (range 0-29) following autologous HSCT, who had not completed RVP. We found that almost all participants had inadequate titres against diphtheria (98.2%) and pneumococcal infection (100%), and a significant proportion had inadequate titres against measles (34.5%). Of those subsequently vaccinated according to available guidelines, many mounted adequate serological responses. These data suggest a pragmatic catch-up approach for autologous HSCT recipients who have not completed RVP is advisable, with universal vaccination against some pathogens (e.g. Streptococcus pneumoniae and diphtheria) and serologically-guided approaches for others (e.g. measles and varicella zoster virus). (c) 2021 Elsevier Ltd. All rights reserved.	[Colton, Hayley; Darton, Thomas C.; de Silva, Thushan, I] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England; [Colton, Hayley; Darton, Thomas C.; de Silva, Thushan, I] Univ Sheffield, Florey Inst Host Pathogen Interact, Sheffield, S Yorkshire, England; [Colton, Hayley; Darton, Thomas C.; de Silva, Thushan, I] Sheffield Teaching Hosp NHS Fdn Trust, South Yorkshire Reg Dept Infect & Trop Med, Sheffield, S Yorkshire, England; [Greenfield, Diana M.] Sheffield Teaching Hosp NHS Fdn Trust, Specialised Canc Serv, Sheffield, S Yorkshire, England; [Snowden, John A.; Wright, Josh] Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England; [Miller, Paul D. E.] St Georges Univ Hosp NHS Fdn Trust, Dept Haematol, London, England; [Morley, Nicholas J.; Evans, Cariad M.] Sheffield Teaching Hosp NHS Fdn Trust, Dept Virol, Sheffield, S Yorkshire, England		Colton, H (通讯作者)，Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England.	h.colton@sheffield.ac.uk	Darton, Thomas/H-2816-2017	Darton, Thomas/0000-0003-2209-9956; Greenfield, Diana/0000-0002-3733-2717; SNOWDEN, JOHN/0000-0001-6819-3476; Colton, Hayley/0000-0002-3287-4103; Miller, Paul/0000-0002-4357-4392			[Anonymous], 2017, Wkly Epidemiol Rec, V92, P417; [Anonymous], 2015, GREEN BOOK, P421; Bailey H, 2015, SCREENING VARICELLA, P1; Bollaerts K, 2017, EPIDEMIOL INFECT, V145, P2666, DOI 10.1017/S0950268817001546; Daly TM, 2015, CLIN VACCINE IMMUNOL, V22, P148, DOI 10.1128/CVI.00735-14; England PH., 2019, GUIDELINES POSTEXPOS, P1; Gilleece MH, 2007, BIOL BLOOD MARROW TR, V13, P75, DOI 10.1016/j.bbmt.2006.12.207; Guzek A, 2020, ANN ONCOL, V31, P319, DOI 10.1016/j.annonc.2019.11.005; Kennedy LB, 2017, BIOL BLOOD MARROW TR, V23, P1614, DOI 10.1016/j.bbmt.2017.06.006; Ljungman P, 2004, BONE MARROW TRANSPL, V34, P589, DOI 10.1038/sj.bmt.1704634; Ljungman P, 2009, BONE MARROW TRANSPL, V44, P521, DOI 10.1038/bmt.2009.263; Maple PAC, 2009, J CLIN VIROL, V44, P9, DOI 10.1016/j.jcv.2008.08.012; Miller PDE, 2017, BONE MARROW TRANSPL, V52, P775, DOI 10.1038/bmt.2016.362; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Ramsay M., 2018, PNEUMOCOCCAL GREEN B; Ramsay ME, 2003, J INFECT DIS, V188, P481, DOI 10.1086/376997; Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI [10.1093/cid/cit816, 10.1093/cid/cit684]; Sheridan SL, 2014, EXPERT REV VACCINES, V13, P1081, DOI 10.1586/14760584.2014.944167; Styczynski J, 2020, BONE MARROW TRANSPL, V55, DOI 10.1038/s41409-019-0624-z; Wagner KS, 2012, VACCINE, V30, P7111, DOI 10.1016/j.vaccine.2012.09.029	20	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4778	4783		10.1016/j.vaccine.2021.07.022		JUL 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34294480				2022-04-29	WOS:000679483400007
J	Galor, I; Hartal, M; Markovich, EP; Avramovich, E				Galor, I.; Hartal, M.; Markovich, E. Perry; Avramovich, E.			Population seroprotection against hepatitis a virus in Israel 18 years after introduction of inactivated vaccine into the routine childhood vaccination schedule: Response letter, to letter to the editor	VACCINE			English	Letter									[Galor, I.; Avramovich, E.] Israel Bar Ilan Univ, Fac Social Sci, Dept Management, Publ Hlth Branch,Israel Def Forces Med Corps, Ramat Gan, Israel; [Hartal, M.] Myers Jdc Brookdale Inst, Jerusalem, Israel; [Markovich, E. Perry] Minist Agr & Rural Dev, Perry Israel Vet Serv, Rishon Lezion, Palestine		Galor, I (通讯作者)，Israel Bar Ilan Univ, Fac Social Sci, Dept Management, Publ Hlth Branch,Israel Def Forces Med Corps, Ramat Gan, Israel.	inbalraj@gmail.com					Barkai G, 2009, PEDIATR INFECT DIS J, V28, P391, DOI 10.1097/INF.0b013e318190655c; Israeli MOH website, EPID DIV WEEK EPID R; Levine H, 2015, EUROSURVEILLANCE, V20, P5, DOI 10.2807/1560-7917.ES2015.20.7.21040; Wasley A, 2006, EPIDEMIOL REV, V28, P101, DOI 10.1093/epirev/mxj012	4	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4777	4777		10.1016/j.vaccine.2021.07.008		JUL 2021	1	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34332696				2022-04-29	WOS:000679483400006
J	Herve, PL; Dhelft, V; Zuniga, A; Ghasparian, A; Rassek, O; Yim, KC; Donne, N; Lambert, PH; Benhamou, PH; Sampson, HA; Mondoulet, L				Herve, Pierre-Louis; Dhelft, Veronique; Zuniga, Armando; Ghasparian, Arin; Rassek, Oliver; Yim, Kevin C.; Donne, Nathalie; Lambert, Paul-Henri; Benhamou, Pierre-Henri; Sampson, Hugh A.; Mondoulet, Lucie			Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus	VACCINE			English	Article						Nanoparticle-based vaccine; Epicutaneous vaccine; RSV-neutralizing antibodies; Synthetic virus like particles; Vaccine boost	FUSION GLYCOPROTEIN; STRUCTURAL BASIS; F-GLYCOPROTEIN; HIGH-RISK; INFECTION; EPITOPES; RSV; NEUTRALIZATION; PALIVIZUMAB; ANTIBODIES	Despite the substantial health and economic burden caused by RSV-associated illness, no vaccine is available. The sole licensed treatment (palivizumab), composed of a monoclonal neutralizing antibody, blocks the fusion of the virus to the host cell but does not prevent infection. The development of a safe and efficacious RSV vaccine is therefore a priority, but also a considerable challenge, and new innovative strategies are warranted. Most of the adult population encounter regular RSV infections and can elicit a robust neutralizing antibody response, but unfortunately it wanes over time and reinfections during subsequent seasons are common. One approach to protect the mother and young infant from RSV infection is to administer a vaccine capable of boosting preexisting RSV immunity during pregnancy, which would provide protection to the fetus through passive transfer of maternal antibodies, thus preventing primary RSV infection in newborns during their first months of life. Here, we describe the preclinical evaluation of an epicutaneous RSV vaccine booster that combines epicutaneous patches as a delivery platform and a Synthetic Virus-Like Particles (SVLP)-based vaccine displaying multiple RSV F-protein site II (FsII, palivizumab epitope) mimetic as antigen (V-306). We demonstrated in mice that epicutaneous immunization with V-306 efficiently boosts preexisting immunity induced by the homologous V-306 administered subcutaneously. This boosting was characterized by a significant increase in F-and FsII-specific antibodies capable of competing with palivizumab for its target antigen and neutralize RSV. More importantly, epicutaneous booster immunization with V-306 significantly decreased lung viral replication in experimental mice after intranasal RSV challenge, without inducing enhanced RSV disease. In conclusion, an epicutaneous booster vaccine based on V-306 is safe and efficacious in enhancing RSV preexisting immunity in mice. This needle-free vaccine candidate would be potentially suited as a booster vaccine for vulnerable populations such as young infants via pregnant women, and the elderly. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Herve, Pierre-Louis; Dhelft, Veronique; Donne, Nathalie; Benhamou, Pierre-Henri; Mondoulet, Lucie] DBV Technol, 177-181 Ave Pierre Brossolette, F-92120 Montrouge, France; [Sampson, Hugh A.] DBV Technol, 12 East 49th St Tower 49,Suite 4001, New York, NY 10017 USA; [Zuniga, Armando; Ghasparian, Arin; Rassek, Oliver] Virometix AG, Wagisstr 14, CH-8952 Schlieren, Switzerland; [Lambert, Paul-Henri] Univ Geneva, Dept Pathol Immunol, WHO Collaborat Ctr Vaccine Immunol, Geneva, Switzerland; [Yim, Kevin C.] Sigmovir Biosyst Inc, 9610 Med Ctr Dr,Suite 100, Rockville, MD 20850 USA; [Zuniga, Armando; Ghasparian, Arin] Shape Biopharmaceut Inc, 245 First St,Riverview 2,18th Floor, Cambridge, MA 02142 USA		Herve, PL (通讯作者)，DBV Technol, 177-181 Ave Pierre Brossolette, F-92120 Montrouge, France.	pierre-louis.herve@dbv-technologies.com			DBV Technologies SA	This work was supported by DBV Technologies SA and Virometix AG.	ARBIZA J, 1992, J GEN VIROL, V73, P2225, DOI 10.1099/0022-1317-73-9-2225; BEELER JA, 1989, J VIROL, V63, P2941, DOI 10.1128/JVI.63.7.2941-2950.1989; Besteman SB, 2019, AM J RESP CRIT CARE, V200, P410, DOI 10.1164/rccm.201901-0233ED; Boato F, 2007, ANGEW CHEM INT EDIT, V46, P9015, DOI 10.1002/anie.200702805; Chang J, 2004, J IMMUNOL, V172, P503, DOI 10.4049/jimmunol.172.1.503; Chatzis O, 2021, CLIN MICROBIOL INFEC, V27, P878, DOI 10.1016/j.cmi.2020.08.033; Chen JJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134711; Chen ZJ, 2018, DRUG DISCOV TODAY, V23, P181, DOI 10.1016/j.drudis.2017.09.017; Eick AA, 2011, ARCH PEDIAT ADOL MED, V165, P104, DOI 10.1001/archpediatrics.2010.192; Falsey AR, 2005, DRUG AGING, V22, P577, DOI 10.2165/00002512-200522070-00004; Fjaerli Hans-Olav, 2005, BMC Pediatr, V5, P31, DOI 10.1186/1471-2431-5-31; Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894; Gavillet BM, 2015, VACCINE, V33, P3450, DOI 10.1016/j.vaccine.2015.05.089; Graham BS, 2017, CURR OPIN VIROL, V23, P107, DOI 10.1016/j.coviro.2017.03.012; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Herve PL, 2019, J CONTROL RELEASE, V298, P12, DOI 10.1016/j.jconrel.2019.02.004; Herve PL, 2017, NANOMED-NANOTECHNOL, V13, P411, DOI 10.1016/j.nano.2016.08.006; Herve PL, 2016, J CONTROL RELEASE, V243, P146, DOI 10.1016/j.jconrel.2016.10.003; Jha A., 2016, SARS MERS OTHER VIRA, P84, DOI 10.1183/2312508X.10010315; JOHNSON KM, 1962, NEW ENGL J MED, V267, P68, DOI 10.1056/NEJM196207122670204; LOPEZ JA, 1993, J GEN VIROL, V74, P2567, DOI 10.1099/0022-1317-74-12-2567; Magro M, 2010, J VIROL, V84, P7970, DOI 10.1128/JVI.00447-10; McLellan JS, 2011, J VIROL, V85, P7788, DOI 10.1128/JVI.00555-11; McLellan JS, 2010, NAT STRUCT MOL BIOL, V17, P248, DOI 10.1038/nsmb.1723; McNamara PS, 2002, BRIT MED BULL, V61, P13, DOI 10.1093/bmb/61.1.13; Mejias A, 2020, ANN ALLERG ASTHMA IM, V125, P36, DOI 10.1016/j.anai.2020.03.017; Mondoulet L, 2010, CLIN EXP ALLERGY, V40, P659, DOI 10.1111/j.1365-2222.2009.03430.x; Mondoulet L, 2015, IMMUNOTHERAPY-UK, V7, P1293, DOI 10.2217/imt.15.86; Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; Olchanski N, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy031; Pancer K, 2011, POL J MICROBIOL, V60, P253, DOI 10.33073/pjm-2011-035; Perriman AW, 2010, SMALL, V6, P1191, DOI 10.1002/smll.200901186; Rodriguez R, 2014, J INFECTION, V68, pS115, DOI 10.1016/j.jinf.2013.09.021; Sananez I, 2018, J INFECT DIS, V218, P75, DOI 10.1093/infdis/jiy180; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stensballe LG, 2009, J PEDIATR-US, V154, P296, DOI 10.1016/j.jpeds.2008.07.053; Swanson KA, 2011, P NATL ACAD SCI USA, V108, P9619, DOI 10.1073/pnas.1106536108; Tamborrini M, 2015, VACCINES, V3, P850, DOI 10.3390/vaccines3040850; TAYLOR G, 1992, J GEN VIROL, V73, P2217, DOI 10.1099/0022-1317-73-9-2217; Teunissen MBM, 2015, VACCINE, V33, P4659, DOI 10.1016/j.vaccine.2015.07.079; Wegzyn C, 2014, INFECT DIS THER, V3, P133, DOI 10.1007/s40121-014-0046-6; Wu PS, 2011, EXPERT REV ANTI-INFE, V9, P731, DOI [10.1586/eri.11.92, 10.1586/ERI.11.92]; Zuniga A, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00347-y	45	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4555	4563		10.1016/j.vaccine.2021.03.081		JUL 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34154864	hybrid			2022-04-29	WOS:000672160300023
J	Yemeke, TT; Mitgang, E; Wedlock, PT; Higgins, C; Chen, HH; Pallas, SW; Abimbola, T; Wallace, A; Bartsch, SM; Lee, BY; Ozawa, S				Yemeke, Tatenda T.; Mitgang, Elizabeth; Wedlock, Patrick T.; Higgins, Colleen; Chen, Hui-Han; Pallas, Sarah W.; Abimbola, Taiwo; Wallace, Aaron; Bartsch, Sarah M.; Lee, Bruce Y.; Ozawa, Sachiko			Promoting, seeking, and reaching vaccination services: A systematic review of costs to immunization programs, beneficiaries, and caregivers	VACCINE			English	Review						Hard-to-reach; Hard-to-vaccinate; Immunization; Vaccination; Costs	RANDOMIZED CONTROLLED-TRIAL; MIDDLE-INCOME COUNTRIES; TEXT MESSAGE REMINDERS; ORAL CHOLERA VACCINE; INCREASING INFLUENZA; EXPANDED PROGRAM; CENTRALIZED REMINDER/RECALL; CHILDHOOD IMMUNIZATIONS; ECONOMIC-EVALUATION; MASS VACCINATION	Introduction: Understanding the costs to increase vaccination demand among under-vaccinated popula-tions, as well as costs incurred by beneficiaries and caregivers for reaching vaccination sites, is essential to improving vaccination coverage. However, there have not been systematic analyses documenting such costs for beneficiaries and caregivers seeking vaccination. Methods: We searched PubMed, Scopus, and the Immunization Delivery Cost Catalogue (IDCC) in 2019 for the costs for beneficiaries and caregivers to 1) seek and know how to access vaccination (i.e., costs to immunization programs for social mobilization and interventions to increase vaccination demand), 2) take time off from work, chores, or school for vaccination (i.e., productivity costs), and 3) travel to vac-cination sites. We assessed if these costs were specific to populations that faced other non-cost barriers, based on a framework for defining hard-to-reach and hard-to-vaccinate populations for vaccination. Results: We found 57 studies describing information, education, and communication (IEC) costs, social mobilization costs, and the costs of interventions to increase vaccination demand, with mean costs per dose at $0.41 (standard deviation (SD) $0.83), $18.86 (SD $50.65) and $28.23 (SD $76.09) in low-, middle-, and high-income countries, respectively. Five studies described productivity losses incurred by beneficiaries and caregivers seeking vaccination ($38.33 per person; SD $14.72; n = 3). We identified six studies on travel costs incurred by beneficiaries and caregivers attending vaccination sites ($11.25 per person; SD $9.54; n = 4). Two studies reported social mobilization costs per dose specific to hard-to-reach populations, which were 2-3.5 times higher than costs for the general population. Eight studies described barriers to vaccination among hard-to-reach populations. Conclusion: Social mobilization/IEC costs are well-characterized, but evidence is limited on costs incurred by beneficiaries and caregivers getting to vaccination sites. Understanding the potential incremental costs for populations facing barriers to reach vaccination sites is essential to improving vaccine program financing and planning. (c) 2021 Published by Elsevier Ltd.	[Yemeke, Tatenda T.; Higgins, Colleen; Chen, Hui-Han; Ozawa, Sachiko] Univ N Carolina, Div Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA; [Mitgang, Elizabeth; Wedlock, Patrick T.; Bartsch, Sarah M.; Lee, Bruce Y.] CUNY, Publ Hlth Informat Computat & Operat Res PHICOR, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA; [Pallas, Sarah W.; Abimbola, Taiwo; Wallace, Aaron] US Ctr Dis Control & Prevent CDC, Global Immunizat Div, Atlanta, GA USA; [Ozawa, Sachiko] Univ N Carolina, Dept Maternal & Child Hlth, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC USA		Ozawa, S (通讯作者)，Univ N Carolina, UNC Eshelman Sch Pharm, Practice Adv & Clin Educ, CB 7574,Beard Hall 115G, Chapel Hill, NC 27599 USA.	ozawa@unc.edu	Chen, Hui-Han/AAY-4928-2020; Ozawa, Sachiko/D-4399-2014	Chen, Hui-Han/0000-0002-7169-4404; Ozawa, Sachiko/0000-0001-7608-9038			Achat H, 1999, AUST NZ J PUBL HEAL, V23, P285, DOI 10.1111/j.1467-842X.1999.tb01257.x; Akil L, 2016, INT J INFECT DIS, V49, P40, DOI 10.1016/j.ijid.2016.05.025; Andersson N, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S8; Banerjee Abhijit Vinayak, 2010, BMJ, V340, pc2220, DOI 10.1136/bmj.c2220; Bangure D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1470-6; Batt K, 2004, B WORLD HEALTH ORGAN, V82, P689; Bhutta ZA, 2011, LANCET, V378, P549, DOI 10.1016/S0140-6736(11)60744-7; Botwright S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182663; Bright T, 2018, TROP MED INT HEALTH, V23, P476, DOI 10.1111/tmi.13044; Byberg S, 2017, TROP MED INT HEALTH, V22, P12, DOI 10.1111/tmi.12793; Castaneda-Orjuela C, 2013, VACCINE, V31, pC72, DOI 10.1016/j.vaccine.2013.05.038; Cavailler P, 2006, VACCINE, V24, P4890, DOI 10.1016/j.vaccine.2005.10.006; Chatterjee S, 2016, INDIAN J MED RES, V143, P801, DOI 10.4103/0971-5916.192073; Colombini A, 2011, VACCINE, V29, P5474, DOI 10.1016/j.vaccine.2011.05.058; Cox SN, 2021, VACCINE, V39, P6796, DOI 10.1016/j.vaccine.2021.05.033; Deuson RR, 2001, ARCH PEDIAT ADOL MED, V155, P909, DOI 10.1001/archpedi.155.8.909; Dombkowski KJ, 2014, AM J PREV MED, V47, P1, DOI 10.1016/j.amepre.2014.02.009; Ebong Cliford E, 2011, Cost Eff Resour Alloc, V9, P9, DOI 10.1186/1478-7547-9-9; Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447; Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004; Field V, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-330; Ginsberg GM, 2001, J HEPATOL, V34, P92, DOI 10.1016/S0168-8278(00)00007-6; Griffiths UK, 2005, HEALTH POLICY PLANN, V20, P50, DOI 10.1093/heapol/czi006; Griffiths UK, 2009, VACCINE, V27, P1426, DOI 10.1016/j.vaccine.2008.12.037; Griffiths UK, 2016, VACCINE, V34, P4213, DOI 10.1016/j.vaccine.2016.06.050; Haji A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2823-5; Hambidge SJ, 2009, PEDIATRICS, V124, P455, DOI 10.1542/peds.2008-0446; Herrett Emily, 2016, BMJ Open, V6, pe010069, DOI 10.1136/bmjopen-2015-010069; Hurley LP, 2018, AM J PREV MED, V55, P231, DOI 10.1016/j.amepre.2018.04.022; Hutton G, 2006, AM J TROP MED HYG, V75, P119, DOI 10.4269/ajtmh.2006.75.119; Hutubessy, 2019, PHARM SCI ASIA, V46, P46; Hutubessy R, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-136; Ilboudo PG, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2885-8; Immunization Costing Action Network (ICAN), 2019, IMM DEL COST CAT; Jani JV, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-161; Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629; Kaucley L, 2015, COST EFFECT RESOUR A, V13, DOI 10.1186/s12962-015-0039-7; Kempe A, 2015, JAMA PEDIATR, V169, P365, DOI 10.1001/jamapediatrics.2014.3670; Kempe A, 2013, AM J PUBLIC HEALTH, V103, P1116, DOI 10.2105/AJPH.2012.301035; Khan IA, 2013, VACCINE, V31, P6058, DOI 10.1016/j.vaccine.2013.10.021; Krieger JW, 2000, AM J PREV MED, V18, P123, DOI 10.1016/S0749-3797(99)00134-8; Lee BY, 2019, VACCINE, V37, P2377, DOI 10.1016/j.vaccine.2019.03.007; Lemstra M, 2011, PAED CHILD HEALT-CAN, V16, pE1, DOI 10.1093/pch/16.1.e1; Lin CJ, 2012, JT COMM J QUAL PATIE, V38, P67, DOI 10.1016/S1553-7250(12)38009-4; Malande OO, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212270; Manakongtreecheep Kasidet, 2017, Pan Afr Med J, V27, P23, DOI 10.11604/pamj.supp.2017.27.3.12115; Mascarenas A, 2005, PUBLIC HEALTH, V119, P542, DOI 10.1016/j.puhe.2004.08.020; McKnight J, 2014, GLOB PUBLIC HEALTH, V9, P1152, DOI 10.1080/17441692.2014.972967; Mogasale V, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004072; Mokaya E, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.24.12631; Montejo L, 2017, WORKPLACE HEALTH SAF, V65, P424, DOI 10.1177/2165079916686591; Morris J, 2015, J ADOLESCENT HEALTH, V56, pS27, DOI 10.1016/j.jadohealth.2015.01.010; Munk C, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4468-4; Ngabo F, 2015, VACCINE, V33, P7357, DOI 10.1016/j.vaccine.2015.10.022; O'Leary ST, 2015, PEDIATRICS, V136, pE1220, DOI 10.1542/peds.2015-1089; OANDA, 2021, CURR CONV; Okwaraji YB, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-476; Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3; Ozawa S, 2019, VACCINE, V37, P5525, DOI 10.1016/j.vaccine.2019.06.081; Ozawa S, 2018, VACCINE, V36, P3641, DOI 10.1016/j.vaccine.2018.05.030; Ozawa S, 2017, B WORLD HEALTH ORGAN, V95, P629, DOI 10.2471/BLT.16.178475; Ozawa S, 2016, VACCINE, V34, P6408, DOI 10.1016/j.vaccine.2016.09.036; Ozawa S, 2016, HEALTH AFFAIR, V35, P2124, DOI 10.1377/hlthaff.2016.0462; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Pegurri E, 2005, VACCINE, V23, P1624, DOI 10.1016/j.vaccine.2004.02.029; Petrie JG, 2016, CLIN INFECT DIS, V62, P448, DOI 10.1093/cid/civ952; Poncin M, 2018, B WORLD HEALTH ORGAN, V96, P86, DOI 10.2471/BLT.16.189241; Portnoy A, 2020, PHARMACOECONOMICS, V38, P995, DOI 10.1007/s40273-020-00930-6; Portnoy A, 2015, VACCINE, V33, pA99, DOI 10.1016/j.vaccine.2014.12.037; Powell-Jackson T, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002519; Quentin W, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-137; Regan AK, 2017, ANN FAM MED, V15, P507, DOI 10.1370/afm.2120; Routh JA, 2017, AM J TROP MED HYG, V97, P37, DOI 10.4269/ajtmh.16-1023; Ruhago GM, 2015, COST EFFECT RESOUR A, V13, DOI 10.1186/s12962-015-0033-0; Sarker AR, 2015, VACCINE, V33, P4916, DOI 10.1016/j.vaccine.2015.07.042; Schaetti C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001844; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; Shoup JA, 2015, AM J MANAG CARE, V21, pE405; Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001; Stockwell MS, 2014, AM J PUBLIC HEALTH, V104, pE7, DOI 10.2105/AJPH.2013.301620; Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502; Suh CA, 2012, PEDIATRICS, V129, pE1437, DOI 10.1542/peds.2011-1714; Szilagyi PG, 2013, ACAD PEDIATR, V13, P204, DOI 10.1016/j.acap.2013.01.002; Szilagyi PG, 2011, ARCH PEDIAT ADOL MED, V165, P547, DOI 10.1001/archpediatrics.2011.73; Teshome S, 2018, HUM VACC IMMUNOTHER, V14, P2427, DOI 10.1080/21645515.2018.1460295; TheWorldBank, 2017, WORLD BANK COU LEND; Topuzoglu A, 2007, EUR J PUBLIC HEALTH, V17, P348, DOI 10.1093/eurpub/ckl250; Torres, 2016, GLOB PEDIAT HLTH, V3; Tubeuf S, 2014, BRIT J GEN PRACT, V64, pE493, DOI 10.3399/bjgp14X680977; Turner HC, 2019, VALUE HEALTH, V22, P1026, DOI 10.1016/j.jval.2019.03.021; United Nations Children's Fund (UNICEF), 2020, IMM COV ARE LOS GROU; US Department of Labor, 2017, CONS PRIC IND; Usuf E, 2014, VACCINE, V32, P1975, DOI 10.1016/j.vaccine.2014.01.045; Vaughan K, 2019, VACCINE-X, V2, DOI 10.1016/j.jvacx.2019.100034; Vora S, 2009, HUM VACCINES, V5, P395, DOI 10.4161/hv.5.6.7282; Wedlock P.T, 2020, IMPROVING VACCINATIO; Winston CA, 2007, AM J MANAG CARE, V13, P581; World Bank, 2018, WORLD DEV IND; World Health Organization, 2019, WHO GUID STAND EC EV; World Health Organization, 2020, WHO UNICEF EST DTP3; Yu WZ, 2018, VACCINE, V36, P3041, DOI 10.1016/j.vaccine.2018.04.008; Zhou FJ, 2014, PEDIATRICS, V133, P577, DOI 10.1542/peds.2013-0698; Zhou FJ, 2003, PEDIATRICS, V111, P1289, DOI 10.1542/peds.111.6.1289; Zhou FJ, 2005, ARCH PEDIAT ADOL MED, V159, P1136, DOI 10.1001/archpedi.159.12.1136	104	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4437	4449		10.1016/j.vaccine.2021.05.075		JUL 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TH5WO	34218959				2022-04-29	WOS:000672160300010
J	Moss, WJ; Shendale, S; Lindstrand, A; O'Brien, AL; Turner, N; Goodman, T; Kretsinger, K				Moss, William J.; Shendale, Stephanie; Lindstrand, Ann; O'Brien, Atherine L.; Turner, Nikki; Goodman, Tracey; Kretsinger, Katrina		SAGE Working Grp Measles Rubella E	Feasibility assessment of measles and rubella eradication	VACCINE			English	Article						Measles; Rubella; Eradication; Elimination; World Health Organization	POLIO ERADICATION; ELIMINATION; OUTBREAK; VACCINATION; WORLDWIDE	This report addresses the epidemiological aspects and feasibility of measles and rubella eradication and the potential resource requirements in response to the request of the Director-General at the Seventieth World Health Assembly held on May 31, 2017. A guiding principle is that the path toward measles and rubella eradication should serve to strengthen primary health care, promote universal health coverage, and be a pathfinder for new vision and strategy for immunization over the next decade as laid out in the Immunization Agenda 2030. Specifically, this report: 1) highlights the importance of measles and rubella as global health priorities; 2) reviews the current global measles and rubella situation; 3) summarizes prior assessments of the feasibility of measles and rubella eradication; 4) assesses the progress and challenges in achieving regional measles and rubella elimination; 5) assesses additional considerations for measles and rubella eradication, including the results of modelling and economic analyses; 6) assesses the implications of establishing a measles and rubella eradication goal and the process for setting an eradication target date; 7) proposes a framework for determining preconditions for setting a target date for measles and rubella eradication and how these preconditions should be understood and used; and 8) concludes with recommendations endorsed by SAGE. (c) 2021 Elsevier Ltd. All rights reserved.	[Moss, William J.] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Epidemiol, Baltimore, MD 21205 USA; [Moss, William J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Shendale, Stephanie; Lindstrand, Ann; O'Brien, Atherine L.; Goodman, Tracey; Kretsinger, Katrina] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland; [Turner, Nikki] Univ Auckland, Div Gen Practice & Primary Hlth Care, Auckland, New Zealand		Moss, WJ (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Epidemiol, Baltimore, MD 21205 USA.; Moss, WJ (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	wmoss1@jhu.edu		Shendale, Stephanie/0000-0003-0126-2849			Andrus JK, 2016, HEALTH AFFAIR, V35, P327, DOI 10.1377/hlthaff.2015.1005; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P97; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205; [Anonymous], 2016, Wkly Epidemiol Rec, V91, P61; [Anonymous], 2011, Wkly Epidemiol Rec, V86, P301; [Anonymous], 2019, WHOPOLIO1904; [Anonymous], 2009, SUMMARY 14 M INT TAS; Arya J, 2016, J CONTROL RELEASE, V240, P135, DOI 10.1016/j.jconrel.2015.11.019; Bandyopadhyay AS, 2019, EMERG INFECT DIS, V25, P1363, DOI 10.3201/eid2507.181703; Biellik RJ, 2018, VACCINE, V36, P5645, DOI 10.1016/j.vaccine.2018.07.029; Brown KE, 2019, MMWR-MORBID MORTAL W, V68, P587, DOI 10.15585/mmwr.mm6826a3; Chen SY, 2011, J INFECT DIS, V203, P1517, DOI 10.1093/infdis/jir115; Cochi SL, 2014, J INFECT DIS, V210, pS540, DOI 10.1093/infdis/jiu345; Cochi SL, 2011, J INFECT DIS, V204, pS4, DOI 10.1093/infdis/jir100; Dabbagh A, 2018, MMWR-MORBID MORTAL W, V67, P1323, DOI 10.15585/mmwr.mm6747a6; Dowell AC, 2019, VACCINE, V37, P4236, DOI 10.1016/j.vaccine.2019.05.096; Durrheim DN, 2017, LANCET PUBLIC HEALTH, V2, pE130, DOI 10.1016/S2468-2667(17)30026-9; Durrheim DN, 2014, VACCINE, V32, P6880, DOI 10.1016/j.vaccine.2014.10.061; Eilertson KE, 2019, STAT MED, V38, P4146, DOI 10.1002/sim.8290; Fine P.E.M., 2018, COMMUNITY PROTECTION, P5, DOI [10.1016/B978-0-323-35761-6.00077-8, DOI 10.1016/B978-0-323-35761-6.00077-8]; Gay NJ, 2004, J INFECT DIS, V189, pS27, DOI 10.1086/381592; Goodson JL, 2017, EXPERT REV VACCINES, V16, P1203, DOI 10.1080/14760584.2017.1393337; Graham M, 2019, SCIENCE, V364, P584, DOI 10.1126/science.aau6299; Grant GB, 2019, VACCINE; Griffiths UK, 2011, J INFECT DIS, V204, pS78, DOI 10.1093/infdis/jir090; Guerra FM, 2018, VACCINE, V36, P1248, DOI 10.1016/j.vaccine.2018.01.002; Guerra FM, 2017, LANCET INFECT DIS, V17, pE420, DOI 10.1016/S1473-3099(17)30307-9; Hughes SL, 2020, VACCINE, V38, P460, DOI 10.1016/j.vaccine.2019.10.090; Lochlainn LMN, 2019, LANCET INFECT DIS, V19, P1235, DOI 10.1016/S1473-3099(19)30395-0; McLean HQ, 2013, MMWR RECOMM REP, V62, P1; Meissner HC, 2004, PEDIATRICS, V114, P1065, DOI 10.1542/peds.2004-0440; Metcalf CJE, 2012, THEOR POPUL BIOL, V82, P275, DOI 10.1016/j.tpb.2011.12.001; Metcalf CJE, 2012, EPIDEMIOL INFECT, V140, P2290, DOI 10.1017/S0950268812000131; Moss WJ, 2011, J INFECT DIS, V204, pS47, DOI 10.1093/infdis/jir065; Nandi A, 2019, VACCINE; Nnadi C, 2017, J INFECT DIS, V216, pS368, DOI 10.1093/infdis/jix175; Omer SB, 2013, NEW ENGL J MED, V368, P1374, DOI 10.1056/NEJMp1300765; Orenstein WA, 2018, VACCINE, V36, pA1, DOI 10.1016/j.vaccine.2017.09.026; Orenstein WA, 2016, EXPERT REV VACCINES, V15, P791, DOI 10.1586/14760584.2016.1165614; Ozawa S, 2017, B WORLD HEALTH ORGAN, V95, P629, DOI 10.2471/BLT.16.178475; Pan American Health Organization, 2012, PLAN ACTION MAINTAIN; Paniz-Mondolfi AE, 2019, EMERG INFECT DIS, V25, P625, DOI 10.3201/eid2504.181305; Parker AA, 2006, NEW ENGL J MED, V355, P447, DOI 10.1056/NEJMoa060775; Patel MK, 2019, LANCET GLOB HEALTH, V7, pE313, DOI 10.1016/S2214-109X(18)30492-3; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Peyraud N, 2019, VACCINE, V37, P4427, DOI 10.1016/j.vaccine.2019.03.035; Recommendations of the Advisory Committee on Immunization Practices (ACIP), 1993, MMWR RECOMM REP, V42, P1; Rosen JB, 2018, JAMA PEDIATR, V172, P811, DOI 10.1001/jamapediatrics.2018.1024; Sanders R, 2011, J INFECT DIS, V204, pS71, DOI 10.1093/infdis/jir133; SENCER DJ, 1967, PUBLIC HEALTH REP, V82, P253, DOI 10.2307/4592985; Shonhai A, 2015, EPIDEMIOL INFECT, V143, P3442, DOI 10.1017/S0950268815000540; Smith G, 2011, J INFECT DIS, V204, pS62, DOI 10.1093/infdis/jir130; Sugerman DE, 2010, PEDIATRICS, V125, P747, DOI 10.1542/peds.2009-1653; Susan Reef, GUIDANCE INCREASING; Verguet S, 2015, VACCINE, V33, P1291, DOI 10.1016/j.vaccine.2014.11.050; Vynnycky E, 2019, HUM VACC IMMUNOTHER, V15, P309, DOI 10.1080/21645515.2018.1532257; Vynnycky E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149160; Winter AK, 2018, J INFECT DIS, V218, P355, DOI 10.1093/infdis/jiy137; World Health Organization, 2018, Weekly Epidemiological Record, V93, P544; World Health Organization, 2011, Weekly Epidemiological Record, V86, P1; World Health Organization, GLOBAL MEASLES RUBEL; World Health Organization, 2018, MEASLES VACCINE PREV; World Health Organization, 2010, GLOBAL ERADICATION M; World Health Organization, 2018, RUBELLA VACCINE PREV; Zimmermann M, 2019, VACCINE, V37, P6039, DOI 10.1016/j.vaccine.2019.08.050	65	2	2	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 16	2021	39	27					3544	3559		10.1016/j.vaccine.2021.04.027		JUN 2021	16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SO5NX	34045102				2022-04-29	WOS:000659020000003
J	Kreps, SE; Kriner, DL				Kreps, S. E.; Kriner, D. L.			Factors influencing Covid-19 vaccine acceptance across subgroups in the United States: Evidence from a conjoint experiment	VACCINE			English	Article						Covid-19; Public opinion; Vaccine hesitancy; Conjoint experiment; Heterogenous effects	PREFERENCES; BELIEFS	Public health officials warn that the greatest barrier to widespread vaccination against Covid-19 will not be scientific or technical, but the considerable public hesitancy to take a novel vaccine. Understanding the factors that influence vaccine acceptance is critical to informing public health campaigns aiming to combat public fears and ensure broad uptake. Employing a conjoint experiment embedded on an online survey of almost 2,000 adult Americans, we show that the effects of seven vaccine attributes on subjects' willingness to vaccinate vary significantly across subgroups. Vaccine efficacy was significantly more influential on vaccine acceptance among whites than among Blacks, while bringing a vaccine to market under a Food and Drug Administration Emergency Use Authorization had a stronger adverse effect on willingness to vaccinate among older Americans and women. Democrats were more sensitive to vaccine efficacy than Republicans, and both groups responded differently to various endorsements of the vaccine. We also explored whether past flu vaccination history, attitudes toward general vaccine safety, and personal contact with severe cases of Covid-19 can explain variation in group vaccination hesitancy. Many subgroups that exhibit the greatest Covid-19 vaccine hesitancy did not report significantly lower frequencies of flu vaccination. Several groups that exhibited greater Covid-19 vaccine hesitancy also reported greater concerns about vaccine safety generally, but others did not. Finally, subgroup variation in reported personal contact with severe cases of Covid-19 did not strongly match subgroup variation in vaccine acceptance. (c) 2021 Elsevier Ltd. All rights reserved.	[Kreps, S. E.; Kriner, D. L.] Cornell Univ, Dept Govt, White Hall, Ithaca, NY 14850 USA; [Kriner, D. L.] 209 White Hall, Ithaca, NY 14850 USA		Kriner, DL (通讯作者)，Cornell Univ, Dept Govt, White Hall, Ithaca, NY 14850 USA.; Kriner, DL (通讯作者)，209 White Hall, Ithaca, NY 14850 USA.	kriner@cornell.edu		Kriner, Douglas/0000-0002-9353-2334	Atkinson Center for Sustainability at Cornell University	This work was supported by the Atkinson Center for Sustainability at Cornell University. Both authors attest they meet the ICMJE criteria for authorship.	CATTIN P, 1982, J MARKETING, V46, P44, DOI 10.2307/1251701; Center PR, 2020, REP DEM MOV EV FURTH; Centers for Disease Control and Prevention, 2020, CENT DIS CONTROL PRE; Chervenak FA, 2021, AM J OBSTET GYNECOL, V224, P470, DOI 10.1016/j.ajog.2021.01.027; Cooper LA, 2020, JAMA-J AM MED ASSOC, V324, P1491, DOI 10.1001/jama.2020.19567; Coppock A, 2019, RES POLITICS, V6, DOI 10.1177/2053168018822174; de Bekker-Grob EW, 2018, VACCINE, V36, P1467, DOI 10.1016/j.vaccine.2018.01.054; de Bekker-Grob EW, 2010, VACCINE, V28, P6692, DOI 10.1016/j.vaccine.2010.08.001; Determann D, 2016, EUROSURVEILLANCE, V21, P20, DOI 10.2807/1560-7917.ES.2016.21.22.30247; Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505; Former, CNN; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Frieden T, 2020, WALL STR J; Gadarian SK, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249596; Galarce EM, 2011, VACCINE, V29, P5284, DOI 10.1016/j.vaccine.2011.05.014; Galvani AP, 2007, P NATL ACAD SCI USA, V104, P5692, DOI 10.1073/pnas.0606774104; Godinot LD, 2021, VACCINE, V39, P805, DOI 10.1016/j.vaccine.2020.12.057; Green J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc2717; Guo N, 2017, VACCINE, V35, P2848, DOI 10.1016/j.vaccine.2017.04.006; Hainmueller J, 2014, POLIT ANAL, V22, P1, DOI 10.1093/pan/mpt024; Hotez P, 2019, PEDIATR RES, V85, P912, DOI 10.1038/s41390-019-0354-3; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Just CW, 2020, SCIENCE 85; Kaplan RM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021726118; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kreps SE, 2022, NPJ VACCINES; Leeper TJ, 2020, POLIT ANAL, V28, P207, DOI 10.1017/pan.2019.30; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Louviere JJ, 2010, J CHOICE MODEL, V3, P57; Lyons B, 2019, HEALTH COMMUN, V34, P1741, DOI 10.1080/10410236.2018.1530526; Martin JA., 2019, BIRTHS FINAL DATA 20; McKee Chephra, 2016, J Pediatr Pharmacol Ther, V21, P104, DOI 10.5863/1551-6776-21.2.104; Motta M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113642; Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Quaife M, 2018, EUR J HEALTH ECON, V19, P1053, DOI 10.1007/s10198-018-0954-6; Quinn SC, 2017, VACCINE, V35, P7154, DOI 10.1016/j.vaccine.2017.10.083; Redelings MD, 2012, VACCINE, V30, P454, DOI 10.1016/j.vaccine.2011.10.050; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Schwarzinger M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010199; Shui IM, 2006, AM J PREV MED, V31, P244, DOI 10.1016/j.amepre.2006.04.006; Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923; Trapero-Bertran M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219905; Velan B, 2011, VACCINE, V29, P1173, DOI 10.1016/j.vaccine.2010.12.006; Veldwijk J, 2014, VACCINE, V32, P6277, DOI 10.1016/j.vaccine.2014.09.004; Verelst F, 2019, VACCINE, V37, P2079, DOI 10.1016/j.vaccine.2019.02.056	48	12	12	2	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 2	2021	39	24					3250	3258		10.1016/j.vaccine.2021.04.044		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SM1SV	33966909	Bronze, Green Published			2022-04-29	WOS:000657392500003
J	Habib, MA; Prymula, R; Carryn, S; Esposito, S; Henry, O; Revault, S; Usonis, V; Wysocki, J; Gillard, P; Povey, M				Habib, Md Ahsan; Prymula, Roman; Carryn, Stephane; Esposito, Susanna; Henry, Ouzama; Revault, Stephanie; Usonis, Vytautas; Wysocki, Jacek; Gillard, Paul; Povey, Michael			Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants	VACCINE			English	Article						Varicella; ELISA; Correlate of protection; Efficacy; Humoral response; Statistical modelling	ZOSTER-VIRUS; ANTIBODY-RESPONSE; CHICKENPOX; IMMUNITY; SAFETY; MODELS	Background: Varicella vaccination confers high and long-lasting protection against chickenpox and induces robust immune responses, but an absolute correlate of protection (CoP) against varicella has not been established. This study models the relationship between varicella humoral response and protec-tion against varicella. Methods: This was a post-hoc analysis of data from a Phase IIIb, multicenter, randomized trial (NCT00226499) conducted in ten varicella-endemic European countries. Healthy children aged 12- 22 months were randomized 3:3:1 to receive one dose of measles-mumps-rubella and one dose of vari-cella vaccine (one-dose group) or two doses of measles-mumps-rubella-varicella vaccine (two-dose group) or two doses of measles-mumps-rubella vaccine (control group) six weeks apart. The study remained observer-blind until completion, except in countries with obligatory additional immunizations. The objective was to correlate varicella-specific antibody concentrations with protection against varicella and probability of varicella breakthrough, using Cox proportional hazards and Dunning and accelerated failure time statistical models. The analysis was guided by the Prentice framework to explore a CoP against varicella. Results: The trial included 5803 participants, 5289 in the efficacy (2266: one-dose group, 2279: two-dose group and 744: control group) and 5235 (2248, 2245 and 742 in the same groups) in the immunogenicity cohort. The trial ended in 2016 with a median follow-up time of 9.8 years. Six weeks after vaccination with one-or two-dose varicella-containing vaccine, more than 93.0% of vaccinees were seropositive for varicella-specific antibodies. Estimated vaccine efficacy correlated positively with antibody concentra-tions. The fourth Prentice CoP criterion was not met, due to predicted positive vaccine efficacy in seroneg-ative participants. Further modelling showed decreased probability of moderate to severe varicella breakthrough with increasing varicella-specific antibody concentrations (ten-year probability <0.1 for antibody concentrations >2-fold above the seropositivity cut-off). Conclusions: Varicella-specific antibody concentrations are a good predictor of protection, given their inverse correlation with varicella occurrence. Clinical trial: NCT00226499. (c) 2021 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Habib, Md Ahsan; Gillard, Paul; Povey, Michael] GSK, Ave Fleming 20, B-1300 Wavre, Belgium; [Prymula, Roman] Charles Univ Prague, Dept Social Med, Fac Med, Simkova St 870, Hradec Kralove 50003, Czech Republic; [Carryn, Stephane; Revault, Stephanie] GSK, Rue Inst 89, B-1330 Rixensart, Belgium; [Esposito, Susanna] Univ Parma, Dept Med & Surg, Pediat Clin Pietro Barilla Childrens Hosp, Via Gramsci 14, I-43126 Parma, Italy; [Henry, Ouzama] GSK, 14200 Shady Grove Rd, Rockville, MD 20850 USA; [Usonis, Vytautas] Vilnius Univ, Clin Childrens Dis, Inst Clin Med, MK Ciurlionio G 21-27, LT-03101 Vilnius, Lithuania; [Wysocki, Jacek] Univ Med Sci, Dept Prevent Med, Ul Swiecickiego 6, PL-60781 Poznan, Poland		Habib, MA (通讯作者)，GSK, Ave Fleming 20, B-1300 Wavre, Belgium.	ahsan.m.habib@gsk.com; prymula@seznam.cz; stephane.x.carryn@gsk.com; susannamariaroberta.esposito@unipr.it; ouzama.n.henry@gsk.com; stephanie.p.ravault@gsk.com; vytautas.usonis@mf.vu.lt; jwysocki@ump.edu.pl; paul.gillard@gsk.com; michael.x.povey@gsk.com	Esposito, Susanna/AAA-8275-2022	Prymula, Roman/0000-0003-1567-2259	GlaxoSmithKline Biologicals S.A.GlaxoSmithKline	This work was supported by GlaxoSmithKline Biologicals S.A., which was involved in all stages of the study conduct and analysis and covered the costs associated with developing and publishing the present article.	Callegaro A, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0687-y; Carryn S, 2019, VACCINE, V37, P5323, DOI 10.1016/j.vaccine.2019.07.049; Chan ISF, 2002, STAT MED, V21, P3411, DOI 10.1002/sim.1268; Chen X, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-29; Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095; Dunning AJ, 2006, STAT MED, V25, P1485, DOI 10.1002/sim.2282; Dunning AJ, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0096-9; European Centre for Disease Prevention and Control, 2015, VARICELLA VACCINATIO; Feyssaguet M, 2020, VACCINE, V38, P3300, DOI 10.1016/j.vaccine.2020.03.009; Freer G, 2018, NEW MICROBIOL, V41, P95; Gershon AA, 2017, J INFECTION, V74, pS27, DOI 10.1016/S0163-4453(17)30188-3; Henry O, 2018, VACCINE, V36, P381, DOI 10.1016/j.vaccine.2017.11.081; Kuter B, 2004, PEDIATR INFECT DIS J, V23, P132, DOI 10.1097/01.inf.0000109287.97518.67; Laing KJ, 2018, J INFECT DIS, V218, pS68, DOI 10.1093/infdis/jiy403; Lal H, 2018, VACCINE, V36, P148, DOI 10.1016/j.vaccine.2017.11.019; Li S, 2002, PEDIATR INFECT DIS J, V21, P337, DOI 10.1097/00006454-200204000-00014; Nguipdop Djomo P., 2013, CORRELATES VACCINE I; Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Povey M, 2019, LANCET INFECT DIS, V19, P287, DOI 10.1016/S1473-3099(18)30716-3; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; Prymula R, 2014, LANCET, V383, P1313, DOI 10.1016/S0140-6736(12)61461-5; Qin L, 2007, J INFECT DIS, V196, P1304, DOI 10.1086/522428; Schwarz TF, 2018, HUM VACC IMMUNOTHER, V14, P1370, DOI 10.1080/21645515.2018.1442162; Shaw J, 2018, VIRAL IMMUNOL, V31, P96, DOI 10.1089/vim.2017.0136; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006; Wutzler P, 2017, EXPERT REV VACCINES, V16, P833, DOI 10.1080/14760584.2017.1343669	27	3	3	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3445	3454		10.1016/j.vaccine.2021.02.074		JUN 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	33736915	hybrid			2022-04-29	WOS:000657001300021
J	Wang, J; Jiang, LN; Zhang, C; He, WT; Tan, Y; Ning, CAY				Wang, Jing; Jiang, Lina; Zhang, Chao; He, Weitao; Tan, Yi; Ning, Chuanyi			The changes in the epidemiology of hand, foot, and mouth disease after the introduction of the EV-A71 vaccine	VACCINE			English	Article						Enteroviruses; HFMD; EV-A71; Vaccine; Epidemic	ENTEROVIRUS 71 VACCINE; CHINA; IMMUNOGENICITY; EFFICACY	Three inactive monovalent EV-A71 vaccines have been launched in China since 2016, which may change the HFMD pathogen spectrum and epidemiological trend. Using notifications from the national surveillance system, we analyzed the epidemiological character profiles and the possible pathogen replacement. The proportion of HFMD cases aged 0-12 months decreased from 23.0% to 15.3% between 2013-2015 and 2017-2019 (p < 0.01). EV-A71 among laboratory-confirmed severe cases in 2013-2015 (62.8%) transformed to other EVs (67.2%) in 2017-2019. The age distribution of EV-A71 infection shifted to the older. The cumulative coverage of the EV-A71 vaccine for children aged six months to five years in Guangxi has increased, while in severe cases, the positive rate declined. After gradually expanded vaccination, EV-A71 associated incidence rate, case-severity rate has decreased, and other serotypes are becoming dominant. Thus, bivalent even polyvalent vaccines are urgently needed to control HFMD. (c) 2021 Elsevier Ltd. All rights reserved.	[Wang, Jing; Jiang, Lina; Zhang, Chao; He, Weitao; Tan, Yi] Guangxi Ctr Dis Prevent & Control, 18 Jinzhou Rd, Nanning 530028, Guangxi, Peoples R China; [Ning, Chuanyi] Guangxi Med Univ, Coll Nursing, Nanning, Guangxi, Peoples R China		Tan, Y (通讯作者)，Guangxi Ctr Dis Prevent & Control, 18 Jinzhou Rd, Nanning 530028, Guangxi, Peoples R China.; Ning, CAY (通讯作者)，Guangxi Med Univ, 8 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.	jcs@gxcdc.com; ningchuanyi@gxmu.edu.cn					Chen MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188640; Fu XM, 2020, VIROL SIN, V35, P21, DOI 10.1007/s12250-019-00169-2; He SZ, 2017, EPIDEMIOL INFECT, V145, P1865, DOI 10.1017/S0950268817000309; Jiang LN, 2020, VACCINE, V38, P1804, DOI 10.1016/j.vaccine.2019.12.025; Koh WM, 2016, PEDIATR INFECT DIS J, V35, pE285, DOI 10.1097/INF.0000000000001242; Li JL, 2014, J INFECTION, V69, P299, DOI 10.1016/j.jinf.2014.04.001; Li JX, 2016, EXPERT REV VACCINES, V15, P129, DOI 10.1586/14760584.2016.1096782; Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224; Takahashi S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001958; Wang JY, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-017-0011-z; Xing WJ, 2014, LANCET INFECT DIS, V14, P308, DOI 10.1016/S1473-3099(13)70342-6; Yang BY, 2017, EUROSURVEILLANCE, V22, P38, DOI 10.2807/1560-7917.ES.2017.22.50.16-00824; Yang BY, 2015, PEDIATR INFECT DIS J, V34, P1399, DOI 10.1097/INF.0000000000000900; Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923	14	0	1	8	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3319	3323		10.1016/j.vaccine.2021.05.009		JUN 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	33994239				2022-04-29	WOS:000657001300004
J	Bezerra, FSB; Silva, MTD; Rezende, ADS; Lopes, AS; de Pinho, RB; Seixas, FK; Collares, TV; Portela, RWD; Azevedo, VAD; Borsuk, S				Brilhante Bezerra, Francisco Silvestre; de Oliveira Silva, Mara Thais; Silva Rezende, Andrea de Fatima; Lopes, Angela Sena; de Pinho, Rodrigo Barros; Seixas, Fabiana Kommling; Collares, Tiago Veiras; Portela, Ricardo Wagner Dias; de Carvalho Azevedo, Vasco Ariston; Borsuk, Sibele			Saponin-adjuvanted recombinant vaccines containing rCP00660 rCP09720 or rCP01850 proteins against Corynebacterium pseudotuberculosis infection in mice	VACCINE			English	Article						Mature epitope density analysis; Caseous lymphadenitis; Recombinant antigens; Immunoprophylaxis	NECROSIS-FACTOR-ALPHA; CASEOUS-LYMPHADENITIS; GAMMA-INTERFERON; IMMUNE-RESPONSE; SUSCEPTIBILITY; TUBERCULOSIS; ASSOCIATION; PROTECTION; ABSENCE; IGG3	Purpose: rCP01850, rCP09729 and rCP00660 proteins from Corynebacterium pseudotuberculosis, predicted as the three best targets to be used in vaccines against Caseous Lymphadenitis in mature epitope density (MED) analysis were tested as vaccinal targets in association to saponin as adjuvant. Methodology: rCP00660, rCP09720 and rCP01850 were expressed in E. coli and purified for immunization assay. Balb/c mice were divided into five groups of sixteen animals each. G1 was injected with saline solution (0.9% NaCl), G2 with saponin, G3, G4 and G5 with, respectively, rCP00660, rCP09720 and rCP01850 added by saponin. Two doses were administered within a 21-days interval, and blood samples were collected for IgG quantification. Twenty-one days after the last immunization, ten mice in each group were challenged with virulent C. pseudotuberculosis MIC-6 strain, and mortality was recorded for 40 days. Meanwhile six mice in each group were used for cytokine quantification by qPCR. Results: G2, G3, G4 and G5 presented protection rates of 10, 30, 40 and 60%, respectively. In spite of levels of total IgG were higher in G4 and G5, production of IgG2a was higher than IgG1 for G5. G3, G4 and G5 presented significant high IFN-gamma levels, however, only G5 showed high TNF-alpha while G3 and G4 showed high IL-17. Conclusion: rCP01850 added by saponin was able to protect efficiently mice against C. pseudotuberculosis challenge, and to induce high IgG, IFN-gamma and TNF-alpha levels. In spite of rCP00660 and rCP09720 had not same adequate protection levels, significant IgG, IFN-gamma, and IL-17 levels and further studies aiming to improve protection rates should be conducted. (C) 2021 Elsevier Ltd. All rights reserved.	[Brilhante Bezerra, Francisco Silvestre; de Oliveira Silva, Mara Thais; Silva Rezende, Andrea de Fatima; Lopes, Angela Sena; de Pinho, Rodrigo Barros; Seixas, Fabiana Kommling; Collares, Tiago Veiras; Borsuk, Sibele] Univ Fed Pelotas UFPel, Lab Biotecnol Infectoparasitaria, Campus Univ S-N, BR-96160000 Capao Do Leao, RS, Brazil; [Brilhante Bezerra, Francisco Silvestre] Univ Fed Rural Semiarido UFERSA, Lab Biotecnol Aplicada Doencas Infectoparasitaria, Rua Francisco Mota Bairro 572 Pres Costa & Silva, BR-59625900 Mossoro, RN, Brazil; [Portela, Ricardo Wagner Dias] Univ Fed Bahia UFBA, Inst Ciencias Saude, Lab Imunol & Biol Mol, Av Reitor Miguel Calmon S-N, BR-40110100 Salvador, BA, Brazil; [de Carvalho Azevedo, Vasco Ariston] Univ Fed Minas Gerais UFMG, Lab Genet Mol & Celular, Inst Ciencias Biol, Av Antonio Carlos 6627, BR-31270910 Belo Horizonte, MG, Brazil		Borsuk, S (通讯作者)，Univ Fed Pelotas UFPel, Lab Biotecnol Infectoparasitaria, Campus Univ S-N, BR-96160000 Capao Do Leao, RS, Brazil.	silvestre@ufersa.edu.br	Azevedo, Vasco A/B-1556-2019; Portela, Ricardo Wagner Dias/W-1794-2019; Portela, RW/H-5638-2013	Azevedo, Vasco A/0000-0002-4775-2280; Portela, Ricardo Wagner Dias/0000-0001-9095-776X; Portela, RW/0000-0001-9095-776X	Coordination for the Improvement of Higher Education Personnel (CAPES, Brazil)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [1608/2011]; National Council for Scientific and Technological Development (CNPq, Brazil)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	Wegratefully acknowledge to Coordination for the Improvement of Higher Education Personnel (CAPES, Brazil) for the financial support through the project number 1608/2011 (Pro-Ensino-Saude), and to National Council for Scientific and Technological Development (CNPq, Brazil) for the scholarship of some of the authors.	Andreasen LV, 2015, VACCINE, V33, P1873, DOI 10.1016/j.vaccine.2015.02.011; Bai H, 2009, J IMMUNOL, V183, P5886, DOI 10.4049/jimmunol.0901584; Baird GJ, 2007, J COMP PATHOL, V137, P179, DOI 10.1016/j.jcpa.2007.07.002; Bastos BL, 2012, J CLIN CELL IMMUNOL, V4, P1, DOI DOI 10.4172/2155-9899.S4-005; Bastos BL, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-254; Bezerra FSB, 2020, MICROB PATHOGENESIS, V149, DOI 10.1016/j.micpath.2020.104354; Brum AA, 2017, J MED MICROBIOL, V66, P635, DOI 10.1099/jmm.0.000477; Vale VLC, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0811-8; D'Afonseca V, 2008, GENET MOL RES, V7, P252, DOI 10.4238/vol7-1gmr438; Silva MTD, 2020, VACCINE, V38, P8099, DOI 10.1016/j.vaccine.2020.11.010; Silva MTD, 2018, VACCINE, V36, P74, DOI 10.1016/j.vaccine.2017.11.029; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Dorella FA, 2009, EXPERT REV VACCINES, V8, P205, DOI 10.1586/14760584.8.2.205; Droppa-Almeida D, 2016, VACCINE, V34, P1091, DOI 10.1016/j.vaccine.2015.12.064; Dummer LA, 2014, VACCINE, V32, P2413, DOI 10.1016/j.vaccine.2014.03.011; El-Enbaawy M I, 2005, Egypt J Immunol, V12, P13; Galvao CE, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1110-7; GERMANN T, 1995, EUR J IMMUNOL, V25, P823, DOI 10.1002/eji.1830250329; Goodswen SJ, 2013, BRIEF BIOINFORM, V14, P753, DOI 10.1093/bib/bbs066; Guimaraes AD, 2011, IIOAB J, V2, P33; Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681; Khader SA, 2005, J IMMUNOL, V175, P788, DOI 10.4049/jimmunol.175.2.788; Lan DTB, 1998, MICROBIOL IMMUNOL, V42, P863, DOI 10.1111/j.1348-0421.1998.tb02362.x; Lan DTB, 1999, J VET MED SCI, V61, P1203; Lefeber DJ, 2003, INFECT IMMUN, V71, P6915, DOI 10.1128/IAI.71.12.6915-6920.2003; Lin YY, 2009, IMMUNITY, V31, P799, DOI 10.1016/j.immuni.2009.08.025; Matsui H, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-37; McLay J, 2002, J IMMUNOL, V168, P3437, DOI 10.4049/jimmunol.168.7.3437; Nascimento IP, 2012, BRAZ J MED BIOL RES, V45, P1102, DOI 10.1590/S0100-879X2012007500142; Norman TE, 2014, J CLIN MICROBIOL, V52, P2684, DOI 10.1128/JCM.01252-14; Olson ME, 2002, CAN J VET RES, V66, P86; Ordway D, 2007, J IMMUNOL, V179, P522, DOI 10.4049/jimmunol.179.1.522; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x; Pinho J. M. R., 2009, Open Veterinary Science Journal, V3, P22, DOI 10.2174/1874318800903010022; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006; Rezende AFS, 2020, ARQ BRAS MED VET ZOO, V72, P199, DOI 10.1590/1678-4162-10790; Santos AR, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-S6-S4; Sena-Lopes A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191797; Silva JW, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0304-6; Rezende ADS, 2016, J MED MICROBIOL, V65, P521, DOI 10.1099/jmm.0.000263; Simmons CP, 1997, INFECT IMMUN, V65, P3048, DOI 10.1128/IAI.65.8.3048-3056.1997; Umemura M, 2007, J IMMUNOL, V178, P3786, DOI 10.4049/jimmunol.178.6.3786; Williamson LH, 2001, VET CLIN N AM-FOOD A, V17, P359, DOI 10.1016/S0749-0720(15)30033-5; Windsor PA, 2011, VET CLIN N AM-FOOD A, V27, P193, DOI 10.1016/j.cvfa.2010.10.019; YOZWIAK ML, 1993, AM J VET RES, V54, P392; ZAKI MM, 1976, RES VET SCI, V20, P197, DOI 10.1016/S0034-5288(18)33456-8	48	1	1	2	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2568	2574		10.1016/j.vaccine.2021.03.062		APR 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33814234				2022-04-29	WOS:000642189300014
J	Russo, AG; Decarli, A; Valsecchi, MG				Russo, Antonio Giampiero; Decarli, Adriano; Valsecchi, Maria Grazia			Strategy to identify priority groups for COVID-19 vaccination: A population based cohort study	VACCINE			English	Article						COVID vaccination; Public Health; Model selection; LASSO regression; Stratification for priorities	RISK-FACTOR	Background: Evidence from COVID-19 outbreak shows that individuals with specific chronic diseases are at higher risk of severe prognosis after infection. Public health authorities are developing vaccination programmes with priorities that minimize the risk of mortality and severe events in individuals and communities. We propose an evidence-based strategy that targets the frailest subjects whose timely vaccination is likely to minimize future deaths and preserve the resilience of the health service by preventing infections. Methods: The cohort includes 146,087 cases with COVID-19 diagnosed in 2020 in Milan (3.49 million inhabitants). Individual level data on 42 chronic diseases and vital status updated as of January 21, 2021, were available in administrative data. Analyses were performed in three sub-cohorts of age (16-64, 65-79 and 80+ years) and comorbidities affecting mortality were selected by means of LASSO cross-validated conditional logistic regression. Simplified models based on previous results identified high-risk categories worth targeting with highest priority. Results adjusted by age and gender, were reported in terms of odds ratios and 95%CI. Results: The final models include as predictors of mortality (7,667 deaths, 5.2%) 10, 12, and 5 chronic diseases, respectively. The older age categories shared, as risk factors, chronic renal failure, chronic heart failure, cerebrovascular disease, Parkinson disease and psychiatric diseases. In the younger age category, predictors included neoplasm, organ transplantation and psychiatric conditions. Results were consistent with those obtained on mortality at 60 days from diagnosis (6,968 deaths). Conclusion: This approach defines a two-level stratification for priorities in the vaccination that can easily be applied by health authorities, eventually adapted to local results in terms of number and types of comorbidities, and rapidly updated with current data. After the early phase of vaccination, data on effectiveness and safety will give the opportunity to revise prioritization and discuss the future approach in the remaining population. (C) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Russo, Antonio Giampiero; Decarli, Adriano] Agcy Hlth Protect Metropolitan Area Milan, Epidemiol Unit, Milan, Italy; [Valsecchi, Maria Grazia] Univ Milano Bicocca, Sch Med & Surg, Bicocca Ctr Bioinformat Biostat & Bioimaging B4 C, Milan, Italy		Russo, AG (通讯作者)，Agcy Hlth Protect Milan, Epidemiol Unit, Cso Italia 52, I-20122 Milan, Italy.	agrusso@ats-milano.it		Russo, Antonio Giampiero/0000-0002-5681-5861			[Anonymous], SAS/STAT User's Guide: SAS ~ 9.4 and SAS; Gosain R, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00934-7; Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319; Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106; Izcovich A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241955; Li LM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.23282; Mantovani A, 2020, NUTR METAB CARDIOVAS, V30, P1236, DOI 10.1016/j.numecd.2020.05.014; Ministero della Salute, **NON-TRADITIONAL**; Moore S, 2020, MODELLING OPTIMAL VA, DOI [10.1101/2020.09.22.20194183, DOI 10.1101/2020.09.22.20194183]; Russo AG, 2021, BMJ OPEN, V11, DOI [10.1136/bmjopen-2020-046044-046044, DOI 10.1136/BMJOPEN-2020-046044-046044]; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Tunesi S, 2020, EPIDEMIOL PREV, V44, P95, DOI 10.19191/EP20.5-6.S2.107; Vahidy FS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245556; Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000; WHO-INT, GUIDANCE DEVELOPING; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4	16	9	9	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2517	2525		10.1016/j.vaccine.2021.03.076		APR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33824037	hybrid, Green Published			2022-04-29	WOS:000642189300008
J	Wierzbicka, M; Klussmann, JP; San Giorgi, MR; Wuerdemann, N; Dikkers, FG				Wierzbicka, Malgorzata; Klussmann, Jens Peter; San Giorgi, Michel R.; Wuerdemann, Nora; Dikkers, Frederik G.			Oral and laryngeal HPV infection: Incidence, prevalence and risk factors, with special regard to concurrent infection in head, neck and genitals	VACCINE			English	Review						HPV; Oral; Larynx; Oropharynx; Infection; Contagiousness; Concurrent oro-genital infection	HUMAN-PAPILLOMAVIRUS INFECTION; OROPHARYNGEAL CANCER; NATURAL-HISTORY; SEXUAL-BEHAVIORS; UNITED-STATES; CHLAMYDIA-TRACHOMATIS; PERIODONTAL-DISEASE; CERVICAL-CANCER; MEN; WOMEN	This review focuses on the importance of oral and laryngeal HPV infection which is present in majority of sexually active individuals at least once in their lifetime. Despite testing, still little is known about prevalence rates, determinants and, especially, the concurrent HPV infection in head and neck, and genitals. The purpose of this review is to clarify some issues of oral HPV incidence, prevalence, and to demonstrate the difficulties in identification of asymptomatic oral HPV carriers. The main premise to take up this topic is the high and still increasing risk for development of oropharyngeal cancer, and potential benefit from screening strategies, education programs and HPV vaccination. Transmission of HPV to the oral cavity and oropharynx is hypothesized to occur mainly through sexual contact. The exposure of oropharyngeal mucosa to HPV infection with consequence of increased risk for oropharyngeal carcinoma depends on specific sexual behavior. Male gender, older age, race or ethnicity, oral hygiene and current cigarette smoking are independently associated with any prevalent oral HPV infection. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Wierzbicka, Malgorzata] Univ Med Sci, Dept Otolaryngol & Laryngol Oncol, 49 Stanislawa Przybyszewskiego, PL-60357 Poznan, Poland; [Klussmann, Jens Peter; Wuerdemann, Nora] Univ Hosp Cologne, ENT Clin, Kerpener Str 62, D-50931 Cologne, Germany; [San Giorgi, Michel R.] Univ Med Ctr Groningen, Dept Otorhinolaryngol Head & Neck Surg, Hanzepl 1, NL-9713 GZ Groningen, Netherlands; [Dikkers, Frederik G.] Univ Amsterdam, Amsterdam UMC, Dept Otorhinolaryngol Head & Neck Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands		Dikkers, FG (通讯作者)，Univ Amsterdam, Amsterdam UMC, Dept Otorhinolaryngol Head & Neck Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	f.g.dikkers@amsterdamumc.nl		Klussmann, Jens Peter/0000-0002-8223-7954; Dikkers, Frederik G/0000-0001-5265-3722; Wierzbicka, Malgorzata/0000-0003-0006-6352			Arbyn M, 2016, J CLIN VIROL, V76, pS14, DOI 10.1016/j.jcv.2015.09.014; Beachler DC, 2015, AM J EPIDEMIOL, V181, P40, DOI 10.1093/aje/kwu247; Beachler DC, 2013, J INFECT DIS, V208, P330, DOI 10.1093/infdis/jit170; Bleeker MCG, 2005, CLIN INFECT DIS, V41, P612, DOI 10.1086/431978; Boda D, 2018, INT J ONCOL, V52, P637, DOI 10.3892/ijo.2018.4256; Bui TC, 2017, SEX TRANSM DIS, V44, P166, DOI 10.1097/OLQ.0000000000000563; Cab-Sanchez BG, 2017, REV CHIL INFECTOL, V34, P557, DOI 10.4067/S0716-10182017000600557; Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403; Chandrupatla SG, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100182; Chaturvedi AK, 2016, ORAL ONCOL, V60, P61, DOI 10.1016/j.oraloncology.2016.06.006; Chaturvedi AK, 2015, CANCER RES, V75, P2468, DOI 10.1158/0008-5472.CAN-14-2843; Chaturvedi AK, 2014, J INFECT DIS, V210, P441, DOI 10.1093/infdis/jiu116; Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chesson HW, 2004, PERSPECT SEX REPRO H, V36, P11, DOI 10.1111/j.1931-2393.2004.tb00003.x; Choi I, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09161-y; Chow LT, 2010, APMIS, V118, P422, DOI 10.1111/j.1600-0463.2010.02625.x; Christensen ND, 2016, MICROB CELL, V3, P476, DOI 10.15698/mic2016.09.530; Ciccarese G, 2017, J MED VIROL, V89, P1121, DOI 10.1002/jmv.24746; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; D'Souza G, 2017, ANN ONCOL, V28, P3065, DOI 10.1093/annonc/mdx535; D'Souza G, 2007, INT J CANCER, V121, P143, DOI 10.1002/ijc.22667; D'Souza G, 2013, AM J PUBLIC HEALTH, V103, pE88, DOI 10.2105/AJPH.2013.301237; D'Souza G, 2009, J INFECT DIS, V199, P1263, DOI 10.1086/597755; Dalla Torre D, 2019, CLIN ORAL INVEST, V23, P179, DOI 10.1007/s00784-018-2425-y; de Souza MMA, 2018, DIAGN MICR INFEC DIS, V90, P267, DOI 10.1016/j.diagmicrobio.2017.12.004; Gonzalez-Losa MD, 2015, BRAZ J MICROBIOL, V46, P301, DOI 10.1590/S1517-838246120130976; Divaris K, 2010, CANCER CAUSE CONTROL, V21, P567, DOI 10.1007/s10552-009-9486-9; Doorbar J, 2018, BEST PRACT RES CL OB, V47, P27, DOI 10.1016/j.bpobgyn.2017.08.001; Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083; Edelstein ZR, 2012, SEX TRANSM DIS, V39, P860, DOI 10.1097/OLQ.0b013e318269d098; EIKE A, 1995, CLIN OTOLARYNGOL, V20, P171, DOI 10.1111/j.1365-2273.1995.tb00038.x; Eliot MN, 2013, CANCER CAUSE CONTROL, V24, P1315, DOI 10.1007/s10552-013-0209-x; Fakhry C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011918; Furquim CP, 2017, J DENT RES, V96, P292, DOI 10.1177/0022034516678169; Galvao-Moreira LV, 2016, ORAL ONCOL, V53, P17, DOI 10.1016/j.oraloncology.2015.11.013; Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025; Gillison ML, 2012, JAMA-J AM MED ASSOC, V307, P693, DOI 10.1001/jama.2012.101; Giuliano AR, 2008, VACCINE, V26, pK17, DOI 10.1016/j.vaccine.2008.06.021; Giuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2; Halpern-Felsher BL, 2005, PEDIATRICS, V115, P845, DOI 10.1542/peds.2004-2108; Haukioja A, 2017, J CLIN VIROL, V97, P4, DOI 10.1016/j.jcv.2017.10.011; Heck JE, 2010, INT J EPIDEMIOL, V39, P166, DOI 10.1093/ije/dyp350; Hernandez BY, 2008, EMERG INFECT DIS, V14, P888, DOI 10.3201/eid1406.070616; Hong AM, 2010, VACCINE, V28, P3269, DOI 10.1016/j.vaccine.2010.02.098; Kay P, 2002, J VIROL METHODS, V105, P159, DOI 10.1016/S0166-0934(02)00100-3; Kedarisetty S, 2016, JAMA OTOLARYNGOL, V142, P457, DOI 10.1001/jamaoto.2016.0064; Kreimer AR, 2013, LANCET, V382, P877, DOI 10.1016/S0140-6736(13)60809-0; Kuhn L, 2020, LANCET GLOB HEALTH, V8, pE296, DOI 10.1016/S2214-109X(19)30527-3; Kurose K, 2004, ORAL SURG ORAL MED O, V98, P91, DOI 10.1016/j.tripleo.2003.12.029; LAWTON G, 1992, J ORAL PATHOL MED, V21, P265, DOI 10.1111/j.1600-0714.1992.tb01008.x; Le HHL, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4175-0; Lin CQ, 2019, LANCET INFECT DIS, V19, P880, DOI 10.1016/S1473-3099(19)30164-1; Lupato V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170091; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Marques AEM, 2015, J ORAL PATHOL MED, V44, P453, DOI 10.1111/jop.12252; Matsushita K, 2011, JPN J INFECT DIS, V64, P34; Mazul AL, 2017, CANCER-AM CANCER SOC, V123, P71, DOI 10.1002/cncr.30312; McQuillan Geraldine, 2017, NCHS Data Brief, P1; Mehanna H, 2012, CURR OPIN OTOLARYNGO, V20, P120, DOI 10.1097/MOO.0b013e3283509735; Nemesio I, 2020, SEX TRANSM INFECT, V96, P408, DOI 10.1136/sextrans-2019-054359; Nyitray AG, 2014, J INFECT DIS, V209, P1007, DOI 10.1093/infdis/jit615; Nyitray AG, 2011, J INFECT DIS, V203, P49, DOI 10.1093/infdis/jiq021; Oliver SE, 2018, SEX TRANSM DIS, V45, P660, DOI 10.1097/OLQ.0000000000000845; Ortiz AP, 2014, P R HEALTH SCI J, V33, P190; Panatto D, 2015, HUM VACC IMMUNOTHER, V11, P270, DOI 10.4161/hv.36163; Patel EU, 2017, J INFECT DIS, V215, P1207, DOI 10.1093/infdis/jix116; Pazol K, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6620a1; Perez-Quintanilla M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227900; Ramqvist T, 2010, EMERG INFECT DIS, V16, P1671, DOI 10.3201/eid1611.100452; Raymond S, 2018, HEAD NECK-J SCI SPEC, V40, P2219, DOI 10.1002/hed.25317; Rintala MAM, 2005, J CLIN MICROBIOL, V43, P376, DOI 10.1128/JCM.43.1.376-381.2005; Robbins HA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143698; San Giorgi MRM, 2016, CLIN OTOLARYNGOL, V41, P448, DOI 10.1111/coa.12565; Schlecht NF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037419; Shah A, 2017, POSTGRAD MED J, V93, P704, DOI 10.1136/postgradmedj-2016-134603; Shigeishi H, 2018, BIOMED REP, V8, P59, DOI 10.3892/br.2017.1025; Shigeishi Hideo, 2016, J Clin Med Res, V8, P721, DOI 10.14740/jocmr2545w; Smith E M, 2004, Infect Dis Obstet Gynecol, V12, P45; Smith EM, 2004, SEX TRANSM DIS, V31, P57, DOI 10.1097/01.OLQ.0000105327.40288.DB; Smith JS, 2002, J INFECT DIS, V185, P324, DOI 10.1086/338569; Sonawane K, 2017, ANN INTERN MED, V167, P714, DOI [10.7326/M17-1363, 10.7326/m17-1363]; Steinau M, 2014, J INFECT DIS, V209, P1739, DOI 10.1093/infdis/jit799; Takes RP, 2015, ORAL ONCOL, V51, P1057, DOI 10.1016/j.oraloncology.2015.10.011; Taylor S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1633-9; Tezal M, 2005, J PERIODONTOL, V76, P1123, DOI 10.1902/jop.2005.76.7.1123; Bui TC, 2013, CANCER PREV RES, V6, P917, DOI 10.1158/1940-6207.CAPR-13-0081; Thorsteinsson K, 2018, J CLIN VIROL, V105, P64, DOI 10.1016/j.jcv.2018.05.010; Turner DO, 2011, BMC ORAL HEALTH, V11, DOI 10.1186/1472-6831-11-28; Uken RB, 2016, EUR ARCH OTO-RHINO-L, V273, P1933, DOI 10.1007/s00405-016-3953-1; Vergori A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-017-2937-0; Wagner S, 2017, BRIT J CANCER, V116, P1604, DOI 10.1038/bjc.2017.132; Wittekindt C, 2019, CANCER PREV RES, V12, P375, DOI 10.1158/1940-6207.CAPR-19-0098	93	5	5	6	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 22	2021	39	17					2344	2350		10.1016/j.vaccine.2021.03.047		APR 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RL7KL	33812740	Green Published, hybrid			2022-04-29	WOS:000639147100006
J	Graupensperger, S; Abdallah, DA; Lee, CM				Graupensperger, Scott; Abdallah, Devon A.; Lee, Christine M.			Social norms and vaccine uptake: College students' COVID vaccination intentions, attitudes, and estimated peer norms and comparisons with influenza vaccine	VACCINE			English	Article						COVID-19; SARS-CoV-2; Vaccination coverage; Vaccine uptake; Young adults	MISPERCEPTIONS	Background: Vaccination may be critical to curtailing the spread of the SARS-CoV-2 virus responsible for the COVID-19 pandemic, but herd immunity can only be realized with high vaccination coverage. There is a need to identify empirically supported strategies to increase uptake, especially among young adults as this subpopulation has shown relatively poor adherence to physical distancing guidelines. Social norms estimates of peers' behavior and attitudes - are robust predictors of health behaviors and norms-based intervention strategies may increase COVID vaccine uptake, once available. This study examined the extent that vaccination intentions and attitudes were associated with estimated social norms as an initial proof-of-concept test. Method: In November of 2020, 647 undergraduate students (46.21% response rate) completed online surveys in which they reported intentions to get COVID and influenza vaccines, perceived importance of these vaccines for young adults, and estimated social norms regarding peers' vaccination behaviors and attitudes. Results: Students reported significantly greater intentions to get a COVID vaccine (91.64%) than an influenza vaccine (76.04%), and perceived COVID vaccination as significantly more important than influenza vaccination. The sample generally held strong intentions to receive a COVID vaccine and thought that doing so was of high importance, but participants, on average, perceived that other young adults would be less likely to be vaccinated and would not think vaccination was as important. Multiple regression models indicated that estimated social norms were positively associated with participants' own intentions and perceived importance of getting a COVID vaccine. Conclusions: These significant associations highlight the potential value in developing and testing norms-based intervention strategies, such as personalized normative feedback, to improve uptake of forthcoming COVID vaccines among young adults. (C) 2021 Elsevier Ltd. All rights reserved.	[Graupensperger, Scott; Abdallah, Devon A.; Lee, Christine M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Graupensperger, S (通讯作者)，Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.	graups@uw.edu			National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [T32AA007455]; Addictions, Drug, & Alcohol Institute at the University of WashingtonUniversity of Washington	This research conducted with support of a training fellowship from the National Institute on Alcohol Abuse and Alcoholism (T32AA007455) and a small project grant from the Addictions, Drug, & Alcohol Institute at the University of Washington. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the University of Washington.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Allen JD, 2009, PREV MED, V48, P420, DOI 10.1016/j.ypmed.2008.12.005; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Andone D, 2020, CNN HEAL; Berkowitz AD., 2004, SOCIAL NORMS APPROAC; Boehmer TK, 2020, MMWR-MORBID MORTAL W, V69, P1404, DOI 10.15585/mmwr.mm6939e1; CDC, 2020, DIS BURD INFL; CDC, 2020, IMPL MIT STRAT COMM; Centers for Disease Control and Prevention (CDC), 2021, CDCS COVID 19 VACC R; CIALDINI RB, 1990, J PERS SOC PSYCHOL, V58, P1015, DOI 10.1037/0022-3514.58.6.1015; Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312; Cornwall W, 2020, SCIENCE, V369, P14, DOI 10.1126/science.369.6499.14; Cox MJ, 2019, PSYCHOL ADDICT BEHAV, V33, P297, DOI 10.1037/adb0000455; Dickler J., 2020, CNBC HEAL SCI; Dotson KB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139518; Faust JS, 2020, JAMA INTERN MED, V180, P1045, DOI 10.1001/jamainternmed.2020.2306; Fidler DP, 2020, SCIENCE, V369, P749, DOI 10.1126/science.abe2275; Fisher KA, 2020, MMWR-MORBID MORTAL W, V69; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fosnacht K, 2017, REV HIGH EDUC, V40, P245, DOI 10.1353/rhe.2017.0003; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Graupensperger S, 2021, EMERG ADULTHOOD, V9, P531, DOI 10.1177/2167696820986742; Graupensperger S, 2020, ALCOHOL CLIN EXP RES, V44, P541, DOI 10.1111/acer.14270; Haynes BF, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abe0948; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Hopfer S, 2011, QUAL HEALTH RES, V21, P262, DOI 10.1177/1049732310383868; Iacobucci G, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4291; Johnson, 2020, ABC NEWS; JOrgensen FJ, 2020, PSYARXIV; LaBrie JW, 2013, J CONSULT CLIN PSYCH, V81, P1074, DOI 10.1037/a0034087; Lee C, 2021, J PRIM PREV; Litt DM, 2014, TRAFFIC INJ PREV, V15, P748, DOI 10.1080/15389588.2013.868892; Lutz CS, 2020, VACCINE, V38, P1393, DOI 10.1016/j.vaccine.2019.12.004; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Mattern JL, 2004, J STUD ALCOHOL, V65, P489, DOI 10.15288/jsa.2004.65.489; Ng TWY, 2020, VACCINE, V38, P690, DOI 10.1016/j.vaccine.2019.10.041; Omer SB, 2018, VACCINATIONS, P25; Perkins JM, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2798-7; Pormohammad A, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2179; Quinn SC, 2017, HEALTH EDUC RES, V32, P473, DOI 10.1093/her/cyx070; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rogers CJ, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6041-1; Stout ME, 2020, J COMMUN HEALTH, V45, P1187, DOI 10.1007/s10900-020-00837-5; Vet R, 2011, HEALTH EDUC RES, V26, P192, DOI 10.1093/her/cyq074; World Health Organization, 2019, 10 THREATS GLOB HLTH; World Health Organization, DRAFT LANDSC COVID 1; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Ye LX, 2021, HUM VACC IMMUNOTHER, V17, P106, DOI 10.1080/21645515.2020.1761201; Zhu TT, 2020, J THORAC IMAG, V35, pW97, DOI 10.1097/RTI.0000000000000513	49	22	22	7	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2060	2067		10.1016/j.vaccine.2021.03.018		APR 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RJ9QH	33741191	Bronze, Green Published			2022-04-29	WOS:000637937500007
J	Sekiya, N; Sunagawa, T; Takahashi, H; Kamiya, H; Yoshino, S; Ohnishi, M; Okabe, N; Taniguchi, K				Sekiya, Noritaka; Sunagawa, Tomimasa; Takahashi, Hideyuki; Kamiya, Hajime; Yoshino, Shuji; Ohnishi, Makoto; Okabe, Nobuhiko; Taniguchi, Kiyosu			Serogroup B invasive meningococcal disease (IMD) outbreak at a Japanese high school dormitory: An outbreak investigation report from the first IMD outbreak in decades	VACCINE			English	Article						Neisseria meningitidis; Invasive meningococcal disease; Outbreak; Serogroup B	NEISSERIA-MENINGITIDIS; RISK; EPIDEMIOLOGY; CARRIAGE; CONTACTS	Purpose: The first outbreak of invasive meningococcal disease (IMD) in decades occurred in a high school dormitory in 2011. This report aims to describe the results of the IMD outbreak investigation and to discuss current issues of IMD in Japan. Methods: We conducted an epidemiological and microbiological investigation against the IMD outbreak of serogroup B among students and staff in a high school dormitory. Information on patients was collected to analyze risk factors for IMD. Control measures and public health actions were summarized. Results: Three cases of meningitis and two cases of bacteremia were identified. Freshmen (15-16 years old) living in the dormitory with preceding cough were high-risk populations in this outbreak. Pulsed-field gel electrophoresis, multilocus sequence typing, and porA gene sequencing results revealed that all isolates were closely related to each other and had deep similarities to the domestic circulating meningococcal strain. The outbreak was terminated after promptly implementing control measures. Based on the results of our investigation, from April 2013, national infectious disease surveillance started to target meningococcal bacteremia as part of IMD, in addition to meningococcal meningitis, which was newly designated as a category II school infectious disease under the School Health and Safety Act. Conclusions: This outbreak has enhanced public health measures against IMD in Japan. The development of national guidelines for appropriate public health interventions on the IMD outbreak response including chemoprophylaxis is still needed. (C) 2021 Published by Elsevier Ltd.	[Sekiya, Noritaka] Field Epidemiol Training Program Japan FETP, Shinjuku kU, 1-23-1 Toyama, Tokyo 1628640, Japan; [Sekiya, Noritaka] Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Infect Prevent & Control, Dept Clin Lab, Komagome Hosp,Bunkyo Ku, Honkomagome 3-18-22, Tokyo 1138677, Japan; [Sunagawa, Tomimasa; Kamiya, Hajime; Okabe, Nobuhiko; Taniguchi, Kiyosu] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan; [Takahashi, Hideyuki; Ohnishi, Makoto] Natl Inst Infect Dis, Dept Bacteriol 1, 1-23-1 Toyama, Tokyo 1628640, Japan; [Yoshino, Shuji] Miyazaki Prefectural Inst Publ Hlth & Environm, Nishi Ku, 2-3-2 Gakuen Kibanadai, Miyazaki, Miyazaki 8892155, Japan; [Okabe, Nobuhiko] Kawasaki City Inst Publ Hlth, Kawasaki Ku, 5-13-10 Ohshima, Kawasaki, Kanagawa 2100834, Japan; [Taniguchi, Kiyosu] Natl Mie Hosp, Dept Clin Res, 357 Ohsato Kubota Cho, Tsu, Mie 5140125, Japan		Sunagawa, T (通讯作者)，Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	sunatomi@niid.go.jp	Sekiya, Noritaka/S-8395-2018	Sekiya, Noritaka/0000-0002-0765-4221	Kobayashi-nishi high school; Kobayashi Public Health Center; Miyazaki Prefectural Institute for Public Health and Environment; Miyazaki Prefectural Government	We appreciate the cooperation and support of Kobayashi-nishi high school, Kobayashi Public Health Center, Miyazaki Prefectural Institute for Public Health and Environment, and Miyazaki Prefectural Government. We specifically would like to mention Dr. Kimiko Kawano of Miyazaki Prefectural Institute for Public Health and Environment, Dr. Shigehiro Fujimoto of Kobayashi Public Health Center, Dr. Naomi Kosaka of Miyakonojyo Public Health Center, Ms. Hiromi Nishi (nursing teacher) of Kobayashi-nishi high school, PhC. Hiroyuki Tawara and Dr. Yuka Ando of FETP and Dr. Hiroki Kawabata of the National Institute of Infectious Disease for their dedicated support of the investigation.	Agematsu R, 2018, INFECT AGENTS SURVEI, V39, P5; [Anonymous], 2019, GUID PUBL HLTH MAN M, P27; Borrow R, 2017, EXPERT REV VACCINES, V16, P313, DOI 10.1080/14760584.2017.1258308; Buckee CO, 2008, P NATL ACAD SCI USA, V105, P15082, DOI 10.1073/pnas.0712019105; CARTWRIGHT KAV, 1991, EPIDEMIOL INFECT, V106, P133, DOI 10.1017/S0950268800056491; Cohn AC, 2013, MMWR RECOMM REP, V62, P1; European Centre for Disease Prevention and Control, 2015, STOCKH OUTBR INV MEN; Fukusumi M, 2016, VACCINE, V34, P4068, DOI 10.1016/j.vaccine.2016.06.018; Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032; Harrison LH, 2008, PEDIATR INFECT DIS J, V27, P193, DOI 10.1097/INF.0b013e31815c1b3a; Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063; Harrison LH, 1999, JAMA-J AM MED ASSOC, V281, P1906, DOI 10.1001/jama.281.20.1906; Health Protection Agency Meningococcus and Haemophilus Forum, 2011, GUID PUBL HLTH MAN M, P18; Kanai M, 2017, WEST PAC SURVEILL RE, V8, DOI [10.5365/wpsar.2016.7.3.007, 10.5365/WPSAR.2016.7.3.007]; Kristiansen BE, 1998, BRIT MED J, V317, P621, DOI 10.1136/bmj.317.7159.621; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; National Institute of Infectious Diseases, 2005, INFECT AGENTS SURVEI, V26, P33; Popovic T, 2001, J CLIN MICROBIOL, V39, P75, DOI 10.1128/JCM.39.1.75-85.2001; Raghunathan PL, 2004, ANNU REV MED, V55, P333, DOI 10.1146/annurev.med.55.091902.103612; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Russell JE, 2004, EMERG INFECT DIS, V10, P674, DOI 10.3201/eid1004.030247; Smith-Palmer A, 2016, EUROSURVEILLANCE, V21, P8, DOI 10.2807/1560-7917.ES.2016.21.45.30392; Takahashi H, 2004, J MED MICROBIOL, V53, P657, DOI 10.1099/jmm.0.45541-0; Takahashi H, 2011, IASR, V32, P298; Takahashi H, 2016, J INFECT CHEMOTHER, V22, P501, DOI 10.1016/j.jiac.2015.12.016; Tanaka Hiroshi, 2005, Kansenshogaku Zasshi, V79, P527; Trotter CL, 2007, FEMS MICROBIOL REV, V31, P27, DOI 10.1111/j.1574-6976.2006.00060.x; Tully J, 2006, BMJ-BRIT MED J, V332, P445, DOI 10.1136/bmj.38725.728472.BE; Yokosuka City, 2017, OUTBREAK INVASIVE ME	29	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2177	2182		10.1016/j.vaccine.2021.02.034		APR 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QH	33736919				2022-04-29	WOS:000637937500021
J	Andrew, MK; McNeil, SA				Andrew, Melissa K.; McNeil, Shelly A.			Influenza vaccination and the evolution of evidence-based recommendations for older adults: A Canadian perspective	VACCINE			English	Review						Influenza vaccine; Recommendation; Advisory Committees[MeSH]; Older adult; Aged; Frail elderly; Canada		Older adults are at high risk from influenza and its complications, and are therefore an important population for prevention efforts. In Canada, public health efforts targeting influenza are multi-pronged and include vaccination programs as well as surveillance which informs the national surveillance reporting platform FluWatch run by the Public Health Agency of Canada. Recommendations regarding use of vaccines are made nationally by the National Advisory Committee on Immunization (NACI) and by the Comite sur l'immunisation du Quebec in Quebec, while vaccination programs are planned and delivered at the provincial/territorial level as opposed to as a harmonized national immunization program. NACI performs rigorous targeted literature reviews to inform their statements, and recommendations also vary by whether they apply on Individual (pertaining to decisions for individual patients) vs. Programmatic (informing policy decisions for implementation of publicly funded vaccination programs) levels. This unique context results in inter-provincial variation in vaccine schedules and funded vaccine products. In this paper, the importance of influenza vaccination for older adults is discussed; to provide insights from the Canadian context, the evolution of NACI evidence reviews and recommendations on influenza vaccination is presented. (C) 2020 The Author(s). Published by Elsevier Ltd.	[Andrew, Melissa K.] Dalhousie Univ, Dept Med, Div Geriatr Med, Halifax, NS, Canada; [McNeil, Shelly A.] Dalhousie Univ, Dept Med, Div Infect Dis, Halifax, NS, Canada		Andrew, MK (通讯作者)，Dalhousie Univ, Dept Med, Div Geriatr Med, Halifax, NS, Canada.	mandrew@dal.ca	Andrew, Melissa/AAR-7052-2021	Andrew, Melissa/0000-0001-7514-8972; McNeil, Shelly/0000-0001-5444-4166	Sanofi Pasteur	This publication was produced with support from Sanofi Pasteur. Manuscripts were accepted after rigorous peer review process that was managed by an expert Guest Editor independently appointed by the Editor-in-Chief.	Acton M, 2019, IDENTIFYING BARRIERS; Andrew MK, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1180-5; Andrew MK, 2019, DRUG AGING, V36, P29, DOI 10.1007/s40266-018-0597-4; Andrew MK, 2017, J INFECT DIS, V216, P405, DOI 10.1093/infdis/jix282; Andrew MK, 2020, INFECT CONT HOSP EP, P1; Becker DL, 2016, HUM VACC IMMUNOTHER, V12, P3036, DOI 10.1080/21645515.2016.1215395; Canada National Advisory Committee on Immunization (NACI), 2011, Canada Communicable Disease Report, V37, P1; CARP, 2019, KEEP CAN HLTH; CFN, 2019, AVOID FRAILT; Chit A, 2015, LANCET INFECT DIS, V15, P1459, DOI 10.1016/S1473-3099(15)00249-2; Chit A, 2015, VACCINE, V33, P734, DOI 10.1016/j.vaccine.2014.10.079; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; CPHA, 2019, HIST PUBL HLTH IMM T; Erickson LJ, 2005, VACCINE, V23, P2470, DOI 10.1016/j.vaccine.2004.10.029; Gemmill I, 2014, Can Commun Dis Rep, V40, P369; Godin J, 2019, HEALTHCARE-BASEL, V7, DOI 10.3390/healthcare7030091; immunize.ca, 2019, PUBL FUND INFL PROGR; Lees C, 2020, J INFECT DIS, V222, P428, DOI 10.1093/infdis/jiaa092; McElhaney JE, 2012, VACCINE, V30, P2060, DOI 10.1016/j.vaccine.2012.01.015; NACI, 2000, CAN COMMUN DIS REP, V26; NACI, 2018, ADV COMM STAT ACS CA; NACI, 2016, VACCINE, V39, pA36; NACI, 2019, ADV COMM STAT ACS NA; National Advisory Committee on Immunization (NACI), 2009, Can Commun Dis Rep, V35, P1; National Advisory Committee on Immunization (NACI), 2018, LIT REV UPD EFF EFF; Nichols MK, 2018, VACCINE, V36, P2166, DOI 10.1016/j.vaccine.2018.02.093; Pereira JA, 2019, HUM VACC IMMUNOTHER, V15, P487, DOI 10.1080/21645515.2018.1520580; PHAC, 2019, FLU INFL FLUWATCH SU; Quebec, 2019, QUEB IMM PROGR; Quebec, 2019, FLU VACC PROGR; Raviotta JM, 2016, J AM GERIATR SOC, V64, P2126, DOI 10.1111/jgs.14323; Sinha S, 2018, UNDERAPPRECIATED BUR; Skowronski DM, 2015, EUROSURVEILLANCE, V20, P7, DOI 10.2807/1560-7917.ES2015.20.4.21022; Wells C, 2019, HIGH DOSE INFLUENZA	34	4	4	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 15	2021	39			1			A36	A41		10.1016/j.vaccine.2020.09.011		MAR 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QV2JM	32958335	hybrid			2022-04-29	WOS:000627802900005
J	Dudley, MZ; Taitel, MS; Smith-Ray, R; Singh, T; Limaye, RJ; Salmon, DA				Dudley, Matthew Z.; Taitel, Michael S.; Smith-Ray, Renae; Singh, Tanya; Limaye, Rupali J.; Salmon, Daniel A.			Effect of educational and financial incentive-based interventions on immunization attitudes, beliefs, intentions and receipt among close contacts of pregnant women	VACCINE			English	Article						Pregnancy; Education; Vaccination; Influenza vaccine; Diphtheria tetanus pertussis vaccine; Video	ACELLULAR PERTUSSIS-VACCINE; INFLUENZA VACCINE; TDAP VACCINATION; UNITED-STATES; DIPHTHERIA; TETANUS; PARENTS; IMPACT; COVERAGE; INFANTS	Introduction: Cocooning, the vaccination of close contacts of a newborn, is a strategy to limit the risk of pertussis and influenza infection among vulnerable infants. Methods: Pregnant women in Colorado and Georgia referred close contacts to an app that provided tailored educational videos about vaccines along with a small pharmacy-based financial incentive for vaccine receipt. The primary objective of this study was to determine the feasibility of implementing this app-based cocooning intervention. Results: Two hundred seventy seven contacts were enrolled in this study. Of those who received the educational videos, 96% found them interesting, 100% found them clear to understand, 97% found them helpful, and 99% trusted them. Completion of the videos led to significant increases in influenza vaccine knowledge (p = 0.025), Tdap vaccine knowledge (p < 0.001), and intention to receive these vaccines (p = 0.046). Of the 136 participants who reported receiving influenza vaccine, 41 (30%) reported receiving it at a pharmacy, and of the 66 who reported receiving Tdap vaccine, 15 (23%) reported receiving it at a pharmacy. Of all participants, 80% reported being comfortable receiving vaccines at a pharmacy instead of a doctor's office. The provision of small pharmacy-based financial incentives combined with individually-tailored educational videos about vaccines led to 6.97 (95%CI: 2.25-21.64) times higher odds of self-reported receipt of influenza vaccine than providing small pharmacy-based financial incentives without these videos. No significant difference was found for Tdap vaccine. Conclusions: Tailored vaccine education can positively impact vaccine knowledge and intentions among adults. An app-based referral program providing education and financial incentives for cocooning vaccination at pharmacies is feasible. (C) 2020 Elsevier Ltd. All rights reserved.	[Dudley, Matthew Z.; Limaye, Rupali J.; Salmon, Daniel A.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, 615 N Wolfe St, Baltimore, MD 21205 USA; [Dudley, Matthew Z.; Limaye, Rupali J.; Salmon, Daniel A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA; [Taitel, Michael S.; Smith-Ray, Renae; Singh, Tanya] Walgreen Co, Walgreens Ctr Hlth & Wellbeing Res, 200 Wilmot Rd, Deerfield, IL 60015 USA; [Limaye, Rupali J.; Salmon, Daniel A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 615 N Wolfe St, Baltimore, MD 21205 USA; [Limaye, Rupali J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA		Dudley, MZ (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, 615 N Wolfe St,W5041, Baltimore, MD 21205 USA.	mattdudley@jhu.edu	Taitel, Michael/AAR-5837-2021	Dudley, Matthew/0000-0003-1201-4066	Walgreen Company	This work was supported by Walgreen Company.	[Anonymous], 2013, Obstet Gynecol, V121, P1411, DOI 10.1097/01.AOG.0000431054.33593.e3; Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1424; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Brunson EK, 2013, PEDIATRICS, V131, pE1397, DOI 10.1542/peds.2012-2452; Buttenheim AM, 2016, VACCINE, V34, P839, DOI 10.1016/j.vaccine.2015.11.068; Cassell JA, 2006, PUBLIC HEALTH, V120, P783, DOI 10.1016/j.puhe.2006.03.011; Centers for Disease Control and Prevention, 2015, EPIDEMIOLOGY PREVENT, V13th; Chung YM, 2017, MATERN CHILD HLTH J, V21, P2178, DOI 10.1007/s10995-017-2336-6; Cialdini RB, 2003, CURR DIR PSYCHOL SCI, V12, P105, DOI 10.1111/1467-8721.01242; Deshpande M, 2013, J AM PHARM ASSOC, V53, P488, DOI 10.1331/JAPhA.2013.13017; Flynn M, 2004, BRIT J GEN PRACT, V54, P526; Forsyth K, 2015, PEDIATRICS, V135, pE1475, DOI 10.1542/peds.2014-3925; Fortner KB, 2012, OBSTET GYNECOL SURV, V67, P251, DOI 10.1097/OGX.0b013e3182524cee; Goad JA, 2013, ANN FAM MED, V11, P429, DOI 10.1370/afm.1542; Gorman JR, 2012, VACCINE, V31, P213, DOI 10.1016/j.vaccine.2012.10.064; Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1; Halperin BA, 2011, CLIN INFECT DIS, V53, P885, DOI 10.1093/cid/cir538; Healy CM, 2011, CLIN INFECT DIS, V52, P157, DOI 10.1093/cid/ciq001; Higginbotham S, 2012, J AM PHARM ASSOC, V52, P367, DOI 10.1331/JAPhA.2012.10083; Hill HA, 2018, MMWR-MORBID MORTAL W, V67, P1123, DOI 10.15585/mmwr.mm6740a4; Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3; Kirkdale C. L., 2017, ANNALES PHARMACEUTIQUES FRANCAISES, V75, P3, DOI 10.1016/j.pharma.2016.08.005; Langreth R, 2017, BLOOMBERG; Marteau TM, 2009, BMJ-BRIT MED J, V9, DOI [10.1136/bmj.b1415b1415., DOI 10.1136/BMJ.B1415B1415]; Mills B, 2014, VACCINE, V32, P521, DOI 10.1016/j.vaccine.2013.11.035; Moriarty LF, 2014, HUM VACC IMMUNOTHER, V10, P2721, DOI 10.4161/hv.29669; Murphy PA, 2012, J AM PHARM ASSOC, V52, P67, DOI 10.1331/JAPhA.2012.10070; O'Leary ST, 2015, PEDIATR INFECT DIS J, V34, P1244, DOI 10.1097/INF.0000000000000873; Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068; Salmon DA, 2019, VACCINE, V37, P6478, DOI 10.1016/j.vaccine.2019.08.080; Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131; Singh M, 2006, CHEST, V130, P1547, DOI 10.1016/S0012-3692(15)37335-9; Sutherland K, 2008, MED CARE RES REV, V65, p36S, DOI 10.1177/1077558708324235; Swamy GK, 2014, EXPERT REV VACCINES, V13, P1107, DOI 10.1586/14760584.2014.944509; Tan L, 2018, VACCINE, V36, P5373, DOI 10.1016/j.vaccine.2017.07.050; Walgreen Co, 2016, STOR COUNT STAT; Walgreen Co, BAL REW PROGR DET; Wheeler M, 2013, HUM VACC IMMUNOTHER, V9, P1782, DOI 10.4161/hv.25959; Zhang LJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001478.pub6	39	1	1	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					961	967		10.1016/j.vaccine.2020.12.067		JAN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PW7FB	33423837				2022-04-29	WOS:000610835100014
J	Cui, YA; Folaranmi, T; Buchwald, UK				Cui, Yadong Adam; Folaranmi, Temitope; Buchwald, Ulrike Kirsten			The Japanese 23-valent pneumococcal polysaccharide vaccine randomized clinical trial: Further reflections on the design and results	VACCINE			English	Editorial Material							PNEUMONIA	The recent article by Gessner et al. discussed several concerns regarding the design and results of the clinical trial by Maruyama et al. in 2010 on the vaccine efficacy (VE) of 23-valent pneumococcal polysaccharide vaccine. First, Gessner et al. questioned the integrity of the study randomization and blinding. Maruyama et al. have indicated that study participants were individually randomized and blinding was maintained throughout the study. Second, Gessner et al. questioned the internal validity of the trial results. Gessner et al. applied the reported VE against pneumococcal pneumonia and assumptions to estimate how much all-cause pneumonia could be prevented resulting in a "VE" estimate of 19.5%. This estimate does not truly qualify as a VE estimate, but as vaccine effectiveness estimate from a hypothetical cohort. The randomized, placebo-controlled trial conducted by Maruyama et al. met the methodological standards for a randomized control trial and its results are unquestionably valid. (C) 2020 Elsevier Ltd. All rights reserved.	[Cui, Yadong Adam; Folaranmi, Temitope; Buchwald, Ulrike Kirsten] Merck & Co Inc, Kenilworth, NJ 07033 USA; [Cui, Yadong Adam] Astellas Pharma Inc, Northbrook, IL 60062 USA		Cui, YA (通讯作者)，Merck & Co Inc, Kenilworth, NJ 07033 USA.; Cui, YA (通讯作者)，Astellas Pharma Inc, Northbrook, IL 60062 USA.	yadong.cui@astellas.com			Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.	Bonnave C, 2019, EUR J CLIN MICROBIOL, V38, P785, DOI 10.1007/s10096-019-03485-3; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368; Gessner BD, 2019, VACCINE, V37, P4853, DOI 10.1016/j.vaccine.2019.07.040; Maruyama T, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1004; McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312; Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3; Ochoa-Gondar O, 2014, CLIN INFECT DIS, V58, P909, DOI 10.1093/cid/ciu002; Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273; Suzuki M, 2017, LANCET INFECT DIS, V17, P313, DOI [10.1016/S1473-3099(17)30049-X, 10.1016/s1473-3099(17)30049-x]	10	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					641	643		10.1016/j.vaccine.2020.12.033		JAN 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PR1FI	33358263				2022-04-29	WOS:000606987100003
J	Emerick, SD; de Carvalho, TV; Miranda, BM; da Silva, AC; Martins, TVF; de Oliveira, LL; Marques-da-Silva, ED				Emerick, Sabrina de Oliveira; de Carvalho, Thais Vieira; Miranda, Bianca Meirelles; da Silva, Adriana Carneiro; Fialho Martins, Thais Viana; de Oliveira, Leandro Licursi; Marques-da-Silva, Eduardo de Almeida			Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis	VACCINE			English	Article						LPG3; Vaccine; Saponin; Visceral leishmaniasis	EFFICACY; PROTECTION; DONOVANI; CELLS; GAMMA; ASSAY	Visceral leishmaniasis (VL) is a serious neglected tropical disease that affects humans and dogs in urban areas. There are no vaccines against human VL, and few licensed canine VL vaccines are currently available, which instigates the search for new antigens and vaccine formulations with prophylactic potential against VL in these hosts. In this study, we evaluated the immunization using the native and recombinant Leishmania infantum chagasi (L. chagasi) lipophosphoglycan-3 (LPG3) and the adjuvants saponin (SAP) and incomplete Freund adjuvant (IFA) against L. chagasi infection in BALB/c mice. The native LPG3 vaccine was immunogenic, inducing splenic IFN-gamma and IL-10 production, and mixed Th1/Th2 response when associated with IFA. However, only mice vaccinated with LPG3-IFA presented a reduction in the splenic parasite load (96% in comparison to the PBS control group), but without a significant reduction in the hepatic parasitism. On the other hand, mice immunized with the LPG3-SAP vaccine presented a reduction of approximately 98% in both splenic and hepatic parasite load, accompanied by a Th1/Th17 response and IL-10 production by L. chagasi antigen (AgLc)-stimulated splenic cells. Importantly, vaccination with recombinant LPG3 (rLPG3)-SAP presented similar results to the native LPG3-SAP vaccine. Therefore, the rLPG3-SAP vaccine is qualified to be used in future tests in canine and human models, considering the technical and economic advantages of the recombinant protein production compared to the native protein and the results obtained in the murine model. (C) 2020 Elsevier Ltd. All rights reserved.	[Emerick, Sabrina de Oliveira; de Carvalho, Thais Vieira; Miranda, Bianca Meirelles; da Silva, Adriana Carneiro; Fialho Martins, Thais Viana; de Oliveira, Leandro Licursi; Marques-da-Silva, Eduardo de Almeida] Univ Fed Vicosa, Dept Gen Biol, Vicosa, MG, Brazil; [de Carvalho, Thais Vieira] Univ Fed Ouro Preto, Lab Immunopathol, Ouro Preto, MG, Brazil; [Fialho Martins, Thais Viana] Univ Fed Vicosa, Lab Mol Biotechnol, Dept Biochem, Vicosa, MG, Brazil		Marques-da-Silva, ED (通讯作者)，Univ Fed Vicosa, Dept Gen Biol, Vicosa, MG, Brazil.	eduardo.marques@ufv.br	Marques-da-Silva, Eduardo/S-5488-2016	Marques-da-Silva, Eduardo/0000-0003-4015-5915	Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) [9553 - FAPEMIG CBB - APQ-00668-13]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) MCTI/CNPq/MEC/Capes Acao TransversalConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF) [06/2011]	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG - Grant number 9553 -FAPEMIG CBB - APQ-00668-13), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) MCTI/CNPq/MEC/Capes Acao Transversal number 06/2011 -Casadinho/Procad.	Abdossamadi Z, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006123; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Badirzadeh A, 2020, J PARASITIC DIS, P1; Badirzadeh A, 2018, AM J TROP MED HYG, V98, P122, DOI 10.4269/ajtmh.17-0490; Banerjee A, 2016, CELL IMMUNOL, V309, P37, DOI 10.1016/j.cellimm.2016.07.004; Beverley SM, 1998, TRENDS MICROBIOL, V6, P35, DOI 10.1016/S0966-842X(97)01180-3; Bhattacharya P, 2013, REV SOC BRAS MED TRO, V46, P128, DOI 10.1590/0037-8682-0022-2012; Bifeld E, 2015, MED MICROBIOL IMMUN, V204, P619, DOI 10.1007/s00430-015-0422-1; Borja-Cabrera GP, 2008, VACCINE, V26, P4991, DOI 10.1016/j.vaccine.2008.07.029; Costa LE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110014; Cotton JA, 2017, TRENDS PARASITOL, V33, P341, DOI 10.1016/j.pt.2017.02.002; Dayakar A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00670; Pereira NCD, 2015, EXP PARASITOL, V153, P180, DOI 10.1016/j.exppara.2015.03.027; Donovan J, 2005, CURR PROTOC NEUROSCI; Duprey ZH, 2006, EMERG INFECT DIS, V12, P440, DOI 10.3201/eid1203.050811; Faleiro RJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002914; Fernandes AP, 2008, VACCINE, V26, P5888, DOI 10.1016/j.vaccine.2008.05.095; Martins TVF, 2018, BIOINFORM BIOL INSIG, V12, DOI 10.1177/1177932218763363; Martins TVF, 2015, MOL BIOCHEM PARASIT, V204, P34, DOI 10.1016/j.molbiopara.2015.12.005; de Mendonca SCF, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00524; GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570; Grimaldi G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185438; Heidari-Kharaji M, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12605; Hosseini M, 2017, BIOMED PHARMACOTHER, V95, P1369, DOI 10.1016/j.biopha.2017.09.061; Jain K, 2015, J IMMUNOL METHODS, V422, P1, DOI 10.1016/j.jim.2015.03.017; Joshi J, 2014, PARASITOL INT, V63, P612, DOI 10.1016/j.parint.2014.04.002; Kamhawi S, 2006, TRENDS PARASITOL, V22, P439, DOI 10.1016/j.pt.2006.06.012; Kaur T, 2011, PARASITE IMMUNOL, V33, P95, DOI 10.1111/j.1365-3024.2010.01253.x; Kumar Prabin, 2019, Trop Parasitol, V9, P30, DOI 10.4103/tp.TP_32_18; Lainson R, 2005, MEM I OSWALDO CRUZ, V100, P811, DOI 10.1590/S0074-02762005000800001; Nascimento MSL, 2015, J INFECT DIS, V211, P1015, DOI 10.1093/infdis/jiu531; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marques-da-Silva ED, 2008, MICROBES INFECT, V10, P850, DOI 10.1016/j.micinf.2008.04.016; Martin V, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-69; Miahipour A, 2016, IMMUNOL INVEST, V45, P692, DOI 10.1080/08820139.2016.1208217; Moafi M, 2019, INT J PREVENTIVE MED, V10, DOI 10.4103/ijpvm.IJPVM_116_18; Montakhab-Yeganeh H, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12461; Moreno J, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001683; Oliva G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003213; Pereira L, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003490; Pirdel L, 2017, SCAND J IMMUNOL, V86, P15, DOI 10.1111/sji.12557; Pirdel L, 2014, PARASITE IMMUNOL, V36, P700, DOI 10.1111/pim.12147; Pirdel L, 2017, PARASITE IMMUNOL, V39; Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813; Rasolzadeh S, 2015, IRAN J PARASITOL, V10, P554; Ratnapriya S, 2019, VACCINE, V37, P3505, DOI 10.1016/j.vaccine.2019.04.092; Regina-Silva S, 2016, VACCINE, V34, P2233, DOI 10.1016/j.vaccine.2016.03.019; Bastos DSS, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110097; Seva AP, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0160058, 10.1371/journal.pone.0162854]; Romero GAS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005706; Singh OP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001874; Solano-Gallego L, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-86; Stober CB, 2005, J IMMUNOL, V175, P2517, DOI 10.4049/jimmunol.175.4.2517; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; van Griensven J, 2019, INFECT DIS CLIN N AM, V33, P79, DOI 10.1016/j.idc.2018.10.005; Viana KF, 2018, VET PARASITOL, V254, P98, DOI 10.1016/j.vetpar.2018.03.010; Vitoriano-Souza J, 2019, VACCINE, V37, P7269, DOI 10.1016/j.vaccine.2019.09.067; WHO, 2010, WHO TECH REP SER, V949, P1	58	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					282	291		10.1016/j.vaccine.2020.11.064			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33309484	Bronze			2022-04-29	WOS:000604750300017
J	Haveri, A; Ikonen, N; Savolainen-Kopra, C; Julkunen, I				Haveri, Anu; Ikonen, Niina; Savolainen-Kopra, Carita; Julkunen, Ilkka			Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines	VACCINE			English	Article						Antibodies; Microneutralization test; Humoral immunity; Influenza A(H5N1); Pre-pandemic vaccine	A/H5N1 VACCINE; DOUBLE-BLIND; H5N1 VIRUS; IMMUNOGENICITY; SAFETY; ADULTS; TRIAL; INFECTION; CANDIDATE; INFANTS	Background: Avian influenza A(H5N1) viruses have caused sporadic infections in humans and thus they pose a significant global health threat. Among symptomatic patients the case fatality rate has been ca. 50%. H5N1 viruses exist in multiple clades and subclades and several candidate vaccines have been developed to prevent A(H5N1) infection as a principal measure for preventing the disease. Methods: Serum antibodies against various influenza A(H5N1) Glade viruses were measured in adults by ELISA-based microneutralization and haemagglutination inhibition tests before and after vaccination with two different A(H5N1) vaccines in 2009 and 2011. Results: Two doses of AS03-adjuvanted A/Indonesia/5/2005 vaccine induced good homologous but poor heterologous neutralizing antibody responses against different Glade viruses. However, non-adjuvanted A/Vietnam/1203/2004 booster vaccination in 2011 induced very strong and long-lasting homologous and heterologous antibody responses while homologous response remained weak in naive subjects. Conclusions: Sequential vaccination with two different A(H5N1) pre-pandemic vaccines induced long-lasting high level cross-Glade immunity against influenza A(H5N1) strains, thus supporting a prime-boost vaccination strategy in pandemic preparedness plans. (C) 2020 The Author(s). Published by Elsevier Ltd.	[Haveri, Anu; Ikonen, Niina; Savolainen-Kopra, Carita; Julkunen, Ilkka] Finnish Inst Hlth & Welf THL, Dept Hlth Secur, Expert Microbiol Unit, POB 30, Helsinki 00271, Finland; [Julkunen, Ilkka] Univ Turku, Inst Biomed, Kiinamyllynkatu 10, Turku 20520, Finland; [Julkunen, Ilkka] Turku Univ Hosp, Kiinamyllynkatu 10, Turku 20520, Finland		Haveri, A (通讯作者)，Finnish Inst Hlth & Welf THL, Dept Hlth Secur, Expert Microbiol Unit, POB 30, Helsinki 00271, Finland.	anu.haveri@thl.fi		Haveri, Anu/0000-0003-4620-7536	Finnish Institute for Health and Welfare (THL); Ministry of Social Affairs and Health (Finland); Identification of Mechanisms Correlating with Susceptibility for Avian Influenza (IMECS) project by the European Commission, DG Research [201169]	The study was supported by funds from the Finnish Institute for Health and Welfare (THL), the Ministry of Social Affairs and Health (Finland) and the Identification of Mechanisms Correlating with Susceptibility for Avian Influenza (IMECS) project (grant no 201169) by the European Commission, DG Research, and the participating member states. The funding organization had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Belshe RB, 2014, JAMA-J AM MED ASSOC, V312, P1420, DOI 10.1001/jama.2014.12609; Bihari I, 2012, CLIN VACCINE IMMUNOL, V19, P1943, DOI 10.1128/CVI.00373-12; Buchy P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010864; Chen TM, 2015, J INFECTION, V71, P702, DOI 10.1016/j.jinf.2015.09.004; Chen WH, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu091; Cheng LW, 2012, J VIROL METHODS, V182, P43, DOI 10.1016/j.jviromet.2012.03.004; Chichester JA, 2012, VIRUSES-BASEL, V4, P3227, DOI 10.3390/v4113227; Cox RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131652; Frey SE, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz107; Gillard P, 2013, INFLUENZA OTHER RESP, V7, P55, DOI 10.1111/j.1750-2659.2012.00349.x; Grund S, 2011, J VIROL METHODS, V171, P369, DOI 10.1016/j.jviromet.2010.11.024; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Haveri A, 2019, VACCINE, V37, P2731, DOI 10.1016/j.vaccine.2019.03.078; Heijmans S, 2011, J INFECT DIS, V203, P1054, DOI 10.1093/infdis/jiq174; HILLIS DM, 1993, METHOD ENZYMOL, V224, P456, DOI 10.1016/0076-6879(93)24035-S; Hoft DF, 2016, J INFECT DIS, V214, P1020, DOI 10.1093/infdis/jiw310; Hsu JP, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-414; Hwang SJ, 2011, J FORMOS MED ASSOC, V110, P780, DOI 10.1016/j.jfma.2011.11.009; Ikonen N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013329; Keitel W, 2010, VACCINE, V28, P840, DOI 10.1016/j.vaccine.2009.10.019; Khurana S, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0076-2; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msv279, 10.1093/molbev/msw054]; Lai SJ, 2016, LANCET INFECT DIS, V16, pE108, DOI 10.1016/S1473-3099(16)00153-5; Langley JM, 2015, VACCINE, V33, P559, DOI 10.1016/j.vaccine.2014.11.018; Langley JM, 2010, J INFECT DIS, V201, P1644, DOI 10.1086/652701; Laurie KL, 2015, CLIN VACCINE IMMUNOL, V22, P957, DOI 10.1128/CVI.00278-15; Lee MS, 2016, VET MICROBIOL, V187, P50, DOI 10.1016/j.vetmic.2016.03.012; Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5; Levine MZ, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0114-8; Levine MZ, 2017, J INFECT DIS, V216, pS555, DOI 10.1093/infdis/jix001; Mbawuike IN, 2016, VACCINE, V34, P547, DOI 10.1016/j.vaccine.2015.11.055; Neumann G, 2015, FUTURE VIROL, V10, P971, DOI 10.2217/FVL.15.62; Nolan T, 2008, VACCINE, V26, P6383, DOI 10.1016/j.vaccine.2008.08.046; Nolan T, 2014, J INFECT DIS, V210, P1800, DOI 10.1093/infdis/jiu359; Qi X, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00706-14; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sansyzbay AR, 2013, CLIN VACCINE IMMUNOL, V20, P1314, DOI 10.1128/CVI.00096-13; Schwarz TF, 2009, VACCINE, V27, P6284, DOI 10.1016/j.vaccine.2009.01.040; Smith GJD, 2015, INFLUENZA OTHER RESP, V9, P271, DOI 10.1111/irv.12324; Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182; Song JY, 2017, HUM VACC IMMUNOTHER, V13, P1190, DOI 10.1080/21645515.2016.1263410; Stephenson I, 2009, EMERG INFECT DIS, V15, P1250, DOI 10.3201/eid1508.081754; Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101; Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778; Phan TL, 2016, VACCINE, V34, P5449, DOI 10.1016/j.vaccine.2016.08.055; van der Velden MVW, 2014, J INFECT DIS, V209, P12, DOI 10.1093/infdis/jit498; van der Velden MVW, 2012, VACCINE, V30, P6127, DOI 10.1016/j.vaccine.2012.07.077; Verschoor CP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131531; Vesikari T, 2012, VACCINE, V30, P1388, DOI 10.1016/j.vaccine.2011.12.009; WHO, 2020, COVID 19 WEEKL EP UP; World Health Organization, 2019, MONTHL RISK ASS SUMM; World Health Organization, 2019, ANT GEN CHAR ZOON IN; World Health Organization, 2007, WHO ACT AV INFL PAND; World Health Organization, 2011, GLOB INFL SURV NETW; World Health Organization, 2019, MONTHL RISK ASS SUMM; World Health Organization (WHO), 2007, REC LAB PROC DET AV; Xu XY, 1999, VIROLOGY, V261, P15, DOI 10.1006/viro.1999.9820; Yang ZF, 2015, NEW ENGL J MED, V373, P487, DOI 10.1056/NEJMc1502983; Yu Y, 2015, J VIROL, V89, P8806, DOI 10.1128/JVI.00653-15; Zhao KK, 2013, VET MICROBIOL, V163, P351, DOI 10.1016/j.vetmic.2012.12.025	60	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					402	411		10.1016/j.vaccine.2020.11.041			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33246672	hybrid			2022-04-29	WOS:000604750300031
J	Kitano, T; Aoki, H				Kitano, Taito; Aoki, Hirosato			A model for the incremental burden of invasive Haemophilus influenzae type b due to a decline of childhood vaccination during the COVID-19 outbreak: A dynamic transmission model in Japan	VACCINE			English	Article						COVID-19; SARS-CoV-2; Coronavirus; Vaccine preventable diseases; Haemophilus influenzae; Impact; Quality-adjusted life years; Disease burden; Mathematical model	CONJUGATE VACCINE; COLONIZATION; DISEASE; MENINGITIS; INFANTS	Background: The current coronavirus disease 2019 (COVID-19) outbreak has caused a persistent decline in childhood vaccination coverage, including Haemophilus influenzae type b (Hib) vaccine, in some countries. Our objective was to evaluate the impact of decreased Hib vaccination due to COVID-19 on invasive Hib disease burden in Japan. Methods: Using a deterministic dynamic transmission model (susceptible-carriage-infection-recovery model), the incidence rates of invasive Hib disease in under 5 year olds in rapid vaccination recovery and persistent vaccination declined scenarios were compared for the next 10 years after 2020. The national Hib vaccination rate after the impact of COVID-19 reduced to 87% and 73% in 2020 from approximately 97% each in 2013-2019 for primary and booster doses. Results: While the persistent decline scenarios revealed an increase in invasive Hib disease incidence to 0.50/100,000 children under 5 years old, the incidence of the rapid recovery scenario slightly increased with a consistent decline of incidence after 2021. The shorter the duration of the decline in vaccination rate was, the smaller the incremental disease burden observed in the model. Compared to the rapid recovery scenario, the permanent decline scenario showed a 296.87 cumulative incremental quality-adjusted life years (QALY) loss for the next 10 years. Conclusions: The persistent decline of Hib vaccination rate due to COVID-19 causes an incremental disease burden irrespective of the possible decline of Hib transmission rate by COVID-19 mitigation measures. A rapid recovery of vaccination coverage rate can prevent this possible incremental disease burden. (C) 2020 Elsevier Ltd. All rights reserved.	[Kitano, Taito] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Infect Dis, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Aoki, Hirosato] Kanagawa Childrens Med Ctr, Dept Neonatol, Minami Ku, 2-138-4 Mutsukawa, Yokohama, Kanagawa 2328555, Japan		Kitano, T (通讯作者)，Univ Toronto, Hosp Sick Children, Dept Pediat, Div Infect Dis, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	taito.kitano@sickkids.ca					Abdollahi E, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01705-8; Ambikapathy Bakiya, 2020, JMIR Public Health Surveill, V6, pe19368, DOI 10.2196/19368; Attema AE, 2018, PHARMACOECONOMICS, V36, P745, DOI 10.1007/s40273-018-0672-z; Booy R, 1997, LANCET, V349, P1197, DOI 10.1016/S0140-6736(96)06392-1; Bramer CA, 2020, MMWR-MORBID MORTAL W, V69, P630, DOI 10.15585/mmwr.mm6920e1; Cabinet Office Government of Japan, 2017, STAT POP AG; Centers for Disease Control and Prevention, ACT BACT COR SURV AB; Cherry JD, 2019, J PEDIAT INF DIS SOC, V8, P334, DOI 10.1093/jpids/piz005; ECDC. European Centre for Disease Prevention and Control, ANN EP REP INV HAEM; Fernandez J, 2000, J INFECT DIS, V182, P1553, DOI 10.1086/315870; Heath PT, 2000, JAMA-J AM MED ASSOC, V284, P2334, DOI 10.1001/jama.284.18.2334; Huh K, 2021, CLIN INFECT DIS, V72, pE184, DOI 10.1093/cid/ciaa1682; Iwata S, 2008, JPN J PEDIAT, V61, P2206; Jackson ML, 2012, EMERG INFECT DIS, V18, P13, DOI 10.3201/eid1801.110336; Jansen AGSC, 2009, VACCINE, V27, P2394, DOI 10.1016/j.vaccine.2009.01.127; Kitano T, 2021, HUM VACC IMMUNOTHER, V17, P1313, DOI 10.1080/21645515.2020.1826799; Kitano T, 2021, HUM VACC IMMUNOTHER, V17, P205, DOI 10.1080/21645515.2020.1765619; Kitano T, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268818003230; Know VPD! Protect Our Children, 2020, PROTECT OUR CHILDREN; Kuroki H, 1997, ACTA PAEDIATR JAPON, V39, P541; McConnell A, 2007, PEDIATR INFECT DIS J, V26, P1025, DOI 10.1097/INF.0b013e31812f4f5b; McDonald HI, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.19.2000848; MICHAELS RH, 1977, J INFECT DIS, V136, P222, DOI 10.1093/infdis/136.2.222; Ministry of Health Labour and Welfare, BAS POL NOV COR DIS; Ministry of Health Labour and Welfare of Japan, HLTH JAP 21 2 TERM A; Ministry of Health Labour and Welfare of Japan, NUMB VACC PERS ROUT; Ministry of Health Labour and Welfare of Japan, COV RAT MEASL VACC P; Ministry of Health Labour and Welfare of Japan, HAEM INFL TYP B VACC; Morris SK, 2008, LANCET INFECT DIS, V8, P435, DOI 10.1016/S1473-3099(08)70152-X; Nakayama T, 2020, J INFECT CHEMOTHER, V26, P651, DOI 10.1016/j.jiac.2019.11.012; Nakayama T, 2013, J INFECT CHEMOTHER, V19, P787, DOI 10.1007/s10156-013-0641-6; National Institute of Infectious Disease, INF DIS WEEKL REP; National Institute of Infectious Diseases, 2017, INFECT AGENTS SURVEI, V38, P165; National Institute of Infectious Diseases, INF DIS SURV ANN REP; Oostenbrink R, 2002, J CLIN EPIDEMIOL, V55, P791, DOI 10.1016/S0895-4356(02)00448-1; Otsuka T, 2012, J INFECT CHEMOTHER, V18, P213, DOI 10.1007/s10156-011-0323-1; Rozenbaum MH, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2509; Saxena S, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2392; Schad M, 2012, EUR J HEALTH ECON, V13, P127, DOI 10.1007/s10198-010-0292-9; Shibayama K, 2013, INFECT AGENTS SURVEI, V34, P197; Shiragami M, 2015, INFECT DIS THER, V4, P93, DOI 10.1007/s40121-014-0053-7; Statistics Bureau Ministry of internal affairs and communications, 2020, STAT JAP STAT YB; Suga S, 2018, VACCINE, V36, P5678, DOI 10.1016/j.vaccine.2018.08.029; Sun CJ, 2020, SUSTAIN CITIES SOC, V62, DOI 10.1016/j.scs.2020.102390; Wang SC, 2017, EXPERT REV VACCINES, V16, P1095, DOI 10.1080/14760584.2017.1383157	45	9	10	1	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					343	349		10.1016/j.vaccine.2020.11.053			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33280853	Bronze			2022-04-29	WOS:000604750300024
J	Bagattini, AM; Policena, G; Minamisava, R; Andrade, ALS; Nishioka, SD; Sinha, A; Russell, LB; Toscano, CM				Bagattini, Angela M.; Policena, Gabriela; Minamisava, Ruth; Andrade, Ana Lucia S.; Nishioka, Sergio de A.; Sinha, Anushua; Russell, Louise B.; Toscano, Cristiana M.			The data used to build the models: Pertussis morbidity and mortality burden considering various Brazilian data sources	VACCINE			English	Article						Pertussis; Whooping cough; Epidemiology; Surveillance; Mortality; Disease disease burden; Modelling	VACCINATION; CHILDREN	Background: Pertussis is associated with significant disease burden in children worldwide. In addition to its cyclical nature, resurgences of pertussis cases, hospitalizations and deaths have been reported by many countries. We describe the dynamics of pertussis in Brazil, a middle-income country that has experienced a resurgence and that provides good quality data to allow building a dynamic transmission disease model. Methods: We conducted a descriptive analysis of pertussis burden considering data from the national disease surveillance system, national hospitalization information system and national mortality registry. Study period was 2000-2016. Absolute numbers and rates per 100,000 inhabitants over time, by age sub-groups and geographical regions are presented. Results: From 2000 to 2016, a total of 37,299 reported pertussis cases, 25,240 hospitalizations, and 601 deaths due to pertussis were reported. Although the outcomes - pertussis cases, hospitalizations, and deaths - come from independent information systems, our results document low disease burden with periodic increases every 3-4 years during the years 2000-2010, followed by a sharp increase which peaked in 2014. In both periods, disease burden is concentrated in young children, while its more serious outcomes - hospitalizations and deaths, are concentrated in infants. Pre-outbreak and outbreak disease burden as well as timing of peak during the outbreak period vary by states and within geographical regions, representing valuable resources of data for modelling purposes. Conclusion: Consistent disease burden patterns were observed over time in Brazil using a variety of data sources. Given the scarcity of good epidemiological data on pertussis available from low- and middle-income countries, our reported data provide valuable information for the assessment of the public health impact and cost-effectiveness modelling studies of newer strategies to prevent and control pertussis. These data were used to build and calibrate a national dynamic transmission model, which was used to evaluate the cost-effectiveness of maternal immunization. (C) 2020 The Authors. Published by Elsevier Ltd.	[Bagattini, Angela M.; Policena, Gabriela; Andrade, Ana Lucia S.; Toscano, Cristiana M.] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil; [Minamisava, Ruth] Univ Fed Goias, Sch Nursing, Goiania, Go, Brazil; [Nishioka, Sergio de A.] Brazilian Minist Hlth, Secretary Hlth Surveillance SVS, Natl Coordinat Transmittable Dis Surveillance, Goiania, Go, Brazil; [Sinha, Anushua] Rutgers New Jersey Med Sch, Dept Med, Div Infect Dis, Newark, NJ USA; [Russell, Louise B.] Univ Penn, Dept Med Eth & Hlth Policy, 423 Guardian Dr, Philadelphia, PA 19104 USA; [Minamisava, Ruth] Univ Fed Goias, Fac Enfermagem, Rua 235 S-N, BR-74605050 Goiania, Go, Brazil; [Andrade, Ana Lucia S.; Toscano, Cristiana M.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Rua 235 S-N, BR-74605050 Goiania, Go, Brazil; [Nishioka, Sergio de A.] Setor Radio & Televisao Norte SRTV 701, BR-70719040 Brasilia, DF, Brazil; [Russell, Louise B.] Dept Med Eth & Hlth Policy, 423 Guardian Dr, Philadelphia, PA 19104 USA		Bagattini, AM (通讯作者)，Univ Fed Goias, IPTSP, Sala 411,3o Andar,Rua 235 S-N, BR-74605050 Goiania, Go, Brazil.	abagattini@discente.ufg.br; ctoscano@terra.com.br	Toscano, Cristiana Maria/N-4019-2014	TOSCANO, CRISTIANA/0000-0002-9453-2643; Russell, Louise/0000-0003-3599-0991	Bill & Melinda Gates Foundation, Seattle, WABill & Melinda Gates Foundation [OPP1124529]; Brazilian National Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]	This work was supported by the Bill & Melinda Gates Foundation, Seattle, WA [grant number OPP1124529]. CMT (#308010/2018-3) receive scientific productivity scholarships from the Brazilian National Council for Scientific and Technological Development (CNPq). AB is a scholar with grant from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) (Finance Code 001).	Acosta A, 2015, INFORME DIAGNOSTICO; Andrade AL, 2017, PLOS ONE, P12, DOI DOI 10.1371/JOURNAL.PONE.0184204E0184204; [Anonymous], 2015, Weekly Epidemiological Record, V90, P433; [Anonymous], 2013, TERRAVIEW 4 22; Bailon H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1700-2; Bierrenbach AL, 2018, HUM VACC IMMUNOTHER, V14, P1138, DOI 10.1080/21645515.2017.1391431; Brasil, 2014, GUIA VIG SAUD; BRASIL. Ministerio da Saude, 2017, GUIA VIG SAUD; BRASIL. Ministerio da Saude, 2009, BRAZ EXP HLTH INF SY; Fernandes EG, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3004-1; Folaranmi T., 2017, Revista Panamericana de Salud Publica/Pan American Journal of Public Health, V41, pe102; Guimaraes LM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1222-3; Instituto Brasileiro de Geografia e Estatistica-IBGE, 2013, PESQ NAC SAUD 2013 C; Lima M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1292-2; Liu XFC, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4468-4; Lozano R, 2018, MEASURING PROGR 1990, DOI [10.1016/S0140-6736(18)32281-5., DOI 10.1016/S0140-6736(18)32281-5]; Luz PM, MODELING COST UNPUB; Moore HC, 2014, J PEDIATR INFECT DIS, V3, P255, DOI 10.1093/jpids/pit036; Sartori AL, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0179222e0179222, DOI 10.1371/JOURNAL.PONE.0179222E0179222]; Skoff TH, 2019, CLIN INFECT DIS, V68, P1634, DOI 10.1093/cid/ciy757; Solano R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3844-9; Sun-Young K, COST EFFECTIVE UNPUB; Ulloa-Virguez AP, 2016, BIOMEDICA, V36, P646, DOI 10.7705/biomedica.v36i4.3699; van der Maas NAT, 2013, VACCINE, V31, P4541, DOI 10.1016/j.vaccine.2013.07.060; van Lier A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153106; Vizzotti C, 2016, VACCINE, V34, P6223, DOI 10.1016/j.vaccine.2016.10.081; Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0	27	3	3	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2021	39	1					137	146		10.1016/j.vaccine.2020.09.007			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PI2XL	33303181	hybrid, Green Published			2022-04-29	WOS:000600959400014
J	Krubiner, CB; Faden, RR; Karron, RA; Little, MO; Lyerly, AD; Abramson, JS; Beigi, RH; Cravioto, AR; Durbin, AP; Gellin, BG; Gupta, SB; Kaslow, DC; Kochhar, S; Luna, F; Saenz, C; Sheffield, JS; Tindana, PO				Krubiner, Carleigh B.; Faden, Ruth R.; Karron, Ruth A.; Little, Margaret O.; Lyerly, Anne D.; Abramson, Jon S.; Beigi, Richard H.; Cravioto, Alejandro R.; Durbin, Anna P.; Gellin, Bruce G.; Gupta, Swati B.; Kaslow, David C.; Kochhar, Sonali; Luna, Florencia; Saenz, Carla; Sheffield, Jeanne S.; Tindana, Paulina O.		PREVENT Working Grp	Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response	VACCINE			English	Review						Epidemics; Pregnancy; Emerging infectious diseases; Maternal immunization; Public health ethics; Research ethics; Vaccines; Research & development	YELLOW-FEVER VACCINATION; IMMUNIZATION SURVEILLANCE SYSTEMS; INACTIVATED INFLUENZA VACCINE; ORAL CHOLERA VACCINE; EBOLA-VIRUS DISEASE; MATERNAL IMMUNIZATION; SPONTANEOUS-ABORTION; GLOBAL PERSPECTIVE; UNITED-STATES; RUBELLA VACCINATION	Zika virus, influenza, and Ebola have called attention to the ways in which infectious disease outbreaks can severely - and at times uniquely - affect the health interests of pregnant women and their offspring. These examples also highlight the critical need to proactively consider pregnant women and their offspring in vaccine research and response efforts to combat emerging and re-emerging infectious diseases. Historically, pregnant women and their offspring have been largely excluded from research agendas and investment strategies for vaccines against epidemic threats, which in turn can lead to exclusion from future vaccine campaigns amidst outbreaks. This state of affairs is profoundly unjust to pregnant women and their offspring, and deeply problematic from the standpoint of public health. To ensure that the needs of pregnant women and their offspring are fairly addressed, new approaches to public health preparedness, vaccine research and development, and vaccine delivery are required. This Guidance offers 22 concrete recommendations that provide a roadmap for the ethically responsible, socially just, and respectful inclusion of the interests of pregnant women in the development and deployment of vaccines against emerging pathogens. The Guidance was developed by the Pregnancy Research Ethics for Vaccines, Epidemics, and New Technologies (PREVENT) Working Group - a multidisciplinary, international team of 17 experts specializing in bioethics, maternal immunization, maternal-fetal medicine, obstetrics, pediatrics, philosophy, public health, and vaccine research and policy - in consultation with a variety of external experts and stakeholders. (C) 2019 Pan American Health Organization. Published by Elsevier Ltd.	[Krubiner, Carleigh B.; Faden, Ruth R.] Johns Hopkins Berman Inst Bioeth, 1809 Ashland Ave, Baltimore, MD USA; [Faden, Ruth R.; Karron, Ruth A.; Durbin, Anna P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Little, Margaret O.] Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA; [Lyerly, Anne D.] Univ N Carolina, Ctr Bioeth, Chapel Hill, NC 27515 USA; [Abramson, Jon S.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Beigi, Richard H.] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Pittsburgh, PA USA; [Cravioto, Alejandro R.] Univ Nacl Autonoma Mexico, Mexico City, DF, Mexico; [Gellin, Bruce G.] Sabin Vaccine Inst, Washington, DC USA; [Gupta, Swati B.] IAVI, New York, NY USA; [Kaslow, David C.] PATH, Seattle, WA USA; [Kochhar, Sonali] Global Healthcare Consulting, Delhi, India; [Luna, Florencia] FLACSO Argentina, Buenos Aires, DF, Argentina; [Luna, Florencia] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina; [Saenz, Carla] Pan Amer Hlth Org, Washington, DC USA; [Sheffield, Jeanne S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Tindana, Paulina O.] Navrongo Hlth Res Ctr, Navrongo, Ghana		Krubiner, CB (通讯作者)，2055 L St NW,5th Floor, Washington, DC 20036 USA.	ckrubiner@cgdev.org	Kochhar, Sonali/H-4036-2012	Kochhar, Sonali/0000-0002-1150-5691; Krubiner, Carleigh/0000-0003-1647-2355; Tindana, Paulina/0000-0002-9171-2083	Wellcome TrustWellcome TrustEuropean Commission [203160/Z/16/Z]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_PC_17221, MR/R005990/1, MC_UU_00026/2, MR/R005990/2] Funding Source: UKRI	This Guidance is a product of the Pregnancy Research Ethics for Vaccines, Epidemics, and New Technologies (PREVENT) Project. PREVENT Project is supported by the Wellcome Trust [203160/Z/16/Z]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Wellcome Trust.	Abramson JS, 2016, LANCET, V388, P2562, DOI 10.1016/S0140-6736(16)30882-0; Adam MP, 2011, AM J MED GENET C, V157C, P175, DOI 10.1002/ajmg.c.30313; Ajayi NA, 2013, INT J INFECT DIS, V17, pE1011, DOI 10.1016/j.ijid.2013.05.015; Ali M, 2017, LANCET INFECT DIS, V17, P538, DOI [10.1016/S1473-3099(16)30523-0, 10.1016/s1473-3099(16)30523-0]; American College of Obstetricians and Gynecologists, 2015, ACOG PRACTICE B, V150; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P477; [Anonymous], 2013, OBSTET GYNECOL, V121; [Anonymous], 2010, ENROLLING PREGNANT W; [Anonymous], 2015, CLIN DEV REQUIREMENT; [Anonymous], 2014, OBSTET GYNECOL, V124; [Anonymous], 2017, REPROD HLTH, V14; [Anonymous], 2016, FDA RES POL WORKSH W; [Anonymous], 2009, ICH TRIP GUID GUID N; Associated Press, 2017, ASS PRESS       0913; Attaran A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001911; Badell ML, 2015, OBSTET GYNECOL, V125, P1439, DOI 10.1097/AOG.0000000000000857; Bar-Oz B, 2004, AM J MED GENET A, V130A, P52, DOI 10.1002/ajmg.a.30225; Baylis Francoise., 2017, CLIN RES INVOLVING P; Bebell LM, 2017, BIRTH DEFECTS RES, V109, P353, DOI 10.1002/bdra.23558; Beck AS, 2015, EXPERT REV VACCINES, V14, P1479, DOI 10.1586/14760584.2015.1083430; Beigi RH, 2014, CLIN INFECT DIS, V59, pS408, DOI 10.1093/cid/ciu708; Black S, 2009, LANCET, V374, P2115, DOI 10.1016/S0140-6736(09)61877-8; Blehar MC, 2013, WOMEN HEALTH ISS, V23, pE39, DOI 10.1016/j.whi.2012.10.003; Bloom DE, 2017, P NATL ACAD SCI USA; Bonhoeffer J, 2016, VACCINE, V34, P5993, DOI 10.1016/j.vaccine.2016.07.006; Bose CL, 2015, REPROD HEALTH, V12, DOI 10.1186/1742-4755-12-S2-S1; Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412; Brown H., 2017, IT IS SAFE RECEIVE F; Cassidy C, 2016, HUM VACC IMMUNOTHER, V12, P2010, DOI 10.1080/21645515.2016.1175697; Cassidy C, 2015, PHARMACOEPIDEM DR S, V24, P361, DOI 10.1002/pds.3754; Cavalcanti DP, 2007, TROP MED INT HEALTH, V12, P833, DOI 10.1111/j.1365-3156.2007.01851.x; Centers for Disease Control and Prevention (CDC), 2016, GUID VACC PREGN WOM; Centers for Disease Control and Prevention (CDS), 2017, FLU VACC POSS SAF SI; CEPI, GLOB INS POL DEF FUT; Chambers CD, 2008, CLIN PHARMACOL THER, V83, P181, DOI 10.1038/sj.clpt.6100448; Charlton R, 2016, SYSTEMATIC OVERVIEW; Coalition for Epidemic Preparedness (CEPI), 2018, DRAFT EQ ACC POL; Cohet C, 2017, VACCINE, V35, P3041, DOI 10.1016/j.vaccine.2017.04.058; Committee for Medicinal Products for Human Use (CHMP), 2005, GUID EXP MED PROD PR; Committee on Ethics, 2015, Obstet Gynecol, V126, pe100, DOI 10.1097/AOG.0000000000001150; Cono J, 2006, EMERG INFECT DIS, V12, P1631, DOI 10.3201/eid1211.060618; Council for International Organizations of Medical Sciences-CIOMS, 2016, INT ETH GUID HLTH RE, V4th; Creanga AA, 2010, OBSTET GYNECOL, V115, P717, DOI 10.1097/AOG.0b013e3181d57947; Cunnington M, 2008, INT REV NEUROBIOL, V83, P283, DOI 10.1016/S0074-7742(08)00017-2; Dahmane A, 2014, T ROY SOC TROP MED H, V108, P126, DOI 10.1093/trstmh/tru009; DeSilva M, 2017, VACCINE, V35, P6472, DOI 10.1016/j.vaccine.2017.01.044; Ding H, 2017, PREGNANT WOMEN FLU V; Ding H, 2017, MMWR-MORBID MORTAL W, V66, P1016, DOI 10.15585/mmwr.mm6638a2; Divala TH, 2015, VACCINE, V33, P6401, DOI 10.1016/j.vaccine.2015.08.042; Donahue JG, 2017, VACCINE, V35, P5314, DOI 10.1016/j.vaccine.2017.06.069; Dzidek B, 2016, IEEE HAPTICS SYM, P161, DOI 10.1109/HAPTICS.2016.7463171; EBBIN AJ, 1973, AM J OBSTET GYNECOL, V117, P505, DOI 10.1016/0002-9378(73)90112-9; Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709; European Medicines Agency (EMA), POST MEAS QUEST ANSW; European Medicines Agency (EMA), COND MARK AUTH; Faden R, 2016, STANFORD ENCY PHILOS; Faherty LJ, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.08.031; Food and Drug Administration (FDA), GUID IND EST PREGN E; Foulkes MA, 2011, J WOMENS HEALTH, V20, P1429, DOI 10.1089/jwh.2011.3118; Frew PM, 2014, CLIN INFECT DIS, V59, pS400, DOI 10.1093/cid/ciu726; Fulton TR, 2015, VACCINE, V33, P6453, DOI 10.1016/j.vaccine.2015.08.043; Gavi, VACC INV STRAT EV CR; Geall AJ, 2013, SEMIN IMMUNOL, V25, P152, DOI 10.1016/j.smim.2013.05.001; Gesser-Edelsburg A, 2017, AM J INFECT CONTROL, V45, P436, DOI 10.1016/j.ajic.2016.11.025; Gilboa SM, 2017, BIRTH DEFECTS RES, V109, P372, DOI 10.1002/bdr2.1007; Goldfarb I, 2011, AM J OBSTET GYNECOL, V204, pS112, DOI 10.1016/j.ajog.2011.01.007; Gomes MF, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0430-2; Grabowski H, 2005, HEALTH AFFAIR, V24, P697, DOI 10.1377/hlthaff.24.3.697; Gray RH, 2005, LANCET, V366, P1182, DOI 10.1016/S0140-6736(05)67481-8; Greene MF, 2015, SEMIN PERINATOL, V39, P520, DOI 10.1053/j.semperi.2015.08.004; Grout L, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004274; Gruber M., 2016, FDA UPDATE VACCINES; Gruber MF, 2003, VACCINE, V21, P3487, DOI 10.1016/S0264-410X(03)00357-8; Haddad LB, 2018, CLIN OBSTET GYNECOL, V61, P186, DOI 10.1097/GRF.0000000000000332; Halabi SF, 2017, JAMA-J AM MED ASSOC, V317, P471, DOI 10.1001/jama.2016.19492; Hayes EB, 2010, VACCINE, V28, P8073, DOI 10.1016/j.vaccine.2010.10.015; Healy CM, 2015, VACCINE, V33, P5445, DOI 10.1016/j.vaccine.2015.08.028; Healy CM, 2012, CLIN OBSTET GYNECOL, V55, P474, DOI 10.1097/GRF.0b013e31824f3acb; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; HHS FDA CBER CDER, 2010, GUID IND M3 R2 NONCL; Hutson MR, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal4055; Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Jones KM, 2016, INFECT DIS OBSTET GY; Kachikis A, 2016, J INFECTION, V72, pS83, DOI 10.1016/j.jinf.2016.04.027; Kass N, 2018, EXPERT WORKING GROUP; Kass NE, 2001, AM J PUBLIC HEALTH, V91, P1776, DOI 10.2105/AJPH.91.11.1776; Khan AI, 2017, VACCINE, V35, P1538, DOI 10.1016/j.vaccine.2017.01.080; Kharbanda EO, 2013, OBSTET GYNECOL, V122, P659, DOI 10.1097/AOG.0b013e3182a1118a; Kochhar S, 2015, CURR DRUG SAF, V10, P55, DOI 10.2174/157488631001150407110435; Kohl KS, 2005, CONCEPTS METHODOLOGY, V2; Krubiner CB, 2016, AIDS, V30, P2261, DOI 10.1097/QAD.0000000000001214; Kummervold PE, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4618-8; Lambach P, 2015, VACCINE, V33, P6376, DOI 10.1016/j.vaccine.2015.08.036; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Larson HJ, 2018, HUM VACCIN IMMUNOTHE, V29, P01; Little MO, 2017, JAMA PEDIATR, V171, P395, DOI 10.1001/jamapediatrics.2016.5046; Lopalco PL, 2015, VACCINE, V33, P1541, DOI 10.1016/j.vaccine.2014.10.047; Lucey DR, 2017, ANN INTERN MED, V167, P664, DOI 10.7326/M17-1337; Lyerly AD, 2007, WILLINGNESS DONATE F, V317, P46, DOI DOI 10.1126/SCIENCE.1145067; Lyerly AD, 2017, JAMA PEDIATR, V171, P719, DOI 10.1001/jamapediatrics.2017.1496; Lyerly AD, 2011, AM J BIOETHICS, V11, P50, DOI 10.1080/15265161.2011.560353; Lyerly AD, 2008, HASTINGS CENT REP, V38, pCOVER3; Lyerly AD, 2009, HASTINGS CENT REP, V39, P34; Lyerly Anne Drapkin, 2008, Int J Fem Approaches Bioeth, V1, P5, DOI 10.2979/FAB.2008.1.2.5; Lyerly AD, 2009, AM J PUBLIC HEALTH, V99, P1742, DOI 10.2105/AJPH.2009.165498; MacDougall DM, 2016, HUM VACC IMMUNOTHER, V12, P857, DOI 10.1080/21645515.2015.1101524; Maciel M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003693; Maharashtra Association of Anthropological Sciences Swiss Tropical and Public Health Institute, 2016, PROJ PROT ASSN AW AC; Mandl CW, 1998, NAT MED, V4, P1438, DOI 10.1038/4031; Mastroianni A, 2001, HASTINGS CENT REP, V31, P21, DOI 10.2307/3527551; Mastroianni A, 1994, WOMEN HLTH RES ETHIC; Mastroianni AC, 2017, HASTINGS CENT REP, V47, P38, DOI 10.1002/hast.706; Maternal immunization working group, 2016, NAT VACC ADV COMM OV; McCormack SA, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00009; McQuaid F, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010790; Menendez C, 2015, LANCET GLOB HEALTH, V3, pE130, DOI 10.1016/S2214-109X(15)70009-4; Merton V, 1996, FEMINISM BIOETHICS R, P216; Mitchell AA, 2003, NEW ENGL J MED, V349, P2556, DOI 10.1056/NEJMsb031395; Monath TP, 2016, LANCET, V387, P1599, DOI 10.1016/S0140-6736(16)30195-7; Monath TP, 2012, EXPERT REV VACCINES, V11, P427, DOI [10.1586/ERV.12.6, 10.1586/erv.12.6]; Monath TP, 2011, NEW ENGL J MED, V364, P1326, DOI 10.1056/NEJMoa1009303; Moodley K, 2013, B WORLD HEALTH ORGAN, V91, P290, DOI 10.2471/BLT.12.113480; Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982; Moretti ME, 2005, EPIDEMIOLOGY, V16, P216, DOI 10.1097/01.ede.0000152903.55579.15; Moro PL, 2016, VACCINE, V34, P5991, DOI 10.1016/j.vaccine.2016.08.026; Munoz FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00436; NASIDI A, 1993, T ROY SOC TROP MED H, V87, P337, DOI 10.1016/0035-9203(93)90156-K; National Committee of BioEthics of Saudi Arabia, 2016, IMPL REG LAW ETH RES; Nesin M, 2015, SEMIN PERINATOL, V39, P524, DOI 10.1053/j.semperi.2015.08.005; Nishioka SD, 1998, TROP MED INT HEALTH, V3, P29, DOI 10.1046/j.1365-3156.1998.00164.x; Omer SB, 2017, NEW ENGL J MED, V376, P1256, DOI 10.1056/NEJMra1509044; Orenstein LAV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046638; PAHO, 2016, ZIK ETH CONS ETH GUI; Pan American Health Organization (PAHO), 2017, MAT NEON IMM FIELD G; Panagiotou OA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4358; Paradiso PR, 2001, VACCINE, V20, pS73, DOI 10.1016/S0264-410X(01)00302-4; Pereira RC, 2015, VACCINE, V33, P4261, DOI 10.1016/j.vaccine.2015.03.077; Plotkin SA, 2015, NEW ENGL J MED, V373, P297, DOI 10.1056/NEJMp1506820; Poland GA, 2018, LANCET INFECT DIS; Powers M, 2006, SOCIAL JUSTICE MORAL, P258; PREBLUD SR, 1980, J INFECT DIS, V142, P776, DOI 10.1093/infdis/142.5.776; Rasmussen SA, 2007, AM J MED GENET A, V143A, P2896, DOI 10.1002/ajmg.a.32077; Rasmussen SA, 2017, BIRTH DEFECTS RES, V109, P363, DOI 10.1002/bdr2.1006; Regan L, 2000, BEST PRACT RES CL OB, V14, P839, DOI 10.1053/beog.2000.0123; Rid A, 2011, KENNEDY INST ETHIC J, V21, P141; Roberts JN, 2015, VACCINE, V33, P966, DOI 10.1016/j.vaccine.2014.12.068; Rottingen JA, 2017, N ENGL J MED 20 0118; Rouse CE, 2017, VACCINE, V35, P6563, DOI 10.1016/j.vaccine.2017.01.047; Saenz C., 2018, REV PANAMERICANA SAL, V41, pe13; Saenz C, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0421-3; Sanz E, 2001, EUR J OBSTET GYN R B, V95, P127, DOI 10.1016/S0301-2115(00)00375-4; Schantz-Dunn Julianna, 2009, Rev Obstet Gynecol, V2, P186; Schlaudecker EP, 2018, VACCINE, V36, P4734, DOI 10.1016/j.vaccine.2018.05.117; Schonfeld T, 2013, THEOR MED BIOETH, V34, P189, DOI 10.1007/s11017-013-9258-0; Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x; Shavell VI, 2012, AM J OBSTET GYNECOL, V207, pS67, DOI 10.1016/j.ajog.2012.06.077; Sheffield JS, 2014, CLIN INFECT DIS, V59, pS437, DOI 10.1093/cid/ciu709; Sinclair SM, 2017, DRUG SAFETY, V40, P1205, DOI 10.1007/s40264-017-0566-6; Sobanjo-ter Meulen A, 2017, LANCET INFECT DIS, V17, P685, DOI 10.1016/S1473-3099(17)30230-X; Sperling RS, 2018, OBSTET GYNECOL, V131, P799, DOI 10.1097/AOG.0000000000002573; Straetemans M, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-236; Sugarman J, 2014, LANCET GLOB HEALTH, V2, pE710, DOI 10.1016/S2214-109X(14)70330-4; Sun LH, 2017, WASH POST; Suzano CES, 2006, VACCINE, V24, P1421, DOI 10.1016/j.vaccine.2005.09.033; Swamy GK, 2015, VACCINE, V33, P6436, DOI 10.1016/j.vaccine.2015.08.035; Swamy GK, 2015, OBSTET GYNECOL, V125, P212, DOI 10.1097/AOG.0000000000000581; U.S. Department of Health and Human Services, 2017, CHART TASK FORC RES; U.S. department of health and human services food and drug administration (FDA) center for drug evaluation and research (CDER), 2018, PREGN WOM SCI ETH CO; U.S. Department of Health and Human Services (HHS), 2016, TROP DIS PRIOR REV V; U.S. food and drug administration center for biologics evaluation and research, 2016, SENT POSTL RAP IMM S; U.S. Institute of Medicine (IOM), 2014, CHAR COMM UNC ASS BE; U.S. National Insitutites of Health (NIH), RFAAI18023 US NIH FO; Uganda National Council for Science and Technology (UNCST), 2014, NAT GUID RES INV HUM; van der Zande ISE, 2016, RES ETHICS FORUM, V3, P65, DOI 10.1007/978-3-319-26512-4_5; VICTORA CG, 1987, ANN HUM BIOL, V14, P49, DOI 10.1080/03014468700008831; Wacholder S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c712; WHO, 2014, SAF IMM PREGN REV EV; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Wilcox AJ, 1999, NEW ENGL J MED, V340, P1796, DOI 10.1056/NEJM199906103402304; Wild V, 2012, INT J FEM APPROACHES, V5, P82; Wilson K, 2007, CAN MED ASSOC J, V176, P1681, DOI 10.1503/cmaj.070610; Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046; World Health Organization, 2014, REP SAGE WORK GROUP; World Health Organization, 2016, R D BLUEPR ACT PREV; World Health Organization, 2016, GUID MAN ETH ISS INF; World Health Organization (WHO), MAT IMM ANT CAR SERV; World Health Organization (WHO), LASS FEV FACT SHEET; World Health Organization (WHO), DRAFT EB MARB RES DE, P3; World Health Organization [WHO], 2016, GOOD PART PRACT GUID; World Health Organization (WHO), DRAFT ROADM RES PROD, P10; World Health Organization (WHO), MAT INFL IMM GUID IN; WYLL SA, 1973, JAMA-J AM MED ASSOC, V225, P1472, DOI 10.1001/jama.225.12.1472; Wynia MK, 2006, AM J BIOETHICS, V6, P4, DOI 10.1080/15265160601021256; Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6; Zimmerman RK, 2007, VACCINE, V25, P2019, DOI 10.1016/j.vaccine.2006.11.045; 2017, WHO TECHN REP SER, V1004, P1	197	56	56	11	29	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2021	39	1					85	120		10.1016/j.vaccine.2019.01.011			36	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PI2XL	31060949	Green Published, hybrid	Y	N	2022-04-29	WOS:000600959400011
J	Yeung, KHT; Lin, SL; Clark, A; McGhee, SM; Janusz, CB; Atherly, D; Chan, KC; Nelson, EAS				Yeung, Karene Hoi Ting; Lin, Shi Lin; Clark, Andrew; McGhee, Sarah M.; Janusz, Cara Bess; Atherly, Deborah; Chan, Kate C.; Nelson, E. Anthony S.			Economic evaluation of the introduction of rotavirus vaccine in Hong Kong	VACCINE			English	Article						Rotavirus; Rotavirus vaccine; Economic evaluation; Cost-effectiveness; Hong Kong; Paediatrics	CHILDREN LESS-THAN-5 YEARS; CONTROLLED CASE-SERIES; COST-EFFECTIVENESS; INTUSSUSCEPTION RISK; CLINICAL-TRIAL; EFFICACY; COUNTRIES; BENEFITS; BURDEN; SIMULATION	Background: Rotavirus is a common cause of severe gastroenteritis in young children in Hong Kong (HK) with a high economic burden. This study aimed to evaluate the cost-effectiveness of introducing rotavirus vaccination into the HK Government's Childhood Immunisation Programme (CIP) and to include the potential protective effect of the vaccine against seizures. Methods: A decision-support model was customised to estimate the potential impact, cost-effectiveness and benefit-risk of rotavirus vaccination in children below 5 years over the period 2020-2029 in HK. Two doses of Rotarix (R) and three doses of RotaTeq (R) were each compared to no vaccination. Rotavirus treatment costs were calculated from a governmental health sector perspective (i.e., costs of public sector treatment) and an overall health sector perspective (both governmental and patient, i.e., costs of public sector treatment, private sector treatment, transport and diapers). We ran probabilistic and deterministic uncertainty analyses. Results: Introduction of rotavirus vaccination in HK could prevent 49,000 (95% uncertainty interval: similar to 44,000-54,000) hospitalisations of rotavirus gastroenteritis and seizures and result in similar to 50 (95% uncertainty interval: similar to 25-85) intussusception hospitalisations, over the period 2020-2029 (a benefit-risk ratio of similar to 1000:1), compared to a scenario with no public or private sector vaccine use. The discounted vaccination cost would be US$51-57 million over the period 2020-2029 based on per-course prices of US$72 (Rotarix (R)) or US$78 (RotaTeq (R)), but this would be offset by discounted treatment cost savings of US$70 million (government) and US$127 million (governmental and patient health sector). There was a greater than 94% probability that the vaccine could be cost-saving irrespective of the vaccine product or perspective considered. All deterministic 'what-iP scenarios were cost-saving from an overall health sector perspective (governmental and patient). Conclusions: Rotavirus vaccination is likely to be cost-saving and have a favourable benefit-risk profile in HK. Based on the assumptions made, our analysis supports its introduction into CIP. (C) 2020 The Author(s). Published by Elsevier Ltd.	[Yeung, Karene Hoi Ting; Lin, Shi Lin; Chan, Kate C.; Nelson, E. Anthony S.] Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China; [Clark, Andrew] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London, England; [McGhee, Sarah M.] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Peoples R China; [Janusz, Cara Bess] Pan Amer Hlth Org, PAHO ProVac Initiat, Washington, DC USA; [Atherly, Deborah] PATH, Ctr Vaccine Innovat & Access, Seattle, WA USA		Nelson, EAS (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, Shatin, 6-F,Lui Che Woo Clin Sci Bldg, Hong Kong, Peoples R China.	tony-nelson@cuhk.edu.hk	Chan, Kate Ching Ching/P-2947-2018	Chan, Kate Ching Ching/0000-0001-7272-8285	Health and Medical Research Fund by the Food and Health Bureau, Government of Hong Kong SAR [16151032]	This work was supported by the Health and Medical Research Fund by the Food and Health Bureau, Government of Hong Kong SAR (Ref: 16151032).	Baker JM, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3816-7; Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418; Biggart R, 2018, VACCINE, V36, P4589, DOI 10.1016/j.vaccine.2018.06.029; Bruijning-Verhagen P, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1134-3; Buttery JP, 2011, PEDIATR INFECT DIS J, V30, pS25, DOI 10.1097/INF.0b013e3181fefdee; Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520; Census and Statistics Department, 2018, THEM HOUS SURV REP; Centers for Disease Control and Prevention, 2018, PINK BOOK ROT; Chan D, 2017, COMMUNICABLE DIS WAT, V14, P23; Chan PKS, 1998, EPIDEMIOL INFECT, V120, P321, DOI 10.1017/S0950268898008747; Chang WC, 2013, VACCINE, V31, P5458, DOI 10.1016/j.vaccine.2013.08.103; Chiang GPK, 2014, VACCINE, V32, P1700, DOI 10.1016/j.vaccine.2014.01.065; Clark AD, 2019, INT J EPIDEMIOL; Clark A, 2019, LANCET GLOB HEALTH, V7, pE1541, DOI 10.1016/S2214-109X(19)30412-7; Clark A, 2019, LANCET INFECT DIS, V19, P717, DOI 10.1016/S1473-3099(19)30126-4; Clark A, 2014, VACCINE, V32, P3604, DOI 10.1016/j.vaccine.2014.04.082; Davis Ron, 2008, INFORMS Transactions on Education, V8, DOI 10.1287/ited.1080.0013; Debellut F, 2019, LANCET GLOB HEALTH, V7, pE1664, DOI 10.1016/S2214-109X(19)30439-5; Desai R, 2013, PEDIATR INFECT DIS J, V32, P1, DOI 10.1097/INF.0b013e318270362c; Haber P, 2015, VACCINE, V33, P4873, DOI 10.1016/j.vaccine.2015.07.054; Haider S, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz117; Ho AMH, 2008, ARCH DIS CHILD, V93, P52, DOI 10.1136/adc.2007.117879; Hong Kong, 2007, HONG KONG MED J, V13, P279; Hoshi SL, 2017, HUM VACC IMMUNOTHER, V13, P1115, DOI 10.1080/21645515.2016.1245252; Hungerford DJ, 2019, J EPIDEMIOL COMMUN H, V73, P1020, DOI 10.1136/jech-2019-213055; Jit M, 2010, VACCINE, V28, P7457, DOI 10.1016/j.vaccine.2010.08.060; Kirkwood CD, 2019, VACCINE, V37, P7328, DOI 10.1016/j.vaccine.2017.03.076; Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014; Lamberti LM, 2016, PEDIATR INFECT DIS J, V35, P992, DOI 10.1097/INF.0000000000001232; Lamrani A, 2017, EURO SURVEILL, V22; Ledent E, 2018, BIODRUGS, V32, P139, DOI 10.1007/s40259-018-0273-6; Ledent E, 2016, DRUG SAFETY, V39, P219, DOI 10.1007/s40264-015-0376-7; Lee H, 2019, VACCINE, V37, P4987, DOI 10.1016/j.vaccine.2019.07.030; Lee SY, 2009, VACCINE, V27, pF97, DOI 10.1016/j.vaccine.2009.09.002; Lopman BA, 2011, J INFECT DIS, V204, P980, DOI 10.1093/infdis/jir492; Mc Ghee SM, 2008, RES FUND CONTROL INF; Nelson EAS, 2005, J INFECT DIS, V192, pS71, DOI 10.1086/431492; Nelson EAS, 2005, J INFECT DIS, V192, pS64, DOI 10.1086/431493; Newall AT, 2007, VACCINE, V25, P8851, DOI 10.1016/j.vaccine.2007.10.009; Pardo-Seco J, 2015, PEDIATR INFECT DIS J, V34, P769, DOI 10.1097/INF.0000000000000723; Payne DC, 2014, CLIN INFECT DIS, V58, P173, DOI 10.1093/cid/cit671; Phua KB, 2012, VACCINE, V30, P4552, DOI 10.1016/j.vaccine.2012.03.030; Pitzer VE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042320; Pringle KD, 2018, J INFECT DIS, V217, P581, DOI 10.1093/infdis/jix589; Reyes JF, 2017, VACCINE, V35, P345, DOI 10.1016/j.vaccine.2016.11.056; Rozenbaum MH, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-462; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8; Sheridan SL, 2016, J PEDIAT INF DIS SOC, V5, P206, DOI 10.1093/jpids/piu097; Stowe J, 2016, VACCINE, V34, P3684, DOI 10.1016/j.vaccine.2016.04.050; Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013; Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1; Troeger C, 2018, JAMA PEDIATR, V172, P958, DOI 10.1001/jamapediatrics.2018.1960; United Nations DoEaSAPD2, 2017, WORLD POP PROSP 2017; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664; Wong CWY, 2015, HONG KONG MED J, V21, P518, DOI 10.12809/hkmj144456; World Bank, 2019, WORLD BANK NAT ACC D; World Health Organization, 2013, 5 WHO; World Health Organization, 2017, CALC VACC VOL COLD C; World Health Organization, 2008, WHOIVB0816; Yeung KHT, 2016, VACCINE, V34, P4935, DOI 10.1016/j.vaccine.2016.08.047; Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164; Yung CF, 2015, J PEDIATR-US, V167, P163, DOI 10.1016/j.jpeds.2015.03.038	63	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2021	39	1					45	58		10.1016/j.vaccine.2020.10.052			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PI2XL	33221066	hybrid, Green Published			2022-04-29	WOS:000600959400007
J	Arevalo-Herrera, M; Miura, K; Solano, E; Ramirez, JS; Long, CA; Corradin, G; Herrera, S				Arevalo-Herrera, Myriam; Miura, Kazutoyo; Solano, Eduardo; Ramirez, Juan Sebastian; Long, Carole A.; Corradin, Giampietro; Herrera, Socrates			Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice	VACCINE			English	Article						Malaria; Plasmodium vivax; Gametocytes; Immunogenicity; Transmission blocking vaccine; Transmission Reducing Activity; Pvs48/45; Vaccines	TRANSMISSION-BLOCKING IMMUNITY; PLASMODIUM-FALCIPARUM; MALARIA; VACCINE; GAMETOCYTES; ADJUVANT; SAFETY; AREAS	Background: Pvs48/45 is a Plasmodium vivax gametocyte surface protein involved in the parasite fertilization process. Previous studies showed that Pvs48/45 proteins expressed in Escherichia coli (E. coli) and Chinese hamster ovary (CHO) cells were highly immunoreactive with sera from malariaendemic areas and highly immunogenic in animal models. Here the immunogenicity in mice of three different vaccine formulations was compared. Methods: Recombinant (r) Pvs48/45 proteins were expressed in E. coli and CHO, purified, formulated in Alhydrogel, GLA-SE and Montanide ISA-51 adjuvants and used to immunize BALB/c mice. Animals were immunized on days 0, 20 and 40, and serum samples were collected for serological analyses of specific antibody responses using ELISA and immunofluorescence (IFAT). Additionally, ex-vivo transmissionreducing activity (TRA) of sera on P. vivax gametocyte-infected human blood fed to Anopheles albimanus in direct membrane feeding assays (DMFA) was evaluated. Results: Most immunized animals seroconverted after the first immunization, and some developed antibody peaks of 10(6) with all adjuvants. However, the three adjuvant formulations induced different antibody responses and TRA efficacy. While GLA-SE formulations of both proteins induced similar antibody profiles, Montanide ISA-51 formulations resulted in higher and longer-lasting antibody titers with CHO-rPvs48/45 than with the E. coli formulation. Although the CHO protein formulated in Alhydrogel generated a high initial antibody peak, antibody responses to both proteins rapidly waned. Likewise, anti-Pvs48/45 antibodies displayed differential recognition of the parasite proteins in IFAT and ex vivo blockade of parasite transmission to mosquitoes. The CHO-rPvs48/45 formulated in Montanide ISA-51 induced the most effective ex vivo parasite blockage. Conclusions: Three out of six vaccine formulations elicited antibodies with ex vivo TRA. The CHOrPvs48/45 Montanide ISA-51 formulation induced the most stable antibody response, recognizing the native protein and the most robust ex vivo TRA. These results encourage further testing of the vaccine potential of this protein. (C) 2021 The Authors. Published by Elsevier Ltd.	[Arevalo-Herrera, Myriam; Ramirez, Juan Sebastian; Herrera, Socrates] Malaria Vaccine & Drug Dev Ctr, Carrera 37 2 Bis 5E-08, Cali, Colombia; [Arevalo-Herrera, Myriam; Solano, Eduardo; Herrera, Socrates] Caucaseco Sci Res Ctr, Cali, Colombia; [Miura, Kazutoyo; Long, Carole A.] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA; [Corradin, Giampietro] Univ Lausanne, Biochem Dept, Lausanne, Switzerland		Arevalo-Herrera, M (通讯作者)，Malaria Vaccine & Drug Dev Ctr, Carrera 37 2 Bis 5E-08, Cali, Colombia.	marevalo@inmuno.org			NIH/NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [1R01AI121237-01]; Intramural Research Program of NIAID, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)	This study was sponsored by NIH/NIAID 1R01AI121237-01 and in part by the Intramural Research Program of NIAID, NIH.	Agnandji ST, 2015, FUTURE MICROBIOL, V10, P1553, DOI 10.2217/fmb.15.90; Arevalo-Herrera M, 2005, AM J TROP MED HYG, V73, P38; Arevalo-Herrera M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.634738; Arevalo-Herrera M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119335; Boudin C, 2005, AM J TROP MED HYG, V73, P1090, DOI 10.4269/ajtmh.2005.73.1090; Castellanos A, 2016, MEM I OSWALDO CRUZ, V111, P59, DOI 10.1590/0074-02760150382; Cespedes N, 2013, VACCINE, V31, P4923, DOI 10.1016/j.vaccine.2013.05.082; Chichester JA, 2018, VACCINE, V36, P5865, DOI 10.1016/j.vaccine.2018.08.033; Chowdhury DR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006352; Coelho CH, 2019, TRENDS PARASITOL, V35, P483, DOI 10.1016/j.pt.2019.04.008; Coler RN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013677; Collins WE, 2006, AM J TROP MED HYG, V74, P215, DOI 10.4269/ajtmh.2006.74.215; Constenla D, 2015, VACCINE, V33, P1527, DOI 10.1016/j.vaccine.2015.01.059; Dhiman S, 2019, INFECT DIS POVERTY, V8, DOI 10.1186/s40249-019-0524-x; Feachem RGA, 2019, LANCET, V394, P1056, DOI 10.1016/S0140-6736(19)31139-0; Herrera S, 2011, AM J TROP MED HYG, V84, P12, DOI 10.4269/ajtmh.2011.09-0516; Ikeda M, 2018, EMERG INFECT DIS, V24, P718, DOI 10.3201/eid2404.170141; Ishino T, 2018, LANCET INFECT DIS, V18, P927, DOI 10.1016/S1473-3099(18)30358-X; Kumar R, 2015, PHARM RES-DORDR, V32, P3827, DOI 10.1007/s11095-015-1743-x; Kumar R, 2014, INFECT IMMUN, V82, P1453, DOI 10.1128/IAI.01438-13; Kurella S, 2000, Indian J Clin Biochem, V15, P83, DOI 10.1007/BF02867548; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Menon V, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01998; Miura K, 2008, VACCINE, V26, P193, DOI 10.1016/j.vaccine.2007.10.064; Miura K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69513-x; Miura K, 2016, VACCINE, V34, P4145, DOI 10.1016/j.vaccine.2016.06.066; Ndungu Francis M, 2019, Wellcome Open Res, V4, P42, DOI 10.12688/wellcomeopenres.15002.1; Oboh MA, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2305062; PETERS W, 1990, Recenti Progressi in Medicina, V81, P749; Ranson H, 2016, TRENDS PARASITOL, V32, P187, DOI 10.1016/j.pt.2015.11.010; Ritacco FV, 2018, BIOTECHNOL PROGR, V34, P1407, DOI 10.1002/btpr.2706; Sagara I, 2018, LANCET INFECT DIS, V18, P969, DOI 10.1016/S1473-3099(18)30344-X; Sinden RE, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006336; Singh M, 2002, PHARM RES-DORDR, V19, P715, DOI 10.1023/A:1016104910582; Talaat KR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163144; Vallejo AF, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1263-0; Vallejo AF, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1104-1; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; van Doorn E, 2016, HUM VACC IMMUNOTHER, V12, P159, DOI 10.1080/21645515.2015.1071455; Vera O, 2015, ANTIMICROB AGENTS CH, V59, P6638, DOI 10.1128/AAC.01136-15; WHO, TACKLING ANTIMALARIA; WHO, 2020, MAL PROGR REP; Wu YM, 2015, ADV PARASIT, V89, P109, DOI 10.1016/bs.apar.2015.04.001; Wu YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002636	44	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					133	140		10.1016/j.vaccine.2021.11.036		DEC 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FV	34802791	hybrid			2022-04-29	WOS:000731299800020
J	Esparza, J; Damaso, CR				Esparza, Jose; Damaso, Clarissa R.			Searching for the origin of the smallpox vaccine: Edward Jenner and his little-known horsepox hypothesis	VACCINE			English	Editorial Material									[Esparza, Jose] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA; [Damaso, Clarissa R.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil		Esparza, J (通讯作者)，Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.	jose.esparza@live.com			Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1216026]; Brazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Tonix Pharmaceuticals	Partially supported by a grant from the Bill & Melinda Gates Foundation (OPP1216026). C.R.D. received additional support from the Brazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Tonix Pharmaceuticals, and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ).	Baron J., 1838, LIFE EDWARD JENNER M; Brinkmann A, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02202-0; Crookshank EM, 1889, HIST PATHOLOGY VACCI; Duggan AT, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02079-z; Esparza J, 2017, VACCINE, V35, P7222, DOI 10.1016/j.vaccine.2017.11.003; Esparza J, 2013, VET REC, V173, P272, DOI 10.1136/vr.f5587; Gershon L., 2021, COMMUNICATION 0625; Jenner E., 1798, INQUIRY CAUSES EFFEC; Loy JG, 1801, ACCOUNT SOME EXPT OR; Schrick L, 2017, NEW ENGL J MED, V377, P1491, DOI 10.1056/NEJMc1707600	10	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					3	4		10.1016/j.vaccine.2021.11.007		DEC 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FV	34794823				2022-04-29	WOS:000731299800002
J	Cannon, K; Elder, C; Young, M; Scott, DA; Scully, IL; Baugher, G; Peng, YH; Jansen, KU; Gruber, WC; Watson, W				Cannon, Kevin; Elder, Charles; Young, Mariano; Scott, Daniel A.; Scully, Ingrid L.; Baugher, Gary; Peng, Yahong; Jansen, Kathrin U.; Gruber, William C.; Watson, Wendy			A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults >= 65 years of age with different prior pneumococcal vaccination	VACCINE			English	Article						Clinical trial; Immunogenicity; Pneumococcal conjugate vaccine; Safety; Streptococcus pneumoniae	POLYSACCHARIDE VACCINE; INITIAL VACCINATION; ADVISORY-COMMITTEE; INVASIVE DISEASE; IMMUNIZATION; RECOMMENDATIONS; PNEUMONIA; CHILDREN; PREVENTION; SEROTYPES	Introduction: A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to expand protection against vaccine-preventable pneumococcal disease. PCV20 contains the components of the 13-valent pneumococcal conjugate vaccine, PCV13, and includes capsular polysaccharide conjugates for 7 additional serotypes. Thus, PCV20 may cover those additional serotypes in individuals previously vaccinated with PCV13 or provide benefits of immunization with a conjugate vaccine to individuals previously immunized with a pneumococcal polysaccharide vaccine. This study described the safety and immunogenicity of PCV20 in adults >65 years of age with prior pneumococcal vaccination. Methods: This phase 3, multicenter, randomized, open-label study was conducted in the United States and Sweden. Adults >65 years of age were enrolled into 1 of 3 cohorts based on their prior pneumococcal vaccination history (23-valent pneumococcal polysaccharide vaccine [PPSV23], PCV13, or both PCV13 and PPSV23). Participants were randomized 2:1 within their cohort to receive a single dose of PCV20 or PCV13 in those with prior PPSV23 only, and PCV20 or PPSV23 in those with prior PCV13 only; all participants with prior PCV13 and PPSV23 received PCV20. Safety was assessed by prompted local reactions within 10 days, systemic events within 7 days, adverse events (AEs) within 1 month, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination. Immune responses 1 month after PCV20 were assessed. Results: The percentages of participants reporting local reactions, systemic events, and AEs after PCV20 administration were similar across cohorts and comparable with the PCV13 and PPSV23 control groups. SAE and NDCMC rates were low in all groups. Robust immune responses, including opsonophagocytic antibody responses, to the 20 vaccine serotypes were observed 1 month after PCV20 regardless of prior pneumococcal vaccination. Conclusions: PCV20 was well tolerated and immunogenic in adults >65 years of age previously vaccinated with different pneumococcal vaccine regimens. Clinicaltrials.gov NCT03835975. (c) 2021 Elsevier Ltd. All rights reserved.	[Cannon, Kevin] PMG Res Wilmington LLC, Wilmington, NC USA; [Elder, Charles] Kaiser Permanente Ctr Hlth Res, Portland, OR USA; [Young, Mariano; Scott, Daniel A.; Baugher, Gary; Peng, Yahong; Watson, Wendy] Pfizer Inc, Vaccine Res & Dev, 500 Arcola Rd, Collegeville, PA 19426 USA; [Scully, Ingrid L.; Jansen, Kathrin U.; Gruber, William C.] Pfizer Inc, Vaccine Res & Dev, Pearl River, NY USA		Young, M (通讯作者)，Pfizer Inc, Vaccine Res & Dev, 500 Arcola Rd, Collegeville, PA 19426 USA.	Mariano.Young-Jr@pfizer.com			Pfizer Inc.Pfizer	This study was sponsored by Pfizer Inc.	[Anonymous], 2019, Weekly Epidemiological Record, V94, P85; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129; [Anonymous], 2015, PNEUMOVAX 23 PNEUMOC; Balsells E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177113; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Castiglia P, 2014, ADV THER, V31, P1011, DOI 10.1007/s12325-014-0157-1; Centers for Disease Control and Prevention, 1984, MMWR RECOMM REP, V33, P273; Clutterbuck EA, 2012, J INFECT DIS, V205, P1408, DOI 10.1093/infdis/jis212; Cohen R, 2021, CLIN INFECT DIS, V72, P1453, DOI 10.1093/cid/ciaa917; Cohen R, 2017, EXPERT REV VACCINES, V16, P625, DOI 10.1080/14760584.2017.1320221; Cohen R, 2016, HUM VACC IMMUNOTHER, V12, P277, DOI 10.1080/21645515.2015.1116654; Cui YDA, 2017, HUM VACC IMMUNOTHER, V13, P1229, DOI 10.1080/21645515.2016.1277300; de Miguel S, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1483, DOI 10.1093/cid/ciaa1483]; Drijkoningen JJC, 2014, CLIN MICROBIOL INFEC, V20, P45, DOI 10.1111/1469-0691.12461; Frenck RW, 2016, VACCINE, V34, P3454, DOI 10.1016/j.vaccine.2016.04.093; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; Gierke R, 2021, CURRENT EPIDEMIOLOGY; Glesby MJ, 2015, J INFECT DIS, V212, P18, DOI 10.1093/infdis/jiu631; Greenberg RN, 2014, VACCINE, V32, P2364, DOI 10.1016/j.vaccine.2014.02.002; Hausdorff WP, 2016, HUM VACC IMMUNOTHER, V12, P358, DOI 10.1080/21645515.2015.1118593; Isturiz RE, 2019, VACCINE, V37, P3352, DOI 10.1016/j.vaccine.2019.04.087; Jackson LA, 2013, VACCINE, V31, P3594, DOI 10.1016/j.vaccine.2013.04.084; Jackson LA, 2013, VACCINE, V31, P3585, DOI 10.1016/j.vaccine.2013.05.010; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245; Kalina WV, 2020, CLIN INFECT DIS, V71, pE430, DOI 10.1093/cid/ciaa158; Lepoutre A, 2008, Euro Surveill, V13; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; McLaughlin JM, 2019, HUM VACC IMMUNOTHER, V15, P841, DOI 10.1080/21645515.2018.1564434; McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312; Metcalf BJ, 2016, CLIN MICROBIOL INFEC, V22, DOI [10.1016/j.cmi.2016.08.001, 10.1016/j.cmi.2015.08.027]; Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3; Perdrizet J, 2020, INT S PNEUM PNEUM DI; Pilishvili T, 2020, IDWEEK; Pilishvili T, 2015, VACCINE, V33, pD60, DOI 10.1016/j.vaccine.2015.05.102; Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273; Schmoele-Thoma B, 2019, HUM VACC IMMUNOTHER, V15, P575, DOI 10.1080/21645515.2018.1538618; Tomczyk S, 2016, CLIN INFECT DIS, V62, P1119, DOI 10.1093/cid/ciw067; Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1; van der Linden M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220453; van der Linden M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131494; van Deursen AMM, 2017, CLIN INFECT DIS, V65, P787, DOI 10.1093/cid/cix419; Wantuch PL, 2019, HUM VACC IMMUNOTHER, V15, P874, DOI 10.1080/21645515.2018.1564444; Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1; Yahiaoui RY, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3341-0; Zintgraff J, 2020, REV ARGENT MICROBIOL, V52, P189, DOI 10.1016/j.ram.2019.11.004	48	1	1	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7494	7502		10.1016/j.vaccine.2021.10.032		DEC 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	34839993				2022-04-29	WOS:000731300100020
J	Hoff, NA; Bratcher, A; Mukadi, P; Ahuka, S; Kabamba, M; Musene, K; Halbrook, M; Dzogong, C; Mwamba, GN; Mbala, P; Kelly, JD; Kompany, JP; Tambu, M; Kaba, D; Kebela-Ilunga, B; Muyemebe-Tamfum, JJ; Rimoin, AW				Hoff, Nicole A.; Bratcher, Anna; Mukadi, Patrick; Ahuka, Steve; Kabamba, Michel; Musene, Kamy; Halbrook, Megan; Dzogong, Camille; Mwamba, Guillaume Ngoie; Mbala, Placide; Kelly, J. Daniel; Kompany, Jean Paul; Tambu, Merly; Kaba, Didine; Kebela-Ilunga, Benoit; Muyemebe-Tamfum, Jean Jacque; Rimoin, Anne W.			Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo	VACCINE			English	Article						Ebola; Vaccination behaviors; rVSV-EBOV; Post-outbreak behaviors; Post-vaccination behaviors		Background: In 2018, the Democratic Republic of the Congo (DRC) declared its 9th and 10th Zaire ebolavirus (EBOV) outbreaks, in the Equateur province (end: July 2018), and in the eastern provinces including North Kivu (end: June 2020). The DRC Ministry of Health deployed the rVSV-vectored glycoprotein (VSVEBOV) vaccine in response during both outbreaks. Methods: A cohort of vaccinated and unvaccinated individuals from the Equateur province were enrolled and followed prospectively for 6 months. Among participants included in this analysis, 505 were vaccinated and 1,418 were unvaccinated. Differences in transmission behaviors pre- and post- outbreak were identified, along with associations between behaviors and vaccination Results: There was an overall increase in the proportion of both unvaccinated and vaccinated individuals in Mbandaka who participated in risky activities post-outbreak. Travel outside of the province preoutbreak was associated with vaccination. Post-outbreak, vaccinated individuals were less likely to participate in funeral traditions than unvaccinated individuals. Conclusion: A net increase in activities considered high risk was observed in both groups despite significant efforts to inform the population of risky behaviors. The absence of a reduction in transmission behavior post-outbreak should be considered for improving future behavior change campaigns in order to prevent recurrent outbreaks. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Hoff, Nicole A.; Bratcher, Anna; Halbrook, Megan; Rimoin, Anne W.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA; [Mukadi, Patrick; Ahuka, Steve; Musene, Kamy; Mbala, Placide; Kompany, Jean Paul; Tambu, Merly; Muyemebe-Tamfum, Jean Jacque] Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO; [Kabamba, Michel; Mwamba, Guillaume Ngoie] Natl Expanded Program Immunizat, Kinshasa, DEM REP CONGO; [Dzogong, Camille] UCLA DRC, Kinshasa, DEM REP CONGO; [Kelly, J. Daniel] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Kaba, Didine] Univ Kinshasa, Ecole Sante Publ, Kinshasa, DEM REP CONGO; [Kebela-Ilunga, Benoit] Minist Sante Publ, Direct Lutte Maladie, Kinshasa, DEM REP CONGO		Hoff, NA (通讯作者)，650 Charles E Young Dr South,Ste 41-275 CHS, Los Angeles, CA 90095 USA.	nhoff84@ucla.edu; abratcher@ucla.edu; meganhalbrook@ucla.edu; dan.kelly@ucsf.edu; didine.kaba@unikin.ac.cd; arimoin@g.ucla.edu		Halbrook, Megan/0000-0002-3892-2655; Bratcher, Anna/0000-0001-5972-1249; Hoff, Nicole/0000-0002-1770-6304; kabamba nzaji, michel/0000-0003-3843-654X; Mukadi, Patrick/0000-0001-9312-9345	Bill & Melinda Gates Founda-tion, Seattle, WABill & Melinda Gates Foundation [OPP1195609]; Faucett Cata-lyst Fund; Shaffer Family Foundation	This work was supported by the Bill & Melinda Gates Founda-tion, Seattle, WA [grant number: OPP1195609] ; The Faucett Cata-lyst Fund and the Shaffer Family Foundation. The funders did not have any role in study design, analysis and interpretation of data, writing of the report, or decision to submit for publication.	Alcayna-Stevens L, 2018, PLANNING POSTEBOLA L; Centers for Disease Control and Prevention (CDC), YEARS EB VIR DIS OUT; Cooper CL, 2015, TRENDS MICROBIOL, V23, P65, DOI 10.1016/j.tim.2014.12.005; Damon IK, 2018, NEW ENGL J MED, V379, P1981, DOI 10.1056/NEJMp1811751; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Henao-Restrepo AM, 2015, LANCET, V386, P857, DOI 10.1016/S0140-6736(15)61117-5; Kasting ML, 2016, HUM VACC IMMUNOTHER, V12, P1435, DOI 10.1080/21645515.2016.1141158; Mbala-Kingebeni P, 2021, NEW ENGL J MED, V384, P1240, DOI 10.1056/NEJMoa2024670; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Stulpin C, 2018, INFECT DIS CHILD, V31, P4; Venkatraman N, 2018, VACCINE, V36, P5454, DOI 10.1016/j.vaccine.2017.07.054; World Health Organization, 10 EB OUTBR DEM REP; World Health Organization (WHO), PREL RES EFF RVSV ZE	13	0	0	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 17	2021	39	51					7464	7469		10.1016/j.vaccine.2021.10.071		DEC 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FY	34799143	Green Published, hybrid			2022-04-29	WOS:000731300100016
J	Kitro, A; Sirikul, W; Piankusol, C; Rirermsoonthorn, P; Seesen, M; Wangsan, K; Assavanopakun, P; Surawattanasakul, V; Kosai, A; Sapbamrer, R				Kitro, Amornphat; Sirikul, Wachiranun; Piankusol, Chanodom; Rirermsoonthorn, Pawaruj; Seesen, Mathuramat; Wangsan, Kampanat; Assavanopakun, Pheerasak; Surawattanasakul, Vithawat; Kosai, Apiradee; Sapbamrer, Ratana			Acceptance, attitude, and factors affecting the intention to accept COVID-19 vaccine among Thai people and expatriates living in Thailand	VACCINE			English	Article						COVID-19; Vaccine acceptance; Thailand; Expatriate		Background: COVID-19 pandemic is a worldwide problem. Vaccination as primary prevention is necessary. Thailand is in the initial phase of the vaccination program. However, the demand for this vaccine among Thais and expatriates living in Thailand is still unknown. This study aims to assess acceptance, attitude, and determinants for COVID-19 vaccination among Thai people and expatriates living in Thailand. Methods: This was a cross-sectional study conducted in Thailand during May 2021. An online survey (REDcap) was distributed through online social media platforms. Adult (>18 years old) Thai and expatriates living in Thailand were invited. Any person who already received any COVID-19 vaccine was excluded from this study. Result: One thousand sixty-six responses were collected in this survey. A total of 959 were available for analysis. Six hundred thirty-seven 637 responses were from Thais and 322 responses from expatriates living in Thailand. The acceptance rate was significantly higher among expatriates than local people (57.8% vs 41.8%, p-value < 0.001). The acceptance rate increased up to 89.0-91.3% if they could select the vaccine brand, and 80.7-83.2% when they were recommended by the health care professionals. Both groups had a similar mean attitude score toward COVID-19 vaccination. Being Thai, health care worker, good compliance to social distancing, accepting serious side effects at level 1 per 100,000, and having a good attitude toward COVID-19 vaccination were associated with vaccine acceptance. Conclusion: Thailand's COVID-19 vaccination program could improve the acceptance rate by informing the public about vaccine efficacy, vaccine benefit, and vaccine safety. Moreover, supplying free of charge high efficacy alternative vaccines and letting all people living in Thailand make their own vaccine choices could increase the acceptance rate. (c) 2021 Elsevier Ltd. All rights reserved.	[Kitro, Amornphat; Sirikul, Wachiranun; Piankusol, Chanodom; Rirermsoonthorn, Pawaruj; Seesen, Mathuramat; Wangsan, Kampanat; Assavanopakun, Pheerasak; Surawattanasakul, Vithawat; Sapbamrer, Ratana] Chiang Mai Univ, Fac Med, Dept Community Med, Chiang Mai 50200, Chiang Mai Prov, Thailand; [Kosai, Apiradee] Chiang Mai Univ, Fac Med, Chiang Mai 50200, Chiang Mai Prov, Thailand		Sapbamrer, R (通讯作者)，Chiang Mai Univ, Fac Med, Dept Community Med, Chiang Mai 50200, Chiang Mai Prov, Thailand.	ratana.sapbamrer@cmu.ac.th		RIRERMSOONTHORN, PAWARUJ/0000-0003-0082-1645; Kitro, Amornphat/0000-0003-4435-8090; Piankusol, Chanodom/0000-0003-1616-5988; Sapbamrer, Ratana/0000-0003-0379-2798; wangsan, kampanat/0000-0002-4657-4515	Faculty of Medicine Research Fund, Chang Mai University, Chi-ang Mai province, Thailand [COM-2564-08080]	Funding Faculty of Medicine Research Fund, Chang Mai University, Chi-ang Mai province, Thailand (Grant number.COM-2564-08080) .	Al-Hanawi MK., FRONT MED, V2021, P8; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; [Anonymous], SURV REP COVID 19 VA; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Fu Chuanxi, 2020, ACCEPTANCE PREFRENCE, DOI [10.1101/2020.04.09.20060103, DOI 10.1101/2020.04.09.20060103, 0.1101/2020.04.09.2006010314]; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Larson HJ, 2020, MEASURING IMPACT EXP, V2020, DOI 10.22.20217513; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Opel DJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25672; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shaw J, 2021, CLIN INFECT DIS, V73, P1776, DOI 10.1093/cid/ciab054; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2	26	4	4	6	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 20	2021	39	52					7554	7561		10.1016/j.vaccine.2021.11.031		DEC 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XQ1EI	34819224	Green Published, Bronze			2022-04-29	WOS:000731295900006
J	Wang, W; Wang, YH; Wang, Y; Yan, F; Wang, N; Fu, CW				Wang, Wei; Wang, Yanhuan; Wang, Ying; Yan, Fei; Wang, Na; Fu, Chaowei			Vaccine bidding, procurement and distribution management practices in mainland China: A nationwide study	VACCINE			English	Article						Vaccine bidding; Vaccine procurement; Vaccine distribution; Practice; Mainland China	PROGRAM	Objective: To conduct a nationwide evaluation of vaccine bidding, procurement and distribution management for understanding and improving the current situation well in mainland China. Methods: An institution survey was carried out to collect information on tendering, procurement, distribution and related issues to vaccines by structured questionnaires administered to 31 provinces in mainland China from April to July 2019. Results: In 13 (41.9%) of 31 provinces, centralized bidding of National Immunization Program (NIP) vaccines was accomplished, and others conducted independent tendering and purchasing in 2018. For nonNIP vaccines, all provinces implemented unified bidding at the provincial level and over half (18, 58.1%) of them chose provincial public resource trading platforms, but their modes varied over provinces. Then procurement was undertaken by the district-level centers for disease control and prevention (CDC) while they were unable to choose the best option of too many vaccines targeted by the province-level CDC for local populations. The distribution modes of NIP and non-National Immunization Program (non-NIP) vaccines were similar overall in a province but very different over provinces. Main mode was that CDCs at different levels delivered about two thirds (64.5%) of NIP vaccines distribution and more than one third (35.5%) of non-NIP vaccines. Another distribution mode was occupied as fully buying the service from third parties in 3 municipalities. Some provinces mixed both modes, too. The total distribution volume of vaccines was 430.7 million doses in 2018. The top five non-NIP vaccines delivered in 2018 were human rabies vaccine, varicella vaccine, EV71 hand foot mouth disease vaccine, hepatitis B vaccine and influenza vaccine. Conclusion: The vaccine biding, procurement and distribution management varied over provinces in mainland China in 2018, especially for non-NIP vaccines. Specific policies and measures should be developed for different regions to improve the immunization management better. (c) 2021 Elsevier Ltd. All rights reserved.	[Wang, Wei; Wang, Yanhuan; Wang, Ying; Yan, Fei; Wang, Na; Fu, Chaowei] Fudan Univ, Sch Publ Hlth, NHC Key Lab Hlth Technol Assessment, Shanghai, Peoples R China		Fu, CW (通讯作者)，Fudan Univ, Sch Publ Hlth, Dept Social Med, Shanghai 200030, Peoples R China.	fcw@fudan.edu.cn			Shenzhen Sanofi-Pasteur Biolocals CO. Ltd.	This work was supported by Shenzhen Sanofi-Pasteur Biolocals CO. Ltd., which had no role on the study design, data analysis and results interpretation.	Cable J, 2020, ANN NY ACAD SCI, V1462, P14, DOI 10.1111/nyas.14235; Close RM, 2016, VACCINE, V34, P4649, DOI 10.1016/j.vaccine.2016.08.025; Danzon PM, 2011, INT J ECON BUS, V18, P239, DOI 10.1080/13571516.2011.584429; Fu C., 2021, CHINA HLTH RESOURCES, V24, P153; GAVI, 2018, CONS COUNTR TARG GAV; Gavi, GAV BUS MOD; He Q, 2020, VACCINE, V38, P6751, DOI 10.1016/j.vaccine.2020.08.039; Jiang H, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.5302; Khandaker G, 2017, COMMUN DIS INTELL, V41, pE33; Li ZQ, 2020, HUM VACC IMMUNOTHER, V16, P76, DOI 10.1080/21645515.2019.1644883; Lydon P, 2015, VACCINE, V33, P3429, DOI 10.1016/j.vaccine.2015.03.042; Meng, 2009, HLTH NEWS; Mvundura M, 2014, VACCINE, V32, P834, DOI 10.1016/j.vaccine.2013.12.029; National Institute for Health and Care Excellence, 2008, SOC VAL JUDG PRINC D; Pan JH, 2021, INNOVATION-AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100113; Parry J, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1750; Remy V, 2014, VALUE HEALTH, V17, pA450, DOI 10.1016/j.jval.2014.08.1211; Ren Q, 2009, PUBLIC HEALTH REP, V124, P745, DOI 10.1177/003335490912400517; Riewpaiboon A, 2015, PUBLIC HEALTH, V129, P899, DOI 10.1016/j.puhe.2015.04.016; Rogers B, 2010, AAOHN J, V58, P337, DOI [10.3928/08910162-20100801-03, 10.3928/08910162-20100716-02]; The Lancet, 2018, Lancet, V392, P360, DOI 10.1016/S0140-6736(18)31695-7; The State Council of China, REG MAN VACC CIRC VA; Varricchio F, 2004, PEDIATR INFECT DIS J, V23, P287, DOI 10.1097/00006454-200404000-00002; Wang K., 1999, CHINESE J EPIDEMIOL, V06, P7; Xu M, 2015, EXPERT REV VACCINES, V14, P763, DOI 10.1586/14760584.2015.1012503; Yakum Martin Ndinakie, 2015, BMC Res Notes, V8, P277, DOI 10.1186/s13104-015-1257-y; Zheng YM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3422-0; Zhuang JL, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030097	28	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 20	2021	39	52					7584	7589		10.1016/j.vaccine.2021.11.020		DEC 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1EI	34802784				2022-04-29	WOS:000731295900010
J	Rodrigues, CMC; Plotkin, SA				Rodrigues, Charlene M. C.; Plotkin, Stanley A.			The influence of interval between doses on response to vaccines Comment	VACCINE			English	Editorial Material							PNEUMOCOCCAL CONJUGATE VACCINE; AS04-ADJUVANTED VACCINE; DOSING SCHEDULES; 2-DOSE REGIMENS; 3-DOSE REGIMEN; IMMUNOGENICITY; BOOSTER; INFANTS; SAFETY; GIRLS		[Rodrigues, Charlene M. C.] Univ Oxford, Dept Zool, Oxford, England; [Rodrigues, Charlene M. C.] Great Ormond St Hosp Children NHS Fdn Trust, Dept Paediat Infect Dis, London, England; [Plotkin, Stanley A.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA		Plotkin, SA (通讯作者)，Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA.	stanley.plotkin@vaxconsult.com		Rodrigues, Charlene/0000-0003-0942-3707			Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bandyopadhyay AS, 2021, LANCET INFECT DIS, V21, P559, DOI 10.1016/S1473-3099(20)30555-7; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Bergman H, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013479; Department of Health and Social Care, 2021, OPT COVID 19 VACC PR; Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; Feng S, 2021, NAT MED, V27, P2032, DOI 10.1038/s41591-021-01540-1; Fleming-Dutra KE, 2014, PEDIATR INFECT DIS J, V33, pS152, DOI 10.1097/INF.0000000000000083; Goldblatt D, 2006, PEDIATR INFECT DIS J, V25, P312, DOI 10.1097/01.inf.0000207483.60267.e7; Graham SP, 2020, NPJ VACCINES, V5, DOI [10.1038/s41541-020-00221-3, DOI 10.1038/S41541-020-00221-3]; Horby Peter, 2021, NERVTAG NOTE B 1 1 7; Iversen OE, 2016, JAMA-J AM MED ASSOC, V316, P2411, DOI 10.1001/jama.2016.17615; Iwarson S, 2002, SCAND J INFECT DIS, V34, P110, DOI 10.1080/00365540110077362; Kandasamy R, 2019, LANCET INFECT DIS, V19, P156, DOI 10.1016/S1473-3099(18)30568-1; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lal H, 2018, VACCINE, V36, P148, DOI 10.1016/j.vaccine.2017.11.019; Landry P, 2000, VACCINE, V19, P399, DOI 10.1016/S0264-410X(00)00188-2; Lipsitch M, 2018, VACCINE, V36, P473, DOI 10.1016/j.vaccine.2017.12.015; Parry H., 2021, EXTENDED INTERVAL BN; Payne R., 2021, SUST T CELL IMM PROT; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Puthanakit T, 2016, J INFECT DIS, V214, P525, DOI 10.1093/infdis/jiw036; Romanowski B, 2011, HUM VACCINES, V7, P1374, DOI 10.4161/hv.7.12.18322; Spijkerman J, 2013, JAMA-J AM MED ASSOC, V310, P930, DOI 10.1001/jama.2013.228052; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Whitney CG, 2014, PEDIATR INFECT DIS J, V33, pS172, DOI 10.1097/INF.0000000000000076; Whitworth HS, 2021, VACCINE, V39, P871, DOI 10.1016/j.vaccine.2020.12.031; Williams J, 2000, VACCINE, V18, P1939, DOI 10.1016/S0264-410X(99)00446-6	29	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 3	2021	39	49					7123	7127		10.1016/j.vaccine.2021.10.050		NOV 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ2JG	34774357	Bronze, Green Published			2022-04-29	WOS:000726620400003
J	Netanel, C; Ben-Aharon, O; Ben-Ari, Z; Chodick, G; Anis, E; Magnezi, R				Netanel, Carmit; Ben-Aharon, Omer; Ben-Ari, Ziv; Chodick, Gabriel; Anis, Emilia; Magnezi, Racheli			Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015-2016	VACCINE			English	Article						Hepatitis B; Screening; Vaccination; Population-based study; Israel	HBSAG POSITIVE MOTHERS; COST-BENEFIT-ANALYSIS; PREGNANT-WOMEN; VIRUS INFECTION; INOCULATION PROGRAM; PREVALENCE; HBV; CARRIERS; TRANSMISSION; IMMUNIZATION	Background and Aims: Universal vaccination against hepatitis B virus (HBV) in infancy was implemented in Israel in 1992. This population-based study aimed to evaluate the coverage rate and cost-benefit of the HBV vaccination program among infants in Israel and the Hepatitis B surface antigen (HBsAg) status in their mothers. Methods: Using the database of a health maintenance organization with 2 million members, we retro-spectively identified, all the infants born in 2015-2016 and their mothers. Maternal data collected included age, ethnicity, country of birth and HBsAg status during pregnancy. HBV vaccination coverage among infants was calculated. A cost-benefit analysis of the HBV vaccination program was conducted based on the actual costs of HBV infection treatments in all HBsAg positive mothers. Results: Our cohort included 72,792 mothers who gave birth to 77,572 live infants. A total of 71,107 (97.7%) mothers were screened for HBV during pregnancy, of them 124 (0.2%), who gave birth to 132 infants were HBsAg positive. HBV vaccination coverage rates were 94%, 93% and 89%, for the first, second and third dose, respectively. Birth dose coverage of 95% among infants born to HBsAg positive mothers was significantly higher compared to HBsAg negative or unscreened mothers (p < 0.001). The percentage of HBsAg positivity among mothers who were born in Israel, the Former Soviet Union or Ethiopia, were 0.1%, 0.8% and 5%, respectively (p < 0.001). Ethnic differences were not found between HBsAg positive and HBsAg negative mothers. Calculated benefit-to-cost ratios were 1.24:1 and 4.15:1, with and without antenatal HBsAg screening, respectively. Conclusions: The Israeli vaccination program against HBV infection is epidemiologically and economically justified. High coverage rates among infants born to HBsAg positive mothers reflect very good adherence to the vaccination program and antenatal screening. Higher HBsAg positivity rates among immigrant mothers identify a high-risk population for HBV infection. (c) 2021 Elsevier Ltd. All rights reserved.	[Netanel, Carmit; Ben-Aharon, Omer; Magnezi, Racheli] Bar Ilan Univ, Dept Management, Ramat Gan, Israel; [Netanel, Carmit; Ben-Ari, Ziv] Sheba Med Ctr, Liver Dis Ctr, Tel Hashomer, Israel; [Ben-Ari, Ziv; Chodick, Gabriel] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Chodick, Gabriel] Maccabi Hlth Care Serv, Maccabi Inst Hlth Serv Res, Tel Aviv, Israel; [Anis, Emilia] Hebrew Univ Jerusalem, Hadassah Med Ctr, Braun Sch Publ Hlth & Community Med, Jerusalem, Israel; [Anis, Emilia] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel; [Anis, Emilia] Minist Hlth, Div Epidemiol, Jerusalem, Israel		Netanel, C (通讯作者)，Bar Ilan Univ, Dept Management, Ramat Gan, Israel.	carmit.netanel@sheba.health.gov.il		Ben-Aharon, Omer/0000-0001-9969-4732; Netanel, Carmit/0000-0003-1739-6382			Al Awaidy S, 2006, J INFECTION, V52, P202, DOI 10.1016/j.jinf.2005.05.006; Aljumah AA, 2019, SAUDI J GASTROENTERO, V25, P73, DOI 10.4103/sjg.SJG_421_18; Anabire NG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210365; [Anonymous], 2020, MEMBERSHIP HMOS 2018; BEASLEY RP, 1983, LANCET, V2, P1099; Boccalini S, 2013, HUM VACC IMMUNOTHER, V9, P1119, DOI 10.4161/hv.23827; BOGOMOLSKIYAHALOM V, 1991, J MED VIROL, V34, P217, DOI 10.1002/jmv.1890340404; Danziger CR, 2018, VACCINE, V36, P3717, DOI 10.1016/j.vaccine.2018.05.047; De Paschale M, 2014, J MED VIROL, V86, P1281, DOI 10.1002/jmv.23951; Denis F, 2004, EUR J EPIDEMIOL, V19, P973, DOI 10.1007/s10654-004-5755-9; Dionne-Odom J, 2016, AM J OBSTET GYNECOL, V214, P6, DOI 10.1016/j.ajog.2015.09.100; European Centre for Disease Prevention and Control, 2017, EFF COST ANT SCREEN; Furuncuoglu Y, 2016, POSTGRAD MED J, V92, P510, DOI 10.1136/postgradmedj-2015-133876; GINSBERG GM, 1992, B WORLD HEALTH ORGAN, V70, P757; GINSBERG GM, 1992, J EPIDEMIOL COMMUN H, V46, P587, DOI 10.1136/jech.46.6.587; Harder KM, 2011, VACCINE, V29, P9303, DOI 10.1016/j.vaccine.2011.10.028; Inoue T, 2016, MICROB CELL, V3, P420, DOI 10.15698/mic2016.09.527; ISACSOHN M, 1994, ISRAEL J MED SCI, V30, P368; Janahi EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087599; Keeble S, 2015, HUM VACC IMMUNOTHER, V11, P1153, DOI 10.1080/21645515.2015.1019977; Kumar M, 2012, J CLIN EXP HEPATOL, V2, P366, DOI 10.1016/j.jceh.2012.09.001; La Torre G, 2016, HUM VACC IMMUNOTHER, V12, P2299, DOI 10.1080/21645515.2016.1166328; Liu JH, 2020, ANN EPIDEMIOL, V49, P13, DOI 10.1016/j.annepidem.2020.05.011; Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1; McMahon BJ, 2009, HEPATOLOGY, V49, pS45, DOI 10.1002/hep.22898; Nelson NP, 2016, CLIN LIVER DIS, V20, P607, DOI 10.1016/j.cld.2016.06.006; Sarin SK, 2016, HEPATOL INT, V10, P1, DOI 10.1007/s12072-015-9675-4; SHOUVAL D, 1981, ISRAEL J MED SCI, V17, P407; World Health Organization, 2017, GLOB HEP REP; World Health Organization, 2015, GUIDELINES PREVENTIO; Zamir C, 1999, PEDIATR INFECT DIS J, V18, P262, DOI 10.1097/00006454-199903000-00011	31	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 26	2021	39	48					7101	7107		10.1016/j.vaccine.2021.09.072		NOV 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XB3QQ	34782158				2022-04-29	WOS:000721246800019
J	Andrade, G				Andrade, Gabriel			Covid-19 vaccine hesitancy, conspiracist beliefs, paranoid ideation and perceived ethnic discrimination in a sample of University students in Venezuela	VACCINE			English	Article						Venezuela; Covid-19; Vaccine hesitancy; Perceived ethnic discrimination	QUESTIONNAIRE; VALIDATION; RACE	Due to complex social, political and economic causes, Venezuela has encountered difficulties managing the Covid-19 pandemic. Although a vaccination program has started, it is still comparatively slow and largely inefficient. One particular challenge has been vaccine hesitancy. Venezuelan policymakers have traditionally not rendered much attention to ethnic disparities. In this study, we assess whether vaccine hesitancy varies across ethnic groups, in a sample of 273 Venezuelan university students. Results come out showing that marginalized ethnic groups in Venezuela are more prone to vaccine hesitancy, and also have greater levels of acceptance regarding conspiracy theories. Coefficients of correlation of ethnic discrimination with vaccine hesitancy and conspiracy beliefs are moderate. Coefficients of correlation of paranoid ideation with vaccine hesitancy and conspiracy beliefs are weak. This suggests that in order to successfully complete the vaccination program, policymakers in Venezuela must begin to approach racial disparities. (c) 2021 Elsevier Ltd. All rights reserved.	[Andrade, Gabriel] Ajman Univ, Ajman, U Arab Emirates		Andrade, G (通讯作者)，Ajman Univ, Ajman, U Arab Emirates.	Gabrielernesto2000@gmail.com					Abalakina-Paap M, 1999, POLIT PSYCHOL, V20, P637, DOI 10.1111/0162-895X.00160; Andrade G, 2020, MED HEALTH CARE PHIL, V23, P505, DOI 10.1007/s11019-020-09951-6; Andrade G, 2020, B LAT AM RES, V39, P500, DOI 10.1111/blar.13019; Arriola LR, 2021, J POLIT, V83, P807, DOI 10.1086/710784; Bonilla-Silva E., 2002, CRIT SOCIOL, V28, P41; Brondolo E, 2005, J APPL SOC PSYCHOL, V35, P335, DOI 10.1111/j.1559-1816.2005.tb02124.x; Brotherton R., 2015, SUSPICIOUS MINDS WHY; Brotherton R, 2015, PERS INDIV DIFFER, V80, P1, DOI 10.1016/j.paid.2015.02.011; Brotherton R, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00279; Burki T, 2020, LANCET INFECT DIS, V20, P547, DOI 10.1016/S1473-3099(20)30303-0; Carter PL, 2017, URBAN EDUC, V52, P207, DOI 10.1177/0042085916660350; Daniels JP, 2019, LANCET INFECT DIS, V19, P28, DOI 10.1016/S1473-3099(18)30745-X; Darwin H, 2011, PERS INDIV DIFFER, V50, P1289, DOI 10.1016/j.paid.2011.02.027; Davis J, 2018, EUR J SOC PSYCHOL, V48, P999, DOI 10.1002/ejsp.2531; Douglas KM, 2017, CURR DIR PSYCHOL SCI, V26, P538, DOI 10.1177/0963721417718261; Drinkwater KG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230365; Fernyhough Charles, 2008, Cogn Neuropsychiatry, V13, P233, DOI 10.1080/13546800801936516; Fox RS, 2019, INT J BEHAV MED, V26, P331, DOI 10.1007/s12529-019-09782-7; Galliford N, 2017, SCAND J PSYCHOL, V58, P422, DOI 10.1111/sjop.12382; GOERTZEL T, 1994, POLIT PSYCHOL, V15, P731, DOI 10.2307/3791630; Gott Richard, 2007, B LAT AM RES, V26, P269; Gulbas LE, 2013, QUAL HEALTH RES, V23, P326, DOI 10.1177/1049732312468335; JONES JH, 1992, HASTINGS CENT REP, V22, P38, DOI 10.2307/3562949; Kwok J, 2011, CULT DIVERS ETHN MIN, V17, P271, DOI 10.1037/a0024034; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Loyo ESL, 2021, LANCET, V397, P1806, DOI 10.1016/S0140-6736(21)00924-7; McKay R, 2006, J NERV MENT DIS, V194, P628, DOI 10.1097/01.nmd.0000231441.48007.a5; Nguyen Long H, 2021, medRxiv, DOI 10.1101/2021.02.25.21252402; Razai MS., COVID 19 VACCINE HES; Shaikh M, 2016, PSYCHIAT RES, V241, P309, DOI 10.1016/j.psychres.2016.05.006; Shapiro GK, 2016, PAPILLOMAVIRUS RES, V2, P167, DOI 10.1016/j.pvr.2016.09.001; Swami V, 2016, PSYCHIAT RES, V236, P86, DOI 10.1016/j.psychres.2015.12.027; Tomljenovic H, 2020, PSYCHOL HEALTH, V35, P538, DOI 10.1080/08870446.2019.1673894; Van Dongen JDM, 2011, PERS INDIV DIFFER, V51, P527, DOI 10.1016/j.paid.2011.05.014; Van Prooijen J. W., 2014, POWER POLITICS PARAN, DOI 10.1017/CBO9781139565417; van Prooijen JW, 2018, APPL COGNITIVE PSYCH, V32, P661, DOI 10.1002/acp.3442; Wood MJ, 2012, SOC PSYCHOL PERS SCI, V3, P767, DOI 10.1177/1948550611434786; Wright WR, 2013, CAFE CON LECHE RACE	38	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6837	6842		10.1016/j.vaccine.2021.10.037		NOV 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WY9EK	34711439	Bronze, Green Published			2022-04-29	WOS:000719580000004
J	Cappozzo, F; Dal Zotto, A; Scollo, M; Bernardini, D; Dal Zotto, AM; Bonvecchio, L; Tognetto, G; Marinangeli, S; Negrello, C; Lanza, PL; Cocco, A; Falivene, P; Vianello, L; Di Caprio, A; Gabutti, G; Saugo, M				Cappozzo, Francesco; Dal Zotto, Alessandra; Scollo, Marcello; Bernardini, Daniele; Dal Zotto, Anna Maria; Bonvecchio, Lucia; Tognetto, Gabriella; Marinangeli, Simonetta; Negrello, Chiara; Lanza, Paola; Cocco, Andrea; Falivene, Patrizia; Vianello, Liviano; Di Caprio, Antonio; Gabutti, Giovanni; Saugo, Mario			dTap vaccination uptake during pregnancy: Pregnant women-focused and health professionals-focused predictors in the Veneto Region (Italy)	VACCINE			English	Article						dTap maternal vaccination; Maternal care providers; Counselling	PERTUSSIS VACCINATION; TDAP VACCINATION; INFLUENZA; PROVIDERS; MOTHERS	Background: Despite recommendations, the uptake of dTap maternal vaccination is still low in many countries. The reasons for this must be investigated both on the patient's and the healthcare professionals' sides. Methods: A record linkage study was performed linking Birth Assitance Certificates and dTap mothers' vaccination records (5183 deliveries) to describe the influence of socioeconomical and obstetrical gynecological factors after the recommendations concerning dTap vaccination in pregnancy issued by the Italian Ministry of Health (August 2018). An interview was also administered to a subgroup of 656 new mothers on the occasion of the first vaccination of their newborns, in order to assess the dTap vaccination advice received from maternal care providers during pregnancy. A generalized linear model (binomial family, log link) was implemented to give a correct estimate of the mother's relative risk of being vaccinated. Results: Several pregnant women-focused factors are evident, but the most important ones are related to maternal care providers' practices: after mutual adjustment, the explicit advice towards dTap maternal vaccination given by the Obstetrician-Gynecologist or the Midwife is associated with a 12-fold increase in the dTap coverage. Conclusions: Multiprofessional training is essential to make Obstetricians-Gynecologists and Midwives more confident in recommending dTaP maternal immunization. (c) 2021 Elsevier Ltd. All rights reserved.	[Cappozzo, Francesco; Scollo, Marcello; Lanza, Paola; Cocco, Andrea] Obstet & Gynecol Dept, Local Hlth Unit 7, Bassano Del Grappa, Italy; [Dal Zotto, Alessandra; Bernardini, Daniele; Dal Zotto, Anna Maria; Bonvecchio, Lucia; Tognetto, Gabriella; Falivene, Patrizia; Vianello, Liviano; Saugo, Mario] Dept Prevent, Local Hlth Unit 7, Bassano Del Grappa, Italy; [Marinangeli, Simonetta; Negrello, Chiara] Family Counseling Ctr, Local Hlth Unit 7, Bassano Del Grappa, Italy; [Di Caprio, Antonio] Local Hlth Unit 7, Bassano Del Grappa, Italy; [Gabutti, Giovanni] Univ Ferrara, Dept Med Sci, Ferrara, Italy		Saugo, M (通讯作者)，Dept Prevent, Local Hlth Unit 7, Bassano Del Grappa, Italy.	mario.saugo@aulss7.veneto.it					Abu-Raya B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01282; Bert F, 2020, EUR J PUBLIC HEALTH, V30, P286, DOI 10.1093/eurpub/ckz209; Bohm S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4437-y; Bonville CA, 2015, HUM VACC IMMUNOTHER, V11, P713, DOI 10.1080/21645515.2015.1011999; Fiasca F, 2021, HUM VACC IMMUNOTHER, V17, P1136, DOI 10.1080/21645515.2020.1806673; Kilich E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234827; Krishnaswamy S, 2018, HUM VACC IMMUNOTHER, V14, P1591, DOI 10.1080/21645515.2018.1445455; Lotter K, 2018, AUST NZ J OBSTET GYN, V58, P417, DOI 10.1111/ajo.12739; Lumley T., 2006, RELATIVE RISK REGRES; Maertens K, 2018, VACCINE, V36, P2687, DOI 10.1016/j.vaccine.2018.03.033; Mak DB, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2051-3; Marchetti F, 2021, J MATERN-FETAL NEO M, V34, P2132, DOI 10.1080/14767058.2019.1659240; Vilca LM, 2018, VACCINE, V36, P5379, DOI 10.1016/j.vaccine.2017.08.017; Mazzilli S, 2021, HUM VACC IMMUNOTHER, V17, P1681, DOI 10.1080/21645515.2020.1833580; Merdrignac L, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.4.1900762; Mohammed H, 2020, VACCINE, V38, P3358, DOI 10.1016/j.vaccine.2020.02.020; Public Health England, 2021, HLTH PROTECTION REPO, V15; Razzaghi H, 2020, MMWR-MORBID MORTAL W, V69, P1391, DOI 10.15585/mmwr.mm6939a2; Regione Toscana, SCHEM ACC REG CON ME; SIGO SItI SIP SIN SIAIP FIMP SIICA SIMIT AMD FIMMG SIMG SID, POS PAP NUOV SFID NE; VV AA., 2019, JPMH, V60, P328; Wilcox CR, 2019, PEDIATR INFECT DIS J, V38, P625, DOI 10.1097/INF.0000000000002242; Wiley K, 2017, AUST PRESCR, V40, P122, DOI 10.18773/austprescr.2017.046; Winslade CG, 2017, PUBLIC HEALTH, V146, P10, DOI 10.1016/j.puhe.2016.12.018	24	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6913	6919		10.1016/j.vaccine.2021.10.012		NOV 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34711438				2022-04-29	WOS:000719580000014
J	Mogekwu, FI; Oteri, JA; Nsubuga, P; Ezebilo, O; Maxwell, N; Wiwa, O; Braka, F; Shuaib, F				Mogekwu, Fred Ikechukwu; Oteri, Joseph A.; Nsubuga, Peter; Ezebilo, Obiora; Maxwell, Nikki; Wiwa, Owens; Braka, Fiona; Shuaib, Faisal			Using data to improve outcomes of supplemental immunisation activities: 2017/2018 Nigeria measles vaccination campaign	VACCINE			English	Article						Data; Action; Micro planning; Verification; Checklist; Implementation		Background: Despite the enormous resources committed to the implementation of supplemental immunisation activities in Nigeria, achieving the required coverage (post-campaign survey) to halt the transmission of vaccine-preventable diseases has continued to seem like an impossibility. A vast volume of data is generated and transmitted during mass vaccination campaigns, but this administrative data does not always culminate into improved coverage. The absence of data-informed guidance from stakeholders with long years of experience in planning and implementing mass vaccination campaigns has impeded achieving 95% coverage in measles campaigns in Nigeria. This study reviews the use of data to guide the implementation of the 2017/2018 measles vaccination campaign in Nigeria. Methods: A central coordinating body was formed at the national level with the same replicated in every state. Tools were developed to measure the performance of the different phases and activities required for the implementation of a mass vaccination campaign as recommended in the international guidelines. Stakeholders were engaged to help ensure that feedback provided by the national measles technical coordinating committee was implemented at the lower level. Results: Monitoring and analysis of daily data submission caused a proper spread of senior supervisors, vaccination posts location during the campaign and helped identify areas targeted for mop-up. Although the verification of states' microplan increased the operational target population by 11.2%, the process aided the distribution of resources as appropriate. Maps showing the likely areas that needed additional effort to achieve required coverage with recommendation on the necessary approach to be deployed were transmitted to the states implementing the campaign. Conclusion: The improvement in the use of data to guide implementation of the Nigeria 2017/2018 measles vaccination campaign caused an increase in the number of states that achieved higher coverage in the post-campaign coverage survey. (C) 2021 World Health Organization. Published by Elsevier Ltd.	[Mogekwu, Fred Ikechukwu; Oteri, Joseph A.; Shuaib, Faisal] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria; [Nsubuga, Peter] Global Publ Hlth Solut, Atlanta, GA USA; [Ezebilo, Obiora] United Nations Childrens Fund, Country Off, Abuja, Nigeria; [Maxwell, Nikki] US Ctr Dis Prevent & Control, Atlanta, GA USA; [Wiwa, Owens] Clinton Hlth Access Initiat, Abuja, Nigeria; [Braka, Fiona] WHO, Country Off, Abuja, Nigeria		Mogekwu, FI (通讯作者)，Plot 130,Cadastral Zone 07-07,Lugbe 1, Abuja, Nigeria.	ikjim@yahoo.com			World Health Organization Country Office in Nigeria	This supplement was sponsored by the World Health Organization Country Office in Nigeria. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors.	[Anonymous], 2016, PLANNING IMPLEMENTIN; Bhatti UA, 2018, HUM VACC IMMUNOTHER, V14, P165, DOI 10.1080/21645515.2017.1379639; Bosch-Capblanch X, 2009, TROP MED INT HEALTH, V14, P2, DOI 10.1111/j.1365-3156.2008.02181.x; Committee NMTC, 2017, FIELD GUID 2017 2018, P1; Danovaro-Holliday MC, 2018, VACCINE, V36, P5150, DOI 10.1016/j.vaccine.2018.07.019; Duclos P, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S2; Gvap WHO, 2013, WHO LIB CAT DATA, P8; Iyal HA, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6192-0; Kamadjeu Raoul, 2017, Pan Afr Med J, V27, P22, DOI 10.11604/pamj.supp.2017.27.3.11062; Marshall A, 2013, MEAS EVAL SPEC REP, P1; Oh David H, 2016, MMWR Morb Mortal Wkly Rep, V65, P1072, DOI 10.15585/mmwr.mm6539a5; Orenstein WA, MEASLES RUBELLA GLOB; Orenstein WA, MEASLES RUBELLA GLOB; Portnoy A, 2018, VACCINE, V36, P170, DOI 10.1016/j.vaccine.2017.10.080; Raja A, 2014, Online J Public Health Inform, V5, P228, DOI 10.5210/ojphi.v5i3.4996; Smith M, 2018, J AM MED INFORM ASSN, V25, P224, DOI 10.1093/jamia/ocx078; Tegegne SG, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6189-8; Theron G, 2015, LANCET, V386, P2324, DOI 10.1016/S0140-6736(15)00321-9; Vaccine G., PLAN STRATEGIC OBJEC; Wagenaar BH, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2661-x; Williams-Roberts H, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0903-0; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	22	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 17	2021	39			3			C38	C45		10.1016/j.vaccine.2020.12.065		NOV 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WZ1KH	33461831	hybrid			2022-04-29	WOS:000719731500006
J	Oteri, AJ; Adamu, U; Dieng, B; Bawa, S; Terna, N; Nsubuga, P; Owoaje, ET; Kassogue, M; Baptiste, AEJ; Braka, F; Shuaib, F				Oteri, Avuwa Joseph; Adamu, Usman; Dieng, Boubacar; Bawa, Samuel; Terna, Nomhwange; Nsubuga, Peter; Owoaje, Eme T.; Kassogue, Modibo; Baptiste, Anne Eudes Jean; Braka, Fiona; Shuaib, Faisal			Nigeria experience on the use of polio assets for the 2017/18 measles vaccination campaign follow-up	VACCINE			English	Article						Polio; Legacy; Measles vaccination campaign; Nigeria	IMMUNIZATION ACTIVITIES; ERADICATION; PROGRESS	Background: The global polio eradication initiative has made giant stride by achieving a 99% reduction in Wild poliovirus (WPV) cases, with Nigeria on the verge of being declared polio-free following over 36 months without a WPV. The initiative has provided multiple resources, assets and lessons learnt that could be transitioned to other public health challenges, including improving the quality and vaccination coverage of measles campaigns in order to reduce the incidences of measles in Nigeria. We documented the polio legacy and assets used to support the national measles campaign in 2017/2018. Methods: We documented the integration of the measles campaign coordination with the Polio Emergency Operation Centre (EOC) at national and state levels for planning and implementing the measles SIA. Specific polio strategies and assets, such as the EOC incident command framework and facilities, human resource surge capacity, polio GIS resource These strategies were adapted and adopted for the MVC implementation overcome challenges and improve vaccination coverage. We evaluated the performance through a set process and outcome indicators. Results: All the 36 states and Federal Capital Territory used the structure and resources in Nigeria and provided counterpart financing for the MVC 2017/ 2018. The 11 polio high-risk states deployed the use of GIS for microplanning process, while daily call-in data were tracked in 99.7% of the LGAs and 70,846 reports were submitted real-time by supervisors using Open data kit (ODK). The national coverage achieved was 87.5% by the post-campaign survey with 65% of states reporting higher coverage in 2018 compared to 2015. Conclusion: Polio eradication assets and lessons learned can be applied to measles elimination efforts as the eradication and elimination efforts have similar strategies and programme implementation infrastructure needs. Leveraging these strategies and resources to support MVC planning and implementation resulted in more realistic planning, improved accountability and availability of human and fiscal resources. This approach may have resulted in better MVC outcomes and contributed to Nigeria's efforts in measles control and elimination. (C) 2021 World Health Organization. Published by Elsevier Ltd.	[Oteri, Avuwa Joseph; Adamu, Usman; Shuaib, Faisal] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria; [Dieng, Boubacar] Global Alliance Vaccines & Immunisat, Abuja, Nigeria; [Bawa, Samuel; Terna, Nomhwange; Baptiste, Anne Eudes Jean; Braka, Fiona] WHO, Country Off, Abuja, Nigeria; [Nsubuga, Peter] Global Publ Hlth Solut, Atlanta, GA USA; [Owoaje, Eme T.] Univ Ibadan, Coll Med, Ibadan, Nigeria; [Kassogue, Modibo] United Nations Childrens Fund, Country Off, Abuja, Nigeria		Oteri, AJ (通讯作者)，Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria.; Bawa, S; Terna, N (通讯作者)，WHO, Country Off, Abuja, Nigeria.	joseph.oteri@nphcda.gov.ng; bawasa@who.int; nomhwanget@who.int		Nomhwange, Terna/0000-0002-1563-4351	World Health Organization Country Office in Nigeria	This supplement was sponsored by the World Health Organization Country Office in Nigeria. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors.	Barau I, 2014, J INFECT DIS, V210, pS102, DOI 10.1093/infdis/jiu010; Cochi SL, 2016, HEALTH AFFAIR, V35, P277, DOI 10.1377/hlthaff.2015.1104; Craig AS, 2017, J INFECT DIS, V216, pS343, DOI 10.1093/infdis/jix034; Gali E, 2016, J INFECT DIS, V213, pS73, DOI 10.1093/infdis/jiv589; Global Polio Eradication Initiative, HIST POL GPEI; Global Polio Eradication Initiative, 2013, POL ER ENDG STRAT PL, P1; Global Polio Eradication Initiative, 2017, NIG GPEI; Goodson JL, 2017, EXPERT REV VACCINES, V16, P1203, DOI 10.1080/14760584.2017.1393337; Independent Monitoring Board of the Global Polio Eradication Initiative, 2018, REV POL END COUNTR; Jegede AS, 2007, PLOS MED, V4, P417, DOI 10.1371/journal.pmed.0040073; Matlin SA, 2017, GLOBAL POLIO ERADICA; Minor PD, 2004, NAT REV MICROBIOL, V2, P473, DOI 10.1038/nrmicro906; Olufowote JO, 2011, HEALTH COMMUN, V26, P743, DOI 10.1080/10410236.2011.566830; Polio Partners Group GPEI, POSTC STRAT PCS UPD; Portnoy A, 2018, VACCINE, V36, P170, DOI 10.1016/j.vaccine.2017.10.080; Rutter PD, 2017, J INFECT DIS, V216, pS287, DOI 10.1093/infdis/jix026; Sutter PW, 2001, INFECT DIS CLIN N AM, V15, P41, DOI 10.1016/S0891-5520(05)70267-1; Tebbens RJD, 2010, VACCINE, V29, P334, DOI 10.1016/j.vaccine.2010.10.026; Tegegne SG, 2016, J INFECT DIS, V213, pS96, DOI 10.1093/infdis/jiv492; The Global Polio Eradication Initiative, 2017, ASS MAPP DAT OV JUL; The Global Polio Eradication Initiative, 1985, CONTR PLEDG GLOB POL; Touray K, 2016, J INFECT DIS, V213, pS67, DOI 10.1093/infdis/jiv493; Utazi CE, 2020, VACCINE, V38, P3062, DOI 10.1016/j.vaccine.2020.02.070; Vaz RG, 2016, J INFECT DIS, V213, pS140, DOI 10.1093/infdis/jiv581; World Health Organization, 2013, GLOB VACC ACT PLAN G; World Health Organization, 2012, GLOB MEASL RUB STRAT; World Health Organization, NIG WHO UNICEF EST I; Yehualashet YG, 2016, J INFECT DIS, V213, pS116, DOI 10.1093/infdis/jiv494	28	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 17	2021	39			3			C3	C11		10.1016/j.vaccine.2021.04.040		NOV 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WZ1KH	33962837	hybrid			2022-04-29	WOS:000719731500002
J	Moore, AK; Ostrowsky, TJ; Kraigsley, MA; Mehr, AJ; Bresee, JS; Friede, MH; Gellin, GB; Golding, JP; Hart, PJ; Moen, A; Weller, CL; Osterholm, MT; Barclay, W; Cavaleri, M; Cohen, C; Cowling, B; Cox, R; Gust, I; Innis, B; Kang, GD; Katz, J; Krammer, F; Pitisuttithum, P; Posts, D; Rudenko, L; Siqueira, M; Weir, J				Moore, A. Kristine; Ostrowsky, T. Julia; Kraigsley, M. Alison; Mehr, Angela J.; Bresee, Joseph S.; Friede, Martin H.; Gellin, Bruce G.; Golding, Josephine P.; Hart, Peter J.; Moen, Ann; Weller, Charlotte L.; Osterholm, Michael T.; Barclay, Wendy; Cavaleri, Marco; Cohen, Cheryl; Cowling, Benjamin; Cox, Rebecca; Gust, Ian; Innis, Bruce; Kang, Gagandeep; Katz, Jacqueline; Krammer, Florian; Pitisuttithum, Punnee; Posts, Diane; Rudenko, Larisa; Siqueira, Marilda; Weir, Jerry		Influenza Vaccines R D Roadmap Tas	A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future	VACCINE			English	Review						Seasonal influenza vaccines; Universal influenza vaccines; Broadly protective influenza vaccines; Roadmap; Influenza; Pandemic preparedness	VIRAL CHALLENGE MODEL; HEMAGGLUTININ STALK; IMMUNE HISTORY; VIRUS VACCINES; ANIMAL-MODELS; UNIVERSAL; LESSONS; DESIGN; VACCINATION; PROTECTION	Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report sum-marizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Moore, A. Kristine; Ostrowsky, T. Julia; Kraigsley, M. Alison; Mehr, Angela J.; Osterholm, Michael T.] Univ Minnesota, Ctr Infect Dis Res & Policy, Minneapolis, MN 55455 USA; [Moore, A. Kristine] Ctr Infect Dis Res & Policy, C315 Mayo Mem Bldg,MMC 263,420 Delaware St, Minneapolis, MN 55455 USA; [Bresee, Joseph S.] Task Force Global Hlth, Univ Influenza Vaccine Dev, Global Funders Consortium, Atlanta, GA USA; [Bresee, Joseph S.] US Ctr Dis Control & Prevent, Atlanta, GA USA; [Friede, Martin H.; Moen, Ann] World Hlth Org, Geneva, Switzerland; [Gellin, Bruce G.] Sabin Vaccine Inst, Washington, DC USA; [Golding, Josephine P.; Hart, Peter J.; Moen, Ann; Osterholm, Michael T.] Wellcome Trust Res Labs, London, England; [Influenza Vaccines R D Roadmap Tas] Univ Ghana, Accra, Ghana; [Barclay, Wendy] Imperial Coll London, London, England; [Cavaleri, Marco] European Med Agcy, Amsterdam, Netherlands; [Cohen, Cheryl] Natl Inst Communicable Dis, Johannesburg, South Africa; [Cavaleri, Marco] Univ Witwatersrand, Johannesburg, South Africa; [Cowling, Benjamin] Univ Hong Kong, Hong Kong, Peoples R China; [Cox, Rebecca] Univ Bergen, Bergen, Norway; [Gust, Ian] Univ Melbourne, Melbourne, Vic, Australia; [Innis, Bruce] PATH Ctr Vaccine Innovat Access, Washington, DC USA; [Kang, Gagandeep] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; [Katz, Jacqueline] US Ctr Dis Control Prevent Retired, Atlanta, GA USA; [Krammer, Florian] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Pitisuttithum, Punnee] Mahidol Univ, Bangkok, Thailand; [Posts, Diane] NIH, Bldg 10, Bethesda, MD 20892 USA; [Rudenko, Larisa] Inst Expt Med, St Petersburg, Russia; [Siqueira, Marilda] Oswaldo Cruz Fdn FIOCRUZ, Rio De Janeiro, Brazil; [Weir, Jerry] Food & Drug Adm, Silver Spring, MD USA		Moore, AK (通讯作者)，Univ Minnesota, Ctr Infect Dis Res & Policy, Minneapolis, MN 55455 USA.; Moore, AK (通讯作者)，Ctr Infect Dis Res & Policy, C315 Mayo Mem Bldg,MMC 263,420 Delaware St, Minneapolis, MN 55455 USA.	kamoore@umn.edu		Barclay, Wendy/0000-0002-3948-0895; Ostrowsky, Julia/0000-0001-7473-2464	Wellcome TrustWellcome TrustEuropean Commission	The work for this project was completed with generous support from the Wellcome Trust.	Agor JK, 2018, HUM VACC IMMUNOTHER, V14, P678, DOI 10.1080/21645515.2017.1423152; Allen JD, 2018, HUM VACC IMMUNOTHER, V14, P1840, DOI 10.1080/21645515.2018.1462639; Amitai A, 2020, CELL SYST, V11, P573, DOI 10.1016/j.cels.2020.09.005; Ampofo WK, 2012, INFLUENZA OTHER RESP, V6, P142, DOI 10.1111/j.1750-2659.2011.00277.x; Angeletti D, 2019, P NATL ACAD SCI USA, V116, P13474, DOI 10.1073/pnas.1816300116; Arevalo CP, 2020, P NATL ACAD SCI USA, V117, P17221, DOI 10.1073/pnas.1920321117; Bajic G, 2019, CELL HOST MICROBE, V25, P827, DOI 10.1016/j.chom.2019.04.003; Bartley JM, 2021, IMMUNOL INVEST, V50, P810, DOI 10.1080/08820139.2021.1909617; Baselga-Moreno V, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6713-5; Belongia EA, 2017, EXPERT REV VACCINES, V16, P723, DOI 10.1080/14760584.2017.1334554; Bill and Melinda Gates Foundation, 2018, END PAND THREAT GRAN; Billington J, 2020, HEALTH SECUR, V18, P241, DOI 10.1089/hs.2020.0043; Bouvier NM, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030058; Bresee JS, 2019, VACCINE, V37, P211, DOI 10.1016/j.vaccine.2018.11.037; Broadbent AJ, 2011, CURR OPIN VIROL, V1, P254, DOI 10.1016/j.coviro.2011.08.002; Broutet N, 2014, VACCINE, V32, P1630, DOI 10.1016/j.vaccine.2014.01.053; Burton DR, 2021, NATURE, V590, P386, DOI 10.1038/d41586-021-00340-4; Calzas C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01605; CDC, 2019, CDC SEAS FLU VACC EF; CDC, 2020, SEL VIR SEAS FLU VAC; CEPI, CEPI NEW VACC SAF WO; Cobey S, 2017, CURR OPIN VIROL, V22, P105, DOI 10.1016/j.coviro.2016.12.004; Cortese M, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a038596; Coughlan L, 2018, CELL HOST MICROBE, V24, P18, DOI 10.1016/j.chom.2018.06.016; Crank MC, 2019, J INFECT DIS, V219, pS107, DOI 10.1093/infdis/jiz043; D'Alessio F, 2018, VACCINE, V36, P6895, DOI 10.1016/j.vaccine.2018.10.024; De Jong NMC, 2020, EXPERT REV VACCINES, V19, P563, DOI 10.1080/14760584.2020.1777861; Dhakal S, 2019, J VIROL, V93, DOI 10.1128/JVI.00797-19; Eichelberger MC, 2019, J INFECT DIS, V219, pS75, DOI 10.1093/infdis/jiz017; Epstein SL, 2018, AM J EPIDEMIOL, V187, P2603, DOI 10.1093/aje/kwy145; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; European External Action Service (EEAS), NEXT GEN INFL VACC P; Gessner BD, 2017, VACCINE, V35, P6255, DOI 10.1016/j.vaccine.2017.09.048; Gianchecchi E, 2019, HUM VACC IMMUNOTHER, V15, P1021, DOI 10.1080/21645515.2019.1565269; GISAID, GISAID MISS 2021; Giurgea LT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030409; Global Funders Consortium for Universal Influenza Vaccine Development, 2017, M REP NOV 2 3; Guthmiller JJ, 2018, CURR OPIN IMMUNOL, V53, P187, DOI 10.1016/j.coi.2018.05.010; Harding AT, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020019; Henry C, 2018, TRENDS IMMUNOL, V39, P70, DOI 10.1016/j.it.2017.08.003; Hughes MM, 2020, CLIN INFECT DIS, V70, P2496, DOI 10.1093/cid/ciz676; Imperial College London, IMPERIAL NEWS; Innis BL, 2019, VACCINE, V37, P4830, DOI 10.1016/j.vaccine.2019.06.053; Innis BL, 2019, VACCINE, V37, P4823, DOI 10.1016/j.vaccine.2019.06.080; International Energy Agency, 2014, ENERGY TECHNOLOGY RO; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; IVR Roadmap Development Team, INFL VACC R D ROADM; Jang YH, 2020, EXPERT OPIN DRUG DIS, V15, P1441, DOI 10.1080/17460441.2020.1801629; Jansen JM, 2019, J CLIN VIROL, V119, P44, DOI 10.1016/j.jcv.2019.08.009; Jorquera PA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39276-1; Kanekiyo M, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a038448; Kanekiyo M, 2019, J INFECT DIS, V219, pS88, DOI 10.1093/infdis/jiy745; Kim SS, 2021, CLIN INFECT DIS, V73, P497, DOI 10.1093/cid/ciaa706; Krammer F, 2020, INFLUENZA OTHER RESP, V14, P237, DOI 10.1111/irv.12706; Krammer F, 2019, J INFECT DIS, V219, pS62, DOI 10.1093/infdis/jiy711; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Krammer F, 2018, MBIO, V9, DOI 10.1128/mBio.02332-17; Kumar A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00600; Lane MC, 2020, VACCINE, V38, P2751, DOI 10.1016/j.vaccine.2020.01.101; Li ZF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020075; Lim WW, 2020, AM J EPIDEMIOL, V189, P185, DOI 10.1093/aje/kwz227; Linderman SL, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a040964; Lopez CE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030434; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Madsen A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030361; Margine I, 2014, PATHOGENS, V3, P845, DOI 10.3390/pathogens3040845; Mathew NR, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02997; McMillan CLD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010026; Mihigo R, 2012, J INFECT DIS, V206, pS22, DOI 10.1093/infdis/jis535; Moderna, 2021, MOD PROV BUS UPD ANN; Morens DM, 2019, J INFECT DIS, V219, pS5, DOI 10.1093/infdis/jiy728; Navarro-Torne Adoracion, 2019, Emerg Infect Dis, V25, DOI 10.3201/eid2502.180359; Novavax, 2020, NOV APP LEAD TEAM AD; Ortiz JR, 2019, J INFECT DIS, V219, pS97, DOI 10.1093/infdis/jiz024; Plotkin SA, 2018, J PEDIAT INF DIS SOC, V7, P178, DOI 10.1093/jpids/piy057; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Porter RM, 2020, VACCINE, V38, P1152, DOI 10.1016/j.vaccine.2019.11.025; Ranjeva S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09652-6; Rappuoli R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2888; Reber A, 2013, EXPERT REV VACCINES, V12, P519, DOI [10.1586/erv.13.35, 10.1586/ERV.13.35]; Richards KA, 2020, J INFECT DIS, V222, P273, DOI 10.1093/infdis/jiz433; Robinson JC, 2021, JAMA-J AM MED ASSOC, V325, P825, DOI 10.1001/jama.2020.25384; Rockman S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111745; Ropero-Alvarez AM, 2012, VACCINE, V30, P916, DOI 10.1016/j.vaccine.2011.11.092; Rosa SS, 2021, VACCINE, V39, P2190, DOI 10.1016/j.vaccine.2021.03.038; Sabin-Aspen Vaccine Science Policy Group, 2019, ACC DEV UN INFL VACC; Secretariat for the Convention on Biological Diversity, NAG PROT ACC BEN SHA; Sparrow E, 2021, VACCINE, V39, P512, DOI 10.1016/j.vaccine.2020.12.018; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Topham DJ, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a038729; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; University of Oxford, HUM CHALL TRIAL LAUN; Viboud C, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008583; Wei CJ, 2020, NAT REV DRUG DISCOV, V19, P239, DOI 10.1038/s41573-019-0056-x; World Health Organization, 2017, WHO PREF PROD CHAR N; World Health Organization (WHO), 2019, GLOB INFL STRAT 2019; Worobey M, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a038471; Wraith S, 2020, VACCINE, V38, P4221, DOI 10.1016/j.vaccine.2020.04.069; Yamayoshi S, 2019, NAT MED, V25, P212, DOI 10.1038/s41591-018-0340-z; Zhu WD, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010068; Zost SJ, 2019, J INFECT DIS, V219, pS38, DOI 10.1093/infdis/jiy696; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	102	3	3	15	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6573	6584		10.1016/j.vaccine.2021.08.010		OCT 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34602302	Green Published, hybrid			2022-04-29	WOS:000708078600003
J	Ozawa, S; Chen, HH; Rao, GG; Eguale, T; Stringer, A				Ozawa, Sachiko; Chen, Hui-Han; Rao, Gauri G.; Eguale, Tadesse; Stringer, Andrew			Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia	VACCINE			English	Article						Vaccination; Immunization; Antimicrobial resistance; Pneumonia; Ethiopia	STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; ANTIBIOTIC USE; RESPIRATORY-INFECTIONS; GLOBAL BURDEN; DISEASE; PHARMACOKINETICS; CHILDREN; IMPACT; AMOXICILLIN	Background: Antimicrobial resistance (AMR) poses an imminent threat to global health security. Pneumococcal vaccination reduces disease incidence, prevents antibiotic use, and decreases antibiotic resistant infections. However, the benefit of vaccination in reducing AMR has been poorly quantified to date. Methods: We developed an agent-based model, DREAMR (Dynamic Representation of the Economics of AMR) to evaluate the economic value of childhood immunization with the pneumococcal conjugate vaccine (PCV) in mitigating the development of AMR. Our model incorporates vaccination coverage, disease incidence, care seeking, and antibiotic use. Accumulation of AMR is simulated based on antibiotic exposure through pharmacokinetics and resulting pharmacodynamics. The model was applied to Ethiopia. Results: Introduction of PCV vaccination has helped slow the development of AMR by 14.77% for amoxicillin and 0.59% for ceftriaxone in Ethiopia since 2011. In addition to the benefit of reduction in disease incidence, PCV vaccination has averted approximately 718,100 antibiotic treatment failures and 9,520 AMR-related deaths (27.8% reduction) in Ethiopia between 2011 and 2017, resulting in savings of $32.7 million. Maintaining current PCV immunization coverage will contribute an additional $7.67 million in annual AMR cost savings over five years compared to no vaccination scenario, which could increase to $11.43 million by increasing PCV coverage to 85% by 2022. Conclusions: This study is the first to demonstrate the broader economic value of pneumococcal vaccination in controlling the development of AMR in Africa. Vaccination not only saves lives by preventing illnesses, but also benefits society by reducing antibiotic utilization and treatment failures due to AMR. (c) 2021 Elsevier Ltd. All rights reserved.	[Ozawa, Sachiko; Chen, Hui-Han] Univ N Carolina, Div Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC 27599 USA; [Ozawa, Sachiko] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27599 USA; [Rao, Gauri G.] Univ N Carolina, UNC Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27599 USA; [Eguale, Tadesse] Addis Ababa Univ, Aklilu Lemma Inst Pathobiol, Addis Ababa, Ethiopia; [Stringer, Andrew] North Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC USA		Ozawa, S (通讯作者)，Univ N Carolina, Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, CB 7574,Beard Hall 115G, Chapel Hill, NC 27599 USA.	ozawa@unc.edu	Chen, Hui-Han/AAY-4928-2020; Ozawa, Sachiko/D-4399-2014	Chen, Hui-Han/0000-0002-7169-4404; Ozawa, Sachiko/0000-0001-7608-9038; Stringer, Andrew/0000-0003-0052-3939			American Academy of Pediatrics, 2015, RED BOOK 2015 REPORT; Anagaw Belay, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P536, DOI 10.1016/S2221-1691(13)60109-4; Arditi M, 1998, PEDIATRICS, V102, P1087, DOI 10.1542/peds.102.5.1087; Barbosa TM, 2000, DRUG RESIST UPDATE, V3, P303, DOI 10.1054/drup.2000.0167; Barghouthi Achalu T, 2017, J ANTIBIO RES, V1, P106; Baxter Healthcare Corporation, 2016, PEN G POT PEN INJ SO; Blank PR, 2012, VACCINE, V30, P4267, DOI 10.1016/j.vaccine.2012.04.028; Bloom DE, 2018, P NATL ACAD SCI USA, V115, P12868, DOI 10.1073/pnas.1717157115; Bloom DE, 2017, VACCINE, V35, pA29, DOI 10.1016/j.vaccine.2016.12.001; BOLME P, 1995, PHARMACOL TOXICOL, V76, P259, DOI 10.1111/j.1600-0773.1995.tb00140.x; Bradley JS, 2011, CLIN INF DIS PUB INF, V53, P25; Briggs A, 2006, DECISION MODELLING H; Callaway E, 2014, NATURE, V512, P14, DOI 10.1038/512014a; Center for Disease Dynamics Economics & Policy, 2015, RESISTANCEMAP; Central Statistical Agency (CSA) [Ethiopia] and ICF, 2016, ETH DEM HLTH SURV 20; Chen HH, 2019, AM J TROP MED HYG, V101, P1042, DOI 10.4269/ajtmh.18-0930; Clinical and Laboratory Standards Institute, 2015, PERFORMANCE STANDARD; CRAIG WA, 1995, DIAGN MICR INFEC DIS, V22, P89, DOI 10.1016/0732-8893(95)00053-D; Dagan R, 2001, PEDIATR INFECT DIS J, V20, P951, DOI 10.1097/00006454-200110000-00008; FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121; Fireman B, 2003, PEDIATR INFECT DIS J, V22, P10, DOI 10.1097/00006454-200301000-00006; Gandra S, 2014, CLIN MICROBIOL INFEC, V20, P973, DOI 10.1111/1469-0691.12798; Gavi, 2020, VACC ALL STRAT 2021; Gebeyehu E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138179; Gebre T, 2017, CHILDREN-BASEL, V4, DOI 10.3390/children4040027; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Grimm V, 2006, ECOL MODEL, V198, P115, DOI 10.1016/j.ecolmodel.2006.04.023; Hackl J, 2019, FUTURE INTERNET, V11, DOI 10.3390/fi11040092; Hammitt LL, 2019, LANCET, V393, P2146, DOI 10.1016/S0140-6736(18)33005-8; Hampton LM, 2012, J INFECT DIS, V205, P401, DOI 10.1093/infdis/jir755; Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598; HODGSON TA, 1982, MILBANK FUND Q, V60, P429, DOI 10.2307/3349801; Howitz MF, 2017, VACCINE, V35, P5858, DOI 10.1016/j.vaccine.2017.09.006; HUMPHREY J H, 1953, Bull World Health Organ, V9, P15; Jansen KU, 2018, HUM VACC IMMUNOTHER, V14, P2142, DOI 10.1080/21645515.2018.1476814; Jit M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0446-9; Kayange N, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-39; Kuti JL., 2016, REV MED CLIN CONDES, V27, P615, DOI 10.1016/j.rmclc.2016.08.001; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; Laxminarayan R, 2016, SCIENCE, V353, P874, DOI 10.1126/science.aaf9286; Laxminarayan R, 2016, LANCET, V387, P168, DOI 10.1016/S0140-6736(15)00474-2; Le Saux N, 2005, CAN MED ASSOC J, V172, P335, DOI 10.1503/cmaj.1040771; Levison ME, 2009, INFECT DIS CLIN N AM, V23, P791, DOI 10.1016/j.idc.2009.06.008; Lewnard JA, 2020, NATURE, V581, P94, DOI 10.1038/s41586-020-2238-4; Lipsitch M, 2016, MBIO, V7, DOI 10.1128/mBio.00428-16; Lu E, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2004933118; Memirie ST, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000166; Mera R, 2008, MICROB DRUG RESIST, V14, P101, DOI 10.1089/mdr.2008.0782; Monasta L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036226; Moore MR, 2016, LANCET RESP MED, V4, P399, DOI 10.1016/S2213-2600(16)00052-7; Niewiadomska AM, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1314-9; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Olesen SW, 2018, ELIFE, V7, DOI 10.7554/eLife.39435; ONeill J., 2016, REV ANTIMICROBIAL RE; Ozawa S, 2017, B WORLD HEALTH ORGAN, V95, P629, DOI 10.2471/BLT.16.178475; Palmu AA, 2014, LANCET RESP MED, V2, P717, DOI 10.1016/S2213-2600(14)70139-0; Public Health Agency of Canada, 2015, CAN ANT RES SURV SYS; Quintiliani R, 2004, INFECT MED, V21, P219; Rappuoli R, 2017, NATURE, V552, P165; Reyes H, 1997, HEALTH POLICY PLANN, V12, P214, DOI 10.1093/heapol/12.3.214; Roca A, 2008, TROP MED INT HEALTH, V13, P818, DOI 10.1111/j.1365-3156.2008.02061.x; RUDOY RC, 1979, ANTIMICROB AGENTS CH, V15, P628, DOI 10.1128/AAC.15.4.628; Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8; SCHAAD UB, 1983, ANTIMICROB AGENTS CH, V23, P252, DOI 10.1128/AAC.23.2.252; Sevilla JP, 2018, P NATL ACAD SCI USA, V115, P12911, DOI 10.1073/pnas.1717161115; Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0; Sime WT, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4024-1; STEELE RW, 1983, ANTIMICROB AGENTS CH, V23, P191, DOI 10.1128/AAC.23.2.191; Tadesse BT, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2713-1; The World Bank, 2017, GDP CAP CURR US 2016; Tomczyk S, 2016, CLIN INFECT DIS, V62, P1119, DOI 10.1093/cid/ciw067; Turnidge J, 2006, CLIN MICROBIOL INFEC, V12, P418, DOI 10.1111/j.1469-0691.2006.01377.x; United Nations Department of Economic and Social Affairs Population Division, WORLD POPULATION PRO; United Nations Inter-agency Group for Child Mortality Estimation World Bank, 2020, LEVELS TRENDS CHILD; Vaz LE, 2014, PEDIATRICS, V133, P375, DOI 10.1542/peds.2013-2903; Venekamp Roderick P, 2014, BMJ Clin Evid, V2014; von Gottberg A, 2014, NEW ENGL J MED, V371, P1889, DOI 10.1056/NEJMoa1401914; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; Wellcome Trust Boston Consulting Group, 2018, VACC TACKL DRUG RES; WHO (World Health Organization), 2015, GLOB ACT PLAN ANT RE, P1; Wilensky U., 2015, INTRO AGENT BASED MO; Wilkinson A, 2018, ANTIBIOTICS-BASEL, V8, DOI 10.3390/antibiotics8010002; World Health Organization, 2020, IMM AG 2030 GLOB STR; World Health Organization, 2015, PNEUM DIS; World Health Organization, 2020, GLOBAL TUBERCULOSIS; World Health Organization, 2017, STUD PUBL HLTH SOC I; World Health Organization United Nations Children's Fund, 2019, WHO UNICEF COV EST 1; World Health Organization (WHO), INT WORK GROUP DRUG; World Health Organization (WHO), 2014, ANT RES GLOB REP SUR; Yadesa TM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138385	91	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6700	6711		10.1016/j.vaccine.2021.04.024		OCT 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34538697				2022-04-29	WOS:000708078600017
J	Fadlyana, E; Rusmil, K; Tarigan, R; Rahmadi, AR; Prodjosoewojo, S; Sofiatin, Y; Khrisna, CV; Sari, RM; Setyaningsih, L; Surachman, F; Bachtiar, NS; Sukandar, H; Megantara, I; Murad, C; Pangesti, KNA; Setiawaty, V; Sudigdoadi, S; Hu, YL; Gao, Q; Kartasasmita, CB				Fadlyana, Eddy; Rusmil, Kusnandi; Tarigan, Rodman; Rahmadi, Andri Reza; Prodjosoewojo, Susantina; Sofiatin, Yulia; Khrisna, Citra, V; Sari, Rini Mulia; Setyaningsih, Lilis; Surachman, Fikrianti; Bachtiar, Novilia Sjafri; Sukandar, Hadyana; Megantara, Imam; Murad, Chrysanti; Pangesti, Krisna Nur A.; Setiawaty, Vivi; Sudigdoadi, Sunarjati; Hu, Yaling; Gao, Qiang; Kartasasmita, Cissy B.			A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia	VACCINE			English	Article						Adults; Efficacy; Safety; Immunogenicity; SARS-CoV-2 Inactivated Vaccine		Background: The WHO declared COVID-19 a pandemic on March 11th, 2020. This serious outbreak and the precipitously increasing numbers of deaths worldwide necessitated the urgent need to develop an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The development of COVID-19 vaccines has moved quickly. In this study, we assessed the efficacy, safety, and immunogenicity of an inactivated (SARS-CoV-2) vaccine. Methods: We conducted a randomized, double-blind, placebo-controlled trial to evaluate the efficacy, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine and its lot-to-lot consistency. A total of 1620 healthy adults aged 18-59 years were randomly assigned to receive 2 injections of the trial vaccine or placebo on a day 0 and 14 schedule. This article was based on an interim report completed within 3 months following the last dose of study vaccine. The interim analysis includes safety and immunogenicity data for 540 participants in the immunogenicity subset and an efficacy analysis of the 1620 subjects. For the safety evaluation, solicited and unsolicited adverse events were collected after the first and second vaccination within 14 and 28 days, respectively. Blood samples were collected for an antibody assay before and 14 days following the second dose. Results: Most of the adverse reactions were in the solicited category and were mild in severity. Pain at the injection site was the most frequently reported symptom. Antibody IgG titer determined by enzymelinked immunosorbent assay was 97.48% for the seroconversion rate. Using a neutralization assay, the seroconversion rate was 87.15%. The efficacy in preventing symptomatic confirmed cases of COVID-19 occurring at least 14 days after the second dose of vaccine using an incidence rate was 65.30%. Conclusions: From the 3-month interim analysis, the vaccine exhibited a 65.30% efficacy at preventing COVID-19 illness with favorable safety and immunogenicity profiles. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Fadlyana, Eddy; Rusmil, Kusnandi; Tarigan, Rodman; Rahmadi, Andri Reza; Prodjosoewojo, Susantina; Sofiatin, Yulia; Khrisna, Citra, V; Sukandar, Hadyana; Megantara, Imam; Murad, Chrysanti; Sudigdoadi, Sunarjati; Kartasasmita, Cissy B.] Univ Padjadjaran, Fac Med, Dr Hasan Sadikin Gen Hosp, Bandung, Indonesia; [Sari, Rini Mulia; Setyaningsih, Lilis; Surachman, Fikrianti; Bachtiar, Novilia Sjafri] PT Bio Farma, Bandung, Indonesia; [Pangesti, Krisna Nur A.; Setiawaty, Vivi] Natl Inst Hlth Res & Dev, Jakarta, Indonesia; [Hu, Yaling; Gao, Qiang] Sinovac Life Sci Co Ltd, Beijing, Peoples R China		Fadlyana, E (通讯作者)，Univ Padjadjaran, Fac Med, Dr Hasan Sadikin Gen Hosp, Bandung, Indonesia.	eddy.fadlyana@unpad.ac.id; y.sofiatin@unpad.ac.id; rini.mulia@biofarma.co.id; lilis.setyaningsih@biofarma.co.id; fikrianti.surachman@biofarma.co.id; novilia@biofarma.co.id; imam.megantara@unpad.ac.id; huyl@sinovac.com; gaoq@sinovac.com		Sofiatin, Yulia/0000-0002-1409-6010			CDC, PRINC EP LESS 3; Fda Cber, 2020, CONT NONB REC DEV LI; Fda Cber, 2020, CONT NONB REC EM US; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fu1 Wenjiang, 2020, COVID 19 VACCINE EFF, DOI [10.1101/ 2020.12.16.20248359, DOI 10.1101/2020.12.16.20248359]; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Garcia-Basteiro AL, 2020, LANCET RESP MED, V8, P440, DOI 10.1016/S2213-2600(20)30162-4; Grzelak L., 2020, MEDRXIV, DOI [10.1101/2020.04.21.20068858, 10.1126/scitranslmed.abc3103]; Gupta SD, 2020, J HEALTH MANAG, V22, P1, DOI 10.1177/0972063420921260; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; KEMENKES, 2020, MENK 413 2020; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Murdin AD, 1996, VACCINE, V14, P735, DOI 10.1016/0264-410X(95)00211-I; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Ophinni Y, 2020, ACTA MED INDONES, V52, P388; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; SAGE (Strategic Advisory Group of Experts), 2021, BACKGR DOC IN VACC S; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Vellozzi C, 2009, VACCINE, V27, P2114, DOI 10.1016/j.vaccine.2009.01.125; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; WHO, 2020, WHO RD BLUEPR NOV CO, V205; WHO) WHO, 2021, DRAFT LANDSCAPE TRAC; WHO) WHO, 2020, CONS EV COVID 19 VAC, V21, P1; World Health Organization, 2020, WEEKL EP UPD COVID 1, V1, P4; World Health Organization, 2020, 7 WHO; World Health Organization (WHO), 2020, COR DIS COVID 19 ADV; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	29	7	8	7	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 22	2021	39	44					6520	6528		10.1016/j.vaccine.2021.09.052		OCT 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WX9RH	34620531	Green Published, hybrid			2022-04-29	WOS:000718925300010
J	Nyanchoga, MM; Lee, P; Barbery, G				Nyanchoga, Mercy Moraa; Lee, Patricia; Barbery, Gaery			Exploring electronic health records to estimate the extent of catch-up immunisation and factors associated with under-immunisation among refugees and asylum seekers in south east Queensland	VACCINE			English	Article						Vaccination; Catch-up immunisation; Refugee; Migrant Health; Digital Health; Electronic Health Records	AUSTRALIA; ACCESS	Background: Australia is one of the leading countries resettling people from refugee-like backgrounds. Catch-up immunisation is a key priority in this cohort. However, few studies have included asylum seek-ers and the adult age group in their study sample. In addition, Electronic Health Records (EHR) has recently been recognised as a vital tool in big data analysis with the capacity to contribute to informed strategic decision making. As such, the main aim of this study is to explore EHR routinely used in a spe-cialised refugee clinic in South East Queensland to estimate the extent of catch-up immunisation and assess the factors associated with under-immunisation among refugees and asylum seekers. Methods: A quantitative study involving a secondary data analysis on a pre-existing dataset was under-taken. Relevant data was extracted from the EHR in the clinic. SPSS was used to perform Statistical data analysis. Results: The majority of clients originated from Papua New Guinea, followed by Iran and Afghanistan. When assessing the uptake of catch-up immunisations among refugees and asylum seekers, MMR (Measles-Mumps-Rubella), Polio and DTP (Diphtheria-Tetanus-Pertussis) had the highest uptake, while HPV (Human Papilloma Virus), Pneumococcal and Hib (Haemophilus influenza type b) immunisations had the lowest uptake. Binary logistic regression revealed that the younger patients, the refugees (com-pared to asylum seekers) and those with a longer residential duration in Australia are at a higher risk of being under-immunised. Conclusion: This study indicates that the broader group of immigrants, and in particular refugees and asy-lum seekers, do not represent a homogenous group in terms of immunisation coverage, and that each cohort should be carefully considered during immunisation interventions and strategies. This will be par-ticularly important during targeted health promotions and future immunisation programs in this cohort. (c) 2021 Elsevier Ltd. All rights reserved.	[Lee, Patricia] Griffith Univ, Sch Med, Gold Coast Campus, Southport, Qld 4222, Australia; [Barbery, Gaery] Griffith Univ, Sch Med, Hlth Serv Management, South Bank, Qld 4101, Australia			moraa.nyanchoga@mater.org.au; patricia.lee@griffith.edu.au; g.barbery@griffith.edu.au		Barbery, Gaery/0000-0001-9129-9201			Abdi I, 2019, VACCINE, V37, P6724, DOI 10.1016/j.vaccine.2019.09.025; [Anonymous], 2018, VACCINATION MIGRANTS; [Anonymous], 2017, REFUGEE HLTH WELLBEI; [Anonymous], 2016, NO JAB NO PAY NEW IM; [Anonymous], 2018, REPORT IMPLEMENTATIO; Australian Government. Department of Health; National Health and Medical Research Council, AUSTR IMM HDB; Berman RS, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160442; Bhatia R, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-48; Biddle L, 2019, EMERG THEMES EPIDEMI, V16, DOI 10.1186/s12982-019-0085-2; Campbell RM, 2014, J IMMIGR MINOR HEALT, V16, P165, DOI 10.1007/s10903-012-9740-1; Charania NA, 2019, VACCINE, V37, P2661, DOI 10.1016/j.vaccine.2019.04.001; Charania NA, 2018, HUM VACC IMMUNOTHER, V14, P3026, DOI 10.1080/21645515.2018.1496769; Chiesa V, 2019, HEALTH POLICY, V123, P888, DOI 10.1016/j.healthpol.2019.07.018; Chuah FLH, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0833-x; Kiang KM, 2018, J PAEDIATR CHILD H, V54, P348, DOI 10.1111/jpc.13822; Kpozehouen E, 2017, AUST NZ J PUBL HEAL, V41, P118, DOI 10.1111/1753-6405.12602; Mahimbo A, 2017, VACCINE, V35, P5148, DOI 10.1016/j.vaccine.2017.08.002; Mesmar S, 2016, J PUBLIC HEALTH POL, V37, pS167, DOI 10.1057/s41271-016-0040-1; Morris MD, 2009, J COMMUN HEALTH, V34, P529, DOI 10.1007/s10900-009-9175-3; Paradis M, 2018, HUM VACC IMMUNOTHER, V14, P1660, DOI 10.1080/21645515.2018.1445449; Paxton GA, 2018, AUST J PRIM HEALTH, V24, P480, DOI 10.1071/PY17049; Paxton GA, 2011, J PAEDIATR CHILD H, V47, P888, DOI 10.1111/j.1440-1754.2011.02099.x; Polonsky MJ, 2018, J PUBLIC POLICY MARK, V37, P306, DOI 10.1177/0743915618813115; Q. Government, 2017, QUEENSL HLTH IMM STR; Russell G, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4235-6; Sackey D, 2020, AUST J PRIM HEALTH, V26, P452, DOI 10.1071/PY20138; Shein-Chung Chow J. S., 2017, STATIST THEOR RELAT, Vthird, DOI [10.1080/24754269.2017.1398000, DOI 10.1080/24754269.2017.1398000]; T. U. R. Agency, 2020, 1 PER CENT HUMANITY; Taylor J, 2018, AUST J PRIM HEALTH, V24, P14, DOI [10.1071/PY16147, 10.1071/py16147]; The UN Refugee Agency, 1951 REF CONV; Toar M, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-214; United Nations, 2015, SUSTAINABLE DEV GOAL; W. H. Organisation, 2020, IMM COV; Wilson L, 2018, VACCINE, V36, P1055, DOI 10.1016/j.vaccine.2018.01.025; World Health Organisation, 2019, DEL IMM SERV REF MIG; Yelland J, 2018, AUST HEALTH REV, V42, P130, DOI 10.1071/AH16164	36	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6238	6244		10.1016/j.vaccine.2021.09.026		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WE7SY	34556368				2022-04-29	WOS:000705822100010
J	Palache, A; Rockman, S; Taylor, B; Akcay, M; Billington, JK; Barbosa, P				Palache, Abraham; Rockman, Steven; Taylor, Beverly; Akcay, Meral; Billington, John K.; Barbosa, Paula		IFPMA Influenza Vaccine Supply IFP	Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use	VACCINE			English	Article						Seasonal influenza; Vaccination policy; Vaccination coverage rates; Pandemic preparedness; Vaccine recommendations; Monitoring and evaluation	DISEASE	Sustainable demand for seasonal influenza vaccines is a component of national security strategies for pandemic preparedness. However, the ongoing COVID-19 pandemic has revealed many weaknesses in the capacity of countries to design and execute sustainable vaccination programs. An influenza pandemic remains a global threat and yet there is no global monitoring system for assessing progress towards influenza vaccination coverage targets. The International Federation of Pharmaceutical Manufacturers and Associations' (IFPMA) Influenza Vaccine Supply International Task Force (IVS) developed a survey method in 2008 to estimate seasonal influenza vaccination coverage rates, which in turn serves as a crude estimate of pandemic preparedness. It provides evidence to guide expanded efforts for pandemic preparedness, specifically for increasing COVID-19 vaccine immunization levels. Furthermore, the results presented herein serve as a proxy for assessing the state of pandemic preparedness at a global and regional level. This paper adds data from 2018 and 2019 to the previous analyses. The current data show an upward or stable global trend in seasonal influenza vaccine dose distributed per 1,000 population with a 7% increase between 2017 and 2018 and 6% increase between 2018 and 2019. However, considerable regional inequities in access to vaccine persist. Three regions, Africa, the Middle-east, and Southeast Asia together account for 50% of the global population but only 6% of distributed seasonal influenza vaccine doses. This is an important finding in the context of the ongoing COVID-19 pandemic, as distribution of influenza vaccine doses in many ways reflects access to COVID-19 vaccines. Moreover, improving seasonal vaccine uptake rates is critical for optimizing the annual benefits by reducing the huge annual influenza-associated societal burdens and by providing protection to vulnerable individuals against serious complications from seasonal influenza infections. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Palache, Abraham] Abbott, CJ Van Houtenlaan 36, NL-1381 CP Weesp, Netherlands; [Rockman, Steven] Seqirus Ltd, 63 Poplar Rd, Parkville, Vic 3052, Australia; [Rockman, Steven] Univ Melbourne, Dept Immunol & Microbiol, Parkville, Vic, Australia; [Taylor, Beverly] Seqirus Vaccines, Renaissance Way, Liverpool L24 9JW, Merseyside, England; [Akcay, Meral] Sanofi Pasteur, 2 Ave Pont Pasteur, F-69007 Lyon, France; [Billington, John K.] GSK Vaccines, Av Fleming 20, B-1300 Wavre, Belgium; [Barbosa, Paula] Int Federat Pharmaceut Manufacturers & Assoc, Ch Mines 9,POB 195, CH-1211 Geneva 20, Switzerland		Palache, A (通讯作者)，Abbott, CJ Van Houtenlaan 36, NL-1381 CP Weesp, Netherlands.	bram.palache@ziggo.nl; Steven.Rockman@Seqirus.com; Beverly.Taylor@Seqirus.com; Meral.Akcay@sanofi.com; john.k.billington@gsk.com; p.barbosa@ifpma.org			IFPMA IVS	The study was commissioned and funded by the IFPMA IVS. The IFPMA IVS provided input into the study design, data collection, analysis, manuscript writing, and decision to submit the manu-script for publication. Consequently, the resultant manuscript is submitted on behalf of IFPMA IVS. The authors gratefully acknowl-edge the writing services of Shawn Gilchrist, president of S Gilchr-ist Consulting Services Inc.	Gonzalez-Block MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243833; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Australian Technical Advisory Group on Immunization (ATAGI), ADV REL TIM ADM INFL; Bachtiger P, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/26734; Centers for Disease Control and Prevention, INFL FLU WEEKL NAT F; Centers for Disease Control and Prevention, VACC IMM INT CLIN CO; Centers for Disease Control and Prevention, WEEKL US INFL SURV R; Gasparini R, 2012, HUM VACC IMMUNOTHER, V8, P21, DOI 10.4161/hv.8.1.17622; Heikkinen T, 2013, PEDIATR INFECT DIS J, V32, P881, DOI 10.1097/INF.0b013e3182918168; International Federation of Pharmaceutical Manufacturers and Associations, 2013, SEASONAL INFLUENZA V; International Federation of Pharmaceutical Manufacturers and Associations, INFL VACC SUPPL IVS; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Kostova D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066312; Laurie KL, 2021, INFLUENZA OTHER RESP, V15, P573, DOI 10.1111/irv.12866; Madjid M, 2007, EUR HEART J, V28, P1205, DOI 10.1093/eurheartj/ehm035; Maltezou HC, 2020, VACCINE, V38, P6078, DOI 10.1016/j.vaccine.2020.07.058; MOSTOW SR, 1986, AM REV RESPIR DIS, V134, P1; National Institutes of Allergy and Disease, UN INFL VACC RES; OECD, 2021, ACC COVID 19 VACC GL; Olsen SJ, 2020, MMWR-MORBID MORTAL W, V69, P1305, DOI 10.15585/mmwr.mm6937a6; Palache A., 2018, INT MED REV, V4, P1, DOI [10.18103/imr.v4i12.775, DOI 10.18103/IMR.V4I12.775]; Palache A, 2020, INTERNAL MED REV, V6; Palache A, 2015, VACCINE, V33, P5598, DOI 10.1016/j.vaccine.2015.08.082; Palache A, 2014, VACCINE, V32, P6369, DOI 10.1016/j.vaccine.2014.07.012; Palache A, 2011, VACCINE, V29, P9459, DOI 10.1016/j.vaccine.2011.10.030; Plans-Rubio Pedro, 2007, Int J Chron Obstruct Pulmon Dis, V2, P41, DOI 10.2147/copd.2007.2.1.41; Preaud E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-813; Reed C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118369; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747; Stowe J, 2021, INT J EPIDEMIOL, V50, P1124, DOI 10.1093/ije/dyab081; The World Bank, POP TOT; UK Health Protection Agency, 2011, SURVEILLANCE INFLUEN; United Nations Department of Economic and Social Affairs Population Division, WORLD POPULATION PRO; US Centers for Disease Control and Prevention, FLU PEOPL DIAB; WHO, 2012, WORLD MALARIA REPORT 2012, P1; Wong T, 2016, STEPS FORWARDS IN DIAGNOSING AND CONTROLLING INFLUENZA, P87, DOI 10.5772/64369; World Health Organization, 2021, REC COMP INFL VIR VA; World Health Organization, INT REC US CHADOX1 S; World Health Organization, INFL UPD 390; World Health Organization, WHO PAND INFL VACC R; World Health Organization, 2017, REP 3 WHO INF CONS; World Health Organization, 2015, INFL VACC RESP START; World Health Organization, REP 2 WHO INF CONS H; World Health Organization, 2017, PAND INFL RISK MAN W; World Health Organization (WHO), 2019, GLOB INFL STRAT 2019	46	3	3	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6081	6087		10.1016/j.vaccine.2021.08.097		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34521551	hybrid, Green Published			2022-04-29	WOS:000701799200011
J	Gorander, S; Honda-Okubo, Y; Backstrom, M; Baldwin, J; Bergstrom, T; Petrovsky, N; Liljeqvist, JA				Gorander, Staffan; Honda-Okubo, Yoshikazu; Backstrom, Malin; Baldwin, Jeremy; Bergstrom, Tomas; Petrovsky, Nikolai; Liljeqvist, Jan-Ake			A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection	VACCINE			English	Article						Herpes simplex virus 2; HSV-2; Vaccine; Adjuvant; Advax; CpG; TLR-9	ZOSTER SUBUNIT VACCINE; DELTA INULIN; RECOMBINANT GLYCOPROTEIN; INFLUENZA VACCINE; MONOCLONAL-ANTIBODIES; TYPE-2 INFECTION; HSV-2 INFECTION; B-CELLS; EFFICACY; IMMUNITY	Herpes simplex virus type 2 (HSV-2) is a common sexually transmitted disease that affects approximately 500 million individuals globally. There is currently no approved vaccine to prevent HSV-2 infection. EXCT4 is a truncated form of the mature glycoprotein G-2 (mgG-2) that unlike full mature form is secreted by expressing cells enabling it to be rapidly scaled up for production. The current study examined whether EXCT4 immunity in mice could be further enhanced through use of adjuvants. EXCT4 formulated with Advax-CpG adjuvant induced a strong Th1-type immune response characterized by interferon gamma (IFN-gamma) and protected animals against a lethal genital challenge with HSV-2. This response was associated with reduced viral load in vaginal washes, spinal cord, and dorsal root ganglia. Together the results provide proof of concept that EXCT4 formulated with Advax-CpG adjuvant is a promising HSV-2 vaccine candidate warranting further investigation. (C) 2021 Elsevier Ltd. All rights reserved.	[Gorander, Staffan; Bergstrom, Tomas; Liljeqvist, Jan-Ake] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Sect Virol,Dept Infect Med, Gothenburg, Sweden; [Backstrom, Malin] Univ Gothenburg, Sahlgrenska Acad, Mammalian Prot Express Core Facil, Gothenburg, Sweden; [Honda-Okubo, Yoshikazu; Baldwin, Jeremy; Petrovsky, Nikolai] Vaxine Pty Ltd, 11 Walkley Ave, Adelaide, SA 5046, Australia; [Honda-Okubo, Yoshikazu; Petrovsky, Nikolai] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA 5042, Australia		Petrovsky, N; Liljeqvist, JA (通讯作者)，Vaxine Pty Ltd, 11 Walkley Ave, Adelaide, SA 5046, Australia.	nikolai.petrovsky@flinders.edu.au; jan-ake.liljeqvist@microbio.gu.se	Honda-Okubo, Yoshikazu/AAM-5898-2021; Petrovsky, Nikolai/P-1912-2017	Honda-Okubo, Yoshikazu/0000-0002-2872-8621; Petrovsky, Nikolai/0000-0002-1580-5245	ALF Foundation at Sahlgrenska University Hospital; Torsten Soderbergs Founda-tion; National Institute of Allergy and Infectious Diseases under National Institutes of Health [HHS-N272201400053C, HHS-N272200800039C, U01-AI061142]	This work was supported by grants from the ALF Foundation at Sahlgrenska University Hospital and Torsten Soderbergs Founda-tion. NP, YHO, and JB and development of Advax and CpG adju-vants were supported by funding from National Institute of Allergy and Infectious Diseases under National Institutes of Health Contracts, HHS-N272201400053C, HHS-N272200800039C and U01-AI061142.	Adamiak B, 2007, J VIROL, V81, P13424, DOI 10.1128/JVI.01528-07; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; Awasthi S, 2014, J INFECT DIS, V210, P571, DOI 10.1093/infdis/jiu177; Awasthi S, 2014, J VIROL, V88, P2000, DOI 10.1128/JVI.03163-13; BALACHANDRAN N, 1987, J VIROL, V61, P1125, DOI 10.1128/JVI.61.4.1125-1135.1987; BALACHANDRAN N, 1982, INFECT IMMUN, V37, P1132, DOI 10.1128/IAI.37.3.1132-1137.1982; Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151; Bourne N, 2005, J INFECT DIS, V192, P2117, DOI 10.1086/498247; Bourne N, 2003, J INFECT DIS, V187, P542, DOI 10.1086/374002; Campadelli-Fiume G, 2012, CURR OPIN VIROL, V2, P28, DOI 10.1016/j.coviro.2011.12.001; Chentoufi AA, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/187585; COREY L, 1988, LANCET, V1, P1; Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331; Counoupas C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09119-y; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; DALLOLIO F, 1987, ARCH VIROL, V97, P237, DOI 10.1007/BF01314424; Davtyan H, 2016, SCI REP-UK, V6, DOI 10.1038/srep28912; De Gregorio E, 2008, EUR J IMMUNOL, V38, P2068, DOI 10.1002/eji.200838648; Dudek TE, 2011, J INFECT DIS, V203, P1434, DOI 10.1093/infdis/jir047; Eriksson K, 2004, J GEN VIROL, V85, P2139, DOI 10.1099/vir.0.79978-0; Garland SM, 2014, BEST PRACT RES CL OB, V28, P1098, DOI 10.1016/j.bpobgyn.2014.07.015; Gorander S, 2014, VIRUSES-BASEL, V6, P4358, DOI 10.3390/v6114358; Gorander S, 2012, J VIROL, V86, P7544, DOI 10.1128/JVI.00186-12; Gordon DL, 2016, VACCINE, V34, P3780, DOI 10.1016/j.vaccine.2016.05.071; Gordon DL, 2012, VACCINE, V30, P5407, DOI 10.1016/j.vaccine.2012.06.009; Gupta R, 2007, LANCET, V370, P2127, DOI 10.1016/S0140-6736(07)61908-4; Harandi AM, 2001, J GEN VIROL, V82, P845, DOI 10.1099/0022-1317-82-4-845; Honda-Okubo Y, 2015, VACCINE, V33, P4892, DOI 10.1016/j.vaccine.2015.07.051; Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14; Hook LM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007095; Hoshino Y, 2005, J VIROL, V79, P410, DOI 10.1128/JVI.79.1.410-418.2005; James C, 2020, B WORLD HEALTH ORGAN, V98, P315, DOI 10.2471/BLT.19.237149; Kim HC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030420; Kollias CM, 2015, J NEUROVIROL, V21, P8, DOI 10.1007/s13365-014-0302-2; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; LANGENBERG AGM, 1995, ANN INTERN MED, V122, P889, DOI 10.7326/0003-4819-122-12-199506150-00001; Liljeqvist JA, 2000, J CLIN MICROBIOL, V38, P4517, DOI 10.1128/JCM.38.12.4517-4522.2000; Liljeqvist JA, 1999, J CLIN MICROBIOL, V37, P2717, DOI 10.1128/JCM.37.8.2717-2718.1999; Looker KJ, 2020, LANCET INFECT DIS, V20, P240, DOI 10.1016/S1473-3099(19)30470-0; Merin A, 2011, J HEALTH PSYCHOL, V16, P80, DOI 10.1177/1359105310367528; Milligan GN, 1997, VIROLOGY, V229, P259, DOI 10.1006/viro.1997.8441; Mirotti LC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00047; PARA MF, 1985, J VIROL, V55, P483, DOI 10.1128/JVI.55.2.483-488.1985; Parr MB, 1999, VIROLOGY, V258, P282, DOI 10.1006/viro.1999.9739; Petrovsky N, 2015, VACCINE, V33, P5920, DOI 10.1016/j.vaccine.2015.09.030; Petrovsky N, 2013, J VIROL, V87, P10324, DOI 10.1128/JVI.00480-13; Saade F, 2013, VACCINE, V31, P1999, DOI 10.1016/j.vaccine.2012.12.077; SCRIBA M, 1976, MED MICROBIOL IMMUN, V162, P201, DOI 10.1007/BF02120998; Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915; Straus SE, 1997, J INFECT DIS, V176, P1129, DOI 10.1086/514103; Zarnitsyna VI, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005692	51	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5866	5875		10.1016/j.vaccine.2021.08.050		SEP 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34456075				2022-04-29	WOS:000697501500021
J	McClain, JB; Chuang, A; Reid, C; Moore, SM; Tsao, E				McClain, J. Bruce; Chuang, Ariel; Reid, Caroline; Moore, Susan M.; Tsao, Eric			Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial	VACCINE			English	Article						Rabies; Post-exposure prophylaxis; Monoclonal antibody; Rabies virus neutralizing activity (RVNA); Vaccine; Clinical trial		Background: SYN023-002 is a randomized, blinded, controlled study comparing rabies virus neutralizing activity (RVNA) and safety of SYN023, a monoclonal anti-rabies antibody mixture, to human-serum derived anti-rabies immunoglobulin (RIG) when administered with commercially available vaccines to healthy adult volunteers. Methods: Participants were randomized among 4 treatment groups (SYN023 + Imovax, SYN023 + RabAvert, HyperRab + Imovax, HyperRab + RabAvert). On Day 0, subjects received 1 dose of RIG (0.3 mg/kg SYN023 or 20 IU/mL HyperRab) and their first of 5 vaccine doses. The primary objective was to compare cumulative RVNA between SYN023 and HyperRab recipients. Secondary objectives were to compare safety and to assess SYN023 pharmacokinetics and immunogenicity. Results: All 164 randomized subjects initiated treatment and were included in safety analyses. At least 34 subjects/treatment group received all treatment and had complete RVNA results, thus were included in the primary endpoint analysis. Mean RVNAs were approximately ten-fold higher in SYN023 recipients compared to HyperRab recipients until Day 14. From Day 14 onwards, mean RVNA was lower in SYN023 recipients, but remained above the RVNA level widely considered adequate (>0.5 IU/mL) through Day 112 (study end). The point estimate of the cumulative RVNA (83.22% SYN023/HyperRab), but not the lower CI bound (90% CI: 66.06%, 104.83%), fell within the protocol-defined similarity margin. Each RIG + vaccine regimen appeared safe with mostly mild AEs and no serious or severe related events observed. Except injection site pain (22% HyperRab recipients vs. 6% SYN023 recipients), treatment-related AEs incidences were similar between RIGs. Anti-SYN023 antibodies were observed but had no apparent effects on PK or safety. Conclusions: SYN023 administered with commercially available vaccines provides adequate antibody coverage beginning earlier than other commercially available RIGs with an acceptable safety profile. Some suppression of vaccine response occurred, but RVNA levels > 0.5 IU/mL were maintained throughout the relevant period. Registration: ClinicalTrials.gov #NCT02956746. Funding: Synermore biologics. (c) 2021 Elsevier Ltd. All rights reserved.	[McClain, J. Bruce; Chuang, Ariel; Reid, Caroline; Tsao, Eric] Synermore Biol Co Ltd, 6F-6,5,Aly 22,Ln 513,Ruiguang Rd, Taipei 11492, Taiwan; [Moore, Susan M.] Kansas State Univ, Diagnost Med Pathobiol Dept, Manhattan, KS 66506 USA; [Moore, Susan M.] 1800 Denison Ave, Manhattan, KS 66506 USA		Tsao, E (通讯作者)，Synermore Biol Co Ltd, 6F-6,5,Aly 22,Ln 513,Ruiguang Rd, Taipei 11492, Taiwan.	drjblmcclain@aol.com; achuang@synermore.com; creid@trialbydesign.ca; smoore@sku.edu; etsao@synermore.com		, Ariel/0000-0002-2666-2526	Ventiv Health Clinical Research Services; PPD Inc; Biostat Solutions Inc	The authors gratefully acknowledge the subjects participating in these studies and inVentiv Health Clinical Research Services, PPD Inc, and Biostat Solutions Inc for their support in study con-duct and analyses.	CABASSO VJ, 1971, B WORLD HEALTH ORGAN, V45, P303; Chao TY, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006133; Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5; Gogtay NJ, 2018, CLIN INFECT DIS, V66, P387, DOI 10.1093/cid/cix791; Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709; Isakov L, 2016, AM J THER, V23, pE1903, DOI 10.1097/MJT.0000000000000391; Kansagra K, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa779, DOI 10.1093/CID/CIAA779]; Kostense S, 2012, ANTIMICROB AGENTS CH, V56, P3524, DOI 10.1128/AAC.06179-11; Matson MA, 2020, HUM VACC IMMUNOTHER, V16, P452, DOI 10.1080/21645515.2019.1656967; McClain JB, 2021, CLIN PHARM DRUG DEV, V10, P807, DOI 10.1002/cpdd.917; Moore SM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000595; Rupprecht CE., 2018, LAB TECHNIQUES RABIE, V5th, P196; WHO, 2018, WHO TECH REP SER, V1012, P1; World Health Organization, 2018, Weekly Epidemiological Record, V93, P201	14	0	0	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5822	5830		10.1016/j.vaccine.2021.08.066		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34483020				2022-04-29	WOS:000697501500015
J	Rotenberg, S; Downer, MB; Cooper, J				Rotenberg, Sara; Downer, Matthew B.; Cooper, Jane			Making COVID-19 vaccinations accessible for people with disabilities	VACCINE			English	Editorial Material									[Rotenberg, Sara] Univ Oxford, Radcliffe Observ Quarter, Nuffield Dept Primary Care Hlth Sci, Woodstock Rd, Oxford OX2 6GG, England; [Downer, Matthew B.] Univ Oxford West Wing, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Headley Way, Oxford OX3 9DU, England; [Cooper, Jane] Univ Toronto, Fac Law, 78 Queens Pk, Toronto, ON M5S 2C5, Canada		Rotenberg, S (通讯作者)，Univ Oxford, Radcliffe Observ Quarter, Nuffield Dept Primary Care Hlth Sci, Woodstock Rd, Oxford OX2 6GG, England.	sara.rotenberg@phc.ox.ac.uk		Cooper, Jane/0000-0003-4983-2812; Rotenberg, Sara/0000-0002-6164-8877			Gleason J, NEJM CATALYST INNOVA, V2; Hatton C., 2021, CHRIS HATTONS BLOG; Kirby J., VOX; McKee M, DISABILITY ACCESSIBI; Office for National Statistics, 2021, UPD EST COR COVID 19; Rotenberg S, SCI BRIEFS ONTARIO C, V2021; Rotenberg S., BMJ-BRIT MED J; The American Association on Health and Disability (AAHD), 2021, COVID 19 VACC DIS SU; WHO, 2012, WORLD MALARIA REPORT 2012, P1; WHO UNICEF, DISAB CONS COVID 19; Williamson EJ, OPENSAFELY RISKS COV, DOI [10.1101/2021.03.08.21253112, DOI 10.1101/2021.03.08.21253112]	11	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5727	5728		10.1016/j.vaccine.2021.08.062		SEP 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34462163	Bronze, Green Published			2022-04-29	WOS:000697501500001
J	Morais, E; El Mouaddin, N; Schuurman, S; De, A				Morais, Edith; El Mouaddin, Nadia; Schuurman, Susanne; De, Atish			Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data	VACCINE			English	Review						HPV; Gender Neutral Vaccination; HPV related Head and Neck Cancers	HPV VACCINATION; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; SURVIVAL; BOYS	Introduction: Head and neck cancers (HNC) accounted for over 450,000 deaths and 900,000 cases in 2018 worldwide. Of those, 38,000 cases were attributable to human papillomavirus (HPV). HNC is two to four times more prevalent in men than in women. The incidence of oropharyngeal cancers (OPC) and oral cavity cancers caused by HPV has increased in recent decades. Given the substantial burden of HPV-related HNC in males, this study aimed to assess whether and how national agencies included HPV-related HNC when evaluating HPV genderneutral vaccination (GNV) programs. Methods: A systematic literature review was conducted in MEDLINE (R) and EMBASE (R), and on the websites of selected national agencies. Results: Searches identified a potential 205 records; seventeen were eligible for the review. Seventy percent of assessments were published by European countries and most were recent (2014-2019). Eleven (65%) reports considered OPC when discussing HNC, and a few included other anatomic sites. All reports that considered incidence data were in consensus that incidence of OPC was higher in men and showed that the mortality rates for HPV-related HNC were also higher in men. When looking at the economic impact, the incremental cost-effectiveness ratios in the assessments varied widely, as the inputs into the analyses were heterogeneous. However, several reports concluded GNV programs were likely to be cost-effective versus not vaccinating males. Conclusion: The burden of HPV-related HNC in the general male population has been recognized by several Heatlth Technology Assessment (HTA) agencies and National Immunization Technical Advisory Groups (NITAGs) when evaluating HPV GNV programs. The assessments identified on GNV programs strongly indicate a cost-effective clinical benefit. Nevertheless, the epidemiological burden of HNC may have been underestimated in some countries due to limited data. Further research is crucial to obtain more robust data that will help address the information gap in epidemiological and economic burden of HPV-associated HNC in men. (C) 2021 The Authors. Published by Elsevier Ltd.	[Morais, Edith] MSD, Ctr Observat & Real World Evidence, Lyon, France; [El Mouaddin, Nadia] ICON Plc, Nanterre, France; [Schuurman, Susanne] ICON Plc, Stockholm, Sweden; [De, Atish] ICON Plc, New York, NY USA		Morais, E (通讯作者)，MSD, Ctr Observat & Real World Evidence, Lyon, France.	edith.morais@msd.com			Merck Sharp Dohme Corp.Merck & Company	This work was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.	Abogunrin S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-968; Advisory Committee on Immunization Practices / Centers for Disease Control and Prevention, 2019, EV REC FRAM HARM CAT; AIRTUM Working Group, 2016, Epidemiol Prev, V40, P1, DOI 10.19191/EP16.1S2.P001.035; Anantharaman D, 2017, INT J CANCER, V140, P1968, DOI 10.1002/ijc.30608; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Belgium cancer registry, 2015, BELG HLTH STAT; Bell S, 2019, HEALTH POLICY PLANN, V34, P271, DOI 10.1093/heapol/czz027; Bogaards JA, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2016; Boiron L, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1483-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brisson M, 2016, LANCET PUBLIC HEALTH, V1, pE8, DOI 10.1016/S2468-2667(16)30001-9; Bryson M, 2010, VACCINE, V28, pA13, DOI 10.1016/j.vaccine.2009.07.089; Canadian Agency for Drugs and Technologies in Health, 2019, CADTH RAP RESP REP S; Canadian Agency for Drugs and Technologies in Health, 2019, CADTHS DAT SEARCH FI; Canfell K, 2012, VACCINE, V30, pF157, DOI 10.1016/j.vaccine.2012.06.091; Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403; Chaturvedi AK, 2018, J CLIN ONCOL, V36, P262, DOI 10.1200/JCO.2017.75.0141; Chesson HW, 2011, VACCINE, V29, P8443, DOI 10.1016/j.vaccine.2011.07.096; Damm O, 2017, COST EFFECT RESOUR A, V15, DOI 10.1186/s12962-017-0080-9; de Kok IMCM, 2011, EUR J CANCER, V47, P428, DOI 10.1016/j.ejca.2010.09.030; de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716; Department of Health and Welfare, 2019, SHOULD BOYS HAV HPV; Elbasha EH, 2008, B MATH BIOL, V70, P2126, DOI 10.1007/s11538-008-9338-x; Favaretti C, 2017, QUADERNI ITALIAN J P, V6, P1; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Finnish Cancer Registry, FINN CANC REG WEB PA; Gezondheidsraad, 2019, VACC TEG HPV; Graham DM, 2015, CANCER-AM CANCER SOC, V121, P1785, DOI 10.1002/cncr.29111; Hartwig S, 2017, INFECT AGENTS CANCER, V12, DOI 10.1186/s13027-017-0129-6; Health Information and Quality Authority, HLTH TECHNOLOGY ASSE; Herrero R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068329; Institut Catala d'Oncologia Information Centre on HPV and Cancer Argentina, 2016, HUMAN PAPILLOMAVIRUS; Italian Institute of Public Health, 2017, VACC ANT 9 VAL REP H; Jansen L, 2018, ORAL ONCOL, V76, P8, DOI 10.1016/j.oraloncology.2017.11.015; Jimenez E., 2015, COST EFFECTIVENESS H; Joint Committee on Vaccination and Immunisation, 2017, JCVI INT STAT EXT HP; Joint Committee on Vaccination and Immunisation, STAT HPV VACC 2018; Kreimer AR, 2020, ORAL ONCOL, V108, DOI 10.1016/j.oraloncology.2020.104736; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Mandall NA, 2005, BRIT DENT J, V199, P659, DOI 10.1038/sj.bdj.4812930; Markowitz LE, 2014, MMWR RECOMM REP, V63, P1; Meites E, 2019, EVIDENCE RECOMMENDAT; Ministerio de salud, 2017, ARG VACC HPV 2017 IN; National Cancer Institute, 2014, SURV EP END RES SEER; National Cancer Institute, 2017, HEAD NECK CANC; National Cancer Registry Ireland, 2016, CANC IR; National Cancer Registry the Netherlands, 2017, DUTCH CANC REG; National Institute for Public Health and the Environment, 2017, HPV VACC BACKGR INF; Ndiaye C, 2014, LANCET ONCOL, V15, P1319, DOI 10.1016/S1470-2045(14)70471-1; Office for National Statistics, 2019, CANC REGISTRATION ST; Parellada C, 2018, INT J INFECT DIS, V73, P82, DOI 10.1016/j.ijid.2018.04.3612; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Petrosky E, 2015, MMWR-MORBID MORTAL W, V64, P300; Pharmaceutical Benefit Advisory Committee, 2011, PUBL SUMM DOC NOV 20; Prue G, 2018, LANCET, V392, P913, DOI 10.1016/S0140-6736(18)31821-X; Public Heath Agency of Sweden (Folkhalsomyndigheten), 2017, HLTH EC EV UN HPV VA; Rettig EM, 2015, SURG ONCOL CLIN N AM, V24, P379, DOI 10.1016/j.soc.2015.03.001; Rossi C, 2018, Rev Med Brux, V39, P352; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590; Socialstyrelsen Cancerregistret, 2017, NAT CANC REG 2010 20; Spence T, 2016, CANCERS, V8, DOI 10.3390/cancers8080075; Takla A, 2018, BUNDESGESUNDHEITSBLA, V61, P1170, DOI 10.1007/s00103-018-2791-2; Thiry N, 2019, 308 KCE; Wissinger E, 2014, PHARMACOECONOMICS, V32, P865, DOI 10.1007/s40273-014-0169-3; World Health Organization, 2009, Vaccine, V27, P7236, DOI 10.1016/j.vaccine.2009.05.019; World Health Organization, 2019, INT CLASSIFICATION D; World Health Organization, 2019, WHO HUM PAP CERV CAN; World Health Organization, 2019, CANC ATTR INF DAT SO; World Health Organization, 2016, INT CLASSIFICATION D; Zentrum fur Krebsregisterdaten, 2017, ZENTR KREBSR DAT	71	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5461	5473		10.1016/j.vaccine.2021.08.043		SEP 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34452775	hybrid			2022-04-29	WOS:000704399700003
J	Malik, AF; Belizan, M; Gutierrez, M; Vilajeliu, A; Sanclemente, LN; Casanova, IG; Jones, D; Omer, S; Ropero, AM; Alonso, JP				Malik, A. Fauzia; Belizan, Maria; Gutierrez, Mariana; Vilajeliu, Alba; Sanclemente, Lauren N.; Casanova, Ines Gonzalez; Jones, Daniel; Omer, Saad; Ropero, Alba Maria; Pedro Alonso, Juan			Pregnant women's perspectives about maternal immunization in Latin America	VACCINE			English	Article						Maternal immunization; Pregnant women; Acceptance; Attitudes; Vaccine uptake; Health education; Clinical expereince; Latin America	DETERMINANTS; VACCINATION	Background: Maternal immunization rates and vaccine uptake in Latin America vary from country to country. This variability stems from factors related to pregnant women, vaccine recommendations from healthcare providers and the health system. The aim of this paper is to describe women's knowledge and attitudes to maternal immunziation, and barriers to access and vaccination related decision-making processes in Latin American countries. Methods: We conducted focus group discussions (FGD) with pregnant women in five middle-income countries: Argentina, Brazil, Honduras, Mexico and Peru, between July 2016 and July 2018. The FGDs were conducted by trained qualitative researchers in diverse clinics located in the capital cities of these countries. Results: A total of 162 pregnant women participated in the FGDs. In general, participants were aware of the recommendation to receive vaccines during pregnancy but lacked knowledge regarding the diseases prevented by these vaccines. Pregnant women expressed a desire for clearer and more detailed communication on maternal vaccines by their healthcare professionals instead of relying on other sources of information such as the internet. Overall, participants had positive attitudes towards maternal immunization and were open to receiving vaccines in pregnancy based on general trust they have in recommendations made by their healthcare providers. The main obstacles pregnant women said they encounter were mainly centered around their clinical experience: long waiting times, vaccine shortages, and impolite behavior of healthcare providers or clinical staff. Conclusion: Important advances have been made in Latin America to promote maternal immunization. Results from this study show that an important aspect that remains to be addressed, and is crucial in improving vaccine uptake in pregnancy, is women's clinical experience. We recommend pregnant women to be treated as a priority population for providing immunization and related healthcare education. It is imperative to train healthcare providers in health communication so they can effectively communicate with pregnant women regarding maternal vaccines and can fill knowledge gaps that otherwise might be covered by unreliable sources dispensing inaccurate information. (C) 2020 The Authors. Published by Elsevier Ltd.	[Malik, A. Fauzia] Yale Sch Med, New Haven, CT USA; [Belizan, Maria; Jones, Daniel; Pedro Alonso, Juan] Inst Clin Effectiveness & Hlth Policy, Qualitat Hlth Res Unit, Buenos Aires, DF, Argentina; [Gutierrez, Mariana; Sanclemente, Lauren N.; Casanova, Ines Gonzalez] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Vilajeliu, Alba; Ropero, Alba Maria] Pan Amer Hlth Org PAHO WHO Reg Off Amer, Comprehens Family Immunizat Unit, Dept Family Hlth Promot & Life Course FPL, Washington, DC USA; [Casanova, Ines Gonzalez] Indiana Univ, Appl Hlth Sci, Sch Publ Hlth, Bloomington, IN 47405 USA; [Omer, Saad] Yale Inst Global Hlth, New Haven, CT USA; [Omer, Saad] Yale Sch Med, Dept Internal Med, New Haven, CT USA; [Omer, Saad] Yale Sch Publ Hlth, Dept Epidemiol Micorbial Dis, New Haven, CT USA		Casanova, IG (通讯作者)，Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.; Casanova, IG (通讯作者)，Indiana Univ, Appl Hlth Sci, Sch Publ Hlth, Bloomington, IN 47405 USA.	inegonza@iu.edu		Gonzalez Casanova, Ines/0000-0001-5747-8636; Gutierrez, Mariana/0000-0002-6993-9249	Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1120377]	The authors would like to thank the Ministries of Health of Argentina, Brazil, Honduras, Mexico and Peru as well as the pregnant women interviewed in each of the countries. This work was supported by the Bill & Melinda Gates Foundation [OPP1120377].	Arriola CS, 2018, VACCINE, V36, P3686, DOI 10.1016/j.vaccine.2018.05.013; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Danchin MH, 2018, VACCINE, V36, P6473, DOI 10.1016/j.vaccine.2017.08.003; Ellingson MK, 2019, EXPERT REV VACCINES, V18, P191, DOI 10.1080/14760584.2019.1562907; Engmann C, 2020, J PERINATOL, V40, P844, DOI 10.1038/s41372-020-0668-3; Fleming JA, 2018, VACCINE, V36, P4054, DOI 10.1016/j.vaccine.2018.05.096; Giles Michelle L, 2018, F1000Res, V7, DOI 10.12688/f1000research.15475.1; Hak E, 2008, NETH J MED, V66, P378; Lutz CS, 2018, VACCINE, V36, P7445, DOI 10.1016/j.vaccine.2018.10.046; MacDougall DM, 2016, HUM VACC IMMUNOTHER, V12, P857, DOI 10.1080/21645515.2015.1101524; Nganga SW, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4537-8; PAHO, 2019, COR IND 2019 HLTH TR; PAHO Technical Advisory Group on Vaccine-Preventable Diseases, 2019, 25 TAG M; Pan American Health Organization, 2019, PAHO WHO UNICEF 2019; Pan American Health Organization, 2015, REG IMM ACT PLAN 201; Pathirana J, 2015, VACCINE, V33, P2971, DOI 10.1016/j.vaccine.2015.04.070; Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046; Yuen CYS, 2014, VACCINE, V32, P4602, DOI 10.1016/j.vaccine.2014.06.067	18	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39			2			B44	B49		10.1016/j.vaccine.2020.09.009		JUL 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UD6SH	32972734	hybrid			2022-04-29	WOS:000687335900006
J	Luo, J; Huo, CL; Qin, H; Hu, JH; Lei, L; Pan, ZS				Luo, Jin; Huo, Chunling; Qin, Huan; Hu, Junhong; Lei, Lei; Pan, Zishu			Chimeric enterovirus 71 virus-like particle displaying conserved coxsackievirus A16 epitopes elicits potent immune responses and protects mice against lethal EV71 and CA16 infection	VACCINE			English	Article						Enterovirus 71; Coxsackievirus A16; Virus-like particle; Chimeric vaccine	ANTIBODY-DEPENDENT ENHANCEMENT; MOUTH-DISEASE; NEUTRALIZING ANTIBODIES; CONFER PROTECTION; STRUCTURAL BASIS; VP1 PROTEIN; VACCINE; HAND; EPIDEMIOLOGY; IMMUNOGENICITY	Hand-foot-and-mouth disease (HFMD) is an infectious disease of infants and young children frequently caused by the enterovirus A species, mainly enterovirus 71 (EV71) and coxsackievirus A16 (CA16). In this study, we prepared the EV71 virus-like particle (EV71-VLP) and its chimeras using recombinant baculovirus (Bac-P1-3CD) co-expressing EV71 P1 (under polyhedrin promoter) and 3CD (under CMV-IE promoter) proteins in Sf9 cells. EV71-VLP chimera ChiEV71(1E)-VLP or ChiEV71(4E)-VLP displayed single CA16 PEP71 epitope in VP1 or four conserved CA16 neutralizing epitopes (PEP71 in VP1, aa136-150 in VP2, aa176-190 in VP3 and aa48-62 in VP4) by substitution of the corresponding regions of EV71 structure proteins, respectively. In mice, EV71-VLP and its chimeras elicited similar EV71-specific IgG and neutralizing antibody (NAb) titers compared to inactivated EV71. Expectedly, vaccination of ChiEV71(1E)VLP or ChiEV71(4E)-VLP resulted in significantly increased CA16-specific IgG and NAb production and improved cross-protection against CA16 infection compared to EV71-VLP. Interestingly, the VLPs induced potent cellular immune responses and significantly decreased Th2 type (IL-4 and IL-10) cytokines secretion in the splenocytes of immunized mice compared to inactivated EV71 or inactivated CA16. Neonatal mice born to dams immunized with the chimeric VLPs or neonatal mice passively transferred with sera of immunized mice were completely protected from lethal EV71 challenge and partially protected from lethal CA16 infection. Our study provides a novel bivalent or multivalent vaccine strategy to prevent EV71 and related-enterovirus infections. (c)& nbsp;2021 Elsevier Ltd. All rights reserved.	[Luo, Jin; Huo, Chunling; Qin, Huan; Hu, Junhong; Lei, Lei; Pan, Zishu] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China; [Lei, Lei] Univ Iowa, Div Pulm Med, Stead Family Dept Pediat, Iowa City, IA 52242 USA		Pan, ZS (通讯作者)，Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.	leilei5865@gmail.com; zspan@whu.edu.cn			National key R&D program of China [2017YFA0505801]; Natural Science Foundation of Hubei Province Innovation Group [2017CFA022]	This work was supported by the National key R&D program of China (2017YFA0505801) and the Natural Science Foundation of Hubei Province Innovation Group (2017CFA022).	Anasir MI, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061256; Ang LW, 2009, ANN ACAD MED SINGAP, V38, P106; Aswathyraj S, 2016, MED MICROBIOL IMMUN, V205, P397, DOI 10.1007/s00430-016-0465-y; Baggen J, 2018, NAT REV MICROBIOL, V16, P368, DOI 10.1038/s41579-018-0005-4; Cao RY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064024; Chang LY, 2006, PEDIATR RES, V60, P466, DOI 10.1203/01.pdr.0000238247.86041.19; Chen HL, 2008, VACCINE, V26, P2882, DOI 10.1016/j.vaccine.2008.03.041; Chen IC, 2013, MED MICROBIOL IMMUN, V202, P259, DOI 10.1007/s00430-013-0289-y; Chen YJ, 2014, HUM VACC IMMUNOTHER, V10, P1366, DOI 10.4161/hv.28397; Chong P, 2015, CLIN INFECT DIS, V60, P797, DOI 10.1093/cid/ciu852; Chong P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049973; Chou AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079783; Chung CY, 2010, VACCINE, V28, P6951, DOI 10.1016/j.vaccine.2010.08.052; Facciabene A, 2004, J VIROL, V78, P8663, DOI 10.1128/JVI.78.16.8663-8672.2004; Fang CY, 2018, EXPERT REV VACCINES, V17, P819, DOI 10.1080/14760584.2018.1510326; Felberbaum RS, 2015, BIOTECHNOL J, V10, P702, DOI 10.1002/biot.201400438; Gong MQ, 2014, J VIROL, V88, P6444, DOI 10.1128/JVI.00200-14; Gorlani A, 2013, CURR HIV RES, V11, P421, DOI 10.2174/1570162X113116660062; Ha B, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12090906; He F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055517; HOFMANN C, 1995, P NATL ACAD SCI USA, V92, P10099, DOI 10.1073/pnas.92.22.10099; Hu YC, 2003, BIOTECHNOL LETT, V25, P919, DOI 10.1023/A:1024071514438; Huo CL, 2017, VACCINE, V35, P7322, DOI 10.1016/j.vaccine.2017.10.101; Joshi H, 2013, VACCINE, V31, P4841, DOI 10.1016/j.vaccine.2013.07.075; Kirk K, 2012, VACCINE, V30, P7105, DOI 10.1016/j.vaccine.2012.09.030; Klein MH, 2015, EXPERT REV VACCINES, V14, P337, DOI 10.1586/14760584.2015.993385; Ku ZQ, 2014, VACCINE, V32, P4296, DOI 10.1016/j.vaccine.2014.06.025; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Lee TC, 2009, PEDIATR INFECT DIS J, V28, P904, DOI 10.1097/INF.0b013e3181a41d63; Li JL, 2014, J GEN VIROL, V95, P1083, DOI 10.1099/vir.0.063560-0; Lin SH, 2017, J TAIWAN INS CHEM EN, V13, P1; Liu CC, 2011, VACCINE, V29, P4362, DOI 10.1016/j.vaccine.2011.04.010; Liu QW, 2012, VACCINE, V30, P6642, DOI 10.1016/j.vaccine.2012.08.071; Lyu K, 2015, J VIROL, V89, P6196, DOI 10.1128/JVI.00422-15; Lyu K, 2014, J VIROL, V88, P3114, DOI 10.1128/JVI.03029-13; Mao QY, 2016, EXPERT REV VACCINES, V15, P599, DOI 10.1586/14760584.2016.1138862; Mao QY, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.73; Mao QY, 2014, HUM VACC IMMUNOTHER, V10, P360, DOI 10.4161/hv.27087; McMinn PC, 2012, CURR OPIN VIROL, V2, P199, DOI 10.1016/j.coviro.2012.02.009; Miao HX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0088077, 10.1371/journal.pone.0096051]; Plevka P, 2014, P NATL ACAD SCI USA, V111, P2134, DOI 10.1073/pnas.1320624111; Qiao L, 2016, ANTIVIR RES, V131, P131, DOI 10.1016/j.antiviral.2016.05.001; Quan FS, 2011, J INFECT DIS, V204, P987, DOI 10.1093/infdis/jir474; Ren JS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2889; Shi JP, 2013, VACCINE, V31, P2130, DOI 10.1016/j.vaccine.2013.02.051; Sun SY, 2014, HUM VACC IMMUNOTHER, V10, P2885, DOI 10.4161/hv.29823; Ventarola D, 2015, CLIN DERMATOL, V33, P340, DOI 10.1016/j.clindermatol.2014.12.011; Wang CY, 2004, PEDIATR INFECT DIS J, V23, P275, DOI 10.1097/01.inf.0000115950.63906.78; Wang XX, 2012, NAT STRUCT MOL BIOL, V19, P424, DOI 10.1038/nsmb.2255; Wang Xiaowen, 2016, BMC Res Notes, V9, P42, DOI 10.1186/s13104-015-1780-x; Wu YT, 2017, VACCINE, V35, P2728, DOI 10.1016/j.vaccine.2017.03.065; Xu LF, 2014, THERANOSTICS, V4, P498, DOI 10.7150/thno.7457; Xu W, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-8; Yang EX, 2014, HUM VACC IMMUNOTHER, V10, P1266, DOI 10.4161/hv.28083; Yang F, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-508; Ye XH, 2014, J VIROL, V88, P72, DOI 10.1128/JVI.01848-13; Yi EJ, 2017, CLIN EXP VACCINE RES, V6, P4, DOI [10.7774/cevr.2017.6.1.4, 10.7774/cevr.2017.6.1.4.]; Yoshida S, 2003, VIROLOGY, V316, P161, DOI 10.1016/j.virol.2003.08.003; Zhang WJ, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/9273241; Zhang Y, 2016, VACCINE, V34, P252, DOI 10.1016/j.vaccine.2015.11.027; Zhao H, 2015, SCI REP-UK, V5, DOI 10.1038/srep07878; Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923	62	0	0	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4135	4143		10.1016/j.vaccine.2021.05.093		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34116877				2022-04-29	WOS:000672535200018
J	Nuzhath, T; Ajayi, KV; Fan, QP; Hotez, P; Colwell, B; Callaghan, T; Regan, AK				Nuzhath, Tasmiah; Ajayi, Kobi V.; Fan, Qiping; Hotez, Peter; Colwell, Brian; Callaghan, Timothy; Regan, Annette K.			Childhood immunization during the COVID-19 pandemic in Texas	VACCINE			English	Article						COVID-19; SARS-CoV-2 pandemic; Childhood immunization; Immunization programs; Vaccine-preventable diseases; Texas	VACCINATION COVERAGE; UNITED-STATES	In 2020, the state of Texas implemented coronavirus disease 2019 (COVID-19) social distancing guidelines in order to prevent surges at Texas hospital emergency rooms and in intensive care units. As noted in other states, an unintended consequence of these activities was significant declines in childhood immunizations. After analyzing state-wide immunization register data for Texas, we observed a 47% relative decline in immunization rates between 2019 and 2020 among 5-month-olds and a 58% decline among 16-month-olds. We observed a small decline (5%) among 24-month-olds, and no decline in vaccines received at birth (Hepatitis B). Declines were larger in rural counties compared to urban. These declines are superimposed on increases in state vaccine exemptions over the last five years due to an aggressive anti-vaccine movement in Texas. There are concerns that continued declines in childhood immunization coverage due to COVID-19 could lead to co-endemics of measles and other vaccine preventable diseases. (c) 2021 Elsevier Ltd. All rights reserved.	[Nuzhath, Tasmiah; Fan, Qiping; Colwell, Brian; Callaghan, Timothy; Regan, Annette K.] Texas A&M Sch Publ Hlth, College Stn, TX USA; [Nuzhath, Tasmiah; Hotez, Peter] Texas A&M Univ, Hagler Inst Adv Study, College Stn, TX USA; [Ajayi, Kobi V.] Texas A&M Univ, Dept Hlth & Kinesiol, College Stn, TX USA; [Ajayi, Kobi V.] Texas A&M Univ, Lab Community Hlth Evaluat & Syst Sci CHESS, College Stn, TX USA; [Hotez, Peter] Baylor Coll Med, Texas Childrens Hosp, Ctr Vaccine Dev, Houston, TX 77030 USA; Baylor Coll Med, Ctr Med Eth & Hlth Policy, Natl Sch Trop Med, Dept Pediat, Houston, TX 77030 USA; [Hotez, Peter] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Natl Sch Trop Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Hotez, Peter] Texas A&M Univ, Scowcroft Inst Int Affairs, Bush Sch Policy & Govt, College Stn, TX USA; [Hotez, Peter] Baylor Univ, Dept Biol, Waco, TX 76798 USA; [Hotez, Peter] Rice Univ, James A Baker III Inst Publ Policy, Houston, TX USA; [Regan, Annette K.] Univ San Francisco, Sch Nursing & Hlth Profess, 2130 Fulton St, San Francisco, CA 94117 USA; [Regan, Annette K.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA		Regan, AK (通讯作者)，Univ San Francisco, Sch Nursing & Hlth Profess, 2130 Fulton St, San Francisco, CA 94117 USA.	akregan@usfca.edu	Fan, Qiping/ABG-1294-2021; Colwell, Brian/AAT-7009-2021; Nuzhath, Tasmiah/AGZ-8042-2022; Regan, Annette/Q-9159-2016	Fan, Qiping/0000-0001-9168-7845; Colwell, Brian/0000-0002-9338-2778; Regan, Annette/0000-0002-3879-6193; Callaghan, Timothy/0000-0002-9056-9123			Bramer CA, 2020, AM J TRANSPLANT, V20, P1930, DOI 10.1111/ajt.16112; Centers for Disease Control and Prevention, 2020, INT GUID ROUT INFL I; Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1; Hill HA, 2020, MMWR-MORBID MORTAL W, V69, P1505, DOI 10.15585/mmwr.mm6942a1; Hoffman H, 2020, VACCINE RATES DROP D; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Jaklevic MC, 2020, JAMA-J AM MED ASSOC, V324, P826, DOI 10.1001/jama.2020.11244; Johns Hopkins University & Medicine, 2020, COV 19 MAP J HOPK CO; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Mervosh Sarah, 2020, SEE WHICH STATES CIT; National Foundation for Infectious Diseases, 2020, COVID 19 ROUT VACC W; Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2; Shapiro E, 2020, CHILD VACCINATIONS P; Suk JE, 2016, EMERG INFECT DIS, V22, P1106, DOI 10.3201/eid2206.151652; Svitek P, 2020, CORONAVIRUS TEXAS; Texas Department of State Health Services, 2020, IMP COV 19 TVFC VACC	16	5	5	3	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 8	2021	39	25					3333	3337		10.1016/j.vaccine.2021.04.050		JUN 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SL6BM	34020814	Green Published, Bronze			2022-04-29	WOS:000657001300007
J	Levin, Y; Balakirski, NM; Caraco, Y; Ben-Ami, E; Atsmon, J; Marcus, H				Levin, Yotam; Balakirski, Noa Madar; Caraco, Yoseph; Ben-Ami, Eytan; Atsmon, Jacob; Marcus, Hadar			Ethics and execution of developing a 2nd wave COVID vaccine - Our interim phase I/II VSV-SARS-CoV2 vaccine experience	VACCINE			English	Editorial Material									[Levin, Yotam; Balakirski, Noa Madar; Atsmon, Jacob; Marcus, Hadar] Israel Inst Biol Res IIBR, Ness Ziona, Israel; [Caraco, Yoseph] Hadassah Med Ctr, Jerusalem, Israel; [Ben-Ami, Eytan] Sheba Med Ctr, Ramat Gan, Israel		Marcus, H (通讯作者)，Israel Inst Biol Res IIBR, Ness Ziona, Israel.	hadarm@iibr.gov.il					Cohen J., MAKERS SUCCESSFUL CO; Levin Y, 2020, SCIENCE, V370, P1277; Rid A, 2021, JAMA-J AM MED ASSOC, V325, P219, DOI 10.1001/jama.2020.25053; Rosen B, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00440-6; Wendler D, 2020, SCIENCE, V370, P1277, DOI 10.1126/science.abf5084; Yahalom-Ronen Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20228-7	6	2	2	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 18	2021	39	21					2821	2823		10.1016/j.vaccine.2021.04.017		MAY 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RX4UJ	33896663	Bronze, Green Published			2022-04-29	WOS:000647220100002
J	Wang, C; Han, BF; Zhao, TS; Liu, HY; Liu, B; Chen, LY; Xie, MZ; Liu, J; Zheng, H; Zhang, SH; Wang, Y; Huang, NH; Du, J; Liu, YQ; Lu, QB; Cui, FQ				Wang, Chao; Han, Bingfeng; Zhao, Tianshuo; Liu, Hanyu; Liu, Bei; Chen, Linyi; Xie, Mingzhu; Liu, Jiang; Zheng, Hui; Zhang, Sihui; Wang, Yu; Huang, Ninghua; Du, Juan; Liu, Ya-Qiong; Lu, Qing-Bin; Cui, Fuqiang			Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study	VACCINE			English	Article						Vaccination; Willingness; Vaccine hesitancy; Confidence; COVID-19 vaccine		Background: Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. To date, there has been a lack of data on COVID-19 vaccination willingness, vaccine hesitancy, and vaccination coverage in China since the vaccine has become available. Methods: We designed and implemented a cross-sectional, population-based online survey to evaluate the willingness, hesitancy, and coverage of the COVID-19 vaccine among the Chinese population. 8742 valid samples were recruited and classified as the vaccine-priority group (n = 3902; 44.6%) and the non-priority group (n = 4840; 55.4%). Results: The proportion of people's trust in the vaccine, delivery system, and government were 69.0%, 78.0% and 81.3%, respectively. 67.1% of the participants were reportedly willing to accept the COVID-19 vaccination, while 9.0% refused it. 834 (35.5%) reported vaccine hesitancy, including acceptors with doubts (48.8%), refusers (39.4%), and delayers (11.8%). The current coverage was 34.4%, far from reaching the requirements of herd immunity. The predicted rate of COVID-19 vaccination was 64.9%, 68.9% and 81.1% based on the rates of vaccine hesitancy, willingness, and refusal, respectively. Conclusions: The COVID-19 vaccine rate is far from reaching the requirements of herd immunity, which will require more flexible and comprehensive efforts to improve the population's confidence and willingness to vaccinate. It should be highlighted that vaccination alone is insufficient to stop the pandemic; further efforts are needed not only to increase vaccination coverage but also to maintain non-specific prevention strategies. (C) 2021 Elsevier Ltd. All rights reserved.	[Wang, Chao; Han, Bingfeng; Zhao, Tianshuo; Liu, Hanyu; Liu, Bei; Chen, Linyi; Xie, Mingzhu; Liu, Jiang; Zheng, Hui; Zhang, Sihui; Wang, Yu; Huang, Ninghua; Du, Juan; Liu, Ya-Qiong; Lu, Qing-Bin; Cui, Fuqiang] Peking Univ, Dept Lab Sci & Technol, Sch Publ Hlth, 38th Xueyuan Rd, Beijing 100191, Peoples R China; [Wang, Chao; Han, Bingfeng; Zhao, Tianshuo; Liu, Hanyu; Liu, Bei; Chen, Linyi; Xie, Mingzhu; Liu, Jiang; Zheng, Hui; Zhang, Sihui; Wang, Yu; Huang, Ninghua; Du, Juan; Liu, Ya-Qiong; Lu, Qing-Bin; Cui, Fuqiang] Peking Univ, Vaccine Res Ctr, Sch Publ Hlth, 38th Xueyuan Rd, Beijing 100191, Peoples R China; [Wang, Chao; Han, Bingfeng; Zhao, Tianshuo; Liu, Hanyu; Liu, Bei; Chen, Linyi; Xie, Mingzhu; Liu, Jiang; Zheng, Hui; Zhang, Sihui; Wang, Yu; Lu, Qing-Bin; Cui, Fuqiang] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China		Lu, QB; Cui, FQ (通讯作者)，Peking Univ, Dept Lab Sci & Technol, Sch Publ Hlth, 38th Xueyuan Rd, Beijing 100191, Peoples R China.; Lu, QB; Cui, FQ (通讯作者)，Peking Univ, Vaccine Res Ctr, Sch Publ Hlth, 38th Xueyuan Rd, Beijing 100191, Peoples R China.	qingbinlu@bjmu.edu.cn; cuifuq@bjmu.edu.cn			Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities; Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation; Joint Research Fund for Beijing Natural Science Foundation and Haidian Original Innovation [L202007]; Peking University Health Science CenterPeking University [BMU20170607]	This work was supported by Fundamental Research Funds for the Central Universities and Peking University Health Science Center (grant numbers BMU20170607), Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation and Joint Research Fund for Beijing Natural Science Foundation and Haidian Original Innovation (L202007).	[Anonymous], 2020, THE PEOPLES DAILY; Bin W, 2021, EFFECTIVE RATE KEXIN; Bin X, 2021, PREVENTION CONTROL O; Brown C.S., 2020, INEQUALITY CORONAVIR, V27549; Chen B, 2015, VACCINE, V33, P1780, DOI 10.1016/j.vaccine.2015.02.046; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046; Du FX, 2020, VACCINE, V38, P7464, DOI 10.1016/j.vaccine.2020.09.075; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Edwards KM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2146; Frank K, STAT CANADA CATALOGU; Haiyan Z, 2019, J NE UNI SOCIAL SCI, V21, P165; Han BF, 2020, J EPIDEMIOL, V30, P474, DOI 10.2188/jea.JE20200148; Irtesam MK, 2021, ACTA TROP, V213; Jiale, 2021, NATL HLTH COMMISSION; Junping W., 2021, THE PEOPLES DAILY; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Lorini C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020154; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Medical Wheat Observation, 2021, IS NEWL DEV COVID 19; Persad G, 2020, JAMA-J AM MED ASSOC, V324, P1601, DOI 10.1001/jama.2020.18513; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Shuli, 2021, NATL HLTH COMMISSION; Sun SF, 2021, PREV MED REP, V22, DOI 10.1016/j.pmedr.2021.101350; The World Health Organization, 2021, COVID 19 VACC; Thunstrom L., 2020, COVID EC, V35, P1; Tu SY, 2020, VACCINE, V38, P6882, DOI 10.1016/j.vaccine.2020.08.063; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; WHO, 2021, **NON-TRADITIONAL**; Xiao W, 2021, SINOPHARMS NEW CROWN; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Zhonghua Y, 2021, CHINA CITY NEWS	34	34	35	12	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 18	2021	39	21					2833	2842		10.1016/j.vaccine.2021.04.020		MAY 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RX4UJ	33896661	Bronze, Green Published			2022-04-29	WOS:000647220100004
J	Prymula, R; Povey, M; Brzostek, J; Cabrnochova, H; Chlibek, R; Czajka, H; Leviniene, G; Man, S; Neamtu, M; Pazdiora, P; Plesca, D; Ruzkova, R; Stefkovicova, M; Usonis, V; Verdanova, D; Wysocki, J; Casabona, G; Habib, MA				Prymula, Roman; Povey, Michael; Brzostek, Jerzy; Cabrnochova, Hana; Chlibek, Roman; Czajka, Hanna; Leviniene, Giedra; Man, Sorin; Neamtu, Mihai; Pazdiora, Petr; Plesca, Doina; Ruzkova, Renata; Stefkovicova, Maria; Usonis, Vytautas; Verdanova, Daniela; Wysocki, Jacek; Casabona, Giacomo; Habib, Md Ahsan			Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries	VACCINE			English	Article						Children; Efficacy; Long-term follow-up; Live-attenuated varicella vaccine; Varicella zoster virus; Measles-mumps-rubella	FEBRILE CONVULSIONS; HEALTHY-CHILDREN; MMRV VACCINATION; RISK	Background: We assessed the 10-year efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine (MMRV) or one dose of a monovalent varicella vaccine (V) in children from Czech Republic, Lithuania, Poland, Romania and Slovakia. Methods: This was a phase IIIB follow-up of an observer-blind, randomized, controlled trial (NCT00226499). In phase A, healthy children aged 12-22 months from 10 European countries were ran-domized in a 3:3:1 ratio to receive two doses of MMRV (MMRV group), one dose of MMR followed by one dose of V (MMR + V group), or two doses of MMR (MMR; control group), 42 days apart. Vaccine efficacy (VE) against varicella (confirmed by viral DNA detection or epidemiological link and clinical assessment) was calculated with 95% confidence intervals using Cox proportional hazards regression model. Immunogenicity was assessed as seropositivity rates and geometric mean concentrations (GMCs). Solicited and unsolicited adverse events (AEs) and serious AEs (SAEs) were recorded. Results: A total of 3705 children were vaccinated (1590, MMRV group; 1586, MMR + V group; 529, MMR group). There were 663 confirmed varicella cases (47, MMRV group; 349, MMR + V group; 267, MMR group). VE ranged between 95.4% (Lithuania) and 97.4% (Slovakia) in the MMRV group and between 59.3% (Lithuania) and 74% (Slovakia) in the MMR + V group. At year 10, seropositivity rates were 99.5%-100% in the MMRV group, 98%-100% in the MMR + V group and 50%-100% in the MMR control group, and the anti-VZV antibody GMCs were comparable between MMRV and MMR + V groups. The occurrence of solicited and unsolicited AEs was similar across groups and no SAE was considered as vaccination-related. No new safety concerns were identified. Conclusions: Our results indicated that two doses of varicella zoster virus-containing vaccine provided better protection than one dose against varicella and induced antibody responses that persisted 10 years post-vaccination. (c) 2021 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Prymula, Roman] Charles Univ Prague, Fac Med, Hradec Kralove, Czech Republic; [Povey, Michael; Casabona, Giacomo; Habib, Md Ahsan] GSK, B-1300 Wavre, Belgium; [Brzostek, Jerzy] Poradnia Chorob Zakaznych ZOZ Debica, Debica, Poland; [Cabrnochova, Hana] Paediat Ctr, Prague, Czech Republic; [Chlibek, Roman] Univ Def, Fac Mil Hlth Sci, Hradec Kralove, Czech Republic; [Czajka, Hanna] Univ Rzeszow, Fac Med, Rzeszow, Poland; [Czajka, Hanna] St Louis Reg Specialised Childrens Hosp, Infect Dis Outpatient Clin, Krakow, Poland; [Leviniene, Giedra] Lithuanian Univ Hlth Sci, Pediat Clin, Kaunas, Lithuania; [Man, Sorin] Univ Med & Pharm Iuliu Hatieganu, Cluj Napoca, Romania; [Neamtu, Mihai] Lucian Blaga Univ Sibiu, Fac Med, Sibiu, Romania; [Pazdiora, Petr] Charles Univ Prague, Dept Epidemiol, Med Fac Pilsen, Prague, Czech Republic; [Plesca, Doina] Univ Med & Pharm Carol Davila, Pediat, Bucharest, Romania; [Ruzkova, Renata] Pediat Off Dr Renata Ruzkova, Prague, Czech Republic; [Stefkovicova, Maria] Alexander Dubcek Univ Trencin, Fac Hlth Care, Trencin, Slovakia; [Usonis, Vytautas] Vilnius Univ, Fac Med, Inst Clin Med, Clin Childrens Dis, Vilnius, Lithuania; [Verdanova, Daniela] Nemocnice S Ambulantni Casti, Jindrichuv Hrade, Czech Republic; [Wysocki, Jacek] Univ Med Sci, Poznan, Poland		Habib, MA (通讯作者)，GSK, B-1300 Wavre, Belgium.	Prymula@seznam.cz; michael.x.povey@gsk.com; jerzy_br@poczta.onet.pl; hana@cabrnoch.cz; roman.chlibek@unob.cz; hanna.czajka@onet.pl; mihai.neamtu@ulbsibiu.ro; PAZDIORA@fnplzen.cz; drruzkova@email.cz; vytautas.usonis@mf.vu.lt; daniela.verdanova@seznam.cz; jwysocki@ump.edu.pl; GIACOMO.X.CASABONA@GSK.COM; AHSAN.M.HABIB@GSK.COM		Prymula, Roman/0000-0003-1567-2259; Neamtu, Mihai Leonida/0000-0003-2781-0970	GlaxoSmithKline Biologicals SAGlaxoSmithKline	This work was supported by GlaxoSmithKline Biologicals SA, which was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.	[Anonymous], 2014, Wkly Epidemiol Rec, V89, P265; Bauchau V, 2015, DRUG SAFETY, V38, P1095, DOI 10.1007/s40264-015-0326-4; Bonanni P, 2013, PEDIATR INFECT DIS J, V32, pE305, DOI 10.1097/INF.0b013e31828b7def; Carryn S, 2019, VACCINE, V37, P5323, DOI 10.1016/j.vaccine.2019.07.049; Centers for Disease Control and Prevention, 2002, THE PINK BOOK; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; COX DR, 1972, J R STAT SOC B, V34, P187; European Centre for Disease Prevention and Control, VACC SCHED; Hanna C, 2009, VACCINE, V27, P6504, DOI 10.1016/j.vaccine.2009.07.076; Heininger U, 2006, LANCET, V368, P1365, DOI 10.1016/S0140-6736(06)69561-5; Henry O, 2018, VACCINE, V36, P381, DOI 10.1016/j.vaccine.2017.11.081; Hirose Maki, 2016, Rev. paul. pediatr., V34, P359, DOI [10.1016/j.rppede.2016.03.001, 10.1016/j.rpped.2015.12.006]; Holl K, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3738-x; Jacobsen SJ, 2009, VACCINE, V27, P4656, DOI 10.1016/j.vaccine.2009.05.056; Klein NP, 2010, PEDIATRICS, V126, pE1, DOI 10.1542/peds.2010-0665; Kreth HW, 2008, BIODRUGS, V22, P387, DOI 10.2165/0063030-200822060-00005; Leung JHY, 2015, EXPERT REV VACCINES, V14, P1149, DOI 10.1586/14760584.2015.1057572; Ma SJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001721; Macartney K, 2017, JAMA PEDIATR, V171, P992, DOI 10.1001/jamapediatrics.2017.1965; Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1; Marin M, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3741; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Povey M, 2019, LANCET INFECT DIS, V19, P287, DOI 10.1016/S1473-3099(18)30716-3; Prymula R, 2014, LANCET, V383, P1313, DOI 10.1016/S0140-6736(12)61461-5; Schink T, 2014, VACCINE, V32, P645, DOI 10.1016/j.vaccine.2013.12.011; Varela FH, 2019, HUM VACC IMMUNOTHER, V15, P645, DOI 10.1080/21645515.2018.1546525; Wutzler P, 2017, EXPERT REV VACCINES, V16, P833, DOI 10.1080/14760584.2017.1343669; Yin MJ, 2018, EXPERT REV VACCINES, V17, P351, DOI 10.1080/14760584.2018.1433999; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	29	2	2	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 6	2021	39	19					2643	2651		10.1016/j.vaccine.2021.03.085		APR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RU2SP	33858718	hybrid			2022-04-29	WOS:000645000500007
J	Kuter, BJ; Offit, PA; Poland, GA				Kuter, Barbara J.; Offit, Paul A.; Poland, Gregory A.			The development of COVID-19 vaccines in the United States: Why and how so fast?	VACCINE			English	Editorial Material							HEPATITIS-A; EFFICACY; SAFETY; TRIAL		[Kuter, Barbara J.; Offit, Paul A.] Childrens Hosp Philadelphia, Vaccine Educ Ctr, Philadelphia, PA 19104 USA; [Poland, Gregory A.] Mayo Clin, Rochester, MN 55905 USA		Poland, GA (通讯作者)，Mayo Clin, Rochester, MN 55905 USA.	poland.gregory@mayo.edu			ICW Ventures	Dr. Poland is the chair of a Safety Evaluation Committee for novel non-COVID investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on non-COVID vaccine development to Merck & Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Emergent Biosolutions, Dynavax, Genentech, and Genevant Sciences, Inc. Dr. Poland has offered consultative advice on COVID vaccine study design and safety to Eli Lilly and Company, Janssen Global Services LLC, and AstraZeneca. Dr. Poland holds patents related to vaccinia and measles peptide vaccines. Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies.	Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), SARS COV 2 VACC CLIN; [Anonymous], 2010, 2009 H1N1 INFL VACC; [Anonymous], 2020, BRIT MED J, V371, DOI [10.1136/bnij.m4759, DOI 10.1136/BNIJ.M4759]; [Anonymous], 2020, EMA INITIATIVES ACCE; [Anonymous], 2021, GUIDANCE MANAGEMENT; [Anonymous], 2020, FDA BRIEF FDA ISSUES; [Anonymous], 2020, EMA INITIATIVES ACCE; Baker S, 2020, BLOOMBERG BUSINESS W; Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y; Centers for Disease Control and Prevention, COVID 19 DIS TRACK; Coalition for Epidemic Preparedness Innovations, 2020, CEPI FUND 3 PROGR DE; Collins FS, 2020, JAMA-J AM MED ASSOC, V323, P2455, DOI 10.1001/jama.2020.8920; Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312; Cornish L, 2020, DEVEX; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; da Costa VG, 2020, ARCH VIROL, V165, P1517, DOI 10.1007/s00705-020-04628-0; FDA, 2021, EM US AUTH VACC PREV; FDA, 2020, DEV LIC VACC PREV CO; Griffin R, 2020, FORTUNE; Health Canada, COVID 19 DRUGS VACC; Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219; Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Krause P, 2020, LANCET, V396, P741, DOI 10.1016/S0140-6736(20)31821-3; KRAUSE PR, 2020, NEW ENGL J MED, V383, DOI DOI 10.1056/NEJM.P203-1373; Offit P.A., 2007, VACCINATED ONE MANS; Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; Shimabukuro T., 2021, COVID 19 VACCINE SAF; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Slaoui M, 2020, NEW ENGL J MED, V383, P1701, DOI 10.1056/NEJMp2027405; Smith J, 2011, LANCET, V378, P428, DOI 10.1016/S0140-6736(11)60478-9; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; World Health Organization, 2020, PNEUM UNK CAUS CHIN; Zhang NR, 2014, EXPERT REV VACCINES, V13, P761, DOI 10.1586/14760584.2014.912134	40	4	4	4	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 28	2021	39	18					2491	2495		10.1016/j.vaccine.2021.03.077		APR 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RQ1OX	33824043	Green Published, Bronze			2022-04-29	WOS:000642189300003
J	Bavananthasivam, J; Alizadeh, M; Astill, J; Alqazlan, N; Matsuyama-Kato, A; Shojadoost, B; Taha-Abdelaziz, K; Sharif, S				Bavananthasivam, Jegarubee; Alizadeh, Mohammadali; Astill, Jake; Alqazlan, Nadiyah; Matsuyama-Kato, Ayumi; Shojadoost, Bahram; Taha-Abdelaziz, Khaled; Sharif, Shayan			Effects of administration of probiotic lactobacilli on immunity conferred by the herpesvirus of turkeys vaccine against challenge with a very virulent Marek's disease virus in chickens	VACCINE			English	Article						Marek's disease; Lactobacillus; Probiotics; Herpesvirus of turkeys; Cytokines; Chickens		Several vaccines have been used to control Marek's disease (MD) in chickens. However, the emergence of new strains of Marek's disease virus (MDV) imposes a threat to vaccine efficacy. Therefore, the current study was carried out to investigate whether concurrent administration of probiotics with the herpesvirus of turkeys (HVT) vaccine enhances its protective efficacy against MDV infection. In this regard, a cocktail comprised of four Lactobacillus species was administered with HVT to chicken embryos at embryonic day 18 (ED18) and/or from day 1 to day 4 post-hatch. The results revealed that the administration of a probiotic Lactobacillus with HVT at ED18 followed by oral gavage with the same lactobacilli cocktail to newly hatched chicks for the first 4 days post-hatch increased the expression of major histocompatibility complex (MHC) II on macrophages and B cells in spleen and decreased the number of CD4(+)CD25(+) T regulatory cells in the spleen. Subsequently, chicks were infected with MDV. The chickens that received in ovo HVT and lactobacilli or HVT had higher expression of IFN-alpha at 21dpi in the spleen compared to the chickens that were challenged with MDV. Also, the expression of IFN-beta in cecal tonsils at 10dpi was higher in the groups that received in ovo HVT and lactobacilli and oral lactobacilli compared to the group that received in ovo HVT alone. Moreover, the expression of tumor growth factor (TGF)-b4 at 4 days post-infection was reduced in the group that received both HVT and probiotics at ED18. Additionally, concurrent probiotics administration reduced tumor incidence by half when compared to HVT vaccine alone indicating enhancing effect of lactobacilli with HVT vaccine on host immune responses. In conclusion, these findings suggest the potential use of probiotic lactobacilli as adjuvants with the HVT vaccine against MDV infection in chickens. (C) 2021 Published by Elsevier Ltd.	[Bavananthasivam, Jegarubee; Alizadeh, Mohammadali; Astill, Jake; Alqazlan, Nadiyah; Matsuyama-Kato, Ayumi; Shojadoost, Bahram; Taha-Abdelaziz, Khaled; Sharif, Shayan] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; [Taha-Abdelaziz, Khaled] Beni Suef Univ, Fac Vet Med, Pathol Dept, Bani Suwayf 62511, Egypt; [Bavananthasivam, Jegarubee] McMaster Univ, McMaster Immunol Res Ctr, MG DeGroote Sch Med, Hamilton, ON L8S 4L8, Canada; [Bavananthasivam, Jegarubee] McMaster Univ, Dept Med, MG DeGroote Sch Med, Hamilton, ON L8S 4L8, Canada		Sharif, S (通讯作者)，Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada.	shayan@uoguelph.ca	Bavananthasivam, Jegarubee/AFO-9233-2022	Bavananthasivam, Jegarubee/0000-0002-0332-4823; Alizadeh, Mohammadali/0000-0003-2696-7079	Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; Ontario Ministry of Agriculture, Food and Rural Affairs; University of Guelph's Food from Thought initiative; Canada First Research Excellence Fund	This work was funded by the Natural Sciences and Engineering Research Council of Canada, and the Ontario Ministry of Agriculture, Food and Rural Affairs, and this research is supported in part by the University of Guelph's Food from Thought initiative, thanks to funding from the Canada First Research Excellence Fund. We would like to thank the staff of the isolation facility of Ontario Veterinary College for housing and caring for the chickens. We would like to acknowledge Boehringer-Ingelheim (Canada) Ltd, Animal Health branch for providing the HVT vaccine free of charge.	Abdul-Careem MF, 2008, VIROLOGY, V379, P256, DOI 10.1016/j.virol.2008.06.027; Abdul-Careem MF, 2006, VIRAL IMMUNOL, V19, P167, DOI 10.1089/vim.2006.19.167; Abdul-Careem MF, 2008, VACCINE, V26, P2369, DOI 10.1016/j.vaccine.2008.02.069; Abdul-Careem MF, 2007, VACCINE, V25, P424, DOI 10.1016/j.vaccine.2006.08.006; Abdul-Careem MF, 2006, J VIROL METHODS, V133, P34, DOI 10.1016/j.jviromet.2005.10.018; Abreu DLC, 2016, BRAZ J POULTRY SCI, V18, P197, DOI 10.1590/18069061-2015-0001; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alizadeh M, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00105; Bavananthasivam J, 2021, VIROLOGY, V553, P122, DOI 10.1016/j.virol.2020.10.011; Bavananthasivam J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34760-6; Bertzbach LD, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121103; Biggs PM, 2012, AVIAN PATHOL, V41, P3, DOI 10.1080/03079457.2011.646238; Biggs PM, 2001, CURR TOP MICROBIOL, V255, P1; Brisbin JT, 2008, DEV COMP IMMUNOL, V32, P563, DOI 10.1016/j.dci.2007.09.003; Brisbin JT, 2011, CLIN VACCINE IMMUNOL, V18, P1447, DOI 10.1128/CVI.05100-11; Brisbin JT, 2010, CLIN VACCINE IMMUNOL, V17, P1337, DOI 10.1128/CVI.00143-10; Bumstead N, 2004, MAREKS DIS EVOL PROB, P112; Conti C, 2009, J PHYSIOL PHARMACOL, V60, P19; Couteaudier M, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-36; Davison F, 2005, EXPERT REV VACCINES, V4, P77, DOI 10.1586/14760584.4.1.77; Gimeno IM, 2016, AVIAN DIS, V60, P662, DOI 10.1637/11415-040116-Reg.1; Gimeno IM, 2008, VACCINE, V26, pC31, DOI 10.1016/j.vaccine.2008.04.009; Guo F, 2008, J IMMUNOL, V181, P2285, DOI 10.4049/jimmunol.181.4.2285; Haghighi HR, 2008, VET MICROBIOL, V126, P225, DOI 10.1016/j.vetmic.2007.06.026; Haq K, 2011, ANTIVIR RES, V90, P218, DOI 10.1016/j.antiviral.2011.04.001; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kukkonen K, 2006, PEDIAT ALLERG IMM-UK, V17, P416, DOI 10.1111/j.1399-3038.2006.00420.x; Lian L, 2010, POULTRY SCI, V89, P2123, DOI 10.3382/ps.2010-00919; Lohr J, 2006, IMMUNOL REV, V212, P149, DOI 10.1111/j.0105-2896.2006.00414.x; Matsuzaki T, 2000, IMMUNOL CELL BIOL, V78, P67, DOI 10.1046/j.1440-1711.2000.00887.x; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Pender CM, 2017, POULTRY SCI, V96, P1052, DOI 10.3382/ps/pew381; Redweik GAJ, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03064; SARMA G, 1995, AVIAN DIS, V39, P211, DOI 10.2307/1591862; Sarson AJ, 2008, ANIM GENET, V39, P232, DOI 10.1111/j.1365-2052.2008.01710.x; Sarson AJ, 2008, VIRAL IMMUNOL, V21, P267, DOI 10.1089/vim.2007.0094; Schat K. A., 2013, DIS POULTRY, P515; SCHAT KA, 1982, AVIAN PATHOL, V11, P593, DOI 10.1080/03079458208436134; Shack LA, 2008, CANCER IMMUNOL IMMUN, V57, P1253, DOI 10.1007/s00262-008-0460-2; Shanmugasundaram R, 2011, J IMMUNOL, V186, P1997, DOI 10.4049/jimmunol.1002040; Shida K, 2011, GUT MICROBES, V2, P109, DOI 10.4161/gmic.2.2.15661; Shrestha A, 2019, ACCESS MICROBIOL, V1, DOI [10.1099/acmi.ac2019.po0026, DOI 10.1099/ACMI.AC2019.PO0026]; Thanthrige-Don N, 2010, VIRAL IMMUNOL, V23, P227, DOI 10.1089/vim.2009.0092; Vitetta L, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040050; Wen K, 2012, VACCINE, V30, P1198, DOI 10.1016/j.vaccine.2011.11.107; Witter RL, 2005, AVIAN PATHOL, V34, P75, DOI 10.1080/03079450500059255; Yarkoni S, 2008, BIOESSAYS, V30, P875, DOI 10.1002/bies.20812; Yitbarek A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31613-0; Zabihollahi R, 2012, DARU, V20, DOI 10.1186/2008-2231-20-53	49	4	4	4	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 22	2021	39	17					2424	2433		10.1016/j.vaccine.2021.03.046		APR 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RL7KL	33781599				2022-04-29	WOS:000639147100015
J	Sadarangani, M; Abu Raya, B; Conway, JM; Iyaniwura, SA; Falcao, RC; Colijn, C; Coombs, D; Gantt, S				Sadarangani, Manish; Abu Raya, Bahaa; Conway, Jessica M.; Iyaniwura, Sarafa A.; Falcao, Rebeca Cardim; Colijn, Caroline; Coombs, Daniel; Gantt, Soren			Importance of COVID-19 vaccine efficacy in older age groups	VACCINE			English	Article						Covid-19 disease; Covid-19 vaccine; Age-structured effectiveness; Mathematical model	MODEL	Importance: An effective vaccine against SARS-CoV-2 will reduce morbidity and mortality and allow substantial relaxation of physical distancing policies. However, the ability of a vaccine to prevent infection or disease depends critically on protecting older individuals, who are at highest risk of severe disease. Objective: We quantitatively estimated the relative benefits of COVID-19 vaccines, in terms of preventing infection and death, with a particular focus on effectiveness in elderly people. Design: We applied compartmental mathematical modelling to determine the relative effects of vaccines that block infection and onward transmission, and those that prevent severe disease. We assumed that vaccines showing high efficacy in adults would be deployed, and examined the effects of lower vaccine efficacy among the elderly population. Setting and participants: Our mathematical model was calibrated to simulate the course of an epidemic among the entire population of British Columbia, Canada. Within our model, the population was structured by age and levels of contact. Main outcome(s) and measure(s): We assessed the effectiveness of possible vaccines in terms of the predicted number of infections within the entire population, and deaths among people aged 65 years and over. Results: In order to reduce the overall rate of infections in the population, high rates of deployment to all age groups will be critical. However, to substantially reduce mortality among people aged 65 years and over, a vaccine must directly protect a high proportion of people in that group. Conclusions and relevance: Effective vaccines deployed to a large fraction of the population are projected to substantially reduce infection in an otherwise susceptible population. However, even if transmission were blocked highly effectively by vaccination of children and younger adults, overall mortality would not be substantially reduced unless the vaccine is also directly protective in elderly people. We strongly recommend: (i) the inclusion of people aged 65 years and over in future trials of COVID-19 vaccine candidates; (ii) careful monitoring of vaccine efficacy in older age groups following vaccination. (C) 2021 Elsevier Ltd. All rights reserved.	[Sadarangani, Manish; Abu Raya, Bahaa] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada; [Sadarangani, Manish] Univ British Columbia, Dept Microbiol, Vancouver, BC, Canada; [Sadarangani, Manish] Univ British Columbia, Dept Immunol, Vancouver, BC, Canada; [Iyaniwura, Sarafa A.; Falcao, Rebeca Cardim; Coombs, Daniel] Univ British Columbia, Dept Math, 1984 Math Rd, Vancouver, BC V6T 1Z2, Canada; [Iyaniwura, Sarafa A.; Falcao, Rebeca Cardim; Coombs, Daniel] Univ British Columbia, Dept Inst Appl Math, Vancouver, BC, Canada; [Sadarangani, Manish; Abu Raya, Bahaa] Univ British Columbia, Vaccine Evaluat Ctr, Vancouver, BC, Canada; [Sadarangani, Manish; Abu Raya, Bahaa] Univ British Columbia, BC Childrens Hosp, Res Inst, Vancouver, BC, Canada; [Conway, Jessica M.] Penn State Univ, Dept Math, University Pk, PA 16802 USA; [Conway, Jessica M.] Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA; [Colijn, Caroline] Simon Fraser Univ, Dept Math, Burnaby, BC, Canada; [Gantt, Soren] Univ Montreal, Dept Microbiol Immunol & Infect Dis, Montreal, PQ, Canada; [Gantt, Soren] CHU St Justine Res Ctr, Montreal, PQ, Canada		Coombs, D (通讯作者)，Univ British Columbia, Dept Math, 1984 Math Rd, Vancouver, BC V6T 1Z2, Canada.	coombs@math.ubc.ca	Abu-Raya, Bahaa/ABC-9889-2021; Sadarangani, Manish/V-5609-2019	Gantt, Soren/0000-0001-5743-3606; Iyaniwura, Sarafa/0000-0002-8854-2335; Colijn, Caroline/0000-0001-6097-6708; Sadarangani, Manish/0000-0002-9985-6452	Michael Smith Foundation for Health Research, British Columbia, Canada	We wish to acknowledge funding from the Michael Smith Foundation for Health Research, British Columbia, Canada.	Andrew MK, 2019, DRUG AGING, V36, P29, DOI 10.1007/s40266-018-0597-4; British Columbia Centre for Disease Control, 2021, BRIT COL COVID 19 SI; Bubar KM, 2021, SCIENCE, V371, P916, DOI 10.1126/science.abe6959; Canada Government, 2021, COR DIS 2019 COVID 1; Conway JM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-932; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; Dhakal S, 2019, J VIROL, V93, DOI 10.1128/JVI.00797-19; Ghisolfi S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003094; Gravenstein S, 2018, HUM VACC IMMUNOTHER, V14, P736, DOI 10.1080/21645515.2017.1398872; Huang AT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18450-4; Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Viner RM, 2020, LANCET CHILD ADOLESC, V4, P397, DOI 10.1016/S2352-4642(20)30095-X; Weitz JS, 2020, NAT MED, V26, P849, DOI 10.1038/s41591-020-0895-3; World Health Organization, 2020, ETH COVID 19 RES ALL; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548	19	8	9	3	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2020	2023		10.1016/j.vaccine.2021.03.020		APR 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QH	33736921	Bronze, Green Published			2022-04-29	WOS:000637937500002
J	Poland, CM; Matthews, AKS; Poland, GA				Poland, Caroline M.; Matthews, Allison K. S.; Poland, Gregory A.			Improving COVID-19 vaccine acceptance: Including insights from human decision-making under conditions of uncertainty and human-centered design	VACCINE			English	Editorial Material							EDUCATION		[Poland, Caroline M.] Poland & Associates Consulting, 10401 N Meridian St,Suite 450, Indianapolis, IN 46290 USA; [Matthews, Allison K. S.] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, 200 1st St SW, Rochester, MN 55905 USA; [Poland, Gregory A.] Mayo Clin, Mayo Vaccine Res Grp, 200 1st St SW, Rochester, MN 55905 USA		Poland, GA (通讯作者)，Mayo Clin, Mayo Vaccine Res Grp, 200 1st St SW, Rochester, MN 55905 USA.	poland.gregory@mayo.edu					de Mooij MJM, 2018, MAYO CLIN PROC, V93, P458, DOI 10.1016/j.mayocp.2018.01.022; Poland CM, 2011, VACCINE, V29, P6145, DOI 10.1016/j.vaccine.2011.07.131; Poland CM, 2015, VACCINOLOGY ESSENTIA; Poland GA, 2016, CURR OPIN VIROL, V17, P116, DOI 10.1016/j.coviro.2016.03.003; Shermer M., 2011, BELIEVING BRAIN GHOS; Whitaker JA, 2018, VACCINE, V36, P1823, DOI 10.1016/j.vaccine.2018.02.082	6	3	3	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 12	2021	39	11					1547	1550					4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QP4DD	33612343	Green Published, Bronze			2022-04-29	WOS:000623785800001
J	Ward, BJ; Seguin, A; Couillard, J; Trepanier, S; Landry, N				Ward, Brian J.; Seguin, Annie; Couillard, Julie; Trepanier, Sonia; Landry, Nathalie			Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age	VACCINE			English	Article						Lot-to-lot; Plant-derived quadrivalent influenza vaccine; Virus-like particles; Nicotiana benthamiana; Safety and immunogenicity; Cell-mediated immunity		Background: The global reliance on eggs to produce most influenza vaccines has several limitations and new approaches to influenza vaccine production are needed. Herein we describe a phase 3, lot-to-lot consistency trial (NCT03321968) of a quadrivalent, recombinant, virus-like particle (VLP) influenza vaccine produced in plants. This platform is based on transient expression of proteins in Nicotiana benthamiana and yields VLPs bearing hemagglutinin (HA) protein trimers that are combined in a quadrivalent vaccine (QVLP). Methods: The HAs targeted in this study were A/California/07/2009 H1N1, A/Hong Kong/4801/2014 H3N2, B/Brisbane/60/08 and B/Phuket/3073/2013: recommended for the 2016-2017 Northern Hemisphere season. Healthy adults 18-49 years of age (n = 1200) were randomized 1:1:1 to receive a 0.5 mL intramuscular injection of QVLP (30 mu g HA/strain) from three sequential lots. Local and systemic reactions were monitored for 21 days post-vaccination and blood was collected pre-vaccination and at day 21 (D21) after vaccination to measure hemagglutination inhibition (HI) antibodies. Results: Subject demographics were similar between groups and compliance with study procedures was 96.3%. The study population was 54.8% female, the mean age (+/- SD) was 29.9 +/- 9.01 and the racial distribution was 77.8% Caucasian, 15.6% Asian, 5.8% Black/African American and 0.8% other. The HI responses met the Center for Biologics Evaluation and Research criteria for seroconversion (SCR >= 40%) and seroprotection rates (SPR >= 70%). The geometric mean fold rise in HI titers was >= 2.5 for all 4 strains for each lot. Lot-to-lot consistency was met with the 95% confidence intervals of the D21 mean geometric titre ratios falling between 0.67 and 1.5 for all four strains. No safety concerns were identified. Solicited adverse events were generally mild and transient: typical for what is reported after inactivated influenza vaccines. Conclusions: This study supported earlier findings of the safety profile and immunogenicity of the plant-derived QVLP and demonstrated the consistency with which it can be produced. Crown Copyright (C) 2021 Published by Elsevier Ltd. All rights reserved.	[Ward, Brian J.; Seguin, Annie; Couillard, Julie; Trepanier, Sonia; Landry, Nathalie] Medicago Inc, 1020 Route Eglise Off 600, Quebec City, PQ G1V 3V9, Canada; [Ward, Brian J.] McGill Univ, Hlth Ctr, Res Inst, 1001 Decarie St,EM3-3248, Montreal, PQ H4A 3J1, Canada; [Couillard, Julie] Angany Inc, Angany Suite 200,873 St Jean, Quebec City, PQ G1R 1R2, Canada		Landry, N (通讯作者)，1020 Route Eglise,Bur 600, Quebec City, PQ G1V 3V9, Canada.	landryn@medicago.com			Medicago Inc.	This study was sponsored by Medicago Inc.	Arntzen CJ, 1997, NAT BIOTECHNOL, V15, P221, DOI 10.1038/nbt0397-221; Bart S, 2016, HUM VACC IMMUNOTHER, V12, P2278, DOI 10.1080/21645515.2016.1182270; Chen ZY, 2008, VACCINE, V26, P361, DOI 10.1016/j.vaccine.2007.11.013; D'Aoust MA, 2008, PLANT BIOTECHNOL J, V6, P930, DOI 10.1111/j.1467-7652.2008.00384.x; Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330; Dunkle LM, 2017, J INFECT DIS, V216, P1219, DOI 10.1093/infdis/jix478; Gorse GJ, 2013, VACCINE, V31, P6034, DOI 10.1016/j.vaccine.2013.09.012; Karg SR, 2009, BIOTECHNOL ADV, V27, P879, DOI 10.1016/j.biotechadv.2009.07.002; Kayser O, 2018, PLANTA MED, V84, P834, DOI 10.1055/a-0631-3876; Landry N, 2014, CLIN IMMUNOL, V154, P164, DOI 10.1016/j.clim.2014.08.003; Landry N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015559; MacDonald J, 2015, BIOTECHNOL ADV, V33, P1572, DOI 10.1016/j.biotechadv.2015.07.007; Merlin M, 2017, BRIT J CLIN PHARMACO, V83, P71, DOI 10.1111/bcp.12949; Mett V, 2008, BIOLOGICALS, V36, P354, DOI 10.1016/j.biologicals.2008.09.001; Mor TS, 2015, BIOTECHNOL LETT, V37, P2147, DOI 10.1007/s10529-015-1908-z; Nakowitsch S, 2014, BIOTECHNOL J, V9, P405, DOI 10.1002/biot.201300225; Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008; Skowronski DM, 2016, EUROSURVEILLANCE, V21, P11, DOI 10.2807/1560-7917.ES.2016.21.3.30112; Skowronski DM, 2018, CLIN INFECT DIS, V67, P1474, DOI 10.1093/cid/ciy350; Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153; Sparrow PAC, 2007, TRANSGENIC RES, V16, P147, DOI 10.1007/s11248-007-9074-2; Subbarao K, 2019, CELL HOST MICROBE, V25, P773, DOI 10.1016/j.chom.2019.05.012; Trombetta CM, 2019, EXPERT REV VACCINES, V18, P737, DOI 10.1080/14760584.2019.1639503; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Ward BJ, 2018, HUM VACC IMMUNOTHER, V14, P647, DOI 10.1080/21645515.2017.1413518; Ward BJ, 2014, VACCINE, V32, P6098, DOI [10.1016/j.vaccine.2014.08.079, 10.10]; Wong-Arce A, 2017, TRENDS BIOTECHNOL, V35, P241, DOI 10.1016/j.tibtech.2016.12.002; Wu NC, 2019, CELL HOST MICROBE, V25, P836, DOI 10.1016/j.chom.2019.04.013; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	29	7	7	3	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 5	2021	39	10					1528	1533		10.1016/j.vaccine.2021.01.004		FEB 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QM3RT	33581920				2022-04-29	WOS:000621700000010
J	Spanos, KE; Kraschnewski, JL; Moss, JL; Wong, A; Calo, WA				Spanos, Katherine E.; Kraschnewski, Jennifer L.; Moss, Jennifer L.; Wong, Ashley; Calo, William A.			Parent support for social media standards combatting vaccine misinformation	VACCINE			English	Article						Human papillomavirus; Vaccines; Social media; Misinformation; Anti-vaccine; Social media users		We sought to assess parental support for varying standards that social media sites can employ to combat vaccine misinformation. Between July and August 2019, we conducted a web-based survey with a national sample of 1073 parents of adolescents and who use social media. The survey assessed support for ten standards about vaccine misinformation. Multivariable logistic regression assessed correlates of support. Overall, 61% of parents supported at least one standard. Support for each standard varied greatly (12-51%), with higher support for less restrictive standards. Parents more often supported standards if their child had already initiated human papillomavirus (HPV) vaccination, if they were non-Hispanic black or Hispanic, if they agreed that vaccine misinformation is harmful, or if they saw information on social media in favor of HPV vaccine (all p < .05). Our findings suggest favorable support for standards that social media sites can implement to combat vaccine misinformation. (C) 2021 Elsevier Ltd. All rights reserved.	[Spanos, Katherine E.; Kraschnewski, Jennifer L.; Moss, Jennifer L.; Wong, Ashley; Calo, William A.] Penn State Coll Med, Dept Publ Hlth Sci, 90 Hope Dr,Mail Code A210, Hershey, PA 17033 USA; [Kraschnewski, Jennifer L.] Penn State Coll Med, Dept Med, Hershey, PA 17033 USA; [Moss, Jennifer L.] Penn State Coll Med, Dept Family & Community Med, Hershey, PA 17033 USA; [Calo, William A.] Penn State Canc Inst, Hershey, PA USA		Calo, WA (通讯作者)，Penn State Coll Med, Dept Publ Hlth Sci, 90 Hope Dr,Mail Code A210, Hershey, PA 17033 USA.	wcalo@phs.psu.edu			American Cancer Society Institutional Research GrantAmerican Cancer Society [124171-IRG-13-043-01]	This study was funded by the American Cancer Society Institutional Research Grant (#124171-IRG-13-043-01). Funders played no role in 1) study design; 2) the collection, analysis, and interpretation of data; 3) the writing of the manuscript; or 4) the decision to submit the manuscript for publication. The content is solely the responsibility of the authors.	American Academy of Pediatrics, 2019, AAP URG MAJ TECHN CO; [Anonymous], BBC NEWS; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Centers for Disease Control and Prevention, 2016, COMM VACC SAF; Centre for Countering Digital Hate, FAIL ACT TECH GIANTS; Dunn AG, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4343; Facebook, OUR FACT CHECK PROGR; Facebook Newsroom, 2019, COMB VACC MIS; Facebook Newsroom, KEEP PEOPL SAF INF C; Guidry JPD, 2020, AM J PUBLIC HEALTH, V110, pS305, DOI 10.2105/AJPH.2020.305827; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Margolis MA, 2019, PREV MED, V118, P251, DOI 10.1016/j.ypmed.2018.11.005; Miller CA, 2020, CANCER EPIDEM BIOMAR, V29, P731, DOI 10.1158/1055-9965.EPI-19-0846; Mohanty S, 2018, VACCINE, V36, P5955, DOI 10.1016/j.vaccine.2018.08.060; Pew Research Center Science and Society, 2017, VAST MAJ AM SAY BEN; Pinterest, HLTH MIS; Politico, INS AD BOYC HAS FAC; Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040; Statista, SHAR US AD WHO FEEF; Strekalova YA, 2017, J CANCER EDUC, V32, P155, DOI 10.1007/s13187-015-0901-5; The American Association for Public Opinion Research Standard Definitions, 2015, FIN DISP CAS COD OUT; Twitter Blog, UPD APPR MISL INF; United Nations Secretary-General, 2020, SECR GEN VID MESS CO; VanWormer JJ, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4787-5; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; YouTube, RUL POL COMM GUID; Zimet GD, 2013, PREV MED, V57, P414, DOI 10.1016/j.ypmed.2013.05.013	29	0	0	2	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 1	2021	39	9					1364	1369		10.1016/j.vaccine.2021.01.005		FEB 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8CD	33551299				2022-04-29	WOS:000618498600002
J	Godinot, LD; Sicsic, J; Lachatre, M; Bouvet, E; Abiteboul, D; Rouveix, E; Pellissier, G; Raude, J; Mueller, JE				Godinot, Leo Donzel; Sicsic, Jonathan; Lachatre, Marie; Bouvet, Elisabeth; Abiteboul, Dominique; Rouveix, Elisabeth; Pellissier, Gerard; Raude, Jocelyn; Mueller, Judith E.			Quantifying preferences around vaccination against frequent, mild disease with risk for vulnerable persons: A discrete choice experiment among French hospital health care workers	VACCINE			English	Article						Vaccination; Influenza; Pertussis; Health care workers; Stated preferences; Single profile choice experiment; Incentives; Social conformism; Free-riding	INFLUENZA VACCINATION; CONJOINT-ANALYSIS; RATES; POPULATION; HESITANCY; INTENTION; COUNTRIES; PERTUSSIS; COVERAGE; PROGRAMS	The individual determinants of vaccine acceptance among health workers (HCWs) have been described in the literature, but there is little evidence regarding the impact of vaccine characteristics and contextual factors (e.g., incentives, communication) on vaccination intentions. We developed a single profile discrete choice experiment (DCE) to assess the impact of seven attributes on stated vaccination intention against an unnamed disease, described as frequent with rapid clinical evolution and epidemic potential (similar to influenza or pertussis). Attributes evaluated vaccine characteristics (effectiveness, security profile), inter-individual aspects (epidemic risk, controversy, potential for indirect protection, vaccine coverage) and incentives (e.g., badge, hierarchical injunction). A total of 1214 French hospital-based HCWs, recruited through professional organizations, completed the online DCE questionnaire. The relative impact of each attribute was estimated using random effects logit models on the whole sample and among specific subgroups. Overall, 52% of included HCWs were vaccinated against influenza during 2017-18 and the average vaccination acceptance rate across all scenarios was 58%. Aside from the management stance, all attributes' levels had significant impact on vaccination decisions. Poor vaccine safety had the most detrimental impact on stated acceptance (OR 0.04 for the level controversy around vaccine safety). The most motivating factor was protection of family (OR 2.41) and contribution to disease control (OR 2.34). Other motivating factors included improved vaccine effectiveness (OR 2.22), high uptake among colleagues (OR 1.89) and epidemic risk declared by health authorities (OR 1.76). Social incentives (e.g., a badge I'm vaccinated) were dissuasive (OR 0.47). Compared to HCWs previously vaccinated against influenza, unvaccinated HCWs who were favorable to vaccination in general were most sensitive towards improved vaccine effectiveness. Our study suggests that vaccine safety considerations dominate vaccine decision-making among French HCWs, while adapted communication on indirect protection and social conformism can contribute to increase vaccination acceptance. (C) 2020 Elsevier Ltd. All rights reserved.	[Godinot, Leo Donzel; Raude, Jocelyn; Mueller, Judith E.] EHESP French Sch Publ Hlth, Paris, France; [Godinot, Leo Donzel; Raude, Jocelyn; Mueller, Judith E.] EHESP French Sch Publ Hlth, Rennes, France; [Sicsic, Jonathan] Univ Paris, LIRAES EA 4470, 45 Rue St Peres, F-75006 Paris, France; [Lachatre, Marie; Bouvet, Elisabeth; Abiteboul, Dominique; Rouveix, Elisabeth; Pellissier, Gerard] Res Grp Prevent Occupat Infect Healthcare Workers, Paris, France; [Lachatre, Marie] Hop Cochin, AP HP, Ctr Invest Clin Cochin Pasteur CIC 1417, Paris, France; [Bouvet, Elisabeth] Commiss Tech Vaccinat CTV, Haute Autorite Sante HAS, La Plaine St Denis, France; [Raude, Jocelyn] Aix Marseille Univ, IRD 190, Insettn 1207, Unite Virus Emergents UVE,IHU Mediterranee Infect, Marseille, France; [Mueller, Judith E.] Inst Pasteur, Paris, France; [Rouveix, Elisabeth] Univ Paris Saclay, CHU Ambroise Pare, AP HP, Paris, France		Sicsic, J (通讯作者)，Univ Paris, LIRAES EA 4470, 45 Rue St Peres, F-75006 Paris, France.	Jonathan.sicsic@u-paris.fr	Sicsic, Jonathan/M-1549-2018	Sicsic, Jonathan/0000-0002-5509-4791; Raude, Jocelyn/0000-0001-8020-4975; Pellissier, Gerard/0000-0002-3872-4536	interdisciplinary research program PRINCEPS (Programme de recherche interdisciplinaire sur les crises et la protection sanitaire) at University of Sorbonne Paris Cite	This study was funded by the interdisciplinary research program PRINCEPS (Programme de recherche interdisciplinaire sur les crises et la protection sanitaire) at University of Sorbonne Paris Cite.	BECKER MH, 1974, HEALTH EDUC QUART, V2, P409, DOI 10.1177/109019817400200407; Betsch C, 2013, HEALTH PSYCHOL, V32, P978, DOI 10.1037/a0031590; Boey L, 2018, VACCINE, V36, P3351, DOI 10.1016/j.vaccine.2018.04.044; Bonmarin I, 2015, VACCINE, V33, P1099, DOI 10.1016/j.vaccine.2015.01.023; Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013; Calugar A, 2006, CLIN INFECT DIS, V42, P981, DOI 10.1086/500321; Canning HS, 2005, J CLIN NURS, V14, P922, DOI 10.1111/j.1365-2702.2005.01190.x; Chang CC, 2016, J HEALTH COMMUN, V21, P954, DOI 10.1080/10810730.2016.1204377; Clark MD, 2014, PHARMACOECONOMICS, V32, P883, DOI 10.1007/s40273-014-0170-x; DECI EL, 1972, J PERS SOC PSYCHOL, V22, P113, DOI 10.1037/h0032355; Determann D, 2016, EUROSURVEILLANCE, V21, P20, DOI 10.2807/1560-7917.ES.2016.21.22.30247; Dorribo V, 2015, OCCUP MED-OXFORD, V65, P739, DOI 10.1093/occmed/kqv116; Doumont D, 2007, VACCINATION GRIPPE A; Gidengil C, 2012, VACCINE, V30, P3445, DOI 10.1016/j.vaccine.2012.03.022; Gigerenzer G, 2008, PERSPECT PSYCHOL SCI, V3, P20, DOI 10.1111/j.1745-6916.2008.00058.x; Gil H, 2006, REV MED INTERNE, V27, P5, DOI 10.1016/j.revmed.2005.09.007; Greene MT, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0143; Guthmann JP, 2012, VACCINE, V30, P4648, DOI 10.1016/j.vaccine.2012.04.098; Hakim H, 2011, VACCINE, V29, P5963, DOI 10.1016/j.vaccine.2011.06.041; Hastings G, 2004, PSYCHOL MARKET, V21, P961, DOI 10.1002/mar.20043; Hayward AC, 2006, BRIT MED J, V333, P1241, DOI 10.1136/bmj.39010.581354.55; Humez M, 2017, B EPIDEMIOL HEBD HOR; Johnson P, 2014, VALUE HEALTH, V17, P380, DOI 10.1016/j.jval.2014.01.002; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Lancsar E, 2007, SOC SCI MED, V64, P1738, DOI 10.1016/j.socscimed.2006.12.007; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Loomis J, 2011, J ECON SURV, V25, P363, DOI 10.1111/j.1467-6419.2010.00675.x; Lugo NR, 2007, AM J INFECT CONTROL, V35, P1, DOI 10.1016/j.ajic.2006.10.004; Luyten J, 2019, SOC SCI MED, V228, P181, DOI 10.1016/j.socscimed.2019.03.025; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Maltezou HC, 2014, VACCINE, V32, P4876, DOI 10.1016/j.vaccine.2013.10.046; Mereckiene J, 2014, EUROSURVEILLANCE, V19, P29, DOI 10.2807/1560-7917.ES2014.19.16.20780; Pluviano S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181640; Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018; Ryan Mandy, 2003, Appl Health Econ Health Policy, V2, P55; Sante Publique France, 2019, B SANT PUBL; Seanehia J, 2017, VACCINE, V35, P2676, DOI 10.1016/j.vaccine.2017.03.086; Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054; Shiell A., 2003, J SOCIO-ECON, V32, P647; Shim E, 2012, J R SOC INTERFACE, V9, P2234, DOI 10.1098/rsif.2012.0115; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Valour F, 2007, MED MALADIES INFECT, V37, P51, DOI 10.1016/j.medmal.2006.10.007; Verelst F, 2019, VACCINE, V37, P2079, DOI 10.1016/j.vaccine.2019.02.056; Verelst F, 2018, SOC SCI MED, V207, P106, DOI 10.1016/j.socscimed.2018.04.038; Verger P., 2017, MEDECINE, V13, P110; Visser O, 2018, VACCINE, V36, P736, DOI 10.1016/j.vaccine.2017.12.021	47	4	4	1	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 29	2021	39	5					805	814		10.1016/j.vaccine.2020.12.057		JAN 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PV7RR	33419603	Green Submitted			2022-04-29	WOS:000610181400007
J	Borriello, A; Master, D; Pellegrini, A; Rose, JM				Borriello, Antonio; Master, Daniel; Pellegrini, Andrea; Rose, John M.			Preferences for a COVID-19 vaccine in Australia	VACCINE			English	Article						COVID-19; Vaccine; Acceptance; Willingness to pay; Uptake	HESITANCY; INFLUENZA; CHILDREN; IMPACT; MODEL	In absence of a COVID-19 vaccine, testing, contact tracing and social restrictions are among the most powerful strategies adopted around the world to slow down the spread of the pandemic. Citizens of most countries are suffering major physical, psychological and economic distress. At this stage, a safe and effective COVID-19 vaccine is the most sustainable option to manage the current pandemic. However, vaccine hesitancy by even a small subset of the population can undermine the success of this strategy. The objective of this research is to investigate the vaccine characteristics that matter the most to Australian citizens and to explore the potential uptake of a COVID-19 vaccine in Australia. Through a stated preference experiment, preferences towards a COVID-19 vaccine of 2136 residents of the Australian states and territories were collected and analysed via a latent class model. Results show that preferences for mild adverse cases, mode of administration, location of administration, price and effectiveness are heterogeneous. Conversely, preferences for immediacy and severe reactions are homogeneous, with respondents preferring a shorter period until vaccine is available and lower instances of severe side effects. The expected uptake of the vaccine is estimated under three different scenarios, with the value of 86% obtained for an average scenario. By calculating individual preferences, the willingness to pay is estimated for immediacy, effectiveness, mild and severe side effects. (C) 2020 Elsevier Ltd. All rights reserved.	[Borriello, Antonio; Master, Daniel; Pellegrini, Andrea; Rose, John M.] Univ Technol Sydney, Ctr Business Intelligence & Data Analyt, Business Sch, 14-28 Ultimo Rd, Ultimo, NSW 2007, Australia		Borriello, A (通讯作者)，Univ Technol Sydney, Ctr Business Intelligence & Data Analyt, Business Sch, 14-28 Ultimo Rd, Ultimo, NSW 2007, Australia.	antonio.borriello@uts.edu.au	Rose, John/AAO-2897-2021	Borriello, Antonio/0000-0001-7709-041X; Rose, John/0000-0003-4211-0980	Swiss National FoundationSwiss National Science Foundation (SNSF) [P2TIP1_187933]	Authors would like to acknowledge support from Swiss National Foundation in that the third author, Dr. Andrea Pellegrini, was funded to visit the University of Technology Sydney by the Swiss National Foundation (P2TIP1_187933).	[Anonymous], 2014, Wkly Epidemiol Rec, V89, P561; Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004; Bines J, 2006, VACCINE, V24, P3772, DOI 10.1016/j.vaccine.2005.07.031; Calkwood J, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0220-1; ChoiceMetrics, 2012, NGEN 1 1 1 US MAN RE; de Bekker-Grob EW, 2010, VACCINE, V28, P6692, DOI 10.1016/j.vaccine.2010.08.001; Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505; Dodd RH, 2020, LANCET INFECT DIS; Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Greene WH, 2003, TRANSPORT RES B-METH, V37, P681, DOI 10.1016/S0191-2615(02)00046-2; Guo N, 2017, VACCINE, V35, P2848, DOI 10.1016/j.vaccine.2017.04.006; Hensher DA, 2015, APPLIED CHOICE ANALYSIS, 2ND EDITION, P1, DOI 10.1017/CBO9781316136232; Hofman R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104772; Hofman R, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-454; KAMAKURA WA, 1989, J MARKETING RES, V26, P379, DOI 10.2307/3172759; Kochhar S, 2020, VACCINE, V38, P6194, DOI 10.1016/j.vaccine.2020.07.013; Koirala A, 2020, PAEDIATR RESPIR REV, V35, P43, DOI 10.1016/j.prrv.2020.06.010; Kongsted Alice, 2017, J Physiother, V63, P55, DOI 10.1016/j.jphys.2016.05.018; Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112; Kwok R, 2011, NATURE, V473, P436, DOI 10.1038/473436a; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Liao QY, 2020, VACCINE, V38, P4557, DOI 10.1016/j.vaccine.2020.05.012; Liu FC, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1766-6; Macartney K, 2020, LANCET CHILD ADOLESC; Marshall HS, 2016, VACCINE, V34, P671, DOI 10.1016/j.vaccine.2015.11.075; Quante M, 2012, Z ORTHOP UNFALLCHIR, V150, P397, DOI 10.1055/s-0031-1298347; Rozbroj T, 2019, VACCINE, V37, P5986, DOI [10.1016/j.vaccine.2019.08.023, 10.1016/j.vaccin]; Sadique MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054149; Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009; Sarkanen TO, 2018, SLEEP MED REV, V38, P177, DOI 10.1016/j.smrv.2017.06.006; Scarpa R, 2003, ECOL ECON, V45, P427, DOI 10.1016/S0921-8009(03)00095-8; Sharpe HR, 2020, IMMUNOLOGY, V160, P223, DOI 10.1111/imm.13222; Sonawane K, 2020, LANCET PUBLIC HEALTH, V5, pE484, DOI 10.1016/S2468-2667(20)30139-0; Veldwijk J, 2014, VACCINE, V32, P6277, DOI 10.1016/j.vaccine.2014.09.004; Verelst F, 2019, VACCINE, V37, P2079, DOI 10.1016/j.vaccine.2019.02.056; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WHO, 2013, WORLD MALARIA REPORT 2013, P1; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468	43	40	41	11	47	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 15	2021	39	3					473	479		10.1016/j.vaccine.2020.12.032			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PN8VN	33358265	Green Published, Bronze	Y	N	2022-04-29	WOS:000604750400005
J	Tomljenovic, M; Petrovic, G; Antoljak, N; Hansen, L				Tomljenovic, Morana; Petrovic, Goranka; Antoljak, Natasa; Hansen, Lisa			Vaccination attitudes, beliefs and behaviours among primary health care workers in northern Croatia	VACCINE			English	Article						Attitude; Health personnel; Vaccination; Primary health care; Croatia	GENERAL-PRACTITIONERS; INFLUENZA VACCINATION; HESITANCY; PHYSICIANS; KNOWLEDGE; COVERAGE; COMPLEMENTARY; CONTROVERSIES; IMMUNIZATION; VACCINES	Primary health care workers (HCWs) provide almost all vaccine services in Croatia, so they play an essential role in vaccine recommendations and uptake. The aim of this study was to determine the level of vaccine hesitancy among primary HCWs, to identify differences between nurses and physicians in attitudes, beliefs and behaviours towards vaccination, and to determine predictors of vaccine hesitancy among HCWs. We conducted a cross-sectional study from July to December in 2018 among physicians and nurses employed in the services of epidemiology, public health, school medicine, pediatrics and general practice/family medicine in Primorje-Gorski Kotar County, a primarily urban region with a population around 300 000 in the northern part of Croatia. The list of primary HCWs offices was obtained from the Croatian Health Insurance Fond website. We used a self-administered questionnaire on their attitudes, beliefs and behaviours relative to vaccination. Obtained response rate was 65.5% (324/495) of eligible primary HCWs; 64.1% (143/223) of physicians and 66.5% (181/272) of nurses. Seventeen percent of HCWs were identified as vaccine hesitant, and in univariate analysis, we observed an association between HCWs occupation and their own vaccination against flu (p = 0.001), measles (p = 0.016) and HPV (p = 0.025). Nurses and physicians differed (p < 0.001) in their general attitude, beliefs and behaviours towards vaccination, with a higher level of hesitancy among nurses. In multiple logistic regression, those more likely to be vaccine-hesitant were nurses (AOR = 5.73, 95%CI = 2.48-13.24), those who were uncertain or would never receive a vaccine against measles (AOR=11.13; 95%CI=5.37-23.10) and HPV (AOR=5.02; 95%CI=2.60-9.74), as well as those who had encountered a serious adverse event following immunization (AOR=7.55; 95%CI=3.13-19.18). As personal hesitancy may have a negative impact on vaccination education and recommendations, and therefore vaccine coverage, it is necessary to implement interventions to increase vaccination knowledge and confidence among primary health care workers, especially nurses. (C) 2020 Elsevier Ltd. All rights reserved.	[Tomljenovic, Morana] Univ Rijeka, Sch Med, Brace Branchetta 20-1, Rijeka 51000, Croatia; [Tomljenovic, Morana] European Ctr Dis Prevent & Control, ECDC, European Programme Intervent Epidemiol Training E, Gustav 3S Blvd 40, Solna, Sweden; [Petrovic, Goranka; Antoljak, Natasa] Croatian Inst Publ Hlth, Rockefeller St 7, Zagreb 10000, Croatia; [Antoljak, Natasa] Univ Zagreb, Sch Med, Salata 3, Zagreb 10000, Croatia; [Hansen, Lisa] Natl Inst Publ Hlth & Environm, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands		Tomljenovic, M (通讯作者)，Univ Rijeka, Sch Med, Brace Branchetta 20-1, Rijeka 51000, Croatia.	morana.tomljenovic@medri.uniri.hr		Hansen, Lisa/0000-0002-2119-8509			Akan H, 2016, VACCINE, V34, P1712, DOI 10.1016/j.vaccine.2016.01.057; Picchio CA, 2019, EUROSURVEILLANCE, V24, P20, DOI 10.2807/1560-7917.ES.2019.24.6.1800117; Castilla J, 2013, PREV MED, V57, P206, DOI 10.1016/j.ypmed.2013.05.021; CDC, 2011, 10 GREAT PUBL HLTH A; Chandler RE, 2017, DRUG SAFETY, V40, P81, DOI 10.1007/s40264-016-0456-3; Collange F, 2016, HUM VACC IMMUNOTHER, V12, P1282, DOI 10.1080/21645515.2015.1138024; Croatian Institute of Public Health (CIPH) Croatian Institute of Public Health (CIPH), 2018, CROAT HLTH STAT YB 2; Dempsey AF, 2015, AM J PREV MED, V49, pS445, DOI 10.1016/j.amepre.2015.04.013; Dominguez A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081200; European Centre for Disease Prevention and Control (ECDC), 2013, REV OUTBR BARR MMR V; Gowda C, 2013, HUM VACC IMMUNOTHER, V9, P1755, DOI 10.4161/hv.25085; Guthmann JP, 2012, VACCINE, V30, P4648, DOI 10.1016/j.vaccine.2012.04.098; Hesse BW, 2005, ARCH INTERN MED, V165, P2618, DOI 10.1001/archinte.165.22.2618; Hussain A, 2018, CUREUS, V10, DOI 10.7759/cureus.2919; Hviid A, 2019, ANN INTERN MED, V170, P513, DOI 10.7326/M18-2101; Johnson PJ, 2012, HEALTH SERV RES, V47, P211, DOI 10.1111/j.1475-6773.2011.01304.x; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; LaVela SL, 2004, INFECT CONT HOSP EP, V25, P933, DOI 10.1086/502323; Le Marechal M, 2018, CLIN MICROBIOL INFEC, V24, P858, DOI 10.1016/j.cmi.2017.10.021; Lindea K, 2015, FAM PRACT, V32, P62, DOI 10.1093/fampra/cmu071; Loulergue P, 2009, VACCINE, V27, P4240, DOI 10.1016/j.vaccine.2009.03.039; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; MacDougall DM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009062; Maltezou HC, 2013, AM J INFECT CONTROL, V41, P66, DOI 10.1016/j.ajic.2012.01.028; Michiels B, 2006, VACCINE, V24, P3145, DOI 10.1016/j.vaccine.2006.01.040; Mistik S, 2012, BRATISL MED J, V113, P384, DOI 10.4149/BLL_2012_088; Nativ Tova, 2010, Harefuah, V149, P626; Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120; Opstelten W, 2008, VACCINE, V26, P5918, DOI 10.1016/j.vaccine.2008.08.049; Opstelten W, 2010, VACCINE, V28, P6164, DOI 10.1016/j.vaccine.2010.07.031; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Ricco M, 2017, INT J OCCUP MED ENV, V30, P775, DOI 10.13075/ijomeh.1896.00895; Riphagen-Dalhuisen J, 2012, OCCUP ENVIRON MED, V69, P230, DOI 10.1136/oemed-2011-100134; Smith TC, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx146; Spencer JP, 2017, AM FAM PHYSICIAN, V95, P786; Taylor LE, 2014, VACCINE, V32, P3623, DOI 10.1016/j.vaccine.2014.04.085; Verger P, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.47.30406; Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018	38	7	7	3	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					738	745		10.1016/j.vaccine.2020.11.049		JAN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PR1FI	33386176				2022-04-29	WOS:000606987100017
J	Valckx, S; Crevecoeur, J; Verelst, F; Vranckx, M; Hendrickx, G; Hens, N; Van Damme, P; Pepermans, K; Beutels, P; Neyens, T				Valckx, Sara; Crevecoeur, Jonas; Verelst, Frederik; Vranckx, Maren; Hendrickx, Greet; Hens, Niel; Van Damme, Pierre; Pepermans, Koen; Beutels, Philippe; Neyens, Thomas			Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020)	VACCINE			English	Article						Vaccine willingness; Vaccine hesitancy; Trust; COVID-19; Socio-demographics; Online survey	PUBLIC PREFERENCES; WILLINGNESS; HESITANCY; ACCEPTABILITY; CONFIDENCE; STRATEGIES; POLICY; STATE	Background: A year after the start of the COVID-19 outbreak, the global rollout of vaccines gives us hope of ending the pandemic. Lack of vaccine confidence, however, poses a threat to vaccination campaigns. This study aims at identifying individuals' characteristics that explain vaccine willingness in Flanders (Belgium), while also describing trends over time (July-December 2020). Methods: The analysis included data of 10 survey waves of the Great Corona Survey, a large-scale online survey that was open to the general public and had 17,722-32,219 respondents per wave. Uni-and multivariable general additive models were fitted to associate vaccine willingness with socio-demographic and behavioral variables, while correcting for temporal and geographical variability. Results: We found 84.2% of the respondents willing to be vaccinated, i.e., respondents answering that they were definitely (61.2%) or probably (23.0%) willing to get a COVID-19 vaccine, while 9.8% indicated maybe, 3.9% probably not and 2.2% definitely not. In Flanders, vaccine willingness was highest in July 2020 (90.0%), decreased over the summer period to 80.2% and started to increase again from late September, reaching 85.9% at the end of December 2020. Vaccine willingness was significantly associated with respondents' characteristics: previous survey participation, age, gender, province, educational attainment, household size, financial situation, employment sector, underlying medical conditions, mental well-being, government trust, knowing someone with severe COVID-19 symptoms and compliance with restrictive measures. These variables could explain much, but not all, variation in vaccine willingness. Conclusions: Both the timing and location of data collection influence vaccine willingness results, emphasizing that comparing data from different regions, countries and/or timepoints should be done with caution. To maximize COVID-19 vaccination coverage, vaccination campaigns should focus on (a combination of) subpopulations: aged 31-50, females, low educational attainment, large households, difficult financial situation, low mental well-being and labourers, unemployed and self-employed citizens. (c) 2021 Elsevier Ltd. All rights reserved.	[Valckx, Sara; Hendrickx, Greet; Van Damme, Pierre] Univ Antwerp, Fac Med & Hlth Sci, Ctr Evaluat Vaccinat, VAXINFECTIO, B-2000 Antwerp, Belgium; [Crevecoeur, Jonas; Neyens, Thomas] Katholieke Univ Leuven, Leuven Biostat & Stat Bioinformat Ctr L BioStat, Fac Med, Kapucijnenvoer 35,Bldg D,Box 7001, B-3000 Leuven, Belgium; [Verelst, Frederik; Hens, Niel; Beutels, Philippe] Univ Antwerp, Fac Med & Hlth Sci, Ctr Hlth Econ Res & Modelling Infect Dis, VAXINFECTIO, B-2000 Antwerp, Belgium; [Crevecoeur, Jonas; Vranckx, Maren; Hens, Niel; Neyens, Thomas] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Data Sci Inst, Martelarenlaan 42, B-3500 Hasselt, Belgium; [Pepermans, Koen] Univ Antwerp, Fac Social Sci, Sint Jacobstr 2, B-2000 Antwerp, Belgium		Valckx, S (通讯作者)，Univ Antwerp, Univ Pl 1,DS2-51, BE-2610 Antwerp, Belgium.	sara.valckx@uantwerpen.be; jonas.crevecoeur@kuleuven.be; frederik.Verelst@uantwerpen.be; maren.vranckx@uhasselt.be; greet.hendrickx@uantwerpen.be; niel.hens@uantwerpen.be; pierre.vandamme@uantwerpen.be; koen.pepermans@uantwerpen.be; philippe.beutels@uantwerpen.be; thomas.neyens@uhasselt.be	Beutels, Philippe/A-1919-2010; Hens, Niel/M-4445-2017	Beutels, Philippe/0000-0001-5034-3595; Neyens, Thomas/0000-0003-2364-7555; Hens, Niel/0000-0003-1881-0637	Research Foundation FlandersFWO [G0G1920N]; University of Antwerp Fund; European Union's Horizon 2020 research and innovation programme [101003688]; Methusalem-Centre of Excellence consortium VAX-IDEA; Methusalem finance programme of the Flemish Government	The Great Corona Survey is supported by the Research Founda-tion Flanders (Grant G0G1920N, 2020) and the University of Antwerp Fund. Authors FV, NH and PB acknowledge funding from the European Union's Horizon 2020 research and innovation pro-gramme (Project EpiPose-No. 101003688, 2020) . All VAXINFECTIO authors acknowledge funding as part of the Methusalem-Centre of Excellence consortium VAX-IDEA. Support from the Methusalem finance programme of the Flemish Government is gratefully acknowledged. These funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.	Amirthalingam G, 2013, EUROSURVEILLANCE, V18, P19, DOI 10.2807/1560-7917.ES2013.18.38.20587; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Centers for disase control and prevention, 2020, PEOPL CERT MED COND; Corona study, 2020, AR YOU DEAL COR; Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041; European Centre for Disease Prevention and Control, 2020, COVID 19 VACC PRIOR; European Commission, 2019, SPECIAL EUROBAROMETE; European Commission, 2020, QUEST ANSW COVID 19; European Commission, 2020, COR VACC STRAT; European Medicines Agency, 2020, COVID 19 VACC DEV EV; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Goldberg D., 1988, USERS GUIDE GEN HLTH; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Guillaume LR, 2004, HEALTH SOC CARE COMM, V10, P5; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Kessels R, 2021, VACCINE, V39, P4716, DOI 10.1016/j.vaccine.2021.05.069; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Larson H, 2019, EUR J PUBLIC HEALTH, V29, P141; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Leung K, 2021, EUROSURVEILLANCE, V26, P15, DOI 10.2807/1560-7917.ES.2020.26.1.2002106; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Luyten J, 2015, VALUE HEALTH, V18, P224, DOI 10.1016/j.jval.2014.12.007; Luyten J, 2014, EUR J PUBLIC HEALTH, V24, P310, DOI 10.1093/eurpub/ckt080; Luyten J, 2013, SOC SCI MED, V77, P84, DOI 10.1016/j.socscimed.2012.11.009; Luyten J, 2011, PUBLIC HEALTH ETH-UK, V4, P280, DOI 10.1093/phe/phr032; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Motta M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113642; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Neyens T, 2020, SPAT SPATIO-TEMPORAL, V35, DOI 10.1016/j.sste.2020.100379; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Poels K, 2020, ONDERZOEK NAAR ATTIT; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Sciensano, 2018, GEZ 2018; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Tjalma WAA, 2018, FACTS VIEWS VIS OBGY, V10, P101; U.S. Food and Drug Administration, 2020, COVID 19 VACC; Vandermeulen C, 2016, STUDIE VACCINATIEGRA; Verelst F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030264; Verelst F, 2020, EUROSURVEILLANCE, V25, P13, DOI 10.2807/1560-7917.ES.2020.25.13.2000323; Verelst F, 2018, SOC SCI MED, V207, P106, DOI 10.1016/j.socscimed.2018.04.038; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wellcome, 2018, WELLC GLOB MON 2018; Wetenschappelijk Instituut Volksgezondheid, 2011, SURV GRIEP BELG SEIZ; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; World Health Organisation, 2019, 10 THREATS GLOB HLTH; World Health Organisation, 2020, COVID 19 VACC SAF SU; World Health Organisation, 2021, DRAFT LANDSC TRACK C; World Health Organisation, 2020, EM US LIST PROC; Wynen J, 2020, TRUSTGOV C	56	5	5	6	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					151	161		10.1016/j.vaccine.2021.10.073		DEC 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XQ1FV	34863621	Bronze, Green Published			2022-04-29	WOS:000731299800022
J	Kowalewicz-Kulbat, M; Locht, C				Kowalewicz-Kulbat, Magdalena; Locht, Camille			BCG for the prevention and treatment of allergic asthma	VACCINE			English	Article						Allergy; Asthma; BCG; Mouse; Rat; Observational studies; Randomized controlled trials	CALMETTE-GUERIN VACCINATION; MYCOBACTERIUM-BOVIS-BCG; TUBERCULIN REACTIVITY; NEONATAL BCG; CHILDHOOD ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; INFLAMMATORY RESPONSES; AIRWAY INFLAMMATION; PRESCHOOL-CHILDREN; LOWER PREVALENCE	Allergic diseases, in particular atopic asthma, have been on the rise in most industrialized countries for several decades now. Allergic asthma is characterized by airway narrowing, bronchial hyperresponsive-ness, excessive airway mucus production, eosinophil influx in the lungs and an imbalance of the Th1/Th2 responses, including elevated IgE levels. Most available interventions provide only short-term relief from disease symptoms and do not alter the underlying immune imbalance. A number of studies, mostly in mouse models, have shown that Mycobacterium bovis bacillus Calmette-Guerin (BCG) treatment is cap-able of preventing or reducing an established allergen-driven inflammatory response, by redirecting pathogenic Th2 towards protective Th1 and/or regulatory T cell responses. Dendritic cells stimulated by BCG appear to be a crucial first step in the immunomodulatory effects of BCG. While the protective and therapeutic effects of BCG against allergy and asthma are well documented in animal models, they are less clear in humans, both in observational studies and in randomized controlled trials. The purpose of this article is to provide an up-to-date overview of the available evidence on the anti-allergy, in par-ticular anti-asthma effects of BCG in mice, rats and humans. (c) 2021 Elsevier Ltd. All rights reserved.	[Kowalewicz-Kulbat, Magdalena; Locht, Camille] Univ Lodz, Fac Biol & Environm Protect, Inst Microbiol Biotechnol & Immunol, Dept Immunol & Infect Biol, Lodz, Poland; [Locht, Camille] Univ Lille, CNRS, INSERM, CHU Lille,Inst Pasteur Lille,U1019 UMR9017 CIIL C, F-59000 Lille, France		Locht, C (通讯作者)，Inst Pasteur, Ctr Infect & Immun Lille, 1 Rue Prof Calmette, F-59019 Lille, France.	camille.locht@pasteur-lille.fr		Kowalewicz-Kulbat, Magdalena/0000-0003-4447-0859			Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; Agache I., 2014, GLOBAL ATLAS ALLERGY; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Alm JS, 2002, GENES IMMUN, V3, P71, DOI 10.1038/sj.gene.6363834; Annus T, 2004, ALLERGY, V59, P1068, DOI 10.1111/j.1398-9995.2004.00557.x; Arikan C, 2004, CLIN EXP ALLERGY, V34, P398, DOI 10.1111/j.1365-2222.2004.01869.x; Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Arnoldussen DL, 2011, J ALLERGY CLIN IMMUN, V127, P246, DOI 10.1016/j.jaci.2010.07.039; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Bager P, 2003, CLIN EXP ALLERGY, V33, P1512, DOI 10.1046/j.1365-2222.2003.01796.x; Barlan IB, 2002, J ASTHMA, V39, P239, DOI 10.1081/JAS-120002473; Biet F, 2005, ALLERGY, V60, P1065, DOI 10.1111/j.1398-9995.2005.00826.x; Biet F, 2002, J MOL MED-JMM, V80, P147, DOI 10.1007/s00109-001-0307-1; Biet F, 2002, INFECT IMMUN, V70, P6549, DOI 10.1128/IAI.70.12.6549-6557.2002; Bilenki L, 2010, J IMMUNOL, V184, P7288, DOI 10.4049/jimmunol.0902829; Bloomfield SF, 2006, CLIN EXP ALLERGY, V36, P402, DOI 10.1111/j.1365-2222.2006.02463.x; Gouveia ACC, 2013, J CLIN IMMUNOL, V33, P235, DOI 10.1007/s10875-012-9746-4; Choi IS, 2007, LUNG, V185, P179, DOI 10.1007/s00408-007-9003-4; Choi IS, 2005, ANN ALLERG ASTHMA IM, V95, P571, DOI 10.1016/S1081-1206(10)61021-6; Choi IS, 2003, ALLERGY, V58, P1114, DOI 10.1034/j.1398-9995.2003.00246.x; Choi IS, 2002, ANN ALLERG ASTHMA IM, V88, P584, DOI 10.1016/S1081-1206(10)61890-X; Cohon A, 2007, J ALLERGY CLIN IMMUN, V120, P210, DOI 10.1016/j.jaci.2007.04.018; da Cunha SS, 2004, ALLERGY, V59, P857; Datau EA, 2008, WORLD ALLERGY ORGAN, V1, P63, DOI 10.1097/WOX.0b013e31816c8b85; de Andrade CR, 2013, RESP MED, V107, P317, DOI 10.1016/j.rmed.2012.10.009; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Deng Y, 2014, VACCINE, V32, P2070, DOI 10.1016/j.vaccine.2014.02.007; Deng Y, 2011, J CLIN IMMUNOL, V31, P419, DOI 10.1007/s10875-010-9503-5; Ealey KN, 2017, IMMUNOL REV, V278, P207, DOI 10.1111/imr.12547; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Eguiluz-Gracia I, 2020, ALLERGY, V75, P2170, DOI 10.1111/all.14177; Eifan AO, 2009, PEDIAT ALLERG IMM-UK, V20, P545, DOI 10.1111/j.1399-3038.2008.00846.x; El-Zein M, 2017, AM J EPIDEMIOL, V186, P344, DOI 10.1093/aje/kwx088; El-Zein M, 2010, INT J EPIDEMIOL, V39, P469, DOI 10.1093/ije/dyp307; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Flohr C, 2012, PEDIAT ALLERG IMM-UK, V23, P324, DOI 10.1111/j.1399-3038.2011.01248.x; Gao XL, 2012, EUR J IMMUNOL, V42, P165, DOI 10.1002/eji.201141833; Garcia-Marcosa L, 2005, INT ARCH ALLERGY IMM, V137, P303, DOI 10.1159/000086461; Garn H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.637087; Gruber C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e36; Gruber C, 2002, PEDIAT ALLERG IMM-UK, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Gurram RK, 2019, CELL MOL IMMUNOL, V16, P225, DOI 10.1038/s41423-019-0210-8; Hammad H, 2021, CELL, V184, P1469, DOI 10.1016/j.cell.2021.02.016; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Jentoft HF, 2002, ALLERGY, V57, P336, DOI 10.1034/j.1398-9995.2002.1s3342.x; Kim YJ, 2014, ALLERGY ASTHMA IMMUN, V6, P201, DOI 10.4168/aair.2014.6.3.201; Kiraly N, 2013, ALLERGY, V68, P1168, DOI 10.1111/all.12216; Kowalewicz-Kulbat M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030277; Kowalewicz-Kulbat M, 2018, VACCINE, V36, P4566, DOI 10.1016/j.vaccine.2018.05.068; Krause TG, 2003, JAMA-J AM MED ASSOC, V289, P1012, DOI 10.1001/jama.289.8.1012; Lambrecht BN, 2019, IMMUNITY, V50, P975, DOI 10.1016/j.immuni.2019.03.018; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Li R, 2006, PEDIATR RES, V59, P210, DOI 10.1203/01.pdr.0000196368.08210.5c; Linehan MF, 2007, J ALLERGY CLIN IMMUN, V119, P1079, DOI 10.1016/j.jaci.2006.12.672; Linehan MF, 2014, J ALLERGY CLIN IMMUN, V133, P688, DOI 10.1016/j.jaci.2013.08.007; Liu MY, 2017, WORLD J GASTROENTERO, V23, P2149, DOI 10.3748/wjg.v23.i12.2149; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lunjani N, 2018, ALLERGY, V73, P2314, DOI 10.1111/all.13634; Major T, 2002, VACCINE, V20, P1532, DOI 10.1016/S0264-410X(01)00496-0; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Messina NL, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-032844; Messing M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041350; Miyake Y, 2008, CLIN EXP ALLERGY, V38, P486, DOI 10.1111/j.1365-2222.2007.02869.x; Mohrenschlager M, 2007, PEDIAT ALLERG IMM-UK, V18, P5, DOI 10.1111/j.1399-3038.2006.00485.x; Nahori MA, 2001, VACCINE, V19, P1484, DOI 10.1016/S0264-410X(00)00345-5; Navaratna S, 2021, ALLERGY, V76, P2135, DOI 10.1111/all.14771; Obihara CC, 2006, CLIN EXP ALLERGY, V36, P70, DOI 10.1111/j.1365-2222.2005.02408.x; Omenaas E, 2000, THORAX, V55, P454, DOI 10.1136/thorax.55.6.454; Ota MOC, 2003, CLIN EXP ALLERGY, V33, P731, DOI 10.1046/j.1365-2222.2003.01599.x; Ou-Yang HF, 2009, IMMUNOLOGY, V128, pe343, DOI 10.1111/j.1365-2567.2008.02970.x; Ozera A, 2003, IMMUNOL LETT, V86, P29, DOI 10.1016/S0165-2478(02)00261-4; Park Sung Soo, 2015, Int J Med Sci, V12, P668, DOI 10.7150/ijms.12233; Qu SY, 2013, RESPIRATION, V85, P49, DOI 10.1159/000340007; Reddel HK, 2014, INT J TUBERC LUNG D, V18, P505, DOI 10.5588/ijtld.14.0246; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Samary CD, 2013, RESP PHYSIOL NEUROBI, V189, P614, DOI 10.1016/j.resp.2013.07.025; Sarinho E, 2000, J ALLERGY CLIN IMMUN, V106, P1199; Shen H, 2008, ALLERGY, V63, P555, DOI 10.1111/j.1398-9995.2008.01637.x; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Singh M, 2013, AM J RHINOL ALLERGY, V27, pE107, DOI 10.2500/ajra.2013.27.3940; Steenhuis TJ, 2008, CLIN EXP ALLERGY, V38, P79, DOI 10.1111/j.1365-2222.2007.02859.x; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Szpakowski P, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/359153; Tarancon R, 2021, EBIOMEDICINE, V64, DOI 10.1016/j.ebiom.2020.103186; TEIXEIRA HC, 1995, IMMUNOL LETT, V46, P15, DOI 10.1016/0165-2478(95)00009-T; Thostesen LM, 2018, ALLERGY, V73, P498, DOI 10.1111/all.13314; Thostesen LM, 2017, J ALLERGY CLIN IMMUN, V140, P1616, DOI 10.1016/j.jaci.2016.12.990; Thostesen LM, 2017, PEDIAT ALLERG IMM-UK, V28, P588, DOI 10.1111/pai.12748; Townley RG, 2004, ANN ALLERG ASTHMA IM, V92, P350, DOI 10.1016/S1081-1206(10)61574-8; Valenta R, 2011, J ALLERGY CLIN IMMUN, V127, P860, DOI 10.1016/j.jaci.2011.02.016; von Hertzen L, 1999, J ALLERGY CLIN IMMUN, V104, P1211, DOI 10.1016/S0091-6749(99)70015-1; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; Xian SJ, 2021, CLIN RESPIR J, V15, P457, DOI 10.1111/crj.13346; Yang X, 2002, IMMUNOLOGY, V105, P336, DOI 10.1046/j.0019-2805.2002.01377.x; Yang X, 1999, IMMUNOLOGY, V98, P329	97	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 8	2021	39	50					7341	7352		10.1016/j.vaccine.2021.07.092		DEC 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK8NB	34417052	Bronze			2022-04-29	WOS:000727714000015
J	Babuadze, GG; Echanove, J; Lamarre, C; Delavega, MA; Fausther-Bovendo, H; Racine, T; Gomez, AM; Azizi, H; Wade, M; Kozak, R; Kobinger, GP				Babuadze, George Giorgi; Echanove, Jose; Lamarre, Claude; Delavega, Marc-Antoine; Fausther-Bovendo, Hugues; Racine, Trina; Gomez, Alejandro M.; Azizi, Hiva; Wade, Mathew; Kozak, Robert; Kobinger, Gary P.			A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity	VACCINE			English	Article						Novel plasmid; DNA; Vaccine; Viral antigens; Immunogenicity	ELECTROPORATION; EFFICACY	The development of new, low-cost vaccines and effective gene therapies requires accurate delivery and high-level expression of candidate genes. We developed a plasmid vector, pIDV-II, that allows for both easy manipulation and high expression of exogenous genes in mammalian cells. This plasmid is based upon the pVax1 plasmid and shares a common structure with typical mammalian transcription units. It is composed of a chicken b-actin promoter (CAG), followed by an intron and flanked by two restriction sites, and also includes a post-transcriptional regulatory element, followed by a transcriptional termina-tion signal. While the modification of pVax1 elements either decreased eGFP expression levels or had no effect at all, replacement of the promoter, the poly-A signal, deletion of the T7 and AmpR promoters, and inversion of the ORI-Neo/Kan cassette, significantly increased in vitro eGFP expression with the modified plasmid called pIDV-II. To further evaluate our vector, expression levels of three viral antigens were com-pared in cell lines transfected either with pVax1 or pCAGGS backbones as controls. Higher transgene expression was consistently observed with pIDV-II. The humoral and cellular responses generated in mice immunized with pIDV-II vs pVax1 expressing each viral antigen individually were superior by 2 -fold or more as measured by ELISA and ELISPOT assays. Overall these results indicate that pIDV-II induces robust transgene expression, with concomitant improved cellular and humoral immune responses against the transgene of interest over pVax1. The new vector, pIDV-II, offers an additional alternative for DNA based vaccination and gene therapy for animal and human use. (c) 2021 Published by Elsevier Ltd.	[Babuadze, George Giorgi; Echanove, Jose; Lamarre, Claude; Delavega, Marc-Antoine; Fausther-Bovendo, Hugues; Racine, Trina; Gomez, Alejandro M.; Azizi, Hiva; Wade, Mathew] Univ Laval, Axe Malad Infect & Immunitaires, Ctr Hosp Univ Quebec, Ctr Rech, Quebec City, PQ G1V 4G2, Canada; [Delavega, Marc-Antoine; Kobinger, Gary P.] Univ Laval, Fac Med, Dept Microbiol Infectiol & Immunol, Quebec City, PQ G1V 0A6, Canada; [Racine, Trina] Int Vaccine Ctr VIDO InterVac, Vaccine & Infect Dis Org, Saskatoon, SK, Canada; [Kobinger, Gary P.] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada; [Kozak, Robert] Sunnybrook Hlth Sci Ctr, Dept Lab Med & Mol Diagnost, Div Microbiol, Toronto, ON, Canada; [Kozak, Robert] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada		Kobinger, GP (通讯作者)，Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.	gakobing@UTMB.edu		LAMARRE, CLAUDE/0000-0001-6156-5564	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [143521, PJT-148747]; Canadian non-profit GUARD	This work was supported by a grant from the Canadian Institutes of Health Research (grant #143521). RK and GPK were authors who received the grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was funded by the Canadian Institute of Health Research grant #PJT-148747 and contribution from the Canadian non-profit GUARD.	Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; Aviles J, 2015, J INFECT DIS, V212, pS389, DOI 10.1093/infdis/jiv175; Buchan S, 2005, J IMMUNOL, V174, P6292, DOI 10.4049/jimmunol.174.10.6292; Coban C, 2008, HUM VACCINES, V4, P453, DOI 10.4161/hv.4.6.6200; Donnelly J J, 1998, Dev Biol Stand, V95, P43; Ferraro B, 2011, CLIN INFECT DIS, V53, P296, DOI 10.1093/cid/cir334; Garg S, 2004, J IMMUNOL, V173, P550, DOI 10.4049/jimmunol.173.1.550; Garrison AR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005908; Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7; Goedhals D, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006149; Haddock E, 2018, NAT MICROBIOL, V3, P556, DOI 10.1038/s41564-018-0141-7; Hasson Sidgi Syed Anwer Abdo, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P344, DOI 10.1016/S2221-1691(15)30366-X; Khan Kishwar Hayat, 2013, Germs, V3, P26, DOI 10.11599/germs.2013.1034; Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432; Laddy DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002517; Modjarrad K, 2019, LANCET INFECT DIS, V19, P1013, DOI 10.1016/S1473-3099(19)30266-X; Patel A, 2017, J IMMUNOL, V198; Pertl U, 2003, BLOOD, V101, P649, DOI 10.1182/blood-2002-02-0391; Racine T, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0179-2; Strasser JE, 2000, J INFECT DIS, V182, P1304, DOI 10.1086/315878; Sun J, 2009, DNA CELL BIOL, V28, P233, DOI 10.1089/dna.2009.0862; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Tebas P., 2017, OPEN FORUM INFECT DI, V4, pS300, DOI [10.1093/ofid/ofx163.693, DOI 10.1093/OFID/OFX163.693]; Wang QT, 2014, J VIROL, V88, P1924, DOI 10.1128/JVI.02757-13; Wong G, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004582; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	26	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 3	2021	39	49					7175	7181		10.1016/j.vaccine.2021.10.008		NOV 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ2JG	34774358				2022-04-29	WOS:000726620400012
J	Maltezou, HC; Panagopoulos, P; Sourri, F; Giannouchos, TV; Raftopoulos, V; Gamaletsou, MN; Karapanou, A; Koukou, DM; Koutsidou, A; Peskelidou, E; Papanastasiou, K; Souliotis, K; Lourida, A; Sipsas, NV; Hatzigeorgiou, D				Maltezou, Helena C.; Panagopoulos, Periklis; Sourri, Flora; Giannouchos, Theodoros, V; Raftopoulos, Vasilios; Gamaletsou, Maria N.; Karapanou, Amalia; Koukou, Dimitra-Maria; Koutsidou, Athanasia; Peskelidou, Emmanuela; Papanastasiou, Konstantina; Souliotis, Kyriakos; Lourida, Athanasia; Sipsas, Nikolaos, V; Hatzigeorgiou, Dimitrios			COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study	VACCINE			English	Article						COVID-19; Healthcare personnel; Morbidity; Absenteeism; Vaccination	DEPARTMENTS; STAFF	Aim: Healthcare personnel (HCP) are prioritized for coronavirus disease 2019 (COVID-19) vaccination to protect them and non-disruptive provision of healthcare services. We assessed the impact of the PfizerBioNTech vaccine on morbidity and absenteeism among HCP. Methods: We studied 7445 HCP in five tertiary-care hospitals in Greece from November 15, 2020 through April 18, 2021. Results: A total of 910 episodes of absenteeism and 9695 days of absence were recorded during the entire study period. Starting from January 4, 2021, 4823/7445 HCP (64.8%) were fully or partially vaccinated. Overall, 535 episodes of absenteeism occurred from January 4, 2021 through April 18, 2021, including 309 (57.76%) episodes among 2622 unvaccinated HCP and 226 (42.24%) episodes among 4823 vaccinated HCP (11.8 versus 4.7 episodes of absenteeism per 100 HCP, respectively; p-value < 0.001). The mean duration of absenteeism was 11.9 days among unvaccinated HCP compared with 6.9 days among vaccinated HCP (p-value < 0.001). Unvaccinated HCP more frequently developed acute respiratory infection, influenza-like illness, and COVID-19 (p-values < 0.001 for all comparisons). Vaccine effectiveness for fully vaccinated HCP was estimated at 94.16% [confidence interval (CI): 88.50%-98.05%) against COVID-19, 83.62% (CI: 73.36%-90.38%) against SARS-CoV-2 infection (asymptomatic or COVID-19), and 66.42% (CI: 56.86%-74.15%) against absenteeism. Conclusion: The COVID-19 pandemic had a considerable impact on healthcare workforce. The PfizerBioNTech vaccine significantly reduced morbidity, COVID-19, absenteeism and duration of absenteeism among HCP during a period of high SARS-CoV-2 circulation in the community. It is expected that HCP vaccination will protect them and healthcare services and contain healthcare costs. (c) 2021 Elsevier Ltd. All rights reserved.	[Maltezou, Helena C.] Natl Publ Hlth Org, Directorate Res Studies & Documentat, 3-5 Agrafon St, Athens 15123, Greece; [Panagopoulos, Periklis] Democritus Univ Thrace, Med Sch, Dept Internal Med 2, Alexandroupolis, Greece; [Sourri, Flora] 251 Hellen Air Force Gen Hosp, Dept Infect Control, Athens, Greece; [Giannouchos, Theodoros, V] Univ South Carolina, Arnold Sch Publ Hlth, Dept Hlth Serv Policy & Management, Columbia, SC 29208 USA; [Raftopoulos, Vasilios] Natl Publ Hlth Org, Dept HIV Surveillance, Athens, Greece; [Gamaletsou, Maria N.; Sipsas, Nikolaos, V] Natl & Kapodistrian Univ Athens, Med Sch, Pathophysiol Dept, Athens, Greece; [Karapanou, Amalia] Laikon Gen Hosp, Infect Control Comm, Athens, Greece; [Koukou, Dimitra-Maria] Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Athens, Greece; [Koutsidou, Athanasia] Alexandroupolis Univ Hosp, Infect Control Comm, Alexandroupolis, Greece; [Peskelidou, Emmanuela] 424 Gen Mil Hosp Thessaloniki, COVID 19 Intens Care Unit, Thessaloniki, Greece; [Papanastasiou, Konstantina] 424 Gen Mil Hosp Thessaloniki, Operating Rooms, Thessaloniki, Greece; [Souliotis, Kyriakos] Univ Peloponnese, Fac Social & Polit Sci, Corinth, Greece; [Souliotis, Kyriakos] Hlth Policy Inst, Athens, Greece; [Lourida, Athanasia] Aghia Sofia Childrens Hosp, Infect Control Comm, Athens, Greece; [Hatzigeorgiou, Dimitrios] Hellen Natl Def Gen Staff, Med Directorate, Athens, Greece		Maltezou, HC (通讯作者)，Natl Publ Hlth Org, Directorate Res Studies & Documentat, 3-5 Agrafon St, Athens 15123, Greece.	helen-maltezou@ath.forthnet.gr					Alquezar-Arbe A, 2020, EMERGENCIAS, V32, P320; Angel Y, 2021, JAMA-J AM MED ASSOC, V325, P2457, DOI 10.1001/jama.2021.7152; Bandyopadhyay S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003097; Challener DW, 2021, INFECT CONT HOSP EP, V42, P388, DOI 10.1017/ice.2020.453; Flores S, 2020, AM J EMERG MED, V38, P1534, DOI 10.1016/j.ajem.2020.04.056; Frederick J, 2018, INFECT CONT HOSP EP, V39, P452, DOI 10.1017/ice.2018.9; Gianino MM, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16050747; Groenewold MR, 2020, MMWR-MORBID MORTAL W, V69, P853, DOI 10.15585/mmwr.mm6927a1; Halloran ME, 1997, AM J EPIDEMIOL, V146, P789; Homrich Paulo Henrique Poti, 2020, Rev Bras Med Trab, V18, P97, DOI 10.5327/Z1679443520200478; Imai C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198685; Keehner J, 2021, NEW ENGL J MED, V384, P1774, DOI 10.1056/NEJMc2101927; Khorasanee R, 2021, CLIN MED, V21, pE150, DOI 10.7861/clinmed.2020-0547; Maltezou HC, 2021, J HOSP INFECT, V114, P126, DOI 10.1016/j.jhin.2021.04.018; Maltezou HC, 2020, CLIN INFECT DIS, V71, P3182, DOI 10.1093/cid/ciaa888; Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141; Romero MM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241030; National Public Health Organization, 2021, WEEKL REP EP SURV IN; National Public Health Organization, GUID IS VACC HCP HCP; National Public Health Organization, DAILY REP EP SURV SA; Nguyen LH, 2020, LANCET PUBLIC HEALTH, V5, pE475, DOI 10.1016/S2468-2667(20)30164-X; Palladino R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165644; Pilishvili T, 2021, MMWR-MORBID MORTAL W, V70, P753, DOI 10.15585/mmwr.mm7020e2externalicon; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Tyrrell CSB, 2021, THORAX, V76, P302, DOI 10.1136/thoraxjnl-2020-215518; Van Buynder PG, 2015, VACCINE, V33, P1625, DOI 10.1016/j.vaccine.2015.01.048; World Health Organization, COR DIS COVID 19 PAN; World Health Organization, 2020, WHO STRAT ADV GROUP; Wu P., 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab271, DOI 10.1093/CID/CIAB271]	29	6	6	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 26	2021	39	48					7021	7027		10.1016/j.vaccine.2021.10.054		NOV 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XB3QQ	34740473	Bronze, Green Published			2022-04-29	WOS:000721246800009
J	Opriessnig, T; Rawal, G; McKeen, L; Favaro, PF; Halbur, PG; Gauger, PC				Opriessnig, Tanja; Rawal, Gaurav; McKeen, Lauren; Favaro, Patricia Filippsen; Halbur, Patrick G.; Gauger, Phillip C.			Evaluation of the intranasal route for porcine reproductive and respiratory disease modified-live virus vaccination	VACCINE			English	Article							IMMUNE-RESPONSES; PRRSV INFECTION; T-CELLS; MUCOSAL; PATHOGENICITY; PROTECTION; EVOLUTION; EFFICACY; DELIVERY; VACCINES	Background: In pigs, modified live virus (MLV) vaccines against porcine reproductive and respiratory syndrome virus (PRRSV) are commonly used and administered by intramuscular (IM) injection. In contrast, PRRSV, as a primary respiratory pathogen, is mainly transmitted via the intranasal (IN) route. The objective of this study was to evaluate the efficacy of a commonly used commercial PRRSV MLV delivered IN compared to the IM route. Methods: Fifty-four pigs were divided into five treatment groups. All vaccinated groups received the same MLV vaccine but administered via different routes. Group IN-JET-VAC was vaccinated with an automated high pressure prototype nasal jet device (IN-JET-VAC, n = 12), group IN-MAD-VAC was vaccinated with a mucosal atomization device (IN-MAD-VAC, n = 12), group IM-VAC was vaccinated intramuscularly (IM-VAC; n = 12) according to label instructions, while the NEG-CONTROL (n = 6) and the POS-CONTROL (n = 12) groups were both unvaccinated. At 28 days post vaccination all vaccinated groups and the POSCONTROL pigs were challenged with a pathogenic US PRRSV isolate. Blood and nasal swabs were collected at regular intervals, and all pigs were necropsied at day 10 post challenge (dpc) when gross and microscopic lung lesions were assessed. Results: Prior to challenge most vaccinated pigs had seroconverted to PRRSV. Clinical signs (fever, inappetence) were most obvious in the POS-CONTROL group from dpc 7 onwards. The vaccinated groups were not different for PRRSV viremia, seroconversion, or average daily weight gain. However, IN-JET-VAC and IN-MAD-VAC had significantly higher neutralizing antibody levels against the vaccine virus at challenge. Conclusions: Comparable vaccine responses were obtained in IN and IM vaccinated pigs, suggesting the intranasal administration route as an alternative option for PRRSV vaccination. (C) 2021 Elsevier Ltd. All rights reserved.	[Opriessnig, Tanja] Univ Edinburgh, Sch Vet Stud, Roslin Inst & Royal Dick, Edinburgh, Midlothian, Scotland; [Opriessnig, Tanja; Rawal, Gaurav; Halbur, Patrick G.; Gauger, Phillip C.] Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, Ames, IA USA; [Favaro, Patricia Filippsen] Univ Wisconsin Madison, Sch Med & Publ Hlth, Madison, WI USA; [McKeen, Lauren] Iowa State Univ, Dept Stat, Ames, IA USA		Opriessnig, T (通讯作者)，Univ Edinburgh, Sch Vet Stud, Roslin Inst & Royal Dick, Edinburgh, Midlothian, Scotland.; Opriessnig, T (通讯作者)，Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, Ames, IA USA.	Tanja.Opriessnig@roslin.ed.ac.uk			National Pork Board (NPB) [18-171]; Biotechnology and Biological Sciences Research Council (BBSRC)UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/J004324/1, BBS/E/D/20241864]	This project was funded by the National Pork Board (NPB project ID: 18-171). T. Opriessnig received support provided by the Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme Grant awarded to the Roslin Institute (BB/J004324/1; BBS/E/D/20241864).	Adams MJ, 2017, ARCH VIROL, V162, P2505, DOI 10.1007/s00705-017-3358-5; An X, ISCIENCE, V2021; Binjawadagi B, 2011, VIRAL IMMUNOL, V24, P475, DOI 10.1089/vim.2011.0040; Brar MS, 2015, J GEN VIROL, V96, P1570, DOI 10.1099/vir.0.000104; COOPER VL, 1995, J VET DIAGN INVEST, V7, P313, DOI 10.1177/104063879500700303; Dwivedi V, 2011, VACCINE, V29, P4067, DOI 10.1016/j.vaccine.2011.03.005; Goldberg TL, 2003, VIROLOGY, V317, P197, DOI 10.1016/j.virol.2003.07.009; Guo ZH, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0910-6; Halbur PG, 1996, VET PATHOL, V33, P159, DOI 10.1177/030098589603300205; HALBUR PG, 1994, J VET DIAGN INVEST, V6, P254, DOI 10.1177/104063879400600219; HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606; Halbur PG, 1996, J VET DIAGN INVEST, V8, P11, DOI 10.1177/104063879600800103; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Hosseini S, 2019, J AEROSOL MED PULM D, V32, P374, DOI 10.1089/jamp.2019.1523; Key KF, 2001, VET MICROBIOL, V83, P249, DOI 10.1016/S0378-1135(01)00427-8; Linhares DCL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144265; Martini V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594470; Masopust D, 2012, J IMMUNOL, V188, P5811, DOI 10.4049/jimmunol.1102695; Mengeling WL, 1996, AM J VET RES, V57, P834; Murtaugh MP, 2002, VIRAL IMMUNOL, V15, P533, DOI 10.1089/088282402320914485; Okuda Y, 2008, J VET MED SCI, V70, P1017, DOI 10.1292/jvms.70.1017; Paploski IAD, VACCINES-BASEL, V2021, P9; Paploski IAD, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02486; Rawal G., TRANSBOUND EMERG DIS; Renukaradhya Gourapura J., 2012, Animal Health Research Reviews, V13, P21, DOI 10.1017/S1466252312000023; Rowland RRR, 1999, VIROLOGY, V259, P262, DOI 10.1006/viro.1999.9789; Sanchez-Cordon PJ, 2017, ANTIVIR RES, V138, P1, DOI 10.1016/j.antiviral.2016.11.021; Shi M, 2010, VIRUS RES, V154, P7, DOI 10.1016/j.virusres.2010.08.014; van Geelen AGM, 2018, VIROLOGY, V513, P168, DOI 10.1016/j.virol.2017.10.002; Van Noort A, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0746-0; Wang Y, 2021, TRANSBOUND EMERG DIS, V68, P1414, DOI 10.1111/tbed.13808; Wang ZH, 2014, CELL IMMUNOL, V287, P69, DOI 10.1016/j.cellimm.2013.12.004; Wu T, 2014, J LEUKOCYTE BIOL, V95, P215, DOI 10.1189/jlb.0313180; Xie CZ, 2020, MICROB PATHOGENESIS, V140, DOI 10.1016/j.micpath.2019.103941; Yoon KJ, 1999, VET RES, V30, P629; Zhang LH, 2007, INT IMMUNOPHARMACOL, V7, P1732, DOI 10.1016/j.intimp.2007.09.012; Zuckermann FA, 2007, VET MICROBIOL, V123, P69, DOI 10.1016/j.vetmic.2007.02.009	37	1	1	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6852	6859		10.1016/j.vaccine.2021.10.033		NOV 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34706840				2022-04-29	WOS:000719580000006
J	Mottelson, A; Vandeweerdt, C; Atchapero, M; Luong, T; Holz, C; Bohm, R; Makransky, G				Mottelson, Aske; Vandeweerdt, Clara; Atchapero, Michael; Luong, Tiffany; Holz, Christian; Bohm, Robert; Makransky, Guido			A self-administered virtual reality intervention increases COVID-19 vaccination intention	VACCINE			English	Article						Vaccination; Vaccine hesitancy; Vaccine advocacy; Virtual reality; COVID-19; Corona virus; Body ownership; Embodiment	OWNERSHIP	Effective interventions for increasing people's intention to get vaccinated are crucial for global health, especially considering COVID-19. We devised a novel intervention using virtual reality (VR) consisting of a consultation with a general practitioner for communicating the benefits of COVID-19 vaccination and, in turn, increasing the intention to get vaccinated against COVID-19. We conducted a preregistered online experiment with a 2 x 2 between-participant design. People with eligible VR headsets were invited to install our experimental application and complete the ten minute virtual consultation study at their own discretion. Participants were randomly assigned across two age conditions (young or old self-body) and two communication conditions (with provision of personal benefit of vaccination only, or collective and personal benefit). The primary outcome was vaccination intention (score range 1-100) measured three times: immediately before and after the study, as well as one week later. Five-hundred-and-seven adults not vaccinated against COVID-19 were recruited. Among the 282 participants with imperfect vaccination intentions (< 100), the VR intervention increased pre-to-post vaccination intentions across intervention conditions (mean difference 8.6, 95% CI 6.1 to 11.1, p < 0.0001). The pre-to-post difference significantly correlated with the vaccination intention one week later, q 1/4 0.20, p < 0.0001. The VR intervention was effective in increasing COVID-19 vaccination intentions both when only personal benefits and personal and collective benefits of vaccination were communicated, with significant retention one week after the intervention. Utilizing recent evidence from health psychology and embodiment research to develop immersive environments with customized and salient communication efforts could therefore be an effective tool to complement public health campaigns. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Mottelson, Aske] IT Univ Copenhagen, Dept Digital Design, Copenhagen, Denmark; [Vandeweerdt, Clara] Univ Copenhagen, Dept Polit Sci, Copenhagen, Denmark; [Atchapero, Michael; Makransky, Guido] Univ Copenhagen, Dept Psychol, Copenhagen, Denmark; [Bohm, Robert] Univ Vienna, Fac Psychol, Vienna, Austria; [Bohm, Robert] Univ Copenhagen, Copenhagen Ctr Social Data Sci SODAS, Copenhagen, Denmark; [Luong, Tiffany; Holz, Christian] Swiss Fed Inst Technol, Dept Comp Sci, Zurich, Switzerland		Mottelson, A (通讯作者)，IT Univ Copenhagen, Dept Digital Design, Copenhagen, Denmark.	asmo@itu.dk		Bohm, Robert/0000-0001-6806-0374; Makransky, Guido/0000-0003-1862-7824; Mottelson, Aske/0000-0003-1827-8513	European Institute of Innovation and Technology, under the EIT Health [210836]	The study was funded by the European Institute of Innovation and Technology, under the EIT Health, Grant No. 210836. We are grateful to Philipp Sprengholz for helpful comments on an earlier draft.	Banakou D, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00917; Banakou D, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00601; Banakou D, 2014, P NATL ACAD SCI USA, V111, P17678, DOI 10.1073/pnas.1414936111; Banakou D, 2013, P NATL ACAD SCI USA, V110, P12846, DOI 10.1073/pnas.1306779110; Betsch C., 2015, SCOTTISH INDEX MULTI, V2, P61, DOI 10.1177/2372732215600716; Betsch C, 2018, NAT HUM BEHAV, V2, P881, DOI 10.1038/s41562-018-0478-1; Betsch C, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0056; Bhopal SS, 2021, LANCET CHILD ADOLESC, V5, pE12, DOI 10.1016/S2352-4642(21)00066-3; Ellerton K, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-038354; Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Freeman D, 2018, LANCET PSYCHIAT, V5, P625, DOI 10.1016/S2215-0366(18)30226-8; Geiger M., 2021, EUR J PSYCHOL ASSESS; Gonzalez Franco M, 2020, FRONT VIRTUAL REAL; Hakim H, 2019, VACCINE, V37, P235, DOI 10.1016/j.vaccine.2018.11.016; Ma X, 2018, WEB CONFERENCE 2018: PROCEEDINGS OF THE WORLD WIDE WEB CONFERENCE (WWW2018), P33, DOI 10.1145/3178876.3186034; Makransky G, 2017, COMPUT HUM BEHAV, V72, P276, DOI 10.1016/j.chb.2017.02.066; Maselli A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00083; Meister L, 2015, TRENDS COGN SCI, V19, P6, DOI 10.1016/j.tics.2014.11.001; Mottelson A, 2021, FRONT VIRTUAL REALIT, V2, P66; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nowak GJ, 2020, VACCINE, V38, P1225, DOI 10.1016/j.vaccine.2019.11.009; Peck TC, 2013, CONSCIOUS COGN, V22, P779, DOI 10.1016/j.concog.2013.04.016; Pfattheicher S, 2020, PSYCHOL SCI, V31, P1363, DOI 10.1177/0956797620964422; Real FJ, 2017, ACAD PEDIATR, V17, P431, DOI 10.1016/j.acap.2017.01.010; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405; Saaksvuori L, 2021, INFORM NUDGES INFLUE; Seanehia J, 2017, VACCINE, V35, P2676, DOI 10.1016/j.vaccine.2017.03.086; Singh Ravi Pratap, 2020, Diabetes Metab Syndr, V14, P661, DOI 10.1016/j.dsx.2020.05.011; Steed A., 2020, INTERACTIONS, V27, P62, DOI [10.1145/3406098, DOI 10.1145/3406098]; Steed A, 2016, IEEE T VIS COMPUT GR, V22, P1406, DOI 10.1109/TVCG.2016.2518135; World Health Organization, 2020, GLOBAL TUBERCULOSIS	32	2	2	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 5	2021	39	46					6746	6753		10.1016/j.vaccine.2021.10.004		NOV 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	YJ0BG	34654579	Green Published, hybrid			2022-04-29	WOS:000744203800005
J	Clements, JD; Gorman, GH; Waters, CN; Lane, HC				Clements, John D.; Gorman, Gregory H.; Waters, Clarice N.; Lane, H. Clifford		Defense Hlth Board	Tackling the burden of mumps in the military: A report of the Defense Health Board	VACCINE			English	Editorial Material							RUBELLA VACCINE; MEASLES; PERSISTENCE; OUTBREAK		[Clements, John D.] Tulane Univ, Dept Microbiol & Immunol, Sch Med, 1430 Tulane Ave Mail Code 8638, New Orleans, LA 70112 USA; [Gorman, Gregory H.] Uniformed Serv Univ Hlth Sci, Dept Pediat, Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Waters, Clarice N.] Knowesis Inc, 8315 Lee Hwy,Suite 400, Falls Church, VA 22031 USA; [Lane, H. Clifford] Natl Inst Hlth, Natl Inst Allergy & Infect Dis, Div Clin Res, 10 Ctr Dr,Rm 4-1479, Bethesda, MD 20892 USA		Clements, JD (通讯作者)，Tulane Univ, Dept Microbiol & Immunol, Sch Med, 1430 Tulane Ave Mail Code 8638, New Orleans, LA 70112 USA.	jclemen@tulane.edu; gregory.h.gorman.mil@mail.com; cwaters@knowesis-inc.com; clane@niaid.nih.gov					Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309; Centers for Disease Control and Prevention, MUMPS; Clemmons N, 2018, MANUAL SURVEILLANCE; Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993; Defense Health Board, 2020, MEASL MUMPS RUB IMM; Defense Health Board, 2010, REC PERT INCL MEASL; Moon JY, 2017, VACCINE, V35, P3913, DOI 10.1016/j.vaccine.2017.06.025; Nelson GE, 2013, PEDIATR INFECT DIS J, V32, P374, DOI 10.1097/INF.0b013e318279f593; Ogbuanu IU, 2012, PEDIATRICS, V130, pE1567, DOI 10.1542/peds.2012-0177; Plotkin SA, 2018, VACCINES-BASEL, V7th; Seagle EE, 2018, VACCINE, V36, P818, DOI 10.1016/j.vaccine.2017.12.075; U.S. Departments of the Army Navy Air Force and the Coast Guard, 2013, IMM CHEM PREV INF DI; Williams Valerie F, 2019, MSMR, V26, P2; Williams Valerie F, 2017, MSMR, V24, P2; Wohl S, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000611	15	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6186	6188		10.1016/j.vaccine.2021.09.006		SEP 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34556365				2022-04-29	WOS:000705822100002
J	Elbasha, EH; Choi, Y; Daniels, V; Goveia, MG				Elbasha, Elamin H.; Choi, Yoonyoung; Daniels, Vince; Goveia, Michelle G.			Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study	VACCINE			English	Article						Cost-effectiveness analysis; Catch-up vaccination; Dynamic transmission model; hepatitis A vaccine; hepatitis A virus; Herd protection; immunity; Simulation	QUALITY-OF-LIFE; DISEASE; OUTBREAK	Background: Despite routine vaccination of children against hepatitis A (HepA), a large segment of the United States population remains unvaccinated, imposing a risk of hepatitis A virus (HAV) to adolescents and adults. In July of 2020, the Advisory Committee on Immunization Practices recommended that all children and adolescents aged 2-18 years who have not previously received a HepA vaccine be vaccinated. We evaluated the public health impact and cost-effectiveness of this HepA catch-up vaccination strategy. Methods: We used a dynamic transmission model to compare adding a HepA catch-up vaccination of persons age 2-18 years to a routine vaccination of children 12-23 months of age with routine vaccination only in the United States. The model included various health compartments: maternal antibodies, susceptible, exposed, asymptomatic infectious, symptomatic infectious (outpatient, hospitalized, liver transplant, post-liver transplant, death), recovered, and vaccinated with and without immunity. Using a 3% annual discount rate, we estimated the incremental cost per quality-adjusted life year (QALY) gained from a societal perspective over a 100-year time horizon. All costs were converted into 2020 US dollars. Findings: Compared with the routine vaccination policy at 12-23 months of age over 100 years, the catch-up program for unvaccinated children and adolescents aged 2-18 years, prevented 70,072 additional symptomatic infections, 51,391 outpatient visits, 16,575 hospitalizations, and 413 deaths. The catch-up vaccination strategy was cost-saving when compared with the routine vaccination strategy. In scenario analysis allowing administering a second dose to partially vaccinated children, the costeffectiveness of was not favorable at a higher vaccination coverage ($196,701/QALY at 5% and $476,241/QALY at 50%). Interpretation: HepA catch-up vaccination in the United States is expected to reduce HepA morbidity and mortality and save cost. The catch-up program would be optimized when focusing on unvaccinated children and adolescents and maximizing their first dose coverage. (c) 2021 Merck Sharp and Dohme Corp. Published by Elsevier Ltd. All rights reserved.	[Elbasha, Elamin H.; Choi, Yoonyoung; Daniels, Vince; Goveia, Michelle G.] Merck & Co Inc, Kenilworth, NJ 07033 USA		Elbasha, EH (通讯作者)，Merck & Co Inc, Kenilworth, NJ 07033 USA.	elamin_elbasha@merck.com			Merck Sharp Dohme Corp.Merck & Company	We thank Alex Ruch for organizing citations for this paper and providing administrative support. Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.	Arias Elizabeth, 2008, Natl Vital Stat Rep, V57, P1; Brinkhof MWG, 2013, VACCINE, V31, P1490, DOI 10.1016/j.vaccine.2013.01.011; Bureau, US CENS BUR; Chong CAKY, 2003, AM J GASTROENTEROL, V98, P630, DOI 10.1111/j.1572-0241.2003.07332.x; Craig AS, 2004, NEW ENGL J MED, V350, P476, DOI 10.1056/NEJMcp031540; Dalton CB, 1996, ARCH INTERN MED, V156, P1013, DOI 10.1001/archinte.156.9.1013; Dhankhar P, 2015, VALUE HEALTH, V18, P358, DOI 10.1016/j.jval.2015.02.004; Fiore Anthony E., 2006, Morbidity and Mortality Weekly Report, V55, P1; Hamborsky J, 2015, EPIDEMIOLOGY PREVENT, P247; Hankin-Wei A, 2016, VACCINE, V34, P4243, DOI 10.1016/j.vaccine.2016.06.040; Hanmer J, 2006, MED DECIS MAKING, V26, P391, DOI 10.1177/0272989X06290497; Klevens RM, 2014, AM J PUBLIC HEALTH, V104, P482, DOI 10.2105/AJPH.2013.301601; Luyten J, 2011, VALUE HEALTH, V14, P282, DOI 10.1016/j.jval.2010.10.004; Luyten J, 2009, PHARMACOECONOMICS, V27, P379, DOI 10.2165/00019053-200927050-00003; Matheny SC, 2012, AM FAM PHYSICIAN, V86, P1027; Nelson NP, 2018, VACCINE, V36, P1650, DOI 10.1016/j.vaccine.2018.01.090; Nelson NP, 2020, MMWR MORBIDITY MORTA; Nelson R, 2018, LANCET INFECT DIS, V18, P33, DOI 10.1016/S1473-3099(17)30718-1; Ott JJ, 2012, VACCINE, V31, P3, DOI 10.1016/j.vaccine.2012.04.104; Prevention, 2020, WID PERS TO PERS OUT; Prevention, 1999, NAT NOT DIS SURV SYS; Prevention C. f.D.C.a., 1981, 2 NAT HLTH NUTR EX S; Prevention C. f.D.C.a., 1996, 76200 PREV CFDCA; Statistics, USBOL EC NEWS REL; U.S. Department of Labor, 2013, BOLS CONS PRIC IND; Wiens BL, 1996, J MED VIROL, V49, P235, DOI 10.1002/(SICI)1096-9071(199607)49:3&lt;235::AID-JMV13&gt;3.0.CO;2-B	26	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6315	6321		10.1016/j.vaccine.2021.08.087		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34538694				2022-04-29	WOS:000705822100022
J	Knuf, M; Haas, H; Garcia-Corbeira, P; Turriani, E; Mukherjee, P; Janssens, W; Berlaimont, V				Knuf, Markus; Haas, Herve; Garcia-Corbeira, Pilar; Turriani, Elisa; Mukherjee, Piyali; Janssens, Winnie; Berlaimont, Valerie			Hexavalent vaccines: What can we learn from head-to-head studies?	VACCINE			English	Review						Hexavalent vaccines; Immunogenicity; Safety; Composition; Head-to-head studies	DTPA-HBV-IPV/HIB; ACELLULAR PERTUSSIS VACCINES; LASTING IMMUNE MEMORY; HEPATITIS-B; FULLY-LIQUID; PRP-T; CLINICAL-TRIAL; DOUBLE-BLIND; VACCINATION; PERSISTENCE	Background: Three hexavalent vaccines against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B virus (HBV), and Haemophilus influenzae type b (Hib) are licensed in Europe: Infanrix hexa (DT3aP-HBVIPV/Hib), Hexyon (DT2aP-HBV-IPV-Hib) and Vaxelis (DT5aP-HBV-IPV-Hib). Methods: A systematic literature search was performed in various electronic databases to identify published peer-reviewed head-to-head studies comparing any licensed hexavalent vaccine to another. Results: Predefined inclusion criteria were met by 12 articles. Individual studies concluded that the 3 hexavalent vaccines have acceptable safety profiles although some significant differences were observed in their reactogenicity profiles. The immunogenicity of DT2aP-HBV-IPV-Hib and DT5aP-HBV-IPV-Hib was non-inferior versus DT3aP-HBV-IPV/Hib. Some differences in immune responses to common antigens were observed, but their clinical relevance was not established. Anti-filamentous hemagglutinin (FHA) from pertussis and anti-polyribosylribitol phosphate (PRP) from Hib antibody concentrations tended to be higher, and anti-HBV and anti-pertussis toxin (PT) from pertussis antibody concentrations lower in DT2aP-HBV-IPV-Hib versus DT3aP-HBV-IPV/Hib vaccinees. Anti-PT and post-primary anti-PRP antibody concentrations tended to be higher, and anti-HBV, anti-FHA, anti-pertactin from pertussis and post booster anti-PRP antibody concentrations lower in DT5aP-HBV-IPV-Hib versus DT3aP-HBV-IPV/Hib recipients. Slightly lower immune responses towards most vaccine antigens were observed with 2 + 1 versus 3 + 1 schedules post-primary vaccination, suggesting that 2 + 1 schedules should only be considered in countries with very high vaccination coverage. Conclusion: Although the licensed hexavalent vaccines are generally considered similar, analyses of immunogenicity data from head-to-head trials highlighted differences that could be related to differences in composition and formulation. In addition, the demonstrated non-inferiority of the immunogenicity of the more recent vaccines versus DT3aP-HBV-IPV/Hib does not allow a full bridging to similar efficacy, effectiveness and safety. The availability of DT3aP-HBV-IPV/Hib over > 20 years allowed to collect a wealth of data on its long-term immunogenicity, safety and effectiveness in clinical and post marketing studies, and makes it a key pillar of pediatric immunization. (c) 2021 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Knuf, Markus] Klinikum Worms, Gabriel von Seidl Str 81, D-67550 Worms, Germany; [Haas, Herve] Princess Grace Hosp, Dept Pediat, Ave Pasteur 1, MC-98000 Monaco, Monaco; [Garcia-Corbeira, Pilar; Turriani, Elisa; Mukherjee, Piyali; Janssens, Winnie; Berlaimont, Valerie] GSK, Ave Fleming 20, B-1300 Wavre, Belgium		Berlaimont, V (通讯作者)，GSK, Ave Fleming 20, B-1300 Wavre, Belgium.	markus.knuf@klinikum-worms.de; herve.haas@chpg.mc; valerie.x.berlaimont@gsk.com		Mukherjee, Piyali/0000-0002-9895-3795; Turriani, Elisa/0000-0002-0114-065X; Janssens, Winnie/0000-0003-1314-3468	GlaxoSmithKline Biologicals SAGlaxoSmithKline	This publication was funded by GlaxoSmithKline Biologicals SA, including all costs associated with the development and publica-tion of this manuscript.	Aronsson B, 2020, P 38 ANN M EUR SOC P; Avdicova M, 2002, EUR J PEDIATR, V161, P581, DOI 10.1007/s00431-002-1079-5; Avdicova M, 2015, VACCINE, V33, P2727, DOI 10.1016/j.vaccine.2014.06.070; Baldo V, 2014, HUM VACC IMMUNOTHER, V10, P129, DOI 10.4161/hv.26269; Bayliss J, 2021, HUM VACC IMMUNOTHER, V17, P176, DOI 10.1080/21645515.2020.1764826; Aquino AGB, 2012, VACCINE, V30, P6492, DOI 10.1016/j.vaccine.2012.07.040; Behre U, 2016, HUM VACC IMMUNOTHER, V12, P2916, DOI 10.1080/21645515.2016.1202388; Brosio F, 2020, INT J INFECT DIS, V91, P143, DOI 10.1016/j.ijid.2019.10.027; De Coster I, 2015, VACCINE, V33, P3976, DOI 10.1016/j.vaccine.2015.06.030; Dolhain J, 2018, EXPERT REV VACCINES, V17, P513, DOI 10.1080/14760584.2018.1419070; European Medicines Agency (EMA), 2021, VACC SCH ALL COUNTR; European Medicines Agency (EMA), 2020, HEX EMA SUMM PROD CH; European Medicines Agency (EMA), HEX DIPHTH TET AC PE; European Medicines Agency (EMA), 2020, VAX EMA SUMM PROD CH; European Medicines Agency (EMA), 2020, INF HEX EMA SUMM PRO; Fernandez J, 2000, J INFECT DIS, V182, P1553, DOI 10.1086/315870; Gabutti G, 2012, EUR J PEDIATR, V171, P1651, DOI 10.1007/s00431-012-1791-8; Hallander HO, 2009, EXPERT REV VACCINES, V8, P1303, DOI [10.1586/erv.09.88, 10.1586/ERV.09.88]; Harriman K, 2020, CLIN INFECT DIS, V70, P208, DOI 10.1093/cid/ciz205; Hellwig SMM, 2003, J INFECT DIS, V188, P738, DOI 10.1086/377283; Kalies H, 2008, VACCINE, V26, P2545, DOI 10.1016/j.vaccine.2008.03.001; Kosalaraksa P, 2018, HUM VACC IMMUNOTHER, V14, P1257, DOI 10.1080/21645515.2018.1426418; Kosalaraksa P, 2011, INT J INFECT DIS, V15, pE249, DOI 10.1016/j.ijid.2010.12.004; Kumar G, 2013, VALUE HEALTH, V16, pA345, DOI 10.1016/j.jval.2013.08.135; Lanata C, 2012, J VACCINES VACCIN, V03, DOI [10.4172/2157-7560.1000128, DOI 10.4172/2157-7560.1000128]; LEININGER E, 1991, P NATL ACAD SCI USA, V88, P345, DOI 10.1073/pnas.88.2.345; Lopez P, 2017, PEDIATR INFECT DIS J, V36, pE272, DOI 10.1097/INF.0000000000001682; Mack I, 2020, VACCINE, V38, P1444, DOI 10.1016/j.vaccine.2019.11.069; Madhi SA, 2019, HUM VACC IMMUNOTHER, V15, P658, DOI 10.1080/21645515.2018.1546524; Martinelli D, 2017, VACCINE, V35, P6297, DOI 10.1016/j.vaccine.2017.09.077; Monge S, 2018, LANCET INFECT DIS, V18, P749, DOI 10.1016/S1473-3099(18)30166-X; Mukherjee P, 2021, EXPERT REV VACCINES, V20, P319, DOI 10.1080/14760584.2021.1892493; Pharma Intelligence, TRIALTR GOLD STAND C; Poolman JT, 2007, EXPERT REV VACCINES, V6, P47, DOI 10.1586/14760584.6.1.47; Poovorawan Y, 2011, J VIRAL HEPATITIS, V18, P369, DOI 10.1111/j.1365-2893.2010.01312.x; Prymula R, 2018, PEDIATR INFECT DIS J, V37, P823, DOI 10.1097/INF.0000000000002109; Puente I, 2020, EXPERT REV VACCINES, V19, P771, DOI 10.1080/14760584.2020.1800458; Robert Koch-Institut, 2020, EPIDEMIOLOGISCHES B, DOI [10.25646/7072, DOI 10.25646/7072]; Schwarz TF, 2019, HUM VACC IMMUNOTHER, V15, P235, DOI 10.1080/21645515.2018.1509658; Silfverdal SA, 2016, VACCINE, V34, P3810, DOI 10.1016/j.vaccine.2016.05.054; Slack M, 2020, EXPERT REV VACCINES, V19, P903, DOI 10.1080/14760584.2020.1825948; Steiner M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-9; Syed YY, 2017, PEDIATR DRUGS, V19, P69, DOI 10.1007/s40272-016-0208-y; Van Damme P, 2019, J VIRAL HEPATITIS, V26, P1066, DOI 10.1111/jvh.13125; Van der Meeren O, 2014, HUM VACC IMMUNOTHER, V10, P1682, DOI 10.4161/hv.28480; Vesikari T, 2020, HUM VACC IMMUNOTHER, V16, P867, DOI 10.1080/21645515.2019.1673119; Vesikari T, 2017, PEDIATR INFECT DIS J, V36, P209, DOI 10.1097/INF.0000000000001406; Vesikari T, 2017, PEDIATR INFECT DIS J, V36, P87, DOI 10.1097/INF.0000000000001358; Virta M, 2021, PEDIATR INFECT DIS J, V40, pE28, DOI 10.1097/INF.0000000000002954; Wang SC, 2017, EXPERT REV VACCINES, V16, P1095, DOI 10.1080/14760584.2017.1383157; Wiedenmayer KA, 2009, VACCINE, V27, P655, DOI 10.1016/j.vaccine.2008.11.045; Wilck MB, 2021, HUM VACC IMMUNOTHER, V17, P191, DOI 10.1080/21645515.2020.1756668; World Health Organization, 2014, 800 WHO, V927; Zinke M, 2010, HUM VACCINES, V6, P189, DOI 10.4161/hv.6.2.10117	54	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6025	6036		10.1016/j.vaccine.2021.08.086		SEP 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34531081	hybrid			2022-04-29	WOS:000701799200004
J	Michos, A; Tatsi, EB; Filippatos, F; Dellis, C; Koukou, D; Efthymiou, V; Kastrinelli, E; Mantzou, A; Syriopoulou, V				Michos, Athanasios; Tatsi, Elizabeth-Barbara; Filippatos, Filippos; Dellis, Charilaos; Koukou, Dimitra; Efthymiou, Vasiliki; Kastrinelli, Evangelia; Mantzou, Aimilia; Syriopoulou, Vasiliki			Association of total and neutralizing SARS-CoV-2 spike-receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and 2nd doses of the BNT162b2 vaccine	VACCINE			English	Article						SARS-CoV-2; COVID-19; BNT162b2; Antibody; Immunity; Spike protein		Background: Data regarding the association of antibody levels elicited after immunization with the BNT162b2 mRNA COVID-19 vaccine with epidemiological and clinical parameters are limited. Methods: We prospectively measured the total (TAbs-RBD) and the neutralizing antibodies (NAbs-RBD) against the receptor binding domain (RBD) of SARS-CoV-2 spike protein in a cohort of 268 Healthcare workers before immunization, 20 days after the 1st dose and 30 days after the 2nd dose of the BNT162b2 vaccine. A statistical analysis for possible association of antibodies' levels with epidemiological and clinical parameters was performed. Results: The mean age (+/- SD) of the participants was 45.45 years (+/- 11.93) (range: 24-70 years) and 211 (79.9%) were females. Statistically significant differences were detected regarding both TAbs-RBD and NAbs-RBD between the first and second doses of the vaccine (P < 0.001). The median (IQR) percentage (%) of NAbs-RBD after the 1st dose was 51.07% (31.60%) and after the 2nd dose 95.31% (3.70%) (P < 0.001). The correlation between the TAbs-RBD and NAbs-RBD was after the 1st dose, Spearman's, rho: 0.861 (P < 0.001) and after the 2nd dose rho: 0.989 (P < 0.001). Twenty days after the 1st dose, 56/264 (21.2%) of the participants had low levels of NAbs-RBD, while one month after the 2nd dose all of them had protective levels of NAbs-RBD. After the 2nd vaccine dose, a statistically significant negative association of TAbs-RBD was detected for age (P < 0.001), smoking (P = 0.011), and immunosuppressive medications (P < 0.001), while a positive association was detected for BMI (P = 0.004) and systemic adverse events after immunization (P = 0.001). Conclusion: A significant correlation of TAbs-RBD and NAbs-RBD was detected after both vaccine doses. Older age, smoking, and immunosuppressive medications negatively affected the final antibody level after SARS-CoV-2 immunization. Our findings emphasize the significance of the 2nd vaccine dose especially in the older age groups. (C) 2021 Elsevier Ltd. All rights reserved.	[Michos, Athanasios; Filippatos, Filippos; Dellis, Charilaos; Koukou, Dimitra; Kastrinelli, Evangelia; Mantzou, Aimilia; Syriopoulou, Vasiliki] Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Infect Dis & Chemotherapy Res Lab, Dept Pediat 1,Med Sch, Athens, Greece; [Tatsi, Elizabeth-Barbara; Efthymiou, Vasiliki] Univ Res Inst Maternal & Child Hlth & Precis Med, Athens, Greece		Michos, A (通讯作者)，Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Infect Dis & Chemotherapy Res Lab, Dept Pediat 1,Med Sch, Athens, Greece.	amichos@med.uoa.gr		Michos, Athanasios/0000-0003-1745-1118; DELLIS, CHARILAOS/0000-0001-6195-0999; Filippatos, Filippos/0000-0003-2775-3670; Tatsi, Elizabeth/0000-0001-7325-6195			Ball P, 2021, NATURE, V589, P16, DOI 10.1038/d41586-020-03626-1; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Fauci AS, 2021, SCIENCE, V372, P109, DOI 10.1126/science.abi8397; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMoa2105000, 10.1056/NEJMc2107808]; Jalkanen P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24285-4; Koch T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030238; Krammer F, 2021, LANCET, V397, P1421, DOI 10.1016/S0140-6736(21)00782-0; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Krause PR, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2031373; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Sharun K, 2021, HUM VACC IMMUNOTHER, V17, P3491, DOI 10.1080/21645515.2021.1923350; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Terpos E, 2021, AM J HEMATOL, V96, pE257, DOI 10.1002/ajh.26185	19	4	4	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5963	5967		10.1016/j.vaccine.2021.07.067		SEP 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34400017	Bronze, Green Published			2022-04-29	WOS:000697501500031
J	Dudley, MZ; Bernier, R; Brewer, J; Salmon, DA				Dudley, Matthew Z.; Bernier, Roger; Brewer, Janesse; Salmon, Daniel A.			Walking the Tightrope: Reevaluating science communication in the era of COVID-19 vaccines	VACCINE			English	Editorial Material						Science; Communication; Vaccines; Hesitancy; COVID-19; Messaging	GOVERNMENT; US	Scientists are trained to be skeptical and not overstate the existing evidence. This cautiousness is a valuable asset when working in scientific research, where the goal is the pursuit of knowledge and truth. It becomes a handicap when scientists are asked to communicate to the public about pressing topics such as COVID-19 vaccines. Often in such contexts, immediate recommendations are sought, and decisions must be made even when complete evidence is lacking. For scientists to be effective public communicators, they must adjust their mindset and embrace brevity, clarity, and other principles of effective communication. Focusing messages on what is known fosters public confidence in taking needed actions, whereas focusing on what is still unknown fosters inaction and seeds doubt. The implementation of principles of effective communication does not inherently con-flict with maintaining scientific accuracy and acknowledging uncertainty, but it does require additional care, effort, and training. (C) 2021 Elsevier Ltd. All rights reserved.	[Dudley, Matthew Z.; Brewer, Janesse; Salmon, Daniel A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA; [Dudley, Matthew Z.; Brewer, Janesse; Salmon, Daniel A.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, 615 N Wolfe St,W5041, Baltimore, MD 21205 USA; [Bernier, Roger] Johns Hopkins Bloomberg Sch Publ Hlth, Epidemiol Monitor, 615 N Wolfe St, Baltimore, MD 21205 USA		Dudley, MZ (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, 615 N Wolfe St,W5041, Baltimore, MD 21205 USA.	mattdudley@jhu.edu		Dudley, Matthew/0000-0003-1201-4066			Diamond D, 2020, TRUMP OFFICIALS INTE; Dudley MZ., 2018, CLIN VACCINE SAFETY; Jamison AM, 2019, SOC SCI MED, V221, P87, DOI 10.1016/j.socscimed.2018.12.020; Kennerly B, 2021, YOUVE HAD 2 DOSES CO; Lee C, 2016, VACCINE, V34, P3972, DOI 10.1016/j.vaccine.2016.06.048; Leonhardt D., 2021, VACCINE ALARMISM; Salmon D, 2021, HEALTH AFFAIR, V40, P419, DOI 10.1377/hlthaff.2020.02254; Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Tufekci Z, 2021, 5 PANDEMIC MISTAKES	10	0	0	6	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 15	2021	39	39					5453	5455		10.1016/j.vaccine.2021.08.037		SEP 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WC6XU	34446317	Bronze			2022-04-29	WOS:000704399700001
J	Alves, MLF; Ferreira, MRA; Donassolo, RA; Rodrigues, RR; Conceicao, FR				Ferreira Alves, Mariliana Luiza; Alves Ferreira, Marcos Roberto; Donassolo, Rafael Amaral; Rodrigues, Rafael Rodrigues; Conceicao, Fabricio Rochedo			Clostridium septicum: A review in the light of alpha-toxin and development of vaccines	VACCINE			English	Review						Epitopes; Bioinformatics; Livestock; Clostridial vaccine; Recombinant vaccine	PORE-FORMING TOXINS; GANGRENOUS DERMATITIS; CELLULITIS; PROTEIN; IDENTIFICATION; PERFRINGENS; VACCINATION; MECHANISMS; GENERATION; CHAUVOEI	Clostridium septicum (CS) is a pathogen that can cause the death of animals in livestock worldwide through its main virulence factor, alpha-toxin (ATX). The aspects involved in diseases caused by ATX, such as economic impact, prevalence, and rapid clinical course, require that animals should be system-atically immunized. This review provides an overview of CS in livestock farming and discusses current immunization methods. Currently, commercial vaccines available against CS involve the cultivation and inactivation of microorganisms and toxins using a time-consuming, expensive, and high biological risk-carrying production platform, and some have been reported to be ineffective. An alternative to this process is the recombinant DNA technology, although recombinant ATX obtained thus far is no longer efficient in stimulating protective antibody titers despite improvements in the production methods. On the other hand, immunized animals have highly favorable levels of survival when subjected to challenge tests, suggesting that high titers of circulating serum antibodies may not be representative of protection after immunization and that the non-immune cellular defenses associated with the particularities of the mechanism of action of ATX may be involved in the immune response of the host. To contribute to the future of global livestock farming through the development of more efficient recombinant vaccines, we suggest novel perspectives and strategies, such as the location of immunodominant epitopes, expression of relevant functional domains, and construction of chimeras, in the rational design of recombinant ATX. (c) 2021 Elsevier Ltd. All rights reserved.	[Ferreira Alves, Mariliana Luiza] Inst Fed Sul Rio Grandense IFSUL, Campus Pelotas,Praca Vinte Setembro 455, BR-96015360 Pelotas, RS, Brazil; [Ferreira Alves, Mariliana Luiza; Alves Ferreira, Marcos Roberto; Donassolo, Rafael Amaral; Rodrigues, Rafael Rodrigues; Conceicao, Fabricio Rochedo] Univ Fed Pelotas, Ctr Desenvolvimento Tecnol, Nucleo Biotecnol, CP 354, BR-96160000 Pelotas, RS, Brazil		Alves, MLF (通讯作者)，Inst Fed Sul Rio Grandense IFSUL, Campus Pelotas,Praca Vinte Setembro 455, BR-96015360 Pelotas, RS, Brazil.	marilianaalves@pelotas.ifsul.edu.br			CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); IFSUL	This study was supported by the CNPq and IFSUL through financial support and scholarships.	Ahlmeyer V, 2018, TRANSMISSIBLE DIS PO, V53, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]; Alberts B, 2011, FUNDAMENTOS BIOL CEL FUNDAMENTOS BIOL CEL, V3rd; Amimoto K, 2002, J VET MED SCI, V64, P67, DOI 10.1292/jvms.64.67; Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906; Aroian R, 2007, CURR OPIN MICROBIOL, V10, P57, DOI 10.1016/j.mib.2006.12.008; BALLARD J, 1995, INFECT IMMUN, V63, P340, DOI 10.1128/IAI.63.1.340-344.1995; BALLARD J, 1992, INFECT IMMUN, V60, P784, DOI 10.1128/IAI.60.3.784-790.1992; BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; Benamar S, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00922-16; Brito C, 2019, CELL MOL LIFE SCI, V76, P1319, DOI 10.1007/s00018-018-2992-8; Buys A, 2020, ACTA VET SCAND, V62, DOI 10.1186/s13028-020-00555-x; CAHFS, 2019, UCDAVIS, P2; Cahfs NEW, 2014, AGR NATURAL RESOURCE; Caly DL, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01336; Carrigan E, 2016, VET MED TXB DIS CATT, V11th, DOI [10.4018/978-1-4666-1897-8.ch015, DOI 10.4018/978-1-4666-1897-8.CH015]; Carter GR., 2004, CLIN VET MICROBIOLOG; Cervino M, 2011, VET REC, V168, DOI 10.1136/vr.c6865; Clark S, 2010, AVIAN DIS, V54, P788, DOI 10.1637/9147-111309-Review.1; Cortinas TI, 1997, ANAEROBE, V3, P199, DOI 10.1006/anae.1997.0105; Dormitzer PR, 2008, TRENDS BIOTECHNOL, V26, P659, DOI 10.1016/j.tibtech.2008.08.002; Ferreira MRA, 2016, TOXINS, V8, DOI 10.3390/toxins8110340; Gaafar BBM, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6124030; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; Gordon VM, 1997, INFECT IMMUN, V65, P4130, DOI 10.1128/IAI.65.10.4130-4134.1997; Gornatti-Churria CD, 2018, J VET DIAGN INVEST, V30, P188, DOI 10.1177/1040638717742435; Haghroosta Ali, 2020, Comp Clin Path, V29, P981, DOI 10.1007/s00580-020-03136-6; Hang'ombe MB, 2004, MICROB PATHOGENESIS, V37, P279, DOI 10.1016/j.micpath.2004.09.001; Hickey MJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000045; Hussain C, 2019, AM J CASE REP, V20, P268, DOI 10.12659/AJCR.913472; IMAGAWA T, 1994, FEMS MICROBIOL LETT, V117, P287, DOI 10.1111/j.1574-6968.1994.tb06781.x; Johnson D.I., 2018, BACT PATHOG THEIR VI, P1, DOI [10.1007/978-3-319-67651-7_1, DOI 10.1007/978-3-319-67651-7_1]; Kamalirousta M, 2018, MICROBIOL RES J INT, V23, P1, DOI [10.9734/mrji/2018/39261, DOI 10.9734/MRJI/2018/39261]; Kar PP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02213; Kennedy CL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000516; Kennedy CL, 2009, INFECT IMMUN, V77, P943, DOI 10.1128/IAI.01267-08; Kennedy CL, 2005, MOL MICROBIOL, V57, P1357, DOI 10.1111/j.1365-2958.2005.04774.x; Knapp O, 2010, TOXICON, V55, P61, DOI 10.1016/j.toxicon.2009.06.037; Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829; Kuhnert P, 1996, INT J SYST BACTERIOL, V46, P1174, DOI 10.1099/00207713-46-4-1174; Lancto CA, 2014, AVIAN DIS, V58, P566, DOI 10.1637/10826-032314-Reg.1; Li GX, 2010, AVIAN PATHOL, V39, P247, DOI 10.1080/03079457.2010.487517; Li Y, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4584-0; Lighty ME, 2016, J APPL POULTRY RES, V25, P104, DOI 10.3382/japr/pfv065; Lima C. G. R. D., 2006, Ciencia Veterinaria nos Tropicos, V9, P106; Lobato F.C.F., 2008, Arq. Inst. Biol., V75, P225, DOI 10.1590/1808-1657v75p2252008; Los FCO, 2013, MICROBIOL MOL BIOL R, V77, P173, DOI 10.1128/MMBR.00052-12; Maboni F, 2010, VET ZOOTEC VET ZOOTEC, V17, P343; Mainil J, 2006, GENUS CLOSTRIDIUM CL; Melton JA, 2004, J BIOL CHEM, V279, P14315, DOI 10.1074/jbc.M313758200; Melton-Witt JA, 2006, BIOCHEMISTRY-US, V45, P14347, DOI 10.1021/bi061334p; Mukamoto M, 2013, MICROBIOL IMMUNOL, V57, P163, DOI 10.1111/1348-0421.12017; Najafi M. F., 2019, Iranian Journal of Veterinary Medicine, V13, P279; Namdar F, 2020, INFECT DRUG RESIST, V13, P2355, DOI [10.2147/DR.S257561, 10.2147/IDR.S257561]; Nampanya S, 2019, VET MED SCI, V5, P118, DOI 10.1002/vms3.152; Nene V, 2012, TICKS TICK-BORNE DIS, V3, P188, DOI 10.1016/j.ttbdis.2011.12.001; Nuccitelli A, 2011, P NATL ACAD SCI USA, V108, P10278, DOI 10.1073/pnas.1106590108; Odani JS, 2009, J VET DIAGN INVEST, V21, P920, DOI 10.1177/104063870902100631; Oliveira CA, 2020, J VET DIAGN INVEST, V32, P175, DOI 10.1177/1040638720905830; Oliveira SJ., 2000, MICROBIOLOGIA VET GU MICROBIOLOGIA VET GU; Passarela AIT, 2011, REV ED CONTIN MED VE, V9, P52; Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139; Peek SF, 2003, EQUINE VET J, V35, P86, DOI 10.2746/042516403775467513; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Popoff MR, 2014, ANAEROBE, V30, P220, DOI 10.1016/j.anaerobe.2014.05.014; Raymundo Djeison Lutier, 2010, Pesq. Vet. Bras., V30, P637, DOI 10.1590/S0100-736X2010000800005; Rossi A, 2018, VET IMMUNOL IMMUNOP, V202, P46, DOI 10.1016/j.vetimm.2018.06.010; Roth F, 1999, FEMS IMMUNOL MED MIC, V24, P353, DOI 10.1016/S0928-8244(99)00053-X; Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160; Sasaki Y, 2002, VET MICROBIOL, V86, P257, DOI 10.1016/S0378-1135(02)00002-0; Schlohsarczyk EK, 2020, VET REC CASE REP, V8, DOI 10.1136/vetreccr-2020-001321; Sellman BR, 1997, MOL MICROBIOL, V25, P429, DOI 10.1046/j.1365-2958.1997.4541820.x; Sellman BR, 1997, MOL MICROBIOL, V23, P551, DOI 10.1046/j.1365-2958.1997.d01-1876.x; Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x; Stokes WS, 2011, PROCEDIA VACCINOL, V5, P84, DOI 10.1016/j.provac.2011.10.006; Tellez G, 2009, J VET DIAGN INVEST, V21, P374, DOI 10.1177/104063870902100313; Thachil AJ, 2012, J APPL POULTRY RES, V21, P358, DOI 10.3382/japr.2011-00435; Thachil AJ, 2013, AVIAN DIS, V57, P214, DOI 10.1637/10421-101512-Reg.1; Thomaz-soccol V, 2016, CURRENT DEV BIOTECHN; Troxel TR, 2001, J ANIM SCI, V79, P2558; Tweten RK, 2001, VET MICROBIOL, V82, P1, DOI 10.1016/S0378-1135(01)00372-8; Uzal FA, 2016, CLOSTRIDIAL DIS ANIM; Vazquez-Iglesias L, 2017, PEERJ, V5, DOI 10.7717/peerj.3407; Weisbroth SH, 2015, LAB ANIMAL MED SERIE, VI, p3A; Wichroski MJ, 2002, INFECT IMMUN, V70, P4353, DOI 10.1128/IAI.70.8.4353-4361.2002; Willoughby DH, 1996, J VET DIAGN INVEST, V8, P259, DOI 10.1177/104063879600800222; Zaragoza NE, 2019, TOXINS, V11, DOI 10.3390/toxins11090525; Zheng ZF, 2005, EUKARYOT CELL, V4, P556, DOI 10.1128/EC.4.3.556-566.2005	87	1	1	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					4949	4956		10.1016/j.vaccine.2021.07.019			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TX3GY	34312008				2022-04-29	WOS:000682979100007
J	Georgiadis, GP; Georgiadis, MC				Georgiadis, Georgios P.; Georgiadis, Michael C.			Optimal planning of the COVID-19 vaccine supply chain	VACCINE			English	Article						COVID-19; Vaccine supply chain; Optimal planning; MILP; Decomposition algorithm	KEY ISSUES; NETWORK; MODEL; OPTIMIZATION	This work presents a novel framework to simultaneously address the optimal planning of COVID-19 vac-cine supply chains and the optimal planning of daily vaccinations in the available vaccination centres. A new mixed integer linear programming (MILP) model is developed to generate optimal decisions regard-ing the transferred quantities between locations, the inventory profiles of central hubs and vaccination centres and the daily vaccination plans in the vaccination centres of the supply chain network. Specific COVID-19 characteristics, such as special cold storage technologies, limited shelf-life of mRNA vaccines in refrigerated conditions and demanding vaccination targets under extreme time pressure, are aptly modelled. The goal of the model is the minimization of total costs, including storage and transportation costs, costs related to fleet and staff requirements, as well as, indirect costs imposed by wasted doses. A two-step decomposition strategy based on a divide-and-conquer and an aggregation approach is pro-posed for the solution of large-scale problems. The applicability and efficiency of the proposed optimization-based framework is illustrated on a study case that simulates the Greek nationwide vacci-nation program. Finally, a rolling horizon technique is employed to reactively deal with possible distur-bances in the vaccination plans. The proposed mathematical framework facilitates the decision-making process in COVID-19 vaccine supply chains into minimizing the underlying costs and the number of doses lost. As a result, the efficiency of the distribution network is improved, thus assisting the mass vaccina-tion campaigns against COVID-19. (c) 2021 Elsevier Ltd. All rights reserved.	[Georgiadis, Georgios P.; Georgiadis, Michael C.] Aristotle Univ Thessaloniki, Dept Chem Engn, Thessaloniki 54124, Greece		Georgiadis, MC (通讯作者)，Aristotle Univ Thessaloniki, Dept Chem Engn, Thessaloniki 54124, Greece.	mgeorg@auth.gr					Amaro ACS, 2008, COMPUT CHEM ENG, V32, P2606, DOI 10.1016/j.compchemeng.2008.03.006; Assi TM, 2013, VACCINE, V31, P2828, DOI 10.1016/j.vaccine.2013.04.011; Brooke A., 1998, GAMS USERS GUIDE; Brown ST, 2014, VACCINE, V32, P4097, DOI 10.1016/j.vaccine.2014.04.090; Chen SI, 2014, IIE TRANS, V46, P853, DOI 10.1080/0740817X.2013.813094; De Carvalho M.I., 2019, PHARM SUPPLY CHAINS, P23; Duijzer LE, 2018, EUR J OPER RES, V268, P174, DOI 10.1016/j.ejor.2018.01.015; Gatica G, 2003, CHEM ENG RES DES, V81, P665, DOI 10.1205/026387603322150516; Hellenic Statistical Authority, 2011, 2011 POPULATION HOUS; Jankauskas K, 2019, COMPUT CHEM ENG, V121, P212, DOI 10.1016/j.compchemeng.2018.09.019; Karakostas P, 2020, COMPUT CHEM ENG, V139, DOI 10.1016/j.compchemeng.2020.106913; Kontoravdi C, 2021, RESOURCES PRODUCTION, P1; Kramer R, 2019, TRANSPORT RES E-LOG, V129, P162, DOI 10.1016/j.tre.2019.07.012; Lee BY, 2017, VACCINE, V35, P4475, DOI 10.1016/j.vaccine.2017.05.096; Lee BY, 2016, VACCINE, V34, P4998, DOI 10.1016/j.vaccine.2016.08.036; Lee BY, 2012, VACCINE, V30, P5637, DOI 10.1016/j.vaccine.2012.06.087; Lemmens S, 2016, CHEM ENG RES DES, V109, P366, DOI 10.1016/j.cherd.2016.02.015; Liu R, 2014, OMEGA-INT J MANAGE S, V47, P17, DOI 10.1016/j.omega.2014.03.003; Liu SS, 2013, OMEGA-INT J MANAGE S, V41, P369, DOI 10.1016/j.omega.2012.03.007; Masoumi AH, 2012, TRANSPORT RES E-LOG, V48, P762, DOI 10.1016/j.tre.2012.01.001; Mula J, 2010, EUR J OPER RES, V204, P377, DOI 10.1016/j.ejor.2009.09.008; Papageorgiou LG, 2001, IND ENG CHEM RES, V40, P275, DOI 10.1021/ie990870t; Papathanasiou MM, 2020, CANCER GENE THER, V27, P799, DOI 10.1038/s41417-019-0157-z; Ramos TRP, 2014, OMEGA-INT J MANAGE S, V48, P60, DOI 10.1016/j.omega.2013.11.006; Rastegar M, 2021, VACCINE, V39, P495, DOI 10.1016/j.vaccine.2020.12.022; Sarkis M, 2021, PROCESSES, V9, DOI 10.3390/pr9030457; Savadkoohi E, 2018, CHEM ENG RES DES, V138, P490, DOI 10.1016/j.cherd.2018.09.008; Shah N, 2004, COMPUT CHEM ENG, V28, P929, DOI 10.1016/j.compchemeng.2003.09.022; Wang X., 2018, COMPUTER AIDED CHEM, V44, P2137, DOI 10.1016/B978-0-444-64241-7.50351-7; Weraikat D, 2016, COMPUT IND ENG, V93, P67, DOI 10.1016/j.cie.2015.12.026; World Health Organization, 2019, REVISING GLOBAL INDI; Yadav P, 2014, VACCINE, V32, P6725, DOI 10.1016/j.vaccine.2014.10.001; Yang Y, 2017, OPTIMAL DESIGN OPERA, P1; Zaffran M, 2013, VACCINE, V31, pB73, DOI 10.1016/j.vaccine.2012.11.036; Zahiri B, 2017, TRANSPORT RES E-LOG, V103, P109, DOI 10.1016/j.tre.2017.04.009	35	2	2	23	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 31	2021	39	37					5302	5312		10.1016/j.vaccine.2021.07.068		AUG 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UC7ZI	34373118	Bronze, Green Published			2022-04-29	WOS:000686741800012
J	Ylade, M; Agrupis, KA; Daag, JV; Crisostomo, MV; Tabuco, MO; Sy, AK; Nealon, J; Macina, D; Sarol, J; Deen, J; Lopez, AL				Ylade, Michelle; Agrupis, Kristal An; Daag, Jedas Veronica; Crisostomo, Maria Vinna; Tabuco, Mark Owen; Sy, Ava Kristy; Nealon, Joshua; Macina, Denis; Sarol, Jesus; Deen, Jacqueline; Lopez, Anna Lena			Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: A case-control study	VACCINE			English	Article						Dengue; Dengue fever; Dengue vaccine; Effectiveness	AEDES-AEGYPTI; SEROSTATUS; DISPERSAL	Background: Dengue fever is an important public health problem in the Philippines. In April 2016, the Department of Health launched a three-dose school based dengue vaccination program of nine-to fourteen-year-old children in three regions with the highest number of dengue cases using CYD-TDV (Dengvaxia, Sanofi Pasteur). In July 2017, a community-based dengue vaccination program was implemented in Cebu province. The program was discontinued in December 2017 amidst public controversy, after the first dose had been administered. We assessed the effectiveness of a single dose of CYD-TDV against hospitalized virologically confirmed dengue (VCD). Methods: We conducted a case-control study in Cebu province following the dengue mass vaccination. Children who were nine to fourteen years of age during the mass vaccination and subsequently admitted to any of four participating public hospitals with suspected dengue were enrolled in the study as cases. Blood for RT-PCR and clinical and socio-demographic information were obtained. To estimate the level of vaccine protection, vaccination status was compared between children with hospitalized virologically confirmed dengue and controls of the same six-year age-group as the cases, matched on sex, neighborhood and time of occurrence of cases. Findings: We enrolled 490 cases and 980 controls. Receipt of one dose of CYD-TDV was associated with 26% (95 % CI,-2 to 47%; p = 0 0675) overall protection against hospitalized virologically confirmed dengue and 51% (95 % CI, 23 to 68; p = 0 0016) protection against dengue with warning signs. Interpretation: A single dose of CYD-TDV given to nine to fourteen-year-old children through a community-based mass vaccination program conferred protection against dengue with warning signs and severe dengue but we were unable to conclude on protection against milder illness. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Ylade, Michelle; Agrupis, Kristal An; Daag, Jedas Veronica; Crisostomo, Maria Vinna; Tabuco, Mark Owen; Deen, Jacqueline; Lopez, Anna Lena] Univ Philippines Manila, Inst Child Hlth & Human Dev, Natl Inst Hlth, Pedro Gil St, Manila, Philippines; [Sarol, Jesus] Univ Illinois, Interdisciplinary Hlth Sci Inst, Urbana, IL USA; [Sy, Ava Kristy] Res Inst Trop Med, Dept Virol, Muntinlupa, Philippines; [Nealon, Joshua; Macina, Denis] Sanofi Pasteur, Lyon, France		Ylade, M (通讯作者)，Univ Philippines Manila, Natl Inst Hlth, Inst Child Hlth & Human Dev, 623 P Gil St, Manila 1000, Philippines.	mcylade@up.edu.ph		Sarol, Jesus/0000-0003-1281-4485			Aldstadt J, 2012, TROP MED INT HEALTH, V17, P1076, DOI 10.1111/j.1365-3156.2012.03040.x; [Anonymous], 2016, Wkly Epidemiol Rec, V91, P266; [Anonymous], 2017, GUIDELINES COMMUNITY; [Anonymous], 2020, REG 7 HOSP MAN; Bravo L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003027; Dayrit M. M., 2018, PHILIPPINES HLTH SYS, V8; Flasche Stefan, 2019, Wellcome Open Res, V4, P165, DOI 10.12688/wellcomeopenres.15507.1; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; Hajizadeh M, 2018, J EPIDEMIOL COMMUN H, V72, P719, DOI 10.1136/jech-2017-210296; Honorio NA, 2003, MEM I OSWALDO CRUZ, V98, P191, DOI 10.1590/S0074-02762003000200005; Kikuti M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003937; Larson HJ, 2018, NAT HUM BEHAV, V2, P316, DOI 10.1038/s41562-018-0331-6; Lopez AL, 2021, LANCET GLOB HEALTH, V9, pE44, DOI 10.1016/S2214-109X(20)30392-2; Muir LE, 1998, AM J TROP MED HYG, V58, P277, DOI 10.4269/ajtmh.1998.58.277; Nascimento EJM, 2018, J VIROL METHODS, V257, P48, DOI 10.1016/j.jviromet.2018.03.007; Sasmono RT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103815; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Verani JR, 2017, VACCINE, V35, P3295, DOI 10.1016/j.vaccine.2017.04.037; WHO, 2018, WKLY EPIDEMIOL REC, P329; WHO/TDR, DENG GUID DIAGN TREA; Wijayanti SPM, 2016, PLOS NEGLECT TROP D, V10, DOI [10.1371/journal.pntd.0004964, 10.1371/journal.pntd.0004500]; Wijayanti SP, 1935, IMPORTANCE SOCIOECON; Wilder-Smith A, 2019, LANCET, V394, P2151, DOI 10.1016/S0140-6736(19)32525-5	23	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 31	2021	39	37					5318	5325		10.1016/j.vaccine.2021.07.042		AUG 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UC7ZI	34373121	hybrid			2022-04-29	WOS:000686741800014
J	Carrico, J; Talbird, SE; La, EM; Poston, S; Poirrier, JE; DeMartino, JK; Hogea, C				Carrico, Justin; Talbird, Sandra E.; La, Elizabeth M.; Poston, Sara; Poirrier, Jean-Etienne; DeMartino, Jessica K.; Hogea, Cosmina			Cost-benefit analysis of vaccination against four preventable diseases in older adults: Impact of an aging population	VACCINE			English	Article						Cost-benefit analysis; Adult vaccines; Economic model; Aging population; Infectious disease	PNEUMOCOCCAL CONJUGATE VACCINE; ZOSTER SUBUNIT VACCINE; UNITED-STATES; INFLUENZA VACCINATION; PERTUSSIS VACCINATION; DIPHTHERIA; EFFICACY; TETANUS; HEALTH; RECOMMENDATIONS	Objective: This exploratory study estimates the economic value of the current vaccination program and increased coverage against four preventable diseases in older adults in the United States (US). Methods: A population-based, age-structured economic model was used to conduct a cost-benefit analysis of vaccination against influenza, pertussis, herpes zoster, and pneumococcal disease among US adults aged 50 years and older, accounting for aging of the population. The model used separate decision trees for each disease to project the discounted number of vaccinated individuals, number of disease cases, and direct medical and indirect costs (2018 US$) over a 30-year period. Benefit-cost ratios (BCRs) and net present values were calculated for two primary analyses comparing current vaccination coverage versus no vaccination and comparing increased coverage versus current coverage. Key parameter values were varied in deterministic sensitivity analyses. Results: Current adult vaccination coverage (vs. no vaccination) is estimated to result in nearly 65 million averted disease cases, $185 billion averted costs of cases, and $136 billion in incremental vaccination costs over a 30-year period from a societal perspective (BCR = 1.4). Increased vaccination coverage (vs. current coverage) is associated with over 33 million additional averted disease cases, $96 billion additional averted costs of cases, and nearly $83 billion in incremental vaccination costs, resulting in a societal BCR of 1.2 over 30 years. Deterministic sensitivity analyses demonstrated that results were most sensitive to disease incidence, vaccine efficacy, and productivity costs for time required for vaccination. Conclusions: Study results highlight the economic value of vaccination programs for older adults in the US and indicate that efforts to further increase vaccination coverage may be warranted and economically justifiable. (c) 2021 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Carrico, Justin; Talbird, Sandra E.] RTI Hlth Solut, Res Triangle Pk, NC USA; [La, Elizabeth M.; Poston, Sara; Poirrier, Jean-Etienne; DeMartino, Jessica K.; Hogea, Cosmina] GSK, Philadelphia, PA USA		Carrico, J (通讯作者)，RTI Hlth Solut, US Hlth Econ, Durham, NC 27709 USA.	jcarrico@rti.org; stalbird@rti.org; liz.m.la@gsk.com; sara.a.poston@gsk.com; cosminahogea@gmail.com		Poirrier, Jean-Etienne/0000-0002-1246-7746; Carrico, Justin/0000-0002-4659-9309; Talbird, Sandra/0000-0003-4719-3703; La, Elizabeth/0000-0001-5652-8961	GlaxoSmithKline Biologicals SAGlaxoSmithKline [HO-17-18466]; GlaxoSmithKline Biologicals SAGlaxoSmithKline	GlaxoSmithKline Biologicals SA was the funding source for the study [GSK study identifier: HO-17-18466]. GlaxoSmithKline Biologicals SA also funded all costs associated with the development and the publishing of the present manuscript. All authors had full access to the data and agreed with the submission of the publication.	Acosta A., 2012, ADV COMM IMM PRACT A; Adams Deborah A, 2017, MMWR Morb Mortal Wkly Rep, V64, P1, DOI 10.15585/mmwr.mm6453a1; Aidoud A, 2020, VACCINE, V38, P4944, DOI 10.1016/j.vaccine.2020.05.070; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Brogan AJ, 2017, HUM VACC IMMUNOTHER, V13, P533, DOI 10.1080/21645515.2016.1242541; Centers for Disease Control and Prevention, 2019, ADULTVAXVIEW 2008 20; Centers for Disease Control and Prevention, 2013, ACT BACT COR SURV RE; Centers for Disease Control and Prevention, 2019, VACC REC GUID ACIP V; Centers for Disease Control and Prevention, 2018, CDC VACC PRIC LIST A; Centers for Disease Control and Prevention, 2018, SEAS VACC EFF EST; Centers for Disease Control and Prevention, 2018, ADULTVAXVIEW VACC CO; Centers for Disease Control and Prevention, 2016, EST INFL ILLN AV VAC; Centers for Disease Control and Prevention, 2017, INFL VACC COV EST PE; Chen JL, 2014, ADV THER, V31, P392, DOI 10.1007/s12325-014-0115-y; Corso P., 2002, PREVENTION EFFECTIVE, P127; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; Curran D, 2018, VACCINE, V36, P5037, DOI 10.1016/j.vaccine.2018.07.005; Deiss RG, 2015, VACCINE, V33, P7160, DOI 10.1016/j.vaccine.2015.11.004; Greby SM., 2018, NAT STAT LEV PLAC FL; Grosse SD, 2019, J MED ECON, V22, P501, DOI 10.1080/13696998.2018.1542520; Havers FP, 2020, VACCINE, V38, P380, DOI 10.1016/j.vaccine.2019.09.104; Johnson BH, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1262-8; Kamiya H, 2016, VACCINE, V34, P1832, DOI 10.1016/j.vaccine.2016.02.027; Kim DK, 2019, ANN INTERN MED, V170, P182, DOI 10.7326/M18-3600; Klaric JS, 2019, MIL MED, V184, P126, DOI 10.1093/milmed/usy343; Kostova D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066312; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Lee GM, 2007, AM J PREV MED, V32, P186, DOI 10.1016/j.amepre.2006.10.016; Macheca M., 2017, ISPOR 22 ANN INT M; Marzorati C, 2017, J MULTIDISCIP HEALTH, V10, P101, DOI 10.2147/JMDH.S122383; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; McGarry LJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0067260, 10.1371/journal.pone.0074170]; McLaughlin JM, 2015, J PRIM PREV, V36, P259, DOI 10.1007/s10935-015-0394-3; Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3; Morrison VA, 2015, CLIN INFECT DIS, V60, P900, DOI 10.1093/cid/ciu918; Nelson JC, 2008, VACCINE, V26, P4947, DOI 10.1016/j.vaccine.2008.07.016; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Ozawa S, 2016, HEALTH AFFAIR, V35, P2124, DOI 10.1377/hlthaff.2016.0462; Preziosi MP, 2003, CLIN INFECT DIS, V37, P772, DOI 10.1086/377270; Prosser LA, 2008, PHARMACOECONOMICS, V26, P163, DOI 10.2165/00019053-200826020-00006; Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195; Simonsen L, 2014, LANCET RESP MED, V2, P387, DOI 10.1016/S2213-2600(14)70032-3; Smith KJ, 2012, JAMA-J AM MED ASSOC, V307, P804, DOI 10.1001/jama.2012.169; Stoecker C, 2016, J GEN INTERN MED, V31, P901, DOI 10.1007/s11606-016-3651-0; Talbird SE, 2021, HUM VACC IMMUNOTHER, V17, P332, DOI 10.1080/21645515.2020.1780847; Talbird SE, 2015, J MANAG CARE SPEC PH, V21, P88, DOI 10.18553/jmcp.2015.21.1.88; Wateska AR, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2967-2; WEISBROD BA, 1961, J POLIT ECON, V69, P425, DOI 10.1086/258535; Zhou FJ, 2014, PEDIATRICS, V133, P577, DOI 10.1542/peds.2013-0698	50	1	1	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5187	5197		10.1016/j.vaccine.2021.07.029		AUG 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34334253	hybrid			2022-04-29	WOS:000684878300015
J	Paul, E; Brown, GW; Kalk, A; Ridde, V				Paul, Elisabeth; Brown, Garrett W.; Kalk, Andreas; Ridde, Valery			Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager	VACCINE			English	Editorial Material							SEROPREVALENCE; SAFETY		[Paul, Elisabeth] Univ Libre Bruxelles, Sch Publ Hlth, Campus Erasme,Route Lennik 808,CP 591, B-1070 Brussels, Belgium; [Brown, Garrett W.] Univ Leeds, Global Hlth Theme, Leeds, W Yorkshire, England; [Kalk, Andreas] Deutsch Gesell Int Zusammenarbeit, Kinshasa Country Off, Kinshasa, DEM REP CONGO; [Ridde, Valery] Univ Paris, INSERM, Inst Rech Dev IRD, CEPED,IRD, Paris, France		Paul, E (通讯作者)，Univ Libre Bruxelles, Sch Publ Hlth, Campus Erasme,Route Lennik 808,CP 591, B-1070 Brussels, Belgium.	Elisabeth.Paul@ulb.be; G.W.Brown@leeds.ac.uk; andreas.kalk@giz.de; valery.ridde@ird.fr		Paul, Elisabeth/0000-0002-3928-4093; Ridde, Valery/0000-0001-9299-8266			Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; [Anonymous], 2021, PHARMANEWS; Aschwanden C, 2021, NATURE, V591, P520, DOI 10.1038/d41586-021-00728-2; Associated Press, 2020, LOS ANGELES TIMES; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bavli I, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4074; Cambon L, 2021, GLOB HEALTH PROMOT, V28, P3, DOI 10.1177/17579759211015129; Cardozo T, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13795; Collateral Global, REG PUBL AN GLOB IMP; Craig P, 2018, TAKING ACCOUNT CONTE; Domingo E, 2021, J VIROL, V95, DOI 10.1128/JVI.02437-20; Doshi P., BMJ OPINION, V2021; Doshi P, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4037; Flores LE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.37640; Harrington DP, 2021, NEW ENGL J MED, V384, P576, DOI 10.1056/NEJMe2034294; He ZY, 2021, LANCET, V397, P1075, DOI 10.1016/S0140-6736(21)00238-5; Hill Andrew, 2021, Open Forum Infect Dis, V8, pofab358, DOI 10.1093/ofid/ofab358; Hipgrave DB, 2021, LANCET, V397, P1181, DOI 10.1016/S0140-6736(21)00442-6; IOANNIDIS JPA, 2021, B WORLD HEALTH ORGAN, V99, P19, DOI [DOI 10.2471/BLT.20.265892, 10.1101/2020.05.13.20101253]; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Keehner J, 2021, NEW ENGL J MED, V384, P1774, DOI 10.1056/NEJMc2101927; Kostoff RN, 2020, TOXICOL REP, V7, P1448, DOI 10.1016/j.toxrep.2020.10.016; Lazarus JV, 2020, NAT MED, V26, P1005, DOI 10.1038/s41591-020-0950-0; Ledford H., NATURE, V591; Ledford H, 2021, NATURE, V594, P164, DOI 10.1038/d41586-021-01505-x; Ledford H, 2020, NATURE, V588, P205, DOI 10.1038/d41586-020-03441-8; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Mallapaty S., NATURE, V2021; Mallapaty S, 2021, NATURE, V590, P197, DOI 10.1038/d41586-021-00316-4; McCartney M, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3473; Meltzer David O, 2020, medRxiv, DOI 10.1101/2020.05.08.20095893; Michel J, 2021, GLOBAL HEALTH ACTION, V14, DOI 10.1080/16549716.2021.1927315; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Paul E, 2020, INT J HEALTH POLICY, DOI 10.34172/ijhpm.2020.240; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Remmel A, 2021, NATURE, V590, P538, DOI 10.1038/d41586-021-00290-x; Rodriguez Mega E., NATURE, V2021; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Shankar-Hari M, 2021, JAMA-J AM MED ASSOC, V326, P499, DOI 10.1001/jama.2021.11330; Soulier M, CLIN INFECT DIS PUBL, V2021; Sturmberg JP, 2018, HLTH SYSTEM REDESIGN; Swinburn BA, 2019, LANCET, V393, P791, DOI 10.1016/S0140-6736(18)32822-8; Turcotte-Tremblay AM, 2021, BMC MED RES METHODOL, V21, DOI 10.1186/s12874-020-01200-x; Vaughn VM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.11788; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Whitmee S, 2015, LANCET, V386, P1973, DOI 10.1016/S0140-6736(15)60901-1; WHO, VACC IMM; World Health Organization, 2021, ACC COVID 19 TOOLS F; Zhou H, NAT COMMUN, V12, P1724	51	3	3	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					4921	4924		10.1016/j.vaccine.2021.07.045		AUG 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TX3GY	34315610	Green Published, Bronze			2022-04-29	WOS:000682979100001
J	Illouz, T; Madar, R; Hirsh, T; Biragyn, A; Okun, E				Illouz, Tomer; Madar, Ravit; Hirsh, Tamir; Biragyn, Arya; Okun, Eitan			Induction of an effective anti-Amyloid-beta humoral response in aged mice	VACCINE			English	Article						Immunosenescence; Alzheimer's disease; Amyloid-p; Vaccine; Priming; Microglia	IMMUNE-RESPONSE; DNA VACCINE; HEPATITIS-B; ALZHEIMERS; IMMUNIZATION; EPITOPE; MICROGLIA; NEURODEGENERATION; SPECIFICITY; MATURATION	Aging-related decline in immune functions, termed immunosenescence, is a primary cause of reduced protective responses to vaccines in the elderly, due to impaired induction of cellular and humoral responses to new antigens (Ag), especially if the response is T cell dependent. The result is a more severe morbidity following infections, more prolonged and frequent hospitalization, and a higher mortality rate than in the general population. Therefore, there is an increasing need to develop vaccination strategies that overcome immunosenescence, especially for aging-related diseases such as Alzheimer's disease (AD). Here we report a new vaccination strategy harnessing memory-based immunity, which is less affected by aging. We found that aged C57BL/6 and 5xFAD mice exhibit a dramatic reduction in anti-Amyloid-beta (A beta) antibody (A beta) production. We aimed to reverse this process by inducing memory response at a young age. To this end, young mice were primed with the vaccine carrier Hepatitis B surface antigen (HBsAg). At an advanced age, these mice were immunized with an A beta(1-11) fused to HBsAg. This vaccination scheme elicited a markedly higher A beta-specific antibody titer than vaccinating aged unprimed mice with the same construct. Importantly, this vaccine strategy more efficiently reduced cerebral A beta levels and altered microglial phenotype. Overall, we provide evidence that priming with an exogenous Ag carrier can overcome impaired humoral responses to self-antigens in the elderly, paving the route for a potent immunotherapy to AD. (C) 2021 Elsevier Ltd. All rights reserved.	[Illouz, Tomer; Madar, Ravit; Hirsh, Tamir; Okun, Eitan] Bar Ilan Univ, Leslie & Susan Gonda Multidisciplinary Brain Res, IL-5290002 Ramat Gan, Israel; [Madar, Ravit; Hirsh, Tamir; Okun, Eitan] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-5290002 Ramat Gan, Israel; [Illouz, Tomer; Madar, Ravit; Hirsh, Tamir; Okun, Eitan] Bar Ilan Univ, Paul Feder Lab Alzheimers Dis Res, IL-5290002 Ramat Gan, Israel; [Biragyn, Arya] NIA, Immunoregulat Sect, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA		Okun, E (通讯作者)，Bar Ilan Univ, Leslie & Susan Gonda Multidisciplinary Brain Res, IL-5290002 Ramat Gan, Israel.	eitan.okun@biu.ac.il	okun, eitan/K-1314-2016	okun, eitan/0000-0001-8474-1487; Madar, Ravit/0000-0002-2025-8178; Hirsh, Tamir/0000-0002-7537-5451; Illouz, Tomer/0000-0003-4123-6469	Clore Israel Foundation; Intramural Research Program of the National Institute on Aging, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)	This study was conducted in the Paul Feder laboratory of Alzheimer's disease research and was supported by the Clore Israel Foundation and in part by the Intramural Research Program of the National Institute on Aging, NIH.	Ahmed M, 2010, NAT STRUCT MOL BIOL, V17, P561, DOI 10.1038/nsmb.1799; Aiello A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02247; Alhajraf F, 2019, DEV NEUROBIOL, V79, P684, DOI 10.1002/dneu.22715; Alzheimer's Assoc, 2018, ALZHEIMERS DEMENT, V14, P367, DOI 10.1016/j.jalz.2018.02.001; Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x; Carroll M C, 2000, Adv Immunol, V74, P61; Carroll MC, 2004, MOL IMMUNOL, V41, P141, DOI 10.1016/j.molimm.2004.03.017; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Das S, 2019, J CLIN TRANSL HEPATO, V7, P165, DOI 10.14218/JCTH.2018.00037; Davtyan H, 2014, HUM VACC IMMUNOTHER, V10, P1248, DOI 10.4161/hv.27882; Davtyan H, 2014, ALZHEIMERS DEMENT, V10, P271, DOI 10.1016/j.jalz.2013.12.003; de Carvalho CA, 2013, ACTA TROP, V125, P128, DOI 10.1016/j.actatropica.2012.10.010; Deng F, 2021, FRONT IMMUNOL, V12, DOI [10.3389/ fimmu.2021.61819610.3389/ fimmu.2021.618196.s001, DOI 10.3389/FIMMU.2021.61819610.3389/FIMMU.2021.618196.S001]; Dhinaut J, 2018, J ANIM ECOL, V87, P448, DOI 10.1111/1365-2656.12661; Evans CF, 2014, ALZHEIMERS DEMENT, V10, P284, DOI 10.1016/j.jalz.2013.04.505; Frasca D, 2020, ANNU REV CELL DEV BI, V36, P551, DOI 10.1146/annurev-cellbio-011620-034148; Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6; Geier Mark R, 2003, Expert Opin Drug Saf, V2, P113, DOI 10.1517/eods.2.2.113.21381; Ghiso Jorge, 2010, Hirosaki Igaku, V61, pS111; Goedert M, 2015, SCIENCE, V349, DOI 10.1126/science.1255555; Goins CL, 2010, J IMMUNOL, V184, P6293, DOI 10.4049/jimmunol.0902530; Gupta M, 2016, MAMM GENOME, V27, P538, DOI 10.1007/s00335-016-9661-8; Hair PS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00558; Hannum LG, 2000, J EXP MED, V192, P931, DOI 10.1084/jem.192.7.931; Illouz T, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01851-6; Illouz T, 2019, BRAIN BEHAV IMMUN, V75, P163, DOI 10.1016/j.bbi.2018.10.004; Illouz T, 2017, J NEUROSCI METH, V291, P28, DOI 10.1016/j.jneumeth.2017.07.022; Illouz T, 2015, BIOESSAYS, V37, P5, DOI 10.1002/bies.201400179; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Korzhevskii D.E., 2016, NEUROSCI BEHAV PHYSI, V46, P284, DOI [10.1007/s11055-016-0231-z, DOI 10.1007/S11055-016-0231-Z]; Kranich J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00225; Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008; Kulik L, 2019, J IMMUNOL, V203, P3136, DOI 10.4049/jimmunol.1900620; Lambracht-Washington D, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0257-7; Lambracht-Washington D, 2017, J ALZHEIMERS DIS, V57, P97, DOI 10.3233/JAD-160947; Lambracht-Washington D, 2015, NEUROBIOL AGING, V36, P1274, DOI 10.1016/j.neurobiolaging.2014.12.011; Lansbury PT, 2006, NATURE, V443, P774, DOI 10.1038/nature05290; Leger M, 2013, NAT PROTOC, V8, P2531, DOI 10.1038/nprot.2013.155; Liu JC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002868; Lueptow LM, 2017, JOVE-J VIS EXP, DOI 10.3791/55718; Mastroeni D, 2018, NEUROBIOL AGING, V63, P12, DOI 10.1016/j.neurobiolaging.2017.10.019; Matsumoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075203; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Motulsky HJ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-123; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Olkhanud PB, 2012, VACCINE, V30, P1650, DOI 10.1016/j.vaccine.2011.12.136; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Petrushina I, 2020, NEUROBIOL DIS, V139, DOI 10.1016/j.nbd.2020.104823; Pyrski M, 2017, VACCINE, V35, P5714, DOI 10.1016/j.vaccine.2017.07.082; Qu BX, 2010, VACCINE, V28, P5280, DOI 10.1016/j.vaccine.2010.05.054; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Rueda N, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/584071; Saupe F, 2015, FASEB J, V29, P3253, DOI 10.1096/fj.15-271502; Seibenhener ML, 2015, JOVE-J VIS EXP, DOI 10.3791/52434; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Steinerman JR, 2008, ARCH NEUROL-CHICAGO, V65, P906, DOI 10.1001/archneur.65.7.906; Streit WJ, 2020, GLIA, V68, P845, DOI 10.1002/glia.23782; Suurmond J, 2015, J CLIN INVEST, V125, P2194, DOI 10.1172/JCI78084; Ukraintseva S, 2020, ALZHEIMERS DEMENTIA, V16, DOI [10.1002/alz.v16.S310.1002/alz.046751, DOI 10.1002/ALZ.V16.S310.1002/ALZ.046751]; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wendeln AC, 2018, NATURE, V556, P332, DOI 10.1038/s41586-018-0023-4; Wisniewski T, 2008, LANCET NEUROL, V7, P805, DOI 10.1016/S1474-4422(08)70170-4; Xing XN, 2012, J NEUROL SCI, V313, P17, DOI 10.1016/j.jns.2011.09.040; Yang YJ, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01741-4; Zhang YW, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-3; Zhao QJ, 2006, HUM VACCINES, V2, P174, DOI 10.4161/hv.2.4.3015	66	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4817	4829		10.1016/j.vaccine.2021.07.023		JUL 2021	13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34294479				2022-04-29	WOS:000679483400013
J	Ingrole, RSJ; Tao, WQ; Joshi, G; Gill, HS				Ingrole, Rohan S. J.; Tao, Wenqian; Joshi, Gaurav; Gill, Harvinder Singh			M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets	VACCINE			English	Article						Broadly protective; Flu; M2e; Particle; Peptide; Universal	VIRUS; TRANSMISSION; PATHOGENESIS; MODELS; H1N1	Currently approved influenza vaccines are not only limited in breadth of protection but also have a lim-ited shelf-life of 12-18 months when stored under appropriate conditions (2-8 degrees C). Inadvertent alteration in storage temperatures during manufacturing, transportation, distribution until delivery to patient, can damage the vaccine thus reducing its efficacy. A thermally stable vaccine can decrease the economic bur -den by reducing reliance on refrigeration system and can also enhance outreach of the vaccination pro-gram by allowing transportation to remote areas of the world where refrigerated conditions are scarce. We have previously developed a broadly protective influenza A vaccine by coupling the highly conserved extracellular region of the matrix 2 protein (M2e) of influenza A virus to gold nanoparticles (AuNPs) and upon subsequent addition of toll-like receptor 9 agonist - CpG, as an adjuvant, have shown its breadth of protection in a mouse model. In this study, we show that the vaccine is thermally stable when stored at 4 degrees C for 3 months, 37 degrees C for 3 months and 50 degrees C for 2 weeks in its lyophilized form, and later it was pos-sible to readily reconstitute it in water without aggregation. Intranasal vaccination of mice using recon-stituted vaccine induced M2e-specific IgG and IgG subtypes in serum similar to the freshly formulated vaccine, and fully protected mice against lethal influenza A challenge. Immunization of ferrets intrana-sally or intramuscularly with the vaccine induced M2e-specific IgG and there was reduced virus level in nasal wash of ferrets immunized through intranasal route. (c) 2021 Elsevier Ltd. All rights reserved.	[Ingrole, Rohan S. J.; Tao, Wenqian; Joshi, Gaurav; Gill, Harvinder Singh] Texas Tech Univ, Dept Chem Engn, 8th St & Canton Ave,Mail Stop 3121, Lubbock, TX 79409 USA		Gill, HS (通讯作者)，Texas Tech Univ, Dept Chem Engn, 8th St & Canton Ave,Mail Stop 3121, Lubbock, TX 79409 USA.	harvinder.gill@ttu.edu	JOSHI, GAURAV/AAD-6135-2022; Gill, Harvinder Singh/D-8252-2014	Gill, Harvinder Singh/0000-0003-0832-5291	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21AI099575 R56AI119397, R01AI137846]; Whitacre Endowed Chair in Science and Engineering	Research reported in this publication was supported in part by the National Institutes of Health (NIH) under award number R21AI099575 R56AI119397 and R01AI137846, and in part by funds from the Whitacre Endowed Chair in Science and Engineering to HSG.	Alkilany AM, 2014, LANGMUIR, V30, P13799, DOI 10.1021/la504000v; Belser JA, 2018, EMERG INFECT DIS, V24, P965, DOI 10.3201/eid2406.172114; Belser JA, 2016, MICROBIOL MOL BIOL R, V80, P733, DOI 10.1128/MMBR.00022-16; Centers for Disease Control and Prevention, 2019, INFL VACC US 2019 20 INFL VACC US 2019 20; Coenen F, 2006, VACCINE, V24, P525, DOI 10.1016/j.vaccine.2005.07.081; Deng L, 2015, VACCINES-BASEL, V3, P105, DOI 10.3390/vaccines3010105; Enkirch T, 2015, VIROLOGY, V479, P259, DOI 10.1016/j.virol.2015.03.017; Fang YA, 2010, J VIROL, V84, P8369, DOI 10.1128/JVI.02305-09; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Flood A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164692; Guidelines on stability evaluation of vaccines, 2009, BIOL J INT ASS BIOL BIOL J INT ASS BIOL, V37, P424; Huang J, 2004, VACCINE, V23, P794, DOI 10.1016/j.vaccine.2004.06.049; Huber SKR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127969; Jester B, 2019, VIROLOGY, V527, P32, DOI 10.1016/j.virol.2018.10.019; Lai MC, 1999, J PHARM SCI-US, V88, P489, DOI 10.1021/js980374e; Link S, 1999, J PHYS CHEM B, V103, P4212, DOI 10.1021/jp984796o; Matthias DM, 2007, VACCINE, V25, P3980, DOI 10.1016/j.vaccine.2007.02.052; Munster VJ, 2009, SCIENCE, V325, P481, DOI 10.1126/science.1177127; Music N, 2016, VACCINE, V34, P466, DOI 10.1016/j.vaccine.2015.12.023; Oxford JS, 2000, REV MED VIROL, V10, P119, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;119::AID-RMV272&gt;3.0.CO;2-O; Prevention CfDCa, 2012, 1 GLOB EST 2009 H1N1 1 GLOB EST 2009 H1N1; Rankin R, 2001, ANTISENSE NUCLEIC A, V11, P333, DOI 10.1089/108729001753231713; Tao WQ, 2017, ANTIVIR RES, V141, P62, DOI 10.1016/j.antiviral.2017.01.021; Tao WQ, 2015, VACCINE, V33, P2307, DOI 10.1016/j.vaccine.2015.03.063; Tao WQ, 2014, NANOMEDICINE-UK, V9, P237, DOI 10.2217/nnm.13.58; Taubenberger JK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5485; Treanor JJ, 2015, VACCINE, V33, pD39, DOI 10.1016/j.vaccine.2015.08.053; van Riel D, 2007, AM J PATHOL, V171, P1215, DOI 10.2353/ajpath.2007.070248; WHO (World Health Organization), 2018, INFL SEAS; World Health Organization, 2017, PAND INFL RISK MAN W	30	3	3	2	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 9	2021	39	34					4800	4809		10.1016/j.vaccine.2021.07.032		JUL 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TS2JX	34301431				2022-04-29	WOS:000679483400011
J	Hines, AM; Murphy, N; Mullin, C; Barillas, J; Barrientos, JC				Hines, Adam M.; Murphy, Neal; Mullin, Christine; Barillas, Julia; Barrientos, Jacqueline C.			Henoch-Schonlein purpura presenting post COVID-19 vaccination	VACCINE			English	Letter									[Hines, Adam M.; Murphy, Neal; Barrientos, Jacqueline C.] Northwell Hlth Canc Inst, New York, NY USA; [Mullin, Christine] North Shore Univ, Northwell Hlth, Div Maternal Fetal Med, New York, NY USA; [Barillas, Julia] Woodhull NYC Hlth Hosp, New York, NY USA; [Barrientos, Jacqueline C.] Zucker Sch Med Hofstra Northwell, New York, NY USA		Barrientos, JC (通讯作者)，410 Lakeville Rd Ste 212, Lake Success, NY 11042 USA.	Jbarrientos@northwell.edu	Barrientos, Jacqueline/AAE-6683-2022; Hines, Adam/AAV-9725-2021	Hines, Adam/0000-0003-4817-5654; Barrientos, Jacqueline/0000-0001-6018-5535			Felicetti P, 2016, VACCINE, V34, P6634, DOI 10.1016/j.vaccine.2015.09.027; McGonagle D, 2021, LANCET RHEUMATOL, V3, pE224, DOI 10.1016/S2665-9913(20)30420-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Schnabel A, 2019, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00421; Watts RA, 2004, SEM RESP CRIT CARE M, V25, P455, DOI 10.1055/s-2004-836139	5	14	14	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4571	4572		10.1016/j.vaccine.2021.06.079		JUL 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	34247902	Green Published, Bronze			2022-04-29	WOS:000681356500001
J	Huang, YD; Seaton, KE; Casapia, M; Polakowski, L; De Rosa, SCD; Cohen, K; Yu, CC; Elizaga, M; Paez, C; Miner, MD; Kelley, CF; Maenza, J; Keefer, M; Lama, JR; Sobieszczyk, M; Buchbinder, S; Badenj, LR; Lee, C; Gulati, V; Sinangil, F; Montefiori, D; McElrath, MJ; Tomaras, GD; Robinsonm, HL; Goepfert, P				Huang, Yunda; Seaton, Kelly E.; Casapia, Martin; Polakowski, Laura; De Rosa, Stephen C.; Cohen, Kristen; Yu, Chenchen; Elizaga, Marnie; Paez, Carmen; Miner, Maurine D.; Kelley, Colleen F.; Maenza, Janine; Keefer, Michael; Lama, Javier R.; Sobieszczyk, Magdalena; Buchbinder, Susan; Badenj, Lindsey R.; Lee, Carter; Gulati, Vineeta; Sinangil, Faruk; Montefiori, David; McElrath, M. Juliana; Tomaras, Georgia D.; Robinsonm, Harriet L.; Goepfert, Paul		NIAID funded HIV Vaccine Trials	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period	VACCINE			English	Article						HIV vaccine; DNA Vaccine; MVA vaccine; Late boost; AIDSVAX	DOUBLE-BLIND; EFFICACY; SUBTYPE; SAFETY; TRIAL; ALVAC; DNA	Background: Eliciting durable humoral immunity with sufficient breadth and magnitude is important for HIV-1 vaccine design. The HVTN 114 vaccine trial evaluated different boost regimens administered after a 7-year rest period in participants previously enrolled in HVTN 205, who received either three MVA/ HIV62B (MMM) or two DNA and two MVA/HIV62B (DDMM) injections; both vaccines expressed multiple HIV-1 antigens in non-infectious virus-like-particles. The primary objective of HVTN 114 was to assess the impact of a heterologous gp120 protein AIDSVAX B/E boost on the magnitude, breadth and durability of vaccine-induced immune responses. Methods: We enrolled 27 participants from HVTN 205 into five groups. Eight participants who previously received MMM were randomized and boosted with either MVA/HIV62B alone (T1; n = 4) or MVA/HIV62B and AIDSVAX B/E (T2; n = 4). Nineteen participants who received DDMM were randomized and boosted with MVA/HIV62B alone (T3; n = 6), MVA/HIV62B and AIDSVAX B/E (T4; n = 6), or AIDSVAX B/E alone (T5; n = 7). Boosts were at months 0 and 4. Participants were followed for safety and immunogenicity for 10 months and were pooled for analysis based on the regimen: MVA-only (T1 + T3), MVA + AIDSVAX (T2 + T4), and AIDSVAX-only (T5). Results: All regimens were safe and well-tolerated. Prior to the boost vaccination, binding antibody and CD4+T-cell responses were observed 7 years after HVTN 205 vaccinations. Late boosting with AIDSVAX, with or without MVA, resulted in high binding antibody responses to gp120 and V1V2 epitopes, with increased magnitude and breadth compared to those observed in HVTN 205. Late boosting with MVA, with or without AIDSVAX, resulted in increased gp140 and gp41 antibody responses and higher CD4 +T-cell responses to Env and Gag. Conclusions: Late boosting with AIDSVAX, alone or in combination with MVA, can broaden binding antibody responses and increase T-cell responses even years following the original MVA/HIV62B with or without DNA-priming vaccine. Published by Elsevier Ltd.	[Huang, Yunda; De Rosa, Stephen C.; Cohen, Kristen; Yu, Chenchen; Elizaga, Marnie; Paez, Carmen; Miner, Maurine D.; Maenza, Janine; McElrath, M. Juliana] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA; [Seaton, Kelly E.; Tomaras, Georgia D.] Duke Univ, Duke Ctr Human Syst Immunol, Dept Surg, Durham, NC USA; [Seaton, Kelly E.; Tomaras, Georgia D.] Duke Univ, Duke Ctr Human Syst Immunol, Dept Immunol, Durham, NC USA; [Seaton, Kelly E.; Tomaras, Georgia D.] Duke Univ, Duke Ctr Human Syst Immunol, Dept Pathol, Durham, NC USA; [Seaton, Kelly E.; Tomaras, Georgia D.] Duke Univ, Duke Ctr Human Syst Immunol, Dept Mol Genet, Durham, NC USA; [Seaton, Kelly E.; Tomaras, Georgia D.] Duke Univ, Duke Ctr Human Syst Immunol, Dept Microbiol, Durham, NC USA; [Casapia, Martin] Univ Nacl Amazonia, Asociac Civil Selva Amazon, Urbanizac Jardin 27, Iquitos, Peru; [Polakowski, Laura] NIAID, Div Aids, Rockville, MD USA; [Kelley, Colleen F.] Emory Univ, Dept Med, Atlanta, GA 30322 USA; [Keefer, Michael] Univ Rochester, Div Infect Dis, Dept Med, Rochester, NY USA; [Lama, Javier R.] Asociac Civil Impacta Salud & Educac, Lima, Peru; [Sobieszczyk, Magdalena] Columbia Univ, Irving Med Ctr, Div Infect Dis, Dept Med, Columbia, SC USA; [Buchbinder, Susan] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA; [Badenj, Lindsey R.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02114 USA; [Lee, Carter] Global Solut Infect Dis, Lafayette, CA USA; [Gulati, Vineeta] Duke Univ, Dept Surg, Durham, NC USA; [Sinangil, Faruk] Duke Univ, Duke Human Vaccine Inst, Durham, NC USA; [Montefiori, David] GeoVax, Atlanta, GA USA; [Goepfert, Paul] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA; [Huang, Yunda] Univ Washington, Dept Global Hlth, Seattle, WA USA		Goepfert, P (通讯作者)，908 20h St South CCB 326, Birmingham, AL 35294 USA.	mcasapia@acsaperu.org; pgoepfert@uabmc.edu		Paez, Carmen A/0000-0001-8640-6623; Miner, Maurine/0000-0002-4637-1283; Polakowski, Laura/0000-0002-5476-7632	National Institute of Allergy and Infectious Diseases (NIAID) U.S. Public Health Service [UM1 AI068614, UM1 AI068635, UM1 AI068618]; Duke CFAR [P30 AI064518]	This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) U.S. Public Health Service Grants UM1 AI068614 [LOC: HIV Vaccine Trials Network] , UM1 AI068635 [HVTN SDMC FHCRC] , UM1 AI068618 [HVTN Laboratory Center FHCRC] , and Duke CFAR P30 AI064518. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Insti-tutes of Health. The funders had no role in study design, data col-lection and analysis, decision to publish, or preparation of the manuscript.	BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Buchbinder Susan P, 2019, Top Antivir Med, V27, P8; Buchbinder SP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179597; Eisinger RW, 2018, EMERG INFECT DIS, V24, P413, DOI 10.3201/eid2403.171797; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Goepfert PA, 2014, J INFECT DIS, V210, P99, DOI 10.1093/infdis/jiu003; Goepfert PA, 2011, J INFECT DIS, V203, P610, DOI 10.1093/infdis/jiq105; Gray GE, 2021, NEW ENGL J MED, V384, P1089, DOI 10.1056/NEJMoa2031499; Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6; Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Horton H, 2007, J IMMUNOL METHODS, V323, P39, DOI 10.1016/j.jim.2007.03.002; Huang YD, 2009, STAT BIOPHARM RES, V1, P81, DOI 10.1198/sbr.2009.0008; Janes H, HVTN SUBSAHARAN AFRI; Laher F, 2020, ARCH VIROL, V165, P2439, DOI 10.1007/s00705-020-04777-2; Lin L, 2015, NAT BIOTECHNOL, V33, P610, DOI 10.1038/nbt.3187; Neidich SD, 2019, J CLIN INVEST, V129, P4838, DOI 10.1172/JCI126391; Palli R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69007-w; Pitisuttithum P, 2004, JAIDS-J ACQ IMM DEF, V37, P1160, DOI 10.1097/01.qai.0000136091.72955.4b; Rerks-Ngarm S, 2017, J INFECT DIS, V215, P1255, DOI 10.1093/infdis/jix099; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Seaton KE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101863; Spearman P, 2019, J INFECT DIS, V219, P1755, DOI 10.1093/infdis/jiz008; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; UNAIDS, UNAIDS DATA 2019; Van Der Meeren O, 2020, VACCINE, V38, P1678, DOI 10.1016/j.vaccine.2019.12.058; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730	29	0	0	2	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4641	4650		10.1016/j.vaccine.2021.06.066		JUL 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	34229888				2022-04-29	WOS:000681356500009
J	Prasad, N; Read, MJ; Jewell, C; Waite, B; Trenholme, AA; Huang, QS; Grant, CC; Newbern, EC; Hogan, BA				Prasad, Namrata; Read, M. Jonathan; Jewell, Christopher; Waite, Ben; Trenholme, A. Adrian; Huang, Q. Sue; Grant, C. Cameron; Newbern, E. Claire; Hogan, B. Alexandra			Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand	VACCINE			English	Article						Respiratory syncytial virus; RSV; Maternal vaccine; Immunoprophylaxis; Mathematical modelling	INFECTIONS; INFANTS; DISEASE; BURDEN	Background: Mathematical models of respiratory syncytial virus (RSV) transmission can help describe seasonal epidemics and assess the impact of potential vaccines and immunoprophylaxis with monoclonal antibodies (mAb). Methods: We developed a deterministic, compartmental model for RSV transmission, which was fitted to population-based RSV hospital surveillance data from Auckland, New Zealand. The model simulated the introduction of either a maternal vaccine or a seasonal mAb among infants aged less than 6 months and estimated the reduction in RSV hospitalizations for a range of effectiveness and coverage values. Results: The model accurately reproduced the annual seasonality of RSV epidemics in Auckland. We found that a maternal vaccine with effectiveness of 30-40% in the first 90 days and 15-20% for the next 90 days could reduce RSV hospitalizations by 18-24% in children younger than 3 months, by 11-14% in children aged 3-5 months, and by 2-3% in children aged 6-23 months. A seasonal infant mAb with 40- 60% effectiveness for 150 days could reduce RSV hospitalizations by 30-43%, 34-48% and by 14-21% in children aged 0-2 months, 3-5 months and 6-23 months, respectively. Conclusions: Our results suggest that either a maternal RSV vaccine or mAb would effectively reduce RSV hospitalization disease burden in New Zealand. Overall, a seasonal mAb resulted in a larger disease pre-vention impact than a maternal vaccine. (c) 2021 Elsevier Ltd. All rights reserved.	[Prasad, Namrata; Waite, Ben; Huang, Q. Sue; Newbern, E. Claire] Inst Environm Sci & Res, Natl Ctr Biosecur & Infect Dis, Wellington, New Zealand; [Prasad, Namrata; Grant, C. Cameron] Univ Auckland, Dept Paediat Child & Youth Hlth, Auckland, New Zealand; [Read, M. Jonathan; Jewell, Christopher] Univ Lancaster, Lancaster Med Sch, Ctr Hlth Informat Comp & Stat, Lancaster, England; [Trenholme, A. Adrian] Counties Manukau Dist Hlth Board, Kidz First Childrens Hosp, Auckland, New Zealand; [Grant, C. Cameron] Starship Childrens Hosp, Gen Paediat, Auckland, New Zealand; [Hogan, B. Alexandra] Imperial Coll London, Sch Publ Hlth, MRC Ctr Global Infect Dis Anal, London, England		Prasad, N (通讯作者)，Inst Environm Sci & Res, Natl Ctr Biosecur & Infect Dis, Wellington, New Zealand.; Prasad, N (通讯作者)，Univ Auckland, Dept Paediat Child & Youth Hlth, Auckland, New Zealand.	namrata.prasad@esr.cri.nz		Huang, Q. Sue/0000-0002-3923-5195; Read, Jonathan/0000-0002-9697-0962; Grant, Cameron/0000-0002-4032-7230	US Centers of Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1U01IP000480-01]; New Zealand Ministry of Health; New Zealand Health Research CouncilHealth Research Council of New Zealand; Imperial College Research Fellowship; MRC Centre for Global Infectious Disease AnalysisUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/R015600/1]; UK Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); UK Foreign, Commonwealth AMP; Development Office (FCDO); European UnionEuropean Commission	This work was supported by the US Centers of Disease Control and Prevention (1U01IP000480-01); New Zealand Ministry of Health; and a New Zealand Health Research Council Doctoral scholarship to NP. ABH acknowledges support from her Imperial College Research Fellowship, and funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.	Bolker B, 2020, MAXIMUM LIKELIHOOD E; Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1665, 10.1542/peds.2014-1666]; Chu HY, 2014, J INFECT DIS, V210, P1582, DOI 10.1093/infdis/jiu316; Cox MJ, 1998, J MED VIROL, V55, P234, DOI 10.1002/(SICI)1096-9071(199807)55:3&lt;234::AID-JMV9&gt;3.0.CO;2-2; Cromer D, 2017, LANCET PUBLIC HEALTH, V2, pE367, DOI 10.1016/S2468-2667(17)30103-2; Deverall EJ, 2018, NEW ZEAL MED J, V131, P42; Fumanelli L, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002673; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Griffin MP, 2020, NEW ENGL J MED, V383, P415, DOI 10.1056/NEJMoa1913556; HALL CB, 1976, J PEDIATR-US, V89, P11, DOI 10.1016/S0022-3476(76)80918-3; Hogan AB, 2017, VACCINE, V35, P6172, DOI 10.1016/j.vaccine.2017.09.043; Hogan AB, 2016, THEOR POPUL BIOL, V110, P78, DOI 10.1016/j.tpb.2016.04.003; Huang QS, 2015, INFLUENZA OTHER RESP, V9, P179, DOI 10.1111/irv.12315; Madhi SA, 2020, NEW ENGL J MED, V383, P426, DOI 10.1056/NEJMoa1908380; McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283; Modjarrad K, 2016, VACCINE, V34, P190, DOI 10.1016/j.vaccine.2015.05.093; Munywoki PK, 2015, J INFECT DIS, V212, P1711, DOI 10.1093/infdis/jiv263; New Zealand Ministry of Health, NZ IMM SCHED; Nyiro JU, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177803; PATH, RSV VACC MAB SNAPSH; Prasad N, 2020, PEDIATR INFECT DIS J, V39, pE176, DOI 10.1097/INF.0000000000002681; Prasad N, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819001377; Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697; Rainisch G, 2020, VACCINE, V38, P251, DOI 10.1016/j.vaccine.2019.10.023; Regnier SA, 2013, PEDIATR INFECT DIS J, V32, P820, DOI 10.1097/INF.0b013e31829061e8; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Shi T, 2015, J GLOB HEALTH, V5, P203, DOI 10.7189/jogh.05.020416; Statistics New Zealand, BIRTHS DEATHS; Statistics New Zealand, 2015, SUBNATIONAL POPULATI; Statistics New Zealand, NZ PERIOD LIFE TABLE; Weber A, 2001, MATH BIOSCI, V172, P95, DOI 10.1016/S0025-5564(01)00066-9; WHO, WHO SURV CAS DEF ILI; Zhang Q., 2017, SCI TRANSL MED, P9	33	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 13	2021	39	31					4383	4390		10.1016/j.vaccine.2021.05.100		JUL 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TG0WP	34147296				2022-04-29	WOS:000671133900021
J	Chyderiotis, S; Sicsic, J; Raude, J; Bonmarin, I; Jeanleboeuf, F; Banaszuk, ASL; Gauchet, A; Bruel, S; Michel, M; Giraudeau, B; Thilly, N; Mueller, JE				Chyderiotis, Sandra; Sicsic, Jonathan; Raude, Jocelyn; Bonmarin, Isabelle; Jeanleboeuf, Florian; Banaszuk, Anne-Sophie Le Duc; Gauchet, Aurelie; Bruel, Sebastien; Michel, Morgane; Giraudeau, Bruno; Thilly, Nathalie; Mueller, Judith E.			Optimising HPV vaccination communication to adolescents: A discrete choice experiment	VACCINE			English	Article						HPV; Vaccine acceptance; Discrete choice experiment; France; Adolescents; Communication	HUMAN-PAPILLOMAVIRUS VACCINATION; CONJOINT-ANALYSIS; PREFERENCES; BENEFITS; COVERAGE; DISEASES; PARENT; GIRLS	Background: Human Papillomavirus (HPV) vaccine coverage in France is below 30%, despite proven effectiveness against HPV infections and (pre-)cancerous cervical lesions. To optimise vaccine promotion among adolescents, we used a discrete choice experiment (DCE) to identify optimal statements regarding a vaccination programme, including vaccine characteristics. Methods: Girls and boys enrolled in the last two years of five middle schools in three French regions (aged 13-15 years) participated in an in-class cross-sectional self-administered internet-based study. In ten hypothetical scenarios, participants decided for or against signing up for a school-based vaccination campaign against an unnamed disease. Scenarios included different levels of four attributes: the type of vaccine-preventable disease, communication on vaccine safety, potential for indirect protection, and information on vaccine uptake among peers. One scenario was repeated with an added mention of sexual transmission. Results: The 1,458 participating adolescents (estimated response rate: 89.4%) theoretically accepted vaccination in 80.1% of scenarios. All attributes significantly impacted theoretical vaccine acceptance. Compared to a febrile respiratory disease, protection against cancer was motivating (odds ratio (OR) 1.29 [95%-CI 1.09-1.52]), but not against genital warts (OR 0.91 [0.78-1.06]). Compared to risk negation ("vaccine does not provoke serious side effects"), a reference to a positive benefit-risk balance despite a confirmed side effect was strongly dissuasive (OR 0.30 [0.24-0.36]), while reference to ongoing international pharmacovigilance without any scientifically confirmed effect was not significantly dissuasive (OR 0.86 [0.71-1.04]). The potential for indirect protection motivated acceptance among girls but not boys (potential for eliminating the disease compared to no indirect protection, OR 1.57 [1.25-1.96]). Compared to mentioning "insufficient coverage", reporting that ">80% of young people in other countries got vaccinated" motivated vaccine acceptance (OR 1.94 [1.61-2.35]). The notion of sexual transmission did not influence acceptance. Conclusion: HPV vaccine communication to adolescents can be tailored to optimise the impact of promotion efforts. (c) 2021 Elsevier Ltd. All rights reserved.	[Chyderiotis, Sandra; Mueller, Judith E.] Inst Pasteur, Unite Rech & Expertise Epidemiol Malad Emergentes, 25 Rue Dr Roux, F-75724 Paris 15, France; [Sicsic, Jonathan] Univ Paris, LIRAES EA 4470, Paris, France; [Raude, Jocelyn; Mueller, Judith E.] Univ Sorbonne Paris Cite, EHESP Rennes, Paris, France; [Raude, Jocelyn] Unite Virus Emergents UVE Aix Marseille Univ IRD, Marseille, France; [Bonmarin, Isabelle] Sante Publ France, St Maurice, France; [Jeanleboeuf, Florian] Univ Lyon, GIMAP Grp Immunite Muqueuses & Agents Pathogenes, EA 3064, Univ Jean Monnet, St Etienne, France; [Jeanleboeuf, Florian] Univ Lyon, Chaire PREVacCI Prevent Vaccinat & Controle Infec, Inst PRESAGE, Univ Jean Monnet, St Etienne, France; [Banaszuk, Anne-Sophie Le Duc] Ctr Reg Coordinat Depistages Canc Pays Loire, Angers, France; [Gauchet, Aurelie] Univ Grenoble Alpes, LIP PC2S, EA 4145, Grenoble, France; [Bruel, Sebastien] St Etienne Lyon Univ, HESPER EA7425, St Etienne, France; [Bruel, Sebastien] Univ Hosp St Etienne, CIC INSERM 1408, St Etienne, France; [Michel, Morgane] Univ Paris, ECEVE, Paris, France; [Michel, Morgane] Hop Robert Debre, Assistance Publ Hop Paris, Hotel Dieu, URC Eco Ile de France,Unite Epidemiol Clin, Paris, France; [Michel, Morgane] ECEVE, INSERM, UMR 1123, Paris, France; [Giraudeau, Bruno] Univ Nantes, Univ Tours, INSERM, SPHERE U1246, Tours, France; [Giraudeau, Bruno] CHRU Tours, INSERM CIC 1415, Tours, France; [Thilly, Nathalie] Univ Lorraine, APEMAC, Nancy, France; [Thilly, Nathalie] Univ Lorraine, CHRU Nancy, Dept Methodol, Promot,Invest, Nancy, France		Chyderiotis, S (通讯作者)，Inst Pasteur, Unite Rech & Expertise Epidemiol Malad Emergentes, 25 Rue Dr Roux, F-75724 Paris 15, France.	sandra.chyderiotis@outlook.com	Sicsic, Jonathan/M-1549-2018	Sicsic, Jonathan/0000-0002-5509-4791; Michel, Morgane/0000-0001-6090-8211; Isabelle, Bonmarin/0000-0002-7384-9828	Institut de Recherche en Sante Publique (IReSP); Institut national de la sante et de la recherche medicale (INSERM)Institut National de la Sante et de la Recherche Medicale (Inserm); ITMO Sante publique AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante/National Alliance for Life Sciences Health); ITMO Cancer	The study was part of the PrevHPV project, conducted with the support of Institut de Recherche en Sante Publique (IReSP) and Institut national de la sante et de la recherche medicale (INSERM), with financial support from ITMO Cancer and ITMO Sante publique AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Sante/National Alliance for Life Sciences & Health) within the framework of the Cancer Plan 2014-2019. The funding sources had no involvement in the study design, the collection, analysis and interpretation of data; in the writing and in the decision to submit the article for publication.	Amessi L., 2016, CONNAISSANCES INFECT; Bansal Anshuma, 2016, Int J Appl Basic Med Res, V6, P84, DOI 10.4103/2229-516X.179027; Berenson AB, 2014, HUM VACC IMMUNOTHER, V10, P1807, DOI 10.4161/hv.28779; Betsch C, 2013, HEALTH PSYCHOL, V32, P146, DOI 10.1037/a0027387; Bonafide KE, 2015, SEX TRANSM DIS, V42, P76, DOI 10.1097/OLQ.0000000000000226; Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013; Chang J, 2018, J PEDIATR ADOL GYNEC, V31, P28, DOI 10.1016/j.jpag.2017.10.003; de Bekker-Grob EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/hec.1697; de Bekker-Grob EW, 2010, VACCINE, V28, P6692, DOI 10.1016/j.vaccine.2010.08.001; Ecollan M, 2016, CONNAISSANCES FACTEU; Fonteneau L., 2019, Bulletin Epidemiologique Hebdomadaire, P424; Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354; Gowda C, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-509; Guillery-Girard, 2011, ADOLESCENCE, V77, P479, DOI DOI 10.3917/AD0.077.0479; Harper DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088493; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hofman R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104772; Institut national du cancer, 2015, CANC FRANC DONN; Jestin C., 2017, B EPIDEMIOL HEBD, P339; Karafillakis E, 2019, HUM VACC IMMUNOTHER, V15, P1615, DOI 10.1080/21645515.2018.1564436; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Louvel A., 2018, QUEST EC SANTE, V229, P1; Mansfield C, 2020, HEALTH ECON, V29, P1307, DOI 10.1002/hec.4124; Marshall HS, 2016, VACCINE, V34, P671, DOI 10.1016/j.vaccine.2015.11.075; Messonnier ML, 2014, ADV HEALTH ECON HEAL, P93; Ministere des Solidarites et de la Sante, 2020, CALENDRIER VACCINATI; Miranda S, 2017, VACCINE, V35, P4761, DOI 10.1016/j.vaccine.2017.06.030; Nguyen-Huu NH, 2020, VACCINE, V38, P1315, DOI 10.1016/j.vaccine.2019.11.081; Nowak GJ, 2015, VACCINE, V33, P4204, DOI 10.1016/j.vaccine.2015.04.039; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Rascon E., 2018, SSRN ELECT J; Raude J, 2020, QUANTIFYING PREFEREN; Ryan M, 1999, SOC SCI MED, V48, P535, DOI 10.1016/S0277-9536(98)00374-8; Ryan M, 2009, HEALTH ECON, V18, P321, DOI 10.1002/hec.1369; Seanehia J, 2017, VACCINE, V35, P2676, DOI 10.1016/j.vaccine.2017.03.086; Sheeran P., 2002, EUR REV SOC PSYCHOL, V12, P1, DOI [10.1080/14792772143000003, DOI 10.1080/14792772143000003]; Sheikh S, 2018, VACCINE, V36, P4979, DOI 10.1016/j.vaccine.2018.06.044; Sinka K, 2014, J EPIDEMIOL COMMUN H, V68, P57, DOI 10.1136/jech-2013-202620; Soekhai V, 2019, PHARMACOECONOMICS, V37, P201, DOI 10.1007/s40273-018-0734-2; Uhart M, 2017, PAPILLOMAVIRUS RES, V3, P73, DOI 10.1016/j.pvr.2017.02.004; Verelst F, 2019, VACCINE, V37, P2079, DOI 10.1016/j.vaccine.2019.02.056; Verelst F, 2018, SOC SCI MED, V207, P106, DOI 10.1016/j.socscimed.2018.04.038; Verrier F., 2019, Bulletin Epidemiologique Hebdomadaire, P450; WANG B, 2017, PLOS ONE, V0012, DOI DOI 10.1371/JOURNAL.PONE.0181073&TYPE=PRINTABLE; Woronoff A-S., 2019, B EPIDEMIOL HEBD; ZARBATANY L, 1985, DEV PSYCHOL, V21, P97, DOI 10.1037/0012-1649.21.1.97	47	2	2	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3916	3925		10.1016/j.vaccine.2021.05.061		JUN 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SV4EN	34088507	Green Submitted			2022-04-29	WOS:000663773600018
J	Lasky, T; McMahon, AW; Hua, W; Forshee, R				Lasky, Tamar; McMahon, Ann W.; Hua, Wei; Forshee, Richard			Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review	VACCINE			English	Review						Vaccination; Infant; Influenza; Pertussis; Pregnancy	INACTIVATED INFLUENZA VACCINE; ACELLULAR PERTUSSIS; TDAP IMMUNIZATION; NEONATAL OUTCOMES; TETANUS; DIPHTHERIA; BIRTH; RISK; ASSOCIATION; INFANTS	Objective: This scoping review mapped studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women. Introduction: In the US, two vaccines are recommended for all pregnant women to prevent illness in the infant: inactivated influenza vaccine (recommended since 2004), and the combined tetanus-diphtheriaacellular pertussis (Tdap) vaccine (recommended since 2013). This scoping review maps the studies conducted to date that address questions about pediatric safety and effectiveness of vaccines administered during pregnancy and provides a knowledge base for evaluating the use of RWD to study this issue. Methods: The scoping review was conducted following a published protocol. Methods included an electronic search of PubMed and Embase, screening of titles and abstracts by two reviewers, and double extraction of data for summary and synthesis. Studies that reported on pregnant women and the effectiveness or safety outcomes in their infants were included. Results: Forty-eight studies met the inclusion criteria of the scoping review protocol using RWD to assess safety or effectiveness of influenza or pertussis vaccinations administered to pregnant women with respect to pregnancy, infant or child outcomes. Detailed information about data sources, linkage of maternal and infant data, and operational definitions for gestational age were largely absent from the majority of studies raising concerns about reproducibility and validity of study findings. Conclusions: A body of literature is available from which to plan and design future studies of vaccination in pregnant women using RWD. This is of intense importance as new vaccines, such as those for COVID19, become available to the general population via approval or authorization without inclusion of pregnant women in the clinical trials. Published by Elsevier Ltd.	[Lasky, Tamar; McMahon, Ann W.] US FDA, Off Commissioner, Silver Spring, MD 20993 USA; [Hua, Wei] US FDA, Ctr Drugs Evaluat & Res, Silver Spring, MD USA; [Forshee, Richard] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA		Lasky, T (通讯作者)，US FDA, Off Commissioner, Silver Spring, MD 20993 USA.	Tamar.Lasky@fda.hhs.gov			FDA's Perinatal Health Center of Excellence (PHCE) Intramural Funding Program	This scoping review has been conducted as part of a project ''Database attributes for assessing pediatric safety and effectiveness of vaccines administered to the mother during pregnancy" funded by FDA's Perinatal Health Center of Excellence (PHCE) Intramural Funding Program. The funders have no input in developing the protocol or conducting the review. Funding supported a postdoctoral fellow (JM) who assisted in screening and data extraction.	Abu Raya B, 2017, LANCET INFECT DIS, V17, pE209, DOI 10.1016/S1473-3099(17)30190-1; ACIP Childhood/Adolescent Immunization Work Group, 2013, MMWR Suppl, V62, P2; Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3; Aromataris E., 2017, BRIGGS I REV MANUAL; Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091; Beau AB, 2014, VACCINE, V32, P1254, DOI 10.1016/j.vaccine.2014.01.021; Becerra-Culqui TA, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0120; Becker-Dreps S, 2018, AM J PREV MED, V55, P159, DOI 10.1016/j.amepre.2018.04.013; Berger ML, 2017, PHARMACOEPIDEM DR S, V26, P1033, DOI 10.1002/pds.4297; Bergin N, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050847; Byrne L, 2018, ARCH DIS CHILD, V103, P224, DOI 10.1136/archdischild-2016-311802; Centers for Disease Control and Prevention, VACC SAF DAT VSD; DeSilva M, 2017, VACCINE, V35, P3655, DOI 10.1016/j.vaccine.2017.05.041; Donahue JG, 2017, VACCINE, V35, P5314, DOI 10.1016/j.vaccine.2017.06.069; Dreyer NA, 2016, J MANAG CARE SPEC PH, V22, P1107, DOI 10.18553/jmcp.2016.22.10.1107; Fabiani M, 2015, VACCINE, V33, P2240, DOI 10.1016/j.vaccine.2015.03.041; Fell DB, 2021, VACCINE, V39, P1882, DOI 10.1016/j.vaccine.2021.02.070; Fell DB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160342; Furuta M, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1559-2; Hall GC, 2012, PHARMACOEPIDEM DR S, V21, P1, DOI 10.1002/pds.2229; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; Irving SA, 2013, OBSTET GYNECOL, V121, P159, DOI [10.1097/AOG.0b013e318279f56f, http://10.1097/AOG.0b013e318279f56f]; Kharbanda EO, 2014, JAMA-J AM MED ASSOC, V312, P1897, DOI 10.1001/jama.2014.14825; Kharbanda EO, 2017, J PEDIATR-US, V187, P234, DOI 10.1016/j.jpeds.2017.04.039; Khodr ZG, 2017, VACCINE, V35, P5603, DOI 10.1016/j.vaccine.2017.08.041; Knox CA, 2019, PHARMACOEPIDEM DR S, V28, P1222, DOI 10.1002/pds.4843; Langan SM, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k3532; Layton JB, 2017, VACCINE, V35, P4072, DOI 10.1016/j.vaccine.2017.06.071; Ludvigsson JF, 2015, BMJ BR MED J, P351; Miksad RA, 2018, CLIN PHARMACOL THER, V103, P202, DOI 10.1002/cpt.946; Molgaard-Nielsen D, 2019, J INTERN MED, V286, P469, DOI 10.1111/joim.12947; Morgan JL, 2015, OBSTET GYNECOL, V125, P1433, DOI 10.1097/AOG.0000000000000862; Moriarty LF, 2014, HUM VACC IMMUNOTHER, V10, P2721, DOI 10.4161/hv.29669; Munn Z, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0611-x; Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633; Nordin JD, 2014, J PEDIATR-US, V164, P1051, DOI 10.1016/j.jpeds.2014.01.037; Nunes MC, 2018, NEW ENGL J MED, V378, P1257, DOI 10.1056/NEJMc1705208; Omer SB, 2017, NEW ENGL J MED, V376, P1256, DOI 10.1056/NEJMra1509044; Peters MDJ, 2017, J BRIGGS I REV MANUA; Peters MDJ, 2020, JBI EVID SYNTH, V18, P2119, DOI 10.11124/JBIES-20-00167; Pratt NL, 2020, PHARMACOEPIDEM DR S, V29, P9, DOI 10.1002/pds.4924; Rasmussen SA, 2014, SEMIN FETAL NEONAT M, V19, P161, DOI 10.1016/j.siny.2013.11.014; Regan AK, 2016, PEDIATR INFECT DIS J, V35, P1097, DOI 10.1097/INF.0000000000001258; Regan AK, 2016, CLIN INFECT DIS, V62, P1221, DOI 10.1093/cid/ciw082; Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131; Shakib JH, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2360; Steinhoff MC, 2012, CAN MED ASSOC J, V184, P645, DOI 10.1503/cmaj.110754; Sukumaran L, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3310; Sukumaran L, 2015, OBSTET GYNECOL, V126, P1069, DOI 10.1097/AOG.0000000000001066; Sukumaran L, 2015, JAMA-J AM MED ASSOC, V314, P1581, DOI 10.1001/jama.2015.12790; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; US Department of Health and Human Services Centers for Disease Control and Prevention, INF AD PAT; US Department of Health and Human Services Food and Drug Administration, 2018, FRAM FDAS REAL WORLD; Vazquez-Benitez G, 2016, AM J EPIDEMIOL, V184, P176, DOI 10.1093/aje/kww043; Vojtek I, 2018, ANN MED, V50, P193, DOI 10.1080/07853890.2017.1421320; Walker JL, 2020, J INFECT DIS, V221, P16, DOI 10.1093/infdis/jiz310; Walsh LK, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4151; Wang SV, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4856	58	0	0	4	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3814	3824		10.1016/j.vaccine.2021.05.071		JUN 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SV4EN	34090699	Green Accepted			2022-04-29	WOS:000663773600007
J	Mbaeyi, C; Moran, T; Wadood, Z; Ather, F; Sykes, E; Nikulin, J; Al Safadi, M; Stehling-Ariza, T; Zomahoun, L; Ismaili, A; Abourshaid, N; Asghar, H; Korukluoglu, G; Duizer, E; Ehrhardt, D; Burns, CC; Sharaf, M				Mbaeyi, Chukwuma; Moran, Thomas; Wadood, Zubair; Ather, Fazal; Sykes, Emma; Nikulin, Joanna; Al Safadi, Mohammad; Stehling-Ariza, Tasha; Zomahoun, Laurel; Ismaili, Abdelkarim; Abourshaid, Nidal; Asghar, Humayun; Korukluoglu, Gulay; Duizer, Erwin; Ehrhardt, Derek; Burns, Cara C.; Sharaf, Magdi			Stopping a polio outbreak in the midst of war: Lessons from Syria	VACCINE			English	Article						Polio; Outbreaks; Vaccine-derived polioviruses; Oral poliovirus vaccine; Syria; Conflict	VACCINE-DERIVED POLIOVIRUS; CIVIL-WAR; WORLDWIDE; PROGRESS; TRANSMISSION; ERADICATION; UPDATE; WILD; SURVEILLANCE; CHALLENGES	Background: Outbreaks of circulating vaccine-derived polioviruses (cVDPVs) pose a threat to the eventual eradication of all polioviruses. In 2017, an outbreak of cVDPV type 2 (cVDPV2) occurred in the midst of a war in Syria. We describe vaccination-based risk factors for and the successful response to the outbreak. Methods: We performed a descriptive analysis of cVDPV2 cases and key indicators of poliovirus surveil-lance and vaccination activities during 2016-2018. In the absence of reliable subnational coverage data, we used the caregiver-reported vaccination status of children with non-polio acute flaccid paralysis (AFP) as a proxy for vaccination coverage. We then estimated the relative odds of being unvaccinated against polio, comparing children in areas affected by the outbreak to children in other parts of Syria in order to establish the presence of poliovirus immunity gaps in outbreak affected areas. Findings: A total of 74 cVDPV2 cases were reported, with paralysis onset ranging from 3 March to 21 September 2017. All but three cases were reported from Deir-ez-Zor governorate and 84% had received < 3 doses of oral poliovirus vaccine (OPV). After adjusting for age and sex, non-polio AFP case-patients aged 6-59 months in outbreak-affected areas had 2.5 (95% CI: 1.1-5.7) increased odds of being unvaccinated with OPV compared with non-polio AFP case-patients in the same age group in other parts of Syria. Three outbreak response rounds of monovalent OPV type 2 (mOPV2) vaccination were con-ducted, with governorate-level coverage mostly exceeding 80%. Interpretation: Significant declines in both national and subnational polio vaccination coverage, precipi-tated by war and a humanitarian crisis, led to a cVDPV2 outbreak in Syria that was successfully contained following three rounds of mOPV2 vaccination. Published by Elsevier Ltd.	[Mbaeyi, Chukwuma; Stehling-Ariza, Tasha; Ehrhardt, Derek; Burns, Cara C.] US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS H24-2, Atlanta, GA 30329 USA; [Moran, Thomas; Wadood, Zubair; Al Safadi, Mohammad; Zomahoun, Laurel] WHO, Ave Appia 20, CH-1202 Geneva, Switzerland; [Ather, Fazal] United Nations Childrens Fund, Middle East & North Africa Off, Abdulqader Al Abed St,Bldg 15, Amman, Jordan; [Sykes, Emma; Nikulin, Joanna; Ismaili, Abdelkarim; Asghar, Humayun; Sharaf, Magdi] WHO, Reg Off Eastern Mediterranean, Mohammad Jamjoum St,Minist Interior Circle Bldg 5, Amman 11181, Jordan; [Abourshaid, Nidal] United Nations Childrens Fund, Syria Country Off, Al Shafiee St, Damascus, Syria; [Korukluoglu, Gulay] Publ Hlth Inst Turkey, Adnan Saygun Cad 55,F Blok 06100 Sihhiye, Ankara, Turkey; [Duizer, Erwin] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Natl Polio Lab, POB 1, NL-3720 BA Bilthoven, Netherlands		Mbaeyi, C (通讯作者)，US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS H24-2, Atlanta, GA 30329 USA.	cmbaeyi@cdc.gov	Korukluoglu, Gulay/AAB-5176-2022; Mbaeyi, Chukwuma/AAC-5407-2022	Mbaeyi, Chukwuma/0000-0002-4519-3075; Sykes, Emma/0000-0002-0055-2409	U.S. Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; World Health OrganizationWorld Health Organization	U.S. Centers for Disease Control and Prevention; World Health Organization.	Aburas R, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1041-7; Bauri M, 2019, MMWR-MORBID MORTAL W, V68, P119, DOI 10.15585/mmwr.mm6805a6; Burns CC, 2014, J INFECT DIS, V210, pS283, DOI 10.1093/infdis/jiu295; Chard AN, 2020, MMWR-MORBID MORTAL W, V69, P784, DOI 10.15585/mmwr.mm6925a4; Doganay M, 2016, HEALTH SECUR, V14, P220, DOI 10.1089/hs.2016.0054; Eboh VA, 2018, MMWR-MORBID MORTAL W, V67, P787, DOI 10.15585/mmwr.mm6728a6; Global Polio Eradication Initiative, 2017, STANDARD OPERATING P; Hampton LM, 2016, MMWR-MORBID MORTAL W, V65, P934, DOI 10.15585/mmwr.mm6535a3; Jorba J, 2019, MMWR-MORBID MORTAL W, V68, P1024, DOI 10.15585/mmwr.mm6845a4; Jorba J, 2018, MMWR-MORBID MORTAL W, V67, P1189, DOI 10.15585/mmwr.mm6742a5; Kennedy J, 2017, HEALTH POLICY PLANN, V32, P690, DOI 10.1093/heapol/czw148; Kew O, 2018, ANNU REV VIROL, V5, P427, DOI 10.1146/annurev-virology-101416-041749; Koopman JS, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0991-5; Macklin G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01103; Mbaeyi C, 2019, MMWR-MORBID MORTAL W, V68, P225, DOI 10.15585/mmwr.mm6809a2; Mbaeyi C, 2018, MMWR-MORBID MORTAL W, V67, P690, DOI 10.15585/mmwr.mm6724a5; Mbaeyi C, 2017, MMWR-MORBID MORTAL W, V66, P27, DOI 10.15585/mmwr.mm6608a6; Moffett DB, 2019, MMWR-MORBID MORTAL W, V68, P825, DOI 10.15585/mmwr.mm6838a3; Moturi EK, 2014, MMWR-MORBID MORTAL W, V63, P468; Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320; Nnadi C, 2017, MMWR-MORBID MORTAL W, V66, P190, DOI 10.15585/mmwr.mm6607a2; Ozaras R, 2016, EXPERT REV ANTI-INFE, V14, P547, DOI 10.1080/14787210.2016.1177457; Patel JC, 2019, MMWR-MORBID MORTAL W, V68, P312, DOI 10.15585/mmwr.mm6813a4; Roberts L, 2014, SCIENCE, V343, P1302, DOI 10.1126/science.343.6177.1302; Sharara SL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004438; Stone-Brown K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7375; Tebbens RJD, 2006, RISK ANAL, V26, P1471, DOI 10.1111/j.1539-6924.2006.00827.x; Tebbens RJD, 2014, J INFECT DIS, V210, pS485, DOI 10.1093/infdis/jit838; Tebbens RJD, 2013, RISK ANAL, V33, P680, DOI 10.1111/risa.12022; Thompson KM, 2006, RISK ANAL, V26, P1541, DOI 10.1111/j.1539-6924.2006.00843.x; Thompson KM, 2014, J INFECT DIS, V210, pS475, DOI 10.1093/infdis/jit845; Thompson KM, 2013, RISK ANAL, V33, P647, DOI 10.1111/j.1539-6924.2012.01891.x; Thompson KM, 2013, RISK ANAL, V33, P516, DOI 10.1111/risa.12019; Vallejo C, 2019, INFECT DIS MODEL, V4, P239, DOI 10.1016/j.idm.2019.06.003; Wassilak SGF, 2014, J INFECT DIS, V210, pS5, DOI 10.1093/infdis/jiu456; World Health Organization, 2017, DIS OUTBREAK NE 0208; World Health Organization, 2012, OUTBREAK SURVEILLANC; World Health Organization, 2019, VACCINE PREVENTABLE	38	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 23	2021	39	28					3717	3723		10.1016/j.vaccine.2021.05.045		JUN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SS0GD	34053791				2022-04-29	WOS:000661420000008
J	Xu, J; Doyon-Plourde, P; Tunis, M; Quach, C				Xu, Janine; Doyon-Plourde, Pamela; Tunis, Matthew; Quach, Caroline			Effect of early measles vaccination on long-term protection: A systematic review	VACCINE			English	Review						Measles vaccination; Vaccine effectiveness; Immunogenicity; Antibodies; Infants	ANTIBODY-LEVELS; RISK-FACTORS; SCHOOL POPULATION; OUTBREAK; CHILDREN; AGE; IMMUNIZATION; EPIDEMIC; INFANTS; RUBELLA	Background: In North America, the first dose of a measles-containing vaccine (MCV1) is administered at >= 12 months of age. However, MCV1 may be given to infants < 12 months living in highly endemic areas or traveling to these areas. Although an early dose of MCV1 leads to immediate protection, it remains unclear how this impacts long-term immunity. Methods: This systematic review and meta-analysis evaluates the impact of MCV1 given at < 12 months vs. >= 12 months of age on long-term immunogenicity and vaccine effectiveness, with long-term defined as at least one-year post-vaccination. PubMed, EMBASE, Global Health, Web of Science and Scopus were searched on October 31st, 2019. Studies were included if they included a cohort of infants vaccinated < 12 months of age and evaluated long-term immunogenicity, vaccine efficacy, or effectiveness. Results: A total of 51 texts were identified: 23 reported outcomes related to vaccine effectiveness and 30 to immunogenicity. Infants vaccinated with MCV1 < 12 months of age showed an overall higher risk of measles compared to >= 12 months of age (RR = 3.16, 95% CI: 2.00, 5.01; OR = 2.46, 95% CI: 1.40, 4.32). Risk of measles decreased with increasing age at first vaccination, with those vaccinated with one dose >= 15 months at a lesser risk compared to 12-14 months or < 12 months. Measles seroconversion and seropositivity was not affected by age at first vaccination, but antibody levels were significantly lower in the MCV1 < 12-month group (MD =-0.40, 95% CI:-0.71,-0.09). Conclusion: Long-term measles seroconversion and seropositivity did not appear to be affected by age at MCV1, while vaccine effectiveness decreased with younger age. There was not enough evidence to look at the effect of age at MCV1 on immune blunting. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Xu, Janine] McGill Univ, Fac Sci, Dept Microbiol & Immunol, Montreal, PQ, Canada; [Doyon-Plourde, Pamela; Quach, Caroline] Univ Montreal, Fac Med, Dept Microbiol Infect Dis & Immunol, Montreal, PQ, Canada; [Tunis, Matthew] Publ Hlth Agcy Canada, Ctr Immunizat & Resp Infect Dis, Ottawa, ON, Canada; [Xu, Janine] 3775 Rue Univ Room 511, Montreal, PQ H3A 2B4, Canada; [Doyon-Plourde, Pamela] 3175 Cote Ste Catherine,B17-003 16, Montreal, PQ H3T 1C5, Canada; [Tunis, Matthew] 130 Colonnade Rd AL 6501H, Ottawa, ON K1A 0K9, Canada		Quach, C (通讯作者)，CHU St Justine, Dept Microbiol & Immunol, 3175 Cote Ste Catherine,Room B17-102, Montreal, PQ H3T 1C5, Canada.	c.quach@umontreal.ca	Quach, Caroline/AAT-6987-2021	Quach, Caroline/0000-0002-1170-9475			[Anonymous], 2020, WHO VACC PREV DIS MO; [Anonymous], MEASL VACC CAN IMM G; BALFOUR HH, 1978, AM J DIS CHILD, V132, P573, DOI 10.1001/archpedi.1978.02120310037006; BARATTA RO, 1970, PEDIATRICS, V46, P397; Biberi-Moroeanu S, 1986, Virologie, V37, P3; Biberi-Moroeanu S, 1982, Arch Roum Pathol Exp Microbiol, V41, P347; BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415; Brinkman ID., 2019, J INFECT DIS, V1; Carazo S, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4870-x; CHEN RT, 1989, AM J EPIDEMIOL, V129, P173, DOI 10.1093/oxfordjournals.aje.a115106; COETZEE N, 1994, S AFR MED J, V84, P145; CURRIER RW, 1972, AM J DIS CHILD, V124, P854, DOI 10.1001/archpedi.1972.02110180056007; DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675; de Oliveira S A, 1993, Rev Soc Bras Med Trop, V26, P77, DOI 10.1590/S0037-86821993000200002; DESERRES G, 1995, EPIDEMIOL INFECT, V115, P315, DOI 10.1017/S0950268800058441; Dine MS, 2004, J INFECT DIS, V189, pS123, DOI 10.1086/380308; FORTUIN M, 1995, T ROY SOC TROP MED H, V89, P326, DOI 10.1016/0035-9203(95)90564-2; Gans HA, 2013, J INFECT DIS, V207, P574, DOI 10.1093/infdis/jis719; Gastanaduy PA., MEASLES CDC; Guerra FM, 2018, VACCINE, V36, P1248, DOI 10.1016/j.vaccine.2018.01.002; HALONEN P, 1965, ARCH GES VIRUSFORSCH, V16, P268, DOI 10.1007/BF01253821; Hayman DTS, 2019, HUM VACC IMMUNOTHER, V15, P28, DOI 10.1080/21645515.2018.1517074; Hennessey KA, 1999, AM J EPIDEMIOL, V150, P1250, DOI 10.1093/oxfordjournals.aje.a009952; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; Hughes SL, 2020, VACCINE, V38, P460, DOI 10.1016/j.vaccine.2019.10.090; Hutchins SS, 2001, AM J EPIDEMIOL, V154, P1064, DOI 10.1093/aje/154.11.1064; JUDELSOHN RG, 1980, AM J PUBLIC HEALTH, V70, P1162, DOI 10.2105/AJPH.70.11.1162; Kontio M, 2016, J INFECT DIS, V213, P2005, DOI 10.1093/infdis/jiw058; Kuyucu N, 1996, INFECTION, V24, P156, DOI 10.1007/BF01713326; Lapeyssonnie L, 1979, Med Trop (Mars), V39, P71; Lee M S, 1998, Int J Infect Dis, V3, P64; LEE MS, 1992, INT J EPIDEMIOL, V21, P1165, DOI 10.1093/ije/21.6.1165; Lee MS, 2001, VACCINE, V19, P4644, DOI 10.1016/S0264-410X(01)00239-0; LEPOW ML, 1975, PEDIATRICS, V55, P348; LINNEMAN.CC, 1972, AM J DIS CHILD, V124, P53, DOI 10.1001/archpedi.1972.02110130055008; LOPES MH, 1989, REV INST MED TROP SP, V31, P322, DOI 10.1590/S0036-46651989000500005; Mahamud A, 2013, VACCINE, V31, P3683, DOI 10.1016/j.vaccine.2013.05.102; MARKOWITZ LE, 1992, J INFECT DIS, V166, P205, DOI 10.1093/infdis/166.1.205; MATSON DO, 1993, PEDIATR INFECT DIS J, V12, P292, DOI 10.1097/00006454-199304000-00007; MCCOMBIE SC, 1988, PUBLIC HEALTH REP, V103, P162; MCDONNELL LF, 1995, MED J AUSTRALIA, V162, P471, DOI 10.5694/j.1326-5377.1995.tb140008.x; Narian J P, 1989, J Ark Med Soc, V85, P383; Nic Lochlainn LM., LANCET INFECT DIS; NKOWANE BM, 1987, AM J PUBLIC HEALTH, V77, P434, DOI 10.2105/AJPH.77.4.434; Papania M, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e59; Perez SC, 2017, CLIN INFECT DIS, V65, P1094, DOI 10.1093/cid/cix510; Poethko-Muller C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042867; Poland GA, 2002, MAYO CLIN PROC, V77, P446; Poland GA, 1999, VACCINE, V17, P1525, DOI 10.1016/S0264-410X(98)00362-4; RAWLS WE, 1975, CAN MED ASSOC J, V113, P941; Redd SC, 2004, J INFECT DIS, V189, pS116, DOI 10.1086/378691; REYNOLDS DW, 1972, AM J DIS CHILD, V124, P848, DOI 10.1001/archpedi.1972.02110180050006; ROBERTSON SE, 1992, PUBLIC HEALTH REP, V107, P24; Scott, 2008, WHO IMMUNOLOGICAL BA; SERRES GD, 1999, J INFECT DIS, V180, P187; SHASBY DM, 1977, NEW ENGL J MED, V296, P585, DOI 10.1056/NEJM197703172961102; SHELTON JD, 1978, PEDIATRICS, V62, P961; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; STETLER HC, 1986, PEDIATRICS, V77, P471; TESORO LJ, 1992, CLIN PEDIATR, V31, P194, DOI 10.1177/000992289203100401; TUCHINDA P, 1968, BIKEN J, V11, P251; Uzicanin A, 2011, J INFECT DIS, V204, pS133, DOI 10.1093/infdis/jir102; VOLTI SL, 1993, EUR J EPIDEMIOL, V9, P311; WILKINS J, 1979, J PEDIATR-US, V94, P865, DOI 10.1016/S0022-3476(79)80203-6; YEAGER AS, 1983, J PEDIATR-US, V102, P191, DOI 10.1016/S0022-3476(83)80517-4; YEAGER AS, 1977, JAMA-J AM MED ASSOC, V237, P347, DOI 10.1001/jama.237.4.347; YUAN L, 1994, CAN MED ASSOC J, V150, P1093	67	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 21	2021	39	22					2929	2937		10.1016/j.vaccine.2021.04.012		MAY 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SE0YP	33926750	hybrid			2022-04-29	WOS:000651801800003
J	Willerton, L; Lucidarme, J; Walker, A; Lekshmi, A; Clark, SA; Gray, SJ; Borrow, R				Willerton, Laura; Lucidarme, Jay; Walker, Andrew; Lekshmi, Aiswarya; Clark, Stephen A.; Gray, Steve J.; Borrow, Ray			Increase in penicillin-resistant invasive meningococcal serogroup W ST-11 complex isolates in England	VACCINE			English	Article						Meningococcal; Serogroup W; ST-11 complex; Antibiotic resistance; Penicillin resistance	NEISSERIA-MENINGITIDIS; GLOBAL EPIDEMIOLOGY; DISEASE; SUSCEPTIBILITY; NETHERLANDS; AUSTRALIA; W135	Introduction: Invasive meningococcal disease (IMD) caused by serogroup W meningococci belonging to the ST-11 complex (MenW:cc11) has been increasing globally since the early 2000s. Penicillin resistance among meningococci due to the production of beta-lactamase remains relatively rare. Isolates displaying resistance and reduced susceptibility to penicillin due to alterations in the penA gene (encoding Penicillin Binding Protein 2) are increasingly reported. In 2016, a penicillin-resistant clade of MenW:cc11 isolates with altered penA genes was identified in Australia. More recently, an increase in penicillin-resistant invasive MenW:cc11 isolates was observed in England. Here, we investigate the distribution of penicillin resistance among English invasive MenW:cc11 isolates. Methods: Isolates from IMD cases in England from July 2010 to August 2019 underwent whole genome sequencing and antibiotic susceptibility testing as part of routine surveillance. The PubMLST Neisseria database was used to determine the distribution of penicillin resistance among English MenW:cc11 isolates and to identify other closely related isolates. Results: Twenty-five out of 897 English invasive MenW:cc11 isolates were resistant to penicillin; identified among six distinct sublineages and a singleton. Expansion of the Australian penicillin-resistant clade included isolates from several new countries as well as 20 English isolates. A newly identified penicillin resistance-associated lineage was also identified among several countries. Conclusion: Penicillin resistance among diverse MenW:cc11 isolates is increasing. Surveillance of antibiotic resistance among meningococci is essential to ensure continued effective use. Crown Copyright (c) 2021 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).	[Willerton, Laura; Lucidarme, Jay; Walker, Andrew; Lekshmi, Aiswarya; Clark, Stephen A.; Gray, Steve J.; Borrow, Ray] Manchester Royal Infirm, Meningococcal Reference Unit, Publ Hlth England, Manchester, Lancs, England		Willerton, L (通讯作者)，Manchester Royal Infirm, Meningococcal Reference Unit, Publ Hlth England, Manchester, Lancs, England.	laura.willerton@phe.gov.uk		Borrow, Ray/0000-0002-0691-6568			Abad R, 2014, EPIDEMIOL INFECT, V142, P2461, DOI 10.1017/S0950268814001149; Acevedo R, 2019, EXPERT REV VACCINES, V18, P15, DOI 10.1080/14760584.2019.1557520; Aguilera JF, 2002, EMERG INFECT DIS, V8, P761, DOI 10.3201/eid0808.010422; Aye AMM, 2020, J INFECTION, V81, P698, DOI 10.1016/j.jinf.2020.07.025; Bond KA, 2016, MED J AUSTRALIA, V204, P265, DOI 10.5694/mja15.01222; Borrow R, 2017, EXPERT REV VACCINES, V16, P313, DOI 10.1080/14760584.2017.1258308; BOTHA P, 1988, LANCET, V1, P54; Bratcher HB, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1138; Deghmane AE, 2018, J ANTIMICROB CHEMOTH, V72, P95; DILLON JR, 1983, LANCET, V1, P779; European Centre for Disease Prevention and Control, 2017, INV MEN DIS ANN EP R; European Committee on Antimicrobial Susceptibility Testing, 2019, NEW DEF S I R 2019; FONTANALS D, 1989, EUR J CLIN MICROBIOL, V8, P90, DOI 10.1007/BF01964130; Gray SJ, 2006, J MED MICROBIOL, V55, P887, DOI 10.1099/jmm.0.46288-0; Grumach AS, 2014, MOL IMMUNOL, V61, P110, DOI 10.1016/j.molimm.2014.06.030; HANSMAN D, 1983, J HYG-CAMBRIDGE, V90, P49, DOI 10.1017/S0022172400063828; Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Jackson L, 1993, LAB BASED SURVEILLAN, V1989-1991, P21; Karch A, 2015, INT J MED MICROBIOL, V305, P729, DOI 10.1016/j.ijmm.2015.08.025; Knol MJ, 2017, LANCET PUBLIC HEALTH, V2, pE473, DOI 10.1016/S2468-2667(17)30157-3; Koumare B, 2007, VACCINE, V25, pA37, DOI 10.1016/j.vaccine.2007.04.038; Ladhani SN, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4146-5; Lucidarme J, 2016, EUROSURVEILLANCE, V21, P15, DOI 10.2807/1560-7917.ES.2016.21.45.30395; Lucidarme J, 2015, J INFECTION, V71, P544, DOI 10.1016/j.jinf.2015.07.007; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; MANESS MJ, 1973, J INFECT DIS, V128, P321, DOI 10.1093/infdis/128.3.321; Martin NV, 2016, COMMUN DIS INTELL, V40, pE454; McNamara LA, 2020, MMWR-MORBID MORTAL W, V69, P735, DOI 10.15585/mmwr.mm6924a2; McNamara LA, 2017, MMWR-MORBID MORTAL W, V66, P734, DOI 10.15585/mmwr.mm6627e1; Mowlaboccus S, 2017, EMERG INFECT DIS, V23, P1364, DOI 10.3201/eid2308.170259; Mustapha MM, 2016, VACCINE, V34, P1515, DOI 10.1016/j.vaccine.2016.02.014; Parikh SR, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-2452; Rouquette-Loughlin CE, 2004, MOL MICROBIOL, V54, P731, DOI 10.1111/j.1365-2958.2004.04299.x; SPANJAARD L, 1987, B WORLD HEALTH ORGAN, V65, P861; Taha MK, 2007, ANTIMICROB AGENTS CH, V51, P2784, DOI 10.1128/AAC.00412-07; Tsang RSW, 2019, J ANTIMICROB CHEMOTH, V74, P22, DOI 10.1093/jac/dky391; Tsang RSW, 2018, INT J INFECT DIS, V69, P55, DOI 10.1016/j.ijid.2018.01.019; Vacca P, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.00207-18; Wang B, 2019, VACCINE, V37, P2768, DOI 10.1016/j.vaccine.2019.04.020; Whiley DM, 2010, J ANTIMICROB CHEMOTH, V65, P1615, DOI 10.1093/jac/dkq187; Zapun A, 2016, ANTIBIOTICS-BASEL, V5, DOI 10.3390/antibiotics5040035	42	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 6	2021	39	19					2719	2729		10.1016/j.vaccine.2021.03.002		APR 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RU2SP	33858720	hybrid			2022-04-29	WOS:000645000500016
J	Ferreira, MN; Netto, EM; Nascimento-Carvalho, CM				Ferreira, Mariana N.; Netto, Eduardo M.; Nascimento-Carvalho, Cristiana M.			The impact of 10-valent pneumococcal conjugate vaccine upon hospitalization rate of children with pneumonia in different Brazilian administrative regions	VACCINE			English	Article						Children; Hospitalization; Pneumococcal pneumonia; Vaccination	COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; HEALTH; COSTS	Background: Streptococcus pneumoniae is the most frequent bacterial causative agent of pneumonia. Due to its significant contribution to the morbidity and mortality profile and the country's economy, the 10-valent pneumococcal vaccine (PCV10) was introduced in Brazil in 2010. Brazil is divided into five administrative regions which differ in social-economic indices among each other. Estimates of PCV10 impact on hospitalization rates due to pneumonia stratified by distinct Brazilian regions are limited. We assessed this issue. Methods: This is a population-based ecological investigation. Data about hospitalizations due to pneumonia, asthma or urinary tract infection (UTI) among patients aged under 20 years in the pre-exposure (2003-2009) and in the post-exposure (2011-2017) periods were retrieved from the National Health System - Hospital Information System (SIH-SUS) database. The total resident population by age group in each year was retrieved from the Brazilian Institute for Geography and Statistics database. Hospitalization rates were estimated for each Brazilian region and the rates obtained in the pre-exposure and in the post-exposure periods were compared by Prais-Winsten regression. The Human Development Index (HDI) evolved differently in the distinct regions during the study period. Results: Overall, hospitalization rates due to pneumonia declined by 34.5%. Similar trends were observed for hospitalization rates due to asthma and UTI. The same pattern was observed in each Brazilian region. However, the North region was the only one that presented an exponential incidence decline pattern, which could be explained by PCV10 implementation (declined by 10.8% in the quadratic regression, p < 0.01). Only in the North region, significant decline was observed among patients aged 0-4 years (-12.5%; p = 0.01), 5-9 years (-38.5%; p < 0.01) or 10-14 years (-10.7%; p = 0.03). Conclusion: Significant variation in the downward trend of hospitalization rate was only found in the North region, which evolved from very low HDI in 2003; medium HDI in 2010 to high HDI in 2017. (C) 2021 Elsevier Ltd. All rights reserved.	[Ferreira, Mariana N.; Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Dept Paediat, Salvador, BA, Brazil; [Netto, Eduardo M.] Univ Fed Bahia, Univ Hosp, Infect Dis Unit, Salvador, BA, Brazil		Ferreira, MN (通讯作者)，Rua Marcio Batista 104-302, BR-41770015 Salvador, BA, Brazil.	mariananf@ufba.br			CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The corresponding author received a scholarship research financed by CNPq from December/19 to June/20.	Afonso ET, 2013, EMERG INFECT DIS, V19, P589, DOI 10.3201/eid1904.121198; Alicino C, 2017, VACCINE, V35, P5776, DOI 10.1016/j.vaccine.2017.09.005; Andrade AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184204; Brandileone MCD, 2019, VACCINE, V37, P5357, DOI 10.1016/j.vaccine.2019.07.043; Cilloniz C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122120; de Albuquerque MV, 2017, CIENC SAUDE COLETIVA, V22, P1055, DOI 10.1590/1413-81232017224.26862016; de Oliveira LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166736; Diaz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153141; Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8; Feldman C, 2016, SEMIN RESP CRIT CARE, V37, P806, DOI 10.1055/s-0036-1592074; Griffin MR, 2014, MMWR-MORBID MORTAL W, V63, P995; Health United States, 2013, 2013 SPEC FEAT EM CA, P297; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Luca DL, 2018, CLIN INFECT DIS, V66, P541, DOI 10.1093/cid/cix850; Mandell LA, 2015, POSTGRAD MED, V127, P607, DOI 10.1080/00325481.2015.1074030; Millar EV, 2006, CLIN INFECT DIS, V43, P8, DOI 10.1086/504802; Nascimento-Carvalho CMC, 2001, J TROP PEDIATRICS, V47, P253, DOI 10.1093/tropej/47.4.253; Noel G, 2017, J PEDIATR INFECT DIS, V6, P129, DOI 10.1093/jpids/piw019; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Park H, 2015, CLIN THER, V37, P1466, DOI 10.1016/j.clinthera.2015.04.013; Prais S.J., 1954, TREND ESTIMATORS SER, V383, P1; Rasella D, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-380; Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632, DOI 10.1086/381547; Schuck-Paim C, 2019, LANCET GLOB HEALTH, V7, pE249, DOI 10.1016/S2214-109X(18)30455-8; Schuck-Paim C, 2017, VACCINE, V35, P118, DOI 10.1016/j.vaccine.2016.11.030; Sgambatti S, 2015, EPIDEMIOL INFECT, V143, P334, DOI 10.1017/S0950268814000922; Sgambatti S, 2016, VACCINE, V34, P663, DOI 10.1016/j.vaccine.2015.12.007; Shioda K, 2019, EPIDEMIOLOGY, V30, P61, DOI 10.1097/EDE.0000000000000938; Silva Sandra Rodrigues da, 2016, Rev. paul. pediatr., V34, P418, DOI [10.1016/j.rppede.2016.03.008, 10.1016/j.rpped.2016.02.003]; Simonsen L, 2014, LANCET RESP MED, V2, P387, DOI 10.1016/S2213-2600(14)70032-3; Suarez V, 2016, VACCINE, V34, P4738, DOI 10.1016/j.vaccine.2016.07.027; van Deursen AMM, 2017, VACCINE, V35, P7107, DOI 10.1016/j.vaccine.2017.10.090; Vieira ILV, 2018, EPIDEMIOL SERV SAUDE, V27, DOI [10.5123/S1679-49742018000400012, 10.5123/s1679-49742018000400012]; Warren JL, 2017, CLIN INFECT DIS, V65, P1813, DOI 10.1093/cid/cix638; WHO UNICEF, 2009, GLOB ACT PLAN PREV C, DOI [10.2471/BLT.08.053348, DOI 10.2471/BLT.08.053348]; Wiese AD, 2019, EXPERT REV VACCINES, V18, P327, DOI 10.1080/14760584.2019.1582337; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	37	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2153	2164		10.1016/j.vaccine.2021.02.051		APR 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QH	33726954				2022-04-29	WOS:000637937500019
J	Kabir, A; Newall, AT; Randall, D; Menzies, R; Sheridan, S; Jayasinghe, S; Fathima, P; Liu, B; Moore, H; McIntyre, P; Gidding, HF				Kabir, Alamgir; Newall, Anthony T.; Randall, Deborah; Menzies, Rob; Sheridan, Sarah; Jayasinghe, Sanjay; Fathima, Parveen; Liu, Bette; Moore, Hannah; McIntyre, Peter; Gidding, Heather F.			Estimating pneumococcal vaccine coverage among Australian Indigenous children and children with medically at-risk conditions using record linkage	VACCINE			English	Article						Coverage; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide vaccine; Data linkage; Indigenous; Medically at-risk conditions	IMMUNIZATION COVERAGE; DISEASE	Background: Risk-based recommendations are common for pneumococcal vaccines but little is known about their uptake. In Australia, pneumococcal conjugate vaccine (PCV) was funded only for Aboriginal or Torres Strait Islander (Indigenous) children and those with underlying medical conditions in 2001, and then there were different booster dose recommendations depending on risk after the introduction of universal PCV vaccination in 2005. Methods: We measured coverage of PCV dose 3 and additional PCV and 23-valent pneumococcal polysaccharide vaccine (PPV23) doses by risk group among children born in July 2001-December 2012 in two Australian states using linked immunisation and hospitalisation data (available until December 2013). We ascertained medical risk conditions using hospitalisation diagnosis codes and Indigenous status using an established algorithm, comparing coverage for children born pre (2001-2004) and post (2005-2012) universal PCV funding. Results: Among 1.3 million children, 63,897 (4.9%) were Indigenous and 32,934 (2.5%) had at least one medically at-risk condition identified by age 6 months. For births in 2001-2004, coverage for PCV dose 3 by 1 year of age was 37% for Indigenous, 15% for medically at-risk and 11% in other children, increasing to 83%, 91% and 92%, respectively for births in 2005-2012. In children with medically at-risk conditions, PCV dose 4 coverage by 2 years was 1% for 2001-2004 births, increasing to 9% for 2005-2012 births, with PPV23 coverage by 6 years 3% in both cohorts. Among eligible Indigenous children, PPV23 coverage by 3 years was 45% for 2001-2004 births and 51% for 2005-2012 births. Conclusions: Coverage with additional recommended booster doses was very low among children with medical conditions, and only modest among Indigenous children. If additional PCV doses are recommended for some risk groups, especially in the context of routine schedules with reduced doses (e.g. 2 + 1 and 1 + 1), measures to improve implementation will be required. (C) 2021 Elsevier Ltd. All rights reserved.	[Kabir, Alamgir; Newall, Anthony T.; Menzies, Rob; Sheridan, Sarah; Liu, Bette; Gidding, Heather F.] Univ New South Wales, Fac Med, Sch Populat Hlth, Sydney, NSW, Australia; [Kabir, Alamgir; Randall, Deborah; Sheridan, Sarah; Gidding, Heather F.] Univ Sydney, Women & Babies Res, Northern Clin Sch, St Leonards, NSW, Australia; [Kabir, Alamgir; Randall, Deborah; Sheridan, Sarah; Gidding, Heather F.] Kolling Inst, Northern Sydney Local Hlth Dist, St Leonards, NSW, Australia; [Sheridan, Sarah; Jayasinghe, Sanjay; McIntyre, Peter; Gidding, Heather F.] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia; [Fathima, Parveen; Moore, Hannah] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Telethon Kids Inst, Crawley, WA, Australia		Kabir, A (通讯作者)，Univ New South Wales, Sch Populat Hlth, Sydney, NSW 2052, Australia.	a.kabir@unsw.edu.au	; Moore, Hannah/W-4727-2018	Menzies, Rob/0000-0003-3833-5765; Moore, Hannah/0000-0001-6434-8290; Kabir, Alamgir/0000-0002-3762-8307; Sheridan, Sarah/0000-0002-8451-3027	Population Health Research Network (PHRN); Commonwealth Government National Collaborative Research Infrastructure Strategy and Education Investment Fund Super Science Initiative; National Health and Medical Research Council (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [APP1082342]; University International Postgraduate Scholarship (UIPA) from UNSW; NHMRC FellowshipsNational Health and Medical Research Council (NHMRC) of Australia	This project was funded by the Population Health Research Network (PHRN), a capability of the Commonwealth Government National Collaborative Research Infrastructure Strategy and Education Investment Fund Super Science Initiative, and a National Health and Medical Research Council (NHMRC) project grant (APP1082342). A. Kabir is supported by a University International Postgraduate Scholarship (UIPA) from UNSW. H. Gidding, B. Liu and H. Moore are supported by NHMRC Fellowships.	Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB; Bloom BR, 2016, THE VACCINE BOOK, V2nd; Christensen D, 2014, AUST J SOC ISSUES, V49, P423, DOI 10.1002/j.1839-4655.2014.tb00322.x; Crawford NW, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-87; Crawford NW, 2010, PEDIATR BLOOD CANCER, V54, P128, DOI 10.1002/pbc.22256; Crawford NW, 2009, J PAEDIATR CHILD H, V45, P602, DOI 10.1111/j.1440-1754.2009.01573.x; Cugley K, 2010, J PAEDIATR CHILD H, V46, P768, DOI 10.1111/j.1440-1754.2010.01836.x; Department of Health Australian Government, 2020, NAT IMM PROGR SCHED; Gidding H F, 2017, Int J Popul Data Sci, V2, P406, DOI 10.23889/ijpds.v2i1.406; Gidding HF, 2018, VACCINE, V36, P2650, DOI 10.1016/j.vaccine.2018.03.058; Gidding HF, 2020, VACCINE, V38, P6057, DOI 10.1016/j.vaccine.2019.09.091; Hendry AJ, 2018, MED J AUSTRALIA, V209, P24, DOI 10.5694/mja18.00063; Hull B, 2013, COMMUN DIS INTELL, V37, pE21; Hull B, 2011, COMMUN DIS INTELL, V35, P132; Hull B, 2009, COMMUN DIS INTELL, V33, P170; Hull BP, 2016, COMMUN DIS INTELL, V40, pE146; Hull BP, 2014, COMMUN DIS INTELL, V38, pE208; Hull BP, 2013, COMMUN DIS INTELL, V37, pE291; Hull BP, 2010, COMMUN DIS INTELL, V34, P241; Jayasinghe S, 2019, PEDIATR INFECT DIS J, V38, P967, DOI 10.1097/INF.0000000000002407; Li-Kim-Moy J, 2016, COMMUN DIS INTELL, V40, pE482; Masson A, 2015, J CYST FIBROS, V14, P615, DOI 10.1016/j.jcf.2015.04.006; Menzies Robert, 2008, Commun Dis Intell Q Rep, V32 Suppl, pS2; Moore HC, 2018, VACCINE, V36, P4062, DOI 10.1016/j.vaccine.2018.05.084; Moore HC, 2016, AUST NZ J PUBL HEAL, V40, P159, DOI 10.1111/1753-6405.12481; National Center for Immunisation Research and Surveillance, 2018, HIST VACC AUSTR; Pandolfi E, 2012, VACCINE, V30, P5172, DOI 10.1016/j.vaccine.2011.02.099; Pelton SI, 2014, CLIN INFECT DIS, V59, P615, DOI 10.1093/cid/ciu348; Public Health England, 2019, PNEUMOCOCCAL VACCINA; Rank C, 2007, COMMUN DIS INTELL, V31, P283; Rose MA, 2014, INT J CLIN PRACT, V68, P8, DOI 10.1111/ijcp.12234; van Hoek AJ, 2012, J INFECTION, V65, P17, DOI 10.1016/j.jinf.2012.02.017; Wei H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1388	33	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 19	2021	39	12					1727	1735		10.1016/j.vaccine.2021.02.015		MAR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QX3ZD	33622589				2022-04-29	WOS:000629283700010
J	Moro, PL; Marquez, P				Moro, Pedro L.; Marquez, Paige			Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013-2020	VACCINE			English	Article						Adverse event; Pharmacovigilance; Surveillance; Cell cultured influenza vaccine; Vaccine safety	SURVEILLANCE	Background: In November 2012, the first cell cultured influenza vaccine, a trivalent subunit inactivated influenza vaccine (Flucelvax((R)), ccIIV3), was approved in the United States for adults aged >= 18 years. A quadrivalent version (ccIIV4) was later approved in 2016 and replaced ccIIV3. The safety of ccIIV3 or ccIIV4 (ccIIV) was not assessed for pregnant women or their infants during pre-licensure studies. Objective: To assess the safety of ccIIV administered during pregnancy in pregnant women and their infants whose reports were submitted to VAERS during 2013-2020. Material and methods: We searched VAERS for United States reports of adverse events (AEs) in pregnant women who received ccIIV from 1 July 2013 through 31 May 2020. Clinicians reviewed reports and available medical records and assigned a primary clinical category for each report. Reports were coded as serious based on the Code of Federal Regulations definition. Results: VAERS received 391 reports following ccIIV administered to pregnant women. Twenty-four (6.1%) were serious. Two neonatal deaths were reported. No maternal deaths occurred. Among reports with trimester information (n = 340), ccIIV was administered during the second trimester in 170 (50%). The most frequent pregnancy-specific AE was premature delivery in 85 (21.7%) reports, followed by dysmature placenta in 13 (3.3%) and pre-eclampsia/eclampsia in ten (2.3%). The most common non-pregnancy specific conditions were infectious conditions in 32 (8.2%). Among infant conditions, low birth weight was reported in 62 (15.9%) reports. Fifteen birth defects were reported; in 12 with gestational age information, administration of the vaccine occurred late in the second trimester or later. Conclusions: Review of maternal ccIIV reports in VAERS was not unexpectedly different from other maternal influenza vaccine safety VAERS reviews. (C) 2020 Elsevier Ltd. All rights reserved.	[Moro, Pedro L.; Marquez, Paige] Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA USA		Moro, PL (通讯作者)，NCEZID Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, 1600 Clifton Rd,MS V18-4, Atlanta, GA 30329 USA.	pmoro@cdc.gov					[Anonymous], 2020, FLUC QYADR PACK INS; Cunningham G, 2010, WILLIAMS OBSTET; Food and Drug Administration, 2017, JUL 7 2017 APPR LETT; Food and Drug Administration, 2012, NOV 20 2012 APPR LET; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Moro P, 2017, DRUG SAFETY, V40, P145, DOI 10.1007/s40264-016-0482-1; Moro PL, 2016, VACCINE, V34, P2349, DOI 10.1016/j.vaccine.2016.03.049; Moro PL, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.047; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; US Food and Drug Administration (FDA), 1997, FED REGISTER, V62, P52252	10	0	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					678	681		10.1016/j.vaccine.2020.12.045		JAN 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PR1FI	33358703				2022-04-29	WOS:000606987100010
J	Lin, C; Tu, P; Terry, TC				Lin, Cheryl; Tu, Pikuei; Terry, Thomas C.			Moving the needle on racial disparity: COVID-19 vaccine trust and hesitancy	VACCINE			English	Article						2021; Health disparity; Equity; Vaccine hesitancy; Access; Health behavior; Attitudes		Health equity has grown in prominence during the pandemic. Racial disparities in COVID-19 infections and vaccine hesitancy (differences up to 26%) have generated concerns, research, and interventions with less-than-satisfactory results. Two longitudinal national surveys in the U.S. revealed previously overlooked patterns in the changes of COVID-19 vaccination intention across race/ethnicity. While White vaccine acceptance bounced back to the March 2020 level (65%) a year later, minority (except Asians) responses continued to lag and fluctuated with greater volatility. Though Hispanics' refusal aligned more with Blacks, the ratio of Hispanics willing to vaccinate was similar to Whites, even intermittently went above. Further, the magnitude and direction of changes varied by race at specific times (e.g., launch of Operation Warp Speed, reports of high vaccine efficacy in clinical trials or FDA approval), indicating subgroups react differently to events and thus require timely identification of driving factors for dynamic communications to encourage uptake. We also briefly reviewed the historical background of distrust in medicine and health authorities, including the Tuskegee Syphilis Study that led to the Belmont Report regulating human subject research and severe adverse reactions from the 1976 mass vaccination against the H1N1 swine flu. These examples, perpetuating inequity in the present healthcare system, and logistical barriers illustrate the contextual complexity and importance of instilling confidence in vaccines among the minority population.	[Lin, Cheryl; Tu, Pikuei] Duke Univ, 2204 Erwin Rd, Durham, NC 27705 USA; [Terry, Thomas C.] Utah State Univ, Logan, UT 84322 USA		Tu, P (通讯作者)，Duke Univ, 2204 Erwin Rd, Durham, NC 27705 USA.	Pikuei.tu@duke.edu					Artiga, 2021, LATEST DATA COVID 19; Bad JJH, 1982, BLOOD TUSKEGEE SYPHI; BRANDT AM, 1978, HASTINGS CENT REP, V8, P21, DOI 10.2307/3561468; CDC, COVID DAT TRACK; Centers for Disease Control and Prevention, VACC EQ RAC ETH MIN; Centers for Disease Control and Prevention, US PUBLIC HLTH SERV; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Mandavilli A., NEW YORK TIMES; Morning Consult, 210281 NAT TRACK POL, V2021, P1092; Office for Human Research Protections, THE BELM REP; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521; Rodriguez MA, 2013, AM J PUBLIC HEALTH, V103, P2122, DOI 10.2105/AJPH.2013.301520; Roelcke V, 2004, LANCET, V364, P6, DOI 10.1016/S0140-6736(04)17619-8; Sencer DJ, 2006, EMERG INFECT DIS, V12, P29; Shuster E, 1997, NEW ENGL J MED, V337, P1436, DOI 10.1056/NEJM199711133372006; Solomon J., FOSTER KIDS AIDS EXP; YouGov, 2021, YAHOO NEWS	18	2	2	7	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					5	8		10.1016/j.vaccine.2021.11.010		DEC 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XQ1FV	34839990	Green Published, Bronze			2022-04-29	WOS:000731299800003
J	Hara, M; Koshida, R; Nakano, T				Hara, Megumi; Koshida, Rie; Nakano, Takashi			Parents' views on mumps, mumps vaccine, and the factors associated with vaccination in Japan	VACCINE			English	Article						Mumps; MMR vaccine; Japan; Mumps virus; Vaccination; Children	ASEPTIC-MENINGITIS; RUBELLA VACCINE; HESITANCY; CHILDREN; MEASLES	Background: The measles-mumps-rubella vaccine was withdrawn from the National Immunization Program in 1993 because aseptic meningitis was reported as a post-vaccination adverse reaction in Japan. This study aimed to measure the uptake of and determinants influencing mumps vaccination, including concerns about adverse reactions. Methods: We conducted this cross-sectional survey for all parents whose children underwent 18-month health checkups in Kanazawa City between October 2019 and February 2020. Community nurses interviewed the parents using a unified questionnaire, and 1422 parents responded. Results: Based on records from maternal and child health handbooks, the mumps vaccination rate was 55.6%. The most common reason for parents not vaccinating their children against mumps was that "it is not a routine vaccine" (35.9%), whereas "concern about adverse reactions" accounted for only 2.2%. In multivariate analysis, the significantly positive factors associated with vaccination against mumps were children whose parents knew that adverse reactions were fever, rash, diarrhea, and vomiting; had received a recommendation for vaccination from their family members; had read the Vaccination Guide issued by the city; vaccinated with other voluntary vaccines or treated for gastroenteritis; and had a deep general understanding of vaccination. Conversely, the significantly negative factor was children whose parents had not received any recommendation for vaccination. Conclusion: The mumps vaccination rate could be improved by adding the mumps vaccine in the routine vaccination program and educating parents by disseminating correct information on mumps and the mumps vaccine, and by primary care physicians routinely recommending vaccination. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Hara, Megumi] Saga Univ, Fac Med, Dept Prevent Med, 5-1-1 Nabeshima, Saga 8498501, Japan; [Koshida, Rie] Kanazawa City Off, Hlth Affairs Dept, 1-1-1 Hirosaka, Kanazawa, Ishikawa 9208577, Japan; [Nakano, Takashi] Kawasaki Med Sch, Dept Pediat, 577 Matsushima, Kurashiki, Okayama 7010192, Japan		Hara, M (通讯作者)，Saga Univ, Fac Med, Dept Prevent Med, 5-1-1 Nabeshima, Saga 8498501, Japan.	harameg@cc.saga-u.ac.jp	Hara, Masayuki/AAH-4361-2019		Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED) [JP20fk0108066, 21fk0108612h0901]	We thank the community nurses in Kanazawa city for their assistance, and all the individuals who participated in this study. We also acknowledge Honyaku center for providing language help, writing assistance, and proofreading assistance. This research was supported by the Japan Agency for Medical Research and Development (AMED) under Grant Numbers JP20fk0108066 and 21fk0108612h0901.	de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dube E, 2018, EXPERT REV VACCINES, V17, P989, DOI 10.1080/14760584.2018.1541406; Infectious Disease Surveillance Center of the National Institute of Infectious Diseases of Japan Non-profit Organization Osaka Emerging and Re-emerging Infectious Disease Control Council, 2006, JAPANESE MED J, V4283, P64; Kimura M, 1996, ACTA PAEDIATR JAPON, V38, P205; Kitano T, 2021, HUM VACC IMMUNOTHER, V17, P205, DOI 10.1080/21645515.2020.1765619; Kumihashi H, 2018, JAPAN J ANTIBIOT, V71, P233; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; MILLER E, 1993, LANCET, V341, P979, DOI 10.1016/0140-6736(93)91069-X; Morikawa Y, 2019, PEDIATR INT, V61, P882, DOI 10.1111/ped.13916; Morimoto N, 2015, J OTOLARYNGOL JAPAN, V121, P1178; Muta H, 2015, VACCINE, V33, P6049, DOI 10.1016/j.vaccine.2015.09.068; Nagai T, 2007, VACCINE, V25, P2742, DOI 10.1016/j.vaccine.2005.11.068; Ozaki T, 2019, JPN J INFECT DIS, V72, P106, DOI 10.7883/yoken.JJID.2018.276; Plotkin SA, 2009, PEDIATR INFECT DIS J, V28, P176, DOI 10.1097/INF.0b013e31818a8cc6; Shiroshita Y, 1995, J CHILD HLTH, V54, P662; Simms KT, 2020, LANCET PUBLIC HEALTH, V5, pE223, DOI 10.1016/S2468-2667(20)30010-4; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Takagi A, 2022, J EPIDEMIOL, V32, P21, DOI 10.2188/jea.JE20200233; Tsuchiya Y, 2016, PUBLIC HEALTH, V137, P95, DOI 10.1016/j.puhe.2016.03.002; UEDA K, 1995, LANCET, V346, P701, DOI 10.1016/S0140-6736(95)92311-X; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WHO, 2007, WEEKLY EPIDEMIOLOGIC, V7	23	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 20	2021	39	52					7677	7683		10.1016/j.vaccine.2021.11.015		DEC 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1EI	34815119	hybrid			2022-04-29	WOS:000731295900020
J	Burke, RM; Shih, SM; Hsiung, CA; Yen, C; Jiang, BM; Parashar, UD; Tate, JE; Wu, FT; Huang, YC				Burke, Rachel M.; Shih, Shuman; Hsiung, Chao Agnes; Yen, Catherine; Jiang, Baoming; Parashar, Umesh D.; Tate, Jacqueline E.; Wu, Fang-Tzy; Huang, Yhu-Chering			Impact of rotavirus vaccination on rotavirus hospitalizations in Taiwanese children	VACCINE			English	Article						Rotavirus; Acute gastroenteritis; Rotavirus vaccine; Vaccine impact; Pediatric gastroenteritis	VACCINES; GASTROENTERITIS; EPIDEMIOLOGY; SURVEILLANCE; LESS-THAN-5; DIARRHEA	ABS T R A C T In 2006, two rotavirus vaccines were licensed in Taiwan but were not added to the national immuniza-tion schedule. National Health Insurance data from 2003 through 2017 were used to compare rotavirus-associated pediatric hospitalizations before and after vaccine introduction. Rotavirus hospitalization rates among children < 5 years of age significantly declined by 24% (95% confidence interval [CI] 23 - 25%) in post-vaccine compared to pre-vaccine rotavirus seasons. Rotavirus hospitalization rates declined by 42% (95% CI 39 - 44%) among infants < 12 months of age, and by 38% (95% CI 36 - 40%) among children 12 - 23 months of age. These findings suggest that, despite not being included in the national immuniza-tion schedule, rotavirus vaccines had a measurable impact on reducing rotavirus hospitalization burden among Taiwanese children. Published by Elsevier Ltd.	[Burke, Rachel M.; Yen, Catherine; Jiang, Baoming; Parashar, Umesh D.; Tate, Jacqueline E.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA; [Shih, Shuman; Hsiung, Chao Agnes] Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan; [Wu, Fang-Tzy] Ctr Dis Control, Ctr Res Diagnost & Vaccine Dev, Taipei, Taiwan; [Huang, Yhu-Chering] Chang Gung Mem Hosp, Div Pediat Infect Dis, Taoyuan, Taiwan; [Huang, Yhu-Chering] Chang Gung Univ, Coll Med, Taoyuan, Taiwan		Wu, FT (通讯作者)，Ctr Dis Control, Ctr Res Diagnost & Vaccine Dev, Taipei, Taiwan.; Huang, YC (通讯作者)，Chang Gung Mem Hosp, Div Pediat Infect Dis, Taoyuan, Taiwan.	RBurke@cdc.gov; fang@cdc.gov.tw; ychuang@cgmh.org.tw		Burke, Rachel/0000-0002-5678-5826; Wu, Fang Tzy/0000-0001-5448-677X			Ai CE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228942; Burnett E, 2018, EXPERT REV VACCINES, V17, P453, DOI 10.1080/14760584.2018.1443008; Chang WC, 2014, PEDIATR INFECT DIS J, V33, pE81, DOI 10.1097/INF.0000000000000105; Chen KT, 2005, J INFECT DIS, V192, pS44, DOI 10.1086/431495; Chen SY, 2013, PEDIATR INFECT DIS J, V32, P1335, DOI 10.1097/INF.0b013e3182a5f5b6; Chiang GPK, 2014, VACCINE, V32, P1700, DOI 10.1016/j.vaccine.2014.01.065; Huang YC, 2020, VACCINE, V38, P6435, DOI 10.1016/j.vaccine.2020.07.067; National Health Research Institutes of Taiwan, NATL HLTH INSURANCE; Phua KB, 2009, VACCINE, V27, P5936, DOI 10.1016/j.vaccine.2009.07.098; Phua KB, 2012, VACCINE, V30, P4552, DOI 10.1016/j.vaccine.2012.03.030; Pitzer VE, 2011, J R SOC INTERFACE, V8, P1584, DOI 10.1098/rsif.2011.0062; Pitzer VE, 2009, SCIENCE, V325, P290, DOI 10.1126/science.1172330; Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013; Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1; Wu FT, 2009, VACCINE, V27, pF50, DOI 10.1016/j.vaccine.2009.08.090; Wu FT, 2015, J MED VIROL, V87, P1462, DOI 10.1002/jmv.24208; Yeung KHT, 2016, VACCINE, V34, P4935, DOI 10.1016/j.vaccine.2016.08.047; Yu WJ, 2018, J FORMOS MED ASSOC, V117, P720, DOI 10.1016/j.jfma.2017.09.009	18	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 3	2021	39	49					7135	7139		10.1016/j.vaccine.2021.10.064		NOV 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ2JG	34785101				2022-04-29	WOS:000726620400006
J	Liang, Q; Li, H; Chang, XY; Zhang, H; Hao, H; Ye, Q; Li, GF				Liang, Qi; Li, Hong; Chang, Xianyun; Zhang, Hao; Hao, Huan; Ye, Qiang; Li, Guifan			A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old	VACCINE			English	Article						Pneumococcus; MINHAI PCV13; Safety; Immunogenicity	PNEUMOCOCCAL CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; SEROTYPE DISTRIBUTION; POLYSACCHARIDE VACCINE; ANTIBODIES; DISEASE; COLONIZATION; IMPACT; ASSAY	Background: Pneumococcus lead to various kinds of invasive disease such as pneumonia, otitis media, meningitis, bacteremia and so on. It has been a great threat to children under 5. A new 13-valent pneumococcal conjugate vaccine (PCV13) with carrier tetanus toxoid and diphtheria toxoid was developed by MINHAI, aiming to prevent pneumococcus infection. In this study, we reported the safety and immunogenicity of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old. Methods: A randomized, double-blinded, parallelized phase III clinical trial was operated in 900 participants. Haemophilus influenzae type B conjugate vaccine (Hib) served as negative control. PCV13 and Hib were intramuscular injected to participants at a ratio of 2:1. Local and systemic adverse events (AEs) and severe adverse events (SAEs) were recorded to evaluate the safety of PCV13. Blood samples were collected before and after immunization for the detecting of serotype-specific anti-polysaccharide immunoglobulin (Ig)G and opsonophagocytosis assay (OPA). The proportion of IgG concentration >= 0.3 5 mu g/mL (IgG positive rate), IgG geometric mean concentration (GMC), OPA geometric mean titer (GMT), and other indicators were analyzed to evaluate the immunogenicity of PCV13. Results: During the study period, no PCV13 associated SAE happened. Incidences of several AEs in PCV13 groups were higher than the Hib groups, but most of them were mild or moderate. For all 13 serotypes, IgG and OPA indicators of the PCV13 groups were generally superior to the Hib groups, and the differences were mostly statistically significant, which indicates that MINHAI PCV13 can effectively induce pneumococcal specific antibody. Conclusion: The study demonstrates that MINHAI PCV13 has sufficient immunogenicity and safety in Chinese children aged from 7 months to 5 years old. (C) 2021 Elsevier Ltd. All rights reserved.	[Liang, Qi] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Peoples R China; [Li, Hong; Ye, Qiang] Natl Inst Food & Drug Control, Beijing, Peoples R China; [Chang, Xianyun; Zhang, Hao; Hao, Huan; Li, Guifan] Minhai Biotechnol Co Ltd, Beijing, Peoples R China		Ye, Q (通讯作者)，Natl Inst Food & Drug Control, Beijing, Peoples R China.; Li, GF (通讯作者)，Minhai Biotechnol Co Ltd, Beijing, Peoples R China.	yeqiang@nifdc.org.cn; liguifan@biominhai.com					Andrews NJ, 2012, VACCINE, V30, P6802, DOI 10.1016/j.vaccine.2012.09.019; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Brenner NR, 2019, CURR OPIN INFECT DIS, V32, P158, DOI 10.1097/QCO.0000000000000536; Burton RL, 2012, CLIN VACCINE IMMUNOL, V19, P835, DOI 10.1128/CVI.00086-12; Center For Drug Evaluation, GUID GRAD STAND ADV; Chen KL, 2018, HUM VACC IMMUNOTHER, V14, P1453, DOI 10.1080/21645515.2018.1435224; Council for International Organizations of Medical Sciences, 2002, Bull Med Ethics, P17; De Montalembert M, 2015, PEDIATR BLOOD CANCER, V62, P1427, DOI 10.1002/pbc.25502; Ferreira-Coimbra J, 2020, ADV THER, V37, P1302, DOI 10.1007/s12325-020-01248-7; Goldstein F W, 1994, Rev Prat, V44, P1068; GWALTNEY JM, 1975, J INFECT DIS, V132, P62, DOI 10.1093/infdis/132.1.62; Jansen WTM, 2001, INFECT IMMUN, V69, P787, DOI 10.1128/IAI.69.2.787-793.2001; Kim SH, 2020, VACCINE, V38, P6065, DOI 10.1016/j.vaccine.2019.09.065; Lee H, 2009, CLIN VACCINE IMMUNOL, V16, P376, DOI 10.1128/CVI.00344-08; Lehmann D, 1999, PEDIATR INFECT DIS J, V18, pS42, DOI 10.1097/00006454-199910001-00008; Lozano Carmen, 2017, Enferm Infecc Microbiol Clin, V35 Suppl 1, P2, DOI 10.1016/S0213-005X(17)30028-9; Lyu S, 2017, EXPERT REV VACCINES, V16, P997, DOI 10.1080/14760584.2017.1360771; McCollum ED, 2020, VACCINE, V38, P6508, DOI 10.1016/j.vaccine.2020.08.035; Moore MR, 2016, LANCET RESP MED, V4, P399, DOI 10.1016/S2213-2600(16)00052-7; PARKINSON AJ, 1994, J INFECT DIS, V170, P461, DOI 10.1093/infdis/170.2.461; Pobre K, 2014, VACCINE, V32, P1423, DOI 10.1016/j.vaccine.2014.01.047; Prymula R, 2018, PEDIATR INFECT DIS J, V37, P823, DOI 10.1097/INF.0000000000002109; Quanhua L, 2013, J CLIN PHARMACOTHERA, V1, P27; Roth A, 2012, J MOL MICROB BIOTECH, V22, P326, DOI 10.1159/000345327; Shea KM, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu024; Tramuto F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010105; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Varghese R, 2017, J MICROBIOL METH, V141, P48, DOI 10.1016/j.mimet.2017.07.015; Wernette CM, 2003, CLIN DIAGN LAB IMMUN, V10, P514, DOI 10.1128/CDLI.10.4.514-519.2003; World Health Organization, PNEUMONIA; World Health Organization, REC ASS QUAL SAF EFF, V927; Wysocki J, 2015, VACCINE, V33, P1719, DOI 10.1016/j.vaccine.2015.02.005; Yun KW, 2019, AM J PERINAT, V36, pS54, DOI 10.1055/s-0039-1691801	33	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6947	6955		10.1016/j.vaccine.2021.09.047		NOV 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34706841				2022-04-29	WOS:000719580000018
J	Verberk, JDM; van Dongen, JAP; van de Kassteele, J; Andrews, NJ; van Gaalen, RD; Hahne, SJM; Vennema, H; Ramsay, M; Braeckman, T; Ladhani, S; Thomas, SL; Walker, JL; de Melker, HE; Fischer, TK; Koch, J; Bruijning-Verhagen, P				Verberk, J. D. M.; van Dongen, J. A. P.; van de Kassteele, J.; Andrews, N. J.; van Gaalen, R. D.; Hahne, S. J. M.; Vennema, H.; Ramsay, M.; Braeckman, T.; Ladhani, S.; Thomas, S. L.; Walker, J. L.; de Melker, H. E.; Fischer, T. K.; Koch, J.; Bruijning-Verhagen, P.			Impact analysis of rotavirus vaccination in various geographic regions in Western Europe	VACCINE			English	Article						Gastroenteritis Rotavirus Vaccines Children; Diarrhoea Europe Impact	ACUTE GASTROENTERITIS; GLOBAL IMPACT; SURVEILLANCE; VACCINES; TIME; HOSPITALIZATIONS; TRANSMISSION; TEMPERATURE; CHILDREN; DISEASE	Background: Universal mass vaccination (UMV) against rotavirus has been implemented in many but not all European countries. This study investigated the impact of UMV on rotavirus incidence trends by com-paring European countries with UMV: Belgium, England/Wales and Germany versus countries without UMV: Denmark and the Netherlands. Methods: For this observational retrospective cohort study, time series data (2001-2016) on rotavirus detections, meteorological factors and population demographics were collected. For each country, several meteorological and population factors were investigated as possible predictors of rotavirus incidence. The final set of predictors were incorporated in negative binomial models accounting for seasonality and serial autocorrelation, and time-varying incidence rate ratios (IRR) were calculated for each age group and country separately. The overall vaccination impact two years after vaccine implementation was esti-mated by pooling the results using a random effects meta-analyses. Independent t-tests were used to compare annual epidemics in the pre-vaccination and post-vaccination era to explore any changes in the timing of rotavirus epidemics. Results: The population size and several meteorological factors were predictors for the rotavirus epidemi-ology. Overall, we estimated a 42% (95%-CI 23;56%) reduction in rotavirus incidence attributable to UMV. Strongest reductions were observed for age-groups 0-, 1-and 2-years (IRR 0.47, 0.48 and 0.63, respec-tively). No herd effect induced by UMV in neighbouring countries was observed. In all UMV countries, the start and/or stop and corresponding peak of the rotavirus season was delayed by 4-7 weeks. Conclusions: The introduction of rotavirus UMV resulted in an overall reduction of 42% in rotavirus inci-dence in Western European countries two years after vaccine introduction and caused a change in sea-sonal pattern. No herd effect induced by UMV neighbouring countries was observed for Denmark and the Netherlands. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Verberk, J. D. M.; van de Kassteele, J.; van Gaalen, R. D.; Hahne, S. J. M.; Vennema, H.; de Melker, H. E.; Bruijning-Verhagen, P.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands; [van Dongen, J. A. P.; Bruijning-Verhagen, P.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Huispostnummer STR 6-131,Postbus 85500, NL-3508 GA Utrecht, Netherlands; [Andrews, N. J.; Ramsay, M.] Publ Hlth England PHE, Stat Modelling & Econ Dept, London, England; [Braeckman, T.] Sciensano Inst, Dept Publ Hlth & Surveillance, Serv Epidemiol Infect Dis, Brussels, Belgium; [Ladhani, S.; Walker, J. L.] Publ Hlth England PHE, Immunisat Dept, London, England; [Thomas, S. L.; Walker, J. L.] London Sch Hyg & Trop Med LSHTM, Fac Epidemiol & Populat Hlth, London, England; [Fischer, T. K.] Statens Serum Inst SSI, Dept Virol & Special Microbiol Diagnost, Virol Surveillance & Res, Copenhagen, Denmark; [Fischer, T. K.] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark; [Koch, J.] Robert Koch Inst RKI, Dept Infect Dis Epidemiol, Immunizat Unit, Berlin, Germany		Bruijning-Verhagen, P (通讯作者)，Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Huispostnummer STR 6-131,Postbus 85500, NL-3508 GA Utrecht, Netherlands.	P.Bruijning@umcutrecht.nl	Fischer, Thea K/AAH-9892-2019; ramsay, mary elizabeth/S-8281-2016	Fischer, Thea K/0000-0003-4812-980X; ramsay, mary elizabeth/0000-0002-7156-7640; Verberk, Janneke/0000-0003-2148-5935			AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Aliabadi N, 2019, LANCET GLOB HEALTH, V7, pE893, DOI 10.1016/s2214-109x(19)30207-4; [Anonymous], 2017, CENTRAAL BUREAU STAT; [Anonymous], 2018, MED ENV DATA MASH UP; Atchison CJ, 2010, P ROY SOC B-BIOL SCI, V277, P933, DOI 10.1098/rspb.2009.1755; Atchison CJ, 2009, EUROSURVEILLANCE, V14; Atchison CJ, 2016, J INFECT DIS, V213, P243, DOI 10.1093/infdis/jiv398; Baker JM, 2018, CLIN INFECT DIS; Braeckman T, 2011, PEDIATR INFECT DIS J, V30, pS21, DOI 10.1097/INF.0b013e3181fefc51; Burnett E, 2016, FUTURE VIROL, V11, P699, DOI 10.2217/fvl-2016-0082; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; D'Souza RM, 2008, EPIDEMIOL INFECT, V136, P56, DOI 10.1017/S0950268807008229; Donaldson CI, 2020, J SPORT SCI, V38, P2517, DOI 10.1080/02640414.2020.1792190; Dudareva-Vizule S, 2012, HUM VACC IMMUNOTHER, V8, P1407, DOI 10.4161/hv.21593; Edwards CH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183306; Gray J, 2011, J INTERN MED, V270, P206, DOI 10.1111/j.1365-2796.2011.02409.x; Hahne S, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.43.20945; Hervas D, 2014, EUR J CLIN MICROBIOL, V33, P1547, DOI 10.1007/s10096-014-2106-y; Hungerford D, 2016, J HOSP INFECT, V93, P117, DOI 10.1016/j.jhin.2015.12.010; Iturriza-Gomara M, 2009, J INFECT DIS, V200, pS215, DOI [10.1086/605049, 10.1086/605052]; Karafillakis E, 2015, VACCINE, V33, P2097, DOI 10.1016/j.vaccine.2015.03.016; Kittel PA, 2018, VACCINE, V36, P243, DOI 10.1016/j.vaccine.2017.11.041; Kraay ANM, 2018, P NATL ACAD SCI USA, V115, pE2782, DOI 10.1073/pnas.1719579115; Krause G, 2007, EMERG INFECT DIS, V13, P1548, DOI 10.3201/eid1310.070253; Leino T, 2017, VACCINE, V35, P5611, DOI 10.1016/j.vaccine.2017.08.052; Marlow R, 2015, EUROSURVEILLANCE, V20, P21, DOI 10.2807/1560-7917.ES.2015.20.48.30077; Marquis A, 2020, PEDIATR INFECT DIS J, V39, pE109, DOI 10.1097/INF.0000000000002656; Payne DC, 2013, NEW ENGL J MED, V368, P1121, DOI 10.1056/NEJMsa1206589; Pitzer VE, 2011, P NATL ACAD SCI USA, V108, P19353, DOI 10.1073/pnas.1110507108; Pitzer VE, 2009, SCIENCE, V325, P290, DOI 10.1126/science.1172330; Poelaert D, 2018, VACCINE, V36, P2243, DOI 10.1016/j.vaccine.2018.02.080; Prelog M, 2016, J INFECT DIS, V214, P546, DOI 10.1093/infdis/jiw186; Quantin C, 1999, AM J EPIDEMIOL, V150, P1188; Rha B, 2014, EXPERT REV VACCINES, V13, P365, DOI 10.1586/14760584.2014.877846; Royal Netherlands Meteorological Institute (KNMI), 2018, BILTH; Sabbe M, 2016, EUROSURVEILLANCE, V21, P19, DOI 10.2807/1560-7917.ES.2016.21.27.30273; Schober P, 2018, ANESTH ANALG, V126, P1763, DOI 10.1213/ANE.0000000000002864; Schurink-van t Klooster TM, 2019, NATL I PUBLIC HLTH E, P102; Shah MP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191429; Soriano-Gabarro M, 2006, PEDIATR INFECT DIS J, V25, pS7, DOI 10.1097/01.inf.0000197622.98559.01; Staat MA, 2006, CLIN INFECT DIS; Sumi A, 2013, EPIDEMIOL INFECT, V141, P1652, DOI 10.1017/S0950268812002208; Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013; Thomas S, 2018, COMMUN DIS INTELL, V2021; Thomas SL, 2017, VACCINE, V35, P680, DOI 10.1016/j.vaccine.2016.11.057; Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1; Uhlig U, 2014, PEDIATR INFECT DIS J, V33, pE299, DOI [10.1097/INF.0000000000000441, 10.1097]; Van Damme P, 2007, J INFECT DIS, V195, pS4, DOI 10.1086/516714; van den Brandhof WE, 2002, RAPPORTAGE VIROLOGIS, V13, P137; van Gaalen RD, 2017, EPIDEMIOLOGY, V28, P503, DOI 10.1097/EDE.0000000000000654; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; Verberk JDM, 2017, PEDIATR INFECT DIS J; Vesikari T, 2013, PEDIATR INFECT DIS J, V32, P1365, DOI 10.1097/INF.0000000000000086	53	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6671	6681		10.1016/j.vaccine.2021.09.059		OCT 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34635375	hybrid			2022-04-29	WOS:000708078600014
J	Moon, JE; Greenleaf, ME; Regules, JA; Debois, M; Duncan, EH; Sedegah, M; Chuang, I; Lee, CK; Sikaffy, AK; Garver, LS; Ivinson, K; Angov, E; Morelle, D; Lievens, M; Ockenhouse, CF; Ngauy, V; Ofori-Anyinam, O				Moon, James E.; Greenleaf, Melissa E.; Regules, Jason A.; Debois, Muriel; Duncan, Elizabeth H.; Sedegah, Martha; Chuang, Ilin; Lee, Cynthia K.; Sikaffy, April K.; Garver, Lindsey S.; Ivinson, Karen; Angov, Evelina; Morelle, Danielle; Lievens, Marc; Ockenhouse, Christian F.; Ngauy, Viseth; Ofori-Anyinam, Opokua		RTS S Malaria Vaccine Working Grp	A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01(E) in a controlled human malaria infection challenge	VACCINE			English	Article						RTS; S/AS01; Booster; Fractional dose; Plasmodium falciparum malaria; Efficacy; Controlled human malaria infection re-challenge	EFFICACY; SAFETY	Background: We previously demonstrated that RTS,S/AS01(B) and RTS,S/AS01(E) vaccination regimens including at least one delayed fractional dose can protect against Plasmodium falciparum malaria in a controlled human malaria infection (CHMI) model, and showed inferiority of a two-dose versus three-dose regimen. In this follow-on trial, we evaluated whether fractional booster vaccination extended or induced protection in previously protected (P-Fx) or non-protected (NP-Fx) participants. Methods: 49 participants (P-Fx: 25; NP-Fx: 24) received a fractional (1/5th dose-volume) RTS,S/AS01(E) booster 12 months post-primary regimen. They underwent P. falciparum CHMI three weeks later and were then followed for six months for safety and immunogenicity. Results: Overall vaccine efficacy against re-challenge was 53% (95% CI: 37-65%), and similar for P-Fx (52% [95% CI: 28-68%]) and NP-Fx (54% [95% CI: 29-70%]). Efficacy appeared unaffected by primary regimen or previous protection status. Anti-CS (repeat region) antibody geometric mean concentrations (GMCs) increased post-booster vaccination. GMCs were maintained over time in primary three-dose groups but declined in the two-dose group. Protection after re-challenge was associated with higher anti-CS antibody responses. The booster was well-tolerated. Conclusions: A fractional RTS,S/AS01(E) booster given one year after completion of a primary two- or threedose RTS,S/AS01 delayed fractional dose regimen can extend or induce protection against CHMI. (C) 2021 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.	[Moon, James E.; Greenleaf, Melissa E.; Regules, Jason A.; Duncan, Elizabeth H.; Sikaffy, April K.; Garver, Lindsey S.; Angov, Evelina; Ngauy, Viseth] Walter Reed Army Inst Res WRAIR, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Debois, Muriel; Morelle, Danielle; Lievens, Marc; Ofori-Anyinam, Opokua] GSK, 20 Ave Fleming, B-1300 Wavre, Belgium; [Sedegah, Martha; Chuang, Ilin] Naval Med Res Ctr NMRC, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Lee, Cynthia K.; Ivinson, Karen; Ockenhouse, Christian F.] PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA		Moon, JE (通讯作者)，Walter Reed Army Inst Res WRAIR, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	james.e.moon.mil@mail.mil; Melissa.e.greenleaf.ctr@mail.mil; jason.a.regules.mil@mail.mil; muriel.l.debois@gsk.com; elizabeth.h.duncangooden.civ@mail.mil; martha.sedegah.civ@mail.mil; Ilin.chuang.mil@mail.mil; clee@path.org; asikaffy@icongphs.com; lindsey.s.garverbaldwin.civ@mail.mil; kivinson@path.org; evelina.angov.civ@mail.mil; danielle.morelle@gsk.com; marc.lievens@gsk.com; cockenhouse@path.org; viseth.ngauy.mil@mail.mil; opokua.ofori-anyinam@gsk.com	Moon, James E./B-6810-2011	Moon, James E./0000-0002-9274-4554; Lee, Cynthia/0000-0003-2615-7420	PATH; United States Department of Defense (DoD)United States Department of Defense; GlaxoSmithKline Biologicals SAGlaxoSmithKline	Funding for this trial was provided by PATH, an international public health organization, and the United States Department of Defense (DoD). Experimental products were provided by GlaxoSmithKline Biologicals SA. This study and related publication were sponsored by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.	Minsoko PA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001685; Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Alderson MR, 2006, J ENDOTOXIN RES, V12, P313, DOI 10.1179/096805106X118753; Clement F, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-384; ClinicalTrials.gov, EFF SAF IMM STUD GSK; Dobano C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10195-z; Garcon Nathalie, 2003, Expert Rev Vaccines, V2, P231, DOI 10.1586/14760584.2.2.231; GORDON DM, 1995, J INFECT DIS, V171, P1576, DOI 10.1093/infdis/171.6.1576; Kensil C R, 1998, Expert Opin Investig Drugs, V7, P1475, DOI 10.1517/13543784.7.9.1475; Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120; Moon JE, 2020, J INFECT DIS, V222, P1681, DOI 10.1093/infdis/jiaa421; Olotu A, 2011, LANCET INFECT DIS, V11, P102, DOI 10.1016/S1473-3099(10)70262-0; Pallikkuth S, 2020, ELIFE, V9, DOI 10.7554/eLife.51889; Rabinovich RN, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002456; Regules JA, 2016, J INFECT DIS, V214, P762, DOI 10.1093/infdis/jiw237; Schwenk R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111020; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Suscovich TJ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb4757; Tamminga C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025868; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Health Organization (WHO), MAL VACC IMPL PROGR; World Health Organization (WHO),, 2013, 2013 UPD MAL VACC TE	23	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 15	2021	39	43					6398	6406		10.1016/j.vaccine.2021.09.024		OCT 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS5LV	34593270	hybrid			2022-04-29	WOS:000715223200011
J	Wang, J; Wu, QS; Lu, J; Ni, YH; Zhou, F				Wang, Jing; Wu, Qiang-song; Lu, Jin; Ni, Yi-hong; Zhou, Feng			Low vaccination coverage of pneumococcal conjugate vaccines (PCVs) in Shanghai, China: A database analysis based on birth cohorts from 2012 to 2020	VACCINE			English	Article						Pneumococcal conjugate vaccine; Coverage; Children	CHILDREN; DISEASE; BURDEN	Background: Pneumococcal vaccines have been developed to protect infants and young children from pneumococcal diseases. Vaccination coverage studies are important in determining a population's vaccination status and strategically adjusting national immunization programs (NIP). In this paper, we aim to describe the coverage of pneumococcal conjugate vaccines (PCVs) immunization for birth cohorts from 2012 to 2020 and discussed the factors influencing the coverage. Methods: Vaccination data were collected via the vaccination information database in Shanghai, China, for children born from 2012 to 2020. The population data used in this study were collected from each community from 2012 to 2020. The coverage of initial immunization (1st dose), basic immunization (three doses) and full immunization (3 + 1 doses) for PCVs was calculated according to the number of doses received. As vaccination coverage was assessed each year, Annual Growth Rate (AGR) was used to describe the variation trend of vaccination coverage. Immunization time and completeness of different PCVs were also analyzed. Results: The total number of births from 2012 to 2020 was 38,268 in Huangpu District, Shanghai, China. The initial immunization coverage of PCVs increased from 12.26% in 2012 to 49.65% in 2020, and the highest coverage was 50.61% in 2019. The cumulative vaccination coverage of PCVs was 19.4% for initial immunization and 16.8% for basic immunization from 2012 to 2020. And cumulative full immunization coverage of PCVs was 12.3% from 2012 to 2019. The PCVs coverage of most vaccination statuses showed an obvious upward trend from 2017 to 2020. Conclusions: Despite an upward trend in vaccination coverage of PCVs, the vaccination coverage of initial, basic and full immunization among children is still low. And given the heavy burden of Streptococcus pneumoniae (Sp) among children in China and the fact that the current vaccination coverage cannot effectively protect children, it is recommended that the government include PCVs into the NIP as soon as possible. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Wang, Jing; Lu, Jin; Ni, Yi-hong; Zhou, Feng] Ctr Dis Control & Prevent, Dept Immunizat Huangpu Dist, Shanghai 200023, Peoples R China; [Wu, Qiang-song] Ctr Dis Control & Prevent, Dept Immunizat Xuhui Dist, Shanghai 200237, Peoples R China		Zhou, F (通讯作者)，Ctr Dis Control & Prevent, 309 Xietu Rd, Shanghai 200023, Peoples R China.	hpcdcpolio@126.com			Shanghai child development research project [2016SHET13]	This work was supported by Shanghai child development research project [2016SHET13]. Availability of data and materials The data of this study is available from the corresponding author on reasonable request. Consent for publication Not applicable.	Berical AC, 2016, ANN AM THORAC SOC, V13, P933, DOI 10.1513/AnnalsATS.201511-778FR; Boulton ML, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2785-7; Choi YH, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002845; Gadama D, 2021, HUM VACC IMMUNOTHER, V17, P397, DOI 10.1080/21645515.2020.1773142; Gavi tva, 2020, VIEW HUB REP GLOB VA; Georgakopoulou T, 2017, HUM VACC IMMUNOTHER, V13, P190, DOI 10.1080/21645515.2016.1230577; Hill HA, 2017, MMWR-MORBID MORTAL W, V66, P1171, DOI 10.15585/mmwr.mm6643a3; Hu Y, 2014, CHINES J VACCINES IM, V20, P245; Laurenz M, 2021, VACCINE, V39, P3287, DOI 10.1016/j.vaccine.2021.04.029; Lin Li-zhi, 2020, Chinese Journal of Biologicals, V33, P50, DOI 10.13200/j.cnki.cjb.002962; Liqun AN, 2017, J PUB HLTH PREV MED, V28, P37; Lower, 2018, LANCET INFECT DIS, V18, P1211; Moreira M, 2017, HUM VACC IMMUNOTHER, V13, P1242, DOI 10.1080/21645515.2016.1263409; Ning GJ, 2017, EC EVALUATION PNEUMO; PEI Yingxin, 2014, CHINESE J VACCINES I, V20, P465; UNICEF, IMM COV WE LOS GROU; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; Wang CL, 2020, S CHINA J PREV MED, V46, P297; Wang H., 2020, CHINESE J VACCINES I, V26, P93, DOI 1006-916X (2020) 01-0093-05; Wang H. Q., 2020, Zhonghua Yufang Yixue Zazhi, V54, P1315, DOI 10.3760/cma.j.cn112150-20201110-01353; Wang YR, 2020, PREV MED, V32, P292; World Health Organization, GLOBAL HLTH OBSERVAT; Wu Q, 2019, CLIN MICROBIOL INFEC, V25, P872, DOI 10.1016/j.cmi.2018.11.013; [岳晨妍 Yue Chenyan], 2018, [中国公共卫生, China Journal of Public Health], V34, P1468; Zheng DY, 2018, CHINESE J VACCINES I, V31, P220	26	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6189	6194		10.1016/j.vaccine.2021.09.011		SEP 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34538698	hybrid			2022-04-29	WOS:000705822100003
J	Pierce-Ruiz, C; Santana, WI; Sutton, WJH; Fischler, DA; Cooper, HC; Marc, LR; Barr, JR; Williams, TL				Pierce-Ruiz, Carrie; Santana, Wanda I.; Sutton, William J. H.; Fischler, David A.; Cooper, Hans C.; Marc, Lidoshka R.; Barr, John R.; Williams, Tracie L.			Quantification of SARS-CoV-2 spike and nucleocapsid proteins using isotope dilution tandem mass spectrometry	VACCINE			English	Article						Coronavirus; COVID-19; SARS-CoV-2; Mass spectrometry; Spike; Nucleocapsid; Quantification; Epidemic; Pandemic; Outbreak; Vaccine	INFLUENZA-VIRUS; RECEPTOR-BINDING; SARS-COV; VACCINE; HEMAGGLUTININ; CORONAVIRUS; SURFACTANT; GENERATION; DIGESTION	The emergence and subsequent global outbreak of the novel coronavirus SARS-CoV-2 prompted our laboratory to launch efforts to develop methods for SARS-CoV-2 antigen detection and quantification. We present an isotope dilution mass spectrometry method (IDMS) for rapid and accurate quantification of the primary antigens, spike and nucleocapsid proteins. This IDMS method utilizes liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyze sample tryptic digests for detection and quantification of selected conserved peptides of SARS-CoV-2 spike and nucleocapsid proteins. The IDMS method has the necessary attributes to be successfully utilized for accurate quantification in SARS-CoV-2 protein-based vaccines and as targets of rapid diagnostic tests. Absolute quantification was achieved by quantifying and averaging 5 peptides for spike protein (3 peptides in the S1 subunit and 2 peptides in the S2 subunit) and 4 peptides for nucleocapsid protein. The overall relative standard deviation of the method was 3.67% for spike protein and 5.11% for nucleocapsid protein. IDMS offers speed (5 h total analysis time), sensitivity (LOQ; 10 fmol/mL) and precision for quantification of SARSCoV-2 spike and nucleocapsid proteins. Published by Elsevier Ltd.	[Pierce-Ruiz, Carrie; Santana, Wanda I.; Cooper, Hans C.; Barr, John R.; Williams, Tracie L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; [Sutton, William J. H.; Fischler, David A.; Marc, Lidoshka R.] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ, Atlanta, GA 30341 USA		Williams, TL (通讯作者)，Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.	CPierce@cdc.gov; WSantana@cdc.gov; WSutton@cdc.gov; DFischler@cdc.gov; HCooper@cdc.gov; LMarc@cdc.gov; JBarr@cdc.gov; tracie.williams@cdc.hhs.gov			U.S. Department of EnergyUnited States Department of Energy (DOE); CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA	This project was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. We gratefully acknowl-edge the following Authors from the Originating laboratories responsible for obtaining specimens and the Submitting laborato-ries where genetic sequence data were generated and shared via GISAID Initiative, on which this research is based.; 1. hCoV19/Wuhan/IVDCHB01/2019; Accession No. EPI_ISL_402119; Collected 20191230; Originating laboratory National Institute for Viral Disease Control and Prevention; Sub-mitting laboratory Chinese Center for Disease Control and Prevention; Authors Wenjie Tan, Xiang Zhao, Wenling Wang, Xuejun Ma, Yongzhong Jiang, Roujian Lu, Ji Wang, Weimin Zhou, Peihua Niu, Peipei Liu, Faxian Zhan, Weifeng Shi, Baoying Huang, Jun Liu, Li Zhao, Yao Meng, Xiaozhou He, Fei Ye, Na Zhu Yang Li, Jing Chen, Wenbo Xu, George F. Gao, Guizhen Wu.; 2. hCoV19/Brazil/AM987/2020 (P.1) ; Accession No. EPI_ISL_833167; Collected 20201216; Originating laboratory DB Diagnosticos do Brasil; Submitting laboratory Instituto Adolfo Lutz, Interdisciplinary Procedures Center, Strategic Laboratory; Authors Claudio Tavares Sacchi, Claudia Regina Goncalves, Erica Valessa Ramos Gomes, Karoline Rodrigues Campos.; 3. hCoV19/England/205090260/2020 (B.1.1.7) ; Accession No. EOI_ISL_728343; Collected 20201222; Originating laboratory Respiratory Virus Unit, National Infection Service, Public Health England; Submitting laboratory COVID-19 Genomics UK (COG-UK) Consortium; Authors PHE Covid Sequencing Team.; 4. hCov19/South Africa/KRISPK006851/2020; (B.1.351) ; Accession No. EPI_ISL_825115; Collected 20201124; Originating laboratory NHLSIALCH; Submitting laboratory KRISP, KZN Research Innovation and Sequencing Platform; Authors Giandhari J, Pillay, S Lessels R, Mdlalose K, York D, Khan S, Tegally H, Wilkin-son E, de Oliveira T.; 5. hCoV19/India/TGCDFDOMC11/2021; Accession No. EPI_ISL_2924251; Collected 20210524; Originating laboratory Osmania Medical College; Submitting laboratory CDFD; Authors Bashyam M, Gupta A, Basu R, Donipadi V, Kammili N, Vashisht D, Dalal A.; References in this paper to any specific commercial products, process, service, manufacturer, or company do not constitute an endorsement or a recommendation by the U.S. Government or the Centers for Disease Control and Prevention. The findings and conclusions reported in this article are those of the author (s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.	Banerjee S, 2020, ACS OMEGA, V5, P2041, DOI 10.1021/acsomega.9b03764; Barr JR, 1996, CLIN CHEM, V42, P1676; Beck ET, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02727-20; Bose ME, 2014, INFLUENZA OTHER RESP, V8, P474, DOI 10.1111/irv.12246; Botelho JC, 2016, ANAL CHEM, V88, P11123, DOI 10.1021/acs.analchem.6b03220; Brun V, 2009, J PROTEOMICS, V72, P740, DOI 10.1016/j.jprot.2009.03.007; Cazares LH, 2016, CLIN PROTEOM, V13, DOI 10.1186/s12014-016-9119-8; Client CN, 2020, NEW CORONAVIRUS PREL NEW CORONAVIRUS PREL; Cobbaert CM, 2021, CLIN CHEM, V67, P478, DOI 10.1093/clinchem/hvaa239; Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19; Cooper HC, 2020, ANAL CHEM, V92, P11879, DOI 10.1021/acs.analchem.0c02252; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; Diao B, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2020.09.057; Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090; Geyer PE, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20156297; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106; Holmes KV, 2003, SCIENCE, V300, P1377, DOI 10.1126/science.1086418; Hoofnagle AN, 2016, CLIN CHEM, V62, P48, DOI 10.1373/clinchem.2015.250563; Johnson A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128982; Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040; Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301; Liu JY, 2021, ANAL METHODS-UK, V13, P626, DOI 10.1039/d0ay02289f; Loos G, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0366; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Mineva EM, 2015, ANAL BIOANAL CHEM, V407, P5615, DOI 10.1007/s00216-015-8733-z; Morgenstern K, 2018, VACCINE, V36, P6144, DOI 10.1016/j.vaccine.2018.08.065; Parker CE, 2014, MOL ONCOL, V8, P840, DOI 10.1016/j.molonc.2014.03.006; Pierce CL, 2017, VACCINE, V35, P5011, DOI 10.1016/j.vaccine.2017.07.049; Pierce CL, 2011, ANAL CHEM, V83, P4729, DOI 10.1021/ac2006526; Prevention, COR DIS 2019 COVID 1 COR DIS 2019 COVID 1; Ridenour C, 2015, INFLUENZA OTHER RESP, V9, P263, DOI 10.1111/irv.12322; Ross DH, 2021, ANAL CHIM ACTA, V1154, DOI 10.1016/j.aca.2021.338270; Ruhaak LR, 2019, CLIN CHEM LAB MED, V57, pE102, DOI 10.1515/cclm-2018-0782; Santana WI, 2014, ANAL CHEM, V86, P4088, DOI 10.1021/ac4040778; Seger C, 2020, CLIN BIOCHEM, V82, P2, DOI 10.1016/j.clinbiochem.2020.03.004; Sharma VK, 2020, MASS SPECTROM REV, V39, P83, DOI 10.1002/mas.21571; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023; Suder P, 2004, RAPID COMMUN MASS SP, V18, P822, DOI 10.1002/rcm.1411; Vesper HW, 2010, J STEROID BIOCHEM, V121, P513, DOI 10.1016/j.jsbmb.2010.03.032; Whiting G, 2020, VACCINE, V38, P1431, DOI 10.1016/j.vaccine.2019.11.082; Williams TL, 2008, VACCINE, V26, P2510, DOI 10.1016/j.vaccine.2008.03.014; Williams TL, 2012, VACCINE, V30, P2475, DOI 10.1016/j.vaccine.2011.12.056; Yu YQ, 2003, ANAL CHEM, V75, P6023, DOI 10.1021/ac0346196	45	1	1	16	26	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5106	5115		10.1016/j.vaccine.2021.07.066		AUG 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34344552	Green Published, Bronze			2022-04-29	WOS:000684878300007
J	Yu, VG; Lasco, G; David, CC				Yu, Vincen Gregory; Lasco, Gideon; David, Clarissa C.			Fear, mistrust, and vaccine hesitancy: Narratives of the dengue vaccine controversy in the Philippines	VACCINE			English	Article						Vaccines; Vaccine hesitancy; Local vaccination culture; Dengue vaccine; Crisis communications; Philippines	REFUSAL; PARENTS; TRUST; MEDIA; DONT	This article applies a qualitative approach to the 2017 dengue vaccine controversy involving Sanofi Pasteur's Dengvaxia to understand vaccine hesitancy and related anxieties in contemporary Philippines. Through a multisited project that investigated the health aspirations and lived experiences of low-and middle-income Filipinos across urban and rural Philippines, this article distills the perspec-tives of both ordinary community members and health workers in local and national capacities regarding the controversy-and how it altered their perceptions toward vaccines, health care, and government. Our study reveals widespread mistrust and fear in the communities toward both the state and health insti-tutions following the controversy, with frontline health workers bearing the brunt of the communities' apprehensions, and the media partly responsible in fomenting these fears. Given the repetitive nature of health and vaccine controversies, this article suggests the importance of responsible journalism, well-calibrated crisis communications, and a people-centered health paradigm that involves exploring local contexts of vaccine hesitancy and mining people's lived experiences in tackling present and future health crises-especially now in the advent of COVID-19 vaccinations. (c) 2021 Elsevier Ltd. All rights reserved.	[Yu, Vincen Gregory; Lasco, Gideon; David, Clarissa C.] Ateneo Manila Univ, Sch Govt, Quezon City, Philippines; [Yu, Vincen Gregory; Lasco, Gideon] Ateneo Manila Univ, Dev Studies Program, Quezon City, Philippines; [Lasco, Gideon] Univ Philippines Diliman, Dept Anthropol, Quezon City, Philippines		Yu, VG (通讯作者)，Ateneo Manila Univ, Sch Govt, Ateneo Policy Ctr, Pacif Ortiz Hall,Fr Arrupe Rd,Social Dev Complex, Quezon City 1108, Philippines.	vincengregoryyu@gmail.com; pdlasco@up.edu.ph		Yu, Vincen Gregory/0000-0001-5076-383X	Department of Science and Technology-Philippine Council for Health Research and Development	This work was supported by the Department of Science and Technology-Philippine Council for Health Research and Development. All authors attest they meet the ICMJE criteria for authorship.	Anderson W, 2007, J HIST MED ALL SCI, V62, P1, DOI 10.1093/jhmas/jrl014; Atassi K, 2020, MCGILL J GLOBAL HLTH, V9, P114; Bazylevych M, 2011, MED ANTHROPOL Q, V25, P436, DOI 10.1111/j.1548-1387.2011.01179.x; Bueza M., 2018, RAPPLER 0203 RAPPLER 0203; Cabato R., WASH POST, V2021; CNN Philippines Staff, 2021, CNN PHILIPPINES; Curato N, 2017, J CONTEMP ASIA, V47, P142, DOI 10.1080/00472336.2016.1239751; Dayrit MM, 2020, J PUBLIC HEALTH POL, V41, P252, DOI 10.1057/s41271-020-00232-3; Estella P, 2019, MEDIA LANDCSAPES PHI; Eysenbach G, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1157; Feldman-Savelsberg P, 2000, MED ANTHROPOL Q, V14, P159, DOI 10.1525/maq.2000.14.2.159; Gotinga J, 2020, RAPPLER 1217 RAPPLER 1217; Halstead SB, 2020, VACCINE, V38, P5572, DOI 10.1016/j.vaccine.2020.06.079; HARDING CM, 1985, CHILD CARE HLTH DEV, V11, P21, DOI 10.1111/j.1365-2214.1985.tb00446.x; Interaksyon, 2017, INTERAKSYON 1214 INTERAKSYON 1214; Jamison AM, 2019, SOC SCI MED, V221, P87, DOI 10.1016/j.socscimed.2018.12.020; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jegede AS, 2007, PLOS MED, V4, P417, DOI 10.1371/journal.pmed.0040073; Karafillakis E, 2019, HUM VACC IMMUNOTHER, V15, P1615, DOI 10.1080/21645515.2018.1564436; Khan TM, 2016, VACCINE, V34, P2074, DOI 10.1016/j.vaccine.2016.03.008; Kusaka W, 2017, KYOTO CSEAS S ASIAN, P1; Larson HJ, 2019, HUM VACC IMMUNOTHER, V15, P625, DOI 10.1080/21645515.2018.1522468; Lasco G, BMJ GLOB HEALTH, V2021, P6, DOI [10.1136/bmjgh-2021-005422-005422, DOI 10.1136/BMJGH-2021-005422-005422]; Lasco G., 2020, PHILIPPINE STUD HIST, V68, P337; Lasco G, 2020, GLOB PUBLIC HEALTH, V15, P334, DOI 10.1080/17441692.2019.1680724; Lasco G, 2019, SOC SCI MED, V221, P1, DOI 10.1016/j.socscimed.2018.12.006; Linde C., 2009, Working with the Past: Narrative and institutional memory; Madarang CRS, INTERAKSYON 0302 INTERAKSYON 0302; Magsambol B, RAPPLER 0326 RAPPLER 0326; Marquez C, PHILIPPINE DAILY INQ, P2021; May T, 2005, BIOETHICS, V19, P407, DOI 10.1111/j.1467-8519.2005.00452.x; Mendoza RU, 2020, CRISIS CONFIDENCE CA, DOI [10.2139/ssrn.3519736, DOI 10.2139/SSRN.3519736]; Migrino J, 2020, WEST PAC SURVEILL RE, V11, DOI 10.5365/wpsar.2019.10.2.006; Mirasol PB, MORE SMARTPHONE DEPE; Montemayor MT, 2019, MEASLES OUTBREAK DUE MEASLES OUTBREAK DUE; National Economic Development Authority, 2017, VIS 2040 FIL PUBL CO VIS 2040 FIL PUBL CO; Navarro K, 2020, JCOM-J SCI COMMUN, V19, DOI 10.22323/2.19010203; Numerato D, 2019, SOCIOL HEALTH ILL, V41, P82, DOI 10.1111/1467-9566.12873; Ong JC, 2018, U MASSACHUSETTS AMHE; Pasteur Sanofi, 2017, SANOFI UPDATES INFOR; Pop CA, 2016, MED ANTHROPOL Q, V30, P563, DOI 10.1111/maq.12290; Rabena AJ, COVID 19 PANDEMIC PH, V2021, P25; Rappler.com, 2020, RAPPLER 1230 RAPPLER 1230; Republic of the Philippines Department of Education, 2016, 50 DEPED REP PHIL DE 50 DEPED REP PHIL DE; Reyes MSGL, 2021, HUM VACC IMMUNOTHER, V17, P1873, DOI 10.1080/21645515.2020.1841541; Sobo EJ, 2016, CULT ANTHROPOL, V31, P342, DOI 10.14506/ca31.3.04; Social Weather Stations, 2021, 1 QUART 2021 SOC WEA; Steffens MS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7659-3; Streefland P, 1999, SOC SCI MED, V49, P1705, DOI 10.1016/S0277-9536(99)00239-7; Talabong R, 2020, RAPPLER 1228 RAPPLER 1228; Tan L, CNN PHILIPPINES, V2021; Tan ML, 1995, REPROD HEALTH MATTER, V3, P29, DOI [10.1016/0968-8080(95)90156-6, DOI 10.1016/0968-8080(95)90156-6]; Thabethe S, 2018, J EMPIR RES HUM RES, V13, P525, DOI 10.1177/1556264618804740; Tomacruz S., 2021, RAPPLER 0302 RAPPLER 0302; Tomacruz S., 2020, RAPPLER 0714 RAPPLER 0714; Tsuda K, 2016, CLIN INFECT DIS, V63, P1634, DOI 10.1093/cid/ciw647; Valido Ezra M, 2018, BMC Res Notes, V11, P661, DOI 10.1186/s13104-018-3766-y; World Health Organization, 2020, PHIL WHO UNICEF EST PHIL WHO UNICEF EST	58	0	0	4	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2021	39	35					4964	4972		10.1016/j.vaccine.2021.07.051		AUG 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TX3GY	34330555				2022-04-29	WOS:000682979100009
J	Hirst, A; Hyer, RN; Janssen, RS				Hirst, Alex; Hyer, Randall N.; Janssen, Robert S.			Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations	VACCINE			English	Article						Vaccine; Cost-effectiveness; Hepatitis B; Adult	CHRONIC KIDNEY-DISEASE; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; CIRRHOTIC-PATIENTS; DIABETIC-PATIENTS; UNITED-STATES; IMMUNOGENICITY; SAFETY; VIRUS; HBSAG-1018	The hepatitis B virus is highly infectious and can cause incurable liver disease, leading to high morbidity rates, increased healthcare utilization, and high mortality. Multiple preventative hepatitis B vaccine options have been available for decades, but adherence to the traditional 6-month vaccine schedule for the approved 3-dose series remains low in adult populations at risk of hepatitis B exposure. A 2-dose hepatitis B vaccine (HEPLISAV-B) approved by the US Food and Drug Administration in 2017 induces rapid seroprotection within 1 month and has a safety profile comparable to a commonly used 3-dose vac-cine. In a previous cost-effectiveness study, HEPLISAV-B had a favorable cost-effectiveness profile for multiple at-risk populations. The goal of the current analysis was to update and extend previous findings by evaluating cost-effectiveness of HEPLISAV-B compared with a 3-dose vaccine (Engerix-B) in selected adult populations, including patients with diabetes, chronic liver or kidney disease, end-stage renal dis-ease, healthcare personnel, travelers to countries with endemic hepatitis B, and a public health popula-tion. Cost-effectiveness was measured as incremental cost-effectiveness ratios using a health economics Markov model that accounts for adherence rates, seroprotection rates, healthcare costs, and current pric-ing considerations. Patients progressed between a series of health states, and the difference in lifetime spending and survival for individuals receiving either HEPLISAV-B or Engerix-B was estimated from the perspective of a US managed care payer, HEPLISAV-B had favorable cost-effectiveness profiles for patients with diabetes, healthcare personnel, travelers, and patients with chronic liver disease and dom-inant incremental cost-effectiveness ratios for patients with chronic kidney disease and end-stage renal disease. A probabilistic sensitivity analysis supported the robustness of the cost-effectiveness profiles, and an additional analysis indicated that HEPLISAV-B was cost-effective in the general adult population. Overall, HEPLISAV-B was cost-effective in multiple adult populations recommended for HBV vaccination in the United States. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Hirst, Alex] ICON Plc, Global HTA, Hlth Econ Reimbursement & Outcomes, Dublin, Ireland; [Hyer, Randall N.; Janssen, Robert S.] Dynavax Technol Corp, Clin Dev, Emeryville, CA 94608 USA; [Hyer, Randall N.] Moderna, 200 Technol Sq, Cambridge, MA 02139 USA		Janssen, RS (通讯作者)，Dynavax Technol Corp, Clin Dev, Emeryville, CA 94608 USA.	Randall.Hyer@modernatx.com; rjanssen@dynavax.com			Dynavax Technologies Corporation, Emeryville, California	This study was sponsored by Dynavax Technologies Corporation, Emeryville, California. Dynavax was involved in study design, data collection, data analysis, data interpretation, writing of the study report, and the decision to submit the paper for publication.	[Anonymous], 2020, DATA FILE; [Anonymous], 2019, GUID HLTH EC STUD PR; Arias Elizabeth, 2017, Natl Vital Stat Rep, V66, P1; Averhoff F, 1998, AM J PREV MED, V15, P1, DOI 10.1016/S0749-3797(98)00003-8; Bond TC, 2009, AM J KIDNEY DIS, V54, P86, DOI 10.1053/j.ajkd.2008.12.038; Bridges CB, 2019, VACCINE, V37, P5111, DOI 10.1016/j.vaccine.2019.05.089; Bruxvoort K, 2019, IDWEEK; Bunn WB, 2008, J OCCUP ENVIRON MED, V50, P935, DOI 10.1097/JOM.0b013e3181808096; BUTI M, 1992, AM J NEPHROL, V12, P144, DOI 10.1159/000168436; Byrd KK, 2013, PUBLIC HEALTH REP, V128, P498, DOI 10.1177/003335491312800609; Centers for Disease Control and Prevention, 2015, VIRAL HEPATITIS SURV; Centers for Disease Control and Prevention, 2016, VIR HEP SURV US 2016; Centers for Disease Control and Prevention, 2017, VACCINATION COVERAGE; Centers for Disease Control and Prevention, 2011, US HEP B VACC AD DIA US HEP B VACC AD DIA; Centers for Disease Control and Prevention Advisory Committee on Immunization Practice, 2019, HEPATITIS VACCINES; Centers for Medicare and Medicaid Services, PHYS FEE SCHED SEARC; Chahal HS, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofy353; Connor BA, 2006, J TRAVEL MED, V13, P273, DOI 10.1111/j.1708-8305.2006.00055.x; Dan AA, 2008, LIVER TRANSPLANT, V14, P321, DOI 10.1002/lt.21376; DaRoza G, 2003, AM J KIDNEY DIS, V42, P1184, DOI 10.1053/j.ajkd.2003.08.019; Dominguez M, 2000, LIVER TRANSPLANT, V6, P440, DOI 10.1053/jlts.2000.8313; Douvin C, 1997, DIABETES CARE, V20, P148, DOI 10.2337/diacare.20.2.148; El-Kamary SS, 2011, CLIN INFECT DIS, V53, P150, DOI 10.1093/cid/cir306; ENGERIX-B ~ (hepatitis B vaccine [recombinant]), 2019, FULL PRESCRIBING INF; Fattovich G, 2008, J HEPATOL, V48, P335, DOI 10.1016/j.jhep.2007.11.011; Finelli L, 2005, SEMIN DIALYSIS, V18, P52, DOI 10.1111/j.1525-139X.2005.18108.x; Fisman DN, 2002, CLIN INFECT DIS, V35, P1368, DOI 10.1086/344271; Habka D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131764; Halperin SA, 2012, VACCINE, V30, P2556, DOI 10.1016/j.vaccine.2012.01.087; HAVRIX ~ (hepatitis A vaccine), 2018, FULL PRESCRIBING INF; HEPLISAV-B, 2020, FULL PRESCRIBING INF; Heyward WL, 2013, VACCINE, V31, P5300, DOI 10.1016/j.vaccine.2013.05.068; Hoerger TJ, 2013, DIABETES CARE, V36, P63, DOI 10.2337/dc12-0759; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1016/0270-9139(95)90434-4; Hutubessy Raymond, 2003, Cost Eff Resour Alloc, V1, P8, DOI 10.1186/1478-7547-1-8; Hyer RN, 2019, VACCINE, V37, P5854, DOI 10.1016/j.vaccine.2019.08.005; Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038; Janssen JM, 2015, VACCINE, V33, P3614, DOI 10.1016/j.vaccine.2015.05.070; Janssen JM, 2015, VACCINE, V33, P833, DOI 10.1016/j.vaccine.2014.12.060; Janssen RS, 2013, VACCINE, V31, P5306, DOI 10.1016/j.vaccine.2013.05.067; Janus N, 2008, NEPHROL DIAL TRANSPL, V23, P800, DOI 10.1093/ndt/gfm851; Kaplan DE, 2018, CLIN GASTROENTEROL H, V16, P106, DOI 10.1016/j.cgh.2017.07.024; Kim DK, 2019, ANN INTERN MED, V170, P182, DOI 10.7326/M18-3600; Kim JJ, 2011, NEW ENGL J MED, V365, P1760, DOI 10.1056/NEJMp1110539; Kuan RK, 2013, VACCINE, V31, P4024, DOI 10.1016/j.vaccine.2013.05.014; Kutner NG, 2009, CLIN J AM SOC NEPHRO, V4, P645, DOI 10.2215/CJN.05721108; La Fauci V, 2016, PUBLIC HEALTH, V139, P198, DOI 10.1016/j.puhe.2016.08.007; Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x; Liu TL, 2016, DIGEST DIS SCI, V61, P3335, DOI 10.1007/s10620-016-4261-8; Mast EE, 1999, VACCINE, V17, P1730, DOI 10.1016/S0264-410X(98)00415-0; Moreno-Fernandez J, 2020, PRIM CARE DIABETES, V14, P343, DOI 10.1016/j.pcd.2019.09.004; Murray KF, 2005, HEPATOLOGY, V41, P1407, DOI 10.1002/hep.20704; Nelson JC, 2009, AM J PUBLIC HEALTH, V99, pS389, DOI 10.2105/AJPH.2008.151332; Nelson NP, 2018, MMWR-MORBID MORTAL W, V67, P1216, DOI 10.15585/mmwr.mm6743a5; Nguyen MH, 2019, J HEPATOL, V70, P24, DOI 10.1016/j.jhep.2018.09.021; Pascasio JM, 2008, TRANSPL P, V40, P2943, DOI 10.1016/j.transproceed.2008.09.029; Pike J, 2019, VACCINE, V37, P7, DOI 10.1016/j.vaccine.2018.11.055; RECOMBIVAX HB., 2018, FULL PRESCRIBING INF; Reilly Meredith L, 2012, J Diabetes Sci Technol, V6, P858; Rosenthal EM, 2020, VACCINE, V38, P8206, DOI 10.1016/j.vaccine.2020.10.067; Sablan BP, 2012, VACCINE, V30, P2689, DOI 10.1016/j.vaccine.2012.02.001; Schillie S, 2018, MMWR-MORBID MORTAL W, V67, P455, DOI 10.15585/mmwr.mm6715a5; Shen AK, 2017, VACCINE, V35, P7302, DOI 10.1016/j.vaccine.2017.10.105; Tancredi M, 2015, NEW ENGL J MED, V373, P1720, DOI 10.1056/NEJMoa1504347; Tian CW, 2019, AM J INFECT CONTROL, V47, P883, DOI 10.1016/j.ajic.2019.02.014; Tohme RA, 2011, VACCINE, V29, P9316, DOI 10.1016/j.vaccine.2011.10.011; Trantham L, 2018, VACCINE, V36, P5333, DOI 10.1016/j.vaccine.2018.05.111; Tsouchnikas I, 2007, CLIN NEPHROL, V68, P228; TWINRIX ~ (hepatitis A & B [recombinant] vaccine), 2018, FULL PRESCRIBING INF; Weinbaum C., 2006, Morbidity and Mortality Weekly Report, V55, P509; WISMANS PJ, 1991, J MED VIROL, V35, P216, DOI 10.1002/jmv.1890350313; Wong LL, 1997, ARCH INTERN MED, V157, P1429, DOI 10.1001/archinte.157.13.1429; World Health Organization, 2017, WHO GLOB HEP REP; World Health Organization, 2015, GUIDELINES PREVENTIO; Yang SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27251	75	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4733	4741		10.1016/j.vaccine.2021.05.020		JUL 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TU9NN	34030898	hybrid			2022-04-29	WOS:000681356500019
J	Carnalla, M; Torres-Ibarra, L; Barrientos-Gutierrez, T; Cruz-Valdez, A; Munoz, N; Herrero, R; Stanley, M; Nyitray, A; Salmeron, J; Lazcano-Ponce, E				Carnalla, Martha; Torres-Ibarra, Leticia; Barrientos-Gutierrez, Tonatiuh; Cruz-Valdez, Aurelio; Munoz, Nubia; Herrero, Rolando; Stanley, Margaret; Nyitray, Alan; Salmeron, Jorge; Lazcano-Ponce, Eduardo			Reduction of HPV16/18 prevalence in young women after eight years of three- and two-dose vaccination schemes	VACCINE			English	Article						HPV-prevalence; HPV vaccines; Alternative schemes; Urine; Mexico	HUMAN-PAPILLOMAVIRUS; IMMUNOGENICITY; INFECTION; EFFICACY; VACCINES	Background: Recommendations for human papillomavirus vaccination have relied on immunogenicity studies and efficacy results derived from adult women. Insufficient information exists regarding HPV effectiveness in vaccinated girls as they become sexually active, regardless of dose scheme. We aimed to compare the prevalence of high-risk HPV between unvaccinated and vaccinated young women eight years after immunization. Methods: After eight years, we recontacted women who received two-dose of bivalent or three-dose- either bivalent or quadrivalent-, HPV vaccine when aged 9-10 years-old as part of a clinical trial. Additionally, we recruited a contemporaneous unvaccinated woman group for comparison. Only those sexually active were included. High-risk HPV DNA was determined in urine samples and compared across groups. Results: The prevalence of HPV16/18 types was 6.8% (95 %CI 3.2-14.1%) in the unvaccinated (n = 6/88), 1.1% (95 %CI 0.2-5.8%) in the three-dose (n = 1/93), and 0.0% (95 %CI 0.0-7.0%) in the two-dose group (n = 0/51). Conclusion: HPV vaccination, with two-dose of bivalent or three-dose schemes-either with the bivalent or quadrivalent vaccine-, was associated with a lower prevalence of HPV16/18 types eight years after primary immunization. (c) 2021 Elsevier Ltd. All rights reserved.	[Carnalla, Martha; Torres-Ibarra, Leticia; Barrientos-Gutierrez, Tonatiuh; Cruz-Valdez, Aurelio] Natl Inst Publ Hlth, Ctr Populat Hlth Res, Av Univ 655, Cuernavaca 62100, Morelos, Mexico; [Munoz, Nubia] Natl Inst Canc, Calle 1 9-85, Bogota, Colombia; [Herrero, Rolando] Agencia Costarricense Invest Biomed, Complejo SOLARIUM,Bodega C8, San Jose, Costa Rica; [Stanley, Margaret] Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England; [Nyitray, Alan] Med Coll Wisconsin, Ctr AIDS Intervent Res, Clin Canc Ctr, 2071 N Summit Ave, Milwaukee, WI 53202 USA; [Salmeron, Jorge] Univ Nacl Autonoma Mexico, Fac Med, Ctr Invest Polit Poblac & Salud, Unidad Univ Edificio CIPPS,Ctr Cultural SN, Mexico City, DF, Mexico; [Lazcano-Ponce, Eduardo] Inst Nacl Salud Publ, Escuela Salud Publ Mexico, Av Univ 655, Cuernavaca 62100, Morelos, Mexico		Lazcano-Ponce, E (通讯作者)，Inst Nacl Salud Publ, Escuela Salud Publ Mexico, Av Univ 655, Cuernavaca 62100, Morelos, Mexico.	martha.carnalla@insp.edu.mx; leticia.torres@insp.mx; tbarrientos@insp.mx; acruz@insp.mx; nubiamunoz@gmail.com; rherrero@acibcr.com; mas1001@cam.ac.uk; anyitray@mcw.edu; jorge.salmec@gmail.com; elazcano@insp.mx		Nyitray, Alan/0000-0003-2020-9904			Garcia-Perdomo HA, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268818003679; Cutts FT, 2007, B WORLD HEALTH ORGAN, V85, P719, DOI 10.2471/BLT.06.038414; Feiring B, 2018, J INFECT DIS, V218, P1900, DOI 10.1093/infdis/jiy432; Hernandez-Avila M, 2016, HUM VACC IMMUNOTHER, V12, P30, DOI 10.1080/21645515.2015.1058458; Jacot-Guillarmod M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2867-x; Kavanagh K, 2014, BRIT J CANCER, V110, P2804, DOI 10.1038/bjc.2014.198; Kavanagh K, 2017, LANCET INFECT DIS, V17, P1293, DOI 10.1016/S1473-3099(17)30468-1; Lazcano-Ponce E, 2019, J INFECT DIS, V219, P41, DOI 10.1093/infdis/jiy465; Lazcano-Ponce E, 2014, VACCINE, V32, P725, DOI 10.1016/j.vaccine.2013.11.059; Lehtinen M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-015867; Lowy DR, 2015, LANCET ONCOL, V16, pE226, DOI 10.1016/S1470-2045(15)70075-6; Combita AL, 2016, CANCER PREV RES, V9, P766, DOI 10.1158/1940-6207.CAPR-16-0038; Malagon T, 2012, LANCET INFECT DIS, V12, P781, DOI 10.1016/S1473-3099(12)70187-1; Markowitz LE, 2020, J INFECT DIS, V221, P910, DOI 10.1093/infdis/jiz555; Markowitz LE, 2018, VACCINE, V36, P4806, DOI 10.1016/j.vaccine.2018.01.057; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; Olsson SE, 2020, PAPILLOMAVIRUS RES, V10, DOI 10.1016/j.pvr.2020.100203; Pathak N, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5264; Schiller JT, 2012, NAT REV MICROBIOL, V10, P681, DOI 10.1038/nrmicro2872; Secretariat of Health, 2015, VACC HUM PAP SPAN; Skinner SR, 2014, LANCET, V384, P2213, DOI 10.1016/S0140-6736(14)60920-X; Sonawane K, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.18571; UNICEF WHO, 2018, PROGR CHALL ACH UN I; Woestenberg PJ, 2018, J INFECT DIS, V217, P213, DOI 10.1093/infdis/jix582; World Health Organization, 2013, IMMUNIZATION VACCINE; World Health Organization, 2014, GUIDELINES PREVENTIO; Yamaguchi M, 2018, PAPILLOMAVIRUS RES, V6, P6, DOI 10.1016/j.pvr.2018.05.002	28	0	0	5	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4419	4422		10.1016/j.vaccine.2021.06.040		JUL 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34183205				2022-04-29	WOS:000672160300007
J	Ostergaard, L; Vesikari, T; Senders, SD; Flodmark, CE; Kosina, P; Jiang, HQ; Maguire, JD; Absalon, J; Jansen, KU; Harris, SL; Maansson, R; Balmer, P; Beeslaar, J; Perez, JL				Ostergaard, Lars; Vesikari, Timo; Senders, Shelly D.; Flodmark, Carl-Erik; Kosina, Pavel; Jiang, Han-Qing; Maguire, Jason D.; Absalon, Judith; Jansen, Kathrin U.; Harris, Shannon L.; Maansson, Roger; Balmer, Paul; Beeslaar, Johannes; Perez, John L.			Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2-or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months	VACCINE			English	Article						Adolescents; Clinical trial; Invasive meningococcal disease; Serogroup B; Vaccines	CONJUGATE VACCINE; BIVALENT RLP2086; ANTIBODY PERSISTENCE; BACTERICIDAL ANTIBODIES; ACELLULAR PERTUSSIS; UNITED-STATES; DISEASE; TETANUS; 4CMENB; IMMUNIZATION	Background: To demonstrate extended protection against meningococcal serogroup B (MenB) disease after MenB-FHbp (bivalent rLP2086) vaccination, this study evaluated immunopersistence through 26 months following MenB-FHbp boosting after 2 or 3 primary doses in adolescents. Study design: This phase 3, open-label study was an extension of 3 phase 2 studies with participants aged 11-18 years randomized to receive primary MenB-FHbp vaccination following 1 of 5 dosing schedules or control. A booster dose was administered 48 months after the primary series. Immunopersistence through 48 months after the last primary dose (persistence stage) and 26 months postbooster (booster stage) was determined by serum bactericidal assays using human complement (hSBAs) against 4 vaccine-heterologous test strains. Safety evaluations included adverse events (AEs) and local and systemic reactions. Results: Overall, 698 and 304 subjects enrolled in the persistence and booster stages, respectively. hSBA titers declined in all groups during 12 months postprimary vaccination, then remained stable through 48 months. One month postbooster, 93.4-100.0% of subjects achieved hSBA titers > lower limit of quantitation against each test strain; percentages at 12 and 26 months postbooster were higher than at similar time points following primary vaccination. Primary and booster MenB-FHbp vaccinations were well tolerated, with < 12.5% of subjects reporting AEs during each stage. The most common local (reported by 84.4-93.8% of subjects) and systemic (68.8-76.6%) reactions to the booster were injection site pain and fatigue and headache, respectively; < 3.7% of subjects reported severe systemic events. Conclusion: Protective hSBA titers initially declined but were retained by many subjects for 4 years irrespective of primary MenB-FHbp vaccination schedule. Boosting at 48 months after primary vaccination was safe, well tolerated, and induced immune responses indicative of immunological memory that persisted through 26 months. Booster vaccination during late adolescence may prolong protection against MenB disease. (c) 2021 Elsevier Ltd. All rights reserved.	[Ostergaard, Lars] Aarhus Univ Hosp, Dept Infect Dis, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark; [Vesikari, Timo] Nordic Res Network Ltd, Biokatu 10, Tampere 33520, Finland; [Senders, Shelly D.] Senders Pediat, 2054 South Green Rd, South Euclid, OH USA; [Flodmark, Carl-Erik] Skane Univ Hosp Malmo, Dept Pediat, Entrance 108, Malmo, Sweden; [Kosina, Pavel] Univ Hosp Hradec Kralove, Dept Infect Dis, Sokolska 581, Hradec Kralove 50005, Czech Republic; [Jiang, Han-Qing; Maguire, Jason D.; Absalon, Judith; Jansen, Kathrin U.; Harris, Shannon L.] Pfizer Vaccine Res & Dev, 401 North Middletown Rd, Pearl River, NY USA; [Maansson, Roger; Perez, John L.] Pfizer Vaccine Res & Dev, 500 Arcola Rd, Collegeville, PA USA; [Balmer, Paul] Pfizer Vaccine Med & Sci Affairs, 500 Arcola Rd, Collegeville, PA USA; [Beeslaar, Johannes] Pfizer UK Vaccine Res & Dev, Horizon Bldg,Honey Lane, Hurley SL6 6RJ, England		Ostergaard, L (通讯作者)，Aarhus Univ Hosp, Dept Infect Dis, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.	larsoest@rm.dk		Harris, Shannon/0000-0002-9354-0748; Ostergaard, Lars/0000-0003-2459-0511; Flodmark, Carl-Erik/0000-0001-9705-4766	Pfizer Inc.Pfizer	This study was funded by Pfizer Inc.	Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P72; Baxter R, 2015, PEDIATR INFECT DIS J, V34, P1236, DOI 10.1097/INF.0000000000000866; Baxter R, 2014, PEDIATR INFECT DIS J, V33, P1169, DOI 10.1097/INF.0000000000000438; Borrow R, 2006, VACCINE, V24, P5093, DOI 10.1016/j.vaccine.2006.03.091; Borrow R, 2005, VACCINE, V23, P2222, DOI 10.1016/j.vaccine.2005.01.051; Centers for Disease Control, 2017, ENH MEN DIS SURV REP; Centers for Disease Control and Prevention, 2017, ENH MEN DIS SURV REP; Centers for Disease Control and Prevention [CDC], 2019, REC CHILD AD IMM SCH; Cohn AC, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2193; Cohn AC, 2013, MMWR RECOMM REP, V62, P1; European Centre for Disease Prevention and Control, 2019, ANN EPIDEMIOLOGICAL; European Centre for Disease Prevention and Control (ECDC), 2018, SURV REP ANN EP REP; European Medicines Agency, 2017, EPAR SUMM PUBLIC TRU; Iro MA, 2017, VACCINE, V35, P395, DOI 10.1016/j.vaccine.2016.11.009; Jacobson RM, 2013, PEDIATR INFECT DIS J, V32, pE170, DOI 10.1097/INF.0b013e318279ac38; Jafri RZ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-17; Marshall HS, 2017, LANCET INFECT DIS, V17, P58, DOI 10.1016/S1473-3099(16)30314-0; Martinon-Torres F, 2014, VACCINE, V32, P5206, DOI 10.1016/j.vaccine.2014.07.049; McQuaid F, 2014, PEDIATR INFECT DIS J, V33, P760, DOI 10.1097/INF.0000000000000327; meningococcal group B vaccine), 2018, FULL PRESCR INF; Muse D, 2016, PEDIATR INFECT DIS J, V35, P673, DOI 10.1097/INF.0000000000001124; Nolan T, 2019, VACCINE, V37, P1209, DOI 10.1016/j.vaccine.2018.12.059; Perez JL, 2018, EXPERT REV VACCINES, V17, P461, DOI 10.1080/14760584.2018.1483726; Sadarangani M, 2017, CAN MED ASSOC J, V189, pE1276, DOI 10.1503/cmaj.161288; Soeters HM, 2019, EMERG INFECT DIS, V25, P434, DOI 10.3201/eid2503.181574; Soeters HM, 2015, MMWR-MORBID MORTAL W, V64, P606; Vesikari T, 2015, J PEDIAT INF DIS SOC, V35, P673; Vesikari T, 2019, VACCINE, V37, P1710, DOI 10.1016/j.vaccine.2018.11.073; Vesikari T, 2016, J PEDIAT INF DIS SOC, V5, P180, DOI 10.1093/jpids/piv064; Vesikari T, 2015, VACCINE, V33, P3850, DOI 10.1016/j.vaccine.2015.06.079; Vesikari T, 2013, LANCET, V381, P825, DOI 10.1016/S0140-6736(12)61961-8	31	2	2	3	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4545	4554		10.1016/j.vaccine.2021.06.005		JUL 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34215452				2022-04-29	WOS:000672160300022
J	Dal-Re, R; Launay, O				Dal-Re, Rafael; Launay, Odile			Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label	VACCINE			English	Editorial Material									[Dal-Re, Rafael] Univ Autonoma Madrid, Fdn Jimenez Diaz, Univ Hosp, Epidemiol Unit,Hlth Res Inst, Avda Reyes Catolicos 2, E-28040 Madrid, Spain; [Launay, Odile] Univ Paris, Innovat Clin Res Network Vaccinol I REIVAC, Fac Med, INSERM,CIC 1417,F CRIN, Paris, France; [Launay, Odile] Hop Cochin Paris, AP HP, CIC Cochin Pasteur, Paris, France		Dal-Re, R (通讯作者)，Univ Autonoma Madrid, Fdn Jimenez Diaz, Univ Hosp, Epidemiol Unit,Hlth Res Inst, Avda Reyes Catolicos 2, E-28040 Madrid, Spain.	rafael.dalre@quironsalud.es					Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; [Anonymous], 2021, REUTERS 0205 REUTERS 0205; [Anonymous], 2021, EURONEWS; [Anonymous], 2021, BBC NEWS 0212 BBC NEWS 0212; Dal-Re R, BRIT J CLIN PHARMACO, V2021, P2405; Dal-Re R, 2021, LANCET RESP MED, V9, pE30, DOI 10.1016/S2213-2600(21)00044-8; European Commission, QUEST ANSW COND MARK QUEST ANSW COND MARK; European Medicines Agency, CLAR COMM DOS INT 20 CLAR COMM DOS INT 20; European Medicines Agency, COVID 19 VACCINE AST; European Parliament, 2020, PARL QUEST 4 DEC 202 PARL QUEST 4 DEC 202; Henley J, 2021, GUARDIAN 0104 GUARDIAN 0104; Higdon M., 2021, LIVE5NEWS 0121 LIVE5NEWS 0121; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Mahase E, BMJ-BRIT MED J, V372, pN12; MHRA, 2021, PUBL ASS REP AUTH TE PUBL ASS REP AUTH TE; Newey S., 2020, TELEGRAPH; WHO, 2021, INT REC USE PFIZ BIO	17	1	1	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4029	4031		10.1016/j.vaccine.2021.05.095		JUN 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34120766	Green Published, Bronze			2022-04-29	WOS:000672535200004
J	Guntuku, SC; Buttenheim, AM; Sherman, G; Merchant, RM				Guntuku, Sharath Chandra; Buttenheim, Alison M.; Sherman, Garrick; Merchant, Raina M.			Twitter discourse reveals geographical and temporal variation in concerns about COVID-19 vaccines in the United States	VACCINE			English	Article						COVID-19 vaccination; Twitter; Natural language processing; Machine learning		The speed at which social media is propagating COVID-19 misinformation and its potential reach and impact is growing, yet little work has focused on the potential applications of these data for informing public health communication about COVID-19 vaccines. We used Twitter to access a random sample of over 78 million vaccine-related tweets posted between December 1, 2020 and February 28, 2021 to describe the geographical and temporal variation in COVID-19 vaccine discourse. Urban suburbs posted about equitable distribution in communities, college towns talked about in-clinic vaccinations near universities, evangelical hubs posted about operation warp speed and thanking God, exurbs posted about the 2020 election, Hispanic centers posted about concerns around food and water, and counties in the ACP African American South posted about issues of trust, hesitancy, and history. The graying America ACP community posted about the federal government's failures; rural middle American counties posted about news press conferences. Topics related to allergic and adverse reactions, misinformation around Bill Gates and China, and issues of trust among Black Americans in the healthcare system were more prevalent in December, topics related to questions about mask wearing, reaching herd immunity and natural infection, and concerns about nursing home residents and workers increased in January, and themes around access to black communities, waiting for appointments, keeping family safe by vaccinating and fighting online misinformation campaigns were more prevalent in February. Twitter discourse around COVID-19 vaccines in the United States varied significantly across different communities and changed over time; these insights could inform targeted messaging and mitigation strategies. (c) 2021 Elsevier Ltd. All rights reserved.	[Guntuku, Sharath Chandra; Merchant, Raina M.] Univ Penn, Penn Med Ctr Digital Hlth, Philadelphia, PA 19104 USA; [Guntuku, Sharath Chandra; Sherman, Garrick] Univ Penn, Sch Engn & Appl Sci, Dept Comp & Informat Sci, Philadelphia, PA 19104 USA; [Buttenheim, Alison M.] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA; [Buttenheim, Alison M.] Univ Penn, Ctr Hlth Incent & Behav Econ, Perelman Sch Med, Philadelphia, PA 19104 USA; [Merchant, Raina M.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA; [Guntuku, Sharath Chandra; Buttenheim, Alison M.; Merchant, Raina M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA		Guntuku, SC (通讯作者)，3330 Walnut St, Philadelphia, PA 19104 USA.	sharathg@upenn.edu		Sherman, Garrick/0000-0002-2146-0706	Google CloudGoogle Incorporated	S.C.G acknowledges support from Google Cloud.	[Anonymous], 2020, KFF COVID 19 VACC MO; Blei DM, 2003, J MACH LEARN RES, V3, P993, DOI 10.1162/jmlr.2003.3.4-5.993; CDC, 2021, REP COUNT LEV COVID; Gimpel, 2011, OUR PATCHWORK NATION; Grammich C., 2012, 2010 US RELIG CENSUS; Guntuku, 2020, DETECTING EMERGING S; Guntuku SC, 2020, J GEN INTERN MED, V35, P2798, DOI 10.1007/s11606-020-05988-8; Julian T., 2011, AM COMMUNITY SURVEY; Koeze E., 2020, NEW YORK TIMES; Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Saha K, 2020, J MED INTERNET RES, V22, DOI 10.2196/22600; Schwartz HA, 2017, P 2017 C EMPIRICAL M, P55; Schwartz Hansen Andrew, 2013, P 7 INT AAAI C WEBL, P583; Sim J, COVACCS NATIONALLY R, DOI [10.1101/ 2020.08.13.20174045, DOI 10.1101/2020.08.13.20174045]; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Zampetakis LA, 2021, APPL PSYCHOL-HLTH WE, V13, P469, DOI 10.1111/aphw.12262	17	4	4	8	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4034	4038		10.1016/j.vaccine.2021.06.014		JUN 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34140171	Bronze, Green Published			2022-04-29	WOS:000672535200006
J	Stoeckel, F; Carter, C; Lyons, BA; Reifler, J				Stoeckel, Florian; Carter, Charlie; Lyons, Benjamin A.; Reifler, Jason			Association of vaccine hesitancy and immunization coverage rates in the European Union	VACCINE			English	Article						Vaccine hesitancy; Immunization coverage; European Union; Vaccination coverage; Public health policy; Surveys	CONFIDENCE; STRATEGIES; ATTITUDES; PARENTS; SCALE	While previous studies have validated vaccine hesitancy scales with uptake behavior at the individual level, the conditions under which aggregated survey data are useful are less clear. We show that vaccine public opinion data aggregated at the subnational level can serve as a valid indicator of aggregate vaccine behaviour. We use a public opinion survey (Eurobarometer EB 91.2) with data on vaccine hesitancy for the EU in 2019. We link this information to (subnational) regional immunization coverage rates for childhood vaccines - DTP3, MCV1, and MCV2 -- obtained from the WHO for 2019. We conduct multilevel regression analyses with data for 177 regions in 20 countries. Given the variation in vaccine hesitancy and immunization rates between countries and within countries, we affirm the valuable role that surveys can play as a public health surveillance tool when it comes to vaccine behavior. We find statistically significantly lower regional vaccine immunization rates in regions where vaccine hesitancy is more pronounced. Our results suggest that different uptake rates across subnational regions are due, at least in part, to differences in attitudes towards vaccines and vaccination. The results are robust to several alternative specifications. (c) 2021 Elsevier Ltd. All rights reserved.	[Stoeckel, Florian; Reifler, Jason] Univ Exeter, Exeter, Devon, England; [Carter, Charlie] London Sch Econ, London, England; [Lyons, Benjamin A.] Univ Utah, Salt Lake City, UT 84112 USA		Stoeckel, F (通讯作者)，Univ Exeter, Exeter, Devon, England.	f.stoeckel@exeter.ac.uk	Lyons, Ben/J-5323-2019; Stoeckel, Florian/ABI-7673-2020	Lyons, Ben/0000-0001-7096-900X; Carter, Charlie/0000-0003-1819-4424	British Academy [SRG20\200348]; European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programEuropean Research Council (ERC) [682758]	Florian Stoeckel reports funding from the British Academy (SRG20\200348). Jason Reifler received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 682758). We would like to thank Fionnuala Donohue at the Health Intelligence Unit Ireland, Yoann Nedelec at the World Health Organisation, and the anonymous reviewers for their thoughtful suggestions. All remaining errors are our own.	Anand S, 2007, LANCET, V369, P1277, DOI 10.1016/S0140-6736(07)60599-6; Arsenault C, 2017, VACCINE, V35, P951, DOI 10.1016/j.vaccine.2016.12.041; Bechini A, 2019, EXPERT REV VACCINES, V18, P693, DOI 10.1080/14760584.2019.1639502; Carle AC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-49; Charron N, 2017, J POLIT, V79, P89, DOI 10.1086/687209; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Downes M, 2020, BIOMETRICAL J, V62, P479, DOI 10.1002/bimj.201900023; Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041; Freed GL, 2010, PEDIATRICS, V125, P654, DOI 10.1542/peds.2009-1962; Gilkey MB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159087; Gilkey MB, 2014, VACCINE, V32, P6259, DOI 10.1016/j.vaccine.2014.09.007; Horne Z, 2015, P NATL ACAD SCI USA, V112, P10321, DOI 10.1073/pnas.1504019112; Hotez PJ, 2021, LANCET, V397, P1165, DOI 10.1016/S0140-6736(21)00372-X; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Larson H., 2018, STATE VACCINE CONFID, V10, DOI 10.2875/241099; Larson HJ, 2018, LANCET, V392, P2244, DOI 10.1016/S0140-6736(18)32608-4; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Loux T, 2019, ANN EPIDEMIOL, V39, P15, DOI 10.1016/j.annepidem.2019.09.005; Martin LR, 2017, ANN BEHAV MED, V51, P652, DOI 10.1007/s12160-017-9888-y; Mohl P, 2010, REG SCI URBAN ECON, V40, P353, DOI 10.1016/j.regsciurbeco.2010.03.005; Motta M, 2020, APSA PREPRINTS, DOI [10.33774/apsa-2020-bbpld-v2, DOI 10.33774/APSA-2020-BBPLD-V2]; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483; Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120; Rawal, 2018, STATE VACCINE CONFID, DOI [10.2875/241099, DOI 10.2875/241099]; Roberts JR, 2015, VACCINE, V33, P1748, DOI 10.1016/j.vaccine.2015.01.068; Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009; Santibanez TA, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-007609; Strelitz B, 2015, VACCINE, V33, P1802, DOI 10.1016/j.vaccine.2015.02.034; Thieren, HLTH SYSTEMS PERFORM, P265	32	1	1	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 29	2021	39	29					3935	3939		10.1016/j.vaccine.2021.05.062		JUN 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SV4EN	34116875				2022-04-29	WOS:000663773600020
J	Brewer, NT; Mitchell, CG; Dailey, SA; Hora, L; Fisher-Borne, M; Tichy, K; McCoy, T				Brewer, Noel T.; Mitchell, Chloe G.; Dailey, Susan Alton; Hora, Liddy; Fisher-Borne, Marcie; Tichy, Kim; McCoy, Timothy			HPV vaccine communication training in healthcare systems: Evaluating a train-the-trainer model	VACCINE			English	Article						Adolescent health; HPV vaccination; Healthcare system; Evaluation; Train-the-trainer; Communication	HUMAN-PAPILLOMAVIRUS VACCINATION; AGED 13-17 YEARS; UNITED-STATES; ADVISORY-COMMITTEE; SCHEDULE; COVERAGE; CANCERS	Background: Large healthcare systems provide an opportunity to disseminate evidence-based interventions to primary care. We evaluated the impact of a train-the-trainer model in two large systems to disseminate the Announcement Approach Training, which teaches providers to communicate about HPV vaccination more effectively. Methods: In collaboration with the American Cancer Society, we partnered with two midwestern healthcare systems that served over 77,000 patients ages 11 through 17. Both systems hosted a 2-hour train the-trainer workshop. Providers from one system then conducted in-person 1-hour CME-eligible trainings, using our standard slide set and script (available at hpvIQ.org). The other system did not implement trainings, providing a natural experiment. Results: The train-the-trainer workshop included physicians, nurses and other clinical staff (n = 11/13 for intervention/comparison systems). The intervention system delivered 18 trainings to 234 physicians, nurses, and other clinic staff. From baseline to 6-month follow-up, the intervention system had an increase in HPV vaccine uptake that was larger than that of the comparison system for adolescents ages 11 through 12 (1.9%, p = .002) and ages 13 through 17 (1.5%, p = .015). Attending the training was associated with increased intentions to routinely recommend HPV vaccine when patients turn 11 or 12 (mean 4.19 (SD = 0.95) vs. 4.43 (SD = 0.83) as well as increased positive vaccine attitudes, self-efficacy, and norms (all p < .001). Participant satisfaction with the trainings was high (90%-94%). Conclusion: The train-the-trainer model was effective in increasing provider motivation to recommend HPV vaccination and led to a small increase in vaccine uptake. Dissemination through large healthcare systems is promising but faces some challenges. (c) 2021 Elsevier Ltd. All rights reserved.	[Brewer, Noel T.; Mitchell, Chloe G.; Dailey, Susan Alton] Univ N Carolina, Dept Hlth Behav, Gillings Sch Global Publ Hlth, 325 Rosenau Hall, Chapel Hill, NC 27599 USA; [Brewer, Noel T.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Hora, Liddy; Fisher-Borne, Marcie] Amer Canc Soc, Atlanta, GA 30329 USA; [Tichy, Kim] Iowa Dept Publ Hlth, Iowa Immunizat Program, Des Moines, IA 50319 USA; [McCoy, Timothy] MercyOne Med Grp Cent Iowa, Des Moines, IA USA		Brewer, NT (通讯作者)，Univ N Carolina, Dept Hlth Behav, Gillings Sch Global Publ Hlth, 325 Rosenau Hall, Chapel Hill, NC 27599 USA.	ntb@unc.edu			CDC via UNC Center for Health Promotion and Disease Prevention [U48DP005017]	Funding/Support: All phases of this study were supported by CDC grant, U48DP005017 via UNC Center for Health Promotion and Disease Prevention.	[Anonymous], 2020, INCR PROP AD WHO GET; Arbyn M, 2018, EXPERT REV VACCINES, V17, P1085, DOI 10.1080/14760584.2018.1548282; Best A, 2012, MILBANK Q, V90, P421, DOI 10.1111/j.1468-0009.2012.00670.x; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764; Brewer NT, 2011, SEX TRANSM DIS, V38, P197, DOI 10.1097/OLQ.0b013e3181f12dbf; Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases National Center for Health Statistics, NAT IMM SURV US GUI; Dempsey AF, 2018, ACAD PEDIATR, V18, pS23, DOI 10.1016/j.acap.2017.09.001; Elam-Evans LD, 2020, MMWR-MORBID MORTAL W, V69, P1109, DOI 10.15585/mmwr.mm6933a1; Elam-Evans LD, 2014, MMWR-MORBID MORTAL W, V63, P625; Gilkey MB, 2015, CANCER EPIDEM BIOMAR, V24, P1673, DOI 10.1158/1055-9965.EPI-15-0326; Hawkins M, 2010, HLTH REFORM DECLINE; Kornides ML, 2018, ACAD PEDIATR, V18, pS37, DOI 10.1016/j.acap.2017.06.008; Lu PJ, 2019, J PEDIATR-US, V206, P33, DOI 10.1016/j.jpeds.2018.10.034; Malo TL, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0743-8; Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5; Opel DJ, 2018, PEDIATRICS, V142, pS149, DOI 10.1542/peds.2018-0516E; Phillips A, 2018, DRUG SAFETY, V41, P329, DOI 10.1007/s40264-017-0625-z; Reiter PL, 2013, AM J PUBLIC HEALTH, V103, P1419, DOI 10.2105/AJPH.2012.301189; Reiter PL, 2013, VACCINE, V31, P2816, DOI 10.1016/j.vaccine.2013.04.010; Robinson CL, 2017, AM J TRANSPLANT, V17, P1136, DOI 10.1111/ajt.14245; Senkomago V, 2019, MMWR-MORBID MORTAL W, V68, P724, DOI 10.15585/mmwr.mm6833a3; Shah PD, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1872; Sturm L, 2017, J ADOLESCENT HEALTH, V61, P246, DOI 10.1016/j.jadohealth.2017.02.006; Van Dyne EA, 2018, MMWR-MORBID MORTAL W, V67, P918, DOI 10.15585/mmwr.mm6733a2	25	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 23	2021	39	28					3731	3736		10.1016/j.vaccine.2021.05.038		JUN 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SS0GD	34078555				2022-04-29	WOS:000661420000010
J	Pastorino, R; Villani, L; La Milia, DI; Ieraci, R; Chini, F; Volpe, E; Barca, A; Fusco, D; Laurenti, P; Ricciardi, W; Boccia, S				Pastorino, Roberta; Villani, Leonardo; La Milia, Daniele Ignazio; Ieraci, Roberto; Chini, Francesco; Volpe, Enrico; Barca, Alessandra; Fusco, Danilo; Laurenti, Patrizia; Ricciardi, Walter; Boccia, Stefania			Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital	VACCINE			English	Article						Flu vaccination; Pneumococcal vaccination; COVID-19; Health outcomes	SEASONAL INFLUENZA; BCG VACCINATION; REDUCE; IMPACT	In order to reduce the burden on healthcare systems and to support differential diagnosis with COVID-19, influenza and pneumococcal vaccinations were strongly recommended during the COVID-19 pandemic, especially in vulnerable groups. However, no univocal and conclusive evidence on the relationship between influenza and pneumococcal vaccinations and COVID-19 outcomes exists. We evaluated the association between such vaccinations, COVID-19 hospitalization, intensive care unit admissions and deaths in a cohort (N = 741) of COVID-19 patients who had access to the emergency room of a large Italian University hospital between March 1, 2020 and June 1, 2020. Results show that influenza and pneumococcal vaccinations did not affect hospitalization, intensive care unit admission and deaths in COVID-19 patients in the overall sample and in those >65 years. The same pattern of results was confirmed considering timing of influenza vaccine administration, vaccination type, and number of uptakes in the last five vaccination campaigns. In conclusion, our study does not support an impact of influenza and pneumococcal vaccinations on COVID-19 outcomes. (c) 2021 Elsevier Ltd. All rights reserved.	[Pastorino, Roberta; Laurenti, Patrizia; Boccia, Stefania] Fdn Policlin Univ A Gemelli IRCCS, Publ Hlth Area, Dept Woman & Child Hlth & Publ Hlth, Rome, Italy; [Villani, Leonardo; La Milia, Daniele Ignazio; Laurenti, Patrizia; Ricciardi, Walter; Boccia, Stefania] Univ Cattolica Sacro Cuore, Univ Dept Life Sci & Publ Hlth, Sect Hyg, Rome, Italy; [Ieraci, Roberto] ASL Roma 1, Local Hlth Units Vaccinat Grp, Rome, Italy; [Chini, Francesco; Volpe, Enrico; Barca, Alessandra; Fusco, Danilo] Reg Directorate Hlth & Social Policy, Rome, Lazio Region, Italy		Villani, L (通讯作者)，Univ Cattolica Sacro Cuore, Dipartimento Sci Salute Donna Bambino & Sanita Pu, Largo Francesco Vito 1, I-00168 Rome, Italy.	leonardo.villani01@icatt.it	LAURENTI, Patrizia/AAB-8268-2022; PASTORINO, Roberta/AAC-1866-2022	LAURENTI, Patrizia/0000-0002-8532-0593; PASTORINO, Roberta/0000-0001-5013-0733; Villani, Leonardo/0000-0001-9375-8731	Fondazione Policlinico Universitario A. Gemelli IRCCS	We would like to thank Franziska M. Lohmeyer, PhD, Fondazione Policlinico Universitario A. Gemelli IRCCS, for her support revising our manuscript.	Amato M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030535; Cassini A, 2018, EUROSURVEILLANCE, V23, P15, DOI 10.2807/1560-7917.ES.2018.23.16.17-00454; CDC, 2021, FREQ ASK INFL FLU QU; Conlon A, 2021, AM J INFECT CONTROL, V49, P694, DOI 10.1016/j.ajic.2021.02.012; Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4; Del Riccio M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217870; Enders CK, 2017, BEHAV RES THER, V98, P4, DOI 10.1016/j.brat.2016.11.008; European Center for Desease prevention and Control (ECDC), 2020, POST INFL COVID 19 P, P19; European External Action Service, 2020, PROKR DIS COV 19 VAC; Fink G, 2020, Inactivated trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in Brazil; Goodridge HS, 2016, NAT REV IMMUNOL, V16, P392, DOI 10.1038/nri.2016.43; Huang KW, 2021, INT J ENVIRON AN CH, V101, P2835, DOI 10.1080/03067319.2020.1711898; Iacobucci G, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3720; Istituto Superiore di Sanita, 2020, Rapp ISS COVID-19, P15; Istituto superiore di Sanita, 2020, 492020 I SUP SAN; Italian Ministry of Health, 2020, FAQ INFL VACC ANT; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jaklevic MC, 2020, JAMA-J AM MED ASSOC, V324, P926, DOI 10.1001/jama.2020.15444; Jehi L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237419; Jehi L, 2020, CHEST, V158, P1364, DOI 10.1016/j.chest.2020.05.580; Maltezou HC, 2020, VACCINE, V38, P6078, DOI 10.1016/j.vaccine.2020.07.058; Marin-Hernandez D, 2021, J MED VIROL, V93, P64, DOI 10.1002/jmv.26120; Ministero della salute, 2020, DAT COP VACC; Murillo-Zamora E, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05408-6; Nelson JC, 2008, VACCINE, V26, P4947, DOI 10.1016/j.vaccine.2008.07.016; Nielsen HL, 2020, GUT, V69, P1952, DOI 10.1136/gutjnl-2019-319771; Noale M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030471; Ortiz-Prado E, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0008958; Poblador-Plou B, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17145171; Ragni P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040675; Regional Service for Epidemiology S and C of ID (SERESMI), AUT MER ALL FORM INT; Rosano A, 2019, INT J INFECT DIS, V88, P127, DOI 10.1016/j.ijid.2019.08.003; Sultana J, 2020, EXPERT REV VACCINES, V19, P919, DOI 10.1080/14760584.2020.1825951; Thindwa D, 2020, VACCINE, V38, P5398, DOI 10.1016/j.vaccine.2020.06.047; Us C. A Strong Defense Against Flu, 2017, GET VACC; Wolff GG, 2020, VACCINE, V38, P350, DOI 10.1016/j.vaccine.2019.10.005; World Health Organization, 2010, EV SEAS INFL VACC PO; World Health Organization, 2020, BAC CALM GUER BCG VA; Yitbarek K, 2020, VACCINE, V38, P6374, DOI 10.1016/j.vaccine.2020.08.018; Zanettini C, 2020, INFLUENZA VACCINATIO, P1	40	0	0	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 11	2021	39	26					3493	3497		10.1016/j.vaccine.2021.05.015		JUN 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SN6KQ	34020813	Green Published, Bronze			2022-04-29	WOS:000658397000007
J	Wilkinson, K; Righolt, CH; Elliott, LJ; Fanella, S; Mahmud, SM				Wilkinson, Krista; Righolt, Christiaan H.; Elliott, Lawrence J.; Fanella, Sergio; Mahmud, Salaheddin M.			Pertussis vaccine effectiveness and duration of protection-A systematic review and meta-analysis	VACCINE			English	Review						Bordetella pertussis; Whooping cough; Pertussis vaccine; Vaccine effectiveness; Systematic review and meta-analysis	CHILDREN; DIPHTHERIA; EFFICACY; TETANUS; SURVEILLANCE; ADOLESCENTS; POPULATION; COMPONENT; OUTBREAK; IMMUNITY	A comprehensive review of observational pertussis vaccine effectiveness (VE) studies is needed to update gaps from previous reviews. We conducted a systematic review of VE and duration of protection studies for the whole-cell (wP) and acellular (aP) pertussis vaccines and conducted a formal meta -analysis using random effects models. Evidence continues to suggest that receipt of any pertussis vac-cine confers protection in the short-term against disease although this protection wanes rapidly for aP vaccine. We detected significant heterogeneity in pooled estimates due, in part, to factors such as bias and confounding which may be mitigated by study design. Our review of possible sources of hetero-geneity may help interpretation of other VE studies and aid design decisions in future pertussis VE research. (c) 2021 Elsevier Ltd. All rights reserved.	[Wilkinson, Krista; Mahmud, Salaheddin M.] Univ Manitoba, Dept Community Hlth Sci, Vaccine & Drug Evaluat Ctr, Winnipeg, MB R3E 0T5, Canada; [Righolt, Christiaan H.; Elliott, Lawrence J.] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada; [Elliott, Lawrence J.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada; [Fanella, Sergio] Univ Manitoba, Dept Pediat Infect Dis, Winnipeg, MB, Canada		Mahmud, SM (通讯作者)，Univ Manitoba, Dept Community Hlth Sci, Vaccine & Drug Evaluat Ctr, Winnipeg, MB R3E 0T5, Canada.	Salah.Mahmud@gmail.com		Righolt, Christiaan/0000-0002-8472-932X	Research Manitoba PhD Studentship; Canada Research Chair ProgramCanada Research Chairs	KW was supported by a Research Manitoba PhD Studentship. SMM's work is supported, in part, by funding from the Canada Research Chair Program. The funders had no role in the design orconduct of the study, including but not limited to, data identification, collection, management, analysis, and interpretation, or preparation, review, or approval of the results. The opinions presented in the report do not necessarily reflect those of the funders.	ACOSTA AM, 2015, EPIDEMIOLOGY, V135, P981; Al-Tawfiq JA, 2007, J INFECTION, V55, P249, DOI 10.1016/j.jinf.2007.04.008; Althouse BM, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0382-8; Anglemyer A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000034.pub2; [Anonymous], 1998, Vaccine, V16, P818; Arciniega JL, 1998, BIOLOGICALS, V26, P195; Barlow RS, 2014, CLIN INFECT DIS, V58, P1523, DOI 10.1093/cid/ciu156; Baxter R, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4249; Bell CA, 2019, VACCINE, V37, P4140, DOI 10.1016/j.vaccine.2019.05.067; BENTSIENCHILL AD, 1997, PEDIATRICS, V15, P301; BERGER F, 2010, BMJ-BRIT MED J, V28, P5147; BISGARD KM, 2005, VACCINE, V116, pE285; BLENNOW M, 1988, VACCINE, V296, P1570; Breakwell L, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3973; BRIERE EC, 2018, PEDIATRICS, V62, P661; BROOME CV, 1981, BRIT MED J, V144, P187; Casey JR, 2005, DRUGS, V65, P1367, DOI 10.2165/00003495-200565100-00005; CDC, EPIDEMIOLOGY PREVENT; Chen CC, 2016, HUM VACC IMMUNOTHER, V12, P2536, DOI 10.1080/21645515.2016.1186313; Chit A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197970; Craig R, 2020, CLIN INFECT DIS, V70, P152, DOI 10.1093/cid/ciz531; Crowcroft NS, 2019, VACCINE, V37, P2617, DOI 10.1016/j.vaccine.2019.02.047; Crowcroft NS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195984; Crowcroft NS, 2020, CLIN INFECT DIS; DESERRES G, 2001, J INFECT DIS, V19, P3004; DESERRES G, 1996, J ADOLESCENT HEALTH, V15, P519; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fulton TR, 2016, CLIN INFECT DIS, V62, P1100, DOI 10.1093/cid/ciw051; GRECO D, 1996, PEDIATR INFECT DIS J, V334, P341; GREENLAND S, 1999, BMJ OPEN, V10, P37; Guiso N, 2020, VACCINE, V38, P1271, DOI 10.1016/j.vaccine.2019.11.022; Guris D, 1997, J INFECT DIS, V176, P456, DOI 10.1086/514064; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Haller S, 2015, PEDIATR INFECT DIS J, V34, P513, DOI 10.1097/INF.0000000000000654; HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2; HARA M, 2015, NEW ENGL J MED, V15, P45; Heininger U, 1998, PEDIATRICS, V102, P546, DOI 10.1542/peds.102.3.546; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT., 2021, COCHRANE HDB SYSTEMA; HVIID A, 2004, BMC INFECT DIS, V22, P3530; Hviid A, 2009, VACCINE, V27, P3035, DOI 10.1016/j.vaccine.2009.03.041; Jefferson T, 2003, VACCINE, V21, P2003, DOI 10.1016/S0264-410X(02)00770-3; Juretzko P, 2002, CLIN INFECT DIS, V35, P162, DOI 10.1086/341027; Kaczmarek MC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010386; Kenyon TA, 1996, PEDIATR INFECT DIS J, V15, P655, DOI 10.1097/00006454-199608000-00004; Khetsuriani N, 2001, PEDIATR INFECT DIS J, V20, P1108, DOI 10.1097/00006454-200112000-00003; Klein NP, 2017, VACCINE, V35, P3395, DOI 10.1016/j.vaccine.2017.05.008; Klein NP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3326; Koepke R, 2014, J INFECT DIS, V210, P942, DOI 10.1093/infdis/jiu322; LATASA P, 2018, PEDIATRICS, V36, P1643; Liese JG, 1997, PEDIATR INFECT DIS J, V16, P1038, DOI 10.1097/00006454-199711000-00007; Liu B, 2019, CLIN INFECT DIS OFFI; LOPALCO PL, 2015, CLIN INFECT DIS, V33, P1541; Lugauer S, 2002, EUR J PEDIATR, V161, P142, DOI 10.1007/s00431-001-0893-5; McGirr A, 2015, PEDIATRICS, V135, P331, DOI 10.1542/peds.2014-1729; MISEGADES LK, 2012, PEDIATR INFECT DIS J, V308, P2126; Mortimer EA, 1911, AM J DIS CHILD, P1990; National Advisory Committee on I, 1997, CANADA COMMUNICABLE, V23; OHFUJI S, 2015, JAMA-J AM MED ASSOC, V33, P1027; OKADA K, 2009, AM J DIS CHILD, V137, P124; ONORATO IM, 1992, JAMA-J AM MED ASSOC, V267, P2745, DOI 10.1001/jama.267.20.2745; PALMER SR, 1991, VACCINE, V66, P854; PREZIOSI MP, 2003, STAT MED, V37, P772; RAMSAY ME, 1993, COCHRANE DB SYST REV, V111, P41; RANK C, 2009, EPIDEMIOL INFECT, V28, P152; Riffelmann M, 2014, EUR J CLIN MICROBIOL, V33, P805, DOI 10.1007/s10096-013-2016-4; Salmaso S, 1998, VACCINE, V16, P1270, DOI 10.1016/S0264-410X(98)00040-1; Salmaso S, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e81; SCHMITT HJ, 1996, PEDIATR INFECT DIS J, V275, P37; Schwartz KL, 2016, CAN MED ASSOC J, V188, pE399, DOI 10.1503/cmaj.160193; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.g7647, 10.1136/bmj.b2700]; SHERIDAN SL, 2014, VACCINE, V200, P334; Stehr K, 1998, PEDIATRICS 1, V101; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; STORSAETER J, 1992, JAMA-J AM MED ASSOC, V146, P167; Tafuri S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-541; Taranger J, 1997, PEDIATR INFECT DIS J, V16, P180, DOI 10.1097/00006454-199702000-00003; TERRANELLA A, 2016, AM J DIS CHILD, V34, P2496; Torm S, 2005, SCAND J INFECT DIS, V37, P664, DOI 10.1080/00365540510044454; TROLLFORS B, 1997, VACCINE, V130, P532; van Twillert I, 2017, SCI REP-UK, V7, DOI 10.1038/srep40328; WARD JI, 2005, SCAND J INFECT DIS, V353, P1555; Wei SC, 2010, CLIN INFECT DIS, V51, P315, DOI 10.1086/653938; Wilkinson K, 2019, VACCINE, V37, P7132, DOI 10.1016/j.vaccine.2019.09.064; WOLFF G, 2015, NEW ENGL J MED, V33, P3228; World Health Organization, GLOB REG IMM PROF; Xu JW, 2019, MEDICINE, V98, DOI [10.1097/MD.0000000000015281, 10.1097/md.0000000000015281]; ZAMIR CS, 2015, CLIN INFECT DIS, V33, P2073; Zerbo O, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2018-3466; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	90	3	3	1	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAY 27	2021	39	23					3120	3130		10.1016/j.vaccine.2021.04.032		MAY 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SF2TJ	33934917				2022-04-29	WOS:000652613400003
J	Dadari, I; Higgins-Steele, A; Sharkey, A; Charlet, D; Shahabuddin, A; Nandy, R; Jackson, D				Dadari, Ibrahim; Higgins-Steele, Ariel; Sharkey, Alyssa; Charlet, Danielle; Shahabuddin, Asm; Nandy, Robin; Jackson, Debra			Pro-equity immunization and health systems strengthening strategies in select Gavi-supported countries	VACCINE			English	Article						Pro-equity strategies; Immunization coverage; Implementation bottlenecks; Health system strengthening; Zero-dose vaccination	INEQUITIES; COVERAGE; VACCINATION; ALLIANCE; NIGERIA; LENS	Background: Achieving universal immunization coverage and reaching every child with life-saving vaccines will require the implementation of pro-equity immunization strategies, especially in poorer countries. Gavi-supported countries continue to implement and report strategies that aim to address implementation challenges and improve equity. This paper summarizes the first mapping of these strategies from country reports. Methods: Thirteen Gavi-supported countries were purposively selected with emphasis on Gavi's priority countries. Following a scoping of different documents submitted to Gavi by countries, 47 Gavi Joint Appraisals (JAs) for the period 2016-2019 from the 13 selected countries were included in the mapping. We used a consolidated framework synthesized from 16 different equity and health systems frameworks, which incorporated UNICEF's coverage and equity assessment approach - an adaptation of the Tanahashi model. Using search terms, the mapping was conducted using a combination of manual search and the MAXQDA qualitative analysis tool. Pro-equity strategies meeting the inclusion criteria were identified and compiled in an Excel database, and then populated on a tableau visualization dashboard. Results: In total, 258 pro-equity strategies were implemented by the 13 sampled Gavi-supported countries between 2016 and 2019. The framework determinants of social norms, utilization, and management and coordination accounted for more than three-quarters of all pro-equity strategies implemented in these countries. The median number of strategies reported per country was 17. Afghanistan, Nigeria, and Uganda reported the highest number of strategies that we considered as pro-equity. Conclusion: Findings from this mapping can be useful in addressing equity gaps, reaching partially immunized, and `zero-dose' vaccinated children, and valuable resource for countries planning to implement pro-equity strategies, especially as immunization stakeholders reimagine immunization delivery in light of COVID-19, and as Gavi finalizes its fifth organizational strategy. Future efforts should seek to identify pro-equity strategies being implemented across additional countries, and to assess the extent to which these strategies have improved immunization coverage and equity. (C) 2021 Elsevier Ltd. All rights reserved.	[Dadari, Ibrahim] UNICEF Pacific Off, Honiara, Solomon Islands; [Dadari, Ibrahim; Higgins-Steele, Ariel; Sharkey, Alyssa; Charlet, Danielle; Shahabuddin, Asm; Nandy, Robin; Jackson, Debra] UNICEF Hlth Sect, New York, NY USA; [Jackson, Debra] Univ Western Cape, Sch Publ Hlth, Cape Town, South Africa; [Jackson, Debra] London Sch Hyg & Trop Med, London, England; [Dadari, Ibrahim] Univ S Florida, Coll Publ Hlth, Tampa, FL 33620 USA; [Charlet, Danielle] Univ Res Co LLC URC, Chevy Chase, MD USA; [Charlet, Danielle] Ctr Human Serv, Silver Spring, MD USA		Dadari, I (通讯作者)，UNICEF Pacific Off, Honiara, Solomon Islands.	idadari@unicef.org		Jackson, Debra/0000-0003-3307-632X; Dadari, Ibrahim/0000-0003-3759-6357	Gavi, the vaccine alliance; UNICEF [SC190170]	This work was conducted as part of the Implementation Research (IR) accelerator grant funding provided by Gavi, the vaccine alliance. UNICEF organizational grant code is SC190170.	Antai D, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-181; Bardenheier B, 2011, MED CARE, V49, P371, DOI 10.1097/MLR.0b013e3182054293; Boyce T, 2019, EUROSURVEILLANCE, V24, P17, DOI 10.2807/1560-7917.ES.2019.24.2.1800204; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Chopra M, 2020, B WORLD HEALTH ORGAN, V98, P146, DOI 10.2471/BLT.19.241620; Corsi DJ, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S3; Dover Douglas C, 2019, Int J Equity Health, V18, P36, DOI 10.1186/s12939-019-0935-0; Feletto M, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001711; Gandhi G, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2521-8; Gavi the Vaccine Alliance [Gavi], JOINT APPR; Gavi the Vaccine Alliance [Gavi], DISB COMM; Ghinai I, 2013, GLOB PUBLIC HEALTH, V8, P1138, DOI 10.1080/17441692.2013.859720; Goeman L, 2010, HEALTH POLICY PLANN, V25, P292, DOI 10.1093/heapol/czq002; Grundy J, 2010, HEALTH POLICY PLANN, V25, P186, DOI 10.1093/heapol/czp047; Hinman AR, 2015, VACCINE, V33, pD72, DOI 10.1016/j.vaccine.2015.09.033; Jalloh MF, 2020, HUM VACC IMMUNOTHER, V16, P1208, DOI 10.1080/21645515.2019.1661206; Joint United Nations Programme on HIV/AIDS [UNAIDS], 2010, COMB HIV PREV TAIL C; Kilbourne AM, 2006, AM J PUBLIC HEALTH, V96, P2113, DOI 10.2105/AJPH.2005.077628; Kuruvilla S, 2018, B WORLD HEALTH ORGAN, V96, P42, DOI 10.2471/BLT.17.198358; Lee K, 2009, GLOB INST, P1; Long LA, 2018, GLOB HEALTH-SCI PRAC, V6, pS41, DOI [10.9745/ghsp-d-18-00167, 10.9745/GHSP-D-18-00167]; Malande OO, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212270; Mathew JL, 2012, INDIAN PEDIATR, V49, P203, DOI 10.1007/s13312-012-0063-z; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Mugali RR, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4193-z; Musa AI, 2015, GLOBAL HLTH COMMUNIC, V1, P21, DOI [10.1080/23762004.2016.1161419., DOI 10.1080/23762004.2016.1161419]; Naimoli JF, 2009, INT J HEALTH PLAN M, V24, P3, DOI 10.1002/hpm.969; Nelson R, 2020, LANCET INFECT DIS, V20, P546, DOI 10.1016/S1473-3099(20)30304-2; O'Neill Institute for National and Global Health Law-Georgetown Law, 2019, HLTH EQ PROGR ACT IM; O'Neill J, 2014, J CLIN EPIDEMIOL, V67, P56, DOI 10.1016/j.jclinepi.2013.08.005; Okwo-Bele J, 2018, ERG DISCUSSION PAPER; Olorunsaiye CZ., 2016, GLOBAL HLTH COMMUNIC, V2, P19, DOI [10.1080/23762004.2016.1206780., DOI 10.1080/23762004.2016.1206780]; Ozawa S, 2019, VACCINE, V37, P5525, DOI 10.1016/j.vaccine.2019.06.081; Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Phillips DE, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2626-0; Saxenian H, 2011, HEALTH AFFAIR, V30, P1122, DOI 10.1377/hlthaff.2011.0332; Sheff MC, 2020, GLOBAL HEALTH ACTION, V13, DOI 10.1080/16549716.2020.1732664; Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001; TANAHASHI T, 1978, B WORLD HEALTH ORGAN, V56, P295; Tromp N, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-454; Tsai FJ, 2016, INT HEALTH, V8, P246, DOI 10.1093/inthealth/ihv063; Vujicic M, 2012, HEALTH POLICY PLANN, V27, P649, DOI 10.1093/heapol/czs012; WHO, WHO VACC PREV DIS MO; Woodward EN, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-019-0861-y; World Health Organization, 2019, IMM COV; World Health Organization, SOCIAL DETERMINANTS; World Health Organization, 2020, IMM AG 2030 GLOB STR; World Health Organization, 2010, SOCIAL DETERMINANTS; World Health Organization [WHO], 2016, TECHNICAL HDB	50	0	0	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 22	2021	39	17					2434	2444		10.1016/j.vaccine.2021.03.044		APR 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RL7KL	33781603	hybrid, Green Accepted			2022-04-29	WOS:000639147100016
J	Gkentzi, D; Aggelopoulos, K; Karatza, A; Sinopidis, X; Dimitriou, G; Fouzas, S				Gkentzi, Despoina; Aggelopoulos, Konstantinos; Karatza, Ageliki; Sinopidis, Xenophon; Dimitriou, Gabriel; Fouzas, Sotirios			Influenza vaccination among caregivers and household contacts of children with asthma	VACCINE			English	Article						Influenza vaccination; Household contacts; Children; Asthma		Data on influenza vaccination status among household contacts of asthmatic children are lacking. Our aim was to assess the influenza vaccination status of parents and caregivers of asthmatic children in the 2018-2019 season as well as to identify reasons for undervaccination. We performed a questionnaire-based survey in parents, caregivers and household contacts of 178 asthmatic children. Only the 50.6% of children were vaccinated, while in 79.8% of cases both parents were unvaccinated. More than 40% of them reported that they were unaware about the necessity of vaccination; approximately 30% stated that they were not properly advised, and the rest were concerned about influenza vaccine side effects and effectiveness. Factor analysis identified three groups: (a) influenza vaccine "believers" who were unaware that vaccination was necessary; (b) "deniers" who were less educated and with older children; (c) older and more educated vaccine "deniers". To improve influenza vaccine coverage among household contacts of asthmatic children, appropriate counseling and targeted interventions should be planned. (C) 2021 Elsevier Ltd. All rights reserved.	[Gkentzi, Despoina; Aggelopoulos, Konstantinos; Karatza, Ageliki; Sinopidis, Xenophon; Dimitriou, Gabriel; Fouzas, Sotirios] Univ Patras, Dept Pediat, Med Sch, Patras 26504, Greece		Gkentzi, D (通讯作者)，Univ Gen Hosp Patras, Patras Med Sch, Dept Pediat, Patras 26504, Greece.	gkentzid@upatras.gr	Gkentzi, D/ABH-3296-2021	Sinopidis, Xenophon/0000-0002-0878-0668			[Anonymous], SUMMARY WHO POSITION; Cho IY, 2019, J CANCER SURVIV, V13, P993, DOI 10.1007/s11764-019-00825-2; Fouzas S, 2010, PEDIATRICS, V126, pE657, DOI 10.1542/peds.2010-0849; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; Global Initiative for Asthma (GINA), 2019, ANN REPORT; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Kam K, 2013, PAED CHILD HEALT-CAN, V18, pE55, DOI 10.1093/pch/18.9.e55; King ME, 2013, MMWR-MORBID MORTAL W, V62, P973; Menec VH, 2003, CAN J PUBLIC HEALTH, V94, P59, DOI 10.1007/BF03405054; Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9; Price SA, 2019, AM J INFECT CONTROL, V47, P468, DOI 10.1016/j.ajic.2018.10.010; Rance F, 2008, Euro Surveill, V13; Santos-Sancho JM, 2013, INFECTION, V41, P465, DOI 10.1007/s15010-013-0414-2; Shen SX, 2019, CAN FAM PHYSICIAN, V65, P175; Yue X, 2018, VACCINE, V36, P7987, DOI 10.1016/j.vaccine.2018.11.001	15	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 22	2021	39	17					2331	2334		10.1016/j.vaccine.2021.03.042		APR 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RL7KL	33775437				2022-04-29	WOS:000639147100004
J	Shen, MW; Zu, J; Fairley, CK; Pagan, JA; An, L; Du, ZW; Guo, YM; Rong, LB; Xiao, YN; Zhuang, GH; Li, Y; Zhang, L				Shen, Mingwang; Zu, Jian; Fairley, Christopher K.; Pagan, Jose A.; An, Li; Du, Zhanwei; Guo, Yuming; Rong, Libin; Xiao, Yanni; Zhuang, Guihua; Li, Yan; Zhang, Lei			Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use	VACCINE			English	Article						COVID-19 vaccine; Vaccine effectiveness; Vaccine coverage; Social distancing; Face mask use		Background: Multiple candidates of COVID-19 vaccines have entered Phase III clinical trials in the United States (US). There is growing optimism that social distancing restrictions and face mask requirements could be eased with widespread vaccine adoption soon. Methods: We developed a dynamic compartmental model of COVID-19 transmission for the four most severely affected states (New York, Texas, Florida, and California). We evaluated the vaccine effectiveness and coverage required to suppress the COVID-19 epidemic in scenarios when social contact was to return to pre-pandemic levels and face mask use was reduced. Daily and cumulative COVID-19 infection and death cases from 26th January to 15th September 2020 were obtained from the Johns Hopkins University Coronavirus resource center and used for model calibration. Results: Without a vaccine (scenario 1), the spread of COVID-19 could be suppressed in these states by maintaining strict social distancing measures and face mask use levels. But relaxing social distancing restrictions to the pre-pandemic level without changing the current face mask use would lead to a new COVID-19 outbreak, resulting in 0.8-4 million infections and 15,000-240,000 deaths across these four states over the next 12 months. Under this circumstance, introducing a vaccine (scenario 2) would partially offset this negative impact even if the vaccine effectiveness and coverage are relatively low. However, if face mask use is reduced by 50% (scenario 3), a vaccine that is only 50% effective (weak vaccine) would require coverage of 55-94% to suppress the epidemic in these states. A vaccine that is 80% effective (moderate vaccine) would only require 32-57% coverage to suppress the epidemic. In contrast, if face mask usage stops completely (scenario 4), a weak vaccine would not suppress the epidemic, and further major outbreaks would occur. A moderate vaccine with coverage of 48-78% or a strong vaccine (100% effective) with coverage of 33-58% would be required to suppress the epidemic. Delaying vaccination rollout for 1-2 months would not substantially alter the epidemic trend if the current non-pharmaceutical interventions are maintained. Conclusions: The degree to which the US population can relax social distancing restrictions and face mask use will depend greatly on the effectiveness and coverage of a potential COVID-19 vaccine if future epidemics are to be prevented. Only a highly effective vaccine will enable the US population to return to life as it was before the pandemic. (C) 2021 The Authors. Published by Elsevier Ltd.	[Shen, Mingwang; Fairley, Christopher K.; Zhuang, Guihua; Zhang, Lei] Xi An Jiao Tong Univ, China Australia Joint Res Ctr Infect Dis, Sch Publ Hlth, Hlth Sci Ctr, Xian, Shaanxi, Peoples R China; [Zu, Jian; Xiao, Yanni] Xi An Jiao Tong Univ, Sch Math & Stat, Xian, Shaanxi, Peoples R China; [Fairley, Christopher K.; Zhang, Lei] Alfred Health, Melbourne Sexual Hlth Ctr, Melbourne, Vic, Australia; [Fairley, Christopher K.; Guo, Yuming; Zhang, Lei] Monash Univ, Fac Med Nursing & Hlth Sci, Cent Clin Sch, Melbourne, Vic, Australia; [Pagan, Jose A.] NYU, Sch Global Publ Hlth, Dept Publ Hlth Policy & Management, New York, NY USA; [Pagan, Jose A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [An, Li] San Diego State Univ, Ctr Complex Human Environm Syst, San Diego, CA 92182 USA; [An, Li] San Diego State Univ, Dept Geog, San Diego, CA 92182 USA; [Du, Zhanwei] Univ Texas Austin, Dept Integrat Biol, Austin, TX USA; [Rong, Libin] Univ Florida, Dept Math, Gainesville, FL 32611 USA; [Li, Yan] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA; [Li, Yan] Icahn Sch Med Mt Sinai, Dept Obstet Gynecol & Reprod Sci, New York, NY USA; [Zhang, Lei] Zhengzhou Univ, Coll Publ Hlth, Dept Epidemiol & Biostat, Zhengzhou, Henan, Peoples R China		Zhang, L (通讯作者)，Xi An Jiao Tong Univ, China Australia Joint Res Ctr Infect Dis, Sch Publ Hlth, Hlth Sci Ctr, Xian, Shaanxi, Peoples R China.; Li, Y (通讯作者)，Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA.	yan.li1@mountsinai.org; lei.zhang1@xjtu.edu.cn		Zu, Jian/0000-0003-3633-0725; Li, Yan/0000-0001-6155-0389; Guo, Yuming/0000-0002-1766-6592	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81950410639, 11801435, 11631012, 11971375]; Outstanding Young Scholars Support Program [3111500001]; Xi'an Jiaotong University Basic Research and Profession Grant [xtr022019003, xzy032020032]; Xi'an Jiaotong University Young Scholar Support Grant [YX6J004]; Bill AMP; Melinda Gates FoundationCGIAR [20200344]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2018M631134, 2020T130095ZX]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [xjh012019055, xzy032020026, xzy032020027]; Natural Science Basic Research Program of Shaanxi Province [2019JQ-187, 2019JM-273]; Xi'an Special Science and Technology Projects on Prevention and Treatment of Novel Coronavirus Penumonia Emergency [20200005YX005]; Science Foundation for COVID-19 of Xi'an Jiaotong University Health Science Center; Qinnong Bank [2008124]; Zhejiang University special scientific research fund for COVID-19 prevention and control [2020XGZX056]; Career Development Fellowships of the Australian National Health and Medical Research CouncilNational Health and Medical Research Council (NHMRC) of Australia [APP1107107, APP1163693]; National Science FoundationNational Science Foundation (NSF) [DMS-1950254]; National Heart, Lung and Blood Institute of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL141427]	This work was supported by the National Natural Science Foundation of China (81950410639 (LZ), 11801435 (MS), 11631012 (YX), 11971375 (JZ)); Outstanding Young Scholars Support Program (3111500001(LZ)); Xi'an Jiaotong University Basic Research and Profession Grant (xtr022019003(LZ), xzy032020032 (LZ)) and Xi'an Jiaotong University Young Scholar Support Grant (YX6J004 (LZ)); the Bill & Melinda Gates Foundation (20200344(LZ)); China Postdoctoral Science Foundation (2018M631134, 2020T130095ZX); the Fundamental Research Funds for the Central Universities (xjh012019055, xzy032020026, xzy032020027); Natural Science Basic Research Program of Shaanxi Province (2019JQ-187, 2019JM-273); Xi'an Special Science and Technology Projects on Prevention and Treatment of Novel Coronavirus Penumonia Emergency (20200005YX005); Science Foundation for COVID-19 of Xi'an Jiaotong University Health Science Center and Qinnong Bank (2008124); Zhejiang University special scientific research fund for COVID-19 prevention and control (2020XGZX056). YG was supported by Career Development Fellowships of the Australian National Health and Medical Research Council (numbers APP1107107 and APP1163693). Libin Rong was supported by the National Science Foundation grant DMS-1950254. Y. Li was supported by the National Heart, Lung and Blood Institute of the National Institutes of Health (R01HL141427). The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the funding institutions.	Adalja AA, 2020, JAMA-J AM MED ASSOC, V323, P1343, DOI 10.1001/jama.2020.3413; Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Bartsch SM, 2020, HLTH AFF MILLWOOD, P10; Bollyky TJ, 2020, JAMA-J AM MED ASSOC, V323, P2462, DOI 10.1001/jama.2020.6641; Bubar Kate M, 2021, medRxiv, DOI [10.1101/2020.09.08.20190629, 10.1126/science.abe6959]; Chen JT, 2021, J PUBLIC HEALTH MAN, V27, pS43, DOI 10.1097/PHH.0000000000001263; Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9; Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312; Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gayle H, 2020, NATL ACAD MED; Iboi EA, 2020, INFECT DIS MODEL, V5, P510, DOI 10.1016/j.idm.2020.07.006; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jarvis CI, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01597-8; JHU, 2020, J HOPK U COR RES CTR; Lyu W, 2020, HEALTH AFFAIR, V39, P1419, DOI 10.1377/hlthaff.2020.00818; Matrajt L, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf1374; Miller IF, 2020, NAT MED, V26, P1212, DOI 10.1038/s41591-020-0952-y; Persad G, 2020, JAMA-J AM MED ASSOC, V324, P1601, DOI 10.1001/jama.2020.18513; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Qiu Y, 2010, SCAND J IMMUNOL, V72, P425, DOI 10.1111/j.1365-3083.2010.02456.x; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Shen MW, 2021, J URBAN HEALTH, V98, P197, DOI 10.1007/s11524-021-00517-2; Shen MW, 2020, INNOVATION-AMSTERDAM, V1, DOI 10.1016/j.xinn.2020.100048; Shen MW, 2020, INT J INFECT DIS, V96, P503, DOI 10.1016/j.ijid.2020.05.019; Studdert DM, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2024274; The New York Times and Dynata, 2020, NEW YORK TIMES; Weinberger DM, 2020, JAMA INTERN MED, V180, P1336, DOI 10.1001/jamainternmed.2020.3391; Zhang JJ, 2020, SCIENCE, V368, P1481, DOI 10.1126/science.abb8001; Zhang L, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003240; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	32	28	28	10	23	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 15	2021	39	16					2295	2302		10.1016/j.vaccine.2021.02.056		APR 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QI	33771391	hybrid, Green Published, Green Submitted			2022-04-29	WOS:000637937900014
J	Steffen, CA; Henaff, L; Durupt, A; El Omeiri, N; Ndiaye, S; Batmunkh, N; Liyanage, JBL; Hasan, Q; Mosina, L; Jones, I; O'Brien, K; Hombach, J				Steffen, Christoph A.; Henaff, Louise; Durupt, Antoine; El Omeiri, Nathalie; Ndiaye, Sidy; Batmunkh, Nyambat; Liyanage, Jayantha B. L.; Hasan, Quamrul; Mosina, Liudmila; Jones, Ian; O'Brien, Katherine; Hombach, Joachim			Evidence-informed vaccination decision-making in countries: Progress, challenges and opportunities	VACCINE			English	Article						Evidence-based decision-making; National immunization technical advisory group; NITAG; Immunization programme	VACCINES; LESSONS	Countries face an increasingly complex vaccination landscape. As well as ever-changing infectious disease epidemiology, the number and diversity of vaccine-preventable diseases, vaccine products, and vaccine technologies continue to increase. To ensure that vaccination decision-making is transparent, country-owned and informed by sound scientific evidence, many countries have established national immunization technical advisory groups (NITAGs) to provide independent expert advice. The past decade has seen substantial growth in NITAG numbers and functionality, and there is now a need to consolidate this progress, by further capacity building, to ensure that NITAGs are responsive to the changing face of immunization over the next decade. (C) 2021 The Authors. Published by Elsevier Ltd.	[Steffen, Christoph A.; Henaff, Louise; Durupt, Antoine; O'Brien, Katherine; Hombach, Joachim] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland; [El Omeiri, Nathalie] WHO, Pan Amer Hlth Org, Reg Off Amer, Washington, DC USA; [Ndiaye, Sidy] WHO, Reg Off Africa, Brazzaville, Rep Congo; [Batmunkh, Nyambat] WHO, Reg Off Western Pacific, Manila, Philippines; [Liyanage, Jayantha B. L.] WHO, Reg Off South East Asia, New Delhi, India; [Hasan, Quamrul] WHO, Reg Off Eastern Mediterranean, Cairo, Egypt; [Mosina, Liudmila] WHO, Reg Off Europe, Copenhagen, Denmark; [Jones, Ian] Jinja Publishing Ltd, Bishops Stortford, England		Steffen, CA (通讯作者)，WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland.	steffenc@who.int		Batmunkh, Nyambat/0000-0002-4532-272X; Steffen, Christoph/0000-0003-0777-5047			Adjagba A, 2017, VACCINE, V35, P3007, DOI 10.1016/j.vaccine.2017.04.039; Adjagba A, 2015, VACCINE, V33, P588, DOI 10.1016/j.vaccine.2014.12.026; African Union World Health Organization., ROADM IMPL ADD DECL; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P301; [Anonymous], EU/EEA National Immunisation Technical Advisory Groups (NITAG) collaboration.; [Anonymous], SYSTEM PREQUALIFICAT; [Anonymous], DECIDE EVIDENCE DECI; [Anonymous], Strengthening immunization to achieve the goals of the global vaccine action plan; [Anonymous], DRAFT LANDSCAPE TRAC; [Anonymous], Partnership with WHO and GAVI to support Timor-Leste NITAG; Bell S, 2019, HEALTH POLICY PLANN, V34, P271, DOI 10.1093/heapol/czz027; Blau J, 2013, VACCINE, V31, P2653, DOI 10.1016/j.vaccine.2013.01.047; Dabanch J, 2019, VACCINE, V37, P4646, DOI 10.1016/j.vaccine.2019.06.069; Dawa J, 2019, VACCINE, V37, P464, DOI 10.1016/j.vaccine.2018.11.062; Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027; EURO NITAGs, GLOB HLTH PROT PROGR; Evans-Gilbert T, 2019, VACCINE, V37, P6584, DOI 10.1016/j.vaccine.2019.09.032; Field RI, 2012, VACCINE, V30, P1009, DOI 10.1016/j.vaccine.2011.12.053; Gavi The Vaccine Alliance, PHAS 5 2021 2025; German Federal Ministry of Health, GLOB REG SYST REV ST; Howard N, 2018, VACCINE, V36, P5536, DOI 10.1016/j.vaccine.2018.07.063; Howard N, 2018, HUM VACC IMMUNOTHER, V14, P1539, DOI 10.1080/21645515.2018.1444321; Jauregui B, 2015, VACCINE, V33, pA21, DOI 10.1016/j.vaccine.2014.12.080; MacDonald N, 2020, VACCINE, V38, P5364, DOI 10.1016/j.vaccine.2020.05.003; MacDonald NE, 2017, VACCINE, V35, P6925, DOI 10.1016/j.vaccine.2017.10.048; Mosina L, 2020, BUILDING IMMUNIZATIO; NITAG Resource Center, TRAIN SECT; Ozawa S, 2012, VACCINE, V31, P96, DOI 10.1016/j.vaccine.2012.10.103; SAGE Decade of Vaccines Working Group, IMM TOD NEXT DEC 201; SIVAC, COMPR NITAG EV TOOL; Top KA, 2020, VACCINE, V38, P1089, DOI 10.1016/j.vaccine.2019.11.033; Uganda National Academy Of Sciences. Uganda National Immunization Technical Advisory Group (UNITAG), PRIOR VACC INTR UNEP; van Zandvoort K, 2019, VACCINE, V37, P430, DOI 10.1016/j.vaccine.2018.11.070; WHO, GLOB VACC ACT PLAN 2; WHO, GUID DEV EV BAS VACC; WHO SAGE Roadmap For Prioritizing Uses Of COVID-19 Vaccines, SAGE ROADM PRIOR US; World Health Organization, WHO VACC POS PAP; World Health Organization, IMM AG 2020 GLOB STR; World Health Organization, 2018, NITAG SIMPL EV TOOL; World Health Organization, CONTR TEMP CHAIN CTC; World Health Organization, TRACK NEW VACC PIP; World Health Organization, **DROPPED REF**; Wu XX, 2016, ENVIRON INT, V86, P14, DOI 10.1016/j.envint.2015.09.007	43	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 8	2021	39	15					2146	2152		10.1016/j.vaccine.2021.02.055		APR 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QH	33712350	hybrid			2022-04-29	WOS:000637937500018
J	Temple, B; Nation, ML; Dai, VTT; Beissbarth, J; Bright, K; Dunne, EM; Hinds, J; Hoan, PT; Lai, JN; Nguyen, CD; Ortika, BD; Phan, TV; Thuy, HNL; Toan, NT; Uyen, DY; Satzke, C; Smith-Vaughan, H; Huu, TN; Mulholland, K				Temple, Beth; Nation, Monica Larissa; Vo Thi Trang Dai; Beissbarth, Jemima; Bright, Kathryn; Dunne, Eileen Margaret; Hinds, Jason; Pham Thi Hoan; Lai, Jana; Nguyen, Cattram Duong; Ortika, Belinda Daniela; Phan, Thanh, V; Ho Nguyen Loc Thuy; Nguyen Trong Toan; Uyen, Doan Y.; Satzke, Catherine; Smith-Vaughan, Heidi; Tran Ngoc Huu; Mulholland, Kim			Effect of a 2+1 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: Results from a randomised controlled trial in Vietnam	VACCINE			English	Article							STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL COLONIZATION; HAEMOPHILUS-INFLUENZAE; CHILDREN	Background: Pneumococcal conjugate vaccines (PCVs) generate herd protection by reducing nasopharyngeal (NP) carriage. Two PCVs, PCV10 and PCV13, have been in use for over a decade, yet there are few data comparing their impact on carriage. Here we report their effect on carriage in a 2+1 schedule, compared with each other and with unvaccinated controls. Methods: Data from four groups within a parallel, open-label randomised controlled trial in Ho Chi Minh City contribute to this article. Three groups were randomised to receive a 2+1 schedule of PCV10 (n = 250), a 2+1 schedule of PCV13 (n = 251), or two doses of PCV10 at 18 and 24 months (controls, n = 197). An additional group (n = 199) was recruited at 18 months to serve as controls from 18 to 24 months. NP swabs collected at 2, 6, 9, 12, 18, and 24 months were analysed (blinded) for pneumococcal carriage. This study aimed to determine if PCV10 and PCV13 have a differential effect on pneumococcal carriage, a secondary outcome of the trial. We also describe the serotype distribution among unvaccinated participants. Trial registration: ClinicalTrials. gov NCT01953510. Findings: Compared with unvaccinated controls, a 2+1 schedule of PCV10 reduced PCV10-type carriage by 45-62% from pre-booster through to 24 months of age, and a 2+1 schedule of PCV13 reduced PCV13-type carriage by 36-49% at 12 and 18 months of age. Compared directly with each other, there were few differences between the vaccines in their impact on carriage. Vaccine serotypes accounted for the majority of carriage in unvaccinated participants. Interpretation: Both PCV10 and PCV13 reduce the carriage of pneumococcal vaccine serotypes. The introduction of either vaccine would have the potential to generate significant herd protection in this population. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Temple, Beth] Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia; [Temple, Beth; Mulholland, Kim] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Temple, Beth; Nation, Monica Larissa; Bright, Kathryn; Dunne, Eileen Margaret; Nguyen, Cattram Duong; Ortika, Belinda Daniela; Satzke, Catherine; Mulholland, Kim] Murdoch Childrens Res Inst, Infect & Immun, Melbourne, Vic, Australia; [Vo Thi Trang Dai; Pham Thi Hoan; Phan, Thanh, V; Ho Nguyen Loc Thuy] Pasteur Inst Ho Chi Minh City, Dept Microbiol & Immunol, Ho Chi Minh City, Vietnam; [Beissbarth, Jemima; Lai, Jana; Smith-Vaughan, Heidi] Charles Darwin Univ, Menzies Sch Hlth Res, Child Hlth Div, Darwin, NT, Australia; [Dunne, Eileen Margaret; Nguyen, Cattram Duong; Satzke, Catherine] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Hinds, Jason] St Georges Univ London, Inst Infect & Immun, London, England; [Hinds, Jason] London Biosci Innovat Ctr, BUGS Biosci, London, England; [Nguyen Trong Toan; Uyen, Doan Y.; Tran Ngoc Huu] Pasteur Inst Ho Chi Minh City, Dept Dis Control & Prevent, Ho Chi Minh City, Vietnam; [Satzke, Catherine] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Dunne, Eileen Margaret] Ctr Dis Control & Prevent, Atlanta, GA USA		Mulholland, K (通讯作者)，Murdoch Childrens Res Inst, Infect & Immun Theme, Melbourne, Vic 3052, Australia.	kim.mulholland@lshtm.ac.uk	Dunne, Eileen M/M-3203-2019	Dunne, Eileen M/0000-0001-5542-0780; Nguyen, Cattram/0000-0002-0599-8645	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council (NHMRC) of Australia [566792]; Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1116833]; NHMRC Career Development FellowshipNational Health and Medical Research Council (NHMRC) of Australia [1087957]; Veski Inspiring Women Fellowship	We thank the study participants and their families, the study staff, and the laboratory staff from the Pasteur Institute of Ho Chi Minh City, the Menzies Child Health team, and the MCRI Translational Microbiology group. We acknowledge the contributions of Dang Duc Anh, Nguyen Thi Hien Anh, Dorota Borys, Jonathan Carapetis, Nguyen Thi Kieu Chinh, Nguyen Le Dang, Lam Trung Duc, Katherine Gould, Ahsan Habib, William Hausdorff, Bernard Hoet, Nguyen Huu Hung, Vu Thi Que Huong (deceased), Phan Trong Lan, Tran Thi Kim Ngan, Vo Thuy Ngoc, Peter Paradiso, Nguyen Thi Minh Phuong (deceased), Nguyen Ngo Quang, Fiona Russell, Hoang Hoa Son, and Lay Myint Yoshida. This work was supported by the National Health and Medical Research Council of Australia (grant number 566792) and the Bill & Melinda Gates Foundation (grant number OPP1116833). CS is the recipient of a NHMRC Career Development Fellowship (1087957) and a Veski Inspiring Women Fellowship. GlaxoSmithKline Biological SA donated the doses of PCV10. We also acknowledge the Victorian Government's Operational Infrastructure Support Program.	Abu Seir R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206927; Ahn JG, 2015, INFECT DIS-NOR, V47, P385, DOI 10.3109/00365548.2014.1001997; [Anonymous], 2019, Weekly Epidemiological Record, V94, P85; [Anonymous], 2017, PNEUMOCOCCAL CONJUGA; Brandileone MCD, 2019, VACCINE, V37, P5357, DOI 10.1016/j.vaccine.2019.07.043; Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027; Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06; Dunne EM, 2018, LANCET GLOB HEALTH, V6, pE1375, DOI 10.1016/S2214-109X(18)30383-8; Dunne EM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195098; Gounder PP, 2014, J INFECT DIS, V209, P1251, DOI 10.1093/infdis/jit642; Hadjipanayis A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163269; Hammitt LL, 2019, LANCET, V393, P2146, DOI 10.1016/S0140-6736(18)33005-8; Hammitt LL, 2014, LANCET GLOB HEALTH, V2, pE397, DOI 10.1016/S2214-109X(14)70224-4; Huong TTV, 2011, PEDIATR INFECT DIS J, V30, P11, DOI 10.1097/INF.0b013e3181f111a2; International Vaccine Access Center (IVAC), JOHNS HOPKINS BLOOMB; Madhi SA, 2020, EXPERT REV VACCINES, V19, P383, DOI 10.1080/14760584.2020.1750377; Manna S, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.06.031; Nguyen TKP, 2017, PAEDIATR RESPIR REV, V21, P102, DOI 10.1016/j.prrv.2016.07.004; Oligbu G, 2016, VACCINE, V34, P6126, DOI 10.1016/j.vaccine.2016.10.050; Pomat WS, 2019, CLIN INFECT DIS, V68, P1472, DOI 10.1093/cid/ciy743; Richter SS, 2008, J CLIN MICROBIOL, V46, P2184, DOI 10.1128/JCM.00461-08; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062; Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0; Short KR, 2012, MBIO, V3, DOI 10.1128/mBio.00255-12; Sigauque B, 2018, PEDIATR INFECT DIS J, V37, P1054, DOI 10.1097/INF.0000000000002134; Temple B, 2019, LANCET INFECT DIS, V19, P497, DOI 10.1016/S1473-3099(18)30734-5; Temple B, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019795; van Selm S, 2003, INFECT IMMUN, V71, P6192, DOI 10.1128/IAI.71.11.6192-6198.2003; World Bank, 2018, POPULATION TOTAL VIE	30	3	3	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 15	2021	39	16					2303	2310		10.1016/j.vaccine.2021.02.043		APR 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QI	33745731	hybrid, Green Published			2022-04-29	WOS:000637937900015
J	Williamson, SL; Gadd, E; Pillay, T; Toldi, G				Williamson, Sarah L.; Gadd, Eleanor; Pillay, Thillagavathie; Toldi, Gergely			Non-specific effects of BCG vaccination on neutrophil and lymphocyte counts of healthy neonates from a developed country	VACCINE			English	Article						Developed country; Emergency granulopoiesis; Infection; Severe combined immunodeficiency; TREC		BCG vaccination is known to reduce neonatal mortality from infections in a pathogen-agnostic manner. In this observational study we report on whether an emergency granulopoietic response is elicited in term babies from a developed country following BCG vaccination. We studied a cohort of neonates re-admitted to the hospital from home for feeding support separated into 2 groups dependent on whether they had received BCG vaccination. Clinical data including gender, weight, gestational age, method of feeding and full blood count results were retrieved retrospectively. While lymphocyte counts increase following BCG vaccination irrespective of gender and in proportion with the time elapsed after vaccination, the increase in neutrophil counts, is only observed in boys. This increase appears to be temporary. Our results confirm the presence of emergency granulopoiesis following BCG vaccination in a neonatal cohort from a developed country. However, this effect appears to be gender-specific and is present only in boys. (C) 2021 Elsevier Ltd. All rights reserved.	[Williamson, Sarah L.; Toldi, Gergely] Birmingham Womens & Childrens NHS Fdn Trust, Dept Neonatol, Birmingham, W Midlands, England; [Gadd, Eleanor] Univ Birmingham, Birmingham Med Sch, Birmingham, W Midlands, England; [Pillay, Thillagavathie] Univ Wolverhampton, Fac Sci & Engn, Wolverhampton, England; [Pillay, Thillagavathie] Univ Hosp Leicester NHS Fdn Trust, Dept Neonatol, Leicester, Leics, England; [Pillay, Thillagavathie] Univ Leicester, Dept Life Sci, Leicester, Leics, England; [Toldi, Gergely] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England		Toldi, G (通讯作者)，Birmingham Womens Hosp, Mindelsohn Way, Birmingham B15 2TG, W Midlands, England.	g.toldi@bham.ac.uk	Toldi, Gergely/AAI-2620-2020	Toldi, Gergely/0000-0003-0178-1243; Gadd, Eleanor/0000-0002-5905-2927; Pillay, Thillagavathie/0000-0002-4159-3282; Williamson, Sarah Louise/0000-0003-3163-2214			AABY P, 1993, BRIT MED J, V307, P1308, DOI 10.1136/bmj.307.6915.1308; Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240; [Anonymous], TUBERCULOSIS GREEN B; Barkai G, 2019, INFECT DIS-NOR, V51, P585, DOI 10.1080/23744235.2019.1628354; Berendsen MLT, 2020, J PEDIAT INF DIS SOC, V9, P166, DOI 10.1093/jpids/piy142; Biering-Sorensen S, 2018, J INFECT DIS, V217, P759, DOI 10.1093/infdis/jix612; Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525; Brook B, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax4517; Cailes B, 2018, ARCH DIS CHILD-FETAL, V103, pF547, DOI 10.1136/archdischild-2017-313203; de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002; Goodridge HS, 2016, NAT REV IMMUNOL, V16, P392, DOI 10.1038/nri.2016.43; Koeken VACM, 2020, J CLIN INVEST, V130, P5591, DOI 10.1172/JCI133935; Kollmann TR, 2020, SCIENCE, V368, P612, DOI 10.1126/science.aaz9447; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Lund N, 2015, CLIN INFECT DIS, V61, P1504, DOI 10.1093/cid/civ617; Lutwama F, 2014, J INFECT DIS, V209, P887, DOI 10.1093/infdis/jit570; Maheshwari A, 2014, CURR OPIN HEMATOL, V21, P43, DOI 10.1097/MOH.0000000000000010; MBRRACE-UK, 2018, PERINATAL MORTALITY; Okomo U, 2019, LANCET INFECT DIS, V19, P1219, DOI 10.1016/S1473-3099(19)30414-1; Ritz N, 2016, VACCINE, V34, P4132, DOI 10.1016/j.vaccine.2016.06.077; Saha SK, 2018, LANCET, V392, P145, DOI 10.1016/S0140-6736(18)31127-9; Schaltz-Buchholzer F, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002993; Schaltz-Buchholzer F, 2019, J INFECT DIS, V219, P624, DOI 10.1093/infdis/jiy544; Seale AC, 2014, LANCET INFECT DIS, V14, P731, DOI 10.1016/S1473-3099(14)70804-7; Stensballe LG, 2019, J PEDIAT INF DIS SOC, V8, P213, DOI 10.1093/jpids/piy029; Storgaard L, 2015, CLIN INFECT DIS, V61, P950, DOI 10.1093/cid/civ452; Velaphi SC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214077	28	4	4	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 1	2021	39	14					1887	1891		10.1016/j.vaccine.2021.02.064		MAR 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RC7NX	33750591	Green Accepted			2022-04-29	WOS:000632984100003
J	Helmkamp, LJ; Szilagyi, PG; Zimet, G; Saville, AW; Gurfinkel, D; Albertin, C; Breck, A; Vangala, S; Kempe, A				Helmkamp, Laura J.; Szilagyi, Peter G.; Zimet, Gregory; Saville, Alison W.; Gurfinkel, Dennis; Albertin, Christina; Breck, Abigail; Vangala, Sitaram; Kempe, Allison			A validated modification of the vaccine hesitancy scale for childhood, influenza and HPV vaccines	VACCINE			English	Article						Hesitancy; Vaccine Hesitancy Scale (VHS); Factor analysis; Childhood vaccines; Influenza vaccine; HPV vaccine	UNITED-STATES; PARENT ATTITUDES; IMMUNIZATION; ASSOCIATION; ADOLESCENTS; EXEMPTIONS; PERTUSSIS; ACCURACY; VALIDITY; REFUSAL	Introduction: Vaccine hesitancy contributes to outbreaks of preventable disease worldwide. The Vaccine Hesitancy Scale (VHS), developed by the international WHO SAGE Working Group, has been validated previously for measuring hesitancy towards childhood vaccines; some psychometric properties were suboptimal. Methods: We collected data using large, nationally-representative samples of parents in the U.S. We adapted the VHS items, and additional hesitancy items, to assess hesitancy towards influenza and HPV vaccines in addition to routine childhood vaccines. We then used exploratory and confirmatory factor analysis to identify latent constructs and create modified scales for childhood (VHS-child), influenza (VHS-flu) and HPV (VHS-HPV) vaccines with improved psychometric properties. Finally, we compared hesitancy scores on the VHS-child, VHS-flu, and VHS-HPV, to self-reported receipt of each vaccine category, and compared subscale scores to assess whether drivers of hesitancy differed by vaccine category. Results: 2052 parents of children <18 years old completed the VHS-child and VHS-flu while 2020 parents of adolescents completed the VHS-HPV. A two-factor structure of 'risks' and a 'lack of confidence' was found for each vaccine category. Slight modifications to the VHS improved psychometric properties. Hesitancy was strongly associated with vaccine receipt: e.g., 76% of parents not hesitant towards influenza vaccine had vaccinated their child the past season, versus 9% of hesitant parents (p < 0.0001). Subscale scores also differed significantly between vaccines: lack of confidence was greater towards influenza (Median (IQR): 2.0 (1.2, 3.3)) and HPV (2.0 (1.3, 3.0)) vaccines than childhood (1.2 (1.0, 1.8), p < 0.0001 for both) vaccines; perceived risks of HPV vaccines (2.7 (1.7, 3.7)) were greater than for childhood vaccines (2.0 (1.3, 3.0), p < 0.0001). Conclusions: Our modified VHS scales perform well psychometrically and allow for consistent measurement of the extent and reasons for hesitancy between vaccine categories. We suggest that future work use these scales to examine hesitancy towards other vaccines and to monitor hesitancy over time. (C) 2021 Elsevier Ltd. All rights reserved.	[Helmkamp, Laura J.; Saville, Alison W.; Gurfinkel, Dennis; Kempe, Allison] Univ Colorado, Adult & Child Consortium Hlth Outcomes Res & Deli, Sch Med, Aurora, CO 80045 USA; [Helmkamp, Laura J.; Saville, Alison W.; Gurfinkel, Dennis; Kempe, Allison] Childrens Hosp Colorado, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA; [Szilagyi, Peter G.; Albertin, Christina; Vangala, Sitaram] Univ Calif Los Angeles, Dept Pediat, UCLA Mattel Childrens Hosp, Los Angeles, CA 90024 USA; [Zimet, Gregory] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Breck, Abigail; Kempe, Allison] Univ Colorado, Dept Pediat, Sch Med, Aurora, CO 80045 USA		Helmkamp, LJ (通讯作者)，Univ Colorado, ACCORDS, Sch Med, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA.	Laura.Helmkamp@CUAnschutz.edu; PSzilagyi@mednet.ucla.edu; gzimet@iu.edu; Alison.saville@CUAnschutz.edu; Dennis.gurfinkel@CUAnschutz.edu; Christina.albertin@urmc.rochester.edu; Abreck@mednet.ucla.edu; SVangala@mednet.ucla.edu; Allison.kempe@childrenscolorado.org			National Institutes of Health (NIH): National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI114903]; National Institutes of Health (NIH): National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA187707]	This work was supported by the National Institutes of Health (NIH) under two awards: National Institute of Allergy and Infectious Diseases grant number R01AI114903 and National Cancer Institute grant number R01CA187707. The findings do not necessarily represent the NIH and are only the author's viewpoints.	Ahmed A, 2018, J INFECT PUBLIC HEAL, V11, P153, DOI 10.1016/j.jiph.2017.09.007; [Anonymous], 2013, Can Commun Dis Rep, V39, P1, DOI 10.14745/ccdr.v39i00a03; Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3; Attanasio L, 2014, PUBLIC HEALTH REP, V129, P237, DOI 10.1177/003335491412900305; Barskey AE, 2012, NEW ENGL J MED, V367, P1704, DOI 10.1056/NEJMoa1202865; Beavis A, 2018, J ADOLESCENT HEALTH, V63, P652, DOI 10.1016/j.jadohealth.2018.06.024; Brown C, 2011, VACCINE, V29, P9488, DOI 10.1016/j.vaccine.2011.10.023; Centers for Disease Control and Prevention, FLUVAXVIEW INFLUENZA; Centers for Disease Control & Prevention [CDC], 2019, MEASL CAS OUTBR; Chyung S.Y., 2017, PERFORMANCE IMPROVEM, V56, P15, DOI [10.1002/pfi.21727, DOI 10.1002/PFI.21727]; Division of Cancer Prevention and Control, 2019, MANY CANCERS ARE LIN; Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046; Feikin DR, 2000, JAMA-J AM MED ASSOC, V284, P3145, DOI 10.1001/jama.284.24.3145; Flannery B, 2015, MMWR-MORBID MORTAL W, V64, P10; Gilkey MB, 2014, VACCINE, V32, P6259, DOI 10.1016/j.vaccine.2014.09.007; Gilkey MB, 2013, PREV MED, V56, P202, DOI 10.1016/j.ypmed.2012.12.019; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Ijaz K, 2020, INT J HUM-COMPUT INT, V36, P1195, DOI 10.1080/10447318.2020.1726107; Imdad A, 2013, PEDIATRICS, V132, P37, DOI 10.1542/peds.2012-3449; Kempe A, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-3852; Kline RB, 2011, PRINCIPLE PRACTICE S; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Maskey R, 2018, ASIAN J SHIPPING LOG, V34, P91, DOI 10.1016/j.ajsl.2018.06.006; McRee AL, 2010, SEX TRANSM DIS, V37, P234, DOI 10.1097/OLQ.0b013e3181c37e15; Miko D, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55060282; Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017; Ojha RP, 2013, ANN EPIDEMIOL, V23, P281, DOI 10.1016/j.annepidem.2013.02.002; Omer SB, 2006, JAMA-J AM MED ASSOC, V296, P1757, DOI 10.1001/jama.296.14.1757; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483; Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115; Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Roberts JR, 2015, VACCINE, V33, P1748, DOI 10.1016/j.vaccine.2015.01.068; Ruderfer D, 2015, PEDIATR ANN, V44, pE76, DOI 10.3928/00904481-20150410-08; Schuler CL, 2014, CLIN PEDIATR, V53, P158, DOI 10.1177/0009922813504026; Shapiro GK, 2018, PREV MED, V116, P203, DOI 10.1016/j.ypmed.2018.09.017; Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043; Sherrard L, 2016, Can Commun Dis Rep, V42, P139; Shimabukuro TT, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1791; Smith PJ, 2010, PUBLIC HEALTH REP, V125, P534, DOI 10.1177/003335491012500408; Strategic Advisory Group of Experts on Immunization, 2017, 2017 ASSESSMENT REPO; Strelitz B, 2015, VACCINE, V33, P1802, DOI 10.1016/j.vaccine.2015.02.034; Szilagyi PG, 2020, VACCINE, V38, P6027, DOI 10.1016/j.vaccine.2020.06.074; Tabachnick B. G., 2007, USING MULTIVARIATE S, V5; van Sonderen E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068967; Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2; Ward JK, 2018, VACCINE, V36, P1801, DOI 10.1016/j.vaccine.2018.02.095; Wheaton B, SOCIOL METHODOL, V8, P84; World Health Organization, 2019, 10 THREATS GLOB HLTH; Zipprich Jennifer, 2012, Morbidity and Mortality Weekly Report, V61, P986	52	5	5	7	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 26	2021	39	13					1831	1839		10.1016/j.vaccine.2021.02.039		MAR 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QY9YH	33676784				2022-04-29	WOS:000630391900007
J	Nisar, MI; Ahmed, S; Jehan, F; Shahid, S; Shakoor, S; Kabir, F; Hotwani, A; Munir, S; Muhammad, S; Khalid, F; Althouse, B; Hu, H; Whitney, C; Ali, A; Zaidi, AKM; Omer, SB; Iqbal, N				Nisar, Muhammad Imran; Ahmed, Sheraz; Jehan, Fyezah; Shahid, Shahira; Shakoor, Sadia; Kabir, Furqan; Hotwani, Aneeta; Munir, Sahrish; Muhammad, Sajid; Khalid, Farah; Althouse, Benjamin; Hu, Hao; Whitney, Cynthia; Ali, Asad; Zaidi, Anita K. M.; Omer, Saad B.; Iqbal, Najeeha			Direct and indirect effect of 10 valent pneumococcal vaccine on nasopharyngeal carriage in children under 2 years of age in Matiari, Pakistan	VACCINE			English	Article						Streptococcus pneumoniae; Pneumococcal vaccines; Herd immunity; Pakistan	STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; HAEMOPHILUS-INFLUENZAE; DISEASE; SEROTYPES; POPULATION; INFECTIONS; INFANTS; BURDEN; PCV13	Background: Pakistan introduced Ten-valent pneumococcal-conjugate-vaccine PCV10 in 2012 as a 3 + 0 schedule without catch-up. Methods: Children <2 years old in Matiari, Sindh provided nasopharyngeal swabs between 2014 and 2018, which were cultured for pneumococcus and serotyped through multiplex PCR at the Aga Khan University Hospital. Carriage rates over time for Vaccine-Type (VT) and Non-VT (NVT) serotypes were used to estimate direct, indirect, total and overall effects of vaccination. Regression analysis was used to determine factors associated with VT carriage. Results: Pneumococcus was detected in 2370/3140 (75%). VT carriage decreased overall, 16.1-9.6% (p-trend <0.001); vaccinated (all 3 doses of PCV10 received) 11.3-8.1% (p-trend 0.031) and unvaccinated (no PCV10 dose received) 17.4-10.3% (p-trend 0.003) with a decline in serotypes 6B, 9V/9A and 19F. Immunization increased from 41.0% to 68.4% (p-trend 0.001). Direct effect of vaccine was 32.8% (95% CI 14.7-47.0%) and indirect effect 44.6%(95% CI 40.6-48.6%). Factors associated with decreased VT colonization were education 1-5 years (aOR 0.7, 95%CI 0.6-1.0), history of difficulty breathing (aOR 0.7, 95%CI 0.5-1.0), exposure to smoke (aOR 0.8, 95% CI 0.6-1.0), child fully immunized (aOR 0.7, 95%CI 0.5-1.0) and enrolled in 3rd (aOR 0.6, 95%CI 0.4-0.8) and 4th (aOR 0.6, 95%CI 0.5-0.9) year of the study whereas history of runny nose (aOR 1.5, 95% CI 1.2-1.9) was positively associated. Conclusions: Decrease in VT pneumococcal carriage in vaccinated and unvaccinated children indicates herd immunity. Sustained increase in vaccine coverage and close long-term surveillance is warranted. (C) 2021 The Authors. Published by Elsevier Ltd.	[Nisar, Muhammad Imran; Ahmed, Sheraz; Jehan, Fyezah; Shahid, Shahira; Kabir, Furqan; Hotwani, Aneeta; Munir, Sahrish; Muhammad, Sajid; Khalid, Farah; Ali, Asad; Zaidi, Anita K. M.; Iqbal, Najeeha] Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, Pakistan; [Shakoor, Sadia] Aga Khan Univ, Dept Pathol & Lab Med, Karachi, Pakistan; [Althouse, Benjamin; Hu, Hao; Zaidi, Anita K. M.] Bill & Melinda Gates Fdn, Seattle, WA USA; [Whitney, Cynthia] Emory Univ, Atlanta, GA 30322 USA; [Omer, Saad B.] Yale Inst Global Hlth, New Haven, CT USA		Nisar, MI (通讯作者)，Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, Pakistan.	Imran.nisar@aku.edu	Muneer, Sahrish/AAI-9216-2021	Muneer, Sahrish/0000-0002-8450-4462	Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1111303]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/L004283/1] Funding Source: UKRI	This work was supported by Bill & Melinda Gates Foundation through grant ID #OPP1111303.	Adetifa IMO, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21837-5; Ali A, 2016, PEDIAT INFECT DIS, V8, P64, DOI 10.1016/j.pid.2016.07.007; Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027; Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06; DAGLORIA CM, 2010, J CLIN MICROBIOL, V48, P1611, DOI DOI 10.1128/JCM.02243-09; Dunne EM, 2018, LANCET GLOB HEALTH, V6, pE1375, DOI 10.1016/S2214-109X(18)30383-8; Galanis I, 2016, EUR RESPIR J, V47, P1208, DOI 10.1183/13993003.01451-2015; Gavi tva, 2020, VIEW HUB REPORT GLOB; Goldblatt D, 2018, LANCET INFECT DIS, V18, P171, DOI 10.1016/S1473-3099(17)30654-0; Greenberg D, 2006, CLIN INFECT DIS, V42, P897, DOI 10.1086/500935; Hammitt LL, 2019, LANCET, V393, P2146, DOI 10.1016/S0140-6736(18)33005-8; Heinsbroek E, 2018, VACCINE, V36, P7369, DOI 10.1016/j.vaccine.2018.10.021; Jin P, 2009, J CLIN MICROBIOL, V47, P2470, DOI 10.1128/JCM.00484-09; Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348; Kim YK, 2016, INFECT CHEMOTHER, V48, P257, DOI 10.3947/ic.2016.48.4.257; Loughlin AM, 2014, PEDIATR INFECT DIS J, V33, P504, DOI 10.1097/INF.0000000000000279; Mackenzie GA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-304; McAllister DA, 2019, LANCET GLOB HEALTH, V7, pE47, DOI 10.1016/S2214-109X(18)30408-X; Neal EFG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231041; Nisar MI, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3608-5; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Owais A, 2010, TROP MED INT HEALTH, V15, P1029, DOI 10.1111/j.1365-3156.2010.02591.x; Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006; Palmu AA, 2017, PEDIATR INFECT DIS J, V36, P1193, DOI 10.1097/INF.0000000000001705; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Riaz A, 2019, INT J INFECT DIS, V80, P28, DOI 10.1016/j.ijid.2018.12.007; Rodrigues F, 2013, PEDIATR INFECT DIS J, V32, P227, DOI 10.1097/INF.0b013e31827687fc; Rudinsky SL, 2009, ACAD EMERG MED, V16, P585, DOI 10.1111/j.1553-2712.2009.00444.x; Satzke C, 2019, VACCINE, V37, P296, DOI 10.1016/j.vaccine.2018.10.077; Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062; Sigauque B, 2018, PEDIATR INFECT DIS J, V37, P1054, DOI 10.1097/INF.0000000000002134; Sigurdsson S, 2017, VACCINE, V35, P5242, DOI 10.1016/j.vaccine.2017.08.020; Silva SM, 2020, EINSTEIN-SAO PAULO, V18, DOI [10.31744/einstein_journal/2020rw4890, 10.31744/einstein_journal/2020RW4890]; Southern J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195799; Steens A, 2015, PEDIATR INFECT DIS J, V34, P875, DOI 10.1097/INF.0000000000000751; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; Usuf E, 2019, CLIN INFECT DIS, V68, P1512, DOI 10.1093/cid/ciy726; von Mollendorf C, 2019, VACCINE, V37, P4068, DOI 10.1016/j.vaccine.2019.05.078; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Weiser JN, 2010, J MOL MED, V88, P97, DOI 10.1007/s00109-009-0557-x; World Health Organisation, 2019, WEEKLY EPIDEMIOLOGIC, V94, P85	41	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1319	1327		10.1016/j.vaccine.2020.12.066		FEB 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33422379	Green Published, hybrid			2022-04-29	WOS:000618493500022
J	Hai, NM; Dung, ND; Pho, DC; Son, VT; Hoan, VN; Dan, PT; Anh, BDT; Giang, LH; Hung, PN				Nguyen Minh Hai; Nguyen Dang Dung; Dinh Cong Pho; Vu Tung Son; Vu Ngoc Hoan; Phan Tan Dan; Bui Dang The Anh; La Huong Giang; Pham Ngoc Hung			Immunogenicity, safety and reactogenicity of ROTAVAC (R) in healthy infants aged 6-8 weeks in Vietnam	VACCINE			English	Article						Rotavirus; ROTAVAC; Vaccine; Vietnam		Background: ROTAVAC (R) is derived from human 116E rotavirus (RV) neonatal strain. In this study, we evaluated the immunogenicity, safety and reactogenicity of ROTAVAC (R) in Vietnam. Method: We conducted a phase IV clinical trial in healthy infants aged 6-8 weeks using the complete regimen of ROTAVAC (R) with three doses. Serum anti-RV IgA was measured by enzyme-linked immunosorbent assay to assess the geometric mean concentration in infants who received the complete regimen of the vaccine. Results: A total of 360 participants were enrolled in this clinical trial. The mean age +/- standard deviation at enrollment was 6.9 +/- 0.6 weeks. The anti-RV IgA titer was 4.01 +/- 3.74 mg/ml pre-vaccination and substantially increased to 29.27 +/- 80.64 mg/ml post-vaccination. The value of loglgA significantly increased (p = 0.003) from 0.28 +/- 0.79 to 1.03 +/- 0.54. The proportion of participants with equal to and greater than 3-fold and 4-fold shifts in pre- to post-vaccination antibody titer (IgA) were 55.4% and 48.3%, respectively. No adverse events or serious adverse events were recorded immediately within 30 min after the administration of each dose. The most common adverse events within 14 days after each visit were fever, unusual crying and irritability. Other adverse events occurred at a low rate, and no case of intus-susception was noted. Conclusions: The complete regimen of ROTAVAC (R) demonstrated an immunological response with clinically acceptable safety profile. Post-completion of this study, ROTAVAC (R) is now a WHO-prequalified vaccine and available in Vietnam. (C) 2021 Elsevier Ltd. All rights reserved.	[Nguyen Minh Hai] Vietnam Mil Med Univ VMMU, Dept Assessment & Accreditat, Hanoi, Vietnam; [Nguyen Dang Dung] Vietnam Mil Med Univ VMMU, Dept Immunol, Hanoi, Vietnam; [Dinh Cong Pho] Vietnam Mil Med Univ, Mil Hosp 103, Dept Infect Control, Hanoi, Vietnam; [Vu Tung Son; Vu Ngoc Hoan; Bui Dang The Anh; La Huong Giang; Pham Ngoc Hung] Vietnam Mil Med Univ, Dept Epidemiol, Hanoi, Vietnam; [Phan Tan Dan] Vietnam Mil Med Dept, Dept Prevent Med, Hanoi, Vietnam; [Pham Ngoc Hung] Vietnam Mil Med Univ, Dept Training, Hanoi, Vietnam		Hung, PN (通讯作者)，Vietnam Mil Med Univ, 160 Phung Hung, Hanoi 100000, Vietnam.	pnhungqy@vmmu.edu.vn			Institute of Clinical Research and Clinical trial support for Vaccine and Biological Products (ICCVB)	This work was supported by Institute of Clinical Research and Clinical trial support for Vaccine and Biological Products (ICCVB).	Ali A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127622; [Anonymous], 2009, Wkly Epidemiol Rec, V84, P533; Appaiahgari MB, 2014, VACCINE, V32, P651, DOI 10.1016/j.vaccine.2013.12.017; Armah GE, 2019, J INFECT DIS, V219, P746, DOI 10.1093/infdis/jiy573; Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6; Baker JM, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1003005; Becker-Dreps S, 2015, PEDIATR INFECT DIS J, V34, P115, DOI 10.1097/INF.0000000000000481; BHAN MK, 1993, J INFECT DIS, V168, P282, DOI 10.1093/infdis/168.2.282; Bhandari N, 2014, VACCINE, V32, pA110, DOI 10.1016/j.vaccine.2014.04.079; Bhandari N, 2014, LANCET, V383, P2136, DOI 10.1016/S0140-6736(13)62630-6; Brunet JP, 2000, J VIROL, V74, P2323, DOI 10.1128/JVI.74.5.2323-2332.2000; Chan J, 2011, VACCINE, V29, P1242, DOI 10.1016/j.vaccine.2010.11.087; Chilengi R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150100; Church JA, 2019, PEDIATR INFECT DIS J, V38, P1242, DOI 10.1097/INF.0000000000002485; Cowley D, 2019, VACCINE, V37, P7233, DOI 10.1016/j.vaccine.2019.09.071; Anh DD, 2012, VACCINE, V30, pA114, DOI 10.1016/j.vaccine.2011.07.118; Ella R, 2018, HUM VACC IMMUNOTHER, V14, P1791, DOI 10.1080/21645515.2018.1450709; Emperador DM, 2016, CLIN INFECT DIS, V62, P150, DOI 10.1093/cid/civ807; Glass RI, 2014, J INFECTION, V68, pS9, DOI 10.1016/j.jinf.2013.09.010; Greenberg HB, 2009, GASTROENTEROLOGY, V136, P1939, DOI 10.1053/j.gastro.2009.02.076; Halder P., 2016, 12 INT ROTAV S MELBO; Harris VC, 2018, CELL HOST MICROBE, V24, P197, DOI 10.1016/j.chom.2018.07.005; Harris VC, 2017, J INFECT DIS, V215, P34, DOI 10.1093/infdis/jiw518; Isanaka S, 2017, NEW ENGL J MED, V376, P1121, DOI [10.1056/nejmoa1609462, 10.1056/NEJMoa1609462]; John J, 2014, VACCINE, V32, pA104, DOI 10.1016/j.vaccine.2014.03.036; John TJ, 2015, INDIAN PEDIATR, V52, P906; Kazi AM, 2017, J INFECT DIS, V215, P786, DOI 10.1093/infdis/jix028; Kim SY, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-29; Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014; Lazarus RP, 2018, VACCINE, V36, P273, DOI 10.1016/j.vaccine.2017.07.116; Levin MJ, 2017, AIDS, V31, P49, DOI 10.1097/QAD.0000000000001258; Li RC, 2016, HUM VACC IMMUNOTHER, V12, P785, DOI 10.1080/21645515.2015.1085143; Loughlin J, 2012, PEDIATR INFECT DIS J, V31, P292, DOI 10.1097/INF.0b013e3182421390; MacLennan CA, 2014, P NATL ACAD SCI USA, V111, P12307, DOI 10.1073/pnas.1400473111; Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797; McGrath EJ, 2014, J PEDIATR GASTR NUTR, V59, P44, DOI 10.1097/MPG.0000000000000361; Moon SS, 2016, CLIN INFECT DIS, V62, P157, DOI 10.1093/cid/civ828; Praharaj I, 2019, CLIN INFECT DIS, V69, P243, DOI 10.1093/cid/ciy896; Riewpaiboon A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3458-2; Rogawski ET, 2018, J INFECT DIS, V217, P861, DOI 10.1093/infdis/jix668; Rongsen-Chandola T, 2014, VACCINE, V32, pA134, DOI 10.1016/j.vaccine.2014.04.078; Rongsen-Chandola T, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-256; Shin S, 2012, VACCINE, V30, pA106, DOI 10.1016/j.vaccine.2011.11.091; Steele AD, 2010, VACCINE, V28, P6542, DOI 10.1016/j.vaccine.2008.08.034; Steele AD, 2011, PEDIATR INFECT DIS J, V30, P125, DOI 10.1097/INF.0b013e3181f42db9; Taniuchi M, 2016, VACCINE, V34, P3068, DOI 10.1016/j.vaccine.2016.04.080; Tregnaghi MW, 2011, PEDIATR INFECT DIS J, V30, pE103, DOI 10.1097/INF.0b013e3182138278; Uprety P, 2017, J INFECT DIS, V215, P928, DOI 10.1093/infdis/jix060; Vesikari T, 2012, PEDIATR INFECT DIS J, V31, P509, DOI 10.1097/INF.0b013e3182489cac; Yin HC, 2017, HUM VACC IMMUNOTHER, V13, P1136, DOI 10.1080/21645515.2016.1267082	50	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 12	2021	39	7					1140	1147		10.1016/j.vaccine.2020.12.086		FEB 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QC9HH	33461837				2022-04-29	WOS:000615141100019
J	Banadyha, N; Rogalskyy, I; Komorovsky, R				Banadyha, Nataliya; Rogalskyy, Igor; Komorovsky, Roman			Reply to 'Could the cause of Kawasaki disease be other triggers besides immunization?'	VACCINE			English	Letter									[Banadyha, Nataliya; Rogalskyy, Igor] I Horbachevsky Ternopil Natl Med Univ, Dept Pediat, Inst Postgrad Educ, Ternopol, Ukraine; [Komorovsky, Roman] I Horbachevsky Ternopil Natl Med Univ, Dept Internal Med 2, Ternopol, Ukraine; [Komorovsky, Roman] Multysono Med Ctr, Echocardiog Lab, Ternopol, Ukraine		Komorovsky, R (通讯作者)，TNMU, Majdan Voli 1, UA-46001 Ternopol, Ukraine.	komorovsky@tdmu.edu.ua	Komorovsky, Roman/J-8665-2014	Komorovsky, Roman/0000-0002-0288-4132			Banadyha N, 2020, VACCINE, V38, P6656, DOI 10.1016/j.vaccine.2020.07.057; Phuong LK, 2016, VACCINE, V34, P6582, DOI 10.1016/j.vaccine.2016.09.025; Poland GA, 2013, VACCINE, V31, P4465, DOI 10.1016/j.vaccine.2013.07.017; Takahashi M., 2017, KAWASAKI DISEASE, P23, DOI [10.1007/978-4-431-56039-5_4., DOI 10.1007/978-4-431-56039-5_4]; World Health Organization, 2019, ADV EV FOLL IMM AEFI	5	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					645	645		10.1016/j.vaccine.2020.12.028		JAN 2021	1	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PR1FI	33446368				2022-04-29	WOS:000606987100005
J	Suau, R; Vidal, M; Aguilar, R; Ruiz-Olalla, G; Vazquez-Santiago, M; Jairoce, C; Nhabomba, AJ; Ben Gyan; Dosoo, D; Asante, KP; Owusu-Agyei, S; Campo, JJ; Izquierdo, L; Cavanagh, D; Coppel, RL; Chauhan, V; Angov, E; Dutta, S; Gaur, D; Beeson, JG; Moncunill, G; Dobano, C				Suau, Roger; Vidal, Marta; Aguilar, Ruth; Ruiz-Olalla, Gemma; Vazquez-Santiago, Miquel; Jairoce, Chenjerai; Nhabomba, Augusto J.; Ben Gyan; Dosoo, David; Asante, Kwaku Poku; Owusu-Agyei, Seth; Campo, Joseph J.; Izquierdo, Luis; Cavanagh, David; Coppel, Ross L.; Chauhan, Virander; Angov, Evelina; Dutta, Sheetij; Gaur, Deepak; Beeson, James G.; Moncunill, Gemma; Dobano, Carlota			RTS,S/AS01(E) malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial	VACCINE			English	Article						IgA; RTS, S vaccine; IgG; African children; Plasmodium falciparum; Malaria.	PLASMODIUM-FALCIPARUM; IMMUNOGLOBULIN-A; IMMUNE-RESPONSE; ANTIBODIES; PROTECTION; PROTEIN; IDENTIFICATION; PNEUMONIAE; SUBCLASSES; EFFICACY	Background: The evaluation of immune responses to RTS,S/AS01 has traditionally focused on immunoglobulin (Ig) G antibodies that are only moderately associated with protection. The role of other antibody isotypes that could also contribute to vaccine efficacy remains unclear. Here we investigated whether RTS,S/AS01(E) elicits antigen-specific serum IgA antibodies to the vaccine and other malaria antigens, and we explored their association with protection. Methods: Ninety-five children (age 5-17 months old at first vaccination) from the RTS,S/AS01(E) phase 3 clinical trial who received 3 doses of RTS,S/AS01(E) or a comparator vaccine were selected for IgA quantification 1 month post primary immunization. Two sites with different malaria transmission intensities (MTI) and clinical malaria cases and controls, were included. Measurements of IgA against different constructs of the circumsporozoite protein (CSP) vaccine antigen and 16 vaccine-unrelated Plasmodium falciparum antigens were performed using a quantitative suspension array assay. Results: RTS,S vaccination induced a 1.2 to 2-fold increase in levels of serum/plasma IgA antibodies to all CSP constructs, which was not observed upon immunization with a comparator vaccine. The IgA response against 13 out of 16 vaccine-unrelated P. falciparum antigens also increased after vaccination, and levels were higher in recipients of RTS,S than in comparators. IgA levels to malaria antigens before vaccination were more elevated in the high MTI than the low MTI site. No statistically significant association of IgA with protection was found in exploratory analyses. Conclusions: RTS,S/AS01(E) induces IgA responses in peripheral blood against CSP vaccine antigens and other P. falciparum vaccine-unrelated antigens, similar to what we previously showed for IgG responses. Collectively, data warrant further investigation of the potential contribution of vaccine-induced IgA responses to efficacy and any possible interplay, either synergistic or antagonistic, with protective IgG, as identifying mediators of protection by RTS,S/AS01(E) immunization is necessary for the design of improved second-generation vaccines. (C) 2020 Elsevier Ltd. All rights reserved.	[Suau, Roger; Vidal, Marta; Aguilar, Ruth; Ruiz-Olalla, Gemma; Vazquez-Santiago, Miquel; Jairoce, Chenjerai; Campo, Joseph J.; Izquierdo, Luis; Moncunill, Gemma; Dobano, Carlota] Univ Barcelona, Hosp Clin, ISGlobal, Carrer Rossello 153 CEK Bldg, E-08036 Barcelona, Catalonia, Spain; [Jairoce, Chenjerai; Nhabomba, Augusto J.; Moncunill, Gemma; Dobano, Carlota] Ctr Invest Saude Manhica CISM, Rua 12, Maputo 1929, Mozambique; [Ben Gyan] Univ Ghana, Noguchi Mem Inst Med Res, Accra, Ghana; [Dosoo, David; Asante, Kwaku Poku; Owusu-Agyei, Seth] Kintampo Hlth Res Ctr, Kintampo, Ghana; [Owusu-Agyei, Seth] London Sch Hyg & Trop Med, Dis Control Dept, London, England; [Cavanagh, David] Univ Edinburgh, Inst Immunol & Infect Res, Sch Biol Sci, Kings Bldg, Edinburgh, Midlothian, Scotland; [Cavanagh, David] Univ Edinburgh, Ctr Immun Infect & Evolut, Sch Biol Sci, Ashworth Labs, Kings Bldg, Edinburgh, Midlothian, Scotland; [Coppel, Ross L.] Monash Univ, Monash Biomed Discovery Inst, Infect & Immun Program, Melbourne, Vic, Australia; [Coppel, Ross L.] Monash Univ, Dept Microbiol, Melbourne, Vic, Australia; [Chauhan, Virander; Gaur, Deepak] Int Ctr Genet Engn & Biotechnol ICGEB, Malaria Grp, New Delhi, India; [Angov, Evelina; Dutta, Sheetij] Walter Reed Army Inst Res WRAIR, US Mil Malaria Vaccine Program, Silver Spring, MD USA; [Gaur, Deepak] Jawaharlal Nehru Univ, Sch Biotechnol, Lab Malaria & Vaccine Res, New Delhi, India; [Beeson, James G.] Burnet Inst, Melbourne, Vic, Australia; [Beeson, James G.] Monash Univ, Cent Clin Sch, Clayton, Vic, Australia; [Beeson, James G.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia		Moncunill, G; Dobano, C (通讯作者)，Univ Barcelona, Hosp Clin, ISGlobal, Carrer Rossello 153 CEK Bldg, E-08036 Barcelona, Catalonia, Spain.	rsuau@igtp.cat; marta.vidal@isglobal.org; ruth.aguilar@isglobal.org; gemma.ruizolalla@isglobal.org; miquel.vazquez@isglobal.org; chenjerai.jairoce@manhica.net; BGyan@noguchi.ug.edu.gh; david.dosoo@kintampo-hrc.org; kwakupoku.asante@kintampo-hrc.org; jcampo@antigendiscovery.com; luis.izquierdo@isglobal.org; david.cavanagh@ed.ac.uk; Ross.Coppel@monash.edu; evelina.angov.civ@mail.mil; sheetij.dutta.civ@mail.mil; beeson@burnet.edu.au; gemma.moncunill@isglobal.org; carlota.dobano@isglobal.org	Ruiz-Olalla, Gemma/AHA-6939-2022; Aguilar, Ruth/D-2147-2018; Jairoce, Chenjerai/AAD-3231-2020; Dobaño, Carlota/N-4119-2014; Cavanagh, David R/A-1828-2008; Izquierdo, Luis/L-9291-2015; Moncunill, Gemma/B-7989-2011	Ruiz-Olalla, Gemma/0000-0002-7393-888X; Aguilar, Ruth/0000-0003-3277-3107; Jairoce, Chenjerai/0000-0001-6060-8673; Dobaño, Carlota/0000-0002-6751-4060; Izquierdo, Luis/0000-0002-3704-9874; Moncunill, Gemma/0000-0001-5105-9836; Vidal Costa, Marta/0000-0001-6891-7032; Vazquez-Santiago, Miquel/0000-0002-9432-4297; Asante, Kwaku Poku/0000-0001-9158-351X	NIH-NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI095789]; PATH Malaria Vaccine Initiative (MVI); Ministerio de Economia y Competitividad (Instituto de Salud Carlos III)Spanish Government [PI11/00423, PI17/02044]; Department of Health, Catalan Government [SLT006/17/00109]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council (NHMRC) of Australia [1077636]; Fundacion Ramon Areces; Spanish Ministry of Science and InnovationSpanish Government [CEX2018-000806-S]; Generalitat de Catalunya through the CERCA Program	Funding was obtained from the NIH-NIAID (R01AI095789), PATH Malaria Vaccine Initiative (MVI), Ministerio de Economia y Competitividad (Instituto de Salud Carlos III, PI11/00423 and PI17/02044). GM had the support of the Department of Health, Catalan Government (SLT006/17/00109). JGB was supported by a Senior Research Fellowship of the National Health and Medical Research Council of Australia (1077636). This research is part of the ISGlobal's Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundacion Ramon Areces. We acknowledge support from the Spanish Ministry of Science and Innovation through the ``Centro de Excelencia Severo Ochoa 2019-2023"Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.	Abd-Alla Mohamed D, 2013, J Egypt Soc Parasitol, V43, P723; Minsoko PA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001685; Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Aguilar R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28325-w; Murata FHA, 2016, REV SOC BRAS MED TRO, V49, P512, DOI 10.1590/0037-8682-0046-2016; ARDESHIR F, 1990, MOL BIOCHEM PARASIT, V40, P113, DOI 10.1016/0166-6851(90)90085-Z; Ballou WR, 2013, VACCINES, P1133, DOI [10.1016/B978-1-4557-0090-5.00056-2, DOI 10.1016/B978-1-4557-0090-5.00056-2]; Balu S, 2011, J IMMUNOL, V186, P3113, DOI 10.4049/jimmunol.1003189; BISWAS S, 1990, Indian Journal of Malariology, V27, P139; BISWAS S, 1995, J BIOSCIENCE, V20, P453, DOI 10.1007/BF02703849; Biswas S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107903; Black CG, 1999, INFECT IMMUN, V67, P2075, DOI 10.1128/IAI.67.5.2075-2081.1999; Boross P, 2013, EMBO MOL MED, V5, P1213, DOI 10.1002/emmm.201201929; Bortnick A, 2013, J IMMUNOL, V190, P5913, DOI 10.4049/jimmunol.1300161; Boyle MJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax4489; Breedveld A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00553; Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Crompton PD, 2014, ANNU REV IMMUNOL, V32, P157, DOI 10.1146/annurev-immunol-032713-120220; Deore S, 2019, MOL BIOL REP, V46, P3801, DOI 10.1007/s11033-019-04822-7; Dobano C, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1378-6; Dobano C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10195-z; Dobano C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00439; Doolan DL, 1996, J BIOL CHEM, V271, P17861, DOI 10.1074/jbc.271.30.17861; Dunachie SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012557; Espinosa DA, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00498-16; Feng NG, 2002, J CLIN INVEST, V109, P1203, DOI 10.1172/JCI200214397; Galatas B, 2016, TRENDS PARASITOL, V32, P296, DOI 10.1016/j.pt.2015.11.015; Guinovart C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005165; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hellwig SMM, 2001, INFECT IMMUN, V69, P4846, DOI 10.1128/IAI.69.8.4846-4850.2001; Hill DL, 2017, INT J PARASITOL, V47, P585, DOI 10.1016/j.ijpara.2017.05.004; Hill DL, 2016, INFECT IMMUN, V84, P2175, DOI 10.1128/IAI.00145-16; Imam M, 2014, J BIOL CHEM, V289, P3856, DOI 10.1074/jbc.M113.520239; Janoff EN, 1999, J CLIN INVEST, V104, P1139, DOI 10.1172/JCI6310; JAUHIAINEN T, 1994, J CLIN MICROBIOL, V32, P839, DOI 10.1128/JCM.32.3.839-840.1994; John CC, 2004, INFECT IMMUN, V72, P5135, DOI 10.1128/IAI.72.9.5135-5142.2004; Kazmin D, 2017, P NATL ACAD SCI USA, V114, P2425, DOI 10.1073/pnas.1621489114; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; Kleinschnitz C, 2007, CIRCULATION, V115, P2323, DOI 10.1161/CIRCULATIONAHA.107.691279; Kolodny N, 2001, J CHROMATOGR B, V762, P77, DOI 10.1016/S0378-4347(01)00340-1; Kumsiri R, 2010, ACTA TROP, V116, P217, DOI 10.1016/j.actatropica.2010.08.012; Kurtovic L, 2021, J INFECT DIS, V224, P1128, DOI 10.1093/infdis/jiaa144; Kurtovic L, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1277-x; Lee DH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161231; Leher H, 1999, EXP EYE RES, V69, P75, DOI 10.1006/exer.1999.0678; Leoratti FMS, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-186; Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394; Musumeci M, 2003, CYTOKINE, V21, P172, DOI 10.1016/S1043-4666(03)00049-8; Nielsen CM, 2018, VACCINE, V36, P1637, DOI 10.1016/j.vaccine.2018.01.069; Olotu A, 2016, NEW ENGL J MED, V374, P2519, DOI 10.1056/NEJMoa1515257; Omer FM, 2000, PARASITOL TODAY, V16, P18, DOI 10.1016/S0169-4758(99)01562-8; Padoan A, 2020, CLIN CHIM ACTA, V507, P164, DOI 10.1016/j.cca.2020.04.026; Perlmann P, 2000, AM J TROP MED HYG, V62, P373, DOI 10.4269/ajtmh.2000.62.373; Persson KEM, 2013, J IMMUNOL, V191, P785, DOI 10.4049/jimmunol.1300444; Pleass RJ, 2009, PARASITE IMMUNOL, V31, P529, DOI 10.1111/j.1365-3024.2009.01101.x; Reddy KS, 2014, INFECT IMMUN, V82, P152, DOI 10.1128/IAI.00970-13; Reiling L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045253; Reiling L, 2010, J IMMUNOL, V185, P6157, DOI 10.4049/jimmunol.1001555; Rivera V, 2001, CAN J MICROBIOL, V47, P464, DOI 10.1139/cjm-47-5-464; Rong S., 2018, LANG ENV STAT COMP, V176; Shi JF, 2011, BMC CANCER, V11, DOI [10.1186/1471-2407-11-239, 10.1186/1472-6750-11-77]; Sirima SB, 2017, VACCINE, V35, P6218, DOI 10.1016/j.vaccine.2017.09.027; Suscovich TJ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb4757; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Ubillos I, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1186-4; Vidal M, 2018, J IMMUNOL METHODS, V455, P41, DOI 10.1016/j.jim.2018.01.009; Vidarsson G, 2001, J IMMUNOL, V166, P6250, DOI 10.4049/jimmunol.166.10.6250; Wang HL, 2016, PARASITE, V23, DOI 10.1051/parasite/2016012; White MT, 2015, LANCET INFECT DIS, V15, P1450, DOI 10.1016/S1473-3099(15)00239-X; WHO, 2010, WORLD MALARIA REPORT 2010, P1; Woof JM, 2006, J PATHOL, V208, P270, DOI 10.1002/path.1877; Yilmaz B, 2014, CELL, V159, P1277, DOI 10.1016/j.cell.2014.10.053; Yu HQ, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01526-2020	74	2	2	5	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 22	2021	39	4					687	698		10.1016/j.vaccine.2020.12.038		JAN 2021	12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PR1FI	33358704	Green Submitted			2022-04-29	WOS:000606987100012
J	Wenzel, NS; Atkins, KE; van Leeuwen, E; Halloran, ME; Baguelin, M				Wenzel, Natasha S.; Atkins, Katherine E.; van Leeuwen, Edwin; Halloran, M. Elizabeth; Baguelin, Marc			Cost-effectiveness of live-attenuated influenza vaccination among school-age children	VACCINE			English	Article						Seasonal influenza; Paediatric vaccination; Mathematical model; Cost-effectiveness analysis; Influenza; Children; Adolescents	UNITED-KINGDOM; ENGLAND; WALES; SCHOOLCHILDREN; HEALTH; END	The current pediatric vaccination program in England and Wales administers Live-Attenuated Influenza Vaccine (LAIV) to children ages 2-16 years old. Annual administration of LAIV to this age group is costly and poses substantial logistical issues. This study aims to evaluate the cost-effectiveness of prioritizing vaccination to age groups within the 2-16 year old age range to mitigate the operational and resource challenges of the current strategy. We performed economic evaluations comparing the influenza vaccination program from 1995-2013 to seven alternative strategies targeted at low risk individuals along the school age divisions Preschool (2-4 years old), Primary school (5-11 years old), and Secondary school (12-16 years old). These extensions are evaluated incrementally on the status quo scenario (vaccinating subgroups at high risk of influenza-related complications and individuals 65+ years old). Impact of vaccination was assessed using a transmission model from a previously published study and updated with new data. At all levels of coverage, all strategies had a 100% probability of being cost-effective at the current National Health Service threshold, 20,000 pound/QALY gained. The incremental analysis demonstrated vaccinating Primary School children was the most cost-efficient strategy compared incrementally against others with an Incremental Cost-Effectiveness Ratio of 639 pound spent per QALY gained (Net Benefit: 404 M pound [155, 795]). When coverage was varied between 30%, 55%, and 70% strategies which included Primary school children had a higher probability of being cost-effective at lower willingness-to-pay levels. Although children were the vaccine target the majority of QALY gains occurred in the 25-44 years old and 65+ age groups. Influenza strain A/H3N2 incurred the greatest costs and QALYs lost regardless of which strategy was used. Improvement could be made to the current LAIV pediatric vaccination strategy by eliminating vaccination of 2-4 year olds and focusing on school-based delivery to Primary and Secondary school children in tandem. (C) 2020 Published by Elsevier Ltd.	[Wenzel, Natasha S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Atkins, Katherine E.] Univ Edinburgh, Edinburgh Med Sch, Usher Inst Populat Hlth Sci & Informat, Ctr Global Hlth, Edinburgh EH8 9AG, Midlothian, Scotland; [Atkins, Katherine E.; Baguelin, Marc] London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, London WC1E 7HT, England; [Atkins, Katherine E.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England; [van Leeuwen, Edwin] Publ Hlth England, Natl Infect Serv, London NW9 5EQ, England; [Wenzel, Natasha S.; Halloran, M. Elizabeth] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1100 Fairview Ave N,Mail Stop M2-C200, Seattle, WA 98109 USA; [Halloran, M. Elizabeth] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Baguelin, Marc] Publ Hlth England, Resp Dis Dept, London NW9 5EQ, England; [Baguelin, Marc] Imperial Coll London, Sch Publ Hlth, Infect Dis Epidemiol, London SW7 2AZ, England		Wenzel, NS (通讯作者)，Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1100 Fairview Ave N,Mail Stop M2-C200, Seattle, WA 98109 USA.	nwenzel@uw.edu					[Anonymous], 2015, AGENDA CHANGE PAY RA; [Anonymous], 2018, 201819 NAT HLTH SERV; [Anonymous], 2014, DEV NICE GUID MAN, VPMG20, P121; [Anonymous], 2016, EXT INFL IMM PROGR C; Atkins K, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009739; Baguelin M, 2017, FLUEVIDENCESYNTHESIS; Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527; Baguelin M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0452-y; Baguelin M, 2012, VACCINE, V30, P3459, DOI 10.1016/j.vaccine.2012.03.019; Basta NE, 2009, AM J EPIDEMIOL, V170, P679, DOI 10.1093/aje/kwp237; Briggs A, 2006, DECISION MODELLING H; C R., 2013, R LANG ENV STAT COMP; Correa A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011092; Cromer D, 2014, J INFECTION, V68, P363, DOI 10.1016/j.jinf.2013.11.013; Curtis LA, 2019, UNIT COSTS HLTH SOCI; Demicheli V, 2018, COCHRANE DATABASE SY; Fitzjohn, 2019, ODIN ODE GENERATION; Gelman A, 1996, Stat Methods Med Res, V5, P339, DOI 10.1177/096228029600500402; Health Protection Agency, 2008, Q VACC COV DAT TABL; Hodgson D, 2017, LANCET PUBLIC HEALTH, V2, pE74, DOI 10.1016/S2468-2667(16)30044-5; Joseph C, 2005, J PUBLIC HEALTH-UK, V27, P371, DOI 10.1093/pubmed/fdi054; Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736; King A., 2019, CPIH ANN RATE ALL IT; Longini IM, 2005, AM J EPIDEMIOL, V161, P303, DOI 10.1093/aje/kwi053; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; NHS England/PH Commissioning, 2018, FLU VACC PROGR DEL 2; Nikolay Balov SS, STATA BLOG GELMAN RU; Pebody R, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES.2015.20.36.30013; Pebody RG, 2014, EURO SURVEILL, V19; Pebody R, 2017, EUROSURVEILLANCE, V22, P10, DOI 10.2807/1560-7917.ES.2017.22.44.17-00306; Pebody R, 2018, ARCH DIS CHILD, V103, P101, DOI 10.1136/archdischild-2016-312165; Pitman RJ, 2013, VACCINE, V31, P927, DOI 10.1016/j.vaccine.2012.12.010; Rajaram S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186739; Ramsay M, 2018, IMMUNISATION INFECT; Reichert TA, 2001, NEW ENGL J MED, V344, P889, DOI 10.1056/NEJM200103223441204; Thommes EW, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1193-4; van Leeuwen E, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005838	37	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 8	2021	39	2					447	456		10.1016/j.vaccine.2020.10.007			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PN8VM	33280855				2022-04-29	WOS:000604750300036
J	Hosangadi, D; Martin, EK; Watson, M; Bruns, R; Connell, N				Hosangadi, Divya; Martin, Elena K.; Watson, Matthew; Bruns, Richard; Connell, Nancy			Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future Comment	VACCINE			English	Editorial Material						COVID-19; Thermostable; Thermostability; Cold chain; Controlled temperature chain; Mass vaccination; Vaccine	CHAIN		[Hosangadi, Divya; Martin, Elena K.; Watson, Matthew; Bruns, Richard; Connell, Nancy] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth & Engn, Johns Hopkins Ctr Hlth Secur, Baltimore, MD 21205 USA		Hosangadi, D (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth & Engn, Johns Hopkins Ctr Hlth Secur, Baltimore, MD 21205 USA.	dhosang1@jhu.edu	Connell, Nancy/AFN-1305-2022	Bruns, Richard/0000-0002-2209-4242			Carter RJ, 2018, J INFECT DIS, V217, pS16, DOI 10.1093/infdis/jix657; Gavi the Vaccine Alliance, OV VIPS PRIOR PROC O; Hanson CM, 2017, VACCINE, V35, P2127, DOI 10.1016/j.vaccine.2016.09.070; Jerving S, DEVEX; Kaiser, SCIENCE; Kristensen DD, 2016, VACCINE, V34, P899, DOI 10.1016/j.vaccine.2016.01.001; Unicef, HIST PUSH PROV ULTR; WHO, COVID 19 VACC SUPPL; World Health Organization, CONTR TEMP CHAIN STR; Yauba S, 2017, J VACCINES VACCIN, V9	10	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 26	2021	39	48					6972	6974		10.1016/j.vaccine.2021.10.065		NOV 2021	3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XB3QQ	34763948	Bronze, Green Published			2022-04-29	WOS:000721246800002
J	Chanthavanich, P; Versage, E; Van Twuijver, E; Hohenboken, M				Chanthavanich, Pornthep; Versage, Eve; Van Twuijver, Esther; Hohenboken, Matthew			Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture-derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects	VACCINE			English	Article						MF59 adjuvant; Influenza pandemic vaccine; Immunogenicity; Safety; Children; Adolescents	PANDEMIC INFLUENZA; MF59; SAFETY; VIRUS; ADJUVANT; IMMUNOGENICITY; PROTECTION; CHILDREN; ASSAY	Background: Vaccines are the main prophylactic measure against pandemic influenza. Adjuvanted, cell culture-derived vaccines, which are not subject to limitations of egg-based vaccine production, have the potential to elicit an antibody response against heterologous strains and may be beneficial in the event of an A/H5N1 pandemic. Methods: A prespecified exploratory analysis of data from a phase 2, randomized, controlled, observer-blind multicenter trial (NCT01776554) to evaluate the immunogenicity of a MF59adjuvanted, cell culture-based A/H5N1 influenza vaccine (aH5N1c), containing 7.5 mg hemagglutinin antigen per dose, in subjects 6 months through 17 years of age was conducted. Geometric mean titers (GMT) were determined using hemagglutination inhibition (HI) and microneutralization (MN) assays, and proportions of patients achieving seroconversion, HI and MN titers > 1:40, and a 4-fold increase in MN titers against 5 heterologous strains (influenza A/H5N1 Anhui/2005, Egypt/2010, Hubei/2010, Indonesia/2005, and Vietnam/1203/2004) three weeks after administration of the second dose were assessed. Results: After the second dose, HI GMTs against heterologous strains increased between 8-and 40-fold, and MN GMTs increased 13-to 160-fold on Day 43 vs Day 1. On Day 43, 32-72% of subjects had HI titers > 1:40 and achieved seroconversion against the heterologous strains. Using the MN assay, 84- 100% of subjects had MN titers > 1:40 and 83-100% achieved an at least 4-fold increase in MN titers against the heterologous strains. The highest responses were consistently against A/H5N1 Egypt/2010. Conclusions: When given to children aged 6 months through 17 years, aH5N1c resulted in increased immunogenicity from baseline against all 5 heterologous A/H5N1 strains tested, demonstrating the potential of an MF59-adjuvanted, cell-derived A/H5N1 vaccine to provide cross-protection against other A/H5N1 strains (NCT01776554). (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).	[Chanthavanich, Pornthep] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, Bangkok, Thailand; [Versage, Eve; Hohenboken, Matthew] Seqirus Inc, Clin Dev, Cambridge, MA 02139 USA; [Van Twuijver, Esther] Seqirus Amsterdam, Clin Dev, Amsterdam, Netherlands		Hohenboken, M (通讯作者)，Seqirus Inc, Clin Dev, Cambridge, MA 02139 USA.	Matthew.Hohenboken@Seqirus.com			Novartis Vaccines and Diagnostics, Inc.; US Office of Public Health Emergency Preparedness, Office of Research and Development Coordination [HHSO100200600012C]	The original study was funded by Novartis Vaccines and Diagnostics, Inc., and also received funding from the US Office of Public Health Emergency Preparedness, Office of Research and Development Coordination, under Contract No. HHSO100200600012C. Novartis' influenza vaccine business was acquired by the CSL Group on July 31, 2015, and currently operates as Seqirus, Inc. The sponsor had primary responsibility for study design and study vaccines, protocol development, study monitoring, data management, and statistical analyses.	Ansaldi F, 2008, VACCINE, V26, P1525, DOI 10.1016/j.vaccine.2008.01.019; Ansaldi F, 2010, VACCINE, V28, P4123, DOI 10.1016/j.vaccine.2010.04.030; Banzhoff A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004384; Barr IG, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0079-z; Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090; Chanthavanich P, 2019, PEDIATR INFECT DIS J, V38, P757, DOI 10.1097/INF.0000000000002345; Committee for Medicinal Products for Human Use, 2016, GUID INFL VACC NONCL; Donis RO, 2014, VACCINE, V32, P6583, DOI 10.1016/j.vaccine.2014.06.045; Eick-Cost A, 2018, INT C EM INF DIS ATL, P54; Erlewyn-Lajeunesse M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3680; Fedson DS, 2003, CLIN INFECT DIS, V36, P1552, DOI 10.1086/375056; Galli G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI 10.1073/pnas.0903181106; Goddard K, 2018, OPEN FORUM INFECT DI, V5, pS764; Hatz C, 2012, VACCINE, V30, P4820, DOI 10.1016/j.vaccine.2012.05.013; Heeringa M, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00750-20; Hegde NR, 2015, HUM VACC IMMUNOTHER, V11, P1223, DOI 10.1080/21645515.2015.1016666; Homeland Security Council, 2005, NAT STRAT PAND INFL; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; KATZ JM, 1987, VIROLOGY, V156, P386, DOI 10.1016/0042-6822(87)90418-1; Keitel W, 2010, VACCINE, V28, P840, DOI 10.1016/j.vaccine.2009.10.019; Khurana S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002336; Khurana S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000624; Knuf M, 2015, VACCINE, V33, P174, DOI 10.1016/j.vaccine.2014.10.085; Nakowitsch S, 2014, BIOTECHNOL J, V9, P405, DOI 10.1002/biot.201300225; Nicholson KG, 2001, LANCET, V357, P1937, DOI 10.1016/S0140-6736(00)05066-2; Nicolay U, 2019, INT J INFECT DIS, V85, pS1, DOI 10.1016/j.ijid.2019.03.026; O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061; O'Hagan DT, 2007, EXPERT REV VACCINES, V6, P699, DOI 10.1586/14760584.6.5.699; Patel MM, 2020, VACCINE, V38, P608, DOI 10.1016/j.vaccine.2019.10.053; Patel SS, 2019, INT J INFECT DIS, V85, pS26, DOI 10.1016/j.ijid.2019.05.009; Pellegrini M, 2009, VACCINE, V27, P6959, DOI 10.1016/j.vaccine.2009.08.101; Rajaram S, 2018, IDWEEK 2018; ROCHA EP, 1993, J GEN VIROL, V74, P2513, DOI 10.1099/0022-1317-74-11-2513; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Schultze V, 2008, VACCINE, V26, P3209, DOI 10.1016/j.vaccine.2008.03.093; Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402; Seubert A, 2011, P NATL ACAD SCI USA, V108, P11169, DOI 10.1073/pnas.1107941108; Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153; Treanor J, 2004, NEW ENGL J MED, V350, P218, DOI 10.1056/NEJMp038238; Trombetta CM, 2014, VACCINES-BASEL, V2, P707, DOI 10.3390/vaccines2040707; van Baalen CA, 2014, J CLIN MICROBIOL, V52, P1672, DOI 10.1128/JCM.03575-13; van Baalen CA, 2017, VACCINE, V35, P46, DOI 10.1016/j.vaccine.2016.11.060; Verschoor CP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131531; Vesikari T, 2018, LANCET RESP MED, V6, P345, DOI [10.1016/S2213-2600(18)30108-5, 10.1016/s2213-2600(18)30108-5]; Vesikari T, 2012, PEDIATR INFECT DIS J, V31, P494, DOI 10.1097/INF.0b013e31824bb179; Vesikari T, 2011, NEW ENGL J MED, V365, P1406, DOI 10.1056/NEJMoa1010331; Vono M, 2013, P NATL ACAD SCI USA, V110, P21095, DOI 10.1073/pnas.1319784110; Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	49	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 16	2021	39	47					6930	6935		10.1016/j.vaccine.2021.10.010		NOV 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY9EK	34711436	hybrid			2022-04-29	WOS:000719580000016
J	Maki, Y; Kashiwagi, S; Kimizuka, Y				Maki, Yohei; Kashiwagi, Satoshi; Kimizuka, Yoshifumi			Laser vaccine adjuvants: Light-augmented immune responses	VACCINE			English	Review						Adjuvant; Laser; Light; Skin; Vaccine	BIPHASIC DOSE-RESPONSE; INTRADERMAL DELIVERY; INFLUENZA VACCINE; SKIN; IMMUNOGENICITY; IMMUNOTHERAPY; THERAPY; SAFETY; PHOTOBIOMODULATION; PHOTOCHEMOTHERAPY	Adjuvants are essential for ensuring the efficacy of modern vaccines. Considering frequent local and systemic adverse reactions, research into the development of safer and more effective adjuvants is being actively conducted. In recent years, the novel concept of laser vaccine adjuvants, which use the physical energy of light, has been developed. For long, light has been known to affect the physiological functions in living organisms. Since the development of lasers as stable light sources, laser adjuvants have evolved explosively in multiple ways over recent decades. Future laser adjuvants would have the potential not only to enhance the efficacy of conventional vaccine preparations but also to salvage candidate vaccines abandoned during development because of insufficient immunogenicity or owing to their inability to be combined with conventional adjuvants. Furthermore, the safety and efficacy of non-invasive laser adju-vants make them advantageous for vaccine dose sparing, which would be favorable for the timely and equitable global distribution of vaccines. In this review, we first describe the basics of light-tissue inter-actions, and then summarize the classification of lasers, the history of laser adjuvants, and the mecha-nisms by which different lasers elicit an immune response. (c) 2021 Elsevier Ltd. All rights reserved.	[Maki, Yohei; Kimizuka, Yoshifumi] Natl Def Med Coll, Dept Internal Med, Div Infect Dis & Resp Med, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan; [Kashiwagi, Satoshi] Massachusetts Gen Hosp, Dept Radiol, Gordon Ctr Med Imaging, 149 13th St, Charlestown, MA 02129 USA		Kimizuka, Y (通讯作者)，Natl Def Med Coll, Dept Internal Med, Div Infect Dis & Resp Med, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	ykimizuka@ndmc.ac.jp			Japan Society for the Promotion of Science (JSPS)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [JP19K16703]; GSK (GlaxoSmithKline) Japan Research Grant; Uehara Memorial FoundationUehara Memorial Foundation	This work was supported by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research under award number JP19K16703 (Y.K.), the GSK (GlaxoSmithKline) Japan Research Grant (Y.K.), and the Uehara Memorial Foundation (Y.K.). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackroyd R, 2001, PHOTOCHEM PHOTOBIOL, V74, P656, DOI 10.1562/0031-8655(2001)074<0656:THOPAP>2.0.CO;2; Bandyopadhyay AS, 2021, LANCET INFECT DIS, V21, P559, DOI 10.1016/S1473-3099(20)30555-7; Bell A.G., 1880, COMPUT J, Vs3-20, P305, DOI DOI 10.2475/AJS.S3-20.118.305; Centers for Disease Control and Prevention, CDC SEAS FLU VACC EF; Chen WR, 1997, CANCER LETT, V115, P25, DOI 10.1016/S0304-3835(97)04707-1; Chen XY, 2012, VACCINE, V31, P159, DOI 10.1016/j.vaccine.2012.10.069; Chen XY, 2012, CLIN CANCER RES, V18, P2240, DOI 10.1158/1078-0432.CCR-11-2654; Chen XY, 2012, J CONTROL RELEASE, V159, P43, DOI 10.1016/j.jconrel.2012.01.002; Chen XY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013776; Combadiere B, 2011, HUM VACCINES, V7, P811, DOI 10.4161/hv.7.8.16274; ENNEVER JF, 1991, PHOTOCHEM PHOTOBIOL, V53, P25, DOI 10.1111/j.1751-1097.1991.tb08463.x; Estrada LD, 2019, J IMMUNOL, V202, P392, DOI 10.4049/jimmunol.1801054; Fehres CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00157; FITZPATRICK TB, 1959, J INVEST DERMATOL, V32, P229, DOI 10.1038/jid.1959.40; Gelfand JA, 2019, FASEB J, V33, P3074, DOI 10.1096/fj.201801095R; Gorse GJ, 2015, VACCINE, V33, P1151, DOI 10.1016/j.vaccine.2015.01.025; Grzybowski A, 2012, CLIN DERMATOL, V30, P451, DOI 10.1016/j.clindermatol.2011.11.019; Heiskanen V, 2018, PHOTOCH PHOTOBIO SCI, V17, P1003, DOI [10.1039/c8pp00176f, 10.1039/c8pp90049c]; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Itoh S, 2017, PEDIATR INT, V59, P959, DOI 10.1111/ped.13332; Jackson LA, 2018, VACCINE, V36, P3976, DOI 10.1016/j.vaccine.2018.05.028; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; Karu T, 2013, PHOTOMED LASER SURG, V31, P189, DOI 10.1089/pho.2013.3510; Karu T, 2010, PHOTOMED LASER SURG, V28, P159, DOI 10.1089/pho.2010.2789; Kashiwagi S, 2020, FASEB J, V34, P3485, DOI 10.1096/fj.201902164R; Kashiwagi Satoshi, 2016, J Vaccines Vaccin, V7; Kashiwagi S, 2014, HUM VACC IMMUNOTHER, V10, P1892, DOI 10.4161/hv.28840; Kashiwagi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082899; Khan R, 2001, J Tissue Viability, V11, P103; Kimizuka Y, 2018, J IMMUNOL, V201, P3587, DOI 10.4049/jimmunol.1701687; Kimizuka Y, 2017, VACCINE, V35, P2404, DOI 10.1016/j.vaccine.2017.03.036; Kobayashi H, 2019, ACCOUNTS CHEM RES, V52, P2332, DOI 10.1021/acs.accounts.9b00273; Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049; Luo M, 2018, INT J HYPERTHER, V34, P1337, DOI 10.1080/02656736.2018.1446221; MAIMAN TH, 1960, NATURE, V187, P493, DOI 10.1038/187493a0; Manila F, 2021, J AM ACAD DERMATOL, V84, P479, DOI 10.1016/j.jaad.2020.04.095; Morse K, 2017, J IMMUNOL, V199, P1319, DOI 10.4049/jimmunol.1601873; Moskvin SV, 2017, J LASERS MED SCI, V8, P56, DOI 10.15171/jlms.2017.11; Munseri PJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119629; Naylor MF, 2017, J BIOPHOTONICS, V10, P618, DOI 10.1002/jbio.201600271; Onikienko S, 2007, INTERACT BACTERIAL E, V1, P32; PARRISH JA, 1974, NEW ENGL J MED, V291, P1207, DOI 10.1056/NEJM197412052912301; PATHAK MA, 1992, J PHOTOCH PHOTOBIO B, V14, P3, DOI 10.1016/1011-1344(92)85080-E; Poder A, 2014, VACCINE, V32, P1121, DOI 10.1016/j.vaccine.2013.11.031; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006; Saedi N, 2011, CLIN PLAST SURG, V38, P449, DOI 10.1016/j.cps.2011.02.008; Saluja R, 2020, FACIAL PLAST SURG CL, V28, P87, DOI 10.1016/j.fsc.2019.09.008; Schijns VEJC, 2011, EXPERT REV VACCINES, V10, P539, DOI [10.1586/erv.11.21, 10.1586/ERV.11.21]; Shardlow E, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0305-2; Shi L, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800149; Sliney DH, 2016, EYE, V30, P222, DOI 10.1038/eye.2015.252; Sticchi L, 2010, J Prev Med Hyg, V51, P7; Terazima M, 2004, PURE APPL CHEM, V76, P1083, DOI 10.1351/pac200476061083; Terhorst D, 2015, J IMMUNOL, V194, P5895, DOI 10.4049/jimmunol.1500564; Tseng SH, 2009, OPT EXPRESS, V17, P14599, DOI 10.1364/OE.17.014599; Villa M, 2013, AM J EPIDEMIOL, V178, P1139, DOI 10.1093/aje/kwt078; Waddington CS, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2649; Wang J, 2015, P NATL ACAD SCI USA, V112, P5005, DOI 10.1073/pnas.1500408112; Wang J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5447; Watad Abdulla, 2017, Mediterr J Rheumatol, V28, P64, DOI 10.31138/mjr.28.2.64; Williams SCP, 2013, P NATL ACAD SCI USA, V110, P10049, DOI 10.1073/pnas.1309653110; Yokomizo S, 2021, NANOPHOTONICS-BERLIN, V10, P3187, DOI 10.1515/nanoph-2021-0133; Zhi DF, 2020, J CONTROL RELEASE, V325, P52, DOI 10.1016/j.jconrel.2020.06.032; Zhou C, 2015, J CONTROL RELEASE, V204, P30, DOI 10.1016/j.jconrel.2015.02.031; Zhou FF, 2018, CLIN CANCER RES, V24, P5335, DOI 10.1158/1078-0432.CCR-18-1126; Zhou FF, 2016, J INNOV OPT HEAL SCI, V9, DOI 10.1142/S1793545816300019; Zhou FF, 2013, J INNOV OPT HEAL SCI, V6, DOI 10.1142/S1793545813500399	69	0	0	5	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	NOV 5	2021	39	46					6805	6812		10.1016/j.vaccine.2021.09.042		NOV 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YJ0BG	34666921				2022-04-29	WOS:000744203800011
J	Fisher, KA; Nguyen, N; Crawford, S; Fouayzi, H; Singh, S; Mazor, KM				Fisher, Kimberly A.; Ngoc Nguyen; Crawford, Sybil; Fouayzi, Hassan; Singh, Sonal; Mazor, Kathleen M.			Preferences for COVID-19 vaccination information and location: Associations with vaccine hesitancy, race and ethnicity	VACCINE			English	Article						COVID-19; COVID-19 vaccines; Vaccine hesitancy; Vaccination		This study examined the association between preferences for being informed about the COVID-19 vaccine and where to receive it with vaccination intent and race/ethnicity. We conducted an online survey, over -sampling Black and Latino panel members. The 1668 participants were 53.2% female, 34.8% White, 33.3% Black, and 31.8% Latino. Participants who were vaccine hesitant (answered "not sure" or "no" to vaccina-tion intent) were more likely to prefer a conversation with their doctor compared to those who answered "yes" (25.0% and 23.4% vs 7.8%, P < .001, respectively). Among participants who responded "not sure", 61.8% prefer to be vaccinated at a doctor's office, compared with 35.2% of those who responded "yes" (P < .001). Preferred location differed by race/ethnicity (P < .001) with 67.6% of Black "not sure" partici-pants preferring a doctor's office compared to 60.2% of Latino and 54.9% of White "not sure" participants. These findings underscore the need to integrate healthcare providers into COVID-19 vaccination programs. (c) 2021 Elsevier Ltd. All rights reserved.	[Fisher, Kimberly A.; Mazor, Kathleen M.] UMass Chan Med Sch, Dept Med, 55 Lake Ave North, Worcester, MA 01655 USA; [Fisher, Kimberly A.; Ngoc Nguyen; Crawford, Sybil; Fouayzi, Hassan; Singh, Sonal; Mazor, Kathleen M.] Meyers Hlth Care Inst, 385 Grove St, Worcester, MA 01605 USA; [Crawford, Sybil] UMass Chan Med Sch, Tan Chingfen Grad Sch Nursing, 55 Lake Ave North, Worcester, MA 01655 USA; [Singh, Sonal] UMass Chan Med Sch, Dept Family Med & Community Hlth, 55 Lake Ave North, Worcester, MA 01655 USA		Fisher, KA (通讯作者)，UMMHC Univ Campus,55 Lake Ave North, Worcester, MA 01655 USA.	Kimberly.Fisher@umassmemorial.org	Singh, Sonal/A-4614-2008	Singh, Sonal/0000-0003-0912-941X; Crawford, Sybil/0000-0001-6621-0439; Nguyen, Ngoc/0000-0002-8265-4846	National Library of Medicine, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [UG4LM012347]; University of Massachusetts, Worcester	This project has been funded in whole or in part with federal funds from the National Library of Medicine, National Institutes of Health, under Cooperative Agreement UG4LM012347 with the University of Massachusetts, Worcester.	Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Hamel Liz, 2021, KFF COVID 19 VACCINE; Hoffman, 2021, NEW YORK TIMES; Jean-Jacques M, 2021, JAMA-J AM MED ASSOC, V325, P829, DOI 10.1001/jama.2021.1205; Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016; Ndugga N, 2021, EARLY STATE VACCINAT; Recht H, 2021, KAISER HLTH NEWS; Smith PJ, 2016, VACCINE, V34, P1604, DOI 10.1016/j.vaccine.2016.01.061; The White House,, 2021, NAT STRAT COVID 19 R	9	2	2	6	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6591	6594		10.1016/j.vaccine.2021.09.058		OCT 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34629210	Bronze, Green Published			2022-04-29	WOS:000708078600004
J	Park, WJ; Yoon, YK; Kim, Y; Park, JS; Pansuriya, R; Cho, SN; Seok, YJ; Ganapathy, R				Park, Wook-Jin; Yoon, Yeon-Kyung; Kim, Youngmi; Park, Ji-Sun; Pansuriya, Ruchirkumar; Cho, Sang-Nae; Seok, Yeong-Jae; Ganapathy, Ravi			Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to AVP8*protein from rotavirus	VACCINE			English	Article						Rotavirus; AVP8*; Carrier protein; Tuberculosis; Conjugate vaccine	ANTIBODY-MEDIATED IMMUNITY; 1-CYANO-4-DIMETHYLAMINOPYRIDINIUM TETRAFLUOROBORATE; SOLUBLE POLYSACCHARIDES; STRUCTURAL FEATURES; DOUBLE-BLIND; PROTEIN; IMMUNOGENICITY; LIPOARABINOMANNAN; SUBUNIT; ACTIVATION	Conjugation of carbohydrate antigens with a carrier protein is a clinically proven strategy to overcome the poor immunogenicity of bacterial polysaccharide. In addition to its primary role, which is to help generate a T cell-mediate long-lasting immune response directed against the carbohydrate antigen, the carrier protein in a glycoconjugate vaccine can also play an important role as a protective antigen. Among carrier proteins currently used in licensed conjugate vaccines, non-typeable Haemophilus influenzae protein D has been used as an antigenically active carrier protein. Our previous studies also indicate that some carrier proteins provide B cell epitopes, along with T cell helper epitopes. Herein we investigated the dual role of truncated rotavirus spike protein AVP8* as a carrier and a protective antigen. Capsular polysaccharide lipoarabinomannan (LAM), purified from Mycobacterium tuberculosis (M.tb), was chemically conjugated with AVP8*. Mouse immunization experiments showed that the resultant conjugates elicited strong and specific immune responses against the polysaccharide antigen, and the responses were comparable to those induced by Diphtheria toxoid (DT)-based conjugates. The conjugate vaccine induced enhanced antibody titers and functional antibodies against AVP8* when compared to immunization with the unconjugated AVP8*. Thus, these results indicate that AVP8* can be a relevant carrier protein for glycoconjugate vaccine and the glycoconjugates consisting of AVP8* with LAM are effective bivalent vaccine candidates against rotavirus and tuberculosis. (c) 2021 Elsevier Ltd. All rights reserved.	[Park, Wook-Jin; Seok, Yeong-Jae] Seoul Natl Univ, Sch Biol Sci, Seoul 08826, South Korea; [Park, Wook-Jin; Seok, Yeong-Jae] Seoul Natl Univ, Inst Microbiol, Seoul 08826, South Korea; [Park, Wook-Jin; Yoon, Yeon-Kyung; Park, Ji-Sun; Pansuriya, Ruchirkumar; Ganapathy, Ravi] Int Vaccine Inst, Seoul 08826, South Korea; [Kim, Youngmi; Cho, Sang-Nae] Yonsei Univ, Coll Med, Seoul 03722, South Korea; [Kim, Youngmi; Cho, Sang-Nae] Yonsei Univ, Inst Immunol & Immunol Dis, Seoul 03722, South Korea		Ganapathy, R (通讯作者)，Int Vaccine Inst, Seoul 08826, South Korea.	ravi.ganapathy@ivi.nt					Achkar JM, 2018, CURR OPIN IMMUNOL, V53, P30, DOI 10.1016/j.coi.2018.04.004; Achkar JM, 2013, CELL HOST MICROBE, V13, P250, DOI 10.1016/j.chom.2013.02.009; An SJ, 2018, VACCINE, V36, P2978, DOI 10.1016/j.vaccine.2018.04.035; Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6; Astronomo RD, 2010, NAT REV DRUG DISCOV, V9, P308, DOI 10.1038/nrd3012; Avci F, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00520-19; Avci FY, 2013, SEMIN IMMUNOL, V25, P146, DOI 10.1016/j.smim.2013.05.005; Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535; Avci FY, 2010, ANNU REV IMMUNOL, V28, P107, DOI 10.1146/annurev-immunol-030409-101159; Avery OT, 1929, J EXP MED, V50, P533, DOI 10.1084/jem.50.4.533; Barrett D J, 1985, Adv Pediatr, V32, P139; Broker M, 2017, VACCINE, V35, P3286, DOI 10.1016/j.vaccine.2017.04.078; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chen TT, 2020, J CLIN INVEST, V130, P1808, DOI 10.1172/JCI128459; Comstock LE, 2006, CELL, V126, P847, DOI 10.1016/j.cell.2006.08.021; Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703; Correia-Neves M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01968; COUTINHO A, 1973, NATURE-NEW BIOL, V245, P12, DOI 10.1038/newbio245012a0; Daffe M., 1999, Tubercle and Lung Disease, V79, P153, DOI 10.1054/tuld.1998.0200; Daffe M, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.MGM2-0021-2013; Desselberger U, 2017, PATHOGENS, V6, DOI 10.3390/pathogens6040065; Dinadayala P, 2008, GLYCOBIOLOGY, V18, P502, DOI 10.1093/glycob/cwn031; Dodd PJ, 2017, LANCET GLOB HEALTH, V5, pE898, DOI [10.1016/S2214-109X(17)30289-9, 10.1016/s2214-109x(17)30289-9]; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Goebel WF, 1929, J EXP MED, V50, P521, DOI 10.1084/jem.50.4.521; Groome MJ, 2020, LANCET INFECT DIS, V20, P851, DOI 10.1016/S1473-3099(20)30001-3; Groome MJ, 2017, LANCET INFECT DIS, V17, P843, DOI [10.1016/S1473-3099(17)30242-6, 10.1016/s1473-3099(17)30242-6]; Hamasur B, 1999, VACCINE, V17, P2853, DOI 10.1016/S0264-410X(99)00124-3; HOSHINO Y, 1984, J INFECT DIS, V149, P694, DOI 10.1093/infdis/149.5.694; Jonesteller CL, 2017, CLIN INFECT DIS, V65, P840, DOI 10.1093/cid/cix369; Kalscheuer R, 2019, BIOCHEM J, V476, P1995, DOI 10.1042/BCJ20190324; Kaur D, 2008, P NATL ACAD SCI USA, V105, P17973, DOI 10.1073/pnas.0807761105; Khoo HH, 2001, J BIOL CHEM, V276, P3863, DOI 10.1074/jbc.M004010200; Kothari N, 2014, VACCINE, V32, P5755, DOI 10.1016/j.vaccine.2014.08.041; Lang SY, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00284; LEES A, 1994, VACCINE, V12, P1160, DOI 10.1016/0264-410X(94)90237-2; Lees A, 1996, VACCINE, V14, P190, DOI 10.1016/0264-410X(95)00195-7; Lees A, 2020, 3 OPTIMIZATION CDAP, P8; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Parashar UD, 2006, EMERG INFECT DIS, V12, P304; Pollabauer EM, 2009, VACCINE, V27, P1674, DOI 10.1016/j.vaccine.2009.01.005; Prados-Rosales R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006250; PRASAD BVV, 1990, NATURE, V343, P476, DOI 10.1038/343476a0; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; Schwebach JR, 2002, INFECT IMMUN, V70, P2566, DOI 10.1128/IAI.70.5.2566-2575.2002; Shafer DE, 2000, VACCINE, V18, P1273, DOI 10.1016/S0264-410X(99)00370-9; Shi Libin, 2008, V465, P23, DOI 10.1007/978-1-59745-207-6_3; Snapper CM, 1996, J IMMUNOL, V157, P2229; Tan M, 2011, J VIROL, V85, P753, DOI 10.1128/JVI.01835-10; Tate JE, 2012, LANCET INFECT DIS, V12, P136, DOI 10.1016/S1473-3099(11)70253-5; Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1; Wen XB, 2014, VACCINE, V32, P4420, DOI 10.1016/j.vaccine.2014.06.060; Wen XB, 2012, VACCINE, V30, P6121, DOI 10.1016/j.vaccine.2012.07.078; WHO, 2020, VACC NATL IMM PROGR; Xia M, 2018, ACS NANO, V12, P10665, DOI 10.1021/acsnano.8b02776; Xue MG, 2016, HUM VACC IMMUNOTHER, V12, P2959, DOI 10.1080/21645515.2016.1204501; Yen C, 2016, HUM VACC IMMUNOTHER, V12, P2580, DOI 10.1080/21645515.2016.1197452; Yen C, 2011, HUM VACCINES, V7, P1282, DOI 10.4161/hv.7.12.18321; Yu X, 2012, CLIN VACCINE IMMUNOL, V19, P198, DOI 10.1128/CVI.05550-11; Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6	64	0	0	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6644	6652		10.1016/j.vaccine.2021.09.067		OCT 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34642087				2022-04-29	WOS:000708078600011
J	Yu, YB; Taraban, MB; Briggs, KT				Yu, Yihua Bruce; Taraban, Marc B.; Briggs, Katharine T.			All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions	VACCINE			English	Editorial Material							IMMUNOGENICITY; SAFETY		[Yu, Yihua Bruce] Univ Maryland, Bio & Nanotechnol Ctr, Sch Pharm, Baltimore, MD 21201 USA; Inst Biosci & Biotechnol Res, 9600 Gudelsky Dr, Rockville, MD 20850 USA		Yu, YB (通讯作者)，Univ Maryland, Bio & Nanotechnol Ctr, Sch Pharm, Baltimore, MD 21201 USA.	byu@rx.umaryland.edu		/0000-0001-7985-9018	FDAUnited States Department of Health & Human Services [75F40119C10104]; NIIMBL [PC2.2-077]	Our research on vaccine manufacturing and quality control is supported by the FDA (75F40119C10104) and NIIMBL (PC2.2-077).	Associated Press, 2021, NBC NEWS; Briggs KT, 2020, VACCINE, V38, P4853, DOI 10.1016/j.vaccine.2020.05.049; Briggs KT, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1405-0; Edwards K, 2019, BIOLOGICALS, V60, P1, DOI 10.1016/j.biologicals.2019.05.005; Haag-Weber M, 2012, CLIN NEPHROL, V77, P8, DOI 10.5414/CN107304; Hatziantoniou S, 2021, VACCINE, V39, P2605, DOI 10.1016/j.vaccine.2021.03.073; Krantz MS, 2021, JAMA INTERN MED, V181, P1530, DOI 10.1001/jamainternmed.2021.3779; Kyodo J., 2021, THE JAPAN TIMES; Levinson DR., 2012, OEI041000430 DEP HLT; McNeil MM, 2018, J ALLERGY CLIN IMMUN, V141, P463, DOI 10.1016/j.jaci.2017.12.971; Myles IA, 2021, VACCINE, V39, P4404, DOI 10.1016/j.vaccine.2021.06.061; Rubic-Schneider T, 2017, BLOOD ADV, V1, P367, DOI 10.1182/bloodadvances.2016001842; Sarkanen TO, 2018, SLEEP MED REV, V38, P177, DOI 10.1016/j.smrv.2017.06.006; Seidl A, 2012, PHARM RES-DORDR, V29, P1454, DOI 10.1007/s11095-011-0621-4; Stanley-Becker Isaac, 2020, WASH POST; Taraban Marc B, 2021, J Diabetes Sci Technol, p19322968211023806, DOI 10.1177/19322968211023806; Taraban MB, 2017, ANAL CHEM, V89, P5494, DOI 10.1021/acs.analchem.7b00464; Tsukimori O., 2021, THE JAPAN TIMES; US Food and Drug Administration, MAUDE ADV EV REP; Weibel D, 2018, VACCINE, V36, P6202, DOI 10.1016/j.vaccine.2018.08.008; Wilson E, 2018, VACCINE, V36, P1516, DOI 10.1016/j.vaccine.2017.10.059; Yu LX, 2017, INT J PHARMACEUT, V528, P354, DOI 10.1016/j.ijpharm.2017.06.039; Yu YHB, 2017, TRENDS BIOTECHNOL, V35, P1140, DOI 10.1016/j.tibtech.2017.08.010	23	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 29	2021	39	45					6565	6569		10.1016/j.vaccine.2021.09.065		OCT 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WI0SZ	34625289	Green Published, Bronze			2022-04-29	WOS:000708078600001
J	Yamamoto, N; Takahashi, Y; Hayashi, S				Yamamoto, Norihisa; Takahashi, Yuichi; Hayashi, Shuichiro			Legal and regulatory processes for Japan's COVID-19 immunization program Comment	VACCINE			English	Editorial Material									[Yamamoto, Norihisa; Hayashi, Shuichiro] Minist Hlth Labour & Welf, Hlth Serv Bur, Immunizat Off, Hlth Serv Div, Tokyo, Japan; [Takahashi, Yuichi] Minist Hlth Labour & Welf, Pharmaceut Safety & Environm Hlth Bur, Pharmaceut Evaluat Div, Tokyo, Japan		Hayashi, S (通讯作者)，1-2-2 Kasumigaseki,Chiyoda, Tokyo 1008916, Japan.	hayashi-shuichiro@mhlw.go.jp					Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Kuter BJ, 2021, VACCINE, V39, P2491, DOI 10.1016/j.vaccine.2021.03.077; Slaoui M, 2020, NEW ENGL J MED, V383, P1701, DOI 10.1056/NEJMp2027405	3	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 15	2021	39	43					6449	6450		10.1016/j.vaccine.2021.09.002		OCT 2021	2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS5LV	34535315	Green Published, Bronze			2022-04-29	WOS:000715223200016
J	Angsuwatcharakon, P; Puthanakit, T; Bunjoungmanee, P; Anugulruengkitt, S; Srimuan, P; Kowitdamrong, E; Savangsindh, P; Sophonphan, J; Tantawichien, T; Tangsathapornpong, A				Angsuwatcharakon, Piyada; Puthanakit, Thanyawee; Bunjoungmanee, Pornumpa; Anugulruengkitt, Suvaporn; Srimuan, Patchareeyawan; Kowitdamrong, Ekkasit; Savangsindh, Pannada; Sophonphan, Jiratchaya; Tantawichien, Terapong; Tangsathapornpong, Auchara			High seroprevalence of rubella in Thai children with a 2-dose MMR national immunization policy	VACCINE			English	Article						Seroprevalence; Rubella; Thai; Children; Adolescents	MEASLES; MUMPS; PERSISTENCE; ANTIBODIES	Rubella is generally a mild disease, but infection during pregnancy can cause congenital rubella syndrome. Thailand has implemented a two-dose MMR vaccination policy since 2010. This study aimed to describe the seroprevalence rate of rubella among children and adolescents in Thailand. We conducted a cross-sectional study of 132 healthy children (aged 3-9 years) who had received 2 doses of rubella vaccine and 424 adolescents (aged 10-18 years) who were expected to receive at least 1 dose of rubella vaccine. Stored serum samples from healthy children and recently drawn serum samples from adolescents were tested for rubella IgG antibody using a commercial enzyme-linked immunosorbent assay (ELISA) kit (EUROIMMUN). Seroprotection was defined as a rubella IgG level > 10 IU/mL. The rubella seroprevalence rate among children and adolescents who had 2 documented doses of MMR was 97.0% (95 %CI 92.5- 99.2%) and 85.4% (95% CI 78.8-90.6%, p < 0.01) respectively. The geometric mean titer of rubella was higher in children, 38.3 (95% CI 33.5-43.9) compared to adolescents, 22.5 (19.4-25.9) IU/mL. We observed an inverse correlation between the rubella titer and time interval from the second rubella containing vaccine dose (R =-0.30, p < 0.01). A 2-dose MMR vaccination course produces a high seroprevalence of rubella immunity in children, which decreases with time, suggesting waning of immunity. Thai clinical trials registry number TCTR20191120001. (c) 2021 Elsevier Ltd. All rights reserved.	[Angsuwatcharakon, Piyada; Tantawichien, Terapong] Queen Saovabha Mem Inst, Thai Red Cross Soc, Bangkok, Thailand; [Angsuwatcharakon, Piyada] Bur Gen Communicable Dis, Dept Dis Control, Bangkok, Thailand; [Puthanakit, Thanyawee; Anugulruengkitt, Suvaporn] Chulalongkorn Univ, Fac Med, Div Infect Dis, Dept Pediat, Bangkok, Thailand; [Puthanakit, Thanyawee; Anugulruengkitt, Suvaporn; Srimuan, Patchareeyawan] Chulalongkorn Univ, Ctr Excellence Pediat Infect Dis & Vaccines, Bangkok, Thailand; [Bunjoungmanee, Pornumpa; Tangsathapornpong, Auchara] Thammasat Univ, Div Infect Dis, Dept Pediat, Fac Med, Bangkok, Thailand; [Kowitdamrong, Ekkasit] Chulalongkorn Univ, Fac Med, Div Virol, Dept Microbiol, Bangkok, Thailand; [Savangsindh, Pannada] Inst HIV Res & Innovat, Bangkok, Thailand; [Sophonphan, Jiratchaya] Thai Red Cross AIDS Res Ctr, HIV NAT, Bangkok, Thailand; [Tantawichien, Terapong] Chulalongkorn Univ, Div Infect Dis, Dept Med, Fac Med, Bangkok, Thailand		Tantawichien, T (通讯作者)，Chulalongkorn Univ, Dept Med, Fac Med, 1873 Rama IV Rd, Bangkok, Thailand.	piyada.angs@gmail.com		Anugulruengkitt, Suvaporn/0000-0002-6965-5537			Bureau of Epidemiology Department of Disease Control Ministry of Public Health Thailand, 2020, SURV DAT RUB; Center for Disease Control Prevention, 2020, FACTS MEASL RUB; Cheong AT, 2008, ASIA-PAC J PUBLIC HE, V20, P340, DOI 10.1177/1010539508322698; Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993; Lambert N, 2015, LANCET, V385, P2297, DOI 10.1016/S0140-6736(14)60539-0; Ng YX, 2020, INT J INFECT DIS, V92, P234, DOI 10.1016/j.ijid.2019.12.015; Peltola H, 2008, LANCET INFECT DIS, V8, P796, DOI 10.1016/S1473-3099(08)70282-2; Poethko-Muller C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042867; Seagle EE, 2018, VACCINE, V36, P818, DOI 10.1016/j.vaccine.2017.12.075; Skendzel LP, 1996, AM J CLIN PATHOL, V106, P170; Tharmaphornpilas P, 2009, J HEALTH POPUL NUTR, V27, P80, DOI 10.3329/jhpn.v27i1.3320; van den Boogaard J, 2021, VACCINE, V39, P889, DOI 10.1016/j.vaccine.2020.12.079; Wanlapakorn N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225606; World Health Organization, 2019, REG OFF S E AS STRAT; World Health Organization. Regional Office for South-East Asia, 2019, EXP PROGR IMM EPI FA; World Health Organization & WHO Expert Committee on Biological Standardization, 2018, WHO EXP COMM BIOL ST	16	0	0	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 8	2021	39	42					6206	6209		10.1016/j.vaccine.2021.08.079		SEP 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WE7SY	34556367				2022-04-29	WOS:000705822100006
J	Albani, VVL; Loria, J; Massad, E; Zubelli, JP				Albani, Vinicius V. L.; Loria, Jennifer; Massad, Eduardo; Zubelli, Jorge P.			The impact of COVID-19 vaccination delay: A data-driven modeling analysis for Chicago and New York City	VACCINE			English	Article						Vaccination; Epidemiological models; COVID-19; Public health strategies; SEIR-type models		Background: By the beginning of December 2020, some vaccines against COVID-19 already presented efficacy and security, which qualify them to be used in mass vaccination campaigns. Thus, setting up strategies of vaccination became crucial to control the COVID-19 pandemic. Methods: We use daily COVID-19 reports from Chicago and New York City (NYC) from 01-Mar2020 to 28 Nov-2020 to estimate the parameters of an SEIR-like epidemiological model that accounts for different severity levels. To achieve data adherent predictions, we let the model parameters to be time dependent. The model is used to forecast different vaccination scenarios, where the campaign starts at different dates, from 01-Oct-2020 to 01-Apr-2021. To generate realistic scenarios, disease control strategies are implemented whenever the number of predicted daily hospitalizations reaches a preset threshold. Results: The model reproduces the empirical data with remarkable accuracy. Delaying the vaccination severely affects the mortality, hospitalization, and recovery projections. In Chicago, the disease spread was under control, reducing the mortality increment as the start of the vaccination was postponed. In NYC, the number of cases was increasing, thus, the estimated model predicted a much larger impact, despite the implementation of contention measures. The earlier the vaccination campaign begins, the larger is its potential impact in reducing the COVID-19 cases, as well as in the hospitalizations and deaths. Moreover, the rate at which cases, hospitalizations and deaths increase with the delay in the vaccination beginning strongly depends on the shape of the incidence of infection in each city. (c) 2021 Elsevier Ltd. All rights reserved.	[Albani, Vinicius V. L.] Univ Fed Santa Catarina, BR-88040900 Florianopolis, SC, Brazil; [Loria, Jennifer] Inst Matematica Pura & Aplicada, Rio De Janeiro, Brazil; [Loria, Jennifer] Univ Costa Rica, San Jose, Costa Rica; [Massad, Eduardo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil; [Massad, Eduardo] LIM01 HCFMUSP, Sao Paulo, Brazil; [Massad, Eduardo] Fundacao Getulio Vargas, Sch Appl Math, Rio De Janeiro, Brazil; [Zubelli, Jorge P.] Khalifa Univ, Math Dept, POB 127788, Abu Dhabi, U Arab Emirates		Zubelli, JP (通讯作者)，Khalifa Univ, Math Dept, POB 127788, Abu Dhabi, U Arab Emirates.	v.albani@ufsc.br; jennyls@impa.br; eduardo.massad@fgv.br; jorge.zubelli@ku.ac.ae	Albani, Vinicius Viana Luiz/M-6640-2018; Zubelli, Jorge/AAA-1468-2022	Albani, Vinicius Viana Luiz/0000-0002-5751-5895; Zubelli, Jorge/0000-0003-1581-9505; Loria Sorio, Jennifer/0000-0002-8490-2962	Conselho Nacional de Desen-volvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [305544/2011-0, 307873/2013-7]; Fundacao Butantan [01/2020]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de JaneiroFundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ) [E-26/202.927/2017]; Universidad de Costa Rica (UCR) [OAICE-CAB-02-022-2016]	This work was supported by the Conselho Nacional de Desen-volvimento Cientifico e Tecnologico (CNPq) [grant numbers 305544/2011-0 and 307873/2013-7] , the FundacAo Butantan [grant number 01/2020] , the FundacAo Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro [grant number E-26/202.927/2017] , and the Universidad de Costa Rica (UCR) [grant number OAICE-CAB-02-022-2016] .	Abate SM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235653; Albani V, 2017, INVERSE PROBL IMAG, V11, P799, DOI 10.3934/ipi.2017038; Albani VVL, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88281-w; Amaku M, MODELLING IMPACT VAC, V2021, DOI [10.1101/ 2021.02.22.21252189, DOI 10.1101/2021.02.22.21252189]; Arastu K., BRIEF INTRO COVID 19, V2021, P1; Bjornstad O. N., 2018, EPIDEMICS MODELS DAT; Byambasuren O, 2020, OFF J ASS MED MICROB, V5, P223, DOI [10.1101/2020.05.10.20097543, DOI 10.3138/JAMMI-2020-0030]; CDC, FACTS COVID 19 VACC; CDC, NEW VAR VIR CAUS COV; Chowell Gerardo, 2017, Infect Dis Model, V2, P379, DOI 10.1016/j.idm.2017.08.001; Christakis N., 2020, APPOLOS ARROW PROFOU; DIEKMANN O, 1990, J MATH BIOL, V28, P365; Funk C, 2020, PEW RES CENT; Kaipio J., 2005, STAT COMPUTATIONAL I, DOI [10.1007/b138659, DOI 10.1007/B138659]; King A, 2020, NEW SCI, V245, P33; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Lopez G., VOX, V2021; MASSAD E, 1987, EVOLUTION, V41, P1127, DOI 10.1111/j.1558-5646.1987.tb05883.x; Mckeown T, 1966, INTRO SOCIAL MED; McKeown T, 1955, POP STUD-J DEMOG, V9, P119, DOI 10.2307/2172162; Ngonghala CN, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108364; Nocedal J, 2006, SPRINGER SER OPER RE, P1, DOI 10.1007/978-0-387-40065-5; Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; WHO, 2020, REPORT WHO CHINA JOI	25	4	4	5	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6088	6094		10.1016/j.vaccine.2021.08.098		SEP 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34507859	Bronze, Green Published			2022-04-29	WOS:000701799200012
J	Fujisawa, S; Murata, S; Takehara, M; Aoyama, J; Morita, A; Isezaki, M; Win, SY; Ariizumi, T; Sato, T; Oishi, E; Taneno, A; Maekawa, N; Okagawa, T; Ichii, O; Konnai, S; Ohashi, K				Fujisawa, Sotaro; Murata, Shiro; Takehara, Masaki; Aoyama, Julia; Morita, Ayu; Isezaki, Masayoshi; Win, Shwe Yee; Ariizumi, Takuma; Sato, Takumi; Oishi, Eiji; Taneno, Akira; Maekawa, Naoya; Okagawa, Tomohiro; Ichii, Osamu; Konnai, Satoru; Ohashi, Kazuhiko			In vitro characterization of adipocyte plasma membrane-associated protein from poultry red mites, Dermanyssus gallinae, as a vaccine antigen for chickens	VACCINE			English	Article						Poultry red mite; Adipocyte plasma membrane-associated protein; Vaccine; Dg-APMAP; Dermanyssus gallinae	MITE DERMANYSSUS-GALLINAE; STRICTOSIDINE SYNTHASE; PROTECTIVE ANTIGEN; IDENTIFICATION; EXPRESSION; ARTHROPOD; IMMUNITY	The poultry red mite (Dermanyssus gallinae; PRM) is a blood-sucking ectoparasite of chickens that is a threat to poultry farming worldwide and significantly reduces productivity in the egg-laying industry. Chemical acaricides that are widely used in poultry farms for the prevention of PRMs are frequently ineffective due to the emergence of acaricide-resistant PRMs. Therefore, alternative control methods are needed, and vaccination is a promising strategy for controlling PRMs. A novel adipocyte-plasma membrane-associated protein-like molecule (Dg-APMAP) is highly expressed in blood-fed PRMs according to a previous RNA sequencing analysis. Here, we attempted to identify the full sequence of DgAPMAP, study its expression in different life stages of PRMs, and evaluate its potential as a vaccine antigen. Dg-APMAP mRNA was expressed in the midgut and ovaries, and in all life stages regardless of feeding states. Importantly, in vitro feeding of PRMs with plasma derived from chickens immunized with the recombinant protein of the extracellular region of Dg-APMAP significantly reduced their survival rate in nymphs and adults, which require blood meals. Our data suggest that the host immune responses induced by vaccination with Dg-APMAP could be an effective strategy to reduce the suffering caused by PRMs in the poultry industry. (c) 2021 Elsevier Ltd. All rights reserved.	[Fujisawa, Sotaro; Murata, Shiro; Takehara, Masaki; Aoyama, Julia; Morita, Ayu; Isezaki, Masayoshi; Win, Shwe Yee; Ariizumi, Takuma; Konnai, Satoru; Ohashi, Kazuhiko] Hokkaido Univ, Fac Vet Med, Dept Dis Control, Sapporo, Hokkaido, Japan; [Murata, Shiro; Maekawa, Naoya; Okagawa, Tomohiro; Konnai, Satoru; Ohashi, Kazuhiko] Hokkaido Univ, Fac Vet Med, Dept Adv Pharmaceut, Sapporo, Hokkaido, Japan; [Sato, Takumi; Oishi, Eiji; Taneno, Akira] Vaxxinova Japan KK, Tokyo, Japan; [Ichii, Osamu] Hokkaido Univ, Fac Vet Med, Dept Basic Vet Sci, Sapporo, Hokkaido, Japan; [Ichii, Osamu] Hokkaido Univ, Fac Agr, Lab Agrobiomed Sci, Sapporo, Hokkaido, Japan		Murata, S (通讯作者)，Kita 18,Nishi 9,Kita Ku, Sapporo, Hokkaido 0600818, Japan.	murata@vetmed.hokudai.ac.jp		Satoru, Konnai/0000-0002-3230-7109	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [18H02332, 20H03137, K21357]	This research was supported in part by Grants-in-Aid for Scien-tific Research (B: 18H02332 and B: 20H03137) and Grant-in-Aid for Challenging Research (Exploratory) (20 K21357) from the Japan Society for the Promotion of Science.	Ariizumi T, 2021, J VET MED SCI, V83, P558, DOI 10.1292/jvms.20-0677; Azhahianambi P, 2009, J Parasitol Res, V2009, DOI 10.1155/2009/165812; Bartley K, 2017, VET PARASITOL, V244, P25, DOI 10.1016/j.vetpar.2017.06.020; Bartley K, 2015, INT J PARASITOL, V45, P819, DOI 10.1016/j.ijpara.2015.07.004; Bartley K, 2012, PARASITOLOGY, V139, P755, DOI 10.1017/S0031182011002356; Chen W, 2021, PARASITE VECTOR, V14, DOI 10.1186/s13071-020-04562-9; Fischereder E, 2014, BIOORGAN MED CHEM, V22, P5633, DOI 10.1016/j.bmc.2014.06.023; Lima-Barbero JF, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030121; Fujisawa S, 2020, PARASITOL INT, V78, DOI 10.1016/j.parint.2020.102156; Harrington D, 2009, VACCINE, V27, P4056, DOI 10.1016/j.vaccine.2009.04.014; Ichii O, 2010, LUPUS, V19, P897, DOI 10.1177/0961203310362534; Ilhan A, 2008, BIOCHEM J, V414, P485, DOI 10.1042/BJ20080503; Lima-Barbero JF, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040190; Ma YH, 2016, J PROTEOME RES, V15, P628, DOI 10.1021/acs.jproteome.5b01030; Mizukami M, 2010, CURR PHARM BIOTECHNO, V11, P251, DOI 10.2174/138920110791112031; Murata S, 2021, PARASITE, V28, DOI 10.1051/parasite/2021005; Pritchard J, 2015, AVIAN PATHOL, V44, P143, DOI 10.1080/03079457.2015.1030589; RAND KN, 1989, P NATL ACAD SCI USA, V86, P9657, DOI 10.1073/pnas.86.24.9657; Ribeiro JMC, 2003, ANNU REV ENTOMOL, V48, P73, DOI 10.1146/annurev.ento.48.060402.102812; Stockigt J, 2008, PLANT PHYSIOL BIOCH, V46, P340, DOI 10.1016/j.plaphy.2007.12.011; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/oxfordjournals.molbev.a040023]; Wikel SK, 1996, ANNU REV ENTOMOL, V41, P1, DOI 10.1146/annurev.en.41.010196.000245; Willadsen P, 1980, Adv Parasitol, V18, P293, DOI 10.1016/S0065-308X(08)60402-9; WILLADSEN P, 1989, J IMMUNOL, V143, P1346; Wright Harry W, 2016, Parasit Vectors, V9, P544; Wright HW, 2009, EXP APPL ACAROL, V48, P81, DOI 10.1007/s10493-009-9243-5; Xu XL, 2020, VACCINE, V38, P7842, DOI 10.1016/j.vaccine.2020.10.010	27	1	1	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	OCT 1	2021	39	41					6057	6066		10.1016/j.vaccine.2021.08.104		SEP 2021	10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UY8XC	34509323				2022-04-29	WOS:000701799200008
J	Clayton, K; Finley, C; Flynn, DJ; Graves, M; Nyhan, B				Clayton, Katherine; Finley, Christine; Flynn, D. J.; Graves, Meredith; Nyhan, Brendan			Evaluating the effects of vaccine messaging on immunization intentions and behavior: Evidence from two randomized controlled trials in Vermont	VACCINE			English	Article						Vaccine hesitancy; Childhood vaccines; Public health; Misperceptions; Myths; Facts; Norms	UNITED-STATES; PARENT ATTITUDES; COVERAGE; KINDERGARTEN; PERCEPTIONS; EXPOSURE; CHILDREN; MYTHS	The effectiveness of vaccines in reducing child morbidity and mortality worldwide relies on public accep-tance. However, relatively little is known about the effects of vaccine communication on vaccine attitudes and immunization behavior. Previous research suggests that common communication approaches may be ineffective or even counterproductive, especially among vaccine-hesitant parents. However, these studies typically rely on observational data or self-reported measures of vaccination intention. Using novel research designs, we tested the attitudinal and behavioral effects of messages encouraging vacci-nation in both a survey experiment conducted among a large sample of parents in Vermont who expressed hesitancy about childhood immunizations and a field experiment among parents whose chil-dren were overdue for vaccines. We find that neither a message promoting immunization as a social norm nor a message correcting common misperceptions about vaccines was measurably more effective than a standard public health message at improving parents' attitudes toward vaccines, intention to vac-cinate their children, or compliance with the recommended vaccine schedule. Our results highlight the need for more research on approaches to successfully reducing vaccine hesitancy among parents. (c) 2021 Elsevier Ltd. All rights reserved.	[Clayton, Katherine] Stanford Univ, Dept Polit Sci, Stanford, CA 94305 USA; [Finley, Christine; Graves, Meredith] Vermont Dept Hlth, Immunizat Program, Burlington, VT 05402 USA; [Flynn, D. J.] IE Univ, Sch Global & Publ Affairs, Segovia, Spain; [Nyhan, Brendan] Dartmouth Coll, Dept Govt, Hanover, NH 03755 USA		Clayton, K (通讯作者)，Stanford Univ, Dept Polit Sci, Stanford, CA 94305 USA.	kpc14@stanford.edu	Clayton, Katherine/ABF-2269-2021	Clayton, Katherine/0000-0003-0740-5230	National Academy of Sciences; Rita Allen Foundation	Christine Finley was the Immunization Program director and Meredith Graves was an epidemiologist at the Vermont Department of Health at the time this study was conducted. We gratefully acknowledge funding support from the National Academy of Sciences and the Rita Allen Foundation and assistance from Jessie Hammond, Bridget Ahrens, and Nick Pain at the Vermont Department of Health. All conclusions and any errors are, of course, our own.	Bartels RD, 2010, PSYCHOL HEALTH, V25, P821, DOI 10.1080/08870440902893708; Bicchieri C., 2019, PUBLIC CHOICE, DOI [10.1007/s11127-019-00684-6, DOI 10.1007/S11127-019-00684-6]; Bloom BR, 2014, SCIENCE, V344, P339, DOI 10.1126/science.1254834; Cameron KA, 2013, PATIENT EDUC COUNS, V92, P381, DOI 10.1016/j.pec.2013.06.017; Carey J, 2022, J ELECT PUBLIC OPIN, V32, P230, DOI 10.1080/17457289.2020.1790577; CIALDINI RB, 1991, ADV EXP SOC PSYCHOL, V24, P201; Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987; Eisend M, 2016, J ADVERTISING, V45, P519, DOI 10.1080/00913367.2016.1185981; Erceg-Hurn DM, 2011, J APPL SOC PSYCHOL, V41, P219, DOI 10.1111/j.1559-1816.2010.00710.x; Facher Lev, 2021, STAT-US; Gerber AS, 2008, AM POLIT SCI REV, V102, P33, DOI 10.1017/S000305540808009X; Gerend MA, 2007, HEALTH PSYCHOL, V26, P745, DOI 10.1037/0278-6133.26.6.745; Ghorayshi Azeen, 2017, BUZZFEED NEWS 0518; Glanz JM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1117; Goldstein NJ, 2008, J CONSUM RES, V35, P472, DOI 10.1086/586910; Henrikson NB, 2015, PEDIATRICS, V136, P70, DOI 10.1542/peds.2014-3199; Horne Z, 2015, P NATL ACAD SCI USA, V112, P10321, DOI 10.1073/pnas.1504019112; Jacob V, 2016, AM J PREV MED, V50, P797, DOI 10.1016/j.amepre.2015.11.003; Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112; Kolb Noyes Amy, 2017, VERMONT PUBLIC 0612; Lakens D, 2018, ADV METH PRACT PSYCH, V1, P259, DOI 10.1177/2515245918770963; Lakens D, 2017, SOC PSYCHOL PERS SCI, V8, P355, DOI 10.1177/1948550617697177; McCaul KD, 2002, HEALTH PSYCHOL, V21, P624, DOI 10.1037//0278-6133.21.6.624; Michael Hallsworth, 2021, BEHAV INSIGHTS 0315; Nowak GJ, 2017, VACCINE, V35, P5543, DOI 10.1016/j.vaccine.2017.08.064; Nuole Chen, 2020, IN PRESS; Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Office of Disease Prevention and Health Promotion, 2020, IMM INF DIS; Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483; Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120; Paluck EL, 2009, ANNU REV PSYCHOL, V60, P339, DOI 10.1146/annurev.psych.60.110707.163607; Pluviano S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181640; Reavis RD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181368; Rosengren S, 2020, J MARKETING, V84, P39, DOI 10.1177/0022242920929288; Rothman AJ, 1997, PSYCHOL BULL, V121, P3, DOI 10.1037/0033-2909.121.1.3; Ruiz JB, 2014, VACCINE, V32, P5776, DOI 10.1016/j.vaccine.2014.08.042; Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013; Seither R, 2019, MMWR-MORBID MORTAL W, V68, P905, DOI 10.15585/mmwr.mm6841e1; Seither R, 2015, MMWR-MORBID MORTAL W, V64, P897, DOI 10.15585/mmwr.mm6433a2; Vermont Department of Health, 2020, VACCINATION COVERAGE; Williams Joshua TB, 2019, PEDIATRICS, V144, P1; Witte K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506; Zhang Jingwen, 2020, PREV MED	44	1	1	3	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5909	5917		10.1016/j.vaccine.2021.08.047		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	US5XJ	34481697				2022-04-29	WOS:000697501500025
J	O'Lorcain, P; Cotter, S; Walsh, C				O'Lorcain, Piaras; Cotter, Suzanne; Walsh, Cathal			Influenza vaccine uptake among healthcare workers and residents in public health care facilities in Ireland over nine influenza seasons (2011-2012 to 2019-2020)	VACCINE			English	Article						Seasonal influenza; Vaccination; Uptake; Healthcare workers	COVERAGE; EFFICACY; RATES; RISK	The influenza vaccine is free to all healthcare workers (HCWs) working in hospitals and long-term/ residential health care facilities in Ireland. To evaluate influenza vaccine uptake, the Health Service Executive-Health Protection Surveillance Centre surveyed HCWs each season between 2011-2012 and 2019-2020. The national HCW uptake target was 40% for the first six seasons and was increased to 75% for the 2019-2020 season. Data on seasonal influenza vaccine uptake among HCWs employed in these healthcare settings were obtained using web-based surveys sent to occupational or management contact points. Data on numbers of staff vaccinated by Health Service Executive (HSE) professional staff grade and numbers eligible for vaccination in each grade were provided. Since the 2017-2018 season, a point prevalence survey for residents to assess influenza vaccine uptake has also been undertaken in long-term/residential care facilities (LTCFs) and aggregate data submitted, initially using a desktop spreadsheet survey tool, but later using web-based survey tools; these surveys were undertaken to investigate how uptake differed between HCWs and residents, both long-term and short-term. Participation by healthcare facilities and influenza vaccine uptake by both HCWs and LTCF-residents in these surveys increased over the nine seasons. Uptake among HCWs employed in publicly-funded hospitals increased from 18.1% (2011-2012) to 58.9% (2019-2020). Uptake in publicly-funded LTCFs increased from 17.8% (2011-2012) to 45.5% (2019-2020). Overall, uptake among hospital nursing staff was lowest among all staff categories for most seasons, but increased from 12.4% in 2011-2012 to 58.1% in 2019- 2020. In all seasons since 2011-2012, medical/dental, management/administrative or health and social care professional staff reported the highest uptake values in public LTCFs. Of the three annual point prevalence surveys between 2017-2018 and 2019-2020, all showed high overall uptake among longterm residents (between 88.9% and 89.4%), and a lower and wider uptake range among respite residents (between 57.5% and 66.5%). (c) 2021 Elsevier Ltd. All rights reserved.	[O'Lorcain, Piaras; Cotter, Suzanne; Walsh, Cathal] Hlth Protect Surveillance Ctr, Dublin, Ireland; [Walsh, Cathal] Univ Limerick, Hlth Res Inst, Limerick, Ireland; [Walsh, Cathal] Univ Limerick, Math Applicat Consortium Sci & Ind MACSI, Limerick, Ireland		O'Lorcain, P (通讯作者)，Hlth Protect Surveillance Ctr HSE HPSC, 25-27 Middle Gardiner St, Dublin 1, Ireland.	piaras.olorcain@hse.ie					Abramson ZH, 2008, VACCINE, V26, P2482, DOI 10.1016/j.vaccine.2008.03.011; [Anonymous], 2018, R LANGUAGE ENV STAT; Bautista D, 2006, INFECT CONT HOSP EP, V27, P73, DOI 10.1086/499148; Black CL, 2018, MMWR-MORBID MORTAL W, V67, P1050, DOI 10.15585/mmwr.mm6738a2; Bridges Carolyn B, 2003, MMWR Recomm Rep, V52, P1; Christini AB, 2007, INFECT CONT HOSP EP, V28, P171, DOI 10.1086/511796; COLES FB, 1992, J AM GERIATR SOC, V40, P589, DOI 10.1111/j.1532-5415.1992.tb02108.x; Commission of the European Communities, 2009, PROP COUNC REC SEAS; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Esposito S, 2007, VACCINE, V25, P5283, DOI 10.1016/j.vaccine.2007.05.011; European Centres for Disease Control, 2012, RISK ASS SEAS INF 20; Giese C, 2016, VACCINE, V34, P3657, DOI 10.1016/j.vaccine.2016.05.028; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; Governement New South Wales, 2018, 781760810351 HCW GOV; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Harbarth S, 1998, INFECT CONT HOSP EP, V19, P337; Haviari S, 2015, HUM VACC IMMUNOTHER, V11, P2522, DOI 10.1080/21645515.2015.1082014; Health Service Excecutive Ireland, 2018, NAT SERV PLAN 2019; Health Service Excecutive Ireland, 2019, NAT GRAD COD LIST PU; Health Service Excecutive Ireland, 2019, NAT SERV PLAN 2020; Health Service Excecutive Ireland, 2017, NAT SERV PLAN 2018; Health Service Excecutive Ireland. National Immunisation Advisory Committee, 2019, IMM GUID CHAP 11 INF, P7; Health Service Executive Ireland, 2015, ROL NAT IMM OFF 2005; Health Service Executive Ireland. National Immunisation Office & National Clinical Lead in Occupational Health, 2019, SEAS INFL PEER VACC; Health Service Executive-Health Protection Surveillance Centre, PUBL HLTH GUID PREV; Hollmeyer H, 2013, INFLUENZA OTHER RESP, V7, P604, DOI 10.1111/irv.12002; Hollmeyer HG, 2009, VACCINE, V27, P3935, DOI 10.1016/j.vaccine.2009.03.056; Johnson SA, 2016, AUST NZ J PUBL HEAL, V40, P281, DOI 10.1111/1753-6405.12517; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Kimura A. C., 2005, Morbidity and Mortality Weekly Report, V54, P196; Maltezou HC, 2019, VACCINE, V37, P7576, DOI 10.1016/j.vaccine.2019.09.061; Mehta M, 2008, J HOSP INFECT, V70, P76, DOI 10.1016/j.jhin.2008.04.028; O'Flanagan D, 2014, EUROSURVEILLANCE, V19, P15, DOI 10.2807/1560-7917.ES2014.19.17.20789; Pharmaceutical society of ireland, 2019, GUID PROV VACC SERV; Quintyne K I, 2018, Ir Med J, V111, P749; Royal College of Physicians of Ireland, 2018, INFL VACC HEALTHC WO; Stevenson CG, 2001, CAN MED ASSOC J, V164, P1413; To KW, 2016, J HOSP INFECT, V94, P133, DOI 10.1016/j.jhin.2016.07.003; Wicker S, 2009, INFECTION, V37, P197, DOI 10.1007/s15010-008-8200-2; World Health Organization, 2003, PREV CONTR INFL PAND	41	2	2	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	SEP 24	2021	39	40					5954	5962		10.1016/j.vaccine.2021.07.082		SEP 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	US5XJ	34462164				2022-04-29	WOS:000697501500030
J	Chhatwal, J; Sapru, A; Sundaram, B; Shenoy, B; Chand, R; Yi, K; Suroju, S; Scott, DA; Lockhart, S				Chhatwal, Jugesh; Sapru, Amita; Sundaram, Balasubramanian; Shenoy, Bhaskar; Chand, Rohit; Yi, Kevin; Suroju, Suresh; Scott, Daniel A.; Lockhart, Stephen			A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India	VACCINE			English	Article						Pneumococcal; PCV13; Phase 4 study; Adolescent vaccination; Children; Safety	STREPTOCOCCUS-PNEUMONIAE; RECOMMENDED IMMUNIZATION; B DISEASE; IMMUNOGENICITY; ADOLESCENTS; SCHEDULE; ACADEMY; BURDEN	Purpose: The 13-valent pneumococcal conjugate vaccine (PCV13) was recently approved in India for the prevention of pneumococcal disease in children aged 6 to 17 years based on global data as well as immunogenicity and safety findings from a phase 3 study. The current phase 4 study in India further eval-uated the safety profile of PCV13 in this age group to support the positive benefit-risk profile of PCV13. Methods: Healthy male and female children aged 6 to 17 years in India were administered a single intra-muscular injection of PCV13. Through 7 days after PCV13 administration, local reactions and systemic events were recorded daily by caregivers in an electronic diary. Adverse events (AEs) were collected from the provision of informed consent through 28-42 days postvaccination. Results: One hundred subjects enrolled in and completed the study. After PCV13 vaccination, 73.9% and 57.8% of subjects reported local reactions and systemic events, respectively. The majority of reactogenicity events were mild to moderate in severity, with injection site pain and fatigue the most frequently reported local reaction and systemic event, respectively. Six subjects reported 7 AEs, all of which were considered unrelated to PCV13. One subject reported a serious AE (acute hepatitis), which was considered unrelated to PCV13 and ultimately resolved. No subjects withdrew because of AEs, and there were no deaths. Conclusion: PCV13 vaccination was well tolerated with an acceptable safety profile in healthy subjects aged 6 to 17 years in India. This work further supports the safety profile of PCV13 for prevention of pneu-mococcal disease in this age group in India. (c) 2021 Elsevier Ltd. All rights reserved.	[Chhatwal, Jugesh] Christian Med Coll & Hosp, Dept Paediat Med, Ludhiana, Punjab, India; [Sapru, Amita] KEM Hosp Res Ctr, Dept Paediat, Pune, Maharashtra, India; [Sundaram, Balasubramanian] Kanchi Kamakoti CHILDS Trust Hosp, Dept Paediat, Chennai, Tamil Nadu, India; [Shenoy, Bhaskar] Manipal Hosp, Dept Paediat, Bengaluru, Karnataka, India; [Chand, Rohit] Pfizer Ltd, Global Site & Study Operat, Mumbai, Maharashtra, India; [Yi, Kevin] Pfizer Inc, Med Dev Vaccines, Collegeville, PA USA; [Suroju, Suresh; Lockhart, Stephen] Pfizer Ltd, Vaccine Clin Res & Dev, Hurley, England; [Scott, Daniel A.] Pfizer Inc, Vaccine Clin Res & Dev, Collegeville, PA USA		Lockhart, S (通讯作者)，Pfizer Vaccine Clin Res & Dev, Hurley, England.	stephen.p.lockhart@pfizer.com		chhatwal, jugesh/0000-0002-7278-8963; Scott, Daniel/0000-0002-4916-145X; Sapru, Amita/0000-0002-2076-2438; Lockhart, Stephen/0000-0002-0805-2193	Pfizer Inc.Pfizer	Editorial/medical writing support was provided by Emily Stackpole, PhD, of ICON plc (North Wales, PA), and was funded by Pfizer Inc.	Agarkhedkar S, 2017, PEDIATR INFECT DIS J, V36, pE283, DOI [10.1097/INF.0000000000001695, 10.1097/inf.0000000000001695]; Amdekar YK, 2013, PEDIATR INFECT DIS J, V32, P509, DOI 10.1097/INF.0b013e31827b478d; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129; Balasubramanian S, 2018, INDIAN PEDIATR, V55, P1066, DOI 10.1007/s13312-018-1444-8; Banerjee AK, 2013, DRUG SAFETY, V36, P1129, DOI 10.1007/s40264-013-0113-z; Bennett NM, 2013, MMWR-MORBID MORTAL W, V62, P521; Coons SJ, 2015, PATIENT, V8, P301, DOI 10.1007/s40271-014-0090-z; De Montalembert M, 2015, PEDIATR BLOOD CANCER, V62, P1427, DOI 10.1002/pbc.25502; Farooqui H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129191; Frenck R, 2014, PEDIATR INFECT DIS J, V33, P183, DOI 10.1097/INF.0000000000000056; Hofstetter AM, 2015, HUM VACC IMMUNOTHER, V11, P2571, DOI 10.1080/21645515.2015.1067350; Hung TY, 2017, CANCER-AM CANCER SOC, V123, P4215, DOI 10.1002/cncr.30764; Jayaraman Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197198; Malik Akash, 2013, Indian J Community Med, V38, P189, DOI 10.4103/0970-0218.120140; Nisarga R, 2015, INDIAN PEDIATR, V52, P205, DOI 10.1007/s13312-015-0607-0; Rudan I, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010401; Shigayeva A, 2016, CLIN INFECT DIS, V62, P139, DOI 10.1093/cid/civ803; Solanki BB, 2017, HUM VACC IMMUNOTHER, V13, P2065, DOI 10.1080/21645515.2017.1331796; Vashishtha VM, 2014, INDIAN PEDIATR, V51, P785, DOI 10.1007/s13312-014-0504-y; Wahl B, 2019, LANCET GLOB HEALTH, V7, pE735, DOI 10.1016/S2214-109X(19)30081-6; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; World Health Organization, PNEUMOCOCCAL CONJUGA	22	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 31	2021	39	37					5313	5317		10.1016/j.vaccine.2021.07.055		AUG 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UC7ZI	34366142				2022-04-29	WOS:000686741800013
J	Rosenthal, EM; Hall, EW; Rosenberg, ES; Harris, A; Nelson, NP; Schillie, S				Rosenthal, Elizabeth M.; Hall, Eric W.; Rosenberg, Eli S.; Harris, Aaron; Nelson, Noele P.; Schillie, Sarah			Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations (vol 38, pg 8206, 2020)	VACCINE			English	Correction									[Rosenthal, Elizabeth M.; Rosenberg, Eli S.] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, 1 Univ Pl, Rensselaer, NY 12222 USA; [Hall, Eric W.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Harris, Aaron; Nelson, Noele P.; Schillie, Sarah] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA		Rosenthal, EM (通讯作者)，SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, 1 Univ Pl, Rensselaer, NY 12222 USA.	emrosenthal@albany.edu		Hall, Eric/0000-0003-0244-7458			Rosenthal EM, 2020, VACCINE, V38, P8206, DOI 10.1016/j.vaccine.2020.10.067	1	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 23	2021	39	36					5231	5231		10.1016/j.vaccine.2021.07.070		AUG 2021	1	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UA0TP	34344554	hybrid			2022-04-29	WOS:000684878300020
J	At Thobari, J; Damayanti, W; Haposan, JH; Nirwati, H; Iskandar, K; Samad; Fahmi, J; Sari, RM; Bachtiar, NS; Watts, E; Bines, JE; Soenarto, Y				At Thobari, Jarir; Damayanti, Wahyu; Haposan, Jonathan Hasian; Nirwati, Hera; Iskandar, Kristy; Samad; Fahmi, Julianita; Sari, Rini Mulia; Bachtiar, Novilia Sjafri; Watts, Emma; Bines, Julie E.; Soenarto, Yati			Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial	VACCINE			English	Article						Rotavirus; Diarrhea; RV3; Rotavirus vaccine	ATTENUATED HUMAN ROTAVIRUS; AFRICAN; IMPACT	Background: Despite safe and effective WHO prequalified rotavirus vaccines, at least 84 million children remain unvaccinated. A birth dose schedule of the RV3-BB vaccine was reported to be highly efficacious against severe rotavirus disease in Indonesian infants and is under further development at PT Bio Farma, Indonesia. The aim is to develop a rotavirus vaccine starting from birth that could improve the implemen-tation, safety, and effectiveness of vaccines. Methods: A multi-site phase I study of a human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, neonates in Indonesia from April 2018 to March 2019. The adult and child cohorts were open-labeled single-dose, while the neonatal cohort was randomized, double-blind, and placebo -controlled three-doses at the age of 0-5 days, 8-10 weeks, and 12-14 weeks. The primary objective was to assess the safety of vaccines with the immunogenicity and vaccine virus fecal shedding as the sec-ondary endpoints in neonates. Results: Twenty-five adults, 25 children, and 50 neonates were recruited, and all but one in the neonatal cohort completed all study procedures. Three serious adverse events were reported (1 adult & 2 neo-nates), but none were assessed related to investigational product (IP). The neonatal vaccine group had a significantly higher positive immune response (cumulative seroconverted SNA and IgA) 28 days after three doses than those in the placebo group (72% vs. 16.7%, respectively). The GMT of serum IgA in the vaccine group was significantly higher at post IP dose 1 (p < 0.05) and post IP dose 3 (p < 0.001) compared to the placebo group. Conclusion: The trial results show that the RV3 rotavirus vaccine (Bio Farma) is well tolerated in all par-ticipant cohorts (adults, children, and neonates). Three doses of this vaccine administered in a neonatal schedule were immunogenic. These promising results support further clinical development of the RV3 rotavirus vaccine (Bio Farma). (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[At Thobari, Jarir] Univ Gadjah Mada, Dept Pharmacol & Therapy, Fac Med Publ Hlth & Nursing, Jalan Farmako, Yogyakarta 55281, Indonesia; [At Thobari, Jarir; Damayanti, Wahyu; Haposan, Jonathan Hasian; Nirwati, Hera; Iskandar, Kristy; Soenarto, Yati] Univ Gadjah Mada, Ctr Child Hlth, Fac Med Publ Hlth & Nursing, Yogyakarta, Indonesia; [Damayanti, Wahyu; Soenarto, Yati] Univ Gadjah Mada, Dept Child Hlth, Fac Med Publ Hlth & Nursing, Sardjito Gen Hosp, Yogyakarta, Indonesia; [Nirwati, Hera] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Microbiol, Yogyakarta, Indonesia; [Iskandar, Kristy] Univ Gadjah Mada, Acad Hosp, Yogyakarta, Indonesia; [Samad] Dr Soeradji Tirtonegoro Gen Hosp, Dept Pediat, Klaten, Central Java, Indonesia; [Fahmi, Julianita; Sari, Rini Mulia; Bachtiar, Novilia Sjafri] PT Bio Farma, Bandung, West Java, Indonesia; [Bachtiar, Novilia Sjafri] Murdoch Childrens Res Inst MCRI, Parkville, Vic, Australia; [Watts, Emma; Bines, Julie E.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Bines, Julie E.] Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Parkville, Vic, Australia		At Thobari, J (通讯作者)，Univ Gadjah Mada, Dept Pharmacol & Therapy, Fac Med Publ Hlth & Nursing, Jalan Farmako, Yogyakarta 55281, Indonesia.	j.atthobari@ugm.ac.id		At Thobari, Jarir/0000-0002-7035-4846; Bines, Julie/0000-0002-5452-6601	PT Bio Farma [07553/DIR/XII/2019, PO00025935]; PT Bio Farma	This trial was funded by PT Bio Farma with ID grant: 07553/DIR/XII/2019, PO00025935. The Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada received funds from PT Bio Farma as stated in the clinical trial agreement.	[Anonymous], 2009, Wkly Epidemiol Rec, V84, P220; Azevedo MSP, 2010, CLIN VACCINE IMMUNOL, V17, P420, DOI 10.1128/CVI.00395-09; Bines JE, 2018, NEW ENGL J MED, V378, P719, DOI 10.1056/NEJMoa1706804; Bines JE, 2015, LANCET INFECT DIS, V15, P1389, DOI 10.1016/S1473-3099(15)00227-3; Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186; CAMERON DJS, 1978, J MED VIROL, V2, P7, DOI 10.1002/jmv.1890020103; Cherian T, 2012, VACCINE, V30, pA3, DOI 10.1016/j.vaccine.2011.10.007; Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2; Clark AD, 2019, INT J EPIDEMIOL, V48, P1316, DOI 10.1093/ije/dyz028; Danchin M, 2013, VACCINE, V31, P2610, DOI 10.1016/j.vaccine.2013.04.008; Danchin MH, 2020, VACCINE, V38, P3235, DOI 10.1016/j.vaccine.2020.02.087; Ella R, 2018, HUM VACC IMMUNOTHER, V14, P1791, DOI 10.1080/21645515.2018.1450709; Kawade A, 2019, VACCINE, V37, P2554, DOI 10.1016/j.vaccine.2019.03.067; Kerdpanich A, 2010, HUM VACCINES, V6, P254, DOI 10.4161/hv.6.3.10428; Lo Vecchio A, 2017, VACCINE, V35, P1637, DOI 10.1016/j.vaccine.2017.01.082; MedDRA MSSO, 2018, MED DICT REG ACT TER MED DICT REG ACT TER, V21; MICLAT NN, 1978, ANESTH ANALG, V57, P98; Mulyani NS, 2018, VACCINE, V36, P7826, DOI 10.1016/j.vaccine.2018.05.031; Padmawati RS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6706-4; Patel M, 2013, J INFECT DIS, V208, P284, DOI 10.1093/infdis/jit166; Rathi N, 2018, VACCINE, V36, P7943, DOI 10.1016/j.vaccine.2018.11.006; Seale H, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1187-3; Soenarto Y, 2009, BURDEN SEVERE ROTAVI, P200; Steele AD, 2010, J INFECT DIS, V202, pS93, DOI 10.1086/653550; Steele AD, 2016, HUM VACC IMMUNOTHER, V12, P2406, DOI 10.1080/21645515.2016.1179412; Teitelbaum JE, 2007, DIGEST DIS SCI, V52, P3396, DOI 10.1007/s10620-007-9743-2; US Food and Drug Administration, 2007, GUID IND TOX GRAD SC; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664; WEISS C, 1985, J GEN VIROL, V66, P2725, DOI 10.1099/0022-1317-66-12-2725; WHO, 2009, MAN ROT DET CHAR MET; World Health Organization, EST ROT DEATHS CHILD; World Health Organization (WHO), 2005, WHO EXP COMM BIOL ST WHO EXP COMM BIOL ST, P3; World Health Organization (WHO), 2015, GUID CLIN EV VACC RE GUID CLIN EV VACC RE; Zhang SR, 2020, HUM VACC IMMUNOTHER, V16, P664, DOI 10.1080/21645515.2019.1671134	34	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4651	4658		10.1016/j.vaccine.2021.06.071		JUL 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	34244006	hybrid			2022-04-29	WOS:000681356500010
J	Sattler, C; Hoffmann, P; Herzberg, PY; Weber, D; Holler, B; Fehn, U; Plentz, A; Beckhove, P; Winkler, J; Edinger, M; Herr, W; Holler, E; Wolff, D				Sattler, Clara; Hoffmann, Petra; Herzberg, Philipp Yorck; Weber, Daniela; Holler, Barbara; Fehn, Ute; Plentz, Annelie; Beckhove, Philipp; Winkler, Julia; Edinger, Matthias; Herr, Wolfgang; Holler, Ernst; Wolff, Daniel			Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation-A single center retrospective efficacy analysis	VACCINE			English	Article						Allogeneic hematopoietic stem cell; transplantation; Vaccination; Immune response; GvHD; B cell reconstitution	VERSUS-HOST-DISEASE; LINKED IMMUNOSORBENT ASSAYS; IMMUNE RECONSTITUTION; MARROW-TRANSPLANTATION; B-CELLS; RECOVERY; VACCINES; TETANUS; LYMPHOPOIESIS; DEFICIENCY	Allogeneic hematopoietic stem cell transplantation (alloHSCT) results in a loss of humoral immunity and subsequent risk for severe infections. Thus, re-vaccination is required but may fail due to incomplete immune reconstitution. We retrospectively analyzed predictors of immune response to primary vaccina-tion applied according to the EBMT (European Blood and Marrow Transplantation Group) recommenda-tions. Serologic response to vaccination against diphtheria (D), tetanus (T), Bordetella pertussis (aP) and Haemophilus influenzae (Hib) (administrated as combined DTaP-Hib-IPV vaccination) was studied in 84 alloHSCT patients transplanted between 2008 and 2015 (age at alloHSCT: 18.6-70.6 years). All patients with a relapse-free survival of >9 months, at least 3 consecutive vaccinations and absence of intravenous immunoglobulin administration within 3 months before and after vaccination met the primary inclusion criteria. Additionally, immunological response to a pneumococcal conjugate vaccine was analyzed in a subgroup of 67 patients. Patients' characteristics at the time of first vaccination were recorded. Responses were measured as vaccine-specific antibody titers. Regarding DTaP-Hib-IPV vaccination, 89.3% (n = 75) of all patients achieved protective titers to at least 3 of the 4 vaccine components and were thus considered responders. 10.7% (n = 9) of the patients were classified as non-responders with positive immune response to less than 3 components. Highest response was observed for Hib (97.4%), tetanus (95.2%) and pneumococcal vaccination (83.6%) while only 68.3% responded to vaccination against Bordetella pertussis. Significant risk factors for failure of vaccination response included low B cell counts (p < 0.001; cut-off: 0.05 B cells/nl) and low IgG levels (p = 0.026; mean IgG of responders 816 mg/dl vs. 475 mg/dl of non-responders). Further, a trend was observed that prior cGvHD impairs vaccination response as 88.9% of the non-responders but only 54.7% of the responders had prior cGvHD (p = 0.073). The results demonstrate, that the currently proposed vaccination strategy leads to seropro-tection in the majority of alloHSCT patients. (c) 2021 Elsevier Ltd. All rights reserved.	[Sattler, Clara; Hoffmann, Petra; Weber, Daniela; Holler, Barbara; Fehn, Ute; Edinger, Matthias; Herr, Wolfgang; Holler, Ernst; Wolff, Daniel] Univ Hosp Regensburg, Dept Internal Med 3, Franz Joseph Strauss Allee 11, D-93053 Regensburg, Germany; [Hoffmann, Petra; Fehn, Ute; Beckhove, Philipp; Edinger, Matthias] Regensburg Ctr Intervent Immunol RCI, Franz Joseph Strauss Allee 11, D-93053 Regensburg, Germany; [Herzberg, Philipp Yorck] Helmut Schmidt Univ Hamburg, Fac Humanities & Social Sci, Personal Psychol & Psychol Assessment, Holstenhofweg 85, D-22043 Hamburg, Germany; [Plentz, Annelie] Univ Hosp Regensburg, Dept Med Microbiol & Hyg, Franz Joseph Strauss Allee 11, D-93053 Regensburg, Germany; [Winkler, Julia] Univ Hosp Erlangen, Dept Med Hematol & Oncol 5, Ulmenweg 18, D-91054 Erlangen, Germany		Wolff, D (通讯作者)，Univ Hosp Regensburg, Dept Internal Med 3, Franz Joseph Strauss Allee 11, D-93053 Regensburg, Germany.	daniel.wolff@ukr.de			German Jose Carreras Foundation project "GVHD Competence center Regensburg"; Regensburg Center of Interventional Immunology; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)German Research Foundation (DFG) [324392634, TRR221]	Daniel Wolff and Ernst Holler have been supported by a grant from the German Jose Carreras Foundation project "GVHD Competence center Regensburg". Ute Fehn was supported by a grant from the Regensburg Center of Interventional Immunology. Daniel Wolff and Julia Winkler received additional support by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Projekt-ID 324392634, TRR221, subproject B10) . All authors attest they meet the ICMJE criteria for authorship.	Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; [Anonymous], 2001, CYTOTHERAPY, V3, P41; Avanzini MA, 2005, EXP HEMATOL, V33, P480, DOI 10.1016/j.exphem.2005.01.005; Basta NE, 2018, P1; Bauters T, 2016, EUR J ONCOL NURS, V21, P212, DOI 10.1016/j.ejon.2015.10.006; Bohmann EM, 2017, ANN HEMATOL, V96, P299, DOI 10.1007/s00277-016-2881-x; Boles EE, 2014, PEDIATR TRANSPLANT, V18, P882, DOI 10.1111/petr.12361; Bosch M, 2012, CURR OPIN HEMATOL, V19, P324, DOI 10.1097/MOH.0b013e328353bc7d; Cherry JD, 1998, VACCINE, V16, P1901, DOI 10.1016/S0264-410X(98)00226-6; Cordonnier C, 2009, CLIN INFECT DIS, V48, P1392, DOI 10.1086/598324; Corre E, 2010, HAEMATOL-HEMATOL J, V95, P1025, DOI 10.3324/haematol.2009.018853; Cox RJ, 2020, NAT REV IMMUNOL, V20, P581, DOI 10.1038/s41577-020-00436-4; Eisenberg RA, 2013, J CLIN IMMUNOL, V33, P388, DOI 10.1007/s10875-012-9813-x; Frasca D, 2010, VACCINE, V28, P8077, DOI 10.1016/j.vaccine.2010.10.023; Goldblatt D, 2007, P1; Gouveia-Alves F, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12903; Greinix HT, 2008, BIOL BLOOD MARROW TR, V14, P208, DOI 10.1016/j.bbmt.2007.10.009; Hilgendorf I, 2012, TRANSPL INT, V25, P87, DOI 10.1111/j.1432-2277.2011.01388.x; Hilgendorf Inken, 2011, Vaccine, V29, P2825, DOI 10.1016/j.vaccine.2011.02.018; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; Lerchenfeldt SM, 2013, TRANSPL INFECT DIS, V15, P634, DOI 10.1111/tid.12110; Ljungman P, 2009, BONE MARROW TRANSPL, V44, P521, DOI 10.1038/bmt.2009.263; Mitchell SA, 2010, BONE MARROW TRANSPL, V45, P762, DOI 10.1038/bmt.2009.238; OCHS L, 1995, BLOOD, V86, P3979, DOI 10.1182/blood.V86.10.3979.bloodjournal86103979; Ogonek J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00507; Oosterhuis-Kafeja F, 2007, VACCINE, V25, P2194, DOI 10.1016/j.vaccine.2006.11.032; Pao M, 2008, BIOL BLOOD MARROW TR, V14, P1022, DOI 10.1016/j.bbmt.2008.06.012; Patel SR, 2007, CLIN INFECT DIS, V44, P625, DOI 10.1086/511641; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Riffelmann M, 2010, J CLIN MICROBIOL, V48, P4459, DOI 10.1128/JCM.01371-10; Robert-Koch-Institut, 2005, EPIDEMIOLOGISCHES B, P1; Roll D, 2012, INFECTION, V40, P153, DOI 10.1007/s15010-011-0206-5; Sarina B, 2010, BLOOD, V115, P3671, DOI 10.1182/blood-2009-12-253856; Scheifele DW, 2009, IMMUNOLOGICAL BASIS, P1; Schoemans HM, 2018, BONE MARROW TRANSPL, V53, P1401, DOI 10.1038/s41409-018-0204-7; Storek J, 2002, TRANSPLANTATION, V73, P1154, DOI 10.1097/00007890-200204150-00026; Storek J, 2003, BLOOD, V101, P3319, DOI 10.1182/blood-2002-05-1376; Storek J, 2001, BLOOD, V98, P489, DOI 10.1182/blood.V98.2.489; Storek J, 2001, BLOOD, V97, P3380, DOI 10.1182/blood.V97.11.3380; Sun J, 2013, CURR OPIN VIROL, V3, P425, DOI 10.1016/j.coviro.2013.05.001; Tittlbach H, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1330-5; Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019; Ullmann AJ, 2016, ANN HEMATOL, V95, P1435, DOI 10.1007/s00277-016-2711-1; van Hoeven KH, 2008, CLIN VACCINE IMMUNOL, V15, P1751, DOI 10.1128/CVI.00254-08; Wirsing von Konig CH, 2017, IMMUNOLOGICAL BASIS, P1; Wolff D, 2011, DTSCH ARZTEBL INT, V108, P732, DOI 10.3238/arztebl.2011.0732	46	1	1	4	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 30	2021	39	33					4742	4750		10.1016/j.vaccine.2021.04.052		JUL 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TU9NN	34049733				2022-04-29	WOS:000681356500020
J	Tuo, WB; Feng, XS; Cao, LL; Vinyard, B; Dubey, JP; Fetterer, R; Jenkins, M				Tuo, Wenbin; Feng, Xiaosheng; Cao, Lili; Vinyard, Bryan; Dubey, J. P.; Fetterer, Raymond; Jenkins, Mark			Vaccination with Neospora caninum-cyclophilin and -profilin confers partial protection against experimental neosporosis-induced abortion in sheep	VACCINE			English	Article						Neospora caninum; Neospora cyclophilin; Neospora profilin; Vaccine; Sheep	REDUCED CEREBRAL INFECTION; VERTICAL TRANSMISSION; BOVINE NEOSPOROSIS; C57BL/6 MICE; TACHYZOITE VACCINE; TOXOPLASMA-GONDII; LIVE TACHYZOITES; IMMUNE-RESPONSE; FETAL LOSS; ANTIGEN	The purpose of this study was to evaluate the protective efficacy of a vaccine consisting of recombinant Neospora caninum-cyclophilin (NcCyP) and-profilin (NcPro) in sheep. At 42 d and 21 d prior to mating, adult Dorset ewes were immunized with the rNcCyP-rNcPro vaccine (Group 1) or co-purifying non-recombinant (NR) control vaccine (Group 2). At 90 days post-mating, all immunized ewes and were chal-lenged by intravenous injection with 10(6) Nesopora caninum Illinois tachyzoites (NcTZ). Significant protec-tion (P < 0.05) was observed in Group 1 with 9 out of 13 ewes giving birth to live-born lambs (69.2%), whereas all Group 2 ewes aborted (6/6). Neospora caninum was detected by PCR in both fetal and placen-tal tissues from all Group 2 aborting ewes and in the placental tissues of Group 1 aborting ewes. In con-trast, tissues and placentas of Group 1 live-born lambs were Neospora DNA-negative. Immunoreactive Neospora antigens were demonstrated in placentas associated with abortions, but not in tissues of aborted fetuses or those of the live-born lambs and their associated placentas. Anti-NcCyP and anti-NcPro titers were high in sera from Group 1 ewes and were further boosted by challenge infection, result-ing in long-lasting (>= 14.5 mos.) elevated titers. Lambs born to Group 1 ewes also had high NcCyP and NcPro titers in pre-colostrum sera. Immunofluorescence staining (IFA) of NcTZ with Group 1 post-immunization sera revealed both surface and internal TZ staining, a pattern consistent with that observed with rabbit sera to rNcCyP or rNcPro. Infection of NR-vaccinated ewes produced high but transient anti-NcCyP and anti-NcPro Ab titers. The results indicate that the NcCyP-NcPro vaccine elicited strong anti-N. caninum responses and conferred significant protection against abortion and transplacental transmission of N. caninum TZ in sheep. (C) 2021 Elsevier Ltd. All rights reserved.	[Tuo, Wenbin; Dubey, J. P.; Fetterer, Raymond; Jenkins, Mark] ARS, Anim Parasit Dis Lab, Beltsville Agr Res Ctr, USDA, Beltsville, MD 20705 USA; [Feng, Xiaosheng] Jilin Univ, Coll Vet Med, Changchun, Peoples R China; [Cao, Lili] Acad Anim Sci & Technol, Changchun, Peoples R China; [Vinyard, Bryan] ARS, USDA, BCS, Beltsville, MD 20705 USA		Jenkins, M (通讯作者)，ARS, Anim Parasit Dis Lab, BARC, USDA, Bldg 1040, Beltsville, MD 20705 USA.	mark.jenkins@ars.usda.gov			USDA-ARS CRIS ProjectUnited States Department of Agriculture (USDA)USDA Agricultural Research Service [12653200006600D]	Authors are grateful to Mr. Eliseo Miramontes, Drs. Oliver Kwok and Celia O'Brien, and Ms. Carolyn Parker for excellent technical assistance. This research was supported by USDA-ARS CRIS Project No. 12653200006600D.	Aguado-Martinez A, 2019, VACCINE, V37, P473, DOI 10.1016/j.vaccine.2018.11.060; Aguado-Martinez A, 2017, INT J PARASITOL, V47, P723, DOI 10.1016/j.ijpara.2017.09.001; Alaeddine F, 2005, J PARASITOL, V91, P657, DOI 10.1645/GE-401R; Alberti J, 2003, NAT IMMUNOL, V4, P485, DOI 10.1038/ni915; ANDERSON ML, 1991, J AM VET MED ASSOC, V198, P241; Andrianarivo AG, 1999, INT J PARASITOL, V29, P1613, DOI 10.1016/S0020-7519(99)00116-2; Baszler TV, 1999, INT J PARASITOL, V29, P1635, DOI 10.1016/S0020-7519(99)00141-1; Benavides J, 2014, PARASITOLOGY, V141, P1471, DOI 10.1017/S0031182014000638; Bengoa-Luoni SA, 2019, ACTA TROP, V198, DOI 10.1016/j.actatropica.2019.105094; Buxton D, 1997, J COMP PATHOL, V117, P1, DOI 10.1016/S0021-9975(97)80062-X; Buxton D, 1998, J COMP PATHOL, V118, P267, DOI 10.1016/S0021-9975(07)80003-X; Buxton D, 1998, VET RES, V29, P289; Cannas A, 2003, PARASITOLOGY, V126, P303, DOI 10.1017/S0031182002002895; Cannas A, 2003, J PARASITOL, V89, P44, DOI 10.1645/0022-3395(2003)089[0044:RCIONC]2.0.CO;2; Mansilla FC, 2016, EXP PARASITOL, V160, P1, DOI 10.1016/j.exppara.2015.10.008; Debache K, 2011, PARASITE IMMUNOL, V33, P81, DOI 10.1111/j.1365-3024.2010.01255.x; Debache K, 2008, INT J PARASITOL, V38, P1455, DOI 10.1016/j.ijpara.2008.04.001; Debache K, 2009, INT J PARASITOL, V39, P1373, DOI 10.1016/j.ijpara.2009.04.006; Dubey J P, 1990, J Vet Diagn Invest, V2, P230; DUBEY JP, 1993, PARASITOL TODAY, V9, P452, DOI 10.1016/0169-4758(93)90099-2; Ellis J, 2008, VACCINE, V26, P5989, DOI 10.1016/j.vaccine.2008.08.043; Eperon S, 1999, PARASITE IMMUNOL, V21, P225, DOI 10.1046/j.1365-3024.1999.00223.x; Feng XS, 2010, J PARASITOL, V96, P717, DOI 10.1645/GE-1900.1; Fereig RM, 2019, VET PARASITOL, V267, P61, DOI 10.1016/j.vetpar.2019.02.003; Fereig RM, 2019, VACCINE, V37, P937, DOI 10.1016/j.vaccine.2019.01.005; Goodswen SJ, 2017, INT J PARASITOL, V47, P779, DOI 10.1016/j.ijpara.2017.08.004; Haldorson GJ, 2005, INT J PARASITOL, V35, P1407, DOI 10.1016/j.ijpara.2005.05.013; Hemphill A, 2016, PARASITOLOGY, V143, P245, DOI 10.1017/S0031182015001596; Horcajo P, 2016, PARASITE IMMUNOL, V38, P709, DOI 10.1111/pim.12342; Jenkins M, 2004, INFECT IMMUN, V72, P1817, DOI 10.1128/IAI.72.3.1817-1819.2004; Jenkins MC, 2010, EXP PARASITOL, V125, P357, DOI 10.1016/j.exppara.2010.03.001; Jenkins MC, 2004, AM J VET RES, V65, P1404, DOI 10.2460/ajvr.2004.65.1404; Jolley WR, 1999, VET PARASITOL, V82, P251, DOI 10.1016/S0304-4017(99)00017-5; Khan IA, 1997, EXP PARASITOL, V85, P24, DOI 10.1006/expr.1996.4110; Liddell S, 1999, INT J PARASITOL, V29, P1583, DOI 10.1016/S0020-7519(99)00101-0; Liddell S, 2003, J PARASITOL, V89, P496, DOI 10.1645/GE-2969; Lindsay DS, 1999, J PARASITOL, V85, P64, DOI 10.2307/3285701; Mansilla FC, 2016, PARASITE IMMUNOL, V38, P663, DOI 10.1111/pim.12354; Marin MS, 2017, VET PARASITOL, V243, P12, DOI 10.1016/j.vetpar.2017.06.005; Marugan-Hernandez V, 2017, J COMP PATHOL, V157, P193, DOI 10.1016/j.jcpa.2017.08.001; Mazuz ML, 2015, PREV VET MED, V120, P232, DOI 10.1016/j.prevetmed.2015.03.020; McAllister MM, 1996, VET PATHOL, V33, P647, DOI 10.1177/030098589603300603; MELLOR DJ, 1979, Q J EXP PHYSIOL CMS, V64, P119, DOI 10.1113/expphysiol.1979.sp002462; Monney T, 2014, EXP PARASITOL, V140, P52, DOI 10.1016/j.exppara.2014.02.015; Moore DP, 2005, VET PARASITOL, V130, P29, DOI 10.1016/j.vetpar.2005.03.010; Muller N, 1996, J CLIN MICROBIOL, V34, P2850; O'Handley RM, 2003, AM J VET RES, V64, P449, DOI 10.2460/ajvr.2003.64.449; Otter A, 1997, VET REC, V140, P175, DOI 10.1136/vr.140.7.175; Pinheiro AF, 2018, VACCINE, V36, P1154, DOI 10.1016/j.vaccine.2018.01.051; Qu GG, 2014, INT J PARASITOL, V44, P355, DOI 10.1016/j.ijpara.2014.01.009; Ramamoorthy S, 2007, INT J PARASITOL, V37, P1531, DOI 10.1016/j.ijpara.2007.04.021; Ramamoorthy S, 2007, INT J PARASITOL, V37, P1521, DOI 10.1016/j.ijpara.2007.04.020; Reichel MP, 2013, INT J PARASITOL, V43, P133, DOI 10.1016/j.ijpara.2012.10.022; Rojo-Montejo S, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-106; Romero JJ, 2004, VET PARASITOL, V123, P149, DOI 10.1016/j.vetpar.2004.06.016; Sammin D, 2009, VET MICROBIOL, V135, P90, DOI 10.1016/j.vetmic.2008.09.054; Tuo W, 2005, J PARASITOL, V91, P564, DOI 10.1645/GE-386R; Tuo W, 2004, PARASITE IMMUNOL, V26, P243, DOI 10.1111/j.0141-9838.2004.00707.x; Tuo WB, 2005, INFECT IMMUN, V73, P5093, DOI 10.1128/IAI.73.8.5093-5100.2005; Tuo WB, 2002, P NATL ACAD SCI USA, V99, P6310, DOI 10.1073/pnas.072071199; Tuo WB, 2011, VACCINE, V29, P2392, DOI 10.1016/j.vaccine.2011.01.041; Vemulapalli R, 2007, VET PARASITOL, V148, P219, DOI 10.1016/j.vetpar.2007.06.029; Weber FH, 2013, CLIN VACCINE IMMUNOL, V20, P99, DOI 10.1128/CVI.00225-12; Williams DJL, 2007, INFECT IMMUN, V75, P1343, DOI 10.1128/IAI.00777-06; Xu J, 2019, VACCINE, V37, P6426, DOI 10.1016/j.vaccine.2019.09.002; Yamage M, 1996, J PARASITOL, V82, P272, DOI 10.2307/3284160; Yin JG, 2012, VET PARASITOL, V187, P28, DOI 10.1016/j.vetpar.2012.01.003	67	0	0	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 22	2021	39	32					4534	4544		10.1016/j.vaccine.2021.06.032		JUL 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TH5WO	34176703				2022-04-29	WOS:000672160300021
J	Hsia, J; Zhao, GX; Lu, PJ; Town, M				Hsia, Jason; Zhao, Guixiang; Lu, Peng-Jun; Town, Machell			Estimating bias from internet non-use for a hybrid web vaccination survey-2013-2017 Behavioral Risk Factor Surveillance System	VACCINE			English	Article						Vaccination survey; Influenza vaccination; Pneumococcal vaccination; Web survey; Undercoverage bias	UNITED-STATES; COVERAGE; INFLUENZA; HEALTH	Objective: To maintain acceptable response rates, the cost has grown for vaccination surveys that use traditional data collection modes, such as face-to-face and telephone interviews. Conducting a web or inter net survey could be a low-cost alternative. However, because the internet is not used by everyone, we need to study how prevalence estimates in web surveys for vaccination surveillance could be affected by internet non-use. Method: We analyzed data from the 2013-2017 Behavioral Risk Factor Surveillance System to assess undercoverage biases from internet non-use by partitioning into proportion of internet non-users and difference in prevalence of influenza and pneumococcal vaccinations between internet and internet non-users, respectively. Results: The proportion of internet non-users decreased monotonically from 43.3% in 2013 to 35.4% in 2017; however, the undercoverage bias from internet use for pneumococcal vaccination increased from 0.8 to 1.5 percentage points at the same time. Overall, the undercoverage bias was-1.1 and 1.5 percentage points for influenza vaccination and pneumococcal vaccination in 2017, respectively. For both vaccinations, we found large absolute and relative biases among certain demographic subgroups. Conclusions: Although the proportion of internet non-users decreased in recent years, undercoverage bias of hybrid internet survey for influenza and pneumococcal vaccinations did not decrease. Despite a small overall undercoverage bias, the bias in subpopulation groups was not negligible. Published by Elsevier Ltd.	[Hsia, Jason; Zhao, Guixiang; Town, Machell] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA; [Lu, Peng-Jun] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30341 USA		Hsia, J (通讯作者)，Ctr Dis Control & Prevent, Div Populat Hlth, 4770 Buford Hwy,MS S107-6, Atlanta, GA 30341 USA.	zxx1@cdc.gov					Bethlehem J., 2012, HDB WEB SURVEYS; Black CL, 2018, MMWR-MORBID MORTAL W, V67, P1050, DOI 10.15585/mmwr.mm6738a2; Centers for Disease Control and Prevention, NAT IMM SURV; Centers for Disease Control and Prevention, NAT HLTH INT SURV; Centers for Disease Control and Prevention, BEH RISK FACT SURV S; Couper MP, 2008, PUBLIC OPIN QUART, V72, P831, DOI 10.1093/poq/nfn066; Czajka J.L., 2016, DECLINING RESPONSE R; Edwards PJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000008.pub4; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Heerwegh D, 2008, PUBLIC OPIN QUART, V72, P836, DOI 10.1093/poq/nfn045; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; NORC at the University of Chicago, NAT FLU SURV NFS; Pierannunzi Carol, 2012, Morbidity and Mortality Weekly Report, V61, P410; Razzaghi H, 2020, MMWR-MORBID MORTAL W, V69, P1391, DOI 10.15585/mmwr.mm6939a2; Ryan C., 2018, AM COMMUNITY SURVEY; Schnell R, 2017, SURV RES METHODS-GER, V11, P105, DOI 10.18148/srm/2017.v11i2.6803; Stanley M, 2019, J SURV STAT METHODOL, V00, P1	17	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4160	4165					6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34127295				2022-04-29	WOS:000672535200021
J	Wang, XS; Xia, AM; Wang, CN; Tian, H; Chang, HL; Zeng, M; Chen, ML				Wang, Xiangshi; Xia, Aimei; Wang, Chuning; Tian, He; Chang, Hailing; Zeng, Mei; Chen, Mingliang			Clinical and molecular characterization of the first culture-confirmed pediatric fulminant meningococcemia case caused by a serogroup Y clonal complex 23 strain in China	VACCINE			English	Article						Neisseria meningitidis; Serogroup Y; China; ST-23 clonal complex; Fulminant invasive meningococcal disease; Genomic analysis; Penicillin resistance	DISEASE	Serogroup Y Neisseria meningitidis (NmY) is rare in China, and only serogroup A and C meningococcal polysaccharide vaccines (MPVs) are included in the national vaccination schedule. We describe a case of fulminant meningococcemia caused by NmY, which occurred in a pediatric patient (2 years old) for the first time in China, confirmed by culture. Although the boy was treated in time, the dry gangrene in his toes and fingers left him with severe sequelae. An NmY isolate was cultured from the blood of the patient, and showed decreased susceptibility to penicillin (minimum inhibitory concentration of 0.125 lg/ml), with sequence type (ST) 1655 assigned to clonal complex (cc) 23. Genomic analysis showed it was clustered with isolates from Italy, UK, Finland, and South Africa, sharing designation of Y:P1.5-1,10-1:F4-1:ST-1655(cc23). The emergence of NmY invasive meningococcal disease cases challenges local immunization strategy and warrants wider usage of MPV-ACYW if there is sustained circulation of NmY. (C) 2021 Elsevier Ltd. All rights reserved.	[Wang, Xiangshi; Xia, Aimei; Wang, Chuning; Tian, He; Chang, Hailing; Zeng, Mei; Chen, Mingliang] Fudan Univ, Childrens Hosp, Dept Infect Dis, 399 Wanyuan Rd, Shanghai 201102, Peoples R China; [Chen, Mingliang] Shanghai Municipal Ctr Dis Control & Prevent, Dept Microbiol, 1380 West Zhongshan Rd, Shanghai 200336, Peoples R China; [Chen, Mingliang] Shanghai Inst Prevent Med, Dept Microbiol, Shanghai, Peoples R China		Zeng, M (通讯作者)，Fudan Univ, Childrens Hosp, Dept Infect Dis, 399 Wanyuan Rd, Shanghai 201102, Peoples R China.; Chen, ML (通讯作者)，Shanghai Municipal Ctr Dis Control & Prevent, Dept Microbiol, 1380 West Zhongshan Rd, Shanghai 200336, Peoples R China.	zengmeigao@aliyun.com; cmlbright@126.com			Wellcome Trust and European UnionWellcome Trust	We thank Dr. Collin Yang of Pediatrics Emergency and Acute Care at BC. Children's Hospital, Canada for his critical comments and language revision. We thank Dr. Baisheng Li of Guangdong CDC for kindly providing the two cc23 genomes before they became publicly available. We thank Dr. Jay Lucidarme of Meningococcal Reference Unit of Public Health England for assistance on genomic analysis. This study made use of Neisseria genomic data deposited in the Neisseria MLST Database (https://pubmlst.org/neisseria/) sited at the University of Oxford (Jolley & Maiden 2018, Wellcome open research, 3:124). The development of this database has been funded by the Wellcome Trust and European Union.	Bratcher HB, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1138; Broker M, 2015, HUM VACC IMMUNOTHER, V11, P2281, DOI 10.1080/21645515.2015.1051276; Chinese Preventive Medicine Association, ZHONGHUA LIU XING BI, V40, P123; CLSI, 2019, M100S29 CLSI; Guo L C, 2016, Zhonghua Yu Fang Yi Xue Za Zhi, V50, P825, DOI 10.3760/cma.j.issn.0253-9624.2016.09.015; Hong E, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00831-18, 10.1128/aac.00831-18]; Krauland MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035699; Li BS, 2019, J INFECTION, V79, P623, DOI 10.1016/j.jinf.2019.07.001; Li J, 2015, CHIN J VACCINE IMMUN, V21, P482; MacNeil JR, 2018, CLIN INFECT DIS, V66, P1276, DOI 10.1093/cid/cix993; Marin JEO, 2021, J ANTIMICROB CHEMOTH, V76, P1155, DOI 10.1093/jac/dkab010; Peruski AH, 2014, EPIDEMIOL INFECT, V142, P2483, DOI 10.1017/S0950268814000259; Potts CC, 2021, CLIN INFECT DIS, V73, P1185, DOI 10.1093/cid/ciab358; Taha MK, 2007, ANTIMICROB AGENTS CH, V51, P2784, DOI 10.1128/AAC.00412-07; Tsang RSW, 2019, J ANTIMICROB CHEMOTH, V74, P22, DOI 10.1093/jac/dky391; Zhou HJ, 2013, EMERG INFECT DIS, V19, P1496, DOI 10.3201/eid1909.130160	16	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 13	2021	39	31					4261	4265		10.1016/j.vaccine.2021.06.019		JUL 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TG0WP	34147293				2022-04-29	WOS:000671133900006
J	Wedlock, PT; Cox, SN; Bartsch, SM; Randall, SL; O'Shea, KJ; Ferguson, MC; Siegmund, SS; Lee, BY				Wedlock, Patrick T.; Cox, Sarah N.; Bartsch, Sarah M.; Randall, Samuel L.; O'Shea, Kelly J.; Ferguson, Marie C.; Siegmund, Sheryl S.; Lee, Bruce Y.			Should countries switch to using five- or ten-dose rotavirus vaccines now that they are available?	VACCINE			English	Article						Rotavirus; Vaccine; Supply chains; Multi-dose vials; Modeling	ROUTINE IMMUNIZATION; SINGLE; IMPACT	Introduction: Single-dose rotavirus vaccines, which are used by a majority of countries, are some of the largest-sized vaccines in immunization programs, and have been shown to constrain supply chains and cause bottlenecks. Efforts have been made to reduce the size of the single-dose vaccines; however, with two-dose, five-dose and ten-dose options available, the question then is whether using multi-dose instead of single-dose rotavirus vaccines will improve vaccine availability. Methods: We used HERMES-generated simulation models of the vaccine supply chains of the Republic of Benin, Mozambique, and Bihar, a state in India, to evaluate the operational and economic impact of implementing each of the nine different rotavirus vaccine presentations. Results: Among single-dose rotavirus vaccines, using Rotarix RV1 MMP (multi-monodose presentation) led to the highest rotavirus vaccine availability (49-80%) and total vaccine availability (56-79%), and decreased total costs per dose administered ($0.02-$0.10) compared to using any other single-dose rota -virus vaccine. Using two-dose ROTASIIL decreased rotavirus vaccine availability by 3-6% across each sup-ply chain compared to Rotarix RV1 MMP, the smallest single-dose vaccine. Using a five-dose rotavirus vaccine improved rotavirus vaccine availability (52-92%) and total vaccine availability (60-85%) com-pared to single-dose and two-dose vaccines. Further, using the ten-dose vaccine led to the highest rota -virus vaccine availability compared to all other rotavirus vaccines in both Benin and Bihar. Conclusion: Our results show that countries that implement five-dose or ten-dose rotavirus vaccines con-sistently reduce cold chain constraints and achieve higher rotavirus and total vaccine availability com-pared to using either single-dose or two-dose rotavirus vaccines. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Wedlock, Patrick T.; Cox, Sarah N.; Bartsch, Sarah M.; Randall, Samuel L.; O'Shea, Kelly J.; Ferguson, Marie C.; Siegmund, Sheryl S.; Lee, Bruce Y.] CUNY, Grad Sch Publ Hlth & Hlth Policy, Publ Hlth Informat Computat & Operat Res PHICOR, New York, NY USA		Lee, BY (通讯作者)，CUNY, Grad Sch Publ Hlth & Hlth Policy, PHICOR, 55 W 125th St, New York, NY 10027 USA.	bruceleemdmba@gmail.com			Bharat Biotech International Limited; National Institute of General Medical Sciences (NIGMS) as part of the Models of Infectious Disease Agent Study (MIDAS) network [R01 GM127512]	This work was supported in part by Bharat Biotech International Limited and by the National Institute of General Medical Sciences (NIGMS) as part of the Models of Infectious Disease Agent Study (MIDAS) network under grant R01 GM127512. The funders did not have any role in the study design, collection, analysis and interpretation of data, writing the report, and the decision to submit the report for publication. The authors of this manuscript are responsible for its content, including data analysis.	[Anonymous], 2020, INDIAN RUPEE INR US; Assi TM, 2011, BMC PUBLIC HEALTH, P11; Bank W, 2018, WORLD BANK NAT ACC P WORLD BANK NAT ACC P; Bank W, 2018, INFL CONS PRIC ANN INFL CONS PRIC ANN; Brown ST, 2014, VACCINE, V32, P4097, DOI 10.1016/j.vaccine.2014.04.090; Brown ST, 2014, VACCINE, V32, P2518, DOI 10.1016/j.vaccine.2014.02.060; Byberg S, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1329968; Cernuschi T, 2018, VACCINE, V36, P6858, DOI 10.1016/j.vaccine.2018.06.012; Flannery B, 2013, VACCINE, V31, P1523, DOI 10.1016/j.vaccine.2013.01.004; Gavi, 2020, DET PROD PROF WHO PR DET PROD PROF WHO PR; Gavi, 2019, GAV SUPP ROT VACC PR GAV SUPP ROT VACC PR; Haidari LA, 2015, VACCINE, V33, P3242, DOI 10.1016/j.vaccine.2015.04.018; International Vaccine Access Center (IVAC), 2020, JH BLOOMB SCH PUBL H JH BLOOMB SCH PUBL H; Kanagat N, 2020, GLOB HEALTH-SCI PRAC, V8, P680, DOI 10.9745/GHSP-D-20-00112; Lee BK, 2011, PLOS ONE, V6; Lee BY, 2017, VACCINE, V35, P4475, DOI 10.1016/j.vaccine.2017.05.096; Lee BY, 2017, VACCINE, V35, pA36, DOI 10.1016/j.vaccine.2016.11.033; Lee BY, 2016, VACCINE, V34, P4998, DOI 10.1016/j.vaccine.2016.08.036; Lee BY, 2012, AM J PUBLIC HEALTH, V102, P269, DOI 10.2105/AJPH.2011.300218; Lee BY, 2011, VACCINE, V29, P3811, DOI 10.1016/j.vaccine.2011.03.013; Lee BY, 2010, VACCINE, V28, P5292, DOI 10.1016/j.vaccine.2010.05.048; Lee BY, 2010, VACCINE, V28, P2806, DOI 10.1016/j.vaccine.2009.09.047; Lee BY., 2019, BMJ GLOB HEALTH, P4; Organization WH, 2014, WHO POL STAT MULT VI WHO POL STAT MULT VI; Organization WH, 2017, CONTR TEMP CHAIN STR CONTR TEMP CHAIN STR; Pecenka C, 2018, VACCINE, V36, P7472, DOI 10.1016/j.vaccine.2018.10.068; Saxenian H, 2015, HEALTH POLICY PLANN, V30, P197, DOI 10.1093/heapol/czu003; UNICEF, 2020, ROT VACC SUPPL DEM U ROT VACC SUPPL DEM U; UNICEF, 2020, VACC PRIC DAT VACC PRIC DAT; Wallace AS, 2017, VACCINE, V35, P6751, DOI 10.1016/j.vaccine.2017.09.082; Wedlock PT, 2019, VACCINE, V37, P637, DOI 10.1016/j.vaccine.2018.12.010; World Health Organization, 2005, MON VACC WAST COUNTR; Wouters OJ, LANCET, V2021; Zaffran M, 2013, VACCINE, V31, pB73, DOI 10.1016/j.vaccine.2012.11.036	34	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 13	2021	39	31					4335	4342		10.1016/j.vaccine.2021.06.021		JUL 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TG0WP	34158215	hybrid			2022-04-29	WOS:000671133900016
J	Ivanov, V; Oomens, AGP; Papin, JF; Staats, R; Reuter, DN; Yu, ZX; Piedra, PA; Wellliver, RC				Ivanov, Vadim; Oomens, Antonius G. P.; Papin, James F.; Staats, Rachel; Reuter, Darlene N.; Yu, Zhongxin; Piedra, Pedro A.; Wellliver, Robert C., Jr.			Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection	VACCINE			English	Article						Respiratory syncytial virus; Mnull RSV accine; RSV vaccine; Infant baboon odel; Bronchiolitis	AEROSOLIZED MEASLES; CANDIDATE; RESPONSES; CHILDREN; DISEASE	Respiratory syncytial virus (RSV) is the major viral respiratory pathogen for human infants and children. Despite a severe global burden incurred by annual RSV epidemics, there is no licensed RSV vaccine. We have developed an RSV vaccine from a human RSV strain from which the gene for the viral M protein has been deleted ("Mnull RSV"). RSV infects airway cells and produces each of its proteins. The M protein is responsible for reassembling the various other synthesized viral proteins into new, intact virus. In the absence of the M protein, therefore, reassembly does not occur, and the Mnull RSV does not replicate. We vaccinated 2-week old infant baboons with Mnull RSV either intranasally (IN) or directly into the lung (intratracheal, or IT), then infected these animals by inoculating human RSV directly into the lung. IN vaccination induced inconsistent serum RSV neutralizing antibody (NA) responses, but provided moderate reductions in respiratory rates, overall signs of illness and viral replication in bronchoalveolar lavage (BAL) fluid following infection. Intratracheal vaccination induced much stronger RSV NA responses, which persisted for at least 4-6 months. Following RSV infection, animals vaccinated by the IT route had much greater reductions in tachypnea and work of breathing than animals vaccinated IN, and had undetectable amounts of virus in BAL fluids. These results support the further development of IT Mnull RSV vaccination to reduce the impact of RSV infection in humans. (c) 2021 Published by Elsevier Ltd.	[Ivanov, Vadim; Staats, Rachel; Wellliver, Robert C., Jr.] Univ Oklahoma, Coll Med, Hlth Sci Ctr, Dept Pediat, 1100 North Lindsay Ave, Oklahoma City, OK 73104 USA; [Oomens, Antonius G. P.] Oklahoma State Univ, Coll Vet Med, Dept Vet Pathol, Room 258 McElroy Hall, Stillwater, OK 74074 USA; [Papin, James F.; Reuter, Darlene N.] Univ Oklahoma, Hlth Sci Ctr, Div Comparat Med, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA; [Yu, Zhongxin] Univ Oklahoma, Coll Med, Hlth Sci Ctr, Dept Pathol, 1100 North Lindsay Ave, Oklahoma City, OK 73104 USA; [Piedra, Pedro A.] Baylor Univ, Baylor Coll Med, Dept Mol Biol & Microbiol & Pediat, 1 Baylor Plaza, Houston, TX 77030 USA		Wellliver, RC (通讯作者)，Univ Oklahoma, Coll Med, Hlth Sci Ctr, Dept Pediat, 1100 North Lindsay Ave, Oklahoma City, OK 73104 USA.	Vadim-Ivanov@OUHSC.edu; Oomens@OKState.edu; James-Papin@OUHSC.edu; Rachel-Staats@OUHSC.edu; Darlene-Reuter@OUHSC.edu; Zhongxin-Yu@OUHSC.edu; PPiedra@BCM.edu; Robert-Welliver@OUHSC.edu			Oklahoma Center for Advancement of Science and Technology (OCAST) [HR13033]; Children's Hospital Foundation HobbsRecknagel Endowed Chair in Pediatrics	This work was funded by a grant from the Oklahoma Center for Advancement of Science and Technology (OCAST) HR13033, and from the Children's Hospital Foundation HobbsRecknagel Endowed Chair in Pediatrics. Neither agency had any role in in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.	Aintablian N, 1998, INFECT CONT HOSP EP, V19, P918; Bennett JV, 2002, B WORLD HEALTH ORGAN, V80, P806; Brinkworth JF, 2012, J MED PRIMATOL, V41, P388, DOI 10.1111/jmp.12002; Foti G, 1997, AM J RESP CRIT CARE, V156, P1210, DOI 10.1164/ajrccm.156.4.96-02031; HALL CB, 1981, J PEDIATR-US, V99, P100, DOI 10.1016/S0022-3476(81)80969-9; Karron RA, 2005, J INFECT DIS, V191, P1093, DOI 10.1086/427813; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Laube Beth L, 2014, Transl Respir Med, V2, P3, DOI 10.1186/2213-0802-2-3; Low N, 2008, VACCINE, V26, P383, DOI 10.1016/j.vaccine.2007.11.010; Malkin E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077104; Wong-Chew RM, 2011, J INFECT DIS, V204, P426, DOI 10.1093/infdis/jir278; Mazur NI, 2018, LANCET INFECT DIS, V18, pE295, DOI 10.1016/S1473-3099(18)30292-5; McFarland EJ, 2018, J INFECT DIS, V217, P1347, DOI 10.1093/infdis/jiy040; MCGEE ZA, 1990, MICROB PATHOGENESIS, V9, P131, DOI 10.1016/0882-4010(90)90087-7; Mejias A, 2020, ANN ALLERG ASTHMA IM, V125, P36, DOI 10.1016/j.anai.2020.03.017; Minne A, 2007, IMMUNOLOGY, V122, P316, DOI 10.1111/j.1365-2567.2007.02641.x; Mitra R, 2012, J VIROL, V86, P4432, DOI 10.1128/JVI.06744-11; Oomens AGP, 2004, J VIROL, V78, P9064, DOI 10.1128/JVI.78.17.9064-9072.2004; Papin JF, 2013, AM J PHYSIOL-LUNG C, V304, pL530, DOI 10.1152/ajplung.00173.2012; Pechenkina, 2013, PRIMATES PATHOGENS E, DOI [10.1007/978-1-4614-7181-3_1, DOI 10.1007/978-1-4614-7181-3_1]; Piedra PA, 2003, VACCINE, V21, P3479, DOI 10.1016/S0264-410X(03)00355-4; PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3; Rose EB, 2018, MMWR-MORBID MORTAL W, V67, P71, DOI 10.15585/mmwr.mm6702a4; Schmidt ME, 2019, J IMMUNOL, V202, P3234, DOI 10.4049/jimmunol.1900050; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Smith DJ, 2003, VACCINE, V21, P2805, DOI 10.1016/S0264-410X(03)00224-X; WHO, RSV VACC RES DEV	27	0	0	3	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4063	4071		10.1016/j.vaccine.2021.06.013		JUN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34140172				2022-04-29	WOS:000672535200010
J	Kochhar, GS; Desai, A; Caldera, F; El Hachem, S; Aoun, E; Sandhu, D; Mohan, BP; Dulai, PS; Farraye, FA				Kochhar, Gursimran S.; Desai, Aakash; Caldera, Freddy; El Hachem, Sandra; Aoun, Elie; Sandhu, Dalbir; Mohan, Babu P.; Dulai, Parambir S.; Farraye, Francis A.			Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease	VACCINE			English	Article						Inflammatory bowel disease; Shingles; Vaccination; Immunity	HERPES-ZOSTER; RISK	Background and Aims: Patients with Inflammatory bowel disease (IBD) are at an increased risk of developing herpes zoster (HZ). The effectiveness of the recombinant zoster vaccine (RZV) in patients with IBD is unknown. Methods: In this retrospective cohort study using Explorys (October 2017-April 2020; IBM Corporation, Somers, NY, USA), the effectiveness of RZV for the prevention of HZ in patients with IBD > 50 years was compared to general population aged > 50 years. Rates of de-novo HZ were compared between patients with IBD and the general population and stratified by number of RZV doses received. Results are presented as odds ratios (OR) with 95% confidence intervals (CI). Results: The overall proportion of IBD patients > 50 years who received HZ vaccination with the live zoster vaccine (ZVL) or RZV was low (n = 11320, out of 112,200 IBD patients in the cohort). A total of 1670 patients received RZV. Receipt of the RZV resulted in a significantly lower rate of HZ in IBD patients (OR 0.36, 95% CI 0.23-0.56) compared to the general population (OR 0.74, 95% CI 0.59-0.92). However, despite vaccination, patients with IBD who received the RZV were still 3-times more likely to develop HZ during the study follow up period compared to the general population receiving the RZV (OR 3.06, 95% CI 1.87- 5.02) and unvaccinated IBD patients were 6-times more likely to develop HZ compared to general population (OR 6.21, 95% CI 6.02-6.41). Conclusion: The recombinant zoster vaccine is effective in reducing the risk of HZ in patients with IBD compared to the general population. During our follow up period, patients with IBD, however, still remain at an increased risk for HZ despite vaccination. (c) 2021 Elsevier Ltd. All rights reserved.	[Kochhar, Gursimran S.; El Hachem, Sandra; Aoun, Elie] Allegheny Hlth Network, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA; [Desai, Aakash; Sandhu, Dalbir] Metro Hlth Hosp, Div Gastroenterol Hepatol & Nutr, Cleveland, OH USA; [Caldera, Freddy] Univ Wisconsin, Div Gastroenterol & Hepatol, Sch Med & Publ Hlth, Madison, WI USA; [Mohan, Babu P.] Univ Arizona, Banner Univ, Med Ctr, Internal Med, Tucson, AZ USA; [Dulai, Parambir S.] Univ Calif San Diego, Div Gastroenterol Hepatol & Nutr, San Diego, CA 92103 USA; [Farraye, Francis A.] Mayo Clin, Div Gastroenterol & Hepatol, Jacksonville, FL USA		Kochhar, GS (通讯作者)，1307 Fed St,Suite B-100, Pittsburgh, PA 15212 USA.			Sandhu, Dalbir/0000-0002-8473-5148; Farraye, Francis/0000-0001-6371-2441; MOHAN, BABU/0000-0002-9512-8693; Desai, Aakash/0000-0002-6604-7712			Altman DG, 1991, PRACTICAL STAT MED R, P455; [Anonymous], REC ADV COMM IMM PRA; Chang K, 2018, CLIN GASTROENTEROL H, V16, P1928, DOI 10.1016/j.cgh.2018.05.024; Cote-Daigneault J, 2019, INFLAMM BOWEL DIS, V25, P914, DOI 10.1093/ibd/izy311; Dagnew AF, 2019, LANCET INFECT DIS, V19, P988, DOI 10.1016/S1473-3099(19)30163-X; Farraye FA, 2017, AM J GASTROENTEROL, V112, P241, DOI 10.1038/ajg.2016.537; Freedman MS, 2021, ANN INTERN MED, V174, P374, DOI 10.7326/M20-8080; Glover M, 2019, DIGEST DIS SCI, V64, P3602, DOI 10.1007/s10620-019-05690-8; Gupta G, 2006, CLIN GASTROENTEROL H, V4, P1483, DOI 10.1016/j.cgh.2006.09.019; Hill E, 2019, MULT SCLER RELAT DIS, V28, P69, DOI 10.1016/j.msard.2018.12.012; Khan N, 2018, CLIN GASTROENTEROL H, V16, P1919, DOI 10.1016/j.cgh.2017.12.052; Kochhar GS, 2020, ALIMENT PHARM THER, V51, P1067, DOI 10.1111/apt.15721; Long MD, 2013, ALIMENT PHARM THER, V37, P420, DOI 10.1111/apt.12182; Olivera PA, 2020, GASTROENTEROLOGY, V158, P1554, DOI 10.1053/j.gastro.2020.01.001; Shingles, 2021, VACC HERP ZOST; Sravanthi Parasa GSC., 2019, J GASTROENTEROL HEPA, V8; Vink P, 2020, CLIN INFECT DIS, V70, P181, DOI 10.1093/cid/ciz177; Vink P, 2019, CANCER-AM CANCER SOC, V125, P1301, DOI 10.1002/cncr.31909	18	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUL 5	2021	39	30					4199	4202		10.1016/j.vaccine.2021.05.043		JUN 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TI1ID	34140170				2022-04-29	WOS:000672535200026
J	Vujovich-Dunn, C; Kaufman, J; King, C; Skinner, SR; Wand, H; Guy, R; Leask, J				Vujovich-Dunn, Cassandra; Kaufman, Jessica; King, Catherine; Skinner, S. Rachel; Wand, Handan; Guy, Rebecca; Leask, Julie			A systematic review and meta-analysis of effectiveness of decision aids for vaccination decision-making	VACCINE			English	Review						Decision aids; Vaccination; Vaccine hesitancy; Decisional conflict; Vaccine uptake	CONTROLLED-TRIAL; PARENTS; STRATEGIES; HESITANCY	Background: This systematic review and meta-analysis aimed to assess the effectiveness of vaccination decision aids compared with usual care on vaccine uptake, vaccine attitudes, decisional conflict, intent to vaccinate and timeliness. Methods: Searches were conducted in OVID Medline, OVID Embase, CINAHL, PsycINFO, the Cochrane Library and SCOPUS. Randomised controlled trials were included if they evaluated the impact of decision aids as defined by the International Patient Decision Aids Standards Collaboration. Where possible, meta analysis was undertaken. Where meta-analysis was not possible, we conducted a narrative synthesis. Risk of bias in included trials was assessed using the Cochrane Collaboration's risk of bias tool. Data were analysed using STATA. Results: Five RCTs were identified that evaluated the effectiveness of decision aids in the context of vaccination decision making. Meta-analysis of four studies showed that decision aids may have slightly increased vaccination uptake, but this was reduced to no effect once studies with higher risk of bias were excluded. Meta-analysis of three studies showed that decision aids moderately increased intention to vaccinate. Narrative synthesis of two studies suggested that decision aids reduced decisional conflict. One study reported that decision aids decreased perceived risk of vaccination. Content, format and delivery method of the decision aids varied across the studies. It was not clear from the information reported whether these variations affected the effectiveness of the decision aids. Conclusion: Decision aids can assist in vaccine decision making. Future studies of decision aids could provide greater detail of the decision aids themselves, which would enable comparison of the effectiveness of different elements and formats. Standardising decision aids would also allow for easier comparison between decision aids. (c) 2021 Elsevier Ltd. All rights reserved.	[Vujovich-Dunn, Cassandra; Wand, Handan; Guy, Rebecca] Univ New South Wales, Fac Med, Kirby Inst, Wallace Wurth Bldg,High St, Kensington, NSW 2052, Australia; [Kaufman, Jessica] Royal Childrens Hosp, Murdoch Childrens Res Inst, 50 Flemington Rd, Parkville, Vic 3052, Australia; [King, Catherine; Leask, Julie] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance, Locked Bag 4001, Westmead, NSW 2145, Australia; [King, Catherine; Skinner, S. Rachel] Univ Sydney, Fac Med & Hlth, Childrens Hosp, Westmead Clin Sch, Locked Bag 4001, Westmead, NSW 2145, Australia; [Skinner, S. Rachel] Univ Sydney, Specialty Child & Adolescent Hlth, Fac Med & Hlth, Camperdown, NSW 2006, Australia; [Leask, Julie] Univ Sydney, Susan Wakil Sch Nursing & Midwifery, Camperdown, NSW 2006, Australia; [Kaufman, Jessica] La Trobe Univ, Sch Psychol & Publ Hlth, Ctr Hlth Commun & Participat, Bundoora, Vic 3086, Australia		Vujovich-Dunn, C (通讯作者)，UNSW, Kirby Inst, Level 6,Wallace Wurth Bldg,High St, Sydney, NSW 2052, Australia.	cvujovich-dunn@kirby.unsw.edu.au; Jess.kaufman@mcri.edu.au; Catherine.king@sydney.edu.au; rachel.skinner@sydney.edu.au; hwand@kirby.unsw.edu.au; rguy@kirby.unsw.edu.au; julie.leask@sydney.edu.au		Kaufman, Jessica/0000-0001-5139-4183			Alf Collins, 2011, MAKING SHARED DECISI; Armstrong S, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013497.pub2; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Bruel S, 2020, EXPERT REV VACCINES, V19, P305, DOI 10.1080/14760584.2020.1742111; Chambers LW, 2012, J HOSP INFECT, V82, P194, DOI 10.1016/j.jhin.2012.08.003; CLANCY CM, 1988, AM J MED, V84, P283, DOI 10.1016/0002-9343(88)90426-3; Corben P, 2016, HUM VACC IMMUNOTHER, V12, P3168, DOI 10.1080/21645515.2016.1221553; Coulter A, 2007, BMJ-BRIT MED J, V335, P24, DOI 10.1136/bmj.39246.581169.80; Craig P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1655; Dube E, 2017, CLIN MICROBIOL INFEC, V23, P279, DOI 10.1016/j.cmi.2016.11.007; Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041; Elwyn G, 2006, BMJ-BRIT MED J, V333, P417, DOI 10.1136/bmj.38926.629329.AE; Global routine vaccination coverage, 2011, MMWR-MORBID MORTAL W, V60, P1520; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; IPSOS, 9 10 AUSTR SAY THEY; Jackson C, 2008, HEALTH EXPECT, V11, P232, DOI 10.1111/j.1369-7625.2008.00496.x; Kaufman J, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010038.pub3; Ma V, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4742-5; Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097; Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; Opel DJ, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0802; Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1; Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013; Shourie S, 2013, VACCINE, V31, P6003, DOI 10.1016/j.vaccine.2013.10.025; Stacey D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001431.pub5; Witteman HO, 2015, RISK ANAL, V35, P1801, DOI 10.1111/risa.12418; Wroe AL, 2005, HEALTH PSYCHOL, V24, P539, DOI 10.1037/0278-6133.24.6.539	32	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 23	2021	39	28					3655	3665		10.1016/j.vaccine.2021.05.021		JUN 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SS0GD	34052064				2022-04-29	WOS:000661420000004
J	Dang, JHT; Stewart, SL; Blumberg, DA; Rodriguez, HP; Chen, MS				Dang, Julie H. T.; Stewart, Susan L.; Blumberg, Dean A.; Rodriguez, Hector P.; Chen Jr, Moon S.			Patient and clinician factors associated with uptake of the human papillomavirus (HPV) vaccine among adolescent patients of a primary care network	VACCINE			English	Article						Human Papillomavirus; Vaccine Uptake; Adolescent; Clinician; Primary Care	ADVISORY-COMMITTEE; UNITED-STATES; CANCER INCIDENCE; UPDATED RECOMMENDATIONS; HEALTH; DISPARITIES; COVERAGE; PERSPECTIVES; COMPLETION; VIETNAMESE	Background: Human papillomavirus (HPV) vaccination rates for adolescents remain relatively low. The purpose of this study is to examine patient and clinician factors associated with HPV vaccination among patients, ages 11-17, of a large community-based primary care network. Methods: Electronic health records and administrative data from a large primary care network from January 2017-June 2018 for patients ages 11-17 (n = 10,682) and the 198 primary care clinicians that saw them were analyzed. Mixed effects logistic regression models examined the association of patient and clinician factors with HPV vaccine uptake. Results: Most patients (63.0%) had at least one dose of the HPV vaccine, and 37.7% were up to date. In adjusted analyses, patients who received the tetanus, diphtheria, and pertussis (Tdap) vaccine (OR = 2.8, 95% CI: 2.1-3.9) compared to those who did not receive the vaccine and patients with five or more medical visits (OR = 1.9, 95% CI: 1.6-2.2) had the greatest odds of being up to date with the HPV vaccine series. Compared to White patients, African American/Black (OR = 0.8, 95% CI: 0.6-1.0) and Alaskan Native/American Indian (OR = 0.5, 95% CI: 0.3-0.9) patients were less likely to be up to date. Boys were also less likely to be up to date with the HPV vaccine series compared to girls (OR = 0.7, 95% CI: 0.7-0.8). Additionally, patients with family/general practice primary care clinicians were less likely to have their patients up to date than those with pediatricians (OR = 0.8, 95% CI: 0.6-1.0). Conclusion: HPV vaccine uptake varied by patient characteristics, heath care utilization and primary care clinician specialty. These findings may inform future evidence-based interventions aimed at increasing HPV vaccine uptake among adolescents by targeting patient sub-groups and reducing missed opportunities for vaccination. (c) 2021 Elsevier Ltd. All rights reserved.	[Dang, Julie H. T.] Univ Calif Davis, Davis Sch Med, Div Hlth Policy & Management, Dept Publ Hlth Sci, 4501 X St,Suite 3003, Sacramento, CA 95817 USA; [Stewart, Susan L.] Univ Calif Davis, Davis Sch Med, Div Biostat, Dept Publ Hlth Sci, 2450 48th St,Suite 1600, Sacramento, CA 95817 USA; [Blumberg, Dean A.] Univ Calif Davis, Davis Hlth, Dept Pediat, 2561 Stockton Blvd, Sacramento, CA 95817 USA; [Rodriguez, Hector P.] Univ Calif Berkeley, Sch Publ Hlth, Div Hlth Policy & Management, 2121 Berkeley Way 5427, Berkeley, CA 94704 USA; [Chen Jr, Moon S.] Univ Calif Davis, Davis Sch Med, Div Hematol & Oncol, 2540 48th St,Suite 1600, Sacramento, CA 95817 USA		Dang, JHT (通讯作者)，Univ Calif Davis, Davis Sch Med, Div Hlth Policy & Management, Dept Publ Hlth Sci, 4501 X St,Suite 3003, Sacramento, CA 95817 USA.	jtdang@ucdavis.edu		RODRIGUEZ, HECTOR/0000-0002-6564-2229	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA093373, U54153499]	This work was supported by the National Cancer Institute [P30 CA093373 and U54153499] .	Ackerson B, 2017, VACCINE, V35, P897, DOI 10.1016/j.vaccine.2017.01.007; Akinsanya-Beysolow L, 2014, MMWR-MORBID MORTAL W, V63, P108; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2015, HLTH PEOPL 2020 NAT; Boakye EA, 2017, HUM VACC IMMUNOTHER, V13, P2713, DOI 10.1080/21645515.2017.1363133; Bodnarczyk RA, 2019, J INFECT DIS, V220, P730, DOI 10.1093/infdis/jiy682; Bruegl AS, 2020, GYNECOL ONCOL, V157, P686, DOI 10.1016/j.ygyno.2020.03.033; Canales MK, 2011, J HEALTH CARE POOR U, V22, P894, DOI 10.1353/hpu.2011.0096; Centers for Disease Control and Prevention, 2019, NTR; Chaturvedi AK, 2011, J CLIN ONCOL, V29, P4294, DOI 10.1200/JCO.2011.36.4596; Chen MS, 2010, HMONG STUD J, V11; Committee on Infectious Diseases, 2012, Pediatrics, V129, P602, DOI 10.1542/peds.2011-3865; Dang J, 2010, J CANCER EDUC, V25, P253, DOI 10.1007/s13187-010-0074-1; Dang JHT, 2020, HUM VACC IMMUNOTHER, V16, P1814, DOI 10.1080/21645515.2019.1710410; Dempsey AF, 2011, SEX TRANSM DIS, V38, P769, DOI 10.1097/OLQ.0b013e318211c248; Donahue KL, 2014, VACCINE, V32, P3883, DOI 10.1016/j.vaccine.2014.05.035; Dorell CG, 2011, PEDIATRICS, V128, P830, DOI 10.1542/peds.2011-0950; Elam-Evans LD, 2020, MMWR-MORBID MORTAL W, V69, P1109, DOI 10.15585/mmwr.mm6933a1; Farmar ALM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-2653; Ferris DG, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-3947; Gilkey MB, 2016, VACCINE, V34, P1187, DOI 10.1016/j.vaccine.2016.01.023; Grout RL, 2016, CLIN PEDIATR, V55, P44, DOI 10.1177/0009922815584215; Hirth J, 2019, HUM VACC IMMUNOTHER, V15, P146, DOI 10.1080/21645515.2018.1512453; Inguva S, 2020, VACCINE, V38, P2051, DOI 10.1016/j.vaccine.2019.12.030; Jemal A, 2013, JNCI-J NATL CANCER I, V105, P175, DOI 10.1093/jnci/djs491; Kennedy Bernice Roberts, 2007, J Cult Divers, V14, P56; Kepka Deanna, 2016, Prev Med Rep, V4, P98, DOI 10.1016/j.pmedr.2016.05.014; Leung SOA, 2019, VACCINE-X, V3, DOI 10.1016/j.jvacx.2019.100037; Lewis RM, 2018, J INFECT DIS, V217, P869, DOI 10.1093/infdis/jix655; Maguire RL, 2017, ADV CANCER RES, V133, P129, DOI 10.1016/bs.acr.2016.09.001; Markowitz LE, 2014, MMWR RECOMM REP, V63, P1; McCracken M, 2007, CA-CANCER J CLIN, V57, P190, DOI 10.3322/canjclin.57.4.190; McRee AL, 2014, J PEDIATR HEALTH CAR, V28, P541, DOI 10.1016/j.pedhc.2014.05.003; Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI [10.15585/mmwr.mm6832a3, 10.1111/ajt.15633]; Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5; Moscicki AB, 2005, J ADOLESCENT HEALTH, V37, pS3, DOI 10.1016/j.jadohealth.2005.09.011; Niccolai LM, 2011, AM J PREV MED, V41, P428, DOI 10.1016/j.amepre.2011.06.032; Palefsky JM, 2010, J ADOLESCENT HEALTH, V46, pS12, DOI 10.1016/j.jadohealth.2010.01.010; Petrosky E, 2015, MMWR-MORBID MORTAL W, V64, P300; Rimer BK, ACCELERATING HPV VAC; Rosen BL, 2018, ACAD PEDIATR, V18, pS53, DOI 10.1016/j.acap.2017.10.007; Saraiya M, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv086; Schmidt-Grimminger D, 2013, J CANCER EDUC, V28, P357, DOI 10.1007/s13187-013-0468-y; Senkomago V, 2019, MMWR-MORBID MORTAL W, V68, P724, DOI 10.15585/mmwr.mm6833a3; Spencer JC, 2019, PREV MED, V123, P197, DOI 10.1016/j.ypmed.2019.03.037; Sriram S, 2019, J FAM MED PRIM CARE, V8, P866, DOI 10.4103/jfmpc.jfmpc_107_19; StataCorp, 2015, STAT STAT SOFTW REL; Stokley S, 2013, MMWR-MORBID MORTAL W, V62, P591; Stupiansky NW, 2012, J ADOLESCENT HEALTH, V50, P103, DOI 10.1016/j.jadohealth.2011.04.010; Taylor VM, 2008, CANCER EPIDEM BIOMAR, V17, P2924, DOI 10.1158/1055-9965.EPI-08-0386; Vadaparampil ST, 2013, CANCER-AM CANCER SOC, V119, P621, DOI 10.1002/cncr.27735; Van Dyne EA, 2018, MMWR-MORBID MORTAL W, V67, P918, DOI 10.15585/mmwr.mm6733a2; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	53	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 11	2021	39	26					3528	3535		10.1016/j.vaccine.2021.04.055		JUN 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SN6KQ	34023133				2022-04-29	WOS:000658397000012
J	McFadden, K; Heywood, A; Dyda, A; Kaufman, J; Seale, H				McFadden, Kathleen; Heywood, Anita; Dyda, Amalie; Kaufman, Jessica; Seale, Holly			Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: Can hospital-based programs be a solution?	VACCINE			English	Article						Adults; Vaccination; Immunization; Influenza; Pneumococcal; Acceptance; Hesitancy; Hospital	INFLUENZA VACCINATION RATES; PNEUMOCOCCAL VACCINATION; STANDING ORDERS; QUALITY IMPROVEMENT; ELDERLY-PEOPLE; AUSTRALIA; REMINDERS; COVERAGE	Background: There has been a recent recognized shift towards a whole-of-life or life-course approach to immunisation. However, coverage amongst at-risk adults for recommended vaccines continues to be sub -optimal. This study examined the perceptions of middle and older aged Australian adults towards hospital-based immunization programs and their previous exposures to receiving vaccines via tertiary care. Methods: A cross-sectional survey was conducted with Australian adults 45 years and older in late 2019 to capture influenza and pneumococcal vaccine uptake, exposure to hospital-based immunization pro-grams, missed opportunities to vaccinate and receptiveness towards the promotion and/or delivery of vaccines in the hospital setting. Results: Only 13 respondents reported receiving a vaccine at hospital, yet 72.2% (931/1292) indicated that they were willing to be vaccinated in that setting. Amongst those who attended hospital during 2019 and were eligible for vaccination, 57.2% and 28.3% of respondents were not immunized for pneumo-coccal and influenza, respectively. Missed opportunities for both vaccines were significantly higher amongst those at low-risk for influenza (<= 65 years (low-risk): 52.9%, <= 65 years (high-risk): 18.3%, > 65 years: 15.1%; p < 0.001) and pneumococcal (<= 65 years (low-risk): 79.1%, <= 65 years (high-risk): 52.4%, > 65 years: 44%; p < 0.001). Among those with a missed opportunity for hospital-based vaccination, the most common reason for not getting immunized was a lack of recommendation. Most (86.4%) reported that their general practitioner was the person or group they trusted most to receive vaccine information from. Conclusions: The findings from this Australian study support international work that shows very low rates of opportunistic vaccination in hospitals despite national recommendations to vaccinate prior to discharge. Considering the need for high levels of uptake of the COVID-19 vaccine, hospitals may need to be considered to opportunistically capture those not accessing the vaccine in other settings. (c) 2021 Elsevier Ltd. All rights reserved.	[McFadden, Kathleen; Heywood, Anita; Seale, Holly] Univ New South Wales, Sch Populat Hlth, Kensington, NSW, Australia; [Dyda, Amalie] Univ Queensland, Sch Publ Hlth, Fac Med, Herston, Qld, Australia; [Kaufman, Jessica] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Kaufman, Jessica] Royal Childrens Hosp, Melbourne, Vic, Australia; [Kaufman, Jessica] Univ Melbourne, Melbourne, Vic, Australia		Seale, H (通讯作者)，Univ New South Wales, Sch Populat Hlth, Kensington, NSW, Australia.	h.seale@unsw.edu.au		Dyda, Amalie/0000-0003-2806-4834; McFadden, Kathleen/0000-0003-1546-8901	Seqirus	We would like to acknowledge Seqirus (unrestricted funds for investigator driven research) for providing the funding for this study.	Australian Bureau of Statistics Australian Bureau of Statistics, 2020, NAT STAT TERR POP; Australian Government Department of Health, 2020, NAT IMM PROGR SCHED; Australian Government Department of Health, 2020, AUSTR IMM HDB; Bertoldo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215978; Bourdet SV, 2003, AM J HEALTH-SYST PH, V60, P1767, DOI 10.1093/ajhp/60.17.1767; Chen YH, 2004, VACCINE, V22, P2806, DOI 10.1016/j.vaccine.2004.01.003; Cheng AC, 2019, COMMUN DIS INTELL, V43, DOI 10.33321/cdi.2019.43.48; Cohen ES, 2015, BMJ QUAL SAF, V24, P221, DOI 10.1136/bmjqs-2014-003556; Coyle CM, 2004, INFECT CONT HOSP EP, V25, P904, DOI 10.1086/502317; Dexter PR, 2004, JAMA-J AM MED ASSOC, V292, P2366, DOI 10.1001/jama.292.19.2366; Dyda A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1820-8; Ferguson-Myrthil N, 2009, HOSP PHARM, V44, P874; Ginson SH, 2000, CANADIAN J HOSP PHAR, V53, DOI 104212/cjhpv53i4750; Gwynne K, 2019, AUST HEALTH REV, V43, P314, DOI 10.1071/AH17142; Hull B, 2019, EXPL AN 1 2 YEARS AD; Jayasinghe S, 2020, AUST PRESCR, V43, P2, DOI 10.18773/austprescr.2020.001; Kan T, 2018, PUBLIC HEALTH, V156, P67, DOI 10.1016/j.puhe.2017.12.007; Kim S, 2014, PREV MED, V67, P119, DOI 10.1016/j.ypmed.2014.07.015; KLEIN RS, 1986, ARCH INTERN MED, V146, P327, DOI 10.1001/archinte.146.2.327; Kohlhammer Y, 2007, PUBLIC HEALTH, V121, P742, DOI 10.1016/j.puhe.2007.02.011; Kreager A M, 2001, Lippincotts Case Manag, V6, P138, DOI 10.1097/00129234-200107000-00002; Lawson F, 2000, J GERONTOL A-BIOL, V55, pM522, DOI 10.1093/gerona/55.9.M522; Lin JL, 2020, VACCINE, V38, P3646, DOI 10.1016/j.vaccine.2020.03.036; MacIntyre CR, 2003, GERONTOLOGY, V49, P33, DOI 10.1159/000066500; NICHOL KL, 1991, AM J MED, V91, P584, DOI 10.1016/0002-9343(91)90210-O; Norman DA, 2019, VACCINE, V37, P2244, DOI 10.1016/j.vaccine.2019.02.077; Organisation WH, 2020, MISSED OPPORTUNITIES; Peterson S, 2015, AM J MED QUAL, V30, P323, DOI 10.1177/1062860614532682; Rao S, 2018, INFLUENZA OTHER RESP, V12, P416, DOI 10.1111/irv.12482; Rees S, 2011, J NURS CARE QUAL, V26, P358, DOI 10.1097/NCQ.0b013e31821fb6bb; Rhew DC, 1999, J GEN INTERN MED, V14, P351, DOI 10.1046/j.1525-1497.1999.00353.x; Skledar SJ, 2007, J AM PHARM ASSOC, V47, P404, DOI 10.1331/JAPhA.2007.06044; Skull SA, 2007, VACCINE, V25, P4775, DOI 10.1016/j.vaccine.2007.04.015; Sokos DR, 2007, AM J HEALTH-SYST PH, V64, P1096, DOI 10.2146/ajhp060321; Tarrant C, 2003, BRIT J GEN PRACT, V53, P798; World Health Organisation, 2017, PLANN GUID RED MISS; World Health Organization, 2017, VACC DEV POL BRIEF R	37	1	1	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JUN 11	2021	39	26					3467	3472		10.1016/j.vaccine.2021.05.027		JUN 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SN6KQ	34024659				2022-04-29	WOS:000658397000003
J	El Bara, A; Pivert, A; Veillon, P; Sang, CNW; Bollahi, M; Abdel, K; Ducancelle, A; Le Guillou-Guillemette, H; Lunel-Fabiani, F				El Bara, Ahmed; Pivert, Adeline; Veillon, Pascal; Sang, Cindy Ng Wing; Bollahi, Mohamed; Abdel, Kader; Ducancelle, Alexandra; Le Guillou-Guillemette, Helene; Lunel-Fabiani, Francoise			From national HBV and HDV screenings to vaccination and treatment in healthcare workers: The Mauritanian pilot study	VACCINE			English	Article						Seroprevalence; HBV; HDV; Healthcare worker; Mauritania; Prevention; Test and treat; HBV vaccine	HEPATITIS-DELTA VIRUS; SUB-SAHARAN AFRICA; PREVALENCE; INFECTION; TRANSMISSION	Objectives: Hepatitis B and D infections are highly endemic in Mauritania, with prevalences ranging from 10 to 20%. With the present prospective transversal pilot study, we aimed to evaluate the prevalences of HBV, HCV, and HDV infections in healthcare workers (HCWs), and offer treatment or vaccination as required. Methods: At inclusion, each HCW was screened for anti-HBc Ab (followed by HBsAg assay when positive). Additional biological analyses were performed for HBsAg + cases. Depending on the results, HBV vaccination or anti-viral treatment was offered. Results: A total of 3,857 HCWs were included, of whom 1,363 tested negative for anti-HBc Ab and received full vaccination. Of the 2,494 HCWs who were positive for anti-HBc Ab, 1,246 were positive for anti-HBs Ab and 418 were positive for HBsAg. Three HCWs were positive for HBeAg; 66 and 18 had HBV DNA levels respectively > 2,000 and > 20,000 IU/mL; and 48 were positive for anti-HDV Ab among whom 10 were positive for HDV RNA. HCV prevalence was 0.5%. Only seven HCWs fulfilled the criteria for treatment and five of them were treated. Conclusion: Few HCWs in Mauritania are immunised against HBV. The prevalences of anti-HBc Ab and HBsAg observed in this work were similar to those observed in our earlier works, whereas prevalence of active HDV infection was less high. HBV and HDV infections are a serious health concern in Mauritania. New recommendations developed in accordance with WHO guidelines should include mandatory HBV screening and immunisation for HCWs. (C) 2021 Elsevier Ltd. All rights reserved.	[El Bara, Ahmed; Bollahi, Mohamed; Abdel, Kader] INRSP, Nouakchott, Mauritania; [Pivert, Adeline; Sang, Cindy Ng Wing; Ducancelle, Alexandra; Le Guillou-Guillemette, Helene; Lunel-Fabiani, Francoise] Angers Univ Hosp, Virol Dept, HIFIH Lab EA3859, LUNAM, 4 Rue Larrey, F-49933 Angers, France; [Veillon, Pascal] Angers Univ Hosp, Pediat Oncol Haematol Immunol Unit, Angers, France		Lunel-Fabiani, F (通讯作者)，Angers Univ Hosp, Virol Dept, HIFIH Lab EA3859, LUNAM, 4 Rue Larrey, F-49933 Angers, France.	FrLunel-Fabiani@chu-angers.fr	Ducancelle, Alexandra/D-6393-2014	Ducancelle, Alexandra/0000-0003-3173-8000	Mauritanian Ministry of Health	This study was partially supported by the Mauritanian Ministry of Health and the Fontevraud group.	Abbas Z, 2012, SAUDI J GASTROENTERO, V18, P18, DOI 10.4103/1319-3767.91731; Alese OO, 2016, J CLIN DIAGN RES, V10, pLC16, DOI 10.7860/JCDR/2016/15936.7329; [Anonymous], 2017, GLOBAL HEPATITS REPO; Auta A, 2018, VACCINE, V36, P4851, DOI 10.1016/j.vaccine.2018.06.043; Birguel J, 2011, Med Trop (Mars), V71, P201; Botelho-Souza LF, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0845-y; Boubker S, 2019, PAN AFR MED J, V33, DOI 10.11604/pamj.2019.33.163.18688; Chen CJ, 2018, GUT, V67, P595, DOI 10.1136/gutjnl-2017-315407; Djeriri K, 2008, OCCUP MED-OXFORD, V58, P419, DOI 10.1093/occmed/kqn071; Hassine NB, 2015, WORLD DEV, V66, P532, DOI 10.1016/j.worlddev.2014.09.011; Ivaniushina V, 2001, J GEN VIROL, V82, P2709, DOI 10.1099/0022-1317-82-11-2709; Jaiswal S P, 1999, Trop Gastroenterol, V20, P29; Le Guillou Guillemette H, 2016, EVALUATION COINFECTI; Lewis JD, 2015, WORLD J HEPATOL, V7, P488, DOI 10.4254/wjh.v7.i3.488; Li ZX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.30; Lunel-Fabiani F, 2013, J INFECTION, V67, P448, DOI 10.1016/j.jinf.2013.06.008; Mansour W, 2012, J CLIN VIROL, V55, P12, DOI 10.1016/j.jcv.2012.05.011; Mansour W, 2012, J MED VIROL, V84, P1186, DOI 10.1002/jmv.23336; Mentha N, 2019, J ADV RES, V17, P3, DOI 10.1016/j.jare.2019.03.009; Motaarefi H, 2016, J CLIN DIAGN RES, V10, pIE1, DOI 10.7860/JCDR/2016/17973.8221; Negro F, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a021550; Nkodila NA, 2019, IND HEALTH; Noubissi-Jouegouo L, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4460-4; Qin YL, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3235-1; Rizzetto M, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021576; Shah Latika JMSA, 2012, NATL J MED RES, V2, P117; Spearman CW, 2017, LANCET GASTROENTEROL, V2, P900, DOI 10.1016/S2468-1253(17)30295-9; Stockdale AJ, 2017, LANCET GLOB HEALTH, V5, pE992, DOI 10.1016/S2214-109X(17)30298-X; Sureau C, 2016, J HEPATOL, V64, pS102, DOI 10.1016/j.jhep.2016.02.013; Ziraba AK, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-191	30	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 15	2021	39	16					2281	2286		10.1016/j.vaccine.2021.03.011		APR 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RJ9QI	33752951				2022-04-29	WOS:000637937900012
J	Lee, J; Li, YH; Li, YH; Cino-Ozuna, AG; Duff, M; Lang, YK; Ma, JJ; Sunwoo, S; Richt, JA; Ma, WJ				Lee, Jinhwa; Li, Yonghai; Li, Yuhao; Cino-Ozuna, A. Giselle; Duff, Michael; Lang, Yuekun; Ma, Jingjiao; Sunwoo, Sunyoung; Richt, Juergen A.; Ma, Wenjun			Bat influenza vectored NS1-truncated live vaccine protects pigs against heterologous virus challenge	VACCINE			English	Article						Swine influenza vaccine; Bat influenza virus vectored live vaccine; Cross-protection; Heterologous virus challenge; Safety and efficacy		Swine influenza is an important disease for the swine industry. Currently used whole inactivated virus (WIV) vaccines can induce vaccine-associated enhanced respiratory disease (VAERD) in pigs when the vaccine strains mismatch with the infected viruses. Live attenuated influenza virus vaccine (LAIV) is effective to protect pigs against homologous and heterologous swine influenza virus infections without inducing VAERD but has safety concerns due to potential reassortment with circulating viruses. Herein, we used a chimeric bat influenza Bat09:mH3mN2 virus, which contains both surface HA and NA gene open reading frames of the A/swine/Texas/4199-2/1998 (H3N2) and six internal genes from the novel bat H17N10 virus, to develop modified live-attenuated viruses (MLVs) as vaccine candidates which cannot reassort with canonical influenza A viruses by co-infection. Two attenuated MLV vaccine candidates including the virus that expresses a truncated NS1 (Bat09:mH3mN2-NS1-128, MLV1) or expresses both a truncated NS1 and the swine IL-18 (Bat09:mH3mN2-NS1-128-IL-18, MLV2) were generated and evaluated in pigs against a heterologous H3N2 virus using the WIV vaccine as a control. Compared to the WIV vaccine, both MLV vaccines were able to reduce lesions and virus replication in lungs and limit nasal virus shedding without VAERD, also induced significantly higher levels of mucosal IgA response in lungs and significantly increased numbers of antigen-specific IFN-gamma secreting cells against the challenge virus. However, no significant difference was observed in efficacy between the MLV1 and MLV2. These results indicate that bat influenza vectored MLV vaccines can be used as a safe live vaccine to prevent swine influenza. (C) 2021 Elsevier Ltd. All rights reserved.	[Lee, Jinhwa; Li, Yonghai; Li, Yuhao; Cino-Ozuna, A. Giselle; Duff, Michael; Lang, Yuekun; Ma, Jingjiao; Sunwoo, Sunyoung; Richt, Juergen A.; Ma, Wenjun] Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS USA; [Ma, Wenjun] Univ Missouri, Coll Vet Med, Dept Vet Pathobiol, Columbia, MO USA; [Ma, Wenjun] Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO USA		Ma, WJ (通讯作者)，Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.; Ma, WJ (通讯作者)，Univ Missouri, Dept Mol Microbiol & Immunol, Columbia, MO 65211 USA.	wma@missouri.edu	li, YUHAO/AFQ-9357-2022	Sunwoo, Sun young/0000-0003-4688-641X	NIH NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [1R01AI134768-01A1]; NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [HHSN272201400006C]	The authors thank staffs from the Comparative Medicine Group at Kansas State University for supporting the animal studies, and Jennifer Phinney from the Kansas State Veterinary Diagnostic Lab for technical assistance with H&E and IHC staining. This work was supported by grants from NIH NIAID 1R01AI134768-01A1 and the NIAID-funded Center of Excellence for Influenza Research and Surveillance (CEIRS, #HHSN272201400006C). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Braucher DR, 2012, CLIN VACCINE IMMUNOL, V19, P1722, DOI 10.1128/CVI.00315-12; Cheng X, 2013, J INFECT DIS, V208, P594, DOI 10.1093/infdis/jit207; Coleman JR, 2008, SCIENCE, V320, P1784, DOI 10.1126/science.1155761; Denton AE, 2007, EUR J IMMUNOL, V37, P368, DOI 10.1002/eji.200636766; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Gauger PC, 2012, VET PATHOL, V49, P900, DOI 10.1177/0300985812439724; Gauger PC, 2014, VIROLOGY, V471, P93, DOI 10.1016/j.virol.2014.10.003; Gauger PC, 2011, VACCINE, V29, P2712, DOI 10.1016/j.vaccine.2011.01.082; Juozapaitis M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5448; Kaplan BS, 2018, VACCINE, V36, P1101, DOI 10.1016/j.vaccine.2018.01.027; Kappes MA, 2012, VACCINE, V30, P280, DOI 10.1016/j.vaccine.2011.10.098; Khurana S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006366; Lee J, 2017, J GEN VIROL, V98, P31, DOI 10.1099/jgv.0.000695; Li Q, 2012, P NATL ACAD SCI USA, V109, P18897, DOI 10.1073/pnas.1211037109; Lindstrom S, 2012, EMERG INFECT DIS, V18, P834, DOI 10.3201/eid1805.111922; Loh L, 2016, P NATL ACAD SCI USA, V113, P10133, DOI 10.1073/pnas.1610750113; Loving CL, 2013, J VIROL, V87, P9895, DOI 10.1128/JVI.01038-13; Loving CL, 2012, VACCINE, V30, P5830, DOI 10.1016/j.vaccine.2012.07.033; Ma JJ, 2015, J VIROL, V89, P2831, DOI 10.1128/JVI.03355-14; Ma W, 2007, P NATL ACAD SCI USA, V104, P20949, DOI 10.1073/pnas.0710286104; Manicassamy B, 2010, P NATL ACAD SCI USA, V107, P11531, DOI 10.1073/pnas.0914994107; Masic A, 2009, J GEN VIROL, V90, P375, DOI 10.1099/vir.0.005447-0; Masic A, 2010, VACCINE, V28, P7098, DOI 10.1016/j.vaccine.2010.08.003; Muneta Y, 2002, J INTERF CYTOK RES, V22, P883, DOI 10.1089/107999002760274908; Pena L, 2011, J VIROL, V85, P456, DOI 10.1128/JVI.01503-10; Pirhonen J, 1999, J IMMUNOL, V162, P7322; Rajao DS, 2016, J GEN VIROL, V97, P1489, DOI 10.1099/jgv.0.000468; Sandbulte MR, 2014, VIROLOGY, V464, P45, DOI 10.1016/j.virol.2014.06.027; Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182; Soema PC, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00237; Solorzano A, 2005, J VIROL, V79, P7535, DOI 10.1128/JVI.79.12.7535-7543.2005; Souza CK, 2016, CLIN VACCINE IMMUNOL, V23, P470, DOI 10.1128/CVI.00563-15; Sridhar S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00195; Sun K, 2011, J IMMUNOL, V186, P987, DOI 10.4049/jimmunol.1002664; Sun XM, 2013, CELL REP, V3, P769, DOI 10.1016/j.celrep.2013.01.025; Tatsis N, 2007, BLOOD, V110, P1916, DOI 10.1182/blood-2007-02-062117; Tong SX, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003657; Tong SX, 2012, P NATL ACAD SCI USA, V109, P4269, DOI 10.1073/pnas.1116200109; Van Reeth K, 2004, VIRUS RES, V103, P115, DOI 10.1016/j.virusres.2004.02.023; Van Reeth K, 2013, CURR TOP MICROBIOL, V370, P173, DOI 10.1007/82_2012_266; Vander Veen RL, 2013, VET REC, V173, P344, DOI 10.1136/vr.101741; Vander Veen RL, 2012, VACCINE, V30, P1944, DOI 10.1016/j.vaccine.2012.01.030; Vincent AL, 2008, VET MICROBIOL, V126, P310, DOI 10.1016/j.vetmic.2007.07.011; Vincent AL, 2007, VACCINE, V25, P7999, DOI 10.1016/j.vaccine.2007.09.019; Vincent AL, 2012, J VIROL, V86, P10597, DOI 10.1128/JVI.01439-12; Vincent AL, 2010, VACCINE, V28, P2782, DOI 10.1016/j.vaccine.2010.01.049; Wesley RD, 2004, VACCINE, V22, P3427, DOI 10.1016/j.vaccine.2004.02.040; Yang JM, 2017, J GEN VIROL, V98, P577, DOI 10.1099/jgv.0.000715; Zhou B, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004420	49	0	0	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	APR 1	2021	39	14					1943	1950		10.1016/j.vaccine.2021.02.077		MAR 2021	8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RC7NX	33715905	Green Accepted, Green Submitted			2022-04-29	WOS:000632984100010
J	Zhang, YX; Li, YR; Chen, ZY; Liu, XG; Peng, XK; He, QS				Zhang, Yuxiao; Li, Yarong; Chen, Zhiyun; Liu, Xiaoguai; Peng, Xiaokang; He, Qiushui			Determination of serum neutralizing antibodies reveals important difference in quality of antibodies against pertussis toxin in children after infection	VACCINE			English	Article						Pertussis; Pertussis toxin neutralizing antibodies; Anti-PT IgG antibodies; Children; China		Objectives: To determine neutralizing antibodies to pertussis toxin (PTNAs) in children with suspected pertussis and to compare results of PTNAs and anti-PT IgG antibodies. Methods: 172 hospitalized children with suspected pertussis were included. Pertussis was confirmed by culture, PCR and/or serology. PTNAs were determined by Chinese hamster ovary (CHO) cell assay. Results: A correlation between titers of PTNAs and anti-PT IgG levels was noticed in 172 patients (Spearman R = 0.68, P < 0.001). Subjects with same concentrations of anti-PT IgG antibodies could have different titers of PTNAs and the maximum difference observed reached to 1024 times in ELISA-confirmed patients. Moreover, subjects with same titers of PTNAs could have different concentrations of anti-PT IgG antibodies. Conclusions: Our results indicated that in some children high concentrations of anti-PT IgG antibodies do not always mean effective PTNAs induced after infection, stressing the importance of detecting PTNAs after infection and vaccination. (C) 2021 Elsevier Ltd. All rights reserved.	[Zhang, Yuxiao; Chen, Zhiyun; He, Qiushui] Capital Med Univ, Dept Med Microbiol, Beijing, Peoples R China; [Li, Yarong; Liu, Xiaoguai; Peng, Xiaokang] Xian Childrens Hosp, Dept Infect Dis, Xian, Peoples R China; [He, Qiushui] Univ Turku, Dept Med Microbiol & Immunol, Turku, Finland		He, QS (通讯作者)，Capital Med Univ, Dept Med Microbiol, Beijing, Peoples R China.; Li, YR (通讯作者)，Xian Childrens Hosp, Dept Infect Dis, Xian, Peoples R China.	lyr640101@163.com; Qiushui.He@utu.fi			Beijing Natural Science FoundationBeijing Natural Science Foundation [19L2043]; Haidian Inovation Joint Project [19L2043]; National 13th five-year Plan Major Infectious Diseases Prevention and Control Science and Technology Major Project [2018ZX10715005-004-006, 2017ZX10202101-004-001]; Xi'an Bureau of Science and Technology [20YXYJ0006]	This work was partly supported by the Beijing Natural Science Foundation and Haidian Inovation Joint Project (19L2043) and the National 13th five-year Plan Major Infectious Diseases Prevention and Control Science and Technology Major Project (2018ZX10715005-004-006; 2017ZX10202101-004-001) and Xi'an Bureau of Science and Technology (20YXYJ0006).	Barkoff AM, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv050; Coutte L, 2015, FUTURE MICROBIOL, V10, P241, DOI [10.2217/fmb.14.123, 10.2217/FMB.14.123]; Dalby T, 2010, APMIS, V118, P968, DOI 10.1111/j.1600-0463.2010.02664.x; Diavatopoulos DA, 2019, LANCET INFECT DIS, V19, pE179, DOI 10.1016/S1473-3099(18)30646-7; Esposito S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01344; Esposito S, 2016, HUM VACC IMMUNOTHER, V12, P1700, DOI 10.1080/21645515.2016.1145847; GILLENIUS P, 1985, J BIOL STAND, V13, P61, DOI 10.1016/S0092-1157(85)80034-2; Knuutila A, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1161; Markey K, 2019, TOXINS, V11, DOI 10.3390/toxins11070417; Moriuchi T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181181; National Health Commission of the People's Republic of China, 2742007 WS NAT HLTH; Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508; Storsaeter J, 1998, VACCINE, V16, P1907, DOI 10.1016/S0264-410X(98)00227-8; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; THOMAS MG, 1989, J INFECT DIS, V160, P838, DOI 10.1093/infdis/160.5.838; TROLLFORS B, 1988, J INFECT DIS, V158, P991, DOI 10.1093/infdis/158.5.991; Wagner LD, 2017, VACCINE, V35, P7160, DOI 10.1016/j.vaccine.2017.10.082; Wang LC, 2012, VACCINE, V30, P7174, DOI 10.1016/j.vaccine.2012.10.009; Wang Z, 2014, CLIN MICROBIOL INFEC, V20, pO825, DOI 10.1111/1469-0691.12671; Xing D, 2010, Pharmeur Bio Sci Notes, V2010, P51	20	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	MAR 26	2021	39	13					1826	1830		10.1016/j.vaccine.2021.02.045		MAR 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QY9YH	33678454				2022-04-29	WOS:000630391900006
J	Carias, C; Pawaskar, M; Nyaku, M; Conway, JH; Roberts, CS; Finelli, L; Chen, YT				Carias, Cristina; Pawaskar, Manjiri; Nyaku, Mawuli; Conway, James H.; Roberts, Craig S.; Finelli, Lyn; Chen, Ya-Ting			Potential impact of COVID-19 pandemic on vaccination coverage in children: A case study of measles-containing vaccine administration in the United States (US)	VACCINE			English	Article						Measles vaccination coverage; Covid-19; Immunization impact		Background: The COVID-19 pandemic and stay-at-home orders have caused an unprecedented decrease in the administration of routinely recommended vaccines. However, the impact of this decrease on overall vaccination coverage in a specific birth cohort is not known. Methods: We projected measles vaccination coverage for the cohort of children becoming one year old in 2020 in the United States, for different durations of stay-at-home orders, along with varying catch-up vaccination efforts. Results: A 15% sustained catch-up rate outside stay-at-home orders (compared to what would be expected via natality information) may be necessary to achieve projected vaccination coverage similar to previous years. Permanent decreases in vaccine administration could lead to projected vaccination coverage levels below 80%. Conclusion: Modeling measles vaccination coverage under a range of scenarios provides useful information about the potential magnitude and impact of under-immunization. Sustained catch-up efforts are needed to assure that measles vaccination coverage remains high. (C) 2020 Elsevier Ltd. All rights reserved.	[Carias, Cristina; Pawaskar, Manjiri; Nyaku, Mawuli; Roberts, Craig S.; Finelli, Lyn; Chen, Ya-Ting] Merck & Co Inc, Kenilworth, NJ USA; [Conway, James H.] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA		Carias, C (通讯作者)，351 N Sumneytown Pike, N Wales, PA 19454 USA.	cristina.da.silva.carias@merck.com		Roberts, Craig/0000-0002-5852-9770			American Academy of Pediatricians, STRAT IMPR IMM RAT; [Anonymous], 2011, VACCINE, V32, P1311; [Anonymous], 2020, CDC MEASLES CASES OU; [Anonymous], 2019, NEW ENG J MED, V382, P1009; Bramer CA, 2020, MMWR-MORBID MORTAL W, V69, P630, DOI 10.15585/mmwr.mm6920e1; Carias C, 2019, AM J PUBLIC HEALTH, V109, pS322, DOI 10.2105/AJPH.2019.305233; Centers for Disease Control, INF MORT; Chandir S, 2020, VACCINE, V38, P7146, DOI 10.1016/j.vaccine.2020.08.019; European Centre for Disease Prevention and Control, MONTHL MEASL RUB MON; Hill HA, 2019, MMWR-MORBID MORTAL W, V68, P913, DOI 10.15585/mmwr.mm6841e2; Jhanjee I, 2004, J AM BOARD FAM PRACT, V17, P324, DOI 10.3122/jabfm.17.5.324; Lo NC, 2017, JAMA PEDIATR, V171, P887, DOI 10.1001/jamapediatrics.2017.1695; Measles & Rubella Initiative, 2020, MORE 117000000 CHILD; Mulholand K, 2020, LANCET INFECT DIS; Ortega-Sanchez IR, EC BURDEN 16 MEASLES; Papania MJ, 2014, JAMA PEDIATR, V168, P148, DOI 10.1001/jamapediatrics.2013.4342; Robinson CL, 2020, MMWR-MORBID MORTAL W, V69, P130, DOI 10.15585/mmwr.mm6905a3; Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2; Smith PJ, 2015, PUBLIC HEALTH REP, V130, P485, DOI 10.1177/003335491513000512; United States Census Bureau, SLOW GROWTH NAT POP; United States Department of Health and Human Services (US DHHS) Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS) Division of Vital Statistics, 2019, NATALITY PUBLIC USE; World Health Organization, 2012, GLOB MEASL RUB STRAT; Zucker JR, 2018, CONSEQUENCES UNDERVA; Zucker ML, 2020, MMWR MORB MORTAL WKL, V69	24	9	9	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1201	1204		10.1016/j.vaccine.2020.11.074		FEB 2021	4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33334618	Bronze, Green Published			2022-04-29	WOS:000618493500009
J	Niyibitegeka, F; Riewpaiboon, A; Youngkong, S; Thavorncharoensap, M				Niyibitegeka, Fulgence; Riewpaiboon, Arthorn; Youngkong, Sitaporn; Thavorncharoensap, Montarat			Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi	VACCINE			English	Article						Rotavirus vaccine; Economic evaluation; Burundi	COST-EFFECTIVENESS; VACCINATION; COUNTRIES; DIARRHEA; EFFICACY; BURDEN	Background: In Burundi, diarrhea is the third leading cause of mortality among children under five years of age. This study conducted an economic analysis of rotavirus vaccination program in Burundi. Methods: A Markov model was constructed to simulate clinical and economic outcomes for the 2019 birth cohort for a period of 5years. Empirical costing data were collected. ICER per episode averted, ICER per death averted, ICER per DALY averted, net present value, and budget impact were estimated for 4 brands of WHO pre-qualified rotavirus vaccines. One-way and probabilistic sensitivity analysis as well as threshold analysis were performed. Results: For the base case, while all four WHO pre-qualified rotavirus vaccines were cost-effective (ICER<3 GDP per capita), three of them (i.e. Rotarix, Rotavac and Rotasiil) were very cost-effective (ICER <1 GDP per capita) from both the provider and societal perspectives. The vaccines were still very cost-effective at a price increase of up to US$ 5.09, US$ 3.16, US$ 3.89, and US$ 2.69 for Rotarix, RotaTeq, Rotavac, and Rotasiil, respectively. Probabilistic sensitivity analysis indicated that vaccination programs with Rotarix, RotaTeq, Rotavac, and Rotasiil are cost-effective at a probability of 93.8%, 27%, 99.1%, and 92.7%, respectively. All vaccination programs were cost-beneficial with a net present value in the range of US$ 5,214,912 and US$ 11,135,997.The budget required to run the vaccination program, estimated with break-even prices, ranged between US$ 42,249,498 and US$ 53,487,935 for a 5-year time period. When compared to the GDP of Burundi in 2019, these are are less than 2%. Conclusion: The rotavirus vaccine is good value for money. Findings from this study offer evidence on potential economic benefits as well as the required budget for different rotavirus vaccination programs, which could be useful for future planning related to rotavirus vaccine coverage in Burundi after graduation from GAVI. (C) 2021 Elsevier Ltd. All rights reserved.	[Niyibitegeka, Fulgence] Mahidol Univ, Fac Pharm, Sci Program Social Econ & Adm Pharm, Bangkok, Thailand; [Riewpaiboon, Arthorn; Youngkong, Sitaporn; Thavorncharoensap, Montarat] Mahidol Univ, Fac Pharm, Dept Pharm, Div Social & Adm Pharm, 447 Sri Ayuthaya Rd, Bangkok 10400, Thailand		Riewpaiboon, A (通讯作者)，Mahidol Univ, Fac Pharm, Dept Pharm, Div Social & Adm Pharm, 447 Sri Ayuthaya Rd, Bangkok 10400, Thailand.	arthorn.rie@mahidol.ac.th	Riewpaiboon, Arthorn/AAV-1115-2021	Riewpaiboon, Arthorn/0000-0003-2959-3244	SEAP program; Thailand International Cooperation Agency (TICA)	This work is a part of study in Master of Science program in Social, Economic and Administrative Pharmacy (SEAP), Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. The study received a research grant from the SEAP program and was supported by the Thailand International Cooperation Agency (TICA).	Al Awaidy ST, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-334; [Anonymous], 2018, WORLD LIFE EXPECTANC; Bar-Zeev N, 2016, CLIN INFECT DIS, V62, pS220, DOI 10.1093/cid/civ1025; Berry SA, 2010, J INFECT DIS, V202, pS108, DOI 10.1086/653578; Centers for Disease Control and Prevention (CDC), 2018, PINKBOOK; Cohen J., 2003, APPL MULTIPLE REGRES, V3; Coyle D, 2012, CAN J INFECT DIS MED, V23, P71, DOI 10.1155/2012/327054; Debellut F, 2019, LANCET GLOB HEALTH, V7, pE1664, DOI 10.1016/S2214-109X(19)30439-5; Drummond MF., 2005, METHODS EC EVALUATIO, V3; Fletcher SM, 2011, J PUBLIC HEALTH AFR, V2, P127, DOI 10.4081/jphia.2011.e30; Gavi,, ROTAVIRUS DIS VACCIN; Gavi,, 2015, ELIGIBILITY TRANSITI; GAVI,, 2019, BURUNDI COUNTRY INFO; Hoshi SL, 2017, HUM VACC IMMUNOTHER, V13, P1115, DOI 10.1080/21645515.2016.1245252; Isanaka S, 2017, NEW ENGL J MED, V376, P1121, DOI [10.1056/nejmoa1609462, 10.1056/NEJMoa1609462]; Jarrahi YM, 2016, HUM VACC IMMUNOTHER, V12, P794, DOI 10.1080/21645515.2015.1087626; Kotirum S, 2017, VACCINE, V35, P3364, DOI 10.1016/j.vaccine.2017.04.051; Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014; Mendelsohn AS, 2008, TROP MED INT HEALTH, V13, P934, DOI 10.1111/j.1365-3156.2008.02094.x; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pike J, 2018, APPL HEALTH ECON HEA, V16, P765, DOI 10.1007/s40258-018-0416-4; Plahte J, 2005, LANCET INFECT DIS, V5, P58, DOI 10.1016/S1473-3099(04)01255-1; Riewpaiboon A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3458-2; Ruhago GM, 2015, COST EFFECT RESOUR A, V13, DOI 10.1186/s12962-015-0033-0; Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8; Saokaew S, 2019, INFECT DIS THER, V8, P397, DOI 10.1007/s40121-019-0246-1; Sigei C, 2015, VACCINE, V33, pA109, DOI 10.1016/j.vaccine.2014.12.079; Soares-Weiser K, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008521.pub4; Tate JE, 2011, VACCINE, V29, P3329, DOI 10.1016/j.vaccine.2010.12.122; The DHS program,, 2017, BURUNDI DHS 2016 201; The World Bank,, 2019, OFFICIAL EXCHANGE RA; The World Bank,, GNI CAPITA CURRENT L; The World Bank,, GDP CURRENT US BURUN; The World Bank,, GDP CAPITA CURRENT U; Thiboonboon K, 2016, APPL HEALTH ECON HEA, V14, P659, DOI 10.1007/s40258-016-0265-y; Trading Economics,, BURUNDI URBAN POPULA; Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1; UNICEF,, DIARRH DIS 2019; UNICEF,, ROTAVIRUS VACCINE RV; UNICEF,, 2017, BUDGET BRIEF 2017 HL; van Hoek AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047511; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; Walker CLF, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-220; World Health Organization,, 2005, GUIDELINES ESTIMATIN; World Health Organization,, GLOBAL USE ROTAVIRUS; World Health Organization, 2018, IMMUNIZATION VACCINE; World Health Organization,, 2011, CHOOSING INTERVENTIO; World Health Organization,, HLTH STAT INFORM SYS; World Health Organization, 2003, MAKING CHOICES HLTH; World Health Organization, IMMUNIZATION VACCINE	50	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 22	2021	39	8					1272	1282		10.1016/j.vaccine.2021.01.031		FEB 2021	11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QH8AG	33487467				2022-04-29	WOS:000618493500016
J	Sohn, S; Hong, K; Hwang, H; Chun, BC				Sohn, Sangho; Hong, Kwan; Hwang, Hari; Chun, Byung Chul			Paradoxical health care utilization patterns among children in Korea who did not receive mandatory pneumococcal vaccination	VACCINE			English	Article						National Immunization Program; Vaccination; Health care utilisation; Pneumococcal conjugate vaccine; Vaccine hesitancy; Public health		Background: Unvaccinated children in the National Immunization Program (NIP) are a public health concern. We used Korean national population data to analyze health care utilization patterns of NIP-eligible children and identify the unvaccinated group. Methods: Pneumococcal vaccination (PCV) records were reviewed to determine the vaccination status of children born between 2013 and 2015. Children who received three doses or more from a 3 + 1 schedule were defined as vaccinated, while those who had not received any pneumococcal vaccinations were defined as unvaccinated. Corresponding health care utilization records were retrieved from the National Health Insurance Review and Assessment Service. The incidence of combined pneumococcal infections and health care utilization rates were estimated and the proportion of complementary and alternative medicine (CAM) utilization among the total health care utilization records was measured. Results: In total, 26,893 (2.1%) of 1,272,685 children remained unvaccinated. The incidence of pneumococcal infection was lower in unvaccinated children, at 10.1 cases (9.8-10.3) per 1000 person-months. However, their health care utilization was significantly lower than that noted for vaccinated children (hospital visit rate: 26.6 (95% confidence interval [CI] 26.5-26.7) vs. 3.2 (3.2-3.3) visits annually), indicating underdetection. CAM treatment was sought at least three times often more in unvaccinated children than in vaccinated children (3.5% vs. 1.1%). Conclusion: Unvaccinated children showed significantly lower utilization of overall health care than the vaccinated children; however, a higher preference for CAM was noted among unvaccinated children than among vaccinated children. These differences in care-seeking patterns should be considered when identifying unvaccinated children and providing protection through vaccination programs. (C) 2021 The Author(s). Published by Elsevier Ltd.	[Sohn, Sangho; Hong, Kwan; Hwang, Hari; Chun, Byung Chul] Korea Univ, Coll Med, Dept Prevent Med, 73 Goryeodae Ro, Seoul 02841, South Korea		Chun, BC (通讯作者)，Korea Univ, Coll Med, Dept Prevent Med, 73 Goryeodae Ro, Seoul 02841, South Korea.	medicine@korea.edu; perfumable@korea.ac.kr; hari0524@naver.com; chun@korea.ac.kr	Chun, Byung Chul/AGO-1458-2022; Chun, Byung Chul/AGO-1390-2022; Hong, Kwan/AAA-3335-2022	Chun, Byung Chul/0000-0001-6576-8916; Chun, Byung Chul/0000-0001-6576-8916; Hong, Kwan/0000-0002-5083-8026; Sohn, Sangho/0000-0003-2736-3461			[Anonymous], 2007, Wkly Epidemiol Rec, V82, P93; [Anonymous], 2017, UK POL FRAM HLTH SOC; Aquino F, 2017, VACCINE, V35, P4494, DOI 10.1016/j.vaccine.2017.07.029; Attwell K, 2018, VACCINE, V36, P1621, DOI 10.1016/j.vaccine.2018.01.076; Chang K, 2019, EPIDEMIOL HEALTH, V41, DOI 10.4178/epih.e2019031; Cheung F, 2011, NATURE, V480, pS82, DOI 10.1038/480S82a; Choe YJ, 2013, J KOREAN MED SCI, V28, P1283, DOI 10.3346/jkms.2013.28.9.1283; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; de Figueiredo A, 2016, LANCET GLOB HEALTH, V4, pE726, DOI 10.1016/S2214-109X(16)30167-X; Ernst E, 2001, VACCINE, V20, pS90, DOI 10.1016/S0264-410X(01)00290-0; Korea Centers for Disease Control and Prevention, 2020, NATL IMMUNIZATION PR; Korea Centers for Disease Control and Prevention, 2019, NATL CHILDHOOD VACCI; Korea Centers for Disease Control and Prevention, 2018, NATL CHILDHOOD VACCI; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Masserey-Spicher V, 2008, EURO SURVEILL, V13; McKee Chephra, 2016, J Pediatr Pharmacol Ther, V21, P104, DOI 10.5863/1551-6776-21.2.104; National Health Insurance Service, 2019, SURVEY BENEFIT COVER; Nelson R, 2019, LANCET INFECT DIS, V19, P248, DOI 10.1016/S1473-3099(19)30074-X; OECD, 2020, CHILD VACCINATION RA; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; Park Bomi, 2018, J Prev Med Public Health, V51, P173, DOI 10.3961/jpmph.18.063; Park HL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429103; Park YS, 2017, J KOREAN MED ASSOC, V60, P912, DOI 10.5124/jkma.2017.60.11.912; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Reingold A., 2008, Morbidity and Mortality Weekly Report, V57, P144; Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013; Shin HY, 2018, VACCINE, V36, P91, DOI 10.1016/j.vaccine.2017.11.035; Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187; Sohn S, 2020, INT J INFECT DIS, V93, P146, DOI 10.1016/j.ijid.2020.01.034; Ward JK, 2018, VACCINE, V36, P1801, DOI 10.1016/j.vaccine.2018.02.095; Wardle J, 2016, VACCINE, V34, P4484, DOI 10.1016/j.vaccine.2016.07.026; Wei FF, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-18; WHO, 2013, WORLD MALARIA REPORT 2013, P1; Wilson K, 2005, PEDIATRICS, V115, pE338, DOI 10.1542/peds.2004-1901; World Health Organization (WHO), 2020, GLOBAL POLIO ERADICA; Yoo KB, 2016, HEALTH POLICY, V120, P960, DOI 10.1016/j.healthpol.2016.07.001; Zuzak TF, 2008, SWISS MED WKLY, V138, P713, DOI 2008/47/smw-12423	37	2	2	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 12	2021	39	7					1096	1100		10.1016/j.vaccine.2021.01.012		FEB 2021	5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QC9HH	33478789	hybrid			2022-04-29	WOS:000615141100014
J	Ackerson, B; Qian, L; Sy, LS; Bruxvoort, K; Wu, J; Luo, Y; Diaz-Decaro, J; Talarico, C; Tseng, HF				Ackerson, Bradley; Qian, Lei; Sy, Lina S.; Bruxvoort, Katia; Wu, Jun; Luo, Yi; Diaz-Decaro, John; Talarico, Carla; Tseng, Hung Fu			Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older	VACCINE			English	Article						Herpes zoster; Vaccine; Adults; Series completion	HERPES-ZOSTER; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; SUBUNIT VACCINE; RECOMMENDATIONS; EFFICACY	Background: In 2017, a new adjuvanted recombinant zoster vaccine (RZV) was recommended for adults >= 50 years as two-dose series 2-6 months apart. We evaluated two-dose RZV completion and factors associated with completion. Methods: The study included Kaiser Permanente Southern California members >= 50 years who received an RZV dose during April-November 2018 and had continuous membership 12 months before to 9 months after the first RZV dose. Completion was defined as receipt of the second dose >= 4 weeks to 9 months after the first dose (allowing 3-month grace period). Characteristics including age, sex, race/ethnicity, Medicaid status, neighborhood level income and education, comorbidities, history of zoster, health care utilization before and after the first dose, receipt of influenza vaccine, vaccination month (supply short-age proxy), concomitant vaccine, medical center, and medically attended reactions, pain, or gout after the first dose were compared between completers and non-completers. Adjusted odds ratios and 95% confidence intervals for factors associated with completion were estimated by multivariable logistic regression. Results: Among 31,120 first dose recipients, 67.2% completed the series within 9 months. In adjusted analyses, higher completion was associated with White compared with Black or Hispanic race/ethnicity, higher neighborhood income and education, no chronic pulmonary disease, diabetes, or dementia, more outpatient visits and fewer emergency department visits before or after the first dose, no hospitalizations after the first dose, receipt of influenza vaccine, receipt of the first dose in June-November rather than April-May 2018, and no concomitant vaccine with the first dose. Systemic reactions or pain after the first dose was not associated with completion. Conclusion: Completion of RZV series appears suboptimal in the early phase of implementation. Despite similar accessibility in a health care system, completion varied by race/ethnicity, socioeconomic status, health status, and care seeking behavior, suggesting areas to target for improvement. (C) 2021 Elsevier Ltd. All rights reserved.	[Ackerson, Bradley; Qian, Lei; Sy, Lina S.; Bruxvoort, Katia; Wu, Jun; Luo, Yi; Tseng, Hung Fu] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA; [Diaz-Decaro, John] GlaxoSmithiKline, Rockville, MD USA; [Talarico, Carla] Moderna, Rockville, MD 20854 USA		Ackerson, B (通讯作者)，Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA.	Bradley.K.Ackerson@kp.org	Sy, Lina/AFM-9458-2022	Sy, Lina/0000-0003-2762-9266; Bruxvoort, Katia/0000-0001-8277-2431	KPSC internal funds	This work was supported by KPSC internal funds.	Bodeker B, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1970-4; Bratzler DW, 2002, ARCH INTERN MED, V162, P2349, DOI 10.1001/archinte.162.20.2349; Bridges CB, 2015, AM J PREV MED, V49, pS455, DOI 10.1016/j.amepre.2015.08.014; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5; Dworkin RH, 1996, PAIN, V67, P241, DOI 10.1016/0304-3959(96)03122-3; Fitzpatrick AL, 2004, AM J PUBLIC HEALTH, V94, P1788, DOI 10.2105/AJPH.94.10.1788; Hales CM, 2014, MMWR-MORBID MORTAL W, V63; Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1; Harpaz R, 2019, CLIN INFECT DIS, V69, P341, DOI 10.1093/cid/ciy953; Hechter RC, 2019, VACCINE, V37, P195, DOI 10.1016/j.vaccine.2018.06.035; Hechter RC, 2013, VACCINE, V31, P4564, DOI 10.1016/j.vaccine.2013.07.053; Kawai K, 2017, MAYO CLIN PROC, V92, P1806, DOI 10.1016/j.mayocp.2017.10.009; Kilgore Paul E., 2003, Journal of Medical Virology, V70, pS111, DOI 10.1002/jmv.10364; Koebnick Corinna, 2012, Perm J, V16, P37; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Lecrenier N, 2018, EXPERT REV VACCINES, V17, P619, DOI 10.1080/14760584.2018.1495565; Lu PJ, 2017, AM J PREV MED, V52, P362, DOI 10.1016/j.amepre.2016.08.031; Lu PJ, 2015, AM J PREV MED, V49, pS412, DOI 10.1016/j.amepre.2015.03.005; Nelson JC, 2009, AM J PUBLIC HEALTH, V99, pS389, DOI 10.2105/AJPH.2008.151332; Oxman MN, 2010, CLIN INFECT DIS, V51, P197, DOI 10.1086/653605; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Tavares-Da-Silva F, 2020, VACCINE, V38, P3489, DOI 10.1016/j.vaccine.2019.11.058; Trantham L, 2018, VACCINE, V36, P5333, DOI 10.1016/j.vaccine.2018.05.111; Tseng HF, 2020, J INFECT DIS, V222, P798, DOI 10.1093/infdis/jiz652; Tseng HF, 2016, J INFECT DIS, V213, P1872, DOI 10.1093/infdis/jiw047; Yawn BP, 2007, MAYO CLIN PROC, V82, P1341, DOI 10.4065/82.11.1341; Yue X, 2018, VACCINE, V36, P1183, DOI 10.1016/j.vaccine.2018.01.033	28	4	4	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					926	932		10.1016/j.vaccine.2020.12.076		JAN 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7FB	33441234	Green Published			2022-04-29	WOS:000610835100010
J	Burger, AE; Reither, EN; Mamelund, SE; Lim, S				Burger, Andrew E.; Reither, Eric N.; Mamelund, Svenn-Erik; Lim, Sojung			Black-white disparities in 2009 H1N1 vaccination among adults in the United States: A cautionary tale for the COVID-19 pandemic	VACCINE			English	Article						Influenza vaccine; Intersectionality; 2009 H1N1; Health inequalities; Racial disparities; Vaccine hesitancy	INFLUENZA-A H1N1; SOCIOECONOMIC-STATUS; ETHNIC DISPARITIES; HEALTH RESEARCH; CARE; CHALLENGES; VACCINES; PATTERNS; BARRIERS; RECEIPT	Background: Prior research has highlighted racial and ethnic disparities in H1N1 vaccination in the United States. Our study adds to this literature by utilizing an intersectionality framework to examine the joint influence of race and sex on H1N1 vaccination beliefs and behaviors among non-Hispanic blacks and non-Hispanic whites (hereafter blacks and whites). Methods: Using data from the National H1N1 Flu Survey of U.S. adults, we measured differences in beliefs about the safety and efficacy of the H1N1 vaccine among black women, black men, white women, and white men. We then estimated a series of nested logistic regression models to examine how race/sex vaccination disparities were influenced by health beliefs, socioeconomic status (SES), pre-existing conditions, and healthcare. Results: Black respondents were more likely than white respondents to express reservations about the safety and efficacy of the H1N1 vaccine. Consistent with those beliefs, white females reported the highest rate of H1N1 vaccination (28.4%), followed by white males (26.3%), black males (21.6%), and black females (17.5%). Differences in health beliefs, SES, pre-existing conditions, and healthcare explained lower odds of H1N1 vaccination among white men and black men, relative to white women. However, black women experienced 35-45% lower odds of vaccination than white women across all models, highlighting the intersectional nature of these associations. Discussion: The 2009 H1N1 influenza pandemic provides a cautionary tale about the distribution of new vaccines across large populations with diverse racial, sex, and socioeconomic characteristics. Despite differences between the H1N1 and COVID-19 pandemics, our study warns that many black Americans will forego COVID-19 vaccines unless swift action is taken to address black-white disparities in access to vital resources. Public health stakeholders can also encourage widespread adoption of COVID-19 vaccines by tailoring health promotion messages for different groups of racial minorities, especially groups like black women who face intersecting disadvantages. (C) 2021 Elsevier Ltd. All rights reserved.	[Burger, Andrew E.] Brigham Young Univ Idaho, 525 S 2nd E, Rexburg, ID 83420 USA; [Reither, Eric N.; Lim, Sojung] Utah State Univ, 0730 Old Main Hill, Logan, UT 84322 USA; [Mamelund, Svenn-Erik] OsloMet, Ctr Welf & Lab Res, Stensberggata 26, N-0170 Oslo, Norway		Burger, AE (通讯作者)，Brigham Young Univ Idaho, 525 S Ctr, Rexburg, ID 83460 USA.	burgera@byui.edu		Mamelund, Svenn-Erik/0000-0002-3980-3818			Armstrong K, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(00)00263-4; Armstrong K, 2008, J GEN INTERN MED, V23, P827, DOI 10.1007/s11606-008-0561-9; Bauer GR, 2014, SOC SCI MED, V110, P10, DOI 10.1016/j.socscimed.2014.03.022; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Braveman PA, 2010, AM J PUBLIC HEALTH, V100, pS186, DOI 10.2105/AJPH.2009.166082; Burger AE, 2018, J IMMIGR MINOR HEALT, V20, P561, DOI 10.1007/s10903-017-0594-4; Burger AE, 2014, VACCINE, V32, P3950, DOI 10.1016/j.vaccine.2014.05.032; Centers for Disease Control and Prevention, 2012, US GUID PUBL US DAT; Centers for Disease Control and Prevention, 2011, FIN IMATES 2009 10 S; Centers for Disease Control and Prevention, 2009, QUEST ANSW 2009 H1N1; Centers for Disease Control and Prevention, CDC COVID DAT TRACK; Centers for Disease Control and Prevention (CDC), 2010, 2009 H1N1 PAND SUMM; Champion V.L., 2008, HLTH BEHAV HLTH ED T, V5th, P45; Chan M., 2009, COMMUNICATION; Coe Antoinette B, 2012, Innov Pharm, V3, P1; Dee DL, 2011, ANN EPIDEMIOL, V21, P623, DOI 10.1016/j.annepidem.2011.03.002; Denavas-Walt C, 2011, INCOME POVERTY HLTH; DeVoe JE, 2003, AM J PUBLIC HEALTH, V93, P786, DOI 10.2105/AJPH.93.5.786; Dong YR, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-222; Freid VM, 2012, NCHS DATA BRIEF, V100; Frew PM, 2012, VACCINE, V30, P4200, DOI 10.1016/j.vaccine.2012.04.053; Galarce EM, 2011, VACCINE, V29, P5284, DOI 10.1016/j.vaccine.2011.05.014; Gamble VN, 1997, AM J PUBLIC HEALTH, V87, P1773, DOI 10.2105/AJPH.87.11.1773; Gargano LM, 2011, HUM VACCINES, V7, P89, DOI 10.4161/hv.7.1.13460; Gochman, 1997, HDB HLTH BEHAV RES, P71; Hankivsky O, 2012, SOC SCI MED, V74, P1712, DOI 10.1016/j.socscimed.2011.11.029; Iyer A, 2008, Glob Public Health, V3 Suppl 1, P13, DOI 10.1080/17441690801892174; Kaiser Family Foundation, 2020, KFF COVID 19 VACC MO KFF COVID 19 VACC MO; Klein Sabra L, 2010, Biol Sex Differ, V1, P5, DOI 10.1186/2042-6410-1-5; Kumar S, 2012, HEALTH EDUC BEHAV, V39, P229, DOI 10.1177/1090198111415105; LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958; Mamelund SE, 2011, EPIDEMICS-NETH, V3, P46, DOI 10.1016/j.epidem.2011.02.001; Martin Joyce A, 2011, Natl Vital Stat Rep, V60, P1; Martinez ME., 2019, HLTH INSURANCE COVER; Morton PM, 2014, WILEY BLACKWELL ENCY, P1975, DOI [10.1002/9781118410868.wbehibs069., DOI 10.1002/9781118410868.WBEHIBS069]; Muthen L.K., 2017, 1998 2012 MPLUS USER; National Center for Immunization and Respiratory Diseases CDC, 2009, MMWR Recomm Rep, V58, P1; Olofsson A, 2014, HEALTH RISK SOC, V16, P417, DOI 10.1080/13698575.2014.942258; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Pew Research Center, 2020, INT GET COVID 19 VAC; Quinn SC, 2011, AM J PUBLIC HEALTH, V101, P285, DOI 10.2105/AJPH.2009.188029; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Shafer K, 2013, J MARRIAGE FAM, V75, P544, DOI 10.1111/jomf.12024; Shrestha SS, 2011, CLIN INFECT DIS, V52, pS75, DOI 10.1093/cid/ciq012; Siordia C, 2015, J RACIAL ETHN HEALTH, V2, P303, DOI 10.1007/s40615-014-0073-8; StataCorp L, 2017, STAT 15; Thompson DL, 2011, AM J PUBLIC HEALTH, V101, P1776, DOI 10.2105/AJPH.2011.300223; U.S. Census Bureau, 2020, POP HLTH INS COV RAC; U.S. Department of Health & Human Services, 2012, NAT 2009 H1N1 FLU SU; U.S. Department of Labor Statistics, 2010, LAB FORC CHAR RAC ET; United States Government Accountability Office, 2011, INFL PAND LESS H1N1; Uscher-Pines L, 2011, AM J PUBLIC HEALTH, V101, P1252, DOI 10.2105/AJPH.2011.300133; Vlahov D, 2012, J COMMUN HEALTH, V37, P282, DOI 10.1007/s10900-011-9443-x; World Health Organization,, 2010, SEX GEND INFL	54	16	16	0	11	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	FEB 5	2021	39	6					943	951		10.1016/j.vaccine.2020.12.069		JAN 2021	9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PW7FB	33454136	Green Published, Bronze			2022-04-29	WOS:000610835100012
J	Zhong, YJ; Clapham, HE; Aishworiya, R; Chua, YX; Mathews, J; Ong, M; Wang, JJ; Murugasu, B; Chiang, WC; Lee, BW; Chin, HL				Zhong, Youjia; Clapham, Hannah Eleanor; Aishworiya, Ramkumar; Chua, Ying Xian; Mathews, Jancy; Ong, Mabel; Wang, Jingji; Murugasu, Belinda; Chiang, Wen Chin; Lee, Bee Wah; Chin, Hui-Lin			Childhood vaccinations: Hidden impact of COVID-19 on children in Singapore	VACCINE			English	Article							UNITED-STATES	Although the direct health impact of Coronavirus disease (COVID-19) pandemic on child health is low, there are indirect impacts across many aspects. We compare childhood vaccine uptake in three types of healthcare facilities in Singapore - public primary care clinics, a hospital paediatric unit, and private paediatrician clinics - from January to April 2020, to baseline, and calculate the impact on herd immunity for measles. We find a 25.6% to 73.6% drop in Measles-Mumps-Rubella (MMR) uptake rates, 0.4 - 10.3% drop for Diphtheria-Tetanus-Pertussis-inactivated Polio-Haemophilus influenza (5-in-1), and 8.0-67.8% drop for Pneumococcal conjugate vaccine (PCV) across all 3 sites. Consequent herd immunity reduces to 74-84% among 12-month- to 2-year-olds, well below the 95% coverage that is protective for measles. This puts the whole community at risk for a measles epidemic. Public health efforts are urgently needed to maintain efficacious coverage for routine childhood vaccines during the COVID-19 pandemic. (C) 2021 Elsevier Ltd. All rights reserved.	[Zhong, Youjia; Aishworiya, Ramkumar; Wang, Jingji; Lee, Bee Wah; Chin, Hui-Lin] Natl Univ Hlth Syst, Khoo Teck Puat Natl Univ Childrens Med Inst, Singapore, Singapore; [Clapham, Hannah Eleanor] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Chua, Ying Xian; Mathews, Jancy; Ong, Mabel] Natl Univ Polyclin, Singapore, Singapore; [Murugasu, Belinda; Chiang, Wen Chin] Mt Elizabeth Med Ctr, Singapore, Singapore; [Lee, Bee Wah] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Paediat, Singapore, Singapore		Aishworiya, R (通讯作者)，Natl Univ Hlth Syst, Natl Univ Hosp, Khoo Teck Puat Natl Univ Childrens Med Inst, Dept Paediat, Singapore, Singapore.	aishworiya_ramkumar@nuhs.edu.sg	Chin, Hui-Lin/AAO-4401-2021	Chin, Hui-Lin/0000-0001-7431-6794; Zhong, Youjia/0000-0002-3795-6319; Chua, Ying Xian/0000-0003-4090-084X			[Anonymous], UNNEWS; [Anonymous], 2020, COVID 19 CIRCUIT BRE; [Anonymous], 2020, CONTINUATION ESSENTI; [Anonymous], 2020, COVID 19 TRAVEL REST; Brown LD, 2001, STAT SCI, V16, P101, DOI 10.1214/ss/1009213286; Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467; Chang HJ, 2004, AM J PUBLIC HEALTH, V94, P562, DOI 10.2105/AJPH.94.4.562; COmmunicable Diseases Division MoH Singapore, 2019, COMM DIS SURV SING 2; Khan IA, 2013, VACCINE, V31, P6058, DOI 10.1016/j.vaccine.2013.10.021; Kobayashi A, 2020, VACCINE, V38, P4996, DOI 10.1016/j.vaccine.2020.05.067; Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5; McDonald HI, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.19.2000848; Nelson R, 2020, LANCET INFECT DIS, V20, P546, DOI 10.1016/S1473-3099(20)30304-2; Patel M, 2019, MMWR-MORBID MORTAL W, V68, P402, DOI 10.15585/mmwr.mm6817e1; Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2; Truelove SA, 2019, VACCINE, V37, P732, DOI 10.1016/j.vaccine.2018.12.012; UNDP, 2014, SYNTHESIS REPORT	17	20	21	2	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 29	2021	39	5					780	785		10.1016/j.vaccine.2020.12.054		JAN 2021	6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PV7RR	33414050	Bronze, Green Published			2022-04-29	WOS:000610181400003
J	Das, MK; Arora, NK; Gupta, B; Sharan, A; Poluru, R; Tate, JE; Parashar, UD; Aggarwal, MK; Haldar, P; Zuber, PLF; Bonhoeffer, J; Ray, A; Maure, CG; Wakhlu, A; Vyas, BR; Bhat, JI; Goswami, JK; Mathai, J; Kameswari, K; Bharadia, L; Sankhe, L; Ajayakumar, MK; Mohan, N; Jena, PK; Sarangi, R; Shad, R; Debbarma, SK; Shyamala, J; Ratan, SK; Sarkar, S; Kumar, V; Dubey, AP; Gupta, A; Sam, CJ; Mufti, GN; Trivedi, H; Shad, J; Lahiri, K; Krishnaswamy, R; Luthra, M; Behera, N; Padmalatha, P; Rajamani, G; Kumar, R; Sarkar, R; Kumar, AS; Sahoo, SK; Ghosh, SK; Mane, S; Dash, AK; Charoo, BA; Tripathy, BB; Prasad, GR; Kumar, SH; Jothilakshmi, K; Sarkar, NR; Arunachalam, P; Mohapatra, SSG; Garge, S; Kaur, H; Chaubey, J; Das, M; Sharma, S; Jain, V				Das, Manoja Kumar; Arora, Narendra Kumar; Gupta, Bini; Sharan, Apoorva; Poluru, Ramesh; Tate, Jacqueline E.; Parashar, Umesh D.; Aggarwal, Mahesh K.; Haldar, Pradeep; Zuber, Patrick L. F.; Bonhoeffer, Jan; Ray, Arindam; Maure, Christine G.; Wakhlu, Ashish; Vyas, Bhadresh R.; Bhat, Javeed Iqbal; Goswami, Jayanta K.; Mathai, John; Kameswari, K.; Bharadia, Lalit; Sankhe, Lalit; Ajayakumar, M. K.; Mohan, Neelam; Jena, Pradeep K.; Sarangi, Rachita; Shad, Rashmi; Debbarma, Sanjib K.; Shyamala, J.; Ratan, Simmi K.; Sarkar, Suman; Kumar, Vijayendra; Dubey, Anand P.; Gupta, Atul; Sam, Cenita J.; Mufti, Gowhar Nazir; Trivedi, Harsh; Shad, Jimmy; Lahiri, Kaushik; Krishnaswamy, R.; Luthra, Meera; Behera, Narendra; Padmalatha, P.; Rajamani, G.; Kumar, Rakesh; Sarkar, Ruchirendu; Kumar, Santosh A.; Sahoo, Subrat Kumar; Ghosh, Sunil K.; Mane, Sushant; Dash, Arun Kumar; Charoo, Bashir Ahmad; Tripathy, Bikasha Bihary; Prasad, Rajendra G.; Kumar, Harish S.; Jothilakshmi, K.; Sarkar, Nihar Ranjan; Arunachalam, Pavai; Mohapatra, Satya Sundar G.; Garge, Saurabh; Kaur, Harshpreet; Chaubey, Janvi; Das, Mrimmaya; Sharma, Shweta; Jain, Vaibhav		INCLEN Intussusception Surveillanc	Risk of intussusception after monovalent rotavirus vaccine (Rotavac) in Indian infants: A self-controlled case series analysis	VACCINE			English	Article						Intussusception; Rotavirus vaccine; Vaccine safety; Self-controlled case-series; Rotavac; Infant; India	CHILDREN; EFFICACY; SURVEILLANCE; IMPACT; HOSPITALIZATIONS; IMMUNIZATION; SAFETY; AGE	Background: An association between rotavirus vaccination and intussusception has been documented in post-licensure studies in some countries. We evaluated the risk of intussusception associated with monovalent rotavirus vaccine (Rotavac) administered at 6, 10 and 14 weeks of age in India. Methods: Active prospective surveillance for intussusception was conducted at 22 hospitals across 16 states from April 2016 through September 2017. Data on demography, clinical features and vaccination were documented. Age-adjusted relative incidence for 1-7, 8-21, and 1-21 days after rotavirus vaccination in children aged 28-364 days at intussusception onset was estimated using the self-controlled caseseries (SCCS) method. Only Brighton Collaboration level 1 cases were included. Results: Out of 670 children aged 2-23 months with intussusception, 311 (46.4%) children were aged 28-364 days with confirmed vaccination status. Out of these, 52 intussusception cases with confirmed receipt of RVV were included in the SCCS analysis. No intussusception case was observed within 21 days of dose 1. Only one case occurred during 8-21 days after the dose 2. Post-dose 3, two cases in 1-7 days and 7 cases during 8-21 days period were observed. There was no increased risk of intussusception during 1-7 days after the doses 1 and 2 (zero cases observed) or dose 3 (relative incidence [RI], 1.71 [95% confidence interval {CI} 0.0-5.11]). Similarly, no increased risk during 8-21 days after the dose 1 (zero cases observed), dose 2 (RI, 0.71 [95% CI, 0.0-3.28]) or dose 3 (RI, 2.52 [95% CI, 0.78-5.61]). The results were similar for 1-21 day periods after the doses separately or pooled. Conclusions: The risk of intussusception during the first 21 days after any dose of rotavirus vaccine (Rotavac) was not higher among the Indian infants than the background risk, based on limited SCCS analysis of 52 children. (C) 2020 The Author(s). Published by Elsevier Ltd.	[Das, Manoja Kumar; Arora, Narendra Kumar; Gupta, Bini; Sharan, Apoorva; Poluru, Ramesh] INCLEN Trust Int, Okhla Ind Area, F1-5,Phase 1, New Delhi 110020, India; [Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA; [Aggarwal, Mahesh K.; Haldar, Pradeep] Minist Hlth & Family Welf, Govt India, New Delhi, India; [Zuber, Patrick L. F.; Maure, Christine G.] World Hlth Org, Global Vaccine Safety & Vigilance Team, Geneva, Switzerland; [Bonhoeffer, Jan] Univ Childrens Hosp, Brighton Collaborat Fdn, Infect Dis & Vaccines, Basel, Switzerland; [Ray, Arindam] Bill & Melinda Gates Fdn, India Country Off, New Delhi, India; [Wakhlu, Ashish] King Georges Med Univ, Dept Paediat Surg, Lucknow, Uttar Pradesh, India; [Vyas, Bhadresh R.] MP Shah Govt Med Coll, Dept Paediat, Jamnagar, Gujarat, India; [Bhat, Javeed Iqbal] Sherikashmir Inst Med Sci, Dept Paediat, Srinagar, Jammu & Kashmir, India; [Goswami, Jayanta K.; Lahiri, Kaushik] Gauhati Med Coll, Dept Paediat Surg, Gauhati, Assam, India; [Mathai, John; Jothilakshmi, K.] PSG Inst Med Sci, Dept Paediat, Coimbatore, Tamil Nadu, India; [Kameswari, K.; Prasad, Rajendra G.] Andhra Med Coll, Dept Paediat Surg, Vishakhapatnam, Andhra Pradesh, India; [Bharadia, Lalit] Fortis Escorts Hosp, Jaipur, Rajasthan, India; [Sankhe, Lalit] Grant Med Coll JJ Hosp, Dept Community Med, Mumbai, Maharashtra, India; [Ajayakumar, M. K.] Govt Med Coll SAT Hosp, Dept Paediat Surg, Thiruvananthapuram, Kerala, India; [Mohan, Neelam] Medanta, Paediat Gastroenterol, Gurgaon, Haryana, India; [Jena, Pradeep K.] SCB Med Coll, Dept Paediat Surg, Cuttack, Odisha, India; [Sarangi, Rachita] IMS & SUM Med Coll & Hosp, Dept Paediat, Bhubaneswar, Odisha, India; [Shad, Rashmi; Garge, Saurabh] Choithram Hosp & Res Ctr, Indore, Madhya Pradesh, India; [Debbarma, Sanjib K.] Agartala Govt Med Coll, Dept Paediat, Agartala, India; [Shyamala, J.; Shad, Jimmy; Kumar, Harish S.] Apollo Hosp, Chennai, Tamil Nadu, India; [Ratan, Simmi K.] Maulana Azad Med Coll, Dept Paediat Surg, Delhi, India; [Sarkar, Suman] Inst Post Grad Med Educ & Res, Dept Paediat, Kolkata, India; [Kumar, Vijayendra] Indira Gandhi Inst Med Sci, Dept Paediat Surg, Patna, Bihar, India; [Dubey, Anand P.] Maulana Azad Med Coll, Dept Paediat, Delhi, India; [Gupta, Atul] Fortis Escorts Hosp, Pediat Surg, Jaipur, Rajasthan, India; [Sam, Cenita J.; Arunachalam, Pavai] PSG Inst Med Sci, Dept Paediat Surg, Coimbatore, Tamil Nadu, India; [Mufti, Gowhar Nazir] Sherikashmir Inst Med Sci, Dept Paediat Surg, Srinagar, Jammu & Kashmir, India; [Trivedi, Harsh] MP Shah Govt Med Coll, Dept Paediat Surg, Jamnagar, Gujarat, India; [Krishnaswamy, R.] Mason Childrens Hosp, Coimbatore, Tamil Nadu, India; [Luthra, Meera] Medanta, Paediat Surg, Gurgaon, Haryana, India; [Behera, Narendra] MKCG Med Coll, Dept Pediat, Berhampur, Odisha, India; [Padmalatha, P.] Andhra Med Coll, Dept Paediat, Vishakhapatnam, Andhra Pradesh, India; [Rajamani, G.] Coimbatore Med Coll, Dept Paediat Surg, Coimbatore, Tamil Nadu, India; [Kumar, Rakesh] Indira Gandhi Inst Med Sci, Dept Paediat, Patna, Bihar, India; [Sarkar, Ruchirendu] Inst Post Grad Med Educ & Res, Dept Paediat Surg, Kolkata, India; [Kumar, Santosh A.] Govt Med Coll & SAT Hosp, Dept Paediat, Thiruvananthapuram, Kerala, India; [Sahoo, Subrat Kumar] IMS & SUM Med Coll & Hosp, Dept Paediat Surg, Bhubaneswar, Odisha, India; [Ghosh, Sunil K.] Agartala Govt Med Coll, Dept Pediat Surg, Agartala, India; [Mane, Sushant] Grant Med Coll & JJ Hosp, Dept Paediat, Mumbai, Maharashtra, India; [Dash, Arun Kumar] MKCG Med Coll, Dept Pediat Surg, Berhampur, Odisha, India; [Charoo, Bashir Ahmad] Sherikashmir Inst Med Sci, Dept Paediat, Srinagar, Jammu & Kashmir, India; [Tripathy, Bikasha Bihary] IMS & SUM Med Coll Hosp, Dept Paediat Surg, Bhubaneswar, Odisha, India; [Sarkar, Nihar Ranjan] Inst Post Grad Med Educ & Res, Dept Radiol, Kolkata, India; [Mohapatra, Satya Sundar G.] IMS & SUM Med Coll Hosp, Dept Radiol, Bhubaneswar, Odisha, India		Das, MK (通讯作者)，INCLEN Trust Int, Okhla Ind Area, F1-5,Phase 1, New Delhi 110020, India.	manoj@inclentrust.org	Poluru, Ramesh/K-8093-2013; iqbal, javeed/ABC-1694-2021; Das, Manoja/I-2558-2017; Ray, Arindam/AAN-1525-2020	Poluru, Ramesh/0000-0002-7693-418X; iqbal, javeed/0000-0002-4094-4634; Das, Manoja/0000-0002-8559-5837; Ray, Arindam/0000-0002-5955-0352	Bill and Melinda Gates Foundation, USABill & Melinda Gates Foundation [OPP1116433]	This project was supported by the Bill and Melinda Gates Foundation, USA to The INCLEN Trust International (grant number OPP1116433). The funder or its representative had no role in the design of the study and collection, analysis, and interpretation of data and writing the manuscript.	Bhandari N, 2020, VACCINE, V38, P5241, DOI 10.1016/j.vaccine.2020.05.093; Bhandari N, 2014, LANCET, V383, P2136, DOI 10.1016/S0140-6736(13)62630-6; Bines JE, 2004, VACCINE, V22, P569, DOI 10.1016/j.vaccine.2003.09.016; Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186; Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520; Carvalho MF, 2019, HUM VACC IMMUNOTHER, V15, P1237, DOI 10.1080/21645515.2018.1520583; Das MK, 2018, METHOD PROTOCOL, V1, DOI 10.3390/mps1020011; Emperador DM, 2016, CLIN INFECT DIS, V62, P150, DOI 10.1093/cid/civ807; Esona MD, 2014, HUM VACC IMMUNOTHER, V10, P25, DOI 10.4161/hv.26731; Farrington CP, 2009, BIOSTATISTICS, V10, P3, DOI 10.1093/biostatistics/kxn013; Groome MJ, 2020, CLIN INFECT DIS, V70, P1606, DOI 10.1093/cid/ciz431; Gupta M, 2018, J TROP PEDIATRICS, V64, P326, DOI 10.1093/tropej/fmx073; Jehangir S, 2014, VACCINE, V32, pA99, DOI 10.1016/j.vaccine.2014.03.028; Jiang JQ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055729, 10.1371/journal.pone.0068482]; Jonesteller CL, 2017, CLIN INFECT DIS, V65, P840, DOI 10.1093/cid/cix369; Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014; Leino T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144812; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; Musonda P, 2006, STAT MED, V25, P2618, DOI 10.1002/sim.2477; Parker EPK, 2018, FUTURE MICROBIOL, V13, P97, DOI 10.2217/fmb-2017-0128; Patel M, 2009, J INFECT DIS, V200, pS39, DOI 10.1086/605035; Patel MM, 2011, NEW ENGL J MED, V364, P2283, DOI 10.1056/NEJMoa1012952; Pendleton A, 2013, HUM VACC IMMUNOTHER, V9, P1617, DOI 10.4161/hv.24831; Perez-Vilar S, 2015, HUM VACC IMMUNOTHER, V11, P1848, DOI 10.1080/21645515.2015.1049787; Press Informationn Beureau, 2016, JP NADD LAUNCH ROT V; Quintanar-Solares M, 2011, PEDIATR INFECT DIS J, V30, pS11, DOI 10.1097/INF.0b013e3181fefb32; Ramani S, 2016, PEDIATR INFECT DIS J, V35, P1137, DOI 10.1097/INF.0000000000001253; Velazquez FR, 2012, PEDIATR INFECT DIS J, V31, P736, DOI 10.1097/INF.0b013e318253add3; ROTA Council, 2020, GLOB INTR STAT; Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434; Singh JV, 2014, VACCINE, V32, pA95, DOI 10.1016/j.vaccine.2014.03.007; Srinivasan R, 2018, VACCINE, V36, P7820, DOI 10.1016/j.vaccine.2017.11.043; Steele AD, 2010, VACCINE, V28, P6542, DOI 10.1016/j.vaccine.2008.08.034; Stowe J, 2016, VACCINE, V34, P3684, DOI 10.1016/j.vaccine.2016.04.050; Tate JE, 2018, NEW ENGL J MED, V378, P1521, DOI [10.1056/NEJMoa1713909, 10.1056/nejmoa1713909]; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664; Weintraub ES, 2014, NEW ENGL J MED, V370, P513, DOI 10.1056/NEJMoa1311738; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Whitaker HJ, 2009, STAT METHODS MED RES, V18, P7, DOI 10.1177/0962280208092342; World Health Organization, 2020, IND WHO UNICEF EST I; Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164; Yung CF, 2015, J PEDIATR-US, V167, P163, DOI 10.1016/j.jpeds.2015.03.038	42	5	5	2	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2021	39	1					78	84		10.1016/j.vaccine.2020.09.019			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PI2XL	32972735	Green Published, hybrid			2022-04-29	WOS:000600959400010
J	Cote-Cyr, M; Gauthier, L; Zottig, X; Bourgault, S; Archambault, D				Cote-Cyr, Melanie; Gauthier, Laurie; Zottig, Ximena; Bourgault, Steve; Archambault, Denis			Recombinant Bacillus subtilis flagellin Hag is a potent immunostimulant with reduced proinflammatory properties compared to Salmonella enterica serovar Typhimurium FljB	VACCINE			English	Article						Flagellin; Vaccine; Adjuvant; Immunostimulant; Toll-like receptor 5; Inflammation	ADJUVANT; IMMUNOGENICITY; PREDICTION; ACTIVATION	Flagellin constitutes a potential adjuvant for vaccines owing to its robust immunostimulatory properties. However, clinical trials have revealed that flagellin derived from Salmonella enterica serovar Typhimurium induces high levels of proinflammatory markers and substantial adverse effects. The flag-ellin from Bacillus subtilis, Hag, shares high sequence homology with Salmonella FljB within the D0 and D1 domains responsible for TLR5 engagement, while the D2 and D3 domains associated with an off-target immune response are absent. Accordingly, we compared the immunostimulatory and proinflammatory properties of Hag with FljB by harnessing an epitope from the matrix 2 protein (M2e) of the influenza virus. Both flagellins engaged TLR5, with FljB showing a 2.5-fold higher potency than Hag. Mice inocula-tion showed a robust FljB-or Hag-induced M2e-specific antibody response, with Hag demonstrating a decreased secretion of proinflammatory markers and reduced weight loss. This study revealed that flag-ellin Hag is a potent immunoadjuvant with reduced proinflammatory properties. (c) 2021 Elsevier Ltd. All rights reserved.	[Cote-Cyr, Melanie; Zottig, Ximena; Bourgault, Steve] Univ Quebec Montreal, Chem Dept, Montreal, PQ, Canada; [Cote-Cyr, Melanie; Gauthier, Laurie; Zottig, Ximena; Bourgault, Steve] Quebec Network Res Prot Funct Engn & Applicat PRO, Quebec City, PQ, Canada; [Cote-Cyr, Melanie; Gauthier, Laurie; Zottig, Ximena; Archambault, Denis] Univ Quebec Montreal, Dept Biol Sci, Montreal, PQ, Canada; [Cote-Cyr, Melanie; Gauthier, Laurie; Zottig, Ximena; Bourgault, Steve; Archambault, Denis] Swine & Poultry Infect Dis Res Ctr CRIPA, St Hyacinthe, PQ, Canada		Bourgault, S (通讯作者)，Univ Quebec Montreal, Chem Dept, Montreal, PQ, Canada.; Bourgault, S (通讯作者)，Quebec Network Res Prot Funct Engn & Applicat PRO, Quebec City, PQ, Canada.; Archambault, D (通讯作者)，Univ Quebec Montreal, Dept Biol Sci, Montreal, PQ, Canada.; Bourgault, S; Archambault, D (通讯作者)，Swine & Poultry Infect Dis Res Ctr CRIPA, St Hyacinthe, PQ, Canada.	bourgault.steve@uqam.ca; archambault.denis@uqam.ca		Cote-Cyr, Melanie/0000-0002-9807-2680	Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); International Development Research Centre (IDRC) [108517]; NSERCNatural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN-2018-06209, RGPN-2016-06532]	The authors acknowledge Dr. Oussama Meziane, Dr. Phuong Trang Nguyen and Jenna Bossart for their technical support. M.CC. and X.Z. acknowledge fellowships from the Natural Sciences and Engineering Research Council of Canada (NSERC). This work was supported by the International Development Research Centre (IDRC; grant number 108517) to D.A. and S. B., and by the NSERC grants RGPIN-2018-06209 (S.B.) and RGPN-2016-06532 (D.A.).	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Biedma ME, 2019, VACCINE, V37, P652, DOI 10.1016/j.vaccine.2018.12.009; Cho KJ, 2015, J VIROL, V89, P3700, DOI 10.1128/JVI.02576-14; Feuillet V, 2006, P NATL ACAD SCI USA, V103, P12487, DOI 10.1073/pnas.0605200103; Gauthier Laurie, 2020, Immunobiology, V225, P151962, DOI 10.1016/j.imbio.2020.151962; Girard A, 2011, VACCINE, V29, P6695, DOI 10.1016/j.vaccine.2011.06.092; Hajam IA, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.172; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006; Honko AN, 2004, INFECT IMMUN, V72, P6676, DOI 10.1128/IAI.72.11.6676-6679.2004; Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062; Huleatt JW, 2007, VACCINE, V25, P763, DOI 10.1016/j.vaccine.2006.08.013; Ibanez LI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059081; Ikeda JS, 2001, INFECT IMMUN, V69, P3021, DOI 10.1128/IAI.69.5.3021-3030.2001; Kim KH, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040066; Louis-Jeune C, 2012, PROTEINS, V80, P374, DOI 10.1002/prot.23188; Lu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep18379; Maki-Yonekura S, 2010, NAT STRUCT MOL BIOL, V17, P417, DOI 10.1038/nsmb.1774; Matusiak M, 2015, P NATL ACAD SCI USA, V112, P1541, DOI 10.1073/pnas.1417945112; Mezhenskaya D, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0572-3; Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Rolli J, 2010, CRIT CARE, V14, DOI 10.1186/cc9235; Skountzou I, 2010, VACCINE, V28, P4103, DOI 10.1016/j.vaccine.2009.07.058; Song WS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40878; Tsujimoto H, 2005, J LEUKOCYTE BIOL, V78, P888, DOI 10.1189/jlb.0105051; Turley CB, 2011, VACCINE, V29, P5145, DOI 10.1016/j.vaccine.2011.05.041; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e; Zhang L, 2015, CELL MOL IMMUNOL, V12, P625, DOI 10.1038/cmi.2014.76	30	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	JAN 3	2022	40	1					11	17		10.1016/j.vaccine.2021.11.049		DEC 2021	7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XQ1FV	34844822				2022-04-29	WOS:000731299800005
J	Murphy, RP; Taaffe, C; Ahern, E; McMahon, G; Muldoon, O				Murphy, Robert P.; Taaffe, Carol; Ahern, Elayne; McMahon, Grace; Muldoon, Orla			A meta-analysis of influenza vaccination following correspondence: Considerations for COVID-19 q	VACCINE			English	Article						Vaccine uptake; COVID-19; Influenza; Direct correspondence; Meta-analysis	RANDOMIZED CONTROLLED-TRIAL; HIGH-RISK PATIENTS; POSTCARD REMINDERS; IMPROVE INFLUENZA; MANAGED CARE; IMMUNIZATION; RATES; INTERVENTIONS; IMPACT; EDUCATION	Background: High vaccination rates are needed to protect against influenza and to end the COVID-19 pandemic. Health authorities need to know if supplementing mass communications with direct correspondence to the community would increase uptake. Objectives: The primary objective is to determine if sending a single written message directly to individuals increases influenza vaccine uptake, and a secondary objective is to identify any identified content shown to increase influenza vaccine uptake. Methods: MEDLINE, Embase, Cochrane CENTRAL, PsycINFO, and PubMed were searched for RCTs testing a single correspondence for members of the community in OECD countries to obtain influenza vaccination. A meta-analysis with inverse-variance, random-effects modelling was used to estimate a mean, weighted risk ratio effect size measure of vaccine uptake. Studies were quality assessed and analysis was undertaken to account for potential publication bias. Results: Twenty-eight randomized controlled trials were included, covering 45 interventions. Of the 45 interventions, 37 (82.2%) report an increase in influenza vaccination rates. A formal meta-analysis shows that sending a single written message increased influenza vaccine uptake by 16%, relative to the no contact comparator group (RR = 1.16, 95% CI [1.13-1.20], Z = 9.25, p < .001). Analysis shows that the intervention is effective across correspondence type, age group, time, and location, and after allowing for risk of publication bias. Limitations: The generalizability of results across the OECD may be questioned. Conclusions and implications: The implication for public health authorities organizing vaccination programs for influenza, and arguably also for COVID-19, is that sending written vaccination correspondence to members of the community is likely to increase uptake. This study is pre-registered on osf.io; details can be found at https://osf.io/98mr7. (c) 2021 Elsevier Ltd. All rights reserved.	[Murphy, Robert P.] Univ Stirling, Stirling Management Sch, Stirling, Ireland; [Murphy, Robert P.; Taaffe, Carol] Dept Hlth, Block 1,Miesian Plaza,50-58 Lower Baggot St, Dublin D02 XW14, Ireland; [Ahern, Elayne] Dublin City Univ, Sch Psychol, Dublin, Ireland; [McMahon, Grace; Muldoon, Orla] Univ Limerick, Dept Psychol, Limerick, Ireland		Murphy, RP (通讯作者)，Dept Hlth, Block 1,Miesian Plaza,50-58 Lower Baggot St, Dublin D02 XW14, Ireland.	r.p.murphy@stir.ac.uk	; Muldoon, Orla/D-1639-2010	Ahern, Elayne/0000-0001-9230-6776; Murphy, Robert P./0000-0002-9549-524X; Muldoon, Orla/0000-0001-9082-2443			Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Atkinson KM, 2019, VACCINE, V37, P3050, DOI 10.1016/j.vaccine.2019.03.063; Baker AM, 1998, J GEN INTERN MED, V13, P469, DOI 10.1046/j.1525-1497.1998.00136.x; Balzarini F, 2020, VACCINE, V38, P5966, DOI 10.1016/j.vaccine.2020.05.083; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Borenstein M., 2009, INTRO META ANAL; BRIMBERRY R, 1988, J FAM PRACTICE, V26, P397; Brombacher F, 2021, Z EVIDENZ FORTBILD Q, V161, P42, DOI 10.1016/j.zefq.2021.01.007; BUCHNER DM, 1987, J AM GERIATR SOC, V35, P755, DOI 10.1111/j.1532-5415.1987.tb06354.x; Bushar JA, 2017, AM J PREV MED, V53, P845, DOI 10.1016/j.amepre.2017.06.021; Clayton AE, 1999, AM J PUBLIC HEALTH, V89, P1235, DOI 10.2105/AJPH.89.8.1235; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Cutrona SL, 2018, J GEN INTERN MED, V33, P659, DOI 10.1007/s11606-017-4266-9; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dordevic JM, 2021, SOC SCI MED, V277, DOI 10.1016/j.socscimed.2021.113930; Frascella B, 2020, VACCINE, V38, P433, DOI 10.1016/j.vaccine.2019.10.089; Galarce EM, 2011, VACCINE, V29, P5284, DOI 10.1016/j.vaccine.2011.05.014; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.03.017, 10.1016/j.jclinepi.2011.06.004]; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS14; Han S, 2000, KOREAN J PREVENTIVE, V33, P109; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Hogg WE, 1998, CAN FAM PHYSICIAN, V44, P81; Hotle Susan, 2020, Transp Res Interdiscip Perspect, V5, P100127, DOI 10.1016/j.trip.2020.100127; Jay, REV INT EVIDENCE BEL; Jhaveri R, 2020, CLIN THER, V42, P736, DOI 10.1016/j.clinthera.2020.04.003; Klassing HM, 2018, J COMMUN HEALTH, V43, P297, DOI 10.1007/s10900-017-0421-9; LARSON EB, 1982, MED CARE, V20, P639, DOI 10.1097/00005650-198206000-00010; Lau D, 2012, ANN FAM MED, V10, P538, DOI 10.1370/afm.1405; Lee WN, 2020, VACCINE, V38, P3508, DOI 10.1016/j.vaccine.2019.11.053; Lipsey M.W., 2001, PRACTICAL META ANAL, V49; MacDonald L, 2013, J HEALTH COMMUN, V18, P1523, DOI 10.1080/10810730.2013.840697; McCaul KD, 2002, HEALTH PSYCHOL, V21, P624, DOI 10.1037//0278-6133.21.6.624; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; McInerney M., 1994, MMWR-MORBID MORTAL W; Minor DS, 2010, AM J MED, V123, P1031, DOI 10.1016/j.amjmed.2010.06.017; MORAN WP, 1992, J GEN INTERN MED, V7, P535, DOI 10.1007/BF02599460; Moran WP, 1996, AM J MED, V101, P612, DOI 10.1016/S0002-9343(96)00327-0; MULLOOLY JP, 1987, AM J PUBLIC HEALTH, V77, P626, DOI 10.2105/AJPH.77.5.626; Nexoe J, 1997, SCAND J PRIM HEALTH, V15, P109, DOI 10.3109/02813439709018497; Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313; Puech M, 1998, AUST NZ J PUBL HEAL, V22, P254, DOI 10.1111/j.1467-842X.1998.tb01183.x; Regan AK, 2017, ANN FAM MED, V15, P507, DOI 10.1370/afm.2120; Roca B, 2012, AM J MANAG CARE, V18, pE446; Sanftenberg L, 2019, DTSCH ARZTEBL INT, V116, P645, DOI 10.3238/arztebl.2019.0645; Santesso N, 2020, J CLIN EPIDEMIOL, V119, P126, DOI 10.1016/j.jclinepi.2019.10.014; Satterthwaite P, 1997, NEW ZEAL MED J, V110, P58; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SPAULDING SA, 1991, J FAM PRACTICE, V33, P495; Szilagyi PG, 2020, JAMA INTERN MED, V180, P962, DOI 10.1001/jamainternmed.2020.1602; Terrell-Perica SMD, 2001, AM J PREV MED, V21, P256, DOI 10.1016/S0749-3797(01)00372-5; Thomas RE, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005188.pub4; Vann JCJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003941.pub3; Ward K, 2012, AUST NZ J PUBL HEAL, V36, P369, DOI 10.1111/j.1753-6405.2012.00897.x; Wijesundara JG, 2020, J MED INTERNET RES, V22, DOI 10.2196/16373; Yokum D, 2018, NAT HUM BEHAV, V2, P743, DOI 10.1038/s41562-018-0432-2; Zhou XJ, 2020, IRAN J PUBLIC HEALTH, V49, P2256, DOI 10.18502/ijph.v49i12.4805	58	0	0	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	DEC 20	2021	39	52					7606	7624		10.1016/j.vaccine.2021.11.025		DEC 2021	19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XQ1EI	34836661	Green Published, Green Submitted, Bronze			2022-04-29	WOS:000731295900013
